38	O
year	O
old	O
male	O
in	O
NYHA	O
functional	O
class	O
II	O
IV	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
History	O
Stage	O
V	O
chronic	O
renal	O
failure	O
CRF	O
due	O
to	O
left	O
renal	O
dysplasia	O
and	O
renal	O
cysts	O
,	O
on	O
haemodialysis	O
for	O
two	O
years	O
.	O
Hyperparathyroidism	O
secondary	O
to	O
CKD	O
,	O
renoureteral	O
carcinoma	O
operated	O
on	O
eight	O
years	O
ago	O
.	O
Hepatic	O
cholestasis	O
,	O
stenosis	O
of	O
main	O
pulmonary	O
arteries	O
,	O
arterial	O
hypertension	O
,	O
dyslipidaemia	O
,	O
active	O
smoking	O
.	O
Daughter	O
underwent	O
liver	O
transplant	O
at	O
the	O
age	O
of	O
seven	O
.	O
Admitted	O
a	O
year	O
ago	O
for	O
an	O
episode	O
of	O
acute	O
pulmonary	O
oedema	O
triggered	O
by	O
volume	O
overload	O
.	O
Clinical	O
history	O
In	O
the	O
haemodialysis	O
session	O
she	O
began	O
with	O
intense	O
dizziness	O
,	O
sweating	O
and	O
dyspnoea	O
;	O
the	O
previous	O
day	O
she	O
had	O
already	O
reported	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
Physical	O
examination	O
revealed	O
poor	O
general	O
condition	O
with	O
a	O
BP	O
of	O
75	O
48	O
,	O
cardiac	O
and	O
pulmonary	O
auscultation	O
revealed	O
the	O
presence	O
of	O
a	O
4	O
6	O
systolic	O
murmur	O
in	O
the	O
aortic	O
focus	O
radiating	O
to	O
the	O
left	O
sternal	O
border	O
and	O
carotid	O
arteries	O
with	O
abolished	O
2nd	O
sound	O
and	O
crackles	O
up	O
to	O
midfield	O
.	O
An	O
ECG	O
was	O
performed	O
which	O
showed	O
ST	O
segment	O
elevation	O
in	O
the	O
lower	O
lateral	O
face	O
and	O
ST	O
segment	O
elevation	O
from	O
V2	O
to	O
V3	O
.	O
Blood	O
tests	O
showed	O
Hb	O
of	O
7	O
.	O
0	O
g	O
dl	O
.	O
Serum	O
therapy	O
was	O
started	O
,	O
with	O
transfusion	O
of	O
two	O
red	O
blood	O
cell	O
concentrates	O
,	O
which	O
corrected	O
the	O
electrocardiographic	O
alterations	O
;	O
after	O
fluid	O
replacement	O
,	O
acute	O
pulmonary	O
oedema	O
began	O
and	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
ICU	O
.	O
Complementary	O
tests	O
Electrocardiogram	O
Sinus	O
rhythm	O
at	O
70	O
bpm	O
,	O
Axis	O
80o	O
,	O
LVH	O
criteria	O
,	O
negative	O
T	O
waves	O
in	O
III	O
,	O
poor	O
growth	O
of	O
r	O
from	O
V1	O
to	O
V3	O
,	O
PR	O
of	O
200	O
ms	O
,	O
asymmetric	O
negative	O
T	O
waves	O
in	O
III	O
and	O
V5	O
V6	O
.	O
CBC	O
Glucose	O
106	O
,	O
urea	O
38	O
,	O
Cr	O
3	O
.	O
1	O
.	O
K	O
3	O
.	O
2	O
,	O
Na	O
138	O
,	O
Hb	O
9	O
.	O
6	O
.	O
MCV	O
89	O
,	O
CPK	O
47	O
,	O
CK	O
MB	O
2	O
.	O
7	O
,	O
TpI	O
0	O
.	O
22	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
0	O
.	O
55	O
,	O
with	O
parahilar	O
alveolar	O
infiltrates	O
.	O
Transthoracic	O
echocardiogram	O
LV	O
with	O
moderate	O
concentric	O
hypertrophy	O
with	O
normal	O
LVEF	O
.	O
Calcium	O
in	O
the	O
mitral	O
annulus	O
.	O
Bicuspid	O
aortic	O
valve	O
with	O
severe	O
stenosis	O
peak	O
gradient	O
76	O
mmHg	O
and	O
mean	O
46	O
50	O
mmHg	O
,	O
area	O
per	O
continuity	O
of	O
0	O
.	O
56	O
cm2	O
m2	O
and	O
mild	O
insufficiency	O
.	O
Normal	O
right	O
chambers	O
with	O
normofunctioning	O
RV	O
.	O
Normal	O
pulmonary	O
valve	O
with	O
somewhat	O
thinned	O
main	O
branches	O
.	O
Cardiac	O
MRI	O
Proximal	O
stenosis	O
of	O
both	O
main	O
branches	O
of	O
the	O
pulmonary	O
artery	O
,	O
right	O
pulmonary	O
artery	O
with	O
a	O
calibre	O
of	O
9x8	O
mm	O
proximally	O
and	O
11x13	O
mm	O
distally	O
and	O
left	O
pulmonary	O
artery	O
with	O
a	O
calibre	O
of	O
9x10	O
mm	O
proximally	O
and	O
8x7	O
mm	O
distally	O
.	O
Right	O
ventricle	O
not	O
dilated	O
,	O
systolic	O
function	O
preserved	O
.	O
RVEF	O
61	O
.	O
9	O
;	O
RVOT	O
136	O
.	O
4	O
ml	O
;	O
STV	O
52	O
ml	O
performed	O
one	O
year	O
prior	O
to	O
admission	O
.	O
Coronary	O
angiography	O
Coronary	O
arteries	O
angiographically	O
without	O
lesions	O
.	O
Severe	O
aortic	O
stenosis	O
.	O
Chest	O
CT	O
angiography	O
Proximal	O
stenosis	O
of	O
both	O
pulmonary	O
arteries	O
right	O
pulmonary	O
artery	O
diameter	O
9	O
mm	O
and	O
left	O
pulmonary	O
artery	O
diameter	O
10	O
mm	O
,	O
cardiomegaly	O
at	O
the	O
expense	O
of	O
the	O
left	O
cavities	O
performed	O
during	O
admission	O
.	O
Clinical	O
evolution	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
with	O
acute	O
pulmonary	O
oedema	O
,	O
which	O
improved	O
after	O
non	O
invasive	O
mechanical	O
ventilation	O
and	O
haemofiltration	O
.	O
An	O
emergency	O
transthoracic	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
severe	O
aortic	O
stenosis	O
in	O
a	O
calcified	O
bicuspid	O
aortic	O
valve	O
with	O
reduced	O
mobility	O
.	O
During	O
admission	O
,	O
a	O
chest	O
CT	O
angiography	O
was	O
performed	O
to	O
assess	O
pulmonary	O
artery	O
stenosis	O
,	O
which	O
had	O
no	O
severity	O
criteria	O
.	O
Once	O
the	O
patient	O
was	O
stabilised	O
,	O
coronary	O
angiography	O
was	O
performed	O
described	O
above	O
with	O
a	O
view	O
to	O
replacing	O
the	O
aortic	O
valve	O
.	O
Finally	O
,	O
the	O
patient	O
underwent	O
surgery	O
with	O
implantation	O
of	O
a	O
Magna	O
Ease	O
size	O
23	O
biological	O
aortic	O
prosthesis	O
,	O
the	O
postoperative	O
period	O
passed	O
without	O
complications	O
.	O
The	O
echocardiogram	O
prior	O
to	O
discharge	O
showed	O
that	O
the	O
prosthesis	O
was	O
functioning	O
normally	O
.	O
Diagnosis	O
Severe	O
aortic	O
stenosis	O
in	O
bicuspid	O
valve	O
Alagille	O
syndrome	O

Medical	O
history	O
and	O
current	O
illness	O
62	O
year	O
old	O
male	O
with	O
no	O
known	O
drug	O
allergies	O
.	O
Hypertensive	O
,	O
dyslipidaemic	O
and	O
type	O
2	O
diabetic	O
on	O
treatment	O
with	O
oral	O
antidiabetics	O
.	O
History	O
of	O
aortic	O
valve	O
replacement	O
with	O
implantation	O
of	O
Sant	O
Jude	O
number	O
27	O
mechanical	O
prosthesis	O
in	O
1998	O
due	O
to	O
severe	O
aortic	O
insufficiency	O
of	O
rheumatic	O
aetiology	O
,	O
presenting	O
as	O
a	O
complication	O
post	O
surgical	O
mediastinitis	O
and	O
tricuspid	O
endocarditis	O
due	O
to	O
penicillin	B-FARMACO
sensitive	O
S	O
.	O
aureus	O
,	O
treated	O
with	O
penicillin	B-FARMACO
and	O
rifampicin	B-FARMACO
and	O
surgical	O
debridement	O
,	O
with	O
good	O
evolution	O
.	O
Followed	O
up	O
annually	O
in	O
Cardiology	O
outpatient	O
clinic	O
with	O
good	O
evolution	O
,	O
with	O
last	O
review	O
with	O
echocardiogram	O
showing	O
normal	O
LVEF	O
.	O
Normal	O
contractility	O
.	O
Normal	O
functioning	O
aortic	O
prosthesis	O
.	O
Mild	O
intraprosthetic	O
aortic	O
insufficiency	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Baseline	O
life	O
functional	O
class	O
I	O
II	O
IV	O
.	O
No	O
oedema	O
,	O
no	O
baseline	O
orthopnoea	O
.	O
Usual	O
treatment	O
synthroid	B-FARMACO
,	O
acovil	B-FARMACO
10	O
,	O
pravastatin	B-FARMACO
and	O
glicazide	B-FARMACO
.	O
She	O
came	O
to	O
the	O
hospital	O
due	O
to	O
an	O
increase	O
in	O
her	O
usual	O
dyspnoea	O
over	O
the	O
last	O
six	O
months	O
until	O
she	O
became	O
moderately	O
exertional	O
,	O
together	O
with	O
episodes	O
of	O
oppressive	O
,	O
non	O
radiating	O
central	O
thoracic	O
pain	O
lasting	O
15	O
20	O
minutes	O
,	O
independent	O
of	O
physical	O
activity	O
,	O
with	O
no	O
other	O
associated	O
symptoms	O
of	O
heart	O
failure	O
,	O
or	O
at	O
any	O
other	O
level	O
.	O
Complementary	O
tests	O
Blood	O
tests	O
haemoglobin	O
15	O
mg	O
dl	O
,	O
haematocrit	O
,	O
leucocytes	O
8000	O
mcl	O
neutrophils	O
75	O
,	O
lymphocytes	O
7	O
,	O
platelets	O
205600	O
mcl	O
.	O
Biochemistry	O
glucose	O
168	O
mg	O
dl	O
,	O
HbA1c	O
7	O
.	O
1	O
,	O
urea	O
39	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
1	O
mg	O
dl	O
,	O
sodium	O
143	O
,	O
potassium	O
5	O
.	O
1	O
,	O
LDH	O
582	O
,	O
C	O
reactive	O
protein	O
20	O
.	O
Coagulation	O
normal	O
.	O
Blood	O
cultures	O
three	O
positive	O
samples	O
for	O
Enterococcus	O
faecalis	O
,	O
sensitive	O
to	O
ampicillin	B-FARMACO
and	O
gentamicin	B-FARMACO
.	O
Urine	O
culture	O
negative	O
.	O
ECG	O
RS	O
at	O
90	O
bpm	O
.	O
Axis	O
60o	O
.	O
First	O
degree	O
BAV	O
280	O
ms	O
QRS	O
less	O
than	O
0	O
.	O
12	O
.	O
Poor	O
progression	O
of	O
R	O
in	O
precordial	O
leads	O
.	O
Rest	O
normal	O
.	O
Transthoracic	O
echocardiogram	O
LV	O
slightly	O
dilated	O
,	O
with	O
end	O
diastolic	O
diameter	O
of	O
62	O
mm	O
.	O
No	O
mild	O
ventricular	O
hypertrophy	O
,	O
normal	O
LVEF	O
55	O
,	O
with	O
paradoxical	O
septal	O
motion	O
,	O
without	O
other	O
alterations	O
of	O
segmental	O
contractility	O
.	O
LA	O
slightly	O
dilated	O
43	O
mm	O
.	O
Aortic	O
metallic	O
prosthesis	O
with	O
normal	O
gradients	O
maximum	O
gradient	O
of	O
17	O
mmHg	O
and	O
mean	O
of	O
9	O
mmHg	O
.	O
Aortic	O
root	O
slightly	O
moderately	O
dilated	O
45	O
mm	O
.	O
Evidence	O
of	O
two	O
yet	O
at	O
the	O
level	O
of	O
ascending	O
thoracic	O
aorta	O
with	O
origin	O
in	O
its	O
tubular	O
sinus	O
portion	O
with	O
orifices	O
of	O
5	O
and	O
3	O
mm	O
respectively	O
,	O
communicating	O
with	O
AD	O
and	O
velocities	O
of	O
4	O
5	O
m	O
s	O
.	O
CCDD	O
slightly	O
dilated	O
.	O
No	O
tricuspid	O
insufficiency	O
to	O
estimate	O
PSAP	O
.	O
Transesophageal	O
echocardiogram	O
in	O
the	O
sinus	O
portion	O
of	O
the	O
aorta	O
,	O
immediately	O
above	O
the	O
valvular	O
plane	O
,	O
multiple	O
pseudoaneurysmal	O
saculations	O
are	O
seen	O
protruding	O
into	O
both	O
atria	O
,	O
with	O
thinned	O
walls	O
.	O
There	O
is	O
a	O
shunt	O
from	O
the	O
left	O
coronary	O
sinus	O
to	O
the	O
right	O
atrium	O
.	O
No	O
shunt	O
is	O
seen	O
between	O
the	O
aorta	O
and	O
RV	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
CTI	O
slightly	O
increased	O
.	O
Chest	O
CT	O
with	O
contrast	O
morphological	O
and	O
functional	O
data	O
normal	O
cardiac	O
cavities	O
.	O
LV	O
of	O
48	O
mm	O
.	O
Parietal	O
septal	O
thickness	O
iv	O
8	O
mm	O
,	O
posterior	O
wall	O
11	O
mm	O
.	O
Normal	O
segmental	O
contractility	O
.	O
Preserved	O
LVEF	O
50	O
.	O
VTD	O
of	O
236	O
cc	O
and	O
VTS	O
120	O
cc	O
.	O
Dilated	O
right	O
ventricle	O
.	O
Atria	O
not	O
dilated	O
.	O
Aortic	O
prosthesis	O
with	O
perivalvular	O
pseudoaneurysmal	O
images	O
,	O
the	O
largest	O
around	O
the	O
left	O
coronary	O
sinus	O
.	O
Below	O
the	O
coronary	O
sinus	O
and	O
at	O
subvalvular	O
level	O
there	O
is	O
a	O
yet	O
of	O
5	O
mm	O
towards	O
the	O
right	O
atrium	O
.	O
The	O
mitral	O
valve	O
is	O
morphologically	O
normal	O
.	O
The	O
rest	O
is	O
normal	O
.	O
Clinical	O
evolution	O
It	O
was	O
decided	O
to	O
admit	O
the	O
patient	O
to	O
hospital	O
.	O
During	O
his	O
stay	O
,	O
the	O
patient	O
remained	O
haemodynamically	O
stable	O
.	O
Broad	O
spectrum	O
antibiotic	O
treatment	O
was	O
started	O
,	O
being	O
replaced	O
by	O
ampicillin	B-FARMACO
and	O
gentamicin	B-FARMACO
after	O
antibiogram	O
.	O
Extracorporeal	O
surgery	O
was	O
performed	O
with	O
deep	O
hypothermia	O
and	O
intermittent	O
blood	O
cardioplegia	O
for	O
adequate	O
myocardial	O
protection	O
,	O
with	O
cannulation	O
of	O
both	O
cavas	O
and	O
ascending	O
aorta	O
.	O
Femoral	O
arteries	O
and	O
veins	O
are	O
cannulated	O
and	O
median	O
resternotomy	O
and	O
release	O
of	O
cardiac	O
adhesions	O
are	O
performed	O
.	O
Clamping	O
of	O
the	O
ascending	O
aorta	O
was	O
performed	O
,	O
with	O
opening	O
of	O
the	O
ascending	O
aorta	O
and	O
right	O
atriotomy	O
,	O
with	O
visualisation	O
of	O
two	O
perivalvular	O
abscesses	O
,	O
one	O
in	O
the	O
mitroaortic	O
junction	O
without	O
fistula	O
to	O
the	O
LA	O
of	O
2	O
3	O
cm	O
in	O
diameter	O
and	O
another	O
abscess	O
at	O
the	O
level	O
of	O
the	O
non	O
coronary	O
sinus	O
with	O
fistulisation	O
to	O
the	O
RA	O
.	O
The	O
aortic	O
prosthesis	O
was	O
explanted	O
and	O
the	O
left	O
cavity	O
drained	O
through	O
the	O
fossa	O
ovalis	O
and	O
both	O
abscesses	O
were	O
closed	O
with	O
a	O
bovine	O
pericardial	O
patch	O
sutured	O
in	O
a	O
circular	O
fashion	O
and	O
a	O
Sant	O
Jude	O
Regent	O
aortic	O
prosthesis	O
number	O
25	O
was	O
implanted	O
,	O
with	O
15	O
U	O
shaped	O
stitches	O
and	O
aortic	O
root	O
lavage	O
.	O
The	O
aortomy	O
and	O
atriotomy	O
were	O
closed	O
with	O
double	O
sutures	O
and	O
the	O
perforation	O
to	O
AD	O
from	O
the	O
right	O
side	O
with	O
stitches	O
supported	O
by	O
pericardium	O
.	O
All	O
this	O
,	O
with	O
adequate	O
haemostatic	O
controls	O
afterwards	O
.	O
With	O
ischaemia	O
time	O
of	O
125	O
minutes	O
and	O
surgical	O
time	O
of	O
143	O
minutes	O
.	O
At	O
the	O
end	O
of	O
the	O
surgery	O
,	O
a	O
transesophageal	O
echocardiogram	O
was	O
performed	O
,	O
with	O
no	O
evidence	O
of	O
flow	O
inside	O
the	O
abscesses	O
.	O
During	O
follow	O
up	O
,	O
the	O
patient	O
has	O
improved	O
functional	O
class	O
and	O
ventricular	O
volumes	O
with	O
LVEDD	O
of	O
55	O
mm	O
,	O
with	O
a	O
slightly	O
depressed	O
LVEF	O
of	O
approximately	O
45	O
.	O
Septal	O
akinesia	O
.	O
Moderately	O
dilated	O
LA	O
.	O
Bidisc	O
prosthesis	O
with	O
normal	O
motion	O
,	O
with	O
gradients	O
in	O
the	O
range	O
of	O
normofunction	O
.	O
Aortic	O
insufficiency	O
with	O
two	O
intraprosthetic	O
mild	O
grade	O
jets	O
.	O
Diagnosis	O
Subacute	O
endocarditis	O
on	O
prosthetic	O
valve	O
due	O
to	O
Enterococcus	O
faecalis	O
complicated	O
by	O
multiple	O
wall	O
abscesses	O
with	O
fistulization	O
to	O
ad	O
.	O
Replacement	O
of	O
mechanical	O
aortic	O
prosthesis	O
closure	O
of	O
abscesses	O
.	O
Mild	O
systolic	O
dysfunction	O
.	O
Carrier	O
of	O
bicameral	O
pacemaker	O
in	O
vvir	O
pacing	O
mode	O
by	O
displacement	O
of	O
atrial	O
electrode	O
.	O
HBP	O
.	O
DL	O
.	O
Type	O
2	O
DM	O
.	O

A	O
77	O
year	O
old	O
man	O
with	O
no	O
drug	O
allergies	O
,	O
hypertension	O
as	O
the	O
only	O
cardiovascular	O
risk	O
factor	O
,	O
on	O
treatment	O
with	O
lisinopril	B-FARMACO
.	O
Other	O
antecedents	O
included	O
nephritic	O
colic	O
,	O
biliary	O
lithiasis	O
and	O
prostatitis	O
.	O
Previously	O
asymptomatic	O
,	O
the	O
patient	O
consulted	O
the	O
emergency	O
department	O
for	O
diaphoresis	O
and	O
dysthermic	O
sensation	O
of	O
24	O
h	O
of	O
evolution	O
,	O
associated	O
with	O
alimentary	O
vomiting	O
,	O
without	O
thermometric	O
fever	O
or	O
abdominal	O
pain	O
.	O
He	O
was	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
.	O
On	O
arrival	O
,	O
temperature	O
37	O
.	O
8oC	O
,	O
blood	O
pressure	O
98	O
56	O
mmHg	O
,	O
HR	O
112	O
bpm	O
and	O
SatO2	O
94	O
on	O
room	O
air	O
.	O
Glasgow	O
14	O
with	O
a	O
tendency	O
to	O
somnolence	O
.	O
Skin	O
pallor	O
with	O
lividity	O
as	O
a	O
sign	O
of	O
poor	O
peripheral	O
perfusion	O
.	O
Rhythmic	O
heart	O
tones	O
,	O
no	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
with	O
preserved	O
vesicular	O
murmur	O
,	O
without	O
rales	O
.	O
The	O
abdomen	O
at	O
this	O
time	O
is	O
depressible	O
,	O
with	O
generalised	O
pain	O
on	O
palpation	O
,	O
without	O
clear	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
extremities	O
.	O
Suspicion	O
of	O
acute	O
abdomen	O
led	O
to	O
a	O
blood	O
test	O
showing	O
acute	O
renal	O
failure	O
with	O
creatinine	O
3	O
.	O
45	O
mg	O
dl	O
and	O
GFR	O
18	O
ml	O
min	O
,	O
metabolic	O
acidosis	O
pH	O
7	O
.	O
3	O
,	O
lactate	O
5	O
mmol	O
l	O
and	O
increased	O
acute	O
phase	O
reactants	O
CRP	O
170	O
mg	O
l	O
,	O
procalcitonin	O
100	O
ng	O
ml	O
,	O
leukocytosis	O
of	O
14	O
,	O
000	O
μl	O
.	O
While	O
in	O
the	O
emergency	O
department	O
awaiting	O
further	O
tests	O
,	O
he	O
presented	O
sudden	O
dyspnoea	O
with	O
significant	O
respiratory	O
work	O
and	O
a	O
slight	O
decrease	O
in	O
the	O
level	O
of	O
consciousness	O
somnolence	O
,	O
pulmonary	O
auscultation	O
compatible	O
with	O
acute	O
pulmonary	O
oedema	O
and	O
electrocardiogram	O
in	O
sinus	O
tachycardia	O
with	O
necrosis	O
and	O
current	O
from	O
an	O
inferoposterior	O
subepicardial	O
lesion	O
.	O
At	O
this	O
point	O
,	O
oxygen	O
therapy	O
was	O
started	O
and	O
the	O
cardiology	O
department	O
was	O
consulted	O
.	O
Bicarbonate	B-FARMACO
perfusion	O
and	O
non	O
invasive	O
mechanical	O
ventilation	O
were	O
started	O
with	O
improvement	O
of	O
the	O
poor	O
perfusion	O
data	O
and	O
a	O
bedside	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
moderate	O
left	O
ventricular	O
dysfunction	O
due	O
to	O
global	O
hypocontractility	O
with	O
inferior	O
hypokinesia	O
,	O
without	O
pericardial	O
effusion	O
.	O
Given	O
the	O
suspicion	O
of	O
Killip	O
IV	O
inferoposterior	O
STEMI	O
,	O
double	O
platelet	O
antiplatelet	O
therapy	O
was	O
administered	O
and	O
emergent	O
coronary	O
angiography	O
was	O
performed	O
,	O
showing	O
2	O
vessel	O
disease	O
with	O
occlusion	O
of	O
the	O
right	O
coronary	O
artery	O
at	O
distal	O
level	O
,	O
on	O
which	O
PCI	O
was	O
performed	O
with	O
implantation	O
of	O
a	O
drug	O
eluting	O
stent	O
.	O
During	O
the	O
procedure	O
,	O
he	O
presented	O
progressive	O
haemodynamic	O
deterioration	O
,	O
so	O
intravenous	O
perfusion	O
of	O
dobutamine	B-FARMACO
was	O
started	O
.	O
Despite	O
this	O
,	O
the	O
patient	O
continued	O
to	O
deteriorate	O
with	O
frank	O
hypotension	O
and	O
tachycardia	O
,	O
and	O
it	O
was	O
decided	O
to	O
add	O
noradrenaline	B-FARMACO
and	O
implant	O
an	O
intra	O
aortic	O
balloon	O
counterpulsation	O
device	O
.	O
After	O
this	O
,	O
he	O
was	O
admitted	O
to	O
the	O
cardiac	O
critical	O
care	O
unit	O
.	O
COMPLEMENTARY	O
TESTS	O
In	O
the	O
emergency	O
department	O
Blood	O
tests	O
Glucose	O
214	O
mg	O
dl	O
,	O
urea	O
84	O
mg	O
dl	O
,	O
creatinine	O
3	O
.	O
45	O
mg	O
dl	O
,	O
bilirubin	O
1	O
.	O
35	O
mg	O
dl	O
,	O
GOT	O
113	O
U	O
l	O
,	O
GPT	O
45	O
U	O
l	O
,	O
Na	O
135	O
.	O
6	O
mEq	O
l	O
,	O
K	O
5	O
'	O
17	O
mEq	O
l	O
,	O
Cl	O
99	O
mEq	O
l	O
,	O
CRP	O
178	O
mg	O
l	O
,	O
procalcitonin	O
100	O
mg	O
l	O
.	O
Haemogram	O
leucocytes	O
14	O
,	O
590	O
μl	O
77	O
neutrophils	O
,	O
haemoglobin	O
18	O
.	O
8	O
g	O
dl	O
,	O
haematocrit	O
55	O
.	O
2	O
,	O
platelets	O
311	O
,	O
000	O
μl	O
.	O
INR	O
1	O
.	O
19	O
.	O
DD	O
3	O
,	O
443	O
ng	O
ml	O
.	O
Markers	O
of	O
myocardial	O
necrosis	O
troponin	O
I	O
US	O
11	O
,	O
955	O
pg	O
ml	O
normal	O
25	O
pg	O
ml	O
,	O
CK	O
1	O
,	O
265	O
U	O
l	O
.	O
Blood	O
gases	O
pH	O
7	O
.	O
01	O
,	O
bicarbonate	B-FARMACO
17	O
.	O
4	O
mmol	O
l	O
,	O
lactate	O
15	O
.	O
5	O
mmol	O
l	O
.	O
Chest	O
X	O
ray	O
,	O
paucisymptomatic	O
cardiac	O
silhouette	O
of	O
normal	O
size	O
,	O
free	O
costophrenic	O
sinuses	O
.	O
Normal	O
lung	O
parenchyma	O
.	O
ECG	O
sinus	O
tachycardia	O
at	O
138	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
QR	O
pattern	O
in	O
DII	O
,	O
DIII	O
and	O
aVF	O
with	O
ST	O
segment	O
elevation	O
of	O
4	O
5	O
mm	O
.	O
ST	O
segment	O
depression	O
of	O
1	O
mm	O
in	O
DI	O
,	O
2	O
mm	O
in	O
aVL	O
due	O
to	O
reciprocal	O
changes	O
.	O
Flat	O
ST	O
segment	O
depression	O
up	O
to	O
4	O
mm	O
in	O
V1	O
V3	O
.	O
Echocardioscopy	O
LV	O
systolic	O
function	O
at	O
least	O
moderately	O
depressed	O
by	O
global	O
hypocontractility	O
and	O
severe	O
inferior	O
hypokinesia	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Emergent	O
coronary	O
angiography	O
2	O
vessel	O
coronary	O
artery	O
disease	O
Anterior	O
descending	O
with	O
diffuse	O
atheromatosis	O
,	O
ectatic	O
area	O
at	O
mid	O
level	O
with	O
40	O
stenosis	O
,	O
in	O
distal	O
LAD	O
70	O
lesion	O
.	O
Right	O
coronary	O
ectatic	O
vessel	O
with	O
occlusion	O
in	O
the	O
middle	O
segment	O
.	O
Percutaneous	O
coronary	O
intervention	O
with	O
implantation	O
of	O
1	O
drug	O
eluting	O
stent	O
.	O
In	O
the	O
cardiology	O
critical	O
care	O
unit	O
Abdominal	O
X	O
ray	O
levels	O
suggestive	O
of	O
upper	O
intestinal	O
obstruction	O
in	O
the	O
left	O
hypochondrium	O
.	O
Chest	O
X	O
ray	O
increased	O
perihilar	O
density	O
with	O
bilateral	O
vascular	O
redistribution	O
.	O
Abdominal	O
CT	O
scan	O
findings	O
compatible	O
with	O
obstructive	O
intestinal	O
ileus	O
of	O
biliary	O
origin	O
.	O
Microbiology	O
Urinary	O
sediment	O
erythrocytes	O
51	O
80	O
field	O
,	O
leukocytes	O
3	O
5	O
field	O
.	O
Blood	O
cultures	O
Bacteroides	O
vulgatus	O
.	O
Urine	O
culture	O
negative	O
.	O
Tracheal	O
aspirate	O
negative	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
admission	O
to	O
the	O
critical	O
cardiology	O
unit	O
,	O
haemodynamic	O
instability	O
persisted	O
under	O
perfusion	O
with	O
noradrenaline	B-FARMACO
,	O
dobutamine	B-FARMACO
and	O
intra	O
aortic	O
balloon	O
counterpulsation	O
.	O
Due	O
to	O
progressive	O
respiratory	O
worsening	O
,	O
orotracheal	O
intubation	O
and	O
mechanical	O
ventilation	O
were	O
decided	O
.	O
Swan	O
Ganz	O
catheter	O
was	O
implanted	O
and	O
the	O
following	O
parameters	O
were	O
obtained	O
,	O
compatible	O
with	O
distributive	O
shock	O
mean	O
arterial	O
pressure	O
70	O
mmHg	O
,	O
HR	O
125	O
bpm	O
,	O
central	O
venous	O
pressure	O
6	O
mmHg	O
,	O
pulmonary	O
artery	O
pressure	O
32	O
18	O
mmHg	O
,	O
pulmonary	O
capillary	O
pressure	O
12	O
mmHg	O
,	O
cardiac	O
output	O
6	O
.	O
8	O
l	O
min	O
,	O
cardiac	O
index	O
3	O
.	O
47	O
l	O
min	O
m	O
,	O
systemic	O
vascular	O
resistances	O
752	O
dyn	O
s	O
cm	O
.	O
Following	O
these	O
findings	O
,	O
intensive	O
fluid	O
therapy	O
is	O
started	O
,	O
noradrenaline	B-FARMACO
dose	O
is	O
increased	O
and	O
dobutamine	B-FARMACO
dose	O
is	O
reduced	O
.	O
Intra	O
aortic	O
balloon	O
counterpulsation	O
support	O
was	O
decreased	O
to	O
1	O
2	O
and	O
withdrawn	O
after	O
a	O
few	O
hours	O
along	O
with	O
dobutamine	B-FARMACO
.	O
In	O
view	O
of	O
the	O
suspicion	O
of	O
intestinal	O
occlusive	O
symptoms	O
,	O
a	O
nasogastric	O
tube	O
was	O
placed	O
with	O
a	O
1	O
litre	O
fecal	O
contents	O
debit	O
.	O
Good	O
haemodynamic	O
evolution	O
with	O
adjustment	O
of	O
vasoactive	O
treatment	O
guided	O
by	O
information	O
from	O
the	O
Swan	O
Ganz	O
catheter	O
,	O
with	O
a	O
control	O
echocardiography	O
showing	O
preserved	O
ventricular	O
function	O
.	O
A	O
thoracoabdominal	O
CT	O
scan	O
was	O
performed	O
showing	O
findings	O
compatible	O
with	O
obstructive	O
intestinal	O
ileus	O
of	O
biliary	O
origin	O
.	O
A	O
multidisciplinary	O
team	O
cardiology	O
,	O
surgery	O
,	O
anaesthesia	O
and	O
intensive	O
care	O
unit	O
agreed	O
on	O
the	O
indication	O
for	O
surgery	O
and	O
decided	O
to	O
delay	O
it	O
until	O
haemodynamic	O
stabilisation	O
.	O
Fever	O
persisted	O
at	O
the	O
infectious	O
level	O
.	O
Blood	O
cultures	O
were	O
taken	O
and	O
empirical	O
antibiotic	O
therapy	O
with	O
piperacillin	B-FARMACO
tazobactam	I-FARMACO
was	O
prescribed	O
.	O
Microbiological	O
screening	O
showed	O
Bacteroides	O
vulgatus	O
in	O
blood	O
cultures	O
,	O
compatible	O
with	O
sepsis	O
of	O
abdominal	O
origin	O
.	O
Finally	O
,	O
after	O
48	O
hours	O
,	O
supra	O
infraumbilical	O
laparotomy	O
was	O
performed	O
,	O
opting	O
to	O
maintain	O
the	O
double	O
antiplatelet	O
therapy	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
and	O
clopidogrel	B-FARMACO
during	O
the	O
operation	O
due	O
to	O
the	O
high	O
thrombotic	O
risk	O
following	O
the	O
recent	O
stent	O
implantation	O
in	O
an	O
ectatic	O
vessel	O
that	O
had	O
an	O
abundant	O
amount	O
of	O
thrombotic	O
material	O
.	O
During	O
surgery	O
,	O
seropurulent	O
free	O
fluid	O
and	O
biliary	O
ileus	O
were	O
found	O
,	O
resulting	O
in	O
a	O
punctate	O
perforation	O
of	O
the	O
jejuno	O
ileum	O
,	O
and	O
resection	O
and	O
anastomosis	O
were	O
performed	O
.	O
After	O
surgery	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
,	O
with	O
a	O
slow	O
but	O
correct	O
evolution	O
,	O
and	O
was	O
finally	O
discharged	O
home	O
after	O
15	O
days	O
of	O
hospitalisation	O
.	O
The	O
echocardiogram	O
at	O
discharge	O
showed	O
mild	O
LV	O
systolic	O
dysfunction	O
due	O
to	O
inferior	O
hypokinesia	O
LVEF	O
49	O
.	O
Treatment	O
at	O
discharge	O
consisted	O
of	O
double	O
antiplatelet	O
therapy	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
24	O
h	O
and	O
clopidogrel	B-FARMACO
75	O
mg	O
24	O
h	O
,	O
neurohormonal	O
treatment	O
with	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
h	O
and	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
h	O
and	O
treatment	O
with	O
a	O
high	O
potency	O
statin	B-FARMACO
atorvastatin	I-FARMACO
80	O
mg	O
24	O
h	O
.	O
DIAGNOSIS	O
Septic	O
shock	O
with	O
multi	O
organ	O
dysfunction	O
,	O
secondary	O
to	O
peritonitis	O
due	O
to	O
intestinal	O
perforation	O
caused	O
by	O
biliary	O
ileus	O
.	O
Bacteraemia	O
due	O
to	O
Bacteroides	O
vulgatus	O
.	O
Acute	O
infero	O
posterior	O
myocardial	O
infarction	O
in	O
the	O
previous	O
context	O
.	O
Urgent	O
percutaneous	O
revascularisation	O
of	O
the	O
middle	O
right	O
coronary	O
artery	O
.	O
Moderate	O
systolic	O
dysfunction	O
in	O
acute	O
phase	O
,	O
mild	O
at	O
discharge	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
family	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
Personal	O
history	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
grade	O
I	O
obesity	O
.	O
No	O
known	O
hypertension	O
,	O
dyslipidaemia	O
or	O
diabetes	O
mellitus	O
.	O
Cardiological	O
history	O
On	O
outpatient	O
follow	O
up	O
for	O
cardiac	O
amyloidosis	O
type	O
AL	O
diagnosed	O
in	O
December	O
2018	O
in	O
NYHA	O
functional	O
class	O
I	O
IV	O
.	O
Pyrophosphate	O
cardiac	O
scan	O
Tc99m	O
DPD	O
pathological	O
radiotracer	O
deposit	O
was	O
observed	O
,	O
with	O
biventricular	O
distribution	O
and	O
intensity	O
greater	O
than	O
that	O
of	O
the	O
adjacent	O
bone	O
grade	O
3	O
,	O
compatible	O
with	O
cardiac	O
amyloidosis	O
.	O
Transthoracic	O
echocardiogram	O
slightly	O
hypertrophic	O
left	O
ventricle	O
with	O
preserved	O
LVEF	O
.	O
Mild	O
mitral	O
insufficiency	O
without	O
other	O
significant	O
valvulopathies	O
.	O
No	O
pericardial	O
effusion	O
.	O
Other	O
history	O
Known	O
chronic	O
hepatitis	O
C	O
since	O
1991	O
.	O
Genotype	O
1b	O
.	O
Has	O
received	O
paritaprevir	B-FARMACO
ritonavir	I-FARMACO
ombitasvir	I-FARMACO
150	O
100	O
25	O
mg	O
one	O
tablet	O
daily	O
plus	O
dasabuvir	B-FARMACO
250	O
mg	O
twice	O
daily	O
in	O
May	O
August	O
2015	O
,	O
with	O
sustained	O
virological	O
response	O
cured	O
infection	O
.	O
AL	O
amyloidosis	O
with	O
histological	O
confirmation	O
.	O
Diagnosis	O
in	O
December	O
2018	O
with	O
cardiac	O
and	O
renal	O
involvement	O
;	O
6	O
cycles	O
of	O
bortezomib	B-FARMACO
,	O
cyclophosphamide	B-FARMACO
and	O
dexamethasone	B-FARMACO
are	O
planned	O
,	O
on	O
admission	O
she	O
is	O
on	O
her	O
fourth	O
cycle	O
.	O
A	O
renal	O
biopsy	O
was	O
performed	O
,	O
with	O
the	O
result	O
of	O
AL	O
amyloidosis	O
.	O
After	O
renal	O
biopsy	O
,	O
complication	O
with	O
retroperitoneal	O
haematoma	O
requiring	O
embolectomy	O
.	O
Usual	O
medication	O
Omeprazole	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
,	O
acyclovir	B-FARMACO
800	O
1	O
0	O
0	O
,	O
hydroferol	B-FARMACO
1	O
15	O
days	O
,	O
allopurinol	B-FARMACO
100	O
1	O
1	O
1	O
,	O
formoterol	B-FARMACO
budesonide	I-FARMACO
160	O
4	O
.	O
5	O
mcg	O
1	O
0	O
1	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
1	O
0	O
.	O
Chemotherapy	O
treatment	O
of	O
myeloma	O
with	O
CyBorDex	B-FARMACO
cyclophosphamide	I-FARMACO
bortezomib	I-FARMACO
dexamethasone	I-FARMACO
.	O
Current	O
disease	O
A	O
63	O
year	O
old	O
male	O
patient	O
with	O
the	O
aforementioned	O
history	O
,	O
who	O
while	O
admitted	O
to	O
the	O
haematology	O
department	O
for	O
febrile	O
syndrome	O
,	O
under	O
active	O
treatment	O
for	O
multiple	O
myeloma	O
,	O
presented	O
with	O
a	O
condition	O
characterised	O
by	O
palpitations	O
.	O
When	O
vital	O
signs	O
were	O
taken	O
,	O
an	O
arrhythmic	O
and	O
rapid	O
pulse	O
curve	O
was	O
observed	O
,	O
and	O
an	O
electrocardiogram	O
ECG	O
was	O
requested	O
,	O
confirming	O
the	O
suspected	O
diagnosis	O
.	O
In	O
view	O
of	O
the	O
ECG	O
findings	O
,	O
a	O
cardiology	O
assessment	O
was	O
requested	O
.	O
She	O
denied	O
current	O
or	O
previous	O
chest	O
pain	O
.	O
Physical	O
examination	O
Conscious	O
and	O
oriented	O
in	O
person	O
,	O
time	O
and	O
place	O
.	O
Collaborative	O
,	O
eupneic	O
at	O
rest	O
and	O
afebrile	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
heart	O
sounds	O
,	O
tachycardic	O
,	O
systolic	O
murmur	O
II	O
VI	O
in	O
mitral	O
focus	O
not	O
radiating	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
sounds	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
.	O
No	O
pain	O
on	O
superficial	O
or	O
deep	O
palpation	O
,	O
no	O
visceromegaly	O
.	O
Preserved	O
hydro	O
aerial	O
sounds	O
.	O
Lower	O
extremities	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Palpable	O
paedial	O
pulses	O
.	O
No	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
count	O
haemoglobin	O
14	O
.	O
2	O
g	O
dl	O
.	O
Red	O
blood	O
cells	O
5	O
.	O
47	O
x10	O
μl	O
.	O
Haematocrit	O
42	O
.	O
3	O
.	O
MCV	O
.	O
84	O
.	O
3	O
fl	O
.	O
Leukocytes	O
3	O
.	O
24	O
x10	O
μ	O
.	O
Neutrophils	O
blood	O
58	O
.	O
7	O
.	O
Lymphocytes	O
33	O
.	O
1	O
.	O
Platelets	O
123	O
x10	O
.	O
Biochemistry	O
glucose	O
111	O
mg	O
dl	O
.	O
Urea	O
91	O
mg	O
d	O
.	O
Creatinine	O
1	O
.	O
52	O
mg	O
dl	O
.	O
Estimated	O
glomerular	O
filtration	O
rate	O
48	O
ml	O
min	O
m	O
.	O
Sodium	O
ion	O
142	O
mmol	O
.	O
Potassium	O
ion	O
4	O
.	O
1	O
mmol	O
l	O
.	O
NT	O
proBNP	O
5	O
,	O
174	O
ng	O
d	O
.	O
VN	O
350	O
.	O
C	O
reactive	O
protein	O
0	O
.	O
2	O
mg	O
dl	O
.	O
Serial	O
myocardial	O
damage	O
markers	O
during	O
admission	O
48	O
hours	O
creatine	O
kinase	O
61	O
49	O
U	O
l	O
.	O
Ultrasensitive	O
troponin	O
T	O
24	O
26	O
ng	O
l	O
.	O
Coagulation	O
T	O
.	O
prothrombin	O
13	O
.	O
00	O
sec	O
.	O
T	O
.	O
partial	O
thromboplastin	O
R	O
.	O
0	O
.	O
98	O
T	O
.	O
prothrombin	O
82	O
.	O
0	O
.	O
Derived	O
fibrinogen	O
477	O
.	O
Prothrombin	O
T	O
.	O
ratio	O
1	O
.	O
14	O
.	O
INR	O
1	O
.	O
14	O
T	O
.	O
partial	O
thromboplastin	O
30	O
.	O
90	O
sec	O
.	O
ECG	O
AF	O
at	O
150	O
L	O
min	O
,	O
narrow	O
QRS	O
,	O
low	O
voltages	O
in	O
limb	O
leads	O
,	O
abnormal	O
R	O
wave	O
progression	O
in	O
precordial	O
leads	O
,	O
normal	O
axis	O
,	O
inverted	O
T	O
waves	O
in	O
high	O
lateral	O
face	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
,	O
no	O
pinched	O
costophrenic	O
angles	O
or	O
increased	O
vascular	O
pattern	O
.	O
Transthoracic	O
echocardiogram	O
normal	O
sized	O
left	O
ventricle	O
with	O
mild	O
hypertrophy	O
interventricular	O
septum	O
thickness	O
14mm	O
,	O
mild	O
global	O
hypokinesia	O
resulting	O
in	O
an	O
LVEF	O
40	O
.	O
Right	O
ventricle	O
RV	O
slightly	O
dilated	O
with	O
mild	O
hypokinesia	O
of	O
the	O
free	O
wall	O
,	O
moderate	O
low	O
functional	O
mitral	O
insufficiency	O
and	O
moderate	O
tricuspid	O
insufficiency	O
with	O
estimated	O
PSAP	O
of	O
33mmHg	O
PVC	O
.	O
Previous	O
complementary	O
tests	O
of	O
interest	O
pyrophosphate	O
scintigraphy	O
Tc99m	O
DPD	O
image	O
2	O
a	O
pathological	O
deposit	O
of	O
radiotracer	O
was	O
observed	O
,	O
with	O
biventricular	O
distribution	O
and	O
intensity	O
greater	O
than	O
that	O
of	O
the	O
adjacent	O
bone	O
grade	O
3	O
,	O
compatible	O
with	O
cardiac	O
amyloidosis	O
.	O
CLINICAL	O
EVOLUTION	O
A	O
63	O
year	O
old	O
male	O
patient	O
was	O
admitted	O
to	O
the	O
haematology	O
department	O
for	O
febrile	O
syndrome	O
,	O
being	O
at	O
the	O
time	O
of	O
admission	O
under	O
active	O
treatment	O
for	O
multiple	O
myeloma	O
with	O
multiple	O
organ	O
involvement	O
and	O
presenting	O
with	O
an	O
episode	O
of	O
atrial	O
fibrillation	O
.	O
The	O
patient	O
commented	O
that	O
the	O
symptoms	O
had	O
started	O
suddenly	O
2	O
hours	O
prior	O
to	O
our	O
assessment	O
.	O
An	O
ECG	O
was	O
performed	O
showing	O
AF	O
with	O
a	O
previously	O
unknown	O
rapid	O
ventricular	O
response	O
.	O
Given	O
that	O
the	O
patient	O
clearly	O
noticed	O
the	O
onset	O
of	O
symptoms	O
and	O
that	O
vital	O
parameters	O
had	O
been	O
within	O
normal	O
limits	O
in	O
the	O
previous	O
24	O
hours	O
heart	O
rate	O
around	O
60	O
80	O
per	O
minute	O
,	O
it	O
was	O
decided	O
to	O
manage	O
the	O
patient	O
with	O
rhythm	O
control	O
.	O
After	O
bolus	O
and	O
infusion	O
amiodarone	B-FARMACO
,	O
the	O
patient	O
recovered	O
sinus	O
rhythm	O
about	O
5	O
hours	O
later	O
.	O
Treatment	O
with	O
oral	O
amiodarone	B-FARMACO
and	O
beta	O
blockers	O
was	O
discontinued	O
.	O
An	O
echocardiogram	O
was	O
performed	O
already	O
in	O
SR	B-FARMACO
showing	O
a	O
slightly	O
hypertrophic	O
left	O
ventricle	O
with	O
normal	O
size	O
and	O
function	O
,	O
with	O
left	O
atrial	O
enlargement	O
,	O
normal	O
right	O
chambers	O
,	O
low	O
moderate	O
mitral	O
regurgitation	O
and	O
minimally	O
elevated	O
PSAP	O
.	O
The	O
patient	O
progressed	O
satisfactorily	O
and	O
did	O
not	O
develop	O
signs	O
or	O
symptoms	O
of	O
congestive	O
heart	O
failure	O
.	O
The	O
management	O
of	O
anticoagulation	O
with	O
this	O
patient	O
,	O
having	O
a	O
CHADS2	O
VA2SC	O
of	O
1	O
CHF	O
was	O
a	O
challenge	O
,	O
as	O
the	O
patient	O
is	O
not	O
adequately	O
represented	O
in	O
current	O
clinical	O
practice	O
guidelines	O
.	O
Being	O
a	O
patient	O
with	O
this	O
score	O
on	O
the	O
CHADS2	O
VA2SC	O
scale	O
and	O
having	O
AL	O
cardiac	O
amyloidosis	O
as	O
comorbidity	O
,	O
it	O
was	O
decided	O
,	O
in	O
consensus	O
with	O
the	O
haematology	O
service	O
,	O
to	O
initiate	O
anticoagulation	O
treatment	O
with	O
rivaroxaban	B-FARMACO
,	O
as	O
he	O
was	O
a	O
patient	O
at	O
high	O
thromboembolic	O
risk	O
.	O
DIAGNOSIS	O
AL	O
cardiac	O
amyloidosis	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
,	O
pharmacological	O
cardioversion	O
.	O
CHADS2	O
VA2SC	O
1	O
point	O
.	O
Moderately	O
impaired	O
LVEF	O
.	O
Moderate	O
low	O
mitral	O
insufficiency	O
.	O
Multiple	O
myeloma	O
with	O
cardiac	O
and	O
renal	O
involvement	O
in	O
active	O
treatment	O
.	O
Febrile	O
syndrome	O
in	O
patient	O
with	O
mild	O
bicytopenia	O
.	O
Chronic	O
renal	O
disease	O
secondary	O
to	O
monoclonal	O
gammopathy	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
58	O
year	O
old	O
man	O
with	O
a	O
history	O
of	O
smoking	O
cessation	O
,	O
arterial	O
hypertension	O
,	O
chronic	O
bronchopathy	O
,	O
microcrystalline	O
arthropathy	O
,	O
atrial	O
fibrillation	O
,	O
mitral	O
annuloplasty	O
two	O
years	O
earlier	O
for	O
severe	O
valvular	O
insufficiency	O
and	O
last	O
admission	O
for	O
decompensation	O
of	O
heart	O
failure	O
a	O
few	O
months	O
earlier	O
due	O
to	O
consumption	O
of	O
non	O
steroidal	O
anti	O
inflammatory	O
drugs	O
and	O
anaemia	O
.	O
Last	O
transthoracic	O
echocardiogram	O
the	O
previous	O
year	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
slight	O
hypertrophy	O
and	O
preserved	O
ejection	O
fraction	O
.	O
Mitral	O
annulopasty	O
with	O
residual	O
insufficiency	O
III	O
IV	O
IV	O
.	O
Moderate	O
pulmonary	O
hypertension	O
.	O
Bicuspid	O
aortic	O
valve	O
.	O
On	O
the	O
other	O
hand	O
,	O
at	O
the	O
end	O
of	O
last	O
year	O
a	O
low	O
anterior	O
intestinal	O
resection	O
was	O
performed	O
for	O
a	O
colon	O
carcinoma	O
in	O
the	O
rectum	O
sigmoid	O
junction	O
,	O
diagnosed	O
as	O
a	O
result	O
of	O
an	O
anaemia	O
study	O
.	O
Previous	O
treatments	O
dabigatran	B-FARMACO
150	O
mg	O
1	O
0	O
1	O
;	O
allopurinol	B-FARMACO
300	O
mg	O
1	O
0	O
1	O
;	O
furosemide	B-FARMACO
40	O
mg	O
1	O
0	O
0	O
;	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
,	O
tiotropium	B-FARMACO
bromide	I-FARMACO
18	O
mcg	O
1	O
0	O
0	O
;	O
budesonide	B-FARMACO
200	O
mcg	O
1	O
0	O
1	O
;	O
ferrous	B-FARMACO
sulphate	I-FARMACO
1	O
0	O
0	O
;	O
alendronic	B-FARMACO
acid	I-FARMACO
70	O
mg	O
1	O
every	O
7	O
days	O
;	O
calcium	B-FARMACO
carbonate	I-FARMACO
500	O
mg	O
400	O
IU	O
1	O
0	O
0	O
.	O
The	O
patient	O
is	O
currently	O
attending	O
the	O
emergency	O
department	O
for	O
a	O
2	O
month	O
history	O
of	O
dyspnoea	O
,	O
predominantly	O
nocturnal	O
with	O
2	O
pillow	O
orthopnoea	O
,	O
paroxysmal	O
nocturnal	O
dyspnoea	O
,	O
progressive	O
deterioration	O
of	O
functional	O
class	O
and	O
cough	O
without	O
expectoration	O
.	O
In	O
addition	O
,	O
the	O
previous	O
4	O
days	O
he	O
started	O
a	O
febrile	O
condition	O
with	O
temperatures	O
up	O
to	O
38	O
.	O
2	O
oC	O
.	O
In	O
the	O
ED	O
he	O
presented	O
with	O
acceptable	O
general	O
condition	O
and	O
mild	O
tachypnoea	O
,	O
maintaining	O
baseline	O
oxygen	O
saturations	O
of	O
98	O
.	O
Cardiopulmonary	O
auscultation	O
revealed	O
a	O
systolic	O
murmur	O
in	O
mitral	O
focus	O
and	O
bibasal	O
crackles	O
.	O
No	O
other	O
findings	O
of	O
interest	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
Biochemistry	O
glucose	O
162	O
.	O
5	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
17	O
mg	O
dl	O
.	O
Sodium	O
135	O
.	O
6	O
mEq	O
l	O
.	O
Potassium	O
4	O
.	O
52	O
mEq	O
l	O
.	O
Chlorine	O
98	O
.	O
6	O
mEq	O
litre	O
.	O
Total	O
protein	O
6	O
.	O
27	O
g	O
dl	O
.	O
Albumin	O
3	O
.	O
29	O
g	O
dl	O
.	O
ALT	O
GPT	O
12	O
,	O
3	O
U	O
l	O
.	O
AST	O
GOT	O
14	O
,	O
4	O
U	O
l	O
.	O
Gamma	O
GT	O
18	O
U	O
l	O
.	O
Alkaline	O
phosphatase	O
76	O
U	O
l	O
.	O
LDH	O
282	O
U	O
l	O
.	O
Bilirubin	O
.	O
51	O
mg	O
dl	O
.	O
C	O
reactive	O
protein	O
13	O
.	O
78	O
mg	O
dl	O
.	O
Iron	O
16	O
mcg	O
dl	O
59	O
158	O
Ferritin	O
99	O
ng	O
ml	O
30	O
400	O
.	O
Transferrin	O
233	O
mg	O
dl	O
200	O
360	O
.	O
TIBC	O
329	O
mcg	O
dl	O
250	O
400	O
.	O
Transferrin	O
saturation	O
4	O
.	O
9	O
20	O
.	O
0	O
50	O
.	O
0	O
NT	O
proBNP	O
2729	O
pg	O
ml	O
X2	O
with	O
respect	O
to	O
previous	O
.	O
Haemolysis	O
index	O
1	O
.	O
Lipaemia	O
index	O
12	O
.	O
Haematology	O
leucocytes	O
9	O
.	O
4	O
x1000	O
μl	O
.	O
Red	O
cells	O
3	O
.	O
87	O
xmill	O
μl	O
.	O
Haemoglobin	O
8	O
.	O
6	O
g	O
dl	O
previous	O
9	O
.	O
7	O
.	O
Haematocrit	O
27	O
.	O
3	O
.	O
MCV	O
70	O
.	O
5	O
fl	O
.	O
MCH	O
22	O
.	O
2	O
pg	O
.	O
MCHC	O
31	O
.	O
5	O
g	O
dl	O
.	O
RDW	O
20	O
.	O
Platelets	O
240	O
x1000	O
μl	O
.	O
MPV	O
7	O
.	O
2	O
fl	O
.	O
Neutrophils	O
7	O
.	O
1	O
x1000	O
μl	O
.	O
Neutrophils	O
75	O
.	O
6	O
.	O
Lymphocytes	O
1	O
.	O
2	O
x1000	O
μl	O
.	O
Lymphocytes	O
12	O
.	O
3	O
.	O
Monocytes	O
1	O
.	O
1	O
x1000	O
μl	O
Monocytes	O
11	O
.	O
5	O
.	O
Eosinophils	O
0	O
x1000	O
μl	O
.	O
Eosinophils	O
.	O
2	O
Basophils	O
0	O
x1000	O
μl	O
Basophils	O
0	O
.	O
Haemostasis	O
prothrombin	O
activity	O
70	O
.	O
INR	O
1	O
.	O
28	O
.	O
TTPa	O
36	O
.	O
6	O
sec	O
.	O
Fibrinogen	O
derivative	O
869	O
mg	O
dl	O
.	O
D	O
dimer	O
507	O
ng	O
ml	O
.	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
86	O
beats	O
,	O
left	O
axis	O
,	O
widened	O
QRS	O
with	O
image	O
compatible	O
with	O
complete	O
left	O
bundle	O
branch	O
block	O
,	O
without	O
other	O
relevant	O
findings	O
.	O
Similar	O
to	O
previous	O
ones	O
.	O
Chest	O
X	O
ray	O
evidence	O
of	O
heart	O
failure	O
without	O
clear	O
consolidations	O
.	O
Nasopharyngeal	O
exudate	O
x2	O
negative	O
for	O
SARS	O
CoV	O
2	O
.	O
Blood	O
cultures	O
2	O
sets	O
isolation	O
of	O
ampicillin	B-FARMACO
resistant	O
Enterococcus	O
faecium	O
,	O
sensitive	O
to	O
linezolid	B-FARMACO
,	O
glycopeptides	O
,	O
daptomycin	B-FARMACO
and	O
synergy	O
with	O
gentamicin	B-FARMACO
.	O
Transthoracic	O
echocardiogram	O
biventricular	O
dilatation	O
.	O
Mitral	O
and	O
aortic	O
insufficiency	O
at	O
least	O
moderate	O
.	O
Transesophageal	O
echocardiogram	O
bicuspid	O
aortic	O
valve	O
with	O
infiltration	O
and	O
destructuring	O
of	O
the	O
entire	O
fused	O
leaflet	O
that	O
prolapses	O
and	O
causes	O
severe	O
insufficiency	O
,	O
with	O
probable	O
perforation	O
of	O
the	O
leaflet	O
.	O
Thickening	O
of	O
the	O
posterior	O
wall	O
of	O
the	O
aorta	O
,	O
surrounding	O
the	O
left	O
coronary	O
artery	O
,	O
which	O
cannot	O
be	O
ruled	O
out	O
as	O
abscessation	O
at	O
that	O
level	O
.	O
Holodiastolic	O
inversion	O
pattern	O
in	O
descending	O
thoracic	O
aorta	O
.	O
Mitral	O
annuloplasty	O
with	O
a	O
12	O
mm	O
filiform	O
and	O
mobile	O
image	O
suggestive	O
of	O
vegetation	O
,	O
leading	O
to	O
severe	O
valvular	O
insufficiency	O
.	O
Magnetic	O
resonance	O
imaging	O
of	O
the	O
brain	O
no	O
intracranial	O
complications	O
of	O
interest	O
were	O
observed	O
.	O
CLINICAL	O
EVOLUTION	O
Initially	O
,	O
under	O
the	O
diagnosis	O
of	O
heart	O
failure	O
probably	O
related	O
to	O
anaemia	O
,	O
the	O
patient	O
was	O
transfused	O
with	O
red	O
blood	O
cell	O
concentrate	O
and	O
depletive	O
treatment	O
was	O
started	O
,	O
with	O
substantial	O
clinical	O
improvement	O
.	O
However	O
,	O
although	O
the	O
patient	O
's	O
dyspnoea	O
and	O
non	O
productive	O
cough	O
could	O
be	O
attributed	O
to	O
his	O
decompensation	O
of	O
heart	O
failure	O
,	O
given	O
the	O
current	O
epidemiological	O
context	O
,	O
especially	O
with	O
the	O
febrile	O
peak	O
,	O
it	O
was	O
imperative	O
to	O
rule	O
out	O
SARS	O
CoV	O
2	O
infection	O
,	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
COVID	O
19	O
hospital	O
and	O
treatment	O
with	O
hydroxychloroquine	B-FARMACO
was	O
initiated	O
.	O
Two	O
negative	O
nasopharyngeal	O
swabs	O
were	O
obtained	O
,	O
which	O
,	O
together	O
with	O
the	O
positivity	O
in	O
the	O
two	O
sets	O
of	O
blood	O
cultures	O
for	O
E	O
.	O
faecium	O
,	O
made	O
it	O
possible	O
to	O
reasonably	O
rule	O
out	O
the	O
diagnosis	O
of	O
coronavirus	O
infection	O
and	O
direct	O
the	O
focus	O
towards	O
a	O
diagnosis	O
of	O
heart	O
failure	O
in	O
the	O
context	O
of	O
infective	O
endocarditis	O
and	O
exacerbation	O
of	O
chronic	O
anaemia	O
.	O
He	O
was	O
therefore	O
transferred	O
from	O
the	O
internal	O
medicine	O
ward	O
of	O
COVID	O
19	O
to	O
the	O
cardiology	O
ward	O
,	O
starting	O
empirical	O
antibiotherapy	O
with	O
daptomycin	B-FARMACO
at	O
the	O
time	O
of	O
positive	O
blood	O
cultures	O
.	O
Once	O
the	O
antibiogram	O
was	O
known	O
,	O
it	O
was	O
decided	O
to	O
extend	O
coverage	O
by	O
adding	O
ampicillin	B-FARMACO
and	O
gentamicin	B-FARMACO
.	O
The	O
case	O
was	O
presented	O
to	O
the	O
cardiac	O
surgery	O
department	O
,	O
who	O
accepted	O
the	O
patient	O
for	O
intervention	O
.	O
A	O
brain	O
MRI	O
was	O
performed	O
which	O
ruled	O
out	O
significant	O
neurological	O
complications	O
.	O
However	O
,	O
it	O
was	O
decided	O
to	O
take	O
another	O
exudate	O
for	O
SARS	O
CoV	O
2	O
PCR	O
as	O
a	O
precautionary	O
measure	O
,	O
and	O
the	O
result	O
was	O
positive	O
.	O
The	O
patient	O
was	O
therefore	O
transferred	O
back	O
to	O
the	O
COVID	O
19	O
internal	O
medicine	O
hospital	O
for	O
medical	O
treatment	O
until	O
the	O
nasopharyngeal	O
exudate	O
was	O
negative	O
,	O
with	O
the	O
option	O
of	O
urgent	O
surgery	O
in	O
the	O
event	O
of	O
worsening	O
resistant	O
to	O
medical	O
treatment	O
.	O
The	O
patient	O
remained	O
for	O
several	O
days	O
with	O
persistent	O
fever	O
and	O
progressive	O
clinical	O
deterioration	O
,	O
with	O
dyspnoea	O
on	O
minimal	O
effort	O
,	O
intense	O
orthopnoea	O
that	O
forced	O
him	O
to	O
sleep	O
sitting	O
up	O
and	O
several	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
,	O
requiring	O
oxygen	O
therapy	O
with	O
a	O
reservoir	O
,	O
so	O
that	O
finally	O
,	O
taking	O
into	O
account	O
the	O
risk	O
benefit	O
balance	O
,	O
it	O
was	O
decided	O
to	O
intervene	O
,	O
performing	O
a	O
double	O
valve	O
replacement	O
with	O
mechanical	O
prostheses	O
.	O
After	O
surgery	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
intensive	O
care	O
,	O
where	O
he	O
experienced	O
a	O
torpid	O
initial	O
evolution	O
,	O
developing	O
mixed	O
cardiogenic	O
and	O
vasoplegic	O
shock	O
in	O
relation	O
to	O
extracorporeal	O
circulation	O
,	O
requiring	O
orotracheal	O
intubation	O
and	O
support	O
with	O
dobutamine	B-FARMACO
and	O
noradrenaline	B-FARMACO
.	O
Echocardioscopy	O
showed	O
volume	O
depletion	O
and	O
moderate	O
deterioration	O
of	O
left	O
ventricular	O
contractility	O
,	O
with	O
a	O
favourable	O
response	O
to	O
levosimendan	B-FARMACO
.	O
He	O
also	O
developed	O
an	O
episode	O
of	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
,	O
which	O
was	O
adequately	O
controlled	O
with	O
digoxin	B-FARMACO
.	O
Finally	O
,	O
in	O
the	O
following	O
days	O
he	O
evolved	O
satisfactorily	O
,	O
and	O
vasoactive	O
support	O
was	O
discontinued	O
and	O
extubation	O
was	O
performed	O
,	O
although	O
he	O
intermittently	O
required	O
non	O
invasive	O
mechanical	O
ventilation	O
.	O
DIAGNOSIS	O
Decompensation	O
of	O
predominantly	O
left	O
sided	O
heart	O
failure	O
secondary	O
to	O
anaemia	O
and	O
infective	O
aortic	O
and	O
mitral	O
endocarditis	O
due	O
to	O
E	O
.	O
faecium	O
with	O
severe	O
failure	O
of	O
both	O
valves	O
.	O
Exacerbation	O
of	O
chronic	O
microcytic	O
hypochromic	O
anaemia	O
,	O
requiring	O
1	O
red	O
blood	O
cell	O
concentrate	O
.	O
Mild	O
respiratory	O
infection	O
due	O
to	O
SARS	O
CoV	O
2	O
.	O
Mixed	O
cardiogenic	O
and	O
vasoplegic	O
shock	O
in	O
relation	O
to	O
extracorporeal	O
circulation	O
,	O
requiring	O
invasive	O
mechanical	O
ventilation	O
and	O
vasoactive	O
support	O
.	O
De	O
novo	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
,	O
controlled	O
with	O
digoxin	B-FARMACO
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
62	O
year	O
old	O
woman	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Toxic	O
habits	O
smoker	O
of	O
1	O
pack	O
of	O
cigarettes	O
per	O
day	O
pack	O
year	O
rate	O
40	O
.	O
No	O
alcohol	O
or	O
other	O
intoxicants	O
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
,	O
dyslipidaemia	O
,	O
type	O
II	O
diabetes	O
mellitus	O
with	O
last	O
HbA1c	O
7	O
.	O
5	O
under	O
control	O
by	O
her	O
primary	O
care	O
physician	O
,	O
without	O
diabetic	O
retinopathy	O
.	O
Morbid	O
obesity	O
with	O
muscle	O
mass	O
index	O
BMI	O
49	O
.	O
22	O
kg	O
m2	O
weight	O
127	O
kg	O
,	O
height	O
161cm	O
.	O
Chronic	O
coronary	O
syndrome	O
diagnosed	O
in	O
2012	O
due	O
to	O
exertional	O
angina	O
with	O
inconclusive	O
stress	O
echocardiogram	O
and	O
initiation	O
of	O
anti	O
ischaemic	O
,	O
antiplatelet	O
and	O
lipid	O
lowering	O
therapy	O
.	O
Subsequent	O
coronary	O
angiography	O
in	O
August	O
2012	O
with	O
significant	O
stenosis	O
in	O
the	O
mid	O
distal	O
anterior	O
descending	O
artery	O
with	O
implantation	O
of	O
a	O
drug	O
eluting	O
stent	O
.	O
Rest	O
of	O
vessels	O
with	O
mild	O
atheromatosis	O
without	O
significant	O
stenosis	O
.	O
Diagnosed	O
since	O
2015	O
with	O
asymptomatic	O
moderate	O
severe	O
aortic	O
stenosis	O
.	O
Control	O
echocardiograms	O
showed	O
a	O
non	O
dilated	O
,	O
moderately	O
hypertrophic	O
left	O
ventricle	O
with	O
good	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O
Sclerocalcified	O
aortic	O
valve	O
with	O
moderate	O
severe	O
stenosis	O
and	O
valve	O
area	O
estimated	O
by	O
continuity	O
equation	O
of	O
1	O
cm	O
.	O
Mild	O
moderate	O
aortic	O
insufficiency	O
.	O
Sclerosed	O
mitral	O
valve	O
with	O
mild	O
insufficiency	O
.	O
Transmitral	O
flow	O
E	O
A	O
,	O
suggestive	O
of	O
prolonged	O
LV	O
relaxation	O
.	O
Moderately	O
dilated	O
left	O
atrium	O
.	O
Right	O
ventricle	O
normal	O
in	O
size	O
and	O
function	O
.	O
Mild	O
tricuspid	O
insufficiency	O
with	O
moderate	O
pulmonary	O
hypertension	O
.	O
Moderately	O
dilated	O
right	O
atrium	O
.	O
No	O
pericardial	O
effusion	O
.	O
No	O
aortic	O
root	O
dilatation	O
.	O
No	O
known	O
bronchopathy	O
.	O
Repeated	O
urinary	O
tract	O
infections	O
.	O
Hepatic	O
steatosis	O
.	O
Surgical	O
interventions	O
umbilical	O
hernia	O
.	O
Usual	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
1	O
tablet	O
at	O
lunch	O
;	O
olmesartan	B-FARMACO
amlodipine	I-FARMACO
20	O
5	O
mg	O
1	O
tablet	O
at	O
breakfast	O
;	O
bisoprolol	B-FARMACO
5	O
mg	O
1	O
tablet	O
at	O
breakfast	O
;	O
metformin	B-FARMACO
850	O
mg	O
1	O
tablet	O
at	O
breakfast	O
and	O
dinner	O
;	O
atorvastatin	B-FARMACO
20	O
mg	O
1	O
tablet	O
at	O
dinner	O
;	O
esomeprazole	B-FARMACO
20	O
mg	O
1	O
tablet	O
at	O
breakfast	O
;	O
nitroglycerin	B-FARMACO
spray	O
on	O
demand	O
.	O
Baseline	O
functional	O
status	O
housewife	O
.	O
Absolute	O
sedentary	O
lifestyle	O
.	O
Current	O
illness	O
Patient	O
under	O
follow	O
up	O
in	O
cardiology	O
consultations	O
for	O
several	O
years	O
due	O
to	O
chronic	O
coronary	O
syndrome	O
with	O
implantation	O
of	O
a	O
drug	O
eluting	O
stent	O
in	O
the	O
mid	O
distal	O
anterior	O
descending	O
artery	O
and	O
asymptomatic	O
moderate	O
severe	O
aortic	O
stenosis	O
.	O
In	O
the	O
March	O
2019	O
consultation	O
,	O
the	O
patient	O
began	O
with	O
previously	O
absent	O
NYHA	O
II	O
III	O
exertional	O
dyspnoea	O
and	O
occasional	O
nocturnal	O
angina	O
at	O
rest	O
,	O
without	O
syncope	O
,	O
palpitations	O
or	O
other	O
additional	O
cardiological	O
symptoms	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
at	O
consultation	O
130	O
80	O
mmHg	O
,	O
heart	O
rate	O
75	O
beats	O
per	O
minute	O
.	O
Oxygen	O
saturation	O
97	O
.	O
Conscious	O
and	O
oriented	O
.	O
Well	O
perfused	O
and	O
hydrated	O
.	O
Eupneic	O
at	O
rest	O
.	O
Severe	O
obesity	O
.	O
Pulmonary	O
auscultation	O
overall	O
decreased	O
vesicular	O
murmur	O
.	O
Cardiac	O
auscultation	O
aortic	O
murmur	O
,	O
systolic	O
,	O
radiating	O
towards	O
the	O
carotid	O
arteries	O
.	O
Abdomen	O
difficult	O
to	O
assess	O
due	O
to	O
obesity	O
,	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
visceromegaly	O
or	O
masses	O
.	O
Preserved	O
hydro	O
aerial	O
sounds	O
.	O
Chronic	O
cutaneous	O
trophic	O
disorders	O
in	O
the	O
lower	O
extremities	O
,	O
with	O
no	O
apparent	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
70	O
beats	O
per	O
minute	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
with	O
30o	O
axis	O
.	O
Left	O
ventricular	O
hypertrophy	O
by	O
Cornell	O
criteria	O
sum	O
of	O
R	O
wave	O
in	O
aVL	O
and	O
S	O
wave	O
in	O
V3	O
21mm	O
with	O
asymmetrical	O
negative	O
T	O
waves	O
in	O
lateral	O
face	O
suggestive	O
of	O
left	O
ventricular	O
systolic	O
overload	O
.	O
Normal	O
QTc	O
.	O
Transthoracic	O
echocardiogram	O
poor	O
acoustic	O
window	O
.	O
Non	O
dilated	O
left	O
ventricle	O
DVItd	O
44mm	O
,	O
with	O
moderate	O
concentric	O
hypertrophy	O
SIVtd	O
14mm	O
,	O
PPtd	O
14mm	O
.	O
Global	O
systolic	O
function	O
preserved	O
LVEF	O
simpson	O
biplane	O
72	O
,	O
without	O
regional	O
contractility	O
asynergies	O
.	O
Mild	O
sclerocalcified	O
mitral	O
valve	O
,	O
with	O
no	O
abnormalities	O
in	O
function	O
.	O
Aortic	O
valve	O
trivalve	O
,	O
severe	O
sclerocalcification	O
and	O
restricted	O
opening	O
.	O
Maximum	O
gradient	O
2	O
of	O
121	O
mmHg	O
and	O
mean	O
of	O
72	O
mmHg	O
.	O
Calculated	O
aortic	O
valve	O
area	O
of	O
0	O
.	O
5	O
0	O
.	O
6	O
cm	O
Mild	O
moderate	O
aortic	O
insufficiency	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
.	O
Right	O
ventricle	O
poorly	O
visualised	O
,	O
apparently	O
of	O
normal	O
dimensions	O
and	O
systolic	O
function	O
.	O
Tricuspid	O
valve	O
poorly	O
visualised	O
,	O
without	O
significant	O
tricuspid	O
insufficiency	O
.	O
Pulmonary	O
artery	O
acceleration	O
time	O
of	O
70	O
msec	O
,	O
suggestive	O
of	O
pulmonary	O
hypertension	O
.	O
Right	O
atrium	O
not	O
dilated	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
.	O
No	O
pericardial	O
effusion	O
.	O
Blood	O
tests	O
Biochemistry	O
glucose	O
163	O
mg	O
dl	O
,	O
urea	O
35	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
64	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
calculated	O
by	O
CKD	O
EPI	O
90	O
ml	O
min	O
1	O
.	O
73	O
m	O
,	O
albumin	O
4	O
.	O
3	O
g	O
dl	O
,	O
Na	O
142	O
mEq	O
l	O
,	O
K	O
4	O
.	O
9	O
mEq	O
l	O
,	O
GPT	O
28	O
U	O
l	O
,	O
GGT	O
39	O
U	O
l	O
.	O
TG	O
137	O
mg	O
dl	O
,	O
total	O
cholesterol	O
167	O
mg	O
dl	O
,	O
HDL	O
33	O
mg	O
dl	O
,	O
LDL	O
107	O
mg	O
dl	O
,	O
non	O
HDL	O
cholesterol	O
134	O
mg	O
dl	O
.	O
CBC	O
haemoglobin	O
16	O
g	O
dl	O
,	O
244	O
,	O
000	O
platelets	O
ul	O
and	O
10	O
,	O
210	O
leucocytes	O
ul	O
.	O
HbA1c	O
7	O
.	O
5	O
.	O
Urine	O
albuminuria	O
29	O
.	O
8	O
mg	O
dl	O
,	O
creatinine	O
107	O
mg	O
dl	O
,	O
albumin	O
creatinine	O
ratio	O
278	O
mg	O
g	O
.	O
Pre	O
TAVI	O
CT	O
scan	O
study	O
from	O
pulmonary	O
apex	O
to	O
symphysis	O
pubis	O
with	O
intravenous	O
contrast	O
and	O
selective	O
acquisition	O
of	O
aortic	O
root	O
with	O
cardiac	O
synchronisation	O
.	O
Thoracic	O
aorta	O
of	O
normal	O
calibre	O
and	O
morphology	O
with	O
slight	O
atheromatous	O
changes	O
.	O
Abdominal	O
and	O
iliac	O
aorta	O
of	O
normal	O
calibre	O
and	O
morphology	O
with	O
little	O
atheromatous	O
changes	O
.	O
Maximum	O
and	O
minimum	O
diameters	O
of	O
the	O
valve	O
plane	O
in	O
end	O
systolic	O
phase	O
25	O
x	O
21mm	O
.	O
Valvular	O
plane	O
area	O
in	O
end	O
systolic	O
phase	O
473	O
mm	O
.	O
Distance	O
from	O
the	O
valve	O
plane	O
to	O
the	O
origin	O
of	O
the	O
left	O
and	O
right	O
coronary	O
arteries	O
,	O
12	O
and	O
14	O
mm	O
,	O
respectively	O
.	O
Maximum	O
diameter	O
of	O
ascending	O
thoracic	O
aorta	O
34	O
mm	O
,	O
aortic	O
arch	O
and	O
descending	O
thoracic	O
aorta	O
32	O
mm	O
.	O
The	O
origin	O
of	O
the	O
supra	O
aortic	O
trunks	O
is	O
normally	O
visualised	O
.	O
Thoracic	O
aorta	O
and	O
abdominal	O
aorta	O
of	O
normal	O
calibre	O
without	O
tortuosity	O
.	O
Calcified	O
plaques	O
in	O
infrarenal	O
abdominal	O
aorta	O
and	O
common	O
iliac	O
with	O
irregularities	O
without	O
significant	O
stenosis	O
.	O
External	O
iliac	O
and	O
femoral	O
aorta	O
without	O
significant	O
atheromatous	O
changes	O
.	O
Minimum	O
diameter	O
of	O
distal	O
abdominal	O
aorta	O
14	O
mm	O
,	O
right	O
common	O
iliac	O
7	O
mm	O
,	O
left	O
7	O
mm	O
,	O
right	O
external	O
iliac	O
7	O
mm	O
,	O
left	O
7	O
mm	O
,	O
right	O
common	O
femoral	O
7	O
mm	O
,	O
left	O
7	O
mm	O
.	O
Pre	O
TAVI	O
coronary	O
angiography	O
common	O
trunk	O
shows	O
mild	O
distal	O
calibre	O
loss	O
not	O
significant	O
.	O
The	O
anterior	O
descending	O
artery	O
shows	O
dense	O
parietal	O
calcification	O
,	O
but	O
no	O
significant	O
stenosis	O
.	O
The	O
circumflex	O
artery	O
is	O
a	O
very	O
poorly	O
developed	O
vessel	O
with	O
no	O
obvious	O
lesions	O
.	O
The	O
dominant	O
and	O
highly	O
developed	O
right	O
coronary	O
artery	O
shows	O
moderate	O
diffuse	O
calcified	O
atheromatosis	O
,	O
with	O
no	O
significant	O
focal	O
stenosis	O
.	O
Conclusion	O
diffuse	O
calcified	O
coronary	O
atheromatosis	O
without	O
significant	O
focal	O
stenosis	O
.	O
Intraprocedural	O
transesophageal	O
echocardiogram	O
ring	O
measured	O
in	O
2D	O
22	O
.	O
5	O
2	O
mm	O
and	O
in	O
3D	O
4	O
.	O
33	O
cm	O
.	O
Post	O
TAVI	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
with	O
moderate	O
concentric	O
left	O
ventricular	O
hypertrophy	O
.	O
Global	O
and	O
segmental	O
systolic	O
function	O
preserved	O
.	O
TAVI	O
in	O
aortic	O
position	O
with	O
maximum	O
and	O
mean	O
gradients	O
of	O
23	O
mmHg	O
and	O
11	O
mmHg	O
,	O
respectively	O
.	O
No	O
aortic	O
insufficiency	O
.	O
Sclerocalcified	O
mitral	O
valve	O
without	O
functional	O
alterations	O
.	O
Transmitral	O
flow	O
suggests	O
prolonged	O
relaxation	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
.	O
Right	O
ventricle	O
normal	O
in	O
size	O
and	O
function	O
.	O
No	O
tricuspid	O
insufficiency	O
,	O
pulmonary	O
artery	O
acceleration	O
time	O
of	O
80	O
msec	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
and	O
inspiratory	O
collapse	O
50	O
.	O
No	O
pericardial	O
effusion	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
.	O
CLINICAL	O
EVOLUTION	O
This	O
clinical	O
case	O
presents	O
a	O
patient	O
with	O
chronic	O
coronary	O
syndrome	O
since	O
2012	O
and	O
double	O
aortic	O
lesion	O
with	O
predominant	O
moderate	O
severe	O
stenosis	O
since	O
2015	O
,	O
asymptomatic	O
after	O
starting	O
antianginal	O
treatment	O
and	O
implantation	O
of	O
a	O
drug	O
eluting	O
stent	O
for	O
any	O
cardiovascular	O
symptoms	O
until	O
March	O
2019	O
.	O
In	O
that	O
year	O
,	O
the	O
patient	O
developed	O
dyspnoea	O
on	O
exertion	O
and	O
the	O
echocardiogram	O
was	O
updated	O
to	O
show	O
a	O
double	O
aortic	O
lesion	O
with	O
predominantly	O
severe	O
stenosis	O
and	O
a	O
critical	O
valve	O
area	O
.	O
Given	O
that	O
the	O
patient	O
had	O
severe	O
symptomatic	O
aortic	O
valve	O
disease	O
,	O
it	O
was	O
decided	O
to	O
act	O
on	O
it	O
.	O
The	O
risks	O
of	O
surgery	O
were	O
calculated	O
,	O
with	O
a	O
EuroScore	O
II	O
of	O
1	O
.	O
97	O
and	O
EuroScore	O
I	O
of	O
5	O
.	O
30	O
,	O
and	O
the	O
case	O
was	O
discussed	O
by	O
the	O
heart	O
team	O
.	O
Despite	O
having	O
a	O
SCORE	O
of	O
low	O
surgical	O
risk	O
according	O
to	O
the	O
scales	O
used	O
,	O
given	O
that	O
the	O
patient	O
was	O
morbidly	O
obese	O
with	O
marked	O
limitation	O
of	O
ambulation	O
,	O
and	O
that	O
these	O
scales	O
do	O
not	O
include	O
factors	O
such	O
as	O
significant	O
obesity	O
with	O
the	O
high	O
surgical	O
risk	O
that	O
this	O
entails	O
,	O
aortic	O
valve	O
replacement	O
surgery	O
was	O
rejected	O
and	O
TAVI	O
was	O
chosen	O
.	O
A	O
pre	O
TAVI	O
CT	O
scan	O
was	O
performed	O
which	O
demonstrated	O
the	O
possibility	O
of	O
performing	O
the	O
technique	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
patient	O
was	O
referred	O
for	O
endocrinology	O
consultations	O
to	O
manage	O
her	O
diabetes	O
and	O
to	O
try	O
to	O
reduce	O
her	O
weight	O
prior	O
to	O
valve	O
replacement	O
.	O
She	O
was	O
initially	O
seen	O
in	O
June	O
2019	O
and	O
several	O
measures	O
were	O
initiated	O
1800	O
kcal	O
diet	O
,	O
increase	O
of	O
metformin	B-FARMACO
dose	O
to	O
850	O
mg	O
1	O
tablet	O
breakfast	O
,	O
lunch	O
and	O
dinner	O
and	O
initiation	O
of	O
semaglutide	B-FARMACO
to	O
better	O
control	O
her	O
diabetes	O
and	O
attempt	O
weight	O
reduction	O
,	O
initially	O
at	O
a	O
dose	O
of	O
0	O
.	O
25	O
mg	O
weekly	O
for	O
the	O
first	O
month	O
and	O
then	O
0	O
.	O
5	O
mg	O
weekly	O
from	O
the	O
following	O
month	O
.	O
She	O
was	O
not	O
started	O
on	O
iSGLT	O
2	O
due	O
to	O
repeated	O
urinary	O
tract	O
infections	O
.	O
She	O
progressively	O
lost	O
weight	O
and	O
was	O
seen	O
in	O
pre	O
anaesthesia	O
consultation	O
in	O
June	O
2019	O
,	O
with	O
surgical	O
risk	O
ASA	O
III	O
and	O
included	O
in	O
the	O
surgical	O
list	O
.	O
In	O
October	O
2019	O
,	O
the	O
operation	O
was	O
performed	O
under	O
general	O
anaesthesia	O
with	O
orotracheal	O
intubation	O
and	O
transesophageal	O
echocardiography	O
.	O
Prior	O
to	O
the	O
procedure	O
,	O
the	O
right	O
jugular	O
vein	O
was	O
cannulated	O
with	O
transient	O
intravenous	O
pacemaker	O
implantation	O
.	O
The	O
left	O
femoral	O
artery	O
was	O
punctured	O
by	O
Doppler	O
ultrasound	O
.	O
The	O
right	O
femoral	O
artery	O
was	O
guided	O
with	O
contralateral	O
angiography	O
,	O
through	O
which	O
a	O
26th	O
Edwards	O
SAPIEN	O
prosthesis	O
was	O
advanced	O
.	O
During	O
prosthesis	O
implantation	O
the	O
patient	O
developed	O
complete	O
left	O
bundle	O
branch	O
block	O
without	O
atrioventricular	O
block	O
.	O
There	O
was	O
minimal	O
aortic	O
regurgitation	O
by	O
TEE	O
and	O
none	O
by	O
aortography	O
.	O
The	O
right	O
femoral	O
access	O
was	O
closed	O
with	O
Prostar	O
,	O
and	O
the	O
absence	O
of	O
complications	O
was	O
verified	O
by	O
contralateral	O
angiography	O
,	O
and	O
the	O
left	O
femoral	O
access	O
was	O
closed	O
with	O
AngioSeal	O
.	O
The	O
patient	O
was	O
extubated	O
in	O
the	O
ward	O
and	O
transferred	O
in	O
good	O
clinical	O
and	O
haemodynamic	O
condition	O
to	O
the	O
coronary	O
unit	O
.	O
Total	O
procedure	O
time	O
60	O
minutes	O
.	O
During	O
her	O
stay	O
in	O
the	O
coronary	O
unit	O
,	O
the	O
patient	O
remained	O
haemodynamically	O
stable	O
,	O
tending	O
to	O
arterial	O
hypertension	O
,	O
requiring	O
intravenous	O
nitroglycerin	B-FARMACO
during	O
the	O
first	O
hours	O
,	O
which	O
could	O
be	O
suspended	O
later	O
after	O
reintroduction	O
of	O
the	O
usual	O
oral	O
antihypertensive	O
treatment	O
.	O
In	O
sinus	O
rhythm	O
with	O
good	O
heart	O
rate	O
on	O
telemetry	O
,	O
with	O
disappearance	O
of	O
left	O
bundle	O
branch	O
block	O
over	O
the	O
hours	O
and	O
no	O
atrioventricular	O
block	O
of	O
any	O
kind	O
.	O
Respiratory	O
stability	O
,	O
initially	O
with	O
Sa02	O
90	O
in	O
the	O
context	O
also	O
of	O
the	O
extrapulmonary	O
restrictive	O
disorder	O
due	O
to	O
obesity	O
associated	O
with	O
some	O
pulmonary	O
congestion	O
,	O
which	O
after	O
occasional	O
administration	O
of	O
IV	O
furosemide	B-FARMACO
improved	O
to	O
Sa02	O
94	O
on	O
room	O
air	O
.	O
Normal	O
renal	O
function	O
with	O
preserved	O
diuresis	O
.	O
Afebrile	O
with	O
low	O
infection	O
parameters	O
.	O
E	O
.	O
coli	O
was	O
isolated	O
in	O
urine	O
100	O
,	O
000	O
CFU	O
ml	O
covered	O
with	O
antibiotic	O
prophylaxis	O
administered	O
pre	O
TAVI	O
curoxime	B-FARMACO
.	O
No	O
complications	O
were	O
observed	O
at	O
the	O
femoral	O
access	O
points	O
,	O
with	O
no	O
haematomas	O
or	O
murmurs	O
,	O
bilateral	O
pedal	O
pulses	O
present	O
and	O
stable	O
haemoglobin	O
in	O
the	O
control	O
tests	O
.	O
Treatment	O
was	O
started	O
with	O
double	O
antiplatelet	O
therapy	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
and	O
clopidogrel	B-FARMACO
and	O
she	O
was	O
transferred	O
to	O
the	O
hospital	O
ward	O
after	O
a	O
24	O
hour	O
stay	O
in	O
the	O
coronary	O
unit	O
.	O
She	O
remained	O
on	O
the	O
hospital	O
ward	O
for	O
4	O
more	O
days	O
with	O
progressive	O
ambulation	O
and	O
no	O
local	O
or	O
systemic	O
complications	O
,	O
and	O
was	O
discharged	O
home	O
.	O
The	O
patient	O
is	O
currently	O
being	O
followed	O
in	O
the	O
valvulopathy	O
clinic	O
with	O
complete	O
disappearance	O
of	O
dyspnoea	O
and	O
angina	O
.	O
She	O
is	O
following	O
the	O
diet	O
proposed	O
by	O
endocrinology	O
and	O
oral	O
antidiabetic	O
treatment	O
consisting	O
of	O
semaglutide	B-FARMACO
and	O
metformin	B-FARMACO
,	O
with	O
a	O
last	O
recorded	O
weight	O
of	O
106	O
kg	O
,	O
with	O
a	O
weight	O
loss	O
of	O
21	O
.	O
5	O
kg	O
and	O
improvement	O
in	O
glycosylated	O
haemoglobin	O
to	O
5	O
.	O
5	O
.	O
DIAGNOSIS	O
Implantation	O
of	O
TAVI	O
Edwards	O
SAPIEN	O
3	O
no	O
26	O
for	O
symptomatic	O
severe	O
aortic	O
stenosis	O
.	O
Chronic	O
coronary	O
syndrome	O
with	O
implantation	O
of	O
a	O
drug	O
eluting	O
stent	O
in	O
2012	O
.	O
Preserved	O
LVEF	O
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
,	O
type	O
II	O
diabetes	O
mellitus	O
,	O
dyslipidaemia	O
,	O
obesity	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Brother	O
and	O
nephew	O
diagnosed	O
with	O
HCM	O
.	O
No	O
history	O
of	O
sudden	O
death	O
in	O
first	O
degree	O
relatives	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Worked	O
in	O
newspaper	O
distribution	O
.	O
Smoker	O
of	O
30	O
cigarettes	O
per	O
day	O
,	O
with	O
a	O
cumulative	O
rate	O
of	O
48	O
packs	O
per	O
year	O
.	O
Cardiovascular	O
risk	O
factors	O
obesity	O
grade	O
I	O
body	O
mass	O
index	O
BMI	O
32	O
kg	O
m2	O
.	O
No	O
hypertension	O
,	O
diabetes	O
or	O
dyslipidaemia	O
.	O
Follow	O
up	O
in	O
cardiology	O
consultations	O
for	O
asymmetric	O
obstructive	O
HCM	O
with	O
inconclusive	O
genetic	O
study	O
.	O
At	O
diagnosis	O
,	O
there	O
was	O
no	O
significant	O
obstruction	O
.	O
However	O
,	O
during	O
subsequent	O
follow	O
up	O
and	O
coinciding	O
with	O
a	O
clear	O
worsening	O
of	O
her	O
functional	O
class	O
,	O
a	O
transthoracic	O
echocardiogram	O
TTE	O
revealed	O
a	O
progressive	O
increase	O
in	O
septal	O
hypertrophy	O
causing	O
an	O
obstructive	O
dynamic	O
gradient	O
and	O
systolic	O
anterior	O
motion	O
SAM	O
in	O
the	O
anterior	O
leaflet	O
of	O
the	O
mitral	O
valve	O
,	O
leading	O
to	O
moderate	O
mitral	O
regurgitation	O
.	O
Cardiogenic	O
syncope	O
in	O
2019	O
,	O
for	O
which	O
it	O
was	O
decided	O
to	O
implant	O
a	O
DDDR	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
in	O
primary	O
prevention	O
,	O
given	O
that	O
the	O
risk	O
of	O
sudden	O
death	O
at	O
5	O
years	O
was	O
7	O
.	O
1	O
.	O
In	O
successive	O
check	O
ups	O
,	O
close	O
monitoring	O
was	O
carried	O
out	O
to	O
control	O
symptoms	O
and	O
drug	O
titration	O
,	O
despite	O
which	O
dyspnoea	O
and	O
angina	O
on	O
exertion	O
persisted	O
.	O
Baseline	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
.	O
Higher	O
functions	O
preserved	O
.	O
Active	O
life	O
.	O
Currently	O
presents	O
dyspnoea	O
on	O
usual	O
exertion	O
,	O
in	O
NYHA	O
functional	O
class	O
III	O
.	O
Usual	O
treatment	O
omeprazole	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
disopriramide	B-FARMACO
100	O
mg	O
8	O
hours	O
,	O
verapamil	B-FARMACO
120	O
mg	O
12	O
hours	O
.	O
Present	O
illness	O
A	O
52	O
year	O
old	O
patient	O
returned	O
to	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
due	O
to	O
chest	O
pain	O
and	O
an	O
increase	O
in	O
his	O
baseline	O
dyspnoea	O
to	O
the	O
point	O
of	O
minimal	O
effort	O
.	O
He	O
did	O
not	O
present	O
orthopnoea	O
,	O
paroxysmal	O
nocturnal	O
dyspnoea	O
crises	O
,	O
decreased	O
diuresis	O
or	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
the	O
patient	O
was	O
haemodynamically	O
stable	O
,	O
with	O
slight	O
tachypnoea	O
at	O
rest	O
,	O
maintaining	O
oxygen	O
saturation	O
98	O
.	O
An	O
electrocardiogram	O
ECG	O
was	O
performed	O
,	O
with	O
no	O
changes	O
with	O
respect	O
to	O
those	O
previously	O
described	O
,	O
as	O
well	O
as	O
serum	O
markers	O
of	O
myocardial	O
damage	O
,	O
which	O
were	O
normal	O
.	O
Admission	O
to	O
cardiology	O
was	O
decided	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
.	O
Normal	O
colour	O
,	O
well	O
hydrated	O
and	O
perfused	O
.	O
Afebrile	O
.	O
Haemodynamically	O
stable	O
blood	O
pressure	O
BP	O
127	O
84	O
mmHg	O
,	O
heart	O
rate	O
HR	O
70	O
bpm	O
.	O
Eupneic	O
at	O
rest	O
.	O
Oxygen	O
saturation	O
99	O
without	O
oxygen	O
therapy	O
.	O
Cardiorespiratory	O
auscultation	O
rhythmic	O
tones	O
at	O
a	O
good	O
frequency	O
,	O
with	O
a	O
panfocal	O
systolic	O
murmur	O
that	O
increases	O
with	O
the	O
Valsalva	O
manoeuvre	O
.	O
Good	O
ventilation	O
in	O
both	O
lung	O
fields	O
with	O
no	O
added	O
pathological	O
noises	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
.	O
No	O
masses	O
or	O
megaliths	O
palpable	O
.	O
Not	O
painful	O
.	O
No	O
signs	O
of	O
peritoneal	O
irritation	O
or	O
peritonism	O
.	O
Lower	O
limbs	O
without	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Pedial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
Biochemistry	O
glucose	O
106	O
mg	O
dl	O
,	O
urea	O
35	O
mg	O
dl	O
,	O
Cr	O
0	O
.	O
92	O
mg	O
dl	O
,	O
uric	O
acid	O
6	O
mg	O
dl	O
,	O
GFR	O
90	O
ml	O
min	O
.	O
Ionogram	O
normal	O
.	O
Abdominal	O
profile	O
total	O
bilirubin	O
2	O
.	O
31	O
mg	O
dl	O
,	O
at	O
the	O
expense	O
of	O
indirect	O
1	O
.	O
69	O
mg	O
dl	O
,	O
rest	O
normal	O
.	O
Total	O
protein	O
6	O
.	O
9	O
g	O
dl	O
.	O
NT	O
proBNP	O
869	O
pg	O
ml	O
.	O
Serial	O
myocardial	O
damage	O
markers	O
normal	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
206	O
mg	O
dl	O
,	O
LDL	O
140	O
mg	O
dl	O
,	O
HDL	O
42	O
mg	O
dl	O
,	O
triglycerides	O
122	O
mg	O
dl	O
.	O
PSA	O
0	O
.	O
16	O
ng	O
ml	O
.	O
HbA1c	O
5	O
.	O
6	O
.	O
CBC	O
haemoglobin	O
14	O
.	O
4	O
g	O
dl	O
,	O
platelets	O
181x109	O
l	O
,	O
leucocytes	O
1073	O
x109	O
l	O
with	O
normal	O
formula	O
.	O
Electrocardiograms	O
ECG	O
emergency	O
ECG	O
pacemaker	O
stimulation	O
at	O
60	O
bpm	O
,	O
evidence	O
of	O
left	O
ventricular	O
hypertrophy	O
.	O
QTc	O
440	O
ms	O
.	O
ECG	O
on	O
the	O
ward	O
in	O
sinus	O
rhythm	O
71	O
bpm	O
.	O
Normal	O
PR	O
.	O
Positive	O
Sokolow	O
's	O
criteria	O
with	O
overload	O
data	O
and	O
negative	O
T	O
waves	O
from	O
V4	O
to	O
V6	O
,	O
I	O
and	O
aVL	O
.	O
TTE	O
severe	O
and	O
asymmetric	O
ventricular	O
hypertrophy	O
with	O
maximum	O
myocardial	O
thickness	O
at	O
septal	O
level	O
26	O
27	O
mm	O
with	O
clear	O
SAM	O
leading	O
to	O
moderate	O
mitral	O
regurgitation	O
.	O
Obstructive	O
dynamic	O
gradient	O
at	O
LVOT	O
level	O
with	O
a	O
gradient	O
of	O
50	O
mmHg	O
,	O
which	O
with	O
Valsalva	O
manoeuvres	O
reaches	O
82	O
mmHg	O
.	O
Preserved	O
left	O
ventricular	O
systolic	O
function	O
with	O
an	O
ejection	O
fraction	O
of	O
70	O
.	O
Low	O
echocardiographic	O
probability	O
of	O
pulmonary	O
hypertension	O
.	O
Transesophageal	O
echocardiogram	O
TEE	O
videos	O
3	O
and	O
4	O
mitral	O
valve	O
with	O
no	O
structural	O
alterations	O
of	O
note	O
.	O
No	O
elongation	O
of	O
leaflets	O
or	O
subvalvular	O
apparatus	O
.	O
Slight	O
thickening	O
of	O
the	O
anterior	O
leaflet	O
at	O
the	O
level	O
of	O
its	O
A2	O
scallop	O
.	O
It	O
presents	O
an	O
alteration	O
of	O
the	O
dynamics	O
consisting	O
of	O
retraction	O
of	O
both	O
leaflets	O
in	O
closure	O
by	O
intraventricular	O
dynamic	O
gradient	O
mechanism	O
at	O
the	O
level	O
of	O
the	O
left	O
LVOT	O
with	O
SAM	O
of	O
both	O
the	O
anterior	O
and	O
posterior	O
leaflets	O
.	O
This	O
alteration	O
of	O
the	O
dynamics	O
generates	O
a	O
mitral	O
insufficiency	O
jet	O
of	O
at	O
least	O
moderate	O
size	O
.	O
No	O
other	O
alterations	O
were	O
observed	O
beyond	O
those	O
found	O
in	O
the	O
HCM	O
mechanism	O
secondary	O
to	O
SAM	O
with	O
involvement	O
of	O
the	O
entire	O
valve	O
apparatus	O
.	O
Coronary	O
angiography	O
angiographically	O
normal	O
coronary	O
arteries	O
.	O
The	O
second	O
septal	O
branch	O
of	O
greater	O
calibre	O
and	O
development	O
is	O
selectively	O
cannulated	O
,	O
as	O
the	O
first	O
branch	O
also	O
fistulises	O
the	O
left	O
ventricle	O
in	O
the	O
angiographic	O
image	O
.	O
After	O
selective	O
occlusion	O
of	O
this	O
branch	O
and	O
injection	O
of	O
ultrasound	O
contrast	O
,	O
TTE	O
shows	O
correct	O
basal	O
opacification	O
of	O
the	O
septum	O
,	O
but	O
with	O
almost	O
complete	O
drainage	O
of	O
the	O
contrast	O
to	O
the	O
left	O
ventricle	O
.	O
Cardiac	O
MRI	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
concentric	O
increase	O
of	O
its	O
mass	O
and	O
severe	O
asymmetric	O
hypertrophy	O
of	O
septal	O
predominance	O
.	O
Maximum	O
myocardial	O
thickness	O
in	O
the	O
basal	O
anteroseptal	O
26	O
mm	O
and	O
mid	O
inferoseptal	O
24	O
mm	O
segments	O
.	O
Thicknesses	O
in	O
apical	O
septal	O
16	O
mm	O
,	O
basal	O
inferoseptal	O
16	O
mm	O
and	O
mid	O
anteroseptal	O
15	O
mm	O
.	O
Rest	O
of	O
segments	O
with	O
maximum	O
thicknesses	O
of	O
13	O
mm	O
.	O
Normal	O
segmental	O
contractility	O
and	O
end	O
systolic	O
collapse	O
of	O
the	O
ventricular	O
cavity	O
leading	O
to	O
hyperdynamic	O
systolic	O
function	O
.	O
At	O
LVOT	O
level	O
,	O
there	O
is	O
systolic	O
flow	O
acceleration	O
and	O
SAM	O
of	O
the	O
anterior	O
mitral	O
leaflet	O
leading	O
to	O
mitral	O
insufficiency	O
conjet	O
directed	O
to	O
the	O
lateral	O
wall	O
of	O
the	O
left	O
atrium	O
.	O
An	O
intramyocardial	O
crypt	O
is	O
seen	O
in	O
the	O
mid	O
segment	O
of	O
the	O
inferior	O
aspect	O
.	O
The	O
ejection	O
fraction	O
measured	O
with	O
the	O
Simpson	O
method	O
was	O
81	O
.	O
LVEDV	O
of	O
144	O
ml	O
,	O
indexed	O
by	O
body	O
surface	O
area	O
of	O
72	O
ml	O
m	O
,	O
LVESV	O
of	O
27	O
ml	O
,	O
indexed	O
by	O
body	O
surface	O
area	O
of	O
13	O
.	O
5	O
ml	O
m	O
Cardiac	O
output	O
of	O
6	O
.	O
8	O
l	O
min	O
.	O
Myocardial	O
mass	O
285	O
g	O
,	O
indexed	O
by	O
body	O
surface	O
area	O
of	O
142	O
.	O
g	O
m	O
Right	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophic	O
,	O
with	O
preserved	O
global	O
and	O
segmental	O
mobility	O
.	O
Ejection	O
fraction	O
measured	O
by	O
Simpson	O
's	O
method	O
of	O
81	O
RVEDV	O
of	O
104	O
ml	O
,	O
indexed	O
by	O
body	O
surface	O
area	O
of	O
52	O
ml	O
m	O
.	O
VTSVD	O
of	O
19	O
ml	O
,	O
indexed	O
by	O
body	O
surface	O
area	O
of	O
9	O
.	O
5	O
ml	O
m	O
.	O
Dilated	O
left	O
atrium	O
with	O
an	O
area	O
of	O
41	O
cm	O
,	O
indexed	O
by	O
20	O
cm	O
m	O
.	O
Normal	O
right	O
atrium	O
21	O
cm	O
,	O
indexed	O
10	O
.	O
5	O
cm	O
m	O
.	O
The	O
first	O
pass	O
perfusion	O
sequence	O
shows	O
no	O
baseline	O
perfusion	O
defects	O
.	O
Late	O
enhancement	O
viability	O
sequence	O
shows	O
no	O
fibrosis	O
or	O
necrosis	O
.	O
Conclusion	O
Asymmetric	O
obstructive	O
HCM	O
without	O
fibrosis	O
.	O
Non	O
dilated	O
left	O
ventricle	O
with	O
preserved	O
systolic	O
function	O
.	O
CLINICAL	O
EVOLUTION	O
Patient	O
diagnosed	O
with	O
asymmetric	O
HCM	O
in	O
2009	O
after	O
consulting	O
for	O
palpitations	O
,	O
without	O
correlating	O
at	O
that	O
time	O
with	O
tachyarrhythmias	O
.	O
At	O
the	O
time	O
of	O
diagnosis	O
,	O
there	O
was	O
no	O
significant	O
LVOT	O
obstruction	O
.	O
Since	O
then	O
,	O
he	O
has	O
been	O
followed	O
up	O
in	O
cardiology	O
outpatient	O
clinics	O
and	O
was	O
found	O
to	O
be	O
asymptomatic	O
after	O
initiation	O
of	O
low	O
dose	O
beta	O
blockers	O
.	O
Subsequent	O
check	O
ups	O
revealed	O
a	O
worsening	O
of	O
his	O
functional	O
class	O
to	O
the	O
point	O
of	O
dyspnoea	O
and	O
angina	O
on	O
minimal	O
exertion	O
.	O
Beta	O
blockers	O
were	O
titrated	O
to	O
maximum	O
doses	O
on	O
an	O
outpatient	O
basis	O
and	O
,	O
taking	O
advantage	O
of	O
the	O
fact	O
that	O
the	O
patient	O
was	O
a	O
DDDR	O
ICD	O
user	O
,	O
the	O
parameters	O
of	O
the	O
latter	O
were	O
optimised	O
to	O
achieve	O
left	O
ventricular	O
pacing	O
greater	O
than	O
90	O
.	O
Despite	O
this	O
,	O
the	O
patient	O
continued	O
to	O
be	O
symptomatic	O
and	O
with	O
a	O
significant	O
obstructive	O
gradient	O
of	O
more	O
than	O
50	O
mmHg	O
.	O
It	O
was	O
decided	O
to	O
start	O
treatment	O
with	O
high	O
doses	O
of	O
calcium	O
antagonists	O
associated	O
with	O
disopyramide	B-FARMACO
and	O
to	O
titrate	O
doses	O
,	O
and	O
the	O
possibility	O
of	O
septal	O
ablation	O
with	O
alcohol	O
or	O
Morrow	O
surgery	O
was	O
considered	O
if	O
there	O
was	O
no	O
adequate	O
clinical	O
response	O
.	O
However	O
,	O
the	O
patient	O
was	O
finally	O
admitted	O
to	O
our	O
care	O
due	O
to	O
worsening	O
symptoms	O
.	O
During	O
admission	O
,	O
it	O
was	O
decided	O
to	O
initiate	O
the	O
preliminary	O
study	O
to	O
assess	O
whether	O
he	O
was	O
a	O
candidate	O
for	O
septal	O
ablation	O
with	O
alcohol	O
or	O
surgical	O
myomectomy	O
while	O
continuing	O
with	O
the	O
titration	O
of	O
medical	O
treatment	O
without	O
being	O
able	O
to	O
reach	O
higher	O
doses	O
due	O
to	O
the	O
presence	O
of	O
anticholinergic	O
symptoms	O
associated	O
with	O
disopyramide	B-FARMACO
.	O
Finally	O
,	O
given	O
the	O
degree	O
of	O
ventricular	O
hypertrophy	O
and	O
the	O
absence	O
of	O
a	O
septal	O
branch	O
suitable	O
for	O
alcohol	O
septal	O
ablation	O
,	O
surgical	O
myomectomy	O
was	O
chosen	O
.	O
DIAGNOSIS	O
Septal	O
HCM	O
with	O
severe	O
LVOT	O
obstruction	O
.	O
Moderate	O
mitral	O
regurgitation	O
due	O
to	O
SAM	O
.	O
Exertional	O
angina	O
and	O
dyspnoea	O
in	O
NYHA	O
functional	O
class	O
III	O
secondary	O
to	O
the	O
above	O
.	O
DDDR	O
ICD	O
carrier	O
in	O
primary	O
prevention	O
risk	O
of	O
sudden	O
death	O
at	O
5	O
years	O
according	O
to	O
the	O
European	O
Society	O
of	O
Cardiology	O
score	O
7	O
.	O
1	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
Cardiovascular	O
risk	O
factors	O
dyslipidaemia	O
,	O
type	O
2	O
diabetes	O
mellitus	O
.	O
Previous	O
cardiological	O
history	O
Chronic	O
ischemic	O
cardiomyopathy	O
.	O
Debut	O
in	O
June	O
2018	O
as	O
evolved	O
anterior	O
myocardial	O
infarction	O
,	O
in	O
Killip	O
Kimbal	O
II	O
haemodynamic	O
situation	O
.	O
Two	O
vessel	O
coronary	O
artery	O
disease	O
completely	O
revascularised	O
percutaneously	O
by	O
implantation	O
of	O
two	O
drug	O
eluting	O
stents	O
at	O
the	O
level	O
of	O
mid	O
first	O
diagonal	O
anterior	O
descending	O
primary	O
angioplasty	O
and	O
posterior	O
interventricular	O
second	O
time	O
.	O
Severe	O
left	O
ventricular	O
dysfunction	O
on	O
echocardiogram	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
30	O
at	O
discharge	O
.	O
Admission	O
in	O
August	O
2018	O
for	O
symptoms	O
compatible	O
with	O
Dressler	O
syndrome	O
.	O
Favourable	O
evolution	O
with	O
the	O
combination	O
of	O
high	O
dose	O
salicylates	O
and	O
colchicine	B-FARMACO
.	O
Subsequent	O
follow	O
up	O
in	O
the	O
heart	O
failure	O
clinic	O
,	O
where	O
the	O
medication	O
has	O
been	O
titrated	O
with	O
prognostic	O
impact	O
.	O
Start	O
of	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
in	O
November	O
2018	O
due	O
to	O
persistence	O
of	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
II	O
Association	O
NYHA	O
functional	O
class	O
II	O
.	O
Ergometry	O
at	O
the	O
end	O
of	O
the	O
cardiac	O
rehabilitation	O
programme	O
clinically	O
and	O
electrically	O
negative	O
for	O
ischaemia	O
,	O
in	O
functional	O
class	O
I	O
12	O
.	O
67	O
METS	O
.	O
No	O
other	O
comorbidities	O
of	O
interest	O
.	O
Current	O
treatment	O
omeprazole	B-FARMACO
20	O
mg	O
day	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
day	O
,	O
prasugrel	B-FARMACO
10	O
mg	O
day	O
,	O
sacubitril	O
valsartan	O
49	O
51	O
mg	O
12	O
hours	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
day	O
,	O
eplerenone	B-FARMACO
50	O
mg	O
day	O
,	O
metformin	B-FARMACO
empaglifozin	I-FARMACO
1000	O
mg	O
5	O
mg	O
every	O
12	O
hours	O
,	O
rosuvastatin	B-FARMACO
10	O
mg	O
day	O
,	O
ezetimibe	B-FARMACO
10	O
mg	O
day	O
.	O
CURRENT	O
DISEASE	O
A	O
49	O
year	O
old	O
man	O
,	O
with	O
a	O
coronary	O
event	O
at	O
an	O
early	O
age	O
,	O
who	O
came	O
for	O
a	O
check	O
up	O
at	O
the	O
heart	O
failure	O
clinic	O
on	O
13	O
November	O
2018	O
.	O
He	O
is	O
asymptomatic	O
in	O
the	O
cardiological	O
sphere	O
.	O
He	O
has	O
not	O
presented	O
angina	O
and	O
has	O
maintained	O
excellent	O
functional	O
class	O
NYHA	O
I	O
since	O
starting	O
sacubitrilo	B-FARMACO
valsartan	I-FARMACO
.	O
On	O
the	O
other	O
hand	O
,	O
since	O
starting	O
treatment	O
with	O
atorvastatin	B-FARMACO
in	O
June	O
2018	O
,	O
he	O
has	O
complained	O
of	O
significant	O
pain	O
and	O
cramps	O
in	O
the	O
calves	O
and	O
thighs	O
,	O
both	O
at	O
rest	O
and	O
when	O
walking	O
,	O
with	O
normal	O
CPK	O
values	O
.	O
She	O
also	O
presented	O
progressive	O
elevation	O
of	O
transaminases	O
and	O
cholestasis	O
enzymes	O
with	O
abdominal	O
ultrasound	O
that	O
ruled	O
out	O
hepatobiliary	O
pathology	O
,	O
so	O
,	O
given	O
the	O
suspicion	O
that	O
the	O
symptoms	O
and	O
laboratory	O
alterations	O
could	O
be	O
related	O
to	O
taking	O
atorvastatin	B-FARMACO
,	O
the	O
doses	O
were	O
progressively	O
reduced	O
to	O
10	O
mg	O
,	O
without	O
any	O
improvement	O
.	O
Treatment	O
with	O
low	O
doses	O
of	O
other	O
statins	O
pitavastatin	B-FARMACO
and	O
simvastatin	B-FARMACO
has	O
also	O
been	O
tried	O
without	O
success	O
and	O
she	O
is	O
currently	O
only	O
clinically	O
tolerating	O
10	O
mg	O
of	O
rosuvastatin	B-FARMACO
but	O
with	O
mild	O
alteration	O
of	O
the	O
hepatic	O
profile	O
.	O
In	O
addition	O
to	O
poor	O
tolerance	O
,	O
LDL	O
C	O
levels	O
have	O
remained	O
persistently	O
elevated	O
at	O
follow	O
up	O
LDL	O
C	O
130	O
mg	O
dl	O
,	O
despite	O
having	O
associated	O
ezetimibe	B-FARMACO
to	O
lipid	O
lowering	O
therapy	O
.	O
PHYSICAL	O
EXAMINATION	O
At	O
consultation	O
17	O
11	O
18	O
Blood	O
pressure	O
100	O
65	O
mmHg	O
.	O
Heart	O
rate	O
sinus	O
rhythm	O
70	O
beats	O
per	O
minute	O
.	O
Weight	O
83	O
kg	O
.	O
Height	O
189	O
cm	O
.	O
Abdominal	O
waist	O
90	O
cm	O
.	O
Body	O
mass	O
index	O
23	O
.	O
2	O
kg	O
m2	O
.	O
Eupneic	O
at	O
rest	O
,	O
tolerating	O
decubitus	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
regular	O
heart	O
sounds	O
without	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
adventitial	O
sounds	O
.	O
Abdomen	O
nondescript	O
.	O
Lower	O
limbs	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Pulses	O
preserved	O
and	O
symmetrical	O
.	O
No	O
stigmata	O
of	O
hyperlipaemia	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
test	O
in	O
consultation	O
11	O
12	O
18	O
glucose	O
126	O
mg	O
dl	O
.	O
HbA1c	O
6	O
.	O
5	O
.	O
ALT	O
82	O
U	O
l	O
,	O
AST	O
55	O
U	O
l	O
.	O
Bilirubin	O
0	O
.	O
8	O
mg	O
dl	O
.	O
Gamma	O
GT	O
108	O
U	O
l	O
.	O
Alkaline	O
phosphatase	O
85	O
U	O
l	O
.	O
CK	O
92	O
U	O
.	O
Creatinine	O
0	O
.	O
86	O
mg	O
dl	O
,	O
eGFR	O
by	O
MDRD	O
4	O
IDMS	O
60	O
ml	O
min	O
1	O
.	O
73	O
m2	O
.	O
Sodium	O
142	O
mmol	O
l	O
.	O
Potassium	O
4	O
.	O
8	O
mmol	O
l	O
.	O
NT	O
proBNP	O
544	O
ng	O
l	O
.	O
Lipid	O
profile	O
triglycerides	O
100	O
mg	O
dl	O
,	O
total	O
cholesterol	O
188	O
mg	O
dl	O
,	O
HDL	O
C	O
37	O
mg	O
dl	O
,	O
LDL	O
C	O
160	O
mg	O
dl	O
.	O
Apolipoprotein	O
A1	O
145	O
mg	O
dl	O
.	O
Apolipoprotein	O
B	O
89	O
mg	O
dl	O
.	O
ApoB	O
ApoA1	O
ratio	O
0	O
.	O
6	O
mg	O
mg	O
.	O
Lipoprotein	O
a	O
90	O
mg	O
dl	O
.	O
ECG	O
in	O
consultation	O
17	O
11	O
18	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
.	O
PR	O
interval	O
140	O
ms	O
.	O
Narrow	O
QRS	O
with	O
normopositioned	O
axis	O
.	O
QS	O
with	O
residual	O
submillimetric	O
ST	O
segment	O
elevation	O
in	O
V1	O
V4	O
,	O
with	O
negative	O
T	O
wave	O
in	O
I	O
,	O
aVL	O
and	O
flattened	O
in	O
V5	O
V6	O
.	O
Transition	O
in	O
V4	O
.	O
No	O
other	O
repolarisation	O
alterations	O
.	O
Echocardiogram	O
in	O
consultation	O
17	O
07	O
18	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
normal	O
wall	O
thickness	O
except	O
for	O
the	O
sigmoid	O
septum	O
.	O
Moderately	O
depressed	O
global	O
systolic	O
function	O
LVEF	O
estimated	O
by	O
Simpson	O
biplane	O
40	O
.	O
Apical	O
akinesia	O
and	O
akinesia	O
of	O
the	O
middle	O
and	O
distal	O
segments	O
of	O
the	O
anterior	O
face	O
and	O
anterior	O
septum	O
.	O
Hypokinesia	O
of	O
the	O
distal	O
third	O
of	O
the	O
inferior	O
septum	O
.	O
Transmitral	O
filling	O
pattern	O
with	O
impaired	O
relaxation	O
.	O
E	O
e	O
12	O
ratio	O
.	O
Non	O
dilated	O
atria	O
.	O
Non	O
dilated	O
right	O
ventricle	O
,	O
with	O
normal	O
global	O
systolic	O
function	O
TAPSE	O
15	O
mm	O
.	O
No	O
significant	O
valvular	O
heart	O
disease	O
.	O
Pulmonary	O
arterial	O
systolic	O
pressure	O
PSAP	O
not	O
estimable	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
,	O
with	O
physiological	O
inspiratory	O
collapse	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
No	O
pericardial	O
effusion	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
24	O
07	O
18	O
study	O
compatible	O
with	O
chronic	O
anteroseptal	O
myocardial	O
infarction	O
with	O
moderate	O
ventricular	O
dysfunction	O
LVEF	O
35	O
.	O
Absence	O
of	O
viability	O
in	O
the	O
territory	O
of	O
the	O
anterior	O
descending	O
artery	O
transmural	O
ischaemic	O
scar	O
of	O
the	O
apex	O
,	O
mid	O
and	O
distal	O
segment	O
of	O
the	O
anterior	O
face	O
and	O
anterior	O
septum	O
,	O
distal	O
half	O
of	O
the	O
inferior	O
septum	O
and	O
distal	O
segment	O
of	O
the	O
inferior	O
face	O
.	O
CLINICAL	O
EVOLUTION	O
Considering	O
the	O
prognostic	O
benefit	O
of	O
the	O
patient	O
young	O
and	O
at	O
very	O
high	O
cardiovascular	O
risk	O
and	O
the	O
inability	O
to	O
reach	O
target	O
LDL	O
C	O
levels	O
despite	O
moderate	O
doses	O
of	O
rosuvastatin	B-FARMACO
and	O
ezetimibe	B-FARMACO
,	O
it	O
was	O
decided	O
to	O
start	O
treatment	O
with	O
evolocumab	B-FARMACO
140	O
mg	O
subcutaneous	O
injection	O
fortnightly	O
.	O
Two	O
weeks	O
after	O
starting	O
evolocumab	B-FARMACO
treatment	O
,	O
LDL	O
C	O
levels	O
dropped	O
sharply	O
from	O
160	O
to	O
9	O
mg	O
dL	O
.	O
The	O
evolution	O
of	O
the	O
lipid	O
profile	O
including	O
levels	O
of	O
lipoprotein	O
a	O
,	O
Lp	O
a	O
in	O
the	O
successive	O
monthly	O
controls	O
up	O
to	O
the	O
present	O
were	O
as	O
follows	O
December	O
2018	O
total	O
cholesterol	O
69	O
mg	O
dl	O
,	O
HDLc	O
40	O
mg	O
dl	O
,	O
LDLc	O
9	O
mg	O
dl	O
.	O
Lp	O
a	O
45	O
mg	O
dl	O
.	O
It	O
is	O
decided	O
to	O
reduce	O
the	O
dose	O
of	O
rosuvastatin	B-FARMACO
from	O
10	O
mg	O
to	O
5	O
mg	O
.	O
January	O
2019	O
total	O
cholesterol	O
75	O
mg	O
dl	O
,	O
HDL	O
C	O
42	O
mg	O
dl	O
,	O
LDL	O
C	O
18	O
mg	O
dl	O
.	O
Lp	O
a	O
50	O
mg	O
dl	O
.	O
It	O
is	O
decided	O
to	O
withdraw	O
ezetimibe	B-FARMACO
.	O
February	O
2019	O
total	O
cholesterol	O
78	O
mg	O
dl	O
,	O
HDLc	O
39	O
mg	O
dl	O
,	O
LDLc	O
26	O
mg	O
dl	O
.	O
Lp	O
a	O
56	O
mg	O
dl	O
March	O
2019	O
total	O
cholesterol	O
83	O
mg	O
dl	O
,	O
HDL	O
C	O
40	O
mg	O
dl	O
,	O
LDL	O
C	O
25	O
mg	O
dl	O
.	O
Lp	O
a	O
52	O
mg	O
dl	O
.	O
For	O
the	O
time	O
being	O
March	O
2019	O
,	O
the	O
patient	O
has	O
not	O
presented	O
any	O
adverse	O
effects	O
related	O
to	O
treatment	O
with	O
proprotein	O
convertase	O
subtilisin	O
kexin	O
type	O
9	O
iPCSK9	O
inhibitors	O
;	O
and	O
after	O
the	O
rosuvastatin	B-FARMACO
dose	O
reduction	O
,	O
the	O
hepatobiliary	O
profile	O
has	O
normalised	O
ALT	O
22	O
U	O
l	O
,	O
AST	O
25	O
U	O
l	O
.	O
and	O
the	O
myalgias	O
have	O
disappeared	O
.	O
Other	O
cardiovascular	O
risk	O
factors	O
remain	O
well	O
controlled	O
blood	O
pressure	O
130	O
90	O
mmHg	O
,	O
baseline	O
blood	O
glucose	O
100	O
mg	O
dl	O
;	O
HbA1c	O
7	O
,	O
BMI	O
25	O
kg	O
m2	O
,	O
abdominal	O
circumference	O
94	O
cm	O
.	O
In	O
light	O
of	O
the	O
CMR	O
results	O
and	O
the	O
evolution	O
of	O
LVEF	O
and	O
functional	O
class	O
,	O
the	O
need	O
for	O
ICD	O
implantation	O
at	O
follow	O
up	O
remains	O
to	O
be	O
considered	O
.	O
DIAGNOSIS	O
Chronic	O
ischaemic	O
heart	O
disease	O
.	O
Canadian	O
Cardiovascular	O
Society	O
CCS	O
functional	O
class	O
I	O
IV	O
.	O
Moderately	O
depressed	O
LVEF	O
.	O
Late	O
transmural	O
anteroseptal	O
enhancement	O
on	O
CMR	O
.	O
Two	O
vessel	O
coronary	O
artery	O
disease	O
completely	O
revascularised	O
percutaneously	O
.	O
Drug	O
eluting	O
stents	O
in	O
DAm	O
D1	O
and	O
IVP	O
.	O
Dyslipidaemia	O
.	O
Hypercholesterolemia	O
.	O
Elevation	O
of	O
lipoprotein	O
a	O
.	O
Statin	O
intolerance	O
.	O
Optimal	O
control	O
of	O
LDL	O
C	O
and	O
Lp	O
a	O
levels	O
after	O
initiation	O
of	O
treatment	O
with	O
iPCSK9	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
,	O
with	O
good	O
glycaemic	O
control	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
HT	O
,	O
smoker	O
.	O
No	O
diabetes	O
mellitus	O
DM	O
,	O
no	O
dyslipidaemia	O
DL	O
.	O
Cardiological	O
history	O
2006	O
out	O
of	O
hospital	O
cardiorespiratory	O
arrest	O
CRA	O
recovered	O
.	O
First	O
rhythm	O
detected	O
ventricular	O
fibrillation	O
.	O
The	O
output	O
electrocardiogram	O
ECG	O
showed	O
ST	O
elevation	O
in	O
precordial	O
leads	O
.	O
Catheterisation	O
non	O
significant	O
lesion	O
in	O
AMD	O
.	O
Positive	O
acetylcholine	O
test	O
.	O
Transthoracic	O
echocardiogram	O
normal	O
LVEF	O
,	O
apical	O
septal	O
dyskinesia	O
.	O
She	O
was	O
discharged	O
with	O
a	O
diagnosis	O
of	O
coronary	O
vasospasm	O
and	O
treatment	O
was	O
started	O
with	O
nitrates	O
and	O
calcium	O
antagonists	O
.	O
Subsequent	O
follow	O
up	O
in	O
cardiology	O
outpatient	O
clinics	O
,	O
she	O
remained	O
stable	O
.	O
It	O
was	O
not	O
possible	O
to	O
increase	O
the	O
dose	O
of	O
diltiazem	B-FARMACO
to	O
maximum	O
doses	O
due	O
to	O
poor	O
tolerance	O
.	O
2009	O
admitted	O
for	O
non	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
NSTEACS	O
.	O
On	O
arrival	O
he	O
reported	O
chest	O
pain	O
,	O
the	O
ECG	O
showed	O
ST	O
segment	O
depression	O
in	O
V1	O
V2	O
and	O
I	O
,	O
aVL	O
;	O
he	O
presented	O
peak	O
Tn	O
I	O
of	O
0	O
.	O
14	O
.	O
Catheterisation	O
coronary	O
arteries	O
without	O
lesions	O
.	O
Transthoracic	O
echocardiogram	O
normal	O
LVEF	O
.	O
No	O
segmental	O
alterations	O
.	O
Baseline	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
.	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
I	O
.	O
Usual	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
d	O
,	O
atorvastatin	B-FARMACO
20	O
mg	O
d	O
,	O
isosorbide	B-FARMACO
mononitrate	I-FARMACO
60	O
mg	O
d	O
,	O
diltiazem	B-FARMACO
retard	I-FARMACO
120	O
mg	O
12h	O
,	O
valsartan	B-FARMACO
320	O
mg	O
12h	O
.	O
Pregabalin	B-FARMACO
,	O
tramadol	B-FARMACO
,	O
naproxen	B-FARMACO
.	O
CURRENT	O
ILLNESS	O
50	O
year	O
old	O
woman	O
brought	O
to	O
the	O
emergency	O
department	O
by	O
SUMMA	O
after	O
recovered	O
out	O
of	O
hospital	O
CRA	O
.	O
Her	O
daughter	O
reported	O
that	O
she	O
woke	O
up	O
this	O
morning	O
with	O
general	O
malaise	O
and	O
chest	O
discomfort	O
.	O
At	O
8	O
o	O
'	O
clock	O
in	O
the	O
morning	O
she	O
presented	O
with	O
witnessed	O
CPR	O
and	O
basic	O
CPR	O
manoeuvres	O
were	O
started	O
immediately	O
.	O
The	O
police	O
arrived	O
after	O
a	O
few	O
minutes	O
and	O
continued	O
with	O
basic	O
CPR	O
.	O
On	O
arrival	O
of	O
SUMMA	O
,	O
ventricular	O
fibrillation	O
was	O
observed	O
and	O
sinus	O
rhythm	O
was	O
recovered	O
after	O
a	O
200	O
J	O
shock	O
.	O
The	O
basic	O
and	O
advanced	O
CPR	O
manoeuvres	O
lasted	O
15	O
20	O
minutes	O
.	O
The	O
emergency	O
services	O
proceeded	O
with	O
orotracheal	O
intubation	O
,	O
sedation	O
and	O
transfer	O
to	O
our	O
centre	O
.	O
PHYSICAL	O
EXAMINATION	O
Intubated	O
,	O
sedated	O
under	O
midazolam	B-FARMACO
perfusion	O
.	O
Blood	O
pressure	O
BP	O
113	O
83	O
mmHg	O
without	O
inotropics	O
.	O
Heart	O
rate	O
HR	O
74	O
bpm	O
.	O
Sat	O
100	O
with	O
VMI	O
with	O
FiO2	O
100	O
,	O
VT	O
500	O
,	O
FR	O
17	O
.	O
Well	O
hydrated	O
,	O
nourished	O
and	O
perfused	O
.	O
Normal	O
colour	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
over	O
additions	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
Pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
performed	O
by	O
the	O
emergency	O
services	O
during	O
transfer	O
to	O
our	O
centre	O
atrial	O
fibrillation	O
at	O
130	O
bpm	O
with	O
normal	O
axis	O
60	O
narrow	O
QRS	O
100	O
ms	O
,	O
diffuse	O
repolarisation	O
alterations	O
.	O
Normal	O
QTc	O
430	O
ms	O
.	O
Chest	O
X	O
ray	O
on	O
arrival	O
technically	O
limited	O
plaque	O
,	O
rotated	O
and	O
tilted	O
no	O
right	O
costophrenic	O
sinus	O
.	O
Aortic	O
elongation	O
.	O
Mediastinum	O
difficult	O
to	O
assess	O
due	O
to	O
the	O
limitations	O
of	O
the	O
X	O
ray	O
.	O
Cardiothoracic	O
index	O
within	O
the	O
normal	O
range	O
.	O
Unspecific	O
alterations	O
of	O
the	O
pulmonary	O
parenchyma	O
.	O
No	O
left	O
pleural	O
effusion	O
was	O
observed	O
.	O
Analysis	O
and	O
blood	O
gases	O
on	O
arrival	O
Hb	O
13	O
.	O
1	O
g	O
dl	O
.	O
Leukocytes	O
23	O
.	O
1	O
x	O
103	O
ul	O
.	O
Platelets	O
265	O
000	O
ul	O
.	O
INR	O
1	O
.	O
Creatinine	O
0	O
.	O
97	O
mg	O
dl	O
.	O
Na	O
143	O
mmol	O
l	O
.	O
K	O
3	O
.	O
7	O
mmol	O
l	O
.	O
Tn	O
I	O
3	O
.	O
55	O
ng	O
ml	O
.	O
CRP	O
2	O
.	O
9	O
mg	O
l	O
.	O
pH	O
7	O
.	O
32	O
,	O
pCO2	O
49	O
mm	O
Hg	O
,	O
pO2	O
87	O
mm	O
Hg	O
,	O
HCO3	O
25	O
mmol	O
l	O
,	O
lactate	O
1	O
.	O
8	O
mmol	O
l	O
.	O
Transthoracic	O
echocardiogram	O
in	O
the	O
resuscitation	O
room	O
left	O
ventricle	O
not	O
dilated	O
,	O
not	O
hypertrophic	O
,	O
with	O
normal	O
global	O
systolic	O
function	O
.	O
Apical	O
akinesia	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
No	O
significant	O
valvular	O
heart	O
disease	O
.	O
No	O
pericardial	O
effusion	O
.	O
Catheterisation	O
epicardial	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O
Normal	O
ventriculography	O
and	O
aortography	O
.	O
CLINICAL	O
EVOLUTION	O
At	O
10	O
00	O
hours	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
,	O
following	O
catheterisation	O
in	O
which	O
coronary	O
arteries	O
were	O
observed	O
without	O
significant	O
lesions	O
and	O
a	O
transthoracic	O
echocardiogram	O
showed	O
normal	O
ventricular	O
function	O
with	O
apical	O
akinesia	O
.	O
The	O
patient	O
was	O
monitored	O
and	O
a	O
therapeutic	O
hypothermia	O
protocol	O
was	O
started	O
.	O
In	O
addition	O
,	O
treatment	O
was	O
started	O
with	O
verapamil	B-FARMACO
via	O
nasogastric	O
tube	O
.	O
Target	O
temperature	O
of	O
32	O
C	O
was	O
reached	O
at	O
16	O
00	O
hours	O
.	O
He	O
remained	O
stable	O
until	O
6	O
58	O
am	O
the	O
following	O
day	O
when	O
he	O
presented	O
with	O
new	O
ventricular	O
fibrillation	O
.	O
Advanced	O
CPR	O
manoeuvres	O
were	O
started	O
and	O
the	O
patient	O
received	O
multiple	O
unsuccessful	O
defibrillations	O
.	O
The	O
cardiac	O
rhythm	O
became	O
asystole	O
agonal	O
rhythm	O
with	O
no	O
recovery	O
of	O
spontaneous	O
circulation	O
at	O
any	O
time	O
.	O
The	O
manoeuvres	O
were	O
prolonged	O
for	O
more	O
than	O
60	O
minutes	O
without	O
success	O
,	O
and	O
the	O
patient	O
received	O
10	O
mg	O
of	O
adrenaline	B-FARMACO
,	O
two	O
boluses	O
of	O
300	O
mg	O
of	O
amiodarone	B-FARMACO
,	O
2	O
ampoules	O
of	O
lidocaine	B-FARMACO
and	O
1	O
ampoule	O
of	O
magnesium	B-FARMACO
.	O
Death	O
was	O
certified	O
at	O
8	O
18	O
hours	O
.	O
On	O
reviewing	O
the	O
patient	O
's	O
telemetry	O
,	O
ST	O
segment	O
depression	O
lead	O
aVF	O
was	O
observed	O
in	O
the	O
previous	O
minutes	O
,	O
with	O
the	O
appearance	O
of	O
increasingly	O
frequent	O
ventricular	O
extrasystoles	O
that	O
progressively	O
led	O
to	O
ST	O
segment	O
elevation	O
in	O
this	O
lead	O
and	O
finally	O
an	O
extrasystole	O
with	O
R	O
over	O
T	O
phenomenon	O
generated	O
an	O
episode	O
of	O
ventricular	O
fibrillation	O
.	O
DIAGNOSIS	O
Out	O
of	O
hospital	O
cardiorespiratory	O
arrest	O
with	O
first	O
ventricular	O
fibrillation	O
rhythm	O
in	O
the	O
context	O
of	O
MINOCA	O
acute	O
myocardial	O
infarction	O
with	O
coronary	O
arteries	O
without	O
significant	O
obstructive	O
lesions	O
,	O
possibly	O
related	O
to	O
coronary	O
vasospasm	O
.	O
In	O
hospital	O
cardiorespiratory	O
arrest	O
and	O
death	O
in	O
a	O
patient	O
under	O
therapeutic	O
hypothermia	O
with	O
first	O
ventricular	O
fibrillation	O
rhythm	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
72	O
year	O
old	O
woman	O
,	O
retired	O
.	O
Lives	O
alone	O
with	O
good	O
family	O
support	O
.	O
Active	O
life	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
smoker	O
or	O
drinker	O
.	O
No	O
known	O
hypertension	O
HTN	O
,	O
diabetes	O
mellitus	O
DM	O
or	O
dyslipidaemia	O
.	O
No	O
known	O
heart	O
disease	O
or	O
bronchopathy	O
.	O
No	O
surgical	O
interventions	O
of	O
interest	O
.	O
No	O
chronic	O
treatments	O
.	O
PRESENT	O
ILLNESS	O
72	O
year	O
old	O
woman	O
brought	O
to	O
the	O
emergency	O
department	O
by	O
the	O
emergency	O
services	O
due	O
to	O
poor	O
general	O
condition	O
and	O
unspecific	O
abdominal	O
pain	O
of	O
several	O
days	O
'	O
evolution	O
.	O
On	O
arrival	O
,	O
poor	O
clinical	O
and	O
haemodynamic	O
condition	O
,	O
with	O
blood	O
pressure	O
around	O
80	O
40	O
mmHg	O
and	O
heart	O
rate	O
HR	O
of	O
190	O
bpm	O
,	O
with	O
peripheral	O
hypoperfusion	O
and	O
lividity	O
in	O
all	O
four	O
extremities	O
together	O
with	O
low	O
level	O
of	O
consciousness	O
.	O
Given	O
the	O
poor	O
clinical	O
condition	O
,	O
orotracheal	O
intubation	O
was	O
performed	O
and	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
ICU	O
was	O
decided	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
85	O
42	O
mmHg	O
,	O
HR	O
190	O
bpm	O
,	O
oxygen	O
saturation	O
SatO2	O
not	O
assessable	O
due	O
to	O
hypoperfusion	O
,	O
afebrile	O
.	O
Poor	O
general	O
condition	O
,	O
low	O
level	O
of	O
consciousness	O
and	O
skin	O
coldness	O
and	O
peripheral	O
hypoperfusion	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
at	O
190x	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
without	O
added	O
pathological	O
sounds	O
.	O
Abdomen	O
abdominal	O
distension	O
,	O
with	O
preserved	O
hydro	O
aerial	O
sounds	O
.	O
Hepatomegaly	O
of	O
2	O
traverses	O
.	O
Upper	O
extremities	O
poor	O
distal	O
perfusion	O
,	O
no	O
palpable	O
pulses	O
.	O
Lividity	O
in	O
both	O
extremities	O
.	O
Upper	O
extremities	O
poor	O
distal	O
perfusion	O
,	O
no	O
palpable	O
pulses	O
.	O
No	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Lividity	O
in	O
both	O
extremities	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
on	O
admission	O
to	O
the	O
ICU	O
Haemogram	O
leucocytes	O
16800	O
μL	O
80	O
polymorphonuclear	O
,	O
Hb	O
12	O
.	O
4	O
g	O
dl	O
,	O
platelets	O
335	O
,	O
000	O
μl	O
.	O
Coagulation	O
INR	O
1	O
.	O
8	O
,	O
aPTT	O
28	O
.	O
3	O
sec	O
.	O
Biochemistry	O
creatinine	O
1	O
.	O
32	O
mg	O
dl	O
,	O
urea	O
87	O
mg	O
dl	O
,	O
sodium	O
127	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
7	O
mEq	O
l	O
,	O
bilirubin	O
1	O
mg	O
dl	O
,	O
aspartate	O
aminotransferase	O
696	O
U	O
l	O
,	O
alanine	O
aminotransferase	O
629	O
U	O
l	O
,	O
gamma	O
glutamyl	O
transpeptidase	O
162	O
U	O
l	O
,	O
amylase	O
97	O
mg	O
dl	O
,	O
troponin	O
T	O
39	O
ng	O
l	O
,	O
C	O
reactive	O
protein	O
13	O
mg	O
dl	O
,	O
procalcitonin	O
0	O
.	O
15	O
ng	O
ml	O
.	O
TSH	O
normal	O
.	O
Electrocardiogram	O
ECG	O
on	O
admission	O
regular	O
tachycardia	O
at	O
200	O
bpm	O
without	O
visualisation	O
of	O
p	O
waves	O
,	O
normal	O
axis	O
,	O
narrow	O
QRS	O
,	O
ST	O
rectification	O
on	O
the	O
inferolateral	O
side	O
.	O
ECG	O
after	O
cardioversion	O
atrial	O
fibrillation	O
AF	O
at	O
90	O
bpm	O
with	O
isolated	O
ventricular	O
extrasystoles	O
,	O
normal	O
axis	O
,	O
narrow	O
QRS	O
,	O
inferolateral	O
ST	O
rectification	O
,	O
normal	O
QT	O
.	O
ICU	O
ECG	O
regular	O
tachycardia	O
at	O
140	O
bpm	O
,	O
inferior	O
axis	O
,	O
wide	O
QRS	O
with	O
morphology	O
of	O
complete	O
right	O
bundle	O
branch	O
block	O
RBBB	O
and	O
secondary	O
repolarisation	O
abnormalities	O
.	O
ECG	O
after	O
transient	O
pacemaker	O
PM	O
implantation	O
atrial	O
rhythm	O
at	O
80	O
bpm	O
stimulated	O
by	O
pacemaker	O
with	O
negative	O
p	O
waves	O
in	O
inferior	O
face	O
with	O
short	O
PR	O
100	O
ms	O
,	O
normal	O
axis	O
,	O
QRS	O
100	O
ms	O
widened	O
with	O
respect	O
to	O
baseline	O
with	O
evident	O
positive	O
pre	O
excitation	O
in	O
V2	O
V5	O
.	O
ECG	O
at	O
discharge	O
RS	O
at	O
60	O
bpm	O
,	O
normal	O
axis	O
,	O
PR	O
120	O
ms	O
,	O
narrow	O
QRS	O
without	O
pre	O
excitation	O
,	O
QT	O
400	O
ms	O
,	O
no	O
signs	O
of	O
acute	O
ischaemia	O
or	O
repolarisation	O
disturbance	O
.	O
Portable	O
chest	O
X	O
ray	O
on	O
admission	O
normal	O
cardiothoracic	O
index	O
.	O
Congestive	O
hilar	O
with	O
slight	O
vascular	O
redistribution	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
No	O
condensation	O
images	O
.	O
CT	O
scan	O
of	O
the	O
abdomen	O
with	O
intravenous	O
contrast	O
on	O
admission	O
bilateral	O
pleural	O
effusion	O
.	O
Hepatomegaly	O
.	O
Marked	O
reduction	O
in	O
the	O
calibre	O
of	O
the	O
main	O
branches	O
of	O
the	O
abdominal	O
aorta	O
,	O
especially	O
the	O
distal	O
branches	O
of	O
the	O
superior	O
mesenteric	O
,	O
which	O
could	O
justify	O
hypoperfusion	O
of	O
the	O
tributary	O
territory	O
of	O
the	O
same	O
.	O
Echocardioscopy	O
on	O
admission	O
performed	O
in	O
regular	O
TQ	O
at	O
190	O
x	O
LV	O
of	O
normal	O
size	O
with	O
marked	O
global	O
hypocontractility	O
and	O
severe	O
systolic	O
dysfunction	O
.	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
Mitral	O
insufficiency	O
that	O
appears	O
mild	O
moderate	O
difficult	O
to	O
quantify	O
in	O
TQ	O
at	O
190x	O
,	O
the	O
rest	O
without	O
relevant	O
incidences	O
.	O
Transthoracic	O
echocardiography	O
prior	O
to	O
discharge	O
non	O
dilated	O
left	O
ventricle	O
LV	O
with	O
slight	O
concentric	O
hypertrophy	O
.	O
No	O
segmental	O
contractility	O
disorders	O
.	O
Diastolic	O
dysfunction	O
grade	O
II	O
.	O
LVEF	O
65	O
by	O
Simpson	O
BP	O
.	O
Right	O
ventricle	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
Anatomically	O
normal	O
mitral	O
valve	O
with	O
central	O
insufficiency	O
jet	O
reaching	O
the	O
roof	O
of	O
the	O
left	O
atrium	O
LA	O
but	O
with	O
protosystolic	O
predominance	O
,	O
which	O
we	O
classify	O
as	O
mild	O
moderate	O
.	O
The	O
rest	O
of	O
the	O
valves	O
were	O
normal	O
with	O
no	O
pathological	O
flows	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
and	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
ICU	O
in	O
a	O
situation	O
of	O
shock	O
of	O
uncertain	O
origin	O
,	O
in	O
MV	O
and	O
requiring	O
noradrenaline	B-FARMACO
to	O
maintain	O
blood	O
pressure	O
.	O
Given	O
the	O
abdominal	O
symptoms	O
reported	O
by	O
the	O
family	O
prior	O
to	O
admission	O
,	O
it	O
was	O
decided	O
to	O
complete	O
studies	O
with	O
an	O
emergent	O
CT	O
scan	O
of	O
the	O
abdomen	O
,	O
which	O
showed	O
a	O
reduction	O
in	O
the	O
calibre	O
of	O
the	O
main	O
branches	O
of	O
the	O
abdominal	O
aorta	O
with	O
possible	O
hypoperfusion	O
of	O
its	O
tributary	O
territory	O
,	O
so	O
an	O
emergent	O
exploratory	O
laparotomy	O
was	O
performed	O
,	O
which	O
showed	O
no	O
pathological	O
findings	O
.	O
Back	O
in	O
the	O
ICU	O
,	O
echocardioscopy	O
was	O
performed	O
with	O
the	O
finding	O
of	O
marked	O
global	O
hypocontractility	O
and	O
severe	O
systolic	O
dysfunction	O
.	O
Given	O
the	O
situation	O
of	O
shock	O
with	O
vasopressor	O
amines	B-FARMACO
and	O
the	O
persistence	O
of	O
rhythmic	O
tachycardia	O
with	O
narrow	O
QRS	O
at	O
200	O
bpm	O
,	O
it	O
was	O
decided	O
to	O
perform	O
electrical	O
cardioversion	O
ECV	O
at	O
200J	O
on	O
suspicion	O
of	O
persistent	O
supraventricular	O
tachycardia	O
,	O
which	O
was	O
effective	O
but	O
the	O
patient	O
immediately	O
presented	O
AF	O
with	O
controlled	O
ventricular	O
rate	O
.	O
The	O
condition	O
was	O
labelled	O
as	O
cardiogenic	O
shock	O
and	O
iv	O
dobutamine	B-FARMACO
perfusion	O
was	O
added	O
,	O
but	O
the	O
patient	O
had	O
a	O
torpid	O
evolution	O
with	O
significant	O
haemodynamic	O
instability	O
despite	O
noradrenaline	B-FARMACO
and	O
dobutamine	B-FARMACO
,	O
progressing	O
to	O
multi	O
organ	O
failure	O
oligoanuric	O
liver	O
and	O
kidney	O
failure	O
requiring	O
haemofiltration	O
.	O
From	O
the	O
arrhythmic	O
point	O
of	O
view	O
,	O
the	O
patient	O
presented	O
several	O
subsequent	O
recurrences	O
of	O
narrow	O
QRS	O
tachycardia	O
at	O
200	O
bpm	O
,	O
in	O
addition	O
to	O
frequent	O
bouts	O
of	O
wide	O
QRS	O
rhythmic	O
tachycardia	O
at	O
140	O
bpm	O
with	O
HRBBB	O
morphology	O
and	O
occasional	O
mildly	O
irregular	O
lower	O
axis	O
.	O
The	O
patient	O
was	O
initially	O
diagnosed	O
as	O
ventricular	O
tachycardia	O
,	O
so	O
amiodarone	B-FARMACO
perfusion	O
was	O
started	O
and	O
discontinued	O
after	O
24	O
hours	O
due	O
to	O
QTc	O
prolongation	O
up	O
to	O
610	O
ms	O
.	O
Given	O
the	O
persistence	O
of	O
this	O
wide	O
QRS	O
tachycardia	O
,	O
which	O
did	O
not	O
subside	O
with	O
procainamide	B-FARMACO
,	O
esmolol	B-FARMACO
and	O
multiple	O
CVE	O
,	O
a	O
transient	O
pacemaker	O
was	O
implanted	O
for	O
over	O
stimulation	O
.	O
Incidentally	O
,	O
the	O
pacemaker	O
lead	O
was	O
placed	O
in	O
the	O
coronary	O
sinus	O
,	O
and	O
the	O
post	O
implantation	O
ECG	O
showed	O
atrial	O
capture	O
with	O
short	O
PR	O
and	O
delta	O
wave	O
suggestive	O
of	O
ventricular	O
pre	O
excitation	O
.	O
During	O
this	O
period	O
,	O
the	O
patient	O
remained	O
in	O
cardiogenic	O
shock	O
,	O
with	O
persistent	O
multi	O
organ	O
failure	O
and	O
the	O
need	O
for	O
vasoactive	O
amines	B-FARMACO
.	O
Control	O
echocardiograms	O
showed	O
a	O
slight	O
improvement	O
in	O
ventricular	O
function	O
,	O
but	O
given	O
the	O
persistence	O
of	O
arrhythmic	O
events	O
despite	O
medical	O
treatment	O
and	O
stimulation	O
,	O
and	O
with	O
the	O
suspicion	O
of	O
a	O
possible	O
accessory	O
pathway	O
,	O
it	O
was	O
decided	O
to	O
perform	O
an	O
electrophysiological	O
study	O
EPS	O
.	O
In	O
the	O
EPS	O
,	O
the	O
clinical	O
wide	O
QRS	O
tachycardia	O
was	O
induced	O
,	O
finding	O
atrial	O
flutter	O
with	O
2	O
1	O
AV	O
conduction	O
and	O
wide	O
QRS	O
with	O
BCRDHH	O
morphology	O
and	O
short	O
HV	O
compatible	O
with	O
pre	O
excited	O
2	O
1	O
flutter	O
.	O
In	O
addition	O
,	O
bouts	O
of	O
orthodromic	O
tachycardia	O
regular	O
with	O
narrow	O
QRS	O
are	O
induced	O
,	O
equal	O
to	O
the	O
clinic	O
with	O
eccentric	O
atrial	O
activation	O
sequence	O
in	O
the	O
coronary	O
sinus	O
with	O
earlier	O
atriogram	O
in	O
S2	O
S3	O
,	O
which	O
frequently	O
degenerate	O
into	O
pre	O
excited	O
AF	O
irregular	O
with	O
irregular	O
wide	O
QRS	O
.	O
Effective	O
ablation	O
was	O
performed	O
on	O
the	O
left	O
posterolateral	O
accessory	O
pathway	O
with	O
disappearance	O
of	O
the	O
pre	O
excitation	O
2	O
seconds	O
after	O
application	O
,	O
and	O
the	O
absence	O
of	O
retrograde	O
conduction	O
through	O
the	O
pathway	O
was	O
verified	O
.	O
After	O
the	O
procedure	O
,	O
the	O
patient	O
returned	O
to	O
the	O
ICU	O
,	O
where	O
she	O
remained	O
in	O
alternating	O
atrial	O
fibrillation	O
and	O
atrial	O
flutter	O
narrow	O
QRS	O
,	O
without	O
pre	O
excitation	O
and	O
with	O
ventricular	O
response	O
controlled	O
with	O
digoxin	B-FARMACO
.	O
During	O
the	O
following	O
days	O
,	O
he	O
showed	O
good	O
haemodynamic	O
and	O
clinical	O
evolution	O
,	O
allowing	O
extubation	O
,	O
withdrawal	O
of	O
perfusions	O
and	O
transfer	O
to	O
the	O
cardiology	O
ward	O
after	O
stabilisation	O
,	O
where	O
he	O
persisted	O
at	O
all	O
times	O
with	O
controlled	O
HR	O
and	O
alternating	O
AF	O
and	O
flutter	O
monitoring	O
without	O
presenting	O
new	O
bouts	O
of	O
tachycardia	O
.	O
After	O
15	O
days	O
of	O
hospitalisation	O
,	O
discharge	O
was	O
decided	O
,	O
with	O
prior	O
performance	O
of	O
a	O
new	O
echocardiography	O
,	O
which	O
showed	O
preserved	O
biventricular	O
systolic	O
function	O
without	O
segmental	O
alterations	O
of	O
contractility	O
,	O
mild	O
moderate	O
functional	O
mitral	O
insufficiency	O
and	O
diastolic	O
dysfunction	O
.	O
DIAGNOSIS	O
Wolff	O
Parkinson	O
White	O
syndrome	O
via	O
left	O
posterolateral	O
approach	O
with	O
orthodromic	O
tachycardia	O
,	O
pre	O
excited	O
atrial	O
fibrillation	O
and	O
flutter	O
.	O
Tachycardiomyopathy	O
secondary	O
to	O
the	O
above	O
with	O
severe	O
systolic	O
dysfunction	O
recovered	O
after	O
accessory	O
pathway	O
ablation	O
.	O
Cardiogenic	O
shock	O
with	O
multi	O
organ	O
failure	O
secondary	O
to	O
previous	O
diagnoses	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
85	O
year	O
old	O
man	O
,	O
with	O
fasting	O
hyperglycaemia	O
as	O
the	O
only	O
history	O
of	O
interest	O
.	O
Active	O
and	O
independent	O
.	O
He	O
had	O
been	O
admitted	O
a	O
year	O
earlier	O
to	O
the	O
geriatric	O
ward	O
for	O
a	O
first	O
episode	O
of	O
heart	O
failure	O
in	O
the	O
context	O
of	O
lower	O
respiratory	O
tract	O
infection	O
.	O
Clinical	O
evolution	O
was	O
favourable	O
with	O
diuretics	O
and	O
empirical	O
antibiotic	O
therapy	O
.	O
Although	O
he	O
was	O
in	O
sinus	O
rhythm	O
on	O
admission	O
,	O
shortly	O
afterwards	O
he	O
developed	O
atrial	O
fibrillation	O
with	O
slightly	O
elevated	O
ventricular	O
response	O
.	O
An	O
echocardiogram	O
ECG	O
was	O
performed	O
with	O
findings	O
of	O
severe	O
ventricular	O
hypertrophy	O
,	O
biauricular	O
dilatation	O
and	O
restrictive	O
diastolic	O
pattern	O
,	O
compatible	O
with	O
infiltrative	O
myocardial	O
disease	O
.	O
He	O
was	O
discharged	O
six	O
days	O
later	O
with	O
acenocoumarol	B-FARMACO
,	O
torasemide	B-FARMACO
20	O
mg	O
and	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
,	O
pending	O
completion	O
of	O
the	O
outpatient	O
study	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
atrial	O
fibrillation	O
with	O
mean	O
ventricular	O
response	O
of	O
60	O
bpm	O
,	O
low	O
voltage	O
in	O
limb	O
leads	O
and	O
pseudoinfarction	O
pattern	O
with	O
QS	O
in	O
V1	O
V2	O
.	O
ANALYTICS	O
amino	O
terminal	O
pro	O
brain	O
natriuretic	O
peptide	O
NT	O
proBNP	O
fraction	O
4	O
,	O
175	O
pg	O
ml	O
,	O
ultra	O
sensitive	O
troponin	O
T	O
65	O
ng	O
l	O
.	O
The	O
rest	O
was	O
normal	O
,	O
including	O
haemogram	O
,	O
glycaemia	O
,	O
renal	O
function	O
,	O
liver	O
function	O
,	O
thyroid	O
hormones	O
,	O
ions	O
,	O
lipids	O
and	O
iron	O
study	O
.	O
The	O
protein	O
study	O
was	O
normal	O
,	O
with	O
proteinogram	O
,	O
serum	O
urine	O
immunofixation	O
and	O
light	O
chains	O
.	O
Control	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
severe	O
concentric	O
hypertrophy	O
of	O
granular	O
pattern	O
,	O
maximum	O
thickness	O
of	O
the	O
basal	O
septum	O
28	O
mm	O
,	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
45	O
50	O
.	O
Severe	O
diastolic	O
dysfunction	O
with	O
restrictive	O
pattern	O
and	O
estimated	O
pulmonary	O
capillary	O
pressure	O
of	O
30	O
mmHg	O
.	O
Moderate	O
biauricular	O
dilatation	O
.	O
Hypertrophic	O
right	O
ventricle	O
.	O
Thickened	O
mitral	O
valve	O
,	O
with	O
mild	O
insufficiency	O
.	O
Estimated	O
systolic	O
pulmonary	O
pressure	O
43	O
mmHg	O
.	O
Mild	O
pericardial	O
effusion	O
.	O
ABDOMINAL	O
ECOGRAPHY	O
mild	O
hepatomegaly	O
,	O
without	O
other	O
pathological	O
findings	O
.	O
HOLTER	O
ECG	O
atrial	O
fibrillation	O
with	O
an	O
average	O
heart	O
rate	O
HR	O
of	O
65	O
bpm	O
.	O
Minimum	O
HR	O
of	O
35	O
bpm	O
during	O
nocturnal	O
rest	O
and	O
maximum	O
of	O
120	O
bpm	O
during	O
physical	O
exercise	O
.	O
Nonsignificant	O
pauses	O
predominantly	O
at	O
night	O
the	O
longest	O
lasting	O
2	O
seconds	O
.	O
Isolated	O
ventricular	O
extrasystoles	O
,	O
infrequent	O
.	O
Abdominal	O
fat	O
and	O
salivary	O
gland	O
biopsies	O
negative	O
for	O
amyloid	O
material	O
.	O
CARDIAC	O
MRI	O
left	O
ventricle	O
with	O
marked	O
diffuse	O
concentric	O
thickening	O
,	O
mild	O
systolic	O
dysfunction	O
.	O
Mild	O
dilatation	O
of	O
both	O
atria	O
.	O
Diffuse	O
parietal	O
late	O
enhancement	O
in	O
all	O
four	O
chambers	O
.	O
Mild	O
pleural	O
effusion	O
,	O
no	O
pericardial	O
effusion	O
.	O
GRAMMAGRAPHY	O
technetium	O
diphostat	O
99mTc	O
DPD	O
intense	O
biventricular	O
tracer	O
uptake	O
,	O
grade	O
2	O
.	O
GENETIC	O
STUDY	O
by	O
Sanger	O
sequencing	O
of	O
the	O
TTR	O
gene	O
negative	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
follow	O
up	O
,	O
the	O
patient	O
has	O
remained	O
stable	O
,	O
with	O
no	O
new	O
admissions	O
or	O
visits	O
to	O
the	O
emergency	O
room	O
for	O
heart	O
failure	O
.	O
He	O
currently	O
reports	O
dyspnoea	O
on	O
moderate	O
exertion	O
,	O
asthenia	O
,	O
two	O
pillow	O
orthopnoea	O
and	O
mild	O
malleolar	O
oedema	O
,	O
predominantly	O
in	O
the	O
evening	O
.	O
Blood	O
pressure	O
is	O
usually	O
low	O
and	O
there	O
are	O
episodes	O
of	O
non	O
syncopal	O
dizziness	O
with	O
orthostatic	O
features	O
.	O
In	O
terms	O
of	O
treatment	O
,	O
acenocoumarol	B-FARMACO
has	O
been	O
replaced	O
by	O
a	O
direct	O
acting	O
anticoagulant	O
due	O
to	O
poor	O
control	O
of	O
the	O
international	O
normalised	O
ratio	O
INR	O
,	O
with	O
time	O
in	O
therapeutic	O
range	O
below	O
30	O
.	O
Bisoprolol	B-FARMACO
has	O
been	O
withdrawn	O
due	O
to	O
relatively	O
slow	O
heart	O
rate	O
50	O
60	O
bpm	O
and	O
hypotension	O
90	O
60	O
mmHg	O
.	O
Current	O
medical	O
treatment	O
is	O
rivaroxaban	B-FARMACO
15	O
mg	O
,	O
torasemide	B-FARMACO
10	O
mg	O
and	O
spironolactone	B-FARMACO
25	O
mg	O
,	O
with	O
a	O
flexible	O
diuretic	O
regimen	O
.	O
DIAGNOSIS	O
Congestive	O
heart	O
failure	O
with	O
mildly	O
depressed	O
ejection	O
fraction	O
,	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
II	O
.	O
Restrictive	O
cardiomyopathy	O
due	O
to	O
TTR	O
wild	O
type	O
amyloidosis	O
,	O
with	O
severe	O
biventricular	O
hypertrophy	O
and	O
severe	O
diastolic	O
dysfunction	O
.	O
Permanent	O
atrial	O
fibrillation	O
,	O
with	O
controlled	O
ventricular	O
response	O
.	O
High	O
cardioembolic	O
risk	O
,	O
anticoagulated	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
71	O
year	O
old	O
patient	O
,	O
with	O
a	O
personal	O
history	O
of	O
Cardiovascular	O
risk	O
factors	O
arterial	O
hypertension	O
,	O
dyslipidaemia	O
,	O
type	O
2	O
diabetes	O
mellitus	O
.	O
Ex	O
smoker	O
for	O
more	O
than	O
15	O
years	O
.	O
Chronic	O
gastritis	O
.	O
Eradication	O
of	O
Helicobacter	O
pylori	O
in	O
2010	O
.	O
Stroke	O
with	O
mild	O
sequelae	O
in	O
2007	O
.	O
Intermittent	O
claudication	O
at	O
100	O
metres	O
.	O
Bilateral	O
femoro	O
popliteal	O
occlusion	O
,	O
without	O
considering	O
surgery	O
by	O
Vascular	O
Surgery	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
.	O
Long	O
history	O
of	O
chronic	O
ischaemic	O
heart	O
disease	O
Anterior	O
infarction	O
in	O
2000	O
,	O
implanting	O
a	O
conventional	O
stent	O
in	O
the	O
proximal	O
anterior	O
descending	O
A	O
.	O
ADA	O
.	O
Progressive	O
angina	O
in	O
2005	O
with	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
of	O
40	O
restenosis	O
of	O
the	O
previous	O
stent	O
in	O
the	O
LAD	O
and	O
severe	O
disease	O
of	O
the	O
circumflex	O
artery	O
CxA	O
and	O
right	O
coronary	O
artery	O
RCA	O
.	O
Bypass	O
of	O
saphenous	O
vein	O
from	O
RCA	O
and	O
internal	O
mammary	O
artery	O
IMA	O
to	O
RCA	O
is	O
performed	O
.	O
The	O
RCA	O
was	O
not	O
revascularised	O
due	O
to	O
its	O
small	O
calibre	O
.	O
In	O
2012	O
,	O
worsening	O
of	O
functional	O
class	O
FC	O
and	O
LVEF	O
30	O
,	O
repeating	O
coronary	O
angiography	O
chronic	O
occlusion	O
of	O
LAD	O
and	O
RCA	O
,	O
bypass	O
of	O
IMA	O
to	O
LAD	O
and	O
saphenous	O
vein	O
to	O
permeable	O
RCA	O
.	O
Single	O
chamber	O
defibrillator	O
ICD	O
implanted	O
for	O
primary	O
prevention	O
no	O
criteria	O
for	O
resynchronisation	O
,	O
QRS	O
125	O
msec	O
.	O
In	O
April	O
2016	O
he	O
underwent	O
an	O
appropriate	O
ICD	O
shock	O
.	O
In	O
May	O
and	O
July	O
2016	O
he	O
needed	O
short	O
admissions	O
for	O
decompensation	O
of	O
heart	O
failure	O
and	O
in	O
August	O
he	O
was	O
readmitted	O
again	O
,	O
this	O
time	O
with	O
the	O
need	O
for	O
levosimendan	B-FARMACO
perfusion	O
.	O
Current	O
illness	O
Three	O
weeks	O
after	O
discharge	O
from	O
hospital	O
,	O
the	O
patient	O
attended	O
the	O
Heart	O
Failure	O
outpatient	O
clinic	O
,	O
reporting	O
NYHA	O
III	O
CF	O
,	O
two	O
pillow	O
orthopnoea	O
and	O
no	O
new	O
data	O
of	O
worsening	O
from	O
the	O
congestive	O
point	O
of	O
view	O
,	O
nor	O
symptoms	O
attributable	O
to	O
low	O
cardiac	O
output	O
.	O
Stable	O
weight	O
around	O
58	O
kg	O
.	O
Since	O
hospital	O
discharge	O
with	O
the	O
following	O
treatment	O
synthroid	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
1	O
24	O
h	O
,	O
enalapril	B-FARMACO
10	O
mg	O
1	O
12	O
h	O
,	O
eplerenone	B-FARMACO
25	O
mg	O
2	O
24	O
h	O
,	O
furosemide	B-FARMACO
40	O
mg	O
3	O
24	O
h	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
1	O
24	O
h	O
,	O
oral	O
iron	B-FARMACO
,	O
metformin	B-FARMACO
850	O
mg	O
1	O
12	O
h	O
,	O
pantoprazole	B-FARMACO
40	O
mg	O
1	O
24	O
h	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
123	O
77	O
mmHg	O
,	O
heart	O
rate	O
63	O
bpm	O
,	O
O2	O
saturation	O
97	O
.	O
Good	O
general	O
condition	O
.	O
Eupneic	O
in	O
decubitus	O
at	O
40o	O
.	O
No	O
jugular	O
venous	O
engorgement	O
.	O
Good	O
distal	O
perfusion	O
and	O
adequate	O
capillary	O
refill	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
added	O
sounds	O
.	O
Abdomen	O
no	O
palpable	O
hepatomegaly	O
.	O
No	O
signs	O
of	O
ascites	O
or	O
wall	O
oedema	O
.	O
Lower	O
limbs	O
no	O
oedema	O
.	O
Trophic	O
changes	O
.	O
Very	O
weak	O
paedial	O
pulses	O
bilaterally	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
68	O
bpm	O
,	O
PR	O
204	O
msec	O
,	O
intraventricular	O
conduction	O
disturbance	O
QRS	O
128	O
msec	O
.	O
Echocardiogram	O
severely	O
dilated	O
left	O
ventricle	O
with	O
severely	O
depressed	O
global	O
systolic	O
function	O
23	O
by	O
Simpson	O
biplane	O
.	O
Restrictive	O
mitral	O
filling	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
function	O
at	O
low	O
limit	O
of	O
normality	O
TAPSE	O
15	O
mm	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Mild	O
TR	O
allowing	O
estimation	O
of	O
systolic	O
pulmonary	O
artery	O
pressure	O
of	O
43	O
mmHg	O
.	O
Electrode	O
in	O
right	O
cavities	O
.	O
No	O
pericardial	O
effusion	O
.	O
CBC	O
NTproBNP	O
6170	O
pg	O
mL	O
,	O
haemoglobin	O
13	O
.	O
4	O
g	O
dl	O
,	O
glucose	O
99	O
mg	O
dl	O
,	O
creatinine	O
1	O
mg	O
dl	O
,	O
urea	O
44	O
mg	O
dl	O
,	O
sodium	O
140	O
mmol	O
l	O
,	O
potassium	O
3	O
.	O
9	O
mmol	O
L	O
.	O
EVOLUTION	O
It	O
was	O
decided	O
to	O
discontinue	O
enalapril	B-FARMACO
and	O
start	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
49	O
51	O
mg	O
,	O
one	O
tablet	O
every	O
12	O
hours	O
,	O
leaving	O
an	O
enalapril	B-FARMACO
washout	O
period	O
of	O
36	O
hours	O
.	O
After	O
3	O
weeks	O
,	O
the	O
patient	O
was	O
re	O
assessed	O
in	O
consultation	O
,	O
with	O
BP	O
of	O
119	O
60	O
mmHg	O
and	O
maintaining	O
renal	O
function	O
and	O
potassium	O
levels	O
in	O
the	O
normal	O
range	O
,	O
so	O
it	O
was	O
increased	O
to	O
97	O
103	O
mg	O
.	O
Two	O
months	O
after	O
starting	O
treatment	O
,	O
a	O
new	O
NTpro	O
BNP	O
measurement	O
was	O
performed	O
,	O
which	O
was	O
2900	O
pg	O
mL	O
.	O
After	O
6	O
months	O
of	O
follow	O
up	O
,	O
the	O
patient	O
has	O
remained	O
in	O
functional	O
class	O
II	O
III	O
subjectively	O
somewhat	O
better	O
than	O
before	O
the	O
change	O
in	O
treatment	O
and	O
has	O
not	O
been	O
admitted	O
for	O
heart	O
failure	O
.	O
He	O
only	O
visited	O
the	O
emergency	O
department	O
on	O
one	O
occasion	O
for	O
mild	O
decompensation	O
of	O
heart	O
failure	O
related	O
to	O
an	O
upper	O
respiratory	O
tract	O
infection	O
,	O
which	O
could	O
be	O
managed	O
from	O
the	O
emergency	O
department	O
and	O
he	O
was	O
discharged	O
early	O
after	O
24	O
hours	O
.	O
DIAGNOSIS	O
Chronic	O
ischaemic	O
heart	O
disease	O
with	O
severe	O
left	O
ventricular	O
dilatation	O
and	O
dysfunction	O
.	O
CF	O
II	O
III	O
.	O
Intraventricular	O
conduction	O
disorder	O
without	O
criteria	O
for	O
resynchronisation	O
.	O
Partial	O
response	O
to	O
treatment	O
with	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
,	O
with	O
a	O
decrease	O
in	O
readmissions	O
for	O
heart	O
failure	O
during	O
6	O
months	O
of	O
follow	O
up	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
An	O
81	O
year	O
old	O
woman	O
,	O
dyslipidaemic	O
,	O
hypertensive	O
,	O
obese	O
,	O
with	O
DDD	O
pacemaker	O
due	O
to	O
complete	O
atrioventricular	O
block	O
AVB	O
,	O
chronic	O
venous	O
insufficiency	O
,	O
hypothyroidism	O
and	O
spondyloarthrosis	O
.	O
She	O
attended	O
the	O
emergency	O
department	O
for	O
a	O
single	O
episode	O
of	O
oppressive	O
central	O
thoracic	O
pain	O
,	O
which	O
did	O
not	O
change	O
with	O
palpation	O
,	O
deep	O
inspiration	O
or	O
movement	O
,	O
not	O
radiating	O
or	O
associated	O
with	O
vegetative	O
cortex	O
,	O
onset	O
at	O
rest	O
,	O
after	O
a	O
situation	O
of	O
family	O
stress	O
,	O
of	O
undetermined	O
duration	O
.	O
There	O
was	O
no	O
evidence	O
of	O
orthopnoea	O
,	O
paroxysmal	O
nocturnal	O
dyspnoea	O
,	O
palpitations	O
,	O
dyspnoea	O
at	O
rest	O
or	O
on	O
exertion	O
,	O
malleolar	O
oedema	O
or	O
reduced	O
diuresis	O
.	O
No	O
dietary	O
transgression	O
or	O
modification	O
of	O
his	O
usual	O
medication	O
.	O
No	O
respiratory	O
,	O
abdominal	O
or	O
genitourinary	O
infections	O
.	O
The	O
patient	O
presented	O
cardiologically	O
stable	O
,	O
with	O
a	O
heart	O
rate	O
of	O
94	O
bpm	O
,	O
blood	O
pressure	O
200	O
110	O
mmHg	O
,	O
afebrile	O
and	O
baseline	O
oxygen	O
saturation	O
95	O
.	O
She	O
was	O
conscious	O
and	O
oriented	O
,	O
in	O
good	O
general	O
condition	O
,	O
eupneic	O
at	O
rest	O
,	O
normohydrated	O
,	O
normal	O
colour	O
and	O
normal	O
depth	O
.	O
Carotid	O
pulses	O
were	O
rhythmic	O
and	O
symmetrical	O
and	O
we	O
did	O
not	O
detect	O
jugular	O
ingurgitation	O
.	O
Cardiopulmonary	O
auscultation	O
was	O
rhythmic	O
and	O
without	O
murmurs	O
,	O
with	O
preserved	O
vesicular	O
murmur	O
.	O
Abdominal	O
examination	O
revealed	O
a	O
soft	O
and	O
depressible	O
abdomen	O
,	O
no	O
pain	O
on	O
superficial	O
or	O
deep	O
palpation	O
,	O
no	O
masses	O
or	O
megaliths	O
,	O
generalised	O
tympanism	O
,	O
no	O
peritonism	O
and	O
positive	O
hydro	O
aerial	O
sounds	O
.	O
The	O
lower	O
extremities	O
showed	O
no	O
malleolar	O
oedema	O
,	O
with	O
symmetrical	O
posterior	O
pedial	O
and	O
tibial	O
pulses	O
present	O
and	O
no	O
stigmata	O
of	O
venous	O
insufficiency	O
or	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
showed	O
haemoglobin	O
11	O
.	O
4	O
g	O
dl	O
,	O
hcto	O
35	O
.	O
1	O
,	O
MCH	O
29	O
.	O
2	O
pg	O
,	O
MCV	O
90	O
fl	O
,	O
normal	O
leukocytes	O
,	O
normal	O
platelets	O
,	O
normal	O
biochemistry	O
,	O
normal	O
CPK	O
,	O
peak	O
troponin	O
I	O
6	O
ng	O
ml	O
,	O
normal	O
renal	O
function	O
,	O
normal	O
ions	O
and	O
normal	O
coagulation	O
.	O
The	O
portable	O
anteroposterior	O
chest	O
X	O
ray	O
showed	O
an	O
increased	O
cardiothoracic	O
index	O
,	O
no	O
alterations	O
of	O
the	O
bronchovascular	O
tract	O
,	O
no	O
alveolar	O
or	O
interstitial	O
infiltrates	O
,	O
with	O
free	O
costodiaphragmatic	O
angles	O
.	O
Electrocardiogram	O
ECG	O
revealed	O
sinus	O
rhythm	O
at	O
81	O
bpm	O
,	O
PR	O
200	O
msec	O
,	O
right	O
bundle	O
branch	O
block	O
RBBB	O
and	O
HMAIHH	O
,	O
QRS	O
axis	O
at	O
60o	O
,	O
isodiphasic	O
T	O
waves	O
from	O
V3	O
V4	O
and	O
symmetric	O
negative	O
waves	O
from	O
V5	O
V6	O
dynamic	O
changes	O
from	O
baseline	O
ECG	O
and	O
QTc	O
394	O
msec	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
coronary	O
care	O
unit	O
,	O
where	O
enzyme	O
seriation	O
and	O
ECG	O
were	O
completed	O
,	O
and	O
antianginal	O
treatment	O
was	O
started	O
.	O
The	O
transthoracic	O
echocardiogram	O
showed	O
a	O
left	O
ventricle	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
,	O
not	O
hypertrophied	O
,	O
with	O
strict	O
anteroapical	O
,	O
inferoapical	O
and	O
apical	O
akinesia	O
and	O
compensatory	O
contractility	O
of	O
basal	O
and	O
middle	O
segments	O
,	O
diastolic	O
pattern	O
of	O
impaired	O
relaxation	O
and	O
moderately	O
depressed	O
systolic	O
function	O
LVEF	O
40	O
by	O
Simpson	O
biplane	O
.	O
The	O
right	O
ventricle	O
was	O
neither	O
dilated	O
nor	O
hypertrophied	O
,	O
with	O
normal	O
systolic	O
function	O
TAPSE	O
18	O
mm	O
,	O
while	O
the	O
right	O
and	O
left	O
atria	O
were	O
normal	O
in	O
size	O
.	O
The	O
mitral	O
valve	O
had	O
discrete	O
thickening	O
of	O
the	O
valve	O
leaflets	O
,	O
with	O
calcification	O
of	O
the	O
posterior	O
annulus	O
,	O
good	O
opening	O
and	O
a	O
regurgitant	O
jet	O
that	O
was	O
suggestive	O
of	O
mild	O
mitral	O
regurgitation	O
MR	O
.	O
The	O
aortic	O
valve	O
had	O
trivalve	O
morphology	O
,	O
with	O
good	O
opening	O
and	O
a	O
regurgitant	O
jet	O
,	O
leading	O
to	O
mild	O
aortic	O
insufficiency	O
AIo	O
,	O
with	O
no	O
apparent	O
dilatation	O
of	O
the	O
aortic	O
root	O
.	O
Morphologically	O
normal	O
tricuspid	O
valve	O
,	O
with	O
good	O
opening	O
and	O
mild	O
insufficiency	O
,	O
which	O
allowed	O
estimation	O
of	O
pulmonary	O
arterial	O
systolic	O
pressure	O
PSAP	O
50	O
mmHg	O
.	O
The	O
pericardium	O
had	O
normal	O
thickness	O
and	O
refractoriness	O
,	O
without	O
effusion	O
,	O
and	O
the	O
inferior	O
vena	O
cava	O
was	O
not	O
dilated	O
,	O
and	O
collapsed	O
adequately	O
50	O
with	O
inspiration	O
.	O
During	O
his	O
stay	O
in	O
the	O
unit	O
he	O
remained	O
cardiologically	O
stable	O
,	O
with	O
a	O
tendency	O
to	O
hypertension	O
,	O
requiring	O
high	O
doses	O
of	O
beta	O
blockers	O
,	O
angiotensin	B-FARMACO
converting	I-FARMACO
enzyme	I-FARMACO
inhibitors	I-FARMACO
ACE	I-FARMACO
inhibitors	I-FARMACO
and	O
nitroglycerin	B-FARMACO
perfusion	O
.	O
He	O
had	O
no	O
new	O
episodes	O
of	O
angina	O
at	O
rest	O
or	O
on	O
slight	O
exertion	O
,	O
palpitations	O
or	O
dyspnoea	O
.	O
Preferential	O
catheterisation	O
confirmed	O
anteroapical	O
and	O
apical	O
cap	O
dyskinesia	O
,	O
with	O
moderately	O
depressed	O
systolic	O
function	O
,	O
and	O
showed	O
coronary	O
arteries	O
without	O
angiographically	O
significant	O
lesions	O
.	O
Given	O
the	O
clinical	O
and	O
haemodynamic	O
stability	O
,	O
the	O
patient	O
was	O
discharged	O
to	O
the	O
cardiology	O
ward	O
,	O
where	O
she	O
remained	O
asymptomatic	O
,	O
with	O
a	O
tendency	O
to	O
hypertension	O
.	O
After	O
adjustment	O
of	O
treatment	O
with	O
beta	O
blockers	O
and	O
angiotensin	B-FARMACO
II	I-FARMACO
receptor	I-FARMACO
antagonist	I-FARMACO
ARAII	I-FARMACO
,	O
blood	O
pressure	O
normalised	O
.	O
No	O
periprocedural	O
complications	O
were	O
reported	O
and	O
the	O
patient	O
was	O
discharged	O
with	O
hygienic	O
dietary	O
recommendations	O
,	O
double	O
antiplatelet	O
therapy	O
,	O
beta	O
blockers	O
,	O
ARA	B-FARMACO
II	I-FARMACO
and	O
statins	B-FARMACO
.	O
Three	O
months	O
later	O
the	O
patient	O
remains	O
clinically	O
asymptomatic	O
,	O
and	O
a	O
follow	O
up	O
echocardiography	O
has	O
revealed	O
full	O
recovery	O
of	O
the	O
segmental	O
alterations	O
described	O
in	O
the	O
acute	O
event	O
.	O
DIAGNOSIS	O
Non	O
ST	O
segment	O
elevation	O
myocardial	O
infarction	O
NSTEMI	O
with	O
normal	O
coronary	O
arteries	O
.	O
Hypertensive	O
emergency	O
.	O
Stress	O
cardiomyopathy	O
tako	O
tsubo	O
syndrome	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
58	O
year	O
old	O
male	O
patient	O
,	O
smoker	O
of	O
one	O
pack	O
of	O
cigarettes	O
day	O
,	O
with	O
no	O
other	O
medical	O
history	O
of	O
interest	O
,	O
who	O
is	O
referred	O
to	O
the	O
cardiology	O
department	O
for	O
a	O
routine	O
ECG	O
requested	O
by	O
his	O
primary	O
care	O
physician	O
,	O
which	O
turns	O
out	O
to	O
be	O
pathological	O
.	O
In	O
the	O
detailed	O
anamnesis	O
,	O
the	O
patient	O
reported	O
no	O
previous	O
episodes	O
of	O
chest	O
pain	O
,	O
although	O
he	O
did	O
report	O
dyspnoea	O
on	O
moderate	O
exertion	O
,	O
without	O
progression	O
in	O
recent	O
weeks	O
.	O
He	O
also	O
reported	O
that	O
a	O
few	O
days	O
prior	O
to	O
admission	O
he	O
had	O
a	O
sudden	O
episode	O
of	O
loss	O
of	O
strength	O
in	O
the	O
right	O
upper	O
limb	O
and	O
facial	O
paralysis	O
,	O
with	O
subsequent	O
complete	O
recovery	O
,	O
going	O
to	O
his	O
health	O
centre	O
from	O
where	O
he	O
was	O
discharged	O
,	O
citing	O
the	O
cervical	O
origin	O
of	O
the	O
symptoms	O
.	O
Physical	O
examination	O
revealed	O
no	O
findings	O
of	O
interest	O
.	O
An	O
echocardiogram	O
was	O
performed	O
in	O
the	O
consultation	O
room	O
and	O
,	O
in	O
view	O
of	O
the	O
findings	O
,	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
the	O
ward	O
to	O
complete	O
the	O
diagnostic	O
study	O
with	O
cardiac	O
magnetic	O
resonance	O
CMR	O
.	O
Initially	O
,	O
given	O
the	O
structural	O
cardiac	O
pathology	O
of	O
the	O
patient	O
and	O
the	O
neurological	O
symptoms	O
that	O
he	O
presented	O
days	O
prior	O
to	O
admission	O
,	O
a	O
transient	O
ischaemic	O
attack	O
TIA	O
was	O
suspected	O
,	O
so	O
a	O
CT	O
scan	O
of	O
the	O
brain	O
was	O
performed	O
,	O
which	O
was	O
found	O
to	O
be	O
normal	O
.	O
While	O
the	O
patient	O
was	O
on	O
the	O
ward	O
,	O
CMR	O
was	O
performed	O
which	O
confirmed	O
the	O
diagnosis	O
of	O
ventricular	O
pseudoaneurysm	O
with	O
abundant	O
thrombus	O
.	O
He	O
was	O
considered	O
a	O
candidate	O
for	O
surgery	O
and	O
coronary	O
angiography	O
was	O
performed	O
,	O
finding	O
a	O
severe	O
lesion	O
of	O
the	O
mid	O
distal	O
left	O
main	O
coronary	O
artery	O
LMCA	O
and	O
the	O
3	O
vessels	O
.	O
COMPLEMENTARY	O
TESTS	O
Transthoracic	O
echocardiography	O
left	O
ventricle	O
LV	O
moderately	O
dilated	O
,	O
with	O
moderate	O
global	O
systolic	O
dysfunction	O
LVEF	O
by	O
Simpson	O
biplanar	O
35	O
,	O
thinning	O
and	O
inferolateral	O
and	O
inferior	O
akinesia	O
and	O
large	O
inferobasal	O
and	O
inferoseptal	O
basal	O
aneurysm	O
,	O
44	O
mm	O
neck	O
and	O
40	O
mm	O
deep	O
,	O
with	O
an	O
oval	O
mass	O
of	O
8	O
x	O
7	O
mm	O
hyperechogenic	O
inside	O
suggestive	O
of	O
thrombus	O
.	O
CHEST	O
X	O
RAY	O
showing	O
slight	O
cardiomegaly	O
.	O
ECG	O
Q	O
waves	O
and	O
negative	O
T	O
waves	O
in	O
inferior	O
leads	O
.	O
Complete	O
ANALYSIS	O
Haemogram	O
14	O
.	O
1	O
g	O
dl	O
.	O
Leukocytes	O
13	O
,	O
500	O
10	O
3	O
μl	O
.	O
Platelets	O
207	O
,	O
000	O
10	O
3	O
μl	O
.	O
Biochemistry	O
glucose	O
134	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
86	O
mg	O
dl	O
.	O
Na	O
139	O
mM	O
l	O
.	O
K	O
4	O
.	O
7	O
mM	O
l	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
149	O
mg	O
dl	O
.	O
HDL	O
33	O
.	O
7	O
mg	O
dl	O
.	O
LDL	O
208U	O
l	O
.	O
Triglycerides	O
82	O
mg	O
dl	O
.	O
Liver	O
profile	O
bilirubin	O
0	O
.	O
42	O
mg	O
dl	O
.	O
GOT	O
17	O
.	O
7	O
U	O
l	O
.	O
GPT	O
29	O
.	O
3	O
U	O
l	O
.	O
GGT	O
29	O
.	O
3	O
U	O
l	O
.	O
GGT	O
49	O
.	O
6	O
U	O
l	O
.	O
Alkaline	O
phosphatase	O
128	O
U	O
l	O
.	O
Glycated	O
Hb	O
6	O
.	O
1	O
.	O
Cardiac	O
MRI	O
ventricular	O
pseudoaneurysm	O
,	O
with	O
image	O
of	O
abundant	O
thrombus	O
in	O
the	O
cul	O
de	O
sac	O
,	O
without	O
compromise	O
of	O
mitral	O
valve	O
function	O
,	O
with	O
ventricular	O
remodelling	O
and	O
moderate	O
systolic	O
dysfunction	O
.	O
CORONARYGRAPHY	O
left	O
coronary	O
trunk	O
with	O
severe	O
lesion	O
in	O
the	O
distal	O
middle	O
third	O
affecting	O
the	O
ostium	O
of	O
the	O
anterior	O
descending	O
and	O
circumflex	O
arteries	O
.	O
Anterior	O
descending	O
with	O
severe	O
stenosis	O
in	O
the	O
proximal	O
third	O
,	O
good	O
distal	O
vessel	O
.	O
Circumflex	O
significant	O
ostial	O
stenosis	O
,	O
occluded	O
at	O
the	O
level	O
of	O
bifurcation	O
with	O
first	O
obtuse	O
marginal	O
which	O
has	O
severe	O
stenosis	O
at	O
the	O
level	O
of	O
bifurcation	O
with	O
subdivision	O
,	O
both	O
vessels	O
of	O
good	O
diameter	O
.	O
Right	O
coronary	O
dominant	O
,	O
ostial	O
occluded	O
,	O
filled	O
by	O
heterocoronary	O
collateral	O
circulation	O
,	O
regular	O
distal	O
vessel	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
remained	O
asymptomatic	O
during	O
his	O
stay	O
on	O
the	O
ward	O
,	O
wandering	O
around	O
,	O
without	O
presenting	O
arrhythmic	O
events	O
on	O
telemetry	O
.	O
Subsequently	O
,	O
and	O
despite	O
maintaining	O
the	O
patient	O
on	O
correct	O
levels	O
of	O
anticoagulation	O
,	O
he	O
again	O
presented	O
motor	O
deficit	O
in	O
the	O
left	O
middle	O
cerebral	O
artery	O
MCA	O
and	O
right	O
anterior	O
cerebral	O
artery	O
territory	O
of	O
cardioembolic	O
cause	O
and	O
with	O
recovery	O
without	O
subsequent	O
deficit	O
,	O
with	O
no	O
sequelae	O
in	O
the	O
control	O
CT	O
scan	O
performed	O
.	O
The	O
transcranial	O
Doppler	O
study	O
showed	O
significant	O
stenosis	O
in	O
MCA	O
I	O
.	O
Finally	O
,	O
he	O
was	O
transferred	O
to	O
the	O
reference	O
hospital	O
for	O
surgery	O
by	O
means	O
of	O
median	O
sternotomy	O
and	O
with	O
the	O
aid	O
of	O
extracorporeal	O
circulation	O
,	O
the	O
aneurysmal	O
area	O
was	O
resected	O
,	O
the	O
intraventricular	O
thrombus	O
was	O
removed	O
and	O
the	O
lower	O
wall	O
was	O
reconstructed	O
with	O
a	O
Dacron	O
patch	O
.	O
Subsequent	O
sequential	O
AMI	O
DA	O
and	O
AMI	O
OM	O
aortocoronary	O
bypass	O
was	O
performed	O
.	O
Although	O
myocardial	O
protection	O
with	O
antegrade	O
and	O
retrograde	O
cardioplegia	O
was	O
performed	O
,	O
removal	O
of	O
extracorporeal	O
circulation	O
proved	O
difficult	O
,	O
requiring	O
high	O
doses	O
of	O
vasoactive	O
amines	O
dobutamine	B-FARMACO
noradrenaline	I-FARMACO
.	O
He	O
was	O
subsequently	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
,	O
where	O
he	O
had	O
a	O
torpid	O
evolution	O
,	O
and	O
died	O
24	O
hours	O
after	O
admission	O
due	O
to	O
refractory	O
cardiogenic	O
shock	O
.	O
DIAGNOSIS	O
Silent	O
infarction	O
complicated	O
by	O
inferior	O
ventricular	O
pseudoaneurysm	O
with	O
mural	O
thrombus	O
inside	O
.	O
Coronary	O
artery	O
disease	O
of	O
LMCA	O
and	O
three	O
vessels	O
.	O
Moderate	O
left	O
ventricular	O
dysfunction	O
.	O
Surgery	O
for	O
resection	O
of	O
the	O
aneurysmal	O
area	O
AMI	O
DA	O
and	O
AMI	O
OM	O
bypass	O
,	O
with	O
torpid	O
postoperative	O
course	O
and	O
death	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
47	O
year	O
old	O
woman	O
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
,	O
dyslipidaemia	O
,	O
smoking	O
,	O
long	O
standing	O
type	O
2	O
diabetes	O
with	O
poor	O
metabolic	O
control	O
despite	O
treatment	O
with	O
metformin	B-FARMACO
,	O
vidagliptin	B-FARMACO
,	O
glimepiride	B-FARMACO
and	O
pioglitazone	B-FARMACO
.	O
No	O
previous	O
cardiological	O
history	O
.	O
Other	O
personal	O
history	O
cholelithiasis	O
.	O
Usual	O
treatment	O
adiro	B-FARMACO
100	O
mg	O
,	O
rosuvastatin	B-FARMACO
10	O
mg	O
,	O
enalapril	B-FARMACO
hydrochlorothiazide	I-FARMACO
20	O
12	O
.	O
5	O
mg	O
,	O
metformin	B-FARMACO
vildagliptin	I-FARMACO
1000	O
50	O
,	O
pioglitazone	B-FARMACO
,	O
glimepiride	B-FARMACO
.	O
Current	O
illness	O
Admitted	O
to	O
Cardiology	O
for	O
acute	O
coronary	O
syndrome	O
with	O
Killip	O
I	O
anterolateral	O
ST	O
elevation	O
.	O
An	O
urgent	O
coronary	O
angiography	O
showed	O
an	O
acute	O
subtotal	O
thrombotic	O
lesion	O
of	O
the	O
proximal	O
anterior	O
descending	O
coronary	O
artery	O
which	O
was	O
treated	O
with	O
the	O
implantation	O
of	O
1	O
drug	O
eluting	O
stent	O
.	O
He	O
also	O
had	O
moderate	O
lesions	O
in	O
OM1	O
and	O
OM2	O
and	O
diffuse	O
DC	O
disease	O
.	O
Echocardiogram	O
showed	O
moderate	O
ventricular	O
dysfunction	O
EF	O
35	O
with	O
anterior	O
,	O
apical	O
and	O
anterior	O
septal	O
akinesia	O
.	O
The	O
patient	O
was	O
discharged	O
after	O
5	O
days	O
without	O
significant	O
incidents	O
with	O
the	O
following	O
treatment	O
adiro	B-FARMACO
100	O
mg	O
0	O
1	O
0	O
,	O
prasugrel	B-FARMACO
10	O
mg	O
1	O
0	O
0	O
,	O
pantoprazole	B-FARMACO
40	O
mg	O
1	O
0	O
0	O
,	O
carvedilol	B-FARMACO
25	O
mg	O
1	O
0	O
1	O
,	O
enalapril	B-FARMACO
5	O
mg	O
1	O
0	O
1	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
0	O
0	O
1	O
,	O
eplerenone	B-FARMACO
50	O
mg	O
1	O
0	O
0	O
,	O
ivabradine	B-FARMACO
5	O
mg	O
1	O
2	O
0	O
1	O
2	O
and	O
her	O
usual	O
antidiabetic	O
treatment	O
.	O
He	O
was	O
referred	O
to	O
the	O
cardiac	O
rehabilitation	O
programme	O
.	O
Physical	O
examination	O
BP	O
107	O
55	O
HR	O
65	O
bpm	O
.	O
Good	O
general	O
condition	O
,	O
eupneic	O
at	O
rest	O
,	O
afebrile	O
.	O
Head	O
and	O
neck	O
no	O
signs	O
of	O
jugular	O
venous	O
engorgement	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
without	O
murmurs	O
or	O
extratonos	O
.	O
AP	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
extra	O
sounds	O
.	O
Lower	O
extremities	O
no	O
oedema	O
.	O
Radial	O
and	O
pedial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
Anthropometric	O
examination	O
weight	O
84	O
.	O
5	O
kg	O
.	O
Height	O
162	O
cm	O
.	O
BMI	O
32	O
.	O
1	O
kg	O
m2	O
.	O
Abdominal	O
circumference	O
112	O
cm	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
haemoglobin	O
12	O
.	O
7	O
g	O
dl	O
.	O
Leukocytes	O
10300	O
.	O
Platelets	O
354000	O
.	O
Normal	O
coagulation	O
.	O
Creatinine	O
0	O
.	O
9	O
mg	O
dl	O
.	O
Urea	O
70	O
.	O
Na	O
140	O
.	O
2	O
.	O
K	O
3	O
,	O
8	O
.	O
Lipoprotein	O
profile	O
total	O
cholesterol	O
125	O
mg	O
dl	O
;	O
LDL	O
82	O
mg	O
dl	O
,	O
HDL	O
28	O
mg	O
dl	O
,	O
Triglycerides	O
223	O
mg	O
dl	O
.	O
HbA1C	O
10	O
.	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
68	O
bpm	O
.	O
signs	O
of	O
anterior	O
necrosis	O
.	O
Chest	O
X	O
ray	O
slightly	O
increased	O
cardiothoracic	O
index	O
.	O
No	O
signs	O
of	O
heart	O
failure	O
.	O
Echocardiogram	O
left	O
ventricle	O
of	O
normal	O
size	O
,	O
slightly	O
hypertrophic	O
.	O
Akinesia	O
of	O
the	O
middle	O
and	O
apical	O
segments	O
of	O
the	O
septal	O
,	O
lateral	O
and	O
anterior	O
face	O
,	O
with	O
hypokinesia	O
of	O
the	O
rest	O
of	O
the	O
segments	O
.	O
All	O
this	O
leads	O
to	O
moderate	O
ventricular	O
dysfunction	O
with	O
an	O
estimated	O
ejection	O
fraction	O
of	O
35	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
No	O
significant	O
valvulopathies	O
.	O
No	O
pericardial	O
effusion	O
.	O
Catheterisation	O
TCI	O
of	O
good	O
calibre	O
,	O
without	O
lesions	O
.	O
LAD	O
normodeveloped	O
of	O
regular	O
calibre	O
,	O
with	O
subtotal	O
thrombotic	O
lesion	O
in	O
bifurcation	O
with	O
diagonal	O
.	O
Distally	O
very	O
thin	O
vessel	O
.	O
ACX	O
of	O
good	O
calibre	O
and	O
development	O
,	O
without	O
lesions	O
in	O
the	O
CX	O
itself	O
.	O
The	O
1st	O
and	O
2nd	O
OM	O
have	O
moderate	O
ostial	O
lesions	O
.	O
ACD	O
dominant	O
,	O
diffuse	O
atheromatous	O
involvement	O
,	O
but	O
without	O
severe	O
lesions	O
.	O
PCI	O
With	O
a	O
3	O
.	O
5	O
6F	O
XB	O
guide	O
catheter	O
,	O
a	O
BMW	O
guide	O
is	O
passed	O
through	O
the	O
lesion	O
in	O
the	O
LAD	O
.	O
Predilatation	O
with	O
a	O
2	O
x	O
14	O
mm	O
balloon	O
at	O
14	O
atmospheres	O
and	O
implantation	O
of	O
a	O
2	O
.	O
5	O
x	O
16	O
mm	O
Promus	O
drug	O
eluting	O
stent	O
at	O
18	O
atmospheres	O
with	O
good	O
angiographic	O
results	O
and	O
no	O
complications	O
.	O
EVOLUTION	O
The	O
patient	O
started	O
a	O
6	O
week	O
cardiac	O
rehabilitation	O
programme	O
consisting	O
of	O
motivational	O
talks	O
and	O
physical	O
training	O
2	O
days	O
a	O
week	O
.	O
During	O
the	O
programme	O
,	O
the	O
importance	O
of	O
smoking	O
cessation	O
and	O
weight	O
loss	O
was	O
emphasised	O
,	O
but	O
one	O
of	O
the	O
main	O
challenges	O
we	O
had	O
to	O
face	O
was	O
undoubtedly	O
the	O
adjustment	O
of	O
the	O
diabetic	O
treatment	O
.	O
Considering	O
the	O
clinical	O
scenario	O
young	O
patient	O
with	O
moderate	O
ischaemic	O
ventricular	O
dysfunction	O
and	O
suboptimal	O
diabetic	O
control	O
HbA1c	O
10	O
despite	O
being	O
treated	O
with	O
four	O
oral	O
antidiabetic	O
drugs	O
,	O
we	O
considered	O
the	O
different	O
options	O
and	O
finally	O
decided	O
to	O
1	O
discontinue	O
pioglitazone	B-FARMACO
,	O
glimepiride	B-FARMACO
and	O
vidagliptin	B-FARMACO
;	O
2	O
maintain	O
metformin	B-FARMACO
;	O
3	O
combine	O
empaglifozin	B-FARMACO
10	O
mg	O
day	O
and	O
insulin	B-FARMACO
therapy	O
both	O
slow	O
and	O
rapid	O
insulin	B-FARMACO
.	O
The	O
patient	O
successfully	O
completed	O
the	O
programme	O
and	O
achieved	O
weight	O
loss	O
,	O
remained	O
smoke	O
free	O
and	O
improved	O
glycaemic	O
control	O
.	O
DIAGNOSIS	O
Acute	O
ST	O
elevation	O
myocardial	O
infarction	O
with	O
Killip	O
1	O
anterior	O
ST	O
elevation	O
.	O
Severe	O
proximal	O
CAD	O
treated	O
with	O
1	O
drug	O
eluting	O
stent	O
implantation	O
.	O
Moderate	O
left	O
ventricular	O
dysfunction	O
.	O
Arterial	O
hypertension	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
with	O
poor	O
control	O
.	O
Dyslipidaemia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
a	O
61	O
year	O
old	O
male	O
who	O
consults	O
for	O
dyspnoea	O
.	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Ex	O
smoker	O
.	O
Ex	O
drinker	O
.	O
Hyperuricaemia	O
with	O
gouty	O
crisis	O
.	O
HYPERTENSION	O
.	O
Dyslipidaemia	O
.	O
Long	O
standing	O
type	O
2	O
diabetes	O
mellitus	O
,	O
under	O
treatment	O
with	O
oral	O
anti	O
diabetics	O
and	O
insulin	B-FARMACO
,	O
with	O
good	O
control	O
.	O
Stage	O
III	O
chronic	O
kidney	O
disease	O
.	O
Cholecystectomy	O
in	O
2012	O
for	O
acute	O
calculous	O
cholecystitis	O
.	O
Repeated	O
nephritic	O
colic	O
,	O
requiring	O
admission	O
to	O
the	O
ICU	O
in	O
one	O
of	O
the	O
episodes	O
.	O
Anxious	O
depressive	O
syndrome	O
being	O
monitored	O
by	O
Psychiatry	O
,	O
with	O
one	O
admission	O
for	O
decompensation	O
in	O
2005	O
,	O
and	O
subsequently	O
good	O
clinical	O
control	O
with	O
medication	O
.	O
In	O
2010	O
,	O
he	O
was	O
referred	O
to	O
Pneumology	O
for	O
dyspnoea	O
and	O
a	O
pathological	O
chest	O
X	O
ray	O
,	O
being	O
diagnosed	O
with	O
sarcoidosis	O
after	O
completing	O
the	O
study	O
with	O
a	O
high	O
resolution	O
thoracic	O
axial	O
tomography	O
TACAR	O
and	O
a	O
biopsy	O
of	O
the	O
mediastinal	O
adenopathies	O
by	O
mediastinoscopy	O
.	O
He	O
was	O
treated	O
for	O
years	O
with	O
oral	O
corticosteroids	O
,	O
which	O
were	O
subsequently	O
withdrawn	O
due	O
to	O
stabilisation	O
of	O
the	O
disease	O
both	O
clinically	O
and	O
radiologically	O
.	O
Follow	O
up	O
since	O
2006	O
in	O
Cardiology	O
Outpatients	O
,	O
being	O
diagnosed	O
with	O
dilated	O
cardiomyopathy	O
with	O
severe	O
systolic	O
dysfunction	O
.	O
Coronary	O
angiography	O
was	O
performed	O
at	O
that	O
time	O
,	O
which	O
ruled	O
out	O
significant	O
coronary	O
stenosis	O
.	O
The	O
patient	O
admitted	O
to	O
consuming	O
about	O
40	O
grams	O
of	O
alcohol	O
per	O
day	O
,	O
which	O
was	O
attributed	O
to	O
the	O
origin	O
of	O
his	O
heart	O
disease	O
.	O
Successive	O
follow	O
up	O
visits	O
were	O
made	O
;	O
eight	O
months	O
after	O
giving	O
up	O
the	O
alcohol	O
habit	O
,	O
the	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
was	O
found	O
to	O
have	O
recovered	O
to	O
55	O
.	O
At	O
that	O
time	O
,	O
he	O
presented	O
an	O
electrocardiogram	O
ECG	O
with	O
complete	O
left	O
bundle	O
branch	O
block	O
LBBB	O
and	O
a	O
QRS	O
of	O
120	O
msec	O
.	O
In	O
2011	O
,	O
he	O
was	O
admitted	O
to	O
Cardiology	O
for	O
chest	O
pain	O
with	O
typical	O
characteristics	O
.	O
Coronary	O
angiography	O
was	O
repeated	O
,	O
with	O
no	O
significant	O
stenosis	O
in	O
the	O
coronary	O
tree	O
.	O
An	O
echocardiogram	O
was	O
performed	O
,	O
which	O
showed	O
a	O
slightly	O
dilated	O
left	O
ventricle	O
with	O
mild	O
systolic	O
dysfunction	O
LVEF	O
45	O
.	O
On	O
admission	O
,	O
after	O
registering	O
bouts	O
of	O
paroxysmal	O
atrial	O
fibrillation	O
and	O
atrial	O
flutter	O
,	O
anticoagulant	O
treatment	O
was	O
started	O
with	O
acenocoumarol	B-FARMACO
;	O
subsequently	O
,	O
due	O
to	O
a	O
low	O
rate	O
of	O
controls	O
in	O
therapeutic	O
range	O
with	O
dicoumarinic	O
drugs	O
,	O
he	O
was	O
switched	O
to	O
apixaban	B-FARMACO
,	O
without	O
incident	O
.	O
In	O
the	O
following	O
years	O
,	O
during	O
outpatient	O
follow	O
up	O
,	O
there	O
was	O
evidence	O
of	O
progressive	O
deterioration	O
of	O
LVEF	O
,	O
which	O
fell	O
to	O
30	O
,	O
as	O
well	O
as	O
the	O
appearance	O
of	O
signs	O
and	O
symptoms	O
of	O
incipient	O
heart	O
failure	O
.	O
Treatment	O
with	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
ACE	O
inhibitors	O
,	O
beta	O
blockers	O
and	O
aldosterone	O
antagonists	O
was	O
initiated	O
.	O
From	O
then	O
on	O
,	O
in	O
the	O
successive	O
ECGs	O
obtained	O
,	O
he	O
alternates	O
complete	O
right	O
bundle	O
branch	O
block	O
RBBBH	O
,	O
with	O
other	O
recordings	O
showing	O
a	O
non	O
specific	O
intraventricular	O
conduction	O
disorder	O
,	O
and	O
QRS	O
between	O
140	O
and	O
150	O
msec	O
.	O
Usual	O
treatment	O
on	O
admission	O
spironolactone	B-FARMACO
25	O
mg	O
24	O
hours	O
,	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
12	O
hours	O
,	O
carvedilol	B-FARMACO
12	O
.	O
5	O
mg	O
12	O
hours	O
,	O
allopurinol	B-FARMACO
100	O
mg	O
24	O
hours	O
,	O
apixaban	B-FARMACO
5	O
mg	O
12	O
hours	O
,	O
atorvastatin	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
digoxin	B-FARMACO
0	O
.	O
25	O
mg	O
24	O
hours	O
,	O
furosemide	B-FARMACO
80	O
mg	O
24	O
hours	O
1	O
1	O
0	O
,	O
insulin	B-FARMACO
glargine	I-FARMACO
16	O
IU	O
24	O
hours	O
,	O
metformin	B-FARMACO
850	O
mg	O
vildagliptin	O
50	O
mg	O
12	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
duloxetine	B-FARMACO
60	O
mg	O
24	O
hours	O
,	O
trazodone	B-FARMACO
100	O
mg	O
24	O
hours	O
,	O
alprazolam	B-FARMACO
0	O
.	O
25	O
mg	O
24	O
hours	O
.	O
Current	O
illness	O
In	O
2013	O
,	O
she	O
came	O
to	O
the	O
Emergency	O
Department	O
with	O
a	O
20	O
day	O
history	O
of	O
progressive	O
increase	O
in	O
her	O
usual	O
dyspnoea	O
ambulatory	O
class	O
II	O
IV	O
,	O
until	O
it	O
became	O
minimal	O
effort	O
,	O
with	O
episodes	O
in	O
the	O
last	O
week	O
of	O
orthopnoea	O
,	O
paroxysmal	O
nocturnal	O
dyspnoea	O
and	O
bendopnoea	O
limiting	O
any	O
physical	O
activity	O
.	O
He	O
also	O
admits	O
a	O
subjective	O
decrease	O
in	O
diuresis	O
and	O
occasional	O
palpitations	O
at	O
rest	O
,	O
with	O
no	O
history	O
of	O
dizziness	O
or	O
syncope	O
.	O
Physical	O
examination	O
Normoperfused	O
.	O
Tachypnoea	O
at	O
rest	O
,	O
with	O
use	O
of	O
accessory	O
muscles	O
.	O
Elevation	O
of	O
jugular	O
venous	O
pressure	O
,	O
with	O
positive	O
hepatojugular	O
reflux	O
.	O
O2	O
saturation	O
93	O
with	O
oxygen	B-FARMACO
supply	O
at	O
3	O
litres	O
per	O
minute	O
through	O
nasal	O
goggles	O
.	O
Blood	O
pressure	O
130	O
70	O
mmHg	O
.	O
Arrhythmic	O
heart	O
sounds	O
at	O
100	O
beats	O
per	O
minute	O
bpm	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
crackles	O
up	O
to	O
midfields	O
.	O
Perimalleolar	O
oedema	O
with	O
fovea	O
in	O
both	O
lower	O
limbs	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
,	O
without	O
masses	O
or	O
megaliths	O
,	O
with	O
hydro	O
aerial	O
sounds	O
present	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
haemogram	O
leucocytes	O
9	O
,	O
000	O
10E3	O
mL	O
no	O
left	O
shift	O
,	O
haemoglobin	O
13	O
g	O
dL	O
,	O
haematocrit	O
39	O
,	O
MCV	O
92	O
fl	O
,	O
platelets	O
163	O
,	O
000	O
10E3	O
mL	O
.	O
Coagulation	O
INR	O
1	O
.	O
3	O
,	O
PT	O
60	O
,	O
TTPa	O
32	O
seconds	O
.	O
Biochemistry	O
glucose	O
116	O
mg	O
dl	O
,	O
urea	O
70	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
6	O
mg	O
dl	O
,	O
FGR	O
MDMR	O
49	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
sodium	O
134	O
mEq	O
L	O
,	O
potassium	O
4	O
.	O
6	O
mEq	O
L	O
,	O
liver	O
function	O
tests	O
normal	O
,	O
protein	O
7	O
.	O
4	O
g	O
dl	O
,	O
albumin	O
4	O
.	O
7	O
g	O
dl	O
,	O
cholesterol	O
132	O
,	O
triglycerides	O
129	O
,	O
HDL	O
cholesterol	O
31	O
,	O
LDL	O
cholesterol	O
75	O
,	O
HbA1c	O
6	O
,	O
thyroid	O
hormones	O
normal	O
,	O
proBNP	O
5900	O
pg	O
ml	O
,	O
ultrasensitive	O
troponin	O
T	O
14	O
ng	O
l	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
increased	O
cardiothoracic	O
index	O
.	O
Bilateral	O
hilar	O
thickening	O
.	O
Alveolar	O
interstitial	O
oedema	O
in	O
both	O
lung	O
fields	O
.	O
Bilateral	O
costophrenic	O
sinus	O
impingement	O
.	O
Fluid	O
in	O
the	O
fissure	O
.	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
,	O
PR	O
180	O
msec	O
,	O
QRS	O
150	O
msec	O
.	O
There	O
was	O
a	O
non	O
specific	O
intraventricular	O
conduction	O
disturbance	O
that	O
did	O
not	O
fully	O
meet	O
the	O
criteria	O
for	O
HRBBB	O
.	O
Block	O
of	O
the	O
left	O
anterior	O
subdivision	O
of	O
the	O
His	O
bundle	O
LADB	O
.	O
Frequent	O
supraventricular	O
extrasystoles	O
.	O
Transthoracic	O
Doppler	O
colour	O
echocardiogram	O
severely	O
dilated	O
left	O
ventricle	O
end	O
diastolic	O
diameter	O
of	O
68	O
mm	O
,	O
with	O
normal	O
wall	O
thicknesses	O
,	O
and	O
severely	O
depressed	O
systolic	O
function	O
LVEF	O
25	O
at	O
the	O
expense	O
of	O
generalised	O
hypokinesia	O
,	O
with	O
no	O
segmental	O
contractility	O
abnormalities	O
identified	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
No	O
significant	O
valvulopathies	O
were	O
detected	O
.	O
No	O
pericardial	O
effusion	O
.	O
No	O
tricuspid	O
insufficiency	O
or	O
other	O
data	O
suggestive	O
of	O
pulmonary	O
hypertension	O
at	O
rest	O
.	O
Ascending	O
aorta	O
of	O
normal	O
size	O
and	O
Doppler	O
flow	O
.	O
No	O
intracardiac	O
shunts	O
were	O
observed	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
left	O
ventricular	O
dilatation	O
LVEDV	O
260	O
ml	O
,	O
140	O
ml	O
m2	O
;	O
LVESV	O
180	O
ml	O
,	O
100	O
ml	O
m2	O
with	O
severe	O
deterioration	O
of	O
systolic	O
function	O
LVEF	O
30	O
due	O
to	O
global	O
hypokinesia	O
.	O
Abnormal	O
movement	O
of	O
the	O
interventricular	O
septum	O
typical	O
of	O
bundle	O
branch	O
block	O
.	O
Perfusion	O
study	O
without	O
pathological	O
findings	O
.	O
Late	O
gadolinium	O
enhancement	O
of	O
intramyocardial	O
distribution	O
in	O
basal	O
and	O
middle	O
segments	O
of	O
the	O
interventricular	O
septum	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
morphology	O
,	O
without	O
abnormalities	O
in	O
global	O
and	O
segmental	O
contractility	O
.	O
Dilated	O
left	O
atrium	O
36	O
cm2	O
and	O
right	O
atrium	O
of	O
normal	O
size	O
20	O
cm2	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
increased	O
cardiothoracic	O
index	O
.	O
Improvement	O
of	O
signs	O
of	O
heart	O
failure	O
with	O
respect	O
to	O
the	O
image	O
on	O
admission	O
,	O
with	O
persistent	O
alveolar	O
interstitial	O
oedema	O
in	O
the	O
lung	O
bases	O
and	O
bilateral	O
hilar	O
congestion	O
.	O
ICD	O
CRT	O
device	O
in	O
cardiac	O
cavities	O
.	O
EVOLUTION	O
After	O
initiating	O
diuretic	O
and	O
intravenous	O
vasodilator	O
treatment	O
at	O
high	O
doses	O
,	O
progressive	O
improvement	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
heart	O
failure	O
was	O
achieved	O
.	O
Once	O
clinical	O
stabilisation	O
was	O
achieved	O
,	O
the	O
study	O
was	O
completed	O
with	O
the	O
echocardiogram	O
and	O
cardiac	O
MRI	O
described	O
above	O
.	O
The	O
findings	O
of	O
these	O
tests	O
,	O
together	O
with	O
the	O
histological	O
characterisation	O
of	O
the	O
biopsy	O
of	O
mediastinal	O
adenopathies	O
performed	O
years	O
earlier	O
,	O
pointed	O
to	O
cardiac	O
sarcoidosis	O
as	O
the	O
most	O
plausible	O
cause	O
of	O
our	O
patient	O
's	O
dilated	O
cardiomyopathy	O
.	O
Due	O
to	O
the	O
severe	O
conduction	O
disturbances	O
with	O
alternating	O
LBBB	O
and	O
non	O
specific	O
intraventricular	O
conduction	O
disturbance	O
LBBB	O
CCRDHH	O
,	O
the	O
occurrence	O
of	O
non	O
sustained	O
ventricular	O
arrhythmias	O
during	O
monitoring	O
,	O
and	O
the	O
presence	O
of	O
non	O
ischaemic	O
dilated	O
cardiomyopathy	O
with	O
severe	O
ventricular	O
dysfunction	O
,	O
in	O
NYHA	O
functional	O
class	O
III	O
IV	O
,	O
and	O
with	O
a	O
QRS	O
of	O
150	O
msec	O
despite	O
not	O
having	O
left	O
bundle	O
branch	O
block	O
morphology	O
at	O
the	O
time	O
of	O
admission	O
,	O
it	O
was	O
decided	O
to	O
implant	O
an	O
ICD	O
CRT	O
device	O
cardiac	O
resynchronisation	O
therapy	O
for	O
primary	O
prevention	O
and	O
to	O
optimise	O
the	O
treatment	O
of	O
heart	O
failure	O
.	O
After	O
titration	O
of	O
the	O
doses	O
of	O
beta	O
blockers	O
,	O
ACE	B-FARMACO
inhibitors	I-FARMACO
and	O
Aldosterone	B-FARMACO
receptor	I-FARMACO
antagonists	I-FARMACO
to	O
the	O
maximum	O
tolerated	O
doses	O
,	O
and	O
confirmation	O
of	O
the	O
patient	O
's	O
euvolemia	O
and	O
clinical	O
stability	O
,	O
he	O
was	O
discharged	O
for	O
outpatient	O
follow	O
up	O
.	O
In	O
the	O
first	O
months	O
after	O
admission	O
,	O
the	O
patient	O
's	O
response	O
to	O
the	O
established	O
therapeutic	O
plan	O
was	O
confirmed	O
,	O
and	O
he	O
remained	O
in	O
stable	O
functional	O
class	O
I	O
II	O
IV	O
for	O
two	O
years	O
.	O
In	O
the	O
ECG	O
at	O
follow	O
up	O
,	O
biventricular	O
pacing	O
rhythm	O
,	O
alternating	O
atrial	O
tachycardia	O
atrial	O
flutter	O
baseline	O
sinus	O
rhythm	O
,	O
and	O
with	O
a	O
QRS	O
of	O
110	O
msec	O
.	O
However	O
,	O
recently	O
,	O
he	O
required	O
a	O
new	O
admission	O
to	O
the	O
Cardiology	O
hospital	O
ward	O
for	O
decompensated	O
heart	O
failure	O
,	O
as	O
well	O
as	O
several	O
visits	O
to	O
the	O
Emergency	O
Department	O
for	O
intravenous	O
diuretic	O
treatment	O
.	O
Therefore	O
,	O
treatment	O
with	O
sacubitrilo	B-FARMACO
valsartan	I-FARMACO
was	O
started	O
after	O
suspending	O
ACE	B-FARMACO
inhibitors	I-FARMACO
for	O
36	O
hours	O
.	O
The	O
response	O
to	O
the	O
new	O
treatment	O
was	O
partial	O
,	O
so	O
a	O
study	O
has	O
been	O
started	O
with	O
a	O
view	O
to	O
a	O
possible	O
heart	O
transplant	O
.	O
DIAGNOSIS	O
Cardiac	O
and	O
pulmonary	O
sarcoidosis	O
.	O
Dilated	O
cardiomyopathy	O
with	O
severe	O
left	O
ventricular	O
systolic	O
dysfunction	O
.	O
Heart	O
failure	O
with	O
reduced	O
ejection	O
fraction	O
,	O
stage	O
D	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
65	O
year	O
old	O
woman	O
with	O
cardiovascular	O
risk	O
factors	O
such	O
as	O
hypertension	O
,	O
dyslipidaemia	O
and	O
active	O
smoking	O
.	O
As	O
personal	O
history	O
,	O
she	O
has	O
a	O
normofunctioning	O
mechanical	O
aortic	O
and	O
mitral	O
prosthesis	O
with	O
preserved	O
ventricular	O
function	O
in	O
outpatient	O
follow	O
up	O
.	O
She	O
is	O
in	O
permanent	O
atrial	O
fibrillation	O
with	O
frequency	O
control	O
strategy	O
,	O
anticoagulated	O
with	O
sintrom	B-FARMACO
,	O
diagnosed	O
after	O
emboligenic	O
debut	O
in	O
2014	O
with	O
episode	O
of	O
transient	O
ischaemic	O
accident	O
without	O
neurological	O
sequelae	O
.	O
She	O
also	O
has	O
unaffiliated	O
chronic	O
kidney	O
disease	O
and	O
moderate	O
polyarticular	O
osteoarthritis	O
.	O
As	O
treatment	O
she	O
takes	O
acenocoumarol	B-FARMACO
4	O
mg	O
daily	O
with	O
good	O
control	O
of	O
the	O
usual	O
INR	O
,	O
enalapril	B-FARMACO
5	O
mg	O
daily	O
,	O
bisoprolol	B-FARMACO
10	O
mg	O
daily	O
,	O
atorvastatin	B-FARMACO
20	O
mg	O
daily	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
daily	O
and	O
paracetamol	B-FARMACO
and	O
metamizole	B-FARMACO
alternately	O
for	O
joint	O
pain	O
.	O
Present	O
illness	O
She	O
presented	O
to	O
the	O
Emergency	O
Department	O
for	O
functional	O
class	O
deterioration	O
2	O
weeks	O
after	O
onset	O
.	O
The	O
patient	O
reports	O
dyspnoea	O
that	O
has	O
progressed	O
to	O
rest	O
,	O
orthopnoea	O
previously	O
absent	O
and	O
currently	O
90	O
degrees	O
,	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
crisis	O
.	O
She	O
also	O
reports	O
oliguria	O
,	O
oedema	O
up	O
to	O
the	O
knees	O
and	O
a	O
feeling	O
of	O
abdominal	O
distension	O
.	O
He	O
also	O
reported	O
frequent	O
episodes	O
of	O
palpitations	O
and	O
the	O
finding	O
of	O
elevated	O
heart	O
rates	O
of	O
over	O
100	O
bpm	O
during	O
his	O
ambulatory	O
blood	O
pressure	O
measurement	O
.	O
Physical	O
examination	O
Physical	O
examination	O
revealed	O
blood	O
pressure	O
of	O
130	O
80	O
mmHg	O
,	O
heart	O
rate	O
of	O
140	O
bpm	O
,	O
tachypnoea	O
with	O
slurred	O
speech	O
and	O
basal	O
saturation	O
of	O
89	O
.	O
She	O
presented	O
jugular	O
venous	O
engorgement	O
up	O
to	O
1	O
3	O
mid	O
cervical	O
with	O
venous	O
repletion	O
up	O
to	O
the	O
mandibular	O
angle	O
due	O
to	O
positive	O
hepatojugular	O
reflux	O
,	O
crackles	O
up	O
to	O
midfields	O
,	O
moderately	O
distended	O
abdomen	O
with	O
painful	O
hepatomegaly	O
of	O
3	O
crossings	O
and	O
with	O
semiology	O
compatible	O
with	O
mild	O
ascites	O
,	O
and	O
oedema	O
up	O
to	O
1	O
3	O
distal	O
thighs	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
tracing	O
compatible	O
with	O
atypical	O
atrial	O
flutter	O
with	O
ventricular	O
response	O
at	O
140	O
bpm	O
and	O
wide	O
QRS	O
with	O
BCRDHH	O
morphology	O
.	O
Blood	O
tests	O
haemoglobin	O
14	O
.	O
4	O
mg	O
dl	O
,	O
platelets	O
226	O
,	O
000	O
,	O
leucocytes	O
12	O
.	O
100	O
with	O
normal	O
formula	O
,	O
INR	O
of	O
3	O
.	O
49	O
,	O
arterial	O
blood	O
gas	O
with	O
pH	O
7	O
.	O
44	O
,	O
pO2	O
54	O
,	O
pCO2	O
36	O
,	O
Sat	O
O2	O
86	O
,	O
lactate	O
1	O
.	O
9	O
,	O
bicarbonate	O
29	O
,	O
creatinine	O
0	O
.	O
89	O
mg	O
dl	O
,	O
sodium	O
142	O
,	O
potassium	O
4	O
.	O
4	O
,	O
ALT	O
55	O
,	O
bilirubin	O
1	O
.	O
6	O
,	O
alkaline	O
phosphatase	O
267	O
,	O
GGT	O
99	O
,	O
NTproBNP	O
5145	O
.	O
Normal	O
C	O
reactive	O
protein	O
and	O
procalcitonin	O
.	O
Chest	O
X	O
ray	O
increased	O
cardiothoracic	O
index	O
.	O
Bilateral	O
pleural	O
effusion	O
and	O
bilateral	O
hilar	O
infiltrate	O
with	O
evidence	O
of	O
vascular	O
redistribution	O
.	O
Transthoracic	O
echocardiogram	O
mechanical	O
prosthesis	O
in	O
normopositioned	O
mitral	O
position	O
,	O
with	O
mean	O
gradient	O
of	O
4	O
mmHg	O
and	O
effective	O
valve	O
area	O
calculated	O
by	O
THP	O
greater	O
than	O
2	O
cm2	O
.	O
Mild	O
insufficiency	O
.	O
Mechanical	O
prosthesis	O
in	O
aortic	O
position	O
with	O
maximum	O
gradient	O
of	O
28	O
mmHg	O
and	O
mean	O
gradient	O
of	O
15	O
mmHg	O
.	O
Mild	O
insufficiency	O
.	O
Morphologically	O
normal	O
tricuspid	O
valve	O
.	O
Mild	O
moderate	O
insufficiency	O
.	O
Pulmonary	O
artery	O
systolic	O
pressure	O
estimated	O
at	O
38	O
mmHg	O
.	O
Left	O
ventricle	O
not	O
dilated	O
,	O
slightly	O
hypertrophic	O
,	O
with	O
severely	O
depressed	O
global	O
systolic	O
function	O
LVEF	O
22	O
by	O
Simpson	O
biplane	O
.	O
Akinesia	O
of	O
the	O
inferior	O
and	O
inferolateral	O
sides	O
,	O
and	O
of	O
the	O
basal	O
and	O
middle	O
segment	O
of	O
the	O
septum	O
.	O
Severe	O
hypokinesia	O
of	O
the	O
rest	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
.	O
Slightly	O
dilated	O
right	O
atrium	O
.	O
Dilated	O
right	O
ventricle	O
,	O
severely	O
hypocontractile	O
.	O
TAPSE	O
12	O
mm	O
.	O
No	O
pericardial	O
effusion	O
.	O
Normal	O
aortic	O
root	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
without	O
inspiratory	O
collapse	O
.	O
EVOLUTION	O
Given	O
the	O
situation	O
of	O
respiratory	O
compromise	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
Acute	O
Cardiac	O
Care	O
Unit	O
,	O
initiating	O
non	O
invasive	O
ventilatory	O
support	O
with	O
Bi	O
PAP	O
,	O
intravenous	O
diuretic	O
and	O
frequency	O
control	O
strategy	O
with	O
intravenous	O
digitalisation	B-FARMACO
,	O
with	O
suboptimal	O
control	O
despite	O
blood	O
digoxin	B-FARMACO
levels	O
in	O
the	O
high	O
range	O
of	O
the	O
safety	O
margin	O
,	O
so	O
intravenous	O
amiodarone	B-FARMACO
and	O
beta	O
blockers	O
at	O
low	O
doses	O
were	O
added	O
to	O
the	O
treatment	O
after	O
a	O
decrease	O
in	O
congestive	O
signs	O
.	O
Heart	O
rate	O
control	O
was	O
achieved	O
,	O
but	O
the	O
patient	O
remained	O
in	O
atrial	O
flutter	O
with	O
a	O
ventricular	O
response	O
of	O
around	O
85	O
bpm	O
.	O
An	O
echocardiogram	O
was	O
performed	O
after	O
initial	O
heart	O
rate	O
control	O
,	O
which	O
yielded	O
the	O
results	O
that	O
can	O
be	O
seen	O
in	O
the	O
complementary	O
tests	O
.	O
In	O
summary	O
,	O
severe	O
biventricular	O
dysfunction	O
was	O
observed	O
with	O
evidence	O
of	O
right	O
congestion	O
,	O
with	O
normofunctioning	O
mechanical	O
prostheses	O
.	O
No	O
significant	O
biauricular	O
dilatation	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
coronary	O
angiography	O
was	O
performed	O
,	O
ruling	O
out	O
significant	O
coronary	O
artery	O
disease	O
,	O
and	O
global	O
heart	O
failure	O
with	O
biventricular	O
dysfunction	O
secondary	O
to	O
tachycardiomyopathy	O
was	O
postulated	O
as	O
the	O
first	O
diagnosis	O
.	O
Progressively	O
favourable	O
evolution	O
with	O
good	O
frequency	O
control	O
and	O
reduction	O
of	O
respiratory	O
work	O
and	O
improvement	O
of	O
congestive	O
symptoms	O
.	O
Intravenous	O
amiodarone	B-FARMACO
was	O
withdrawn	O
and	O
oral	O
impregnation	O
was	O
maintained	O
,	O
beta	O
blockers	O
were	O
progressively	O
titrated	O
up	O
to	O
a	O
maximum	O
dose	O
of	O
10	O
mg	O
per	O
day	O
and	O
oral	O
digoxin	B-FARMACO
was	O
maintained	O
,	O
with	O
good	O
control	O
.	O
Spironolactone	B-FARMACO
25	O
mg	O
per	O
day	O
and	O
furosemide	B-FARMACO
40	O
mg	O
in	O
the	O
morning	O
were	O
added	O
to	O
the	O
treatment	O
,	O
maintaining	O
enalapril	B-FARMACO
5	O
mg	O
every	O
12	O
hours	O
,	O
acenocoumarol	B-FARMACO
and	O
the	O
rest	O
of	O
his	O
usual	O
medication	O
.	O
Finally	O
,	O
after	O
discussing	O
the	O
case	O
with	O
electrophysiology	O
,	O
considering	O
a	O
complex	O
approach	O
for	O
ablation	O
of	O
atypical	O
flutter	O
substrate	O
requiring	O
left	O
access	O
,	O
an	O
endovascular	O
electrophysiological	O
study	O
was	O
rejected	O
and	O
unsuccessful	O
electrical	O
cardioversion	O
was	O
scheduled	O
after	O
the	O
application	O
of	O
3	O
shocks	O
.	O
In	O
euvolemic	O
and	O
stable	O
condition	O
,	O
in	O
atypical	O
flutter	O
with	O
controlled	O
ventricular	O
response	O
,	O
she	O
was	O
discharged	O
and	O
referred	O
for	O
follow	O
up	O
in	O
the	O
Cardiology	O
Day	O
Hospital	O
and	O
heart	O
failure	O
consultation	O
.	O
Subsequent	O
follow	O
up	O
in	O
the	O
Cardiology	O
day	O
hospital	O
showed	O
the	O
patient	O
to	O
be	O
stable	O
,	O
in	O
functional	O
class	O
II	O
with	O
no	O
evidence	O
of	O
heart	O
failure	O
decompensation	O
.	O
However	O
,	O
she	O
returned	O
to	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
2	O
months	O
later	O
with	O
global	O
heart	O
failure	O
again	O
,	O
reporting	O
palpitations	O
and	O
elevated	O
heart	O
rates	O
on	O
the	O
home	O
blood	O
pressure	O
monitor	O
.	O
The	O
ECG	O
showed	O
the	O
same	O
atypical	O
atrial	O
flutter	O
at	O
140	O
bpm	O
.	O
He	O
was	O
again	O
admitted	O
to	O
the	O
Acute	O
Cardiac	O
Care	O
Unit	O
,	O
where	O
non	O
invasive	O
ventilation	O
,	O
intravenous	O
furosemide	B-FARMACO
and	O
perfused	O
amiodarone	B-FARMACO
were	O
started	O
again	O
,	O
maintaining	O
beta	O
blockers	O
and	O
digoxin	B-FARMACO
,	O
with	O
a	O
progressively	O
favourable	O
evolution	O
,	O
although	O
it	O
was	O
impossible	O
to	O
control	O
the	O
heart	O
rate	O
,	O
maintaining	O
symptoms	O
and	O
semiology	O
of	O
decompensated	O
heart	O
failure	O
.	O
Considering	O
the	O
patient	O
's	O
tachycardiomyopathy	O
,	O
with	O
severe	O
biventricular	O
dysfunction	O
,	O
and	O
after	O
ruling	O
out	O
another	O
flutter	O
substrate	O
approach	O
due	O
to	O
the	O
need	O
for	O
left	O
access	O
with	O
potential	O
associated	O
complications	O
in	O
an	O
anticoagulated	O
patient	O
,	O
the	O
Heart	O
Team	O
decided	O
to	O
implant	O
a	O
pacemaker	O
cardiac	O
resynchronisation	O
therapy	O
CCP	O
CRT	O
in	O
the	O
first	O
stage	O
and	O
later	O
ablation	O
of	O
the	O
atrioventricular	O
node	O
.	O
Thus	O
,	O
during	O
admission	O
,	O
endocavitary	O
left	O
cephalic	O
endocardial	O
CRT	O
PCM	O
was	O
successfully	O
implanted	O
,	O
which	O
allowed	O
subsequent	O
titration	O
of	O
bisoprolol	B-FARMACO
up	O
to	O
supramax	O
doses	O
of	O
20	O
mg	O
per	O
day	O
with	O
very	O
good	O
tolerance	O
,	O
achieving	O
good	O
heart	O
rate	O
control	O
and	O
resolution	O
of	O
acute	O
heart	O
failure	O
.	O
Finally	O
,	O
he	O
was	O
discharged	O
in	O
stable	O
,	O
euvolemic	O
condition	O
,	O
maintaining	O
treatment	O
with	O
furosemide	B-FARMACO
40	O
mg	O
per	O
day	O
,	O
acenocoumarol	B-FARMACO
3	O
mg	O
per	O
day	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
per	O
day	O
,	O
enalapril	B-FARMACO
5	O
mg	O
every	O
12	O
hours	O
,	O
and	O
bisoprolol	B-FARMACO
10	O
mg	O
every	O
12	O
hours	O
.	O
The	O
following	O
month	O
,	O
and	O
as	O
scheduled	O
,	O
atrioventricular	O
node	O
ablation	O
was	O
performed	O
without	O
incident	O
,	O
and	O
the	O
patient	O
was	O
discharged	O
from	O
the	O
Cardiology	O
day	O
hospital	O
without	O
requiring	O
hospitalisation	O
.	O
Subsequent	O
follow	O
up	O
in	O
heart	O
failure	O
consultations	O
was	O
stable	O
,	O
without	O
new	O
episodes	O
of	O
heart	O
failure	O
,	O
with	O
a	O
control	O
echocardiogram	O
at	O
6	O
months	O
in	O
which	O
a	O
recovery	O
of	O
left	O
ventricular	O
function	O
measured	O
by	O
LVEF	O
of	O
up	O
to	O
37	O
was	O
observed	O
,	O
with	O
normofunction	O
of	O
the	O
right	O
ventricle	O
.	O
DIAGNOSIS	O
Tachycardiomyopathy	O
secondary	O
to	O
atypical	O
atrial	O
flutter	O
with	O
rapid	O
ventricular	O
response	O
.	O
Severe	O
biventricular	O
dysfunction	O
.	O
Pacemaker	O
implantation	O
cardiac	O
resynchronisation	O
therapy	O
and	O
nodal	O
ablation	O
.	O
Rheumatic	O
valve	O
disease	O
.	O
Carrier	O
of	O
normofunctioning	O
aortic	O
and	O
mitral	O
valve	O
prostheses	O
.	O

BACKGROUND	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
No	O
known	O
drug	O
allergies	O
.	O
Active	O
smoking	O
40	O
pack	O
years	O
.	O
CVRF	O
hypertensive	O
,	O
obese	O
.	O
Lumbar	O
canal	O
stenosis	O
.	O
During	O
follow	O
up	O
,	O
right	O
hypernephroma	O
was	O
diagnosed	O
.	O
IQ	O
herniated	O
disc	O
L5	O
S1	O
in	O
2006	O
.	O
Cardiological	O
history	O
Permanent	O
atrial	O
fibrillation	O
Rheumatic	O
valve	O
disease	O
.	O
Double	O
mitral	O
lesion	O
with	O
severe	O
stenosis	O
,	O
severe	O
TR	O
and	O
PHT	O
.	O
Intervention	O
in	O
2006	O
by	O
mitral	O
valve	O
replacement	O
with	O
mechanical	O
prosthesis	O
Sorin	O
Bicarbon	O
no	O
27	O
and	O
tricuspid	O
annuloplasty	O
.	O
Usual	O
treatment	O
omeprazole	B-FARMACO
20	O
mg	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
,	O
verapamil	B-FARMACO
80	O
mg	O
12	O
h	O
,	O
acenocoumarol	B-FARMACO
,	O
oxycodone	B-FARMACO
naloxone	I-FARMACO
,	O
duloxetine	B-FARMACO
60mg	O
,	O
gabapentin	B-FARMACO
300	O
mg	O
8	O
h	O
,	O
naproxen	B-FARMACO
.	O
ʟʟ	O
SFB	O
active	O
life	O
,	O
functional	O
limitation	O
due	O
to	O
lumbosciatica	O
with	O
neurogenic	O
claudication	O
.	O
NYHA	O
I	O
IV	O
.	O
Present	O
illness	O
Admitted	O
to	O
Urology	O
for	O
radical	O
right	O
nephrectomy	O
,	O
scheduled	O
for	O
6	O
September	O
.	O
Anticoagulated	O
with	O
enoxaparin	B-FARMACO
60	O
mg	O
24	O
h	O
for	O
5	O
days	O
prior	O
to	O
surgery	O
1	O
to	O
5	O
September	O
and	O
with	O
enoxaparin	B-FARMACO
40	O
mg	O
24	O
h	O
for	O
5	O
days	O
after	O
surgery	O
6	O
to	O
10	O
September	O
.	O
On	O
10	O
September	O
she	O
began	O
to	O
experience	O
dizziness	O
,	O
dyspnoea	O
on	O
exertion	O
and	O
hypotension	O
.	O
Initially	O
assessed	O
by	O
Cardiology	O
,	O
it	O
was	O
interpreted	O
as	O
decompensation	O
of	O
heart	O
failure	O
,	O
diuretics	O
were	O
started	O
and	O
anticoagulation	O
was	O
increased	O
to	O
enoxaparin	B-FARMACO
80	O
mg	O
12h	O
.	O
On	O
day	O
13	O
,	O
sudden	O
respiratory	O
worsening	O
,	O
requiring	O
OTI	O
and	O
profound	O
hypotension	O
requiring	O
noradrenaline	B-FARMACO
in	O
continuous	O
perfusion	O
at	O
increasing	O
doses	O
up	O
to	O
1	O
.	O
5	O
μg	O
kg	O
min	O
.	O
A	O
CT	O
angiography	O
was	O
performed	O
,	O
without	O
finding	O
PET	O
,	O
showing	O
left	O
renal	O
and	O
splenic	O
infarctions	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
resuscitation	O
unit	O
and	O
on	O
call	O
cardiology	O
was	O
notified	O
for	O
assessment	O
.	O
PHYSICAL	O
EXPLORATION	O
on	O
admission	O
to	O
the	O
Coronary	O
Unit	O
BP	O
106	O
49	O
mmHg	O
IABP	O
noradrenaline	O
;	O
PAP	O
63	O
45	O
mmHg	O
;	O
PCP	O
50	O
mmHg	O
;	O
HR	O
145	O
bpm	O
;	O
SatO2	O
97	O
FiO2	O
80	O
;	O
central	O
temperature	O
38	O
.	O
7	O
C	O
.	O
Sedated	O
,	O
well	O
adapted	O
to	O
the	O
ventilator	O
.	O
Peripheral	O
lividity	O
,	O
with	O
acral	O
coldness	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
heart	O
at	O
120	O
bpm	O
,	O
gallop	O
.	O
Pulmonary	O
auscultation	O
scattered	O
rhonchi	O
and	O
universal	O
crackles	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
no	O
defence	O
on	O
palpation	O
.	O
Lower	O
extremities	O
lividity	O
,	O
no	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Chest	O
X	O
ray	O
cardiomegaly	O
,	O
perihilar	O
alveolar	O
infiltrates	O
,	O
compatible	O
with	O
acute	O
pulmonary	O
oedema	O
.	O
Swan	O
Ganz	O
catheter	O
in	O
pulmonary	O
branch	O
,	O
counterpulsation	O
balloon	O
at	O
the	O
level	O
of	O
the	O
tracheal	O
carina	O
,	O
orotracheal	O
intubation	O
tube	O
in	O
normal	O
position	O
.	O
Mechanical	O
prosthesis	O
in	O
mitral	O
position	O
.	O
Angio	O
CT	O
scan	O
ruled	O
out	O
PTE	O
.	O
Data	O
of	O
heart	O
failure	O
and	O
renal	O
and	O
splenic	O
infarcts	O
.	O
ECG	O
AF	O
with	O
ventricular	O
response	O
at	O
130	O
bpm	O
,	O
axis	O
at	O
0o	O
.	O
No	O
repolarisation	O
alterations	O
.	O
Analysis	O
on	O
admission	O
to	O
the	O
Coronary	O
Unit	O
PO2	O
65	O
mmHg	O
.	O
PCO2	O
44	O
mmHg	O
.	O
pH	O
7	O
,	O
22	O
.	O
HCO3	O
18	O
mmol	O
l	O
.	O
SaO2	O
92	O
.	O
Lactate	O
24	O
mg	O
dl	O
.	O
Glucose	O
287	O
mg	O
dl	O
.	O
Urea	O
72	O
mg	O
dl	O
.	O
Creatinine	O
2	O
.	O
45	O
mg	O
dl	O
.	O
GPT	O
55	O
U	O
L	O
.	O
CK	O
89	O
U	O
L	O
.	O
LDH	O
519	O
U	O
L	O
.	O
Corrected	O
calcium	O
8	O
.	O
56	O
mg	O
dl	O
.	O
Sodium	O
133	O
mmol	O
L	O
.	O
Potassium	O
5	O
mmol	O
L	O
.	O
C	O
reactive	O
protein	O
13	O
.	O
09	O
mg	O
dl	O
.	O
Haemoglobin	O
14	O
.	O
4	O
g	O
dl	O
.	O
Haematocrit	O
44	O
.	O
Platelets	O
227	O
.	O
000	O
μL	O
.	O
Leukocytes	O
16	O
,	O
500	O
μL	O
neutrophils	O
83	O
.	O
Prothrombin	O
index	O
70	O
.	O
INR	O
1	O
.	O
28	O
.	O
TTPA	O
41	O
.	O
3	O
s	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophic	O
,	O
with	O
moderate	O
global	O
dysfunction	O
estimated	O
LVEF	O
35	O
40	O
,	O
without	O
clear	O
asynergies	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
without	O
functional	O
alterations	O
.	O
Metal	O
prosthesis	O
in	O
mitral	O
position	O
with	O
restriction	O
of	O
the	O
opening	O
of	O
the	O
antero	O
medial	O
disc	O
,	O
leaving	O
the	O
postero	O
lateral	O
disc	O
fixed	O
.	O
Maximum	O
velocity	O
across	O
the	O
valve	O
230	O
cm	O
s	O
,	O
mean	O
gradient	O
16	O
mmHg	O
.	O
Severely	O
dilated	O
left	O
atrium	O
.	O
Poor	O
access	O
to	O
right	O
chambers	O
.	O
No	O
pericardial	O
effusion	O
.	O
Transesophageal	O
echocardiogram	O
metallic	O
prosthesis	O
in	O
mitral	O
position	O
with	O
restriction	O
of	O
the	O
opening	O
of	O
the	O
antero	O
medial	O
disc	O
and	O
absence	O
of	O
movement	O
of	O
the	O
postero	O
lateral	O
disc	O
;	O
leading	O
to	O
an	O
acceleration	O
of	O
flow	O
in	O
systole	O
with	O
maximum	O
velocity	O
and	O
mean	O
gradient	O
coinciding	O
with	O
the	O
TTE	O
.	O
An	O
attempt	O
is	O
made	O
to	O
measure	O
the	O
thrombus	O
,	O
with	O
an	O
approximate	O
diameter	O
of	O
21	O
.	O
7	O
mm	O
.	O
Severely	O
dilated	O
left	O
atrium	O
with	O
smoke	O
inside	O
.	O
Left	O
atrial	O
appendage	O
with	O
an	O
image	O
suggestive	O
of	O
thrombus	O
inside	O
.	O
EVOLUTION	O
On	O
arrival	O
at	O
the	O
resuscitation	O
department	O
,	O
the	O
patient	O
was	O
sedated	O
and	O
intubated	O
,	O
well	O
adapted	O
to	O
the	O
ventilator	O
.	O
Haemodynamically	O
unstable	O
,	O
requiring	O
increasing	O
doses	O
of	O
noradrenaline	B-FARMACO
in	O
continuous	O
perfusion	O
up	O
to	O
1	O
.	O
5	O
μg	O
kg	O
min	O
to	O
maintain	O
TAS	O
80	O
mmHg	O
,	O
in	O
atrial	O
fibrillation	O
at	O
140	O
bpm	O
.	O
Transthoracic	O
echocardiography	O
V	O
Scan	O
was	O
performed	O
,	O
which	O
showed	O
moderate	O
LV	O
dysfunction	O
,	O
with	O
obstructive	O
thrombus	O
on	O
the	O
mitral	O
prosthetic	O
valve	O
,	O
limiting	O
the	O
opening	O
of	O
the	O
discs	O
.	O
Given	O
the	O
poor	O
clinical	O
and	O
haemodynamic	O
situation	O
,	O
intra	O
aortic	O
balloon	O
counterpulsation	O
was	O
implanted	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
Coronary	O
Unit	O
,	O
where	O
right	O
pressures	O
were	O
monitored	O
using	O
a	O
Swan	O
Ganz	O
catheter	O
.	O
The	O
patient	O
has	O
been	O
in	O
anuria	O
since	O
the	O
onset	O
of	O
the	O
condition	O
.	O
Given	O
the	O
history	O
of	O
major	O
surgery	O
in	O
the	O
previous	O
8	O
days	O
,	O
the	O
size	O
of	O
the	O
thrombus	O
,	O
the	O
presence	O
of	O
systemic	O
embolisms	O
and	O
the	O
presence	O
of	O
a	O
thrombus	O
in	O
the	O
atrial	O
appendage	O
,	O
fibrinolysis	O
was	O
rejected	O
and	O
the	O
cardiac	O
surgeon	O
on	O
duty	O
was	O
notified	O
,	O
who	O
agreed	O
to	O
perform	O
urgent	O
surgery	O
.	O
Valve	O
replacement	O
with	O
a	O
biological	O
mitral	O
valve	O
prosthesis	O
Perimount	O
plus	O
no	O
.	O
27	O
was	O
performed	O
.	O
During	O
the	O
postoperative	O
period	O
,	O
in	O
the	O
Coronary	O
Unit	O
,	O
he	O
developed	O
septic	O
shock	O
secondary	O
to	O
pneumonia	O
,	O
without	O
any	O
germ	O
being	O
isolated	O
in	O
the	O
cultures	O
.	O
He	O
was	O
treated	O
with	O
intensive	O
antibiotic	O
therapy	O
,	O
with	O
good	O
evolution	O
.	O
Two	O
weeks	O
later	O
he	O
was	O
transferred	O
to	O
the	O
hospital	O
ward	O
.	O
She	O
was	O
finally	O
discharged	O
from	O
hospital	O
one	O
month	O
after	O
cardiac	O
surgery	O
.	O
DIAGNOSIS	O
Right	O
radical	O
nephrectomy	O
for	O
hypernephroma	O
.	O
Thrombosis	O
on	O
mechanical	O
mitral	O
prosthesis	O
in	O
relation	O
to	O
perioperative	O
bridging	O
therapy	O
with	O
enoxaparin	B-FARMACO
.	O
Secondary	O
cardiogenic	O
shock	O
.	O
Mitral	O
valve	O
replacement	O
with	O
biological	O
prosthesis	O
.	O
Septic	O
shock	O
due	O
to	O
right	O
basal	O
pneumonia	O
,	O
resolved	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
36	O
year	O
old	O
woman	O
,	O
with	O
the	O
following	O
medical	O
history	O
No	O
known	O
adverse	O
drug	O
reactions	O
.	O
Never	O
smoked	O
.	O
No	O
consumption	O
of	O
alcohol	O
or	O
other	O
intoxicants	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
No	O
history	O
of	O
heart	O
disease	O
in	O
the	O
family	O
.	O
Pregestational	O
arterial	O
hypertension	O
with	O
debut	O
at	O
33	O
years	O
of	O
age	O
,	O
currently	O
on	O
treatment	O
with	O
labetalol	B-FARMACO
100	O
mg	O
every	O
12	O
hours	O
.	O
Dyslipidaemia	O
LDL	O
200	O
mg	O
dl	O
.	O
Primiparous	O
woman	O
in	O
recent	O
puerperium	O
after	O
scheduled	O
caesarean	O
section	O
performed	O
10	O
days	O
ago	O
,	O
without	O
immediate	O
complications	O
,	O
with	O
a	O
healthy	O
male	O
newborn	O
weighing	O
2	O
,	O
930g	O
.	O
The	O
patient	O
consulted	O
the	O
emergency	O
department	O
for	O
several	O
episodes	O
in	O
the	O
last	O
3	O
days	O
of	O
oppressive	O
precordial	O
pain	O
without	O
associated	O
irradiation	O
or	O
vegetative	O
cortex	O
,	O
lasting	O
between	O
5	O
and	O
30	O
minutes	O
,	O
of	O
variable	O
intensity	O
and	O
unrelated	O
to	O
exertion	O
,	O
with	O
a	O
tendency	O
to	O
hypertension	O
during	O
the	O
episodes	O
.	O
Consultation	O
for	O
a	O
new	O
episode	O
of	O
greater	O
intensity	O
and	O
duration	O
.	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
blood	O
pressure	O
BP	O
165	O
104	O
mmHg	O
;	O
heart	O
rate	O
HR	O
79	O
bpm	O
,	O
oxygen	O
saturation	O
98	O
FiO2	O
0	O
.	O
21	O
;	O
temperature	O
36	O
.	O
5	O
oC	O
.	O
On	O
physical	O
examination	O
,	O
the	O
patient	O
was	O
conscious	O
,	O
oriented	O
,	O
eupneic	O
at	O
rest	O
,	O
without	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
with	O
regular	O
tones	O
and	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
with	O
preserved	O
vesicular	O
murmur	O
without	O
aggregates	O
.	O
Radial	O
and	O
pedial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
Absence	O
of	O
peripheral	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
1	O
ECG	O
on	O
arrival	O
,	O
with	O
pain	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
,	O
PR	O
180	O
ms	O
,	O
narrow	O
QRS	O
with	O
axis	O
at	O
30o	O
,	O
ST	O
segment	O
depression	O
0	O
.	O
5	O
mm	O
in	O
V4	O
to	O
V6	O
,	O
flattened	O
T	O
in	O
III	O
.	O
Painless	O
ECG	O
2	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
,	O
PR	O
180	O
ms	O
,	O
narrow	O
QRS	O
with	O
axis	O
at	O
60o	O
,	O
J	O
point	O
rise	O
of	O
0	O
.	O
5	O
mm	O
in	O
V2	O
,	O
biphasic	O
T	O
from	O
V2	O
to	O
V5	O
,	O
negative	O
in	O
I	O
and	O
aVL	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiomediastinal	O
silhouette	O
,	O
without	O
images	O
of	O
consolidation	O
or	O
pleural	O
effusion	O
.	O
Laboratory	O
tests	O
Myocardial	O
damage	O
marker	O
curve	O
ultrasensitive	O
troponin	O
T	O
TnTus	O
58	O
.	O
7	O
to	O
420	O
pg	O
ml	O
at	O
3h	O
normal	O
values	O
14	O
pg	O
ml	O
.	O
N	O
terminal	O
pro	O
brain	O
natriuretic	O
peptide	O
NT	O
proBNP	O
157	O
pg	O
ml	O
.	O
D	O
dimer	O
1560	O
ng	O
ml	O
.	O
Other	O
biochemistry	O
,	O
haemogram	O
and	O
coagulation	O
anodine	O
.	O
Bedside	O
echocardioscopy	O
non	O
dilated	O
left	O
ventricle	O
with	O
preserved	O
LVEF	O
and	O
anterior	O
hypokinesia	O
at	O
mid	O
apical	O
level	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
good	O
systolic	O
function	O
.	O
Absence	O
of	O
significant	O
valvular	O
heart	O
disease	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Abdominal	O
ultrasound	O
placental	O
debris	O
ruled	O
out	O
.	O
Coronary	O
angiography	O
1	O
abrupt	O
decrease	O
in	O
the	O
calibre	O
of	O
the	O
middle	O
and	O
distal	O
anterior	O
descending	O
artery	O
after	O
the	O
exit	O
of	O
the	O
second	O
diagonal	O
developed	O
,	O
image	O
compatible	O
with	O
spontaneous	O
coronary	O
dissection	O
.	O
Distal	O
flow	O
TIMI	O
3	O
.	O
Rest	O
of	O
arteries	O
without	O
lesions	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
with	O
stable	O
,	O
pain	O
free	O
condition	O
,	O
with	O
low	O
dose	O
nitroglycerine	O
perfusion	O
and	O
controlled	O
blood	O
pressure	O
,	O
and	O
early	O
coronary	O
angiography	O
was	O
performed	O
with	O
the	O
findings	O
described	O
.	O
Given	O
the	O
absence	O
of	O
angina	O
and	O
TIMI	O
3	O
distal	O
flow	O
,	O
conservative	O
management	O
in	O
the	O
coronary	O
unit	O
was	O
initially	O
decided	O
.	O
In	O
the	O
following	O
days	O
,	O
the	O
patient	O
presented	O
several	O
short	O
episodes	O
of	O
precordial	O
pain	O
lasting	O
a	O
few	O
minutes	O
,	O
with	O
no	O
electrical	O
changes	O
or	O
increase	O
in	O
markers	O
of	O
myocardial	O
damage	O
.	O
On	O
the	O
third	O
day	O
of	O
admission	O
,	O
she	O
presented	O
a	O
new	O
episode	O
of	O
pain	O
of	O
greater	O
intensity	O
,	O
with	O
an	O
electrocardiogram	O
ECG	O
3	O
showing	O
ST	O
segment	O
elevation	O
1mm	O
in	O
V1	O
to	O
V4	O
and	O
0	O
.	O
5mm	O
in	O
III	O
and	O
aVF	O
.	O
It	O
was	O
decided	O
to	O
perform	O
a	O
new	O
coronary	O
angiography	O
video	O
2	O
.	O
Coronary	O
angiography	O
2	O
which	O
showed	O
distal	O
progression	O
of	O
the	O
dissection	O
,	O
with	O
worsening	O
of	O
the	O
lumen	O
of	O
the	O
artery	O
at	O
the	O
medial	O
level	O
and	O
complete	O
collapse	O
of	O
the	O
same	O
in	O
the	O
apical	O
segment	O
,	O
with	O
weak	O
homolateral	O
collaterals	O
Rentrop	O
1	O
.	O
Given	O
the	O
haemodynamic	O
stability	O
,	O
the	O
disappearance	O
of	O
pain	O
with	O
electrocardiographic	O
improvement	O
after	O
medical	O
treatment	O
and	O
the	O
location	O
of	O
the	O
occlusion	O
in	O
the	O
distal	O
apical	O
segment	O
,	O
conservative	O
management	O
was	O
again	O
decided	O
,	O
with	O
good	O
initial	O
evolution	O
and	O
progressive	O
decrease	O
in	O
markers	O
of	O
myocardial	O
damage	O
.	O
Six	O
days	O
later	O
,	O
the	O
patient	O
presented	O
a	O
new	O
episode	O
of	O
intense	O
precordial	O
pain	O
accompanied	O
by	O
haemodynamic	O
deterioration	O
with	O
hypotension	O
TAS	O
70	O
mmHg	O
requiring	O
vasoactive	O
drugs	O
,	O
respiratory	O
deterioration	O
,	O
radiological	O
worsening	O
compatible	O
with	O
acute	O
pulmonary	O
oedema	O
chest	O
X	O
ray	O
and	O
new	O
elevation	O
of	O
myocardial	O
damage	O
markers	O
from	O
500	O
to	O
3750	O
pg	O
ml	O
.	O
The	O
ECG	O
ECG	O
4	O
shows	O
ST	O
segment	O
elevation	O
2	O
mm	O
in	O
V4	O
V5	O
and	O
0	O
.	O
5	O
mm	O
in	O
II	O
,	O
III	O
and	O
aVF	O
.	O
It	O
was	O
decided	O
to	O
perform	O
a	O
new	O
coronary	O
angiography	O
Coronary	O
angiography	O
3	O
which	O
showed	O
progression	O
of	O
the	O
dissection	O
at	O
the	O
proximal	O
level	O
,	O
with	O
complete	O
occlusion	O
of	O
the	O
vessel	O
at	O
the	O
middle	O
level	O
and	O
distal	O
vessel	O
weakly	O
visualised	O
by	O
homocoronary	O
collaterals	O
Rentrop	O
1	O
.	O
In	O
view	O
of	O
the	O
shock	O
situation	O
and	O
TIMI	O
0	O
flow	O
,	O
it	O
was	O
decided	O
to	O
intervene	O
guided	O
by	O
intravascular	O
ultrasound	O
IVUS	O
,	O
and	O
after	O
placing	O
the	O
angioplasty	O
catheter	O
and	O
passing	O
the	O
guidewire	O
to	O
ADA	O
and	O
diagonal	O
,	O
an	O
image	O
of	O
dissection	O
in	O
the	O
distal	O
left	O
coronary	O
artery	O
possibly	O
facilitated	O
by	O
the	O
tip	O
of	O
the	O
catheter	O
on	O
a	O
susceptible	O
intima	O
with	O
TIMI	O
0	O
flow	O
in	O
all	O
branches	O
was	O
observed	O
.	O
A	O
3	O
.	O
5	O
x	O
28	O
mm	O
drug	O
eluting	O
stent	O
was	O
implanted	O
in	O
the	O
coronary	O
trunk	O
to	O
the	O
proximal	O
anterior	O
descending	O
coronary	O
artery	O
and	O
a	O
second	O
3	O
.	O
5	O
3	O
.	O
0x60	O
mm	O
stent	O
was	O
implanted	O
distally	O
,	O
restoring	O
TIMI	O
3	O
flow	O
in	O
the	O
distal	O
anterior	O
descending	O
artery	O
although	O
with	O
persistent	O
non	O
occlusive	O
dissection	O
,	O
and	O
first	O
diagonal	O
with	O
TIMI	O
1	O
flow	O
.	O
Finally	O
,	O
conservative	O
management	O
of	O
the	O
circumflex	O
artery	O
ostium	O
was	O
chosen	O
after	O
restoring	O
distal	O
TIMI	O
3	O
flow	O
,	O
once	O
the	O
entry	O
port	O
had	O
been	O
sealed	O
.	O
The	O
patient	O
evolved	O
favourably	O
over	O
the	O
following	O
days	O
,	O
with	O
resolution	O
of	O
the	O
shock	O
situation	O
and	O
discharge	O
to	O
the	O
cardiology	O
ward	O
.	O
Regular	O
echocardiography	O
was	O
performed	O
video	O
4	O
and	O
the	O
study	O
was	O
completed	O
with	O
cardiac	O
magnetic	O
resonance	O
imaging	O
video	O
5	O
,	O
showing	O
dilatation	O
of	O
the	O
left	O
ventricle	O
with	O
severe	O
depression	O
of	O
its	O
systolic	O
function	O
LVEF	O
34	O
secondary	O
to	O
alterations	O
in	O
segmental	O
contractility	O
in	O
apical	O
segments	O
and	O
on	O
the	O
lateral	O
side	O
,	O
transmural	O
necrosis	O
of	O
4	O
segments	O
of	O
the	O
LAD	O
territory	O
apical	O
segments	O
and	O
non	O
transmural	O
necrosis	O
on	O
the	O
lateral	O
side	O
.	O
During	O
follow	O
up	O
at	O
discharge	O
from	O
the	O
heart	O
failure	O
unit	O
,	O
prognostically	O
evident	O
drugs	O
were	O
prescribed	O
and	O
,	O
given	O
the	O
absence	O
of	O
improvement	O
in	O
systolic	O
function	O
,	O
an	O
ICD	O
was	O
placed	O
for	O
primary	O
prevention	O
.	O
DIAGNOSIS	O
Spontaneous	O
coronary	O
artery	O
dissection	O
associated	O
with	O
pregnancy	O
.	O
Non	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
NSTEACS	O
.	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
NSTEMI	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
an	O
89	O
year	O
old	O
male	O
with	O
a	O
history	O
of	O
Arterial	O
hypertension	O
under	O
treatment	O
with	O
good	O
control	O
.	O
Common	O
flutter	O
treated	O
with	O
cavotricuspid	O
isthmus	O
ablation	O
.	O
Implantation	O
of	O
a	O
VDD	O
pacemaker	O
in	O
2007	O
after	O
cardiogenic	O
syncope	O
no	O
reports	O
.	O
Non	O
ST	O
elevation	O
acute	O
coronary	O
syndrome	O
in	O
2013	O
with	O
coronary	O
angiography	O
showing	O
no	O
significant	O
lesions	O
.	O
Usual	O
treatment	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
at	O
breakfast	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
at	O
breakfast	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
at	O
dinner	O
,	O
tamsulosin	B-FARMACO
dutasteride	I-FARMACO
0	O
.	O
4	O
0	O
.	O
5	O
mg	O
at	O
breakfast	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
at	O
lunch	O
,	O
acenocoumarol	B-FARMACO
as	O
prescribed	O
,	O
calcifediol	B-FARMACO
0	O
.	O
266	O
mg	O
monthly	O
.	O
Baseline	O
condition	O
physically	O
active	O
,	O
no	O
cognitive	O
deterioration	O
.	O
The	O
patient	O
was	O
under	O
cardiological	O
follow	O
up	O
for	O
aortic	O
stenosis	O
,	O
of	O
degenerative	O
origin	O
,	O
progressing	O
to	O
severe	O
,	O
the	O
patient	O
being	O
asymptomatic	O
.	O
Last	O
echocardiographic	O
control	O
in	O
October	O
19	O
,	O
where	O
preserved	O
LVEF	O
and	O
severe	O
aortic	O
stenosis	O
were	O
found	O
aortic	O
valve	O
area	O
AVA	O
by	O
continuity	O
equation	O
of	O
0	O
.	O
72	O
cm2	O
0	O
.	O
38	O
cm2	O
m2	O
,	O
maximum	O
average	O
gradients	O
of	O
79	O
44	O
mmHg	O
,	O
a	O
maximum	O
velocity	O
of	O
4	O
.	O
5	O
m	O
s	O
and	O
an	O
integral	O
LVOT	O
aorta	O
ratio	O
of	O
0	O
.	O
21	O
.	O
In	O
January	O
2021	O
,	O
a	O
telephone	O
consultation	O
was	O
made	O
in	O
which	O
the	O
patient	O
reported	O
that	O
he	O
continued	O
to	O
carry	O
out	O
his	O
daily	O
activities	O
without	O
difficulty	O
and	O
was	O
asymptomatic	O
,	O
in	O
class	O
I	O
of	O
the	O
New	O
York	O
Heart	O
Association	O
NYHA	O
.	O
Two	O
months	O
after	O
this	O
consultation	O
,	O
the	O
patient	O
needed	O
to	O
be	O
hospitalised	O
in	O
another	O
centre	O
for	O
acute	O
heart	O
failure	O
in	O
the	O
context	O
of	O
SARS	O
CoV	O
2	O
pneumonia	O
.	O
The	O
patient	O
made	O
good	O
progress	O
on	O
the	O
ward	O
with	O
diuretic	O
oxygen	O
therapy	O
.	O
His	O
doctors	O
contacted	O
our	O
clinic	O
,	O
and	O
the	O
patient	O
was	O
discharged	O
without	O
congestive	O
data	O
and	O
with	O
an	O
appointment	O
for	O
preferential	O
assessment	O
in	O
the	O
week	O
following	O
hospital	O
discharge	O
.	O
However	O
,	O
a	O
few	O
days	O
after	O
discharge	O
,	O
the	O
patient	O
needed	O
to	O
visit	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
due	O
to	O
the	O
appearance	O
of	O
oppressive	O
chest	O
pain	O
triggered	O
by	O
slight	O
exertion	O
,	O
which	O
subsided	O
with	O
rest	O
and	O
which	O
was	O
self	O
limiting	O
,	O
with	O
none	O
of	O
the	O
episodes	O
lasting	O
more	O
than	O
5	O
minutes	O
.	O
In	O
addition	O
,	O
she	O
reports	O
a	O
feeling	O
of	O
dizziness	O
that	O
makes	O
it	O
difficult	O
for	O
her	O
to	O
walk	O
.	O
All	O
this	O
has	O
occurred	O
since	O
the	O
last	O
hospital	O
admission	O
.	O
Physical	O
examination	O
revealed	O
a	O
blood	O
pressure	O
of	O
160	O
83	O
mmHg	O
at	O
64	O
beats	O
per	O
minute	O
,	O
saturation	O
of	O
98	O
of	O
ambient	O
air	O
and	O
normothermia	O
.	O
There	O
was	O
also	O
an	O
ejection	O
murmur	O
in	O
aortic	O
focus	O
III	O
VI	O
,	O
radiating	O
to	O
the	O
suprasternal	O
and	O
carotid	O
cavities	O
with	O
effacement	O
of	O
the	O
second	O
tone	O
.	O
Pulmonary	O
auscultation	O
showed	O
bibasal	O
crackles	O
.	O
Oedema	O
with	O
pretibial	O
fovea	O
in	O
both	O
lower	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
Last	O
outpatient	O
echocardiogram	O
severe	O
aortic	O
stenosis	O
with	O
the	O
following	O
additional	O
data	O
aortic	O
valve	O
area	O
AVA	O
by	O
continuity	O
equation	O
of	O
0	O
.	O
72	O
cm2	O
0	O
.	O
38	O
cm2	O
m2	O
,	O
maximum	O
average	O
gradients	O
of	O
79	O
44	O
mmHg	O
,	O
a	O
maximum	O
velocity	O
of	O
4	O
.	O
5	O
m	O
s	O
and	O
an	O
integral	O
ratio	O
of	O
0	O
.	O
21	O
.	O
ED	O
electrocardiogram	O
digitised	O
recording	O
not	O
available	O
alternating	O
sinus	O
rhythm	O
around	O
70	O
bpm	O
with	O
electro	O
stimulated	O
tachycardia	O
130	O
bpm	O
.	O
Chest	O
X	O
ray	O
in	O
the	O
ED	O
study	O
limited	O
by	O
technique	O
.	O
Increased	O
cardiothoracic	O
index	O
,	O
without	O
clear	O
parenchymal	O
consolidation	O
.	O
Impression	O
of	O
absence	O
of	O
pleural	O
effusion	O
.	O
Normopositioned	O
pacemaker	O
electrocatheter	O
.	O
Emergency	O
blood	O
tests	O
CBC	O
red	O
cells	O
4	O
.	O
77	O
xmill	O
μl	O
,	O
haemoglobin	O
13	O
.	O
2	O
g	O
dl	O
,	O
haematocrit	O
39	O
.	O
1	O
,	O
MCV	O
82	O
.	O
1	O
fl	O
,	O
MCH	O
27	O
.	O
7	O
pg	O
,	O
MCHC	O
33	O
.	O
8	O
g	O
dl	O
,	O
RDW	O
17	O
.	O
0	O
,	O
platelets	O
216	O
x1000	O
μl	O
,	O
MPV	O
9	O
.	O
2	O
fl	O
,	O
leukocytes	O
8	O
.	O
3	O
x1000	O
μl	O
,	O
neutrophils	O
5	O
.	O
9	O
x1000	O
μl	O
,	O
neutrophils	O
71	O
.	O
3	O
,	O
lymphocytes	O
1	O
.	O
3	O
x1000	O
μl	O
,	O
lymphocytes	O
15	O
.	O
8	O
,	O
monocytes	O
1	O
.	O
0	O
x1000	O
μl	O
,	O
monocytes	O
12	O
.	O
0	O
,	O
eosinophils	O
0	O
.	O
0	O
x1000	O
μl	O
,	O
eosinophils	O
0	O
.	O
6	O
,	O
basophils	O
0	O
.	O
0	O
x1000	O
μl	O
,	O
basophils	O
0	O
.	O
3	O
.	O
Biochemistry	O
glucose	O
120	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
85	O
mg	O
dl	O
,	O
sodium	O
128	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
21	O
mEq	O
l	O
,	O
chlorine	O
83	O
mEq	O
l	O
,	O
ALT	O
GPT	O
33	O
U	O
l	O
,	O
AST	O
GOT	O
36	O
U	O
l	O
,	O
gamma	O
GT	O
41	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
89	O
U	O
l	O
,	O
LDH	O
290	O
U	O
l	O
,	O
bilirubin	O
0	O
.	O
6	O
mg	O
dl	O
,	O
CK	O
87	O
U	O
l	O
,	O
troponin	O
T	O
hs	O
852	O
.	O
6	O
ng	O
l	O
,	O
NTproBNP	O
14	O
,	O
106	O
pg	O
ml	O
,	O
C	O
reactive	O
protein	O
0	O
.	O
84	O
mg	O
dl	O
.	O
Haemostasis	O
prothrombin	O
activity	O
9	O
,	O
prothrombin	O
time	O
79	O
.	O
5	O
s	O
,	O
INR	O
lab	O
7	O
.	O
76	O
,	O
TTPa	O
51	O
s	O
,	O
fibrinogen	O
derivative	O
405	O
mg	O
dl	O
,	O
D	O
dimer	O
243	O
ng	O
ml	O
.	O
Blood	O
tests	O
during	O
admission	O
enzyme	O
serology	O
with	O
peak	O
troponin	O
T	O
hs	O
of	O
1	O
,	O
440	O
ng	O
l	O
.	O
Echocardiogram	O
during	O
admission	O
non	O
dilated	O
left	O
ventricle	O
with	O
moderate	O
hypertrophy	O
.	O
Segmental	O
contractility	O
alterations	O
global	O
hypokinesia	O
and	O
apical	O
,	O
inferior	O
and	O
inferolateral	O
inferoseptal	O
akinesia	O
with	O
severe	O
systolic	O
dysfunction	O
LVEF	O
33	O
.	O
The	O
aortic	O
valve	O
was	O
severely	O
calcified	O
and	O
unstructured	O
with	O
marked	O
restriction	O
of	O
leaflet	O
mobility	O
AVA	O
0	O
.	O
48	O
cm2	O
0	O
.	O
26	O
cm2	O
m2	O
,	O
peak	O
average	O
gradients	O
of	O
87	O
52	O
mmHg	O
,	O
peak	O
velocity	O
of	O
4	O
.	O
7	O
m	O
s	O
and	O
an	O
integral	O
ratio	O
of	O
0	O
.	O
12	O
,	O
all	O
compatible	O
with	O
severe	O
critical	O
aortic	O
stenosis	O
.	O
In	O
addition	O
,	O
the	O
tricuspid	O
valve	O
exhibited	O
mild	O
insufficiency	O
allowing	O
an	O
estimated	O
pulmonary	O
arterial	O
systolic	O
pressure	O
of	O
63	O
mmHg	O
.	O
Coronary	O
angiography	O
significant	O
calcification	O
of	O
the	O
coronary	O
tree	O
.	O
Left	O
main	O
coronary	O
artery	O
of	O
good	O
calibre	O
,	O
with	O
mild	O
atheromatosis	O
.	O
Anterior	O
descending	O
artery	O
LAD	O
of	O
good	O
calibre	O
and	O
development	O
.	O
Proximal	O
LAD	O
with	O
mild	O
atheromatosis	O
.	O
Mid	O
LAD	O
with	O
moderate	O
focal	O
lesion	O
at	O
the	O
level	O
of	O
the	O
bifurcation	O
with	O
the	O
2nd	O
dominant	O
diagonal	O
without	O
lesions	O
.	O
Distal	O
LAD	O
without	O
lesions	O
.	O
Non	O
dominant	O
circumflex	O
with	O
moderate	O
ostial	O
atheromatosis	O
.	O
Dominant	O
right	O
coronary	O
artery	O
with	O
diffuse	O
mild	O
atheromatosis	O
.	O
Study	O
superimposable	O
to	O
the	O
previous	O
one	O
in	O
2013	O
.	O
CLINICAL	O
EVOLUTION	O
Given	O
the	O
chest	O
pain	O
with	O
elevated	O
troponin	O
T	O
hs	O
and	O
semiological	O
data	O
compatible	O
with	O
decompensation	O
of	O
heart	O
failure	O
,	O
depletive	O
treatment	O
with	O
intravenous	O
furosemide	B-FARMACO
was	O
started	O
in	O
the	O
emergency	O
department	O
,	O
obtaining	O
a	O
favourable	O
response	O
and	O
subsequently	O
allowing	O
the	O
patient	O
to	O
be	O
started	O
on	O
drugs	O
for	O
ventricular	O
dysfunction	O
.	O
On	O
the	O
other	O
hand	O
,	O
in	O
view	O
of	O
the	O
patient	O
's	O
tachycardia	O
,	O
the	O
pacemaker	O
was	O
interrogated	O
,	O
confirming	O
a	O
pacemaker	O
mediated	O
tachycardia	O
,	O
which	O
was	O
resolved	O
after	O
extending	O
the	O
post	O
ventricular	O
atrial	O
refractory	O
period	O
.	O
A	O
new	O
transthoracic	O
echocardiogram	O
showed	O
a	O
non	O
dilated	O
left	O
ventricle	O
with	O
moderate	O
hypertrophy	O
,	O
alterations	O
of	O
segmental	O
contractility	O
global	O
hypokinesia	O
and	O
apical	O
,	O
inferior	O
and	O
inferolateral	O
inferoseptal	O
akinesia	O
with	O
severely	O
depressed	O
systolic	O
function	O
LVEF	O
33	O
.	O
The	O
aortic	O
valve	O
was	O
severely	O
calcified	O
,	O
with	O
the	O
following	O
additional	O
data	O
AVA	O
0	O
.	O
48	O
cm2	O
0	O
.	O
26	O
cm2	O
m2	O
,	O
peak	O
average	O
gradients	O
of	O
87	O
52	O
mmHg	O
,	O
peak	O
velocity	O
of	O
4	O
.	O
7	O
m	O
s	O
and	O
an	O
integral	O
ratio	O
of	O
0	O
.	O
12	O
,	O
all	O
compatible	O
with	O
severe	O
critical	O
aortic	O
stenosis	O
.	O
In	O
addition	O
,	O
the	O
tricuspid	O
valve	O
exhibited	O
mild	O
insufficiency	O
allowing	O
an	O
estimated	O
pulmonary	O
arterial	O
systolic	O
pressure	O
of	O
63	O
mmHg	O
.	O
Given	O
the	O
previous	O
findings	O
,	O
coronary	O
angiography	O
was	O
performed	O
and	O
showed	O
non	O
significant	O
coronary	O
lesions	O
.	O
The	O
case	O
was	O
discussed	O
in	O
a	O
medical	O
surgical	O
session	O
and	O
transcatheter	O
valve	O
implantation	O
via	O
the	O
femoral	O
artery	O
TAVI	O
was	O
chosen	O
.	O
In	O
addition	O
,	O
the	O
possibility	O
of	O
urgent	O
percutaneous	O
valvotomy	O
was	O
considered	O
if	O
the	O
patient	O
's	O
situation	O
required	O
it	O
at	O
some	O
point	O
during	O
admission	O
.	O
However	O
,	O
the	O
patient	O
evolved	O
favourably	O
and	O
was	O
discharged	O
pending	O
completion	O
of	O
the	O
outpatient	O
TAVI	O
study	O
.	O
DIAGNOSIS	O
Severe	O
symptomatic	O
aortic	O
stenosis	O
.	O
Pacemaker	O
mediated	O
tachycardia	O
.	O
Decompensation	O
of	O
heart	O
failure	O
secondary	O
to	O
previous	O
.	O
Acute	O
myocardial	O
infarction	O
without	O
type	O
II	O
ST	O
elevation	O
within	O
the	O
prior	O
.	O
Severe	O
left	O
ventricular	O
systolic	O
dysfunction	O
.	O
Severe	O
pulmonary	O
hypertension	O
.	O
Acute	O
renal	O
failure	O
.	O
Mild	O
hyponatraemia	O
.	O
Acenocoumarol	B-FARMACO
overdosage	O
.	O

Personal	O
history	O
Asthmatic	O
bronchitis	O
.	O
Hypothyroidism	O
.	O
High	O
blood	O
pressure	O
.	O
Hypercholesterolemia	O
.	O
Hepatic	O
steatosis	O
.	O
Sigmoid	O
diverticulosis	O
.	O
Carpal	O
tunnel	O
syndrome	O
Benign	O
prostatic	O
hypertrophy	O
.	O
Hiatus	O
hernia	O
and	O
dyspepsia	O
in	O
follow	O
up	O
by	O
the	O
Digestive	O
Department	O
.	O
Allergic	O
rhinitis	O
.	O
On	O
regular	O
treatment	O
with	O
levothyroxine	B-FARMACO
50	O
ug	O
24h	O
,	O
tamsulosin	B-FARMACO
0	O
.	O
4	O
mg	O
dutasteride	B-FARMACO
0	O
.	O
5	O
mg	O
24h	O
,	O
levogastrol	B-FARMACO
25	O
mg	O
24h	O
,	O
cinitrapide	B-FARMACO
every	O
8	O
hours	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Present	O
illness	O
On	O
14	O
11	O
14	O
he	O
presented	O
with	O
chest	O
pain	O
that	O
persisted	O
until	O
15	O
11	O
14	O
due	O
to	O
persistent	O
chest	O
pain	O
and	O
was	O
diagnosed	O
with	O
STEMI	O
,	O
and	O
it	O
was	O
decided	O
to	O
revascularise	O
by	O
primary	O
PCI	O
on	O
15	O
11	O
14	O
.	O
The	O
patient	O
evolved	O
favourably	O
and	O
was	O
discharged	O
from	O
hospital	O
.	O
On	O
16	O
12	O
14	O
he	O
was	O
readmitted	O
to	O
the	O
Internal	O
Medicine	O
department	O
for	O
chest	O
pain	O
with	O
atypical	O
characteristics	O
,	O
heart	O
failure	O
,	O
abundant	O
cough	O
and	O
whitish	O
expectoration	O
due	O
to	O
possible	O
respiratory	O
infection	O
.	O
Examination	O
on	O
admission	O
15	O
11	O
14	O
Good	O
general	O
condition	O
,	O
normohydrated	O
,	O
normal	O
colour	O
,	O
eupneic	O
at	O
rest	O
with	O
no	O
signs	O
of	O
respiratory	O
distress	O
,	O
tolerating	O
decubitus	O
.	O
RCA	O
rhythmic	O
heart	O
tones	O
without	O
murmurs	O
.	O
Vesicular	O
murmur	O
preserved	O
with	O
bibasal	O
moist	O
crackles	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
,	O
without	O
focality	O
.	O
MMII	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Exploration	O
on	O
re	O
admission	O
16	O
12	O
14	O
Good	O
general	O
condition	O
,	O
normohydrated	O
,	O
normal	O
colour	O
,	O
eupneic	O
at	O
rest	O
with	O
no	O
signs	O
of	O
respiratory	O
distress	O
.	O
He	O
does	O
not	O
tolerate	O
decubitus	O
.	O
No	O
neurological	O
focality	O
,	O
no	O
meningeal	O
signs	O
.	O
RCA	O
rhythmic	O
heart	O
tones	O
without	O
audible	O
murmurs	O
.	O
Decreased	O
vesicular	O
murmur	O
,	O
bibasal	O
crackles	O
and	O
scattered	O
rhonchi	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
,	O
no	O
masses	O
or	O
megaliths	O
,	O
no	O
peritonism	O
.	O
Blumberg	O
,	O
psoas	O
and	O
Murphy	O
negative	O
.	O
Preserved	O
hydro	O
aerial	O
sounds	O
.	O
PPR	O
negative	O
.	O
MMII	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Peripheral	O
pulses	O
preserved	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
On	O
admission	O
15	O
11	O
14	O
ECG	O
on	O
admission	O
to	O
the	O
ER	O
,	O
prior	O
to	O
PCI	O
sinus	O
rhythm	O
with	O
ST	O
segment	O
elevation	O
of	O
more	O
than	O
4	O
mm	O
from	O
V2	O
V4	O
and	O
2	O
mm	O
in	O
I	O
and	O
aVL	O
,	O
and	O
negative	O
T	O
waves	O
in	O
I	O
,	O
aVL	O
,	O
therefore	O
administering	O
loading	O
doses	O
of	O
aspirin	B-FARMACO
and	O
clopidogrel	B-FARMACO
,	O
deciding	O
on	O
primary	O
angioplasty	O
and	O
admission	O
to	O
the	O
coronary	O
unit	O
.	O
Analysis	O
blood	O
count	O
and	O
biochemistry	O
glycaemia	O
123	O
mg	O
dl	O
,	O
urea	O
29	O
.	O
9	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
2	O
mg	O
dl	O
,	O
total	O
bilirubin	O
0	O
.	O
9	O
mg	O
del	O
.	O
Sodium	O
137	O
mEq	O
L	O
,	O
potassium	O
4	O
.	O
59	O
mEq	O
L	O
.	O
Aspartate	O
transaminase	O
131	O
.	O
3	O
U	O
L	O
,	O
alanine	O
transaminase	O
48	O
.	O
2	O
U	O
L	O
,	O
alpha	O
amylase	O
52	O
U	O
L	O
.	O
CRP	O
13	O
.	O
12	O
mg	O
dl	O
,	O
ultrasensitive	O
troponin	O
T	O
3390	O
pg	O
ml	O
,	O
haemoglobin	O
16	O
.	O
5g	O
dl	O
,	O
haematocrit	O
47	O
.	O
2	O
,	O
leukocytes	O
17	O
.	O
27x10	O
3	O
l	O
Coagulation	O
prothrombin	O
activity	O
INR	O
INR	O
1	O
.	O
3	O
,	O
prothrombin	O
activity	O
sec	O
.	O
12	O
.	O
8	O
se	O
,	O
prothrombin	O
activity	O
77	O
.	O
6	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
sec	O
40	O
.	O
2	O
se	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
ratio	O
1	O
.	O
3	O
ratio	O
,	O
fibrinogen	O
587	O
.	O
20	O
mg	O
dl	O
.	O
Primary	O
PCI	O
Coronary	O
angiography	O
right	O
dominance	O
.	O
Middle	O
right	O
coronary	O
artery	O
with	O
40	O
stenosis	O
.	O
Middle	O
anterior	O
descending	O
artery	O
with	O
100	O
stenosis	O
.	O
Circumflex	O
artery	O
with	O
irregularities	O
without	O
stenosis	O
.	O
PTCA	O
middle	O
LAD	O
,	O
stent	O
implantation	O
Integity	O
2	O
.	O
75x15	O
mm	O
and	O
thrombotic	O
material	O
extractor	O
device	O
.	O
ECG	O
on	O
the	O
Cardiology	O
ward	O
,	O
after	O
PCI	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
.	O
PR	O
120	O
msec	O
.	O
Normal	O
axis	O
.	O
QS	O
V1	O
V5	O
with	O
ST	O
segment	O
elevation	O
of	O
more	O
than	O
2	O
mm	O
from	O
V1	O
V5	O
.	O
ECG	O
on	O
discharge	O
from	O
Cardiology	O
ward	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
PR	O
160	O
msec	O
Normal	O
axis	O
.	O
QS	O
V1	O
V5	O
,	O
with	O
persistent	O
elevation	O
of	O
more	O
than	O
1	O
mm	O
from	O
V1	O
V6	O
with	O
negative	O
T	O
waves	O
in	O
these	O
leads	O
.	O
COMPLEMENTARY	O
TESTS	O
On	O
the	O
Cardiology	O
ward	O
18	O
11	O
2014	O
CBC	O
blood	O
count	O
and	O
biochemistry	O
glycaemia	O
95	O
.	O
5	O
mg	O
dl	O
,	O
urea	O
47	O
.	O
6	O
g	O
dl	O
,	O
creatinine	O
1	O
.	O
2	O
mg	O
dl	O
.	O
Ions	O
normal	O
.	O
Liver	O
function	O
normal	O
.	O
Haemogram	O
14	O
.	O
8	O
g	O
dl	O
,	O
haematocrit	O
45	O
.	O
8	O
,	O
MCV	O
96	O
.	O
7	O
fl	O
.	O
Leukocytes	O
12070	O
neutrophils	O
75	O
,	O
lymphocytes	O
12	O
.	O
3	O
,	O
platelets	O
285000	O
.	O
Coagulation	O
INR	O
1	O
.	O
13	O
,	O
prothrombin	O
activity	O
12	O
.	O
9	O
sec	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
42	O
.	O
5	O
sec	O
,	O
T4	O
0	O
.	O
95	O
.	O
TSH	O
9	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
,	O
cardiophrenic	O
and	O
costo	O
diaphragmatic	O
sinuses	O
pinched	O
.	O
No	O
pleural	O
effusion	O
,	O
no	O
infiltrates	O
or	O
consolidation	O
.	O
Echocardiography	O
non	O
dilated	O
left	O
ventricle	O
with	O
apical	O
dyskinesia	O
,	O
akinesia	O
of	O
the	O
middle	O
segments	O
of	O
the	O
anterior	O
face	O
,	O
anterior	O
septum	O
and	O
lateral	O
face	O
.	O
LVEF	O
30	O
.	O
On	O
readmission	O
to	O
the	O
Internal	O
Medicine	O
ward	O
16	O
12	O
14	O
ECG	O
sinus	O
rhythm	O
at	O
93	O
bpm	O
.	O
Axis	O
at	O
0	O
.	O
No	O
conduction	O
disturbances	O
.	O
Negative	O
T	O
waves	O
in	O
I	O
and	O
aVL	O
,	O
V5	O
and	O
V6	O
already	O
described	O
in	O
previous	O
ECGs	O
.	O
Arterial	O
blood	O
gases	O
pH	O
7	O
.	O
51	O
,	O
pO2	O
68	O
.	O
6	O
pCO2	O
28	O
.	O
7	O
,	O
saturation	O
02	O
94	O
CBC	O
haemogram	O
leucocytes	O
13110	O
79	O
PMN	O
.	O
Platelets	O
270000	O
.	O
B	O
13	O
,	O
7	O
.	O
Biochemistry	O
glycaemia	O
115	O
mg	O
dl	O
,	O
urea	O
39	O
.	O
9	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
85	O
mg	O
dl	O
,	O
sodium	O
138	O
mEq	O
L	O
,	O
potassium	O
4	O
.	O
65	O
mEq	O
L	O
,	O
CRP	O
12	O
.	O
76	O
.	O
Cardiac	O
markers	O
.	O
TpnT	O
115	O
120	O
.	O
Chest	O
X	O
ray	O
probable	O
condensation	O
in	O
the	O
left	O
lower	O
lobe	O
.	O
Urine	O
Ag	O
.	O
Legionella	O
negative	O
.	O
Ag	O
streptococcus	O
pneumoniane	O
negative	O
.	O
Sputum	O
culture	O
development	O
of	O
oropharyngeal	O
flora	O
.	O
CT	O
saccular	O
formation	O
in	O
cardiac	O
apex	O
of	O
about	O
50	O
mm	O
,	O
compatible	O
with	O
left	O
ventricular	O
aneurysm	O
pseudoaneurysm	O
.	O
No	O
signs	O
of	O
PTE	O
.	O
Nodule	O
in	O
the	O
left	O
upper	O
lobe	O
of	O
about	O
11	O
mm	O
with	O
central	O
calcification	O
probably	O
corresponding	O
to	O
previous	O
granuloma	O
.	O
Laminar	O
bibasal	O
atelectasis	O
.	O
Echocardiography	O
left	O
ventricle	O
with	O
extensive	O
apical	O
aneurysm	O
and	O
pseudoaneurysm	O
.	O
Contained	O
cardiac	O
rupture	O
.	O
LVEF	O
15	O
.	O
On	O
the	O
Cardiology	O
ward	O
Echocardiography	O
26	O
12	O
14	O
dilated	O
left	O
ventricle	O
with	O
thinned	O
apical	O
region	O
,	O
akinetic	O
and	O
expanded	O
apical	O
aneurysm	O
.	O
Neocavity	O
at	O
the	O
level	O
of	O
the	O
anterolateral	O
apical	O
region	O
communicating	O
with	O
the	O
left	O
ventricle	O
with	O
a	O
neck	O
of	O
12	O
mm	O
and	O
a	O
diameter	O
of	O
5x3	O
cm	O
,	O
contained	O
by	O
pericardium	O
with	O
flow	O
passage	O
,	O
compatible	O
with	O
pseudoaneurysm	O
on	O
apical	O
aneurysm	O
.	O
Ejection	O
fraction	O
very	O
severely	O
depressed	O
by	O
visual	O
estimation	O
.	O
Normal	O
left	O
atrium	O
.	O
Right	O
ventricle	O
with	O
normal	O
diameter	O
,	O
walls	O
and	O
ejection	O
fraction	O
.	O
Normal	O
right	O
atrium	O
.	O
Mitral	O
valve	O
with	O
good	O
opening	O
and	O
mild	O
moderate	O
secondary	O
mitral	O
insufficiency	O
.	O
Aortic	O
valve	O
without	O
significant	O
structural	O
or	O
functional	O
alterations	O
.	O
Right	O
valves	O
without	O
significant	O
structural	O
or	O
functional	O
alterations	O
.	O
Inferolateral	O
pericardial	O
detachment	O
in	O
the	O
peri	O
pseudoaneurysm	O
area	O
.	O
Inferior	O
cava	O
not	O
dilated	O
with	O
preserved	O
inspiratory	O
collapse	O
On	O
the	O
Cardiovascular	O
Surgery	O
Ward	O
Preoperative	O
blood	O
count	O
haemoglobin	O
13	O
.	O
4	O
g	O
dl	O
,	O
leucocytes	O
10	O
.	O
4x10	O
3	O
L	O
,	O
platelets	O
384000	O
.	O
Urea	O
49	O
mg	O
dl	O
,	O
creatinine	O
1	O
mg	O
dl	O
,	O
Pro	O
BPN	O
290	O
.	O
Normal	O
coagulation	O
.	O
Control	O
after	O
surgery	O
haemoglobin	O
9	O
.	O
9	O
,	O
renal	O
function	O
and	O
ions	O
normal	O
.	O
ECG	O
sinus	O
rhythm	O
with	O
extensive	O
anteroseptal	O
and	O
lateral	O
necrosis	O
wave	O
.	O
Echocardiography	O
12	O
01	O
14	O
after	O
surgery	O
left	O
ventricle	O
with	O
normal	O
diameters	O
.	O
Apical	O
akinesia	O
and	O
part	O
of	O
anteroseptal	O
,	O
anterior	O
and	O
lateral	O
mid	O
segment	O
with	O
increased	O
echogenicity	O
in	O
endocardial	O
area	O
suggestive	O
of	O
Dacron	O
patch	O
;	O
thickening	O
and	O
increased	O
echogenicity	O
of	O
apical	O
parietal	O
pericardium	O
.	O
Inferior	O
apical	O
hypokinesia	O
.	O
Basal	O
hypokinesia	O
and	O
part	O
of	O
anterior	O
media	O
.	O
Rest	O
lateral	O
and	O
inferolateral	O
with	O
compensatory	O
hyperkinesia	O
.	O
Moderately	O
depressed	O
ejection	O
fraction	O
,	O
around	O
35	O
40	O
by	O
visual	O
estimation	O
.	O
Simpson	O
biplane	O
of	O
38	O
,	O
filling	O
pattern	O
suggestive	O
of	O
impaired	O
relaxation	O
.	O
Normal	O
left	O
atrium	O
and	O
right	O
chambers	O
.	O
Left	O
and	O
right	O
valves	O
without	O
significant	O
structural	O
or	O
functional	O
alterations	O
.	O
Aortic	O
root	O
and	O
ascending	O
aorta	O
slightly	O
dilated	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Normal	O
inferior	O
vena	O
cava	O
.	O
EVOLUTION	O
The	O
patient	O
started	O
on	O
14th	O
November	O
at	O
23	O
00	O
hours	O
with	O
oppressive	O
central	O
thoracic	O
pain	O
radiating	O
to	O
the	O
left	O
arm	O
with	O
sweating	O
.	O
The	O
patient	O
remained	O
at	O
home	O
and	O
decided	O
not	O
to	O
consult	O
the	O
doctor	O
because	O
he	O
did	O
not	O
attach	O
any	O
importance	O
to	O
the	O
situation	O
.	O
After	O
spending	O
the	O
whole	O
night	O
with	O
pain	O
and	O
persisting	O
with	O
the	O
same	O
on	O
the	O
morning	O
of	O
the	O
15th	O
he	O
decided	O
to	O
go	O
to	O
his	O
reference	O
hospital	O
,	O
where	O
on	O
arrival	O
an	O
ECG	O
was	O
performed	O
15	O
11	O
14	O
described	O
in	O
complementary	O
tests	O
.	O
STEMI	O
was	O
detected	O
and	O
primary	O
PCI	O
was	O
decided	O
.	O
On	O
the	O
cardiology	O
ward	O
,	O
the	O
patient	O
evolved	O
favourably	O
and	O
a	O
TSH	O
of	O
9	O
was	O
discovered	O
,	O
so	O
levothyroxine	B-FARMACO
was	O
increased	O
.	O
Given	O
the	O
good	O
evolution	O
,	O
the	O
patient	O
was	O
discharged	O
with	O
a	O
diagnosis	O
of	O
Anterior	O
STEMI	O
treated	O
with	O
primary	O
angioplasty	O
and	O
implantation	O
of	O
a	O
stent	O
in	O
the	O
mid	O
LAD	O
.	O
Severe	O
ventricular	O
dysfunction	O
.	O
Pharmacological	O
treatment	O
on	O
discharge	O
from	O
the	O
Cardiology	O
ward	O
22	O
11	O
14	O
Usual	O
medication	O
for	O
benign	O
prostatic	O
hypertrophy	O
and	O
dyspepsia	O
.	O
Acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
,	O
1	O
tablet	O
at	O
noon	O
.	O
Clopidogrel	B-FARMACO
75	O
mg	O
,	O
1	O
tablet	O
at	O
breakfast	O
.	O
Omeprazole	B-FARMACO
20	O
mg	O
,	O
1	O
tablet	O
at	O
breakfast	O
.	O
Levothyroxine	B-FARMACO
75	O
mcg	O
,	O
1	O
tablet	O
at	O
breakfast	O
.	O
Ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
,	O
half	O
a	O
tablet	O
at	O
dinner	O
.	O
Furosemide	B-FARMACO
40	O
mg	O
,	O
half	O
a	O
tablet	O
at	O
breakfast	O
.	O
Eplerenone	B-FARMACO
25	O
mg	O
,	O
1	O
tablet	O
at	O
midday	O
.	O
Atorvastatin	B-FARMACO
80	O
mg	O
,	O
1	O
tablet	O
at	O
dinner	O
.	O
It	O
was	O
decided	O
not	O
to	O
introduce	O
beta	O
blockers	O
due	O
to	O
asthmatic	O
bronchitis	O
.	O
The	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
on	O
11	O
December	O
due	O
to	O
the	O
onset	O
of	O
chest	O
pain	O
of	O
atypical	O
characteristics	O
lasting	O
hours	O
and	O
exacerbating	O
with	O
respiratory	O
movements	O
.	O
No	O
clinical	O
signs	O
of	O
decompensation	O
of	O
heart	O
failure	O
.	O
The	O
analytical	O
tests	O
performed	O
and	O
the	O
ECG	O
were	O
similar	O
to	O
those	O
on	O
discharge	O
from	O
hospital	O
and	O
the	O
pain	O
subsided	O
with	O
the	O
usual	O
intravenous	O
analgesia	O
paracetamol	B-FARMACO
,	O
metamizole	B-FARMACO
,	O
so	O
he	O
was	O
discharged	O
from	O
the	O
emergency	O
department	O
.	O
He	O
returned	O
to	O
the	O
ED	O
on	O
16	O
December	O
due	O
to	O
recurrence	O
of	O
atypical	O
chest	O
pain	O
,	O
which	O
caused	O
shortness	O
of	O
breath	O
,	O
increasing	O
with	O
inspiration	O
and	O
lasting	O
for	O
hours	O
,	O
as	O
well	O
as	O
symptoms	O
compatible	O
with	O
heart	O
failure	O
dyspnoea	O
on	O
minimal	O
exertion	O
,	O
orthopnoea	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
He	O
also	O
reported	O
cough	O
with	O
whitish	O
expectoration	O
without	O
thermometric	O
fever	O
.	O
Pneumonia	O
was	O
suspected	O
in	O
the	O
emergency	O
department	O
and	O
he	O
was	O
admitted	O
to	O
Internal	O
Medicine	O
with	O
a	O
diagnosis	O
of	O
pneumonia	O
.	O
During	O
admission	O
to	O
Internal	O
Medicine	O
,	O
complementary	O
tests	O
were	O
carried	O
out	O
which	O
revealed	O
a	O
pseudoaneurysm	O
on	O
apical	O
aneurysm	O
and	O
so	O
he	O
was	O
referred	O
to	O
a	O
referral	O
hospital	O
with	O
Cardiac	O
Surgery	O
,	O
being	O
admitted	O
under	O
the	O
care	O
of	O
Cardiology	O
.	O
The	O
patient	O
was	O
presented	O
at	O
the	O
medical	O
surgical	O
session	O
where	O
he	O
was	O
finally	O
accepted	O
for	O
surgery	O
and	O
underwent	O
surgery	O
on	O
30	O
December	O
.	O
He	O
had	O
occasional	O
chest	O
pain	O
with	O
pleuro	O
pericardial	O
characteristics	O
and	O
clopidogrel	B-FARMACO
was	O
withdrawn	O
5	O
days	O
prior	O
to	O
surgery	O
.	O
Surgery	O
was	O
performed	O
resection	O
of	O
the	O
ventricular	O
aneurysm	O
by	O
means	O
of	O
a	O
central	O
incision	O
and	O
implantation	O
of	O
a	O
Dacron	O
patch	O
.	O
The	O
patch	O
was	O
covered	O
with	O
the	O
walls	O
of	O
the	O
pseudoaneurysm	O
,	O
which	O
was	O
reinforced	O
with	O
three	O
Teflon	O
strips	O
,	O
with	O
no	O
intraoperative	O
incidents	O
.	O
During	O
his	O
stay	O
on	O
the	O
Cardiac	O
Surgery	O
ward	O
,	O
he	O
evolved	O
favourably	O
,	O
starting	O
to	O
ambulate	O
,	O
with	O
no	O
signs	O
of	O
decompensated	O
heart	O
failure	O
,	O
and	O
was	O
discharged	O
on	O
13	O
01	O
15	O
.	O
Pharmacological	O
treatment	O
on	O
discharge	O
from	O
the	O
Cardiovascular	O
Surgery	O
ward	O
13	O
01	O
15	O
Usual	O
medication	O
for	O
benign	O
prostatic	O
hypertrophy	O
,	O
dyspepsia	O
and	O
hypothyroidism	O
same	O
.	O
Aspirin	B-FARMACO
100	O
mg	O
,	O
1	O
tablet	O
at	O
breakfast	O
.	O
Clopidogrel	B-FARMACO
75	O
mg	O
,	O
1	O
tablet	O
at	O
breakfast	O
.	O
Omeprazole	B-FARMACO
20	O
mg	O
,	O
1	O
tablet	O
at	O
breakfast	O
.	O
Atorvastatin	B-FARMACO
40	O
mg	O
,	O
1	O
tablet	O
at	O
dinner	O
.	O
Bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
,	O
1	O
tablet	O
at	O
breakfast	O
.	O
Ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
,	O
1	O
tablet	O
at	O
breakfast	O
.	O
Eplerenone	B-FARMACO
25	O
mg	O
,	O
1	O
tablet	O
at	O
lunch	O
.	O
Furosemide	B-FARMACO
40	O
mg	O
,	O
at	O
breakfast	O
.	O
DIAGNOSIS	O
Contained	O
cardiac	O
rupture	O
pseudoaneurysm	O
over	O
apical	O
aneurysm	O
.	O

Personal	O
history	O
The	O
patient	O
is	O
a	O
53	O
year	O
old	O
male	O
,	O
with	O
no	O
drug	O
allergies	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
of	O
3	O
years	O
of	O
evolution	O
,	O
treated	O
with	O
oral	O
antidiabetics	O
with	O
good	O
control	O
,	O
without	O
other	O
classic	O
cardiovascular	O
risk	O
factors	O
.	O
Depressive	O
syndrome	O
under	O
pharmacological	O
treatment	O
In	O
August	O
2014	O
4	O
months	O
prior	O
to	O
admission	O
to	O
the	O
emergency	O
department	O
he	O
underwent	O
an	O
outpatient	O
study	O
in	O
Internal	O
Medicine	O
due	O
to	O
asthenia	O
,	O
anorexia	O
and	O
weight	O
loss	O
with	O
splenomegaly	O
and	O
Raynaud	O
's	O
,	O
positive	O
ANAs	O
1	O
640	O
with	O
homogeneous	O
nucleolar	O
pattern	O
and	O
positive	O
aniScl	O
70	O
;	O
a	O
diagnosis	O
of	O
systemic	O
sclerosis	O
was	O
established	O
and	O
immunosuppressant	O
treatment	O
,	O
haemorrheological	O
treatment	O
and	O
calcium	O
antagonists	O
were	O
started	O
.	O
The	O
patient	O
continues	O
chronic	O
treatment	O
with	O
methotrexate	B-FARMACO
15	O
mg	O
every	O
24	O
hours	O
,	O
pentoxifylline	B-FARMACO
400	O
mg	O
every	O
24	O
hours	O
,	O
diltiazem	B-FARMACO
60	O
mg	O
every	O
8	O
hours	O
,	O
calcium	B-FARMACO
folinate	I-FARMACO
15	O
mg	O
every	O
24	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
every	O
24	O
hours	O
,	O
glimepiride	B-FARMACO
2	O
mg	O
every	O
24	O
hours	O
and	O
desvenlafaxine	B-FARMACO
50	O
mg	O
every	O
24	O
hours	O
.	O
Current	O
illness	O
48	O
hours	O
prior	O
to	O
his	O
arrival	O
at	O
the	O
ED	O
,	O
the	O
patient	O
reported	O
marked	O
asthenia	O
and	O
dyspnoea	O
on	O
minimal	O
exertion	O
,	O
for	O
which	O
he	O
discontinued	O
diltiazem	B-FARMACO
on	O
the	O
recommendation	O
of	O
his	O
primary	O
care	O
physician	O
.	O
Despite	O
this	O
,	O
his	O
symptoms	O
persisted	O
and	O
his	O
dyspnoea	O
even	O
worsened	O
the	O
following	O
morning	O
,	O
so	O
his	O
family	O
called	O
112	O
and	O
he	O
was	O
attended	O
at	O
home	O
by	O
the	O
SAMU	O
who	O
performed	O
an	O
electrocardiogram	O
ECG	O
which	O
revealed	O
complete	O
atrioventricular	O
block	O
AVB	O
with	O
wide	O
QRS	O
escape	O
at	O
30x	O
,	O
deciding	O
on	O
superficial	O
sedation	O
,	O
implantation	O
of	O
a	O
transcutaneous	O
pacemaker	O
and	O
transfer	O
to	O
the	O
Emergency	O
Department	O
of	O
our	O
centre	O
.	O
He	O
denied	O
any	O
other	O
symptoms	O
of	O
heart	O
failure	O
,	O
fever	O
or	O
other	O
symptoms	O
of	O
interest	O
.	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
a	O
new	O
ECG	O
showed	O
complete	O
AVB	O
with	O
wide	O
QRS	O
leakage	O
alternating	O
with	O
transcutaneous	O
MCP	O
rhythm	O
in	O
command	O
mode	O
with	O
no	O
capture	O
failures	O
,	O
and	O
on	O
telemetry	O
,	O
asymptomatic	O
,	O
self	O
limited	O
bouts	O
of	O
polymorphic	O
ventricular	O
tachycardia	O
of	O
the	O
torsades	O
de	O
pointes	O
type	O
.	O
Urgent	O
admission	O
to	O
the	O
Coronary	O
Unit	O
was	O
decided	O
.	O
Physical	O
examination	O
in	O
the	O
emergency	O
department	O
Blood	O
pressure	O
170	O
90	O
mmHg	O
.	O
Heart	O
rate	O
65	O
beats	O
per	O
minute	O
with	O
transcutaneous	O
MCP	O
.	O
To	O
36	O
.	O
2	O
C	O
.	O
Sat	O
O2	O
96	O
with	O
oxygen	B-FARMACO
goggles	O
at	O
2	O
litres	O
per	O
minute	O
.	O
Dark	O
complexion	O
,	O
microstomia	O
,	O
sclerodermic	O
skin	O
on	O
trunk	O
and	O
hands	O
,	O
no	O
telangiectasias	O
,	O
no	O
ulcers	O
,	O
no	O
calcinosis	O
lesions	O
,	O
no	O
tendon	O
rubbing	O
.	O
Complete	O
normal	O
neurological	O
examination	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Carotid	O
auscultation	O
no	O
murmurs	O
cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
bilateral	O
dry	O
crackles	O
predominantly	O
in	O
the	O
basal	O
and	O
lateral	O
areas	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
,	O
with	O
palpable	O
splenomegaly	O
.	O
Upper	O
limbs	O
symmetrical	O
peripheral	O
pulses	O
.	O
Lower	O
limbs	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
,	O
with	O
symmetrical	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
During	O
admission	O
Biochemistry	O
basal	O
glycaemia	O
95	O
mg	O
dL	O
,	O
urea	O
55	O
76	O
128	O
160	O
159	O
212	O
212	O
mg	O
dL	O
;	O
creatinine	O
1	O
.	O
97	O
2	O
.	O
36	O
3	O
.	O
7	O
4	O
.	O
52	O
5	O
.	O
16	O
7	O
.	O
08	O
mg	O
dL	O
;	O
estimated	O
glomerular	O
filtration	O
rate	O
30	O
25	O
21	O
14	O
12	O
8	O
mL	O
min	O
;	O
sodium	O
ion	O
132	O
mmol	O
L	O
;	O
potassium	O
ion	O
4	O
.	O
1	O
mmol	O
L	O
;	O
creatine	O
kinase	O
160	O
140	O
182	O
U	O
L	O
;	O
troponin	O
T	O
320	O
370	O
486	O
ng	O
L	O
cut	O
off	O
point	O
35	O
ng	O
L	O
;	O
NT	O
ProBNP	O
70000	O
;	O
liver	O
function	O
tests	O
normal	O
;	O
albumin	O
33	O
g	O
l	O
;	O
total	O
cholesterol	O
145	O
mg	O
dL	O
;	O
LDL	O
89	O
;	O
HDL	O
29	O
;	O
TAG	O
132	O
;	O
HbA1c	O
6	O
.	O
5	O
.	O
Thyroid	O
hormones	O
normal	O
.	O
Arterial	O
blood	O
gases	O
on	O
admission	O
pH	O
7	O
.	O
48	O
,	O
pO2	O
64	O
PCO2	O
33	O
,	O
HCO3	O
25	O
.	O
During	O
the	O
episode	O
of	O
APE	O
pH	O
7	O
.	O
30	O
,	O
pO2	O
55	O
,	O
PCO2	O
48	O
,	O
HCO3	O
25	O
.	O
24	O
hours	O
after	O
APE	O
pH	O
7	O
.	O
40	O
,	O
pO2	O
67	O
PCO2	O
35	O
,	O
HCO3	O
29	O
.	O
CBC	O
Hb	O
12	O
.	O
6	O
11	O
.	O
5	O
10	O
12	O
g	O
dl	O
elevated	O
RDW	O
,	O
leukocytes	O
10970	O
17240	O
12300	O
9430	O
μl	O
and	O
plaq	O
293	O
230	O
145	O
130	O
130	O
μl	O
.	O
Coagulation	O
study	O
PT	O
96	O
,	O
TTPA	O
34	O
.	O
5	O
sec	O
,	O
fibrinogen	O
530	O
mg	O
d	O
.	O
Immunoglobulins	O
Ig	O
G	O
17	O
,	O
94	O
,	O
Ig	O
A	O
2	O
,	O
86	O
,	O
Ig	O
M	O
3	O
,	O
46	O
,	O
C3	O
0	O
,	O
79	O
,	O
C4	O
0	O
,	O
18	O
.	O
Autoimmunity	O
ANA	O
positive	O
1	O
640	O
,	O
homogeneous	O
nucleolar	O
pattern	O
.	O
Anti	O
MPO	O
,	O
Anti	O
MBG	O
,	O
ANCA	O
negative	O
.	O
ENAS	O
positive	O
.	O
Positive	O
anti	O
Scl	O
70	O
.	O
Negative	O
anti	O
SSA	O
Ro60	O
,	O
SSA	O
Ro52	O
,	O
SSB	O
,	O
RNP	O
,	O
Sm	O
and	O
Jo	O
1	O
.	O
Serologies	O
HBV	O
,	O
HCV	O
,	O
HIV	O
negative	O
.	O
Urine	O
sediment	O
and	O
urine	O
system	O
pH	O
5	O
.	O
5	O
,	O
density	O
1008	O
,	O
protein	O
1	O
,	O
blood	O
2	O
50	O
red	O
blood	O
cells	O
field	O
,	O
rest	O
negative	O
.	O
Urine	O
electrophoresis	O
electrophoretic	O
profile	O
of	O
mixed	O
proteinuria	O
tubular	O
and	O
minor	O
non	O
selective	O
glomerular	O
proteinuria	O
.	O
Urine	O
immunofixation	O
no	O
monoclonal	O
component	O
observed	O
.	O
ECG	O
prior	O
to	O
the	O
event	O
,	O
at	O
the	O
Internal	O
Medicine	O
consultation	O
sinus	O
rhythm	O
at	O
60	O
beats	O
per	O
minute	O
,	O
with	O
left	O
anterior	O
hemiblock	O
and	O
incomplete	O
right	O
bundle	O
branch	O
block	O
.	O
ECG	O
SA	O
MU	O
at	O
home	O
complete	O
atrioventricular	O
block	O
with	O
wide	O
QRS	O
leak	O
at	O
20	O
bpm	O
.	O
ECG	O
ED	O
Complete	O
AVB	O
with	O
wide	O
QRS	O
escape	O
alternating	O
with	O
transcutaneous	O
MCP	O
rhythm	O
at	O
command	O
without	O
capture	O
failure	O
.	O
Telemetry	O
ED	O
bouts	O
of	O
polymorphic	O
torsades	O
de	O
pointes	O
like	O
ventricular	O
tachycardia	O
,	O
self	O
limited	O
.	O
ECG	O
post	O
definitive	O
MCP	O
sinus	O
tachycardia	O
at	O
112	O
bpm	O
with	O
ventricular	O
pacing	O
by	O
MCP	O
with	O
self	O
paced	O
monitoring	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
increased	O
cardiothoracic	O
index	O
with	O
vascular	O
redistribution	O
and	O
bilateral	O
diffuse	O
interstitial	O
predominance	O
pattern	O
.	O
Provisional	O
MCP	O
electrode	O
in	O
normal	O
position	O
in	O
the	O
RV	O
.	O
Chest	O
X	O
ray	O
during	O
the	O
episode	O
of	O
PAD	O
increased	O
cardiothoracic	O
index	O
with	O
bilateral	O
diffuse	O
alveolar	O
pattern	O
,	O
predominantly	O
right	O
and	O
more	O
marked	O
at	O
the	O
perihilar	O
level	O
,	O
compatible	O
with	O
PAD	O
.	O
MCP	O
generator	O
with	O
right	O
atrial	O
and	O
ventricular	O
electrode	O
normally	O
positioned	O
.	O
Chest	O
X	O
ray	O
4	O
days	O
after	O
admission	O
,	O
48	O
hours	O
post	O
PAE	O
increased	O
cardiothoracic	O
index	O
with	O
great	O
improvement	O
in	O
the	O
diffuse	O
alveolar	O
pattern	O
,	O
but	O
interstitial	O
pattern	O
with	O
vascular	O
redistribution	O
persists	O
.	O
MCP	O
generator	O
with	O
normopositioned	O
right	O
atrial	O
and	O
ventricular	O
electrode	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
LV	O
of	O
normal	O
size	O
and	O
thickness	O
,	O
with	O
mildly	O
impaired	O
systolic	O
function	O
.	O
Prolonged	O
diastolic	O
relaxation	O
pattern	O
.	O
Severe	O
hypokinesia	O
of	O
mid	O
and	O
apical	O
septal	O
segments	O
.	O
RV	O
of	O
normal	O
size	O
and	O
systolic	O
function	O
.	O
Mitral	O
valve	O
with	O
thickened	O
leaflets	O
,	O
with	O
moderate	O
insufficiency	O
.	O
Tricuspid	O
valve	O
with	O
mild	O
insufficiency	O
.	O
Estimated	O
PSAP	O
of	O
37	O
mmHg	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
.	O
No	O
pericardial	O
effusion	O
.	O
Abdominal	O
echo	O
homogeneous	O
splenomegaly	O
of	O
15	O
cm	O
in	O
length	O
without	O
other	O
alterations	O
.	O
Chest	O
CT	O
scan	O
bicameral	O
pacemaker	O
.	O
Cardiomegaly	O
.	O
Increase	O
in	O
the	O
calibre	O
of	O
the	O
pulmonary	O
artery	O
compatible	O
with	O
pulmonary	O
hypertension	O
.	O
Increased	O
density	O
in	O
"	O
ground	O
glass	O
"	O
with	O
predominance	O
in	O
posterior	O
segments	O
of	O
both	O
lung	O
fields	O
compatible	O
with	O
pulmonary	O
oedema	O
over	O
underlying	O
pulmonary	O
fibrosis	O
.	O
Calcified	O
mediastinal	O
and	O
bilateral	O
hilar	O
calcified	O
adenopathies	O
of	O
chronic	O
inflammatory	O
character	O
.	O
Coronary	O
angiography	O
epicardial	O
coronary	O
arteries	O
without	O
significant	O
angiographic	O
stenosis	O
.	O
Left	O
dominance	O
with	O
CD	O
of	O
scarce	O
development	O
and	O
course	O
.	O
Renal	O
biopsy	O
marked	O
interstitial	O
fibrosis	O
in	O
40	O
of	O
the	O
sample	O
.	O
Tubular	O
atrophy	O
with	O
thickening	O
and	O
folding	O
of	O
the	O
tubular	O
basement	O
membrane	O
.	O
No	O
interstitial	O
inflammatory	O
infiltrate	O
.	O
Medium	O
sized	O
arteries	O
show	O
marked	O
intimal	O
thickening	O
,	O
with	O
deposition	O
of	O
mucinous	O
material	O
in	O
the	O
intima	O
.	O
Arterioles	O
with	O
media	O
proliferation	O
with	O
severe	O
luminal	O
involvement	O
90	O
of	O
arteries	O
.	O
No	O
fibrin	O
thrombi	O
or	O
fibrinoid	O
necrosis	O
.	O
20	O
glomeruli	O
were	O
studied	O
,	O
in	O
all	O
of	O
them	O
there	O
was	O
retraction	O
of	O
the	O
ball	O
,	O
with	O
an	O
increase	O
in	O
Bowman	O
's	O
space	O
,	O
folding	O
of	O
the	O
glomerular	O
capillary	O
walls	O
and	O
2	O
glomeruli	O
with	O
small	O
aneurysms	O
.	O
No	O
necrotising	O
lesions	O
.	O
Immunofluorescence	O
C1q	O
,	O
C3	O
focal	O
mesangial	O
granular	O
,	O
C4	O
,	O
IgA	O
,	O
IgG	O
,	O
IgM	O
,	O
albumin	O
in	O
tubular	O
basement	O
membranes	O
and	O
Bowman	O
's	O
capsule	O
,	O
fibrinogen	O
kappa	O
and	O
lambda	O
light	O
chains	O
.	O
Summary	O
tubulointerstitial	O
nephropathy	O
with	O
severe	O
involvement	O
and	O
secondary	O
vascular	O
changes	O
.	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
where	O
a	O
provisional	O
pacemaker	O
was	O
implanted	O
via	O
the	O
right	O
jugular	O
vein	O
,	O
maintaining	O
the	O
MCP	O
rhythm	O
in	O
a	O
command	O
regime	O
and	O
without	O
any	O
new	O
rhythm	O
alterations	O
being	O
observed	O
in	O
the	O
telemetry	O
.	O
Haemodynamically	O
stable	O
with	O
normal	O
baseline	O
blood	O
gases	O
and	O
BP	O
160	O
90	O
,	O
amlodipine	B-FARMACO
5	O
mg	O
12h	O
was	O
added	O
to	O
the	O
usual	O
treatment	O
without	O
diltiazem	B-FARMACO
.	O
Transthoracic	O
echocardiography	O
TTE	O
showed	O
a	O
non	O
dilated	O
LV	O
with	O
severe	O
hypokinesia	O
of	O
the	O
middle	O
and	O
apical	O
septal	O
segments	O
,	O
slightly	O
impaired	O
systolic	O
function	O
,	O
prolonged	O
relaxation	O
with	O
non	O
high	O
filling	O
pressures	O
,	O
right	O
chambers	O
of	O
normal	O
size	O
and	O
function	O
,	O
mitral	O
insufficiency	O
grade	O
II	O
IV	O
and	O
PSAP	O
37	O
PVC	O
.	O
The	O
following	O
morning	O
,	O
DDDR	O
definitive	O
MCP	O
was	O
implanted	O
,	O
being	O
in	O
MCP	O
rhythm	O
on	O
command	O
and	O
with	O
no	O
new	O
pathological	O
findings	O
on	O
monitoring	O
,	O
but	O
BP	O
160	O
95	O
persisted	O
despite	O
treatment	O
with	O
amlodipine	B-FARMACO
10	O
mg	O
12h	O
and	O
doxazosin	B-FARMACO
8	O
mg	O
24h	O
in	O
a	O
patient	O
with	O
no	O
known	O
chronic	O
hypertension	O
and	O
with	O
elevated	O
renal	O
function	O
figures	O
since	O
admission	O
.	O
On	O
the	O
afternoon	O
of	O
the	O
implant	O
,	O
the	O
patient	O
began	O
sudden	O
dyspnoea	O
with	O
BP	O
220	O
130	O
in	O
a	O
situation	O
of	O
radiological	O
APE	O
with	O
bilateral	O
pleural	O
effusion	O
,	O
respiratory	O
acidosis	O
with	O
global	O
respiratory	O
failure	O
requiring	O
the	O
start	O
of	O
non	O
invasive	O
ventilation	O
with	O
BIPAP	O
,	O
intensive	O
diuretic	O
treatment	O
,	O
intravenous	O
nitrates	O
and	O
combination	O
with	O
full	O
dose	O
antihypertensive	O
drugs	O
amlodipine	B-FARMACO
,	O
doxazosin	B-FARMACO
;	O
ACE	B-FARMACO
inhibitors	I-FARMACO
were	O
not	O
started	O
due	O
to	O
renal	O
dysfunction	O
.	O
A	O
new	O
emergent	O
TTE	O
was	O
performed	O
,	O
which	O
showed	O
the	O
previous	O
findings	O
.	O
After	O
8	O
hours	O
of	O
treatment	O
,	O
there	O
was	O
a	O
clear	O
clinical	O
,	O
radiological	O
and	O
blood	O
gas	O
improvement	O
,	O
so	O
non	O
invasive	O
ventilation	O
was	O
withdrawn	O
and	O
diuretic	O
treatment	O
was	O
reduced	O
;	O
however	O
,	O
persistently	O
high	O
BP	O
levels	O
persisted	O
despite	O
high	O
dose	O
IV	O
NTG	B-FARMACO
and	O
full	O
doses	O
of	O
amlodipine	B-FARMACO
and	O
doxazosin	B-FARMACO
;	O
and	O
the	O
deterioration	O
of	O
renal	O
function	O
with	O
proteinuria	O
and	O
haematuria	O
was	O
increasing	O
,	O
although	O
with	O
negative	O
balances	O
,	O
accompanied	O
by	O
plateletopenia	O
and	O
anaemia	O
with	O
reticulocytosis	O
.	O
Again	O
72	O
hours	O
after	O
the	O
episode	O
of	O
PAD	O
,	O
he	O
suffered	O
a	O
new	O
crisis	O
of	O
dyspnoea	O
accompanied	O
by	O
a	O
hypertensive	O
crisis	O
with	O
figures	O
of	O
190	O
100	O
with	O
worsening	O
renal	O
function	O
and	O
oliguria	O
.	O
At	O
this	O
point	O
,	O
taking	O
into	O
account	O
the	O
patient	O
's	O
history	O
and	O
the	O
complementary	O
tests	O
see	O
section	O
on	O
complementary	O
tests	O
,	O
a	O
presumptive	O
diagnosis	O
was	O
made	O
,	O
which	O
was	O
later	O
confirmed	O
with	O
definitive	O
diagnostic	O
tests	O
.	O
Specific	O
treatment	O
was	O
prescribed	O
,	O
with	O
improvement	O
of	O
the	O
respiratory	O
symptoms	O
and	O
control	O
of	O
BP	O
levels	O
.	O
However	O
,	O
the	O
deterioration	O
of	O
renal	O
function	O
was	O
persistent	O
and	O
progressive	O
,	O
requiring	O
a	O
right	O
femoral	O
catheter	O
for	O
haemodialysis	O
.	O
Subsequently	O
,	O
a	O
renal	O
biopsy	O
was	O
performed	O
which	O
revealed	O
tubulointerstitial	O
nephropathy	O
and	O
vascular	O
involvement	O
that	O
led	O
to	O
stage	O
V	O
renal	O
disease	O
with	O
the	O
need	O
for	O
renal	O
replacement	O
therapy	O
.	O
A	O
right	O
jugular	O
tunnelled	O
catheter	O
was	O
placed	O
and	O
the	O
patient	O
was	O
discharged	O
home	O
day	O
58	O
since	O
admission	O
on	O
an	O
outpatient	O
chronic	O
haemodialysis	O
programme	O
.	O
Subsequent	O
outpatient	O
evolution	O
was	O
very	O
unfavourable	O
and	O
despite	O
specific	O
treatment	O
and	O
haemodialysis	O
first	O
every	O
48	O
hours	O
and	O
then	O
daily	O
,	O
the	O
patient	O
died	O
two	O
months	O
later	O
.	O
DIAGNOSIS	O
Diffuse	O
systemic	O
sclerosis	O
with	O
scleroderma	O
renal	O
crisis	O
.	O
Pulmonary	O
fibrosis	O
2nd	O
to	O
pulmonary	O
involvement	O
of	O
diffuse	O
systemic	O
sclerosis	O
.	O
Complete	O
atrioventricular	O
block	O
,	O
myocardial	O
fibrosis	O
and	O
mild	O
ventricular	O
dysfunction	O
2nd	O
to	O
cardiac	O
involvement	O
of	O
diffuse	O
systemic	O
sclerosis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
57	O
year	O
old	O
woman	O
with	O
a	O
history	O
of	O
hypertension	O
,	O
diabetes	O
mellitus	O
and	O
chronic	O
atrial	O
fibrillation	O
.	O
She	O
has	O
had	O
a	O
mitral	O
valve	O
prosthesis	O
for	O
six	O
months	O
surgery	O
at	O
a	O
private	O
centre	O
in	O
March	O
2014	O
due	O
to	O
a	O
double	O
rheumatic	O
mitral	O
lesion	O
with	O
severe	O
mitral	O
regurgitation	O
MR	O
.	O
The	O
preoperative	O
echocardiogram	O
also	O
showed	O
a	O
moderate	O
double	O
aortic	O
lesion	O
,	O
moderate	O
pulmonary	O
hypertension	O
and	O
non	O
dilated	O
left	O
ventricle	O
with	O
preserved	O
systolic	O
function	O
.	O
On	O
chronic	O
treatment	O
with	O
aldocumar	B-FARMACO
,	O
digoxin	B-FARMACO
,	O
metformin	B-FARMACO
vildagliptin	I-FARMACO
,	O
carvedilol	B-FARMACO
,	O
spironolactone	B-FARMACO
,	O
escitalopram	B-FARMACO
and	O
furosemide	B-FARMACO
.	O
She	O
was	O
referred	O
from	O
a	O
private	O
clinic	O
for	O
progressive	O
dyspnoea	O
in	O
the	O
last	O
three	O
weeks	O
to	O
the	O
point	O
of	O
minimal	O
effort	O
,	O
two	O
pillow	O
orthopnoea	O
and	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
She	O
has	O
not	O
presented	O
chest	O
pain	O
or	O
other	O
associated	O
symptoms	O
.	O
No	O
infectious	O
episodes	O
since	O
surgery	O
,	O
fever	O
or	O
febrile	O
fever	O
.	O
No	O
recent	O
invasive	O
dental	O
or	O
surgical	O
procedures	O
.	O
On	O
examination	O
she	O
had	O
ʟʟ	O
BP	O
108	O
74	O
mmHg	O
.	O
hR	O
94	O
bpm	O
.	O
ʟʟʟ	O
Ta	O
36	O
C	O
.	O
ʟʟʟ	O
Cardiac	O
auscultation	O
arrhythmic	O
,	O
with	O
presence	O
of	O
mitral	O
click	O
,	O
systolic	O
murmur	O
in	O
aortic	O
focus	O
IV	O
VI	O
and	O
systolic	O
murmur	O
in	O
tricuspid	O
focus	O
.	O
pulmonary	O
auscultation	O
crepitant	O
sounds	O
in	O
both	O
bases	O
.	O
No	O
other	O
relevant	O
findings	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
atrial	O
fibrillation	O
at	O
93	O
beats	O
per	O
minute	O
,	O
with	O
evidence	O
of	O
systolic	O
overload	O
.	O
Blood	O
tests	O
haemogram	O
within	O
the	O
normal	O
range	O
,	O
biochemistry	O
and	O
renal	O
and	O
hepatic	O
function	O
parameters	O
without	O
alterations	O
,	O
INR	O
1	O
.	O
9	O
.	O
There	O
was	O
a	O
discrete	O
mobilisation	O
of	O
myocardial	O
damage	O
markers	O
in	O
plateau	O
troponin	O
I	O
1	O
.	O
9	O
1	O
.	O
7	O
ng	O
mL	O
;	O
NT	O
ProBNP	O
20528	O
,	O
HbA1C	O
8	O
.	O
6	O
and	O
ESR	O
25	O
.	O
Blood	O
cultures	O
were	O
negative	O
in	O
two	O
independent	O
determinations	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
mitral	O
valve	O
prosthesis	O
and	O
reinforcement	O
of	O
the	O
peribronchovascular	O
mesh	O
,	O
with	O
no	O
other	O
significant	O
findings	O
.	O
Initial	O
transthoracic	O
echocardiogram	O
TTE	O
and	O
serial	O
transesophageal	O
echocardiograms	O
TEE	O
.	O
Initial	O
TTE	O
left	O
ventricle	O
slightly	O
hypertrophic	O
,	O
dilated	O
VTD	O
154	O
VTS	O
115	O
ml	O
,	O
with	O
severe	O
depression	O
of	O
LVEF	O
by	O
Simpson	O
25	O
.	O
Global	O
hypokinesia	O
.	O
MAPSE	O
8	O
mm	O
.	O
Mitral	O
filling	O
pattern	O
with	O
single	O
E	O
wave	O
.	O
Dilated	O
LA	O
,	O
AP	O
diameter	O
68	O
mm	O
,	O
area	O
48	O
cm2	O
.	O
Sclerocalcified	O
aortic	O
valve	O
,	O
with	O
limited	O
opening	O
M	O
mode	O
0	O
.	O
8	O
.	O
Double	O
aortic	O
lesion	O
,	O
both	O
of	O
which	O
appear	O
moderate	O
.	O
Maximum	O
gradient	O
33	O
,	O
mean	O
21	O
.	O
5	O
mmHg	O
;	O
IVT	O
AVAo	O
of	O
0	O
.	O
9	O
cm2	O
LVOT	O
diameter	O
18	O
mm	O
,	O
with	O
low	O
systolic	O
volume	O
47	O
mL	O
.	O
Moderate	O
aortic	O
insufficiency	O
.	O
Mechanical	O
mitral	O
prosthesis	O
with	O
correct	O
opening	O
of	O
both	O
hemidiscs	O
.	O
Maximum	O
velocity	O
2	O
cm	O
s	O
.	O
No	O
significant	O
leaks	O
.	O
Right	O
ventricle	O
with	O
DTD	O
in	O
apical	O
4C	O
of	O
40	O
mm	O
at	O
basal	O
level	O
,	O
midventricular	O
of	O
31	O
mm	O
.	O
TAPSE	O
of	O
10	O
mm	O
.	O
S	O
"	O
wave	O
5	O
cm	O
s	O
.	O
Dilated	O
RA	O
.	O
Moderate	O
TR	O
.	O
RV	O
AD	O
gradient	O
of	O
45	O
mmHg	O
.	O
IP	O
trivial	O
.	O
Transpulmonary	O
acceleration	O
time	O
85	O
ms	O
.	O
Dilated	O
IVC	O
20	O
mm	O
that	O
does	O
not	O
collapse	O
with	O
inspiration	O
.	O
No	O
pericardial	O
effusion	O
.	O
ETE	O
1	O
FEVI	O
20	O
.	O
Preserved	O
mitral	O
prosthetic	O
opening	O
,	O
maximum	O
velocity	O
1	O
.	O
7	O
m	O
s	O
.	O
Mild	O
periprosthetic	O
leak	O
.	O
Images	O
on	O
mitral	O
annulus	O
of	O
morphology	O
and	O
density	O
compatible	O
with	O
thrombotic	O
tamponade	O
and	O
less	O
probably	O
pannus	O
.	O
Image	O
on	O
ventricular	O
side	O
of	O
prosthetic	O
annulus	O
interposed	O
between	O
disc	O
and	O
annulus	O
,	O
causing	O
mild	O
insufficiency	O
.	O
Dense	O
spontaneous	O
contrast	O
effect	O
in	O
LA	O
and	O
left	O
atrial	O
appendage	O
.	O
Image	O
in	O
the	O
LA	O
roof	O
at	O
the	O
mouth	O
of	O
the	O
left	O
pulmonary	O
veins	O
showing	O
thrombus	O
.	O
Calcified	O
trivalve	O
aortic	O
valve	O
,	O
with	O
severely	O
reduced	O
opening	O
but	O
could	O
be	O
due	O
to	O
reduced	O
transvalvular	O
volume	O
VAo	O
planimetry	O
0	O
.	O
7	O
cm2	O
.	O
Aortic	O
annulus	O
19	O
mm	O
.	O
Ascending	O
aorta	O
31	O
mm	O
.	O
Dilated	O
RV	O
,	O
tricuspid	O
annulus	O
45	O
mm	O
.	O
Moderate	O
TR	O
.	O
No	O
intracardiac	O
shunts	O
.	O
TEE	O
2	O
partial	O
resolution	O
of	O
the	O
echodense	O
image	O
around	O
the	O
mitral	O
prosthetic	O
ring	O
.	O
It	O
presents	O
two	O
mobile	O
images	O
the	O
largest	O
13x9	O
mm	O
anchored	O
in	O
the	O
anterior	O
annulus	O
,	O
retroaortic	O
,	O
low	O
echogenicity	O
,	O
deflected	O
,	O
which	O
prolapses	O
in	O
diastole	O
through	O
the	O
annulus	O
.	O
The	O
smallest	O
in	O
the	O
posterior	O
annulus	O
4	O
mm	O
.	O
Compatible	O
in	O
this	O
context	O
with	O
evolution	O
to	O
residual	O
hypermobile	O
thrombus	O
as	O
first	O
option	O
.	O
No	O
periprosthetic	O
insufficiencies	O
.	O
Image	O
compatible	O
with	O
fixed	O
mural	O
thrombus	O
at	O
the	O
entrance	O
of	O
the	O
left	O
atrial	O
appendage	O
.	O
Significant	O
smoke	O
effect	O
in	O
the	O
entire	O
atrium	O
.	O
There	O
is	O
still	O
a	O
mural	O
echodense	O
image	O
at	O
the	O
bottom	O
of	O
the	O
left	O
atrium	O
in	O
relation	O
to	O
the	O
origin	O
of	O
the	O
right	O
pulmonary	O
vein	O
described	O
in	O
the	O
previous	O
study	O
.	O
TEE	O
3	O
large	O
echodense	O
image	O
in	O
the	O
atrial	O
side	O
of	O
the	O
mitral	O
prosthesis	O
that	O
generates	O
complete	O
blockage	O
of	O
the	O
anterior	O
prosthetic	O
disc	O
,	O
with	O
transprosthetic	O
gradients	O
maximum	O
8	O
.	O
1	O
and	O
average	O
3	O
.	O
8	O
mmHg	O
.	O
Significant	O
smoke	O
effect	O
in	O
the	O
left	O
atrium	O
and	O
in	O
the	O
atrial	O
appendage	O
,	O
the	O
latter	O
presenting	O
an	O
image	O
suggestive	O
of	O
upholstery	O
on	O
its	O
lateral	O
wall	O
.	O
Coronary	O
angiography	O
non	O
significant	O
stenosis	O
in	O
the	O
ostial	O
trunk	O
,	O
around	O
30	O
.	O
The	O
rest	O
of	O
the	O
coronary	O
arteries	O
had	O
no	O
lesions	O
.	O
EVOLUTION	O
Patient	O
with	O
the	O
aforementioned	O
history	O
,	O
with	O
a	O
mitral	O
prosthesis	O
for	O
six	O
months	O
,	O
admitted	O
for	O
heart	O
failure	O
.	O
Diuretic	O
treatment	O
was	O
started	O
with	O
a	O
good	O
response	O
and	O
systolic	O
function	O
and	O
valve	O
functionality	O
were	O
re	O
evaluated	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
showed	O
severe	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
a	O
normally	O
functioning	O
mitral	O
prosthesis	O
and	O
moderate	O
severe	O
aortic	O
stenosis	O
.	O
In	O
evaluation	O
with	O
transesophageal	O
echocardiography	O
TEE	O
,	O
an	O
image	O
compatible	O
with	O
intraventricular	O
thrombus	O
lining	O
the	O
mitral	O
annulus	O
was	O
observed	O
and	O
treatment	O
with	O
sodium	B-FARMACO
heparin	I-FARMACO
and	O
ASA	B-FARMACO
was	O
started	O
.	O
Subsequent	O
echographic	O
controls	O
showed	O
an	O
increase	O
in	O
its	O
size	O
,	O
which	O
came	O
to	O
block	O
the	O
anterior	O
prosthetic	O
disc	O
despite	O
APTT	O
in	O
the	O
appropriate	O
range	O
.	O
Blood	O
cultures	O
were	O
taken	O
and	O
were	O
negative	O
in	O
serial	O
determinations	O
.	O
The	O
patient	O
was	O
stable	O
and	O
afebrile	O
,	O
in	O
good	O
general	O
condition	O
and	O
ambulating	O
around	O
the	O
ward	O
,	O
with	O
no	O
evidence	O
of	O
heart	O
failure	O
.	O
On	O
the	O
tenth	O
day	O
of	O
admission	O
,	O
she	O
presented	O
acute	O
pain	O
in	O
the	O
right	O
lower	O
limb	O
,	O
with	O
a	O
sensation	O
of	O
paraesthesia	O
and	O
distal	O
pallor	O
and	O
echo	O
Doppler	O
data	O
of	O
acute	O
ischaemia	O
of	O
the	O
right	O
lower	O
limb	O
.	O
Urgent	O
transfemoral	O
embolectomy	O
of	O
the	O
right	O
external	O
iliac	O
artery	O
was	O
performed	O
,	O
with	O
recovery	O
of	O
distal	O
pulses	O
and	O
triphasic	O
Doppler	O
flow	O
on	O
leaving	O
the	O
operating	O
theatre	O
.	O
With	O
the	O
diagnosis	O
of	O
suspected	O
prosthetic	O
thrombosis	O
with	O
poor	O
evolution	O
complicated	O
by	O
peripheral	O
embolism	O
,	O
urgent	O
surgery	O
was	O
requested	O
on	O
prosthetic	O
mitral	O
valve	O
and	O
aortic	O
valve	O
replacement	O
,	O
as	O
the	O
patient	O
met	O
the	O
criteria	O
for	O
this	O
.	O
Surgical	O
cleaning	O
of	O
the	O
mitral	O
prosthesis	O
was	O
carried	O
out	O
,	O
which	O
was	O
found	O
to	O
be	O
covered	O
and	O
partially	O
blocked	O
by	O
a	O
mass	O
that	O
appeared	O
to	O
be	O
a	O
large	O
thrombus	O
,	O
and	O
sent	O
to	O
the	O
microbiology	O
laboratory	O
for	O
analysis	O
.	O
The	O
aortic	O
valve	O
was	O
also	O
replaced	O
with	O
a	O
metallic	O
prosthesis	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
resuscitation	O
unit	O
sedated	O
,	O
haemodynamically	O
stable	O
and	O
respiratory	O
stable	O
with	O
invasive	O
mechanical	O
ventilation	O
.	O
Eight	O
hours	O
after	O
admission	O
to	O
the	O
unit	O
,	O
a	O
positive	O
result	O
was	O
reported	O
for	O
Aspergillus	O
in	O
the	O
septifast	O
of	O
the	O
"	O
mitral	O
valve	O
thrombus	O
"	O
,	O
so	O
treatment	O
was	O
started	O
with	O
amphotericin	B-FARMACO
B	I-FARMACO
and	O
voriconazole	B-FARMACO
and	O
the	O
case	O
was	O
re	O
evaluated	O
,	O
and	O
a	O
new	O
urgent	O
surgery	O
was	O
scheduled	O
for	O
removal	O
of	O
the	O
mitral	O
prosthesis	O
.	O
Intracardiac	O
cleaning	O
with	O
amphotericin	B-FARMACO
B	I-FARMACO
and	O
implantation	O
of	O
a	O
new	O
mechanical	O
prosthesis	O
was	O
performed	O
without	O
complications	O
during	O
the	O
procedure	O
.	O
Adequate	O
stabilisation	O
was	O
achieved	O
with	O
suspension	O
of	O
vasoactive	O
agents	O
and	O
extubation	O
was	O
performed	O
after	O
48	O
hours	O
,	O
with	O
good	O
tolerance	O
.	O
Five	O
days	O
after	O
surgery	O
,	O
the	O
patient	O
had	O
decreased	O
visual	O
acuity	O
in	O
the	O
right	O
eye	O
.	O
On	O
neurological	O
examination	O
she	O
presented	O
right	O
homonymous	O
haemianopsia	O
on	O
threat	O
examination	O
,	O
with	O
no	O
other	O
alterations	O
.	O
An	O
urgent	O
cranial	O
CT	O
scan	O
was	O
performed	O
,	O
which	O
revealed	O
a	O
2	O
.	O
5	O
cm	O
cystic	O
lesion	O
in	O
the	O
left	O
occipital	O
lobe	O
with	O
adjacent	O
oedema	O
compatible	O
,	O
in	O
the	O
clinical	O
context	O
of	O
the	O
patient	O
,	O
with	O
aspergilloma	O
figure	O
1	O
.	O
Overall	O
,	O
the	O
picture	O
is	O
labelled	O
as	O
a	O
stroke	O
in	O
the	O
left	O
posterior	O
cerebral	O
artery	O
territory	O
with	O
a	O
haemorrhagic	O
infectious	O
component	O
probably	O
related	O
to	O
septic	O
embolus	O
due	O
to	O
Aspergillus	O
.	O
Once	O
the	O
need	O
for	O
neurosurgical	O
intervention	O
was	O
dismissed	O
,	O
antifungal	O
coverage	O
was	O
extended	O
with	O
caspofungin	B-FARMACO
.	O
One	O
week	O
postoperatively	O
,	O
he	O
presented	O
a	O
sudden	O
clinical	O
deterioration	O
with	O
acute	O
respiratory	O
failure	O
requiring	O
invasive	O
mechanical	O
ventilation	O
and	O
intense	O
haemodynamic	O
instability	O
requiring	O
high	O
dose	O
amine	B-FARMACO
support	O
.	O
Urgent	O
TEE	O
was	O
requested	O
,	O
which	O
showed	O
severe	O
depression	O
of	O
global	O
LV	O
contractility	O
without	O
segmental	O
alterations	O
and	O
normofunctioning	O
prosthetic	O
valves	O
,	O
without	O
definitive	O
data	O
of	O
pulmonary	O
thromboembolism	O
.	O
Finally	O
,	O
exitus	O
was	O
triggered	O
by	O
electromechanical	O
dissociation	O
despite	O
advanced	O
cardiopulmonary	O
resuscitation	O
measures	O
.	O
Subsequent	O
analysis	O
of	O
the	O
valve	O
revealed	O
the	O
presence	O
of	O
a	O
dense	O
,	O
partially	O
thrombosed	O
structure	O
anchored	O
to	O
the	O
prosthetic	O
disc	O
,	O
composed	O
of	O
thick	O
septate	O
and	O
branched	O
mycelia	O
,	O
compatible	O
with	O
aspergilloma	O
.	O
Aspergillus	O
fumigatus	O
grew	O
in	O
the	O
culture	O
of	O
this	O
mass	O
.	O
DIAGNOSIS	O
Fungal	O
endocarditis	O
on	O
prosthetic	O
mitral	O
valve	O
,	O
complicated	O
by	O
Prosthetic	O
valve	O
block	O
.	O
Peripheral	O
embolism	O
with	O
acute	O
ischaemia	O
of	O
the	O
right	O
lower	O
limb	O
,	O
requiring	O
urgent	O
embolectomy	O
.	O
Stroke	O
in	O
left	O
posterior	O
cerebral	O
artery	O
territory	O
of	O
probable	O
septic	O
origin	O
aspergilloma	O
.	O
Cardiogenic	O
shock	O
,	O
electromechanical	O
dissociation	O
.	O
Exitus	O
.	O

Background	O
A	O
37	O
year	O
old	O
man	O
of	O
South	O
American	O
origin	O
who	O
had	O
been	O
living	O
in	O
Spain	O
for	O
5	O
years	O
.	O
No	O
drug	O
allergies	O
.	O
Active	O
life	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
.	O
No	O
toxic	O
habits	O
.	O
No	O
family	O
history	O
of	O
cardiomyopathy	O
or	O
other	O
hereditary	O
diseases	O
.	O
No	O
relevant	O
medical	O
surgical	O
history	O
.	O
Current	O
illness	O
The	O
patient	O
came	O
to	O
the	O
Cardiology	O
department	O
referred	O
by	O
his	O
company	O
doctor	O
after	O
a	O
routine	O
medical	O
examination	O
revealed	O
striking	O
electrocardiographic	O
alterations	O
.	O
He	O
reported	O
only	O
sporadic	O
episodes	O
of	O
regular	O
palpitations	O
of	O
short	O
duration	O
2	O
3	O
minutes	O
unrelated	O
to	O
exertion	O
that	O
subsided	O
spontaneously	O
,	O
with	O
a	O
weekly	O
frequency	O
.	O
She	O
denies	O
chest	O
pain	O
or	O
dyspnoea	O
.	O
She	O
has	O
not	O
presented	O
syncope	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
.	O
BP	O
110	O
60	O
mmHg	O
.	O
HR	O
60	O
bpm	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
fixed	O
splitting	O
of	O
the	O
second	O
sound	O
.	O
No	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
rales	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
no	O
masses	O
or	O
organomegaly	O
.	O
Lower	O
limbs	O
no	O
oedema	O
.	O
Symmetrical	O
paedial	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
,	O
first	O
degree	O
atrioventricular	O
block	O
PR	O
210	O
ms	O
,	O
complete	O
right	O
bundle	O
branch	O
block	O
and	O
left	O
anterior	O
hemiblock	O
,	O
convex	O
ST	O
segment	O
elevation	O
and	O
T	O
wave	O
inversion	O
in	O
precordial	O
leads	O
.	O
24	O
hour	O
Holter	O
no	O
supra	O
or	O
ventricular	O
arrhythmias	O
were	O
detected	O
.	O
No	O
evidence	O
of	O
advanced	O
atrioventricular	O
block	O
.	O
Laboratory	O
tests	O
glucose	O
98	O
mg	O
dL	O
,	O
urea	O
32	O
mg	O
dL	O
,	O
creatinine	O
0	O
.	O
86	O
mg	O
dL	O
CrCl	O
110	O
ml	O
min	O
1	O
.	O
73	O
m2	O
CKD	O
EPI	O
,	O
sodium	O
143	O
mEq	O
L	O
,	O
potassium	O
4	O
mEq	O
L	O
,	O
NT	O
proBNP	O
102	O
pg	O
ml	O
,	O
CK	O
387	O
ng	O
ml	O
,	O
CK	O
MB	O
9	O
.	O
8	O
ng	O
ml	O
,	O
TnT	O
0	O
.	O
01	O
,	O
haemoglobin	O
14	O
g	O
dL	O
,	O
haematocrit	O
45	O
,	O
MCV	O
85	O
fL	O
,	O
leucocytes	O
7980	O
mm3	O
,	O
platelets	O
270000	O
mm3	O
,	O
INR	O
0	O
,	O
9	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
,	O
no	O
pulmonary	O
infiltrates	O
,	O
free	O
costophrenic	O
sinuses	O
,	O
normal	O
mediastinum	O
.	O
Transthoracic	O
echocardiography	O
LV	O
slightly	O
dilated	O
LVEDD	O
indexed	O
by	O
CS	O
of	O
3	O
.	O
3	O
cm	O
m2	O
with	O
normal	O
wall	O
thickness	O
.	O
No	O
alterations	O
in	O
segmental	O
contractility	O
.	O
LVEF	O
52	O
.	O
Transmitral	O
Doppler	O
filling	O
pattern	O
of	O
impaired	O
relaxation	O
.	O
RV	O
of	O
normal	O
dimensions	O
with	O
systolic	O
function	O
by	O
longitudinal	O
parameters	O
at	O
the	O
lower	O
limit	O
of	O
normality	O
.	O
Cardiac	O
MRI	O
minimal	O
dilatation	O
of	O
both	O
ventricles	O
LVEDV	O
181	O
VTSVI	O
96	O
ml	O
with	O
slightly	O
depressed	O
biventricular	O
systolic	O
function	O
LVEF	O
50	O
.	O
The	O
late	O
enhancement	O
sequence	O
showed	O
multiple	O
foci	O
of	O
transmural	O
enhancement	O
with	O
patchy	O
distribution	O
of	O
septal	O
,	O
basal	O
lateral	O
and	O
apical	O
predominance	O
suggestive	O
of	O
fibrosis	O
.	O
EVOLUTION	O
Taking	O
into	O
account	O
that	O
the	O
patient	O
came	O
from	O
a	O
Chagas	O
disease	O
endemic	O
area	O
,	O
serological	O
tests	O
were	O
performed	O
to	O
detect	O
circulating	O
antibodies	O
against	O
Trypanosoma	O
cruzi	O
both	O
were	O
positive	O
ELISA	O
8	O
and	O
immunofluorescence	O
1	O
160	O
,	O
confirming	O
the	O
diagnosis	O
of	O
chronic	O
infection	O
by	O
this	O
parasite	O
.	O
Oesophagogastric	O
barium	O
transit	O
and	O
abdominal	O
radiography	O
were	O
also	O
performed	O
and	O
ruled	O
out	O
gastrointestinal	O
involvement	O
.	O
The	O
patient	O
was	O
diagnosed	O
with	O
chronic	O
chagasic	O
cardiomyopathy	O
CCM	O
based	O
on	O
the	O
results	O
of	O
serology	O
,	O
ECG	O
,	O
transthoracic	O
echocardiogram	O
and	O
cardiac	O
MRI	O
;	O
and	O
treatment	O
with	O
benznidazole	B-FARMACO
100	O
mg	O
8h	O
for	O
two	O
months	O
was	O
indicated	O
and	O
completed	O
with	O
good	O
tolerance	O
.	O
Ten	O
months	O
after	O
diagnosis	O
,	O
the	O
patient	O
died	O
suddenly	O
while	O
playing	O
tennis	O
.	O
He	O
was	O
attended	O
by	O
the	O
emergency	O
services	O
who	O
detected	O
asystole	O
as	O
the	O
first	O
rhythm	O
on	O
arrival	O
.	O
Advanced	O
CPR	O
manoeuvres	O
were	O
unsuccessful	O
and	O
the	O
patient	O
finally	O
died	O
.	O
As	O
death	O
occurred	O
in	O
an	O
out	O
of	O
hospital	O
environment	O
,	O
a	O
forensic	O
autopsy	O
was	O
performed	O
.	O
Macroscopic	O
and	O
microscopic	O
examination	O
of	O
the	O
heart	O
confirmed	O
the	O
characteristic	O
involvement	O
of	O
CCM	O
.	O
DIAGNOSIS	O
Chronic	O
chagasic	O
cardiomyopathy	O
.	O
Dilatation	O
and	O
mild	O
biventricular	O
systolic	O
dysfunction	O
with	O
transmural	O
patchy	O
LV	O
fibrosis	O
.	O
Sudden	O
cardiac	O
death	O
.	O

Personal	O
history	O
We	O
present	O
the	O
case	O
of	O
a	O
patient	O
who	O
consulted	O
for	O
dyspnoea	O
.	O
She	O
was	O
a	O
69	O
year	O
old	O
woman	O
with	O
no	O
adverse	O
drug	O
reactions	O
and	O
type	O
2	O
diabetic	O
on	O
treatment	O
with	O
metformin	B-FARMACO
850	O
mg	O
and	O
slow	O
insulin	B-FARMACO
20	O
units	O
per	O
day	O
.	O
She	O
had	O
no	O
known	O
previous	O
heart	O
or	O
lung	O
disease	O
.	O
She	O
is	O
in	O
a	O
baseline	O
NYHA	O
I	O
condition	O
.	O
He	O
is	O
not	O
limited	O
in	O
physical	O
activity	O
.	O
Present	O
illness	O
For	O
the	O
last	O
week	O
he	O
has	O
been	O
experiencing	O
dyspnoea	O
on	O
moderate	O
exertion	O
.	O
He	O
refers	O
to	O
going	O
out	O
for	O
walks	O
without	O
being	O
able	O
to	O
follow	O
his	O
usual	O
rhythm	O
.	O
Since	O
the	O
day	O
before	O
admission	O
,	O
he	O
has	O
had	O
episodes	O
of	O
nausea	O
,	O
sweating	O
and	O
dizziness	O
with	O
a	O
worsening	O
of	O
the	O
degree	O
of	O
dyspnoea	O
,	O
for	O
which	O
he	O
decides	O
to	O
consult	O
the	O
doctor	O
.	O
Physical	O
examination	O
BP	O
150	O
72	O
.	O
HR	O
91	O
bpm	O
.	O
Ta	O
afebrile	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
.	O
II	O
VI	O
murmur	O
in	O
aortic	O
focus	O
with	O
4s	O
.	O
Pulmonary	O
auscultation	O
teleinspiratory	O
crackles	O
in	O
lung	O
bases	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
non	O
painful	O
on	O
palpation	O
,	O
with	O
no	O
palpable	O
masses	O
or	O
megaliths	O
.	O
Lower	O
limbs	O
Minimal	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
Complementary	O
examinations	O
in	O
the	O
emergency	O
department	O
ECG	O
RS	O
at	O
75lpm	O
.	O
PR	O
160ms	O
.	O
Narrow	O
QRS	O
at	O
60	O
bpm	O
.	O
QS	O
in	O
V1	O
2	O
.	O
Negative	O
T	O
wave	O
in	O
V5	O
6	O
.	O
Low	O
voltages	O
in	O
limb	O
leads	O
.	O
No	O
changes	O
in	O
serial	O
ECG	O
.	O
Urgent	O
CBC	O
glucose	O
263	O
mg	O
dL	O
;	O
urea	O
39	O
mg	O
dL	O
;	O
creatinine	O
0	O
.	O
55	O
mg	O
dL	O
;	O
sodium	O
140	O
mEq	O
L	O
;	O
K	O
4	O
.	O
0	O
mEq	O
L	O
;	O
haemoglobin	O
14	O
.	O
8	O
g	O
dL	O
;	O
haematocrit	O
42	O
.	O
5	O
;	O
MCV	O
89	O
.	O
3	O
fL	O
;	O
platelets	O
217	O
.	O
0	O
10e3	O
uL	O
;	O
leucocytes	O
8	O
.	O
47	O
10e3	O
uL	O
;	O
INR	O
1	O
.	O
03	O
;	O
NT	O
proBNP	O
4806	O
.	O
0	O
pg	O
mL	O
;	O
serial	O
cardiac	O
enzymes	O
CK	O
1	O
247	O
.	O
0	O
;	O
CKMB	O
1	O
12	O
.	O
0	O
;	O
troponin	O
T	O
1	O
163	O
.	O
0	O
pg	O
ml	O
;	O
CK	O
2	O
226	O
.	O
0	O
;	O
CKMB	O
2	O
12	O
.	O
0	O
;	O
troponin	O
T	O
2	O
168	O
.	O
0	O
pg	O
ml	O
;	O
Chest	O
X	O
ray	O
cardiomegaly	O
.	O
Congestive	O
hilae	O
.	O
Minimal	O
alveolar	O
infiltrates	O
in	O
lung	O
bases	O
.	O
Complementary	O
examinations	O
in	O
hospital	O
Echocardiography	O
left	O
ventricle	O
of	O
reduced	O
internal	O
dimensions	O
.	O
Concentric	O
hypertrophy	O
.	O
LVEF	O
of	O
55	O
60	O
.	O
Pseudonormal	O
mitral	O
filling	O
pattern	O
.	O
Reduced	O
mitral	O
annulus	O
velocities	O
by	O
DTI	O
that	O
together	O
with	O
a	O
global	O
strain	O
2D	O
suggests	O
a	O
study	O
compatible	O
with	O
infiltrative	O
cardiomyopathy	O
.	O
Mild	O
infero	O
posterior	O
hypokinesia	O
and	O
basal	O
septum	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
mild	O
hypertrophy	O
and	O
preserved	O
contractility	O
.	O
Dilated	O
left	O
atrium	O
.	O
Normal	O
sized	O
right	O
atrium	O
.	O
Mild	O
mitral	O
insufficiency	O
mild	O
tricuspid	O
insufficiency	O
allowing	O
an	O
estimated	O
PSAP	O
of	O
55	O
60	O
mmHg	O
.	O
Slightly	O
thickened	O
aortic	O
valve	O
with	O
normal	O
dynamics	O
.	O
Normal	O
pulmonary	O
valve	O
.	O
Inferior	O
vena	O
cava	O
19	O
mm	O
with	O
absence	O
of	O
inspiratory	O
collapse	O
.	O
Global	O
pericardial	O
effusion	O
of	O
severe	O
posterolateral	O
predominance	O
.	O
Phasic	O
respiratory	O
filling	O
changes	O
in	O
atrioventricular	O
patterns	O
.	O
Partial	O
collapse	O
of	O
the	O
right	O
atrium	O
.	O
Conclusion	O
study	O
suggestive	O
of	O
infiltrative	O
cardiomyopathy	O
.	O
LVH	O
with	O
LVEF	O
55	O
60	O
.	O
Severe	O
pericardial	O
effusion	O
.	O
Moderate	O
severe	O
pulmonary	O
hypertension	O
.	O
ECG	O
sinus	O
pause	O
with	O
nodal	O
escape	O
rhythm	O
at	O
40	O
bpm	O
with	O
narrow	O
QRS	O
,	O
low	O
voltage	O
in	O
frontal	O
leads	O
with	O
flattened	O
repolarisation	O
.	O
Cardiac	O
MRI	O
biventricular	O
concentric	O
hypertrophy	O
with	O
normal	O
volumes	O
and	O
no	O
contractility	O
alterations	O
.	O
Preserved	O
biventricular	O
systolic	O
function	O
.	O
Severe	O
dilatation	O
of	O
the	O
LA	O
.	O
Diffuse	O
pericardial	O
effusion	O
up	O
to	O
24	O
mm	O
thick	O
,	O
lateral	O
to	O
the	O
LV	O
,	O
without	O
haemodynamic	O
repercussions	O
.	O
After	O
administration	O
of	O
gadolinium	O
,	O
there	O
was	O
no	O
adequate	O
suppression	O
of	O
the	O
myocardial	O
signal	O
;	O
it	O
was	O
suboptimally	O
suppressed	O
with	O
T1	O
at	O
160	O
ms	O
lower	O
than	O
usual	O
in	O
healthy	O
patients	O
and	O
then	O
there	O
was	O
diffuse	O
patchy	O
mesocardial	O
enhancement	O
in	O
both	O
ventricles	O
.	O
These	O
findings	O
are	O
suggestive	O
of	O
infiltrative	O
cardiomyopathy	O
,	O
including	O
amyloid	O
cardiomyopathy	O
.	O
Coronary	O
angiography	O
right	O
femoral	O
access	O
.	O
Coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O
Direct	O
Coomb	O
test	O
negative	O
.	O
Negative	O
irregular	O
antibodies	O
.	O
Thyroid	O
hormones	O
T4L	O
1	O
.	O
11	O
ng	O
dl	O
,	O
TSH	O
0	O
.	O
756	O
IUI	O
ml	O
.	O
Bone	O
marrow	O
aspirate	O
normocellular	O
marrow	O
.	O
Megakaryocytes	O
present	O
,	O
normal	O
in	O
number	O
and	O
morphology	O
.	O
Infiltration	O
by	O
23	O
of	O
small	O
sized	O
atypical	O
plasma	O
cells	O
with	O
eccentric	O
nucleus	O
without	O
visible	O
nucleolus	O
,	O
moderate	O
cytoplasm	O
without	O
inclusions	O
.	O
No	O
atypical	O
cells	O
are	O
observed	O
in	O
SP	O
.	O
Flow	O
cytometry	O
CMF	O
4	O
.	O
37	O
of	O
the	O
total	O
number	O
of	O
MO	O
cells	O
.	O
Of	O
these	O
,	O
96	O
.	O
0	O
show	O
an	O
aberrant	O
pathological	O
phenotype	O
CD45	O
weak	O
CD38	O
CD138	O
CD138	O
CD56	O
CD27	O
weak	O
CD28	O
CD19	O
CD20	O
CD117	O
and	O
monoclonal	O
IgCit	O
of	O
Kappa	O
type	O
,	O
no	O
expression	O
of	O
IgG	O
,	O
IgA	O
or	O
IgM	O
heavy	O
chains	O
is	O
detected	O
,	O
a	O
phenotype	O
compatible	O
with	O
plasma	O
cell	O
dyscrasia	O
of	O
the	O
Kappa	O
light	O
chain	O
secreting	O
myeloma	O
type	O
.	O
Quantification	O
of	O
immunoglobulins	O
IgG	O
693	O
,	O
IgA	O
199	O
,	O
IgM	O
28	O
,	O
IgD	O
23	O
.	O
IEF	O
in	O
blood	O
Bence	O
Jones	O
Kappa	O
protein	O
.	O
Free	O
Kappa	O
chains	O
in	O
serum	O
1110	O
mgr	O
l	O
,	O
free	O
Lambda	O
chains	O
in	O
serum	O
34	O
.	O
6	O
mg	O
l	O
.	O
Kappa	O
Lambda	O
ratio	O
32	O
.	O
Urine	O
FEF	O
Bence	O
Jones	O
positive	O
.	O
Bence	O
Jones	O
Kappa	O
protein	O
.	O
Free	O
chains	O
Kappa	O
urine	O
24	O
hours	O
222	O
mg	O
,	O
free	O
chains	O
Lambda	O
urine	O
24	O
hours	O
4	O
.	O
77	O
.	O
ANOE	O
S	O
anti	O
parietal	O
G	O
cell	O
antibodies	O
positive	O
1	O
640	O
.	O
Anti	O
intrinsic	O
factor	O
antibodies	O
negative	O
.	O
Gastric	O
ATPase	O
positive	O
.	O
ANCAS	O
negative	O
.	O
Oncological	O
bone	O
series	O
lytic	O
lesions	O
in	O
the	O
skull	O
.	O
Virus	O
serology	O
HBV	O
negative	O
,	O
HCV	O
negative	O
,	O
CMV	O
IgG	O
positive	O
.	O
Weak	O
positive	O
IgM	O
.	O
Cardiac	O
biopsy	O
macroscopic	O
description	O
five	O
muscle	O
fragments	O
of	O
0	O
.	O
2	O
0	O
.	O
3	O
cm	O
.	O
Microscopic	O
description	O
endomyocardial	O
biopsy	O
fragments	O
showing	O
an	O
acellular	O
interstitial	O
deposit	O
atrophying	O
myocytes	O
,	O
sometimes	O
also	O
around	O
vessels	O
in	O
a	O
cracked	O
form	O
.	O
The	O
deposit	O
stains	O
faintly	O
for	O
Masson	O
,	O
not	O
deep	O
blue	O
in	O
areas	O
somewhat	O
purplish	O
.	O
In	O
the	O
posterior	O
slice	O
for	O
Congo	O
red	O
the	O
sample	O
is	O
very	O
poorly	O
represented	O
and	O
in	O
polarised	O
light	O
only	O
occasionally	O
appears	O
to	O
refract	O
in	O
apple	O
green	O
,	O
which	O
given	O
the	O
clinical	O
data	O
,	O
the	O
pattern	O
with	O
haematoxylin	O
eosin	O
and	O
Masson	O
's	O
technique	O
,	O
although	O
not	O
conclusive	O
,	O
is	O
highly	O
suggestive	O
of	O
amyloidosis	O
.	O
No	O
iron	O
deposition	O
is	O
identified	O
with	O
Perls	O
technique	O
and	O
no	O
glycogen	O
deposition	O
with	O
Pas	O
.	O
In	O
other	O
focal	O
areas	O
myocytes	O
show	O
mild	O
hypertrophy	O
changes	O
and	O
little	O
chronic	O
non	O
specific	O
inflammation	O
.	O
EVOLUTION	O
Evolution	O
in	O
the	O
emergency	O
department	O
the	O
clinical	O
picture	O
appears	O
to	O
be	O
the	O
first	O
episode	O
of	O
decompensated	O
heart	O
failure	O
,	O
with	O
characteristic	O
elevation	O
of	O
myocardial	O
enzymes	O
which	O
do	O
not	O
present	O
a	O
curve	O
in	O
their	O
serialisation	O
,	O
marked	O
elevation	O
of	O
Pro	O
BNP	O
and	O
ECG	O
showing	O
low	O
voltages	O
in	O
the	O
limb	O
leads	O
.	O
All	O
this	O
suggests	O
possible	O
infiltrative	O
cardiomyopathy	O
.	O
Evolution	O
on	O
the	O
Cardiology	O
ward	O
the	O
patient	O
was	O
admitted	O
to	O
Cardiology	O
for	O
treatment	O
of	O
heart	O
failure	O
and	O
study	O
of	O
possible	O
infiltrative	O
cardiomyopathy	O
.	O
As	O
it	O
was	O
impossible	O
to	O
rule	O
out	O
acute	O
coronary	O
syndrome	O
,	O
treatment	O
was	O
started	O
with	O
ASA	B-FARMACO
100	O
mg	O
a	O
day	O
and	O
clopidogrel	B-FARMACO
75	O
mg	O
a	O
day	O
,	O
ACE	O
inhibitors	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
a	O
day	O
and	O
beta	O
blockers	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
a	O
day	O
.	O
Complementary	O
tests	O
were	O
performed	O
to	O
complete	O
the	O
study	O
.	O
Forty	O
eight	O
hours	O
after	O
starting	O
treatment	O
,	O
he	O
suffered	O
an	O
episode	O
of	O
dizziness	O
and	O
general	O
malaise	O
.	O
With	O
BP	O
90	O
45	O
mmHg	O
,	O
HR	O
39	O
.	O
Sweating	O
,	O
mucocutaneous	O
pallor	O
and	O
distal	O
coldness	O
.	O
AC	O
arrhythmic	O
,	O
bradycardic	O
.	O
ECG	O
was	O
performed	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
ICU	O
and	O
after	O
discontinuation	O
of	O
beta	O
blockers	O
and	O
once	O
reversible	O
acute	O
process	O
had	O
been	O
ruled	O
out	O
,	O
it	O
was	O
decided	O
to	O
implant	O
a	O
permanent	O
pacemaker	O
in	O
DDD	O
mode	O
.	O
48	O
hours	O
after	O
pacemaker	O
implantation	O
,	O
the	O
patient	O
suffered	O
cardiorespiratory	O
arrest	O
in	O
the	O
context	O
of	O
ventricular	O
tachycardia	O
that	O
degenerated	O
into	O
ventricular	O
fibrillation	O
,	O
which	O
ended	O
after	O
defibrillation	O
with	O
150J	O
.	O
Again	O
in	O
the	O
ICU	O
,	O
the	O
MP	O
was	O
questioned	O
and	O
VT	O
spells	O
were	O
observed	O
before	O
the	O
episode	O
of	O
VF	O
.	O
Finally	O
,	O
it	O
was	O
decided	O
to	O
implant	O
an	O
ICD	O
for	O
secondary	O
prevention	O
.	O
DIAGNOSIS	O
A	O
diagnosis	O
of	O
Kappa	O
BJ	O
K	O
ISS	O
1	O
stage	O
IIIA	O
light	O
chain	O
multiple	O
myeloma	O
with	O
primary	O
amyloidosis	O
AL	O
with	O
cardiac	O
involvement	O
and	O
Mayo	O
Clinic	O
prognostic	O
stage	O
III	O
score	O
value	O
2	O
was	O
finally	O
made	O
.	O
Treatment	O
was	O
started	O
with	O
velcade	B-FARMACO
dexamethasone	I-FARMACO
,	O
associated	O
with	O
treatment	O
of	O
heart	O
failure	O
,	O
with	O
excellent	O
tolerance	O
and	O
clinical	O
improvement	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
79	O
year	O
old	O
woman	O
,	O
with	O
no	O
known	O
drug	O
allergies	O
,	O
hypertensive	O
on	O
treatment	O
with	O
olmesartan	B-FARMACO
40	O
mg	O
and	O
amlodipine	B-FARMACO
5	O
mg	O
per	O
day	O
and	O
independent	O
for	O
ABVD	O
.	O
She	O
presented	O
with	O
oppressive	O
chest	O
pain	O
at	O
rest	O
,	O
not	O
radiating	O
or	O
associated	O
with	O
vegetative	O
cortex	O
,	O
of	O
three	O
days	O
'	O
evolution	O
,	O
accompanied	O
by	O
an	O
increase	O
in	O
her	O
usual	O
dyspnoea	O
until	O
it	O
became	O
minimal	O
effort	O
.	O
On	O
examination	O
she	O
was	O
normotensive	O
and	O
afebrile	O
with	O
preserved	O
vesicular	O
murmur	O
and	O
no	O
pathological	O
sounds	O
,	O
rhythmic	O
and	O
without	O
murmurs	O
.	O
There	O
is	O
no	O
oedema	O
.	O
The	O
neurological	O
and	O
abdominal	O
examination	O
was	O
unremarkable	O
.	O
The	O
ECG	O
showed	O
sinus	O
rhythm	O
,	O
with	O
ST	O
segment	O
depression	O
in	O
V2	O
V6	O
,	O
DI	O
and	O
aVL	O
maximum	O
2	O
mm	O
in	O
V2	O
,	O
which	O
partially	O
corrected	O
after	O
becoming	O
asymptomatic	O
figure	O
1	O
.	O
First	O
enzyme	O
measurement	O
ultrasensitive	O
troponin	O
T	O
1890	O
ng	O
L	O
0	O
14	O
,	O
CK	O
319	O
U	O
L	O
26	O
167	O
.	O
Treatment	O
was	O
started	O
with	O
double	O
antiplatelet	O
therapy	O
ASA	O
and	O
clopidogrel	B-FARMACO
,	O
low	B-FARMACO
molecular	I-FARMACO
weight	I-FARMACO
heparin	I-FARMACO
,	O
atorvastatin	B-FARMACO
,	O
candesartan	B-FARMACO
and	O
bisoprolol	B-FARMACO
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
cardiology	O
department	O
with	O
a	O
diagnosis	O
of	O
STEMI	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
glucose	O
98	O
mg	O
dl	O
;	O
urea	O
60	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
71	O
mg	O
dl	O
;	O
GFR	O
31	O
ml	O
min	O
;	O
sodium	O
140	O
mmol	O
l	O
;	O
potassium	O
4	O
.	O
7	O
mmol	O
l	O
,	O
CK	O
319	O
U	O
L	O
26	O
167	O
;	O
ultrasensitive	O
troponin	O
T	O
1890	O
ng	O
L	O
0	O
14	O
;	O
leukocytes	O
9	O
.	O
95x103	O
;	O
neutrophils	O
5	O
.	O
92x103	O
59	O
.	O
4	O
;	O
lymphocytes	O
1	O
.	O
38x103	O
19	O
.	O
9	O
;	O
monocytes	O
1	O
.	O
01x103	O
10	O
.	O
2	O
;	O
eosinophils	O
1	O
.	O
63x103	O
16	O
.	O
4	O
normal	O
0	O
6	O
,	O
basophils	O
0	O
.	O
01x103	O
0	O
.	O
1	O
Hb	O
12	O
.	O
5	O
g	O
dl	O
;	O
Hto	O
38	O
.	O
9	O
;	O
MCV81	O
.	O
7	O
fl	O
;	O
platelets	O
61	O
x	O
103	O
;	O
leukocytes	O
and	O
eosinophils	O
were	O
as	O
high	O
as	O
20	O
.	O
950	O
and	O
46	O
respectively	O
.	O
Chest	O
X	O
ray	O
CTI	O
0	O
.	O
5	O
,	O
no	O
infiltrates	O
.	O
C	O
costophrenic	O
sinuses	O
were	O
free	O
.	O
Echocardiography	O
LV	O
not	O
dilated	O
,	O
with	O
slightly	O
depressed	O
systolic	O
function	O
and	O
no	O
contractility	O
alterations	O
.	O
Right	O
chambers	O
not	O
dilated	O
with	O
normal	O
systolic	O
function	O
.	O
LA	O
dilated	O
.	O
Impaired	O
relaxation	O
.	O
Mild	O
MI	O
and	O
TR	O
.	O
Coronary	O
angiography	O
right	O
dominance	O
.	O
Coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O
Cardiac	O
MR	O
and	O
viability	O
non	O
dilated	O
LV	O
with	O
slightly	O
depressed	O
LVEF	O
50	O
.	O
Apparent	O
thickening	O
of	O
the	O
wall	O
without	O
being	O
able	O
to	O
specify	O
whether	O
it	O
corresponds	O
to	O
cardiac	O
muscle	O
,	O
which	O
is	O
more	O
significant	O
in	O
the	O
lateral	O
wall	O
,	O
with	O
a	O
maximum	O
end	O
diastolic	O
thickness	O
of	O
18	O
mm	O
.	O
In	O
the	O
early	O
study	O
after	O
intravenous	O
gadolinium	O
administration	O
,	O
an	O
area	O
of	O
hyperenhancement	O
was	O
observed	O
in	O
the	O
lower	O
basal	O
segment	O
and	O
hypocaptive	O
foci	O
of	O
subendocardial	O
location	O
on	O
the	O
lateral	O
wall	O
,	O
which	O
could	O
correspond	O
to	O
small	O
thrombi	O
.	O
Dilated	O
LA	O
.	O
Mild	O
MI	O
and	O
TR	O
.	O
Cerebral	O
MRI	O
multiple	O
ischaemic	O
lesions	O
affecting	O
both	O
cerebral	O
and	O
cerebellar	O
hemispheres	O
.	O
No	O
images	O
suggestive	O
of	O
intraparenchymal	O
bleeding	O
.	O
The	O
ventricular	O
system	O
is	O
symmetrical	O
and	O
of	O
normal	O
calibre	O
.	O
Parasites	O
in	O
stool	O
negative	O
.	O
Determination	O
of	O
IgE	O
negative	O
ECA	O
40	O
;	O
ANA	O
negative	O
Hep	O
2	O
1	O
320	O
;	O
ANCA	O
IFI	O
positive	O
.	O
P	O
ANCA	O
and	O
c	O
ANCA	O
negative	O
.	O
Tumour	O
markers	O
CA	O
125	O
40	O
0	O
35	O
;	O
Beta	O
2	O
microglobulin	O
3494	O
1200	O
2500	O
;	O
CYFRA	O
21	O
1	O
4	O
.	O
4	O
0	O
3	O
.	O
3	O
IF	O
plasma	O
orine	O
absence	O
of	O
monoclonal	O
peaks	O
.	O
ACS	O
.	O
Antiphospholipids	O
negative	O
.	O
Bone	O
marrow	O
aspirate	O
flow	O
cytometry	O
MO	O
with	O
19	O
lymphocytes	O
,	O
of	O
which	O
73	O
are	O
T	O
lymphocytes	O
and	O
16	O
are	O
B	O
lymphocytes	O
.	O
A	O
TCR	O
Beta	O
sequencing	O
study	O
was	O
performed	O
and	O
no	O
clonal	O
population	O
was	O
identified	O
.	O
Cytogenetics	O
absence	O
of	O
FIP1L	O
PDGFRRa	O
and	O
PDGFRb	O
mutations	O
.	O
Helminth	O
serology	O
Strongyloides	O
,	O
Toxocara	O
,	O
Trichinella	O
,	O
Echinococcus	O
,	O
Fasciola	O
negative	O
.	O
Electroencephalogram	O
marked	O
destructuring	O
and	O
global	O
slowing	O
of	O
brain	O
activity	O
.	O
These	O
findings	O
indicate	O
the	O
existence	O
of	O
moderate	O
to	O
severe	O
diffuse	O
encephalic	O
involvement	O
.	O
Thoracoabdominal	O
CT	O
no	O
pulmonary	O
thromboembolism	O
was	O
identified	O
in	O
the	O
main	O
lobar	O
or	O
segmental	O
arteries	O
.	O
Bronchiectasis	O
of	O
the	O
anterior	O
segment	O
of	O
the	O
LSI	O
.	O
Discrete	O
thickening	O
of	O
the	O
subpleural	O
interstitium	O
.	O
Two	O
right	O
apical	O
perilymphatic	O
nodules	O
of	O
4mm	O
are	O
identified	O
,	O
probably	O
corresponding	O
to	O
intrapulmonary	O
lymph	O
nodes	O
.	O
Global	O
cardiomegaly	O
associated	O
with	O
myocardial	O
thickening	O
in	O
the	O
left	O
ventricle	O
up	O
to	O
21	O
mm	O
in	O
its	O
lateral	O
aspect	O
.	O
Minimal	O
bilateral	O
laminar	O
pleural	O
effusion	O
.	O
10	O
mm	O
prevascular	O
adenopathy	O
with	O
no	O
evidence	O
of	O
other	O
significant	O
mediastinal	O
adenopathy	O
.	O
No	O
significant	O
retroperitoneal	O
adenopathy	O
.	O
Normal	O
liver	O
.	O
Bilateral	O
cortical	O
renal	O
cysts	O
.	O
Uncomplicated	O
digmoid	O
diverticulosis	O
.	O
EVOLUTION	O
On	O
admission	O
,	O
coronary	O
angiography	O
showed	O
coronary	O
arteries	O
without	O
lesions	O
.	O
Transthoracic	O
echocardiography	O
showed	O
a	O
non	O
dilated	O
LV	O
with	O
slightly	O
depressed	O
LVEF	O
51	O
.	O
Dilated	O
LA	O
.	O
Impaired	O
relaxation	O
.	O
Mild	O
MI	O
and	O
TR	O
.	O
Due	O
to	O
persistent	O
eosinophilia	O
16	O
45	O
it	O
was	O
decided	O
to	O
request	O
cardiac	O
MRI	O
which	O
was	O
compatible	O
with	O
eosinophilic	O
cardiomyopathy	O
.	O
Ten	O
days	O
after	O
admission	O
the	O
patient	O
had	O
a	O
stroke	O
with	O
left	O
hemiplegia	O
and	O
decreased	O
level	O
of	O
consciousness	O
.	O
Brain	O
MRI	O
showed	O
multiple	O
infarcts	O
in	O
both	O
cerebral	O
and	O
cerebellar	O
hemispheres	O
.	O
Doppler	O
ultrasound	O
of	O
the	O
supra	O
aortic	O
trunks	O
was	O
normal	O
.	O
A	O
study	O
of	O
hypereosinophilic	O
syndrome	O
was	O
initiated	O
ANA	O
1	O
320	O
;	O
ANCA	O
IFI	O
;	O
no	O
paraproteins	O
were	O
detected	O
in	O
blood	O
or	O
urine	O
.	O
Bone	O
marrow	O
aspirate	O
ruled	O
out	O
eosinophilic	O
leukaemia	O
.	O
Parasitological	O
stool	O
culture	O
was	O
also	O
negative	O
and	O
IgE	O
values	O
were	O
within	O
normal	O
range	O
.	O
Corticotherapy	O
was	O
started	O
with	O
prednisone	B-FARMACO
60	O
mg	O
day	O
1	O
mg	O
kg	O
day	O
.	O
Given	O
the	O
persistence	O
of	O
hypereosinophilia	O
with	O
systemic	O
repercussions	O
cardiac	O
and	O
CNS	O
,	O
treatment	O
was	O
started	O
with	O
bolus	O
methylprednisolone	B-FARMACO
,	O
without	O
response	O
or	O
neurological	O
improvement	O
.	O
Treatment	O
was	O
started	O
with	O
imatinib	B-FARMACO
while	O
awaiting	O
the	O
results	O
of	O
FIP1L	O
PDGFRa	O
,	O
obtaining	O
a	O
transitory	O
decrease	O
in	O
the	O
levels	O
of	O
eosinophils	O
in	O
the	O
blood	O
.	O
Imatinib	B-FARMACO
was	O
discontinued	O
after	O
a	O
further	O
increase	O
in	O
eosinophils	O
and	O
hydroxyurea	B-FARMACO
was	O
started	O
.	O
He	O
also	O
presented	O
with	O
a	O
polymicrobial	O
infection	O
of	O
a	O
decubitus	O
ulcer	O
,	O
isolating	O
SAMS	O
.	O
A	O
month	O
and	O
a	O
half	O
after	O
admission	O
,	O
he	O
presented	O
with	O
abundant	O
rectorrhagia	O
,	O
for	O
which	O
2	O
red	O
blood	O
cell	O
concentrates	O
were	O
transfused	O
and	O
due	O
to	O
the	O
clinical	O
situation	O
it	O
was	O
decided	O
not	O
to	O
perform	O
a	O
colonoscopy	O
.	O
After	O
48	O
hours	O
he	O
presented	O
a	O
new	O
episode	O
of	O
rectorrhagia	O
together	O
with	O
a	O
worsening	O
of	O
his	O
general	O
and	O
neurological	O
condition	O
.	O
In	O
consensus	O
with	O
the	O
family	O
,	O
it	O
was	O
decided	O
to	O
start	O
perfusion	O
sedoanalgesia	O
,	O
and	O
the	O
patient	O
died	O
a	O
few	O
days	O
later	O
.	O
DIAGNOSIS	O
Primary	O
hypersosinophilic	O
syndrome	O
with	O
severe	O
cardiac	O
and	O
neurological	O
involvement	O
Eosinophilic	O
cardiomyopathy	O
Multiple	O
cerebral	O
ischaemic	O
infarcts	O
Renal	O
failure	O
Thrombocytopenia	O
Polymicrobial	O
infection	O
Lower	O
gastrointestinal	O
bleeding	O
AHT	O

Background	O
Female	O
,	O
51	O
years	O
old	O
.	O
Arterial	O
hypertension	O
.	O
Chronic	O
glaucoma	O
.	O
No	O
known	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
On	O
treatment	O
with	O
telmisartan	B-FARMACO
80	O
mg	O
day	O
.	O
Baseline	O
situation	O
active	O
.	O
Independent	O
for	O
activities	O
of	O
daily	O
living	O
.	O
Dyspnoea	O
on	O
moderate	O
exertion	O
NHYA	O
II	O
.	O
Current	O
illness	O
She	O
visits	O
her	O
family	O
doctor	O
for	O
moderate	O
dyspnoea	O
of	O
about	O
3	O
months	O
of	O
evolution	O
.	O
Since	O
then	O
she	O
has	O
also	O
presented	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
She	O
reported	O
no	O
previous	O
history	O
of	O
chest	O
pain	O
or	O
palpitations	O
.	O
A	O
chest	O
X	O
ray	O
was	O
performed	O
and	O
in	O
view	O
of	O
the	O
presence	O
of	O
cardiomegaly	O
,	O
preferential	O
assessment	O
in	O
the	O
outpatient	O
cardiology	O
department	O
was	O
requested	O
.	O
Physical	O
examination	O
BP	O
130	O
90	O
mmHg	O
HR	O
77	O
bpm	O
SatO2	O
98	O
Head	O
and	O
neck	O
normal	O
.	O
No	O
IY	O
CA	O
rhythmic	O
,	O
holosystolic	O
murmur	O
II	O
VI	O
with	O
R2	O
splitting	O
AP	O
VCM	O
in	O
both	O
lung	O
fields	O
Abdomen	O
nondescript	O
LES	O
oedema	O
with	O
perimalleolar	O
fovea	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
with	O
signs	O
of	O
AD	O
growth	O
,	O
normal	O
PR	O
,	O
wide	O
QRS	O
150	O
msec	O
with	O
morphology	O
of	O
complete	O
right	O
bundle	O
branch	O
block	O
and	O
secondary	O
repolarisation	O
alterations	O
.	O
Echocardiography	O
severe	O
dilatation	O
of	O
right	O
chambers	O
.	O
Apical	O
displacement	O
of	O
the	O
insertion	O
point	O
of	O
the	O
tricuspid	O
septal	O
leaflet	O
about	O
2	O
.	O
5	O
cm	O
with	O
respect	O
to	O
the	O
plane	O
of	O
the	O
mitral	O
annulus	O
.	O
Massive	O
TR	O
due	O
to	O
lack	O
of	O
leaflet	O
coaptation	O
.	O
Assessment	O
of	O
RV	O
systolic	O
function	O
is	O
difficult	O
but	O
appears	O
to	O
be	O
severely	O
depressed	O
.	O
The	O
pulmonary	O
trunk	O
is	O
of	O
normal	O
size	O
.	O
The	O
pulmonary	O
valve	O
has	O
no	O
abnormalities	O
.	O
The	O
left	O
chambers	O
are	O
small	O
in	O
size	O
and	O
displaced	O
by	O
the	O
right	O
chambers	O
.	O
LV	O
systolic	O
function	O
is	O
visually	O
at	O
the	O
lower	O
limit	O
of	O
normal	O
.	O
The	O
left	O
valves	O
are	O
normal	O
.	O
Mitral	O
filling	O
pattern	O
of	O
impaired	O
relaxation	O
.	O
No	O
ASD	O
although	O
assessment	O
is	O
difficult	O
,	O
no	O
other	O
shunts	O
.	O
Normal	O
aortic	O
arch	O
.	O
Slight	O
systemic	O
venous	O
congestion	O
.	O
EVOLUTION	O
Furosemide	B-FARMACO
40	O
mg	O
day	O
was	O
added	O
to	O
the	O
treatment	O
,	O
and	O
cardiac	O
magnetic	O
resonance	O
was	O
requested	O
for	O
anatomical	O
characterisation	O
and	O
better	O
assessment	O
of	O
RV	O
function	O
.	O
At	O
the	O
6	O
month	O
check	O
up	O
,	O
the	O
patient	O
was	O
asymptomatic	O
.	O
The	O
result	O
of	O
the	O
cardiac	O
MRI	O
was	O
brought	O
in	O
a	O
study	O
of	O
very	O
poor	O
technical	O
quality	O
movement	O
artefacts	O
.	O
Dilatation	O
of	O
the	O
right	O
chambers	O
,	O
with	O
apical	O
displacement	O
of	O
the	O
tricuspid	O
leaflets	O
,	O
which	O
do	O
not	O
coapt	O
.	O
Free	O
tricuspid	O
regurgitation	O
.	O
RVEF	O
43	O
.	O
No	O
associated	O
malformations	O
are	O
seen	O
.	O
Left	O
ventricle	O
displaced	O
by	O
the	O
right	O
,	O
with	O
preserved	O
ventricular	O
function	O
.	O
Given	O
the	O
improvement	O
in	O
symptoms	O
,	O
it	O
was	O
decided	O
to	O
maintain	O
medical	O
treatment	O
and	O
outpatient	O
monitoring	O
at	O
6	O
months	O
with	O
new	O
echocardiography	O
,	O
new	O
MRI	O
and	O
cardiopulmonary	O
stress	O
test	O
.	O
DIAGNOSIS	O
Mild	O
heart	O
failure	O
on	O
debut	O
Ebstein	O
's	O
anomaly	O
Severe	O
tricuspid	O
regurgitation	O
and	O
mild	O
RV	O
systolic	O
dysfunction	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
55	O
years	O
old	O
,	O
with	O
no	O
known	O
drug	O
allergies	O
and	O
no	O
known	O
cardiovascular	O
risk	O
factors	O
.	O
Personal	O
history	O
ʟʟ	O
Previous	O
heart	O
disease	O
dilated	O
cardiomyopathy	O
due	O
to	O
Chagas	O
disease	O
with	O
severe	O
systolic	O
dysfunction	O
and	O
implantation	O
of	O
a	O
single	O
chamber	O
ICD	O
in	O
2007	O
for	O
primary	O
prevention	O
.	O
Regular	O
follow	O
up	O
in	O
the	O
arrhythmia	O
unit	O
of	O
our	O
department	O
during	O
follow	O
up	O
he	O
presented	O
an	O
episode	O
of	O
SMVT	O
that	O
subsided	O
with	O
ATP	B-FARMACO
,	O
without	O
requiring	O
shock	O
.	O
On	O
24	O
March	O
2015	O
he	O
was	O
admitted	O
to	O
our	O
department	O
for	O
ICD	O
generator	O
replacement	O
.	O
Other	O
history	O
sensory	O
,	O
axonal	O
and	O
demyelinating	O
polyneuropathy	O
of	O
moderate	O
degree	O
in	O
the	O
upper	O
and	O
lower	O
extremities	O
.	O
Chronic	O
treatment	O
ramipril	B-FARMACO
5	O
mg	O
24	O
hours	O
.	O
carvedilol	B-FARMACO
25	O
mg	O
24	O
hours	O
.	O
Sintrom	B-FARMACO
according	O
to	O
guideline	O
.	O
Present	O
illness	O
Patient	O
referred	O
to	O
the	O
emergency	O
department	O
of	O
his	O
reference	O
hospital	O
after	O
being	O
found	O
at	O
home	O
disoriented	O
,	O
confused	O
and	O
with	O
sphincter	O
incontinence	O
by	O
his	O
work	O
colleagues	O
.	O
They	O
went	O
to	O
look	O
for	O
him	O
as	O
he	O
had	O
not	O
been	O
at	O
work	O
for	O
the	O
last	O
three	O
days	O
.	O
Anamnesis	O
impossible	O
to	O
perform	O
on	O
the	O
patient	O
due	O
to	O
his	O
neurological	O
deterioration	O
.	O
Physical	O
examination	O
BP	O
85	O
60	O
mmHg	O
.	O
HR	O
85	O
bpm	O
.	O
RR	O
26	O
rpm	O
.	O
Sat02	O
96	O
with	O
nasal	O
goggles	O
at	O
2	O
bpm	O
.	O
NRL	O
conscious	O
and	O
oriented	O
in	O
space	O
and	O
person	O
.	O
Lethargic	O
.	O
Fluent	O
language	O
without	O
aphasic	O
components	O
.	O
Pupils	O
isochoric	O
and	O
normoreactive	O
.	O
Left	O
facial	O
paresis	O
.	O
Cranial	O
nerves	O
centred	O
.	O
Preserved	O
strength	O
and	O
sensibility	O
in	O
extremities	O
.	O
Preserved	O
ROTs	O
.	O
CA	O
very	O
muffled	O
cardiac	O
tones	O
,	O
no	O
murmurs	O
.	O
AP	O
rhonchi	O
in	O
both	O
lung	O
fields	O
.	O
No	O
other	O
superimposed	O
sounds	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
masses	O
or	O
megaliths	O
.	O
No	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
MMII	O
No	O
oedema	O
.	O
Pulses	O
preserved	O
.	O
General	O
pterygium	O
over	O
the	O
right	O
eye	O
.	O
Ulcer	O
in	O
the	O
wound	O
of	O
the	O
ICD	O
generator	O
in	O
the	O
left	O
subclavian	O
region	O
.	O
COMPLEMENTARY	O
TESTS	O
In	O
the	O
emergency	O
department	O
of	O
the	O
hospital	O
,	O
the	O
study	O
began	O
with	O
the	O
extraction	O
of	O
blood	O
cultures	O
due	O
to	O
fever	O
38	O
.	O
5	O
C	O
,	O
and	O
the	O
following	O
complementary	O
tests	O
were	O
performed	O
CBC	O
9000	O
platelets	O
,	O
14	O
,	O
400	O
leukocytes	O
,	O
INR	O
10	O
,	O
AP	O
6	O
.	O
5	O
,	O
CRP	O
67	O
.	O
11	O
,	O
procalcitonin	O
24	O
.	O
4	O
,	O
creatinine	O
1	O
.	O
77	O
,	O
total	O
bilirubin	O
6	O
.	O
2	O
at	O
the	O
expense	O
of	O
direct	O
.	O
Chest	O
X	O
ray	O
increased	O
CTI	O
,	O
hilar	O
congestion	O
with	O
bilateral	O
nodular	O
images	O
.	O
Cranial	O
CT	O
hypodensity	O
in	O
right	O
basal	O
ganglia	O
compatible	O
with	O
old	O
lacunar	O
infarcts	O
.	O
Hypodensity	O
in	O
the	O
left	O
parietal	O
convexity	O
compatible	O
with	O
residual	O
ischaemic	O
lesion	O
.	O
No	O
LOES	O
,	O
contusion	O
images	O
or	O
haemorrhage	O
.	O
Ventricular	O
system	O
within	O
normality	O
.	O
Thoracic	O
abdominal	O
CT	O
scan	O
in	O
the	O
mediastinum	O
there	O
were	O
small	O
lymph	O
nodes	O
smaller	O
than	O
1	O
cm	O
of	O
doubtful	O
pathological	O
significance	O
.	O
Poorly	O
defined	O
nodular	O
densities	O
can	O
be	O
seen	O
in	O
the	O
lung	O
fields	O
.	O
Although	O
cavitation	O
is	O
not	O
seen	O
,	O
in	O
the	O
clinical	O
context	O
of	O
the	O
patient	O
,	O
the	O
possibility	O
of	O
septic	O
emboli	O
should	O
be	O
considered	O
.	O
Elevation	O
of	O
the	O
right	O
hemidiaphragm	O
.	O
Minimal	O
right	O
pleural	O
effusion	O
enlargement	O
.	O
Abdomen	O
normal	O
sized	O
liver	O
with	O
no	O
evidence	O
of	O
focal	O
lesions	O
.	O
Bile	O
duct	O
,	O
pancreas	O
,	O
spleen	O
,	O
kidneys	O
and	O
adrenal	O
glands	O
without	O
significant	O
findings	O
.	O
No	O
free	O
fluid	O
or	O
collections	O
were	O
seen	O
.	O
In	O
view	O
of	O
these	O
findings	O
and	O
with	O
clinical	O
suspicion	O
of	O
severe	O
septic	O
shock	O
,	O
noradrenaline	B-FARMACO
perfusion	O
and	O
empirical	O
antibiotic	O
treatment	O
with	O
imipenem	B-FARMACO
and	O
cloxacillin	B-FARMACO
was	O
started	O
,	O
with	O
poor	O
clinical	O
evolution	O
,	O
and	O
the	O
patient	O
was	O
referred	O
to	O
the	O
ICU	O
of	O
our	O
hospital	O
.	O
On	O
arrival	O
at	O
the	O
ICU	O
,	O
the	O
following	O
tests	O
were	O
performed	O
CBC	O
sodium	O
135	O
,	O
K	O
4	O
.	O
5	O
,	O
Cl	O
101	O
,	O
glucose	O
187	O
,	O
urea	O
107	O
,	O
creatinine	O
1	O
.	O
28	O
,	O
CPK	O
109	O
,	O
total	O
bilirubin	O
6	O
.	O
19	O
direct	O
5	O
.	O
86	O
,	O
indirect	O
0	O
.	O
33	O
,	O
CRP	O
26	O
,	O
procalcitonin	O
17	O
.	O
3	O
,	O
Hb	O
13	O
.	O
1	O
g	O
dl	O
,	O
Hto	O
37	O
.	O
2	O
,	O
9000	O
platelets	O
,	O
14850	O
leukocytes	O
,	O
INR	O
1	O
.	O
53	O
,	O
AP	O
52	O
.	O
ECG	O
RS	O
at	O
75	O
bpm	O
.	O
PR	O
200msg	O
,	O
QRS	O
80msg	O
with	O
normal	O
axis	O
and	O
low	O
voltages	O
in	O
frontal	O
leads	O
.	O
No	O
acute	O
repolarisation	O
alterations	O
.	O
Transthoracic	O
echocardiography	O
dilated	O
LV	O
with	O
apical	O
aneurysm	O
and	O
hypokinesia	O
of	O
the	O
remaining	O
segments	O
,	O
causing	O
moderate	O
severe	O
systolic	O
dysfunction	O
LVEF	O
38	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
without	O
gradients	O
or	O
pathological	O
flows	O
.	O
Mitral	O
valve	O
with	O
mild	O
central	O
insufficiency	O
.	O
Right	O
chambers	O
of	O
normal	O
dimensions	O
with	O
normal	O
systolic	O
function	O
.	O
LAD	O
cable	O
with	O
abundant	O
hyperechogenic	O
material	O
adhered	O
along	O
its	O
trajectory	O
,	O
with	O
independent	O
movement	O
suggestive	O
of	O
vegetation	O
.	O
Transesophageal	O
echocardiogram	O
This	O
study	O
confirmed	O
the	O
previous	O
findings	O
.	O
During	O
his	O
stay	O
in	O
the	O
ICU	O
,	O
antibiotic	O
treatment	O
with	O
daptomycin	B-FARMACO
was	O
continued	O
,	O
new	O
blood	O
cultures	O
were	O
taken	O
and	O
the	O
device	O
was	O
removed	O
generator	O
and	O
ICD	O
cable	O
,	O
by	O
traction	O
after	O
48	O
hours	O
,	O
and	O
samples	O
were	O
sent	O
to	O
Microbiology	O
Blood	O
cultures	O
x2	O
isolation	O
of	O
methicillin	O
resistant	O
S	O
.	O
aureus	O
resistant	O
to	O
cloxacillin	B-FARMACO
and	O
penicillin	B-FARMACO
.	O
LAD	O
cable	O
isolation	O
of	O
methicillin	O
resistant	O
S	O
.	O
aureus	O
.	O
EVOLUTION	O
In	O
view	O
of	O
these	O
findings	O
,	O
he	O
was	O
assessed	O
by	O
the	O
Infectious	O
Diseases	O
Department	O
,	O
and	O
the	O
positive	O
blood	O
cultures	O
persisted	O
.	O
Antibiotic	O
treatment	O
was	O
adjusted	O
and	O
he	O
was	O
finally	O
placed	O
on	O
vancomycin	B-FARMACO
,	O
fosfomycin	B-FARMACO
and	O
linezolid	B-FARMACO
.	O
In	O
the	O
following	O
days	O
,	O
a	O
repeat	O
chest	O
CT	O
scan	O
confirmed	O
the	O
presence	O
of	O
septic	O
pulmonary	O
emboli	O
,	O
bilateral	O
pleural	O
effusion	O
and	O
associated	O
compressive	O
atelectasis	O
.	O
And	O
the	O
transesophageal	O
echocardiogram	O
was	O
repeated	O
,	O
which	O
showed	O
a	O
mass	O
attached	O
to	O
the	O
posterior	O
tricuspid	O
leaflet	O
measuring	O
33x18	O
mm	O
,	O
hypermobile	O
and	O
with	O
anchorage	O
that	O
progressed	O
to	O
the	O
subvalvular	O
apparatus	O
,	O
with	O
another	O
smaller	O
vegetation	O
on	O
the	O
free	O
edge	O
of	O
the	O
septal	O
leaflet	O
.	O
No	O
pulmonary	O
,	O
mitral	O
or	O
aortic	O
valve	O
involvement	O
.	O
Antibiotic	O
treatment	O
was	O
continued	O
in	O
the	O
following	O
weeks	O
,	O
with	O
progressive	O
normalisation	O
of	O
renal	O
and	O
hepatic	O
function	O
parameters	O
,	O
coagulation	O
and	O
inflammatory	O
markers	O
.	O
Cardiac	O
MRI	O
was	O
requested	O
,	O
which	O
confirmed	O
biventricular	O
dilatation	O
with	O
moderate	O
systolic	O
dysfunction	O
and	O
the	O
presence	O
of	O
an	O
apical	O
aneurysm	O
.	O
A	O
new	O
chest	O
CT	O
scan	O
showed	O
resolution	O
of	O
the	O
septic	O
embolisms	O
;	O
and	O
the	O
various	O
echocardiographies	O
performed	O
showed	O
no	O
persistent	O
valve	O
vegetation	O
.	O
Once	O
antibiotic	O
treatment	O
was	O
completed	O
,	O
and	O
the	O
patient	O
remained	O
clinically	O
stable	O
,	O
a	O
new	O
single	O
chamber	O
ICD	O
was	O
implanted	O
on	O
the	O
contralateral	O
side	O
without	O
incident	O
.	O
DIAGNOSIS	O
Severe	O
septic	O
shock	O
secondary	O
to	O
infective	O
endocarditis	O
due	O
to	O
methicillin	O
resistant	O
S	O
.	O
aureus	O
.	O
Dilated	O
cardiomyopathy	O
of	O
chagasic	O
aetiology	O
.	O
Severe	O
systolic	O
dysfunction	O
.	O
ICD	O
carrier	O
in	O
primary	O
prevention	O
.	O
Explant	O
and	O
reimplantation	O
of	O
single	O
chamber	O
ICD	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
31	O
year	O
old	O
male	O
patient	O
from	O
Spain	O
,	O
with	O
a	O
history	O
of	O
anxiety	O
disorder	O
,	O
no	O
other	O
pathological	O
history	O
of	O
interest	O
,	O
no	O
known	O
allergies	O
.	O
No	O
current	O
treatment	O
.	O
He	O
came	O
for	O
consultation	O
due	O
to	O
exertional	O
dyspnoea	O
,	O
presyncopal	O
episodes	O
and	O
anxiety	O
symptoms	O
.	O
She	O
was	O
referred	O
to	O
haematology	O
due	O
to	O
an	O
increase	O
in	O
eosinophils	O
in	O
the	O
haemogram	O
.	O
Examination	O
revealed	O
Conscious	O
,	O
oriented	O
,	O
alert	O
.	O
Normal	O
language	O
.	O
Normal	O
cranial	O
nerves	O
.	O
Rhythmic	O
heart	O
sounds	O
without	O
murmurs	O
.	O
Bladder	O
murmur	O
preserved	O
without	O
aggregate	O
noises	O
.	O
With	O
palpable	O
splenomegaly	O
6	O
centimetres	O
below	O
the	O
left	O
costal	O
ridge	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
Normal	O
peripheral	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
The	O
analysis	O
showed	O
an	O
increase	O
in	O
eosinophil	O
values	O
.	O
With	O
suspicion	O
of	O
hypereosinophilic	O
syndrome	O
,	O
a	O
new	O
blood	O
test	O
and	O
extension	O
study	O
were	O
requested	O
.	O
Absence	O
of	O
parasitic	O
infection	O
,	O
allergy	O
or	O
pulmonary	O
disease	O
justifying	O
the	O
eosinophilia	O
.	O
Laboratory	O
tests	O
leucocytes	O
3	O
.	O
8x10e3	O
uL	O
3	O
.	O
5	O
12	O
,	O
haemoglobin	O
11	O
.	O
9	O
g	O
dl	O
13	O
.	O
5	O
17	O
.	O
2	O
,	O
platelets	O
196x10e3	O
uL	O
.	O
Creatinine	O
1	O
.	O
32	O
mg	O
dl	O
.	O
Peripheral	O
eosinophilia	O
of	O
5000	O
elements	O
mmc	O
.	O
Troponin	O
0	O
.	O
020	O
ng	O
ml	O
0	O
0	O
.	O
056	O
.	O
Genetic	O
study	O
4q12	O
deletion	O
associated	O
with	O
FIP1L1	O
PDFGFRA	O
rearrangement	O
.	O
Echocardiogram	O
with	O
signs	O
of	O
endomyocardial	O
infiltration	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
56	O
bpm	O
,	O
narrow	O
QRS	O
of	O
normal	O
configuration	O
,	O
60o	O
axis	O
and	O
transition	O
in	O
V3	O
.	O
Universal	O
negative	O
T	O
waves	O
.	O
Abdominal	O
ultrasound	O
homogeneous	O
splenomegaly	O
of	O
17	O
.	O
5	O
cm	O
.	O
Thoracic	O
CT	O
scan	O
no	O
pulmonary	O
infiltrates	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
1	O
MRI	O
1	O
restrictive	O
pattern	O
in	O
the	O
right	O
cavities	O
small	O
ventricle	O
,	O
preserved	O
ejection	O
fraction	O
,	O
atrial	O
dilatation	O
with	O
apical	O
myocardial	O
fibrosis	O
.	O
Transmural	O
fibrosis	O
in	O
the	O
mid	O
apical	O
inferolateral	O
wall	O
of	O
the	O
left	O
ventricle	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
2	O
MRI	O
2	O
two	O
hypointense	O
images	O
of	O
crescentic	O
morphology	O
are	O
observed	O
in	O
the	O
apex	O
that	O
could	O
correspond	O
to	O
thrombi	O
.	O
Late	O
enhancement	O
with	O
areas	O
of	O
signal	O
hyperintensity	O
of	O
the	O
RV	O
apex	O
and	O
inferior	O
aspect	O
of	O
the	O
LV	O
apex	O
that	O
have	O
not	O
changed	O
with	O
respect	O
to	O
the	O
previous	O
description	O
.	O
Findings	O
of	O
hypereosinophilia	O
with	O
biventricular	O
restrictive	O
cardiomyopathy	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
3	O
MRI	O
3	O
control	O
.	O
Morphological	O
abnormalities	O
previously	O
described	O
FE	O
59	O
,	O
hypointense	O
areas	O
are	O
observed	O
in	O
the	O
apex	O
of	O
both	O
ventricles	O
of	O
linear	O
morphology	O
that	O
probably	O
correspond	O
to	O
fibrosis	O
raising	O
the	O
differential	O
diagnosis	O
with	O
laminar	O
thrombus	O
.	O
EVOLUTION	O
Treatment	O
was	O
started	O
with	O
imatinib	B-FARMACO
at	O
a	O
dose	O
of	O
400	O
mg	O
daily	O
,	O
well	O
tolerated	O
and	O
with	O
a	O
rapid	O
haematological	O
response	O
that	O
allowed	O
a	O
dose	O
reduction	O
to	O
100	O
mg	O
daily	O
after	O
2	O
months	O
.	O
A	O
control	O
ultrasound	O
scan	O
of	O
the	O
abdomen	O
showed	O
the	O
absence	O
of	O
splenomegaly	O
.	O
Symptom	O
improvement	O
.	O
Subsequently	O
,	O
arterial	O
hypertension	O
was	O
diagnosed	O
.	O
We	O
started	O
treatment	O
with	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
daily	O
,	O
which	O
we	O
had	O
to	O
discontinue	O
due	O
to	O
intense	O
asthenia	O
.	O
We	O
replaced	O
bisoprolol	B-FARMACO
with	O
olmesartan	B-FARMACO
10	O
mg	O
daily	O
with	O
good	O
tolerance	O
and	O
good	O
control	O
.	O
Studies	O
for	O
secondary	O
causes	O
were	O
negative	O
.	O
Cardiac	O
MRI	O
was	O
requested	O
where	O
a	O
restrictive	O
pattern	O
was	O
observed	O
as	O
described	O
in	O
the	O
complementary	O
tests	O
MRI	O
1	O
.	O
In	O
the	O
control	O
cardiac	O
MRI	O
MRI	O
2	O
performed	O
at	O
12	O
months	O
,	O
we	O
detected	O
images	O
of	O
crescentic	O
morphology	O
at	O
the	O
level	O
of	O
the	O
apex	O
.	O
The	O
images	O
offer	O
a	O
reasonable	O
doubt	O
between	O
laminar	O
thrombi	O
at	O
the	O
apical	O
level	O
versus	O
artefacts	O
.	O
In	O
favour	O
of	O
thrombi	O
is	O
the	O
fact	O
that	O
they	O
are	O
located	O
over	O
the	O
areas	O
of	O
fibrosis	O
detected	O
in	O
the	O
MRI	O
and	O
the	O
high	O
thrombogenicity	O
of	O
this	O
disease	O
,	O
although	O
the	O
fact	O
that	O
they	O
appear	O
in	O
both	O
ventricles	O
suggests	O
that	O
it	O
could	O
also	O
be	O
an	O
artefact	O
.	O
Echocardiography	O
showed	O
no	O
evidence	O
of	O
intracavitary	O
thrombus	O
.	O
We	O
explained	O
the	O
situation	O
to	O
the	O
patient	O
and	O
decided	O
to	O
start	O
anticoagulation	O
with	O
sintrom	B-FARMACO
,	O
which	O
we	O
again	O
had	O
to	O
suspend	O
due	O
to	O
intense	O
asthenia	O
and	O
osteomuscular	O
pain	O
.	O
We	O
raised	O
the	O
possibility	O
of	O
starting	O
treatment	O
with	O
rivaroxaban	B-FARMACO
20	O
mg	O
daily	O
,	O
for	O
off	O
label	O
use	O
.	O
After	O
explaining	O
to	O
the	O
patient	O
that	O
this	O
is	O
not	O
an	O
indication	O
studied	O
in	O
clinical	O
trials	O
or	O
approved	O
by	O
the	O
Ministry	O
,	O
we	O
decided	O
to	O
treat	O
the	O
patient	O
jointly	O
;	O
in	O
the	O
controls	O
he	O
presented	O
good	O
tolerance	O
and	O
disappearance	O
of	O
the	O
symptoms	O
attributed	O
to	O
the	O
synthroid	B-FARMACO
.	O
In	O
the	O
control	O
MRI	O
MRI	O
3	O
,	O
after	O
3	O
months	O
of	O
anticoagulation	O
,	O
the	O
same	O
images	O
continue	O
to	O
appear	O
,	O
which	O
are	O
not	O
present	O
in	O
the	O
echocardiography	O
.	O
However	O
,	O
given	O
that	O
thrombotic	O
phenomena	O
appear	O
in	O
up	O
to	O
25	O
of	O
cases	O
and	O
that	O
the	O
current	O
indications	O
for	O
anticoagulation	O
contemplate	O
starting	O
treatment	O
when	O
thrombosis	O
has	O
already	O
occurred	O
,	O
we	O
decided	O
to	O
maintain	O
treatment	O
,	O
even	O
with	O
an	O
off	O
label	O
drug	O
.	O
DIAGNOSIS	O
Myeloproliferative	O
neoplasm	O
with	O
eosinophilia	O
associated	O
with	O
FIP1L1	O
PDGFR	O
rearrangement	O
.	O
Restrictive	O
cardiomyopathy	O
with	O
apical	O
and	O
inferolateral	O
LV	O
and	O
apical	O
RV	O
myocardial	O
fibrosis	O
.	O
Probable	O
LV	O
apex	O
thrombi	O
in	O
hypersosinophilic	O
syndrome	O
Essential	O
arterial	O
hypertension	O
.	O

Personal	O
history	O
Patient	O
aged	O
49	O
,	O
baker	O
by	O
profession	O
.	O
Cardiovascular	O
risk	O
factors	O
smoker	O
of	O
more	O
than	O
25	O
pack	O
years	O
,	O
obese	O
and	O
moderate	O
drinker	O
.	O
No	O
HBP	O
,	O
DM	O
,	O
LBP	O
or	O
other	O
history	O
of	O
interest	O
.	O
No	O
cardiological	O
history	O
.	O
No	O
other	O
diseases	O
of	O
interest	O
or	O
chronic	O
treatments	O
.	O
Current	O
illness	O
Consultation	O
in	O
the	O
emergency	O
department	O
for	O
10	O
days	O
of	O
progressive	O
dyspnoea	O
,	O
reaching	O
minimal	O
effort	O
,	O
with	O
orthopnoea	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
He	O
denies	O
precordial	O
pain	O
,	O
palpitations	O
,	O
syncope	O
,	O
fever	O
or	O
infectious	O
symptoms	O
at	O
another	O
level	O
.	O
Physical	O
examination	O
BP	O
128	O
90	O
.	O
HR	O
105	O
.	O
SatO2	O
92	O
.	O
Afebrile	O
,	O
PVC	O
15	O
with	O
mild	O
RHY	O
.	O
BMI	O
of	O
34	O
.	O
AC	O
arrhythmic	O
RsCs	O
at	O
110	O
bpm	O
,	O
no	O
murmurs	O
.	O
AP	O
bibasal	O
crackles	O
.	O
Abdomen	O
globular	O
,	O
without	O
free	O
fluid	O
or	O
megaliths	O
.	O
LES	O
oedema	O
with	O
fovea	O
in	O
the	O
lower	O
1	O
2	O
2	O
.	O
Peripheral	O
pulses	O
present	O
and	O
symmetrical	O
.	O
No	O
carotid	O
,	O
abdominal	O
or	O
femoral	O
murmurs	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
count	O
,	O
biochemistry	O
and	O
coagulation	O
normal	O
.	O
Myocardial	O
damage	O
markers	O
HbA1c	O
,	O
TSH	O
,	O
cholesterol	O
normal	O
.	O
Blood	O
gases	O
on	O
admission	O
hypoxaemia	O
and	O
hypercapnia	O
pO2	O
60	O
,	O
pCO2	O
47	O
and	O
bicarbonate	O
26	O
.	O
Chest	O
X	O
ray	O
compatible	O
with	O
heart	O
failure	O
.	O
ECG	O
rapid	O
atrial	O
fibrillation	O
AF	O
on	O
admission	O
,	O
unknown	O
.	O
Echocardiogram	O
LA	O
moderately	O
dilated	O
.	O
RA	O
slightly	O
dilated	O
.	O
LV	O
slightly	O
dilated	O
and	O
hypertrophic	O
,	O
with	O
global	O
hypocontractility	O
and	O
moderately	O
depressed	O
global	O
systolic	O
function	O
.	O
EF	O
35	O
40	O
.	O
RV	O
with	O
impaired	O
function	O
due	O
to	O
TAPSE	O
,	O
mild	O
TR	O
,	O
estimated	O
PSAP	O
of	O
26mmHG	O
PVC	O
.	O
MV	O
with	O
good	O
opening	O
and	O
mild	O
reflux	O
.	O
AO	O
normofunctioning	O
.	O
Dilated	O
vena	O
cava	O
with	O
partial	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Moderate	O
biventricular	O
dysfunction	O
with	O
slightly	O
dilated	O
and	O
hypertrophic	O
vi	O
with	O
LVEF	O
35	O
40	O
.	O
Coronary	O
angiography	O
coronary	O
arteries	O
without	O
significant	O
coronary	O
lesions	O
.	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
with	O
a	O
diagnosis	O
of	O
decompensated	O
heart	O
failure	O
due	O
to	O
unknown	O
rapid	O
atrial	O
fibrillation	O
.	O
Dilatation	O
and	O
moderate	O
biventricular	O
dysfunction	O
were	O
observed	O
.	O
When	O
ischaemic	O
origin	O
was	O
ruled	O
out	O
by	O
coronary	O
angiography	O
,	O
it	O
was	O
attributed	O
as	O
possibly	O
secondary	O
to	O
tachycardiomyopathy	O
or	O
alcohol	O
induced	O
cardiomyopathy	O
.	O
During	O
admission	O
,	O
telemetry	O
showed	O
a	O
spontaneous	O
pause	O
of	O
12	O
seconds	O
coinciding	O
with	O
sleep	O
apnoea	O
,	O
leaving	O
the	O
patient	O
's	O
own	O
rhythm	O
with	O
narrow	O
QRS	O
.	O
The	O
patient	O
was	O
questioned	O
about	O
sleep	O
habits	O
and	O
,	O
with	O
a	O
high	O
suspicion	O
of	O
sleep	O
apnoea	O
hypopnoea	O
syndrome	O
SAOS	O
,	O
a	O
consultation	O
with	O
Pneumology	O
was	O
requested	O
.	O
The	O
patient	O
was	O
diagnosed	O
with	O
COPD	O
GOLD	O
II	O
and	O
severe	O
OSAHS	O
.	O
An	O
outpatient	O
polysomnography	O
also	O
revealed	O
severe	O
associated	O
oxygen	O
desaturation	O
.	O
Prior	O
to	O
admission	O
,	O
the	O
patient	O
was	O
"	O
apparently	O
healthy	O
"	O
.	O
Special	O
emphasis	O
is	O
placed	O
on	O
the	O
importance	O
of	O
hygienic	O
dietary	O
measures	O
,	O
which	O
together	O
with	O
CPAP	O
,	O
will	O
be	O
the	O
most	O
important	O
treatment	O
in	O
this	O
case	O
,	O
more	O
than	O
any	O
pharmacological	O
treatment	O
.	O
The	O
patient	O
commits	O
to	O
a	O
change	O
in	O
lifestyle	O
and	O
anticoagulation	O
is	O
started	O
in	O
order	O
to	O
programme	O
electrical	O
cardioversion	O
of	O
AF	O
.	O
Follow	O
up	O
after	O
3	O
months	O
an	O
effective	O
electrical	O
cardioversion	O
is	O
performed	O
,	O
with	O
the	O
patient	O
going	O
into	O
sinus	O
rhythm	O
and	O
AF	O
therefore	O
becoming	O
persistent	O
.	O
Control	O
echocardiogram	O
after	O
3	O
months	O
in	O
sinus	O
rhythm	O
,	O
without	O
alcohol	O
consumption	O
,	O
with	O
BMI	O
33	O
.	O
3	O
and	O
CPAP	O
treatment	O
non	O
dilated	O
ventricle	O
with	O
preserved	O
LVEF	O
.	O
It	O
is	O
therefore	O
a	O
reversible	O
ventricular	O
dysfunction	O
.	O
We	O
cannot	O
say	O
whether	O
the	O
dysfunction	O
was	O
secondary	O
to	O
rapid	O
AF	O
,	O
alcohol	O
or	O
even	O
to	O
severe	O
OSAHS	O
itself	O
.	O
DIAGNOSIS	O
First	O
episode	O
of	O
heart	O
failure	O
.	O
Atrial	O
fibrillation	O
.	O
Effective	O
electrical	O
cardioversion	O
.	O
moderate	O
biventricular	O
isfunction	O
.	O
Tachycardiomyopathy	O
.	O
Severe	O
sleep	O
apnoea	O
hypopnoea	O
syndrome	O
SAOS	O
.	O
COPD	O
GOLD	O
II	O
type	O
.	O
Smoking	O
.	O
Obesity	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
70	O
year	O
old	O
woman	O
.	O
Personal	O
history	O
No	O
known	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
.	O
Pulmonary	O
thromboembolism	O
in	O
2006	O
.	O
OI	O
haemianopsia	O
since	O
2010	O
due	O
to	O
anterior	O
ischaemic	O
neuropathy	O
.	O
Undifferentiated	O
connective	O
tissue	O
disease	O
with	O
ANA	O
,	O
under	O
control	O
by	O
Rheumatology	O
.	O
Secondary	O
hyperparathyroidism	O
.	O
Right	O
renal	O
lithiasis	O
.	O
Depressive	O
syndrome	O
.	O
IQ	O
appendectomy	O
,	O
cholecystectomy	O
.	O
Usual	O
treatment	O
omeprazole	B-FARMACO
,	O
ASA	B-FARMACO
,	O
leflunomide	B-FARMACO
,	O
hydroxychloroquine	B-FARMACO
,	O
denosumab	B-FARMACO
,	O
duloxetine	B-FARMACO
.	O
ʟʟ	O
Baseline	O
functional	O
status	O
active	O
life	O
,	O
independent	O
in	O
basic	O
activities	O
of	O
daily	O
living	O
.	O
Preserved	O
higher	O
functions	O
.	O
Current	O
illness	O
She	O
came	O
to	O
the	O
emergency	O
department	O
for	O
24	O
hours	O
of	O
progressive	O
dyspnoea	O
until	O
she	O
became	O
resting	O
,	O
together	O
with	O
palpitations	O
and	O
intermittent	O
episodes	O
of	O
oppressive	O
,	O
non	O
radiating	O
precordial	O
pain	O
,	O
without	O
vegetative	O
cortex	O
and	O
self	O
limited	O
in	O
a	O
few	O
minutes	O
.	O
She	O
did	O
not	O
report	O
oliguria	O
or	O
oedema	O
in	O
the	O
previous	O
days	O
.	O
Physical	O
examination	O
BP	O
136	O
84mmHg	O
.	O
HR	O
124lpm	O
;	O
SatO2	O
with	O
O2	O
at	O
3L	O
95	O
.	O
Afebrile	O
.	O
Conscious	O
and	O
oriented	O
.	O
Impression	O
of	O
gravity	O
.	O
Prostrate	O
and	O
sweating	O
,	O
but	O
with	O
good	O
peripheral	O
perfusion	O
.	O
Tachypnoea	O
at	O
26	O
rpm	O
at	O
rest	O
.	O
Head	O
and	O
neck	O
no	O
jugular	O
plethora	O
.	O
AC	O
rhythmic	O
tachycardia	O
,	O
systolic	O
murmur	O
II	O
IV	O
in	O
aortic	O
and	O
mitral	O
focus	O
.	O
PA	O
crackles	O
up	O
to	O
bilateral	O
midfields	O
,	O
no	O
other	O
superimposed	O
sounds	O
.	O
Abdomen	O
soft	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
without	O
signs	O
of	O
peritonism	O
.	O
Bowel	O
sounds	O
present	O
.	O
Extremities	O
no	O
oedema	O
or	O
signs	O
of	O
DVT	O
.	O
Femoral	O
and	O
pedial	O
pulses	O
present	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
tachycardia	O
at	O
114	O
bpm	O
,	O
QRS	O
axis	O
at	O
0o	O
.	O
Symmetrical	O
negative	O
T	O
waves	O
in	O
III	O
and	O
avF	O
.	O
Chest	O
X	O
ray	O
bilateral	O
alveolar	O
infiltrates	O
,	O
predominantly	O
perihilar	O
,	O
more	O
marked	O
in	O
the	O
right	O
hemithorax	O
.	O
Pinching	O
of	O
both	O
costophrenic	O
sinuses	O
.	O
Blood	O
tests	O
arterial	O
blood	O
gases	O
pO2	O
64mmHg	O
,	O
pCO2	O
32	O
mmHg	O
,	O
pH	O
7	O
.	O
27	O
,	O
HCO3	O
18	O
.	O
Biochemistry	O
glucose	O
142mg	O
dL	O
,	O
urea	O
110	O
mg	O
dL	O
,	O
creatinine	O
0	O
.	O
96	O
mg	O
dL	O
,	O
albumin	O
3	O
.	O
56	O
g	O
dL	O
,	O
CK	O
159	O
U	O
L	O
,	O
ultrasensitive	O
TnT	O
418	O
.	O
GPT	O
63	O
U	O
l	O
.	O
Na	O
142	O
mmol	O
L	O
,	O
K	O
4	O
.	O
7	O
mmol	O
L	O
.	O
Haemocytometry	O
Hb	O
12	O
.	O
6	O
g	O
dL	O
,	O
MCV	O
93	O
fL	O
,	O
Hcto	O
31	O
.	O
9	O
.	O
Platelets	O
170	O
,	O
000	O
.	O
Leukocytes	O
12	O
,	O
100	O
82	O
polymoronuclear	O
.	O
Coagulation	O
Prothrombin	O
index	O
72	O
,	O
INR	O
1	O
.	O
15	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
38	O
sec	O
.	O
Angio	O
CT	O
of	O
pulmonary	O
arteries	O
no	O
repletion	O
defects	O
in	O
pulmonary	O
arteries	O
and	O
their	O
branches	O
suggestive	O
of	O
PTE	O
.	O
Aorta	O
of	O
normal	O
calibre	O
and	O
morphology	O
along	O
its	O
thoracic	O
course	O
.	O
Extensive	O
alveolar	O
infiltrates	O
in	O
the	O
right	O
upper	O
lobe	O
and	O
middle	O
lobe	O
.	O
Bilateral	O
pleural	O
effusion	O
,	O
larger	O
in	O
the	O
right	O
hemithorax	O
.	O
Signs	O
of	O
right	O
heart	O
failure	O
with	O
contrast	O
reflux	O
to	O
the	O
inferior	O
cava	O
and	O
suprahepatic	O
arteries	O
,	O
and	O
rectification	O
of	O
the	O
interventricular	O
septum	O
.	O
Transthoracic	O
echocardiogram	O
LV	O
not	O
dilated	O
or	O
hypertrophic	O
,	O
with	O
hypokinesia	O
of	O
mediobasal	O
segments	O
of	O
inferior	O
and	O
posterior	O
inferolateral	O
face	O
and	O
good	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
normofunctioning	O
.	O
Prolapse	O
of	O
the	O
posterior	O
leaflet	O
of	O
the	O
mitral	O
valve	O
due	O
to	O
rupture	O
of	O
the	O
chordae	O
tendineae	O
,	O
causing	O
a	O
massive	O
eccentric	O
mitral	O
flail	O
directed	O
towards	O
the	O
interatrial	O
septum	O
.	O
Non	O
dilated	O
left	O
atrium	O
.	O
Non	O
dilated	O
RV	O
with	O
moderate	O
dysfunction	O
.	O
No	O
pericardial	O
effusion	O
.	O
Coronary	O
angiography	O
the	O
common	O
trunk	O
shows	O
mild	O
atheromatosis	O
.	O
The	O
anterior	O
descending	O
artery	O
shows	O
diffuse	O
irregularities	O
with	O
a	O
moderate	O
lesion	O
in	O
the	O
middle	O
segment	O
affecting	O
the	O
origin	O
of	O
the	O
first	O
diagonal	O
,	O
with	O
moderate	O
stenosis	O
.	O
The	O
circumflex	O
artery	O
is	O
of	O
medium	O
development	O
,	O
destined	O
to	O
two	O
obtuse	O
marginal	O
branches	O
with	O
mild	O
atheromatosis	O
,	O
without	O
significant	O
lesions	O
.	O
The	O
right	O
coronary	O
artery	O
is	O
the	O
dominant	O
vessel	O
,	O
of	O
great	O
development	O
.	O
In	O
its	O
middle	O
segment	O
there	O
is	O
a	O
very	O
angulated	O
lesion	O
with	O
severe	O
stenosis	O
.	O
Good	O
distal	O
bed	O
.	O
EVOLUTION	O
The	O
patient	O
was	O
assessed	O
in	O
the	O
emergency	O
department	O
and	O
was	O
found	O
to	O
have	O
acute	O
pulmonary	O
oedema	O
with	O
haemodynamic	O
stability	O
initially	O
.	O
Echocardioscopy	O
performed	O
in	O
the	O
emergency	O
department	O
revealed	O
severe	O
mitral	O
insufficiency	O
due	O
to	O
posterior	O
mitral	O
prolapse	O
and	O
possible	O
rupture	O
of	O
the	O
chordae	O
tendineae	O
,	O
so	O
it	O
was	O
decided	O
to	O
transfer	O
her	O
to	O
the	O
coronary	O
care	O
unit	O
,	O
while	O
Cardiac	O
Surgery	O
on	O
duty	O
was	O
contacted	O
to	O
assess	O
urgent	O
surgery	O
,	O
and	O
the	O
haemodynamicist	O
on	O
duty	O
to	O
perform	O
coronary	O
angiography	O
,	O
with	O
the	O
findings	O
described	O
above	O
.	O
On	O
arrival	O
at	O
the	O
coronary	O
unit	O
,	O
oxygen	O
therapy	O
was	O
administered	O
with	O
100	O
oxygen	B-FARMACO
reservoir	O
,	O
intravenous	O
diuretic	O
and	O
low	O
dose	O
ACE	O
inhibitors	O
,	O
despite	O
which	O
he	O
continued	O
to	O
worsen	O
both	O
from	O
the	O
respiratory	O
and	O
haemodynamic	O
point	O
of	O
view	O
,	O
and	O
was	O
admitted	O
to	O
the	O
operating	O
theatre	O
as	O
an	O
emergency	O
patient	O
.	O
Under	O
extracorporeal	O
circulation	O
,	O
aortocoronary	O
saphenous	O
bypass	O
is	O
performed	O
to	O
the	O
middle	O
right	O
coronary	O
artery	O
,	O
with	O
good	O
vessel	O
quality	O
.	O
Subsequently	O
,	O
access	O
was	O
gained	O
to	O
the	O
left	O
atrium	O
,	O
where	O
a	O
rupture	O
of	O
a	O
chordae	O
tendineae	O
was	O
observed	O
at	O
the	O
level	O
of	O
the	O
head	O
of	O
one	O
belly	O
of	O
the	O
posteromedial	O
papillary	O
muscle	O
and	O
a	O
moderately	O
unstructured	O
mitral	O
valve	O
,	O
for	O
which	O
reason	O
it	O
was	O
decided	O
to	O
replace	O
the	O
mitral	O
valve	O
,	O
implanting	O
a	O
biological	O
prosthesis	O
of	O
no	O
.	O
27	O
.	O
The	O
patient	O
was	O
transferred	O
back	O
to	O
the	O
coronary	O
unit	O
.	O
In	O
the	O
postoperative	O
evolution	O
,	O
the	O
patient	O
presented	O
severe	O
pump	O
failure	O
in	O
the	O
first	O
hours	O
,	O
requiring	O
,	O
in	O
addition	O
to	O
inotropic	O
support	O
,	O
intra	O
aortic	O
balloon	O
counterpulsation	O
,	O
which	O
could	O
be	O
removed	O
after	O
24	O
hours	O
,	O
with	O
subsequent	O
haemodynamic	O
stabilisation	O
.	O
He	O
also	O
presented	O
complete	O
atrioventricular	O
block	O
,	O
recovered	O
in	O
less	O
than	O
48	O
hours	O
,	O
and	O
perioperative	O
atrial	O
fibrillation	O
,	O
which	O
was	O
managed	O
with	O
a	O
course	O
of	O
intravenous	O
amiodarone	B-FARMACO
.	O
Once	O
on	O
the	O
hospital	O
ward	O
,	O
he	O
presented	O
septic	O
symptoms	O
of	O
probable	O
respiratory	O
origin	O
,	O
requiring	O
prolonged	O
treatment	O
with	O
intravenous	O
meropenem	B-FARMACO
and	O
vancomycin	B-FARMACO
for	O
3	O
weeks	O
.	O
After	O
a	O
prolonged	O
admission	O
with	O
slow	O
physical	O
rehabilitation	O
due	O
to	O
the	O
significant	O
loss	O
of	O
muscle	O
mass	O
,	O
the	O
patient	O
was	O
finally	O
discharged	O
from	O
hospital	O
,	O
with	O
monitoring	O
by	O
Cardiology	O
and	O
Cardiac	O
Surgery	O
.	O
DIAGNOSIS	O
Acute	O
pulmonary	O
oedema	O
Severe	O
mitral	O
insufficiency	O
due	O
to	O
partial	O
rupture	O
of	O
the	O
papillary	O
muscle	O
Ischaemic	O
heart	O
disease	O
with	O
severe	O
1	O
vessel	O
disease	O
medium	O
CD	O

History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
82	O
year	O
old	O
female	O
patient	O
with	O
a	O
history	O
of	O
arterial	O
hypertension	O
,	O
hypercholesterolemia	O
,	O
stage	O
II	O
chronic	O
kidney	O
disease	O
,	O
hepatitis	O
C	O
virus	O
positive	O
,	O
atrial	O
fibrillation	O
of	O
one	O
year	O
's	O
evolution	O
.	O
On	O
regular	O
treatment	O
with	O
acenocoumarol	B-FARMACO
,	O
doxazosin	B-FARMACO
4	O
mg	O
one	O
tablet	O
a	O
day	O
,	O
diltiazem	B-FARMACO
120	O
mg	O
one	O
tablet	O
a	O
day	O
,	O
furosemide	B-FARMACO
40	O
mg	O
one	O
tablet	O
a	O
day	O
,	O
pitavastatin	B-FARMACO
2	O
mg	O
and	O
mirtazapine	B-FARMACO
30	O
mg	O
.	O
Previously	O
asymptomatic	O
,	O
the	O
patient	O
was	O
referred	O
to	O
our	O
hospital	O
for	O
progressive	O
dyspnoea	O
of	O
two	O
weeks	O
'	O
duration	O
until	O
she	O
became	O
resting	O
in	O
the	O
last	O
few	O
days	O
,	O
with	O
significant	O
abdominal	O
distension	O
and	O
oedematisation	O
of	O
the	O
lower	O
limbs	O
.	O
She	O
had	O
no	O
chest	O
pain	O
or	O
palpitations	O
.	O
She	O
had	O
symptoms	O
of	O
non	O
specific	O
dizziness	O
,	O
sometimes	O
spinning	O
,	O
which	O
intensified	O
with	O
episodes	O
of	O
dyspnoea	O
at	O
rest	O
.	O
On	O
physical	O
examination	O
,	O
the	O
patient	O
was	O
in	O
good	O
general	O
condition	O
,	O
conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Well	O
hydrated	O
and	O
perfused	O
,	O
tachypnoeic	O
at	O
rest	O
and	O
unable	O
to	O
tolerate	O
decubitus	O
.	O
Afebrile	O
.	O
Blood	O
pressure	O
of	O
111	O
50	O
.	O
Heart	O
rate	O
of	O
100	O
bpm	O
.	O
Oxygen	O
saturation	O
at	O
room	O
air	O
of	O
91	O
.	O
Cardiac	O
auscultation	O
with	O
irregular	O
sounds	O
and	O
a	O
panfocal	O
systolic	O
murmur	O
II	O
III	O
VI	O
.	O
Pulmonary	O
auscultation	O
with	O
global	O
hypoventilation	O
and	O
semiology	O
of	O
right	O
pleural	O
effusion	O
and	O
bibasal	O
crackles	O
.	O
Abdomen	O
globular	O
and	O
distended	O
,	O
not	O
painful	O
on	O
palpation	O
and	O
with	O
semiology	O
of	O
minimal	O
ascites	O
,	O
signs	O
of	O
dubious	O
positive	O
surge	O
.	O
No	O
signs	O
of	O
jugular	O
ingurgitation	O
.	O
Tibio	O
malleolar	O
oedema	O
up	O
to	O
the	O
knees	O
with	O
fovea	O
.	O
Complementary	O
tests	O
CBC	O
on	O
admission	O
glucose	O
1	O
.	O
533	O
,	O
urea	O
233	O
,	O
creatinine	O
5	O
.	O
28	O
,	O
K	O
7	O
.	O
9	O
mEq	O
L	O
,	O
Na	O
114	O
,	O
Cl	O
68	O
,	O
Ca	O
7	O
.	O
5	O
,	O
Mg	O
2	O
.	O
3	O
,	O
Ca	O
ion	O
0	O
.	O
83	O
,	O
EAB	O
pH	O
7	O
.	O
07	O
,	O
pCO2	O
21	O
mmHg	O
,	O
pO2	O
113	O
,	O
HCO3	O
6	O
.	O
1	O
,	O
EB	O
24	O
,	O
SpaO2	O
96	O
,	O
Hb	O
8	O
.	O
2	O
,	O
HTO	O
26	O
.	O
8	O
,	O
leukocytes	O
15	O
.	O
520	O
,	O
neutrophils	O
92	O
.	O
7	O
,	O
platelets	O
283	O
,	O
000	O
,	O
PT	O
68	O
,	O
aPTT	O
31	O
.	O
7	O
secs	O
,	O
fibrinogen	O
282	O
,	O
INR	O
1	O
.	O
28	O
,	O
CK	O
169	O
,	O
CKMB	O
5	O
.	O
4	O
,	O
TnTUS	O
93	O
.	O
95	O
,	O
ANION	O
GAP	O
114	O
68	O
6	O
.	O
1	O
39	O
.	O
9	O
.	O
ʟʟ	O
Electrocardiogram	O
atrial	O
fibrillation	O
with	O
mean	O
ventricular	O
response	O
at	O
100	O
bpm	O
.	O
QRS	O
120	O
ms	O
with	O
morphology	O
of	O
complete	O
right	O
bundle	O
branch	O
block	O
and	O
secondary	O
repolarisation	O
disturbances	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
.	O
Bilateral	O
pleural	O
effusion	O
predominantly	O
on	O
the	O
right	O
.	O
Left	O
costophrenic	O
sinus	O
impingement	O
.	O
Interstitial	O
oedema	O
in	O
butterfly	O
wings	O
.	O
Urgent	O
laboratory	O
findings	O
creatinine	O
1	O
.	O
54	O
mg	O
dL	O
,	O
urea	O
71	O
mg	O
dL	O
,	O
sodium	O
141	O
mmol	O
L	O
,	O
potassium	O
4	O
mmol	O
L	O
,	O
haemoglobin	O
10	O
.	O
8	O
g	O
dL	O
,	O
INR	O
6	O
.	O
91	O
.	O
Baseline	O
arterial	O
blood	O
gas	O
PH	O
7	O
.	O
40	O
,	O
PO2	O
56	O
.	O
7	O
mmHg	O
,	O
PCo2	O
50	O
.	O
7	O
mmHg	O
,	O
HCO3	O
30	O
.	O
50	O
.	O
Transthoracic	O
echocardiography	O
moderate	O
left	O
ventricular	O
wall	O
hypertrophy	O
13	O
mm	O
;	O
12	O
mm	O
with	O
preserved	O
left	O
ventricular	O
systolic	O
function	O
LVEF	O
Simpson	O
63	O
.	O
Biauricular	O
dilatation	O
.	O
Mild	O
mitral	O
regurgitation	O
II	O
IV	O
.	O
Significant	O
coronary	O
sinus	O
dilatation	O
.	O
Significant	O
dilatation	O
of	O
the	O
left	O
coronary	O
artery	O
at	O
the	O
level	O
of	O
the	O
ostium	O
12	O
mm	O
with	O
fistulous	O
trajectory	O
in	O
a	O
mosaic	O
pattern	O
suggestive	O
of	O
coronary	O
fistula	O
that	O
seems	O
to	O
be	O
directed	O
to	O
the	O
left	O
atrial	O
appendage	O
,	O
but	O
probably	O
drains	O
into	O
the	O
coronary	O
sinus	O
given	O
the	O
significant	O
dilatation	O
of	O
the	O
same	O
.	O
Dilatation	O
of	O
right	O
chambers	O
with	O
depressed	O
contractility	O
TAPSE	O
14	O
mm	O
.	O
Moderate	O
severe	O
tricuspid	O
insufficiency	O
III	O
IV	O
with	O
PAPS	O
of	O
48	O
mmHg	O
.	O
Qp	O
Qs	O
1	O
.	O
49	O
.	O
Cardiac	O
MRI	O
left	O
ventricular	O
septal	O
hypertrophy	O
16	O
mm	O
with	O
preserved	O
left	O
ventricular	O
volumes	O
and	O
function	O
.	O
Right	O
ventricle	O
at	O
the	O
high	O
limit	O
of	O
normality	O
VTDVD	O
92	O
ml	O
m2	O
;	O
VTSVD	O
49	O
ml	O
m2	O
with	O
mild	O
depression	O
of	O
right	O
ventricular	O
function	O
.	O
Flattening	O
of	O
the	O
interventricular	O
septum	O
.	O
Very	O
dilated	O
atria	O
left	O
atrium	O
43	O
cm2	O
;	O
right	O
atrium	O
36	O
cm2	O
.	O
Tubular	O
portion	O
of	O
ascending	O
aorta	O
dilated	O
.	O
Pulmonary	O
trunk	O
and	O
both	O
branches	O
dilated	O
pulmonary	O
trunk	O
36	O
mm	O
,	O
left	O
pulmonary	O
artery	O
23	O
mm	O
and	O
right	O
pulmonary	O
artery	O
33	O
mm	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
26	O
mm	O
without	O
inspiratory	O
collapse	O
.	O
Dilated	O
left	O
main	O
trunk	O
.	O
Anterior	O
descending	O
artery	O
of	O
normal	O
size	O
.	O
Circumflex	O
artery	O
with	O
large	O
dilatation	O
along	O
its	O
entire	O
length	O
10	O
14	O
mm	O
and	O
saccular	O
aneurysm	O
in	O
the	O
distal	O
portion	O
of	O
3	O
.	O
5	O
cm	O
in	O
diameter	O
with	O
drainage	O
into	O
the	O
coronary	O
sinus	O
.	O
No	O
communication	O
with	O
pulmonary	O
vessels	O
was	O
observed	O
.	O
Coronography	O
large	O
aneurysmal	O
dilatation	O
of	O
the	O
left	O
coronary	O
trunk	O
from	O
the	O
origin	O
that	O
continues	O
with	O
the	O
circumflex	O
artery	O
very	O
aneurysmal	O
and	O
with	O
great	O
tortuosity	O
.	O
Large	O
aneurysm	O
dependent	O
on	O
the	O
marginal	O
branch	O
.	O
The	O
circumflex	O
artery	O
flows	O
into	O
the	O
right	O
coronary	O
artery	O
through	O
the	O
very	O
dilated	O
coronary	O
sinus	O
.	O
Rest	O
of	O
coronary	O
arteries	O
without	O
findings	O
.	O
Multislice	O
CT	O
angiography	O
dilatation	O
of	O
the	O
circumflex	O
artery	O
with	O
saccular	O
aneurysm	O
in	O
its	O
distal	O
portion	O
and	O
drainage	O
in	O
the	O
coronary	O
sinus	O
.	O
Clinical	O
evolution	O
Diuretic	O
treatment	O
and	O
poor	O
tolerance	O
to	O
vasodilator	O
and	O
beta	O
blocker	O
treatment	O
,	O
so	O
initial	O
management	O
was	O
restricted	O
to	O
intravenous	O
diuretic	O
infusion	O
with	O
oral	O
potassium	B-FARMACO
and	O
oral	O
ACE	O
inhibitors	O
,	O
as	O
well	O
as	O
anticoagulation	O
.	O
The	O
patient	O
had	O
symptoms	O
of	O
dizziness	O
and	O
significant	O
asthenia	O
,	O
which	O
made	O
it	O
necessary	O
to	O
start	O
beta	O
blockers	O
progressively	O
,	O
starting	O
with	O
minimal	O
doses	O
,	O
and	O
finally	O
achieving	O
good	O
tolerance	O
.	O
She	O
presented	O
several	O
episodes	O
of	O
atrial	O
fibrillation	O
with	O
ventricular	O
response	O
at	O
170	O
bpm	O
symptomatic	O
with	O
clinical	O
dyspnoea	O
and	O
non	O
specific	O
dizziness	O
,	O
but	O
with	O
good	O
haemodynamic	O
response	O
,	O
which	O
meant	O
that	O
,	O
given	O
the	O
poor	O
initial	O
tolerance	O
of	O
the	O
beta	O
blockers	O
,	O
digoxin	B-FARMACO
had	O
to	O
be	O
associated	O
,	O
despite	O
the	O
renal	O
failure	O
,	O
with	O
correct	O
control	O
of	O
renal	O
function	O
,	O
which	O
did	O
not	O
worsen	O
.	O
Finally	O
,	O
significant	O
improvement	O
in	O
congestive	O
symptoms	O
was	O
achieved	O
with	O
diuretics	O
,	O
heart	O
rate	O
control	O
with	O
digoxin	B-FARMACO
and	O
beta	O
blockers	O
,	O
as	O
well	O
as	O
control	O
of	O
blood	O
pressure	O
.	O
After	O
performing	O
the	O
complementary	O
examinations	O
,	O
the	O
therapeutic	O
possibilities	O
for	O
the	O
patient	O
were	O
discussed	O
in	O
a	O
joint	O
cardiology	O
and	O
cardiovascular	O
surgery	O
session	O
,	O
presenting	O
a	O
surgical	O
risk	O
of	O
15	O
.	O
9	O
according	O
to	O
the	O
logistic	O
score	O
.	O
After	O
proposing	O
surgery	O
to	O
the	O
patient	O
and	O
her	O
relatives	O
,	O
given	O
the	O
patient	O
's	O
age	O
and	O
current	O
situation	O
,	O
with	O
significant	O
clinical	O
improvement	O
,	O
they	O
decided	O
on	O
an	O
initially	O
conservative	O
management	O
,	O
considering	O
the	O
surgical	O
option	O
at	O
a	O
later	O
stage	O
if	O
the	O
patient	O
worsened	O
again	O
at	O
home	O
.	O
After	O
12	O
days	O
in	O
the	O
cardiology	O
ward	O
,	O
the	O
patient	O
was	O
discharged	O
home	O
with	O
diuretic	O
treatment	O
,	O
beta	O
blocker	O
,	O
digoxin	B-FARMACO
for	O
three	O
days	O
a	O
week	O
,	O
anticoagulation	O
and	O
antihypertensive	O
treatment	O
.	O
The	O
patient	O
was	O
seen	O
in	O
outpatient	O
clinics	O
and	O
was	O
clinically	O
stable	O
with	O
no	O
new	O
episodes	O
of	O
heart	O
failure	O
.	O
Three	O
months	O
after	O
discharge	O
,	O
while	O
at	O
home	O
,	O
she	O
presented	O
an	O
episode	O
of	O
sudden	O
death	O
that	O
triggered	O
the	O
patient	O
's	O
death	O
,	O
the	O
origin	O
of	O
this	O
event	O
being	O
unknown	O
.	O
Diagnosis	O
Debut	O
of	O
heart	O
failure	O
.	O
Symptomatic	O
left	O
coronary	O
fistula	O
in	O
an	O
elderly	O
patient	O
of	O
probable	O
congenital	O
origin	O
.	O

A	O
75	O
year	O
old	O
male	O
patient	O
was	O
referred	O
to	O
the	O
emergency	O
department	O
from	O
the	O
outpatient	O
cardiology	O
department	O
for	O
significant	O
clinical	O
deterioration	O
,	O
with	O
dyspnoea	O
on	O
minimal	O
effort	O
,	O
orthopnoea	O
,	O
paroxysmal	O
nocturnal	O
dyspnoea	O
and	O
palpitations	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Risk	O
factors	O
diabetes	O
mellitus	O
2	O
,	O
hypertension	O
,	O
dyslipidaemia	O
.	O
Ex	O
smoker	O
for	O
7	O
years	O
of	O
50	O
packs	O
year	O
.	O
Medical	O
history	O
COPD	O
.	O
Ischaemic	O
stroke	O
of	O
middle	O
cerebral	O
artery	O
in	O
March	O
2008	O
.	O
Surgical	O
interventions	O
haemorrhoids	O
,	O
epigastric	O
hernia	O
,	O
colonic	O
polypectomy	O
.	O
Bladder	O
tumour	O
treated	O
with	O
TUR	O
in	O
2011	O
and	O
2013	O
.	O
Previous	O
heart	O
disease	O
dilated	O
cardiomyopathy	O
diagnosed	O
in	O
2002	O
with	O
severely	O
depressed	O
systolic	O
function	O
LVEF	O
20	O
,	O
and	O
normal	O
coronary	O
arteries	O
in	O
cardiac	O
catheterisation	O
.	O
Follow	O
up	O
in	O
cardiology	O
outpatient	O
clinics	O
,	O
with	O
significant	O
improvement	O
in	O
ventricular	O
function	O
with	O
medical	O
treatment	O
LVEF	O
50	O
in	O
echocardiograms	O
in	O
2008	O
,	O
2010	O
and	O
2012	O
.	O
In	O
November	O
2013	O
,	O
she	O
presented	O
with	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
,	O
electrical	O
cardioversion	O
was	O
performed	O
in	O
the	O
emergency	O
department	O
,	O
which	O
was	O
effective	O
and	O
she	O
was	O
discharged	O
.	O
A	O
week	O
later	O
,	O
he	O
returned	O
to	O
the	O
emergency	O
department	O
for	O
atrial	O
fibrillation	O
,	O
where	O
electrical	O
cardioversion	O
was	O
again	O
performed	O
,	O
and	O
he	O
was	O
discharged	O
to	O
sinus	O
rhythm	O
.	O
On	O
review	O
at	O
the	O
outpatient	O
clinic	O
in	O
January	O
2014	O
,	O
the	O
patient	O
was	O
again	O
in	O
atrial	O
fibrillation	O
.	O
Usual	O
treatment	O
dabigatran	B-FARMACO
110	O
mg	O
12h	O
,	O
bisoprolol	B-FARMACO
10	O
mg	O
24h	O
,	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
24h	O
,	O
rosuvastatin	B-FARMACO
20	O
mg	O
24h	O
,	O
omeprazole	B-FARMACO
40	O
mg	O
24h	O
,	O
furosemide	B-FARMACO
20	O
mg	O
12h	O
administered	O
as	O
needed	O
,	O
inhaled	O
tiotropium	B-FARMACO
bromide	I-FARMACO
,	O
repaglinide	B-FARMACO
0	O
.	O
5	O
mg	O
,	O
fluoxetine	B-FARMACO
20	O
mg	O
,	O
alprazolam	B-FARMACO
0	O
.	O
5	O
mg	O
24h	O
.	O
Present	O
illness	O
75	O
year	O
old	O
male	O
patient	O
referred	O
to	O
the	O
emergency	O
department	O
from	O
the	O
cardiology	O
outpatient	O
department	O
for	O
presenting	O
significant	O
clinical	O
deterioration	O
in	O
recent	O
weeks	O
,	O
with	O
dyspnoea	O
on	O
minimal	O
exertion	O
,	O
orthopnoea	O
,	O
paroxysmal	O
nocturnal	O
dyspnoea	O
,	O
and	O
palpitations	O
in	O
recent	O
days	O
.	O
He	O
did	O
not	O
report	O
any	O
respiratory	O
infection	O
or	O
other	O
accompanying	O
symptoms	O
.	O
On	O
admission	O
,	O
he	O
presented	O
atrial	O
fibrillation	O
with	O
ventricular	O
response	O
at	O
130	O
150	O
bpm	O
despite	O
treatment	O
with	O
maximum	O
doses	O
of	O
beta	O
blockers	O
,	O
so	O
he	O
was	O
referred	O
for	O
admission	O
to	O
cardiology	O
to	O
attempt	O
rate	O
control	O
or	O
cardioversion	O
.	O
Physical	O
examination	O
BP	O
120	O
65	O
mmHg	O
.	O
HR	O
155	O
bpm	O
,	O
Ta	O
36	O
.	O
5	O
oC	O
.	O
O2	O
Sat	O
.	O
O2	O
96	O
with	O
FiO2	O
of	O
0	O
.	O
21	O
.	O
Patient	O
conscious	O
,	O
normal	O
colour	O
and	O
normohydrated	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
cardiac	O
tones	O
,	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
generalised	O
decrease	O
in	O
vesicular	O
murmur	O
,	O
with	O
bibasal	O
crackles	O
.	O
lower	O
limbs	O
no	O
oedema	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Abdomen	O
soft	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
Additional	O
tests	O
ECG	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
,	O
narrow	O
QRS	O
,	O
no	O
intraventricular	O
conduction	O
disturbances	O
.	O
Signs	O
of	O
left	O
ventricular	O
overload	O
in	O
V5	O
V6	O
and	O
DI	O
and	O
aVL	O
.	O
Chest	O
X	O
ray	O
bibasal	O
alveolar	O
interstitial	O
infiltrates	O
suggestive	O
of	O
heart	O
failure	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
Cardiothoracic	O
index	O
less	O
than	O
0	O
.	O
5	O
.	O
Blood	O
tests	O
carried	O
out	O
on	O
the	O
cardiology	O
ward	O
ʟʟ	O
Leucocytes	O
12	O
.	O
4x10e9	O
L	O
,	O
Hb17	O
.	O
5	O
g	O
dl	O
,	O
platelets	O
262x10e9	O
L	O
.	O
Coagulation	O
PTT	O
15s	O
,	O
IQ	O
76	O
,	O
APTT	O
35	O
.	O
3s	O
.	O
Glucose	O
140	O
mg	O
dl	O
,	O
urea	O
64	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
21	O
mg	O
dl	O
,	O
K	O
5	O
MM	O
L	O
,	O
Na	O
143	O
MM	O
L	O
,	O
AST	O
31	O
U	O
L	O
,	O
ALT	O
41	O
MM	O
L	O
,	O
LDH	O
244	O
U	O
L	O
,	O
CRP	O
0	O
.	O
2	O
mg	O
dl	O
,	O
pro	O
BNP	O
16727	O
pg	O
ml	O
.	O
Glycosylated	O
haemoglobin	O
6	O
.	O
9	O
.	O
Echocardiogram	O
Poor	O
echocardiographic	O
window	O
.	O
Left	O
ventricle	O
slightly	O
dilated	O
,	O
not	O
hypertrophic	O
,	O
with	O
severely	O
depressed	O
global	O
contraction	O
20	O
25	O
,	O
severe	O
apex	O
hypokinesia	O
.	O
Moderately	O
dilated	O
left	O
atrium	O
.	O
Mitral	O
valve	O
thickened	O
,	O
with	O
mild	O
insufficiency	O
.	O
Sclerosed	O
aortic	O
valve	O
,	O
with	O
good	O
opening	O
,	O
without	O
insufficiency	O
.	O
Right	O
chambers	O
with	O
moderately	O
dilated	O
atrium	O
.	O
Preserved	O
RVEF	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
,	O
with	O
good	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Clinical	O
evolution	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
cardiology	O
ward	O
with	O
atrial	O
fibrillation	O
with	O
ventricular	O
response	O
at	O
140	O
150	O
bpm	O
without	O
being	O
able	O
to	O
control	O
it	O
despite	O
increasing	O
bisoprolol	B-FARMACO
to	O
a	O
dose	O
of	O
15	O
mg	O
24h	O
and	O
adding	O
digoxin	O
and	O
amiodarone	B-FARMACO
,	O
remaining	O
with	O
a	O
ventricular	O
rate	O
of	O
130	O
140	O
bpm	O
for	O
the	O
following	O
3	O
days	O
.	O
Given	O
the	O
failure	O
of	O
rhythm	O
control	O
in	O
previous	O
episodes	O
and	O
difficult	O
heart	O
rate	O
control	O
,	O
the	O
clinical	O
team	O
,	O
electrophysiologists	O
and	O
the	O
family	O
decided	O
together	O
to	O
ablate	O
the	O
atrioventricular	O
node	O
and	O
place	O
a	O
pacemaker	O
.	O
A	O
permanent	O
pacemaker	O
was	O
placed	O
,	O
with	O
the	O
intention	O
of	O
also	O
placing	O
an	O
LV	O
lead	O
for	O
cardiac	O
resynchronisation	O
therapy	O
CRT	O
,	O
but	O
this	O
was	O
not	O
possible	O
due	O
to	O
coronary	O
sinus	O
dissection	O
.	O
Finally	O
,	O
a	O
DDD	O
pacemaker	O
was	O
placed	O
.	O
Five	O
days	O
later	O
,	O
atrioventricular	O
node	O
ablation	O
was	O
performed	O
without	O
incident	O
.	O
The	O
patient	O
was	O
discharged	O
with	O
better	O
clinical	O
control	O
,	O
maintaining	O
the	O
same	O
anticoagulant	O
treatment	O
,	O
withdrawing	O
digoxin	B-FARMACO
,	O
amiodarone	B-FARMACO
and	O
the	O
very	O
high	O
doses	O
of	O
bisoprolol	B-FARMACO
with	O
which	O
he	O
had	O
tried	O
to	O
reduce	O
the	O
heart	O
rate	O
.	O
Medication	O
for	O
the	O
management	O
of	O
heart	O
failure	O
was	O
maintained	O
.	O
Diagnosis	O
Atrial	O
fibrillation	O
with	O
difficult	O
to	O
control	O
rapid	O
ventricular	O
response	O
.	O
Rate	O
control	O
strategy	O
by	O
AV	O
node	O
ablation	O
and	O
pacemaker	O
implantation	O
.	O
Tachycardiomyopathy	O
with	O
severe	O
ventricular	O
dysfunction	O
.	O

History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Personal	O
history	O
88	O
year	O
old	O
male	O
with	O
a	O
personal	O
history	O
of	O
arterial	O
hypertension	O
,	O
VDD	O
pacemaker	O
due	O
to	O
complete	O
AV	O
block	O
implanted	O
4	O
months	O
ago	O
,	O
complicated	O
by	O
post	O
implant	O
cardiac	O
tamponade	O
and	O
recent	O
admission	O
to	O
the	O
Geriatrics	O
Department	O
for	O
pneumonia	O
in	O
the	O
right	O
upper	O
lobe	O
.	O
Baseline	O
situation	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
,	O
without	O
cognitive	O
impairment	O
.	O
Dyspnoea	O
on	O
moderate	O
exertion	O
.	O
Usual	O
treatment	O
enalapril	B-FARMACO
5	O
mg	O
per	O
day	O
and	O
torasemide	B-FARMACO
10	O
mg	O
per	O
day	O
.	O
Present	O
illness	O
she	O
attended	O
the	O
emergency	O
department	O
for	O
generalised	O
oedema	O
and	O
oligoanuria	O
of	O
three	O
days	O
'	O
evolution	O
,	O
with	O
intense	O
asthenia	O
and	O
anorexia	O
.	O
She	O
also	O
reported	O
catarrhal	O
symptoms	O
,	O
with	O
rhinorrhoea	O
and	O
dry	O
cough	O
,	O
without	O
thermometric	O
fever	O
.	O
Physical	O
examination	O
BP	O
190	O
80	O
mmHg	O
,	O
HR	O
95	O
bpm	O
,	O
temperature	O
37	O
.	O
7	O
oC	O
,	O
saturation	O
with	O
2	O
litre	O
nasal	O
spectacles	O
94	O
.	O
General	O
condition	O
was	O
fair	O
,	O
mucocutaneous	O
pallor	O
,	O
eupneic	O
at	O
rest	O
.	O
Auscultation	O
revealed	O
a	O
mesosystolic	O
murmur	O
in	O
the	O
lower	O
left	O
sternal	O
border	O
and	O
rhonchi	O
in	O
the	O
right	O
lung	O
base	O
.	O
The	O
rest	O
was	O
unaltered	O
.	O
Complementary	O
tests	O
Laboratory	O
tests	O
Hb	O
10	O
.	O
3	O
g	O
dl	O
,	O
MCV	O
100	O
,	O
creatinine	O
3	O
.	O
49	O
mg	O
dl	O
previously	O
1	O
.	O
4	O
mg	O
dl	O
,	O
Na	O
144	O
,	O
K	O
5	O
.	O
5	O
and	O
moderate	O
haematuria	O
in	O
the	O
urine	O
sediment	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
,	O
signs	O
of	O
pulmonary	O
congestion	O
and	O
infiltrate	O
in	O
the	O
right	O
lower	O
pulmonary	O
lobe	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
94	O
bpm	O
with	O
electrostimulated	O
ventricular	O
response	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
with	O
severe	O
concentric	O
hypertrophy	O
and	O
moderate	O
systolic	O
dysfunction	O
.	O
Degenerative	O
aortic	O
stenosis	O
.	O
Non	O
dilated	O
right	O
ventricle	O
.	O
Normopositioned	O
pacemaker	O
lead	O
,	O
with	O
a	O
wart	O
of	O
approximately	O
1	O
.	O
8	O
cm2	O
,	O
close	O
to	O
the	O
tricuspid	O
leaflets	O
and	O
synchronous	O
movement	O
with	O
them	O
,	O
with	O
mild	O
tricuspid	O
insufficiency	O
.	O
Estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
of	O
31	O
mmHg	O
.	O
Slight	O
pericardial	O
effusion	O
and	O
severe	O
left	O
pleural	O
effusion	O
.	O
Clinical	O
course	O
The	O
patient	O
was	O
admitted	O
in	O
a	O
serious	O
condition	O
with	O
intense	O
asthenia	O
and	O
oligoanuria	O
with	O
worsening	O
renal	O
function	O
.	O
In	O
view	O
of	O
the	O
echocardiographic	O
findings	O
and	O
the	O
diagnosis	O
of	O
endocarditis	O
on	O
the	O
pacemaker	O
lead	O
,	O
antibiotic	O
treatment	O
with	O
rifampicin	B-FARMACO
and	O
daptomycin	B-FARMACO
was	O
started	O
.	O
It	O
was	O
decided	O
to	O
remove	O
the	O
entire	O
MCP	O
system	O
and	O
reimplant	O
a	O
new	O
device	O
as	O
the	O
patient	O
was	O
in	O
full	O
AVB	O
,	O
but	O
the	O
clinical	O
evolution	O
was	O
very	O
torpid	O
with	O
intense	O
negative	O
mood	O
symptoms	O
and	O
poor	O
functional	O
reserve	O
,	O
and	O
the	O
patient	O
died	O
a	O
few	O
days	O
after	O
admission	O
without	O
being	O
able	O
to	O
remove	O
the	O
pacemaker	O
.	O
Diagnosis	O
We	O
present	O
the	O
case	O
of	O
an	O
octogenarian	O
patient	O
with	O
endocarditis	O
on	O
a	O
pacemaker	O
lead	O
with	O
a	O
very	O
torpid	O
evolution	O
.	O
The	O
postulated	O
pathogenic	O
mechanisms	O
are	O
as	O
follows	O
Local	O
contamination	O
of	O
the	O
pacemaker	O
.	O
This	O
is	O
the	O
most	O
frequent	O
mechanism	O
.	O
It	O
usually	O
occurs	O
during	O
implantation	O
of	O
the	O
device	O
.	O
Often	O
the	O
infection	O
starts	O
in	O
the	O
generator	O
pocket	O
and	O
spreads	O
to	O
the	O
lead	O
.	O
The	O
clinical	O
course	O
may	O
be	O
acute	O
or	O
larval	O
,	O
manifesting	O
itself	O
even	O
years	O
later	O
.	O
The	O
duration	O
of	O
the	O
procedure	O
,	O
inadequate	O
asepsis	O
and	O
operator	O
inexperience	O
are	O
responsible	O
factors	O
.	O
Skin	O
erosion	O
or	O
necrosis	O
of	O
the	O
generator	O
pocket	O
or	O
the	O
skin	O
adjacent	O
to	O
the	O
electrode	O
,	O
which	O
act	O
as	O
a	O
gateway	O
for	O
microorganisms	O
.	O
Factors	O
involved	O
in	O
this	O
mechanism	O
include	O
inadequate	O
technique	O
and	O
site	O
of	O
implantation	O
,	O
generator	O
size	O
,	O
and	O
patient	O
malnutrition	O
.	O
Haematogenous	O
infection	O
.	O
Arrival	O
of	O
the	O
micro	O
organism	O
via	O
the	O
blood	O
from	O
another	O
distant	O
infectious	O
source	O
.	O
The	O
source	O
of	O
bacteraemia	O
may	O
be	O
a	O
central	O
venous	O
catheter	O
,	O
a	O
valve	O
prosthesis	O
or	O
invasive	O
therapeutic	O
procedures	O
.	O
The	O
most	O
frequently	O
isolated	O
microorganisms	O
are	O
staphylococci	O
.	O
S	O
.	O
aureus	O
is	O
the	O
predominant	O
bacterium	O
in	O
cases	O
of	O
acute	O
infection	O
,	O
while	O
coagulase	O
negative	O
staphylococci	O
are	O
the	O
micro	O
organisms	O
responsible	O
for	O
the	O
majority	O
of	O
late	O
infections	O
.	O
Other	O
microorganisms	O
involved	O
include	O
Pseudomonas	O
aeruginosa	O
,	O
enterobacteria	O
,	O
Propionibacterium	O
acnes	O
and	O
Corynebacterium	O
sp	O
.	O
,	O
and	O
polymicrobial	O
infections	O
have	O
been	O
described	O
,	O
especially	O
in	O
diabetic	O
patients	O
or	O
those	O
taking	O
corticosteroids	O
.	O
When	O
the	O
pacemaker	O
infection	O
is	O
secondary	O
to	O
left	O
sided	O
endocarditis	O
,	O
the	O
microbiological	O
profile	O
is	O
different	O
,	O
in	O
line	O
with	O
the	O
microorganisms	O
causing	O
the	O
valve	O
infection	O
.	O

History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
A	O
79	O
year	O
old	O
woman	O
under	O
follow	O
up	O
for	O
frequent	O
palpitations	O
without	O
associated	O
structural	O
heart	O
disease	O
,	O
who	O
was	O
referred	O
for	O
an	O
electrophysiological	O
study	O
and	O
possible	O
ablation	O
of	O
atrial	O
tachycardia	O
.	O
She	O
had	O
a	O
history	O
of	O
hypertension	O
and	O
dyslipidaemia	O
.	O
Physical	O
examination	O
was	O
normal	O
.	O
The	O
echocardiogram	O
showed	O
a	O
non	O
dilated	O
left	O
ventricle	O
with	O
preserved	O
LVEF	O
and	O
no	O
significant	O
valvular	O
abnormalities	O
.	O
In	O
a	O
Holter	O
study	O
,	O
there	O
were	O
episodes	O
of	O
non	O
sustained	O
atrial	O
tachycardia	O
.	O
The	O
usual	O
laboratory	O
tests	O
were	O
normal	O
and	O
the	O
chest	O
X	O
ray	O
showed	O
no	O
evidence	O
of	O
pleuropulmonary	O
disease	O
or	O
significant	O
alterations	O
in	O
the	O
cardiopericardial	O
silhouette	O
.	O
He	O
was	O
on	O
antiarrhythmic	O
treatment	O
with	O
atenolol	B-FARMACO
50	O
mg	O
12h	O
.	O
Other	O
cardiological	O
treatment	O
eprosartan	B-FARMACO
,	O
hydrochlorothiazide	B-FARMACO
,	O
amlodipine	B-FARMACO
,	O
furosemide	B-FARMACO
,	O
pitavastatin	B-FARMACO
,	O
ezetimibe	B-FARMACO
.	O
Complementary	O
tests	O
Baseline	O
electrocardiogram	O
sinus	O
rhythm	O
at	O
101	O
bpm	O
.	O
PR	O
173	O
ms	O
,	O
QRS	O
99	O
ms	O
.	O
Left	O
ventricular	O
systolic	O
overload	O
.	O
Non	O
sustained	O
atrial	O
tachycardia	O
.	O
Clinical	O
course	O
Electrocatheters	O
were	O
introduced	O
via	O
femoral	O
approach	O
for	O
electrophysiological	O
studies	O
in	O
the	O
RA	O
,	O
RV	O
and	O
His	O
,	O
in	O
the	O
coronary	O
sinus	O
,	O
as	O
well	O
as	O
an	O
ablation	O
catheter	O
.	O
Basically	O
,	O
non	O
sustained	O
atrial	O
tachycardia	O
was	O
observed	O
with	O
a	O
negative	O
P	O
wave	O
in	O
the	O
inferior	O
face	O
,	O
positive	O
in	O
D1	O
and	O
aVL	O
.	O
Under	O
isoproterenol	B-FARMACO
administration	O
it	O
becomes	O
sustained	O
.	O
AH	O
120	O
ms	O
and	O
HV	O
48	O
ms	O
.	O
Electroanatomical	O
mapping	O
of	O
the	O
RA	O
was	O
performed	O
,	O
with	O
greater	O
precocity	O
in	O
the	O
perihisian	O
region	O
.	O
Patent	O
foramen	O
ovale	O
.	O
Retrograde	O
aortic	O
mapping	O
was	O
performed	O
,	O
with	O
greater	O
precocity	O
in	O
the	O
posterior	O
aortic	O
sinus	O
in	O
the	O
vicinity	O
of	O
the	O
right	O
aortic	O
sinus	O
.	O
In	O
this	O
area	O
a	O
precocity	O
of	O
39	O
ms	O
is	O
obtained	O
with	O
respect	O
to	O
the	O
P	O
wave	O
.	O
RF	O
energy	O
is	O
applied	O
with	O
interruption	O
of	O
the	O
tachycardia	O
in	O
the	O
first	O
second	O
.	O
Then	O
3	O
minutes	O
of	O
safety	O
is	O
applied	O
around	O
the	O
area	O
,	O
first	O
with	O
20	O
watts	O
and	O
then	O
with	O
30	O
watts	O
.	O
At	O
the	O
end	O
of	O
the	O
procedure	O
,	O
sinus	O
rhythm	O
of	O
75	O
bpm	O
and	O
HRBBB	O
of	O
mechanical	O
aetiology	O
was	O
observed	O
.	O
There	O
were	O
no	O
significant	O
complications	O
and	O
the	O
patient	O
was	O
discharged	O
the	O
day	O
after	O
the	O
procedure	O
.	O
Diagnosis	O
Atrial	O
tachycardia	O
originating	O
in	O
the	O
posterior	O
aortic	O
sinus	O
region	O
.	O
Radiofrequency	O
ablation	O
of	O
the	O
tachycardia	O
via	O
retrograde	O
aortic	O
route	O
with	O
efficacy	O
criteria	O
.	O

History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Reason	O
for	O
consultation	O
dyspnoea	O
Personal	O
history	O
No	O
known	O
drug	O
allergies	O
.	O
Diabetes	O
mellitus	O
secondary	O
to	O
pancreatoduedectomy	O
performed	O
in	O
2005	O
due	O
to	O
a	O
mass	O
in	O
the	O
head	O
of	O
the	O
pancreas	O
with	O
suspected	O
ampuloma	O
and	O
corresponding	O
to	O
chronic	O
sclerosing	O
pancreatitis	O
;	O
spenectomy	O
in	O
the	O
same	O
surgical	O
act	O
also	O
cholecystectomy	O
and	O
appendectomy	O
.	O
Multicentric	O
Castleman	O
's	O
disease	O
,	O
plasmacytic	O
variant	O
,	O
diagnosed	O
in	O
January	O
2006	O
.	O
Initially	O
treated	O
with	O
CHOP	O
8	O
cycles	O
with	O
good	O
response	O
.	O
Due	O
to	O
gastric	O
parietal	O
thickening	O
,	O
a	O
gastroscopy	O
was	O
performed	O
which	O
revealed	O
grade	O
2	O
oesophageal	O
varices	O
,	O
without	O
fundic	O
varices	O
and	O
a	O
biopsy	O
of	O
the	O
gastric	O
body	O
compatible	O
with	O
chronic	O
gastritis	O
without	O
significant	O
atrophy	O
.	O
In	O
November	O
of	O
the	O
same	O
year	O
,	O
due	O
to	O
persistent	O
PET	O
CT	O
activity	O
,	O
treatment	O
was	O
started	O
with	O
chlorambucil	B-FARMACO
and	O
later	O
rituximab	B-FARMACO
,	O
which	O
was	O
maintained	O
intermittently	O
due	O
to	O
supra	O
and	O
infradiaphragmatic	O
metabolic	O
progression	O
until	O
January	O
2013	O
.	O
She	O
continued	O
to	O
be	O
monitored	O
by	O
the	O
haematology	O
outpatient	O
clinic	O
,	O
with	O
suspicion	O
of	O
deep	O
vein	O
thrombosis	O
of	O
the	O
left	O
lower	O
limb	O
,	O
which	O
was	O
ruled	O
out	O
by	O
normal	O
Doppler	O
ultrasound	O
.	O
Baseline	O
situation	O
IABVD	O
.	O
NYHA	O
functional	O
class	O
I	O
.	O
Previous	O
treatment	O
pantoprazole	B-FARMACO
40	O
mg	O
1	O
0	O
0	O
,	O
pancreatin	B-FARMACO
10000	O
U	O
3	O
3	O
3	O
,	O
insulin	B-FARMACO
as	O
prescribed	O
,	O
paracetamol	B-FARMACO
if	O
necessary	O
.	O
Present	O
illness	O
62	O
year	O
old	O
patient	O
attended	O
the	O
emergency	O
department	O
for	O
progressive	O
exertional	O
dyspnoea	O
of	O
1	O
month	O
's	O
evolution	O
until	O
becoming	O
resting	O
in	O
the	O
last	O
few	O
days	O
,	O
orthopnoea	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
;	O
nocturnal	O
decubitus	O
cough	O
and	O
nocturia	O
.	O
He	O
also	O
reported	O
an	O
increase	O
in	O
abdominal	O
perimeter	O
and	O
oedema	O
of	O
the	O
lower	O
limbs	O
,	O
discomfort	O
in	O
the	O
right	O
hypochondrium	O
suggestive	O
of	O
hepatic	O
congestion	O
in	O
the	O
anamnesis	O
.	O
No	O
chest	O
pain	O
.	O
She	O
did	O
report	O
occasional	O
palpitations	O
during	O
the	O
last	O
20	O
days	O
lasting	O
up	O
to	O
30	O
minutes	O
.	O
Uncontrolled	O
blood	O
pressure	O
at	O
home	O
.	O
Denies	O
non	O
compliance	O
with	O
treatment	O
.	O
No	O
fever	O
.	O
No	O
expectoration	O
.	O
No	O
nausea	O
,	O
no	O
vomiting	O
,	O
no	O
alteration	O
in	O
stool	O
frequency	O
or	O
stool	O
characteristics	O
.	O
Physical	O
examination	O
BP	O
136	O
57	O
mmHg	O
,	O
HR	O
68	O
bpm	O
,	O
afebrile	O
.	O
Weight	O
67	O
kg	O
,	O
height	O
170	O
cm	O
.	O
BEG	O
.	O
Normal	O
colour	O
,	O
normoperfused	O
and	O
normohydrated	O
.	O
Head	O
and	O
neck	O
jugular	O
ingurgitation	O
.	O
AC	O
rhythmic	O
tones	O
,	O
no	O
murmurs	O
.	O
PA	O
semiology	O
of	O
pleural	O
effusion	O
in	O
the	O
lower	O
half	O
of	O
the	O
right	O
hemithorax	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
pain	O
in	O
the	O
right	O
hypochondrium	O
without	O
peritoneal	O
irritation	O
or	O
defence	O
,	O
no	O
masses	O
or	O
visceromegaly	O
.	O
Extremities	O
oedema	O
with	O
fovea	O
up	O
to	O
the	O
root	O
of	O
the	O
thighs	O
,	O
no	O
signs	O
of	O
DVT	O
,	O
positive	O
pedal	O
pulses	O
.	O
Complementary	O
tests	O
CBC	O
leukocytes	O
8	O
.	O
7	O
thousands	O
mcL	O
,	O
haemoglobin	O
15	O
.	O
3	O
g	O
dL	O
,	O
haematocrit	O
47	O
.	O
7	O
,	O
MCV	O
98	O
fl	O
,	O
platelets	O
191	O
thousands	O
mcL	O
.	O
ESR	O
1	O
hour	O
64	O
mm	O
.	O
Activ	O
.	O
Prot	O
.	O
84	O
,	O
APTT	O
37	O
sec	O
,	O
Fng	O
453	O
mg	O
dL	O
,	O
Gluc	O
145	O
mg	O
dL	O
,	O
CRP	O
0	O
.	O
27	O
mg	O
dL	O
,	O
Creat	O
.	O
1	O
.	O
07	O
mg	O
dL	O
,	O
urea	O
39	O
mg	O
dL	O
,	O
sodium	O
137	O
mmol	O
L	O
,	O
potassium	O
4	O
.	O
6	O
mmol	O
L	O
,	O
calcium	O
8	O
.	O
5	O
mg	O
dL	O
,	O
phosphorus	O
4	O
.	O
4	O
mg	O
dL	O
,	O
GOT	O
24	O
IU	O
L	O
,	O
GPT	O
16	O
IU	O
L	O
,	O
GGT	O
25	O
IU	O
L	O
,	O
FA	O
109	O
IU	O
L	O
,	O
total	O
cholesterol	O
123	O
mg	O
dL	O
,	O
LDH	O
509	O
IU	O
L	O
,	O
triglycerides	O
52	O
mg	O
dL	O
,	O
HDL	O
46	O
mg	O
dL	O
,	O
total	O
protein	O
7	O
.	O
5	O
g	O
dL	O
.	O
TSH	O
2	O
.	O
12	O
mcU	O
mL	O
.	O
ʟʟ	O
Auto	O
antibodies	O
ANA	O
and	O
ANCA	O
negative	O
.	O
Serology	O
HBV	O
and	O
HCV	O
negative	O
.	O
Total	O
proteins	O
8	O
.	O
80	O
g	O
dl	O
,	O
albumin	O
42	O
.	O
9	O
3	O
.	O
78	O
g	O
dl	O
,	O
Alpha	O
1	O
globulins	O
3	O
.	O
5	O
0	O
.	O
31	O
g	O
dl	O
,	O
Alpha	O
2	O
globulins	O
10	O
.	O
7	O
0	O
.	O
94	O
g	O
dl	O
,	O
ß	O
globulins	O
9	O
.	O
2	O
0	O
.	O
81	O
g	O
dl	O
,	O
Gamma	O
globulins	O
33	O
.	O
7	O
2	O
,	O
97	O
g	O
dl	O
,	O
polyclonal	O
hypergammaglobulinaemia	O
,	O
serum	O
immunoglobulin	O
G	O
3120	O
mg	O
dl	O
,	O
immunoglobulin	O
A	O
134	O
mg	O
dl	O
,	O
immunoglobulin	O
M	O
40	O
.	O
4	O
mg	O
dl	O
,	O
serum	O
Beta	O
2	O
microglobulin	O
4	O
.	O
59	O
μg	O
ml	O
.	O
Baseline	O
arterial	O
blood	O
gases	O
pH	O
7	O
.	O
39	O
,	O
pCO2	O
31	O
mmHg	O
,	O
pO2	O
68	O
mmHg	O
.	O
ʟʟ	O
24	O
hour	O
urine	O
clearance	O
59	O
ml	O
min	O
,	O
total	O
proteinuria	O
219	O
mg	O
24	O
hours	O
,	O
Ca	O
73	O
mg	O
24	O
hours	O
.	O
Bence	O
Jones	O
proteinuria	O
kappa	O
and	O
lambda	O
light	O
chains	O
in	O
urine	O
negative	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
,	O
mediastinum	O
and	O
both	O
hilar	O
normal	O
,	O
thickening	O
of	O
the	O
greater	O
fissure	O
,	O
bilateral	O
pleural	O
effusion	O
,	O
predominantly	O
in	O
the	O
right	O
hemithorax	O
.	O
Electrocardiogram	O
sinus	O
rhythm	O
with	O
first	O
degree	O
AV	O
block	O
and	O
left	O
anterior	O
hemiblock	O
.	O
Isolated	O
ventricular	O
extrasystoles	O
.	O
During	O
the	O
hospital	O
stay	O
,	O
he	O
had	O
several	O
episodes	O
of	O
palpitations	O
,	O
and	O
the	O
electrocardiogram	O
showed	O
paroxysmal	O
atrial	O
fibrillation	O
with	O
ventricular	O
response	O
at	O
130lpm	O
and	O
spontaneous	O
reversion	O
to	O
sinus	O
rhythm	O
after	O
a	O
strategy	O
of	O
ventricular	O
rate	O
control	O
with	O
beta	O
blockers	O
and	O
anticoagulation	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
slightly	O
dilated	O
VTD	O
145	O
ml	O
,	O
VTD	O
SC	O
81mL	O
m2	O
,	O
not	O
hypertrophied	O
,	O
with	O
hypokinesia	O
of	O
all	O
segments	O
at	O
baseline	O
and	O
moderate	O
systolic	O
dysfunction	O
.	O
Grade	O
III	O
diastolic	O
dysfunction	O
mean	O
E	O
e	O
"	O
16	O
,	O
observing	O
restrictive	O
mitral	O
filling	O
pattern	O
that	O
pseudonormalises	O
with	O
respiratory	O
movements	O
.	O
Estimated	O
global	O
LVEF	O
moderately	O
depressed	O
LVEF	O
41	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
with	O
slightly	O
dilated	O
aortic	O
root	O
and	O
ascending	O
aorta	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
preserved	O
systolic	O
function	O
.	O
Mitral	O
valve	O
with	O
thin	O
leaflets	O
without	O
stenosis	O
and	O
with	O
mild	O
insufficiency	O
.	O
Trivalve	O
aortic	O
valve	O
without	O
significant	O
stenosis	O
or	O
insufficiency	O
.	O
No	O
tricuspid	O
insufficiency	O
that	O
would	O
allow	O
estimation	O
of	O
PSAP	O
.	O
Inferior	O
cava	O
not	O
dilated	O
with	O
normal	O
inspiratory	O
collapse	O
.	O
Intact	O
interatrial	O
septum	O
.	O
Minimal	O
pericardial	O
effusion	O
.	O
Bilateral	O
pleural	O
effusion	O
.	O
Whole	O
body	O
PET	O
CT	O
fluorodeoxyglucose	O
F18	O
the	O
images	O
obtained	O
still	O
show	O
a	O
localised	O
adenopathy	O
in	O
the	O
left	O
internal	O
mammary	O
chain	O
,	O
with	O
no	O
significant	O
metabolic	O
or	O
morphological	O
change	O
with	O
respect	O
to	O
the	O
previous	O
study	O
,	O
current	O
maximum	O
SUV	O
of	O
1	O
.	O
2	O
the	O
same	O
as	O
the	O
previous	O
one	O
.	O
At	O
the	O
infradiaphragmatic	O
level	O
,	O
some	O
lymph	O
node	O
formations	O
are	O
visualised	O
in	O
both	O
external	O
iliac	O
chains	O
with	O
slight	O
metabolic	O
detectability	O
SUV	O
max	O
around	O
1	O
.	O
8	O
,	O
similar	O
to	O
previous	O
and	O
without	O
significant	O
variations	O
in	O
their	O
size	O
or	O
number	O
.	O
An	O
adenopathy	O
is	O
seen	O
in	O
the	O
right	O
obturator	O
region	O
with	O
slight	O
detectability	O
SUV	O
max	O
of	O
1	O
.	O
5	O
which	O
was	O
not	O
visualised	O
before	O
.	O
In	O
addition	O
,	O
there	O
are	O
still	O
innumerable	O
nodular	O
lesions	O
,	O
already	O
seen	O
in	O
the	O
previous	O
study	O
,	O
in	O
the	O
mesentery	O
,	O
although	O
with	O
an	O
overall	O
decrease	O
in	O
their	O
metabolism	O
and	O
size	O
.	O
The	O
lesion	O
previously	O
described	O
in	O
the	O
mesentery	O
,	O
at	O
the	O
right	O
pelvic	O
level	O
,	O
close	O
to	O
the	O
midline	O
,	O
is	O
not	O
currently	O
visible	O
,	O
which	O
suggests	O
a	O
probable	O
reactive	O
inflammatory	O
nature	O
as	O
there	O
is	O
no	O
evidence	O
of	O
new	O
treatments	O
since	O
the	O
last	O
PET	O
scan	O
.	O
In	O
the	O
localising	O
CT	O
scan	O
,	O
bilateral	O
pleural	O
effusion	O
is	O
seen	O
,	O
predominantly	O
on	O
the	O
right	O
,	O
without	O
metabolic	O
detectability	O
;	O
multiple	O
pseudonodular	O
infiltrates	O
are	O
also	O
seen	O
,	O
predominantly	O
in	O
the	O
bases	O
,	O
with	O
slight	O
metabolic	O
detectability	O
.	O
Conclusion	O
slight	O
metabolic	O
improvement	O
with	O
respect	O
to	O
the	O
previous	O
control	O
of	O
1	O
year	O
ago	O
with	O
persistence	O
of	O
detectable	O
supra	O
and	O
infradiaphragmatic	O
metabolic	O
lymphadenopathies	O
with	O
predominance	O
of	O
the	O
latter	O
location	O
.	O
Ergometry	O
SPECT	O
inconclusive	O
ergometry	O
due	O
to	O
not	O
reaching	O
submaximal	O
heart	O
rate	O
HR	O
.	O
Up	O
to	O
the	O
load	O
reached	O
5	O
METS	O
no	O
signs	O
of	O
ischaemia	O
were	O
observed	O
.	O
Chronotropic	O
incompetence	O
.	O
Slow	O
HR	O
recovery	O
.	O
Moderately	O
reduced	O
functional	O
capacity	O
64	O
of	O
predicted	O
.	O
ʟʟ	O
Gated	O
SPECT	O
of	O
myocardial	O
perfusion	O
is	O
performed	O
after	O
ergometric	O
stress	O
and	O
injection	O
of	O
the	O
radiopharmaceutical	O
at	O
the	O
time	O
of	O
maximum	O
stress	O
.	O
Delayed	O
resting	O
study	O
with	O
injection	O
of	O
the	O
same	O
activity	O
.	O
Two	O
day	O
protocol	O
.	O
The	O
images	O
obtained	O
post	O
stress	O
show	O
a	O
slight	O
perfusion	O
defect	O
in	O
the	O
basal	O
and	O
middle	O
segment	O
of	O
the	O
inferior	O
wall	O
that	O
remains	O
with	O
similar	O
characteristics	O
when	O
the	O
radiological	O
attenuation	O
correction	O
technique	O
is	O
applied	O
,	O
improving	O
moderately	O
in	O
the	O
resting	O
acquisition	O
.	O
There	O
is	O
also	O
an	O
increase	O
in	O
the	O
size	O
of	O
the	O
left	O
ventricle	O
in	O
the	O
post	O
stress	O
study	O
,	O
which	O
reaches	O
a	O
STV	O
of	O
approximately	O
101	O
ml	O
,	O
with	O
global	O
hypokinesia	O
in	O
the	O
stress	O
study	O
,	O
which	O
decreases	O
significantly	O
at	O
rest	O
,	O
also	O
improving	O
LVEF	O
.	O
In	O
the	O
GATED	O
study	O
,	O
the	O
following	O
functional	O
values	O
were	O
obtained	O
post	O
stress	O
rest	O
LVEF	O
29	O
52	O
,	O
STV	O
101	O
mL	O
62	O
mL	O
,	O
TDV	O
142	O
mL	O
131	O
mL	O
.	O
VTD	O
SC	O
80	O
mL	O
m2	O
at	O
stress	O
and	O
74	O
mL	O
m2	O
at	O
rest	O
.	O
Conclusion	O
findings	O
compatible	O
with	O
mild	O
moderate	O
and	O
moderately	O
extensive	O
stress	O
induced	O
lower	O
wall	O
ischaemia	O
,	O
with	O
transient	O
ventricular	O
dysfunction	O
at	O
post	O
stress	O
compared	O
to	O
rest	O
as	O
an	O
indirect	O
sign	O
of	O
severity	O
.	O
abdominal	O
ultrasound	O
liver	O
of	O
normal	O
size	O
with	O
homogeneous	O
echogenicity	O
and	O
regular	O
contours	O
without	O
evidence	O
of	O
focal	O
lesions	O
.	O
Portal	O
vein	O
of	O
normal	O
calibre	O
.	O
No	O
dilatation	O
of	O
the	O
suprahepatic	O
veins	O
.	O
Absence	O
of	O
gallbladder	O
and	O
spleen	O
due	O
to	O
previous	O
surgery	O
.	O
Retroperitoneal	O
region	O
not	O
adequately	O
assessed	O
due	O
to	O
intestinal	O
gas	O
interposition	O
.	O
Both	O
kidneys	O
are	O
of	O
normal	O
size	O
,	O
with	O
preserved	O
cortices	O
,	O
without	O
dilatation	O
of	O
the	O
excretory	O
tract	O
or	O
images	O
suggestive	O
of	O
lithiasis	O
.	O
No	O
free	O
fluid	O
was	O
seen	O
in	O
the	O
abdominal	O
cavity	O
.	O
Clinical	O
course	O
Given	O
the	O
presence	O
of	O
cardiovascular	O
risk	O
factors	O
,	O
it	O
was	O
decided	O
to	O
request	O
a	O
diagnostic	O
coronary	O
angiography	O
.	O
The	O
patient	O
showed	O
clinical	O
improvement	O
of	O
heart	O
failure	O
with	O
treatment	O
.	O
Coronary	O
angiography	O
coronary	O
arteries	O
without	O
significant	O
stenosis	O
.	O
Ventriculography	O
showed	O
a	O
slightly	O
dilated	O
left	O
ventricle	O
with	O
moderately	O
depressed	O
systolic	O
function	O
LVEF	O
38	O
and	O
global	O
hypokinesia	O
.	O
Absence	O
of	O
mitral	O
insufficiency	O
.	O
Given	O
that	O
the	O
coronary	O
angiography	O
was	O
normal	O
and	O
the	O
possible	O
aetiology	O
of	O
coronary	O
macroagiopathy	O
was	O
ruled	O
out	O
as	O
the	O
cause	O
of	O
the	O
ventricular	O
dysfunction	O
,	O
it	O
was	O
decided	O
to	O
request	O
an	O
outpatient	O
MRI	O
to	O
rule	O
out	O
infiltrative	O
lesions	O
probably	O
related	O
to	O
Castleman	O
's	O
disease	O
,	O
the	O
results	O
of	O
which	O
are	O
currently	O
pending	O
.	O
Diagnosis	O
Main	O
diagnosis	O
at	O
discharge	O
congestive	O
heart	O
failure	O
with	O
moderate	O
systolic	O
dysfunction	O
and	O
grade	O
III	O
diastolic	O
dysfunction	O
.	O
Secondary	O
diagnoses	O
non	O
valvular	O
paroxysmal	O
atrial	O
fibrillation	O
.	O
CHA2DS2	O
VASc	O
Score	O
2	O
high	O
embolic	O
risk	O
.	O
HAS	O
BLED	O
Score	O
0	O
low	O
bleeding	O
risk	O
.	O
Multicentric	O
Castleman	O
's	O
disease	O
.	O
Diabetes	O
mellitus	O
secondary	O
to	O
pancreatectomy	O
.	O
Treatment	O
salt	O
and	O
fat	O
free	O
diet	O
.	O
Daily	O
exercise	O
.	O
Medication	O
Pancreatin	B-FARMACO
10	O
,	O
000	O
U	O
3	O
tablets	O
at	O
breakfast	O
,	O
3	O
tablets	O
at	O
lunch	O
and	O
3	O
tablets	O
at	O
dinner	O
.	O
Continue	O
with	O
the	O
usual	O
regimen	O
of	O
novomix	B-FARMACO
26	O
IU	O
at	O
breakfast	O
,	O
14	O
IU	O
at	O
lunch	O
and	O
18	O
IU	O
at	O
dinner	O
.	O
Furosemide	B-FARMACO
40	O
mg	O
1	O
tablet	O
at	O
breakfast	O
and	O
half	O
a	O
tablet	O
at	O
lunch	O
.	O
Bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
1	O
2	O
tablet	O
at	O
breakfast	O
.	O
Rivaroxaban	B-FARMACO
20	O
mg	O
1	O
tablet	O
at	O
breakfast	O
.	O
Spironolactone	B-FARMACO
100	O
mg	O
1	O
2	O
tablet	O
at	O
breakfast	O
.	O
Ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
12	O
hours	O
.	O
Pantoprazole	B-FARMACO
40	O
mg	O
1	O
tablet	O
at	O
breakfast	O
.	O

A	O
43	O
year	O
old	O
man	O
with	O
human	O
immunodeficiency	O
virus	O
HIV	O
infection	O
for	O
at	O
least	O
ten	O
years	O
,	O
on	O
antiretroviral	O
treatment	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Hepatitis	O
C	O
1b	O
RNA	O
virus	O
infection	O
with	O
hypertransaminasemia	O
.	O
Probable	O
clinically	O
resolved	O
cerebral	O
toxoplasmosis	O
with	O
stable	O
residual	O
lesions	O
in	O
radiological	O
controls	O
.	O
Secondary	O
comic	O
crisis	O
,	O
without	O
recurrence	O
.	O
Ex	O
smoker	O
.	O
No	O
other	O
history	O
of	O
interest	O
.	O
As	O
usual	O
treatment	O
for	O
his	O
HIV	O
infection	O
the	O
patient	O
had	O
a	O
regimen	O
based	O
on	O
two	O
protease	O
inhibitors	O
atazanavir	B-FARMACO
ritonavir	I-FARMACO
together	O
with	O
a	O
combination	O
of	O
nucleoside	B-FARMACO
analogue	O
antiretrovirals	O
emtricitabine	B-FARMACO
tenofovir	I-FARMACO
.	O
The	O
patient	O
was	O
brought	O
to	O
the	O
emergency	O
department	O
after	O
starting	O
a	O
week	O
earlier	O
with	O
symptoms	O
of	O
respiratory	O
infection	O
,	O
followed	O
by	O
rapidly	O
progressive	O
dyspnoea	O
.	O
On	O
arrival	O
,	O
he	O
presented	O
with	O
severe	O
respiratory	O
distress	O
,	O
arterial	O
oxygen	O
desaturation	O
and	O
bronchospasm	O
,	O
so	O
400	O
mg	O
of	O
hydrocortisone	B-FARMACO
were	O
administered	O
together	O
with	O
nebulisations	O
of	O
salbutamol	B-FARMACO
and	O
ipratropium	B-FARMACO
bromide	I-FARMACO
.	O
Despite	O
this	O
,	O
he	O
presented	O
a	O
poor	O
clinical	O
evolution	O
,	O
with	O
progressive	O
arterial	O
desaturation	O
83	O
despite	O
high	O
flow	O
oxygen	O
therapy	O
and	O
marked	O
hypertension	O
200	O
100	O
mmHg	O
.	O
Auscultation	O
showed	O
bilateral	O
crackles	O
up	O
to	O
midfield	O
.	O
Chest	O
X	O
ray	O
showed	O
severe	O
cardiomegaly	O
and	O
bilateral	O
alveolar	O
oedema	O
compatible	O
with	O
acute	O
pulmonary	O
oedema	O
.	O
An	O
urgent	O
echocardiogram	O
showed	O
a	O
dilated	O
left	O
ventricle	O
with	O
very	O
severe	O
global	O
systolic	O
dysfunction	O
estimated	O
LVEF	O
of	O
15	O
,	O
with	O
severe	O
generalised	O
hypokinesia	O
,	O
and	O
severe	O
mitral	O
insufficiency	O
of	O
functional	O
origin	O
.	O
He	O
was	O
admitted	O
to	O
the	O
ICU	O
where	O
high	O
dose	O
intravenous	O
diuretic	O
treatment	O
and	O
non	O
invasive	O
mechanical	O
ventilation	O
were	O
started	O
,	O
stabilising	O
the	O
patient	O
and	O
initiating	O
progressive	O
clinical	O
improvement	O
over	O
the	O
following	O
hours	O
.	O
Serial	O
analyses	O
showed	O
elevated	O
markers	O
of	O
myocardial	O
damage	O
,	O
with	O
a	O
CPK	O
peak	O
of	O
3	O
,	O
300	O
and	O
troponin	O
I	O
of	O
6	O
.	O
He	O
presented	O
two	O
febrile	O
peaks	O
of	O
38	O
.	O
4oC	O
,	O
with	O
several	O
negative	O
blood	O
cultures	O
.	O
Complementary	O
tests	O
ECG	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
sinus	O
tachycardia	O
at	O
156	O
bpm	O
.	O
Left	O
axis	O
.	O
Signs	O
of	O
left	O
ventricular	O
hypertrophy	O
.	O
Anterior	O
and	O
inferior	O
Q	O
,	O
with	O
1	O
mm	O
ST	O
supradelevation	O
from	O
V1	O
to	O
V4	O
.	O
Echocardiogram	O
severely	O
dilated	O
left	O
ventricle	O
,	O
with	O
severely	O
reduced	O
systolic	O
function	O
ejection	O
fraction	O
by	O
Simpson	O
biplane	O
of	O
15	O
,	O
due	O
to	O
severe	O
generalised	O
hypokinesia	O
.	O
Severe	O
functional	O
mitral	O
insufficiency	O
.	O
Moderately	O
dilated	O
left	O
atrium	O
.	O
Right	O
ventricle	O
of	O
borderline	O
size	O
with	O
reduced	O
TAPSE	O
14	O
mm	O
.	O
Inferior	O
cava	O
not	O
dilated	O
with	O
inspiratory	O
collapse	O
present	O
.	O
Absence	O
of	O
tricuspid	O
insufficiency	O
to	O
estimate	O
pulmonary	O
artery	O
pressure	O
.	O
Minimal	O
detachment	O
of	O
pericardial	O
leaflets	O
.	O
Coronography	O
Left	O
common	O
trunk	O
of	O
good	O
calibre	O
with	O
no	O
notable	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
LAD	O
with	O
segment	O
with	O
severe	O
atheromatosis	O
that	O
includes	O
its	O
ostium	O
,	O
the	O
proximal	O
medial	O
LAD	O
and	O
the	O
ostium	O
of	O
the	O
first	O
diagonal	O
.	O
Critical	O
lesion	O
in	O
the	O
middle	O
LAD	O
.	O
Small	O
second	O
ramaseptal	O
with	O
severe	O
disease	O
and	O
very	O
thin	O
calibre	O
.	O
Circumflex	O
of	O
medium	O
calibre	O
and	O
good	O
development	O
with	O
severe	O
lesion	O
90	O
in	O
the	O
proximal	O
third	O
,	O
of	O
complex	O
appearance	O
.	O
Dominant	O
right	O
coronary	O
artery	O
,	O
with	O
diffuse	O
atheromatosis	O
,	O
multisegment	O
.	O
More	O
severe	O
lesion	O
in	O
distal	O
third	O
60	O
.	O
Moderate	O
lesion	O
in	O
posterolateral	O
branch	O
50	O
,	O
with	O
distal	O
bed	O
of	O
fine	O
calibre	O
.	O
Lipid	O
profile	O
cholesterol	O
241	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
41	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
179	O
mg	O
dl	O
,	O
triglycerides	O
104	O
mg	O
dl	O
0	O
.	O
0	O
150	O
.	O
0	O
.	O
Clinical	O
course	O
With	O
non	O
invasive	O
mechanical	O
ventilation	O
and	O
treatment	O
with	O
diuretics	O
and	O
vasodilators	O
,	O
the	O
patient	O
's	O
clinical	O
evolution	O
was	O
favourable	O
over	O
the	O
following	O
days	O
.	O
Once	O
the	O
heart	O
failure	O
was	O
resolved	O
,	O
a	O
study	O
of	O
dilated	O
cardiomyopathy	O
was	O
performed	O
,	O
suspecting	O
,	O
after	O
elevation	O
of	O
markers	O
of	O
myocardial	O
damage	O
,	O
ischaemic	O
origin	O
of	O
the	O
same	O
.	O
Coronary	O
angiography	O
showed	O
diffuse	O
three	O
vessel	O
coronary	O
artery	O
disease	O
,	O
with	O
severe	O
lesions	O
on	O
the	O
LAD	O
and	O
CX	O
,	O
which	O
were	O
treated	O
by	O
angioplasty	O
and	O
implantation	O
of	O
drug	O
eluting	O
stents	O
.	O
There	O
were	O
no	O
subsequent	O
complications	O
,	O
and	O
he	O
was	O
finally	O
discharged	O
with	O
medical	O
treatment	O
.	O
Diagnosis	O
Ischaemic	O
dilated	O
cardiomyopathy	O
in	O
a	O
patient	O
with	O
chronic	O
HIV	O
infection	O
.	O

Anamnesis	O
Male	O
,	O
79	O
years	O
old	O
.	O
Self	O
assisted	O
.	O
From	O
Salto	O
.	O
Pathological	O
history	O
Chronic	O
arterial	O
hypertension	O
.	O
Ex	O
smoker	O
.	O
Diabetes	O
mellitus	O
type	O
2	O
with	O
macro	O
and	O
microvascular	O
repercussions	O
ischaemic	O
heart	O
disease	O
,	O
arteriopathy	O
of	O
MMII	O
with	O
amputation	O
of	O
both	O
hallux	O
,	O
chronic	O
kidney	O
disease	O
,	O
diabetic	O
retinopathy	O
.	O
Aortic	O
valve	O
replacement	O
surgery	O
AVR	O
for	O
symptomatic	O
severe	O
aortic	O
stenosis	O
in	O
March	O
2015	O
together	O
with	O
myocardial	O
revascularisation	O
surgery	O
.	O
Current	O
illness	O
8	O
11	O
16	O
Infection	O
of	O
the	O
second	O
toe	O
of	O
the	O
right	O
foot	O
fluxive	O
signs	O
and	O
fever	O
which	O
led	O
to	O
consultation	O
in	O
Salto	O
,	O
oral	O
antibiotic	O
therapy	O
was	O
indicated	O
and	O
complied	O
with	O
for	O
seven	O
days	O
the	O
antibiotic	O
is	O
unknown	O
with	O
transient	O
remission	O
of	O
symptoms	O
.	O
15	O
11	O
16	O
Confusional	O
syndrome	O
,	O
fever	O
40o	O
C	O
axillary	O
and	O
dyspnoea	O
.	O
Reconsultation	O
at	O
the	O
hospital	O
in	O
Salto	O
.	O
On	O
examination	O
GCS	O
12	O
,	O
FR	O
26	O
rpm	O
,	O
BP	O
100	O
60mmHg	O
,	O
Ta	O
x	O
38	O
.	O
5o	O
.	O
Normal	O
colour	O
.	O
Splinter	O
haemorrhages	O
and	O
Osler	O
nodules	O
in	O
hands	O
.	O
PP	O
bibasal	O
crepitant	O
rales	O
.	O
CV	O
RR	O
110	O
cpm	O
,	O
holosystolic	O
ejective	O
murmur	O
2	O
6	O
in	O
mesocardium	O
,	O
IY	O
and	O
RHY	O
discrete	O
.	O
Abdomen	O
soft	O
and	O
painless	O
,	O
no	O
visceromegaly	O
.	O
PNM	O
consciousness	O
described	O
,	O
normal	O
meningeal	O
sector	O
,	O
no	O
alterations	O
of	O
cranial	O
nerves	O
or	O
spinal	O
level	O
.	O
MMII	O
amputation	O
of	O
both	O
hallux	O
,	O
second	O
toe	O
of	O
right	O
foot	O
with	O
wet	O
necrosis	O
.	O
Relevant	O
diagnostic	O
tests	O
RxTx	O
Redistribution	O
of	O
flow	O
to	O
both	O
vertexes	O
.	O
Congestive	O
hilae	O
.	O
Haemoglobin	O
10	O
g	O
dL	O
,	O
WBC	O
10000	O
mL	O
,	O
platelets	O
49000	O
mL	O
.	O
ESR	O
74	O
mm	O
h	O
.	O
Creatinemia	O
3	O
mg	O
dL	O
,	O
azoemia	O
153	O
mg	O
dL	O
.	O
Blood	O
gases	O
metabolic	O
acidosis	O
,	O
normal	O
ionogram	O
.	O
ECG	O
first	O
degree	O
atrioventricular	O
block	O
AVB	O
Blood	O
cultures	O
2	O
Staphylococcusaureusmethicillin	O
sensitive	O
Staphylococcus	O
SAMS	O
developed	O
Transesophageal	O
echocardiogram	O
TEE	O
18	O
11	O
normofunctioning	O
aortic	O
biological	O
prosthesis	O
,	O
aortic	O
valve	O
area	O
1	O
.	O
7	O
cm2	O
without	O
leaks	O
.	O
Rounded	O
7x7	O
mm	O
mass	O
adhering	O
to	O
the	O
free	O
edge	O
of	O
the	O
left	O
leaflet	O
and	O
projecting	O
into	O
the	O
aorta	O
in	O
systole	O
.	O
Mitral	O
valve	O
with	O
calcification	O
of	O
the	O
annulus	O
and	O
moderate	O
mitral	O
insufficiency	O
.	O
Assessment	O
of	O
complications	O
CT	O
abdomen	O
images	O
compatible	O
with	O
splenic	O
infarction	O
ECG	O
second	O
degree	O
AVB	O
Aggravation	O
of	O
renal	O
insufficiency	O
with	O
dialysis	O
requirement	O
Diagnosis	O
I	O
Infective	O
endocarditis	O
IE	O
on	O
prosthetic	O
aortic	O
valve	O
,	O
late	O
.	O
Aetiology	O
sensitive	O
Staphylococcus	O
aureus	O
methicillinus	O
SAMS	O
.	O
Complicated	O
with	O
heart	O
failure	O
,	O
valve	O
abscess	O
,	O
splenic	O
infarcts	O
and	O
renal	O
injury	O
.	O
Treatment	O
Cefazolin2g	B-FARMACO
c	O
8	O
hs	O
iv	O
;	O
gentamicin	B-FARMACO
3mg	O
kg	O
day	O
iv	O
;	O
rifampicin	B-FARMACO
600	O
mg	O
c	O
12	O
hsvo	O
.	O
Early	O
surgical	O
treatment	O
is	O
considered	O
.	O
Evolution	O
72	O
hours	O
after	O
starting	O
treatment	O
20	O
11	O
febrile	O
increased	O
pulmonary	O
oedema	O
.	O
Amputation	O
of	O
second	O
toe	O
.	O
Evolves	O
to	O
complete	O
AVB	O
requiring	O
transient	O
pacemaker	O
.	O
TEE	O
persists	O
in	O
very	O
mobile	O
mass	O
of	O
7x7	O
mm	O
attached	O
to	O
the	O
left	O
valvula	O
.	O
Mitroaortic	O
thickening	O
compatible	O
with	O
abscess	O
.	O
Mitral	O
valve	O
with	O
calcified	O
ring	O
,	O
small	O
masses	O
on	O
the	O
anterior	O
leaflet	O
on	O
the	O
atrial	O
side	O
,	O
mobile	O
.	O
Diagnosis	O
II	O
IE	O
to	O
late	O
prosthetic	O
aortic	O
SAMS	O
and	O
complicated	O
native	O
mitral	O
.	O
Cardiac	O
surgery	O
on	O
23	O
11	O
.	O
PreQ	O
prophylaxis	O
amikacin	B-FARMACO
1g	O
and	O
vancomycin	B-FARMACO
1g	O
.	O
Aortic	O
valve	O
replacement	O
and	O
mitral	O
valve	O
vegectomy	O
Culture	O
of	O
aortic	O
prosthetic	O
material	O
no	O
development	O
.	O
In	O
apyrexia	O
,	O
no	O
evidence	O
of	O
heart	O
failure	O
.	O
Confusional	O
syndrome	O
remitted	O
.	O
Pacemaker	O
was	O
removed	O
,	O
no	O
reinstalled	O
bradyarrhythmias	O
in	O
the	O
evolution	O
.	O
Improvement	O
of	O
renal	O
function	O
figures	O
.	O
Creatinemia	O
stable	O
at	O
2	O
mg	O
dl	O
.	O
Completed	O
6	O
weeks	O
of	O
antibiotic	O
treatment	O
after	O
surgery	O
with	O
cefazolin	B-FARMACO
and	O
rifampicin	B-FARMACO
,	O
having	O
completed	O
two	O
weeks	O
of	O
IV	O
gentamicin	B-FARMACO
.	O
Discharged	O
on	O
9	O
12	O
.	O

We	O
are	O
dealing	O
with	O
a	O
26	O
year	O
old	O
male	O
who	O
presented	O
to	O
the	O
Emergency	O
Department	O
for	O
dyspnoea	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Personal	O
history	O
Allergic	O
to	O
ASA	B-FARMACO
development	O
of	O
urticaria	O
and	O
angioedema	O
.	O
Smoker	O
of	O
1	O
pack	O
day	O
,	O
occasionally	O
marijuana	O
.	O
No	O
other	O
toxic	O
habits	O
.	O
Viral	O
myocarditis	O
about	O
ten	O
years	O
ago	O
,	O
diagnosed	O
in	O
Colombia	O
.	O
Admitted	O
the	O
previous	O
month	O
to	O
Cardiology	O
for	O
dyspnoea	O
,	O
diagnosed	O
with	O
rapid	O
ACFA	O
and	O
HF	O
,	O
requesting	O
voluntary	O
discharge	O
without	O
completing	O
the	O
study	O
.	O
Usual	O
treatment	O
Digoxin	B-FARMACO
1	O
.	O
0	O
.	O
0	O
.	O
0	O
,	O
Acovil	B-FARMACO
5	O
1	O
.	O
0	O
.	O
0	O
.	O
0	O
,	O
Seguril	B-FARMACO
1	O
.	O
1	O
.	O
0	O
,	O
which	O
the	O
patient	O
reported	O
not	O
taking	O
.	O
Current	O
illness	O
Progressive	O
dyspnoea	O
of	O
3	O
4	O
weeks	O
'	O
evolution	O
,	O
which	O
in	O
the	O
last	O
few	O
days	O
has	O
become	O
minimal	O
effort	O
,	O
together	O
with	O
orthopnoea	O
,	O
cough	O
and	O
non	O
thermometric	O
dysthermic	O
sensation	O
.	O
He	O
denies	O
chest	O
pain	O
,	O
palpitations	O
or	O
other	O
accompanying	O
organotropic	O
symptoms	O
.	O
General	O
examination	O
BP	O
104	O
72	O
mm	O
Hg	O
,	O
HR	O
176	O
bpm	O
,	O
Ta	O
36	O
.	O
7	O
oC	O
,	O
baseline	O
Sat02	O
94	O
.	O
The	O
patient	O
is	O
conscious	O
,	O
oriented	O
,	O
well	O
hydrated	O
and	O
perfused	O
,	O
normocholoured	O
and	O
eupneic	O
at	O
rest	O
.	O
C	O
C	O
No	O
IY	O
.	O
AC	O
Arrhythmic	O
,	O
pansystolic	O
murmur	O
in	O
mitral	O
focus	O
,	O
with	O
3rd	O
noise	O
.	O
AP	O
bibasal	O
crackles	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
sounds	O
present	O
.	O
No	O
liver	O
or	O
splenomegaly	O
.	O
No	O
peritonism	O
.	O
Lower	O
extremities	O
No	O
oedema	O
or	O
signs	O
of	O
DVT	O
.	O
Pedial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
Complementary	O
tests	O
ECG	O
thick	O
wave	O
ACFA	O
at	O
170	O
180	O
bpm	O
.	O
Axis	O
a	O
60o	O
.	O
Rest	O
of	O
the	O
tracing	O
normal	O
.	O
Chest	O
X	O
ray	O
Cardiomegaly	O
,	O
with	O
aneurysmal	O
LA	O
.	O
No	O
obvious	O
condensation	O
.	O
Interstitial	O
pattern	O
.	O
Laboratory	O
tests	O
Biochemistry	O
and	O
haemacytometry	O
normal	O
.	O
INR	O
1	O
.	O
07	O
.	O
Chagas	O
serology	O
Negative	O
.	O
Urine	O
toxicity	O
Positive	O
for	O
Cannabis	O
.	O
Echocardiography	O
severely	O
dilated	O
LV	O
,	O
with	O
increased	O
wall	O
thickness	O
,	O
and	O
increased	O
trabeculation	O
,	O
especially	O
in	O
the	O
mid	O
apical	O
segments	O
of	O
the	O
entire	O
ventricle	O
,	O
respecting	O
the	O
basal	O
segments	O
,	O
with	O
very	O
severe	O
trabeculation	O
throughout	O
the	O
apex	O
the	O
findings	O
were	O
confirmed	O
after	O
administration	O
of	O
echocardiographic	O
contrast	O
.	O
Severe	O
systolic	O
dysfunction	O
EF	O
by	O
Simpson	O
biplane	O
27	O
.	O
DTD	O
66	O
;	O
DTS	O
55	O
.	O
Aneurysmal	O
LA	O
80	O
mm	O
.	O
Fibrotic	O
and	O
thickened	O
mitral	O
valve	O
with	O
severe	O
MR	O
directed	O
towards	O
the	O
posterolateral	O
wall	O
of	O
the	O
LV	O
,	O
secondary	O
to	O
annular	O
dilatation	O
and	O
tenting	O
with	O
pseudoprolapse	O
of	O
the	O
anterior	O
leaflet	O
.	O
Normofunctioning	O
trivalve	O
aortic	O
valve	O
.	O
Slightly	O
dilated	O
right	O
chambers	O
.	O
RV	O
with	O
moderate	O
severe	O
dysfunction	O
TAPSE	O
of	O
14	O
mm	O
and	O
tricuspid	O
annulus	O
S	O
wave	O
of	O
6	O
cm	O
s	O
.	O
Mild	O
TR	O
with	O
RV	O
AD	O
gradient	O
of	O
40	O
estimated	O
PSAP	O
of	O
60	O
as	O
the	O
inferior	O
vena	O
cava	O
is	O
26	O
mm	O
,	O
without	O
inspiratory	O
collapse	O
.	O
Slight	O
pericardial	O
effusion	O
.	O
MRI	O
LV	O
severely	O
dilated	O
with	O
severely	O
depressed	O
global	O
and	O
segmental	O
systolic	O
dysfunction	O
with	O
preserved	O
diffuse	O
hypokinesia	O
.	O
EF	O
29	O
.	O
Absence	O
of	O
compaction	O
except	O
in	O
basal	O
segments	O
and	O
medial	O
septum	O
with	O
a	O
ratio	O
of	O
non	O
compacted	O
myocardium	O
compacted	O
myocardium	O
greater	O
than	O
3	O
1	O
At	O
the	O
level	O
of	O
the	O
lateral	O
apical	O
face	O
,	O
findings	O
compatible	O
with	O
non	O
compacted	O
cardiomyopathy	O
.	O
No	O
RV	O
involvement	O
is	O
demonstrated	O
.	O
No	O
thrombi	O
are	O
visualised	O
.	O
Thinning	O
of	O
the	O
compacted	O
myocardium	O
in	O
the	O
affected	O
segments	O
,	O
especially	O
in	O
the	O
mid	O
anterior	O
face	O
with	O
a	O
thickness	O
of	O
4	O
mm	O
in	O
the	O
end	O
diastolic	O
phase	O
.	O
Severe	O
dilatation	O
of	O
the	O
left	O
atrium	O
.	O
Mitral	O
insufficiency	O
which	O
appears	O
significant	O
.	O
Small	O
pericardial	O
effusion	O
.	O
Non	O
dilated	O
RV	O
with	O
moderate	O
dysfunction	O
.	O
EF	O
31	O
.	O
In	O
the	O
late	O
enhancement	O
sequences	O
no	O
pathological	O
uptakes	O
are	O
seen	O
.	O
Clinical	O
course	O
The	O
patient	O
was	O
diagnosed	O
with	O
non	O
compaction	O
cardiomyopathy	O
with	O
severe	O
LV	O
dysfunction	O
.	O
Medical	O
treatment	O
was	O
started	O
with	O
diuretics	O
,	O
ACE	O
inhibitors	O
,	O
beta	O
blockers	O
,	O
aldosterone	O
inhibitors	O
and	O
oral	O
anticoagulants	O
,	O
with	O
rapid	O
clinical	O
improvement	O
.	O
After	O
completing	O
the	O
study	O
,	O
it	O
was	O
decided	O
to	O
discharge	O
him	O
home	O
with	O
the	O
treatment	O
described	O
above	O
,	O
with	O
subsequent	O
appointments	O
at	O
our	O
hospital	O
's	O
Heart	O
Failure	O
Department	O
.	O
First	O
degree	O
relatives	O
were	O
contacted	O
to	O
perform	O
a	O
structural	O
study	O
,	O
by	O
means	O
of	O
echocardiography	O
and	O
genetic	O
testing	O
.	O
Diagnosis	O
Non	O
compaction	O
cardiomyopathy	O
with	O
severe	O
left	O
ventricular	O
systolic	O
dysfunction	O
Severe	O
mitral	O
insufficiency	O
Atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O

61	O
year	O
old	O
woman	O
with	O
a	O
history	O
of	O
high	O
blood	O
pressure	O
and	O
smoking	O
.	O
Family	O
history	O
a	O
sister	O
who	O
"	O
suffers	O
from	O
heart	O
disease	O
"	O
,	O
with	O
no	O
other	O
relevant	O
data	O
.	O
History	O
,	O
current	O
disease	O
and	O
physical	O
examination	O
Her	O
medical	O
history	O
includes	O
a	O
transthoracic	O
echocardiography	O
in	O
2010	O
with	O
the	O
following	O
data	O
Obstructive	O
hypertrophic	O
cardiomyopathy	O
.	O
Moderate	O
MI	O
.	O
Normal	O
LV	O
systolic	O
function	O
.	O
Slightly	O
dilated	O
LA	O
LA	O
volume	O
30	O
ml	O
m2	O
.	O
LV	O
hypertrophy	O
mainly	O
at	O
the	O
level	O
of	O
the	O
interventricular	O
septum	O
.	O
Mitral	O
valve	O
function	O
with	O
incomplete	O
SAM	O
and	O
dynamic	O
gradient	O
in	O
LVOT	O
Baseline	O
40	O
mmHg	O
,	O
which	O
after	O
Valsalva	O
manoeuvres	O
reaches	O
up	O
to	O
57	O
mmHg	O
.	O
The	O
patient	O
had	O
not	O
undergone	O
subsequent	O
follow	O
up	O
.	O
She	O
came	O
to	O
the	O
emergency	O
department	O
in	O
November	O
2012	O
,	O
reporting	O
a	O
progressive	O
increase	O
in	O
dyspnoea	O
for	O
about	O
four	O
months	O
,	O
which	O
in	O
recent	O
weeks	O
has	O
evolved	O
rapidly	O
to	O
the	O
point	O
of	O
becoming	O
resting	O
,	O
and	O
which	O
is	O
accompanied	O
by	O
intense	O
asthenia	O
.	O
He	O
denies	O
other	O
associated	O
cardiological	O
or	O
infectious	O
symptoms	O
.	O
She	O
denies	O
a	O
history	O
of	O
palpitations	O
or	O
syncope	O
.	O
Examination	O
revealed	O
the	O
presence	O
of	O
an	O
intense	O
systolic	O
murmur	O
on	O
cardiac	O
auscultation	O
,	O
predominantly	O
in	O
the	O
left	O
parasternal	O
border	O
,	O
which	O
increased	O
with	O
Valsalva	O
manoeuvres	O
and	O
did	O
not	O
clear	O
the	O
second	O
tone	O
.	O
There	O
was	O
also	O
a	O
loud	O
regurgitation	O
murmur	O
in	O
the	O
mitral	O
focus	O
radiating	O
to	O
the	O
axilla	O
.	O
Pulmonary	O
auscultation	O
showed	O
crackles	O
up	O
to	O
the	O
apex	O
and	O
generalised	O
wheezing	O
.	O
A	O
symmetrical	O
magnus	O
and	O
celer	O
pulse	O
was	O
palpated	O
.	O
Otherwise	O
he	O
is	O
haemodynamically	O
stable	O
with	O
basal	O
saturation	O
of	O
90	O
and	O
blood	O
pressure	O
of	O
183	O
89	O
.	O
Heart	O
rate	O
73	O
bpm	O
.	O
Complementary	O
tests	O
ECG	O
On	O
admission	O
with	O
sinus	O
rhythm	O
at	O
76	O
bpm	O
.	O
Doubtful	O
ST	O
elevation	O
,	O
1mm	O
in	O
V1	O
,	O
similar	O
to	O
previous	O
ECG	O
.	O
Criteria	O
for	O
left	O
ventricular	O
hypertrophy	O
.	O
Chest	O
X	O
ray	O
shows	O
borderline	O
CTI	O
and	O
bilateral	O
centrifugal	O
alveolar	O
infiltrate	O
.	O
Laboratory	O
tests	O
showed	O
BNP	O
of	O
3	O
,	O
000	O
with	O
no	O
other	O
relevant	O
alterations	O
.	O
Transthoracic	O
echocardiogram	O
Performed	O
during	O
his	O
admission	O
to	O
the	O
Cardiology	O
Department	O
of	O
our	O
hospital	O
.	O
It	O
reflected	O
the	O
following	O
findings	O
LVH	O
data	O
with	O
interventricular	O
septum	O
of	O
27	O
mm	O
,	O
LV	O
posterior	O
wall	O
of	O
20	O
mm	O
.	O
Gradient	O
across	O
the	O
LVOT	O
reaching	O
120	O
mmHg	O
.	O
Presence	O
of	O
systolic	O
anterior	O
motion	O
of	O
the	O
anterior	O
leaflet	O
of	O
the	O
mitral	O
valve	O
contributing	O
to	O
the	O
mechanism	O
of	O
moderate	O
severe	O
MI	O
.	O
24	O
hour	O
Holter	O
ECG	O
Showing	O
sinus	O
rhythm	O
throughout	O
the	O
recording	O
,	O
with	O
high	O
density	O
polymorphic	O
ventricular	O
extrasystoles	O
,	O
isolated	O
,	O
sparsely	O
bigeminy	O
and	O
in	O
pairs	O
,	O
as	O
well	O
as	O
several	O
bouts	O
of	O
ventricular	O
tachycardia	O
,	O
the	O
most	O
prolonged	O
of	O
eight	O
beats	O
.	O
No	O
pathological	O
pauses	O
.	O
Haemodynamic	O
study	O
hypertrophic	O
cardiomyopathy	O
with	O
a	O
dynamic	O
gradient	O
of	O
130	O
to	O
140	O
mmHg	O
,	O
accompanied	O
by	O
severe	O
mitral	O
insufficiency	O
III	O
IV	O
.	O
Coronary	O
angiography	O
showed	O
no	O
significant	O
lesions	O
and	O
evidenced	O
the	O
existence	O
of	O
an	O
anatomically	O
adequate	O
septal	O
branch	O
for	O
septal	O
ablation	O
.	O
Clinical	O
evolution	O
With	O
this	O
information	O
,	O
the	O
existing	O
therapeutic	O
possibilities	O
were	O
discussed	O
with	O
the	O
patient	O
,	O
who	O
opted	O
to	O
undergo	O
percutaneous	O
septal	O
ablation	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
haemodynamics	O
room	O
where	O
,	O
under	O
sedation	O
,	O
the	O
intervention	O
was	O
performed	O
.	O
The	O
MCP	O
cable	O
was	O
placed	O
in	O
the	O
right	O
ventricle	O
with	O
access	O
through	O
the	O
right	O
femoral	O
vein	O
.	O
A	O
balloon	O
catheter	O
was	O
introduced	O
via	O
the	O
arterial	O
route	O
through	O
the	O
left	O
coronary	O
artery	O
until	O
it	O
reached	O
the	O
first	O
septal	O
branch	O
.	O
Subsequently	O
,	O
the	O
expected	O
response	O
to	O
ischaemia	O
induced	O
by	O
occluding	O
the	O
first	O
septal	O
branch	O
by	O
inflating	O
the	O
balloon	O
at	O
that	O
level	O
,	O
together	O
with	O
the	O
injection	O
of	O
echocardiographic	O
contrast	O
,	O
is	O
assessed	O
by	O
echocardiographic	O
support	O
.	O
Induction	O
of	O
ischaemia	O
in	O
the	O
desired	O
proximal	O
septal	O
region	O
is	O
verified	O
,	O
as	O
well	O
as	O
a	O
fall	O
in	O
the	O
gradient	O
across	O
the	O
LVOT	O
,	O
so	O
alcohol	O
is	O
infused	O
in	O
this	O
area	O
.	O
At	O
this	O
point	O
the	O
patient	O
becomes	O
dependent	O
on	O
MCP	O
pacing	O
.	O
After	O
a	O
few	O
minutes	O
,	O
a	O
significant	O
drop	O
in	O
the	O
gradient	O
to	O
70	O
mmHg	O
and	O
a	O
decrease	O
in	O
mitral	O
regurgitation	O
was	O
observed	O
.	O
Angiographically	O
,	O
a	O
small	O
sub	O
branch	O
of	O
the	O
aforementioned	O
septal	O
branch	O
was	O
observed	O
to	O
be	O
permeable	O
,	O
so	O
an	O
additional	O
1cc	O
of	O
absolute	O
alcohol	O
was	O
infused	O
,	O
bringing	O
the	O
gradient	O
down	O
a	O
further	O
10	O
mmHg	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
Coronary	O
Unit	O
with	O
alternating	O
pacing	O
and	O
pacemaker	O
pacing	O
,	O
and	O
in	O
a	O
stable	O
haemodynamic	O
condition	O
.	O
Enzyme	O
seriation	O
showed	O
a	O
peak	O
troponin	O
level	O
of	O
90	O
ng	O
dL	O
.	O
No	O
malignant	O
ventricular	O
arrhythmias	O
were	O
recorded	O
in	O
the	O
monitoring	O
and	O
given	O
the	O
good	O
evolution	O
of	O
the	O
patient	O
,	O
it	O
was	O
decided	O
to	O
transfer	O
her	O
to	O
the	O
ward	O
after	O
72	O
hours	O
.	O
On	O
admission	O
,	O
the	O
woman	O
presented	O
with	O
severe	O
acute	O
pulmonary	O
oedema	O
in	O
the	O
context	O
of	O
heart	O
failure	O
due	O
to	O
severe	O
obstruction	O
of	O
the	O
left	O
ventricular	O
outflow	O
tract	O
and	O
associated	O
mitral	O
insufficiency	O
.	O
Symptomatic	O
treatment	O
was	O
initiated	O
with	O
careful	O
use	O
of	O
diuretics	O
and	O
lusotopics	O
,	O
and	O
after	O
reaching	O
the	O
diagnosis	O
by	O
careful	O
examination	O
and	O
imaging	O
techniques	O
,	O
the	O
patient	O
was	O
offered	O
the	O
available	O
treatment	O
options	O
.	O
At	O
discharge	O
,	O
there	O
was	O
still	O
a	O
high	O
gradient	O
,	O
around	O
60	O
mmHg	O
,	O
and	O
moderate	O
mitral	O
regurgitation	O
,	O
but	O
the	O
patient	O
showed	O
a	O
marked	O
symptomatic	O
improvement	O
,	O
being	O
eupneic	O
in	O
decubitus	O
,	O
with	O
good	O
tolerance	O
to	O
the	O
onset	O
of	O
physical	O
activity	O
and	O
in	O
a	O
clinical	O
situation	O
that	O
she	O
described	O
as	O
excellent	O
.	O
She	O
was	O
discharged	O
with	O
generous	O
doses	O
of	O
lusotopic	O
treatment	O
and	O
was	O
soon	O
to	O
be	O
reviewed	O
by	O
the	O
Cardiology	O
Department	O
.	O
Diagnosis	O
Heart	O
failure	O
with	O
acute	O
pulmonary	O
oedema	O
.	O
Hypertrophic	O
obstructive	O
cardiomyopathy	O
with	O
severe	O
LVOT	O
obstruction	O
.	O
Treated	O
by	O
percutaneous	O
alcohol	O
ablation	O
of	O
the	O
first	O
septal	O
branch	O
.	O
Complete	O
AV	O
block	O
during	O
the	O
procedure	O
resolved	O
at	O
discharge	O
.	O
Moderate	O
mitral	O
insufficiency	O
.	O

A	O
71	O
year	O
old	O
woman	O
came	O
to	O
the	O
emergency	O
department	O
with	O
a	O
sensation	O
of	O
continuous	O
precordial	O
palpitation	O
accompanied	O
by	O
dyspnoea	O
at	O
rest	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
71	O
year	O
old	O
woman	O
with	O
slowly	O
progressive	O
dyspnoea	O
of	O
2	O
years	O
'	O
evolution	O
,	O
reaching	O
functional	O
class	O
II	O
IV	O
.	O
Arterial	O
hypertension	O
,	O
type	O
2	O
diabetes	O
mellitus	O
.	O
She	O
denies	O
toxic	O
habits	O
.	O
Multiple	O
visits	O
to	O
the	O
Emergency	O
Department	O
for	O
non	O
condensing	O
respiratory	O
infection	O
and	O
bronchial	O
hyperreactivity	O
for	O
approximately	O
10	O
years	O
.	O
Habitual	O
orthopnoea	O
for	O
which	O
he	O
uses	O
two	O
pillows	O
.	O
Usual	O
treatment	O
Metformin	B-FARMACO
,	O
enalapril	B-FARMACO
,	O
hydrochlorothiazide	B-FARMACO
,	O
inhaled	O
bronchodilators	O
irregularly	O
.	O
He	O
presents	O
progressive	O
clinical	O
worsening	O
in	O
the	O
last	O
2	O
months	O
,	O
reports	O
occasional	O
chest	O
palpitations	O
,	O
dyspnoea	O
on	O
minimal	O
exertion	O
,	O
worsening	O
of	O
his	O
orthopnoea	O
requiring	O
greater	O
inclination	O
to	O
sleep	O
,	O
oedematisation	O
of	O
the	O
lower	O
limbs	O
,	O
asthenia	O
and	O
adynamia	O
.	O
She	O
denies	O
infectious	O
symptoms	O
and	O
has	O
never	O
presented	O
episodes	O
of	O
chest	O
pain	O
.	O
In	O
the	O
last	O
3	O
days	O
she	O
presented	O
with	O
a	O
sensation	O
of	O
continuous	O
precordial	O
palpitation	O
accompanied	O
by	O
dyspnoea	O
at	O
rest	O
,	O
which	O
prompted	O
her	O
to	O
go	O
to	O
the	O
emergency	O
department	O
.	O
Examination	O
on	O
admission	O
Conscious	O
,	O
oriented	O
,	O
reactive	O
,	O
perceptive	O
.	O
Heart	O
rate	O
120	O
bpm	O
,	O
respiratory	O
rate	O
30	O
rpm	O
,	O
BP	O
117	O
70	O
mmHg	O
.	O
Jugular	O
ingurgitation	O
at	O
45	O
degrees	O
.	O
Tachycardic	O
and	O
arrhythmic	O
heart	O
tones	O
,	O
fixed	O
split	O
second	O
tone	O
.	O
Opening	O
snap	O
.	O
Diffusely	O
diminished	O
vescicular	O
murmur	O
with	O
expiratory	O
wheezing	O
and	O
crepitant	O
rales	O
up	O
to	O
midfields	O
.	O
Oedema	O
of	O
lower	O
limbs	O
up	O
to	O
middle	O
third	O
of	O
both	O
legs	O
.	O
Complementary	O
tests	O
Haemogram	O
Hb	O
13	O
g	O
dL	O
,	O
HTC	O
39	O
,	O
leucocytes	O
8	O
,	O
760	O
mm3	O
,	O
platelets	O
201	O
,	O
000	O
mm3	O
.	O
Biochemistry	O
glucose	O
108	O
mg	O
dL	O
,	O
creatinine	O
0	O
.	O
79	O
mg	O
dL	O
,	O
sodium	O
138	O
mEq	O
L	O
,	O
potassium	O
4	O
mEq	O
L	O
,	O
chlorine	O
101	O
mEq	O
L	O
.	O
Electrocardiogram	O
Atrial	O
fibrillation	O
with	O
RVR	O
at	O
120	O
bpm	O
,	O
normal	O
axis	O
,	O
without	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
Cardio	O
thoracic	O
index	O
increased	O
with	O
dilatation	O
of	O
RA	O
and	O
pulmonary	O
arteries	O
,	O
small	O
aortic	O
button	O
.	O
Increased	O
pulmonary	O
capillary	O
pressure	O
.	O
Pulmonary	O
parenchyma	O
without	O
significant	O
pathological	O
findings	O
.	O
Transthoracic	O
echocardiogram	O
transesophageal	O
echocardiogram	O
Dilated	O
right	O
chambers	O
,	O
LA	O
46	O
mm	O
.	O
Thickened	O
rheumatic	O
mitral	O
valve	O
with	O
calcified	O
annulus	O
and	O
reduced	O
opening	O
.	O
Mitral	O
planimetry	O
of	O
1	O
.	O
15	O
.	O
Aortic	O
valve	O
with	O
normal	O
opening	O
.	O
Left	O
ventricle	O
of	O
normal	O
geometry	O
and	O
volume	O
with	O
homogeneous	O
contraction	O
and	O
preserved	O
contractility	O
.	O
Aneurysm	O
of	O
the	O
fossa	O
ovalis	O
with	O
CIA	O
ostium	O
secundum	O
of	O
12	O
mm	O
.	O
Cavae	O
and	O
suprahepatic	O
normal	O
.	O
Doppler	O
Stenotic	O
mitral	O
filling	O
in	O
AF	O
with	O
Hattle	O
area	O
of	O
1	O
.	O
2	O
cm2	O
.	O
Mild	O
TR	O
.	O
PSP	O
50	O
mmHg	O
.	O
Flow	O
at	O
the	O
level	O
of	O
the	O
fossa	O
ovalis	O
I	O
D	O
of	O
moderate	O
amount	O
.	O
Wilkins	O
score	O
11	O
points	O
.	O
Clinical	O
evolution	O
He	O
was	O
hospitalised	O
in	O
the	O
Cardiology	O
ward	O
where	O
he	O
evolved	O
satisfactorily	O
,	O
responding	O
favourably	O
to	O
the	O
depletive	O
management	O
.	O
She	O
spontaneously	O
reverted	O
to	O
sinus	O
rhythm	O
and	O
showed	O
marked	O
symptomatic	O
improvement	O
,	O
mainly	O
by	O
reducing	O
her	O
dyspnoea	O
.	O
Cardiac	O
catheterisation	O
showed	O
diffuse	O
coronary	O
atherosclerosis	O
without	O
significant	O
coronary	O
lesions	O
.	O
Calcified	O
mitral	O
valve	O
with	O
moderate	O
severe	O
stenosis	O
.	O
Gorlin	O
area	O
of	O
1	O
cm2	O
with	O
mean	O
gradient	O
of	O
8	O
mmHg	O
without	O
end	O
diastolic	O
gradient	O
due	O
to	O
restrictive	O
ASD	O
.	O
Mean	O
RA	O
pressure	O
of	O
14	O
mmHg	O
through	O
which	O
I	O
D	O
shunt	O
of	O
2	O
.	O
55	O
occurs	O
.	O
Moderate	O
mixed	O
passive	O
hyperdynamic	O
passive	O
pulmonary	O
hypertension	O
.	O
Reduced	O
IC	O
.	O
Preserved	O
LVEF	O
.	O
Occlusion	O
test	O
A	O
significant	O
increase	O
in	O
mean	O
LA	O
pressure	O
was	O
observed	O
with	O
increased	O
transmitral	O
gradients	O
and	O
increased	O
interlocking	O
pressure	O
,	O
demonstrating	O
the	O
presence	O
of	O
severe	O
mitral	O
stenosis	O
.	O
The	O
case	O
was	O
presented	O
at	O
SMQ	O
and	O
it	O
was	O
decided	O
to	O
perform	O
mitral	O
valve	O
replacement	O
and	O
closure	O
of	O
the	O
ASD	O
.	O
Diagnosis	O
Severe	O
rheumatic	O
aortic	O
stenosis	O
Atrial	O
septal	O
defect	O
,	O
ostium	O
secundum	O
type	O
Lutembacher	O
's	O
syndrome	O

42	O
year	O
old	O
male	O
presenting	O
with	O
chest	O
pain	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Personal	O
history	O
Rheumatic	O
fever	O
in	O
childhood	O
.	O
IQ	O
Osteosynthesis	O
in	O
EID	O
.	O
Seaman	O
by	O
profession	O
.	O
No	O
usual	O
treatment	O
.	O
AF	O
Brother	O
died	O
at	O
35	O
years	O
of	O
age	O
due	O
to	O
AMI	O
.	O
Present	O
illness	O
42	O
year	O
old	O
male	O
presenting	O
with	O
epigastric	O
and	O
oppressive	O
precordial	O
pain	O
associated	O
with	O
vegetative	O
cortex	O
lasting	O
3	O
hours	O
.	O
The	O
previous	O
month	O
he	O
had	O
presented	O
with	O
sinusitis	O
treated	O
with	O
antibiotics	O
.	O
In	O
view	O
of	O
his	O
clinical	O
presentation	O
,	O
he	O
went	O
to	O
his	O
health	O
centre	O
,	O
where	O
an	O
ECG	O
was	O
performed	O
.	O
Physical	O
examination	O
Patient	O
conscious	O
and	O
oriented	O
.	O
Eupneic	O
.	O
BP	O
130	O
90	O
mmHg	O
,	O
HR	O
73	O
bpm	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
no	O
pathological	O
findings	O
.	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
DVT	O
.	O
Distal	O
pulses	O
present	O
and	O
symmetrical	O
.	O
Complementary	O
tests	O
ECG	O
regular	O
wide	O
QRS	O
tachycardia	O
,	O
220	O
bpm	O
,	O
right	O
bundle	O
branch	O
block	O
morphology	O
and	O
superior	O
axis	O
.	O
Catheterisation	O
Coronary	O
angiography	O
No	O
angiographically	O
significant	O
coronary	O
lesions	O
.	O
Left	O
ventriculography	O
Severe	O
systolic	O
dysfunction	O
.	O
Laboratory	O
tests	O
Peak	O
TnT	O
ultrasensitive	O
peak	O
of	O
267	O
ng	O
L	O
.	O
Echocardiogram	O
3	O
days	O
after	O
admission	O
non	O
dilated	O
left	O
ventricle	O
with	O
slightly	O
depressed	O
global	O
systolic	O
function	O
and	O
severe	O
hypokinesia	O
of	O
the	O
basal	O
and	O
middle	O
segments	O
of	O
the	O
lateral	O
,	O
inferior	O
and	O
posterior	O
face	O
,	O
without	O
significant	O
valvulopathies	O
.	O
Cardiac	O
MRI	O
Hypokinesia	O
of	O
mid	O
apical	O
segments	O
of	O
the	O
lateral	O
face	O
and	O
akinesia	O
of	O
the	O
basal	O
segment	O
of	O
the	O
lateral	O
face	O
.	O
In	O
the	O
late	O
myocardial	O
enhancement	O
series	O
,	O
subepicardial	O
base	O
uptake	O
is	O
demonstrated	O
,	O
respecting	O
the	O
subendocardium	O
,	O
affecting	O
lateral	O
and	O
inferior	O
segments	O
at	O
basal	O
and	O
mid	O
level	O
.	O
Mild	O
pericardial	O
effusion	O
.	O
Findings	O
compatible	O
with	O
acute	O
myocarditis	O
.	O
Electrophysiological	O
study	O
Using	O
a	O
digital	O
anatomical	O
reconstruction	O
system	O
,	O
two	O
areas	O
of	O
subventricular	O
eschar	O
are	O
evident	O
.	O
Ventricular	O
tachycardias	O
of	O
the	O
same	O
morphology	O
as	O
that	O
presented	O
by	O
the	O
patient	O
on	O
admission	O
were	O
induced	O
on	O
several	O
occasions	O
,	O
but	O
with	O
poor	O
clinical	O
tolerance	O
that	O
prevented	O
their	O
mapping	O
and	O
forced	O
them	O
to	O
be	O
terminated	O
with	O
over	O
stimulation	O
.	O
Finally	O
,	O
it	O
was	O
decided	O
to	O
perform	O
several	O
radiofrequency	O
applications	O
around	O
the	O
bedsores	O
in	O
sinus	O
rhythm	O
.	O
Clinical	O
evolution	O
In	O
view	O
of	O
the	O
patient	O
's	O
clinical	O
and	O
ECG	O
findings	O
,	O
the	O
Emergency	O
Department	O
was	O
notified	O
,	O
who	O
prescribed	O
sedation	O
and	O
performed	O
synchronised	O
ECV	O
at	O
100J	O
,	O
reverting	O
to	O
sinus	O
rhythm	O
,	O
and	O
the	O
patient	O
was	O
subsequently	O
transferred	O
to	O
the	O
Intensive	O
Care	O
Unit	O
of	O
his	O
referral	O
hospital	O
.	O
At	O
the	O
centre	O
,	O
coronary	O
angiography	O
and	O
serial	O
analyses	O
were	O
performed	O
,	O
with	O
the	O
aforementioned	O
results	O
.	O
Once	O
clinical	O
stability	O
was	O
achieved	O
,	O
the	O
patient	O
was	O
discharged	O
to	O
the	O
hospital	O
ward	O
and	O
treatment	O
was	O
started	O
with	O
ACE	O
inhibitors	O
and	O
beta	O
blockers	O
with	O
good	O
clinical	O
tolerance	O
.	O
An	O
echocardiogram	O
was	O
performed	O
,	O
which	O
showed	O
an	O
improvement	O
in	O
left	O
ventricular	O
function	O
compared	O
to	O
the	O
ventriculography	O
performed	O
on	O
admission	O
,	O
and	O
cardiac	O
MRI	O
,	O
with	O
findings	O
compatible	O
with	O
acute	O
myocarditis	O
.	O
Following	O
an	O
electrophysiological	O
study	O
,	O
an	O
ICD	O
was	O
implanted	O
without	O
incident	O
,	O
and	O
the	O
patient	O
was	O
discharged	O
home	O
with	O
ACE	O
inhibitors	O
and	O
beta	O
blockers	O
.	O
Diagnosis	O
Sustained	O
monomorphic	O
ventricular	O
tachycardia	O
reverted	O
to	O
sinus	O
rhythm	O
with	O
CVE	O
in	O
the	O
context	O
of	O
probable	O
acute	O
myocarditis	O
.	O

A	O
47	O
year	O
old	O
male	O
patient	O
came	O
to	O
our	O
centre	O
to	O
rule	O
out	O
acute	O
coronary	O
syndrome	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
A	O
47	O
year	O
old	O
male	O
patient	O
from	O
the	O
Philippines	O
,	O
with	O
no	O
known	O
toxic	O
habits	O
or	O
drug	O
allergies	O
.	O
Pathological	O
history	O
hypertension	O
treated	O
with	O
ARA	B-FARMACO
II	I-FARMACO
.	O
Moderate	O
severe	O
aortic	O
insufficiency	O
with	O
last	O
echocardiogram	O
in	O
2004	O
with	O
preserved	O
EF	O
.	O
First	O
degree	O
AV	O
block	O
PR	O
300	O
320	O
msec	O
.	O
No	O
other	O
history	O
of	O
interest	O
.	O
Current	O
illness	O
Consultation	O
to	O
the	O
emergency	O
department	O
for	O
cough	O
and	O
fever	O
.	O
He	O
was	O
discharged	O
with	O
a	O
diagnosis	O
of	O
bronchial	O
infection	O
and	O
was	O
prescribed	O
treatment	O
with	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
and	O
nebulisations	O
.	O
Ten	O
days	O
later	O
,	O
he	O
re	O
consulted	O
at	O
another	O
hospital	O
due	O
to	O
persistent	O
cough	O
,	O
to	O
which	O
dyspnoea	O
and	O
mechanical	O
lumbar	O
pain	O
were	O
added	O
.	O
He	O
denied	O
fever	O
,	O
febrile	O
equivalents	O
or	O
symptoms	O
suggestive	O
of	O
bacteraemia	O
.	O
A	O
thoraco	O
abdominal	O
CT	O
scan	O
ruled	O
out	O
pulmonary	O
thromboembolism	O
and	O
discordant	O
aortic	O
aneurysm	O
,	O
but	O
a	O
pulmonary	O
infiltrate	O
was	O
observed	O
in	O
the	O
left	O
upper	O
lobe	O
.	O
Laboratory	O
tests	O
showed	O
CRP	O
41	O
mg	O
dl	O
,	O
the	O
only	O
determination	O
of	O
TnT	O
US	O
103	O
ng	O
L	O
.	O
At	O
that	O
time	O
he	O
was	O
referred	O
to	O
our	O
centre	O
to	O
rule	O
out	O
acute	O
coronary	O
syndrome	O
.	O
Physical	O
examination	O
in	O
the	O
emergency	O
department	O
Good	O
general	O
condition	O
,	O
conscious	O
and	O
oriented	O
.	O
BP	O
124	O
50	O
,	O
Axillary	O
T	O
.	O
36	O
.	O
4	O
,	O
SatO2	O
99	O
Cardiovascular	O
Regular	O
sounds	O
,	O
2	O
4	O
pandiastolic	O
murmur	O
.	O
No	O
IY	O
,	O
no	O
RHY	O
.	O
No	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Pulses	O
symmetrical	O
,	O
alive	O
and	O
jumping	O
.	O
No	O
carotid	O
murmurs	O
.	O
Respiratory	O
Bladder	O
murmur	O
preserved	O
,	O
no	O
other	O
added	O
sounds	O
.	O
Digestive	O
No	O
signs	O
of	O
peritonism	O
,	O
positive	O
right	O
renal	O
fist	O
percussion	O
.	O
Neurological	O
No	O
signs	O
of	O
neurological	O
focality	O
or	O
meningism	O
.	O
Complementary	O
tests	O
Laboratory	O
tests	O
Urea	O
36	O
mg	O
dL	O
,	O
creatinine	O
0	O
.	O
86	O
mg	O
dL	O
,	O
sodium	O
140	O
mmol	O
L	O
,	O
potassium	O
4	O
.	O
04	O
mmol	O
L	O
,	O
chlorine	O
108	O
mmol	O
L	O
.	O
CRP	O
7	O
.	O
4	O
mg	O
dL	O
.	O
Hb	O
10	O
.	O
8	O
g	O
dL	O
.	O
Leukocytes	O
10	O
,	O
500	O
cells	O
mm3	O
.	O
Platelets	O
280	O
.	O
000	O
,	O
PT	O
64	O
.	O
Urine	O
sediment	O
S5	O
red	O
blood	O
cells	O
,	O
S0	O
leukocytes	O
.	O
Sputum	O
BK	O
1st	O
negative	O
.	O
Urine	O
Ag	O
pneumococcus	O
and	O
legionella	O
negative	O
.	O
ECG	O
Sinus	O
rhythm	O
.	O
FC	O
68	O
bpm	O
.	O
PR	O
320	O
msec	O
already	O
described	O
.	O
QRS	O
duration	O
100	O
msec	O
.	O
QRS	O
0	O
QTc	O
axis	O
420	O
msec	O
.	O
Criteria	O
left	O
ventricular	O
enlargement	O
.	O
Non	O
specific	O
intra	O
ventricular	O
conduction	O
disorder	O
.	O
Chest	O
X	O
ray	O
Condensation	O
in	O
LSI	O
.	O
Thoracic	O
abdominal	O
CT	O
angiography	O
reviewed	O
by	O
the	O
Radiology	O
Department	O
of	O
our	O
centre	O
Large	O
cardiomegaly	O
with	O
a	O
certain	O
component	O
of	O
heart	O
failure	O
reflux	O
of	O
contrast	O
towards	O
the	O
hepatic	O
veins	O
in	O
addition	O
to	O
a	O
focus	O
of	O
sub	O
pleural	O
condensation	O
in	O
LSI	O
with	O
a	O
ground	O
glass	O
halo	O
that	O
could	O
correspond	O
to	O
a	O
pneumonic	O
focus	O
.	O
Renal	O
micro	O
density	O
of	O
less	O
than	O
1	O
cm	O
,	O
non	O
specific	O
.	O
No	O
other	O
findings	O
of	O
note	O
.	O
Clinical	O
evolution	O
An	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
an	O
image	O
suggestive	O
of	O
vegetation	O
10	O
mm	O
in	O
the	O
bicuspid	O
aortic	O
valve	O
.	O
Severe	O
aortic	O
insufficiency	O
.	O
In	O
the	O
mitral	O
valve	O
,	O
perforation	O
of	O
the	O
anterior	O
leaflet	O
with	O
moderate	O
severe	O
insufficiency	O
.	O
Ascending	O
aorta	O
45	O
mm	O
.	O
Global	O
hypokinesia	O
,	O
left	O
ventricular	O
ejection	O
fraction	O
45	O
,	O
mild	O
tricuspid	O
insufficiency	O
.	O
Moderate	O
pulmonary	O
hypertension	O
.	O
At	O
that	O
time	O
the	O
Cardiology	O
Service	O
was	O
notified	O
.	O
Physical	O
examination	O
revealed	O
signs	O
of	O
heart	O
failure	O
.	O
Electrocardiogram	O
showed	O
PR	O
lengthening	O
up	O
to	O
400	O
msec	O
.	O
Given	O
the	O
suspicion	O
of	O
endocarditis	O
complicated	O
by	O
heart	O
failure	O
,	O
valvular	O
rupture	O
and	O
possible	O
abscess	O
in	O
the	O
aortic	O
annulus	O
,	O
it	O
was	O
decided	O
to	O
transfer	O
the	O
patient	O
to	O
the	O
Coronary	O
Unit	O
to	O
await	O
surgery	O
.	O
Treatment	O
was	O
started	O
with	O
ampicillin	B-FARMACO
,	O
gentamicin	B-FARMACO
and	O
cloxacillin	B-FARMACO
.	O
Blood	O
cultures	O
were	O
negative	O
at	O
all	O
times	O
.	O
Due	O
to	O
intraventricular	O
conduction	O
disturbance	O
,	O
a	O
provisional	O
MCP	O
was	O
implanted	O
and	O
a	O
transesophageal	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
an	O
abscess	O
at	O
the	O
mitro	O
aortic	O
junction	O
draining	O
into	O
the	O
left	O
ventricular	O
outflow	O
tract	O
LVOT	O
and	O
fistulisation	O
into	O
the	O
right	O
atrium	O
RA	O
.	O
Non	O
invasive	O
digital	O
angiography	O
with	O
pre	O
surgical	O
multi	O
detector	O
CT	O
showed	O
no	O
significant	O
coronary	O
lesions	O
and	O
confirmed	O
the	O
LVOT	O
to	O
AD	O
fistula	O
.	O
Surgical	O
intervention	O
revealed	O
vegetations	O
in	O
the	O
right	O
coronary	O
and	O
non	O
coronary	O
leaflets	O
of	O
the	O
aortic	O
valve	O
,	O
with	O
extension	O
to	O
the	O
anterior	O
mitral	O
leaflet	O
of	O
the	O
mitral	O
valve	O
.	O
The	O
aortic	O
valve	O
was	O
replaced	O
with	O
a	O
21	O
mm	O
mechanical	O
prosthesis	O
and	O
the	O
mitral	O
valve	O
was	O
replaced	O
with	O
a	O
27	O
mm	O
mechanical	O
prosthesis	O
,	O
preserving	O
the	O
mitro	O
aortic	O
junction	O
.	O
Antibiotic	O
treatment	O
was	O
continued	O
with	O
amipicillin	B-FARMACO
,	O
gentamicin	B-FARMACO
and	O
cloxacillin	B-FARMACO
.	O
Blood	O
cultures	O
,	O
catheter	O
and	O
surgical	O
specimen	O
cultures	O
were	O
negative	O
.	O
Due	O
to	O
persistent	O
episodes	O
of	O
advanced	O
atrioventricular	O
block	O
AVB	O
,	O
on	O
the	O
fifteenth	O
post	O
operative	O
day	O
,	O
a	O
permanent	O
VDD	O
pacemaker	O
was	O
implanted	O
without	O
incident	O
.	O
Due	O
to	O
the	O
appearance	O
of	O
pleural	O
and	O
pericardial	O
effusion	O
,	O
with	O
auscultation	O
of	O
pericardial	O
friction	O
rub	O
,	O
treatment	O
was	O
started	O
with	O
ASA	B-FARMACO
and	O
colchicine	B-FARMACO
.	O
Due	O
to	O
persistent	O
pericardial	O
effusion	O
and	O
the	O
appearance	O
of	O
haemodynamic	O
compromise	O
,	O
pericardiocentesis	O
via	O
the	O
left	O
anterior	O
subcostal	O
route	O
was	O
decided	O
.	O
The	O
puncture	O
was	O
performed	O
without	O
complications	O
.	O
A	O
fluid	O
with	O
haematic	O
characteristics	O
was	O
obtained	O
and	O
sent	O
for	O
analysis	O
.	O
After	O
removal	O
of	O
approximately	O
800	O
cc	O
of	O
fluid	O
,	O
a	O
negative	O
pressure	O
drainage	O
system	O
was	O
left	O
in	O
place	O
.	O
Post	O
procedural	O
ECHO	O
showed	O
a	O
significant	O
reduction	O
in	O
pericardial	O
effusion	O
,	O
with	O
persistent	O
posterior	O
predominance	O
of	O
fluid	O
,	O
now	O
with	O
better	O
expansion	O
of	O
the	O
right	O
cavities	O
compared	O
to	O
the	O
previous	O
ECHO	O
.	O
Since	O
then	O
,	O
haemodynamically	O
stable	O
with	O
blood	O
pressure	O
of	O
130	O
70	O
mmHg	O
and	O
improvement	O
of	O
his	O
general	O
condition	O
.	O
At	O
24	O
hours	O
the	O
drain	O
was	O
removed	O
with	O
a	O
total	O
extraction	O
of	O
950	O
cc	O
.	O
Echocardiogram	O
after	O
removal	O
of	O
the	O
drain	O
moderate	O
pericardial	O
effusion	O
predominantly	O
inferoposterior	O
.	O
Despite	O
this	O
,	O
24	O
00	O
hours	O
after	O
removal	O
of	O
the	O
pericardial	O
drain	O
,	O
he	O
complained	O
of	O
intense	O
dizziness	O
and	O
profuse	O
sweating	O
accompanied	O
by	O
hypotension	O
93	O
50	O
mm	O
Hg	O
.	O
In	O
view	O
of	O
the	O
suspicion	O
of	O
new	O
tamponade	O
,	O
a	O
portable	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
anterior	O
pericardial	O
effusion	O
,	O
especially	O
basal	O
25	O
mm	O
with	O
echoes	O
inside	O
suggesting	O
haematoma	O
with	O
compression	O
of	O
the	O
RV	O
,	O
which	O
could	O
not	O
be	O
approached	O
by	O
subcostal	O
puncture	O
,	O
for	O
which	O
reason	O
the	O
patient	O
was	O
again	O
referred	O
to	O
Cardiac	O
Surgery	O
for	O
urgent	O
surgery	O
.	O
The	O
patient	O
evolved	O
favourably	O
after	O
surgery	O
and	O
was	O
discharged	O
home	O
after	O
2	O
weeks	O
postoperatively	O
.	O
Diagnosis	O
Aortic	O
valve	O
endocarditis	O
with	O
negative	O
blood	O
cultures	O
complicated	O
by	O
Severe	O
aortic	O
insufficiency	O
Mitral	O
insufficiency	O
due	O
to	O
perforation	O
of	O
the	O
anterior	O
mitral	O
leaflet	O
Secondary	O
heart	O
failure	O
Periaortic	O
abscess	O
Complete	O
atrioventricular	O
atrial	O
ventricular	O
block	O
secondary	O
to	O
abscess	O
Left	O
ventricular	O
outflow	O
tract	O
fistula	O
to	O
left	O
atrium	O
secondary	O
to	O
abscess	O
.	O

A	O
43	O
year	O
old	O
man	O
presented	O
to	O
the	O
Emergency	O
Department	O
with	O
ischaemic	O
chest	O
pain	O
of	O
more	O
than	O
a	O
week	O
's	O
duration	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Personal	O
history	O
NAMC	O
.	O
Former	O
cocaine	O
user	O
.	O
Smoker	O
and	O
heavy	O
drinker	O
.	O
Nodal	O
tuberculosis	O
diagnosed	O
in	O
July	O
2011	O
with	O
necrotizing	O
granulomatous	O
lymphadenitis	O
with	O
tuberculous	O
profile	O
.	O
Syphilis	O
.	O
Deep	O
vein	O
thrombosis	O
of	O
DID	O
and	O
portomesenteric	O
thrombosis	O
.	O
Recent	O
anterior	O
AMI	O
.	O
Usual	O
treatment	O
Sintrom	B-FARMACO
,	O
pantecta	B-FARMACO
,	O
rifampicin	B-FARMACO
isoniazid	I-FARMACO
,	O
ethambutol	B-FARMACO
,	O
ASA	B-FARMACO
,	O
atorvastatin	B-FARMACO
,	O
coropres	B-FARMACO
,	O
acovil	B-FARMACO
,	O
omeprazole	B-FARMACO
.	O
BFS	O
Higher	O
functions	O
preserved	O
,	O
autonomous	O
for	O
ABVD	O
.	O
Current	O
illness	O
Admitted	O
to	O
the	O
Coronary	O
Unit	O
on	O
11	O
10	O
2012	O
for	O
previous	O
AMI	O
,	O
requesting	O
voluntary	O
discharge	O
without	O
catheterisation	O
or	O
medical	O
treatment	O
.	O
Since	O
then	O
,	O
he	O
has	O
presented	O
recurrent	O
chest	O
pains	O
and	O
so	O
he	O
came	O
to	O
the	O
emergency	O
department	O
again	O
on	O
20	O
10	O
2012	O
for	O
another	O
episode	O
of	O
pain	O
,	O
referred	O
by	O
his	O
primary	O
care	O
physician	O
.	O
With	O
a	O
diagnosis	O
of	O
advanced	O
AMI	O
,	O
she	O
was	O
again	O
transferred	O
to	O
the	O
Coronary	O
Care	O
Unit	O
.	O
Examination	O
BP	O
134	O
91	O
mm	O
Hg	O
;	O
HR	O
100	O
bpm	O
;	O
Ta	O
36	O
.	O
2	O
oC	O
.	O
Conscious	O
and	O
oriented	O
,	O
cooperative	O
.	O
Good	O
peripheral	O
perfusion	O
.	O
Adequate	O
muco	O
cutaneous	O
colouring	O
.	O
Eupneic	O
at	O
rest	O
.	O
Head	O
and	O
neck	O
No	O
IY	O
.	O
AC	O
rhythmic	O
at	O
100	O
bpm	O
,	O
systolic	O
murmur	O
in	O
mitral	O
focus	O
.	O
AP	O
VCM	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
evidence	O
of	O
peritoneal	O
irritation	O
.	O
Sounds	O
present	O
.	O
Hepatomegaly	O
.	O
Lower	O
extremities	O
No	O
oedema	O
or	O
evidence	O
of	O
DVT	O
.	O
Complementary	O
tests	O
ECG	O
Sinus	O
rhythm	O
at	O
100	O
bpm	O
,	O
QRS	O
axis	O
at	O
0o	O
,	O
Q	O
waves	O
in	O
inferior	O
face	O
,	O
ST	O
segment	O
elevation	O
in	O
anteroseptal	O
face	O
and	O
negative	O
T	O
waves	O
in	O
all	O
precordial	O
leads	O
.	O
Echocardiogram	O
LV	O
slightly	O
dilated	O
LVEDD	O
56	O
mm	O
with	O
normal	O
wall	O
thickness	O
.	O
Moderately	O
depressed	O
systolic	O
function	O
LVED	O
40	O
due	O
to	O
apical	O
aneurysm	O
,	O
akinesia	O
of	O
the	O
mid	O
apical	O
segments	O
of	O
the	O
septum	O
,	O
inferior	O
and	O
anterior	O
face	O
,	O
hypokinesia	O
of	O
the	O
posterior	O
face	O
,	O
maintaining	O
only	O
the	O
contractility	O
of	O
the	O
lateral	O
face	O
and	O
basal	O
segments	O
of	O
the	O
rest	O
of	O
the	O
faces	O
.	O
A	O
large	O
thrombus	O
is	O
observed	O
adhered	O
to	O
the	O
apex	O
.	O
Pseudonormalised	O
diastolic	O
pattern	O
.	O
Mitral	O
valve	O
with	O
moderate	O
central	O
regurgitation	O
.	O
Aortic	O
root	O
not	O
dilated	O
35	O
mm	O
.	O
Aortic	O
valve	O
without	O
detectable	O
functional	O
alterations	O
.	O
Slight	O
biauricular	O
dilatation	O
.	O
RV	O
not	O
dilated	O
and	O
without	O
signs	O
of	O
dysfunction	O
.	O
Moderate	O
tricuspid	O
regurgitation	O
with	O
a	O
RV	O
AD	O
gradient	O
of	O
35	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
Chest	O
X	O
ray	O
Cardiomegaly	O
,	O
no	O
pulmonary	O
condensation	O
images	O
,	O
free	O
costophrenic	O
sinuses	O
.	O
Given	O
that	O
it	O
was	O
an	O
AMI	O
of	O
more	O
than	O
a	O
week	O
's	O
evolution	O
,	O
with	O
necrosis	O
in	O
the	O
ECG	O
and	O
development	O
of	O
apical	O
aneurysm	O
and	O
an	O
intracavitary	O
thrombus	O
in	O
the	O
echocardiogram	O
,	O
urgent	O
catheterisation	O
was	O
not	O
performed	O
and	O
medical	O
treatment	O
was	O
prescribed	O
with	O
antiplatelet	O
therapy	O
,	O
anticoagulation	O
at	O
full	O
doses	O
,	O
lipid	O
lowering	O
agents	O
,	O
beta	O
blockers	O
and	O
ACE	O
inhibitors	O
,	O
maintaining	O
his	O
tuberculostatic	O
treatment	O
.	O
The	O
study	O
was	O
completed	O
with	O
Catheterisation	O
Left	O
coronary	O
angiography	O
The	O
common	O
trunk	O
shows	O
no	O
lesions	O
.	O
The	O
anterior	O
descending	O
artery	O
is	O
occluded	O
in	O
its	O
distal	O
segment	O
after	O
the	O
birth	O
of	O
a	O
large	O
diagonal	O
branch	O
.	O
The	O
circumflex	O
artery	O
is	O
of	O
medium	O
development	O
without	O
lesions	O
.	O
Right	O
coronary	O
angiography	O
It	O
is	O
the	O
dominant	O
vessel	O
and	O
of	O
great	O
extension	O
.	O
Mild	O
atheromatosis	O
in	O
the	O
middle	O
third	O
.	O
Conclusions	O
Severe	O
single	O
vessel	O
coronary	O
artery	O
disease	O
due	O
to	O
distal	O
occlusion	O
of	O
the	O
LAD	O
.	O
Cardiac	O
MRI	O
dilated	O
LV	O
with	O
severe	O
systolic	O
dysfunction	O
.	O
LVEF	O
28	O
.	O
Saccular	O
dilatation	O
at	O
the	O
level	O
of	O
the	O
apex	O
with	O
akinesia	O
of	O
the	O
apical	O
segments	O
of	O
all	O
the	O
faces	O
with	O
heterogeneous	O
density	O
content	O
with	O
liquid	O
areas	O
inside	O
that	O
in	O
the	O
perfusion	O
sequences	O
do	O
not	O
seem	O
to	O
be	O
related	O
to	O
the	O
ventricular	O
cavity	O
.	O
Likewise	O
,	O
the	O
lateral	O
aspect	O
does	O
not	O
show	O
continuity	O
of	O
the	O
myocardium	O
with	O
the	O
saccular	O
area	O
described	O
.	O
Late	O
enhancement	O
sequences	O
show	O
50	O
subendocardial	O
enhancement	O
in	O
mid	O
apical	O
segments	O
of	O
the	O
inferior	O
face	O
and	O
septum	O
,	O
with	O
transmural	O
enhancement	O
in	O
the	O
rest	O
of	O
the	O
apical	O
segments	O
.	O
The	O
patient	O
had	O
a	O
torpid	O
evolution	O
with	O
heart	O
failure	O
that	O
was	O
difficult	O
to	O
manage	O
and	O
systemic	O
embolisation	O
despite	O
anticoagulation	O
,	O
so	O
in	O
view	O
of	O
this	O
clinical	O
picture	O
and	O
given	O
the	O
findings	O
described	O
anterior	O
AMI	O
evolved	O
with	O
apical	O
aneurysm	O
and	O
thrombus	O
inside	O
,	O
together	O
with	O
doubtful	O
rupture	O
of	O
the	O
LV	O
wall	O
with	O
some	O
associated	O
pericardial	O
effusion	O
,	O
cardiac	O
surgery	O
was	O
consulted	O
and	O
surgery	O
was	O
scheduled	O
.	O
He	O
underwent	O
surgery	O
on	O
17	O
11	O
2012	O
and	O
left	O
ventricular	O
aneurysm	O
resection	O
and	O
thrombus	O
extraction	O
,	O
with	O
subsequent	O
closure	O
with	O
a	O
pericardial	O
patch	O
.	O
No	O
rupture	O
of	O
the	O
LV	O
free	O
wall	O
was	O
visualised	O
.	O
In	O
the	O
immediate	O
postoperative	O
period	O
he	O
required	O
vasoactive	O
drugs	O
due	O
to	O
haemodynamic	O
instability	O
,	O
which	O
could	O
be	O
suspended	O
on	O
the	O
2nd	O
day	O
post	O
IQ	O
.	O
He	O
was	O
extubated	O
and	O
the	O
rest	O
of	O
the	O
postoperative	O
period	O
was	O
uneventful	O
.	O
He	O
was	O
discharged	O
to	O
the	O
ward	O
after	O
3	O
days	O
in	O
the	O
Coronary	O
Unit	O
and	O
home	O
a	O
week	O
later	O
.	O
Diagnosis	O
Evolved	O
Killip	O
II	O
IV	O
anterior	O
infarction	O
with	O
severe	O
systolic	O
dysfunction	O
.	O
Apical	O
aneurysm	O
with	O
intraventricular	O
thrombosis	O
.	O
Surgical	O
intervention	O
with	O
resection	O
of	O
the	O
LV	O
aneurysm	O
and	O
extraction	O
of	O
the	O
intraventricular	O
thrombus	O
.	O

Emergency	O
due	O
to	O
dizziness	O
and	O
fall	O
to	O
the	O
floor	O
at	O
home	O
,	O
without	O
loss	O
of	O
consciousness	O
and	O
without	O
injuries	O
secondary	O
to	O
the	O
trauma	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
78	O
year	O
old	O
female	O
patient	O
,	O
allergic	O
to	O
penicillins	O
,	O
with	O
a	O
personal	O
history	O
of	O
obesity	O
,	O
hypertension	O
and	O
dyslipidaemia	O
,	O
on	O
treatment	O
with	O
hydrochlorothiazide	B-FARMACO
40	O
mg	O
olmersatan	B-FARMACO
25	O
mg	O
,	O
atorvastatin	B-FARMACO
20	O
mg	O
and	O
omeprazole	B-FARMACO
20	O
mg	O
.	O
Appendectomised	O
.	O
Baseline	O
situation	O
NYHA	O
function	O
class	O
I	O
II	O
.	O
She	O
presented	O
suddenly	O
at	O
9	O
00	O
am	O
,	O
with	O
dizziness	O
and	O
a	O
fall	O
to	O
the	O
floor	O
at	O
home	O
,	O
without	O
loss	O
of	O
consciousness	O
and	O
without	O
injuries	O
secondary	O
to	O
the	O
trauma	O
.	O
She	O
was	O
seen	O
a	O
few	O
hours	O
later	O
by	O
a	O
relative	O
,	O
who	O
found	O
her	O
very	O
anxious	O
due	O
to	O
her	O
inability	O
to	O
get	O
up	O
from	O
the	O
floor	O
after	O
the	O
fall	O
.	O
Emergency	O
services	O
were	O
called	O
and	O
she	O
was	O
transferred	O
to	O
our	O
Emergency	O
Department	O
.	O
On	O
arrival	O
,	O
Glasgow	O
15	O
,	O
BP	O
80	O
40	O
mmHg	O
,	O
HR	O
110	O
bpm	O
,	O
02	O
saturation	O
80	O
,	O
tachypnoea	O
of	O
25	O
rpm	O
.	O
While	O
in	O
the	O
observation	O
room	O
,	O
she	O
presented	O
with	O
self	O
limited	O
tonic	O
clonic	O
crises	O
,	O
after	O
which	O
she	O
reported	O
intense	O
central	O
thoracic	O
pain	O
,	O
oppressive	O
,	O
radiating	O
to	O
the	O
interscapular	O
area	O
and	O
significant	O
accompanying	O
vegetative	O
cortex	O
.	O
Physical	O
examination	O
Conscious	O
and	O
oriented	O
.	O
Poor	O
general	O
condition	O
.	O
Skin	O
pallor	O
.	O
Central	O
cyanosis	O
.	O
Carotids	O
symmetrical	O
and	O
rhythmic	O
.	O
Jugular	O
ingurgitation	O
.	O
CVM	O
with	O
bilateral	O
crackles	O
up	O
to	O
midfields	O
.	O
Rhythmic	O
heart	O
tones	O
;	O
systolic	O
murmur	O
III	O
IV	O
in	O
mitral	O
focus	O
,	O
radiating	O
to	O
the	O
axilla	O
.	O
Abdomen	O
without	O
pathological	O
alterations	O
.	O
Palpable	O
and	O
symmetrical	O
paedial	O
pulses	O
.	O
Malleolar	O
oedema	O
II	O
IV	O
.	O
Complementary	O
tests	O
CBC	O
Leukocytes	O
13	O
.	O
800	O
thousands	O
μl	O
,	O
PMN	O
70	O
,	O
HB	O
12	O
.	O
2	O
gr	O
dl	O
,	O
OHT	O
36	O
.	O
3	O
,	O
platelets	O
127	O
thousands	O
μl	O
,	O
prothrombin	O
activity	O
98	O
,	O
aTTP	O
27	O
.	O
5	O
,	O
fibrinogen	O
343	O
mg	O
dl	O
,	O
Glu	O
159	O
mg	O
dl	O
,	O
urea	O
39	O
mg	O
dl	O
,	O
Cr	O
1	O
mg	O
dl	O
,	O
Na	O
142	O
mmol	O
l	O
,	O
K	O
4	O
.	O
1	O
4	O
.	O
2	O
mmol	O
,	O
Mg	O
1	O
.	O
8	O
mmol	O
L	O
,	O
Cl	O
116	O
mmol	O
L	O
,	O
CPK	O
810	O
Ui	O
L	O
,	O
CKMB	O
63	O
ng	O
ml	O
,	O
troponin	O
I	O
17	O
.	O
98	O
ng	O
ml	O
.	O
Arterial	O
blood	O
gas	O
pH	O
7	O
.	O
38	O
,	O
pC02	O
27	O
mmHg	O
,	O
P02	O
110	O
mmHg	O
,	O
HC03	O
13	O
24	O
.	O
8	O
mmol	O
,	O
EB	O
7	O
.	O
7	O
,	O
Sat02	O
98	O
,	O
lactate	O
12mg	O
dl	O
.	O
Chest	O
X	O
ray	O
Cardiothoracic	O
index	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
,	O
hilar	O
thickening	O
,	O
fluid	O
in	O
cystic	O
cracks	O
and	O
pinched	O
costophrenic	O
sinuses	O
.	O
ECG	O
RS	O
at	O
90lpm	O
,	O
with	O
generalised	O
ST	O
segment	O
decline	O
and	O
ST	O
rise	O
of	O
1	O
mm	O
in	O
aVR	O
.	O
Urgent	O
TTE	O
Left	O
ventricle	O
without	O
significant	O
hypertrophy	O
or	O
dilatation	O
,	O
with	O
severely	O
depressed	O
systolic	O
function	O
15	O
.	O
Mid	O
apical	O
hypokinesia	O
,	O
with	O
preserved	O
contractility	O
at	O
the	O
level	O
of	O
the	O
basal	O
segments	O
.	O
Grade	O
III	O
mitral	O
insufficiency	O
.	O
Mild	O
aortic	O
insufficiency	O
and	O
moderate	O
pulmonary	O
hypertension	O
.	O
No	O
dynamic	O
obstruction	O
of	O
the	O
left	O
ventricular	O
outflow	O
tract	O
.	O
No	O
pericardial	O
effusion	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
with	O
inspiratory	O
collapse	O
less	O
than	O
50	O
.	O
Clinical	O
course	O
In	O
cardiogenic	O
shock	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
Coronary	O
Care	O
Unit	O
CCU	O
,	O
starting	O
vasoactive	O
support	O
with	O
noradrenaline	B-FARMACO
0	O
.	O
6	O
μg	O
kg	O
min	O
and	O
dobutamine	B-FARMACO
10	O
12	O
μg	O
kg	O
min	O
.	O
Coronary	O
angiography	O
showed	O
parietal	O
irregularities	O
,	O
without	O
angiographically	O
significant	O
lesions	O
.	O
Ventriculography	O
showed	O
severe	O
ventricular	O
dysfunction	O
and	O
typical	O
Tako	O
tsubo	O
morphology	O
.	O
During	O
the	O
procedure	O
,	O
an	O
intra	O
aortic	O
balloon	O
pump	O
IABP	O
was	O
implanted	O
via	O
the	O
right	O
femoral	O
artery	O
.	O
In	O
the	O
first	O
24	O
hours	O
of	O
admission	O
,	O
the	O
patient	O
required	O
non	O
invasive	O
mechanical	O
ventilation	O
due	O
to	O
hypoxaemic	O
respiratory	O
failure	O
related	O
to	O
acute	O
pulmonary	O
oedema	O
.	O
The	O
patient	O
's	O
evolution	O
was	O
favourable	O
,	O
allowing	O
the	O
IABP	O
to	O
be	O
withdrawn	O
48	O
hours	O
after	O
admission	O
and	O
ventilatory	O
support	O
to	O
be	O
provided	O
gradually	O
over	O
the	O
following	O
days	O
.	O
The	O
enzyme	O
peak	O
was	O
CPK	O
1430	O
,	O
CK	O
MB	O
60	O
.	O
2	O
and	O
troponin	O
I	O
19	O
.	O
06	O
.	O
Prior	O
to	O
discharge	O
,	O
TTE	O
was	O
repeated	O
and	O
showed	O
recovery	O
of	O
systolic	O
function	O
LVEF	O
by	O
Simpson	O
biplane	O
45	O
with	O
persistence	O
of	O
discrete	O
hypokinesia	O
of	O
the	O
middle	O
portions	O
.	O
After	O
twelve	O
days	O
in	O
the	O
CCU	O
,	O
she	O
was	O
discharged	O
to	O
the	O
cardiology	O
ward	O
.	O
Diagnosis	O
Tako	O
tsubo	O
syndrome	O
complicated	O
by	O
cardiogenic	O
shock	O
.	O

A	O
48	O
year	O
old	O
man	O
came	O
to	O
the	O
emergency	O
department	O
with	O
a	O
sudden	O
episode	O
of	O
non	O
radiating	O
stabbing	O
chest	O
pain	O
that	O
started	O
suddenly	O
while	O
he	O
was	O
driving	O
.	O
It	O
was	O
not	O
accompanied	O
by	O
dyspnoea	O
,	O
palpitations	O
or	O
syncope	O
.	O
History	O
,	O
present	O
illness	O
and	O
physical	O
examination	O
48	O
year	O
old	O
male	O
,	O
with	O
no	O
known	O
allergies	O
,	O
with	O
several	O
cardiovascular	O
risk	O
factors	O
including	O
heavy	O
smoking	O
2	O
3	O
packs	O
day	O
,	O
untreated	O
hypertension	O
and	O
moderate	O
obesity	O
,	O
with	O
no	O
other	O
history	O
of	O
interest	O
.	O
By	O
profession	O
,	O
Labrador	O
.	O
He	O
came	O
to	O
the	O
emergency	O
department	O
for	O
an	O
episode	O
of	O
non	O
radiating	O
stabbing	O
chest	O
pain	O
that	O
started	O
suddenly	O
while	O
he	O
was	O
driving	O
.	O
It	O
was	O
not	O
accompanied	O
by	O
dyspnoea	O
,	O
palpitations	O
or	O
syncope	O
.	O
On	O
arrival	O
,	O
he	O
was	O
in	O
poor	O
general	O
condition	O
,	O
with	O
profuse	O
sweating	O
and	O
tachypnoea	O
.	O
Blood	O
pressure	O
was	O
200	O
81	O
mmHg	O
,	O
heart	O
rate	O
95	O
beats	O
per	O
minute	O
and	O
oxygen	O
saturation	O
86	O
.	O
Physical	O
examination	O
revealed	O
an	O
IV	O
VI	O
diastolic	O
murmur	O
,	O
more	O
noticeable	O
on	O
the	O
left	O
sternal	O
border	O
,	O
generalised	O
hypoventilation	O
with	O
crackles	O
in	O
both	O
lung	O
bases	O
,	O
tibiomalleolar	O
oedema	O
with	O
fovea	O
and	O
peripheral	O
pulses	O
present	O
and	O
symmetrical	O
.	O
The	O
rest	O
of	O
the	O
physical	O
examination	O
was	O
unremarkable	O
.	O
Complementary	O
tests	O
ECG	O
on	O
admission	O
Sinus	O
rhythm	O
at	O
90	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
Voltage	O
criteria	O
for	O
left	O
ventricular	O
hypertrophy	O
.	O
Negative	O
T	O
in	O
lateral	O
face	O
.	O
Emergency	O
analytical	O
Highlights	O
glycaemia	O
185	O
mg	O
dl	O
,	O
CRP	O
60	O
and	O
elevated	O
myocardial	O
necrosis	O
markers	O
maximum	O
US	O
TnT	O
180	O
ng	O
ml	O
,	O
without	O
typical	O
curve	O
.	O
Chest	O
X	O
ray	O
Cardiomegaly	O
.	O
Aortic	O
elongation	O
.	O
Hilar	O
thickening	O
.	O
CT	O
angiography	O
aortic	O
root	O
and	O
proximal	O
segment	O
of	O
ascending	O
aorta	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
,	O
with	O
the	O
rest	O
of	O
the	O
aorta	O
of	O
normal	O
calibre	O
,	O
without	O
signs	O
suggestive	O
of	O
aortic	O
syndrome	O
.	O
Mild	O
cardiomegaly	O
and	O
small	O
pericardial	O
effusion	O
.	O
At	O
the	O
abdominal	O
level	O
,	O
there	O
was	O
only	O
discrete	O
hepatomegaly	O
with	O
hepatic	O
steatosis	O
.	O
Transthoracic	O
echocardiogram	O
The	O
main	O
finding	O
was	O
the	O
presence	O
of	O
moderate	O
severe	O
aortic	O
insufficiency	O
over	O
the	O
trivalve	O
valve	O
,	O
secondary	O
to	O
dilatation	O
of	O
the	O
aortic	O
annulus	O
.	O
The	O
left	O
ventricle	O
is	O
slightly	O
dilated	O
end	O
diastolic	O
diameter	O
of	O
60	O
mm	O
with	O
severe	O
concentric	O
hypertrophy	O
15	O
16	O
mm	O
and	O
preserved	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O
Both	O
the	O
right	O
ventricle	O
and	O
the	O
rest	O
of	O
the	O
valves	O
show	O
no	O
pathological	O
findings	O
.	O
Cardiac	O
MRI	O
The	O
study	O
was	O
of	O
suboptimal	O
technical	O
quality	O
due	O
to	O
lack	O
of	O
cooperation	O
from	O
the	O
patient	O
to	O
correctly	O
perform	O
apnoeas	O
.	O
The	O
left	O
ventricle	O
showed	O
moderate	O
eccentric	O
hypertrophy	O
,	O
dilatation	O
telediastolic	O
volume	O
of	O
124	O
ml	O
m2	O
and	O
end	O
systolic	O
volume	O
of	O
50	O
ml	O
m2	O
and	O
segmental	O
and	O
global	O
systolic	O
function	O
within	O
normal	O
limits	O
ejection	O
fraction	O
of	O
60	O
.	O
The	O
right	O
ventricle	O
was	O
normal	O
in	O
dimensions	O
and	O
systolic	O
function	O
.	O
There	O
was	O
no	O
evidence	O
of	O
oedema	O
or	O
alterations	O
in	O
perfusion	O
or	O
late	O
gadolinium	O
enhancement	O
.	O
Significant	O
apparent	O
aortic	O
insufficiency	O
was	O
detected	O
,	O
but	O
the	O
poor	O
quality	O
of	O
the	O
study	O
did	O
not	O
allow	O
adequate	O
quantification	O
.	O
Aortic	O
root	O
dilatation	O
sinuses	O
of	O
Valsalva	O
50	O
mm	O
,	O
21	O
mm	O
m2	O
and	O
tubular	O
portion	O
of	O
ascending	O
aorta	O
48	O
mm	O
,	O
20	O
mm	O
m2	O
were	O
observed	O
.	O
Diagnostic	O
cardiac	O
catheterisation	O
The	O
main	O
finding	O
is	O
in	O
the	O
aortography	O
,	O
where	O
there	O
is	O
evidence	O
of	O
dilatation	O
of	O
the	O
ascending	O
aorta	O
from	O
the	O
root	O
,	O
with	O
effacement	O
of	O
the	O
sinuses	O
of	O
Valsalva	O
,	O
and	O
grade	O
IV	O
aortic	O
insufficiency	O
.	O
The	O
coronary	O
arteries	O
showed	O
no	O
significant	O
angiographic	O
lesions	O
.	O
Transesophageal	O
echocardiogram	O
This	O
was	O
interrupted	O
due	O
to	O
poor	O
tolerance	O
given	O
the	O
patient	O
's	O
clinical	O
situation	O
heart	O
failure	O
.	O
Only	O
a	O
trivalve	O
aortic	O
valve	O
with	O
correct	O
opening	O
was	O
visualised	O
,	O
without	O
being	O
able	O
to	O
assess	O
aortic	O
root	O
or	O
valvular	O
insufficiency	O
.	O
Analysis	O
on	O
the	O
hospital	O
ward	O
There	O
was	O
moderate	O
renal	O
failure	O
,	O
with	O
urea	O
78	O
mg	O
dL	O
,	O
creatinine	O
1	O
.	O
53	O
mg	O
dL	O
and	O
an	O
estimated	O
glomerular	O
filtration	O
rate	O
of	O
48	O
.	O
82	O
mL	O
minute	O
.	O
Liver	O
enzymes	O
were	O
slightly	O
elevated	O
,	O
and	O
glycosylated	O
haemoglobin	O
was	O
7	O
.	O
8	O
.	O
The	O
rest	O
of	O
the	O
biochemistry	O
,	O
as	O
well	O
as	O
the	O
haemogram	O
,	O
were	O
normal	O
.	O
Clinical	O
course	O
During	O
his	O
stay	O
in	O
the	O
ED	O
,	O
CT	O
angiography	O
was	O
performed	O
to	O
rule	O
out	O
acute	O
aortic	O
syndrome	O
given	O
the	O
patient	O
's	O
presentation	O
with	O
hypertensive	O
emergency	O
,	O
stabbing	O
pain	O
and	O
troponin	O
elevation	O
.	O
The	O
CT	O
angiography	O
was	O
reported	O
as	O
normal	O
,	O
so	O
the	O
patient	O
was	O
admitted	O
to	O
cardiology	O
to	O
study	O
chest	O
pain	O
with	O
elevated	O
markers	O
of	O
myocardial	O
necrosis	O
and	O
heart	O
failure	O
.	O
On	O
the	O
second	O
day	O
of	O
admission	O
to	O
cardiology	O
,	O
the	O
patient	O
presented	O
a	O
fever	O
peak	O
of	O
38	O
.	O
5o	O
,	O
with	O
no	O
apparent	O
infectious	O
focus	O
neither	O
clinically	O
nor	O
in	O
complementary	O
tests	O
,	O
and	O
with	O
negative	O
blood	O
cultures	O
.	O
Given	O
the	O
presence	O
of	O
moderate	O
severe	O
aortic	O
insufficiency	O
in	O
the	O
transthoracic	O
echocardiogram	O
,	O
a	O
transesophageal	O
study	O
was	O
performed	O
on	O
suspicion	O
of	O
endocarditis	O
as	O
a	O
possible	O
aetiology	O
of	O
the	O
clinical	O
picture	O
.	O
The	O
patient	O
's	O
clinical	O
condition	O
meant	O
that	O
he	O
did	O
not	O
tolerate	O
the	O
procedure	O
adequately	O
,	O
and	O
although	O
no	O
clear	O
signs	O
of	O
endocarditis	O
were	O
observed	O
,	O
the	O
study	O
was	O
of	O
poor	O
quality	O
and	O
was	O
stopped	O
early	O
.	O
In	O
the	O
following	O
days	O
,	O
the	O
patient	O
does	O
not	O
present	O
fever	O
or	O
infectious	O
symptoms	O
again	O
.	O
There	O
were	O
no	O
new	O
episodes	O
of	O
chest	O
pain	O
;	O
however	O
,	O
in	O
the	O
serial	O
ECGs	O
there	O
was	O
a	O
negative	O
T	O
wave	O
in	O
the	O
anterior	O
face	O
,	O
so	O
a	O
stress	O
cardiac	O
MRI	O
was	O
requested	O
to	O
assess	O
the	O
presence	O
of	O
necrosis	O
or	O
inducible	O
ischaemia	O
.	O
The	O
MRI	O
was	O
negative	O
,	O
ruling	O
out	O
signs	O
of	O
myocarditis	O
or	O
myocardial	O
necrosis	O
,	O
but	O
aortic	O
insufficiency	O
of	O
severe	O
appearance	O
was	O
again	O
observed	O
.	O
However	O
,	O
given	O
that	O
the	O
patient	O
continued	O
to	O
present	O
progressive	O
elevation	O
of	O
troponin	O
and	O
the	O
electrical	O
changes	O
persisted	O
deepening	O
of	O
the	O
T	O
wave	O
on	O
the	O
lateral	O
side	O
,	O
a	O
diagnostic	O
cardiac	O
catheterisation	O
was	O
requested	O
,	O
which	O
showed	O
a	O
non	O
significant	O
lesion	O
in	O
the	O
RCA	O
and	O
confirmed	O
the	O
severity	O
of	O
the	O
aortic	O
insufficiency	O
.	O
On	O
the	O
5th	O
day	O
of	O
admission	O
,	O
the	O
patient	O
presented	O
a	O
new	O
febrile	O
peak	O
of	O
38o	O
,	O
and	O
an	O
episode	O
of	O
rapid	O
atrial	O
fibrillation	O
with	O
failed	O
pharmacological	O
and	O
electrical	O
cardioversion	O
,	O
in	O
the	O
context	O
of	O
mild	O
decompensation	O
of	O
heart	O
failure	O
.	O
Once	O
again	O
,	O
a	O
battery	O
of	O
tests	O
was	O
requested	O
to	O
rule	O
out	O
infection	O
,	O
which	O
was	O
ruled	O
out	O
,	O
with	O
negative	O
blood	O
cultures	O
again	O
.	O
On	O
the	O
7th	O
day	O
of	O
admission	O
to	O
Cardiology	O
,	O
he	O
presented	O
an	O
episode	O
of	O
desaturation	O
,	O
tachypnoea	O
and	O
hypotension	O
,	O
compatible	O
with	O
acute	O
pulmonary	O
oedema	O
,	O
for	O
which	O
he	O
was	O
admitted	O
to	O
the	O
Coronary	O
Unit	O
and	O
finally	O
required	O
orotracheal	O
intubation	O
and	O
mechanical	O
ventilation	O
,	O
as	O
well	O
as	O
inotropic	O
support	O
with	O
vasoactive	O
drugs	O
.	O
A	O
transesophageal	O
echocardiogram	O
was	O
performed	O
with	O
the	O
patient	O
intubated	O
,	O
ruling	O
out	O
endocarditis	O
,	O
and	O
finally	O
a	O
localised	O
dissection	O
of	O
the	O
aortic	O
root	O
responsible	O
for	O
the	O
severe	O
aortic	O
insufficiency	O
was	O
observed	O
,	O
and	O
Cardiovascular	O
Surgery	O
was	O
contacted	O
for	O
urgent	O
intervention	O
.	O
Intraoperatively	O
,	O
a	O
type	O
A	O
dissection	O
was	O
observed	O
,	O
with	O
circumferential	O
intimal	O
rupture	O
at	O
the	O
level	O
of	O
the	O
sinotubular	O
junction	O
causing	O
sagging	O
of	O
all	O
the	O
commissures	O
,	O
this	O
being	O
the	O
mechanism	O
of	O
the	O
aortic	O
insufficiency	O
observed	O
.	O
During	O
his	O
admission	O
to	O
the	O
Coronary	O
Unit	O
after	O
surgery	O
,	O
he	O
evolved	O
slowly	O
but	O
favourably	O
,	O
without	O
new	O
febrile	O
peaks	O
and	O
with	O
improvement	O
in	O
the	O
clinical	O
signs	O
of	O
heart	O
failure	O
,	O
and	O
was	O
discharged	O
on	O
the	O
7th	O
day	O
post	O
surgery	O
.	O
One	O
month	O
later	O
,	O
the	O
patient	O
is	O
clinically	O
stable	O
and	O
asymptomatic	O
from	O
the	O
cardiological	O
point	O
of	O
view	O
,	O
with	O
no	O
aortic	O
insufficiency	O
in	O
the	O
outpatient	O
echocardiogram	O
.	O
Diagnosis	O
Localised	O
aortic	O
root	O
dissection	O
with	O
acute	O
severe	O
aortic	O
insufficiency	O
.	O

A	O
59	O
year	O
old	O
woman	O
presented	O
to	O
the	O
Emergency	O
Department	O
for	O
sudden	O
dyspnoea	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
A	O
59	O
year	O
old	O
woman	O
from	O
San	O
Juan	O
Argentina	O
attended	O
the	O
Emergency	O
Department	O
for	O
sudden	O
dyspnoea	O
,	O
with	O
the	O
following	O
history	O
Ischaemic	O
heart	O
disease	O
silent	O
inferior	O
infarction	O
of	O
undetermined	O
date	O
.	O
Previous	O
myocardial	O
infarction	O
1	O
year	O
earlier	O
,	O
treated	O
with	O
fibrinolysis	O
and	O
subsequent	O
cardiac	O
catheterisation	O
in	O
which	O
he	O
had	O
an	O
intermediate	O
lesion	O
in	O
the	O
anterior	O
descending	O
and	O
circumflex	O
arteries	O
and	O
chronic	O
occlusion	O
of	O
the	O
DC	O
,	O
not	O
revascularised	O
,	O
dilated	O
left	O
ventricle	O
with	O
depressed	O
LVEF	O
40	O
.	O
Cardiovascular	O
risk	O
factors	O
Arterial	O
hypertension	O
.	O
Dyslipidaemia	O
.	O
Obesity	O
.	O
Ex	O
.	O
smoker	O
of	O
10	O
cigarettes	O
day	O
for	O
the	O
last	O
3	O
months	O
.	O
Chronic	O
venous	O
insufficiency	O
of	O
the	O
lower	O
limbs	O
.	O
Family	O
history	O
Father	O
with	O
Chagas	O
disease	O
and	O
myocardial	O
infarction	O
at	O
the	O
age	O
of	O
59	O
.	O
Surgical	O
interventions	O
cholecystectomy	O
,	O
tonsillectomy	O
,	O
appendectomy	O
.	O
Usual	O
treatment	O
Clopidogrel	B-FARMACO
acetylsalicylic	I-FARMACO
acid	I-FARMACO
75	O
100	O
mg	O
c	O
24h	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
24h	O
,	O
ramipril	B-FARMACO
2	O
.	O
5	O
24h	O
,	O
ranitidine	B-FARMACO
150mg	O
c	O
24h	O
,	O
alprazolam	B-FARMACO
0	O
.	O
25	O
mg	O
c	O
24h	O
.	O
The	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
for	O
sudden	O
and	O
intense	O
dyspnoea	O
of	O
less	O
than	O
1	O
hour	O
's	O
duration	O
,	O
at	O
rest	O
,	O
without	O
chest	O
pain	O
.	O
She	O
presented	O
1	O
vomit	O
of	O
food	O
coinciding	O
with	O
the	O
dyspnoea	O
.	O
He	O
denies	O
fever	O
,	O
withdrawal	O
of	O
medication	O
or	O
other	O
intercurrent	O
process	O
.	O
He	O
also	O
reports	O
exertional	O
dyspnoea	O
in	O
recent	O
months	O
,	O
which	O
has	O
been	O
progressing	O
until	O
it	O
has	O
become	O
light	O
exertion	O
and	O
nocturnal	O
dyspnoea	O
for	O
weeks	O
.	O
She	O
has	O
been	O
sleeping	O
with	O
three	O
pillows	O
for	O
years	O
.	O
On	O
physical	O
examination	O
the	O
patient	O
was	O
awake	O
,	O
alert	O
,	O
tachypneic	O
,	O
sweating	O
,	O
afebrile	O
.	O
BP	O
140	O
80	O
MMHG	O
,	O
intercostal	O
stretch	O
,	O
intolerance	O
to	O
decubitus	O
,	O
no	O
jugular	O
engorgement	O
,	O
no	O
carotid	O
murmurs	O
.	O
AC	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
AP	O
preserved	O
vesicular	O
murmur	O
,	O
isolated	O
wheezing	O
and	O
bibasal	O
crackles	O
.	O
The	O
rest	O
of	O
the	O
physical	O
examination	O
was	O
unremarkable	O
.	O
Complementary	O
tests	O
Biochemistry	O
sodium	O
145	O
mmol	O
L	O
,	O
potassium	O
3	O
.	O
6	O
mmol	O
L	O
CPK	O
MB	O
3	O
.	O
7	O
ng	O
mL	O
,	O
myoglobin	O
86	O
ng	O
mL	O
VN	O
15	O
72	O
,	O
ultrasensitive	O
troponin	O
T	O
44	O
.	O
5	O
ng	O
L	O
VN	O
0	O
14	O
,	O
urea	O
64	O
,	O
creatinine	O
1	O
.	O
30	O
mg	O
dL	O
.	O
Haemoglobin	O
13	O
.	O
1	O
g	O
dL	O
,	O
haematocrit	O
39	O
.	O
8	O
,	O
leucocytes	O
9	O
,	O
320	O
,	O
platelets	O
244	O
,	O
00	O
.	O
Coagulation	O
normal	O
.	O
Blood	O
gas	O
on	O
arrival	O
Global	O
respiratory	O
failure	O
with	O
acidosis	O
pH	O
7	O
.	O
145	O
,	O
pCO2	O
61	O
.	O
3	O
mmHg	O
,	O
pO2	O
46	O
.	O
6	O
mmHg	O
.	O
Bicarbonate	O
20	O
.	O
6	O
mmol	O
L	O
,	O
O2Sat	O
66	O
.	O
2	O
.	O
Blood	O
gases	O
after	O
treatment	O
pH	O
7	O
,	O
365	O
,	O
pCO2	O
32	O
.	O
6	O
mmHg	O
,	O
pO2	O
65	O
.	O
6	O
mmHg	O
.	O
Bicarbonate	O
18	O
.	O
2	O
mmol	O
L	O
,	O
O2Sat	O
92	O
.	O
9	O
.	O
ECG	O
Sinus	O
rhythm	O
at	O
90	O
bpm	O
.	O
Axis	O
60o	O
.	O
Inferior	O
Q	O
and	O
QS	O
V3	O
V6	O
,	O
with	O
negative	O
T	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
110ms	O
similar	O
to	O
previous	O
recordings	O
.	O
Chest	O
X	O
ray	O
global	O
cardiomegaly	O
,	O
pulmonary	O
vascular	O
redistribution	O
.	O
Chest	O
CT	O
Large	O
cardiomegaly	O
.	O
Signs	O
of	O
apical	O
vascular	O
redistribution	O
.	O
Moderate	O
bilateral	O
pleural	O
effusion	O
.	O
Bilateral	O
basal	O
atelectasis	O
of	O
lung	O
tissue	O
,	O
mainly	O
on	O
the	O
right	O
.	O
Mild	O
signs	O
of	O
bilateral	O
interstitial	O
pattern	O
.	O
No	O
signs	O
of	O
PTE	O
central	O
bilateral	O
.	O
Echocardiogram	O
Left	O
ventricle	O
severely	O
dilated	O
Dd	O
6	O
.	O
9	O
cm	O
,	O
volume	O
222	O
cm3	O
,	O
with	O
thinning	O
of	O
walls	O
,	O
akinesia	O
of	O
all	O
anterior	O
segments	O
,	O
only	O
basal	O
septum	O
and	O
lateral	O
segments	O
contracting	O
.	O
Estimated	O
LVEF	O
31	O
M	O
mode	O
and	O
35	O
by	O
Simpson	O
.	O
Restrictive	O
mitral	O
pattern	O
E	O
A	O
2	O
.	O
8	O
;	O
deceleration	O
time	O
170	O
ms	O
.	O
Dilated	O
left	O
atrium	O
4	O
.	O
4	O
cm	O
area	O
30	O
cm2	O
.	O
Dilated	O
right	O
chambers	O
,	O
with	O
decreased	O
TAPSE	O
.	O
Aorta	O
not	O
dilated	O
.	O
No	O
significant	O
valvular	O
alterations	O
.	O
Pulmonary	O
acceleration	O
time	O
shortened	O
by	O
87	O
ms	O
.	O
Normal	O
pericardium	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
.	O
Clinical	O
evolution	O
The	O
patient	O
improved	O
rapidly	O
with	O
the	O
treatment	O
prescribed	O
in	O
the	O
emergency	O
department	O
high	O
flow	O
oxygen	B-FARMACO
,	O
nitroglycerine	B-FARMACO
and	O
morphine	O
chloride	O
.	O
Given	O
the	O
suddenness	O
of	O
the	O
symptoms	O
with	O
acute	O
respiratory	O
failure	O
and	O
elevated	O
D	O
dimers	O
,	O
a	O
chest	O
CT	O
scan	O
was	O
performed	O
to	O
rule	O
out	O
pulmonary	O
thromboembolism	O
.	O
He	O
was	O
subsequently	O
transferred	O
to	O
the	O
cardiology	O
ward	O
where	O
he	O
remained	O
clinically	O
and	O
haemodynamically	O
stable	O
,	O
tolerating	O
increasing	O
doses	O
of	O
beta	O
blockers	O
,	O
ACE	O
inhibitors	O
and	O
eplerenone	B-FARMACO
and	O
progressive	O
reduction	O
of	O
furosemide	B-FARMACO
.	O
A	O
new	O
cardiac	O
catheterisation	O
was	O
performed	O
which	O
showed	O
no	O
changes	O
in	O
the	O
coronary	O
arteries	O
with	O
respect	O
to	O
the	O
one	O
performed	O
a	O
year	O
earlier	O
.	O
The	O
patient	O
had	O
dilated	O
cardiomyopathy	O
of	O
probable	O
ischaemic	O
origin	O
with	O
progressive	O
deterioration	O
until	O
dyspnoea	O
at	O
rest	O
.	O
However	O
,	O
the	O
patient	O
came	O
from	O
a	O
Chagas	O
endemic	O
area	O
and	O
had	O
a	O
family	O
history	O
of	O
the	O
disease	O
,	O
so	O
it	O
was	O
decided	O
to	O
request	O
serology	O
for	O
Trypanosoma	O
cruzi	O
,	O
which	O
was	O
positive	O
.	O
DNA	O
amplification	O
by	O
PCR	O
of	O
Trypanosoma	O
cruzi	O
in	O
whole	O
blood	O
was	O
also	O
positive	O
and	O
the	O
patient	O
was	O
diagnosed	O
with	O
chronic	O
Chagas	O
disease	O
.	O
Given	O
the	O
severe	O
ventricular	O
dysfunction	O
and	O
poor	O
functional	O
class	O
that	O
persisted	O
despite	O
optimising	O
medical	O
treatment	O
,	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
was	O
implanted	O
as	O
primary	O
prevention	O
of	O
sudden	O
death	O
.	O
In	O
our	O
case	O
we	O
are	O
left	O
with	O
the	O
doubt	O
as	O
to	O
whether	O
the	O
cardiac	O
involvement	O
is	O
only	O
due	O
to	O
ischaemic	O
heart	O
disease	O
,	O
as	O
seems	O
more	O
likely	O
,	O
or	O
whether	O
there	O
is	O
also	O
chagasic	O
involvement	O
due	O
to	O
the	O
patient	O
being	O
chronically	O
infected	O
with	O
Trypanosoma	O
cruzi	O
.	O
We	O
have	O
not	O
found	O
any	O
case	O
in	O
the	O
literature	O
in	O
which	O
both	O
processes	O
are	O
described	O
together	O
.	O
Diagnosis	O
Acute	O
heart	O
failure	O
Acute	O
pulmonary	O
oedema	O
.	O
Dilated	O
cardiomyopathy	O
of	O
probable	O
ischaemic	O
origin	O
with	O
severe	O
ventricular	O
dysfunction	O
LVEF	O
30	O
35	O
vs	O
.	O
chagasic	O
cardiomyopathy	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
inferior	O
and	O
anterior	O
necrosis	O
.	O

Clinical	O
history	O
and	O
current	O
illness	O
A	O
54	O
year	O
old	O
man	O
,	O
of	O
Uruguayan	O
origin	O
,	O
who	O
was	O
living	O
in	O
our	O
health	O
care	O
area	O
for	O
work	O
reasons	O
as	O
a	O
transporter	O
.	O
He	O
was	O
admitted	O
with	O
heart	O
failure	O
and	O
episodes	O
of	O
back	O
pain	O
.	O
No	O
known	O
drug	O
allergies	O
Smoker	O
of	O
1	O
pack	O
of	O
cigarettes	O
day	O
History	O
of	O
depressive	O
syndrome	O
Hypertensive	O
and	O
dyslipidaemic	O
Carrier	O
of	O
chronic	O
anti	O
aggregation	O
atrial	O
fibrillation	O
.	O
No	O
previous	O
cardiology	O
assessment	O
.	O
No	O
family	O
history	O
of	O
cardiovascular	O
disease	O
of	O
interest	O
Home	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
,	O
digoxin	B-FARMACO
,	O
furosemide	B-FARMACO
,	O
pravastatin	B-FARMACO
Patient	O
with	O
the	O
aforementioned	O
history	O
was	O
admitted	O
4	O
days	O
ago	O
to	O
the	O
Digestive	O
Service	O
with	O
a	O
clinical	O
diagnosis	O
of	O
cholelithiasis	O
with	O
suspicion	O
of	O
cholangitis	O
,	O
based	O
on	O
clinical	O
manifestations	O
of	O
abdominal	O
pain	O
of	O
increasing	O
intensity	O
,	O
colicky	O
,	O
which	O
intensified	O
with	O
palpation	O
of	O
the	O
right	O
hypochondrium	O
and	O
epigastrium	O
,	O
accompanied	O
by	O
fever	O
and	O
laboratory	O
data	O
compatible	O
with	O
infection	O
discrete	O
leukocytosis	O
13450	O
leukocytes	O
uL	O
with	O
left	O
deviation	O
91	O
neutrophils	O
with	O
8	O
casts	O
.	O
During	O
his	O
stay	O
in	O
the	O
Digestive	O
Department	O
,	O
abdominal	O
pain	O
was	O
controlled	O
with	O
the	O
use	O
of	O
WHO	O
scale	O
1	O
analgesics	O
.	O
However	O
,	O
in	O
view	O
of	O
the	O
marked	O
clinical	O
manifestations	O
of	O
right	O
sided	O
heart	O
failure	O
,	O
an	O
echocardiogram	O
was	O
requested	O
and	O
a	O
referral	O
to	O
the	O
Cardiology	O
Department	O
was	O
made	O
.	O
The	O
transthoracic	O
echocardiogram	O
revealed	O
a	O
type	O
A	O
aortic	O
dissection	O
with	O
a	O
dilated	O
root	O
and	O
severe	O
aortic	O
insufficiency	O
,	O
as	O
well	O
as	O
severe	O
mitral	O
insufficiency	O
with	O
a	O
dilated	O
and	O
dysfunctional	O
left	O
ventricle	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
Coronary	O
Unit	O
to	O
complete	O
the	O
study	O
chest	O
CT	O
scan	O
prior	O
to	O
surgery	O
.	O
On	O
cross	O
examination	O
,	O
the	O
patient	O
reported	O
progressive	O
dyspnoea	O
up	O
to	O
NYHA	O
class	O
II	O
for	O
a	O
month	O
and	O
a	O
half	O
,	O
and	O
in	O
the	O
last	O
week	O
several	O
episodes	O
of	O
back	O
pain	O
that	O
required	O
the	O
administration	O
of	O
anti	O
inflammatory	O
drugs	O
.	O
He	O
did	O
not	O
clearly	O
complain	O
of	O
chest	O
pain	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
120	O
80	O
mmHg	O
.	O
Heart	O
rate	O
88	O
bpm	O
.	O
Temperature	O
36	O
.	O
7	O
C	O
.	O
Good	O
general	O
appearance	O
.	O
Normal	O
hydration	O
,	O
normal	O
colour	O
,	O
normoperfused	O
.	O
Eupneic	O
SaO2	O
98	O
with	O
nasal	O
cannulae	O
at	O
3	O
bpm	O
.	O
Head	O
and	O
neck	O
no	O
goitre	O
.	O
Carotids	O
rhythmic	O
and	O
without	O
murmurs	O
.	O
No	O
jugular	O
venous	O
engorgement	O
at	O
45	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
.	O
Decreasing	O
diastolic	O
exhalation	O
murmur	O
in	O
accessory	O
aortic	O
focus	O
of	O
intensity	O
IV	O
VI	O
Levine	O
scale	O
.	O
Decreasing	O
holosystolic	O
murmur	O
of	O
IV	O
VI	O
intensity	O
in	O
mitral	O
focus	O
with	O
irradiation	O
to	O
the	O
axilla	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
with	O
bibasal	O
crackles	O
.	O
Abdomen	O
globular	O
,	O
soft	O
,	O
depressible	O
.	O
No	O
masses	O
palpable	O
.	O
Hepatomegaly	O
of	O
2	O
finger	O
widths	O
.	O
Discomfort	O
on	O
palpation	O
in	O
the	O
right	O
hypochondrium	O
.	O
No	O
signs	O
of	O
acute	O
abdomen	O
.	O
Peristaltic	O
sounds	O
preserved	O
.	O
No	O
abdominal	O
murmurs	O
.	O
Extremities	O
pulses	O
present	O
and	O
symmetrical	O
in	O
the	O
upper	O
extremities	O
.	O
In	O
lower	O
limbs	O
,	O
presence	O
of	O
oedema	O
with	O
fovea	O
up	O
to	O
the	O
middle	O
region	O
of	O
both	O
legs	O
,	O
preventing	O
the	O
determination	O
of	O
peripheral	O
pulses	O
.	O
Signs	O
of	O
venous	O
insufficiency	O
with	O
no	O
evidence	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Neurological	O
no	O
gross	O
neurological	O
focality	O
.	O
Complementary	O
tests	O
ECG	O
atrial	O
fibrillation	O
at	O
88	O
bpm	O
.	O
Signs	O
of	O
left	O
ventricular	O
hypertrophy	O
with	O
evidence	O
of	O
systolic	O
overload	O
.	O
CBC	O
haemoglobin	O
12	O
.	O
7	O
g	O
dL	O
,	O
haematocrit	O
40	O
.	O
7	O
,	O
leukocytes	O
13830	O
uL	O
85	O
neutrophils	O
,	O
8	O
.	O
3	O
lymphocytes	O
,	O
platelets	O
245000	O
uL	O
;	O
biochemistry	O
glucose	O
102	O
mg	O
dL	O
,	O
urea	O
44	O
.	O
0	O
mg	O
dL	O
,	O
creatinine	O
1	O
.	O
1	O
mg	O
dL	O
,	O
total	O
bilirubin	O
4	O
.	O
6	O
mg	O
dL	O
,	O
GOT	O
AST	O
ASAT	O
41	O
IU	O
L	O
,	O
GPT	O
ALT	O
ALAT	O
32	O
IU	O
L	O
,	O
GGT	O
70	O
IU	O
L	O
,	O
alkaline	O
phosphatases	O
191	O
IU	O
L	O
,	O
CK	O
85	O
IU	O
L	O
,	O
troponin	O
I	O
0	O
.	O
09	O
ng	O
dL	O
,	O
sodium	O
130	O
mMol	O
L	O
,	O
potassium	O
4	O
.	O
5	O
mMol	O
L	O
;	O
coagulation	O
quick	O
's	O
time	O
21	O
.	O
0	O
,	O
ratio	O
1	O
.	O
86	O
,	O
INR	O
1	O
.	O
84	O
,	O
aPTT	O
29	O
.	O
7	O
,	O
aPTT	O
ratio	O
0	O
.	O
99	O
.	O
Chest	O
X	O
ray	O
enlarged	O
cardiopericardial	O
silhouette	O
with	O
Kerley	O
's	O
B	O
lines	O
and	O
right	O
costophrenic	O
sinus	O
impingement	O
.	O
Echocardiogram	O
severely	O
dilated	O
left	O
ventricle	O
DTD	O
78	O
DTS	O
67	O
,	O
with	O
normal	O
thickness	O
septum	O
10	O
and	O
posterior	O
wall	O
9	O
mm	O
.	O
Global	O
hypokinesia	O
more	O
marked	O
in	O
anterior	O
and	O
septal	O
territory	O
,	O
leading	O
to	O
severe	O
left	O
ventricular	O
dysfunction	O
LVEF	O
Teich	O
27	O
.	O
Aortic	O
valve	O
trivava	O
,	O
with	O
severe	O
regurgitation	O
flow	O
jet	O
diameter	O
adjusted	O
by	O
outflow	O
tract	O
diameter	O
greater	O
than	O
70	O
secondary	O
to	O
anterior	O
leaflet	O
prolapse	O
.	O
Sclerosed	O
mitral	O
valve	O
,	O
with	O
eccentric	O
holosystolic	O
insufficiency	O
,	O
towards	O
the	O
lateral	O
wall	O
of	O
the	O
left	O
atrium	O
,	O
of	O
severe	O
degree	O
vena	O
contracta	O
9	O
mm	O
,	O
secondary	O
to	O
dilatation	O
of	O
the	O
mitral	O
annulus	O
52	O
mm	O
with	O
tenting	O
of	O
the	O
posterior	O
leaflet	O
.	O
Dilated	O
left	O
atrium	O
area	O
38	O
cm2	O
.	O
Dilated	O
right	O
ventricle	O
basal	O
DTD	O
50	O
mm	O
.	O
Moderate	O
tricuspid	O
insufficiency	O
,	O
with	O
RV	O
AD	O
gradient	O
25	O
mmHg	O
.	O
TAPSE	O
16	O
mm	O
.	O
Dilated	O
vena	O
cava	O
26	O
mm	O
with	O
50	O
collapse	O
.	O
Aneurysmal	O
ascending	O
aorta	O
59	O
m	O
with	O
an	O
image	O
suggestive	O
of	O
flap	O
about	O
20	O
mm	O
from	O
the	O
aortic	O
root	O
showing	O
double	O
lumen	O
.	O
It	O
is	O
not	O
possible	O
to	O
assess	O
the	O
aortic	O
arch	O
.	O
Slight	O
pericardial	O
effusion	O
at	O
the	O
level	O
of	O
the	O
roof	O
of	O
the	O
right	O
atrium	O
.	O
Thoracic	O
CT	O
aneurysm	O
in	O
the	O
ascending	O
thoracic	O
aorta	O
with	O
diameters	O
in	O
the	O
valvular	O
annulus	O
3	O
.	O
7x3	O
.	O
5	O
cm	O
,	O
in	O
the	O
sinus	O
portion	O
5	O
.	O
4x5	O
.	O
9	O
cm	O
,	O
in	O
the	O
sinotubular	O
junction	O
5	O
.	O
2x5	O
.	O
1	O
cm	O
,	O
maximum	O
in	O
the	O
ascending	O
aorta	O
6	O
.	O
86x6	O
.	O
4	O
cm	O
,	O
anterior	O
to	O
the	O
brachiocephalic	O
trunk	O
exit	O
4	O
.	O
5x4	O
.	O
4	O
cm	O
,	O
posterior	O
to	O
the	O
brachiocephalic	O
trunk	O
exit	O
4x3	O
.	O
4	O
cm	O
,	O
in	O
the	O
descending	O
aorta	O
3	O
.	O
2x3	O
cm	O
.	O
Type	O
A	O
aortic	O
dissection	O
starting	O
in	O
the	O
sinus	O
plane	O
of	O
the	O
ascending	O
thoracic	O
aorta	O
and	O
extending	O
to	O
the	O
descending	O
thoracic	O
aorta	O
2	O
cm	O
distal	O
to	O
the	O
origin	O
of	O
the	O
left	O
subclavian	O
artery	O
.	O
There	O
is	O
a	O
focal	O
haematoma	O
thrombus	O
at	O
the	O
origin	O
of	O
the	O
dissection	O
which	O
occupies	O
the	O
non	O
coronary	O
sinus	O
and	O
extends	O
into	O
the	O
region	O
of	O
the	O
sinotubular	O
junction	O
.	O
All	O
three	O
supra	O
aortic	O
trunks	O
and	O
both	O
carotids	O
originate	O
from	O
the	O
true	O
lumen	O
.	O
Multiple	O
repletion	O
defects	O
in	O
the	O
pulmonary	O
arterial	O
tree	O
in	O
association	O
with	O
pulmonary	O
thromboembolism	O
.	O
At	O
the	O
level	O
of	O
the	O
right	O
pulmonary	O
tree	O
in	O
the	O
right	O
superior	O
lobar	O
artery	O
with	O
extension	O
to	O
its	O
three	O
segmental	O
branches	O
and	O
several	O
sub	O
segmental	O
branches	O
and	O
in	O
the	O
bifurcation	O
of	O
the	O
middle	O
lobar	O
artery	O
with	O
extension	O
to	O
its	O
two	O
segmental	O
branches	O
.	O
At	O
the	O
level	O
of	O
the	O
left	O
pulmonary	O
tree	O
in	O
multiple	O
segmental	O
and	O
subsegmental	O
arteries	O
of	O
the	O
LSI	O
including	O
lingular	O
arteries	O
and	O
LII	O
.	O
Multiple	O
peripheral	O
focal	O
pulmonary	O
opacities	O
in	O
the	O
right	O
upper	O
hemithorax	O
and	O
consolidations	O
in	O
the	O
posterior	O
regions	O
of	O
both	O
lower	O
lobes	O
more	O
prominent	O
in	O
the	O
left	O
compatible	O
with	O
areas	O
of	O
atelectasis	O
and	O
or	O
infarction	O
.	O
Bilateral	O
pleural	O
effusion	O
.	O
Hepatomegaly	O
with	O
diffuse	O
altered	O
enhancement	O
in	O
relation	O
to	O
stasis	O
liver	O
.	O
This	O
finding	O
together	O
with	O
an	O
increased	O
calibre	O
of	O
the	O
inferior	O
vena	O
cava	O
slightly	O
larger	O
than	O
the	O
adjacent	O
abdominal	O
aorta	O
,	O
the	O
diffuse	O
infiltration	O
of	O
the	O
abdominal	O
subcutaneous	O
fat	O
and	O
the	O
minimal	O
amount	O
of	O
perirenal	O
fluid	O
suggest	O
altered	O
haemodynamic	O
status	O
due	O
to	O
probable	O
right	O
heart	O
failure	O
.	O
Gall	O
bladder	O
stone	O
measuring	O
2	O
.	O
3x1	O
.	O
7x3	O
cm	O
in	O
relation	O
to	O
cholelithiasis	O
.	O
Clinical	O
course	O
A	O
54	O
year	O
old	O
man	O
was	O
admitted	O
to	O
the	O
Coronary	O
Care	O
Unit	O
from	O
the	O
Digestive	O
Department	O
where	O
he	O
had	O
been	O
admitted	O
for	O
cholelithiasis	O
under	O
study	O
.	O
The	O
reason	O
for	O
his	O
transfer	O
was	O
a	O
type	O
A	O
aortic	O
dissection	O
,	O
in	O
the	O
context	O
of	O
biventricular	O
dysfunction	O
with	O
severe	O
aortic	O
and	O
mitral	O
insufficiency	O
,	O
both	O
of	O
them	O
severe	O
.	O
As	O
a	O
serious	O
associated	O
comorbidity	O
,	O
he	O
also	O
presented	O
bilateral	O
pulmonary	O
thromboembolism	O
with	O
acceptable	O
haemodynamic	O
tolerance	O
.	O
Given	O
the	O
coexistence	O
of	O
both	O
entities	O
and	O
the	O
initial	O
clinical	O
and	O
haemodynamic	O
stability	O
of	O
the	O
patient	O
,	O
it	O
was	O
decided	O
to	O
manage	O
the	O
patient	O
conservatively	O
at	O
first	O
,	O
trying	O
to	O
resolve	O
the	O
heart	O
failure	O
data	O
and	O
see	O
the	O
evolution	O
of	O
the	O
pulmonary	O
arterial	O
pathology	O
,	O
as	O
there	O
was	O
a	O
limitation	O
in	O
the	O
use	O
of	O
anticoagulation	O
at	O
recommended	O
doses	O
in	O
the	O
presence	O
of	O
aortic	O
dissection	O
.	O
In	O
addition	O
,	O
a	O
venous	O
echo	O
Doppler	O
of	O
the	O
lower	O
limbs	O
was	O
performed	O
,	O
which	O
ruled	O
out	O
the	O
presence	O
of	O
deep	O
vein	O
thrombosis	O
that	O
could	O
justify	O
the	O
implantation	O
of	O
a	O
cava	O
filter	O
to	O
prevent	O
recurrence	O
of	O
pulmonary	O
thromboembolism	O
in	O
a	O
patient	O
limited	O
to	O
anticoagulation	O
.	O
However	O
,	O
in	O
subsequent	O
days	O
the	O
patient	O
evolved	O
unfavourably	O
,	O
with	O
recurrent	O
episodes	O
of	O
chest	O
pain	O
and	O
cardiac	O
arrest	O
secondary	O
to	O
electromechanical	O
dissociation	O
that	O
required	O
advanced	O
cardiopulmonary	O
resuscitation	O
manoeuvres	O
,	O
which	O
were	O
successfully	O
resolved	O
.	O
The	O
emergent	O
echocardiogram	O
ruled	O
out	O
cardiac	O
tamponade	O
and	O
the	O
emergent	O
aortic	O
angio	O
CT	O
ruled	O
out	O
aortic	O
rupture	O
or	O
associated	O
complications	O
,	O
although	O
it	O
showed	O
retrograde	O
progression	O
of	O
the	O
aortic	O
dissection	O
towards	O
the	O
right	O
sinus	O
of	O
Valsalva	O
without	O
involvement	O
of	O
the	O
right	O
coronary	O
artery	O
.	O
In	O
view	O
of	O
this	O
clinical	O
situation	O
,	O
the	O
decision	O
was	O
made	O
to	O
perform	O
urgent	O
surgery	O
.	O
A	O
Bentall	O
procedure	O
was	O
performed	O
with	O
a	O
valved	O
tube	O
and	O
mitral	O
annuloplasty	O
with	O
a	O
Carpentier	O
ring	O
,	O
and	O
the	O
patient	O
died	O
in	O
the	O
operating	O
theatre	O
after	O
unresponsive	O
cardiac	O
arrest	O
.	O
Diagnosis	O
Type	O
A	O
aortic	O
dissection	O
Bilateral	O
pulmonary	O
thromboembolism	O
Severe	O
biventricular	O
dysfunction	O
Severe	O
aortic	O
and	O
mitral	O
regurgitation	O

Clinical	O
history	O
and	O
current	O
illness	O
22	O
year	O
old	O
woman	O
with	O
a	O
personal	O
history	O
of	O
fibromyalgia	O
,	O
ex	O
smoker	O
of	O
6	O
8	O
cigarettes	O
a	O
day	O
and	O
elective	O
caesarean	O
section	O
the	O
month	O
prior	O
to	O
the	O
current	O
admission	O
,	O
with	O
subsequent	O
readmission	O
for	O
febrile	O
syndrome	O
secondary	O
to	O
possible	O
infection	O
of	O
the	O
surgical	O
wound	O
.	O
Microbiological	O
isolation	O
of	O
wound	O
exudate	O
was	O
not	O
obtained	O
and	O
she	O
was	O
discharged	O
home	O
.	O
Fever	O
persists	O
associated	O
with	O
catarrhal	O
symptoms	O
of	O
the	O
upper	O
respiratory	O
tract	O
,	O
followed	O
by	O
progressive	O
dyspnoea	O
on	O
exertion	O
until	O
she	O
rested	O
,	O
chest	O
pain	O
with	O
pleuritic	O
characteristics	O
and	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
Physical	O
examination	O
On	O
admission	O
,	O
general	O
condition	O
was	O
fair	O
,	O
tachypneic	O
at	O
rest	O
and	O
with	O
slight	O
jugular	O
engorgement	O
.	O
Blood	O
pressure	O
110	O
80	O
mmHg	O
.	O
No	O
abnormal	O
decrease	O
in	O
systolic	O
pressure	O
and	O
pulse	O
amplitude	O
during	O
inspiration	O
paradoxical	O
pulse	O
was	O
detected	O
.	O
Afebrile	O
.	O
Cardiorespiratory	O
auscultation	O
rhythmic	O
,	O
without	O
murmurs	O
,	O
tachycardic	O
at	O
140	O
beats	O
per	O
minute	O
bpm	O
,	O
good	O
bilateral	O
vesicular	O
murmur	O
with	O
slight	O
bibasal	O
crackles	O
and	O
left	O
basal	O
hypophonesis	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
and	O
without	O
visceromegaly	O
.	O
Lower	O
limbs	O
with	O
slight	O
pretibial	O
oedema	O
.	O
The	O
rest	O
of	O
the	O
examination	O
was	O
unremarkable	O
.	O
Complementary	O
tests	O
Electrocardiogram	O
ECG	O
sinus	O
tachycardia	O
at	O
146	O
bpm	O
,	O
low	O
voltage	O
and	O
low	O
R	O
wave	O
from	O
V1	O
to	O
V3	O
.	O
Laboratory	O
tests	O
biochemistry	O
with	O
normal	O
ions	O
and	O
renal	O
function	O
.	O
Haemogram	O
with	O
normocytic	O
anaemia	O
,	O
normochromic	O
haemoglobin	O
8	O
g	O
dl	O
,	O
slight	O
lymphopenia	O
.	O
Coagulation	O
normal	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
,	O
slight	O
left	O
pleural	O
effusion	O
.	O
Transthoracic	O
echocardiography	O
non	O
dilated	O
left	O
ventricle	O
LV	O
with	O
end	O
diastolic	O
diameter	O
EDD	O
of	O
42	O
mm	O
,	O
slight	O
concentric	O
hypertrophy	O
12	O
13	O
mm	O
.	O
Generalised	O
hypokinesia	O
with	O
severely	O
depressed	O
ejection	O
fraction	O
LVEF	O
less	O
than	O
30	O
measured	O
by	O
Simpson	O
method	O
in	O
apical	O
four	O
chambers	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Moderate	O
severe	O
pericardial	O
effusion	O
PD	O
,	O
circumferential	O
,	O
1	O
.	O
9	O
2	O
cm	O
,	O
predominantly	O
inferior	O
,	O
posterior	O
and	O
lateral	O
LV	O
.	O
Extension	O
to	O
the	O
free	O
wall	O
of	O
the	O
right	O
ventricle	O
RV	O
and	O
right	O
atrium	O
RA	O
,	O
with	O
partial	O
collapse	O
.	O
In	O
the	O
diaphragmatic	O
face	O
,	O
a	O
1	O
.	O
3	O
cm	O
chamber	O
was	O
observed	O
.	O
No	O
respiratory	O
variations	O
in	O
valvular	O
flows	O
.	O
Inferior	O
vena	O
cava	O
with	O
a	O
diameter	O
of	O
20	O
mm	O
,	O
without	O
inspiratory	O
collapse	O
.	O
Clinical	O
evolution	O
Initially	O
conservative	O
management	O
,	O
with	O
administration	O
of	O
serum	O
therapy	O
,	O
transfusion	O
of	O
2	O
red	O
blood	O
cell	O
concentrates	O
the	O
anaemia	O
was	O
initially	O
related	O
to	O
the	O
recent	O
caesarean	O
section	O
and	O
oral	O
non	O
steroidal	O
anti	O
inflammatory	O
drugs	O
NSAIDs	O
.	O
Elective	O
pericardiocentesis	O
was	O
performed	O
via	O
the	O
left	O
parasternal	O
route	O
,	O
draining	O
490	O
ml	O
of	O
serous	O
fluid	O
with	O
biochemical	O
characteristics	O
of	O
exudate	O
and	O
total	O
debit	O
of	O
790	O
ml	O
.	O
Low	O
dose	O
beta	O
blockers	O
and	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
were	O
started	O
,	O
with	O
good	O
initial	O
tolerance	O
.	O
Subsequently	O
,	O
he	O
began	O
with	O
increased	O
work	O
of	O
breathing	O
and	O
signs	O
of	O
pulmonary	O
congestion	O
,	O
which	O
led	O
to	O
the	O
initiation	O
of	O
intravenous	O
diuretics	O
.	O
Chest	O
X	O
ray	O
showed	O
an	O
increase	O
in	O
the	O
amount	O
of	O
left	O
pleural	O
effusion	O
,	O
and	O
diagnostic	O
therapeutic	O
thoracentesis	O
was	O
performed	O
,	O
obtaining	O
serous	O
fluid	O
.	O
Poor	O
clinical	O
evolution	O
,	O
even	O
initiating	O
a	O
pre	O
transplant	O
study	O
protocol	O
.	O
Control	O
transthoracic	O
echocardiography	O
was	O
performed	O
,	O
showing	O
LV	O
with	O
severe	O
systolic	O
dysfunction	O
LVEF	O
20	O
25	O
,	O
in	O
addition	O
to	O
severe	O
RV	O
systolic	O
dysfunction	O
,	O
tricuspid	O
regurgitation	O
TR	O
grade	O
II	O
over	O
IV	O
and	O
estimated	O
pulmonary	O
systolic	O
pressure	O
PAPs	O
of	O
40	O
mmHg	O
.	O
Minimal	O
PD	O
.	O
After	O
a	O
targeted	O
re	O
examination	O
of	O
the	O
patient	O
,	O
and	O
faced	O
with	O
the	O
need	O
to	O
make	O
a	O
differential	O
diagnosis	O
,	O
she	O
reported	O
the	O
appearance	O
of	O
skin	O
lesions	O
related	O
to	O
sun	O
exposure	O
over	O
several	O
years	O
of	O
evolution	O
.	O
This	O
,	O
together	O
with	O
the	O
analytical	O
data	O
of	O
normocytic	O
normochromic	O
anaemia	O
,	O
lymphopenia	O
,	O
febrile	O
syndrome	O
and	O
pleuropericardial	O
serositis	O
,	O
led	O
us	O
to	O
suspect	O
a	O
possible	O
outbreak	O
of	O
systemic	O
lupus	O
erythematosus	O
SLE	O
with	O
myocardial	O
involvement	O
as	O
the	O
aetiology	O
.	O
After	O
further	O
laboratory	O
tests	O
,	O
positive	O
antinuclear	O
antibodies	O
ANA	O
,	O
positive	O
anti	O
DNA	O
,	O
hypocomplementemia	O
,	O
moderate	O
levels	O
of	O
anticardiolipin	O
antibodies	O
,	O
hypergammagrobulinaemia	O
,	O
elevated	O
LDH	O
and	O
positive	O
Coombs	O
test	O
sign	O
of	O
haemolytic	O
anaemia	O
were	O
obtained	O
,	O
which	O
led	O
to	O
a	O
definitive	O
diagnosis	O
of	O
a	O
lupus	O
outbreak	O
with	O
expression	O
of	O
pancarditis	O
and	O
severe	O
biventricular	O
systolic	O
dysfunction	O
.	O
Diagnosis	O
Lupus	O
flare	O
with	O
expression	O
of	O
pancarditis	O
,	O
cardiac	O
tamponade	O
and	O
severe	O
biventricular	O
systolic	O
dysfunction	O
.	O

Medical	O
history	O
and	O
current	O
illness	O
A	O
61	O
year	O
old	O
man	O
consulted	O
for	O
dyspnoea	O
and	O
chest	O
pain	O
.	O
AP	O
long	O
standing	O
IDDM	O
.	O
Diabetic	O
retinopathy	O
photocoagulation	O
.	O
DLP	O
.	O
Smoker	O
of	O
1	O
pack	O
day	O
until	O
September	O
2011	O
No	O
COPD	O
.	O
Recurrent	O
spixtasis	O
in	O
2008	O
,	O
requiring	O
arteriography	O
and	O
embolisation	O
of	O
both	O
internal	O
maxillary	O
arteries	O
.	O
Admission	O
in	O
September	O
2009	O
self	O
limited	O
confusional	O
disorder	O
with	O
normal	O
tests	O
CT	O
,	O
MRI	O
and	O
EEG	O
,	O
classified	O
as	O
probably	O
of	O
ischaemic	O
origin	O
.	O
AE	O
admission	O
in	O
September	O
2011	O
exertional	O
angina	O
HF	O
NYHA	O
functional	O
class	O
II	O
of	O
two	O
weeks	O
'	O
evolution	O
.	O
EF	O
systolic	O
murmur	O
in	O
aortic	O
focus	O
with	O
reduction	O
of	O
aortic	O
component	O
of	O
2R	O
that	O
does	O
not	O
disappear	O
.	O
4R	O
present	O
.	O
No	O
crackles	O
.	O
Complementary	O
tests	O
CBC	O
glucose	O
,	O
renal	O
function	O
and	O
ions	O
normal	O
.	O
Serial	O
CK	O
and	O
TnT	O
US	O
normal	O
.	O
Normal	O
liver	O
profile	O
.	O
ProBNP	O
1256	O
.	O
Normal	O
haemogram	O
.	O
ECG	O
Sinus	O
rhythm	O
at	O
65	O
bpm	O
,	O
constant	O
PR	O
,	O
narrow	O
QRS	O
,	O
scarce	O
growth	O
of	O
R	O
in	O
precordials	O
.	O
Left	O
axis	O
.	O
Chest	O
X	O
ray	O
cardiac	O
silhouette	O
of	O
normal	O
size	O
.	O
Pulmonary	O
parenchyma	O
without	O
findings	O
of	O
interest	O
.	O
Echocardiography	O
LA	O
normal	O
size	O
.	O
Moderate	O
severe	O
concentric	O
LVH	O
,	O
without	O
segmental	O
contractility	O
defects	O
,	O
preserved	O
LVEF	O
.	O
RV	O
normal	O
.	O
MV	O
and	O
TVR	O
normal	O
.	O
Bicuspid	O
aortic	O
valve	O
severely	O
calcified	O
and	O
very	O
unstructured	O
with	O
significant	O
restriction	O
to	O
valve	O
opening	O
,	O
without	O
being	O
able	O
to	O
adequately	O
record	O
transvalvular	O
gradients	O
.	O
Ascending	O
aorta	O
dilated	O
from	O
the	O
root	O
45mm	O
.	O
Coronary	O
angiography	O
LMCA	O
without	O
lesions	O
.	O
LAD	O
with	O
severe	O
lesion	O
at	O
the	O
beginning	O
of	O
bifurcational	O
middle	O
segment	O
with	O
diagonal	O
branch	O
,	O
good	O
distal	O
beds	O
.	O
ACX	O
without	O
significant	O
lesions	O
.	O
ACD	O
with	O
moderate	O
lesion	O
in	O
the	O
middle	O
segment	O
,	O
rest	O
of	O
the	O
vessel	O
without	O
lesions	O
.	O
Severe	O
AoS	O
with	O
peak	O
to	O
peak	O
gradient	O
50	O
mmHg	O
.	O
Angio	O
CT	O
aorta	O
diffuse	O
aneurysmal	O
dilatation	O
of	O
the	O
aortic	O
root	O
and	O
ascending	O
aorta	O
measuring	O
45x46	O
mm	O
.	O
Normalises	O
diameter	O
from	O
the	O
aortic	O
arch	O
maximum	O
arch	O
diameter	O
28	O
mm	O
,	O
proximal	O
descending	O
thoracic	O
aorta	O
28	O
mm	O
,	O
distal	O
descending	O
thoracic	O
aorta	O
22	O
mm	O
.	O
Clinical	O
evolution	O
He	O
progressed	O
favourably	O
on	O
the	O
Cardiology	O
ward	O
with	O
diuretic	O
treatment	O
which	O
was	O
subsequently	O
suspended	O
,	O
in	O
addition	O
to	O
ASA	B-FARMACO
100	O
mg	O
1cp	O
24h	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
1cp	O
12h	O
,	O
simvastatin	B-FARMACO
40	O
mg	O
1cp	O
at	O
dinner	O
,	O
ramipril	B-FARMACO
10	O
mg	O
1cp	O
at	O
breakfast	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1cp	O
at	O
breakfast	O
,	O
NTG	B-FARMACO
patch	O
10	O
mg	O
9	O
23h	O
,	O
insulin	B-FARMACO
Humalog	I-FARMACO
mix	O
21	O
22	O
21	O
.	O
He	O
was	O
considered	O
to	O
require	O
aortic	O
valve	O
replacement	O
surgery	O
,	O
repair	O
of	O
the	O
ascending	O
aorta	O
valved	O
tube	O
and	O
coronary	O
artery	O
bypass	O
surgery	O
.	O
He	O
was	O
discharged	O
home	O
on	O
6	O
October	O
2011	O
.	O
Preferential	O
appointment	O
was	O
requested	O
for	O
cardiac	O
surgery	O
.	O
She	O
was	O
readmitted	O
on	O
16	O
October	O
2011	O
due	O
to	O
chest	O
pain	O
with	O
an	O
ischaemic	O
profile	O
and	O
decompensated	O
heart	O
failure	O
in	O
acute	O
pulmonary	O
oedema	O
.	O
He	O
required	O
NIMV	O
and	O
was	O
admitted	O
to	O
the	O
coronary	O
ICU	O
,	O
being	O
discharged	O
to	O
the	O
cardiology	O
ward	O
after	O
a	O
good	O
clinical	O
evolution	O
three	O
days	O
later	O
.	O
He	O
presented	O
an	O
episode	O
of	O
AF	O
with	O
RVR	O
reverting	O
to	O
RS	O
after	O
PC	O
of	O
amiodarone	B-FARMACO
.	O
ECG	O
unchanged	O
.	O
Serial	O
myocardial	O
damage	O
enzymes	O
were	O
normal	O
.	O
Echocardiography	O
was	O
repeated	O
severe	O
AoS	O
,	O
peak	O
gradient	O
69	O
mmHg	O
,	O
mean	O
gradient	O
43	O
mmHg	O
,	O
peak	O
velocity	O
4	O
.	O
2	O
m	O
s	O
,	O
gradients	O
recorded	O
in	O
the	O
right	O
parasternal	O
plane	O
.	O
Given	O
the	O
negative	O
clinical	O
evolution	O
of	O
the	O
patient	O
on	O
the	O
ward	O
,	O
a	O
transfer	O
to	O
the	O
Cardiac	O
Surgery	O
Department	O
of	O
his	O
reference	O
hospital	O
was	O
requested	O
on	O
27	O
October	O
.	O
He	O
was	O
admitted	O
to	O
the	O
Cardiac	O
Surgery	O
Department	O
from	O
27	O
October	O
to	O
1	O
December	O
2011	O
.	O
Repeat	O
PPCC	O
new	O
CNG	O
severe	O
bifurcated	O
lesion	O
of	O
the	O
medial	O
LAD	O
and	O
diagonal	O
branch	O
.	O
Preoperative	O
echocardiography	O
calcified	O
aortic	O
valve	O
with	O
very	O
reduced	O
opening	O
,	O
maximum	O
gradient	O
70	O
mmHg	O
,	O
mean	O
40	O
mmHg	O
could	O
be	O
underestimated	O
.	O
Aortic	O
root	O
measurements	O
45	O
mm	O
in	O
sinuses	O
of	O
Valsalva	O
;	O
43	O
mm	O
tubular	O
level	O
.	O
Aortic	O
annulus	O
28	O
mm	O
.	O
LV	O
with	O
septal	O
hypertrophy	O
18	O
m	O
,	O
not	O
dilated	O
with	O
EF	O
64	O
.	O
Imaging	O
test	O
recommended	O
to	O
better	O
define	O
the	O
dimensions	O
of	O
the	O
ascending	O
aorta	O
not	O
performed	O
.	O
Intervention	O
on	O
9	O
November	O
2011	O
resection	O
of	O
aortic	O
valve	O
Mitroflow	O
biological	O
prosthesis	O
no	O
.	O
25	O
.	O
Elongated	O
aorta	O
,	O
no	O
impression	O
of	O
great	O
disproportion	O
with	O
the	O
rest	O
of	O
the	O
cardiac	O
structures	O
.	O
DA	O
of	O
good	O
quality	O
.	O
Mammary	O
bypass	O
is	O
performed	O
to	O
ADA	O
.	O
Good	O
anoxia	O
and	O
pump	O
output	O
.	O
Left	O
pleural	O
drainage	O
and	O
two	O
mediastinal	O
drains	O
.	O
Postoperative	O
moderate	O
pericardial	O
effusion	O
associated	O
with	O
haemodynamic	O
instability	O
required	O
amines	B-FARMACO
.	O
Exploratory	O
re	O
intervention	O
abundant	O
clots	O
stuck	O
to	O
the	O
LV	O
,	O
cavity	O
cleaning	O
was	O
performed	O
NO	O
active	O
bleeding	O
point	O
.	O
Evolution	O
purulent	O
secretions	O
through	O
orotracheal	O
tube	O
and	O
leukocytosis	O
treatment	O
piperacillin	B-FARMACO
tazobactam	I-FARMACO
.	O
Left	O
pleural	O
effusion	O
serohematic	O
.	O
Episodes	O
of	O
AF	O
requiring	O
amiodarone	B-FARMACO
CP	O
.	O
Discharge	O
to	O
the	O
ward	O
in	O
RS	O
.	O
Postoperative	O
echocardiography	O
moderate	O
LVH	O
,	O
without	O
dilatation	O
,	O
postoperative	O
septal	O
alterations	O
with	O
slight	O
loss	O
of	O
septal	O
thickening	O
and	O
hypokinesia	O
,	O
hypokinesia	O
and	O
loss	O
of	O
inferobasal	O
thickening	O
.	O
LVEF	O
50	O
57	O
,	O
aortic	O
prosthesis	O
with	O
peak	O
gradient	O
13	O
mmHg	O
,	O
mean	O
5	O
mmHg	O
.	O
Normal	O
areas	O
2	O
.	O
6	O
cm2	O
without	O
regurgitation	O
,	O
normal	O
mitral	O
valve	O
,	O
reversed	O
diastolic	O
pattern	O
,	O
no	O
PHT	O
,	O
dilated	O
IVC	O
17	O
mm	O
,	O
partially	O
collapsible	O
PVC	O
,	O
Minimal	O
posterior	O
pericardial	O
effusion	O
7	O
mm	O
,	O
slight	O
bibasal	O
pleural	O
effusion	O
.	O
Treatment	O
at	O
discharge	O
fat	O
free	O
heart	O
healthy	O
diet	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1cp	O
24h	O
,	O
ASA	B-FARMACO
100	O
mg	O
1cp	O
24h	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
1cp	O
12h	O
,	O
simvastatin	B-FARMACO
40	O
mg	O
1cp	O
at	O
dinner	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1cp	O
at	O
breakfast	O
,	O
ramipril	B-FARMACO
5	O
mg	O
1cp	O
12h	O
,	O
amiodarone	B-FARMACO
200	O
mg	O
1cp	O
24h	O
,	O
deflazacort	B-FARMACO
30	O
mg	O
in	O
descending	O
pattern	O
.	O
Insulin	O
therapy	O
adjustments	O
by	O
Endocrinology	O
.	O
Diagnosis	O
Severe	O
aortic	O
stenosis	O
with	O
bicuspid	O
valve	O
Dilatation	O
of	O
aortic	O
root	O
and	O
ascending	O
aorta	O
45	O
46	O
mm	O
Severe	O
bifurcated	O
lesion	O
of	O
the	O
anterior	O
descending	O
artery	O
in	O
its	O
middle	O
segment	O
and	O
diagonal	O
branch	O
Aortic	O
valve	O
replacement	O
with	O
Mitflow	O
biological	O
prosthesis	O
no	O
.	O
25	O
.	O

We	O
describe	O
the	O
case	O
of	O
a	O
25	O
year	O
old	O
male	O
patient	O
admitted	O
to	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
.	O
The	O
patient	O
was	O
a	O
resident	O
of	O
a	O
rural	O
area	O
in	O
contact	O
with	O
various	O
farmyard	O
animals	O
,	O
with	O
a	O
history	O
of	O
Down	O
syndrome	O
,	O
severe	O
mental	O
retardation	O
and	O
chronic	O
renal	O
failure	O
left	O
renal	O
atrophy	O
.	O
He	O
consulted	O
for	O
intermittent	O
fever	O
of	O
3	O
months	O
'	O
evolution	O
,	O
weight	O
loss	O
and	O
nocturnal	O
diaphoresis	O
.	O
In	O
the	O
last	O
week	O
,	O
he	O
became	O
dyspnoeic	O
,	O
which	O
is	O
why	O
his	O
relatives	O
decided	O
to	O
consult	O
him	O
.	O
Physical	O
examination	O
findings	O
blood	O
pressure	O
120	O
80mmHg	O
,	O
heart	O
rate	O
100lpm	O
,	O
respiratory	O
rate	O
22min	O
and	O
oxygen	O
saturation	O
88	O
.	O
Teeth	O
in	O
good	O
condition	O
,	O
no	O
jugular	O
distension	O
,	O
no	O
cervical	O
lymphadenopathy	O
.	O
Systolic	O
heart	O
murmur	O
grade	O
2	O
4	O
in	O
mitral	O
focus	O
,	O
as	O
well	O
as	O
cramp	O
in	O
both	O
lung	O
bases	O
.	O
Abdomen	O
without	O
alterations	O
.	O
Oedema	O
in	O
the	O
lower	O
limbs	O
,	O
without	O
skin	O
lesions	O
or	O
neurological	O
focalisation	O
.	O
The	O
initial	O
diagnostic	O
impression	O
was	O
sepsis	O
of	O
pulmonary	O
origin	O
.	O
Treatment	O
was	O
started	O
with	O
piperacillin	B-FARMACO
tazobactam	I-FARMACO
4	O
.	O
5g	O
iv	O
every	O
8h	O
after	O
taking	O
blood	O
cultures	O
for	O
4	O
days	O
.	O
Paraclinical	O
tests	O
showed	O
normocytic	O
normochromic	O
anaemia	O
haemoglobin	O
9g	O
dl	O
associated	O
with	O
thrombocytopenia	O
100	O
,	O
000	O
mm3	O
,	O
hypoalbuminaemia	O
3g	O
dl	O
,	O
microscopic	O
haematuria	O
,	O
proteinuria	O
and	O
renal	O
failure	O
creatinine	O
1	O
.	O
6mg	O
dl	O
,	O
which	O
led	O
to	O
glomerulonephritis	O
;	O
in	O
addition	O
,	O
the	O
chest	O
X	O
ray	O
and	O
later	O
a	O
chest	O
CT	O
scan	O
ruled	O
out	O
not	O
only	O
pulmonary	O
infection	O
,	O
but	O
also	O
lymphadenopathy	O
and	O
hepatosplenomegaly	O
,	O
although	O
they	O
showed	O
signs	O
of	O
pulmonary	O
congestion	O
.	O
Subsequently	O
,	O
the	O
patient	O
underwent	O
transesophageal	O
echocardiography	O
,	O
which	O
showed	O
prolapse	O
of	O
the	O
anterior	O
leaflet	O
of	O
the	O
mitral	O
valve	O
,	O
with	O
severe	O
insufficiency	O
and	O
an	O
image	O
of	O
2	O
.	O
1	O
1	O
.	O
1cm	O
in	O
the	O
distal	O
third	O
,	O
compatible	O
with	O
endocardial	O
vegetation	O
.	O
Blood	O
cultures	O
taken	O
on	O
admission	O
reported	O
growth	O
in	O
the	O
2	O
bottles	O
19	O
and	O
20h	O
incubation	O
of	O
Gram	O
positive	O
catalase	O
negative	O
cocci	O
,	O
of	O
which	O
phenotypic	O
identification	O
of	O
the	O
species	O
was	O
performed	O
in	O
VITEK2	O
automated	O
equipment	O
bioMérieux	O
as	O
S	O
.	O
pluranimalium	O
,	O
with	O
in	O
vitro	O
sensitivity	O
to	O
penicillin	B-FARMACO
,	O
clindamycin	B-FARMACO
,	O
erythromycin	B-FARMACO
,	O
linezolid	B-FARMACO
,	O
cefotaxime	B-FARMACO
and	O
vancomycin	B-FARMACO
by	O
the	O
Kirby	O
Bauer	O
method	O
.	O
Based	O
on	O
the	O
modified	O
Duke	O
criteria1	O
,	O
a	O
diagnosis	O
of	O
infective	O
endocarditis	O
was	O
made	O
,	O
meeting	O
one	O
major	O
criterion	O
presence	O
of	O
vegetation	O
on	O
echocardiography	O
and	O
four	O
minor	O
criteria	O
predisposing	O
cardiac	O
condition	O
,	O
fever	O
,	O
glomerulonephritis	O
and	O
positive	O
blood	O
cultures	O
of	O
a	O
germ	O
that	O
did	O
not	O
meet	O
the	O
characteristics	O
of	O
the	O
major	O
criterion	O
.	O
Because	O
the	O
patient	O
had	O
severe	O
mitral	O
insufficiency	O
with	O
signs	O
and	O
symptoms	O
of	O
heart	O
failure	O
,	O
and	O
the	O
size	O
of	O
the	O
vegetation	O
was	O
greater	O
than	O
15mm	O
,	O
transfer	O
to	O
surgery	O
for	O
mitral	O
valve	O
replacement	O
biological	O
valve	O
was	O
considered	O
.	O
It	O
should	O
be	O
noted	O
that	O
despite	O
being	O
a	O
young	O
patient	O
,	O
biological	O
valve	O
implantation	O
was	O
decided	O
because	O
the	O
patient	O
's	O
social	O
conditions	O
severe	O
mental	O
retardation	O
and	O
living	O
in	O
a	O
rural	O
area	O
made	O
it	O
very	O
difficult	O
for	O
him	O
to	O
travel	O
to	O
attend	O
anticoagulation	O
check	O
ups	O
.	O
Control	O
blood	O
cultures	O
were	O
performed	O
8	O
days	O
after	O
the	O
start	O
of	O
antibiotic	O
therapy	O
with	O
no	O
microbiological	O
growth	O
,	O
and	O
antibiotic	O
treatment	O
was	O
completed	O
with	O
ampicillin	B-FARMACO
sulbactam	I-FARMACO
adjusted	O
according	O
to	O
the	O
sensitivity	O
profile	O
for	O
up	O
to	O
28	O
days	O
,	O
in	O
accordance	O
with	O
the	O
recommendation	O
of	O
the	O
guidelines	O
for	O
the	O
treatment	O
of	O
streptococcus	O
.	O
He	O
did	O
not	O
receive	O
gentamicin	B-FARMACO
due	O
to	O
renal	O
compromise	O
.	O
The	O
patient	O
was	O
discharged	O
without	O
complications	O
or	O
sequelae	O
.	O

Medical	O
history	O
and	O
current	O
illness	O
40	O
year	O
old	O
male	O
.	O
Cardiovascular	O
risk	O
factors	O
untreated	O
dyslipidaemia	O
,	O
smoking	O
30	O
cigarettes	O
day	O
since	O
the	O
age	O
of	O
18	O
,	O
obesity	O
.	O
Mother	O
died	O
of	O
stroke	O
at	O
the	O
age	O
of	O
54	O
.	O
Uncomplicated	O
peptic	O
ulcus	O
15	O
years	O
ago	O
.	O
She	O
came	O
to	O
the	O
emergency	O
department	O
for	O
a	O
transient	O
loss	O
of	O
strength	O
in	O
the	O
left	O
hemibody	O
lasting	O
about	O
30	O
minutes	O
with	O
deviation	O
of	O
the	O
corner	O
of	O
the	O
mouth	O
and	O
falling	O
to	O
the	O
floor	O
,	O
without	O
loss	O
of	O
consciousness	O
.	O
In	O
the	O
last	O
month	O
she	O
had	O
presented	O
3	O
episodes	O
of	O
intense	O
oppressive	O
central	O
thoracic	O
pain	O
,	O
at	O
rest	O
,	O
lasting	O
30	O
minutes	O
and	O
spontaneous	O
cessation	O
,	O
for	O
which	O
she	O
did	O
not	O
consult	O
the	O
doctor	O
.	O
Dyspnoea	O
on	O
moderate	O
exertion	O
in	O
recent	O
weeks	O
.	O
Physical	O
examination	O
BP	O
115	O
79	O
mmHg	O
,	O
HR	O
85	O
bpm	O
,	O
weight	O
100	O
kg	O
,	O
height	O
177	O
cm	O
,	O
BMI	O
32	O
.	O
Abdominal	O
circumference	O
117	O
,	O
AC	O
rhythmic	O
,	O
minimal	O
protosystolic	O
murmur	O
in	O
the	O
apex	O
.	O
AP	O
vesicular	O
murmur	O
preserved	O
.	O
Extremities	O
peripheral	O
pulses	O
present	O
,	O
symmetrical	O
.	O
Rest	O
without	O
relevant	O
findings	O
.	O
Complementary	O
tests	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
100	O
bpm	O
.	O
PR	O
200	O
ms	O
.	O
QRS	O
90	O
ms	O
.	O
Q	O
wave	O
in	O
II	O
,	O
III	O
and	O
aVF	O
.	O
ST	O
elevation	O
0	O
.	O
5	O
mm	O
in	O
III	O
,	O
aVF	O
and	O
V3	O
.	O
ST	O
segment	O
elevation	O
0	O
.	O
5	O
mm	O
in	O
I	O
,	O
aVL	O
,	O
V5	O
to	O
V6	O
with	O
negative	O
T	O
wave	O
in	O
V2	O
,	O
isodiphasic	O
in	O
V3	O
and	O
flattened	O
from	O
V4	O
to	O
V6	O
.	O
Transthoracic	O
echocardiogram	O
severely	O
dilated	O
left	O
ventricle	O
,	O
without	O
hypertrophy	O
and	O
with	O
severely	O
depressed	O
systolic	O
function	O
ejection	O
fraction	O
25	O
,	O
with	O
extensive	O
alterations	O
of	O
segmental	O
contractility	O
in	O
the	O
inferior	O
and	O
anterior	O
faces	O
.	O
Restrictive	O
transmitral	O
filling	O
.	O
Basal	O
and	O
apical	O
inferior	O
aneurysms	O
.	O
Apical	O
intraventricular	O
thrombus	O
of	O
14x18	O
mm	O
.	O
Moderate	O
ischaemic	O
mitral	O
insufficiency	O
.	O
Laboratory	O
tests	O
maximum	O
troponin	O
I	O
0	O
.	O
43	O
ng	O
dL	O
,	O
total	O
cholesterol	O
223	O
mg	O
dL	O
,	O
HDL	O
cholesterol	O
31	O
mg	O
dL	O
,	O
LDL	O
cholesterol	O
164	O
mg	O
dL	O
,	O
triglycerides	O
142	O
mg	O
dL	O
.	O
Basal	O
blood	O
glucose	O
88	O
mg	O
dL	O
.	O
HbA1c	O
4	O
.	O
9	O
.	O
Normal	O
haemogram	O
,	O
coagulation	O
,	O
renal	O
function	O
,	O
ions	O
,	O
liver	O
profile	O
,	O
iron	O
profile	O
and	O
thyroid	O
profile	O
.	O
Cardiac	O
catheterisation	O
coronary	O
angiography	O
severe	O
obstructive	O
coronary	O
artery	O
disease	O
of	O
3	O
main	O
vessels	O
,	O
multi	O
segment	O
,	O
with	O
suboptimal	O
distal	O
beds	O
.	O
Cardiac	O
MRI	O
dilated	O
left	O
ventricle	O
,	O
with	O
severely	O
depressed	O
systolic	O
function	O
.	O
Apical	O
segments	O
of	O
anterior	O
,	O
inferior	O
and	O
septal	O
face	O
non	O
viable	O
.	O
Remaining	O
segments	O
viable	O
.	O
Apical	O
thrombus	O
.	O
Cardiac	O
catheterisation	O
percutaneous	O
coronary	O
intervention	O
angioplasty	O
and	O
implantation	O
of	O
3	O
drug	O
eluting	O
stents	O
on	O
proximal	O
and	O
middle	O
anterior	O
descending	O
artery	O
,	O
and	O
angioplasty	O
and	O
implantation	O
of	O
1	O
drug	O
eluting	O
stent	O
on	O
obtuse	O
marginal	O
artery	O
,	O
with	O
good	O
angiographic	O
results	O
.	O
In	O
a	O
second	O
stage	O
,	O
angioplasty	O
and	O
implantation	O
of	O
1	O
drug	O
eluting	O
stent	O
on	O
the	O
distal	O
right	O
coronary	O
artery	O
and	O
posterior	O
interventricular	O
artery	O
and	O
1	O
drug	O
eluting	O
stent	O
at	O
the	O
level	O
of	O
the	O
crux	O
,	O
with	O
good	O
angiographic	O
results	O
.	O
Clinical	O
course	O
A	O
40	O
year	O
old	O
man	O
was	O
admitted	O
for	O
a	O
transient	O
ischaemic	O
attack	O
in	O
the	O
right	O
carotid	O
artery	O
and	O
a	O
history	O
of	O
chest	O
pain	O
.	O
The	O
diagnostic	O
study	O
revealed	O
an	O
evolved	O
inferior	O
and	O
apical	O
infarction	O
,	O
severe	O
ventricular	O
dysfunction	O
and	O
an	O
intraventricular	O
thrombus	O
,	O
three	O
vessel	O
multisegment	O
disease	O
with	O
suboptimal	O
distal	O
beds	O
,	O
and	O
viability	O
in	O
the	O
proximal	O
and	O
middle	O
anterior	O
descending	O
and	O
inferior	O
territory	O
.	O
Given	O
the	O
poor	O
distal	O
quality	O
of	O
the	O
anterior	O
descending	O
artery	O
and	O
the	O
absence	O
of	O
diabetes	O
mellitus	O
,	O
percutaneous	O
revascularisation	O
was	O
chosen	O
,	O
and	O
complete	O
revascularisation	O
was	O
achieved	O
with	O
drug	O
eluting	O
stents	O
.	O
The	O
patient	O
evolved	O
favourably	O
during	O
admission	O
,	O
with	O
no	O
clinical	O
signs	O
of	O
heart	O
failure	O
or	O
new	O
neurological	O
focality	O
.	O
Diagnosis	O
Ischaemic	O
heart	O
disease	O
advanced	O
inferior	O
and	O
apical	O
infarction	O
Obstructive	O
atherosclerotic	O
coronary	O
artery	O
disease	O
of	O
three	O
main	O
vessels	O
Severe	O
left	O
ventricular	O
systolic	O
dysfunction	O
Apical	O
intraventricular	O
thrombus	O
Transient	O
ischaemic	O
attack	O
due	O
to	O
cardioembolism	O
Complete	O
percutaneous	O
revascularisation	O
with	O
drug	O
eluting	O
stents	O
Dyslipidaemia	O
Smoking	O
Obesity	O

Medical	O
history	O
and	O
current	O
illness	O
61	O
year	O
old	O
male	O
,	O
ex	O
smoker	O
of	O
10	O
cigarettes	O
a	O
day	O
for	O
5	O
years	O
,	O
hypertensive	O
and	O
dyslipidaemic	O
under	O
pharmacological	O
treatment	O
.	O
He	O
denied	O
a	O
family	O
history	O
of	O
heart	O
disease	O
.	O
A	O
sister	O
of	O
his	O
had	O
only	O
one	O
kidney	O
since	O
birth	O
and	O
a	O
niece	O
had	O
been	O
diagnosed	O
with	O
polysplenia	O
since	O
childhood	O
.	O
Cardiologically	O
,	O
he	O
had	O
been	O
diagnosed	O
5	O
years	O
ago	O
with	O
dilated	O
cardiomyopathy	O
in	O
the	O
context	O
of	O
a	O
routine	O
medical	O
check	O
up	O
,	O
being	O
completely	O
asymptomatic	O
,	O
NYHA	O
functional	O
class	O
I	O
.	O
He	O
had	O
a	O
history	O
of	O
dilated	O
cardiomyopathy	O
.	O
It	O
was	O
a	O
dilated	O
cardiomyopathy	O
with	O
moderate	O
left	O
ventricular	O
dysfunction	O
,	O
with	O
normal	O
coronary	O
arteries	O
and	O
associated	O
mild	O
aortic	O
stenosis	O
and	O
moderate	O
MI	O
due	O
to	O
P2	O
prolapse	O
.	O
He	O
was	O
asymptomatic	O
and	O
under	O
medical	O
treatment	O
until	O
four	O
years	O
after	O
diagnosis	O
,	O
when	O
,	O
following	O
the	O
onset	O
of	O
moderate	O
exertional	O
dyspnoea	O
,	O
an	O
echocardiogram	O
was	O
performed	O
which	O
revealed	O
severe	O
MR	O
.	O
He	O
underwent	O
surgery	O
with	O
Carpentier	O
mitral	O
annuloplasty	O
.	O
After	O
3	O
months	O
,	O
he	O
was	O
readmitted	O
for	O
heart	O
failure	O
with	O
moderate	O
MR	O
that	O
became	O
severe	O
on	O
stress	O
echocardiography	O
.	O
At	O
that	O
time	O
,	O
reintervention	O
was	O
discouraged	O
given	O
the	O
history	O
of	O
previous	O
surgery	O
and	O
the	O
presence	O
of	O
severe	O
ventricular	O
dysfunction	O
.	O
After	O
three	O
months	O
he	O
fell	O
into	O
AF	O
,	O
which	O
could	O
not	O
be	O
cardioverted	O
chemically	O
or	O
electrically	O
,	O
so	O
he	O
was	O
anticoagulated	O
and	O
managed	O
with	O
rate	O
control	O
.	O
He	O
was	O
referred	O
for	O
evaluation	O
of	O
cardiac	O
transplantation	O
.	O
Complementary	O
tests	O
ECG	O
AF	O
and	O
a	O
ventricular	O
response	O
at	O
80	O
bpm	O
with	O
a	O
narrow	O
QRS	O
were	O
observed	O
.	O
Chest	O
X	O
ray	O
increased	O
CTI	O
with	O
no	O
evidence	O
of	O
pulmonary	O
congestion	O
.	O
The	O
blood	O
test	O
showed	O
an	O
NTproBNP	O
of	O
14000	O
,	O
with	O
no	O
other	O
findings	O
of	O
interest	O
.	O
Serology	O
was	O
positive	O
for	O
Toxoplasma	O
IgG	O
and	O
CMV	O
IgG	O
and	O
negative	O
for	O
hepatitis	O
virus	O
and	O
HIV	O
.	O
He	O
had	O
a	O
positive	O
anti	O
lymphocyte	O
antibody	O
panel	O
of	O
20	O
.	O
Echocardiogram	O
a	O
dilated	O
LV	O
with	O
an	O
EF	O
of	O
25	O
,	O
moderate	O
severe	O
MR	O
and	O
severe	O
low	O
gradient	O
aortic	O
stenosis	O
that	O
had	O
not	O
been	O
described	O
in	O
previous	O
echocardiograms	O
AVA	O
0	O
.	O
5	O
cm2	O
;	O
mean	O
gradient	O
20	O
with	O
contractile	O
reserve	O
was	O
described	O
.	O
Ergometry	O
with	O
gas	O
consumption	O
estimated	O
VO2	O
PEAK	O
of	O
8	O
.	O
5	O
ml	O
kg	O
min	O
20	O
of	O
the	O
maximum	O
theoretical	O
value	O
.	O
Weber	O
Janicki	O
functional	O
class	O
D	O
.	O
In	O
the	O
6	O
minute	O
test	O
he	O
performed	O
320	O
metres	O
without	O
stopping	O
or	O
desaturation	O
.	O
Right	O
catheterisation	O
showed	O
a	O
PCP	O
of	O
32	O
,	O
a	O
PAP	O
68	O
32	O
44	O
,	O
and	O
a	O
cardiac	O
index	O
of	O
2	O
.	O
6	O
l	O
min	O
m2	O
.	O
Screening	O
with	O
thoracoabdominal	O
CT	O
with	O
a	O
view	O
to	O
probable	O
cardiac	O
transplantation	O
showed	O
polysplenia	O
,	O
hepatic	O
and	O
splenic	O
inversion	O
and	O
anomalies	O
in	O
venous	O
drainage	O
left	O
superior	O
vena	O
cava	O
draining	O
into	O
the	O
coronary	O
sinus	O
;	O
absence	O
of	O
vena	O
cava	O
above	O
the	O
renal	O
veins	O
,	O
draining	O
the	O
entire	O
infrahepatic	O
venous	O
system	O
directly	O
into	O
the	O
right	O
superior	O
vena	O
cava	O
via	O
the	O
azygos	O
system	O
.	O
Clinical	O
course	O
Without	O
complications	O
during	O
admission	O
,	O
the	O
case	O
was	O
discussed	O
in	O
a	O
medical	O
surgical	O
session	O
.	O
Aortic	O
and	O
mitral	O
prosthesis	O
surgery	O
was	O
considered	O
an	O
excessive	O
risk	O
and	O
the	O
patient	O
was	O
accepted	O
as	O
a	O
candidate	O
for	O
heart	O
transplant	O
on	O
the	O
elective	O
list	O
.	O
Diagnosis	O
Chronic	O
heart	O
failure	O
in	O
advanced	O
NYHA	O
functional	O
class	O
III	O
,	O
with	O
evidence	O
of	O
poor	O
prognosis	O
Dilated	O
cardiomyopathy	O
of	O
probable	O
valvular	O
origin	O
Carpentier	O
annuloplasty	O
one	O
year	O
ago	O
Recurrence	O
of	O
severe	O
MI	O
and	O
current	O
severe	O
aortic	O
stenosis	O
Severe	O
systolic	O
ventricular	O
dysfunction	O
Pending	O
decision	O
to	O
be	O
placed	O
on	O
elective	O
cardiac	O
transplant	O
waiting	O
list	O
Polysplenia	O
,	O
hepatic	O
inversion	O
,	O
situs	O
sólitus	O
Left	O
superior	O
vena	O
cava	O
and	O
venous	O
drainage	O
anomalies	O
Previous	O

Clinical	O
history	O
and	O
current	O
disease	O
A	O
22	O
year	O
old	O
Brazilian	O
national	O
who	O
had	O
been	O
living	O
in	O
our	O
country	O
for	O
2	O
years	O
,	O
with	O
a	O
personal	O
history	O
of	O
long	O
standing	O
arterial	O
hypertension	O
treated	O
with	O
amlodipine	B-FARMACO
,	O
dyslipidaemia	O
,	O
tonsillitis	O
resolved	O
with	O
antibiotherapy	O
,	O
mild	O
bilateral	O
hypoacusis	O
of	O
unknown	O
aetiology	O
and	O
left	O
thoracic	O
herpes	O
zoster	O
.	O
He	O
had	O
been	O
diagnosed	O
with	O
chronic	O
renal	O
failure	O
of	O
unknown	O
aetiology	O
in	O
another	O
hospital	O
for	O
two	O
years	O
,	O
when	O
he	O
had	O
an	O
episode	O
of	O
acute	O
pulmonary	O
oedema	O
in	O
the	O
context	O
of	O
renal	O
failure	O
with	O
glomerular	O
filtration	O
rate	O
of	O
3	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
requiring	O
urgent	O
haemodialysis	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
normal	O
cardiac	O
cavities	O
,	O
left	O
ventricle	O
LV	O
with	O
eccentric	O
hypertrophy	O
and	O
preserved	O
biventricular	O
systolic	O
function	O
.	O
Since	O
then	O
,	O
he	O
has	O
been	O
on	O
haemodialysis	O
.	O
He	O
was	O
referred	O
to	O
our	O
centre	O
a	O
year	O
ago	O
to	O
assess	O
living	O
donor	O
renal	O
transplantation	O
.	O
The	O
echocardiogram	O
performed	O
as	O
a	O
pre	O
transplant	O
protocol	O
showed	O
biventricular	O
dilatation	O
and	O
severe	O
dysfunction	O
of	O
both	O
ventricles	O
.	O
On	O
admission	O
,	O
intense	O
cutaneous	O
pallor	O
,	O
cutaneous	O
mucosal	O
subictericia	O
.	O
Afebrile	O
.	O
BP	O
120	O
70	O
mmHg	O
.	O
There	O
was	O
an	O
arteriovenous	O
fistula	O
with	O
large	O
debit	O
in	O
the	O
right	O
upper	O
extremity	O
.	O
The	O
patient	O
reported	O
usual	O
functional	O
class	O
III	O
IV	O
NYHA	O
,	O
with	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
,	O
decubitus	O
cough	O
and	O
orthopnoea	O
in	O
recent	O
weeks	O
.	O
Given	O
the	O
haemodynamic	O
situation	O
of	O
heart	O
failure	O
,	O
he	O
was	O
admitted	O
to	O
our	O
care	O
for	O
study	O
.	O
On	O
auscultation	O
,	O
rhythmic	O
tones	O
at	O
90	O
bpm	O
,	O
with	O
gallop	O
and	O
systolic	O
murmur	O
in	O
mitral	O
focus	O
.	O
Bilateral	O
normoventilation	O
.	O
Hepatomegaly	O
of	O
1	O
2	O
finger	O
widths	O
,	O
painful	O
on	O
palpation	O
.	O
Malleolar	O
oedema	O
with	O
fovea	O
.	O
No	O
carotid	O
murmurs	O
.	O
Signs	O
of	O
peripheral	O
hypoperfusion	O
.	O
Complementary	O
tests	O
Laboratory	O
tests	O
on	O
admission	O
proBNP	O
of	O
547	O
,	O
000	O
pg	O
ml	O
,	O
glomerular	O
filtration	O
rate	O
of	O
18	O
mL	O
min	O
1	O
.	O
73	O
m2	O
and	O
anaemia	O
with	O
haemoglobin	O
of	O
10	O
g	O
dl	O
and	O
haematocrit	O
of	O
30	O
.	O
ECG	O
sinus	O
rhythm	O
with	O
left	O
ventricular	O
enlargement	O
and	O
unspecific	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
severe	O
cardiomegaly	O
.	O
Vascular	O
redistribution	O
and	O
bilateral	O
pleural	O
effusion	O
.	O
Serology	O
positive	O
for	O
hepatitis	O
A	O
virus	O
,	O
varicella	O
zoster	O
,	O
herpes	O
simplex	O
,	O
cytomegalovirus	O
and	O
Ebstein	O
Barr	O
virus	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
showed	O
severely	O
dilated	O
LV	O
end	O
diastolic	O
diameter	O
73	O
mm	O
,	O
global	O
hypocontractility	O
with	O
ejection	O
fraction	O
LVEF	O
of	O
20	O
,	O
cardiac	O
output	O
CO	O
3	O
.	O
67	O
L	O
min	O
,	O
elevated	O
preload	O
criteria	O
.	O
Right	O
ventricle	O
RV	O
moderately	O
dilated	O
and	O
frankly	O
hypocontractile	O
.	O
Moderate	O
mitral	O
insufficiency	O
MI	O
.	O
Severe	O
tricuspid	O
insufficiency	O
TI	O
.	O
Dilated	O
suprahepatic	O
veins	O
and	O
inferior	O
vena	O
cava	O
without	O
inspiratory	O
collapse	O
.	O
Systolic	O
pulmonary	O
artery	O
pressure	O
PAP	O
of	O
45	O
mmHg	O
.	O
Severe	O
pericardial	O
effusion	O
,	O
with	O
no	O
evidence	O
of	O
haemodynamic	O
compromise	O
.	O
Coronary	O
angiography	O
coronary	O
tree	O
free	O
of	O
angiographically	O
evident	O
lesions	O
.	O
Ventriculography	O
severely	O
dilated	O
LV	O
,	O
LVEF	O
20	O
and	O
end	O
diastolic	O
pressure	O
of	O
25	O
mmHg	O
.	O
Right	O
catheterisation	O
mean	O
right	O
atrial	O
pressure	O
11	O
mmHg	O
,	O
systolic	O
PAP	O
50	O
mmHg	O
and	O
mean	O
37	O
mmHg	O
.	O
Cardiac	O
output	O
6	O
.	O
42	O
L	O
min	O
.	O
Mean	O
pulmonary	O
capillary	O
pressure	O
30	O
mmHg	O
,	O
with	O
'	O
V	O
'	O
wave	O
up	O
to	O
45	O
50	O
mmHg	O
.	O
Thoracoabdominal	O
CT	O
bilateral	O
pleural	O
effusion	O
,	O
pericardial	O
effusion	O
,	O
ascites	O
and	O
stasis	O
liver	O
,	O
all	O
related	O
to	O
heart	O
failure	O
.	O
Clinical	O
evolution	O
During	O
admission	O
to	O
our	O
department	O
,	O
daily	O
haemodialysis	O
sessions	O
were	O
started	O
,	O
with	O
progressive	O
improvement	O
in	O
his	O
haemodynamic	O
situation	O
.	O
The	O
cardiological	O
situation	O
was	O
re	O
evaluated	O
and	O
a	O
slight	O
left	O
ventricular	O
improvement	O
was	O
observed	O
,	O
but	O
with	O
persistent	O
dilatation	O
and	O
severe	O
RV	O
dysfunction	O
and	O
no	O
findings	O
of	O
specific	O
aetiology	O
.	O
Therefore	O
,	O
the	O
patient	O
was	O
proposed	O
for	O
cardiorenal	O
transplantation	O
,	O
and	O
after	O
a	O
favourable	O
evolution	O
,	O
he	O
was	O
discharged	O
.	O
During	O
follow	O
up	O
,	O
hypovolaemia	O
with	O
hypotension	O
made	O
it	O
necessary	O
to	O
reduce	O
the	O
frequency	O
of	O
haemodialysis	O
sessions	O
to	O
6	O
days	O
a	O
week	O
and	O
to	O
reduce	O
pharmacological	O
treatment	O
.	O
He	O
presented	O
with	O
a	O
catarrhal	O
episode	O
with	O
associated	O
febrile	O
syndrome	O
,	O
for	O
which	O
a	O
chest	O
X	O
ray	O
was	O
performed	O
showing	O
slight	O
cardiomegaly	O
,	O
so	O
a	O
TTE	O
was	O
performed	O
which	O
showed	O
a	O
slight	O
reduction	O
in	O
LV	O
diameter	O
with	O
discrete	O
improvement	O
in	O
systolic	O
function	O
.	O
Six	O
months	O
after	O
hospital	O
discharge	O
,	O
he	O
was	O
readmitted	O
as	O
a	O
transplant	O
recipient	O
and	O
his	O
initial	O
evaluation	O
showed	O
a	O
drastic	O
reduction	O
in	O
radiological	O
cardiomegaly	O
since	O
his	O
last	O
check	O
up	O
,	O
so	O
a	O
TTE	O
was	O
performed	O
which	O
showed	O
significant	O
improvement	O
LV	O
with	O
a	O
DTD	O
of	O
49	O
mm	O
,	O
global	O
hypokinesia	O
with	O
LVEF	O
of	O
30	O
,	O
minimal	O
TR	O
allowing	O
calculation	O
of	O
PAPs	O
of	O
32	O
mmHg	O
.	O
In	O
view	O
of	O
the	O
findings	O
,	O
it	O
was	O
decided	O
to	O
perform	O
an	O
isolated	O
renal	O
transplant	O
procedure	O
,	O
which	O
took	O
place	O
without	O
incident	O
.	O
During	O
this	O
admission	O
,	O
no	O
inotropic	O
drugs	O
were	O
required	O
and	O
there	O
was	O
no	O
LV	O
failure	O
.	O
On	O
discharge	O
TTE	O
,	O
systolic	O
function	O
improved	O
LVEF	O
34	O
,	O
with	O
moderate	O
concentric	O
hypertrophy	O
,	O
CO	O
3	O
.	O
8	O
l	O
min	O
and	O
RV	O
slightly	O
dilated	O
and	O
normocontractile	O
.	O
At	O
present	O
,	O
the	O
patient	O
is	O
in	O
NYHA	O
functional	O
class	O
I	O
.	O
Subsequent	O
follow	O
up	O
showed	O
progressive	O
clinical	O
improvement	O
and	O
improvement	O
in	O
echocardiographic	O
parameters	O
.	O
Good	O
nephrological	O
evolution	O
.	O
At	O
present	O
,	O
the	O
patient	O
is	O
in	O
functional	O
class	O
I	O
NYHA	O
.	O
The	O
last	O
TTE	O
2	O
months	O
ago	O
showed	O
a	O
non	O
dilated	O
and	O
non	O
hypertrophied	O
LV	O
with	O
excellent	O
systolic	O
LVEF	O
71	O
and	O
diastolic	O
function	O
,	O
normal	O
RV	O
in	O
size	O
and	O
function	O
,	O
no	O
MR	O
,	O
minimal	O
TR	O
with	O
PAPs	O
25	O
mmHg	O
and	O
absence	O
of	O
pericardial	O
effusion	O
.	O
Diagnosis	O
Cardiorenal	O
syndrome	O
Beneficial	O
effect	O
of	O
renal	O
transplantation	O
on	O
ventricular	O
dysfunction	O

Clinical	O
history	O
and	O
current	O
disease	O
27	O
year	O
old	O
male	O
patient	O
with	O
a	O
history	O
of	O
nephrotic	O
syndrome	O
due	O
to	O
focal	O
and	O
segmental	O
hyalinosis	O
diagnosed	O
at	O
4	O
years	O
of	O
age	O
.	O
He	O
was	O
treated	O
with	O
peritoneal	O
dialysis	O
until	O
1998	O
,	O
when	O
he	O
was	O
transplanted	O
.	O
In	O
2007	O
he	O
presented	O
chronic	O
rejection	O
and	O
recurrence	O
of	O
hyalinosis	O
;	O
therefore	O
,	O
in	O
2008	O
he	O
underwent	O
embolisation	O
of	O
the	O
renal	O
graft	O
and	O
restarted	O
peritoneal	O
dialysis	O
again	O
until	O
the	O
present	O
day	O
.	O
Severe	O
pericardial	O
effusion	O
in	O
2008	O
of	O
uraemic	O
aetiology	O
.	O
One	O
year	O
ago	O
total	O
thyroidectomy	O
for	O
papillary	O
carcinoma	O
of	O
follicular	O
pattern	O
,	O
with	O
foci	O
in	O
both	O
thyroid	O
lobes	O
and	O
micrometastasis	O
in	O
one	O
lymph	O
node	O
of	O
the	O
23	O
isolated	O
lymph	O
nodes	O
;	O
she	O
subsequently	O
received	O
treatment	O
with	O
radioactive	O
iodine	O
.	O
Clinical	O
picture	O
of	O
48	O
hours	O
of	O
evolution	O
consisting	O
of	O
progressive	O
dyspnoea	O
and	O
asthenia	O
.	O
Physical	O
examination	O
on	O
admission	O
patient	O
alert	O
,	O
conscious	O
,	O
oriented	O
,	O
tachypneic	O
and	O
intolerant	O
to	O
decubitus	O
.	O
BP	O
85	O
46	O
HR	O
128	O
bpm	O
FR	O
28	O
Afebrile	O
SaO2	O
92	O
with	O
nasal	O
goggles	O
.	O
Head	O
and	O
neck	O
jugular	O
ingurgitation	O
at	O
45o	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
and	O
regular	O
,	O
with	O
diminished	O
intensity	O
.	O
Lung	O
fields	O
well	O
ventilated	O
,	O
without	O
over	O
aggregate	O
sounds	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
.	O
Extremities	O
with	O
present	O
and	O
symmetrical	O
pulses	O
,	O
grade	O
I	O
IV	O
malleolar	O
oedema	O
.	O
Complementary	O
tests	O
CBC	O
leukocytes	O
6	O
,	O
600	O
with	O
adequate	O
differential	O
count	O
,	O
Hb	O
8	O
.	O
7	O
,	O
haematocrit	O
26	O
,	O
MCV	O
79	O
.	O
5	O
,	O
MCH	O
26	O
.	O
6	O
,	O
platelets	O
214	O
,	O
000	O
,	O
Act	O
.	O
PT	O
71	O
.	O
7	O
,	O
aTTP	O
30	O
.	O
42	O
,	O
glucose	O
109	O
mg	O
dl	O
,	O
urea	O
74	O
,	O
creatinine	O
6	O
.	O
8	O
,	O
total	O
protein	O
4	O
.	O
2	O
.	O
Ions	O
and	O
cardiac	O
enzymes	O
within	O
normal	O
limits	O
.	O
ECG	O
sinus	O
tachycardia	O
at	O
128	O
bpm	O
,	O
decreased	O
voltages	O
.	O
Chest	O
X	O
ray	O
significant	O
increase	O
in	O
cardiothoracic	O
index	O
.	O
Right	O
costophrenic	O
sinus	O
pinched	O
,	O
left	O
costophrenic	O
sinus	O
not	O
visible	O
by	O
the	O
cardiac	O
silhouette	O
.	O
TT	O
echocardiography	O
pericardial	O
effusion	O
with	O
maximum	O
diameters	O
in	O
end	O
diastole	O
of	O
up	O
to	O
4	O
cm	O
and	O
signs	O
of	O
haemodynamic	O
compromise	O
.	O
Clinical	O
evolution	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
and	O
evacuating	O
pericardiocentesis	O
was	O
performed	O
after	O
superficial	O
sedation	O
with	O
echo	O
guided	O
propofol	B-FARMACO
.	O
Given	O
the	O
high	O
possibility	O
of	O
pericardial	O
effusion	O
of	O
probable	O
uraemic	O
aetiology	O
,	O
it	O
was	O
notable	O
that	O
after	O
uncomplicated	O
puncture	O
the	O
drainage	O
fluid	O
had	O
a	O
significant	O
haematic	O
component	O
,	O
so	O
it	O
was	O
decided	O
to	O
perform	O
an	O
echocardiographic	O
test	O
with	O
agitated	O
serum	O
through	O
a	O
catheter	O
needle	O
to	O
check	O
the	O
correct	O
location	O
;	O
bubbles	O
were	O
clearly	O
observed	O
in	O
the	O
pericardial	O
space	O
.	O
After	O
drainage	O
of	O
600	O
cc	O
,	O
an	O
increase	O
in	O
blood	O
pressure	O
was	O
observed	O
,	O
but	O
he	O
remained	O
tachycardic	O
and	O
presented	O
desaturation	O
requiring	O
O2	O
supply	O
with	O
a	O
reservoir	O
.	O
Chest	O
X	O
ray	O
after	O
puncture	O
showed	O
complete	O
veiling	O
of	O
the	O
left	O
hemithorax	O
,	O
in	O
addition	O
to	O
an	O
evident	O
interstitial	O
pattern	O
in	O
the	O
right	O
hemithorax	O
compared	O
to	O
the	O
previous	O
X	O
ray	O
.	O
An	O
urgent	O
chest	O
CT	O
scan	O
was	O
requested	O
with	O
findings	O
of	O
opacification	O
of	O
the	O
left	O
upper	O
lobe	O
with	O
air	O
bronchogram	O
suggestive	O
of	O
atelectasis	O
,	O
alveolar	O
oedema	O
and	O
moderate	O
bilateral	O
pleural	O
effusion	O
31	O
mm	O
thick	O
in	O
the	O
right	O
base	O
and	O
25	O
mm	O
in	O
the	O
left	O
base	O
which	O
surrounds	O
the	O
atelectasized	O
parenchyma	O
at	O
the	O
level	O
of	O
the	O
left	O
apex	O
;	O
severe	O
circumferential	O
pericardial	O
effusion	O
which	O
at	O
the	O
left	O
posterolateral	O
level	O
reaches	O
up	O
to	O
5	O
cm	O
in	O
thickness	O
;	O
pericardial	O
catheter	O
located	O
anterior	O
to	O
the	O
right	O
ventricular	O
outflow	O
tract	O
.	O
The	O
patient	O
was	O
treated	O
with	O
non	O
invasive	O
mechanical	O
ventilation	O
and	O
diuretics	O
,	O
obtaining	O
a	O
rapid	O
clinical	O
response	O
with	O
progressive	O
re	O
expansion	O
of	O
the	O
left	O
upper	O
lobe	O
and	O
clear	O
improvement	O
of	O
the	O
radiological	O
signs	O
of	O
heart	O
failure	O
,	O
until	O
respiratory	O
stability	O
and	O
O2	O
saturations	O
of	O
99	O
were	O
obtained	O
with	O
nasal	O
goggles	O
.	O
Total	O
pericardial	O
drainage	O
was	O
1800	O
cc	O
.	O
The	O
fluid	O
study	O
showed	O
red	O
blood	O
cells	O
of	O
800000	O
mm3	O
and	O
other	O
parameters	O
within	O
normal	O
limits	O
,	O
with	O
no	O
bacteria	O
in	O
the	O
gram	O
,	O
negative	O
cultures	O
for	O
aerobes	O
and	O
anaerobes	O
;	O
and	O
negative	O
for	O
malignant	O
cells	O
in	O
the	O
pathological	O
anatomy	O
study	O
.	O
Diagnosis	O
Severe	O
pericardial	O
effusion	O
with	O
signs	O
of	O
haemodynamic	O
compromise	O
in	O
a	O
patient	O
with	O
chronic	O
kidney	O
disease	O
on	O
peritoneal	O
dialysis	O
Alveolar	O
oedema	O
and	O
pleural	O
effusion	O
ex	O
vacuo	O
secondary	O
to	O
pericardiocentesis	O
Left	O
upper	O
lobe	O
atelectasis	O
secondary	O
to	O
sedation	O

Clinical	O
history	O
and	O
current	O
illness	O
A	O
66	O
year	O
old	O
man	O
came	O
to	O
the	O
emergency	O
department	O
for	O
progressive	O
dyspnoea	O
after	O
a	O
respiratory	O
infection	O
.	O
No	O
known	O
cardiovascular	O
risk	O
factors	O
.	O
No	O
toxic	O
habits	O
.	O
Under	O
study	O
for	O
probable	O
OSA	O
.	O
Cataract	O
surgery	O
years	O
ago	O
without	O
complications	O
.	O
The	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
for	O
progressive	O
exertional	O
dyspnoea	O
of	O
one	O
week	O
's	O
evolution	O
,	O
following	O
a	O
lower	O
respiratory	O
tract	O
infection	O
with	O
cough	O
and	O
greenish	O
expectoration	O
.	O
There	O
was	O
no	O
documented	O
fever	O
,	O
although	O
there	O
was	O
a	O
feeling	O
of	O
dystrophy	O
during	O
the	O
first	O
few	O
days	O
of	O
the	O
episode	O
.	O
No	O
other	O
symptoms	O
.	O
Physical	O
examination	O
37	O
.	O
6	O
oC	O
,	O
BP	O
140	O
50	O
mmHg	O
,	O
HR	O
100	O
bpm	O
.	O
Pulse	O
was	O
clear	O
,	O
no	O
signs	O
of	O
jugular	O
venous	O
engorgement	O
.	O
AP	O
crackles	O
in	O
both	O
bases	O
,	O
hypophonesis	O
in	O
right	O
base	O
.	O
AC	O
rhythmic	O
tones	O
,	O
aortic	O
regurgitant	O
diastolic	O
murmur	O
grade	O
3	O
6	O
.	O
Abdomen	O
without	O
alterations	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
Complementary	O
tests	O
The	O
following	O
complementary	O
tests	O
were	O
performed	O
ECG	O
sinus	O
rhythm	O
at	O
95	O
bpm	O
.	O
Normal	O
PR	O
segment	O
.	O
Signs	O
of	O
left	O
ventricular	O
enlargement	O
.	O
Left	O
anterior	O
hemiblock	O
.	O
No	O
repolarisation	O
alterations	O
.	O
CBC	O
normal	O
haemogram	O
,	O
basic	O
biochemistry	O
and	O
normal	O
ions	O
.	O
Chest	O
X	O
ray	O
signs	O
of	O
vascular	O
redistribution	O
,	O
interstitial	O
oedema	O
in	O
lower	O
fields	O
and	O
bilateral	O
pleural	O
effusion	O
,	O
predominantly	O
on	O
the	O
right	O
.	O
No	O
apparent	O
parenchymal	O
infiltrates	O
.	O
Transthoracic	O
echocardiogram	O
dilated	O
left	O
ventricle	O
with	O
end	O
diastolic	O
diameter	O
of	O
65	O
mm	O
and	O
end	O
systolic	O
diameter	O
of	O
40	O
mm	O
,	O
with	O
hyperdynamic	O
global	O
systolic	O
function	O
.	O
An	O
aortic	O
insufficiency	O
jet	O
was	O
detected	O
,	O
which	O
was	O
difficult	O
to	O
quantify	O
as	O
it	O
was	O
an	O
eccentric	O
jet	O
that	O
collided	O
with	O
the	O
anterior	O
mitral	O
leaflet	O
,	O
and	O
was	O
suggestive	O
of	O
significant	O
aortic	O
insufficiency	O
.	O
Absence	O
of	O
mitral	O
valve	O
disease	O
.	O
Normal	O
right	O
chambers	O
with	O
pulmonary	O
systolic	O
pressure	O
not	O
estimable	O
in	O
the	O
absence	O
of	O
tricuspid	O
insufficiency	O
,	O
with	O
no	O
indirect	O
evidence	O
of	O
pulmonary	O
hypertension	O
.	O
No	O
vegetations	O
or	O
other	O
signs	O
of	O
endocarditis	O
visible	O
by	O
this	O
technique	O
,	O
no	O
other	O
pathological	O
findings	O
.	O
Blood	O
cultures	O
x2	O
in	O
two	O
batches	O
taken	O
,	O
one	O
before	O
and	O
one	O
after	O
the	O
start	O
of	O
antibiotic	O
treatment	O
negative	O
Clinical	O
evolution	O
Treatment	O
was	O
started	O
with	O
diuretics	O
and	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
,	O
in	O
addition	O
to	O
antibiotic	O
treatment	O
with	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
,	O
with	O
excellent	O
clinical	O
evolution	O
.	O
Following	O
clinical	O
improvement	O
,	O
a	O
transesophageal	O
echocardiogram	O
was	O
performed	O
to	O
evaluate	O
the	O
cause	O
of	O
the	O
aortic	O
regurgitation	O
.	O
This	O
test	O
documented	O
severe	O
aortic	O
regurgitation	O
due	O
to	O
severe	O
prolapse	O
flail	O
of	O
one	O
of	O
the	O
valve	O
leaflets	O
,	O
causing	O
an	O
eccentric	O
jet	O
directed	O
towards	O
the	O
anterior	O
mitral	O
leaflet	O
.	O
Slope	O
of	O
the	O
jet	O
of	O
very	O
pronounced	O
aortic	O
insufficiency	O
and	O
holodiastolic	O
inversion	O
of	O
the	O
flow	O
in	O
the	O
descending	O
aorta	O
,	O
compatible	O
with	O
severe	O
aortic	O
insufficiency	O
.	O
Other	O
findings	O
superimposed	O
on	O
those	O
reported	O
in	O
the	O
transthoracic	O
echocardiogram	O
.	O
Diagnosis	O
Heart	O
failure	O
triggered	O
by	O
respiratory	O
infection	O
,	O
in	O
a	O
patient	O
with	O
severe	O
aortic	O
valve	O
disease	O
severe	O
aortic	O
insufficiency	O
due	O
to	O
flail	O
of	O
one	O
of	O
the	O
leaflets	O
.	O

Medical	O
history	O
and	O
current	O
illness	O
62	O
year	O
old	O
woman	O
Active	O
life	O
No	O
known	O
drug	O
allergies	O
Smoker	O
of	O
0	O
.	O
5	O
packs	O
of	O
tobacco	O
day	O
Obesity	O
grade	O
2	O
No	O
high	O
blood	O
pressure	O
No	O
diabetes	O
Hypercholesterolemia	O
Hypothyroidism	O
Chronic	O
venous	O
insufficiency	O
Severe	O
dorso	O
lumbar	O
scoliosis	O
No	O
cardiological	O
history	O
Home	O
treatment	O
lyrica	B-FARMACO
,	O
pitavastatin	B-FARMACO
,	O
furosemide	B-FARMACO
,	O
daflon	B-FARMACO
,	O
voltaren	B-FARMACO
,	O
levothroid	B-FARMACO
Complementary	O
tests	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
.	O
Old	O
inferior	O
necrosis	O
.	O
PR	O
171	O
msec	O
.	O
QRS	O
86	O
msec	O
.	O
QTc	O
413	O
msec	O
.	O
Cardiac	O
axis	O
60o	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
cardiomegaly	O
,	O
increased	O
bilateral	O
interstitial	O
tissue	O
with	O
bibasal	O
predominance	O
.	O
Blood	O
tests	O
on	O
admission	O
glucose	O
150	O
mg	O
dl	O
,	O
urea	O
90	O
mg	O
dl	O
,	O
creatinine	O
3	O
.	O
3	O
mg	O
dl	O
,	O
sodium	O
138	O
mMol	O
l	O
,	O
potassium	O
4	O
.	O
4	O
mMol	O
l	O
,	O
INR	O
1	O
.	O
21	O
,	O
aPTT	O
25	O
.	O
8	O
,	O
leukocytes	O
42900	O
ul	O
,	O
PMN	O
95	O
.	O
1	O
,	O
lymphocytes	O
2000	O
ul	O
,	O
keys	O
13	O
,	O
haemoglobin	O
9	O
.	O
9	O
g	O
dl	O
,	O
haematocrit	O
30	O
.	O
3	O
,	O
MCV	O
88	O
.	O
7	O
,	O
MHC	O
28	O
.	O
9	O
,	O
platelets	O
16000	O
uL	O
.	O
Cranial	O
CT	O
scan	O
on	O
admission	O
poorly	O
demarcated	O
right	O
frontal	O
hypodense	O
lesion	O
.	O
Brain	O
MRI	O
multiple	O
brain	O
lesions	O
with	O
fine	O
annular	O
enhancement	O
and	O
perilesional	O
oedema	O
,	O
the	O
largest	O
measuring	O
2	O
cm	O
in	O
diameter	O
,	O
located	O
in	O
the	O
right	O
frontal	O
lobe	O
and	O
both	O
occipital	O
lobes	O
,	O
compatible	O
with	O
brain	O
abscesses	O
.	O
Transthoracic	O
echocardiogram	O
on	O
admission	O
cardiac	O
cavities	O
not	O
dilated	O
.	O
Preserved	O
left	O
ventricular	O
function	O
.	O
Mitral	O
valve	O
with	O
calcification	O
in	O
the	O
posterior	O
annulus	O
,	O
sclerosis	O
and	O
thickening	O
of	O
the	O
posterior	O
leaflet	O
in	O
which	O
a	O
mobile	O
hyperechoic	O
image	O
was	O
observed	O
adhered	O
to	O
the	O
free	O
edge	O
,	O
without	O
being	O
able	O
to	O
rule	O
out	O
vegetation	O
,	O
leading	O
to	O
mild	O
moderate	O
mitral	O
insufficiency	O
.	O
No	O
other	O
significant	O
valvulopathies	O
.	O
No	O
pericardial	O
effusion	O
.	O
Transesophageal	O
echocardiogram	O
on	O
admission	O
two	O
images	O
were	O
observed	O
at	O
the	O
level	O
of	O
the	O
posterior	O
leaflets	O
1	O
.	O
4x1	O
.	O
3	O
cm	O
and	O
anterior	O
mitral	O
leaflets	O
0	O
.	O
8x0	O
.	O
9	O
cm	O
suggestive	O
of	O
vegetation	O
.	O
Moderate	O
mitral	O
insufficiency	O
.	O
Control	O
echocardiogram	O
colour	O
Doppler	O
image	O
suggestive	O
of	O
perforation	O
of	O
the	O
posterior	O
mitral	O
leaflet	O
.	O
The	O
vegetation	O
in	O
the	O
posterior	O
leaflet	O
was	O
observed	O
to	O
have	O
disappeared	O
.	O
Image	O
in	O
the	O
anterior	O
leaflet	O
suggestive	O
of	O
evolved	O
vegetation	O
.	O
Moderate	O
mitral	O
insufficiency	O
.	O
Abdominal	O
ultrasound	O
medical	O
renal	O
disease	O
with	O
parenchymal	O
scarring	O
.	O
Splenic	O
infarcts	O
.	O
Thrombosis	O
of	O
the	O
celiac	O
trunk	O
.	O
Blood	O
cultures	O
on	O
admission	O
positive	O
for	O
Sth	O
.	O
Aureus	O
sensitive	O
to	O
cloxacillin	B-FARMACO
.	O
Control	O
blood	O
cultures	O
negative	O
.	O
Clinical	O
evolution	O
Patient	O
initially	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
in	O
septic	O
shock	O
,	O
with	O
acute	O
oliguric	O
renal	O
failure	O
,	O
requiring	O
volume	O
support	O
and	O
vasoactive	O
amines	O
and	O
a	O
brain	O
lesion	O
of	O
uncertain	O
aetiology	O
.	O
There	O
were	O
no	O
septic	O
foci	O
detectable	O
at	O
abdominal	O
level	O
by	O
CT	O
scan	O
,	O
but	O
a	O
transthoracic	O
echocardiogram	O
showed	O
a	O
suspicious	O
image	O
of	O
vegetation	O
on	O
the	O
mitral	O
valve	O
,	O
which	O
was	O
confirmed	O
by	O
transesophageal	O
echocardiogram	O
.	O
There	O
was	O
also	O
evidence	O
of	O
preserved	O
systolic	O
function	O
and	O
moderate	O
mitral	O
insufficiency	O
.	O
Treated	O
on	O
admission	O
with	O
meropenem	B-FARMACO
,	O
once	O
diagnosed	O
with	O
mitral	O
endocarditis	O
,	O
treatment	O
was	O
started	O
with	O
vancomycin	B-FARMACO
and	O
gentamicin	B-FARMACO
.	O
After	O
the	O
initial	O
blood	O
cultures	O
were	O
positive	O
for	O
cloxacillin	B-FARMACO
sensitive	O
Sthaphylococcus	O
aureus	O
,	O
the	O
antibiotic	O
regimen	O
was	O
changed	O
to	O
cloxacillin	B-FARMACO
gentamicin	I-FARMACO
.	O
The	O
study	O
was	O
completed	O
with	O
brain	O
MRI	O
,	O
which	O
confirmed	O
the	O
presence	O
of	O
several	O
lesions	O
compatible	O
with	O
brain	O
abscesses	O
,	O
all	O
of	O
them	O
smaller	O
than	O
2	O
cm	O
.	O
After	O
an	O
initial	O
favourable	O
evolution	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
cardiology	O
ward	O
for	O
further	O
treatment	O
.	O
On	O
admission	O
to	O
the	O
ward	O
,	O
the	O
patient	O
showed	O
signs	O
of	O
global	O
heart	O
failure	O
,	O
with	O
optimal	O
response	O
to	O
diuretics	O
.	O
In	O
the	O
first	O
few	O
days	O
,	O
she	O
also	O
developed	O
septic	O
embolism	O
in	O
the	O
left	O
lower	O
limb	O
.	O
An	O
urgent	O
transfemoral	O
embolectomy	O
was	O
performed	O
,	O
which	O
was	O
successful	O
.	O
Abdominal	O
ultrasound	O
revealed	O
the	O
presence	O
of	O
several	O
splenic	O
infarctions	O
and	O
an	O
image	O
of	O
an	O
embolus	O
at	O
the	O
level	O
of	O
the	O
celiac	O
trunk	O
the	O
patient	O
did	O
not	O
present	O
intestinal	O
symptoms	O
at	O
any	O
time	O
,	O
which	O
were	O
not	O
present	O
in	O
the	O
previous	O
abdominal	O
CT	O
scan	O
.	O
Control	O
echocardiograms	O
showed	O
a	O
reduction	O
in	O
the	O
size	O
of	O
the	O
vegetation	O
,	O
persistence	O
of	O
moderate	O
insufficiency	O
,	O
preserved	O
function	O
.	O
Continuing	O
prolonged	O
therapy	O
with	O
cloxacillin	B-FARMACO
for	O
eight	O
weeks	O
,	O
due	O
to	O
the	O
presence	O
of	O
brain	O
abscesses	O
,	O
the	O
patient	O
experienced	O
progressive	O
clinical	O
improvement	O
and	O
improvement	O
of	O
analytical	O
parameters	O
,	O
with	O
disappearance	O
of	O
data	O
suggestive	O
of	O
active	O
infection	O
,	O
normalisation	O
of	O
renal	O
function	O
parameters	O
,	O
remaining	O
afebrile	O
and	O
stable	O
.	O
The	O
case	O
was	O
discussed	O
in	O
a	O
medical	O
surgical	O
session	O
,	O
at	O
which	O
time	O
the	O
patient	O
had	O
emboligenic	O
mitral	O
endocarditis	O
with	O
brain	O
abscesses	O
,	O
chronic	O
anaemia	O
,	O
renal	O
insufficiency	O
with	O
GFR	O
around	O
30	O
ml	O
min	O
.	O
Given	O
the	O
high	O
surgical	O
risk	O
and	O
the	O
favourable	O
response	O
to	O
antibiotic	O
treatment	O
,	O
it	O
was	O
decided	O
to	O
continue	O
with	O
medical	O
management	O
,	O
and	O
mitral	O
valve	O
replacement	O
surgery	O
was	O
not	O
ruled	O
out	O
in	O
the	O
event	O
of	O
a	O
progression	O
of	O
the	O
infectious	O
condition	O
.	O
Once	O
the	O
antibiotic	O
regimen	O
was	O
completed	O
,	O
and	O
given	O
the	O
clinical	O
and	O
haemodynamic	O
stability	O
,	O
discharge	O
home	O
was	O
decided	O
.	O
Diagnosis	O
Endocarditis	O
on	O
native	O
mitral	O
valve	O
,	O
due	O
to	O
Sthaphylococcus	O
aureus	O
sensitive	O
to	O
cloxacillin	B-FARMACO
,	O
emboligenic	O
.	O
Septic	O
shock	O
Preserved	O
systolic	O
function	O
.	O
Moderate	O
mitral	O
regurgitation	O
.	O
Perforation	O
of	O
posterior	O
leaflet	O
of	O
mitral	O
valve	O
Renal	O
failure	O
of	O
mixed	O
aetiology	O
nephrotoxic	O
,	O
glomerulonephritis	O
,	O
prerenal	O
Congestive	O
heart	O
failure	O
Cerebral	O
septic	O
embolism	O
.	O
Cerebral	O
abscesses	O
smaller	O
than	O
2	O
cm	O
Femoral	O
arterial	O
septic	O
embolism	O
.	O
Urgent	O
transfemoral	O
embolectomy	O
Asymptomatic	O
celiac	O
trunk	O
embolism	O
Splenic	O
embolism	O
with	O
infarction	O

Medical	O
history	O
and	O
current	O
illness	O
36	O
year	O
old	O
woman	O
with	O
a	O
history	O
of	O
AHT	O
.	O
No	O
DM	O
or	O
known	O
hyperlipidaemia	O
.	O
Smoker	O
of	O
20	O
cigarettes	O
day	O
.	O
No	O
drinker	O
.	O
She	O
denies	O
consumption	O
of	O
other	O
toxic	O
substances	O
.	O
No	O
known	O
heart	O
disease	O
or	O
bronchopathy	O
.	O
Preoperative	O
ECG	O
detected	O
LBBB	O
.	O
Hepatic	O
analytical	O
alteration	O
.	O
Originally	O
from	O
the	O
province	O
of	O
Cordoba	O
in	O
Argentina	O
.	O
IQ	O
caesarean	O
section	O
.	O
Cholecystectomy	O
in	O
January	O
2011	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
On	O
treatment	O
only	O
with	O
oral	O
contraceptives	O
.	O
Previously	O
asymptomatic	O
since	O
3	O
days	O
before	O
admission	O
,	O
she	O
reported	O
asthenia	O
and	O
progressive	O
dyspnoea	O
on	O
exertion	O
.	O
Occasional	O
epigastralgia	O
.	O
Complementary	O
tests	O
Physical	O
examination	O
conscious	O
and	O
oriented	O
,	O
well	O
hydrated	O
and	O
perfused	O
,	O
good	O
skin	O
colour	O
,	O
no	O
IY	O
,	O
no	O
fever	O
.	O
BP	O
165	O
120	O
.	O
AC	O
rhythmic	O
sounds	O
without	O
murmurs	O
.	O
AR	O
hypoventilation	O
in	O
both	O
bases	O
.	O
Basal	O
O2	O
sats	O
98	O
.	O
Abdomen	O
soft	O
,	O
pain	O
on	O
pressure	O
in	O
the	O
epigastrium	O
.	O
EE	O
.	O
II	O
No	O
oedema	O
.	O
Pedes	O
little	O
wide	O
.	O
ECG	O
RS	O
.	O
BRIHH	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
.	O
Right	O
predominant	O
insterstitial	O
pattern	O
.	O
Right	O
costophrenic	O
sinus	O
impingement	O
.	O
Angio	O
CT	O
performed	O
in	O
the	O
emergency	O
department	O
PTE	O
was	O
ruled	O
out	O
.	O
Bilateral	O
pleural	O
effusion	O
,	O
more	O
important	O
on	O
the	O
right	O
side	O
.	O
Right	O
paratracheal	O
lymphadenopathies	O
of	O
pathological	O
size	O
were	O
observed	O
.	O
Laboratory	O
tests	O
1	O
hour	O
ESR	O
14	O
mm	O
.	O
Red	O
blood	O
count	O
and	O
platelets	O
normal	O
.	O
Leukocytes	O
11	O
,	O
003	O
with	O
normal	O
formula	O
.	O
Urate	O
7	O
.	O
9	O
.	O
Total	O
cholesterol	O
192	O
.	O
HDL	O
C	O
43	O
.	O
LDL	O
C	O
132	O
,	O
2	O
.	O
Triglycerides	O
84	O
.	O
ProBNP	O
871	O
.	O
4	O
.	O
GGT	O
174	O
.	O
GPT	O
52	O
.	O
Ultrasensitive	O
TnT	O
on	O
admission	O
12	O
.	O
1	O
.	O
Total	O
bilirubin	O
,	O
creatinine	O
,	O
glomerular	O
filtrate	O
,	O
glucose	O
,	O
urea	O
,	O
PT	O
,	O
chlorine	O
,	O
sodium	O
,	O
potassium	O
,	O
iron	O
,	O
GOT	O
,	O
FFAA	O
,	O
total	O
CK	O
,	O
and	O
TSH	O
,	O
within	O
normal	O
limits	O
.	O
Echocardiogram	O
with	O
global	O
hypokinesia	O
and	O
EF	O
of	O
30	O
.	O
Normal	O
diastolic	O
function	O
.	O
LV	O
hypertrophy	O
in	O
the	O
posterior	O
face	O
.	O
Dilated	O
LA	O
23	O
cm2	O
.	O
Thickened	O
mitral	O
valve	O
with	O
mild	O
moderate	O
MR	O
.	O
Mild	O
TR	O
with	O
PSAP	O
of	O
54	O
mmHg	O
.	O
A	O
referral	O
was	O
made	O
to	O
the	O
Pneumology	O
Department	O
to	O
assess	O
right	O
paratracheal	O
adenopathy	O
,	O
performing	O
mantoux	O
negative	O
,	O
recommending	O
a	O
CT	O
scan	O
within	O
2	O
months	O
and	O
subsequent	O
assessment	O
by	O
the	O
outpatient	O
Pneumology	O
Department	O
.	O
Clinical	O
evolution	O
Given	O
the	O
patient	O
's	O
origin	O
,	O
serology	O
for	O
Chagas	O
disease	O
Trypanosoma	O
cruzi	O
was	O
performed	O
and	O
was	O
positive	O
.	O
The	O
diagnosis	O
of	O
Chagas	O
disease	O
was	O
confirmed	O
by	O
IFA	O
and	O
ELISA	O
,	O
both	O
positive	O
.	O
She	O
was	O
discharged	O
with	O
candesartan	B-FARMACO
,	O
bisoprolol	B-FARMACO
and	O
benznidazole	B-FARMACO
3	O
tablets	O
together	O
every	O
24	O
hours	O
for	O
follow	O
up	O
in	O
the	O
Heart	O
Failure	O
and	O
Infectious	O
Diseases	O
departments	O
.	O
Diagnosis	O
Chronic	O
Chagas	O
disease	O
Severe	O
grade	O
systolic	O
dysfunction	O

PERSONAL	O
HISTORY	O
No	O
known	O
drug	O
allergies	O
.	O
Toxic	O
habits	O
ex	O
smoker	O
for	O
5	O
years	O
,	O
smoked	O
1	O
pack	O
day	O
for	O
20	O
years	O
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
HT	O
with	O
poor	O
control	O
at	O
home	O
,	O
SBP	O
around	O
180	O
,	O
dyslipidaemia	O
LD	O
,	O
type	O
II	O
diabetes	O
mellitus	O
DM	O
.	O
Cardiological	O
history	O
chronic	O
ischaemic	O
heart	O
disease	O
since	O
2006	O
,	O
anterior	O
descending	O
AD	O
occlusion	O
with	O
collateral	O
filling	O
,	O
diffuse	O
atheromatosis	O
.	O
Positive	O
ergometry	O
at	O
high	O
loads	O
,	O
so	O
medical	O
management	O
was	O
decided	O
.	O
Paroxysmal	O
AF	O
anticoagulated	O
with	O
synthrom	B-FARMACO
.	O
Medical	O
surgical	O
psoriatic	O
arthropathy	O
,	O
treated	O
with	O
methotrexate	B-FARMACO
.	O
Admitted	O
in	O
2016	O
for	O
influenza	O
A	O
infection	O
and	O
respiratory	O
failure	O
.	O
Home	O
treatment	O
atenolol	B-FARMACO
50	O
mg	O
24h	O
,	O
Uniket	B-FARMACO
reatard	I-FARMACO
50	O
mg	O
24h	O
,	O
telmisartan	B-FARMACO
80	O
mg	O
24h	O
,	O
amlodipine	B-FARMACO
5	O
mg	O
24h	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
24h	O
,	O
ezetimibe	B-FARMACO
10	O
mg	O
24h	O
,	O
metformin	B-FARMACO
1000	O
mg	O
sitagliptin	B-FARMACO
50	O
mg	O
12h	O
,	O
deflazacort	B-FARMACO
6	O
mg	O
24h	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
24h	O
,	O
sintrom	B-FARMACO
4	O
mg	O
,	O
empagliflozin	B-FARMACO
10	O
mg	O
24h	O
,	O
folic	B-FARMACO
acid	I-FARMACO
5	O
mg	O
24h	O
,	O
methotrexate	B-FARMACO
15	O
mg	O
sc	O
every	O
7	O
days	O
,	O
vesomni	B-FARMACO
6	O
0	O
.	O
4	O
mg	O
24h	O
.	O
CURRENT	O
ILLNESS	O
A	O
71	O
year	O
old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
for	O
chest	O
pain	O
.	O
The	O
patient	O
reported	O
that	O
in	O
the	O
last	O
few	O
days	O
he	O
had	O
presented	O
approximately	O
5	O
episodes	O
per	O
day	O
of	O
central	O
chest	O
tightness	O
associated	O
with	O
dyspnoea	O
triggered	O
by	O
minimal	O
exertion	O
walking	O
on	O
level	O
ground	O
for	O
less	O
than	O
50	O
m	O
lasting	O
about	O
10	O
minutes	O
,	O
which	O
improved	O
after	O
rest	O
.	O
He	O
denied	O
palpitations	O
,	O
syncope	O
,	O
decreased	O
diuresis	O
or	O
increased	O
circumference	O
of	O
the	O
lower	O
limbs	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
114	O
53	O
mmHg	O
.	O
Heart	O
rate	O
87	O
bpm	O
.	O
Afebrile	O
.	O
Basal	O
sats	O
O2	O
95	O
.	O
Head	O
and	O
neck	O
no	O
IVY	O
at	O
45	O
and	O
no	O
hepatojugular	O
reflux	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
added	O
sounds	O
,	O
hypophonesis	O
at	O
the	O
bases	O
with	O
no	O
clear	O
crackles	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
Lower	O
limbs	O
no	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
with	O
frequent	O
ventricular	O
extrasystoles	O
in	O
bigeminy	O
.	O
PR	O
162	O
ms	O
,	O
QRS	O
102	O
ms	O
,	O
60o	O
axis	O
,	O
ST	O
segment	O
rectification	O
from	O
V2	O
to	O
V6	O
already	O
described	O
in	O
previous	O
ECGs	O
.	O
Control	O
ECG	O
sinus	O
bradycardia	O
at	O
60	O
bpm	O
,	O
isolated	O
ventricular	O
extrasystoles	O
,	O
unchanged	O
from	O
previous	O
ECG	O
.	O
Chest	O
X	O
ray	O
mediastinal	O
structures	O
centred	O
.	O
Cardiopericardial	O
silhouette	O
of	O
normal	O
morphology	O
.	O
Pulmonary	O
hilae	O
of	O
vascular	O
morphology	O
.	O
Free	O
costodiaphragmatic	O
sinuses	O
.	O
No	O
evidence	O
of	O
active	O
pleuroparenchymal	O
lesions	O
at	O
the	O
present	O
time	O
.	O
Blood	O
gases	O
pH	O
7	O
.	O
455	O
,	O
San	O
pCO2	O
32	O
.	O
1	O
mmHg	O
,	O
San	O
pO2	O
80	O
.	O
7	O
mmHg	O
,	O
O2	O
saturation	O
95	O
.	O
5	O
,	O
San	O
sodium	O
133	O
.	O
7	O
mmol	O
l	O
,	O
San	O
potassium	O
4	O
.	O
58	O
mmol	O
l	O
,	O
San	O
lactate	O
2	O
.	O
89	O
mmol	O
l	O
.	O
Laboratory	O
ED	O
leucocytes	O
6	O
.	O
65	O
.	O
Haemoglobin	O
11	O
.	O
5	O
.	O
Haematocrit	O
33	O
.	O
6	O
.	O
MCV	O
83	O
.	O
7	O
.	O
Platelets	O
316	O
.	O
0	O
.	O
Neutrophils	O
67	O
.	O
8	O
.	O
Glucose	O
100	O
.	O
0	O
.	O
Urea	O
90	O
.	O
0	O
.	O
Uric	O
acid	O
6	O
.	O
0	O
.	O
Creatinine	O
0	O
.	O
86	O
.	O
Sodium	O
139	O
.	O
0	O
.	O
Potassium	O
4	O
.	O
4	O
.	O
Total	O
bilirubin	O
0	O
.	O
9	O
.	O
Aspartate	O
aminotransferase	O
AST	O
GOT	O
31	O
.	O
0	O
.	O
Alanine	O
aminotransferase	O
ALT	O
GPT	O
63	O
.	O
0	O
.	O
Gamma	O
glutamyl	O
transferase	O
GGT	O
28	O
.	O
0	O
.	O
Alkaline	O
phosphatase	O
136	O
.	O
0	O
.	O
Serial	O
myocardial	O
necrosis	O
markers	O
negative	O
.	O
Central	O
laboratory	O
iron	O
44	O
.	O
0	O
.	O
Ferritin	O
72	O
.	O
0	O
.	O
Transferrin	O
saturation	O
index	O
13	O
.	O
0	O
.	O
Transferrin	O
243	O
.	O
0	O
.	O
Iron	O
binding	O
capacity	O
of	O
transferrin	O
340	O
.	O
0	O
.	O
Folate	O
19	O
.	O
7	O
.	O
Vitamin	O
B12	O
cobalamin	O
283	O
.	O
0	O
.	O
Cholesterol	O
76	O
.	O
0	O
.	O
Triglycerides	O
109	O
.	O
0	O
.	O
HDL	O
cholesterol	O
16	O
.	O
0	O
.	O
Non	O
HDL	O
cholesterol	O
60	O
.	O
0	O
.	O
LDL	O
cholesterol	O
calculated	O
38	O
.	O
0	O
.	O
Thyrotropin	O
TSH	O
2	O
.	O
2	O
.	O
N	O
terminal	O
pro	O
brain	O
natriuretic	O
peptide	O
NT	O
proBNP	O
2092	O
.	O
0	O
.	O
Haemoglobin	O
A1c	O
7	O
.	O
7	O
.	O
Faecal	O
occult	O
blood	O
test	O
negative	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
left	O
ventricle	O
not	O
dilated	O
,	O
slightly	O
hypertrophied	O
VTD	O
70	O
ml	O
,	O
VTS	O
30	O
ml	O
,	O
SIV	O
13	O
mm	O
.	O
Preserved	O
systolic	O
function	O
LVEF	O
by	O
Simpson	O
57	O
,	O
without	O
segmental	O
alterations	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Normal	O
transmitral	O
filling	O
pattern	O
E	O
0	O
.	O
90	O
m	O
s	O
A	O
0	O
.	O
58m	O
s	O
E	O
A	O
1	O
.	O
5	O
;	O
e	O
lateral	O
0	O
.	O
08	O
e	O
septal	O
0	O
.	O
10	O
E	O
e	O
11	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
sclerocalcified	O
with	O
preserved	O
opening	O
max	O
transvalvular	O
gradient	O
16	O
.	O
5	O
mmHg	O
mean	O
9	O
.	O
32	O
mmHg	O
.	O
No	O
aortic	O
insufficiency	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
area	O
23	O
cm2	O
,	O
volume	O
66	O
ml	O
.	O
Ascending	O
atrium	O
not	O
dilated	O
37	O
mm	O
.	O
Non	O
dilated	O
right	O
ventricle	O
basal	O
DTD	O
40	O
mm	O
,	O
mean	O
DTD	O
32	O
mm	O
TAPSE	O
22	O
mm	O
S	O
0	O
.	O
11	O
m	O
s	O
.	O
Right	O
atrium	O
slightly	O
dilated	O
area	O
23	O
cm2	O
.	O
Thin	O
pulmonary	O
valve	O
.	O
Mild	O
pulmonary	O
insufficiency	O
.	O
No	O
pulmonary	O
valve	O
stenosis	O
.	O
Pulmonary	O
artery	O
flow	O
acceleration	O
time	O
of	O
80	O
ms	O
.	O
Fine	O
tricuspid	O
valve	O
,	O
mild	O
insufficiency	O
,	O
RV	O
AD	O
gradient	O
39	O
mmHg	O
.	O
Pulmonary	O
systolic	O
pressure	O
44	O
mmHg	O
.	O
Cavainferior	O
cavainferior	O
vein	O
not	O
dilated	O
,	O
collapse	O
50	O
.	O
Impressed	O
absence	O
of	O
pericardial	O
effusion	O
.	O
Diagnostic	O
coronary	O
angiography	O
atheromatous	O
left	O
main	O
coronary	O
artery	O
LMCA	O
with	O
eccentric	O
calcified	O
lesion	O
at	O
distal	O
level	O
leading	O
to	O
significant	O
stenosis	O
at	O
distal	O
level	O
in	O
LMCA	O
Cx	O
,	O
with	O
distal	O
luminal	O
area	O
of	O
5	O
.	O
6	O
cm2	O
measured	O
by	O
IVUS	O
.	O
LAD	O
occluded	O
at	O
ostial	O
level	O
;	O
distal	O
vessel	O
by	O
homo	O
and	O
heterocoronary	O
collaterals	O
,	O
of	O
small	O
calibre	O
.	O
Circumflex	O
CX	O
diffusely	O
calcified	O
,	O
with	O
severe	O
lesion	O
at	O
ostial	O
TCI	O
CX	O
and	O
proximal	O
level	O
.	O
Dominant	O
right	O
coronary	O
artery	O
RCA	O
with	O
diffuse	O
calcification	O
and	O
no	O
significant	O
stenosis	O
.	O
Colonoscopy	O
and	O
upper	O
gastrointestinal	O
endoscopy	O
no	O
evidence	O
of	O
blood	O
or	O
bleeding	O
lesions	O
of	O
the	O
visible	O
mucosa	O
.	O
Percutaneous	O
coronary	O
intervention	O
a	O
guide	O
wire	O
is	O
advanced	O
to	O
distal	O
Cx	O
.	O
The	O
Cx	O
LCT	O
lesion	O
is	O
predilated	O
and	O
an	O
everolimus	B-FARMACO
eluting	O
stent	O
3	O
.	O
5	O
15	O
mm	O
at	O
18	O
atm	O
is	O
implanted	O
with	O
good	O
angiographic	O
results	O
covering	O
the	O
lesion	O
.	O
The	O
proximal	O
CX	O
lesion	O
is	O
then	O
predilated	O
and	O
an	O
everolimus	B-FARMACO
eluting	O
drug	O
eluting	O
stent	O
3	O
18	O
mm	O
at	O
18	O
atm	O
is	O
implanted	O
with	O
good	O
final	O
angiographic	O
results	O
.	O
CLINICAL	O
EVOLUTION	O
A	O
71	O
year	O
old	O
man	O
was	O
admitted	O
for	O
unstable	O
angina	O
.	O
A	O
transthoracic	O
echocardiogram	O
showed	O
preserved	O
biventricular	O
systolic	O
function	O
and	O
no	O
valvular	O
heart	O
disease	O
.	O
A	O
coronary	O
angiogram	O
was	O
also	O
performed	O
,	O
showing	O
occlusion	O
of	O
the	O
ostial	O
anterior	O
descending	O
artery	O
already	O
known	O
,	O
a	O
significant	O
lesion	O
in	O
the	O
distal	O
trunk	O
affecting	O
the	O
circumflex	O
ostium	O
and	O
a	O
severe	O
distal	O
lesion	O
.	O
A	O
mild	O
iron	O
deficiency	O
anaemia	O
was	O
found	O
,	O
which	O
is	O
why	O
,	O
after	O
discussing	O
the	O
case	O
in	O
the	O
medical	O
surgical	O
session	O
,	O
an	O
anaemia	O
study	O
was	O
indicated	O
to	O
exclude	O
bleeding	O
foci	O
prior	O
to	O
percutaneous	O
intervention	O
.	O
Telemetry	O
showed	O
ventricular	O
bigeminy	O
,	O
which	O
was	O
jugulated	O
with	O
beta	O
blockers	O
;	O
no	O
major	O
ventricular	O
arrhythmias	O
.	O
Digestive	O
endoscopy	O
was	O
performed	O
without	O
documentation	O
of	O
potentially	O
bleeding	O
lesions	O
.	O
The	O
patient	O
under	O
double	O
antiplatelet	O
therapy	O
and	O
low	B-FARMACO
weight	I-FARMACO
heparins	I-FARMACO
has	O
not	O
presented	O
clinical	O
bleeding	O
and	O
has	O
improved	O
ferrokinetics	O
and	O
haemoglobin	O
with	O
oral	O
iron	B-FARMACO
.	O
Excluding	O
major	O
bleeding	O
and	O
without	O
anaemia	O
under	O
double	O
antiplatelet	O
therapy	O
plus	O
heparin	B-FARMACO
,	O
the	O
patient	O
underwent	O
percutaneous	O
coronary	O
intervention	O
with	O
implantation	O
of	O
two	O
stents	O
with	O
a	O
good	O
final	O
angiographic	O
result	O
.	O
Post	O
procedural	O
evolution	O
was	O
favourable	O
,	O
with	O
no	O
clinical	O
events	O
.	O
Given	O
her	O
clinical	O
stability	O
,	O
with	O
no	O
further	O
in	O
hospital	O
procedures	O
required	O
,	O
she	O
was	O
discharged	O
home	O
.	O
Treatment	O
at	O
discharge	O
Rivaroxaban	O
15	O
mg	O
1	O
tablet	O
at	O
noon	O
.	O
Clopidogrel	B-FARMACO
75	O
mg	O
1	O
tablet	O
with	O
food	O
for	O
1	O
year	O
.	O
Acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	O
100mg	O
1	O
tablet	O
with	O
food	O
for	O
1	O
month	O
.	O
Pantoprazole	B-FARMACO
40	O
mg	O
1	O
tablet	O
on	O
an	O
empty	O
stomach	O
.	O
Bisoprolol	B-FARMACO
5	O
mg	O
.	O
1	O
tablet	O
with	O
breakfast	O
.	O
Amlodipine	B-FARMACO
5	O
mg	O
.	O
1	O
tablet	O
with	O
dinner	O
.	O
Isosorbide	B-FARMACO
mononitrate	I-FARMACO
retard	O
50	O
mg	O
.	O
1	O
tablet	O
with	O
breakfast	O
.	O
Atorvastatin	B-FARMACO
80	O
mg	O
ezetimibe	B-FARMACO
10	O
mg	O
.	O
1	O
tablet	O
with	O
evening	O
meal	O
Furosemide	B-FARMACO
40	O
mg	O
.	O
1	O
tablet	O
with	O
breakfast	O
.	O
Tardyferon	B-FARMACO
80	O
mg	O
.	O
1	O
tablet	O
15	O
minutes	O
before	O
breakfast	O
for	O
3	O
months	O
.	O

PERSONAL	O
HISTORY	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
arterial	O
hypertension	O
HT	O
.	O
Dyslipidaemia	O
LD	O
.	O
Never	O
smoker	O
.	O
Cardiological	O
history	O
of	O
interest	O
chronic	O
ischaemic	O
heart	O
disease	O
.	O
Coronary	O
artery	O
disease	O
of	O
the	O
left	O
coronary	O
trunk	O
LMCA	O
and	O
3	O
vessels	O
surgically	O
revascularised	O
in	O
1992	O
AMII	O
DA	O
and	O
AMID	O
OM	O
.	O
Admitted	O
for	O
unstable	O
angina	O
in	O
2010	O
,	O
with	O
90	O
disease	O
of	O
LMCA	O
,	O
occlusion	O
of	O
LMAD	O
and	O
occlusion	O
of	O
CXp	O
and	O
CDp	O
;	O
permeable	O
bridges	O
,	O
so	O
it	O
was	O
decided	O
to	O
indicate	O
medical	O
treatment	O
.	O
Last	O
coronary	O
angiography	O
in	O
April	O
2014	O
due	O
to	O
stable	O
angina	O
CCS	O
III	O
with	O
positive	O
exercise	O
echocardiogram	O
for	O
extensive	O
global	O
ischaemia	O
,	O
implantation	O
of	O
drug	O
eluting	O
stents	O
on	O
LMCA	O
was	O
performed	O
with	O
good	O
results	O
same	O
coronary	O
anatomy	O
,	O
permeable	O
bridges	O
.	O
Persistent	O
atrial	O
fibrillation	O
with	O
controlled	O
ventricular	O
response	O
.	O
CHADSVASc	O
score	O
4	O
.	O
Other	O
relevant	O
background	O
Stable	O
bronchial	O
asthma	O
under	O
follow	O
up	O
in	O
pulmonology	O
.	O
Spirometry	O
performed	O
in	O
2014	O
FVC	O
3840	O
100	O
,	O
FEV1	O
2610	O
98	O
,	O
index	O
71	O
,	O
negative	O
bronchodilator	O
test	O
.	O
Stage	O
3	O
chronic	O
renal	O
failure	O
secondary	O
to	O
probable	O
nephroangiosclerosis	O
.	O
Secondary	O
hyperparathyroidism	O
.	O
Secondary	O
chronic	O
anaemia	O
.	O
Hyperuricaemia	O
.	O
Benign	O
prostatic	O
hyperplasia	O
.	O
Surgical	O
interventions	O
cholecystectomy	O
.	O
Functional	O
status	O
dyspnoea	O
NYHA	O
functional	O
class	O
II	O
.	O
Stable	O
angina	O
CCS	O
I	O
.	O
Retired	O
taxi	O
driver	O
,	O
occasionally	O
works	O
as	O
a	O
carpenter	O
.	O
Usual	O
treatment	O
fluticasone	B-FARMACO
salmeterol	I-FARMACO
50	O
500	O
,	O
aclidinium	B-FARMACO
bromide	I-FARMACO
322	O
mcg	O
,	O
salbutamol	B-FARMACO
if	O
necessary	O
,	O
nitroglycerin	O
transdermal	O
patch	O
15	O
mg	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
,	O
dabigatran	B-FARMACO
110	O
mg	O
12h	O
,	O
allopurinol	B-FARMACO
100	O
mg	O
,	O
tamsulosin	B-FARMACO
0	O
.	O
4	O
mg	O
,	O
calcitriol	B-FARMACO
0	O
.	O
5	O
mg	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
.	O
CURRENT	O
ILLNESS	O
77	O
year	O
old	O
patient	O
admitted	O
to	O
the	O
pulmonology	O
department	O
in	O
January	O
2015	O
with	O
clinical	O
manifestations	O
of	O
cough	O
with	O
haemoptotic	O
expectoration	O
and	O
increased	O
dyspnoea	O
,	O
afebrile	O
.	O
Initially	O
managed	O
with	O
outpatient	O
levofloxacin	B-FARMACO
.	O
Given	O
the	O
torpid	O
evolution	O
,	O
he	O
was	O
transferred	O
to	O
the	O
emergency	O
department	O
,	O
where	O
a	O
chest	O
X	O
ray	O
showed	O
cardiomegaly	O
and	O
bilateral	O
pulmonary	O
infiltrates	O
,	O
especially	O
in	O
the	O
upper	O
lobes	O
.	O
After	O
15	O
days	O
on	O
antibiotics	O
,	O
oxygen	O
therapy	O
,	O
corticosteroids	O
and	O
diuretics	O
,	O
the	O
clinical	O
symptoms	O
subsided	O
and	O
he	O
was	O
discharged	O
in	O
January	O
2015	O
.	O
During	O
admission	O
,	O
an	O
autoimmune	O
and	O
infectious	O
study	O
was	O
performed	O
with	O
negative	O
results	O
,	O
and	O
a	O
thoracic	O
CT	O
scan	O
showed	O
ground	O
glass	O
images	O
in	O
the	O
upper	O
lobes	O
suggestive	O
of	O
pulmonary	O
haemorrhage	O
.	O
Bronchoscopy	O
was	O
performed	O
with	O
hyperemic	O
mucosa	O
with	O
no	O
evidence	O
of	O
active	O
bleeding	O
,	O
with	O
bronchoaspirate	O
with	O
haemosiderophages	O
30	O
of	O
macrophages	O
with	O
ferric	O
material	O
with	O
positive	O
Perls	O
staining	O
and	O
on	O
discharge	O
he	O
was	O
diagnosed	O
with	O
alveolar	O
haemorrhage	O
of	O
probable	O
infectious	O
aetiology	O
.	O
He	O
was	O
admitted	O
again	O
in	O
February	O
2015	O
from	O
the	O
outpatient	O
pulmonology	O
department	O
as	O
an	O
emergency	O
due	O
to	O
dyspnoea	O
on	O
slight	O
exertion	O
,	O
orthopnoea	O
and	O
a	O
new	O
episode	O
of	O
haemoptysis	O
.	O
A	O
new	O
chest	O
X	O
ray	O
was	O
performed	O
showing	O
cardiomegaly	O
,	O
data	O
suggestive	O
of	O
heart	O
failure	O
and	O
right	O
basal	O
infiltrate	O
suggestive	O
of	O
pneumonia	O
,	O
afebrile	O
,	O
and	O
a	O
new	O
hospital	O
admission	O
was	O
decided	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
141	O
72	O
mmHg	O
,	O
heart	O
rate	O
HR	O
75	O
bpm	O
,	O
SatO2	O
92	O
with	O
FiO2	O
30	O
.	O
Tachypnoea	O
at	O
rest	O
.	O
Good	O
general	O
condition	O
.	O
CBC	O
minimal	O
IVY	O
at	O
45	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
,	O
aortic	O
systolic	O
murmur	O
3	O
6	O
with	O
decreased	O
R2	O
;	O
Gallavardin	O
phenomenon	O
.	O
Pulmonary	O
auscultation	O
bilateral	O
wet	O
crackles	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
.	O
Lower	O
limbs	O
perimalleolar	O
oedema	O
.	O
No	O
evidence	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
atrial	O
fibrillation	O
at	O
75	O
bpm	O
.	O
Lateral	O
ST	O
rectification	O
.	O
CBC	O
haemogram	O
white	O
blood	O
cells	O
6	O
.	O
08	O
x10	O
9	O
l	O
.	O
Haematocrit	O
27	O
.	O
6	O
.	O
Haemoglobin	O
9	O
.	O
1	O
g	O
dl	O
.	O
Platelets	O
289	O
x10	O
9	O
l	O
.	O
Biochemistry	O
glucose	O
90	O
mg	O
dl	O
.	O
Urea	O
57	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
33	O
mg	O
dl	O
.	O
Sodium	O
139	O
mmol	O
l	O
.	O
Potassium	O
4	O
.	O
3	O
mmol	O
l	O
,	O
ESR	O
1	O
hour	O
65	O
mm	O
.	O
NT	O
proBNP	O
4700	O
pg	O
ml	O
.	O
Chest	O
X	O
ray	O
increased	O
cardiopericardial	O
silhouette	O
.	O
Vascular	O
redistribution	O
,	O
bilateral	O
perihilar	O
oedema	O
and	O
minimal	O
right	O
pleural	O
effusion	O
.	O
Right	O
basal	O
consolidation	O
.	O
Control	O
chest	O
X	O
ray	O
significant	O
radiological	O
improvement	O
,	O
with	O
resolution	O
of	O
the	O
right	O
basal	O
infiltrate	O
.	O
Bilateral	O
alveolar	O
infiltrates	O
persist	O
.	O
Coronary	O
angiography	O
no	O
changes	O
with	O
respect	O
to	O
the	O
previous	O
study	O
.	O
Aorto	O
iliac	O
axes	O
not	O
suitable	O
for	O
percutaneous	O
prosthesis	O
implantation	O
severe	O
tortuosity	O
in	O
the	O
right	O
axis	O
,	O
ulcerated	O
plaque	O
in	O
the	O
left	O
common	O
iliac	O
.	O
Echocardiogram	O
left	O
ventricle	O
LV	O
of	O
normal	O
size	O
.	O
Moderate	O
concentric	O
wall	O
thickening	O
.	O
Preserved	O
LV	O
systolic	O
function	O
LVEF	O
55	O
.	O
LA	O
moderately	O
dilated	O
49	O
mm	O
.	O
RV	O
slightly	O
dilated	O
45	O
mm	O
with	O
preserved	O
RVSF	O
.	O
Normal	O
mitral	O
valve	O
with	O
central	O
1	O
4	O
mitral	O
regurgitation	O
.	O
Normal	O
appearing	O
tricuspid	O
valve	O
,	O
central	O
2	O
4	O
IT	O
with	O
mild	O
pulmonary	O
hypertension	O
PH	O
.	O
Sclerocalcified	O
aortic	O
valve	O
,	O
with	O
severe	O
aortic	O
stenosis	O
Vmax	O
4	O
.	O
5	O
m	O
s	O
,	O
mean	O
gradient	O
40	O
mmHg	O
,	O
aortic	O
valve	O
area	O
0	O
.	O
78	O
cm2	O
,	O
TVI	O
ratio	O
0	O
.	O
23	O
;	O
aortic	O
regurgitation	O
2	O
4	O
central	O
.	O
Normal	O
sized	O
IVC	O
with	O
collapse	O
50	O
.	O
No	O
pericardial	O
effusion	O
.	O
Transesophageal	O
echocardiogram	O
monitoring	O
transapical	O
TAVI	O
implantation	O
Baseline	O
TEE	O
slightly	O
calcified	O
aortic	O
valve	O
with	O
severe	O
stenosis	O
and	O
central	O
insufficiency	O
grade	O
2	O
4	O
.	O
Aortic	O
annulus	O
2	O
.	O
75	O
cm2	O
2D	O
18	O
mm	O
,	O
3D	O
diameters	O
17	O
.	O
5x18	O
mm	O
.	O
Aortic	O
valve	O
annulus	O
ICD	O
ostium	O
distance	O
11	O
.	O
8	O
mm	O
.	O
Mitral	O
valve	O
insufficiency	O
grade	O
1	O
4	O
.	O
Tricuspid	O
valve	O
insufficiency	O
grade	O
2	O
4	O
.	O
Normal	O
LV	O
systolic	O
function	O
LVEF	O
55	O
.	O
No	O
pericardial	O
effusion	O
.	O
Intervention	O
implantation	O
of	O
a	O
23	O
mm	O
SAPIEN	O
3	O
prosthesis	O
via	O
transapical	O
route	O
.	O
Post	O
implantation	O
TEE	O
well	O
positioned	O
,	O
normofunctioning	O
biological	O
aortic	O
valve	O
prosthesis	O
,	O
with	O
trivial	O
periprosthetic	O
insufficiency	O
.	O
Normal	O
LV	O
systolic	O
function	O
.	O
Rest	O
unchanged	O
with	O
respect	O
to	O
the	O
previous	O
study	O
.	O
CLINICAL	O
EVOLUTION	O
This	O
is	O
a	O
patient	O
with	O
repeated	O
admissions	O
for	O
haemoptysis	O
with	O
migratory	O
pulmonary	O
infiltrates	O
and	O
examination	O
data	O
suggestive	O
of	O
decompensation	O
of	O
heart	O
failure	O
,	O
as	O
well	O
as	O
elevated	O
natriuretic	O
peptide	O
levels	O
,	O
with	O
good	O
clinical	O
radiological	O
evolution	O
in	O
the	O
various	O
admissions	O
with	O
diuretic	O
treatment	O
.	O
The	O
complementary	O
tests	O
performed	O
were	O
suggestive	O
of	O
alveolar	O
haemorrhage	O
although	O
the	O
bronchoscopy	O
showed	O
no	O
evidence	O
of	O
active	O
bleeding	O
,	O
it	O
was	O
performed	O
in	O
a	O
stable	O
clinical	O
situation	O
after	O
resolution	O
of	O
the	O
haemoptysis	O
,	O
showing	O
haemosiderin	O
laden	O
macrophages	O
with	O
no	O
evidence	O
of	O
active	O
infection	O
,	O
the	O
substrate	O
of	O
which	O
seems	O
to	O
be	O
decompensation	O
of	O
heart	O
failure	O
in	O
the	O
context	O
of	O
severe	O
aortic	O
stenosis	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
the	O
case	O
was	O
discussed	O
with	O
cardiology	O
,	O
and	O
the	O
case	O
was	O
presented	O
at	O
a	O
medical	O
surgical	O
session	O
,	O
and	O
a	O
decision	O
was	O
made	O
to	O
replace	O
the	O
aortic	O
valve	O
.	O
Given	O
the	O
EuroScore	O
of	O
7	O
.	O
3	O
,	O
percutaneous	O
replacement	O
by	O
femoral	O
access	O
was	O
initially	O
considered	O
,	O
but	O
was	O
ruled	O
out	O
after	O
angiography	O
in	O
which	O
inadequate	O
aorto	O
iliac	O
axes	O
were	O
observed	O
.	O
For	O
this	O
reason	O
,	O
it	O
was	O
decided	O
to	O
implant	O
the	O
prosthesis	O
via	O
transapical	O
access	O
.	O
On	O
24	O
02	O
2015	O
,	O
a	O
23	O
mm	O
Edwards	O
SAPIEN	O
3	O
biological	O
prosthesis	O
was	O
implanted	O
under	O
echocardiographic	O
monitoring	O
.	O
After	O
the	O
intervention	O
he	O
was	O
transferred	O
to	O
the	O
coronary	O
ICU	O
,	O
being	O
extubated	O
a	O
few	O
hours	O
later	O
without	O
complications	O
.	O
He	O
remained	O
in	O
the	O
CICU	O
for	O
48	O
hours	O
with	O
good	O
clinical	O
evolution	O
,	O
requiring	O
transfusion	O
of	O
three	O
red	O
blood	O
cell	O
concentrates	O
and	O
slight	O
deterioration	O
of	O
renal	O
function	O
,	O
and	O
was	O
transferred	O
to	O
the	O
cardiac	O
surgery	O
ward	O
.	O
During	O
his	O
stay	O
on	O
the	O
cardiac	O
surgery	O
ward	O
he	O
evolved	O
favourably	O
without	O
complications	O
and	O
was	O
discharged	O
after	O
7	O
days	O
.	O
Since	O
then	O
,	O
the	O
patient	O
has	O
been	O
under	O
active	O
follow	O
up	O
in	O
cardiology	O
consultations	O
with	O
no	O
new	O
admissions	O
for	O
haemoptysis	O
or	O
decompensation	O
of	O
heart	O
failure	O
,	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
status	O
I	O
II	O
,	O
with	O
control	O
echocardiograms	O
showing	O
preserved	O
systolic	O
function	O
and	O
a	O
normofunctioning	O
prosthesis	O
with	O
trivial	O
periprosthetic	O
insufficiency	O
.	O
DIAGNOSIS	O
Symptomatic	O
severe	O
aortic	O
stenosis	O
with	O
heart	O
failure	O
decompensation	O
.	O
Diffuse	O
alveolar	O
haemorrhage	O
secondary	O
to	O
heart	O
failure	O
.	O
Transapical	O
aortic	O
valve	O
replacement	O
with	O
biological	O
prosthesis	O
Edward	O
Sapien	O
3	O
No23	O
.	O
Normofunctioning	O
prosthesis	O
at	O
follow	O
up	O
.	O
Preserved	O
systolic	O
function	O
.	O
Moderate	O
tricuspid	O
regurgitation	O
.	O
Mild	O
PH	O
.	O
Stable	O
chronic	O
ischaemic	O
heart	O
disease	O
.	O
LMCA	O
and	O
3	O
vessel	O
disease	O
revascularised	O
surgically	O
IAMI	O
AD	O
,	O
IAMI	O
OM	O
in	O
1997	O
and	O
percutaneously	O
stent	O
implantation	O
in	O
LMCA	O
AD	O
in	O
2013	O
.	O
Permanent	O
atrial	O
fibrillation	O
AF	O
anticoagulated	O
with	O
pradaxa	B-FARMACO
.	O
Cardiovascular	O
risk	O
factors	O
HBP	O
.	O
LD	O
.	O

PERSONAL	O
HISTORY	O
Allergy	O
to	O
sulphonamides	O
and	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
.	O
Cardiovascular	O
risk	O
factors	O
dyslipidaemia	O
under	O
pharmacological	O
treatment	O
.	O
No	O
diabetes	O
mellitus	O
.	O
No	O
arterial	O
hypertension	O
AHT	O
.	O
No	O
toxic	O
habits	O
.	O
Cardiological	O
history	O
severe	O
symptomatic	O
aortic	O
stenosis	O
.	O
Aortic	O
valve	O
replacement	O
was	O
performed	O
in	O
May	O
2008	O
with	O
implantation	O
of	O
St	O
.	O
Jude	O
No	O
19	O
mechanical	O
aortic	O
prosthesis	O
.	O
Last	O
control	O
echocardiography	O
in	O
2012	O
normofunctioning	O
prosthesis	O
with	O
preserved	O
LVEF	O
.	O
Other	O
history	O
of	O
interest	O
Bronchial	O
asthma	O
under	O
inhaled	O
treatment	O
with	O
good	O
control	O
.	O
Macular	O
thrombosis	O
and	O
vitreous	O
detachment	O
in	O
the	O
right	O
eye	O
,	O
treated	O
with	O
laser	O
in	O
2015	O
.	O
Pelvic	O
fracture	O
in	O
August	O
2017	O
right	O
ischium	O
and	O
coccyx	O
resolved	O
.	O
L1	O
impingement	O
fracture	O
in	O
2016	O
.	O
Surgical	O
interventions	O
replacement	O
of	O
total	O
right	O
hip	O
prosthesis	O
one	O
month	O
ago	O
due	O
to	O
fracture	O
of	O
the	O
neck	O
of	O
the	O
right	O
femur	O
.	O
Previous	O
medication	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
,	O
enalapril	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
,	O
ecomcor	B-FARMACO
2	O
.	O
5	O
mg	O
1	O
2	O
0	O
1	O
2	O
,	O
atorvastatin	B-FARMACO
10	O
mg	O
0	O
0	O
1	O
,	O
acenocoumarol	B-FARMACO
according	O
to	O
haematology	O
guidelines	O
after	O
hip	O
surgery	O
,	O
in	O
bridging	O
therapy	O
with	O
low	B-FARMACO
molecular	I-FARMACO
weight	I-FARMACO
heparins	I-FARMACO
dose	O
enoxaparin	B-FARMACO
sc	O
40	O
mg	O
c	O
24	O
hours	O
.	O
CURRENT	O
DISEASE	O
Patient	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
a	O
sudden	O
increase	O
in	O
dyspnoea	O
.	O
She	O
reported	O
clinical	O
symptoms	O
of	O
upper	O
respiratory	O
symptoms	O
3	O
4	O
days	O
previously	O
,	O
with	O
cough	O
and	O
increased	O
expectoration	O
,	O
which	O
was	O
treated	O
with	O
azithromycin	B-FARMACO
.	O
Discharged	O
1	O
month	O
ago	O
after	O
admission	O
for	O
hip	O
replacement	O
.	O
PHYSICAL	O
EXAMINATION	O
Vital	O
signs	O
on	O
arrival	O
at	O
the	O
emergency	O
department	O
blood	O
pressure	O
BP	O
98	O
56	O
mmHg	O
;	O
SatO2	O
92	O
with	O
oxygen	O
therapy	O
by	O
VentiMask	O
at	O
35	O
.	O
Temperature	O
36	O
.	O
2	O
C	O
.	O
Weight	O
68	O
kg	O
.	O
Height	O
162	O
cm	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Well	O
hydrated	O
and	O
perfused	O
.	O
Tachypneic	O
on	O
speech	O
.	O
Cannot	O
tolerate	O
decubitus	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
rhythms	O
,	O
prosthetic	O
metallic	O
click	O
with	O
systolic	O
murmur	O
III	O
VI	O
,	O
and	O
systolic	O
murmur	O
in	O
mitral	O
focus	O
II	O
III	O
VI	O
.	O
Pulmonary	O
auscultation	O
coarse	O
crackles	O
up	O
to	O
midfields	O
.	O
Abdomen	O
soft	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
palpation	O
of	O
masses	O
or	O
megaliths	O
,	O
peristalsis	O
preserved	O
.	O
Normal	O
percussion	O
.	O
Lower	O
extremities	O
oedema	O
with	O
fovea	O
up	O
to	O
the	O
knees	O
.	O
No	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
biochemistry	O
glucose	O
246	O
mg	O
dl	O
.	O
Urea	O
38	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
93	O
mg	O
dl	O
GFR	O
59	O
ml	O
min	O
.	O
CRP	O
0	O
.	O
96	O
.	O
Troponin	O
T	O
ultrasensitive	O
256	O
ng	O
dl	O
.	O
Haemogram	O
14	O
,	O
500	O
leucocytes	O
7	O
,	O
900	O
N	O
,	O
5	O
,	O
400	O
L	O
,	O
900	O
M	O
,	O
200	O
E	O
.	O
Hb	O
10	O
.	O
8	O
mh	O
dl	O
and	O
MCV	O
88	O
.	O
2	O
.	O
Platelets	O
553	O
,	O
000	O
.	O
Coagulation	O
INR	O
1	O
.	O
70	O
.	O
Prothrombin	O
rate	O
39	O
.	O
8	O
.	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
.	O
Left	O
bundle	O
branch	O
block	O
LBBB	O
already	O
present	O
in	O
previous	O
ECGs	O
.	O
No	O
other	O
alterations	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
.	O
Bilateral	O
pleural	O
effusion	O
.	O
Pulmonary	O
vasculation	O
in	O
relation	O
to	O
pulmonary	O
oedema	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
left	O
ventricle	O
with	O
concentric	O
hypertrophy	O
septum	O
12	O
mm	O
,	O
abnormal	O
septal	O
motion	O
with	O
septal	O
akinesia	O
and	O
moderately	O
affected	O
global	O
systolic	O
function	O
.	O
LA	O
of	O
17	O
.	O
3	O
cm2	O
.	O
Valve	O
prosthesis	O
in	O
aortic	O
position	O
poorly	O
visualised	O
,	O
with	O
severe	O
regurgitation	O
THP	O
160ms	O
and	O
obtaining	O
a	O
max	O
gradient	O
of	O
94	O
mmHg	O
mean	O
59	O
mmHg	O
.	O
Fibrocalcified	O
mitral	O
valve	O
mostly	O
posteriorly	O
with	O
at	O
least	O
moderate	O
regurgitation	O
grade	O
III	O
,	O
reaching	O
the	O
atrial	O
roof	O
.	O
Normal	O
sized	O
right	O
chambers	O
with	O
TAPSE	O
of	O
12	O
mm	O
and	O
moderate	O
TR	O
with	O
a	O
calculated	O
PsAP	O
of	O
32	O
mmHg	O
PVC	O
.	O
No	O
pericardial	O
effusion	O
.	O
IVC	O
of	O
18	O
mm	O
with	O
inspiratory	O
collapse	O
50	O
.	O
Transesophageal	O
echocardiogram	O
metallic	O
prosthesis	O
in	O
aortic	O
position	O
with	O
very	O
reduced	O
disc	O
mobility	O
,	O
low	O
echogenic	O
density	O
material	O
is	O
observed	O
at	O
disc	O
level	O
.	O
Severe	O
stenosis	O
with	O
velocities	O
greater	O
than	O
5	O
ms	O
s	O
and	O
severe	O
insufficiency	O
.	O
Moderate	O
mitral	O
insufficiency	O
.	O
Left	O
ventricle	O
LV	O
not	O
dilated	O
,	O
mild	O
hypertrophy	O
,	O
moderately	O
impaired	O
systolic	O
function	O
.	O
Non	O
dilated	O
right	O
ventricle	O
RV	O
with	O
normal	O
function	O
.	O
CLINICAL	O
COURSE	O
The	O
patient	O
is	O
a	O
76	O
year	O
old	O
woman	O
admitted	O
with	O
acute	O
pulmonary	O
oedema	O
.	O
Emergent	O
TTE	O
was	O
performed	O
and	O
showed	O
a	O
moderately	O
affected	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
with	O
severe	O
aortic	O
stenosis	O
and	O
insufficiency	O
secondary	O
to	O
dysfunction	O
of	O
the	O
mechanical	O
aortic	O
valve	O
prosthesis	O
.	O
Given	O
his	O
history	O
of	O
previous	O
surgery	O
with	O
under	O
therapeutic	O
doses	O
of	O
anticoagulation	O
,	O
acute	O
subacute	O
prosthetic	O
thrombosis	O
was	O
suspected	O
on	O
admission	O
as	O
the	O
main	O
aetiology	O
.	O
For	O
this	O
reason	O
,	O
a	O
TEE	O
study	O
was	O
completed	O
which	O
led	O
to	O
this	O
diagnosis	O
.	O
Medical	O
treatment	O
was	O
started	O
with	O
intravenous	O
diuretics	O
.	O
The	O
patient	O
evolved	O
unfavourably	O
and	O
was	O
haemodynamically	O
unstable	O
,	O
requiring	O
vasoactive	O
support	O
,	O
so	O
given	O
the	O
situation	O
of	O
cardiogenic	O
shock	O
,	O
emergency	O
aortic	O
valve	O
replacement	O
surgery	O
was	O
decided	O
.	O
Emergent	O
surgery	O
was	O
performed	O
,	O
in	O
which	O
a	O
St	O
Jude	O
aortic	O
prosthesis	O
no	O
19	O
blocked	O
by	O
the	O
presence	O
of	O
two	O
small	O
clots	O
of	O
less	O
than	O
5	O
mm	O
in	O
both	O
hinges	O
was	O
visualised	O
.	O
The	O
prosthesis	O
was	O
explanted	O
and	O
the	O
annulus	O
was	O
enlarged	O
with	O
a	O
pericardial	O
patch	O
in	O
the	O
non	O
coronary	O
leaflet	O
towards	O
the	O
mitral	O
annulus	O
in	O
order	O
to	O
implant	O
the	O
Magna	O
Ease	O
No	O
19	O
biological	O
prosthesis	O
.	O
He	O
presented	O
with	O
an	O
episode	O
of	O
ventricular	O
fibrillation	O
that	O
reverted	O
after	O
defibrillation	O
,	O
so	O
it	O
was	O
decided	O
to	O
re	O
enter	O
CPB	O
and	O
implant	O
intra	O
aortic	O
balloon	O
counterpulsation	O
IABP	O
via	O
the	O
right	O
femoral	O
artery	O
with	O
insufficient	O
haemodynamic	O
response	O
and	O
severe	O
left	O
ventricular	O
dysfunction	O
;	O
finally	O
it	O
was	O
decided	O
to	O
implant	O
a	O
peripheral	O
femoro	O
femoral	O
venoarterial	O
extracorporeal	O
membrane	O
oxygenator	O
ECMO	O
.	O
Poor	O
evolution	O
during	O
the	O
days	O
following	O
surgery	O
,	O
in	O
a	O
situation	O
of	O
cardiogenic	O
shock	O
refractory	O
to	O
maximum	O
support	O
measures	O
,	O
evolving	O
towards	O
multi	O
organ	O
failure	O
,	O
finally	O
dying	O
.	O
DIAGNOSIS	O
Heart	O
failure	O
in	O
a	O
situation	O
of	O
acute	O
pulmonary	O
oedema	O
.	O
Acute	O
thrombosis	O
of	O
mechanical	O
aortic	O
prosthesis	O
with	O
stenosis	O
and	O
severe	O
insufficiency	O
secondary	O
to	O
anticoagulation	O
underdosage	O
after	O
hip	O
surgery	O
.	O
Aortic	O
valve	O
replacement	O
with	O
implantation	O
of	O
a	O
biological	O
prosthesis	O
.	O
Refractory	O
cardiogenic	O
shock	O
.	O
ECMO	O
implantation	O
.	O
Multi	O
organ	O
failure	O
.	O
Death	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
54	O
year	O
old	O
woman	O
from	O
Paraguay	O
.	O
She	O
had	O
a	O
history	O
of	O
arterial	O
hypertension	O
treated	O
with	O
diuretics	O
and	O
a	O
probable	O
episode	O
of	O
pulmonary	O
embolism	O
for	O
which	O
she	O
had	O
received	O
anticoagulant	O
treatment	O
in	O
2013	O
,	O
which	O
the	O
patient	O
described	O
imprecisely	O
.	O
She	O
remained	O
asymptomatic	O
after	O
this	O
episode	O
.	O
However	O
,	O
4	O
months	O
prior	O
to	O
the	O
current	O
admission	O
,	O
she	O
began	O
to	O
present	O
symptoms	O
of	O
progressive	O
dyspnoea	O
until	O
she	O
became	O
resting	O
,	O
oedema	O
in	O
the	O
lower	O
limbs	O
and	O
a	O
weight	O
loss	O
of	O
10	O
kg	O
,	O
for	O
which	O
reason	O
she	O
consulted	O
a	O
cardiologist	O
in	O
Paraguay	O
.	O
A	O
transthoracic	O
echocardiogram	O
showed	O
moderate	O
pulmonary	O
hypertension	O
PSAP	O
55	O
mmHg	O
,	O
severe	O
tricuspid	O
insufficiency	O
TI	O
and	O
a	O
dilated	O
right	O
ventricle	O
with	O
normal	O
function	O
TAPSE	O
24	O
mm	O
.	O
For	O
this	O
reason	O
,	O
he	O
was	O
prescribed	O
treatment	O
with	O
spironolactone	B-FARMACO
25	O
mg	O
,	O
furosemide	B-FARMACO
40	O
mg	O
and	O
carvedilol	B-FARMACO
12	O
.	O
5	O
mg	O
every	O
12	O
hours	O
.	O
At	O
that	O
time	O
,	O
thyroid	O
hormone	O
tests	O
were	O
not	O
performed	O
,	O
although	O
they	O
were	O
recommended	O
,	O
because	O
her	O
health	O
insurance	O
did	O
not	O
cover	O
such	O
tests	O
.	O
A	O
few	O
months	O
later	O
she	O
travelled	O
to	O
Spain	O
on	O
holiday	O
,	O
presenting	O
with	O
diarrhoea	O
for	O
3	O
days	O
and	O
colicky	O
abdominal	O
pain	O
,	O
for	O
which	O
reason	O
she	O
went	O
to	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
.	O
On	O
arrival	O
,	O
he	O
presented	O
evident	O
signs	O
of	O
heart	O
failure	O
,	O
predominantly	O
right	O
sided	O
,	O
with	O
oedema	O
in	O
the	O
legs	O
,	O
jugular	O
ingurgitation	O
and	O
dyspnoea	O
at	O
rest	O
with	O
paradoxical	O
breathing	O
and	O
supraclavicular	O
tugging	O
,	O
for	O
which	O
the	O
coronary	O
unit	O
was	O
notified	O
.	O
On	O
admission	O
to	O
the	O
coronary	O
unit	O
he	O
had	O
a	O
blood	O
pressure	O
of	O
137	O
47	O
mmHg	O
and	O
heart	O
rate	O
of	O
42	O
bpm	O
in	O
the	O
absence	O
of	O
beta	O
blockers	O
,	O
temperature	O
of	O
36	O
C	O
and	O
oxygen	O
saturation	O
of	O
96	O
.	O
Physical	O
examination	O
revealed	O
marked	O
jugular	O
engorgement	O
,	O
a	O
jugular	O
venous	O
pulse	O
with	O
oscillating	O
stop	O
at	O
5	O
cm	O
from	O
the	O
angle	O
of	O
Louis	O
and	O
Kussmaull	O
's	O
sign	O
.	O
In	O
addition	O
,	O
a	O
large	O
goitre	O
with	O
palpable	O
thrill	O
and	O
a	O
continuous	O
thyroid	O
murmur	O
,	O
not	O
irradiated	O
and	O
accompanied	O
by	O
bilateral	O
exophthalmos	O
,	O
was	O
documented	O
.	O
Cardiopulmonary	O
examination	O
revealed	O
palpation	O
of	O
the	O
right	O
ventricle	O
in	O
the	O
right	O
parasternal	O
region	O
,	O
as	O
well	O
as	O
a	O
tricuspid	O
regurgitation	O
murmur	O
.	O
On	O
pulmonary	O
auscultation	O
,	O
the	O
vesicular	O
murmur	O
was	O
abolished	O
in	O
both	O
lung	O
bases	O
.	O
The	O
patient	O
also	O
showed	O
hepatomegaly	O
3	O
cm	O
below	O
the	O
costal	O
margin	O
and	O
oedema	O
with	O
fovea	O
up	O
to	O
the	O
root	O
of	O
the	O
lower	O
limbs	O
.	O
After	O
diuretic	O
treatment	O
the	O
signs	O
of	O
congestion	O
improved	O
and	O
bilateral	O
pretibial	O
oedema	O
without	O
fovea	O
compatible	O
with	O
myxoedema	O
could	O
be	O
observed	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
showed	O
a	O
nodal	O
rhythm	O
at	O
42	O
bpm	O
,	O
with	O
low	O
voltages	O
in	O
the	O
limb	O
leads	O
and	O
diffusely	O
flattened	O
T	O
's	O
in	O
all	O
leads	O
.	O
Chest	O
X	O
ray	O
showed	O
right	O
pleural	O
effusion	O
,	O
with	O
deflected	O
hilarity	O
and	O
enlarged	O
cardiac	O
silhouette	O
.	O
At	O
this	O
time	O
,	O
an	O
emergency	O
portable	O
transthoracic	O
echocardiogram	O
was	O
performed	O
showing	O
severe	O
right	O
ventricular	O
dilatation	O
and	O
dysfunction	O
and	O
severe	O
PH	O
estimated	O
PSAP	O
of	O
60	O
mmHg	O
,	O
together	O
with	O
severe	O
tricuspid	O
regurgitation	O
and	O
evidence	O
of	O
peripheral	O
congestion	O
.	O
The	O
patient	O
was	O
admitted	O
under	O
initial	O
suspicion	O
of	O
chronic	O
pulmonary	O
embolism	O
as	O
the	O
origin	O
of	O
the	O
condition	O
.	O
Anticoagulant	O
and	O
intravenous	O
diuretic	O
treatment	O
was	O
started	O
,	O
which	O
resulted	O
in	O
large	O
negative	O
balances	O
and	O
clinical	O
improvement	O
.	O
Analyses	O
showed	O
anaemia	O
Hb	O
8	O
.	O
8	O
g	O
dl	O
,	O
thrombopenia	O
93	O
,	O
000	O
platelets	O
mcl	O
,	O
cholestasis	O
without	O
hepatic	O
cytolysis	O
GGT	O
95	O
IU	O
;	O
alkaline	O
phosphatase	O
223	O
IU	O
,	O
total	O
bilirubin	O
1	O
.	O
9	O
mg	O
dl	O
,	O
normal	O
GOT	O
and	O
GPT	O
and	O
spontaneous	O
INR	O
of	O
1	O
.	O
7	O
,	O
all	O
compatible	O
with	O
a	O
stasis	O
liver	O
.	O
Impaired	O
renal	O
function	O
Cr	O
1	O
.	O
7	O
mg	O
dl	O
,	O
hyponatraemia	O
Na	O
127	O
and	O
hyperkalaemia	O
K	O
6	O
.	O
4	O
,	O
markedly	O
elevated	O
NT	O
proBNP	O
values	O
11	O
,	O
617	O
pg	O
ml	O
were	O
also	O
documented	O
.	O
D	O
dimer	O
levels	O
were	O
also	O
elevated	O
2	O
,	O
400	O
ng	O
ml	O
.	O
Antibody	O
tests	O
ANA	O
,	O
rheumatoid	O
factor	O
,	O
anti	O
glomerular	O
basement	O
membrane	O
,	O
c	O
ANCA	O
and	O
p	O
ANCA	O
,	O
anti	O
beta2	O
glycoprotein	O
,	O
anticardiolipin	O
and	O
serology	O
HIV	O
,	O
HCV	O
,	O
HBV	O
,	O
syphilis	O
were	O
also	O
negative	O
.	O
Ultrasound	O
scans	O
of	O
the	O
lower	O
limbs	O
and	O
abdomen	O
ruled	O
out	O
the	O
presence	O
of	O
deep	O
vein	O
thrombosis	O
and	O
revealed	O
ascites	O
and	O
liver	O
stasis	O
,	O
respectively	O
.	O
Given	O
the	O
apparent	O
chronic	O
nature	O
of	O
the	O
condition	O
,	O
and	O
the	O
deterioration	O
of	O
renal	O
function	O
,	O
a	O
ventilation	O
perfusion	O
scan	O
was	O
requested	O
instead	O
of	O
CT	O
angiography	O
of	O
the	O
pulmonary	O
arteries	O
,	O
with	O
the	O
aim	O
of	O
establishing	O
the	O
diagnosis	O
of	O
chronic	O
pulmonary	O
embolism	O
.	O
The	O
result	O
of	O
the	O
test	O
was	O
inconclusive	O
,	O
so	O
pending	O
a	O
definitive	O
diagnosis	O
,	O
anticoagulant	O
treatment	O
was	O
maintained	O
.	O
Computed	O
tomography	O
was	O
not	O
performed	O
as	O
a	O
first	O
choice	O
due	O
to	O
the	O
deterioration	O
of	O
renal	O
function	O
.	O
Once	O
anticoagulant	O
and	O
diuretic	O
therapy	O
had	O
been	O
started	O
,	O
we	O
obtained	O
the	O
following	O
thyroid	O
hormone	O
results	O
undetectable	O
TSH	O
,	O
T3L	O
15	O
.	O
79	O
mlU	O
l	O
and	O
T4L	O
59	O
.	O
20	O
mlU	O
l	O
.	O
Given	O
these	O
results	O
,	O
the	O
patient	O
was	O
referred	O
to	O
the	O
endocrinology	O
department	O
,	O
who	O
considered	O
the	O
condition	O
to	O
be	O
primary	O
autoimmune	O
hyperthyroidism	O
Graves	O
Basedow	O
disease	O
with	O
secondary	O
hypoaldosteronism	O
and	O
cytopenias	O
,	O
as	O
the	O
first	O
diagnostic	O
possibility	O
.	O
Treatment	O
was	O
started	O
with	O
antithyroid	O
drugs	O
thiamazole	B-FARMACO
,	O
beta	O
blockers	O
propranolol	B-FARMACO
and	O
corticosteroids	O
dexamethasone	B-FARMACO
.	O
The	O
results	O
of	O
antithyroid	O
antibodies	O
were	O
positive	O
.	O
During	O
admission	O
,	O
the	O
patient	O
presented	O
,	O
after	O
the	O
first	O
72	O
hours	O
,	O
with	O
a	O
fever	O
of	O
38	O
C	O
related	O
to	O
bacteraemia	O
due	O
to	O
methicillin	O
sensitive	O
Staphylococcus	O
aureus	O
,	O
which	O
was	O
treated	O
with	O
a	O
10	O
day	O
course	O
of	O
antibiotherapy	O
with	O
cloxacillin	B-FARMACO
.	O
After	O
completing	O
the	O
course	O
,	O
he	O
again	O
developed	O
fever	O
and	O
retrocardiac	O
pulmonary	O
infiltrate	O
with	O
sputum	O
positive	O
for	O
Rothia	O
mucilaginosa	O
.	O
He	O
was	O
treated	O
with	O
levofloxacin	B-FARMACO
,	O
ceftriaxone	B-FARMACO
and	O
azithromycin	B-FARMACO
with	O
good	O
response	O
and	O
satisfactory	O
resolution	O
of	O
the	O
infectious	O
picture	O
.	O
Once	O
renal	O
function	O
improved	O
,	O
a	O
chest	O
CT	O
scan	O
was	O
performed	O
which	O
definitively	O
ruled	O
out	O
the	O
presence	O
of	O
lung	O
embolism	O
,	O
highlighting	O
the	O
dilatation	O
of	O
the	O
right	O
heart	O
cavities	O
and	O
the	O
presence	O
of	O
significant	O
right	O
pleural	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
one	O
month	O
of	O
antithyroid	O
treatment	O
,	O
a	O
repeat	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
which	O
showed	O
complete	O
normalisation	O
of	O
both	O
the	O
function	O
and	O
size	O
of	O
the	O
right	O
ventricle	O
.	O
Normalisation	O
of	O
pulmonary	O
pressure	O
and	O
the	O
presence	O
of	O
minimal	O
tricuspid	O
regurgitation	O
were	O
also	O
documented	O
.	O
The	O
patient	O
was	O
finally	O
discharged	O
once	O
the	O
alterations	O
at	O
the	O
right	O
ventricular	O
level	O
and	O
in	O
the	O
pulmonary	O
circulation	O
had	O
resolved	O
with	O
correction	O
of	O
the	O
significant	O
thyroid	O
disorder	O
.	O
Our	O
patient	O
presented	O
a	O
complete	O
resolution	O
of	O
cardiopulmonary	O
symptoms	O
after	O
normalisation	O
of	O
thyroid	O
hormone	O
levels	O
.	O
DIAGNOSIS	O
Right	O
predominant	O
heart	O
failure	O
.	O
Severe	O
right	O
ventricular	O
dysfunction	O
and	O
severe	O
tricuspid	O
regurgitation	O
in	O
the	O
context	O
of	O
pulmonary	O
hypertension	O
.	O
Severe	O
pulmonary	O
hypertension	O
secondary	O
to	O
primary	O
autoimmune	O
hyperthyroidism	O
Graves	O
Basedow	O
disease	O
.	O
Primary	O
autoimmune	O
hyperthyroidism	O
Graves	O
Basedow	O
disease	O
.	O
Acute	O
renal	O
failure	O
.	O

PERSONAL	O
HISTORY	O
Urological	O
examination	O
for	O
elevated	O
PSA	O
,	O
transrectal	O
biopsy	O
with	O
result	O
of	O
low	O
grade	O
prostate	O
adenocarcinoma	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
type	O
2	O
diabetes	O
mellitus	O
DM	O
on	O
treatment	O
with	O
oral	O
antidiabetics	O
HbA1c	O
7	O
.	O
3	O
.	O
Hypercholesterolemia	O
.	O
Ex	O
smoker	O
for	O
4	O
months	O
IPA	O
30	O
paq	O
year	O
.	O
Cardiovascular	O
history	O
November	O
2017	O
evolved	O
anterior	O
infarction	O
KK	O
IV	O
,	O
performing	O
emergent	O
coronary	O
angiography	O
,	O
and	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
PTCA	O
to	O
proximal	O
anterior	O
descending	O
artery	O
LAD	O
with	O
implantation	O
of	O
drug	O
eluting	O
stent	O
,	O
with	O
no	O
other	O
angiographically	O
significant	O
lesions	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
in	O
cardiogenic	O
shock	O
,	O
requiring	O
occasional	O
doses	O
of	O
IV	O
noradrenaline	B-FARMACO
.	O
Treatment	O
with	O
angiotensin	B-FARMACO
converting	I-FARMACO
enzyme	I-FARMACO
inhibitors	I-FARMACO
ACE	I-FARMACO
inhibitors	I-FARMACO
and	O
beta	O
blockers	O
was	O
not	O
started	O
due	O
to	O
a	O
tendency	O
to	O
hypotension	O
,	O
and	O
ivabradine	B-FARMACO
was	O
started	O
due	O
to	O
a	O
tendency	O
to	O
tachycardia	O
.	O
On	O
discharge	O
echocardiogram	O
,	O
the	O
presence	O
of	O
an	O
apical	O
aneurysm	O
with	O
apical	O
thrombus	O
was	O
documented	O
.	O
As	O
well	O
as	O
apical	O
akinesia	O
,	O
anterior	O
septal	O
and	O
middle	O
segments	O
of	O
the	O
inferior	O
,	O
anterior	O
and	O
posteroseptal	O
walls	O
.	O
LVEF	O
27	O
.	O
Mild	O
moderate	O
mitral	O
insufficiency	O
.	O
Usual	O
treatment	O
adiro	B-FARMACO
100	O
mg	O
c	O
24	O
hours	O
,	O
clopidogrel	B-FARMACO
75	O
mg	O
c	O
24	O
hours	O
,	O
pantoprazole	B-FARMACO
40	O
mg	O
c	O
24	O
hours	O
,	O
ivabradine	B-FARMACO
5	O
mg	O
c	O
12	O
hours	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
c	O
24	O
hours	O
,	O
metformin	B-FARMACO
850	O
mg	O
c	O
12	O
hours	O
,	O
sintrom	B-FARMACO
according	O
to	O
guideline	O
.	O
CURRENT	O
ILLNESS	O
The	O
patient	O
presented	O
2	O
months	O
after	O
his	O
infarction	O
with	O
clinical	O
symptoms	O
consisting	O
of	O
anorexia	O
,	O
asthenia	O
and	O
continuous	O
pain	O
in	O
the	O
right	O
hypochondrium	O
unrelated	O
to	O
ingestion	O
,	O
referred	O
to	O
as	O
a	O
feeling	O
of	O
fullness	O
.	O
The	O
patient	O
reports	O
nausea	O
,	O
vomiting	O
,	O
choluria	O
and	O
acholia	O
,	O
with	O
no	O
clear	O
dysthermic	O
sensation	O
;	O
he	O
also	O
denies	O
intestinal	O
transit	O
disorders	O
.	O
He	O
has	O
two	O
dogs	O
,	O
vaccinated	O
and	O
dewormed	O
.	O
She	O
has	O
not	O
made	O
any	O
recent	O
trips	O
to	O
foreign	O
countries	O
or	O
outings	O
to	O
the	O
countryside	O
,	O
she	O
denies	O
the	O
consumption	O
of	O
toxic	O
substances	O
,	O
herbal	O
products	O
and	O
alcohol	O
.	O
No	O
recent	O
changes	O
in	O
treatment	O
.	O
He	O
has	O
no	O
relatives	O
or	O
people	O
in	O
his	O
environment	O
with	O
similar	O
symptoms	O
.	O
From	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
the	O
patient	O
has	O
evolved	O
favourably	O
,	O
being	O
asymptomatic	O
since	O
discharge	O
he	O
walks	O
6	O
km	O
day	O
without	O
dyspnoea	O
or	O
angina	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
107	O
62	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
92	O
bpm	O
.	O
Temperature	O
37	O
.	O
2	O
C	O
.	O
Height	O
170	O
cm	O
.	O
Weight	O
63	O
kg	O
.	O
Waist	O
circumference	O
86	O
cm	O
.	O
Body	O
mass	O
index	O
BMI	O
22	O
kg	O
m2	O
.	O
Patient	O
in	O
good	O
general	O
condition	O
.	O
Well	O
hydrated	O
,	O
nourished	O
and	O
perfused	O
.	O
Eupneic	O
at	O
rest	O
.	O
Head	O
and	O
neck	O
jaundiced	O
conjunctiva	O
.	O
Jugular	O
venous	O
pulse	O
PVY	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
extra	O
sounds	O
.	O
Abdominal	O
auscultation	O
hydro	O
aerial	O
sounds	O
present	O
,	O
normal	O
tone	O
,	O
abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
to	O
superficial	O
or	O
deep	O
abdominal	O
palpation	O
,	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
PPR	O
negative	O
bilaterally	O
.	O
Lower	O
extremities	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
No	O
oedema	O
.	O
Preserved	O
paedial	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
on	O
admission	O
Hb	O
12	O
.	O
4	O
g	O
dl	O
.	O
Ht	O
36	O
.	O
5	O
.	O
MCV	O
85	O
fl	O
.	O
Leukocytes	O
14	O
,	O
200	O
mm3	O
N	O
70	O
.	O
2	O
,	O
L	O
7	O
.	O
25	O
,	O
Eo	O
22	O
.	O
53	O
.	O
Platelets	O
409	O
.	O
000	O
mm3	O
.	O
CRP	O
12	O
.	O
8	O
mg	O
dl	O
.	O
INR	O
25	O
.	O
Glucose	O
224	O
mg	O
dl	O
.	O
Urea	O
52	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
95	O
mg	O
dl	O
.	O
GFR	O
86	O
.	O
6	O
ml	O
min	O
.	O
Sodium	O
136	O
mEq	O
l	O
.	O
Potassium	O
4	O
.	O
6	O
mEq	O
l	O
.	O
LDH	O
627	O
U	O
l	O
.	O
CK	O
76	O
.	O
ALT	O
202	O
u	O
l	O
.	O
AST	O
167	O
u	O
l	O
.	O
GGT	O
897	O
u	O
l	O
.	O
FA	O
546	O
u	O
l	O
.	O
BT	O
3	O
.	O
5	O
mg	O
dl	O
BD	O
2	O
.	O
11	O
mg	O
dl	O
.	O
Lipase	O
32	O
u	O
l	O
.	O
Calcium	O
10	O
.	O
1	O
mg	O
dl	O
.	O
Magnesium	O
1	O
,	O
6	O
mg	O
dl	O
.	O
Total	O
cholesterol	O
261	O
mg	O
dl	O
,	O
triglycerides	O
130	O
mg	O
dl	O
,	O
HDL	O
60	O
mg	O
dl	O
,	O
LDL	O
174	O
mg	O
dl	O
.	O
Lp	O
a	O
160	O
mg	O
dl	O
,	O
Apo	O
A	O
157	O
mg	O
dl	O
,	O
Apo	O
B	O
136	O
mg	O
dl	O
.	O
TSH	O
1	O
.	O
13	O
μU	O
ml	O
,	O
T4	O
11	O
.	O
7	O
mcg	O
dl	O
.	O
Glycosylated	O
haemoglobin	O
7	O
.	O
4	O
.	O
Ferritin	O
487	O
mg	O
dl	O
.	O
Iron	O
93	O
mg	O
dl	O
.	O
IST	O
17	O
.	O
GV	O
on	O
admission	O
pH	O
7	O
.	O
40	O
,	O
pCO2	O
37	O
mmHg	O
,	O
pO2	O
57	O
mmHg	O
,	O
HCO3	O
23	O
mEq	O
l	O
,	O
lactate	O
1	O
.	O
2	O
mmol	O
l	O
.	O
Electrocardiogram	O
ECG	O
RS	O
at	O
70	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
QS	O
on	O
anterolateral	O
side	O
with	O
no	O
progression	O
of	O
R	O
in	O
precordial	O
leads	O
,	O
persistent	O
ST	O
segment	O
elevation	O
in	O
anterolateral	O
side	O
.	O
Cardiac	O
MRI	O
acute	O
myocardial	O
infarction	O
AMI	O
in	O
the	O
left	O
anterior	O
descending	O
LAD	O
territory	O
with	O
mildly	O
dilated	O
left	O
ventricle	O
LV	O
,	O
apical	O
aneurysm	O
and	O
akinesia	O
of	O
the	O
anterior	O
face	O
and	O
mid	O
and	O
distal	O
anterior	O
septum	O
and	O
all	O
distal	O
segments	O
.	O
Severe	O
LV	O
systolic	O
dysfunction	O
LVEF	O
25	O
.	O
Late	O
enhancement	O
of	O
ischaemic	O
features	O
with	O
absence	O
of	O
viability	O
in	O
anterior	O
face	O
and	O
mid	O
and	O
distal	O
septum	O
and	O
in	O
all	O
distal	O
segments	O
except	O
lateral	O
face	O
.	O
No	O
intraventricular	O
thrombi	O
are	O
seen	O
.	O
Mild	O
right	O
ventricular	O
RV	O
systolic	O
dysfunction	O
RVEF	O
45	O
.	O
Abdominal	O
ultrasound	O
discrete	O
hepatomegaly	O
without	O
identifying	O
a	O
clear	O
focal	O
lesion	O
.	O
Portal	O
vein	O
permeable	O
.	O
The	O
gallbladder	O
has	O
no	O
clear	O
content	O
inside	O
.	O
No	O
dilatation	O
of	O
the	O
biliary	O
tract	O
.	O
The	O
visible	O
part	O
of	O
the	O
pancreas	O
shows	O
no	O
alterations	O
.	O
There	O
are	O
several	O
lymphadenopathies	O
in	O
the	O
hepatic	O
hilum	O
and	O
the	O
celiac	O
region	O
,	O
the	O
largest	O
of	O
pathological	O
size	O
10	O
mm	O
11	O
mm	O
short	O
axis	O
.	O
The	O
trunk	O
of	O
the	O
portal	O
vein	O
is	O
permeable	O
,	O
of	O
normal	O
calibre	O
with	O
hepatopetal	O
flow	O
.	O
Splenic	O
and	O
superior	O
mesenteric	O
veins	O
also	O
patent	O
,	O
not	O
dilated	O
.	O
Suprahepatic	O
veins	O
patent	O
,	O
of	O
normal	O
calibre	O
.	O
Inferior	O
vena	O
cava	O
also	O
of	O
normal	O
calibre	O
.	O
Homogeneous	O
spleen	O
of	O
normal	O
size	O
.	O
Kidneys	O
without	O
pyelocaliceal	O
dilatation	O
or	O
clear	O
lithiasis	O
.	O
Distended	O
bladder	O
without	O
clear	O
alterations	O
.	O
Prostatic	O
calcifications	O
.	O
Volume	O
21	O
cc	O
.	O
No	O
free	O
fluid	O
.	O
Cholangio	O
MRI	O
the	O
signal	O
and	O
morphology	O
of	O
the	O
liver	O
are	O
normal	O
.	O
No	O
focal	O
lesions	O
.	O
The	O
bile	O
duct	O
has	O
normal	O
calibre	O
,	O
both	O
intrahepatic	O
and	O
extrahepatic	O
.	O
No	O
content	O
is	O
identified	O
inside	O
the	O
common	O
bile	O
duct	O
.	O
Morphologically	O
there	O
are	O
no	O
notable	O
alterations	O
affecting	O
the	O
pancreas	O
,	O
adrenal	O
glands	O
,	O
kidneys	O
or	O
spleen	O
.	O
Minimal	O
pleural	O
effusion	O
on	O
both	O
sides	O
.	O
Serology	O
HAV	O
and	O
HCV	O
negative	O
.	O
Anti	O
HBs	O
30	O
mIU	O
ml	O
,	O
negative	O
anti	O
HBc	O
compatible	O
with	O
vaccination	O
against	O
HBV	O
,	O
positive	O
IgG	O
against	O
VZV	O
and	O
CMV	O
,	O
negative	O
IgG	O
against	O
EBV	O
.	O
Immunology	O
anti	O
parietal	O
cell	O
antibodies	O
,	O
anti	O
LC1	O
,	O
antiLKM	O
,	O
anti	O
mitochondrial	O
,	O
anti	O
smooth	O
muscle	O
,	O
anti	O
reticulin	O
,	O
cANCA	O
,	O
anti	O
glomerular	O
basement	O
membrane	O
,	O
pANCA	O
negative	O
.	O
Stool	O
parasites	O
negative	O
.	O
CLINICAL	O
COURSE	O
A	O
61	O
year	O
old	O
man	O
with	O
dilated	O
cardiomyopathy	O
of	O
ischaemic	O
aetiology	O
consulted	O
the	O
emergency	O
department	O
for	O
asthenia	O
,	O
anorexia	O
,	O
jaundice	O
,	O
choluria	O
and	O
acholia	O
of	O
one	O
week	O
's	O
evolution	O
,	O
associated	O
with	O
thermometric	O
fever	O
of	O
up	O
to	O
37	O
.	O
9	O
C	O
.	O
Analysis	O
on	O
arrival	O
revealed	O
elevated	O
transaminases	O
and	O
a	O
marked	O
increase	O
in	O
the	O
cholestasis	O
profile	O
with	O
hyperbilirubinaemia	O
at	O
the	O
expense	O
of	O
direct	O
bilirubin	O
,	O
as	O
well	O
as	O
leukocytosis	O
and	O
eosinophilia	O
together	O
with	O
elevated	O
acute	O
phase	O
reactants	O
and	O
coagulopathy	O
,	O
with	O
an	O
INR	O
of	O
25	O
,	O
requiring	O
the	O
administration	O
of	O
1	O
ampoule	O
of	O
vitamin	O
K	O
for	O
correction	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
internal	O
medicine	O
department	O
to	O
complete	O
the	O
aetiological	O
study	O
of	O
the	O
condition	O
,	O
and	O
all	O
medication	O
was	O
withdrawn	O
except	O
for	O
aspirin	B-FARMACO
and	O
clopidogrel	B-FARMACO
,	O
replacing	O
acenocoumarol	B-FARMACO
treatment	O
with	O
enoxaparin	B-FARMACO
.	O
To	O
this	O
end	O
,	O
serology	O
for	O
hepatotropic	O
viruses	O
,	O
determination	O
of	O
parasites	O
in	O
faeces	O
and	O
immunology	O
tests	O
were	O
carried	O
out	O
,	O
all	O
of	O
which	O
were	O
negative	O
.	O
Imaging	O
studies	O
were	O
also	O
carried	O
out	O
by	O
abdominal	O
ultrasound	O
and	O
cholangio	O
MRI	O
,	O
which	O
only	O
revealed	O
the	O
presence	O
of	O
lymphadenopathies	O
in	O
the	O
hepatic	O
hilar	O
and	O
celiac	O
region	O
,	O
without	O
content	O
or	O
dilatation	O
at	O
the	O
level	O
of	O
the	O
biliary	O
tree	O
.	O
Having	O
ruled	O
out	O
an	O
infectious	O
,	O
autoimmune	O
or	O
obstructive	O
aetiology	O
,	O
a	O
systematic	O
review	O
of	O
the	O
literature	O
was	O
carried	O
out	O
and	O
cases	O
of	O
idiosyncratic	O
hepatitis	O
secondary	O
to	O
the	O
administration	O
of	O
statins	O
were	O
found	O
.	O
The	O
allergology	O
and	O
gastroenterology	O
departments	O
were	O
consulted	O
and	O
confirmed	O
the	O
diagnosis	O
of	O
suspected	O
idiosyncratic	O
hepatitis	O
,	O
recommending	O
definitive	O
discontinuation	O
of	O
statin	O
treatment	O
and	O
reintroduction	O
of	O
the	O
rest	O
of	O
the	O
treatment	O
that	O
had	O
been	O
withdrawn	O
on	O
admission	O
.	O
With	O
regard	O
to	O
the	O
subsequent	O
evolution	O
,	O
the	O
patient	O
presented	O
a	O
resolution	O
of	O
the	O
cytolysis	O
profile	O
and	O
normalisation	O
of	O
eosinophilia	O
within	O
8	O
days	O
of	O
withdrawal	O
of	O
atorvastatin	B-FARMACO
;	O
he	O
persisted	O
with	O
a	O
discrete	O
elevation	O
of	O
the	O
cholestasis	O
pattern	O
at	O
discharge	O
.	O
Clinically	O
,	O
the	O
patient	O
experienced	O
a	O
marked	O
improvement	O
,	O
with	O
resolution	O
of	O
abdominal	O
symptoms	O
,	O
as	O
well	O
as	O
resolution	O
of	O
choluria	O
and	O
acholia	O
.	O
In	O
relation	O
to	O
the	O
above	O
,	O
and	O
given	O
that	O
the	O
patient	O
had	O
high	O
LDL	O
cholesterol	O
levels	O
LDL	O
174	O
mg	O
dl	O
,	O
he	O
was	O
referred	O
to	O
the	O
lipid	O
unit	O
of	O
our	O
centre	O
in	O
order	O
to	O
consider	O
the	O
use	O
of	O
PCSK9	O
inhibitors	O
,	O
and	O
was	O
assessed	O
1	O
month	O
later	O
,	O
with	O
transaminase	O
and	O
cytolysis	O
enzyme	O
levels	O
within	O
normal	O
limits	O
in	O
control	O
analyses	O
.	O
From	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
a	O
control	O
echocardiogram	O
and	O
magnetic	O
resonance	O
imaging	O
were	O
performed	O
during	O
admission	O
,	O
showing	O
persistent	O
severe	O
left	O
ventricular	O
dysfunction	O
LVEF	O
25	O
,	O
with	O
anteroseptal	O
akinesia	O
and	O
apical	O
aneurysm	O
.	O
For	O
this	O
reason	O
,	O
treatment	O
for	O
ventricular	O
dysfunction	O
was	O
progressively	O
introduced	O
with	O
enalapril	B-FARMACO
,	O
eplerenone	B-FARMACO
and	O
metoprolol	B-FARMACO
,	O
with	O
adequate	O
tolerance	O
,	O
and	O
ICD	O
implantation	O
was	O
performed	O
as	O
primary	O
prevention	O
40	O
days	O
after	O
the	O
acute	O
event	O
.	O
DIAGNOSIS	O
Dilated	O
cardiomyopathy	O
of	O
ischaemic	O
aetiology	O
with	O
severe	O
ventricular	O
dysfunction	O
LVEF	O
25	O
.	O
Idiosyncratic	O
hepatitis	O
secondary	O
to	O
taking	O
atorvastatin	B-FARMACO
.	O
Advanced	O
anterior	O
infarction	O
,	O
with	O
extensive	O
anteroapical	O
aneurysm	O
and	O
intraventricular	O
thrombus	O
.	O
Implantation	O
of	O
ICD	O
in	O
primary	O
prevention	O
.	O
CVRF	O
type	O
2	O
diabetes	O
mellitus	O
,	O
hypercholesterolemia	O
,	O
ex	O
smoker	O
.	O

PERSONAL	O
HISTORY	O
79	O
year	O
old	O
woman	O
,	O
allergic	O
to	O
penicillin	B-FARMACO
and	O
metamizole	B-FARMACO
.	O
She	O
is	O
a	O
Jehovah	O
's	O
Witness	O
and	O
therefore	O
formally	O
refuses	O
blood	O
transfusions	O
.	O
Cardiological	O
history	O
arterial	O
hypertension	O
,	O
chronic	O
atrial	O
fibrillation	O
,	O
and	O
carrier	O
of	O
Omnicarbon	O
No	O
29	O
mitral	O
valve	O
prosthesis	O
implanted	O
30	O
years	O
ago	O
due	O
to	O
severe	O
rheumatic	O
mitral	O
valve	O
stenosis	O
.	O
Annual	O
follow	O
up	O
in	O
cardiology	O
outpatient	O
clinic	O
.	O
Home	O
medication	O
acenocoumarol	B-FARMACO
,	O
furosemide	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
losartan	B-FARMACO
50	O
mg	O
12	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
digoxin	B-FARMACO
0	O
.	O
25	O
mg	O
24	O
hours	O
5	O
days	O
a	O
week	O
.	O
CURRENT	O
ILLNESS	O
The	O
patient	O
presented	O
in	O
the	O
last	O
9	O
months	O
with	O
progressive	O
clinical	O
symptoms	O
of	O
asthenia	O
and	O
dyspnoea	O
on	O
moderate	O
exertion	O
,	O
with	O
jaundice	O
of	O
the	O
skin	O
and	O
mucous	O
membranes	O
.	O
She	O
was	O
admitted	O
to	O
the	O
gastrointestinal	O
department	O
for	O
anaemia	O
,	O
ruling	O
out	O
biliary	O
or	O
pancreatic	O
involvement	O
or	O
any	O
other	O
digestive	O
pathology	O
that	O
might	O
justify	O
it	O
.	O
Due	O
to	O
the	O
haemolytic	O
profile	O
of	O
the	O
anaemia	O
elevated	O
bilirubin	O
at	O
the	O
expense	O
of	O
the	O
indirect	O
fraction	O
,	O
elevated	O
reticulocytes	O
,	O
undetectable	O
haptoglobin	O
,	O
etc	O
.	O
in	O
a	O
patient	O
with	O
a	O
prosthetic	O
valve	O
,	O
she	O
was	O
transferred	O
to	O
the	O
cardiology	O
department	O
to	O
rule	O
out	O
possible	O
prosthetic	O
valve	O
dysfunction	O
.	O
PHYSICAL	O
EXAMINATION	O
Conscious	O
,	O
oriented	O
and	O
well	O
hydrated	O
.	O
Cutaneous	O
mucosal	O
jaundice	O
.	O
Marked	O
increase	O
in	O
jugular	O
venous	O
pressure	O
estimated	O
CVP	O
of	O
16	O
cmH2O	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
heart	O
sounds	O
at	O
84	O
bpm	O
with	O
systolic	O
murmur	O
II	O
VI	O
in	O
mitral	O
focus	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
no	O
alterations	O
.	O
Oedema	O
with	O
fovea	O
up	O
to	O
the	O
middle	O
third	O
of	O
the	O
lower	O
extremities	O
,	O
in	O
addition	O
to	O
signs	O
of	O
chronic	O
venous	O
insufficiency	O
.	O
COMPLEMENTARY	O
TESTS	O
Biochemistry	O
creatinine	O
1	O
.	O
25	O
mg	O
dl	O
,	O
normal	O
ions	O
and	O
transaminases	O
,	O
basal	O
glucose	O
91	O
mg	O
dl	O
,	O
total	O
cholesterol	O
145	O
mg	O
dl	O
,	O
LDH	O
1	O
,	O
308	O
U	O
l	O
,	O
haptoglobin	O
absent	O
,	O
increased	O
reticulocytes	O
7	O
,	O
increased	O
total	O
bilirubin	O
2	O
.	O
1	O
mg	O
dl	O
and	O
direct	O
bilirubin	O
0	O
.	O
6	O
mg	O
dl	O
.	O
Direct	O
and	O
indirect	O
Coombs	O
test	O
negative	O
.	O
Vitamin	O
B12	O
and	O
folic	O
acid	O
normal	O
.	O
Mild	O
iron	O
deficiency	O
IST	O
15	O
.	O
Haemoglobin	O
8	O
g	O
dl	O
,	O
haematocrit	O
24	O
,	O
platelets	O
71	O
,	O
000	O
mm3	O
.	O
Transesophageal	O
echocardiography	O
normofunctioning	O
mitral	O
prosthesis	O
with	O
moderate	O
periprosthetic	O
leak	O
in	O
the	O
posterior	O
wall	O
;	O
at	O
5	O
6	O
hours	O
of	O
9	O
x	O
5	O
mm	O
with	O
regurgitation	O
not	O
reaching	O
the	O
atrial	O
roof	O
.	O
Free	O
atrial	O
appendage	O
.	O
Normal	O
sized	O
left	O
ventricle	O
LV	O
with	O
mild	O
concentric	O
hypertrophy	O
and	O
preserved	O
systolic	O
function	O
EF	O
67	O
.	O
Dilatation	O
and	O
mild	O
dysfunction	O
of	O
the	O
right	O
ventricle	O
RV	O
.	O
PET	O
CT	O
scan	O
No	O
1	O
increased	O
fixation	O
of	O
the	O
periprosthetic	O
radiotracer	O
in	O
the	O
form	O
of	O
an	O
incomplete	O
ring	O
suggestive	O
of	O
endocarditis	O
on	O
mitral	O
prosthesis	O
.	O
PET	O
CT	O
scan	O
No	O
2	O
resolution	O
of	O
periprosthetic	O
uptake	O
is	O
observed	O
.	O
CLINICAL	O
EVOLUTION	O
Given	O
a	O
severe	O
haemolytic	O
anaemia	O
in	O
a	O
patient	O
with	O
a	O
metallic	O
valve	O
prosthesis	O
without	O
any	O
other	O
cause	O
,	O
a	O
transesophageal	O
echocardiogram	O
was	O
requested	O
which	O
confirmed	O
a	O
de	O
novo	O
perivalvular	O
leak	O
with	O
associated	O
moderate	O
mitral	O
insufficiency	O
.	O
Due	O
to	O
the	O
appearance	O
of	O
a	O
new	O
paravalvular	O
leak	O
,	O
a	O
PET	O
CT	O
scan	O
was	O
performed	O
in	O
search	O
of	O
an	O
aetiology	O
,	O
showing	O
perivalvular	O
uptake	O
suggestive	O
of	O
infective	O
endocarditis	O
.	O
Although	O
the	O
patient	O
was	O
afebrile	O
throughout	O
admission	O
and	O
all	O
blood	O
cultures	O
were	O
negative	O
without	O
having	O
received	O
previous	O
antibiotic	O
treatment	O
,	O
he	O
had	O
high	O
titres	O
of	O
Coxiella	O
IgG	O
,	O
so	O
antibiotic	O
treatment	O
was	O
started	O
with	O
ceftriaxone	B-FARMACO
for	O
6	O
weeks	O
and	O
doxycycline	B-FARMACO
for	O
18	O
months	O
.	O
Six	O
weeks	O
after	O
starting	O
the	O
antibiotic	O
regimen	O
,	O
a	O
new	O
PET	O
CT	O
scan	O
was	O
performed	O
,	O
which	O
no	O
longer	O
showed	O
mitral	O
uptake	O
.	O
Treatment	O
with	O
erythropoietin	B-FARMACO
and	O
folic	B-FARMACO
acid	I-FARMACO
was	O
also	O
started	O
to	O
treat	O
the	O
haemolytic	O
anaemia	O
.	O
Despite	O
the	O
resolution	O
of	O
the	O
infectious	O
condition	O
,	O
asthenia	O
and	O
anaemia	O
persisted	O
in	O
the	O
context	O
of	O
valve	O
dysfunction	O
,	O
so	O
it	O
was	O
decided	O
to	O
intervene	O
on	O
the	O
valve	O
.	O
Due	O
to	O
the	O
high	O
surgical	O
risk	O
of	O
open	O
surgery	O
,	O
increased	O
by	O
the	O
patient	O
's	O
refusal	O
to	O
use	O
blood	B-FARMACO
transfusions	I-FARMACO
and	O
blood	O
products	O
,	O
it	O
was	O
finally	O
decided	O
to	O
proceed	O
with	O
percutaneous	O
closure	O
of	O
the	O
paravalvular	O
leak	O
.	O
Postoperative	O
transesophageal	O
echocardiography	O
TEE	O
was	O
performed	O
and	O
showed	O
an	O
acceptable	O
result	O
.	O
DIAGNOSIS	O
Late	O
infective	O
endocarditis	O
on	O
mitral	O
prosthesis	O
due	O
to	O
Coxiella	O
burnetii	O
.	O
Haemolytic	O
anaemia	O
due	O
to	O
prosthetic	O
dysfunction	O
.	O
Percutaneous	O
closure	O
of	O
periprosthetic	O
leak	O
.	O

PERSONAL	O
HISTORY	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiological	O
history	O
ventricular	O
septal	O
defect	O
under	O
follow	O
up	O
by	O
cardiology	O
.	O
No	O
known	O
cardiovascular	O
risk	O
factors	O
CVRF	O
.	O
No	O
surgical	O
interventions	O
.	O
No	O
contact	O
with	O
animals	O
.	O
No	O
toxic	O
habits	O
.	O
No	O
habitual	O
treatment	O
.	O
CURRENT	O
ILLNESS	O
Patient	O
with	O
a	O
history	O
of	O
febrile	O
fever	O
and	O
thermometric	O
fever	O
of	O
up	O
to	O
38	O
C	O
with	O
profuse	O
night	O
sweats	O
for	O
the	O
last	O
two	O
years	O
.	O
She	O
did	O
not	O
report	O
any	O
other	O
accompanying	O
infectious	O
symptoms	O
.	O
She	O
also	O
has	O
a	O
general	O
syndrome	O
with	O
a	O
weight	O
loss	O
of	O
10	O
kg	O
in	O
the	O
last	O
year	O
4	O
kg	O
in	O
the	O
last	O
month	O
.	O
For	O
the	O
last	O
week	O
she	O
has	O
been	O
complaining	O
of	O
moderate	O
exertion	O
dyspnoea	O
with	O
orthopnoea	O
.	O
PHYSICAL	O
EXAMINATION	O
Good	O
general	O
condition	O
.	O
Blood	O
pressure	O
130	O
60	O
mmHg	O
.	O
No	O
peripheral	O
adenopathies	O
or	O
skin	O
lesions	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
at	O
100	O
bpm	O
,	O
systolic	O
murmur	O
in	O
FM	O
II	O
VI	O
,	O
aortic	O
systolic	O
murmur	O
III	O
VI	O
with	O
diastolic	O
leakage	O
IV	O
IV	O
.	O
Pulmonary	O
auscultation	O
bibasal	O
crackles	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
without	O
masses	O
or	O
megaliths	O
,	O
preserved	O
hydro	O
aerial	O
sounds	O
.	O
Not	O
painful	O
on	O
palpation	O
.	O
Lower	O
extremities	O
without	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
leukocytes	O
11	O
,	O
800	O
90	O
polymorphonuclear	O
,	O
Hb	O
13	O
g	O
dl	O
,	O
platelets	O
195	O
,	O
000	O
.	O
VSG	O
23	O
.	O
PCR	O
11	O
.	O
LDH	O
334	O
.	O
Glomerular	O
filtration	O
rate	O
95	O
ml	O
min	O
.	O
Proteinogram	O
compatible	O
with	O
inflammatory	O
process	O
.	O
Autoimmunity	O
negative	O
.	O
Beta2	O
microglobulin	O
3	O
.	O
62	O
,	O
NT	O
proBNP	O
2	O
.	O
360	O
pg	O
ml	O
.	O
Bronchoaspirate	O
negative	O
microbiology	O
.	O
Mantoux	O
negative	O
.	O
Other	O
laboratory	O
tests	O
were	O
normal	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
95	O
bpm	O
,	O
normal	O
PR	O
,	O
wide	O
QRS	O
with	O
morphology	O
of	O
complete	O
left	O
bundle	O
branch	O
block	O
LBBB	O
,	O
left	O
ventricular	O
LV	O
enlargement	O
,	O
left	O
axis	O
deviation	O
.	O
Blood	O
culture	O
antibiogram	O
Abiotrophia	O
defectiva	O
sensitive	O
to	O
cephalosporins	B-FARMACO
.	O
Chest	O
X	O
ray	O
increased	O
cardiothoracic	O
index	O
,	O
signs	O
of	O
vascular	O
redistribution	O
and	O
presence	O
of	O
fluid	O
in	O
cystole	O
.	O
Echocardiogram	O
left	O
ventricular	O
dilatation	O
LVEDD	O
64	O
mm	O
with	O
preserved	O
EF	O
,	O
without	O
segmental	O
contractility	O
abnormalities	O
.	O
Images	O
suggestive	O
of	O
infective	O
endocarditis	O
on	O
the	O
aortic	O
valve	O
,	O
with	O
valvular	O
rupture	O
causing	O
grade	O
IV	O
insufficiency	O
,	O
functional	O
mitral	O
regurgitation	O
grade	O
III	O
Carpentier	O
's	O
type	O
I	O
,	O
due	O
to	O
dilatation	O
of	O
the	O
annulus	O
,	O
with	O
left	O
atrial	O
dilatation	O
and	O
severe	O
pulmonary	O
hypertension	O
at	O
rest	O
.	O
Tricuspid	O
valve	O
involvement	O
septal	O
leaflet	O
with	O
severe	O
regurgitation	O
.	O
Restrictive	O
infracristal	O
infracristal	O
perimembranous	O
ventricular	O
septal	O
defect	O
gradient	O
66	O
mmHg	O
.	O
Other	O
complementary	O
tests	O
Gastroscopy	O
normal	O
.	O
Duodenal	O
biopsies	O
without	O
alterations	O
.	O
Colonoscopy	O
haemorrhoids	O
.	O
No	O
other	O
findings	O
.	O
Thoracic	O
abdominal	O
CT	O
scan	O
no	O
lesions	O
.	O
Coronary	O
CT	O
calcium	O
score	O
0	O
.	O
Coronary	O
arteries	O
without	O
plaques	O
or	O
lesions	O
.	O
Culture	O
of	O
aortic	O
and	O
tricuspid	O
valve	O
vegetation	O
positive	O
for	O
Abiotropha	O
defectiva	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
with	O
a	O
general	O
syndrome	O
,	O
fever	O
and	O
dyspnoea	O
.	O
After	O
positive	O
blood	O
cultures	O
for	O
Abiotrophia	O
defectiva	O
former	O
Streptococcus	O
viridans	O
,	O
antibiotic	O
treatment	O
was	O
started	O
with	O
ceftriaxone	B-FARMACO
.	O
Diuretic	O
treatment	O
was	O
also	O
associated	O
with	O
diuretic	O
treatment	O
to	O
control	O
congestive	O
symptoms	O
.	O
An	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
infective	O
endocarditis	O
on	O
the	O
tricuspid	O
and	O
aortic	O
valves	O
,	O
with	O
severe	O
aortic	O
insufficiency	O
and	O
dilated	O
LV	O
.	O
After	O
adding	O
gentamicin	B-FARMACO
to	O
ceftriaxone	B-FARMACO
,	O
he	O
remained	O
afebrile	O
.	O
A	O
gastroscopy	O
and	O
colonoscopy	O
were	O
performed	O
,	O
with	O
no	O
evidence	O
of	O
active	O
bleeding	O
,	O
and	O
a	O
CT	O
scan	O
of	O
the	O
abdomen	O
and	O
pelvis	O
showed	O
no	O
evidence	O
of	O
masses	O
or	O
other	O
relevant	O
pathology	O
.	O
He	O
was	O
presented	O
at	O
the	O
medical	O
surgical	O
session	O
and	O
was	O
accepted	O
for	O
surgical	O
treatment	O
.	O
He	O
underwent	O
surgery	O
placement	O
of	O
a	O
mechanical	O
aortic	O
prosthesis	O
,	O
mitral	O
annuloplasty	O
and	O
tricuspid	O
annuloplasty	O
and	O
closure	O
of	O
the	O
ventricular	O
septal	O
defect	O
VSD	O
,	O
without	O
complications	O
.	O
After	O
a	O
joint	O
assessment	O
with	O
the	O
infectious	O
diseases	O
department	O
,	O
antibiotic	O
treatment	O
was	O
decided	O
6	O
weeks	O
after	O
surgery	O
,	O
and	O
he	O
was	O
transferred	O
to	O
cardiology	O
to	O
complete	O
treatment	O
.	O
Antibiotic	O
treatment	O
was	O
completed	O
and	O
a	O
control	O
echocardiogram	O
was	O
performed	O
with	O
no	O
images	O
suggestive	O
of	O
vegetations	O
,	O
and	O
the	O
patient	O
was	O
discharged	O
from	O
hospital	O
.	O
DIAGNOSIS	O
Endocarditis	O
on	O
aortic	O
and	O
tricuspid	O
valve	O
.	O
Heart	O
failure	O
with	O
preserved	O
ejection	O
fraction	O
,	O
secondary	O
to	O
valvular	O
heart	O
disease	O
.	O
Grade	O
IV	O
aortic	O
insufficiency	O
due	O
to	O
valve	O
destruction	O
.	O
Grade	O
III	O
tricuspid	O
regurgitation	O
due	O
to	O
destruction	O
of	O
the	O
septal	O
leaflet	O
.	O
Grade	O
III	O
functional	O
mitral	O
insufficiency	O
.	O
Perimembranous	O
ventricular	O
septal	O
defect	O
.	O
Severe	O
pulmonary	O
hypertension	O
at	O
rest	O
.	O
Aortic	O
valve	O
replacement	O
by	O
mechanical	O
prosthesis	O
,	O
mitral	O
annuloplasty	O
,	O
tricuspid	O
annuloplasty	O
and	O
VSD	O
closure	O
.	O

PERSONAL	O
HISTORY	O
No	O
known	O
allergies	O
.	O
Family	O
history	O
mother	O
with	O
depressive	O
syndrome	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
.	O
Previous	O
illnesses	O
migraine	O
,	O
asthma	O
.	O
No	O
surgical	O
history	O
of	O
interest	O
.	O
Previous	O
medication	O
formoterol	B-FARMACO
,	O
budesonide	B-FARMACO
,	O
ipratropium	B-FARMACO
bromide	I-FARMACO
,	O
paroxetine	B-FARMACO
,	O
rizatriptan	B-FARMACO
.	O
Social	O
and	O
professional	O
history	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
until	O
the	O
onset	O
of	O
the	O
disease	O
one	O
year	O
ago	O
,	O
with	O
progressive	O
worsening	O
of	O
her	O
dyspnoea	O
.	O
Lives	O
alone	O
in	O
her	O
flat	O
.	O
She	O
has	O
worked	O
as	O
a	O
social	O
worker	O
until	O
the	O
onset	O
of	O
this	O
episode	O
.	O
CURRENT	O
ILLNESS	O
A	O
36	O
year	O
old	O
woman	O
presents	O
with	O
progressive	O
exertional	O
dyspnoea	O
of	O
three	O
to	O
four	O
months	O
'	O
duration	O
,	O
which	O
has	O
become	O
minimal	O
effort	O
in	O
the	O
last	O
two	O
weeks	O
.	O
She	O
refers	O
to	O
having	O
attributed	O
the	O
symptoms	O
to	O
her	O
asthma	O
and	O
now	O
consults	O
because	O
of	O
the	O
lack	O
of	O
improvement	O
despite	O
bronchodilator	O
treatment	O
.	O
He	O
also	O
complains	O
of	O
oedema	O
in	O
the	O
lower	O
limbs	O
and	O
increased	O
abdominal	O
circumference	O
with	O
a	O
feeling	O
of	O
fullness	O
,	O
nausea	O
and	O
vomiting	O
in	O
the	O
last	O
few	O
days	O
.	O
He	O
denies	O
orthopnoea	O
,	O
paroxysmal	O
nocturnal	O
dyspnoea	O
and	O
oliguria	O
.	O
Refers	O
bendopnoea	O
.	O
No	O
anginal	O
chest	O
pain	O
.	O
Occasional	O
palpitations	O
on	O
exertion	O
,	O
never	O
at	O
rest	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
114	O
82	O
mmHg	O
,	O
heart	O
rate	O
110	O
bpm	O
.	O
Baseline	O
SpO2	O
98	O
.	O
Afebrile	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
tachycardic	O
,	O
systolic	O
murmur	O
in	O
the	O
left	O
parasternal	O
border	O
EIB	O
and	O
mitral	O
focus	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
minimal	O
crackles	O
in	O
the	O
right	O
base	O
.	O
Oedema	O
with	O
fovea	O
in	O
both	O
malleoli	O
.	O
Abdomen	O
distended	O
,	O
without	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Not	O
painful	O
.	O
No	O
hepatomegaly	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
on	O
admission	O
sinus	O
tachycardia	O
at	O
110	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
,	O
normal	O
axis	O
.	O
No	O
acute	O
repolarisation	O
alterations	O
.	O
ECG	O
at	O
discharge	O
RS	O
at	O
60	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
BIRDHH	O
.	O
T	O
negative	O
in	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V4	O
V6	O
.	O
CBC	O
26	O
12	O
2018	O
haemoglobin	O
12	O
.	O
1	O
g	O
dl	O
12	O
15	O
.	O
6	O
,	O
haematocrit	O
39	O
.	O
3	O
35	O
.	O
5	O
45	O
.	O
5	O
,	O
leukocytes	O
7	O
.	O
7	O
,	O
x10e3	O
μl	O
3	O
.	O
9	O
10	O
.	O
2	O
,	O
neutrophils	O
60	O
.	O
7	O
42	O
77	O
,	O
platelets	O
258	O
x10e3	O
μl	O
150	O
370	O
,	O
INR	O
1	O
.	O
2	O
0	O
.	O
8	O
1	O
.	O
2	O
,	O
fibrinogen	O
296	O
mg	O
dl	O
150	O
450	O
,	O
AST	O
35	O
IU	O
l	O
15	O
37	O
,	O
ALT	O
60	O
IU	O
l	O
13	O
56	O
,	O
GGT	O
35	O
IU	O
l	O
5	O
55	O
,	O
c	O
reactive	O
protein	O
7	O
.	O
5	O
mg	O
l	O
0	O
3	O
,	O
glucose	O
102	O
mg	O
dl	O
74	O
106	O
,	O
urea	O
36	O
mg	O
dl	O
15	O
39	O
,	O
creatinine	O
1	O
.	O
08	O
mg	O
dl	O
0	O
.	O
55	O
1	O
.	O
02	O
,	O
glomerular	O
filtration	O
rate	O
CKD	O
EPI	O
66	O
,	O
2	O
ml	O
mn	O
1	O
.	O
73	O
m2	O
60	O
999999	O
,	O
sodium	O
138	O
.	O
7	O
mmol	O
l	O
136	O
145	O
,	O
potassium	O
3	O
.	O
80	O
mmol	O
l	O
3	O
.	O
5	O
5	O
.	O
1	O
,	O
chlorine	O
107	O
.	O
0	O
mmol	O
l	O
98	O
107	O
,	O
NT	O
proBNP	O
4300	O
.	O
CBC	O
at	O
discharge	O
red	O
blood	O
cells	O
4	O
.	O
31	O
x10e6	O
μl	O
3	O
.	O
9	O
5	O
.	O
2	O
,	O
haemoglobin	O
12	O
g	O
dl	O
12	O
15	O
.	O
6	O
,	O
haematocrit	O
40	O
35	O
.	O
5	O
45	O
.	O
5	O
,	O
leucocytes	O
6	O
.	O
3	O
x10e3	O
μl	O
3	O
.	O
9	O
10	O
.	O
2	O
,	O
neutrophils	O
49	O
42	O
77	O
,	O
lymphocytes	O
40	O
.	O
1	O
20	O
44	O
,	O
platelets	O
271	O
x10e3	O
μl	O
150	O
370	O
,	O
creatinine	O
1	O
,	O
00	O
mg	O
dl	O
0	O
.	O
55	O
1	O
.	O
02	O
,	O
sodium	O
134	O
.	O
3	O
mmol	O
l	O
136	O
145	O
,	O
potassium	O
3	O
.	O
80	O
mmol	O
l	O
3	O
.	O
5	O
5	O
.	O
1	O
,	O
chlorine	O
97	O
.	O
0	O
mmol	O
l	O
98	O
107	O
,	O
NT	O
proBNP	O
2813	O
pg	O
ml	O
0	O
125	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
alteration	O
of	O
the	O
morphology	O
of	O
the	O
cardiomediastinal	O
silhouette	O
with	O
growth	O
mainly	O
of	O
the	O
left	O
atrium	O
LA	O
and	O
right	O
ventricle	O
RV	O
.	O
Vascular	O
redistribution	O
in	O
upper	O
lung	O
fields	O
to	O
be	O
assessed	O
with	O
the	O
patient	O
's	O
baseline	O
cardiac	O
function	O
.	O
Pulmonary	O
parenchyma	O
with	O
non	O
specific	O
alterations	O
.	O
Transthoracic	O
echocardiogram	O
moderately	O
dilated	O
left	O
ventricle	O
DTDVI	O
60	O
mm	O
,	O
somewhat	O
spherical	O
,	O
and	O
with	O
systolic	O
dysfunction	O
that	O
appears	O
mild	O
by	O
this	O
technique	O
.	O
The	O
end	O
of	O
the	O
apex	O
is	O
not	O
adequately	O
defined	O
,	O
which	O
,	O
although	O
it	O
could	O
be	O
explained	O
by	O
a	O
certain	O
degree	O
of	O
obliteration	O
of	O
the	O
apex	O
,	O
may	O
also	O
be	O
related	O
to	O
the	O
ultrasound	O
window	O
.	O
There	O
is	O
mild	O
eccentric	O
hypertrophy	O
,	O
with	O
some	O
linear	O
hyperechogenicity	O
of	O
the	O
septum	O
.	O
Pseudonormal	O
diastolic	O
pattern	O
with	O
shortened	O
deceleration	O
time	O
0	O
.	O
08	O
seconds	O
.	O
Slightly	O
dilated	O
right	O
ventricle	O
RVOT	O
45	O
mm	O
,	O
with	O
systolic	O
function	O
parameters	O
at	O
the	O
limit	O
of	O
normality	O
TAPSE	O
17	O
mm	O
,	O
shortening	O
fraction	O
34	O
,	O
systolic	O
wave	O
9	O
.	O
4	O
cm	O
s	O
.	O
Moderate	O
severe	O
dilatation	O
of	O
the	O
LA	O
and	O
mild	O
moderate	O
dilatation	O
of	O
the	O
right	O
atrium	O
RA	O
.	O
Mitral	O
valve	O
with	O
leaflets	O
not	O
clearly	O
thickened	O
or	O
calcified	O
,	O
with	O
preserved	O
opening	O
and	O
moderate	O
severe	O
insufficiency	O
,	O
reaching	O
the	O
roof	O
of	O
the	O
atrium	O
with	O
coanda	O
effect	O
although	O
it	O
is	O
more	O
important	O
in	O
proto	O
mesosystolic	O
.	O
Morphologically	O
and	O
functionally	O
normal	O
aortic	O
valve	O
.	O
Slightly	O
eccentric	O
tricuspid	O
insufficiency	O
,	O
of	O
mild	O
moderate	O
degree	O
,	O
which	O
allows	O
estimating	O
a	O
PSAP	O
of	O
around	O
60	O
65	O
mmHg	O
.	O
Minimal	O
amount	O
of	O
pericardial	O
fluid	O
.	O
Visualised	O
segments	O
of	O
the	O
aorta	O
and	O
pulmonary	O
arteries	O
without	O
alterations	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
1	O
.	O
Morphological	O
study	O
the	O
LV	O
is	O
of	O
normal	O
size	O
with	O
high	O
cardiac	O
output	O
7l	O
min	O
.	O
It	O
is	O
not	O
hypertrophic	O
.	O
Its	O
function	O
is	O
at	O
the	O
low	O
limit	O
of	O
normality	O
LVEF	O
51	O
.	O
Eccentric	O
mitral	O
regurgitation	O
MR	O
towards	O
the	O
posterior	O
aspect	O
of	O
the	O
LA	O
is	O
at	O
least	O
moderate	O
.	O
After	O
contrast	O
administration	O
,	O
a	O
laminar	O
thrombus	O
is	O
observed	O
along	O
the	O
entire	O
LV	O
apex	O
,	O
with	O
a	O
maximum	O
thickness	O
of	O
5	O
mm	O
.	O
Diffuse	O
subendocardial	O
perfusion	O
defect	O
with	O
subendocardial	O
late	O
enhancement	O
25	O
is	O
seen	O
throughout	O
the	O
LV	O
wall	O
.	O
The	O
right	O
ventricle	O
is	O
of	O
normal	O
size	O
with	O
moderate	O
dysfunction	O
RVEF	O
38	O
with	O
global	O
hypokinesia	O
.	O
There	O
is	O
rectification	O
of	O
the	O
interventricular	O
septum	O
suggestive	O
of	O
RV	O
pressure	O
overload	O
.	O
Tricuspid	O
insufficiency	O
TI	O
,	O
which	O
appears	O
moderate	O
.	O
No	O
significant	O
enhancement	O
was	O
observed	O
after	O
contrast	O
administration	O
.	O
Biauricular	O
dilatation	O
.	O
LA	O
65	O
x	O
60	O
x	O
58	O
mm	O
.	O
RA	O
68	O
x	O
58	O
mm	O
.	O
Intact	O
atrial	O
septum	O
.	O
Small	O
amount	O
of	O
bilateral	O
pleural	O
and	O
pericardial	O
effusion	O
.	O
Mild	O
hepatomegaly	O
.	O
Dilatation	O
of	O
the	O
inferior	O
vena	O
cava	O
IVC	O
.	O
Cystic	O
image	O
in	O
the	O
right	O
breast	O
.	O
2	O
.	O
Ventricular	O
function	O
study	O
calculated	O
on	O
short	O
axis	O
left	O
ventricle	O
end	O
diastolic	O
volume	O
144	O
ml	O
86	O
ml	O
m2	O
.	O
Telesystolic	O
volume	O
70	O
ml	O
42	O
ml	O
m2	O
.	O
Systolic	O
volume	O
74	O
ml	O
.	O
Cardiac	O
output	O
7	O
l	O
min	O
.	O
Ejection	O
fraction	O
EF	O
51	O
.	O
Mass	O
103	O
g	O
62	O
g	O
m2	O
.	O
Right	O
ventricle	O
end	O
diastolic	O
volume	O
130	O
ml	O
78	O
ml	O
m2	O
.	O
End	O
systolic	O
volume	O
81	O
ml	O
49	O
ml	O
m2	O
.	O
Systolic	O
volume	O
49	O
ml	O
.	O
Cardiac	O
output	O
4	O
.	O
6	O
l	O
min	O
.	O
Ejection	O
fraction	O
EF	O
38	O
.	O
3	O
.	O
Flow	O
quantification	O
pulmonary	O
aortic	O
flow	O
.	O
Systolic	O
volume	O
39	O
.	O
8	O
ml	O
.	O
Anterograde	O
volume	O
40	O
.	O
8	O
ml	O
.	O
Retrograde	O
volume	O
1	O
ml	O
.	O
Regurgitant	O
fraction	O
2	O
.	O
4	O
.	O
Maximum	O
velocity	O
1	O
m	O
s	O
.	O
Systolic	O
volume	O
33	O
.	O
8	O
ml	O
.	O
Anterograde	O
volume	O
35	O
.	O
6	O
ml	O
.	O
Retrograde	O
volume	O
1	O
.	O
8	O
ml	O
.	O
Regurgitant	O
fraction	O
5	O
.	O
Mean	O
velocity	O
7	O
.	O
2	O
cm	O
s	O
.	O
Conclusion	O
LV	O
neither	O
dilated	O
nor	O
hypertrophic	O
with	O
function	O
at	O
the	O
lower	O
limit	O
of	O
normality	O
and	O
high	O
cardiac	O
output	O
.	O
Subendocardial	O
enhancement	O
in	O
all	O
segments	O
with	O
laminar	O
thrombus	O
in	O
the	O
apex	O
.	O
RV	O
neither	O
dilated	O
nor	O
hypertrophic	O
with	O
moderate	O
dysfunction	O
.	O
Biauricular	O
dilatation	O
.	O
MR	O
and	O
TR	O
at	O
least	O
moderate	O
.	O
The	O
findings	O
suggest	O
restrictive	O
cardiomyopathy	O
with	O
the	O
most	O
likely	O
cause	O
being	O
endomyocardial	O
fibrosis	O
.	O
Endomyocardial	O
biopsy	O
study	O
of	O
four	O
samples	O
showing	O
findings	O
compatible	O
with	O
endomyocardial	O
fibrosis	O
with	O
the	O
presence	O
of	O
extensive	O
fibrosis	O
and	O
severe	O
endocardial	O
thickening	O
,	O
as	O
well	O
as	O
images	O
compatible	O
with	O
thrombus	O
.	O
Right	O
catheterisation	O
pressure	O
study	O
.	O
RA	O
pressure	O
12	O
mmHg	O
,	O
systolic	O
right	O
ventricular	O
pressure	O
65	O
mmHg	O
,	O
pulmonary	O
artery	O
pressure	O
64	O
28	O
40	O
mmHg	O
,	O
pulmonary	O
capillary	O
pressure	O
20	O
mmHg	O
,	O
transpulmonary	O
gradient	O
20	O
mmHg	O
,	O
cardiac	O
output	O
2	O
.	O
6	O
bpm	O
,	O
cardiac	O
index	O
1	O
.	O
5	O
bpm	O
m2	O
.	O
Pulmonary	O
vascular	O
resistance	O
7	O
.	O
7	O
UW	O
.	O
Abdominal	O
ultrasound	O
conclusion	O
hepatic	O
venous	O
congestion	O
.	O
Microbiology	O
blood	O
cultures	O
2	O
1	O
E	O
.	O
cloacae	O
.	O
Urine	O
culture	O
4	O
1	O
contaminated	O
urine	O
.	O
Blood	O
cultures	O
18	O
1	O
sterile	O
.	O
Urine	O
culture	O
19	O
1	O
negative	O
.	O
Serology	O
Syphilis	O
IgG	O
negative	O
,	O
toxoplasma	O
IgG	O
negative	O
,	O
rubella	O
IgG	O
positive	O
,	O
HSV	O
IgG	O
negative	O
,	O
IgM	O
negative	O
,	O
varicella	O
IgG	O
doubtful	O
,	O
cytomegalovirus	O
IgG	O
positive	O
,	O
IgM	O
negative	O
,	O
HAV	O
IgM	O
negative	O
,	O
IgG	O
positive	O
,	O
HBs	O
Ag	O
negative	O
,	O
anti	O
HBs	O
Ag	O
negative	O
,	O
anti	O
HBs	O
borderline	O
positive	O
,	O
HAV	O
IgG	O
positive	O
,	O
HIV	O
1	O
2	O
negative	O
,	O
measles	O
IgG	O
positive	O
,	O
mumps	O
IgG	O
positive	O
.	O
CLINICAL	O
COURSE	O
A	O
36	O
year	O
old	O
woman	O
was	O
admitted	O
for	O
the	O
first	O
episode	O
of	O
heart	O
failure	O
.	O
Depletive	O
treatment	O
was	O
started	O
with	O
good	O
clinical	O
evolution	O
.	O
An	O
echocardiogram	O
was	O
performed	O
showing	O
restrictive	O
cardiomyopathy	O
with	O
mild	O
left	O
ventricular	O
dysfunction	O
and	O
moderate	O
severe	O
MI	O
with	O
severe	O
pulmonary	O
hypertension	O
.	O
Treatment	O
for	O
heart	O
failure	O
was	O
started	O
with	O
good	O
tolerance	O
,	O
titrating	O
low	O
doses	O
of	O
enalapril	B-FARMACO
due	O
to	O
a	O
tendency	O
to	O
hypotension	O
.	O
He	O
subsequently	O
presented	O
signs	O
of	O
low	O
cardiac	O
output	O
,	O
with	O
discrete	O
deterioration	O
of	O
renal	O
function	O
and	O
elevation	O
of	O
liver	O
enzymes	O
and	O
coagulation	O
alteration	O
.	O
A	O
course	O
of	O
levosimendan	B-FARMACO
was	O
administered	O
with	O
clinical	O
improvement	O
.	O
She	O
presented	O
a	O
fever	O
peak	O
on	O
the	O
fifth	O
day	O
of	O
admission	O
with	O
shivering	O
and	O
haemodynamic	O
worsening	O
,	O
requiring	O
admission	O
to	O
the	O
coronary	O
unit	O
and	O
inotropic	O
support	O
with	O
intravenous	O
noradrenaline	B-FARMACO
in	O
the	O
context	O
of	O
bacteraemia	O
due	O
to	O
Enterobacter	O
cloacae	O
,	O
which	O
was	O
treated	O
with	O
a	O
course	O
of	O
intravenous	O
meropenem	B-FARMACO
.	O
In	O
the	O
following	O
days	O
the	O
patient	O
improved	O
clinically	O
,	O
and	O
the	O
noradrenaline	B-FARMACO
was	O
withdrawn	O
and	O
diuretic	O
doses	O
were	O
reduced	O
.	O
A	O
CMR	O
was	O
performed	O
which	O
showed	O
findings	O
compatible	O
with	O
endomyocardial	O
fibrosis	O
and	O
the	O
presence	O
of	O
a	O
laminar	O
thrombus	O
in	O
the	O
apex	O
.	O
In	O
view	O
of	O
the	O
suspicion	O
of	O
endomyocardial	O
fibrosis	O
,	O
an	O
endomyocardial	O
biopsy	O
was	O
performed	O
which	O
confirmed	O
the	O
diagnosis	O
.	O
A	O
right	O
heart	O
catheterisation	O
was	O
also	O
performed	O
,	O
showing	O
pulmonary	O
hypertension	O
group	O
2	O
with	O
increased	O
pulmonary	O
vascular	O
resistance	O
and	O
low	O
cardiac	O
output	O
.	O
Due	O
to	O
the	O
presentation	O
in	O
cardiogenic	O
shock	O
and	O
the	O
poor	O
prognostic	O
data	O
,	O
a	O
pre	O
transplant	O
cardiac	O
study	O
was	O
initiated	O
.	O
DIAGNOSIS	O
First	O
episode	O
of	O
heart	O
failure	O
Restrictive	O
cardiomyopathy	O
endomyocardial	O
fibrosis	O
.	O
Moderate	O
severe	O
mitral	O
insufficiency	O
MI	O
.	O
Moderate	O
tricuspid	O
regurgitation	O
TR	O
.	O
Severe	O
pulmonary	O
hypertension	O
group	O
2	O
.	O
LV	O
apex	O
thrombus	O
.	O
Cardiogenic	O
shock	O
and	O
septic	O
shock	O
associated	O
with	O
Enterobacter	O
cloacae	O
bacteraemia	O
.	O
Adaptive	O
syndrome	O
with	O
anxious	O
depressive	O
symptoms	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
21	O
year	O
old	O
girl	O
,	O
with	O
no	O
personal	O
history	O
of	O
interest	O
or	O
usual	O
treatment	O
.	O
Pregnancy	O
at	O
term	O
with	O
euthyphalic	O
vaginal	O
delivery	O
in	O
a	O
private	O
clinic	O
48	O
hours	O
before	O
being	O
brought	O
to	O
the	O
emergency	O
department	O
.	O
The	O
gestation	O
was	O
uncomplicated	O
,	O
as	O
was	O
the	O
delivery	O
.	O
However	O
,	O
48	O
hours	O
after	O
delivery	O
,	O
the	O
patient	O
began	O
with	O
pinkish	O
expectoration	O
and	O
rapidly	O
progressive	O
dyspnoea	O
and	O
was	O
referred	O
to	O
our	O
hospital	O
.	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
her	O
vital	O
signs	O
were	O
Blood	O
pressure	O
100	O
69	O
mmHg	O
.	O
Heart	O
rate	O
140	O
bpm	O
.	O
Respiratory	O
rate	O
24	O
rpm	O
.	O
O2	O
saturation	O
96	O
with	O
FiO2	O
100	O
.	O
On	O
physical	O
examination	O
she	O
was	O
pale	O
and	O
sweaty	O
,	O
with	O
distal	O
coldness	O
.	O
There	O
was	O
no	O
jugular	O
ingurgitation	O
at	O
45o	O
.	O
Cardiac	O
auscultation	O
was	O
rhythmic	O
with	O
a	O
gallop	O
rhythm	O
on	O
the	O
third	O
sound	O
.	O
Pulmonary	O
auscultation	O
with	O
bibasal	O
crackles	O
.	O
Abdomen	O
distended	O
.	O
Upper	O
and	O
lower	O
extremities	O
without	O
oedema	O
,	O
with	O
palpable	O
distal	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
on	O
arrival	O
,	O
sinus	O
tachycardia	O
,	O
with	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
without	O
repolarisation	O
disorders	O
.	O
Blood	O
tests	O
Baseline	O
arterial	O
blood	O
gas	O
on	O
arrival	O
pH	O
7	O
.	O
44	O
,	O
pCO2	O
27	O
.	O
6	O
mmHg	O
,	O
pO2	O
55	O
.	O
9	O
mmHg	O
,	O
HCO3	O
18	O
.	O
6	O
mmol	O
l	O
.	O
Biochemistry	O
glucose	O
84	O
mg	O
dl	O
,	O
urea	O
47	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
85	O
mg	O
dl	O
,	O
Na	O
140	O
mEq	O
l	O
,	O
K	O
4	O
.	O
3	O
mEq	O
l	O
,	O
chlorine	O
105	O
mEq	O
l	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
CKD	O
EPI	O
60	O
,	O
troponin	O
0	O
.	O
06	O
0	O
.	O
09	O
0	O
.	O
03	O
ng	O
ml	O
.	O
Lactate	O
18	O
.	O
7	O
mg	O
dl	O
,	O
NT	O
proBNP	O
12442	O
pg	O
ml	O
.	O
Haemocytes	O
leucocytes	O
5	O
.	O
1	O
10e3	O
μl	O
,	O
haemoglobin	O
11	O
.	O
2	O
g	O
dl	O
,	O
MCV	O
70	O
fl	O
,	O
platelets	O
234	O
10e3	O
μl	O
.	O
Coagulation	O
prothrombin	O
activity	O
81	O
,	O
INR	O
1	O
,	O
16	O
.	O
Chest	O
X	O
ray	O
perihilar	O
interstitial	O
pattern	O
compatible	O
with	O
acute	O
pulmonary	O
oedema	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
on	O
admission	O
slightly	O
dilated	O
left	O
ventricle	O
LVED	O
57	O
mm	O
with	O
very	O
severe	O
systolic	O
dysfunction	O
LVEF	O
10	O
15	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Tricuspid	O
and	O
normofunctioning	O
aortic	O
valve	O
.	O
Normal	O
mitral	O
valve	O
with	O
mild	O
mitral	O
regurgitation	O
MR	O
.	O
Indirect	O
evidence	O
of	O
increased	O
left	O
filling	O
pressures	O
.	O
Normal	O
tricuspid	O
valve	O
without	O
insufficiency	O
.	O
Type	O
I	O
pulmonary	O
flow	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
with	O
inspiratory	O
collapse	O
.	O
No	O
coarctation	O
of	O
the	O
aorta	O
.	O
Calculated	O
GCS	O
for	O
continuity	O
of	O
3	O
.	O
7	O
l	O
min	O
.	O
Pleural	O
effusion	O
in	O
both	O
lung	O
bases	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
dilated	O
left	O
ventricle	O
LV	O
with	O
end	O
diastolic	O
volume	O
164	O
ml	O
corrected	O
for	O
body	O
surface	O
area	O
of	O
100	O
ml	O
m2	O
.	O
Telesystolic	O
volume	O
132	O
ml	O
80	O
ml	O
m	O
.	O
EF	O
20	O
.	O
Diffuse	O
hypokinesia	O
without	O
clear	O
segmental	O
changes	O
.	O
No	O
abnormal	O
intramyocardial	O
enhancement	O
after	O
contrast	O
injection	O
at	O
early	O
or	O
late	O
times	O
.	O
No	O
evidence	O
of	O
significant	O
pericardial	O
effusion	O
.	O
Rest	O
of	O
the	O
study	O
without	O
alterations	O
.	O
Severe	O
LV	O
systolic	O
dysfunction	O
EF	O
20	O
.	O
In	O
the	O
clinical	O
context	O
suggests	O
peripartum	O
cardiomyopathy	O
.	O
Other	O
tests	O
PCR	O
adenovirus	O
,	O
enterovirus	O
and	O
herpes	O
virus	O
negative	O
.	O
Serology	O
for	O
Toxoplasma	O
,	O
CMV	O
,	O
herpes	O
zoster	O
,	O
Epstein	O
Barr	O
,	O
HSV	O
1	O
and	O
2	O
,	O
HIV	O
and	O
hepatitis	O
negative	O
.	O
Transthoracic	O
echocardiogram	O
at	O
discharge	O
left	O
ventricle	O
slightly	O
dilated	O
.	O
Severe	O
LV	O
systolic	O
dysfunction	O
.	O
LVEF	O
25	O
.	O
Paradoxical	O
septal	O
motion	O
.	O
Right	O
ventricle	O
RV	O
not	O
dilated	O
with	O
preserved	O
RV	O
systolic	O
function	O
.	O
Mitral	O
regurgitation	O
in	O
the	O
mild	O
range	O
.	O
Normal	O
diastolic	O
Doppler	O
pattern	O
.	O
Normal	O
diastolic	O
tissue	O
Doppler	O
pattern	O
.	O
Normal	O
pulmonary	O
artery	O
pressure	O
PAP	O
14	O
mmHg	O
PVC	O
.	O
Vena	O
cava	O
not	O
dilated	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
coronary	O
unit	O
was	O
notified	O
due	O
to	O
suspicion	O
of	O
pulmonary	O
thromboembolism	O
PTE	O
,	O
as	O
the	O
patient	O
presented	O
poor	O
general	O
condition	O
,	O
tachypnoea	O
,	O
desaturation	O
and	O
a	O
tendency	O
to	O
hypotension	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
at	O
the	O
bedside	O
showing	O
very	O
severe	O
LV	O
systolic	O
dysfunction	O
LVEF	O
15	O
with	O
hyperdynamic	O
RV	O
,	O
so	O
,	O
on	O
suspicion	O
of	O
acute	O
pulmonary	O
oedema	O
triggered	O
by	O
peripartum	O
cardiomyopathy	O
,	O
she	O
was	O
urgently	O
transferred	O
to	O
our	O
unit	O
.	O
After	O
being	O
urgently	O
admitted	O
to	O
the	O
coronary	O
unit	O
,	O
inotropic	O
treatment	O
was	O
started	O
with	O
dobutamine	B-FARMACO
and	O
diuretics	O
,	O
both	O
at	O
high	O
doses	O
.	O
In	O
the	O
following	O
hours	O
the	O
evolution	O
was	O
adequate	O
,	O
with	O
significant	O
negative	O
balance	O
,	O
improved	O
oxygenation	O
and	O
organ	O
perfusion	O
data	O
.	O
This	O
allowed	O
for	O
a	O
progressive	O
decrease	O
in	O
inotropic	O
and	O
diuretic	O
support	O
.	O
Dobutamine	B-FARMACO
perfusion	O
was	O
suspended	O
and	O
neurohormonal	O
treatment	O
with	O
bisoprolol	B-FARMACO
and	O
enalapril	B-FARMACO
was	O
started	O
,	O
with	O
good	O
tolerance	O
.	O
ten	O
days	O
after	O
admission	O
,	O
she	O
was	O
discharged	O
to	O
the	O
cardiology	O
ward	O
,	O
where	O
the	O
study	O
was	O
completed	O
with	O
a	O
cardiac	O
magnetic	O
resonance	O
that	O
ruled	O
out	O
pathological	O
enhancements	O
and	O
an	O
inflammatory	O
component	O
at	O
cardiac	O
level	O
with	O
an	O
estimated	O
LVEF	O
of	O
20	O
.	O
Based	O
on	O
these	O
data	O
,	O
and	O
given	O
the	O
high	O
risk	O
of	O
ventricular	O
arrhythmias	O
in	O
a	O
very	O
young	O
patient	O
,	O
it	O
was	O
decided	O
to	O
implant	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
.	O
The	O
subcutaneous	O
route	O
was	O
chosen	O
,	O
given	O
the	O
possible	O
improvement	O
or	O
recovery	O
of	O
ventricular	O
function	O
experienced	O
by	O
some	O
patients	O
with	O
peripartum	O
cardiomyopathy	O
in	O
the	O
following	O
months	O
,	O
as	O
reported	O
in	O
the	O
literature	O
.	O
A	O
genetic	O
study	O
was	O
requested	O
and	O
a	O
frameshift	O
variant	O
was	O
found	O
in	O
the	O
TTN	O
gene	O
encoding	O
titin	O
,	O
which	O
is	O
considered	O
pathogenic	O
.	O
DIAGNOSIS	O
Acute	O
pulmonary	O
oedema	O
.	O
Peripartum	O
cardiomyopathy	O
with	O
severe	O
left	O
ventricular	O
dysfunction	O
.	O
Subcutaneous	O
ICD	O
implantation	O
as	O
primary	O
prevention	O
of	O
ventricular	O
arrhythmias	O
.	O
Positive	O
genetic	O
study	O
for	O
pathogenic	O
variant	O
in	O
the	O
titin	O
gene	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
39	O
year	O
old	O
man	O
presented	O
with	O
dyspnoea	O
.	O
BACKGROUND	O
Family	O
history	O
paternal	O
grandmother	O
,	O
paternal	O
uncles	O
and	O
father	O
suffered	O
from	O
dilated	O
cardiomyopathy	O
and	O
died	O
of	O
sudden	O
death	O
.	O
He	O
has	O
two	O
living	O
sisters	O
diagnosed	O
with	O
dilated	O
cardiomyopathy	O
.	O
Cardiovascular	O
risk	O
factors	O
active	O
smoker	O
of	O
1	O
pack	O
a	O
day	O
,	O
obese	O
,	O
dyslipidaemia	O
type	O
hypertriglyceridaemia	O
.	O
He	O
was	O
also	O
a	O
moderate	O
drinker	O
,	O
with	O
no	O
alcohol	O
consumption	O
at	O
present	O
.	O
Cardiological	O
history	O
diagnosed	O
in	O
2012	O
with	O
dilated	O
cardiomyopathy	O
with	O
severe	O
biventricular	O
systolic	O
dysfunction	O
,	O
non	O
ischaemic	O
,	O
with	O
criteria	O
of	O
non	O
compaction	O
cardiomyopathy	O
on	O
magnetic	O
resonance	O
imaging	O
after	O
admission	O
to	O
cardiology	O
for	O
heart	O
failure	O
HF	O
videos	O
1	O
2	O
.	O
It	O
was	O
reported	O
as	O
dilated	O
left	O
ventricle	O
LV	O
end	O
diastolic	O
volume	O
EDV	O
195	O
ml	O
m2	O
and	O
end	O
systolic	O
volume	O
ESV	O
161	O
ml	O
m2	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
of	O
17	O
due	O
to	O
diffuse	O
severe	O
hypokinesia	O
.	O
Lateral	O
and	O
apical	O
predominant	O
hypertrabeculation	O
meeting	O
radiological	O
criteria	O
for	O
non	O
compaction	O
.	O
Small	O
area	O
of	O
intramyocardial	O
late	O
enhancement	O
at	O
the	O
basal	O
insertion	O
of	O
both	O
ventricles	O
.	O
Dilated	O
right	O
ventricle	O
RV	O
RVT	O
141	O
ml	O
m2	O
and	O
STV	O
106	O
ml	O
m2	O
.	O
Right	O
ventricular	O
ejection	O
fraction	O
RVEF	O
of	O
25	O
with	O
global	O
hypocontractility	O
.	O
Severely	O
dilated	O
left	O
atrium	O
LA	O
and	O
right	O
atrium	O
RA	O
.	O
Dilatation	O
of	O
pulmonary	O
artery	O
,	O
inferior	O
vena	O
cava	O
and	O
suprahepatic	O
veins	O
.	O
Normal	O
pericardium	O
.	O
During	O
this	O
admission	O
,	O
a	O
coronary	O
angiography	O
was	O
also	O
performed	O
,	O
which	O
showed	O
right	O
dominance	O
and	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O
Followed	O
in	O
cardiology	O
outpatient	O
clinic	O
since	O
then	O
.	O
Stable	O
,	O
with	O
adequate	O
compliance	O
with	O
hygienic	O
dietary	O
measures	O
.	O
Angiotensin	B-FARMACO
converting	I-FARMACO
enzyme	I-FARMACO
inhibitor	I-FARMACO
ACE	I-FARMACO
inhibitor	I-FARMACO
,	O
beta	B-FARMACO
blocker	I-FARMACO
BB	I-FARMACO
and	O
aldosterone	B-FARMACO
inhibitors	I-FARMACO
up	O
to	O
maximum	O
tolerated	O
doses	O
,	O
together	O
with	O
ivabradine	B-FARMACO
.	O
Ergospirometry	O
was	O
performed	O
in	O
June	O
2013	O
with	O
the	O
following	O
result	O
forced	O
vital	O
capacity	O
FVC	O
4	O
.	O
48	O
l	O
76	O
,	O
forced	O
expiratory	O
volume	O
in	O
one	O
second	O
FEV1	O
4	O
.	O
22	O
l	O
83	O
,	O
FEV1	O
87	O
.	O
Suggestive	O
of	O
restrictive	O
disorder	O
due	O
to	O
obesity	O
.	O
VO2	O
max	O
21	O
ml	O
kg	O
min	O
,	O
coincides	O
with	O
the	O
threshold	O
.	O
VE	O
max	O
106	O
l	O
min	O
Eq	O
CO2	O
at	O
threshold	O
30	O
.	O
Maximum	O
heart	O
rate	O
HR	O
149	O
bpm	O
80	O
maximum	O
theoretical	O
heart	O
rate	O
MTHRF	O
.	O
Exercise	O
time	O
10	O
.	O
3	O
min	O
.	O
Implantable	O
cardioverter	O
defibrillator	O
ICD	O
implantation	O
was	O
decided	O
for	O
primary	O
prevention	O
after	O
imaging	O
studies	O
showed	O
persistent	O
LVEF	O
30	O
.	O
Last	O
check	O
up	O
6	O
months	O
before	O
admission	O
,	O
in	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
II	O
.	O
Other	O
history	O
sleep	O
apnoea	O
hypopnoea	O
syndrome	O
under	O
treatment	O
with	O
continuous	O
positive	O
airway	O
pressure	O
CPAP	O
.	O
Usual	O
treatment	O
enalapril	B-FARMACO
10	O
mg	O
1	O
tablet	O
at	O
breakfast	O
,	O
carvedilol	B-FARMACO
25	O
mg	O
1	O
tablet	O
at	O
breakfast	O
and	O
1	O
tablet	O
at	O
dinner	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
2	O
tablets	O
at	O
dinner	O
,	O
ivabradine	B-FARMACO
5	O
mg	O
1	O
tablet	O
at	O
breakfast	O
and	O
1	O
tablet	O
at	O
dinner	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
tablet	O
at	O
breakfast	O
.	O
CURRENT	O
DISEASE	O
In	O
NYHA	O
functional	O
class	O
II	O
until	O
5	O
weeks	O
ago	O
,	O
refers	O
progressive	O
worsening	O
due	O
to	O
increased	O
dyspnoea	O
until	O
becoming	O
minimal	O
effort	O
,	O
with	O
orthopnoea	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
The	O
patient	O
,	O
in	O
view	O
of	O
the	O
functional	O
worsening	O
,	O
increased	O
the	O
dose	O
of	O
oral	O
furosemide	B-FARMACO
from	O
40	O
mg	O
to	O
a	O
dose	O
of	O
160	O
mg	O
per	O
day	O
2	O
tablets	O
at	O
breakfast	O
and	O
2	O
tablets	O
at	O
snack	O
time	O
.	O
As	O
he	O
continued	O
with	O
dyspnoea	O
on	O
minimal	O
exertion	O
without	O
improvement	O
,	O
he	O
consulted	O
the	O
emergency	O
department	O
.	O
Due	O
to	O
his	O
work	O
situation	O
,	O
he	O
reported	O
non	O
compliance	O
with	O
hygiene	O
and	O
dietary	O
measures	O
in	O
recent	O
weeks	O
,	O
with	O
dietary	O
transgressions	O
.	O
The	O
rest	O
of	O
the	O
medical	O
history	O
was	O
negative	O
.	O
PHYSICAL	O
EXAMINATION	O
On	O
examination	O
he	O
is	O
conscious	O
and	O
oriented	O
,	O
well	O
perfused	O
.	O
He	O
weighs	O
110	O
kg	O
.	O
Blood	O
pressure	O
BP	O
was	O
120	O
90	O
mmHg	O
.	O
Jugular	O
venous	O
pressure	O
is	O
not	O
measurable	O
due	O
to	O
obesity	O
.	O
Cardiac	O
auscultation	O
is	O
rhythmic	O
at	O
80	O
beats	O
per	O
minute	O
,	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
shows	O
good	O
ventilation	O
in	O
all	O
fields	O
.	O
The	O
abdomen	O
is	O
soft	O
and	O
slightly	O
painful	O
hepatomegaly	O
of	O
about	O
2	O
centimetres	O
is	O
palpable	O
.	O
The	O
lower	O
extremities	O
are	O
oedematous	O
up	O
to	O
mid	O
leg	O
.	O
Distal	O
capillary	O
refill	O
is	O
good	O
.	O
COMPLEMENTARY	O
TESTS	O
ELECTROCARDIOGRAM	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
at	O
100	O
bpm	O
.	O
PR	O
interval	O
of	O
normal	O
duration	O
and	O
QRS	O
of	O
110	O
ms	O
.	O
Scarce	O
R	O
wave	O
progression	O
in	O
precordials	O
and	O
asymmetric	O
negative	O
T	O
waves	O
in	O
DI	O
,	O
aVL	O
,	O
V5	O
and	O
V6	O
.	O
THORAX	O
RADIOGRAPHY	O
cardiomegaly	O
and	O
slight	O
vascular	O
redistribution	O
to	O
upper	O
fields	O
.	O
No	O
parenchymal	O
condensation	O
.	O
ANALYSIS	O
during	O
admission	O
haemoglobin	O
11	O
.	O
7	O
g	O
dl	O
,	O
leukocytes	O
10	O
,	O
000	O
mm3	O
normal	O
formula	O
,	O
platelets	O
255	O
.	O
000	O
mm3	O
,	O
glucose	O
87	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
8	O
mg	O
dl	O
,	O
urea	O
45	O
mg	O
dl	O
,	O
sodium	O
137	O
mEq	O
dl	O
,	O
potassium	O
4	O
.	O
4	O
mEq	O
l	O
,	O
total	O
cholesterol	O
112	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
75	O
mg	O
dl	O
,	O
uric	O
acid	O
9	O
.	O
3	O
mg	O
dl	O
,	O
gamma	O
GT	O
74	O
U	O
l	O
,	O
total	O
bilirubin	O
1	O
.	O
6	O
mg	O
dl	O
,	O
ferritin	O
52	O
ng	O
dl	O
,	O
transferrin	O
saturation	O
index	O
4	O
.	O
3	O
,	O
glycosylated	O
haemoglobin	O
6	O
.	O
0	O
.	O
Normal	O
TSH	O
.	O
amino	O
terminal	O
pro	O
brain	O
natriuretic	O
peptide	O
NT	O
proBNP	O
fraction	O
on	O
admission	O
1	O
,	O
607	O
pg	O
dl	O
,	O
on	O
discharge	O
858	O
pg	O
dl	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
cardiology	O
ward	O
for	O
the	O
first	O
episode	O
of	O
decompensation	O
after	O
diagnosis	O
of	O
HF	O
.	O
Intravenous	O
diuretic	O
treatment	O
was	O
started	O
with	O
improvement	O
of	O
the	O
signs	O
of	O
congestion	O
and	O
symptoms	O
.	O
The	O
patient	O
lost	O
4	O
kg	O
of	O
weight	O
during	O
admission	O
.	O
Hygiene	O
and	O
dietary	O
measures	O
were	O
emphasised	O
and	O
the	O
patient	O
was	O
included	O
in	O
the	O
HF	O
consultation	O
,	O
and	O
an	O
early	O
visit	O
one	O
week	O
after	O
discharge	O
was	O
scheduled	O
.	O
On	O
discharge	O
,	O
the	O
previous	O
neurohormonal	O
treatment	O
was	O
maintained	O
with	O
a	O
daily	O
dose	O
of	O
160	O
mg	O
of	O
oral	O
furosemide	B-FARMACO
.	O
At	O
the	O
first	O
review	O
,	O
the	O
patient	O
was	O
in	O
NYHA	O
functional	O
class	O
II	O
and	O
in	O
euvolemia	O
,	O
so	O
the	O
dose	O
of	O
furosemide	B-FARMACO
had	O
been	O
reduced	O
to	O
80	O
mg	O
per	O
day	O
.	O
With	O
BP	O
of	O
125	O
70	O
mmHg	O
and	O
given	O
the	O
patient	O
's	O
profile	O
,	O
with	O
risk	O
of	O
readmission	O
and	O
progression	O
of	O
the	O
disease	O
,	O
it	O
was	O
decided	O
to	O
suspend	O
enalapril	B-FARMACO
and	O
after	O
36	O
hours	O
,	O
treatment	O
was	O
started	O
with	O
sacubitril	O
valsartan	O
24	O
26	O
mg	O
every	O
12	O
hours	O
.	O
A	O
new	O
check	O
up	O
was	O
scheduled	O
after	O
3	O
weeks	O
.	O
On	O
the	O
second	O
visit	O
to	O
the	O
clinic	O
,	O
the	O
patient	O
was	O
found	O
to	O
be	O
euvolaemic	O
and	O
with	O
BP	O
levels	O
around	O
120	O
60	O
mmHg	O
.	O
The	O
dose	O
of	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
was	O
increased	O
to	O
49	O
51	O
mg	O
every	O
12	O
hours	O
.	O
Five	O
days	O
after	O
the	O
consultation	O
,	O
the	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
for	O
severe	O
dizziness	O
.	O
Hypotension	O
of	O
90	O
50	O
mmHg	O
was	O
noted	O
.	O
When	O
assessed	O
by	O
the	O
cardiology	O
ward	O
,	O
it	O
was	O
decided	O
to	O
maintain	O
the	O
dose	O
of	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
at	O
49	O
51	O
mg	O
every	O
12	O
hours	O
,	O
but	O
the	O
dose	O
of	O
furosemide	O
was	O
reduced	O
to	O
40	O
mg	O
,	O
given	O
that	O
he	O
showed	O
no	O
signs	O
of	O
congestion	O
.	O
At	O
the	O
next	O
visit	O
,	O
systolic	O
BP	O
was	O
around	O
110	O
120	O
mmHg	O
,	O
with	O
no	O
signs	O
of	O
congestion	O
.	O
Prior	O
to	O
the	O
last	O
dose	O
titration	O
of	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
,	O
it	O
was	O
decided	O
to	O
reduce	O
the	O
dose	O
of	O
furosemide	B-FARMACO
40	O
mg	O
to	O
half	O
a	O
tablet	O
at	O
breakfast	O
.	O
The	O
patient	O
was	O
titrated	O
to	O
the	O
maximum	O
dose	O
of	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
97	O
103	O
mg	O
without	O
symptomatic	O
hypotension	O
.	O
Iron	O
deficiency	O
was	O
also	O
corrected	O
with	O
the	O
administration	O
of	O
iron	B-FARMACO
carboxymaltose	I-FARMACO
in	O
the	O
day	O
hospital	O
.	O
At	O
a	O
review	O
after	O
2	O
months	O
,	O
the	O
patient	O
was	O
found	O
to	O
be	O
in	O
functional	O
class	O
I	O
in	O
a	O
situation	O
of	O
euvolemia	O
.	O
Treatment	O
after	O
consultation	O
follow	O
up	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
97	O
103	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
,	O
carvedilol	B-FARMACO
25	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
,	O
ivabradine	B-FARMACO
5	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
2	O
tablet	O
at	O
breakfast	O
spironolactone	B-FARMACO
25	O
mg	O
2	O
tablets	O
at	O
dinner	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
tablet	O
at	O
breakfast	O
.	O
DIAGNOSIS	O
HF	O
in	O
a	O
patient	O
with	O
non	O
ischaemic	O
dilated	O
cardiomyopathy	O
with	O
severe	O
biventricular	O
systolic	O
dysfunction	O
and	O
criteria	O
for	O
non	O
compaction	O
cardiomyopathy	O
.	O
NYHA	O
functional	O
class	O
I	O
.	O
Euvolemic	O
state	O
.	O
ICD	O
carrier	O
in	O
primary	O
prevention	O
.	O

A	O
35	O
year	O
old	O
man	O
with	O
a	O
history	O
of	O
upper	O
gastrointestinal	O
bleeding	O
,	O
beta	O
thalassaemia	O
and	O
spondyloarthropathy	O
,	O
under	O
treatment	O
with	O
certolizumab	B-FARMACO
anti	O
tumour	O
necrosis	O
factor	O
TNF	O
drug	O
,	O
who	O
came	O
to	O
the	O
emergency	O
department	O
for	O
congruent	O
left	O
lower	O
homonymous	O
quadrantanopsia	O
,	O
with	O
no	O
other	O
clinical	O
manifestations	O
.	O
Brain	O
computed	O
tomography	O
CT	O
showed	O
a	O
right	O
arachnoid	O
cyst	O
as	O
an	O
incidental	O
finding	O
.	O
With	O
a	O
murmur	O
on	O
auscultation	O
,	O
transthoracic	O
echocardiography	O
TTE	O
was	O
performed	O
,	O
diagnosing	O
a	O
mass	O
on	O
the	O
right	O
coronary	O
leaflet	O
,	O
with	O
a	O
friable	O
surface	O
,	O
which	O
generated	O
a	O
double	O
aortic	O
lesion	O
moderate	O
stenosis	O
and	O
severe	O
insufficiency	O
.	O
Laboratory	O
tests	O
showed	O
leukocytosis	O
with	O
neutrophilia	O
.	O
Suspecting	O
IE	O
,	O
he	O
underwent	O
urgent	O
surgery	O
with	O
implantation	O
of	O
a	O
24	O
mm	O
bidisc	O
mechanical	O
aortic	O
prosthesis	O
.	O
There	O
were	O
firm	O
pericardial	O
adhesions	O
.	O
The	O
aortic	O
valve	O
was	O
trivalve	O
,	O
dysplastic	O
,	O
with	O
severe	O
thickening	O
of	O
the	O
right	O
coronary	O
leaflet	O
,	O
yellowish	O
parduous	O
in	O
colour	O
,	O
with	O
necrotic	O
material	O
inside	O
.	O
The	O
left	O
coronary	O
leaflet	O
had	O
a	O
similar	O
implant	O
in	O
proximity	O
to	O
the	O
commissure	O
with	O
the	O
non	O
coronary	O
leaflet	O
.	O
The	O
non	O
coronary	O
leaflet	O
was	O
thickened	O
and	O
appeared	O
hypoplastic	O
.	O
The	O
postoperative	O
course	O
was	O
characterised	O
by	O
the	O
need	O
for	O
reoperation	O
due	O
to	O
late	O
cardiac	O
tamponade	O
,	O
without	O
a	O
bleeding	O
site	O
.	O
Left	O
inferior	O
quadrantanopsia	O
persisted	O
,	O
with	O
normal	O
fundus	O
and	O
brain	O
CT	O
with	O
right	O
occipital	O
hypodensity	O
due	O
to	O
subacute	O
established	O
infarction	O
in	O
the	O
territory	O
of	O
the	O
right	O
posterior	O
cerebral	O
artery	O
,	O
without	O
mass	O
effect	O
or	O
haemorrhagic	O
transformation	O
.	O
Although	O
all	O
microbiological	O
cultures	O
were	O
negative	O
pre	O
,	O
intra	O
and	O
postoperatively	O
,	O
empirical	O
antibiotic	O
therapy	O
was	O
maintained	O
with	O
vancomycin	B-FARMACO
and	O
gentamicin	B-FARMACO
,	O
which	O
was	O
subsequently	O
de	O
escalated	O
to	O
ceftriaxone	B-FARMACO
.	O
The	O
patient	O
had	O
not	O
received	O
antibiotic	O
treatment	O
prior	O
to	O
diagnosis	O
that	O
could	O
have	O
decapitated	O
the	O
blood	O
cultures	O
.	O
Pathology	O
showed	O
polymorphonuclear	O
and	O
histiocyte	O
aggregates	O
surrounding	O
an	O
amorphous	O
basophilic	O
substance	O
,	O
without	O
confirmation	O
of	O
PAS	O
positive	O
material	O
.	O
The	O
control	O
TTE	O
was	O
unaltered	O
,	O
and	O
the	O
patient	O
was	O
discharged	O
with	O
outpatient	O
follow	O
up	O
due	O
to	O
complications	O
in	O
the	O
healing	O
of	O
the	O
surgical	O
wound	O
.	O
He	O
was	O
admitted	O
again	O
at	O
the	O
fourth	O
postoperative	O
month	O
due	O
to	O
complete	O
atrioventricular	O
block	O
,	O
requiring	O
permanent	O
pacemaker	O
implantation	O
.	O
TTE	O
and	O
transesophageal	O
echocardiography	O
TEE	O
showed	O
an	O
oscillating	O
mass	O
in	O
the	O
left	O
ventricular	O
outflow	O
tract	O
in	O
the	O
most	O
anterior	O
aspect	O
of	O
the	O
ventricular	O
side	O
of	O
the	O
prosthesis	O
,	O
without	O
clear	O
images	O
of	O
abscess	O
.	O
Presence	O
of	O
mild	O
aortic	O
regurgitation	O
that	O
could	O
not	O
be	O
correctly	O
defined	O
as	O
intra	O
or	O
periprosthetic	O
due	O
to	O
the	O
acoustic	O
shadow	O
of	O
the	O
prosthesis	O
.	O
In	O
the	O
thoracic	O
CT	O
scan	O
,	O
dehiscence	O
of	O
the	O
prosthesis	O
at	O
the	O
level	O
of	O
the	O
area	O
between	O
the	O
non	O
coronary	O
sinus	O
and	O
the	O
right	O
coronary	O
sinus	O
,	O
with	O
saccular	O
dilatation	O
of	O
the	O
aorta	O
.	O
In	O
view	O
of	O
the	O
suspicion	O
of	O
early	O
prosthetic	O
endocarditis	O
with	O
pseudoaneurysm	O
,	O
it	O
was	O
decided	O
to	O
re	O
intervene	O
.	O
Dehiscence	O
was	O
found	O
in	O
the	O
non	O
coronary	O
sinus	O
area	O
,	O
with	O
disruption	O
of	O
the	O
native	O
aortic	O
annulus	O
and	O
a	O
subannular	O
pseudoaneurysmal	O
cavity	O
.	O
After	O
explantation	O
of	O
the	O
prosthesis	O
,	O
the	O
entire	O
native	O
annulus	O
was	O
affected	O
,	O
with	O
devitalised	O
tissue	O
and	O
sloughing	O
,	O
requiring	O
complete	O
aortic	O
transection	O
for	O
a	O
successful	O
approach	O
.	O
The	O
pseudoaneurysm	O
was	O
repaired	O
with	O
a	O
pericardial	O
patch	O
,	O
the	O
entire	O
circumference	O
of	O
the	O
native	O
annulus	O
was	O
reconstructed	O
with	O
the	O
same	O
and	O
a	O
new	O
18	O
mm	O
bidisc	O
mechanical	O
prosthesis	O
was	O
implanted	O
.	O
Revision	O
for	O
late	O
cardiac	O
tamponade	O
,	O
as	O
in	O
the	O
first	O
operation	O
,	O
with	O
no	O
bleeding	O
point	O
observed	O
.	O
He	O
completed	O
a	O
new	O
course	O
of	O
empirical	O
antibiotherapy	O
with	O
daptomycin	B-FARMACO
and	O
cloxacillin	B-FARMACO
.	O
The	O
case	O
was	O
re	O
evaluated	O
jointly	O
with	O
Rheumatology	O
and	O
Infectious	O
Diseases	O
.	O
Certolizumab	B-FARMACO
had	O
been	O
withdrawn	O
after	O
the	O
first	O
operation	O
as	O
a	O
possible	O
cause	O
of	O
alterations	O
in	O
healing	O
and	O
immunity	O
.	O
All	O
requested	O
microbiological	O
cultures	O
,	O
serology	O
and	O
nucleic	O
acid	O
detection	O
were	O
negative	O
,	O
as	O
in	O
the	O
first	O
episode	O
.	O
Detection	O
of	O
Tropheryma	O
whipplei	O
T	O
.	O
whipplei	O
in	O
the	O
surgical	O
specimen	O
,	O
saliva	O
,	O
faeces	O
and	O
duodenal	O
biopsy	O
was	O
negative	O
.	O
Cytomegalovirus	O
was	O
also	O
not	O
detected	O
in	O
gastric	O
biopsy	O
.	O
A	O
prolonged	O
platelet	O
aggregation	O
time	O
was	O
found	O
,	O
with	O
no	O
other	O
alterations	O
in	O
haemostasis	O
.	O
Absence	O
of	O
autoimmunity	O
markers	O
.	O
Subsequent	O
TTE	O
detected	O
only	O
moderately	O
elevated	O
prosthesis	O
gradients	O
.	O
Five	O
months	O
after	O
the	O
second	O
operation	O
,	O
the	O
patient	O
attended	O
the	O
emergency	O
department	O
for	O
progressive	O
dyspnoea	O
with	O
significant	O
congestive	O
symptoms	O
.	O
TTE	O
with	O
very	O
severe	O
aortic	O
regurgitation	O
and	O
reappearance	O
of	O
extensive	O
periprosthetic	O
pseudoaneurysm	O
causing	O
prosthesis	O
nodding	O
.	O
Dilated	O
left	O
ventricle	O
,	O
but	O
with	O
apparently	O
preserved	O
systolic	O
function	O
.	O
The	O
patient	O
underwent	O
urgent	O
surgery	O
,	O
with	O
aortic	O
homograft	O
implantation	O
in	O
the	O
subcoronary	O
position	O
and	O
closure	O
of	O
the	O
pseudoaneurysm	O
with	O
the	O
same	O
stitches	O
.	O
Although	O
the	O
intraoperative	O
TEE	O
showed	O
mild	O
aortic	O
insufficiency	O
,	O
the	O
subsequent	O
TTE	O
showed	O
a	O
probably	O
moderate	O
intrahomograft	O
insufficiency	O
,	O
difficult	O
to	O
quantify	O
as	O
it	O
was	O
an	O
eccentric	O
jet	O
,	O
with	O
no	O
limitation	O
in	O
the	O
mobility	O
of	O
the	O
leaflets	O
at	O
its	O
opening	O
.	O
Dilated	O
left	O
ventricle	O
with	O
moderate	O
severe	O
depression	O
of	O
function	O
.	O
Reproduction	O
of	O
a	O
cavity	O
in	O
the	O
aortic	O
root	O
.	O
It	O
was	O
decided	O
to	O
complete	O
a	O
new	O
regimen	O
of	O
empirical	O
antibiotic	O
therapy	O
and	O
discharge	O
with	O
outpatient	O
control	O
to	O
repeat	O
complementary	O
tests	O
,	O
while	O
awaiting	O
the	O
results	O
of	O
cultures	O
.	O
The	O
TEE	O
at	O
one	O
month	O
after	O
the	O
last	O
intervention	O
showed	O
the	O
insufficiency	O
with	O
an	O
eccentric	O
jet	O
in	O
the	O
anterior	O
direction	O
,	O
at	O
least	O
moderate	O
.	O
In	O
the	O
aortic	O
root	O
there	O
was	O
a	O
cavity	O
with	O
systolic	O
expansion	O
compatible	O
with	O
pseudoaneurysm	O
,	O
confirmed	O
by	O
thoracic	O
CT	O
.	O
The	O
polymerase	O
chain	O
reaction	O
of	O
the	O
surgical	O
specimen	O
from	O
the	O
latter	O
procedure	O
was	O
positive	O
for	O
T	O
.	O
whipplei	O
.	O
Given	O
the	O
clinical	O
stability	O
and	O
complexity	O
of	O
the	O
case	O
,	O
it	O
was	O
decided	O
to	O
start	O
treatment	O
for	O
Whipple	O
's	O
disease	O
with	O
doxycycline	B-FARMACO
and	O
hydroxychloroquine	B-FARMACO
,	O
and	O
outpatient	O
monitoring	O
.	O
Currently	O
,	O
in	O
the	O
sixth	O
postoperative	O
month	O
,	O
the	O
clinical	O
situation	O
is	O
stationary	O
,	O
asymptomatic	O
for	O
dyspnoea	O
or	O
other	O
cardiorespiratory	O
symptoms	O
.	O
A	O
new	O
TTE	O
and	O
CT	O
scan	O
showed	O
no	O
changes	O
with	O
respect	O
to	O
previous	O
scans	O
,	O
and	O
conservative	O
management	O
was	O
chosen	O
for	O
the	O
time	O
being	O
,	O
given	O
the	O
complexity	O
of	O
the	O
case	O
.	O
IE	O
is	O
a	O
serious	O
disease	O
,	O
which	O
requires	O
rapid	O
management	O
based	O
on	O
a	O
diagnosis	O
of	O
suspicion	O
for	O
optimal	O
medical	O
and	O
surgical	O
treatment	O
,	O
with	O
decisions	O
made	O
by	O
a	O
multidisciplinary	O
team	O
.	O
It	O
may	O
be	O
a	O
consequence	O
of	O
previous	O
antibiotic	O
treatment	O
or	O
due	O
to	O
fungi	O
and	O
bacteria	O
of	O
demanding	O
culture	O
.	O
Microorganisms	O
requiring	O
serology	O
for	O
diagnosis	O
,	O
such	O
as	O
Coxiella	O
burnetii	O
,	O
Bartonella	O
,	O
Aspergillus	O
,	O
Mycoplasma	O
pneumoniae	O
,	O
Brucella	O
and	O
Legionella	O
pneumophila	O
,	O
and	O
microorganisms	O
requiring	O
polymerase	O
chain	O
reaction	O
tests	O
such	O
as	O
T	O
.	O
whipplei	O
,	O
Bartonella	O
and	O
fungi	O
stand	O
out	O
.	O

Male	O
patient	O
,	O
70	O
years	O
of	O
age	O
,	O
white	O
,	O
agricultural	O
worker	O
,	O
with	O
no	O
remarkable	O
pathological	O
history	O
.	O
He	O
presented	O
with	O
fever	O
,	O
vomiting	O
and	O
dehydration	O
,	O
interpreted	O
as	O
bacterial	O
bronchopneumonia	O
,	O
for	O
which	O
he	O
was	O
treated	O
with	O
antimicrobials	O
.	O
Two	O
weeks	O
later	O
,	O
he	O
complained	O
of	O
general	O
malaise	O
,	O
malaise	O
and	O
dizziness	O
.	O
He	O
was	O
re	O
evaluated	O
and	O
a	O
second	O
degree	O
atrioventricular	O
block	O
was	O
detected	O
,	O
so	O
the	O
heart	O
rate	O
was	O
regulated	O
with	O
a	O
transient	O
pacemaker	O
PM	O
,	O
to	O
later	O
implant	O
the	O
permanent	O
generator	O
.	O
The	O
referred	O
symptoms	O
worsened	O
and	O
dyspnoea	O
appeared	O
.	O
A	O
transthoracic	O
echocardiographic	O
TTE	O
study	O
detected	O
an	O
intracardiac	O
mass	O
and	O
he	O
was	O
referred	O
to	O
our	O
centre	O
.	O
Physical	O
examination	O
revealed	O
a	O
diminished	O
vesicular	O
murmur	O
towards	O
the	O
lung	O
bases	O
,	O
with	O
wheezing	O
,	O
and	O
a	O
diastolic	O
murmur	O
towards	O
the	O
tip	O
that	O
appeared	O
to	O
change	O
with	O
changes	O
in	O
the	O
patient	O
's	O
position	O
.	O
The	O
baseline	O
electrocardiogram	O
showed	O
a	O
rhythm	O
of	O
MP	O
to	O
80	O
beats	O
per	O
minute	O
,	O
and	O
the	O
chest	O
X	O
ray	O
showed	O
a	O
small	O
left	O
pleural	O
effusion	O
with	O
pulmonary	O
oedema	O
.	O
There	O
was	O
anaemia	O
and	O
mild	O
leukocytosis	O
with	O
a	O
predominance	O
of	O
polymorphonuclear	O
cells	O
.	O
Transesophageal	O
echocardiography	O
TEE	O
showed	O
the	O
tumour	O
mass	O
attached	O
to	O
the	O
anterior	O
mitral	O
leaflet	O
on	O
its	O
atrial	O
side	O
,	O
which	O
prolapsed	O
into	O
the	O
left	O
ventricle	O
LV	O
in	O
diastole	O
,	O
producing	O
a	O
peak	O
transvalvular	O
mitral	O
diastolic	O
gradient	O
of	O
20	O
mmHg	O
,	O
and	O
a	O
mean	O
of	O
10	O
mmHg	O
,	O
with	O
a	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
of	O
60	O
.	O
5	O
.	O
Coronary	O
angiography	O
showed	O
no	O
significant	O
coronary	O
lesions	O
,	O
and	O
the	O
patient	O
was	O
prepared	O
for	O
urgent	O
surgery	O
.	O
In	O
the	O
operating	O
theatre	O
,	O
after	O
longitudinal	O
median	O
sternotomy	O
,	O
arterial	O
and	O
venous	O
cannulation	O
for	O
extracorporeal	O
circulation	O
ECC	O
,	O
right	O
atriotomy	O
,	O
aortic	O
clamping	O
and	O
anoxic	O
arrest	O
with	O
isothermal	O
haematic	O
cardioplegia	O
,	O
the	O
interatrial	O
septum	O
AIS	O
was	O
opened	O
with	O
extension	O
to	O
the	O
roof	O
of	O
the	O
left	O
atrium	O
LA	O
.	O
This	O
exposed	O
a	O
yellowish	O
brown	O
oval	O
tumour	O
mass	O
,	O
approximately	O
8	O
cm	O
in	O
diameter	O
,	O
with	O
an	O
implantation	O
base	O
extending	O
into	O
the	O
mitral	O
annulus	O
involving	O
its	O
anterior	O
leaflet	O
and	O
causing	O
loss	O
of	O
mitral	O
annulus	O
integrity	O
.	O
The	O
tumour	O
was	O
completely	O
resected	O
next	O
to	O
the	O
mitral	O
leaflet	O
and	O
a	O
Sorin	O
Carbomedics	O
Standard	O
25	O
mm	O
bi	O
disc	O
mechanical	O
prosthesis	O
was	O
implanted	O
.	O
The	O
procedure	O
was	O
completed	O
in	O
a	O
conventional	O
manner	O
,	O
without	O
difficulties	O
,	O
using	O
87	O
minutes	O
of	O
aortic	O
clamping	O
and	O
120	O
minutes	O
of	O
cardiopulmonary	O
bypass	O
.	O
He	O
was	O
extubated	O
2	O
hours	O
after	O
arrival	O
at	O
the	O
Surgical	O
Intensive	O
Care	O
Unit	O
,	O
transferred	O
to	O
the	O
conventional	O
ward	O
on	O
the	O
second	O
day	O
,	O
and	O
discharged	O
on	O
the	O
sixth	O
postoperative	O
day	O
.	O
At	O
three	O
months	O
follow	O
up	O
the	O
patient	O
was	O
asymptomatic	O
,	O
in	O
sinus	O
rhythm	O
inhibited	O
PM	O
and	O
TTE	O
showed	O
a	O
left	O
LA	O
free	O
of	O
tumour	O
masses	O
,	O
a	O
normofunctioning	O
mechanical	O
prosthesis	O
,	O
with	O
a	O
transvalvular	O
gradient	O
of	O
12	O
mmHg	O
and	O
LVEF	O
of	O
58	O
.	O

A	O
77	O
year	O
old	O
male	O
patient	O
with	O
a	O
clinical	O
history	O
of	O
arterial	O
hypertension	O
,	O
permanent	O
atrial	O
fibrillation	O
with	O
anticoagulation	O
,	O
and	O
a	O
surgical	O
history	O
of	O
implantation	O
of	O
a	O
definitive	O
endocavitary	O
VVI	O
pacemaker	O
several	O
years	O
ago	O
.	O
The	O
patient	O
suddenly	O
presented	O
with	O
language	O
impairment	O
,	O
characterised	O
by	O
difficulty	O
in	O
uttering	O
and	O
understanding	O
language	O
,	O
and	O
behavioural	O
changes	O
,	O
for	O
which	O
he	O
was	O
taken	O
to	O
the	O
emergency	O
department	O
.	O
Physical	O
examination	O
revealed	O
a	O
fever	O
of	O
38	O
.	O
1	O
C	O
.	O
Pulmonary	O
auscultation	O
showed	O
slight	O
crackles	O
,	O
predominantly	O
in	O
the	O
left	O
base	O
,	O
with	O
no	O
signs	O
of	O
bronchospasm	O
.	O
Cardiac	O
auscultation	O
revealed	O
protodiastolic	O
acoustic	O
vibration	O
in	O
the	O
pulmonary	O
focus	O
.	O
The	O
neurological	O
examination	O
showed	O
the	O
patient	O
to	O
be	O
conscious	O
,	O
not	O
speaking	O
and	O
obeying	O
simple	O
commands	O
.	O
A	O
CT	O
scan	O
of	O
the	O
brain	O
showed	O
left	O
frontal	O
intraparenchymal	O
haemorrhage	O
and	O
doubtful	O
left	O
fronto	O
parietal	O
hypodensity	O
.	O
Chest	O
X	O
ray	O
showed	O
left	O
pleural	O
effusion	O
.	O
Blood	O
cultures	O
showed	O
S	O
.	O
bovis	O
type	O
I	O
gallolyticus	O
.	O
To	O
rule	O
out	O
possible	O
endocarditis	O
,	O
an	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
aortic	O
sclerosis	O
with	O
double	O
aortic	O
lesion	O
,	O
nodular	O
and	O
mobile	O
images	O
that	O
prolapse	O
in	O
diastole	O
to	O
LV	O
outflow	O
chambers	O
of	O
half	O
a	O
centimetre	O
in	O
diameter	O
,	O
indicative	O
of	O
aortic	O
vegetation	O
.	O
Preserved	O
LV	O
systolic	O
function	O
.	O
2	O
cm	O
1	O
.	O
1	O
cm	O
image	O
in	O
hypermobile	O
pulmonary	O
valve	O
prolapsing	O
in	O
protodiastole	O
into	O
the	O
right	O
ventricular	O
outflow	O
tract	O
and	O
generating	O
the	O
protodiastolic	O
acoustic	O
vibration	O
described	O
on	O
auscultation	O
.	O
The	O
case	O
was	O
referred	O
to	O
the	O
Cardiac	O
Surgery	O
Department	O
;	O
due	O
to	O
the	O
context	O
of	O
his	O
haemorrhagic	O
stroke	O
,	O
we	O
decided	O
to	O
wait	O
at	O
least	O
4	O
weeks	O
with	O
antibiotic	O
treatment	O
before	O
performing	O
surgery	O
.	O
During	O
his	O
hospitalisation	O
the	O
patient	O
remained	O
stable	O
,	O
aortic	O
and	O
pulmonary	O
vegetations	O
persisted	O
in	O
the	O
control	O
echocardiograms	O
.	O
A	O
thoraco	O
abdominal	O
CT	O
scan	O
was	O
performed	O
;	O
the	O
chest	O
showed	O
a	O
small	O
bilateral	O
pleural	O
effusion	O
and	O
a	O
probable	O
repletion	O
defect	O
of	O
7	O
.	O
5	O
mm	O
,	O
compatible	O
with	O
vegetation	O
at	O
the	O
level	O
of	O
the	O
aortic	O
valve	O
.	O
Its	O
appearance	O
is	O
rounded	O
and	O
suggests	O
a	O
simple	O
cyst	O
or	O
hamartoma	O
rather	O
than	O
an	O
infarct	O
;	O
multiple	O
diverticula	O
are	O
observed	O
in	O
the	O
colon	O
,	O
and	O
colonoscopy	O
is	O
recommended	O
.	O
In	O
the	O
colonoscopy	O
,	O
diverticula	O
and	O
polyps	O
are	O
found	O
;	O
polypectomy	O
is	O
performed	O
.	O
The	O
results	O
of	O
the	O
pathological	O
anatomy	O
report	O
a	O
tubulovillous	O
adenoma	O
with	O
low	O
grade	O
dysplasia	O
.	O
After	O
4	O
weeks	O
of	O
antibiotic	O
treatment	O
,	O
the	O
patient	O
underwent	O
surgery	O
.	O

A	O
48	O
year	O
old	O
man	O
with	O
no	O
medical	O
history	O
presented	O
with	O
dyspnoea	O
on	O
slight	O
exertion	O
and	O
malleolar	O
oedema	O
of	O
15	O
days	O
'	O
duration	O
.	O
Examination	O
showed	O
bibasal	O
crackles	O
and	O
blood	O
tests	O
showed	O
11	O
,	O
600	O
leukocytes	O
with	O
78	O
.	O
5	O
segmented	O
,	O
13	O
.	O
4	O
lymphocytes	O
and	O
7	O
.	O
2	O
monocytes	O
,	O
in	O
addition	O
to	O
normal	O
biomarkers	O
.	O
The	O
electrocardiogram	O
showed	O
previously	O
known	O
left	O
bundle	O
branch	O
block	O
.	O
Chest	O
X	O
ray	O
revealed	O
cardiomegaly	O
and	O
bilateral	O
interstitial	O
infiltrates	O
and	O
chest	O
CT	O
showed	O
diffuse	O
interstitial	O
thickening	O
over	O
"	O
ground	O
glass	O
"	O
images	O
"	O
crazy	O
paving	O
"	O
pattern	O
.	O
Given	O
the	O
findings	O
suggestive	O
of	O
interstitial	O
pneumonitis	O
,	O
it	O
was	O
decided	O
not	O
to	O
initiate	O
antibiotic	O
therapy	O
.	O
Transthoracic	O
echocardiography	O
revealed	O
ventricular	O
dilatation	O
with	O
severe	O
systolic	O
dysfunction	O
,	O
so	O
he	O
was	O
transferred	O
to	O
cardiology	O
.	O
Coronary	O
angiography	O
showed	O
severe	O
lesions	O
in	O
the	O
distal	O
anterior	O
descending	O
,	O
proximal	O
circumflex	O
and	O
acute	O
marginal	O
arteries	O
,	O
which	O
did	O
not	O
justify	O
myocardial	O
dysfunction	O
.	O
Cardiac	O
MRI	O
was	O
performed	O
one	O
month	O
after	O
symptom	O
onset	O
and	O
showed	O
anterolateral	O
hyperintensity	O
with	O
late	O
subepicardial	O
enhancement	O
,	O
left	O
ventricular	O
dilatation	O
and	O
LVEF	O
of	O
13	O
,	O
compatible	O
with	O
subacute	O
myocarditis	O
.	O
Anti	O
CMV	O
IgM	O
and	O
IgG	O
antibodies	O
and	O
anti	O
CMV	O
PCR	O
were	O
positive	O
,	O
so	O
treatment	O
with	O
oral	O
valganciclovir	B-FARMACO
was	O
started	O
for	O
two	O
weeks	O
.	O
He	O
progressed	O
satisfactorily	O
and	O
three	O
months	O
later	O
remained	O
clinically	O
stable	O
,	O
with	O
baseline	O
NYHA	O
class	O
II	O
dyspnoea	O
and	O
LVEF	O
of	O
45	O
according	O
to	O
control	O
echocardiography	O
.	O

We	O
present	O
the	O
case	O
of	O
an	O
80	O
year	O
old	O
patient	O
with	O
endocarditis	O
on	O
a	O
biological	O
prosthetic	O
valve	O
,	O
of	O
uncertain	O
aetiology	O
,	O
which	O
caused	O
an	O
abscess	O
on	O
the	O
valve	O
with	O
dehiscence	O
of	O
the	O
annulus	O
.	O
The	O
patient	O
had	O
no	O
known	O
allergies	O
.	O
He	O
had	O
been	O
an	O
ex	O
smoker	O
of	O
20	O
cigarettes	O
day	O
for	O
more	O
than	O
20	O
years	O
,	O
and	O
consumed	O
2	O
glasses	O
of	O
wine	O
per	O
day	O
.	O
Independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
.	O
Two	O
years	O
ago	O
he	O
went	O
to	O
the	O
emergency	O
department	O
of	O
his	O
reference	O
hospital	O
for	O
progressive	O
dyspnoea	O
to	O
the	O
point	O
of	O
minimal	O
effort	O
.	O
At	O
that	O
time	O
,	O
the	O
patient	O
had	O
a	O
personal	O
history	O
of	O
glaucoma	O
,	O
hyperuricaemia	O
,	O
DM	O
II	O
and	O
hypercholesterolaemia	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
performed	O
during	O
admission	O
revealed	O
a	O
silent	O
myocardial	O
infarction	O
in	O
the	O
inferolateral	O
wall	O
akinesia	O
with	O
thinning	O
of	O
the	O
wall	O
,	O
moderate	O
mitral	O
insufficiency	O
,	O
dilated	O
left	O
ventricle	O
LV	O
end	O
diastolic	O
volume	O
155	O
ml	O
and	O
hypertrophic	O
interventricular	O
septum	O
in	O
diastole	O
13	O
mm	O
with	O
a	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
of	O
60	O
by	O
the	O
Simpson	O
biplanar	O
method	O
.	O
He	O
was	O
discharged	O
with	O
a	O
diagnosis	O
of	O
emphysema	O
type	O
COPD	O
with	O
bilateral	O
subpleural	O
pulmonary	O
bullae	O
FEV1	O
FVC	O
40	O
.	O
94	O
post	O
BD	O
and	O
established	O
infarction	O
of	O
uncertain	O
chronology	O
inferolaterally	O
.	O
At	O
the	O
one	O
year	O
follow	O
up	O
TTE	O
,	O
severe	O
eccentric	O
mitral	O
regurgitation	O
was	O
detected	O
with	O
a	O
drop	O
in	O
ejection	O
fraction	O
and	O
worsening	O
dyspnoea	O
LVEF	O
47	O
by	O
Simpson	O
biplanar	O
.	O
The	O
patient	O
was	O
proposed	O
for	O
cardiac	O
surgery	O
.	O
Preoperative	O
coronary	O
angiography	O
showed	O
significant	O
2	O
vessel	O
coronary	O
artery	O
disease	O
severe	O
stenosis	O
in	O
the	O
LAD	O
and	O
proximal	O
DC	O
,	O
and	O
he	O
underwent	O
aortocoronary	O
bypass	O
left	O
internal	O
mammary	O
to	O
anterior	O
descending	O
,	O
and	O
replacement	O
of	O
the	O
mitral	O
valve	O
with	O
a	O
Labcor	O
No	O
.	O
31	O
biological	O
prosthesis	O
,	O
preserving	O
the	O
posterior	O
leaflet	O
of	O
the	O
native	O
valve	O
non	O
revascularised	O
DC	O
,	O
non	O
viable	O
territory	O
.	O
In	O
the	O
immediate	O
postoperative	O
period	O
he	O
presented	O
a	O
postcardiotomy	O
syndrome	O
with	O
good	O
response	O
to	O
depletive	O
and	O
anti	O
inflammatory	O
treatment	O
colchicine	B-FARMACO
for	O
6	O
months	O
.	O
The	O
patient	O
remained	O
asymptomatic	O
.	O
In	O
the	O
control	O
echocardiography	O
6	O
months	O
after	O
surgery	O
,	O
a	O
19	O
x	O
11	O
mm	O
thrombus	O
was	O
detected	O
on	O
the	O
atrial	O
side	O
of	O
the	O
septal	O
leaflet	O
of	O
the	O
biological	O
prosthesis	O
.	O
Anticoagulation	O
therapy	O
was	O
optimised	O
.	O
Nineteen	O
days	O
after	O
admission	O
,	O
he	O
presented	O
a	O
fever	O
peak	O
of	O
up	O
to	O
38	O
.	O
5	O
oC	O
with	O
no	O
apparent	O
focus	O
.	O
Serial	O
cultures	O
were	O
taken	O
all	O
negative	O
and	O
empirical	O
antibiotic	O
treatment	O
was	O
prescribed	O
for	O
10	O
days	O
.	O
25	O
days	O
after	O
optimisation	O
of	O
anticoagulant	O
treatment	O
,	O
an	O
echocardiographic	O
check	O
up	O
was	O
performed	O
and	O
it	O
appeared	O
that	O
the	O
thrombus	O
was	O
no	O
longer	O
present	O
.	O
Two	O
months	O
later	O
the	O
patient	O
presented	O
with	O
an	O
episode	O
of	O
weakness	O
,	O
unilateral	O
loss	O
of	O
vision	O
and	O
nausea	O
.	O
During	O
his	O
admission	O
,	O
the	O
reappearance	O
of	O
the	O
intraprosthetic	O
thrombus	O
was	O
observed	O
,	O
and	O
anticoagulant	O
treatment	O
was	O
optimised	O
again	O
inflammation	O
parameters	O
and	O
serial	O
cultures	O
were	O
negative	O
.	O
Before	O
discharge	O
,	O
he	O
presented	O
an	O
episode	O
of	O
isolated	O
febrile	O
fever	O
of	O
37	O
.	O
4	O
oC	O
,	O
so	O
serial	O
cultures	O
were	O
repeated	O
and	O
TEE	O
was	O
repeated	O
,	O
showing	O
a	O
sessile	O
and	O
mobile	O
endocardial	O
wart	O
on	O
the	O
anterior	O
leaflet	O
of	O
the	O
mitral	O
valve	O
,	O
measuring	O
8	O
.	O
5	O
mm	O
.	O
In	O
the	O
area	O
where	O
the	O
thrombus	O
had	O
developed	O
,	O
a	O
new	O
finding	O
was	O
detected	O
pseudoaneurysm	O
of	O
the	O
mitral	O
valve	O
annulus	O
measuring	O
20	O
x	O
6	O
mm	O
high	O
suspicion	O
of	O
endocardial	O
process	O
.	O
Given	O
the	O
suspicion	O
of	O
infective	O
endocarditis	O
in	O
the	O
TEE	O
,	O
empirical	O
antibiotic	O
treatment	O
was	O
started	O
.	O
Cultures	O
were	O
negative	O
,	O
as	O
were	O
serologies	O
and	O
PCR	O
.	O
A	O
PET	O
CT	O
study	O
was	O
performed	O
which	O
showed	O
images	O
suggestive	O
of	O
infective	O
endocarditis	O
on	O
the	O
mitral	O
prosthetic	O
valve	O
.	O
In	O
addition	O
,	O
a	O
follow	O
up	O
TEE	O
performed	O
1	O
month	O
later	O
showed	O
a	O
new	O
onset	O
mitral	O
valve	O
annulus	O
perforation	O
severe	O
periprosthetic	O
insufficiency	O
.	O
The	O
patient	O
required	O
further	O
depletive	O
treatment	O
.	O
Given	O
the	O
diagnosis	O
of	O
endocarditis	O
with	O
negative	O
blood	O
cultures	O
,	O
in	O
addition	O
to	O
repeating	O
the	O
different	O
cultures	O
,	O
serology	O
for	O
Bartonella	O
,	O
Brucella	O
,	O
Chlamydia	O
,	O
Coxiella	O
,	O
Legionella	O
,	O
Mycoplasma	O
and	O
Borrelia	O
was	O
performed	O
.	O
Serology	O
for	O
Bartonella	O
henselae	O
was	O
positive	O
on	O
two	O
occasions	O
IgG	O
1	O
2048	O
,	O
IgM	O
1	O
40	O
.	O
In	O
view	O
of	O
these	O
results	O
,	O
antibiotic	O
treatment	O
was	O
adjusted	O
.	O
In	O
addition	O
,	O
given	O
the	O
presence	O
of	O
a	O
local	O
complication	O
in	O
early	O
prosthetic	O
endocarditis	O
,	O
the	O
patient	O
was	O
proposed	O
for	O
surgery	O
.	O
The	O
patient	O
decided	O
not	O
to	O
undergo	O
surgery	O
.	O
For	O
this	O
reason	O
,	O
oral	O
doxycycline	B-FARMACO
treatment	O
was	O
maintained	O
indefinitely	O
B	O
.	O
henseale	O
.	O
A	O
control	O
transthoracic	O
echocardiography	O
performed	O
1	O
month	O
after	O
the	O
start	O
of	O
treatment	O
revealed	O
a	O
mitral	O
perivalvular	O
abscess	O
with	O
partial	O
"	O
disinsertion	O
"	O
of	O
the	O
mitral	O
annulus	O
rocking	O
motion	O
.	O
Given	O
the	O
patient	O
's	O
decision	O
,	O
medical	O
treatment	O
was	O
optimised	O
again	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
48	O
year	O
old	O
woman	O
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
under	O
medical	O
treatment	O
.	O
Ex	O
smoker	O
accumulated	O
20	O
packs	O
year	O
.	O
Overweight	O
body	O
mass	O
index	O
29	O
kg	O
m2	O
.	O
Habitual	O
ethanol	O
consumer	O
20	O
grams	O
day	O
.	O
Cardiological	O
history	O
Bicuspid	O
aortic	O
valve	O
diagnosed	O
in	O
childhood	O
due	O
to	O
murmur	O
,	O
with	O
evolution	O
towards	O
severe	O
aortic	O
stenosis	O
.	O
In	O
2005	O
aortic	O
valve	O
replacement	O
St	O
Jude	O
Regent	O
No19	O
prosthesis	O
and	O
30	O
mm	O
ascending	O
aorta	O
graft	O
.	O
Subsequent	O
follow	O
up	O
in	O
cardiology	O
outpatient	O
clinic	O
with	O
good	O
functional	O
class	O
NYHA	O
I	O
II	O
and	O
reporting	O
occasional	O
palpitations	O
.	O
The	O
last	O
echocardiogram	O
in	O
2016	O
showed	O
preserved	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
and	O
a	O
normofunctioning	O
prosthesis	O
although	O
with	O
slightly	O
elevated	O
gradients	O
maximum	O
gradient	O
of	O
47	O
and	O
mean	O
gradient	O
of	O
24	O
,	O
estimated	O
aortic	O
valve	O
area	O
AVA	O
of	O
1	O
.	O
5	O
cm2	O
.	O
Other	O
history	O
Anxiety	O
depression	O
disorder	O
to	O
mental	O
health	O
follow	O
up	O
since	O
2016	O
.	O
Assessed	O
in	O
neurology	O
in	O
2015	O
for	O
visual	O
phenomena	O
,	O
with	O
small	O
lacunar	O
infarcts	O
and	O
microembolism	O
on	O
cranial	O
magnetic	O
resonance	O
imaging	O
MRI	O
.	O
Bronchial	O
asthma	O
.	O
Psoriasis	O
.	O
Surgical	O
interventions	O
Gastric	O
bypass	O
Roux	O
en	O
Y	O
and	O
eventroplasty	O
as	O
a	O
treatment	O
for	O
morbid	O
obesity	O
in	O
2008	O
.	O
Cholecystectomy	O
and	O
hysterectomy	O
in	O
2009	O
.	O
Home	O
medication	O
Acenocoumarol	B-FARMACO
according	O
to	O
guideline	O
,	O
amiodarone	B-FARMACO
200	O
mg	O
24	O
h	O
,	O
enalapril	B-FARMACO
20	O
mg	O
24	O
h	O
,	O
diltiazem	B-FARMACO
60	O
mg	O
8	O
h	O
,	O
furosemide	B-FARMACO
40	O
mg	O
24	O
h	O
,	O
almotriptan	B-FARMACO
12	O
.	O
5	O
mg	O
24	O
h	O
,	O
escitalopram	B-FARMACO
20	O
mg	O
24	O
h	O
,	O
ketazolam	B-FARMACO
15	O
mg	O
24	O
h	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
24	O
h	O
,	O
formoterol	B-FARMACO
budesonide	I-FARMACO
24	O
h	O
,	O
5	O
mg	O
folic	B-FARMACO
acid	I-FARMACO
24	O
h	O
,	O
lorazepam	B-FARMACO
1	O
mg	O
24	O
h	O
,	O
salbutamol	B-FARMACO
if	O
required	O
.	O
Present	O
illness	O
A	O
48	O
year	O
old	O
woman	O
attended	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
due	O
to	O
sudden	O
dyspnoea	O
in	O
the	O
last	O
few	O
hours	O
,	O
accompanied	O
by	O
dizziness	O
,	O
general	O
malaise	O
and	O
palpitations	O
.	O
She	O
reported	O
good	O
adherence	O
to	O
medical	O
treatment	O
,	O
although	O
higher	O
than	O
usual	O
ethanol	O
consumption	O
in	O
recent	O
months	O
and	O
regular	O
control	O
of	O
anticoagulation	O
levels	O
with	O
significant	O
fluctuations	O
.	O
Physical	O
examination	O
Vital	O
signs	O
blood	O
pressure	O
80	O
40	O
mmHg	O
,	O
heart	O
rate	O
110	O
bpm	O
,	O
saturation	O
90	O
.	O
General	O
condition	O
fair	O
,	O
sweating	O
and	O
respiratory	O
work	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
systolic	O
murmur	O
in	O
aortic	O
focus	O
,	O
no	O
auscultation	O
of	O
prosthetic	O
click	O
.	O
Pulmonary	O
auscultation	O
scattered	O
crackles	O
and	O
rhonchi	O
.	O
Jugular	O
ingurgitation	O
.	O
Absence	O
of	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
CBC	O
haemoglobin	O
14	O
.	O
1	O
g	O
dl	O
,	O
leukocytes	O
6	O
.	O
55	O
x10E3	O
μl	O
,	O
platelets	O
128	O
x10E3	O
μl	O
.	O
Biochemistry	O
Na	O
138	O
mmol	O
l	O
,	O
K	O
4	O
.	O
5	O
mmol	O
l	O
,	O
Cr	O
0	O
.	O
93	O
mg	O
dl	O
,	O
ultrasensitive	O
troponin	O
T	O
158	O
ng	O
l	O
,	O
NTproBNP	O
13000	O
.	O
Coagulation	O
INR	O
1	O
.	O
10	O
.	O
Arterial	O
blood	O
gas	O
pH	O
7	O
.	O
45	O
,	O
pO2	O
51	O
mmHg	O
,	O
pCO2	O
33	O
mmHg	O
,	O
HCO3	O
23	O
.	O
5	O
mmHg	O
.	O
Electrocardiogram	O
ECG	O
sinus	O
tachycardia	O
at	O
100	O
bpm	O
with	O
diffuse	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
Middle	O
sternotomy	O
wires	O
and	O
aortic	O
ring	O
.	O
No	O
data	O
of	O
acute	O
pathology	O
.	O
Angio	O
CT	O
of	O
pulmonary	O
arteries	O
no	O
evidence	O
of	O
TEPA	O
.	O
No	O
signs	O
of	O
congestion	O
.	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
with	O
mild	O
hypertrophy	O
and	O
mildly	O
impaired	O
systolic	O
function	O
.	O
High	O
filling	O
pressures	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
.	O
Mechanical	O
aortic	O
prosthesis	O
with	O
severe	O
double	O
lesion	O
,	O
very	O
high	O
gradients	O
maximum	O
gradient	O
of	O
100	O
and	O
mean	O
of	O
75	O
mmHg	O
.	O
Moderate	O
mitral	O
insufficiency	O
.	O
Moderate	O
tricuspid	O
insufficiency	O
allowing	O
estimation	O
of	O
a	O
PSAP	O
of	O
55	O
.	O
Fluoroscopy	O
absence	O
of	O
movement	O
of	O
one	O
of	O
the	O
prosthetic	O
discs	O
.	O
Transesophageal	O
echocardiogram	O
image	O
compatible	O
with	O
thrombus	O
on	O
the	O
ventricular	O
side	O
of	O
the	O
most	O
posterior	O
disc	O
and	O
another	O
image	O
on	O
the	O
aortic	O
side	O
of	O
the	O
most	O
anterior	O
disc	O
,	O
indicating	O
very	O
severe	O
aortic	O
stenosis	O
and	O
severe	O
aortic	O
insufficiency	O
in	O
the	O
context	O
of	O
prosthetic	O
thrombosis	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
the	O
patient	O
presented	O
with	O
significant	O
dyspnoea	O
associated	O
with	O
respiratory	O
distress	O
.	O
Initially	O
,	O
given	O
the	O
clinical	O
situation	O
and	O
normal	O
chest	O
X	O
ray	O
and	O
prior	O
to	O
the	O
arrival	O
of	O
the	O
analytical	O
results	O
,	O
an	O
angio	O
CT	O
scan	O
of	O
the	O
pulmonary	O
arteries	O
was	O
performed	O
which	O
ruled	O
out	O
pulmonary	O
thromboembolism	O
and	O
showed	O
no	O
evidence	O
of	O
fluid	O
overload	O
.	O
Urgent	O
cardiology	O
assessment	O
was	O
requested	O
and	O
a	O
transthoracic	O
echocardiogram	O
described	O
above	O
was	O
performed	O
,	O
showing	O
a	O
severe	O
double	O
aortic	O
lesion	O
with	O
very	O
high	O
gradients	O
.	O
Suspicion	O
of	O
acute	O
prosthetic	O
thrombosis	O
led	O
to	O
fluoroscopy	O
,	O
which	O
confirmed	O
the	O
diagnosis	O
.	O
However	O
,	O
for	O
a	O
better	O
aetiological	O
affiliation	O
,	O
a	O
transesophageal	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
images	O
suggestive	O
of	O
thrombus	O
in	O
both	O
discs	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
cardiac	O
intensive	O
care	O
unit	O
and	O
remained	O
in	O
a	O
poor	O
haemodynamic	O
condition	O
,	O
hypotensive	O
and	O
tachycardic	O
,	O
with	O
little	O
response	O
to	O
diuretic	O
treatment	O
.	O
Urgent	O
assessment	O
by	O
cardiac	O
surgery	O
was	O
requested	O
,	O
who	O
decided	O
to	O
perform	O
emergency	O
aortic	O
valve	O
replacement	O
.	O
Intraoperative	O
findings	O
showed	O
blockage	O
of	O
the	O
prosthetic	O
discs	O
due	O
to	O
the	O
presence	O
of	O
organised	O
thrombus	O
in	O
both	O
hinges	O
.	O
Finally	O
,	O
an	O
ATS	O
No	O
18	O
mechanical	O
prosthesis	O
was	O
implanted	O
,	O
given	O
the	O
impossibility	O
of	O
implanting	O
a	O
biological	O
prosthesis	O
due	O
to	O
the	O
size	O
of	O
the	O
annulus	O
,	O
without	O
complications	O
.	O
The	O
postoperative	O
period	O
passed	O
without	O
complications	O
,	O
allowing	O
early	O
discharge	O
to	O
the	O
ward	O
.	O
The	O
control	O
echocardiogram	O
showed	O
a	O
normally	O
functioning	O
mechanical	O
prosthesis	O
maximum	O
gradient	O
27	O
.	O
5	O
and	O
mean	O
gradient	O
14	O
.	O
6	O
mmHg	O
and	O
hospital	O
discharge	O
was	O
therefore	O
decided	O
.	O
DIAGNOSIS	O
Acute	O
mechanical	O
aortic	O
prosthetic	O
prosthesis	O
thrombosis	O
.	O
Cardiogenic	O
shock	O
secondary	O
to	O
the	O
same	O
.	O
Implantation	O
of	O
a	O
mechanical	O
aortic	O
prosthesis	O
ATS	O
No18	O
.	O
LVEF	O
preserved	O
at	O
discharge	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
in	O
our	O
clinical	O
case	O
is	O
a	O
40	O
year	O
old	O
woman	O
from	O
León	O
,	O
with	O
no	O
contact	O
with	O
the	O
rural	O
environment	O
or	O
animals	O
.	O
She	O
has	O
no	O
drug	O
allergies	O
and	O
her	O
relevant	O
history	O
includes	O
epidemiological	O
contact	O
with	O
tuberculosis	O
that	O
required	O
chemoprophylactic	O
treatment	O
in	O
childhood	O
,	O
with	O
no	O
evidence	O
of	O
subsequent	O
development	O
of	O
the	O
disease	O
,	O
and	O
a	O
benign	O
ovarian	O
tumour	O
being	O
followed	O
up	O
by	O
gynaecology	O
.	O
She	O
attended	O
her	O
referral	O
hospital	O
with	O
a	O
clinical	O
picture	O
of	O
one	O
week	O
's	O
evolution	O
consisting	O
of	O
general	O
malaise	O
,	O
dyspnoea	O
and	O
suprasternal	O
pain	O
with	O
palpitations	O
.	O
She	O
also	O
reported	O
an	O
episode	O
of	O
generalised	O
urticaria	O
that	O
resolved	O
after	O
taking	O
antihistamines	O
at	O
home	O
.	O
Suspecting	O
thyroid	O
pathology	O
,	O
she	O
was	O
discharged	O
under	O
beta	O
blocker	O
treatment	O
,	O
pending	O
analytical	O
results	O
.	O
Due	O
to	O
persistent	O
symptoms	O
,	O
she	O
requested	O
a	O
second	O
opinion	O
at	O
another	O
centre	O
,	O
where	O
she	O
underwent	O
a	O
transthoracic	O
echocardiogram	O
that	O
showed	O
dilatation	O
of	O
the	O
right	O
chambers	O
and	O
pulmonary	O
hypertension	O
,	O
together	O
with	O
cystic	O
images	O
in	O
the	O
liver	O
.	O
She	O
was	O
referred	O
to	O
the	O
emergency	O
department	O
of	O
her	O
referral	O
hospital	O
to	O
rule	O
out	O
acute	O
pulmonary	O
thromboembolism	O
.	O
Physical	O
examination	O
on	O
arrival	O
BP	O
102	O
55	O
mm	O
Hg	O
.	O
HR	O
100	O
bpm	O
.	O
Ta	O
36	O
.	O
2oC	O
.	O
SpO2	O
93	O
basal	O
.	O
Regular	O
general	O
condition	O
.	O
Conscious	O
,	O
oriented	O
in	O
the	O
3	O
spheres	O
and	O
cooperative	O
.	O
Normal	O
colour	O
,	O
normohydrated	O
and	O
normoperfused	O
.	O
Discreetly	O
tachypnoeic	O
at	O
rest	O
,	O
with	O
good	O
respiratory	O
dynamics	O
.	O
Head	O
and	O
neck	O
absence	O
of	O
jugular	O
ingurgitation	O
.	O
No	O
palpable	O
goitres	O
or	O
adenopathies	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
tachycardic	O
heart	O
sounds	O
.	O
No	O
murmurs	O
or	O
extratonos	O
are	O
heard	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
in	O
both	O
hemithoraxes	O
,	O
no	O
extra	O
sounds	O
.	O
Abdomen	O
hydro	O
aerial	O
sounds	O
present	O
and	O
of	O
normal	O
characteristics	O
.	O
Soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
superficial	O
or	O
deep	O
palpation	O
,	O
with	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Lower	O
extremities	O
pedial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
No	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
at	O
the	O
referral	O
hospital	O
elevated	O
NT	O
proBNP	O
5981	O
pg	O
ml	O
,	O
D	O
dimers	O
20887	O
ng	O
ml	O
.	O
Other	O
parameters	O
in	O
normal	O
range	O
.	O
Angio	O
CT	O
scan	O
at	O
the	O
referral	O
hospital	O
hypodense	O
mass	O
was	O
observed	O
occupying	O
the	O
left	O
pulmonary	O
artery	O
and	O
extending	O
obstructing	O
all	O
ipsilateral	O
lobar	O
and	O
segmental	O
arteries	O
,	O
as	O
well	O
as	O
a	O
second	O
mass	O
of	O
similar	O
characteristics	O
in	O
the	O
right	O
interlobar	O
artery	O
,	O
in	O
addition	O
to	O
an	O
area	O
in	O
the	O
right	O
lower	O
lobe	O
suggestive	O
of	O
pneumonitis	O
or	O
pulmonary	O
infarction	O
and	O
a	O
cavity	O
with	O
a	O
mass	O
inside	O
it	O
in	O
the	O
meniscus	O
sign	O
in	O
the	O
left	O
lower	O
lobe	O
.	O
There	O
was	O
also	O
dilatation	O
of	O
the	O
pulmonary	O
artery	O
trunk	O
and	O
evidence	O
of	O
right	O
ventricular	O
overload	O
,	O
findings	O
suggestive	O
of	O
pulmonary	O
hypertension	O
.	O
Magnetic	O
resonance	O
imaging	O
MRI	O
of	O
the	O
liver	O
at	O
his	O
referral	O
hospital	O
a	O
large	O
cystic	O
lesion	O
with	O
calcified	O
wall	O
in	O
the	O
right	O
hepatic	O
lobe	O
corresponding	O
to	O
a	O
hydatid	O
cyst	O
with	O
daughter	O
vesicles	O
,	O
with	O
rupture	O
of	O
the	O
capsule	O
with	O
focal	O
extension	O
and	O
invasion	O
of	O
the	O
inferior	O
vena	O
cava	O
.	O
Transthoracic	O
echocardiogram	O
in	O
our	O
centre	O
mild	O
right	O
ventricular	O
dysfunction	O
,	O
with	O
severe	O
pulmonary	O
hypertension	O
estimated	O
PSAP	O
60	O
65	O
mmHg	O
,	O
showing	O
intraluminal	O
masses	O
in	O
the	O
pulmonary	O
artery	O
and	O
extrinsic	O
compression	O
of	O
the	O
vena	O
cava	O
.	O
Normal	O
left	O
ventricular	O
function	O
and	O
absence	O
of	O
significant	O
valvular	O
heart	O
disease	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
view	O
of	O
these	O
findings	O
,	O
serology	O
for	O
hydatidosis	O
was	O
performed	O
,	O
which	O
was	O
positive	O
,	O
so	O
antiparasitic	O
treatment	O
was	O
started	O
with	O
albendazole	B-FARMACO
400	O
mg	O
12	O
h	O
and	O
oral	O
praziquantel	B-FARMACO
600	O
mg	O
8	O
h	O
.	O
Initial	O
evolution	O
was	O
favourable	O
,	O
although	O
he	O
persisted	O
with	O
hypoxaemia	O
dependent	O
on	O
oxygen	O
therapy	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
our	O
centre	O
for	O
assessment	O
by	O
the	O
multidisciplinary	O
pulmonary	O
hypertension	O
unit	O
.	O
On	O
arrival	O
at	O
our	O
centre	O
,	O
the	O
patient	O
was	O
haemodynamically	O
stable	O
.	O
Laboratory	O
tests	O
showed	O
discrete	O
elevation	O
of	O
NT	O
proBNP	O
2612	O
pg	O
ml	O
and	O
acute	O
phase	O
reactants	O
leukocyte	O
count	O
at	O
the	O
upper	O
limit	O
of	O
normal	O
with	O
significant	O
neutrophilia	O
,	O
C	O
reactive	O
protein	O
24	O
.	O
5	O
mg	O
dl	O
,	O
fibrinogen	O
1320	O
mg	O
dl	O
.	O
Positive	O
serology	O
for	O
hydatidosis	O
was	O
confirmed	O
by	O
ELISA	O
test	O
.	O
A	O
new	O
transthoracic	O
echocardiogram	O
was	O
repeated	O
images	O
7	O
9	O
,	O
showing	O
mild	O
right	O
ventricular	O
dysfunction	O
,	O
with	O
severe	O
pulmonary	O
hypertension	O
estimated	O
PSP	O
60	O
65	O
mmHg	O
,	O
intraluminal	O
masses	O
in	O
the	O
pulmonary	O
artery	O
and	O
extrinsic	O
compression	O
of	O
the	O
vena	O
cava	O
,	O
as	O
well	O
as	O
normal	O
left	O
ventricular	O
function	O
and	O
no	O
significant	O
valvular	O
heart	O
disease	O
.	O
After	O
reviewing	O
the	O
tests	O
performed	O
at	O
his	O
referral	O
centre	O
,	O
the	O
case	O
was	O
presented	O
at	O
a	O
multidisciplinary	O
session	O
involving	O
the	O
cardiology	O
,	O
radiology	O
,	O
infectious	O
diseases	O
unit	O
,	O
cardiac	O
surgery	O
,	O
thoracic	O
surgery	O
and	O
general	O
surgery	O
departments	O
.	O
At	O
this	O
session	O
,	O
a	O
two	O
stage	O
approach	O
was	O
decided	O
initially	O
cyst	O
extraction	O
and	O
scheduled	O
hepatectomy	O
and	O
subsequently	O
pulmonary	O
endarterectomy	O
of	O
hydatid	O
cysts	O
.	O
While	O
awaiting	O
this	O
intervention	O
,	O
admitted	O
to	O
the	O
cardiology	O
ward	O
,	O
the	O
patient	O
presented	O
symptoms	O
compatible	O
with	O
anaphylactic	O
shock	O
requiring	O
administration	O
of	O
intramuscular	O
adrenaline	B-FARMACO
and	O
steroid	O
boluses	O
and	O
the	O
start	O
of	O
intensive	O
fluid	O
therapy	O
,	O
despite	O
which	O
she	O
remained	O
unstable	O
both	O
respiratory	O
SpO2	O
70	O
and	O
haemodynamic	O
BP	O
50	O
40	O
mmHg	O
,	O
so	O
she	O
was	O
transferred	O
to	O
the	O
coronary	O
unit	O
,	O
where	O
a	O
central	O
line	O
was	O
started	O
and	O
adrenaline	B-FARMACO
and	O
noradrenaline	B-FARMACO
perfusion	O
was	O
started	O
.	O
She	O
was	O
also	O
connected	O
to	O
non	O
invasive	O
mechanical	O
ventilation	O
EPAP	O
2	O
,	O
IPAP	O
9	O
,	O
FiO2	O
100	O
.	O
Given	O
the	O
persistence	O
of	O
haemodynamic	O
deterioration	O
despite	O
adequate	O
support	O
measures	O
,	O
a	O
new	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
severe	O
left	O
ventricular	O
dysfunction	O
.	O
The	O
electrocardiogram	O
showed	O
no	O
evidence	O
of	O
ischaemia	O
and	O
no	O
significant	O
elevation	O
of	O
myocardial	O
damage	O
markers	O
troponin	O
T	O
hs	O
84	O
ng	O
l	O
,	O
CK	O
152	O
U	O
l	O
.	O
With	O
the	O
suspicion	O
of	O
stress	O
cardiomyopathy	O
in	O
relation	O
to	O
the	O
episode	O
of	O
anaphylactic	O
shock	O
requiring	O
high	O
doses	O
of	O
catecholamines	B-FARMACO
which	O
at	O
this	O
time	O
included	O
the	O
administration	O
of	O
dobutamine	B-FARMACO
,	O
the	O
possibility	O
of	O
implantation	O
of	O
veno	O
arterial	O
ECMO	O
was	O
assessed	O
.	O
However	O
,	O
the	O
implantation	O
of	O
the	O
device	O
was	O
rejected	O
for	O
various	O
reasons	O
the	O
presence	O
of	O
left	O
ventricular	O
dysfunction	O
that	O
made	O
the	O
risk	O
of	O
the	O
surgical	O
intervention	O
that	O
the	O
patient	O
needed	O
to	O
cure	O
her	O
unacceptable	O
at	O
that	O
time	O
;	O
the	O
risk	O
of	O
new	O
dissemination	O
or	O
rupture	O
of	O
cysts	O
with	O
the	O
manipulation	O
of	O
lines	O
and	O
cannulas	O
in	O
the	O
venous	O
territory	O
,	O
and	O
the	O
complexity	O
of	O
the	O
management	O
of	O
assistance	O
in	O
a	O
patient	O
with	O
severe	O
pulmonary	O
circulation	O
alteration	O
.	O
In	O
this	O
context	O
,	O
expectant	O
management	O
was	O
decided	O
,	O
awaiting	O
spontaneous	O
recovery	O
to	O
reactivate	O
the	O
initial	O
plan	O
.	O
During	O
the	O
hours	O
immediately	O
after	O
the	O
episode	O
,	O
the	O
patient	O
showed	O
discrete	O
haemodynamic	O
improvement	O
that	O
allowed	O
suspension	O
of	O
adrenaline	B-FARMACO
perfusion	O
and	O
a	O
decrease	O
in	O
noradrenaline	B-FARMACO
to	O
0	O
.	O
2	O
μg	O
kg	O
min	O
with	O
progressive	O
improvement	O
of	O
the	O
distal	O
hypoperfusion	O
data	O
.	O
Under	O
low	O
doses	O
of	O
dobutamine	B-FARMACO
,	O
a	O
new	O
echocardiogram	O
was	O
performed	O
where	O
severe	O
left	O
ventricular	O
dysfunction	O
persisted	O
.	O
Respiratory	O
stability	O
was	O
such	O
that	O
ventilatory	O
support	O
could	O
be	O
reduced	O
with	O
acceptable	O
clinical	O
tolerance	O
.	O
However	O
,	O
24	O
hours	O
after	O
the	O
anaphylactic	O
shock	O
episode	O
,	O
she	O
presented	O
a	O
sudden	O
episode	O
of	O
desaturation	O
,	O
with	O
associated	O
hypotension	O
and	O
spontaneous	O
recovery	O
after	O
starting	O
support	O
with	O
high	O
flow	O
glasses	O
with	O
FiO2	O
of	O
1	O
,	O
with	O
data	O
compatible	O
with	O
pulmonary	O
congestion	O
on	O
chest	O
X	O
ray	O
.	O
Hours	O
later	O
,	O
he	O
presented	O
with	O
frank	O
haemodynamic	O
deterioration	O
,	O
with	O
associated	O
episodes	O
of	O
desaturation	O
and	O
urticaria	O
suggesting	O
a	O
new	O
case	O
of	O
anaphylaxis	O
,	O
probably	O
due	O
to	O
the	O
release	O
of	O
hydatid	O
vesicles	O
.	O
Initially	O
,	O
doses	O
of	O
vasoactive	O
drugs	O
were	O
increased	O
,	O
intramuscular	O
adrenaline	B-FARMACO
and	O
bolus	O
corticotherapy	O
were	O
started	O
,	O
despite	O
which	O
she	O
presented	O
with	O
new	O
haemodynamic	O
deterioration	O
,	O
with	O
moderate	O
severe	O
dilatation	O
of	O
the	O
right	O
ventricle	O
on	O
urgent	O
echocardiography	O
,	O
maintaining	O
severe	O
left	O
ventricular	O
dysfunction	O
.	O
The	O
patient	O
presented	O
with	O
a	O
new	O
episode	O
of	O
desaturation	O
,	O
associated	O
urticaria	O
and	O
loss	O
of	O
consciousness	O
that	O
required	O
orotracheal	O
intubation	O
,	O
after	O
which	O
electromechanical	O
dissociation	O
was	O
observed	O
,	O
which	O
could	O
not	O
be	O
reversed	O
after	O
25	O
minutes	O
of	O
advanced	O
CPR	O
manoeuvres	O
.	O
When	O
these	O
manoeuvres	O
were	O
stopped	O
,	O
asystole	O
and	O
thrombosis	O
of	O
both	O
ventricles	O
were	O
observed	O
on	O
transthoracic	O
echocardiography	O
.	O
Relatives	O
were	O
informed	O
and	O
the	O
possibility	O
of	O
performing	O
an	O
autopsy	O
was	O
explained	O
,	O
which	O
they	O
rejected	O
.	O
DIAGNOSIS	O
Severe	O
pulmonary	O
hypertension	O
secondary	O
to	O
compromise	O
of	O
the	O
pulmonary	O
arterial	O
tree	O
by	O
hydatid	O
vesicles	O
,	O
probably	O
secondary	O
to	O
migration	O
from	O
a	O
giant	O
hepatic	O
hydatid	O
cyst	O
.	O
Right	O
ventricular	O
dysfunction	O
in	O
the	O
context	O
of	O
the	O
above	O
.	O
Anaphylactic	O
shock	O
in	O
relation	O
to	O
disseminated	O
hepatic	O
hydatid	O
disease	O
,	O
with	O
stress	O
cardiomyopathy	O
with	O
development	O
of	O
secondary	O
severe	O
left	O
ventricular	O
dysfunction	O
.	O
Cardiorespiratory	O
arrest	O
in	O
electromechanical	O
dissociation	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
65	O
year	O
old	O
woman	O
.	O
Allergy	O
to	O
methimazole	B-FARMACO
.	O
No	O
known	O
cardiovascular	O
risk	O
factors	O
.	O
No	O
history	O
of	O
known	O
heart	O
disease	O
.	O
Primary	O
hyperthyroidism	O
due	O
to	O
Graves	O
Basedow	O
disease	O
,	O
treated	O
with	O
radioactive	B-FARMACO
iodine	I-FARMACO
I	O
131	O
.	O
Current	O
situation	O
of	O
hypothyroidism	O
under	O
replacement	O
therapy	O
.	O
Left	O
breast	O
nodule	O
with	O
histology	O
compatible	O
with	O
solid	O
pattern	O
carcinoma	O
with	O
multifocal	O
neuroendocrine	O
differentiation	O
somatostatin	O
and	O
chromogranin	O
receptors	O
positive	O
,	O
undergoing	O
conservative	O
surgery	O
in	O
2011	O
and	O
sentinel	O
node	O
biopsy	O
,	O
which	O
was	O
negative	O
.	O
Subsequent	O
follow	O
up	O
by	O
oncology	O
,	O
with	O
stability	O
of	O
the	O
disease	O
until	O
2014	O
,	O
when	O
in	O
the	O
context	O
of	O
diarrhoeal	O
syndrome	O
,	O
the	O
diagnosis	O
of	O
carcinoid	O
syndrome	O
due	O
to	O
metastatic	O
liver	O
disease	O
with	O
positive	O
gammagraphic	O
uptake	O
for	O
somatostatin	O
analogues	O
was	O
established	O
.	O
Stability	O
by	O
imaging	O
studies	O
since	O
the	O
start	O
of	O
treatment	O
with	O
somatostatin	O
analogues	O
,	O
although	O
an	O
increase	O
in	O
analytical	O
biomarkers	O
that	O
led	O
to	O
changes	O
in	O
the	O
usual	O
treatment	O
.	O
Usual	O
treatment	O
levothyroxine	B-FARMACO
sodium	I-FARMACO
75	O
mcg	O
orally	O
every	O
24	O
hours	O
,	O
lanreotide	B-FARMACO
autogel	O
120	O
mg	O
injectable	O
every	O
21	O
days	O
.	O
Present	O
illness	O
He	O
came	O
to	O
the	O
emergency	O
department	O
for	O
marked	O
swelling	O
of	O
the	O
lower	O
limbs	O
and	O
weight	O
gain	O
5	O
kg	O
in	O
the	O
last	O
month	O
,	O
although	O
without	O
greater	O
dyspnoea	O
than	O
usual	O
on	O
exertion	O
.	O
She	O
also	O
reported	O
an	O
increase	O
in	O
the	O
frequency	O
of	O
diarrhoeal	O
episodes	O
in	O
the	O
last	O
6	O
months	O
,	O
since	O
the	O
last	O
oncology	O
check	O
up	O
.	O
She	O
denies	O
other	O
symptoms	O
.	O
Physical	O
examination	O
Conscious	O
and	O
oriented	O
in	O
time	O
,	O
space	O
and	O
person	O
.	O
Facial	O
flushing	O
.	O
Blood	O
pressure	O
125	O
68	O
mmHg	O
.	O
Eupneic	O
at	O
rest	O
,	O
with	O
saturation	O
by	O
pulse	O
oximetry	O
99	O
without	O
contributions	O
.	O
Pulmonary	O
auscultation	O
physiological	O
vesicular	O
murmur	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
at	O
78	O
bpm	O
,	O
with	O
pansystolic	O
murmur	O
intensity	O
III	O
VI	O
predominantly	O
in	O
the	O
left	O
parasternal	O
border	O
,	O
which	O
increases	O
with	O
inspiration	O
.	O
Abdominal	O
examination	O
not	O
painful	O
on	O
palpation	O
,	O
with	O
discrete	O
hepatomegaly	O
,	O
without	O
signs	O
of	O
ascites	O
.	O
Examination	O
of	O
the	O
extremities	O
oedema	O
with	O
fovea	O
up	O
to	O
the	O
middle	O
third	O
of	O
the	O
lower	O
limbs	O
,	O
with	O
preserved	O
and	O
symmetrical	O
distal	O
pulses	O
.	O
No	O
acute	O
inflammatory	O
data	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
72	O
bpm	O
.	O
QRS	O
axis	O
60o	O
.	O
PR	O
interval	O
160	O
msec	O
.	O
QRS	O
of	O
normal	O
voltage	O
and	O
amplitude	O
.	O
Minimal	O
non	O
significant	O
ST	O
segment	O
underleveling	O
in	O
inferior	O
leads	O
.	O
Corrected	O
QT	O
interval	O
Bazett	O
460	O
msec	O
.	O
Chest	O
X	O
ray	O
slightly	O
increased	O
cardiothoracic	O
index	O
.	O
No	O
costophrenic	O
sinus	O
impingement	O
.	O
No	O
infiltrates	O
or	O
condensation	O
.	O
No	O
images	O
suggestive	O
of	O
masses	O
.	O
Laboratory	O
tests	O
in	O
the	O
emergency	O
department	O
mild	O
hyperbilirubinaemia	O
total	O
bilirubin	O
1	O
.	O
5	O
mg	O
dl	O
and	O
hyponatraemia	O
Na	O
133	O
mmol	O
l	O
.	O
Blood	O
count	O
,	O
coagulation	O
,	O
renal	O
function	O
parameters	O
and	O
the	O
rest	O
of	O
the	O
ionogram	O
in	O
normal	O
ranges	O
.	O
Laboratory	O
tests	O
on	O
the	O
hospital	O
ward	O
normal	O
thyroid	O
hormone	O
profile	O
.	O
Normal	O
iron	O
profile	O
.	O
5	O
hydroxyindolacetic	O
acid	O
355	O
μmol	O
orine	O
24	O
h	O
normal	O
values	O
10	O
40	O
μmol	O
orine	O
24	O
h	O
.	O
Chromogranin	O
A	O
serum	O
1697	O
ng	O
ml	O
normal	O
values	O
up	O
to	O
100	O
ng	O
ml	O
.	O
NT	O
proBNP	O
767	O
ng	O
ml	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
LV	O
neither	O
dilated	O
nor	O
hypertrophic	O
,	O
with	O
preserved	O
global	O
systolic	O
function	O
LVEF	O
60	O
,	O
without	O
alterations	O
in	O
segmental	O
contractility	O
.	O
Transmitral	O
filling	O
pattern	O
with	O
impaired	O
relaxation	O
E	O
A	O
0	O
.	O
7	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
32	O
ml	O
m2	O
.	O
Mitral	O
valve	O
morphologically	O
normal	O
,	O
with	O
no	O
organ	O
involvement	O
of	O
interest	O
or	O
significant	O
functional	O
alterations	O
.	O
Tricuspid	O
aortic	O
valve	O
,	O
without	O
organic	O
involvement	O
of	O
interest	O
,	O
with	O
jet	O
of	O
aortic	O
regurgitation	O
of	O
central	O
origin	O
and	O
direction	O
that	O
conditions	O
mild	O
aortic	O
insufficiency	O
.	O
Aortic	O
root	O
of	O
normal	O
dimensions	O
26	O
mm	O
.	O
Proximal	O
ascending	O
aorta	O
and	O
aortic	O
arch	O
of	O
normal	O
size	O
28	O
mm	O
and	O
26	O
mm	O
,	O
respectively	O
.	O
Right	O
ventricle	O
slightly	O
dilated	O
at	O
mid	O
basal	O
level	O
dimensions	O
basal	O
diameter	O
43	O
mm	O
,	O
mid	O
diameter	O
37	O
mm	O
,	O
length	O
68	O
mm	O
,	O
proximal	O
outflow	O
tract	O
diameter	O
33	O
mm	O
,	O
distal	O
outflow	O
tract	O
diameter	O
24	O
mm	O
,	O
with	O
decreased	O
longitudinal	O
function	O
parameters	O
TAPSE	O
15	O
mm	O
,	O
S	O
"	O
wave	O
9	O
cm	O
sec	O
.	O
Slightly	O
dilated	O
right	O
atrium	O
area	O
20	O
cm2	O
.	O
Tricuspid	O
valve	O
with	O
fibrosis	O
at	O
the	O
leaflet	O
level	O
and	O
restricted	O
movement	O
of	O
the	O
leaflets	O
causing	O
a	O
central	O
coaptation	O
deficit	O
and	O
a	O
tricuspid	O
regurgitation	O
jet	O
leading	O
to	O
severe	O
tricuspid	O
regurgitation	O
,	O
with	O
a	O
maximum	O
gradient	O
possible	O
underestimation	O
due	O
to	O
severity	O
of	O
regurgitation	O
of	O
50	O
mmHg	O
.	O
Pulmonary	O
valve	O
adequately	O
visualised	O
,	O
with	O
normal	O
appearance	O
.	O
No	O
evidence	O
of	O
shuntintracardiac	O
.	O
Inferior	O
vena	O
cava	O
with	O
dimensions	O
in	O
the	O
upper	O
normal	O
range	O
20	O
mm	O
and	O
inspiratory	O
collapse	O
greater	O
than	O
50	O
.	O
Trivial	O
pericardial	O
effusion	O
.	O
Whole	O
body	O
gammagraphic	O
study	O
of	O
somatostatin	O
receptors	O
in	O
comparison	O
with	O
the	O
previous	O
study	O
18	O
months	O
earlier	O
,	O
multiple	O
bilobular	O
liver	O
lesions	O
were	O
observed	O
.	O
The	O
largest	O
lesion	O
segment	O
VII	O
shows	O
an	O
increase	O
in	O
volume	O
136	O
x	O
94	O
x	O
136	O
mm	O
in	O
anteroposterior	O
transverse	O
craniocaudal	O
diameters	O
,	O
compared	O
to	O
110	O
x	O
70	O
x	O
115	O
mm	O
in	O
the	O
previous	O
study	O
.	O
There	O
were	O
no	O
other	O
new	O
lesions	O
compared	O
to	O
the	O
previous	O
study	O
.	O
Conclusion	O
scintigraphic	O
study	O
compatible	O
with	O
progression	O
of	O
the	O
disease	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
for	O
a	O
complete	O
study	O
,	O
confirming	O
the	O
progression	O
of	O
the	O
disease	O
by	O
means	O
of	O
a	O
somatostatin	O
receptor	O
scintigraphy	O
study	O
.	O
Given	O
the	O
clinical	O
suspicion	O
of	O
cardiac	O
involvement	O
due	O
to	O
carcinoid	O
syndrome	O
clinical	O
symptoms	O
and	O
new	O
onset	O
murmur	O
,	O
a	O
transthoracic	O
echocardiographic	O
study	O
was	O
requested	O
,	O
which	O
revealed	O
severe	O
tricuspid	O
insufficiency	O
,	O
confirming	O
the	O
diagnosis	O
of	O
carcinoid	O
heart	O
disease	O
.	O
After	O
initiation	O
of	O
depletive	O
treatment	O
with	O
diuretics	O
and	O
intensification	O
of	O
treatment	O
with	O
somatostatin	O
analogues	O
,	O
the	O
patient	O
progressed	O
favourably	O
,	O
with	O
symptomatic	O
improvement	O
reduction	O
of	O
oedema	O
in	O
the	O
lower	O
limbs	O
,	O
reduction	O
in	O
the	O
number	O
of	O
bowel	O
movements	O
,	O
no	O
episodes	O
of	O
hot	O
flushes	O
.	O
The	O
case	O
was	O
discussed	O
in	O
a	O
clinical	O
session	O
with	O
the	O
participation	O
of	O
medical	O
oncology	O
and	O
cardiology	O
,	O
estimating	O
a	O
vital	O
prognosis	O
of	O
less	O
than	O
12	O
months	O
,	O
and	O
it	O
was	O
decided	O
to	O
discharge	O
the	O
patient	O
from	O
hospital	O
with	O
an	O
increase	O
in	O
the	O
dose	O
of	O
somatostatin	O
analogues	O
.	O
Despite	O
this	O
,	O
the	O
patient	O
had	O
a	O
torpid	O
subsequent	O
evolution	O
,	O
with	O
several	O
readmissions	O
in	O
the	O
following	O
months	O
for	O
episodes	O
similar	O
to	O
the	O
one	O
described	O
,	O
finally	O
leading	O
to	O
her	O
death	O
.	O
DIAGNOSIS	O
Stage	O
IV	O
mammary	O
neuroendocrine	O
neoplasia	O
.	O
Carcinoid	O
syndrome	O
with	O
cardiac	O
involvement	O
severe	O
tricuspid	O
insufficiency	O
.	O
Cardiac	O
insufficiency	O
of	O
right	O
predominance	O
.	O
Exitus	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
untreated	O
dyslipidaemia	O
,	O
overweight	O
grade	O
2	O
.	O
Cardiological	O
history	O
11	O
years	O
ago	O
an	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
no	O
abnormalities	O
during	O
an	O
admission	O
for	O
pneumonia	O
.	O
Other	O
history	O
Chronic	O
hepatitis	O
C	O
virus	O
genotype	O
1	O
liver	O
disease	O
,	O
non	O
responsive	O
to	O
interferon	B-FARMACO
and	O
ribavirin	B-FARMACO
therapy	O
.	O
Treatment	O
was	O
started	O
with	O
ledipasvir	B-FARMACO
and	O
sofosbuvir	B-FARMACO
with	O
prior	O
withdrawal	O
of	O
omeprazole	B-FARMACO
from	O
her	O
usual	O
treatment	O
to	O
avoid	O
interaction	O
.	O
She	O
finished	O
treatment	O
2	O
months	O
ago	O
,	O
totally	O
asymptomatic	O
,	O
with	O
sustained	O
viral	O
response	O
.	O
Systemic	O
sarcoidosis	O
secondary	O
to	O
treatment	O
with	O
interferon	B-FARMACO
,	O
which	O
was	O
treated	O
with	O
corticosteroids	O
and	O
interruption	O
of	O
interferon	B-FARMACO
therapy	O
,	O
with	O
no	O
current	O
activity	O
.	O
Usual	O
treatment	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
tablet	O
per	O
day	O
.	O
Current	O
disease	O
A	O
74	O
year	O
old	O
female	O
patient	O
was	O
being	O
followed	O
up	O
by	O
hepatology	O
outpatients	O
for	O
chronic	O
HCV	O
infection	O
.	O
During	O
a	O
follow	O
up	O
visit	O
to	O
the	O
hepatology	O
outpatient	O
clinic	O
2	O
months	O
after	O
finishing	O
treatment	O
with	O
anti	O
HCV	O
,	O
the	O
patient	O
reported	O
deterioration	O
of	O
functional	O
class	O
to	O
dyspnoea	O
on	O
moderate	O
exertion	O
,	O
with	O
two	O
pillow	O
orthopnoea	O
,	O
peripheral	O
oedematisation	O
and	O
subjective	O
decrease	O
in	O
daily	O
diuresis	O
volume	O
,	O
for	O
which	O
reason	O
she	O
was	O
referred	O
to	O
cardiology	O
.	O
She	O
reported	O
no	O
chest	O
pain	O
at	O
rest	O
or	O
on	O
exertion	O
,	O
no	O
presyncopal	O
episodes	O
and	O
no	O
infectious	O
symptoms	O
due	O
to	O
equipment	O
.	O
At	O
the	O
cardiology	O
outpatient	O
clinic	O
,	O
anamnesis	O
was	O
performed	O
,	O
in	O
accordance	O
with	O
the	O
above	O
,	O
and	O
NT	O
proBNP	O
and	O
transthoracic	O
echocardiogram	O
was	O
requested	O
,	O
which	O
showed	O
dilated	O
cardiomyopathy	O
with	O
severe	O
left	O
ventricular	O
dysfunction	O
.	O
Treatment	O
was	O
started	O
with	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
24	O
26	O
mg	O
every	O
12	O
hours	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
daily	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
and	O
atorvastatin	B-FARMACO
ezetimibe	I-FARMACO
80	O
10	O
mg	O
daily	O
.	O
Due	O
to	O
evidence	O
of	O
iron	O
deficiency	O
anaemia	O
in	O
decompensated	O
heart	O
failure	O
HF	O
,	O
treatment	O
was	O
started	O
with	O
IV	O
iron	B-FARMACO
carboxymaltose	I-FARMACO
in	O
15	O
minutes	O
each	O
dose	O
1	O
,	O
500	O
mg	O
in	O
total	O
;	O
1	O
,	O
000	O
mg	O
in	O
the	O
first	O
week	O
and	O
500	O
mg	O
in	O
the	O
following	O
week	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
is	O
requested	O
and	O
a	O
new	O
appointment	O
is	O
made	O
in	O
one	O
month	O
.	O
Physical	O
examination	O
Conscious	O
and	O
oriented	O
in	O
the	O
three	O
spheres	O
,	O
normohydrated	O
,	O
cutaneous	O
mucosal	O
pallor	O
,	O
good	O
general	O
condition	O
.	O
Blood	O
pressure	O
107	O
65	O
mmHg	O
,	O
heart	O
rate	O
75	O
bpm	O
,	O
O2	O
saturation	O
98	O
room	O
air	O
,	O
temperature	O
36	O
.	O
3	O
oC	O
.	O
Cardiac	O
auscultation	O
regular	O
,	O
third	O
sound	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
VCM	O
,	O
humid	O
bibasal	O
crackles	O
.	O
Extremities	O
tibiomalleolar	O
oedema	O
with	O
fovea	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
AP	O
chest	O
X	O
ray	O
signs	O
of	O
venous	O
congestion	O
,	O
with	O
perihilar	O
interstitial	O
infiltrate	O
,	O
no	O
pinching	O
of	O
costophrenic	O
sinuses	O
,	O
cardiothoracic	O
index	O
CTI	O
not	O
assessable	O
by	O
projection	O
.	O
Electrocardiogram	O
ECG	O
RS	O
at	O
75	O
bpm	O
,	O
PR	O
160	O
ms	O
,	O
QRS	O
100	O
ms	O
,	O
Axis	O
0o	O
,	O
LVH	O
criteria	O
Sokolov	O
Lyon	O
,	O
flattened	O
T	O
waves	O
in	O
V5	O
V6	O
,	O
aVL	O
Blood	O
tests	O
CBC	O
red	O
blood	O
cells	O
4	O
.	O
52	O
10	O
12	O
l	O
.	O
Haemoglobin	O
9	O
.	O
6	O
g	O
dl	O
.	O
Haematocrit	O
32	O
.	O
8	O
.	O
MCV	O
77	O
.	O
3	O
fl	O
.	O
MCH	O
22	O
.	O
1	O
pg	O
.	O
MCHC	O
26	O
.	O
4	O
g	O
dl	O
.	O
ADE	O
14	O
.	O
Leukocytes	O
6	O
.	O
8	O
10	O
9	O
l	O
.	O
Neutrophils	O
3	O
.	O
3	O
10	O
9	O
l	O
.	O
Lymphocytes	O
2	O
.	O
9	O
10	O
9	O
l	O
.	O
Monocytes	O
0	O
,	O
4	O
10	O
9	O
l	O
.	O
Eosinophils	O
0	O
,	O
2	O
10	O
9	O
l	O
.	O
Basophils	O
0	O
.	O
1	O
10	O
9	O
l	O
.	O
Platelets	O
280	O
10	O
9	O
l	O
.	O
Haemostasis	O
prothrombin	O
time	O
PT	O
11	O
.	O
1	O
sec	O
.	O
Quick	O
index	O
100	O
.	O
INR	O
0	O
.	O
97	O
.	O
APTT	O
26	O
.	O
9	O
sec	O
.	O
Ratio	O
aPTT	O
0	O
.	O
9	O
.	O
Derived	O
fibrinogen	O
311	O
mg	O
dl	O
.	O
Biochemistry	O
glucose	O
105	O
mg	O
d	O
.	O
Sodium	O
141	O
mEq	O
l	O
.	O
Potassium	O
5	O
mEq	O
l	O
.	O
Chlorine	O
103	O
mEq	O
l	O
.	O
Total	O
birubin	O
0	O
.	O
54	O
mg	O
dl	O
.	O
Aspartate	O
aminotransferase	O
GOT	O
26	O
U	O
l	O
.	O
Alanine	O
aminotransferase	O
GPT	O
13	O
U	O
l	O
.	O
Alkaline	O
phosphatase	O
73	O
U	O
.	O
Gamma	O
glutamyl	O
transferase	O
13	O
U	O
l	O
.	O
Creatinine	O
0	O
.	O
94	O
mg	O
dl	O
.	O
Estimated	O
GFR	O
CKD	O
EPI	O
60	O
.	O
8	O
ml	O
min	O
1	O
.	O
73	O
m	O
.	O
Uric	O
acid	O
4	O
.	O
8	O
mg	O
dl	O
.	O
Protein	O
7	O
.	O
2	O
g	O
dl	O
.	O
Creatine	O
phosphokinase	O
119	O
U	O
l	O
.	O
Iron	O
profile	O
ferritin	O
54	O
μg	O
l	O
.	O
Iron	O
94	O
μg	O
dl	O
.	O
Total	O
Fe	O
fixation	O
capacity	O
371	O
ug	O
dl	O
.	O
Transferrin	O
saturation	O
index	O
12	O
.	O
3	O
.	O
Latent	O
Fe	O
binding	O
capacity	O
277	O
ug	O
dl	O
.	O
Immunological	O
markers	O
rheumatoid	O
factor	O
9	O
U	O
ml	O
.	O
C	O
reactive	O
protein	O
0	O
.	O
0	O
mg	O
dl	O
.	O
Lactate	O
dehydrogenase	O
374	O
U	O
l	O
.	O
Angiotensin	O
converting	O
enzyme	O
60	O
U	O
l	O
.	O
Congestion	O
markers	O
NT	O
proBNP	O
3407	O
pg	O
ml	O
.	O
Ag	O
.	O
Carbohydrate	O
125	O
CA125	O
107	O
IU	O
ml	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
319	O
mg	O
dl	O
.	O
Triglycerides	O
90	O
mg	O
dl	O
.	O
HDL	O
cholesterol	O
72	O
mg	O
dl	O
.	O
LDL	O
cholesterol	O
229	O
mg	O
dl	O
.	O
Total	O
cholesterol	O
HDL	O
cholesterol	O
4	O
.	O
4	O
.	O
Hormones	O
thyrotropin	O
TSH	O
1	O
.	O
77	O
uIU	O
ml	O
.	O
Calciuria	O
24	O
hours	O
within	O
normal	O
limits	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
severely	O
dilated	O
left	O
ventricle	O
LV	O
with	O
severe	O
systolic	O
dysfunction	O
LVEF	O
30	O
due	O
to	O
global	O
hypokinesia	O
.	O
Normal	O
sized	O
atria	O
.	O
Mild	O
central	O
functional	O
mitral	O
regurgitation	O
.	O
Aortic	O
valve	O
without	O
findings	O
of	O
interest	O
.	O
Right	O
ventricle	O
RV	O
slightly	O
dilated	O
at	O
baseline	O
with	O
preserved	O
contractility	O
.	O
Trivial	O
TR	O
with	O
PAPs	O
25	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
.	O
Cardiac	O
MRI	O
videos	O
2	O
,	O
3	O
,	O
4	O
and	O
5	O
LV	O
volumes	O
at	O
the	O
upper	O
limit	O
of	O
normal	O
IVTDVI	O
93	O
l	O
m	O
;	O
IVTSVI	O
52	O
ml	O
m	O
with	O
eccentric	O
hypertrophy	O
IMVI	O
84	O
g	O
m	O
and	O
moderately	O
depressed	O
systolic	O
function	O
LVEF	O
44	O
.	O
Generalised	O
mild	O
hypokinesia	O
.	O
Absence	O
of	O
myocardial	O
oedema	O
.	O
Normal	O
RV	O
volumes	O
IVTDVD	O
69	O
ml	O
m2	O
;	O
IVTSVD	O
26	O
ml	O
m2	O
with	O
normal	O
systolic	O
function	O
RVEF	O
62	O
.	O
Atria	O
and	O
great	O
vessels	O
of	O
normal	O
size	O
.	O
Lung	O
resistance	O
within	O
normal	O
values	O
2	O
.	O
6	O
U	O
.	O
Wood	O
.	O
First	O
pass	O
perfusion	O
at	O
rest	O
with	O
e	O
.	O
v	O
.	O
gadolinium	O
.	O
meglumine	O
gadoterate	O
0	O
.	O
15	O
mmol	O
kg	O
no	O
complications	O
.	O
Absence	O
of	O
significant	O
perfusion	O
defects	O
.	O
Focal	O
late	O
gadolinium	O
enhancement	O
in	O
the	O
medial	O
inferior	O
septum	O
at	O
the	O
intersection	O
with	O
the	O
right	O
ventricle	O
.	O
Although	O
small	O
necrosis	O
cannot	O
be	O
ruled	O
out	O
as	O
it	O
also	O
affects	O
the	O
subendocardium	O
,	O
it	O
could	O
also	O
be	O
a	O
focal	O
sarcoid	O
lesion	O
.	O
In	O
summary	O
findings	O
of	O
dilated	O
cardiomyopathy	O
DCM	O
of	O
uncertain	O
origin	O
,	O
probably	O
not	O
ischaemic	O
although	O
it	O
presents	O
a	O
focal	O
lesion	O
compatible	O
with	O
necrosis	O
vs	O
.	O
sarcoid	O
lesion	O
.	O
Catheterisation	O
right	O
dominance	O
.	O
Coronary	O
tree	O
without	O
angiographically	O
significant	O
lesions	O
.	O
High	O
resolution	O
pulmonary	O
CT	O
scan	O
mediastinal	O
structures	O
centred	O
with	O
small	O
right	O
paratracheal	O
lymph	O
node	O
not	O
exceeding	O
one	O
centimetre	O
in	O
maximum	O
diameter	O
,	O
without	O
appreciable	O
lymph	O
node	O
growths	O
in	O
the	O
hilar	O
or	O
axillary	O
hollows	O
.	O
No	O
pleural	O
or	O
pericardial	O
effusions	O
.	O
No	O
pulmonary	O
nodules	O
,	O
masses	O
or	O
intraparenchymal	O
infiltrates	O
.	O
Free	O
main	O
tracheobronchial	O
tree	O
.	O
Cardiac	O
MRI	O
control	O
in	O
6	O
months	O
LV	O
of	O
normal	O
volumes	O
VTD	O
70	O
ml	O
m	O
,	O
VTS	O
34	O
ml	O
m	O
,	O
IMVI	O
74	O
g	O
m2	O
without	O
significant	O
hypertrophy	O
of	O
its	O
walls	O
or	O
alterations	O
of	O
segmental	O
contractility	O
at	O
rest	O
and	O
with	O
slightly	O
depressed	O
global	O
systolic	O
function	O
LVEF	O
51	O
.	O
Abnormal	O
septal	O
motion	O
.	O
Non	O
dilated	O
RV	O
RVOT	O
66	O
ml	O
m	O
,	O
STV	O
25	O
ml	O
m	O
with	O
preserved	O
global	O
systolic	O
function	O
LVEF	O
62	O
.	O
Aorta	O
and	O
great	O
vessels	O
of	O
normal	O
diameter	O
and	O
morphology	O
.	O
Atria	O
of	O
normal	O
dimensions	O
.	O
Normal	O
pulmonary	O
vascular	O
resistance	O
mean	O
pulmonary	O
velocity	O
14	O
.	O
3	O
cm	O
sec	O
.	O
Compared	O
with	O
the	O
August	O
2017	O
examination	O
,	O
the	O
LV	O
volumes	O
improved	O
,	O
as	O
did	O
LVEF	O
.	O
CLINICAL	O
EVOLUTION	O
Continuing	O
with	O
the	O
study	O
of	O
the	O
left	O
ventricular	O
dysfunction	O
detected	O
at	O
the	O
outpatient	O
level	O
,	O
cardiac	O
MRI	O
was	O
performed	O
3	O
weeks	O
after	O
the	O
consultation	O
,	O
showing	O
improvement	O
in	O
ventricular	O
function	O
,	O
with	O
moderate	O
dysfunction	O
,	O
and	O
catheterisation	O
was	O
performed	O
due	O
to	O
the	O
late	O
gadolinium	O
enhancement	O
image	O
suggestive	O
of	O
necrosis	O
,	O
which	O
showed	O
no	O
significant	O
angiographic	O
lesions	O
.	O
The	O
patient	O
did	O
not	O
report	O
catarrhal	O
or	O
other	O
symptoms	O
prior	O
to	O
the	O
current	O
process	O
suggestive	O
of	O
myocarditis	O
prodrome	O
.	O
Only	O
the	O
introduction	O
and	O
completion	O
of	O
HCV	O
antivirals	O
coincided	O
in	O
time	O
.	O
Given	O
the	O
findings	O
of	O
late	O
gadolinium	O
enhancement	O
that	O
could	O
be	O
partially	O
explained	O
by	O
sarcoidosis	O
in	O
a	O
patient	O
with	O
a	O
history	O
of	O
iatrogenic	O
sarcoidosis	O
secondary	O
to	O
the	O
use	O
of	O
interferon	B-FARMACO
,	O
a	O
high	O
resolution	O
CT	O
scan	O
of	O
the	O
lungs	O
was	O
performed	O
,	O
which	O
showed	O
no	O
data	O
suggestive	O
of	O
pulmonary	O
or	O
adenopathic	O
sarcoidosis	O
,	O
nor	O
analytical	O
data	O
of	O
activity	O
ACE	O
,	O
calciuria	O
or	O
elevation	O
of	O
acute	O
phase	O
reactants	O
.	O
A	O
literature	O
search	O
was	O
conducted	O
on	O
cardiotoxicity	O
due	O
to	O
direct	O
antivirals	O
against	O
HCV	O
.	O
Although	O
there	O
is	O
no	O
reference	O
to	O
toxic	O
myocarditis	O
in	O
the	O
data	O
sheet	O
,	O
articles	O
were	O
found	O
referring	O
to	O
toxicity	O
from	O
drugs	O
that	O
act	O
on	O
the	O
same	O
targets	O
and	O
were	O
withdrawn	O
from	O
clinical	O
trials	O
,	O
reversible	O
global	O
longitudinal	O
destrain	O
worsening	O
after	O
sofosbuvir	B-FARMACO
and	O
exclusion	O
of	O
patients	O
with	O
heart	O
disease	O
and	O
without	O
adequate	O
controls	O
with	O
echocardiography	O
of	O
cardiovascular	O
safety	O
in	O
pivotal	O
trials	O
of	O
antiviral	O
drugs	O
against	O
HCV	O
.	O
Because	O
of	O
this	O
,	O
left	O
ventricular	O
dysfunction	O
is	O
attributed	O
to	O
the	O
use	O
of	O
HCV	O
antivirals	O
.	O
After	O
starting	O
treatment	O
,	O
the	O
patient	O
was	O
asymptomatic	O
,	O
with	O
no	O
dyspnoea	O
for	O
activities	O
of	O
daily	O
living	O
.	O
A	O
follow	O
up	O
cardiac	O
MRI	O
was	O
requested	O
after	O
6	O
months	O
,	O
showing	O
normalisation	O
of	O
left	O
ventricular	O
volumes	O
without	O
hypertrophy	O
and	O
improvement	O
in	O
left	O
ventricular	O
function	O
,	O
with	O
mild	O
dysfunction	O
remaining	O
.	O
Subsequently	O
,	O
in	O
echocardiographic	O
controls	O
up	O
to	O
the	O
present	O
,	O
LVEF	O
has	O
normalised	O
and	O
diameters	O
are	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
.	O
The	O
study	O
of	O
iron	O
deficiency	O
anaemia	O
showed	O
three	O
polyps	O
in	O
the	O
right	O
colon	O
at	O
colonoscopy	O
,	O
which	O
were	O
removed	O
without	O
significant	O
histopathological	O
findings	O
.	O
In	O
summary	O
,	O
this	O
is	O
a	O
case	O
of	O
severe	O
left	O
ventricular	O
dysfunction	O
secondary	O
to	O
reversible	O
dilated	O
cardiomyopathy	O
.	O
Although	O
the	O
findings	O
could	O
be	O
explained	O
by	O
a	O
past	O
asymptomatic	O
myocarditis	O
,	O
we	O
consider	O
more	O
likely	O
the	O
possibility	O
of	O
toxic	O
myocarditis	O
related	O
to	O
direct	O
antivirals	O
against	O
HCV	O
,	O
a	O
pathology	O
little	O
studied	O
in	O
our	O
environment	O
,	O
and	O
with	O
drugs	O
widely	O
used	O
in	O
our	O
health	O
system	O
.	O
DIAGNOSIS	O
Non	O
ischaemic	O
dilated	O
cardiomyopathy	O
with	O
severe	O
left	O
ventricular	O
dysfunction	O
,	O
recovered	O
.	O
Suspected	O
toxic	O
myocarditis	O
due	O
to	O
HCV	O
antivirals	O
.	O
Iron	O
deficiency	O
anaemia	O
secondary	O
to	O
colonic	O
polyps	O
.	O
Dyslipidaemia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
known	O
classical	O
cardiovascular	O
risk	O
factors	O
.	O
Obesity	O
type	O
1	O
.	O
Toxic	O
habits	O
ex	O
smoker	O
since	O
youth	O
,	O
until	O
the	O
debut	O
of	O
ischaemic	O
heart	O
disease	O
,	O
with	O
an	O
accumulated	O
consumption	O
of	O
30	O
packets	O
year	O
.	O
Non	O
drinker	O
and	O
non	O
consumer	O
of	O
other	O
toxic	O
substances	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
with	O
debut	O
in	O
2011	O
with	O
acute	O
myocardial	O
infarction	O
with	O
ST	O
segment	O
elevation	O
STEMI	O
anteroseptal	O
Killip	O
III	O
undergoing	O
emergent	O
angioplasty	O
on	O
proximal	O
anterior	O
descending	O
artery	O
ADA	O
with	O
a	O
drug	O
eluting	O
stent	O
and	O
observing	O
chronic	O
occlusion	O
of	O
distal	O
circumflex	O
artery	O
ACx	O
.	O
Currently	O
in	O
dilated	O
phase	O
with	O
very	O
severe	O
ventricular	O
dysfunction	O
LVEF	O
25	O
28	O
in	O
2012	O
,	O
2013	O
and	O
2015	O
,	O
20	O
in	O
2017	O
and	O
18	O
in	O
the	O
last	O
control	O
in	O
2019	O
in	O
follow	O
up	O
by	O
the	O
advanced	O
heart	O
failure	O
and	O
heart	O
transplant	O
unit	O
.	O
Carrier	O
of	O
a	O
Medtronic	O
Protecta	O
single	O
chamber	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
in	O
primary	O
prevention	O
since	O
2012	O
.	O
Peripheral	O
artery	O
disease	O
with	O
70	O
stenosis	O
in	O
the	O
left	O
common	O
iliac	O
artery	O
due	O
to	O
calcified	O
plaque	O
,	O
asymptomatic	O
.	O
Left	O
kidney	O
with	O
abundant	O
cysts	O
some	O
of	O
them	O
calcified	O
in	O
which	O
no	O
renal	O
parenchyma	O
can	O
be	O
seen	O
,	O
which	O
appears	O
non	O
functioning	O
.	O
Current	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
24	O
hours	O
,	O
carvedilol	B-FARMACO
6	O
.	O
25	O
mg	O
12	O
hours	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
24	O
hours	O
,	O
ezetimibe	B-FARMACO
10	O
mg	O
24	O
hours	O
,	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
24	O
26	O
mg	O
12	O
hours	O
,	O
eplerenone	B-FARMACO
25	O
mg	O
24	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
24	O
hours	O
.	O
Present	O
illness	O
53	O
year	O
old	O
male	O
with	O
the	O
previously	O
described	O
history	O
,	O
including	O
ischaemic	O
heart	O
disease	O
in	O
dilated	O
phase	O
with	O
two	O
vessel	O
disease	O
proximal	O
LAD	O
revascularised	O
in	O
2011	O
and	O
chronic	O
occluded	O
ACx	O
at	O
distal	O
level	O
with	O
very	O
severe	O
residual	O
left	O
ventricular	O
dysfunction	O
who	O
was	O
referred	O
to	O
the	O
advanced	O
heart	O
failure	O
and	O
heart	O
transplant	O
unit	O
for	O
evaluation	O
in	O
2017	O
as	O
he	O
was	O
in	O
NYHA	O
functional	O
class	O
III	O
.	O
At	O
that	O
time	O
,	O
a	O
complete	O
pre	O
transplant	O
study	O
was	O
performed	O
without	O
finding	O
any	O
contraindication	O
for	O
transplantation	O
,	O
although	O
given	O
that	O
after	O
adjustment	O
and	O
optimisation	O
of	O
medical	O
treatment	O
the	O
patient	O
remained	O
in	O
good	O
functional	O
condition	O
,	O
it	O
was	O
decided	O
not	O
to	O
include	O
him	O
on	O
the	O
transplant	O
waiting	O
list	O
.	O
He	O
has	O
been	O
clinically	O
monitored	O
by	O
this	O
unit	O
on	O
an	O
outpatient	O
basis	O
since	O
then	O
,	O
with	O
medication	O
readjustments	O
as	O
required	O
.	O
In	O
the	O
2017	O
analytical	O
control	O
,	O
he	O
presented	O
absolute	O
iron	O
deficiency	O
,	O
which	O
was	O
treated	O
with	O
a	O
cycle	O
of	O
intravenous	O
iron	B-FARMACO
carboxymaltose	I-FARMACO
in	O
a	O
single	O
dose	O
of	O
1000	O
mg	O
.	O
At	O
that	O
visit	O
,	O
the	O
patient	O
maintained	O
his	O
usual	O
physical	O
activity	O
,	O
although	O
with	O
certain	O
limitations	O
to	O
moderate	O
efforts	O
,	O
which	O
improved	O
after	O
the	O
replenishment	O
of	O
iron	O
deposits	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Well	O
hydrated	O
and	O
perfused	O
.	O
Height	O
174	O
cm	O
.	O
Weight	O
100	O
kg	O
.	O
Body	O
mass	O
index	O
BMI	O
33	O
.	O
Blood	O
pressure	O
BP	O
in	O
range	O
,	O
in	O
consultation	O
110	O
70	O
mmHg	O
,	O
and	O
heart	O
rate	O
60	O
bpm	O
.	O
Eupneic	O
at	O
rest	O
and	O
when	O
speaking	O
,	O
with	O
no	O
semiology	O
of	O
heart	O
failure	O
.	O
On	O
auscultation	O
,	O
rhythmic	O
heart	O
tones	O
with	O
mitral	O
systolic	O
murmur	O
I	O
II	O
VI	O
without	O
third	O
sound	O
or	O
gallop	O
rhythm	O
.	O
Bladder	O
murmur	O
was	O
preserved	O
without	O
crackles	O
or	O
other	O
added	O
sounds	O
.	O
Abdominal	O
examination	O
was	O
unremarkable	O
.	O
Lower	O
limbs	O
without	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
in	O
consultations	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
.	O
Axis	O
normopositioned	O
at	O
0o	O
.	O
PR	O
200	O
msec	O
.	O
Wide	O
QRS	O
of	O
160	O
msec	O
very	O
variegated	O
with	O
morphology	O
of	O
complete	O
left	O
bundle	O
branch	O
block	O
LBBB	O
and	O
secondary	O
repolarisation	O
disorders	O
.	O
CBC	O
November	O
2019	O
blood	O
glucose	O
106	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
07	O
mg	O
dl	O
,	O
urea	O
26	O
mg	O
dl	O
,	O
sodium	O
144	O
mEq	O
l	O
,	O
potassium	O
5	O
.	O
3	O
mEq	O
l	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
119	O
mg	O
dl	O
,	O
HDL	O
C	O
46	O
mg	O
dl	O
,	O
LDL	O
C	O
60	O
mg	O
dl	O
,	O
triglycerides	O
66	O
mg	O
dl	O
.	O
Normal	O
liver	O
and	O
thyroid	O
profiles	O
.	O
Glycated	O
haemoglobin	O
5	O
.	O
9	O
.	O
Glomerular	O
filtration	O
rate	O
77	O
ml	O
min	O
MDRD	O
.	O
NT	O
proBNP	O
198	O
pg	O
ml	O
.	O
Haemogram	O
without	O
leukocytosis	O
with	O
normal	O
formula	O
.	O
Hb	O
142	O
g	O
l	O
.	O
Platelets	O
262	O
,	O
000	O
.	O
Normal	O
coagulation	O
study	O
.	O
Iron	O
metabolism	O
ferritin	O
45	O
μg	O
l	O
and	O
saturation	O
index	O
of	O
20	O
.	O
Analysis	O
control	O
after	O
treatment	O
with	O
intravenous	O
carboxymaltose	B-FARMACO
ferritin	O
141	O
μg	O
l	O
and	O
saturation	O
index	O
of	O
23	O
.	O
Other	O
parameters	O
were	O
similar	O
to	O
those	O
of	O
the	O
previous	O
control	O
.	O
Chest	O
X	O
ray	O
cardio	O
thoracic	O
index	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
with	O
left	O
hilum	O
slightly	O
blurred	O
and	O
vascular	O
redistribution	O
to	O
the	O
vertex	O
,	O
without	O
evidence	O
of	O
pulmonary	O
congestion	O
.	O
Single	O
chamber	O
ICD	O
with	O
normal	O
positioned	O
electrode	O
in	O
the	O
right	O
ventricular	O
apex	O
.	O
Transthoracic	O
echocardiography	O
November	O
2019	O
slightly	O
dilated	O
left	O
atrium	O
46	O
mm	O
AP	O
.	O
LVOT	O
37	O
ml	O
m2	O
.	O
Mitral	O
valve	O
without	O
organic	O
involvement	O
,	O
preserved	O
opening	O
with	O
symmetric	O
tenting	O
closure	O
and	O
central	O
jet	O
of	O
mild	O
insufficiency	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
without	O
organicity	O
and	O
with	O
normal	O
flows	O
.	O
Aortic	O
root	O
not	O
dilated	O
SV	O
of	O
33	O
mm	O
.	O
Severely	O
dilated	O
left	O
ventricle	O
DTD	O
75	O
mm	O
,	O
DTS	O
68	O
ml	O
,	O
VTD	O
387	O
ml	O
,	O
VTS	O
258	O
ml	O
.	O
LVEF	O
20	O
with	O
global	O
hypokinesia	O
more	O
marked	O
in	O
mid	O
and	O
apical	O
segments	O
.	O
Mitral	O
E	O
85	O
cm	O
sec	O
,	O
A	O
36	O
cm	O
sec	O
,	O
E	O
A	O
2	O
.	O
85	O
,	O
TDE	O
130	O
msec	O
.	O
Septal	O
E	O
'	O
4	O
.	O
8	O
cm	O
sec	O
,	O
lateral	O
E	O
'	O
9	O
.	O
6	O
cm	O
sec	O
,	O
average	O
E	O
e	O
'	O
11	O
.	O
8	O
.	O
Right	O
cavities	O
not	O
dilated	O
.	O
ICD	O
electrode	O
.	O
TAPSE	O
21	O
mm	O
.	O
Light	O
IP	O
.	O
PAP	O
m	O
20	O
mm	O
Hg	O
.	O
Normal	O
IVC	O
.	O
Absence	O
of	O
effusion	O
.	O
Conclusions	O
dilated	O
cardiomyopathy	O
with	O
severe	O
left	O
ventricular	O
dysfunction	O
LVD	O
and	O
mild	O
functional	O
mitral	O
regurgitation	O
MR	O
.	O
Ergospirometry	O
November	O
2018	O
the	O
test	O
was	O
performed	O
according	O
to	O
the	O
modified	O
Bruce	O
ramp	O
protocol	O
without	O
complications	O
.	O
Exercise	O
time	O
12	O
24	O
min	O
,	O
stopped	O
due	O
to	O
fatigue	O
.	O
It	O
reached	O
129	O
bpm	O
,	O
77	O
of	O
the	O
FCMT	O
.	O
The	O
RER	O
at	O
peak	O
effort	O
was	O
1	O
.	O
05	O
which	O
confirms	O
that	O
this	O
is	O
a	O
conclusive	O
test	O
.	O
The	O
test	O
shows	O
a	O
slightly	O
decreased	O
functional	O
capacity	O
with	O
respect	O
to	O
predicted	O
Weber	O
Stage	O
B	O
,	O
peak	O
oxygen	O
consumption	O
19	O
.	O
6	O
ml	O
kg	O
min	O
,	O
76	O
with	O
respect	O
to	O
theoretical	O
,	O
ventilatory	O
class	O
II	O
VE	O
VCO2	O
slope	O
30	O
.	O
6	O
having	O
reached	O
ventilatory	O
threshold	O
2	O
.	O
Baseline	O
CO2	O
PET	O
36	O
increasing	O
to	O
40	O
mmHg	O
.	O
No	O
EOV	O
.	O
No	O
alteration	O
of	O
the	O
ventilatory	O
reserve	O
,	O
not	O
suggesting	O
concomitant	O
ventilatory	O
alteration	O
.	O
From	O
the	O
ECG	O
point	O
of	O
view	O
,	O
there	O
were	O
no	O
dynamic	O
changes	O
.	O
Isolated	O
EV	O
in	O
the	O
recovery	O
phase	O
.	O
Normal	O
blood	O
pressure	O
behaviour	O
baseline	O
124	O
80	O
mmHg	O
and	O
at	O
maximum	O
effort	O
150	O
90	O
mmHg	O
.	O
Conclusions	O
slight	O
decrease	O
in	O
functional	O
capacity	O
with	O
no	O
data	O
of	O
poor	O
prognosis	O
in	O
ergospirometry	O
.	O
CLINICAL	O
EVOLUTION	O
Since	O
the	O
administration	O
of	O
intravenous	O
iron	B-FARMACO
carboxymaltose	I-FARMACO
in	O
2017	O
,	O
the	O
patient	O
has	O
remained	O
asymptomatic	O
and	O
without	O
the	O
need	O
for	O
medication	O
readjustments	O
,	O
with	O
only	O
one	O
admission	O
for	O
decompensation	O
of	O
heart	O
failure	O
in	O
a	O
period	O
of	O
2	O
years	O
.	O
On	O
an	O
outpatient	O
basis	O
,	O
being	O
in	O
a	O
stable	O
phase	O
of	O
heart	O
failure	O
,	O
regular	O
monitoring	O
of	O
iron	O
metabolism	O
has	O
been	O
carried	O
out	O
,	O
as	O
well	O
as	O
the	O
state	O
of	O
the	O
iron	O
deposits	O
,	O
which	O
at	O
all	O
times	O
has	O
maintained	O
stable	O
figures	O
.	O
In	O
the	O
last	O
analytical	O
control	O
November	O
2019	O
,	O
as	O
we	O
can	O
see	O
in	O
PPCC	O
,	O
she	O
again	O
presented	O
data	O
of	O
iron	O
deficit	O
with	O
depleted	O
deposits	O
,	O
without	O
associated	O
anaemia	O
,	O
and	O
it	O
was	O
decided	O
to	O
prescribe	O
a	O
new	O
cycle	O
of	O
intravenous	O
iron	B-FARMACO
carboxymaltose	I-FARMACO
with	O
a	O
dose	O
adjusted	O
according	O
to	O
the	O
patient	O
's	O
weight	O
,	O
and	O
in	O
the	O
last	O
outpatient	O
review	O
by	O
the	O
advanced	O
heart	O
failure	O
and	O
heart	O
transplant	O
unit	O
of	O
our	O
centre	O
she	O
reported	O
an	O
improvement	O
in	O
her	O
current	O
functional	O
situation	O
currently	O
NYHA	O
II	O
.	O
DIAGNOSIS	O
Advanced	O
chronic	O
heart	O
failure	O
.	O
Severe	O
LV	O
systolic	O
dysfunction	O
in	O
a	O
patient	O
with	O
chronic	O
ischaemic	O
heart	O
disease	O
in	O
NYHA	O
functional	O
class	O
II	O
.	O
Carrier	O
of	O
single	O
chamber	O
ICD	O
in	O
primary	O
prevention	O
with	O
no	O
events	O
during	O
follow	O
up	O
.	O
Iron	O
deficiency	O
treated	O
with	O
intravenous	O
iron	B-FARMACO
carboxymaltose	I-FARMACO
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
We	O
present	O
a	O
68	O
year	O
old	O
man	O
,	O
with	O
no	O
known	O
drug	O
allergies	O
,	O
a	O
former	O
smoker	O
for	O
three	O
months	O
and	O
with	O
alcohol	O
consumption	O
only	O
at	O
weekends	O
.	O
His	O
personal	O
history	O
includes	O
arterial	O
hypertension	O
on	O
treatment	O
with	O
torasemide	B-FARMACO
5	O
mg	O
24	O
hours	O
,	O
dyslipidaemia	O
on	O
treatment	O
with	O
simvastatin	B-FARMACO
20	O
mg	O
24	O
hours	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
GOLD	O
1A	O
last	O
spirometry	O
performed	O
in	O
2017	O
TI	O
75	O
,	O
FVC	O
104	O
,	O
FEV1	O
83	O
under	O
follow	O
up	O
by	O
his	O
primary	O
care	O
physician	O
.	O
She	O
has	O
no	O
history	O
of	O
known	O
heart	O
disease	O
.	O
In	O
2018	O
he	O
underwent	O
a	O
right	O
inguinal	O
hernioplasty	O
and	O
in	O
July	O
2019	O
he	O
underwent	O
a	O
retropubic	O
prostatic	O
adenomectomy	O
for	O
benign	O
prostatic	O
hyperplasia	O
with	O
repeated	O
acute	O
urinary	O
retention	O
,	O
having	O
subsequently	O
presented	O
with	O
episodes	O
of	O
haematuria	O
.	O
Present	O
illness	O
The	O
patient	O
was	O
initially	O
referred	O
to	O
the	O
emergency	O
department	O
from	O
his	O
primary	O
care	O
physician	O
for	O
progressive	O
exertional	O
dyspnoea	O
of	O
one	O
month	O
's	O
duration	O
that	O
began	O
after	O
prostate	O
surgery	O
.	O
The	O
dyspnoea	O
was	O
accompanied	O
by	O
two	O
pillow	O
orthopnoea	O
,	O
occasional	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
and	O
bilateral	O
oedema	O
with	O
fovea	O
in	O
the	O
lower	O
extremities	O
.	O
His	O
regular	O
physician	O
had	O
increased	O
the	O
dose	O
of	O
torasemide	O
to	O
double	O
10	O
mg	O
24	O
hours	O
,	O
after	O
which	O
he	O
presented	O
with	O
a	O
weight	O
loss	O
of	O
3	O
kg	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
the	O
patient	O
was	O
haemodynamically	O
stable	O
,	O
tachycardic	O
at	O
110	O
bpm	O
and	O
had	O
a	O
baseline	O
saturation	O
of	O
95	O
.	O
Given	O
the	O
presence	O
of	O
congestive	O
signs	O
hypoventilation	O
in	O
the	O
right	O
base	O
with	O
bilateral	O
crackles	O
,	O
discrete	O
hepatomegaly	O
and	O
oedema	O
with	O
bilateral	O
fovea	O
up	O
to	O
the	O
thighs	O
and	O
an	O
elevation	O
of	O
NT	O
proBNP	O
up	O
to	O
4623	O
pg	O
ml	O
normal	O
range	O
0	O
300	O
pg	O
ml	O
,	O
he	O
was	O
admitted	O
to	O
the	O
cardiology	O
department	O
to	O
study	O
the	O
first	O
episode	O
of	O
heart	O
failure	O
.	O
Physical	O
examination	O
On	O
admission	O
to	O
the	O
cardiology	O
department	O
,	O
the	O
patient	O
was	O
haemodynamically	O
stable	O
,	O
with	O
a	O
blood	O
pressure	O
of	O
114	O
75	O
mmHg	O
,	O
tachycardic	O
at	O
110	O
bpm	O
and	O
oxygen	O
saturation	O
around	O
96	O
baseline	O
.	O
There	O
was	O
no	O
jugular	O
plethora	O
.	O
On	O
cardiac	O
auscultation	O
he	O
was	O
rhythmic	O
,	O
with	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
posterior	O
plane	O
showed	O
decreased	O
vesicular	O
murmur	O
in	O
the	O
right	O
base	O
with	O
bilateral	O
crackles	O
.	O
He	O
had	O
a	O
hepatomegaly	O
of	O
3	O
4	O
cm	O
,	O
and	O
on	O
the	O
extremities	O
there	O
was	O
bilateral	O
oedema	O
with	O
pitting	O
up	O
to	O
the	O
thighs	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
100	O
bpm	O
,	O
normal	O
PR	O
,	O
QRS	O
axis	O
at	O
0o	O
,	O
narrow	O
QRS	O
,	O
with	O
known	O
flattened	O
T	O
waves	O
and	O
frequent	O
supraventricular	O
extrasystoles	O
.	O
Laboratory	O
tests	O
on	O
admission	O
Venous	O
blood	O
gas	O
pH	O
7	O
.	O
51	O
,	O
pCO2	O
32	O
mmHg	O
,	O
bicarbonate	O
26	O
mEq	O
ml	O
.	O
Biochemistry	O
glucose	O
112	O
mg	O
dl	O
;	O
urea	O
56	O
mg	O
dl	O
;	O
creatinine	O
1	O
.	O
00	O
mg	O
dl	O
;	O
GPT	O
25	O
U	O
l	O
;	O
bilirubin	O
1	O
.	O
4	O
mg	O
dl	O
;	O
calcium	O
8	O
.	O
9	O
mg	O
dl	O
;	O
sodium	O
145	O
mEq	O
l	O
;	O
potassium	O
3	O
.	O
6	O
mEq	O
l	O
;	O
chloride	O
108	O
mEq	O
l	O
;	O
CRP	O
2	O
.	O
28	O
mg	O
l	O
;	O
creatine	O
kinase	O
71	O
U	O
l	O
;	O
lactate	O
dehydrogenase	O
188	O
U	O
l	O
;	O
NT	O
proBNP	O
4623	O
pg	O
ml	O
.	O
Haemoglobin	O
10	O
.	O
8	O
g	O
dl	O
;	O
haematocrit	O
34	O
.	O
4	O
;	O
mean	O
corpuscular	O
volume	O
MCV	O
96	O
.	O
1	O
fl	O
;	O
mean	O
corpuscular	O
haemoglobin	O
concentration	O
31	O
.	O
4	O
g	O
dl	O
;	O
mean	O
erythrocyte	O
corpuscular	O
haemoglobin	O
MCH	O
30	O
.	O
2	O
pg	O
;	O
erythrocyte	O
distribution	O
amplitude	O
EDA	O
14	O
.	O
5	O
;	O
platelets	O
209	O
10	O
3	O
ƒÊL	O
;	O
leucocytes	O
6	O
.	O
61	O
10	O
3	O
ƒÊL	O
.	O
Coagulation	O
INR	O
1	O
.	O
3	O
.	O
Other	O
laboratory	O
tests	O
of	O
interest	O
Lipid	O
profile	O
total	O
cholesterol	O
142	O
mg	O
dl	O
,	O
triglycerides	O
85	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
36	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
calculated	O
89	O
mg	O
dl	O
,	O
non	O
HDL	O
cholesterol	O
106	O
mg	O
dl	O
,	O
urate	O
6	O
.	O
2	O
mg	O
dl	O
.	O
Iron	O
profile	O
iron	O
38	O
ug	O
ml	O
,	O
transferrin	O
345	O
mg	O
dl	O
,	O
transferrin	O
saturation	O
index	O
TSI	O
8	O
,	O
ferritin	O
50	O
ng	O
ml	O
.	O
Vitamin	O
B12	O
406	O
pg	O
ml	O
,	O
folate	O
4	O
.	O
6	O
ng	O
ml	O
.	O
Glycosylated	O
haemoglobin	O
5	O
.	O
8	O
.	O
Thyrotropin	O
TSH	O
2	O
.	O
61	O
mU	O
l	O
.	O
Serology	O
HCV	O
negative	O
,	O
HIV	O
negative	O
,	O
CMV	O
negative	O
,	O
parvovirus	O
B19	O
Ig	O
G	O
positive	O
Ig	O
M	O
negative	O
,	O
enterovirus	O
negative	O
,	O
adenovirus	O
pending	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
cardiothoracic	O
index	O
at	O
the	O
limit	O
,	O
with	O
pinching	O
of	O
both	O
costophrenic	O
sinuses	O
without	O
other	O
condensations	O
.	O
Chest	O
X	O
ray	O
prior	O
to	O
discharge	O
minimal	O
impingement	O
of	O
the	O
right	O
costophrenic	O
sinus	O
with	O
significant	O
improvement	O
compared	O
to	O
the	O
previous	O
one	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
videos	O
1	O
,	O
2	O
,	O
3	O
severely	O
dilated	O
left	O
ventricle	O
,	O
with	O
severely	O
reduced	O
systolic	O
function	O
LVEF	O
estimated	O
by	O
Simpson	O
biplane	O
15	O
21	O
due	O
to	O
severe	O
global	O
hypokinesia	O
.	O
Doppler	O
transmitral	O
flow	O
pattern	O
suggested	O
restrictive	O
physiology	O
.	O
Mildly	O
dilated	O
right	O
ventricle	O
with	O
mildly	O
depressed	O
function	O
.	O
Moderately	O
dilated	O
left	O
atrium	O
and	O
mildly	O
to	O
moderately	O
dilated	O
right	O
atrium	O
.	O
Mitral	O
valve	O
leaflets	O
thickened	O
,	O
with	O
moderate	O
mitral	O
insufficiency	O
.	O
The	O
tricuspid	O
valve	O
had	O
moderate	O
severe	O
insufficiency	O
,	O
with	O
a	O
maximum	O
RV	O
AD	O
gradient	O
of	O
60	O
.	O
7	O
mmHg	O
,	O
and	O
an	O
estimated	O
PSAP	O
of	O
75	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
was	O
dilated	O
and	O
inspiratory	O
collapse	O
was	O
less	O
than	O
50	O
.	O
The	O
aortic	O
valve	O
was	O
trivalve	O
,	O
with	O
sclerodegenerative	O
leaflets	O
with	O
only	O
mild	O
moderate	O
aortic	O
insufficiency	O
,	O
without	O
aortic	O
root	O
dilatation	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
performed	O
during	O
outpatient	O
follow	O
up	O
severely	O
dilated	O
left	O
ventricle	O
with	O
severely	O
depressed	O
global	O
function	O
with	O
diffuse	O
hypokinesia	O
LVEF	O
29	O
.	O
Mildly	O
dilated	O
right	O
ventricle	O
with	O
mild	O
systolic	O
dysfunction	O
LVEF	O
44	O
.	O
Late	O
enhancement	O
sequence	O
shows	O
linear	O
intramyocardial	O
enhancement	O
in	O
the	O
basal	O
septum	O
and	O
septal	O
insertion	O
points	O
,	O
non	O
ischaemic	O
.	O
In	O
addition	O
,	O
a	O
mild	O
bilateral	O
pleural	O
effusion	O
was	O
observed	O
as	O
an	O
extracardiac	O
finding	O
.	O
Catheterisation	O
via	O
the	O
right	O
radial	O
artery	O
Left	O
coronary	O
angiography	O
common	O
trunk	O
without	O
lesions	O
.	O
The	O
anterior	O
descending	O
artery	O
shows	O
diffuse	O
calcified	O
atheromatosis	O
with	O
mild	O
stenosis	O
without	O
any	O
significant	O
stenosis	O
.	O
The	O
circumflex	O
artery	O
of	O
medium	O
extension	O
and	O
ectatic	O
calibre	O
at	O
the	O
proximal	O
level	O
also	O
shows	O
diffuse	O
calcified	O
atheromatosis	O
with	O
moderate	O
stenosis	O
at	O
the	O
marginal	O
proximal	O
level	O
.	O
Right	O
coronary	O
angiography	O
the	O
right	O
coronary	O
artery	O
is	O
the	O
dominant	O
vessel	O
,	O
very	O
atheromatous	O
and	O
with	O
an	O
ectatic	O
and	O
irregular	O
calibre	O
all	O
the	O
way	O
to	O
the	O
lumen	O
.	O
There	O
is	O
a	O
severe	O
ulcerated	O
lesion	O
at	O
the	O
proximal	O
level	O
70	O
.	O
At	O
the	O
end	O
of	O
the	O
middle	O
segment	O
there	O
is	O
a	O
calcified	O
focal	O
stenosis	O
with	O
severe	O
stenosis	O
85	O
.	O
The	O
posterior	O
descending	O
branch	O
is	O
of	O
medium	O
extension	O
and	O
with	O
severe	O
focal	O
stenosis	O
proximally	O
.	O
Pressure	O
guidewire	O
in	O
the	O
circumflex	O
the	O
moderate	O
circumflex	O
lesion	O
is	O
explored	O
with	O
pressure	O
guidewire	O
without	O
adenosine	O
RFR	O
,	O
parameter	O
at	O
rest	O
and	O
is	O
found	O
not	O
to	O
cause	O
ischaemia	O
RFR	O
0	O
.	O
96	O
0	O
.	O
98	O
and	O
is	O
therefore	O
not	O
treated	O
.	O
Coronary	O
intervention	O
the	O
stenosis	O
described	O
in	O
the	O
middle	O
segment	O
of	O
the	O
DC	O
is	O
predilated	O
with	O
a	O
4	O
.	O
0	O
mm	O
balloon	O
with	O
subsequent	O
implantation	O
of	O
a	O
pharmacoactive	O
usntent	O
with	O
post	O
dilatation	O
with	O
a	O
4	O
.	O
5	O
mm	O
balloon	O
at	O
20	O
atm	O
with	O
good	O
results	O
.	O
Subsequently	O
,	O
after	O
predilatation	O
with	O
a	O
4	O
.	O
0	O
mm	O
balloon	O
,	O
another	O
drug	O
eluting	O
stent	O
was	O
implanted	O
over	O
the	O
ulcerated	O
lesion	O
described	O
in	O
the	O
proximal	O
segment	O
.	O
A	O
severe	O
residual	O
stenosis	O
is	O
evident	O
at	O
its	O
proximal	O
edge	O
,	O
which	O
makes	O
it	O
necessary	O
to	O
implant	O
another	O
stent	O
at	O
this	O
level	O
,	O
covering	O
the	O
vessel	O
ostium	O
.	O
These	O
last	O
two	O
stents	O
were	O
post	O
dilated	O
with	O
a	O
4	O
.	O
5	O
NC	O
balloon	O
at	O
high	O
pressure	O
with	O
a	O
good	O
final	O
result	O
slight	O
under	O
expansion	O
at	O
the	O
ostial	O
level	O
of	O
around	O
20	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
a	O
68	O
year	O
old	O
man	O
admitted	O
for	O
a	O
first	O
episode	O
of	O
heart	O
failure	O
following	O
planned	O
prostate	O
surgery	O
.	O
During	O
admission	O
,	O
diuretic	O
treatment	O
was	O
started	O
,	O
initially	O
intravenously	O
,	O
and	O
was	O
later	O
changed	O
to	O
oral	O
therapy	O
due	O
to	O
the	O
excellent	O
response	O
to	O
it	O
,	O
with	O
rapid	O
resolution	O
of	O
the	O
congestive	O
signs	O
.	O
In	O
addition	O
,	O
after	O
the	O
acute	O
phase	O
,	O
neurohormonal	O
treatment	O
was	O
started	O
progressively	O
with	O
good	O
tolerance	O
nebivolol	B-FARMACO
5	O
mg	O
half	O
tablet	O
every	O
12	O
hours	O
as	O
he	O
was	O
a	O
bronchopathic	O
patient	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
and	O
finally	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
24	O
26	O
mg	O
every	O
12	O
hours	O
,	O
with	O
no	O
alterations	O
in	O
renal	O
function	O
or	O
symptomatic	O
hypotension	O
.	O
An	O
echocardiogram	O
showed	O
dilated	O
cardiomyopathy	O
with	O
severe	O
left	O
ventricular	O
dysfunction	O
due	O
to	O
severe	O
global	O
hypokinesia	O
,	O
and	O
the	O
aetiological	O
study	O
of	O
this	O
entity	O
was	O
initiated	O
.	O
A	O
directed	O
anamnesis	O
was	O
performed	O
,	O
in	O
which	O
a	O
significant	O
history	O
of	O
enolism	O
and	O
exposure	O
to	O
toxins	O
,	O
previous	O
chest	O
pain	O
or	O
angina	O
pectoris	O
,	O
and	O
data	O
suspicious	O
of	O
myocarditis	O
were	O
ruled	O
out	O
.	O
Due	O
to	O
the	O
characteristics	O
of	O
our	O
centre	O
and	O
the	O
availability	O
of	O
performing	O
a	O
catheterisation	O
more	O
quickly	O
than	O
a	O
cardiac	O
magnetic	O
resonance	O
imaging	O
,	O
cardiac	O
catheterisation	O
was	O
performed	O
first	O
,	O
which	O
revealed	O
severe	O
stenosis	O
of	O
the	O
right	O
coronary	O
artery	O
in	O
which	O
three	O
drug	O
eluting	O
stents	O
were	O
implanted	O
.	O
A	O
cardiac	O
magnetic	O
resonance	O
imaging	O
was	O
still	O
to	O
be	O
performed	O
at	O
the	O
time	O
of	O
discharge	O
.	O
On	O
the	O
other	O
hand	O
,	O
blood	O
tests	O
showed	O
normochromic	O
normocytic	O
anaemia	O
with	O
a	O
normal	O
range	O
of	O
red	O
blood	O
cell	O
distribution	O
,	O
but	O
with	O
low	O
iron	O
,	O
ferritin	O
and	O
transferrin	O
saturation	O
index	O
.	O
The	O
digestive	O
tract	O
was	O
ruled	O
out	O
as	O
the	O
origin	O
of	O
the	O
anaemia	O
,	O
as	O
there	O
were	O
no	O
clinical	O
signs	O
to	O
suggest	O
this	O
and	O
the	O
faecal	O
occult	O
blood	O
test	O
performed	O
during	O
admission	O
was	O
negative	O
.	O
In	O
addition	O
,	O
vitamin	O
B12	O
and	O
folic	O
acid	O
deficiency	O
were	O
ruled	O
out	O
as	O
possible	O
alternative	O
causes	O
although	O
the	O
characteristics	O
of	O
the	O
anaemia	O
did	O
not	O
suggest	O
this	O
aetiology	O
.	O
The	O
anaemia	O
was	O
interpreted	O
in	O
the	O
context	O
of	O
the	O
previous	O
episodes	O
of	O
haematuria	O
and	O
the	O
recent	O
surgery	O
,	O
and	O
it	O
was	O
decided	O
to	O
start	O
treatment	O
with	O
intravenous	O
iron	B-FARMACO
in	O
the	O
form	O
of	O
iron	B-FARMACO
carboxymaltose	I-FARMACO
at	O
an	O
initial	O
dose	O
of	O
1000	O
mg	O
,	O
without	O
complications	O
during	O
the	O
infusion	O
.	O
At	O
discharge	O
,	O
the	O
patient	O
was	O
euvolaemic	O
,	O
with	O
no	O
congestive	O
signs	O
,	O
and	O
the	O
heart	O
failure	O
unit	O
of	O
our	O
hospital	O
was	O
contacted	O
,	O
who	O
decided	O
to	O
include	O
the	O
patient	O
in	O
the	O
remote	O
telemonitoring	O
programme	O
for	O
close	O
patient	O
follow	O
up	O
.	O
During	O
subsequent	O
follow	O
up	O
in	O
the	O
heart	O
failure	O
unit	O
,	O
the	O
patient	O
reported	O
being	O
stable	O
since	O
discharge	O
,	O
with	O
NYHA	O
II	O
III	O
IV	O
dyspnoea	O
,	O
stable	O
weight	O
,	O
minimal	O
oedema	O
in	O
the	O
ankles	O
and	O
good	O
tolerance	O
to	O
neurohormonal	O
treatment	O
.	O
Approximately	O
two	O
months	O
after	O
discharge	O
,	O
the	O
patient	O
again	O
began	O
to	O
show	O
signs	O
of	O
congestion	O
he	O
reported	O
an	O
increase	O
in	O
his	O
baseline	O
dyspnoea	O
and	O
oedema	O
with	O
fovea	O
in	O
the	O
lower	O
limbs	O
which	O
led	O
to	O
an	O
increase	O
in	O
oral	O
diuretic	O
treatment	O
,	O
with	O
a	O
good	O
clinical	O
response	O
.	O
In	O
addition	O
,	O
a	O
control	O
blood	O
test	O
showed	O
anaemia	O
haemoglobin	O
12	O
.	O
6	O
g	O
dl	O
with	O
a	O
ferritin	O
level	O
of	O
49	O
ng	O
ml	O
and	O
a	O
transferrin	O
saturation	O
index	O
of	O
11	O
.	O
1	O
,	O
without	O
the	O
patient	O
reporting	O
bleeding	O
at	O
any	O
level	O
,	O
so	O
it	O
was	O
decided	O
to	O
start	O
a	O
new	O
course	O
of	O
intravenous	O
iron	B-FARMACO
carboxymaltose	I-FARMACO
with	O
the	O
aim	O
of	O
improving	O
the	O
patient	O
's	O
exercise	O
capacity	O
and	O
quality	O
of	O
life	O
.	O
After	O
the	O
administration	O
of	O
an	O
initial	O
dose	O
of	O
1000	O
mg	O
in	O
the	O
day	O
hospital	O
of	O
our	O
centre	O
,	O
with	O
no	O
incidents	O
during	O
the	O
same	O
,	O
a	O
new	O
evaluation	O
of	O
the	O
patient	O
is	O
pending	O
to	O
assess	O
the	O
need	O
to	O
complete	O
the	O
regimen	O
with	O
intravenous	O
iron	B-FARMACO
.	O
DIAGNOSIS	O
Heart	O
failure	O
,	O
first	O
episode	O
.	O
Dilated	O
cardiomyopathy	O
,	O
non	O
ischaemic	O
,	O
with	O
severely	O
depressed	O
LVEF	O
LVEF	O
estimated	O
by	O
Simpson	O
biplane	O
15	O
20	O
.	O
Moderate	O
functional	O
mitral	O
regurgitation	O
.	O
Moderate	O
severe	O
tricuspid	O
regurgitation	O
with	O
severe	O
pulmonary	O
hypertension	O
.	O
Severe	O
single	O
vessel	O
coronary	O
artery	O
disease	O
right	O
coronary	O
treated	O
with	O
implantation	O
of	O
three	O
drug	O
eluting	O
stents	O
,	O
and	O
moderate	O
single	O
vessel	O
coronary	O
artery	O
disease	O
obtuse	O
marginal	O
.	O
Normocytic	O
normochromic	O
anaemia	O
with	O
iron	O
deficiency	O
.	O

Background	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
arterial	O
hypertension	O
HT	O
with	O
target	O
organ	O
damage	O
,	O
type	O
2	O
diabetes	O
mellitus	O
DM	O
with	O
macro	O
and	O
microvascular	O
involvement	O
,	O
LBP	O
,	O
active	O
smoker	O
estimated	O
IPA	O
135	O
.	O
Stage	O
II	O
chronic	O
kidney	O
disease	O
of	O
probably	O
mixed	O
aetiology	O
hypertensive	O
and	O
diabetic	O
,	O
with	O
estimated	O
glomerular	O
filtration	O
rate	O
around	O
60	O
ml	O
min	O
and	O
proteinuria	O
in	O
non	O
nephrotic	O
range	O
1	O
.	O
1	O
g	O
24	O
hours	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
with	O
severe	O
three	O
vessel	O
disease	O
surgically	O
revascularised	O
in	O
2016	O
AMI	O
DA	O
and	O
VSI	O
OM	O
grafts	O
,	O
the	O
latter	O
chronically	O
occluded	O
,	O
with	O
mild	O
LV	O
systolic	O
dysfunction	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
AF	O
anticoagulated	O
with	O
acenocoumarol	B-FARMACO
.	O
Ischaemic	O
stroke	O
in	O
the	O
right	O
posterior	O
cerebral	O
artery	O
PCA	O
territory	O
of	O
probable	O
cardioembolic	O
aetiology	O
.	O
Moderate	O
sleep	O
apnoea	O
hypopnoea	O
syndrome	O
SAHS	O
.	O
Chronic	O
grade	O
IIA	O
ischaemia	O
in	O
the	O
right	O
lower	O
limb	O
.	O
Home	O
treatment	O
Atorvastatin	B-FARMACO
80	O
mg	O
0	O
0	O
1	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
0	O
1	O
0	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
1	O
0	O
1	O
,	O
acenocoumarol	B-FARMACO
according	O
to	O
INR	O
controls	O
,	O
ivabradine	B-FARMACO
5	O
mg	O
1	O
0	O
1	O
,	O
amlodipine	B-FARMACO
5	O
mg	O
1	O
0	O
0	O
,	O
candesartan	B-FARMACO
4	O
mg	O
1	O
0	O
1	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
1	O
0	O
0	O
,	O
metformin	B-FARMACO
850	O
mg	O
1	O
0	O
0	O
,	O
furosemide	B-FARMACO
40	O
mg	O
2	O
0	O
.	O
5	O
0	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
.	O
Present	O
illness	O
The	O
patient	O
is	O
a	O
60	O
year	O
old	O
man	O
with	O
the	O
aforementioned	O
history	O
,	O
including	O
multiple	O
CVRF	O
and	O
established	O
vascular	O
disease	O
,	O
with	O
chronic	O
ischaemic	O
heart	O
disease	O
,	O
surgically	O
revascularised	O
and	O
with	O
mild	O
residual	O
LV	O
systolic	O
dysfunction	O
,	O
who	O
is	O
admitted	O
to	O
the	O
neurology	O
department	O
for	O
ischaemic	O
stroke	O
of	O
atherothrombotic	O
aetiology	O
in	O
the	O
left	O
middle	O
cerebral	O
artery	O
MCA	O
,	O
with	O
mechanical	O
thrombectomy	O
and	O
destent	O
implantation	O
at	O
the	O
level	O
of	O
the	O
left	O
carotid	O
artery	O
.	O
During	O
admission	O
,	O
the	O
patient	O
presented	O
an	O
episode	O
of	O
decompensation	O
of	O
heart	O
failure	O
and	O
was	O
transferred	O
to	O
the	O
cardiology	O
department	O
for	O
monitoring	O
,	O
study	O
and	O
intensive	O
diuretic	O
treatment	O
.	O
Physical	O
examination	O
On	O
assessment	O
by	O
cardiology	O
General	O
condition	O
is	O
fair	O
.	O
Conscious	O
,	O
oriented	O
in	O
all	O
3	O
spheres	O
and	O
cooperative	O
.	O
Normal	O
colour	O
,	O
normohydrated	O
and	O
normoperfused	O
.	O
Afebrile	O
to	O
the	O
touch	O
.	O
Tachypneic	O
at	O
rest	O
,	O
with	O
intolerance	O
to	O
decubitus	O
.	O
Blood	O
pressure	O
BP	O
160	O
70	O
mm	O
Hg	O
.	O
Heart	O
rate	O
HR	O
73	O
bpm	O
.	O
SpO2	O
91	O
with	O
low	O
flow	O
oxygen	O
therapy	O
nasal	O
cannulas	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
.	O
No	O
murmurs	O
,	O
extratonos	O
or	O
pericardial	O
friction	O
rub	O
.	O
Pulmonary	O
auscultation	O
generalised	O
hypoventilation	O
in	O
both	O
lung	O
fields	O
.	O
Lower	O
extremities	O
pedial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
Edema	O
with	O
bilateral	O
fovea	O
up	O
to	O
the	O
knees	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
,	O
PR	O
160	O
ms	O
,	O
narrow	O
QRS	O
,	O
without	O
repolarisation	O
alterations	O
suggestive	O
of	O
acute	O
ischaemia	O
.	O
Chest	O
X	O
ray	O
AP	O
projection	O
.	O
Bilateral	O
pleural	O
effusion	O
minimal	O
left	O
,	O
more	O
evident	O
on	O
the	O
right	O
.	O
Congestive	O
hilarity	O
and	O
vascular	O
redistribution	O
.	O
Laboratory	O
tests	O
on	O
admission	O
Biochemistry	O
glucose	O
186	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
98	O
mg	O
dl	O
,	O
sodium	O
140	O
mEq	O
l	O
,	O
total	O
protein	O
7	O
.	O
5	O
g	O
dl	O
,	O
potassium	O
4	O
.	O
59	O
mEq	O
l	O
,	O
albumin	O
4	O
.	O
0	O
g	O
dl	O
,	O
chlorine	O
102	O
mEq	O
l	O
,	O
ALT	O
GPT	O
21	O
U	O
l	O
,	O
AST	O
GOT	O
25	O
U	O
l	O
,	O
gamma	O
GT	O
34	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
125	O
U	O
l	O
,	O
LDH	O
384	O
U	O
l	O
,	O
bilirubin	O
0	O
.	O
8	O
mg	O
dl	O
,	O
C	O
reactive	O
protein	O
3	O
.	O
02	O
mg	O
dl	O
.	O
Haemogram	O
red	O
cells	O
4	O
.	O
56	O
xmill	O
μl	O
,	O
haemoglobin	O
14	O
.	O
9	O
g	O
dl	O
,	O
haematocrit	O
45	O
.	O
6	O
,	O
MCH	O
32	O
.	O
8	O
pg	O
,	O
MCV	O
100	O
.	O
2	O
fl	O
,	O
MCHC	O
32	O
.	O
7	O
g	O
dl	O
,	O
RDW	O
14	O
.	O
5	O
,	O
platelets	O
277	O
x1000	O
μl	O
,	O
MPV	O
8	O
.	O
8	O
fl	O
,	O
leucocytes	O
8	O
.	O
4	O
x1000	O
μl	O
,	O
neutrophils	O
6	O
.	O
8	O
x1000	O
μl	O
,	O
neutrophils	O
81	O
.	O
2	O
,	O
lymphocytes	O
0	O
.	O
8	O
x1000	O
μl	O
,	O
lymphocytes	O
9	O
.	O
9	O
,	O
monocytes	O
0	O
.	O
7	O
x1000	O
μl	O
,	O
monocytes	O
7	O
.	O
9	O
,	O
eosinophils	O
0	O
.	O
0	O
x1000	O
μl	O
,	O
eosinophils	O
0	O
.	O
5	O
,	O
basophils	O
0	O
.	O
0	O
x1000	O
μl	O
,	O
basophils	O
0	O
.	O
5	O
.	O
Coagulation	O
prothrombin	O
time	O
16	O
.	O
3	O
sec	O
,	O
prothrombin	O
activity	O
61	O
,	O
INR	O
lab	O
1	O
.	O
41	O
,	O
TTPa	O
36	O
sec	O
,	O
fibrinogen	O
derivative	O
597	O
mg	O
dl	O
.	O
NT	O
proBNP	O
10053	O
pg	O
ml	O
.	O
Blood	O
tests	O
with	O
cardiovascular	O
risk	O
factors	O
Hb	O
glycated	O
DCCT	O
7	O
.	O
2	O
Hbtotal	O
,	O
TSH	O
4	O
.	O
49	O
μlU	O
ml	O
,	O
free	O
T4	O
1	O
.	O
17	O
ng	O
dl	O
,	O
cholesterol	O
108	O
mg	O
dl	O
,	O
triglycerides	O
102	O
mg	O
dl	O
,	O
LDL	O
Friedewald	O
estimation	O
67	O
mg	O
dl	O
,	O
HDL	O
21	O
mg	O
dl	O
.	O
Blood	O
tests	O
at	O
discharge	O
glucose	O
153	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
69	O
mg	O
dl	O
,	O
sodium	O
134	O
mEq	O
l	O
,	O
potassium	O
5	O
.	O
1mEq	O
l	O
,	O
chlorine	O
98	O
mEq	O
l	O
,	O
calcium	O
9	O
.	O
2	O
mg	O
dl	O
,	O
NT	O
proBNP	O
2640	O
pg	O
ml	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
not	O
dilated	O
,	O
with	O
normal	O
wall	O
thickness	O
.	O
Moderately	O
depressed	O
systolic	O
function	O
with	O
alterations	O
in	O
segmental	O
contractility	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
normal	O
systolic	O
function	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
.	O
Moderate	O
severe	O
pulmonary	O
hypertension	O
.	O
Coronary	O
angiography	O
severe	O
lesion	O
in	O
the	O
proximal	O
segment	O
of	O
the	O
anterior	O
descending	O
artery	O
ADA	O
,	O
which	O
is	O
revascularised	O
with	O
drug	O
eluting	O
stent	O
.	O
Mammary	O
anastomosis	O
permeable	O
and	O
without	O
lesions	O
.	O
Non	O
dominant	O
circumflex	O
,	O
giving	O
a	O
first	O
OM	O
occluded	O
from	O
the	O
origin	O
,	O
with	O
distal	O
filling	O
by	O
homocoronary	O
circulation	O
.	O
Saphenous	O
graft	O
and	O
right	O
coronary	O
artery	O
not	O
probed	O
as	O
they	O
were	O
previously	O
occluded	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
had	O
a	O
good	O
clinical	O
and	O
analytical	O
evolution	O
initial	O
NT	O
proBNP	O
of	O
10053	O
pg	O
ml	O
and	O
final	O
of	O
2640	O
pg	O
ml	O
after	O
starting	O
combined	O
diuretic	O
treatment	O
furosemide	B-FARMACO
,	O
chlorthalidone	B-FARMACO
and	O
3	O
day	O
cycle	O
of	O
acetazolamide	B-FARMACO
given	O
the	O
tendency	O
to	O
metabolic	O
alkalosis	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
deterioration	O
of	O
ventricular	O
function	O
compared	O
to	O
the	O
previous	O
study	O
;	O
in	O
addition	O
,	O
the	O
patient	O
reported	O
episodes	O
of	O
typical	O
chest	O
pain	O
both	O
at	O
home	O
and	O
during	O
admission	O
,	O
so	O
coronary	O
angiography	O
was	O
performed	O
,	O
revealing	O
severe	O
stenosis	O
in	O
the	O
proximal	O
segment	O
of	O
the	O
LAD	O
,	O
which	O
was	O
revascularised	O
by	O
implanting	O
a	O
drug	O
eluting	O
stent	O
.	O
She	O
was	O
maintained	O
on	O
triple	O
antithrombotic	O
therapy	O
with	O
ASA	B-FARMACO
,	O
clopidogrel	B-FARMACO
and	O
dabigatran	B-FARMACO
110	O
mg	O
during	O
hospitalisation	O
,	O
and	O
ASA	B-FARMACO
was	O
withdrawn	O
on	O
discharge	O
.	O
Given	O
the	O
analytical	O
finding	O
of	O
poor	O
chronic	O
metabolic	O
control	O
of	O
his	O
type	O
2	O
DM	O
Hb	O
glycaemia	O
7	O
.	O
2	O
,	O
it	O
was	O
decided	O
to	O
introduce	O
an	O
iSGLT2	O
empagliflozin	B-FARMACO
for	O
secondary	O
prevention	O
of	O
cardiovascular	O
events	O
despite	O
acute	O
renal	O
failure	O
of	O
probably	O
mixed	O
origin	O
pre	O
renal	O
and	O
contrast	O
nephropathy	O
,	O
with	O
a	O
glomerular	O
filtration	O
rate	O
GFR	O
at	O
discharge	O
calculated	O
according	O
to	O
the	O
CKD	O
EPI	O
formula	O
of	O
43	O
ml	O
min	O
m	O
.	O
DIAGNOSIS	O
Congestive	O
heart	O
failure	O
in	O
anasarca	O
.	O
Moderate	O
left	O
ventricular	O
dysfunction	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
with	O
poor	O
chronic	O
metabolic	O
control	O
HbA1c	O
7	O
.	O
2	O
and	O
macro	O
and	O
microvascular	O
involvement	O
.	O
Three	O
vessel	O
coronary	O
artery	O
disease	O
severe	O
stenosis	O
of	O
the	O
proximal	O
anterior	O
descending	O
artery	O
,	O
revascularised	O
percutaneously	O
by	O
means	O
of	O
a	O
drug	O
eluting	O
dsetent	O
implant	O
.	O
Ischaemic	O
stroke	O
secondary	O
to	O
left	O
carotid	O
artery	O
occlusion	O
,	O
revascularised	O
by	O
stent	O
.	O
Initial	O
NIHSS	O
of	O
9	O
.	O
NIHSS	O
at	O
discharge	O
of	O
2	O
.	O

Functional	O
situation	O
Physical	O
status	O
IABVD	O
.	O
Current	O
history	O
84	O
year	O
old	O
woman	O
with	O
no	O
PA	O
of	O
interest	O
presented	O
with	O
progressive	O
dyspnoea	O
of	O
more	O
than	O
2	O
weeks	O
'	O
evolution	O
until	O
minimal	O
effort	O
,	O
orthopnoea	O
and	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
She	O
reported	O
dubious	O
palpitations	O
for	O
several	O
days	O
but	O
denied	O
angina	O
,	O
syncope	O
or	O
other	O
symptoms	O
.	O
No	O
recent	O
infections	O
,	O
no	O
changes	O
in	O
medication	O
or	O
any	O
other	O
cause	O
justifying	O
the	O
decompensation	O
.	O
Physical	O
examination	O
Admission	O
BP	O
138	O
90	O
mmHg	O
HR	O
166	O
bpm	O
.	O
Ta	O
36	O
.	O
2	O
C	O
.	O
SatO2	O
95	O
basal	O
BEG	O
.	O
IY	O
.	O
ACP	O
Arrhythmic	O
without	O
murmurs	O
;	O
MVC	O
with	O
crackles	O
up	O
to	O
midfields	O
.	O
MMII	O
oedema	O
up	O
to	O
middle	O
third	O
,	O
no	O
signs	O
of	O
DVT	O
.	O
At	O
discharge	O
BP	O
100	O
70	O
mmHg	O
HR	O
80	O
bpm	O
.	O
ACP	O
Arrhythmic	O
without	O
murmurs	O
;	O
CVM	O
with	O
crackles	O
in	O
right	O
base	O
.	O
MMII	O
no	O
oedema	O
or	O
signs	O
of	O
DVT	O
.	O
Summary	O
of	O
complementary	O
tests	O
Laboratory	O
Urgent	O
CBC	O
03	O
09	O
2021	O
21	O
16	O
Red	O
cells	O
4	O
,	O
770	O
,	O
000	O
pL	O
,	O
Hb	O
14	O
.	O
1	O
g	O
dL	O
,	O
Hto	O
43	O
,	O
MCV	O
90	O
.	O
1	O
fL	O
,	O
MCH	O
29	O
.	O
5	O
pg	O
,	O
Leukocytes	O
7140	O
pL	O
N	O
4180	O
,	O
L	O
2150	O
,	O
M	O
380	O
,	O
E	O
250	O
,	O
B	O
40	O
,	O
LUC	O
150	O
,	O
N	O
L	O
1	O
.	O
94	O
,	O
Platelets	O
156	O
,	O
000	O
4	O
,	O
PWV	O
12	O
.	O
8	O
fL	O
,	O
PT	O
12	O
s	O
77	O
,	O
INR	O
1	O
.	O
1	O
,	O
Fibrinogen	O
335	O
mg	O
dL	O
,	O
TTPa	O
24	O
.	O
7	O
s	O
ratio	O
0	O
.	O
92	O
,	O
Glycaemia	O
105	O
mg	O
dL	O
,	O
Creatinine	O
0	O
.	O
82	O
mg	O
dL	O
,	O
Filtrate	O
66	O
mL	O
min	O
,	O
Urea	O
55	O
mg	O
dL	O
,	O
Na	O
139	O
mmol	O
L	O
,	O
K	O
4	O
.	O
6	O
mmol	O
L	O
,	O
Cl	O
105	O
mmol	O
L	O
,	O
ASAT	O
77	O
IU	O
L	O
,	O
ALAT	O
85	O
IU	O
L	O
,	O
LDH	O
270	O
U1	O
L	O
,	O
GGT	O
120	O
IU	O
L	O
,	O
BRT	O
0	O
.	O
87	O
mg	O
dL	O
,	O
BRD	O
0	O
.	O
26	O
mg	O
dL	O
,	O
BRI	O
0	O
.	O
61	O
mg	O
dL	O
,	O
NT	O
proBNP	O
3145	O
pg	O
mL	O
,	O
PCR	O
3	O
.	O
7	O
mg	O
L	O
CBC	O
delayed	O
06	O
09	O
2021	O
08	O
30	O
Red	O
cells	O
4	O
,	O
720	O
,	O
000	O
11	O
,	O
Hb	O
13	O
.	O
8	O
g	O
dL	O
,	O
Hto	O
42	O
.	O
3	O
,	O
MCV	O
89	O
.	O
6	O
fL	O
,	O
MCH	O
29	O
.	O
3	O
pg	O
,	O
Leukocytes	O
7410	O
pL	O
N	O
3790	O
,	O
L	O
2660	O
,	O
M	O
470	O
,	O
E	O
300	O
,	O
B	O
40	O
,	O
LUC	O
140	O
,	O
N	O
L	O
1	O
.	O
42	O
,	O
Platelets	O
175	O
,	O
000	O
pL	O
,	O
PWV	O
12	O
.	O
8	O
fL	O
,	O
PT	O
13	O
s	O
65	O
,	O
INR	O
1	O
.	O
2	O
,	O
Fibrinogen	O
361	O
mg	O
dL	O
,	O
TTPa	O
26	O
.	O
6	O
s	O
ratio	O
0	O
.	O
99	O
,	O
Blood	O
glucose	O
99	O
mg	O
dL	O
,	O
HbA1C	O
5	O
.	O
4	O
,	O
Total	O
cholesterol	O
160	O
mg	O
dL	O
,	O
HDL	O
58	O
mg	O
dL	O
,	O
non	O
HDL	O
102	O
mg	O
dL	O
,	O
LDLc	O
88	O
mg	O
dL	O
,	O
TG	O
71	O
mg	O
dL	O
,	O
Creatinine	O
1	O
.	O
16	O
mg	O
dL	O
,	O
Filtrate	O
43	O
mL	O
min	O
,	O
Urate	O
7	O
.	O
7	O
mg	O
dL	O
,	O
Na	O
140	O
mmol	O
L	O
,	O
K	O
3	O
.	O
9	O
mmol	O
L	O
,	O
Cl	O
100	O
mmol	O
L	O
,	O
ASAT	O
38	O
Ul	O
L	O
,	O
ALAT	O
63	O
Ul	O
L	O
,	O
FAIc	O
102	O
Ul	O
L	O
,	O
GGT	O
96	O
Ul	O
L	O
,	O
BRT	O
0	O
.	O
74	O
mg	O
dL	O
,	O
CPK	O
46	O
Ul	O
L	O
,	O
Proteins	O
6	O
.	O
2	O
g	O
dL	O
,	O
CRP	O
3	O
.	O
1	O
mg	O
L	O
,	O
Iron	O
45	O
pg	O
dL	O
,	O
Transferrin	O
199	O
mg	O
dL	O
,	O
CTTH	O
281	O
pg	O
dL	O
,	O
IST	O
16	O
,	O
Ferritin	O
121	O
ng	O
mL	O
,	O
TSH	O
3	O
.	O
16	O
pUl	O
mL	O
CBC	O
at	O
discharge	O
09	O
09	O
2021	O
08	O
32	O
22	O
Hemoglobin	O
13	O
.	O
4	O
g	O
dL	O
11	O
.	O
8	O
15	O
.	O
8	O
,	O
Hematocrit	O
41	O
.	O
1	O
35	O
45	O
,	O
M	O
.	O
C	O
.	O
V	O
.	O
91	O
.	O
1	O
fL	O
80	O
101	O
,	O
Leukocytes	O
8	O
.	O
58	O
x10e3	O
pL	O
3	O
.	O
6	O
10	O
.	O
5	O
,	O
Platelets	O
154	O
x10e3	O
pL	O
150	O
370	O
,	O
INR	O
1	O
.	O
1	O
0	O
.	O
8	O
1	O
.	O
2	O
,	O
SERUM	O
GLUCOSE	O
107	O
mg	O
dL	O
74	O
106	O
,	O
SERUM	O
CREATININE	O
0	O
.	O
72	O
mg	O
dL	O
0	O
.	O
5	O
1	O
.	O
1	O
,	O
GLOMERULAR	O
FILTERING	O
CKD	O
EPI	O
77	O
mL	O
min	O
1	O
.	O
73m2	O
45	O
999999	O
,	O
SERUM	O
SODIUM	O
134	O
mmol	O
L	O
136	O
145	O
,	O
SERUM	O
POTASSIUM	O
4	O
.	O
2	O
mmol	O
L	O
3	O
.	O
5	O
5	O
.	O
1	O
,	O
NT	O
proBNP	O
4177	O
pg	O
mL	O
0	O
450	O
Image	O
Chest	O
CXR	O
03	O
08	O
21	O
increased	O
CTI	O
,	O
marked	O
vascular	O
redistribution	O
without	O
clear	O
pleural	O
effusion	O
.	O
No	O
consolidation	O
Echocardioscopy	O
03	O
08	O
21	O
Performed	O
in	O
AF	O
at	O
about	O
130	O
140Ipm	O
,	O
LV	O
not	O
dilated	O
mild	O
mod	O
dysfunctioning	O
.	O
RV	O
normal	O
.	O
Moderate	O
severe	O
TR	O
with	O
no	O
other	O
valvular	O
heart	O
disease	O
.	O
No	O
effusion	O
.	O
Biauricular	O
dilatation	O
.	O
Dilated	O
vena	O
cava	O
with	O
hardly	O
any	O
respiratory	O
fields	O
.	O
Echocardiogram	O
06	O
09	O
21	O
study	O
performed	O
in	O
AF	O
at	O
100	O
130	O
Ipm	O
.	O
Left	O
ventricle	O
not	O
dilated	O
,	O
mild	O
hypertrophy	O
,	O
with	O
slightly	O
depressed	O
global	O
systolic	O
function	O
.	O
LVEF	O
BP	O
47	O
with	O
global	O
hypokinesia	O
and	O
septal	O
motion	O
related	O
to	O
right	O
overload	O
.	O
Mitral	O
insufficiency	O
at	O
least	O
moderate	O
.	O
Moderate	O
dilatation	O
of	O
both	O
atria	O
.	O
Slightly	O
dilated	O
right	O
ventricle	O
with	O
moderate	O
dysfunction	O
.	O
Moderate	O
to	O
severe	O
tricuspid	O
insufficiency	O
due	O
to	O
dilatation	O
of	O
the	O
annulus	O
.	O
Estimated	O
PSAP	O
around	O
45	O
50	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
and	O
with	O
physiological	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Other	O
tests	O
ECG	O
urg	O
03	O
08	O
21	O
AF	O
with	O
RVR	O
at	O
120	O
Ipm	O
,	O
normal	O
axis	O
,	O
narrow	O
QRS	O
without	O
repolarisation	O
alterations	O
.	O
ECG	O
08	O
09	O
21	O
AF	O
with	O
RVR	O
at	O
108	O
Ipm	O
,	O
normal	O
axis	O
,	O
narrow	O
QRS	O
without	O
repolarization	O
alterations	O
.	O
PCR	O
COVID	O
03	O
08	O
21	O
negative	O
Evolution	O
and	O
comments	O
Admitted	O
for	O
a	O
first	O
episode	O
of	O
HF	O
in	O
the	O
context	O
of	O
AF	O
with	O
rapid	O
ventricular	O
response	O
.	O
Rapid	O
improvement	O
with	O
intravenous	O
diuretic	O
treatment	O
.	O
HF	O
control	O
bisoprolol	B-FARMACO
and	O
digoxin	B-FARMACO
at	O
low	O
doses	O
was	O
chosen	O
as	O
the	O
atria	O
were	O
dilated	O
and	O
he	O
presented	O
moderate	O
severe	O
TR	O
as	O
well	O
as	O
at	O
least	O
moderate	O
1M	O
.	O
Medical	O
treatment	O
was	O
adjusted	O
and	O
anticoagulation	O
with	O
rivaroxaban	B-FARMACO
was	O
started	O
,	O
and	O
the	O
patient	O
was	O
referred	O
for	O
follow	O
up	O
.	O
1ECA	O
was	O
not	O
prescribed	O
due	O
to	O
a	O
tendency	O
to	O
hypotension	O
.	O
Main	O
diagnosis	O
First	O
episode	O
of	O
HF	O
.	O
Atrial	O
fibrillation	O
with	O
rapid	O
RV	O
.	O
CHADS	O
Vasc	O
4	O
.	O
Moderate	O
to	O
severe	O
TR	O
,	O
at	O
least	O
moderate	O
1M	O
and	O
biauricular	O
dilatation	O
.	O
Slightly	O
depressed	O
LVEF	O
47	O
.	O
Treatment	O
Drugs	O
Xarelto	B-FARMACO
20	O
mg	O
1	O
tablet	O
at	O
dinner	O
.	O
Bisoprolol	B-FARMACO
5	O
mg	O
1	O
tablet	O
at	O
breakfast	O
and	O
dinner	O
.	O
Digoxin	B-FARMACO
0	O
.	O
25	O
mg	O
1	O
2	O
tablet	O
daily	O
.	O
Jardiance	B-FARMACO
10	O
mg	O
1	O
tablet	O
at	O
breakfast	O
.	O
Elecor	O
eplerenone	B-FARMACO
25	O
mg	O
1	O
tablet	O
at	O
breakfast	O
.	O
Seguril	B-FARMACO
1	O
tablet	O
at	O
breakfast	O
for	O
one	O
week	O
and	O
discontinue	O
.	O
In	O
case	O
of	O
oedema	O
,	O
rapid	O
weight	O
gain	O
or	O
dyspnoea	O
,	O
you	O
can	O
temporarily	O
take	O
2	O
3	O
tablets	O
daily	O
.	O
Continue	O
with	O
home	O
pharmacological	O
treatment	O
CITALOPRAM	B-FARMACO
10	O
MG	O
1	O
0	O
0	O
,	O
OMEPRAZOL	B-FARMACO
20	O
MG	O
0	O
1	O
0	O
,	O
NOLOTIL	B-FARMACO
575MG	O
1	O
1	O
1	O
if	O
severe	O
pain	O
,	O
MASTICAL	B-FARMACO
D	I-FARMACO
500	O
MG	O
800	O
UI	O
0	O
0	O
1	O
and	O
PARACETAMOL	B-FARMACO
1000	O
MG	O
1	O
0	O
1	O
Other	O
Recommendations	O
Review	O
in	O
Primary	O
Care	O
and	O
Cardiology	O
consultations	O
appointment	O
attached	O
.	O
MEDICATION	O
SHEET	O
DRUGS	O
PARACETAMOL	B-FARMACO
1000	O
MG	O
40	O
TABLETS	O
Breakfast	O
1	O
Lunch	O
Dinner	O
1	O
At	O
Bedtime	O
Start	O
Date	O
02	O
10	O
12	O
End	O
Date	O
CRONIC	O
CITALOPRAM	B-FARMACO
10	O
MG	O
28	O
TABLETS	O
Breakfast	O
1	O
Lunch	O
Dinner	O
At	O
Bedtime	O
Start	O
Date	O
06	O
13	O
19	O
End	O
Date	O
CRONIC	O
MASTICAL	B-FARMACO
D	I-FARMACO
500	O
MG	O
800	O
UI	O
TABLETS	O
Breakfast	O
Lunch	O
Dinner	O
1	O
At	O
Bedtime	O
Start	O
Date	O
28	O
04	O
15	O
End	O
Date	O
CRONIC	O
OMEPRAZOLE	B-FARMACO
20	O
MG	O
28	O
CAPSULES	O
Breakfast	O
Lunch	O
1	O
Dinner	O
At	O
Bedtime	O
Start	O
Date	O
15	O
04	O
16	O
End	O
Date	O
CRONIC	O
NOLOTIL	B-FARMACO
575MG	O
20	O
CAPSULES	O
Units	O
CAPSULE	O
,	O
Route	O
ORAL	O
Breakfast	O
1	O
Lunch	O
1	O
Dinner	O
1	O
At	O
Bedtime	O
Start	O
Date	O
12	O
13	O
16	O
End	O
Date	O
CHRONIC	O
IF	O
SEVERE	O
PAIN	O
XARELTO	B-FARMACO
20	O
MG	O
FILM	O
COATED	O
TABLETS	O
WITH	O
Units	O
PILL	O
,	O
Route	O
ORAL	O
Breakfast	O
Lunch	O
Dinner	O
1	O
At	O
Bedtime	O
Start	O
Date	O
09	O
09	O
21	O
End	O
Date	O
CRONIC	O
BISOPROLOL	B-FARMACO
5	O
MG	O
60	O
TABLETS	O
Units	O
PILL	O
,	O
Route	O
ORAL	O
Breakfast	O
1	O
Lunch	O
Dinner	O
1	O
At	O
Bedtime	O
Start	O
Date	O
09	O
09	O
21	O
End	O
Date	O
CRONIC	O
DIGOXIN	B-FARMACO
KERN	O
PHARMA	O
0	O
,	O
25MG	O
50	O
TABLETS	O
Units	O
PILL	O
,	O
Route	O
ORAL	O
Breakfast	O
0	O
,	O
5	O
Lunch	O
Dinner	O
At	O
Bedtime	O
Start	O
Date	O
09	O
09	O
21	O
End	O
Date	O
CRONIC	O
JARDIANCE	B-FARMACO
10MG	O
FILM	O
COATED	O
TABLETS	O
WITH	O
Units	O
POCKET	O
,	O
Route	O
ORAL	O
Breakfast	O
1	O
Lunch	O
Dinner	O
At	O
Bedtime	O
Start	O
Date	O
09	O
09	O
21	O
End	O
Date	O
CRONIC	O
EPLERENONE	B-FARMACO
25	O
MG	O
30	O
TABLETS	O
Units	O
PILL	O
,	O
Route	O
ORAL	O
Breakfast	O
1	O
Lunch	O
Dinner	O
At	O
Bedtime	O
Start	O
Date	O
09	O
09	O
21	O
End	O
Date	O
CRONIC	O
SEGURIL	B-FARMACO
40MG	O
30	O
TABLETS	O
Units	O
PILL	O
,	O
Route	O
ORAL	O
Breakfast	O
1	O
Lunch	O
Dinner	O
At	O
Bedtime	O
Start	O
Date	O
09	O
09	O
21	O
End	O
Date	O
CRONIC	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
diabetes	O
mellitus	O
2	O
DM2	O
.	O
No	O
known	O
hypertension	O
or	O
dyslipidaemia	O
.	O
Toxic	O
habits	O
ex	O
smoker	O
previously	O
smoked	O
1	O
.	O
5	O
packs	O
day	O
from	O
the	O
age	O
of	O
12	O
to	O
46	O
years	O
.	O
No	O
current	O
drinker	O
,	O
previously	O
a	O
weekend	O
drinker	O
of	O
5	O
6	O
beers	O
and	O
4	O
5	O
drinks	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
Surgical	O
interventions	O
conisation	O
in	O
2010	O
.	O
Previous	O
home	O
treatment	O
metformin	B-FARMACO
850	O
mg	O
12	O
hours	O
.	O
Current	O
illness	O
50	O
year	O
old	O
woman	O
,	O
ex	O
smoker	O
,	O
with	O
no	O
previous	O
cardiological	O
history	O
,	O
who	O
for	O
the	O
last	O
4	O
months	O
,	O
in	O
relation	O
to	O
exertion	O
,	O
has	O
had	O
episodes	O
of	O
non	O
radiating	O
central	O
thoracic	O
oppression	O
associated	O
with	O
dyspnoea	O
,	O
without	O
accompanying	O
vegetative	O
cortex	O
and	O
relieved	O
by	O
rest	O
.	O
These	O
episodes	O
were	O
initially	O
triggered	O
by	O
heavy	O
exertion	O
,	O
and	O
the	O
level	O
of	O
exertion	O
at	O
which	O
they	O
appear	O
has	O
progressively	O
decreased	O
,	O
with	O
these	O
changes	O
being	O
more	O
pronounced	O
in	O
the	O
last	O
two	O
weeks	O
.	O
They	O
now	O
appear	O
with	O
small	O
efforts	O
walking	O
more	O
quickly	O
or	O
climbing	O
stairs	O
.	O
Curiously	O
,	O
she	O
does	O
daily	O
bicycle	O
exercise	O
of	O
about	O
30	O
minutes	O
without	O
the	O
onset	O
of	O
symptoms	O
.	O
Given	O
that	O
the	O
baseline	O
electrocardiogram	O
showed	O
complete	O
left	O
bundle	O
branch	O
block	O
LBBB	O
,	O
exercise	O
testing	O
was	O
ruled	O
out	O
and	O
the	O
patient	O
was	O
admitted	O
to	O
cardiology	O
to	O
complete	O
the	O
study	O
.	O
He	O
denied	O
orthopnoea	O
or	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
PND	O
.	O
There	O
was	O
no	O
increase	O
in	O
peripheral	O
oedema	O
or	O
reduction	O
in	O
diuresis	O
.	O
She	O
reported	O
weight	O
gain	O
in	O
recent	O
months	O
.	O
No	O
syncope	O
presyncope	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
,	O
well	O
hydrated	O
and	O
perfused	O
,	O
conscious	O
and	O
cooperative	O
at	O
all	O
times	O
.	O
Clinically	O
and	O
haemodynamically	O
stable	O
on	O
admission	O
to	O
the	O
cardiology	O
ward	O
.	O
Afebrile	O
.	O
Blood	O
pressure	O
136	O
81	O
mmHg	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
at	O
a	O
good	O
frequency	O
.	O
No	O
murmurs	O
were	O
heard	O
.	O
Respiratory	O
auscultation	O
good	O
vesicular	O
murmur	O
without	O
pathological	O
noises	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
without	O
visceromegaly	O
or	O
other	O
noteworthy	O
findings	O
.	O
Lower	O
limbs	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
The	O
rest	O
of	O
the	O
examination	O
was	O
unremarkable	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
78	O
bpm	O
.	O
PR	O
160	O
ms	O
.	O
Normal	O
axis	O
.	O
Wide	O
QRS	O
120	O
ms	O
with	O
LBBB	O
image	O
.	O
Secondary	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
not	O
increased	O
in	O
size	O
.	O
No	O
images	O
of	O
pulmonary	O
condensation	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
Analysis	O
Glucose	O
143	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
84	O
mg	O
dl	O
.	O
Urea	O
41	O
mg	O
dl	O
.	O
Sodium	O
148	O
mEq	O
l	O
.	O
Potassium	O
4	O
.	O
8	O
mEq	O
l	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
148	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
62	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
68	O
mg	O
dl	O
,	O
triglycerides	O
90	O
mg	O
dl	O
.	O
Normal	O
liver	O
profile	O
.	O
Normal	O
thyroid	O
hormones	O
.	O
Glycated	O
haemoglobin	O
7	O
.	O
3	O
.	O
No	O
mobilisation	O
of	O
myocardial	O
damage	O
markers	O
peak	O
ultrasensitive	O
cTnT	O
9	O
ng	O
dl	O
.	O
Haemogram	O
with	O
4	O
,	O
990	O
leucocytes	O
normal	O
formula	O
,	O
Hb	O
13	O
.	O
2	O
g	O
dl	O
and	O
203	O
,	O
000	O
platelets	O
.	O
Coagulation	O
normal	O
.	O
Echocardiography	O
moderately	O
dilated	O
left	O
atrium	O
LA	O
42	O
mm	O
AP	O
diameter	O
;	O
Vol	O
42	O
ml	O
m2	O
.	O
Normal	O
mitral	O
valve	O
morphology	O
,	O
with	O
fibrocalcification	O
of	O
the	O
posterior	O
annulus	O
and	O
2	O
restriction	O
of	O
the	O
posterior	O
leaflet	O
mobility	O
,	O
with	O
central	O
insufficiency	O
grade	O
II	O
ORE	O
0	O
.	O
15	O
c	O
.	O
m	O
.	O
Dilated	O
left	O
ventricle	O
DTD	O
61	O
mm	O
;	O
DTS	O
48	O
mm	O
;	O
VTD	O
197	O
ml	O
;	O
VTD	O
index	O
98	O
ml	O
m2	O
;	O
VTS	O
120	O
ml	O
,	O
normal	O
myocardial	O
thickness	O
septum	O
6	O
mm	O
;	O
pp	O
7	O
mm	O
.	O
LVEF	O
40	O
calculated	O
by	O
Simpson	O
Biplane	O
,	O
with	O
akinesia	O
of	O
the	O
basal	O
and	O
middle	O
segments	O
of	O
the	O
septum	O
and	O
inferior	O
face	O
,	O
as	O
well	O
as	O
hypokinesia	O
of	O
the	O
anterior	O
face	O
,	O
with	O
better	O
contractility	O
of	O
the	O
apical	O
segments	O
and	O
lateral	O
inferior	O
face	O
.	O
GLS	O
15	O
with	O
more	O
diminished	O
values	O
in	O
the	O
septal	O
and	O
inferior	O
segments	O
.	O
Mitral	O
filling	O
E	O
A	O
1	O
.	O
3	O
E	O
108	O
.	O
7	O
cm	O
s	O
;	O
A	O
84	O
cm	O
s	O
;	O
e	O
'	O
sept	O
5	O
.	O
15	O
cm	O
s	O
;	O
e	O
'	O
lat	O
8	O
.	O
7	O
cm	O
s	O
.	O
E	O
e	O
'	O
15	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
with	O
preserved	O
opening	O
and	O
closing	O
,	O
without	O
insufficiency	O
.	O
Annulus	O
20	O
mm	O
.	O
Sinuses	O
of	O
Valsalva	O
32	O
mm	O
.	O
Right	O
ventricle	O
RV	O
of	O
normal	O
dimensions	O
RVDVD	O
29	O
mm	O
,	O
with	O
preserved	O
systolic	O
function	O
.	O
TAPSE	O
26	O
mm	O
.	O
S	O
'	O
12	O
.	O
6	O
cm	O
s	O
.	O
Trivial	O
IT	O
that	O
does	O
not	O
allow	O
estimation	O
of	O
pulmonary	O
gradient	O
.	O
Pulmonary	O
flow	O
with	O
acceleration	O
time	O
of	O
110	O
ms	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
,	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Conclusions	O
1	O
dilated	O
cardiomyopathy	O
with	O
moderate	O
dysfunction	O
and	O
the	O
described	O
contractility	O
alterations	O
.	O
2	O
Diastolic	O
dysfunction	O
dilated	O
LA	O
,	O
E	O
e	O
'	O
14	O
;	O
e	O
'	O
10	O
.	O
3	O
Functional	O
mitral	O
regurgitation	O
MR	O
grade	O
II	O
.	O
4	O
RV	O
with	O
preserved	O
systolic	O
function	O
.	O
Coronary	O
angiography	O
right	O
radial	O
access	O
.	O
Angiographically	O
normal	O
coronary	O
arteries	O
.	O
Right	O
dominance	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
normal	O
relationships	O
and	O
anatomical	O
arrangement	O
of	O
the	O
central	O
cardiovascular	O
structures	O
.	O
No	O
interatrial	O
septal	O
defects	O
or	O
anatomical	O
alterations	O
in	O
cardiac	O
valves	O
.	O
Normal	O
systemic	O
and	O
pulmonary	O
venous	O
drainage	O
.	O
Systolic	O
area	O
AD	O
20	O
cm2	O
;	O
left	O
atrium	O
21	O
.	O
6	O
cm2	O
4C	O
plane	O
estimate	O
.	O
Right	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophic	O
,	O
without	O
alterations	O
in	O
segmental	O
contractility	O
,	O
with	O
preserved	O
systolic	O
function	O
EF	O
66	O
.	O
Dilated	O
left	O
ventricle	O
dTD	O
61	O
mm	O
;	O
VTD	O
126	O
.	O
2	O
ml	O
m	O
,	O
without	O
alterations	O
in	O
segmental	O
thickness	O
images	O
4	O
5	O
.	O
No	O
alterations	O
in	O
segmental	O
thickening	O
were	O
observed	O
.	O
Dyssynchronous	O
movement	O
of	O
the	O
septum	O
with	O
respect	O
to	O
the	O
non	O
septal	O
wall	O
of	O
the	O
LV	O
,	O
attributable	O
to	O
HH	O
bundle	O
branch	O
block	O
,	O
to	O
be	O
correlated	O
with	O
ECG	O
findings	O
.	O
Moderately	O
depressed	O
systolic	O
function	O
EF	O
40	O
.	O
Jet	O
of	O
central	O
mitral	O
insufficiency	O
.	O
Estimated	O
regurgitant	O
fraction	O
between	O
13	O
.	O
6	O
by	O
calculation	O
from	O
ventricular	O
volumes	O
and	O
17	O
.	O
8	O
by	O
calculation	O
from	O
LVlat	O
and	O
aorta	O
.	O
In	O
the	O
black	O
myocardial	O
sequences	O
,	O
a	O
subtle	O
linear	O
intramyocardial	O
enhancement	O
is	O
recognisable	O
in	O
the	O
basal	O
and	O
middle	O
septum	O
,	O
as	O
well	O
as	O
in	O
some	O
areas	O
of	O
free	O
wall	O
,	O
especially	O
in	O
the	O
lateral	O
and	O
lower	O
middle	O
basal	O
wall	O
.	O
Assessment	O
in	O
several	O
sequences	O
is	O
very	O
limited	O
by	O
respiratory	O
motion	O
.	O
Conclusions	O
non	O
ischaemic	O
left	O
dilated	O
cardiomyopathy	O
,	O
associated	O
with	O
moderate	O
systolic	O
dysfunction	O
LVEF	O
40	O
.	O
Dyssynchronous	O
movement	O
of	O
the	O
septum	O
.	O
Non	O
coronary	O
late	O
enhancement	O
pattern	O
,	O
as	O
described	O
above	O
.	O
Compatible	O
with	O
sequelae	O
of	O
myocarditis	O
.	O
Mitral	O
insufficiency	O
RF	O
13	O
.	O
6	O
17	O
.	O
8	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
admission	O
,	O
after	O
echocardiography	O
detected	O
findings	O
of	O
dilated	O
cardiomyopathy	O
with	O
the	O
segmental	O
alterations	O
described	O
,	O
the	O
next	O
step	O
in	O
the	O
diagnostic	O
algorithm	O
was	O
coronary	O
angiography	O
,	O
which	O
ruled	O
out	O
the	O
presence	O
of	O
coronary	O
artery	O
disease	O
.	O
In	O
view	O
of	O
this	O
,	O
cardiac	O
MRI	O
was	O
requested	O
for	O
the	O
aetiological	O
study	O
of	O
the	O
ventricular	O
dysfunction	O
,	O
the	O
result	O
of	O
which	O
suggested	O
a	O
non	O
ischaemic	O
origin	O
of	O
the	O
condition	O
with	O
a	O
pattern	O
of	O
enhancement	O
compatible	O
with	O
the	O
sequelae	O
of	O
myocarditis	O
.	O
The	O
response	O
during	O
admission	O
to	O
depletive	O
treatment	O
was	O
adequate	O
,	O
and	O
treatment	O
with	O
beta	O
blockers	O
,	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
ACE	O
inhibitors	O
and	O
mineralocorticoid	O
receptor	O
antagonists	O
MRAs	O
was	O
initiated	O
,	O
with	O
good	O
tolerance	O
and	O
consequent	O
disappearance	O
of	O
the	O
symptoms	O
that	O
led	O
to	O
admission	O
.	O
On	O
discharge	O
from	O
hospital	O
,	O
treatment	O
was	O
prescribed	O
with	O
enalapril	B-FARMACO
5	O
mg	O
12	O
hours	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
24	O
hours	O
and	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
12	O
hours	O
.	O
As	O
for	O
anti	O
diabetic	O
treatment	O
,	O
the	O
patient	O
was	O
under	O
treatment	O
with	O
metformin	B-FARMACO
850	O
mg	O
12	O
hours	O
and	O
,	O
despite	O
this	O
,	O
she	O
had	O
a	O
glycosylated	O
haemoglobin	O
of	O
7	O
.	O
3	O
,	O
above	O
the	O
target	O
recommended	O
by	O
the	O
guidelines	O
in	O
patients	O
such	O
as	O
the	O
one	O
we	O
present	O
7	O
.	O
In	O
this	O
regard	O
,	O
dapagliflozin	B-FARMACO
was	O
added	O
based	O
on	O
the	O
results	O
of	O
cardiovascular	O
efficacy	O
obtained	O
with	O
this	O
drug	O
in	O
recent	O
studies	O
on	O
patients	O
with	O
heart	O
failure	O
.	O
In	O
addition	O
,	O
in	O
order	O
to	O
improve	O
adherence	O
to	O
treatment	O
,	O
both	O
hypoglycaemic	O
drugs	O
were	O
prescribed	O
in	O
a	O
single	O
presentation	O
metformin	B-FARMACO
850	O
mg	O
dapagliflozin	B-FARMACO
5	O
mg	O
every	O
12	O
hours	O
.	O
After	O
discharge	O
,	O
the	O
patient	O
remains	O
asymptomatic	O
11	O
months	O
later	O
and	O
has	O
not	O
had	O
any	O
new	O
hospital	O
readmissions	O
to	O
date	O
.	O
In	O
addition	O
,	O
the	O
last	O
blood	O
test	O
showed	O
an	O
objective	O
decrease	O
in	O
HbA1c	O
to	O
6	O
.	O
5	O
,	O
below	O
the	O
recommended	O
target	O
level	O
.	O
DIAGNOSIS	O
Idiopathic	O
dilated	O
cardiomyopathy	O
with	O
moderate	O
dysfunction	O
EF	O
40	O
probably	O
in	O
the	O
context	O
of	O
old	O
myocarditis	O
.	O
Coronary	O
arteries	O
without	O
angiographically	O
significant	O
lesions	O
.	O
DM2	O
without	O
optimal	O
control	O
Hb1Ac	O
7	O
.	O
3	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
,	O
type	O
2	O
diabetes	O
mellitus	O
,	O
ex	O
smoker	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
CHA2DS2	O
VASc	O
7	O
in	O
treatment	O
with	O
acenocoumarol	B-FARMACO
.	O
Chronic	O
obstructive	O
pulmonary	O
disease	O
COPD	O
.	O
Stroke	O
in	O
2010	O
,	O
without	O
sequelae	O
.	O
Stage	O
3a	O
chronic	O
kidney	O
disease	O
secondary	O
to	O
diabetic	O
nephropathy	O
.	O
Deep	O
vein	O
thrombosis	O
in	O
lower	O
limbs	O
in	O
2006	O
.	O
Usual	O
treatment	O
insulin	B-FARMACO
glargine	I-FARMACO
10	O
IU	O
at	O
dinner	O
;	O
atorvastatin	B-FARMACO
10	O
mg	O
;	O
acenocoumarol	B-FARMACO
4	O
mg	O
as	O
prescribed	O
;	O
tiotropium	B-FARMACO
bromide	I-FARMACO
18	O
mcg	O
1	O
0	O
0	O
;	O
alogliptin	B-FARMACO
metformin	I-FARMACO
12	O
.	O
5	O
1	O
,	O
000	O
mg	O
1	O
0	O
0	O
;	O
ranolazine	B-FARMACO
375	O
mg	O
1	O
0	O
1	O
.	O
Present	O
illness	O
83	O
year	O
old	O
male	O
under	O
follow	O
up	O
in	O
cardiology	O
for	O
stable	O
angina	O
.	O
The	O
patient	O
reports	O
that	O
despite	O
adjustment	O
of	O
medical	O
treatment	O
,	O
he	O
persists	O
with	O
oppressive	O
precordial	O
pain	O
,	O
radiating	O
to	O
the	O
jaw	O
and	O
left	O
arm	O
,	O
which	O
is	O
triggered	O
when	O
he	O
climbs	O
more	O
than	O
two	O
flights	O
of	O
stairs	O
and	O
which	O
disappears	O
after	O
approximately	O
5	O
minutes	O
'	O
rest	O
.	O
No	O
dyspnoea	O
,	O
palpitations	O
or	O
syncope	O
.	O
The	O
last	O
transthoracic	O
echocardiogram	O
showed	O
a	O
left	O
ventricle	O
with	O
an	O
ejection	O
fraction	O
of	O
38	O
,	O
akinesia	O
of	O
the	O
lower	O
basal	O
and	O
middle	O
segments	O
with	O
thinning	O
of	O
the	O
wall	O
and	O
an	O
image	O
of	O
scarring	O
.	O
He	O
was	O
referred	O
to	O
our	O
hospital	O
for	O
catheterisation	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
150	O
95	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
70	O
bpm	O
.	O
Oxygen	O
saturation	O
98	O
on	O
room	O
air	O
.	O
Good	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
,	O
eupneic	O
,	O
well	O
perfused	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
extra	O
sounds	O
.	O
Lower	O
limbs	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
,	O
pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Baseline	O
electrocardiogram	O
ECG	O
sinus	O
rhythm	O
with	O
PR	O
280	O
ms	O
,	O
QRS	O
140	O
ms	O
with	O
left	O
bundle	O
branch	O
block	O
LBBB	O
and	O
secondary	O
repolarisation	O
alterations	O
.	O
CBC	O
haemoglobin	O
12	O
.	O
4	O
g	O
dl	O
.	O
Leukocytes	O
8	O
,	O
700	O
μl	O
N	O
82	O
.	O
3	O
.	O
Platelets	O
163	O
,	O
000	O
μl	O
.	O
INR	O
1	O
.	O
1	O
.	O
Creatinine	O
1	O
.	O
85	O
mg	O
dl	O
.	O
Glomerular	O
filtration	O
rate	O
45	O
ml	O
min	O
1	O
.	O
73	O
m	O
.	O
Sodium	O
140	O
mmol	O
l	O
.	O
Potassium	O
3	O
.	O
6	O
mmol	O
l	O
.	O
AST	O
377	O
IU	O
l	O
.	O
ALT	O
88	O
IU	O
l	O
.	O
Alkaline	O
phosphatase	O
48	O
IU	O
l	O
.	O
GGT	O
30	O
IU	O
l	O
.	O
Total	O
bilirubin	O
1	O
.	O
11	O
mg	O
dl	O
.	O
CK	O
1018	O
IU	O
l	O
.	O
Protein	O
5	O
.	O
3	O
g	O
dl	O
.	O
HbA1c	O
NGSP	O
7	O
.	O
9	O
.	O
Total	O
cholesterol	O
100	O
mg	O
dl	O
,	O
HDL	O
26	O
mg	O
dl	O
,	O
LDL	O
48	O
mg	O
dl	O
,	O
triglycerides	O
133	O
mg	O
dl	O
.	O
Chest	O
X	O
ray	O
CTI	O
within	O
normal	O
limits	O
,	O
lung	O
parenchyma	O
without	O
alterations	O
.	O
Echocardiogram	O
on	O
admission	O
left	O
ventricle	O
with	O
ejection	O
fraction	O
38	O
,	O
akinesia	O
of	O
lower	O
basal	O
and	O
middle	O
segments	O
with	O
wall	O
thinning	O
and	O
scar	O
image	O
.	O
Hypokinesia	O
of	O
the	O
inferolateral	O
side	O
.	O
Coronary	O
angiography	O
1	O
multivessel	O
coronary	O
artery	O
disease	O
.	O
Chronic	O
occlusion	O
of	O
the	O
middle	O
right	O
coronary	O
artery	O
RCA	O
.	O
Severe	O
atheromatosis	O
of	O
proximal	O
middle	O
anterior	O
descending	O
artery	O
AD	O
,	O
percutaneous	O
coronary	O
intervention	O
PCI	O
and	O
implantation	O
of	O
overlapping	O
drug	O
eluting	O
stents	O
.	O
Severe	O
atheromatosis	O
of	O
proximal	O
circumflex	O
artery	O
Cx	O
first	O
obtuse	O
marginal	O
OM1	O
treated	O
with	O
drug	O
eluting	O
stent	O
implantation	O
.	O
Acute	O
stent	O
thrombosis	O
resolved	O
during	O
the	O
procedure	O
.	O
Coronary	O
angiography	O
2	O
proximal	O
Cx	O
stent	O
thrombosis	O
with	O
new	O
implantation	O
of	O
two	O
drug	O
eluting	O
stents	O
.	O
Echocardiogram	O
at	O
discharge	O
left	O
ventricle	O
with	O
ejection	O
fraction	O
28	O
,	O
extensive	O
inferoposterolateral	O
akinesia	O
,	O
with	O
anterior	O
hypokinesia	O
.	O
Moderate	O
severe	O
ischaemic	O
mitral	O
regurgitation	O
.	O
CLINICAL	O
EVOLUTION	O
Catheterisation	O
programmed	O
due	O
to	O
angina	O
and	O
ventricular	O
dysfunction	O
.	O
Prior	O
to	O
the	O
procedure	O
,	O
the	O
patient	O
was	O
being	O
treated	O
with	O
acenocoumarol	B-FARMACO
,	O
which	O
was	O
discontinued	O
48	O
hours	O
before	O
admission	O
,	O
and	O
250	O
mg	O
of	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
was	O
administered	O
without	O
the	O
addition	O
of	O
a	O
P2Y12	B-FARMACO
inhibitor	I-FARMACO
,	O
pending	O
confirmation	O
of	O
the	O
need	O
for	O
percutaneous	O
coronary	O
revascularisation	O
.	O
Coronary	O
angiography	O
revealed	O
a	O
severe	O
lesion	O
in	O
the	O
proximal	O
LAD	O
,	O
a	O
moderate	O
severe	O
lesion	O
in	O
Cx	O
OM1	O
and	O
chronic	O
occlusion	O
of	O
the	O
LMCA	O
,	O
with	O
little	O
likelihood	O
of	O
viability	O
in	O
its	O
territory	O
.	O
Clopidogrel	B-FARMACO
600	O
mg	O
was	O
administered	O
and	O
revascularisation	O
of	O
the	O
LAD	O
and	O
Cx	O
was	O
performed	O
.	O
She	O
presented	O
with	O
periprocedural	O
AMI	O
due	O
to	O
hyperacute	O
thrombosis	O
of	O
the	O
Cx	O
stent	O
and	O
treatment	O
was	O
started	O
with	O
IV	O
cangrelor	B-FARMACO
.	O
Admitted	O
to	O
the	O
coronary	O
unit	O
,	O
presenting	O
acute	O
heart	O
failure	O
,	O
acute	O
pulmonary	O
oedema	O
with	O
arterial	O
hypotension	O
,	O
requiring	O
oxygen	O
therapy	O
with	O
high	O
flow	O
glasses	O
,	O
perfusion	O
of	O
furosemide	B-FARMACO
and	O
noradrenaline	B-FARMACO
at	O
low	O
doses	O
.	O
In	O
addition	O
,	O
renal	O
function	O
deterioration	O
was	O
observed	O
with	O
a	O
pre	O
renal	O
component	O
and	O
in	O
relation	O
to	O
contrast	O
nephropathy	O
.	O
After	O
48	O
hours	O
of	O
admission	O
,	O
the	O
patient	O
presented	O
an	O
episode	O
of	O
self	O
limited	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
SMVT	O
followed	O
by	O
several	O
bouts	O
of	O
non	O
sustained	O
ventricular	O
tachycardia	O
NSVT	O
with	O
ST	O
segment	O
depression	O
in	O
V3	O
to	O
V6	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
a	O
repeat	O
diagnostic	O
coronary	O
angiography	O
showed	O
thrombosis	O
of	O
the	O
Cx	O
stent	O
,	O
which	O
was	O
revascularised	O
,	O
with	O
a	O
new	O
cangrelor	B-FARMACO
perfusion	O
and	O
a	O
change	O
in	O
antiplatelet	O
therapy	O
from	O
clopidogrel	B-FARMACO
to	O
ticagrelor	B-FARMACO
.	O
He	O
was	O
subsequently	O
transferred	O
to	O
the	O
hospital	O
ward	O
where	O
he	O
presented	O
good	O
clinical	O
evolution	O
,	O
without	O
new	O
episodes	O
of	O
arrhythmias	O
,	O
with	O
improvement	O
in	O
renal	O
function	O
GFR	O
48	O
ml	O
min	O
.	O
He	O
was	O
discharged	O
with	O
triple	O
antithrombotic	O
therapy	O
with	O
rivaroxaban	B-FARMACO
10	O
mg	O
daily	O
,	O
adiro	B-FARMACO
100	O
mg	O
daily	O
and	O
ticagrelor	B-FARMACO
90	O
mg	O
every	O
12	O
hours	O
for	O
1	O
month	O
;	O
to	O
continue	O
with	O
double	O
therapy	O
with	O
rivaroxaban	B-FARMACO
10	O
mg	O
and	O
ticagrelor	B-FARMACO
90	O
mg	O
for	O
6	O
months	O
and	O
then	O
only	O
with	O
rivaroxaban	B-FARMACO
15	O
mg	O
daily	O
if	O
the	O
GFR	O
remained	O
below	O
50	O
ml	O
min	O
.	O
DIAGNOSIS	O
Ischaemic	O
heart	O
disease	O
,	O
CCS	O
class	O
II	O
stable	O
exertional	O
angina	O
with	O
moderate	O
LV	O
systolic	O
dysfunction	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
.	O
Elective	O
cardiac	O
catheterisation	O
Three	O
vessel	O
coronary	O
artery	O
disease	O
.	O
Percutaneous	O
revascularisation	O
of	O
LAD	O
and	O
Cx	O
.	O
Periprocedural	O
AMI	O
due	O
to	O
hyperacute	O
stent	O
thrombosis	O
in	O
Cx	O
.	O
Acute	O
pulmonary	O
oedema	O
resolved	O
.	O
SMVT	O
in	O
the	O
context	O
of	O
new	O
subacute	O
Cx	O
stent	O
thrombosis	O
.	O
Severe	O
LV	O
systolic	O
dysfunction	O
.	O
Acute	O
chronic	O
renal	O
failure	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
57	O
year	O
old	O
male	O
,	O
no	O
known	O
allergies	O
,	O
active	O
,	O
currently	O
unemployed	O
.	O
History	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
obesity	O
grade	O
II	O
BMI	O
of	O
39	O
.	O
Active	O
smoker	O
of	O
10	O
cigarettes	O
day	O
12	O
packs	O
year	O
.	O
Hypertension	O
diagnosed	O
3	O
years	O
ago	O
.	O
Dyslipidaemia	O
diagnosed	O
10	O
years	O
ago	O
.	O
Diabetes	O
mellitus	O
DM	O
type	O
2	O
diagnosed	O
at	O
38	O
years	O
of	O
age	O
,	O
with	O
poor	O
metabolic	O
control	O
over	O
the	O
years	O
.	O
As	O
a	O
result	O
,	O
she	O
has	O
diabetic	O
retinopathy	O
and	O
diabetic	O
nephropathy	O
.	O
Chronic	O
obstructive	O
pulmonary	O
disease	O
COPD	O
GOLD	O
2	O
and	O
sleep	O
apnoea	O
hypopnoea	O
syndrome	O
SAHS	O
treated	O
with	O
nocturnal	O
continuous	O
positive	O
airway	O
pressure	O
CPAP	O
.	O
From	O
the	O
cardiological	O
point	O
of	O
view	O
,	O
in	O
2017	O
he	O
had	O
presented	O
an	O
episode	O
of	O
persistent	O
atrial	O
fibrillation	O
associated	O
with	O
tachycardiomyopathy	O
LVEF	O
35	O
with	O
normal	O
sized	O
LV	O
with	O
LVEF	O
recovery	O
to	O
normal	O
after	O
effective	O
reversion	O
to	O
sinus	O
rhythm	O
and	O
without	O
subsequent	O
cardiology	O
follow	O
up	O
.	O
He	O
is	O
currently	O
on	O
home	O
treatment	O
with	O
acenocoumarol	B-FARMACO
4	O
mg	O
as	O
prescribed	O
;	O
atorvastatin	B-FARMACO
20	O
mg	O
24	O
hours	O
;	O
fenofibrate	B-FARMACO
145	O
mg	O
24	O
hours	O
;	O
bisoprolol	B-FARMACO
5	O
mg	O
24	O
hours	O
;	O
olmesartan	B-FARMACO
amlodipine	I-FARMACO
40	O
5	O
mg	O
24	O
hours	O
;	O
formoterol	B-FARMACO
budesonin	I-FARMACO
160	O
4	O
.	O
5	O
mg	O
inhaled	O
12	O
hours	O
;	O
insulin	B-FARMACO
novomix	I-FARMACO
30	O
36	B-FARMACO
36	B-FARMACO
34	I-FARMACO
IU	O
breakfast	O
lunch	O
dinner	O
sc	O
;	O
dulaglutide	B-FARMACO
1	O
.	O
5	O
mg	O
weekly	O
sc	O
;	O
metformin	B-FARMACO
1000	O
mg	O
24	O
hours	O
;	O
salbutamol	B-FARMACO
on	O
demand	O
;	O
bromazepam	B-FARMACO
3	O
mg	O
24	O
hours	O
.	O
Present	O
illness	O
Consultation	O
at	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
due	O
to	O
increased	O
dyspnoea	O
for	O
approximately	O
4	O
6	O
weeks	O
,	O
with	O
two	O
pillow	O
orthopnoea	O
,	O
bendopnoea	O
and	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
She	O
does	O
not	O
report	O
subjective	O
oliguria	O
but	O
progressive	O
oedematisation	O
of	O
the	O
lower	O
limbs	O
.	O
No	O
palpitations	O
or	O
chest	O
pain	O
.	O
No	O
loss	O
of	O
appetite	O
.	O
No	O
associated	O
fever	O
or	O
other	O
concurrent	O
symptoms	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
90	O
95	O
60	O
65	O
;	O
heart	O
rate	O
HR	O
156	O
bpm	O
;	O
oxygen	O
saturation	O
in	O
ambient	O
air	O
90	O
,	O
temperature	O
36	O
.	O
2	O
oC	O
.	O
Conscious	O
,	O
oriented	O
,	O
sweating	O
,	O
with	O
skin	O
pallor	O
,	O
although	O
not	O
deep	O
.	O
Tachypneic	O
,	O
with	O
abdominal	O
breathing	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
and	O
tachycardic	O
,	O
no	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
generalised	O
hypophonesis	O
with	O
bilateral	O
crackling	O
rales	O
up	O
to	O
midfields	O
.	O
Abdomen	O
distended	O
,	O
soft	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
visceromegaly	O
.	O
Hydro	O
aerial	O
sounds	O
present	O
.	O
Oedema	O
with	O
fovea	O
up	O
to	O
both	O
knees	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
and	O
weak	O
symmetrical	O
pedal	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
on	O
admission	O
Haemogram	O
Hb	O
12	O
.	O
7	O
g	O
dl	O
.	O
Red	O
cells	O
6	O
.	O
29	O
x10E6	O
μl	O
.	O
MCV	O
70	O
.	O
3	O
fl	O
.	O
MCH	O
20	O
.	O
2	O
pg	O
.	O
MCHC	O
28	O
.	O
7	O
g	O
dl	O
.	O
Leucocytes	O
14	O
.	O
18	O
x10E3	O
μl	O
.	O
Neutrophils	O
blood	O
65	O
.	O
4	O
.	O
Neutrophils	O
9	O
.	O
27	O
x10E3	O
μl	O
.	O
Lymphocytes	O
22	O
.	O
8	O
.	O
Lymphocytes	O
3	O
.	O
24	O
x10E3	O
μl	O
.	O
Monocytes	O
blood	O
10	O
.	O
8	O
.	O
Monocytes	O
1	O
.	O
53	O
x10E3	O
μl	O
.	O
Eosinophils	O
blood	O
0	O
.	O
6	O
.	O
Basophils	O
blood	O
0	O
.	O
4	O
.	O
Immature	O
granulocytes	O
1	O
.	O
10	O
.	O
Immature	O
granulocytes	O
0	O
.	O
15	O
x10E3	O
μl	O
.	O
UPLAQ	O
platelets	O
205	O
x10E3	O
μ	O
.	O
VPM	O
11	O
.	O
5	O
fL	O
.	O
SR	O
R	O
.	O
D	O
.	O
W	O
.	O
coefficient	O
of	O
variation	O
19	O
.	O
3	O
.	O
Haematocrit	O
44	O
.	O
2	O
.	O
Biochemistry	O
glucose	O
146	O
mg	O
dl	O
.	O
Urea	O
76	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
87	O
mg	O
dl	O
.	O
FGR	O
CKD	O
EPI	O
39	O
ml	O
min	O
1	O
.	O
73	O
m	O
.	O
Sodium	O
ion	O
141	O
mmol	O
l	O
.	O
Plasma	O
potassium	O
ion	O
7	O
mmol	O
l	O
,	O
Creatine	O
kinase	O
404	O
U	O
l	O
.	O
Troponin	O
T	O
112	O
ng	O
l	O
.	O
NT	O
proBNP	O
2298	O
.	O
Procalcitonin	O
0	O
.	O
08	O
.	O
Heparin	B-FARMACO
plasma	O
C	O
reactive	O
protein	O
0	O
.	O
5	O
mg	O
dl	O
.	O
Coagulation	O
Prothrombin	O
T	O
.	O
27	O
.	O
10	O
sec	O
,	O
INR	O
2	O
.	O
36	O
.	O
Prothrombin	O
T	O
.	O
31	O
.	O
0	O
.	O
Partial	O
thromboplastin	O
time	O
32	O
.	O
30	O
sec	O
.	O
Derived	O
fibrinogen	O
457	O
.	O
D	O
dimer	O
616	O
ng	O
m	O
.	O
Blood	O
gases	O
pH	O
arterial	O
blood	O
gas	O
7	O
.	O
43	O
.	O
pO2	O
arterial	O
blood	O
gas	O
75	O
mmHg	O
.	O
pCO2	O
arterial	O
blood	O
gas	O
31	O
mmHg	O
.	O
Total	O
CO2	O
arterial	O
gas	O
21	O
.	O
9	O
mmol	O
l	O
.	O
Bicarbonate	O
arterial	O
gas	O
22	O
.	O
4	O
mmol	O
l	O
.	O
Excess	O
bases	O
arterial	O
gas	O
3	O
.	O
3	O
mmol	O
l	O
.	O
Oxyhaemoglobin	O
saturation	O
arterial	O
gas	O
95	O
.	O
Electrocardiogram	O
ECG	O
on	O
admission	O
atrial	O
fibrillation	O
at	O
150	O
bpm	O
with	O
narrow	O
QRS	O
and	O
secondary	O
repolarisation	O
disorders	O
.	O
Postcardioversion	O
ECG	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
with	O
normal	O
PR	O
,	O
P	O
wave	O
widening	O
suggestive	O
of	O
atrial	O
enlargement	O
.	O
Late	O
progression	O
of	O
R	O
in	O
precordial	O
leads	O
.	O
Intraventricular	O
conduction	O
disturbance	O
with	O
QRS	O
110ms	O
.	O
QTc	O
443	O
ms	O
.	O
Chest	O
X	O
rays	O
PA	O
and	O
LAT	O
on	O
admission	O
very	O
enlarged	O
CTI	O
,	O
no	O
condensation	O
or	O
masses	O
were	O
observed	O
.	O
Diffuse	O
interstitial	O
pattern	O
with	O
perihilar	O
deflections	O
suggestive	O
of	O
heart	O
failure	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
Echocardiograms	O
during	O
admission	O
dilated	O
left	O
ventricle	O
DTd	O
6	O
.	O
3	O
cm	O
;	O
VolTd	O
203	O
ml	O
,	O
slightly	O
hypertrophic	O
,	O
with	O
severe	O
left	O
ventricular	O
systolic	O
dysfunction	O
EF	O
by	O
Simpson	O
bp	O
29	O
and	O
transmitral	O
pattern	O
suggestive	O
of	O
pseudonormalisation	O
with	O
high	O
filling	O
pressures	O
.	O
Right	O
ventricle	O
with	O
slightly	O
reduced	O
systolic	O
function	O
TAPSE	O
15	O
mm	O
.	O
Biauricular	O
dilatation	O
.	O
No	O
significant	O
valvular	O
heart	O
disease	O
.	O
No	O
pericardial	O
effusion	O
.	O
Coronary	O
angiography	O
coronary	O
arteries	O
with	O
diffuse	O
atheromatosis	O
without	O
significant	O
lesions	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
the	O
history	O
prior	O
to	O
admission	O
,	O
the	O
patient	O
had	O
taken	O
a	O
certain	O
amount	O
of	O
hypoglycaemic	O
drugs	O
over	O
the	O
previous	O
4	O
years	O
Until	O
2015	O
the	O
patient	O
was	O
taking	O
metformin	B-FARMACO
1000	O
mg	O
every	O
12	O
hours	O
,	O
with	O
poor	O
follow	O
up	O
and	O
therapeutic	O
adherence	O
during	O
years	O
of	O
illness	O
.	O
At	O
the	O
end	O
of	O
that	O
year	O
,	O
after	O
visiting	O
the	O
health	O
centre	O
,	O
his	O
primary	O
care	O
doctor	O
managed	O
to	O
recover	O
some	O
follow	O
up	O
and	O
associated	O
insulin	O
therapy	O
Lantus	B-FARMACO
SoloStar	I-FARMACO
100	O
IU	O
ml	O
,	O
30	O
IU	O
in	O
the	O
morning	O
,	O
and	O
referred	O
him	O
to	O
the	O
endocrinology	O
department	O
.	O
In	O
February	O
2016	O
,	O
he	O
had	O
an	O
Hb1Ac	O
of	O
10	O
.	O
8	O
,	O
BMI	O
of	O
40	O
and	O
weight	O
of	O
110	O
kg	O
,	O
eGFR	O
of	O
55	O
ml	O
min	O
1	O
.	O
73	O
m	O
,	O
so	O
the	O
endocrinologist	O
implemented	O
a	O
diabetology	O
education	O
course	O
,	O
and	O
changed	O
Lantus	B-FARMACO
to	O
Novomix	B-FARMACO
30	O
70	O
at	O
20	O
20	O
18	O
IU	O
breakfast	O
lunch	O
dinner	O
,	O
while	O
associating	O
metformin	B-FARMACO
vildagliptin	I-FARMACO
50	O
1000	O
mg	O
every	O
12	O
hours	O
.	O
June	O
2016	O
,	O
insulinisation	O
takes	O
effect	O
and	O
Hb1Ac	O
is	O
reduced	O
to	O
8	O
.	O
5	O
.	O
BMI	O
remains	O
at	O
40	O
.	O
Novomix	B-FARMACO
30	O
is	O
maintained	O
,	O
increasing	O
the	O
doses	O
to	O
26	O
26	O
24	O
IU	O
breakfast	O
lunch	O
dinner	O
.	O
The	O
analysis	O
showed	O
a	O
GFR	O
estimated	O
by	O
CDK	O
EPI	O
of	O
40	O
ml	O
min	O
1	O
.	O
73	O
cm2	O
,	O
so	O
it	O
was	O
decided	O
to	O
discontinue	O
metformin	B-FARMACO
vildagliptin	I-FARMACO
50	O
1000	O
mg	O
,	O
maintaining	O
only	O
metformin	B-FARMACO
1000	O
mg	O
24	O
hours	O
.	O
In	O
June	O
2017	O
during	O
admission	O
to	O
cardiology	O
for	O
an	O
episode	O
of	O
rapid	O
atrial	O
fibrillation	O
,	O
associated	O
with	O
tachycardiomyopathy	O
.	O
Hb1Ac	O
is	O
7	O
.	O
1	O
.	O
The	O
eGFR	O
had	O
decreased	O
by	O
28	O
ml	O
min	O
1	O
.	O
73	O
m	O
.	O
Metformin	B-FARMACO
was	O
discontinued	O
.	O
In	O
February	O
2018	O
after	O
cardiology	O
review	O
she	O
had	O
fully	O
recovered	O
LVEF	O
.	O
Renal	O
function	O
had	O
improved	O
eGFR	O
51	O
ml	O
min	O
1	O
.	O
73	O
m2	O
.	O
Hb1Ac	O
8	O
.	O
3	O
.	O
BMI	O
was	O
still	O
40	O
.	O
Discussion	O
with	O
endocrinology	O
,	O
the	O
patient	O
's	O
profile	O
is	O
optimal	O
for	O
starting	O
a	O
GLP1	O
analogue	O
diabetic	O
with	O
10	O
years	O
of	O
evolution	O
,	O
with	O
metabolic	O
syndrome	O
,	O
obesity	O
BMI	O
35	O
kg	O
m2	O
and	O
previous	O
cardiovascular	O
disease	O
.	O
It	O
was	O
decided	O
to	O
start	O
dulaglutide	B-FARMACO
0	O
.	O
75	O
mg	O
weekly	O
subcutaneously	O
and	O
progressively	O
increased	O
to	O
1	O
.	O
50	O
mg	O
weekly	O
,	O
without	O
gastrointestinal	O
side	O
effects	O
,	O
with	O
good	O
adaptation	O
and	O
tolerance	O
to	O
the	O
drug	O
.	O
Metformin	B-FARMACO
was	O
restarted	O
at	O
the	O
same	O
time	O
.	O
Novomix	B-FARMACO
therapy	O
was	O
maintained	O
.	O
Six	O
months	O
later	O
,	O
the	O
patient	O
was	O
reviewed	O
and	O
reported	O
a	O
weight	O
loss	O
of	O
5	O
kg	O
,	O
he	O
was	O
more	O
animated	O
,	O
with	O
Hb1Ac	O
7	O
.	O
Metformin	B-FARMACO
was	O
again	O
discontinued	O
due	O
to	O
reduced	O
glomerular	O
filtration	O
rate	O
.	O
Returning	O
to	O
the	O
current	O
cardiology	O
admission	O
in	O
2020	O
,	O
the	O
patient	O
presented	O
adequate	O
clinical	O
evolution	O
in	O
hospitalisation	O
after	O
intravenous	O
diuretic	O
treatment	O
,	O
improving	O
from	O
the	O
point	O
of	O
view	O
of	O
heart	O
failure	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
showing	O
a	O
dilated	O
left	O
ventricle	O
DTd	O
6	O
.	O
3	O
cm	O
;	O
VolTd	O
203	O
ml	O
with	O
severe	O
left	O
ventricular	O
systolic	O
dysfunction	O
EF	O
by	O
Simpson	O
bp	O
29	O
and	O
transmitral	O
pattern	O
suggestive	O
of	O
pseudonormalisation	O
with	O
high	O
filling	O
pressures	O
.	O
Right	O
ventricle	O
with	O
slightly	O
reduced	O
systolic	O
function	O
TAPSE	O
15	O
mm	O
.	O
Biauricular	O
dilatation	O
.	O
No	O
significant	O
valvular	O
heart	O
disease	O
.	O
No	O
pericardial	O
effusion	O
.	O
Coronary	O
angiography	O
with	O
diffuse	O
atheromatosis	O
in	O
the	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O
It	O
was	O
therefore	O
interpreted	O
as	O
suggestive	O
of	O
a	O
priori	O
non	O
ischaemic	O
dilated	O
cardiomyopathy	O
decompensated	O
by	O
rapid	O
AF	O
,	O
and	O
outpatient	O
magnetic	O
resonance	O
imaging	O
MRI	O
was	O
requested	O
to	O
complete	O
the	O
study	O
.	O
He	O
was	O
treated	O
with	O
amiodarone	B-FARMACO
200	O
mg	O
24	O
hours	O
orally	O
,	O
remaining	O
in	O
sinus	O
rhythm	O
,	O
without	O
new	O
falls	O
in	O
atrial	O
fibrillation	O
.	O
In	O
the	O
admission	O
blood	O
test	O
,	O
Hb1Ac	O
was	O
8	O
.	O
1	O
.	O
The	O
BMI	O
was	O
39	O
.	O
7	O
.	O
On	O
discharge	O
,	O
as	O
this	O
was	O
a	O
male	O
with	O
a	O
clear	O
metabolic	O
syndrome	O
and	O
diabetes	O
mellitus	O
with	O
poor	O
control	O
,	O
the	O
treatment	O
was	O
optimised	O
as	O
much	O
as	O
possible	O
,	O
and	O
as	O
an	O
option	O
,	O
treatment	O
with	O
dulaglutide	B-FARMACO
was	O
replaced	O
with	O
semaglutide	B-FARMACO
0	O
.	O
5	O
mg	O
weekly	O
and	O
progressively	O
after	O
4	O
weeks	O
the	O
dose	O
was	O
increased	O
to	O
1	O
mg	O
in	O
an	O
attempt	O
to	O
improve	O
weight	O
loss	O
and	O
metabolic	O
control	O
,	O
maintaining	O
the	O
same	O
insulin	B-FARMACO
units	O
,	O
as	O
blood	O
glucose	O
levels	O
during	O
admission	O
were	O
in	O
range	O
and	O
his	O
HbA1c	O
was	O
8	O
.	O
Metformin	B-FARMACO
is	O
not	O
associated	O
as	O
the	O
glomerular	O
filtration	O
rate	O
at	O
discharge	O
is	O
39	O
ml	O
min	O
by	O
CDK	O
EPI	O
,	O
with	O
urine	O
albuminuria	O
of	O
146	O
mg	O
g	O
.	O
Finally	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
24	O
hours	O
,	O
which	O
the	O
patient	O
was	O
taking	O
,	O
was	O
replaced	O
by	O
rosuvastatin	B-FARMACO
20	O
mg	O
24	O
hours	O
.	O
Over	O
the	O
last	O
4	O
years	O
,	O
the	O
patient	O
has	O
undergone	O
various	O
hypoglycaemic	O
treatments	O
,	O
with	O
frequent	O
changes	O
,	O
mainly	O
due	O
not	O
to	O
side	O
effects	O
but	O
to	O
variable	O
renal	O
function	O
.	O
The	O
advantage	O
of	O
GLP1	O
analogues	O
is	O
that	O
they	O
are	O
not	O
limited	O
by	O
this	O
fact	O
.	O
CKD	O
is	O
often	O
present	O
in	O
long	O
standing	O
diabetic	O
patients	O
with	O
poor	O
control	O
,	O
since	O
,	O
as	O
we	O
know	O
,	O
diabetic	O
nephropathy	O
is	O
one	O
of	O
their	O
vascular	O
complications	O
.	O
This	O
can	O
lead	O
to	O
frequent	O
changes	O
in	O
medication	O
,	O
which	O
are	O
associated	O
with	O
treatment	O
errors	O
and	O
poorer	O
long	O
term	O
adherence	O
of	O
patients	O
to	O
medications	O
.	O
To	O
get	O
the	O
most	O
benefit	O
from	O
therapy	O
,	O
it	O
is	O
important	O
to	O
know	O
the	O
indications	O
,	O
limitations	O
,	O
adverse	O
effects	O
and	O
to	O
tailor	O
the	O
decision	O
of	O
which	O
drug	O
to	O
prescribe	O
to	O
the	O
patient	O
's	O
profile	O
.	O
DIAGNOSIS	O
Type	O
2	O
diabetes	O
mellitus	O
that	O
is	O
difficult	O
to	O
control	O
.	O
Metabolic	O
syndrome	O
.	O
Heart	O
failure	O
with	O
reduced	O
LVEF	O
.	O
Non	O
ischemic	O
dilated	O
cardiomyopathy	O
decompensated	O
by	O
rapid	O
AF	O
associated	O
tachycardiomyopathy	O
component	O
.	O
Persistent	O
cardioverted	O
persistent	O
atrial	O
fibrillation	O
electrically	O
anticoagulated	O
with	O
vitamin	O
K	O
antagonists	O
.	O
Stage	O
IIIb	O
A2	O
chronic	O
kidney	O
disease	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Male	O
,	O
75	O
years	O
old	O
.	O
History	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
hypertension	O
HT	O
.	O
Type	O
2	O
DM	O
with	O
baseline	O
glycosylated	O
haemoglobin	O
HbA1c	O
around	O
8	O
.	O
5	O
.	O
Dyslipidaemia	O
.	O
Ex	O
smoker	O
.	O
Obesity	O
body	O
mass	O
index	O
BMI	O
34	O
kg	O
m2	O
.	O
Cardiological	O
history	O
Chronic	O
ischaemic	O
heart	O
disease	O
admission	O
for	O
acute	O
myocardial	O
infarction	O
AMI	O
not	O
inferior	O
Q	O
4	O
years	O
earlier	O
.	O
Catheterisation	O
left	O
main	O
coronary	O
artery	O
normal	O
.	O
Anterior	O
descending	O
artery	O
AD	O
with	O
significant	O
severely	O
calcified	O
lesion	O
in	O
proximal	O
and	O
middle	O
segment	O
.	O
Right	O
coronary	O
artery	O
RCA	O
with	O
significant	O
lesion	O
in	O
proximal	O
segment	O
.	O
Conclusions	O
two	O
vessel	O
disease	O
.	O
Percutaneous	O
coronary	O
interventionism	O
PCI	O
with	O
balloon	O
and	O
implantation	O
of	O
2	O
stents	O
in	O
the	O
proximal	O
RCA	O
and	O
proximal	O
middle	O
LAD	O
.	O
Implantation	O
of	O
a	O
definitive	O
bicameral	O
pacemaker	O
MCP	O
2	O
years	O
ago	O
due	O
to	O
syncope	O
and	O
atrioventricular	O
block	O
Mobitz	O
II	O
and	O
2	O
1	O
programmed	O
in	O
DDD	O
.	O
Last	O
echocardiogram	O
1	O
year	O
ago	O
preserved	O
left	O
ventricular	O
LV	O
systolic	O
function	O
,	O
with	O
no	O
alterations	O
in	O
segmental	O
contractility	O
.	O
No	O
significant	O
valvulopathies	O
.	O
Other	O
renal	O
colic	O
.	O
Surgical	O
interventions	O
appendectomy	O
,	O
cholecystectomy	O
.	O
Usual	O
treatment	O
Empagliflozin	B-FARMACO
10	O
mg	O
,	O
1	O
tablet	O
daily	O
.	O
Metformin	B-FARMACO
850	O
mg	O
,	O
1	O
tablet	O
every	O
12	O
hours	O
.	O
Bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
,	O
1	O
tablet	O
daily	O
.	O
Ranolazine	B-FARMACO
500	O
mg	O
,	O
1	O
tablet	O
every	O
12	O
hours	O
.	O
Nitroglycerin	B-FARMACO
15	O
mg	O
,	O
1	O
transdermal	O
patch	O
daily	O
.	O
Clopidogrel	B-FARMACO
75	O
mg	O
,	O
1	O
tablet	O
daily	O
.	O
Omeprazole	B-FARMACO
20	O
mg	O
,	O
1	O
capsule	O
daily	O
.	O
Atorvastatin	B-FARMACO
acetylsalicylic	I-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
ramipril	I-FARMACO
20	O
100	O
5	O
mg	O
,	O
1	O
capsule	O
daily	O
.	O
Current	O
disease	O
Chronic	O
stable	O
angina	O
CCS	O
II	O
IV	O
with	O
worsening	O
in	O
the	O
last	O
month	O
,	O
until	O
the	O
onset	O
of	O
angina	O
with	O
mild	O
exertion	O
walking	O
10	O
metres	O
,	O
associated	O
with	O
progressive	O
dyspnoea	O
until	O
it	O
became	O
mild	O
exertion	O
,	O
orthopnoea	O
and	O
oedema	O
in	O
the	O
lower	O
limbs	O
lower	O
limbs	O
.	O
He	O
reported	O
poor	O
blood	O
pressure	O
control	O
at	O
home	O
around	O
150	O
160	O
100	O
mmHg	O
.	O
Physical	O
examination	O
On	O
arrival	O
at	O
the	O
hospital	O
the	O
patient	O
was	O
in	O
good	O
general	O
condition	O
,	O
eupneic	O
at	O
rest	O
.	O
Blood	O
pressure	O
BP	O
170	O
95	O
mmHg	O
,	O
heart	O
rate	O
HR	O
84	O
bpm	O
,	O
oxygen	O
saturation	O
SatO2	O
96	O
on	O
room	O
air	O
,	O
afebrile	O
.	O
Presence	O
of	O
jugular	O
engorgement	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
,	O
systolic	O
murmur	O
II	O
VI	O
in	O
aortic	O
focus	O
.	O
Pulmonary	O
auscultation	O
mild	O
bibasal	O
crackles	O
.	O
Lower	O
limbs	O
slight	O
perimalleolar	O
oedema	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
,	O
pulses	O
preserved	O
.	O
COMPLEMENTARY	O
TESTS	O
Complementary	O
tests	O
during	O
admission	O
Electrocardiogram	O
ECG	O
rhythm	O
stimulated	O
by	O
bicameral	O
pacemaker	O
at	O
60	O
bpm	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
,	O
right	O
costophrenic	O
sinus	O
impingement	O
and	O
vascular	O
redistribution	O
to	O
upper	O
fields	O
.	O
Laboratory	O
tests	O
Blood	O
count	O
haemoglobin	O
11	O
g	O
dl	O
.	O
Haematocrit	O
30	O
.	O
Leukocytes	O
,	O
leukocyte	O
formula	O
and	O
platelets	O
without	O
alterations	O
.	O
Coagulation	O
no	O
alterations	O
.	O
Biochemistry	O
glucose	O
161	O
mg	O
dl	O
.	O
HbA1c	O
8	O
.	O
3	O
.	O
Urea	O
50	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
2	O
mg	O
dl	O
.	O
Ions	O
in	O
normal	O
range	O
,	O
liver	O
function	O
without	O
alterations	O
.	O
CRP	O
1	O
.	O
1	O
mg	O
dl	O
.	O
Lipid	O
study	O
total	O
cholesterol153	O
mg	O
dl	O
,	O
triglycerides	O
77	O
mg	O
dl	O
,	O
HDL	O
44	O
mg	O
dl	O
,	O
LDL	O
94	O
mg	O
dl	O
.	O
Iron	O
metabolism	O
ferritin	O
59	O
μg	O
l	O
.	O
Iron	O
48	O
μg	O
l	O
.	O
IST	O
13	O
.	O
9	O
.	O
Biomarkers	O
of	O
myocardial	O
damage	O
hsTnI	O
80	O
ng	O
l	O
170	O
ng	O
l	O
60	O
ng	O
l	O
normal	O
19	O
.	O
8	O
ng	O
l	O
.	O
Heart	O
failure	O
markers	O
NT	O
proBNP	O
maximum	O
6	O
,	O
290	O
pg	O
ml	O
,	O
CA125	O
30	O
IU	O
ml	O
.	O
Echocardiogram	O
left	O
ventricle	O
slightly	O
dilated	O
,	O
with	O
generalised	O
hypokinesia	O
of	O
all	O
its	O
segments	O
and	O
severely	O
depressed	O
global	O
systolic	O
function	O
LVEF	O
by	O
Simpson	O
28	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Sclerosed	O
aortic	O
valve	O
,	O
with	O
normal	O
opening	O
and	O
normal	O
transvalvular	O
gradients	O
.	O
Dilated	O
left	O
atrium	O
.	O
Normal	O
diastolic	O
pattern	O
,	O
with	O
no	O
increase	O
in	O
LV	O
filling	O
pressures	O
.	O
Slightly	O
dilated	O
right	O
ventricle	O
with	O
borderline	O
systolic	O
function	O
TAPSE	O
17	O
mm	O
.	O
Mild	O
tricuspid	O
insufficiency	O
TI	O
allowing	O
an	O
estimated	O
PAP	O
of	O
46	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
with	O
inspiratory	O
collapse	O
less	O
than	O
50	O
.	O
Coronary	O
angiography	O
,	O
left	O
radial	O
artery	O
stents	O
in	O
CD	O
and	O
DA	O
permeable	O
and	O
without	O
restenosis	O
.	O
Significant	O
stenosis	O
in	O
diagonal	O
branch	O
of	O
reduced	O
calibre	O
,	O
not	O
susceptible	O
to	O
revascularisation	O
.	O
Complementary	O
tests	O
at	O
3	O
months	O
CBC	O
Blood	O
count	O
and	O
coagulation	O
haemoglobin	O
14	O
g	O
dl	O
.	O
Haematocrit	O
44	O
.	O
Leukocyte	O
formula	O
,	O
platelets	O
and	O
coagulation	O
without	O
alterations	O
.	O
Biochemistry	O
glucose	O
150	O
mg	O
dl	O
,	O
HbA1c	O
7	O
.	O
5	O
.	O
Urea	O
47	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
22	O
mg	O
dl	O
.	O
GFR	O
Estimated	O
CKD	O
EPI	O
59	O
ml	O
min	O
1	O
.	O
73	O
m	O
.	O
Ions	O
in	O
range	O
.	O
Liver	O
function	O
without	O
alterations	O
.	O
Lipid	O
study	O
total	O
cholesterol	O
182	O
mg	O
dl	O
,	O
triglycerides	O
200	O
mg	O
dl	O
,	O
HDL	O
45	O
mg	O
dl	O
,	O
LDL	O
85	O
mg	O
dl	O
.	O
Iron	O
metabolism	O
ferritin	O
190	O
μg	O
l	O
.	O
Iron	O
70	O
μg	O
L	O
.	O
IST	O
35	O
.	O
Heart	O
failure	O
markers	O
NT	O
proBNP	O
2	O
,	O
503	O
pg	O
ml	O
,	O
CA125	O
17	O
IU	O
ml	O
.	O
Echocardiogram	O
left	O
ventricle	O
slightly	O
dilated	O
,	O
with	O
generalised	O
hypokinesia	O
of	O
all	O
its	O
segments	O
and	O
moderately	O
depressed	O
global	O
systolic	O
function	O
LVEF	O
32	O
,	O
with	O
asynchrony	O
due	O
to	O
RV	O
stimulation	O
.	O
Absence	O
of	O
significant	O
valvulopathies	O
.	O
Normal	O
diastolic	O
pattern	O
.	O
Right	O
ventricle	O
with	O
preserved	O
function	O
.	O
Non	O
dilated	O
IVC	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
Complementary	O
tests	O
at	O
6	O
months	O
CBC	O
Blood	O
count	O
and	O
coagulation	O
no	O
alterations	O
.	O
Biochemistry	O
glucose	O
140	O
mg	O
dl	O
,	O
HbA1c	O
6	O
.	O
7	O
.	O
Urea	O
42	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
17	O
mg	O
dl	O
.	O
GFR	O
Estimated	O
CKD	O
EPI	O
60	O
ml	O
min	O
1	O
.	O
73	O
m	O
.	O
Ions	O
in	O
range	O
.	O
Liver	O
function	O
without	O
alterations	O
.	O
Lipid	O
study	O
total	O
cholesterol	O
162	O
mg	O
dl	O
,	O
triglycerides	O
225	O
mg	O
dl	O
,	O
HDL	O
46	O
mg	O
dl	O
,	O
LDL	O
70	O
mg	O
dl	O
.	O
Iron	O
metabolism	O
ferritin	O
180	O
μg	O
l	O
,	O
iron	O
68	O
μg	O
l	O
,	O
IST	O
32	O
.	O
Heart	O
failure	O
markers	O
NT	O
proBNP	O
1	O
,	O
153	O
pg	O
ml	O
,	O
CA125	O
14	O
IU	O
ml	O
.	O
Echocardiogram	O
videos	O
3	O
and	O
4	O
non	O
dilated	O
left	O
ventricle	O
with	O
preserved	O
LVEF	O
LVEF	O
by	O
Simpson	O
61	O
.	O
Preserved	O
diameters	O
and	O
volumes	O
,	O
basal	O
anterior	O
septal	O
hypokinesia	O
.	O
Mild	O
mitral	O
regurgitation	O
.	O
Diastolic	O
pattern	O
of	O
impaired	O
relaxation	O
with	O
no	O
increase	O
in	O
end	O
diastolic	O
pressures	O
.	O
Normofunctioning	O
RV	O
with	O
trivial	O
TR	O
and	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAPs	O
40	O
mmHg	O
.	O
IVC	O
15	O
mm	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
This	O
is	O
a	O
patient	O
with	O
chronic	O
ischaemic	O
heart	O
disease	O
and	O
a	O
bicameral	O
CCM	O
,	O
who	O
presented	O
progression	O
of	O
his	O
angina	O
to	O
minimal	O
effort	O
angina	O
,	O
as	O
well	O
as	O
deterioration	O
of	O
functional	O
class	O
,	O
associated	O
with	O
the	O
appearance	O
of	O
severe	O
left	O
ventricular	O
dysfunction	O
previously	O
preserved	O
LVEF	O
,	O
for	O
which	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
cardiology	O
for	O
study	O
and	O
treatment	O
.	O
During	O
his	O
stay	O
in	O
the	O
cardiology	O
ward	O
,	O
depletive	O
and	O
antianginal	O
treatment	O
was	O
administered	O
,	O
with	O
a	O
progressive	O
decrease	O
in	O
dyspnoea	O
,	O
without	O
new	O
episodes	O
of	O
chest	O
pain	O
,	O
tolerating	O
ambulation	O
.	O
Coronary	O
angiography	O
showed	O
progression	O
of	O
the	O
non	O
revascularisable	O
coronary	O
artery	O
disease	O
,	O
so	O
it	O
was	O
decided	O
to	O
optimise	O
the	O
antianginal	O
and	O
heart	O
failure	O
medical	O
treatment	O
.	O
Spironolactone	B-FARMACO
and	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
were	O
started	O
without	O
incident	O
.	O
Given	O
the	O
presence	O
of	O
poorly	O
controlled	O
diabetes	O
associated	O
with	O
obesity	O
and	O
difficult	O
to	O
control	O
hypertension	O
in	O
a	O
patient	O
with	O
ischaemic	O
heart	O
disease	O
and	O
heart	O
failure	O
,	O
it	O
was	O
decided	O
to	O
add	O
liraglutide	B-FARMACO
0	O
.	O
6	O
mg	O
daily	O
to	O
the	O
treatment	O
and	O
the	O
statin	B-FARMACO
dose	O
was	O
increased	O
.	O
Given	O
the	O
iron	O
deficiency	O
anaemia	O
,	O
treatment	O
was	O
associated	O
with	O
intravenous	O
ferrotherapy	O
,	O
with	O
a	O
good	O
response	O
.	O
At	O
hospital	O
discharge	O
,	O
BP	O
100	O
66	O
mmHg	O
,	O
HR	O
84	O
bpm	O
,	O
SatO2	O
99	O
,	O
in	O
a	O
state	O
of	O
euvolemia	O
.	O
He	O
was	O
admitted	O
to	O
the	O
heart	O
failure	O
unit	O
for	O
close	O
outpatient	O
monitoring	O
.	O
After	O
3	O
months	O
,	O
severe	O
ventricular	O
dysfunction	O
persisted	O
and	O
cardiac	O
resynchronisation	O
therapy	O
CRT	O
was	O
decided	O
given	O
the	O
contribution	O
to	O
the	O
dysfunction	O
of	O
continuous	O
RV	O
pacing	O
pacemaker	O
dependent	O
patient	O
.	O
After	O
6	O
months	O
of	O
optimal	O
medical	O
treatment	O
titrated	O
to	O
maximum	O
tolerated	O
doses	O
and	O
3	O
months	O
of	O
CRT	O
implantation	O
,	O
the	O
patient	O
was	O
re	O
evaluated	O
clinically	O
,	O
analytically	O
and	O
echocardiographically	O
.	O
The	O
patient	O
presented	O
NYHA	O
I	O
without	O
symptoms	O
of	O
heart	O
failure	O
or	O
signs	O
of	O
pulmonary	O
or	O
peripheral	O
congestion	O
,	O
normalisation	O
of	O
ventricular	O
function	O
,	O
absence	O
of	O
chest	O
pain	O
and	O
adequate	O
blood	O
pressure	O
control	O
at	O
home	O
.	O
Significant	O
weight	O
loss	O
BMI	O
28	O
and	O
marked	O
improvement	O
in	O
glycaemic	O
control	O
were	O
also	O
confirmed	O
,	O
reaching	O
target	O
HbA1c	O
.	O
The	O
patient	O
has	O
had	O
no	O
new	O
decompensations	O
or	O
admissions	O
during	O
the	O
current	O
2	O
year	O
follow	O
up	O
.	O
DIAGNOSIS	O
Main	O
diagnosis	O
Chronic	O
ischaemic	O
heart	O
disease	O
.	O
Unstable	O
angina	O
Ib	O
with	O
myocardial	O
damage	O
in	O
AMI	O
range	O
.	O
2	O
vessel	O
coronary	O
artery	O
disease	O
with	O
permeable	O
stents	O
and	O
new	O
non	O
revascularisable	O
lesion	O
in	O
diagonal	O
branch	O
.	O
Heart	O
failure	O
with	O
severely	O
depressed	O
ejection	O
fraction	O
of	O
multifactorial	O
origin	O
diabetic	O
,	O
ischaemic	O
and	O
post	O
RV	O
pacing	O
myocardiopathy	O
.	O
Other	O
diagnoses	O
Iron	O
deficiency	O
anaemia	O
.	O
Arterial	O
hypertension	O
.	O
Poorly	O
controlled	O
type	O
2	O
diabetes	O
mellitus	O
.	O
Dyslipidaemia	O
without	O
meeting	O
LDL	O
targets	O
.	O
Obesity	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Patient	O
aged	O
43	O
years	O
with	O
no	O
personal	O
or	O
family	O
cardiological	O
history	O
.	O
Active	O
smoking	O
of	O
1	O
pack	O
day	O
,	O
no	O
other	O
toxic	O
habits	O
.	O
No	O
recent	O
trips	O
.	O
No	O
regular	O
medication	O
.	O
Current	O
illness	O
Patient	O
referred	O
from	O
the	O
emergency	O
department	O
of	O
a	O
regional	O
hospital	O
for	O
an	O
abrupt	O
picture	O
of	O
language	O
alteration	O
,	O
with	O
subtle	O
nominative	O
difficulties	O
,	O
paraphasia	O
and	O
fragmented	O
and	O
incoherent	O
speech	O
together	O
with	O
a	O
tendency	O
to	O
somnolence	O
of	O
12	O
hours	O
of	O
evolution	O
.	O
The	O
previous	O
day	O
the	O
patient	O
had	O
been	O
skiing	O
,	O
without	O
incident	O
.	O
A	O
cranial	O
computerised	O
axial	O
tomography	O
CAT	O
scan	O
was	O
performed	O
,	O
showing	O
only	O
an	O
old	O
left	O
subthalamic	O
infarction	O
,	O
and	O
a	O
lumbar	O
puncture	O
,	O
with	O
normal	O
biochemistry	O
according	O
to	O
protocol	O
,	O
PCR	O
for	O
viruses	O
was	O
not	O
indicated	O
.	O
On	O
suspicion	O
of	O
an	O
evolving	O
cerebrovascular	O
accident	O
CVA	O
,	O
he	O
was	O
referred	O
to	O
our	O
hospital	O
.	O
On	O
arrival	O
he	O
was	O
assessed	O
by	O
the	O
emergency	O
department	O
.	O
In	O
the	O
anamnesis	O
,	O
the	O
family	O
commented	O
that	O
they	O
had	O
had	O
a	O
mild	O
upper	O
respiratory	O
catarrh	O
two	O
months	O
ago	O
,	O
which	O
had	O
resolved	O
.	O
However	O
,	O
our	O
patient	O
had	O
presented	O
with	O
a	O
persistent	O
non	O
productive	O
cough	O
for	O
the	O
last	O
30	O
days	O
,	O
which	O
she	O
did	O
not	O
attach	O
particular	O
importance	O
to	O
.	O
In	O
addition	O
,	O
in	O
the	O
last	O
week	O
,	O
intolerance	O
to	O
decubitus	O
together	O
with	O
slight	O
oedematisation	O
of	O
the	O
extremities	O
,	O
all	O
compatible	O
with	O
cardiac	O
decompensation	O
.	O
A	O
joint	O
assessment	O
by	O
neurology	O
and	O
cardiology	O
was	O
requested	O
.	O
Physical	O
examination	O
Initially	O
,	O
the	O
patient	O
was	O
assessed	O
neurologically	O
.	O
Of	O
note	O
Hypofluent	O
language	O
,	O
with	O
subtle	O
nominative	O
disorder	O
,	O
isolated	O
phonetic	O
paraphasia	O
,	O
with	O
preserved	O
repetition	O
and	O
execution	O
of	O
complex	O
commands	O
.	O
Emotional	O
lability	O
with	O
a	O
tendency	O
to	O
cry	O
,	O
fluctuating	O
.	O
Slightly	O
reduced	O
attentional	O
spaming	O
with	O
alteration	O
of	O
working	O
memory	O
and	O
minimal	O
tendency	O
to	O
pronation	O
without	O
claudication	O
of	O
the	O
right	O
upper	O
extremity	O
.	O
MIS	O
0	O
8	O
.	O
The	O
rest	O
of	O
the	O
neurological	O
examination	O
was	O
normal	O
.	O
Subsequently	O
,	O
the	O
cardiology	O
examination	O
was	O
performed	O
Blood	O
pressure	O
BP	O
152	O
100	O
mmHg	O
,	O
tendency	O
to	O
sinus	O
tachycardia	O
,	O
oxygen	O
saturation	O
with	O
nasal	O
goggles	O
at	O
3	O
bpm	O
95	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
at	O
95	O
bpm	O
,	O
third	O
sound	O
,	O
systolic	O
murmur	O
in	O
mitral	O
focus	O
.	O
Pulmonary	O
auscultation	O
crackles	O
to	O
right	O
midfield	O
and	O
left	O
base	O
.	O
Abdomen	O
without	O
semiology	O
of	O
ascites	O
,	O
hepatomegaly	O
of	O
medial	O
predominance	O
of	O
two	O
traverses	O
.	O
Jugular	O
ingurgitation	O
.	O
Slight	O
bimalleolar	O
oedema	O
in	O
decubitus	O
.	O
Urine	O
toxins	O
,	O
enterovirus	O
,	O
RSV	O
and	O
influenza	O
serology	O
were	O
requested	O
,	O
all	O
negative	O
.	O
Admission	O
to	O
cardiology	O
with	O
joint	O
management	O
by	O
both	O
specialties	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
93	O
bpm	O
,	O
normal	O
PR	O
,	O
QRS	O
90	O
ms	O
,	O
QTc	O
416	O
ms	O
.	O
Sokolow	O
Lyon	O
criteria	O
for	O
LVH	O
.	O
Negative	O
T	O
wave	O
in	O
III	O
,	O
AVF	O
,	O
V5	O
V6	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
,	O
signs	O
of	O
vascular	O
redistribution	O
.	O
Pinching	O
of	O
both	O
costophrenic	O
sinuses	O
in	O
relation	O
to	O
small	O
bilateral	O
pleural	O
effusion	O
.	O
Blood	O
tests	O
urea	O
29	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
02	O
mg	O
dl	O
,	O
calcium	O
8	O
.	O
2	O
mEq	O
l	O
,	O
magnesium	O
2	O
mEq	O
l	O
,	O
chlorine	O
108	O
mEq	O
l	O
,	O
sodium	O
137	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
9	O
mEq	O
l	O
,	O
GGT	O
70	O
U	O
l	O
,	O
GOT	O
84	O
U	O
l	O
,	O
GPT	O
111	O
U	O
l	O
,	O
total	O
bilirubin	O
1	O
.	O
58	O
mg	O
dl	O
,	O
leukocytes	O
7300	O
mm	O
,	O
haemoglobin	O
12	O
.	O
9	O
g	O
dl	O
,	O
haematocrit	O
37	O
.	O
5	O
,	O
platelets	O
173000	O
mm	O
,	O
prothrombin	O
activity	O
95	O
,	O
NT	O
proBNP	O
12396	O
pg	O
ml	O
,	O
CRP	O
2	O
.	O
66	O
mg	O
dl	O
,	O
ultrasensitive	O
troponin	O
I	O
1346	O
ng	O
l	O
,	O
D	O
dimer	O
2511	O
ng	O
ml	O
.	O
Negative	O
urine	O
toxins	O
.	O
Lumbar	O
puncture	O
biochemistry	O
5	O
red	O
blood	O
cells	O
,	O
0	O
nucleated	O
cells	O
,	O
chlorine	O
130	O
,	O
glucose	O
0	O
.	O
68	O
,	O
protein	O
0	O
.	O
37	O
.	O
Gram	O
no	O
microorganisms	O
found	O
.	O
Bacterial	O
culture	O
negative	O
.	O
Microbiology	O
nasopharyngeal	O
swab	O
negative	O
for	O
influenza	O
,	O
enterovirus	O
and	O
respiratory	O
syncytial	O
virus	O
.	O
Rectal	O
smear	O
negative	O
for	O
enterovirus	O
.	O
CT	O
scan	O
of	O
the	O
brain	O
on	O
admission	O
midline	O
structures	O
centred	O
.	O
Symmetrical	O
ventricular	O
system	O
of	O
normal	O
size	O
and	O
morphology	O
.	O
Cortical	O
sulci	O
,	O
peritroncular	O
cisterns	O
and	O
cranial	O
base	O
without	O
alterations	O
.	O
No	O
haemorrhagic	O
lesions	O
were	O
observed	O
.	O
Bedside	O
echocardiogram	O
on	O
admission	O
dilated	O
left	O
ventricle	O
LV	O
LVED	O
60	O
mm	O
with	O
normal	O
wall	O
thickness	O
,	O
severe	O
ventricular	O
dysfunction	O
with	O
estimated	O
LVEF	O
15	O
20	O
.	O
Global	O
hypocontractility	O
with	O
no	O
clear	O
contractile	O
asymmetries	O
.	O
Mitral	O
valve	O
MV	O
thickened	O
leaflets	O
,	O
tenting	O
of	O
both	O
leaflets	O
leading	O
to	O
severe	O
secondary	O
or	O
functional	O
mitral	O
regurgitation	O
.	O
Competent	O
aortic	O
valve	O
.	O
Right	O
ventricle	O
RV	O
of	O
normal	O
size	O
,	O
good	O
longitudinal	O
function	O
but	O
CAF	O
25	O
.	O
Severe	O
PI	O
.	O
Mild	O
TR	O
allowing	O
estimation	O
of	O
RV	O
RA	O
gradient	O
35	O
mmHg	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
with	O
abolished	O
inspiratory	O
collapse	O
,	O
moderate	O
pulmonary	O
hypertension	O
.	O
Minimal	O
pericardial	O
effusion	O
lamina	O
Magnetic	O
resonance	O
imaging	O
MRI	O
of	O
the	O
brain	O
craniovertebral	O
junction	O
of	O
normal	O
morphology	O
.	O
No	O
midline	O
abnormalities	O
detected	O
.	O
Posterior	O
fossa	O
of	O
normal	O
configuration	O
.	O
Ventricular	O
system	O
of	O
normal	O
size	O
and	O
morphology	O
.	O
Base	O
cisterns	O
free	O
.	O
Vascular	O
structures	O
of	O
correct	O
configuration	O
,	O
dural	O
venous	O
sinuses	O
permeable	O
.	O
T2	O
signal	O
alteration	O
in	O
the	O
left	O
thalamic	O
region	O
with	O
a	O
distribution	O
suggesting	O
lacunar	O
infarction	O
by	O
lenticulostriate	O
artery	O
,	O
with	O
almost	O
complete	O
restitution	O
of	O
diffusion	O
.	O
It	O
suggests	O
subacute	O
infarction	O
.	O
A	O
small	O
subcortical	O
T2	O
hypersignal	O
is	O
detected	O
in	O
the	O
right	O
insula	O
,	O
in	O
the	O
posterior	O
frontal	O
cortex	O
,	O
predominantly	O
in	O
the	O
left	O
hemisphere	O
and	O
in	O
the	O
right	O
occipital	O
juxtacortical	O
white	O
matter	O
.	O
Some	O
small	O
diffusion	O
brightening	O
is	O
observed	O
in	O
the	O
left	O
frontal	O
cortex	O
,	O
indicating	O
acute	O
cortical	O
infarction	O
at	O
present	O
.	O
Conclusion	O
subacute	O
lacunar	O
infarction	O
in	O
the	O
left	O
thalamic	O
region	O
and	O
acute	O
cortical	O
microinfarcts	O
in	O
the	O
left	O
posterior	O
frontal	O
cortex	O
.	O
Cardiac	O
MRI	O
poor	O
image	O
quality	O
and	O
impossibility	O
of	O
completing	O
the	O
study	O
due	O
to	O
the	O
patient	O
's	O
neurological	O
condition	O
.	O
Dilated	O
LV	O
with	O
severely	O
depressed	O
LVEF	O
20	O
.	O
Failure	O
of	O
isovolumetric	O
relaxation	O
.	O
Normal	O
myocardial	O
thickness	O
and	O
global	O
hypocontractility	O
.	O
No	O
oedema	O
swelling	O
in	O
myocardial	O
thickness	O
.	O
Late	O
enhancement	O
not	O
acquired	O
because	O
the	O
patient	O
was	O
unable	O
to	O
complete	O
the	O
examination	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
with	O
mild	O
hypocontractility	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
Pericardial	O
effusion	O
10	O
mm	O
thick	O
.	O
Echocardiogram	O
at	O
discharge	O
moderately	O
dilated	O
left	O
ventricle	O
with	O
normal	O
thickness	O
DTDVI	O
60	O
mm	O
,	O
indexed	O
VTD	O
94	O
ml	O
m2	O
.	O
Moderate	O
LV	O
systolic	O
dysfunction	O
LVEF	O
estimated	O
by	O
Simpson	O
biplanar	O
35	O
.	O
Global	O
hypocontractility	O
.	O
Pseudonormal	O
diastole	O
.	O
Slightly	O
dilated	O
A	O
.	O
I	O
.	O
MV	O
thickened	O
cusp	O
leaflets	O
4	O
mm	O
.	O
Dilated	O
annulus	O
38	O
mm	O
.	O
Preserved	O
opening	O
with	O
posterior	O
leaflet	O
restriction	O
.	O
MI	O
of	O
central	O
origin	O
with	O
jet	O
directed	O
towards	O
the	O
posterolateral	O
wall	O
of	O
LA	O
reaching	O
the	O
roof	O
of	O
the	O
same	O
,	O
without	O
reverse	O
systolic	O
flow	O
in	O
PVs	O
with	O
decreased	O
systolic	O
component	O
VC	O
6	O
mm	O
,	O
estimated	O
ORE	O
0	O
.	O
30	O
cm2	O
and	O
RV	O
51	O
ml	O
,	O
which	O
by	O
all	O
data	O
is	O
estimated	O
in	O
grade	O
III	O
IV	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Tricuspid	O
valve	O
normal	O
in	O
structure	O
and	O
function	O
.	O
Mild	O
TR	O
.	O
Non	O
dilated	O
IVC	O
with	O
preserved	O
inspiratory	O
collapse	O
.	O
Estimated	O
normal	O
PAPs	O
.	O
Left	O
and	O
right	O
catheterisation	O
coronary	O
arteries	O
without	O
angiographically	O
significant	O
lesions	O
.	O
Normal	O
pulmonary	O
pressures	O
.	O
Endomyocardial	O
biopsy	O
EMB	O
insufficient	O
material	O
.	O
Myocardial	O
fragments	O
with	O
preserved	O
structure	O
.	O
Interstitial	O
inflammatory	O
infiltrate	O
consisting	O
of	O
neutrophilic	O
polymorphonuclear	O
neutrophils	O
and	O
lymphocytes	O
,	O
without	O
myocyte	O
damage	O
.	O
There	O
were	O
polymorphonuclear	O
cells	O
mm2	O
and	O
3	O
CD3	O
lymphocytes	O
mm	O
.	O
Viral	O
PCR	O
negative	O
.	O
Echocardiogram	O
at	O
follow	O
up	O
6	O
months	O
after	O
discharge	O
LV	O
indexed	O
slightly	O
dilated	O
,	O
normal	O
wall	O
thickness	O
.	O
Global	O
systolic	O
function	O
preserved	O
LVEF	O
60	O
,	O
without	O
regional	O
contractile	O
abnormalities	O
.	O
Both	O
atria	O
of	O
normal	O
size	O
.	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
MV	O
preserved	O
opening	O
,	O
mild	O
MI	O
.	O
Estimated	O
pulmonary	O
pressure	O
normal	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
Given	O
the	O
multidisciplinary	O
management	O
during	O
admission	O
,	O
the	O
neurological	O
and	O
cardiological	O
evolution	O
of	O
our	O
patient	O
will	O
be	O
differentiated	O
Neurological	O
evolution	O
MRI	O
was	O
requested	O
on	O
admission	O
showing	O
a	O
lesion	O
compatible	O
with	O
left	O
anterior	O
thalamic	O
infarction	O
and	O
EEG	O
with	O
no	O
findings	O
of	O
interest	O
.	O
She	O
remained	O
alert	O
and	O
cooperative	O
,	O
mild	O
bradypsychia	O
,	O
and	O
showed	O
some	O
despair	O
when	O
faced	O
with	O
cognitive	O
tests	O
when	O
she	O
could	O
not	O
remember	O
.	O
MOCA	O
16	O
30	O
,	O
mainly	O
in	O
TE	O
orientation	O
,	O
language	O
fluency	O
and	O
delayed	O
counting	O
.	O
Reads	O
,	O
but	O
does	O
not	O
achieve	O
full	O
comprehension	O
.	O
Maintains	O
some	O
abstract	O
thinking	O
.	O
Pending	O
assessment	O
by	O
neuropsychologist	O
after	O
discharge	O
.	O
Subsequent	O
periodic	O
neuropsychological	O
studies	O
should	O
be	O
carried	O
out	O
in	O
order	O
to	O
determine	O
whether	O
there	O
is	O
an	O
evolutionary	O
recovery	O
of	O
the	O
cognitive	O
disorders	O
or	O
to	O
conclude	O
her	O
diagnosis	O
as	O
thalamic	O
vascular	O
dementia	O
.	O
Cardiological	O
evolution	O
Admission	O
with	O
frank	O
heart	O
failure	O
with	O
orthopnoea	O
,	O
bilateral	O
pleural	O
effusion	O
,	O
hepatomegaly	O
and	O
oedema	O
.	O
Treatment	O
was	O
started	O
with	O
levosimendan	B-FARMACO
and	O
furosemide	B-FARMACO
with	O
progressive	O
improvement	O
of	O
congestive	O
signs	O
.	O
Once	O
stabilised	O
,	O
given	O
acute	O
HF	O
of	O
3	O
months	O
of	O
evolution	O
with	O
a	O
history	O
of	O
upper	O
respiratory	O
tract	O
infection	O
,	O
a	O
cardiac	O
MRI	O
was	O
performed	O
which	O
estimated	O
severely	O
depressed	O
ventricular	O
function	O
LVEF	O
20	O
,	O
with	O
no	O
evidence	O
of	O
myocardial	O
oedema	O
,	O
limited	O
by	O
the	O
impossibility	O
of	O
administering	O
gadolinium	O
given	O
the	O
patient	O
's	O
neurological	O
condition	O
.	O
Subsequently	O
,	O
coronary	O
angiography	O
was	O
performed	O
,	O
with	O
no	O
lesions	O
,	O
right	O
catheterisation	O
showing	O
normal	O
pulmonary	O
pressures	O
and	O
PVR	O
and	O
endomyocardial	O
biopsy	O
of	O
the	O
RV	O
.	O
The	O
biopsy	O
showed	O
an	O
interstitial	O
inflammatory	O
infiltrate	O
consisting	O
of	O
polymorphonuclear	O
6	O
m	O
and	O
CD3	O
T	O
lymphocytes	O
3	O
mm2	O
but	O
myocytes	O
with	O
preserved	O
structure	O
.	O
Echocardiogram	O
at	O
discharge	O
showed	O
improvement	O
in	O
ventricular	O
function	O
,	O
estimated	O
at	O
35	O
.	O
Once	O
stabilised	O
,	O
neurohormonal	O
treatment	O
was	O
started	O
with	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
,	O
carvedilol	B-FARMACO
and	O
spironolactone	B-FARMACO
,	O
pending	O
a	O
new	O
control	O
echocardiography	O
three	O
months	O
after	O
discharge	O
,	O
which	O
showed	O
complete	O
recovery	O
of	O
ventricular	O
function	O
and	O
normalisation	O
of	O
repolarisation	O
in	O
the	O
patient	O
's	O
ECG	O
.	O
DIAGNOSIS	O
Dilated	O
cardiomyopathy	O
with	O
recovered	O
severe	O
ventricular	O
dysfunction	O
;	O
suspected	O
acute	O
myocarditis	O
borderline	O
.	O
Congestive	O
heart	O
failure	O
of	O
subacute	O
onset	O
.	O
Left	O
thalamic	O
stroke	O
of	O
cardioembolic	O
origin	O
strategic	O
location	O
for	O
cognitive	O
impairment	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Male	O
,	O
73	O
years	O
old	O
,	O
independent	O
,	O
with	O
an	O
active	O
life	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
ex	O
smoker	O
until	O
30	O
years	O
ago	O
of	O
about	O
30	O
packs	O
year	O
.	O
High	O
blood	O
pressure	O
HBP	O
under	O
pharmacological	O
treatment	O
with	O
good	O
control	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
DM	O
treated	O
with	O
oral	O
medication	O
with	O
good	O
control	O
.	O
Dyslipidaemia	O
under	O
pharmacological	O
treatment	O
.	O
No	O
alcohol	O
habit	O
.	O
Previous	O
cardiological	O
history	O
diagnosed	O
in	O
October	O
2017	O
due	O
to	O
episode	O
of	O
oppressive	O
chest	O
pain	O
of	O
degenerative	O
aortic	O
valve	O
disease	O
with	O
double	O
lesion	O
severe	O
aortic	O
stenosis	O
and	O
moderate	O
aortic	O
insufficiency	O
,	O
ascending	O
aortic	O
aneurysm	O
52	O
mm	O
and	O
1	O
vessel	O
coronary	O
artery	O
disease	O
diffusely	O
diseased	O
DC	O
with	O
poor	O
distal	O
bed	O
.	O
In	O
February	O
2018	O
,	O
valve	O
replacement	O
was	O
performed	O
,	O
with	O
a	O
number	O
21	O
Magna	O
Ease	O
biological	O
aortic	O
prosthesis	O
and	O
a	O
Hemashield	O
No	O
28	O
supracoronary	O
tube	O
.	O
Other	O
history	O
Duodenal	O
ulcus	O
requiring	O
Billroth	O
II	O
gastrectomy	O
.	O
Synchronous	O
lower	O
rectal	O
and	O
pulmonary	O
neoplasia	O
in	O
2016	O
.	O
Received	O
radio	O
and	O
chemotherapy	O
;	O
subsequently	O
pulmonary	O
lobectomy	O
and	O
rectal	O
resection	O
.	O
Grade	O
II	O
chronic	O
lower	O
limb	O
ischaemia	O
due	O
to	O
femoropopliteal	O
obstruction	O
in	O
MID	O
and	O
distal	O
popliteal	O
stenosis	O
in	O
MMII	O
.	O
Neurinoma	O
of	O
the	O
left	O
acoustic	O
nerve	O
causing	O
hypoacusis	O
in	O
the	O
left	O
ear	O
,	O
therapeutic	O
attitude	O
pending	O
decision	O
.	O
Usual	O
treatment	O
rosuvastatin	B-FARMACO
10	O
mg	O
0	O
0	O
1	O
,	O
clopidogrel	B-FARMACO
75	O
mg	O
0	O
1	O
0	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
,	O
oxycodone	B-FARMACO
5	O
mg	O
1	O
cp	O
c	O
4h	O
sp	O
,	O
paracetamol	B-FARMACO
sp	O
and	O
lactulose	B-FARMACO
sp	O
.	O
Present	O
illness	O
73	O
year	O
old	O
patient	O
admitted	O
to	O
neurology	O
in	O
April	O
2019	O
for	O
diplopia	O
and	O
gait	O
instability	O
.	O
In	O
the	O
previous	O
month	O
,	O
he	O
had	O
presented	O
with	O
a	O
general	O
syndrome	O
with	O
weight	O
loss	O
and	O
asthenia	O
,	O
accompanied	O
by	O
febrile	O
fever	O
.	O
Twenty	O
four	O
hours	O
after	O
admission	O
to	O
neurology	O
to	O
complete	O
studies	O
,	O
having	O
previously	O
been	O
asymptomatic	O
from	O
the	O
cardiological	O
point	O
of	O
view	O
,	O
he	O
began	O
with	O
oppressive	O
central	O
thoracic	O
pain	O
with	O
electrocardiographic	O
changes	O
right	O
bundle	O
branch	O
block	O
RBBB	O
not	O
previously	O
seen	O
and	O
ST	O
elevation	O
on	O
the	O
anterolateral	O
side	O
.	O
The	O
infarction	O
code	O
was	O
activated	O
and	O
loading	O
doses	O
of	O
antithrombotic	O
treatment	O
were	O
administered	O
.	O
A	O
few	O
minutes	O
later	O
,	O
he	O
presented	O
complete	O
atrioventricular	O
block	O
with	O
bouts	O
of	O
prolonged	O
asystole	O
and	O
haemodynamic	O
instability	O
,	O
so	O
orotracheal	O
intubation	O
and	O
connection	O
to	O
mechanical	O
ventilation	O
was	O
performed	O
.	O
He	O
required	O
noradrenaline	B-FARMACO
to	O
maintain	O
blood	O
pressure	O
.	O
On	O
arrival	O
at	O
the	O
haemodynamics	O
ward	O
,	O
a	O
transient	O
pacemaker	O
was	O
placed	O
via	O
the	O
right	O
femoral	O
vein	O
and	O
a	O
coronary	O
angiography	O
was	O
performed	O
showing	O
100	O
stenosis	O
of	O
the	O
anterior	O
descending	O
artery	O
as	O
the	O
vessel	O
responsible	O
for	O
the	O
infarction	O
.	O
Primary	O
angioplasty	O
and	O
pharmacoactive	O
destent	O
implantation	O
was	O
performed	O
with	O
good	O
angiographic	O
results	O
.	O
He	O
was	O
then	O
admitted	O
to	O
the	O
cardiac	O
intensive	O
care	O
unit	O
.	O
Physical	O
examination	O
On	O
admission	O
to	O
neurology	O
Neurological	O
examination	O
unstable	O
gait	O
with	O
lateropulsion	O
to	O
the	O
right	O
,	O
right	O
palpebral	O
ptosis	O
and	O
diplopia	O
in	O
various	O
gaze	O
positions	O
.	O
Blood	O
pressure	O
BP	O
135	O
73	O
mmHg	O
.	O
Oxygen	O
saturation	O
SatO2	O
97	O
basal	O
.	O
Temperature	O
37	O
.	O
4	O
oC	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
without	O
added	O
noises	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
with	O
systolic	O
murmur	O
II	O
VI	O
in	O
aortic	O
focus	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
and	O
non	O
painful	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
On	O
admission	O
to	O
the	O
cardiac	O
ICU	O
SAPS	O
3	O
Simplified	O
Acute	O
Physiology	O
Score	O
3	O
76	O
points	O
67	O
.	O
4	O
probability	O
of	O
death	O
on	O
admission	O
.	O
BP	O
115	O
56	O
mmHg	O
with	O
noradrenaline	B-FARMACO
perfusion	O
at	O
0	O
.	O
7	O
μg	O
kg	O
min	O
.	O
Heart	O
rate	O
HR	O
70	O
bpm	O
.	O
Temperature	O
36o	O
C	O
.	O
SatO2	O
100	O
FiO2	O
0	O
.	O
5	O
.	O
Respiratory	O
rate	O
RR	O
19	O
rpm	O
.	O
Under	O
sedoanalgesia	O
,	O
pupils	O
half	O
reactive	O
.	O
Upper	O
limb	O
flexion	O
MMSS	O
to	O
algesic	O
stimulus	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
without	O
added	O
noises	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
with	O
systolic	O
murmur	O
II	O
VI	O
in	O
aortic	O
focus	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
with	O
preserved	O
peristalsis	O
,	O
with	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
No	O
masses	O
or	O
megaliths	O
were	O
palpable	O
.	O
The	O
lower	O
extremities	O
were	O
well	O
perfused	O
,	O
with	O
preserved	O
and	O
symmetrical	O
pulses	O
,	O
with	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Cranial	O
CT	O
scan	O
without	O
contrast	O
no	O
signs	O
of	O
bleeding	O
,	O
compressions	O
or	O
displacements	O
in	O
the	O
endocranial	O
structures	O
visualised	O
.	O
Hypodense	O
lesions	O
in	O
the	O
periventricular	O
white	O
matter	O
with	O
a	O
subacute	O
ischaemic	O
appearance	O
.	O
Laboratory	O
tests	O
blood	O
biochemistry	O
glucose	O
255	O
mg	O
dl	O
,	O
urea	O
49	O
mg	O
dL	O
,	O
creatinine	O
0	O
.	O
95	O
mg	O
dl	O
,	O
CK	O
5	O
,	O
955	O
U	O
l	O
,	O
TnT	O
14	O
,	O
890	O
ng	O
l	O
.	O
Haemoglobin	O
9	O
.	O
3	O
g	O
dl	O
,	O
haematocrit	O
27	O
.	O
4	O
,	O
leucocytes	O
14	O
,	O
550	O
mm	O
neutrophils	O
91	O
.	O
9	O
,	O
platelets	O
149	O
,	O
000	O
mm	O
.	O
Coagulation	O
PT	O
61	O
,	O
TTPa	O
15	O
.	O
9	O
s	O
,	O
fibrinogen	O
432	O
mg	O
dl	O
.	O
Electrocardiogram	O
ECG	O
with	O
chest	O
pain	O
sinus	O
rhythm	O
at	O
97	O
bpm	O
.	O
BRDHH	O
.	O
ST	O
elevation	O
on	O
the	O
anterolateral	O
side	O
.	O
Emergent	O
coronary	O
angiography	O
Implantation	O
of	O
a	O
transient	O
balloon	O
pacemaker	O
via	O
right	O
femoral	O
vein	O
.	O
Left	O
main	O
coronary	O
artery	O
no	O
stenosis	O
.	O
Anterior	O
descending	O
100	O
stenosis	O
,	O
TIMI	O
0	O
flow	O
in	O
proximal	O
segment	O
.	O
Circumflex	O
no	O
stenosis	O
.	O
Right	O
coronary	O
artery	O
severe	O
stenosis	O
of	O
99	O
in	O
its	O
distal	O
segment	O
and	O
100	O
stenosis	O
in	O
its	O
middle	O
segment	O
,	O
with	O
impression	O
of	O
chronic	O
occlusion	O
,	O
with	O
bad	O
distal	O
bed	O
.	O
Primary	O
angioplasty	O
via	O
the	O
right	O
femoral	O
artery	O
,	O
with	O
JL4	O
guidewire	O
,	O
guidefloppy	O
is	O
advanced	O
to	O
the	O
distal	O
LAD	O
,	O
recovering	O
arterial	O
flow	O
.	O
Subsequently	O
,	O
direct	O
implantation	O
of	O
a	O
Resolute	O
Onyx	O
3	O
.	O
5	O
x	O
22	O
mm	O
drug	O
eluting	O
device	O
was	O
performed	O
in	O
the	O
proximal	O
segment	O
with	O
success	O
and	O
without	O
complications	O
.	O
Good	O
angiographic	O
result	O
and	O
final	O
TIMI	O
3	O
flow	O
.	O
Transesophageal	O
echocardiography	O
Study	O
performed	O
in	O
ICU	O
with	O
patient	O
on	O
mechanical	O
ventilation	O
.	O
Biological	O
prosthesis	O
in	O
aortic	O
position	O
with	O
a	O
large	O
wart	O
about	O
24	O
mm	O
,	O
multilobulated	O
and	O
irregular	O
,	O
which	O
moves	O
from	O
LVOT	O
to	O
aorta	O
with	O
the	O
cardiac	O
cycle	O
.	O
Mild	O
valvular	O
insufficiency	O
.	O
Peak	O
gradient	O
of	O
43	O
and	O
mean	O
of	O
30	O
mmHg	O
previous	O
14	O
and	O
6	O
mmHg	O
with	O
VTI	O
ratio	O
0	O
.	O
26	O
.	O
Perivalvular	O
aortic	O
abscess	O
extending	O
to	O
mitro	O
aortic	O
junction	O
.	O
Moderate	O
severe	O
mitral	O
insufficiency	O
due	O
to	O
de	O
structuring	O
of	O
the	O
valvular	O
annulus	O
in	O
relation	O
to	O
abscess	O
in	O
the	O
mitro	O
aortic	O
junction	O
.	O
Severe	O
systolic	O
dysfunction	O
due	O
to	O
extensive	O
akinesia	O
of	O
all	O
apical	O
segments	O
,	O
anterior	O
face	O
and	O
mid	O
septal	O
and	O
basal	O
segment	O
of	O
anterior	O
septum	O
.	O
No	O
pericardial	O
effusion	O
.	O
Blood	O
cultures	O
taken	O
on	O
admission	O
.	O
Multisensitive	O
Staphylococcus	O
epidermidis	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
cardiac	O
ICU	O
in	O
shock	O
with	O
high	O
suspicion	O
of	O
infective	O
endocarditis	O
due	O
to	O
febrile	O
fever	O
,	O
being	O
a	O
biological	O
prosthesis	O
holder	O
and	O
the	O
characteristics	O
of	O
the	O
lesion	O
of	O
the	O
anterior	O
descending	O
artery	O
suggesting	O
embolic	O
origin	O
.	O
Transthoracic	O
echocardiography	O
was	O
performed	O
on	O
admission	O
and	O
progressed	O
to	O
transesophageal	O
echocardiography	O
which	O
confirmed	O
the	O
diagnosis	O
of	O
late	O
prosthetic	O
infective	O
endocarditis	O
.	O
In	O
addition	O
,	O
the	O
results	O
of	O
the	O
blood	O
cultures	O
taken	O
on	O
admission	O
were	O
positive	O
for	O
multisensitive	O
Staphylococcus	O
epidermidis	O
.	O
Joint	O
assessment	O
with	O
cardiac	O
surgery	O
.	O
Given	O
the	O
situation	O
of	O
cardiogenic	O
shock	O
,	O
emergency	O
surgery	O
was	O
ruled	O
out	O
.	O
Despite	O
antibiotic	O
treatment	O
,	O
inotropes	O
at	O
increasing	O
doses	O
and	O
intra	O
aortic	O
balloon	O
counterpulsation	O
implantation	O
,	O
the	O
patient	O
was	O
unable	O
to	O
overcome	O
the	O
shock	O
situation	O
.	O
Acute	O
renal	O
failure	O
,	O
in	O
anuria	O
.	O
Haemofiltration	O
was	O
performed	O
,	O
without	O
improvement	O
.	O
He	O
developed	O
multi	O
organ	O
failure	O
and	O
finally	O
died	O
.	O
DIAGNOSIS	O
Death	O
due	O
to	O
late	O
prosthetic	O
infective	O
endocarditis	O
caused	O
by	O
Staphylococcus	O
epidermidis	O
,	O
complicated	O
by	O
Previous	O
STEMI	O
in	O
haemodynamic	O
Killip	O
Kimball	O
IVs	O
cardiogenic	O
hock	O
.	O
2	O
vessel	O
coronary	O
artery	O
disease	O
.	O
Chronic	O
right	O
middle	O
coronary	O
artery	O
occlusion	O
.	O
Embolic	O
occlusion	O
of	O
proximal	O
anterior	O
descending	O
artery	O
,	O
primary	O
angioplasty	O
with	O
drug	O
eluting	O
stent	O
implantation	O
.	O
Severely	O
impaired	O
left	O
ventricular	O
systolic	O
function	O
.	O
Shock	O
of	O
mixed	O
origin	O
,	O
cardiogenic	O
and	O
septic	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
42	O
year	O
old	O
man	O
who	O
was	O
admitted	O
to	O
cardiology	O
for	O
a	O
first	O
episode	O
of	O
heart	O
failure	O
,	O
with	O
a	O
diagnosis	O
of	O
dilated	O
cardiomyopathy	O
.	O
His	O
personal	O
history	O
includes	O
abuse	O
of	O
various	O
intoxicants	O
GHB	O
gamma	O
hydroxybutyric	O
acid	O
,	O
mephedrone	O
and	O
methamphetamines	O
on	O
a	O
regular	O
basis	O
;	O
occasional	O
cocaine	O
;	O
smoker	O
of	O
10	O
cigarettes	O
a	O
day	O
;	O
occasional	O
testosterone	O
cycles	O
.	O
He	O
is	O
HIV	O
positive	O
with	O
good	O
immunovirological	O
control	O
under	O
treatment	O
with	O
dolutegravir	B-FARMACO
rilpivirine	I-FARMACO
,	O
and	O
had	O
syphilis	O
which	O
was	O
correctly	O
treated	O
.	O
He	O
came	O
to	O
the	O
emergency	O
department	O
for	O
one	O
week	O
of	O
progressive	O
dyspnoea	O
until	O
he	O
became	O
resting	O
,	O
associated	O
with	O
orthopnoea	O
and	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
She	O
also	O
presented	O
with	O
neurological	O
symptoms	O
consisting	O
of	O
dyschromatopsia	O
and	O
retroocular	O
headache	O
.	O
She	O
had	O
not	O
suffered	O
from	O
chest	O
pain	O
,	O
palpitations	O
or	O
other	O
cardiovascular	O
symptoms	O
.	O
Physical	O
examination	O
revealed	O
the	O
presence	O
of	O
jugular	O
venous	O
engorgement	O
,	O
with	O
a	O
gallop	O
rhythm	O
in	O
the	O
third	O
tone	O
and	O
crackles	O
up	O
to	O
midfield	O
on	O
pulmonary	O
auscultation	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
tachycardia	O
at	O
125	O
beats	O
per	O
minute	O
.	O
Narrow	O
QRS	O
,	O
axis	O
deviated	O
to	O
the	O
left	O
.	O
Poor	O
R	O
growth	O
in	O
precordial	O
leads	O
.	O
Flattened	O
T	O
waves	O
with	O
normal	O
QTc	O
interval	O
.	O
Chest	O
X	O
ray	O
increased	O
cardiothoracic	O
index	O
.	O
Signs	O
of	O
pulmonary	O
congestion	O
.	O
Transthoracic	O
echocardiogram	O
on	O
admission	O
very	O
dilated	O
left	O
ventricle	O
,	O
with	O
severe	O
systolic	O
dysfunction	O
.	O
LVEF	O
12	O
.	O
Mobile	O
images	O
in	O
apex	O
,	O
at	O
least	O
3	O
,	O
maximum	O
1	O
.	O
8	O
x	O
1	O
.	O
0	O
cm	O
,	O
hypermobile	O
,	O
compatible	O
with	O
thrombi	O
.	O
Dilated	O
right	O
ventricle	O
,	O
with	O
severe	O
systolic	O
dysfunction	O
.	O
Signs	O
of	O
elevated	O
filling	O
pressures	O
.	O
Moderate	O
mitral	O
insufficiency	O
.	O
Moderate	O
pulmonary	O
hypertension	O
.	O
Laboratory	O
tests	O
on	O
admission	O
NT	O
proBNP	O
15678	O
ng	O
dl	O
.	O
Undetectable	O
HIV	O
load	O
.	O
Cranial	O
computerised	O
axial	O
tomography	O
CAT	O
appearance	O
of	O
cortico	O
subcortical	O
hypodensity	O
in	O
the	O
right	O
PCA	O
territory	O
,	O
probably	O
related	O
to	O
an	O
ischaemic	O
event	O
of	O
uncertain	O
evolution	O
.	O
Cranial	O
magnetic	O
resonance	O
imaging	O
MRI	O
cortical	O
lesions	O
with	O
contrast	O
uptake	O
and	O
mild	O
diffusion	O
restriction	O
suggesting	O
subacute	O
phase	O
infarcts	O
,	O
the	O
largest	O
right	O
basal	O
occipital	O
with	O
haemorrhagic	O
transformation	O
.	O
There	O
are	O
also	O
three	O
millimetric	O
cortical	O
lesions	O
with	O
intense	O
restriction	O
right	O
frontal	O
,	O
left	O
frontal	O
and	O
right	O
parietal	O
that	O
also	O
suggest	O
infarcts	O
but	O
with	O
a	O
shorter	O
evolution	O
time	O
.	O
Cardiac	O
MRI	O
severely	O
depressed	O
biventricular	O
systolic	O
function	O
LVEF	O
12	O
,	O
RVEF	O
14	O
.	O
Mild	O
moderate	O
mitral	O
insufficiency	O
.	O
Severe	O
left	O
atrial	O
dilatation	O
.	O
No	O
intracavitary	O
thrombi	O
.	O
Pathological	O
late	O
enhancement	O
in	O
the	O
insertion	O
region	O
of	O
the	O
right	O
ventricular	O
free	O
wall	O
and	O
linear	O
intramyocardial	O
uptake	O
in	O
the	O
basal	O
septum	O
of	O
non	O
ischaemic	O
aetiology	O
.	O
Diagnostic	O
coronary	O
angiography	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O
Genetic	O
study	O
negative	O
.	O
CLINICAL	O
EVOLUTION	O
From	O
the	O
point	O
of	O
view	O
of	O
heart	O
failure	O
,	O
the	O
patient	O
evolved	O
favourably	O
with	O
diuretic	O
treatment	O
until	O
complete	O
resolution	O
of	O
the	O
congestive	O
symptoms	O
.	O
Disease	O
modifying	O
treatment	O
was	O
started	O
with	O
sacubritril	O
valsartan	O
,	O
low	O
dose	O
bisoprolol	B-FARMACO
due	O
to	O
suboptimal	O
tolerance	O
,	O
spironolactone	B-FARMACO
and	O
ivabradine	B-FARMACO
.	O
On	O
monitoring	O
,	O
episodes	O
of	O
paroxysmal	O
atrial	O
fibrillation	O
were	O
detected	O
,	O
as	O
well	O
as	O
episodes	O
of	O
non	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
.	O
Therefore	O
,	O
in	O
view	O
of	O
the	O
negative	O
ventricular	O
remodelling	O
and	O
the	O
presence	O
of	O
late	O
enhancement	O
on	O
MRI	O
,	O
it	O
was	O
decided	O
to	O
implant	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
for	O
primary	O
prevention	O
.	O
As	O
a	O
study	O
of	O
ventricular	O
dysfunction	O
,	O
ischaemic	O
aetiology	O
was	O
ruled	O
out	O
by	O
coronary	O
angiography	O
and	O
familial	O
aetiology	O
by	O
genetic	O
study	O
;	O
the	O
possibilities	O
were	O
toxic	O
or	O
HIV	O
associated	O
cardiomyopathy	O
.	O
Regarding	O
antithrombotic	O
treatment	O
,	O
anticoagulant	O
treatment	O
was	O
started	O
on	O
admission	O
with	O
low	O
molecular	O
weight	O
heparins	O
due	O
to	O
the	O
presence	O
of	O
intracavitary	O
thrombi	O
and	O
paroxysmal	O
atrial	O
fibrillation	O
.	O
It	O
was	O
discontinued	O
during	O
admission	O
after	O
brain	O
MRI	O
showed	O
haemorrhagic	O
transformation	O
of	O
the	O
cerebral	O
infarction	O
.	O
At	O
discharge	O
,	O
in	O
the	O
absence	O
of	O
new	O
bleedings	O
and	O
once	O
the	O
absence	O
of	O
interactions	O
with	O
antiretroviral	O
treatment	O
had	O
been	O
verified	O
,	O
oral	O
anticoagulation	O
with	O
rivaroxaban	B-FARMACO
was	O
started	O
.	O
DIAGNOSIS	O
First	O
episode	O
of	O
heart	O
failure	O
.	O
Severe	O
biventricular	O
dysfunction	O
.	O
Coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O
Non	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
.	O
Intracavitary	O
thrombus	O
left	O
ventricle	O
,	O
not	O
seen	O
in	O
cardiac	O
MRI	O
after	O
initiation	O
of	O
anticoagulation	O
.	O
Subacute	O
ischaemic	O
stroke	O
in	O
the	O
right	O
PCA	O
territory	O
of	O
probable	O
cardioembolic	O
aetiology	O
,	O
with	O
subsequent	O
haemorrhagic	O
transformation	O
.	O
HIV	O
infection	O
under	O
treatment	O
with	O
good	O
control	O
.	O
Intake	O
of	O
toxic	O
substances	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
We	O
present	O
a	O
78	O
year	O
old	O
male	O
patient	O
,	O
non	O
smoker	O
,	O
with	O
no	O
known	O
cardiovascular	O
risk	O
factors	O
CVRF	O
or	O
other	O
toxic	O
habits	O
.	O
In	O
2013	O
he	O
presented	O
an	O
episode	O
of	O
paroxysmal	O
atrial	O
fibrillation	O
,	O
with	O
no	O
alterations	O
in	O
the	O
echocardiogram	O
or	O
ergometry	O
,	O
for	O
which	O
he	O
was	O
discharged	O
.	O
The	O
patient	O
was	O
not	O
anticoagulated	O
as	O
he	O
had	O
a	O
CHA2DS2	O
Vasc	O
of	O
1	O
point	O
at	O
that	O
time	O
.	O
Since	O
then	O
,	O
the	O
patient	O
's	O
only	O
treatment	O
was	O
occasional	O
lorazepam	B-FARMACO
.	O
Oncological	O
history	O
In	O
October	O
2016	O
,	O
the	O
patient	O
started	O
with	O
intermittent	O
dysphonia	O
.	O
Computed	O
tomography	O
CT	O
scan	O
showed	O
a	O
lung	O
mass	O
in	O
the	O
right	O
hemithorax	O
measuring	O
approximately	O
33	O
mm	O
and	O
multiple	O
homolateral	O
hilar	O
and	O
mediastinal	O
hilar	O
adenopathies	O
.	O
A	O
right	O
pleural	O
effusion	O
with	O
multiple	O
pseudonodular	O
images	O
and	O
segmental	O
atelectasis	O
in	O
the	O
middle	O
lobe	O
were	O
also	O
seen	O
.	O
Due	O
to	O
these	O
findings	O
,	O
the	O
patient	O
was	O
referred	O
to	O
the	O
pulmonologist	O
,	O
who	O
performed	O
bronchoscopy	O
with	O
aspiration	O
and	O
positron	O
emission	O
tomography	O
PET	O
,	O
which	O
confirmed	O
a	O
hypermetabolic	O
mass	O
in	O
the	O
right	O
upper	O
lobe	O
compatible	O
with	O
a	O
primary	O
pulmonary	O
neoplasm	O
.	O
The	O
patient	O
also	O
presented	O
hypermetabolic	O
adenopathies	O
at	O
different	O
levels	O
,	O
including	O
a	O
right	O
supraclavicuar	O
adenopathy	O
,	O
a	O
right	O
pleural	O
effusion	O
and	O
hypermetabolic	O
lesions	O
in	O
the	O
sixth	O
costal	O
arch	O
.	O
Anatomo	O
pathological	O
study	O
revealed	O
adenocarcinoma	O
ADC	O
of	O
the	O
lung	O
,	O
and	O
genetic	O
analysis	O
identified	O
ALK	O
translocation	O
,	O
which	O
has	O
been	O
found	O
to	O
be	O
strongly	O
associated	O
with	O
the	O
genesis	O
of	O
this	O
type	O
of	O
tumour	O
.	O
Finally	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
stage	O
IV	O
lung	O
adenocarcinoma	O
T2aN2M1	O
with	O
ALK	O
translocation	O
,	O
and	O
first	O
line	O
palliative	O
treatment	O
with	O
crizotinib	B-FARMACO
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
was	O
initiated	O
.	O
After	O
two	O
cycles	O
of	O
chemotherapy	O
,	O
a	O
control	O
CT	O
scan	O
showed	O
a	O
partial	O
response	O
with	O
reduction	O
of	O
the	O
lung	O
mass	O
20	O
mm	O
,	O
reduction	O
of	O
the	O
size	O
of	O
the	O
paratracheal	O
adenopathies	O
and	O
disappearance	O
of	O
the	O
pleural	O
effusion	O
.	O
From	O
January	O
2017	O
to	O
June	O
2017	O
,	O
he	O
received	O
a	O
total	O
of	O
6	O
cycles	O
of	O
crizotinib	B-FARMACO
500	O
mg	O
24	O
hours	O
and	O
the	O
patient	O
achieved	O
stable	O
disease	O
.	O
During	O
this	O
period	O
,	O
the	O
patient	O
had	O
no	O
relevant	O
adverse	O
events	O
.	O
Since	O
then	O
,	O
the	O
patient	O
was	O
clinically	O
monitored	O
every	O
month	O
and	O
a	O
follow	O
up	O
CT	O
scan	O
was	O
performed	O
every	O
six	O
months	O
.	O
He	O
had	O
no	O
adverse	O
effects	O
related	O
to	O
the	O
oncological	O
treatment	O
and	O
the	O
disease	O
remained	O
stable	O
according	O
to	O
RECIST	O
criteria	O
.	O
Current	O
disease	O
In	O
November	O
2019	O
,	O
during	O
a	O
follow	O
up	O
oncology	O
consultation	O
,	O
the	O
patient	O
reported	O
slow	O
but	O
progressive	O
onset	O
of	O
oedema	O
in	O
the	O
lower	O
extremities	O
and	O
weight	O
gain	O
of	O
up	O
to	O
5	O
kg	O
in	O
the	O
last	O
few	O
months	O
.	O
He	O
also	O
reported	O
noticing	O
an	O
even	O
slower	O
heart	O
rate	O
than	O
usual	O
,	O
around	O
30	O
40	O
beats	O
per	O
minute	O
without	O
dizziness	O
or	O
syncope	O
,	O
and	O
mild	O
dyspnoea	O
without	O
clear	O
orthopnoea	O
.	O
A	O
follow	O
up	O
CT	O
scan	O
showed	O
that	O
the	O
lung	O
mass	O
remained	O
stable	O
,	O
but	O
a	O
mild	O
pleural	O
effusion	O
,	O
a	O
laminar	O
pericardial	O
effusion	O
and	O
a	O
periportal	O
hypodensity	O
compatible	O
with	O
oedema	O
were	O
observed	O
.	O
It	O
was	O
decided	O
to	O
temporarily	O
suspend	O
crizotinib	B-FARMACO
,	O
treatment	O
with	O
a	O
loop	O
diuretic	O
was	O
started	O
and	O
the	O
patient	O
was	O
referred	O
to	O
the	O
cardio	O
oncology	O
department	O
to	O
rule	O
out	O
congestive	O
heart	O
failure	O
.	O
Physical	O
examination	O
At	O
the	O
first	O
visit	O
to	O
the	O
cardio	O
oncology	O
department	O
,	O
the	O
patient	O
was	O
hypertensive	O
187	O
91	O
mmHg	O
and	O
oxygen	O
saturation	O
was	O
normal	O
.	O
Physical	O
examination	O
revealed	O
no	O
jugular	O
plethora	O
but	O
he	O
had	O
hepatojugular	O
reflex	O
and	O
oedema	O
with	O
pitting	O
in	O
both	O
lower	O
extremities	O
.	O
Cardiac	O
auscultation	O
was	O
rhythmic	O
at	O
about	O
40	O
beats	O
per	O
minute	O
,	O
with	O
no	O
murmurs	O
.	O
COMPLEMENTARY	O
TESTS	O
The	O
electrocardiogram	O
showed	O
sinus	O
rhythm	O
at	O
43	O
beats	O
per	O
minute	O
,	O
with	O
first	O
degree	O
atrioventricular	O
block	O
and	O
normal	O
QT	O
QTc	O
422	O
ms	O
.	O
No	O
significant	O
alterations	O
were	O
evident	O
in	O
the	O
blood	O
tests	O
glucose	O
82	O
mg	O
dl	O
,	O
urea	O
38	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
15	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
CKD	O
EPI	O
60	O
ml	O
min	O
1	O
.	O
73	O
m	O
,	O
sodium	O
145	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
6	O
mEq	O
l	O
,	O
magnesium	O
2	O
.	O
2	O
mg	O
dl	O
,	O
albumin	O
3	O
.	O
8	O
g	O
dl	O
,	O
cholesterol	O
177	O
mg	O
dl	O
,	O
haemoglobin	O
14	O
g	O
dl	O
,	O
leucocytes	O
4	O
.	O
41	O
x	O
103	O
ml	O
,	O
platelets	O
149	O
x	O
103	O
ml	O
.	O
NT	O
proBNP	O
was	O
determined	O
once	O
diuretic	O
treatment	O
had	O
been	O
started	O
and	O
the	O
patient	O
's	O
clinical	O
situation	O
had	O
improved	O
,	O
and	O
the	O
value	O
was	O
115	O
pg	O
ml	O
normal	O
range	O
0	O
to	O
300	O
pg	O
ml	O
.	O
An	O
echocardiogram	O
was	O
also	O
performed	O
and	O
showed	O
mild	O
to	O
moderate	O
septal	O
hypertrophy	O
with	O
preserved	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
estimated	O
LVEF	O
58	O
.	O
The	O
aortic	O
root	O
was	O
mildly	O
dilated	O
42	O
mm	O
ascending	O
aorta	O
with	O
mild	O
aortic	O
and	O
mitral	O
valve	O
regurgitation	O
.	O
The	O
left	O
atrium	O
was	O
mildly	O
dilated	O
.	O
The	O
right	O
ventricle	O
was	O
normal	O
in	O
size	O
and	O
function	O
.	O
There	O
was	O
mild	O
tricuspid	O
regurgitation	O
without	O
significant	O
pulmonary	O
hypertension	O
,	O
and	O
mild	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
the	O
first	O
visit	O
,	O
the	O
patient	O
's	O
condition	O
was	O
suspected	O
to	O
be	O
heart	O
failure	O
secondary	O
to	O
bradycardia	O
.	O
Bradycardia	O
is	O
a	O
common	O
cardiovascular	O
adverse	O
effect	O
of	O
crizotinib	B-FARMACO
,	O
which	O
can	O
also	O
cause	O
heart	O
failure	O
.	O
According	O
to	O
the	O
Framingham	O
criteria	O
for	O
heart	O
failure	O
,	O
the	O
patient	O
met	O
two	O
major	O
and	O
three	O
minor	O
criteria	O
.	O
The	O
diagnosis	O
was	O
further	O
supported	O
by	O
echocardiographic	O
findings	O
of	O
mild	O
to	O
moderate	O
septal	O
hypertrophy	O
with	O
preserved	O
LVEF	O
and	O
mild	O
pericardial	O
effusion	O
.	O
Differential	O
diagnosis	O
was	O
made	O
with	O
other	O
entities	O
that	O
could	O
cause	O
systemic	O
congestion	O
Systemic	O
congestion	O
can	O
be	O
caused	O
by	O
both	O
renal	O
disturbances	O
and	O
nephrotic	O
syndrome	O
.	O
The	O
association	O
between	O
lung	O
cancer	O
and	O
paraneoplastic	O
syndromes	O
is	O
frequent	O
,	O
including	O
nephrotic	O
syndrome	O
.	O
As	O
we	O
can	O
see	O
from	O
the	O
laboratory	O
results	O
,	O
the	O
patient	O
's	O
renal	O
function	O
was	O
normal	O
and	O
albumin	O
and	O
cholesterol	O
were	O
within	O
normal	O
ranges	O
.	O
Liver	O
failure	O
can	O
also	O
be	O
a	O
cause	O
of	O
oedema	O
,	O
but	O
the	O
patient	O
had	O
no	O
history	O
of	O
ethylism	O
,	O
and	O
both	O
bilirubin	O
and	O
liver	O
enzymes	O
were	O
normal	O
.	O
It	O
should	O
also	O
be	O
noted	O
that	O
venous	O
compression	O
due	O
to	O
tumour	O
progression	O
could	O
cause	O
oedema	O
in	O
the	O
lower	O
extremities	O
.	O
However	O
,	O
no	O
abdomino	O
pelvic	O
or	O
inguinal	O
adenopathies	O
were	O
seen	O
on	O
the	O
follow	O
up	O
CT	O
scan	O
in	O
October	O
2019	O
.	O
Some	O
medications	O
that	O
are	O
part	O
of	O
the	O
different	O
oncological	O
treatments	O
can	O
cause	O
systemic	O
congestion	O
e	O
.	O
g	O
.	O
corticosteroids	O
,	O
analgesics	O
such	O
as	O
ibruprofen	B-FARMACO
,	O
naproxen	B-FARMACO
.	O
.	O
.	O
.	O
Our	O
patient	O
,	O
however	O
,	O
was	O
not	O
receiving	O
treatment	O
with	O
any	O
of	O
them	O
.	O
By	O
the	O
time	O
the	O
patient	O
was	O
referred	O
to	O
the	O
cardio	O
oncology	O
department	O
,	O
crizonitib	B-FARMACO
had	O
already	O
been	O
discontinued	O
and	O
the	O
loop	O
diuretic	O
was	O
started	O
.	O
Since	O
then	O
,	O
the	O
patient	O
progressed	O
favourably	O
,	O
losing	O
up	O
to	O
2	O
3	O
kilograms	O
.	O
In	O
addition	O
,	O
enalapril	B-FARMACO
5	O
mg	O
24	O
hours	O
daily	O
was	O
started	O
due	O
to	O
the	O
hypertension	O
observed	O
in	O
the	O
consultation	O
.	O
The	O
patient	O
was	O
finally	O
diagnosed	O
with	O
symptomatic	O
bradycardia	O
secondary	O
to	O
crizotinib	B-FARMACO
and	O
congestive	O
heart	O
failure	O
with	O
preserved	O
LVEF	O
.	O
After	O
one	O
week	O
of	O
treatment	O
the	O
patient	O
lost	O
5	O
kg	O
and	O
had	O
no	O
congestive	O
signs	O
.	O
He	O
also	O
reported	O
an	O
increased	O
heart	O
rate	O
.	O
Holter	O
blood	O
pressure	O
monitoring	O
showed	O
that	O
the	O
patient	O
had	O
grade	O
1	O
hypertension	O
,	O
and	O
treatment	O
was	O
adjusted	O
.	O
The	O
loop	O
diuretic	O
could	O
be	O
withdrawn	O
because	O
the	O
patient	O
evolved	O
favourably	O
,	O
the	O
congestive	O
signs	O
resolved	O
,	O
no	O
serious	O
heart	O
disease	O
was	O
observed	O
in	O
the	O
tests	O
performed	O
,	O
and	O
his	O
heart	O
rate	O
was	O
around	O
60	O
beats	O
per	O
minute	O
.	O
After	O
a	O
multidisciplinary	O
consultation	O
,	O
and	O
considering	O
the	O
spectacular	O
response	O
he	O
had	O
previously	O
shown	O
,	O
it	O
was	O
decided	O
to	O
restart	O
crizotinib	B-FARMACO
with	O
close	O
monitoring	O
.	O
DIAGNOSIS	O
Heart	O
failure	O
with	O
preserved	O
LVEF	O
secondary	O
to	O
sinus	O
bradycardia	O
.	O
Sinus	O
bradycardia	O
secondary	O
to	O
crizotinib	B-FARMACO
.	O
Stage	O
IV	O
lung	O
adenocarcinoma	O
with	O
ALK	O
translocation	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Social	O
and	O
family	O
history	O
22	O
year	O
old	O
male	O
patient	O
,	O
medical	O
student	O
.	O
Thin	O
.	O
Smoker	O
of	O
1	O
cigarette	O
a	O
day	O
for	O
3	O
years	O
.	O
Occasional	O
cannabis	O
user	O
.	O
Maternal	O
grandfather	O
with	O
heart	O
attack	O
at	O
the	O
age	O
of	O
60	O
.	O
Mother	O
diagnosed	O
with	O
familial	O
hypercholesterolemia	O
with	O
positive	O
genetic	O
study	O
.	O
Personal	O
history	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
no	O
known	O
arterial	O
hypertension	O
AHT	O
,	O
diabetes	O
mellitus	O
DM	O
or	O
dyslipidaemia	O
DL	O
.	O
No	O
cardiological	O
history	O
of	O
interest	O
.	O
Other	O
history	O
Irritable	O
colon	O
.	O
Migraine	O
.	O
Usual	O
medication	O
Does	O
not	O
take	O
any	O
medication	O
.	O
Present	O
illness	O
The	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
due	O
to	O
oppressive	O
chest	O
pain	O
of	O
great	O
intensity	O
,	O
which	O
started	O
at	O
rest	O
,	O
radiating	O
to	O
the	O
left	O
arm	O
,	O
unchanged	O
with	O
inspiratory	O
movements	O
,	O
accompanying	O
vegetative	O
symptoms	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
the	O
patient	O
had	O
been	O
in	O
pain	O
for	O
more	O
than	O
an	O
hour	O
,	O
with	O
no	O
improvement	O
since	O
onset	O
.	O
He	O
reported	O
symptoms	O
of	O
precordial	O
oppression	O
with	O
exercise	O
since	O
3	O
months	O
earlier	O
.	O
No	O
symptoms	O
suggestive	O
of	O
catecholaminergic	O
release	O
.	O
Physical	O
examination	O
On	O
arrival	O
at	O
the	O
ED	O
he	O
was	O
afebrile	O
,	O
normoperfused	O
,	O
with	O
chest	O
pain	O
.	O
SatO2	O
96	O
on	O
room	O
air	O
,	O
blood	O
pressure	O
123	O
84	O
mm	O
Hg	O
,	O
heart	O
rate	O
92	O
l	O
min	O
.	O
Neck	O
symmetrical	O
,	O
no	O
jugular	O
ingurgitation	O
or	O
hepatojugular	O
reflux	O
.	O
No	O
murmurs	O
on	O
carotid	O
auscultation	O
.	O
Cardiac	O
auscultation	O
regular	O
heart	O
sounds	O
without	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
vesicular	O
murmur	O
present	O
,	O
well	O
ventilated	O
fields	O
,	O
no	O
extra	O
sounds	O
.	O
Abdominal	O
examination	O
nondescript	O
.	O
Lower	O
limbs	O
symmetrical	O
,	O
no	O
signs	O
of	O
DVT	O
or	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
count	O
haemoglobin	O
17	O
.	O
2	O
g	O
dl	O
,	O
haematocrit	O
49	O
.	O
5	O
,	O
red	O
blood	O
cells	O
5	O
.	O
66x10	O
,	O
leukocytes	O
21	O
,	O
800	O
,	O
neutrophils	O
11	O
,	O
570	O
,	O
lymphocytes	O
8	O
,	O
270	O
,	O
eosinophils	O
520	O
,	O
platelets	O
429	O
,	O
000	O
.	O
Biochemistry	O
glucose	O
124	O
mg	O
dl	O
,	O
urea	O
37	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
19	O
mg	O
dl	O
,	O
glomerular	O
filtrate	O
90	O
ml	O
min	O
1	O
.	O
78	O
m	O
,	O
sodium	O
ion	O
142	O
mmol	O
l	O
,	O
potassium	O
ion	O
3	O
.	O
2	O
mmol	O
l	O
,	O
troponin	O
T	O
7	O
ng	O
l	O
,	O
creatine	O
kinase	O
225	O
U	O
l	O
,	O
urate	O
6	O
.	O
8	O
mg	O
dl	O
,	O
alkaline	O
phosphatase	O
121	O
U	O
l	O
,	O
AST	O
37	O
U	O
l	O
,	O
ALT	O
59	O
U	O
l	O
,	O
GGT	O
45	O
U	O
l	O
,	O
total	O
bilirubin	O
1	O
.	O
0	O
mg	O
dl	O
,	O
total	O
cholesterol	O
98	O
md	O
dl	O
,	O
HDL	O
41	O
mg	O
dl	O
,	O
triglycerides	O
43	O
mg	O
dl	O
,	O
calculated	O
LDL	O
cholesterol	O
49	O
mg	O
dl	O
,	O
HbA1C	O
5	O
.	O
6	O
,	O
TSH	O
2	O
.	O
33	O
mU	O
l	O
.	O
Coagulation	O
normal	O
in	O
all	O
parameters	O
.	O
Urine	O
toxicity	O
benzodiazepines	O
,	O
opiates	O
,	O
cocaine	O
,	O
cannabinoids	O
and	O
methamphetamines	O
negative	O
.	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
80	O
L	O
min	O
,	O
normal	O
PR	O
interval	O
,	O
narrow	O
QRS	O
,	O
normal	O
axis	O
at	O
40	O
,	O
ST	O
segment	O
elevation	O
up	O
to	O
3	O
mm	O
on	O
the	O
anterolateral	O
side	O
with	O
mirror	O
image	O
on	O
the	O
inferior	O
side	O
.	O
Coronary	O
angiography	O
CD	O
artery	O
without	O
angiographic	O
lesions	O
.	O
Cx	O
artery	O
without	O
angiographic	O
lesions	O
.	O
DA	O
artery	O
with	O
thrombotic	O
occlusion	O
in	O
its	O
middle	O
third	O
,	O
immediately	O
distal	O
to	O
the	O
exit	O
of	O
the	O
first	O
diagonal	O
.	O
Angioplasty	O
with	O
XB	O
3	O
.	O
5	O
Sion	O
is	O
advanced	O
to	O
distal	O
DA	O
recovering	O
flow	O
.	O
Due	O
to	O
abundant	O
thrombotic	O
content	O
,	O
tirofiban	B-FARMACO
is	O
administered	O
i	O
.	O
v	O
.	O
bolus	O
perfusion	O
.	O
Direct	O
implantation	O
of	O
a	O
Synergy	O
4	O
x	O
20	O
mm	O
drug	O
eluting	O
stent	O
was	O
performed	O
in	O
the	O
mid	O
proximal	O
segment	O
.	O
Due	O
to	O
an	O
image	O
of	O
under	O
expansion	O
at	O
mid	O
stent	O
level	O
,	O
post	O
dilatation	O
with	O
a	O
4	O
.	O
5	O
mm	O
NC	O
balloon	O
was	O
performed	O
,	O
achieving	O
adequate	O
expansion	O
.	O
A	O
thrombus	O
floating	O
distal	O
to	O
the	O
stent	O
was	O
found	O
floating	O
intra	O
arterially	O
,	O
so	O
it	O
was	O
decided	O
to	O
perform	O
thromboaspiration	O
with	O
a	O
Pronto	O
device	O
,	O
extracting	O
a	O
large	O
red	O
thrombus	O
.	O
Excellent	O
angiographic	O
result	O
after	O
thromboaspiration	O
and	O
final	O
TIMI	O
3	O
flow	O
.	O
Echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
LV	O
with	O
extensive	O
anterior	O
,	O
anteroseptal	O
and	O
lateral	O
akinesia	O
middle	O
segments	O
and	O
apical	O
cap	O
with	O
normal	O
contractility	O
of	O
the	O
inferior	O
territory	O
,	O
infero	O
lateral	O
and	O
basal	O
inferior	O
septum	O
.	O
Extended	O
CBC	O
Serial	O
myocardial	O
damage	O
markers	O
on	O
admission	O
,	O
at	O
3	O
hours	O
,	O
12	O
hours	O
and	O
36	O
hours	O
,	O
respectively	O
Ultrasensitive	O
troponin	O
T	O
ng	O
l	O
7	O
7	O
.	O
611	O
9	O
.	O
234	O
3	O
.	O
215	O
Creatinine	O
kinase	O
U	O
l	O
225	O
3	O
.	O
764	O
3	O
.	O
546	O
912	O
Genetic	O
study	O
for	O
familial	O
hypercholesterolemia	O
negative	O
.	O
Liporpotein	O
A	O
90	O
.	O
7	O
mg	O
dl	O
normal	O
30	O
mg	O
dl	O
.	O
Chromatography	O
and	O
electrophoresis	O
acid	O
diuresis	O
1	O
.	O
850	O
.	O
Collection	O
time	O
chromatography	O
metanephrine	O
24	O
hours	O
198	O
,	O
7	O
μg	O
24	O
hours	O
.	O
Normetanephrine	O
24	O
hours	O
377	O
.	O
4	O
μg	O
24	O
hours	O
.	O
Toxicology	O
metanephrine	O
30	O
.	O
Normetanephrine	O
122	O
Serology	O
antiphospholipid	O
syndrome	O
anti	O
cardiolipin	O
IgG	O
and	O
IgM	O
negative	O
1	O
.	O
6	O
GPL	O
U	O
ml	O
and	O
0	O
.	O
8	O
MPL	O
U	O
ml	O
,	O
respectively	O
,	O
anti	O
beta2	O
glycoprotein	O
IgM	O
and	O
IgG	O
negative	O
1	O
.	O
4	O
U	O
ml	O
and	O
1	O
.	O
5	O
U	O
ml	O
,	O
respectively	O
.	O
Endocrinology	O
consultation	O
metanephrine	O
and	O
metanephrine	O
levels	O
in	O
urine	O
were	O
normal	O
and	O
plasma	O
levels	O
were	O
only	O
slightly	O
elevated	O
in	O
normetanephrine	O
,	O
which	O
,	O
together	O
with	O
the	O
absence	O
of	O
compatible	O
clinical	O
manifestations	O
,	O
makes	O
the	O
presence	O
of	O
pheochromocytoma	O
or	O
parnaganglioma	O
highly	O
improbable	O
.	O
CLINICAL	O
EVOLUTION	O
We	O
present	O
the	O
case	O
of	O
a	O
very	O
young	O
23	O
year	O
old	O
patient	O
admitted	O
to	O
cardiology	O
for	O
an	O
acute	O
coronary	O
syndrome	O
with	O
ST	O
segment	O
elevation	O
STEACS	O
in	O
extensive	O
anterior	O
face	O
,	O
for	O
which	O
the	O
heart	O
code	O
is	O
activated	O
.	O
An	O
emergent	O
coronary	O
angiography	O
showed	O
coronary	O
artery	O
disease	O
in	O
one	O
vessel	O
,	O
with	O
thrombotic	O
occlusion	O
of	O
the	O
middle	O
LAD	O
coronary	O
artery	O
,	O
and	O
angioplasty	O
was	O
performed	O
with	O
implantation	O
of	O
a	O
drug	O
eluting	O
stent	O
,	O
perfusion	O
of	O
tirofiban	B-FARMACO
and	O
aspiration	O
of	O
the	O
remains	O
of	O
the	O
thrombotic	O
material	O
.	O
During	O
his	O
stay	O
on	O
the	O
hospital	O
ward	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
,	O
and	O
the	O
causal	O
study	O
of	O
this	O
acute	O
coronary	O
syndrome	O
was	O
carried	O
out	O
.	O
It	O
is	O
noteworthy	O
that	O
the	O
patient	O
's	O
cardiovascular	O
risk	O
factors	O
were	O
that	O
he	O
was	O
a	O
smoker	O
with	O
a	O
cumulative	O
consumption	O
of	O
less	O
than	O
1	O
packet	O
year	O
,	O
with	O
no	O
other	O
known	O
metabolic	O
disorders	O
.	O
There	O
is	O
a	O
maternal	O
history	O
of	O
ischaemic	O
heart	O
disease	O
and	O
his	O
mother	O
is	O
diagnosed	O
with	O
familial	O
hypercholesterolaemia	O
.	O
The	O
patient	O
underwent	O
a	O
lipid	O
profile	O
analysis	O
which	O
did	O
not	O
show	O
any	O
markedly	O
elevated	O
total	O
cholesterol	O
or	O
LDL	O
values	O
,	O
but	O
rather	O
a	O
low	O
CV	O
risk	O
profile	O
.	O
Urine	O
toxins	O
were	O
requested	O
and	O
were	O
negative	O
,	O
and	O
a	O
study	O
of	O
coagulopathies	O
was	O
carried	O
out	O
,	O
also	O
negative	O
.	O
Serum	O
and	O
urine	O
metanephrines	O
were	O
requested	O
and	O
the	O
patient	O
was	O
referred	O
to	O
endocrinology	O
,	O
who	O
considered	O
that	O
there	O
was	O
a	O
low	O
probability	O
of	O
pheochromocytoma	O
.	O
Finally	O
,	O
it	O
was	O
decided	O
to	O
expand	O
the	O
lipid	O
profile	O
with	O
a	O
lipoprotein	O
A	O
Lp	O
a	O
,	O
which	O
was	O
found	O
to	O
be	O
elevated	O
for	O
cardiovascular	O
risk	O
with	O
a	O
value	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O
The	O
patient	O
evolved	O
satisfactorily	O
,	O
with	O
no	O
clinical	O
signs	O
of	O
heart	O
failure	O
,	O
although	O
on	O
discharge	O
he	O
presented	O
moderate	O
LV	O
dysfunction	O
,	O
due	O
to	O
extensive	O
anterior	O
,	O
anteroseptal	O
and	O
lateral	O
akinesia	O
middle	O
segments	O
and	O
apical	O
cap	O
.	O
DIAGNOSIS	O
Extensive	O
anterior	O
STEACS	O
.	O
Haemodynamic	O
status	O
KK1	O
.	O
Single	O
vessel	O
coronary	O
artery	O
disease	O
SCAD	O
.	O
Percutaneous	O
total	O
revascularisation	O
using	O
a	O
drug	O
eluting	O
stent	O
.	O
Moderate	O
LV	O
dysfunction	O
LVEF	O
44	O
.	O
Hyperlipoproteinaemia	O
A	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
47	O
year	O
old	O
woman	O
with	O
cardiovascular	O
risk	O
factors	O
hypertension	O
,	O
smoking	O
and	O
dyslipidaemia	O
.	O
History	O
of	O
chronic	O
stable	O
angina	O
in	O
functional	O
class	O
II	O
without	O
previous	O
treatment	O
.	O
She	O
consulted	O
a	O
centre	O
in	O
the	O
city	O
of	O
Buenos	O
Aires	O
Argentina	O
due	O
to	O
atypical	O
and	O
characteristic	O
precordial	O
pain	O
at	O
rest	O
of	O
1	O
hour	O
's	O
duration	O
.	O
Physical	O
examination	O
on	O
admission	O
showed	O
blood	O
pressure	O
BP	O
120	O
65	O
mmHg	O
,	O
heart	O
rate	O
HR	O
130	O
bpm	O
,	O
SatO2	O
90	O
on	O
room	O
air	O
.	O
Jugular	O
ingurgitation	O
3	O
3	O
without	O
inspiratory	O
collapse	O
.	O
Rhythmic	O
heart	O
sounds	O
,	O
no	O
murmurs	O
.	O
Regular	O
ventilatory	O
mechanics	O
at	O
the	O
expense	O
of	O
tachypnoea	O
and	O
use	O
of	O
accessory	O
muscles	O
,	O
generalised	O
hypoventilation	O
and	O
regular	O
bilateral	O
air	O
entry	O
,	O
with	O
intolerance	O
to	O
decubitus	O
.	O
Good	O
peripheral	O
perfusion	O
with	O
positive	O
symmetrical	O
pulses	O
.	O
Bilateral	O
malleolar	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
tachycardia	O
at	O
130	O
bpm	O
,	O
PR	O
120	O
ms	O
,	O
QRS	O
80	O
ms	O
.	O
ST	O
segment	O
depression	O
less	O
than	O
1	O
mm	O
in	O
DII	O
,	O
DIII	O
,	O
aVF	O
and	O
from	O
V3	O
to	O
V6	O
.	O
Initial	O
Q	O
wave	O
in	O
DI	O
and	O
aVL	O
with	O
ST	O
elevation	O
of	O
1	O
mm	O
.	O
CBC	O
haematocrit	O
29	O
,	O
haemoglobin	O
9	O
.	O
5	O
g	O
dl	O
,	O
leukocytes	O
19	O
,	O
500	O
μl	O
,	O
platelets	O
212	O
,	O
000	O
μl	O
.	O
Baseline	O
coagulation	O
,	O
renal	O
function	O
and	O
ions	O
normal	O
.	O
Myocardial	O
damage	O
markers	O
Troponin	O
T	O
US	O
15	O
ng	O
l	O
and	O
24	O
ng	O
l	O
normal	O
0	O
14	O
ng	O
l	O
.	O
CK	O
CK	O
MB	O
550	O
180	O
IU	O
l	O
.	O
Cardiac	O
catheterisation	O
right	O
dominance	O
.	O
Right	O
coronary	O
artery	O
without	O
lesions	O
.	O
Patent	O
anterior	O
descending	O
and	O
circumflex	O
arteries	O
,	O
with	O
non	O
significant	O
lesions	O
in	O
the	O
middle	O
third	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
LV	O
not	O
dilated	O
,	O
mild	O
LV	O
systolic	O
dysfunction	O
.	O
Parasternal	O
short	O
axis	O
shows	O
pseudoaneurysm	O
in	O
the	O
lateral	O
aspect	O
of	O
the	O
LV	O
.	O
No	O
significant	O
valvular	O
heart	O
disease	O
.	O
Chest	O
X	O
ray	O
left	O
paracardiac	O
radiopacity	O
probably	O
compatible	O
with	O
the	O
location	O
of	O
the	O
ventricular	O
pseudoaneurysm	O
,	O
bilateral	O
pleural	O
effusion	O
.	O
Chest	O
CT	O
scan	O
saccular	O
image	O
on	O
the	O
lateral	O
aspect	O
of	O
the	O
LV	O
compatible	O
with	O
ventricular	O
pseudoaneurysm	O
.	O
CLINICAL	O
EVOLUTION	O
ECG	O
showed	O
sinus	O
tachycardia	O
at	O
130	O
bpm	O
with	O
high	O
lateral	O
subepicardial	O
lesion	O
image	O
1	O
and	O
positive	O
troponin	O
,	O
so	O
emergency	O
coronary	O
angiography	O
was	O
performed	O
,	O
showing	O
patent	O
arteries	O
with	O
non	O
significant	O
lesions	O
in	O
the	O
anterior	O
descending	O
and	O
circumflex	O
arteries	O
,	O
so	O
angioplasty	O
was	O
not	O
performed	O
and	O
medical	O
treatment	O
was	O
started	O
.	O
After	O
72	O
hours	O
,	O
the	O
patient	O
presented	O
with	O
new	O
precordial	O
pain	O
of	O
intensity	O
10	O
10	O
,	O
and	O
an	O
ECG	O
was	O
performed	O
with	O
no	O
changes	O
with	O
respect	O
to	O
the	O
previous	O
one	O
and	O
negative	O
biomarkers	O
.	O
An	O
echocardiogram	O
was	O
performed	O
which	O
revealed	O
a	O
ventricular	O
pseudoaneurysm	O
in	O
the	O
lateral	O
aspect	O
of	O
the	O
left	O
ventricle	O
,	O
for	O
which	O
urgent	O
referral	O
to	O
our	O
centre	O
for	O
cardiovascular	O
surgery	O
was	O
requested	O
.	O
Chest	O
X	O
ray	O
showed	O
left	O
cardiac	O
radiopacity	O
compatible	O
with	O
probable	O
pseudoaneurysm	O
and	O
chest	O
CT	O
scan	O
showed	O
a	O
large	O
saccular	O
formation	O
measuring	O
59	O
x	O
68	O
x	O
75	O
mm	O
depending	O
on	O
the	O
lateral	O
wall	O
of	O
the	O
LV	O
,	O
contained	O
by	O
pericardium	O
and	O
connected	O
by	O
an	O
orifice	O
to	O
the	O
myocardium	O
with	O
the	O
presence	O
of	O
thrombi	O
adhering	O
to	O
the	O
inner	O
wall	O
of	O
this	O
formation	O
,	O
associated	O
with	O
haemopericardium	O
and	O
bilateral	O
pleural	O
effusion	O
,	O
predominantly	O
on	O
the	O
right	O
.	O
Emergency	O
surgery	O
was	O
performed	O
with	O
closure	O
of	O
the	O
aneurysm	O
neck	O
,	O
placement	O
of	O
a	O
Dacron	O
patch	O
and	O
Prolene	O
reinforcement	O
at	O
the	O
edge	O
of	O
the	O
rupture	O
image	O
6	O
.	O
In	O
the	O
immediate	O
postoperative	O
period	O
,	O
the	O
patient	O
presented	O
hypovolemic	O
shock	O
and	O
subsequent	O
right	O
ventricular	O
failure	O
,	O
which	O
evolved	O
favourably	O
with	O
volume	O
expansion	O
and	O
inotropic	O
drugs	O
.	O
Prior	O
to	O
discharge	O
,	O
a	O
new	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
good	O
ventricular	O
function	O
,	O
with	O
slight	O
pericardial	O
effusion	O
.	O
DIAGNOSIS	O
Acute	O
coronary	O
syndrome	O
with	O
ST	O
segment	O
elevation	O
STEMI	O
in	O
the	O
upper	O
lateral	O
face	O
.	O
Coronary	O
arteries	O
without	O
acute	O
thrombotic	O
occlusion	O
.	O
Ventricular	O
pseudoaneurysm	O
as	O
a	O
mechanical	O
complication	O
,	O
with	O
signs	O
of	O
imminent	O
rupture	O
and	O
requiring	O
emergency	O
surgical	O
repair	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
77	O
year	O
old	O
man	O
who	O
,	O
after	O
eating	O
fresh	O
fish	O
,	O
developed	O
severe	O
anaphylaxis	O
requiring	O
the	O
administration	O
of	O
intramuscular	O
adrenaline	B-FARMACO
with	O
subsequent	O
chest	O
pain	O
and	O
ST	O
segment	O
elevation	O
,	O
accompanied	O
by	O
clinical	O
and	O
laboratory	O
data	O
of	O
low	O
cardiac	O
output	O
.	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
ex	O
smoker	O
,	O
hypertension	O
HT	O
,	O
type	O
2	O
diabetes	O
mellitus	O
DM2	O
,	O
high	O
blood	O
pressure	O
.	O
No	O
known	O
heart	O
disease	O
or	O
bronchopathy	O
.	O
Chronic	O
ischaemia	O
syndrome	O
of	O
both	O
lower	O
extremities	O
,	O
grade	O
IV	O
.	O
Transphalangeal	O
amputation	O
of	O
the	O
second	O
toe	O
of	O
the	O
left	O
lower	O
extremity	O
IBD	O
in	O
June	O
2017	O
.	O
Amputation	O
of	O
the	O
fourth	O
toe	O
of	O
the	O
right	O
lower	O
extremity	O
EID	O
in	O
October	O
2018	O
.	O
Infracondylar	O
amputation	O
of	O
EID	O
on	O
26	O
08	O
2019	O
.	O
Previous	O
surgical	O
interventions	O
cataract	O
of	O
right	O
eye	O
.	O
Usual	O
treatment	O
insulin	B-FARMACO
glargine	I-FARMACO
,	O
20	O
units	O
at	O
dinner	O
;	O
metformin	B-FARMACO
850	O
mg	O
,	O
1	O
tablet	O
every	O
12	O
hours	O
;	O
sitagliptin	B-FARMACO
50	O
mg	O
,	O
1	O
tablet	O
every	O
12	O
hours	O
,	O
repaglinide	B-FARMACO
1	O
mg	O
,	O
1	O
tablet	O
breakfast	O
,	O
lunch	O
,	O
dinner	O
;	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
,	O
1	O
tablet	O
at	O
lunch	O
;	O
enalapril	B-FARMACO
lercanidipine	O
20	O
20	O
mg	O
,	O
1	O
tablet	O
at	O
breakfast	O
;	O
atorvastatin	B-FARMACO
20	O
mg	O
,	O
1	O
tablet	O
at	O
dinner	O
;	O
allopurinol	B-FARMACO
300	O
mg	O
,	O
1	O
tablet	O
at	O
breakfast	O
;	O
etoricoxib	B-FARMACO
120	O
mg	O
,	O
1	O
tablet	O
per	O
day	O
;	O
metamizole	B-FARMACO
575	O
mg	O
;	O
paracetamol	B-FARMACO
1	O
g	O
,	O
on	O
demand	O
.	O
Baseline	O
functional	O
status	O
cognitive	O
functions	O
preserved	O
.	O
Wheelchair	O
bound	O
due	O
to	O
recent	O
infracondylar	O
amputation	O
of	O
DID	O
.	O
No	O
angina	O
or	O
dyspnoea	O
in	O
his	O
usual	O
life	O
.	O
Present	O
illness	O
A	O
77	O
year	O
old	O
man	O
,	O
who	O
after	O
having	O
dined	O
on	O
fresh	O
hake	O
and	O
clams	O
,	O
started	O
after	O
4	O
hours	O
with	O
generalised	O
erythema	O
,	O
intense	O
palmo	O
plantar	O
pruritus	O
,	O
genital	O
pruritus	O
and	O
tongue	O
oedema	O
with	O
slight	O
dysphonia	O
.	O
On	O
arrival	O
of	O
basic	O
life	O
support	O
,	O
he	O
was	O
administered	O
intravenous	O
dexchlorpheniramine	B-FARMACO
and	O
Actocortin	B-FARMACO
i	O
.	O
v	O
.	O
,	O
despite	O
which	O
,	O
on	O
arrival	O
at	O
the	O
emergency	O
department	O
of	O
his	O
hospital	O
of	O
reference	O
,	O
he	O
persisted	O
with	O
slight	O
pruritus	O
and	O
notable	O
tongue	O
oedema	O
,	O
so	O
it	O
was	O
decided	O
to	O
administer	O
adrenaline	B-FARMACO
0	O
.	O
5	O
mg	O
intramuscular	O
i	O
.	O
m	O
.	O
,	O
starting	O
instantly	O
with	O
intense	O
chest	O
pain	O
radiating	O
to	O
the	O
left	O
upper	O
limb	O
.	O
An	O
electrocardiogram	O
ECG	O
was	O
performed	O
showing	O
anteroseptal	O
ST	O
elevation	O
with	O
specular	O
decrease	O
in	O
the	O
inferior	O
face	O
,	O
which	O
did	O
not	O
improve	O
after	O
sublingual	O
nitroglycerine	B-FARMACO
,	O
with	O
accompanying	O
signs	O
of	O
low	O
cardiac	O
output	O
arterial	O
hypotension	O
,	O
acral	O
coldness	O
and	O
obnubilation	O
,	O
so	O
continuous	O
perfusion	O
of	O
dobutamine	B-FARMACO
DBT	I-FARMACO
and	O
noradrenaline	B-FARMACO
NAD	I-FARMACO
was	O
started	O
.	O
Suspicion	O
of	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
STEMI	O
anteroseptal	O
Killip	O
IV	O
,	O
the	O
infarction	O
code	O
was	O
activated	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
haemodynamics	O
ward	O
of	O
our	O
hospital	O
for	O
emergent	O
percutaneous	O
coronary	O
intervention	O
PCI	O
.	O
On	O
arrival	O
,	O
the	O
patient	O
was	O
conscious	O
and	O
oriented	O
,	O
affected	O
by	O
pain	O
,	O
under	O
continuous	O
perfusion	O
of	O
NAD	B-FARMACO
at	O
0	O
.	O
8	O
mcg	O
kg	O
min	O
and	O
DBT	B-FARMACO
at	O
5	O
mcg	O
kg	O
min	O
with	O
a	O
tendency	O
to	O
arterial	O
hypotension	O
blood	O
pressure	O
BP	O
75	O
50	O
mmHg	O
and	O
sinus	O
tachycardia	O
heart	O
rate	O
HR	O
120	O
bpm	O
.	O
The	O
ECG	O
showed	O
persistent	O
anteroseptal	O
ST	O
elevation	O
,	O
and	O
on	O
arrival	O
echocardiography	O
,	O
moderate	O
LV	O
dysfunction	O
with	O
akinesia	O
of	O
all	O
mid	O
apical	O
and	O
anterior	O
segments	O
.	O
He	O
was	O
transferred	O
directly	O
to	O
the	O
haemodynamics	O
ward	O
.	O
Time	O
of	O
onset	O
of	O
chest	O
pain	O
5	O
15	O
am	O
.	O
Time	O
of	O
arrival	O
at	O
the	O
emergency	O
room	O
5	O
30	O
am	O
.	O
Time	O
of	O
opening	O
of	O
the	O
artery	O
7	O
08	O
hours	O
.	O
TIMI	O
risk	O
scale	O
12	O
points	O
35	O
.	O
9	O
.	O
CRUSADE	O
risk	O
scale	O
59	O
points	O
,	O
19	O
.	O
5	O
high	O
haemorrhagic	O
risk	O
.	O
Physical	O
examination	O
On	O
admission	O
to	O
the	O
coronary	O
unit	O
BP	O
75	O
50	O
mmHg	O
;	O
HR	O
120	O
bpm	O
;	O
baseline	O
SatO2	O
95	O
;	O
afebrile	O
.	O
Somnolent	O
.	O
Poor	O
distal	O
perfusion	O
with	O
lividity	O
in	O
the	O
lower	O
extremities	O
and	O
acral	O
coldness	O
.	O
Head	O
and	O
neck	O
no	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
clear	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
bibasal	O
crackles	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
normal	O
hydro	O
aural	O
sounds	O
.	O
Lower	O
extremities	O
amputation	O
of	O
the	O
DID	O
,	O
no	O
oedema	O
in	O
the	O
lower	O
extremities	O
,	O
palpable	O
left	O
foot	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
in	O
the	O
emergency	O
department	O
of	O
the	O
regional	O
hospital	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
,	O
long	O
PR	O
,	O
right	O
bundle	O
branch	O
block	O
RBBB	O
,	O
ST	O
elevation	O
of	O
V1	O
V5	O
,	O
I	O
and	O
AVL	O
,	O
maximum	O
of	O
9	O
mm	O
in	O
V3	O
,	O
with	O
specular	O
decrease	O
in	O
inferior	O
face	O
.	O
ECG	O
on	O
admission	O
to	O
the	O
coronary	O
unit	O
sinus	O
tachycardia	O
at	O
115	O
bpm	O
,	O
long	O
PR	O
,	O
persistent	O
ST	O
elevation	O
in	O
precordial	O
leads	O
,	O
maximum	O
of	O
6	O
mm	O
in	O
V3	O
.	O
Chest	O
X	O
ray	O
cardiac	O
silhouette	O
not	O
enlarged	O
,	O
vascular	O
redistribution	O
,	O
free	O
costophrenic	O
sinuses	O
,	O
no	O
apparent	O
condensation	O
.	O
Laboratory	O
tests	O
on	O
admission	O
to	O
the	O
coronary	O
unit	O
Arterial	O
blood	O
gas	O
pH	O
7	O
.	O
27	O
,	O
PCO2	O
31	O
mmHg	O
,	O
PO2	O
90	O
mmHg	O
,	O
HCO3	O
14	O
mmol	O
l	O
,	O
lactate	O
4	O
.	O
5	O
.	O
Biochemistry	O
urea	O
80	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
96	O
mg	O
dl	O
,	O
GPT	O
14	O
U	O
L	O
,	O
total	O
bilirubin	O
0	O
.	O
3	O
mg	O
dl	O
,	O
sodium	O
134	O
mEq	O
l	O
,	O
potassium	O
5	O
mEq	O
l	O
,	O
CRP	O
16	O
mg	O
l	O
,	O
CK	O
138	O
U	O
l	O
,	O
LDH	O
450	O
U	O
l	O
,	O
ultrasensitive	O
troponin	O
T	O
118	O
ng	O
l	O
normal	O
14	O
.	O
CBC	O
haemoglobin	O
10	O
.	O
5	O
g	O
dl	O
,	O
platelets	O
469	O
,	O
000	O
,	O
leucocytes	O
31	O
,	O
000	O
with	O
86	O
neutrophils	O
.	O
Coagulation	O
aPTT	O
180	O
sg	O
,	O
INR	O
1	O
.	O
2	O
.	O
Enzyme	O
peak	O
peak	O
CK	O
779	O
U	O
l	O
,	O
peak	O
troponin	O
T	O
2016	O
ng	O
dl	O
.	O
Other	O
analytical	O
results	O
HbA1c	O
7	O
.	O
5	O
.	O
TSH	O
1	O
.	O
01	O
in	O
range	O
.	O
Lipid	O
panel	O
total	O
cholesterol	O
102	O
,	O
triglycerides	O
112	O
,	O
HDL	O
33	O
,	O
LDL	O
47	O
.	O
Laboratory	O
tests	O
requested	O
by	O
the	O
allergology	O
department	O
tryptase	O
curve	O
9	O
9	O
2019	O
Regional	O
hospital	O
24	O
;	O
4	O
hours	O
after	O
onset	O
of	O
symptoms	O
11	O
;	O
24	O
hours	O
10	O
;	O
normal	O
tryptase	O
value	O
undetectable	O
,	O
or	O
1	O
.	O
2	O
mg	O
l	O
.	O
IgE	O
190	O
.	O
00	O
kUA	O
L	O
elevated	O
;	O
Anisakis	O
Ac	O
.	O
IgE	O
36	O
.	O
90	O
kUA	O
L	O
very	O
positive	O
.	O
Urgent	O
catheterisation	O
short	O
common	O
trunk	O
with	O
non	O
significant	O
distal	O
atheromatosis	O
.	O
Anterior	O
descending	O
AD	O
subtotal	O
ostial	O
lesion	O
in	O
the	O
AD	O
,	O
with	O
the	O
rest	O
of	O
the	O
vessel	O
with	O
mild	O
atheromatosis	O
,	O
TIMI	O
2	O
flow	O
.	O
The	O
1st	O
and	O
2nd	O
diagonals	O
present	O
moderate	O
ostial	O
stenosis	O
.	O
Circumflex	O
Cx	O
proximal	O
moderate	O
lesion	O
and	O
distal	O
moderate	O
long	O
atheromatosis	O
.	O
Right	O
coronary	O
artery	O
RC	O
dominant	O
.	O
Mild	O
proximal	O
moderate	O
atheromatosis	O
and	O
severe	O
short	O
lesion	O
at	O
the	O
level	O
of	O
the	O
IVP	O
cross	O
ostium	O
.	O
Primary	O
PCI	O
the	O
severe	O
lesion	O
of	O
the	O
ostial	O
LAD	O
is	O
pre	O
dilated	O
with	O
a	O
3	O
.	O
0	O
mm	O
balloon	O
and	O
a	O
3	O
.	O
5	O
24	O
mm	O
ANGIOLITE	O
stent	O
is	O
implanted	O
from	O
ostial	O
CT	O
with	O
an	O
optimal	O
result	O
.	O
The	O
most	O
distal	O
LAD	O
at	O
the	O
apical	O
level	O
is	O
occluded	O
and	O
does	O
not	O
recover	O
flow	O
after	O
PTCA	O
at	O
the	O
level	O
of	O
the	O
2	O
.	O
0	O
mm	O
balloon	O
occlusion	O
.	O
Echocardiogram	O
on	O
admission	O
left	O
ventricle	O
LV	O
neither	O
dilated	O
DTD	O
45mm	O
nor	O
hypertrophic	O
IVS	O
9mm	O
,	O
PP	O
9mm	O
with	O
moderately	O
depressed	O
global	O
systolic	O
function	O
at	O
the	O
expense	O
of	O
akinesia	O
of	O
all	O
mid	O
apical	O
segments	O
with	O
hypercontractility	O
of	O
the	O
rest	O
.	O
Non	O
dilated	O
right	O
ventricle	O
RV	O
,	O
preserved	O
global	O
function	O
with	O
apical	O
akinesia	O
.	O
Sclerosed	O
aortic	O
valve	O
with	O
preserved	O
opening	O
,	O
without	O
functional	O
alterations	O
.	O
Sclerosed	O
mitral	O
valve	O
with	O
slight	O
restriction	O
of	O
the	O
posterior	O
leaflet	O
and	O
moderate	O
mitral	O
insufficiency	O
,	O
directed	O
towards	O
the	O
posterior	O
wall	O
of	O
the	O
left	O
atrium	O
LA	O
.	O
Normal	O
appearing	O
tricuspid	O
valve	O
with	O
mild	O
mitral	O
insufficiency	O
MI	O
and	O
RV	O
AD	O
gradient	O
25	O
30	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
with	O
inspiratory	O
collapse	O
estimated	O
PSAP	O
30	O
35	O
mmHg	O
,	O
no	O
pulmonary	O
hypertension	O
.	O
No	O
pericardial	O
effusion	O
.	O
ECG	O
at	O
discharge	O
from	O
the	O
coronary	O
unit	O
sinus	O
rhythm	O
at	O
100	O
bpm	O
,	O
long	O
PR	O
,	O
axis	O
at	O
60a	O
,	O
LBBB	O
HAIHH	O
.	O
Second	O
time	O
catheterisation	O
with	O
PCI	O
to	O
CD	O
after	O
advancing	O
the	O
guidewires	O
to	O
PL	O
and	O
IVP	O
,	O
a	O
RESOLUTE	O
2	O
.	O
5	O
x	O
15	O
mm	O
direct	O
drug	O
eluting	O
stent	O
is	O
implanted	O
in	O
distal	O
Cd	O
IVP	O
,	O
leaving	O
slight	O
under	O
expansion	O
,	O
so	O
it	O
is	O
post	O
dilated	O
with	O
a	O
2	O
.	O
5	O
x	O
8	O
mm	O
NC	O
balloon	O
with	O
a	O
good	O
final	O
result	O
.	O
The	O
LP	O
was	O
caged	O
,	O
with	O
no	O
ostial	O
lesion	O
.	O
The	O
PVI	O
,	O
distal	O
to	O
the	O
stent	O
,	O
is	O
diffusely	O
atheromatous	O
with	O
severe	O
distal	O
small	O
vessel	O
lesions	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
is	O
admitted	O
to	O
the	O
coronary	O
unit	O
after	O
emergent	O
catheterisation	O
where	O
severe	O
bivascular	O
coronary	O
artery	O
disease	O
with	O
acute	O
thrombotic	O
lesion	O
of	O
the	O
ostial	O
LAD	O
is	O
detected	O
and	O
treated	O
with	O
a	O
stent	O
in	O
the	O
LAD	O
CT	O
with	O
good	O
results	O
.	O
Immediate	O
haemodynamic	O
improvement	O
was	O
observed	O
and	O
dobutamine	B-FARMACO
could	O
be	O
discontinued	O
in	O
the	O
haemodynamics	O
room	O
.	O
He	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
in	O
a	O
stable	O
condition	O
and	O
was	O
able	O
to	O
completely	O
discontinue	O
noradrenaline	B-FARMACO
2	O
hours	O
after	O
admission	O
.	O
On	O
admission	O
,	O
he	O
reported	O
some	O
residual	O
mild	O
chest	O
discomfort	O
that	O
resolved	O
in	O
the	O
first	O
4	O
hours	O
.	O
Suspicion	O
of	O
anaphylaxis	O
tongue	O
oedema	O
,	O
pruritus	O
,	O
etc	O
.	O
led	O
to	O
serial	O
tryptase	O
determinations	O
during	O
the	O
first	O
24	O
hours	O
,	O
which	O
were	O
positive	O
.	O
He	O
was	O
maintained	O
during	O
his	O
admission	O
to	O
the	O
coronary	O
unit	O
with	O
corticoid	O
and	O
intravenous	O
dexchlorpheniramine	B-FARMACO
Polaramine	I-FARMACO
with	O
complete	O
resolution	O
of	O
genital	O
itching	O
and	O
tongue	O
oedema	O
in	O
the	O
first	O
12	O
hours	O
,	O
remaining	O
asymptomatic	O
thereafter	O
.	O
He	O
was	O
assessed	O
by	O
the	O
allergology	O
department	O
,	O
which	O
analysed	O
him	O
for	O
specific	O
IgE	O
and	O
found	O
elevated	O
IgE	O
for	O
Anisakis	O
and	O
negative	O
IgE	O
for	O
hake	O
and	O
clams	O
.	O
According	O
to	O
the	O
recommendation	O
of	O
the	O
allergology	O
department	O
,	O
the	O
intravenous	O
glucocorticoid	O
doses	O
were	O
reduced	O
and	O
Polaramine	B-FARMACO
antiH1	O
was	O
maintained	O
throughout	O
the	O
hospital	O
stay	O
until	O
5	O
days	O
after	O
the	O
acute	O
event	O
.	O
She	O
was	O
also	O
forbidden	O
to	O
eat	O
fish	O
or	O
seafood	O
until	O
further	O
assessment	O
by	O
her	O
after	O
discharge	O
from	O
hospital	O
.	O
Haemodynamically	O
,	O
he	O
remained	O
stable	O
during	O
the	O
48	O
hours	O
of	O
admission	O
with	O
a	O
tendency	O
towards	O
asymptomatic	O
mild	O
hypotension	O
TAS	O
90	O
100	O
mmHg	O
and	O
sinus	O
tachycardia	O
95	O
110	O
bpm	O
,	O
without	O
new	O
exploratory	O
or	O
analytical	O
data	O
of	O
low	O
perfusion	O
,	O
with	O
moderate	O
LV	O
dysfunction	O
persisting	O
at	O
discharge	O
,	O
and	O
the	O
introduction	O
of	O
beta	B-FARMACO
blockers	I-FARMACO
or	O
angiotensin	B-FARMACO
converting	I-FARMACO
enzyme	I-FARMACO
inhibitors	I-FARMACO
ACE	I-FARMACO
inhibitors	I-FARMACO
not	O
being	O
possible	O
due	O
to	O
mild	O
hypotension	O
.	O
Spironolactone	B-FARMACO
is	O
started	O
,	O
with	O
good	O
tolerance	O
.	O
Respiratory	O
status	O
remained	O
stable	O
,	O
with	O
the	O
appearance	O
on	O
the	O
first	O
day	O
of	O
admission	O
of	O
mild	O
heart	O
failure	O
bibasal	O
crackles	O
without	O
dyspnoea	O
or	O
desaturation	O
.	O
A	O
daily	O
dose	O
of	O
oral	O
furosemide	B-FARMACO
was	O
started	O
and	O
was	O
well	O
tolerated	O
.	O
He	O
presented	O
a	O
single	O
febrile	O
peak	O
up	O
to	O
38	O
.	O
3oC	O
without	O
shivering	O
on	O
the	O
third	O
day	O
of	O
admission	O
11	O
9	O
2019	O
with	O
no	O
clinical	O
evidence	O
of	O
infection	O
.	O
Samples	O
were	O
taken	O
for	O
culture	O
blood	O
urine	O
culture	O
and	O
empirical	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
was	O
prescribed	O
.	O
During	O
his	O
admission	O
,	O
he	O
was	O
assessed	O
by	O
the	O
vascular	O
surgery	O
department	O
for	O
evaluation	O
of	O
the	O
recent	O
surgical	O
wound	O
of	O
amputation	O
of	O
DID	O
,	O
the	O
wounds	O
were	O
found	O
to	O
be	O
in	O
a	O
good	O
state	O
of	O
healing	O
with	O
some	O
necrotic	O
spots	O
but	O
with	O
no	O
evidence	O
of	O
infection	O
,	O
and	O
intradermal	O
suture	O
removal	O
was	O
pending	O
.	O
Once	O
the	O
condition	O
had	O
stabilised	O
,	O
it	O
was	O
decided	O
to	O
transfer	O
the	O
patient	O
to	O
the	O
ward	O
for	O
evolutionary	O
control	O
and	O
to	O
perform	O
a	O
new	O
catheterisation	O
in	O
the	O
second	O
stage	O
,	O
with	O
PCI	O
to	O
CD	O
IVP	O
,	O
which	O
was	O
successful	O
.	O
During	O
his	O
stay	O
on	O
the	O
ward	O
,	O
the	O
patient	O
remained	O
haemodynamically	O
and	O
respiratory	O
stable	O
,	O
asymptomatic	O
,	O
and	O
after	O
re	O
evaluation	O
by	O
the	O
allergology	O
service	O
,	O
the	O
patient	O
was	O
discharged	O
with	O
an	O
outpatient	O
appointment	O
for	O
joint	O
follow	O
up	O
by	O
allergology	O
and	O
cardiology	O
.	O
DIAGNOSIS	O
Main	O
diagnosis	O
Killip	O
IV	O
STEACS	O
Kounis	O
syndrome	O
type	O
II	O
.	O
Severe	O
Anisakis	O
anaphylaxis	O
in	O
the	O
context	O
of	O
fresh	O
fish	O
ingestion	O
.	O
Severe	O
two	O
vessel	O
coronary	O
artery	O
disease	O
DA	O
and	O
CD	O
.	O
Acute	O
thrombotic	O
lesion	O
in	O
ostial	O
LAD	O
with	O
severe	O
stenosis	O
.	O
Primary	O
PCI	O
with	O
drug	O
eluting	O
stent	O
implantation	O
in	O
TC	O
DA	O
axis	O
.	O
Second	O
stage	O
PCI	O
with	O
drug	O
eluting	O
stent	O
implantation	O
in	O
DC	O
PVI	O
with	O
moderately	O
depressed	O
LVEF	O
.	O
Secondary	O
diagnoses	O
Cardiovascular	O
risk	O
factors	O
ex	O
smoker	O
,	O
AHT	O
,	O
DM2	O
.	O
Grade	O
IV	O
chronic	O
ischaemia	O
syndrome	O
of	O
the	O
LVES	O
.	O
Recent	O
postoperative	O
infracondylar	O
amputation	O
of	O
DID	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
73	O
year	O
old	O
woman	O
attended	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
due	O
to	O
dyspnoea	O
.	O
History	O
The	O
patient	O
had	O
the	O
following	O
medical	O
history	O
Cardiovascular	O
risk	O
factors	O
dyslipidaemia	O
in	O
treatment	O
with	O
a	O
lipid	O
lowering	O
drug	O
in	O
monotherapy	O
,	O
with	O
last	O
LDL	O
C	O
of	O
80	O
mg	O
dl	O
.	O
Cardiological	O
history	O
medical	O
records	O
show	O
detection	O
of	O
a	O
heart	O
murmur	O
more	O
than	O
20	O
years	O
ago	O
in	O
check	O
ups	O
by	O
a	O
primary	O
care	O
doctor	O
,	O
never	O
studied	O
.	O
Other	O
relevant	O
medical	O
history	O
locally	O
advanced	O
adenocarcinoma	O
of	O
the	O
left	O
breast	O
at	O
the	O
age	O
of	O
38	O
,	O
treated	O
with	O
radical	O
mastectomy	O
,	O
lymphadenectomy	O
and	O
chemoradiotherapy	O
,	O
free	O
of	O
disease	O
since	O
then	O
with	O
no	O
recurrences	O
.	O
Usual	O
treatment	O
simvastatin	O
20	O
mg	O
every	O
24	O
hours	O
.	O
Present	O
illness	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
the	O
patient	O
reported	O
a	O
clinical	O
picture	O
of	O
approximately	O
4	O
weeks	O
of	O
progressive	O
deterioration	O
of	O
functional	O
class	O
to	O
the	O
point	O
of	O
presenting	O
dyspnoea	O
at	O
rest	O
NYHA	O
IV	O
,	O
as	O
well	O
as	O
orthopnoea	O
that	O
forced	O
her	O
to	O
sleep	O
in	O
a	O
sitting	O
position	O
.	O
She	O
also	O
reported	O
a	O
subjective	O
decrease	O
in	O
the	O
volume	O
of	O
diuresis	O
,	O
without	O
associated	O
swelling	O
of	O
the	O
lower	O
limbs	O
.	O
She	O
had	O
no	O
anginal	O
chest	O
pain	O
either	O
at	O
rest	O
or	O
on	O
exertion	O
.	O
He	O
denied	O
any	O
infectious	O
symptoms	O
when	O
questioned	O
by	O
apparatus	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
122	O
70	O
mmHg	O
,	O
heart	O
rate	O
HR	O
100	O
bpm	O
,	O
O2	O
Sat	O
95	O
with	O
FiO2	O
35	O
.	O
Jugular	O
venous	O
pressure	O
increased	O
15	O
cm	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
with	O
systolic	O
murmur	O
in	O
aortic	O
focus	O
radiating	O
to	O
IV	O
VI	O
carotid	O
arteries	O
,	O
with	O
abolition	O
of	O
the	O
second	O
sound	O
.	O
Systolic	O
murmur	O
in	O
mitral	O
focus	O
radiating	O
to	O
axilla	O
III	O
VI	O
.	O
Pulmonary	O
auscultation	O
mediobasal	O
crackles	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
deep	O
palpation	O
,	O
no	O
masses	O
or	O
megaliths	O
,	O
Blumberg	O
and	O
Murphy	O
negative	O
.	O
Positive	O
hepatojugular	O
reflux	O
.	O
Extremities	O
no	O
oedema	O
in	O
the	O
lower	O
extremities	O
,	O
peripheral	O
pulses	O
preserved	O
and	O
symmetrical	O
,	O
no	O
signs	O
of	O
phlebitis	O
.	O
Echoscopy	O
was	O
performed	O
at	O
the	O
bedside	O
in	O
the	O
emergency	O
department	O
,	O
which	O
showed	O
calcification	O
of	O
the	O
aortic	O
valve	O
with	O
severely	O
limited	O
opening	O
,	O
as	O
well	O
as	O
calcification	O
of	O
the	O
mitral	O
valve	O
apparatus	O
with	O
significant	O
regurgitation	O
,	O
so	O
it	O
was	O
decided	O
to	O
admit	O
the	O
patient	O
to	O
the	O
cardiology	O
ward	O
for	O
stabilisation	O
,	O
complete	O
the	O
study	O
and	O
assess	O
therapeutic	O
options	O
.	O
COMPLEMENTARY	O
TESTS	O
Portable	O
chest	O
X	O
ray	O
on	O
admission	O
cardiomediastinal	O
silhouette	O
not	O
assessable	O
.	O
Left	O
costophrenic	O
sinus	O
impingement	O
.	O
Prominent	O
pulmonary	O
hilarity	O
with	O
a	O
vascular	O
appearance	O
.	O
Signs	O
of	O
vascular	O
redistribution	O
.	O
Electrocardiogram	O
sinus	O
tachycardia	O
at	O
110	O
bpm	O
.	O
Normal	O
PR	O
.	O
Normal	O
axis	O
.	O
Voltage	O
criteria	O
of	O
left	O
ventricular	O
hypertrophy	O
.	O
QRS	O
120	O
ms	O
with	O
intraventricular	O
conduction	O
disturbance	O
type	O
BRI	O
.	O
Signs	O
of	O
systolic	O
overload	O
.	O
Laboratory	O
tests	O
on	O
admission	O
Haemoglobin	O
16	O
.	O
2	O
g	O
dl	O
,	O
no	O
leukocytosis	O
or	O
left	O
shift	O
,	O
platelets	O
232	O
x	O
10	O
9	O
l	O
.	O
Haemostasis	O
INR	O
1	O
.	O
2	O
,	O
APTT	O
30	O
.	O
1	O
sec	O
.	O
Biochemistry	O
glucose	O
127	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
00	O
mg	O
dl	O
,	O
GFR	O
55	O
.	O
8	O
ml	O
min	O
1	O
.	O
72	O
m	O
,	O
sodium	O
137	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
5	O
mEq	O
l	O
,	O
total	O
bilirubin	O
1	O
.	O
2	O
mg	O
dl	O
,	O
GOT	O
45	O
IU	O
l	O
,	O
GPT	O
35	O
IU	O
l	O
,	O
C	O
reactive	O
protein	O
0	O
.	O
1	O
mg	O
dl	O
.	O
Blood	O
tests	O
after	O
clinical	O
deterioration	O
Haemoglobin	O
15	O
.	O
4	O
g	O
dl	O
,	O
no	O
leukocytosis	O
or	O
left	O
shift	O
,	O
platelets	O
195	O
x	O
10	O
9	O
l	O
.	O
Haemostasis	O
INR	O
1	O
.	O
9	O
,	O
aPTT	O
40	O
sec	O
.	O
Biochemistry	O
glucose	O
150	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
94	O
mg	O
dl	O
,	O
GFR	O
25	O
.	O
1	O
ml	O
min	O
1	O
.	O
72	O
m	O
,	O
sodium	O
143	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
2	O
mEq	O
l	O
,	O
total	O
bilirubin	O
2	O
.	O
7	O
mg	O
dl	O
,	O
GOT	O
150	O
IU	O
l	O
,	O
GPT	O
263	O
IU	O
l	O
,	O
C	O
reactive	O
protein	O
2	O
.	O
3	O
mg	O
dl	O
.	O
Echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
LV	O
with	O
mild	O
concentric	O
hypertrophy	O
.	O
Global	O
hypokinesia	O
of	O
septal	O
and	O
anterior	O
predominance	O
with	O
severely	O
depressed	O
GSF	O
LVEF	O
25	O
.	O
Dilated	O
left	O
atrium	O
.	O
Double	O
aortic	O
lesion	O
on	O
severely	O
calcified	O
valve	O
severe	O
stenosis	O
planimetry	O
0	O
.	O
5	O
c	O
,	O
mGm	O
52	O
mmHg	O
.	O
Moderate	O
regurgitation	O
THP	O
260	O
ms	O
.	O
Moderate	O
mitral	O
regurgitation	O
II	O
III	O
VI	O
on	O
sclerodegenerative	O
valve	O
ERO	O
by	O
PISA	O
0	O
.	O
25	O
cm2	O
.	O
RV	O
with	O
non	O
enlarged	O
diameters	O
and	O
preserved	O
GSF	O
TAPSE	O
18	O
mm	O
.	O
Moderate	O
tricuspid	O
regurgitation	O
that	O
allows	O
estimating	O
PsAP	O
at	O
70	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
plethoric	O
.	O
Coronary	O
angiography	O
1	O
calcification	O
of	O
ascending	O
aorta	O
,	O
intensely	O
calcified	O
sigmoid	O
arteries	O
with	O
reduced	O
opening	O
,	O
severe	O
stenosis	O
peak	O
gradient	O
55	O
mmHg	O
.	O
Coronary	O
arteries	O
normal	O
trunk	O
.	O
Anterior	O
descending	O
artery	O
with	O
80	O
lesion	O
in	O
the	O
middle	O
segment	O
.	O
Circumflex	O
artery	O
with	O
irregularities	O
without	O
stenosis	O
.	O
Right	O
coronary	O
artery	O
with	O
90	O
lesion	O
in	O
proximal	O
segment	O
.	O
Thoracic	O
CT	O
without	O
contrast	O
marked	O
calcified	O
atheromatosis	O
in	O
the	O
thoracic	O
aorta	O
,	O
especially	O
in	O
the	O
location	O
of	O
the	O
aortic	O
button	O
.	O
Calcification	O
of	O
the	O
aortic	O
valve	O
,	O
tricuspid	O
valve	O
and	O
right	O
coronary	O
artery	O
.	O
Coronary	O
angiography	O
2	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
PTCA	O
was	O
performed	O
on	O
the	O
LAD	O
and	O
RCA	O
lesions	O
with	O
implantation	O
of	O
everolimus	B-FARMACO
eluting	O
drug	O
eluting	O
stents	O
,	O
with	O
good	O
angiographic	O
results	O
.	O
TAVI	O
implantation	O
after	O
balloon	O
valvuloplasty	O
,	O
a	O
23	O
mm	O
SAPIEN	O
ULTRA	O
prosthesis	O
was	O
implanted	O
.	O
After	O
implantation	O
,	O
electromechanical	O
dissociation	O
without	O
identifying	O
coronary	O
occlusion	O
,	O
contrast	O
extravasation	O
to	O
the	O
pericardium	O
,	O
aortic	O
rupture	O
or	O
prosthetic	O
embolisation	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
admission	O
to	O
the	O
cardiology	O
ward	O
,	O
the	O
patient	O
initially	O
evolved	O
favourably	O
,	O
but	O
subsequently	O
presented	O
clinical	O
deterioration	O
due	O
to	O
a	O
new	O
increase	O
in	O
dyspnoea	O
associated	O
with	O
a	O
marked	O
decrease	O
in	O
the	O
volume	O
of	O
diuresis	O
10	O
ml	O
kg	O
h	O
and	O
hypotension	O
BP	O
73	O
35	O
mmHg	O
,	O
so	O
that	O
in	O
view	O
of	O
the	O
situation	O
of	O
cardiogenic	O
shock	O
it	O
was	O
decided	O
to	O
admit	O
her	O
to	O
the	O
coronary	O
unit	O
for	O
stabilisation	O
.	O
Vasoactive	O
support	O
was	O
started	O
with	O
noradrenaline	B-FARMACO
at	O
12	O
mcg	O
min	O
and	O
inotropic	O
support	O
with	O
dobutamine	B-FARMACO
at	O
10	O
mcg	O
kg	O
min	O
,	O
as	O
well	O
as	O
intensive	O
diuretic	O
therapy	O
with	O
iv	O
perfusion	O
of	O
furosemide	B-FARMACO
at	O
20	O
mg	O
h	O
,	O
with	O
an	O
initial	O
favourable	O
response	O
that	O
allowed	O
negative	O
balances	O
to	O
be	O
maintained	O
without	O
the	O
need	O
to	O
start	O
ultrafiltration	O
therapy	O
.	O
The	O
echocardiographic	O
study	O
confirmed	O
the	O
presence	O
of	O
severe	O
ventricular	O
dysfunction	O
and	O
severe	O
aortic	O
stenosis	O
and	O
moderate	O
aortic	O
regurgitation	O
and	O
diagnostic	O
coronary	O
angiography	O
detected	O
severe	O
two	O
vessel	O
coronary	O
artery	O
disease	O
,	O
as	O
well	O
as	O
significant	O
calcification	O
of	O
the	O
ascending	O
aorta	O
,	O
which	O
was	O
confirmed	O
by	O
non	O
contrast	O
thoracic	O
CT	O
.	O
With	O
these	O
findings	O
,	O
the	O
case	O
was	O
presented	O
at	O
the	O
medical	O
surgical	O
session	O
,	O
and	O
surgical	O
valve	O
replacement	O
by	O
the	O
HEART	O
Team	O
was	O
rejected	O
given	O
the	O
patient	O
's	O
clinical	O
situation	O
,	O
with	O
an	O
excessive	O
surgical	O
risk	O
EuroSCORE	O
II	O
80	O
.	O
35	O
,	O
as	O
well	O
as	O
her	O
anatomical	O
characteristics	O
,	O
with	O
very	O
marked	O
aortic	O
calcification	O
that	O
unacceptably	O
limited	O
the	O
possibilities	O
of	O
cannulation	O
for	O
extracorporeal	O
circulation	O
.	O
In	O
addition	O
,	O
given	O
the	O
presence	O
of	O
at	O
least	O
moderate	O
aortic	O
regurgitation	O
,	O
aortic	O
balloon	O
valvuloplasty	O
as	O
a	O
bridge	O
to	O
TAVI	O
was	O
ruled	O
out	O
and	O
it	O
was	O
decided	O
to	O
initially	O
stabilise	O
the	O
patient	O
in	O
the	O
OCU	O
and	O
,	O
depending	O
on	O
the	O
evolution	O
,	O
to	O
consider	O
two	O
stage	O
treatment	O
with	O
percutaneous	O
revascularisation	O
of	O
the	O
coronary	O
lesions	O
and	O
subsequent	O
percutaneous	O
aortic	O
valve	O
replacement	O
.	O
During	O
his	O
stay	O
in	O
the	O
OCU	O
,	O
the	O
evolution	O
was	O
slowly	O
favourable	O
and	O
,	O
after	O
treatment	O
with	O
IV	O
levosinendan	B-FARMACO
,	O
inotropic	O
support	O
could	O
be	O
withdrawn	O
,	O
requiring	O
only	O
vasopressor	O
support	O
with	O
low	O
doses	O
0	O
.	O
1	O
0	O
.	O
2	O
mcg	O
kg	O
min	O
of	O
NA	B-FARMACO
.	O
Percutaneous	O
revascularisation	O
of	O
the	O
AD	O
and	O
DC	O
lesions	O
was	O
performed	O
.	O
Finally	O
,	O
percutaneous	O
valve	O
replacement	O
via	O
the	O
right	O
femoral	O
artery	O
was	O
attempted	O
,	O
and	O
after	O
expansion	O
of	O
the	O
bioprosthesis	O
,	O
the	O
patient	O
presented	O
cardiac	O
arrest	O
due	O
to	O
electromechanical	O
dissociation	O
,	O
with	O
no	O
immediate	O
complications	O
derived	O
from	O
the	O
technique	O
coronary	O
occlusion	O
,	O
pericardial	O
contrast	O
extravasation	O
,	O
aortic	O
rupture	O
,	O
or	O
prosthetic	O
embolisation	O
,	O
so	O
advanced	O
cardiopulmonary	O
resuscitation	O
manoeuvres	O
were	O
started	O
,	O
resulting	O
in	O
exitus	O
after	O
40	O
min	O
without	O
achieving	O
recovery	O
of	O
spontaneous	O
circulation	O
.	O
DIAGNOSIS	O
Double	O
sclerodegenerative	O
aortic	O
lesion	O
severe	O
stenosis	O
and	O
moderate	O
regurgitation	O
.	O
Moderate	O
mitral	O
regurgitation	O
on	O
sclerodegenerative	O
valve	O
.	O
Severe	O
ventricular	O
dysfunction	O
LVEF	O
25	O
.	O
Ischaemic	O
heart	O
disease	O
two	O
vessel	O
disease	O
CDp	O
90	O
,	O
DAm	O
80	O
.	O
PCI	O
with	O
implantation	O
of	O
two	O
everolimus	B-FARMACO
eluting	O
drug	O
eluting	O
stents	O
.	O
Porcelain	O
aorta	O
.	O
Cardiogenic	O
shock	O
.	O
Failed	O
percutaneous	O
aortic	O
bioprosthesis	O
implantation	O
due	O
to	O
death	O
during	O
the	O
procedure	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Male	O
,	O
79	O
years	O
old	O
.	O
History	O
High	O
blood	O
pressure	O
.	O
Altered	O
basal	O
glycaemia	O
.	O
Valvular	O
heart	O
disease	O
consisting	O
of	O
severe	O
degenerative	O
mitral	O
insufficiency	O
,	O
severe	O
tricuspid	O
insufficiency	O
and	O
severe	O
pulmonary	O
hypertension	O
.	O
Preserved	O
left	O
and	O
right	O
ventricular	O
function	O
.	O
Permanent	O
atrial	O
fibrillation	O
.	O
Moderate	O
severe	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O
Sleep	O
apnoea	O
hypopnoea	O
syndrome	O
,	O
in	O
treatment	O
with	O
nocturnal	O
CPAP	O
.	O
Stage	O
3a	O
chronic	O
kidney	O
disease	O
secondary	O
to	O
nephroangiosclerosis	O
.	O
Bronchial	O
carcinoid	O
tumour	O
T2	O
N0	O
M0	O
,	O
operated	O
by	O
right	O
lower	O
lobectomy	O
and	O
currently	O
in	O
complete	O
remission	O
.	O
Polymyalgia	O
rheumatica	O
.	O
Gouty	O
arthritis	O
.	O
Usual	O
treatment	O
telmisartan	B-FARMACO
hydrochlorothiazide	I-FARMACO
80	O
25	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
;	O
furosemide	B-FARMACO
40	O
mg	O
1	O
tablet	O
at	O
breakfast	O
and	O
half	O
a	O
tablet	O
at	O
lunch	O
;	O
spironolactone	B-FARMACO
25	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
,	O
amlodipine	B-FARMACO
5	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
;	O
acenocoumarol	B-FARMACO
4	O
mg	O
according	O
to	O
INR	O
;	O
bicarbonate	B-FARMACO
500	O
mg	O
every	O
12	O
hours	O
;	O
resin	B-FARMACO
calcium	I-FARMACO
15	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
.	O
Present	O
illness	O
Referred	O
from	O
pulmonology	O
for	O
increased	O
dyspnoea	O
on	O
exertion	O
and	O
worsening	O
of	O
functional	O
class	O
in	O
recent	O
months	O
,	O
with	O
a	O
recent	O
admission	O
for	O
decompensated	O
failure	O
.	O
No	O
exertional	O
angina	O
.	O
In	O
stable	O
condition	O
,	O
he	O
reported	O
minimal	O
effort	O
dyspnoea	O
NYHA	O
class	O
III	O
IV	O
,	O
orthopnoea	O
on	O
2	O
pillows	O
.	O
Physical	O
examination	O
At	O
the	O
outpatient	O
clinic	O
Blood	O
pressure	O
BP	O
130	O
65	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
72	O
bpm	O
.	O
Baseline	O
SatO2	O
94	O
.	O
Afebrile	O
.	O
Good	O
general	O
condition	O
,	O
normohydrated	O
,	O
normoperfused	O
.	O
Jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
tones	O
,	O
systolic	O
murmur	O
in	O
mitral	O
focus	O
III	O
VI	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
generalised	O
hypoventilation	O
,	O
no	O
crackles	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
,	O
with	O
no	O
signs	O
of	O
ascites	O
.	O
Oedema	O
with	O
perimalleolar	O
fovea	O
.	O
Distal	O
pulses	O
present	O
and	O
symmetrical	O
.	O
No	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
in	O
the	O
lower	O
extremities	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
in	O
consultations	O
atrial	O
fibrillation	O
at	O
74	O
bpm	O
,	O
narrow	O
QRS	O
with	O
normal	O
axis	O
,	O
flattened	O
T	O
wave	O
in	O
inferolateral	O
face	O
without	O
other	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
post	O
surgical	O
alterations	O
with	O
volume	O
loss	O
in	O
the	O
right	O
hemithorax	O
and	O
fracture	O
calluses	O
of	O
the	O
costal	O
arches	O
history	O
of	O
right	O
lower	O
lobectomy	O
.	O
No	O
pulmonary	O
consolidations	O
were	O
observed	O
.	O
Cardiothoracic	O
index	O
CTI	O
increased	O
.	O
No	O
pleural	O
effusion	O
.	O
Transthoracic	O
echocardiogram	O
absence	O
of	O
pericardial	O
effusion	O
.	O
Left	O
ventricle	O
slightly	O
dilated	O
DTD	O
67	O
mm	O
,	O
VTD	O
142	O
ml	O
with	O
normal	O
wall	O
thickness	O
and	O
normal	O
systolic	O
function	O
LVEF	O
67	O
,	O
without	O
alterations	O
of	O
segmental	O
contractility	O
.	O
Severe	O
dilatation	O
of	O
both	O
atria	O
.	O
Dilated	O
right	O
ventricle	O
tricuspid	O
annulus	O
52	O
mm	O
,	O
basal	O
diameter	O
4C	O
57	O
mm	O
with	O
preserved	O
systolic	O
function	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
leaflet	O
sclerosis	O
and	O
adequate	O
opening	O
movements	O
.	O
Mild	O
moderate	O
aortic	O
insufficiency	O
.	O
Mitral	O
valve	O
with	O
thickening	O
of	O
the	O
anterior	O
leaflet	O
without	O
clear	O
atrial	O
prolapse	O
by	O
this	O
technique	O
and	O
restrictive	O
systolic	O
motion	O
of	O
the	O
posterior	O
leaflet	O
;	O
calcification	O
of	O
the	O
posterior	O
portion	O
of	O
the	O
annulus	O
and	O
the	O
subvalvular	O
apparatus	O
.	O
Mitral	O
insufficiency	O
that	O
appears	O
severe	O
with	O
a	O
very	O
eccentric	O
jet	O
in	O
a	O
postero	O
lateral	O
direction	O
,	O
significant	O
coanda	O
effect	O
,	O
up	O
to	O
the	O
atrial	O
roof	O
,	O
ORE	O
estimated	O
by	O
PISA	O
of	O
0	O
.	O
50	O
cm	O
.	O
Tricuspid	O
valve	O
with	O
large	O
central	O
coaptation	O
defect	O
.	O
Massive	O
tricuspid	O
insufficiency	O
allowing	O
an	O
estimated	O
PSAP	O
of	O
63	O
mmHg	O
.	O
Aortic	O
root	O
43	O
mm	O
and	O
ascending	O
aorta	O
41	O
mm	O
slightly	O
dilated	O
.	O
Severely	O
dilated	O
inferior	O
vena	O
cava	O
31	O
mm	O
with	O
abolished	O
inspiratory	O
collapse	O
.	O
Transesophageal	O
echocardiogram	O
pre	O
procedure	O
moderate	O
calcification	O
of	O
the	O
mitral	O
annulus	O
with	O
normal	O
opening	O
.	O
Restrictive	O
systolic	O
movement	O
of	O
the	O
posterior	O
leaflet	O
,	O
with	O
a	O
maximum	O
length	O
of	O
13	O
mm	O
and	O
associated	O
prolapse	O
of	O
the	O
anterior	O
leaflet	O
A2	O
scallop	O
with	O
an	O
image	O
of	O
probable	O
rupture	O
of	O
the	O
chordae	O
tendineae	O
at	O
this	O
level	O
.	O
Severe	O
mitral	O
insufficiency	O
codne	O
codne	O
eccentric	O
pansystolic	O
regurgitation	O
that	O
runs	O
along	O
the	O
lateral	O
wall	O
of	O
the	O
left	O
atrium	O
,	O
reaching	O
its	O
roof	O
and	O
causing	O
inversion	O
of	O
the	O
S	O
wave	O
in	O
the	O
pulmonary	O
veins	O
.	O
Contracted	O
vein	O
of	O
7	O
mm	O
,	O
ORE	O
by	O
PISA	O
0	O
.	O
81	O
cm	O
.	O
No	O
image	O
of	O
ruptured	O
cord	O
is	O
visualised	O
.	O
Mitral	O
annulus	O
34	O
mm	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
slightly	O
thickened	O
leaflets	O
,	O
normal	O
opening	O
and	O
mild	O
insufficiency	O
.	O
Tricuspid	O
valve	O
with	O
normal	O
structure	O
and	O
large	O
dilatation	O
of	O
the	O
annulus	O
55	O
mm	O
,	O
causing	O
a	O
large	O
central	O
coaptation	O
defect	O
with	O
severe	O
insufficiency	O
.	O
Normal	O
pulmonary	O
valve	O
.	O
No	O
intracavitary	O
masses	O
and	O
or	O
thrombi	O
are	O
visualised	O
.	O
Thoracic	O
aorta	O
of	O
normal	O
dimensions	O
with	O
some	O
small	O
uncomplicated	O
atherosclerotic	O
plaque	O
.	O
Septum	O
intact	O
.	O
Rest	O
of	O
the	O
study	O
unchanged	O
with	O
respect	O
to	O
the	O
transthoracic	O
echocardiogram	O
.	O
Transesophageal	O
echocardiogram	O
haemodynamic	O
monitoring	O
transseptal	O
ultrasound	O
guided	O
puncture	O
was	O
performed	O
without	O
incident	O
.	O
A	O
first	O
clip	O
was	O
implanted	O
in	O
a	O
central	O
position	O
that	O
clearly	O
limited	O
the	O
eversion	O
of	O
the	O
A2	O
scallop	O
,	O
with	O
moderate	O
residual	O
insufficiency	O
persisting	O
in	O
the	O
medial	O
region	O
.	O
It	O
was	O
decided	O
to	O
implant	O
a	O
second	O
clip	O
medial	O
to	O
the	O
first	O
,	O
with	O
good	O
results	O
.	O
The	O
overall	O
insufficiency	O
after	O
the	O
procedure	O
was	O
considered	O
grade	O
II	O
mild	O
moderate	O
,	O
with	O
gradients	O
of	O
around	O
3	O
mmHg	O
,	O
without	O
haemodynamically	O
significant	O
stenosis	O
.	O
After	O
removal	O
of	O
the	O
material	O
,	O
an	O
atrial	O
septal	O
defect	O
with	O
diameters	O
of	O
11	O
x	O
5	O
mm	O
was	O
observed	O
by	O
3D	O
planimetry	O
,	O
with	O
predominant	O
right	O
to	O
left	O
Doppler	O
shunt	O
,	O
which	O
was	O
finally	O
sealed	O
with	O
a	O
12	O
mm	O
Amplatzer	O
device	O
,	O
leaving	O
a	O
residual	O
,	O
non	O
significant	O
intradevice	O
minimohunt	O
.	O
Good	O
left	O
ventricular	O
systolic	O
function	O
after	O
the	O
procedure	O
,	O
with	O
no	O
pericardial	O
effusion	O
.	O
Transthoracic	O
echocardiogram	O
pre	O
discharge	O
severely	O
dilated	O
left	O
atrium	O
.	O
Severely	O
dilated	O
right	O
atrium	O
.	O
Mitral	O
valve	O
closure	O
by	O
means	O
of	O
two	O
mitral	O
clips	O
that	O
behaves	O
as	O
a	O
double	O
residual	O
lesion	O
mild	O
moderate	O
mitral	O
insufficiency	O
and	O
mild	O
mitral	O
stenosis	O
.	O
The	O
right	O
ventricle	O
is	O
moderately	O
dilated	O
with	O
preserved	O
systolic	O
function	O
.	O
Left	O
ventricle	O
with	O
moderate	O
hypertrophy	O
,	O
not	O
dilated	O
and	O
with	O
hyperdynamic	O
contractility	O
LVEF	O
73	O
.	O
Ascending	O
aorta	O
slightly	O
dilated	O
.	O
Double	O
aortic	O
valve	O
lesion	O
mild	O
.	O
Severe	O
tricuspid	O
insufficiency	O
.	O
Moderate	O
pulmonary	O
hypertension	O
.	O
Closure	O
of	O
atrial	O
septal	O
defect	O
ASD	O
secondary	O
to	O
intervention	O
by	O
means	O
of	O
Amplatzer	O
percutaneous	O
device	O
without	O
residual	O
shunt	O
.	O
No	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
This	O
is	O
a	O
patient	O
under	O
cardiological	O
follow	O
up	O
for	O
his	O
valvular	O
heart	O
disease	O
,	O
consisting	O
of	O
severe	O
mitral	O
insufficiency	O
,	O
who	O
was	O
referred	O
to	O
our	O
clinic	O
preferentially	O
due	O
to	O
worsening	O
functional	O
class	O
and	O
recent	O
admission	O
for	O
heart	O
failure	O
.	O
At	O
this	O
time	O
,	O
mitral	O
valve	O
treatment	O
is	O
being	O
considered	O
.	O
Taking	O
into	O
account	O
the	O
patient	O
's	O
comorbidities	O
moderate	O
surgical	O
risk	O
,	O
EuroSCORE	O
II	O
4	O
.	O
46	O
and	O
history	O
of	O
pulmonary	O
resection	O
with	O
severe	O
chronic	O
lung	O
disease	O
,	O
he	O
was	O
considered	O
the	O
best	O
candidate	O
for	O
percutaneous	O
mitral	O
valve	O
treatment	O
.	O
Thus	O
,	O
the	O
patient	O
is	O
admitted	O
on	O
a	O
scheduled	O
basis	O
for	O
the	O
procedure	O
.	O
It	O
is	O
performed	O
in	O
the	O
cath	O
lab	O
under	O
general	O
anaesthesia	O
and	O
monitored	O
by	O
transesophageal	O
echocardiography	O
.	O
Two	O
mitral	O
clips	O
are	O
released	O
with	O
reduction	O
of	O
the	O
mitral	O
regurgitation	O
grade	O
to	O
mild	O
moderate	O
grade	O
II	O
IV	O
,	O
maintaining	O
a	O
good	O
opening	O
area	O
without	O
significant	O
increase	O
in	O
valve	O
gradients	O
mean	O
gradients	O
of	O
3	O
mmHg	O
.	O
The	O
procedure	O
was	O
terminated	O
,	O
but	O
when	O
the	O
catheter	O
was	O
removed	O
,	O
the	O
patient	O
presented	O
significant	O
desaturation	O
with	O
hypoxaemia	O
in	O
the	O
arterial	O
blood	O
gas	O
analysis	O
,	O
with	O
the	O
rest	O
of	O
the	O
vital	O
signs	O
remaining	O
stable	O
.	O
The	O
transesophageal	O
echocardiogram	O
showed	O
that	O
the	O
mitral	O
clips	O
had	O
not	O
embolised	O
,	O
biventricular	O
systolic	O
function	O
was	O
good	O
and	O
there	O
was	O
no	O
pericardial	O
effusion	O
.	O
However	O
,	O
a	O
significant	O
right	O
to	O
left	O
Doppler	O
flow	O
was	O
observed	O
at	O
the	O
level	O
of	O
the	O
atrial	O
septal	O
defect	O
secondary	O
to	O
the	O
transseptal	O
puncture	O
.	O
The	O
decrease	O
in	O
left	O
atrial	O
pressure	O
as	O
the	O
degree	O
of	O
mitral	O
regurgitation	O
decreased	O
,	O
together	O
with	O
the	O
very	O
high	O
right	O
atrial	O
pressures	O
due	O
to	O
severe	O
pulmonary	O
hypertension	O
and	O
tricuspid	O
regurgitation	O
,	O
explains	O
this	O
phenomenon	O
.	O
Since	O
the	O
patient	O
persisted	O
with	O
hypoxaemia	O
despite	O
100	O
oxygen	O
concentrations	O
on	O
the	O
ventilator	O
,	O
it	O
was	O
decided	O
to	O
percutaneously	O
close	O
the	O
atrial	O
septal	O
defect	O
with	O
an	O
Amplatzer	O
device	O
.	O
The	O
patient	O
's	O
oxygenation	O
improved	O
and	O
he	O
was	O
transferred	O
to	O
the	O
post	O
surgical	O
critical	O
care	O
unit	O
where	O
he	O
was	O
extubated	O
without	O
incident	O
.	O
In	O
the	O
following	O
days	O
,	O
the	O
patient	O
evolved	O
favourably	O
and	O
did	O
not	O
present	O
any	O
complications	O
at	O
the	O
vascular	O
access	O
level	O
or	O
deterioration	O
of	O
renal	O
function	O
or	O
clinical	O
signs	O
of	O
heart	O
failure	O
.	O
A	O
control	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
good	O
placement	O
of	O
the	O
mitral	O
clips	O
,	O
mild	O
to	O
moderate	O
insufficiency	O
and	O
normal	O
gradients	O
.	O
The	O
patient	O
was	O
discharged	O
from	O
hospital	O
on	O
the	O
fourth	O
day	O
of	O
admission	O
.	O
On	O
subsequent	O
cardiology	O
reviews	O
,	O
he	O
remained	O
clinically	O
stable	O
,	O
in	O
NYHA	O
II	O
IV	O
with	O
mild	O
heart	O
failure	O
predominantly	O
on	O
the	O
right	O
,	O
which	O
was	O
controlled	O
with	O
a	O
daily	O
tablet	O
of	O
furosemide	B-FARMACO
40	O
mg	O
.	O
DIAGNOSIS	O
Severe	O
organic	O
,	O
degenerative	O
mitral	O
regurgitation	O
,	O
effectively	O
treated	O
percutaneously	O
with	O
the	O
implantation	O
of	O
two	O
mitral	O
clips	O
MitraClip	O
.	O
Residual	O
mitral	O
regurgitation	O
grade	O
II	O
mild	O
moderate	O
.	O
Significant	O
right	O
to	O
left	O
atrial	O
septal	O
defect	O
and	O
secondary	O
hypoxaemia	O
.	O
Effective	O
closure	O
of	O
the	O
defect	O
with	O
Amplatzer	O
device	O
.	O
Severe	O
tricuspid	O
regurgitation	O
.	O
Severe	O
pulmonary	O
hypertension	O
.	O
Preserved	O
left	O
ventricular	O
function	O
.	O
Permanent	O
atrial	O
fibrillation	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Hereditary	O
family	O
diseases	O
Father	O
died	O
at	O
78	O
years	O
of	O
age	O
suddenly	O
with	O
unspecified	O
heart	O
disease	O
.	O
There	O
were	O
7	O
siblings	O
,	O
5	O
of	O
them	O
died	O
approximately	O
in	O
the	O
neonatal	O
period	O
.	O
Surviving	O
is	O
an	O
older	O
brother	O
aged	O
70	O
with	O
unspecified	O
heart	O
disease	O
,	O
not	O
a	O
carrier	O
of	O
Val26Ala	O
in	O
the	O
emerin	O
gene	O
mutation	O
EMD	O
.	O
She	O
has	O
3	O
children	O
,	O
the	O
first	O
of	O
whom	O
died	O
suddenly	O
at	O
the	O
age	O
of	O
38	O
,	O
diagnosed	O
with	O
DCM	O
.	O
The	O
second	O
is	O
a	O
39	O
year	O
old	O
male	O
who	O
is	O
not	O
a	O
carrier	O
and	O
has	O
no	O
heart	O
disease	O
.	O
Finally	O
,	O
a	O
27	O
year	O
old	O
male	O
,	O
a	O
carrier	O
and	O
apparently	O
without	O
heart	O
disease	O
.	O
Previous	O
illnesses	O
No	O
known	O
drug	O
allergies	O
.	O
Toxic	O
habits	O
non	O
smoker	O
and	O
non	O
drinker	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
.	O
Fibromyalgia	O
.	O
Chronic	O
venous	O
insufficiency	O
in	O
lower	O
limbs	O
.	O
Cardiological	O
history	O
Dilated	O
cardiomyopathy	O
diagnosed	O
in	O
2007	O
.	O
Val26Ala	O
mutation	O
in	O
DME	O
in	O
heterozygosis	O
.	O
Last	O
transthoracic	O
echocardiogram	O
TTE	O
severe	O
LVSD	O
LVEF	O
27	O
,	O
right	O
ventricle	O
RV	O
with	O
mildly	O
depressed	O
systolic	O
function	O
,	O
severe	O
functional	O
MR	O
,	O
severe	O
functional	O
tricuspid	O
regurgitation	O
TR	O
.	O
Pattern	O
of	O
Pulmonary	O
hypertension	O
PH	O
at	O
least	O
moderate	O
.	O
Advanced	O
heart	O
failure	O
with	O
poor	O
prognostic	O
data	O
restrictive	O
filling	O
.	O
Ergospirometry	O
with	O
O2	O
consumption	O
of	O
10	O
.	O
8	O
ml	O
kg	O
min	O
56	O
of	O
predicted	O
theoretical	O
,	O
class	O
C	O
D	O
.	O
Refractory	O
congestion	O
with	O
need	O
for	O
high	O
dose	O
diuretics	O
.	O
Cardiorenal	O
syndrome	O
type	O
2	O
with	O
frequent	O
episodes	O
of	O
renal	O
function	O
deterioration	O
with	O
intolerance	O
to	O
neurohormonal	O
drugs	O
.	O
Persistently	O
elevated	O
biomarkers	O
despite	O
optimal	O
medical	O
treatment	O
.	O
NT	O
proBNP	O
7739	O
pg	O
ml	O
.	O
Left	O
bundle	O
branch	O
block	O
LBBB	O
with	O
implantation	O
of	O
Boston	O
ICD	O
resynchroniser	O
in	O
2013	O
in	O
primary	O
prevention	O
.	O
Events	O
related	O
to	O
ventricular	O
arrhythmias	O
one	O
episode	O
of	O
ventricular	O
tachycardia	O
VT	O
requiring	O
therapies	O
.	O
Paroxysmal	O
AF	O
.	O
Medication	O
bisoprolol	B-FARMACO
1	O
.	O
25	O
mg	O
one	O
tablet	O
every	O
12	O
hours	O
;	O
furosemide	B-FARMACO
40	O
mg	O
one	O
tablet	O
every	O
24	O
hours	O
;	O
torasemide	B-FARMACO
10	O
mg	O
one	O
tablet	O
every	O
8	O
hours	O
;	O
levosulpiride	B-FARMACO
25	O
mg	O
every	O
8	O
hours	O
;	O
lormetazepam	B-FARMACO
1	O
mg	O
at	O
dinner	O
;	O
omeprazole	B-FARMACO
20	O
mg	O
at	O
breakfast	O
;	O
sintrom	B-FARMACO
4	O
mg	O
as	O
prescribed	O
.	O
Present	O
illness	O
60	O
year	O
old	O
woman	O
with	O
the	O
previously	O
described	O
history	O
,	O
who	O
in	O
the	O
last	O
year	O
required	O
admission	O
on	O
three	O
occasions	O
due	O
to	O
HF	O
and	O
low	O
cardiac	O
output	O
,	O
requiring	O
levosimendan	B-FARMACO
perfusion	O
and	O
intensive	O
diuretic	O
treatment	O
with	O
good	O
response	O
.	O
After	O
three	O
attempts	O
at	O
titration	O
,	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
was	O
discontinued	O
due	O
to	O
progressive	O
deterioration	O
of	O
renal	O
function	O
up	O
to	O
Cr	O
3	O
.	O
18	O
mg	O
dl	O
and	O
GFR	O
20	O
ml	O
min	O
.	O
In	O
view	O
of	O
the	O
poor	O
prognosis	O
data	O
,	O
a	O
pre	O
transplant	O
study	O
was	O
started	O
at	O
his	O
reference	O
centre	O
and	O
he	O
was	O
transferred	O
to	O
our	O
centre	O
to	O
assess	O
treatment	O
options	O
.	O
On	O
admission	O
to	O
our	O
centre	O
she	O
was	O
clinically	O
and	O
haemodynamically	O
stable	O
with	O
no	O
evidence	O
of	O
low	O
cardiac	O
output	O
.	O
Currently	O
in	O
NYHA	O
functional	O
class	O
FC	O
III	O
.	O
He	O
climbed	O
two	O
flights	O
of	O
stairs	O
without	O
dyspnoea	O
,	O
no	O
orthopnoea	O
,	O
bendopnoea	O
,	O
DPN	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
limbs	O
,	O
no	O
increase	O
in	O
abdominal	O
perimeter	O
,	O
no	O
weight	O
gain	O
weight	O
68	O
kg	O
and	O
no	O
decrease	O
in	O
diuresis	O
rate	O
since	O
discharge	O
from	O
the	O
last	O
admission	O
a	O
month	O
ago	O
.	O
Physical	O
examination	O
Systolic	O
blood	O
pressure	O
SBP	O
85	O
mmHg	O
,	O
diastolic	O
blood	O
pressure	O
DBP	O
48	O
mmHg	O
,	O
mean	O
arterial	O
blood	O
pressure	O
MAP	O
57	O
mmHg	O
,	O
heart	O
rate	O
HR	O
61	O
bpm	O
,	O
SpO2	O
96	O
.	O
Temperature	O
35	O
.	O
4	O
o	O
C	O
.	O
Weight	O
68	O
kg	O
.	O
Conscious	O
,	O
alert	O
and	O
oriented	O
.	O
Good	O
general	O
condition	O
.	O
Well	O
perfused	O
.	O
PVC	O
Normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
systolic	O
murmur	O
II	O
III	O
VI	O
in	O
tricuspid	O
and	O
mitral	O
focus	O
,	O
3R	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
VCM	O
without	O
added	O
noise	O
.	O
Abdomen	O
RHA	O
,	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
no	O
masses	O
or	O
megaliths	O
.	O
No	O
signs	O
of	O
peritonism	O
.	O
Lower	O
limbs	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Pedial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
CBC	O
red	O
cells	O
4	O
.	O
01	O
xmill	O
μl	O
,	O
haemoglobin	O
11	O
.	O
5	O
g	O
dl	O
,	O
haematocrit	O
34	O
.	O
2	O
,	O
MCV	O
85	O
.	O
3	O
fl	O
,	O
MCH	O
28	O
.	O
7	O
pg	O
,	O
MCHC	O
33	O
.	O
6	O
g	O
dl	O
,	O
RDW	O
17	O
.	O
0	O
,	O
platelets	O
141	O
x1000	O
μl	O
,	O
MPV	O
10	O
.	O
2	O
fl	O
,	O
leukocytes	O
6	O
.	O
3	O
x1000	O
μl	O
,	O
neutrophils	O
3	O
.	O
9	O
x1000	O
μl	O
,	O
neutrophils	O
62	O
.	O
1	O
,	O
lymphocytes	O
1	O
.	O
6	O
x1000	O
μl	O
,	O
lymphocytes	O
25	O
.	O
2	O
,	O
monocytes	O
0	O
.	O
4	O
x1000	O
μl	O
,	O
monocytes	O
6	O
.	O
3	O
,	O
eosinophils	O
0	O
.	O
4	O
x1000	O
μl	O
,	O
eosinophils	O
5	O
.	O
7	O
,	O
basophils	O
0	O
.	O
0	O
x1000	O
μl	O
,	O
basophils	O
0	O
.	O
7	O
.	O
Coagulation	O
prothrombin	O
activity	O
20	O
,	O
prothrombin	O
time	O
38	O
.	O
0	O
sec	O
,	O
INR	O
lab	O
3	O
.	O
34	O
,	O
TTP	O
41	O
sec	O
,	O
fibrinogen	O
derivative	O
370	O
mg	O
dl	O
.	O
Biochemistry	O
14	O
08	O
2019	O
creatinine	O
1	O
.	O
77	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
ckd	O
epi	O
31	O
ml	O
min	O
1	O
.	O
73m	O
,	O
sodium	O
144	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
68	O
mEq	O
l	O
,	O
chlorine	O
103	O
mEq	O
l	O
,	O
calcium	O
9	O
.	O
1	O
mg	O
dl	O
,	O
ALT	O
GPT	O
16	O
U	O
l	O
,	O
AST	O
GOT	O
17	O
U	O
l	O
,	O
gamma	O
GT	O
55	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
58	O
U	O
l	O
,	O
bilirubin	O
1	O
.	O
1	O
mg	O
dl	O
,	O
CK	O
31	O
U	O
l	O
,	O
C	O
reactive	O
protein	O
0	O
.	O
16	O
mg	O
dl	O
.	O
NT	O
proBNP	O
7051	O
pg	O
ml	O
.	O
Iron	O
profile	O
ferritin	O
103	O
ng	O
ml	O
,	O
iron	O
49	O
μg	O
dl	O
,	O
transferrin	O
249	O
mg	O
dl	O
,	O
transferrin	O
saturation	O
14	O
.	O
0	O
,	O
TIBC	O
351	O
μg	O
dl	O
.	O
Glycaemic	O
profile	O
glycated	O
Hb	O
DCCT	O
5	O
.	O
7	O
,	O
glycated	O
Hb	O
IFCC	O
38	O
.	O
8	O
mmol	O
mol	O
.	O
Lipid	O
profile	O
cholesterol	O
139	O
mg	O
dl	O
,	O
triglycerides	O
74	O
mg	O
dl	O
,	O
HDL	O
43	O
mg	O
dl	O
,	O
LDL	O
Friedewald	O
estimation	O
81	O
mg	O
dl	O
,	O
LDL	O
HDL	O
ratio	O
1	O
,	O
90	O
,	O
cholesterol	O
HDL	O
ratio	O
3	O
,	O
25	O
.	O
Chest	O
X	O
ray	O
increased	O
cardiothoracic	O
index	O
CTI	O
,	O
vascular	O
redistribution	O
.	O
ICD	O
CRT	O
generator	O
in	O
the	O
left	O
pectoral	O
region	O
with	O
electrocatheters	O
normally	O
positioned	O
in	O
the	O
RA	O
,	O
RV	O
and	O
coronary	O
sinus	O
.	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
with	O
ventricular	O
stimulation	O
at	O
70	O
bpm	O
.	O
Isolated	O
monomorphic	O
ventricular	O
extrasystoles	O
.	O
Paced	O
QRS	O
of	O
160	O
ms	O
.	O
Echocardiogram	O
20	O
8	O
2019	O
left	O
ventricle	O
LV	O
dilated	O
,	O
remodelled	O
,	O
with	O
severe	O
systolic	O
dysfunction	O
LVEF	O
24	O
.	O
Elevated	O
filling	O
pressures	O
.	O
Reduced	O
stroke	O
volume	O
.	O
Right	O
ventricle	O
RV	O
slightly	O
dilated	O
with	O
mild	O
systolic	O
dysfunction	O
.	O
Severe	O
functional	O
mitral	O
regurgitation	O
MR	O
.	O
Moderate	O
tricuspid	O
insufficiency	O
TI	O
III	O
IV	O
,	O
in	O
relation	O
to	O
annular	O
dilatation	O
and	O
with	O
electrode	O
.	O
Moderately	O
elevated	O
pulmonary	O
pressures	O
.	O
Mild	O
aortic	O
insufficiency	O
.	O
Left	O
catheterisation	O
right	O
dominance	O
.	O
Coronary	O
tree	O
without	O
significant	O
lesions	O
.	O
Right	O
catheterisation	O
moderate	O
postcapillary	O
pulmonary	O
hypertension	O
56	O
27	O
37	O
mmHg	O
.	O
Pressure	O
in	O
RA	O
slightly	O
elevated	O
8	O
mmHg	O
.	O
Elevated	O
PCP	O
27	O
mmHg	O
.	O
Cardiac	O
output	O
decreased	O
.	O
PVR	O
at	O
high	O
limit	O
.	O
CLINICAL	O
EVOLUTION	O
He	O
was	O
admitted	O
to	O
our	O
centre	O
on	O
13	O
08	O
2019	O
in	O
a	O
situation	O
of	O
haemodynamic	O
stability	O
with	O
no	O
data	O
of	O
low	O
CO	O
or	O
decompensated	O
HF	O
.	O
In	O
CF	O
III	O
of	O
the	O
NYHA	O
,	O
INTERMACS	O
6	O
.	O
Renal	O
function	O
stable	O
with	O
creatinine	O
around	O
1	O
.	O
7	O
mg	O
dl	O
with	O
good	O
diuresis	O
rate	O
under	O
his	O
usual	O
oral	O
diuretic	O
treatment	O
.	O
The	O
iron	O
profile	O
showed	O
ferritin	O
103	O
ng	O
ml	O
with	O
transferrin	O
saturation	O
14	O
.	O
0	O
and	O
haemoglobin	O
11	O
.	O
5	O
mg	O
dl	O
,	O
so	O
1000	O
mg	O
of	O
iron	B-FARMACO
carboxymaltose	I-FARMACO
were	O
administered	O
.	O
A	O
right	O
heart	O
catheterisation	O
was	O
performed	O
in	O
euvolemic	O
conditions	O
,	O
showing	O
slightly	O
elevated	O
filling	O
pressures	O
with	O
moderate	O
post	O
capillary	O
pulmonary	O
hypertension	O
with	O
decreased	O
CO	O
thermodilution	O
CO	O
3	O
.	O
41	O
l	O
min	O
CI	O
1	O
.	O
82	O
l	O
min	O
m	O
.	O
Fick	O
CO	O
4	O
.	O
1	O
l	O
min	O
IC	O
219	O
l	O
min	O
m2	O
with	O
PVR	O
at	O
the	O
high	O
limit	O
with	O
PWG	O
of	O
10	O
mmHg	O
.	O
The	O
patient	O
has	O
been	O
evaluated	O
by	O
the	O
familial	O
heart	O
disease	O
unit	O
as	O
a	O
carrier	O
of	O
the	O
Val26Ala	O
mutation	O
in	O
the	O
emerin	O
gene	O
in	O
heterozygosis	O
detected	O
in	O
a	O
Sanger	O
.	O
However	O
,	O
the	O
age	O
at	O
presentation	O
and	O
sex	O
raise	O
doubts	O
about	O
a	O
possible	O
secondhit	O
.	O
Moreover	O
,	O
the	O
family	O
history	O
is	O
also	O
inconsistent	O
with	O
the	O
finding	O
of	O
only	O
one	O
emerin	O
,	O
so	O
a	O
complete	O
genetic	O
panel	O
is	O
requested	O
.	O
The	O
genetic	O
study	O
by	O
NGS	O
panel	O
only	O
reports	O
the	O
previously	O
described	O
mutation	O
,	O
with	O
no	O
evidence	O
of	O
a	O
secondhit	O
.	O
In	O
this	O
context	O
,	O
it	O
is	O
possible	O
that	O
the	O
picture	O
corresponds	O
to	O
random	O
X	O
inactivation	O
with	O
involvement	O
possible	O
but	O
unlikely	O
in	O
a	O
heterozygous	O
female	O
.	O
For	O
the	O
moment	O
,	O
without	O
other	O
positive	O
results	O
,	O
it	O
is	O
considered	O
that	O
this	O
mutation	O
is	O
responsible	O
for	O
the	O
family	O
history	O
After	O
completing	O
the	O
pre	O
transplant	O
study	O
,	O
confirming	O
the	O
presence	O
of	O
data	O
on	O
advanced	O
heart	O
failure	O
,	O
and	O
given	O
the	O
absence	O
of	O
significant	O
comorbidity	O
only	O
stable	O
CKD	O
with	O
mild	O
proteinuria	O
in	O
probable	O
relation	O
to	O
type	O
2	O
cardiorenal	O
syndrome	O
on	O
23	O
08	O
2019	O
she	O
was	O
presented	O
at	O
the	O
multidisciplinary	O
session	O
and	O
included	O
on	O
the	O
elective	O
waiting	O
list	O
for	O
heart	O
transplant	O
.	O
One	O
month	O
later	O
,	O
the	O
patient	O
was	O
readmitted	O
with	O
decompensation	O
after	O
catarrhal	O
symptoms	O
sputum	O
culture	O
and	O
rhinovirus	O
negative	O
with	O
increased	O
dyspnoea	O
of	O
3	O
days	O
'	O
evolution	O
until	O
becoming	O
resting	O
and	O
marked	O
orthopnoea	O
without	O
peripheral	O
congestion	O
.	O
During	O
the	O
first	O
weeks	O
of	O
admission	O
,	O
he	O
presented	O
clinical	O
worsening	O
with	O
fine	O
B	O
lines	O
of	O
significant	O
size	O
in	O
the	O
lung	O
ultrasound	O
and	O
data	O
of	O
low	O
postprandial	O
output	O
.	O
For	O
all	O
these	O
reasons	O
,	O
and	O
after	O
optimising	O
diuretic	O
treatment	O
,	O
it	O
was	O
decided	O
to	O
start	O
dobutamine	B-FARMACO
at	O
low	O
doses	O
2	O
.	O
5	O
mg	O
with	O
evident	O
clinical	O
improvement	O
,	O
which	O
was	O
maintained	O
for	O
a	O
week	O
.	O
Subsequently	O
,	O
she	O
received	O
a	O
new	O
course	O
of	O
levosimendan	B-FARMACO
.	O
Given	O
the	O
patient	O
's	O
evolution	O
and	O
the	O
presence	O
of	O
severe	O
MI	O
,	O
she	O
was	O
assessed	O
for	O
MitraClip	O
implantation	O
,	O
which	O
was	O
performed	O
without	O
incident	O
on	O
16	O
10	O
2019	O
,	O
leaving	O
mild	O
to	O
moderate	O
MI	O
.	O
After	O
this	O
,	O
intravenous	O
diuretics	O
were	O
withdrawn	O
and	O
the	O
patient	O
was	O
discharged	O
euvolaemic	O
,	O
without	O
orthopnoea	O
,	O
in	O
CF	O
II	O
and	O
having	O
observed	O
a	O
decrease	O
in	O
NT	O
proBNP	O
.	O
ARA	B-FARMACO
II	I-FARMACO
was	O
reintroduced	O
at	O
low	O
doses	O
with	O
good	O
clinical	O
and	O
analytical	O
tolerance	O
.	O
At	O
discharge	O
,	O
treatment	O
was	O
as	O
follows	O
candesartan	B-FARMACO
4	O
mg	O
half	O
a	O
tablet	O
at	O
dinner	O
,	O
hydralazine	B-FARMACO
25	O
mg	O
every	O
8	O
hours	O
,	O
furosemide	B-FARMACO
40	O
mg	O
one	O
tablet	O
at	O
breakfast	O
and	O
another	O
at	O
lunch	O
with	O
a	O
flexible	O
regimen	O
,	O
spironolactone	B-FARMACO
100	O
mg	O
every	O
24	O
hours	O
at	O
lunch	O
,	O
levosulpiride	B-FARMACO
25	O
mg	O
every	O
8	O
hours	O
,	O
lormetazepam	B-FARMACO
1	O
mg	O
one	O
tablet	O
at	O
dinner	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
one	O
capsule	O
at	O
breakfast	O
,	O
Mastical	O
D	O
1	O
.	O
500	O
1	O
,	O
000U	O
one	O
tablet	O
every	O
24	O
hours	O
and	O
sintrom	B-FARMACO
4	O
mg	O
according	O
to	O
INR	O
control	O
.	O
DIAGNOSIS	O
Main	O
diagnosis	O
Advanced	O
chronic	O
heart	O
failure	O
CF	O
III	O
NYHA	O
INTERMACS	O
6	O
due	O
to	O
familial	O
dilated	O
cardiomyopathy	O
Val26Ala	O
mutation	O
in	O
the	O
EMD	O
gene	O
in	O
heterozygosis	O
with	O
severe	O
LVSD	O
LVEF	O
24	O
and	O
included	O
in	O
elective	O
waiting	O
list	O
for	O
heart	O
transplantation	O
.	O
Other	O
diagnoses	O
Severe	O
functional	O
mitral	O
insufficiency	O
and	O
moderate	O
functional	O
tricuspid	O
insufficiency	O
.	O
MitraClip	O
holder	O
.	O
Moderate	O
postcapillary	O
pulmonary	O
hypertension	O
.	O
Carrier	O
of	O
ICD	O
CRT	O
Boston	O
in	O
primary	O
prevention	O
.	O
NSMVT	O
on	O
Holter	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
.	O
Chronic	O
renal	O
failure	O
G3A2	O
due	O
to	O
cardiorenal	O
syndrome	O
type	O
2	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
70	O
year	O
old	O
man	O
attended	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
due	O
to	O
dyspnoea	O
.	O
History	O
Cardiovascular	O
risk	O
factors	O
no	O
arterial	O
hypertension	O
,	O
no	O
diabetes	O
mellitus	O
,	O
no	O
dyslipidaemia	O
.	O
Active	O
smoker	O
of	O
1	O
pack	O
a	O
day	O
since	O
the	O
age	O
of	O
20	O
50	O
packs	O
year	O
.	O
Obesity	O
grade	O
II	O
body	O
mass	O
index	O
BMI	O
37	O
kg	O
m2	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
Moderate	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
chronic	O
bronchitis	O
type	O
FEV1	O
51	O
of	O
predicted	O
,	O
non	O
exacerbating	O
.	O
Follow	O
up	O
in	O
outpatient	O
pulmonology	O
department	O
.	O
Stage	O
IIIb	O
colon	O
adenocarcinoma	O
p3T3N1M0	O
diagnosed	O
in	O
2015	O
,	O
treated	O
with	O
laparoscopic	O
right	O
colectomy	O
adjuvant	O
chemotherapy	O
with	O
5	B-FARMACO
fluoruracil	B-FARMACO
oxaliplatin	I-FARMACO
which	O
ended	O
in	O
2017	O
,	O
free	O
of	O
disease	O
with	O
normal	O
serial	O
colonoscopies	O
to	O
date	O
.	O
Benign	O
prostatic	O
hypertrophy	O
.	O
Usual	O
treatment	O
tamsulosin	B-FARMACO
solifenacin	I-FARMACO
0	O
.	O
4	O
6	O
mg	O
,	O
1	O
tablet	O
per	O
day	O
.	O
Salmeterol	B-FARMACO
fluticasone	I-FARMACO
25	O
250	O
mcg	O
,	O
1	O
inhaled	O
capsule	O
per	O
day	O
.	O
Present	O
illness	O
Progressive	O
increase	O
in	O
baseline	O
dyspnoea	O
of	O
2	O
weeks	O
'	O
evolution	O
usual	O
CF	O
NYHA	O
II	O
,	O
in	O
the	O
context	O
of	O
bronchopathy	O
until	O
presenting	O
dyspnoea	O
at	O
rest	O
,	O
associated	O
with	O
orthopnoea	O
that	O
forced	O
him	O
to	O
sleep	O
in	O
a	O
sitting	O
position	O
,	O
oedematisation	O
of	O
the	O
lower	O
limbs	O
and	O
subjective	O
decrease	O
in	O
the	O
volume	O
of	O
diuresis	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
137	O
70	O
mmHg	O
,	O
heart	O
rate	O
HR	O
90	O
bpm	O
,	O
Sat	O
2O89	O
on	O
room	O
air	O
.	O
Jugular	O
venous	O
pressure	O
at	O
12	O
cm	O
H2O	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
with	O
a	O
systolic	O
murmur	O
in	O
mitral	O
focus	O
III	O
VI	O
,	O
radiating	O
to	O
the	O
axilla	O
.	O
Pulmonary	O
auscultation	O
bilateral	O
crackles	O
in	O
midfields	O
and	O
bases	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
no	O
masses	O
or	O
megaliths	O
.	O
Hepatojugular	O
reflux	O
positive	O
Extremities	O
oedema	O
up	O
to	O
the	O
knees	O
,	O
peripheral	O
pulses	O
preserved	O
and	O
symmetrical	O
,	O
no	O
signs	O
of	O
phlebitis	O
.	O
Echocardioscopy	O
performed	O
at	O
the	O
bedside	O
in	O
the	O
emergency	O
department	O
revealed	O
dilatation	O
and	O
biventricular	O
dysfunction	O
,	O
as	O
well	O
as	O
significant	O
mitral	O
regurgitation	O
,	O
so	O
it	O
was	O
decided	O
to	O
admit	O
the	O
patient	O
for	O
stabilisation	O
and	O
study	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
.	O
Narrow	O
QRS	O
,	O
axis	O
at	O
30o	O
.	O
ST	O
segment	O
depression	O
of	O
1	O
mm	O
from	O
V3	O
to	O
V5	O
with	O
negative	O
T	O
wave	O
.	O
Asymmetric	O
negative	O
T	O
wave	O
in	O
lateral	O
face	O
as	O
a	O
sign	O
of	O
systolic	O
overload	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
posteroanterior	O
projection	O
.	O
Increased	O
cardiothoracic	O
index	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
Prominent	O
pulmonary	O
hilae	O
.	O
Signs	O
of	O
vascular	O
redistribution	O
to	O
upper	O
fields	O
.	O
Laboratory	O
tests	O
on	O
admission	O
Haemoglobin	O
14	O
.	O
7	O
g	O
dl	O
,	O
MCV	O
89	O
fl	O
,	O
MCH	O
28	O
.	O
3	O
pg	O
,	O
leukocytes	O
5	O
.	O
5	O
x	O
10	O
9	O
l	O
,	O
platelets	O
183	O
x	O
10	O
9	O
l	O
.	O
Haemostasis	O
I	O
.	O
Quick	O
93	O
.	O
7	O
,	O
INR	O
1	O
.	O
1	O
,	O
TTPa	O
ratio	O
0	O
.	O
95	O
.	O
Biochemistry	O
glucose	O
110	O
mg	O
dl	O
,	O
HbA1c	O
5	O
.	O
6	O
,	O
sodium	O
141	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
9	O
mEq	O
l	O
,	O
creatinine	O
1	O
mg	O
dl	O
,	O
urea	O
41	O
mg	O
dl	O
,	O
NT	O
proBNP	O
6	O
,	O
789	O
pg	O
ml	O
,	O
LDL	O
C	O
92	O
mg	O
dl	O
.	O
Myocardial	O
damage	O
biomarker	O
curve	O
hsTnI	O
,	O
normal	O
19	O
.	O
8	O
ng	O
l	O
32	O
.	O
6	O
37	O
.	O
8	O
35	O
.	O
4	O
ng	O
l	O
.	O
Echocardiogram	O
moderately	O
dilated	O
left	O
ventricle	O
,	O
with	O
normal	O
thickness	O
.	O
Global	O
hypokinesia	O
,	O
with	O
LVEF	O
30	O
.	O
Transmitral	O
filling	O
type	O
relaxation	O
disturbance	O
with	O
estimated	O
normal	O
left	O
ventricular	O
end	O
diastolic	O
pressures	O
E	O
E	O
'	O
7	O
.	O
Severely	O
dilated	O
left	O
atrium	O
.	O
Moderate	O
functional	O
mitral	O
regurgitation	O
with	O
ORE	O
by	O
PISA	O
of	O
0	O
.	O
2	O
cm	O
.	O
Sclerosed	O
,	O
normofunctioning	O
aortic	O
valve	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Right	O
ventricle	O
of	O
normal	O
diameters	O
and	O
mild	O
ventricular	O
dysfunction	O
TAPSE	O
15	O
mm	O
.	O
Mild	O
tricuspid	O
insufficiency	O
that	O
allows	O
estimating	O
PSAP	O
of	O
60	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
19	O
mm	O
with	O
respiratory	O
variation	O
50	O
.	O
Coronary	O
angiography	O
1	O
calcified	O
left	O
main	O
coronary	O
artery	O
with	O
20	O
30	O
stenosis	O
distally	O
.	O
LAD	O
with	O
severe	O
proximal	O
and	O
middle	O
disease	O
with	O
stenosis	O
around	O
80	O
.	O
Borderline	O
lesion	O
in	O
the	O
ostial	O
circumflex	O
artery	O
50	O
and	O
significant	O
lesion	O
in	O
the	O
first	O
marginal	O
branch	O
.	O
Right	O
coronary	O
artery	O
with	O
70	O
lesion	O
in	O
the	O
proximal	O
segment	O
and	O
50	O
at	O
the	O
level	O
of	O
the	O
crux	O
cordis	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
left	O
ventricle	O
with	O
increased	O
volumes	O
VTD	O
107	O
ml	O
m	O
,	O
VTS	O
75	O
ml	O
m	O
with	O
mild	O
eccentric	O
hypertrophy	O
IMVI	O
97	O
g	O
m2	O
,	O
generalised	O
global	O
hypokinesia	O
and	O
severe	O
depression	O
of	O
global	O
systolic	O
function	O
LVEF	O
30	O
.	O
No	O
myocardial	O
oedema	O
is	O
seen	O
on	O
STIR	O
sequences	O
.	O
Non	O
dilated	O
right	O
ventricle	O
RVOT	O
58	O
ml	O
m	O
,	O
STV	O
33	O
ml	O
m	O
with	O
slightly	O
depressed	O
global	O
systolic	O
function	O
due	O
to	O
generalised	O
hypokinesia	O
RVEF	O
43	O
.	O
Aortic	O
root	O
diameters	O
at	O
the	O
upper	O
limit	O
of	O
normal	O
sinus	O
portion	O
38	O
mm	O
with	O
moderate	O
dilatation	O
of	O
the	O
tubular	O
portion	O
of	O
47	O
mm	O
.	O
Fallen	O
32	O
mm	O
.	O
Descending	O
aorta	O
29	O
mm	O
.	O
Left	O
atrium	O
slightly	O
dilated	O
maximum	O
diameter	O
50	O
mm	O
,	O
area	O
15	O
cm2	O
m2	O
.	O
Increased	O
pulmonary	O
vascular	O
resistance	O
,	O
estimated	O
at	O
6	O
UW	O
mean	O
pulmonary	O
velocity	O
8	O
.	O
4	O
cm	O
sec	O
.	O
No	O
perfusion	O
defects	O
detected	O
at	O
rest	O
.	O
Necrosis	O
and	O
viability	O
detection	O
study	O
presence	O
of	O
late	O
gadolinium	O
enhancement	O
suggestive	O
of	O
linear	O
intramyocardial	O
fibrosis	O
at	O
septal	O
anterior	O
basal	O
and	O
medial	O
level	O
and	O
focal	O
at	O
septal	O
inferior	O
and	O
inferior	O
basal	O
and	O
medial	O
level	O
,	O
at	O
the	O
LV	O
and	O
RV	O
junction	O
.	O
Coronary	O
angiography	O
2	O
videos	O
5	O
7	O
Impella	O
device	O
is	O
positioned	O
by	O
right	O
femoral	O
access	O
.	O
Angiography	O
is	O
performed	O
via	O
left	O
radial	O
access	O
.	O
Severe	O
LAD	O
lesions	O
are	O
pre	O
dilated	O
and	O
everolimus	B-FARMACO
eluting	O
drug	O
eluting	O
stents	O
3	O
x	O
48	O
mm	O
and	O
3	O
.	O
5	O
x	O
18	O
mm	O
are	O
implanted	O
.	O
The	O
distal	O
circumflex	O
guidewire	O
was	O
crossed	O
and	O
IVUS	O
aostium	O
was	O
performed	O
,	O
detecting	O
a	O
luminal	O
area	O
6	O
mm2	O
and	O
therefore	O
not	O
significant	O
.	O
The	O
lesion	O
was	O
treated	O
in	O
the	O
first	O
obtuse	O
marginal	O
area	O
with	O
a	O
constant	O
everolimus	B-FARMACO
releasing	O
drug	O
2	O
.	O
5	O
x	O
33	O
mm	O
with	O
good	O
results	O
.	O
The	O
guidewire	O
was	O
crossed	O
to	O
the	O
distal	O
DC	O
,	O
predilatation	O
of	O
the	O
lesion	O
in	O
the	O
proximal	O
segment	O
and	O
implantation	O
of	O
a	O
3	O
.	O
5	O
x	O
15	O
mm	O
everolimus	B-FARMACO
eluting	O
drug	O
eluting	O
stent	O
.	O
Good	O
result	O
.	O
Finally	O
,	O
the	O
Impella	O
device	O
is	O
removed	O
according	O
to	O
protocol	O
.	O
Femoral	O
haemostasis	O
with	O
Proglide	O
intravascular	O
suture	O
device	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
admission	O
to	O
the	O
cardiology	O
ward	O
,	O
intensive	O
depletive	O
treatment	O
was	O
started	O
,	O
with	O
40	O
mg	O
of	O
i	O
.	O
v	O
.	O
furosemide	B-FARMACO
every	O
6	O
hours	O
,	O
with	O
excellent	O
response	O
to	O
the	O
same	O
,	O
with	O
dyspnoea	O
disappearing	O
at	O
rest	O
and	O
progressive	O
toleration	O
of	O
ambulation	O
without	O
incident	O
.	O
A	O
regulated	O
echocardiogram	O
confirmed	O
the	O
presence	O
of	O
severe	O
left	O
ventricular	O
dysfunction	O
,	O
so	O
treatment	O
was	O
started	O
with	O
enalapril	B-FARMACO
2	O
.	O
5	O
mg	O
daily	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
daily	O
and	O
spironolactone	B-FARMACO
25	O
mg	O
daily	O
with	O
good	O
tolerance	O
.	O
As	O
part	O
of	O
the	O
aetiological	O
study	O
of	O
the	O
ventricular	O
dysfunction	O
,	O
elective	O
coronary	O
angiography	O
was	O
performed	O
,	O
which	O
revealed	O
3	O
vessel	O
disease	O
,	O
with	O
a	O
SINTAX	O
score	O
of	O
26	O
.	O
The	O
case	O
was	O
presented	O
at	O
a	O
medical	O
surgical	O
session	O
.	O
Given	O
the	O
patient	O
's	O
comorbidities	O
moderate	O
severe	O
chronic	O
obstructive	O
pulmonary	O
disease	O
COPD	O
,	O
obesity	O
,	O
severe	O
ventricular	O
dysfunction	O
,	O
STS	O
score	O
3	O
.	O
7	O
,	O
EuroScore	O
II	O
of	O
6	O
.	O
7	O
,	O
despite	O
the	O
SINTAX	O
score	O
favourable	O
to	O
surgical	O
revascularisation	O
,	O
it	O
was	O
decided	O
to	O
perform	O
percutaneous	O
revascularisation	O
assisted	O
with	O
Impella	O
device	O
as	O
the	O
procedure	O
was	O
considered	O
high	O
risk	O
,	O
to	O
be	O
performed	O
on	O
an	O
outpatient	O
basis	O
.	O
The	O
patient	O
was	O
discharged	O
with	O
the	O
following	O
medical	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
per	O
day	O
,	O
enalapril	B-FARMACO
2	O
.	O
5	O
mg	O
per	O
day	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
per	O
day	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
per	O
day	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
tablet	O
at	O
breakfast	O
and	O
lunch	O
for	O
2	O
weeks	O
followed	O
by	O
1	O
tablet	O
at	O
breakfast	O
,	O
tamsulosin	B-FARMACO
solifenacin	I-FARMACO
0	O
.	O
4	O
6	O
mg	O
1	O
tablet	O
per	O
day	O
,	O
salmeterol	B-FARMACO
fluticasone	I-FARMACO
25	O
250	O
mcg	O
1	O
inhaled	O
capsule	O
per	O
day	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
per	O
day	O
,	O
pantoprazole	B-FARMACO
20	O
mg	O
per	O
day	O
.	O
The	O
importance	O
of	O
weight	O
loss	O
,	O
physical	O
exercise	O
and	O
smoking	O
cessation	O
was	O
stressed	O
.	O
She	O
consulted	O
the	O
emergency	O
department	O
one	O
week	O
after	O
discharge	O
due	O
to	O
palpitations	O
lasting	O
2	O
hours	O
,	O
with	O
new	O
onset	O
paroxysmal	O
atrial	O
fibrillation	O
detected	O
on	O
electrocardiogram	O
.	O
A	O
rhythm	O
control	O
strategy	O
was	O
followed	O
,	O
achieving	O
pharmacological	O
cardioversion	O
after	O
an	O
intravenous	O
bolus	O
of	O
300	O
mg	O
of	O
amiodarone	B-FARMACO
.	O
At	O
discharge	O
,	O
treatment	O
with	O
apixaban	B-FARMACO
5	O
mg	O
every	O
12	O
hours	O
was	O
added	O
due	O
to	O
CHADs	O
VASc	O
of	O
3	O
and	O
oral	O
amiodarone	B-FARMACO
200	O
mg	O
5	O
days	O
a	O
week	O
.	O
Subsequently	O
,	O
percutaneous	O
revascularisation	O
was	O
programmed	O
with	O
mechanical	O
assistance	O
with	O
Impella	O
CP	O
device	O
,	O
which	O
was	O
performed	O
without	O
incident	O
.	O
He	O
received	O
clopidogrel	B-FARMACO
300	O
mg	O
the	O
night	O
before	O
admission	O
.	O
After	O
24	O
hours	O
of	O
hospitalisation	O
,	O
he	O
was	O
discharged	O
with	O
the	O
addition	O
of	O
clopidogrel	B-FARMACO
75	O
mg	O
per	O
day	O
to	O
the	O
aforementioned	O
treatment	O
.	O
After	O
1	O
month	O
of	O
triple	O
therapy	O
ASA	B-FARMACO
clopidogrel	I-FARMACO
apixaban	I-FARMACO
,	O
treatment	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
was	O
discontinued	O
.	O
Six	O
months	O
after	O
revascularisation	O
,	O
the	O
patient	O
attended	O
a	O
clinical	O
control	O
visit	O
,	O
and	O
was	O
found	O
to	O
be	O
practically	O
asymptomatic	O
for	O
dyspnoea	O
or	O
other	O
symptoms	O
of	O
heart	O
failure	O
,	O
in	O
NYHA	O
functional	O
class	O
I	O
.	O
He	O
is	O
currently	O
awaiting	O
echocardiography	O
.	O
He	O
is	O
currently	O
awaiting	O
a	O
follow	O
up	O
echocardiogram	O
.	O
No	O
further	O
visits	O
to	O
the	O
emergency	O
department	O
were	O
required	O
due	O
to	O
decompensation	O
.	O
DIAGNOSIS	O
Acute	O
heart	O
failure	O
due	O
to	O
ischaemic	O
dilated	O
cardiomyopathy	O
with	O
severe	O
left	O
ventricular	O
dysfunction	O
LVEF	O
by	O
cardiac	O
MRI	O
30	O
.	O
Three	O
vessel	O
coronary	O
artery	O
disease	O
with	O
a	O
SINTAX	O
score	O
of	O
26	O
points	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
CHADs	O
VASc	O
3	O
,	O
HAS	O
BLED	O
2	O
.	O
High	O
risk	O
device	O
assisted	O
PCI	O
with	O
Impella	O
CP	O
device	O
with	O
complete	O
revascularisation	O
proximal	O
LAD	O
,	O
mid	O
LAD	O
,	O
distal	O
DC	O
and	O
1OM	O
with	O
excellent	O
angiographic	O
outcome	O
.	O
Moderate	O
COPD	O
phenotype	O
chronic	O
bronchitis	O
.	O
Smoking	O
on	O
admission	O
.	O
Obesity	O
.	O

56	O
year	O
old	O
patient	O
with	O
a	O
history	O
of	O
type	O
2	O
diabetes	O
and	O
obesity	O
.	O
He	O
was	O
admitted	O
for	O
several	O
weeks	O
of	O
fever	O
,	O
chills	O
,	O
general	O
malaise	O
,	O
vomiting	O
and	O
diffuse	O
pain	O
in	O
the	O
thorax	O
and	O
lumbar	O
region	O
.	O
On	O
examination	O
,	O
the	O
general	O
condition	O
was	O
acceptable	O
,	O
temperature	O
39oC	O
,	O
and	O
a	O
systolic	O
murmur	O
of	O
intensity	O
II	O
VI	O
in	O
the	O
mitral	O
focus	O
radiating	O
to	O
the	O
left	O
axilla	O
,	O
while	O
the	O
rest	O
of	O
the	O
examination	O
was	O
normal	O
.	O
Blood	O
tests	O
showed	O
white	O
blood	O
cells	O
11	O
,	O
400	O
mm3	O
69	O
granulocytes	O
,	O
platelets	O
92	O
,	O
000	O
mm3	O
,	O
erythrocyte	O
sedimentation	O
rate	O
52mm	O
in	O
the	O
first	O
hour	O
,	O
glucose	O
281	O
mg	O
dl	O
,	O
triglycerides	O
279	O
mg	O
dl	O
and	O
alkaline	O
phosphatase	O
322	O
IU	O
l	O
,	O
while	O
the	O
rest	O
of	O
the	O
blood	O
count	O
,	O
biochemistry	O
and	O
coagulation	O
were	O
normal	O
.	O
In	O
the	O
urine	O
,	O
100	O
mg	O
dl	O
protein	O
,	O
250	O
mg	O
dl	O
glucose	O
and	O
25	O
red	O
blood	O
cells	O
per	O
field	O
were	O
detected	O
in	O
the	O
sediment	O
.	O
The	O
electrocardiogram	O
showed	O
an	O
anterior	O
haemiblockage	O
as	O
the	O
only	O
abnormality	O
.	O
Chest	O
and	O
spine	O
X	O
rays	O
,	O
abdominal	O
ultrasound	O
and	O
computed	O
tomography	O
were	O
normal	O
.	O
Echocardiography	O
shows	O
an	O
unstructured	O
mitral	O
valve	O
with	O
prolapse	O
of	O
both	O
leaflets	O
.	O
Blood	O
cultures	O
showed	O
Streptococcus	O
agalactiae	O
,	O
so	O
treatment	O
was	O
started	O
with	O
cefotaxime	B-FARMACO
at	O
a	O
dose	O
of	O
1	O
gram	O
every	O
8	O
hours	O
intravenously	O
.	O
Initially	O
there	O
was	O
a	O
good	O
clinical	O
response	O
,	O
with	O
disappearance	O
of	O
the	O
fever	O
,	O
but	O
5	O
days	O
after	O
starting	O
treatment	O
the	O
patient	O
began	O
to	O
experience	O
palpitations	O
,	O
dyspnoea	O
and	O
orthopnoea	O
,	O
and	O
the	O
fever	O
reappeared	O
.	O
At	O
this	O
time	O
,	O
the	O
systolic	O
murmur	O
was	O
IV	O
VI	O
,	O
and	O
there	O
was	O
abundant	O
crackles	O
in	O
both	O
thoracic	O
bases	O
.	O
New	O
chest	O
X	O
rays	O
showed	O
changes	O
highly	O
suggestive	O
of	O
acute	O
pulmonary	O
oedema	O
.	O
Follow	O
up	O
echocardiography	O
revealed	O
further	O
mitral	O
valve	O
destructuring	O
,	O
vegetations	O
on	O
both	O
mitral	O
valve	O
leaflets	O
and	O
severe	O
mitral	O
regurgitation	O
.	O
Despite	O
intensive	O
treatment	O
with	O
diuretics	O
,	O
vasodilators	O
,	O
synotropic	O
agents	O
,	O
high	O
dose	O
penicillin	B-FARMACO
and	O
gentamicin	B-FARMACO
,	O
she	O
progressed	O
unfavourably	O
,	O
developed	O
third	O
degree	O
atrioventricular	O
block	O
,	O
requiring	O
the	O
implantation	O
of	O
a	O
temporary	O
pacemaker	O
,	O
and	O
died	O
about	O
12	O
hours	O
after	O
the	O
onset	O
of	O
dyspnoea	O
,	O
while	O
preparations	O
were	O
being	O
made	O
for	O
surgical	O
treatment	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
46	O
year	O
old	O
female	O
,	O
civil	O
servant	O
,	O
with	O
no	O
illnesses	O
of	O
interest	O
or	O
regular	O
medication	O
.	O
Never	O
smoked	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
or	O
consumption	O
of	O
alcohol	O
or	O
other	O
toxic	O
substances	O
.	O
No	O
family	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
Intervened	O
tonsillectomy	O
in	O
infancy	O
,	O
caesarean	O
section	O
and	O
hysterectomy	O
.	O
Cardiovascular	O
asymptomatic	O
until	O
the	O
previous	O
2	O
weeks	O
,	O
who	O
begins	O
with	O
moderate	O
exertional	O
dyspnoea	O
that	O
prevents	O
her	O
from	O
carrying	O
out	O
her	O
normal	O
life	O
,	O
together	O
with	O
orthopnoea	O
,	O
oliguria	O
and	O
the	O
appearance	O
of	O
progressive	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
At	O
all	O
times	O
he	O
denies	O
chest	O
pain	O
,	O
palpitations	O
,	O
dizziness	O
or	O
syncope	O
.	O
Neither	O
did	O
he	O
present	O
febrile	O
syndrome	O
or	O
infectious	O
symptoms	O
.	O
Physical	O
examination	O
revealed	O
a	O
blood	O
pressure	O
of	O
130	O
60	O
mmHg	O
,	O
a	O
heart	O
rate	O
of	O
90	O
bpm	O
,	O
afebrile	O
and	O
eupneic	O
with	O
nasal	O
spectacles	O
at	O
2	O
bpm	O
.	O
On	O
auscultation	O
,	O
she	O
had	O
a	O
bibasal	O
crackles	O
and	O
a	O
diastolic	O
murmur	O
II	O
IV	O
at	O
mitral	O
level	O
with	O
an	O
occasional	O
"	O
plop	O
"	O
.	O
Abdomen	O
with	O
no	O
findings	O
and	O
lower	O
extremities	O
with	O
oedema	O
with	O
distal	O
fovea	O
,	O
with	O
no	O
evidence	O
of	O
venous	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
,	O
normal	O
PR	O
152	O
ms	O
with	O
bimodal	O
P	O
in	O
relation	O
to	O
left	O
atrial	O
enlargement	O
.	O
Narrow	O
QRS	O
with	O
normal	O
axis	O
without	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
with	O
discrete	O
vascular	O
redistribution	O
.	O
Analyses	O
Biochemistry	O
glucose	O
98	O
mg	O
dl	O
70	O
110	O
,	O
urea	O
16	O
mg	O
dl	O
10	O
50	O
,	O
creatinine	O
0	O
.	O
78	O
mg	O
dl	O
0	O
.	O
7	O
1	O
.	O
2	O
,	O
glomerular	O
filtration	O
rate	O
60	O
ml	O
min	O
MDRD	O
4	O
60	O
,	O
Na	O
144	O
mmol	O
l	O
135	O
145	O
,	O
K	O
3	O
.	O
9	O
mmol	O
l	O
3	O
.	O
5	O
5	O
.	O
1	O
.	O
ProBNP	O
2110	O
pg	O
ml	O
10	O
125	O
.	O
Normal	O
liver	O
function	O
tests	O
.	O
Thyroid	O
hormones	O
normal	O
.	O
CBC	O
leukocytes	O
9	O
,	O
400	O
cc	O
normal	O
formula	O
4	O
,	O
500	O
11	O
,	O
400	O
,	O
Hb	O
14	O
.	O
8	O
g	O
dl	O
13	O
.	O
2	O
16	O
.	O
8	O
,	O
platelets	O
211	O
,	O
000	O
157	O
,	O
000	O
334	O
,	O
000	O
.	O
Coagulation	O
INR	O
1	O
.	O
13	O
0	O
.	O
8	O
1	O
.	O
3	O
,	O
PT	O
82	O
70	O
120	O
,	O
aPTT	O
24	O
.	O
4s	O
24	O
.	O
8	O
40	O
.	O
3	O
.	O
PET	O
CT	O
scan	O
protocol	O
no	O
repletion	O
defects	O
in	O
the	O
pulmonary	O
trunk	O
or	O
main	O
or	O
segmental	O
branches	O
suggestive	O
of	O
thromboembolism	O
were	O
observed	O
.	O
A	O
well	O
defined	O
hypodense	O
mass	O
measuring	O
5	O
x	O
4	O
cm	O
located	O
at	O
the	O
level	O
of	O
the	O
left	O
atrium	O
,	O
which	O
crosses	O
the	O
valve	O
towards	O
the	O
left	O
ventricle	O
,	O
is	O
striking	O
,	O
ruling	O
out	O
myxoma	O
or	O
large	O
thrombus	O
.	O
It	O
is	O
accompanied	O
by	O
bilateral	O
pleural	O
effusions	O
and	O
a	O
linear	O
interstitial	O
pattern	O
,	O
with	O
thickening	O
of	O
interlobular	O
septa	O
compatible	O
with	O
heart	O
failure	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
LV	O
of	O
normal	O
size	O
and	O
thickness	O
,	O
with	O
preserved	O
LVEF	O
60	O
and	O
no	O
segmental	O
contractility	O
abnormalities	O
.	O
Right	O
ventricle	O
RV	O
of	O
normal	O
size	O
and	O
function	O
TAPSE	O
20	O
mm	O
.	O
Moderate	O
left	O
atrial	O
dilatation	O
with	O
a	O
large	O
round	O
heterogeneous	O
mass	O
measuring	O
5	O
x	O
3	O
cm	O
,	O
adhered	O
to	O
the	O
interatrial	O
septum	O
which	O
in	O
diastole	O
is	O
introduced	O
through	O
the	O
mitral	O
annulus	O
producing	O
a	O
moderate	O
severe	O
stenosis	O
maximum	O
gradient	O
of	O
24	O
mmHg	O
and	O
mean	O
of	O
14	O
mmHg	O
,	O
estimated	O
area	O
of	O
1	O
.	O
4	O
cm2	O
,	O
without	O
insufficiency	O
.	O
Aortic	O
and	O
tricuspid	O
valve	O
without	O
significant	O
dysfunction	O
.	O
Transesophageal	O
echocardiogram	O
rounded	O
intra	O
atrial	O
mass	O
measuring	O
5	O
x	O
3	O
.	O
5	O
cm	O
,	O
heterogeneous	O
,	O
with	O
a	O
wide	O
pedicle	O
measuring	O
2	O
.	O
7	O
x	O
1	O
cm	O
that	O
adheres	O
to	O
the	O
inferior	O
interatrial	O
septum	O
below	O
the	O
fossa	O
ovalis	O
,	O
which	O
it	O
respects	O
,	O
which	O
in	O
diastole	O
is	O
introduced	O
into	O
the	O
mitral	O
annulus	O
producing	O
a	O
significant	O
stenosis	O
effective	O
area	O
of	O
1	O
.	O
4	O
cm2	O
,	O
with	O
a	O
mitral	O
valve	O
with	O
thin	O
leaflets	O
without	O
alterations	O
.	O
This	O
mass	O
is	O
compatible	O
with	O
an	O
atrial	O
myxoma	O
.	O
The	O
atrial	O
appendage	O
is	O
free	O
of	O
thrombus	O
.	O
Haemodynamic	O
study	O
coronary	O
arteries	O
without	O
significant	O
stenosis	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
attended	O
the	O
emergency	O
department	O
where	O
,	O
given	O
the	O
presence	O
of	O
dyspnoea	O
in	O
a	O
patient	O
with	O
no	O
known	O
heart	O
disease	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
CAT	O
scan	O
with	O
PET	O
protocol	O
,	O
which	O
ruled	O
out	O
the	O
presence	O
of	O
pulmonary	O
thromboembolism	O
but	O
revealed	O
a	O
striking	O
mass	O
in	O
the	O
left	O
atrium	O
,	O
for	O
which	O
reason	O
cardiology	O
was	O
consulted	O
and	O
admitted	O
to	O
his	O
care	O
as	O
the	O
debut	O
of	O
heart	O
failure	O
.	O
Based	O
on	O
the	O
CT	O
scan	O
findings	O
and	O
pathological	O
auscultation	O
,	O
with	O
a	O
clear	O
clinical	O
suspicion	O
,	O
a	O
transthoracic	O
and	O
transesophageal	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
the	O
presence	O
of	O
a	O
giant	O
pedunculated	O
mass	O
in	O
the	O
left	O
atrium	O
compatible	O
with	O
a	O
myxoma	O
which	O
,	O
in	O
diastole	O
,	O
protruded	O
into	O
the	O
left	O
ventricle	O
causing	O
significant	O
mitral	O
stenosis	O
.	O
The	O
case	O
was	O
presented	O
to	O
cardiac	O
surgery	O
and	O
it	O
was	O
decided	O
to	O
remove	O
the	O
mass	O
.	O
Intraoperatively	O
,	O
a	O
tumour	O
with	O
a	O
base	O
of	O
implantation	O
inferior	O
to	O
the	O
fossa	O
ovalis	O
in	O
continuity	O
with	O
the	O
posterior	O
mitral	O
annulus	O
was	O
observed	O
and	O
complete	O
excision	O
was	O
performed	O
,	O
including	O
part	O
of	O
the	O
interatrial	O
septum	O
,	O
with	O
subsequent	O
closure	O
of	O
the	O
defect	O
with	O
a	O
patch	O
of	O
autologous	O
pericardium	O
.	O
The	O
mitral	O
valve	O
is	O
morphologically	O
normal	O
,	O
with	O
thin	O
leaflets	O
,	O
and	O
intraoperative	O
transesophageal	O
echocardiography	O
shows	O
normal	O
function	O
after	O
removal	O
of	O
the	O
mass	O
.	O
She	O
was	O
extubated	O
a	O
few	O
hours	O
later	O
without	O
incident	O
and	O
,	O
after	O
a	O
few	O
days	O
,	O
was	O
discharged	O
.	O
The	O
results	O
of	O
the	O
pathological	O
anatomy	O
confirmed	O
the	O
presence	O
of	O
atrial	O
myxoma	O
,	O
with	O
no	O
evidence	O
of	O
malignancy	O
.	O
She	O
is	O
currently	O
being	O
monitored	O
on	O
an	O
outpatient	O
basis	O
by	O
the	O
cardiology	O
department	O
.	O
A	O
follow	O
up	O
echocardiogram	O
was	O
performed	O
one	O
year	O
later	O
,	O
which	O
showed	O
no	O
abnormalities	O
,	O
with	O
no	O
recurrence	O
of	O
the	O
myxoma	O
,	O
and	O
since	O
then	O
she	O
has	O
been	O
stable	O
and	O
asymptomatic	O
.	O
DIAGNOSIS	O
Congestive	O
heart	O
failure	O
.	O
First	O
episode	O
.	O
Giant	O
atrial	O
myxoma	O
.	O
Moderate	O
severe	O
dynamic	O
mitral	O
stenosis	O
.	O
Excision	O
of	O
the	O
mass	O
and	O
repair	O
of	O
the	O
septum	O
with	O
pericardial	O
patch	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
72	O
year	O
old	O
male	O
pacemaker	O
user	O
with	O
complete	O
atrioventricular	O
AV	O
block	O
who	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
heart	O
failure	O
and	O
constitutional	O
syndrome	O
.	O
HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
HT	O
,	O
dyslipidaemia	O
and	O
type	O
2	O
diabetes	O
mellitus	O
DM2	O
treated	O
with	O
oral	O
antidiabetics	O
.	O
No	O
toxic	O
habits	O
.	O
Cardiologic	O
history	O
VDD	O
pacemaker	O
holder	O
since	O
2003	O
due	O
to	O
complete	O
AVB	O
.	O
Generator	O
replacement	O
in	O
March	O
2019	O
.	O
Last	O
cardiology	O
consultation	O
in	O
January	O
2020	O
,	O
when	O
severe	O
ventricular	O
dysfunction	O
was	O
observed	O
with	O
marked	O
asynchrony	O
due	O
to	O
ventricular	O
stimulation	O
by	O
MCP	O
,	O
and	O
he	O
was	O
referred	O
to	O
the	O
arrhythmia	O
unit	O
for	O
evaluation	O
of	O
upgrade	O
to	O
tri	O
chamber	O
pacemaker	O
TRC	O
.	O
Other	O
medical	O
and	O
surgical	O
history	O
Obstructive	O
sleep	O
apnoea	O
syndrome	O
OSA	O
with	O
nocturnal	O
continuous	O
positive	O
airway	O
pressure	O
CPAP	O
.	O
Anaemia	O
and	O
dysphagia	O
under	O
study	O
by	O
digestive	O
medicine	O
and	O
internal	O
medicine	O
.	O
Gastroscopy	O
and	O
colonoscopy	O
negative	O
.	O
Pending	O
thoraco	O
abdomino	O
pelvic	O
CT	O
scan	O
and	O
oesophageal	O
manometry	O
.	O
Current	O
treatment	O
atorvastatin	B-FARMACO
30	O
mg	O
1	O
tablet	O
at	O
dinner	O
,	O
vildagliptin	B-FARMACO
metformin	I-FARMACO
50	O
850	O
mg	O
1	O
tablet	O
per	O
day	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
capsule	O
at	O
breakfast	O
,	O
ramipril	B-FARMACO
10	O
mg	O
1	O
tablet	O
per	O
day	O
.	O
Since	O
the	O
January	O
consultation	O
bisoprolol	B-FARMACO
5	O
mg	O
1	O
tablet	O
at	O
breakfast	O
,	O
eplerenone	B-FARMACO
25	O
mg	O
1	O
tablet	O
at	O
breakfast	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
tablet	O
at	O
breakfast	O
.	O
Present	O
illness	O
A	O
72	O
year	O
old	O
man	O
came	O
to	O
the	O
emergency	O
department	O
for	O
dyspnoea	O
.	O
He	O
reported	O
progressive	O
deterioration	O
of	O
his	O
functional	O
class	O
basically	O
NYHA	O
I	O
for	O
5	O
months	O
,	O
with	O
marked	O
worsening	O
in	O
the	O
last	O
two	O
months	O
,	O
presenting	O
dyspnoea	O
on	O
minimal	O
effort	O
,	O
subjective	O
decrease	O
in	O
diuresis	O
and	O
nocturia	O
,	O
without	O
orthopnoea	O
,	O
PND	O
,	O
oedema	O
or	O
other	O
symptoms	O
of	O
congestion	O
.	O
He	O
had	O
asthenia	O
,	O
intermittent	O
dysthymic	O
sensation	O
and	O
weight	O
loss	O
of	O
20	O
kg	O
during	O
this	O
period	O
.	O
Absence	O
of	O
improvement	O
after	O
initiation	O
of	O
diuretics	O
by	O
departmental	O
cardiology	O
following	O
echocardiographic	O
findings	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
100	O
60	O
mmHg	O
,	O
heart	O
rate	O
HR	O
85	O
bpm	O
,	O
SpO2	O
93	O
with	O
O2	O
through	O
nasal	O
goggles	O
at	O
2	O
L	O
min	O
.	O
Afebrile	O
.	O
Good	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
.	O
Skin	O
pallor	O
.	O
Eupneic	O
at	O
rest	O
,	O
tolerates	O
decubitus	O
.	O
No	O
jugular	O
engorgement	O
.	O
Cardiac	O
auscultation	O
regular	O
heart	O
sounds	O
,	O
systolic	O
murmur	O
III	O
VI	O
in	O
left	O
sternal	O
border	O
and	O
mitral	O
focus	O
.	O
Pulmonary	O
auscultation	O
bibasal	O
crackles	O
,	O
rest	O
of	O
lung	O
fields	O
with	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
no	O
palpable	O
masses	O
or	O
megaliths	O
,	O
no	O
peritoneal	O
irritation	O
,	O
preserved	O
peristalsis	O
.	O
Lower	O
limbs	O
with	O
discrete	O
tibiomalleolar	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
with	O
ventricular	O
conduction	O
mediated	O
by	O
electrostimulation	O
,	O
wide	O
QRS	O
with	O
morphology	O
of	O
left	O
bundle	O
branch	O
block	O
,	O
secondary	O
repolarisation	O
alterations	O
.	O
Ventricular	O
extrasystoles	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
slightly	O
increased	O
cardiothoracic	O
index	O
CTI	O
,	O
prominent	O
hilarity	O
,	O
no	O
alveolar	O
consolidation	O
or	O
pleural	O
effusion	O
.	O
Pacemaker	O
lead	O
normally	O
positioned	O
in	O
the	O
right	O
ventricle	O
.	O
Laboratory	O
tests	O
CBC	O
red	O
cells	O
4	O
.	O
19	O
10	O
12	O
l	O
;	O
Hb	O
10	O
.	O
2	O
g	O
dl	O
nadir	O
8	O
;	O
Htc	O
31	O
.	O
6	O
;	O
MCV	O
75	O
.	O
3	O
fl	O
;	O
leukocytes	O
6000	O
L	O
PMN	O
76	O
.	O
7	O
;	O
nadir	O
100	O
cells	O
μL	O
;	O
platelets	O
109000	O
l	O
;	O
MPV	O
8	O
.	O
8	O
fl	O
;	O
platelets	O
citrate	O
89	O
10	O
9	O
L	O
nadir	O
31000	O
.	O
Biochemistry	O
glucose	O
139	O
mg	O
dl	O
;	O
sodium	O
135	O
mEq	O
l	O
;	O
potassium	O
3	O
.	O
9	O
mEq	O
l	O
;	O
chlorine	O
101	O
mEq	O
l	O
;	O
urea	O
74	O
mg	O
dl	O
;	O
creatinine	O
0	O
.	O
98	O
mg	O
dl	O
,	O
estimated	O
GFR	O
CKD	O
EPI	O
76	O
.	O
71	O
ml	O
min	O
1	O
.	O
73	O
m2	O
;	O
total	O
bilirubin	O
0	O
.	O
82	O
mg	O
dl	O
,	O
GPT	O
26	O
U	O
l	O
,	O
GOT	O
21	O
U	O
l	O
,	O
GGT	O
24	O
U	O
l	O
;	O
protein	O
5	O
.	O
8	O
g	O
dl	O
;	O
CRP	O
10	O
.	O
9	O
mg	O
dl	O
.	O
Coagulation	O
prothrombin	O
time	O
PT	O
15	O
.	O
6	O
sec	O
;	O
Quick	O
index	O
69	O
;	O
INR	O
1	O
.	O
33	O
;	O
aPTT	O
30	O
.	O
2	O
sec	O
;	O
ratio	O
aPTT	O
1	O
.	O
01	O
;	O
derived	O
fibrinogen	O
410	O
mg	O
dl	O
.	O
Serial	O
blood	O
cultures	O
during	O
the	O
entire	O
admission	O
,	O
in	O
standard	O
and	O
special	O
media	O
,	O
for	O
bacteria	O
and	O
fungi	O
negative	O
.	O
Bacterial	O
and	O
viral	O
serologies	O
negative	O
.	O
Autoimmunity	O
,	O
including	O
ANA	O
,	O
ANCA	O
,	O
rheumatoid	O
factor	O
,	O
antiphospholipid	O
antibodies	O
negative	O
.	O
Haemolysis	O
markers	O
such	O
as	O
LDH	O
,	O
haptoglobin	O
and	O
reticulocytes	O
negative	O
.	O
Bone	O
marrow	O
aspirate	O
no	O
significant	O
alterations	O
observed	O
.	O
Correct	O
myeloerythroid	O
quotient	O
.	O
Microbiological	O
cultures	O
and	O
parasite	O
study	O
negative	O
.	O
Cultures	O
of	O
resected	O
valve	O
material	O
and	O
explanted	O
pacemaker	O
wire	O
negative	O
.	O
Thoracic	O
abdominal	O
pelvic	O
CT	O
with	O
contrast	O
thorax	O
both	O
main	O
and	O
lobar	O
pulmonary	O
arteries	O
show	O
normal	O
morphology	O
and	O
calibre	O
.	O
No	O
repletion	O
defects	O
are	O
observed	O
.	O
No	O
axillary	O
,	O
mediastinal	O
or	O
hilar	O
adenopathies	O
of	O
significant	O
size	O
are	O
identified	O
.	O
Hypoventilation	O
bands	O
in	O
both	O
lower	O
lobes	O
.	O
No	O
pleural	O
effusion	O
.	O
Abdomen	O
pelvis	O
liver	O
with	O
lobulated	O
contours	O
and	O
slightly	O
heterogeneous	O
density	O
,	O
suggestive	O
of	O
chronic	O
liver	O
disease	O
.	O
Pancreas	O
and	O
adrenal	O
glands	O
are	O
normal	O
.	O
Bilateral	O
simple	O
renal	O
cysts	O
.	O
Lithiasis	O
in	O
the	O
right	O
kidney	O
,	O
with	O
no	O
significant	O
impact	O
on	O
the	O
excretory	O
tract	O
.	O
Splenomegaly	O
of	O
16	O
.	O
6	O
cm	O
with	O
several	O
foci	O
of	O
infarction	O
inside	O
.	O
No	O
retroperitoneal	O
or	O
mesenteric	O
adenopathy	O
.	O
No	O
free	O
intra	O
abdominal	O
fluid	O
.	O
Diverticulosis	O
of	O
the	O
sigma	O
.	O
Transesophageal	O
echocardiography	O
TEE	O
and	O
transthoracic	O
echocardiography	O
TTE	O
left	O
ventricle	O
with	O
moderate	O
eccentric	O
hypertrophy	O
TIV	O
and	O
PPVI	O
14	O
mm	O
,	O
DTDVI	O
62	O
mm	O
,	O
increased	O
volumes	O
VTD	O
BP	O
170	O
mL	O
and	O
severe	O
depression	O
of	O
global	O
systolic	O
function	O
LVEF	O
BP	O
27	O
with	O
marked	O
asynchrony	O
,	O
wide	O
anomalous	O
septoapical	O
movement	O
by	O
electrostimulation	O
.	O
Slight	O
aortic	O
root	O
dilatation	O
without	O
valve	O
dysfunction	O
.	O
endocarditis	O
over	O
native	O
pulmonary	O
valve	O
large	O
pedunculated	O
vegetation	O
with	O
a	O
maximum	O
diameter	O
of	O
40	O
mm	O
,	O
with	O
deflected	O
edges	O
,	O
with	O
great	O
mobility	O
and	O
systodiastolic	O
protrusion	O
over	O
the	O
pulmonary	O
valve	O
.	O
No	O
significant	O
valvular	O
involvement	O
was	O
observed	O
.	O
No	O
vegetations	O
or	O
other	O
pathological	O
changes	O
were	O
observed	O
on	O
the	O
tricuspid	O
valve	O
or	O
pacemaker	O
lead	O
.	O
endocarditis	O
on	O
mitral	O
valve	O
with	O
vegetation	O
image	O
on	O
anterior	O
mitral	O
leaflet	O
of	O
11	O
mm	O
.	O
Moderate	O
mitral	O
insufficiency	O
ORE	O
by	O
PISA	O
0	O
.	O
3	O
cm2	O
due	O
to	O
slight	O
eversion	O
of	O
the	O
leaflet	O
,	O
with	O
rupture	O
of	O
the	O
chordae	O
tendineae	O
and	O
eccentric	O
jet	O
directed	O
to	O
the	O
posterior	O
face	O
of	O
the	O
atrium	O
.	O
Diastolic	O
pattern	O
compatible	O
with	O
impaired	O
relaxation	O
E	O
90	O
cm	O
s	O
,	O
A	O
113	O
cm	O
s	O
,	O
with	O
significant	O
increase	O
in	O
filling	O
pressures	O
E	O
e	O
'	O
17	O
.	O
Biauricular	O
dilatation	O
.	O
Right	O
ventricle	O
of	O
normal	O
diameters	O
with	O
preserved	O
global	O
systolic	O
function	O
TAPSE	O
22	O
mm	O
.	O
Mild	O
TR	O
allowing	O
estimation	O
of	O
PAPs	O
of	O
approximately	O
50	O
mmHg	O
moderate	O
PHT	O
.	O
Inferior	O
vena	O
cava	O
plethora	O
IVC	O
.	O
Coronary	O
angiography	O
Truncus	O
description	O
normal	O
.	O
Anterior	O
descending	O
description	O
severe	O
stenosis	O
in	O
proximal	O
segment	O
.	O
Diagonal	O
branch	O
distal	O
to	O
the	O
lesion	O
very	O
developed	O
double	O
DA	O
system	O
.	O
Circumflex	O
description	O
normal	O
.	O
Right	O
coronary	O
description	O
dominant	O
.	O
No	O
stenosis	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
initially	O
admitted	O
to	O
the	O
cardiology	O
ward	O
with	O
depletive	O
and	O
disease	O
modifying	O
treatment	O
for	O
heart	O
failure	O
.	O
In	O
view	O
of	O
the	O
constitutional	O
syndrome	O
,	O
a	O
thoracic	O
abdominal	O
pelvic	O
CT	O
scan	O
was	O
requested	O
to	O
rule	O
out	O
concomitant	O
neoplasia	O
.	O
There	O
were	O
no	O
findings	O
compatible	O
with	O
neoplastic	O
disease	O
.	O
However	O
,	O
splenomegaly	O
with	O
foci	O
of	O
splenic	O
infarction	O
was	O
noted	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
a	O
repeat	O
TTE	O
was	O
performed	O
,	O
which	O
revealed	O
,	O
in	O
addition	O
to	O
the	O
ventricular	O
dysfunction	O
already	O
observed	O
in	O
the	O
study	O
performed	O
in	O
the	O
previous	O
3	O
weeks	O
,	O
a	O
large	O
mobile	O
mass	O
in	O
the	O
pulmonary	O
valve	O
and	O
moderate	O
mitral	O
insufficiency	O
on	O
a	O
valve	O
with	O
a	O
small	O
mass	O
compatible	O
with	O
endocarditis	O
.	O
Transesophageal	O
echocardiography	O
was	O
performed	O
,	O
confirming	O
the	O
diagnosis	O
,	O
so	O
serial	O
blood	O
cultures	O
were	O
taken	O
and	O
empirical	O
antibiotic	O
therapy	O
was	O
started	O
with	O
vancomycin	B-FARMACO
20	O
mg	O
kg	O
12	O
hours	O
i	O
.	O
v	O
.	O
and	O
gentamicin	B-FARMACO
3	O
mg	O
kg	O
day	O
i	O
.	O
v	O
.	O
.	O
In	O
the	O
first	O
days	O
of	O
admission	O
,	O
the	O
patient	O
remained	O
very	O
symptomatic	O
,	O
with	O
dyspnoea	O
on	O
minimal	O
exertion	O
and	O
episodes	O
of	O
sudden	O
dyspnoea	O
,	O
although	O
afebrile	O
.	O
Chest	O
CT	O
angiography	O
was	O
performed	O
on	O
suspicion	O
of	O
septic	O
embolism	O
,	O
which	O
was	O
ruled	O
out	O
.	O
The	O
case	O
was	O
discussed	O
at	O
a	O
medical	O
surgical	O
session	O
and	O
scheduled	O
for	O
surgery	O
.	O
However	O
,	O
the	O
patient	O
evolved	O
unfavourably	O
,	O
presenting	O
an	O
episode	O
of	O
acute	O
pulmonary	O
oedema	O
and	O
requiring	O
transfer	O
to	O
the	O
coronary	O
unit	O
for	O
stabilisation	O
.	O
Progressive	O
blood	O
tests	O
showed	O
significant	O
anaemisation	O
,	O
with	O
a	O
drop	O
to	O
8	O
g	O
dl	O
,	O
requiring	O
transfusion	O
given	O
the	O
clinical	O
condition	O
.	O
In	O
addition	O
,	O
severe	O
neutropenia	O
and	O
thrombopenia	O
were	O
observed	O
nadir	O
of	O
100	O
cells	O
μl	O
and	O
31000	O
l	O
,	O
respectively	O
.	O
Because	O
of	O
this	O
,	O
it	O
was	O
decided	O
to	O
postpone	O
surgery	O
.	O
He	O
was	O
assessed	O
by	O
haematology	O
,	O
started	O
on	O
treatment	O
with	O
granulocyte	O
colony	O
stimulating	O
factors	O
G	O
CSF	O
,	O
and	O
a	O
bone	O
marrow	O
aspirate	O
was	O
performed	O
.	O
Due	O
to	O
neutropenia	O
,	O
meropenem	B-FARMACO
1g	O
8h	O
i	O
.	O
v	O
.	O
was	O
added	O
to	O
the	O
treatment	O
,	O
with	O
the	O
appearance	O
of	O
a	O
generalised	O
maculopapular	O
rash	O
that	O
forced	O
its	O
interruption	O
.	O
Meanwhile	O
,	O
the	O
result	O
of	O
the	O
aspirate	O
showed	O
no	O
pathological	O
findings	O
,	O
so	O
it	O
was	O
considered	O
that	O
the	O
origin	O
of	O
the	O
haematological	O
alteration	O
could	O
be	O
drug	O
related	O
,	O
and	O
it	O
was	O
decided	O
to	O
replace	O
vancomycin	B-FARMACO
with	O
daptomycin	B-FARMACO
10	O
mg	O
kg	O
day	O
i	O
.	O
v	O
.	O
.	O
With	O
this	O
measure	O
and	O
the	O
administration	O
of	O
G	B-FARMACO
CSF	B-FARMACO
,	O
the	O
patient	O
showed	O
progressive	O
analytical	O
improvement	O
.	O
Coronary	O
angiography	O
was	O
performed	O
as	O
part	O
of	O
the	O
preoperative	O
study	O
,	O
showing	O
a	O
severe	O
lesion	O
in	O
the	O
proximal	O
anterior	O
descending	O
artery	O
,	O
which	O
was	O
left	O
for	O
surgical	O
revascularisation	O
.	O
All	O
blood	O
cultures	O
in	O
standard	O
and	O
special	O
media	O
for	O
fungi	O
and	O
bacteria	O
were	O
negative	O
.	O
Serology	O
and	O
even	O
autoimmunity	O
tests	O
were	O
performed	O
,	O
all	O
of	O
which	O
were	O
negative	O
and	O
the	O
microorganism	O
responsible	O
could	O
not	O
be	O
identified	O
.	O
Nuclear	O
medicine	O
tests	O
were	O
considered	O
in	O
view	O
of	O
the	O
lack	O
of	O
an	O
aetiological	O
diagnosis	O
;	O
however	O
,	O
given	O
the	O
patient	O
's	O
clinical	O
situation	O
,	O
they	O
were	O
not	O
carried	O
out	O
.	O
Finally	O
,	O
clinical	O
stability	O
was	O
achieved	O
,	O
and	O
surgery	O
was	O
performed	O
to	O
replace	O
the	O
mitral	O
and	O
pulmonary	O
valves	O
with	O
biological	O
prostheses	O
.	O
In	O
addition	O
,	O
the	O
pacemaker	O
lead	O
and	O
generator	O
were	O
removed	O
and	O
epicardial	O
leads	O
were	O
implanted	O
in	O
the	O
AD	O
,	O
RV	O
and	O
LV	O
for	O
resynchronisation	O
,	O
with	O
placement	O
of	O
a	O
new	O
generator	O
in	O
the	O
right	O
abdominal	O
subcostal	O
region	O
.	O
Bypass	O
over	O
the	O
LAD	O
was	O
ruled	O
out	O
as	O
the	O
vessel	O
could	O
not	O
be	O
adequately	O
exposed	O
due	O
to	O
the	O
presence	O
of	O
abundant	O
epicardial	O
fat	O
,	O
so	O
percutaneous	O
coronary	O
intervention	O
PCI	O
over	O
the	O
LAD	O
will	O
be	O
performed	O
at	O
a	O
later	O
date	O
.	O
The	O
valve	O
debris	O
and	O
the	O
distal	O
end	O
of	O
the	O
wire	O
were	O
sent	O
to	O
microbiology	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
cardiac	O
resuscitation	O
,	O
where	O
he	O
progressed	O
favourably	O
,	O
was	O
transferred	O
to	O
the	O
ward	O
and	O
was	O
discharged	O
after	O
2	O
weeks	O
,	O
with	O
follow	O
up	O
in	O
the	O
heart	O
failure	O
unit	O
and	O
arrhythmia	O
unit	O
.	O
DIAGNOSIS	O
Endocarditis	O
on	O
native	O
pulmonary	O
and	O
mitral	O
valves	O
,	O
with	O
moderate	O
mitral	O
insufficiency	O
with	O
eversion	O
of	O
the	O
anterior	O
leaflet	O
due	O
to	O
rupture	O
of	O
the	O
chordae	O
tendineae	O
.	O
Heart	O
failure	O
with	O
depressed	O
ejection	O
fraction	O
with	O
marked	O
asynchrony	O
due	O
to	O
ventricular	O
electrostimulation	O
.	O
Splenic	O
infarcts	O
secondary	O
to	O
infective	O
endocarditis	O
.	O
Agranulocytosis	O
and	O
thrombopenia	O
of	O
probable	O
drug	O
origin	O
.	O
Toxicoderma	O
due	O
to	O
meropenem	B-FARMACO
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
59	O
year	O
old	O
woman	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Toxic	O
habits	O
smoker	O
since	O
youth	O
of	O
15	O
cigarettes	O
a	O
day	O
30	O
pack	O
years	O
.	O
Cardiovascular	O
risk	O
factors	O
no	O
arterial	O
hypertension	O
AHT	O
,	O
no	O
diabetes	O
mellitus	O
DM	O
.	O
Dyslipidaemia	O
such	O
as	O
hypertriglyceridaemia	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
Other	O
personal	O
history	O
of	O
interest	O
Hepatic	O
haemangiomas	O
monitored	O
by	O
abdominal	O
ultrasound	O
annually	O
.	O
Primary	O
biliary	O
cholangitis	O
being	O
monitored	O
by	O
the	O
digestive	O
system	O
.	O
Generalised	O
anxiety	O
disorder	O
being	O
monitored	O
by	O
psychiatry	O
.	O
Usual	O
treatment	O
Ursodeoxycholic	B-FARMACO
acid	I-FARMACO
300	O
mg	O
2	O
tablets	O
every	O
12	O
hours	O
,	O
bezafibrate	B-FARMACO
400	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
,	O
quetiapine	B-FARMACO
100	O
mg	O
1	O
.	O
5	O
tablets	O
at	O
bedtime	O
,	O
lorazepam	B-FARMACO
1	O
mg	O
1	O
tablet	O
for	O
breakfast	O
,	O
lunch	O
and	O
dinner	O
.	O
Present	O
illness	O
For	O
48	O
hours	O
prior	O
to	O
attending	O
the	O
emergency	O
department	O
,	O
the	O
patient	O
began	O
with	O
clinical	O
symptoms	O
of	O
central	O
thoracic	O
oppression	O
radiating	O
towards	O
the	O
left	O
scapula	O
of	O
intermittent	O
course	O
,	O
which	O
increased	O
with	O
decubitus	O
and	O
coughing	O
and	O
decreased	O
with	O
sitting	O
.	O
She	O
had	O
suffered	O
a	O
catarrhal	O
episode	O
several	O
weeks	O
earlier	O
,	O
which	O
was	O
self	O
limiting	O
.	O
On	O
the	O
other	O
hand	O
,	O
she	O
also	O
reported	O
intense	O
emotional	O
distress	O
in	O
the	O
last	O
few	O
days	O
.	O
When	O
asked	O
about	O
cardiovascular	O
symptoms	O
in	O
previous	O
months	O
,	O
the	O
patient	O
reported	O
a	O
non	O
radiating	O
central	O
thoracic	O
pressure	O
that	O
occurred	O
on	O
exertion	O
,	O
lasting	O
several	O
minutes	O
and	O
which	O
subsided	O
with	O
rest	O
,	O
which	O
had	O
been	O
present	O
for	O
about	O
6	O
months	O
but	O
which	O
did	O
not	O
exactly	O
remind	O
her	O
of	O
the	O
current	O
pain	O
.	O
No	O
dyspnoea	O
,	O
syncope	O
or	O
other	O
relevant	O
symptoms	O
in	O
the	O
anamnesis	O
by	O
apparatus	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
123	O
83	O
mmHg	O
;	O
heart	O
rate	O
77	O
beats	O
per	O
minute	O
;	O
S02	O
97	O
room	O
air	O
;	O
temperature	O
36	O
.	O
6	O
oC	O
Conscious	O
and	O
oriented	O
.	O
Well	O
perfused	O
and	O
hydrated	O
.	O
Eupneic	O
at	O
rest	O
.	O
Head	O
and	O
neck	O
no	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
with	O
pan	O
focal	O
systolic	O
murmur	O
and	O
no	O
other	O
pathological	O
sounds	O
no	O
friction	O
sounds	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
masses	O
or	O
megaliths	O
palpable	O
.	O
No	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Preserved	O
hydro	O
aerial	O
sounds	O
.	O
Femoral	O
and	O
radial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
Lower	O
extremities	O
without	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
performed	O
in	O
the	O
emergency	O
department	O
sinus	O
rhythm	O
at	O
75	O
beats	O
per	O
minute	O
.	O
PR	O
of	O
normal	O
duration	O
with	O
a	O
decrease	O
in	O
the	O
PR	O
in	O
the	O
inferior	O
face	O
and	O
an	O
increase	O
in	O
the	O
aVR	O
.	O
Narrow	O
QRS	O
with	O
rSr	O
'	O
morphology	O
in	O
V1	O
.	O
Rectilinear	O
ST	O
elevation	O
of	O
1	O
mm	O
in	O
inferolateral	O
face	O
with	O
symmetrical	O
ST	O
descent	O
in	O
precordials	O
.	O
Symmetrical	O
negative	O
T	O
waves	O
V3	O
V6	O
.	O
QTc	O
430	O
msec	O
.	O
Laboratory	O
tests	O
performed	O
in	O
the	O
emergency	O
department	O
Biochemistry	O
glucose	O
84	O
mg	O
dl	O
,	O
urea	O
24	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
78	O
mg	O
dl	O
,	O
GPT	O
42	O
U	O
l	O
,	O
bilirubin	O
0	O
.	O
4	O
mg	O
dl	O
,	O
amylase	O
90	O
U	O
l	O
,	O
calcium	O
9	O
.	O
6	O
mg	O
dl	O
,	O
albumin	O
4	O
.	O
1	O
g	O
dl	O
,	O
Na	O
144	O
mEq	O
l	O
,	O
K	O
4	O
.	O
1	O
mEq	O
l	O
,	O
Cl	O
109	O
mEq	O
l	O
,	O
CRP	O
7	O
mg	O
l	O
,	O
CK	O
200	O
U	O
l	O
,	O
LDH	O
233	O
U	O
l	O
,	O
TnT	O
457	O
ng	O
l	O
99th	O
percentile	O
in	O
our	O
hospital	O
14	O
ng	O
l	O
.	O
Haemogram	O
haemoglobin	O
13	O
.	O
4	O
g	O
dl	O
,	O
8	O
,	O
390	O
leukocytes	O
ul	O
with	O
normal	O
leukocyte	O
formula	O
,	O
192	O
,	O
000	O
platelets	O
ul	O
.	O
Haemostasis	O
APTT	O
31	O
seconds	O
,	O
prothrombin	O
time	O
100	O
,	O
INR	O
1	O
,	O
fibrinogen	O
283	O
mg	O
dl	O
.	O
Arterial	O
blood	O
gases	O
Fi02	O
0	O
.	O
21	O
pH	O
7	O
.	O
45	O
,	O
pCO2	O
31	O
mmHg	O
,	O
pO2	O
96	O
mmHg	O
,	O
bicarbonate	O
22	O
mmol	O
l	O
,	O
lactate	O
1	O
.	O
1	O
mmol	O
l	O
.	O
Chest	O
X	O
ray	O
performed	O
in	O
the	O
emergency	O
department	O
cardiomediastinal	O
silhouette	O
preserved	O
,	O
without	O
pleural	O
effusion	O
or	O
gross	O
condensation	O
in	O
the	O
lung	O
parenchyma	O
.	O
Echocardiogram	O
performed	O
on	O
admission	O
to	O
the	O
coronary	O
unit	O
left	O
ventricle	O
neither	O
dilated	O
DVItd	O
37mm	O
nor	O
hypertrophic	O
SIVtd	O
8mm	O
and	O
PPtd	O
8mm	O
with	O
prominent	O
septal	O
knee	O
.	O
Moderate	O
severe	O
systolic	O
dysfunction	O
.	O
Mid	O
apical	O
akinesia	O
of	O
all	O
faces	O
with	O
hypercontractility	O
of	O
the	O
bases	O
leading	O
to	O
a	O
dynamic	O
gradient	O
in	O
the	O
left	O
ventricular	O
outflow	O
tract	O
of	O
up	O
to	O
42	O
mmHg	O
and	O
SAM	O
,	O
resulting	O
in	O
moderate	O
severe	O
mitral	O
regurgitation	O
.	O
The	O
transmitral	O
flow	O
pattern	O
suggests	O
prolonged	O
relaxation	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
preserved	O
opening	O
and	O
functionally	O
normal	O
.	O
Right	O
ventricle	O
normal	O
in	O
structure	O
and	O
function	O
.	O
Tricuspid	O
valve	O
normal	O
in	O
structure	O
.	O
Mild	O
moderate	O
tricuspid	O
insufficiency	O
with	O
RV	O
AD	O
gradient	O
28	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
22	O
mm	O
and	O
inspiratory	O
collapse	O
50	O
.	O
Estimated	O
PSAP	O
38	O
mmHg	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
.	O
Echocardiographic	O
contrast	O
is	O
injected	O
in	O
which	O
the	O
presence	O
of	O
apical	O
thrombus	O
is	O
ruled	O
out	O
by	O
this	O
technique	O
.	O
Urgent	O
coronary	O
angiography	O
videos	O
4	O
,	O
5	O
and	O
6	O
right	O
radial	O
access	O
.	O
Truncus	O
,	O
anterior	O
descending	O
and	O
circumflex	O
arteries	O
without	O
lesions	O
.	O
Dominant	O
right	O
coronary	O
artery	O
without	O
lesions	O
mechanical	O
spasm	O
due	O
to	O
proximal	O
cannulation	O
of	O
the	O
catheter	O
,	O
resolved	O
with	O
intracoronary	O
NTG	B-FARMACO
.	O
Non	O
dilated	O
left	O
ventriculography	O
with	O
midventricular	O
akinesia	O
on	O
all	O
sides	O
.	O
Moderate	O
mitral	O
insufficiency	O
.	O
Intraventricular	O
gradient	O
of	O
30	O
mmHg	O
between	O
apex	O
and	O
LV	O
outflow	O
tract	O
.	O
There	O
is	O
an	O
image	O
of	O
contrast	O
repletion	O
defect	O
at	O
inferoapical	O
level	O
to	O
rule	O
out	O
intracavitary	O
thrombus	O
with	O
echocardiography	O
.	O
Peak	O
myocardial	O
damage	O
markers	O
CK	O
200	O
U	O
l	O
,	O
TnT	O
457	O
ng	O
l	O
.	O
Regulated	O
echocardiogram	O
prior	O
to	O
hospital	O
discharge	O
left	O
ventricle	O
neither	O
dilated	O
DVItd	O
38mm	O
,	O
VTD	O
BP	O
indexed	O
43	O
.	O
8ml	O
m2	O
nor	O
hypertrophic	O
SIVtd	O
8mm	O
,	O
PPtd	O
9mm	O
with	O
prominent	O
septal	O
knee	O
.	O
Mild	O
moderately	O
depressed	O
systolic	O
function	O
Simpson	O
biplane	O
42	O
.	O
3	O
.	O
Mediastinal	O
akinesia	O
of	O
all	O
faces	O
with	O
hypercontractility	O
of	O
the	O
bases	O
,	O
without	O
generating	O
dynamic	O
gradient	O
in	O
the	O
left	O
ventricular	O
outflow	O
tract	O
.	O
Structurally	O
normal	O
mitral	O
valve	O
,	O
without	O
associated	O
SAM	O
.	O
Mild	O
central	O
mitral	O
insufficiency	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
preserved	O
opening	O
and	O
functionally	O
normal	O
.	O
Right	O
ventricle	O
normal	O
in	O
structure	O
and	O
function	O
.	O
Tricuspid	O
valve	O
normal	O
in	O
structure	O
.	O
Tricuspid	O
insufficiency	O
mildly	O
moderate	O
with	O
maximum	O
gradient	O
VD	O
AD	O
29	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
16	O
mm	O
and	O
with	O
inspiratory	O
collapse	O
50	O
.	O
Estimated	O
PSAP	O
34	O
mmHg	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
33mm	O
.	O
Minimal	O
enveloping	O
pericardial	O
effusion	O
.	O
MRI	O
after	O
several	O
months	O
no	O
myocardial	O
oedema	O
or	O
pathological	O
late	O
enhancements	O
suggesting	O
myocarditis	O
or	O
previous	O
ischaemic	O
heart	O
disease	O
.	O
Biventricular	O
function	O
preserved	O
without	O
alterations	O
of	O
segmental	O
contractility	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
arrival	O
of	O
the	O
patient	O
at	O
the	O
emergency	O
department	O
,	O
the	O
on	O
call	O
cardiology	O
department	O
was	O
contacted	O
.	O
On	O
anamnesis	O
,	O
the	O
patient	O
reported	O
pain	O
compatible	O
in	O
part	O
with	O
pericardial	O
characteristics	O
changes	O
in	O
intensity	O
with	O
posture	O
and	O
coughing	O
,	O
previous	O
respiratory	O
infection	O
,	O
etc	O
.	O
but	O
the	O
type	O
of	O
pain	O
was	O
oppressive	O
and	O
she	O
also	O
reported	O
what	O
appeared	O
to	O
be	O
exertional	O
angina	O
in	O
recent	O
months	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
patient	O
reported	O
an	O
emotional	O
upset	O
in	O
the	O
days	O
prior	O
to	O
the	O
onset	O
of	O
the	O
pain	O
.	O
Initial	O
laboratory	O
tests	O
showed	O
elevated	O
markers	O
of	O
myocardial	O
damage	O
TnT	O
457	O
ng	O
l	O
,	O
CK	O
200	O
U	O
l	O
and	O
a	O
minimal	O
elevation	O
of	O
CRP	O
7	O
mg	O
l	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
ECG	O
showed	O
ST	O
segment	O
elevation	O
in	O
the	O
inferolateral	O
face	O
with	O
a	O
decrease	O
in	O
the	O
PR	O
and	O
negative	O
T	O
waves	O
in	O
the	O
precordial	O
leads	O
described	O
above	O
.	O
Bedside	O
echocardiography	O
showed	O
the	O
same	O
findings	O
as	O
in	O
the	O
initial	O
echocardiography	O
,	O
i	O
.	O
e	O
.	O
moderate	O
severe	O
left	O
ventricular	O
systolic	O
dysfunction	O
due	O
to	O
mid	O
apical	O
akinesia	O
of	O
all	O
segments	O
together	O
with	O
significant	O
mitral	O
regurgitation	O
due	O
to	O
SAM	O
and	O
presence	O
of	O
aliasing	O
in	O
the	O
left	O
ventricular	O
outflow	O
tract	O
.	O
At	O
that	O
time	O
,	O
we	O
considered	O
several	O
differential	O
diagnoses	O
inferolateral	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
STEMI	O
,	O
pericarditis	O
,	O
myopericarditis	O
,	O
tako	O
tsubo	O
syndrome	O
or	O
a	O
mixed	O
picture	O
.	O
The	O
decision	O
was	O
made	O
to	O
activate	O
the	O
haemodynamics	O
unit	O
to	O
perform	O
an	O
emergent	O
coronary	O
angiography	O
,	O
which	O
did	O
not	O
show	O
coronary	O
lesions	O
that	O
would	O
justify	O
the	O
current	O
picture	O
,	O
so	O
the	O
picture	O
was	O
initially	O
interpreted	O
as	O
a	O
tako	O
tsubo	O
syndrome	O
that	O
would	O
justify	O
the	O
elevation	O
of	O
the	O
markers	O
of	O
myocardial	O
damage	O
together	O
with	O
the	O
alterations	O
in	O
segmental	O
contractility	O
and	O
associated	O
pericarditis	O
.	O
During	O
her	O
stay	O
in	O
the	O
coronary	O
unit	O
,	O
the	O
patient	O
remained	O
haemodynamically	O
stable	O
with	O
a	O
tendency	O
to	O
arterial	O
hypotension	O
,	O
and	O
neurohormonal	O
medication	O
could	O
not	O
be	O
introduced	O
.	O
Control	O
echocardiograms	O
showed	O
a	O
disappearance	O
of	O
the	O
gradient	O
and	O
SAM	O
with	O
improvement	O
of	O
LVEF	O
to	O
mild	O
moderate	O
dysfunction	O
.	O
The	O
control	O
ECG	O
showed	O
a	O
QTc	O
of	O
up	O
to	O
500	O
msec	O
without	O
arrhythmic	O
events	O
in	O
the	O
telemetry	O
with	O
subsequent	O
normalisation	O
of	O
the	O
QTc	O
,	O
with	O
persistent	O
symmetrical	O
negative	O
T	O
waves	O
in	O
anterior	O
precordial	O
leads	O
.	O
During	O
her	O
stay	O
in	O
the	O
coronary	O
unit	O
and	O
on	O
the	O
hospital	O
ward	O
,	O
she	O
presented	O
chest	O
pain	O
with	O
pericardial	O
characteristics	O
that	O
subsided	O
after	O
initiation	O
of	O
treatment	O
with	O
non	O
steroidal	O
anti	O
inflammatory	O
drugs	O
NSAIDs	O
.	O
At	O
the	O
time	O
of	O
discharge	O
,	O
the	O
patient	O
was	O
completely	O
asymptomatic	O
in	O
the	O
anamnesis	O
by	O
apparatus	O
.	O
She	O
was	O
discharged	O
with	O
treatment	O
for	O
her	O
pericarditis	O
with	O
anti	O
inflammatory	O
drugs	O
and	O
subsequent	O
follow	O
up	O
by	O
local	O
cardiology	O
.	O
Neurohormonal	O
treatment	O
ACE	O
inhibitors	O
ARA	O
II	O
could	O
not	O
be	O
started	O
due	O
to	O
a	O
tendency	O
to	O
arterial	O
hypotension	O
.	O
After	O
3	O
months	O
,	O
cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
was	O
performed	O
on	O
an	O
outpatient	O
basis	O
,	O
showing	O
complete	O
recovery	O
of	O
ventricular	O
function	O
with	O
no	O
alterations	O
in	O
segmental	O
contractility	O
and	O
no	O
oedema	O
or	O
late	O
enhancement	O
,	O
thus	O
supporting	O
the	O
diagnosis	O
of	O
tako	O
tsubo	O
syndrome	O
and	O
ruling	O
out	O
the	O
presence	O
of	O
myocardial	O
damage	O
due	O
to	O
myocarditis	O
or	O
ischaemic	O
heart	O
disease	O
.	O
DIAGNOSIS	O
Tako	O
tsubo	O
syndrome	O
.	O
Acute	O
pericarditis	O
.	O
No	O
evidence	O
of	O
myocarditis	O
.	O
Left	O
ventricular	O
outflow	O
tract	O
gradient	O
and	O
moderate	O
to	O
severe	O
mitral	O
regurgitation	O
due	O
to	O
SAM	O
in	O
the	O
context	O
of	O
tako	O
tsubo	O
syndrome	O
,	O
resolved	O
on	O
discharge	O
.	O
Moderately	O
severely	O
depressed	O
left	O
ventricular	O
systolic	O
function	O
on	O
admission	O
in	O
the	O
context	O
of	O
tako	O
tsubo	O
syndrome	O
,	O
with	O
recovery	O
to	O
mild	O
moderate	O
on	O
discharge	O
.	O
Coronary	O
arteries	O
without	O
significant	O
lesions	O
or	O
anomalous	O
origins	O
.	O
CVRF	O
active	O
smoker	O
,	O
dyslipidaemia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
78	O
year	O
old	O
male	O
with	O
the	O
following	O
history	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
arterial	O
hypertension	O
AHT	O
,	O
type	O
2	O
diabetes	O
mellitus	O
DM2	O
,	O
dyslipidaemia	O
.	O
Cardiological	O
history	O
heart	O
failure	O
with	O
preserved	O
LVEF	O
.	O
Hypertensive	O
heart	O
disease	O
under	O
cardiology	O
follow	O
up	O
last	O
NT	O
proBNP	O
2127	O
pg	O
ml	O
in	O
the	O
previous	O
month	O
.	O
Other	O
history	O
biliary	O
colic	O
secondary	O
to	O
cholelithiasis	O
.	O
Usual	O
treatment	O
nebivolol	B-FARMACO
2	O
.	O
5	O
mg	O
each	O
day	O
;	O
eplerenone	B-FARMACO
25	O
mg	O
each	O
day	O
;	O
furosemide	B-FARMACO
40	O
mg	O
each	O
day	O
;	O
dapagliflozin	B-FARMACO
metformin	I-FARMACO
5	O
1000	O
mg	O
each	O
12	O
hours	O
;	O
fenofibrate	B-FARMACO
160	O
mg	O
each	O
day	O
;	O
simvastatin	B-FARMACO
20	O
mg	O
each	O
day	O
;	O
amlodipine	B-FARMACO
valsartan	I-FARMACO
hydrochlorothiazide	I-FARMACO
10	O
160	O
12	O
.	O
5	O
mg	O
each	O
day	O
;	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
each	O
day	O
;	O
omeprazole	B-FARMACO
20	O
mg	O
each	O
day	O
;	O
gabapentin	B-FARMACO
300	O
mg	O
every	O
8	O
hours	O
;	O
clorazepate	B-FARMACO
5	O
mg	O
each	O
day	O
.	O
Present	O
illness	O
A	O
78	O
year	O
old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
progressive	O
dyspnoea	O
in	O
the	O
last	O
month	O
until	O
minimal	O
effort	O
NYHA	O
III	O
IV	O
with	O
previous	O
NYHA	O
I	O
II	O
IV	O
,	O
associated	O
with	O
oedematisation	O
of	O
the	O
lower	O
limbs	O
MMII	O
,	O
without	O
orthopnoea	O
,	O
paroxysmal	O
nocturnal	O
dyspnoea	O
or	O
oliguria	O
.	O
In	O
addition	O
,	O
he	O
reported	O
episodes	O
of	O
self	O
limited	O
chest	O
pain	O
during	O
the	O
last	O
few	O
months	O
,	O
related	O
to	O
exertion	O
,	O
for	O
which	O
he	O
had	O
previously	O
consulted	O
the	O
emergency	O
department	O
,	O
with	O
no	O
electrocardiographic	O
changes	O
or	O
mobilisation	O
of	O
markers	O
of	O
myocardial	O
damage	O
.	O
Physical	O
examination	O
On	O
arrival	O
at	O
the	O
hospital	O
,	O
the	O
patient	O
was	O
in	O
fair	O
general	O
condition	O
,	O
tachypnoea	O
,	O
blood	O
pressure	O
BP	O
190	O
99	O
mmHg	O
,	O
heart	O
rate	O
HR	O
80	O
bpm	O
and	O
SpO2	O
88	O
,	O
so	O
supplementary	O
O2	B-FARMACO
,	O
diuretics	O
,	O
intravenous	O
nitroglycerin	B-FARMACO
and	O
bronchodilators	O
were	O
started	O
,	O
obtaining	O
the	O
following	O
constants	O
BP	O
170	O
85	O
mmHg	O
;	O
HR	O
70	O
bpm	O
;	O
SatO2	O
94	O
FiO2	O
0	O
.	O
26	O
.	O
Cardiac	O
auscultation	O
regular	O
heart	O
sounds	O
,	O
no	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
bilateral	O
midbasal	O
crackles	O
and	O
hypophonesis	O
in	O
the	O
right	O
base	O
.	O
Tibiomalleolar	O
oedema	O
in	O
MMII	O
.	O
COMPLEMENTARY	O
TESTS	O
Tests	O
performed	O
in	O
the	O
emergency	O
department	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
63	O
bpm	O
.	O
PR	O
200	O
ms	O
,	O
0o	O
axis	O
,	O
narrow	O
QRS	O
,	O
ST	O
segment	O
sub	O
rectification	O
in	O
V4	O
V6	O
,	O
II	O
and	O
aVF	O
.	O
Chest	O
X	O
ray	O
increased	O
cardiothoracic	O
index	O
.	O
Bilateral	O
cottony	O
infiltrates	O
.	O
Right	O
pleural	O
effusion	O
.	O
No	O
condensation	O
was	O
seen	O
.	O
Laboratory	O
tests	O
Blood	O
count	O
haemoglobin	O
11	O
g	O
dl	O
.	O
Haematocrit	O
32	O
.	O
5	O
.	O
MCV	O
86	O
.	O
4	O
fl	O
.	O
Leukocytes	O
,	O
leukocyte	O
formula	O
and	O
platelets	O
without	O
alterations	O
.	O
Coagulation	O
no	O
alterations	O
.	O
Biochemistry	O
glucose	O
145	O
mg	O
dl	O
,	O
urea	O
77	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
89	O
mg	O
dl	O
.	O
Ions	O
in	O
range	O
,	O
liver	O
function	O
without	O
alterations	O
.	O
Calcium	O
8	O
.	O
9	O
mg	O
dl	O
.	O
Protein	O
6	O
.	O
7	O
g	O
dl	O
.	O
CRP	O
1	O
.	O
1	O
mg	O
dl	O
.	O
Biomarkers	O
of	O
myocardial	O
damage	O
hsTnI	O
22	O
ng	O
l	O
30	O
ng	O
l	O
.	O
Tests	O
performed	O
during	O
admission	O
Heart	O
failure	O
markers	O
NT	O
proBNP	O
maximum	O
3258	O
.	O
0	O
pg	O
ml	O
.	O
CA	O
125	O
17	O
IU	O
ml	O
.	O
Echocardiography	O
left	O
ventricle	O
with	O
moderate	O
concentric	O
hypertrophy	O
of	O
septal	O
predominance	O
,	O
with	O
normal	O
diameters	O
,	O
increased	O
volumes	O
and	O
preserved	O
global	O
systolic	O
function	O
.	O
Normal	O
aortic	O
root	O
and	O
valve	O
.	O
Pseudonormal	O
transmitral	O
filling	O
,	O
with	O
data	O
suggestive	O
of	O
increased	O
end	O
diastolic	O
pressures	O
grade	O
II	O
diastolic	O
dysfunction	O
.	O
Normal	O
right	O
ventricle	O
.	O
Inferior	O
vena	O
cava	O
plethora	O
.	O
Mild	O
tricuspid	O
insufficiency	O
that	O
allows	O
estimation	O
of	O
pulmonary	O
artery	O
systolic	O
pressure	O
at	O
50	O
mmHg	O
moderate	O
pulmonary	O
hypertension	O
.	O
Examination	O
in	O
sinus	O
rhythm	O
.	O
Coronary	O
angiography	O
via	O
the	O
left	O
radial	O
artery	O
mild	O
moderate	O
stenosis	O
in	O
the	O
proximomedial	O
LAD	O
and	O
proximal	O
segment	O
of	O
the	O
1st	O
diagonal	O
.	O
It	O
was	O
decided	O
to	O
perform	O
a	O
functional	O
assessment	O
of	O
both	O
lesions	O
with	O
a	O
pressure	O
guide	O
,	O
obtaining	O
negative	O
results	O
both	O
at	O
rest	O
iFR	O
and	O
with	O
i	O
.	O
v	O
.	O
regadenoson	O
FFR	O
.	O
Given	O
chest	O
pain	O
and	O
HF	O
with	O
preserved	O
LVEF	O
,	O
an	O
acetylcholine	O
test	O
was	O
performed	O
.	O
After	O
the	O
second	O
dose	O
20	O
mcg	O
,	O
electrocardiographic	O
changes	O
were	O
observed	O
ST	O
segment	O
elevation	O
and	O
mild	O
negativisation	O
of	O
T	O
waves	O
in	O
V1	O
V3	O
and	O
III	O
,	O
diffuse	O
vasospasm	O
of	O
the	O
entire	O
left	O
coronary	O
tree	O
,	O
associated	O
with	O
central	O
thoracic	O
oppression	O
.	O
Signs	O
and	O
symptoms	O
resolved	O
with	O
intracoronary	O
nitroglycerin	B-FARMACO
.	O
Conclusion	O
functionally	O
non	O
significant	O
moderate	O
stenosis	O
in	O
LAD	O
and	O
diagonal	O
.	O
Positive	O
epicardial	O
acetylcholine	O
test	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
his	O
stay	O
in	O
the	O
cardiology	O
ward	O
,	O
depletive	O
treatment	O
was	O
administered	O
and	O
,	O
given	O
the	O
results	O
of	O
the	O
coronary	O
angiography	O
,	O
beta	O
blocker	O
treatment	O
nebivolol	B-FARMACO
was	O
suspended	O
and	O
a	O
non	O
dihydropyridine	O
calcium	O
antagonist	O
diltiazem	B-FARMACO
was	O
added	O
.	O
The	O
patient	O
showed	O
clinical	O
and	O
haemodynamic	O
improvement	O
,	O
with	O
resolution	O
of	O
peripheral	O
oedema	O
and	O
dyspnoea	O
,	O
tolerating	O
ambulation	O
without	O
new	O
episodes	O
of	O
chest	O
pain	O
or	O
other	O
complications	O
.	O
Following	O
improvement	O
in	O
renal	O
function	O
,	O
discharge	O
home	O
was	O
decided	O
.	O
During	O
outpatient	O
follow	O
up	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
without	O
dyspnoea	O
or	O
chest	O
pain	O
,	O
with	O
NYHA	O
functional	O
class	O
I	O
.	O
DIAGNOSIS	O
Acute	O
hypertensive	O
pulmonary	O
oedema	O
in	O
a	O
patient	O
with	O
heart	O
failure	O
and	O
preserved	O
systolic	O
function	O
.	O
Endothelial	O
dysfunction	O
with	O
epicardial	O
coronary	O
vasospasm	O
.	O
Grade	O
II	O
diastolic	O
dysfunction	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
70	O
year	O
old	O
female	O
patient	O
admitted	O
for	O
the	O
onset	O
of	O
heart	O
failure	O
.	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
no	O
toxic	O
habits	O
.	O
Arterial	O
hypertension	O
AHT	O
and	O
dyslipidaemia	O
without	O
pharmacological	O
treatment	O
.	O
No	O
family	O
history	O
of	O
sudden	O
death	O
or	O
early	O
ischaemic	O
heart	O
disease	O
.	O
Cardiological	O
history	O
assessed	O
by	O
the	O
primary	O
care	O
physician	O
for	O
dyspnoea	O
,	O
initiating	O
treatment	O
with	O
spironolactone	B-FARMACO
and	O
furosemide	B-FARMACO
,	O
pending	O
outpatient	O
assessment	O
by	O
the	O
cardiology	O
team	O
.	O
Other	O
antecedents	O
hypothyroidism	O
on	O
replacement	O
therapy	O
.	O
Monoclonal	O
gammopathy	O
of	O
uncertain	O
significance	O
studied	O
by	O
haematology	O
in	O
2009	O
,	O
ruling	O
out	O
multiple	O
myeloma	O
.	O
Colonic	O
diverticulosis	O
.	O
Colonic	O
polypectomy	O
in	O
2016	O
polyps	O
with	O
low	O
grade	O
dysplasia	O
.	O
Partial	O
gastrectomy	O
for	O
duodenal	O
ulcer	O
and	O
partial	O
adnexectomy	O
for	O
endometriosis	O
.	O
Usual	O
treatment	O
spironolactone	B-FARMACO
25	O
mg	O
every	O
48	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
0	O
0	O
,	O
calcium	B-FARMACO
carbonate	I-FARMACO
cholecarciferol	I-FARMACO
.	O
Present	O
illness	O
The	O
patient	O
reports	O
that	O
in	O
the	O
two	O
months	O
prior	O
to	O
admission	O
,	O
she	O
began	O
with	O
a	O
sensation	O
of	O
dyspnoea	O
on	O
exertion	O
that	O
progressively	O
worsened	O
until	O
it	O
became	O
minimal	O
exertion	O
.	O
She	O
also	O
reports	O
that	O
since	O
the	O
week	O
prior	O
to	O
admission	O
she	O
has	O
had	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
She	O
denies	O
chest	O
pain	O
,	O
palpitations	O
or	O
syncope	O
.	O
She	O
reported	O
that	O
for	O
several	O
years	O
she	O
had	O
been	O
suffering	O
from	O
periorbital	O
haematomas	O
that	O
resolved	O
spontaneously	O
,	O
for	O
which	O
she	O
had	O
not	O
consulted	O
.	O
Since	O
the	O
week	O
prior	O
to	O
admission	O
,	O
he	O
had	O
again	O
presented	O
haematoma	O
around	O
both	O
orbits	O
.	O
He	O
came	O
to	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
and	O
it	O
was	O
decided	O
to	O
admit	O
him	O
for	O
treatment	O
and	O
study	O
.	O
Physical	O
examination	O
On	O
admission	O
Baseline	O
O2	O
saturation	O
89	O
.	O
Blood	O
pressure	O
110	O
70	O
mmHg	O
.	O
Heart	O
rate	O
110	O
bpm	O
.	O
Jugular	O
venous	O
pulse	O
JVP	O
elevated	O
,	O
hepatojugular	O
reflux	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
left	O
parasternal	O
systolic	O
murmur	O
II	O
VI	O
.	O
Pulmonary	O
auscultation	O
bibasal	O
crackles	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
hepatomegaly	O
of	O
2	O
cm	O
.	O
Lower	O
extremities	O
oedema	O
up	O
to	O
the	O
pretibial	O
region	O
.	O
Bilateral	O
periorbital	O
purpura	O
,	O
especially	O
on	O
the	O
left	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
.	O
First	O
degree	O
BAV	O
PR	O
220	O
ms	O
.	O
Narrow	O
QRS	O
.	O
Anterior	O
pseudoinfarction	O
pattern	O
QS	O
V1	O
V4	O
.	O
HBAI	O
.	O
Blood	O
tests	O
General	O
biochemistry	O
glucose	O
99	O
mg	O
dL	O
,	O
urea	O
47	O
mg	O
dL	O
,	O
creatinine	O
1	O
.	O
02	O
mg	O
dL	O
,	O
glomerular	O
filtration	O
rate	O
CKD	O
EPI	O
56	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
sodium	O
142	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
1	O
mmol	O
l	O
.	O
AST	O
33	O
IU	O
l	O
,	O
ALT	O
43	O
IU	O
l	O
,	O
ALP	O
126	O
IU	O
l	O
,	O
GGT	O
127	O
IU	O
l	O
,	O
HbA1C	O
5	O
.	O
9	O
,	O
TSH	O
6	O
.	O
3	O
mIU	O
l	O
,	O
free	O
T4	O
1	O
.	O
31	O
ng	O
dl	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
211	O
mg	O
dl	O
,	O
triglycerides	O
102	O
mg	O
dl	O
,	O
HDL	O
49	O
mg	O
dl	O
,	O
LDL	O
142	O
mg	O
dl	O
.	O
NT	O
proBNP	O
4828	O
pg	O
ml	O
.	O
Troponin	O
T	O
ultrasensitive	O
72	O
ng	O
l	O
.	O
Ferrokinetics	O
iron	O
75	O
μg	O
dl	O
,	O
transferrin	O
315	O
mg	O
dl	O
,	O
IST	O
24	O
,	O
ferritin	O
92	O
ng	O
ml	O
.	O
Haemoglobin	O
14	O
.	O
6	O
g	O
dl	O
,	O
leucocytes	O
8	O
,	O
300	O
μl	O
,	O
platelets	O
292	O
,	O
000	O
μl	O
,	O
reticulocytes	O
1	O
.	O
5	O
,	O
haptoglobin	O
44	O
.	O
Coagulation	O
INR	O
1	O
.	O
09	O
,	O
prothrombin	O
rate	O
87	O
,	O
activated	O
partial	O
T	O
.	O
T	O
.	O
35	O
.	O
9	O
sec	O
.	O
Immunoglobulins	O
serum	O
free	O
kappa	O
chains	O
7	O
.	O
7	O
mg	O
l	O
reference	O
values	O
3	O
.	O
3	O
19	O
,	O
serum	O
free	O
lambda	O
chains	O
517	O
mg	O
l	O
5	O
.	O
71	O
26	O
.	O
3	O
,	O
free	O
Kappa	O
Lambda	O
ratio	O
0	O
.	O
01	O
0	O
.	O
26	O
1	O
.	O
65	O
,	O
free	O
Lambda	O
Kappa	O
ratio	O
67	O
.	O
Proteinogram	O
IgG	O
Lambda	O
monoclonal	O
band	O
in	O
late	O
gamma	O
additional	O
monoclonal	O
component	O
in	O
mid	O
gamma	O
also	O
of	O
Lambda	O
light	O
chain	O
with	O
no	O
clear	O
association	O
to	O
IgG	O
,	O
IgA	O
or	O
IgM	O
heavy	O
chain	O
.	O
24	O
hour	O
urine	O
creatinine	O
clearance	O
23	O
.	O
31	O
ml	O
FG	O
.	O
Quantitative	O
protein	O
2	O
.	O
4	O
mg	O
dl	O
,	O
urea	O
7	O
.	O
31	O
g	O
24	O
hours	O
,	O
creatinine	O
0	O
.	O
34	O
g	O
24	O
hours	O
.	O
Kappa	O
chains	O
0	O
.	O
66	O
mg	O
dl	O
0	O
0	O
.	O
75	O
,	O
lambda	O
chains	O
1	O
.	O
68	O
0	O
0	O
.	O
41	O
,	O
kappa	O
lambda	O
ratio	O
0	O
.	O
39	O
.	O
Concentration	O
of	O
urine	O
x20	O
shows	O
elimination	O
of	O
monoclonal	O
component	O
of	O
lambda	O
free	O
light	O
chain	O
in	O
gamma	O
zone	O
.	O
Detection	O
limit	O
of	O
the	O
technique	O
anti	O
IgG	O
IgA	O
IgM	O
,	O
anti	O
kappa	O
,	O
anti	O
lambda	O
1	O
.	O
25	O
mg	O
l	O
,	O
free	O
anti	O
kappa	O
,	O
free	O
anti	O
lambda	O
2	O
.	O
5	O
mg	O
l	O
.	O
Chest	O
X	O
ray	O
PA	O
and	O
lateral	O
cardiomegaly	O
at	O
the	O
expense	O
of	O
left	O
cavities	O
,	O
flow	O
cephalisation	O
,	O
Kerley	O
lines	O
A	O
and	O
B	O
,	O
left	O
pleural	O
effusion	O
,	O
right	O
costophrenic	O
sinus	O
impingement	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
with	O
severe	O
asymmetric	O
hypertrophy	O
interventricular	O
septum	O
13	O
mm	O
,	O
posterior	O
wall	O
16	O
mm	O
with	O
preserved	O
ejection	O
fraction	O
60	O
by	O
Simpson	O
biplanar	O
.	O
Hyper	O
refringent	O
myocardium	O
,	O
suggestive	O
of	O
deposition	O
cardiomyopathy	O
.	O
Type	O
III	O
diastolic	O
dysfunction	O
.	O
Hypertrophic	O
right	O
ventricle	O
with	O
normal	O
function	O
TAPSE	O
22	O
mm	O
.	O
Mild	O
biauricular	O
dilatation	O
left	O
atrium	O
20	O
cm2	O
,	O
right	O
atrium	O
18	O
cm2	O
.	O
Mitral	O
insufficiency	O
grade	O
2	O
.	O
Moderate	O
tricuspid	O
insufficiency	O
with	O
evidence	O
of	O
PHT	O
at	O
rest	O
PSAP	O
40	O
mmHg	O
PVC	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
25	O
mm	O
,	O
with	O
respiratory	O
variation	O
50	O
.	O
Cardiac	O
MRI	O
left	O
ventricle	O
of	O
normal	O
size	O
46	O
mm	O
with	O
thickening	O
of	O
the	O
basal	O
anterior	O
wall	O
16	O
m	O
,	O
basal	O
lateral	O
wall	O
13	O
mm	O
,	O
medial	O
septum	O
14	O
mm	O
and	O
apical	O
septum	O
10	O
mm	O
.	O
No	O
alterations	O
in	O
global	O
or	O
segmental	O
contractility	O
were	O
identified	O
.	O
LVEF	O
58	O
.	O
LV	O
DVT	O
109	O
ml	O
69	O
ml	O
m2	O
.	O
LV	O
STV	O
46	O
ml	O
29	O
ml	O
m2	O
.	O
LV	O
SVL	O
VI	O
64	O
ml	O
40	O
ml	O
m2	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
with	O
diffuse	O
myocardial	O
thickening	O
,	O
mainly	O
of	O
its	O
free	O
wall	O
.	O
Function	O
preserved	O
.	O
Thickening	O
of	O
the	O
interatrial	O
septum	O
.	O
Slight	O
biauricular	O
dilatation	O
RA	O
21	O
cm2	O
;	O
LA	O
22	O
cm2	O
.	O
After	O
intravenous	O
contrast	O
administration	O
,	O
the	O
myocardial	O
signal	O
is	O
not	O
annulled	O
,	O
identifying	O
diffuse	O
enhancement	O
of	O
the	O
myocardial	O
wall	O
of	O
the	O
left	O
ventricle	O
,	O
the	O
right	O
ventricle	O
,	O
the	O
interatrial	O
septum	O
and	O
the	O
wall	O
of	O
both	O
atria	O
.	O
Slight	O
bilateral	O
pleural	O
effusions	O
.	O
Myocardial	O
scintigraphy	O
with	O
diphosphonates	O
the	O
study	O
shows	O
no	O
pathological	O
uptake	O
compatible	O
with	O
amyloidosis	O
due	O
to	O
transthyretin	O
deposition	O
.	O
Cardiac	O
catheterisation	O
coronary	O
arteries	O
without	O
angiographically	O
significant	O
stenosis	O
.	O
Fine	O
needle	O
puncture	O
of	O
abdominal	O
subcutaneous	O
fat	O
adipose	O
tissue	O
with	O
the	O
presence	O
of	O
nodular	O
deposits	O
that	O
stain	O
with	O
Congo	O
red	O
stain	O
and	O
show	O
green	O
birefringence	O
in	O
the	O
study	O
under	O
polarised	O
light	O
.	O
Immunohistochemistry	O
lambda	O
positive	O
.	O
Kappa	O
,	O
A	O
component	O
,	O
P	O
component	O
and	O
transthyretin	O
negative	O
.	O
The	O
result	O
of	O
the	O
immunohistochemical	O
study	O
is	O
in	O
favour	O
of	O
AL	O
amyloid	O
.	O
CLINICAL	O
EVOLUTION	O
Patient	O
with	O
no	O
known	O
cardiological	O
history	O
,	O
who	O
had	O
previously	O
presented	O
with	O
periorbital	O
purpura	O
,	O
and	O
who	O
consulted	O
for	O
clinical	O
symptoms	O
of	O
progressive	O
dyspnoea	O
of	O
weeks	O
'	O
evolution	O
.	O
She	O
attended	O
the	O
emergency	O
department	O
and	O
was	O
admitted	O
to	O
the	O
cardiology	O
hospital	O
ward	O
for	O
the	O
first	O
episode	O
of	O
heart	O
failure	O
with	O
evidence	O
of	O
systemic	O
and	O
pulmonary	O
congestion	O
.	O
After	O
an	O
echocardiogram	O
suggestive	O
of	O
deposit	O
disease	O
,	O
it	O
was	O
decided	O
to	O
complement	O
the	O
study	O
with	O
magnetic	O
resonance	O
imaging	O
,	O
cardiac	O
scintigraphy	O
and	O
light	O
chains	O
in	O
plasma	O
and	O
urine	O
.	O
After	O
obtaining	O
the	O
results	O
,	O
a	O
referral	O
was	O
made	O
to	O
the	O
haematology	O
department	O
,	O
which	O
requested	O
an	O
abdominal	O
subcutaneous	O
fat	O
puncture	O
.	O
From	O
the	O
clinical	O
point	O
of	O
view	O
,	O
she	O
responded	O
well	O
to	O
intravenous	O
diuretic	O
treatment	O
;	O
however	O
,	O
she	O
had	O
a	O
tendency	O
to	O
hypotension	O
,	O
and	O
in	O
view	O
of	O
the	O
electrocardiogram	O
with	O
baseline	O
conduction	O
disorder	O
,	O
it	O
was	O
decided	O
not	O
to	O
start	O
treatment	O
with	O
ACE	B-FARMACO
inhibitors	I-FARMACO
or	O
beta	O
blockers	O
.	O
She	O
was	O
discharged	O
stable	O
,	O
in	O
NYHA	O
functional	O
class	O
II	O
IV	O
,	O
pending	O
anatomopathological	O
results	O
of	O
subcutaneous	O
fat	O
.	O
Two	O
weeks	O
after	O
admission	O
,	O
she	O
returned	O
to	O
the	O
emergency	O
department	O
for	O
chest	O
pain	O
and	O
decompensation	O
of	O
heart	O
failure	O
,	O
and	O
was	O
again	O
admitted	O
to	O
the	O
cardiology	O
ward	O
.	O
Cardiac	O
catheterisation	O
was	O
performed	O
,	O
ruling	O
out	O
associated	O
coronary	O
disease	O
.	O
The	O
anatomopathological	O
result	O
of	O
the	O
subcutaneous	O
fat	O
was	O
in	O
favour	O
of	O
AL	O
amyloid	O
.	O
Diagnosed	O
with	O
AL	O
amyloidosis	O
,	O
haematology	O
started	O
treatment	O
with	O
cyclophosphamide	B-FARMACO
,	O
bortezomib	B-FARMACO
and	O
dexamethasone	B-FARMACO
.	O
She	O
remained	O
at	O
home	O
,	O
stable	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
with	O
outpatient	O
monitoring	O
by	O
haematology	O
.	O
Three	O
months	O
after	O
his	O
first	O
admission	O
,	O
he	O
had	O
an	O
ischaemic	O
stroke	O
of	O
the	O
left	O
hemisphere	O
in	O
the	O
left	O
middle	O
cerebral	O
artery	O
with	O
an	O
image	O
compatible	O
with	O
a	O
small	O
thrombus	O
at	O
the	O
level	O
of	O
the	O
left	O
M1	O
,	O
and	O
was	O
admitted	O
to	O
neurology	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
was	O
detected	O
and	O
anticoagulation	O
with	O
heparin	B-FARMACO
and	O
acenocoumarol	B-FARMACO
was	O
started	O
,	O
with	O
lower	O
gastrointestinal	O
bleeding	O
.	O
A	O
gastroscopy	O
was	O
performed	O
with	O
no	O
relevant	O
findings	O
and	O
colonoscopy	O
revealed	O
haemorrhoids	O
.	O
During	O
admission	O
she	O
developed	O
critical	O
patient	O
neuropathy	O
and	O
was	O
transferred	O
to	O
a	O
rehabilitation	O
centre	O
for	O
treatment	O
with	O
low	B-FARMACO
molecular	I-FARMACO
weight	I-FARMACO
heparin	I-FARMACO
,	O
pending	O
outpatient	O
percutaneous	O
closure	O
of	O
the	O
appendage	O
.	O
DIAGNOSIS	O
AHA	O
ACC	O
stage	O
C	O
congestive	O
heart	O
failure	O
,	O
with	O
pulmonary	O
and	O
systemic	O
congestion	O
.	O
AL	O
amyloidosis	O
with	O
cardiac	O
involvement	O
.	O
Left	O
hemispheric	O
stroke	O
of	O
probable	O
cardioembolic	O
origin	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
.	O
Polyneuropathy	O
in	O
critically	O
ill	O
patients	O
.	O
Preserved	O
left	O
ventricular	O
systolic	O
function	O
.	O
Restrictive	O
pattern	O
diastolic	O
dysfunction	O
.	O
Mitral	O
insufficiency	O
grade	O
2	O
.	O
Stage	O
3a	O
chronic	O
kidney	O
disease	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Male	O
,	O
68	O
years	O
old	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
He	O
denies	O
current	O
consumption	O
of	O
toxic	O
substances	O
.	O
Episode	O
of	O
right	O
renal	O
colic	O
in	O
2010	O
,	O
with	O
discrete	O
ectasia	O
at	O
pyelocaliceal	O
level	O
.	O
Normal	O
renal	O
function	O
.	O
Cardiological	O
history	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
arterial	O
hypertension	O
AHT	O
and	O
dyslipidaemia	O
on	O
pharmacological	O
treatment	O
.	O
Ex	O
smoker	O
for	O
20	O
years	O
IPA	O
of	O
30	O
packs	O
year	O
.	O
No	O
diabetes	O
mellitus	O
.	O
Known	O
left	O
bundle	O
branch	O
block	O
LBBB	O
.	O
Chronic	O
coronary	O
syndrome	O
that	O
debuted	O
in	O
1986	O
with	O
AMI	O
,	O
with	O
surgical	O
revascularisation	O
with	O
double	O
aortocoronary	O
bridge	O
marginal	O
saphenous	O
obtuse	O
and	O
anterior	O
saphenous	O
descendant	O
.	O
Subsequently	O
,	O
several	O
episodes	O
of	O
unstable	O
angina	O
in	O
2002	O
and	O
2003	O
,	O
with	O
percutaneous	O
revascularisation	O
percutaneous	O
coronary	O
intervention	O
PCI	O
with	O
implantation	O
of	O
a	O
drug	O
eluting	O
stent	O
in	O
the	O
LAD	O
distal	O
to	O
the	O
saphenous	O
graft	O
,	O
two	O
stents	O
in	O
the	O
first	O
proximal	O
medial	O
diagonal	O
branch	O
,	O
and	O
a	O
stent	O
in	O
the	O
middle	O
DC	O
.	O
In	O
2010	O
a	O
new	O
coronary	O
angiography	O
was	O
performed	O
,	O
on	O
a	O
scheduled	O
basis	O
,	O
where	O
a	O
severe	O
stenosis	O
of	O
70	O
was	O
observed	O
in	O
distal	O
CT	O
,	O
with	O
stent	O
placement	O
,	O
with	O
a	O
good	O
result	O
.	O
Last	O
control	O
echocardiogram	O
2018	O
dilated	O
cardiomyopathy	O
with	O
severe	O
ventricular	O
dysfunction	O
LVEF	O
25	O
with	O
moderate	O
severe	O
mitral	O
insufficiency	O
due	O
to	O
tenting	O
and	O
mild	O
pulmonary	O
hypertension	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
of	O
the	O
same	O
year	O
severely	O
dilated	O
left	O
ventricle	O
LV	O
with	O
severe	O
dysfunction	O
.	O
LVEF	O
25	O
.	O
5	O
.	O
Dyskinesia	O
of	O
the	O
true	O
apex	O
,	O
akinesia	O
of	O
the	O
basal	O
half	O
of	O
the	O
inferior	O
,	O
inferolateral	O
and	O
anterolateral	O
sides	O
,	O
as	O
well	O
as	O
of	O
the	O
basalmost	O
posterior	O
septum	O
.	O
Thinning	O
of	O
the	O
inferior	O
and	O
inferolateral	O
aspect	O
3	O
mm	O
.	O
Abnormal	O
septal	O
motion	O
.	O
Non	O
dilated	O
right	O
ventricle	O
RV	O
with	O
preserved	O
global	O
and	O
segmental	O
function	O
.	O
RVEF	O
52	O
.	O
5	O
.	O
Mitral	O
insufficiency	O
jet	O
is	O
seen	O
.	O
Late	O
enhancement	O
sequences	O
showed	O
ischaemic	O
enhancement	O
in	O
regions	O
of	O
the	O
basal	O
and	O
medial	O
posterior	O
septum	O
,	O
basal	O
and	O
medial	O
inferolateral	O
,	O
and	O
basal	O
anterolateral	O
.	O
In	O
outpatient	O
follow	O
up	O
in	O
heart	O
failure	O
consultation	O
,	O
with	O
six	O
monthly	O
annual	O
check	O
ups	O
.	O
Clinically	O
asymptomatic	O
,	O
NYHA	O
I	O
IV	O
,	O
with	O
no	O
new	O
episodes	O
of	O
angina	O
.	O
Follows	O
cardiac	O
rehabilitation	O
programme	O
.	O
Usual	O
treatment	O
omeprazole	B-FARMACO
20	O
mg	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
day	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
12	O
hours	O
,	O
furosemide	B-FARMACO
20	O
mg	O
day	O
,	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
97	O
103	O
mg	O
day	O
,	O
rosuvastatin	B-FARMACO
20	O
mg	O
day	O
.	O
Present	O
illness	O
The	O
patient	O
consulted	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
due	O
to	O
a	O
progressive	O
increase	O
in	O
dyspnoea	O
during	O
the	O
last	O
week	O
,	O
to	O
the	O
point	O
of	O
minimal	O
effort	O
,	O
associated	O
with	O
orthopnoea	O
and	O
oliguria	O
during	O
the	O
last	O
3	O
days	O
.	O
No	O
angina	O
or	O
palpitations	O
.	O
Poor	O
compliance	O
with	O
hygienic	O
dietary	O
measures	O
during	O
the	O
last	O
few	O
days	O
,	O
with	O
increased	O
water	O
intake	O
.	O
No	O
infections	O
or	O
changes	O
in	O
medication	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
120	O
70	O
mmHg	O
,	O
heart	O
rate	O
HR	O
100	O
bpm	O
,	O
SO2	O
90	O
baseline	O
improving	O
with	O
O2	O
2	O
bpm	O
to	O
95	O
.	O
Afebrile	O
.	O
Minimal	O
jugular	O
plethora	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
with	O
systolic	O
murmur	O
in	O
mitral	O
focus	O
III	O
IV	O
,	O
AP	O
with	O
bibasal	O
crackles	O
up	O
to	O
midfields	O
.	O
Abdomen	O
was	O
nondescript	O
.	O
Bilateral	O
oedema	O
with	O
fovea	O
in	O
EEII	O
to	O
pretibial	O
level	O
.	O
In	O
view	O
of	O
symptoms	O
compatible	O
with	O
decompensated	O
heart	O
failure	O
,	O
it	O
was	O
decided	O
to	O
admit	O
the	O
patient	O
to	O
the	O
cardiology	O
department	O
for	O
treatment	O
and	O
clinical	O
evolution	O
.	O
COMPLEMENTARY	O
TESTS	O
In	O
the	O
emergency	O
department	O
ECG	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
,	O
PR	O
220	O
ms	O
,	O
with	O
known	O
LBBB	O
,	O
with	O
QRS	O
complex	O
duration	O
of	O
170	O
ms	O
.	O
Chest	O
X	O
ray	O
borderline	O
cardiothoracic	O
index	O
,	O
with	O
pinching	O
of	O
both	O
costophrenic	O
sinuses	O
,	O
without	O
infiltrates	O
in	O
the	O
lung	O
parenchyma	O
.	O
Blood	O
tests	O
glycaemia	O
80mg	O
dl	O
,	O
urea	O
,	O
creatinine	O
and	O
hepatic	O
battery	O
normal	O
.	O
Na	O
135	O
mEq	O
l	O
,	O
K	O
4	O
.	O
2	O
mEq	O
l	O
.	O
Hb	O
15	O
g	O
dl	O
,	O
leukocytes	O
4	O
,	O
800	O
,	O
platelets	O
205	O
,	O
000	O
.	O
Coagulation	O
normal	O
,	O
with	O
INR	O
1	O
.	O
1	O
.	O
NTproBNP	O
in	O
the	O
ED	O
1	O
,	O
050	O
pg	O
ml	O
.	O
On	O
the	O
cardiology	O
ward	O
Extended	O
CBC	O
with	O
ferric	O
profile	O
,	O
TSH	O
and	O
HbA1c	O
ferritin	O
250	O
ug	O
l	O
with	O
TSI	O
12	O
.	O
TSH	O
normal	O
.	O
HbA1c	O
5	O
.	O
4	O
.	O
Transthoracic	O
echocardiogram	O
video	O
1	O
ischaemic	O
dilated	O
cardiomyopathy	O
with	O
severely	O
dilated	O
LV	O
.	O
Mild	O
LVH	O
.	O
Severe	O
dysfunction	O
LVEF	O
22	O
with	O
global	O
hypokinesia	O
.	O
Severe	O
mitral	O
insufficiency	O
MI	O
due	O
to	O
tenting	O
.	O
Asynchronous	O
septal	O
motion	O
in	O
relation	O
to	O
LBBB	O
.	O
Moderate	O
tricuspid	O
insufficiency	O
TI	O
.	O
Normofunctioning	O
RV	O
with	O
moderate	O
pulmonary	O
hypertension	O
PH	O
.	O
Similar	O
to	O
previous	O
echocardiographic	O
findings	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
remained	O
in	O
hospital	O
with	O
good	O
clinical	O
evolution	O
and	O
excellent	O
response	O
to	O
intravenous	O
diuretic	O
treatment	O
,	O
with	O
notable	O
clinical	O
improvement	O
and	O
complete	O
resolution	O
of	O
the	O
congestive	O
semiology	O
,	O
which	O
made	O
it	O
possible	O
to	O
de	O
escalate	O
the	O
diuretic	O
treatment	O
to	O
the	O
usual	O
oral	O
dose	O
at	O
home	O
.	O
The	O
pre	O
discharge	O
NT	O
proBNP	O
test	O
was	O
repeated	O
,	O
with	O
notable	O
improvement	O
600	O
pg	O
ml	O
.	O
The	O
patient	O
was	O
already	O
on	O
outpatient	O
neurohormonal	O
treatment	O
,	O
which	O
was	O
not	O
modified	O
previously	O
,	O
the	O
introduction	O
of	O
ivabradine	B-FARMACO
had	O
been	O
attempted	O
in	O
consultations	O
,	O
but	O
was	O
poorly	O
tolerated	O
and	O
therefore	O
discontinued	O
.	O
The	O
patient	O
was	O
re	O
interviewed	O
and	O
reported	O
episodes	O
of	O
increased	O
dyspnoea	O
during	O
the	O
last	O
4	O
months	O
.	O
It	O
was	O
decided	O
to	O
raise	O
the	O
case	O
with	O
the	O
electrophysiology	O
section	O
of	O
our	O
department	O
for	O
the	O
implantation	O
of	O
an	O
ICD	O
CRT	O
for	O
primary	O
prevention	O
,	O
which	O
was	O
accepted	O
.	O
The	O
implantation	O
took	O
place	O
without	O
incident	O
,	O
achieving	O
partial	O
correction	O
of	O
the	O
interventricular	O
asynchrony	O
.	O
At	O
the	O
analytical	O
level	O
,	O
it	O
is	O
worth	O
noting	O
ferropenia	O
data	O
,	O
without	O
associated	O
anaemia	O
.	O
As	O
this	O
was	O
a	O
patient	O
with	O
heart	O
failure	O
with	O
reduced	O
ejection	O
fraction	O
and	O
symptoms	O
NYHA	O
III	O
IV	O
on	O
admission	O
,	O
and	O
given	O
the	O
data	O
on	O
improved	O
exercise	O
capacity	O
,	O
quality	O
of	O
life	O
and	O
functional	O
capacity	O
demonstrated	O
by	O
intravenous	O
ferrotherapy	O
in	O
these	O
patients	O
,	O
it	O
was	O
decided	O
to	O
administer	O
iron	B-FARMACO
carboxymaltose	I-FARMACO
in	O
a	O
single	O
dose	O
of	O
500	O
mg	O
.	O
The	O
patient	O
was	O
again	O
educated	O
in	O
hygienic	O
dietary	O
measures	O
,	O
was	O
discharged	O
and	O
continued	O
regular	O
check	O
ups	O
at	O
the	O
heart	O
failure	O
clinic	O
.	O
Eight	O
months	O
after	O
discharge	O
,	O
he	O
was	O
clinically	O
stable	O
,	O
asymptomatic	O
,	O
with	O
baseline	O
NYHA	O
I	O
IV	O
,	O
with	O
no	O
new	O
episodes	O
of	O
HF	O
decompensation	O
.	O
A	O
repeat	O
echocardiogram	O
showed	O
an	O
improvement	O
in	O
LVEF	O
to	O
33	O
,	O
with	O
mild	O
moderate	O
mitral	O
regurgitation	O
.	O
The	O
control	O
analysis	O
again	O
showed	O
an	O
iron	O
deficiency	O
profile	O
ferritin	O
80	O
ug	O
l	O
with	O
TST	O
10	O
,	O
with	O
associated	O
microcytic	O
anaemia	O
Hb	O
11	O
g	O
l	O
,	O
with	O
MCV	O
80	O
fl	O
,	O
which	O
was	O
not	O
present	O
on	O
admission	O
.	O
In	O
this	O
case	O
,	O
our	O
patient	O
was	O
clinically	O
asymptomatic	O
for	O
his	O
heart	O
failure	O
NYHA	O
I	O
,	O
but	O
with	O
associated	O
anaemia	O
,	O
so	O
it	O
was	O
decided	O
to	O
re	O
administer	O
IV	O
ferrotherapy	O
1000	O
mg	O
of	O
ferric	B-FARMACO
carboxymaltose	I-FARMACO
in	O
a	O
single	O
dose	O
,	O
with	O
a	O
further	O
administration	O
of	O
another	O
500	O
mg	O
the	O
following	O
week	O
in	O
the	O
day	O
hospital	O
.	O
A	O
faecal	O
occult	O
blood	O
test	O
was	O
requested	O
,	O
which	O
was	O
positive	O
,	O
so	O
the	O
patient	O
was	O
referred	O
to	O
the	O
gastrointestinal	O
department	O
for	O
further	O
evaluation	O
with	O
the	O
relevant	O
studies	O
.	O
DIAGNOSIS	O
Chronic	O
decompensated	O
heart	O
failure	O
,	O
with	O
severely	O
reduced	O
LVEF	O
.	O
Ischaemic	O
dilated	O
cardiomyopathy	O
.	O
Chronic	O
coronary	O
syndrome	O
with	O
trivial	O
coronary	O
artery	O
disease	O
with	O
multiple	O
surgical	O
and	O
percutaneous	O
revascularisations	O
.	O
Microcytic	O
anaemia	O
with	O
iron	O
deficiency	O
profile	O
pending	O
digestive	O
study	O
.	O
Procedures	O
performed	O
first	O
implantation	O
of	O
automatic	O
implantable	O
cardioverter	O
defibrillator	O
with	O
cardiac	O
resynchronisation	O
therapy	O
ICD	O
CRT	O
in	O
primary	O
prevention	O
and	O
intravenous	O
ferrotherapy	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Family	O
history	O
mother	O
with	O
presbycusis	O
at	O
the	O
age	O
of	O
68	O
.	O
Personal	O
history	O
Ex	O
smoker	O
of	O
half	O
a	O
pack	O
of	O
cigarettes	O
a	O
day	O
for	O
12	O
years	O
ICAT	O
6	O
packs	O
year	O
.	O
Bilateral	O
profound	O
sensorineural	O
deafness	O
with	O
cochlear	O
implantation	O
at	O
47	O
years	O
of	O
age	O
,	O
with	O
a	O
baseline	O
electrocardiogram	O
ECG	O
compatible	O
with	O
ventricular	O
pre	O
excitation	O
.	O
Clinically	O
,	O
she	O
presented	O
with	O
self	O
limited	O
palpitations	O
and	O
was	O
advised	O
to	O
undergo	O
an	O
electrophysiological	O
study	O
and	O
accessory	O
pathway	O
ablation	O
,	O
which	O
the	O
patient	O
refused	O
.	O
She	O
had	O
no	O
previous	O
cardiological	O
history	O
,	O
nor	O
any	O
other	O
medical	O
or	O
surgical	O
history	O
of	O
interest	O
.	O
Present	O
illness	O
A	O
57	O
year	O
old	O
woman	O
presented	O
with	O
dyspnoea	O
in	O
functional	O
class	O
IV	O
,	O
intolerance	O
to	O
decubitus	O
,	O
oliguria	O
and	O
ulcerated	O
oedema	O
in	O
the	O
lower	O
limbs	O
for	O
3	O
weeks	O
with	O
a	O
torpid	O
evolution	O
.	O
Physical	O
examination	O
Afebrile	O
.	O
Blood	O
pressure	O
BP	O
91	O
52	O
mmHg	O
,	O
heart	O
rate	O
HR	O
135	O
bpm	O
,	O
SatO2	O
93	O
room	O
air	O
.	O
Regular	O
general	O
condition	O
,	O
cooperative	O
and	O
conscious	O
.	O
Not	O
hydrated	O
,	O
delayed	O
capillary	O
refill	O
with	O
acral	O
coldness	O
.	O
Tachypneic	O
with	O
supraclavicular	O
pull	O
.	O
Orthopnoea	O
of	O
45o	O
.	O
With	O
jugular	O
venous	O
engorgement	O
.	O
Cardiac	O
and	O
pulmonary	O
auscultation	O
rapid	O
and	O
rhythmic	O
heart	O
tones	O
,	O
without	O
murmurs	O
or	O
extratones	O
.	O
Vesicular	O
murmur	O
preserved	O
with	O
bibasal	O
crackles	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
signs	O
of	O
peritonism	O
.	O
No	O
masses	O
or	O
megaliths	O
palpable	O
.	O
Hydro	O
aerial	O
noises	O
present	O
.	O
Lower	O
limbs	O
lower	O
limbs	O
oedema	O
up	O
to	O
the	O
root	O
of	O
the	O
lower	O
limbs	O
with	O
distal	O
ulcers	O
in	O
the	O
second	O
,	O
third	O
,	O
fourth	O
and	O
fifth	O
phalanx	O
of	O
the	O
lower	O
limbs	O
.	O
No	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Pedal	O
pulses	O
not	O
palpable	O
due	O
to	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Prior	O
to	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
ICU	O
CBC	O
haemoglobin	O
18	O
g	O
dl	O
,	O
leukocytes	O
15	O
,	O
490	O
cells	O
mm3	O
85	O
N	O
and	O
7	O
.	O
5	O
L	O
,	O
platelets	O
25	O
,	O
2000	O
,	O
glycaemia	O
174	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
75	O
mg	O
dl	O
,	O
urea	O
176	O
mg	O
dl	O
,	O
sodium	O
130	O
mEq	O
l	O
,	O
K	O
4	O
.	O
70	O
mEq	O
l	O
,	O
CPK	O
1936	O
,	O
LDH	O
1158	O
pg	O
ml	O
,	O
CRP	O
133	O
pg	O
ml	O
.	O
Procalcitonin	O
7	O
ng	O
ml	O
.	O
HsTnI	O
3	O
,	O
909	O
pg	O
ml	O
and	O
BNP	O
4	O
,	O
915	O
pg	O
ml	O
.	O
Venous	O
blood	O
gases	O
pH	O
7	O
.	O
24	O
,	O
CO2	O
36	O
,	O
HCO3	O
13	O
.	O
4	O
,	O
lactate	O
5	O
.	O
9	O
mmol	O
l	O
.	O
Chest	O
X	O
ray	O
global	O
cardiomegaly	O
at	O
the	O
expense	O
of	O
the	O
left	O
chambers	O
,	O
double	O
contour	O
sign	O
and	O
slight	O
evidence	O
of	O
pulmonary	O
venous	O
congestion	O
.	O
During	O
his	O
admission	O
to	O
the	O
ICU	O
Initial	O
echocardiography	O
left	O
ventricle	O
with	O
normal	O
internal	O
diameters	O
.	O
Normal	O
wall	O
thickness	O
,	O
increased	O
echogenicity	O
.	O
Severe	O
global	O
hypokinesia	O
.	O
Severely	O
depressed	O
EF	O
25	O
by	O
visual	O
estimation	O
.	O
Large	O
mass	O
in	O
the	O
apical	O
region	O
of	O
the	O
left	O
ventricle	O
,	O
with	O
low	O
mobility	O
,	O
smooth	O
surface	O
,	O
moderate	O
echogenicity	O
,	O
independent	O
of	O
the	O
underlying	O
myocardium	O
without	O
parietal	O
thinning	O
in	O
this	O
region	O
,	O
about	O
30x	O
18	O
mm	O
in	O
diameter	O
.	O
Suggestive	O
of	O
large	O
apical	O
thrombus	O
.	O
Left	O
atrium	O
in	O
normal	O
limits	O
.	O
Right	O
ventricle	O
of	O
normal	O
internal	O
diameters	O
and	O
wall	O
thickness	O
.	O
Reduced	O
longitudinal	O
shortening	O
.	O
Visual	O
EF	O
moderately	O
depressed	O
.	O
Right	O
atrium	O
in	O
normal	O
limits	O
.	O
Mitral	O
valve	O
with	O
slight	O
thickening	O
of	O
leaflets	O
,	O
good	O
opening	O
.	O
Secondary	O
mild	O
moderate	O
central	O
insufficiency	O
.	O
Aortic	O
valve	O
without	O
alterations	O
.	O
Right	O
valves	O
without	O
significant	O
structural	O
alterations	O
.	O
Slight	O
tricuspid	O
insufficiency	O
.	O
Thoracic	O
aorta	O
without	O
pathological	O
findings	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
normal	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Estimated	O
normal	O
PSAP	O
.	O
Conclusions	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
severe	O
global	O
hypokinesia	O
and	O
severely	O
depressed	O
EF	O
.	O
Apical	O
thrombus	O
.	O
Serology	O
positive	O
serology	O
for	O
hepatic	O
virus	O
C	O
,	O
as	O
well	O
as	O
IgG	O
and	O
IgM	O
against	O
cytomegalovirus	O
and	O
IgG	O
against	O
Epstein	O
Barr	O
virus	O
.	O
All	O
other	O
tests	O
were	O
negative	O
enterovirus	O
PCR	O
,	O
HIV	O
,	O
HBV	O
,	O
HSV	O
,	O
Parvovirus	O
B19	O
,	O
Brucella	O
,	O
Rickettsia	O
,	O
Mycoplasma	O
,	O
Chlamydia	O
pneumoniae	O
,	O
Borrelia	O
burgdorferi	O
.	O
Coronary	O
angiography	O
non	O
significant	O
stenosis	O
of	O
distal	O
anterior	O
descending	O
artery	O
30	O
without	O
other	O
significant	O
angiographic	O
stenosis	O
.	O
On	O
the	O
ward	O
Complete	O
blood	O
count	O
glycaemia	O
146	O
mg	O
dl	O
,	O
HbA1c	O
7	O
.	O
5	O
,	O
creatinine	O
0	O
.	O
82	O
mg	O
dl	O
,	O
K	O
4	O
.	O
4	O
meq	O
l	O
,	O
Na	O
139	O
meq	O
l	O
,	O
Cl	O
105	O
meq	O
l	O
,	O
Ca	O
9	O
.	O
9	O
,	O
phosphorus	O
4	O
,	O
magnesium	O
2	O
.	O
2	O
.	O
LDH	O
555	O
U	O
l	O
.	O
Iron	O
107	O
ug	O
dl	O
,	O
ferritin	O
747	O
ng	O
ml	O
,	O
IST	O
28	O
.	O
2	O
.	O
Total	O
cholesterol	O
157	O
mg	O
dl	O
,	O
HDL	O
51	O
,	O
LDL	O
86	O
.	O
TG	O
103	O
mg	O
dl	O
.	O
TSH	O
3	O
.	O
33	O
IU	O
ml	O
.	O
BNP	O
1479	O
decreasing	O
.	O
CRP	O
2	O
.	O
9	O
mg	O
l	O
.	O
Troponins	O
2354	O
pg	O
ml	O
.	O
Normal	O
proteinogram	O
albumin	O
3	O
.	O
6	O
,	O
percentage	O
albumin	O
53	O
.	O
8	O
,	O
alpha	O
1	O
globulins	O
0	O
.	O
3	O
,	O
percentage	O
5	O
.	O
2	O
,	O
alpha	O
2	O
0	O
.	O
7	O
,	O
percentage	O
10	O
.	O
8	O
,	O
beta	O
globulins	O
0	O
.	O
7	O
percentage	O
11	O
.	O
2	O
,	O
gamma	O
globulins	O
1	O
.	O
3	O
percentage	O
19	O
.	O
Light	O
chains	O
free	O
kappa	O
chains	O
64	O
.	O
15	O
,	O
free	O
lambda	O
chains	O
31	O
.	O
5	O
.	O
24	O
hour	O
urine	O
protein	O
light	O
chains	O
normal	O
.	O
Kappa	O
chains	O
1	O
.	O
85	O
mg	O
dl	O
,	O
lambda	O
chains	O
5	O
mg	O
dl	O
.	O
CBC	O
haemoglobin	O
13	O
.	O
7	O
g	O
dl	O
,	O
haematocrit	O
42	O
.	O
8	O
,	O
mean	O
corpuscular	O
volume	O
90fKl	O
,	O
leucocytes	O
9150	O
microL	O
,	O
neutrophils	O
54	O
.	O
8	O
,	O
platelets	O
279000	O
microL	O
.	O
GSV	O
pH	O
7	O
.	O
3242	O
.	O
pCO2	O
39	O
.	O
5	O
,	O
bicarbonate	O
30	O
.	O
1mmHg	O
,	O
lactic	O
acid	O
3	O
.	O
7	O
.	O
Echocardiography	O
after	O
ICU	O
discharge	O
left	O
ventricle	O
with	O
slightly	O
reduced	O
internal	O
diameters	O
.	O
Slightly	O
increased	O
wall	O
thickness	O
diffusely	O
in	O
relation	O
to	O
the	O
diameter	O
of	O
the	O
cavity	O
and	O
increased	O
echogenicity	O
.	O
Mild	O
global	O
hypokinesia	O
.	O
Moderately	O
depressed	O
ejection	O
fraction	O
41	O
by	O
Simpson	O
biplane	O
.	O
Restrictive	O
mitral	O
filling	O
pattern	O
.	O
E	O
e	O
ratio	O
16	O
.	O
Muscular	O
trabeculae	O
at	O
the	O
apical	O
level	O
without	O
intraventricular	O
thrombus	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
.	O
Right	O
ventricle	O
of	O
normal	O
diameter	O
and	O
walls	O
with	O
decreased	O
longitudinal	O
shortening	O
and	O
depressed	O
ejection	O
fraction	O
TAPSE	O
10	O
.	O
Slightly	O
dilated	O
right	O
atrium	O
.	O
Thin	O
leaflet	O
aortic	O
valve	O
with	O
mild	O
central	O
regurgitation	O
.	O
Mitral	O
valve	O
with	O
diffuse	O
mild	O
leaflet	O
thickening	O
,	O
moderate	O
central	O
insufficiency	O
,	O
with	O
an	O
ERO	O
of	O
0	O
.	O
2	O
,	O
5	O
mm	O
vena	O
contracta	O
,	O
regurgitant	O
volume	O
of	O
22	O
ml	O
and	O
PISA	O
radius	O
of	O
0	O
.	O
6	O
.	O
Tricuspid	O
valve	O
with	O
fine	O
leaflets	O
,	O
good	O
opening	O
and	O
moderate	O
central	O
insufficiency	O
.	O
Aortic	O
root	O
and	O
ascending	O
aorta	O
without	O
pathological	O
findings	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
with	O
reduced	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Estimated	O
PSAP	O
of	O
44	O
mmHg	O
.	O
Free	O
fluid	O
in	O
the	O
abdominal	O
cavity	O
.	O
Conclusions	O
left	O
ventricle	O
with	O
slightly	O
thickened	O
walls	O
in	O
relation	O
to	O
the	O
diameter	O
of	O
the	O
cavity	O
,	O
with	O
increased	O
echogenicity	O
.	O
Global	O
hypokinesia	O
with	O
moderately	O
depressed	O
ejection	O
fraction	O
.	O
Signs	O
of	O
advanced	O
diastolic	O
dysfunction	O
.	O
Right	O
ventricle	O
of	O
normal	O
wall	O
and	O
diameter	O
with	O
depressed	O
ejection	O
fraction	O
.	O
Moderate	O
central	O
mitral	O
regurgitation	O
.	O
Mild	O
pulmonary	O
hypertension	O
.	O
Thrombophilia	O
and	O
autoimmunity	O
study	O
negative	O
lupus	O
anticoagulant	O
,	O
normal	O
protein	O
C	O
and	O
S	O
,	O
no	O
resistance	O
to	O
activated	O
protein	O
C	O
,	O
normal	O
coagulation	O
factors	O
V	O
,	O
VII	O
and	O
von	O
Willebrand	O
and	O
antithrombin	O
.	O
No	O
mutations	O
in	O
prothrombin	O
genes	O
,	O
factor	O
V	O
Leiden	O
gene	O
,	O
MTHFR	O
gene	O
,	O
factor	O
XII	O
gene	O
.	O
Normal	O
anti	O
cardiolipin	O
and	O
anti	O
beta	O
2	O
glycoprotein	O
antibodies	O
.	O
Rectal	O
biopsy	O
rectal	O
mucosa	O
without	O
relevant	O
morphological	O
changes	O
.	O
No	O
abnormal	O
deposits	O
are	O
observed	O
after	O
staining	O
with	O
Congo	O
red	O
and	O
the	O
rectal	O
mucosa	O
without	O
relevant	O
morphological	O
changes	O
.	O
Subcutaneous	O
fat	O
biopsy	O
Congo	O
red	O
techniques	O
were	O
performed	O
on	O
serial	O
sections	O
and	O
immunohistochemistry	O
for	O
amyloid	O
A	O
,	O
immunoglobulin	O
heavy	O
and	O
light	O
chains	O
with	O
negative	O
results	O
.	O
During	O
outpatient	O
follow	O
up	O
Echocardiography	O
last	O
check	O
up	O
,	O
prior	O
to	O
readmission	O
left	O
ventricle	O
with	O
slightly	O
thickened	O
walls	O
in	O
relation	O
to	O
the	O
diameter	O
of	O
the	O
cavity	O
,	O
absolute	O
diameters	O
within	O
the	O
normal	O
range	O
,	O
with	O
increased	O
echogenicity	O
.	O
Global	O
hypokinesia	O
with	O
severely	O
depressed	O
ejection	O
fraction	O
27	O
.	O
Signs	O
of	O
advanced	O
diastolic	O
dysfunction	O
.	O
Mass	O
in	O
the	O
apex	O
compatible	O
with	O
thrombus	O
.	O
Right	O
ventricle	O
of	O
normal	O
wall	O
and	O
diameter	O
with	O
depressed	O
ejection	O
fraction	O
.	O
Moderate	O
secondary	O
mitral	O
insufficiency	O
.	O
Severe	O
tricuspid	O
insufficiency	O
.	O
PET	O
CT	O
scan	O
no	O
cervical	O
,	O
supraclavicular	O
or	O
mediastinal	O
hypercapillary	O
lymphadenopathy	O
with	O
lambdoid	O
pattern	O
suggestive	O
of	O
lymph	O
node	O
sarcoidosis	O
.	O
There	O
are	O
no	O
pulmonary	O
lesions	O
suspicious	O
of	O
pulmonary	O
sarcoidosis	O
.	O
No	O
pleural	O
or	O
pericardial	O
effusion	O
or	O
hyperenhancement	O
suspicious	O
for	O
active	O
pleuritis	O
or	O
pericarditis	O
.	O
Diffuse	O
myocardial	O
hyperenhancement	O
of	O
mild	O
intensity	O
SUVmax	O
2	O
.	O
3	O
and	O
very	O
homogeneous	O
,	O
suggesting	O
a	O
non	O
specific	O
dilated	O
cardiomyopathy	O
that	O
could	O
be	O
of	O
viral	O
origin	O
CMV	O
among	O
other	O
possibilities	O
.	O
Conclusions	O
there	O
are	O
no	O
PET	O
findings	O
suggestive	O
of	O
pulmonary	O
,	O
lymph	O
node	O
or	O
cardiac	O
sarcoidosis	O
.	O
Nonspecific	O
diffuse	O
cardiomyopathy	O
that	O
could	O
be	O
of	O
viral	O
origin	O
CMV	O
IgM	O
.	O
DPD	O
scan	O
no	O
pathological	O
uptake	O
in	O
the	O
cardiac	O
projection	O
area	O
.	O
No	O
foci	O
of	O
pathological	O
bone	O
uptake	O
were	O
seen	O
in	O
the	O
rest	O
of	O
the	O
bone	O
scan	O
.	O
Conclusion	O
negative	O
study	O
for	O
detection	O
of	O
cardiomyopathy	O
due	O
to	O
TTR	O
amyloid	O
deposition	O
.	O
Laboratory	O
tests	O
glucose	O
133	O
mg	O
dl	O
,	O
urea	O
51	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
32	O
mg	O
dl	O
,	O
total	O
protein	O
6	O
.	O
6	O
g	O
dl	O
,	O
total	O
bilirubin	O
1	O
.	O
35	O
mg	O
dl	O
,	O
direct	O
bilirubin	O
0	O
.	O
65	O
mg	O
dl	O
,	O
aspartate	O
transaminase	O
GOT	O
37	O
U	O
,	O
alanine	O
transaminase	O
GPT	O
39	O
U	O
l	O
,	O
gamma	O
glutamyl	O
transferase	O
GGT	O
67	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
ALP	O
103	O
U	O
l	O
,	O
alpha	O
amylase	O
34	O
U	O
l	O
,	O
CPK	O
253	O
U	O
l	O
,	O
lactate	O
dehydrogenase	O
LDH	O
402	O
U	O
l	O
,	O
sodium	O
139	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
90	O
mEq	O
l	O
,	O
chlorine	O
108	O
mEq	O
l	O
.	O
C	O
reactive	O
protein	O
10	O
.	O
4	O
mg	O
l	O
.	O
Brain	O
natriuretic	O
peptide	O
BNP	O
1579	O
pg	O
ml	O
previos	O
370	O
150	O
429	O
.	O
Troponin	O
I	O
high	O
sensitivity	O
2044	O
.	O
3	O
pg	O
ml	O
previous	O
2384	O
650	O
1500	O
1196	O
.	O
Genetic	O
study	O
of	O
mitochondrial	O
disease	O
detection	O
of	O
the	O
most	O
frequent	O
mutations	O
associated	O
with	O
mitochondrial	O
encephalopathy	O
type	O
MELAS	O
.	O
The	O
presence	O
of	O
the	O
m	O
.	O
3243A	O
Gen	O
mutation	O
in	O
the	O
MT	O
TL1	O
gene	O
has	O
been	O
detected	O
.	O
This	O
variant	O
has	O
been	O
found	O
in	O
heteroplasmy	O
with	O
13	O
of	O
the	O
mutated	O
G	O
allele	O
.	O
Endomyocardial	O
biopsy	O
numerous	O
cox	O
negative	O
fibres	O
50	O
.	O
Although	O
an	O
increase	O
in	O
COX	O
negative	O
cardiomyocytes	O
attributed	O
to	O
age	O
is	O
reported	O
,	O
such	O
a	O
high	O
percentage	O
could	O
be	O
compatible	O
with	O
a	O
disease	O
of	O
mitochondrial	O
origin	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
the	O
ED	O
,	O
with	O
clinical	O
suspicion	O
of	O
subacute	O
onset	O
heart	O
failure	O
of	O
uncertain	O
aetiology	O
but	O
with	O
severe	O
current	O
situation	O
with	O
hypotension	O
and	O
peripheral	O
hypoperfusion	O
in	O
addition	O
to	O
infectious	O
analytical	O
parameters	O
and	O
marked	O
increase	O
in	O
markers	O
of	O
myocardial	O
damage	O
,	O
infusion	O
of	O
volume	O
expanders	O
and	O
initiation	O
of	O
oxygen	O
therapy	O
with	O
Ventimask	O
FiO2	O
31	O
and	O
i	O
.	O
v	O
.	O
antibiotic	O
therapy	O
were	O
decided	O
.	O
In	O
the	O
absence	O
of	O
response	O
to	O
initial	O
emergency	O
measures	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
ICU	O
in	O
cardiogenic	O
shock	O
requiring	O
support	O
with	O
vasoactive	O
drugs	O
dobutamine	B-FARMACO
and	O
noradrenaline	B-FARMACO
.	O
On	O
admission	O
,	O
an	O
urgent	O
echocardiogram	O
was	O
performed	O
showing	O
severe	O
biventricular	O
systolic	O
dysfunction	O
LVEF	O
15	O
with	O
severe	O
secondary	O
mitral	O
regurgitation	O
and	O
an	O
apical	O
ventricular	O
thrombus	O
,	O
for	O
which	O
anticoagulation	O
with	O
enoxaparin	B-FARMACO
was	O
initiated	O
and	O
levosimendan	B-FARMACO
perfusion	O
was	O
started	O
.	O
An	O
emergency	O
coronary	O
angiography	O
ruled	O
out	O
coronary	O
artery	O
disease	O
and	O
the	O
patient	O
was	O
labelled	O
cardiogenic	O
shock	O
in	O
the	O
context	O
of	O
probable	O
acute	O
myocarditis	O
.	O
During	O
the	O
first	O
hours	O
of	O
ICU	O
stay	O
,	O
the	O
patient	O
was	O
sleepy	O
but	O
reactive	O
and	O
conscious	O
,	O
maintaining	O
AMT	O
75	O
mmHg	O
with	O
a	O
heart	O
rate	O
of	O
around	O
80	O
bpm	O
,	O
but	O
requiring	O
vasoactive	O
support	O
.	O
Some	O
improvement	O
in	O
renal	O
function	O
with	O
polyuria	O
as	O
well	O
as	O
from	O
the	O
respiratory	O
point	O
of	O
view	O
,	O
requiring	O
support	O
only	O
with	O
nasal	O
cannulas	O
.	O
Acceptable	O
distal	O
perfusion	O
with	O
good	O
gasometric	O
controls	O
but	O
with	O
persistently	O
high	O
lactic	O
acid	O
.	O
During	O
the	O
following	O
7	O
10	O
days	O
the	O
patient	O
remained	O
stationary	O
,	O
dependent	O
on	O
vasoactive	O
drugs	O
VAD	O
,	O
with	O
persistently	O
elevated	O
troponins	O
and	O
BNP	O
levels	O
although	O
slightly	O
decreasing	O
and	O
no	O
improvement	O
in	O
cardiac	O
ventricular	O
function	O
.	O
During	O
her	O
admission	O
to	O
the	O
ICU	O
she	O
was	O
also	O
assessed	O
by	O
angiology	O
,	O
who	O
considered	O
it	O
necessary	O
to	O
perform	O
a	O
metatarsophalangeal	O
amputation	O
of	O
the	O
second	O
fourth	O
MII	O
phalanges	O
in	O
a	O
few	O
weeks	O
,	O
due	O
to	O
necrosis	O
of	O
the	O
same	O
,	O
probably	O
secondary	O
to	O
low	O
cardiac	O
output	O
,	O
high	O
doses	O
of	O
VAD	O
and	O
ventricular	O
thrombus	O
embolism	O
.	O
Given	O
the	O
suspicion	O
of	O
myocarditis	O
with	O
a	O
possible	O
infectious	O
aetiology	O
due	O
to	O
the	O
data	O
of	O
severe	O
global	O
dysfunction	O
and	O
elevated	O
cardiac	O
markers	O
and	O
acute	O
phase	O
reactants	O
,	O
serological	O
tests	O
were	O
requested	O
,	O
with	O
positive	O
liver	O
virus	O
C	O
,	O
as	O
well	O
as	O
IgG	O
and	O
IgM	O
against	O
cytomegalovirus	O
and	O
IgG	O
against	O
Epstein	O
Barr	O
virus	O
,	O
and	O
the	O
rest	O
of	O
the	O
tests	O
were	O
negative	O
.	O
Blood	O
cultures	O
were	O
requested	O
and	O
were	O
negative	O
.	O
CardioMRI	O
with	O
LGE	O
was	O
requested	O
,	O
but	O
as	O
the	O
patient	O
had	O
a	O
cochlear	O
implant	O
it	O
was	O
not	O
possible	O
to	O
perform	O
it	O
.	O
After	O
a	O
month	O
of	O
admission	O
to	O
the	O
coronary	O
unit	O
,	O
with	O
slow	O
but	O
progressive	O
improvement	O
,	O
remaining	O
haemodynamically	O
stable	O
after	O
withdrawal	O
of	O
vasoactive	O
drugs	O
,	O
she	O
was	O
finally	O
transferred	O
to	O
the	O
hospital	O
ward	O
.	O
A	O
new	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
an	O
improvement	O
in	O
biventricular	O
function	O
LVEF	O
41	O
,	O
with	O
no	O
intraventricular	O
thrombus	O
visible	O
.	O
At	O
the	O
myocardial	O
level	O
,	O
slight	O
concentric	O
hypertrophy	O
of	O
the	O
left	O
ventricle	O
was	O
observed	O
,	O
which	O
appeared	O
hyperechogenic	O
and	O
with	O
a	O
reduced	O
ventricular	O
cavity	O
size	O
and	O
data	O
of	O
advanced	O
diastolic	O
dysfunction	O
with	O
increased	O
filling	O
pressures	O
and	O
left	O
atrial	O
size	O
,	O
with	O
no	O
other	O
valvular	O
alterations	O
other	O
than	O
the	O
aforementioned	O
mitral	O
insufficiency	O
.	O
The	O
data	O
were	O
suggestive	O
of	O
deposit	O
or	O
infiltrative	O
disease	O
,	O
with	O
an	O
inflammatory	O
viral	O
origin	O
being	O
less	O
likely	O
.	O
Given	O
these	O
findings	O
,	O
an	O
extensive	O
aetiological	O
study	O
was	O
continued	O
,	O
ruling	O
out	O
autoimmune	O
diseases	O
negative	O
autoantibody	O
battery	O
and	O
prothrombotic	O
diseases	O
special	O
coagulation	O
study	O
with	O
heterozygosity	O
for	O
mutation	O
in	O
the	O
gene	O
for	O
factor	O
XII	O
,	O
methyltetrahydrofolate	O
reductase	O
and	O
factor	O
V	O
Leiden	O
.	O
For	O
the	O
study	O
of	O
possible	O
infiltrative	O
disease	O
,	O
cardiac	O
amyloidosis	O
,	O
both	O
AA	O
,	O
AL	O
and	O
by	O
transthyretin	O
TTR	O
,	O
was	O
the	O
first	O
study	O
target	O
.	O
Urine	O
proteinogram	O
and	O
urine	O
light	O
chains	O
were	O
negative	O
,	O
and	O
a	O
rectal	O
and	O
subcutaneous	O
fat	O
biopsy	O
with	O
Congo	O
red	O
staining	O
were	O
negative	O
.	O
To	O
rule	O
out	O
familial	O
or	O
senile	O
transthyretin	O
amyloidosis	O
,	O
a	O
technetium	O
99	O
diphosphonate	O
scan	O
was	O
performed	O
,	O
which	O
did	O
not	O
identify	O
abnormal	O
TTR	O
deposits	O
.	O
For	O
the	O
study	O
of	O
possible	O
cardiac	O
sarcoidosis	O
,	O
a	O
whole	O
body	O
PET	O
CT	O
scan	O
with	O
18	O
fluorodeoxyglucose	O
was	O
performed	O
,	O
which	O
showed	O
a	O
diffuse	O
,	O
homogeneous	O
circumferential	O
uptake	O
in	O
the	O
entire	O
left	O
ventricular	O
myocardium	O
,	O
suggestive	O
of	O
deposit	O
disease	O
rather	O
than	O
inflammatory	O
,	O
but	O
not	O
compatible	O
with	O
the	O
typical	O
cardiac	O
involvement	O
of	O
sarcoidosis	O
,	O
which	O
is	O
usually	O
patchy	O
.	O
A	O
blood	O
test	O
ruled	O
out	O
the	O
presence	O
of	O
haemochromatosis	O
normal	O
ferritin	O
,	O
transferrin	O
and	O
transferrin	O
saturation	O
index	O
,	O
as	O
well	O
as	O
Wilson	O
's	O
disease	O
and	O
Fabry	O
's	O
disease	O
.	O
The	O
patient	O
was	O
discharged	O
in	O
good	O
functional	O
class	O
,	O
after	O
more	O
than	O
2	O
months	O
of	O
hospitalisation	O
,	O
with	O
a	O
diagnosis	O
of	O
cardiomyopathy	O
of	O
unaffiliated	O
origin	O
,	O
and	O
reviewed	O
in	O
consultation	O
every	O
three	O
months	O
.	O
Initially	O
she	O
presented	O
clinical	O
and	O
analytical	O
improvement	O
;	O
however	O
,	O
from	O
the	O
eighth	O
month	O
after	O
discharge	O
,	O
there	O
was	O
a	O
progressive	O
worsening	O
with	O
an	O
increase	O
in	O
BNP	O
and	O
troponin	O
,	O
as	O
well	O
as	O
a	O
decrease	O
in	O
LVEF	O
and	O
the	O
need	O
for	O
a	O
new	O
admission	O
due	O
to	O
recurrence	O
of	O
the	O
intraventricular	O
thrombus	O
.	O
For	O
this	O
reason	O
,	O
treatment	O
was	O
started	O
with	O
apixaban	B-FARMACO
5	O
mg	O
every	O
12	O
hours	O
and	O
diuretic	O
and	O
heart	O
failure	O
treatment	O
was	O
optimised	O
.	O
After	O
discharge	O
from	O
hospital	O
,	O
the	O
patient	O
was	O
referred	O
to	O
the	O
outpatient	O
clinic	O
for	O
family	O
heart	O
disease	O
in	O
order	O
to	O
clarify	O
whether	O
she	O
might	O
have	O
a	O
cardiomyopathy	O
of	O
this	O
type	O
.	O
On	O
closer	O
examination	O
,	O
the	O
patient	O
's	O
short	O
stature	O
126	O
cm	O
,	O
the	O
presence	O
of	O
sensorineural	O
hearing	O
loss	O
and	O
Wolff	O
Parkinson	O
White	O
syndrome	O
WPW	O
were	O
noted	O
,	O
leading	O
to	O
the	O
suspicion	O
of	O
mitochondrial	O
MELAS	O
disease	O
.	O
A	O
genetic	O
study	O
was	O
then	O
requested	O
to	O
confirm	O
this	O
and	O
indeed	O
it	O
showed	O
an	O
m	O
.	O
3243A	O
G	O
mutation	O
in	O
the	O
MT	O
TL1	O
gene	O
,	O
with	O
heteroplasmy	O
of	O
13	O
in	O
peripheral	O
blood	O
,	O
this	O
being	O
the	O
variant	O
most	O
frequently	O
associated	O
with	O
mitochondrial	O
diseases	O
,	O
and	O
in	O
particular	O
with	O
MELAS	O
syndrome	O
mitochondrial	O
encephalopathy	O
,	O
lactic	O
acidosis	O
and	O
stroke	O
like	O
episodes	O
.	O
In	O
order	O
to	O
demonstrate	O
a	O
greater	O
degree	O
of	O
heteroplasmy	O
at	O
the	O
myocardial	O
level	O
and	O
the	O
possible	O
association	O
of	O
myocarditis	O
as	O
a	O
possible	O
trigger	O
for	O
such	O
a	O
marked	O
worsening	O
of	O
cardiac	O
function	O
,	O
an	O
endomyocardial	O
biopsy	O
was	O
performed	O
,	O
which	O
confirmed	O
this	O
suspicion	O
.	O
The	O
patient	O
has	O
also	O
been	O
referred	O
for	O
neurological	O
assessment	O
and	O
a	O
matrilineal	O
family	O
study	O
has	O
been	O
initiated	O
.	O
DIAGNOSIS	O
Possible	O
acute	O
myocarditis	O
on	O
underlying	O
heart	O
disease	O
presenting	O
as	O
cardiogenic	O
shock	O
with	O
favourable	O
evolution	O
.	O
MELAS	O
mitochondrial	O
disease	O
with	O
m	O
.	O
3243A	O
G	O
mutation	O
in	O
MT	O
TL1	O
gene	O
.	O
Hypertrophic	O
cardiomyopathy	O
secondary	O
to	O
MELAS	O
.	O
WPW	O
syndrome	O
left	O
latera	O
tract	O
.	O
Recurrent	O
intraventricular	O
thrombus	O
with	O
peripheral	O
embolism	O
necrosis	O
and	O
amputation	O
of	O
lower	O
phalanges	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
75	O
year	O
old	O
male	O
patient	O
.	O
No	O
known	O
allergic	O
reactions	O
to	O
medication	O
.	O
Ex	O
smoker	O
of	O
12	O
pack	O
years	O
.	O
Arterial	O
hypertension	O
.	O
No	O
enolic	O
habit	O
.	O
Cardiological	O
history	O
advanced	O
heart	O
failure	O
.	O
Severe	O
left	O
ventricular	O
systolic	O
dysfunction	O
left	O
ventricular	O
ejection	O
fraction	O
20	O
in	O
last	O
echocardiographic	O
study	O
in	O
November	O
2019	O
.	O
Right	O
ventricular	O
dysfunction	O
with	O
severe	O
tricuspid	O
regurgitation	O
and	O
severe	O
pulmonary	O
hypertension	O
.	O
Transposition	O
of	O
great	O
vessels	O
congenitally	O
corrected	O
,	O
not	O
intervened	O
.	O
Last	O
coronary	O
angiography	O
in	O
2017	O
without	O
angiographically	O
significant	O
coronary	O
lesions	O
.	O
Primary	O
prevention	O
with	O
a	O
resynchronised	O
defibrillator	O
.	O
NYHA	O
functional	O
class	O
III	O
IV	O
.	O
Discarded	O
for	O
cardiac	O
transplant	O
or	O
ventricular	O
assistance	O
by	O
his	O
reference	O
unit	O
due	O
to	O
age	O
and	O
associated	O
comorbidity	O
.	O
Other	O
antecedents	O
hyperuricaemia	O
.	O
Stage	O
3aA1	O
chronic	O
kidney	O
disease	O
.	O
Urothelial	O
carcinoma	O
operated	O
on	O
in	O
2019	O
by	O
transurethral	O
resection	O
.	O
Anxiosodepressive	O
syndrome	O
.	O
Family	O
history	O
no	O
history	O
of	O
sudden	O
cardiac	O
death	O
,	O
cardiac	O
surgery	O
or	O
heart	O
transplant	O
.	O
Denies	O
cases	O
of	O
early	O
cardiovascular	O
disease	O
in	O
the	O
family	O
.	O
On	O
regular	O
treatment	O
with	O
furosemide	B-FARMACO
80	O
mg	O
daily	O
;	O
bisoprolol	B-FARMACO
5	O
mg	O
daily	O
;	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
24	O
26	O
mg	O
12	O
hours	O
;	O
eplerenone	B-FARMACO
25	O
mg	O
daily	O
;	O
allopurinol	B-FARMACO
100	O
mg	O
daily	O
;	O
sertraline	B-FARMACO
50	O
mg	O
daily	O
;	O
omeprazole	B-FARMACO
40	O
mg	O
daily	O
.	O
Present	O
illness	O
Patient	O
who	O
was	O
admitted	O
to	O
our	O
centre	O
on	O
a	O
scheduled	O
basis	O
to	O
start	O
outpatient	O
cycles	O
of	O
levosimendan	B-FARMACO
.	O
The	O
patient	O
was	O
referred	O
from	O
his	O
reference	O
centre	O
in	O
the	O
Community	O
of	O
Madrid	O
due	O
to	O
the	O
overload	O
of	O
the	O
system	O
due	O
to	O
the	O
onset	O
of	O
the	O
SARS	O
CoV	O
2	O
viral	O
pandemic	O
.	O
On	O
admission	O
,	O
he	O
denied	O
an	O
increase	O
in	O
basal	O
oedema	O
in	O
the	O
lower	O
limbs	O
and	O
an	O
increase	O
in	O
basal	O
dyspnoea	O
which	O
persisted	O
on	O
minimal	O
exertion	O
,	O
although	O
not	O
at	O
rest	O
.	O
However	O
,	O
he	O
reported	O
an	O
increase	O
in	O
the	O
use	O
of	O
a	O
pillow	O
in	O
the	O
last	O
week	O
to	O
achieve	O
a	O
good	O
night	O
's	O
rest	O
.	O
Physical	O
examination	O
Temperature	O
36	O
.	O
7	O
oC	O
;	O
blood	O
pressure	O
108	O
69	O
mmHg	O
;	O
heart	O
rate	O
60	O
bpm	O
;	O
O2	O
saturation	O
93	O
with	O
no	O
oxygen	B-FARMACO
intake	O
.	O
Weight	O
on	O
admission	O
72	O
kg	O
.	O
No	O
signs	O
of	O
tachypnoea	O
at	O
rest	O
.	O
Neurological	O
examination	O
without	O
alterations	O
.	O
Cardiac	O
auscultation	O
was	O
rhythmic	O
,	O
with	O
a	O
low	O
intensity	O
systolic	O
murmur	O
in	O
the	O
aortic	O
focus	O
,	O
non	O
radiated	O
,	O
and	O
pulmonary	O
auscultation	O
with	O
fine	O
crackles	O
in	O
the	O
right	O
base	O
.	O
On	O
abdominal	O
examination	O
,	O
no	O
organomegaly	O
was	O
palpable	O
;	O
hepatojugular	O
reflux	O
was	O
positive	O
.	O
The	O
lower	O
limbs	O
showed	O
oedema	O
in	O
the	O
distal	O
third	O
and	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Pulses	O
were	O
palpable	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
on	O
admission	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
with	O
ventricular	O
stimulation	O
by	O
resynchroniser	O
.	O
No	O
significant	O
artefacts	O
or	O
signs	O
of	O
acute	O
ischaemia	O
.	O
Laboratory	O
tests	O
on	O
admission	O
haemoglobin	O
11	O
.	O
8	O
g	O
dl	O
,	O
MCV	O
91	O
fl	O
,	O
MCHC	O
33	O
.	O
5	O
g	O
dl	O
,	O
leukocytes	O
2400	O
μl	O
1900	O
segmented	O
300	O
lymphocytes	O
200	O
monocytes	O
,	O
platelets	O
130000	O
μl	O
;	O
glycaemia	O
92	O
mg	O
dl	O
,	O
urea	O
94	O
mg	O
dl	O
,	O
creatinine	O
2	O
.	O
2	O
mg	O
dl	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
MDRD	O
26	O
ml	O
min	O
1	O
.	O
73	O
,	O
total	O
bilirubin	O
1	O
,	O
GOT	O
39	O
,	O
GPT	O
26	O
,	O
sodium	O
131	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
8	O
mol	O
l	O
,	O
calcium	O
8	O
mg	O
dl	O
,	O
magnesium	O
2	O
.	O
3	O
mg	O
dl	O
.	O
Urgent	O
chest	O
X	O
ray	O
increased	O
cardiothoracic	O
index	O
with	O
discrete	O
signs	O
of	O
vascular	O
redistribution	O
.	O
Parenchymal	O
infiltrate	O
in	O
the	O
right	O
lower	O
lung	O
lobe	O
.	O
There	O
was	O
minimal	O
associated	O
pleural	O
effusion	O
.	O
The	O
patient	O
had	O
a	O
resynchronisation	O
device	O
,	O
with	O
normally	O
positioned	O
three	O
chamber	O
electrodes	O
.	O
Microbiological	O
study	O
rapid	O
influenza	O
A	O
and	O
B	O
test	O
negative	O
;	O
antigenuria	O
for	O
pneumococcus	O
negative	O
;	O
antigenuria	O
for	O
Legionella	O
serogroup	O
1	O
negative	O
;	O
PCR	O
for	O
SARS	O
CoV2	O
coronavirus	O
positive	O
.	O
Control	O
analytical	O
study	O
haemoglobin	O
11	O
.	O
5	O
g	O
dl	O
,	O
MCV	O
93	O
fl	O
,	O
MCHC	O
32	O
g	O
dl	O
,	O
Leukocytes	O
4700	O
μl	O
3600	O
segmented	O
900	O
lymphocytes	O
150	O
monocytes	O
,	O
platelets	O
237000	O
μl	O
;	O
glycaemia	O
109	O
mg	O
dl	O
,	O
urea	O
67	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
7	O
mg	O
dl	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
MDRD	O
37	O
ml	O
min	O
1	O
.	O
73	O
,	O
total	O
bilirubin	O
1	O
.	O
3	O
,	O
GOT	O
29	O
,	O
GPT	O
25	O
,	O
sodium	O
136	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
2	O
mol	O
l	O
,	O
calcium	O
8	O
.	O
3	O
mg	O
dl	O
,	O
magnesium	O
1	O
.	O
8	O
mg	O
dl	O
.	O
Cardiac	O
biomarkers	O
ultrasensitive	O
troponin	O
I	O
78	O
μg	O
l	O
reference	O
limit	O
20	O
μg	O
l	O
CPK	O
121	O
IU	O
,	O
ProBNP	O
4325	O
pg	O
ml	O
.	O
Anaemia	O
profile	O
iron	O
147	O
μg	O
dl	O
ref	O
175	O
,	O
ferritin	O
94	O
μg	O
ml	O
,	O
transferrin	O
187	O
mg	O
dl	O
,	O
IST	O
7	O
,	O
folic	O
acid	O
24	O
ng	O
ml	O
.	O
Chest	O
X	O
ray	O
prior	O
to	O
discharge	O
the	O
right	O
pulmonary	O
infiltrate	O
practically	O
disappeared	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
had	O
been	O
seen	O
in	O
outpatient	O
cardiology	O
consultations	O
at	O
our	O
centre	O
the	O
previous	O
week	O
for	O
re	O
evaluation	O
of	O
the	O
case	O
,	O
in	O
which	O
he	O
reported	O
an	O
absence	O
of	O
symptoms	O
suggestive	O
of	O
COVID	O
19	O
infection	O
.	O
However	O
,	O
he	O
did	O
describe	O
the	O
symptoms	O
described	O
previously	O
,	O
compatible	O
with	O
an	O
increase	O
in	O
his	O
usual	O
orthopnoea	O
.	O
A	O
blood	O
test	O
drawn	O
by	O
protocol	O
prior	O
to	O
the	O
first	O
cycle	O
with	O
levosimendan	B-FARMACO
showed	O
lymphopenia	O
and	O
thrombocytopenia	O
with	O
an	O
increase	O
in	O
acute	O
phase	O
reactants	O
.	O
The	O
patient	O
was	O
re	O
evaluated	O
in	O
a	O
targeted	O
manner	O
,	O
on	O
this	O
occasion	O
referring	O
to	O
the	O
existence	O
of	O
a	O
diarrhoeal	O
syndrome	O
with	O
stools	O
without	O
pathological	O
products	O
in	O
the	O
last	O
4	O
days	O
,	O
which	O
he	O
had	O
not	O
previously	O
described	O
.	O
His	O
temperature	O
had	O
not	O
been	O
taken	O
,	O
although	O
he	O
did	O
not	O
describe	O
fever	O
or	O
chills	O
.	O
She	O
did	O
report	O
intense	O
asthenia	O
,	O
which	O
she	O
had	O
attributed	O
to	O
her	O
cardiac	O
pathology	O
.	O
A	O
chest	O
X	O
ray	O
was	O
requested	O
,	O
which	O
revealed	O
the	O
presence	O
of	O
a	O
right	O
pneumonic	O
infiltrate	O
.	O
In	O
this	O
context	O
,	O
the	O
COVID	O
19	O
suspicion	O
protocol	O
was	O
activated	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
an	O
isolation	O
area	O
,	O
where	O
microbiological	O
samples	O
were	O
taken	O
.	O
Treatment	O
was	O
started	O
with	O
hydroxychloroquine	B-FARMACO
and	O
lopinavir	B-FARMACO
ritonavir	I-FARMACO
,	O
given	O
the	O
high	O
suspicion	O
in	O
a	O
patient	O
at	O
risk	O
with	O
pulmonary	O
infiltrate	O
,	O
and	O
diuretic	O
treatment	O
was	O
reinforced	O
by	O
adding	O
intravenous	O
furosemide	B-FARMACO
80	O
mg	O
daily	O
to	O
his	O
usual	O
treatment	O
.	O
During	O
admission	O
,	O
serial	O
electrocardiographic	O
and	O
analytical	O
determinations	O
were	O
performed	O
.	O
At	O
the	O
last	O
check	O
up	O
after	O
finishing	O
the	O
hydroxychloroquine	B-FARMACO
regimen	O
,	O
an	O
iron	O
profile	O
study	O
was	O
performed	O
and	O
ferropenia	O
was	O
detected	O
,	O
so	O
it	O
was	O
proposed	O
to	O
start	O
treatment	O
with	O
1	O
gram	O
of	O
hierrocarboxymaltose	B-FARMACO
prior	O
to	O
discharge	O
.	O
Administration	O
was	O
carried	O
out	O
without	O
incident	O
.	O
The	O
patient	O
had	O
a	O
favourable	O
clinical	O
evolution	O
,	O
remaining	O
afebrile	O
and	O
with	O
minimal	O
oxygen	B-FARMACO
intake	O
throughout	O
admission	O
.	O
He	O
showed	O
a	O
weight	O
reduction	O
of	O
5	O
.	O
5	O
kg	O
.	O
He	O
completed	O
the	O
treatment	O
regimen	O
with	O
hydroxychloroquine	B-FARMACO
and	O
,	O
after	O
consultation	O
with	O
the	O
patient	O
,	O
it	O
was	O
decided	O
to	O
administer	O
the	O
first	O
course	O
of	O
levosimendan	B-FARMACO
,	O
with	O
good	O
haemodynamic	O
tolerance	O
and	O
no	O
notable	O
complications	O
.	O
Three	O
weeks	O
after	O
discharge	O
,	O
the	O
patient	O
received	O
the	O
second	O
cycle	O
of	O
levosimendan	B-FARMACO
with	O
excellent	O
tolerance	O
.	O
When	O
contacted	O
by	O
telephone	O
,	O
the	O
patient	O
reported	O
symptomatic	O
improvement	O
with	O
a	O
reduction	O
in	O
the	O
number	O
of	O
pillows	O
and	O
a	O
decrease	O
in	O
dyspnoea	O
to	O
NYHA	O
functional	O
class	O
II	O
.	O
The	O
asthenia	O
had	O
disappeared	O
.	O
DIAGNOSIS	O
Advanced	O
chronic	O
heart	O
failure	O
with	O
severely	O
depressed	O
ejection	O
fraction	O
.	O
Congenitally	O
corrected	O
transposition	O
of	O
great	O
vessels	O
.	O
Right	O
lower	O
pneumonia	O
due	O
to	O
SARS	O
CoV	O
2	O
COVID	O
19	O
.	O
Re	O
exacerbated	O
chronic	O
kidney	O
disease	O
.	O
Iron	O
deficiency	O
treated	O
with	O
intravenous	O
administration	O
of	O
iron	B-FARMACO
carboxymaltose	I-FARMACO
.	O

We	O
present	O
the	O
case	O
of	O
a	O
68	O
year	O
old	O
man	O
with	O
a	O
history	O
of	O
mitro	O
aortic	O
valve	O
disease	O
who	O
presented	O
with	O
new	O
onset	O
left	O
heart	O
failure	O
,	O
which	O
highlights	O
the	O
importance	O
of	O
finding	O
its	O
cause	O
for	O
its	O
aetiological	O
treatment	O
.	O
HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
arterial	O
hypertension	O
AHT	O
of	O
more	O
than	O
10	O
years	O
of	O
evolution	O
in	O
treatment	O
with	O
irbesartan	B-FARMACO
with	O
good	O
control	O
.	O
LD	O
of	O
8	O
years	O
of	O
evolution	O
.	O
No	O
diabetes	O
mellitus	O
DM	O
.	O
Cardiological	O
history	O
aortic	O
valve	O
disease	O
of	O
unknown	O
origin	O
no	O
reports	O
available	O
,	O
which	O
required	O
valve	O
surgery	O
with	O
implantation	O
of	O
a	O
biological	O
aortic	O
prosthesis	O
at	O
the	O
age	O
of	O
33	O
1979	O
,	O
replacement	O
with	O
a	O
BJORK	O
mechanical	O
aortic	O
prosthesis	O
monodisc	O
no	O
21	O
at	O
the	O
age	O
of	O
43	O
1989	O
.	O
And	O
new	O
cardiac	O
surgery	O
for	O
implantation	O
of	O
mechanical	O
mitral	O
prosthesis	O
Omnicarbon	O
No	O
27	O
at	O
the	O
age	O
of	O
55	O
2001	O
,	O
due	O
to	O
mitral	O
insufficiency	O
of	O
degenerative	O
origin	O
.	O
Permanent	O
atrial	O
fibrillation	O
AF	O
since	O
the	O
age	O
of	O
53	O
cardioversion	O
in	O
2002	O
,	O
2003	O
,	O
2005	O
not	O
effective	O
.	O
Severe	O
pulmonary	O
hypertension	O
prior	O
to	O
mitral	O
valve	O
surgery	O
.	O
Preserved	O
LVEF	O
.	O
Other	O
medical	O
history	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O
Surgical	O
interventions	O
no	O
other	O
surgical	O
antecedents	O
of	O
interest	O
.	O
Usual	O
treatment	O
bromazepam	B-FARMACO
1	O
.	O
5	O
mg	O
24	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
irbesartan	B-FARMACO
150	O
mg	O
24	O
hours	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
12	O
hours	O
,	O
furosemide	B-FARMACO
40	O
mg	O
24	O
hours	O
,	O
digoxin	B-FARMACO
1	O
.	O
25	O
mg	O
24	O
hours	O
,	O
tadalafil	B-FARMACO
40	O
mg	O
24	O
hours	O
,	O
paracetamol	B-FARMACO
1	O
g	O
8	O
hours	O
if	O
needed	O
,	O
sintrom	B-FARMACO
according	O
to	O
guideline	O
.	O
Baseline	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
.	O
Dyspnoea	O
on	O
moderate	O
exertion	O
.	O
Orthopnoea	O
on	O
2	O
pillows	O
.	O
No	O
cognitive	O
impairment	O
.	O
Present	O
illness	O
A	O
68	O
year	O
old	O
man	O
with	O
increased	O
dyspnoea	O
of	O
moderate	O
to	O
minimal	O
exertion	O
for	O
10	O
12	O
days	O
.	O
No	O
chest	O
pain	O
.	O
Orthopnoea	O
on	O
3	O
pillows	O
.	O
Reduced	O
diuresis	O
.	O
Increased	O
nocturnal	O
cough	O
without	O
expectoration	O
.	O
Afebrile	O
.	O
Increase	O
in	O
the	O
perimeter	O
of	O
the	O
lower	O
limbs	O
MMII	O
.	O
Treated	O
with	O
azithromycin	B-FARMACO
and	O
Flutox	B-FARMACO
without	O
improvement	O
.	O
Generalised	O
myalgias	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
184	O
85	O
mmHg	O
,	O
heart	O
rate	O
HR	O
77	O
bpm	O
,	O
temperature	O
36	O
oC	O
,	O
SatO2	O
91	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
,	O
metallic	O
click	O
in	O
aortic	O
focus	O
,	O
systolic	O
murmur	O
in	O
left	O
parasternal	O
border	O
.	O
Pulmonary	O
auscultation	O
bilateral	O
crackles	O
with	O
abolition	O
of	O
vesicular	O
murmur	O
in	O
the	O
left	O
hemithorax	O
.	O
Abdomen	O
RHA	O
,	O
globular	O
,	O
tympanised	O
,	O
scarcely	O
depressible	O
,	O
not	O
painful	O
on	O
deep	O
palpation	O
.	O
MMII	O
malleolar	O
oedema	O
with	O
bilateral	O
fovea	O
,	O
chronic	O
venous	O
insufficiency	O
with	O
trophic	O
disorders	O
in	O
the	O
skin	O
.	O
COMPLEMENTARY	O
TESTS	O
Chest	O
X	O
ray	O
left	O
pleural	O
effusion	O
,	O
image	O
with	O
increased	O
density	O
in	O
the	O
posterior	O
lobe	O
of	O
the	O
right	O
hemithorax	O
,	O
left	O
laminar	O
atelectasis	O
,	O
rounded	O
laminar	O
atelectasis	O
.	O
Electrocardiogram	O
ECG	O
AF	O
with	O
controlled	O
RV	O
.	O
Cornell	O
LVH	O
.	O
Repolarisation	O
alterations	O
in	O
V5	O
,	O
V6	O
,	O
I	O
,	O
aVL	O
,	O
II	O
in	O
digitised	O
patient	O
.	O
CBC	O
leukocytes	O
11	O
,	O
300	O
thousands	O
mcl	O
,	O
sodium	O
68	O
.	O
4	O
,	O
Hb	O
12	O
.	O
6	O
g	O
dl	O
Hto	O
39	O
.	O
2	O
,	O
platelets	O
179	O
,	O
000	O
thousands	O
mcl	O
,	O
urea	O
81	O
mg	O
dl	O
,	O
Cr	O
1	O
.	O
08	O
mg	O
dl	O
,	O
GOT	O
32	O
Ul	O
l	O
,	O
GPT	O
29	O
Ul	O
l	O
,	O
CPK	O
29	O
,	O
Na	O
135	O
mEq	O
l	O
,	O
K	O
4	O
.	O
5	O
mEq	O
l	O
.	O
Echocardiogram	O
severely	O
dilated	O
right	O
atrium	O
.	O
Severely	O
dilated	O
right	O
ventricle	O
.	O
Severe	O
pulmonary	O
hypertension	O
PHT	O
.	O
RVEF	O
at	O
the	O
limit	O
.	O
Functional	O
tricuspid	O
insufficiency	O
due	O
to	O
dilatation	O
of	O
the	O
annulus	O
and	O
stretching	O
of	O
the	O
chordae	O
tendineae	O
,	O
severe	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
.	O
Anomalous	O
septal	O
motion	O
,	O
paradoxical	O
.	O
Slightly	O
depressed	O
LVEF	O
45	O
.	O
Mitral	O
and	O
aortic	O
metallic	O
prosthesis	O
of	O
monodisc	O
appearance	O
and	O
preserved	O
mobility	O
.	O
Chest	O
CT	O
water	O
retention	O
in	O
the	O
right	O
hemithorax	O
evanescent	O
tumour	O
,	O
a	O
subacute	O
chronic	O
aortic	O
dissection	O
,	O
Standford	O
type	O
A	O
or	O
type	O
I	O
according	O
to	O
the	O
Bakey	O
classification	O
,	O
without	O
involvement	O
of	O
the	O
coronary	O
arteries	O
.	O
Abdomen	O
pelvis	O
CT	O
scan	O
the	O
dissection	O
extended	O
to	O
the	O
right	O
external	O
iliac	O
artery	O
and	O
reached	O
the	O
right	O
common	O
femoral	O
artery	O
.	O
The	O
true	O
lumen	O
irrigated	O
the	O
celiac	O
trunk	O
,	O
superior	O
and	O
inferior	O
mesenteric	O
artery	O
and	O
both	O
renal	O
arteries	O
.	O
The	O
thoracic	O
portion	O
of	O
the	O
descending	O
aorta	O
had	O
a	O
diameter	O
of	O
33	O
.	O
4	O
mm	O
and	O
26	O
mm	O
at	O
the	O
level	O
of	O
the	O
diaphragmatic	O
hiatus	O
.	O
The	O
false	O
lumen	O
measured	O
11	O
.	O
7	O
mm	O
.	O
There	O
was	O
also	O
a	O
mild	O
right	O
and	O
moderate	O
left	O
pleural	O
effusion	O
of	O
posterobasal	O
and	O
subpulmonary	O
location	O
and	O
a	O
loculated	O
effusion	O
in	O
the	O
right	O
major	O
fissure	O
evanescent	O
tumour	O
with	O
a	O
smooth	O
and	O
regular	O
edge	O
measuring	O
65	O
x	O
35	O
mm	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
hospital	O
for	O
further	O
investigation	O
and	O
treatment	O
.	O
After	O
an	O
initial	O
assessment	O
,	O
the	O
diagnosis	O
was	O
compatible	O
with	O
right	O
and	O
left	O
heart	O
failure	O
,	O
the	O
latter	O
being	O
a	O
new	O
onset	O
,	O
for	O
which	O
diuretic	O
treatment	O
was	O
prescribed	O
.	O
There	O
was	O
clinical	O
improvement	O
and	O
the	O
increase	O
in	O
density	O
found	O
in	O
the	O
X	O
ray	O
taken	O
during	O
the	O
stay	O
in	O
the	O
emergency	O
department	O
was	O
partially	O
reduced	O
,	O
although	O
it	O
did	O
not	O
disappear	O
.	O
A	O
chest	O
CT	O
scan	O
was	O
requested	O
to	O
assess	O
the	O
image	O
in	O
the	O
right	O
hemithorax	O
,	O
which	O
showed	O
water	O
retention	O
at	O
that	O
level	O
evanescent	O
tumour	O
and	O
detected	O
a	O
subacute	O
chronic	O
aortic	O
dissection	O
of	O
Standford	O
type	O
A	O
or	O
type	O
I	O
according	O
to	O
the	O
Bakey	O
classification	O
,	O
without	O
involvement	O
of	O
the	O
coronary	O
arteries	O
.	O
Subsequent	O
studies	O
showed	O
its	O
extension	O
to	O
the	O
right	O
external	O
iliac	O
artery	O
until	O
it	O
reached	O
the	O
right	O
common	O
femoral	O
artery	O
.	O
The	O
true	O
lumen	O
irrigated	O
the	O
celiac	O
trunk	O
,	O
superior	O
and	O
inferior	O
mesenteric	O
artery	O
and	O
both	O
renal	O
arteries	O
.	O
The	O
patient	O
reported	O
no	O
chest	O
pain	O
at	O
any	O
time	O
.	O
Given	O
the	O
findings	O
,	O
sintrom	B-FARMACO
was	O
suspended	O
and	O
i	O
.	O
v	O
.	O
sodium	B-FARMACO
heparin	I-FARMACO
was	O
started	O
.	O
The	O
case	O
was	O
discussed	O
with	O
the	O
cardiac	O
surgery	O
service	O
of	O
the	O
referral	O
hospital	O
and	O
it	O
was	O
decided	O
to	O
transfer	O
the	O
patient	O
for	O
surgery	O
.	O
The	O
patient	O
underwent	O
aortic	O
surgery	O
,	O
implanting	O
a	O
FlowWeave	O
Bioseal	O
32	O
mm	O
supracoronary	O
vascular	O
prosthesis	O
,	O
"	O
transforming	O
"	O
the	O
Stanford	O
type	O
A	O
dissection	O
into	O
a	O
type	O
B	O
,	O
together	O
with	O
tricuspid	O
Vega	O
annuloplasty	O
.	O
DIAGNOSIS	O
Subacute	O
Stanford	O
type	O
A	O
aortic	O
dissection	O
candidate	O
for	O
cardiac	O
surgery	O
.	O
Normofunctioning	O
mitral	O
and	O
aortic	O
prosthesis	O
.	O
Mildly	O
affected	O
LVEF	O
with	O
borderline	O
RVEF	O
.	O
Severe	O
PHT	O
.	O
Permanent	O
AF	O
.	O
AHT	O
.	O
DLP	O
.	O

The	O
patient	O
was	O
a	O
52	O
year	O
old	O
man	O
who	O
came	O
to	O
the	O
emergency	O
department	O
for	O
a	O
syncopal	O
episode	O
while	O
he	O
was	O
watching	O
his	O
son	O
's	O
football	O
match	O
.	O
Due	O
to	O
the	O
infrequent	O
aetiopathogenesis	O
of	O
the	O
condition	O
and	O
treatment	O
,	O
we	O
consider	O
it	O
interesting	O
to	O
report	O
it	O
.	O
HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Active	O
smoking	O
3	O
4	O
cigars	O
day	O
.	O
Chronic	O
alcoholism	O
.	O
No	O
other	O
cardiovascular	O
risk	O
factors	O
CVRF	O
.	O
No	O
surgical	O
history	O
.	O
In	O
treatment	O
with	O
disulfiram	B-FARMACO
,	O
with	O
no	O
other	O
chronic	O
medications	O
.	O
Present	O
illness	O
A	O
52	O
year	O
old	O
man	O
came	O
to	O
the	O
emergency	O
department	O
for	O
a	O
syncopal	O
episode	O
with	O
a	O
fall	O
to	O
the	O
ground	O
while	O
watching	O
a	O
football	O
match	O
.	O
The	O
episode	O
was	O
preceded	O
by	O
facial	O
flushing	O
,	O
sweating	O
,	O
general	O
malaise	O
and	O
pallor	O
.	O
He	O
had	O
no	O
chest	O
pain	O
,	O
dyspnoea	O
or	O
palpitations	O
.	O
Eyewitnesses	O
denied	O
convulsive	O
movements	O
.	O
Emergency	O
medical	O
services	O
were	O
contacted	O
and	O
he	O
was	O
treated	O
on	O
the	O
spot	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
on	O
arrival	O
at	O
the	O
emergency	O
department	O
90	O
50	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
70	O
bpm	O
.	O
Oxygen	O
saturation	O
96	O
on	O
room	O
air	O
.	O
Respiratory	O
rate	O
16	O
rpm	O
.	O
Good	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
.	O
No	O
obvious	O
neurological	O
focality	O
.	O
Afebrile	O
.	O
Sweating	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
extra	O
sounds	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
extremities	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
Blood	O
count	O
normal	O
.	O
Biochemistry	O
basal	O
glucose	O
94	O
mg	O
dl	O
;	O
creatinine	O
0	O
.	O
9	O
mg	O
dl	O
;	O
normal	O
ions	O
and	O
transaminases	O
;	O
total	O
cholesterol	O
152	O
mg	O
dl	O
;	O
LDL	O
C	O
87	O
mg	O
dl	O
.	O
Hyperlactacidemia	O
without	O
acidosis	O
,	O
transient	O
.	O
Maximal	O
serial	O
myocardial	O
necrosis	O
markers	O
troponin	O
T	O
us	O
657	O
ng	O
l	O
normal	O
13	O
ng	O
l	O
.	O
Baseline	O
coagulation	O
INR	O
1	O
.	O
13	O
;	O
PT	O
87	O
;	O
aPTT	O
ratio	O
1	O
.	O
15	O
.	O
Electrocardiogram	O
On	O
arrival	O
of	O
the	O
emergency	O
medical	O
team	O
image	O
1	O
sinus	O
tachycardia	O
at	O
110	O
bpm	O
.	O
Narrow	O
QRS	O
,	O
axis	O
at	O
15o	O
.	O
Embryonic	O
R	O
wave	O
with	O
flat	O
T	O
wave	O
in	O
DIII	O
and	O
aVF	O
.	O
J	O
point	O
descent	O
of	O
1	O
mm	O
in	O
V1	O
V2	O
.	O
Discrete	O
elevation	O
maximum	O
1	O
mm	O
in	O
V5	O
of	O
the	O
ST	O
segment	O
from	O
V3	O
to	O
V6	O
.	O
At	O
discharge	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
,	O
with	O
high	O
R	O
wave	O
in	O
V2	O
and	O
negative	O
T	O
waves	O
in	O
inferior	O
face	O
.	O
Echocardiogram	O
left	O
ventricle	O
LV	O
of	O
normal	O
size	O
and	O
thickness	O
,	O
preserved	O
systolic	O
function	O
EF	O
60	O
with	O
mild	O
inferior	O
hypokinesia	O
.	O
Left	O
atrium	O
LA	O
and	O
right	O
chambers	O
normal	O
.	O
No	O
significant	O
valvular	O
abnormalities	O
.	O
No	O
pulmonary	O
hypertension	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
.	O
No	O
pericardial	O
effusion	O
.	O
Interconsultation	O
with	O
the	O
psychosomatic	O
department	O
treatment	O
for	O
addiction	O
is	O
reinforced	O
.	O
Start	O
of	O
clomethiazole	B-FARMACO
.	O
Coronary	O
angiography	O
images	O
of	O
intracoronary	O
thrombus	O
without	O
complicated	O
plaque	O
in	O
proximal	O
medial	O
DC	O
.	O
After	O
1	O
week	O
of	O
treatment	O
with	O
i	O
.	O
v	O
.	O
sodium	B-FARMACO
heparin	I-FARMACO
,	O
the	O
thrombus	O
resolved	O
.	O
Optical	O
coherence	O
tomography	O
OCT	O
showed	O
an	O
image	O
suggestive	O
of	O
plaque	O
erosion	O
in	O
the	O
proximal	O
medial	O
right	O
coronary	O
artery	O
RCA	O
,	O
which	O
was	O
not	O
treated	O
medical	O
treatment	O
.	O
The	O
rest	O
of	O
the	O
coronary	O
arteries	O
showed	O
no	O
significant	O
lesions	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
arrival	O
of	O
the	O
emergency	O
medical	O
team	O
,	O
frank	O
arterial	O
hypotension	O
was	O
observed	O
70	O
40	O
mmHg	O
and	O
an	O
ECG	O
was	O
performed	O
showing	O
ST	O
segment	O
underleveling	O
from	O
V3	O
to	O
V6	O
,	O
which	O
subsequently	O
evolved	O
to	O
discrete	O
ST	O
segment	O
supralowing	O
in	O
these	O
leads	O
,	O
for	O
which	O
reason	O
he	O
was	O
transferred	O
to	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
.	O
On	O
arrival	O
,	O
the	O
ECG	O
normalised	O
.	O
Despite	O
initially	O
denying	O
it	O
,	O
he	O
admitted	O
alcohol	O
intake	O
minutes	O
before	O
the	O
syncopal	O
episode	O
currently	O
under	O
treatment	O
with	O
disulfiram	B-FARMACO
.	O
After	O
documenting	O
a	O
significant	O
increase	O
in	O
ultrasensitive	O
troponin	O
T	O
in	O
serial	O
determinations	O
,	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
the	O
cardiology	O
ward	O
for	O
study	O
and	O
treatment	O
with	O
an	O
initial	O
diagnosis	O
of	O
high	O
risk	O
non	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
NSTEACS	O
.	O
During	O
his	O
stay	O
on	O
the	O
ward	O
he	O
remained	O
stable	O
and	O
asymptomatic	O
.	O
The	O
echocardiogram	O
showed	O
preserved	O
LV	O
systolic	O
function	O
with	O
slight	O
inferior	O
hypokinesia	O
.	O
Early	O
coronary	O
angiography	O
revealed	O
the	O
presence	O
of	O
a	O
thrombus	O
in	O
the	O
proximal	O
and	O
middle	O
DC	O
,	O
secondary	O
to	O
the	O
acetaldehyde	O
reaction	O
due	O
to	O
alcohol	O
disulfiram	O
interaction	O
,	O
and	O
the	O
decision	O
was	O
made	O
to	O
maintain	O
double	O
antiplatelet	O
therapy	O
and	O
initiate	O
anticoagulation	O
with	O
i	O
.	O
v	O
.	O
sodium	B-FARMACO
heparin	I-FARMACO
for	O
1	O
week	O
.	O
After	O
a	O
week	O
of	O
anticoagulation	O
,	O
coronary	O
angiography	O
was	O
repeated	O
,	O
showing	O
the	O
disappearance	O
of	O
the	O
thrombus	O
in	O
the	O
DC	O
,	O
although	O
OCT	O
detected	O
plaque	O
erosion	O
in	O
this	O
location	O
,	O
which	O
was	O
not	O
considered	O
necessary	O
to	O
revascularise	O
.	O
The	O
need	O
to	O
maintain	O
alcohol	O
abstinence	O
and	O
avoid	O
alcohol	O
intake	O
under	O
treatment	O
with	O
disulfiram	B-FARMACO
,	O
as	O
well	O
as	O
smoking	O
cessation	O
,	O
is	O
insisted	O
upon	O
.	O
Treatment	O
at	O
discharge	O
with	O
double	O
antiplatelet	O
therapy	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
and	O
ticagrelor	B-FARMACO
,	O
PPI	O
omeprazole	B-FARMACO
,	O
and	O
treatment	O
by	O
the	O
psychiatrist	O
,	O
maintaining	O
disulfiram	O
with	O
strict	O
control	O
and	O
clomethiazole	B-FARMACO
.	O
DIAGNOSIS	O
Acute	O
non	O
Q	O
myocardial	O
infarction	O
of	O
inferior	O
location	O
,	O
secondary	O
to	O
acetaldehyde	O
reaction	O
due	O
to	O
alcohol	O
disulfiram	O
interaction	O
with	O
intracoronary	O
thrombus	O
formation	O
in	O
proximal	O
and	O
middle	O
DC	O
,	O
resolved	O
after	O
double	O
antiplatelet	O
therapy	O
and	O
1	O
week	O
of	O
parenteral	O
anticoagulation	O
.	O
Preserved	O
LV	O
systolic	O
function	O
with	O
inferior	O
hypokinesia	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
59	O
year	O
old	O
male	O
patient	O
who	O
was	O
referred	O
to	O
our	O
hospital	O
from	O
the	O
cardiology	O
outpatient	O
department	O
after	O
reviewing	O
the	O
images	O
of	O
a	O
cardiac	O
magnetic	O
resonance	O
imaging	O
CMR	O
performed	O
on	O
an	O
outpatient	O
basis	O
and	O
requested	O
due	O
to	O
a	O
pathological	O
electrocardiogram	O
ECG	O
.	O
HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
allergic	O
reactions	O
to	O
drugs	O
.	O
Toxic	O
habits	O
smoker	O
of	O
1	O
pack	O
a	O
day	O
cumulative	O
exposure	O
of	O
40	O
packs	O
year	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
hypercholesterolemia	O
.	O
No	O
family	O
history	O
of	O
early	O
ischaemic	O
heart	O
disease	O
.	O
Surgical	O
history	O
laparoscopic	O
Nissen	O
fundoplication	O
in	O
2011	O
.	O
Usual	O
treatment	O
omeprazole	B-FARMACO
20	O
mg	O
day	O
,	O
atorvastatin	B-FARMACO
20	O
mg	O
day	O
.	O
Current	O
disease	O
A	O
59	O
year	O
old	O
male	O
patient	O
came	O
to	O
the	O
cardiology	O
outpatient	O
clinic	O
referred	O
from	O
primary	O
care	O
for	O
evaluation	O
after	O
a	O
casual	O
finding	O
of	O
a	O
pathological	O
electrocardiographic	O
tracing	O
in	O
a	O
health	O
check	O
up	O
at	O
his	O
company	O
.	O
The	O
patient	O
brought	O
to	O
the	O
consultation	O
an	O
ECG	O
showing	O
Q	O
waves	O
in	O
the	O
inferior	O
aspect	O
and	O
an	O
echocardiographic	O
study	O
performed	O
in	O
a	O
private	O
clinic	O
describing	O
alterations	O
of	O
contractility	O
in	O
the	O
inferior	O
aspect	O
at	O
mid	O
basal	O
level	O
with	O
a	O
moderately	O
depressed	O
left	O
ventricular	O
ejection	O
fraction	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
magnetic	O
resonance	O
imaging	O
MRI	O
was	O
requested	O
,	O
which	O
showed	O
chronic	O
necrosis	O
of	O
4	O
segments	O
of	O
the	O
territory	O
belonging	O
to	O
the	O
right	O
coronary	O
artery	O
and	O
a	O
pseudoaneurysm	O
in	O
the	O
inferior	O
face	O
of	O
the	O
middle	O
segment	O
,	O
so	O
it	O
was	O
decided	O
to	O
admit	O
the	O
patient	O
to	O
hospital	O
to	O
complete	O
the	O
study	O
and	O
present	O
the	O
case	O
at	O
the	O
medical	O
surgical	O
session	O
.	O
In	O
the	O
anamnesis	O
,	O
the	O
patient	O
denied	O
any	O
previous	O
episodes	O
of	O
chest	O
pain	O
.	O
Nor	O
did	O
he	O
report	O
cardinal	O
symptoms	O
of	O
heart	O
failure	O
or	O
suggestive	O
of	O
systemic	O
embolism	O
.	O
NYHA	O
functional	O
class	O
I	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
,	O
normohydrated	O
,	O
normal	O
colour	O
.	O
Eupneic	O
at	O
rest	O
without	O
use	O
of	O
accessory	O
muscles	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
,	O
without	O
apparent	O
neurological	O
focality	O
.	O
Blood	O
pressure	O
BP	O
136	O
67	O
mmHg	O
,	O
heart	O
rate	O
HR	O
72	O
bpm	O
,	O
oxygen	O
saturation	O
SatO2	O
99	O
ambient	O
air	O
.	O
Cardiac	O
auscultation	O
regular	O
sounds	O
,	O
no	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
rales	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
Radial	O
and	O
femoral	O
pulses	O
present	O
.	O
COMPLEMENTARY	O
TESTS	O
The	O
following	O
complementary	O
tests	O
were	O
performed	O
on	O
an	O
outpatient	O
basis	O
ECG	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
,	O
PR	O
160	O
ms	O
,	O
narrow	O
QRS	O
with	O
axis	O
at	O
30	O
,	O
Q	O
wave	O
in	O
II	O
,	O
III	O
and	O
aVF	O
,	O
flattened	O
T	O
wave	O
V4	O
V6	O
.	O
CMR	O
normal	O
left	O
ventricular	O
volumes	O
with	O
moderately	O
depressed	O
systolic	O
function	O
LVEF	O
37	O
.	O
Hypokinesia	O
of	O
inferoseptal	O
,	O
inferior	O
and	O
inferolateral	O
basal	O
segments	O
.	O
Severe	O
dyskinesia	O
and	O
thinning	O
2	O
mm	O
located	O
in	O
the	O
lower	O
middle	O
segment	O
,	O
with	O
rupture	O
of	O
the	O
wall	O
and	O
image	O
of	O
pseudoaneurysm	O
contained	O
by	O
the	O
pericardium	O
neck	O
7	O
mm	O
;	O
width	O
28	O
mm	O
;	O
depth	O
18	O
mm	O
.	O
Partial	O
thrombosis	O
is	O
observed	O
lining	O
its	O
inner	O
wall	O
.	O
Absence	O
of	O
myocardial	O
oedema	O
.	O
Normal	O
right	O
ventricular	O
volumes	O
,	O
with	O
normal	O
systolic	O
function	O
RVEF	O
63	O
.	O
Normal	O
sized	O
atria	O
.	O
Normal	O
sized	O
great	O
vessels	O
.	O
First	O
pass	O
hypoperfusion	O
at	O
rest	O
in	O
the	O
dysfunctioning	O
segments	O
.	O
Intravenous	O
gadolinium	O
meglumine	O
gadoterate	O
0	O
.	O
15	O
mmol	O
kg	O
is	O
administered	O
.	O
Late	O
gadolinium	O
enhancement	O
suggestive	O
of	O
transmural	O
necrosis	O
in	O
mid	O
inferior	O
segment	O
and	O
subendocardial	O
necrosis	O
in	O
inferoseptal	O
,	O
inferior	O
and	O
inferolateral	O
basal	O
segments	O
.	O
In	O
summary	O
chronic	O
necrosis	O
of	O
4	O
segments	O
of	O
the	O
RCA	O
,	O
pseudoaneurysm	O
in	O
inferior	O
inferior	O
mid	O
segment	O
and	O
moderately	O
depressed	O
left	O
ventricular	O
systolic	O
function	O
.	O
After	O
admission	O
,	O
the	O
study	O
was	O
completed	O
with	O
the	O
following	O
examinations	O
Chest	O
X	O
ray	O
mediastinal	O
silhouette	O
of	O
normal	O
size	O
.	O
No	O
areas	O
of	O
alveolar	O
consolidation	O
or	O
pleural	O
effusion	O
were	O
observed	O
.	O
Laboratory	O
tests	O
glucose	O
81	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
85	O
mg	O
dl	O
,	O
urea	O
39	O
mg	O
dl	O
,	O
sodium	O
138	O
mmol	O
l	O
,	O
potassium	O
4	O
mmol	O
l	O
,	O
total	O
cholesterol	O
188	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
113	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
56	O
mg	O
dl	O
,	O
triglycerides	O
99	O
mg	O
dl	O
,	O
leucocytes	O
6	O
.	O
05	O
x	O
109	O
l	O
,	O
haemoglobin	O
14	O
.	O
6	O
g	O
dl	O
,	O
platelets	O
226	O
x	O
109	O
l	O
,	O
glycated	O
haemoglobin	O
5	O
.	O
4	O
,	O
ultrasensitive	O
troponin	O
T	O
26	O
pg	O
ml	O
normal	O
14	O
pg	O
ml	O
,	O
NT	O
proBNP	O
1	O
.	O
780	O
pg	O
ml	O
.	O
Transthoracic	O
echocardiography	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
slight	O
septal	O
hypertrophy	O
and	O
akinesia	O
of	O
the	O
basal	O
and	O
mid	O
inferior	O
and	O
inferoseptal	O
wall	O
thinned	O
and	O
echorefringent	O
wall	O
suggestive	O
of	O
chronic	O
necrosis	O
,	O
with	O
presence	O
of	O
a	O
defect	O
in	O
the	O
mid	O
segment	O
inferior	O
wall	O
wall	O
rupture	O
and	O
image	O
of	O
saccular	O
pseudoaneurysm	O
,	O
narrow	O
neck	O
ostium	O
7	O
8	O
mm	O
,	O
visible	O
in	O
parasternal	O
short	O
axis	O
and	O
mainly	O
in	O
apical	O
planes	O
of	O
2C	O
and	O
3C	O
.	O
Moderately	O
depressed	O
LV	O
global	O
systolic	O
function	O
biplane	O
Simpson	O
LVEF	O
40	O
.	O
Severely	O
dilated	O
left	O
atrium	O
.	O
Mitral	O
valve	O
with	O
good	O
opening	O
and	O
minimal	O
valve	O
regurgitation	O
.	O
Aortic	O
valve	O
with	O
normal	O
transvalvular	O
gradients	O
,	O
without	O
valvular	O
regurgitation	O
.	O
Right	O
ventricle	O
not	O
dilated	O
,	O
with	O
good	O
contractility	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Diagnostic	O
coronary	O
catheterisation	O
videos	O
1	O
and	O
2	O
left	O
main	O
coronary	O
artery	O
LMCA	O
without	O
lesions	O
.	O
Long	O
anterior	O
descending	O
artery	O
ADA	O
,	O
good	O
calibre	O
,	O
with	O
severe	O
lesion	O
80	O
in	O
proximal	O
segment	O
,	O
very	O
calcified	O
and	O
significant	O
lesion	O
60	O
in	O
middle	O
segment	O
with	O
feasible	O
percutaneous	O
revascularisation	O
.	O
Circumflex	O
artery	O
ACx	O
non	O
dominant	O
,	O
with	O
non	O
significant	O
wall	O
irregularities	O
.	O
Dominant	O
right	O
coronary	O
artery	O
RCA	O
,	O
with	O
long	O
ostial	O
chronic	O
total	O
occlusion	O
,	O
with	O
coin	O
stack	O
image	O
in	O
proximal	O
cap	O
,	O
and	O
distal	O
vessel	O
of	O
good	O
calibre	O
and	O
visible	O
development	O
by	O
epicardial	O
and	O
septal	O
heterocoronary	O
circulation	O
Rentrop	O
3	O
with	O
poor	O
profile	O
for	O
percutaneous	O
revascularisation	O
.	O
Conclusions	O
two	O
vessel	O
coronary	O
artery	O
disease	O
with	O
severe	O
lesion	O
in	O
proximal	O
and	O
significant	O
medial	O
LAD	O
and	O
chronic	O
total	O
occlusion	O
of	O
ostial	O
RCA	O
.	O
Transthoracic	O
echocardiography	O
postoperative	O
control	O
left	O
ventricle	O
with	O
akinesia	O
of	O
the	O
inferior	O
wall	O
and	O
basal	O
and	O
medial	O
inferoseptal	O
wall	O
,	O
with	O
thinned	O
and	O
echorefringent	O
wall	O
,	O
with	O
no	O
pseudoaneurysmal	O
cavity	O
observed	O
in	O
the	O
inferior	O
face	O
.	O
Moderately	O
reduced	O
global	O
systolic	O
function	O
of	O
the	O
left	O
ventricle	O
.	O
Rest	O
of	O
the	O
study	O
unchanged	O
with	O
respect	O
to	O
previous	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
admission	O
,	O
the	O
preoperative	O
study	O
was	O
completed	O
with	O
the	O
complementary	O
tests	O
described	O
above	O
.	O
Transthoracic	O
echocardiography	O
confirmed	O
the	O
findings	O
described	O
in	O
the	O
CMR	O
,	O
while	O
coronary	O
catheterisation	O
showed	O
two	O
vessel	O
coronary	O
artery	O
disease	O
consisting	O
of	O
a	O
severe	O
lesion	O
in	O
the	O
proximal	O
LAD	O
and	O
significant	O
mid	O
LAD	O
,	O
and	O
a	O
chronic	O
ostial	O
occlusion	O
of	O
the	O
RCA	O
.	O
During	O
surgery	O
,	O
a	O
left	O
ventricular	O
pseudoaneurysm	O
was	O
visualised	O
on	O
the	O
inferior	O
aspect	O
of	O
approximately	O
3	O
cm	O
in	O
diameter	O
with	O
thickened	O
and	O
calcified	O
walls	O
,	O
with	O
thrombotic	O
content	O
inside	O
and	O
an	O
ostium	O
communicating	O
with	O
the	O
left	O
ventricle	O
of	O
approximately	O
1	O
cm2	O
.	O
A	O
posterior	O
descending	O
artery	O
of	O
small	O
calibre	O
and	O
located	O
in	O
the	O
scar	O
territory	O
of	O
the	O
pseudoaneurysm	O
was	O
also	O
visualised	O
and	O
was	O
therefore	O
ruled	O
out	O
as	O
a	O
tributary	O
vessel	O
for	O
aortocoronary	O
bypass	O
.	O
Finally	O
,	O
resection	O
of	O
the	O
aneurysmal	O
area	O
and	O
reconstruction	O
of	O
the	O
lower	O
wall	O
with	O
an	O
autologous	O
pericardial	O
patch	O
were	O
performed	O
.	O
Subsequently	O
,	O
a	O
double	O
aortocoronary	O
bypass	O
was	O
performed	O
to	O
the	O
middle	O
ADA	O
with	O
the	O
left	O
mammary	O
artery	O
and	O
to	O
the	O
first	O
diagonal	O
with	O
the	O
saphenous	O
artery	O
,	O
both	O
of	O
them	O
end	O
to	O
side	O
.	O
The	O
patient	O
's	O
stay	O
in	O
the	O
resuscitation	O
unit	O
was	O
uneventful	O
with	O
early	O
extubation	O
and	O
discharge	O
to	O
the	O
hospital	O
ward	O
48	O
hours	O
after	O
surgery	O
.	O
A	O
control	O
transthoracic	O
echocardiography	O
was	O
performed	O
,	O
which	O
did	O
not	O
show	O
the	O
pseudoaneurysmal	O
cavity	O
and	O
ruled	O
out	O
early	O
postoperative	O
complications	O
.	O
Postoperative	O
evolution	O
was	O
satisfactory	O
with	O
clinical	O
and	O
haemodynamic	O
stability	O
,	O
and	O
he	O
was	O
discharged	O
from	O
hospital	O
for	O
outpatient	O
follow	O
up	O
in	O
cardiology	O
and	O
cardiac	O
surgery	O
outpatient	O
clinics	O
.	O
DIAGNOSIS	O
Silent	O
myocardial	O
infarction	O
complicated	O
by	O
left	O
inferior	O
ventricular	O
pseudoaneurysm	O
.	O
2	O
vessel	O
coronary	O
artery	O
disease	O
proximal	O
and	O
middle	O
LAD	O
and	O
ostial	O
LAD	O
.	O
Moderate	O
left	O
ventricular	O
dysfunction	O
.	O
Aneurysm	O
resection	O
surgery	O
and	O
coronary	O
revascularisation	O
of	O
LAD	O
.	O
Hypercholesterolemia	O
.	O
Smoking	O
.	O

The	O
patient	O
was	O
a	O
72	O
year	O
old	O
white	O
man	O
with	O
a	O
history	O
of	O
apparent	O
health	O
and	O
no	O
evidence	O
of	O
previous	O
valvular	O
heart	O
disease	O
who	O
2	O
months	O
prior	O
to	O
admission	O
began	O
to	O
present	O
with	O
fever	O
and	O
weakness	O
,	O
with	O
general	O
malaise	O
and	O
dyspnoea	O
on	O
exertion	O
.	O
The	O
fever	O
was	O
never	O
higher	O
than	O
39oC	O
and	O
usually	O
appeared	O
in	O
the	O
afternoons	O
.	O
Initially	O
it	O
subsided	O
quickly	O
with	O
the	O
usual	O
antipyretic	O
measures	O
,	O
but	O
became	O
more	O
persistent	O
until	O
it	O
appeared	O
for	O
10	O
to	O
12	O
hours	O
a	O
day	O
.	O
In	O
his	O
health	O
care	O
area	O
it	O
was	O
interpreted	O
as	O
a	O
fever	O
of	O
unknown	O
origin	O
until	O
leukocytosis	O
and	O
accelerated	O
erythrocyte	O
sedimentation	O
were	O
observed	O
.	O
Without	O
specifying	O
the	O
cause	O
,	O
treatment	O
with	O
penicillin	B-FARMACO
was	O
started	O
and	O
on	O
the	O
fifth	O
day	O
amikacin	B-FARMACO
was	O
added	O
as	O
the	O
desired	O
improvement	O
was	O
not	O
achieved	O
.	O
He	O
was	O
then	O
referred	O
to	O
our	O
centre	O
for	O
an	O
echocardiogram	O
and	O
on	O
physical	O
examination	O
we	O
found	O
a	O
III	O
VI	O
sitolic	O
murmur	O
at	O
the	O
tip	O
radiating	O
towards	O
the	O
axilla	O
with	O
a	O
small	O
diastolic	O
murmur	O
,	O
hepatosplenomegaly	O
and	O
the	O
presence	O
of	O
crepitant	O
rales	O
in	O
both	O
lung	O
bases	O
.	O
A	O
transthoracic	O
echocardiogram	O
revealed	O
the	O
presence	O
of	O
a	O
mass	O
on	O
the	O
posterior	O
mitral	O
leaflet	O
compatible	O
with	O
endocardial	O
vegetation	O
.	O
We	O
then	O
decided	O
to	O
admit	O
the	O
patient	O
with	O
the	O
diagnostic	O
impression	O
of	O
IE	O
,	O
took	O
samples	O
for	O
blood	O
cultures	O
and	O
started	O
treatment	O
with	O
vancomycin	B-FARMACO
and	O
gentamicin	B-FARMACO
,	O
considering	O
the	O
possibility	O
of	O
Staphylococcus	O
aureus	O
as	O
the	O
causative	O
agent	O
,	O
but	O
the	O
fever	O
persisted	O
,	O
the	O
patient	O
's	O
clinical	O
condition	O
worsened	O
and	O
we	O
received	O
8	O
negative	O
blood	O
cultures	O
.	O
We	O
took	O
samples	O
to	O
use	O
special	O
culture	O
media	O
and	O
found	O
the	O
presence	O
of	O
Candida	O
albicans	O
,	O
so	O
we	O
started	O
treatment	O
with	O
amphotericin	B-FARMACO
B	I-FARMACO
,	O
but	O
,	O
although	O
the	O
fever	O
decreased	O
,	O
the	O
haemodynamic	O
status	O
did	O
not	O
improve	O
and	O
we	O
decided	O
to	O
perform	O
surgery	O
.	O
The	O
patient	O
underwent	O
mitral	O
valve	O
replacement	O
without	O
complications	O
,	O
and	O
a	O
mechanical	O
bidisc	O
prosthesis	O
was	O
used	O
.	O
The	O
pathological	O
examination	O
confirmed	O
the	O
diagnosis	O
.	O
The	O
patient	O
completed	O
his	O
hospital	O
course	O
of	O
amphotericin	B-FARMACO
B	I-FARMACO
and	O
was	O
discharged	O
on	O
oral	O
ketoconazole	B-FARMACO
,	O
in	O
addition	O
to	O
digitalis	O
,	O
diuretics	O
and	O
anticoagulants	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Male	O
,	O
59	O
years	O
old	O
.	O
History	O
Cardiovascular	O
risk	O
factors	O
ex	O
smoker	O
,	O
arterial	O
hypertension	O
AHT	O
,	O
hypercholesterolemia	O
,	O
insulinised	O
type	O
2	O
diabetes	O
mellitus	O
.	O
Severe	O
apnoea	O
hypopnoea	O
syndrome	O
treated	O
with	O
continuous	O
positive	O
airway	O
pressure	O
CPAP	O
.	O
Peripheral	O
arterial	O
disease	O
.	O
Implantation	O
of	O
mechanical	O
aortic	O
prosthesis	O
for	O
severe	O
aortic	O
stenosis	O
18	O
days	O
ago	O
.	O
Echocardiogram	O
at	O
discharge	O
biventricular	O
function	O
preserved	O
and	O
normofunctioning	O
aortic	O
prosthesis	O
.	O
Treatment	O
ivabradine	B-FARMACO
5	O
mg	O
12	O
hours	O
,	O
furosemide	B-FARMACO
40	O
mg	O
24	O
hours	O
,	O
bisoprolol	B-FARMACO
10	O
mg	O
24	O
hours	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
24	O
hours	O
,	O
metformin	B-FARMACO
850	O
mg	O
12	O
hours	O
,	O
Lantus	B-FARMACO
38	O
IU	O
at	O
dinner	O
,	O
novorapid	B-FARMACO
10	O
IU	O
at	O
breakfast	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
24	O
hours	O
,	O
acenocoumarol	B-FARMACO
.	O
Present	O
illness	O
The	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
on	O
Friday	O
afternoon	O
with	O
malaise	O
,	O
fever	O
with	O
shivering	O
and	O
dyspnoea	O
on	O
minimal	O
exertion	O
for	O
24	O
hours	O
.	O
Cough	O
with	O
expectoration	O
5	O
days	O
ago	O
,	O
currently	O
in	O
remission	O
,	O
without	O
other	O
focality	O
.	O
He	O
denies	O
chest	O
pain	O
.	O
Given	O
the	O
history	O
of	O
aortic	O
valve	O
surgery	O
18	O
days	O
ago	O
,	O
he	O
was	O
assessed	O
by	O
cardiology	O
during	O
his	O
stay	O
in	O
the	O
emergency	O
department	O
.	O
Echocardioscopy	O
showed	O
mild	O
concentric	O
left	O
ventricular	O
hypertrophy	O
LVH	O
with	O
preserved	O
global	O
and	O
segmental	O
systolic	O
function	O
,	O
normofunctioning	O
aortic	O
prosthesis	O
,	O
known	O
mild	O
moderate	O
central	O
mitral	O
regurgitation	O
,	O
dilated	O
LA	O
,	O
normal	O
right	O
chambers	O
,	O
absence	O
of	O
pericardial	O
effusion	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
infectious	O
diseases	O
unit	O
for	O
empirical	O
treatment	O
with	O
ceftriaxone	B-FARMACO
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
135	O
70	O
mmHg	O
on	O
arrival	O
at	O
triage	O
,	O
at	O
physician	O
assessment	O
85	O
60	O
mmHG	O
,	O
rising	O
to	O
100	O
60	O
mmHG	O
after	O
serum	O
therapy	O
500	O
ml	O
saline	O
.	O
Heart	O
rate	O
HR	O
80	O
bpm	O
.	O
Temperature	O
39	O
.	O
5oC	O
.	O
SatO2	O
91	O
on	O
room	O
air	O
.	O
Sweaty	O
,	O
well	O
perfused	O
,	O
eupneic	O
.	O
Mild	O
jugular	O
engorgement	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
aortic	O
systolic	O
murmur	O
II	O
VI	O
,	O
prosthetic	O
sounds	O
.	O
Pulmonary	O
auscultation	O
minimal	O
crackles	O
in	O
the	O
bases	O
.	O
Normal	O
abdomen	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
extremities	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
in	O
the	O
emergency	O
room	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
,	O
atrioventricular	O
block	O
of	O
1o	O
with	O
PR	O
220	O
ms	O
.	O
Signs	O
of	O
LV	O
hypertrophy	O
.	O
Emergency	O
laboratory	O
tests	O
glucose	O
242	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
53	O
mg	O
dl	O
.	O
Urea	O
19	O
mg	O
dl	O
.	O
GPT	O
29	O
U	O
l	O
.	O
Bilirubin	O
0	O
.	O
8	O
mg	O
dl	O
.	O
Sodium	O
137	O
mEq	O
l	O
.	O
Potassium	O
4	O
.	O
4	O
mEq	O
litre	O
.	O
Calcium	O
8	O
.	O
6	O
mg	O
dl	O
.	O
Albumin	O
3	O
.	O
1	O
g	O
dl	O
.	O
CK	O
399	O
U	O
l	O
.	O
LDH	O
250	O
U	O
l	O
.	O
CRP	O
46	O
.	O
5	O
mg	O
l	O
.	O
PCT	O
0	O
,	O
36	O
ng	O
ml	O
.	O
Haemoglobin	O
9	O
.	O
7	O
g	O
dl	O
.	O
Haematocrit	O
31	O
.	O
0	O
.	O
Platelets	O
211	O
10	O
3	O
μl	O
.	O
Leucocytes	O
7	O
.	O
9	O
10	O
3	O
μl	O
.	O
Neutrophils	O
72	O
.	O
7	O
.	O
Neutrophils	O
5	O
.	O
7	O
10	O
3	O
μl	O
.	O
Lymphocytes	O
17	O
.	O
3	O
.	O
Lymphocytes	O
1	O
.	O
4	O
10	O
3	O
μl	O
.	O
Prothrombin	O
time	O
49	O
.	O
INR1	O
.	O
7	O
.	O
APTT	O
53	O
sg	O
.	O
Fibrinogen	O
503	O
mg	O
dl	O
.	O
Chest	O
X	O
ray	O
in	O
the	O
ED	O
no	O
evidence	O
of	O
HF	O
.	O
ECG	O
on	O
the	O
ward	O
sinus	O
rhythm	O
with	O
2	O
1	O
atrioventricular	O
block	O
,	O
QRS	O
axis	O
at	O
60o	O
.	O
ST	O
elevation	O
in	O
inferior	O
face	O
II	O
,	O
III	O
,	O
and	O
aVF	O
and	O
ST	O
descent	O
in	O
I	O
aVL	O
.	O
Regulated	O
transthoracic	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
with	O
mild	O
LVH	O
with	O
ejection	O
fraction	O
LVEF	O
50	O
.	O
Hypokinesia	O
of	O
the	O
inferior	O
,	O
posterior	O
and	O
basal	O
face	O
of	O
the	O
posterior	O
septum	O
,	O
of	O
the	O
apical	O
segment	O
of	O
the	O
anterior	O
septum	O
,	O
apical	O
of	O
the	O
anterior	O
face	O
and	O
strict	O
apex	O
.	O
Thickened	O
and	O
sclerosed	O
mitral	O
valve	O
with	O
severe	O
mitral	O
regurgitation	O
,	O
unclear	O
mechanism	O
no	O
clear	O
tenting	O
or	O
posterior	O
leaflet	O
stiffness	O
.	O
Mechanical	O
aortic	O
prosthesis	O
with	O
excrescent	O
and	O
mobile	O
images	O
in	O
the	O
left	O
ventricular	O
outflow	O
tract	O
LVOT	O
compatible	O
with	O
endocardial	O
grafts	O
.	O
No	O
aortic	O
regurgitation	O
.	O
Maximum	O
transprosthetic	O
gradient	O
of	O
35	O
mmHg	O
.	O
Right	O
ventricle	O
slightly	O
dilated	O
,	O
hypokinetic	O
,	O
with	O
mild	O
global	O
dysfunction	O
.	O
Severe	O
tricuspid	O
insufficiency	O
TI	O
.	O
Vd	O
Ad	O
gradient	O
of	O
45	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
Diagnosis	O
images	O
compatible	O
with	O
aortic	O
endocarditis	O
.	O
Inferior	O
and	O
apical	O
akinesia	O
.	O
Severe	O
mitral	O
and	O
tricuspid	O
regurgitation	O
.	O
Catheterisation	O
left	O
dominance	O
.	O
Severe	O
two	O
vessel	O
coronary	O
artery	O
disease	O
mid	O
distal	O
anterior	O
descending	O
AD	O
occlusion	O
,	O
subocclusive	O
lesion	O
in	O
distal	O
circumflex	O
Cx	O
,	O
posterior	O
descending	O
occlusion	O
.	O
Balloon	O
aspiration	O
and	O
angioplasty	O
was	O
performed	O
in	O
the	O
LAD	O
and	O
distal	O
Cx	O
with	O
good	O
results	O
,	O
except	O
for	O
the	O
posterior	O
descending	O
artery	O
,	O
which	O
remained	O
occluded	O
.	O
Transesophageal	O
echocardiogram	O
hypermobile	O
endocardial	O
graft	O
protruding	O
into	O
LVOT	O
on	O
aortic	O
prosthesis	O
with	O
periaortic	O
thickening	O
suggestive	O
of	O
abscess	O
.	O
In	O
addition	O
,	O
a	O
mobile	O
image	O
in	O
the	O
right	O
atrium	O
in	O
continuity	O
with	O
the	O
mitral	O
abscess	O
and	O
very	O
close	O
to	O
the	O
tricuspid	O
septal	O
leaflet	O
with	O
severe	O
TR	O
.	O
The	O
mitral	O
valve	O
was	O
explored	O
and	O
no	O
endocardial	O
warts	O
were	O
seen	O
on	O
the	O
mitral	O
valve	O
,	O
but	O
there	O
was	O
moderate	O
to	O
severe	O
mitral	O
insufficiency	O
in	O
relation	O
to	O
tenting	O
and	O
central	O
coaptation	O
deficit	O
.	O
The	O
overall	O
LVEF	O
is	O
at	O
the	O
low	O
limit	O
of	O
normal	O
with	O
hypocytosis	O
of	O
the	O
inferior	O
,	O
posterior	O
and	O
posterior	O
septum	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
admission	O
to	O
the	O
Infectious	O
Diseases	O
department	O
,	O
fever	O
of	O
38	O
.	O
5oC	O
and	O
shivering	O
persisted	O
throughout	O
the	O
weekend	O
.	O
The	O
blood	O
cultures	O
taken	O
in	O
the	O
emergency	O
department	O
had	O
been	O
lost	O
,	O
so	O
new	O
blood	O
cultures	O
HC	O
were	O
taken	O
on	O
Saturday	O
and	O
antibiotic	O
therapy	O
was	O
upgraded	O
to	O
vancomycin	B-FARMACO
levofloxacin	I-FARMACO
as	O
empirical	O
treatment	O
for	O
fever	O
without	O
a	O
clear	O
focus	O
.	O
On	O
Sunday	O
,	O
fever	O
persisted	O
,	O
with	O
a	O
slight	O
worsening	O
of	O
the	O
general	O
condition	O
.	O
On	O
Monday	O
there	O
was	O
an	O
evident	O
clinical	O
worsening	O
with	O
hypotension	O
despite	O
fluid	O
therapy	O
,	O
bradycardia	O
and	O
increased	O
dyspnoea	O
.	O
The	O
laboratory	O
was	O
notified	O
of	O
S	O
.	O
epidermidis	O
growth	O
in	O
4	O
of	O
4	O
bottles	O
.	O
With	O
these	O
data	O
,	O
the	O
cardiology	O
department	O
was	O
contacted	O
again	O
for	O
a	O
new	O
echocardiogram	O
and	O
clinical	O
assessment	O
.	O
An	O
ECG	O
was	O
performed	O
showing	O
2nd	O
degree	O
2	O
1	O
atrioventricular	O
block	O
AVB	O
together	O
with	O
ST	O
elevation	O
in	O
inferior	O
leads	O
with	O
ST	O
descent	O
on	O
the	O
lateral	O
side	O
.	O
On	O
further	O
questioning	O
,	O
the	O
patient	O
reported	O
some	O
intermittent	O
precordial	O
discomfort	O
associated	O
with	O
dyspnoea	O
since	O
that	O
morning	O
.	O
The	O
transthoracic	O
echocardiogram	O
showed	O
endocarditis	O
over	O
the	O
aortic	O
prosthesis	O
and	O
alterations	O
in	O
segmental	O
contractility	O
.	O
In	O
view	O
of	O
the	O
clinical	O
,	O
electrocardiographic	O
and	O
echocardiographic	O
findings	O
,	O
emergent	O
catheterisation	O
was	O
performed	O
.	O
After	O
revascularisation	O
,	O
clinical	O
worsening	O
persisted	O
with	O
dyspnoea	O
and	O
haemodynamic	O
instability	O
hypotension	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
for	O
a	O
transesophageal	O
echocardiogram	O
TEE	O
and	O
stabilisation	O
.	O
In	O
view	O
of	O
progressive	O
dyspnoea	O
and	O
the	O
impossibility	O
of	O
tolerating	O
TEE	O
,	O
orotracheal	O
intubation	O
and	O
connection	O
to	O
invasive	O
mechanical	O
ventilation	O
were	O
performed	O
,	O
as	O
well	O
as	O
the	O
start	O
of	O
perfusion	O
of	O
noradrenaline	B-FARMACO
and	O
dobutamine	B-FARMACO
at	O
low	O
doses	O
,	O
despite	O
which	O
instability	O
persisted	O
with	O
significant	O
bradycardia	O
,	O
for	O
which	O
reason	O
a	O
transient	O
transjugular	O
pacemaker	O
was	O
implanted	O
.	O
With	O
all	O
the	O
data	O
and	O
with	O
the	O
diagnosis	O
of	O
infective	O
endocarditis	O
on	O
prosthetic	O
aortic	O
valve	O
complicated	O
with	O
mitroaortic	O
abscess	O
,	O
extension	O
to	O
tricuspid	O
valve	O
,	O
AVB	O
,	O
septic	O
coronary	O
embolisms	O
and	O
cardiogenic	O
septic	O
shock	O
,	O
emergency	O
cardiac	O
surgery	O
was	O
decided	O
where	O
aortic	O
valve	O
replacement	O
with	O
biological	O
prosthesis	O
,	O
tricuspid	O
valve	O
replacement	O
with	O
biological	O
prosthesis	O
and	O
mitral	O
ring	O
placement	O
were	O
performed	O
.	O
After	O
66	O
days	O
in	O
the	O
ICU	O
and	O
multiple	O
complications	O
including	O
acute	O
renal	O
failure	O
requiring	O
continuous	O
venovenous	O
haemodiafiltration	O
,	O
acute	O
respiratory	O
failure	O
,	O
pneumonia	O
associated	O
with	O
mechanical	O
ventilation	O
due	O
to	O
gram	O
negative	O
bacillus	O
,	O
acute	O
tracheobronchitis	O
due	O
to	O
A	O
.	O
fumigatus	O
,	O
persistent	O
complete	O
AVB	O
,	O
C	O
.	O
parapsilopsis	O
bacteraemia	O
associated	O
with	O
central	O
venous	O
catheter	O
,	O
ischaemic	O
hepatitis	O
,	O
paralytic	O
ileus	O
,	O
multifactorial	O
encephalopathy	O
with	O
a	O
significant	O
component	O
of	O
hypoxia	O
and	O
significant	O
truncal	O
diencephalic	O
damage	O
with	O
persistent	O
coma	O
,	O
and	O
finally	O
death	O
.	O
DIAGNOSIS	O
Early	O
endocarditis	O
on	O
mechanical	O
prosthetic	O
aortic	O
valve	O
due	O
to	O
Staphylococcus	O
epidermidis	O
.	O
Mitroaortic	O
junction	O
abscess	O
with	O
extension	O
to	O
tricuspid	O
valve	O
.	O
Severe	O
mitral	O
and	O
tricuspid	O
regurgitation	O
.	O
Atrioventricular	O
block	O
2	O
1	O
.	O
Acute	O
myocardial	O
infarction	O
with	O
lower	O
ST	O
elevation	O
.	O
Septic	O
coronary	O
embolisms	O
in	O
the	O
dominant	O
circumflex	O
and	O
anterior	O
descending	O
coronary	O
artery	O
.	O
Thromboaspiration	O
and	O
balloon	O
angioplasty	O
over	O
LAD	O
and	O
Cx	O
.	O
Mixed	O
cardiogenic	O
septic	O
shock	O
.	O
Emergent	O
surgery	O
for	O
aortic	O
,	O
tricuspid	O
and	O
mitral	O
ring	O
valve	O
replacement	O
.	O
Death	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
85	O
year	O
old	O
male	O
admitted	O
from	O
outpatients	O
for	O
poor	O
outpatient	O
control	O
of	O
congestive	O
signs	O
and	O
symptoms	O
in	O
the	O
context	O
of	O
decompensation	O
of	O
heart	O
failure	O
.	O
No	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
essential	O
hypertension	O
,	O
no	O
diabetes	O
mellitus	O
DM	O
or	O
dyslipidaemia	O
.	O
Toxic	O
habits	O
ex	O
smoker	O
since	O
the	O
age	O
of	O
65	O
,	O
previously	O
smoked	O
about	O
ten	O
cigars	O
a	O
day	O
for	O
48	O
years	O
.	O
Cardiological	O
history	O
permanent	O
atrial	O
fibrillation	O
CHAD2DS2	O
VASc	O
4	O
with	O
controlled	O
ventricular	O
response	O
and	O
on	O
anticoagulant	O
treatment	O
with	O
apixaban	B-FARMACO
.	O
Congestive	O
heart	O
failure	O
labelled	O
as	O
hypertensive	O
aetiology	O
,	O
with	O
preserved	O
ejection	O
fraction	O
.	O
Other	O
history	O
chronic	O
kidney	O
disease	O
of	O
probable	O
origin	O
due	O
to	O
nephroangiosclerosis	O
,	O
stage	O
3a	O
KDIGO	O
usual	O
creatinine	O
1	O
.	O
3	O
mg	O
dl	O
.	O
Rigid	O
kinetic	O
syndrome	O
of	O
right	O
predominance	O
.	O
Chronic	O
iron	O
deficiency	O
anaemia	O
due	O
to	O
digestive	O
losses	O
.	O
Benign	O
prostatic	O
hyperplasia	O
and	O
chronic	O
open	O
angle	O
glaucoma	O
in	O
both	O
eyes	O
.	O
Usual	O
treatment	O
furosemide	B-FARMACO
40	O
mg	O
2	O
2	O
0	O
;	O
apixaban	B-FARMACO
2	O
.	O
5	O
mg	O
1	O
0	O
1	O
;	O
nebivolol	B-FARMACO
5	O
mg	O
0	O
0	O
.	O
5	O
0	O
;	O
spironolactone	B-FARMACO
25	O
mg	O
0	O
2	O
0	O
;	O
dutasteride	B-FARMACO
0	O
.	O
5	O
mg	O
1	O
0	O
0	O
;	O
carbidopa	B-FARMACO
levodopa	I-FARMACO
25	O
100	O
mg	O
2	O
2	O
2	O
;	O
allopurinol	B-FARMACO
100	O
mg	O
0	O
1	O
0	O
;	O
pantoprazole	B-FARMACO
40mg	O
1	O
0	O
0	O
;	O
brimonidine	B-FARMACO
timolol	I-FARMACO
eye	O
drops	O
1	O
0	O
1	O
.	O
Present	O
illness	O
The	O
patient	O
reports	O
oedema	O
in	O
the	O
lower	O
limbs	O
and	O
dyspnoea	O
on	O
moderate	O
exertion	O
since	O
his	O
last	O
admission	O
for	O
heart	O
failure	O
in	O
a	O
private	O
centre	O
a	O
few	O
months	O
ago	O
.	O
He	O
also	O
reports	O
two	O
pillow	O
orthopnoea	O
.	O
Symptomatology	O
has	O
not	O
improved	O
despite	O
high	O
doses	O
of	O
oral	O
diuretics	O
and	O
weekly	O
boluses	O
of	O
intravenous	O
furosemide	B-FARMACO
in	O
a	O
day	O
hospital	O
.	O
He	O
denies	O
paroxysmal	O
nocturnal	O
dyspnoea	O
,	O
chest	O
pain	O
or	O
palpitations	O
.	O
No	O
infectious	O
symptoms	O
.	O
She	O
admits	O
frequent	O
dietary	O
transgressions	O
.	O
Physical	O
examination	O
On	O
arrival	O
he	O
was	O
in	O
good	O
general	O
condition	O
,	O
conscious	O
and	O
oriented	O
,	O
normohydrated	O
,	O
normoperfused	O
and	O
normal	O
colour	O
.	O
Weight	O
58	O
kg	O
.	O
Blood	O
pressure	O
115	O
83	O
mmHg	O
,	O
heart	O
rate	O
75	O
bpm	O
,	O
basal	O
oxygen	O
saturation	O
93	O
and	O
temperature	O
36	O
.	O
8	O
oC	O
.	O
Jugular	O
venous	O
engorgement	O
up	O
to	O
the	O
mandibular	O
angle	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
,	O
no	O
murmurs	O
or	O
friction	O
rubs	O
.	O
Pulmonary	O
auscultation	O
coarse	O
crackles	O
and	O
hypophonesis	O
up	O
to	O
midfields	O
.	O
Abdomen	O
normal	O
hydro	O
aerial	O
sounds	O
,	O
soft	O
and	O
depressible	O
.	O
No	O
masses	O
or	O
visceromegaly	O
.	O
No	O
pain	O
on	O
palpation	O
,	O
no	O
evidence	O
of	O
peritoneal	O
irritation	O
or	O
wall	O
oedema	O
.	O
Lower	O
extremities	O
oedema	O
with	O
fovea	O
up	O
to	O
the	O
middle	O
of	O
both	O
legs	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
on	O
admission	O
atrial	O
fibrillation	O
AF	O
at	O
about	O
60	O
bpm	O
,	O
normal	O
axis	O
,	O
complete	O
right	O
bundle	O
branch	O
block	O
RBBB	O
with	O
secondary	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
bilateral	O
pleural	O
effusion	O
of	O
left	O
predominance	O
.	O
Evidence	O
of	O
vascular	O
redistribution	O
.	O
Aortic	O
calcification	O
.	O
Spondyloarthrosis	O
.	O
Blood	O
tests	O
on	O
admission	O
Haemogram	O
red	O
blood	O
cells	O
3	O
.	O
85	O
million	O
mm3	O
.	O
Haemoglobin	O
11	O
.	O
6	O
gr	O
dl	O
.	O
Haematocrit	O
36	O
.	O
6	O
.	O
MCV	O
.	O
95	O
.	O
1	O
fl	O
,	O
MCH	O
30	O
.	O
1	O
pg	O
.	O
MCHC	O
31	O
.	O
7	O
g	O
dl	O
.	O
RDW	O
CV	O
16	O
.	O
3	O
.	O
Normoblasts	O
0	O
.	O
0	O
.	O
Platelets	O
275	O
Thousands	O
mm3	O
.	O
Leukocytes	O
7	O
.	O
45	O
thousands	O
mm3	O
.	O
Neutrophils	O
59	O
.	O
1	O
.	O
Lymphocytes	O
23	O
.	O
9	O
.	O
Monocytes	O
14	O
.	O
1	O
.	O
Eosinophils	O
0	O
.	O
9	O
.	O
Basophils	O
0	O
,	O
3	O
.	O
Granulocytes	O
Imm	O
.	O
1	O
.	O
7	O
,	O
ESR	O
88	O
mm	O
h	O
.	O
Coagulation	O
study	O
INR	O
1	O
.	O
61	O
.	O
Prothrombin	O
activity	O
52	O
.	O
Cephalin	O
time	O
31	O
.	O
9	O
seconds	O
,	O
Prothrombin	O
time	O
18	O
.	O
0	O
s	O
.	O
Biochemistry	O
glucose	O
83	O
mg	O
dl	O
,	O
urea	O
107	O
mg	O
dl	O
,	O
creatinine	O
2	O
.	O
09	O
mg	O
dl	O
,	O
estimated	O
glomerular	O
filtrate	O
CKD	O
EPI	O
28	O
.	O
02	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
sodium	O
137	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
6	O
mEq	O
l	O
,	O
chlorine	O
94	O
mEq	O
l	O
,	O
total	O
protein	O
7	O
.	O
2	O
g	O
dl	O
,	O
albumin	O
3	O
.	O
9	O
g	O
dl	O
,	O
total	O
bilirubin	O
1	O
.	O
80	O
mg	O
dl	O
,	O
direct	O
bilirubin	O
1	O
.	O
05	O
mg	O
dl	O
,	O
indirect	O
bilirubin	O
0	O
.	O
75	O
mg	O
dl	O
,	O
GOT	O
AST	O
18	O
U	O
l	O
,	O
GPT	O
ALT	O
5	O
U	O
l	O
,	O
GGT	O
143	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
217	O
U	O
l	O
,	O
cholesterol	O
116	O
mg	O
dl	O
,	O
uric	O
acid	O
8	O
.	O
3	O
mg	O
dl	O
,	O
total	O
calcium	O
9	O
.	O
0	O
mg	O
dl	O
,	O
magnesium	O
2	O
.	O
71	O
mg	O
dl	O
,	O
inorganic	O
phosphorus	O
2	O
.	O
3	O
mg	O
dl	O
,	O
iron	O
333	O
ug	O
dl	O
,	O
transferrin	O
190	O
mg	O
dl	O
,	O
ferritin	O
1409	O
ng	O
ml	O
,	O
transferrin	O
saturation	O
138	O
,	O
C	O
reactive	O
protein	O
2	O
.	O
77	O
mg	O
dl	O
,	O
folic	O
acid	O
5	O
.	O
6	O
ng	O
ml	O
,	O
vitamin	O
B12	O
401	O
pg	O
ml	O
,	O
Natriur	O
peptide	O
.	O
pro	O
BNP	O
of	O
2300	O
pg	O
ml	O
.	O
ECG	O
on	O
the	O
fifth	O
day	O
of	O
admission	O
rhythm	O
strip	O
blocked	O
atrial	O
fibrillation	O
,	O
ventricular	O
escape	O
rhythm	O
with	O
QRS	O
morphology	O
different	O
from	O
baseline	O
,	O
at	O
about	O
30	O
bpm	O
.	O
Urgent	O
laboratory	O
tests	O
on	O
the	O
fifth	O
day	O
of	O
admission	O
Haemogram	O
red	O
blood	O
cells	O
3	O
.	O
64	O
million	O
mm3	O
,	O
haemoglobin	O
11	O
.	O
0	O
g	O
dl	O
,	O
haematocrit	O
34	O
.	O
7	O
,	O
MCV	O
95	O
.	O
3	O
fl	O
,	O
MCH	O
30	O
.	O
2	O
pg	O
,	O
MCHC	O
31	O
.	O
7	O
g	O
dl	O
,	O
RDW	O
CV	O
16	O
.	O
6	O
,	O
platelets	O
233	O
thousands	O
mm3	O
,	O
leukocytes	O
7	O
.	O
05	O
thousands	O
mm3	O
,	O
neutrophils	O
68	O
.	O
2	O
4	O
.	O
81	O
,	O
lymphocytes	O
19	O
.	O
9	O
1	O
.	O
40	O
,	O
monocytes	O
11	O
.	O
1	O
0	O
.	O
78	O
,	O
eosinophils	O
0	O
.	O
7	O
0	O
.	O
05	O
,	O
basophils	O
0	O
.	O
1	O
0	O
.	O
01	O
.	O
E	O
.	O
Coagulation	O
INR	O
2	O
.	O
06	O
,	O
prothrombin	O
activity	O
38	O
,	O
cephalin	O
time	O
32	O
.	O
8	O
seconds	O
.	O
Biochemistry	O
glucose	O
141	O
mg	O
dl	O
,	O
urea	O
114	O
mg	O
dl	O
,	O
creatinine	O
2	O
.	O
08	O
mg	O
dl	O
,	O
sodium	O
134	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
4	O
mEq	O
l	O
,	O
chlorine	O
92	O
mEq	O
l	O
,	O
venous	O
blood	O
gases	O
pH	O
7	O
.	O
45	O
pCO2	O
40	O
mmHg	O
pO2	O
110	O
mmHg	O
,	O
bicarbonate	O
27	O
.	O
8	O
mmol	O
l	O
,	O
methaemoglobin	O
0	O
.	O
9	O
L	O
Lactate	O
1	O
.	O
9	O
mmol	O
l	O
,	O
ionic	O
calcium	O
Calc	O
4	O
.	O
40	O
mg	O
dl	O
Ions	O
in	O
gas	O
sample	O
k	O
4	O
.	O
3	O
mmol	O
l	O
Na	O
129	O
mmol	O
l	O
.	O
ECG	O
at	O
discharge	O
image	O
5	O
AF	O
with	O
RV	O
at	O
60	O
bpm	O
.	O
HR	O
CDBHR	O
similar	O
to	O
the	O
admission	O
ECG	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
decompensation	O
of	O
HF	O
refractory	O
to	O
oral	O
and	O
intravenous	O
diuretics	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
cardiology	O
with	O
high	O
dose	O
intravenous	O
loop	O
diuretics	O
in	O
combination	O
with	O
oral	O
thiazide	B-FARMACO
.	O
The	O
ECG	O
performed	O
on	O
admission	O
showed	O
atrial	O
fibrillation	O
at	O
about	O
60	O
bpm	O
,	O
normal	O
axis	O
,	O
HRBBB	O
with	O
secondary	O
repolarisation	O
alterations	O
,	O
and	O
chest	O
X	O
ray	O
showed	O
bilateral	O
pleural	O
effusion	O
,	O
predominantly	O
on	O
the	O
left	O
,	O
with	O
evidence	O
of	O
vascular	O
redistribution	O
,	O
aortic	O
calcification	O
and	O
spondyloarthrosis	O
.	O
Laboratory	O
tests	O
on	O
admission	O
showed	O
worsening	O
renal	O
function	O
in	O
the	O
context	O
.	O
The	O
transthoracic	O
echocardiogram	O
showed	O
a	O
non	O
dilated	O
left	O
ventricle	O
with	O
moderate	O
concentric	O
hypertrophy	O
,	O
preserved	O
ejection	O
fraction	O
with	O
impaired	O
relaxation	O
,	O
no	O
significant	O
valvular	O
heart	O
disease	O
,	O
normal	O
estimated	O
PSAP	O
,	O
dilated	O
inferior	O
vena	O
cava	O
IVC	O
.	O
Good	O
diuretic	O
response	O
and	O
marked	O
improvement	O
in	O
decongestion	O
.	O
On	O
the	O
fifth	O
day	O
of	O
admission	O
,	O
the	O
patient	O
had	O
an	O
episode	O
of	O
dizziness	O
,	O
bradycardia	O
and	O
BP	O
of	O
85	O
60	O
mmHg	O
.	O
The	O
nurse	O
notified	O
the	O
doctor	O
on	O
duty	O
,	O
who	O
found	O
that	O
the	O
patient	O
was	O
conscious	O
,	O
although	O
drowsy	O
and	O
sleepy	O
,	O
and	O
reactive	O
to	O
verbal	O
stimuli	O
.	O
On	O
physical	O
examination	O
he	O
was	O
cold	O
,	O
bradycardic	O
,	O
rhythmic	O
,	O
with	O
no	O
murmurs	O
and	O
no	O
signs	O
of	O
congestion	O
at	O
the	O
time	O
.	O
AC	O
bradycardic	O
,	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
ECG	O
atrial	O
fibrillation	O
with	O
complete	O
atrioventricular	O
block	O
AVB	O
with	O
ventricular	O
escape	O
,	O
with	O
a	O
different	O
morphology	O
to	O
the	O
baseline	O
,	O
at	O
about	O
30	O
bpm	O
image	O
4	O
.	O
Urgent	O
laboratory	O
tests	O
were	O
requested	O
to	O
rule	O
out	O
ionic	O
alterations	O
,	O
but	O
the	O
ions	O
were	O
in	O
range	O
and	O
his	O
renal	O
function	O
was	O
stable	O
with	O
no	O
worsening	O
with	O
respect	O
to	O
previous	O
years	O
.	O
Blood	O
pressure	O
improved	O
after	O
infusion	O
of	O
1000	O
cc	O
of	O
physiological	B-FARMACO
saline	I-FARMACO
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
coronary	O
unit	O
for	O
monitoring	O
.	O
After	O
ruling	O
out	O
ionic	O
aetiology	O
,	O
in	O
view	O
of	O
a	O
possible	O
pharmacological	O
trigger	O
,	O
it	O
was	O
decided	O
to	O
suspend	O
doses	O
of	O
beta	O
blocker	O
nebivolol	B-FARMACO
2	O
.	O
5	O
mg	O
and	O
eye	O
drops	O
brimonidine	B-FARMACO
timolol	I-FARMACO
.	O
However	O
,	O
a	O
comparison	O
of	O
the	O
medication	O
administered	O
showed	O
that	O
two	O
tablets	O
of	O
carbidopa	B-FARMACO
levodopa	I-FARMACO
25	O
250	O
mg	O
plus	O
formulation	O
were	O
accidentally	O
administered	O
every	O
eight	O
hours	O
,	O
instead	O
of	O
the	O
usual	O
dose	O
of	O
carbidopa	B-FARMACO
levodopa	I-FARMACO
25	O
100	O
mg	O
.	O
After	O
discontinuation	O
of	O
all	O
three	O
drugs	O
,	O
without	O
the	O
need	O
for	O
implantation	O
of	O
pacing	O
devices	O
,	O
the	O
patient	O
showed	O
improvement	O
of	O
atrioventricular	O
conduction	O
disturbance	O
,	O
recovering	O
1	O
1	O
conduction	O
in	O
less	O
than	O
24	O
hours	O
.	O
Subsequently	O
,	O
the	O
patient	O
remained	O
in	O
AF	O
with	O
controlled	O
VR	O
and	O
after	O
48	O
hours	O
in	O
the	O
presence	O
of	O
elevated	O
HR	O
nebivolol	B-FARMACO
could	O
be	O
reintroduced	O
at	O
its	O
previous	O
doses	O
without	O
incident	O
.	O
The	O
patient	O
is	O
discharged	O
with	O
improved	O
renal	O
function	O
and	O
congestive	O
data	O
in	O
AF	O
with	O
controlled	O
VR	O
under	O
treatment	O
with	O
a	O
well	O
tolerated	O
beta	O
blocker	O
.	O
DIAGNOSIS	O
Complete	O
AVB	O
due	O
to	O
accidental	O
carbidopa	B-FARMACO
levodopa	I-FARMACO
overdose	O
.	O
Decompensated	O
heart	O
failure	O
with	O
preserved	O
ejection	O
fraction	O
.	O
Permanent	O
atrial	O
fibrillation	O
CHAD2DS2	O
VASc	O
4	O
.	O
Exacerbation	O
of	O
stage	O
3a	O
chronic	O
kidney	O
disease	O
.	O
Stiff	O
kinetic	O
syndrome	O
on	O
treatment	O
with	O
carbidopa	B-FARMACO
levodopa	I-FARMACO
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
A	O
63	O
year	O
old	O
man	O
,	O
operated	O
in	O
1986	O
for	O
ascending	O
thoracic	O
aortic	O
aneurysm	O
and	O
severe	O
aortic	O
insufficiency	O
secondary	O
to	O
bicuspid	O
aortic	O
valve	O
.	O
He	O
underwent	O
Bentall	O
Bono	O
surgery	O
with	O
implantation	O
of	O
a	O
bicuspid	O
aortic	O
valve	O
prosthesis	O
Bono	O
surgery	O
was	O
performed	O
with	O
implantation	O
of	O
a	O
mechanical	O
prosthesis	O
.	O
As	O
a	O
complication	O
,	O
he	O
presented	O
with	O
extensive	O
anteroseptal	O
infarction	O
after	O
the	O
patient	O
was	O
taken	O
off	O
cardiopulmonary	O
bypass	O
,	O
which	O
led	O
to	O
severe	O
systolic	O
dysfunction	O
with	O
a	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
of	O
30	O
.	O
The	O
patient	O
has	O
remained	O
asymptomatic	O
ever	O
since	O
.	O
Treatment	O
lisinopril	B-FARMACO
5	O
mg	O
24	O
hours	O
,	O
acenocoumarol	B-FARMACO
,	O
atorvastatin	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
hours	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
24	O
hours	O
.	O
Present	O
illness	O
The	O
patient	O
came	O
for	O
consultation	O
because	O
for	O
the	O
last	O
6	O
months	O
he	O
has	O
presented	O
with	O
moderate	O
exertional	O
dyspnoea	O
not	O
previously	O
present	O
.	O
He	O
does	O
not	O
report	O
chest	O
pain	O
or	O
increased	O
oedema	O
in	O
the	O
lower	O
limbs	O
or	O
any	O
other	O
symptoms	O
compatible	O
with	O
heart	O
failure	O
.	O
He	O
also	O
reported	O
the	O
appearance	O
of	O
a	O
lump	O
in	O
the	O
upper	O
third	O
of	O
the	O
sternum	O
,	O
without	O
skin	O
opening	O
,	O
fever	O
or	O
redness	O
in	O
the	O
area	O
.	O
Physical	O
examination	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
aortic	O
prosthetic	O
sounds	O
.	O
Systolic	O
murmur	O
II	O
VI	O
in	O
mitral	O
focus	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
No	O
crackles	O
.	O
Lump	O
at	O
the	O
level	O
of	O
the	O
upper	O
third	O
of	O
the	O
sternotomy	O
next	O
to	O
the	O
sternal	O
notch	O
,	O
on	O
the	O
right	O
edge	O
of	O
the	O
sternum	O
.	O
No	O
redness	O
or	O
increase	O
in	O
temperature	O
.	O
No	O
clear	O
signs	O
of	O
infection	O
.	O
Liquid	O
content	O
to	O
the	O
touch	O
.	O
The	O
presence	O
of	O
thrill	O
on	O
auscultation	O
and	O
to	O
the	O
touch	O
is	O
striking	O
.	O
Not	O
painful	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
.	O
Left	O
bundle	O
branch	O
block	O
with	O
secondary	O
repolarisation	O
alterations	O
.	O
Echocardiogram	O
dilated	O
left	O
ventricle	O
LV	O
with	O
severely	O
depressed	O
LVEF	O
.	O
Extensive	O
anterior	O
,	O
anteroseptal	O
and	O
septal	O
akinesia	O
.	O
Moderate	O
functional	O
mitral	O
insufficiency	O
MI	O
.	O
Aortic	O
prosthesis	O
with	O
no	O
evidence	O
of	O
dysfunction	O
.	O
Right	O
ventricle	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
No	O
tricuspid	O
insufficiency	O
TI	O
that	O
would	O
allow	O
estimation	O
of	O
pulmonary	O
systolic	O
pressure	O
.	O
Transesophageal	O
echocardiogram	O
focused	O
on	O
assessing	O
mitral	O
insufficiency	O
moderate	O
functional	O
mitral	O
insufficiency	O
MI	O
effective	O
regurgitant	O
orifice	O
ERO	O
2D	O
0	O
.	O
12	O
cm2	O
,	O
area	O
of	O
vena	O
contracta	O
3D	O
0	O
.	O
15	O
cm2	O
.	O
Anatomy	O
suitable	O
for	O
mitral	O
clip	O
implantation	O
.	O
Aortic	O
valved	O
tube	O
with	O
no	O
evidence	O
of	O
dysfunction	O
.	O
Given	O
the	O
findings	O
of	O
the	O
physical	O
examination	O
in	O
relation	O
to	O
the	O
bultoma	O
,	O
it	O
was	O
decided	O
to	O
request	O
a	O
CT	O
scan	O
of	O
the	O
aorta	O
to	O
rule	O
out	O
vascular	O
complications	O
at	O
this	O
level	O
.	O
The	O
CT	O
scan	O
showed	O
a	O
skin	O
lesion	O
in	O
the	O
anterior	O
mediastinal	O
region	O
,	O
in	O
contact	O
with	O
the	O
ascending	O
thoracic	O
aorta	O
through	O
a	O
bone	O
defect	O
in	O
the	O
sternal	O
manubrium	O
.	O
However	O
,	O
there	O
is	O
no	O
contrast	O
in	O
its	O
interior	O
so	O
it	O
should	O
not	O
have	O
flow	O
in	O
the	O
arterial	O
phase	O
.	O
Chronic	O
dissections	O
are	O
seen	O
in	O
the	O
intervened	O
ascending	O
aorta	O
,	O
one	O
of	O
them	O
with	O
a	O
connection	O
to	O
the	O
cutaneous	O
lesion	O
.	O
CLINICAL	O
EVOLUTION	O
Given	O
the	O
presence	O
of	O
pseudoaneurysm	O
contained	O
in	O
the	O
valved	O
tube	O
,	O
it	O
was	O
decided	O
to	O
perform	O
repair	O
surgery	O
.	O
Prior	O
to	O
surgery	O
,	O
a	O
transeophageal	O
echocardiogram	O
was	O
performed	O
to	O
confirm	O
the	O
severity	O
of	O
the	O
MR	O
,	O
coronary	O
artery	O
catheterisation	O
was	O
also	O
performed	O
,	O
which	O
ruled	O
out	O
the	O
presence	O
of	O
lesions	O
,	O
and	O
the	O
presence	O
of	O
double	O
lumen	O
in	O
the	O
valved	O
tube	O
was	O
confirmed	O
by	O
aortography	O
.	O
It	O
was	O
jointly	O
decided	O
that	O
as	O
the	O
patient	O
was	O
going	O
to	O
undergo	O
cardiac	O
surgery	O
,	O
he	O
would	O
benefit	O
from	O
mitral	O
valvuloplasty	O
with	O
a	O
ring	O
.	O
Surgery	O
was	O
performed	O
with	O
hypothermic	O
arrest	O
at	O
18o	O
given	O
the	O
high	O
risk	O
of	O
rupture	O
of	O
the	O
pseudoaneurysm	O
when	O
performing	O
the	O
sternotomy	O
.	O
The	O
pseudoaneurysm	O
was	O
confirmed	O
with	O
an	O
entry	O
port	O
at	O
the	O
anastomosis	O
of	O
the	O
valved	O
tube	O
with	O
the	O
aortic	O
root	O
.	O
It	O
is	O
completely	O
removed	O
and	O
replaced	O
with	O
a	O
biological	O
valved	O
tube	O
.	O
Ring	O
annuloplasty	O
is	O
also	O
performed	O
.	O
Postoperative	O
period	O
was	O
uneventful	O
.	O
One	O
year	O
later	O
,	O
a	O
control	O
echocardiogram	O
showed	O
aortic	O
prosthesis	O
with	O
no	O
evidence	O
of	O
dysfunction	O
,	O
mitral	O
annuloplasty	O
with	O
significant	O
MR	O
that	O
was	O
difficult	O
to	O
quantify	O
,	O
dilated	O
LV	O
with	O
severely	O
depressed	O
LVEF	O
30	O
and	O
akinesia	O
of	O
the	O
anterior	O
,	O
anteroseptal	O
and	O
septal	O
faces	O
.	O
Transesophageal	O
echocardiography	O
was	O
then	O
requested	O
to	O
quantify	O
the	O
MR	O
,	O
which	O
showed	O
mitral	O
annuloplasty	O
with	O
severe	O
functional	O
MR	O
ORE	O
2D	O
0	O
.	O
34	O
cm2	O
.	O
Dehiscence	O
of	O
the	O
mitral	O
annulus	O
between	O
7	O
and	O
9	O
o	O
'	O
clock	O
in	O
surgical	O
position	O
,	O
leaving	O
a	O
communication	O
between	O
the	O
upper	O
and	O
lower	O
part	O
of	O
the	O
annulus	O
of	O
1	O
.	O
68	O
cm2	O
.	O
Biological	O
aortic	O
prosthesis	O
and	O
aortic	O
tube	O
with	O
no	O
evidence	O
of	O
dysfunction	O
.	O
Rest	O
of	O
the	O
study	O
superimposable	O
to	O
previous	O
ones	O
.	O
Given	O
that	O
the	O
patient	O
was	O
asymptomatic	O
for	O
the	O
moment	O
,	O
it	O
was	O
decided	O
to	O
maintain	O
a	O
wait	O
and	O
see	O
attitude	O
with	O
regard	O
to	O
mitral	O
insufficiency	O
.	O
In	O
March	O
2020	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
bilateral	O
SARS	O
CoV	O
2	O
coronavirus	O
pneumonia	O
.	O
During	O
his	O
admission	O
,	O
the	O
patient	O
developed	O
respiratory	O
distress	O
syndrome	O
and	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
ICU	O
,	O
requiring	O
invasive	O
mechanical	O
ventilation	O
.	O
After	O
12	O
days	O
in	O
the	O
ICU	O
,	O
the	O
patient	O
evolved	O
correctly	O
and	O
was	O
extubated	O
and	O
transferred	O
to	O
the	O
ward	O
,	O
where	O
he	O
is	O
currently	O
progressing	O
favourably	O
.	O
DIAGNOSIS	O
Bicuspid	O
aortic	O
valve	O
.	O
Ascending	O
aortic	O
aneurysm	O
.	O
Bentall	O
Bono	O
surgery	O
with	O
implantation	O
of	O
mechanical	O
aortic	O
prosthesis	O
.	O
Type	O
V	O
myocardial	O
infarction	O
in	O
relation	O
to	O
surgery	O
.	O
Heart	O
failure	O
with	O
severely	O
depressed	O
LVEF	O
.	O
Pseudoaneurysm	O
of	O
valved	O
aortic	O
tube	O
.	O
Severe	O
functional	O
mitral	O
regurgitation	O
.	O
New	O
Bentall	O
Bono	O
surgery	O
with	O
implantation	O
of	O
a	O
biological	O
aortic	O
prosthesis	O
.	O
Dehiscence	O
of	O
mitral	O
valvuloplasty	O
ring	O
with	O
severe	O
residual	O
MR	O
.	O
Severe	O
bilateral	O
SARS	O
CoV	O
2	O
pneumonia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
26	O
year	O
old	O
woman	O
with	O
no	O
relevant	O
past	O
history	O
except	O
for	O
well	O
controlled	O
extrinsic	O
asthma	O
,	O
who	O
came	O
to	O
the	O
emergency	O
department	O
for	O
a	O
febrile	O
syndrome	O
of	O
2	O
weeks	O
'	O
duration	O
accompanied	O
by	O
general	O
malaise	O
,	O
generalised	O
arthromyalgia	O
,	O
headache	O
and	O
epigastralgia	O
.	O
He	O
reported	O
having	O
started	O
with	O
this	O
clinical	O
condition	O
after	O
returning	O
from	O
a	O
trip	O
to	O
Southeast	O
Asia	O
.	O
One	O
week	O
before	O
the	O
consultation	O
,	O
he	O
started	O
with	O
diarrhoea	O
without	O
pathological	O
products	O
.	O
In	O
addition	O
,	O
about	O
72	O
hours	O
before	O
admission	O
,	O
he	O
presented	O
continuous	O
chest	O
pain	O
with	O
pleuropericardial	O
characteristics	O
,	O
which	O
persisted	O
at	O
the	O
time	O
of	O
assessment	O
.	O
He	O
reported	O
having	O
been	O
correctly	O
vaccinated	O
for	O
the	O
trip	O
and	O
had	O
followed	O
the	O
health	O
recommendations	O
.	O
On	O
arrival	O
he	O
presented	O
with	O
a	O
low	O
grade	O
fever	O
temperature	O
37	O
.	O
5oC	O
.	O
Skin	O
pallor	O
and	O
general	O
state	O
of	O
health	O
,	O
with	O
rhythmic	O
tachycardia	O
at	O
140	O
beats	O
per	O
minute	O
and	O
blood	O
pressure	O
of	O
90	O
60	O
mmHg	O
.	O
Adequate	O
basal	O
saturation	O
.	O
No	O
heart	O
murmurs	O
,	O
pulmonary	O
crackles	O
or	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
Among	O
the	O
complementary	O
tests	O
performed	O
in	O
the	O
initial	O
assessment	O
,	O
we	O
highlight	O
the	O
following	O
Electrocardiogram	O
sinus	O
tachycardia	O
at	O
122	O
bpm	O
with	O
complete	O
right	O
bundle	O
branch	O
block	O
unknown	O
and	O
ST	O
elevation	O
in	O
the	O
antero	O
septal	O
aspect	O
.	O
Portable	O
chest	O
X	O
ray	O
normal	O
CTI	O
.	O
Discrete	O
vascular	O
redistribution	O
,	O
absence	O
of	O
pleural	O
effusion	O
or	O
infiltrates	O
.	O
Urgent	O
laboratory	O
tests	O
with	O
normal	O
values	O
from	O
the	O
reference	O
laboratory	O
pH	O
7	O
.	O
42	O
7	O
.	O
35	O
7	O
.	O
45	O
,	O
creatinine	O
0	O
.	O
55	O
mg	O
dl	O
0	O
.	O
5	O
0	O
.	O
9	O
,	O
potassium	O
4	O
.	O
20	O
mmol	O
l	O
3	O
.	O
5	O
5	O
.	O
0	O
,	O
troponin	O
I	O
30	O
.	O
52	O
μg	O
l	O
0	O
.	O
0	O
0	O
.	O
06	O
,	O
CK	O
871	O
IU	O
l	O
.	O
C	O
reactive	O
protein	O
119	O
.	O
90	O
mg	O
l	O
0	O
.	O
1	O
10	O
.	O
0	O
,	O
NT	O
proBNP	O
13114	O
pg	O
ml	O
10	O
125	O
.	O
Lactate	O
2	O
.	O
2	O
mmol	O
l	O
.	O
Leukocytes	O
14	O
.	O
26	O
x10E3	O
μl	O
4	O
.	O
0	O
11	O
.	O
5	O
with	O
neutrophils	O
10	O
.	O
27	O
x10E3	O
μl	O
.	O
Haemolobin	O
12	O
.	O
8	O
g	O
dl	O
.	O
INR	O
1	O
.	O
02	O
.	O
Urgent	O
transthoracic	O
echocardiogram	O
moderately	O
hypertrophic	O
left	O
ventricle	O
with	O
oedematous	O
appearance	O
and	O
moderately	O
depressed	O
systolic	O
function	O
subjective	O
LVEF	O
35	O
40	O
.	O
Right	O
ventricle	O
normal	O
in	O
size	O
and	O
function	O
.	O
Mildly	O
moderate	O
mitral	O
regurgitation	O
.	O
Minimal	O
tricuspid	O
insufficiency	O
.	O
No	O
pericardial	O
effusion	O
,	O
normal	O
inferior	O
vena	O
cava	O
.	O
During	O
admission	O
,	O
the	O
following	O
tests	O
were	O
performed	O
Serology	O
no	O
relevant	O
findings	O
.	O
Blood	O
cultures	O
negative	O
.	O
Urine	O
cultures	O
negative	O
.	O
Pharyngeal	O
smear	O
and	O
tracheal	O
exudate	O
negative	O
.	O
ASLO	O
negative	O
.	O
Endomyocardial	O
biopsy	O
endomyocardial	O
biopsy	O
3	O
fragments	O
with	O
interstitial	O
lymphohistiocytic	O
infiltrates	O
with	O
myofibrillar	O
damage	O
,	O
compatible	O
with	O
myocarditis	O
.	O
ECG	O
at	O
discharge	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
.	O
Wide	O
QRS	O
150	O
ms	O
with	O
morphology	O
of	O
complete	O
right	O
bundle	O
branch	O
block	O
RBBB	O
.	O
Generalised	O
low	O
voltage	O
.	O
Echocardiography	O
at	O
discharge	O
left	O
ventricle	O
of	O
normal	O
dimensions	O
,	O
with	O
moderate	O
systolic	O
dysfunction	O
and	O
global	O
hypokinesia	O
,	O
although	O
more	O
pronounced	O
at	O
septal	O
level	O
.	O
Global	O
longitudinal	O
Strain	O
12	O
.	O
8	O
.	O
Normal	O
right	O
ventricle	O
.	O
Minimal	O
mitral	O
insufficiency	O
.	O
No	O
tricuspid	O
insufficiency	O
.	O
No	O
pericardial	O
effusion	O
.	O
Normal	O
IVC	O
.	O
Cardiac	O
MRI	O
findings	O
compatible	O
with	O
myocarditis	O
.	O
Slightly	O
reduced	O
global	O
contractility	O
LVEF	O
47	O
.	O
Thinning	O
,	O
hypokinesia	O
and	O
increased	O
signal	O
in	O
STIR	O
sequences	O
and	O
basal	O
anteroseptal	O
midventricular	O
enhancement	O
.	O
Late	O
enhancement	O
of	O
the	O
lateral	O
wall	O
of	O
the	O
right	O
ventricle	O
.	O
Mild	O
pericardial	O
effusion	O
.	O
Renal	O
and	O
hepatic	O
function	O
and	O
biomarkers	O
of	O
myocardial	O
damage	O
at	O
discharge	O
creatinine	O
1	O
.	O
3	O
mg	O
dl	O
.	O
Total	O
bilirubin	O
1	O
.	O
4	O
mg	O
dl	O
.	O
GGT	O
51	O
U	O
l	O
.	O
Maximum	O
troponin	O
I	O
102	O
μg	O
l	O
.	O
NT	O
proBNP	O
maximum	O
of	O
110000	O
pg	O
ml	O
,	O
at	O
discharge	O
4259	O
pg	O
ml	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
being	O
assessed	O
by	O
the	O
cardiology	O
team	O
,	O
it	O
was	O
decided	O
to	O
transfer	O
her	O
to	O
the	O
acute	O
cardiac	O
care	O
unit	O
for	O
close	O
monitoring	O
,	O
where	O
she	O
presented	O
poor	O
initial	O
evolution	O
with	O
criteria	O
of	O
cardiogenic	O
shock	O
,	O
both	O
clinical	O
and	O
analytical	O
,	O
so	O
inotropic	O
and	O
vasoactive	O
support	O
treatment	O
was	O
started	O
.	O
An	O
endomyocardial	O
biopsy	O
was	O
performed	O
,	O
confirming	O
the	O
diagnosis	O
of	O
lymphocytic	O
myocarditis	O
,	O
and	O
it	O
was	O
decided	O
to	O
administer	O
intravenous	O
corticosteroids	O
three	O
doses	O
of	O
methylprednisolone	B-FARMACO
.	O
In	O
the	O
first	O
hours	O
of	O
admission	O
,	O
the	O
patient	O
began	O
with	O
slow	O
ventricular	O
tachycardia	O
with	O
haemodynamic	O
instability	O
and	O
incessant	O
behaviour	O
,	O
despite	O
treatment	O
with	O
intravenous	O
antiarrhythmics	O
and	O
several	O
attempts	O
at	O
electrical	O
cardioversion	O
.	O
It	O
was	O
decided	O
by	O
consensus	O
with	O
the	O
shock	O
team	O
to	O
implant	O
an	O
intra	O
aortic	O
balloon	O
pump	O
IABP	O
,	O
with	O
subsequent	O
peripheral	O
veno	O
arterial	O
ECMO	O
extracorporeal	O
membrane	O
oxygenation	O
cannulation	O
.	O
The	O
patient	O
also	O
required	O
renal	O
replacement	O
therapy	O
in	O
the	O
first	O
days	O
of	O
admission	O
due	O
to	O
acute	O
renal	O
failure	O
.	O
After	O
5	O
days	O
of	O
mechanical	O
circulatory	O
support	O
and	O
in	O
view	O
of	O
the	O
favourable	O
evolution	O
,	O
ECMO	O
and	O
IABP	O
were	O
gradually	O
withdrawn	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
cardiology	O
ward	O
to	O
continue	O
her	O
evolution	O
and	O
start	O
the	O
titration	O
of	O
neurohormonal	O
medication	O
for	O
heart	O
failure	O
with	O
reduced	O
ejection	O
fraction	O
.	O
Control	O
echocardiography	O
at	O
discharge	O
showed	O
improvement	O
in	O
ventricular	O
function	O
with	O
moderate	O
dysfunction	O
and	O
magnetic	O
resonance	O
imaging	O
showed	O
findings	O
compatible	O
with	O
myocarditis	O
.	O
The	O
patient	O
was	O
discharged	O
after	O
three	O
weeks	O
of	O
admission	O
with	O
a	O
diagnosis	O
of	O
cardiogenic	O
shock	O
secondary	O
to	O
fulminant	O
lymphocytic	O
myocarditis	O
histopathological	O
diagnosis	O
,	O
but	O
none	O
of	O
the	O
serologies	O
,	O
multiple	O
cultures	O
or	O
other	O
samples	O
were	O
able	O
to	O
identify	O
a	O
specific	O
aetiological	O
agent	O
.	O
At	O
the	O
office	O
evaluation	O
more	O
than	O
one	O
year	O
later	O
,	O
the	O
patient	O
had	O
recovered	O
ventricular	O
function	O
and	O
was	O
in	O
NYHA	O
functional	O
class	O
I	O
.	O
She	O
was	O
maintained	O
on	O
neurohormonal	O
treatment	O
.	O
Neurohormonal	O
treatment	O
for	O
systolic	O
dysfunction	O
has	O
been	O
maintained	O
.	O
DIAGNOSIS	O
Refractory	O
cardiogenic	O
shock	O
INTERMACS	O
1	O
,	O
SCAI	O
E	O
with	O
need	O
for	O
mechanical	O
circulatory	O
support	O
ECMO	O
IABP	O
.	O
Fulminant	O
lymphocytic	O
myocarditis	O
.	O
Heart	O
failure	O
with	O
depressed	O
ejection	O
fraction	O
,	O
recovered	O
after	O
one	O
year	O
of	O
evolution	O
with	O
neurohormonal	O
treatment	O
.	O
CF	O
I	O
NYHA	O
.	O
Acute	O
renal	O
failure	O
Cardiorenal	O
syndrome	O
type	O
I	O
,	O
resolved	O
.	O

A	O
38	O
year	O
old	O
patient	O
from	O
Luque	O
,	O
a	O
dressmaker	O
,	O
known	O
to	O
be	O
hypertensive	O
and	O
on	O
irregular	O
treatment	O
with	O
Losartan	B-FARMACO
50	O
mg	O
day	O
.	O
Obstetric	O
and	O
gynaecological	O
history	O
of	O
three	O
pregnancies	O
,	O
two	O
births	O
,	O
one	O
stillbirth	O
and	O
refers	O
that	O
her	O
mother	O
has	O
been	O
a	O
carrier	O
of	O
arthritis	O
since	O
the	O
age	O
of	O
50	O
.	O
She	O
reports	O
a	O
clinical	O
picture	O
of	O
terebrante	O
pain	O
located	O
in	O
the	O
interphalangeal	O
joints	O
radiating	O
bilaterally	O
and	O
symmetrically	O
to	O
the	O
wrist	O
with	O
signs	O
of	O
inflammation	O
and	O
functional	O
impotence	O
,	O
predominantly	O
in	O
the	O
morning	O
,	O
of	O
11	O
months	O
of	O
evolution	O
;	O
three	O
months	O
before	O
admission	O
,	O
a	O
feverish	O
sensation	O
was	O
added	O
to	O
the	O
picture	O
,	O
predominantly	O
at	O
night	O
with	O
profuse	O
sweating	O
accompanied	O
by	O
progressive	O
dyspnoea	O
,	O
first	O
on	O
moderate	O
exertion	O
and	O
then	O
on	O
mild	O
exertion	O
.	O
Three	O
weeks	O
before	O
admission	O
,	O
pain	O
with	O
the	O
same	O
characteristics	O
migrated	O
to	O
the	O
left	O
ankle	O
and	O
became	O
bilateral	O
and	O
symmetrical	O
,	O
and	O
did	O
not	O
subside	O
with	O
common	O
analgesics	O
.	O
Two	O
weeks	O
before	O
admission	O
,	O
due	O
to	O
the	O
persistence	O
of	O
the	O
symptoms	O
,	O
she	O
consulted	O
a	O
doctor	O
who	O
requested	O
complementary	O
studies	O
and	O
found	O
a	O
sudden	O
drop	O
in	O
haemoglobin	O
levels	O
,	O
and	O
indicated	O
referral	O
to	O
the	O
Haematology	O
Department	O
.	O
Two	O
days	O
before	O
admission	O
to	O
the	O
department	O
,	O
the	O
symptoms	O
arthralgias	O
,	O
fever	O
and	O
dyspnoea	O
were	O
exacerbated	O
and	O
the	O
patient	O
went	O
to	O
the	O
emergency	O
department	O
where	O
she	O
was	O
assessed	O
by	O
a	O
haematologist	O
who	O
requested	O
additional	O
tests	O
.	O
Subsequently	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
ward	O
with	O
the	O
following	O
laboratory	O
results	O
.	O
Data	O
of	O
value	O
on	O
physical	O
examination	O
were	O
On	O
ectoscopy	O
,	O
dyspnoeic	O
fascies	O
,	O
pallor	O
of	O
skin	O
and	O
mucous	O
membranes	O
;	O
in	O
the	O
respiratory	O
system	O
,	O
poor	O
respiratory	O
mechanics	O
,	O
tachypnoea	O
,	O
dyspnoea	O
,	O
on	O
percussion	O
,	O
dullness	O
in	O
both	O
bases	O
,	O
on	O
auscultation	O
,	O
subcrepitant	O
in	O
both	O
midfields	O
,	O
abolished	O
in	O
both	O
bases	O
;	O
in	O
the	O
cardiovascular	O
system	O
,	O
heart	O
sounds	O
with	O
regular	O
rhythm	O
,	O
tachycardia	O
,	O
R1	O
and	O
R2	O
hypophonetic	O
,	O
no	O
galloping	O
,	O
diastolic	O
murmur	O
in	O
aortic	O
focus	O
and	O
holosystolic	O
in	O
mitral	O
focus	O
with	O
irradiation	O
to	O
the	O
axilla	O
;	O
abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
,	O
slight	O
splenomegaly	O
,	O
no	O
palpable	O
hepatomegaly	O
;	O
in	O
the	O
osteoarticular	O
system	O
,	O
inflammatory	O
signs	O
at	O
the	O
level	O
of	O
the	O
right	O
knee	O
.	O
No	O
inflammatory	O
signs	O
in	O
other	O
joints	O
.	O
Based	O
on	O
these	O
data	O
,	O
the	O
following	O
diagnoses	O
were	O
proposed	O
left	O
heart	O
failure	O
,	O
mitroaortic	O
insufficiency	O
,	O
collagenopathy	O
to	O
be	O
confirmed	O
,	O
anaemic	O
syndrome	O
,	O
controlled	O
arterial	O
hypertension	O
.	O
In	O
the	O
following	O
days	O
the	O
patient	O
presented	O
febrile	O
peaks	O
and	O
polycultures	O
were	O
performed	O
.	O
A	O
volume	O
of	O
concentrated	O
red	O
blood	O
cells	O
was	O
transfused	O
and	O
the	O
patient	O
's	O
dyspnoea	O
worsened	O
,	O
having	O
previously	O
returned	O
a	O
negative	O
direct	O
Coombs	O
'	O
test	O
.	O
A	O
simple	O
CT	O
scan	O
of	O
the	O
chest	O
showed	O
a	O
diffuse	O
interstitial	O
pattern	O
with	O
bilateral	O
pleural	O
effusion	O
in	O
both	O
bases	O
,	O
and	O
so	O
,	O
with	O
the	O
possibility	O
of	O
collagenopathy	O
,	O
boluses	O
of	O
methylprednisolone	B-FARMACO
5	O
grams	O
were	O
started	O
,	O
to	O
which	O
she	O
responded	O
favourably	O
.	O
Rheumatological	O
profiles	O
were	O
requested	O
ANA	O
,	O
anti	O
DNA	O
,	O
anti	O
CCP	O
,	O
C3	O
,	O
C4	O
,	O
Anti	O
B2	O
glycoprotein	O
,	O
Antiphospholipid	O
,	O
Anticardiolipin	O
,	O
Lupus	O
anticoagulant	O
,	O
Antithrombin	O
III	O
,	O
Prot	O
.	O
C	O
and	O
S	O
which	O
all	O
returned	O
in	O
the	O
normal	O
range	O
except	O
FR	O
in	O
dilution	O
1	O
512	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
vegetation	O
on	O
the	O
aortic	O
and	O
mitral	O
valves	O
,	O
with	O
pseudoaneurysm	O
of	O
one	O
aortic	O
and	O
one	O
mitral	O
leaflet	O
,	O
as	O
well	O
as	O
perforation	O
of	O
one	O
aortic	O
leaflet	O
,	O
which	O
led	O
to	O
a	O
diagnosis	O
of	O
endocarditis	O
and	O
empirical	O
antibiotic	O
therapy	O
was	O
started	O
immediately	O
,	O
even	O
though	O
the	O
laboratory	O
tests	O
returned	O
with	O
few	O
variations	O
.	O
Days	O
later	O
,	O
blood	O
cultures	O
returned	O
positive	O
for	O
Streptococcus	O
alpha	O
haemolyticus	O
in	O
3	O
of	O
8	O
bottles	O
.	O
Subsequently	O
,	O
the	O
patient	O
underwent	O
bivalvular	O
replacement	O
with	O
mechanical	O
valves	O
,	O
which	O
was	O
successful	O
.	O
She	O
returns	O
the	O
results	O
of	O
the	O
pathological	O
anatomy	O
of	O
the	O
vegetations	O
which	O
reports	O
the	O
following	O
"	O
Cardiac	O
valves	O
with	O
marked	O
degenerative	O
changes	O
fibrosis	O
,	O
hyalinisation	O
and	O
myxoid	O
changes	O
.	O
There	O
are	O
also	O
numerous	O
reactive	O
fibroblasts	O
,	O
some	O
of	O
them	O
with	O
changes	O
suggestive	O
of	O
previous	O
rheumatological	O
pathology	O
.	O
On	O
the	O
surface	O
there	O
is	O
a	O
marked	O
acute	O
inflammatory	O
infiltrate	O
and	O
fibrin	O
deposits	O
corresponding	O
to	O
vegetations	O
.	O
The	O
histological	O
findings	O
are	O
compatible	O
with	O
acute	O
bacterial	O
endocarditis	O
"	O
The	O
definitive	O
anatomopathological	O
diagnosis	O
is	O
Acute	O
Bacterial	O
Endocarditis	O
due	O
to	O
the	O
visualisation	O
of	O
Anitschkow	O
cells	O
,	O
which	O
due	O
to	O
the	O
chronicity	O
of	O
the	O
symptoms	O
is	O
clinically	O
presumed	O
to	O
be	O
Subacute	O
Bacterial	O
Endocarditis	O
,	O
with	O
suspected	O
comorbidity	O
,	O
a	O
collagenopathy	O
to	O
be	O
confirmed	O
with	O
subsequent	O
follow	O
up	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
a	O
72	O
year	O
old	O
male	O
,	O
allergic	O
to	O
penicillin	B-FARMACO
and	O
intolerant	O
to	O
tramadol	B-FARMACO
and	O
metformin	B-FARMACO
,	O
with	O
criteria	O
of	O
metabolic	O
syndrome	O
with	O
central	O
obesity	O
.	O
He	O
has	O
been	O
diagnosed	O
with	O
hypertension	O
HT	O
,	O
dyslipidaemia	O
DLP	O
and	O
DM2	O
for	O
a	O
long	O
time	O
,	O
with	O
erratic	O
control	O
of	O
these	O
CVRF	O
to	O
date	O
.	O
Ex	O
smoker	O
for	O
about	O
8	O
years	O
.	O
Multifactorial	O
chronic	O
kidney	O
disease	O
CKD	O
with	O
creatinine	O
levels	O
around	O
1	O
.	O
5	O
mg	O
dl	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
COPD	O
and	O
sleep	O
apnoea	O
syndrome	O
OSAHS	O
with	O
indication	O
for	O
CPAP	O
.	O
He	O
had	O
undergone	O
lumbar	O
canal	O
surgery	O
five	O
years	O
earlier	O
posterior	O
cord	O
electrostimulator	O
,	O
under	O
follow	O
up	O
by	O
the	O
pain	B-FARMACO
unit	O
and	O
resection	O
of	O
colon	O
polyps	O
benign	O
.	O
His	O
cardiological	O
history	O
begins	O
in	O
the	O
1990s	O
,	O
when	O
he	O
was	O
diagnosed	O
with	O
ischaemic	O
heart	O
disease	O
debut	O
as	O
AMI	O
,	O
with	O
three	O
vessel	O
disease	O
on	O
coronary	O
angiography	O
.	O
He	O
underwent	O
surgical	O
revascularisation	O
by	O
double	O
bypass	O
internal	O
mammary	O
artery	O
IMA	O
to	O
anterior	O
descending	O
artery	O
ADA	O
and	O
saphenous	O
vein	O
to	O
circumflex	O
artery	O
ACx	O
;	O
without	O
approaching	O
the	O
right	O
coronary	O
artery	O
RCA	O
due	O
to	O
severe	O
and	O
diffuse	O
disease	O
.	O
He	O
was	O
assessed	O
for	O
the	O
first	O
time	O
in	O
2010	O
in	O
the	O
HF	O
unit	O
of	O
his	O
hospital	O
due	O
to	O
clinical	O
worsening	O
,	O
with	O
the	O
finding	O
of	O
ventricular	O
dysfunction	O
LVEF	O
35	O
40	O
in	O
transthoracic	O
echocardiography	O
,	O
unknown	O
until	O
then	O
.	O
Repeat	O
coronary	O
angiography	O
showed	O
patency	O
of	O
the	O
AMI	O
ADA	O
bypass	O
,	O
with	O
occlusion	O
of	O
the	O
saphenous	O
vein	O
graft	O
to	O
ACx	O
thin	O
vessel	O
and	O
diffuse	O
disease	O
,	O
which	O
was	O
considered	O
for	O
conservative	O
management	O
.	O
First	O
admission	O
for	O
HF	O
in	O
2015	O
,	O
with	O
decompensation	O
occurring	O
in	O
the	O
context	O
of	O
atrial	O
flutter	O
,	O
which	O
underwent	O
cavotricuspid	O
isthmus	O
ablation	O
.	O
Implantation	O
of	O
a	O
single	O
chamber	O
ICD	O
for	O
primary	O
prevention	O
that	O
same	O
year	O
,	O
with	O
no	O
arrhythmic	O
events	O
to	O
date	O
.	O
New	O
admission	O
for	O
dyspnoea	O
and	O
chest	O
pain	O
in	O
2016	O
,	O
with	O
no	O
notable	O
changes	O
in	O
the	O
control	O
coronary	O
angiography	O
.	O
More	O
than	O
two	O
admissions	O
throughout	O
2017	O
,	O
with	O
clear	O
clinical	O
deterioration	O
,	O
for	O
which	O
an	O
assessment	O
was	O
requested	O
in	O
our	O
HF	O
unit	O
two	O
years	O
ago	O
.	O
On	O
consultation	O
,	O
the	O
patient	O
reported	O
minimal	O
effort	O
dyspnoea	O
NYHA	O
III	O
,	O
chronic	O
two	O
pillow	O
orthopnoea	O
and	O
bendopnoea	O
,	O
without	O
clear	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
There	O
were	O
also	O
signs	O
of	O
water	O
retention	O
,	O
mainly	O
oedema	O
in	O
the	O
lower	O
limbs	O
lower	O
limbs	O
.	O
No	O
clinical	O
data	O
suggestive	O
of	O
low	O
output	O
.	O
Regular	O
blood	O
pressure	O
control	O
at	O
home	O
with	O
ambulatory	O
systolic	O
blood	O
pressure	O
SBP	O
of	O
around	O
160	O
mmHg	O
.	O
Physical	O
examination	O
showed	O
good	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
in	O
all	O
three	O
spheres	O
.	O
Tendency	O
to	O
hypertension	O
160	O
90	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
70	O
bpm	O
.	O
Basal	O
saturation	O
94	O
.	O
Weight	O
119	O
kilograms	O
kg	O
.	O
Height	O
1	O
.	O
72	O
metres	O
m	O
.	O
Body	O
mass	O
index	O
BMI	O
40	O
.	O
2	O
kg	O
m	O
.	O
Obesity	O
class	O
III	O
.	O
Auscultation	O
is	O
rhythmic	O
and	O
there	O
are	O
no	O
murmurs	O
.	O
Minimal	O
crackles	O
at	O
the	O
bases	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
without	O
palpable	O
masses	O
or	O
megaliths	O
.	O
MMII	O
with	O
oedema	O
from	O
the	O
knee	O
.	O
Acceptable	O
distal	O
capillary	O
refill	O
.	O
The	O
treatment	O
he	O
was	O
taking	O
at	O
the	O
time	O
is	O
summarised	O
below	O
acenocoumarol	B-FARMACO
for	O
target	O
INR	O
2	O
3	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
1	O
0	O
0	O
,	O
carvedilol	B-FARMACO
25	O
mg	O
0	O
.	O
5	O
0	O
0	O
.	O
5	O
,	O
enalapril	B-FARMACO
20	O
mg	O
1	O
0	O
1	O
,	O
eplerenone	B-FARMACO
25	O
mg	O
0	O
1	O
0	O
,	O
furosemide	B-FARMACO
40	O
mg	O
2	O
2	O
0	O
,	O
chlorthalidone	B-FARMACO
50	O
mg	O
half	O
tablet	O
every	O
other	O
day	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
0	O
0	O
1	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
,	O
tiotropium	B-FARMACO
bromide	I-FARMACO
one	O
inhalation	O
per	O
day	O
,	O
insulin	B-FARMACO
aapid	O
34	O
32	O
38	O
,	O
paracetamol	B-FARMACO
and	O
metamizole	B-FARMACO
on	O
demand	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
1	O
initial	O
glucose	O
127	O
mg	O
dl	O
60	O
.	O
0	O
100	O
.	O
0	O
,	O
urea	O
64	O
mg	O
dl	O
21	O
.	O
0	O
50	O
.	O
0	O
,	O
creatinine	O
1	O
.	O
46	O
mg	O
dl	O
0	O
.	O
6	O
1	O
.	O
2	O
,	O
glomerular	O
filtration	O
rate	O
48	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
uric	O
acid	O
7	O
.	O
8	O
mg	O
dl	O
3	O
.	O
4	O
7	O
.	O
0	O
,	O
cholesterol	O
183	O
mg	O
dl	O
,	O
hDL	O
C	O
32	O
mg	O
dl	O
,	O
LDL	O
C	O
107	O
mg	O
dl	O
,	O
triglycerides	O
221	O
mg	O
dl	O
,	O
total	O
protein	O
7	O
.	O
4	O
g	O
dl	O
6	O
.	O
0	O
8	O
.	O
0	O
,	O
albumin	O
4	O
.	O
4	O
g	O
dl	O
3	O
.	O
5	O
5	O
.	O
0	O
,	O
sodium	O
142	O
mmol	O
l	O
135	O
.	O
0	O
145	O
.	O
0	O
,	O
potassium	O
4	O
.	O
2	O
mmol	O
l	O
3	O
.	O
5	O
5	O
.	O
0	O
,	O
total	O
bilirubin	O
0	O
.	O
5	O
mg	O
dl	O
0	O
.	O
3	O
1	O
.	O
1	O
,	O
NT	O
proBNP	O
3463	O
pg	O
ml	O
10	O
.	O
0	O
125	O
.	O
0	O
,	O
LDH	O
335	O
U	O
l	O
230	O
.	O
0	O
460	O
.	O
0	O
,	O
ALT	O
GPT	O
21	O
U	O
l	O
6	O
.	O
0	O
40	O
.	O
0	O
,	O
AST	O
GOT	O
25	O
U	O
l	O
6	O
.	O
0	O
40	O
.	O
0	O
,	O
alkaline	O
phosphatase	O
96	O
U	O
l	O
40	O
,	O
0	O
128	O
.	O
0	O
,	O
gamma	O
glutamyltransferase	O
216	O
U	O
l	O
8	O
.	O
0	O
61	O
.	O
0	O
,	O
c	O
reactive	O
protein	O
20	O
.	O
0	O
mg	O
l	O
0	O
.	O
1	O
10	O
.	O
0	O
glycohaemoglobin	O
HbA1c	O
8	O
.	O
8	O
,	O
leucocytes	O
8	O
.	O
92	O
x10E3	O
microL	O
,	O
haemoglobin	O
17	O
.	O
40	O
g	O
dl	O
,	O
platelets	O
245	O
.	O
00	O
10E3	O
microL	O
,	O
INR	O
1	O
.	O
47	O
R	O
.	O
N	O
.	O
CBC	O
2	O
at	O
six	O
months	O
glucose	O
117	O
mg	O
dl	O
,	O
urea	O
53	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
36	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
53	O
mL	O
min	O
1	O
.	O
73	O
mE2	O
,	O
uric	O
acid	O
6	O
.	O
6	O
mg	O
dl	O
,	O
cholesterol	O
160	O
mg	O
dl	O
,	O
HDL	O
C	O
34	O
mg	O
dl	O
,	O
LDL	O
C	O
calculated	O
89	O
mg	O
dl	O
,	O
triglycerides	O
185	O
mg	O
dl	O
,	O
total	O
protein	O
6	O
.	O
9	O
g	O
dl	O
,	O
albumin	O
4	O
,	O
1	O
g	O
dl	O
,	O
calcium	O
9	O
.	O
3	O
mg	O
dl	O
,	O
sodium	O
143	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
8	O
mmol	O
l	O
,	O
NT	O
proBNP	O
1010	O
pg	O
ml	O
,	O
LDH	O
333	O
U	O
l	O
,	O
ALT	O
GPT	O
11	O
U	O
l	O
,	O
AST	O
GOT	O
16	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
67	O
U	O
l	O
,	O
gamma	O
glutamyltransferase	O
80	O
U	O
l	O
,	O
glycohaemoglobin	O
HbA1c	O
8	O
.	O
0	O
,	O
leucocytes	O
7	O
.	O
92	O
x10E3	O
microL	O
,	O
haemoglobin	O
18	O
.	O
40	O
g	O
dl	O
,	O
platelets	O
180	O
.	O
00	O
10E3	O
microL	O
,	O
INR	O
2	O
.	O
10	O
R	O
.	O
N	O
.	O
CBC	O
3	O
at	O
one	O
year	O
glucose	O
103	O
mg	O
dl	O
,	O
urea	O
50	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
31	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
55	O
ml	O
min	O
1	O
.	O
73	O
mE2	O
,	O
uric	O
acid	O
6	O
.	O
8	O
mg	O
dl	O
,	O
cholesterol	O
143	O
mg	O
dl	O
,	O
HDLc	O
35	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
calculated	O
76	O
mg	O
dl	O
,	O
triglycerides	O
163	O
mg	O
dl	O
,	O
total	O
proteins	O
6	O
.	O
9	O
g	O
dl	O
,	O
albumin	O
4	O
.	O
2	O
g	O
dl	O
,	O
calcium	O
9	O
.	O
2	O
mg	O
dl	O
,	O
sodium	O
139	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
9	O
mmol	O
l	O
,	O
NT	O
proBNP	O
835	O
pg	O
ml	O
,	O
LDH	O
330	O
U	O
l	O
,	O
ALT	O
GPT	O
13	O
U	O
l	O
,	O
AST	O
GOT	O
16	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
69	O
U	O
l	O
,	O
gamma	O
glutamyltransferase	O
71	O
U	O
l	O
,	O
glycohaemoglobin	O
HbA1c	O
7	O
.	O
3	O
,	O
leucocytes	O
6	O
.	O
46	O
x10E3	O
microL	O
,	O
haemoglobin	O
17	O
.	O
20	O
g	O
dl	O
,	O
platelets	O
202	O
.	O
00	O
10E3	O
microL	O
,	O
INR	O
2	O
.	O
6	O
R	O
.	O
N	O
.	O
Electrocardiogram	O
sinus	O
bradycardia	O
at	O
50	O
bpm	O
.	O
Left	O
axis	O
.	O
Atrial	O
enlargement	O
data	O
.	O
PR	O
200	O
ms	O
.	O
Wide	O
QRS	O
120	O
ms	O
.	O
Inferior	O
Q	O
.	O
Inferolateral	O
ST	O
rectified	O
,	O
flattening	O
in	O
DI	O
and	O
AvL	O
.	O
QTc	O
470	O
ms	O
.	O
Chest	O
X	O
ray	O
increased	O
cardiothoracic	O
index	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
Generator	O
and	O
electrode	O
in	O
normal	O
position	O
.	O
No	O
images	O
of	O
condensation	O
or	O
pleural	O
effusion	O
.	O
Transthoracic	O
echocardiogram	O
study	O
limited	O
by	O
poor	O
acoustic	O
window	O
and	O
obesity	O
.	O
Dilated	O
cardiomyopathy	O
with	O
moderately	O
dilated	O
left	O
ventricle	O
LV	O
,	O
with	O
moderately	O
depressed	O
contractility	O
.	O
EF	O
35	O
38	O
.	O
Extensive	O
inferior	O
,	O
posterior	O
and	O
lateral	O
akinesia	O
.	O
Diastolic	O
dysfunction	O
.	O
Aortic	O
valve	O
sclerosis	O
.	O
Valvular	O
flows	O
without	O
significant	O
alterations	O
.	O
Minimal	O
mitral	O
insufficiency	O
MI	O
that	O
does	O
not	O
allow	O
estimation	O
of	O
PAPs	O
,	O
but	O
without	O
data	O
of	O
severe	O
pulmonary	O
hypertension	O
PHT	O
due	O
to	O
pulmonary	O
acceleration	O
.	O
Implantable	O
cardioverter	O
defibrillator	O
ICD	O
lead	O
in	O
right	O
cavities	O
.	O
Right	O
ventricle	O
RV	O
apparently	O
normal	O
with	O
preserved	O
longitudinal	O
systolic	O
function	O
.	O
No	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
the	O
first	O
consultation	O
assessment	O
and	O
,	O
given	O
the	O
clinical	O
situation	O
and	O
analytical	O
results	O
see	O
analytical	O
1	O
in	O
complementary	O
tests	O
,	O
it	O
was	O
decided	O
to	O
start	O
neurohormonal	O
medication	O
for	O
HF	O
with	O
reduced	O
ejection	O
fraction	O
EFred	O
,	O
increasing	O
the	O
dose	O
of	O
beta	O
blocker	O
carvedilol	B-FARMACO
was	O
increased	O
to	O
25	O
mg	O
every	O
12	O
hours	O
.	O
Enalapril	B-FARMACO
is	O
replaced	O
by	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
24	O
26	O
mg	O
every	O
12	O
hours	O
with	O
a	O
blanking	O
period	O
due	O
to	O
prior	O
treatment	O
with	O
ACE	B-FARMACO
inhibitors	I-FARMACO
.	O
The	O
dose	O
of	O
mineralocorticoid	O
receptor	O
antagonist	O
MRA	O
is	O
doubled	O
to	O
50	O
mg	O
eplerenone	B-FARMACO
daily	O
.	O
ASA	B-FARMACO
was	O
also	O
discontinued	O
,	O
maintaining	O
oral	O
anticoagulation	O
.	O
It	O
was	O
decided	O
to	O
add	O
ezemitiba	B-FARMACO
as	O
lipid	O
lowering	O
treatment	O
for	O
LDL	O
outside	O
the	O
target	O
range	O
for	O
ischaemic	O
patients	O
.	O
Given	O
the	O
results	O
of	O
glycated	O
haemoglobin	O
Hb1Ac	O
and	O
given	O
that	O
this	O
was	O
a	O
patient	O
with	O
HF	O
,	O
a	O
sodium	B-FARMACO
glucose	I-FARMACO
cotransporter	I-FARMACO
receptor	I-FARMACO
inhibitor	I-FARMACO
iSGLT2	I-FARMACO
was	O
added	O
empagliflozin	B-FARMACO
10	O
mg	O
every	O
24	O
hours	O
.	O
Given	O
the	O
volemia	O
situation	O
in	O
the	O
consultation	O
and	O
,	O
prioritising	O
the	O
titration	O
of	O
drugs	O
for	O
HF	O
with	O
FEred	O
,	O
the	O
dose	O
of	O
furosemide	B-FARMACO
was	O
reduced	O
to	O
2	O
1	O
0	O
and	O
chlorthalidone	B-FARMACO
was	O
discontinued	O
.	O
On	O
the	O
other	O
hand	O
,	O
a	O
reduction	O
in	O
the	O
need	O
for	O
diuretics	O
was	O
expected	O
after	O
starting	O
iSGLT2	O
.	O
The	O
patient	O
was	O
assessed	O
again	O
after	O
6	O
months	O
in	O
consultations	O
.	O
He	O
has	O
not	O
been	O
admitted	O
for	O
decompensation	O
of	O
HF	O
and	O
suggests	O
clinical	O
stability	O
.	O
He	O
reported	O
improvement	O
in	O
functional	O
class	O
,	O
with	O
current	O
dyspnoea	O
on	O
moderate	O
exertion	O
NYHA	O
II	O
,	O
although	O
he	O
was	O
still	O
limited	O
by	O
muscular	O
pain	O
related	O
to	O
his	O
lumbar	O
pathology	O
.	O
He	O
also	O
reports	O
a	O
significant	O
reduction	O
in	O
oedema	O
in	O
the	O
lower	O
limbs	O
and	O
has	O
lost	O
about	O
8	O
kg	O
in	O
weight	O
since	O
the	O
last	O
visit	O
he	O
acknowledges	O
better	O
dietary	O
compliance	O
.	O
He	O
periodically	O
monitors	O
his	O
blood	O
pressure	O
,	O
with	O
TAS	O
values	O
of	O
around	O
130	O
140	O
mmHg	O
.	O
On	O
examination	O
,	O
the	O
patient	O
is	O
in	O
good	O
general	O
condition	O
.	O
Haemodynamically	O
stable	O
with	O
BP	O
140	O
80	O
mmHg	O
.	O
HR	O
55	O
bpm	O
.	O
O2	O
saturation	O
95	O
.	O
Weight	O
111	O
kg	O
.	O
Height	O
1	O
.	O
72	O
m	O
.	O
BMI	O
37	O
.	O
5	O
kg	O
m	O
.	O
Obesity	O
class	O
II	O
.	O
Minimal	O
crackles	O
on	O
auscultation	O
,	O
with	O
limitation	O
of	O
oedema	O
to	O
the	O
bimalleolar	O
area	O
.	O
Good	O
distal	O
capillary	O
filling	O
persists	O
.	O
The	O
clinical	O
improvement	O
corresponds	O
with	O
the	O
analytical	O
results	O
see	O
analytical	O
2	O
in	O
complementary	O
tests	O
,	O
showing	O
a	O
reduction	O
of	O
NT	O
proBNP	O
from	O
3463	O
pg	O
ml	O
to	O
1010	O
pg	O
ml	O
.	O
Glycaemic	O
and	O
lipid	O
control	O
,	O
although	O
still	O
outside	O
target	O
values	O
,	O
has	O
also	O
improved	O
HbA1c	O
has	O
been	O
reduced	O
to	O
8	O
and	O
LDL	O
is	O
around	O
90	O
mg	O
dl	O
.	O
At	O
this	O
visit	O
,	O
it	O
was	O
decided	O
to	O
increase	O
the	O
dose	O
of	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
to	O
49	O
51	O
mg	O
every	O
12	O
hours	O
due	O
to	O
good	O
clinical	O
and	O
haemodynamic	O
tolerance	O
,	O
with	O
no	O
deterioration	O
in	O
renal	O
function	O
.	O
Atorvastatin	B-FARMACO
was	O
replaced	O
by	O
rosuvastatin	B-FARMACO
in	O
an	O
attempt	O
to	O
achieve	O
target	O
LDL	O
.	O
Finally	O
,	O
given	O
the	O
clinical	O
context	O
DM2	O
patient	O
with	O
obesity	O
and	O
poor	O
glycaemic	O
control	O
,	O
under	O
treatment	O
with	O
insulin	B-FARMACO
and	O
iSGLT2	B-FARMACO
,	O
it	O
was	O
decided	O
to	O
add	O
a	O
1glucagon	O
like	O
peptide	O
receptor	O
agonist	O
aGLP1	O
subcutaneous	O
liraglutide	B-FARMACO
0	O
.	O
6	O
mg	O
day	O
for	O
one	O
week	O
and	O
then	O
1	O
.	O
2	O
mg	O
day	O
.	O
At	O
the	O
new	O
clinical	O
review	O
,	O
the	O
patient	O
again	O
reported	O
subjective	O
improvement	O
,	O
with	O
no	O
admissions	O
for	O
HF	O
.	O
He	O
has	O
lost	O
another	O
7	O
kg	O
in	O
weight	O
and	O
is	O
more	O
agile	O
,	O
having	O
started	O
physical	O
activity	O
he	O
does	O
pilates	O
.	O
He	O
remains	O
in	O
NYHA	O
functional	O
class	O
II	O
,	O
with	O
better	O
control	O
of	O
lumbar	O
discomfort	O
by	O
the	O
pain	O
unit	O
.	O
His	O
blood	O
pressure	O
continues	O
to	O
be	O
in	O
the	O
target	O
range	O
ambulatory	O
blood	O
pressure	O
around	O
120	O
130	O
mmHg	O
.	O
No	O
data	O
suggesting	O
water	O
retention	O
,	O
with	O
remission	O
of	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
No	O
adverse	O
effects	O
attributable	O
to	O
the	O
use	O
of	O
iSGLT2	B-FARMACO
or	O
ARGLP1	B-FARMACO
.	O
At	O
the	O
consultation	O
examination	O
the	O
patient	O
weighs	O
104	O
kg	O
,	O
which	O
means	O
a	O
reduction	O
in	O
BMI	O
to	O
35	O
.	O
6	O
kg	O
m2	O
class	O
II	O
obesity	O
.	O
Blood	O
pressure	O
135	O
78	O
mmHg	O
.	O
HR	O
62	O
bpm	O
.	O
Sat	O
95	O
.	O
No	O
evidence	O
of	O
congestion	O
or	O
low	O
output	O
.	O
The	O
blood	O
test	O
showed	O
a	O
reduction	O
in	O
NT	O
proBNP	O
to	O
835	O
pg	O
ml	O
.	O
The	O
evolution	O
of	O
Hb1Ac	O
continues	O
to	O
be	O
favourable	O
7	O
and	O
LDL	O
is	O
practically	O
in	O
the	O
target	O
range	O
76	O
mg	O
dl	O
.	O
It	O
was	O
decided	O
to	O
continue	O
outpatient	O
follow	O
up	O
,	O
maintaining	O
check	O
ups	O
every	O
6	O
9	O
months	O
in	O
consultations	O
,	O
given	O
the	O
situation	O
of	O
clinical	O
stability	O
.	O
DIAGNOSIS	O
HF	O
with	O
reduced	O
EF	O
.	O
Initial	O
CF	O
III	O
with	O
clinical	O
and	O
analytical	O
improvement	O
after	O
titration	O
of	O
neuhormonal	O
medication	O
.	O
Currently	O
NYHA	O
II	O
.	O
Moderate	O
left	O
ventricular	O
systolic	O
dysfunction	O
LVEF	O
35	O
of	O
ischaemic	O
aetiology	O
.	O
Surgically	O
revascularised	O
chronic	O
ischaemic	O
heart	O
disease	O
IMA	O
ADA	O
and	O
saphenous	O
bypass	O
to	O
ACx	O
.	O
Subsequent	O
control	O
coronary	O
angiography	O
with	O
patency	O
of	O
the	O
mammary	O
graft	O
and	O
occlusion	O
of	O
the	O
saphenous	O
graft	O
severe	O
and	O
diffuse	O
disease	O
,	O
for	O
conservative	O
management	O
.	O
ACD	O
thin	O
and	O
diffusely	O
diseased	O
vessel	O
,	O
discouraged	O
for	O
revascularisation	O
.	O
Metabolic	O
syndrome	O
with	O
type	O
III	O
obesity	O
and	O
poor	O
initial	O
control	O
of	O
classic	O
CVRFs	O
.	O
Improvement	O
of	O
metabolic	O
control	O
and	O
weight	O
reduction	O
with	O
medical	O
treatment	O
aGLP1	O
.	O
Current	O
BMI	O
35	O
.	O
6	O
kg	O
m2	O
type	O
II	O
obesity	O
.	O
DM2	O
better	O
controlled	O
after	O
initiation	O
of	O
iSGLT2	B-FARMACO
and	O
aGLP1	B-FARMACO
.	O
Multifactorial	O
chronic	O
CKD	O
with	O
creatinine	O
levels	O
stable	O
at	O
around	O
1	O
.	O
3	O
1	O
.	O
5	O
mg	O
dl	O
.	O
Ex	O
smoker	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
60	O
year	O
old	O
male	O
,	O
with	O
no	O
known	O
drug	O
allergies	O
and	O
no	O
family	O
history	O
of	O
interest	O
.	O
Personal	O
history	O
of	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
obesity	O
,	O
arterial	O
hypertension	O
and	O
ex	O
smoker	O
Surgical	O
intervention	O
of	O
vasectomy	O
complicated	O
with	O
epididymitis	O
32	O
years	O
ago	O
On	O
treatment	O
with	O
amlodipine	B-FARMACO
5	O
mg	O
at	O
breakfast	O
.	O
Current	O
illness	O
He	O
presented	O
with	O
5	O
months	O
of	O
progressive	O
exertional	O
dyspnoea	O
with	O
frank	O
worsening	O
in	O
the	O
last	O
month	O
to	O
NYHA	O
class	O
III	O
,	O
associated	O
with	O
oedema	O
of	O
the	O
lower	O
extremities	O
up	O
to	O
the	O
abdominal	O
wall	O
,	O
orthopnoea	O
and	O
decreased	O
diuresis	O
,	O
for	O
which	O
he	O
attended	O
the	O
emergency	O
department	O
.	O
In	O
the	O
initial	O
study	O
in	O
the	O
ED	O
,	O
after	O
finding	O
elevated	O
D	O
dimer	O
and	O
signs	O
of	O
right	O
heart	O
failure	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
thoracic	O
CT	O
angiography	O
,	O
initially	O
ruling	O
out	O
pulmonary	O
thromboembolism	O
but	O
revealing	O
thickening	O
and	O
moderate	O
pericardial	O
effusion	O
.	O
Hospital	O
admission	O
was	O
decided	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
130	O
80	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
128	O
bpm	O
,	O
profuse	O
diaphoresis	O
,	O
sensation	O
of	O
gravity	O
,	O
although	O
good	O
distal	O
perfusion	O
.	O
Head	O
and	O
neck	O
jugular	O
ingurgitation	O
with	O
hepatojugular	O
reflux	O
.	O
Cardiac	O
auscultation	O
irregular	O
and	O
muffled	O
sounds	O
.	O
Pulmonary	O
auscultation	O
global	O
hypophonesis	O
with	O
crackles	O
in	O
the	O
right	O
base	O
.	O
Abdomen	O
distended	O
,	O
wall	O
oedema	O
with	O
fovea	O
.	O
Lower	O
limbs	O
oedema	O
with	O
fovea	O
up	O
to	O
the	O
root	O
of	O
the	O
thighs	O
.	O
COMPLEMENTARY	O
TESTS	O
12	O
lead	O
surface	O
electrocardiogram	O
ECG	O
atrial	O
fibrillation	O
at	O
115	O
bpm	O
with	O
decreased	O
QRS	O
amplitude	O
.	O
EV	O
isolated	O
.	O
The	O
corrected	O
QT	O
interval	O
is	O
normal	O
.	O
Chest	O
X	O
ray	O
right	O
costophrenic	O
sinus	O
impingement	O
and	O
marked	O
cardiomegaly	O
.	O
Laboratory	O
tests	O
in	O
the	O
ED	O
NT	O
proBNP	O
of	O
114	O
pg	O
ml	O
.	O
Haemogram	O
,	O
renal	O
function	O
parameters	O
and	O
ionogram	O
in	O
normal	O
ranges	O
.	O
Coagulation	O
normal	O
except	O
for	O
elevated	O
D	O
dimer	O
1100	O
mg	O
dl	O
.	O
CBC	O
hospitalisation	O
normal	O
haemogram	O
,	O
ESR	O
51	O
mm	O
h	O
.	O
Normal	O
blood	O
biochemistry	O
,	O
normal	O
transaminases	O
and	O
ions	O
.	O
Normal	O
iron	O
profile	O
Immunoglobulins	O
IgG	O
1170	O
mg	O
dl	O
768	O
1632	O
,	O
IgA	O
395	O
mg	O
dl	O
68	O
378	O
,	O
IgM	O
115	O
mg	O
dl	O
60	O
263	O
.	O
Beta	O
2	O
microglobulin	O
3	O
.	O
72	O
mcg	O
ml	O
1	O
.	O
9	O
2	O
.	O
53	O
.	O
Interferon	O
gamma	O
TBC	O
negative	O
.	O
Serology	O
HIV	O
,	O
HBV	O
,	O
HCV	O
,	O
Lues	O
,	O
EBV	O
,	O
HSV	O
negative	O
.	O
Pathological	O
anatomy	O
of	O
pericardial	O
fluid	O
positive	O
cytology	O
for	O
malignancy	O
.	O
Immunohistochemical	O
study	O
CD79a	O
,	O
CD3	O
in	O
accompanying	O
cellularity	O
,	O
PAX5	O
,	O
CD20	O
,	O
Bcl2	O
,	O
Bcl6	O
,	O
MUM1	O
,	O
C	O
Myc	O
weakly	O
positive	O
in	O
40	O
of	O
cells	O
,	O
CD10	O
,	O
CD30	O
,	O
EBER	O
,	O
CD138	O
,	O
CD38	O
,	O
HHV8	O
negative	O
.	O
Ki	O
67	O
80	O
.	O
Compatible	O
with	O
diffuse	O
large	O
B	O
cell	O
lymphoma	O
.	O
Flow	O
cytometry	O
of	O
pericardial	O
fluid	O
in	O
the	O
sample	O
analysed	O
77	O
of	O
lymphocytes	O
were	O
observed	O
,	O
95	O
of	O
which	O
correspond	O
to	O
an	O
apparently	O
mature	O
B	O
population	O
CD20	O
,	O
FMC7	O
,	O
CD10	O
and	O
without	O
intracytoplasmic	O
TdT	O
,	O
suggesting	O
a	O
B	O
lymphoproliferative	O
process	O
with	O
a	O
non	O
specific	O
phenotype	O
.	O
Pericardial	O
fluid	O
culture	O
no	O
development	O
of	O
microorganisms	O
.	O
Pathological	O
anatomy	O
of	O
the	O
iliac	O
crest	O
bone	O
biopsy	O
normocellular	O
bone	O
marrow	O
,	O
no	O
infiltration	O
by	O
lymphoma	O
.	O
Chest	O
CT	O
scan	O
subpleural	O
pseudonodule	O
10	O
mm	O
in	O
diameter	O
located	O
in	O
the	O
posterior	O
segment	O
of	O
the	O
right	O
upper	O
lobe	O
to	O
be	O
monitored	O
.	O
Moderate	O
pericardial	O
effusion	O
with	O
wall	O
thickening	O
.	O
Cardiac	O
cavities	O
within	O
normal	O
.	O
Ascitic	O
fluid	O
.	O
Dorsal	O
spondylosis	O
.	O
PET	O
CT	O
imaging	O
shows	O
no	O
significant	O
hypermetabolism	O
in	O
the	O
thickened	O
pericardium	O
.	O
Small	O
left	O
laterocervical	O
,	O
supraclavicular	O
lymph	O
nodes	O
with	O
SUV	O
max	O
1	O
.	O
33	O
,	O
infracentimetric	O
and	O
an	O
analogous	O
one	O
on	O
the	O
right	O
with	O
SUV	O
max	O
1	O
.	O
9	O
.	O
In	O
the	O
mediastinum	O
small	O
lymph	O
nodes	O
with	O
SUV	O
max	O
1	O
.	O
57	O
,	O
the	O
largest	O
12	O
.	O
8	O
mm	O
and	O
highest	O
metabolic	O
activity	O
SUV	O
max	O
2	O
.	O
5	O
.	O
Retroperitoneal	O
small	O
crural	O
,	O
pericellular	O
and	O
para	O
aortic	O
nodes	O
with	O
low	O
metabolic	O
SUV	O
1	O
.	O
08	O
.	O
Hypermetabolic	O
lesion	O
SUV	O
max	O
9	O
hyperdense	O
and	O
irregular	O
morphology	O
in	O
left	O
testicle	O
highly	O
suggestive	O
of	O
malignancy	O
.	O
Testicular	O
ultrasound	O
image	O
of	O
a	O
10	O
mm	O
spermatocele	O
in	O
the	O
head	O
of	O
the	O
left	O
epididymis	O
and	O
changes	O
secondary	O
to	O
left	O
vasectomy	O
.	O
Left	O
testicular	O
pathological	O
anatomy	O
left	O
orchiectomy	O
specimen	O
no	O
evidence	O
of	O
neoplasia	O
.	O
Acute	O
and	O
chronic	O
epididymitis	O
associated	O
with	O
fibrous	O
and	O
histiocytic	O
reaction	O
.	O
Testicular	O
parenchyma	O
and	O
spermatic	O
cord	O
without	O
histological	O
alterations	O
.	O
Transthoracic	O
echocardiogram	O
preserved	O
left	O
ventricular	O
systolic	O
function	O
52	O
,	O
moderate	O
biauricular	O
dilatation	O
and	O
severe	O
pericardial	O
effusion	O
with	O
evidence	O
of	O
visceral	O
pericardial	O
thickening	O
without	O
cavity	O
collapse	O
or	O
respiratory	O
variations	O
of	O
valvular	O
flows	O
.	O
Control	O
transthoracic	O
echocardiogram	O
LVEF	O
61	O
,	O
mild	O
pericardial	O
effusion	O
,	O
without	O
clear	O
evidence	O
of	O
constrictive	O
physiology	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
for	O
study	O
and	O
treatment	O
with	O
the	O
combined	O
participation	O
of	O
the	O
cardiology	O
,	O
internal	O
medicine	O
and	O
haematology	O
departments	O
.	O
Initially	O
,	O
the	O
patient	O
showed	O
little	O
response	O
to	O
depletive	O
treatment	O
,	O
with	O
persistence	O
of	O
marked	O
signs	O
of	O
right	O
heart	O
failure	O
and	O
systolic	O
blood	O
pressure	O
around	O
90	O
100	O
mmHg	O
,	O
although	O
without	O
clear	O
evidence	O
of	O
haemodynamic	O
compromise	O
.	O
He	O
maintained	O
a	O
good	O
response	O
to	O
atrioventricular	O
AV	O
node	O
braking	O
therapy	O
and	O
anticoagulation	O
by	O
CHASVASC	O
2	O
and	O
HASBLED	O
1	O
with	O
rivaroxaban	B-FARMACO
was	O
initiated	O
.	O
As	O
part	O
of	O
the	O
complementary	O
study	O
,	O
transthoracic	O
echocardiography	O
showed	O
severe	O
pericardial	O
effusion	O
without	O
significant	O
repercussions	O
on	O
the	O
right	O
chambers	O
,	O
and	O
a	O
diagnostic	O
therapeutic	O
pericardiocentesis	O
was	O
considered	O
.	O
This	O
technique	O
yielded	O
950	O
cc	O
of	O
serohaematic	O
fluid	O
with	O
a	O
clear	O
immediate	O
clinical	O
improvement	O
and	O
samples	O
were	O
sent	O
to	O
microbiology	O
and	O
pathological	O
anatomy	O
,	O
for	O
filiation	O
of	O
the	O
effusion	O
,	O
which	O
finally	O
demonstrated	O
the	O
presence	O
of	O
blast	O
cells	O
compatible	O
with	O
diffuse	O
large	O
B	O
cell	O
lymphoma	O
,	O
with	O
no	O
infectious	O
microbiological	O
evidence	O
.	O
The	O
study	O
was	O
completed	O
with	O
a	O
PET	O
CT	O
scan	O
showing	O
lymphadenopathy	O
with	O
slight	O
increased	O
metabolism	O
and	O
a	O
hypercapillary	O
lesion	O
in	O
the	O
left	O
testicle	O
image	O
4	O
with	O
metabolic	O
criteria	O
of	O
malignancy	O
,	O
and	O
we	O
requested	O
a	O
testicular	O
ultrasound	O
scan	O
which	O
did	O
not	O
reveal	O
a	O
clear	O
malignant	O
testicular	O
mass	O
10	O
mm	O
spermatocele	O
in	O
the	O
head	O
of	O
the	O
left	O
epididymis	O
and	O
changes	O
secondary	O
to	O
vasectomy	O
.	O
Given	O
that	O
the	O
origin	O
of	O
the	O
malignant	O
process	O
had	O
not	O
been	O
identified	O
and	O
the	O
patient	O
was	O
not	O
in	O
a	O
suitable	O
clinical	O
condition	O
to	O
take	O
a	O
biopsy	O
of	O
the	O
pericardium	O
or	O
mediastinal	O
lymph	O
nodes	O
by	O
thoracoscopy	O
,	O
the	O
case	O
was	O
assessed	O
by	O
the	O
haematological	O
tumour	O
committee	O
and	O
given	O
the	O
intense	O
PET	O
CT	O
uptake	O
in	O
the	O
left	O
testicle	O
,	O
a	O
diagnostic	O
orchiectomy	O
was	O
decided	O
for	O
assessment	O
of	O
malignancy	O
at	O
this	O
level	O
,	O
given	O
the	O
prognostic	O
and	O
therapeutic	O
implications	O
of	O
testicular	O
involvement	O
by	O
high	O
grade	O
lymphoma	O
.	O
With	O
the	O
diagnosis	O
of	O
high	O
grade	O
B	O
lymphoma	O
in	O
the	O
pericardium	O
,	O
it	O
was	O
decided	O
not	O
to	O
delay	O
chemotherapy	O
treatment	O
with	O
R	O
CHOP	O
21	O
,	O
administering	O
the	O
first	O
cycle	O
with	O
Truxima	B-FARMACO
and	O
with	O
no	O
immediate	O
adverse	O
reactions	O
.	O
We	O
performed	O
a	O
control	O
transthoracic	O
echocardiogram	O
with	O
mild	O
pericardial	O
effusion	O
and	O
increased	O
LVEF	O
61	O
.	O
Oedema	O
resolved	O
and	O
he	O
remained	O
cardiologically	O
stable	O
.	O
There	O
were	O
no	O
complications	O
with	O
haematological	O
treatment	O
,	O
so	O
it	O
was	O
decided	O
to	O
discharge	O
him	O
and	O
continue	O
his	O
treatment	O
on	O
an	O
outpatient	O
basis	O
.	O
Weeks	O
later	O
,	O
the	O
result	O
of	O
the	O
testicular	O
biopsy	O
was	O
negative	O
for	O
malignancy	O
.	O
DIAGNOSIS	O
Effusivoconstrictive	O
pericarditis	O
.	O
Atrial	O
fibrillation	O
with	O
rapid	O
mid	O
ventricular	O
response	O
first	O
episode	O
.	O
Congestive	O
heart	O
failure	O
with	O
preserved	O
LVEF	O
.	O
Stage	O
IV	O
diffuse	O
large	O
B	O
cell	O
lymphoma	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
49	O
year	O
old	O
woman	O
,	O
a	O
professional	O
climber	O
,	O
with	O
episodes	O
of	O
transient	O
ischaemic	O
attacks	O
.	O
She	O
never	O
had	O
chest	O
pain	O
,	O
dyspnoea	O
or	O
any	O
of	O
the	O
other	O
symptoms	O
we	O
are	O
accustomed	O
to	O
recording	O
in	O
our	O
histories	O
,	O
but	O
she	O
presented	O
a	O
compendium	O
of	O
cardiac	O
alterations	O
that	O
allowed	O
us	O
to	O
get	O
to	O
the	O
top	O
of	O
her	O
pathology	O
.	O
HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
drug	O
allergies	O
.	O
Toxic	O
habits	O
smoker	O
of	O
7	O
cigarettes	O
day	O
.	O
No	O
other	O
known	O
cardiovascular	O
risk	O
factors	O
CVRF	O
.	O
Professional	O
climber	O
.	O
No	O
usual	O
treatment	O
.	O
Current	O
illness	O
Our	O
patient	O
was	O
admitted	O
to	O
the	O
neurology	O
department	O
for	O
an	O
episode	O
of	O
hypoaesthesia	O
and	O
paraesthesia	O
in	O
the	O
right	O
hemibody	O
,	O
self	O
limited	O
for	O
2	O
to	O
3	O
hours	O
2	O
months	O
ago	O
.	O
One	O
month	O
ago	O
,	O
episode	O
of	O
paresis	O
in	O
the	O
right	O
hemisphere	O
,	O
which	O
she	O
recovered	O
within	O
half	O
an	O
hour	O
.	O
Last	O
episode	O
the	O
day	O
before	O
admission	O
,	O
with	O
the	O
same	O
characteristics	O
but	O
of	O
longer	O
duration	O
.	O
At	O
no	O
time	O
did	O
she	O
report	O
chest	O
pain	O
,	O
dyspnoea	O
or	O
other	O
cardiological	O
symptoms	O
.	O
During	O
the	O
study	O
,	O
an	O
electrocardiogram	O
ECG	O
and	O
transthoracic	O
echocardiogram	O
were	O
performed	O
,	O
which	O
showed	O
alterations	O
,	O
so	O
an	O
assessment	O
was	O
requested	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
,	O
well	O
hydrated	O
and	O
perfused	O
.	O
Blood	O
pressure	O
BP	O
118	O
71	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
65	O
bpm	O
.	O
Afebrile	O
.	O
Eupneic	O
at	O
rest	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
at	O
60	O
bpm	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
without	O
alterations	O
.	O
Lower	O
limbs	O
no	O
oedema	O
,	O
pulses	O
preserved	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
.	O
PR	O
140	O
msg	O
.	O
Narrow	O
QRS	O
.	O
Q	O
wave	O
in	O
V1	O
V4	O
,	O
DI	O
and	O
aVL	O
with	O
isodiphasic	O
T	O
wave	O
in	O
V2	O
V4	O
,	O
flat	O
in	O
V5	O
V6	O
,	O
DI	O
and	O
aVL	O
and	O
inferior	O
leads	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
,	O
no	O
evidence	O
of	O
heart	O
failure	O
.	O
Laboratory	O
tests	O
CBC	O
haemoglobin	O
14	O
.	O
3	O
g	O
dl	O
,	O
leucocytes	O
5	O
,	O
600	O
μl	O
with	O
normal	O
formula	O
,	O
platelets	O
190	O
,	O
000	O
μl	O
.	O
Coagulation	O
INR	O
1	O
,	O
TTPa	O
29	O
s	O
.	O
Biochemistry	O
glucose	O
88	O
mg	O
dl	O
,	O
urea	O
29	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
68	O
mg	O
dl	O
,	O
FGR	O
60	O
ml	O
min	O
,	O
Na	O
140	O
mmol	O
l	O
,	O
K	O
4	O
.	O
8	O
mmol	O
l	O
,	O
total	O
cholesterol	O
136	O
mg	O
dl	O
,	O
HDL	O
52	O
mg	O
dl	O
,	O
LDL	O
71	O
mg	O
dl	O
,	O
TG	O
64	O
mg	O
dl	O
,	O
Inmonoglubulins	O
normal	O
.	O
CRP	O
1	O
mg	O
dl	O
.	O
Rheumatoid	O
factor	O
10	O
IU	O
ml	O
.	O
Folic	O
acid	O
and	O
vitamin	O
B12	O
normal	O
.	O
Autoimmunity	O
negative	O
.	O
Complement	O
normal	O
.	O
Thyroid	O
hormone	O
normal	O
.	O
Hb1Ac	O
5	O
.	O
3	O
.	O
Factor	O
Leiden	O
factor	O
and	O
factor	O
II	O
20	O
,	O
210	O
negative	O
.	O
Homocysteine	O
normal	O
.	O
Proteinogram	O
normal	O
.	O
Serology	O
HIV	O
,	O
Herpes	O
simplex	O
,	O
EBV	O
,	O
CMV	O
,	O
Brucella	O
,	O
Lues	O
and	O
Borrelia	O
negative	O
.	O
Echocardiogram	O
left	O
ventricle	O
LV	O
slightly	O
dilated	O
with	O
severe	O
depression	O
of	O
LVEF	O
25	O
30	O
,	O
with	O
extensive	O
apical	O
akinesia	O
and	O
remodelling	O
,	O
extensive	O
anterior	O
akinesia	O
,	O
lower	O
mid	O
apical	O
and	O
mid	O
apical	O
septum	O
.	O
Grade	O
II	O
mitral	O
regurgitation	O
.	O
Mobile	O
thrombus	O
in	O
LV	O
apex	O
measuring	O
18	O
x	O
8	O
mm	O
.	O
Haemodynamic	O
study	O
right	O
dominance	O
.	O
No	O
coronary	O
calcification	O
.	O
Coronary	O
disease	O
of	O
1	O
vessel	O
.	O
Left	O
main	O
coronary	O
artery	O
without	O
significant	O
stenosis	O
.	O
Anterior	O
descending	O
occluded	O
at	O
the	O
origin	O
,	O
with	O
TIMI	O
0	O
distal	O
flow	O
.	O
The	O
distal	O
vessel	O
is	O
visualised	O
by	O
homo	O
and	O
heterocoronary	O
circulation	O
.	O
The	O
appearance	O
of	O
the	O
distal	O
vessel	O
is	O
highly	O
suggestive	O
of	O
spiroid	O
dissection	O
and	O
haematoma	O
of	O
the	O
anterior	O
descending	O
artery	O
from	O
its	O
origin	O
.	O
Right	O
circumflex	O
and	O
coronary	O
artery	O
of	O
good	O
calibre	O
and	O
development	O
,	O
with	O
smooth	O
edges	O
,	O
without	O
angiographically	O
significant	O
stenosis	O
.	O
Renal	O
angiography	O
rectilinear	O
right	O
renal	O
artery	O
with	O
small	O
deformations	O
along	O
its	O
entire	O
course	O
,	O
in	O
both	O
arterial	O
borders	O
.	O
Double	O
left	O
arterial	O
system	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
LV	O
of	O
normal	O
size	O
with	O
mid	O
apical	O
anterior	O
akinesia	O
,	O
apical	O
lateral	O
,	O
apical	O
septum	O
,	O
apical	O
inferior	O
and	O
apex	O
.	O
Severe	O
hypokinesia	O
of	O
medial	O
septum	O
,	O
medial	O
lateral	O
,	O
medial	O
inferior	O
.	O
LVEF	O
36	O
.	O
Hypoperfusion	O
of	O
the	O
middle	O
segment	O
of	O
the	O
anterior	O
wall	O
and	O
middle	O
septum	O
,	O
middle	O
segment	O
of	O
the	O
lateral	O
wall	O
and	O
all	O
apical	O
segments	O
.	O
Very	O
extensive	O
transmural	O
late	O
enhancement	O
of	O
the	O
basal	O
,	O
mid	O
and	O
apical	O
segments	O
of	O
the	O
anterior	O
wall	O
,	O
apical	O
inferior	O
,	O
mid	O
apical	O
lateral	O
,	O
mid	O
anterior	O
septum	O
,	O
apical	O
septum	O
and	O
the	O
entire	O
apex	O
.	O
Large	O
apical	O
thrombus	O
28	O
x	O
9	O
mm	O
,	O
mobile	O
.	O
Right	O
ventricle	O
RV	O
of	O
normal	O
size	O
.	O
Normal	O
right	O
atrium	O
RA	O
.	O
Left	O
atrium	O
LA	O
slightly	O
dilated	O
.	O
Cranial	O
CT	O
corticosubcortical	O
hypodensity	O
in	O
the	O
left	O
parietal	O
convexity	O
and	O
in	O
the	O
nuclei	O
of	O
the	O
left	O
base	O
,	O
which	O
may	O
correspond	O
to	O
ischaemic	O
lesions	O
.	O
Doubtful	O
hyperdensity	O
at	O
the	O
level	O
of	O
the	O
top	O
of	O
the	O
basilar	O
artery	O
,	O
without	O
identifying	O
ischaemic	O
lesions	O
in	O
the	O
posterior	O
circulation	O
.	O
Normal	O
ventricular	O
system	O
.	O
Centred	O
midline	O
.	O
Echo	O
Doppler	O
of	O
supra	O
aortic	O
trunks	O
no	O
alterations	O
.	O
Ambulatory	O
control	O
echocardiogram	O
dilated	O
LV	O
with	O
akinesia	O
of	O
the	O
mid	O
apical	O
segments	O
of	O
the	O
anterior	O
and	O
lateral	O
face	O
,	O
apical	O
of	O
the	O
inferior	O
septum	O
and	O
inferior	O
face	O
,	O
with	O
apical	O
aneurysmal	O
image	O
.	O
Moderate	O
left	O
ventricular	O
systolic	O
dysfunction	O
LVEF	O
35	O
.	O
Normal	O
sized	O
RV	O
with	O
preserved	O
systolic	O
function	O
.	O
Mild	O
LA	O
dilatation	O
.	O
Protomesystolic	O
mitral	O
regurgitation	O
located	O
between	O
A2	O
P2	O
,	O
mild	O
moderate	O
grade	O
grade	O
II	O
.	O
No	O
other	O
valvular	O
abnormalities	O
.	O
Normal	O
pericardium	O
.	O
Apical	O
thrombus	O
image	O
measuring	O
14	O
x	O
7	O
mm	O
,	O
without	O
mobile	O
structures	O
,	O
resting	O
on	O
the	O
area	O
of	O
the	O
aneurysm	O
.	O
Compared	O
to	O
the	O
previous	O
study	O
,	O
there	O
is	O
a	O
reduction	O
in	O
the	O
volume	O
of	O
the	O
thrombus	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
neurology	O
with	O
a	O
diagnosis	O
of	O
left	O
hemispheric	O
embolic	O
stroke	O
with	O
good	O
clinical	O
evolution	O
.	O
She	O
was	O
assessed	O
by	O
cardiology	O
with	O
the	O
diagnosis	O
of	O
extensive	O
anterior	O
myocardial	O
infarction	O
with	O
severe	O
depression	O
of	O
LVEF	O
and	O
mobile	O
apical	O
thrombus	O
,	O
due	O
to	O
spontaneous	O
coronary	O
dissection	O
probably	O
related	O
to	O
intense	O
exercise	O
.	O
The	O
study	O
was	O
completed	O
with	O
cardiac	O
MRI	O
.	O
During	O
outpatient	O
follow	O
up	O
,	O
medical	O
treatment	O
was	O
titrated	O
,	O
limited	O
by	O
low	O
BP	O
and	O
HR	O
figures	O
,	O
up	O
to	O
maximum	O
tolerated	O
doses	O
Acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
daily	O
,	O
acenocoumarol	B-FARMACO
for	O
INR	O
between	O
2	O
and	O
3	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
daily	O
,	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
49	O
51	O
mg	O
every	O
12	O
hours	O
,	O
carvedilol	B-FARMACO
3	O
.	O
125	O
mg	O
every	O
12	O
hours	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
daily	O
,	O
atorvastatin	B-FARMACO
10	O
mg	O
daily	O
.	O
An	O
echocardiogram	O
was	O
performed	O
3	O
months	O
after	O
optimising	O
medication	O
,	O
with	O
an	O
LVEF	O
of	O
35	O
in	O
NYHA	O
functional	O
class	O
II	O
,	O
so	O
it	O
was	O
decided	O
to	O
implant	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
for	O
primary	O
prevention	O
.	O
DIAGNOSIS	O
Left	O
hemispheric	O
embolic	O
stroke	O
.	O
Apical	O
LV	O
thrombus	O
as	O
a	O
source	O
of	O
cardioembolism	O
.	O
Ischaemic	O
heart	O
disease	O
.	O
Anterior	O
descending	O
coronary	O
artery	O
occlusion	O
due	O
to	O
spiroid	O
dissection	O
.	O
Established	O
anterior	O
myocardial	O
infarction	O
.	O
Apical	O
aneurysm	O
with	O
thrombus	O
.	O
Heart	O
failure	O
with	O
reduced	O
ejection	O
fraction	O
,	O
in	O
NYHA	O
functional	O
class	O
II	O
after	O
optimisation	O
of	O
medical	O
treatment	O
.	O
Implantation	O
of	O
ICD	O
in	O
primary	O
prevention	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
62	O
year	O
old	O
patient	O
with	O
asthenia	O
in	O
which	O
the	O
physical	O
examination	O
is	O
key	O
.	O
HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
ex	O
smoker	O
of	O
1	O
pack	O
a	O
day	O
for	O
24	O
years	O
IPA	O
38	O
Cardiological	O
history	O
acute	O
idiopathic	O
pericarditis	O
diagnosed	O
5	O
years	O
ago	O
.	O
Medical	O
history	O
chronic	O
venous	O
insufficiency	O
,	O
rhizarthrosis	O
.	O
Surgical	O
history	O
surgery	O
for	O
Dupuytren	O
's	O
disease	O
in	O
the	O
left	O
hand	O
.	O
Family	O
history	O
not	O
relevant	O
Home	O
treatment	O
chondroitin	B-FARMACO
sulphate	I-FARMACO
,	O
paracetamol	B-FARMACO
on	O
demand	O
.	O
Current	O
illness	O
A	O
62	O
year	O
old	O
woman	O
with	O
a	O
history	O
of	O
acute	O
idiopathic	O
pericarditis	O
and	O
mild	O
pericardial	O
effusion	O
diagnosed	O
5	O
years	O
ago	O
,	O
requiring	O
anti	O
inflammatory	O
treatment	O
.	O
She	O
was	O
subsequently	O
examined	O
by	O
the	O
internal	O
medicine	O
department	O
for	O
constitutional	O
syndrome	O
without	O
finding	O
any	O
apparent	O
cause	O
.	O
She	O
was	O
referred	O
for	O
outpatient	O
cardiology	O
consultation	O
due	O
to	O
dyspnoea	O
and	O
asthenia	O
on	O
moderate	O
exertion	O
NYHA	O
functional	O
class	O
II	O
IV	O
together	O
with	O
episodes	O
of	O
dizziness	O
and	O
presyncope	O
on	O
exertion	O
,	O
which	O
limited	O
her	O
daily	O
life	O
.	O
No	O
orthopnoea	O
,	O
no	O
paroxysmal	O
nocturnal	O
dyspnoea	O
PND	O
,	O
no	O
oliguria	O
,	O
no	O
chest	O
pain	O
or	O
syncopal	O
episodes	O
.	O
Physical	O
examination	O
In	O
consultation	O
Not	O
hydrated	O
and	O
normal	O
colour	O
.	O
Afebrile	O
.	O
Eupneic	O
.	O
BP	O
130	O
70	O
.	O
Basal	O
oxygen	O
saturation	O
95	O
.	O
Jugular	O
venous	O
pressure	O
JVP	O
elevated	O
up	O
to	O
the	O
mandibular	O
angle	O
with	O
Kussmaul	O
's	O
sign	O
present	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
with	O
obvious	O
protodiastolic	O
knock	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
sounds	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
slight	O
non	O
painful	O
hepatomegaly	O
.	O
MMII	O
pulses	O
present	O
at	O
all	O
levels	O
.	O
No	O
oedema	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
.	O
PR	O
160ms	O
.	O
Narrow	O
QRS	O
.	O
Axis	O
50o	O
.	O
Asymmetric	O
negative	O
T	O
wave	O
in	O
inferior	O
and	O
lateral	O
face	O
,	O
suggestive	O
of	O
left	O
ventricular	O
overload	O
.	O
QTc	O
within	O
normal	O
limits	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
in	O
the	O
upper	O
limit	O
of	O
normality	O
.	O
Prominent	O
pulmonary	O
artery	O
cone	O
.	O
No	O
evidence	O
of	O
vascular	O
redistribution	O
.	O
Slight	O
calcification	O
of	O
the	O
aortic	O
arch	O
.	O
Pinching	O
of	O
both	O
posterior	O
costodiaphragmatic	O
sinuses	O
.	O
No	O
pericardial	O
calcification	O
.	O
Dorsal	O
kyphosis	O
.	O
Blood	O
tests	O
Haemogram	O
7900	O
leukocytes	O
mm3	O
normal	O
leukocyte	O
formula	O
,	O
haemoglobin	O
12	O
.	O
5	O
dl	O
,	O
haematocrit	O
36	O
.	O
9	O
,	O
platelets	O
150	O
,	O
000	O
mm	O
.	O
Coagulation	O
INR	O
1	O
.	O
08	O
,	O
prothrombin	O
activity	O
88	O
.	O
Biochemistry	O
creatinine	O
0	O
.	O
82	O
mg	O
dl	O
glomerular	O
filtration	O
rate	O
65	O
ml	O
min	O
m	O
,	O
urea	O
46	O
mg	O
dl	O
,	O
ions	O
normal	O
.	O
NT	O
proBNP	O
540pg	O
ml	O
.	O
Hb1AC	O
5	O
.	O
8	O
,	O
thyroid	O
profile	O
and	O
cholesterol	O
levels	O
within	O
normal	O
limits	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
of	O
normal	O
size	O
,	O
not	O
hypertrophic	O
with	O
preserved	O
systolic	O
function	O
62	O
by	O
Simpson	O
biplane	O
without	O
segmental	O
abnormalities	O
of	O
contractility	O
.	O
Normal	O
diastolic	O
function	O
.	O
Normal	O
sized	O
right	O
ventricle	O
with	O
tubular	O
morphology	O
suggesting	O
pericardial	O
tethering	O
.	O
Meandering	O
motion	O
of	O
the	O
interatrial	O
septum	O
with	O
protodiastolic	O
notch	O
in	O
M	O
mode	O
.	O
Mild	O
tricuspid	O
regurgitation	O
without	O
other	O
valvulopathies	O
.	O
Decreased	O
mitral	O
E	O
wave	O
velocity	O
with	O
inspiration	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
with	O
absence	O
of	O
respiratory	O
variability	O
;	O
dilated	O
suprahepatic	O
veins	O
,	O
retrograde	O
D	O
wave	O
in	O
pulsed	O
Doppler	O
mode	O
increasing	O
with	O
inspiration	O
.	O
Pericardium	O
apparently	O
normal	O
with	O
no	O
pericardial	O
effusion	O
.	O
No	O
indirect	O
data	O
of	O
pulmonary	O
hypertension	O
by	O
echocardiographic	O
study	O
.	O
Cardiac	O
MRI	O
left	O
ventricle	O
LV	O
of	O
normal	O
size	O
with	O
preserved	O
LVEF	O
60	O
.	O
Right	O
ventricle	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
Atrial	O
chambers	O
of	O
normal	O
size	O
.	O
Focal	O
pericardial	O
thickening	O
with	O
a	O
maximum	O
thickness	O
of	O
6	O
.	O
5	O
mm	O
at	O
the	O
lateral	O
wall	O
of	O
the	O
RV	O
in	O
the	O
atrioventricular	O
AV	O
groove	O
.	O
Prominent	O
inferior	O
vena	O
cava	O
IVC	O
with	O
dilatation	O
of	O
the	O
suprahepatic	O
veins	O
.	O
No	O
pathological	O
gadolinium	O
uptake	O
on	O
late	O
enhancement	O
sequences	O
.	O
No	O
pericardial	O
effusion	O
.	O
Left	O
heart	O
catheterisation	O
coronary	O
arteries	O
without	O
angiographically	O
significant	O
stenosis	O
.	O
Right	O
heart	O
catheterisation	O
cardiac	O
output	O
4	O
.	O
96	O
l	O
min	O
;	O
IC	O
3	O
.	O
2	O
l	O
min	O
.	O
Pulmonary	O
arterial	O
resistance	O
1	O
.	O
21	O
Wood	O
units	O
.	O
AD	O
15	O
mmHg	O
with	O
deep	O
sinus	O
"	O
y	O
"	O
.	O
Equalized	O
end	O
diastolic	O
pressures	O
in	O
both	O
ventricles	O
with	O
ventricular	O
interdependence	O
phenomenon	O
with	O
inspiration	O
.	O
PAP	O
34	O
24	O
15	O
mmHg	O
.	O
Pulmonary	O
capillary	O
pressure	O
PCP	O
18	O
mmHg	O
.	O
Ventriculography	O
LV	O
of	O
normal	O
size	O
VTD	O
55	O
ml	O
m2	O
;	O
VTS	O
20	O
ml	O
m2	O
.	O
EF	O
64	O
.	O
No	O
mitral	O
regurgitation	O
was	O
observed	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
the	O
initial	O
evaluation	O
in	O
the	O
consultation	O
room	O
,	O
a	O
blood	O
analysis	O
was	O
requested	O
with	O
parameters	O
within	O
normal	O
parameters	O
,	O
including	O
an	O
NT	O
proBNP	O
value	O
of	O
540	O
pg	O
ml	O
,	O
within	O
normal	O
limits	O
for	O
age	O
and	O
an	O
echocardiogram	O
which	O
showed	O
data	O
compatible	O
with	O
constrictive	O
pericarditis	O
that	O
would	O
justify	O
the	O
patient	O
's	O
clinical	O
symptoms	O
of	O
asthenia	O
.	O
A	O
cardiac	O
MRI	O
was	O
also	O
requested	O
,	O
which	O
revealed	O
focal	O
thickening	O
of	O
the	O
pericardium	O
at	O
the	O
level	O
of	O
the	O
RV	O
in	O
the	O
AV	O
groove	O
,	O
which	O
caused	O
a	O
haemodynamically	O
significant	O
constrictive	O
physiology	O
that	O
could	O
explain	O
the	O
patient	O
's	O
symptoms	O
of	O
presyncope	O
and	O
low	O
cardiac	O
output	O
on	O
exertion	O
.	O
Prior	O
to	O
presenting	O
the	O
case	O
at	O
the	O
medical	O
surgical	O
session	O
,	O
a	O
left	O
haemodynamic	O
study	O
was	O
requested	O
which	O
showed	O
coronary	O
arteries	O
without	O
significant	O
stenosis	O
and	O
a	O
right	O
heart	O
catheterisation	O
which	O
confirmed	O
the	O
diagnosis	O
of	O
constrictive	O
physiology	O
.	O
The	O
case	O
was	O
presented	O
jointly	O
with	O
the	O
cardiac	O
surgery	O
service	O
and	O
the	O
patient	O
was	O
accepted	O
for	O
surgery	O
,	O
and	O
the	O
operation	O
was	O
performed	O
2	O
months	O
later	O
.	O
Intraoperatively	O
she	O
presented	O
severe	O
pericardial	O
adhesions	O
with	O
severe	O
pericardial	O
thickening	O
at	O
the	O
level	O
of	O
the	O
lateral	O
aspect	O
of	O
the	O
RV	O
,	O
extending	O
towards	O
the	O
intercaval	O
line	O
and	O
lateral	O
aspect	O
of	O
the	O
LV	O
without	O
pericardial	O
calcification	O
,	O
and	O
interphrenic	O
pericardiectomy	O
was	O
performed	O
,	O
confirming	O
by	O
pathological	O
anatomy	O
the	O
fibrous	O
thickening	O
of	O
the	O
pericardium	O
with	O
intense	O
chronic	O
inflammation	O
.	O
After	O
the	O
intervention	O
,	O
the	O
patient	O
reported	O
neither	O
asthenia	O
nor	O
the	O
presyncopal	O
episodes	O
she	O
had	O
previously	O
presented	O
,	O
and	O
was	O
in	O
NYHA	O
functional	O
class	O
I	O
IV	O
.	O
DIAGNOSIS	O
Focal	O
constrictive	O
pericarditis	O
with	O
haemodynamic	O
repercussions	O
.	O
Preserved	O
biventricular	O
function	O
.	O
Successful	O
interphrenic	O
pericardiectomy	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
66	O
year	O
old	O
woman	O
consulted	O
for	O
dyspnoea	O
and	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
She	O
denies	O
toxic	O
habits	O
.	O
Cardiovascular	O
risk	O
factors	O
dyslipidaemia	O
.	O
Type	O
2	O
diabetes	O
under	O
treatment	O
with	O
oral	O
antidiabetics	O
with	O
good	O
control	O
last	O
HbA1c	O
6	O
.	O
8	O
.	O
Permanent	O
atrial	O
fibrillation	O
anticoagulated	O
with	O
warfarin	B-FARMACO
.	O
Rheumatic	O
valvular	O
heart	O
disease	O
with	O
severe	O
mitral	O
stenosis	O
and	O
moderate	O
double	O
aortic	O
lesion	O
,	O
operated	O
on	O
19	O
June	O
18	O
.	O
Mitral	O
and	O
aortic	O
valve	O
replacement	O
with	O
mechanical	O
prostheses	O
.	O
Postoperative	O
period	O
uncomplicated	O
,	O
except	O
for	O
anaemia	O
which	O
required	O
transfusion	O
of	O
1	O
red	O
blood	O
cell	O
concentrate	O
.	O
Discharged	O
from	O
hospital	O
on	O
28	O
June	O
2018	O
.	O
Home	O
treatment	O
after	O
surgery	O
omeprazole	B-FARMACO
20	O
mg	O
daily	O
,	O
carvedilol	B-FARMACO
6	O
.	O
25	O
mg	O
every	O
12	O
hours	O
,	O
pravastatin	B-FARMACO
40	O
mg	O
daily	O
,	O
warfarin	B-FARMACO
10	O
mg	O
according	O
to	O
haematology	O
guidelines	O
and	O
gliclazide	B-FARMACO
30	O
mg	O
every	O
12	O
hours	O
.	O
Present	O
illness	O
Patient	O
admitted	O
from	O
the	O
emergency	O
department	O
for	O
progressive	O
dyspnoea	O
until	O
minimal	O
effort	O
and	O
oedema	O
in	O
the	O
lower	O
limbs	O
2	O
weeks	O
after	O
being	O
discharged	O
following	O
valve	O
replacement	O
surgery	O
.	O
She	O
associated	O
two	O
pillow	O
orthopnoea	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
crises	O
.	O
The	O
patient	O
denied	O
non	O
adherence	O
to	O
treatment	O
or	O
dietary	O
transgressions	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
atrial	O
flutter	O
was	O
observed	O
with	O
rapid	O
ventricular	O
response	O
and	O
congestive	O
data	O
on	O
examination	O
,	O
and	O
the	O
patient	O
was	O
admitted	O
to	O
hospital	O
by	O
the	O
cardiology	O
department	O
.	O
Physical	O
examination	O
General	O
condition	O
preserved	O
.	O
Conscious	O
and	O
oriented	O
.	O
Well	O
hydrated	O
and	O
perfused	O
.	O
Pallor	O
of	O
skin	O
and	O
mucous	O
membranes	O
.	O
Blood	O
pressure	O
125	O
80	O
mmHg	O
.	O
Eupneic	O
at	O
rest	O
,	O
with	O
basal	O
oxygen	O
saturation	O
94	O
.	O
Heart	O
rate	O
100	O
bpm	O
.	O
No	O
jugular	O
ingurgitation	O
or	O
hepatojugular	O
reflux	O
.	O
Cardiorespiratory	O
auscultation	O
arrhythmic	O
heart	O
at	O
about	O
100	O
bpm	O
.	O
Prosthetic	O
metallic	O
click	O
.	O
No	O
audible	O
murmurs	O
.	O
Good	O
pulmonary	O
ventilation	O
with	O
slight	O
crackles	O
in	O
both	O
lung	O
bases	O
,	O
with	O
no	O
other	O
added	O
pathological	O
sounds	O
.	O
Abdomen	O
no	O
masses	O
or	O
megaliths	O
,	O
not	O
painful	O
on	O
deep	O
palpation	O
.	O
No	O
evidence	O
of	O
peritoneal	O
irritation	O
.	O
Oedema	O
up	O
to	O
the	O
knees	O
with	O
fovea	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
in	O
the	O
emergency	O
department	O
Haemogram	O
7430	O
leucocytes	O
with	O
normal	O
formula	O
,	O
haemoglobin	O
9	O
g	O
dl	O
,	O
MCV	O
90	O
.	O
60	O
fl	O
,	O
platelets	O
179000	O
.	O
Coagulation	O
INR	O
2	O
.	O
07	O
.	O
Biochemistry	O
normal	O
renal	O
function	O
and	O
ionogram	O
.	O
C	O
reactive	O
protein	O
58	O
.	O
1	O
mg	O
l	O
.	O
NT	O
proBNP	O
1404	O
pg	O
dl	O
.	O
Serial	O
myocardial	O
damage	O
enzymes	O
CK	O
36	O
22	O
U	O
l	O
,	O
ultrasensitive	O
troponin	O
T	O
28	O
31	O
ng	O
l	O
.	O
Electrocardiogram	O
atrial	O
flutter	O
with	O
variable	O
ventricular	O
response	O
around	O
120	O
bpm	O
.	O
Normal	O
axis	O
.	O
Narrow	O
QRS	O
.	O
Good	O
R	O
progression	O
in	O
precordial	O
leads	O
.	O
Negative	O
T	O
waves	O
V4	O
V6	O
,	O
without	O
other	O
repolarisation	O
alterations	O
.	O
Transthoracic	O
echocardiography	O
non	O
dilated	O
left	O
ventricle	O
with	O
mild	O
concentric	O
hypertrophy	O
.	O
Dilated	O
left	O
atrium	O
.	O
Normal	O
right	O
chambers	O
.	O
Sections	O
of	O
aorta	O
studied	O
within	O
normality	O
.	O
Valves	O
normopositioned	O
mechanical	O
mitral	O
prosthesis	O
and	O
no	O
nodding	O
,	O
with	O
preserved	O
disc	O
mobility	O
,	O
no	O
signs	O
of	O
insufficiency	O
and	O
mean	O
gradient	O
4	O
mmHg	O
video	O
1	O
.	O
Normopositioned	O
mechanical	O
aortic	O
prosthesis	O
with	O
no	O
pitching	O
,	O
preserved	O
disc	O
mobility	O
,	O
no	O
insufficiency	O
jets	O
and	O
normal	O
anterograde	O
gradients	O
maximum	O
velocity	O
2	O
.	O
3	O
m	O
sec	O
.	O
Preserved	O
left	O
ventricular	O
systolic	O
function	O
estimated	O
at	O
60	O
by	O
biplane	O
Simpson	O
,	O
without	O
segmental	O
contractility	O
disorders	O
.	O
Preserved	O
right	O
ventricular	O
systolic	O
function	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
Initial	O
evolution	O
was	O
favourable	O
after	O
intravenous	O
diuretic	O
treatment	O
and	O
transfusion	O
of	O
blood	O
products	O
.	O
However	O
,	O
on	O
the	O
sixth	O
day	O
of	O
admission	O
,	O
the	O
patient	O
's	O
platelet	O
count	O
dropped	O
from	O
160	O
,	O
000	O
to	O
23	O
,	O
000	O
.	O
Given	O
the	O
suspicion	O
of	O
heparin	O
induced	O
thrombopenia	O
HIT	O
,	O
it	O
was	O
decided	O
to	O
replace	O
this	O
drug	O
with	O
fondaparinux	B-FARMACO
and	O
antiplatelet	O
factor	O
IV	O
antibodies	O
were	O
requested	O
,	O
which	O
were	O
found	O
to	O
be	O
positive	O
.	O
After	O
replacing	O
heparin	B-FARMACO
with	O
fondaparinux	B-FARMACO
,	O
platelets	O
progressively	O
rose	O
to	O
normal	O
,	O
allowing	O
the	O
reintroduction	O
of	O
warfarin	B-FARMACO
,	O
his	O
usual	O
anticoagulant	O
therapy	O
.	O
During	O
treatment	O
with	O
fondaparinux	B-FARMACO
,	O
there	O
were	O
no	O
haemorrhagic	O
or	O
thrombotic	O
complications	O
.	O
Before	O
discharge	O
,	O
a	O
new	O
echocardiogram	O
was	O
performed	O
and	O
both	O
prosthetic	O
valves	O
were	O
found	O
to	O
be	O
normally	O
functioning	O
and	O
showed	O
no	O
evidence	O
of	O
thrombosis	O
.	O
Intercurrently	O
,	O
the	O
patient	O
presented	O
with	O
micturition	O
symptoms	O
with	O
dysuria	O
,	O
frequency	O
of	O
urination	O
and	O
urinary	O
urgency	O
;	O
a	O
urine	O
culture	O
showed	O
E	O
.	O
coli	O
producing	O
extended	O
spectrum	O
beta	O
lactamase	O
E	O
.	O
coli	O
BLEE	O
.	O
Given	O
the	O
patient	O
's	O
high	O
comorbidity	O
and	O
the	O
risk	O
of	O
endocarditis	O
in	O
the	O
event	O
of	O
bacteraemia	O
due	O
to	O
the	O
recent	O
implantation	O
of	O
two	O
mechanical	O
prostheses	O
,	O
it	O
was	O
decided	O
to	O
start	O
broad	O
spectrum	O
antibiotherapy	O
with	O
ertapenem	B-FARMACO
.	O
Two	O
days	O
after	O
starting	O
treatment	O
with	O
ertapenem	O
,	O
the	O
patient	O
developed	O
generalised	O
polyarthralgia	O
,	O
predominantly	O
in	O
the	O
lower	O
limbs	O
,	O
and	O
non	O
pruritic	O
skin	O
lesions	O
,	O
which	O
progressively	O
worsened	O
,	O
some	O
of	O
them	O
acquiring	O
a	O
bull	O
's	O
eye	O
morphology	O
.	O
Suspecting	O
toxicoderma	O
due	O
to	O
ertapenem	B-FARMACO
,	O
we	O
replaced	O
this	O
drug	O
with	O
fosfomycin	B-FARMACO
,	O
and	O
the	O
symptoms	O
resolved	O
completely	O
within	O
48	O
hours	O
.	O
A	O
skin	O
biopsy	O
was	O
obtained	O
with	O
a	O
result	O
of	O
small	O
vessel	O
leukocytoclastic	O
vasculitis	O
compatible	O
with	O
genuine	O
serum	O
sickness	O
or	O
sickness	O
associated	O
with	O
taking	O
the	O
drugs	O
,	O
findings	O
consistent	O
with	O
the	O
initial	O
suspicion	O
of	O
ertapenem	B-FARMACO
induced	O
toxicoderma	O
.	O
DIAGNOSIS	O
Decompensation	O
of	O
heart	O
failure	O
in	O
association	O
with	O
Subacute	O
normocytic	O
anaemia	O
in	O
probable	O
relation	O
to	O
surgery	O
.	O
Atrial	O
flutter	O
with	O
rapid	O
ventricular	O
response	O
.	O
Heparin	B-FARMACO
induced	O
thrombopenia	O
HIT	O
.	O
BLEE	O
E	O
.	O
coli	O
urinary	O
tract	O
infection	O
.	O
Small	O
vessel	O
leukocytoclastic	O
vasculitis	O
secondary	O
to	O
administration	O
of	O
carbapenemics	O
ertapenem	B-FARMACO
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
An	O
82	O
year	O
old	O
man	O
came	O
to	O
our	O
emergency	O
department	O
for	O
chest	O
pain	O
.	O
History	O
Allergic	O
to	O
penicillins	B-FARMACO
with	O
tolerance	O
to	O
cephalosporins	B-FARMACO
.	O
Toxic	O
habits	O
ex	O
smoker	O
IPA	O
30	O
pack	O
years	O
.	O
Cardivascular	O
risk	O
factors	O
CVRF	O
arterial	O
hypertension	O
AHT	O
.	O
Mild	O
chronic	O
obstructive	O
pulmonary	O
disease	O
COPD	O
on	O
chronic	O
bronchodilator	O
treatment	O
.	O
Solitary	O
pulmonary	O
nodule	O
,	O
monitored	O
by	O
the	O
pulmonology	O
department	O
,	O
unchanged	O
since	O
2008	O
.	O
Multinodular	O
goitre	O
.	O
Cardiological	O
history	O
Paroxysmal	O
atrial	O
fibrillation	O
flutter	O
first	O
episode	O
in	O
2013	O
in	O
context	O
of	O
admission	O
for	O
septic	O
shock	O
and	O
second	O
episode	O
documented	O
during	O
postoperative	O
knee	O
surgery	O
in	O
January	O
2020	O
.	O
On	O
anticoagulant	O
treatment	O
with	O
acenocoumarol	B-FARMACO
.	O
In	O
2017	O
,	O
after	O
surgery	O
for	O
sacral	O
ulcer	O
,	O
episode	O
of	O
chest	O
pain	O
compatible	O
with	O
unstable	O
angina	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
with	O
no	O
abnormalities	O
,	O
preserved	O
LVEF	O
.	O
An	O
outpatient	O
study	O
was	O
completed	O
with	O
ergometry	O
,	O
negative	O
for	O
ischaemia	O
.	O
During	O
postoperative	O
knee	O
surgery	O
in	O
January	O
2020	O
,	O
he	O
presented	O
with	O
non	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
NSTEACS	O
with	O
an	O
electrocardiographic	O
image	O
compatible	O
with	O
a	O
left	O
main	O
coronary	O
artery	O
lesion	O
.	O
Given	O
the	O
patient	O
's	O
fragility	O
,	O
he	O
was	O
managed	O
conservatively	O
and	O
discharged	O
with	O
triple	O
antithrombotic	O
therapy	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
clopidogrel	I-FARMACO
acenocoumarol	I-FARMACO
.	O
Last	O
TTE	O
March	O
2020	O
preserved	O
LVEF	O
without	O
segmental	O
contractility	O
abnormalities	O
,	O
mild	O
aortic	O
root	O
dilatation	O
,	O
mild	O
moderate	O
mitral	O
regurgitation	O
grade	O
II	O
.	O
Rest	O
unchanged	O
with	O
respect	O
to	O
previous	O
study	O
.	O
Digestive	O
history	O
Gastro	O
oesophageal	O
reflux	O
disease	O
GORD	O
with	O
grade	O
IV	O
IV	O
oesophagitis	O
and	O
duodenitis	O
.	O
Achalasia	O
in	O
2004	O
.	O
Oesophageal	O
diverticulectomy	O
with	O
anti	O
reflux	O
myocardiomyotomy	O
2008	O
,	O
complicated	O
with	O
respiratory	O
infection	O
by	O
P	O
.	O
aeruginosa	O
,	O
sacral	O
eschar	O
infection	O
by	O
E	O
.	O
coli	O
.	O
Cholecystectomy	O
for	O
alliasic	O
cholecystitis	O
.	O
Diverticulosis	O
of	O
the	O
colon	O
with	O
haemorrhage	O
.	O
Gastroscopy	O
and	O
colonoscopy	O
for	O
iron	O
deficiency	O
anaemia	O
in	O
2018	O
chronic	O
gastritis	O
as	O
the	O
only	O
notable	O
finding	O
.	O
Pedunculated	O
polyp	O
at	O
30	O
cm	O
from	O
the	O
anal	O
margin	O
of	O
approximately	O
1	O
.	O
5	O
cm	O
that	O
is	O
resected	O
.	O
Multiple	O
diverticula	O
along	O
the	O
entire	O
explored	O
tract	O
.	O
Angiodysplasia	O
of	O
the	O
intestine	O
with	O
isolated	O
haemorrhage	O
in	O
2015	O
.	O
Baseline	O
functional	O
status	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
,	O
walks	O
with	O
a	O
cane	O
.	O
Higher	O
functions	O
preserved	O
.	O
Usual	O
treatment	O
omeprazole	B-FARMACO
40	O
mg	O
;	O
acenocoumarol	B-FARMACO
4	O
mg	O
as	O
prescribed	O
;	O
clopidogrel	B-FARMACO
75	O
mg	O
;	O
ASA	B-FARMACO
100	O
mg	O
;	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
per	O
day	O
;	O
losartan	B-FARMACO
50	O
mg	O
per	O
day	O
;	O
atorvastatin	B-FARMACO
40	O
mg	O
;	O
lorazepam	B-FARMACO
1	O
mg	O
;	O
mirtazapine	B-FARMACO
15	O
mg	O
.	O
Present	O
illness	O
The	O
patient	O
starts	O
with	O
oppressive	O
central	O
thoracic	O
discomfort	O
on	O
the	O
night	O
before	O
going	O
to	O
the	O
medical	O
services	O
.	O
On	O
the	O
day	O
of	O
admission	O
in	O
the	O
morning	O
,	O
a	O
new	O
episode	O
of	O
sudden	O
onset	O
pain	O
,	O
radiating	O
to	O
the	O
back	O
and	O
neck	O
.	O
She	O
reported	O
no	O
melena	O
,	O
vomiting	O
or	O
macroscopic	O
bleeding	O
in	O
previous	O
days	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
pain	O
persisted	O
with	O
a	O
tendency	O
to	O
arterial	O
hypotension	O
,	O
tachypnoea	O
and	O
poor	O
distal	O
perfusion	O
.	O
Electrocardiogram	O
ECG	O
showed	O
diffuse	O
ST	O
segment	O
depression	O
,	O
with	O
elevation	O
in	O
aVR	O
,	O
suggestive	O
of	O
a	O
lesion	O
in	O
the	O
left	O
main	O
coronary	O
artery	O
.	O
Emergency	O
echocardioscopy	O
was	O
performed	O
,	O
showing	O
moderate	O
left	O
ventricular	O
LV	O
dysfunction	O
.	O
Transfer	O
to	O
the	O
coronary	O
unit	O
and	O
emergency	O
coronary	O
angiography	O
was	O
decided	O
.	O
GRACE	O
risk	O
scale	O
36	O
.	O
7	O
in	O
hospital	O
mortality	O
,	O
61	O
.	O
5	O
estimated	O
risk	O
of	O
death	O
at	O
one	O
year	O
.	O
CRUSADE	O
risk	O
scale	O
59	O
points	O
,	O
19	O
.	O
5	O
risk	O
of	O
major	O
in	O
hospital	O
bleeding	O
,	O
very	O
high	O
haemorrhagic	O
risk	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
95	O
50	O
mmHg	O
;	O
heart	O
rate	O
HR	O
80	O
bpm	O
;	O
oxygen	O
saturation	O
90	O
with	O
nasal	O
goggles	O
at	O
3	O
bpm	O
;	O
afebrile	O
.	O
Conscious	O
and	O
oriented	O
.	O
Mucocutaneous	O
pallor	O
,	O
poor	O
distal	O
perfusion	O
,	O
tachypneic	O
.	O
Jugular	O
plethora	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
with	O
bilateral	O
pulmonary	O
crackles	O
up	O
to	O
midfields	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
.	O
Discrete	O
lividity	O
in	O
the	O
lower	O
extremities	O
and	O
hands	O
.	O
No	O
palpable	O
paedial	O
pulses	O
,	O
no	O
oedema	O
or	O
evidence	O
of	O
venous	O
thrombosis	O
in	O
the	O
lower	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
admission	O
to	O
the	O
ED	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
,	O
normal	O
PR	O
,	O
QRS	O
axis	O
at	O
30o	O
,	O
diffuse	O
ST	O
segment	O
depression	O
,	O
maximum	O
of	O
4	O
mm	O
in	O
V5	O
V6	O
,	O
with	O
ST	O
segment	O
elevation	O
of	O
1	O
mm	O
in	O
V1	O
and	O
2	O
mm	O
in	O
aVR	O
.	O
ECG	O
after	O
catheterisation	O
atrial	O
fibrillation	O
with	O
ventricular	O
response	O
at	O
80	O
bpm	O
,	O
ST	O
segment	O
elevation	O
in	O
V2	O
V5	O
maximum	O
2	O
mm	O
in	O
V4	O
.	O
ECG	O
at	O
discharge	O
from	O
the	O
coronary	O
unit	O
common	O
atrial	O
flutter	O
with	O
ventricular	O
response	O
at	O
75	O
bpm	O
,	O
Q	O
waves	O
in	O
inferior	O
face	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
,	O
increased	O
perihilar	O
density	O
predominantly	O
on	O
the	O
right	O
with	O
associated	O
pleural	O
effusion	O
.	O
Laboratory	O
tests	O
on	O
admission	O
glucose	O
102	O
mg	O
dl	O
,	O
urea	O
66	O
mg	O
dl	O
,	O
Cr	O
1	O
.	O
39	O
mg	O
dl	O
,	O
GPT	O
13	O
U	O
l	O
,	O
Bi	O
0	O
.	O
2	O
mg	O
dl	O
,	O
Ca	O
9	O
.	O
9	O
mg	O
dl	O
,	O
albumin	O
4	O
.	O
2	O
g	O
dl	O
,	O
Na	O
132	O
mEq	O
l	O
,	O
K	O
4	O
,	O
3	O
mEq	O
l	O
,	O
Cl	O
96	O
mEq	O
l	O
,	O
CK	O
142	O
U	O
l	O
,	O
TnT	O
US	O
146	O
ng	O
l	O
normal	O
0	O
14	O
ng	O
l	O
,	O
Hb	O
6	O
.	O
5	O
g	O
dl	O
,	O
MCV	O
84	O
fl	O
,	O
MCH	O
25	O
pg	O
,	O
ADE	O
15	O
.	O
9	O
,	O
platelets	O
351	O
.	O
000	O
ul	O
,	O
leukocytes	O
12	O
.	O
510	O
ul	O
75	O
neutrophilia	O
.	O
Coagulation	O
in	O
normal	O
range	O
.	O
Enzymatic	O
peak	O
maximum	O
CK	O
1	O
.	O
237	O
U	O
l	O
,	O
maximum	O
troponin	O
T	O
us	O
4	O
.	O
224	O
ng	O
l	O
.	O
Other	O
analytical	O
results	O
lipidogram	O
total	O
cholesterol	O
123	O
mg	O
dL	O
,	O
triglycerides	O
127	O
mg	O
dL	O
,	O
HDL	O
cholesterol	O
48	O
mg	O
dL	O
and	O
LDL	O
50	O
mg	O
dL	O
.	O
HbA1c	O
5	O
.	O
6	O
Microbiology	O
SARS	O
CoV2	O
serology	O
negative	O
.	O
SARS	O
CoV2	O
PCR	O
not	O
detectable	O
.	O
On	O
admission	O
to	O
the	O
coronary	O
unit	O
,	O
methicillin	O
resistant	O
S	O
.	O
aureus	O
MRSA	O
was	O
isolated	O
in	O
a	O
nasal	O
sample	O
.	O
Gram	O
negative	O
coccobacilli	O
colonies	O
were	O
isolated	O
in	O
sputum	O
,	O
with	O
growth	O
of	O
Haemophilus	O
influenzae	O
.	O
Sacral	O
ulcer	O
culture	O
isolated	O
gram	O
positive	O
cocci	O
,	O
with	O
growth	O
of	O
MRSA	O
.	O
Echocardiogram	O
on	O
admission	O
dilated	O
LV	O
DTD	O
70	O
mm	O
,	O
with	O
mild	O
septal	O
LV	O
hypertrophy	O
LVH	O
IVS	O
13	O
mm	O
,	O
LVSP	O
10	O
mm	O
.	O
Moderately	O
to	O
severely	O
depressed	O
LV	O
systolic	O
function	O
LVEF	O
30	O
due	O
to	O
akinesia	O
of	O
the	O
apex	O
,	O
mid	O
apical	O
anterior	O
septum	O
,	O
lateral	O
and	O
anterior	O
face	O
.	O
Restrictive	O
relaxation	O
pattern	O
type	O
III	O
.	O
Aortic	O
root	O
not	O
dilated	O
36	O
mm	O
.	O
Sclerocalcified	O
aortic	O
valve	O
,	O
trivalve	O
,	O
with	O
good	O
opening	O
and	O
mild	O
insufficiency	O
.	O
Moderately	O
dilated	O
LA	O
.	O
Sclerocalcified	O
mitral	O
valve	O
,	O
thickened	O
leaflets	O
,	O
with	O
moderate	O
severe	O
regurgitation	O
consisting	O
of	O
two	O
jets	O
reaching	O
both	O
atrial	O
roofs	O
but	O
no	O
reverse	O
flow	O
in	O
pulmonary	O
veins	O
.	O
Mildly	O
dilated	O
right	O
ventricle	O
RV	O
baseline	O
DTD	O
42	O
mm	O
.	O
Borderline	O
RV	O
systolic	O
function	O
TAPSE	O
15	O
mm	O
.	O
Tricuspid	O
insufficiency	O
TI	O
mild	O
moderate	O
.	O
Vd	O
Ad	O
gradient	O
45	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
mildly	O
dilated	O
with	O
complete	O
inspiratory	O
collapse	O
50	O
.	O
Estimated	O
PSAP	O
55	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
Echocardiogram	O
prior	O
to	O
discharge	O
normal	O
LVEF	O
53	O
.	O
No	O
significant	O
valvulopathies	O
.	O
No	O
data	O
suggesting	O
significant	O
pulmonary	O
hypertension	O
.	O
Emergent	O
coronary	O
angiography	O
on	O
admission	O
common	O
trunk	O
with	O
critical	O
stenosis	O
of	O
irregular	O
appearance	O
in	O
its	O
ostium	O
and	O
middle	O
segment	O
causing	O
a	O
severe	O
drop	O
in	O
luminal	O
pressure	O
during	O
selective	O
catheterisation	O
of	O
the	O
vessel	O
.	O
The	O
anterior	O
descending	O
artery	O
has	O
only	O
non	O
significant	O
irregularities	O
.	O
The	O
circumflex	O
artery	O
is	O
a	O
vessel	O
of	O
remarkable	O
development	O
showing	O
no	O
significant	O
lesions	O
.	O
Anatomically	O
dominant	O
right	O
coronary	O
artery	O
,	O
diffusely	O
atheromatous	O
,	O
but	O
without	O
significant	O
focal	O
stenosis	O
.	O
Percutaneous	O
coronary	O
intervention	O
PCI	O
was	O
performed	O
in	O
the	O
common	O
trunk	O
,	O
with	O
implantation	O
of	O
a	O
Synergy	O
4	O
x	O
12	O
mm	O
stent	O
,	O
without	O
reaching	O
the	O
distal	O
bifurcation	O
and	O
allowing	O
some	O
protrusion	O
of	O
the	O
device	O
into	O
the	O
sinus	O
of	O
Valsalva	O
.	O
After	O
overexpanding	O
the	O
proximal	O
portion	O
of	O
the	O
stent	O
with	O
a	O
4	O
.	O
5	O
mm	O
NC	O
balloon	O
,	O
a	O
good	O
angiographic	O
result	O
was	O
achieved	O
.	O
Capsule	O
endoscopic	O
study	O
during	O
admission	O
to	O
the	O
cardiology	O
ward	O
absence	O
of	O
haematic	O
debris	O
throughout	O
the	O
examination	O
.	O
Angiodysplasia	O
in	O
the	O
stomach	O
with	O
no	O
evidence	O
of	O
active	O
bleeding	O
.	O
Millimetric	O
polyp	O
in	O
the	O
cecum	O
of	O
little	O
relevance	O
for	O
the	O
patient	O
's	O
age	O
and	O
current	O
clinical	O
situation	O
.	O
Gastroscopy	O
and	O
colonoscopy	O
are	O
recommended	O
when	O
the	O
patient	O
's	O
clinical	O
situation	O
permits	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
the	O
revascularisation	O
procedure	O
,	O
the	O
patient	O
suffers	O
several	O
episodes	O
of	O
hypotension	O
up	O
to	O
70	O
40	O
mmHg	O
with	O
poor	O
distal	O
perfusion	O
and	O
respiratory	O
worsening	O
.	O
Four	O
ampoules	O
of	O
i	O
.	O
v	O
.	O
furosemide	B-FARMACO
are	O
administered	O
,	O
oxygen	O
therapy	O
with	O
FiO2	O
of	O
50	O
maintaining	O
oxygen	O
saturation	O
90	O
.	O
He	O
also	O
required	O
boluses	O
of	O
phenylephrine	B-FARMACO
up	O
to	O
50	O
mcg	O
and	O
the	O
start	O
of	O
noradrenaline	B-FARMACO
perfusion	O
up	O
to	O
0	O
.	O
1	O
mcg	O
kg	O
min	O
for	O
TAM	O
70	O
mmHg	O
.	O
He	O
progressively	O
showed	O
respiratory	O
improvement	O
with	O
good	O
diuretic	O
response	O
and	O
haemodynamic	O
improvement	O
.	O
During	O
his	O
admission	O
to	O
the	O
coronary	O
unit	O
and	O
subsequently	O
to	O
the	O
cardiology	O
ward	O
Haemodynamically	O
,	O
he	O
presented	O
good	O
clinical	O
evolution	O
,	O
noradrenaline	B-FARMACO
was	O
discontinued	O
48	O
hours	O
after	O
admission	O
,	O
and	O
he	O
was	O
subsequently	O
maintained	O
with	O
AMT	O
70	O
mmHg	O
without	O
the	O
need	O
for	O
vasoactive	O
support	O
.	O
He	O
alternated	O
sinus	O
rhythm	O
with	O
spells	O
of	O
atrial	O
fibrillation	O
,	O
requiring	O
an	O
occasional	O
dose	O
of	O
digoxin	B-FARMACO
to	O
control	O
the	O
ventricular	O
rate	O
.	O
Echocardioscopy	O
72	O
hours	O
after	O
admission	O
showed	O
recovery	O
of	O
LVEF	O
.	O
The	O
TTE	O
prior	O
to	O
discharge	O
confirmed	O
this	O
improvement	O
in	O
ventricular	O
function	O
,	O
with	O
no	O
evidence	O
of	O
valvulopathy	O
or	O
pulmonary	O
hypertension	O
.	O
Respiratory	O
improvement	O
of	O
congestive	O
signs	O
after	O
negative	O
water	O
balance	O
,	O
maintaining	O
oxygen	O
saturation	O
92	O
initially	O
with	O
nasal	O
goggles	O
and	O
subsequently	O
with	O
ambient	O
air	O
,	O
with	O
no	O
congestive	O
signs	O
on	O
physical	O
examination	O
at	O
discharge	O
.	O
Nephro	O
urological	O
forced	O
diuresis	O
with	O
diuretic	O
with	O
good	O
response	O
,	O
being	O
possible	O
to	O
progressively	O
reduce	O
the	O
furosemide	B-FARMACO
boluses	O
,	O
until	O
switching	O
to	O
oral	O
administration	O
,	O
presenting	O
progressive	O
improvement	O
of	O
renal	O
function	O
until	O
normalisation	O
72	O
hours	O
after	O
admission	O
,	O
without	O
electrolyte	O
alterations	O
.	O
Infectious	O
afebrile	O
,	O
with	O
no	O
need	O
for	O
antibiotic	O
treatment	O
,	O
with	O
negative	O
PCR	O
and	O
serology	O
for	O
COVID	O
19	O
,	O
with	O
maximum	O
C	O
reactive	O
protein	O
of	O
64	O
mg	O
dl	O
,	O
but	O
normal	O
procalcitonin	O
and	O
leukocytes	O
.	O
Samples	O
were	O
taken	O
from	O
a	O
pressure	O
ulcer	O
in	O
the	O
sacral	O
area	O
already	O
known	O
,	O
isolating	O
MRSA	O
,	O
which	O
was	O
treated	O
with	O
local	O
dressings	O
.	O
During	O
her	O
stay	O
on	O
the	O
hospital	O
ward	O
,	O
she	O
presented	O
febrile	O
peaks	O
of	O
37	O
.	O
2oC	O
with	O
cough	O
and	O
expectoration	O
.	O
When	O
H	O
.	O
Influenzae	O
was	O
found	O
in	O
sputum	O
culture	O
,	O
oral	O
antibiotherapy	O
with	O
cephalosporins	B-FARMACO
was	O
started	O
according	O
to	O
the	O
antibiogram	O
results	O
.	O
Digestive	O
in	O
the	O
analysis	O
on	O
admission	O
,	O
there	O
was	O
progressive	O
anaemia	O
Hb	O
July	O
2019	O
13	O
g	O
dl	O
January	O
2020	O
10	O
.	O
1	O
g	O
dl	O
March	O
2020	O
8	O
.	O
3	O
g	O
dl	O
with	O
Hb	O
on	O
admission	O
of	O
6	O
.	O
5	O
g	O
dl	O
,	O
normocytic	O
,	O
hypochromic	O
with	O
high	O
ADE	O
,	O
so	O
despite	O
the	O
patient	O
denying	O
melena	O
or	O
other	O
macroscopic	O
bleeding	O
,	O
intravenous	O
pantoprazole	B-FARMACO
perfusion	O
was	O
started	O
and	O
2	O
red	O
blood	O
cell	O
concentrates	O
were	O
transfused	O
.	O
Subsequently	O
,	O
his	O
blood	O
counts	O
remained	O
stable	O
at	O
around	O
8	O
.	O
5	O
g	O
dl	O
,	O
with	O
no	O
signs	O
of	O
macroscopic	O
bleeding	O
and	O
stools	O
with	O
no	O
apparent	O
haematic	O
debris	O
.	O
Initially	O
on	O
an	O
absolute	O
diet	O
,	O
she	O
was	O
well	O
tolerated	O
when	O
starting	O
an	O
oral	O
diet	O
.	O
Despite	O
having	O
an	O
indication	O
for	O
anticoagulation	O
due	O
to	O
AF	O
CHA2DS2VASC	O
5	O
,	O
HAS	O
BLED	O
5	O
,	O
it	O
was	O
initially	O
decided	O
to	O
maintain	O
double	O
antiplatelet	O
therapy	O
with	O
ASA	B-FARMACO
and	O
clopidogrel	B-FARMACO
.	O
She	O
was	O
referred	O
to	O
the	O
gastrointestinal	O
department	O
of	O
our	O
centre	O
,	O
which	O
indicated	O
an	O
endoscopic	O
capsule	O
study	O
,	O
after	O
clinical	O
stabilisation	O
absence	O
of	O
haematic	O
debris	O
throughout	O
the	O
examination	O
.	O
Angiodysplasias	O
in	O
the	O
stomach	O
and	O
cecum	O
with	O
no	O
active	O
bleeding	O
.	O
On	O
discharge	O
,	O
treatment	O
with	O
oral	O
iron	B-FARMACO
and	O
follow	O
up	O
in	O
the	O
outpatient	O
gastroenterology	O
department	O
for	O
gastroscopy	O
colonoscopy	O
for	O
electrocoagulation	O
of	O
the	O
angiodysplastic	O
lesions	O
was	O
decided	O
.	O
The	O
time	O
in	O
therapeutic	O
range	O
TRT	O
with	O
sintrom	B-FARMACO
is	O
estimated	O
to	O
be	O
in	O
the	O
low	O
range	O
for	O
the	O
last	O
6	O
months	O
TRT	O
53	O
;	O
therefore	O
,	O
treatment	O
with	O
clopidogrel	B-FARMACO
75	O
mg	O
rivaroxaban	B-FARMACO
15	O
mg	O
day	O
as	O
dual	O
therapy	O
is	O
considered	O
as	O
a	O
possibility	O
for	O
discharge	O
,	O
based	O
on	O
the	O
strategy	O
of	O
the	O
PIONEER	O
study	O
,	O
which	O
has	O
shown	O
the	O
same	O
efficacy	O
and	O
lower	O
bleeding	O
rates	O
as	O
the	O
classic	O
triple	O
therapy	O
with	O
vitamin	B-FARMACO
K	I-FARMACO
antagonist	O
anticoagulants	O
and	O
dual	O
antiplatelet	O
therapy	O
.	O
In	O
good	O
clinical	O
condition	O
,	O
he	O
was	O
discharged	O
home	O
,	O
with	O
subsequent	O
follow	O
up	O
in	O
cardiology	O
consultations	O
,	O
and	O
pending	O
completion	O
of	O
a	O
digestive	O
study	O
.	O
DIAGNOSIS	O
Killip	O
IV	O
NSTEACS	O
.	O
Severe	O
coronary	O
artery	O
disease	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
LMCA	O
with	O
critical	O
lesion	O
.	O
Implantation	O
of	O
drug	O
eluting	O
stent	O
in	O
LMCA	O
.	O
Severe	O
LV	O
systolic	O
dysfunction	O
recovered	O
at	O
discharge	O
LVEF	O
53	O
.	O
Acute	O
anaemia	O
requiring	O
red	O
blood	O
cell	O
transfusion	O
probably	O
digestive	O
origin	O
.	O
Angiodysplasias	O
in	O
stomach	O
and	O
cecum	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
flutter	O
.	O
Acute	O
renal	O
failure	O
resolved	O
.	O

A	O
67	O
year	O
old	O
woman	O
came	O
to	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
referred	O
by	O
her	O
primary	O
care	O
physician	O
with	O
a	O
one	O
week	O
history	O
of	O
dyspnoea	O
,	O
orthopnoea	O
and	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
Her	O
personal	O
history	O
included	O
arterial	O
hypertension	O
,	O
diabetes	O
mellitus	O
treated	O
with	O
oral	O
antidiabetics	O
,	O
dyslipidaemia	O
,	O
permanent	O
atrial	O
fibrillation	O
anticoagulated	O
with	O
acenocoumarol	B-FARMACO
and	O
prosthetic	O
mitral	O
valve	O
replacement	O
6	O
years	O
ago	O
due	O
to	O
rheumatic	O
stenosis	O
with	O
severe	O
pulmonary	O
hypertension	O
.	O
It	O
should	O
be	O
mentioned	O
that	O
the	O
patient	O
had	O
no	O
history	O
of	O
known	O
nephrourological	O
pathology	O
,	O
with	O
analytical	O
studies	O
prior	O
to	O
admission	O
showing	O
normal	O
renal	O
function	O
,	O
without	O
proteinuria	O
or	O
sediment	O
alterations	O
.	O
He	O
was	O
admitted	O
to	O
Cardiology	O
with	O
the	O
diagnosis	O
of	O
a	O
first	O
episode	O
of	O
decompensation	O
of	O
heart	O
failure	O
,	O
with	O
no	O
clear	O
trigger	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
showing	O
a	O
normal	O
functioning	O
mitral	O
prosthesis	O
,	O
aortic	O
valve	O
calcification	O
and	O
severe	O
right	O
ventricular	O
dysfunction	O
,	O
with	O
no	O
other	O
significant	O
findings	O
.	O
On	O
the	O
third	O
day	O
of	O
admission	O
he	O
presented	O
with	O
a	O
fever	O
peak	O
related	O
to	O
peripheral	O
phlebitis	O
,	O
so	O
blood	O
cultures	O
were	O
taken	O
,	O
the	O
IV	O
was	O
changed	O
and	O
empirical	O
antibiotic	O
therapy	O
with	O
Ceftriaxone	B-FARMACO
was	O
started	O
.	O
In	O
the	O
following	O
24	O
hours	O
,	O
the	O
growth	O
of	O
SAMS	O
was	O
confirmed	O
in	O
the	O
blood	O
cultures	O
,	O
and	O
Ceftriaxone	B-FARMACO
was	O
replaced	O
by	O
intravenous	O
Cloxacillin	B-FARMACO
.	O
A	O
transesophageal	O
echocardiogram	O
was	O
performed	O
to	O
rule	O
out	O
infective	O
endocarditis	O
,	O
revealing	O
an	O
anchored	O
vegetative	O
image	O
at	O
the	O
level	O
of	O
the	O
posterolateral	O
mitral	O
annulus	O
and	O
another	O
,	O
smaller	O
,	O
anterolateral	O
filiform	O
image	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
a	O
diagnosis	O
of	O
infective	O
endocarditis	O
due	O
to	O
methicillin	O
sensitive	O
S	O
.	O
aureus	O
SAMS	O
on	O
the	O
prosthetic	O
valve	O
was	O
made	O
,	O
and	O
Rifampicin	B-FARMACO
was	O
added	O
to	O
the	O
aforementioned	O
treatment	O
.	O
The	O
patient	O
was	O
assessed	O
by	O
the	O
Cardiac	O
Surgery	O
Department	O
and	O
it	O
was	O
decided	O
to	O
surgically	O
replace	O
the	O
prosthesis	O
.	O
Since	O
then	O
,	O
she	O
has	O
had	O
a	O
long	O
and	O
complicated	O
postoperative	O
period	O
,	O
with	O
initial	O
multi	O
organ	O
dysfunction	O
in	O
the	O
context	O
of	O
cardiac	O
tamponade	O
that	O
required	O
urgent	O
reintervention	O
.	O
In	O
a	O
situation	O
of	O
severe	O
haemodynamic	O
failure	O
,	O
with	O
no	O
evidence	O
of	O
sepsis	O
and	O
maintaining	O
antibiotic	O
coverage	O
,	O
he	O
developed	O
acute	O
oligoanuric	O
renal	O
function	O
deterioration	O
attributed	O
to	O
hypoperfusion	O
with	O
the	O
need	O
for	O
extra	O
renal	O
depuration	O
by	O
continuous	O
venovenous	O
haemofiltration	O
for	O
a	O
week	O
.	O
Urine	O
studies	O
performed	O
at	O
this	O
time	O
showed	O
decreased	O
sodium	O
excretion	O
FENa	O
1	O
without	O
proteinuria	O
or	O
sediment	O
alterations	O
.	O
In	O
the	O
following	O
days	O
,	O
haemodynamic	O
recovery	O
is	O
accompanied	O
by	O
a	O
progressive	O
increase	O
in	O
diuresis	O
and	O
improvement	O
in	O
renal	O
function	O
parameters	O
Crp	O
0	O
.	O
8	O
mg	O
dL	O
,	O
and	O
haemofiltration	O
can	O
be	O
withdrawn	O
.	O
He	O
developed	O
multiple	O
complications	O
during	O
the	O
following	O
months	O
,	O
of	O
which	O
the	O
most	O
relevant	O
are	O
highlighted	O
below	O
.	O
Eight	O
weeks	O
after	O
the	O
operation	O
,	O
he	O
suffered	O
an	O
episode	O
of	O
upper	O
gastrointestinal	O
bleeding	O
,	O
for	O
which	O
an	O
endoscopic	O
study	O
was	O
carried	O
out	O
,	O
revealing	O
millimetric	O
gastric	O
erosions	O
of	O
uncertain	O
origin	O
.	O
Two	O
weeks	O
later	O
,	O
non	O
pruritic	O
raised	O
petechiae	O
were	O
found	O
on	O
the	O
trunk	O
,	O
extremities	O
,	O
folds	O
and	O
slopes	O
.	O
Coinciding	O
with	O
the	O
above	O
,	O
the	O
urinary	O
sediment	O
showed	O
proteinuria	O
of	O
less	O
than	O
1	O
gram	O
per	O
day	O
,	O
with	O
normal	O
renal	O
function	O
Crp	O
0	O
.	O
84	O
mg	O
dl	O
.	O
Urgent	O
determination	O
of	O
anti	O
neutrophil	O
cytoplasmic	O
antibodies	O
ANCAs	O
and	O
anti	O
glomerular	O
basement	O
membrane	O
antibodies	O
anti	O
GBM	O
was	O
requested	O
,	O
which	O
were	O
negative	O
.	O
The	O
dermatology	O
department	O
was	O
consulted	O
and	O
a	O
skin	O
biopsy	O
was	O
taken	O
,	O
which	O
was	O
compatible	O
with	O
leukocytoclastic	O
vasculitis	O
,	O
and	O
treatment	O
with	O
Prednisone	B-FARMACO
at	O
a	O
dose	O
of	O
0	O
.	O
5	O
mg	O
kg	O
day	O
was	O
indicated	O
.	O
One	O
week	O
later	O
he	O
presented	O
with	O
anaemia	O
without	O
externalisation	O
of	O
bleeding	O
and	O
a	O
chest	O
X	O
ray	O
showed	O
bilateral	O
de	O
novo	O
interstitial	O
infiltrates	O
.	O
All	O
this	O
coincided	O
with	O
a	O
new	O
deterioration	O
of	O
renal	O
function	O
Crp	O
1	O
.	O
78	O
mg	O
dL	O
,	O
oliguria	O
,	O
proteinuria	O
of	O
850	O
mg	O
day	O
,	O
macroscopic	O
haematuria	O
and	O
the	O
presence	O
of	O
dysmorphic	O
red	O
blood	O
cells	O
and	O
haematic	O
and	O
leukocyte	O
casts	O
in	O
the	O
urinary	O
sediment	O
.	O
Given	O
the	O
suspicion	O
of	O
pulmonary	O
haemorrhage	O
in	O
an	O
anticoagulated	O
patient	O
,	O
fibrobronchoscopy	O
was	O
performed	O
,	O
confirming	O
the	O
presence	O
of	O
fresh	O
haematic	O
debris	O
in	O
both	O
bronchial	O
trees	O
,	O
suggestive	O
of	O
alveolar	O
haemorrhage	O
.	O
Renal	O
function	O
progressively	O
deteriorated	O
,	O
and	O
the	O
patient	O
remained	O
in	O
a	O
situation	O
of	O
oligoanuria	O
and	O
secondary	O
hydrosaline	O
overload	O
,	O
with	O
persistent	O
haematuria	O
and	O
proteinuria	O
.	O
Given	O
the	O
clinical	O
diagnosis	O
of	O
nephritic	O
syndrome	O
with	O
pulmonary	O
haemorrhage	O
,	O
an	O
immunological	O
study	O
was	O
completed	O
,	O
highlighting	O
a	O
decrease	O
in	O
C3	O
78	O
.	O
8	O
mg	O
dL	O
and	O
C4	O
14	O
.	O
4	O
mg	O
dL	O
levels	O
,	O
the	O
presence	O
of	O
circulating	O
immunocomplexes	O
and	O
positive	O
rheumatoid	O
factor	O
190	O
mg	O
dL	O
,	O
with	O
negative	O
ANAs	O
,	O
antiDNA	O
,	O
ANCAs	O
and	O
antiMBG	O
,	O
as	O
well	O
as	O
negative	O
cryoglobulins	O
.	O
The	O
patient	O
's	O
respiratory	O
condition	O
progressively	O
deteriorated	O
,	O
anticoagulation	O
was	O
discontinued	O
,	O
and	O
it	O
was	O
decided	O
to	O
start	O
treatment	O
with	O
plasmapheresis	O
,	O
oral	O
cyclophosphamide	B-FARMACO
100	O
mg	O
day	O
and	O
increasing	O
the	O
dose	O
of	O
prednisone	B-FARMACO
1	O
mg	O
kg	O
day	O
in	O
view	O
of	O
the	O
renopulmonary	O
syndrome	O
.	O
Prior	O
to	O
the	O
start	O
of	O
the	O
immunosuppressive	O
regimen	O
,	O
blood	O
cultures	O
were	O
taken	O
on	O
several	O
occasions	O
and	O
were	O
persistently	O
negative	O
,	O
although	O
all	O
of	O
them	O
were	O
removed	O
and	O
the	O
patient	O
continued	O
with	O
antibiotherapy	O
.	O
With	O
these	O
measures	O
,	O
there	O
was	O
a	O
slight	O
improvement	O
from	O
the	O
respiratory	O
point	O
of	O
view	O
,	O
both	O
clinically	O
and	O
radiologically	O
,	O
but	O
the	O
progressive	O
deterioration	O
of	O
renal	O
function	O
persisted	O
,	O
again	O
requiring	O
extra	O
renal	O
depuration	O
by	O
means	O
of	O
continuous	O
venovenous	O
haemofiltration	O
.	O
Finally	O
,	O
as	O
there	O
was	O
no	O
improvement	O
in	O
the	O
following	O
days	O
,	O
a	O
renal	O
biopsy	O
was	O
performed	O
with	O
the	O
suspicion	O
of	O
acute	O
glomerulonephritis	O
related	O
to	O
the	O
infection	O
.	O
The	O
renal	O
biopsy	O
showed	O
areas	O
of	O
increased	O
mesangial	O
matrix	O
and	O
presence	O
of	O
thickening	O
in	O
the	O
membranes	O
of	O
the	O
glomerular	O
capillaries	O
.	O
Direct	O
immunofluorescence	O
techniques	O
showed	O
granular	O
mesangial	O
IgA	O
and	O
C3	O
fixation	O
,	O
with	O
a	O
predominance	O
of	O
IgA	O
deposits	O
,	O
and	O
therefore	O
compatible	O
with	O
infection	O
related	O
IgA	O
dominant	O
glomerulonephritis	O
.	O
In	O
view	O
of	O
these	O
findings	O
and	O
the	O
extrarenal	O
manifestations	O
characteristic	O
of	O
Henoch	O
Schönlein	O
purpura	O
,	O
we	O
requested	O
an	O
extension	O
of	O
the	O
immunofluorescence	O
of	O
the	O
skin	O
biopsy	O
,	O
which	O
also	O
showed	O
IgA	O
deposits	O
.	O
All	O
these	O
findings	O
were	O
therefore	O
compatible	O
with	O
IgA	O
dominant	O
glomerulonephritis	O
related	O
to	O
infective	O
endocarditis	O
due	O
to	O
SAMS	O
with	O
manifestations	O
of	O
Schönlein	O
Henoch	O
purpura	O
"	O
Schönlein	O
Henoch	O
like	O
"	O
.	O
Despite	O
therapeutic	O
measures	O
,	O
the	O
patient	O
had	O
a	O
torpid	O
evolution	O
with	O
massive	O
alveolar	O
haemorrhage	O
and	O
no	O
recovery	O
of	O
renal	O
function	O
,	O
finally	O
leading	O
to	O
exitus	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
74	O
year	O
old	O
male	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
hypertension	O
.	O
Dyslipidaemia	O
.	O
Ex	O
smoker	O
.	O
Previous	O
cardiological	O
history	O
Chronic	O
ischaemic	O
heart	O
disease	O
with	O
normal	O
LVEF	O
,	O
two	O
vessel	O
coronary	O
artery	O
disease	O
with	O
complete	O
percutaneous	O
revascularisation	O
.	O
Unstable	O
angina	O
in	O
1999	O
,	O
implantation	O
of	O
two	O
drug	O
eluting	O
stents	O
in	O
the	O
right	O
coronary	O
artery	O
and	O
circumflex	O
artery	O
.	O
Aortic	O
valve	O
sclerosis	O
.	O
Single	O
episode	O
of	O
self	O
limited	O
atrial	O
fibrillation	O
during	O
treatment	O
with	O
brentuximab	B-FARMACO
for	O
Hodgkin	O
's	O
lymphoma	O
.	O
It	O
was	O
decided	O
not	O
to	O
anticoagulate	O
due	O
to	O
the	O
high	O
haemorrhagic	O
risk	O
and	O
because	O
the	O
paroxysm	O
of	O
atrial	O
fibrillation	O
was	O
considered	O
reactive	O
to	O
treatment	O
.	O
Follow	O
up	O
in	O
cardio	O
oncology	O
consultations	O
.	O
Last	O
check	O
up	O
in	O
December	O
2019	O
,	O
without	O
angina	O
.	O
Infrarenal	O
abdominal	O
aortic	O
aneurysm	O
operated	O
on	O
in	O
2003	O
,	O
complicated	O
by	O
acute	O
renal	O
failure	O
secondary	O
to	O
right	O
renal	O
ischaemia	O
,	O
with	O
the	O
need	O
for	O
haemofiltration	O
in	O
the	O
postoperative	O
period	O
.	O
Stage	O
3	O
chronic	O
kidney	O
disease	O
,	O
secondary	O
to	O
ischaemic	O
nephropathy	O
functional	O
annulment	O
of	O
the	O
right	O
kidney	O
.	O
Secondary	O
hyperparathyroidism	O
.	O
Repeated	O
nephritic	O
colic	O
.	O
Haematological	O
history	O
Hodgkin	O
's	O
lymphoma	O
nodular	O
sclerosis	O
type	O
,	O
probable	O
stage	O
IV	O
due	O
to	O
pulmonary	O
involvement	O
.	O
Treatment	O
within	O
the	O
BREPEM	O
clinical	O
trial	O
brentuximab	B-FARMACO
with	O
cyclophosphamide	B-FARMACO
,	O
procarbazine	B-FARMACO
,	O
prednisone	B-FARMACO
and	O
mitoxantrone	B-FARMACO
,	O
suspended	O
due	O
to	O
toxicity	O
febrile	O
neutropenia	O
of	O
abdominal	O
focus	O
and	O
water	O
overload	O
.	O
Subsequently	O
two	O
cycles	O
of	O
ABVD	O
adriamycin	B-FARMACO
,	O
bleomycin	B-FARMACO
,	O
vinblastine	B-FARMACO
,	O
dacarbazine	B-FARMACO
.	O
Remission	O
with	O
the	O
exception	O
of	O
lung	O
nodule	O
DS	O
4	O
,	O
biopsied	O
and	O
without	O
findings	O
.	O
Recent	O
computed	O
tomography	O
CT	O
scan	O
of	O
the	O
chest	O
with	O
suspected	O
progression	O
,	O
pending	O
histological	O
confirmation	O
at	O
present	O
.	O
Usual	O
medication	O
atorvastatin	B-FARMACO
40	O
mg	O
24	O
hours	O
,	O
ezetimibe	B-FARMACO
10	O
mg	O
24	O
hours	O
,	O
clopidogrel	B-FARMACO
75	O
mg	O
24	O
hours	O
,	O
nitroglycerin	O
patch	O
5	O
mg	O
,	O
atenolol	B-FARMACO
25	O
mg	O
24	O
hours	O
,	O
furosemide	B-FARMACO
60	O
mg	O
24	O
hours	O
,	O
allopurinol	B-FARMACO
100	O
mg	O
24	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
trimethoprim	B-FARMACO
cotrimoxazole	I-FARMACO
160	O
800	O
mg	O
24	O
hours	O
,	O
folic	B-FARMACO
acid	I-FARMACO
5	O
mg	O
24	O
hours	O
,	O
hydroferol	B-FARMACO
0	O
.	O
266	O
mg	O
monthly	O
.	O
Present	O
illness	O
She	O
attended	O
the	O
emergency	O
department	O
for	O
an	O
episode	O
of	O
oppressive	O
central	O
thoracic	O
pain	O
that	O
started	O
at	O
rest	O
,	O
accompanied	O
by	O
general	O
malaise	O
and	O
sweating	O
,	O
self	O
limited	O
in	O
30	O
40	O
minutes	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
she	O
presented	O
a	O
new	O
episode	O
similar	O
to	O
the	O
previous	O
one	O
,	O
although	O
of	O
shorter	O
duration	O
.	O
At	O
the	O
time	O
of	O
cardiology	O
assessment	O
,	O
he	O
was	O
already	O
asymptomatic	O
for	O
chest	O
pain	O
.	O
In	O
addition	O
,	O
he	O
reported	O
a	O
fever	O
peak	O
of	O
38	O
.	O
5oC	O
the	O
day	O
before	O
the	O
consultation	O
,	O
accompanied	O
by	O
cough	O
with	O
scant	O
yellowish	O
expectoration	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
107	O
63	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
110	O
bpm	O
.	O
Temperature	O
38	O
.	O
3	O
oC	O
.	O
Oxygen	O
saturation	O
94	O
with	O
nasal	O
goggles	O
at	O
1	O
.	O
5	O
litres	O
.	O
Eupneic	O
at	O
rest	O
,	O
tolerating	O
decubitus	O
at	O
30o	O
.	O
Jugular	O
venous	O
pressure	O
JVP	O
in	O
the	O
middle	O
third	O
of	O
the	O
neck	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
tachycardia	O
,	O
systolic	O
murmurs	O
II	O
IV	O
in	O
aortic	O
focus	O
with	O
preserved	O
second	O
tone	O
.	O
Pulmonary	O
auscultation	O
crackles	O
in	O
the	O
lower	O
third	O
of	O
both	O
hemithoraxes	O
and	O
disseminated	O
wheezing	O
.	O
Oedema	O
with	O
fovea	O
in	O
the	O
lower	O
third	O
of	O
both	O
legs	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
with	O
pain	O
atrial	O
fibrillation	O
with	O
ventricular	O
response	O
at	O
120	O
bpm	O
,	O
narrow	O
QRS	O
,	O
abrupt	O
R	O
wave	O
transition	O
in	O
V4	O
,	O
ST	O
elevation	O
in	O
V1	O
and	O
aVR	O
and	O
diffuse	O
ST	O
descent	O
in	O
the	O
rest	O
of	O
the	O
leads	O
.	O
ST	O
segment	O
alterations	O
corrected	O
in	O
ECG	O
without	O
pain	O
.	O
Blood	O
tests	O
on	O
admission	O
Haemoglobin	O
8	O
.	O
1	O
g	O
dl	O
,	O
MCV	O
101	O
.	O
4	O
fl	O
,	O
leucocytes	O
13	O
,	O
700	O
mcl	O
,	O
neutrophils	O
11	O
,	O
800	O
mcl	O
,	O
platelets	O
100	O
.	O
000	O
mcl	O
.	O
INR	O
1	O
,	O
28	O
,	O
APTT	O
ratio	O
1	O
,	O
07	O
.	O
Glucose	O
83	O
ml	O
dl	O
,	O
creatinine	O
1	O
.	O
72	O
mg	O
dl	O
,	O
GFR	O
51	O
ml	O
min	O
m	O
,	O
sodium	O
136	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
9	O
mEq	O
l	O
,	O
magnesium	O
1	O
.	O
9	O
mEq	O
l	O
,	O
phosphate	O
2	O
.	O
9	O
mEq	O
l	O
,	O
bilirubin	O
1	O
mg	O
dl	O
,	O
alkaline	O
phosphatase	O
96	O
U	O
I	O
,	O
GGT	O
70	O
U	O
I	O
,	O
ALT	O
37	O
U	O
I	O
,	O
CRP	O
8	O
mg	O
dl	O
,	O
procalcitonin	O
0	O
.	O
5	O
.	O
NT	O
proBNP	O
7	O
,	O
490	O
pg	O
ml	O
.	O
Troponin	O
I	O
ultrasensitive	O
831	O
1	O
,	O
600	O
ng	O
l	O
normal	O
34	O
ng	O
l	O
.	O
CK	O
47	O
U	O
I	O
.	O
Lipid	O
profile	O
triglycerides	O
89	O
mg	O
dl	O
,	O
total	O
cholesterol	O
81	O
mg	O
dl	O
,	O
HDL	O
29	O
mg	O
dl	O
,	O
LDL	O
34	O
mg	O
dl	O
.	O
Iron	O
profile	O
iron	O
26	O
mg	O
dl	O
,	O
ferritin	O
2	O
,	O
703	O
ng	O
ml	O
,	O
transterrin	O
saturation	O
index	O
20	O
.	O
TSH	O
1	O
.	O
01	O
mcIU	O
ml	O
.	O
Glycosylated	O
Hb	O
6	O
.	O
4	O
.	O
Microbiology	O
Blood	O
cultures	O
sterile	O
after	O
5	O
days	O
incubation	O
.	O
Nasopharyngeal	O
exudate	O
negative	O
for	O
influenza	O
and	O
RSV	O
.	O
Urine	O
culture	O
negative	O
.	O
Legionella	O
and	O
Pneumococcus	O
antigens	O
in	O
urine	O
negative	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
.	O
Perihilar	O
and	O
peribronchovascular	O
thickening	O
and	O
costophrenic	O
sinus	O
impingement	O
,	O
compatible	O
with	O
heart	O
failure	O
.	O
White	O
left	O
lung	O
already	O
present	O
in	O
previous	O
cases	O
.	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
slight	O
concentric	O
hypertrophy	O
,	O
hyperdynamic	O
,	O
with	O
normal	O
global	O
systolic	O
function	O
,	O
despite	O
basal	O
inferior	O
akinesia	O
and	O
inferior	O
septal	O
akinesia	O
.	O
Transmitral	O
filling	O
pattern	O
with	O
single	O
wave	O
.	O
Left	O
atrium	O
slightly	O
dilated	O
.	O
Non	O
dilated	O
right	O
atrium	O
.	O
Right	O
ventricle	O
not	O
dilated	O
,	O
hyperdynamic	O
,	O
with	O
normal	O
global	O
systolic	O
function	O
.	O
Aortic	O
valve	O
slightly	O
sclerosed	O
,	O
with	O
maximum	O
transvalvular	O
velocity	O
of	O
2	O
.	O
1m	O
s	O
,	O
without	O
insufficiency	O
.	O
Mitral	O
valve	O
functionally	O
normal	O
.	O
Morphologically	O
normal	O
tricuspid	O
valve	O
with	O
mild	O
insufficiency	O
.	O
Pulmonary	O
artery	O
systolic	O
pressure	O
estimated	O
at	O
43	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
physiological	O
inspiratory	O
collapse	O
.	O
Slight	O
circumferential	O
pericardial	O
effusion	O
,	O
with	O
no	O
evidence	O
of	O
haemodynamic	O
compromise	O
,	O
with	O
epicardial	O
fat	O
.	O
Diagnostic	O
coronary	O
angiography	O
access	O
via	O
right	O
radial	O
artery	O
,	O
contrast	O
100	O
cc	O
.	O
Left	O
main	O
coronary	O
artery	O
LMCA	O
atheromatous	O
with	O
significant	O
lesion	O
70	O
distal	O
involving	O
the	O
bifurcation	O
.	O
Anterior	O
descending	O
artery	O
AD	O
of	O
good	O
development	O
and	O
calibre	O
,	O
with	O
diffuse	O
mild	O
atheromatosis	O
without	O
significant	O
lesions	O
.	O
Circumflex	O
Cx	O
well	O
developed	O
and	O
of	O
good	O
calibre	O
,	O
composed	O
mainly	O
of	O
a	O
main	O
marginal	O
branch	O
with	O
a	O
permeable	O
stent	O
without	O
lesions	O
,	O
vessel	O
with	O
diffuse	O
mild	O
atheromatosis	O
,	O
without	O
significant	O
lesions	O
.	O
Right	O
coronary	O
artery	O
RCA	O
dominant	O
,	O
chronic	O
occlusion	O
in	O
its	O
proximal	O
segment	O
;	O
distal	O
vessel	O
of	O
moderate	O
calibre	O
with	O
no	O
significant	O
lesions	O
due	O
to	O
collateral	O
circulation	O
.	O
Therapeutic	O
coronary	O
angiography	O
access	O
via	O
the	O
right	O
femoral	O
artery	O
guided	O
by	O
ultrasound	O
,	O
contrast	O
227	O
cc	O
.	O
Intervencionsimo	O
on	O
the	O
left	O
coronary	O
trunk	O
guidewire	O
is	O
crossed	O
to	O
circumflex	O
and	O
anterior	O
descending	O
artery	O
.	O
DK	O
Crush	O
technique	O
.	O
Drug	O
eluting	O
implant	O
in	O
TCI	O
Cx	O
.	O
First	O
kissing	O
balloon	O
and	O
second	O
drug	O
eluting	O
stent	O
is	O
implanted	O
in	O
LMCA	O
AD	O
.	O
Second	O
kissing	O
balloon	O
is	O
performed	O
.	O
Good	O
angiographic	O
and	O
IVUS	O
results	O
.	O
Vascular	O
closure	O
with	O
percutaneous	O
closure	O
device	O
,	O
checking	O
correct	O
common	O
femoral	O
puncture	O
by	O
fluoroscopy	O
and	O
persistence	O
of	O
flow	O
by	O
echo	O
Doppler	O
.	O
CLINICAL	O
EVOLUTION	O
A	O
75	O
year	O
old	O
man	O
with	O
the	O
aforementioned	O
history	O
was	O
admitted	O
for	O
an	O
episode	O
of	O
angina	O
at	O
rest	O
.	O
He	O
also	O
presented	O
with	O
semiology	O
of	O
decompensated	O
heart	O
failure	O
and	O
rapid	O
atrial	O
fibrillation	O
of	O
uncertain	O
onset	O
.	O
All	O
this	O
in	O
the	O
context	O
of	O
a	O
possible	O
relapse	O
of	O
the	O
underlying	O
haematological	O
pathology	O
,	O
symptoms	O
of	O
respiratory	O
infection	O
and	O
anaemisation	O
with	O
respect	O
to	O
baseline	O
haemoglobin	O
levels	O
.	O
ECG	O
suggestive	O
of	O
TCI	O
disease	O
and	O
elevation	O
of	O
markers	O
of	O
myocardial	O
damage	O
with	O
ascending	O
curve	O
.	O
Asymptomatic	O
for	O
chest	O
pain	O
when	O
assessed	O
by	O
cardiology	O
.	O
Initially	O
,	O
two	O
red	O
blood	O
cell	O
concentrates	O
were	O
transfused	O
,	O
intravenous	O
depletive	O
treatment	O
was	O
started	O
and	O
,	O
given	O
the	O
respiratory	O
infection	O
in	O
an	O
immunocompromised	O
patient	O
,	O
empirical	O
broad	O
spectrum	O
antibiotic	O
treatment	O
was	O
started	O
with	O
piperacillin	B-FARMACO
tazobactam	I-FARMACO
.	O
Double	O
antiplatelet	O
therapy	O
was	O
also	O
started	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
and	O
clopidogrel	B-FARMACO
,	O
initially	O
without	O
anticoagulation	O
.	O
Coronary	O
angiography	O
showed	O
significant	O
distal	O
LMCA	O
disease	O
involving	O
the	O
bifurcation	O
with	O
LAD	O
and	O
Cx	O
,	O
in	O
addition	O
to	O
chronic	O
LMCA	O
occlusion	O
.	O
As	O
this	O
was	O
a	O
highly	O
complex	O
patient	O
,	O
with	O
significant	O
comorbidity	O
and	O
high	O
ischaemic	O
and	O
haemorrhagic	O
risk	O
,	O
it	O
was	O
decided	O
not	O
to	O
intervene	O
until	O
the	O
case	O
was	O
presented	O
to	O
the	O
heart	O
team	O
.	O
Comorbidity	O
included	O
Hodgkin	O
's	O
lymphoma	O
with	O
suspected	O
progression	O
at	O
present	O
probable	O
stage	O
IV	O
due	O
to	O
pulmonary	O
involvement	O
in	O
recent	O
CT	O
scan	O
,	O
although	O
histological	O
confirmation	O
was	O
pending	O
.	O
During	O
admission	O
,	O
an	O
assessment	O
by	O
haematology	O
was	O
requested	O
,	O
who	O
estimated	O
a	O
poor	O
medium	O
term	O
prognosis	O
.	O
In	O
addition	O
,	O
our	O
patient	O
had	O
chronic	O
multifactorial	O
normocytic	O
normochromic	O
anaemia	O
haematological	O
disease	O
,	O
chronic	O
disorders	O
,	O
chronic	O
renal	O
disease	O
,	O
chronic	O
treatment	O
with	O
trimethoprim	B-FARMACO
cotrimoxazole	I-FARMACO
with	O
usual	O
Hb	O
levels	O
of	O
10	O
mg	O
dl	O
,	O
presenting	O
on	O
arrival	O
with	O
anaemisation	O
up	O
to	O
Hb	O
8	O
.	O
1	O
mg	O
dl	O
.	O
Despite	O
transfusion	O
with	O
stabilisation	O
of	O
Hb	O
levels	O
around	O
baseline	O
,	O
negative	O
balance	O
,	O
controlled	O
ventricular	O
response	O
and	O
titration	O
of	O
antianginal	O
medical	O
treatment	O
,	O
the	O
patient	O
persisted	O
with	O
minimal	O
effort	O
angina	O
in	O
the	O
cardiology	O
ward	O
.	O
The	O
case	O
was	O
presented	O
to	O
the	O
heart	O
team	O
,	O
who	O
decided	O
to	O
perform	O
percutaneous	O
revascularisation	O
of	O
the	O
LMCA	O
,	O
given	O
the	O
high	O
surgical	O
risk	O
.	O
A	O
new	O
coronary	O
angiography	O
was	O
performed	O
via	O
the	O
right	O
femoral	O
artery	O
with	O
implantation	O
of	O
two	O
drug	O
eluting	O
stents	O
in	O
the	O
LMCA	O
AD	O
and	O
LMCA	O
Cx	O
using	O
the	O
DK	O
Crusch	O
technique	O
,	O
without	O
immediate	O
complications	O
and	O
with	O
resolution	O
of	O
angina	O
.	O
Following	O
the	O
PIONEER	O
strategy	O
,	O
antithrombotic	O
treatment	O
was	O
maintained	O
with	O
simple	O
antiplatelet	O
therapy	O
with	O
clopidogrel	B-FARMACO
75	O
mg	O
24	O
hours	O
and	O
anticoagulation	O
with	O
low	O
dose	O
rivaroxaban	B-FARMACO
10	O
mg	O
24	O
hours	O
adjusted	O
to	O
renal	O
function	O
.	O
After	O
discharge	O
,	O
the	O
patient	O
remains	O
asymptomatic	O
for	O
angina	O
and	O
without	O
haemorrhagic	O
complications	O
.	O
However	O
,	O
pulmonary	O
progression	O
of	O
Hodgkin	O
's	O
lymphoma	O
was	O
confirmed	O
and	O
he	O
died	O
one	O
month	O
after	O
discharge	O
.	O
DIAGNOSIS	O
Acute	O
myocardial	O
infarction	O
without	O
ST	O
elevation	O
,	O
Killip	O
II	O
.	O
Revascularisation	O
of	O
distal	O
left	O
main	O
coronary	O
artery	O
with	O
two	O
drug	O
eluting	O
stents	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
with	O
preserved	O
LVEF	O
.	O
Coronary	O
artery	O
disease	O
partially	O
revascularised	O
percutaneously	O
,	O
chronic	O
occlusion	O
of	O
the	O
right	O
coronary	O
artery	O
.	O
Persistent	O
atrial	O
fibrillation	O
.	O
Decompensation	O
of	O
heart	O
failure	O
secondary	O
to	O
previous	O
events	O
.	O
Respiratory	O
infection	O
in	O
immunosuppressed	O
patient	O
.	O
Chronic	O
multifactorial	O
exacerbated	O
anaemia	O
.	O
Stage	O
IV	O
Hodgkin	O
's	O
lymphoma	O
due	O
to	O
pulmonary	O
involvement	O
.	O
Stage	O
3	O
chronic	O
kidney	O
disease	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
24	O
year	O
old	O
male	O
,	O
working	O
in	O
a	O
hardware	O
store	O
,	O
with	O
no	O
known	O
drug	O
allergies	O
or	O
toxic	O
habits	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
CVRF	O
.	O
Hypothyroidism	O
on	O
replacement	O
therapy	O
.	O
In	O
June	O
2008	O
,	O
he	O
consulted	O
for	O
cough	O
and	O
progressive	O
dyspnoea	O
of	O
6	O
months	O
'	O
evolution	O
,	O
and	O
was	O
diagnosed	O
by	O
the	O
pulmonology	O
department	O
as	O
having	O
sarcoidosis	O
with	O
grade	O
II	O
pulmonary	O
involvement	O
,	O
with	O
associated	O
bronchial	O
hyperresponsiveness	O
.	O
Immunosuppressive	O
treatment	O
with	O
corticosteroids	O
was	O
started	O
.	O
In	O
September	O
2008	O
he	O
was	O
admitted	O
for	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
with	O
haemodynamic	O
instability	O
.	O
During	O
admission	O
,	O
a	O
dilated	O
left	O
ventricle	O
with	O
severe	O
systolic	O
dysfunction	O
was	O
observed	O
.	O
A	O
haemodynamic	O
study	O
showed	O
coronary	O
arteries	O
without	O
stenosis	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
showed	O
a	O
dilated	O
left	O
ventricle	O
with	O
a	O
maximum	O
telediastolic	O
diameter	O
of	O
60	O
mm	O
,	O
apical	O
thinning	O
with	O
apical	O
inferior	O
,	O
anterior	O
and	O
lateral	O
akinesia	O
,	O
medial	O
lateral	O
,	O
medial	O
anterior	O
hypokinesia	O
and	O
medial	O
inferior	O
hypokinesia	O
,	O
with	O
severe	O
systolic	O
dysfunction	O
LVEF	O
20	O
.	O
Late	O
subendocardial	O
enhancement	O
in	O
basal	O
inferior	O
and	O
basal	O
lateral	O
face	O
,	O
with	O
extension	O
to	O
papillary	O
muscles	O
;	O
and	O
transmural	O
in	O
mid	O
and	O
apical	O
lateral	O
,	O
mid	O
and	O
apical	O
inferior	O
,	O
and	O
apical	O
anterior	O
face	O
.	O
Implantable	O
cardioverter	O
defibrillator	O
ICD	O
implantation	O
was	O
performed	O
in	O
October	O
2008	O
.	O
He	O
was	O
admitted	O
in	O
December	O
2008	O
due	O
to	O
infection	O
of	O
the	O
surgical	O
wound	O
of	O
the	O
ICD	O
,	O
the	O
system	O
was	O
explanted	O
and	O
antibiotics	O
were	O
administered	O
,	O
despite	O
which	O
the	O
infectious	O
clinical	O
symptoms	O
persisted	O
with	O
febrile	O
syndrome	O
,	O
and	O
the	O
studies	O
were	O
extended	O
and	O
tricuspid	O
endocarditis	O
was	O
detected	O
,	O
complicated	O
with	O
pulmonary	O
embolisms	O
.	O
With	O
progressive	O
deterioration	O
of	O
his	O
functional	O
status	O
and	O
refractory	O
heart	O
failure	O
,	O
associated	O
with	O
several	O
episodes	O
of	O
non	O
sustained	O
and	O
sustained	O
ventricular	O
tachycardia	O
VT	O
with	O
poor	O
haemodynamic	O
tolerance	O
.	O
On	O
9	O
February	O
2009	O
,	O
he	O
suffered	O
cardiorespiratory	O
arrest	O
CRA	O
due	O
to	O
primary	O
ventricular	O
fibrillation	O
VF	O
,	O
recovered	O
after	O
2	O
shocks	O
,	O
with	O
no	O
sequelae	O
.	O
She	O
was	O
referred	O
to	O
the	O
reference	O
centre	O
for	O
evaluation	O
for	O
cardiac	O
transplant	O
,	O
which	O
was	O
performed	O
on	O
20	O
02	O
2009	O
.	O
During	O
admission	O
,	O
he	O
presented	O
with	O
complications	O
such	O
as	O
avascular	O
necrosis	O
of	O
both	O
hips	O
,	O
probably	O
related	O
to	O
corticosteroid	O
treatment	O
.	O
Subsequently	O
,	O
in	O
May	O
2011	O
,	O
he	O
underwent	O
bilateral	O
hip	O
replacement	O
surgery	O
.	O
During	O
the	O
following	O
years	O
,	O
he	O
was	O
admitted	O
on	O
multiple	O
occasions	O
for	O
infectious	O
complications	O
lung	O
abscess	O
in	O
2010	O
,	O
thoracic	O
herpes	O
zoster	O
in	O
2010	O
,	O
repeated	O
UTI	O
,	O
gastroenteritis	O
.	O
In	O
January	O
2013	O
he	O
presented	O
with	O
an	O
episode	O
of	O
acute	O
grade	O
3R	O
rejection	O
symptomatic	O
for	O
dizziness	O
,	O
dyspnoea	O
on	O
minimal	O
exertion	O
and	O
complete	O
atrioventricular	O
block	O
AVB	O
.	O
After	O
treatment	O
with	O
corticosteroid	O
boluses	O
,	O
the	O
condition	O
was	O
reversed	O
,	O
with	O
disappearance	O
of	O
AVB	O
and	O
clinical	O
improvement	O
.	O
In	O
the	O
control	O
biopsy	O
,	O
the	O
acute	O
cellular	O
rejection	O
was	O
in	O
resolution	O
.	O
Prior	O
to	O
discharge	O
,	O
he	O
presented	O
an	O
episode	O
of	O
atrial	O
deflutter	O
,	O
treated	O
with	O
atrial	O
overstimulation	O
.	O
A	O
control	O
biopsy	O
was	O
repeated	O
6	O
months	O
later	O
,	O
with	O
no	O
evidence	O
of	O
rejection	O
.	O
He	O
was	O
admitted	O
on	O
23	O
06	O
2013	O
for	O
self	O
limited	O
epigastric	O
pain	O
radiating	O
to	O
the	O
back	O
,	O
associated	O
with	O
a	O
feeling	O
of	O
breathlessness	O
,	O
lasting	O
about	O
15	O
minutes	O
,	O
after	O
walking	O
for	O
10	O
minutes	O
.	O
Previously	O
,	O
the	O
patient	O
had	O
been	O
suffering	O
from	O
asthenia	O
for	O
a	O
week	O
,	O
with	O
no	O
other	O
associated	O
cardiovascular	O
symptoms	O
.	O
He	O
denied	O
any	O
infectious	O
symptoms	O
or	O
fever	O
.	O
He	O
suffered	O
an	O
episode	O
of	O
alimentary	O
vomiting	O
in	O
the	O
emergency	O
department	O
.	O
On	O
physical	O
examination	O
,	O
the	O
patient	O
had	O
a	O
good	O
general	O
appearance	O
,	O
was	O
haemodynamically	O
stable	O
,	O
with	O
no	O
congestive	O
symptoms	O
,	O
and	O
was	O
eupneic	O
at	O
baseline	O
.	O
On	O
cardiac	O
auscultation	O
,	O
he	O
was	O
tachycardic	O
,	O
with	O
no	O
murmurs	O
or	O
friction	O
rubs	O
.	O
Abdomen	O
painful	O
on	O
palpation	O
in	O
the	O
right	O
hypochondrium	O
,	O
soft	O
,	O
depressible	O
and	O
with	O
no	O
evidence	O
of	O
peritoneal	O
irritation	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
tachycardia	O
at	O
135	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
ST	O
rectification	O
of	O
V1	O
V4	O
and	O
convex	O
ST	O
in	O
inferior	O
face	O
.	O
ECG	O
sinus	O
tachycardia	O
at	O
105	O
bpm	O
,	O
inferior	O
ST	O
elevation	O
,	O
ST	O
depression	O
of	O
V1	O
V3	O
,	O
inferior	O
posterior	O
Q	O
wave	O
.	O
ECG	O
complete	O
VAB	O
spells	O
in	O
the	O
context	O
of	O
myocardial	O
ischaemia	O
.	O
CBC	O
blood	O
count	O
leukocytes	O
13	O
,	O
600	O
μl	O
normal	O
leukocyte	O
formula	O
,	O
haemoglobin	O
13	O
.	O
7	O
g	O
dl	O
,	O
haematocrit	O
43	O
.	O
9	O
,	O
platelets	O
206	O
,	O
000	O
μl	O
.	O
Coagulation	O
To	O
.	O
T	O
.	O
Partial	O
Activated	O
29	O
.	O
9	O
s	O
,	O
INR	O
1	O
.	O
22	O
,	O
prothrombin	O
rate	O
77	O
.	O
Biochemistry	O
glucose	O
80	O
mg	O
dl	O
,	O
urea	O
58	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
10	O
mg	O
dl	O
,	O
GFR	O
79	O
ml	O
min	O
,	O
sodium	O
142	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
6	O
mEq	O
l	O
,	O
chlorine	O
109	O
mEq	O
l	O
,	O
GOT	O
AST	O
109	O
U	O
l	O
,	O
GPT	O
ALT	O
58	O
U	O
l	O
,	O
amylase	O
35	O
U	O
l	O
,	O
total	O
bilirubin	O
1	O
.	O
3	O
mg	O
dl	O
.	O
Serialisation	O
of	O
myocardial	O
damage	O
markers	O
ultrasensitive	O
troponin	O
1919	O
ng	O
l	O
1964	O
ng	O
l	O
1990	O
ng	O
l	O
0	O
13	O
.	O
Coronary	O
angiography	O
three	O
vessel	O
coronary	O
artery	O
disease	O
,	O
with	O
poor	O
distal	O
beds	O
and	O
diffuse	O
disease	O
,	O
with	O
thrombotic	O
occlusion	O
of	O
the	O
proximal	O
right	O
coronary	O
artery	O
RCA	O
.	O
During	O
percutaneous	O
coronary	O
intervention	O
PCI	O
,	O
multiple	O
dilatations	O
with	O
balloon	O
angioplasty	O
were	O
attempted	O
to	O
recanalise	O
the	O
coronary	O
artery	O
,	O
but	O
no	O
flow	O
was	O
achieved	O
due	O
to	O
severe	O
no	O
reflow	O
phenomenon	O
.	O
CLINICAL	O
COURSE	O
The	O
patient	O
was	O
admitted	O
with	O
initial	O
suspicion	O
of	O
acute	O
myocarditis	O
versus	O
acute	O
coronary	O
syndrome	O
type	O
NSTEMI	O
,	O
with	O
flat	O
enzyme	O
mobilisation	O
in	O
the	O
following	O
12	O
hours	O
.	O
The	O
ECG	O
on	O
admission	O
showed	O
sinus	O
tachycardia	O
,	O
with	O
subtle	O
changes	O
in	O
the	O
repolarisation	O
of	O
ST	O
rectification	O
in	O
V1	O
V4	O
and	O
convex	O
ST	O
in	O
the	O
inferior	O
face	O
.	O
At	O
21	O
00h	O
on	O
the	O
day	O
of	O
admission	O
,	O
the	O
patient	O
began	O
with	O
dyspnoea	O
,	O
tachypnoea	O
and	O
vegetative	O
symptoms	O
.	O
The	O
ECG	O
showed	O
sinus	O
tachycardia	O
with	O
lower	O
ST	O
elevation	O
,	O
with	O
self	O
limited	O
spells	O
of	O
complete	O
AVB	O
,	O
and	O
an	O
emergent	O
haemodynamic	O
study	O
was	O
performed	O
.	O
Catheterisation	O
revealed	O
three	O
vessel	O
coronary	O
artery	O
disease	O
,	O
with	O
poor	O
distal	O
beds	O
and	O
diffuse	O
disease	O
,	O
with	O
thrombotic	O
occlusion	O
of	O
the	O
proximal	O
DC	O
.	O
During	O
PCI	O
,	O
multiple	O
dilatations	O
with	O
balloon	O
angioplasty	O
were	O
attempted	O
,	O
but	O
no	O
flow	O
was	O
achieved	O
due	O
to	O
no	O
reflow	O
.	O
During	O
the	O
procedure	O
the	O
patient	O
suffered	O
complete	O
AVB	O
with	O
severe	O
haemodynamic	O
deterioration	O
Killip	O
IV	O
,	O
which	O
triggered	O
ventricular	O
fibrillation	O
.	O
Despite	O
multiple	O
shocks	O
at	O
200J	O
and	O
advanced	O
CPR	O
for	O
a	O
prolonged	O
period	O
,	O
the	O
patient	O
did	O
not	O
respond	O
to	O
these	O
measures	O
and	O
died	O
.	O
DIAGNOSIS	O
Acute	O
coronary	O
syndrome	O
with	O
ST	O
segment	O
elevation	O
STEACS	O
lower	O
Killip	O
IV	O
.	O
Complete	O
AVB	O
due	O
to	O
myocardial	O
ischaemia	O
.	O
CRP	O
due	O
to	O
VF	O
.	O
Graft	O
vascular	O
disease	O
in	O
heart	O
transplant	O
patients	O
.	O
Proximal	O
DC	O
thrombotic	O
occlusion	O
.	O
Death	O
.	O
Previous	O
Sarcoidosis	O
with	O
pulmonary	O
and	O
cardiac	O
involvement	O
,	O
on	O
corticosteroid	O
treatment	O
.	O
Infiltrative	O
cardiomyopathy	O
in	O
dilated	O
phase	O
due	O
to	O
sarcoidosis	O
,	O
with	O
severe	O
systolic	O
dysfunction	O
,	O
ACC	O
AHA	O
stage	O
D	O
CHF	O
.	O
Multiple	O
infectious	O
complications	O
probably	O
related	O
to	O
immunosuppressive	O
treatment	O
.	O
Acute	O
tricuspid	O
infective	O
endocarditis	O
.	O
Cardiac	O
transplant	O
.	O
Acute	O
rejection	O
resolved	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
No	O
known	O
drug	O
allergies	O
.	O
Long	O
standing	O
high	O
blood	O
pressure	O
,	O
although	O
in	O
recent	O
years	O
her	O
medication	O
has	O
had	O
to	O
be	O
reduced	O
and	O
is	O
currently	O
controlled	O
only	O
with	O
dietary	O
measures	O
.	O
Diabetes	O
mellitus	O
type	O
2	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
.	O
Mild	O
chronic	O
kidney	O
disease	O
with	O
a	O
baseline	O
glomerular	O
filtration	O
rate	O
of	O
around	O
48	O
ml	O
min	O
.	O
Hepatitis	O
C	O
.	O
Under	O
digestive	O
follow	O
up	O
for	O
hiatus	O
hernia	O
and	O
history	O
of	O
duodenal	O
ulcer	O
.	O
Lumbar	O
canal	O
stenosis	O
.	O
Surgical	O
history	O
right	O
knee	O
prosthesis	O
and	O
bilateral	O
carpal	O
tunnel	O
surgery	O
.	O
Usual	O
treatment	O
acenocoumarol	B-FARMACO
for	O
INR	O
2	O
3	O
,	O
metformin	B-FARMACO
875	O
mg	O
every	O
12	O
hours	O
,	O
paracetamol	B-FARMACO
1	O
g	O
every	O
8	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
daily	O
and	O
lorazepam	B-FARMACO
1	O
mg	O
before	O
bedtime	O
.	O
CURRENT	O
ILLNESS	O
The	O
patient	O
is	O
an	O
85	O
year	O
old	O
woman	O
with	O
symptoms	O
of	O
biventricular	O
heart	O
failure	O
,	O
reporting	O
dyspnoea	O
and	O
orthopnoea	O
as	O
well	O
as	O
oedema	O
of	O
progressive	O
intensity	O
in	O
the	O
last	O
month	O
.	O
She	O
also	O
refers	O
cough	O
with	O
greenish	O
expectoration	O
and	O
fever	O
peaks	O
in	O
the	O
last	O
3	O
days	O
,	O
for	O
which	O
her	O
primary	O
care	O
physician	O
has	O
prescribed	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
for	O
7	O
days	O
.	O
The	O
patient	O
also	O
reports	O
abdominal	O
distension	O
and	O
a	O
burning	O
sensation	O
after	O
meals	O
more	O
intense	O
in	O
the	O
last	O
few	O
weeks	O
,	O
facial	O
pain	O
,	O
especially	O
when	O
eating	O
,	O
and	O
pain	O
in	O
both	O
knees	O
with	O
a	O
mechanical	O
profile	O
.	O
PHYSICAL	O
EXAMINATION	O
Vital	O
signs	O
blood	O
pressure	O
116	O
69	O
mmHg	O
,	O
oxygen	O
saturation	O
95	O
with	O
nasal	O
goggles	O
at	O
2	O
l	O
min	O
,	O
temperature	O
36	O
.	O
8	O
C	O
.	O
Usual	O
weight	O
48	O
kg	O
,	O
height	O
1	O
.	O
50	O
m	O
,	O
body	O
surface	O
1	O
.	O
41	O
m2	O
.	O
Weight	O
on	O
admission	O
60	O
kg	O
.	O
Neck	O
increased	O
jugular	O
venous	O
pressure	O
with	O
hepatojugular	O
reflux	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
and	O
systolic	O
murmur	O
III	O
VI	O
in	O
aortic	O
focus	O
that	O
does	O
not	O
clear	O
the	O
second	O
tone	O
.	O
Pulmonary	O
auscultation	O
crackles	O
up	O
to	O
midfield	O
and	O
abolition	O
of	O
vesicular	O
murmur	O
in	O
both	O
bases	O
.	O
Abdomen	O
increased	O
abdominal	O
perimeter	O
with	O
no	O
evidence	O
of	O
peritoneal	O
irritation	O
.	O
Lower	O
extremities	O
oedema	O
in	O
both	O
lower	O
limbs	O
up	O
to	O
the	O
groin	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
creatinine	O
1	O
.	O
2	O
mg	O
dl	O
estimated	O
GFR	O
32	O
ml	O
min	O
,	O
potassium	O
4	O
.	O
5	O
mEq	O
l	O
,	O
sodium	O
132	O
mEq	O
l	O
,	O
BNP	O
1	O
,	O
890	O
pg	O
ml	O
,	O
leukocytes	O
12	O
,	O
220	O
μl	O
,	O
haemoglobin	O
12	O
.	O
3	O
g	O
dl	O
,	O
platelets	O
210	O
,	O
000	O
μl	O
,	O
INR	O
2	O
.	O
8	O
.	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
.	O
QRS	O
of	O
120	O
ms	O
with	O
normal	O
axis	O
.	O
Low	O
voltages	O
in	O
limb	O
leads	O
.	O
Millimetric	O
negative	O
T	O
wave	O
in	O
V5	O
V6	O
.	O
Echocardiography	O
Cavities	O
non	O
dilated	O
left	O
ventricle	O
of	O
small	O
cavity	O
with	O
severe	O
concentric	O
hypertrophy	O
.	O
Mild	O
moderate	O
right	O
ventricular	O
hypertrophy	O
.	O
Valves	O
Mild	O
mitral	O
and	O
tricuspid	O
insufficiency	O
.	O
Moderate	O
pulmonary	O
hypertension	O
40	O
45	O
mmHg	O
estimated	O
systolic	O
pulmonary	O
pressure	O
.	O
Moderate	O
severe	O
aortic	O
stenosis	O
.	O
Valvular	O
area	O
by	O
continuity	O
equation	O
is	O
0	O
.	O
97	O
cm2	O
,	O
with	O
a	O
mean	O
gradient	O
of	O
30	O
mmHg	O
and	O
peak	O
of	O
47	O
mmHg	O
.	O
Diastolic	O
function	O
restrictive	O
mitral	O
filling	O
.	O
Clear	O
increase	O
in	O
filling	O
pressures	O
.	O
Other	O
bilateral	O
pleural	O
effusion	O
and	O
mild	O
pericardial	O
effusion	O
,	O
predominantly	O
at	O
the	O
right	O
retroatrial	O
level	O
.	O
The	O
study	O
was	O
completed	O
with	O
a	O
longitudinal	O
deformation	O
analysis	O
.	O
99mTc	O
DPD	O
scan	O
moderate	O
uptake	O
of	O
the	O
radiomarker	O
at	O
cardiac	O
level	O
,	O
diffuse	O
and	O
biventricular	O
.	O
Cardiac	O
magnetic	O
resonance	O
images	O
corresponding	O
to	O
late	O
enhancement	O
sequences	O
and	O
extracellular	O
volume	O
mapping	O
are	O
attached	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
intravenous	O
treatment	O
with	O
diuretics	O
,	O
a	O
weight	O
reduction	O
of	O
10	O
kg	O
was	O
achieved	O
with	O
marked	O
improvement	O
in	O
the	O
patient	O
's	O
clinical	O
condition	O
and	O
oedema	O
.	O
Self	O
limited	O
episode	O
of	O
paroxysmal	O
atrial	O
fibrillation	O
at	O
100	O
110	O
bpm	O
during	O
admission	O
.	O
Once	O
again	O
in	O
sinus	O
rhythm	O
and	O
with	O
a	O
good	O
response	O
to	O
oral	O
diuretics	O
,	O
she	O
was	O
discharged	O
with	O
oral	O
furosemide	B-FARMACO
80	O
mg	O
per	O
day	O
in	O
addition	O
to	O
her	O
usual	O
treatment	O
,	O
to	O
continue	O
studies	O
and	O
outpatient	O
treatment	O
.	O
However	O
,	O
3	O
days	O
later	O
,	O
the	O
patient	O
returned	O
to	O
the	O
emergency	O
department	O
for	O
syncope	O
with	O
mild	O
cranioencephalic	O
trauma	O
on	O
getting	O
out	O
of	O
bed	O
.	O
She	O
did	O
not	O
recall	O
any	O
prodromal	O
symptoms	O
,	O
but	O
reported	O
increased	O
asthenia	O
in	O
the	O
last	O
few	O
days	O
.	O
After	O
ECG	O
monitoring	O
for	O
24	O
hours	O
and	O
reduction	O
of	O
furosemide	B-FARMACO
treatment	O
to	O
40	O
mg	O
per	O
day	O
,	O
the	O
patient	O
was	O
discharged	O
with	O
clinical	O
improvement	O
.	O
She	O
is	O
currently	O
under	O
clinical	O
follow	O
up	O
,	O
with	O
persistent	O
joint	O
pain	O
and	O
abdominal	O
discomfort	O
,	O
although	O
with	O
a	O
significant	O
improvement	O
in	O
the	O
semiology	O
of	O
heart	O
failure	O
.	O
DIAGNOSIS	O
Heart	O
failure	O
with	O
preserved	O
systolic	O
function	O
.	O
Respiratory	O
infection	O
as	O
a	O
probable	O
trigger	O
for	O
exacerbation	O
.	O
Transthyretin	O
amyloidosis	O
with	O
cardiac	O
involvement	O
.	O
Moderate	O
severe	O
aortic	O
stenosis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
77	O
year	O
old	O
woman	O
,	O
allergic	O
to	O
propifenazone	O
,	O
with	O
a	O
history	O
of	O
arterial	O
hypertension	O
for	O
more	O
than	O
20	O
years	O
and	O
dyslipidaemia	O
,	O
both	O
under	O
medical	O
treatment	O
with	O
good	O
control	O
.	O
No	O
other	O
cardiovascular	O
risk	O
factors	O
.	O
Cardiological	O
history	O
Diagnosed	O
with	O
persistent	O
atrial	O
fibrillation	O
in	O
October	O
2011	O
,	O
with	O
mild	O
hypertensive	O
heart	O
disease	O
left	O
ventricle	O
LV	O
of	O
normal	O
size	O
,	O
slightly	O
hypertrophic	O
,	O
normal	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
with	O
moderately	O
dilated	O
left	O
atrium	O
LA	O
on	O
transthoracic	O
echocardiography	O
TTE	O
,	O
which	O
required	O
pharmacological	O
cardioversion	O
in	O
March	O
2012	O
and	O
pulmonary	O
vein	O
ablation	O
in	O
October	O
2012	O
.	O
He	O
initially	O
remained	O
in	O
sinus	O
rhythm	O
under	O
antiarrhythmic	O
treatment	O
with	O
flecainide	O
50	O
mg	O
,	O
half	O
a	O
tablet	O
every	O
12	O
hours	O
,	O
which	O
was	O
discontinued	O
in	O
October	O
2013	O
,	O
and	O
anticoagulation	O
with	O
dabigatran	B-FARMACO
150	O
mg	O
every	O
12	O
hours	O
.	O
He	O
subsequently	O
presented	O
arrhythmic	O
recurrence	O
in	O
the	O
form	O
of	O
atrial	O
fibrillation	O
and	O
left	O
flutter	O
in	O
early	O
June	O
2014	O
,	O
which	O
required	O
reablation	O
of	O
the	O
left	O
atrial	O
substrate	O
,	O
atrial	O
roof	O
line	O
and	O
mitral	O
isthmus	O
.	O
Recurrence	O
of	O
left	O
flutter	O
at	O
the	O
end	O
of	O
June	O
2014	O
,	O
which	O
required	O
new	O
electrical	O
cardioversion	O
in	O
the	O
same	O
month	O
.	O
On	O
admission	O
,	O
antiarrhythmic	O
treatment	O
was	O
started	O
with	O
a	O
loading	O
dose	O
of	O
intravenous	O
amiodarone	B-FARMACO
with	O
facial	O
flushing	O
and	O
discomfort	O
,	O
so	O
the	O
infusion	O
was	O
stopped	O
and	O
outpatient	O
management	O
with	O
oral	O
flecainide	B-FARMACO
100	O
mg	O
,	O
half	O
a	O
tablet	O
every	O
12	O
hours	O
and	O
atenolol	B-FARMACO
50	O
mg	O
,	O
one	O
and	O
a	O
half	O
tablets	O
every	O
24	O
hours	O
was	O
decided	O
.	O
She	O
was	O
reviewed	O
in	O
February	O
2015	O
for	O
an	O
episode	O
of	O
clumsiness	O
in	O
the	O
right	O
leg	O
that	O
temporarily	O
coincided	O
with	O
arrhythmic	O
recurrence	O
in	O
the	O
form	O
of	O
atrial	O
fibrillation	O
.	O
In	O
view	O
of	O
this	O
situation	O
,	O
a	O
referral	O
to	O
neurology	O
was	O
requested	O
and	O
a	O
diagnosis	O
of	O
transient	O
ischaemic	O
attack	O
was	O
made	O
following	O
a	O
cranial	O
MRI	O
in	O
which	O
acute	O
subacute	O
ischaemic	O
lesions	O
were	O
ruled	O
out	O
.	O
Since	O
then	O
,	O
amiodarone	B-FARMACO
200	O
mg	O
every	O
8	O
hours	O
was	O
started	O
as	O
a	O
loading	O
dose	O
for	O
a	O
week	O
and	O
then	O
200	O
mg	O
every	O
24	O
hours	O
.	O
Since	O
then	O
in	O
sinus	O
rhythm	O
.	O
In	O
August	O
2015	O
antiacogulation	O
is	O
changed	O
from	O
dabigatran	B-FARMACO
150	O
mg	O
every	O
12	O
hours	O
to	O
rivaroxaban	B-FARMACO
15	O
mg	O
,	O
every	O
24	O
hours	O
due	O
to	O
worsening	O
renal	O
function	O
.	O
Other	O
relevant	O
background	O
information	O
On	O
the	O
other	O
hand	O
,	O
in	O
January	O
2016	O
,	O
there	O
were	O
episodes	O
of	O
copious	O
and	O
recurrent	O
anterior	O
epistaxis	O
with	O
significant	O
anaemisation	O
,	O
despite	O
the	O
treatment	O
applied	O
by	O
the	O
otorhinolaryngology	O
department	O
cauterisation	O
with	O
silver	B-FARMACO
nitrate	I-FARMACO
and	O
placement	O
of	O
spogostan	O
and	O
bactroban	O
film	O
.	O
In	O
view	O
of	O
this	O
situation	O
,	O
percutaneous	O
closure	O
of	O
the	O
left	O
atrial	O
appendage	O
was	O
decided	O
in	O
February	O
2016	O
with	O
a	O
28	O
mm	O
Amulet	O
device	O
.	O
Treatment	O
was	O
started	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
and	O
clopidogrel	B-FARMACO
75	O
mg	O
every	O
24	O
hours	O
and	O
anti	O
clotting	O
agents	O
were	O
discontinued	O
.	O
In	O
April	O
2016	O
,	O
double	O
antiplatelet	O
therapy	O
was	O
discontinued	O
and	O
single	O
antiplatelet	O
therapy	O
was	O
maintained	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
,	O
every	O
24	O
hours	O
.	O
Medical	O
treatment	O
Amiodarone	B-FARMACO
200	O
mg	O
1	O
tablet	O
at	O
breakfast	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
1	O
tablet	O
at	O
lunch	O
and	O
valsartan	B-FARMACO
50	O
mg	O
1	O
tablet	O
at	O
breakfast	O
.	O
CURRENT	O
ILLNESS	O
Asymptomatic	O
for	O
dyspnoea	O
,	O
palpitations	O
and	O
chest	O
pain	O
until	O
August	O
2018	O
,	O
at	O
which	O
time	O
she	O
attended	O
the	O
emergency	O
department	O
reporting	O
progressive	O
exertional	O
dyspnoea	O
and	O
dry	O
cough	O
,	O
which	O
prevented	O
her	O
from	O
carrying	O
out	O
her	O
daily	O
activities	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
150	O
90	O
mmHg	O
,	O
heart	O
rate	O
HR	O
65	O
bpm	O
,	O
SatO2	O
92	O
,	O
temperature	O
37	O
.	O
5	O
C	O
.	O
Acceptable	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
in	O
the	O
three	O
spheres	O
.	O
Normal	O
colour	O
,	O
normohydrated	O
and	O
normoperfused	O
.	O
Carotids	O
rhythmic	O
and	O
symmetrical	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
without	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
vesicular	O
murmur	O
abolished	O
in	O
lung	O
bases	O
with	O
dry	O
crackles	O
up	O
to	O
midfields	O
.	O
Abdomen	O
hydro	O
aerial	O
sounds	O
present	O
,	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
deep	O
palpation	O
.	O
No	O
masses	O
or	O
megaliths	O
.	O
Lower	O
extremities	O
No	O
oedema	O
.	O
Peripheral	O
pulses	O
present	O
.	O
No	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
glucose	O
88	O
mg	O
d	O
,	O
urea	O
44	O
mg	O
dl	O
,	O
Cr	O
1	O
.	O
2	O
mg	O
dl	O
,	O
MDRD	O
46	O
ml	O
min	O
1	O
.	O
73m2	O
,	O
Na	O
142	O
mEq	O
l	O
,	O
K	O
4	O
.	O
4	O
mEq	O
l	O
,	O
Cl	O
104	O
mEq	O
l	O
,	O
CO2	O
23	O
mEq	O
l	O
,	O
GOT	O
16	O
IU	O
l	O
,	O
GPT	O
10	O
IU	O
l	O
,	O
gamma	O
glutamyltransferase	O
8	O
IU	O
l	O
,	O
alkaline	O
phosphatase	O
110	O
IU	O
l	O
,	O
LDH	O
410	O
IU	O
l	O
,	O
total	O
bilirubin	O
0	O
.	O
76	O
mg	O
dl	O
,	O
TSH	O
0	O
.	O
74	O
μU	O
ml	O
,	O
C	O
reactive	O
protein	O
5	O
.	O
31	O
mg	O
dl	O
,	O
procalcitonin	O
0	O
.	O
068	O
ng	O
ml	O
,	O
proBNP	O
320	O
pg	O
ml	O
,	O
Hb	O
11	O
.	O
9	O
mg	O
dl	O
,	O
Hto	O
.	O
37	O
.	O
37	O
,	O
MCV	O
84	O
.	O
9	O
fl	O
,	O
platelets	O
462	O
109	O
l	O
,	O
leukocytes	O
11	O
.	O
6	O
109	O
l	O
,	O
neutrophils	O
8	O
.	O
31	O
109	O
l	O
.	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
.	O
Left	O
axis	O
.	O
Left	O
anterior	O
hemiblock	O
.	O
Posteroanterior	O
and	O
lateral	O
chest	O
X	O
ray	O
atheromatosis	O
of	O
the	O
aortic	O
arch	O
.	O
Aortic	O
elongation	O
.	O
Borderline	O
cardiothoracic	O
index	O
with	O
percutaneous	O
left	O
atrial	O
appendage	O
closure	O
device	O
.	O
Areas	O
of	O
bibasal	O
consolidation	O
with	O
interstitial	O
pattern	O
up	O
to	O
midfields	O
and	O
mild	O
bilateral	O
pleural	O
effusion	O
.	O
Rest	O
of	O
lung	O
parenchyma	O
with	O
acceptable	O
aeration	O
.	O
TTE	O
08	O
18	O
left	O
ventricle	O
slightly	O
dilated	O
,	O
mild	O
hypertrophy	O
and	O
normal	O
systolic	O
function	O
.	O
Ejection	O
fraction	O
62	O
.	O
No	O
regional	O
contractility	O
abnormalities	O
.	O
Pseudonormal	O
filling	O
pattern	O
,	O
high	O
filling	O
pressures	O
E	O
E	O
19	O
.	O
Right	O
ventricle	O
with	O
normal	O
morphology	O
and	O
systolic	O
function	O
.	O
Severe	O
left	O
atrial	O
dilatation	O
.	O
Minimal	O
mitral	O
and	O
aortic	O
regurgitation	O
.	O
Minimal	O
tricuspid	O
insufficiency	O
that	O
allows	O
estimating	O
a	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAPs	O
within	O
the	O
normal	O
range	O
.	O
No	O
signs	O
of	O
pericardial	O
pathology	O
.	O
Vena	O
cava	O
of	O
normal	O
calibre	O
collapsing	O
with	O
inspiration	O
.	O
Atrial	O
appendage	O
closure	O
device	O
.	O
Chest	O
computed	O
tomography	O
CT	O
08	O
18	O
pulmonary	O
involvement	O
characterised	O
by	O
areas	O
of	O
pulmonary	O
consolidation	O
with	O
alveolar	O
pattern	O
and	O
air	O
bronchogram	O
predominantly	O
peripheral	O
and	O
in	O
lower	O
lobes	O
,	O
patchy	O
foci	O
of	O
ground	O
glass	O
and	O
small	O
nodular	O
opacities	O
.	O
It	O
is	O
associated	O
with	O
a	O
peripheral	O
coarse	O
reticular	O
interstitial	O
pattern	O
and	O
traction	O
bronchiectasis	O
,	O
suggestive	O
of	O
chronicity	O
.	O
Compatible	O
with	O
cryptogenic	O
organised	O
pneumonia	O
.	O
No	O
pleural	O
effusion	O
is	O
observed	O
.	O
Left	O
atrial	O
appendage	O
closure	O
device	O
.	O
Main	O
trunk	O
of	O
pulmonary	O
artery	O
of	O
29	O
mm	O
,	O
at	O
the	O
high	O
limit	O
of	O
normality	O
.	O
Multinodular	O
goitre	O
at	O
the	O
expense	O
of	O
the	O
left	O
lobe	O
,	O
partially	O
endothoracic	O
,	O
with	O
the	O
largest	O
nodule	O
measuring	O
20	O
mm	O
in	O
the	O
left	O
thyroid	O
lobe	O
.	O
Diffuse	O
increased	O
attenuation	O
of	O
the	O
liver	O
parenchyma	O
study	O
without	O
contrast	O
.	O
Bronchoscopy	O
normal	O
.	O
Bronchoalveolar	O
lavage	O
with	O
predominantly	O
neutrophilic	O
phenotype	O
,	O
no	O
microbiological	O
isolates	O
and	O
pathological	O
anatomy	O
with	O
fatty	O
macrophages	O
.	O
Respiratory	O
function	O
tests	O
08	O
18	O
mild	O
restrictive	O
ventilatory	O
abnormality	O
.	O
Severe	O
decrease	O
in	O
diffusing	O
capacity	O
.	O
6	O
minute	O
walk	O
test	O
08	O
18	O
Respiratory	O
function	O
tests	O
after	O
corticosteroid	O
treatment	O
09	O
18	O
normal	O
respiratory	O
function	O
tests	O
.	O
Isolated	O
moderate	O
decrease	O
in	O
diffusing	O
capacity	O
.	O
Improvement	O
of	O
3	O
ml	O
mmHG	O
min	O
in	O
diffusing	O
capacity	O
compared	O
to	O
previous	O
tests	O
.	O
6	O
minute	O
walk	O
test	O
after	O
corticosteroid	O
treatment	O
09	O
18	O
Chest	O
CT	O
scan	O
10	O
18	O
persistent	O
peripheral	O
pattern	O
of	O
predominance	O
in	O
bases	O
,	O
interstitial	O
,	O
ground	O
glass	O
and	O
with	O
thickening	O
of	O
interlobar	O
septa	O
,	O
which	O
shows	O
a	O
clear	O
improvement	O
compared	O
to	O
the	O
August	O
scan	O
,	O
with	O
almost	O
complete	O
disappearance	O
of	O
the	O
areas	O
of	O
consolidation	O
.	O
Nodular	O
goitre	O
predominantly	O
on	O
the	O
left	O
with	O
some	O
endothoracic	O
component	O
.	O
Left	O
atrial	O
closure	O
device	O
.	O
Dilatation	O
of	O
the	O
left	O
atrium	O
.	O
No	O
pleural	O
or	O
pericardial	O
effusion	O
was	O
observed	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
view	O
of	O
the	O
elevated	O
inflammatory	O
parameters	O
and	O
the	O
radiological	O
pulmonary	O
alterations	O
areas	O
of	O
bibasal	O
consolidation	O
and	O
bilateral	O
pleural	O
effusion	O
,	O
it	O
was	O
decided	O
to	O
admit	O
the	O
patient	O
to	O
the	O
cardiology	O
ward	O
for	O
aetiological	O
study	O
and	O
treatment	O
.	O
Due	O
to	O
increased	O
inflammatory	O
parameters	O
,	O
it	O
was	O
decided	O
to	O
administer	O
intravenous	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
1	O
,	O
000	O
mg	O
every	O
8	O
hours	O
and	O
oral	O
azithromycin	B-FARMACO
500	O
mg	O
every	O
24	O
hours	O
for	O
three	O
days	O
.	O
In	O
addition	O
,	O
despite	O
no	O
clinical	O
signs	O
of	O
systemic	O
congestion	O
,	O
given	O
the	O
mildly	O
elevated	O
pro	O
BNP	O
and	O
the	O
possible	O
association	O
of	O
incipient	O
heart	O
failure	O
in	O
the	O
context	O
of	O
primary	O
pulmonary	O
pathology	O
,	O
intravenous	O
furosemide	B-FARMACO
was	O
added	O
as	O
part	O
of	O
the	O
initial	O
treatment	O
.	O
Amiodarone	B-FARMACO
was	O
also	O
suspended	O
due	O
to	O
suspicion	O
of	O
pulmonary	O
toxicity	O
until	O
the	O
aetiology	O
of	O
the	O
pulmonary	O
involvement	O
and	O
its	O
evolution	O
were	O
known	O
.	O
During	O
the	O
first	O
48	O
hours	O
,	O
there	O
was	O
no	O
improvement	O
in	O
her	O
clinical	O
condition	O
,	O
and	O
a	O
thoracic	O
CT	O
scan	O
was	O
completed	O
,	O
which	O
showed	O
a	O
pulmonary	O
pattern	O
compatible	O
with	O
cryptogenic	O
organised	O
pneumonia	O
with	O
fibrotic	O
changes	O
of	O
chronic	O
profile	O
.	O
The	O
patient	O
was	O
assessed	O
by	O
pulmonology	O
during	O
admission	O
and	O
studies	O
of	O
interstitial	O
lung	O
disease	O
were	O
completed	O
.	O
Respiratory	O
function	O
tests	O
showed	O
a	O
mild	O
restrictive	O
ventilatory	O
abnormality	O
,	O
and	O
a	O
severe	O
decrease	O
in	O
diffusing	O
capacity	O
,	O
with	O
a	O
6	O
minute	O
walk	O
test	O
with	O
desaturation	O
of	O
up	O
to	O
83	O
84	O
over	O
a	O
maximum	O
distance	O
covered	O
of	O
390m	O
.	O
They	O
also	O
performed	O
a	O
bronchoscopy	O
which	O
revealed	O
no	O
pathological	O
findings	O
,	O
with	O
bronchoalveolar	O
lavage	O
showing	O
a	O
predominantly	O
neutrophilic	O
phenotype	O
,	O
no	O
microbiological	O
isolates	O
and	O
pathological	O
anatomy	O
with	O
fatty	O
macrophages	O
.	O
With	O
the	O
diagnosis	O
of	O
cryptogenic	O
organised	O
pneumonia	O
probably	O
related	O
to	O
amiodarone	B-FARMACO
suspended	O
on	O
admission	O
,	O
corticosteroid	O
treatment	O
with	O
intravenous	O
methylprednisolone	B-FARMACO
40	O
mg	O
24	O
hours	O
was	O
started	O
during	O
admission	O
.	O
Prior	O
to	O
discharge	O
,	O
a	O
thyroid	O
ultrasound	O
was	O
requested	O
,	O
which	O
showed	O
multiple	O
benign	O
nodules	O
with	O
normal	O
thyroid	O
function	O
.	O
She	O
was	O
discharged	O
after	O
7	O
days	O
of	O
admission	O
,	O
with	O
partial	O
improvement	O
of	O
her	O
respiratory	O
symptoms	O
with	O
outpatient	O
steroid	O
treatment	O
oral	O
methylprednisolone	B-FARMACO
,	O
40	O
mg	O
until	O
further	O
review	O
in	O
one	O
month	O
.	O
The	O
rest	O
of	O
the	O
treatment	O
at	O
discharge	O
was	O
as	O
follows	O
pantoprazole	B-FARMACO
40	O
mg	O
at	O
breakfast	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
at	O
lunch	O
,	O
valsartan	B-FARMACO
80	O
mg	O
at	O
dinner	O
and	O
calcium	B-FARMACO
and	O
vitamin	B-FARMACO
D3	I-FARMACO
1250	O
mg	O
at	O
breakfast	O
.	O
She	O
came	O
for	O
a	O
check	O
up	O
at	O
the	O
end	O
of	O
September	O
2018	O
,	O
reporting	O
a	O
clear	O
improvement	O
in	O
respiratory	O
function	O
.	O
Complete	O
respiratory	O
function	O
tests	O
were	O
repeated	O
,	O
showing	O
an	O
improvement	O
in	O
respiratory	O
function	O
normal	O
function	O
,	O
with	O
an	O
improvement	O
in	O
diffusion	O
capacity	O
of	O
3	O
ml	O
mmHg	O
with	O
respect	O
to	O
the	O
previous	O
test	O
and	O
in	O
the	O
6	O
minute	O
walk	O
test	O
in	O
which	O
she	O
was	O
able	O
to	O
complete	O
445	O
metres	O
.	O
A	O
chest	O
CT	O
scan	O
was	O
performed	O
in	O
October	O
2018	O
in	O
which	O
a	O
peripheral	O
interstitial	O
pattern	O
persisted	O
,	O
predominantly	O
basal	O
,	O
in	O
ground	O
glass	O
,	O
with	O
thickening	O
of	O
the	O
interlobar	O
septa	O
,	O
although	O
with	O
a	O
clear	O
improvement	O
compared	O
to	O
the	O
previous	O
CT	O
scan	O
,	O
with	O
almost	O
complete	O
disappearance	O
of	O
the	O
areas	O
of	O
consolidation	O
.	O
DIAGNOSIS	O
Interstitial	O
pneumonitis	O
probably	O
secondary	O
to	O
pharmacological	O
toxicity	O
due	O
to	O
amiodarone	B-FARMACO
.	O
Hypertensive	O
heart	O
disease	O
with	O
normal	O
ventricular	O
function	O
,	O
without	O
signs	O
of	O
heart	O
failure	O
.	O
Systemic	O
arterial	O
hypertension	O
with	O
good	O
pharmacological	O
control	O
.	O
Persistent	O
atrial	O
fibrillation	O
treated	O
by	O
ablation	O
in	O
2012	O
and	O
2014	O
.	O
Arrhythmic	O
recurrence	O
with	O
low	O
afterload	O
.	O
Currently	O
in	O
sinus	O
rhythm	O
.	O
History	O
of	O
recurrent	O
epistaxis	O
under	O
treatment	O
with	O
oral	O
anticoagulation	O
.	O
Carrier	O
of	O
Amulet	O
28	O
mm	O
atrial	O
appendage	O
closure	O
device	O
and	O
on	O
treatment	O
with	O
simple	O
antiplatelet	O
therapy	O
.	O
Benign	O
thyroid	O
nodules	O
without	O
alterations	O
in	O
thyroid	O
function	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
Male	O
patient	O
aged	O
77	O
years	O
.	O
No	O
known	O
allergic	O
reactions	O
to	O
medication	O
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
,	O
dyslipidaemia	O
.	O
Chronic	O
obstructive	O
pulmonary	O
disease	O
COPD	O
secondary	O
to	O
bilateral	O
calcific	O
pachypleuritis	O
flour	O
factory	O
worker	O
,	O
with	O
no	O
need	O
for	O
home	O
oxygen	O
therapy	O
.	O
Mild	O
cor	O
pulmonale	O
.	O
Ischaemic	O
stroke	O
in	O
the	O
territory	O
of	O
the	O
left	O
middle	O
cerebral	O
artery	O
in	O
November	O
2016	O
.	O
Stage	O
3A	O
chronic	O
kidney	O
disease	O
.	O
Spinal	O
canal	O
stenosis	O
,	O
right	O
hip	O
prosthesis	O
.	O
Usual	O
treatment	O
Rabeprazole	B-FARMACO
20	O
mg	O
every	O
24	O
hours	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
24	O
hours	O
,	O
diosmin	B-FARMACO
500	O
mg	O
every	O
12	O
hours	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
300	O
mg	O
every	O
24	O
hours	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
every	O
24	O
hours	O
,	O
enalapril	B-FARMACO
5	O
mg	O
every	O
24	O
hours	O
,	O
glycopyrronium	B-FARMACO
bromide	I-FARMACO
44	O
mcg	O
1	O
inhalation	O
every	O
24	O
hours	O
,	O
vilanterol	B-FARMACO
fluticasone	I-FARMACO
22	O
92	O
mcg	O
1	O
inhalation	O
every	O
24	O
hours	O
.	O
CURRENT	O
ILLNESS	O
The	O
patient	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
an	O
increase	O
in	O
dry	O
cough	O
with	O
no	O
change	O
in	O
the	O
usual	O
sputum	O
for	O
the	O
past	O
week	O
.	O
He	O
also	O
presented	O
with	O
a	O
progressive	O
increase	O
in	O
his	O
baseline	O
dyspnoea	O
to	O
the	O
point	O
of	O
minimal	O
effort	O
.	O
Since	O
two	O
days	O
before	O
,	O
he	O
presented	O
fever	O
up	O
to	O
38	O
.	O
4	O
oC	O
,	O
without	O
chills	O
.	O
PHYSICAL	O
EXAMINATION	O
Temperature	O
36	O
C	O
.	O
Blood	O
pressure	O
BP	O
159	O
83	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
70	O
bpm	O
;	O
SatO2	O
91	O
with	O
nasal	O
goggles	O
at	O
1	O
.	O
5	O
l	O
and	O
after	O
bronchodilators	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
with	O
crackles	O
in	O
both	O
bases	O
and	O
some	O
isolated	O
wheezing	O
.	O
Abdominal	O
examination	O
showed	O
no	O
palpable	O
organomegaly	O
,	O
hepatojugular	O
reflux	O
was	O
negative	O
and	O
there	O
was	O
no	O
semiology	O
of	O
ascites	O
.	O
The	O
lower	O
limbs	O
were	O
oedematous	O
up	O
to	O
the	O
middle	O
third	O
of	O
the	O
lower	O
extremities	O
,	O
with	O
fovea	O
.	O
COMPLEMENTARY	O
TESTS	O
Chest	O
X	O
ray	O
posteroanterior	O
and	O
lateral	O
projections	O
increased	O
cardiothoracic	O
index	O
.	O
Right	O
costophrenic	O
sinus	O
impingement	O
.	O
Pleural	O
and	O
probably	O
pericardial	O
plaques	O
.	O
Increased	O
bronchoalveolar	O
tract	O
.	O
CBC	O
leucocytes	O
8900	O
u	O
ml	O
,	O
haemoglobin	O
13	O
.	O
3	O
g	O
dl	O
,	O
platelets	O
145	O
.	O
000	O
u	O
l	O
,	O
ESR	O
28	O
mm	O
;	O
no	O
coagulation	O
alterations	O
,	O
basal	O
glucose	O
73	O
mg	O
dl	O
,	O
urea	O
83	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
3	O
mg	O
dl	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
MDRD	O
4	O
53	O
ml	O
min	O
1	O
.	O
73m2	O
,	O
total	O
bilirubin	O
0	O
.	O
6	O
mg	O
dl	O
,	O
GOT	O
18	O
UI	O
l	O
,	O
CPK	O
47	O
UI	O
l	O
,	O
Na	O
144	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
7	O
mmol	O
l	O
,	O
corrected	O
calcium	O
9	O
.	O
1	O
mg	O
dl	O
,	O
basal	O
TSH	O
1	O
.	O
34	O
mcU	O
ml	O
,	O
total	O
cholesterol	O
184	O
mg	O
dl	O
,	O
HDL	O
C	O
50	O
mg	O
dl	O
,	O
LDL	O
c	O
109	O
mg	O
dl	O
,	O
triglycerides	O
126	O
mg	O
dl	O
,	O
immunoglobulins	O
in	O
normal	O
range	O
.	O
Proteinogram	O
total	O
protein	O
6	O
.	O
60	O
g	O
dl	O
,	O
albumin	O
3	O
.	O
19	O
g	O
dl	O
48	O
.	O
3	O
;	O
B	O
globulins	O
10	O
.	O
2	O
,	O
gamma	O
globulins	O
21	O
.	O
8	O
;	O
serum	O
B2	O
microglobulin	O
5	O
.	O
19	O
ug	O
ml	O
,	O
ref	O
.	O
value	O
0	O
.	O
8	O
3	O
.	O
1	O
ug	O
ml	O
.	O
Serum	O
light	O
chains	O
Kappa	O
18	O
.	O
5	O
mg	O
dl	O
ref	O
.	O
value	O
3	O
.	O
3	O
19	O
.	O
4	O
mg	O
dl	O
,	O
Lambda	O
17	O
.	O
9	O
mg	O
dl	O
ref	O
.	O
value	O
5	O
.	O
7	O
26	O
.	O
3	O
.	O
Urine	O
light	O
chains	O
negative	O
,	O
amyloid	O
A	O
8	O
.	O
0	O
mg	O
l	O
ref	O
.	O
value	O
5	O
,	O
NT	O
Pro	O
BNP	O
11	O
,	O
562	O
pg	O
ml	O
ref	O
.	O
value	O
125	O
pg	O
ml	O
.	O
Electrocardiogram	O
ECG	O
during	O
admission	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
,	O
first	O
degree	O
atrioventricular	O
block	O
PR	O
245	O
ms	O
,	O
intraventricular	O
conduction	O
disturbance	O
QRS	O
105	O
ms	O
.	O
Posteroinferior	O
hemiblock	O
.	O
Image	O
of	O
pseudoinfarction	O
in	O
the	O
anterior	O
face	O
.	O
QTc	O
461	O
ms	O
.	O
Transthoracic	O
echocardiography	O
end	O
diastolic	O
volume	O
132	O
ml	O
,	O
end	O
systolic	O
volume	O
86	O
ml	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
35	O
by	O
Simpson	O
biplane	O
.	O
Left	O
ventricle	O
not	O
dilated	O
,	O
severely	O
hypertrophied	O
,	O
with	O
moderately	O
depressed	O
global	O
systolic	O
function	O
.	O
Generalised	O
hypokinesia	O
,	O
without	O
segmental	O
alterations	O
.	O
Septal	O
hyperrefringence	O
.	O
Restrictive	O
filling	O
pattern	O
.	O
Mild	O
mitral	O
insufficiency	O
of	O
central	O
origin	O
,	O
without	O
notable	O
alterations	O
in	O
the	O
aortic	O
valve	O
.	O
Dilated	O
left	O
atrium	O
48	O
mm	O
in	O
M	O
mode	O
.	O
End	O
diastolic	O
velocity	O
of	O
pulmonary	O
insufficiency	O
17	O
mmHg	O
,	O
allowing	O
calculation	O
of	O
a	O
diastolic	O
pulmonary	O
artery	O
pressure	O
PAP	O
of	O
27	O
mmHg	O
.	O
Slightly	O
dilated	O
right	O
ventricle	O
without	O
hypertrophy	O
with	O
preserved	O
systolic	O
function	O
.	O
Right	O
atrium	O
not	O
dilated	O
.	O
No	O
tricuspid	O
insufficiency	O
.	O
Pericardium	O
with	O
posterior	O
effusion	O
of	O
5	O
mm	O
.	O
Inferior	O
vena	O
cava	O
21	O
mm	O
,	O
with	O
respiratory	O
collapse	O
greater	O
than	O
50	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
right	O
atrium	O
63	O
x	O
54	O
mm	O
.	O
Right	O
ventricle	O
RV	O
94	O
x	O
51	O
x	O
69	O
mm	O
.	O
Left	O
atrium	O
69	O
x	O
56	O
mm	O
.	O
Left	O
Ventricle	O
LV	O
48	O
x	O
49	O
x	O
93	O
mm	O
.	O
Interatrial	O
Septum	O
8	O
mm	O
.	O
Minimal	O
circumferential	O
pericardial	O
fluid	O
tab	O
.	O
LVEF	O
35	O
.	O
Beat	O
volume	O
33	O
.	O
4	O
ml	O
m2	O
,	O
cardiac	O
output	O
5	O
.	O
1	O
l	O
min	O
;	O
end	O
diastolic	O
volume	O
EDV	O
96	O
.	O
6	O
ml	O
m2	O
,	O
end	O
systolic	O
volume	O
ESV	O
63	O
.	O
2	O
ml	O
m2	O
.	O
LV	O
wall	O
mass	O
155	O
.	O
6	O
g	O
m2	O
.	O
RV	O
ejection	O
fraction	O
27	O
;	O
LV	O
stroke	O
volume	O
57	O
.	O
2	O
ml	O
m2	O
;	O
cardiac	O
output	O
4	O
.	O
3	O
l	O
min	O
;	O
end	O
diastolic	O
volume	O
106	O
.	O
1	O
ml	O
m2	O
,	O
end	O
systolic	O
volume	O
77	O
.	O
5	O
ml	O
m2	O
.	O
LV	O
with	O
moderate	O
severe	O
concentric	O
hypertrophy	O
,	O
predominantly	O
septal	O
hypertrophy	O
,	O
with	O
wall	O
thickness	O
in	O
IVS	O
up	O
to	O
23	O
mm	O
,	O
anterolateral	O
segment	O
18	O
mm	O
and	O
inferior	O
segment	O
15	O
mm	O
at	O
baseline	O
.	O
Global	O
generalised	O
hypocontractility	O
,	O
more	O
accentuated	O
at	O
the	O
basal	O
level	O
of	O
the	O
RV	O
with	O
hypertrophy	O
up	O
to	O
6	O
7	O
mm	O
thick	O
.	O
After	O
intravenous	O
contrast	O
administration	O
,	O
diffuse	O
global	O
subendocardial	O
pathological	O
enhancement	O
is	O
observed	O
,	O
as	O
well	O
as	O
transmural	O
enhancement	O
in	O
septobasal	O
.	O
T1	O
values	O
mid	O
level	O
levels	O
of	O
1194	O
103	O
ms	O
in	O
the	O
lateral	O
aspect	O
showing	O
some	O
focal	O
areas	O
within	O
the	O
lateral	O
aspect	O
levels	O
of	O
up	O
to	O
1224	O
85	O
ms	O
,	O
ECV	O
48	O
.	O
1	O
in	O
the	O
lateral	O
aspect	O
and	O
up	O
to	O
54	O
.	O
7	O
in	O
focal	O
areas	O
of	O
the	O
lateral	O
aspect	O
.	O
Pyrophosphate	O
scintigraphy	O
increased	O
uptake	O
of	O
the	O
radiotracer	O
at	O
cardiac	O
level	O
,	O
more	O
intense	O
than	O
in	O
bone	O
structures	O
,	O
compatible	O
with	O
transthyretin	O
amyloidosis	O
Perugini	O
grade	O
3	O
.	O
Genetic	O
test	O
negative	O
result	O
for	O
genetic	O
variants	O
related	O
to	O
cardiac	O
amyloidosis	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
pulmonology	O
department	O
with	O
suspected	O
acute	O
COPD	O
.	O
During	O
his	O
admission	O
he	O
did	O
not	O
present	O
complete	O
symptomatic	O
resolution	O
and	O
a	O
chest	O
computed	O
tomography	O
CT	O
scan	O
was	O
requested	O
to	O
assess	O
the	O
progression	O
of	O
his	O
disease	O
.	O
This	O
test	O
showed	O
the	O
presence	O
of	O
pericardial	O
effusion	O
and	O
signs	O
of	O
heart	O
failure	O
,	O
so	O
transthoracic	O
echocardiography	O
was	O
performed	O
.	O
After	O
finding	O
an	O
echocardiographic	O
pattern	O
suggestive	O
of	O
cardiac	O
amyloidosis	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
cardiology	O
department	O
.	O
Cardio	O
MRI	O
was	O
requested	O
,	O
which	O
again	O
showed	O
a	O
pattern	O
compatible	O
with	O
cardiac	O
amyloidosis	O
.	O
In	O
addition	O
,	O
a	O
fat	O
biopsy	O
was	O
requested	O
the	O
patient	O
refused	O
a	O
rectal	O
biopsy	O
,	O
which	O
was	O
negative	O
,	O
a	O
48	O
hour	O
Holter	O
recording	O
with	O
no	O
alterations	O
,	O
a	O
proteinogram	O
and	O
detection	O
of	O
light	O
chains	O
in	O
serum	O
and	O
urine	O
,	O
which	O
was	O
negative	O
,	O
and	O
a	O
scintigraphy	O
with	O
technetium	O
99	O
diphosphonate	O
Tc99	O
DPN	O
with	O
intense	O
uptake	O
.	O
With	O
these	O
results	O
see	O
section	O
on	O
complementary	O
tests	O
the	O
patient	O
was	O
diagnosed	O
with	O
cardiac	O
amyloidosis	O
due	O
to	O
transthyretin	O
.	O
A	O
genetic	O
study	O
was	O
performed	O
which	O
did	O
not	O
detect	O
any	O
pathogenic	O
variants	O
and	O
the	O
diagnosis	O
was	O
therefore	O
made	O
as	O
senile	O
or	O
wild	O
type	O
.	O
The	O
patient	O
was	O
discharged	O
with	O
furosemide	B-FARMACO
80	O
mg	O
every	O
24	O
hours	O
and	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
12	O
hours	O
,	O
in	O
addition	O
to	O
his	O
usual	O
treatment	O
.	O
Spironolactone	B-FARMACO
and	O
renin	O
angiotensin	O
axis	O
antagonists	O
could	O
not	O
be	O
added	O
due	O
to	O
impaired	O
renal	O
function	O
and	O
hyperkalaemia	O
.	O
At	O
the	O
outpatient	O
level	O
,	O
the	O
patient	O
was	O
in	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
III	O
.	O
Treatment	O
of	O
systolic	O
dysfunction	O
was	O
optimised	O
by	O
adding	O
low	O
doses	O
of	O
sacubitril	O
valsartan	O
,	O
as	O
the	O
patient	O
reported	O
no	O
evidence	O
of	O
orthostatic	O
hypotension	O
or	O
other	O
manifestations	O
of	O
dysautonomia	O
.	O
On	O
subsequent	O
examinations	O
,	O
renal	O
function	O
remained	O
stable	O
,	O
as	O
well	O
as	O
blood	O
pressure	O
and	O
potassium	O
levels	O
,	O
so	O
he	O
was	O
maintained	O
on	O
sacubitrile	B-FARMACO
valsartan	I-FARMACO
24	O
26	O
m	O
12	O
hours	O
.	O
He	O
did	O
not	O
present	O
orthostatic	O
hypotension	O
and	O
finally	O
low	O
doses	O
of	O
eplerenone	B-FARMACO
every	O
48	O
hours	O
could	O
be	O
added	O
to	O
the	O
treatment	O
.	O
The	O
patient	O
reported	O
relative	O
clinical	O
improvement	O
,	O
as	O
well	O
as	O
a	O
decrease	O
in	O
NT	O
proBNP	O
levels	O
from	O
11	O
,	O
562	O
pg	O
ml	O
to	O
6	O
,	O
244	O
pg	O
ml	O
.	O
The	O
same	O
treatment	O
was	O
continued	O
and	O
to	O
date	O
the	O
patient	O
has	O
not	O
been	O
admitted	O
to	O
hospital	O
.	O
DIAGNOSIS	O
Heart	O
failure	O
with	O
depressed	O
LVEF	O
.	O
Cardiac	O
amyloidosis	O
due	O
to	O
transthyretin	O
,	O
senile	O
form	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
We	O
present	O
the	O
case	O
of	O
an	O
80	O
year	O
old	O
female	O
patient	O
,	O
autonomous	O
and	O
without	O
cognitive	O
impairment	O
.	O
She	O
had	O
a	O
history	O
of	O
hypertension	O
under	O
treatment	O
with	O
lisinopril	B-FARMACO
hydrochlorothiazide	I-FARMACO
20	O
12	O
.	O
5	O
mg	O
daily	O
;	O
type	O
2	O
diabetic	O
with	O
good	O
metabolic	O
control	O
and	O
without	O
micro	O
or	O
macrovascular	O
complications	O
under	O
treatment	O
with	O
metformin	B-FARMACO
1000	O
mg	O
sitagliptin	B-FARMACO
50	O
mg	O
at	O
breakfast	O
and	O
dinner	O
;	O
and	O
dyslipidaemia	O
under	O
treatment	O
with	O
simvastatin	B-FARMACO
20	O
mg	O
at	O
dinner	O
.	O
In	O
addition	O
,	O
he	O
has	O
stage	O
IV	O
colorectal	O
adenocarcinoma	O
with	O
lung	O
metastases	O
metastatic	O
debut	O
in	O
2015	O
on	O
third	O
line	O
treatment	O
with	O
binimetanib	B-FARMACO
and	O
nivolumab	B-FARMACO
since	O
September	O
2018	O
.	O
Current	O
history	O
She	O
consulted	O
the	O
ED	O
three	O
weeks	O
after	O
initiation	O
of	O
immunotherapy	O
for	O
progressive	O
picture	O
of	O
exertional	O
dyspnoea	O
and	O
two	O
pillow	O
orthopnoea	O
along	O
with	O
anorexia	O
,	O
asthenia	O
and	O
dizziness	O
.	O
He	O
denied	O
angina	O
,	O
syncope	O
,	O
as	O
well	O
as	O
infectious	O
focality	O
or	O
fever	O
.	O
He	O
also	O
reported	O
no	O
palpitations	O
or	O
other	O
typical	O
cardiological	O
symptoms	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
95	O
63	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
85	O
bpm	O
.	O
External	O
jugular	O
ingurgitation	O
in	O
the	O
middle	O
third	O
,	O
eupneic	O
in	O
decubitus	O
at	O
45	O
with	O
O2	O
saturation	O
94	O
ambient	O
air	O
.	O
Rhythmic	O
cardiac	O
auscultation	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
with	O
good	O
bilateral	O
ventilation	O
,	O
moist	O
crackles	O
in	O
the	O
bases	O
.	O
Oedema	O
with	O
bilateral	O
pretibial	O
fovea	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
on	O
arrival	O
at	O
the	O
emergency	O
department	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
,	O
normal	O
PR	O
.	O
Wide	O
QRS	O
of	O
120	O
ms	O
with	O
BRD	O
morphology	O
and	O
secondary	O
repolarisation	O
alterations	O
.	O
QTc	O
465ms	O
.	O
PA	O
and	O
lateral	O
chest	O
X	O
ray	O
on	O
admission	O
cardiothoracic	O
index	O
not	O
increased	O
,	O
bilateral	O
perihilar	O
thickening	O
with	O
vascular	O
redistribution	O
without	O
occupation	O
of	O
costophrenic	O
sinuses	O
.	O
Emergency	O
laboratory	O
tests	O
haemoglobin	O
9	O
.	O
9	O
g	O
dl	O
,	O
MCV	O
89	O
.	O
4	O
fl	O
,	O
leukocytes	O
5880	O
μl	O
with	O
normal	O
formula	O
,	O
platelets	O
132000	O
μl	O
.	O
INR	O
0	O
.	O
93	O
,	O
APTT	O
29	O
.	O
2	O
sec	O
.	O
Glucose	O
178	O
mg	O
dl	O
,	O
ALT	O
42	O
U	O
l	O
,	O
GGT	O
50	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
101	O
U	O
l	O
,	O
bilirubin	O
0	O
.	O
3	O
mg	O
dl	O
,	O
albumin	O
4	O
g	O
dl	O
,	O
creatinine	O
1	O
.	O
45	O
mg	O
dl	O
,	O
sodium	O
142	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
6	O
mmol	O
l	O
,	O
C	O
reactive	O
protein	O
7	O
.	O
8	O
mg	O
dl	O
,	O
CK	O
2423	O
U	O
l	O
,	O
ultrasensitive	O
troponin	O
I	O
640	O
.	O
4	O
ng	O
l	O
VN	O
21	O
ng	O
l	O
,	O
NT	O
proBNP	O
1509	O
ng	O
l	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophic	O
,	O
normofunctioning	O
with	O
hypokinesia	O
of	O
basal	O
and	O
medial	O
inferolateral	O
segments	O
.	O
Mitral	O
filling	O
pattern	O
with	O
impaired	O
relaxation	O
.	O
Non	O
dilated	O
left	O
atrium	O
.	O
Normal	O
right	O
chambers	O
.	O
Normal	O
mitral	O
valve	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
with	O
mild	O
sclerosis	O
and	O
slightly	O
elevated	O
gradients	O
peak	O
20	O
mmHg	O
.	O
No	O
evidence	O
of	O
pulmonary	O
hypertension	O
.	O
IVT	O
in	O
RV	O
outflow	O
tract	O
23	O
cm	O
normal	O
.	O
No	O
pericardial	O
effusion	O
.	O
Inferior	O
cava	O
not	O
dilated	O
,	O
physiologically	O
collapsed	O
.	O
Cardiac	O
MRI	O
with	O
contrast	O
left	O
ventricle	O
of	O
normal	O
size	O
,	O
with	O
slightly	O
increased	O
wall	O
thickness	O
.	O
No	O
alterations	O
of	O
segmental	O
contraction	O
.	O
Practical	O
systolic	O
collapse	O
of	O
the	O
distal	O
cavity	O
,	O
hyperdynamic	O
,	O
with	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
72	O
.	O
In	O
STIR	O
sequences	O
,	O
predominantly	O
mid	O
distal	O
signal	O
hyperintensity	O
.	O
Data	O
suggestive	O
of	O
diffuse	O
inflammation	O
in	O
T2	O
maps	O
.	O
Late	O
enhancement	O
without	O
alterations	O
.	O
Triceps	O
muscle	O
biopsy	O
H	O
E	O
shows	O
several	O
necrotic	O
fibres	O
with	O
myophagocytosis	O
and	O
scant	O
clustering	O
of	O
nuclei	O
.	O
The	O
HE	O
technique	O
identifies	O
a	O
slight	O
inflammatory	O
infiltrate	O
composed	O
mainly	O
of	O
histiocytes	O
.	O
Immunohistochemistry	O
revealed	O
CD68	O
positive	O
and	O
HLA	O
1	O
positive	O
patchy	O
HLA	O
1	O
predominantly	O
in	O
the	O
perifascicular	O
region	O
.	O
CD3	O
negative	O
.	O
Findings	O
globally	O
compatible	O
with	O
the	O
diagnosis	O
of	O
necrotising	O
inflammatory	O
myopathy	O
.	O
ECG	O
at	O
discharge	O
image	O
6	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
with	O
normal	O
PR	O
and	O
normopositioned	O
narrow	O
QRS	O
with	O
adequate	O
progression	O
in	O
precordials	O
without	O
repolarisation	O
alterations	O
.	O
Blood	O
tests	O
at	O
discharge	O
haemoglobin	O
10	O
.	O
4	O
g	O
dl	O
,	O
MCV	O
91	O
.	O
2	O
fl	O
,	O
leukocytes	O
7200	O
μl	O
with	O
normal	O
formula	O
,	O
platelets	O
225000	O
μl	O
.	O
INR	O
0	O
.	O
81	O
,	O
APTT	O
27	O
.	O
7	O
sec	O
.	O
Glucose	O
101	O
mg	O
dl	O
,	O
ALT	O
42	O
U	O
l	O
,	O
GGT	O
19	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
76	O
U	O
l	O
,	O
bilirubin	O
0	O
.	O
3	O
mg	O
dl	O
,	O
albumin	O
3	O
.	O
8	O
g	O
dl	O
,	O
creatinine	O
0	O
.	O
97	O
mg	O
dl	O
,	O
sodium	O
141	O
mmol	O
l	O
,	O
potassium	O
3	O
.	O
7	O
mmol	O
l	O
,	O
C	O
reactive	O
protein	O
0	O
.	O
4	O
mg	O
dl	O
,	O
CK	O
67	O
U	O
l	O
,	O
ultrasensitive	O
troponin	O
I	O
11	O
ng	O
l	O
VN	O
21	O
ng	O
l	O
,	O
NT	O
proBNP	O
149	O
ng	O
l	O
.	O
Anti	O
striated	O
muscle	O
antibodies	O
immunofluorescence	O
positive	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
arrival	O
,	O
and	O
given	O
the	O
suspected	O
diagnosis	O
,	O
empirical	O
treatment	O
was	O
started	O
with	O
high	O
dose	O
corticosteroids	O
methylprednisolone	B-FARMACO
2	O
mg	O
kg	O
day	O
,	O
oral	O
diuretic	O
at	O
medium	O
doses	O
and	O
telemetry	O
monitoring	O
.	O
During	O
admission	O
,	O
there	O
was	O
a	O
progressive	O
normalisation	O
of	O
electrocardiographic	O
alterations	O
and	O
markers	O
of	O
myocardial	O
damage	O
,	O
as	O
well	O
as	O
an	O
evident	O
parallel	O
clinical	O
improvement	O
,	O
tolerating	O
a	O
subsequent	O
tapering	O
regimen	O
of	O
systemic	O
corticosteroids	O
.	O
Transthoracic	O
echocardiography	O
and	O
magnetic	O
resonance	O
imaging	O
showed	O
preserved	O
biventricular	O
function	O
,	O
without	O
valvular	O
heart	O
disease	O
or	O
late	O
enhancement	O
.	O
Diffuse	O
oedema	O
predominantly	O
mediodistal	O
on	O
T2	O
STIR	O
sequences	O
compatible	O
with	O
a	O
myocarditis	O
type	O
inflammatory	O
process	O
with	O
no	O
apparent	O
sequelae	O
.	O
In	O
addition	O
,	O
the	O
positive	O
result	O
of	O
anti	O
striated	O
muscle	O
antibodies	O
and	O
triceps	O
brachii	O
biopsy	O
were	O
consistent	O
with	O
the	O
diagnosis	O
of	O
myositis	O
.	O
It	O
is	O
worth	O
mentioning	O
that	O
neither	O
coronary	O
angiography	O
nor	O
endomyocardial	O
biopsy	O
was	O
necessary	O
in	O
this	O
case	O
since	O
the	O
clinical	O
,	O
analytical	O
and	O
ECG	O
alterations	O
,	O
completely	O
reversible	O
with	O
anti	O
inflammatory	O
drugs	O
,	O
together	O
with	O
the	O
autoimmunity	O
,	O
the	O
muscle	O
biopsy	O
and	O
the	O
data	O
from	O
the	O
T2	O
STIR	O
sequences	O
and	O
maps	O
are	O
sufficiently	O
important	O
to	O
establish	O
the	O
diagnosis	O
of	O
myocarditis	O
due	O
to	O
immunotherapy	O
nivolumab	B-FARMACO
.	O
Months	O
later	O
,	O
she	O
is	O
still	O
under	O
outpatient	O
follow	O
up	O
in	O
cardio	O
oncology	O
outpatient	O
clinics	O
,	O
asymptomatic	O
,	O
with	O
normal	O
ECG	O
and	O
troponins	O
.	O
Nivolumab	B-FARMACO
,	O
suspended	O
after	O
admission	O
,	O
has	O
not	O
been	O
restarted	O
.	O
DIAGNOSIS	O
Myocarditis	O
and	O
myositis	O
due	O
to	O
nivolumab	B-FARMACO
.	O
Metastatic	O
colorectal	O
adenocarcinoma	O
.	O
Essential	O
arterial	O
hypertension	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
.	O

A	O
71	O
year	O
old	O
male	O
patient	O
with	O
a	O
history	O
of	O
prostatectomy	O
for	O
Gleason	O
7	O
prostate	O
adenocarcinoma	O
2	O
years	O
ago	O
,	O
not	O
carrying	O
a	O
Foley	O
catheter	O
and	O
who	O
was	O
regularly	O
monitored	O
by	O
the	O
Urology	O
Department	O
after	O
the	O
operation	O
.	O
One	O
year	O
ago	O
,	O
he	O
underwent	O
cystoscopy	O
for	O
recurrent	O
UTIs	O
and	O
underwent	O
surgical	O
dilatation	O
for	O
vesicourethral	O
stenosis	O
.	O
Subsequently	O
,	O
she	O
was	O
diagnosed	O
with	O
paroxysmal	O
atrial	O
fibrillation	O
due	O
to	O
severe	O
aortic	O
insufficiency	O
caused	O
by	O
a	O
bicuspid	O
valve	O
,	O
and	O
a	O
valve	O
prosthesis	O
was	O
fitted	O
.	O
Three	O
months	O
after	O
the	O
surgery	O
,	O
he	O
came	O
to	O
the	O
emergency	O
department	O
complaining	O
of	O
arthralgia	O
,	O
fever	O
and	O
new	O
onset	O
postvoid	O
drip	O
.	O
Physical	O
examination	O
revealed	O
splenomegaly	O
and	O
initial	O
laboratory	O
tests	O
showed	O
CRP	O
26	O
.	O
9	O
mg	O
dL	O
reference	O
values	O
0	O
8	O
mg	O
dL	O
,	O
abundant	O
bacteria	O
and	O
pyuria	O
in	O
the	O
urinary	O
sediment	O
.	O
Abdominal	O
CT	O
scan	O
showed	O
splenic	O
infarction	O
and	O
biochemistry	O
was	O
expanded	O
with	O
troponin	O
T	O
319	O
.	O
6	O
ng	O
L	O
reference	O
values	O
0	O
14	O
ng	O
L	O
,	O
and	O
pro	O
BNP	O
45	O
,	O
140	O
pg	O
mL	O
reference	O
values	O
0	O
100	O
pg	O
mL	O
.	O
Microbiological	O
study	O
of	O
urine	O
in	O
CLED	O
culture	O
medium	O
showed	O
no	O
growth	O
and	O
Gram	O
staining	O
of	O
urine	O
identified	O
gram	O
positive	O
cocci	O
.	O
A	O
blood	O
agar	O
culture	O
was	O
performed	O
and	O
gram	O
positive	O
cocci	O
colony	O
growth	O
was	O
observed	O
.	O
Identification	O
to	O
genus	O
and	O
species	O
level	O
,	O
Aerococcus	O
urinae	O
,	O
was	O
performed	O
by	O
MALDI	O
TOF	O
mass	O
spectrometry	O
.	O
In	O
the	O
4	O
bottles	O
of	O
the	O
two	O
blood	O
cultures	O
there	O
was	O
also	O
growth	O
and	O
the	O
same	O
micro	O
organism	O
was	O
identified	O
.	O
The	O
antibiogram	O
was	O
as	O
follows	O
sensitive	O
to	O
penicillin	B-FARMACO
MIC	O
0	O
.	O
012	O
mg	O
L	O
,	O
cefotaxime	B-FARMACO
MIC	O
0	O
.	O
064	O
mg	O
L	O
,	O
levofloxacin	B-FARMACO
MIC	O
0	O
.	O
25	O
mg	O
L	O
,	O
vancomycin	B-FARMACO
and	O
linezolid	B-FARMACO
.	O
Transesophageal	O
echocardiography	O
showed	O
evidence	O
of	O
prosthetic	O
valve	O
with	O
perivalvular	O
abscess	O
.	O
The	O
patient	O
initially	O
received	O
cloxacillin	B-FARMACO
gentamicin	I-FARMACO
and	O
later	O
continued	O
with	O
ceftriaxone	B-FARMACO
daptomycin	I-FARMACO
,	O
with	O
subsequent	O
negative	O
blood	O
cultures	O
.	O
However	O
,	O
the	O
clinical	O
evolution	O
,	O
inflammatory	O
markers	O
and	O
myocardial	O
function	O
were	O
compatible	O
with	O
sepsis	O
and	O
acute	O
pulmonary	O
oedema	O
,	O
with	O
fatal	O
evolution	O
towards	O
irreversible	O
ventricular	O
failure	O
.	O
He	O
finally	O
died	O
due	O
to	O
a	O
rupture	O
of	O
the	O
aortic	O
annulus	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
No	O
allergic	O
drug	O
reactions	O
.	O
No	O
hypertension	O
or	O
diabetes	O
mellitus	O
.	O
Dyslipidaemia	O
.	O
Ex	O
smoker	O
for	O
more	O
than	O
20	O
years	O
.	O
No	O
alcoholism	O
.	O
Obesity	O
.	O
Cardiological	O
history	O
not	O
reported	O
.	O
Other	O
history	O
Last	O
admission	O
to	O
neurology	O
one	O
year	O
ago	O
cortical	O
cerebral	O
venous	O
thrombosis	O
with	O
associated	O
parietal	O
subarachnoid	O
haemorrhage	O
.	O
Negative	O
thrombophilia	O
study	O
.	O
ANA	O
Positive	O
1	O
160	O
,	O
no	O
apparent	O
autoimmune	O
symptoms	O
.	O
G3	O
P3	O
C0	O
A0	O
.	O
Hypermenorrhoea	O
due	O
to	O
uterine	O
myoma	O
.	O
Previous	O
surgical	O
interventions	O
cholecystectomy	O
20	O
years	O
ago	O
.	O
Usual	O
treatment	O
atorvastatin	B-FARMACO
20	O
mg	O
0	O
0	O
1	O
,	O
citicoline	B-FARMACO
1g	O
1	O
0	O
0	O
.	O
On	O
treatment	O
with	O
acenocoumarol	B-FARMACO
until	O
10	O
days	O
before	O
the	O
current	O
event	O
.	O
As	O
there	O
were	O
no	O
pathological	O
findings	O
requiring	O
indefinite	O
maintenance	O
of	O
anticoagulation	O
,	O
anticoagulation	O
treatment	O
was	O
discontinued	O
.	O
CURRENT	O
DISEASE	O
A	O
44	O
year	O
old	O
woman	O
came	O
to	O
the	O
emergency	O
department	O
with	O
oppressive	O
chest	O
pain	O
of	O
24	O
hours	O
'	O
duration	O
.	O
She	O
reported	O
moderate	O
intensity	O
epigastralgia	O
with	O
subsequent	O
irradiation	O
to	O
the	O
central	O
thoracic	O
region	O
and	O
neck	O
associated	O
with	O
vegetative	O
cramping	O
,	O
which	O
did	O
not	O
subside	O
after	O
taking	O
several	O
tablets	O
of	O
non	O
steroidal	O
anti	O
inflammatory	O
drugs	O
.	O
No	O
dyspnoea	O
or	O
presyncope	O
.	O
She	O
denied	O
previous	O
episodes	O
of	O
chest	O
pain	O
.	O
Given	O
the	O
persistence	O
of	O
the	O
pain	O
,	O
she	O
decided	O
to	O
go	O
to	O
the	O
emergency	O
department	O
.	O
On	O
arrival	O
,	O
an	O
electrocardiogram	O
ECG	O
was	O
performed	O
showing	O
a	O
subepicardial	O
lesion	O
current	O
in	O
the	O
inferolateral	O
and	O
anterior	O
face	O
V3	O
V6	O
and	O
II	O
,	O
III	O
and	O
aVF	O
.	O
A	O
haemodynamic	O
alert	O
was	O
activated	O
and	O
emergent	O
catheterisation	O
was	O
performed	O
via	O
the	O
left	O
radial	O
route	O
according	O
to	O
the	O
usual	O
technique	O
with	O
a	O
6F	O
introducer	O
.	O
Right	O
dominance	O
.	O
Evidence	O
of	O
thrombosis	O
at	O
the	O
level	O
of	O
the	O
ostial	O
anterior	O
descending	O
AD	O
artery	O
.	O
Thromboaspiration	O
was	O
performed	O
with	O
extraction	O
of	O
scarce	O
white	O
thrombus	O
but	O
recovering	O
distal	O
flow	O
TIMI	O
2	O
3	O
.	O
The	O
lesion	O
was	O
predilated	O
with	O
a	O
balloon	O
,	O
a	O
drug	O
eluting	O
stent	O
was	O
implanted	O
and	O
the	O
proximal	O
segment	O
of	O
the	O
stent	O
was	O
post	O
dilated	O
with	O
a	O
balloon	O
with	O
good	O
results	O
.	O
However	O
,	O
there	O
was	O
later	O
evidence	O
of	O
TIMI	O
1	O
distal	O
mid	O
distal	O
LAD	O
flow	O
that	O
did	O
not	O
improve	O
despite	O
multiple	O
doses	O
of	O
intracoronary	O
nitroglycerin	B-FARMACO
icNTG	I-FARMACO
or	O
percutaneous	O
coronary	O
intervention	O
PCI	O
balloon	O
guidewire	O
manipulation	O
no	O
reflow	O
effect	O
.	O
Periprocedural	O
complications	O
included	O
ventricular	O
fibrillation	O
with	O
haemodynamic	O
instability	O
requiring	O
electrical	O
cardioversion	O
and	O
vasoactive	O
support	O
.	O
Given	O
the	O
patient	O
's	O
history	O
of	O
cavernous	O
sinus	O
thrombosis	O
and	O
subsequent	O
subarachnoid	O
haemorrhage	O
SAH	O
,	O
it	O
was	O
decided	O
not	O
to	O
administer	O
potent	O
antiplatelet	O
therapy	O
or	O
abciximab	B-FARMACO
,	O
so	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
250	O
mg	O
and	O
clopidogrel	B-FARMACO
600	O
mg	O
were	O
administered	O
.	O
After	O
transfer	O
to	O
the	O
coronary	O
unit	O
,	O
a	O
portable	O
transthoracic	O
echocardiography	O
showed	O
severe	O
ventricular	O
dysfunction	O
and	O
an	O
image	O
suggestive	O
of	O
apical	O
thrombus	O
.	O
Given	O
the	O
suspicion	O
of	O
apical	O
thrombus	O
,	O
enoxaparin	B-FARMACO
is	O
maintained	O
at	O
anticoagulant	O
doses	O
.	O
Two	O
hours	O
after	O
the	O
percutaneous	O
procedure	O
,	O
the	O
pain	O
recurred	O
and	O
a	O
new	O
ST	O
segment	O
elevation	O
was	O
observed	O
,	O
so	O
it	O
was	O
decided	O
to	O
activate	O
a	O
second	O
haemodynamic	O
alert	O
.	O
Emergent	O
coronary	O
angiography	O
was	O
performed	O
.	O
Acute	O
thrombosis	O
of	O
the	O
stent	O
in	O
the	O
LAD	O
was	O
evidenced	O
and	O
balloon	O
predilatation	O
was	O
performed	O
,	O
restoring	O
TIMI	O
3	O
flow	O
with	O
good	O
expansion	O
of	O
the	O
stent	O
,	O
with	O
no	O
images	O
of	O
dissection	O
of	O
the	O
distal	O
edge	O
of	O
the	O
stent	O
;	O
however	O
,	O
there	O
was	O
still	O
a	O
large	O
mobile	O
thrombotic	O
cast	O
.	O
Tirofiban	B-FARMACO
is	O
administered	O
.	O
After	O
several	O
minutes	O
the	O
thrombotic	O
component	O
persists	O
with	O
TIMI	O
3	O
flow	O
,	O
so	O
thromboaspiration	O
is	O
performed	O
with	O
a	O
good	O
final	O
angiographic	O
result	O
.	O
He	O
was	O
transferred	O
to	O
the	O
coronary	O
unit	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
90	O
50	O
mmHg	O
,	O
heart	O
rate	O
HR	O
120	O
bpm	O
,	O
SatO2	O
97	O
with	O
Ventimask	O
with	O
FiO2	O
50	O
.	O
Rhythmic	O
heart	O
tones	O
,	O
at	O
120	O
bpm	O
,	O
with	O
3R	O
and	O
4R	O
.	O
Bladder	O
murmur	O
preserved	O
with	O
no	O
over	O
additions	O
.	O
Lower	O
extremities	O
without	O
oedema	O
,	O
peripheral	O
pulses	O
preserved	O
and	O
symmetrical	O
,	O
no	O
signs	O
of	O
phlebitis	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
Emergency	O
ECG	O
image	O
1	O
sinus	O
tachycardia	O
at	O
140	O
bpm	O
,	O
normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
Q	O
wave	O
in	O
II	O
,	O
III	O
and	O
aVF	O
,	O
V3	O
6	O
with	O
ST	O
rise	O
in	O
these	O
leads	O
and	O
fall	O
in	O
I	O
,	O
aVL	O
V1	O
2	O
.	O
ECG	O
2	O
hours	O
after	O
catheterisation	O
with	O
recurrence	O
of	O
pain	O
sinus	O
tachycardia	O
at	O
125	O
bpm	O
,	O
normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
ST	O
elevation	O
in	O
II	O
,	O
III	O
and	O
aVF	O
as	O
well	O
as	O
in	O
V4	O
6	O
with	O
Q	O
wave	O
in	O
II	O
,	O
III	O
and	O
aVF	O
and	O
ST	O
descent	O
in	O
I	O
,	O
aVL	O
,	O
V1	O
V2	O
.	O
ECG	O
at	O
discharge	O
OCU	O
ECG	O
.	O
Sinus	O
rhythm	O
at	O
100	O
bpm	O
,	O
normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
Anteroseptal	O
necrosis	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
image	O
3	O
CTI	O
within	O
normality	O
,	O
no	O
costophrenic	O
sinus	O
pinching	O
;	O
image	O
of	O
vascular	O
redistribution	O
.	O
CBC	O
Haemoglobin	O
10	O
.	O
2	O
g	O
dl	O
,	O
haematocrit	O
31	O
.	O
2	O
,	O
MCV	O
83	O
.	O
8	O
fl	O
,	O
MCH	O
27	O
.	O
3	O
pg	O
,	O
MCHC	O
32	O
.	O
6	O
g	O
dl	O
,	O
ADE	O
16	O
.	O
7	O
,	O
leucocytes	O
7	O
.	O
9	O
10	O
9	O
l	O
,	O
neutrophils	O
59	O
.	O
4	O
,	O
platelets	O
531	O
10	O
9	O
l	O
.	O
Biochemistry	O
sodium	O
138	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
4	O
mEq	O
l	O
,	O
chlorine	O
103	O
mEq	O
l	O
,	O
haemostasis	O
Quick	O
index	O
88	O
.	O
INR	O
1	O
.	O
08	O
TTPA	O
30	O
.	O
3	O
sec	O
.	O
Peak	O
hsTnI	O
21	O
,	O
000ng	O
dl	O
limits	O
of	O
normality	O
0	O
.	O
0	O
11	O
.	O
6	O
.	O
NT	O
ProBNP	O
6300ng	O
dl	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
214	O
mg	O
dl	O
,	O
triglycerides	O
164	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
47	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
134	O
.	O
Glycaemic	O
metabolic	O
profile	O
glycosylated	O
haemoglobin	O
US	O
5	O
.	O
2	O
,	O
thyrotropin	O
TSH	O
1	O
.	O
05	O
uIU	O
ml	O
.	O
Iron	O
profile	O
ferritin	O
31	O
ng	O
l	O
,	O
iron	O
23	O
ng	O
dl	O
,	O
total	O
Fe	O
binding	O
capacity	O
381	O
ug	O
dl	O
,	O
transferrin	O
saturation	O
index	O
6	O
,	O
latent	O
Fe	O
binding	O
capacity	O
357	O
.	O
6	O
ug	O
dl	O
.	O
Thrombophilia	O
profile	O
antithrombin	O
119	O
,	O
protein	O
C	O
functional	O
153	O
,	O
protein	O
S	O
Functional	O
115	O
.	O
1	O
,	O
lupus	O
anticoagulant	O
negative	O
.	O
lupus	O
anticoagulant	O
TVVRd	O
0	O
.	O
9	O
,	O
lupus	O
anticoagulant	O
SCT	O
0	O
.	O
96	O
,	O
anti	O
cardiolipin	O
IgG	O
negative	O
,	O
anti	O
cardiolipin	O
IgM	O
negative	O
,	O
anti	O
cardiolipin	O
IgM	O
negative	O
,	O
anti	O
cardiolipin	O
IgM	O
negative	O
.	O
anticardiolipin	O
IgM	O
negative	O
,	O
beta	O
2	O
glycoprotein	O
I	O
IgG	O
negative	O
,	O
beta	O
2	O
glycoprotein	O
I	O
IgM	O
negative	O
,	O
activated	O
protein	O
C	O
resistance	O
2	O
.	O
8	O
,	O
factor	O
V	O
Leiden	O
negative	O
,	O
factor	O
II	O
G20210A	O
mutation	O
negative	O
.	O
Tumour	O
markers	O
CEA	O
1	O
.	O
5	O
ng	O
ml	O
,	O
carbohydrate	O
ag	O
.	O
15	O
.	O
3	O
CA15	O
.	O
3	O
9	O
.	O
1	O
IU	O
ml	O
.	O
Ag	O
.	O
carbohydrate	O
19	O
.	O
9	O
CA19	O
.	O
9	O
3	O
.	O
3	O
IU	O
ml	O
.	O
Ag	O
.	O
carbohydrate	O
125	O
CA125	O
42	O
IU	O
ml	O
.	O
Alpha	O
fetoprotein	O
AFP	O
1	O
.	O
9	O
ng	O
ml	O
.	O
Immunological	O
profile	O
immunoglobulin	O
IgG	O
1060	O
mg	O
dl	O
,	O
immunoglobulin	O
IgA	O
351	O
mg	O
dl	O
,	O
immunoglobulin	O
IgM	O
81	O
mg	O
dl	O
,	O
ANA	O
immunofluorescence	O
positive	O
1	O
160	O
dsDNA	O
,	O
antibodies	O
9	O
.	O
8	O
IU	O
ml	O
,	O
homogeneous	O
IFA	O
pattern	O
ENA	O
screening	O
negative	O
.	O
Albumin	O
52	O
.	O
4	O
.	O
Alpha	O
1	O
globulin	O
9	O
.	O
Alpha	O
2	O
globulin	O
11	O
.	O
1	O
.	O
Beta	O
globulin	O
12	O
.	O
2	O
.	O
Gamma	O
globulin	O
15	O
.	O
3	O
.	O
Albumin	O
globulin	O
ratio	O
1	O
.	O
1	O
.	O
Echocardiogram	O
First	O
day	O
in	O
coronary	O
unit	O
akinesia	O
of	O
all	O
apical	O
,	O
anterior	O
and	O
mid	O
lateral	O
segments	O
.	O
Contractility	O
more	O
preserved	O
in	O
bases	O
.	O
Estimated	O
LVEF	O
30	O
.	O
RV	O
of	O
normal	O
size	O
with	O
preserved	O
contractility	O
.	O
Mitral	O
pattern	O
with	O
E	O
minor	O
A	O
.	O
Mild	O
TR	O
with	O
estimated	O
PAPs	O
45	O
mmHg	O
.	O
IVC	O
17	O
mm	O
without	O
respiratory	O
variations	O
.	O
Possible	O
apical	O
thrombus	O
.	O
At	O
discharge	O
severe	O
left	O
ventricular	O
dysfunction	O
LVEF	O
34	O
secondary	O
to	O
apical	O
aneurysm	O
and	O
marked	O
hypokinesia	O
of	O
anterior	O
,	O
lateral	O
and	O
septal	O
mid	O
segments	O
.	O
Absence	O
of	O
apical	O
thrombus	O
.	O
Mild	O
to	O
moderate	O
mitral	O
regurgitation	O
grade	O
II	O
IV	O
secondary	O
to	O
posterior	O
leaflet	O
retraction	O
.	O
Filling	O
pattern	O
compatible	O
with	O
increased	O
end	O
diastolic	O
pressures	O
.	O
Normal	O
right	O
ventricle	O
with	O
indirect	O
signs	O
of	O
increased	O
PAP	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
LV	O
with	O
normal	O
volumes	O
VTD	O
78	O
ml	O
m2	O
,	O
VTS	O
52	O
ml	O
m2	O
,	O
IMVI	O
54	O
g	O
m2	O
without	O
significant	O
hypertrophy	O
of	O
its	O
walls	O
,	O
with	O
anterior	O
and	O
anteroseptal	O
akinesia	O
basal	O
and	O
medial	O
and	O
anterior	O
and	O
apical	O
septal	O
and	O
strict	O
apex	O
with	O
hypercontractility	O
of	O
the	O
remaining	O
segments	O
and	O
severe	O
depression	O
of	O
global	O
systolic	O
function	O
at	O
rest	O
LVEF	O
33	O
.	O
STIR	O
sequences	O
show	O
myocardial	O
oedema	O
in	O
the	O
akinetic	O
segments	O
.	O
Non	O
dilated	O
RV	O
RVOT	O
37	O
ml	O
m2	O
,	O
STV	O
14	O
ml	O
m2	O
with	O
preserved	O
global	O
systolic	O
function	O
RVEF	O
64	O
.	O
Aorta	O
and	O
great	O
vessels	O
of	O
normal	O
diameter	O
and	O
morphology	O
.	O
Atria	O
of	O
normal	O
dimensions	O
.	O
Perfusion	O
study	O
video	O
10	O
Gadoteric	O
acid	O
0	O
.	O
15	O
mm	O
kg	O
is	O
administered	O
and	O
well	O
tolerated	O
by	O
the	O
patient	O
.	O
Resting	O
perfusion	O
defects	O
are	O
detected	O
in	O
the	O
akinetic	O
segments	O
.	O
Necrosis	O
and	O
viability	O
detection	O
study	O
presence	O
of	O
myocardial	O
LGE	O
suggestive	O
of	O
transmural	O
necrosis	O
at	O
the	O
anterior	O
and	O
anteroseptal	O
basal	O
and	O
mid	O
and	O
anterior	O
and	O
apical	O
septal	O
level	O
and	O
strict	O
apex	O
with	O
presence	O
of	O
microvascular	O
obstruction	O
in	O
these	O
segments	O
absence	O
of	O
viability	O
in	O
7	O
segments	O
out	O
of	O
17	O
,	O
DA	O
dependent	O
.	O
Presence	O
of	O
minimal	O
pericardial	O
and	O
pleural	O
effusion	O
.	O
Conclusion	O
acute	O
ischaemic	O
LV	O
heart	O
disease	O
with	O
preserved	O
volumes	O
and	O
severe	O
depression	O
of	O
GSF	O
LVEF	O
33	O
with	O
contractile	O
alteration	O
,	O
oedema	O
,	O
perfusion	O
defect	O
and	O
transmural	O
necrosis	O
with	O
MVO	O
at	O
the	O
level	O
of	O
7	O
proximal	O
LAD	O
dependent	O
segments	O
.	O
Absence	O
of	O
intraventricular	O
thrombus	O
.	O
Total	O
Body	O
CT	O
Thoracic	O
CT	O
centred	O
mediastinum	O
with	O
no	O
evidence	O
of	O
ganglionic	O
formations	O
of	O
significant	O
size	O
.	O
No	O
pulmonary	O
nodules	O
or	O
condensations	O
are	O
observed	O
.	O
No	O
pleural	O
or	O
pericardial	O
effusion	O
is	O
observed	O
.	O
Abdominopelvic	O
CT	O
scan	O
heterogeneous	O
uterus	O
,	O
enlarged	O
probably	O
due	O
to	O
the	O
presence	O
of	O
myomas	O
.	O
Nodular	O
image	O
of	O
17	O
mm	O
with	O
peripheral	O
contrast	O
uptake	O
in	O
left	O
dense	O
topography	O
theoretically	O
suggestive	O
of	O
corpus	O
luteum	O
.	O
Liver	O
of	O
normal	O
size	O
and	O
morphology	O
with	O
no	O
evidence	O
of	O
focal	O
lesions	O
or	O
dilatation	O
of	O
the	O
intra	O
or	O
extrahepatic	O
bile	O
duct	O
.	O
Cholecystectomy	O
.	O
Spleen	O
,	O
pancreas	O
,	O
adrenal	O
glands	O
and	O
both	O
kidneys	O
were	O
normal	O
.	O
No	O
lymph	O
node	O
formations	O
of	O
significant	O
size	O
were	O
observed	O
in	O
the	O
abdominopelvic	O
chains	O
.	O
Normal	O
calibre	O
and	O
distribution	O
of	O
intestinal	O
loops	O
.	O
No	O
signs	O
of	O
metastatic	O
bone	O
involvement	O
were	O
observed	O
by	O
this	O
technique	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
readmission	O
to	O
the	O
coronary	O
unit	O
,	O
he	O
presented	O
haemodynamic	O
lability	O
requiring	O
increased	O
vasoactive	O
support	O
with	O
noradrenaline	B-FARMACO
and	O
dobutamine	B-FARMACO
,	O
so	O
it	O
was	O
decided	O
to	O
implant	O
an	O
intra	O
aortic	O
balloon	O
counterpulsation	O
device	O
.	O
Progressive	O
weaning	O
of	O
haemodynamic	O
support	O
was	O
achieved	O
,	O
with	O
withdrawal	O
of	O
balloon	O
counterpulsation	O
and	O
dobutamine	B-FARMACO
on	O
the	O
third	O
day	O
.	O
On	O
the	O
fourth	O
day	O
,	O
despite	O
noradrenaline	B-FARMACO
support	O
,	O
levosimendan	B-FARMACO
was	O
started	O
due	O
to	O
sustained	O
hypotension	O
.	O
Norepinephrine	B-FARMACO
was	O
withdrawn	O
on	O
the	O
sixth	O
day	O
.	O
No	O
ventricular	O
arrhythmias	O
were	O
observed	O
on	O
monitoring	O
.	O
Spontaneous	O
diuresis	O
greater	O
than	O
1500	O
ml	O
per	O
day	O
with	O
accumulated	O
negative	O
balance	O
.	O
An	O
MRI	O
was	O
performed	O
which	O
confirmed	O
severe	O
ventricular	O
dysfunction	O
and	O
ruled	O
out	O
the	O
presence	O
of	O
intracavitary	O
thrombus	O
.	O
Discharge	O
to	O
the	O
cardiology	O
ward	O
was	O
decided	O
to	O
continue	O
the	O
study	O
.	O
During	O
his	O
stay	O
on	O
the	O
ward	O
he	O
remained	O
stable	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
with	O
no	O
new	O
episodes	O
of	O
chest	O
pain	O
.	O
He	O
began	O
to	O
ambulate	O
with	O
dyspnoea	O
on	O
moderate	O
exertion	O
NYHA	O
III	O
IV	O
with	O
no	O
other	O
signs	O
of	O
heart	O
failure	O
;	O
he	O
also	O
reported	O
no	O
palpitations	O
,	O
syncopal	O
or	O
presyncopal	O
episodes	O
.	O
Pharmacological	O
titration	O
was	O
carried	O
out	O
,	O
verifying	O
progressive	O
tolerance	O
bisoprolol	B-FARMACO
5	O
mg	O
12h	O
,	O
enalapril	B-FARMACO
2	O
.	O
5	O
mg	O
12h	O
,	O
eplerenone	B-FARMACO
50	O
mg	O
24h	O
,	O
ivabradine	B-FARMACO
10	O
mg	O
12h	O
.	O
Given	O
that	O
the	O
patient	O
had	O
presented	O
two	O
thromboembolic	O
events	O
in	O
different	O
vascular	O
territories	O
,	O
the	O
last	O
of	O
which	O
coincided	O
with	O
withdrawal	O
of	O
acenocoumarol	B-FARMACO
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
complete	O
thrombophilia	O
study	O
.	O
A	O
CT	O
scan	O
of	O
the	O
abdomen	O
and	O
abdomen	O
and	O
pelvis	O
was	O
performed	O
to	O
rule	O
out	O
tumours	O
and	O
a	O
complete	O
blood	O
analysis	O
was	O
performed	O
.	O
No	O
relevant	O
findings	O
were	O
observed	O
in	O
any	O
of	O
them	O
.	O
The	O
patient	O
was	O
discharged	O
home	O
with	O
follow	O
up	O
in	O
the	O
heart	O
failure	O
unit	O
with	O
the	O
following	O
treatment	O
regimen	O
Enoxaparin	B-FARMACO
80	O
mg	O
one	O
subcutaneous	O
injection	O
at	O
breakfast	O
and	O
dinner	O
,	O
as	O
a	O
bridge	O
to	O
acenocoumarol	B-FARMACO
.	O
acenocoumarol	B-FARMACO
1	O
mg	O
two	O
tablets	O
at	O
lunch	O
.	O
ASA	B-FARMACO
100	O
mg	O
one	O
tablet	O
at	O
breakfast	O
.	O
Ticagrelol	B-FARMACO
90	O
mg	O
one	O
tablet	O
at	O
breakfast	O
and	O
dinner	O
.	O
Atorvastatin	B-FARMACO
40	O
mg	O
one	O
tablet	O
at	O
dinner	O
.	O
Bisoprolol	B-FARMACO
5	O
mg	O
one	O
tablet	O
at	O
breakfast	O
and	O
dinner	O
.	O
Ivabradine	B-FARMACO
5	O
mg	O
one	O
tablet	O
at	O
breakfast	O
and	O
dinner	O
.	O
Eplerenone	B-FARMACO
50	O
mg	O
one	O
tablet	O
at	O
lunch	O
.	O
Enalapril	B-FARMACO
2	O
.	O
5	O
mg	O
one	O
tablet	O
at	O
dinner	O
.	O
Furosemide	B-FARMACO
40	O
mg	O
one	O
tablet	O
at	O
breakfast	O
.	O
Omeprazole	B-FARMACO
20	O
mg	O
one	O
tablet	O
at	O
breakfast	O
.	O
DIAGNOSIS	O
KILLIP	O
IV	O
STEMI	O
acute	O
thrombotic	O
occlusion	O
of	O
the	O
ostial	O
LAD	O
.	O
Primary	O
angioplasty	O
with	O
DES	O
implantation	O
in	O
complicated	O
LAD	O
with	O
no	O
reflow	O
phenomenon	O
and	O
subsequent	O
acute	O
stent	O
thrombosis	O
.	O
Secondary	O
diagnoses	O
Severe	O
systolic	O
ventricular	O
dysfunction	O
.	O
Apical	O
aneurysm	O
.	O
Dyslipidaemia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
Male	O
,	O
56	O
years	O
old	O
,	O
from	O
Colombia	O
,	O
with	O
no	O
known	O
drug	O
allergies	O
.	O
No	O
family	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
His	O
toxic	O
habits	O
include	O
moderate	O
alcohol	O
consumption	O
until	O
several	O
years	O
ago	O
.	O
He	O
was	O
a	O
non	O
smoker	O
.	O
Cardiovascular	O
risk	O
factors	O
include	O
arterial	O
hypertension	O
and	O
dyslipidaemia	O
,	O
both	O
without	O
pharmacological	O
treatment	O
or	O
control	O
by	O
any	O
physician	O
,	O
and	O
morbid	O
obesity	O
BMI	O
57	O
kg	O
m2	O
.	O
Other	O
history	O
of	O
interest	O
severe	O
sleep	O
apnoea	O
syndrome	O
without	O
treatment	O
and	O
hypothyroidism	O
.	O
She	O
denies	O
regular	O
treatment	O
for	O
any	O
of	O
her	O
comorbidities	O
.	O
CURRENT	O
ILLNESS	O
She	O
came	O
to	O
the	O
emergency	O
department	O
for	O
progressive	O
dyspnoea	O
of	O
15	O
days	O
of	O
evolution	O
until	O
she	O
became	O
resting	O
,	O
together	O
with	O
orthopnoea	O
,	O
increased	O
abdominal	O
perimeter	O
and	O
oedema	O
in	O
the	O
extremities	O
.	O
She	O
reported	O
no	O
chest	O
pain	O
,	O
palpitations	O
,	O
dizziness	O
or	O
syncope	O
in	O
the	O
weeks	O
prior	O
to	O
consultation	O
.	O
PHYSICAL	O
EXAMINATION	O
Weight	O
171	O
kg	O
;	O
height	O
173	O
cm	O
;	O
body	O
mass	O
index	O
BMI	O
57	O
kg	O
m2	O
.	O
Afebrile	O
;	O
blood	O
pressure	O
BP	O
100	O
60	O
mmHg	O
;	O
heart	O
rate	O
HR	O
132	O
bpm	O
;	O
baseline	O
SatO2	O
98	O
.	O
Conscious	O
and	O
oriented	O
,	O
normohydrated	O
,	O
eupneic	O
at	O
rest	O
,	O
jugular	O
ingurgitation	O
present	O
at	O
45	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
heart	O
sounds	O
at	O
132	O
bpm	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
bibasal	O
crackles	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
very	O
globular	O
,	O
not	O
painful	O
to	O
deep	O
or	O
superficial	O
palpation	O
,	O
peristalsis	O
present	O
,	O
without	O
peritonism	O
.	O
Lower	O
extremities	O
bilateral	O
oedema	O
with	O
pitting	O
up	O
to	O
the	O
knee	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
admission	O
atrial	O
fibrillation	O
AF	O
with	O
ventricular	O
response	O
at	O
132	O
bpm	O
.	O
Q	O
wave	O
in	O
DIII	O
.	O
Low	O
voltages	O
.	O
Chest	O
X	O
ray	O
radiological	O
cardiomegaly	O
.	O
Interstitial	O
oedema	O
.	O
Blood	O
tests	O
biochemistry	O
glucose	O
93	O
mg	O
dl	O
;	O
HbA1c	O
6	O
.	O
2	O
;	O
urea	O
0	O
.	O
44	O
g	O
l	O
;	O
creatinine	O
1	O
.	O
19	O
mg	O
dl	O
;	O
glomerular	O
filtration	O
rate	O
67	O
ml	O
min	O
;	O
total	O
cholesterol	O
223	O
mg	O
dl	O
;	O
LDL	O
cholesterol	O
150	O
mg	O
dl	O
;	O
HDL	O
cholesterol	O
23	O
mg	O
dl	O
;	O
triglycerides	O
250	O
mg	O
dl	O
;	O
sodium	O
145	O
mEq	O
l	O
;	O
potassium	O
4	O
.	O
8	O
mEq	O
l	O
.	O
TSH	O
2	O
.	O
01	O
mcU	O
ml	O
.	O
Normal	O
liver	O
function	O
tests	O
.	O
Haemoglobin	O
14	O
.	O
8	O
g	O
dl	O
;	O
haematocrit	O
45	O
.	O
7	O
;	O
leucocytes	O
8	O
,	O
100	O
mm3	O
;	O
platelets	O
198	O
,	O
000	O
mm3	O
.	O
Transthoracic	O
echocardiogram	O
with	O
Sonovue	O
echocontrast	O
severely	O
dilated	O
left	O
atrium	O
A4C	O
60	O
cm2	O
.	O
Thin	O
leaflet	O
mitral	O
valve	O
with	O
preserved	O
mobility	O
and	O
opening	O
;	O
mild	O
regurgitation	O
grade	O
I	O
IV	O
.	O
Moderately	O
dilated	O
left	O
ventricle	O
indexed	O
biplane	O
LVEDV	O
93	O
cm3	O
m2	O
with	O
severely	O
depressed	O
systolic	O
function	O
LVEF	O
32	O
due	O
to	O
global	O
impairment	O
.	O
Thin	O
aortic	O
valve	O
with	O
good	O
opening	O
and	O
mobility	O
;	O
no	O
regurgitation	O
.	O
Slightly	O
dilated	O
aortic	O
root	O
.	O
Slightly	O
dilated	O
right	O
atrium	O
A4C	O
26	O
cm2	O
.	O
Dilated	O
right	O
ventricle	O
basal	O
diameter	O
53	O
mm	O
;	O
mean	O
37	O
mm	O
;	O
with	O
slightly	O
depressed	O
contractility	O
TAPSE	O
15	O
mm	O
.	O
Tricuspid	O
valve	O
with	O
good	O
opening	O
and	O
mobility	O
;	O
grade	O
II	O
IV	O
insufficiency	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
with	O
inspiratory	O
collapse	O
.	O
Estimated	O
pulmonary	O
arterial	O
systolic	O
pressure	O
51	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
Left	O
heart	O
catheterisation	O
ventriculography	O
dilated	O
left	O
ventricle	O
with	O
severe	O
systolic	O
dysfunction	O
.	O
No	O
mitral	O
regurgitation	O
.	O
Coronary	O
angiography	O
left	O
dominance	O
.	O
No	O
angiographically	O
significant	O
lesions	O
in	O
the	O
epicardial	O
coronary	O
arteries	O
.	O
Respiratory	O
function	O
tests	O
spirometry	O
moderate	O
decrease	O
in	O
obstructive	O
ventilatory	O
function	O
.	O
FEV1	O
2	O
.	O
12	O
l	O
59	O
;	O
FVC	O
3	O
.	O
38	O
l	O
73	O
;	O
FEV1	O
FVC	O
62	O
.	O
67	O
.	O
Bronchodilator	O
test	O
positive	O
;	O
significant	O
improvement	O
in	O
FEV1	O
18	O
320	O
ml	O
.	O
Electrocardiogram	O
at	O
discharge	O
atrial	O
fibrillation	O
with	O
ventricular	O
response	O
at	O
80	O
bpm	O
.	O
Q	O
wave	O
in	O
III	O
.	O
Low	O
voltages	O
.	O
CLINICAL	O
EVOLUTION	O
Initial	O
cardiological	O
assessment	O
in	O
the	O
emergency	O
department	O
revealed	O
clinical	O
signs	O
of	O
congestive	O
heart	O
failure	O
,	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
at	O
132	O
bpm	O
and	O
left	O
systolic	O
dysfunction	O
on	O
echocardioscopy	O
,	O
and	O
the	O
patient	O
was	O
admitted	O
for	O
appropriate	O
treatment	O
and	O
to	O
complete	O
aetiological	O
studies	O
.	O
The	O
patient	O
showed	O
significant	O
clinical	O
improvement	O
during	O
the	O
first	O
days	O
of	O
admission	O
with	O
depletive	O
treatment	O
with	O
intravenous	O
diuretics	O
,	O
reaching	O
a	O
dry	O
weight	O
of	O
156	O
kg	O
compared	O
to	O
the	O
initial	O
171	O
kg	O
.	O
A	O
regulated	O
echocardiogram	O
was	O
performed	O
with	O
echocontrast	O
due	O
to	O
a	O
poor	O
echocardiographic	O
window	O
,	O
which	O
confirmed	O
the	O
echocardiographic	O
findings	O
,	O
also	O
showing	O
elevated	O
filling	O
pressures	O
with	O
significant	O
pulmonary	O
hypertension	O
and	O
associated	O
right	O
sided	O
dysfunction	O
.	O
Furthermore	O
,	O
the	O
aetiological	O
study	O
was	O
completed	O
with	O
coronary	O
angiography	O
to	O
rule	O
out	O
ischaemic	O
aetiology	O
of	O
dilated	O
cardiomyopathy	O
,	O
showing	O
no	O
angiographically	O
significant	O
lesions	O
in	O
the	O
epicardial	O
coronary	O
arteries	O
.	O
Therefore	O
,	O
the	O
condition	O
was	O
interpreted	O
as	O
heart	O
failure	O
with	O
reduced	O
ejection	O
fraction	O
in	O
the	O
context	O
of	O
non	O
ischaemic	O
dilated	O
cardiomyopathy	O
,	O
without	O
being	O
able	O
to	O
rule	O
out	O
a	O
toxic	O
origin	O
enolic	O
together	O
with	O
a	O
certain	O
component	O
of	O
associated	O
tachycardiomyopathy	O
.	O
During	O
admission	O
,	O
treatments	O
with	O
prognostic	O
value	O
in	O
heart	O
failure	O
with	O
depressed	O
systolic	O
function	O
were	O
successfully	O
initiated	O
,	O
with	O
good	O
tolerance	O
to	O
them	O
,	O
achieving	O
good	O
heart	O
rate	O
control	O
with	O
beta	O
blockers	O
at	O
medium	O
doses	O
and	O
being	O
discharged	O
with	O
ACE	B-FARMACO
inhibitors	I-FARMACO
,	O
beta	O
blockers	O
and	O
antialdosteronics	O
at	O
maximum	O
doses	O
tolerated	O
by	O
blood	O
pressure	O
.	O
In	O
addition	O
,	O
during	O
his	O
hospitalisation	O
the	O
patient	O
received	O
nutritional	O
education	O
for	O
changes	O
in	O
eating	O
habits	O
,	O
as	O
well	O
as	O
instructions	O
to	O
begin	O
physical	O
exercise	O
.	O
In	O
the	O
case	O
of	O
a	O
patient	O
with	O
pre	O
diabetes	O
and	O
morbid	O
obesity	O
with	O
LDL	O
150	O
mg	O
dl	O
,	O
statins	O
were	O
started	O
to	O
achieve	O
target	O
LDL	O
100	O
mg	O
dl	O
.	O
In	O
collaboration	O
with	O
the	O
pulmonology	O
department	O
,	O
CPAP	O
treatment	O
was	O
started	O
during	O
admission	O
for	O
his	O
sleep	O
apnoea	O
,	O
with	O
good	O
tolerance	O
.	O
Regarding	O
his	O
atrial	O
fibrillation	O
of	O
uncertain	O
onset	O
,	O
with	O
a	O
CHADS	O
VASc	O
score	O
of	O
2	O
and	O
HASBLED	O
of	O
0	O
,	O
he	O
was	O
anticoagulated	O
on	O
admission	O
with	O
weight	O
adjusted	O
LMWH	B-FARMACO
.	O
An	O
initial	O
strategy	O
of	O
rate	O
control	O
was	O
proposed	O
so	O
that	O
,	O
after	O
clinical	O
stabilisation	O
and	O
one	O
month	O
of	O
anticoagulation	O
,	O
programmed	O
electrical	O
cardioversion	O
was	O
performed	O
for	O
rhythm	O
control	O
purposes	O
.	O
Regarding	O
the	O
choice	O
of	O
anticoagulation	O
therapy	O
at	O
discharge	O
,	O
the	O
patient	O
refused	O
to	O
take	O
VKA	O
for	O
personal	O
reasons	O
,	O
which	O
added	O
to	O
his	O
high	O
weight	O
and	O
BMI	O
posed	O
a	O
major	O
dilemma	O
.	O
In	O
agreement	O
with	O
the	O
haematology	O
service	O
,	O
it	O
was	O
decided	O
to	O
start	O
rivaroxaban	B-FARMACO
20	O
mg	O
and	O
laboratory	O
measurements	O
of	O
his	O
peak	O
and	O
trough	O
levels	O
were	O
performed	O
to	O
check	O
that	O
they	O
were	O
in	O
therapeutic	O
range	O
.	O
After	O
this	O
,	O
he	O
was	O
discharged	O
with	O
this	O
treatment	O
on	O
a	O
continuous	O
basis	O
.	O
In	O
the	O
outpatient	O
follow	O
up	O
,	O
the	O
patient	O
has	O
improved	O
clinically	O
,	O
has	O
reduced	O
his	O
weight	O
to	O
130	O
kg	O
BMI	O
43	O
kg	O
m2	O
and	O
is	O
in	O
functional	O
grade	O
II	O
.	O
Titration	O
of	O
prognostic	O
drugs	O
in	O
heart	O
failure	O
has	O
continued	O
,	O
replacing	O
ACE	B-FARMACO
inhibitors	I-FARMACO
with	O
sacubitrilo	B-FARMACO
valsartan	I-FARMACO
.	O
Two	O
unsuccessful	O
attempts	O
at	O
electrical	O
cardioversion	O
were	O
made	O
,	O
opting	O
to	O
continue	O
with	O
heart	O
rate	O
control	O
,	O
which	O
was	O
proving	O
adequate	O
.	O
In	O
the	O
control	O
echocardiography	O
after	O
3	O
months	O
of	O
optimised	O
medical	O
treatment	O
,	O
an	O
improvement	O
in	O
LVEF	O
of	O
up	O
to	O
50	O
was	O
observed	O
.	O
DIAGNOSIS	O
Heart	O
failure	O
with	O
depressed	O
left	O
ventricular	O
ejection	O
fraction	O
.	O
Non	O
ischaemic	O
dilated	O
cardiomyopathy	O
possible	O
toxic	O
damage	O
due	O
to	O
enolism	O
and	O
associated	O
tachycardiomyopathy	O
.	O
Atrial	O
fibrillation	O
AF	O
of	O
undetermined	O
onset	O
CHADSVASc	O
2	O
,	O
HASBLED	O
0	O
.	O
Coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O
Very	O
severe	O
sleep	O
apnoea	O
syndrome	O
.	O
Morbid	O
obesity	O
.	O
Arterial	O
hypertension	O
with	O
good	O
control	O
at	O
discharge	O
.	O
Prediabetes	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
37	O
year	O
old	O
male	O
of	O
Indian	O
origin	O
with	O
no	O
cardiovascular	O
risk	O
factors	O
CVRF	O
was	O
referred	O
to	O
our	O
hospital	O
with	O
a	O
diagnosis	O
of	O
hypertrophic	O
cardiomyopathy	O
and	O
Wolff	O
Parkinson	O
White	O
syndrome	O
.	O
The	O
patient	O
made	O
his	O
debut	O
at	O
the	O
age	O
of	O
16	O
years	O
in	O
1990	O
with	O
syncope	O
while	O
playing	O
football	O
.	O
He	O
had	O
no	O
family	O
history	O
of	O
sudden	O
death	O
or	O
relevant	O
diseases	O
.	O
An	O
electrocardiogram	O
ECG	O
showed	O
signs	O
of	O
left	O
ventricular	O
LV	O
hypertrophy	O
with	O
negative	O
T	O
waves	O
in	O
the	O
precordial	O
leads	O
and	O
pre	O
excitation	O
.	O
Severe	O
concentric	O
ventricular	O
hypertrophy	O
was	O
corroborated	O
on	O
echocardiography	O
,	O
with	O
a	O
maximum	O
IVS	O
diameter	O
of	O
22	O
mm	O
,	O
diastolic	O
dysfunction	O
and	O
mild	O
biventricular	O
systolic	O
dysfunction	O
.	O
He	O
subsequently	O
presented	O
with	O
an	O
episode	O
of	O
pre	O
excited	O
atrial	O
fibrillation	O
AF	O
at	O
more	O
than	O
200	O
bpm	O
,	O
and	O
electrophysiological	O
studies	O
demonstrated	O
the	O
existence	O
of	O
a	O
posteroseptal	O
medioseptal	O
accessory	O
pathway	O
near	O
the	O
normal	O
conduction	O
system	O
that	O
could	O
not	O
be	O
ablated	O
by	O
radiofrequency	O
after	O
three	O
unsuccessful	O
attempts	O
in	O
three	O
different	O
procedures	O
,	O
so	O
he	O
was	O
managed	O
with	O
medical	O
treatment	O
.	O
In	O
2012	O
aged	O
27	O
years	O
he	O
presented	O
with	O
an	O
episode	O
of	O
acute	O
pain	O
in	O
the	O
right	O
lower	O
limb	O
,	O
being	O
diagnosed	O
by	O
angio	O
CT	O
of	O
an	O
acute	O
thrombosis	O
in	O
the	O
femoral	O
artery	O
,	O
presumably	O
due	O
to	O
an	O
embolism	O
secondary	O
to	O
a	O
paroxysm	O
of	O
AF	O
,	O
so	O
treatment	O
with	O
warfarin	O
was	O
started	O
.	O
To	O
better	O
define	O
the	O
myocardium	O
,	O
cardiac	O
magnetic	O
resonance	O
imaging	O
CMR	O
was	O
performed	O
and	O
showed	O
severe	O
biventricular	O
hypertrophy	O
with	O
a	O
maximum	O
IVS	O
thickness	O
of	O
up	O
to	O
30	O
mm	O
;	O
slightly	O
depressed	O
LVEF	O
and	O
extensive	O
diffuse	O
fibrosis	O
in	O
the	O
areas	O
of	O
hypertrophy	O
.	O
Several	O
24	O
hour	O
Holter	O
recordings	O
were	O
performed	O
during	O
the	O
evolution	O
without	O
detecting	O
ventricular	O
tachycardias	O
or	O
frequent	O
ventricular	O
extrasystoles	O
or	O
new	O
episodes	O
of	O
AF	O
,	O
although	O
the	O
patient	O
reported	O
palpitations	O
about	O
twice	O
a	O
month	O
.	O
On	O
arrival	O
at	O
our	O
centre	O
,	O
to	O
which	O
he	O
was	O
referred	O
as	O
a	O
referral	O
unit	O
for	O
cardiomyopathies	O
and	O
other	O
familial	O
heart	O
diseases	O
,	O
the	O
patient	O
had	O
blood	O
pressure	O
BP	O
136	O
89	O
mmHg	O
,	O
RS	O
at	O
52	O
bpm	O
,	O
without	O
jugular	O
venous	O
engorgement	O
.	O
On	O
auscultation	O
,	O
cardiac	O
tones	O
were	O
rhythmic	O
without	O
murmurs	O
,	O
with	O
preserved	O
vesicular	O
murmur	O
and	O
no	O
pathological	O
sounds	O
.	O
The	O
lower	O
limbs	O
showed	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
There	O
were	O
no	O
skin	O
lesions	O
suggestive	O
of	O
cardio	O
cutaneous	O
syndromes	O
such	O
as	O
Fabry	O
or	O
Leopard	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
bradycardia	O
at	O
47	O
bpm	O
.	O
PR	O
140	O
ms	O
with	O
positive	O
delta	O
wave	O
in	O
V1	O
suggestive	O
of	O
left	O
accessory	O
pathway	O
.	O
QRS	O
160	O
ms	O
.	O
Left	O
axis	O
.	O
Elevated	O
R	O
wave	O
voltages	O
especially	O
in	O
left	O
precordial	O
and	O
deep	O
negative	O
T	O
waves	O
from	O
V1	O
to	O
V6	O
,	O
in	O
I	O
and	O
aVL	O
and	O
flattened	O
in	O
inferior	O
face	O
.	O
ECG	O
in	O
pre	O
excited	O
AF	O
irregular	O
wide	O
QRS	O
tachycardia	O
at	O
more	O
than	O
200	O
bpm	O
,	O
with	O
irregularity	O
in	O
QRS	O
morphology	O
and	O
width	O
and	O
in	O
RR	O
.	O
First	O
transthoracic	O
echocardiogram	O
TTE	O
concentric	O
hypertrophy	O
of	O
22	O
mm	O
and	O
midcavitary	O
obliteration	O
.	O
Severe	O
diastolic	O
dysfunction	O
.	O
Dilated	O
left	O
atrium	O
LA	O
.	O
LVEF	O
57	O
.	O
Moderate	O
right	O
ventricular	O
RV	O
dysfunction	O
.	O
CMR	O
short	O
axis	O
and	O
4	O
chambers	O
showing	O
severe	O
biventricular	O
hypertrophy	O
.	O
3C	O
,	O
D	O
and	O
E	O
sagittal	O
plane	O
,	O
4	O
chambers	O
and	O
short	O
axis	O
late	O
gadolinium	O
enhancement	O
showing	O
extensive	O
and	O
diffuse	O
uptake	O
in	O
areas	O
of	O
hypertrophy	O
.	O
First	O
24	O
hour	O
Holter	O
sinus	O
rhythm	O
at	O
45	O
87	O
bpm	O
.	O
No	O
significant	O
pauses	O
.	O
Low	O
density	O
ventricular	O
extrasystoles	O
.	O
Frequent	O
atrial	O
extrasystoles	O
.	O
Absence	O
of	O
ventricular	O
arrhythmias	O
or	O
AF	O
.	O
No	O
symptoms	O
reported	O
in	O
the	O
diary	O
.	O
First	O
electrophysiological	O
study	O
EPS	O
the	O
posteroseptal	O
medioseptal	O
accessory	O
pathway	O
was	O
identified	O
and	O
radiofrequency	O
ablation	O
was	O
attempted	O
.	O
The	O
procedure	O
was	O
performed	O
in	O
two	O
phases	O
,	O
but	O
neither	O
operator	O
was	O
able	O
to	O
achieve	O
even	O
transient	O
block	O
of	O
the	O
accessory	O
pathway	O
.	O
Ergometry	O
Bruce	O
protocol	O
.	O
The	O
test	O
was	O
stopped	O
after	O
6	O
minutes	O
due	O
to	O
fatigue	O
,	O
having	O
reached	O
53	O
of	O
maximum	O
heart	O
rate	O
HR	O
.	O
Normal	O
blood	O
pressure	O
response	O
.	O
No	O
arrhythmias	O
,	O
repolarisation	O
disturbances	O
or	O
chest	O
pain	O
.	O
Last	O
TTE	O
dilated	O
left	O
ventricle	O
LV	O
,	O
concentric	O
hypertrophy	O
more	O
striking	O
in	O
the	O
septum	O
with	O
apical	O
and	O
lateral	O
hypertrabeculation	O
,	O
severe	O
systolic	O
dysfunction	O
Simpson	O
biplane	O
10	O
15	O
.	O
Mild	O
moderate	O
mitral	O
insufficiency	O
MI	O
,	O
biauricular	O
dilatation	O
,	O
severely	O
dilated	O
RV	O
with	O
poor	O
systolic	O
function	O
,	O
moderate	O
tricuspid	O
insufficiency	O
TI	O
,	O
estimated	O
pulmonary	O
systolic	O
pressure	O
51	O
56	O
mmHg	O
.	O
CLINICAL	O
EVOLUTION	O
At	O
the	O
first	O
assessment	O
in	O
our	O
centre	O
2013	O
,	O
an	O
ECG	O
was	O
performed	O
which	O
showed	O
the	O
previously	O
described	O
findings	O
and	O
a	O
new	O
echocardiogram	O
,	O
where	O
in	O
addition	O
to	O
severe	O
hypertrophy	O
,	O
biauricular	O
dilatation	O
,	O
severe	O
biventricular	O
systolic	O
dysfunction	O
and	O
diastolic	O
dysfunction	O
with	O
signs	O
of	O
increased	O
filling	O
pressures	O
were	O
observed	O
.	O
An	O
exercise	O
stress	O
test	O
was	O
performed	O
and	O
stopped	O
after	O
6	O
minutes	O
due	O
to	O
pain	O
in	O
MID	O
,	O
having	O
reached	O
53	O
of	O
target	O
HR	O
,	O
with	O
normal	O
blood	O
pressure	O
response	O
,	O
no	O
chest	O
pain	O
and	O
no	O
repolarisation	O
abnormalities	O
.	O
Due	O
to	O
the	O
atypical	O
presentation	O
of	O
the	O
clinical	O
picture	O
,	O
with	O
severe	O
concentric	O
biventricular	O
hypertrophy	O
,	O
diffuse	O
late	O
enhancement	O
,	O
systolic	O
and	O
diastolic	O
dysfunction	O
,	O
onset	O
of	O
AF	O
at	O
an	O
early	O
age	O
and	O
presence	O
of	O
pre	O
excitation	O
,	O
the	O
differential	O
diagnosis	O
of	O
hypertrophic	O
cardiomyopathy	O
was	O
made	O
due	O
to	O
pathogenic	O
variants	O
in	O
the	O
sarcomeric	O
genes	O
with	O
other	O
possible	O
aetiologies	O
.	O
A	O
genetic	O
study	O
was	O
performed	O
in	O
which	O
a	O
pathogenic	O
variant	O
in	O
PRKAG2	O
was	O
found	O
.	O
In	O
2015	O
he	O
was	O
admitted	O
again	O
for	O
asthenia	O
and	O
general	O
malaise	O
,	O
and	O
severe	O
sinus	O
bradycardia	O
with	O
complete	O
paroxysmal	O
AVB	O
was	O
detected	O
.	O
Due	O
to	O
the	O
need	O
for	O
pacing	O
and	O
the	O
high	O
risk	O
of	O
sudden	O
death	O
severe	O
biventricular	O
hypertrophy	O
,	O
systolic	O
dysfunction	O
,	O
dilated	O
LA	O
,	O
non	O
ablatable	O
accessory	O
pathway	O
with	O
antegrade	O
conduction	O
at	O
more	O
than	O
200	O
bpm	O
,	O
a	O
confirmed	O
episode	O
of	O
pre	O
excited	O
AF	O
and	O
cardiogenic	O
syncope	O
,	O
it	O
was	O
decided	O
to	O
implant	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
.	O
During	O
the	O
evolution	O
,	O
diastolic	O
and	O
systolic	O
dysfunction	O
progressed	O
to	O
become	O
severe	O
despite	O
optimal	O
medical	O
treatment	O
with	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
ACE	B-FARMACO
inhibitors	I-FARMACO
,	O
antialdosterone	O
and	O
beta	O
blockers	O
,	O
and	O
the	O
patient	O
,	O
aged	O
40	O
years	O
,	O
is	O
currently	O
in	O
a	O
pre	O
transplant	O
cardiac	O
situation	O
.	O
DIAGNOSIS	O
Severe	O
biventricular	O
hypertrophy	O
.	O
Pathogenic	O
variant	O
in	O
PRKAG2	O
.	O
Extensive	O
myocardial	O
fibrosis	O
in	O
CMR	O
.	O
Wolff	O
Parkinson	O
White	O
syndrome	O
by	O
left	O
posteromedial	O
accessory	O
pathway	O
.	O
Episode	O
of	O
pre	O
excited	O
AF	O
.	O
Cardiogenic	O
syncope	O
of	O
unfiliated	O
aetiology	O
pre	O
excited	O
AF	O
vs	O
VT	O
.	O
Progressive	O
biventricular	O
systolic	O
dysfunction	O
and	O
diastolic	O
dysfunction	O
.	O
Embolism	O
in	O
right	O
femoral	O
artery	O
possibly	O
secondary	O
to	O
AF	O
paroxysm	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
41	O
year	O
old	O
woman	O
.	O
No	O
drug	O
allergies	O
.	O
Medical	O
history	O
migraines	O
.	O
Early	O
menopause	O
at	O
the	O
age	O
of	O
37	O
,	O
no	O
other	O
known	O
illnesses	O
.	O
Abortion	O
at	O
the	O
age	O
of	O
21	O
.	O
No	O
family	O
history	O
of	O
heart	O
disease	O
.	O
Active	O
smoking	O
.	O
When	O
asked	O
about	O
other	O
toxic	O
habits	O
,	O
she	O
did	O
not	O
mention	O
them	O
.	O
CURRENT	O
ILLNESS	O
On	O
10	O
02	O
2019	O
she	O
was	O
referred	O
to	O
the	O
hospital	O
emergency	O
room	O
from	O
her	O
health	O
centre	O
,	O
accompanied	O
by	O
her	O
brother	O
,	O
for	O
presenting	O
progressive	O
dyspnoea	O
of	O
one	O
month	O
's	O
evolution	O
until	O
becoming	O
minimal	O
effort	O
accompanied	O
by	O
cough	O
and	O
orthopnoea	O
on	O
two	O
pillows	O
in	O
the	O
last	O
3	O
days	O
.	O
Cough	O
without	O
productive	O
expectoration	O
,	O
on	O
one	O
occasion	O
with	O
haematic	O
strands	O
.	O
There	O
was	O
no	O
concomitant	O
infectious	O
semiology	O
.	O
In	O
the	O
last	O
three	O
days	O
he	O
also	O
reported	O
central	O
thoracic	O
discomfort	O
on	O
exertion	O
and	O
deep	O
inspiration	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
140	O
95	O
mmHg	O
.	O
Conscious	O
and	O
oriented	O
,	O
slightly	O
tachypnoeic	O
at	O
rest	O
24	O
breaths	O
per	O
minute	O
.	O
Jugular	O
venous	O
pulse	O
elevated	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
at	O
105	O
bpm	O
with	O
audible	O
third	O
sound	O
.	O
Pulmonary	O
auscultation	O
semiology	O
of	O
bilateral	O
pleural	O
effusion	O
,	O
more	O
marked	O
on	O
the	O
left	O
.	O
No	O
oedema	O
in	O
the	O
extremities	O
or	O
decubitus	O
.	O
The	O
on	O
call	O
cardiology	O
department	O
was	O
contacted	O
at	O
that	O
time	O
.	O
We	O
performed	O
portable	O
echocardioscopy	O
we	O
observed	O
dilated	O
left	O
ventricle	O
with	O
systolic	O
dysfunction	O
at	O
the	O
expense	O
of	O
global	O
hypocontractility	O
,	O
mitral	O
valve	O
with	O
dilation	O
of	O
the	O
mitral	O
annulus	O
and	O
functional	O
central	O
insufficiency	O
that	O
appears	O
to	O
be	O
of	O
moderate	O
degree	O
and	O
bilateral	O
pleural	O
effusion	O
.	O
It	O
was	O
decided	O
to	O
admit	O
the	O
patient	O
to	O
the	O
cardiology	O
ward	O
as	O
the	O
first	O
episode	O
of	O
heart	O
failure	O
in	O
a	O
patient	O
with	O
no	O
personal	O
cardiological	O
history	O
and	O
,	O
a	O
priori	O
,	O
without	O
a	O
definite	O
aetiology	O
,	O
in	O
order	O
to	O
study	O
the	O
systolic	O
dysfunction	O
and	O
decompensation	O
.	O
On	O
arrival	O
at	O
the	O
ward	O
and	O
once	O
the	O
patient	O
was	O
in	O
the	O
room	O
,	O
her	O
brother	O
approached	O
us	O
to	O
tell	O
us	O
something	O
important	O
that	O
the	O
patient	O
had	O
been	O
hiding	O
from	O
us	O
it	O
turns	O
out	O
that	O
our	O
patient	O
,	O
although	O
she	O
had	O
previously	O
denied	O
it	O
,	O
is	O
a	O
regular	O
user	O
of	O
amphetamines	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
with	O
negative	O
T	O
waves	O
in	O
V2	O
V6	O
and	O
inferior	O
face	O
.	O
Blood	O
tests	O
Biochemistry	O
glucose	O
96	O
mg	O
dl	O
,	O
urea	O
0	O
.	O
37	O
g	O
l	O
,	O
creatinine	O
1	O
.	O
06	O
mg	O
dl	O
,	O
troponin	O
Tus	O
41	O
.	O
73	O
ng	O
l	O
,	O
sodium	O
142	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
67	O
mEq	O
l	O
,	O
NT	O
proBNP	O
5993	O
pg	O
ml	O
.	O
Arterial	O
blood	O
gases	O
pH	O
7	O
.	O
43	O
,	O
pO2	O
104mmHg	O
,	O
pCO2	O
32mmHg	O
,	O
sPO	O
298	O
.	O
2	O
,	O
CO3H	O
21	O
.	O
4mmol	O
l	O
.	O
Blood	O
count	O
Hb	O
11	O
.	O
8	O
g	O
dl	O
,	O
Hct	O
34	O
.	O
6	O
,	O
leukocytes	O
8l3	O
mil	O
mm3	O
with	O
55	O
neutrophils	O
,	O
platelets	O
172	O
mil	O
mm3	O
.	O
Coagulation	O
no	O
alterations	O
,	O
fibrinogen	O
378	O
mg	O
dl	O
.	O
Urine	O
toxicity	O
positive	O
for	O
amphetamines	O
.	O
Chest	O
X	O
ray	O
signs	O
of	O
interstitial	O
oedema	O
together	O
with	O
cardiomegaly	O
,	O
left	O
costophrenic	O
sinus	O
impingement	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
LV	O
dilated	O
and	O
hypertrabeculated	O
at	O
apical	O
level	O
with	O
moderate	O
dysfunction	O
Simpson	O
biplane	O
33	O
at	O
the	O
expense	O
of	O
global	O
hypocontractility	O
.	O
Increased	O
filling	O
pressures	O
mean	O
E	O
e	O
"	O
17	O
cm	O
sec	O
.	O
Left	O
atrial	O
dilatation	O
volume	O
94	O
ml	O
with	O
atrial	O
septal	O
aneurysm	O
without	O
shunt	O
.	O
Mild	O
functional	O
mitral	O
insufficiency	O
.	O
Right	O
ventricle	O
RV	O
equally	O
hypertrabeculated	O
with	O
normal	O
size	O
and	O
contractility	O
.	O
Dilated	O
IVC	O
.	O
Normal	O
pericardium	O
.	O
Coronary	O
angiography	O
left	O
dominance	O
.	O
Non	O
significant	O
stenosis	O
in	O
the	O
first	O
obtuse	O
marginal	O
.	O
Rest	O
of	O
the	O
coronary	O
tree	O
without	O
angiographic	O
lesions	O
.	O
Cardiac	O
MRI	O
severely	O
dilated	O
LV	O
LVEDV	O
240	O
ml	O
,	O
LVESV	O
144	O
ml	O
hypertrabeculated	O
at	O
apical	O
and	O
lateral	O
level	O
,	O
with	O
discrete	O
improvement	O
of	O
ventricular	O
function	O
LVEF	O
40	O
with	O
global	O
hypokinesia	O
and	O
akinesia	O
at	O
mid	O
inferolateral	O
,	O
apical	O
and	O
mid	O
inferior	O
septal	O
level	O
.	O
RV	O
of	O
normal	O
size	O
,	O
hypertrabeculated	O
at	O
the	O
free	O
wall	O
level	O
and	O
with	O
RVEF	O
67	O
.	O
There	O
was	O
also	O
evidence	O
of	O
a	O
small	O
apical	O
thrombus	O
6	O
x	O
9	O
mm	O
.	O
In	O
the	O
T1	O
weighted	O
sequences	O
,	O
two	O
foci	O
of	O
subendocardial	O
enhancement	O
are	O
observed	O
at	O
the	O
mid	O
and	O
apical	O
inferolateral	O
level	O
and	O
mid	O
and	O
apical	O
septo	O
inferior	O
septal	O
level	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
had	O
a	O
very	O
good	O
response	O
to	O
depletive	O
treatment	O
with	O
improvement	O
of	O
the	O
congestive	O
signs	O
.	O
Treatment	O
was	O
started	O
for	O
heart	O
failure	O
with	O
systolic	O
dysfunction	O
using	O
beta	O
blockers	O
,	O
ACE	B-FARMACO
inhibitors	I-FARMACO
and	O
antialdosterone	O
.	O
The	O
study	O
was	O
completed	O
with	O
a	O
regular	O
echocardiogram	O
and	O
coronary	O
angiography	O
.	O
The	O
diuretic	O
dose	O
was	O
titrated	O
during	O
admission	O
and	O
the	O
patient	O
was	O
discharged	O
a	O
few	O
days	O
later	O
with	O
functional	O
class	O
I	O
,	O
maintaining	O
treatment	O
of	O
the	O
systolic	O
dysfunction	O
.	O
Cardiac	O
MRI	O
was	O
performed	O
on	O
an	O
outpatient	O
basis	O
once	O
the	O
patient	O
was	O
discharged	O
one	O
month	O
after	O
the	O
echocardiogram	O
.	O
After	O
hospital	O
discharge	O
,	O
the	O
patient	O
has	O
ceased	O
the	O
consumption	O
of	O
toxic	O
substances	O
,	O
remains	O
in	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
I	O
II	O
,	O
and	O
has	O
not	O
presented	O
new	O
episodes	O
of	O
decompensation	O
.	O
DIAGNOSIS	O
Acute	O
congestive	O
heart	O
failure	O
,	O
first	O
episode	O
of	O
decompensation	O
.	O
Dilated	O
cardiomyopathy	O
with	O
moderate	O
systolic	O
dysfunction	O
secondary	O
to	O
chronic	O
amphetamine	O
use	O
.	O
Ejection	O
fraction	O
slightly	O
recovered	O
at	O
follow	O
up	O
.	O
Amphetamine	O
abuse	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
71	O
year	O
old	O
woman	O
,	O
with	O
no	O
known	O
drug	O
allergies	O
,	O
hypertensive	O
,	O
obese	O
,	O
dyslipidemic	O
and	O
diabetic	O
;	O
with	O
a	O
history	O
of	O
hypothyroidism	O
under	O
replacement	O
therapy	O
and	O
left	O
knee	O
replacement	O
surgery	O
5	O
years	O
ago	O
.	O
No	O
personal	O
or	O
family	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
She	O
is	O
on	O
regular	O
treatment	O
with	O
omeprazole	B-FARMACO
20	O
mg	O
24h	O
,	O
simvastatin	B-FARMACO
20	O
mg	O
24h	O
,	O
olmesartan	B-FARMACO
amlodipine	I-FARMACO
hydrochlorothiazide	I-FARMACO
40	O
10	O
12	O
.	O
5	O
mg	O
24h	O
,	O
levothyroxine	B-FARMACO
175	O
mcg	O
24h	O
and	O
insulin	B-FARMACO
.	O
CURRENT	O
ILLNESS	O
The	O
patient	O
consults	O
because	O
for	O
the	O
last	O
3	O
days	O
she	O
has	O
been	O
presenting	O
progressive	O
dyspnoea	O
until	O
minimal	O
effort	O
,	O
together	O
with	O
episodes	O
of	O
orthopnoea	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
;	O
she	O
does	O
not	O
report	O
episodes	O
of	O
angina	O
or	O
other	O
associated	O
symptoms	O
.	O
She	O
presented	O
significant	O
respiratory	O
distress	O
,	O
so	O
the	O
emergency	O
health	O
services	O
were	O
notified	O
and	O
she	O
was	O
transferred	O
to	O
our	O
centre	O
.	O
Prior	O
to	O
admission	O
,	O
the	O
patient	O
was	O
in	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
I	O
IV	O
.	O
PHYSICAL	O
EXAMINATION	O
General	O
condition	O
was	O
fair	O
.	O
Blood	O
pressure	O
BP	O
140	O
70	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
110	O
bpm	O
.	O
PVY	O
not	O
assessable	O
.	O
O2	O
saturation	O
with	O
reservoir	O
FiO2	O
50	O
80	O
.	O
Tachypneic	O
,	O
with	O
significant	O
respiratory	O
work	O
.	O
Conscious	O
and	O
oriented	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
.	O
Systolic	O
murmur	O
in	O
mitral	O
focus	O
III	O
VI	O
.	O
Pulmonary	O
auscultation	O
fine	O
crackles	O
to	O
upper	O
lung	O
fields	O
and	O
auscultatory	O
silence	O
in	O
the	O
right	O
hemithorax	O
.	O
Abdomen	O
globular	O
,	O
non	O
painful	O
.	O
No	O
masses	O
or	O
megaliths	O
palpable	O
.	O
No	O
ascites	O
.	O
Lower	O
limbs	O
pulses	O
present	O
with	O
slight	O
bilateral	O
pretibial	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
,	O
PR	O
220ms	O
,	O
narrow	O
QRS	O
.	O
Inferior	O
Q	O
wave	O
.	O
Poor	O
R	O
wave	O
progression	O
in	O
precordial	O
leads	O
.	O
QTc	O
of	O
520	O
ms	O
.	O
Portable	O
chest	O
X	O
ray	O
on	O
admission	O
cardiomegaly	O
.	O
Bilateral	O
alveolar	O
oedema	O
.	O
Right	O
pleural	O
effusion	O
.	O
Laboratory	O
tests	O
during	O
admission	O
Haemogram	O
11	O
,	O
100	O
leukocytes	O
76	O
neutrophils	O
,	O
haemoglobin	O
12	O
.	O
5	O
g	O
dl	O
,	O
haematocrit	O
43	O
,	O
388	O
,	O
000	O
platelets	O
,	O
Biochemistry	O
creatinine	O
1	O
.	O
02	O
mg	O
dl	O
glomerular	O
filtration	O
rate	O
52	O
ml	O
min	O
m2	O
,	O
urea	O
46	O
mg	O
dl	O
,	O
ions	O
normal	O
.	O
Peak	O
myocardial	O
damage	O
markers	O
CK	O
316	O
U	O
l	O
CK	O
MB40	O
,	O
TnUS	O
332	O
ng	O
dl	O
.	O
Hb1AC	O
6	O
.	O
8	O
.	O
Total	O
cholesterol	O
143	O
g	O
dl	O
,	O
HDL	O
41	O
mg	O
dl	O
,	O
Triglycerides	O
76	O
mg	O
dl	O
.	O
Coagulation	O
INR	O
1	O
.	O
06	O
;	O
prothrombin	O
rate	O
91	O
.	O
proBNP	O
on	O
admission	O
17680	O
pg	O
ml	O
.	O
Transthoracic	O
echocardiogram	O
dilated	O
left	O
ventricle	O
DTd	O
61	O
mm	O
,	O
with	O
postero	O
basal	O
and	O
infero	O
basal	O
akinesia	O
.	O
LVEF	O
calculated	O
by	O
Simpson	O
biplane	O
of	O
35	O
.	O
Right	O
ventricular	O
dysfunction	O
TAPSE	O
11	O
mm	O
.	O
Severe	O
mitral	O
insufficiency	O
by	O
Carpentier	O
mechanism	O
IIIb	O
.	O
Mild	O
tricuspid	O
regurgitation	O
with	O
pulmonary	O
hypertension	O
at	O
rest	O
50	O
mmHg	O
.	O
Transesophageal	O
echocardiogram	O
mitral	O
valve	O
with	O
calcification	O
of	O
the	O
annulus	O
,	O
fibrosis	O
of	O
the	O
leaflets	O
with	O
restriction	O
of	O
movement	O
of	O
the	O
posterior	O
leaflet	O
leading	O
to	O
severe	O
regurgitation	O
.	O
Posterior	O
leaflet	O
10	O
11mm	O
.	O
Mild	O
tricuspid	O
regurgitation	O
.	O
Right	O
ventricular	O
dysfunction	O
.	O
Left	O
atrial	O
appendage	O
free	O
of	O
thrombus	O
.	O
Haemodynamic	O
study	O
three	O
vessel	O
coronary	O
artery	O
disease	O
.	O
Right	O
dominance	O
.	O
Coronary	O
anomaly	O
consisting	O
of	O
origin	O
of	O
all	O
the	O
coronary	O
arteries	O
in	O
the	O
right	O
sinus	O
of	O
Valsalva	O
,	O
with	O
independent	O
ostium	O
.	O
Severe	O
stenosis	O
of	O
the	O
middle	O
anterior	O
descending	O
artery	O
ADA	O
,	O
severe	O
stenosis	O
in	O
the	O
first	O
obtuse	O
marginal	O
OM1	O
and	O
occlusion	O
of	O
chronic	O
appearance	O
in	O
the	O
distal	O
right	O
coronary	O
artery	O
RCA	O
,	O
whose	O
distal	O
vessel	O
is	O
filled	O
by	O
heterocoronary	O
circulation	O
.	O
Ventriculography	O
severely	O
dilated	O
left	O
ventricle	O
LV	O
,	O
with	O
severe	O
depression	O
of	O
LVEF	O
31	O
at	O
the	O
expense	O
of	O
inferior	O
and	O
posterolateral	O
akinesia	O
and	O
hypokinesia	O
of	O
the	O
remaining	O
segments	O
.	O
Angioplasty	O
the	O
OM1	O
lesion	O
was	O
predilated	O
and	O
a	O
2	O
.	O
75	O
x	O
15	O
mm	O
drug	O
eluting	O
stent	O
was	O
implanted	O
to	O
cover	O
the	O
lesion	O
with	O
good	O
angiographic	O
results	O
.	O
The	O
middle	O
LAD	O
lesion	O
is	O
then	O
predilated	O
with	O
a	O
balloon	O
and	O
a	O
2	O
.	O
25	O
x	O
38	O
mm	O
drug	O
eluting	O
stent	O
is	O
implanted	O
with	O
a	O
good	O
final	O
angiographic	O
result	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
the	O
patient	O
was	O
found	O
to	O
have	O
acute	O
pulmonary	O
oedema	O
and	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
,	O
where	O
ventilatory	O
support	O
was	O
started	O
with	O
non	O
invasive	O
mechanical	O
ventilation	O
and	O
diuretic	O
and	O
vasodilator	O
treatment	O
with	O
a	O
good	O
response	O
,	O
achieving	O
stabilisation	O
of	O
the	O
clinical	O
picture	O
within	O
a	O
few	O
hours	O
.	O
An	O
echocardiogram	O
showed	O
severe	O
mitral	O
regurgitation	O
due	O
to	O
restriction	O
of	O
posterior	O
leaflet	O
mobility	O
mechanism	O
IIIb	O
of	O
Carpentier	O
's	O
classification	O
.	O
Subsequently	O
,	O
a	O
haemodynamic	O
study	O
was	O
performed	O
which	O
revealed	O
a	O
coronary	O
anomaly	O
consisting	O
of	O
the	O
origin	O
of	O
the	O
left	O
coronary	O
tree	O
in	O
the	O
right	O
sinus	O
of	O
Valsalva	O
and	O
severe	O
three	O
vessel	O
coronary	O
artery	O
disease	O
.	O
After	O
discussing	O
the	O
case	O
with	O
the	O
cardiac	O
surgery	O
department	O
of	O
our	O
centre	O
,	O
percutaneous	O
revascularisation	O
of	O
OM1	O
and	O
ADA	O
was	O
decided	O
,	O
with	O
subsequent	O
re	O
evaluation	O
of	O
mitral	O
insufficiency	O
MI	O
.	O
After	O
percutaneous	O
revascularisation	O
,	O
the	O
patient	O
showed	O
good	O
clinical	O
evolution	O
,	O
although	O
the	O
heart	O
failure	O
data	O
persisted	O
despite	O
diuretic	O
treatment	O
,	O
so	O
after	O
discussing	O
the	O
therapeutic	O
alternatives	O
with	O
the	O
heart	O
team	O
and	O
in	O
agreement	O
with	O
the	O
patient	O
,	O
percutaneous	O
treatment	O
of	O
her	O
mitral	O
valve	O
pathology	O
was	O
decided	O
using	O
a	O
MitraClip	O
device	O
;	O
this	O
procedure	O
was	O
successfully	O
performed	O
one	O
month	O
after	O
hospital	O
discharge	O
,	O
with	O
a	O
single	O
clip	O
implanted	O
in	O
the	O
mitral	O
position	O
,	O
guided	O
by	O
fluoroscopy	O
and	O
transesophageal	O
echocardiography	O
,	O
with	O
a	O
reduction	O
in	O
regurgitation	O
from	O
grade	O
4	O
to	O
1	O
,	O
with	O
no	O
post	O
implant	O
residual	O
mitral	O
stenosis	O
.	O
After	O
the	O
procedure	O
,	O
the	O
patient	O
had	O
a	O
good	O
clinical	O
evolution	O
and	O
was	O
discharged	O
two	O
days	O
after	O
the	O
procedure	O
.	O
DIAGNOSIS	O
Dilated	O
cardiomyopathy	O
of	O
ischaemic	O
aetiology	O
with	O
moderate	O
left	O
ventricular	O
dysfunction	O
35	O
.	O
Old	O
inferior	O
myocardial	O
infarction	O
.	O
Coronary	O
anomaly	O
origin	O
of	O
all	O
coronary	O
arteries	O
in	O
the	O
right	O
sinus	O
of	O
Valsalva	O
,	O
with	O
independent	O
ostium	O
.	O
Severe	O
three	O
vessel	O
coronary	O
artery	O
disease	O
.	O
Partial	O
percutaneous	O
revascularisation	O
anterior	O
descending	O
AD	O
and	O
circumflex	O
Cx	O
.	O
Severe	O
mitral	O
regurgitation	O
by	O
Carpentier	O
mechanism	O
IIIb	O
.	O
Percutaneous	O
mitral	O
repair	O
by	O
MitraClip	O
device	O
successful	O
and	O
without	O
complications	O
.	O

PERSONAL	O
HISTORY	O
Toxic	O
habits	O
smoker	O
of	O
1	O
cigarette	O
day	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
.	O
Anxiety	O
depressive	O
syndrome	O
.	O
Usual	O
treatment	O
fluoxetine	B-FARMACO
20	O
mg	O
.	O
CURRENT	O
ILLNESS	O
A	O
54	O
year	O
old	O
man	O
consulted	O
for	O
chest	O
pain	O
of	O
8	O
hours	O
'	O
duration	O
,	O
oppressive	O
,	O
radiating	O
to	O
the	O
left	O
upper	O
limb	O
and	O
jaw	O
.	O
Although	O
the	O
pain	O
started	O
in	O
the	O
early	O
hours	O
of	O
the	O
morning	O
,	O
the	O
patient	O
did	O
not	O
consult	O
his	O
primary	O
care	O
centre	O
until	O
late	O
in	O
the	O
morning	O
.	O
He	O
reported	O
similar	O
symptoms	O
in	O
the	O
previous	O
days	O
,	O
with	O
similar	O
episodes	O
of	O
chest	O
pain	O
that	O
were	O
self	O
limiting	O
within	O
the	O
first	O
10	O
minutes	O
.	O
She	O
denies	O
intercurrent	O
infectious	O
clinical	O
manifestations	O
.	O
No	O
other	O
symptoms	O
.	O
On	O
arrival	O
at	O
the	O
primary	O
care	O
centre	O
,	O
an	O
electrocardiogram	O
was	O
performed	O
showing	O
sinus	O
rhythm	O
at	O
85	O
bpm	O
with	O
ST	O
segment	O
elevation	O
in	O
inferior	O
leads	O
.	O
Acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
300	O
mg	O
and	O
ticagrelor	B-FARMACO
180	O
mg	O
were	O
administered	O
and	O
the	O
Infarction	O
Code	O
was	O
activated	O
.	O
On	O
arrival	O
at	O
our	O
centre	O
,	O
the	O
patient	O
was	O
found	O
to	O
be	O
sweaty	O
,	O
in	O
fair	O
general	O
condition	O
,	O
with	O
persistent	O
chest	O
pain	O
and	O
the	O
electrocardiographic	O
abnormalities	O
described	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
140	O
60	O
mmHg	O
,	O
heart	O
rate	O
HR	O
85	O
bpm	O
,	O
Sat	O
95	O
baseline	O
.	O
General	O
condition	O
was	O
fair	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
added	O
noises	O
.	O
The	O
rest	O
of	O
the	O
examination	O
was	O
of	O
no	O
interest	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
.	O
PR	O
200	O
msg	O
.	O
Narrow	O
QRS	O
.	O
Normal	O
axis	O
.	O
ST	O
segment	O
elevation	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
and	O
V6	O
.	O
Chest	O
X	O
ray	O
CTI	O
at	O
the	O
limit	O
of	O
normality	O
.	O
No	O
pleural	O
effusion	O
.	O
No	O
radiological	O
congestive	O
data	O
.	O
Analysis	O
on	O
arrival	O
haemoglobin	O
12	O
.	O
4	O
g	O
dl	O
.	O
Leukocytes	O
10	O
.	O
82	O
Miles	O
mm3	O
.	O
Urea	O
49	O
.	O
0	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
85	O
mg	O
dl	O
.	O
Sodium	O
135	O
mEq	O
l	O
.	O
Potassium	O
3	O
.	O
8	O
mEq	O
l	O
.	O
Total	O
bilirubin	O
0	O
.	O
64	O
mg	O
dl	O
.	O
GOT	O
AST	O
63	O
U	O
l	O
.	O
GPT	O
ALT	O
134	O
U	O
l	O
.	O
GGT	O
503	O
U	O
l	O
.	O
LDH	O
702	O
U	O
l	O
.	O
Alkaline	O
phosphatase	O
214	O
U	O
l	O
.	O
CK	O
259	O
U	O
l	O
.	O
Troponin	O
T	O
high	O
sensitivity	O
2790	O
.	O
00	O
ng	O
l	O
.	O
Coronary	O
angiography	O
thrombotic	O
occlusion	O
of	O
the	O
circumflex	O
artery	O
ACx	O
,	O
immediately	O
distal	O
to	O
an	O
aneurysmal	O
segment	O
.	O
The	O
thrombotic	O
lesion	O
was	O
crossed	O
with	O
an	O
angioplasty	O
guidewire	O
,	O
partially	O
recovering	O
distal	O
flow	O
,	O
visualising	O
an	O
intraluminal	O
contrast	O
defect	O
compatible	O
with	O
a	O
large	O
amount	O
of	O
intracoronary	O
thrombus	O
.	O
For	O
this	O
reason	O
it	O
was	O
decided	O
to	O
perform	O
thromboaspiration	O
;	O
abundant	O
red	O
thrombus	O
was	O
removed	O
,	O
thus	O
recovering	O
distal	O
TIMI	O
3	O
flow	O
.	O
A	O
marginal	O
branch	O
remained	O
occluded	O
despite	O
repeated	O
attempts	O
at	O
thromboaspiration	O
and	O
balloon	O
angioplasty	O
.	O
Given	O
the	O
high	O
thrombotic	O
content	O
,	O
intracoronary	O
abciximab	B-FARMACO
was	O
added	O
to	O
the	O
double	O
antiplatelet	O
therapy	O
already	O
administered	O
and	O
it	O
was	O
decided	O
to	O
maintain	O
anticoagulation	O
with	O
enoxaparin	B-FARMACO
at	O
therapeutic	O
doses	O
.	O
Echocardiogram	O
after	O
catheterisation	O
left	O
ventricle	O
of	O
normal	O
size	O
with	O
inferior	O
akinesia	O
and	O
inferolateral	O
hypokinesia	O
,	O
leading	O
to	O
moderate	O
ventricular	O
dysfunction	O
LVEF	O
35	O
.	O
Normal	O
RVEF	O
.	O
Normal	O
sized	O
atria	O
.	O
Absence	O
of	O
significant	O
valvular	O
heart	O
disease	O
.	O
Trivial	O
tricuspid	O
insufficiency	O
that	O
allows	O
estimating	O
a	O
systolic	O
pressure	O
in	O
the	O
pulmonary	O
artery	O
of	O
25	O
mmHg	O
.	O
Mild	O
detachment	O
of	O
pericardial	O
leaflets	O
.	O
Normal	O
sized	O
inferior	O
vena	O
cava	O
with	O
physiological	O
inspiratory	O
collapse	O
.	O
ECG	O
at	O
discharge	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
.	O
Normal	O
PR	O
.	O
Q	O
wave	O
in	O
II	O
,	O
III	O
and	O
AVF	O
.	O
Persistence	O
of	O
minimal	O
ST	O
underleveling	O
in	O
these	O
leads	O
and	O
in	O
V5	O
V6	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
initially	O
presented	O
a	O
good	O
evolution	O
in	O
the	O
coronary	O
unit	O
,	O
with	O
no	O
new	O
episodes	O
of	O
chest	O
pain	O
or	O
signs	O
of	O
heart	O
failure	O
.	O
Monitoring	O
showed	O
no	O
ventricular	O
arrhythmias	O
.	O
Two	O
days	O
later	O
,	O
he	O
began	O
to	O
experience	O
chest	O
pain	O
that	O
worsened	O
with	O
inspiration	O
and	O
decubitus	O
,	O
with	O
a	O
clear	O
pericardial	O
profile	O
,	O
accompanied	O
by	O
elevated	O
acute	O
phase	O
reactants	O
in	O
the	O
blood	O
tests	O
CRP	O
16	O
,	O
ESR	O
95	O
.	O
A	O
new	O
echocardiogram	O
was	O
performed	O
and	O
reported	O
"	O
Study	O
performed	O
with	O
HR	O
87	O
bpm	O
and	O
BP	O
102	O
73	O
mmHg	O
.	O
Left	O
ventricle	O
LV	O
without	O
being	O
able	O
to	O
estimate	O
real	O
size	O
,	O
with	O
normal	O
wall	O
thickness	O
,	O
except	O
for	O
the	O
lower	O
basal	O
segment	O
.	O
Severe	O
ventricular	O
dysfunction	O
LVEF	O
33	O
.	O
Lateral	O
and	O
inferior	O
akinesia	O
and	O
severe	O
hypokinesia	O
of	O
the	O
rest	O
of	O
the	O
segments	O
.	O
Right	O
ventricle	O
RV	O
of	O
normal	O
size	O
with	O
mild	O
systolic	O
dysfunction	O
.	O
Normal	O
sized	O
atria	O
,	O
with	O
right	O
atrium	O
with	O
diastolic	O
collapse	O
.	O
Mitral	O
valve	O
of	O
normal	O
appearance	O
and	O
function	O
.	O
Anatomically	O
normal	O
aortic	O
valve	O
with	O
aortic	O
flow	O
recording	O
with	O
inspiratory	O
descent	O
of	O
20	O
.	O
Severe	O
circumferential	O
pericardial	O
effusion	O
maximum	O
diameter	O
28	O
mm	O
in	O
subxiphoid	O
plane	O
,	O
rest	O
of	O
the	O
planes	O
approximately	O
15	O
18	O
mm	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
at	O
the	O
limit	O
of	O
dilatation	O
with	O
absence	O
of	O
inspiratory	O
collapse	O
and	O
pattern	O
in	O
suprahepatic	O
veins	O
with	O
inversion	O
of	O
the	O
respiratory	O
sinus	O
Y	O
,	O
compatible	O
with	O
haemodynamic	O
compromise	O
.	O
Contrast	O
was	O
administered	O
to	O
assess	O
extravasation	O
to	O
the	O
pericardial	O
space	O
without	O
contrast	O
passage	O
.	O
After	O
the	O
echocardiogram	O
,	O
pericardiocentesis	O
was	O
performed	O
with	O
extraction	O
of	O
abundant	O
haematic	O
fluid	O
.	O
Subsequently	O
,	O
the	O
patient	O
evolved	O
satisfactorily	O
without	O
further	O
incidents	O
.	O
DIAGNOSIS	O
Acute	O
ST	O
segment	O
elevation	O
myocardial	O
infarction	O
STEMI	O
inferolateral	O
Killip	O
I	O
.	O
Severe	O
vessel	O
disease	O
circumflex	O
artery	O
with	O
aneurysm	O
and	O
thrombotic	O
occlusion	O
.	O
Effective	O
thromboaspiration	O
.	O
Severe	O
ventricular	O
dysfunction	O
.	O
Epistenocardial	O
pericarditis	O
.	O
Severe	O
pericardial	O
effusion	O
with	O
cardiac	O
tamponade	O
.	O
Evacuative	O
pericardiocentesis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Male	O
,	O
78	O
years	O
old	O
.	O
PERSONAL	O
HISTORY	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
hypertension	O
HT	O
,	O
diabetes	O
mellitus	O
with	O
poor	O
metabolic	O
control	O
with	O
target	O
organ	O
damage	O
,	O
dyslipidaemia	O
.	O
Cardiovascular	O
history	O
Rheumatic	O
fever	O
in	O
childhood	O
.	O
Rheumatic	O
mitro	O
aortic	O
valve	O
disease	O
.	O
Mitral	O
valve	O
replacement	O
on	O
three	O
occasions	O
Surgery	O
for	O
severe	O
mitral	O
stenosis	O
in	O
2006	O
.	O
St	O
Jude	O
metal	O
mitral	O
prosthesis	O
.	O
Mitral	O
valve	O
replacement	O
with	O
biological	O
prosthesis	O
due	O
to	O
valve	O
thrombosis	O
2007	O
.	O
Mitral	O
and	O
aortic	O
valve	O
replacement	O
with	O
biological	O
prosthesis	O
2018	O
due	O
to	O
mitral	O
prosthetic	O
degeneration	O
and	O
moderate	O
aortic	O
stenosis	O
.	O
Recent	O
admission	O
discharged	O
one	O
week	O
ago	O
after	O
prolonged	O
admission	O
30	O
day	O
stay	O
due	O
to	O
clinical	O
heart	O
failure	O
,	O
deterioration	O
of	O
renal	O
function	O
in	O
this	O
context	O
and	O
complications	O
of	O
the	O
critically	O
ill	O
patient	O
.	O
Atrial	O
fibrillation	O
.	O
Frequency	O
control	O
strategy	O
.	O
Under	O
treatment	O
with	O
sintrom	B-FARMACO
and	O
bisoprolol	B-FARMACO
.	O
Coronary	O
arteries	O
without	O
lesions	O
in	O
coronary	O
angiography	O
October	O
2018	O
.	O
Other	O
history	O
Chronic	O
kidney	O
disease	O
of	O
diabetic	O
aetiology	O
.	O
Baseline	O
creatinine	O
1	O
.	O
4	O
mg	O
dl	O
glomerular	O
filtration	O
rate	O
GFR	O
47	O
ml	O
min	O
1	O
.	O
73	O
m2	O
.	O
Moderate	O
sleep	O
apnoea	O
hypopnoea	O
syndrome	O
SAHS	O
,	O
without	O
treatment	O
with	O
continuous	O
positive	O
airway	O
pressure	O
CPAP	O
due	O
to	O
poor	O
tolerance	O
.	O
Prostatectomy	O
due	O
to	O
prostate	O
carcinoma	O
.	O
Usual	O
treatment	O
Acenocoumarol	B-FARMACO
4	O
mg	O
.	O
DTS	O
15	O
mg	O
.	O
Recent	O
stable	O
INR	O
controls	O
.	O
Spironolactone	B-FARMACO
50	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
.	O
Bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
.	O
Simvastatin	B-FARMACO
20	O
mg	O
1	O
tablet	O
daily	O
.	O
Omeprazole	B-FARMACO
40	O
mg	O
1	O
tablet	O
per	O
day	O
.	O
Furosemide	B-FARMACO
40	O
mg	O
two	O
tablets	O
at	O
breakfast	O
,	O
one	O
at	O
lunch	O
and	O
one	O
at	O
dinner	O
.	O
Slow	O
insulin	B-FARMACO
18	O
IU	O
per	O
day	O
.	O
Rapid	O
insulin	B-FARMACO
6	O
8	O
8	O
IU	O
per	O
day	O
.	O
Metamizole	B-FARMACO
575	O
mg	O
1	O
amp	O
every	O
8	O
hours	O
if	O
pain	O
.	O
Baseline	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
BADL	O
.	O
He	O
goes	O
out	O
on	O
a	O
daily	O
basis	O
.	O
Manages	O
her	O
medication	O
.	O
Does	O
not	O
meet	O
frailty	O
criteria	O
robust	O
.	O
KATZ	O
A	O
.	O
CURRENT	O
ILLNESS	O
He	O
presented	O
with	O
worsening	O
functional	O
class	O
,	O
with	O
dyspnoea	O
on	O
minimal	O
effort	O
,	O
increased	O
oedema	O
in	O
the	O
lower	O
limbs	O
and	O
orthopnoea	O
which	O
led	O
him	O
to	O
sleep	O
in	O
a	O
sitting	O
position	O
the	O
night	O
before	O
admission	O
.	O
Recent	O
admission	O
discharged	O
7	O
days	O
ago	O
from	O
another	O
centre	O
following	O
mitral	O
and	O
aortic	O
valve	O
replacement	O
surgery	O
.	O
The	O
patient	O
reported	O
congestive	O
symptoms	O
a	O
few	O
days	O
after	O
discharge	O
.	O
He	O
acknowledges	O
salt	O
intake	O
in	O
his	O
usual	O
diet	O
at	O
home	O
,	O
and	O
has	O
also	O
started	O
taking	O
non	O
steroidal	O
anti	O
inflammatory	O
drugs	O
NSAIDs	O
as	O
a	O
result	O
of	O
pain	O
secondary	O
to	O
musculoskeletal	O
pathology	O
exacerbated	O
after	O
the	O
recent	O
admission	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
140	O
80	O
mmHg	O
,	O
heart	O
rate	O
HR	O
120	O
bpm	O
,	O
Sat	O
93	O
with	O
nose	O
glasses	O
.	O
Head	O
and	O
neck	O
no	O
jugular	O
venous	O
engorgement	O
Cardiac	O
auscultation	O
arrhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
crackles	O
in	O
both	O
bases	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
haemoglobin	O
10	O
.	O
3	O
mg	O
dl	O
.	O
Urea	O
62	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
8	O
mg	O
dl	O
GFR	O
39	O
mg	O
ml	O
1	O
.	O
73	O
m2	O
,	O
NT	O
proBNP	O
4550	O
pg	O
ml	O
.	O
Iron	O
profile	O
total	O
Fe	O
136	O
,	O
ferritin	O
150	O
g	O
l	O
;	O
IST	O
18	O
.	O
TSH	O
2	O
.	O
1	O
.	O
HbA1C	O
7	O
.	O
9	O
.	O
Albumin	O
2	O
.	O
6	O
mg	O
dl	O
.	O
Prealbumin	O
13	O
mg	O
dl	O
.	O
ECG	O
atrial	O
fibrillation	O
at	O
140	O
bpm	O
.	O
QRS	O
110	O
msg	O
.	O
Normal	O
axis	O
.	O
No	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
.	O
Vascular	O
redistribution	O
.	O
Bilateral	O
pleural	O
effusion	O
.	O
Previous	O
sternotomy	O
sutures	O
.	O
Echocardiogram	O
left	O
ventricle	O
with	O
normal	O
size	O
,	O
with	O
concentric	O
hypertrophy	O
of	O
moderate	O
degree	O
,	O
without	O
significant	O
alterations	O
of	O
segmental	O
contractility	O
and	O
with	O
preserved	O
global	O
systolic	O
function	O
.	O
Right	O
ventricle	O
with	O
preserved	O
size	O
and	O
function	O
.	O
Both	O
atria	O
severely	O
dilated	O
.	O
Mitral	O
biological	O
prosthesis	O
with	O
no	O
signs	O
of	O
dysfunction	O
.	O
Aortic	O
biological	O
prosthesis	O
with	O
no	O
signs	O
of	O
dysfunction	O
.	O
Trivial	O
IT	O
allowing	O
estimation	O
of	O
systolic	O
pulmonary	O
pressure	O
of	O
35	O
mmHg	O
.	O
Aortic	O
root	O
and	O
proximal	O
ascending	O
aorta	O
of	O
normal	O
size	O
.	O
Inferior	O
vena	O
cava	O
severely	O
dilated	O
and	O
no	O
respiratory	O
changes	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
Poor	O
evolution	O
during	O
the	O
first	O
days	O
with	O
persistence	O
of	O
congestive	O
data	O
despite	O
high	O
doses	O
of	O
loop	O
diuretic	O
furosemide	O
180	O
mg	O
per	O
day	O
,	O
in	O
intravenous	O
boluses	O
,	O
control	O
of	O
water	O
intake	O
less	O
than	O
1	O
.	O
5	O
litres	O
per	O
day	O
and	O
controlled	O
salt	O
intake	O
at	O
meals	O
dose	O
of	O
2	O
g	O
sodium	O
chloride	O
per	O
day	O
.	O
The	O
patient	O
presented	O
progressive	O
deterioration	O
of	O
renal	O
function	O
in	O
consecutive	O
analyses	O
,	O
with	O
creatinine	O
levels	O
of	O
up	O
to	O
2	O
.	O
6	O
mg	O
dl	O
GFR	O
24	O
ml	O
min	O
1	O
.	O
73	O
m2	O
.	O
In	O
view	O
of	O
this	O
worsening	O
renal	O
function	O
,	O
with	O
glomerular	O
filtration	O
rates	O
below	O
30	O
ml	O
h	O
,	O
it	O
was	O
decided	O
to	O
discontinue	O
treatment	O
with	O
spironolactone	B-FARMACO
.	O
As	O
a	O
strategy	O
,	O
given	O
that	O
positive	O
water	O
balances	O
persisted	O
daily	O
with	O
worsening	O
congestive	O
data	O
third	O
tone	O
,	O
increased	O
crackles	O
,	O
worsening	O
peripheral	O
oedema	O
,	O
a	O
combination	O
diuretic	O
strategy	O
was	O
decided	O
upon	O
.	O
Bolus	O
doses	O
of	O
loop	O
diuretics	O
were	O
discontinued	O
and	O
replaced	O
by	O
intravenous	O
infusion	O
of	O
furosemide	B-FARMACO
,	O
and	O
thiazide	O
diuretics	O
hydrochlorothiazide	B-FARMACO
and	O
carbonic	O
anhydrase	O
inhibitor	O
diuretics	O
acetazolamide	B-FARMACO
were	O
added	O
to	O
the	O
treatment	O
.	O
Due	O
to	O
the	O
history	O
of	O
recent	O
prolonged	O
hospitalisation	O
and	O
data	O
of	O
protein	O
malnutrition	O
,	O
the	O
nutrition	O
service	O
was	O
contacted	O
and	O
protein	O
rich	O
nutritional	O
supplements	O
were	O
started	O
.	O
Twelve	O
hours	O
after	O
initiating	O
this	O
new	O
treatment	O
strategy	O
,	O
the	O
patient	O
persisted	O
with	O
neutral	O
balances	O
.	O
The	O
patient	O
presented	O
clinical	O
deterioration	O
compatible	O
with	O
acute	O
pulmonary	O
oedema	O
,	O
which	O
required	O
admission	O
to	O
the	O
coronary	O
unit	O
and	O
ventilatory	O
support	O
with	O
non	O
invasive	O
mechanical	O
ventilation	O
.	O
At	O
this	O
point	O
,	O
different	O
therapeutic	O
options	O
were	O
considered	O
.	O
Various	O
pharmacological	O
treatment	O
options	O
were	O
considered	O
,	O
including	O
increasing	O
the	O
dose	O
of	O
thiazide	O
diuretics	O
,	O
prescribing	O
hypertonic	B-FARMACO
saline	I-FARMACO
perfusion	O
together	O
with	O
loop	O
diuretic	O
perfusion	O
and	O
even	O
a	O
more	O
invasive	O
strategy	O
was	O
considered	O
,	O
contacting	O
the	O
nephrology	O
department	O
to	O
schedule	O
haemodiafiltration	O
sessions	O
if	O
necessary	O
.	O
The	O
patient	O
was	O
reluctant	O
to	O
this	O
last	O
option	O
,	O
so	O
it	O
was	O
decided	O
to	O
wait	O
for	O
a	O
diuretic	O
response	O
in	O
the	O
following	O
hours	O
,	O
adding	O
hypertonic	B-FARMACO
saline	I-FARMACO
perfusion	O
to	O
the	O
treatment	O
perfusion	O
of	O
100	O
ml	O
of	O
0	O
.	O
9	O
physiological	B-FARMACO
saline	I-FARMACO
with	O
the	O
addition	O
of	O
1	O
ampoule	O
of	O
20	O
ClNa	B-FARMACO
.	O
Finally	O
,	O
the	O
patient	O
started	O
with	O
a	O
good	O
diuretic	O
rhythm	O
,	O
achieving	O
negative	O
water	O
balances	O
.	O
A	O
few	O
days	O
later	O
,	O
the	O
improvement	O
of	O
congestion	O
data	O
was	O
evident	O
,	O
with	O
improvement	O
of	O
pulmonary	O
auscultation	O
and	O
reduction	O
of	O
peripheral	O
oedema	O
,	O
cardiac	O
auscultation	O
free	O
of	O
third	O
tone	O
.	O
All	O
this	O
was	O
accompanied	O
by	O
an	O
analytical	O
improvement	O
in	O
renal	O
function	O
,	O
until	O
creatinine	O
levels	O
before	O
admission	O
returned	O
to	O
normal	O
.	O
All	O
this	O
good	O
evolution	O
finally	O
allowed	O
the	O
patient	O
to	O
be	O
discharged	O
from	O
hospital	O
.	O
DIAGNOSIS	O
Decompensation	O
of	O
heart	O
failure	O
.	O
Probable	O
dietary	O
transgression	O
NSAID	O
intake	O
.	O
Preserved	O
LVEF	O
.	O
Biological	O
normofunctioning	O
mitral	O
and	O
aortic	O
prosthesis	O
.	O
Atrial	O
fibrillation	O
anticoagulated	O
with	O
acenocoumarol	B-FARMACO
.	O
Impaired	O
renal	O
function	O
in	O
patients	O
with	O
chronic	O
kidney	O
disease	O
CKD	O
.	O
Probable	O
cardio	O
renal	O
syndrome	O
.	O
Normocytic	O
normochromic	O
anaemia	O
.	O
Diuretic	O
resistance	O
syndrome	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
42	O
year	O
old	O
woman	O
from	O
Venezuela	O
.	O
Resident	O
in	O
Spain	O
since	O
February	O
2018	O
.	O
Last	O
trip	O
to	O
her	O
country	O
of	O
origin	O
June	O
2018	O
.	O
No	O
family	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
No	O
known	O
drug	O
reactions	O
.	O
No	O
classic	O
cardiovascular	O
risk	O
factors	O
CVRF	O
or	O
toxic	O
habits	O
.	O
Subclinical	O
hypothyroidism	O
.	O
Repeated	O
tonsillitis	O
in	O
childhood	O
.	O
Fibrocystic	O
mastopathy	O
with	O
bilateral	O
partial	O
mastectomy	O
in	O
2016	O
.	O
G2A0P0C2	O
.	O
Two	O
healthy	O
children	O
.	O
No	O
chronic	O
home	O
treatment	O
.	O
CURRENT	O
DISEASE	O
At	O
the	O
beginning	O
of	O
February	O
2019	O
,	O
the	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
with	O
a	O
4	O
day	O
history	O
of	O
continuous	O
,	O
oppressive	O
,	O
non	O
radiating	O
central	O
thoracic	O
pain	O
,	O
with	O
no	O
associated	O
vegetative	O
cortex	O
,	O
which	O
worsens	O
with	O
decubitus	O
and	O
deep	O
inspiration	O
and	O
improves	O
with	O
sitting	O
and	O
leaning	O
forward	O
.	O
In	O
addition	O
,	O
he	O
reported	O
a	O
parallel	O
decrease	O
in	O
the	O
rate	O
of	O
diuresis	O
.	O
Prior	O
to	O
this	O
,	O
he	O
had	O
a	O
non	O
productive	O
cough	O
for	O
3	O
days	O
,	O
generalised	O
arthromyalgia	O
,	O
a	O
feeling	O
of	O
dystrophy	O
and	O
intense	O
asthenia	O
.	O
He	O
denies	O
orthopnoea	O
,	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
,	O
bendopnoea	O
,	O
increased	O
abdominal	O
or	O
lower	O
limb	O
circumference	O
,	O
weight	O
gain	O
,	O
palpitations	O
or	O
other	O
cardiovascular	O
symptoms	O
.	O
Denies	O
abdominal	O
pain	O
,	O
nausea	O
,	O
vomiting	O
,	O
diarrhoea	O
,	O
micturition	O
symptoms	O
or	O
other	O
infectious	O
organ	O
focality	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
87	O
59	O
mmHg	O
,	O
heart	O
rate	O
HR	O
100	O
bpm	O
.	O
Temperature	O
36	O
.	O
1	O
C	O
.	O
SpO2	O
100	O
basal	O
.	O
Regular	O
general	O
condition	O
.	O
Conscious	O
,	O
oriented	O
in	O
the	O
3	O
spheres	O
and	O
cooperative	O
.	O
Normal	O
colour	O
,	O
normohydrated	O
and	O
normoperfused	O
.	O
Eupneic	O
at	O
rest	O
,	O
with	O
good	O
respiratory	O
dynamics	O
.	O
Head	O
and	O
neck	O
oropharynx	O
normal	O
.	O
No	O
jugular	O
venous	O
engorgement	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
tachycardic	O
heart	O
sounds	O
.	O
No	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
extra	O
sounds	O
.	O
Abdomen	O
hydro	O
aerial	O
sounds	O
present	O
and	O
of	O
normal	O
characteristics	O
.	O
Soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
signs	O
of	O
peritoneal	O
irritation	O
or	O
ascitic	O
semiology	O
.	O
No	O
masses	O
or	O
organomegaly	O
palpable	O
.	O
Lower	O
extremities	O
pedial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
No	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Emergency	O
ECG	O
sinus	O
rhythm	O
at	O
88	O
bpm	O
,	O
vertical	O
cardiac	O
axis	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
low	O
voltages	O
.	O
Poor	O
R	O
wave	O
growth	O
in	O
precordial	O
leads	O
.	O
No	O
relevant	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
in	O
the	O
ED	O
Cardiothoracic	O
index	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
this	O
is	O
an	O
anteroposterior	O
projection	O
.	O
The	O
costophrenic	O
sinuses	O
are	O
free	O
.	O
No	O
parenchymal	O
infiltrates	O
or	O
parenchymal	O
consolidations	O
were	O
observed	O
,	O
nor	O
was	O
there	O
any	O
evidence	O
of	O
frank	O
pulmonary	O
congestion	O
.	O
Laboratory	O
tests	O
in	O
the	O
emergency	O
department	O
Venous	O
blood	O
gases	O
anion	O
GAP	O
10	O
,	O
pH	O
7	O
.	O
29	O
.	O
pCO2	O
47	O
mmHg	O
,	O
pO2	O
6	O
mmHg	O
.	O
HCO3	O
23	O
mmol	O
l	O
.	O
BEb	O
4	O
.	O
2	O
mmol	O
l	O
.	O
sO2	O
18	O
.	O
Na	O
135	O
mEq	O
l	O
.	O
K	O
4	O
.	O
5	O
mEq	O
l	O
.	O
Cl	O
107	O
mEq	O
l	O
.	O
Ca	O
2	O
1	O
,	O
11	O
mmol	O
l	O
.	O
Glucose	O
152	O
mg	O
dl	O
.	O
Lactate	O
4	O
.	O
2	O
mmol	O
l	O
.	O
Oxyhaemoglobin	O
18	O
.	O
Carboxyhaemoglobin	O
0	O
.	O
Methaemoglobin	O
1	O
.	O
Reduced	O
haemoglobin	O
81	O
.	O
Haemoglobin	O
13	O
.	O
4	O
g	O
dl	O
.	O
sO2	O
c	O
4	O
.	O
Biochemistry	O
glucose	O
153	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
58	O
mg	O
dl	O
.	O
Sodium	O
141	O
mEq	O
l	O
.	O
Total	O
protein	O
6	O
g	O
dl	O
.	O
Potassium	O
4	O
,	O
75	O
mEq	O
l	O
.	O
Albumin	O
3	O
.	O
1	O
g	O
dl	O
.	O
Chlorine	O
102	O
mEq	O
l	O
.	O
ALT	O
GPT	O
11	O
U	O
l	O
.	O
AST	O
GOT	O
29	O
U	O
l	O
.	O
Gamma	O
GT	O
7	O
U	O
l	O
.	O
Alkaline	O
phosphatase	O
41	O
U	O
l	O
.	O
LDH	O
326	O
U	O
l	O
.	O
Bilirubin	O
0	O
.	O
2	O
mg	O
dl	O
.	O
Calcium	O
8	O
mg	O
dl	O
.	O
Magnesium	O
1	O
.	O
72	O
mg	O
d	O
.	O
C	O
reactive	O
protein	O
0	O
.	O
76	O
mg	O
dl	O
.	O
Urea	O
23	O
mg	O
dl	O
.	O
Haemogram	O
red	O
blood	O
cells	O
5	O
.	O
02	O
x	O
mill	O
μl	O
.	O
Haemoglobin	O
13	O
.	O
3	O
g	O
dl	O
.	O
Haematocrit	O
41	O
.	O
5	O
.	O
MCH	O
26	O
.	O
5	O
pg	O
.	O
MCV	O
82	O
.	O
6	O
fl	O
.	O
MCCH	O
32	O
.	O
1	O
g	O
dl	O
.	O
RDW	O
15	O
.	O
Platelets	O
235	O
.	O
000	O
μl	O
.	O
MPV	O
8	O
.	O
6	O
fl	O
.	O
Leukocytes	O
9	O
,	O
600	O
μl	O
.	O
Neutrophils	O
8	O
,	O
100	O
μl	O
.	O
Neutrophils	O
84	O
.	O
1	O
.	O
Lymphocytes	O
900	O
μl	O
.	O
Lymphocytes	O
9	O
.	O
1	O
.	O
Monocytes	O
600	O
μl	O
.	O
Monocytes	O
6	O
.	O
4	O
.	O
Eosinophils	O
0	O
μl	O
.	O
Eosinophils	O
0	O
.	O
1	O
per	O
cent	O
.	O
Basophils	O
0	O
μl	O
.	O
Basophils	O
0	O
.	O
3	O
.	O
Coagulation	O
prothrombin	O
time	O
12	O
.	O
9	O
s	O
.	O
Prothrombin	O
activity	O
82	O
.	O
Prothrombin	O
activity	O
82	O
.	O
INR	O
1	O
.	O
12	O
.	O
TTPa	O
29	O
s	O
.	O
Fibrinogen	O
280	O
mg	O
dl	O
.	O
D	O
dimer	O
461	O
ng	O
ml	O
.	O
Markers	O
of	O
myocardial	O
damage	O
CK	O
218	O
U	O
l	O
.	O
Troponin	O
T	O
hs	O
295	O
.	O
3	O
ng	O
l	O
normal	O
14	O
ng	O
l	O
.	O
NT	O
proBNP	O
7	O
,	O
836	O
pg	O
ml	O
.	O
Microbiology	O
PCR	O
for	O
respiratory	O
viruses	O
in	O
nasopharyngeal	O
exudate	O
positive	O
for	O
influenza	O
A	O
,	O
subtyping	O
H1N1	O
.	O
Urgent	O
transthoracic	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
with	O
global	O
hypokinesia	O
.	O
LVEF	O
25	O
30	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
normal	O
EF	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Thin	O
film	O
of	O
effusion	O
0	O
.	O
5	O
1	O
mm	O
around	O
the	O
right	O
chambers	O
and	O
inferolateral	O
to	O
the	O
left	O
ventricle	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
,	O
adequate	O
respiratory	O
variation	O
.	O
Transthoracic	O
echocardiogram	O
on	O
admission	O
to	O
the	O
coronary	O
unit	O
study	O
performed	O
in	O
sinus	O
tachycardia	O
at	O
120	O
bpm	O
.	O
Left	O
ventricle	O
not	O
dilated	O
,	O
slightly	O
hypertrophic	O
.	O
Systolic	O
function	O
severely	O
depressed	O
LVEF	O
28	O
by	O
Simpson	O
biplane	O
due	O
to	O
global	O
hypokinesia	O
.	O
Normal	O
diastolic	O
function	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
depressed	O
systolic	O
function	O
TAPSE	O
10	O
mm	O
,	O
S	O
wave	O
8	O
.	O
5	O
cm	O
s	O
,	O
FAC	O
25	O
,	O
subjective	O
mild	O
moderate	O
dysfunction	O
with	O
global	O
hypokinesia	O
.	O
Normal	O
sized	O
left	O
atrium	O
.	O
Right	O
atrium	O
of	O
normal	O
size	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
morphologically	O
and	O
functionally	O
normal	O
.	O
Mitral	O
valve	O
with	O
mild	O
insufficiency	O
.	O
Tricuspid	O
valve	O
morphologically	O
normal	O
,	O
with	O
slight	O
insufficiency	O
that	O
does	O
not	O
allow	O
estimation	O
of	O
PSAP	O
.	O
No	O
indirect	O
signs	O
of	O
pulmonary	O
hypertension	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
collapse	O
50	O
with	O
inspiration	O
.	O
Aortic	O
root	O
,	O
ascending	O
aorta	O
and	O
aortic	O
arch	O
of	O
normal	O
size	O
.	O
Slight	O
pericardial	O
effusion	O
without	O
haemodynamic	O
compromise	O
.	O
Transthoracic	O
echocardiogram	O
during	O
ECMO	O
weaning	O
systolic	O
function	O
preserved	O
throughout	O
the	O
study	O
.	O
No	O
changes	O
in	O
biventricular	O
size	O
and	O
function	O
with	O
ECMO	O
flow	O
reduction	O
up	O
to	O
0	O
.	O
5	O
l	O
min	O
.	O
Study	O
performed	O
in	O
sinus	O
tachycardia	O
at	O
105	O
bpm	O
.	O
Left	O
ventricle	O
not	O
dilated	O
,	O
with	O
normal	O
wall	O
thickness	O
.	O
Segmental	O
contractility	O
with	O
mild	O
hypokinesia	O
of	O
inferior	O
aspect	O
and	O
septum	O
.	O
Myocardial	O
thickness	O
10	O
11	O
mm	O
.	O
Preserved	O
systolic	O
function	O
LVEF	O
55	O
by	O
Simpson	O
biplane	O
,	O
improvement	O
with	O
respect	O
to	O
the	O
study	O
of	O
48h	O
ago	O
.	O
Diastolic	O
function	O
with	O
E	O
A	O
,	O
diastolic	O
predominance	O
in	O
pulmonary	O
vein	O
flow	O
,	O
normal	O
E	O
E	O
'	O
.	O
Right	O
ventricle	O
not	O
dilated	O
basal	O
DTD	O
31	O
mm	O
with	O
normal	O
systolic	O
function	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
Aortic	O
valve	O
morphologically	O
and	O
functionally	O
normal	O
.	O
Mitral	O
valve	O
with	O
slight	O
thickening	O
of	O
the	O
anterior	O
leaflet	O
,	O
mild	O
trivial	O
insufficiency	O
.	O
Tricuspid	O
valve	O
morphologically	O
normal	O
,	O
with	O
moderate	O
II	O
IV	O
insufficiency	O
allowing	O
estimation	O
of	O
PSAP	O
of	O
29	O
mmHg	O
DBP	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
.	O
Pericardium	O
of	O
normal	O
thickness	O
and	O
refractoriness	O
,	O
without	O
effusion	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
images	O
3	O
9	O
,	O
videos	O
8	O
and	O
9	O
left	O
ventricle	O
not	O
dilated	O
or	O
hypertrophic	O
,	O
normal	O
global	O
and	O
segmental	O
systolic	O
function	O
LVEF	O
56	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
normal	O
systolic	O
function	O
LVEF	O
60	O
.	O
No	O
alterations	O
in	O
segmental	O
contractility	O
.	O
Atria	O
not	O
dilated	O
.	O
Morphologically	O
and	O
functionally	O
normal	O
valves	O
.	O
No	O
pericardial	O
abnormalities	O
.	O
Late	O
enhancement	O
sequences	O
show	O
areas	O
of	O
faint	O
diffuse	O
intramyocardial	O
uptake	O
with	O
no	O
distribution	O
corresponding	O
to	O
any	O
coronary	O
territory	O
.	O
This	O
corresponds	O
to	O
the	O
presence	O
of	O
signal	O
hyperintensity	O
on	O
the	O
STIR	O
sequence	O
.	O
These	O
data	O
suggest	O
the	O
presence	O
of	O
oedema	O
and	O
inflammatory	O
changes	O
.	O
Extracardiac	O
findings	O
consolidation	O
in	O
the	O
left	O
lower	O
lobe	O
and	O
atelectasis	O
subsegmental	O
infiltrates	O
in	O
the	O
right	O
lower	O
lobe	O
.	O
Conclusion	O
LV	O
and	O
RV	O
with	O
normal	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O
Signs	O
of	O
oedema	O
and	O
inflammatory	O
changes	O
in	O
the	O
LV	O
with	O
diffuse	O
distribution	O
compatible	O
with	O
the	O
clinical	O
diagnosis	O
of	O
myocarditis	O
.	O
Pathological	O
anatomy	O
of	O
endomyocardial	O
biopsy	O
histological	O
sections	O
of	O
the	O
submitted	O
sample	O
correspond	O
to	O
fragments	O
of	O
endomyocardial	O
tissue	O
that	O
do	O
not	O
show	O
endocardial	O
lesions	O
and	O
show	O
myocardium	O
without	O
architectural	O
loss	O
,	O
with	O
no	O
granulomas	O
or	O
giant	O
cells	O
or	O
neutrophilic	O
or	O
lymphocytic	O
inflammatory	O
infiltrates	O
.	O
There	O
are	O
no	O
signs	O
of	O
vasculitis	O
.	O
No	O
malignancy	O
is	O
noted	O
.	O
CLINICAL	O
COURSE	O
Initially	O
,	O
given	O
the	O
hypotension	O
observed	O
in	O
the	O
emergency	O
department	O
,	O
intensive	O
serum	O
therapy	O
was	O
started	O
with	O
little	O
response	O
.	O
Given	O
the	O
patient	O
's	O
symptoms	O
and	O
blood	O
tests	O
,	O
the	O
emergency	O
department	O
requested	O
cardiology	O
assessment	O
,	O
who	O
performed	O
an	O
urgent	O
transthoracic	O
echocardiogram	O
,	O
which	O
revealed	O
severe	O
left	O
ventricular	O
dysfunction	O
with	O
global	O
hypokinesia	O
,	O
as	O
well	O
as	O
a	O
thin	O
layer	O
of	O
pericardial	O
effusion	O
that	O
did	O
not	O
produce	O
echocardiographic	O
involvement	O
of	O
the	O
cavities	O
.	O
Given	O
the	O
clinical	O
and	O
analytical	O
data	O
of	O
haemodynamic	O
instability	O
hypotension	O
that	O
did	O
not	O
respond	O
to	O
serum	O
therapy	O
,	O
progressive	O
distal	O
hypoperfusion	O
,	O
hyperlactacidemia	O
,	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
the	O
coronary	O
unit	O
for	O
monitoring	O
and	O
initiation	O
of	O
vasoactive	O
drugs	O
.	O
Also	O
,	O
given	O
the	O
previous	O
clinical	O
manifestations	O
of	O
upper	O
respiratory	O
tract	O
infection	O
,	O
a	O
nasopharyngeal	O
swab	O
was	O
requested	O
for	O
respiratory	O
viruses	O
positive	O
for	O
influenza	O
A	O
virus	O
and	O
empirical	O
antimicrobial	O
therapy	O
was	O
started	O
with	O
oseltamivir	B-FARMACO
,	O
ceftriaxone	B-FARMACO
and	O
levofloxacin	B-FARMACO
,	O
the	O
latter	O
to	O
cover	O
possible	O
bacterial	O
superinfection	O
.	O
In	O
the	O
coronary	O
unit	O
,	O
vasopressor	O
support	O
was	O
started	O
with	O
noradrenaline	B-FARMACO
at	O
increasing	O
doses	O
and	O
inotropic	O
support	O
with	O
dobutamine	B-FARMACO
,	O
despite	O
which	O
the	O
patient	O
persisted	O
with	O
mean	O
BP	O
around	O
65	O
mmHg	O
.	O
Invasive	O
haemodynamic	O
monitoring	O
by	O
Swan	O
Ganz	O
catheter	O
showed	O
the	O
following	O
initial	O
parameters	O
cardiac	O
index	O
around	O
2	O
l	O
min	O
m2	O
,	O
PAPm	O
17	O
mmHg	O
,	O
PCP	O
15	O
mmHg	O
,	O
mixed	O
venous	O
saturation	O
50	O
.	O
A	O
new	O
transthoracic	O
echocardiogram	O
was	O
also	O
performed	O
,	O
confirming	O
the	O
findings	O
of	O
the	O
previous	O
one	O
,	O
with	O
a	O
biplane	O
Simpson	O
LVEF	O
of	O
28	O
,	O
and	O
also	O
showing	O
at	O
least	O
moderate	O
right	O
ventricular	O
dysfunction	O
with	O
global	O
hypokinesia	O
and	O
mild	O
mitral	O
insufficiency	O
.	O
During	O
the	O
following	O
24	O
hours	O
,	O
the	O
patient	O
showed	O
a	O
poor	O
clinical	O
and	O
analytical	O
response	O
NT	O
proBNP	O
of	O
18	O
,	O
528	O
pg	O
ml	O
at	O
this	O
time	O
to	O
the	O
treatment	O
given	O
,	O
with	O
progressive	O
worsening	O
of	O
haemodynamic	O
parameters	O
lactic	O
acid	O
6	O
.	O
5	O
mmol	O
l	O
,	O
cardiac	O
index	O
in	O
decline	O
,	O
oliguria	O
despite	O
support	O
with	O
dobutamine	B-FARMACO
at	O
13	O
mcg	O
kg	O
min	O
and	O
noradrenaline	B-FARMACO
at	O
0	O
.	O
35	O
mcg	O
kg	O
min	O
,	O
so	O
it	O
was	O
decided	O
to	O
implant	O
an	O
intra	O
aortic	O
balloon	O
counterpulsation	O
device	O
.	O
During	O
the	O
balloon	O
implantation	O
,	O
he	O
presented	O
an	O
episode	O
of	O
severe	O
hypotension	O
with	O
a	O
drop	O
in	O
cardiac	O
index	O
to	O
1	O
.	O
5	O
,	O
requiring	O
a	O
significant	O
increase	O
in	O
vasopressor	O
support	O
,	O
with	O
noradrenaline	B-FARMACO
infusion	O
of	O
up	O
to	O
2	O
mcg	O
kg	O
min	O
,	O
despite	O
which	O
lactic	O
acid	O
levels	O
rose	O
to	O
9	O
.	O
5	O
.	O
In	O
this	O
context	O
,	O
it	O
was	O
decided	O
to	O
contact	O
cardiac	O
surgery	O
for	O
urgent	O
implantation	O
of	O
veno	O
arterial	O
ECMO	O
Cardiohelp	O
system	O
,	O
which	O
was	O
performed	O
at	O
the	O
bedside	O
without	O
the	O
need	O
for	O
orotracheal	O
intubation	O
awake	O
ECMO	O
implantation	O
,	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
cardiac	O
ICU	O
for	O
continuity	O
of	O
care	O
.	O
During	O
her	O
stay	O
in	O
the	O
cardiac	O
ICU	O
,	O
there	O
was	O
a	O
progressive	O
improvement	O
in	O
haemodynamic	O
parameters	O
that	O
allowed	O
early	O
withdrawal	O
of	O
noradrenaline	B-FARMACO
.	O
A	O
few	O
hours	O
later	O
,	O
he	O
began	O
to	O
show	O
symptoms	O
compatible	O
with	O
acute	O
ischaemia	O
of	O
the	O
right	O
lower	O
limb	O
,	O
and	O
the	O
femoral	O
artery	O
was	O
cannulated	O
for	O
distal	O
perfusion	O
,	O
which	O
had	O
not	O
been	O
possible	O
at	O
first	O
due	O
to	O
the	O
urgency	O
of	O
the	O
cannulation	O
.	O
An	O
endomyocardial	O
biopsy	O
was	O
also	O
performed	O
,	O
with	O
no	O
peri	O
or	O
post	O
procedural	O
complications	O
and	O
no	O
pathological	O
findings	O
.	O
After	O
3	O
days	O
of	O
ECMO	O
support	O
,	O
the	O
echocardiogram	O
showed	O
recovery	O
of	O
ventricular	O
function	O
,	O
so	O
weaning	O
was	O
attempted	O
under	O
echocardiographic	O
control	O
.	O
In	O
this	O
context	O
,	O
the	O
patient	O
presented	O
congestive	O
symptoms	O
with	O
desaturation	O
and	O
worsening	O
respiratory	O
mechanics	O
,	O
without	O
simultaneous	O
ventricular	O
dysfunction	O
on	O
echocardiography	O
,	O
but	O
with	O
a	O
possible	O
component	O
of	O
diastolic	O
dysfunction	O
,	O
so	O
it	O
was	O
decided	O
not	O
to	O
withdraw	O
assistance	O
.	O
Chest	O
X	O
ray	O
and	O
lung	O
ultrasound	O
showed	O
a	O
large	O
left	O
pleural	O
effusion	O
,	O
which	O
was	O
drained	O
by	O
thoracentesis	O
,	O
obtaining	O
about	O
1	O
,	O
000	O
ml	O
of	O
serous	O
fluid	O
.	O
A	O
levosimendan	B-FARMACO
infusion	O
was	O
also	O
started	O
,	O
which	O
was	O
well	O
tolerated	O
from	O
the	O
haemodynamic	O
point	O
of	O
view	O
,	O
and	O
after	O
10	O
days	O
of	O
support	O
,	O
ECMO	O
was	O
withdrawn	O
.	O
In	O
this	O
context	O
,	O
he	O
presented	O
with	O
significant	O
bleeding	O
with	O
secondary	O
instability	O
,	O
requiring	O
polytransfusion	O
and	O
reinitiation	O
of	O
vasoactive	O
support	O
,	O
but	O
with	O
a	O
good	O
evolution	O
that	O
also	O
allowed	O
the	O
removal	O
of	O
the	O
counterpulsation	O
balloon	O
.	O
Once	O
respiratory	O
and	O
haemodynamic	O
stability	O
was	O
achieved	O
,	O
she	O
was	O
discharged	O
to	O
the	O
conventional	O
cardiology	O
hospital	O
ward	O
,	O
where	O
she	O
remained	O
asymptomatic	O
at	O
all	O
times	O
,	O
with	O
no	O
arrhythmic	O
or	O
other	O
events	O
during	O
her	O
stay	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
was	O
performed	O
,	O
showing	O
data	O
compatible	O
with	O
myocarditis	O
,	O
as	O
well	O
as	O
preserved	O
biventricular	O
function	O
,	O
and	O
cardiac	O
and	O
functional	O
rehabilitation	O
was	O
started	O
with	O
good	O
learning	O
and	O
clear	O
improvement	O
.	O
The	O
only	O
sequelae	O
of	O
the	O
patient	O
was	O
a	O
slight	O
limitation	O
to	O
dorsiflexion	O
of	O
the	O
right	O
foot	O
.	O
After	O
21	O
days	O
of	O
total	O
hospitalisation	O
and	O
being	O
practically	O
in	O
her	O
baseline	O
condition	O
,	O
she	O
was	O
discharged	O
home	O
with	O
subsequent	O
review	O
in	O
cardiology	O
consultations	O
.	O
DIAGNOSIS	O
Cardiogenic	O
shock	O
with	O
need	O
for	O
ECMO	O
V	O
A	O
implantation	O
secondary	O
to	O
fulminant	O
myocarditis	O
due	O
to	O
influenza	O
A	O
.	O
Transient	O
severe	O
LV	O
systolic	O
dysfunction	O
in	O
the	O
context	O
of	O
the	O
above	O
.	O
Viral	O
upper	O
respiratory	O
tract	O
infection	O
due	O
to	O
influenza	O
A	O
.	O
Partial	O
acute	O
respiratory	O
failure	O
secondary	O
to	O
all	O
of	O
the	O
above	O
.	O
Acute	O
right	O
lower	O
limb	O
ischaemia	O
after	O
ECMO	O
V	O
A	O
cannulation	O
,	O
resolved	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
42	O
year	O
old	O
male	O
,	O
with	O
no	O
known	O
cardiovascular	O
risk	O
factors	O
.	O
History	O
of	O
heart	O
murmur	O
in	O
childhood	O
,	O
operated	O
on	O
for	O
pectus	O
excavatum	O
and	O
diaphragmatic	O
hernia	O
.	O
Under	O
treatment	O
with	O
ibandronic	B-FARMACO
acid	I-FARMACO
and	O
calcium	B-FARMACO
carbonate	I-FARMACO
.	O
He	O
was	O
initially	O
assessed	O
at	O
his	O
reference	O
hospital	O
for	O
a	O
murmur	O
,	O
and	O
the	O
echocardiogram	O
showed	O
a	O
slightly	O
dilated	O
left	O
ventricle	O
LV	O
with	O
slightly	O
depressed	O
systolic	O
function	O
LVEF	O
45	O
according	O
to	O
Simpson	O
,	O
a	O
myxomatous	O
mitral	O
valve	O
with	O
prolapse	O
of	O
both	O
leaflets	O
leading	O
to	O
mild	O
insufficiency	O
,	O
a	O
right	O
ventricle	O
RV	O
of	O
normal	O
size	O
,	O
but	O
with	O
an	O
aneurysmal	O
and	O
akinetic	O
apex	O
and	O
depressed	O
systolic	O
function	O
,	O
and	O
aortic	O
root	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
he	O
was	O
referred	O
for	O
specific	O
consultation	O
of	O
familial	O
heart	O
disease	O
for	O
suspected	O
arrhythmogenic	O
right	O
ventricular	O
cardiomyopathy	O
ARVC	O
.	O
At	O
the	O
first	O
visit	O
,	O
the	O
patient	O
was	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
.	O
Physical	O
examination	O
revealed	O
a	O
marfanoid	O
appearance	O
,	O
with	O
rhythmic	O
heart	O
tones	O
and	O
a	O
systolic	O
murmur	O
II	O
VI	O
in	O
the	O
mitral	O
focus	O
radiating	O
to	O
the	O
axilla	O
,	O
with	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
additional	O
sounds	O
on	O
pulmonary	O
auscultation	O
and	O
no	O
oedema	O
in	O
the	O
lower	O
extremities	O
.	O
During	O
outpatient	O
follow	O
up	O
,	O
he	O
began	O
to	O
experience	O
dyspnoea	O
on	O
moderate	O
exertion	O
.	O
To	O
complete	O
the	O
study	O
,	O
Holter	O
ECG	O
,	O
cardiac	O
magnetic	O
resonance	O
,	O
transesophageal	O
echocardiogram	O
and	O
genetic	O
study	O
were	O
performed	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
in	O
consultation	O
sinus	O
rhythm	O
with	O
incomplete	O
right	O
bundle	O
branch	O
block	O
and	O
a	O
deflection	O
from	O
S	O
to	O
pseudoR	O
55	O
ms	O
.	O
The	O
24	O
hour	O
Holter	O
showed	O
ventricular	O
extrasystoles	O
originating	O
from	O
the	O
RV	O
outflow	O
tract	O
with	O
a	O
density	O
of	O
3	O
6	O
,	O
935	O
beats	O
and	O
a	O
burst	O
of	O
non	O
sustained	O
ventricular	O
tachycardia	O
NSVT	O
with	O
RV	O
outflow	O
tract	O
morphology	O
of	O
11	O
beats	O
,	O
totally	O
asymptomatic	O
.	O
Cardiac	O
MRI	O
showed	O
a	O
non	O
dilated	O
RV	O
with	O
apical	O
hypertrabeculation	O
with	O
dyskinetic	O
movement	O
of	O
the	O
free	O
and	O
apical	O
anterior	O
wall	O
,	O
with	O
doubtful	O
linear	O
fibrofatty	O
infiltration	O
at	O
that	O
level	O
and	O
moderately	O
depressed	O
right	O
systolic	O
function	O
RVEF	O
36	O
.	O
The	O
left	O
ventricle	O
was	O
slightly	O
dilated	O
,	O
with	O
apical	O
hypertrabeculation	O
associated	O
with	O
lateral	O
mid	O
apical	O
hypocontractility	O
and	O
mildly	O
depressed	O
systolic	O
function	O
LVEF	O
48	O
.	O
Transesophageal	O
echocardiogram	O
showed	O
a	O
myxomatous	O
mitral	O
valve	O
with	O
prolapse	O
of	O
both	O
leaflets	O
with	O
mild	O
insufficiency	O
,	O
aortic	O
root	O
at	O
the	O
high	O
limit	O
of	O
normality	O
and	O
mild	O
LV	O
systolic	O
dysfunction	O
.	O
The	O
genetic	O
study	O
identified	O
him	O
as	O
a	O
heterozygous	O
carrier	O
of	O
a	O
mutation	O
in	O
the	O
fibrillin	O
1	O
gene	O
associated	O
with	O
Marfan	O
syndrome	O
NC_000015	O
.	O
9	O
mutation	O
g	O
.	O
48737574delC	O
,	O
with	O
no	O
mutations	O
in	O
the	O
genes	O
related	O
to	O
arrhythmogenic	O
RV	O
dysplasia	O
.	O
In	O
view	O
of	O
these	O
findings	O
and	O
given	O
the	O
patient	O
's	O
phenotype	O
and	O
clinical	O
manifestations	O
,	O
we	O
diagnosed	O
Marfan	O
syndrome	O
and	O
extended	O
the	O
genetic	O
study	O
to	O
his	O
children	O
,	O
who	O
were	O
found	O
to	O
be	O
carriers	O
,	O
one	O
of	O
whom	O
was	O
also	O
affected	O
with	O
mild	O
aortic	O
dilatation	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
view	O
of	O
the	O
findings	O
of	O
the	O
complementary	O
tests	O
and	O
despite	O
the	O
fact	O
that	O
the	O
genetic	O
test	O
for	O
arrhythmogenic	O
RV	O
dysplasia	O
was	O
negative	O
,	O
we	O
considered	O
that	O
the	O
patient	O
had	O
this	O
diagnosis	O
,	O
since	O
he	O
had	O
one	O
major	O
criterion	O
anterior	O
and	O
apical	O
RV	O
dyskinesia	O
with	O
dysfunction	O
40	O
and	O
3	O
minor	O
ones	O
500	O
VSD	O
on	O
Holter	O
,	O
NSVT	O
with	O
RV	O
outflow	O
tract	O
morphology	O
and	O
deflection	O
from	O
S	O
to	O
pseudoR	O
55	O
ms	O
on	O
the	O
electrocardiogram	O
.	O
Given	O
the	O
results	O
of	O
the	O
complementary	O
tests	O
and	O
the	O
history	O
of	O
asymptomatic	O
non	O
sustained	O
ventricular	O
tachycardia	O
,	O
it	O
was	O
decided	O
to	O
implant	O
an	O
automatic	O
defibrillator	O
ICD	O
for	O
primary	O
prevention	O
,	O
in	O
addition	O
to	O
medical	O
treatment	O
with	O
beta	O
blockers	O
and	O
angiotensin	B-FARMACO
converting	I-FARMACO
enzyme	I-FARMACO
inhibitors	I-FARMACO
ACE	I-FARMACO
inhibitors	I-FARMACO
.	O
Since	O
ICD	O
implantation	O
,	O
the	O
patient	O
has	O
had	O
no	O
shocks	O
and	O
remains	O
in	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
II	O
during	O
follow	O
up	O
visits	O
.	O
DIAGNOSIS	O
Biventricular	O
arrhythmogenic	O
cardiomyopathy	O
with	O
mild	O
left	O
and	O
moderate	O
right	O
dysfunction	O
,	O
with	O
mild	O
left	O
ventricular	O
dilatation	O
,	O
anterior	O
and	O
apical	O
RV	O
dyskinesia	O
and	O
negative	O
genetic	O
study	O
for	O
RV	O
arrhythmogenic	O
cardiomyopathy	O
.	O
Marfan	O
syndrome	O
;	O
heterozygous	O
carrier	O
of	O
mutation	O
in	O
the	O
fibrillin	O
1	O
gene	O
.	O

A	O
51	O
year	O
old	O
man	O
,	O
healthy	O
until	O
1	O
month	O
ago	O
,	O
came	O
to	O
the	O
hospital	O
and	O
reported	O
dyspnoea	O
on	O
exertion	O
and	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
He	O
came	O
from	O
an	O
urban	O
environment	O
,	O
had	O
no	O
toxic	O
habits	O
,	O
had	O
not	O
travelled	O
abroad	O
and	O
had	O
no	O
contact	O
with	O
animals	O
.	O
Physical	O
examination	O
revealed	O
a	O
fever	O
of	O
37	O
.	O
5oC	O
and	O
blood	O
pressure	O
of	O
175	O
76	O
.	O
Auscultation	O
revealed	O
a	O
3	O
6	O
diastolic	O
systolic	O
murmur	O
in	O
the	O
aortic	O
focus	O
and	O
crackles	O
in	O
the	O
left	O
base	O
.	O
There	O
was	O
hepatomegaly	O
at	O
5	O
cm	O
from	O
the	O
costal	O
margin	O
and	O
oedema	O
in	O
the	O
lower	O
limbs	O
with	O
fovea	O
.	O
Laboratory	O
tests	O
showed	O
intense	O
leukocytosis	O
with	O
left	O
deviation	O
.	O
An	O
echocardiogram	O
showed	O
a	O
heart	O
rate	O
of	O
95	O
bpm	O
,	O
severe	O
aortic	O
insufficiency	O
with	O
a	O
large	O
vegetation	O
on	O
the	O
aortic	O
valve	O
and	O
a	O
smaller	O
one	O
on	O
the	O
mitral	O
valve	O
,	O
a	O
slightly	O
dilated	O
and	O
hypertrophic	O
left	O
ventricle	O
with	O
a	O
normal	O
LVEF	O
.	O
In	O
view	O
of	O
the	O
diagnosis	O
of	O
infective	O
endocarditis	O
,	O
3	O
blood	O
cultures	O
were	O
taken	O
,	O
a	O
serum	O
sample	O
was	O
extracted	O
for	O
serological	O
studies	O
and	O
treatment	O
was	O
started	O
with	O
diuretics	O
,	O
captopril	B-FARMACO
,	O
vancomycin	B-FARMACO
and	O
gentamicin	B-FARMACO
.	O
Blood	O
cultures	O
remained	O
negative	O
after	O
5	O
days	O
of	O
incubation	O
,	O
at	O
which	O
point	O
ceftriaxone	B-FARMACO
was	O
added	O
to	O
the	O
previous	O
antibiotic	O
treatment	O
.	O
Five	O
days	O
after	O
admission	O
,	O
the	O
patient	O
required	O
valve	O
replacement	O
surgery	O
;	O
the	O
aortic	O
valve	O
was	O
replaced	O
with	O
a	O
mechanical	O
prosthesis	O
and	O
the	O
mitral	O
valve	O
was	O
repaired	O
.	O
The	O
culture	O
of	O
the	O
valve	O
was	O
negative	O
and	O
its	O
study	O
with	O
a	O
technique	O
recently	O
incorporated	O
into	O
the	O
microbiology	O
laboratory	O
provided	O
the	O
aetiological	O
diagnosis	O
the	O
day	O
after	O
surgery	O
.	O
Several	O
days	O
later	O
,	O
the	O
anatomo	O
pathological	O
study	O
of	O
the	O
valve	O
confirms	O
the	O
results	O
.	O
After	O
20	O
days	O
of	O
incubation	O
,	O
the	O
blood	O
cultures	O
were	O
still	O
negative	O
.	O
The	O
patient	O
presented	O
with	O
infective	O
endocarditis	O
with	O
negative	O
blood	O
cultures	O
.	O
Between	O
2	O
.	O
5	O
and	O
30	O
of	O
cases	O
of	O
infective	O
endocarditis	O
have	O
negative	O
conventional	O
blood	O
cultures	O
.	O
In	O
about	O
half	O
of	O
these	O
cases	O
the	O
cause	O
is	O
antibiotic	O
treatment	O
prior	O
to	O
blood	O
culture	O
and	O
in	O
the	O
remainder	O
it	O
is	O
caused	O
by	O
microorganisms	O
that	O
are	O
difficult	O
to	O
culture	O
.	O
Depending	O
on	O
the	O
clinical	O
epidemiological	O
context	O
,	O
the	O
most	O
likely	O
etiological	O
agents	O
are	O
Coxiella	O
burnetii	O
,	O
Brucella	O
species	O
,	O
Bartonella	O
species	O
,	O
HACEK	O
group	O
bacteria	O
and	O
to	O
a	O
lesser	O
extent	O
Tropheryma	O
whipplei	O
,	O
Chlamydia	O
species	O
,	O
Legionella	O
pneumophila	O
and	O
others	O
.	O
In	O
this	O
case	O
the	O
patient	O
had	O
not	O
taken	O
antibiotics	O
and	O
we	O
should	O
suspect	O
microorganisms	O
that	O
cannot	O
be	O
cultured	O
under	O
normal	O
conditions	O
.	O
The	O
serologies	O
performed	O
for	O
Coxiella	O
burnetii	O
,	O
Brucella	O
,	O
Bartonella	O
,	O
Chlamydia	O
,	O
Mycoplasma	O
and	O
L	O
.	O
pneumophila	O
were	O
negative	O
,	O
making	O
it	O
difficult	O
to	O
establish	O
an	O
aetiological	O
diagnosis	O
.	O
Empirical	O
broad	O
spectrum	O
antibiotic	O
treatment	O
and	O
special	O
tests	O
were	O
therefore	O
necessary	O
to	O
reach	O
a	O
diagnosis	O
.	O
Currently	O
,	O
the	O
main	O
method	O
for	O
the	O
aetiological	O
diagnosis	O
of	O
infective	O
endocarditis	O
is	O
still	O
blood	O
culture	O
.	O
Three	O
blood	O
cultures	O
two	O
bottles	O
per	O
blood	O
culture	O
,	O
aerobic	O
and	O
anaerobic	O
should	O
be	O
taken	O
before	O
antibiotic	O
treatment	O
is	O
instituted	O
.	O
When	O
blood	O
cultures	O
are	O
negative	O
,	O
serology	O
is	O
the	O
most	O
effective	O
diagnostic	O
method	O
if	O
the	O
endocarditis	O
is	O
caused	O
by	O
C	O
.	O
burnetii	O
,	O
Bartonella	O
and	O
Brucella	O
as	O
in	O
these	O
cases	O
it	O
has	O
a	O
chronic	O
course	O
and	O
high	O
antibody	O
titres	O
are	O
produced	O
and	O
a	O
single	O
serum	O
is	O
necessary	O
.	O
In	O
the	O
case	O
of	O
other	O
microorganisms	O
such	O
as	O
Chlamydia	O
,	O
Mycoplasma	O
and	O
L	O
.	O
pneumophila	O
,	O
cross	O
reactions	O
must	O
be	O
ruled	O
out	O
and	O
their	O
diagnostic	O
value	O
is	O
lower	O
.	O
In	O
our	O
case	O
,	O
a	O
positive	O
result	O
was	O
obtained	O
on	O
the	O
same	O
day	O
of	O
surgery	O
for	O
a	O
universal	O
16S	O
rRNA	O
PCR	O
performed	O
with	O
DNA	O
extracted	O
from	O
aortic	O
valve	O
tissue	O
.	O
The	O
amplification	O
product	O
was	O
sequenced	O
the	O
following	O
day	O
and	O
the	O
sequence	O
obtained	O
was	O
aligned	O
in	O
Genebank	O
using	O
BLAST	O
software	O
http	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
blast	O
,	O
presenting	O
100	O
identity	O
with	O
the	O
T	O
.	O
whipplei	O
sequence	O
.	O
To	O
confirm	O
the	O
diagnosis	O
,	O
specific	O
PCR	O
of	O
the	O
hsp65	O
region	O
of	O
T	O
.	O
whipplei	O
was	O
performed	O
and	O
was	O
also	O
positive	O
,	O
confirming	O
the	O
identity	O
of	O
the	O
product	O
obtained	O
by	O
sequencing	O
.	O
Therefore	O
,	O
in	O
case	O
of	O
endocarditis	O
with	O
negative	O
blood	O
cultures	O
,	O
a	O
serum	O
should	O
be	O
obtained	O
for	O
serology	O
for	O
the	O
mentioned	O
microorganisms	O
and	O
,	O
if	O
possible	O
,	O
the	O
heart	O
valve	O
should	O
be	O
sent	O
to	O
a	O
reference	O
laboratory	O
for	O
universal	O
PCR	O
of	O
the	O
16S	O
rRNA	O
gene	O
.	O
A	O
fragment	O
of	O
the	O
valve	O
or	O
vegetation	O
should	O
be	O
sent	O
to	O
the	O
anatomical	O
pathology	O
laboratory	O
to	O
confirm	O
the	O
diagnosis	O
of	O
infective	O
endocarditis	O
and	O
to	O
perform	O
special	O
stains	O
Gram	O
,	O
Wartin	O
Starry	O
Bartonella	O
,	O
PAS	O
T	O
.	O
whipplei	O
,	O
etc	O
.	O
,	O
which	O
have	O
high	O
sensitivity	O
and	O
specificity	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
81	O
year	O
old	O
female	O
patient	O
,	O
with	O
the	O
following	O
history	O
of	O
interest	O
Baseline	O
situation	O
lives	O
alone	O
.	O
Independent	O
.	O
Active	O
life	O
for	O
her	O
age	O
.	O
Unborn	O
children	O
.	O
She	O
worked	O
as	O
an	O
assistant	O
.	O
Cardiovascular	O
risk	O
factors	O
high	O
blood	O
pressure	O
of	O
long	O
evolution	O
.	O
Obesity	O
.	O
Cardiological	O
history	O
Paroxysmal	O
paroxysmal	O
atrial	O
fibrillation	O
AF	O
anticoagulated	O
with	O
aldocumar	B-FARMACO
with	O
good	O
INR	O
control	O
.	O
She	O
had	O
been	O
assessed	O
1	O
2	O
years	O
previously	O
in	O
outpatient	O
cardiology	O
consultations	O
and	O
bisoprolol	B-FARMACO
was	O
withdrawn	O
due	O
to	O
first	O
degree	O
atrioventricular	O
block	O
.	O
An	O
exercise	O
test	O
was	O
performed	O
to	O
assess	O
chest	O
pain	O
,	O
which	O
was	O
clinically	O
and	O
electrically	O
negative	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
November	O
2016	O
non	O
dilated	O
left	O
ventricle	O
LV	O
with	O
mild	O
concentric	O
hypertrophy	O
,	O
unaltered	O
contractility	O
with	O
normal	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
,	O
pseudonormal	O
diastolic	O
pattern	O
with	O
data	O
suggestive	O
of	O
elevated	O
pressures	O
.	O
No	O
significant	O
aortic	O
valvular	O
heart	O
disease	O
.	O
Right	O
ventricle	O
RV	O
not	O
dilated	O
with	O
normal	O
systolic	O
function	O
.	O
Moderate	O
left	O
atrial	O
LA	O
dilatation	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Mild	O
tricuspid	O
insufficiency	O
.	O
Estimated	O
normal	O
pulmonary	O
arterial	O
systolic	O
pressure	O
PSAP	O
.	O
Other	O
history	O
Studied	O
by	O
pulmonology	O
for	O
dyspnoea	O
without	O
specific	O
diagnosis	O
.	O
Normal	O
respiratory	O
function	O
tests	O
;	O
chronically	O
on	O
a	O
bronchodilator	O
.	O
Arthrosis	O
.	O
Depressive	O
syndrome	O
.	O
She	O
denies	O
surgical	O
interventions	O
of	O
interest	O
.	O
Previous	O
medication	O
aldocumar	B-FARMACO
1	O
mg	O
1	O
tablet	O
every	O
day	O
except	O
Thursday	O
and	O
Sunday	O
when	O
he	O
takes	O
1	O
and	O
a	O
half	O
,	O
furosemide	B-FARMACO
40	O
mg	O
half	O
a	O
tablet	O
every	O
48	O
hours	O
,	O
paroxetine	B-FARMACO
20	O
mg	O
1	O
tablet	O
at	O
breakfast	O
and	O
half	O
at	O
lunch	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
tablet	O
at	O
breakfast	O
,	O
quetiapine	B-FARMACO
25	O
mg	O
1	O
tablet	O
at	O
dinner	O
,	O
umeclidinium	B-FARMACO
vilanterol	I-FARMACO
55	O
22	O
mcg	O
inh	O
every	O
24	O
hours	O
,	O
paracetamol	B-FARMACO
1	O
g	O
if	O
required	O
,	O
hydroferol	B-FARMACO
0	O
.	O
266	O
mg	O
every	O
15	O
days	O
.	O
CURRENT	O
ILLNESS	O
An	O
81	O
year	O
old	O
woman	O
,	O
with	O
the	O
history	O
described	O
above	O
,	O
attended	O
the	O
emergency	O
department	O
due	O
to	O
worsening	O
of	O
dyspnoea	O
in	O
previous	O
days	O
until	O
she	O
became	O
resting	O
with	O
associated	O
tachypnoea	O
and	O
significant	O
respiratory	O
distress	O
.	O
The	O
patient	O
and	O
family	O
were	O
told	O
of	O
progressive	O
dyspnoea	O
that	O
had	O
started	O
as	O
moderate	O
exertion	O
in	O
previous	O
weeks	O
with	O
wheezing	O
.	O
On	O
the	O
day	O
of	O
admission	O
,	O
her	O
daughter	O
went	O
home	O
and	O
found	O
her	O
with	O
dyspnoea	O
and	O
respiratory	O
work	O
complaining	O
of	O
epigastralgia	O
that	O
the	O
patient	O
could	O
not	O
define	O
.	O
She	O
also	O
reported	O
cough	O
and	O
rhinorrhoea	O
in	O
recent	O
weeks	O
without	O
fever	O
.	O
She	O
denies	O
chest	O
pain	O
only	O
occasionally	O
with	O
coughing	O
or	O
palpitations	O
.	O
No	O
orthopnoea	O
or	O
paroxysmal	O
nocturnal	O
dyspnoea	O
,	O
although	O
the	O
family	O
reports	O
that	O
she	O
has	O
been	O
sleeping	O
badly	O
for	O
the	O
last	O
few	O
days	O
.	O
She	O
did	O
not	O
report	O
decreased	O
diuresis	O
or	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
In	O
the	O
initial	O
emergency	O
department	O
assessment	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
acute	O
pulmonary	O
oedema	O
and	O
treatment	O
was	O
started	O
with	O
parenteral	O
bolus	O
amiodarone	B-FARMACO
,	O
given	O
that	O
he	O
was	O
in	O
rapid	O
atrial	O
fibrillation	O
,	O
which	O
was	O
poorly	O
tolerated	O
clinically	O
.	O
PHYSICAL	O
EXAMINATION	O
Arrival	O
afebrile	O
36	O
.	O
7	O
C	O
,	O
heart	O
rate	O
HR	O
120	O
145	O
bpm	O
,	O
blood	O
pressure	O
BP	O
114	O
96	O
mmHg	O
,	O
RF	O
31	O
rpm	O
,	O
baseline	O
SatO2	O
90	O
.	O
After	O
amiodarone	B-FARMACO
bolus	O
HR	O
120	O
bpm	O
,	O
BP	O
65	O
57	O
30	O
37	O
mmHg	O
,	O
SatO2	O
100	O
with	O
NIV	O
.	O
Global	O
inspection	O
conscious	O
,	O
oriented	O
in	O
the	O
three	O
spheres	O
and	O
cooperative	O
.	O
With	O
regular	O
general	O
condition	O
.	O
Tachyonic	O
with	O
tugging	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
.	O
No	O
murmurs	O
or	O
extratonos	O
were	O
heard	O
.	O
Artefactual	O
respiratory	O
sounds	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
CVM	O
bilaterally	O
with	O
crackles	O
up	O
to	O
midfields	O
and	O
scattered	O
wheezing	O
.	O
Abdomen	O
hydro	O
aerial	O
sounds	O
present	O
.	O
Slightly	O
distended	O
,	O
diffusely	O
tender	O
on	O
palpation	O
.	O
No	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
No	O
masses	O
or	O
visceromegaly	O
.	O
Extremities	O
no	O
oedema	O
or	O
signs	O
of	O
phlogosis	O
.	O
COMPLEMENTARY	O
TESTS	O
On	O
admission	O
Blood	O
count	O
haemoglobin	O
12	O
.	O
6	O
g	O
dl	O
.	O
Red	O
cells	O
4	O
.	O
38	O
x10E6	O
μl	O
.	O
MCV	O
85	O
.	O
6	O
fl	O
.	O
MCH	O
28	O
.	O
8	O
pg	O
.	O
Leukocytes	O
8	O
.	O
09	O
x10E3	O
μl	O
.	O
Neutrophils	O
blood	O
89	O
.	O
6	O
,	O
7	O
.	O
25	O
x10E3	O
μl	O
.	O
Lymphocytes	O
5	O
.	O
4	O
.	O
Lymphocytes	O
0	O
.	O
44	O
x10E3	O
μl	O
.	O
UPLAQ	O
platelets	O
313	O
x10E3	O
μl	O
.	O
Haematocrit	O
37	O
.	O
5	O
.	O
Biochemistry	O
glucose	O
155	O
mg	O
dl	O
.	O
Urea	O
53	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
49	O
mg	O
dl	O
.	O
Sodium	O
ion	O
136	O
mmol	O
l	O
.	O
Plasma	O
potassium	O
ion	O
4	O
.	O
5	O
mmol	O
l	O
.	O
Cardiac	O
markers	O
creatine	O
kinase	O
254	O
304	O
U	O
l	O
.	O
Troponin	O
T	O
328	O
382	O
ng	O
l	O
.	O
NTproBNP	O
3531	O
.	O
Coagulation	O
partial	O
thromboplastin	O
R	O
1	O
.	O
05	O
.	O
Prothrombin	O
T	O
.	O
ratio	O
2	O
.	O
28	O
.	O
INR	O
2	O
.	O
22	O
.	O
T	O
.	O
partial	O
thromboplastin	O
30	O
.	O
40	O
sec	O
.	O
T	O
.	O
prothrombin	O
25	O
.	O
50	O
sec	O
.	O
Fibrinogen	O
derivative	O
478	O
.	O
Ddimer	O
482	O
.	O
00	O
ng	O
ml	O
.	O
FEU	O
T	O
.	O
prothrombin	O
34	O
.	O
0	O
.	O
Blood	O
gas	O
pH	O
arterial	O
blood	O
gas	O
7	O
.	O
39	O
,	O
pO2	O
arterial	O
blood	O
gas	O
68	O
mmHg	O
,	O
pCO2	O
arterial	O
blood	O
gas	O
30	O
mmHg	O
,	O
total	O
CO2	O
arterial	O
blood	O
gas	O
19	O
.	O
1	O
mmol	O
l	O
.	O
Bicarbonate	O
arterial	O
gas	O
19	O
.	O
7	O
mmol	O
l	O
.	O
Excess	O
bases	O
arterial	O
gas	O
6	O
.	O
9	O
mmol	O
l	O
.	O
Oxyhaemoglobin	O
saturation	O
arterial	O
gas	O
94	O
.	O
Electrocardiogram	O
ECG	O
AF	O
at	O
160	O
bpm	O
,	O
with	O
Q	O
wave	O
in	O
III	O
and	O
R	O
wave	O
amputation	O
up	O
to	O
V5	O
not	O
present	O
in	O
previous	O
ECGs	O
.	O
Diffuse	O
flattening	O
of	O
repolarisation	O
.	O
After	O
CVE	O
1	O
shock	O
150	O
J	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
,	O
Q	O
wave	O
in	O
III	O
and	O
aVF	O
as	O
well	O
as	O
V1	O
V3	O
.	O
Chest	O
X	O
ray	O
decubitus	O
study	O
of	O
poor	O
quality	O
but	O
with	O
signs	O
of	O
water	O
overload	O
and	O
interstitial	O
pattern	O
.	O
Probable	O
cardiomegaly	O
although	O
oversized	O
by	O
the	O
projection	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
in	O
HED	O
in	O
patient	O
in	O
RS	O
at	O
80	O
bpm	O
in	O
sedentary	O
position	O
suboptimal	O
window	O
.	O
Moderately	O
dilated	O
LV	O
with	O
severe	O
LV	O
dysfunction	O
LVEF	O
visu	O
20	O
25	O
.	O
Better	O
basal	O
segment	O
contractility	O
,	O
but	O
difficult	O
to	O
assess	O
segmental	O
alterations	O
.	O
Prolonged	O
relaxation	O
Doppler	O
pattern	O
.	O
RV	O
with	O
mild	O
systolic	O
dysfunction	O
.	O
TAPSE	O
15	O
mm	O
.	O
Mild	O
moderate	O
mitral	O
insufficiency	O
of	O
mixed	O
degenerative	O
origin	O
and	O
secondary	O
to	O
LV	O
dilatation	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
slight	O
calcification	O
of	O
the	O
free	O
edge	O
of	O
the	O
leaflets	O
.	O
No	O
significant	O
gradients	O
.	O
Minimal	O
aortic	O
insufficiency	O
AIo	O
.	O
Moderate	O
tricuspid	O
insufficiency	O
,	O
with	O
A	O
V	O
gradient	O
of	O
25	O
30	O
mmHg	O
.	O
Vena	O
cava	O
not	O
visualised	O
.	O
At	O
discharge	O
Blood	O
count	O
haemoglobin	O
12	O
.	O
4	O
g	O
dl	O
.	O
Red	O
cells	O
4	O
.	O
30	O
x10E6	O
μl	O
.	O
MCV	O
84	O
.	O
0	O
fl	O
.	O
MCH	O
28	O
.	O
8	O
pg	O
.	O
MCHC	O
34	O
.	O
3	O
g	O
dl	O
.	O
Leukocytes	O
5	O
.	O
85	O
x10E3	O
μl	O
.	O
Neutrophils	O
blood	O
64	O
.	O
4	O
.	O
Neutrophils	O
3	O
.	O
77	O
x10E3	O
μl	O
.	O
Lymphocytes	O
23	O
.	O
9	O
.	O
Lymphocytes	O
1	O
.	O
40	O
x10E3	O
μl	O
.	O
Monocytes	O
blood	O
9	O
.	O
6	O
.	O
UPLAQ	O
platelets	O
271	O
x10E3	O
μl	O
.	O
VPM	O
10	O
.	O
5	O
fl	O
.	O
SR	O
RDW	O
coefficient	O
of	O
variation	O
17	O
.	O
6	O
.	O
Haematocrit	O
36	O
.	O
1	O
.	O
Biochemistry	O
glucose	O
89	O
mg	O
d	O
.	O
Urea	O
44	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
56	O
mg	O
dl	O
.	O
Sodium	O
ion	O
134	O
mmol	O
.	O
Potassium	O
ion	O
4	O
.	O
1	O
mmol	O
l	O
.	O
Plasma	O
potassium	O
ion	O
4	O
.	O
2	O
mmol	O
l	O
.	O
Amylase	O
75	O
U	O
l	O
.	O
Lipase	O
29	O
U	O
l	O
.	O
Creatine	O
kinase	O
15	O
U	O
l	O
.	O
Troponin	O
T	O
50	O
ng	O
l	O
.	O
NT	O
proBNP	O
1213	O
.	O
Procalcitonin	O
0	O
.	O
06	O
.	O
Total	O
bilirubin	O
1	O
.	O
3	O
mg	O
dl	O
.	O
Direct	O
bilirubin	O
0	O
.	O
4	O
mg	O
dl	O
.	O
Alanine	O
aminotransferase	O
70	O
U	O
l	O
.	O
Calcium	O
2	O
.	O
21	O
mmol	O
l	O
.	O
Transferrin	O
221	O
mg	O
dl	O
.	O
Phosphate	O
1	O
.	O
09	O
mmol	O
l	O
.	O
Lactate	O
dehydrogenase	O
216	O
U	O
l	O
.	O
Aspartate	O
aminotransferase	O
37	O
U	O
l	O
.	O
Transferrin	O
saturation	O
index	O
23	O
.	O
Iron	O
71	O
μg	O
dl	O
.	O
Folate	O
6	O
.	O
35	O
.	O
Albumin	O
31	O
g	O
l	O
.	O
C	O
reactive	O
protein	O
0	O
.	O
6	O
mg	O
dl	O
.	O
Hours	O
of	O
evolution	O
X	O
.	O
Gamma	O
glutamyltransferase	O
40	O
U	O
l	O
.	O
Magnesium	O
0	O
.	O
74	O
mmol	O
l	O
.	O
C	O
reactive	O
protein	O
5	O
,	O
3	O
mg	O
dl	O
.	O
Ferritin	O
272	O
.	O
HDL	O
cholesterol	O
51	O
mg	O
dl	O
.	O
Urate	O
7	O
.	O
4	O
mg	O
dl	O
.	O
Total	O
cholesterol	O
122	O
mg	O
dl	O
.	O
Total	O
protein	O
62	O
g	O
l	O
.	O
Vitamin	O
B12	O
1482	O
.	O
Triglycerides	O
66	O
mg	O
dl	O
.	O
Estimated	O
glomerular	O
filtration	O
38	O
.	O
Calculated	O
LDL	O
cholesterol	O
57	O
mg	O
dl	O
.	O
Lactate	O
2	O
,	O
2	O
mmol	O
l	O
.	O
Ionic	O
calcium	O
0	O
.	O
94	O
mmol	O
l	O
.	O
Coagulation	O
T	O
.	O
partial	O
thromboplastin	O
R	O
0	O
,	O
96	O
T	O
.	O
prothrombin	O
ratio	O
1	O
,	O
13	O
.	O
INR	O
1	O
.	O
12	O
.	O
T	O
.	O
partial	O
thromboplastin	O
27	O
.	O
70	O
sec	O
.	O
T	O
.	O
prothrombin	O
12	O
.	O
60	O
sec	O
.	O
derived	O
fibrinogen	O
625	O
.	O
Ddimer	O
482	O
.	O
00	O
ng	O
ml	O
.	O
FEU	O
T	O
.	O
prothrombin	O
84	O
.	O
0	O
.	O
Blood	O
gas	O
pH	O
arterial	O
blood	O
gas	O
7	O
.	O
39	O
.	O
pO2	O
arterial	O
blood	O
gas	O
68	O
mmHg	O
.	O
pCO2	O
arterial	O
blood	O
gas	O
30	O
mmHg	O
.	O
Total	O
CO2	O
arterial	O
gas	O
19	O
.	O
1	O
mmol	O
l	O
.	O
Bicarbonate	O
arterial	O
gas	O
19	O
.	O
7	O
mmol	O
l	O
.	O
Excess	O
bases	O
arterial	O
gas	O
6	O
.	O
9	O
mmol	O
l	O
.	O
Oxyhaemoglobin	O
saturation	O
arterial	O
gas	O
94	O
.	O
Microbiology	O
antigenuria	O
negative	O
.	O
Virology	O
RSV	O
positive	O
7748	O
,	O
the	O
rest	O
undetectable	O
.	O
ECG	O
1	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
.	O
Atrioventricular	O
block	O
AVB	O
first	O
degree	O
.	O
Q	O
inferior	O
face	O
and	O
V1	O
V4	O
and	O
R	O
amputated	O
V5	O
V6	O
.	O
Negative	O
T	O
precordial	O
,	O
I	O
and	O
aVL	O
.	O
QTc	O
670ms	O
.	O
ECG	O
2	O
AF	O
with	O
controlled	O
MVR	O
at	O
89	O
bpm	O
.	O
Q	O
waves	O
in	O
inferior	O
face	O
suggestive	O
of	O
necrosis	O
of	O
DIII	O
and	O
aVF	O
already	O
in	O
the	O
first	O
degree	O
DIII	O
and	O
aVF	O
already	O
observed	O
in	O
previous	O
ECGs	O
ST	O
underlevel	O
in	O
anterior	O
and	O
lateral	O
face	O
with	O
asymmetrical	O
negative	O
T	O
waves	O
.	O
ECG	O
3	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
.	O
Q	O
waves	O
in	O
inferior	O
face	O
suggestive	O
of	O
necrosis	O
of	O
DIII	O
and	O
aVF	O
already	O
seen	O
in	O
previous	O
ECGs	O
with	O
ST	O
segment	O
elevation	O
in	O
anterior	O
and	O
lateral	O
face	O
with	O
asymmetric	O
negative	O
T	O
waves	O
.	O
Telemetry	O
bouts	O
of	O
non	O
sustained	O
polymorphic	O
ventricular	O
tachycardia	O
until	O
yesterday	O
at	O
approximately	O
22	O
30	O
hours	O
yesterday	O
at	O
15	O
00	O
hours	O
bout	O
of	O
PSVT	O
.	O
Since	O
then	O
abundant	O
VE	O
with	O
some	O
doublets	O
triplets	O
.	O
Transthoracic	O
echocardiography	O
1	O
Moderately	O
dilated	O
LV	O
with	O
severe	O
LV	O
dysfunction	O
LVEF	O
visu	O
20	O
25	O
.	O
Better	O
contractility	O
of	O
basal	O
segments	O
,	O
but	O
difficult	O
to	O
assess	O
segmental	O
alterations	O
.	O
Prolonged	O
relaxation	O
Doppler	O
pattern	O
.	O
RV	O
with	O
normal	O
systolic	O
dysfunction	O
TAPSE	O
16	O
mm	O
.	O
Mild	O
moderate	O
mitral	O
insufficiency	O
of	O
mixed	O
degenerative	O
origin	O
and	O
secondary	O
to	O
LV	O
dilatation	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
slight	O
calcification	O
of	O
the	O
free	O
edge	O
of	O
the	O
leaflets	O
.	O
No	O
significant	O
gradients	O
.	O
Minimal	O
AIo	O
.	O
Slightly	O
dilated	O
LA	O
.	O
Moderate	O
tricuspid	O
insufficiency	O
,	O
difficult	O
alignment	O
.	O
Vena	O
cava	O
not	O
visualised	O
.	O
Coronary	O
angiography	O
coronary	O
arteries	O
without	O
significant	O
angiographic	O
lesions	O
.	O
Transthoracic	O
echocardiography	O
2	O
study	O
performed	O
in	O
AF	O
with	O
RVR	O
at	O
120x	O
,	O
alternating	O
with	O
bursts	O
of	O
RS	O
at	O
80x	O
non	O
dilated	O
LV	O
with	O
normal	O
thickness	O
,	O
segmental	O
contractility	O
very	O
poorly	O
visualised	O
but	O
impressions	O
of	O
akinesia	O
of	O
basal	O
and	O
mid	O
lateral	O
and	O
lower	O
basal	O
segment	O
.	O
Moderate	O
LV	O
dysfunction	O
with	O
LVEFbp	O
43	O
.	O
RV	O
with	O
normal	O
systolic	O
function	O
.	O
Mixed	O
mild	O
moderate	O
mitral	O
insufficiency	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
slight	O
calcification	O
of	O
the	O
free	O
edge	O
of	O
the	O
leaflets	O
.	O
No	O
significant	O
gradients	O
.	O
Minimal	O
AoI	O
.	O
Slightly	O
dilated	O
LA	O
.	O
Tricuspid	O
insufficiency	O
poorly	O
visualised	O
.	O
Vena	O
cava	O
not	O
dilated	O
.	O
Improvement	O
of	O
mitral	O
function	O
and	O
mitral	O
insufficiency	O
with	O
respect	O
to	O
previous	O
study	O
.	O
Cardiac	O
MRI	O
LV	O
normal	O
size	O
with	O
moderate	O
to	O
mild	O
systolic	O
dysfunction	O
.	O
Global	O
hypokinesia	O
.	O
Severe	O
hypokinesia	O
in	O
basal	O
mid	O
inferolateral	O
segment	O
with	O
small	O
focus	O
of	O
late	O
subendocardial	O
enhancement	O
of	O
50	O
in	O
basal	O
inferolateral	O
segment	O
of	O
ischaemic	O
profile	O
.	O
Assess	O
the	O
possibility	O
of	O
tachycardiomyopathy	O
.	O
Normal	O
sized	O
RV	O
with	O
normal	O
systolic	O
function	O
.	O
Voluminous	O
sliding	O
hiatal	O
hernia	O
.	O
Assess	O
the	O
possibility	O
of	O
tachycardiomyopathy	O
.	O
CLINICAL	O
EVOLUTION	O
81	O
year	O
old	O
patient	O
,	O
with	O
the	O
history	O
described	O
above	O
,	O
admitted	O
to	O
the	O
coronary	O
cardiology	O
unit	O
for	O
acute	O
pulmonary	O
oedema	O
secondary	O
to	O
AF	O
with	O
rapid	O
ventricular	O
response	O
.	O
Initially	O
,	O
pharmacological	O
cardioversion	O
was	O
performed	O
with	O
bolus	O
administration	O
and	O
perfusion	O
of	O
amiodarone	B-FARMACO
,	O
which	O
was	O
ineffective	O
,	O
and	O
,	O
together	O
with	O
taking	O
antidepressants	O
at	O
home	O
,	O
induced	O
the	O
appearance	O
of	O
a	O
long	O
QT	O
.	O
Secondary	O
to	O
QT	O
prolongation	O
,	O
symptomatic	O
polymorphic	O
ventricular	O
tachycardias	O
were	O
recorded	O
,	O
although	O
without	O
loss	O
of	O
pulse	O
.	O
After	O
pharmacological	O
lavage	O
with	O
fluid	O
therapy	O
and	O
withdrawal	O
of	O
antidepressants	O
,	O
the	O
QT	O
interval	O
was	O
corrected	O
and	O
the	O
ventricular	O
arrhythmias	O
disappeared	O
.	O
In	O
this	O
context	O
,	O
transthoracic	O
echocardiography	O
was	O
carried	O
out	O
,	O
with	O
the	O
following	O
findings	O
LVEF	O
severely	O
affected	O
.	O
In	O
the	O
admission	O
analysis	O
,	O
elevated	O
liver	O
function	O
tests	O
were	O
observed	O
,	O
and	O
a	O
referral	O
was	O
made	O
to	O
the	O
gastroenterologist	O
,	O
who	O
,	O
in	O
the	O
light	O
of	O
the	O
clinical	O
evolution	O
and	O
abdominal	O
ultrasound	O
,	O
diagnosed	O
ischaemic	O
hepatitis	O
.	O
Subsequently	O
,	O
he	O
was	O
transferred	O
to	O
the	O
hospital	O
ward	O
,	O
with	O
progressive	O
improvement	O
of	O
symptoms	O
of	O
acute	O
heart	O
failure	O
.	O
Due	O
to	O
associated	O
respiratory	O
symptoms	O
,	O
viral	O
serologies	O
were	O
extracted	O
and	O
were	O
positive	O
for	O
respiratory	O
syncytial	O
virus	O
.	O
These	O
symptoms	O
progressively	O
disappeared	O
with	O
bronchodilator	O
treatment	O
.	O
Regular	O
transthoracic	O
echocardiography	O
was	O
performed	O
,	O
confirming	O
severe	O
ventricular	O
dysfunction	O
,	O
a	O
finding	O
that	O
was	O
also	O
visualised	O
in	O
nuclear	O
magnetic	O
resonance	O
.	O
Due	O
to	O
persistent	O
AF	O
,	O
electrical	O
cardioversion	O
was	O
performed	O
with	O
reversion	O
to	O
sinus	O
rhythm	O
,	O
remaining	O
in	O
sinus	O
rhythm	O
at	O
the	O
time	O
of	O
discharge	O
,	O
under	O
treatment	O
with	O
amiodarone	B-FARMACO
.	O
Days	O
after	O
cardioversion	O
,	O
transthoracic	O
echocardiography	O
was	O
performed	O
,	O
showing	O
improvement	O
in	O
left	O
ventricular	O
dysfunction	O
,	O
confirming	O
the	O
diagnosis	O
of	O
tachycardiomyopathy	O
.	O
During	O
his	O
hospital	O
stay	O
,	O
he	O
presented	O
several	O
episodes	O
of	O
oligosymptomatic	O
coronary	O
vasospasm	O
,	O
with	O
ST	O
elevation	O
in	O
the	O
inferior	O
face	O
and	O
sustained	O
polymorphic	O
ventricular	O
tachycardias	O
maximum	O
of	O
12	O
seconds	O
.	O
Diagnostic	O
coronary	O
angiography	O
was	O
performed	O
,	O
showing	O
normal	O
coronary	O
arteries	O
,	O
and	O
after	O
starting	O
treatment	O
with	O
nitrates	B-FARMACO
and	O
dihydropyridine	O
calcium	O
antagonists	O
,	O
the	O
episodes	O
disappeared	O
.	O
Magnetic	O
resonance	O
imaging	O
performed	O
during	O
admission	O
previously	O
mentioned	O
showed	O
late	O
subendocardial	O
enhancement	O
in	O
the	O
inferolateral	O
segment	O
with	O
an	O
ischaemic	O
profile	O
,	O
probably	O
in	O
the	O
context	O
of	O
these	O
vasospastic	O
episodes	O
.	O
Due	O
to	O
the	O
withdrawal	O
of	O
antidepressant	O
medication	O
,	O
the	O
patient	O
began	O
to	O
show	O
signs	O
of	O
major	O
depression	O
anhedonia	O
,	O
abulia	O
.	O
.	O
.	O
and	O
so	O
a	O
consultation	O
with	O
psychiatry	O
was	O
requested	O
,	O
and	O
after	O
reintroduction	O
of	O
paroxetine	B-FARMACO
,	O
the	O
condition	O
was	O
stabilised	O
.	O
The	O
patient	O
being	O
asymptomatic	O
and	O
stable	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
she	O
was	O
discharged	O
home	O
.	O
DIAGNOSIS	O
Acute	O
congestive	O
heart	O
failure	O
with	O
acute	O
pulmonary	O
oedema	O
.	O
Persistent	O
AF	O
with	O
rapid	O
ventricular	O
response	O
cardioverted	O
chemically	O
and	O
electrically	O
.	O
Tachycardiomyopathy	O
with	O
moderate	O
postcardioversion	O
ventricular	O
dysfunction	O
.	O
Sustained	O
polymorphic	O
ventricular	O
tachycardia	O
torsade	O
de	O
pointes	O
.	O
Long	O
QT	O
pharmacological	O
.	O
Coronary	O
vasospasm	O
Prinzmetal	O
's	O
angina	O
with	O
ventricular	O
arrhythmias	O
.	O
Acute	O
bronchitis	O
without	O
signs	O
of	O
respiratory	O
infection	O
.	O
Ischaemic	O
hepatitis	O
.	O
Cholelithiasis	O
.	O
Major	O
depressive	O
disorder	O
with	O
psychotic	O
symptoms	O
.	O
Intolerance	O
to	O
angiotensin	B-FARMACO
converting	I-FARMACO
enzyme	I-FARMACO
inhibitors	I-FARMACO
ACE	O
inhibitors	O
.	O
Contraindication	O
to	O
beta	O
blockers	O
due	O
to	O
vasospasm	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
69	O
year	O
old	O
male	O
with	O
no	O
known	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
high	O
blood	O
pressure	O
HBP	O
,	O
overweight	O
,	O
ex	O
smoker	O
.	O
Sleep	O
apnoea	O
hypopnoea	O
syndrome	O
SAHS	O
under	O
treatment	O
with	O
continuous	O
positive	O
airway	O
pressure	O
CPAP	O
.	O
Diagnosed	O
with	O
oesophageal	O
spasms	O
with	O
manometry	O
,	O
following	O
an	O
admission	O
to	O
cardiology	O
in	O
2007	O
for	O
chest	O
pain	O
without	O
structural	O
heart	O
disease	O
.	O
Glomerulonephritis	O
in	O
infancy	O
labelled	O
as	O
post	O
streptococcal	O
.	O
Uncomplicated	O
cholelithiasis	O
.	O
Surgical	O
interventions	O
cataracts	O
,	O
retinal	O
detachment	O
,	O
varicose	O
veins	O
,	O
tonsillectomy	O
,	O
haemorrhoids	O
.	O
CURRENT	O
ILLNESS	O
She	O
came	O
to	O
the	O
emergency	O
department	O
with	O
dyspnoea	O
,	O
asthenia	O
,	O
anorexia	O
and	O
weight	O
loss	O
of	O
two	O
months	O
'	O
duration	O
.	O
No	O
clear	O
orthopnoea	O
or	O
oedematisation	O
of	O
the	O
lower	O
limbs	O
.	O
No	O
syncopal	O
episodes	O
or	O
palpitations	O
.	O
When	O
assessed	O
in	O
the	O
emergency	O
department	O
,	O
atrial	O
fibrillation	O
with	O
ventricular	O
response	O
at	O
100	O
bpm	O
was	O
detected	O
.	O
In	O
view	O
of	O
this	O
finding	O
,	O
the	O
worsening	O
of	O
functional	O
class	O
and	O
the	O
elevation	O
of	O
NTproBNP	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
heart	O
failure	O
and	O
admitted	O
to	O
the	O
cardiology	O
department	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
145	O
80	O
mmHg	O
.	O
Heart	O
rate	O
100	O
bpm	O
.	O
Basal	O
saturation	O
95	O
.	O
Temperature	O
37	O
.	O
4	O
C	O
.	O
Height	O
175	O
cm	O
,	O
weight	O
86	O
kg	O
,	O
body	O
mass	O
index	O
BMI	O
28	O
.	O
No	O
palpable	O
adenopathies	O
or	O
skin	O
lesions	O
.	O
Conscious	O
,	O
oriented	O
,	O
normal	O
colour	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
,	O
no	O
significant	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
normal	O
ventilation	O
.	O
Abdomen	O
soft	O
,	O
not	O
painful	O
,	O
no	O
masses	O
or	O
megaliths	O
,	O
persistalsis	O
preserved	O
.	O
Lower	O
extremities	O
no	O
oedema	O
.	O
No	O
ulcerative	O
lesions	O
in	O
the	O
upper	O
airways	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
biochemistry	O
glycaemia	O
91	O
mg	O
dl	O
,	O
urea	O
44	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
86	O
mg	O
dl	O
,	O
triglycerides	O
135	O
mg	O
dl	O
,	O
LDL	O
87	O
mg	O
dl	O
,	O
sodium	O
138	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
3	O
mEq	O
l	O
.	O
NT	O
proBNP	O
2606	O
pg	O
ml	O
.	O
Thyroid	O
function	O
TSH	O
1	O
.	O
49	O
mIU	O
l	O
,	O
T4	O
1	O
.	O
17	O
ng	O
dl	O
.	O
Haemoglobin	O
10	O
.	O
2	O
g	O
dl	O
,	O
haematocrit	O
30	O
.	O
8	O
,	O
leucocytes	O
6	O
,	O
700	O
mm3	O
,	O
platelets	O
350	O
,	O
000	O
mm3	O
.	O
Anti	O
DNA	O
and	O
antiENA	O
negative	O
.	O
pANCA	O
1459	O
.	O
7	O
.	O
ESR	O
91	O
.	O
Urinalysis	O
microalbuminuria	O
3	O
.	O
03	O
mg	O
dl	O
,	O
microhaematuria	O
.	O
Chest	O
X	O
ray	O
global	O
cardiomegaly	O
.	O
Pulmonary	O
hyperinflation	O
.	O
Residual	O
impingement	O
of	O
the	O
left	O
costophrenic	O
sinus	O
.	O
No	O
pulmonary	O
parenchymal	O
infiltrates	O
.	O
ECG	O
on	O
admission	O
atrial	O
fibrillation	O
with	O
rapid	O
RV	O
at	O
110x	O
,	O
complete	O
left	O
bundle	O
branch	O
block	O
LBBB	O
and	O
low	O
voltages	O
.	O
Transthoracic	O
echocardiogram	O
slightly	O
dilated	O
atria	O
.	O
Left	O
ventricle	O
LV	O
of	O
normal	O
size	O
.	O
Mild	O
left	O
ventricular	O
hypertrophy	O
LVH	O
.	O
Global	O
contractility	O
preserved	O
,	O
without	O
observing	O
segmental	O
alterations	O
.	O
LVEFbp	O
60	O
.	O
No	O
criteria	O
for	O
elevated	O
left	O
ventricular	O
end	O
diastolic	O
pressure	O
LVEDP	O
.	O
Trivalve	O
aortic	O
valve	O
VAo	O
with	O
sclerosis	O
of	O
the	O
leaflet	O
cusps	O
and	O
calcification	O
on	O
the	O
NC	O
leaflet	O
.	O
It	O
maintains	O
adequate	O
opening	O
,	O
with	O
no	O
regurgitant	O
flows	O
.	O
Mitral	O
valve	O
MV	O
with	O
normal	O
appearance	O
and	O
function	O
.	O
Cava	O
and	O
suprahepatic	O
valves	O
not	O
dilated	O
,	O
without	O
flow	O
reversal	O
and	O
normal	O
inspiratory	O
collapse	O
.	O
Normal	O
PPs	O
.	O
Mild	O
moderate	O
pericardial	O
effusion	O
without	O
haemodynamic	O
involvement	O
,	O
with	O
leaflet	O
separation	O
2	O
mm	O
over	O
the	O
anterior	O
sac	O
and	O
over	O
the	O
roof	O
of	O
the	O
right	O
atrium	O
RA	O
,	O
7	O
mm	O
in	O
the	O
posterior	O
,	O
10	O
mm	O
in	O
the	O
lateral	O
LV	O
and	O
7	O
mm	O
over	O
the	O
lateral	O
RV	O
.	O
Fibrin	O
tracts	O
with	O
partially	O
organised	O
effusion	O
on	O
the	O
lateral	O
aspect	O
of	O
the	O
RV	O
and	O
the	O
apex	O
of	O
the	O
right	O
ventricle	O
RV	O
are	O
observed	O
without	O
increased	O
movement	O
on	O
the	O
lateral	O
aspect	O
of	O
the	O
RA	O
and	O
RV	O
and	O
normocolapse	O
of	O
the	O
cava	O
.	O
Thoracoabdominal	O
CT	O
no	O
axillary	O
lymph	O
nodes	O
.	O
Subcentimetric	O
right	O
paratracheal	O
,	O
bilateral	O
prevascular	O
and	O
subcarinal	O
mediastinal	O
nodes	O
,	O
as	O
well	O
as	O
right	O
bronchopulmonary	O
nodes	O
,	O
all	O
of	O
them	O
with	O
a	O
reactive	O
appearance	O
.	O
Bilateral	O
laminar	O
atelectasis	O
.	O
Discrete	O
left	O
pleural	O
effusion	O
with	O
passive	O
atelectasis	O
of	O
the	O
underlying	O
lung	O
parenchyma	O
,	O
showing	O
an	O
aerial	O
image	O
that	O
could	O
correspond	O
to	O
a	O
bulla	O
in	O
the	O
collapsed	O
parenchyma	O
vs	O
.	O
bubble	O
at	O
the	O
level	O
of	O
the	O
pleural	O
fluid	O
assess	O
history	O
of	O
manipulation	O
.	O
Pericardial	O
effusion	O
with	O
a	O
maximum	O
thickness	O
of	O
27	O
mm	O
in	O
the	O
lateral	O
region	O
of	O
the	O
left	O
ventricle	O
.	O
Homogeneous	O
liver	O
,	O
normal	O
size	O
and	O
morphology	O
,	O
with	O
a	O
millimetric	O
hypodense	O
lesion	O
in	O
the	O
dome	O
,	O
unspecific	O
due	O
to	O
its	O
small	O
size	O
.	O
Cholelithiasis	O
.	O
Bile	O
duct	O
of	O
normal	O
calibre	O
.	O
Pancreas	O
and	O
spleen	O
without	O
alterations	O
.	O
Slight	O
bilateral	O
adrenal	O
thickening	O
with	O
hyperplastic	O
appearance	O
.	O
Kidneys	O
of	O
normal	O
size	O
and	O
morphology	O
,	O
with	O
good	O
bilateral	O
and	O
symmetrical	O
function	O
.	O
Bilateral	O
simple	O
cortical	O
cysts	O
,	O
the	O
largest	O
of	O
53	O
mm	O
in	O
the	O
upper	O
pole	O
of	O
the	O
left	O
kidney	O
and	O
52	O
mm	O
in	O
the	O
upper	O
third	O
of	O
the	O
right	O
kidney	O
.	O
No	O
excretory	O
tract	O
ectasia	O
.	O
The	O
bladder	O
is	O
scarcely	O
replete	O
,	O
with	O
no	O
obvious	O
parietal	O
alterations	O
.	O
Prostate	O
with	O
a	O
transverse	O
axis	O
of	O
44	O
mm	O
.	O
Sigmoid	O
diverticulosis	O
with	O
no	O
signs	O
of	O
complication	O
.	O
No	O
significant	O
intra	O
abdominal	O
adenopathy	O
or	O
intraperitoneal	O
free	O
fluid	O
.	O
Bone	O
degenerative	O
signs	O
.	O
Electroneurogram	O
study	O
compatible	O
with	O
sensory	O
motor	O
polyneuropathy	O
PNP	O
in	O
the	O
lower	O
limbs	O
,	O
of	O
severe	O
degree	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
questioning	O
the	O
patient	O
again	O
,	O
he	O
reported	O
asthenia	O
,	O
anorexia	O
and	O
weight	O
loss	O
about	O
10	O
kg	O
in	O
the	O
last	O
3	O
months	O
,	O
which	O
he	O
attributed	O
to	O
the	O
start	O
of	O
a	O
hypocaloric	O
diet	O
from	O
primary	O
care	O
.	O
He	O
also	O
reported	O
left	O
cervical	O
adenopathy	O
that	O
disappeared	O
after	O
taking	O
ibuprofen	B-FARMACO
together	O
with	O
erythematopapular	O
lesions	O
,	O
which	O
improved	O
with	O
topical	O
corticosteroids	O
,	O
two	O
months	O
before	O
his	O
current	O
admission	O
;	O
migratory	O
arthralgias	O
in	O
the	O
elbows	O
and	O
right	O
shoulder	O
,	O
persistent	O
afternoon	O
fever	O
of	O
3	O
months	O
'	O
duration	O
,	O
haematuria	O
and	O
proteinuria	O
in	O
urine	O
with	O
normal	O
renal	O
function	O
confirmed	O
in	O
a	O
general	O
analysis	O
at	O
his	O
primary	O
care	O
centre	O
several	O
weeks	O
earlier	O
.	O
Episode	O
of	O
rhinitis	O
and	O
epistaxis	O
two	O
months	O
earlier	O
,	O
resolved	O
with	O
intranasal	O
corticosteroids	O
.	O
An	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
no	O
significant	O
valvular	O
heart	O
disease	O
,	O
slight	O
pleural	O
effusion	O
and	O
moderate	O
pericardial	O
effusion	O
without	O
repercussions	O
.	O
In	O
view	O
of	O
the	O
significant	O
general	O
and	O
systemic	O
involvement	O
,	O
acute	O
phase	O
reactants	O
and	O
autoimmunity	O
tests	O
were	O
requested	O
,	O
with	O
significant	O
elevation	O
of	O
CRP	O
,	O
ESR	O
and	O
positive	O
P	O
ANCA	O
and	O
C	O
ANCA	O
autoantibodies	O
.	O
Given	O
the	O
high	O
suspicion	O
of	O
vasculitis	O
with	O
renal	O
involvement	O
,	O
a	O
discussion	O
was	O
held	O
with	O
the	O
nephrology	O
department	O
,	O
who	O
did	O
not	O
consider	O
a	O
renal	O
biopsy	O
to	O
be	O
indicated	O
at	O
the	O
present	O
time	O
,	O
and	O
with	O
the	O
internal	O
medicine	O
department	O
autoimmune	O
diseases	O
.	O
The	O
study	O
was	O
completed	O
with	O
an	O
electroneurogram	O
which	O
showed	O
data	O
compatible	O
with	O
severe	O
polyneuropathy	O
of	O
the	O
lower	O
limbs	O
.	O
Given	O
the	O
diagnosis	O
of	O
C	O
ANCA	O
positive	O
vasculitis	O
,	O
treatment	O
with	O
corticoids	O
was	O
started	O
,	O
in	O
agreement	O
with	O
the	O
autoimmune	O
unit	O
,	O
with	O
significant	O
improvement	O
in	O
general	O
condition	O
and	O
reduction	O
of	O
pericardial	O
effusion	O
,	O
which	O
at	O
discharge	O
was	O
only	O
slight	O
moderate	O
in	O
the	O
posterior	O
sac	O
.	O
From	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
he	O
remains	O
in	O
atrial	O
fibrillation	O
with	O
adequate	O
heart	O
rate	O
control	O
with	O
beta	O
blockers	O
.	O
Initially	O
,	O
given	O
that	O
he	O
has	O
not	O
completed	O
4	O
weeks	O
of	O
anticoagulation	O
and	O
that	O
the	O
main	O
problem	O
is	O
his	O
autoimmune	O
pathology	O
,	O
a	O
strategy	O
of	O
rate	O
control	O
is	O
advocated	O
,	O
considering	O
elective	O
cardioversion	O
on	O
an	O
outpatient	O
basis	O
according	O
to	O
clinical	O
evolution	O
.	O
Clinically	B-FARMACO
and	O
haemodynamically	O
stable	O
,	O
he	O
was	O
discharged	O
from	O
hospital	O
with	O
the	O
following	O
treatment	O
methotrexate	B-FARMACO
20	O
mg	O
one	O
injection	O
weekly	O
,	O
folic	B-FARMACO
acid	I-FARMACO
5	O
mg	O
1	O
tablet	O
weekly	O
after	O
methotrexate	B-FARMACO
injection	O
,	O
prednisone	B-FARMACO
30	O
mg	O
2	O
tablets	O
at	O
breakfast	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
at	O
breakfast	O
and	O
2	O
.	O
5	O
mg	O
at	O
dinner	O
,	O
apixaban	B-FARMACO
5	O
mg	O
at	O
breakfast	O
and	O
dinner	O
,	O
simvastatin	B-FARMACO
40	O
mg	O
at	O
dinner	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
fasting	O
and	O
furosemide	B-FARMACO
40	O
mg	O
at	O
breakfast	O
.	O
DIAGNOSIS	O
Vasculitis	O
C	O
ANCA	O
positive	O
.	O
Pleuropericardial	O
effusion	O
of	O
autoimmune	O
aetiology	O
.	O
Atrial	O
fibrillation	O
of	O
uncertain	O
onset	O
with	O
controlled	O
ventricular	O
response	O
at	O
discharge	O
,	O
CHADSVASc	O
2	O
,	O
HASBLED	O
1	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
a	O
57	O
year	O
old	O
male	O
,	O
a	O
former	O
smoker	O
,	O
dyslipidaemic	O
and	O
with	O
a	O
history	O
of	O
chronic	O
ischaemic	O
heart	O
disease	O
.	O
One	O
year	O
ago	O
,	O
after	O
suffering	O
unstable	O
angina	O
with	O
positive	O
ergometry	O
,	O
coronary	O
angiography	O
was	O
performed	O
which	O
revealed	O
coronary	O
artery	O
disease	O
of	O
the	O
anterior	O
descending	O
artery	O
,	O
which	O
was	O
revascularised	O
by	O
implanting	O
a	O
drug	O
eluting	O
stent	O
.	O
He	O
also	O
had	O
gastro	O
oesophageal	O
reflux	O
and	O
had	O
undergone	O
surgery	O
for	O
an	O
inguinal	O
hernia	O
.	O
He	O
was	O
currently	O
being	O
treated	O
with	O
aspirin	B-FARMACO
,	O
torasemide	B-FARMACO
and	O
pantoprazole	B-FARMACO
.	O
He	O
attended	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
for	O
progressive	O
dyspnoea	O
of	O
4	O
months	O
'	O
evolution	O
associated	O
with	O
intense	O
asthenia	O
,	O
generalised	O
weakness	O
,	O
weight	O
loss	O
of	O
25	O
kg	O
in	O
this	O
period	O
and	O
frequent	O
episodes	O
of	O
diarrhoea	O
.	O
There	O
had	O
been	O
a	O
clear	O
clinical	O
worsening	O
of	O
the	O
dyspnoea	O
in	O
the	O
last	O
two	O
weeks	O
to	O
the	O
point	O
of	O
minimal	O
effort	O
,	O
together	O
with	O
the	O
appearance	O
of	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
He	O
denied	O
episodes	O
of	O
central	O
chest	O
pain	O
,	O
orthopnoea	O
or	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
He	O
also	O
reported	O
no	O
cough	O
,	O
expectoration	O
,	O
fever	O
or	O
night	O
sweats	O
or	O
bleeding	O
.	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
blood	O
pressure	O
BP	O
was	O
110	O
60	O
,	O
heart	O
rate	O
HR	O
was	O
90	O
bpm	O
and	O
baseline	O
O2	O
SatO2	O
was	O
96	O
.	O
Physical	O
examination	O
revealed	O
increased	O
jugular	O
venous	O
pressure	O
,	O
a	O
flail	O
chest	O
and	O
the	O
presence	O
of	O
Raynaud	O
's	O
phenomenon	O
in	O
both	O
hands	O
.	O
Cardiopulmonary	O
auscultation	O
revealed	O
rhythmic	O
heart	O
sounds	O
with	O
a	O
systolic	O
murmur	O
in	O
the	O
mitral	O
focus	O
and	O
crackles	O
in	O
the	O
left	O
base	O
.	O
He	O
also	O
had	O
oedema	O
with	O
fovea	O
up	O
to	O
the	O
knee	O
.	O
COMPLEMENTARY	O
TESTS	O
Baseline	O
electrocardiogram	O
RS	O
at	O
75	O
bpm	O
,	O
PR	O
200	O
ms	O
,	O
right	O
bundle	O
branch	O
block	O
RBBB	O
with	O
signs	O
of	O
right	O
ventricular	O
RV	O
overload	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
CTI	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
,	O
possible	O
paratracheal	O
lymphadenopathy	O
.	O
Minimal	O
vascular	O
redistribution	O
.	O
Laboratory	O
tests	O
Biochemistry	O
glucose	O
89	O
,	O
creatinine	O
0	O
.	O
75	O
,	O
urea	O
36	O
,	O
uric	O
acid	O
8	O
.	O
5	O
,	O
Na	O
140	O
,	O
K	O
4	O
,	O
NTproBNP	O
1800	O
,	O
CRP	O
50	O
.	O
Interferon	O
B	O
negative	O
,	O
B2	O
microglobulin	O
3	O
.	O
27	O
,	O
ANA	O
1	O
640	O
with	O
rest	O
of	O
autoimmunity	O
study	O
normal	O
,	O
complement	O
normal	O
,	O
tumour	O
markers	O
negative	O
.	O
Serology	O
negative	O
.	O
Haemogram	O
Hb	O
9	O
.	O
4	O
,	O
leukocytes	O
6	O
,	O
400	O
normal	O
formula	O
,	O
platelets	O
66	O
,	O
000	O
.	O
Coagulation	O
INR	O
1	O
.	O
4	O
,	O
PT	O
67	O
.	O
Echocardiogram	O
left	O
ventricle	O
of	O
normal	O
size	O
and	O
preserved	O
function	O
with	O
mild	O
hypertrophy	O
interventricular	O
septum	O
12	O
mm	O
.	O
Diastolic	O
dysfunction	O
with	O
pseudonormal	O
mitral	O
filling	O
pattern	O
E	O
e	O
'	O
lateral	O
side	O
of	O
15	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
No	O
evidence	O
of	O
pulmonary	O
hypertension	O
at	O
rest	O
.	O
Mild	O
mitral	O
insufficiency	O
without	O
other	O
associated	O
valvulopathies	O
.	O
Mild	O
pericardial	O
effusion	O
without	O
echocardiographic	O
data	O
of	O
haemodynamic	O
compromise	O
.	O
Cardiac	O
MRI	O
moderate	O
bilateral	O
pleural	O
effusion	O
with	O
passive	O
atelectasis	O
of	O
the	O
left	O
lower	O
lobe	O
.	O
Circumferential	O
pericardial	O
effusion	O
with	O
a	O
maximum	O
thickness	O
of	O
2	O
cm	O
on	O
the	O
right	O
lateral	O
aspect	O
.	O
Myocardial	O
thickness	O
preserved	O
.	O
Perfusion	O
study	O
without	O
alterations	O
.	O
No	O
pathological	O
gadolinium	O
deposits	O
were	O
observed	O
.	O
Biventricular	O
function	O
preserved	O
.	O
Angio	O
CT	O
of	O
pulmonary	O
arteries	O
no	O
signs	O
of	O
pulmonary	O
thromboembolism	O
.	O
CT	O
scan	O
small	O
moderate	O
right	O
pleural	O
effusion	O
and	O
left	O
pleural	O
effusion	O
sheet	O
.	O
Both	O
lung	O
bases	O
show	O
a	O
cobblestone	O
pattern	O
with	O
bronchiectasis	O
,	O
parenchymal	O
distortion	O
and	O
honeycomb	O
cysts	O
.	O
Bilateral	O
hilar	O
adenopathy	O
.	O
Cardiomegaly	O
and	O
pericardial	O
effusion	O
.	O
In	O
conclusion	O
study	O
compatible	O
with	O
non	O
specific	O
interstitial	O
pulmonary	O
fibrosis	O
that	O
may	O
correspond	O
to	O
collagen	O
disease	O
systemic	O
sclerosis	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
initially	O
admitted	O
to	O
our	O
department	O
for	O
heart	O
failure	O
with	O
associated	O
pericardial	O
effusion	O
,	O
and	O
diuretic	O
treatment	O
was	O
started	O
with	O
marked	O
clinical	O
improvement	O
.	O
Once	O
stable	O
and	O
having	O
ruled	O
out	O
clinical	O
and	O
echocardiographic	O
signs	O
of	O
cardiac	O
tamponade	O
and	O
the	O
presence	O
of	O
pulmonary	O
thromboembolism	O
by	O
means	O
of	O
an	O
angio	O
CT	O
scan	O
of	O
the	O
pulmonary	O
arteries	O
,	O
a	O
referral	O
was	O
made	O
to	O
the	O
gastrointestinal	O
department	O
to	O
study	O
a	O
diarrhoeal	O
process	O
secondary	O
to	O
possible	O
inflammatory	O
bowel	O
disease	O
and	O
to	O
internal	O
medicine	O
for	O
a	O
study	O
of	O
the	O
general	O
syndrome	O
.	O
As	O
part	O
of	O
the	O
battery	O
of	O
tests	O
performed	O
during	O
admission	O
,	O
a	O
colonoscopy	O
was	O
requested	O
in	O
order	O
to	O
rule	O
out	O
digestive	O
tumour	O
pathology	O
causing	O
this	O
general	O
syndrome	O
.	O
After	O
administering	O
the	O
preparation	O
for	O
this	O
test	O
,	O
the	O
patient	O
suffered	O
an	O
episode	O
of	O
sudden	O
dizziness	O
and	O
the	O
electrocardiogram	O
showed	O
the	O
presence	O
of	O
complete	O
atrioventricular	O
block	O
with	O
wide	O
QRS	O
leakage	O
at	O
40	O
bpm	O
,	O
at	O
which	O
time	O
he	O
was	O
being	O
treated	O
with	O
low	O
dose	O
atenolol	B-FARMACO
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
coronary	O
unit	O
where	O
a	O
temporary	O
electrode	O
was	O
implanted	O
via	O
the	O
right	O
jugular	O
vein	O
.	O
After	O
a	O
negative	O
chronotropic	O
medication	O
washout	O
period	O
and	O
verification	O
of	O
the	O
absence	O
of	O
adequate	O
atrioventricular	O
conduction	O
,	O
a	O
DDDR	O
bicameral	O
permanent	O
pacemaker	O
was	O
implanted	O
without	O
incident	O
.	O
He	O
had	O
a	O
good	O
postoperative	O
course	O
and	O
was	O
discharged	O
.	O
Given	O
the	O
suspicion	O
of	O
an	O
infiltrative	O
cardiomyopathy	O
secondary	O
to	O
a	O
systemic	O
disease	O
with	O
involvement	O
of	O
several	O
organs	O
,	O
the	O
patient	O
was	O
assessed	O
by	O
the	O
rheumatology	O
department	O
and	O
the	O
internal	O
medicine	O
department	O
.	O
The	O
study	O
was	O
completed	O
with	O
a	O
CAT	O
scan	O
that	O
showed	O
a	O
pattern	O
in	O
both	O
bases	O
suggestive	O
of	O
interstitial	O
pulmonary	O
fibrosis	O
,	O
a	O
spirometry	O
that	O
showed	O
moderate	O
restriction	O
and	O
a	O
slight	O
decrease	O
in	O
diffusion	O
and	O
an	O
electromyogram	O
in	O
which	O
data	O
compatible	O
with	O
myopathy	O
were	O
observed	O
.	O
In	O
addition	O
,	O
a	O
skin	O
biopsy	O
was	O
performed	O
which	O
revealed	O
histological	O
findings	O
compatible	O
with	O
scleroderma	O
.	O
With	O
these	O
data	O
,	O
and	O
with	O
the	O
persistence	O
of	O
episodes	O
of	O
self	O
limited	O
diarrhoea	O
due	O
to	O
a	O
probable	O
malabsorptive	O
component	O
,	O
the	O
diagnosis	O
of	O
diffuse	O
systemic	O
sclerosis	O
with	O
cutaneous	O
,	O
cardiac	O
atrioventricular	O
block	O
,	O
pericardial	O
effusion	O
,	O
pulmonary	O
interstitial	O
pulmonary	O
fibrosis	O
and	O
digestive	O
malabsorption	O
involvement	O
was	O
confirmed	O
.	O
Treatment	O
with	O
cyclophosphamide	B-FARMACO
was	O
started	O
,	O
with	O
poor	O
tolerance	O
due	O
to	O
renal	O
and	O
bone	O
marrow	O
toxicity	O
.	O
Subsequently	O
,	O
he	O
presented	O
poor	O
clinical	O
evolution	O
with	O
progressive	O
worsening	O
of	O
his	O
functional	O
class	O
and	O
suffered	O
several	O
admissions	O
for	O
heart	O
failure	O
with	O
a	O
predominance	O
of	O
congestion	O
data	O
refractory	O
to	O
diuretic	O
treatment	O
,	O
and	O
the	O
patient	O
died	O
one	O
year	O
after	O
diagnosis	O
.	O
DIAGNOSIS	O
Diffuse	O
systemic	O
sclerosis	O
with	O
cutaneous	O
,	O
pulmonary	O
,	O
cardiac	O
and	O
digestive	O
involvement	O
.	O
Congestive	O
heart	O
failure	O
with	O
preserved	O
EF	O
.	O
Mild	O
moderate	O
pleuro	O
pericardial	O
effusion	O
.	O
Complete	O
atrioventricular	O
block	O
.	O
Implantation	O
of	O
DDDR	O
bicameral	O
definitive	O
pacemaker	O
.	O
Thrombopenia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
55	O
year	O
old	O
male	O
patient	O
with	O
the	O
following	O
personal	O
history	O
No	O
known	O
adverse	O
drug	O
reactions	O
.	O
Cardiovascular	O
risk	O
factors	O
smoker	O
.	O
No	O
family	O
history	O
of	O
interest	O
.	O
Cardiological	O
history	O
chronic	O
ischaemic	O
heart	O
disease	O
2004	O
ACS	O
.	O
Conservative	O
management	O
.	O
October	O
2018	O
assessed	O
in	O
cardiology	O
outpatient	O
clinic	O
for	O
angina	O
.	O
The	O
patient	O
had	O
no	O
signs	O
of	O
heart	O
failure	O
and	O
the	O
electrocardiogram	O
ECG	O
showed	O
no	O
alterations	O
of	O
interest	O
.	O
The	O
following	O
complementary	O
tests	O
were	O
requested	O
Transthoracic	O
echocardiography	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
a	O
slight	O
increase	O
in	O
septal	O
wall	O
thickness	O
.	O
Slight	O
hypokinesia	O
at	O
the	O
septal	O
level	O
in	O
the	O
basal	O
and	O
middle	O
segments	O
with	O
adequate	O
contractility	O
of	O
the	O
remaining	O
segments	O
,	O
with	O
overall	O
preserved	O
LV	O
systolic	O
function	O
.	O
No	O
aortic	O
and	O
left	O
atrial	O
root	O
dilatation	O
.	O
Right	O
chambers	O
not	O
dilated	O
with	O
preserved	O
right	O
ventricular	O
systolic	O
function	O
.	O
No	O
significant	O
organic	O
valvular	O
pathology	O
.	O
Vena	O
cava	O
not	O
dilated	O
with	O
adequate	O
respiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Diagnostic	O
coronary	O
angiography	O
Coronary	O
trunk	O
with	O
non	O
significant	O
angiographic	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
with	O
severe	O
stenosis	O
from	O
its	O
origin	O
to	O
the	O
middle	O
segment	O
and	O
in	O
the	O
distal	O
third	O
with	O
thin	O
distal	O
bed	O
and	O
TIMI	O
2	O
flow	O
.	O
Recanalisation	O
of	O
septal	O
branches	O
by	O
heterocoronary	O
circulation	O
.	O
Circumflex	O
artery	O
Cx	O
with	O
non	O
significant	O
angiographic	O
lesions	O
.	O
Dominant	O
right	O
coronary	O
artery	O
,	O
diffusely	O
diseased	O
,	O
with	O
non	O
significant	O
focal	O
lesion	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
it	O
was	O
decided	O
to	O
assess	O
myocardial	O
viability	O
in	O
order	O
to	O
decide	O
on	O
the	O
approach	O
to	O
revascularisation	O
.	O
Stress	O
echocardiography	O
was	O
requested	O
a	O
stress	O
test	O
was	O
performed	O
with	O
dobutamine	B-FARMACO
,	O
until	O
reaching	O
15	O
mcg	O
kg	O
min	O
and	O
doubling	O
the	O
baseline	O
heart	O
rate	O
HR	O
,	O
showing	O
an	O
improvement	O
until	O
almost	O
normalisation	O
of	O
the	O
motility	O
of	O
the	O
septal	O
segments	O
described	O
with	O
hyperdynamic	O
systolic	O
function	O
.	O
Absence	O
of	O
complications	O
.	O
Clinically	O
asymptomatic	O
and	O
without	O
electrical	O
changes	O
.	O
Preserved	O
LVEF	O
,	O
viable	O
myocardium	O
.	O
November	O
2018	O
patient	O
placed	O
on	O
waiting	O
list	O
for	O
surgical	O
revascularisation	O
Usual	O
treatment	O
ramipril	B-FARMACO
5	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
,	O
nitroglycerin	B-FARMACO
patch	O
10	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
,	O
fluvastatin	B-FARMACO
80	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
and	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
.	O
On	O
6	O
December	O
,	O
while	O
the	O
patient	O
was	O
out	O
for	O
a	O
walk	O
,	O
he	O
began	O
to	O
feel	O
generally	O
unwell	O
and	O
then	O
suffered	O
syncope	O
.	O
Witnesses	O
tried	O
unsuccessfully	O
to	O
wake	O
him	O
up	O
and	O
called	O
the	O
emergency	O
services	O
.	O
The	O
emergency	O
team	O
took	O
approximately	O
10	O
minutes	O
to	O
arrive	O
,	O
finding	O
cardiorespiratory	O
arrest	O
,	O
with	O
bradycardia	O
at	O
45	O
bpm	O
and	O
no	O
pulse	O
electromechanical	O
dissociation	O
.	O
In	O
this	O
context	O
,	O
advanced	O
cardiopulmonary	O
resuscitation	O
CPR	O
manoeuvres	O
were	O
started	O
,	O
a	O
total	O
of	O
3	O
ampoules	O
of	O
adrenaline	B-FARMACO
were	O
administered	O
and	O
the	O
patient	O
was	O
intubated	O
orotracheally	O
.	O
After	O
20	O
minutes	O
of	O
performing	O
these	O
manoeuvres	O
,	O
a	O
ventricular	O
fibrillation	O
rhythm	O
was	O
observed	O
,	O
from	O
which	O
the	O
patient	O
was	O
defibrillated	O
with	O
a	O
shock	O
at	O
360	O
Joules	O
.	O
An	O
ECG	O
was	O
then	O
performed	O
showing	O
irregular	O
tachycardia	O
at	O
130	O
bpm	O
,	O
QRS	O
at	O
120	O
ms	O
,	O
ST	O
segment	O
elevation	O
in	O
inferior	O
leads	O
and	O
V1	O
.	O
QS	O
pattern	O
in	O
V2	O
and	O
V3	O
with	O
ST	O
elevation	O
of	O
2	O
3	O
mm	O
in	O
V2	O
V4	O
and	O
aVR	O
.	O
On	O
call	O
cardiology	O
was	O
contacted	O
,	O
the	O
haemodynamics	O
service	O
was	O
activated	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
our	O
centre	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
an	O
urgent	O
echocardiogram	O
was	O
performed	O
,	O
documenting	O
severe	O
left	O
ventricular	O
LV	O
dysfunction	O
with	O
severe	O
hypokinesia	O
in	O
the	O
territory	O
of	O
the	O
anterior	O
descending	O
artery	O
LAD	O
.	O
The	O
patient	O
was	O
haemodynamically	O
unstable	O
and	O
noradrenaline	B-FARMACO
and	O
dobutamine	B-FARMACO
perfusion	O
was	O
started	O
.	O
Primary	O
angioplasty	O
is	O
then	O
performed	O
.	O
COMPLEMENTARY	O
TESTS	O
First	O
ECG	O
after	O
recovery	O
of	O
spontaneous	O
circulation	O
irregular	O
tachycardia	O
at	O
about	O
130	O
bpm	O
,	O
QRS	O
at	O
120	O
ms	O
,	O
ST	O
segment	O
elevation	O
in	O
inferior	O
leads	O
and	O
V1	O
.	O
QS	O
pattern	O
in	O
V2	O
and	O
V3	O
with	O
ST	O
elevation	O
of	O
2	O
3	O
mm	O
in	O
V2	O
V4	O
and	O
aVR	O
.	O
Transthoracic	O
echocardiography	O
in	O
the	O
emergency	O
department	O
limited	O
study	O
due	O
to	O
poor	O
echocardiographic	O
window	O
but	O
showing	O
severe	O
left	O
ventricular	O
dysfunction	O
,	O
with	O
severe	O
hypokinesia	O
in	O
the	O
territory	O
of	O
the	O
anterior	O
descending	O
artery	O
.	O
Primary	O
percutaneous	O
coronary	O
intervention	O
diseased	O
left	O
main	O
trunk	O
with	O
significant	O
ostial	O
involvement	O
.	O
Diffusely	O
diseased	O
LAD	O
with	O
severe	O
proximal	O
plaque	O
and	O
no	O
visualisation	O
of	O
the	O
distal	O
bed	O
.	O
Cx	O
with	O
significant	O
proximal	O
plaque	O
;	O
rest	O
of	O
vessel	O
without	O
lesions	O
.	O
Right	O
coronary	O
artery	O
with	O
diffuse	O
lesions	O
not	O
amenable	O
to	O
revascularisation	O
.	O
Percutaneous	O
coronary	O
intervention	O
PCI	O
on	O
the	O
left	O
main	O
coronary	O
artery	O
LMCA	O
,	O
CX	O
and	O
ADA	O
given	O
the	O
situation	O
observed	O
,	O
it	O
was	O
decided	O
to	O
pass	O
the	O
guidewire	O
to	O
the	O
ADA	O
and	O
the	O
CX	O
,	O
implant	O
a	O
drug	O
eluting	O
stent	O
Resolute	O
Onyx	O
3	O
.	O
5	O
x	O
8	O
mm	O
ostial	O
and	O
a	O
"	O
V	O
"	O
stent	O
towards	O
the	O
Cx	O
Resolute	O
Onyx	O
3	O
x	O
22	O
mm	O
and	O
towards	O
the	O
ADA	O
Resolute	O
Onyx	O
3	O
x	O
26	O
mm	O
.	O
Balloon	O
angioplasty	O
2	O
.	O
25	O
and	O
2	O
.	O
5	O
mm	O
was	O
then	O
performed	O
to	O
the	O
LAD	O
and	O
a	O
stent	O
was	O
implanted	O
overlapping	O
the	O
previous	O
one	O
Resolute	O
Onyx	O
2	O
.	O
75	O
x	O
18	O
mm	O
,	O
with	O
a	O
good	O
final	O
angiographic	O
result	O
.	O
Laboratory	O
tests	O
on	O
admission	O
to	O
the	O
coronary	O
unit	O
Hb	O
13	O
.	O
7	O
g	O
dl	O
,	O
haematocrit	O
44	O
.	O
Normal	O
white	O
blood	O
count	O
but	O
with	O
lymphocytosis	O
of	O
7	O
,	O
140	O
.	O
Platelets	O
232	O
,	O
000	O
.	O
Blood	O
glucose	O
261	O
mg	O
dl	O
.	O
Cr	O
1	O
.	O
40	O
mg	O
dl	O
,	O
urea	O
34	O
mg	O
dl	O
.	O
Na	O
133	O
,	O
K	O
3	O
.	O
8	O
.	O
NT	O
proBNP	O
4623	O
pg	O
ml	O
.	O
CPK	O
180	O
3824	O
1266	O
464	O
1181	O
2959	O
1373	O
408	O
;	O
and	O
TnT	O
20	O
4518	O
5207	O
3664	O
4535	O
3483	O
3809	O
1472	O
.	O
GSV	O
pH	O
6	O
.	O
8	O
;	O
Lactic	O
12	O
.	O
9	O
;	O
pCO2	O
74	O
mm	O
Hg	O
.	O
Total	O
cholesterol	O
95	O
mg	O
dl	O
;	O
HDL	O
cholesterol	O
30	O
mg	O
dl	O
;	O
LDL	O
cholesterol	O
22	O
mg	O
dl	O
;	O
triglycerides	O
241	O
.	O
Neuro	O
specific	O
enolase	O
28	O
.	O
1	O
.	O
Transthoracic	O
echocardiography	O
at	O
discharge	O
left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophic	O
with	O
hypokinesia	O
of	O
mid	O
and	O
apical	O
antero	O
septal	O
segments	O
,	O
without	O
other	O
segmental	O
contractility	O
disorders	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
of	O
51	O
by	O
Simpson	O
biplane	O
.	O
Left	O
atrium	O
not	O
dilated	O
.	O
Right	O
chambers	O
of	O
normal	O
size	O
and	O
function	O
with	O
preserved	O
right	O
ventricular	O
ejection	O
fraction	O
RVEF	O
.	O
Mild	O
degenerative	O
mitro	O
aortic	O
signs	O
without	O
significant	O
associated	O
valvulopathies	O
.	O
No	O
pericardial	O
effusion	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
the	O
intervention	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
coronary	O
unit	O
and	O
on	O
arrival	O
a	O
neurological	O
window	O
was	O
performed	O
,	O
showing	O
a	O
motor	O
Glasgow	O
of	O
5	O
points	O
,	O
so	O
it	O
was	O
decided	O
to	O
perform	O
therapeutic	O
hypothermia	O
,	O
with	O
a	O
target	O
temperature	O
of	O
33	O
C	O
,	O
using	O
the	O
Artic	O
Sun	O
device	O
.	O
He	O
was	O
sedated	O
with	O
propofol	B-FARMACO
,	O
relaxed	O
with	O
rocuronium	B-FARMACO
and	O
analgesia	O
with	O
fentanyl	B-FARMACO
for	O
24	O
hours	O
.	O
During	O
this	O
period	O
,	O
haemodynamic	O
improvement	O
was	O
observed	O
,	O
which	O
allowed	O
for	O
the	O
progressive	O
withdrawal	O
of	O
amine	B-FARMACO
support	O
.	O
After	O
24	O
hours	O
,	O
rewarming	O
is	O
started	O
.	O
Once	O
the	O
protocol	O
is	O
completed	O
,	O
sedoanalgesia	O
and	O
relaxation	O
medication	O
is	O
withdrawn	O
.	O
The	O
patient	O
awoke	O
slowly	O
and	O
,	O
during	O
this	O
process	O
,	O
an	O
electroencephalographic	O
study	O
was	O
carried	O
out	O
,	O
which	O
described	O
"	O
Abnormal	O
electroencephalographic	O
tracing	O
due	O
to	O
the	O
absence	O
of	O
normal	O
rhythms	O
and	O
generalised	O
slowing	O
of	O
baseline	O
activity	O
,	O
with	O
no	O
clear	O
EEG	O
response	O
to	O
stimuli	O
,	O
reflecting	O
mild	O
moderate	O
diffuse	O
brain	O
damage	O
.	O
No	O
epileptiform	O
activity	O
or	O
significant	O
asymmetries	O
were	O
recorded	O
"	O
.	O
The	O
evolution	O
was	O
slow	O
and	O
he	O
presented	O
several	O
complications	O
aspiration	O
pneumonia	O
,	O
acute	O
renal	O
failure	O
,	O
moderate	O
neurogenic	O
oropharyngeal	O
dysphagia	O
.	O
Finally	O
,	O
after	O
a	O
total	O
of	O
17	O
days	O
in	O
the	O
coronary	O
unit	O
,	O
he	O
was	O
transferred	O
to	O
the	O
cardiology	O
ward	O
.	O
His	O
evolution	O
on	O
the	O
ward	O
was	O
very	O
good	O
;	O
he	O
started	O
to	O
ambulate	O
progressively	O
and	O
was	O
finally	O
discharged	O
home	O
.	O
DIAGNOSIS	O
Out	O
of	O
hospital	O
cardiorespiratory	O
arrest	O
recovered	O
;	O
pulseless	O
electrical	O
activity	O
.	O
Acute	O
ST	O
segment	O
elevation	O
myocardial	O
infarction	O
STEMI	O
KK	O
IV	O
.	O
Multivessel	O
coronary	O
artery	O
disease	O
.	O
PCI	O
with	O
DES	O
implantation	O
in	O
LMCA	O
,	O
ADA	O
and	O
Cx	O
.	O
Therapeutic	O
hypothermia	O
.	O
Post	O
arrest	O
anoxic	O
ischaemic	O
encephalopathy	O
.	O
Slightly	O
depressed	O
left	O
ventricular	O
systolic	O
function	O
.	O

A	O
59	O
year	O
old	O
man	O
came	O
to	O
the	O
Emergency	O
Department	O
with	O
a	O
history	O
of	O
malaise	O
in	O
the	O
last	O
month	O
and	O
confusion	O
in	O
the	O
last	O
3	O
days	O
.	O
He	O
reported	O
no	O
fever	O
or	O
localised	O
complaints	O
.	O
The	O
patient	O
had	O
a	O
history	O
of	O
poorly	O
controlled	O
diabetes	O
,	O
dyslipidaemia	O
and	O
schizoaffective	O
disorder	O
.	O
He	O
was	O
agitated	O
,	O
his	O
temperature	O
was	O
38	O
.	O
3oC	O
,	O
cardiopulmonary	O
auscultation	O
was	O
normal	O
and	O
he	O
had	O
mild	O
ankle	O
oedema	O
.	O
The	O
most	O
significant	O
laboratory	O
data	O
were	O
18	O
,	O
700	O
leukocytes	O
mm3	O
,	O
10	O
.	O
4	O
g	O
dL	O
haemoglobin	O
,	O
plasma	O
glucose	O
750	O
mg	O
dL	O
and	O
C	O
reactive	O
protein	O
12	O
.	O
6	O
mg	O
dL	O
.	O
A	O
blood	O
culture	O
was	O
drawn	O
,	O
he	O
was	O
admitted	O
with	O
a	O
presumptive	O
diagnosis	O
of	O
hyperosmolar	O
non	O
ketotic	O
syndrome	O
secondary	O
to	O
acute	O
infection	O
,	O
and	O
was	O
treated	O
with	O
intravenous	O
fluids	O
,	O
insulin	B-FARMACO
and	O
cefuroxime	B-FARMACO
.	O
Improvement	O
was	O
noted	O
.	O
On	O
the	O
third	O
day	O
,	O
the	O
clinical	O
microbiology	O
laboratory	O
detected	O
growth	O
of	O
small	O
gram	O
negative	O
bacilli	O
in	O
both	O
blood	O
culture	O
bottles	O
.	O
One	O
day	O
later	O
,	O
rough	O
,	O
raised	O
,	O
non	O
hemolytic	O
,	O
non	O
hemolytic	O
colonies	O
of	O
various	O
sizes	O
grew	O
on	O
the	O
blood	O
agar	O
and	O
chocolate	O
agar	O
plates	O
,	O
but	O
not	O
on	O
the	O
MacConkey	O
agar	O
plate	O
.	O
The	O
colonies	O
were	O
positive	O
for	O
oxidase	O
and	O
negative	O
for	O
lacatalase	O
,	O
indole	O
and	O
urease	O
.	O
The	O
isolate	O
was	O
identified	O
,	O
using	O
the	O
API	O
20E	O
bioMérieux	O
and	O
RapIDNF	O
Plus	O
Remel	O
systems	O
,	O
as	O
Pasteurella	O
haemolytica	O
and	O
reported	O
as	O
sensitive	O
to	O
cefuroxime	B-FARMACO
.	O
The	O
patient	O
was	O
re	O
interviewed	O
and	O
reported	O
that	O
he	O
had	O
a	O
cat	O
at	O
home	O
that	O
had	O
bitten	O
him	O
several	O
times	O
in	O
the	O
last	O
month	O
.	O
During	O
the	O
remainder	O
of	O
his	O
hospitalisation	O
the	O
patient	O
was	O
afebrile	O
but	O
had	O
several	O
episodes	O
of	O
pulmonary	O
congestion	O
.	O
A	O
transthoracic	O
echocardiogram	O
TTE	O
revealed	O
moderate	O
left	O
ventricular	O
dysfunction	O
and	O
mild	O
mitral	O
regurgitation	O
.	O
When	O
stabilised	O
,	O
he	O
was	O
transferred	O
to	O
a	O
rehabilitation	O
unit	O
where	O
he	O
completed	O
a	O
10	O
day	O
course	O
of	O
cefuroxime	B-FARMACO
.	O
One	O
week	O
later	O
he	O
was	O
readmitted	O
for	O
increased	O
dyspnoea	O
and	O
peripheral	O
oedema	O
.	O
He	O
was	O
treated	O
with	O
diuretics	O
with	O
minimal	O
improvement	O
.	O
He	O
underwent	O
a	O
repeat	O
TTE	O
which	O
this	O
time	O
showed	O
significant	O
aortic	O
regurgitation	O
and	O
moderate	O
mitral	O
regurgitation	O
.	O
Due	O
to	O
persistent	O
pulmonary	O
congestion	O
the	O
patient	O
was	O
referred	O
to	O
surgery	O
for	O
replacement	O
of	O
his	O
aortic	O
and	O
mitral	O
valves	O
.	O
Small	O
vegetations	O
on	O
the	O
aortic	O
valve	O
were	O
observed	O
at	O
the	O
operation	O
.	O
Blood	O
culture	O
criteria	O
require	O
the	O
isolation	O
of	O
a	O
microorganism	O
of	O
the	O
Streptococcus	O
viridans	O
group	O
,	O
Streptococcus	O
bovis	O
,	O
one	O
of	O
the	O
HACEK	O
group	O
Haemophilus	O
species	O
,	O
Actinobacillus	O
actinomycetemcomitans	O
,	O
Cardiobacterium	O
hominis	O
,	O
Eikenellacorrodens	O
and	O
Kingella	O
species	O
or	O
Staphylococcus	O
aureus	O
in	O
at	O
least	O
2	O
blood	O
cultures	O
taken	O
12	O
or	O
more	O
hours	O
apart	O
.	O
Therefore	O
,	O
the	O
collection	O
of	O
more	O
than	O
one	O
blood	O
culture	O
before	O
starting	O
antibiotic	O
treatment	O
and	O
the	O
correct	O
identification	O
of	O
blood	O
isolates	O
are	O
of	O
paramount	O
value	O
in	O
the	O
diagnosis	O
of	O
IE	O
.	O
Valvular	O
vegetation	O
was	O
cultured	O
,	O
but	O
no	O
growth	O
was	O
obtained	O
;	O
there	O
was	O
also	O
no	O
growth	O
in	O
the	O
additional	O
blood	O
cultures	O
taken	O
on	O
the	O
second	O
admission	O
.	O
Culture	O
negative	O
endocarditis	O
can	O
result	O
from	O
the	O
use	O
of	O
inadequate	O
microbiological	O
techniques	O
,	O
infection	O
by	O
very	O
demanding	O
pathogens	O
such	O
as	O
Bartonella	O
,	O
Brucella	O
or	O
Chlamydia	O
species	O
,	O
or	O
antimicrobial	O
administration	O
prior	O
to	O
blood	O
culture	O
collection	O
.	O
In	O
the	O
present	O
case	O
,	O
the	O
16S	O
rRNA	O
amplicon	O
sequence	O
of	O
the	O
valve	O
tissue	O
had	O
99	O
concordance	O
with	O
that	O
of	O
Haemophilus	O
aphrophilus	O
.	O
Subsequently	O
,	O
the	O
blood	O
isolate	O
previously	O
identified	O
as	O
Pasteurella	O
haemolytica	O
was	O
identified	O
as	O
H	O
.	O
aphrophilus	O
.	O
In	O
the	O
present	O
case	O
,	O
the	O
"	O
chain	O
of	O
errors	O
"	O
started	O
with	O
insufficient	O
inoculum	O
to	O
the	O
tubes	O
with	O
oxidation	O
fermentation	O
medium	O
resulting	O
in	O
the	O
erroneous	O
characterisation	O
of	O
the	O
isolate	O
as	O
"	O
non	O
fermenting	O
"	O
which	O
led	O
to	O
the	O
selection	O
of	O
identification	O
systems	O
used	O
for	O
non	O
fermenting	O
gram	O
negative	O
bacteria	O
,	O
irrelevant	O
in	O
this	O
case	O
.	O
Another	O
possible	O
cause	O
of	O
confusion	O
for	O
clinical	O
microbiologists	O
is	O
that	O
H	O
.	O
aphrophilus	O
is	O
one	O
of	O
only	O
two	O
Haemophilus	O
species	O
the	O
other	O
being	O
Haemophilus	O
ducreyi	O
that	O
does	O
not	O
require	O
NAD	O
factor	O
V	O
for	O
growth	O
and	O
therefore	O
can	O
grow	O
on	O
blood	O
agar	O
.	O
The	O
genera	O
Haemophilus	O
and	O
Pasteurella	O
both	O
belong	O
to	O
the	O
same	O
family	O
Pasteurelleae	O
and	O
misidentification	O
of	O
H	O
.	O
aphrophilus	O
as	O
Pasteurella	O
using	O
commercial	O
identification	O
kits	O
is	O
well	O
known	O
.	O
In	O
the	O
present	O
case	O
,	O
it	O
is	O
possible	O
that	O
correct	O
identification	O
and	O
reporting	O
of	O
the	O
isolate	O
would	O
have	O
alerted	O
the	O
clinician	O
to	O
the	O
possibility	O
of	O
IE	O
and	O
would	O
have	O
led	O
to	O
appropriate	O
treatment	O
at	O
the	O
first	O
hospital	O
admission	O
.	O
Therefore	O
,	O
it	O
could	O
have	O
prevented	O
the	O
progression	O
of	O
valve	O
destruction	O
and	O
the	O
need	O
for	O
valve	O
replacement	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
This	O
is	O
a	O
75	O
year	O
old	O
male	O
patient	O
with	O
a	O
history	O
of	O
smoking	O
,	O
hypertension	O
,	O
insulin	B-FARMACO
dependent	O
diabetes	O
mellitus	O
and	O
obesity	O
.	O
His	O
cardiological	O
history	O
includes	O
ischaemic	O
heart	O
disease	O
in	O
dilated	O
phase	O
with	O
surgical	O
revascularisation	O
and	O
mitral	O
valve	O
replacement	O
with	O
mechanical	O
prosthesis	O
due	O
to	O
severe	O
mitral	O
insufficiency	O
in	O
2005	O
.	O
Single	O
chamber	O
pacemaker	O
implantation	O
with	O
atrioventricular	O
node	O
ablation	O
was	O
performed	O
due	O
to	O
multiple	O
admissions	O
for	O
acute	O
myocardial	O
infarction	O
AMI	O
type	O
2	O
in	O
the	O
context	O
of	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
.	O
In	O
2000	O
he	O
underwent	O
amputation	O
of	O
the	O
right	O
foot	O
and	O
right	O
femoral	O
popliteal	O
bypass	O
and	O
in	O
2008	O
exclusion	O
of	O
the	O
left	O
iliac	O
and	O
femoral	O
aneurysm	O
.	O
The	O
last	O
echocardiogram	O
in	O
May	O
2018	O
showed	O
severe	O
left	O
ventricular	O
dysfunction	O
,	O
mitral	O
prosthesis	O
with	O
mean	O
gradient	O
of	O
4	O
mmHg	O
without	O
periprosthetic	O
insufficiency	O
and	O
moderate	O
aortic	O
insufficiency	O
.	O
Standard	O
treatment	O
sacubitril	O
valsartan	O
97	O
103	O
mg	O
1	O
tablet	O
at	O
breakfast	O
and	O
1	O
tablet	O
at	O
dinner	O
,	O
metoprolol	B-FARMACO
100	O
mg	O
1	O
tablet	O
at	O
breakfast	O
and	O
1	O
tablet	O
at	O
dinner	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
tablet	O
at	O
breakfast	O
and	O
1	O
tablet	O
at	O
lunch	O
,	O
acenocoumarol	B-FARMACO
according	O
to	O
haematology	O
guidelines	O
,	O
insulin	B-FARMACO
lantus	I-FARMACO
20	O
IU	O
at	O
breakfast	O
,	O
eplerenone	B-FARMACO
25	O
mg	O
1	O
2	O
tablet	O
at	O
lunch	O
,	O
atorvastatin	B-FARMACO
20	O
mg	O
1	O
tablet	O
at	O
dinner	O
,	O
salmeterol	B-FARMACO
fluticasone	I-FARMACO
25	O
50	O
mcg	O
1	O
inhalation	O
every	O
12	O
hours	O
,	O
chronic	O
home	O
oxygen	O
.	O
CURRENT	O
ILLNESS	O
Admitted	O
in	O
February	O
2019	O
for	O
critical	O
right	O
lower	O
limb	O
ischaemia	O
due	O
to	O
right	O
femoro	O
popliteal	O
bypass	O
thrombosis	O
,	O
right	O
anterior	O
femoro	O
tibial	O
bypass	O
was	O
performed	O
.	O
During	O
this	O
admission	O
,	O
acenocoumarol	B-FARMACO
was	O
withdrawn	O
and	O
anticoagulation	O
with	O
low	O
molecular	O
weight	O
heparins	O
LMWH	O
was	O
prescribed	O
,	O
with	O
poor	O
compliance	O
by	O
the	O
patient	O
.	O
In	O
usual	O
functional	O
class	O
III	O
IV	O
,	O
he	O
was	O
admitted	O
to	O
internal	O
medicine	O
with	O
progressive	O
worsening	O
of	O
the	O
same	O
until	O
presenting	O
dyspnoea	O
at	O
rest	O
,	O
paroxysmal	O
nocturnal	O
dyspnoea	O
,	O
orthopnoea	O
,	O
oliguria	O
and	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
No	O
chest	O
pain	O
or	O
other	O
symptoms	O
of	O
interest	O
.	O
Treatment	O
was	O
intensified	O
with	O
diuretics	O
and	O
vasodilators	O
without	O
improvement	O
.	O
He	O
presented	O
with	O
an	O
episode	O
of	O
acute	O
pulmonary	O
oedema	O
and	O
was	O
transferred	O
to	O
the	O
coronary	O
unit	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
147	O
66	O
mmHg	O
.	O
Heart	O
rate	O
80	O
bpm	O
.	O
Oxygen	O
saturation	O
91	O
with	O
nasal	O
goggles	O
at	O
4	O
litres	O
,	O
jugular	O
venous	O
pressure	O
elevated	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
with	O
prosthetic	O
click	O
.	O
Pulmonary	O
auscultation	O
crackles	O
up	O
to	O
midfield	O
.	O
Abdomen	O
globular	O
,	O
depressible	O
,	O
with	O
non	O
painful	O
hepatomegaly	O
3	O
cm	O
below	O
the	O
costal	O
margin	O
.	O
Lower	O
extremities	O
oedema	O
up	O
to	O
the	O
knees	O
with	O
amputation	O
of	O
the	O
right	O
foot	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
atrial	O
fibrillation	O
.	O
Ventricular	O
stimulation	O
at	O
70	O
bpm	O
,	O
without	O
sensing	O
or	O
capture	O
failures	O
.	O
X	O
ray	O
increased	O
cardiothoracic	O
index	O
CTI	O
,	O
with	O
vascular	O
cephalisation	O
,	O
Kerley	O
's	O
B	O
lines	O
.	O
Blood	O
tests	O
Biochemistry	O
urea	O
91	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
45mg	O
dl	O
,	O
glomerular	O
filtration	O
47	O
ml	O
min	O
,	O
NT	O
proBNP	O
6	O
,	O
587	O
pg	O
ml	O
,	O
procalcitonin	O
0	O
.	O
096	O
ng	O
ml	O
,	O
C	O
reactive	O
protein	O
96	O
.	O
5	O
mg	O
l	O
.	O
Basal	O
venous	O
blood	O
gases	O
pH	O
7	O
.	O
38	O
,	O
PCO2	O
44	O
.	O
5	O
mmHg	O
,	O
PO2	O
37	O
.	O
6	O
mmHg	O
,	O
bicarbonate	O
24	O
.	O
6	O
mmol	O
l	O
,	O
oxygen	O
saturation	O
65	O
.	O
4	O
.	O
Haemogram	O
leukocytes	O
8	O
,	O
300	O
mm3	O
,	O
leukocyte	O
formula	O
normal	O
,	O
haemoglobin	O
12	O
.	O
7	O
g	O
dl	O
,	O
platelets	O
161	O
,	O
000	O
mm3	O
.	O
Coagulation	O
INR	O
1	O
.	O
76	O
,	O
prothrombin	O
time	O
47	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
36	O
.	O
2	O
seconds	O
.	O
Transesophageal	O
echocardiogram	O
bidisc	O
mitral	O
mechanical	O
prosthesis	O
with	O
immobility	O
of	O
the	O
anterolateral	O
disc	O
in	O
semi	O
closed	O
position	O
and	O
incomplete	O
mobility	O
of	O
the	O
other	O
disc	O
,	O
with	O
two	O
symmetrical	O
small	O
jets	O
of	O
intraprosthetic	O
regurgitation	O
,	O
with	O
image	O
of	O
thrombus	O
in	O
hinge	O
and	O
prosthetic	O
ring	O
without	O
relevant	O
mobile	O
images	O
.	O
Mean	O
transmitral	O
gradient	O
of	O
19	O
mmHg	O
.	O
Coronary	O
CT	O
angiography	O
mechanical	O
prosthesis	O
in	O
mitral	O
position	O
,	O
showing	O
a	O
soft	O
tissue	O
density	O
of	O
low	O
attenuation	O
hypodense	O
,	O
located	O
between	O
the	O
two	O
valve	O
discs	O
and	O
extending	O
along	O
the	O
atrial	O
and	O
ventricular	O
side	O
of	O
the	O
posterior	O
disc	O
,	O
which	O
remains	O
immobile	O
throughout	O
the	O
cardiac	O
cycle	O
.	O
This	O
lesion	O
has	O
a	O
low	O
attenuation	O
Hounsfield	O
units	O
between	O
60	O
80	O
,	O
which	O
is	O
compatible	O
with	O
valvular	O
thrombus	O
and	O
,	O
given	O
its	O
attenuation	O
values	O
,	O
probably	O
responds	O
well	O
to	O
fibrinolytic	O
treatment	O
.	O
Radioscopy	O
immobility	O
of	O
the	O
anterolateral	O
disc	O
and	O
incomplete	O
mobility	O
of	O
the	O
other	O
disc	O
of	O
the	O
mechanical	O
mitral	O
prosthesis	O
.	O
Transthoracic	O
echocardiogram	O
after	O
two	O
fibrinolysis	O
decrease	O
in	O
transmitral	O
gradient	O
of	O
7	O
.	O
8	O
mmHg	O
after	O
two	O
consecutive	O
fibrinolysis	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
the	O
coronary	O
unit	O
,	O
antithrombotic	O
treatment	O
was	O
intensified	O
with	O
sodium	B-FARMACO
heparin	I-FARMACO
,	O
acenocoumarol	B-FARMACO
and	O
clopidogrel	B-FARMACO
.	O
After	O
failing	O
to	O
resolve	O
the	O
thrombus	O
and	O
in	O
view	O
of	O
the	O
worsening	O
clinical	O
condition	O
,	O
it	O
was	O
decided	O
to	O
present	O
the	O
case	O
at	O
a	O
medical	O
surgical	O
session	O
,	O
and	O
the	O
patient	O
was	O
rejected	O
for	O
valve	O
replacement	O
surgery	O
due	O
to	O
multiple	O
comorbidities	O
and	O
a	O
high	O
risk	O
of	O
mortality	O
around	O
90	O
.	O
Fibrinolytic	O
treatment	O
was	O
decided	O
,	O
in	O
our	O
case	O
with	O
alteplase	O
,	O
taking	O
the	O
coronary	O
angio	O
CT	O
result	O
as	O
a	O
predictor	O
of	O
a	O
favourable	O
outcome	O
after	O
fibrinolysis	O
.	O
Twenty	O
four	O
hours	O
after	O
treatment	O
with	O
alteplase	O
,	O
the	O
patient	O
showed	O
substantial	O
improvement	O
in	O
congestive	O
signs	O
and	O
symptoms	O
,	O
with	O
adequate	O
diuresis	O
with	O
intravenous	O
furosemide	B-FARMACO
,	O
stable	O
haemodynamic	O
parameters	O
and	O
a	O
decrease	O
in	O
the	O
mean	O
mitral	O
transprosthetic	O
gradient	O
from	O
20	O
to	O
10	O
mmHg	O
.	O
Despite	O
the	O
decrease	O
in	O
the	O
gradient	O
,	O
it	O
was	O
still	O
high	O
,	O
so	O
a	O
second	O
fibrinolysis	O
was	O
decided	O
96	O
hours	O
after	O
the	O
first	O
dose	O
,	O
presenting	O
a	O
transmitral	O
gradient	O
of	O
7	O
mmHg	O
48	O
hours	O
after	O
this	O
second	O
therapy	O
.	O
As	O
a	O
haemorrhagic	O
event	O
,	O
he	O
only	O
presented	O
self	O
limited	O
haematuria	O
with	O
no	O
significant	O
decrease	O
in	O
haemoglobin	O
levels	O
.	O
DIAGNOSIS	O
Severe	O
mitral	O
stenosis	O
due	O
to	O
very	O
late	O
mitral	O
valve	O
prosthetic	O
thrombosis	O
related	O
to	O
non	O
compliance	O
with	O
anticoagulation	O
therapy	O
.	O
Decompensated	O
chronic	O
heart	O
failure	O
,	O
NYHA	O
functional	O
class	O
IV	O
IV	O
,	O
stage	O
C	O
AHA	O
ACC	O
.	O
Good	O
response	O
after	O
two	O
consecutive	O
fibrinolysis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
Allergic	O
reaction	O
to	O
sulphonamides	O
.	O
Denies	O
toxic	O
habits	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
arterial	O
hypertension	O
AHT	O
.	O
Stage	O
IIIB	O
endometrial	O
carcinosarcoma	O
,	O
treated	O
by	O
surgery	O
and	O
adjuvant	O
chemotherapy	O
cisplatin	B-FARMACO
and	O
ifosfamide	B-FARMACO
in	O
2011	O
.	O
Recurrence	O
at	O
the	O
level	O
of	O
the	O
vaginal	O
vault	O
in	O
2012	O
,	O
for	O
which	O
she	O
received	O
radiotherapy	O
and	O
brachytherapy	O
.	O
Currently	O
free	O
of	O
disease	O
.	O
Infiltrating	O
colon	O
adenocarcinoma	O
over	O
tubular	O
adenoma	O
resected	O
in	O
2011	O
.	O
Currently	O
free	O
of	O
disease	O
.	O
Chronic	O
normocytic	O
anaemia	O
.	O
Surgical	O
history	O
hysterectomy	O
and	O
double	O
adnexectomy	O
in	O
2011	O
;	O
resection	O
of	O
colonic	O
polyp	O
in	O
2011	O
;	O
bilateral	O
inguinal	O
hernia	O
,	O
nasal	O
septoplasty	O
.	O
Usual	O
treatment	O
enalapril	B-FARMACO
hydrochlorothiazide	I-FARMACO
20	O
12	O
.	O
5	O
mg	O
day	O
,	O
lorazepam	B-FARMACO
1	O
mg	O
day	O
.	O
CURRENT	O
ILLNESS	O
A	O
79	O
year	O
old	O
female	O
patient	O
attended	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
presenting	O
with	O
progressive	O
dyspnoea	O
of	O
one	O
month	O
's	O
duration	O
until	O
becoming	O
minimal	O
effort	O
in	O
the	O
last	O
48	O
72	O
hours	O
,	O
together	O
with	O
accompanying	O
asthenia	O
and	O
weakness	O
.	O
He	O
denied	O
clinical	O
signs	O
of	O
chest	O
pain	O
.	O
No	O
cough	O
,	O
no	O
expectoration	O
,	O
no	O
fever	O
,	O
no	O
dysthermic	O
sensation	O
.	O
PHYSICAL	O
EXAMINATION	O
General	O
condition	O
was	O
normal	O
,	O
normohydrated	O
,	O
normal	O
colour	O
.	O
Eupneic	O
at	O
rest	O
with	O
no	O
use	O
of	O
accessory	O
muscles	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
,	O
with	O
no	O
apparent	O
neurological	O
focality	O
.	O
Blood	O
pressure	O
BP	O
95	O
55	O
mmHg	O
,	O
heart	O
rate	O
HR	O
130	O
bpm	O
,	O
oxygen	O
saturation	O
SatO2	O
98	O
ambient	O
air	O
.	O
Cardiac	O
auscultation	O
regular	O
sounds	O
,	O
tachycardic	O
,	O
no	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
generalised	O
hypoventilation	O
,	O
no	O
rales	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
During	O
his	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
ICU	O
the	O
following	O
complementary	O
tests	O
were	O
performed	O
Electrocardiogram	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
at	O
96	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
with	O
axis	O
at	O
0o	O
,	O
ST	O
underlevel	O
of	O
up	O
to	O
2	O
mm	O
in	O
V3	O
V6	O
with	O
1	O
mm	O
sublevel	O
in	O
aVR	O
.	O
Isolated	O
ventricular	O
extrasystole	O
.	O
Chest	O
X	O
ray	O
hyperventilated	O
lungs	O
with	O
normal	O
parenchymal	O
density	O
,	O
no	O
nodular	O
condensation	O
.	O
No	O
alveolar	O
space	O
condensation	O
.	O
Normal	O
mediastinal	O
silhouette	O
and	O
pulmonary	O
hilarity	O
,	O
with	O
no	O
space	O
occupying	O
lesions	O
.	O
Laboratory	O
tests	O
on	O
admission	O
creatinine	O
1	O
.	O
65	O
mg	O
dl	O
,	O
C	O
reactive	O
protein	O
CRP	O
111	O
.	O
6	O
mg	O
l	O
,	O
leukocytes	O
11	O
.	O
71x10	O
9	O
l	O
,	O
neutrophils	O
4	O
.	O
58	O
x10	O
9	O
l	O
,	O
lymphocytes	O
0	O
.	O
96	O
x10	O
9	O
l	O
,	O
monocytes	O
0	O
.	O
28	O
x10	O
9	O
l	O
,	O
eosinophils	O
5	O
.	O
88	O
x10	O
9	O
l	O
,	O
basophils	O
0	O
.	O
01	O
x10	O
9	O
l	O
,	O
haemoglobin	O
10	O
g	O
dl	O
,	O
ultrasensitive	O
troponin	O
T	O
1	O
.	O
911	O
pg	O
ml	O
.	O
Coronary	O
angiography	O
normal	O
epicardial	O
coronary	O
arteries	O
.	O
Ventriculography	O
normal	O
.	O
During	O
his	O
hospitalisation	O
in	O
cardiology	O
the	O
following	O
complementary	O
tests	O
were	O
performed	O
Transthoracic	O
echocardiography	O
normal	O
sized	O
left	O
ventricle	O
with	O
moderate	O
concentric	O
hypertrophy	O
without	O
apparent	O
alterations	O
in	O
segmental	O
contractility	O
and	O
with	O
preserved	O
systolic	O
function	O
.	O
Diastolic	O
filling	O
pattern	O
of	O
impaired	O
relaxation	O
.	O
Mild	O
aortic	O
insufficiency	O
on	O
degenerative	O
valve	O
with	O
normal	O
transvalvular	O
gradients	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
normal	O
systolic	O
function	O
.	O
Mild	O
tricuspid	O
insufficiency	O
TI	O
allowing	O
estimation	O
of	O
a	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAPs	O
of	O
32	O
mmHg	O
.	O
No	O
significant	O
pericardial	O
effusion	O
is	O
observed	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
left	O
ventricle	O
with	O
concentric	O
hypertrophy	O
14	O
mm	O
,	O
preserved	O
mass	O
IMVI	O
71	O
g	O
m2	O
,	O
concentric	O
remodelling	O
pattern	O
,	O
reduced	O
volumes	O
IVTDVI	O
38	O
ml	O
m2	O
;	O
IVTSVI	O
14	O
ml	O
m2	O
and	O
segmental	O
and	O
global	O
systolic	O
function	O
within	O
normal	O
LVEF	O
64	O
.	O
Widespread	O
patchy	O
subendocardial	O
and	O
intramyocardial	O
oedema	O
,	O
more	O
marked	O
on	O
the	O
lateral	O
aspect	O
,	O
basal	O
anterior	O
and	O
apex	O
.	O
Right	O
ventricular	O
volume	O
IVTDVD	O
26	O
ml	O
m2	O
;	O
IVTSVD	O
11	O
ml	O
m2	O
and	O
systolic	O
function	O
preserved	O
RVEF	O
58	O
.	O
Atria	O
and	O
great	O
vessels	O
of	O
preserved	O
dimensions	O
.	O
First	O
pass	O
perfusion	O
at	O
rest	O
IV	O
dimeglumine	O
gadobenate	O
0	O
.	O
0075	O
mmol	O
kg	O
with	O
patchy	O
subendocardial	O
defects	O
.	O
Absence	O
of	O
myocardial	O
necrosis	O
.	O
Presence	O
of	O
small	O
foci	O
of	O
subendocardial	O
uptake	O
at	O
the	O
level	O
of	O
the	O
basal	O
anterior	O
and	O
medial	O
lateral	O
aspect	O
,	O
also	O
affecting	O
papillary	O
muscles	O
.	O
Slight	O
pericardial	O
effusion	O
.	O
In	O
summary	O
,	O
acute	O
myocarditis	O
pattern	O
with	O
pseudohypertrophy	O
due	O
to	O
multifocal	O
myocardial	O
oedema	O
,	O
preserved	O
systolic	O
function	O
and	O
small	O
foci	O
of	O
late	O
uptake	O
in	O
the	O
left	O
ventricle	O
.	O
Peripheral	O
blood	O
smear	O
discrete	O
erythrocyte	O
anisopoikilocytosis	O
with	O
the	O
presence	O
of	O
some	O
isolated	O
spherocytes	O
and	O
elliptocytes	O
.	O
Normocytic	O
anaemia	O
with	O
a	O
tendency	O
to	O
hypochromia	O
is	O
confirmed	O
.	O
No	O
other	O
morphological	O
findings	O
of	O
interest	O
.	O
Manual	O
leukocyte	O
formula	O
26	O
segmented	O
,	O
6	O
lymphocytes	O
,	O
68	O
mature	O
looking	O
eosinophils	O
.	O
Specific	O
proteins	O
complement	O
C3	O
110	O
mg	O
dl	O
,	O
complement	O
C4	O
47	O
mg	O
dl	O
,	O
total	O
IgE	O
immunoglobulin	O
E	O
306	O
.	O
3	O
IU	O
ml	O
.	O
Parasite	O
studies	O
negative	O
.	O
Serology	O
only	O
positive	O
for	O
Toxoplasma	O
gondii	O
IgG	O
.	O
Bone	O
marrow	O
aspirate	O
abundant	O
lump	O
that	O
is	O
conspicuously	O
absent	O
of	O
cellularity	O
.	O
Only	O
some	O
plasma	O
cells	O
and	O
peripheral	O
blood	O
cells	O
are	O
seen	O
.	O
Conclusion	O
bone	O
marrow	O
with	O
abundant	O
lump	O
empty	O
of	O
cellularity	O
.	O
Bone	O
marrow	O
biopsy	O
bone	O
marrow	O
aplasia	O
,	O
without	O
correlation	O
with	O
peripheral	O
blood	O
.	O
CLINICAL	O
EVOLUTION	O
When	O
an	O
ECG	O
was	O
performed	O
in	O
the	O
emergency	O
department	O
,	O
ST	O
segment	O
alterations	O
were	O
observed	O
ST	O
segment	O
depression	O
of	O
up	O
to	O
2	O
mm	O
in	O
V3	O
V6	O
with	O
a	O
1	O
mm	O
depression	O
in	O
aVR	O
,	O
and	O
a	O
blood	O
test	O
for	O
ultrasensitive	O
troponin	O
T	O
was	O
requested	O
,	O
the	O
result	O
of	O
which	O
was	O
1	O
,	O
911	O
pg	O
ml	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
ICU	O
with	O
initial	O
suspicion	O
of	O
high	O
risk	O
non	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
NSTEACS	O
.	O
During	O
her	O
stay	O
in	O
the	O
ICU	O
,	O
coronary	O
angiography	O
was	O
performed	O
which	O
ruled	O
out	O
coronary	O
artery	O
disease	O
and	O
ventriculography	O
showed	O
no	O
alterations	O
,	O
and	O
she	O
was	O
discharged	O
to	O
the	O
cardiology	O
ward	O
with	O
a	O
diagnosis	O
of	O
MINOCA	O
acute	O
myocardial	O
infarction	O
without	O
obstructive	O
atherosclerotic	O
coronary	O
disease	O
to	O
complete	O
studies	O
and	O
appropriate	O
treatment	O
.	O
After	O
admission	O
to	O
cardiology	O
,	O
the	O
patient	O
remained	O
asthenic	O
with	O
stable	O
haemoglobin	O
levels	O
of	O
around	O
10	O
g	O
dL	O
and	O
eosinophilia	O
that	O
progressively	O
increased	O
to	O
a	O
maximum	O
of	O
8	O
.	O
35x10	O
9	O
l	O
absolute	O
eosinophils	O
.	O
Treatment	O
with	O
beta	O
blockers	O
was	O
started	O
and	O
he	O
remained	O
at	O
absolute	O
rest	O
with	O
progressive	O
control	O
of	O
heart	O
rate	O
and	O
without	O
tachy	O
or	O
bradyarrhythmias	O
,	O
nor	O
presenting	O
symptoms	O
suggestive	O
of	O
these	O
.	O
At	O
no	O
time	O
did	O
she	O
present	O
symptoms	O
compatible	O
with	O
heart	O
failure	O
.	O
In	O
view	O
of	O
the	O
CMR	O
findings	O
and	O
the	O
hypereosinophilia	O
in	O
peripheral	O
blood	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
eosinophilic	O
myocarditis	O
and	O
treatment	O
was	O
started	O
with	O
prednisone	B-FARMACO
50	O
mg	O
per	O
day	O
with	O
overall	O
symptomatic	O
improvement	O
,	O
with	O
a	O
gradual	O
decrease	O
in	O
peripheral	O
eosinophilia	O
,	O
as	O
well	O
as	O
a	O
decrease	O
in	O
ultrasensitive	O
troponin	O
T	O
.	O
Therefore	O
,	O
the	O
dose	O
of	O
prednisone	B-FARMACO
was	O
gradually	O
reduced	O
.	O
Therefore	O
,	O
the	O
dose	O
of	O
beta	O
blocker	O
was	O
progressively	O
reduced	O
and	O
she	O
started	O
to	O
ambulate	O
with	O
good	O
tolerance	O
.	O
During	O
her	O
admission	O
,	O
she	O
was	O
studied	O
by	O
the	O
internal	O
medicine	O
and	O
haematology	O
departments	O
and	O
various	O
complementary	O
tests	O
were	O
performed	O
,	O
such	O
as	O
bone	O
marrow	O
biopsy	O
,	O
among	O
others	O
,	O
labelling	O
the	O
symptoms	O
as	O
hypereosinophilia	O
of	O
uncertain	O
origin	O
,	O
without	O
finding	O
an	O
underlying	O
aetiology	O
negative	O
autoimmunity	O
,	O
negative	O
OM	O
biopsy	O
,	O
negative	O
parasites	O
,	O
and	O
so	O
she	O
was	O
left	O
to	O
continue	O
follow	O
up	O
after	O
discharge	O
from	O
outpatient	O
clinics	O
.	O
After	O
10	O
days	O
of	O
hospitalisation	O
,	O
with	O
the	O
patient	O
stable	O
and	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
tolerating	O
ambulation	O
without	O
symptoms	O
of	O
heart	O
failure	O
or	O
arrhythmic	O
complications	O
,	O
with	O
markers	O
of	O
myocardial	O
damage	O
in	O
decline	O
and	O
electrocardiographic	O
normalisation	O
,	O
it	O
was	O
decided	O
to	O
discharge	O
her	O
from	O
hospital	O
with	O
close	O
outpatient	O
monitoring	O
and	O
treatment	O
with	O
prednisone	B-FARMACO
in	O
a	O
descending	O
pattern	O
until	O
a	O
maintenance	O
dose	O
of	O
10	O
mg	O
was	O
achieved	O
for	O
at	O
least	O
6	O
months	O
depending	O
on	O
her	O
evolution	O
.	O
DIAGNOSIS	O
Acute	O
eosinophilic	O
myocarditis	O
.	O
Hypereosinophilia	O
of	O
uncertain	O
origin	O
.	O
Arterial	O
hypertension	O
.	O
Chronic	O
anaemia	O
.	O
Disease	O
free	O
uterine	O
carcinosarcoma	O
.	O
Disease	O
free	O
adenocarcinoma	O
of	O
the	O
colon	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
arterial	O
hypertension	O
AHT	O
,	O
dyslipidaemia	O
,	O
hyperuricaemia	O
untreated	O
,	O
ex	O
smoker	O
.	O
Cardiological	O
history	O
rheumatic	O
aortic	O
insufficiency	O
.	O
Other	O
history	O
haemochromatosis	O
described	O
mutation	O
double	O
heterozygous	O
,	O
C282YH63D	O
,	O
glaucoma	O
.	O
Surgical	O
interventions	O
hydatid	O
cyst	O
operated	O
on	O
in	O
1969	O
.	O
Usual	O
treatment	O
nevibolol	B-FARMACO
hydrochlorothiazide	I-FARMACO
5	O
25	O
1	O
0	O
1	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
0	O
1	O
0	O
,	O
ezetimibe	B-FARMACO
10	O
0	O
0	O
1	O
,	O
latanoprost	B-FARMACO
eye	O
drops	O
50	O
2	O
.	O
5	O
.	O
CURRENT	O
DISEASE	O
Asymptomatic	O
until	O
three	O
months	O
prior	O
to	O
admission	O
,	O
when	O
he	O
began	O
with	O
moderate	O
exertion	O
dyspnoea	O
,	O
which	O
progressively	O
became	O
minimal	O
exertion	O
dyspnoea	O
in	O
the	O
last	O
15	O
days	O
,	O
accompanied	O
by	O
orthopnoea	O
and	O
nocturnal	O
cough	O
.	O
No	O
subjective	O
sensation	O
of	O
increased	O
abdominal	O
perimeter	O
,	O
oedema	O
in	O
the	O
limbs	O
or	O
decreased	O
diuresis	O
.	O
No	O
clinical	O
signs	O
of	O
angina	O
,	O
palpitations	O
or	O
infectious	O
symptoms	O
.	O
The	O
only	O
other	O
clinical	O
manifestations	O
were	O
nocturnal	O
paresthesia	O
in	O
both	O
upper	O
limbs	O
,	O
more	O
noticeable	O
in	O
the	O
right	O
upper	O
limb	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
152	O
82	O
.	O
Heart	O
rate	O
HR	O
86	O
bpm	O
.	O
Afebrile	O
.	O
Basal	O
saturation	O
98	O
.	O
Increased	O
central	O
venous	O
pressure	O
CVP	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
.	O
Diastolic	O
murmur	O
in	O
aortic	O
focus	O
II	O
IV	O
radiating	O
to	O
mitral	O
focus	O
.	O
Pulmonary	O
auscultation	O
global	O
hypoventilation	O
with	O
wheezing	O
in	O
the	O
left	O
hemithorax	O
and	O
abolition	O
of	O
vesicular	O
murmur	O
in	O
the	O
right	O
base	O
.	O
Abdomen	O
scar	O
in	O
the	O
right	O
hypochondrium	O
.	O
Soft	O
,	O
depressible	O
,	O
non	O
painful	O
.	O
Hepatomegaly	O
of	O
2	O
cm	O
.	O
Lower	O
extremities	O
peripheral	O
pulses	O
preserved	O
.	O
Edema	O
with	O
bilateral	O
pitting	O
up	O
to	O
the	O
knee	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
88	O
bpm	O
.	O
PR	O
170	O
ms	O
.	O
Narrow	O
QRS	O
with	O
BIRDHH	O
morphology	O
.	O
Presence	O
of	O
QS	O
in	O
inferior	O
face	O
.	O
Chest	O
X	O
ray	O
Cardiothoracic	O
index	O
CTI	O
borderline	O
.	O
Vascular	O
redistribution	O
with	O
bilateral	O
pleural	O
effusion	O
,	O
greater	O
in	O
the	O
right	O
lung	O
.	O
CBC	O
CBC	O
8	O
,	O
300	O
leukocytes	O
mm	O
c	O
,	O
Hb	O
18	O
.	O
3	O
g	O
dl	O
,	O
226	O
,	O
000	O
platelets	O
.	O
Coagulation	O
PT	O
100	O
,	O
INR	O
1	O
,	O
TTPa	O
28	O
.	O
2	O
.	O
Biochemistry	O
glucose	O
84	O
mg	O
dl	O
,	O
urea	O
69	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
57	O
mg	O
dl	O
,	O
FG	O
43	O
ml	O
min	O
,	O
uric	O
acid	O
7	O
.	O
16	O
mg	O
dl	O
,	O
GOT	O
41	O
U	O
l	O
,	O
GPT	O
55	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
64	O
U	O
l	O
,	O
GGT	O
230	O
U	O
l	O
,	O
total	O
cholesterol	O
195	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
131	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
50	O
mg	O
dl	O
,	O
triglycerides	O
74	O
mg	O
dl	O
,	O
iron	O
106	O
mcg	O
dl	O
,	O
transferrin	O
181	O
mcg	O
dl	O
,	O
TSI	O
59	O
,	O
ferritin	O
247	O
ng	O
dl	O
,	O
vitamin	O
B12	O
948	O
pg	O
ml	O
,	O
folic	O
acid	O
13	O
.	O
50	O
nmol	O
l	O
,	O
sodium	O
140	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
7	O
mEq	O
l	O
,	O
thyroid	O
hormones	O
normal	O
.	O
HbA1C	O
6	O
.	O
Serum	O
immunoglobulins	O
kappa	O
chains	O
33	O
.	O
9	O
mg	O
ml	O
,	O
lambda	O
chains	O
17	O
.	O
6	O
mg	O
ml	O
,	O
kappa	O
lambda	O
ratio	O
1	O
.	O
93	O
normal	O
0	O
.	O
26	O
2	O
.	O
Urine	O
protein	O
study	O
normal	O
.	O
NT	O
proBNP	O
18367	O
pg	O
ml	O
.	O
Transthoracic	O
echocardiogram	O
hypertrophic	O
left	O
ventricle	O
LV	O
with	O
IVS	O
of	O
15	O
mm	O
,	O
mottling	O
inside	O
and	O
segmental	O
abnormalities	O
of	O
apical	O
contractility	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
40	O
.	O
Longitudinal	O
Strain	O
of	O
8	O
.	O
Right	O
ventricle	O
RV	O
of	O
normal	O
size	O
and	O
function	O
TAPSE	O
19	O
mm	O
.	O
Mild	O
left	O
atrial	O
dilatation	O
.	O
Tricuspid	O
aortic	O
valve	O
with	O
fibrous	O
leaflets	O
and	O
severe	O
insufficiency	O
.	O
Mild	O
tricuspid	O
insufficiency	O
TI	O
,	O
with	O
no	O
evidence	O
of	O
PHT	O
at	O
rest	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
LV	O
of	O
normal	O
size	O
45	O
mm	O
with	O
myocardial	O
thickening	O
,	O
the	O
greatest	O
thicknesses	O
being	O
as	O
follows	O
mid	O
anterior	O
septum	O
16	O
mm	O
,	O
mid	O
inferior	O
septum	O
11	O
mm	O
,	O
apical	O
septum	O
12	O
mm	O
,	O
apical	O
postero	O
inferior	O
wall	O
10	O
mm	O
.	O
LVEF	O
37	O
.	O
VTD	O
VI	O
134	O
ml	O
85	O
ml	O
m2	O
,	O
VTS	O
VI	O
84	O
ml	O
50	O
ml	O
m2	O
,	O
VL	O
VI	O
50	O
ml	O
32	O
ml	O
m2	O
.	O
RV	O
of	O
normal	O
size	O
33	O
mm	O
with	O
mild	O
dysfunction	O
due	O
to	O
altered	O
longitudinal	O
and	O
radial	O
contractility	O
the	O
latter	O
to	O
a	O
lesser	O
extent	O
.	O
No	O
perfusion	O
defects	O
are	O
observed	O
.	O
The	O
myocardial	O
signal	O
is	O
not	O
cancelled	O
,	O
identifying	O
a	O
late	O
intramyocardial	O
enhancement	O
,	O
patchy	O
and	O
diffuse	O
throughout	O
the	O
myocardium	O
of	O
the	O
left	O
ventricle	O
,	O
also	O
in	O
the	O
right	O
ventricle	O
with	O
enhancement	O
of	O
the	O
wall	O
of	O
both	O
atria	O
.	O
Normal	O
right	O
atrium	O
RA	O
17	O
cm2	O
.	O
Dilated	O
left	O
atrium	O
LA	O
27	O
cm2	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
sclerosed	O
leaflets	O
and	O
slightly	O
reduced	O
opening	O
.	O
Flow	O
turbulence	O
in	O
relation	O
to	O
aortic	O
insufficiency	O
AIo	O
.	O
Conclusion	O
the	O
findings	O
described	O
are	O
compatible	O
with	O
clinical	O
suspicion	O
of	O
cardiac	O
amyloidosis	O
.	O
Myocardial	O
scintigraphy	O
images	O
of	O
the	O
chest	O
were	O
obtained	O
in	O
anterior	O
and	O
posterior	O
projections	O
.	O
Radiopharmaceutical	O
uptake	O
was	O
observed	O
in	O
the	O
cardiac	O
muscle	O
,	O
a	O
finding	O
compatible	O
with	O
amyloidosis	O
due	O
to	O
transthyretin	O
deposits	O
.	O
Electromyogram	O
the	O
neurophysiological	O
study	O
showed	O
data	O
compatible	O
with	O
bilateral	O
carpal	O
tunnel	O
syndrome	O
of	O
moderate	O
intensity	O
and	O
predominantly	O
on	O
the	O
right	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
his	O
stay	O
on	O
the	O
hospital	O
ward	O
,	O
the	O
patient	O
responded	O
favourably	O
to	O
depletive	O
treatment	O
with	O
diuretics	O
,	O
mainly	O
loop	O
diuretics	O
.	O
He	O
also	O
receives	O
treatment	O
with	O
mineralcorticoid	O
receptor	O
inhibitors	O
,	O
which	O
must	O
be	O
adjusted	O
due	O
to	O
the	O
impairment	O
of	O
renal	O
function	O
,	O
which	O
is	O
detrimentally	O
affected	O
by	O
the	O
contrast	O
used	O
in	O
the	O
various	O
diagnostic	O
tests	O
.	O
As	O
an	O
incidence	O
during	O
hospitalisation	O
,	O
the	O
patient	O
presents	O
multiple	O
bouts	O
of	O
non	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
NSMVT	O
on	O
telemetry	O
,	O
requiring	O
treatment	O
with	O
beta	O
blockers	O
at	O
low	O
doses	O
despite	O
being	O
in	O
heart	O
failure	O
,	O
due	O
to	O
the	O
problems	O
caused	O
by	O
the	O
use	O
of	O
other	O
antiarrhythmic	O
drugs	O
in	O
amyloidosis	O
.	O
Although	O
the	O
patient	O
presents	O
segmental	O
contractility	O
alterations	O
in	O
the	O
transthoracic	O
echocardiogram	O
and	O
multiple	O
cardiovascular	O
risk	O
factors	O
,	O
due	O
to	O
renal	O
impairment	O
and	O
low	O
clinical	O
suspicion	O
,	O
diagnostic	O
catheterisation	O
to	O
rule	O
out	O
ischaemic	O
involvement	O
is	O
discouraged	O
.	O
Due	O
to	O
the	O
patient	O
's	O
neurological	O
symptoms	O
,	O
it	O
was	O
decided	O
to	O
perform	O
an	O
electromyogram	O
which	O
confirmed	O
bilateral	O
carpal	O
tunnel	O
syndrome	O
and	O
a	O
referral	O
was	O
made	O
to	O
neurology	O
,	O
who	O
recommended	O
further	O
study	O
on	O
an	O
outpatient	O
basis	O
due	O
to	O
possible	O
polyneuropathy	O
.	O
With	O
regard	O
to	O
the	O
progression	O
of	O
aortic	O
insufficiency	O
,	O
surgical	O
treatment	O
was	O
ruled	O
out	O
as	O
the	O
symptoms	O
of	O
dyspnoea	O
were	O
mainly	O
due	O
to	O
the	O
deposition	O
disease	O
predominantly	O
right	O
,	O
the	O
LVEF	O
was	O
normal	O
and	O
there	O
was	O
no	O
left	O
ventricular	O
dilatation	O
,	O
so	O
there	O
was	O
no	O
indication	O
for	O
valve	O
replacement	O
and	O
outpatient	O
follow	O
up	O
was	O
considered	O
appropriate	O
.	O
On	O
discharge	O
,	O
the	O
patient	O
was	O
referred	O
to	O
a	O
family	O
heart	O
disease	O
consultation	O
and	O
to	O
a	O
neurology	O
consultation	O
following	O
electromyography	O
of	O
the	O
lower	O
limbs	O
.	O
DIAGNOSIS	O
Heart	O
failure	O
first	O
episode	O
.	O
Amyloidosis	O
due	O
to	O
transthyretin	O
pending	O
completion	O
of	O
filiation	O
.	O
Severe	O
aortic	O
insufficiency	O
.	O
Moderately	O
depressed	O
LVEF	O
.	O
Bilateral	O
carpal	O
tunnel	O
syndrome	O
.	O
Chronic	O
renal	O
failure	O
,	O
stage	O
3A	O
.	O
Possible	O
peripheral	O
polyneuropathy	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
No	O
known	O
drug	O
allergies	O
.	O
Social	O
background	O
gypsy	O
ethnicity	O
.	O
Lives	O
with	O
his	O
family	O
.	O
Sporadic	O
work	O
as	O
a	O
street	O
vendor	O
.	O
No	O
family	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
Cardiovascular	O
risk	O
factors	O
no	O
known	O
metabolic	O
diseases	O
.	O
Toxic	O
habits	O
active	O
smoker	O
of	O
1	O
packet	O
of	O
cigarettes	O
per	O
day	O
cumulative	O
consumption	O
of	O
20	O
packs	O
per	O
year	O
.	O
Sporadic	O
use	O
of	O
cannabis	O
.	O
Denies	O
alcohol	O
or	O
other	O
substance	O
intake	O
.	O
Previous	O
cardiological	O
history	O
Biventricular	O
arrhythmogenic	O
dysplasia	O
with	O
recently	O
diagnosed	O
LMNA	O
gene	O
mutation	O
.	O
Debuts	O
in	O
October	O
2018	O
with	O
an	O
episode	O
of	O
congestive	O
heart	O
failure	O
CHF	O
,	O
showing	O
severe	O
biventricular	O
dysfunction	O
on	O
transthoracic	O
echocardiogram	O
TTE	O
and	O
cardiac	O
magnetic	O
resonance	O
CMR	O
,	O
with	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
23	O
.	O
A	O
genetic	O
study	O
confirmed	O
arrhythmogenic	O
cardiomyopathy	O
due	O
to	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
LMNA	O
gene	O
.	O
From	O
October	O
2018	O
to	O
March	O
2019	O
,	O
the	O
patient	O
required	O
three	O
hospital	O
admissions	O
for	O
decompensation	O
of	O
CHF	O
.	O
Outpatient	O
follow	O
up	O
is	O
performed	O
by	O
the	O
advanced	O
heart	O
failure	O
unit	O
,	O
but	O
the	O
patient	O
does	O
not	O
keep	O
medical	O
appointments	O
and	O
has	O
poor	O
compliance	O
with	O
treatment	O
.	O
Patient	O
with	O
a	O
Medtronic	O
visia	O
SR	O
MRI	O
model	O
single	O
chamber	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
for	O
secondary	O
prevention	O
,	O
after	O
several	O
bouts	O
of	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
SMVT	O
on	O
admission	O
in	O
November	O
2018	O
Right	O
atrial	O
appendage	O
thrombus	O
evidenced	O
in	O
CMR	O
performed	O
in	O
November	O
2018	O
,	O
starting	O
anticoagulation	O
with	O
low	O
molecular	O
weight	O
heparins	O
LMWH	O
since	O
then	O
.	O
Complementary	O
tests	O
performed	O
to	O
date	O
TTE	O
left	O
ventricle	O
LV	O
slightly	O
dilated	O
with	O
normal	O
wall	O
thickness	O
.	O
Severe	O
LV	O
hypokinesia	O
of	O
all	O
segments	O
,	O
diffusely	O
.	O
Severely	O
depressed	O
LVEF	O
23	O
by	O
biplane	O
Simpson	O
's	O
Simpson	O
biplane	O
.	O
Normal	O
transmitral	O
filling	O
flow	O
.	O
Dilated	O
right	O
ventricle	O
RV	O
with	O
severely	O
depressed	O
function	O
.	O
Slightly	O
displaced	O
LV	O
septum	O
as	O
a	O
sign	O
of	O
right	O
chamber	O
overload	O
.	O
Severe	O
tricuspid	O
insufficiency	O
,	O
with	O
central	O
regurgitation	O
jet	O
due	O
to	O
leaflet	O
coaptation	O
deficit	O
,	O
possibly	O
of	O
functional	O
origin	O
.	O
Estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
PSAP	O
25	O
30	O
mmHg	O
.	O
No	O
other	O
valvulopathies	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
dilated	O
,	O
not	O
collapsing	O
on	O
inspiration	O
.	O
No	O
pericardial	O
effusion	O
.	O
DCM	O
dilated	O
cardiomyopathy	O
with	O
severe	O
dysfunction	O
of	O
both	O
ventricles	O
and	O
dilatation	O
of	O
both	O
atria	O
.	O
Aneurysmal	O
dilatation	O
and	O
akinesia	O
of	O
the	O
RV	O
outflow	O
tract	O
.	O
Areas	O
of	O
late	O
enhancement	O
in	O
RV	O
free	O
wall	O
and	O
intramyocardial	O
enhancement	O
in	O
lateral	O
and	O
inferior	O
aspects	O
of	O
the	O
LV	O
.	O
Thrombi	O
in	O
the	O
right	O
atrial	O
appendage	O
.	O
Computed	O
tomography	O
CT	O
of	O
coronary	O
arteries	O
no	O
anomalies	O
in	O
the	O
origin	O
of	O
the	O
coronary	O
arteries	O
or	O
significant	O
lesions	O
in	O
them	O
.	O
Right	O
dominance	O
.	O
Ascending	O
aorta	O
and	O
aortic	O
root	O
of	O
normal	O
size	O
.	O
Genetic	O
study	O
carrier	O
of	O
the	O
variant	O
p	O
.	O
Arg190Trp	O
chr1	O
156104248	O
,	O
c	O
.	O
568C	O
T	O
in	O
exon	O
3	O
of	O
the	O
LMNA	O
gene	O
.	O
Variant	O
classified	O
as	O
probably	O
pathogenic	O
according	O
to	O
the	O
criteria	O
of	O
the	O
American	O
College	O
of	O
Genetic	O
Medicine	O
ACGM	O
.	O
Other	O
history	O
haematology	O
follow	O
up	O
for	O
FV	O
and	O
FVII	O
deficiency	O
,	O
probably	O
related	O
to	O
vitamin	O
K	O
deficiency	O
.	O
Home	O
medication	O
bisoprolol	B-FARMACO
5	O
mg	O
1	O
tablet	O
at	O
breakfast	O
and	O
dinner	O
,	O
enalapril	B-FARMACO
5	O
mg	O
half	O
a	O
tablet	O
at	O
dinner	O
,	O
eplerenone	B-FARMACO
50	O
mg	O
1	O
tablet	O
at	O
lunch	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
tablet	O
at	O
breakfast	O
,	O
enoxaparin	B-FARMACO
60	O
mg	O
1	O
subcutaneous	O
injection	O
every	O
12	O
hours	O
CURRENT	O
ILLNESS	O
Patient	O
attended	O
the	O
hospital	O
emergency	O
department	O
in	O
the	O
early	O
hours	O
of	O
the	O
morning	O
accompanying	O
her	O
mother	O
,	O
who	O
presented	O
with	O
febrile	O
syndrome	O
probably	O
related	O
to	O
respiratory	O
infection	O
.	O
While	O
in	O
the	O
waiting	O
room	O
,	O
she	O
suddenly	O
lost	O
consciousness	O
with	O
loss	O
of	O
postural	O
tone	O
.	O
On	O
first	O
medical	O
contact	O
very	O
early	O
due	O
to	O
the	O
patient	O
's	O
location	O
,	O
a	O
pulse	O
and	O
spontaneous	O
breathing	O
were	O
observed	O
,	O
but	O
with	O
a	O
low	O
level	O
of	O
consciousness	O
;	O
the	O
patient	O
was	O
monitored	O
and	O
sustained	O
ventricular	O
tachycardia	O
was	O
observed	O
,	O
with	O
several	O
appropriate	O
ICD	O
shocks	O
without	O
achieving	O
reversion	O
to	O
sinus	O
rhythm	O
,	O
and	O
degeneration	O
of	O
SMVT	O
to	O
ventricular	O
fibrillation	O
with	O
effective	O
shock	O
,	O
with	O
subsequent	O
reversion	O
to	O
sinus	O
rhythm	O
and	O
recovery	O
of	O
the	O
pulse	O
.	O
Following	O
loss	O
of	O
pulse	O
in	O
sinus	O
rhythm	O
with	O
electromechanical	O
dissociation	O
,	O
advanced	O
cardiopulmonary	O
resuscitation	O
manoeuvres	O
were	O
initiated	O
for	O
18	O
minutes	O
,	O
including	O
3	O
ampoules	O
of	O
adrenaline	B-FARMACO
,	O
orotracheal	O
intubation	O
and	O
initiation	O
of	O
invasive	O
mechanical	O
ventilation	O
.	O
Pulse	O
recovery	O
was	O
achieved	O
,	O
but	O
the	O
patient	O
remained	O
in	O
cardiogenic	O
shock	O
and	O
required	O
very	O
high	O
doses	O
of	O
vasoactive	O
drugs	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
60	O
38	O
mmHg	O
,	O
heart	O
rate	O
HR	O
75	O
bpm	O
.	O
Afebrile	O
.	O
Orotracheal	O
intubation	O
.	O
Sedoanalgesia	O
.	O
Poorly	O
perfused	O
,	O
with	O
generalised	O
lividity	O
.	O
Weak	O
peripheral	O
pulses	O
,	O
with	O
slow	O
capillary	O
refill	O
.	O
Jugular	O
venous	O
pressure	O
elevated	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
crackles	O
up	O
to	O
bilateral	O
midfields	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
no	O
masses	O
or	O
megaliths	O
palpable	O
.	O
Hydro	O
aerial	O
sounds	O
present	O
.	O
Lower	O
extremities	O
oedema	O
with	O
fovea	O
in	O
both	O
pretibial	O
regions	O
.	O
Pedial	O
pulses	O
not	O
palpable	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
CBC	O
haemoglobin	O
15	O
.	O
2	O
g	O
dl	O
,	O
red	O
cells	O
5	O
.	O
17	O
x10E6	O
μl	O
,	O
MCV	O
88	O
.	O
6	O
fl	O
,	O
MCH	O
29	O
.	O
4	O
pg	O
,	O
MCHC	O
33	O
.	O
2	O
g	O
dl	O
,	O
leucocytes	O
10	O
.	O
39	O
x10E3	O
μl	O
,	O
neutrophils	O
blood	O
75	O
.	O
3	O
,	O
neutrophils	O
7	O
.	O
83	O
x10E3	O
μl	O
,	O
lymphocytes	O
20	O
.	O
9	O
,	O
lymphocytes	O
2	O
.	O
17	O
x10E3	O
μl	O
,	O
monocytes	O
blood	O
2	O
.	O
0	O
,	O
monocytes	O
0	O
.	O
21	O
x10E3	O
μl	O
,	O
eosinophils	O
blood	O
1	O
.	O
3	O
,	O
basophils	O
blood	O
0	O
.	O
5	O
,	O
immature	O
granulocytes	O
5	O
.	O
20	O
,	O
immature	O
granulocytes	O
0	O
.	O
54	O
x10E3	O
μl	O
,	O
platelets	O
UPLAQ	O
191	O
x10E3	O
μl	O
,	O
VPM	O
10	O
.	O
9	O
fl	O
.	O
SR	O
RDW	O
coefficient	O
of	O
variation	O
15	O
.	O
2	O
,	O
haematocrit	O
45	O
.	O
8	O
.	O
Biochemistry	O
glucose	O
117	O
mg	O
dl	O
,	O
urea	O
37	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
80	O
mg	O
d	O
,	O
sodium	O
ion	O
138	O
mmol	O
l	O
,	O
plasma	O
potassium	O
ion	O
3	O
.	O
1	O
mmol	O
l	O
,	O
creatinine	O
kinase	O
720	O
U	O
l	O
,	O
troponin	O
T	O
US	O
23	O
ng	O
dl	O
,	O
C	O
reactive	O
protein	O
1	O
.	O
5	O
mg	O
dl	O
.	O
Coagulation	O
prothrombin	O
time	O
17	O
.	O
10	O
seconds	O
,	O
prothrombin	O
time	O
ratio	O
1	O
.	O
53	O
,	O
prothrombin	O
time	O
54	O
.	O
Partial	O
thromboplastin	O
time	O
30	O
.	O
60	O
seconds	O
,	O
derived	O
fibrinogen	O
308	O
,	O
INR	O
1	O
.	O
53	O
.	O
Arterial	O
blood	O
gases	O
pH	O
7	O
.	O
30	O
,	O
pCO2	O
40	O
mmHg	O
,	O
pO2	O
95	O
mmHg	O
,	O
lactic	O
acid	O
14	O
.	O
7	O
mmmol	O
l	O
,	O
EB	O
6	O
.	O
9	O
mmol	O
l	O
,	O
bicarbonate	O
19	O
.	O
4	O
mmol	O
l	O
.	O
Electrocardiogram	O
ECG	O
on	O
admission	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
with	O
left	O
bundle	O
branch	O
block	O
morphology	O
,	O
inferior	O
axis	O
and	O
transition	O
in	O
V3	O
V4	O
.	O
ECG	O
after	O
initial	O
stabilisation	O
sinus	O
rhythm	O
at	O
72	O
bpm	O
.	O
Normal	O
PR	O
interval	O
.	O
Right	O
bundle	O
branch	O
block	O
with	O
secondary	O
repolarisation	O
abnormalities	O
.	O
QTc	O
interval	O
450	O
ms	O
by	O
Bazett	O
formula	O
.	O
Chest	O
X	O
ray	O
portable	O
,	O
anterior	O
posterior	O
AP	O
projection	O
.	O
Increased	O
cardiothoracic	O
index	O
.	O
Bilateral	O
vascular	O
redistribution	O
.	O
Normopositioned	O
single	O
chamber	O
ICD	O
.	O
No	O
obliteration	O
of	O
costophrenic	O
sinuses	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
ICU	O
in	O
refractory	O
cardiogenic	O
shock	O
after	O
arrhythmic	O
storm	O
,	O
with	O
haemodynamic	O
instability	O
despite	O
infusion	O
of	O
vasoactive	O
drugs	O
at	O
very	O
high	O
doses	O
,	O
and	O
electrical	O
instability	O
,	O
with	O
repeated	O
episodes	O
of	O
SMVT	O
and	O
VF	O
,	O
which	O
were	O
controlled	O
after	O
perfusion	O
of	O
procainamide	B-FARMACO
and	O
sedoanalgesia	O
with	O
propofol	B-FARMACO
.	O
Subsequent	O
evolution	O
is	O
poor	O
.	O
Neurologically	O
with	O
poor	O
prognostic	O
data	O
mydriatic	O
pupils	O
,	O
isochoric	O
arreactive	O
.	O
Absence	O
of	O
trunk	O
reflexes	O
.	O
No	O
response	O
to	O
stimulus	O
.	O
Haemodynamically	O
in	O
VVI	O
pacemaker	O
rhythm	O
accelerated	O
to	O
85	O
bpm	O
,	O
with	O
procainamide	B-FARMACO
in	O
continuous	O
perfusion	O
,	O
in	O
maintained	O
shock	O
situation	O
with	O
NA	O
at	O
1	O
.	O
6	O
mcg	O
kg	O
min	O
.	O
Cold	O
.	O
Poor	O
general	O
perfusion	O
with	O
hyperlactacidemia	O
and	O
metabolic	O
acidosis	O
maintained	O
,	O
evolving	O
towards	O
a	O
situation	O
of	O
multi	O
organ	O
dysfunction	O
with	O
oligoanuric	O
renal	O
failure	O
and	O
liver	O
failure	O
with	O
hypoglycaemia	O
and	O
marked	O
coagulopathy	O
with	O
PT	O
of	O
28	O
.	O
In	O
our	O
patient	O
,	O
extracorporeal	O
membrane	O
oxygenation	O
ECMO	O
was	O
considered	O
as	O
a	O
bridge	O
to	O
ablation	O
or	O
transplantation	O
.	O
However	O
,	O
the	O
patient	O
had	O
a	O
contraindication	O
to	O
heart	O
transplantation	O
at	O
the	O
time	O
of	O
admission	O
,	O
given	O
his	O
lack	O
of	O
adherence	O
to	O
treatment	O
and	O
previous	O
check	O
ups	O
.	O
In	O
addition	O
,	O
in	O
a	O
situation	O
of	O
refractory	O
shock	O
,	O
multi	O
organ	O
failure	O
and	O
a	O
bleak	O
neurological	O
prognosis	O
,	O
it	O
was	O
decided	O
,	O
in	O
agreement	O
with	O
the	O
different	O
units	O
responsible	O
,	O
not	O
to	O
escalate	O
treatment	O
.	O
Finally	O
,	O
he	O
presented	O
marked	O
haemodynamic	O
deterioration	O
and	O
died	O
24	O
hours	O
after	O
admission	O
.	O
DIAGNOSIS	O
Arrhythmic	O
storm	O
in	O
a	O
patient	O
with	O
arrhythmogenic	O
cardiomyopathy	O
with	O
LMNA	O
gene	O
mutation	O
and	O
severe	O
biventricular	O
dysfunction	O
.	O
Refractory	O
cardiogenic	O
shock	O
secondary	O
to	O
arrhythmic	O
storm	O
.	O
Postanoxic	O
diffuse	O
encephalopathy	O
.	O
Multi	O
organ	O
failure	O
.	O
Death	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
Father	O
died	O
of	O
acute	O
myocardial	O
infarction	O
AMI	O
at	O
the	O
age	O
of	O
54	O
.	O
Sporadic	O
smoker	O
for	O
5	O
years	O
.	O
Very	O
occasional	O
alcohol	O
consumption	O
.	O
No	O
hypertension	O
,	O
diabetes	O
mellitus	O
or	O
dyslipidaemia	O
.	O
No	O
history	O
of	O
chest	O
trauma	O
or	O
traffic	O
accidents	O
.	O
No	O
previously	O
known	O
cardiopathies	O
.	O
She	O
consulted	O
the	O
emergency	O
department	O
4	O
years	O
ago	O
due	O
to	O
sudden	O
chest	O
pain	O
radiating	O
to	O
the	O
jaw	O
.	O
Chest	O
X	O
ray	O
,	O
electrocardiogram	O
and	O
cardiac	O
enzyme	O
serum	O
tests	O
were	O
normal	O
.	O
Non	O
specific	O
low	O
back	O
pain	O
.	O
No	O
usual	O
medical	O
treatment	O
.	O
CURRENT	O
ILLNESS	O
A	O
32	O
year	O
old	O
man	O
consulted	O
the	O
cardiology	O
department	O
due	O
to	O
episodes	O
of	O
central	O
thoracic	O
pain	O
radiating	O
to	O
the	O
left	O
upper	O
limb	O
and	O
cervical	O
region	O
,	O
of	O
years	O
of	O
evolution	O
.	O
At	O
the	O
beginning	O
,	O
the	O
pain	O
occurred	O
with	O
heavy	O
exertion	O
,	O
but	O
in	O
recent	O
weeks	O
it	O
increased	O
in	O
frequency	O
and	O
the	O
exercise	O
threshold	O
for	O
its	O
onset	O
was	O
reduced	O
.	O
The	O
pain	O
does	O
not	O
change	O
with	O
postural	O
changes	O
and	O
does	O
not	O
subside	O
after	O
taking	O
paracetamol	B-FARMACO
or	O
non	O
steroidal	O
anti	O
inflammatory	O
drugs	O
.	O
She	O
denies	O
associated	O
dyspnoea	O
,	O
no	O
syncope	O
or	O
presyncope	O
.	O
His	O
primary	O
care	O
doctor	O
detected	O
a	O
panfocal	O
murmur	O
on	O
auscultation	O
and	O
referred	O
him	O
to	O
our	O
clinic	O
for	O
further	O
investigation	O
.	O
PHYSICAL	O
EXAMINATION	O
Normoconstituted	O
.	O
Blood	O
pressure	O
130	O
70	O
.	O
Heart	O
rate	O
90	O
bpm	O
.	O
O2	O
saturation	O
99	O
breathing	O
room	O
air	O
.	O
Mild	O
jugular	O
engorgement	O
.	O
Jumping	O
heart	O
tones	O
,	O
aortic	O
murmur	O
systolic	O
III	O
VI	O
and	O
diastolic	O
III	O
IV	O
.	O
Good	O
bilateral	O
vesicular	O
murmur	O
.	O
Peripheral	O
pulses	O
preserved	O
and	O
symmetrical	O
.	O
No	O
congestive	O
data	O
.	O
COMPLEMENTARY	O
TESTS	O
Chest	O
X	O
ray	O
4	O
years	O
earlier	O
normal	O
cardiothoracic	O
index	O
.	O
No	O
abnormalities	O
in	O
the	O
cardiac	O
silhouette	O
.	O
Chest	O
X	O
ray	O
in	O
the	O
emergency	O
department	O
postero	O
anterior	O
projection	O
,	O
with	O
marked	O
mediastinal	O
widening	O
.	O
Electrocardiogram	O
ECG	O
in	O
consultation	O
sinus	O
rhythm	O
80	O
bpm	O
,	O
left	O
axis	O
,	O
signs	O
of	O
LV	O
enlargement	O
with	O
sharp	O
T	O
waves	O
in	O
precordial	O
leads	O
.	O
Q	O
wave	O
in	O
V5	O
V6	O
.	O
Transthoracic	O
echocardiogram	O
in	O
consultation	O
LV	O
globular	O
,	O
hypertrabeculated	O
and	O
dilated	O
with	O
LVEDDVI	O
67	O
mm	O
,	O
mild	O
LV	O
hypertrophy	O
of	O
13	O
14	O
mm	O
,	O
slightly	O
depressed	O
systolic	O
function	O
LVEF	O
45	O
.	O
LA	O
normal	O
.	O
Normal	O
right	O
chambers	O
.	O
Large	O
aortic	O
aneurysm	O
,	O
with	O
a	O
maximum	O
diameter	O
of	O
10	O
cm	O
in	O
the	O
ascending	O
section	O
,	O
rest	O
of	O
the	O
vessel	O
not	O
visible	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
severe	O
functional	O
aortic	O
insufficiency	O
due	O
to	O
loss	O
of	O
morphology	O
of	O
the	O
sinotubular	O
junction	O
.	O
Rest	O
of	O
valves	O
normal	O
.	O
Pericardium	O
without	O
effusion	O
.	O
Urgent	O
laboratory	O
tests	O
no	O
pathological	O
values	O
.	O
Serial	O
troponin	O
T	O
hs	O
negative	O
0	O
.	O
014	O
μg	O
l	O
.	O
D	O
dimer	O
0	O
.	O
5	O
μg	O
ml	O
.	O
Thoracic	O
abdominal	O
CT	O
angiography	O
urgent	O
images	O
5	O
10	O
ascending	O
aortic	O
aneurysm	O
and	O
AoAD	O
type	O
A	O
with	O
an	O
entry	O
portal	O
in	O
the	O
anterior	O
wall	O
of	O
the	O
aortic	O
root	O
,	O
extending	O
into	O
the	O
abdominal	O
aorta	O
.	O
The	O
aneurysm	O
has	O
a	O
maximum	O
diameter	O
of	O
11	O
cm	O
.	O
In	O
the	O
ascending	O
aorta	O
,	O
the	O
existence	O
of	O
an	O
intimal	O
flap	O
in	O
the	O
anterior	O
margin	O
of	O
the	O
aortic	O
root	O
is	O
observed	O
above	O
the	O
valvular	O
ring	O
,	O
in	O
relation	O
to	O
type	O
A	O
aortic	O
dissection	O
.	O
The	O
origin	O
of	O
the	O
right	O
coronary	O
artery	O
arises	O
from	O
the	O
lumen	O
of	O
smaller	O
calibre	O
,	O
which	O
is	O
the	O
true	O
lumen	O
.	O
As	O
for	O
the	O
coronary	O
tree	O
,	O
a	O
normal	O
origin	O
is	O
seen	O
with	O
the	O
right	O
coronary	O
artery	O
RCA	O
arising	O
just	O
at	O
the	O
limit	O
of	O
the	O
beginning	O
of	O
the	O
dilatation	O
of	O
the	O
aorta	O
.	O
As	O
for	O
the	O
supra	O
aortic	O
trunks	O
,	O
involvement	O
of	O
the	O
left	O
common	O
carotid	O
artery	O
and	O
left	O
subclavian	O
artery	O
.	O
In	O
the	O
study	O
of	O
the	O
abdominal	O
aorta	O
,	O
the	O
left	O
main	O
renal	O
artery	O
and	O
the	O
inferior	O
mesenteric	O
artery	O
arise	O
from	O
the	O
small	O
lumen	O
,	O
the	O
true	O
lumen	O
.	O
The	O
dissection	O
ends	O
before	O
the	O
aortic	O
bifurcation	O
.	O
Angio	O
CT	O
chest	O
at	O
3	O
weeks	O
dilated	O
cardiomyopathy	O
with	O
significant	O
increase	O
in	O
the	O
cross	O
sectional	O
diameter	O
of	O
the	O
left	O
ventricular	O
cavity	O
.	O
No	O
notable	O
alterations	O
were	O
observed	O
in	O
the	O
valved	O
tube	O
;	O
there	O
were	O
no	O
gross	O
alterations	O
in	O
the	O
coronary	O
arteries	O
or	O
signs	O
of	O
periprosthetic	O
leakage	O
.	O
Likewise	O
,	O
no	O
significant	O
alterations	O
were	O
identified	O
in	O
the	O
stent	O
placed	O
in	O
the	O
true	O
lumen	O
of	O
the	O
proximal	O
segment	O
of	O
the	O
descending	O
aorta	O
.	O
No	O
collapse	O
or	O
thrombosis	O
was	O
observed	O
.	O
Images	O
of	O
dissection	O
persist	O
below	O
the	O
stent	O
and	O
in	O
the	O
segment	O
adjacent	O
to	O
the	O
stent	O
the	O
false	O
lumen	O
is	O
only	O
partially	O
filled	O
with	O
contrast	O
,	O
either	O
due	O
to	O
partial	O
thrombosis	O
or	O
because	O
it	O
has	O
not	O
had	O
time	O
to	O
fill	O
with	O
contrast	O
during	O
image	O
acquisition	O
.	O
There	O
is	O
no	O
evidence	O
of	O
dissection	O
in	O
the	O
supra	O
aortic	O
trunks	O
,	O
although	O
there	O
are	O
some	O
linear	O
images	O
,	O
especially	O
in	O
the	O
left	O
common	O
carotid	O
artery	O
,	O
which	O
in	O
principle	O
seem	O
to	O
be	O
artefacts	O
of	O
the	O
high	O
concentration	O
of	O
contrast	O
in	O
the	O
innominate	O
vein	O
.	O
There	O
is	O
a	O
significant	O
bilateral	O
pleural	O
effusion	O
that	O
does	O
not	O
average	O
high	O
density	O
to	O
think	O
it	O
is	O
a	O
haemothorax	O
.	O
Conclusions	O
Postoperative	O
changes	O
as	O
described	O
in	O
the	O
commentary	O
.	O
Significant	O
bilateral	O
pleural	O
effusion	O
.	O
Post	O
surgical	O
echocardiogram	O
3	O
months	O
after	O
surgery	O
very	O
globular	O
,	O
hypertrabeculated	O
and	O
dilated	O
LV	O
with	O
LVEDD	O
77	O
mm	O
,	O
even	O
more	O
than	O
before	O
surgery	O
severely	O
depressed	O
LVEF	O
estimated	O
at	O
20	O
with	O
overall	O
hypocontractility	O
.	O
Valved	O
aortic	O
tube	O
with	O
criteria	O
of	O
prosthetic	O
normofunctioning	O
and	O
low	O
gradients	O
max	O
16	O
,	O
mean	O
10	O
mmHg	O
.	O
Signs	O
of	O
low	O
LVOT	O
output	O
IVT	O
10	O
cm	O
.	O
Mild	O
moderate	O
functional	O
mitral	O
regurgitation	O
.	O
Rest	O
of	O
valves	O
normal	O
.	O
Pericardium	O
without	O
effusion	O
.	O
Angio	O
CT	O
of	O
thoracoabdominal	O
aorta	O
post	O
surgery	O
10	O
months	O
ascending	O
valved	O
tube	O
and	O
trifurcated	O
in	O
patent	O
arch	O
,	O
without	O
images	O
of	O
periprosthetic	O
leaks	O
or	O
other	O
notable	O
alterations	O
.	O
Aortic	O
valve	O
prosthesis	O
.	O
The	O
endovascular	O
prosthesis	O
in	O
the	O
descending	O
aorta	O
is	O
adequately	O
distended	O
,	O
patent	O
,	O
and	O
does	O
not	O
present	O
images	O
suggestive	O
of	O
kinking	O
,	O
migration	O
,	O
endoleaks	O
or	O
other	O
complications	O
.	O
Chronic	O
AoD	O
in	O
the	O
descending	O
thoracic	O
aorta	O
distal	O
to	O
the	O
prosthesis	O
and	O
in	O
the	O
abdominal	O
aorta	O
,	O
with	O
both	O
lumens	O
patent	O
.	O
Maximum	O
diameter	O
including	O
both	O
lumens	O
of	O
50	O
mm	O
.	O
Rest	O
unchanged	O
.	O
Known	O
dilated	O
cardiomyopathy	O
.	O
No	O
pleural	O
or	O
pericardial	O
effusion	O
identified	O
.	O
Pacemaker	O
in	O
left	O
anterosuperior	O
chest	O
wall	O
with	O
catheter	O
ends	O
in	O
right	O
cavities	O
.	O
Conclusion	O
AoD	O
treated	O
surgically	O
and	O
endovascularly	O
,	O
with	O
no	O
signs	O
of	O
complications	O
or	O
changes	O
with	O
respect	O
to	O
the	O
previous	O
study	O
.	O
Follow	O
up	O
echocardiogram	O
16	O
months	O
after	O
surgery	O
LV	O
not	O
dilated	O
,	O
with	O
DTD	O
of	O
42	O
mm	O
,	O
with	O
moderate	O
concentric	O
hypertrophy	O
of	O
its	O
walls	O
of	O
15	O
mm	O
overall	O
thickness	O
.	O
Preserved	O
LVEF	O
,	O
calculated	O
at	O
66	O
by	O
biplane	O
Simpson	O
with	O
no	O
alterations	O
in	O
segmental	O
contractility	O
.	O
Mitral	O
filling	O
with	O
altered	O
relaxation	O
pattern	O
without	O
diastolic	O
dysfunction	O
criteria	O
.	O
Left	O
atrium	O
LA	O
of	O
39	O
mm	O
transverse	O
diameter	O
.	O
Right	O
chambers	O
of	O
normal	O
dimensions	O
.	O
Right	O
ventricular	O
RV	O
systolic	O
function	O
preserved	O
.	O
Ascending	O
aorta	O
tube	O
24	O
mm	O
.	O
40	O
mm	O
abdominal	O
aorta	O
.	O
Mechanical	O
aortic	O
prosthesis	O
in	O
aortic	O
position	O
with	O
normal	O
appearance	O
,	O
slightly	O
elevated	O
antegrade	O
gradients	O
with	O
Vmax	O
of	O
3	O
.	O
2	O
m	O
s	O
and	O
mean	O
gradient	O
of	O
22	O
mmHg	O
,	O
but	O
with	O
a	O
V1	O
V2	O
of	O
0	O
.	O
35	O
IVT	O
in	O
LVOT	O
of	O
25	O
cm	O
.	O
A	O
very	O
mild	O
periprosthetic	O
insufficiency	O
jet	O
is	O
seen	O
at	O
1	O
hour	O
in	O
parasternal	O
short	O
axis	O
.	O
Structural	O
appearance	O
and	O
normal	O
function	O
of	O
the	O
mitral	O
valve	O
.	O
No	O
tricuspid	O
insufficiency	O
,	O
low	O
probability	O
of	O
pulmonary	O
hypertension	O
.	O
Genetic	O
test	O
no	O
pathogenic	O
mutations	O
found	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
ultrasound	O
findings	O
in	O
consultation	O
were	O
more	O
suggestive	O
of	O
a	O
chronic	O
course	O
of	O
an	O
aneurysm	O
than	O
of	O
AoD	O
as	O
the	O
initial	O
problem	O
.	O
However	O
,	O
the	O
clinical	O
manifestations	O
of	O
chest	O
pain	O
made	O
it	O
necessary	O
to	O
rule	O
out	O
this	O
pathology	O
.	O
He	O
was	O
referred	O
to	O
the	O
emergency	O
department	O
to	O
be	O
assessed	O
by	O
angio	O
CT	O
to	O
rule	O
out	O
dissection	O
and	O
,	O
if	O
there	O
was	O
no	O
dissection	O
,	O
to	O
schedule	O
cardiac	O
surgery	O
as	O
a	O
priority	O
,	O
given	O
that	O
with	O
such	O
dimensions	O
the	O
risk	O
of	O
aortic	O
rupture	O
was	O
high	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
a	O
chest	O
X	O
ray	O
was	O
performed	O
showing	O
mediastinal	O
widening	O
not	O
present	O
in	O
the	O
previous	O
X	O
ray	O
performed	O
in	O
2010	O
.	O
An	O
angio	O
CT	O
scan	O
confirmed	O
the	O
dilatation	O
of	O
the	O
ascending	O
aorta	O
and	O
showed	O
the	O
presence	O
of	O
Stanford	O
type	O
A	O
A	O
AoD	O
with	O
an	O
entry	O
point	O
in	O
the	O
anterior	O
wall	O
of	O
the	O
aortic	O
root	O
.	O
The	O
patient	O
was	O
referred	O
to	O
the	O
cardiovascular	O
surgery	O
referral	O
centre	O
for	O
urgent	O
surgery	O
and	O
the	O
aortic	O
root	O
was	O
replaced	O
with	O
a	O
valved	O
tube	O
using	O
the	O
Bono	O
Bentall	O
technique	O
with	O
coronary	O
artery	O
reimplantation	O
and	O
stenting	O
of	O
the	O
descending	O
aorta	O
.	O
Postoperatively	O
,	O
left	O
recurrential	O
paralysis	O
with	O
secondary	O
aphonia	O
was	O
observed	O
.	O
Three	O
days	O
after	O
discharge	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
emergency	O
department	O
for	O
mechanical	O
chest	O
pain	O
and	O
self	O
limited	O
loss	O
of	O
consciousness	O
.	O
A	O
thoraco	O
abdominal	O
CT	O
angiography	O
was	O
performed	O
and	O
,	O
apart	O
from	O
the	O
surgical	O
changes	O
considered	O
to	O
be	O
within	O
the	O
expected	O
range	O
,	O
a	O
significant	O
bilateral	O
pleural	O
effusion	O
was	O
described	O
which	O
was	O
considered	O
to	O
be	O
secondary	O
to	O
the	O
operation	O
and	O
which	O
resolved	O
with	O
the	O
passing	O
of	O
days	O
.	O
A	O
cranial	O
CAT	O
scan	O
was	O
also	O
performed	O
,	O
which	O
was	O
normal	O
.	O
Post	O
surgical	O
echocardiogram	O
showed	O
a	O
dilated	O
and	O
globular	O
LV	O
with	O
severe	O
systolic	O
dysfunction	O
.	O
After	O
3	O
months	O
,	O
with	O
optimal	O
medical	O
treatment	O
,	O
severe	O
dysfunction	O
with	O
New	O
York	O
Heart	O
Association	O
NHYA	O
functional	O
class	O
II	O
III	O
was	O
maintained	O
,	O
so	O
it	O
was	O
decided	O
to	O
implant	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
for	O
primary	O
prevention	O
.	O
During	O
subsequent	O
follow	O
up	O
while	O
maintaining	O
optimal	O
medical	O
treatment	O
,	O
at	O
16	O
months	O
he	O
presented	O
a	O
reduction	O
in	O
LV	O
volumes	O
and	O
LVEF	O
recovery	O
to	O
normal	O
ranges	O
.	O
The	O
patient	O
is	O
able	O
to	O
perform	O
moderate	O
exertion	O
and	O
only	O
suffers	O
from	O
back	O
discomfort	O
that	O
forces	O
him	O
to	O
stand	O
intermittently	O
.	O
A	O
striking	O
fact	O
was	O
that	O
in	O
the	O
subsequent	O
follow	O
up	O
his	O
sister	O
presented	O
with	O
a	O
very	O
extensive	O
type	O
B	O
aortic	O
dissection	O
,	O
complicated	O
and	O
requiring	O
urgent	O
surgical	O
intervention	O
.	O
A	O
genetic	O
study	O
was	O
requested	O
and	O
no	O
pathogenic	O
mutations	O
associated	O
with	O
aortic	O
pathology	O
or	O
connective	O
tissue	O
disease	O
were	O
detected	O
.	O
Simultaneous	O
follow	O
up	O
by	O
cardiovascular	O
surgery	O
,	O
periodic	O
monitoring	O
of	O
the	O
descending	O
thoracic	O
aorta	O
by	O
angio	O
CT	O
was	O
requested	O
stable	O
size	O
of	O
the	O
descending	O
thoracic	O
aorta	O
of	O
5	O
cm	O
with	O
a	O
patent	O
false	O
lumen	O
.	O
Current	O
treatment	O
aldocumar	B-FARMACO
,	O
omeprazole	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
ramipril	B-FARMACO
5	O
mg	O
at	O
breakfast	O
and	O
2	O
.	O
5	O
mg	O
at	O
dinner	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
hours	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
24	O
hours	O
,	O
lorazepam	B-FARMACO
1	O
mg	O
24	O
hours	O
.	O
DIAGNOSIS	O
11	O
cm	O
dissecting	O
aortic	O
aneurysm	O
with	O
Stanford	O
type	O
A	O
dissection	O
.	O
Emergent	O
surgical	O
intervention	O
by	O
aortic	O
replacement	O
and	O
valve	O
replacement	O
.	O
Severe	O
postoperative	O
LV	O
dilatation	O
and	O
dysfunction	O
,	O
which	O
reversed	O
after	O
optimal	O
medical	O
treatment	O
.	O
ICD	O
carrier	O
in	O
primary	O
prevention	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
68	O
year	O
old	O
woman	O
,	O
with	O
no	O
medical	O
or	O
surgical	O
history	O
of	O
interest	O
,	O
was	O
referred	O
to	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
for	O
oppressive	O
central	O
thoracic	O
pain	O
.	O
The	O
patient	O
denies	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
include	O
obesity	O
and	O
type	O
2	O
diabetes	O
mellitus	O
on	O
metformin	B-FARMACO
.	O
She	O
has	O
no	O
family	O
history	O
of	O
early	O
ischaemic	O
heart	O
disease	O
or	O
sudden	O
cardiovascular	O
death	O
.	O
Previously	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
on	O
the	O
day	O
of	O
admission	O
,	O
during	O
an	O
intense	O
discussion	O
in	O
the	O
neighbourhood	O
,	O
she	O
reported	O
the	O
onset	O
of	O
oppressive	O
central	O
thoracic	O
pain	O
,	O
radiating	O
to	O
the	O
back	O
and	O
left	O
upper	O
limb	O
,	O
lasting	O
approximately	O
45	O
minutes	O
,	O
for	O
which	O
she	O
alerted	O
the	O
emergency	O
services	O
,	O
who	O
transferred	O
her	O
to	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
.	O
At	O
our	O
assessment	O
,	O
she	O
persisted	O
with	O
central	O
thoracic	O
pain	O
of	O
similar	O
intensity	O
,	O
with	O
no	O
significant	O
improvement	O
after	O
nitrates	B-FARMACO
.	O
The	O
patient	O
denied	O
other	O
accompanying	O
symptoms	O
no	O
associated	O
vegetative	O
cortex	O
,	O
dizziness	O
or	O
dyspnoea	O
.	O
On	O
physical	O
examination	O
,	O
the	O
patient	O
was	O
in	O
relatively	O
good	O
general	O
condition	O
,	O
eupneic	O
at	O
rest	O
baseline	O
sats	O
O2	O
100	O
,	O
well	O
perfused	O
,	O
with	O
blood	O
pressure	O
around	O
180	O
83	O
mmHg	O
,	O
heart	O
rate	O
45	O
bpm	O
.	O
Cardiac	O
auscultation	O
is	O
rhythmic	O
,	O
with	O
no	O
audible	O
murmurs	O
.	O
No	O
evidence	O
of	O
congestion	O
normal	O
jugular	O
venous	O
pressure	O
,	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
noise	O
,	O
lower	O
extremities	O
without	O
oedema	O
,	O
and	O
with	O
preserved	O
pulses	O
at	O
all	O
levels	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
admission	O
complete	O
atrioventricular	O
block	O
AVB	O
with	O
wide	O
QRS	O
leak	O
with	O
morphology	O
of	O
left	O
bundle	O
branch	O
block	O
LBBB	O
at	O
50	O
bpm	O
.	O
Repolarisation	O
consistent	O
with	O
LBBB	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
,	O
with	O
no	O
evidence	O
of	O
pulmonary	O
congestion	O
or	O
other	O
pathological	O
findings	O
.	O
Laboratory	O
tests	O
on	O
admission	O
haemogram	O
leucocytes	O
6	O
,	O
600	O
μl	O
,	O
haemoglobin	O
12	O
.	O
2	O
g	O
dl	O
,	O
platelets	O
227	O
,	O
000	O
μl	O
.	O
Coagulation	O
INR	O
1	O
,	O
PT	O
100	O
.	O
Biochemistry	O
glucose	O
164	O
mg	O
dl	O
,	O
urea	O
31	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
89	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
67	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
sodium	O
143	O
mEq	O
dl	O
,	O
potassium	O
3	O
.	O
5	O
mEq	O
dl	O
,	O
proBNP	O
3	O
,	O
664	O
pg	O
ml	O
at	O
discharge	O
314	O
pg	O
ml	O
.	O
Peak	O
myocardial	O
damage	O
markers	O
CK	O
193	O
10	O
195	O
IU	O
l	O
,	O
troponin	O
US	O
194	O
.	O
8	O
0	O
13	O
ng	O
l	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
videos	O
1	O
5	O
left	O
ventricle	O
not	O
hypertrophic	O
and	O
size	O
at	O
the	O
high	O
limit	O
of	O
normal	O
LVEDD	O
52	O
mm	O
,	O
IVS	O
11	O
mm	O
,	O
PP	O
9	O
mm	O
.	O
Mid	O
apical	O
septal	O
akinesia	O
,	O
mid	O
apical	O
lateral	O
,	O
mid	O
apical	O
anterior	O
and	O
the	O
rest	O
of	O
the	O
apical	O
segments	O
,	O
with	O
hypercontractility	O
of	O
the	O
bases	O
and	O
moderately	O
depressed	O
global	O
systolic	O
function	O
EF	O
35	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
TAPSE	O
21	O
mm	O
,	O
S	O
wave	O
0	O
.	O
14	O
m	O
s	O
.	O
Mitral	O
valve	O
with	O
sclerosed	O
leaflets	O
and	O
mild	O
insufficiency	O
.	O
Conclusion	O
segmental	O
alterations	O
compatible	O
with	O
transient	O
apical	O
dyskinesia	O
syndrome	O
,	O
with	O
moderately	O
depressed	O
systolic	O
dysfunction	O
.	O
Emergent	O
haemodynamic	O
study	O
1	O
vessel	O
coronary	O
artery	O
disease	O
due	O
to	O
severe	O
stenosis	O
of	O
small	O
diagonal	O
1a	O
,	O
with	O
the	O
rest	O
of	O
the	O
vessels	O
without	O
significant	O
lesions	O
moderate	O
stenosis	O
in	O
the	O
middle	O
third	O
of	O
the	O
anterior	O
descending	O
artery	O
.	O
Ventriculography	O
was	O
performed	O
,	O
showing	O
a	O
dilated	O
ventricular	O
chamber	O
,	O
with	O
akinesia	O
of	O
the	O
apical	O
segments	O
and	O
hypercontractility	O
of	O
the	O
basal	O
segments	O
,	O
suggestive	O
of	O
tako	O
tsubo	O
syndrome	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
normal	O
sized	O
left	O
ventricle	O
53	O
mm	O
with	O
akinesia	O
of	O
the	O
apical	O
anterior	O
wall	O
,	O
apical	O
inferior	O
wall	O
and	O
apical	O
septum	O
.	O
Hypokinesia	O
of	O
the	O
basal	O
and	O
medial	O
inferior	O
wall	O
.	O
Oedema	O
of	O
the	O
mid	O
septum	O
,	O
mid	O
anterior	O
,	O
apical	O
segments	O
except	O
lateral	O
wall	O
and	O
LV	O
apex	O
.	O
No	O
areas	O
of	O
hypoperfusion	O
or	O
late	O
enhancement	O
are	O
identified	O
.	O
LVEF	O
52	O
.	O
LV	O
DVT	O
91mL	O
.	O
LV	O
STV	O
44mL	O
.	O
LV	O
LV	O
47mL	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
with	O
no	O
abnormalities	O
in	O
contractility	O
and	O
preserved	O
morphology	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
Conclusion	O
study	O
compatible	O
with	O
clinical	O
suspicion	O
of	O
tako	O
tsubo	O
syndrome	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
view	O
of	O
the	O
clinical	O
manifestations	O
and	O
the	O
alterations	O
in	O
the	O
electrocardiogram	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
of	O
our	O
department	O
to	O
complete	O
studies	O
and	O
initiate	O
therapeutic	O
measures	O
.	O
An	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
segmental	O
alterations	O
compatible	O
with	O
transient	O
apical	O
dyskinesia	O
syndrome	O
,	O
with	O
moderately	O
depressed	O
systolic	O
dysfunction	O
LVEF	O
35	O
,	O
and	O
it	O
was	O
decided	O
to	O
perform	O
an	O
emergent	O
haemodynamic	O
study	O
which	O
described	O
1	O
vessel	O
coronary	O
artery	O
disease	O
due	O
to	O
severe	O
stenosis	O
of	O
small	O
diagonal	O
1a	O
,	O
with	O
the	O
rest	O
of	O
the	O
vessels	O
without	O
significant	O
lesions	O
moderate	O
stenosis	O
in	O
the	O
middle	O
third	O
of	O
the	O
anterior	O
descending	O
coronary	O
artery	O
.	O
Ventriculography	O
was	O
performed	O
,	O
in	O
which	O
a	O
dilated	O
ventricular	O
chamber	O
was	O
observed	O
,	O
with	O
akinesia	O
of	O
the	O
apical	O
segments	O
and	O
hypercontractility	O
of	O
the	O
basal	O
segments	O
,	O
suggestive	O
of	O
tako	O
tsubo	O
syndrome	O
.	O
In	O
the	O
following	O
days	O
,	O
the	O
studies	O
were	O
completed	O
with	O
a	O
cardiac	O
MRI	O
consistent	O
with	O
the	O
diagnosis	O
of	O
transient	O
apical	O
dyskinesia	O
,	O
in	O
which	O
an	O
improvement	O
in	O
LV	O
ejection	O
fraction	O
was	O
observed	O
.	O
However	O
,	O
the	O
patient	O
persisted	O
with	O
complete	O
AVB	O
1	O
week	O
after	O
her	O
debut	O
,	O
so	O
it	O
was	O
decided	O
to	O
implant	O
a	O
DDDR	O
permanent	O
pacemaker	O
.	O
DIAGNOSIS	O
Transient	O
apical	O
dyskinesia	O
syndrome	O
.	O
LVEF	O
52	O
at	O
discharge	O
.	O
Complete	O
BAV	O
with	O
wide	O
QRS	O
escape	O
rhythm	O
.	O
DDDR	O
pacemaker	O
implantation	O
.	O
1	O
vessel	O
coronary	O
artery	O
disease	O
significant	O
stenosis	O
of	O
D1	O
small	O
calibre	O
vessel	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
52	O
year	O
old	O
male	O
,	O
ex	O
smoker	O
of	O
10	O
cigarettes	O
a	O
day	O
for	O
the	O
last	O
5	O
years	O
,	O
with	O
no	O
personal	O
or	O
family	O
history	O
of	O
interest	O
.	O
He	O
does	O
not	O
take	O
any	O
treatment	O
.	O
CURRENT	O
ILLNESS	O
He	O
presented	O
at	O
home	O
with	O
oppressive	O
chest	O
pain	O
,	O
continuous	O
,	O
with	O
associated	O
vegetative	O
crusade	O
.	O
After	O
about	O
10	O
hours	O
with	O
these	O
symptoms	O
,	O
he	O
suffered	O
syncope	O
,	O
for	O
which	O
he	O
finally	O
consulted	O
an	O
external	O
centre	O
.	O
An	O
electrocardiogram	O
showed	O
complete	O
atrioventricular	O
block	O
AVB	O
with	O
ST	O
segment	O
elevation	O
predominantly	O
in	O
DII	O
DIII	O
and	O
aVF	O
.	O
The	O
infarction	O
code	O
was	O
activated	O
and	O
immediate	O
fibrinolysis	O
was	O
performed	O
,	O
starting	O
antiplatelet	O
therapy	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	O
and	O
clopidogrel	B-FARMACO
,	O
according	O
to	O
local	O
protocol	O
.	O
Subsequently	O
,	O
he	O
was	O
transferred	O
urgently	O
to	O
our	O
hospital	O
,	O
where	O
persistent	O
chest	O
pain	O
and	O
ST	O
segment	O
elevation	O
were	O
observed	O
90	O
minutes	O
after	O
fibrinolysis	O
.	O
Rescue	O
angioplasty	O
was	O
performed	O
,	O
revealing	O
generalised	O
vasoconstriction	O
of	O
the	O
left	O
tree	O
,	O
with	O
atheromatosis	O
but	O
without	O
significant	O
stenosis	O
and	O
a	O
subtotal	O
lesion	O
in	O
the	O
middle	O
third	O
of	O
the	O
right	O
coronary	O
artery	O
RCA	O
.	O
After	O
passing	O
the	O
guidewire	O
through	O
the	O
culprit	O
lesion	O
,	O
an	O
image	O
compatible	O
with	O
coronary	O
dissection	O
was	O
observed	O
,	O
which	O
was	O
resolved	O
by	O
implanting	O
three	O
drug	O
eluting	O
stents	O
in	O
the	O
origin	O
,	O
middle	O
and	O
distal	O
third	O
of	O
the	O
right	O
coronary	O
artery	O
RCA	O
,	O
with	O
acceptable	O
angiographic	O
results	O
and	O
good	O
clinical	O
response	O
.	O
After	O
72	O
hours	O
in	O
the	O
intensive	O
care	O
unit	O
ICU	O
,	O
he	O
was	O
transferred	O
to	O
the	O
hospital	O
ward	O
.	O
PHYSICAL	O
EXAMINATION	O
General	O
appearance	O
was	O
fair	O
.	O
Skin	O
pallor	O
.	O
Dyspnoea	O
on	O
speech	O
.	O
SpO2	O
97	O
with	O
oxygen	O
therapy	O
in	O
nasal	O
goggles	O
at	O
2	O
l	O
min	O
.	O
Jugular	O
ingurgitation	O
present	O
at	O
45o	O
.	O
Blood	O
pressure	O
105	O
79	O
mmHg	O
.	O
Good	O
capillary	O
refill	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
at	O
95	O
bpm	O
,	O
no	O
audible	O
murmurs	O
.	O
Hypoventilation	O
at	O
both	O
bases	O
,	O
no	O
added	O
sounds	O
.	O
Lower	O
limbs	O
without	O
oedema	O
or	O
impaction	O
.	O
Peripheral	O
pulses	O
present	O
.	O
COMPLEMENTARY	O
TESTS	O
Admission	O
CBC	O
leukocytes	O
19630	O
mm3	O
with	O
79	O
neutrophils	O
.	O
Hb	O
14	O
g	O
dl	O
.	O
Platelets	O
293000	O
.	O
No	O
alterations	O
in	O
the	O
coagulation	O
study	O
.	O
Glucose	O
183	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
1	O
mg	O
dl	O
.	O
Urea	O
44	O
mg	O
dl	O
.	O
Na	O
139	O
mEq	O
l	O
.	O
K	O
4	O
.	O
1	O
mEq	O
l	O
.	O
GGT	O
122	O
U	O
I	O
.	O
AST	O
339	O
U	O
I	O
.	O
Bilirubin	O
0	O
.	O
8	O
mg	O
dl	O
.	O
CK	O
3472	O
UI	O
.	O
cTnT	O
hs	O
3779	O
ng	O
l	O
normal	O
values	O
0	O
14	O
.	O
Total	O
cholesterol	O
155	O
mg	O
dl	O
.	O
Triglycerides	O
145	O
mg	O
dl	O
.	O
Urgent	O
echocardiography	O
on	O
the	O
ward	O
non	O
dilated	O
left	O
ventricle	O
LV	O
with	O
akinesia	O
of	O
the	O
entire	O
inferior	O
wall	O
and	O
compensatory	O
hyperkinesia	O
of	O
the	O
anterior	O
and	O
lateral	O
wall	O
.	O
Overall	O
,	O
there	O
is	O
mild	O
LV	O
dysfunction	O
,	O
with	O
an	O
estimated	O
ejection	O
fraction	O
of	O
48	O
.	O
Significant	O
dilatation	O
of	O
the	O
right	O
chambers	O
with	O
very	O
severe	O
right	O
ventricular	O
RV	O
systolic	O
dysfunction	O
TAPSE	O
2	O
mm	O
and	O
S	O
tricuspid	O
annulus	O
2	O
.	O
5	O
cm	O
s	O
and	O
suggestive	O
of	O
increased	O
central	O
venous	O
pressure	O
.	O
Acute	O
tricuspid	O
insufficiency	O
with	O
triangular	O
morphology	O
of	O
its	O
Doppler	O
spectrum	O
as	O
a	O
sign	O
of	O
severity	O
and	O
mild	O
mitral	O
insufficiency	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Electrocardiogram	O
ECG	O
on	O
the	O
ward	O
sinus	O
rhythm	O
at	O
92	O
bpm	O
,	O
PR	O
134	O
ms	O
.	O
QRS	O
112	O
ms	O
,	O
lower	O
QS	O
with	O
persistent	O
ST	O
elevated	O
1	O
mm	O
in	O
these	O
leads	O
and	O
in	O
V3	O
V4	O
with	O
high	O
voltage	O
R	O
in	O
V2	O
.	O
QTc	O
442	O
ms	O
.	O
Coronary	O
angiography	O
second	O
procedure	O
Left	O
coronary	O
artery	O
after	O
intracoronary	O
injection	O
of	O
nitroglycerin	B-FARMACO
,	O
atheromatous	O
arteries	O
are	O
observed	O
,	O
although	O
without	O
angiographically	O
significant	O
lesions	O
.	O
Right	O
coronary	O
artery	O
ostial	O
occlusion	O
.	O
Some	O
heterocoronary	O
collaterals	O
are	O
observed	O
retrogradely	O
filling	O
the	O
more	O
distal	O
branches	O
.	O
Repermeabilisation	O
was	O
attempted	O
with	O
poor	O
results	O
,	O
only	O
a	O
slight	O
anterograde	O
flow	O
with	O
a	O
distal	O
image	O
of	O
thrombus	O
and	O
residual	O
dissection	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
his	O
stay	O
on	O
the	O
hospital	O
ward	O
,	O
the	O
patient	O
presented	O
unfavourable	O
clinical	O
data	O
,	O
with	O
the	O
development	O
of	O
symptoms	O
and	O
signs	O
of	O
acute	O
right	O
heart	O
failure	O
HF	O
.	O
We	O
performed	O
an	O
urgent	O
echocardiography	O
,	O
which	O
revealed	O
very	O
severe	O
dilatation	O
and	O
dysfunction	O
of	O
the	O
RV	O
.	O
Taking	O
into	O
account	O
this	O
evolution	O
and	O
knowing	O
that	O
the	O
epicardial	O
coronary	O
flow	O
,	O
which	O
was	O
achieved	O
in	O
the	O
first	O
coronary	O
angiography	O
was	O
TIMI	O
II	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
new	O
coronary	O
angiography	O
96	O
hours	O
after	O
the	O
first	O
one	O
,	O
which	O
showed	O
a	O
total	O
occlusion	O
of	O
the	O
RCA	O
compatible	O
with	O
subacute	O
thrombosis	O
of	O
the	O
stent	O
previously	O
implanted	O
at	O
the	O
ostial	O
level	O
,	O
and	O
repermeabilisation	O
was	O
attempted	O
with	O
poor	O
results	O
due	O
to	O
the	O
presence	O
of	O
thrombus	O
and	O
residual	O
dissection	O
.	O
After	O
the	O
procedure	O
,	O
he	O
was	O
admitted	O
to	O
the	O
ICU	O
,	O
where	O
an	O
infusion	O
of	O
levosimendan	B-FARMACO
was	O
started	O
.	O
A	O
few	O
hours	O
later	O
,	O
the	O
patient	O
presented	O
with	O
a	O
marked	O
drop	O
in	O
blood	O
pressure	O
,	O
accompanied	O
by	O
a	O
loud	O
and	O
intense	O
holosystolic	O
murmur	O
on	O
cardiac	O
auscultation	O
.	O
A	O
new	O
bedside	O
echocardiography	O
was	O
performed	O
,	O
showing	O
a	O
continuity	O
solution	O
in	O
the	O
interventricular	O
septum	O
at	O
the	O
lower	O
basal	O
level	O
and	O
a	O
left	O
right	O
shunt	O
with	O
a	O
maximum	O
gradient	O
of	O
40	O
mmHg	O
,	O
compatible	O
with	O
a	O
ventricular	O
septal	O
defect	O
VSD	O
as	O
an	O
acute	O
mechanical	O
complication	O
of	O
acute	O
myocardial	O
infarction	O
AMI	O
.	O
In	O
view	O
of	O
this	O
situation	O
,	O
he	O
was	O
transferred	O
to	O
the	O
transplant	O
centre	O
of	O
reference	O
to	O
assess	O
the	O
implantation	O
of	O
an	O
extracorporeal	O
membrane	O
oxygenator	O
ECMO	O
.	O
12	O
hours	O
after	O
transfer	O
,	O
peripheral	O
veno	O
arterial	O
V	O
A	O
femoral	O
femoral	O
ECMO	O
was	O
implanted	O
as	O
a	O
bridge	O
to	O
decision	O
,	O
maintaining	O
continuous	O
perfusion	O
of	O
dobutamine	B-FARMACO
at	O
10	O
mcg	O
kg	O
min	O
and	O
noradrenaline	B-FARMACO
at	O
0	O
.	O
5	O
mcg	O
kg	O
min	O
.	O
The	O
patient	O
required	O
mechanical	O
ventilation	O
due	O
to	O
respiratory	O
failure	O
.	O
At	O
a	O
multidisciplinary	O
meeting	O
,	O
given	O
the	O
impossibility	O
of	O
surgically	O
treating	O
the	O
defect	O
and	O
the	O
poor	O
haemodynamic	O
evolution	O
,	O
it	O
was	O
decided	O
to	O
include	O
the	O
patient	O
in	O
emergency	O
0	O
for	O
cardiac	O
transplantation	O
.	O
After	O
7	O
days	O
of	O
circulatory	O
support	O
with	O
ECMO	O
,	O
an	O
orthotopic	O
heart	O
transplant	O
from	O
a	O
brain	O
dead	O
donor	O
was	O
performed	O
.	O
Extracorporeal	O
circulation	O
was	O
discontinued	O
with	O
peripheral	O
V	O
A	O
femoro	O
axillary	O
ECMO	O
due	O
to	O
haemodynamic	O
lability	O
and	O
preoperative	O
hypoxaemia	O
.	O
ECMO	O
was	O
withdrawn	O
on	O
the	O
fourth	O
day	O
after	O
transplantation	O
,	O
with	O
good	O
evolution	O
.	O
The	O
patient	O
was	O
discharged	O
after	O
67	O
days	O
of	O
hospitalisation	O
.	O
DIAGNOSIS	O
Inferior	O
and	O
right	O
ventricular	O
AMI	O
.	O
Ineffective	O
fibrinolysis	O
.	O
Thrombotic	O
occlusion	O
of	O
the	O
RCA	O
.	O
Percutaneous	O
transluminal	O
coronary	O
angioplasty	O
PTCA	O
complicated	O
by	O
coronary	O
dissection	O
.	O
Implantation	O
of	O
three	O
drug	O
eluting	O
stents	O
in	O
RCA	O
.	O
Subacute	O
thrombosis	O
of	O
the	O
stents	O
implanted	O
in	O
the	O
RCA	O
.	O
Unsuccessful	O
PTCA	O
.	O
Acute	O
HF	O
and	O
cardiogenic	O
shock	O
secondary	O
to	O
RV	O
failure	O
.	O
Ruptured	O
interventricular	O
septum	O
.	O
ECMO	O
as	O
mechanical	O
circulatory	O
support	O
bridging	O
to	O
transplantation	O
.	O
Orthotopic	O
heart	O
transplantation	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
71	O
year	O
old	O
man	O
attending	O
for	O
a	O
scheduled	O
check	O
up	O
.	O
BACKGROUND	O
No	O
known	O
allergies	O
.	O
Dyslipidaemia	O
under	O
treatment	O
.	O
Carbohydrate	O
intolerance	O
diagnosed	O
in	O
2010	O
.	O
Followed	O
diet	O
,	O
losing	O
8	O
kg	O
,	O
and	O
glycaemia	O
was	O
controlled	O
with	O
baseline	O
figures	O
of	O
100	O
110	O
mg	O
dl	O
and	O
glycohaemoglobin	O
HbA1c	O
of	O
5	O
.	O
9	O
.	O
Ex	O
smoker	O
until	O
2007	O
,	O
cumulative	O
dose	O
of	O
30	O
packs	O
year	O
.	O
Prostate	O
carcinoma	O
clinical	O
stage	O
T1c	O
Nx	O
Mx	O
,	O
treated	O
with	O
brachytherapy	O
in	O
2014	O
.	O
Normal	O
prostate	O
specific	O
antigen	O
PSA	O
test	O
in	O
last	O
controls	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
In	O
2007	O
acute	O
anterior	O
myocardial	O
infarction	O
,	O
treated	O
with	O
fibrinolysis	O
without	O
reperfusion	O
and	O
rescue	O
angioplasty	O
with	O
conventional	O
stent	O
implantation	O
over	O
anterior	O
descending	O
DA	O
.	O
1	O
vessel	O
coronary	O
artery	O
disease	O
,	O
with	O
complete	O
revascularisation	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
of	O
40	O
at	O
discharge	O
.	O
In	O
2014	O
,	O
asymptomatic	O
,	O
he	O
came	O
for	O
a	O
check	O
up	O
.	O
Echocardiogram	O
ECG	O
with	O
moderate	O
LV	O
systolic	O
dysfunction	O
at	O
the	O
expense	O
of	O
extensive	O
segmental	O
alteration	O
in	O
the	O
LAD	O
territory	O
.	O
Moderate	O
dilatation	O
of	O
the	O
left	O
atrium	O
.	O
No	O
significant	O
valvulopathies	O
.	O
In	O
2016	O
,	O
she	O
consulted	O
for	O
exertional	O
dyspnoea	O
class	O
II	O
of	O
the	O
New	O
York	O
Heart	O
Association	O
NYHA	O
of	O
1	O
month	O
's	O
duration	O
.	O
His	O
primary	O
care	O
physician	O
detected	O
unknown	O
atrial	O
fibrillation	O
with	O
left	O
bundle	O
branch	O
block	O
,	O
which	O
appeared	O
to	O
be	O
frequency	O
dependent	O
.	O
He	O
was	O
referred	O
to	O
the	O
emergency	O
department	O
,	O
where	O
he	O
was	O
started	O
on	O
oral	O
anticoagulation	O
with	O
rivaroxaban	B-FARMACO
and	O
the	O
dose	O
of	O
beta	O
blocker	O
was	O
increased	O
to	O
optimise	O
heart	O
rate	O
control	O
.	O
Home	O
medication	O
omeprazole	B-FARMACO
20	O
mg	O
24	O
h	O
,	O
pravastatin	B-FARMACO
40	O
mg	O
24	O
h	O
,	O
bisoprolol	B-FARMACO
10	O
mg	O
24	O
h	O
,	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
12	O
h	O
,	O
rivaroxaban	B-FARMACO
15	O
mg	O
24	O
h	O
GFR	O
46	O
ml	O
min	O
when	O
prescribed	O
,	O
isosorbide	B-FARMACO
mononitrate	I-FARMACO
retard	I-FARMACO
50	O
mg	O
24	O
h	O
,	O
nitroglycerin	B-FARMACO
s	O
.	O
l	O
.	O
which	O
he	O
did	O
not	O
require	O
.	O
CURRENT	O
ILLNESS	O
Subjectively	O
well	O
,	O
no	O
dyspnoea	O
or	O
chest	O
pain	O
with	O
the	O
activities	O
he	O
performs	O
.	O
She	O
does	O
not	O
remember	O
when	O
the	O
last	O
episode	O
of	O
angina	O
occurred	O
,	O
probably	O
in	O
2007	O
.	O
No	O
palpitations	O
.	O
No	O
oedema	O
.	O
No	O
orthopnoea	O
or	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
His	O
wife	O
states	O
that	O
he	O
has	O
greatly	O
reduced	O
his	O
physical	O
activity	O
.	O
He	O
has	O
stopped	O
going	O
out	O
for	O
walks	O
.	O
He	O
acknowledges	O
that	O
he	O
avoids	O
stairs	O
and	O
slopes	O
.	O
PHYSICAL	O
EXAMINATION	O
Weight	O
77	O
kg	O
,	O
height	O
1	O
.	O
70	O
m	O
.	O
Muscle	O
mass	O
index	O
BMI	O
26	O
.	O
6	O
kg	O
m2	O
.	O
Blood	O
pressure	O
BP	O
130	O
70	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
60	O
bpm	O
.	O
O2	O
saturation	O
SatO2	O
97	O
on	O
room	O
air	O
.	O
Eupneic	O
at	O
rest	O
.	O
Jugular	O
venous	O
pressure	O
slightly	O
elevated	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Radial	O
,	O
femoral	O
and	O
pedial	O
pulses	O
present	O
.	O
Lower	O
extremities	O
with	O
1	O
2	O
mm	O
pretibial	O
fovea	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
atrial	O
fibrillation	O
with	O
controlled	O
heart	O
rate	O
at	O
65	O
bpm	O
.	O
Amputated	O
R	O
wave	O
from	O
V1	O
to	O
V4	O
.	O
Narrow	O
QRS	O
,	O
width	O
100	O
ms	O
,	O
axis	O
at	O
30o	O
.	O
ANALYSIS	O
haemoglobin	O
13	O
.	O
1	O
g	O
dl	O
,	O
haematocrit	O
38	O
,	O
platelets	O
240	O
,	O
000	O
μl	O
,	O
leucocytes	O
14	O
,	O
000	O
μl	O
.	O
International	O
normalised	O
ratio	O
INR	O
2	O
.	O
07	O
.	O
Basal	O
glycaemia	O
128	O
mg	O
dl	O
,	O
HbA1c	O
7	O
.	O
3	O
.	O
Urea	O
78	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
7	O
mg	O
dl	O
estimated	O
glomerular	O
filtration	O
rate	O
GFR	O
43	O
ml	O
min	O
,	O
sodium	O
139	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
1	O
mEq	O
l	O
.	O
Total	O
cholesterol	O
141	O
mg	O
dl	O
,	O
HDL	O
47	O
mg	O
dl	O
,	O
LDL	O
67	O
mg	O
dl	O
,	O
triglycerides	O
134	O
mg	O
dl	O
.	O
TSH	O
normal	O
.	O
Iron	O
40	O
mcg	O
dl	O
,	O
ferritin	O
110	O
ng	O
ml	O
,	O
transferrin	O
IS	O
12	O
.	O
N	O
terminal	O
pro	O
brain	O
natriuretic	O
peptide	O
NT	O
proBNP	O
1	O
,	O
250	O
pg	O
ml	O
.	O
Transthoracic	O
ECG	O
LV	O
dilated	O
with	O
DTD	O
65	O
mm	O
,	O
remodelled	O
.	O
Akinesia	O
and	O
thinning	O
of	O
anterior	O
septum	O
and	O
all	O
apical	O
segments	O
.	O
Severe	O
systolic	O
dysfunction	O
with	O
LVEF	O
27	O
.	O
Dilated	O
LA	O
.	O
Mild	O
moderate	O
functional	O
mitral	O
regurgitation	O
.	O
Normal	O
aortic	O
valve	O
.	O
Right	O
chambers	O
of	O
normal	O
size	O
and	O
contractility	O
.	O
Mild	O
tricuspid	O
insufficiency	O
,	O
with	O
atrioventricular	O
gradient	O
of	O
21	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
inspiratory	O
collapse	O
less	O
than	O
50	O
.	O
ERGOMETRY	O
Bruce	O
protocol	O
.	O
Exercise	O
time	O
3	O
30	O
min	O
.	O
Under	O
bisoprolol	B-FARMACO
10	O
mg	O
daily	O
.	O
Reaches	O
67	O
of	O
maximum	O
theoretical	O
heart	O
rate	O
with	O
a	O
workload	O
of	O
6	O
.	O
6	O
METs	O
.	O
Dyspnoea	O
from	O
the	O
first	O
stage	O
,	O
which	O
increases	O
and	O
forces	O
to	O
suspend	O
the	O
test	O
.	O
Functional	O
class	O
II	O
III	O
.	O
Atrial	O
fibrillation	O
as	O
baseline	O
rhythm	O
.	O
No	O
angina	O
or	O
significant	O
ST	O
alterations	O
.	O
CLINICAL	O
EVOLUTION	O
An	O
ECG	O
was	O
performed	O
to	O
check	O
LV	O
systolic	O
function	O
,	O
which	O
was	O
currently	O
severely	O
depressed	O
,	O
and	O
ergometry	O
for	O
an	O
objective	O
assessment	O
of	O
functional	O
class	O
,	O
revealing	O
dyspnoea	O
that	O
the	O
patient	O
minimised	O
.	O
Laboratory	O
tests	O
showed	O
moderate	O
renal	O
insufficiency	O
,	O
poor	O
control	O
of	O
diabetes	O
mellitus	O
and	O
an	O
altered	O
iron	O
profile	O
.	O
With	O
all	O
this	O
,	O
the	O
treatment	O
was	O
adjusted	O
and	O
the	O
patient	O
was	O
referred	O
to	O
a	O
specific	O
heart	O
failure	O
consultation	O
.	O
After	O
a	O
year	O
of	O
follow	O
up	O
,	O
with	O
optimisation	O
of	O
medical	O
treatment	O
,	O
improvement	O
of	O
LVEF	O
to	O
32	O
was	O
achieved	O
;	O
he	O
persisted	O
with	O
limitation	O
of	O
his	O
physical	O
activity	O
,	O
in	O
functional	O
class	O
II	O
.	O
Implantable	O
cardioverter	O
defibrillator	O
ICD	O
implantation	O
was	O
performed	O
for	O
primary	O
prevention	O
.	O
DIAGNOSIS	O
Chronic	O
ischaemic	O
heart	O
disease	O
.	O
Old	O
anterior	O
infarction	O
,	O
single	O
vessel	O
disease	O
with	O
complete	O
revascularisation	O
.	O
Severe	O
LV	O
systolic	O
dysfunction	O
.	O
No	O
current	O
angina	O
.	O
Chronic	O
heart	O
failure	O
in	O
NYHA	O
functional	O
class	O
II	O
III	O
.	O
Permanent	O
atrial	O
fibrillation	O
.	O
Oral	O
anticoagulation	O
and	O
heart	O
rate	O
HR	O
control	O
strategy	O
.	O
Chronic	O
kidney	O
disease	O
,	O
stage	O
IIIb	O
.	O
Diabetes	O
mellitus	O
.	O
Iron	O
deficiency	O
without	O
anaemia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Male	O
,	O
74	O
years	O
old	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Ex	O
smoker	O
of	O
one	O
pack	O
a	O
day	O
until	O
12	O
years	O
ago	O
.	O
Diagnosed	O
with	O
arterial	O
hypertension	O
,	O
currently	O
being	O
treated	O
with	O
olmesartan	B-FARMACO
20	O
mg	O
,	O
with	O
good	O
control	O
of	O
blood	O
pressure	O
.	O
The	O
patient	O
consulted	O
his	O
primary	O
care	O
doctor	O
for	O
dyspnoea	O
on	O
moderate	O
exertion	O
.	O
In	O
addition	O
,	O
he	O
has	O
recently	O
noticed	O
frequent	O
episodes	O
of	O
dizziness	O
and	O
blurred	O
vision	O
when	O
walking	O
,	O
of	O
very	O
short	O
duration	O
,	O
which	O
disappear	O
immediately	O
when	O
he	O
stops	O
walking	O
.	O
She	O
has	O
had	O
no	O
loss	O
of	O
consciousness	O
or	O
other	O
cardiovascular	O
symptoms	O
.	O
An	O
electrocardiogram	O
ECG	O
was	O
performed	O
which	O
showed	O
atrioventricular	O
conduction	O
disorder	O
with	O
second	O
degree	O
Wenckebach	O
type	O
block	O
,	O
and	O
she	O
was	O
referred	O
to	O
our	O
clinic	O
.	O
It	O
was	O
decided	O
to	O
extend	O
the	O
study	O
with	O
a	O
24	O
hour	O
Holter	O
,	O
which	O
showed	O
bouts	O
of	O
2	O
1	O
atrioventricular	O
block	O
AVB	O
and	O
nodal	O
escape	O
rhythm	O
.	O
In	O
addition	O
,	O
transthoracic	O
echocardiography	O
was	O
performed	O
,	O
which	O
was	O
found	O
to	O
be	O
compatible	O
with	O
normality	O
.	O
During	O
the	O
test	O
,	O
complete	O
AVB	O
was	O
observed	O
,	O
and	O
he	O
was	O
admitted	O
to	O
cardiology	O
with	O
monitoring	O
.	O
Blood	O
pressure	O
150	O
53	O
mmHg	O
.	O
Heart	O
rate	O
32	O
beats	O
per	O
minute	O
.	O
Oxygen	O
saturation	O
with	O
ambient	O
air	O
98	O
.	O
Good	O
general	O
condition	O
,	O
conscious	O
,	O
oriented	O
,	O
cooperative	O
,	O
eupneic	O
and	O
afebrile	O
.	O
Jugular	O
venous	O
pressure	O
not	O
elevated	O
.	O
Rhythmic	O
cardiac	O
auscultation	O
with	O
systolic	O
murmur	O
in	O
mitral	O
and	O
aortic	O
focus	O
II	O
VI	O
.	O
Pulmonary	O
auscultation	O
with	O
normal	O
vesicular	O
murmur	O
,	O
without	O
added	O
noises	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
to	O
deep	O
palpation	O
,	O
without	O
masses	O
or	O
visceromegaly	O
.	O
Positive	O
and	O
symmetrical	O
peripheral	O
pulses	O
in	O
all	O
four	O
extremities	O
.	O
Lower	O
limbs	O
without	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
admission	O
sinus	O
activity	O
at	O
60	O
beats	O
per	O
minute	O
.	O
Complete	O
AVB	O
with	O
ventricular	O
escape	O
rhythm	O
at	O
40	O
beats	O
per	O
minute	O
,	O
narrow	O
QRS	O
,	O
without	O
repolarisation	O
alterations	O
.	O
ECG	O
with	O
pain	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
.	O
PR	O
220	O
ms	O
.	O
QRS	O
stimulated	O
by	O
pacemaker	O
.	O
Concave	O
ST	O
elevation	O
from	O
V2	O
to	O
V6	O
and	O
in	O
inferior	O
leads	O
,	O
with	O
a	O
maximum	O
of	O
4	O
mm	O
in	O
V4	O
.	O
ECG	O
at	O
discharge	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
.	O
Normal	O
PR	O
.	O
QRS	O
stimulated	O
by	O
pacemaker	O
.	O
ANALYSIS	O
haemoglobin	O
13	O
.	O
6	O
g	O
dl	O
,	O
haematocrit	O
40	O
.	O
1	O
,	O
platelets	O
136	O
,	O
000	O
mm3	O
,	O
leukocytes	O
5	O
,	O
970	O
mm3	O
normal	O
formula	O
.	O
Coagulation	O
prothrombin	O
rate	O
91	O
,	O
INR	O
1	O
.	O
06	O
,	O
aPTT	O
ratio	O
0	O
.	O
90	O
.	O
Biochemistry	O
glucose	O
91	O
mg	O
dl	O
,	O
urea	O
65	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
16	O
mg	O
dl	O
,	O
sodium	O
138	O
mEq	O
l	O
,	O
potassium	O
5	O
.	O
1	O
mEq	O
l	O
.	O
Troponin	O
I	O
3	O
.	O
37	O
ng	O
l	O
,	O
maximum	O
peak	O
6	O
.	O
37	O
ng	O
ml	O
normal	O
up	O
to	O
0	O
.	O
06	O
.	O
THORAX	O
RADIOGRAPHY	O
normal	O
.	O
At	O
discharge	O
,	O
generator	O
in	O
left	O
infraclavicular	O
region	O
.	O
Electrodes	O
in	O
right	O
atrium	O
and	O
ventricle	O
.	O
Transthoracic	O
echocardiogram	O
on	O
admission	O
LV	O
normal	O
size	O
with	O
mild	O
concentric	O
hypertrophy	O
IVS	O
13	O
mm	O
,	O
DTD	O
53	O
mm	O
,	O
PP	O
11	O
mm	O
.	O
Normal	O
global	O
systolic	O
function	O
,	O
without	O
alterations	O
of	O
segmental	O
contractility	O
.	O
Normal	O
filling	O
pattern	O
for	O
age	O
with	O
E	O
E	O
"	O
ratio	O
of	O
9	O
.	O
RV	O
of	O
normal	O
size	O
and	O
systolic	O
function	O
.	O
Dilatation	O
of	O
both	O
atria	O
,	O
severe	O
left	O
atrial	O
dilatation	O
LA	O
volume	O
67	O
ml	O
m2	O
.	O
No	O
significant	O
valvular	O
heart	O
disease	O
.	O
Inferior	O
vena	O
cava	O
of	O
normal	O
size	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
Great	O
vessels	O
of	O
normal	O
calibre	O
.	O
Normal	O
pericardium	O
.	O
Transthoracic	O
echocardiogram	O
during	O
admission	O
akinesia	O
of	O
all	O
middle	O
and	O
apical	O
segments	O
,	O
with	O
preserved	O
contractility	O
in	O
basal	O
segments	O
,	O
which	O
conditions	O
a	O
moderately	O
depressed	O
systolic	O
function	O
biplane	O
LVEF	O
35	O
.	O
Control	O
transthoracic	O
echocardiogram	O
normal	O
systolic	O
function	O
biplane	O
LVEF	O
66	O
,	O
with	O
no	O
alterations	O
in	O
segmental	O
contractility	O
.	O
CARDIAC	O
CATHETERISM	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O
Left	O
ventricle	O
with	O
medioapical	O
akinesia	O
and	O
moderate	O
systolic	O
dysfunction	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
attended	O
an	O
outpatient	O
echocardiogram	O
,	O
referred	O
from	O
the	O
outpatient	O
clinic	O
.	O
Given	O
the	O
finding	O
of	O
paroxysms	O
of	O
complete	O
AVB	O
,	O
which	O
explained	O
the	O
dizziness	O
and	O
dyspnoea	O
on	O
exertion	O
for	O
which	O
he	O
consulted	O
,	O
he	O
was	O
informed	O
and	O
urgently	O
admitted	O
to	O
the	O
hospital	O
ward	O
with	O
electrocardiographic	O
monitoring	O
.	O
He	O
was	O
very	O
nervous	O
and	O
worried	O
.	O
During	O
his	O
stay	O
on	O
the	O
ward	O
,	O
he	O
was	O
found	O
to	O
be	O
asymptomatic	O
at	O
rest	O
,	O
with	O
complete	O
AVB	O
and	O
heart	O
rate	O
below	O
30	O
bpm	O
,	O
so	O
treatment	O
was	O
started	O
with	O
isoproterenol	B-FARMACO
.	O
The	O
following	O
morning	O
,	O
a	O
permanent	O
bicameral	O
pacemaker	O
was	O
implanted	O
without	O
complications	O
.	O
That	O
same	O
afternoon	O
,	O
after	O
implantation	O
,	O
the	O
cardiologist	O
on	O
duty	O
was	O
notified	O
due	O
to	O
severe	O
oppressive	O
central	O
thoracic	O
pain	O
with	O
associated	O
vegetative	O
cramping	O
.	O
An	O
ECG	O
was	O
performed	O
showing	O
an	O
anterolateral	O
subepicardial	O
lesion	O
wave	O
and	O
an	O
echocardiogram	O
showing	O
alterations	O
in	O
contractility	O
in	O
mid	O
apical	O
segments	O
with	O
moderately	O
depressed	O
systolic	O
function	O
.	O
Emergent	O
coronary	O
angiography	O
was	O
performed	O
,	O
showing	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
and	O
ventriculography	O
compatible	O
with	O
tako	O
tsubo	O
syndrome	O
.	O
After	O
pain	O
control	O
,	O
the	O
patient	O
showed	O
good	O
clinical	O
evolution	O
,	O
with	O
improvement	O
of	O
the	O
alterations	O
in	O
segmental	O
contractility	O
and	O
was	O
discharged	O
in	O
a	O
stable	O
condition	O
.	O
Three	O
months	O
after	O
discharge	O
he	O
remained	O
asymptomatic	O
,	O
with	O
a	O
good	O
appearance	O
of	O
the	O
surgical	O
wound	O
and	O
complete	O
normalisation	O
of	O
the	O
segmental	O
alterations	O
and	O
ventricular	O
function	O
.	O
DIAGNOSIS	O
Complete	O
paroxysmal	O
atrioventricular	O
block	O
.	O
DDDR	O
definitive	O
pacemaker	O
implantation	O
.	O
Post	O
procedural	O
tako	O
tsubo	O
syndrome	O
.	O
Psychological	O
stress	O
due	O
to	O
unplanned	O
hospital	O
admission	O
and	O
administration	O
of	O
isoproterenol	B-FARMACO
as	O
possible	O
inducers	O
.	O
Transient	O
moderate	O
LV	O
systolic	O
dysfunction	O
,	O
at	O
the	O
expense	O
of	O
mid	O
and	O
apical	O
segment	O
akinesia	O
.	O
Coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O

This	O
is	O
a	O
46	O
year	O
old	O
male	O
patient	O
,	O
unknown	O
illness	O
,	O
with	O
no	O
history	O
of	O
drug	O
addiction	O
,	O
with	O
a	O
3	O
month	O
subacute	O
history	O
of	O
constitutional	O
symptoms	O
associated	O
with	O
hyporexia	O
,	O
asthenia	O
and	O
adynamia	O
with	O
involuntary	O
weight	O
loss	O
of	O
8	O
kg	O
.	O
In	O
addition	O
,	O
with	O
evidence	O
of	O
quantified	O
fever	O
predominantly	O
at	O
night	O
and	O
progressive	O
dyspnoea	O
at	O
rest	O
associated	O
with	O
podalic	O
oedema	O
.	O
A	O
transthoracic	O
echocardiogram	O
showed	O
aortic	O
endocarditis	O
with	O
a	O
highly	O
mobile	O
aortic	O
vegetation	O
of	O
12	O
mm	O
,	O
severe	O
aortic	O
insufficiency	O
,	O
severe	O
mitral	O
insufficiency	O
and	O
congestive	O
heart	O
failure	O
.	O
A	O
positive	O
blood	O
culture	O
for	O
penicillin	B-FARMACO
sensitive	O
Streptococcus	O
gallolyticus	O
was	O
documented	O
,	O
and	O
antibiotic	O
coverage	O
was	O
initiated	O
.	O
Among	O
the	O
laboratory	O
studies	O
,	O
a	O
computed	O
axial	O
tomography	O
of	O
the	O
lumbar	O
spine	O
was	O
performed	O
,	O
which	O
showed	O
hypodense	O
areas	O
in	O
the	O
spleen	O
suggestive	O
of	O
infarction	O
.	O
In	O
addition	O
,	O
a	O
coronary	O
catheterisation	O
was	O
performed	O
,	O
documenting	O
an	O
aneurysm	O
in	O
the	O
right	O
coronary	O
artery	O
of	O
8	O
.	O
3mm	O
permeable	O
,	O
without	O
lesions	O
.	O
The	O
patient	O
presented	O
criteria	O
for	O
emergency	O
surgery	O
;	O
however	O
,	O
due	O
to	O
the	O
germ	O
associated	O
with	O
this	O
case	O
,	O
surgery	O
was	O
postponed	O
in	O
search	O
of	O
gastrointestinal	O
neoplasia	O
.	O
On	O
the	O
eighth	O
day	O
of	O
antibiotic	O
treatment	O
,	O
the	O
patient	O
presented	O
sudden	O
deterioration	O
of	O
consciousness	O
,	O
the	O
CT	O
scan	O
of	O
the	O
central	O
nervous	O
system	O
showed	O
right	O
intraparenchymal	O
haemorrhage	O
,	O
so	O
he	O
was	O
taken	O
to	O
the	O
operating	O
room	O
and	O
a	O
ruptured	O
aneurysm	O
of	O
the	O
right	O
middle	O
cerebral	O
artery	O
suggestive	O
of	O
mycotic	O
aneurysm	O
was	O
documented	O
,	O
the	O
haematoma	O
was	O
drained	O
and	O
clipped	O
.	O
The	O
patient	O
died	O
two	O
days	O
after	O
surgery	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
Patient	O
aged	O
73	O
years	O
.	O
Allergy	O
to	O
penicillin	B-FARMACO
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
hypertension	O
HT	O
,	O
type	O
2	O
diabetes	O
mellitus	O
DM	O
.	O
Dyslipidaemia	O
.	O
Obesity	O
.	O
Neoplasia	O
of	O
the	O
right	O
breast	O
in	O
2004	O
,	O
with	O
surgery	O
,	O
radiotherapy	O
,	O
chemotherapy	O
and	O
hormone	O
therapy	O
.	O
Cardiological	O
history	O
under	O
study	O
due	O
to	O
clinical	O
manifestations	O
of	O
exertional	O
chest	O
pain	O
with	O
angina	O
like	O
features	O
.	O
In	O
2015	O
,	O
a	O
stress	O
echocardiogram	O
was	O
performed	O
,	O
which	O
was	O
inconclusive	O
due	O
to	O
the	O
low	O
functional	O
capacity	O
obtained	O
without	O
reaching	O
the	O
theoretical	O
submaximal	O
frequency	O
.	O
The	O
patient	O
refused	O
to	O
undergo	O
cardiac	O
catheterisation	O
.	O
Treatment	O
was	O
started	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
and	O
nitroglycerin	B-FARMACO
5	O
mg	O
patch	O
.	O
CURRENT	O
ILLNESS	O
Admitted	O
to	O
cardiology	O
for	O
presenting	O
again	O
with	O
symptoms	O
suggestive	O
of	O
progressive	O
exertional	O
angina	O
.	O
Usual	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
II	O
.	O
No	O
syncope	O
or	O
palpitations	O
.	O
No	O
oedematization	O
of	O
the	O
extremities	O
.	O
Good	O
adherence	O
to	O
treatment	O
.	O
Due	O
to	O
the	O
previous	O
inconclusive	O
stress	O
echocardiography	O
,	O
it	O
was	O
decided	O
to	O
perform	O
rest	O
and	O
stress	O
SPECT	O
,	O
which	O
was	O
compatible	O
with	O
mild	O
inducible	O
ischaemia	O
in	O
the	O
lower	O
territory	O
.	O
It	O
was	O
decided	O
to	O
request	O
cardiac	O
catheterisation	O
,	O
which	O
the	O
patient	O
finally	O
accepted	O
.	O
PHYSICAL	O
EXAMINATION	O
Eupneic	O
at	O
rest	O
.	O
Blood	O
pressure	O
BP	O
135	O
85	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
70	O
bpm	O
.	O
Oxygen	O
saturation	O
98	O
basal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
normoventilation	O
.	O
Lower	O
extremities	O
no	O
oedema	O
,	O
distal	O
pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
,	O
first	O
degree	O
atrioventricular	O
block	O
AVB	O
,	O
incomplete	O
left	O
bundle	O
branch	O
block	O
LBBB	O
.	O
No	O
changes	O
in	O
serial	O
ECG	O
.	O
ANALYTICS	O
TnI	O
0	O
.	O
03	O
,	O
myoglobin	O
31	O
.	O
6	O
.	O
Glucose	O
106	O
mg	O
dl	O
,	O
urea	O
61	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
03	O
mg	O
dl	O
,	O
uric	O
acid	O
8	O
.	O
1	O
mg	O
dl	O
,	O
triglycerides	O
221	O
mg	O
dl	O
,	O
total	O
cholesterol	O
143	O
mg	O
dl	O
,	O
HDL	O
33	O
mg	O
dl	O
,	O
LDL	O
66	O
mg	O
dl	O
,	O
sodium	O
140	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
6	O
mEq	O
l	O
,	O
AST	O
35	O
U	O
L	O
,	O
ALT	O
31	O
U	O
L	O
,	O
GGT	O
47	O
U	O
L	O
,	O
FA	O
117	O
U	O
L	O
,	O
CK	O
40	O
U	O
L	O
.	O
Bi	O
0	O
.	O
48	O
mg	O
dl	O
.	O
Thyroid	O
function	O
TSH	O
0	O
.	O
91	O
mIU	O
l	O
,	O
T4	O
1	O
.	O
02	O
ng	O
dl	O
.	O
Haemoglobin	O
13	O
.	O
4	O
g	O
dl	O
,	O
haematocrit	O
41	O
,	O
MCV	O
90	O
fl	O
,	O
leucocytes	O
8900	O
mm3	O
46	O
N	O
,	O
platelets	O
124000	O
mm3	O
.	O
HBa1C	O
7	O
.	O
9	O
.	O
Chest	O
X	O
ray	O
calcified	O
atheromatosis	O
of	O
the	O
aorta	O
.	O
Cardiomegaly	O
.	O
Hilar	O
thickening	O
of	O
vascular	O
appearance	O
.	O
No	O
acute	O
pleuroparenchymal	O
alterations	O
are	O
observed	O
.	O
Dorsal	O
spondylosis	O
.	O
Transthoracic	O
echocardiography	O
left	O
ventricle	O
LV	O
of	O
normal	O
size	O
.	O
Moderate	O
left	O
ventricular	O
hypertrophy	O
LVH	O
with	O
septal	O
predominance	O
.	O
Normal	O
global	O
systolic	O
function	O
,	O
without	O
segmental	O
asymmetries	O
of	O
contractility	O
.	O
Acceleration	O
of	O
flow	O
in	O
the	O
left	O
ventricular	O
outflow	O
tract	O
LVOT	O
without	O
significant	O
dynamic	O
gradient	O
maximum	O
10	O
mmHg	O
either	O
at	O
baseline	O
or	O
after	O
Valsalva	O
manoeuvres	O
.	O
Mild	O
diastolic	O
dysfunction	O
with	O
no	O
current	O
data	O
of	O
elevated	O
left	O
ventricular	O
end	O
diastolic	O
pressure	O
LVEDP	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
.	O
Normal	O
right	O
chambers	O
;	O
right	O
ventricle	O
RV	O
normocontractile	O
TAPSE	O
19	O
mm	O
S	O
wave	O
13	O
.	O
Mitral	O
valve	O
MV	O
calcium	O
in	O
medial	O
posterior	O
annulus	O
,	O
thin	O
leaflets	O
,	O
not	O
limited	O
in	O
its	O
opening	O
,	O
competent	O
.	O
Aortic	O
valve	O
VAo	O
trivalve	O
,	O
mild	O
sclerosis	O
of	O
leaflets	O
,	O
not	O
limited	O
in	O
its	O
opening	O
,	O
competent	O
.	O
Aortic	O
root	O
and	O
visualised	O
portion	O
of	O
proximal	O
ascending	O
aorta	O
normal	O
.	O
Minimal	O
end	O
systolic	O
tricuspid	O
regurgitation	O
TR	O
allowing	O
estimation	O
of	O
normal	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAPS	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
with	O
normal	O
inspiratory	O
collapse	O
.	O
Normal	O
estimated	O
PAPS	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
and	O
intracavitary	O
masses	O
through	O
this	O
access	O
route	O
.	O
Stress	O
myocardial	O
perfusion	O
SPECT	O
and	O
synchronised	O
resting	O
myocardial	O
perfusion	O
SPECT	O
radiopharmaceutical	O
99mTc	O
tetrofosmin	O
.	O
Dose	O
stress	O
7	O
.	O
2mCi	O
.	O
Rest	O
21	O
.	O
3mCi	O
.	O
Ergometry	O
in	O
Bruce	O
protocol	O
of	O
3	O
.	O
30	O
minutes	O
duration	O
ended	O
due	O
to	O
inability	O
to	O
maintain	O
the	O
rhythm	O
of	O
the	O
treadmill	O
,	O
reaching	O
86	O
of	O
the	O
heart	O
rate	O
predicted	O
for	O
age	O
and	O
BP	O
max	O
130	O
80140	O
70	O
.	O
No	O
chest	O
pain	O
.	O
Decreased	O
functional	O
capacity	O
maximum	O
load	O
reached	O
5	O
METs	O
.	O
Absence	O
of	O
arrhythmias	O
.	O
In	O
the	O
low	O
dose	O
SPECT	O
CT	O
study	O
,	O
mild	O
hypoperfusion	O
of	O
mild	O
intensity	O
was	O
observed	O
in	O
the	O
effort	O
phase	O
in	O
the	O
basal	O
lower	O
segment	O
,	O
which	O
partially	O
normalised	O
in	O
the	O
rest	O
phase	O
and	O
was	O
compatible	O
with	O
mild	O
inducible	O
ischaemia	O
.	O
CORONARYGRAPHY	O
puncture	O
of	O
right	O
radial	O
artery	O
6F	O
.	O
Right	O
dominance	O
.	O
Epicardial	O
coronary	O
arteries	O
without	O
significant	O
angiographic	O
stenosis	O
.	O
Multiple	O
coronary	O
fistulas	O
to	O
LV	O
from	O
all	O
major	O
coronary	O
territories	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
the	O
result	O
of	O
the	O
cardiac	O
catheterisation	O
,	O
treatment	O
was	O
started	O
with	O
low	O
dose	O
bisoprolol	B-FARMACO
,	O
which	O
was	O
tolerated	O
,	O
and	O
nitroglycerin	B-FARMACO
and	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
were	O
maintained	O
.	O
The	O
patient	O
was	O
discharged	O
from	O
hospital	O
.	O
After	O
6	O
months	O
of	O
outpatient	O
follow	O
up	O
,	O
the	O
patient	O
has	O
shown	O
clinical	O
improvement	O
with	O
a	O
decrease	O
in	O
angina	O
,	O
with	O
two	O
isolated	O
episodes	O
of	O
severe	O
exertion	O
.	O
DIAGNOSIS	O
Progressive	O
exertional	O
angina	O
.	O
Multiple	O
conorary	O
ventricular	O
fistulas	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
Subclinical	O
hypothyroidism	O
and	O
migraine	O
with	O
aura	O
,	O
as	O
well	O
as	O
family	O
history	O
aunt	O
with	O
heart	O
disease	O
at	O
an	O
early	O
age	O
who	O
does	O
not	O
know	O
how	O
to	O
specify	O
and	O
sister	O
with	O
Hodgkin	O
's	O
lymphoma	O
.	O
Cardiovascular	O
risk	O
factors	O
absent	O
Usual	O
treatment	O
none	O
CURRENT	O
ILLNESS	O
19	O
year	O
old	O
female	O
basketball	O
player	O
,	O
presenting	O
to	O
the	O
ED	O
on	O
11	O
11	O
2016	O
for	O
5	O
days	O
of	O
exertional	O
dyspnoea	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
II	O
,	O
with	O
previous	O
normal	O
functional	O
class	O
athlete	O
,	O
orthopnoea	O
and	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
PND	O
,	O
together	O
with	O
prick	O
like	O
chest	O
discomfort	O
and	O
self	O
limited	O
palpitations	O
,	O
unrelated	O
to	O
courtship	O
or	O
exertion	O
.	O
He	O
denies	O
syncope	O
,	O
palpitations	O
or	O
other	O
symptoms	O
.	O
PHYSICAL	O
EXAMINATION	O
Physical	O
examination	O
in	O
the	O
emergency	O
department	O
constants	O
heart	O
rate	O
HR	O
87	O
bpm	O
.	O
Temperature	O
34	O
.	O
5	O
C	O
.	O
Blood	O
pressure	O
BP	O
124	O
60	O
.	O
Oxygen	O
saturation	O
SatO2	O
100	O
.	O
Impression	O
of	O
good	O
general	O
condition	O
.	O
Conscious	O
,	O
oriented	O
,	O
cooperative	O
and	O
attentive	O
.	O
Normohydrated	O
,	O
normoperfused	O
,	O
normo	O
coloured	O
.	O
No	O
increase	O
in	O
central	O
venous	O
pressure	O
CVP	O
.	O
Pulmonary	O
auscultation	O
good	O
bilateral	O
and	O
symmetrical	O
air	O
entry	O
.	O
Auscultation	O
of	O
the	O
lungs	O
good	O
bilateral	O
and	O
symmetrical	O
air	O
inflow	O
,	O
no	O
other	O
added	O
sounds	O
.	O
No	O
work	O
of	O
breathing	O
or	O
signs	O
of	O
respiratory	O
distress	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
left	O
parasternal	O
diastolic	O
murmur	O
IV	O
VI	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
.	O
Not	O
painful	O
on	O
palpation	O
.	O
No	O
masses	O
or	O
megaliths	O
palpable	O
.	O
Murphy	O
,	O
Blumberg	O
and	O
Rovsing	O
negative	O
.	O
No	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Upper	O
limbs	O
distal	O
pulses	O
preserved	O
and	O
symmetrical	O
.	O
Lower	O
limbs	O
distal	O
coldness	O
,	O
no	O
oedema	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Pedial	O
pulses	O
were	O
preserved	O
and	O
symmetrical	O
.	O
An	O
echocardiogram	O
was	O
performed	O
in	O
the	O
emergency	O
department	O
showing	O
dilatation	O
of	O
the	O
aortic	O
root	O
and	O
ascending	O
aorta	O
and	O
severe	O
aortic	O
insufficiency	O
,	O
with	O
dilatation	O
of	O
the	O
left	O
ventricle	O
LV	O
and	O
moderate	O
severe	O
systolic	O
dysfunction	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
it	O
was	O
decided	O
to	O
admit	O
the	O
patient	O
to	O
cardiology	O
to	O
study	O
and	O
optimise	O
treatment	O
.	O
COMPLEMENTARY	O
TESTS	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
at	O
69	O
bpm	O
,	O
normal	O
PR	O
,	O
normal	O
axis	O
,	O
left	O
bundle	O
branch	O
block	O
,	O
evidence	O
of	O
LV	O
enlargement	O
and	O
secondary	O
repolarisation	O
disorder	O
asymmetrical	O
negative	O
T	O
waves	O
in	O
lateral	O
and	O
inferior	O
face	O
.	O
THORAX	O
RADIOGRAPHY	O
cardiomegaly	O
and	O
data	O
of	O
CHF	O
.	O
ANALYSIS	O
amino	O
terminal	O
pro	O
brain	O
natriuretic	O
peptide	O
NT	O
ProBNP	O
of	O
4860	O
pg	O
ml	O
,	O
lactate	O
1	O
.	O
2	O
mmol	O
l	O
,	O
no	O
increase	O
in	O
acute	O
phase	O
reactants	O
or	O
markers	O
of	O
myocardial	O
damage	O
,	O
normal	O
haemogram	O
and	O
biochemistry	O
.	O
Autoimmunity	O
was	O
negative	O
,	O
except	O
for	O
antithyroglobulin	O
antibodies	O
329	O
IU	O
ml	O
10	O
115	O
,	O
with	O
normal	O
thyroid	O
profile	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
pre	O
surgery	O
15	O
11	O
2016	O
severely	O
dilated	O
LV	O
DD	O
89	O
mm	O
,	O
SD	O
74	O
mm	O
;	O
LVEDVT	O
357	O
ml	O
,	O
SD	O
74	O
mm	O
;	O
LVEDVT	O
357	O
ml	O
.	O
Global	O
hypokinesia	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
by	O
Simpson	O
biplane	O
42	O
.	O
Normal	O
mitral	O
filling	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
normal	O
opening	O
.	O
Dilatation	O
at	O
the	O
level	O
of	O
the	O
sinuses	O
with	O
asymmetry	O
of	O
the	O
leaflets	O
greater	O
development	O
of	O
the	O
right	O
coronary	O
artery	O
RCA	O
with	O
the	O
non	O
coronary	O
artery	O
NC	O
being	O
the	O
least	O
developed	O
.	O
Distance	O
to	O
the	O
coaptation	O
point	O
CD	O
38	O
mm	O
,	O
CI	O
30	O
mm	O
,	O
NC	O
25	O
mm	O
.	O
Maximum	O
diameters	O
at	O
the	O
level	O
of	O
the	O
sinuses	O
CD	O
commissure	O
sinus	O
67	O
mm	O
;	O
NC	O
IC	O
sinus	O
67	O
mm	O
.	O
Severe	O
aortic	O
insufficiency	O
with	O
eccentric	O
jet	O
directed	O
towards	O
the	O
anterior	O
mitral	O
leaflet	O
secondary	O
to	O
mixed	O
mechanism	O
asymmetric	O
leaflet	O
dilatation	O
and	O
central	O
coaptation	O
defect	O
.	O
Aortic	O
annulus	O
diameter	O
28	O
mm	O
.	O
Erased	O
sinotubular	O
junction	O
.	O
Distal	O
ascending	O
,	O
arch	O
and	O
descending	O
aorta	O
of	O
normal	O
calibre	O
26	O
mm	O
,	O
24	O
mm	O
and	O
18	O
mm	O
,	O
respectively	O
.	O
Mitral	O
valve	O
with	O
ballooning	O
of	O
the	O
anterior	O
leaflet	O
towards	O
the	O
left	O
atrium	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
normal	O
ejection	O
fraction	O
.	O
Non	O
dilated	O
atria	O
.	O
ANGIO	O
CT	O
aorta	O
with	O
intravenous	O
contrast	O
21	O
11	O
16	O
Trivalve	O
aortic	O
valve	O
.	O
Dilatation	O
at	O
the	O
level	O
of	O
the	O
coronary	O
sinuses	O
with	O
asymmetry	O
of	O
the	O
leaflets	O
,	O
with	O
greater	O
development	O
of	O
the	O
CD	O
sinus	O
.	O
Distance	O
to	O
the	O
coaptation	O
point	O
CD	O
38	O
.	O
6	O
mm	O
,	O
CI	O
35	O
.	O
3	O
mm	O
,	O
NC	O
36	O
mm	O
.	O
Diameters	O
at	O
sinus	O
level	O
CD	O
commissure	O
sinus	O
66	O
mm	O
;	O
NC	O
commissure	O
sinus	O
66	O
mm	O
,	O
CI	O
commissure	O
sinus	O
66	O
mm	O
.	O
Sinus	O
sinus	O
diameters	O
NC	O
CI	O
sinus	O
65	O
.	O
1	O
mm	O
;	O
CI	O
CD	O
sinus	O
61	O
.	O
8	O
mm	O
;	O
CD	O
NC	O
sinus	O
65	O
.	O
7	O
mm	O
.	O
Maximum	O
diameter	O
of	O
ascending	O
aorta	O
measured	O
at	O
4	O
cm	O
from	O
the	O
valvular	O
plane	O
80	O
x	O
81	O
mm	O
.	O
Aortic	O
arch	O
diameter	O
31	O
x	O
29	O
mm	O
.	O
Diameter	O
of	O
descending	O
aorta	O
at	O
the	O
level	O
of	O
the	O
pulmonary	O
artery	O
bifurcation	O
31	O
x	O
29	O
mm	O
.	O
Diameter	O
of	O
the	O
descending	O
aorta	O
at	O
the	O
level	O
of	O
the	O
diaphragm	O
25	O
x	O
20	O
mm	O
.	O
Diameter	O
of	O
the	O
suprarenal	O
abdominal	O
aorta	O
25	O
x	O
21	O
mm	O
.	O
Infrarenal	O
abdominal	O
aorta	O
diameter	O
20	O
mm	O
.	O
Severely	O
dilated	O
left	O
ventricle	O
.	O
Abdominal	O
study	O
without	O
significant	O
findings	O
,	O
except	O
for	O
findings	O
compatible	O
with	O
dural	O
ectasia	O
arachnoid	O
cysts	O
in	O
the	O
sacrum	O
.	O
Conclusion	O
dilatation	O
of	O
aortic	O
root	O
and	O
ascending	O
aorta	O
.	O
Aortic	O
sagging	O
,	O
descending	O
thoracic	O
aorta	O
and	O
abdominal	O
aorta	O
of	O
normal	O
calibre	O
.	O
CARDIAC	O
MAGNETIC	O
RESONANCE	O
MRI	O
Signs	O
of	O
dural	O
ectasia	O
,	O
with	O
no	O
apparent	O
evidence	O
of	O
lumbosacral	O
radicular	O
involvement	O
.	O
Anterior	O
sacral	O
arachnoid	O
cysts	O
meningoceles	O
.	O
INTERCONSULTATION	O
WITH	O
OPHTHALMOLOGY	O
Biomicroscopy	O
AO	O
cornea	O
normal	O
,	O
crystalline	O
lens	O
clear	O
and	O
well	O
.	O
Post	O
surgical	O
TTE	O
02	O
12	O
2016	O
severely	O
dilated	O
left	O
ventricle	O
VolTD	O
LV	O
308	O
ml	O
;	O
DTDVI	O
77	O
mm	O
,	O
with	O
preserved	O
parietal	O
thicknesses	O
.	O
Global	O
severe	O
hypokinesia	O
.	O
Severely	O
depressed	O
systolic	O
function	O
LVEF	O
by	O
Simpson	O
biplane	O
29	O
.	O
Restrictive	O
mitral	O
filling	O
pattern	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
mild	O
systolic	O
dysfunction	O
.	O
Aortic	O
valve	O
with	O
post	O
surgical	O
changes	O
in	O
leaflets	O
,	O
preserved	O
mobility	O
.	O
There	O
is	O
a	O
jet	O
of	O
mild	O
aortic	O
insufficiency	O
.	O
No	O
outflow	O
stenosis	O
G	O
.	O
Max	O
12	O
mmHg	O
.	O
Both	O
tubular	O
prostheses	O
are	O
visualised	O
,	O
normoexpanded	O
,	O
with	O
laminar	O
flows	O
inside	O
without	O
any	O
leakage	O
.	O
Union	O
with	O
the	O
aortic	O
arch	O
without	O
significant	O
findings	O
.	O
Morphologically	O
normal	O
descending	O
thoracic	O
and	O
abdominal	O
aorta	O
without	O
flow	O
alterations	O
.	O
Mitral	O
valve	O
with	O
elongated	O
anterior	O
leaflet	O
,	O
preserved	O
mobility	O
,	O
with	O
minimal	O
protosystolic	O
insufficiency	O
.	O
Tricuspid	O
valve	O
of	O
normal	O
appearance	O
,	O
with	O
mild	O
protosystolic	O
insufficiency	O
allowing	O
estimation	O
of	O
pulmonary	O
systolic	O
pressure	O
PSP	O
of	O
25	O
mmHg	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
28	O
mm	O
with	O
50	O
inspiratory	O
collapse	O
.	O
Slight	O
lateral	O
pericardial	O
effusion	O
7	O
mm	O
.	O
Postoperative	O
hyperechogenic	O
changes	O
were	O
observed	O
at	O
the	O
aortic	O
valve	O
and	O
tubular	O
prosthesis	O
level	O
.	O
TTE	O
March	O
2017	O
dilated	O
LV	O
LVEDV	O
142	O
ml	O
not	O
hypertrophic	O
.	O
Moderately	O
depressed	O
systolic	O
function	O
44	O
Simpson	O
biplane	O
.	O
Abnormal	O
septal	O
motion	O
.	O
Basal	O
inferior	O
hypokinesia	O
.	O
Impaired	O
relaxation	O
.	O
Right	O
ventricle	O
RV	O
not	O
dilated	O
,	O
normal	O
systolic	O
function	O
.	O
Left	O
atrium	O
slightly	O
dilated	O
,	O
right	O
atrium	O
not	O
dilated	O
.	O
Aortic	O
plasty	O
David	O
technique	O
,	O
thin	O
leaflets	O
,	O
good	O
opening	O
max	O
gradient	O
5	O
mmHg	O
average	O
gradient	O
2mmHg	O
.	O
Mildly	O
moderate	O
II	O
IV	O
insufficiency	O
jet	O
reaches	O
anterior	O
mitral	O
leaflet	O
.	O
Mitral	O
valve	O
elongated	O
anterior	O
leaflet	O
,	O
minimal	O
insufficiency	O
.	O
Tricuspid	O
valve	O
good	O
opening	O
,	O
mild	O
insufficiency	O
,	O
does	O
not	O
allow	O
estimation	O
of	O
pulmonary	O
artery	O
systolic	O
pressure	O
PSAP	O
.	O
Normal	O
pulmonary	O
acceleration	O
time	O
.	O
Normoexpanded	O
tubular	O
prosthesis	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
,	O
adequate	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
the	O
cardiology	O
ward	O
he	O
evolved	O
favourably	O
after	O
starting	O
treatment	O
for	O
heart	O
failure	O
furosemide	B-FARMACO
,	O
ramipril	B-FARMACO
,	O
bisoprolol	B-FARMACO
,	O
remaining	O
haemodynamically	O
stable	O
.	O
A	O
TTE	O
study	O
was	O
completed	O
,	O
showing	O
trivalve	O
aortic	O
valve	O
with	O
aneurysmal	O
dilatation	O
of	O
the	O
sinuses	O
of	O
Valsalva	O
,	O
severe	O
aortic	O
insufficiency	O
,	O
severely	O
dilated	O
LV	O
with	O
moderate	O
systolic	O
dysfunction	O
estimated	O
LVEF	O
42	O
;	O
CT	O
angiography	O
of	O
the	O
aorta	O
showed	O
dilatation	O
of	O
the	O
aortic	O
root	O
and	O
ascending	O
aorta	O
,	O
with	O
aortic	O
arch	O
,	O
descending	O
thoracic	O
aorta	O
and	O
abdominal	O
aorta	O
of	O
normal	O
calibre	O
.	O
For	O
the	O
aetiological	O
study	O
,	O
autoimmunity	O
was	O
requested	O
,	O
which	O
was	O
negative	O
,	O
ruling	O
out	O
the	O
possibility	O
of	O
vasculitis	O
of	O
large	O
vessels	O
Takayasu	O
.	O
Likewise	O
,	O
in	O
the	O
presence	O
of	O
tall	O
stature	O
,	O
long	O
upper	O
limbs	O
,	O
joint	O
laxity	O
,	O
etc	O
.	O
,	O
with	O
the	O
suspicion	O
of	O
connective	O
tissue	O
.	O
with	O
the	O
suspicion	O
of	O
connective	O
tissue	O
disease	O
,	O
tests	O
were	O
requested	O
in	O
search	O
of	O
this	O
diagnosis	O
,	O
especially	O
Marfan	O
syndrome	O
acetabular	O
X	O
ray	O
without	O
protrusion	O
,	O
sacral	O
MRI	O
which	O
showed	O
dural	O
ectasia	O
at	O
lumbar	O
and	O
sacral	O
level	O
,	O
ophthalmology	O
consultation	O
which	O
ruled	O
out	O
ectopia	O
lentis	O
,	O
presenting	O
myopia	O
;	O
and	O
even	O
genetic	O
study	O
which	O
remained	O
pending	O
on	O
discharge	O
being	O
subsequently	O
confirmed	O
with	O
pathogenic	O
mutation	O
in	O
the	O
gene	O
fibrillin	O
1	O
FBN1	O
c	O
.	O
3656A	O
G	O
p	O
.	O
Tyr1219Cys	O
.	O
In	O
relation	O
to	O
the	O
management	O
of	O
aneurysmal	O
dilatation	O
of	O
the	O
aortic	O
root	O
and	O
ascending	O
aorta	O
with	O
secondary	O
aortic	O
insufficiency	O
,	O
the	O
case	O
was	O
discussed	O
with	O
cardiac	O
surgery	O
and	O
the	O
patient	O
underwent	O
surgery	O
on	O
28	O
11	O
16	O
.	O
The	O
aneurysm	O
of	O
the	O
root	O
and	O
ascending	O
aorta	O
was	O
resected	O
and	O
a	O
Hemashield	O
Platinum	O
tubular	O
prosthesis	O
No	O
28	O
and	O
No	O
34	O
with	O
valve	O
preservation	O
according	O
to	O
David	O
's	O
technique	O
Miller	O
's	O
modification	O
,	O
as	O
well	O
as	O
aortic	O
valve	O
plasty	O
.	O
Subsequent	O
good	O
evolution	O
in	O
the	O
intensive	O
care	O
unit	O
where	O
she	O
remained	O
for	O
two	O
days	O
,	O
being	O
discharged	O
on	O
the	O
eleventh	O
postoperative	O
day	O
with	O
echocardiography	O
at	O
discharge	O
showing	O
well	O
expanded	O
tubular	O
prostheses	O
in	O
the	O
ascending	O
aorta	O
without	O
alterations	O
,	O
severely	O
dilated	O
LV	O
,	O
severe	O
systolic	O
and	O
diastolic	O
dysfunction	O
LVEF	O
29	O
,	O
aortic	O
valve	O
with	O
postoperative	O
changes	O
and	O
mild	O
insufficiency	O
,	O
mild	O
mitral	O
insufficiency	O
and	O
mild	O
pericardial	O
effusion	O
.	O
During	O
outpatient	O
follow	O
up	O
,	O
she	O
remained	O
cardiovascular	O
asymptomatic	O
,	O
functional	O
class	O
I	O
,	O
with	O
upward	O
titration	O
of	O
angiotensin	B-FARMACO
converting	I-FARMACO
enzyme	I-FARMACO
inhibitor	I-FARMACO
ACE	O
and	O
beta	O
blocker	O
doses	O
and	O
improvement	O
in	O
LV	O
function	O
to	O
LVEF	O
44	O
see	O
echocardiogram	O
March	O
2017	O
.	O
DIAGNOSIS	O
MFS	O
carrier	O
of	O
pathogenic	O
mutation	O
in	O
FBN1	O
p	O
.	O
tyr1219cys	O
.	O
Aneurysm	O
of	O
ascending	O
aorta	O
and	O
secondary	O
severe	O
aortic	O
insufficiency	O
.	O
David	O
's	O
plasty	O
and	O
aortic	O
tube	O
.	O
Secondary	O
left	O
ventricular	O
dilatation	O
and	O
systolic	O
dysfunction	O
,	O
severe	O
at	O
discharge	O
,	O
currently	O
moderate	O
LVEF	O
44	O
with	O
NYHA	O
functional	O
class	O
I	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
Hypercholesterolemia	O
.	O
Diabetes	O
mellitus	O
DM	O
type	O
2	O
of	O
15	O
years	O
of	O
evolution	O
with	O
good	O
metabolic	O
control	O
,	O
currently	O
with	O
oral	O
antidiabetic	O
drugs	O
ADO	O
and	O
insulin	B-FARMACO
.	O
Obesity	O
grade	O
I	O
.	O
Ex	O
smoker	O
for	O
9	O
years	O
IPA	O
56	O
.	O
Absence	O
of	O
arterial	O
hypertension	O
.	O
Sedentary	O
.	O
Leriche	O
syndrome	O
operated	O
with	O
aortobifemoral	O
bypass	O
.	O
Advanced	O
non	O
ischaemic	O
HF	O
with	O
reduced	O
LVEF	O
and	O
pulmonary	O
arterial	O
hypertension	O
LVEF	O
according	O
to	O
magnetic	O
resonance	O
imaging	O
MRI	O
2014	O
34	O
.	O
Permanent	O
atrial	O
fibrillation	O
AF	O
and	O
left	O
bundle	O
branch	O
block	O
LBBB	O
.	O
Implantable	O
cardioverter	O
defibrillator	O
ICD	O
in	O
primary	O
prevention	O
implanted	O
in	O
2015	O
.	O
Stage	O
IIIb	O
chronic	O
kidney	O
disease	O
.	O
Thrombophilia	O
with	O
mutation	O
of	O
the	O
prothrombin	O
gene	O
20210A	O
.	O
Chronic	O
obstructive	O
pulmonary	O
disease	O
COPD	O
GOLD	O
B	O
with	O
forced	O
expiratory	O
volume	O
in	O
the	O
first	O
second	O
FEV1	O
67	O
,	O
non	O
acute	O
.	O
T1bN0M0	O
right	O
upper	O
lobe	O
lung	O
adenocarcinoma	O
LSD	O
,	O
treated	O
with	O
surgery	O
and	O
radiotherapy	O
in	O
2016	O
,	O
currently	O
disease	O
free	O
.	O
Seropositive	O
polyarthritis	O
with	O
carpal	O
involvement	O
.	O
Gout	O
.	O
Subclinical	O
hyperthyroidism	O
with	O
multinodular	O
thyroid	O
.	O
Allergies	O
.	O
Not	O
known	O
.	O
Previous	O
treatment	O
chronic	O
home	O
oxygen	O
therapy	O
,	O
acenocoumarol	B-FARMACO
10	O
mg	O
weekly	O
,	O
insulin	B-FARMACO
lantus	I-FARMACO
26	O
IU	O
,	O
insulin	B-FARMACO
glulisine	I-FARMACO
12	O
10	O
8	O
,	O
metformin	B-FARMACO
850	O
mg	O
0	O
1	O
0	O
,	O
empaglifozin	B-FARMACO
10	O
mg	O
0	O
1	O
0	O
,	O
ezetimibe	B-FARMACO
10	I-FARMACO
mg	I-FARMACO
simvastatin	I-FARMACO
40	O
mg	O
0	O
1	O
0	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
1	O
0	O
changing	O
doses	O
according	O
to	O
clinical	O
situation	O
,	O
carvedilol	B-FARMACO
6	O
.	O
25	O
mg	O
1	O
0	O
1	O
2	O
,	O
eplerenone	B-FARMACO
25	O
mg	O
0	O
1	O
2	O
0	O
,	O
sacubitrilo	B-FARMACO
valsartan	I-FARMACO
97	O
103	O
mg	O
1	O
0	O
1	O
,	O
lansoprazole	B-FARMACO
30	O
mg	O
1	O
0	O
0	O
,	O
allopurinol	B-FARMACO
100	O
mg	O
0	O
1	O
0	O
,	O
escitalopram	B-FARMACO
15	O
mg	O
,	O
indacaterol	B-FARMACO
glycopyrronium	I-FARMACO
bromide	I-FARMACO
.	O
CURRENT	O
ILLNESS	O
79	O
year	O
old	O
male	O
with	O
the	O
history	O
described	O
,	O
under	O
follow	O
up	O
by	O
the	O
advanced	O
HF	O
unit	O
and	O
on	O
treatment	O
with	O
intermittent	O
doses	O
of	O
levosimendan	B-FARMACO
,	O
who	O
consults	O
for	O
progressive	O
worsening	O
of	O
functional	O
class	O
,	O
currently	O
IIIb	O
IV	O
.	O
He	O
denies	O
palpitations	O
,	O
chest	O
pain	O
or	O
syncope	O
.	O
No	O
cough	O
,	O
no	O
expectoration	O
,	O
no	O
increase	O
in	O
sputum	O
purulence	O
.	O
No	O
dysthermic	O
sensation	O
or	O
infectious	O
semiology	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
100	O
60	O
,	O
heart	O
rate	O
HR	O
64	O
bpm	O
,	O
oxygen	O
saturation	O
SatO2	O
97	O
,	O
respiratory	O
rate	O
RF	O
20	O
rpm	O
.	O
Afebrile	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
,	O
no	O
audible	O
murmurs	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
.	O
Extremities	O
with	O
discrete	O
oedema	O
with	O
fovea	O
,	O
without	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYTICS	O
biochemistry	O
glucose	O
83	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
60	O
mg	O
dl	O
,	O
GFR	O
MDRD	O
38	O
.	O
56	O
ml	O
min	O
,	O
urea	O
62	O
mg	O
dl	O
,	O
sodium	O
131	O
mm	O
l	O
,	O
potassium	O
4	O
.	O
5	O
mm	O
l	O
,	O
chlorine	O
100	O
mm	O
l	O
,	O
calcium	O
7	O
.	O
9	O
mg	O
dl	O
,	O
phosphorus	O
2	O
.	O
5	O
mg	O
dl	O
,	O
albumin	O
2	O
.	O
8	O
g	O
dl	O
,	O
total	O
protein	O
5	O
.	O
5	O
g	O
dl	O
,	O
total	O
bilirubin	O
0	O
.	O
99	O
mg	O
dl	O
,	O
creatine	O
kinase	O
CK	O
50	O
U	O
l	O
,	O
BNP	O
401	O
pg	O
ml	O
.	O
Haemoglobin	O
16	O
.	O
6	O
g	O
dl	O
,	O
haematocrit	O
53	O
.	O
5	O
,	O
platelets	O
150	O
,	O
000	O
μl	O
,	O
leukocytes	O
8430	O
μl	O
,	O
neutrophils	O
66	O
.	O
20	O
.	O
Coagulation	O
prothrombin	O
time	O
13	O
.	O
70	O
sg	O
,	O
prothrombin	O
activity	O
69	O
.	O
40	O
,	O
international	O
normalised	O
ratio	O
INR	O
1	O
.	O
23	O
,	O
cephalin	O
time	O
35	O
.	O
70	O
sg	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
,	O
signs	O
of	O
redistribution	O
,	O
increased	O
bronchovascular	O
tract	O
.	O
Device	O
in	O
the	O
pectoral	O
region	O
,	O
access	O
through	O
the	O
subclavian	O
vein	O
and	O
tipped	O
in	O
the	O
right	O
cavities	O
.	O
ELECTROCARDIOGRAM	O
atrial	O
fibrillation	O
at	O
66	O
bpm	O
.	O
QRS	O
of	O
120	O
ms	O
with	O
LBBB	O
morphology	O
.	O
QTc	O
Bazett	O
,	O
V4	O
440	O
ms	O
.	O
The	O
8th	O
QRS	O
represents	O
an	O
isolated	O
ventricular	O
extrasystole	O
.	O
ECHO	O
CARDIOGRAM	O
video1	O
moderate	O
severe	O
global	O
LV	O
systolic	O
dysfunction	O
LVEF	O
37	O
.	O
The	O
s	O
e	O
p	O
t	O
a	O
l	O
m	O
o	O
v	O
e	O
m	O
e	O
n	O
t	O
m	O
o	O
v	O
e	O
m	O
e	O
n	O
t	O
i	O
s	O
c	O
o	O
m	O
p	O
a	O
t	O
i	O
b	O
l	O
e	O
w	O
i	O
t	O
h	O
a	O
n	O
o	O
m	O
a	O
l	O
y	O
a	O
n	O
o	O
m	O
a	O
l	O
y	O
o	O
f	O
t	O
h	O
e	O
c	O
o	O
n	O
d	O
u	O
c	O
t	O
i	O
o	O
n	O
.	O
Abnormal	O
apical	O
motion	O
may	O
reflect	O
pacemaker	O
activation	O
.	O
ICD	O
lead	O
in	O
right	O
chambers	O
.	O
Mild	O
mitral	O
insufficiency	O
MI	O
and	O
tricuspid	O
insufficiency	O
TI	O
.	O
Mild	O
pulmonary	O
arterial	O
hypertension	O
PAH	O
.	O
CLINICAL	O
EVOLUTION	O
Given	O
the	O
patient	O
's	O
progressive	O
dyspnoea	O
and	O
poor	O
response	O
to	O
pharmacological	O
treatments	O
for	O
HF	O
not	O
escalated	O
to	O
evidence	O
based	O
doses	O
due	O
to	O
the	O
appearance	O
of	O
adverse	O
effects	O
,	O
the	O
implantation	O
of	O
a	O
carotid	O
baroreceptor	O
stimulator	O
was	O
proposed	O
as	O
a	O
therapeutic	O
complement	O
.	O
Previously	O
,	O
cardiac	O
resynchronisation	O
therapy	O
CRT	O
was	O
ruled	O
out	O
due	O
to	O
QRS	O
110	O
120	O
ms	O
and	O
ivabradine	B-FARMACO
due	O
to	O
permanent	O
AF	O
.	O
On	O
the	O
other	O
hand	O
,	O
it	O
was	O
decided	O
to	O
change	O
therapy	O
to	O
direct	O
acting	O
anticoagulants	O
due	O
to	O
INR	O
lability	O
.	O
The	O
patient	O
was	O
admitted	O
on	O
a	O
scheduled	O
basis	O
and	O
the	O
Barostim	O
neo	O
device	O
was	O
implanted	O
without	O
complications	O
control	O
X	O
ray	O
.	O
The	O
patient	O
was	O
discharged	O
24	O
hours	O
later	O
.	O
45	O
days	O
later	O
,	O
the	O
patient	O
reports	O
improvement	O
in	O
his	O
functional	O
class	O
,	O
currently	O
II	O
IV	O
,	O
with	O
a	O
decrease	O
in	O
daily	O
furosemide	B-FARMACO
doses	O
and	O
no	O
need	O
,	O
for	O
the	O
time	O
being	O
,	O
for	O
intermittent	O
therapy	O
with	O
levosimendan	B-FARMACO
.	O
Pre	O
implantation	O
brain	O
natriuretic	O
peptide	O
BNP	O
values	O
401	O
.	O
2	O
pg	O
ml	O
;	O
BNP	O
45	O
days	O
post	O
implantation	O
371	O
.	O
3	O
pg	O
ml	O
.	O
DIAGNOSIS	O
HF	O
with	O
reduced	O
LVEF	O
HFrEF	O
of	O
non	O
ischaemic	O
aetiology	O
,	O
stage	O
D	O
and	O
functional	O
class	O
II	O
in	O
treatment	O
with	O
carotid	O
baroreceptor	O
stimulator	O
.	O
Hypercholesterolemia	O
.	O
Type	O
II	O
DM	O
for	O
15	O
years	O
with	O
good	O
metabolic	O
control	O
,	O
currently	O
insulin	O
dependent	O
.	O
Grade	O
I	O
obesity	O
.	O
Ex	O
smoker	O
for	O
9	O
years	O
IPA	O
56	O
.	O
No	O
arterial	O
hypertension	O
.	O
Sedentary	O
.	O
Leriche	O
syndrome	O
operated	O
with	O
aortobifemoral	O
bypass	O
.	O
Advanced	O
non	O
ischemic	O
HF	O
with	O
reduced	O
LVEF	O
and	O
pulmonary	O
hypertension	O
LVEF	O
according	O
to	O
MRI	O
2014	O
34	O
.	O
AF	O
and	O
LBBB	O
.	O
ICD	O
in	O
primary	O
prevention	O
implanted	O
in	O
2015	O
.	O
Stage	O
IIIb	O
CKD	O
.	O
Thrombophilia	O
with	O
mutation	O
of	O
the	O
prothrombin	O
gene	O
20210A	O
.	O
COPD	O
GOLD	O
B	O
with	O
FEV1	O
67	O
,	O
non	O
acute	O
.	O
LSD	O
T1bN0M0	O
lung	O
adenocarcinoma	O
,	O
treated	O
with	O
surgery	O
and	O
radiotherapy	O
in	O
2016	O
,	O
currently	O
disease	O
free	O
.	O
Seropositive	O
polyarthritis	O
with	O
carpal	O
involvement	O
.	O
Gout	O
.	O
Subclinical	O
hyperthyroidism	O
with	O
multinodular	O
thyroid	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
75	O
year	O
old	O
woman	O
presenting	O
with	O
dyspnoea	O
and	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
BACKGROUND	O
No	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
systemic	O
arterial	O
hypertension	O
,	O
type	O
2	O
diabetes	O
mellitus	O
DM	O
,	O
dyslipidaemia	O
.	O
Cardiological	O
history	O
chronic	O
ischaemic	O
heart	O
disease	O
.	O
Previous	O
acute	O
myocardial	O
infarction	O
AMI	O
treated	O
with	O
primary	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
PTCA	O
and	O
conventional	O
stenting	O
to	O
the	O
anterior	O
descending	O
AD	O
artery	O
with	O
loss	O
of	O
S1	O
and	O
D2	O
in	O
2005	O
.	O
Reinfarction	O
in	O
2008	O
due	O
to	O
occlusion	O
of	O
the	O
LAD	O
proximal	O
to	O
D1	O
.	O
Coated	O
stent	O
implanted	O
,	O
with	O
loss	O
of	O
the	O
first	O
diagonal	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
at	O
discharge	O
30	O
.	O
Admission	O
for	O
HF	O
in	O
December	O
2012	O
and	O
2016	O
in	O
the	O
context	O
of	O
medical	O
dietary	O
transgression	O
,	O
with	O
incidental	O
finding	O
of	O
atrial	O
fibrillation	O
AF	O
.	O
A	O
frequency	O
control	O
strategy	O
was	O
decided	O
.	O
Bilateral	O
segmental	O
pulmonary	O
thromboembolism	O
of	O
high	O
intermediate	O
risk	O
in	O
March	O
2017	O
,	O
with	O
dilatation	O
and	O
moderate	O
residual	O
right	O
ventricular	O
dysfunction	O
.	O
Admission	O
to	O
cardiology	O
in	O
July	O
and	O
November	O
2017	O
for	O
HF	O
related	O
to	O
dietary	O
transgressions	O
.	O
In	O
January	O
2018	O
,	O
a	O
new	O
decompensation	O
.	O
Severe	O
right	O
ventricular	O
dysfunction	O
was	O
observed	O
,	O
forcing	O
discontinuation	O
of	O
beta	O
blockers	O
.	O
Since	O
then	O
,	O
frequency	O
control	O
with	O
low	O
doses	O
of	O
digoxin	B-FARMACO
.	O
Permanent	O
AF	O
anticoagulated	O
with	O
apixaban	B-FARMACO
.	O
Other	O
personal	O
history	O
chronic	O
kidney	O
disease	O
of	O
diabetic	O
aetiology	O
glomerular	O
filtration	O
rate	O
estimated	O
at	O
40	O
ml	O
min	O
,	O
hyperuricaemia	O
,	O
depression	O
and	O
gonarthrosis	O
.	O
Situation	O
and	O
life	O
at	O
baseline	O
no	O
cognitive	O
impairment	O
.	O
Good	O
baseline	O
quality	O
of	O
life	O
and	O
adequate	O
family	O
support	O
.	O
Usual	O
treatment	O
spironolactone	B-FARMACO
25	O
mg	O
1	O
0	O
0	O
,	O
furosemide	B-FARMACO
40	O
mg	O
2	O
0	O
0	O
,	O
sitagliptin	B-FARMACO
50	O
mg	O
1	O
0	O
0	O
,	O
lisinopril	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
,	O
pantoprazole	B-FARMACO
40	O
mg	O
1	O
0	O
0	O
,	O
atorvastatin	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
,	O
sertraline	B-FARMACO
50	O
mg	O
1	O
0	O
0	O
,	O
apixaban	B-FARMACO
5	O
mg	O
1	O
0	O
1	O
,	O
digoxin	B-FARMACO
0	O
.	O
25	O
mg	O
0	O
.	O
5	O
0	O
0	O
,	O
Monday	O
to	O
Friday	O
.	O
CURRENT	O
ILLNESS	O
She	O
attends	O
for	O
progressive	O
deterioration	O
of	O
functional	O
class	O
to	O
minimal	O
effort	O
dyspnoea	O
,	O
with	O
increasing	O
orthopnoea	O
of	O
up	O
to	O
three	O
pillows	O
and	O
episodes	O
compatible	O
with	O
paroxysmal	O
nocturnal	O
dyspnoea	O
PND	O
.	O
Increased	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
She	O
denies	O
dietary	O
and	O
medication	O
transgressions	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
139	O
90	O
mmHg	O
,	O
heart	O
rate	O
95	O
bpm	O
,	O
oxygen	O
saturation	O
SatO2	O
96	O
with	O
GN	O
at	O
3l	O
.	O
Haemodynamically	O
stable	O
and	O
eupneic	O
at	O
rest	O
,	O
with	O
intolerance	O
to	O
decubitus	O
.	O
Jugular	O
venous	O
ingurgitation	O
up	O
to	O
the	O
angle	O
of	O
the	O
jaw	O
.	O
Auscultation	O
arrhythmic	O
without	O
murmurs	O
or	O
extratonos	O
.	O
Hypoventilation	O
and	O
humid	O
bibasal	O
crackles	O
.	O
Abdomen	O
hepatomegaly	O
of	O
2	O
traverses	O
.	O
Extremities	O
bilateral	O
oedema	O
with	O
fovea	O
up	O
to	O
two	O
thirds	O
of	O
the	O
legs	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYSIS	O
haemoglobin	O
14	O
.	O
0	O
g	O
dl	O
,	O
platelets	O
207	O
,	O
000	O
μl	O
,	O
leucocytes	O
6	O
,	O
500	O
μl	O
,	O
INR	O
1	O
.	O
61	O
.	O
pH	O
7	O
.	O
45	O
,	O
pCO2	O
41	O
mmHg	O
,	O
bicarbonate	O
28	O
mmol	O
l	O
,	O
glucose	O
119	O
mg	O
dl	O
,	O
uric	O
acid	O
8	O
.	O
3	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
eFG	O
40	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
sodium	O
142	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
6	O
mmol	O
l	O
,	O
NT	O
proBNP	O
8	O
,	O
505	O
ng	O
l	O
.	O
THORAX	O
X	O
RAY	O
increased	O
cardiothoracic	O
index	O
.	O
Bilateral	O
pinching	O
of	O
costophrenic	O
sinuses	O
.	O
Enlarged	O
hilae	O
.	O
Vascular	O
redistribution	O
.	O
ELECTROCARDIOGRAM	O
ECG	O
AF	O
with	O
ventricular	O
response	O
95	O
bpm	O
wide	O
QRS	O
with	O
morphology	O
of	O
complete	O
left	O
bundle	O
branch	O
block	O
,	O
secondary	O
repolarisation	O
alterations	O
.	O
REGULATED	O
TRANSTORACIC	O
ECG	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
LVEF	O
of	O
25	O
,	O
akinesia	O
of	O
apex	O
and	O
distal	O
segments	O
and	O
middle	O
segment	O
of	O
the	O
anterior	O
face	O
.	O
Right	O
ventricle	O
severely	O
dilated	O
with	O
depressed	O
systolic	O
function	O
.	O
Mitral	O
valve	O
with	O
degenerative	O
changes	O
and	O
mild	O
insufficiency	O
.	O
Sclerosed	O
aortic	O
valve	O
with	O
mild	O
insufficiency	O
.	O
Tricuspid	O
valve	O
with	O
mild	O
to	O
moderate	O
regurgitation	O
.	O
Pulmonary	O
artery	O
systolic	O
pressure	O
estimated	O
at	O
50	O
mmHg	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
without	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Aortic	O
root	O
and	O
ascending	O
aorta	O
not	O
dilated	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
readmitted	O
for	O
new	O
decompensation	O
of	O
HF	O
after	O
recent	O
discharge	O
.	O
Intensive	O
intravenous	O
depletive	O
treatment	O
was	O
started	O
with	O
a	O
good	O
initial	O
response	O
,	O
rapidly	O
achieving	O
euvolemia	O
,	O
which	O
was	O
maintained	O
after	O
switching	O
to	O
oral	O
diuretics	O
.	O
As	O
this	O
was	O
a	O
patient	O
with	O
chronic	O
HF	O
with	O
depressed	O
LVEF	O
and	O
frequent	O
readmissions	O
due	O
to	O
decompensation	O
despite	O
optimal	O
medical	O
treatment	O
in	O
the	O
last	O
6	O
months	O
with	O
adequate	O
medical	O
compliance	O
,	O
lisinopril	B-FARMACO
was	O
replaced	O
during	O
admission	O
by	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
24	O
26	O
mg	O
every	O
12	O
hours	O
pending	O
titration	O
to	O
optimal	O
doses	O
on	O
an	O
outpatient	O
basis	O
.	O
The	O
patient	O
was	O
last	O
seen	O
in	O
the	O
cardiology	O
day	O
hospital	O
on	O
20	O
April	O
2018	O
.	O
In	O
the	O
3	O
months	O
she	O
has	O
been	O
on	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
,	O
she	O
has	O
had	O
no	O
readmissions	O
,	O
remains	O
in	O
functional	O
class	O
II	O
III	O
and	O
on	O
the	O
initial	O
dose	O
of	O
24	O
26	O
mg	O
every	O
12	O
hours	O
due	O
to	O
a	O
tendency	O
towards	O
low	O
blood	O
pressure	O
.	O
Renal	O
function	O
has	O
remained	O
stable	O
creatinine	O
in	O
the	O
last	O
control	O
1	O
.	O
5	O
mg	O
dl	O
and	O
potassium	O
4	O
.	O
6	O
mmol	O
l	O
.	O
DIAGNOSIS	O
Decompensated	O
HF	O
with	O
American	O
Heart	O
Association	O
AHA	O
stage	O
C	O
reduced	O
LVEF	O
.	O
New	O
York	O
Heart	O
Association	O
NYHA	O
ambulatory	O
functional	O
class	O
III	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
.	O
Percutaneous	O
revascularisation	O
of	O
the	O
LAD	O
on	O
two	O
occasions	O
.	O
Probable	O
pulmonary	O
hypertension	O
of	O
Dana	O
point	O
groups	O
2	O
and	O
4	O
.	O
Severely	O
depressed	O
LVEF	O
.	O
Severe	O
right	O
ventricular	O
dysfunction	O
.	O
Permanent	O
non	O
valvular	O
AF	O
anticoagulated	O
with	O
apixaban	B-FARMACO
.	O
Chronic	O
kidney	O
disease	O
due	O
to	O
diabetic	O
nephropathy	O
.	O
Systemic	O
arterial	O
hypertension	O
.	O
Dyslipidaemia	O
.	O
Type	O
2	O
DM	O
with	O
good	O
glycaemic	O
control	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
75	O
year	O
old	O
male	O
patient	O
presenting	O
with	O
chest	O
pain	O
.	O
BACKGROUND	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
Arterial	O
hypertension	O
AHT	O
.	O
Dyslipidaemia	O
.	O
Obesity	O
.	O
Intermittent	O
claudication	O
.	O
Hepatic	O
steatosis	O
.	O
Benign	O
prostatic	O
hyperplasia	O
.	O
Admission	O
in	O
November	O
2017	O
to	O
the	O
neurology	O
unit	O
for	O
acute	O
ischaemic	O
stroke	O
in	O
right	O
middle	O
cerebral	O
arterial	O
territory	O
of	O
undetermined	O
aetiology	O
NIHSS	O
11	O
.	O
Effective	O
primary	O
mechanical	O
thrombectomy	O
.	O
Complete	O
recovery	O
and	O
no	O
evidence	O
of	O
sequelae	O
at	O
present	O
.	O
Surgical	O
interventions	O
bilateral	O
inguinal	O
hernia	O
,	O
appendectomy	O
,	O
hydrocele	O
.	O
Cardiological	O
history	O
moderate	O
aortic	O
stenosis	O
under	O
follow	O
up	O
in	O
valvulopathy	O
module	O
.	O
Baseline	O
status	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
.	O
Rank	O
0	O
.	O
Barthel	O
Index	O
100	O
.	O
Home	O
treatment	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
0	O
0	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
1	O
0	O
0	O
,	O
rosuvastatin	B-FARMACO
10	O
mg	O
0	O
0	O
1	O
,	O
tamsulosin	B-FARMACO
0	O
.	O
4	O
mg	O
0	O
0	O
1	O
,	O
finasteride	B-FARMACO
5	O
mg	O
1	O
0	O
0	O
,	O
lorazepam	B-FARMACO
1	O
mg	O
0	O
0	O
1	O
.	O
CURRENT	O
ILLNESS	O
The	O
patient	O
refers	O
clinical	O
complaints	O
of	O
pain	O
in	O
the	O
left	O
lower	O
limb	O
,	O
also	O
noting	O
it	O
colder	O
than	O
the	O
contralateral	O
leg	O
.	O
The	O
following	O
day	O
he	O
began	O
to	O
experience	O
oppressive	O
central	O
thoracic	O
pain	O
,	O
without	O
irradiation	O
or	O
vegetative	O
cortex	O
,	O
as	O
well	O
as	O
very	O
unspecific	O
abdominal	O
pain	O
,	O
which	O
is	O
why	O
he	O
decided	O
to	O
go	O
to	O
hospital	O
.	O
PHYSICAL	O
EXAMINATION	O
Sweaty	O
.	O
Blood	O
pressure	O
BP	O
120	O
60	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
75	O
bpm	O
.	O
Cardiopulmonary	O
auscultation	O
arrhythmic	O
heart	O
sounds	O
with	O
systolic	O
ejection	O
murmur	O
in	O
aortic	O
focus	O
grade	O
II	O
VI	O
in	O
addition	O
to	O
soft	O
murmur	O
in	O
peak	O
grade	O
II	O
VI	O
.	O
Abdomen	O
globular	O
,	O
depressible	O
,	O
no	O
masses	O
,	O
diffusely	O
painful	O
with	O
no	O
signs	O
of	O
peritonitis	O
.	O
Left	O
lower	O
limb	O
cold	O
and	O
pale	O
,	O
with	O
absence	O
of	O
paedial	O
pulse	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYSIS	O
haemoglobin	O
14	O
.	O
6	O
g	O
dl	O
,	O
haematocrit	O
44	O
.	O
6	O
,	O
leucocytes	O
16	O
,	O
000	O
mm3	O
.	O
Neutrophils	O
80	O
.	O
3	O
,	O
platelets	O
236	O
,	O
000	O
mm3	O
,	O
D	O
dimer	O
1367	O
ng	O
ml	O
,	O
INR	O
1	O
.	O
01	O
,	O
basal	O
glucose	O
128	O
mg	O
dl	O
.	O
BUN	O
16	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
90	O
mg	O
dl	O
,	O
GFR	O
MDRD	O
4	O
87	O
ml	O
min	O
sup	O
,	O
sodium	O
139	O
meq	O
l	O
,	O
potassium	O
4	O
.	O
1	O
meq	O
l	O
,	O
GOT	O
333	O
U	O
L	O
,	O
GPT	O
69	O
U	O
L	O
,	O
CK	O
NAC	O
1486	O
U	O
L	O
,	O
CK	O
MB	O
144	O
U	O
L	O
,	O
peak	O
troponin	O
I	O
48	O
ng	O
ml	O
,	O
NTproBNP	O
3840	O
pg	O
ml	O
.	O
ECG	O
in	O
the	O
ED	O
AF	O
with	O
adequate	O
ventricular	O
response	O
with	O
ST	O
elevation	O
less	O
than	O
1	O
mm	O
in	O
inferior	O
and	O
high	O
lateral	O
leads	O
with	O
high	O
R	O
in	O
precordial	O
leads	O
.	O
ECG	O
in	O
coronary	O
ICU	O
sinus	O
rhythm	O
,	O
lower	O
Q	O
waves	O
with	O
negative	O
T	O
waves	O
evolving	O
pattern	O
.	O
Chest	O
X	O
RAY	O
PA	O
increased	O
cardiothoracic	O
index	O
.	O
Bilateral	O
congestion	O
with	O
vascular	O
redistribution	O
to	O
apexes	O
.	O
COMPUTER	O
CAT	O
SCAN	O
CT	O
chest	O
abdomen	O
image	O
suggestive	O
of	O
posterobasal	O
myocardial	O
infarction	O
in	O
LV	O
.	O
Laminar	O
pleural	O
effusion	O
predominantly	O
on	O
the	O
right	O
,	O
reaching	O
a	O
maximum	O
thickness	O
of	O
15	O
mm	O
.	O
Hypodense	O
cortical	O
lesions	O
in	O
both	O
kidneys	O
,	O
predominantly	O
on	O
the	O
left	O
,	O
suggestive	O
of	O
renal	O
infarction	O
.	O
Dorsolumbar	O
spondylosis	O
with	O
stenosis	O
of	O
the	O
L3	O
L4	O
and	O
L4	O
L5	O
canal	O
,	O
to	O
be	O
correlated	O
with	O
clinical	O
findings	O
.	O
Arterial	O
DOPPLER	O
ECOGRAPHY	O
of	O
MMII	O
performed	O
on	O
previous	O
admission	O
to	O
the	O
neurology	O
department	O
severe	O
stenosis	O
in	O
the	O
right	O
iliac	O
artery	O
and	O
mild	O
stenosis	O
in	O
the	O
left	O
iliac	O
artery	O
.	O
Bilateral	O
femoro	O
popliteal	O
atheromatosis	O
.	O
ECHO	O
CARDIOGRAPHY	O
moderate	O
concentric	O
left	O
ventricular	O
hypertrophy	O
LVH	O
,	O
inferior	O
akinesia	O
and	O
lateral	O
hypokinesia	O
with	O
preserved	O
global	O
contractility	O
.	O
Severe	O
aortic	O
calcification	O
with	O
moderate	O
limitation	O
of	O
aortic	O
opening	O
V	O
.	O
max	O
3	O
.	O
3	O
m	O
sec	O
mean	O
gradient	O
19	O
mmHg	O
,	O
mild	O
aortic	O
insufficiency	O
.	O
Mitral	O
valve	O
calcification	O
with	O
mild	O
mitral	O
regurgitation	O
.	O
Non	O
dilated	O
right	O
ventricle	O
RV	O
with	O
normal	O
global	O
contractility	O
TAPSE	O
18	O
mm	O
,	O
mild	O
tricuspid	O
regurgitation	O
TR	O
with	O
RV	O
RA	O
gradient	O
28	O
mmHg	O
.	O
CARDIAC	O
CATHETERISM	O
coronary	O
artery	O
disease	O
with	O
angiographic	O
image	O
compatible	O
with	O
thrombus	O
in	O
distal	O
first	O
obtuse	O
marginal	O
OM	O
,	O
which	O
is	O
located	O
at	O
the	O
end	O
of	O
the	O
bifurcation	O
with	O
a	O
secondary	O
branch	O
of	O
small	O
calibre	O
.	O
Rest	O
of	O
the	O
coronary	O
tree	O
free	O
of	O
significant	O
obstructive	O
lesions	O
.	O
Left	O
ventricle	O
LV	O
of	O
normal	O
size	O
with	O
mildly	O
depressed	O
global	O
contractility	O
EF	O
50	O
.	O
Lower	O
segmental	O
contractility	O
disorder	O
.	O
Calcified	O
aortic	O
valve	O
disease	O
unquantified	O
aortic	O
stenosis	O
with	O
mean	O
gradient	O
of	O
22	O
.	O
5	O
mmHg	O
.	O
CLINICAL	O
EVOLUTION	O
A	O
75	O
year	O
old	O
male	O
patient	O
with	O
the	O
personal	O
history	O
described	O
above	O
was	O
admitted	O
for	O
acute	O
myocardial	O
infarction	O
AMI	O
with	O
lower	O
Q	O
wave	O
Killip	O
I	O
and	O
acute	O
ischaemia	O
of	O
the	O
left	O
lower	O
limb	O
.	O
During	O
admission	O
,	O
previously	O
undiagnosed	O
AF	O
was	O
detected	O
.	O
Treatment	O
was	O
started	O
with	O
double	O
antiplatelet	O
therapy	O
and	O
anticoagulation	O
.	O
An	O
angiographic	O
study	O
was	O
performed	O
showing	O
a	O
significant	O
obstructive	O
lesion	O
due	O
to	O
distal	O
thrombus	O
in	O
the	O
first	O
OM	O
that	O
was	O
not	O
revascularised	O
.	O
Given	O
that	O
the	O
patient	O
evolves	O
favourably	O
from	O
the	O
point	O
of	O
view	O
of	O
ischaemia	O
of	O
the	O
left	O
lower	O
limb	O
mobilises	O
fingers	O
with	O
good	O
perfusion	O
and	O
presence	O
of	O
distal	O
pulse	O
and	O
without	O
data	O
of	O
recurrence	O
of	O
myocardial	O
ischaemia	O
,	O
discharge	O
and	O
follow	O
up	O
by	O
cardiology	O
and	O
vascular	O
surgery	O
consultations	O
is	O
decided	O
.	O
DIAGNOSIS	O
Acute	O
coronary	O
syndrome	O
with	O
ST	O
segment	O
elevation	O
STEACS	O
lower	O
Killip	O
I	O
.	O
Peripheral	O
arterial	O
disease	O
acute	O
ischaemia	O
of	O
the	O
left	O
lower	O
limb	O
.	O
Bilateral	O
renal	O
infarction	O
.	O
Debut	O
AF	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
No	O
known	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
CVR	O
ex	O
smoker	O
for	O
17	O
years	O
.	O
Well	O
controlled	O
arterial	O
hypertension	O
AHT	O
.	O
Dyslipidaemia	O
without	O
medical	O
treatment	O
.	O
Hyperuricaemia	O
.	O
Obstructive	O
sleep	O
apnoea	O
hypopnoea	O
syndrome	O
OSAHS	O
under	O
treatment	O
with	O
continuous	O
positive	O
airway	O
pressure	O
CPAP	O
.	O
Haematological	O
history	O
polyglobulia	O
with	O
periodic	O
bleeding	O
.	O
In	O
September	O
2017	O
diagnosed	O
with	O
lymphocytic	O
lymphoma	O
with	O
p53	O
gene	O
deletion	O
.	O
Degenerative	O
shoulder	O
arthropathy	O
and	O
acromioclavicular	O
osteophytosis	O
assessed	O
by	O
traumatology	O
and	O
rehabilitation	O
.	O
Surgical	O
interventions	O
inguinal	O
hernia	O
.	O
Usual	O
treatment	O
enalapril	B-FARMACO
HCTZ	I-FARMACO
20	O
12	O
.	O
5	O
1	O
0	O
0	O
,	O
allopurinol	B-FARMACO
300	O
mg	O
0	O
1	O
0	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
.	O
Preserved	O
higher	O
functions	O
SFB	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
BADL	O
.	O
Lives	O
with	O
his	O
wife	O
.	O
CURRENT	O
ILLNESS	O
During	O
the	O
first	O
visit	O
,	O
the	O
patient	O
reports	O
feeling	O
tired	O
,	O
with	O
more	O
asthenia	O
than	O
usual	O
.	O
However	O
,	O
he	O
denies	O
dyspnoea	O
,	O
both	O
on	O
exertion	O
and	O
at	O
rest	O
,	O
orthopnoea	O
,	O
oliguria	O
or	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
There	O
was	O
no	O
history	O
of	O
chest	O
pain	O
or	O
palpitations	O
.	O
An	O
electrocardiogram	O
ECG	O
was	O
performed	O
and	O
a	O
blood	O
test	O
and	O
echocardiogram	O
were	O
requested	O
to	O
complete	O
the	O
study	O
.	O
Given	O
the	O
poor	O
prognosis	O
criteria	O
associated	O
with	O
lymphocytic	O
leukaemia	O
,	O
the	O
haematology	O
department	O
decided	O
to	O
start	O
treatment	O
with	O
ibrutinib	B-FARMACO
Bruton	I-FARMACO
's	I-FARMACO
tyrosine	I-FARMACO
kinase	I-FARMACO
inhibitor	I-FARMACO
.	O
Approximately	O
one	O
month	O
after	O
starting	O
treatment	O
,	O
the	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
with	O
palpitations	O
and	O
a	O
feeling	O
of	O
central	O
thoracic	O
oppression	O
.	O
On	O
arrival	O
,	O
an	O
ECG	O
showed	O
a	O
common	O
atrial	O
flutter	O
with	O
ventricular	O
response	O
at	O
150	O
bpm	O
.	O
There	O
were	O
no	O
signs	O
of	O
heart	O
failure	O
on	O
physical	O
examination	O
or	O
chest	O
X	O
ray	O
.	O
Treatment	O
with	O
beta	O
blockers	O
was	O
administered	O
and	O
spontaneously	O
reverted	O
to	O
sinus	O
rhythm	O
after	O
a	O
few	O
hours	O
,	O
and	O
the	O
patient	O
was	O
discharged	O
and	O
referred	O
to	O
outpatient	O
cardio	O
oncohaematology	O
consultations	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
,	O
complete	O
right	O
bundle	O
branch	O
block	O
RBBB	O
with	O
secondary	O
repolarisation	O
abnormalities	O
.	O
No	O
acute	O
repolarisation	O
alterations	O
.	O
ANALYSIS	O
glucose	O
92	O
mg	O
dl	O
,	O
urea	O
117	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
19	O
mg	O
dl	O
,	O
albumin	O
3	O
.	O
66	O
mg	O
dl	O
,	O
sodium	O
138	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
72	O
mmol	O
l	O
,	O
haemoglobin	O
12	O
.	O
4	O
g	O
dl	O
,	O
leukocytes	O
11	O
,	O
600	O
μL	O
N	O
68	O
,	O
platelets	O
77000	O
μL	O
.	O
ECOCARDIOGRAM	O
left	O
ventricle	O
LV	O
not	O
dilated	O
or	O
hypertrophic	O
,	O
with	O
preserved	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O
Sclerocalcified	O
aortic	O
valve	O
without	O
functional	O
alterations	O
.	O
Sclerosed	O
mitral	O
valve	O
with	O
mild	O
regurgitation	O
.	O
Left	O
atrium	O
LA	O
slightly	O
dilated	O
.	O
Right	O
ventricle	O
RV	O
not	O
dilated	O
with	O
good	O
function	O
.	O
Tricuspid	O
insufficiency	O
TI	O
was	O
not	O
detected	O
.	O
The	O
pulmonary	O
acceleration	O
curve	O
does	O
not	O
suggest	O
significant	O
pulmonary	O
hypertension	O
.	O
IVC	O
not	O
dilated	O
.	O
No	O
pericardial	O
effusion	O
.	O
Emergency	O
ECG	O
common	O
atrial	O
flutter	O
with	O
ventricular	O
response	O
at	O
150	O
bpm	O
.	O
Chest	O
X	O
ray	O
enlarged	O
cardiac	O
silhouette	O
.	O
No	O
costophrenic	O
sinus	O
impingement	O
or	O
other	O
signs	O
of	O
heart	O
failure	O
.	O
CLINICAL	O
COURSE	O
After	O
a	O
first	O
episode	O
of	O
atrial	O
flutter	O
,	O
the	O
patient	O
met	O
the	O
criteria	O
for	O
anticoagulant	O
treatment	O
CHA2DS2VASc	O
3	O
due	O
to	O
age	O
75	O
and	O
hypertension	O
,	O
so	O
treatment	O
was	O
started	O
with	O
rivaroxaban	B-FARMACO
15	O
mg	O
,	O
1	O
tablet	O
per	O
day	O
,	O
and	O
low	O
dose	O
beta	O
blockers	O
bisoprolol	B-FARMACO
1	O
.	O
25	O
mg	O
,	O
1	O
tablet	O
per	O
day	O
.	O
One	O
month	O
later	O
,	O
he	O
presented	O
a	O
new	O
episode	O
of	O
palpitations	O
together	O
with	O
dyspnoea	O
on	O
exertion	O
and	O
went	O
to	O
the	O
emergency	O
department	O
.	O
This	O
time	O
the	O
ECG	O
showed	O
atrial	O
fibrillation	O
AF	O
with	O
rapid	O
ventricular	O
response	O
.	O
It	O
was	O
decided	O
to	O
apply	O
a	O
rate	O
control	O
strategy	O
by	O
administering	O
digoxin	B-FARMACO
and	O
a	O
higher	O
dose	O
of	O
beta	O
blocker	O
bisoprolol	B-FARMACO
5	O
mg	O
.	O
Once	O
the	O
heart	O
rate	O
had	O
been	O
controlled	O
and	O
there	O
were	O
no	O
congestive	O
symptoms	O
,	O
the	O
patient	O
was	O
discharged	O
with	O
an	O
earlier	O
cardio	O
oncohaematology	O
appointment	O
.	O
The	O
patient	O
was	O
assessed	O
one	O
week	O
later	O
in	O
the	O
consultation	O
room	O
,	O
where	O
an	O
ECG	O
was	O
performed	O
showing	O
sinus	O
rhythm	O
,	O
so	O
flecainide	B-FARMACO
was	O
started	O
at	O
low	O
doses	O
50	O
mg	O
at	O
breakfast	O
and	O
50	O
mg	O
at	O
dinner	O
and	O
beta	O
blocker	O
treatment	O
was	O
maintained	O
reducing	O
the	O
bisoprolol	B-FARMACO
dose	O
to	O
2	O
.	O
5	O
mg	O
.	O
Despite	O
this	O
treatment	O
,	O
the	O
patient	O
returned	O
to	O
the	O
clinic	O
20	O
days	O
later	O
with	O
palpitations	O
of	O
one	O
week	O
's	O
duration	O
,	O
dyspnoea	O
on	O
medium	O
exertion	O
and	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
The	O
ECG	O
showed	O
HF	O
atrial	O
flutter	O
with	O
ventricular	O
response	O
at	O
170	O
bpm	O
,	O
and	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
cardiology	O
ward	O
.	O
During	O
admission	O
,	O
treatment	O
with	O
flecainide	B-FARMACO
was	O
suspended	O
and	O
a	O
heart	O
rate	O
control	O
strategy	O
was	O
initiated	O
with	O
high	O
dose	O
beta	O
blockers	O
bisoprolol	B-FARMACO
10	O
mg	O
per	O
day	O
and	O
digoxin	B-FARMACO
,	O
spontaneously	O
reverting	O
to	O
sinus	O
rhythm	O
.	O
Diuretic	O
treatment	O
was	O
also	O
started	O
,	O
with	O
a	O
good	O
response	O
and	O
disappearance	O
of	O
the	O
congestive	O
signs	O
,	O
and	O
the	O
patient	O
was	O
discharged	O
a	O
week	O
later	O
.	O
DIAGNOSIS	O
AF	O
paroxysmal	O
atrial	O
flutter	O
in	O
the	O
context	O
of	O
ibrutinib	B-FARMACO
.	O
Episode	O
of	O
HF	O
atrial	O
flutter	O
after	O
taking	O
flecainide	B-FARMACO
.	O
Preserved	O
biventricular	O
function	O
.	O
Lymphocytic	O
lymphoma	O
in	O
treatment	O
with	O
ibrutinib	B-FARMACO
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
Arterial	O
hypertension	O
.	O
Dyslipidaemia	O
.	O
No	O
known	O
diabetes	O
mellitus	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
.	O
Acute	O
myocardial	O
infarction	O
with	O
ST	O
segment	O
elevation	O
STEMI	O
evolved	O
in	O
December	O
2016	O
.	O
Due	O
to	O
refractory	O
angina	O
,	O
scheduled	O
percutaneous	O
angioplasty	O
was	O
performed	O
with	O
implantation	O
of	O
a	O
stent	O
covered	O
by	O
a	O
thrombotic	O
occlusion	O
of	O
the	O
proximal	O
right	O
coronary	O
artery	O
.	O
Chronic	O
under	O
occlusion	O
of	O
untreated	O
first	O
obtuse	O
marginal	O
fine	O
calibre	O
vessel	O
.	O
Echocardiography	O
at	O
discharge	O
showed	O
a	O
slightly	O
dilated	O
left	O
ventricle	O
LV	O
with	O
mild	O
concentric	O
hypertrophy	O
and	O
a	O
large	O
area	O
of	O
akinesia	O
dyskinesia	O
in	O
inferior	O
and	O
inferolateral	O
segments	O
with	O
an	O
image	O
of	O
a	O
large	O
pseudoaneurysm	O
and	O
abundant	O
thrombotic	O
material	O
lining	O
the	O
walls	O
of	O
the	O
pseudoaneurysm	O
.	O
Normal	O
contractility	O
of	O
the	O
rest	O
and	O
moderately	O
depressed	O
residual	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
40	O
.	O
Discharged	O
with	O
triple	O
therapy	O
with	O
acenocoumarol	B-FARMACO
,	O
without	O
resolution	O
of	O
the	O
intracavitary	O
thrombus	O
on	O
echocardiography	O
6	O
months	O
after	O
discharge	O
.	O
Other	O
pathologies	O
stage	O
3B	O
chronic	O
kidney	O
disease	O
.	O
Fontaine	O
grade	O
IIb	O
peripheral	O
arterial	O
disease	O
.	O
Alzheimer	O
's	O
type	O
dementia	O
.	O
Current	O
treatment	O
acenocoumarol	B-FARMACO
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
24	O
hours	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
24	O
hours	O
,	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
hours	O
,	O
furosemide	B-FARMACO
40	O
mg	O
24	O
hours	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
24	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
24	O
hours	O
.	O
Functional	O
status	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
II	O
.	O
Moderate	O
cognitive	O
impairment	O
.	O
Bed	O
chair	O
life	O
.	O
Family	O
history	O
brother	O
with	O
acute	O
myocardial	O
infarction	O
AMI	O
at	O
51	O
years	O
of	O
age	O
.	O
CURRENT	O
ILLNESS	O
Patient	O
attended	O
for	O
a	O
check	O
up	O
of	O
his	O
ischaemic	O
heart	O
disease	O
.	O
No	O
recurrence	O
of	O
angina	O
,	O
although	O
her	O
physical	O
activity	O
is	O
very	O
limited	O
,	O
she	O
only	O
reports	O
dyspnoea	O
with	O
postural	O
changes	O
.	O
No	O
relevant	O
bleeding	O
under	O
triple	O
therapy	O
,	O
she	O
discontinued	O
clopidogrel	B-FARMACO
one	O
year	O
after	O
starting	O
it	O
.	O
PHYSICAL	O
EXAMINATION	O
Weight	O
78	O
.	O
0	O
kg	O
.	O
Height	O
165	O
cm	O
.	O
Blood	O
pressure	O
BP	O
98	O
56	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
67	O
bpm	O
.	O
Oxygen	O
saturation	O
SatO2	O
96	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
VCM	O
without	O
pathological	O
additions	O
.	O
Abdomen	O
was	O
nondescript	O
.	O
Lower	O
extremities	O
without	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Normal	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
Recent	O
ANALYTICS	O
glucose	O
108	O
mg	O
dl	O
,	O
urea	O
32	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
45	O
mg	O
dl	O
,	O
bilirubin	O
0	O
.	O
7	O
.	O
GOT	O
21	O
.	O
0	O
.	O
GPT	O
28	O
.	O
0	O
g	O
dl	O
.	O
Total	O
cholesterol	O
155	O
mg	O
dl	O
,	O
triglycerides	O
123	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
43	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
98	O
mg	O
dl	O
.	O
Sodium	O
141	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
6	O
mEq	O
l	O
.	O
Haemoglobin	O
15	O
.	O
4	O
g	O
dl	O
,	O
haematocrit	O
44	O
.	O
5	O
,	O
MCV	O
84	O
.	O
3	O
fl	O
,	O
platelets	O
237	O
.	O
0	O
10e3	O
ul	O
,	O
leucocytes	O
6	O
.	O
73	O
10e3	O
ul	O
,	O
HbA1c	O
5	O
.	O
6	O
.	O
ELECTROCARDIOGRAM	O
ECG	O
performed	O
in	O
consultations	O
sinus	O
rhythm	O
at	O
66	O
bpm	O
,	O
PR	O
200	O
ms	O
,	O
QRS	O
110	O
ms	O
,	O
QRS	O
110	O
ms	O
,	O
Q	O
wave	O
in	O
inferior	O
derivations	O
with	O
ST	O
supradelevation	O
of	O
up	O
to	O
1	O
.	O
5	O
mm	O
and	O
negative	O
inferolateral	O
T	O
wave	O
.	O
Recent	O
echocardiography	O
inferior	O
basal	O
and	O
posterior	O
basal	O
dyskinesia	O
,	O
akinesia	O
of	O
mid	O
posterior	O
septum	O
.	O
Hypokinesia	O
of	O
the	O
medial	O
lateral	O
face	O
.	O
The	O
described	O
dyskinetic	O
areas	O
present	O
an	O
image	O
of	O
a	O
large	O
pseudoaneurysm	O
with	O
an	O
image	O
of	O
thrombotic	O
material	O
inside	O
.	O
Normal	O
contractility	O
of	O
the	O
rest	O
and	O
moderately	O
depressed	O
residual	O
LVEF	O
that	O
is	O
not	O
quantified	O
by	O
the	O
presence	O
of	O
aneurysm	O
,	O
visually	O
estimated	O
at	O
35	O
40	O
.	O
Slight	O
valvular	O
degenerative	O
signs	O
,	O
with	O
preserved	O
opening	O
.	O
Left	O
atrial	O
dilatation	O
.	O
Slight	O
pericardial	O
effusion	O
in	O
the	O
area	O
adjacent	O
to	O
the	O
posterior	O
face	O
,	O
with	O
no	O
evidence	O
of	O
haemodynamic	O
compromise	O
.	O
Inferior	O
vena	O
cava	O
and	O
suprahepatic	O
vein	O
not	O
dilated	O
,	O
with	O
adequate	O
inspiratory	O
collapse	O
,	O
which	O
excludes	O
the	O
presence	O
of	O
significant	O
systemic	O
venous	O
hypertension	O
.	O
CARDIAC	O
MAGNETIC	O
RESONANCE	O
a	O
saccular	O
image	O
of	O
approximately	O
4	O
.	O
8	O
x	O
4	O
.	O
4	O
cm	O
communicating	O
directly	O
with	O
the	O
left	O
ventricular	O
cavity	O
,	O
showing	O
an	O
abrupt	O
change	O
in	O
the	O
contour	O
of	O
the	O
LV	O
wall	O
,	O
inferior	O
and	O
inferolateral	O
basal	O
location	O
compatible	O
with	O
LV	O
pseudoaneurysm	O
.	O
It	O
shows	O
a	O
wide	O
neck	O
of	O
3	O
.	O
6	O
cm	O
.	O
In	O
the	O
gradient	O
echo	O
sequence	O
with	O
long	O
TI	O
550	O
ms	O
after	O
administration	O
of	O
IV	O
contrast	O
,	O
a	O
hypointense	O
image	O
with	O
crescent	O
morphology	O
is	O
seen	O
in	O
its	O
interior	O
,	O
approximately	O
13	O
mm	O
in	O
maximum	O
thickness	O
,	O
compatible	O
with	O
thrombus	O
.	O
Late	O
enhancement	O
sequences	O
do	O
not	O
show	O
hyperintense	O
areas	O
suggestive	O
of	O
necrotic	O
myocardial	O
wall	O
forming	O
tissue	O
.	O
Moderate	O
severe	O
LV	O
dysfunction	O
LVEF	O
35	O
.	O
Mild	O
aortic	O
and	O
mitral	O
regurgitation	O
.	O
CLINICAL	O
EVOLUTION	O
Given	O
the	O
morphological	O
findings	O
described	O
in	O
the	O
complementary	O
tests	O
,	O
the	O
possibility	O
of	O
surgical	O
intervention	O
of	O
the	O
pseudoaneurysm	O
was	O
considered	O
.	O
This	O
option	O
was	O
finally	O
rejected	O
in	O
consensus	O
with	O
the	O
patient	O
,	O
given	O
the	O
high	O
comorbidity	O
and	O
clinical	O
stability	O
since	O
discharge	O
no	O
episodes	O
of	O
decompensation	O
due	O
to	O
heart	O
failure	O
,	O
ventricular	O
arrhythmias	O
or	O
recurrence	O
of	O
angina	O
.	O
Instead	O
,	O
a	O
strategy	O
of	O
clinical	O
follow	O
up	O
and	O
periodic	O
imaging	O
techniques	O
was	O
proposed	O
to	O
assess	O
signs	O
of	O
progression	O
or	O
alarm	O
.	O
In	O
this	O
regard	O
,	O
during	O
follow	O
up	O
,	O
the	O
absence	O
of	O
resolution	O
of	O
the	O
intraventricular	O
thrombus	O
was	O
confirmed	O
under	O
adequate	O
anticoagulant	O
therapy	O
time	O
in	O
INR	O
2	O
3	O
range	O
60	O
.	O
Therefore	O
,	O
considering	O
the	O
low	O
risk	O
of	O
embolisation	O
given	O
its	O
morphological	O
characteristics	O
and	O
the	O
patient	O
's	O
high	O
risk	O
of	O
bleeding	O
,	O
anticoagulant	O
treatment	O
was	O
definitively	O
withdrawn	O
.	O
Finally	O
,	O
ezetimibe	B-FARMACO
10	O
mg	O
24	O
hours	O
was	O
added	O
to	O
the	O
treatment	O
to	O
try	O
to	O
achieve	O
target	O
LDL	O
cholesterol	O
concentrations	O
70	O
mg	O
dl	O
.	O
DIAGNOSIS	O
Chronic	O
ischaemic	O
heart	O
disease	O
.	O
Advanced	O
inferior	O
STEACS	O
.	O
Revascularisation	O
with	O
drug	O
eluting	O
stent	O
to	O
proximal	O
right	O
coronary	O
artery	O
.	O
Left	O
ventricular	O
pseudoaneurysm	O
with	O
intracavitary	O
thrombus	O
image	O
.	O
Moderate	O
ventricular	O
dysfunction	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
Patient	O
aged	O
44	O
years	O
,	O
with	O
no	O
drug	O
allergies	O
or	O
medical	O
history	O
of	O
interest	O
.	O
No	O
consumption	O
of	O
toxic	O
substances	O
.	O
No	O
history	O
of	O
early	O
ischaemic	O
heart	O
disease	O
or	O
sudden	O
death	O
in	O
first	O
degree	O
relatives	O
.	O
CURRENT	O
ILLNESS	O
The	O
patient	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
retrosternal	O
pain	O
associated	O
with	O
vomiting	O
of	O
food	O
,	O
followed	O
by	O
presyncopal	O
symptoms	O
.	O
An	O
electrocardiogram	O
ECG	O
was	O
performed	O
and	O
showed	O
ST	O
segment	O
elevation	O
in	O
the	O
anterior	O
face	O
,	O
so	O
after	O
administration	O
of	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
300	O
mg	O
and	O
ticagrelor	B-FARMACO
180	O
mg	O
as	O
a	O
loading	O
dose	O
of	O
double	O
antiplatelet	O
therapy	O
,	O
the	O
infarction	O
code	O
was	O
activated	O
for	O
urgent	O
coronary	O
angiography	O
.	O
This	O
could	O
not	O
be	O
performed	O
due	O
to	O
the	O
impossibility	O
of	O
channelling	O
a	O
peripheral	O
arterial	O
access	O
chronic	O
occlusion	O
of	O
both	O
radial	O
arteries	O
and	O
both	O
iliac	O
arteries	O
so	O
,	O
given	O
the	O
impossibility	O
of	O
percutaneous	O
intervention	O
,	O
fibrinolysis	O
was	O
performed	O
with	O
tenecteplase	B-FARMACO
6000	O
U	O
iv	O
.	O
The	O
patient	O
showed	O
no	O
electrocardiographic	O
evidence	O
of	O
reperfusion	O
after	O
fibrinolysis	O
,	O
although	O
she	O
remained	O
asymptomatic	O
.	O
Her	O
blood	O
pressure	O
remained	O
low	O
on	O
non	O
invasive	O
and	O
peripheral	O
monitoring	O
during	O
her	O
admission	O
.	O
Echocardiogram	O
showed	O
left	O
ventricular	O
dysfunction	O
LVEF	O
27	O
with	O
akinesia	O
of	O
all	O
apical	O
segments	O
and	O
severe	O
hypokinesia	O
of	O
basal	O
and	O
mid	O
anterior	O
and	O
basal	O
and	O
mid	O
anteroseptal	O
segments	O
.	O
After	O
performing	O
angio	O
CT	O
and	O
locating	O
the	O
level	O
of	O
vascular	O
occlusions	O
,	O
vascular	O
access	O
to	O
the	O
right	O
brachycephalic	O
trunk	O
was	O
finally	O
achieved	O
by	O
means	O
of	O
interventional	O
radiology	O
.	O
Coronary	O
angiography	O
showed	O
severe	O
stenosis	O
at	O
the	O
proximal	O
medial	O
level	O
of	O
the	O
anterior	O
descending	O
artery	O
,	O
where	O
a	O
drug	O
eluting	O
stent	O
was	O
implanted	O
.	O
Given	O
the	O
case	O
of	O
a	O
young	O
patient	O
with	O
no	O
cardiovascular	O
risk	O
factors	O
and	O
multiple	O
occlusions	O
of	O
arterial	O
trunks	O
,	O
a	O
large	O
vessel	O
vasculitis	O
possibly	O
Takayasu	O
's	O
disease	O
was	O
suspected	O
and	O
treatment	O
was	O
started	O
with	O
methylprednisone	B-FARMACO
60	O
mg	O
24	O
hours	O
and	O
cyclophosphamide	B-FARMACO
120	O
mg	O
24	O
hours	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
right	O
arm	O
75	O
45	O
mmHg	O
;	O
blood	O
pressure	O
left	O
arm	O
92	O
57	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
80	O
bpm	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
with	O
systolic	O
murmur	O
II	O
VI	O
in	O
mitral	O
focus	O
.	O
A	O
murmur	O
was	O
also	O
heard	O
at	O
the	O
level	O
of	O
the	O
right	O
subclavian	O
artery	O
.	O
Lower	O
extremities	O
no	O
oedema	O
.	O
No	O
palpation	O
of	O
the	O
pedial	O
or	O
tibial	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
SELF	O
IMMUNITY	O
STUDY	O
ESR	O
88	O
mm	O
;	O
C	O
reactive	O
protein	O
14	O
.	O
1	O
mg	O
dl	O
.	O
ANAs	O
,	O
ENAs	O
,	O
antiDNA	O
,	O
rheumatoid	O
factor	O
,	O
anticardiolipin	O
,	O
lupus	O
anticoagulant	O
,	O
ANCAs	O
negative	O
.	O
The	O
main	O
serologies	O
were	O
also	O
negative	O
.	O
MARKERS	O
OF	O
MYOCARDIAL	O
DAMAGE	O
peak	O
troponin	O
T	O
HS	O
peak	O
10	O
,	O
000	O
ng	O
l	O
.	O
CK	O
8294	O
U	O
l	O
;	O
CKMB	O
1261	O
U	O
l	O
.	O
ECG	O
on	O
admission	O
RS	O
at	O
90	O
.	O
ST	O
elevation	O
6	O
7	O
mm	O
in	O
V2	O
V6	O
,	O
I	O
and	O
aVL	O
.	O
ST	O
segment	O
depression	O
in	O
inferior	O
face	O
ECG	O
at	O
discharge	O
RS	O
at	O
70	O
bpm	O
.	O
Q	O
wave	O
in	O
V1	O
V3	O
,	O
I	O
and	O
aVL	O
.	O
Negative	O
T	O
wave	O
in	O
V2	O
V6	O
,	O
I	O
and	O
aVL	O
.	O
Echocardiogram	O
at	O
discharge	O
moderate	O
depression	O
of	O
ejection	O
fraction	O
LVEF	O
41	O
due	O
to	O
anterior	O
and	O
mid	O
septal	O
aneurysm	O
and	O
all	O
apical	O
segments	O
with	O
restrictive	O
filling	O
pattern	O
and	O
high	O
diastolic	O
pressures	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
ANGIO	O
CT	O
of	O
the	O
aorta	O
and	O
supra	O
aortic	O
trunks	O
70	O
stenosis	O
of	O
the	O
right	O
brachiocephalic	O
trunk	O
.	O
Stenosis	O
of	O
the	O
right	O
subclavian	O
artery	O
in	O
its	O
proximal	O
section	O
in	O
90	O
.	O
Anatomical	O
variant	O
with	O
a	O
left	O
common	O
trunk	O
that	O
is	O
100	O
obstructed	O
in	O
the	O
initial	O
2	O
.	O
5	O
mm	O
long	O
section	O
.	O
Atheromatosis	O
in	O
the	O
aortic	O
arch	O
and	O
descending	O
thoracic	O
artery	O
.	O
Complete	O
obstruction	O
of	O
the	O
vascular	O
lumen	O
in	O
the	O
infrarenal	O
abdominal	O
aorta	O
proximal	O
to	O
the	O
renal	O
arteries	O
and	O
recanalisation	O
in	O
the	O
primitive	O
iliac	O
arteries	O
.	O
CORONARYGRAPHY	O
severe	O
stenosis	O
in	O
the	O
middle	O
anterior	O
descending	O
artery	O
in	O
bifurcation	O
with	O
diagonal	O
branch	O
.	O
There	O
is	O
also	O
diffuse	O
atheromatosis	O
at	O
mid	O
and	O
distal	O
level	O
with	O
moderate	O
plaque	O
at	O
that	O
level	O
.	O
Right	O
coronary	O
artery	O
and	O
circumflex	O
without	O
lesions	O
.	O
CLINICAL	O
EVOLUTION	O
She	O
was	O
discharged	O
in	O
good	O
functional	O
class	O
with	O
moderately	O
depressed	O
systolic	O
dysfunction	O
LVEF	O
41	O
at	O
the	O
expense	O
of	O
apical	O
segments	O
.	O
DIAGNOSIS	O
Acute	O
myocardial	O
infarction	O
AMI	O
Q	O
anterior	O
.	O
Takayasu	O
's	O
disease	O
.	O

A	O
26	O
year	O
old	O
female	O
patient	O
,	O
with	O
no	O
relevant	O
past	O
history	O
,	O
was	O
admitted	O
to	O
the	O
hospital	O
from	O
another	O
institution	O
with	O
a	O
fever	O
of	O
39	O
C	O
,	O
arterial	O
hypotension	O
refractory	O
to	O
volume	O
resuscitation	O
,	O
cutaneous	O
hyperaesthesia	O
.	O
The	O
condition	O
had	O
been	O
interpreted	O
as	O
toxic	O
shock	O
,	O
and	O
she	O
was	O
blood	O
cultured	O
and	O
antibiotic	O
treatment	O
was	O
started	O
prior	O
to	O
referral	O
.	O
On	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
of	O
our	O
hospital	O
,	O
the	O
patient	O
was	O
confused	O
,	O
tachycardic	O
120	O
min	O
,	O
hypotensive	O
70	O
40	O
mmHg	O
and	O
afebrile	O
.	O
She	O
had	O
painful	O
purpuric	O
lesions	O
on	O
the	O
palms	O
,	O
soles	O
,	O
subungual	O
and	O
periungual	O
region	O
,	O
and	O
on	O
the	O
palpebral	O
conjunctiva	O
,	O
compatible	O
with	O
peripheral	O
embolisms	O
.	O
No	O
heart	O
murmurs	O
were	O
heard	O
.	O
There	O
were	O
no	O
other	O
alterations	O
on	O
physical	O
examination	O
.	O
Laboratory	O
tests	O
on	O
admission	O
showed	O
plateletopenia	O
39	O
,	O
000	O
mm3	O
,	O
4500	O
leukocytes	O
mm3	O
,	O
low	O
prothrombin	O
time	O
58	O
and	O
parameters	O
of	O
Acute	O
Renal	O
Failure	O
elevated	O
creatininemia	O
.	O
Urine	O
sediment	O
showed	O
albuminuria	O
,	O
microscopic	O
haematuria	O
and	O
granular	O
casts	O
.	O
The	O
rest	O
of	O
the	O
analyses	O
were	O
within	O
normal	O
parameters	O
haematocrit	O
,	O
hepatogram	O
,	O
HIV	O
negative	O
,	O
b	O
subunit	O
negative	O
.	O
The	O
fundus	O
examination	O
was	O
normal	O
.	O
Chest	O
X	O
ray	O
showed	O
cardiomegaly	O
and	O
bilateral	O
interstitial	O
alveolar	O
infiltrate	O
.	O
The	O
picture	O
was	O
interpreted	O
as	O
septic	O
shock	O
,	O
blood	O
cultures	O
were	O
performed	O
under	O
antibiotics	O
because	O
he	O
had	O
received	O
1	O
dose	O
of	O
cefotaxime	B-FARMACO
clindamycin	I-FARMACO
amikacin	I-FARMACO
and	O
treatment	O
was	O
started	O
with	O
cefotaxime	B-FARMACO
clindamycin	I-FARMACO
gentamicin	I-FARMACO
,	O
after	O
consultation	O
with	O
Infectious	O
Diseases	O
.	O
On	O
the	O
second	O
day	O
of	O
hospitalisation	O
,	O
the	O
patient	O
persisted	O
with	O
signs	O
of	O
heart	O
failure	O
on	O
chest	O
X	O
ray	O
,	O
adding	O
bilateral	O
infiltrates	O
of	O
the	O
pulmonary	O
oedema	O
type	O
and	O
compatible	O
semiology	O
,	O
for	O
which	O
a	O
referral	O
to	O
the	O
cardiology	O
department	O
was	O
requested	O
to	O
perform	O
a	O
transthoracic	O
echocardiogram	O
where	O
vegetation	O
was	O
observed	O
in	O
the	O
mitral	O
valve	O
with	O
moderate	O
mitral	O
regurgitation	O
and	O
moderate	O
left	O
ventricular	O
dysfunction	O
.	O
A	O
diagnosis	O
of	O
infective	O
endocarditis	O
was	O
made	O
24	O
hours	O
after	O
the	O
patient	O
's	O
admission	O
.	O
Treatment	O
with	O
clindamycin	B-FARMACO
was	O
discontinued	O
.	O
During	O
her	O
evolution	O
,	O
the	O
patient	O
's	O
haemodynamics	O
worsened	O
,	O
requiring	O
inotropic	O
drugs	O
and	O
her	O
respiratory	O
mechanics	O
required	O
non	O
invasive	O
ventilation	O
.	O
After	O
several	O
days	O
of	O
antibiotic	O
treatment	O
she	O
continued	O
with	O
febrile	O
registers	O
.	O
A	O
transesophageal	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
an	O
image	O
compatible	O
with	O
mitral	O
annulus	O
abscess	O
.	O
Due	O
to	O
the	O
patient	O
's	O
haemodynamic	O
instability	O
,	O
the	O
cardiovascular	O
surgery	O
department	O
decided	O
not	O
to	O
perform	O
surgery	O
at	O
that	O
time	O
.	O
Four	O
days	O
after	O
admission	O
,	O
the	O
first	O
blood	O
cultures	O
obtained	O
were	O
positive	O
for	O
Staphylococcus	O
aureus	O
,	O
aminoglycosides	B-FARMACO
were	O
discontinued	O
and	O
Vancomycin	B-FARMACO
was	O
indicated	O
.	O
The	O
patient	O
's	O
haemodynamic	O
and	O
laboratory	O
parameters	O
improved	O
,	O
her	O
renal	O
insufficiency	O
was	O
reversed	O
,	O
the	O
skin	O
lesions	O
disappeared	O
,	O
and	O
after	O
16	O
days	O
she	O
was	O
allowed	O
to	O
be	O
transferred	O
to	O
Buenos	O
Aires	O
to	O
continue	O
antibiotic	O
treatment	O
and	O
plan	O
the	O
surgical	O
strategy	O
.	O

A	O
38	O
year	O
old	O
male	O
presented	O
to	O
the	O
Emergency	O
Department	O
for	O
dyspnoea	O
.	O
HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
No	O
family	O
history	O
of	O
interest	O
,	O
no	O
known	O
allergies	O
.	O
Smoker	O
of	O
10	O
cigarettes	O
day	O
,	O
occasional	O
weekend	O
drinker	O
and	O
sporadic	O
ex	O
consumer	O
of	O
cocaine	O
and	O
marijuana	O
.	O
Does	O
not	O
take	O
regular	O
treatment	O
.	O
Patient	O
with	O
an	O
active	O
life	O
,	O
asymptomatic	O
from	O
the	O
cardiological	O
point	O
of	O
view	O
until	O
two	O
months	O
prior	O
to	O
admission	O
,	O
who	O
began	O
with	O
progressive	O
deterioration	O
of	O
functional	O
class	O
with	O
dyspnoea	O
on	O
moderate	O
exertion	O
until	O
becoming	O
resting	O
.	O
For	O
this	O
reason	O
,	O
he	O
came	O
to	O
the	O
hospital	O
one	O
week	O
prior	O
to	O
admission	O
,	O
with	O
a	O
predominantly	O
nocturnal	O
cough	O
and	O
intermittent	O
mild	O
pain	O
in	O
the	O
anterior	O
chest	O
region	O
,	O
and	O
was	O
diagnosed	O
with	O
a	O
possible	O
respiratory	O
tract	O
infection	O
.	O
Antibiotic	O
and	O
corticoid	O
treatment	O
was	O
prescribed	O
.	O
Since	O
then	O
,	O
clinical	O
worsening	O
with	O
paroxysmal	O
nocturnal	O
dyspnoea	O
,	O
orthopnoea	O
of	O
up	O
to	O
two	O
pillows	O
associated	O
with	O
oedema	O
up	O
to	O
2	O
3	O
in	O
the	O
lower	O
limbs	O
and	O
weight	O
gain	O
in	O
the	O
last	O
week	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
BP	O
110	O
60	O
.	O
HR	O
120	O
bpm	O
.	O
Basal	O
SatO2	O
97	O
.	O
Weight	O
74	O
kg	O
.	O
Good	O
general	O
condition	O
well	O
hydrated	O
,	O
well	O
nourished	O
and	O
perfused	O
,	O
normal	O
colour	O
.	O
Neck	O
no	O
palpable	O
lymph	O
nodes	O
or	O
evidence	O
of	O
jugular	O
engorgement	O
.	O
Cardiac	O
auscultation	O
gallop	O
rhythm	O
by	O
R3	O
.	O
Pulmonary	O
auscultation	O
bibasal	O
crackles	O
in	O
the	O
lower	O
third	O
of	O
both	O
lung	O
fields	O
.	O
Abdomen	O
RHA	O
,	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
deep	O
or	O
superficial	O
palpation	O
.	O
Lower	O
limbs	O
oedema	O
up	O
to	O
the	O
lower	O
third	O
of	O
both	O
lower	O
limbs	O
without	O
fovea	O
,	O
peripheral	O
pulses	O
.	O
No	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Complementary	O
tests	O
on	O
admission	O
ECG	O
sinus	O
tachycardia	O
at	O
120	O
bpm	O
.	O
Narrow	O
QRS	O
with	O
unspecific	O
repolarisation	O
alterations	O
negative	O
T	O
waves	O
in	O
I	O
,	O
aVL	O
and	O
from	O
V4	O
to	O
V6	O
.	O
Haemogram	O
leucocytes	O
8	O
,	O
000	O
.	O
Hb	O
14	O
.	O
7	O
g	O
dl	O
.	O
Platelets	O
217	O
,	O
000	O
ul	O
.	O
Haemostasis	O
APTT	O
31	O
.	O
3	O
.	O
PT	O
12	O
.	O
8	O
.	O
INR	O
1	O
.	O
11	O
.	O
Biochemistry	O
glucose	O
121	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
9	O
mg	O
dl	O
.	O
Albumin	O
3	O
.	O
6	O
g	O
dl	O
.	O
Calcium	O
8	O
.	O
6	O
mg	O
dl	O
.	O
GOT	O
29	O
U	O
l	O
.	O
GPT	O
50	O
U	O
l	O
.	O
CK	O
111	O
.	O
Troponin	O
0	O
.	O
09	O
ng	O
ml	O
.	O
Bilirubin	O
0	O
,	O
4	O
mg	O
dl	O
.	O
Amylase	O
44	O
.	O
Lipase	O
37	O
.	O
Na	O
144	O
.	O
K	O
4	O
,	O
2	O
mmol	O
l	O
.	O
Chlorine	O
109	O
mmol	O
l	O
.	O
GOT	O
20	O
U	O
I	O
GPT	O
32	O
U	O
I	O
GGT	O
117U	O
I	O
4	O
.	O
BNP	O
405	O
pg	O
ml	O
.	O
Arterial	O
blood	O
gases	O
pH	O
7	O
.	O
49	O
,	O
pCO2	O
27	O
mmHg	O
,	O
pO2	O
89	O
mmHg	O
,	O
HCO3	O
20	O
mmol	O
l	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
.	O
No	O
parenchymal	O
infiltrates	O
.	O
Vascular	O
redistribution	O
with	O
evidence	O
of	O
CHF	O
.	O
Portable	O
echocardiogram	O
Vscan	O
dilated	O
LV	O
with	O
severe	O
global	O
systolic	O
dysfunction	O
with	O
generalised	O
hypokinesia	O
and	O
RV	O
systolic	O
dysfunction	O
.	O
Moderate	O
MI	O
.	O
Severe	O
TR	O
.	O
No	O
pericardial	O
effusion	O
.	O
In	O
view	O
of	O
the	O
findings	O
,	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
the	O
ward	O
for	O
treatment	O
and	O
to	O
complete	O
the	O
study	O
.	O
Complementary	O
tests	O
on	O
the	O
ward	O
ECG	O
dilatation	O
and	O
severe	O
LV	O
dysfunction	O
with	O
LVEF	O
around	O
15	O
.	O
Restrictive	O
filling	O
with	O
mild	O
MI	O
.	O
Dilatation	O
and	O
dysfunction	O
of	O
the	O
RV	O
with	O
PSAP	O
around	O
55	O
mmHg	O
.	O
Biochemistry	O
TSH	O
2	O
.	O
28	O
.	O
CRP	O
3	O
.	O
4	O
.	O
Ferritin	O
59	O
ng	O
ml	O
.	O
Vitamin	O
B12	O
464	O
ng	O
dl	O
A	O
.	O
Folic	O
5	O
.	O
HDL	O
32	O
mg	O
dl	O
.	O
LDL	O
99	O
.	O
4	O
mg	O
dl	O
.	O
Serology	O
anti	O
HIV	O
1	O
2	O
.	O
IgM	O
anti	O
CMV	O
.	O
EBV	O
IgG	O
.	O
Toxoplasma	O
IgG	O
.	O
IgG	O
antiHBc	O
.	O
HCV	O
.	O
Catheterisation	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O
Chest	O
X	O
ray	O
at	O
discharge	O
cardiomegaly	O
with	O
no	O
evidence	O
of	O
pulmonary	O
congestion	O
.	O
Walking	O
test	O
prior	O
to	O
discharge	O
6	O
minute	O
test	O
was	O
performed	O
,	O
covering	O
426	O
metres	O
,	O
finishing	O
at	O
100	O
110	O
bpm	O
and	O
with	O
a	O
baseline	O
saturation	O
of	O
95	O
.	O
Cardiac	O
MRI	O
prior	O
to	O
discharge	O
dilated	O
cardiomyopathy	O
with	O
severe	O
LV	O
and	O
mild	O
RV	O
dysfunction	O
.	O
Mild	O
MI	O
and	O
TR	O
.	O
No	O
evidence	O
of	O
myocardial	O
fibrosis	O
.	O
EVOLUTION	O
Treatment	O
with	O
beta	O
blockers	O
,	O
antialdosterone	O
and	O
ACE	O
inhibitors	O
was	O
started	O
on	O
the	O
hospital	O
ward	O
,	O
and	O
the	O
latter	O
had	O
to	O
be	O
discontinued	O
due	O
to	O
symptomatic	O
arterial	O
hypotension	O
of	O
up	O
to	O
85	O
40	O
mmHg	O
.	O
During	O
the	O
first	O
days	O
of	O
admission	O
he	O
required	O
inotropic	O
support	O
with	O
levosimendan	B-FARMACO
and	O
intravenous	O
depletive	O
treatment	O
with	O
diuretics	O
,	O
losing	O
approximately	O
8	O
kg	O
of	O
weight	O
since	O
admission	O
.	O
He	O
was	O
monitored	O
with	O
telemetry	O
during	O
admission	O
and	O
only	O
isolated	O
ventricular	O
extrasystoles	O
were	O
observed	O
.	O
A	O
regular	O
echocardiogram	O
confirmed	O
the	O
presence	O
of	O
dilated	O
cardiomyopathy	O
with	O
severe	O
LV	O
dysfunction	O
,	O
with	O
no	O
significant	O
valvulopathy	O
to	O
justify	O
it	O
.	O
In	O
order	O
to	O
rule	O
out	O
coronary	O
artery	O
disease	O
,	O
coronary	O
angiography	O
was	O
performed	O
,	O
ruling	O
out	O
coronary	O
artery	O
disease	O
.	O
Due	O
to	O
a	O
tendency	O
to	O
sinus	O
tachycardia	O
with	O
BP	O
figures	O
of	O
90	O
100	O
50	O
60	O
that	O
prevented	O
an	O
increase	O
in	O
the	O
dose	O
of	O
beta	O
blockers	O
,	O
it	O
was	O
decided	O
to	O
associate	O
ivabradine	B-FARMACO
,	O
achieving	O
a	O
resting	O
heart	O
rate	O
of	O
around	O
70	O
80	O
bpm	O
.	O
With	O
the	O
aim	O
of	O
prognostic	O
stratification	O
and	O
with	O
a	O
view	O
to	O
assessing	O
myocardial	O
fibrosis	O
,	O
MRI	O
was	O
performed	O
,	O
ruling	O
it	O
out	O
,	O
showing	O
a	O
slight	O
improvement	O
in	O
LV	O
LVEF	O
25	O
and	O
RV	O
function	O
with	O
respect	O
to	O
the	O
initial	O
echocardiographic	O
study	O
.	O
Also	O
for	O
prognostic	O
purposes	O
,	O
a	O
walking	O
test	O
was	O
performed	O
prior	O
to	O
discharge	O
,	O
reaching	O
more	O
than	O
300	O
metres	O
in	O
6	O
minutes	O
and	O
without	O
desaturation	O
.	O
Given	O
the	O
stability	O
and	O
good	O
clinical	O
evolution	O
,	O
he	O
was	O
discharged	O
pending	O
the	O
optimisation	O
of	O
pharmacological	O
treatment	O
on	O
an	O
outpatient	O
basis	O
in	O
consultations	O
,	O
as	O
well	O
as	O
early	O
re	O
evaluation	O
with	O
the	O
aim	O
of	O
considering	O
an	O
ICD	O
if	O
ventricular	O
function	O
did	O
not	O
improve	O
.	O
DIAGNOSIS	O
Congestive	O
heart	O
failure	O
.	O
Idiopathic	O
dilated	O
cardiomyopathy	O
.	O
Severe	O
LV	O
dysfunction	O
.	O
Mild	O
RV	O
dysfunction	O
.	O
Coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
56	O
year	O
old	O
male	O
ex	O
smoker	O
,	O
with	O
insulin	O
dependent	O
type	O
2	O
diabetes	O
mellitus	O
,	O
hypertensive	O
,	O
dyslipidaemic	O
,	O
hyperuricaemic	O
and	O
obese	O
,	O
with	O
peripheral	O
arterial	O
disease	O
bilateral	O
femoropopliteal	O
stenosis	O
not	O
requiring	O
revascularisation	O
after	O
evaluation	O
by	O
vascular	O
surgery	O
whose	O
cardiological	O
history	O
was	O
ischaemic	O
heart	O
disease	O
in	O
the	O
dilated	O
phase	O
.	O
In	O
2003	O
she	O
had	O
an	O
anteroseptal	O
fibrinolysis	O
AMI	O
and	O
coronary	O
angiography	O
was	O
not	O
performed	O
.	O
A	O
new	O
posteroinferior	O
AMI	O
in	O
2005	O
with	O
coronary	O
angiography	O
showed	O
chronic	O
occlusion	O
of	O
the	O
middle	O
anterior	O
descending	O
artery	O
,	O
90	O
lesion	O
in	O
the	O
posterolateral	O
artery	O
,	O
40	O
lesion	O
in	O
the	O
proximal	O
right	O
coronary	O
artery	O
and	O
80	O
lesion	O
in	O
the	O
obtuse	O
marginal	O
artery	O
.	O
Echocardiogram	O
showed	O
LVEF	O
of	O
26	O
.	O
Surgical	O
revascularisation	O
was	O
performed	O
with	O
bypass	O
of	O
the	O
internal	O
mammary	O
artery	O
to	O
the	O
anterior	O
descending	O
artery	O
,	O
saphenous	O
artery	O
to	O
the	O
obtuse	O
marginal	O
artery	O
and	O
saphenous	O
artery	O
to	O
the	O
posterior	O
descending	O
artery	O
.	O
In	O
2013	O
,	O
a	O
single	O
chamber	O
defibrillator	O
implant	O
was	O
indicated	O
for	O
primary	O
prevention	O
.	O
Currently	O
being	O
monitored	O
by	O
Cardiology	O
in	O
NYHA	O
functional	O
class	O
II	O
.	O
Usual	O
treatment	O
carvedilol	B-FARMACO
12	O
.	O
5	O
mg	O
every	O
12	O
hours	O
,	O
ivabradine	B-FARMACO
5	O
mg	O
every	O
12	O
hours	O
,	O
enalapril	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
12	O
hours	O
,	O
furosemide	B-FARMACO
80	O
mg	O
per	O
day	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
,	O
ASA	B-FARMACO
100	O
mg	O
,	O
eplerenone	B-FARMACO
25	O
mg	O
,	O
allopurinol	B-FARMACO
300	O
mg	O
,	O
insulin	B-FARMACO
lantus	I-FARMACO
40	O
units	O
per	O
day	O
and	O
insulin	B-FARMACO
novorrapid	I-FARMACO
.	O
The	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
for	O
progressive	O
dyspnoea	O
in	O
recent	O
weeks	O
until	O
he	O
became	O
resting	O
,	O
with	O
three	O
pillow	O
orthopnoea	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
He	O
also	O
reported	O
oedema	O
in	O
both	O
legs	O
and	O
decreased	O
diuresis	O
.	O
He	O
did	O
not	O
report	O
palpitations	O
or	O
chest	O
pain	O
.	O
Physical	O
examination	O
showed	O
blood	O
pressure	O
145	O
70	O
mmHg	O
,	O
HR	O
80	O
beats	O
minute	O
,	O
BMI	O
41	O
.	O
2	O
kg	O
m2	O
,	O
baseline	O
oxygen	O
saturation	O
90	O
,	O
tachypnoea	O
,	O
and	O
he	O
was	O
afebrile	O
.	O
He	O
showed	O
jugular	O
ingurgitation	O
up	O
to	O
the	O
mandibular	O
angle	O
,	O
moist	O
crepitant	O
rales	O
up	O
to	O
midfields	O
,	O
rhythmic	O
hypophonic	O
tones	O
with	O
systolic	O
murmur	O
in	O
mitral	O
focus	O
II	O
VI	O
,	O
a	O
globular	O
abdomen	O
with	O
no	O
palpable	O
megaliths	O
,	O
no	O
signs	O
of	O
ascites	O
and	O
tibio	O
malleolar	O
oedema	O
with	O
fovea	O
up	O
to	O
the	O
proximal	O
third	O
.	O
Chest	O
X	O
ray	O
,	O
electrocardiogram	O
,	O
blood	O
tests	O
showed	O
absence	O
of	O
anaemia	O
,	O
slightly	O
impaired	O
renal	O
function	O
,	O
normal	O
ions	O
and	O
mild	O
elevation	O
of	O
cardiac	O
biomarkers	O
in	O
plateau	O
,	O
and	O
tristatic	O
echocardiogram	O
showed	O
severe	O
dilatation	O
of	O
the	O
left	O
ventricle	O
,	O
severely	O
depressed	O
LVEF	O
and	O
severe	O
functional	O
mitral	O
regurgitation	O
.	O
COMPLEMENTARY	O
TESTS	O
Chest	O
X	O
ray	O
cardiomegaly	O
at	O
the	O
expense	O
of	O
the	O
left	O
cavities	O
,	O
fluid	O
in	O
the	O
medial	O
cisure	O
,	O
vascular	O
redistribution	O
and	O
perihilar	O
alveolar	O
interstitial	O
infiltrate	O
.	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
75	O
beats	O
minute	O
,	O
intraventricular	O
conduction	O
disorder	O
with	O
QRS	O
of	O
170	O
ms	O
,	O
Q	O
wave	O
in	O
aVL	O
and	O
secondary	O
repolarisation	O
disorders	O
.	O
CBC	O
leukocytes	O
8	O
,	O
600	O
mm3	O
,	O
haemoglobin	O
11	O
.	O
5	O
g	O
dl	O
,	O
MCV	O
86	O
mm3	O
,	O
MCH	O
28	O
cell	O
,	O
platelets	O
220	O
.	O
000	O
mm3	O
,	O
normal	O
coagulation	O
,	O
creatinine	O
1	O
.	O
34	O
mg	O
dl	O
,	O
urea	O
50	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
50	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
Na	O
137	O
mEq	O
L	O
,	O
K	O
4	O
.	O
5	O
mEq	O
L	O
,	O
CPK	O
130	O
IU	O
L	O
,	O
troponin	O
I	O
0	O
.	O
8	O
ng	O
ml	O
,	O
NT	O
pro	O
BNP	O
9350	O
pg	O
mL	O
,	O
glycosylated	O
haemoglobin	O
10	O
.	O
Echocardiogram	O
regular	O
acoustic	O
window	O
.	O
Severely	O
dilated	O
left	O
ventricle	O
.	O
Very	O
severely	O
depressed	O
LVEF	O
15	O
by	O
Simpson	O
biplane	O
with	O
impaired	O
global	O
contractility	O
.	O
Pseudonormal	O
diastolic	O
pattern	O
with	O
average	O
E	O
e	O
"	O
of	O
15	O
.	O
6	O
.	O
Mitral	O
valve	O
with	O
mild	O
leaflet	O
thickening	O
and	O
mild	O
annular	O
calcification	O
.	O
Severe	O
central	O
mitral	O
regurgitation	O
of	O
functional	O
origin	O
predominantly	O
with	O
central	O
tenthering	O
.	O
Contracted	O
vein	O
of	O
8	O
mm	O
and	O
ORE	O
by	O
PISA	O
of	O
0	O
.	O
31	O
cm2	O
.	O
Normofunctioning	O
aortic	O
valve	O
.	O
Severely	O
dilated	O
left	O
atrium	O
.	O
Moderately	O
dilated	O
right	O
chambers	O
with	O
moderately	O
depressed	O
right	O
ventricular	O
systolic	O
function	O
with	O
fractional	O
shortening	O
of	O
25	O
.	O
Moderate	O
tricuspid	O
regurgitation	O
with	O
PSAP	O
of	O
60	O
mmHg	O
.	O
Pericardium	O
without	O
effusion	O
.	O
Inferior	O
vena	O
cava	O
22	O
mm	O
with	O
reduced	O
inspiratory	O
collapse	O
.	O
Coronary	O
angiography	O
left	O
common	O
trunk	O
without	O
significant	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
with	O
moderate	O
proximal	O
diffuse	O
atheromatosis	O
and	O
chronic	O
occlusion	O
of	O
the	O
middle	O
portion	O
,	O
after	O
origin	O
of	O
1st	O
diagonal	O
being	O
visible	O
the	O
distal	O
vessel	O
with	O
severe	O
diffuse	O
atheromatosis	O
by	O
bypass	O
of	O
internal	O
mammary	O
to	O
anterior	O
descending	O
artery	O
.	O
Circumflex	O
with	O
severe	O
proximal	O
lesion	O
anterior	O
to	O
1st	O
obtuse	O
marginal	O
.	O
Distal	O
vessel	O
of	O
obtuse	O
marginalis	O
without	O
significant	O
lesions	O
visible	O
through	O
patent	O
saphenous	O
bypass	O
.	O
Right	O
coronary	O
artery	O
with	O
chronic	O
occlusion	O
in	O
middle	O
portion	O
.	O
Chronically	O
occluded	O
right	O
saphenous	O
to	O
coronary	O
artery	O
immediately	O
after	O
its	O
origin	O
.	O
Adenosine	O
SPECT	O
severe	O
dilatation	O
of	O
the	O
left	O
ventricle	O
with	O
severe	O
and	O
extensive	O
anterior	O
hypoperfusion	O
as	O
well	O
as	O
moderate	O
hypoperfusion	O
in	O
mid	O
basal	O
segments	O
of	O
the	O
inferolateral	O
wall	O
,	O
all	O
without	O
significant	O
changes	O
in	O
the	O
study	O
at	O
rest	O
.	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
Cardiology	O
and	O
perfusion	O
of	O
furosemide	B-FARMACO
and	O
nitroglycerine	B-FARMACO
was	O
started	O
,	O
achieving	O
negative	O
water	O
balance	O
and	O
clinical	O
improvement	O
,	O
despite	O
which	O
dyspnoea	O
persisted	O
on	O
minimal	O
effort	O
.	O
Hygrotona	B-FARMACO
was	O
added	O
and	O
the	O
dose	O
of	O
antialdosterone	O
was	O
increased	O
to	O
achieve	O
resolution	O
of	O
the	O
congestion	O
.	O
In	O
addition	O
,	O
the	O
remaining	O
treatment	O
for	O
heart	O
failure	O
was	O
titrated	O
.	O
Given	O
the	O
clinical	O
deterioration	O
of	O
the	O
patient	O
,	O
coronary	O
angiography	O
was	O
performed	O
,	O
which	O
showed	O
patent	O
bypasses	O
from	O
mammary	O
to	O
anterior	O
descending	O
and	O
from	O
saphenous	O
to	O
obtuse	O
marginal	O
1a	O
and	O
very	O
proximal	O
occlusion	O
of	O
the	O
saphenous	O
bypass	O
to	O
the	O
right	O
coronary	O
artery	O
.	O
This	O
artery	O
showed	O
chronic	O
occlusion	O
in	O
its	O
middle	O
segment	O
,	O
and	O
was	O
not	O
considered	O
to	O
be	O
susceptible	O
to	O
percutaneous	O
treatment	O
as	O
a	O
viability	O
test	O
was	O
performed	O
with	O
SPECT	O
,	O
which	O
showed	O
no	O
viability	O
in	O
this	O
territory	O
.	O
He	O
was	O
discharged	O
with	O
120	O
mg	O
of	O
furosemide	B-FARMACO
per	O
day	O
,	O
spironolactone	B-FARMACO
100	O
mg	O
per	O
day	O
,	O
hygrotona	B-FARMACO
50	O
mg	O
every	O
48	O
hours	O
,	O
carvedilol	B-FARMACO
25	O
mg	O
every	O
12	O
hours	O
,	O
ivabradine	B-FARMACO
7	O
.	O
5	O
mg	O
every	O
12	O
hours	O
,	O
enalapril	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
12	O
hours	O
,	O
ASA	B-FARMACO
,	O
omeprazole	B-FARMACO
,	O
atorvastatin	B-FARMACO
,	O
allopurinol	B-FARMACO
and	O
insulin	O
therapy	O
.	O
Based	O
on	O
the	O
electrocardiographic	O
findings	O
,	O
the	O
clinical	O
situation	O
and	O
the	O
patient	O
's	O
LVEF	O
,	O
an	O
upgrade	O
to	O
resynchronisation	O
therapy	O
was	O
indicated	O
.	O
In	O
this	O
procedure	O
,	O
venography	O
was	O
performed	O
,	O
showing	O
occlusion	O
at	O
various	O
levels	O
of	O
the	O
coronary	O
sinus	O
without	O
identifying	O
any	O
practicable	O
subsidiary	O
vein	O
.	O
Only	O
a	O
middle	O
cardiac	O
vein	O
independent	O
of	O
the	O
coronary	O
sinus	O
was	O
observed	O
,	O
which	O
could	O
not	O
be	O
cannulated	O
despite	O
the	O
use	O
of	O
several	O
subselectors	O
and	O
angioplasty	O
guides	O
,	O
so	O
cardiac	O
resynchronisation	O
therapy	O
by	O
percutaneous	O
approach	O
could	O
not	O
be	O
performed	O
.	O
A	O
few	O
months	O
later	O
,	O
he	O
was	O
readmitted	O
due	O
to	O
decompensation	O
of	O
his	O
heart	O
failure	O
related	O
to	O
a	O
respiratory	O
infection	O
and	O
was	O
discharged	O
with	O
an	O
increased	O
dose	O
of	O
diuretic	O
.	O
Given	O
the	O
patient	O
's	O
age	O
and	O
NYHA	O
functional	O
class	O
II	O
III	O
,	O
the	O
patient	O
was	O
referred	O
to	O
a	O
reference	O
centre	O
for	O
evaluation	O
for	O
inclusion	O
on	O
the	O
heart	O
transplant	O
waiting	O
list	O
.	O
Right	O
heart	O
catheterisation	O
was	O
performed	O
and	O
showed	O
a	O
PCP	O
of	O
30	O
mmHg	O
,	O
mean	O
PAP	O
of	O
34	O
mmHg	O
,	O
PVR	O
2	O
.	O
6	O
uW	O
and	O
cardiac	O
output	O
of	O
2	O
.	O
6	O
L	O
min	O
,	O
and	O
ergospirometry	O
showed	O
a	O
peak	O
oxygen	O
consumption	O
of	O
14	O
ml	O
kg	O
min	O
.	O
Due	O
to	O
comorbidities	O
,	O
poorly	O
controlled	O
diabetes	O
,	O
obesity	O
and	O
peripheral	O
arterial	O
disease	O
,	O
he	O
was	O
not	O
considered	O
a	O
candidate	O
for	O
heart	O
transplantation	O
.	O
On	O
outpatient	O
follow	O
up	O
,	O
the	O
patient	O
maintained	O
NYHA	O
functional	O
class	O
II	O
III	O
with	O
NT	O
proBNP	O
of	O
4350	O
pg	O
mL	O
.	O
It	O
was	O
decided	O
to	O
switch	O
from	O
enalapril	B-FARMACO
to	O
sacubritil	B-FARMACO
valsartan	I-FARMACO
49	O
51	O
mm	O
every	O
12	O
hours	O
after	O
the	O
36	O
hour	O
washout	O
period	O
.	O
After	O
one	O
week	O
of	O
treatment	O
and	O
without	O
worsening	O
renal	O
and	O
ion	O
function	O
,	O
the	O
dose	O
was	O
titrated	O
to	O
97	O
103	O
mg	O
every	O
12	O
hours	O
.	O
The	O
patient	O
reported	O
significant	O
clinical	O
improvement	O
after	O
this	O
medication	O
change	O
and	O
diuretic	O
dose	O
reduction	O
was	O
possible	O
.	O
As	O
resynchronisation	O
therapy	O
was	O
not	O
possible	O
due	O
to	O
the	O
unfavourable	O
anatomy	O
of	O
the	O
cardiac	O
veins	O
,	O
the	O
possibility	O
of	O
electrode	O
implantation	O
in	O
the	O
epicardium	O
of	O
the	O
left	O
ventricle	O
by	O
cardiac	O
surgery	O
was	O
offered	O
.	O
With	O
the	O
clinical	O
improvement	O
after	O
the	O
introduction	O
of	O
sacubritil	B-FARMACO
valsartan	I-FARMACO
,	O
the	O
patient	O
decided	O
to	O
postpone	O
this	O
intervention	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
patient	O
had	O
severe	O
functional	O
mitral	O
regurgitation	O
and	O
occlusion	O
of	O
the	O
right	O
saphenous	O
coronary	O
bypass	O
.	O
At	O
the	O
medical	O
surgical	O
session	O
,	O
he	O
was	O
not	O
considered	O
a	O
candidate	O
for	O
mitral	O
repair	O
and	O
a	O
new	O
coronary	O
artery	O
bypass	O
given	O
the	O
lack	O
of	O
viability	O
of	O
the	O
lower	O
territory	O
,	O
obesity	O
and	O
surgical	O
risk	O
.	O
However	O
,	O
the	O
possibility	O
of	O
Mitraclip	O
implantation	O
for	O
treatment	O
of	O
mitral	O
insufficiency	O
was	O
offered	O
.	O
Given	O
the	O
patient	O
's	O
symptomatic	O
improvement	O
with	O
the	O
change	O
from	O
ACE	B-FARMACO
inhibitors	I-FARMACO
to	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
,	O
this	O
therapeutic	O
option	O
has	O
not	O
been	O
implemented	O
for	O
the	O
time	O
being	O
.	O
DIAGNOSIS	O
Heart	O
failure	O
with	O
reduced	O
EF	O
.	O
Ischaemic	O
heart	O
disease	O
in	O
dilated	O
phase	O
with	O
severely	O
depressed	O
systolic	O
function	O
.	O
Severe	O
functional	O
mitral	O
regurgitation	O
.	O
Severe	O
three	O
vessel	O
coronary	O
artery	O
disease	O
with	O
occlusion	O
of	O
saphenous	O
to	O
right	O
coronary	O
artery	O
bypass	O
and	O
permeable	O
mammary	O
to	O
anterior	O
descending	O
and	O
saphenous	O
to	O
first	O
obtuse	O
marginal	O
bypass	O
.	O
Secondary	O
diagnoses	O
Insulin	O
dependent	O
type	O
2	O
diabetes	O
mellitus	O
.	O
Arterial	O
hypertension	O
.	O
Dyslipidaemia	O
.	O
Grade	O
2	O
obesity	O
.	O
Chronic	O
lower	O
limb	O
ischaemia	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
69	O
year	O
old	O
female	O
patient	O
with	O
a	O
personal	O
history	O
of	O
breast	O
carcinoma	O
who	O
,	O
after	O
starting	O
chemotherapy	O
treatment	O
,	O
presented	O
with	O
an	O
episode	O
of	O
chest	O
pain	O
.	O
HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
No	O
known	O
allergic	O
drug	O
reactions	O
.	O
Cardiovascular	O
risk	O
factors	O
arterial	O
hypertension	O
.	O
Dyslipidaemia	O
.	O
No	O
known	O
diabetes	O
mellitus	O
.	O
No	O
toxic	O
habits	O
.	O
Infiltrating	O
breast	O
carcinoma	O
of	O
non	O
special	O
histological	O
subtype	O
G3	O
,	O
stage	O
IIB	O
,	O
binodal	O
pT2	O
2	O
.	O
2	O
cm	O
1	O
.	O
5	O
cm	O
distant	O
0	O
.	O
5	O
mm	O
from	O
upper	O
margin	O
and	O
0	O
.	O
3	O
cm	O
from	O
lower	O
margin	O
respectively	O
,	O
V1	O
,	O
pN1	O
2	O
17	O
,	O
Mx	O
.	O
ER	O
,	O
PR	O
,	O
HER2	O
3	O
,	O
ki67	O
20	O
30	O
,	O
CK	O
19	O
.	O
Segmentectomy	O
and	O
axillary	O
emptying	O
of	O
levels	O
I	O
and	O
II	O
was	O
performed	O
on	O
14	O
12	O
16	O
.	O
On	O
20	O
1	O
17	O
she	O
was	O
assessed	O
in	O
Oncology	O
consultations	O
and	O
it	O
was	O
decided	O
to	O
start	O
adjuvant	O
chemotherapy	O
with	O
the	O
following	O
therapeutic	O
plan	O
FEC	O
x	O
4	O
cycles	O
5	B-FARMACO
fluorouracil	B-FARMACO
epirubicin	I-FARMACO
cyclophosphamide	I-FARMACO
placlitaxel	I-FARMACO
iv	O
trastuzumab	B-FARMACO
sc	O
x	O
12	O
weeks	O
radiotherapy	O
trastuzumab	B-FARMACO
three	O
weekly	O
until	O
completing	O
one	O
year	O
.	O
Echocardiogram	O
prior	O
to	O
the	O
start	O
of	O
chemotherapy	O
no	O
structural	O
heart	O
disease	O
and	O
LVEF	O
estimated	O
by	O
Simpson	O
biplane	O
of	O
60	O
.	O
Usual	O
treatment	O
enalapril	B-FARMACO
5	O
mg	O
1	O
0	O
0	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
0	O
0	O
1	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
.	O
Current	O
disease	O
patient	O
with	O
the	O
personal	O
history	O
described	O
above	O
received	O
the	O
first	O
cycle	O
of	O
chemotherapy	O
C1	O
FEC	O
on	O
10	O
February	O
2017	O
.	O
Six	O
days	O
later	O
she	O
presented	O
with	O
a	O
prolonged	O
episode	O
more	O
than	O
two	O
hours	O
of	O
oppressive	O
central	O
thoracic	O
pain	O
radiating	O
to	O
the	O
left	O
upper	O
limb	O
with	O
vegetative	O
crust	O
.	O
The	O
pain	O
gradually	O
resolved	O
without	O
any	O
medication	O
.	O
Consultation	O
in	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
revealed	O
elevated	O
cardiac	O
biomarkers	O
,	O
as	O
well	O
as	O
electrocardiographic	O
changes	O
.	O
Admission	O
to	O
the	O
Cardiology	O
Intermediate	O
Care	O
Unit	O
was	O
decided	O
.	O
No	O
previous	O
similar	O
episodes	O
.	O
No	O
dyspnoea	O
,	O
no	O
orthopnoea	O
,	O
no	O
paroxysmal	O
dyspnoea	O
crises	O
or	O
other	O
symptoms	O
from	O
a	O
cardiological	O
point	O
of	O
view	O
.	O
Physical	O
examination	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
general	O
condition	O
was	O
acceptable	O
.	O
Asymptomatic	O
.	O
Well	O
hydrated	O
and	O
perfused	O
.	O
BP	O
110	O
60	O
mmHg	O
,	O
HR	O
100	O
bpm	O
.	O
Eupneic	O
at	O
rest	O
,	O
tolerating	O
decubitus	O
,	O
not	O
requiring	O
supplementary	O
oxygen	O
therapy	O
with	O
SpO2	O
98	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
without	O
aggregates	O
.	O
Abdomen	O
was	O
nondescript	O
.	O
No	O
peripheral	O
oedema	O
or	O
other	O
signs	O
of	O
congestion	O
.	O
COMPLEMENTARY	O
TESTS	O
Admission	O
electrocardiogram	O
sinus	O
tachycardia	O
at	O
100	O
bpm	O
,	O
left	O
axis	O
with	O
QS	O
in	O
inferior	O
face	O
.	O
QRS	O
80	O
ms	O
.	O
Deep	O
symmetrical	O
negative	O
T	O
waves	O
in	O
V2	O
6	O
,	O
DI	O
,	O
DII	O
,	O
aVL	O
and	O
aVF	O
.	O
Chest	O
X	O
ray	O
slight	O
cardiomegaly	O
.	O
No	O
images	O
of	O
parenchymal	O
condensation	O
.	O
Minimal	O
impingement	O
of	O
both	O
costophrenic	O
sinuses	O
.	O
Laboratory	O
haemogram	O
leucocytes	O
7	O
,	O
270	O
N	O
82	O
.	O
6	O
,	O
Hb	O
14	O
.	O
3	O
g	O
dl	O
,	O
platelets	O
256	O
,	O
000	O
.	O
Renal	O
function	O
and	O
ions	O
Cr	O
0	O
.	O
66	O
mg	O
dl	O
,	O
urea	O
35	O
mg	O
dl	O
,	O
sodium	O
132	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
1	O
mEq	O
l	O
.	O
Coagulation	O
normal	O
with	O
INR	O
0	O
.	O
97	O
.	O
Cardiac	O
biomarkers	O
TnT	O
US	O
peak	O
788	O
.	O
8	O
ng	O
L	O
14	O
negative	O
.	O
Peak	O
CK	O
599	O
mUu	O
ml	O
24	O
195	O
.	O
Cardiac	O
monitoring	O
no	O
arrhythmic	O
events	O
of	O
interest	O
,	O
in	O
sinus	O
rhythm	O
at	O
all	O
times	O
.	O
Echocardiogram	O
on	O
admission	O
dilated	O
left	O
atrium	O
AP	O
diameter	O
40	O
mm	O
,	O
volume	O
41	O
cc	O
m	O
AP	O
40	O
mm	O
,	O
volume	O
41	O
cc	O
m2	O
.	O
Mitral	O
valve	O
with	O
slightly	O
thickened	O
leaflets	O
,	O
with	O
preserved	O
opening	O
and	O
tenting	O
closure	O
with	O
moderate	O
degree	O
of	O
insufficiency	O
jet	O
.	O
Dilated	O
left	O
ventricle	O
DTD	O
57	O
mm	O
,	O
VTDi	O
93	O
ml	O
m2	O
,	O
DTS	O
54	O
mm	O
,	O
VTSi	O
77	O
ml	O
m2	O
.	O
Normal	O
myocardial	O
thickness	O
with	O
8	O
mm	O
septum	O
and	O
inferolateral	O
wall	O
.	O
Global	O
hypokinesia	O
with	O
severely	O
depressed	O
systolic	O
function	O
.	O
LVEF	O
estimated	O
by	O
Simpson	O
biplane	O
at	O
27	O
.	O
Mitral	O
filling	O
pattern	O
with	O
impaired	O
relaxation	O
.	O
Mild	O
aortic	O
insufficiency	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
systolic	O
function	O
at	O
the	O
lower	O
limit	O
of	O
normal	O
TAPSE	O
16	O
mm	O
.	O
Mild	O
tricuspid	O
insufficiency	O
allowing	O
an	O
estimated	O
PSAP	O
of	O
46	O
mmHg	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
with	O
little	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Coronary	O
angiography	O
angiographically	O
normal	O
coronary	O
arteries	O
.	O
Right	O
dominance	O
.	O
Cardiac	O
MRI	O
left	O
ventricle	O
LVEDD	O
65	O
mm	O
,	O
LVEDV	O
197	O
ml	O
,	O
LVESV	O
137	O
mL	O
,	O
LVEF	O
30	O
,	O
with	O
a	O
systolic	O
volume	O
of	O
60	O
mL	O
and	O
an	O
estimated	O
cardiac	O
output	O
of	O
4	O
.	O
2	O
L	O
min	O
.	O
Right	O
ventricle	O
RVEDVD	O
42	O
mm	O
,	O
RVEDVD	O
129	O
mL	O
,	O
RVSVD	O
75	O
mL	O
,	O
RVEF	O
41	O
.	O
Cine	O
sequences	O
show	O
a	O
central	O
jet	O
of	O
mitral	O
regurgitation	O
.	O
Late	O
gadolinium	O
enhancement	O
sequences	O
show	O
no	O
areas	O
of	O
myocardial	O
fibrosis	O
shield	O
.	O
Echocardiogram	O
in	O
consultation	O
,	O
after	O
hospital	O
discharge	O
non	O
dilated	O
left	O
ventricle	O
with	O
LVEDDVI	O
of	O
51	O
mm	O
with	O
LVEF	O
estimated	O
by	O
Simpson	O
Biplane	O
of	O
45	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Normal	O
right	O
chambers	O
with	O
preserved	O
right	O
ventricular	O
systolic	O
function	O
.	O
EVOLUTION	O
Patient	O
diagnosed	O
with	O
breast	O
carcinoma	O
of	O
non	O
special	O
histological	O
subtype	O
.	O
Segmentectomy	O
and	O
lymph	O
node	O
removal	O
was	O
performed	O
in	O
December	O
2016	O
.	O
After	O
assessment	O
by	O
Oncology	O
,	O
the	O
first	O
cycle	O
of	O
chemotherapy	O
with	O
FEC	O
5	B-FARMACO
fluorouracil	B-FARMACO
epirubicin	I-FARMACO
cyclophosphamide	I-FARMACO
was	O
started	O
at	O
the	O
beginning	O
of	O
February	O
2017	O
.	O
One	O
week	O
later	O
,	O
she	O
presented	O
with	O
an	O
episode	O
of	O
prolonged	O
chest	O
pain	O
with	O
mobilisation	O
markers	O
of	O
myocardial	O
damage	O
,	O
electrocardiographic	O
changes	O
and	O
severe	O
left	O
ventricular	O
dysfunction	O
not	O
present	O
in	O
the	O
previous	O
echocardiogram	O
.	O
Coronary	O
angiography	O
was	O
performed	O
without	O
evidence	O
of	O
coronary	O
artery	O
disease	O
.	O
Suspicion	O
of	O
acute	O
toxic	O
myocarditis	O
was	O
suspected	O
and	O
cardiac	O
MRI	O
was	O
performed	O
,	O
which	O
was	O
finally	O
ruled	O
out	O
.	O
The	O
patient	O
had	O
a	O
good	O
clinical	O
evolution	O
,	O
with	O
no	O
new	O
episodes	O
of	O
chest	O
pain	O
or	O
signs	O
of	O
heart	O
failure	O
,	O
and	O
was	O
discharged	O
from	O
hospital	O
with	O
the	O
following	O
treatment	O
bisoprolol	B-FARMACO
5	O
mg	O
c	O
12	O
h	O
,	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
c	O
24	O
h	O
,	O
eplerrenone	B-FARMACO
25	O
mg	O
c	O
24	O
h	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
c	O
24	O
h	O
,	O
esomeprazole	B-FARMACO
20	O
mg	O
c	O
24	O
h	O
.	O
After	O
discharge	O
from	O
hospital	O
,	O
she	O
was	O
reviewed	O
in	O
Oncology	O
and	O
the	O
next	O
scheduled	O
cycles	O
of	O
chemotherapy	O
with	O
FEC	O
were	O
suspended	O
due	O
to	O
the	O
existence	O
of	O
acute	O
cardiotoxicity	O
after	O
the	O
first	O
cycle	O
.	O
Four	O
weeks	O
later	O
she	O
was	O
assessed	O
in	O
the	O
outpatient	O
cardiology	O
department	O
and	O
the	O
echocardiogram	O
was	O
repeated	O
with	O
an	O
improvement	O
in	O
LVEF	O
.	O
DIAGNOSIS	O
Cardiomyopathy	O
with	O
severe	O
left	O
ventricular	O
dysfunction	O
induced	O
by	O
acute	O
cardiotoxicity	O
after	O
starting	O
chemotherapy	O
treatment	O
5	B-FARMACO
FU	B-FARMACO
epirubicin	I-FARMACO
cyclophosphamide	I-FARMACO
.	O
NYHA	O
functional	O
class	O
I	O
IV	O
.	O
Infiltrating	O
breast	O
carcinoma	O
of	O
non	O
special	O
histological	O
subtype	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
58	O
year	O
old	O
male	O
,	O
ex	O
smoker	O
,	O
ex	O
drinker	O
and	O
overweight	O
,	O
with	O
a	O
history	O
of	O
ischaemic	O
stroke	O
of	O
unidentified	O
aetiology	O
in	O
2015	O
in	O
the	O
middle	O
cerebral	O
artery	O
with	O
motor	O
aphasia	O
as	O
the	O
main	O
sequelae	O
.	O
The	O
echocardiogram	O
performed	O
on	O
admission	O
showed	O
slight	O
dilatation	O
of	O
the	O
right	O
ventricle	O
with	O
hypertrabeculation	O
and	O
left	O
ventricular	O
ejection	O
fraction	O
at	O
the	O
lower	O
limit	O
of	O
normality	O
as	O
the	O
only	O
relevant	O
findings	O
.	O
The	O
patient	O
was	O
awaiting	O
outpatient	O
cardiac	O
magnetic	O
resonance	O
imaging	O
to	O
complete	O
the	O
study	O
.	O
Usual	O
treatment	O
ASA	B-FARMACO
100	O
mg	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
and	O
ranitidine	B-FARMACO
300	O
mg	O
every	O
24	O
hours	O
.	O
The	O
patient	O
presented	O
at	O
home	O
with	O
sudden	O
dyspnoea	O
and	O
general	O
malaise	O
,	O
so	O
he	O
called	O
the	O
Emergency	O
Services	O
who	O
performed	O
an	O
electrocardiogram	O
that	O
showed	O
regular	O
wide	O
QRS	O
tachycardia	O
at	O
205	O
beats	O
per	O
minute	O
with	O
an	O
image	O
of	O
left	O
bundle	O
branch	O
block	O
and	O
right	O
superior	O
axis	O
.	O
Given	O
that	O
the	O
patient	O
presented	O
acceptable	O
clinical	O
tolerance	O
,	O
iv	O
amiodarone	B-FARMACO
was	O
started	O
and	O
subsequently	O
,	O
given	O
the	O
lack	O
of	O
response	O
,	O
electrical	O
cardioversion	O
was	O
performed	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
our	O
centre	O
in	O
sinus	O
rhythm	O
,	O
maintaining	O
haemodynamic	O
stability	O
and	O
with	O
symptomatic	O
improvement	O
.	O
At	O
our	O
centre	O
,	O
he	O
was	O
admitted	O
to	O
the	O
Coronary	O
Unit	O
,	O
where	O
amiodarone	B-FARMACO
perfusion	O
and	O
low	O
dose	O
bisoprolol	B-FARMACO
treatment	O
were	O
started	O
,	O
despite	O
which	O
he	O
presented	O
another	O
episode	O
of	O
tachycardia	O
similar	O
to	O
the	O
one	O
described	O
,	O
which	O
required	O
electrical	O
cardioversion	O
.	O
He	O
did	O
not	O
report	O
chest	O
pain	O
or	O
syncope	O
or	O
any	O
other	O
symptoms	O
in	O
the	O
anamnesis	O
.	O
Physical	O
examination	O
showed	O
blood	O
pressure	O
95	O
60	O
mmHg	O
,	O
80	O
beats	O
minute	O
,	O
BMI	O
28	O
kg	O
m2	O
,	O
baseline	O
oxygen	O
saturation	O
93	O
,	O
and	O
he	O
was	O
afebrile	O
.	O
There	O
was	O
no	O
evidence	O
of	O
jugular	O
ingurgitation	O
.	O
Cardiopulmonary	O
auscultation	O
showed	O
no	O
heart	O
murmurs	O
and	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
added	O
sounds	O
.	O
Abdomen	O
without	O
masses	O
or	O
megaliths	O
and	O
lower	O
limbs	O
without	O
oedema	O
.	O
Chest	O
X	O
ray	O
,	O
blood	O
tests	O
showed	O
no	O
anaemia	O
,	O
normal	O
renal	O
function	O
and	O
ions	O
,	O
and	O
mild	O
elevation	O
of	O
cardiac	O
biomarkers	O
.	O
Transthoracic	O
echocardiogram	O
showed	O
mild	O
left	O
ventricular	O
and	O
severe	O
right	O
ventricular	O
dilatation	O
,	O
severely	O
depressed	O
LVEF	O
and	O
severe	O
right	O
ventricular	O
systolic	O
dysfunction	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
1	O
regular	O
wide	O
QRS	O
tachycardia	O
at	O
205	O
bpm	O
with	O
atrioventricular	O
dissociation	O
,	O
left	O
bundle	O
branch	O
block	O
image	O
morphology	O
and	O
right	O
superior	O
axis	O
.	O
Electrocardiogram	O
2	O
sinus	O
bradycardia	O
at	O
55	O
bpm	O
,	O
PR	O
220	O
ms	O
first	O
degree	O
BAV	O
,	O
small	O
voltage	O
r	O
wave	O
up	O
to	O
V6	O
and	O
positive	O
deflection	O
at	O
the	O
end	O
of	O
QRS	O
in	O
V1	O
compatible	O
with	O
epsilon	O
wave	O
,	O
negative	O
T	O
waves	O
from	O
V1	O
to	O
V5	O
and	O
flattened	O
in	O
V6	O
and	O
frontal	O
leads	O
.	O
Portable	O
chest	O
X	O
ray	O
cardiomegaly	O
and	O
vascular	O
redistribution	O
,	O
without	O
pleural	O
effusion	O
.	O
CBC	O
leukocytes	O
7500	O
mm3	O
,	O
haemoglobin	O
14	O
.	O
5	O
g	O
dl	O
,	O
MCV	O
85	O
mm3	O
,	O
MCH	O
33	O
cell	O
,	O
platelets	O
225	O
,	O
000	O
mm3	O
,	O
normal	O
coagulation	O
,	O
creatinine	O
1	O
.	O
05	O
mg	O
dl	O
,	O
urea	O
30	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
74	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
Na	O
138	O
mEq	O
L	O
,	O
K	O
4	O
.	O
6	O
mEq	O
L	O
,	O
CPK	O
210	O
IU	O
L	O
,	O
troponin	O
I	O
0	O
.	O
7	O
ng	O
ml	O
peak	O
.	O
Transthoracic	O
echocardiogram	O
poor	O
acoustic	O
window	O
in	O
apical	O
window	O
.	O
Left	O
ventricle	O
slightly	O
dilated	O
DDVI	O
59	O
mm	O
.	O
Severely	O
depressed	O
LVEF	O
25	O
by	O
Teicholz	O
with	O
decreased	O
global	O
contractility	O
.	O
Prolonged	O
diastolic	O
relaxation	O
pattern	O
and	O
mean	O
E	O
e	O
"	O
of	O
11	O
.	O
Normofunctioning	O
mitral	O
valve	O
and	O
aortic	O
valve	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
.	O
Severely	O
dilated	O
right	O
chambers	O
.	O
Parasternal	O
long	O
axis	O
RVOT	O
diameter	O
52	O
mm	O
,	O
parasternal	O
short	O
axis	O
52	O
mm	O
.	O
RV	O
free	O
wall	O
hypertrabeculation	O
and	O
depressed	O
systolic	O
function	O
with	O
TAPSE	O
of	O
12	O
.	O
9	O
mm	O
.	O
No	O
adequate	O
recording	O
of	O
tricuspid	O
registry	O
for	O
PSAP	O
estimation	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
,	O
inferior	O
vena	O
cava	O
21	O
mm	O
with	O
inspiratory	O
collapse	O
less	O
than	O
50	O
.	O
Coronary	O
angiography	O
angiographically	O
normal	O
coronary	O
arteries	O
.	O
Cardio	O
MRI	O
RA	O
67	O
x	O
55	O
mm	O
36	O
cm2	O
,	O
RV	O
100	O
x	O
70	O
x	O
60	O
mm	O
,	O
LA	O
66	O
x	O
38	O
mm	O
,	O
LV	O
58	O
x	O
58	O
x	O
66	O
mm	O
,	O
IVS	O
thickness	O
11	O
mm	O
,	O
RVOT	O
55	O
mm	O
.	O
Left	O
ventricular	O
function	O
study	O
LVEF	O
44	O
,	O
Beat	O
volume	O
36	O
.	O
5	O
ml	O
m2	O
,	O
cardiac	O
output	O
4	O
.	O
8	O
l	O
m	O
,	O
TVD	O
83	O
.	O
8	O
ml	O
m2	O
,	O
STV	O
47	O
.	O
3	O
ml	O
m2	O
.	O
Right	O
ventricular	O
function	O
study	O
LVEF	O
15	O
,	O
stroke	O
volume	O
24	O
.	O
6	O
ml	O
m2	O
,	O
cardiac	O
output	O
3	O
.	O
3	O
l	O
min	O
,	O
VTD	O
165	O
.	O
5	O
ml	O
m2	O
,	O
VTS	O
141	O
.	O
9	O
ml	O
m2	O
.	O
Great	O
dilatation	O
of	O
the	O
right	O
ventricle	O
with	O
areas	O
of	O
anteroinferior	O
hypokinesia	O
of	O
2	O
cm	O
close	O
to	O
the	O
valvular	O
plane	O
.	O
At	O
the	O
level	O
of	O
the	O
left	O
ventricle	O
there	O
is	O
a	O
thinned	O
,	O
irregular	O
lateral	O
face	O
,	O
with	O
probable	O
fatty	O
infiltration	O
,	O
presenting	O
a	O
small	O
aneurysmal	O
dilatation	O
of	O
15	O
mm	O
in	O
the	O
middle	O
inferolateral	O
segment	O
.	O
Middle	O
inferolateral	O
akinesia	O
and	O
apicolateral	O
dyskinesia	O
.	O
Lateral	O
fat	O
replacement	O
.	O
After	O
contrast	O
iv	O
enhancement	O
is	O
seen	O
throughout	O
the	O
subepicardial	O
lateral	O
wall	O
of	O
the	O
thinned	O
LV	O
and	O
inferolateral	O
segment	O
in	O
addition	O
to	O
anterior	O
,	O
inferior	O
basal	O
and	O
right	O
ventricular	O
outflow	O
tract	O
areas	O
.	O
EVOLUTION	O
The	O
patient	O
presented	O
two	O
more	O
episodes	O
of	O
ventricular	O
tachycardia	O
under	O
treatment	O
with	O
amiodarone	B-FARMACO
requiring	O
electrical	O
cardioversion	O
.	O
He	O
was	O
switched	O
to	O
treatment	O
with	O
sotalol	B-FARMACO
,	O
achieving	O
electrical	O
and	O
clinical	O
stability	O
.	O
Based	O
on	O
clinical	O
,	O
electrocardiographic	O
and	O
cardiac	O
imaging	O
findings	O
,	O
a	O
diagnosis	O
of	O
arrhythmogenic	O
cardiomyopathy	O
of	O
the	O
right	O
and	O
left	O
ventricle	O
was	O
established	O
.	O
A	O
bicameral	O
bibovine	O
ICD	O
was	O
implanted	O
as	O
secondary	O
prevention	O
with	O
an	O
electrode	O
terminal	O
placed	O
in	O
the	O
middle	O
septum	O
without	O
complications	O
.	O
Subsequent	O
evolution	O
was	O
favourable	O
,	O
with	O
no	O
new	O
episodes	O
or	O
defibrillator	O
shocks	O
.	O
Treatment	O
was	O
started	O
with	O
angiotensin	B-FARMACO
converting	I-FARMACO
enzyme	I-FARMACO
inhibitor	I-FARMACO
together	O
with	O
low	O
dose	O
bisoprolol	B-FARMACO
and	O
sotalol	B-FARMACO
and	O
,	O
given	O
the	O
previous	O
cerebrovascular	O
event	O
,	O
it	O
was	O
decided	O
,	O
in	O
conjunction	O
with	O
neurology	O
,	O
to	O
start	O
treatment	O
with	O
apixaban	B-FARMACO
due	O
to	O
the	O
likelihood	O
of	O
cardioembolic	O
aetiology	O
.	O
There	O
were	O
no	O
known	O
cases	O
of	O
this	O
condition	O
in	O
the	O
family	O
,	O
so	O
genetic	O
testing	O
was	O
requested	O
results	O
pending	O
.	O
DIAGNOSIS	O
Sustained	O
ventricular	O
tachycardia	O
in	O
a	O
patient	O
with	O
arrhythmogenic	O
cardiomyopathy	O
of	O
the	O
right	O
and	O
left	O
ventricle	O
.	O
Severe	O
right	O
and	O
moderate	O
left	O
ventricular	O
systolic	O
dysfunction	O
.	O
First	O
degree	O
AVB	O
,	O
arterial	O
hypertension	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
57	O
year	O
old	O
patient	O
with	O
CVRF	O
and	O
a	O
history	O
of	O
anterior	O
and	O
apical	O
AMI	O
in	O
1997	O
with	O
surgical	O
revascularisation	O
with	O
VSF	O
DA	O
and	O
VSF	O
CD	O
bypass	O
.	O
The	O
patient	O
was	O
being	O
monitored	O
by	O
the	O
Cardiology	O
department	O
with	O
CF	O
NYHA	O
I	O
II	O
.	O
After	O
observing	O
NSVT	O
on	O
Holter	O
monitoring	O
,	O
it	O
was	O
decided	O
to	O
perform	O
EPS	O
with	O
induction	O
of	O
polymorphic	O
VT	O
.	O
A	O
programmed	O
single	O
chamber	O
ICD	O
was	O
implanted	O
in	O
2003	O
with	O
a	O
therapy	O
zone	O
starting	O
at	O
200	O
bpm	O
.	O
In	O
the	O
last	O
control	O
echocardiogram	O
severely	O
dilated	O
LV	O
,	O
with	O
severely	O
depressed	O
systolic	O
function	O
25	O
and	O
anteroseptal	O
and	O
apical	O
akinesia	O
.	O
Given	O
the	O
presence	O
of	O
LVEF	O
35	O
,	O
CF	O
NYHA	O
II	O
,	O
QRS	O
160	O
ms	O
BRD	O
HBAS	O
with	O
adequate	O
medical	O
treatment	O
,	O
it	O
was	O
decided	O
to	O
upgrade	O
to	O
ICD	O
with	O
cardiac	O
resynchronisation	O
therapy	O
ICD	O
CRT	O
on	O
an	O
outpatient	O
basis	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
our	O
department	O
for	O
the	O
procedure	O
.	O
The	O
procedure	O
was	O
carried	O
out	O
with	O
implantation	O
of	O
a	O
tetrapolar	O
electrode	O
in	O
the	O
left	O
lateral	O
vein	O
very	O
difficult	O
access	O
due	O
to	O
the	O
ostimum	O
valve	O
in	O
the	O
coronary	O
sinus	O
and	O
an	O
electrode	O
in	O
the	O
right	O
atrial	O
appendage	O
.	O
Programming	O
optimisation	O
was	O
performed	O
and	O
DDDR	O
45	O
was	O
finally	O
programmed	O
,	O
Biv	O
30	O
ms	O
with	O
3	O
shell	O
ring	O
pacing	O
,	O
resulting	O
in	O
a	O
stimulated	O
QRS	O
of	O
128	O
ms	O
.	O
A	O
few	O
hours	O
after	O
implantation	O
,	O
the	O
patient	O
presented	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
at	O
160	O
bpm	O
with	O
inferior	O
axis	O
and	O
QS	O
morphology	O
in	O
precordial	O
leads	O
with	O
good	O
haemodynamic	O
tolerance	O
.	O
Treatment	O
was	O
started	O
with	O
amioradone	B-FARMACO
and	O
intravenous	O
beta	O
blocker	O
,	O
reprogramming	O
the	O
device	O
to	O
therapy	O
from	O
140	O
bpm	O
previously	O
programmed	O
from	O
200	O
bpm	O
.	O
An	O
attempt	O
was	O
made	O
at	O
ATP	O
and	O
after	O
sedation	O
with	O
midazolam	B-FARMACO
and	O
etomidate	B-FARMACO
,	O
two	O
attempts	O
were	O
made	O
at	O
internal	O
CV	O
with	O
ICD	O
and	O
two	O
more	O
attempts	O
with	O
external	O
defibrillator	O
which	O
were	O
not	O
effective	O
.	O
Finally	O
,	O
it	O
was	O
during	O
anaesthetic	O
induction	O
with	O
propofol	B-FARMACO
that	O
the	O
patient	O
reverted	O
to	O
sinus	O
rhythm	O
.	O
Physical	O
examination	O
BP	O
110	O
57	O
mmHg	O
,	O
HR	O
160	O
bpm	O
,	O
T	O
36	O
.	O
4	O
oC	O
,	O
baseline	O
SatO2	O
95	O
.	O
Patient	O
conscious	O
and	O
oriented	O
,	O
normohydrated	O
and	O
normal	O
colour	O
.	O
Mild	O
tachypnoea	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
normoventilation	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
no	O
masses	O
or	O
megaliths	O
palpable	O
.	O
Peristalsis	O
preserved	O
.	O
Jugular	O
ingurgitation	O
,	O
hepatojugular	O
reflux	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
extremities	O
or	O
signs	O
of	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Transthoracic	O
echocardiogram	O
LV	O
severely	O
dilated	O
LVEDD	O
74	O
mm	O
.	O
Severely	O
depressed	O
LVEF	O
estimated	O
by	O
Simpson	O
25	O
.	O
Akinesia	O
with	O
septal	O
and	O
apical	O
hyperenhancement	O
with	O
an	O
impression	O
of	O
eschar	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
MV	O
mild	O
calcification	O
of	O
the	O
posterior	O
mitral	O
annulus	O
with	O
mild	O
MR	O
.	O
VAo	O
trivalva	O
with	O
mild	O
sclerosis	O
of	O
the	O
sigmoid	O
valve	O
without	O
restricting	O
its	O
opening	O
.	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
Mild	O
TR	O
with	O
RV	O
AD	O
gradient	O
of	O
25	O
mmHg	O
.	O
IVC	O
not	O
dilated	O
with	O
normal	O
inspiratory	O
collapse	O
.	O
Stimulated	O
PAPs	O
of	O
30	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
.	O
No	O
signs	O
of	O
acute	O
HF	O
.	O
DAITRC	O
electrodes	O
in	O
normal	O
position	O
.	O
ECG	O
wide	O
QRS	O
tachycardia	O
160	O
bpm	O
with	O
inferior	O
axis	O
and	O
QS	O
morphology	O
in	O
precordial	O
leads	O
suggestive	O
of	O
VT	O
of	O
apical	O
anterior	O
origin	O
.	O
Blood	O
tests	O
cardiac	O
markers	O
TnI	O
0	O
.	O
09	O
,	O
myoglobin	O
160	O
,	O
ProBNP	O
2400	O
.	O
Biochemistry	O
glycaemia	O
139	O
mg	O
dL	O
,	O
creatinine	O
0	O
.	O
97	O
mg	O
dL	O
,	O
Na	O
135	O
mEq	O
l	O
,	O
Cl	O
98	O
mEq	O
l	O
,	O
K	O
4	O
.	O
1	O
mEq	O
l	O
,	O
Ca	O
9	O
.	O
2	O
mg	O
dL	O
.	O
Mg	O
2	O
mEq	O
l	O
.	O
Normal	O
thyroid	O
function	O
with	O
TSH	O
4	O
.	O
7	O
and	O
T4	O
0	O
.	O
88	O
.	O
Haemogram	O
leucocytes	O
8	O
,	O
800	O
mL	O
with	O
77	O
neutrophils	O
.	O
Hb	O
13	O
.	O
4	O
g	O
dl	O
,	O
platelets	O
225	O
,	O
000	O
mcL	O
.	O
Coagulation	O
normal	O
.	O
EVOLUTION	O
After	O
the	O
patient	O
went	O
into	O
sinus	O
rhythm	O
,	O
he	O
was	O
admitted	O
to	O
the	O
Coronary	O
Unit	O
for	O
monitoring	O
and	O
treatment	O
.	O
The	O
case	O
was	O
discussed	O
with	O
the	O
Arrhythmia	O
Unit	O
of	O
our	O
hospital	O
and	O
VT	O
ablation	O
was	O
decided	O
.	O
Using	O
the	O
CARTO	O
3	O
navigation	O
system	O
,	O
an	O
anatomical	O
reconstruction	O
and	O
LV	O
voltage	O
mapping	O
was	O
performed	O
,	O
identifying	O
a	O
dense	O
anteroseptal	O
and	O
apical	O
scar	O
with	O
late	O
potentials	O
LP	O
at	O
its	O
edges	O
.	O
The	O
pacemapping	O
was	O
very	O
similar	O
to	O
the	O
clinical	O
VT	O
.	O
It	O
is	O
noteworthy	O
after	O
different	O
radiological	O
projections	O
that	O
this	O
area	O
was	O
close	O
to	O
the	O
location	O
of	O
ring	O
3	O
of	O
the	O
LV	O
pacing	O
electrode	O
,	O
which	O
was	O
programmed	O
with	O
ring	O
3	O
shell	O
pacing	O
.	O
The	O
LPs	O
were	O
abolished	O
by	O
radiofrequency	O
RF	O
application	O
.	O
Subsequently	O
,	O
pacing	O
manoeuvres	O
were	O
performed	O
from	O
RV	O
and	O
LV	O
,	O
without	O
tachycardia	O
induction	O
.	O
Finally	O
,	O
LV	O
bipolar	O
pacing	O
was	O
reprogrammed	O
from	O
ring	O
1	O
2	O
area	O
furthest	O
from	O
the	O
scar	O
.	O
Based	O
on	O
these	O
data	O
,	O
it	O
was	O
concluded	O
that	O
we	O
were	O
dealing	O
with	O
a	O
possible	O
case	O
of	O
proarrhythmia	O
after	O
cardiac	O
resynchronisation	O
.	O
The	O
patient	O
was	O
discharged	O
from	O
hospital	O
,	O
stable	O
and	O
asymptomatic	O
with	O
no	O
new	O
arrhythmic	O
events	O
.	O
He	O
is	O
being	O
monitored	O
by	O
the	O
Arrhythmia	O
Unit	O
and	O
the	O
Heart	O
Failure	O
Unit	O
of	O
our	O
Department	O
.	O
DIAGNOSIS	O
Sustained	O
monomorphic	O
ventricular	O
tachycardia	O
possibly	O
induced	O
after	O
cardiac	O
resynchronisation	O
therapy	O
in	O
a	O
patient	O
with	O
ischaemic	O
dilated	O
cardiomyopathy	O
with	O
severely	O
depressed	O
systolic	O
function	O
.	O
Radiofrequency	O
ablation	O
of	O
ischaemic	O
VT	O
substrate	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
a	O
65	O
year	O
old	O
man	O
with	O
no	O
medical	O
history	O
of	O
interest	O
except	O
for	O
dyslipidaemia	O
controlled	O
by	O
means	O
of	O
hygienic	O
dietary	O
measures	O
.	O
Non	O
smoker	O
and	O
moderate	O
drinker	O
.	O
He	O
leads	O
an	O
active	O
life	O
,	O
independent	O
in	O
terms	O
of	O
ADLs	O
.	O
He	O
reports	O
a	O
clinical	O
history	O
of	O
approximately	O
one	O
month	O
of	O
moderate	O
exertion	O
dyspnoea	O
together	O
with	O
episodes	O
of	O
palpitations	O
and	O
chest	O
pain	O
in	O
the	O
last	O
two	O
weeks	O
.	O
The	O
previous	O
night	O
she	O
had	O
presented	O
incessant	O
palpitations	O
and	O
consulted	O
her	O
primary	O
care	O
physician	O
.	O
On	O
arrival	O
at	O
the	O
outpatient	O
clinic	O
,	O
an	O
ECG	O
was	O
performed	O
showing	O
a	O
regular	O
tachycardia	O
with	O
wide	O
QRS	O
at	O
180lpm	O
.	O
The	O
patient	O
was	O
haemodynamically	O
stable	O
with	O
a	O
slight	O
feeling	O
of	O
dizziness	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
hospital	O
and	O
an	O
amiodarone	B-FARMACO
infusion	O
was	O
started	O
,	O
but	O
was	O
not	O
effective	O
in	O
reverting	O
to	O
sinus	O
rhythm	O
.	O
The	O
patient	O
began	O
to	O
become	O
hypotensive	O
and	O
a	O
CVE	O
at	O
100J	O
was	O
performed	O
,	O
leaving	O
in	O
SR	O
after	O
shock	O
.	O
On	O
arrival	O
at	O
the	O
Emergency	O
Department	O
,	O
the	O
patient	O
was	O
stable	O
,	O
somewhat	O
hypotensive	O
,	O
with	O
an	O
unremarkable	O
physical	O
examination	O
,	O
with	O
no	O
signs	O
of	O
HF	O
on	O
examination	O
,	O
and	O
reported	O
to	O
be	O
asymptomatic	O
at	O
that	O
time	O
.	O
COMPLEMENTARY	O
TESTS	O
Outpatient	O
ECG	O
regular	O
tachycardia	O
with	O
wide	O
QRS	O
at	O
180lpm	O
,	O
BRDHH	O
image	O
with	O
concordance	O
in	O
precordial	O
and	O
inferior	O
axis	O
ECG	O
on	O
arrival	O
at	O
the	O
ED	O
sinus	O
rhythm	O
at	O
about	O
65lpm	O
,	O
axis	O
at	O
30o	O
,	O
BAV	O
1st	O
degree	O
PR	O
280	O
msg	O
,	O
narrow	O
QRS	O
,	O
abundant	O
VE	O
of	O
different	O
morphologies	O
,	O
some	O
of	O
the	O
same	O
morphology	O
as	O
VT	O
but	O
others	O
of	O
different	O
ventricular	O
focus	O
.	O
CBC	O
on	O
admission	O
arterial	O
ABE	O
PO2	O
140	O
.	O
0	O
mmHg	O
75	O
95	O
,	O
PCO2	O
33	O
.	O
0	O
mmHg	O
35	O
45	O
,	O
pH	O
7	O
.	O
350	O
7	O
.	O
350	O
7	O
.	O
450	O
,	O
bicarbonate	O
HCO3	O
18	O
.	O
2	O
mmol	O
l	O
21	O
26	O
,	O
lactate	O
18	O
.	O
0	O
mg	O
dl	O
4	O
.	O
5	O
19	O
.	O
8	O
.	O
Biochemistry	O
glucose	O
181	O
mg	O
dl	O
70	O
110	O
,	O
urea	O
59	O
mg	O
dl	O
10	O
50	O
,	O
creatinine	O
1	O
.	O
53	O
mg	O
dl	O
.	O
40	O
1	O
.	O
20	O
,	O
albumin	O
4	O
.	O
38	O
g	O
dl	O
3	O
.	O
50	O
5	O
.	O
50	O
,	O
total	O
bilirubin	O
1	O
.	O
47	O
mg	O
dl	O
0	O
1	O
.	O
2	O
,	O
GPT	O
154	O
U	O
L	O
5	O
41	O
,	O
CK	O
214	O
U	O
L	O
0	O
195	O
,	O
troponin	O
T	O
142	O
ng	O
l	O
0	O
14	O
,	O
total	O
calcium	O
9	O
.	O
78	O
mg	O
dl	O
8	O
.	O
40	O
10	O
.	O
40	O
,	O
sodium	O
141	O
.	O
0	O
mmol	O
l	O
135	O
145	O
,	O
potassium	O
3	O
.	O
94	O
mmol	O
l	O
3	O
.	O
50	O
5	O
.	O
10	O
,	O
C	O
reactive	O
protein	O
0	O
.	O
33	O
mg	O
dl	O
0	O
.	O
50	O
,	O
HbA1c	O
5	O
.	O
9	O
.	O
HRF	O
haemoglobin	O
16	O
.	O
6	O
g	O
dl	O
14	O
.	O
1	O
18	O
,	O
platelets	O
260	O
10	O
3	O
μL	O
135	O
450	O
,	O
leucocytes	O
13	O
.	O
0	O
10	O
3	O
μL	O
4	O
.	O
5	O
11	O
neutrophils	O
73	O
.	O
8	O
,	O
lymphocytes	O
18	O
.	O
5	O
.	O
Coagulation	O
prothrombin	O
index	O
95	O
65	O
120	O
,	O
INR	O
1	O
.	O
03	O
,	O
APTT	O
33	O
.	O
6	O
sg	O
25	O
40	O
,	O
functional	O
fibrinogen	O
324	O
mg	O
dL	O
200	O
450	O
.	O
Enzyme	O
curve	O
CK	O
182	O
U	O
L	O
,	O
troponin	O
T	O
157	O
ng	O
L	O
.	O
Other	O
analytical	O
determinations	O
lipidogram	O
total	O
cholesterol	O
206	O
mg	O
dL	O
,	O
HDL	O
61	O
mg	O
dL	O
,	O
triglycerides	O
203	O
mg	O
dL	O
.	O
Iron	O
metabolism	O
iron	O
93	O
μg	O
dl	O
59	O
158	O
,	O
ferritin	O
223	O
ng	O
ml	O
30	O
400	O
.	O
Immunological	O
study	O
ANAs	O
,	O
PR3	O
ANCA	O
,	O
MPO	O
ANCA	O
antibodies	O
negative	O
.	O
Normal	O
thyroid	O
hormones	O
TSH	O
1	O
.	O
29	O
μU	O
ml	O
0	O
.	O
27	O
4	O
.	O
20	O
,	O
free	O
T4	O
14	O
.	O
8	O
pmol	O
l	O
10	O
.	O
3	O
26	O
.	O
0	O
.	O
Enzymes	O
ACE	O
31	O
U	O
L	O
10	O
50	O
.	O
Negative	O
serologies	O
for	O
CMV	O
,	O
enterovirus	O
,	O
parvovirus	O
,	O
HCV	O
,	O
HIV	O
,	O
Trypanosoma	O
cruzi	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
not	O
dilated	O
,	O
slightly	O
hypertrophic	O
and	O
with	O
good	O
overall	O
systolic	O
function	O
but	O
at	O
the	O
limit	O
of	O
normality	O
LVEF	O
54	O
.	O
Doubtful	O
hypokinesia	O
in	O
the	O
lower	O
basal	O
segment	O
.	O
No	O
valvulopathies	O
.	O
Right	O
chambers	O
not	O
dilated	O
and	O
with	O
good	O
function	O
.	O
Mild	O
PHT	O
.	O
Coronary	O
angio	O
CT	O
coronary	O
network	O
without	O
significant	O
lesions	O
CMR	O
LV	O
slightly	O
dilated	O
with	O
mildly	O
depressed	O
global	O
function	O
.	O
Hypokinesia	O
of	O
the	O
basal	O
medial	O
inferior	O
aspect	O
.	O
EF	O
50	O
.	O
In	O
the	O
Stir	O
potentiated	O
sequences	O
an	O
area	O
of	O
oedema	O
was	O
visualised	O
in	O
basal	O
septal	O
segments	O
.	O
In	O
the	O
early	O
enhancement	O
sequences	O
,	O
enhancement	O
was	O
visualised	O
in	O
the	O
segments	O
in	O
which	O
late	O
enhancement	O
was	O
identified	O
.	O
In	O
the	O
late	O
enhancement	O
sequences	O
intramyocardial	O
enhancement	O
with	O
transmural	O
areas	O
in	O
basal	O
septal	O
segments	O
,	O
subepicardial	O
enhancement	O
in	O
medial	O
lower	O
basal	O
segments	O
and	O
extending	O
with	O
subendocardial	O
enhancement	O
to	O
the	O
inferolateral	O
basal	O
segment	O
.	O
Electrophysiological	O
study	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
.	O
Substrate	O
ablation	O
with	O
RDF	O
.	O
ICD	O
implantation	O
is	O
indicated	O
.	O
The	O
patient	O
arrived	O
at	O
the	O
study	O
in	O
sinus	O
rhythm	O
at	O
55	O
bpm	O
with	O
first	O
degree	O
AVB	O
and	O
narrow	O
QRS	O
.	O
The	O
procedure	O
was	O
performed	O
under	O
sedation	O
with	O
propofol	B-FARMACO
and	O
ultiva	B-FARMACO
and	O
with	O
the	O
Navex	O
precision	O
system	O
.	O
The	O
left	O
ventricle	O
was	O
mapped	O
with	O
the	O
ablation	O
catheter	O
obtaining	O
an	O
anatomy	O
and	O
voltage	O
map	O
showing	O
a	O
single	O
area	O
of	O
low	O
voltage	O
in	O
the	O
lateral	O
area	O
of	O
the	O
mitral	O
annulus	O
,	O
where	O
pacemapping	O
reproduced	O
the	O
morphology	O
of	O
the	O
tachycardia	O
.	O
Induction	O
of	O
clinical	O
VT	O
is	O
attempted	O
but	O
not	O
achieved	O
at	O
baseline	O
.	O
After	O
iv	O
.	O
isoproterenol	B-FARMACO
,	O
clinical	O
VT	O
is	O
induced	O
and	O
RDF	O
is	O
applied	O
to	O
the	O
lateral	O
aspect	O
of	O
the	O
mitral	O
annulus	O
where	O
early	O
potential	O
and	O
good	O
prior	O
pacemapping	O
is	O
obtained	O
.	O
During	O
application	O
,	O
VT	O
changes	O
morphology	O
and	O
accelerates	O
to	O
a	O
ventricular	O
flutter	O
that	O
requires	O
an	O
electric	O
shock	O
for	O
its	O
termination	O
.	O
It	O
is	O
decided	O
to	O
continue	O
with	O
substrate	O
ablation	O
by	O
administering	O
a	O
corona	O
of	O
lesions	O
around	O
the	O
previous	O
area	O
in	O
the	O
mitral	O
annulus	O
.	O
EVOLUTION	O
In	O
the	O
case	O
of	O
the	O
patient	O
in	O
question	O
,	O
given	O
that	O
he	O
had	O
remained	O
stable	O
at	O
all	O
times	O
,	O
showed	O
no	O
signs	O
of	O
heart	O
failure	O
and	O
remained	O
asymptomatic	O
,	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
the	O
ward	O
with	O
telemetry	O
and	O
treatment	O
was	O
started	O
with	O
beta	O
blockers	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
,	O
1	O
0	O
1	O
.	O
Given	O
that	O
most	O
VTs	O
occur	O
in	O
the	O
context	O
of	O
ischaemic	O
heart	O
disease	O
,	O
it	O
seems	O
reasonable	O
that	O
this	O
was	O
the	O
first	O
possibility	O
to	O
rule	O
out	O
,	O
despite	O
the	O
fact	O
that	O
neither	O
the	O
clinical	O
,	O
analytical	O
nor	O
echocardiographic	O
data	O
corresponded	O
to	O
ischaemic	O
heart	O
disease	O
.	O
As	O
this	O
was	O
a	O
patient	O
with	O
few	O
CVRFs	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
coronary	O
angio	O
CT	O
scan	O
.	O
This	O
showed	O
a	O
coronary	O
network	O
with	O
no	O
significant	O
lesions	O
.	O
Therefore	O
,	O
this	O
cause	O
was	O
ruled	O
out	O
as	O
a	O
possible	O
diagnosis	O
.	O
To	O
complete	O
the	O
study	O
,	O
a	O
cardiac	O
magnetic	O
resonance	O
CMR	O
was	O
scheduled	O
.	O
The	O
findings	O
could	O
be	O
related	O
to	O
myocarditis	O
as	O
a	O
first	O
possibility	O
due	O
to	O
its	O
frequency	O
,	O
but	O
these	O
enhancements	O
are	O
described	O
in	O
other	O
less	O
probable	O
entities	O
,	O
such	O
as	O
sarcoidosis	O
or	O
Chagas	O
disease	O
.	O
The	O
possibility	O
of	O
sarcoidosis	O
was	O
considered	O
,	O
since	O
the	O
patient	O
had	O
a	O
long	O
RP	O
and	O
AVBs	O
are	O
quite	O
frequent	O
in	O
this	O
entity	O
.	O
This	O
possibility	O
was	O
also	O
ruled	O
out	O
since	O
,	O
although	O
there	O
are	O
few	O
cases	O
of	O
cardiac	O
sarcoidosis	O
without	O
systemic	O
involvement	O
,	O
there	O
were	O
no	O
mediastinal	O
adenopathies	O
,	O
restrictive	O
signs	O
or	O
myocardial	O
thickening	O
to	O
further	O
support	O
this	O
diagnosis	O
.	O
Acute	O
myocarditis	O
was	O
therefore	O
the	O
first	O
possibility	O
.	O
During	O
admission	O
,	O
the	O
patient	O
remained	O
in	O
sinus	O
rhythm	O
at	O
all	O
times	O
with	O
HR	O
around	O
60	O
75	O
bpm	O
,	O
with	O
increasingly	O
infrequent	O
VT	O
,	O
but	O
even	O
after	O
a	O
week	O
in	O
hospital	O
,	O
there	O
were	O
still	O
bouts	O
of	O
non	O
sustained	O
monomorphic	O
VT	O
,	O
self	O
limited	O
almost	O
daily	O
,	O
with	O
a	O
maximum	O
duration	O
of	O
about	O
20	O
seconds	O
,	O
with	O
haemodynamic	O
repercussions	O
in	O
some	O
cases	O
,	O
for	O
which	O
reason	O
amiodarone	B-FARMACO
was	O
associated	O
without	O
reducing	O
the	O
number	O
of	O
daily	O
events	O
.	O
In	O
view	O
of	O
this	O
situation	O
,	O
it	O
was	O
decided	O
to	O
ablate	O
the	O
VT	O
substrate	O
.	O
In	O
the	O
electrophysiological	O
study	O
,	O
during	O
radiofrequency	O
application	O
,	O
the	O
VT	O
changes	O
morphology	O
and	O
accelerates	O
to	O
a	O
ventricular	O
flutter	O
that	O
requires	O
an	O
electric	O
shock	O
for	O
its	O
termination	O
.	O
It	O
is	O
decided	O
to	O
continue	O
with	O
substrate	O
ablation	O
by	O
administering	O
a	O
lesion	O
corona	O
around	O
the	O
previous	O
area	O
in	O
the	O
mitral	O
annulus	O
.	O
The	O
reproducibility	O
of	O
post	O
ablation	O
VT	O
was	O
not	O
tested	O
for	O
fear	O
of	O
replaying	O
the	O
ventricular	O
flutter	O
and	O
implantation	O
of	O
a	O
bicameral	O
ICD	O
was	O
indicated	O
.	O
A	O
couple	O
of	O
days	O
later	O
the	O
ICD	O
was	O
implanted	O
without	O
complications	O
and	O
the	O
patient	O
was	O
discharged	O
.	O
The	O
patient	O
is	O
currently	O
asymptomatic	O
and	O
is	O
being	O
treated	O
with	O
beta	O
blockers	O
bisoprolol	B-FARMACO
5	O
mg	O
,	O
1	O
0	O
1	O
.	O
Periodic	O
follow	O
up	O
is	O
carried	O
out	O
in	O
electrophysiology	O
consultations	O
and	O
control	O
of	O
the	O
device	O
by	O
remote	O
monitoring	O
.	O
So	O
far	O
,	O
5	O
months	O
after	O
the	O
episode	O
presented	O
,	O
no	O
arrhythmia	O
requiring	O
ICD	O
discharge	O
has	O
been	O
recorded	O
,	O
with	O
only	O
a	O
few	O
asymptomatic	O
and	O
self	O
limited	O
episodes	O
of	O
NSTEVM	O
.	O
DIAGNOSIS	O
Sustained	O
ventricular	O
tachycardia	O
in	O
the	O
context	O
of	O
probable	O
acute	O
myocarditis	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
case	O
in	O
question	O
focuses	O
on	O
a	O
72	O
year	O
old	O
male	O
admitted	O
to	O
the	O
coronary	O
care	O
unit	O
CCU	O
for	O
arrhythmic	O
storm	O
in	O
November	O
2016	O
.	O
The	O
personal	O
history	O
of	O
this	O
patient	O
is	O
Independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
ABVD	O
.	O
Smoker	O
.	O
Arterial	O
hypertension	O
AHT	O
,	O
dyslipidaemia	O
,	O
type	O
2	O
diabetes	O
mellitus	O
on	O
treatment	O
with	O
oral	O
antidiabetics	O
OAD	O
.	O
Stage	O
3A	O
chronic	O
kidney	O
disease	O
CKD	O
.	O
Severe	O
chronic	O
obstructive	O
pulmonary	O
disease	O
COPD	O
.	O
Bladder	O
neoplasia	O
in	O
2011	O
treated	O
with	O
surgery	O
cystoprostatectomy	O
Bricker	O
ureteroileostomy	O
and	O
later	O
QT	O
.	O
Cardiological	O
history	O
chronic	O
ischaemic	O
heart	O
disease	O
acute	O
myocardial	O
infarction	O
AMI	O
in	O
1999	O
stable	O
,	O
with	O
follow	O
up	O
by	O
his	O
primary	O
care	O
physician	O
.	O
As	O
previously	O
mentioned	O
,	O
the	O
patient	O
was	O
admitted	O
in	O
an	O
arrhythmic	O
storm	O
.	O
To	O
stop	O
the	O
arrhythmic	O
problem	O
in	O
the	O
acute	O
phase	O
,	O
the	O
patient	O
required	O
five	O
cardioversions	O
and	O
continuous	O
venous	O
perfusion	O
of	O
procainamide	B-FARMACO
.	O
Due	O
to	O
persistent	O
non	O
sustained	O
ventricular	O
tachycardia	O
NSVT	O
of	O
similar	O
morphology	O
to	O
that	O
described	O
above	O
,	O
the	O
patient	O
was	O
overstimulated	O
by	O
femoral	O
electrocatheter	O
,	O
and	O
the	O
arrhythmogenic	O
activity	O
was	O
resolved	O
.	O
During	O
his	O
admission	O
,	O
coronary	O
angiography	O
was	O
performed	O
which	O
showed	O
diffuse	O
ischaemic	O
heart	O
disease	O
,	O
with	O
3	O
vessel	O
disease	O
,	O
without	O
acute	O
lesions	O
and	O
cardiac	O
surgery	O
was	O
ruled	O
out	O
,	O
given	O
the	O
patient	O
's	O
high	O
surgical	O
risk	O
.	O
The	O
patient	O
was	O
referred	O
for	O
electrophysiological	O
study	O
EPS	O
and	O
ablation	O
of	O
ventricular	O
tachycardia	O
VT	O
which	O
,	O
as	O
a	O
complication	O
,	O
presented	O
complete	O
atrioventricular	O
AV	O
block	O
that	O
persisted	O
after	O
1	O
week	O
of	O
EPS	O
,	O
it	O
was	O
therefore	O
finally	O
decided	O
to	O
implant	O
a	O
bicameral	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
because	O
he	O
had	O
ischaemic	O
heart	O
disease	O
without	O
acute	O
lesions	O
that	O
could	O
explain	O
the	O
arrhythmic	O
storm	O
,	O
with	O
severe	O
ventricular	O
dysfunction	O
EF4C	O
Simpson	O
30	O
and	O
a	O
prognosis	O
of	O
more	O
than	O
12	O
months	O
and	O
he	O
was	O
discharged	O
with	O
the	O
following	O
treatment	O
adiro	B-FARMACO
100	O
mg	O
1	O
tablet	O
daily	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
1	O
tablet	O
in	O
the	O
morning	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
1	O
tablet	O
in	O
the	O
evening	O
,	O
amiodarone	B-FARMACO
200	O
mg	O
every	O
24	O
hours	O
at	O
lunch	O
,	O
inhaled	O
indacaterol	B-FARMACO
glycopyrronium	I-FARMACO
every	O
24	O
hours	O
,	O
budesonide	B-FARMACO
200	O
mcg	O
every	O
12	O
hours	O
,	O
hydroferol	B-FARMACO
ampoule	O
drinkable	O
every	O
10	O
days	O
.	O
The	O
patient	O
remained	O
asymptomatic	O
for	O
angina	O
and	O
ventricular	O
arrhythmias	O
for	O
8	O
months	O
,	O
until	O
July	O
2017	O
when	O
he	O
was	O
admitted	O
to	O
internal	O
medicine	O
for	O
febrile	O
syndrome	O
under	O
study	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYTICS	O
on	O
admission	O
23	O
July	O
2017	O
creatinine	O
1	O
.	O
95	O
mg	O
dl	O
33	O
.	O
9	O
ml	O
mi	O
1	O
.	O
73	O
m2	O
,	O
urea	O
52	O
mg	O
dl	O
,	O
sodium	O
137	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
3	O
mEq	O
l	O
,	O
CRP	O
37	O
.	O
2	O
mg	O
dl	O
,	O
INR	O
1	O
.	O
02	O
,	O
Hb	O
10	O
.	O
7	O
g	O
dl	O
,	O
Hto	O
31	O
.	O
2	O
,	O
leukocytes	O
21900	O
PMN	O
92	O
,	O
platelets	O
207000	O
.	O
HEMOCULTURES	O
23	O
07	O
positive	O
for	O
Staphylococcus	O
aureus	O
oxacillin	O
sensitive	O
.	O
06	O
08	O
negative	O
.	O
09	O
08	O
negative	O
.	O
11	O
08	O
Staphylococcus	O
epidermidis	O
grows	O
in	O
a	O
bottle	O
considered	O
contamination	O
.	O
14	O
08	O
negative	O
.	O
16	O
08	O
negative	O
.	O
21	O
08	O
negative	O
.	O
24	O
08	O
negative	O
.	O
28	O
08	O
negative	O
.	O
THORAX	O
RADIOGRAPHY	O
slightly	O
rotated	O
plaque	O
with	O
cardiothoracic	O
index	O
CTI	O
at	O
the	O
limit	O
of	O
normality	O
,	O
slight	O
signs	O
of	O
vascular	O
redistribution	O
.	O
Right	O
atrium	O
RA	O
and	O
right	O
ventricle	O
RV	O
electrodes	O
in	O
normal	O
position	O
,	O
with	O
no	O
signs	O
of	O
fracture	O
.	O
PET	O
CT	O
scan	O
Focal	O
uptake	O
in	O
the	O
path	O
of	O
the	O
LAD	O
lead	O
at	O
the	O
level	O
of	O
the	O
left	O
subclavian	O
artery	O
suspected	O
to	O
correspond	O
to	O
the	O
infectious	O
process	O
causing	O
the	O
bacteraemia	O
and	O
fever	O
,	O
with	O
another	O
smaller	O
and	O
milder	O
uptake	O
observed	O
in	O
the	O
posterosuperior	O
face	O
of	O
the	O
LAD	O
at	O
the	O
exit	O
of	O
the	O
lead	O
,	O
probably	O
related	O
to	O
the	O
same	O
aetiology	O
.	O
Discrete	O
bilateral	O
pleural	O
effusion	O
.	O
Post	O
radical	O
cystoprostatectomy	O
changes	O
with	O
Bricker	O
shunt	O
.	O
No	O
other	O
hypermetabolic	O
locations	O
in	O
the	O
rest	O
of	O
the	O
study	O
.	O
TEE	O
non	O
dilated	O
left	O
ventricle	O
LV	O
,	O
with	O
severe	O
depression	O
of	O
myocardial	O
function	O
and	O
akinesia	O
of	O
all	O
anterior	O
and	O
lateral	O
segments	O
.	O
RV	O
with	O
LAD	O
lead	O
,	O
in	O
which	O
at	O
the	O
level	O
of	O
the	O
tricuspid	O
valve	O
there	O
is	O
a	O
sessile	O
,	O
beating	O
image	O
,	O
compatible	O
with	O
vegetation	O
dependent	O
on	O
the	O
device	O
lead	O
,	O
measuring	O
3	O
x	O
5	O
mm	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
remained	O
asymptomatic	O
for	O
8	O
months	O
until	O
July	O
2017	O
,	O
when	O
he	O
was	O
admitted	O
to	O
internal	O
medicine	O
for	O
febrile	O
syndrome	O
under	O
study	O
.	O
Blood	O
cultures	O
2	O
x	O
2	O
serial	O
cultures	O
showed	O
Staphylococcus	O
aureus	O
.	O
A	O
transesophageal	O
echocardiogram	O
was	O
requested	O
,	O
which	O
showed	O
vegetation	O
on	O
the	O
device	O
.	O
A	O
PET	O
CT	O
scan	O
was	O
requested	O
,	O
which	O
showed	O
infection	O
of	O
the	O
ICD	O
lead	O
.	O
Initially	O
,	O
daptomycin	B-FARMACO
had	O
been	O
prescribed	O
,	O
which	O
was	O
changed	O
to	O
cloxacillin	B-FARMACO
with	O
the	O
antibiogram	O
results	O
.	O
After	O
confirming	O
infection	O
of	O
the	O
ICD	O
catheter	O
,	O
daptomycin	B-FARMACO
adjusted	O
to	O
glomerular	O
filtration	O
rate	O
and	O
rifampicin	B-FARMACO
were	O
reintroduced	O
.	O
Gentamicin	B-FARMACO
was	O
not	O
added	O
due	O
to	O
deterioration	O
of	O
renal	O
function	O
.	O
He	O
was	O
transferred	O
to	O
cardiac	O
surgery	O
at	O
the	O
reference	O
centre	O
for	O
explant	O
of	O
the	O
device	O
,	O
and	O
extraction	O
with	O
energy	O
sources	O
was	O
performed	O
.	O
Subsequently	O
,	O
she	O
was	O
readmitted	O
to	O
the	O
OCU	O
,	O
remaining	O
with	O
an	O
escape	O
rate	O
of	O
36	O
38	O
bpm	O
with	O
good	O
tolerance	O
.	O
Antibiotic	O
therapy	O
with	O
cloxacillin	B-FARMACO
was	O
maintained	O
during	O
admission	O
.	O
The	O
patient	O
had	O
episodes	O
of	O
NSVT	O
and	O
,	O
despite	O
the	O
bradycardia	O
,	O
amiodarone	B-FARMACO
was	O
reintroduced	O
.	O
The	O
patient	O
tolerated	O
sitting	O
and	O
ambulation	O
with	O
no	O
signs	O
of	O
low	O
cardiac	O
output	O
.	O
After	O
negative	O
culture	O
serology	O
and	O
a	O
control	O
echocardiogram	O
with	O
no	O
evidence	O
of	O
vegetation	O
,	O
it	O
was	O
decided	O
to	O
implant	O
a	O
new	O
device	O
.	O
The	O
possibility	O
of	O
an	O
epicardial	O
approach	O
was	O
discussed	O
,	O
but	O
finally	O
,	O
transvenous	O
ICD	O
DDD	O
implantation	O
was	O
performed	O
.	O
After	O
discharge	O
,	O
the	O
patient	O
was	O
monitored	O
by	O
the	O
infectious	O
disease	O
service	O
of	O
our	O
centre	O
and	O
has	O
remained	O
clinically	O
stable	O
to	O
date	O
.	O
DIAGNOSIS	O
Endocarditis	O
due	O
to	O
methicillin	O
sensitive	O
S	O
.	O
aureus	O
on	O
native	O
tricuspid	O
valve	O
associated	O
with	O
device	O
.	O
Complete	O
AV	O
block	O
post	O
ablation	O
.	O
History	O
of	O
arrhythmic	O
storm	O
that	O
led	O
to	O
ICD	O
implantation	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
.	O
Mild	O
ventricular	O
dysfunction	O
.	O
Moderate	O
pulmonary	O
hypertension	O
.	O
Severe	O
COPD	O
.	O
Stage	O
3A	O
chronic	O
kidney	O
disease	O
.	O
Functional	O
monorenal	O
.	O
Cystoprostatectomy	O
and	O
Bricker	O
ureteroileostomy	O
for	O
bladder	O
neoplasia	O
in	O
2011	O
and	O
prostatic	O
adenocarcinoma	O
.	O
Arterial	O
hypertension	O
.	O
Diabetes	O
mellitus	O
.	O
Dyslipemia	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
38	O
year	O
old	O
man	O
with	O
no	O
CVRF	O
,	O
family	O
history	O
or	O
previous	O
cardiological	O
history	O
.	O
Under	O
digestive	O
follow	O
up	O
for	O
Crohn	O
's	O
disease	O
with	O
enterovesical	O
fistula	O
and	O
recent	O
admission	O
for	O
severe	O
infectious	O
disease	O
of	O
abdominal	O
origin	O
.	O
Clinical	O
judgement	O
at	O
discharge	O
was	O
septic	O
shock	O
secondary	O
to	O
perforation	O
of	O
toxic	O
megacolon	O
with	O
faecaloid	O
peritonitis	O
,	O
requiring	O
urgent	O
surgical	O
intervention	O
subtotal	O
colectomy	O
ileostomy	O
.	O
Three	O
days	O
after	O
discharge	O
from	O
the	O
general	O
surgery	O
department	O
,	O
he	O
consulted	O
for	O
chest	O
pain	O
.	O
This	O
discomfort	O
was	O
atypical	O
and	O
partially	O
improved	O
with	O
non	O
steroidal	O
anti	O
inflammatory	O
drugs	O
NSAIDs	O
.	O
He	O
also	O
reported	O
progressive	O
dyspnoea	O
that	O
started	O
at	O
the	O
same	O
time	O
and	O
became	O
minimal	O
effort	O
New	O
York	O
Heart	O
Association	O
functional	O
class	O
III	O
NYHA	O
III	O
.	O
There	O
were	O
no	O
other	O
cardiological	O
symptoms	O
in	O
the	O
anamnesis	O
.	O
On	O
examination	O
,	O
the	O
patient	O
's	O
general	O
condition	O
was	O
acceptable	O
.	O
He	O
is	O
eupneic	O
at	O
rest	O
and	O
tolerates	O
decubitus	O
.	O
Blood	O
pressure	O
BP	O
90	O
70	O
mmHg	O
.	O
Tachycardic	O
at	O
110	O
bpm	O
.	O
Afebrile	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Tracheostomy	O
previous	O
prolonged	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
ICU	O
without	O
complication	O
data	O
.	O
Cardiopulmonary	O
auscultation	O
was	O
unremarkable	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
with	O
normofunctioning	O
ileostomy	O
.	O
There	O
was	O
a	O
soft	O
tissue	O
lesion	O
in	O
the	O
left	O
fossa	O
with	O
mucopurulent	O
secretion	O
.	O
Lower	O
limbs	O
without	O
oedema	O
.	O
The	O
electrocardiogram	O
performed	O
in	O
the	O
consultation	O
room	O
showed	O
sinus	O
tachycardia	O
with	O
generalised	O
flattening	O
of	O
the	O
T	O
wave	O
.	O
The	O
chest	O
X	O
ray	O
was	O
unremarkable	O
.	O
Blood	O
tests	O
showed	O
haemoglobin	O
Hb	O
of	O
8	O
.	O
6	O
g	O
dl	O
and	O
elevated	O
C	O
reactive	O
protein	O
CRP	O
without	O
leukocytosis	O
.	O
D	O
dimer	O
negative	O
.	O
Serial	O
ultrasensitive	O
troponin	O
T	O
TnTus	O
maintained	O
at	O
around	O
30	O
25	O
30	O
29	O
ng	O
l	O
,	O
normal	O
CPK	O
.	O
Urgent	O
echocardiography	O
was	O
performed	O
,	O
showing	O
severe	O
left	O
ventricular	O
dysfunction	O
LVEF	O
30	O
with	O
global	O
hypokinesia	O
,	O
and	O
the	O
patient	O
was	O
admitted	O
to	O
cardiology	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYTICS	O
renal	O
function	O
preserved	O
.	O
No	O
leukocytosis	O
or	O
neutrophilia	O
.	O
Hb	O
8	O
.	O
6	O
g	O
dl	O
.	O
Platelets	O
and	O
coagulation	O
in	O
range	O
.	O
D	O
dimer	O
negative	O
.	O
TNT	O
US	O
25	O
30	O
29	O
.	O
THORAX	O
RADIOGRAPHY	O
normal	O
cardiothoracic	O
index	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
Slight	O
increase	O
of	O
interstitial	O
tissue	O
at	O
the	O
bases	O
.	O
No	O
images	O
of	O
condensation	O
or	O
pleural	O
effusion	O
.	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
tachycardia	O
at	O
100	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
Generalised	O
flattening	O
of	O
the	O
T	O
wave	O
.	O
Normal	O
QTc	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
left	O
atrium	O
of	O
normal	O
dimensions	O
24	O
mm	O
in	O
AP	O
.	O
Mitral	O
valve	O
with	O
fine	O
leaflets	O
and	O
good	O
mobility	O
opening	O
and	O
closing	O
preserved	O
.	O
Left	O
ventricle	O
LV	O
of	O
normal	O
dimensions	O
end	O
diastolic	O
diameter	O
EDD	O
49	O
mm	O
and	O
end	O
systolic	O
diameter	O
ESD	O
43	O
mm	O
with	O
end	O
diastolic	O
volume	O
EDV	O
and	O
end	O
systolic	O
volume	O
ESV	O
of	O
136	O
ml	O
and	O
97	O
ml	O
,	O
respectively	O
.	O
Normal	O
myocardial	O
thickness	O
8	O
mm	O
septum	O
and	O
7	O
mm	O
inferolateral	O
wall	O
.	O
Generalised	O
hypocontractility	O
and	O
ejection	O
fraction	O
EF	O
estimated	O
by	O
biplane	O
disc	O
of	O
29	O
.	O
Aortic	O
valve	O
with	O
fine	O
leaflets	O
and	O
good	O
opening	O
.	O
Left	O
ventricular	O
outflow	O
tract	O
LVOT	O
21	O
mm	O
,	O
sinuses	O
of	O
Valsalva	O
31	O
mm	O
,	O
UST	O
23	O
mm	O
.	O
Right	O
ventricle	O
RV	O
of	O
normal	O
dimensions	O
with	O
normal	O
systolic	O
function	O
.	O
Mild	O
1	O
tricuspid	O
insufficiency	O
TI	O
jet	O
with	O
suboptimal	O
Doppler	O
to	O
estimate	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAPs	O
.	O
No	O
pericardial	O
effusion	O
.	O
CORONARYGRAPHY	O
coronary	O
arteries	O
without	O
angiographic	O
lesions	O
.	O
CARDIAC	O
MAGNETIC	O
RESONANCE	O
CMR	O
generalised	O
hypokinesia	O
,	O
more	O
accentuated	O
in	O
the	O
septum	O
inferior	O
segment	O
in	O
the	O
middle	O
and	O
apical	O
zones	O
.	O
Severely	O
depressed	O
LVEF	O
34	O
.	O
6	O
.	O
RV	O
of	O
normal	O
dimensions	O
and	O
preserved	O
right	O
ventricular	O
ejection	O
fraction	O
RVEF	O
.	O
Myocardial	O
thickness	O
and	O
tissue	O
signal	O
in	O
T2	O
and	O
STIR	O
sequences	O
short	O
TI	O
Inversion	O
Recovery	O
normal	O
.	O
No	O
significant	O
valvulopathies	O
.	O
No	O
pericardial	O
effusion	O
.	O
Conclusion	O
signs	O
of	O
severe	O
contractile	O
dysfunction	O
of	O
the	O
LV	O
without	O
deriving	O
from	O
this	O
exploration	O
data	O
to	O
guide	O
possible	O
aetiology	O
.	O
The	O
examination	O
was	O
not	O
complete	O
as	O
it	O
was	O
interrupted	O
at	O
the	O
patient	O
's	O
express	O
wish	O
incomplete	O
sequence	O
no	O
late	O
gadolinium	O
enhancement	O
.	O
Control	O
abdominal	O
CT	O
scan	O
resolution	O
of	O
the	O
previous	O
effusions	O
.	O
14	O
mm	O
lesion	O
in	O
segment	O
VI	O
of	O
the	O
liver	O
haemangioma	O
.	O
Discrete	O
splenomegaly	O
12	O
.	O
2	O
x	O
5	O
.	O
6	O
cm	O
.	O
Collections	O
in	O
the	O
anterior	O
abdominal	O
wall	O
one	O
under	O
the	O
laparotomy	O
scar	O
30	O
x	O
7	O
x	O
10	O
mm	O
and	O
another	O
more	O
caudalsupravesical	O
12	O
x	O
13	O
x	O
38	O
mm	O
.	O
At	O
retroperitoneal	O
level	O
in	O
right	O
anterior	O
pararenal	O
space	O
56	O
x	O
20	O
x	O
52	O
mm	O
and	O
right	O
posterior	O
pararenal	O
space	O
60	O
x	O
29	O
x	O
137	O
mm	O
and	O
left	O
anterior	O
pararenal	O
space	O
38	O
x	O
17	O
x	O
47	O
mm	O
.	O
Uncomplicated	O
right	O
vacuum	O
ileostomy	O
.	O
Loops	O
of	O
normal	O
calibre	O
with	O
no	O
mucosal	O
hypercaptation	O
or	O
mural	O
thickening	O
suggestive	O
of	O
current	O
inflammatory	O
bowel	O
disease	O
IBD	O
.	O
No	O
other	O
striking	O
alterations	O
.	O
CLINICAL	O
EVOLUTION	O
A	O
regular	O
TTE	O
was	O
requested	O
which	O
showed	O
severe	O
left	O
ventricular	O
dysfunction	O
LVEF	O
by	O
Simpson	O
biplane	O
of	O
29	O
with	O
global	O
hypocontractility	O
see	O
complete	O
report	O
in	O
complementary	O
tests	O
.	O
Ischaemic	O
aetiology	O
of	O
the	O
systolic	O
dysfunction	O
was	O
ruled	O
out	O
by	O
coronary	O
angiography	O
.	O
To	O
complete	O
the	O
study	O
,	O
CMR	O
was	O
performed	O
,	O
which	O
showed	O
no	O
data	O
suggesting	O
an	O
aetiology	O
normal	O
T2	O
and	O
STIR	O
,	O
without	O
being	O
able	O
to	O
administer	O
late	O
enhancement	O
due	O
to	O
the	O
patient	O
's	O
refusal	O
see	O
full	O
report	O
in	O
complementary	O
tests	O
.	O
After	O
reviewing	O
the	O
literature	O
and	O
,	O
taking	O
into	O
account	O
the	O
clinical	O
context	O
of	O
the	O
patient	O
,	O
two	O
diagnostic	O
possibilities	O
are	O
evaluated	O
,	O
which	O
are	O
not	O
mutually	O
exclusive	O
Severe	O
ventricular	O
dysfunction	O
in	O
the	O
context	O
of	O
gram	O
negative	O
sepsis	O
recent	O
faecaloid	O
peritonitis	O
.	O
Deficiency	O
cardiomyopathy	O
in	O
a	O
patient	O
with	O
probable	O
nutritional	O
deficit	O
Crohn	O
's	O
disease	O
with	O
prolonged	O
admission	O
to	O
the	O
ICU	O
.	O
The	O
patient	O
started	O
treatment	O
for	O
systolic	O
dysfunction	O
during	O
admission	O
carvedilol	B-FARMACO
6	O
.	O
25	O
mg	O
2	O
0	O
1	O
,	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
1	O
2	O
tablet	O
at	O
breakfast	O
,	O
oral	O
ferrotherapy	O
1	O
tablet	O
on	O
an	O
empty	O
stomach	O
and	O
loop	O
diuretics	O
in	O
initial	O
phases	O
.	O
Treatment	O
with	O
spironolactone	B-FARMACO
was	O
not	O
started	O
due	O
to	O
low	O
blood	O
pressure	O
with	O
a	O
minimum	O
dose	O
of	O
angiotensin	B-FARMACO
converting	I-FARMACO
enzyme	I-FARMACO
inhibitor	I-FARMACO
ACE	I-FARMACO
inhibitor	I-FARMACO
.	O
The	O
possibility	O
of	O
vitamin	O
vitamin	O
D	O
thiamine	O
and	O
trace	O
element	O
selenium	O
iron	O
deficiency	O
was	O
assessed	O
.	O
Samples	O
were	O
taken	O
for	O
intraerythrocyte	O
trancetolase	O
activity	O
and	O
selenium	O
,	O
iron	O
profile	O
,	O
vitamin	O
D	O
and	O
folic	O
acid	O
.	O
Treatment	O
was	O
started	O
with	O
IV	O
thiamine	B-FARMACO
,	O
polyvitamin	O
complex	O
,	O
polymeric	O
supplements	O
and	O
an	O
optimised	O
oral	O
diet	O
.	O
The	O
patient	O
's	O
follow	O
up	O
during	O
admission	O
was	O
multidisciplinary	O
Digestive	O
general	O
surgery	O
treatment	O
with	O
azathioprine	B-FARMACO
was	O
restarted	O
.	O
A	O
control	O
CAT	O
scan	O
was	O
performed	O
see	O
complementary	O
tests	O
and	O
,	O
in	O
view	O
of	O
the	O
patient	O
's	O
good	O
evolution	O
,	O
it	O
was	O
decided	O
to	O
continue	O
with	O
antibibiotherapy	O
metronidazole	B-FARMACO
,	O
clinical	O
follow	O
up	O
and	O
re	O
evaluation	O
by	O
imaging	O
test	O
in	O
two	O
months	O
'	O
time	O
.	O
Nutrition	O
supervises	O
treatment	O
during	O
admission	O
,	O
achieving	O
a	O
weight	O
gain	O
of	O
3	O
kg	O
.	O
Otorhinolaryngology	O
assesses	O
the	O
tracheostomy	O
and	O
proceeds	O
to	O
decannulation	O
.	O
The	O
tracheostomy	O
was	O
closed	O
by	O
second	O
intention	O
.	O
The	O
patient	O
's	O
evolution	O
was	O
favourable	O
,	O
being	O
discharged	O
without	O
chest	O
pain	O
and	O
in	O
good	O
functional	O
class	O
.	O
Treatment	O
at	O
discharge	O
was	O
as	O
follows	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
.	O
carvedilol	B-FARMACO
6	O
.	O
25	O
mg	O
2	O
0	O
1	O
,	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
0	O
.	O
5	O
0	O
0	O
,	O
metronidazole	B-FARMACO
250	O
mg	O
every	O
8	O
hours	O
,	O
oral	O
iron	B-FARMACO
1	O
0	O
0	O
,	O
vitamin	O
complex	O
2	O
tablets	O
per	O
day	O
,	O
cinitapride	B-FARMACO
1	O
mg	O
every	O
8	O
hours	O
,	O
thiamine	B-FARMACO
300	O
mg	O
every	O
24	O
hours	O
,	O
Ca	O
VitD	B-FARMACO
1000	O
U	O
complex	O
2	O
tablets	O
per	O
day	O
,	O
calorie	O
shakes	O
,	O
citalopram	B-FARMACO
20	O
mg	O
1	O
tablet	O
per	O
day	O
,	O
lorazepam	B-FARMACO
1	O
mg	O
at	O
night	O
,	O
fibre	O
free	O
diet	O
avoiding	O
excess	O
fibre	O
.	O
At	O
the	O
consultation	O
two	O
months	O
after	O
admission	O
,	O
the	O
patient	O
was	O
asymptomatic	O
and	O
there	O
was	O
no	O
recurrence	O
of	O
chest	O
pain	O
.	O
TTE	O
showed	O
normalisation	O
of	O
LVEF	O
.	O
The	O
patient	O
has	O
regained	O
weight	O
and	O
has	O
had	O
no	O
new	O
Crohn	O
's	O
flares	O
abdominal	O
complications	O
.	O
The	O
tracheostomy	O
has	O
closed	O
by	O
second	O
intention	O
.	O
Discharge	O
was	O
decided	O
by	O
the	O
advanced	O
HF	O
and	O
transplant	O
team	O
for	O
periodic	O
follow	O
up	O
in	O
the	O
local	O
cardiology	O
department	O
.	O
DIAGNOSIS	O
Heart	O
failure	O
in	O
a	O
patient	O
with	O
transient	O
severe	O
left	O
ventricular	O
dysfunction	O
in	O
the	O
context	O
of	O
Gram	O
negative	O
sepsis	O
.	O
Possibly	O
aggravated	O
by	O
nutritional	O
deficits	O
secondary	O
to	O
his	O
digestive	O
pathology	O
Crohn	O
's	O
disease	O
and	O
recent	O
prolonged	O
hospitalisation	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
62	O
year	O
old	O
man	O
from	O
León	O
,	O
who	O
is	O
in	O
our	O
health	O
area	O
on	O
holiday	O
.	O
Currently	O
retired	O
,	O
he	O
worked	O
as	O
a	O
boilermaker	O
.	O
BACKGROUND	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
arterial	O
hypertension	O
,	O
diabetes	O
mellitus	O
on	O
treatment	O
with	O
oral	O
antidiabetics	O
with	O
good	O
control	O
.	O
Ex	O
smoker	O
for	O
3	O
years	O
of	O
half	O
a	O
packet	O
day	O
since	O
youth	O
40	O
packets	O
year	O
.	O
No	O
other	O
toxic	O
habits	O
.	O
Previous	O
cardiological	O
history	O
refers	O
to	O
coronary	O
angiography	O
following	O
exertional	O
angina	O
in	O
another	O
hospital	O
with	O
implantation	O
of	O
at	O
least	O
one	O
stent	O
coronary	O
anatomy	O
unknown	O
at	O
the	O
time	O
of	O
the	O
initial	O
anamnesis	O
.	O
Chronic	O
treatment	O
ranolazine	B-FARMACO
,	O
acovil	B-FARMACO
,	O
metoprolol	B-FARMACO
,	O
pantoprazole	B-FARMACO
,	O
metformin	B-FARMACO
vildagliptin	I-FARMACO
,	O
repaglinide	B-FARMACO
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
,	O
pravastatin	B-FARMACO
fenofibrate	I-FARMACO
.	O
CURRENT	O
ILLNESS	O
A	O
62	O
year	O
old	O
male	O
patient	O
with	O
the	O
above	O
described	O
history	O
was	O
referred	O
to	O
the	O
emergency	O
department	O
for	O
evaluation	O
due	O
to	O
elevated	O
markers	O
of	O
myocardial	O
damage	O
.	O
The	O
patient	O
consulted	O
for	O
clinical	O
symptoms	O
of	O
dizziness	O
,	O
general	O
malaise	O
and	O
instability	O
in	O
the	O
previous	O
24	O
hours	O
.	O
In	O
addition	O
,	O
he	O
reported	O
atypical	O
chest	O
pain	O
throughout	O
the	O
day	O
,	O
coinciding	O
with	O
the	O
rest	O
of	O
the	O
clinical	O
picture	O
,	O
which	O
he	O
differentiated	O
from	O
his	O
previous	O
angina	O
.	O
He	O
was	O
accompanied	O
by	O
his	O
wife	O
,	O
who	O
was	O
suffering	O
symptoms	O
of	O
headache	O
and	O
dizziness	O
similar	O
to	O
those	O
of	O
our	O
patient	O
.	O
PHYSICAL	O
EXAMINATION	O
Conscious	O
,	O
oriented	O
,	O
cooperative	O
.	O
Blood	O
pressure	O
BP	O
110	O
55	O
mmHg	O
.	O
Heart	O
rate	O
77	O
bpm	O
.	O
Well	O
perfused	O
.	O
Eupneic	O
at	O
rest	O
without	O
oxygen	B-FARMACO
.	O
Rhythmic	O
heart	O
sounds	O
,	O
no	O
murmurs	O
.	O
Bladder	O
murmur	O
preserved	O
.	O
Normal	O
abdominal	O
examination	O
.	O
Lower	O
limbs	O
without	O
oedema	O
.	O
Positive	O
pedia	O
bilaterally	O
.	O
No	O
neurological	O
focality	O
.	O
COMPLEMENTARY	O
TESTS	O
Haemogram	O
red	O
blood	O
cells	O
4	O
.	O
76	O
x10E6	O
μl	O
,	O
haemoglobin	O
13	O
.	O
6	O
g	O
dl	O
,	O
haematocrit	O
38	O
.	O
8	O
.	O
MCV	O
81	O
.	O
5	O
fl	O
.	O
MCH	O
28	O
.	O
6	O
pg	O
.	O
MCHC	O
35	O
.	O
1	O
g	O
dl	O
.	O
Leukocytes	O
14	O
.	O
73	O
x10E3	O
μl	O
.	O
Neutrophils	O
blood	O
74	O
.	O
9	O
.	O
Neutrophils	O
11	O
.	O
03	O
x10E3	O
μl	O
.	O
Lymphocytes	O
15	O
.	O
8	O
.	O
Lymphocytes	O
2	O
.	O
33	O
x10E3	O
μl	O
.	O
Monocytes	O
blood	O
9	O
.	O
Monocytes	O
1	O
.	O
33	O
x10E3	O
μl	O
.	O
Eosinophils	O
blood	O
0	O
.	O
1	O
.	O
Eosinophils	O
0	O
.	O
01	O
x10E3	O
μl	O
low	O
a	O
.	O
Basophils	O
blood	O
0	O
.	O
2	O
.	O
Basophils	O
0	O
.	O
03	O
x10E3	O
μl	O
.	O
UPLAQ	O
platelets	O
214	O
x10E3	O
μl	O
.	O
VPM	O
12	O
.	O
6	O
fl	O
.	O
SR	O
RDW	O
Coefficient	O
of	O
variation	O
14	O
.	O
5	O
.	O
BIOCHEMISTRY	O
Glucose	O
449	O
mg	O
dl	O
.	O
Urea	O
94	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
4	O
mg	O
dl	O
.	O
Sodium	O
ion	O
135	O
mmol	O
l	O
.	O
Plasma	O
potassium	O
ion	O
4	O
.	O
6	O
mmol	O
l	O
.	O
ARTERIAL	O
GASOMETRY	O
pH	O
arterial	O
gas	O
7	O
.	O
41	O
,	O
pCO2	O
arterial	O
gas	O
31	O
mmHg	O
low	O
,	O
pO2	O
arterial	O
gas	O
71	O
mmHg	O
low	O
.	O
Bicarbonate	O
arterial	O
gas	O
21	O
.	O
4	O
mmol	O
l	O
.	O
Total	O
CO2	O
arterial	O
gas	O
21	O
mmol	O
l	O
.	O
Excess	O
bases	O
arterial	O
gas	O
4	O
.	O
5	O
mmol	O
l	O
low	O
.	O
Oxyhaemoglobin	O
saturation	O
arterial	O
gas	O
93	O
low	O
.	O
Carboxyhaemoglobin	O
on	O
admission	O
14	O
.	O
Carboxyhaemoglobin	O
after	O
hyperbaric	O
chamber	O
normal	O
.	O
MARKERS	O
OF	O
MYOCARDIAL	O
DAMAGE	O
CK	O
U	O
L	O
1985	O
2508	O
at	O
24	O
hours	O
441	O
at	O
48	O
hours	O
.	O
TnT	O
ng	O
l	O
,	O
normal	O
to	O
35	O
1836	O
3828	O
at	O
24	O
hours	O
6000	O
at	O
48	O
hours	O
.	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
.	O
Signs	O
of	O
left	O
atrial	O
enlargement	O
and	O
left	O
bundle	O
branch	O
block	O
LBBB	O
.	O
THORAX	O
RADIOGRAPHY	O
normal	O
cardiothoracic	O
index	O
.	O
No	O
condensation	O
or	O
signs	O
of	O
heart	O
failure	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
urgent	O
left	O
ventricle	O
slightly	O
dilated	O
with	O
severe	O
systolic	O
dysfunction	O
at	O
the	O
expense	O
of	O
akinesia	O
of	O
the	O
middle	O
and	O
apical	O
segment	O
of	O
the	O
septum	O
and	O
global	O
hypokinesia	O
of	O
the	O
rest	O
of	O
the	O
segments	O
,	O
more	O
marked	O
in	O
the	O
inferolateral	O
and	O
inferior	O
wall	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
systolic	O
function	O
.	O
Left	O
atrium	O
of	O
normal	O
size	O
.	O
Aortic	O
valve	O
with	O
good	O
opening	O
,	O
slightly	O
calcified	O
.	O
Trivial	O
mitral	O
insufficiency	O
.	O
No	O
indirect	O
signs	O
of	O
pulmonary	O
hypertension	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
.	O
No	O
pericardial	O
effusion	O
.	O
CORONARYGRAPHY	O
coronary	O
arteries	O
with	O
irregularities	O
,	O
without	O
significant	O
lesions	O
.	O
Good	O
appearance	O
of	O
the	O
stent	O
implanted	O
in	O
the	O
right	O
coronary	O
artery	O
CD	O
,	O
which	O
shows	O
no	O
significant	O
restenosis	O
.	O
CLINICAL	O
EVOLUTION	O
Carbon	O
monoxide	O
poisoning	O
was	O
suspected	O
wood	O
cooker	O
at	O
home	O
and	O
carboxyhaemoglobin	O
was	O
requested	O
,	O
which	O
turned	O
out	O
to	O
be	O
14	O
,	O
confirming	O
the	O
diagnosis	O
.	O
Hyperbaric	O
chamber	O
treatment	O
was	O
indicated	O
with	O
a	O
session	O
at	O
2	O
.	O
3	O
ATA	O
,	O
which	O
left	O
the	O
patient	O
asymptomatic	O
and	O
normalised	O
carboxyhaemoglobin	O
levels	O
after	O
24	O
hours	O
.	O
Given	O
the	O
marked	O
elevation	O
of	O
biomarkers	O
,	O
cardiological	O
assessment	O
was	O
requested	O
after	O
the	O
hyperbaric	O
chamber	O
session	O
.	O
At	O
that	O
time	O
the	O
patient	O
was	O
asymptomatic	O
in	O
the	O
anamnesis	O
by	O
systems	O
,	O
although	O
the	O
ECG	O
showed	O
complete	O
left	O
bundle	O
branch	O
block	O
LBBB	O
,	O
which	O
we	O
did	O
not	O
know	O
if	O
it	O
was	O
already	O
known	O
.	O
An	O
urgent	O
echocardiogram	O
was	O
performed	O
and	O
showed	O
a	O
dilated	O
left	O
ventricle	O
with	O
impaired	O
contractility	O
and	O
severe	O
systolic	O
dysfunction	O
.	O
The	O
patient	O
was	O
diagnosed	O
with	O
high	O
risk	O
non	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
NSTEACS	O
secondary	O
to	O
carbon	O
monoxide	O
poisoning	O
and	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
,	O
under	O
routine	O
treatment	O
and	O
management	O
.	O
Twenty	O
four	O
hours	O
after	O
admission	O
,	O
coronary	O
angiography	O
was	O
performed	O
,	O
showing	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
with	O
good	O
results	O
of	O
the	O
stent	O
previously	O
implanted	O
in	O
the	O
right	O
coronary	O
artery	O
.	O
Subsequently	O
,	O
we	O
were	O
able	O
to	O
contact	O
the	O
patient	O
's	O
cardiologist	O
,	O
who	O
informed	O
us	O
of	O
the	O
existence	O
of	O
LBBB	O
and	O
contractility	O
alterations	O
.	O
DIAGNOSIS	O
Carbon	O
monoxide	O
poisoning	O
treated	O
by	O
hyperbaric	O
chamber	O
.	O
High	O
risk	O
NSTEACS	O
in	O
the	O
context	O
of	O
the	O
above	O
.	O
Dilated	O
left	O
ventricle	O
with	O
severely	O
depressed	O
LVEF	O
.	O
LBBB	O
.	O
Ischaemic	O
heart	O
disease	O
with	O
1	O
vessel	O
disease	O
DC	O
with	O
drug	O
eluting	O
stent	O
implantation	O
in	O
DC	O
,	O
with	O
no	O
evidence	O
of	O
thrombosis	O
or	O
restenosis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Male	O
,	O
61	O
years	O
old	O
.	O
BACKGROUND	O
Arterial	O
hypertension	O
.	O
Dyslipidaemia	O
.	O
Dilated	O
cardiomyopathy	O
of	O
ischaemic	O
origin	O
with	O
moderate	O
ventricular	O
dysfunction	O
,	O
non	O
revascularised	O
chronic	O
ischaemic	O
heart	O
disease	O
.	O
Permanent	O
atrial	O
fibrillation	O
AF	O
anticoagulated	O
with	O
acenocoumarol	B-FARMACO
.	O
Rheumatic	O
mitral	O
valve	O
disease	O
with	O
mechanical	O
prosthesis	O
implantation	O
in	O
1977	O
and	O
subsequent	O
replacement	O
in	O
2001	O
.	O
Medical	O
treatment	O
telmisartan	B-FARMACO
40	O
mg	O
day	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
day	O
,	O
eplerenone	B-FARMACO
25	O
mg	O
day	O
,	O
digoxin	B-FARMACO
0	O
.	O
25	O
mg	O
day	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
day	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
day	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
day	O
,	O
ranolazine	B-FARMACO
375	O
mg	O
12	O
hours	O
,	O
acenocoumarol	B-FARMACO
according	O
to	O
controls	O
.	O
CURRENT	O
DISEASE	O
She	O
attended	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
in	O
February	O
2015	O
due	O
to	O
an	O
increase	O
in	O
her	O
usual	O
dyspnoea	O
from	O
moderate	O
to	O
minimal	O
exertion	O
,	O
in	O
the	O
last	O
week	O
.	O
She	O
denied	O
cough	O
,	O
fever	O
or	O
other	O
concomitant	O
symptoms	O
.	O
She	O
was	O
admitted	O
to	O
cardiology	O
with	O
a	O
diagnosis	O
of	O
acute	O
pulmonary	O
oedema	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
140	O
60	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
110	O
bpm	O
.	O
Jugular	O
venous	O
pulse	O
PVY	O
normal	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
tones	O
with	O
mitral	O
opening	O
click	O
and	O
pansystolic	O
murmur	O
in	O
mitral	O
focus	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
VCM	O
with	O
crackles	O
up	O
to	O
the	O
middle	O
third	O
of	O
both	O
lung	O
fields	O
.	O
Lower	O
extremities	O
no	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYTICS	O
Cr	O
1	O
.	O
23	O
mg	O
dl	O
.	O
CK	O
3	O
U	O
L	O
.	O
Total	O
bilirubin	O
1	O
.	O
37	O
mg	O
dl	O
.	O
Direct	O
bilirubin	O
0	O
.	O
36	O
mg	O
dl	O
.	O
Indirect	O
bilirubin	O
1	O
.	O
01	O
mg	O
dl	O
.	O
LDH	O
1	O
.	O
086	O
U	O
L	O
.	O
Sodium	O
137	O
mmol	O
l	O
.	O
Potassium	O
4	O
.	O
4	O
mmol	O
l	O
.	O
CRP	O
3	O
.	O
7	O
mg	O
l	O
.	O
Haptoglobin	O
3	O
mg	O
dl	O
.	O
Hb	O
9	O
.	O
4	O
g	O
dl	O
.	O
Hcto	O
28	O
.	O
2	O
.	O
MCV	O
84	O
.	O
1	O
fl	O
.	O
Leukocytes	O
7	O
,	O
670	O
u	O
l	O
.	O
Platelets	O
163	O
.	O
000	O
u	O
l	O
.	O
APTT	O
50	O
.	O
6	O
s	O
.	O
T	O
.	O
protombin	O
35	O
.	O
2	O
.	O
INR	O
3	O
.	O
3	O
.	O
Fibrinogen	O
598	O
mg	O
dl	O
.	O
Admission	O
electrocardiogram	O
ECG	O
AF	O
with	O
ventricular	O
response	O
at	O
140	O
bpm	O
,	O
LBBB	O
with	O
secondary	O
repolarisation	O
alterations	O
.	O
Transthoracic	O
echocardiography	O
February	O
2015	O
dilated	O
left	O
atrium	O
and	O
left	O
ventricle	O
with	O
mild	O
moderate	O
ventricular	O
hypertrophy	O
with	O
mild	O
inferior	O
hypokinesia	O
,	O
preserved	O
remaining	O
segmental	O
contractility	O
and	O
slightly	O
depressed	O
systolic	O
function	O
LVEF	O
47	O
.	O
Mitral	O
mechanical	O
prosthesis	O
with	O
mild	O
moderate	O
obstruction	O
mean	O
gradient	O
5	O
6	O
mmHg	O
,	O
AVM	O
per	O
THP	O
1	O
.	O
4	O
1	O
.	O
45	O
cm2	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
slightly	O
thickened	O
with	O
mild	O
regurgitation	O
.	O
Ascending	O
aorta	O
slightly	O
dilated	O
.	O
Structurally	O
and	O
functionally	O
normal	O
pulmonary	O
valve	O
.	O
Structurally	O
normal	O
tricuspid	O
valve	O
with	O
trivial	O
regurgitation	O
.	O
Very	O
dilated	O
inferior	O
vena	O
cava	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Transesophageal	O
echocardiography	O
June	O
2015	O
paraseptal	O
periprosthetic	O
dehiscence	O
in	O
A3	O
P3	O
of	O
6	O
mm	O
in	O
diameter	O
causing	O
moderate	O
severe	O
mitral	O
regurgitation	O
with	O
jet	O
directed	O
towards	O
the	O
interatrial	O
septum	O
,	O
reaching	O
the	O
roof	O
of	O
the	O
left	O
atrium	O
.	O
CARDIAC	O
CATHETERISM	O
February	O
2015	O
right	O
dominance	O
.	O
Left	O
common	O
trunk	O
without	O
lesions	O
.	O
Lesion	O
of	O
90	O
in	O
the	O
middle	O
anterior	O
descending	O
artery	O
.	O
Lesion	O
of	O
90	O
in	O
bisector	O
.	O
Long	O
lesion	O
in	O
middle	O
circumflex	O
artery	O
.	O
90	O
lesions	O
in	O
proximal	O
,	O
middle	O
and	O
distal	O
right	O
coronary	O
artery	O
.	O
After	O
this	O
,	O
the	O
third	O
cardiac	O
surgery	O
is	O
performed	O
,	O
with	O
closure	O
of	O
the	O
leak	O
and	O
coronary	O
revascularisation	O
.	O
Transesophageal	O
echocardiography	O
June	O
2015	O
after	O
surgical	O
repair	O
periprosthetic	O
paravalvular	O
dehiscence	O
of	O
6	O
mm	O
in	O
diameter	O
,	O
which	O
caused	O
moderate	O
to	O
severe	O
mitral	O
regurgitation	O
with	O
a	O
jet	O
directed	O
towards	O
the	O
interatrial	O
septum	O
reaching	O
the	O
roof	O
of	O
the	O
atrium	O
.	O
CARDIAC	O
CATHETERISM	O
September	O
2015	O
percutaneous	O
closure	O
of	O
periprosthetic	O
leak	O
with	O
retrograde	O
transfemoral	O
arterial	O
approach	O
.	O
Transesophageal	O
echocardiography	O
September	O
2015	O
in	O
the	O
periprocedural	O
haemodynamics	O
room	O
the	O
device	O
is	O
correctly	O
implanted	O
with	O
new	O
appearance	O
of	O
another	O
periprosthetic	O
leak	O
.	O
3D	O
Transesophageal	O
Cardiac	O
Echocardiography	O
September	O
2015	O
in	O
the	O
periprocedural	O
cath	O
lab	O
the	O
device	O
is	O
correctly	O
implanted	O
with	O
the	O
appearance	O
of	O
another	O
periprosthetic	O
leak	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
admission	O
,	O
transesophageal	O
echocardiography	O
revealed	O
a	O
mitral	O
periprosthetic	O
leak	O
at	O
A3	O
P3	O
,	O
leading	O
to	O
severe	O
mitral	O
regurgitation	O
.	O
Coronary	O
angiography	O
showed	O
3	O
vessel	O
disease	O
,	O
so	O
after	O
clinical	O
stabilisation	O
with	O
diuretics	O
,	O
he	O
was	O
accepted	O
for	O
surgery	O
,	O
with	O
triple	O
bypass	O
and	O
closure	O
of	O
the	O
leak	O
with	O
four	O
stitches	O
,	O
with	O
a	O
good	O
result	O
on	O
postoperative	O
echocardiography	O
.	O
During	O
the	O
following	O
months	O
,	O
the	O
patient	O
presented	O
several	O
admissions	O
for	O
decompensated	O
heart	O
failure	O
HF	O
and	O
haemolytic	O
anaemia	O
that	O
required	O
several	O
periodic	O
transfusions	O
.	O
Transesophageal	O
echocardiography	O
showed	O
the	O
presence	O
of	O
a	O
new	O
periprosthetic	O
paravalvular	O
dehiscence	O
of	O
6	O
mm	O
in	O
diameter	O
,	O
causing	O
moderate	O
severe	O
mitral	O
regurgitation	O
with	O
a	O
jet	O
directed	O
towards	O
the	O
interatrial	O
septum	O
reaching	O
the	O
roof	O
of	O
the	O
atrium	O
.	O
Given	O
the	O
high	O
surgical	O
risk	O
due	O
to	O
previous	O
cardiac	O
surgery	O
and	O
associated	O
comorbidities	O
,	O
percutaneous	O
closure	O
of	O
the	O
periprosthetic	O
leak	O
with	O
retrograde	O
transfemoral	O
arterial	O
approach	O
was	O
chosen	O
.	O
During	O
implantation	O
of	O
the	O
Amplatzer	O
device	O
,	O
a	O
new	O
paravalvular	O
leak	O
appeared	O
showing	O
mild	O
to	O
moderate	O
mitral	O
regurgitation	O
with	O
a	O
central	O
jet	O
,	O
making	O
it	O
impossible	O
to	O
approach	O
during	O
this	O
procedure	O
videos	O
5	O
and	O
6	O
.	O
It	O
was	O
therefore	O
decided	O
to	O
discharge	O
the	O
patient	O
and	O
monitor	O
his	O
progress	O
.	O
In	O
the	O
following	O
months	O
and	O
progressively	O
,	O
he	O
presented	O
poor	O
ambulatory	O
functional	O
class	O
,	O
requiring	O
several	O
admissions	O
for	O
decompensated	O
HF	O
secondary	O
to	O
the	O
appearance	O
of	O
this	O
last	O
periprosthetic	O
dehiscence	O
close	O
to	O
the	O
severe	O
Amplatzer	O
device	O
21	O
x	O
37	O
mm	O
.	O
Thus	O
,	O
we	O
are	O
dealing	O
with	O
a	O
young	O
patient	O
with	O
recurrent	O
paravalvular	O
dehiscences	O
,	O
who	O
presents	O
a	O
high	O
surgical	O
risk	O
and	O
requires	O
a	O
safe	O
intervention	O
with	O
a	O
high	O
success	O
rate	O
.	O
Accordingly	O
,	O
despite	O
the	O
need	O
for	O
a	O
thoracostomy	O
and	O
apical	O
puncture	O
,	O
the	O
transapical	O
approach	O
was	O
the	O
best	O
option	O
for	O
the	O
patient	O
.	O
A	O
rectangular	O
Occlutech	O
PDL	O
device	O
was	O
implanted	O
in	O
the	O
appropriate	O
position	O
under	O
transesophageal	O
echocardiography	O
guidance	O
.	O
Control	O
transesophageal	O
echocardiography	O
showed	O
that	O
the	O
paravalvular	O
leak	O
was	O
sealed	O
with	O
minimal	O
residual	O
regurgitation	O
.	O
The	O
patient	O
was	O
discharged	O
4	O
days	O
after	O
the	O
procedure	O
and	O
the	O
post	O
procedure	O
course	O
was	O
uneventful	O
during	O
the	O
2	O
year	O
follow	O
up	O
.	O
DIAGNOSIS	O
Ischaemic	O
heart	O
disease	O
.	O
3	O
vessel	O
coronary	O
artery	O
disease	O
with	O
surgical	O
revascularisation	O
.	O
Mild	O
systolic	O
dysfunction	O
and	O
left	O
ventricular	O
LV	O
dilatation	O
.	O
Rheumatic	O
valve	O
disease	O
with	O
mitral	O
involvement	O
.	O
Valve	O
replacement	O
by	O
mechanical	O
prosthesis	O
on	O
two	O
occasions	O
.	O
Multiple	O
recurrent	O
periprosthetic	O
mitral	O
leaks	O
,	O
treated	O
with	O
surgical	O
suture	O
and	O
percutaneous	O
closure	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
77	O
year	O
old	O
woman	O
,	O
with	O
no	O
cardiovascular	O
risk	O
factors	O
.	O
Personal	O
history	O
of	O
bronchial	O
asthma	O
with	O
occasional	O
bronchodilator	O
treatment	O
and	O
two	O
episodes	O
of	O
superficial	O
venous	O
thrombosis	O
.	O
Cardiological	O
history	O
she	O
consulted	O
the	O
cardiology	O
department	O
for	O
episodes	O
of	O
central	O
thoracic	O
pressure	O
on	O
exertion	O
accompanied	O
by	O
dizziness	O
,	O
sweating	O
and	O
trembling	O
of	O
the	O
limbs	O
.	O
They	O
occurred	O
almost	O
daily	O
,	O
so	O
she	O
has	O
limited	O
her	O
physical	O
activity	O
.	O
PHYSICAL	O
EXAMINATION	O
Notable	O
systolic	O
murmur	O
in	O
aortic	O
focus	O
without	O
erasing	O
second	O
noise	O
.	O
The	O
electrocardiogram	O
showed	O
sinus	O
tachycardia	O
at	O
110	O
bpm	O
without	O
acute	O
repolarisation	O
alterations	O
.	O
Echocardioscopy	O
showed	O
a	O
hypertrophic	O
left	O
ventricle	O
LV	O
,	O
non	O
dilated	O
,	O
with	O
preserved	O
ejection	O
fraction	O
LVEF	O
,	O
without	O
alterations	O
in	O
segmental	O
motility	O
or	O
significant	O
valvular	O
heart	O
disease	O
,	O
or	O
pericardial	O
effusion	O
.	O
On	O
suspicion	O
of	O
ischaemic	O
heart	O
disease	O
,	O
treatment	O
was	O
started	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
,	O
beta	O
blockers	O
and	O
statins	O
,	O
and	O
an	O
outpatient	O
study	O
with	O
exercise	O
echocardiogram	O
was	O
requested	O
.	O
The	O
exercise	O
echocardiogram	O
showed	O
moderate	O
baseline	O
left	O
ventricular	O
hypertrophy	O
with	O
mitral	O
systolic	O
anterior	O
systolic	O
motion	O
,	O
baseline	O
dynamic	O
gradient	O
of	O
40	O
mmHg	O
and	O
akinesia	O
of	O
all	O
apical	O
segments	O
.	O
During	O
exercise	O
the	O
akinesia	O
extended	O
to	O
mid	O
segments	O
of	O
all	O
sides	O
with	O
moderate	O
dysfunction	O
and	O
increased	O
dynamic	O
gradient	O
to	O
95	O
mmHg	O
.	O
Preferential	O
catheterisation	O
and	O
routine	O
laboratory	O
tests	O
were	O
requested	O
.	O
A	O
few	O
days	O
later	O
,	O
the	O
patient	O
visited	O
her	O
primary	O
care	O
physician	O
for	O
worsening	O
functional	O
class	O
with	O
dyspnoea	O
and	O
mild	O
exertional	O
chest	O
pain	O
.	O
Physical	O
examination	O
revealed	O
crackles	O
in	O
the	O
right	O
base	O
and	O
oedema	O
in	O
the	O
ankles	O
.	O
The	O
electrocardiogram	O
ECG	O
showed	O
sinus	O
rhythm	O
with	O
negative	O
T	O
waves	O
,	O
symmetrical	O
and	O
deep	O
V3	O
V6	O
and	O
negative	O
T	O
waves	O
in	O
the	O
inferior	O
face	O
.	O
In	O
addition	O
,	O
the	O
analysis	O
requested	O
by	O
the	O
cardiologist	O
showed	O
suppressed	O
thyroid	O
stimulating	O
hormone	O
TSH	O
with	O
free	O
T4	O
63	O
.	O
7	O
normal	O
reference	O
values	O
10	O
.	O
6	O
26	O
.	O
She	O
was	O
referred	O
to	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
.	O
On	O
arrival	O
she	O
was	O
haemodynamically	O
stable	O
with	O
blood	O
pressure	O
BP	O
105	O
50	O
mmHg	O
;	O
heart	O
rate	O
HR	O
85	O
bpm	O
.	O
Afebrile	O
.	O
Oxygen	O
saturation	O
SatO2	O
94	O
.	O
Well	O
perfused	O
and	O
slightly	O
tachypneic	O
25	O
rpm	O
at	O
rest	O
.	O
Physical	O
examination	O
revealed	O
jugular	O
ingurgitation	O
at	O
the	O
base	O
of	O
the	O
neck	O
,	O
systolic	O
murmur	O
in	O
the	O
aortic	O
focus	O
,	O
crackles	O
in	O
the	O
lung	O
bases	O
and	O
discrete	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
While	O
in	O
the	O
emergency	O
department	O
he	O
presented	O
with	O
an	O
episode	O
of	O
precordial	O
pain	O
at	O
rest	O
,	O
with	O
no	O
dynamic	O
changes	O
in	O
the	O
ECG	O
.	O
Suspicion	O
of	O
unstable	O
angina	O
led	O
to	O
admission	O
to	O
the	O
coronary	O
unit	O
.	O
COMPLEMENTARY	O
TESTS	O
STRESS	O
ECOCARDIOGRAM	O
outpatient	O
Baseline	O
echocardiogram	O
moderate	O
left	O
ventricular	O
hypertrophy	O
.	O
Akinesia	O
of	O
the	O
apical	O
half	O
of	O
the	O
inferior	O
,	O
anterior	O
and	O
posterior	O
septum	O
and	O
of	O
the	O
apical	O
segment	O
of	O
the	O
anterior	O
face	O
and	O
anterior	O
septum	O
.	O
Systolic	O
function	O
preserved	O
but	O
at	O
the	O
lower	O
limit	O
of	O
normal	O
.	O
Left	O
atrium	O
slightly	O
dilated	O
20	O
30	O
cm2	O
.	O
Slightly	O
thickened	O
mitral	O
valve	O
,	O
with	O
SAM	O
leading	O
to	O
mild	O
mitral	O
regurgitation	O
MR	O
.	O
The	O
right	O
ventricle	O
RV	O
is	O
normal	O
in	O
terms	O
of	O
size	O
and	O
systolic	O
function	O
.	O
Mild	O
moderate	O
tricuspid	O
regurgitation	O
with	O
Vd	O
Ad	O
gradient	O
of	O
48	O
mmHg	O
.	O
Estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
PSAP	O
of	O
55	O
mmHg	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
normofunctioning	O
.	O
In	O
the	O
left	O
ventricular	O
outflow	O
tract	O
LVOT	O
there	O
is	O
turbulent	O
flow	O
with	O
a	O
dynamic	O
gradient	O
of	O
40	O
mmHg	O
.	O
The	O
aortic	O
root	O
is	O
of	O
normal	O
size	O
.	O
Stress	O
echocardiogram	O
he	O
performed	O
55	O
seconds	O
of	O
the	O
first	O
step	O
,	O
presenting	O
intense	O
dyspnoea	O
that	O
forced	O
the	O
test	O
to	O
be	O
suspended	O
.	O
He	O
reached	O
100	O
of	O
the	O
maximum	O
theoretical	O
heart	O
rate	O
MTHRF	O
.	O
During	O
exercise	O
,	O
akinesia	O
extends	O
to	O
the	O
middle	O
segments	O
of	O
all	O
faces	O
with	O
moderate	O
dysfunction	O
and	O
an	O
increase	O
in	O
the	O
dynamic	O
gradient	O
to	O
95	O
mmHg	O
.	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
at	O
86	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
with	O
axis	O
at	O
60o	O
,	O
negative	O
T	O
waves	O
in	O
V3	O
V6	O
and	O
inferior	O
face	O
,	O
QTc	O
433	O
ms	O
.	O
ANALYTICS	O
biochemistry	O
glucose	O
106	O
mg	O
dl	O
,	O
urea	O
42	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
40	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
CKD	O
EPI	O
90	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
total	O
cholesterol	O
114	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
59	O
mg	O
dl	O
,	O
non	O
HDL	O
cholesterol	O
55	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
37	O
mg	O
dl	O
,	O
triglycerides	O
91	O
mg	O
dl	O
,	O
albumin	O
3	O
.	O
64	O
g	O
dl	O
,	O
total	O
bilirubin	O
0	O
.	O
74	O
mg	O
dl	O
,	O
GOT	O
33	O
U	O
l	O
,	O
GPT	O
39	O
U	O
l	O
,	O
GGT	O
74	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
64	O
U	O
l	O
,	O
phosphorus	O
2	O
.	O
55	O
mg	O
dl	O
,	O
total	O
calcium	O
9	O
.	O
32	O
mg	O
dl	O
,	O
sodium	O
143	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
46	O
mmol	O
l	O
,	O
iron	O
103	O
μg	O
dl	O
,	O
C	O
reactive	O
protein	O
0	O
.	O
1	O
mg	O
dl	O
,	O
ferritin	O
106	O
ng	O
ml	O
,	O
HbA1c	O
5	O
.	O
8	O
.	O
TSH	O
0	O
.	O
005	O
μU	O
ml	O
,	O
free	O
T4	O
63	O
.	O
7	O
pmol	O
l	O
.	O
Myocardial	O
damage	O
marker	O
curve	O
TnT	O
17	O
ng	O
l	O
normal	O
0	O
14	O
20	O
14	O
,	O
CK	O
34	O
U	O
l	O
33	O
39	O
.	O
Haemogram	O
haemoglobin	O
13	O
.	O
1	O
g	O
dl	O
,	O
platelets	O
279	O
10	O
3	O
μl	O
,	O
leucocytes	O
5	O
.	O
7	O
10	O
3	O
μl	O
,	O
neutrophils	O
43	O
.	O
4	O
,	O
lymphocytes	O
33	O
.	O
3	O
,	O
monocytes	O
14	O
.	O
9	O
,	O
eosinophils	O
7	O
.	O
5	O
,	O
basophils	O
0	O
.	O
9	O
.	O
CHEST	O
X	O
RAY	O
no	O
cardiomegaly	O
,	O
slight	O
vascular	O
redistribution	O
to	O
upper	O
fields	O
,	O
free	O
costophrenic	O
sinuses	O
.	O
ECHOCARDIOGRAM	O
on	O
admission	O
non	O
dilated	O
LV	O
with	O
moderate	O
concentric	O
hypertrophy	O
.	O
Preserved	O
global	O
systolic	O
function	O
LVEF	O
64	O
with	O
no	O
abnormalities	O
of	O
segmental	O
contractility	O
.	O
Tricuspid	O
aortic	O
valve	O
with	O
preserved	O
opening	O
,	O
without	O
significant	O
functional	O
alterations	O
.	O
Dynamic	O
gradient	O
in	O
LVOT	O
,	O
maximum	O
of	O
28	O
mmHg	O
.	O
SAM	O
is	O
observed	O
with	O
mild	O
protosystolic	O
MR	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
.	O
RV	O
not	O
dilated	O
with	O
preserved	O
systolic	O
function	O
.	O
Mild	O
tricuspid	O
insufficiency	O
,	O
with	O
Vd	O
Ad	O
gradient	O
22	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
CARDIAC	O
CATHETERISM	O
coronary	O
network	O
without	O
lesions	O
.	O
AL	O
ALTA	O
ECOCARDIOGRAM	O
small	O
LV	O
with	O
mild	O
concentric	O
parietal	O
hypertrophy	O
and	O
moderate	O
septal	O
hypertrophy	O
.	O
Global	O
systolic	O
function	O
preserved	O
,	O
compared	O
with	O
previous	O
outpatient	O
study	O
,	O
having	O
disappeared	O
the	O
alterations	O
of	O
apical	O
motility	O
and	O
basal	O
hyperdynamics	O
that	O
caused	O
systolic	O
gradient	O
.	O
Diastolic	O
pattern	O
of	O
elongated	O
relaxation	O
.	O
RV	O
is	O
normal	O
with	O
respect	O
to	O
size	O
and	O
function	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
20	O
30	O
cm2	O
.	O
Mild	O
calcification	O
of	O
the	O
posterior	O
mitral	O
annulus	O
with	O
mild	O
MR	O
.	O
Mild	O
tricuspid	O
insufficiency	O
TI	O
with	O
Vd	O
Ad	O
gradient	O
31	O
mmHg	O
.	O
Estimated	O
PSAP	O
36	O
mmHg	O
.	O
Mild	O
pulmonary	O
hypertension	O
.	O
Sclerosed	O
aortic	O
valve	O
,	O
trivalve	O
,	O
without	O
functional	O
alterations	O
.	O
The	O
aortic	O
root	O
is	O
of	O
normal	O
size	O
.	O
No	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
with	O
a	O
suspected	O
diagnosis	O
of	O
unstable	O
angina	O
.	O
During	O
her	O
stay	O
she	O
remained	O
haemodynamically	O
stable	O
with	O
a	O
slight	O
tendency	O
to	O
arterial	O
hypotension	O
.	O
In	O
the	O
echocardiogram	O
on	O
admission	O
,	O
no	O
alterations	O
in	O
segmental	O
contractility	O
were	O
observed	O
,	O
with	O
a	O
dynamic	O
gradient	O
persisting	O
in	O
the	O
LVOT	O
but	O
of	O
a	O
lesser	O
magnitude	O
than	O
in	O
the	O
outpatient	O
echocardiogram	O
.	O
In	O
the	O
first	O
24	O
hours	O
of	O
admission	O
,	O
the	O
patient	O
presented	O
several	O
episodes	O
of	O
central	O
thoracic	O
pressure	O
accompanied	O
by	O
intense	O
sweating	O
,	O
nausea	O
and	O
tremor	O
of	O
the	O
extremities	O
.	O
Given	O
the	O
presence	O
of	O
a	O
dynamic	O
gradient	O
in	O
LVOT	O
and	O
the	O
analytical	O
results	O
compatible	O
with	O
thyrotoxicosis	O
,	O
beta	O
blocker	O
treatment	O
with	O
atenolol	B-FARMACO
was	O
intensified	O
for	O
adequate	O
symptomatic	O
control	O
and	O
the	O
congestive	O
symptoms	O
were	O
resolved	O
with	O
intravenous	O
diuretic	O
treatment	O
.	O
She	O
was	O
assessed	O
by	O
the	O
endocrinology	O
department	O
where	O
,	O
given	O
the	O
abruptness	O
of	O
the	O
hyperthyroid	O
symptoms	O
,	O
eosinophilia	O
and	O
relative	O
lymphomonocytosis	O
,	O
they	O
suspected	O
Graves	O
Basedow	O
disease	O
as	O
the	O
first	O
possibility	O
and	O
indicated	O
treatment	O
with	O
methimazole	B-FARMACO
15	O
mg	O
12	O
hours	O
.	O
Coronary	O
angiography	O
was	O
performed	O
,	O
revealing	O
a	O
coronary	O
arterial	O
network	O
without	O
lesions	O
.	O
Given	O
these	O
results	O
,	O
the	O
improvement	O
of	O
the	O
segmental	O
alterations	O
in	O
the	O
echocardiography	O
,	O
the	O
recovery	O
of	O
left	O
ventricular	O
systolic	O
function	O
and	O
the	O
good	O
symptomatic	O
control	O
with	O
the	O
prescribed	O
treatment	O
,	O
the	O
condition	O
was	O
interpreted	O
as	O
tako	O
tsubo	O
syndrome	O
in	O
the	O
context	O
of	O
the	O
debut	O
of	O
primary	O
hyperthyroidism	O
.	O
The	O
process	O
was	O
continued	O
in	O
outpatient	O
endocrinology	O
and	O
cardiology	O
consultations	O
.	O
She	O
remained	O
euthyroid	O
and	O
asymptomatic	O
,	O
without	O
dyspnoea	O
or	O
exertional	O
angina	O
,	O
palpitations	O
or	O
other	O
cardiovascular	O
symptoms	O
,	O
and	O
was	O
discharged	O
after	O
3	O
months	O
of	O
follow	O
up	O
.	O
DIAGNOSIS	O
Tako	O
tsubo	O
syndrome	O
secondary	O
to	O
primary	O
hyperthyroidism	O
,	O
suspected	O
Graves	O
Basedow	O
disease	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
Arterial	O
hypertension	O
.	O
Diabetes	O
mellitus	O
type	O
2	O
.	O
Hypercholesterolemia	O
.	O
Osteoporosis	O
.	O
Symptomatic	O
cholelithiasis	O
and	O
hepatic	O
steatosis	O
under	O
follow	O
up	O
by	O
digestive	O
specialist	O
.	O
Surgical	O
history	O
ovarian	O
cyst	O
and	O
urinary	O
incontinence	O
.	O
Admission	O
to	O
cardiology	O
in	O
2013	O
Sinus	O
rhythm	O
at	O
60	O
bpm	O
,	O
complete	O
left	O
bundle	O
branch	O
block	O
pattern	O
LBBB	O
.	O
Transthoracic	O
echocardiography	O
23	O
04	O
13	O
severe	O
left	O
ventricular	O
LV	O
systolic	O
dysfunction	O
,	O
with	O
ejection	O
fraction	O
EF	O
24	O
.	O
Mitral	O
valve	O
with	O
degenerative	O
changes	O
,	O
moderate	O
fibrosis	O
and	O
severe	O
mitral	O
insufficiency	O
MI	O
.	O
Severe	O
pulmonary	O
hypertension	O
.	O
Moderate	O
tricuspid	O
insufficiency	O
.	O
Cardiac	O
catheterisation	O
20	O
08	O
13	O
reduced	O
cardiac	O
output	O
and	O
cardiac	O
index	O
.	O
Right	O
atrial	O
,	O
pulmonary	O
artery	O
and	O
pulmonary	O
venocapillary	O
pressures	O
within	O
normal	O
range	O
.	O
Coronary	O
arteries	O
free	O
of	O
obstructive	O
lesions	O
.	O
LV	O
of	O
normal	O
size	O
and	O
morphology	O
with	O
severely	O
depressed	O
global	O
contractility	O
,	O
with	O
EF	O
30	O
.	O
Stress	O
test	O
with	O
O2	O
consumption	O
peak	O
O2	O
consumption	O
17	O
.	O
3	O
ml	O
kg	O
min	O
,	O
which	O
is	O
80	O
of	O
the	O
calculated	O
theoretical	O
.	O
7	O
.	O
9	O
METs	O
achieved	O
.	O
Weber	O
Janicki	O
Class	O
B	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
dilated	O
cardiomyopathy	O
of	O
uncertain	O
origin	O
with	O
severe	O
left	O
ventricular	O
dysfunction	O
,	O
LV	O
ejection	O
fraction	O
LVEF	O
30	O
.	O
Assessment	O
in	O
2014	O
O2	O
consumption	O
stress	O
test	O
peak	O
O2	O
consumption	O
16	O
.	O
2	O
ml	O
kg	O
min	O
.	O
Weber	O
Janicki	O
Class	O
C	O
.	O
Normal	O
BP	O
and	O
no	O
arrhythmias	O
.	O
Admitted	O
to	O
cardiology	O
in	O
2016	O
Transthoracic	O
echocardiography	O
with	O
severe	O
systolic	O
dysfunction	O
with	O
LVEF	O
33	O
.	O
Severe	O
MI	O
.	O
Mild	O
pulmonary	O
hypertension	O
.	O
Mild	O
moderate	O
tricuspid	O
insufficiency	O
.	O
Boston	O
type	O
resynchronising	O
defibrillator	O
ICD	O
CRT	O
cardiac	O
resynchronisation	O
therapy	O
implanted	O
.	O
Follow	O
up	O
in	O
a	O
monographic	O
HF	O
clinic	O
with	O
stable	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
II	O
Association	O
NYHA	O
functional	O
class	O
II	O
.	O
Usual	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
0	O
1	O
0	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
0	O
1	O
0	O
,	O
bisoprolol	B-FARMACO
1	O
.	O
25	O
mg	O
1	O
0	O
1	O
,	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
49	O
51	O
mg	O
1	O
0	O
1	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
0	O
0	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
,	O
pravastatin	B-FARMACO
40	O
mg	O
0	O
0	O
1	O
,	O
empaglifozin	B-FARMACO
metformin	I-FARMACO
5	O
1000	O
mg	O
1	O
0	O
0	O
.	O
CURRENT	O
ILLNESS	O
Admitted	O
for	O
dyspnoea	O
on	O
moderate	O
exertion	O
in	O
recent	O
months	O
,	O
which	O
has	O
been	O
worsening	O
in	O
recent	O
days	O
,	O
for	O
which	O
reason	O
he	O
is	O
no	O
longer	O
able	O
to	O
leave	O
his	O
home	O
.	O
He	O
reports	O
walking	O
1	O
2	O
metres	O
and	O
getting	O
tired	O
and	O
having	O
to	O
sit	O
down	O
due	O
to	O
dyspnoea	O
.	O
No	O
increase	O
in	O
oedema	O
in	O
the	O
lower	O
limbs	O
or	O
other	O
symptoms	O
.	O
No	O
infectious	O
symptoms	O
.	O
No	O
chest	O
pain	O
or	O
palpitations	O
.	O
PHYSICAL	O
EXAMINATION	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Good	O
general	O
condition	O
.	O
Blood	O
pressure	O
BP	O
120	O
70	O
.	O
Heart	O
rate	O
HR	O
65	O
bpm	O
.	O
Oxygen	O
saturation	O
SatO2	O
96	O
basal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
with	O
systolic	O
murmur	O
in	O
the	O
apex	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
noises	O
.	O
Abdomen	O
nondescript	O
.	O
Lower	O
limbs	O
no	O
oedema	O
.	O
Pedial	O
pulses	O
present	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYSIS	O
haemoglobin	O
13	O
.	O
7	O
g	O
dl	O
.	O
Leukocytes	O
10	O
,	O
800	O
mm3	O
.	O
Neutrophils	O
69	O
.	O
9	O
.	O
Platelets	O
246	O
,	O
000	O
mm3	O
.	O
INR	O
1	O
.	O
26	O
.	O
Creatinine	O
0	O
.	O
90	O
mg	O
dl	O
.	O
Sodium	O
138	O
meq	O
l	O
.	O
Potassium	O
4	O
.	O
8	O
meq	O
l	O
.	O
Total	O
bilirubin	O
1	O
.	O
9	O
mg	O
dl	O
.	O
Indirect	O
bilirubin	O
1	O
.	O
40	O
mg	O
dl	O
.	O
GOT	O
51	O
U	O
l	O
.	O
GPT	O
49	O
U	O
l	O
.	O
Troponin	O
I	O
0	O
.	O
012	O
ng	O
ml	O
,	O
NT	O
proBNP	O
5270	O
pg	O
ml	O
.	O
CRP	O
24	O
.	O
50	O
mg	O
l	O
.	O
Sideremia	O
28	O
ug	O
dl	O
.	O
Transferrin	O
264	O
mg	O
dl	O
.	O
CTFH	O
372	O
ug	O
dl	O
.	O
Ferritin	O
74	O
ng	O
ml	O
.	O
IST	O
7	O
.	O
5	O
.	O
THORAX	O
RADIOGRAPHY	O
standing	O
upright	O
,	O
posteroanterior	O
.	O
Cardiothoracic	O
index	O
in	O
the	O
high	O
limit	O
.	O
Normopositioned	O
LAD	O
.	O
No	O
infiltrates	O
or	O
condensation	O
.	O
ELECTROCARDIOGRAM	O
ECG	O
pacemaker	O
rhythm	O
with	O
biventricular	O
stimulation	O
.	O
QRS	O
150	O
ms	O
with	O
BCRDHH	O
morphology	O
.	O
Transthoracic	O
echocardiography	O
dilated	O
LV	O
with	O
severe	O
systolic	O
dysfunction	O
.	O
Severe	O
functional	O
MI	O
.	O
IVT	O
12	O
.	O
Pseudonormalised	O
filling	O
pattern	O
.	O
Right	O
ventricle	O
RV	O
not	O
dilated	O
,	O
normocontractile	O
.	O
Electrode	O
in	O
RV	O
,	O
with	O
mild	O
triscuspid	O
insufficiency	O
.	O
RVAD	O
gradient	O
41	O
mmHg	O
.	O
CLINICAL	O
EVOLUTION	O
74	O
year	O
old	O
female	O
patient	O
,	O
with	O
a	O
history	O
of	O
dilated	O
cardiomyopathy	O
,	O
admitted	O
for	O
chronic	O
HF	O
with	O
no	O
clear	O
trigger	O
.	O
Given	O
the	O
signs	O
of	O
poor	O
peripheral	O
perfusion	O
and	O
haemodynamic	O
deterioration	O
,	O
it	O
was	O
decided	O
to	O
administer	O
a	O
pulse	O
of	O
levosimendan	B-FARMACO
as	O
positive	O
inotropic	O
support	O
to	O
achieve	O
early	O
recovery	O
from	O
acute	O
HF	O
.	O
This	O
was	O
carried	O
out	O
with	O
good	O
haemodynamic	O
tolerance	O
and	O
good	O
clinical	O
response	O
,	O
achieving	O
stabilisation	O
with	O
diuretic	O
support	O
72	O
hours	O
after	O
admission	O
following	O
decompensation	O
.	O
Likewise	O
,	O
the	O
resynchronisation	O
therapy	O
of	O
the	O
ICD	O
CRT	O
device	O
was	O
optimised	O
,	O
presenting	O
a	O
QRS	O
of	O
150	O
ms	O
on	O
admission	O
,	O
and	O
after	O
optimisation	O
and	O
adjustment	O
of	O
the	O
interventricular	O
delay	O
,	O
a	O
reduction	O
to	O
132	O
ms	O
was	O
achieved	O
.	O
After	O
compensation	O
of	O
the	O
acute	O
HF	O
condition	O
and	O
prior	O
to	O
discharge	O
,	O
medication	O
for	O
the	O
treatment	O
of	O
chronic	O
HF	O
was	O
optimised	O
in	O
order	O
to	O
plan	O
a	O
transition	O
after	O
the	O
decompensation	O
and	O
subsequent	O
follow	O
up	O
in	O
outpatient	O
clinics	O
,	O
for	O
which	O
the	O
previous	O
home	O
treatment	O
was	O
reinstated	O
and	O
an	O
analysis	O
of	O
the	O
iron	O
deposits	O
was	O
carried	O
out	O
.	O
The	O
patient	O
was	O
discharged	O
from	O
hospital	O
and	O
followed	O
up	O
in	O
the	O
HF	O
outpatient	O
clinic	O
,	O
where	O
the	O
continuation	O
of	O
medication	O
titration	O
,	O
correction	O
of	O
the	O
functional	O
iron	O
deficiency	O
and	O
inclusion	O
in	O
a	O
treatment	O
programme	O
with	O
repeated	O
doses	O
of	O
levosimendan	B-FARMACO
on	O
an	O
outpatient	O
basis	O
were	O
considered	O
.	O
DIAGNOSIS	O
Non	O
ischemic	O
dilated	O
cardiomyopathy	O
with	O
severe	O
left	O
ventricular	O
dysfunction	O
.	O
Severe	O
functional	O
mitral	O
regurgitation	O
.	O
Chronic	O
heart	O
failure	O
stage	O
C	O
.	O
NYHA	O
functional	O
class	O
III	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
woman	O
with	O
a	O
history	O
of	O
atrial	O
fibrillation	O
AF	O
,	O
intracavitary	O
thrombus	O
and	O
absolute	O
contraindication	O
for	O
long	O
term	O
anticoagulant	O
treatment	O
due	O
to	O
associated	O
comorbidities	O
.	O
BACKGROUND	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
Hypertension	O
and	O
dyslipidaemia	O
.	O
No	O
known	O
diabetes	O
.	O
Diagnosed	O
with	O
hypertensive	O
heart	O
disease	O
with	O
mild	O
ischaemia	O
in	O
latero	O
apical	O
segments	O
and	O
admitted	O
in	O
July	O
2014	O
for	O
transient	O
ST	O
elevation	O
without	O
evidence	O
of	O
significant	O
coronary	O
lesions	O
on	O
coronary	O
angiography	O
.	O
Paroxysmal	O
AF	O
of	O
uncertain	O
chronology	O
diagnosed	O
in	O
February	O
2014	O
,	O
anticoagulated	O
with	O
synthrom	B-FARMACO
.	O
Small	O
vessel	O
cerebrovascular	O
disease	O
being	O
monitored	O
by	O
neurology	O
.	O
Doppler	O
of	O
TSA	O
normal	O
.	O
Hiatal	O
hernia	O
.	O
Haemorrhoidal	O
syndrome	O
.	O
Previous	O
surgical	O
interventions	O
appendectomy	O
.	O
Usual	O
treatment	O
Synthrom	B-FARMACO
according	O
to	O
established	O
guidelines	O
based	O
on	O
periodic	O
INR	O
controls	O
,	O
diltiazem	B-FARMACO
120	O
mg	O
every	O
12	O
hours	O
,	O
carvedilol	B-FARMACO
25	O
mg	O
every	O
12	O
hours	O
.	O
Torasemide	B-FARMACO
5mg	O
every	O
24	O
hours	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
every	O
24	O
hours	O
.	O
Omeprazole	B-FARMACO
20	O
mg	O
every	O
24	O
hours	O
.	O
Lorazepam	B-FARMACO
1	O
mg	O
in	O
the	O
evening	O
.	O
CURRENT	O
ILLNESS	O
Admitted	O
to	O
cardiology	O
for	O
worsening	O
functional	O
class	O
of	O
months	O
of	O
evolution	O
with	O
clear	O
onset	O
of	O
dyspnoea	O
on	O
moderate	O
exertion	O
,	O
occasional	O
episodes	O
of	O
palpitations	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
in	O
the	O
days	O
prior	O
to	O
ED	O
consultation	O
.	O
On	O
admission	O
,	O
he	O
presented	O
fever	O
of	O
up	O
to	O
38oC	O
maintained	O
for	O
3	O
days	O
without	O
an	O
objectifiable	O
focus	O
,	O
and	O
a	O
microbiological	O
examination	O
was	O
performed	O
,	O
which	O
was	O
negative	O
.	O
The	O
condition	O
progressed	O
to	O
a	O
deterioration	O
in	O
the	O
level	O
of	O
consciousness	O
and	O
a	O
cranial	O
CT	O
scan	O
was	O
requested	O
,	O
showing	O
a	O
right	O
frontal	O
intraparenchymal	O
haematoma	O
that	O
did	O
not	O
move	O
the	O
midline	O
or	O
open	O
to	O
the	O
ventricles	O
,	O
and	O
did	O
not	O
require	O
surgical	O
drainage	O
.	O
For	O
this	O
reason	O
,	O
anticoagulation	O
with	O
low	B-FARMACO
molecular	I-FARMACO
weight	I-FARMACO
heparin	I-FARMACO
started	O
on	O
admission	O
instead	O
of	O
synthroid	B-FARMACO
was	O
suspended	O
and	O
neurology	O
was	O
contacted	O
to	O
assess	O
the	O
case	O
.	O
Magnetic	O
resonance	O
imaging	O
MRI	O
of	O
the	O
skull	O
was	O
performed	O
and	O
a	O
diagnosis	O
of	O
probable	O
amyloid	O
angiopathy	O
was	O
made	O
.	O
Once	O
the	O
haemorrhagic	O
focus	O
was	O
stabilised	O
and	O
given	O
the	O
high	O
embolic	O
risk	O
CHA2DS2	O
VASc	O
4	O
and	O
high	O
haemorrhagic	O
risk	O
HAS	O
BLED	O
3	O
points	O
,	O
the	O
patient	O
was	O
proposed	O
as	O
a	O
candidate	O
for	O
programmed	O
left	O
atrial	O
appendage	O
closure	O
class	O
IIb	O
B	O
indication	O
according	O
to	O
the	O
ESC	O
2016	O
guidelines	O
on	O
the	O
diagnosis	O
and	O
treatment	O
of	O
AF	O
,	O
and	O
was	O
referred	O
for	O
discharge	O
with	O
mono	O
antiplatelet	O
therapy	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
every	O
24	O
hours	O
.	O
PHYSICAL	O
EXAMINATION	O
Good	O
general	O
condition	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Afebrile	O
on	O
admission	O
.	O
Haemodynamically	O
stable	O
with	O
blood	O
pressure	O
BP	O
110	O
70	O
mmHg	O
and	O
heart	O
rate	O
HR	O
85	O
bpm	O
.	O
Eupneic	O
at	O
rest	O
and	O
speech	O
with	O
head	O
at	O
30o	O
.	O
No	O
jugular	O
ingurgitation	O
or	O
hepatojugular	O
reflux	O
.	O
On	O
auscultation	O
,	O
arrhythmic	O
cardiac	O
tones	O
without	O
audible	O
murmurs	O
.	O
Vesicular	O
murmur	O
preserved	O
with	O
bibasal	O
crackles	O
.	O
Lower	O
limbs	O
without	O
oedema	O
or	O
signs	O
of	O
DVT	O
.	O
No	O
other	O
noteworthy	O
findings	O
on	O
examination	O
.	O
COMPLEMENTARY	O
TESTS	O
ELECTROCARDIOGRAM	O
ECG	O
AF	O
at	O
130	O
bpm	O
.	O
Wide	O
QRS	O
with	O
morphology	O
of	O
complete	O
left	O
bundle	O
branch	O
block	O
LBBB	O
,	O
previously	O
known	O
.	O
ANALYSIS	O
no	O
mobilisation	O
of	O
cardiac	O
biomarkers	O
ultrasensitive	O
troponin	O
T	O
TnTus	O
peak	O
16	O
ng	O
l	O
.	O
Other	O
findings	O
were	O
unremarkable	O
.	O
THORAX	O
RADIOGRAPHY	O
cardiomegaly	O
,	O
no	O
other	O
pathological	O
findings	O
.	O
Absence	O
of	O
pulmonary	O
congestion	O
.	O
TRANSTORACIC	O
ECOCARDIOGRAPHY	O
LA	O
diameter	O
AP	O
31mm	O
.	O
Apical	O
area	O
24	O
cm2	O
and	O
volume	O
79	O
ml	O
.	O
Dilated	O
left	O
ventricle	O
LV	O
LVEDV	O
57	O
mm	O
,	O
globular	O
morphology	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
severely	O
depressed	O
,	O
by	O
Simpson	O
LVEF	O
17	O
,	O
with	O
global	O
hypokinesia	O
.	O
Monophasic	O
E	O
filling	O
pattern	O
.	O
Mitral	O
valve	O
with	O
tenting	O
closure	O
resulting	O
in	O
mild	O
functional	O
mitral	O
regurgitation	O
MR	O
.	O
Aortic	O
valve	O
with	O
preserved	O
opening	O
and	O
function	O
.	O
Non	O
dilated	O
right	O
ventricle	O
RV	O
RVDVD	O
22	O
.	O
6	O
mm	O
with	O
TAPSE	O
14	O
mm	O
.	O
Tricuspid	O
insufficiency	O
TI	O
grade	O
II	O
with	O
peak	O
RV	O
RA	O
gradient	O
29	O
mmHg	O
,	O
which	O
allows	O
estimating	O
a	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAPs	O
35	O
40	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
with	O
normal	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
UROCULTURE	O
and	O
HEMOCULTURE	O
negative	O
.	O
Cranial	O
CT	O
scan	O
right	O
frontal	O
intraparenchymal	O
haematoma	O
that	O
did	O
not	O
displace	O
the	O
midline	O
or	O
open	O
into	O
the	O
ventricles	O
.	O
Cranial	O
MRI	O
right	O
frontal	O
lobar	O
haemorrhage	O
and	O
small	O
vessel	O
vasculopathy	O
,	O
findings	O
compatible	O
with	O
probable	O
amyloid	O
angiopathy	O
.	O
ANGIO	O
CT	O
chest	O
drainage	O
of	O
left	O
pulmonary	O
veins	O
into	O
normal	O
left	O
atrium	O
,	O
through	O
two	O
independent	O
ostia	O
.	O
The	O
left	O
atrial	O
appendage	O
has	O
a	O
digitiform	O
morphology	O
and	O
an	O
implantation	O
base	O
with	O
a	O
wide	O
neck	O
,	O
approximately	O
2	O
x	O
2	O
cm	O
.	O
Adherent	O
thrombotic	O
material	O
,	O
probably	O
of	O
chronic	O
evolution	O
,	O
can	O
be	O
seen	O
in	O
its	O
cul	O
de	O
sac	O
.	O
Dilated	O
LV	O
transverse	O
diameter	O
of	O
about	O
55	O
mm	O
.	O
Right	O
atrium	O
RA	O
55	O
mm	O
.	O
Left	O
atrium	O
LA	O
47	O
mm	O
.	O
Transesophageal	O
echocardiography	O
left	O
atrial	O
appendage	O
with	O
an	O
entrance	O
of	O
17	O
x	O
19	O
mm	O
,	O
depth	O
of	O
30	O
mm	O
,	O
thrombus	O
is	O
seen	O
inside	O
the	O
left	O
atrial	O
appendage	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
discharge	O
,	O
the	O
patient	O
was	O
scheduled	O
for	O
a	O
chest	O
CT	O
angiography	O
and	O
transesophageal	O
echocardiography	O
prior	O
to	O
atrial	O
appendage	O
closure	O
.	O
Both	O
tests	O
showed	O
the	O
existence	O
of	O
thrombus	O
in	O
the	O
left	O
atrial	O
appendage	O
,	O
a	O
situation	O
that	O
contraindicated	O
its	O
closure	O
.	O
Therefore	O
,	O
the	O
case	O
was	O
assessed	O
in	O
a	O
medical	O
session	O
heart	O
team	O
and	O
it	O
was	O
decided	O
to	O
start	O
anticoagulation	O
with	O
dabigatran	B-FARMACO
110	O
mg	O
every	O
12	O
hours	O
for	O
3	O
months	O
,	O
for	O
resolution	O
of	O
the	O
thrombus	O
and	O
subsequent	O
echocardiographic	O
control	O
.	O
During	O
these	O
3	O
months	O
of	O
treatment	O
with	O
dabigatran	B-FARMACO
,	O
she	O
evolved	O
without	O
incident	O
,	O
being	O
asymptomatic	O
and	O
without	O
haemorrhagic	O
complications	O
.	O
After	O
echocardiographic	O
control	O
confirmed	O
the	O
resolution	O
of	O
the	O
thrombus	O
video	O
3	O
,	O
the	O
left	O
atrial	O
appendage	O
was	O
closed	O
with	O
the	O
Amplatzer	O
Amulet	O
device	O
,	O
without	O
complications	O
during	O
the	O
procedure	O
and	O
with	O
a	O
good	O
final	O
result	O
.	O
Subsequently	O
,	O
anticoagulation	O
was	O
maintained	O
with	O
dabigatran	B-FARMACO
110	O
mg	O
every	O
12	O
hours	O
for	O
a	O
further	O
45	O
days	O
,	O
with	O
no	O
associated	O
haemorrhagic	O
complications	O
,	O
and	O
after	O
its	O
withdrawal	O
the	O
patient	O
was	O
kept	O
on	O
mono	O
antiplatelet	O
therapy	O
indefinitely	O
with	O
ASA	B-FARMACO
100	O
mg	O
every	O
24	O
hours	O
.	O
Subsequent	O
echocardiographic	O
controls	O
showed	O
the	O
Amulet	O
device	O
to	O
be	O
correctly	O
placed	O
and	O
the	O
left	O
atrial	O
appendage	O
to	O
be	O
free	O
of	O
thrombus	O
.	O
Likewise	O
,	O
due	O
to	O
the	O
patient	O
's	O
baseline	O
cardiomyopathy	O
with	O
severe	O
ventricular	O
dysfunction	O
,	O
it	O
was	O
decided	O
to	O
implant	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
for	O
primary	O
prevention	O
.	O
Currently	O
,	O
she	O
maintains	O
a	O
good	O
functional	O
class	O
and	O
is	O
asymptomatic	O
from	O
the	O
cardiological	O
point	O
of	O
view	O
.	O
DIAGNOSIS	O
Dilated	O
cardiomyopathy	O
with	O
severe	O
ventricular	O
dysfunction	O
LVEF	O
17	O
.	O
Permanent	O
AF	O
CHA2DS2	O
VASc	O
4	O
points	O
,	O
HAS	O
BLED	O
3	O
points	O
.	O
Probable	O
amyloid	O
angiopathy	O
leading	O
to	O
right	O
lobar	O
lobar	O
intraparenchymal	O
haematoma	O
.	O
Thrombus	O
in	O
left	O
atrial	O
appendage	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
75	O
year	O
old	O
male	O
with	O
a	O
history	O
of	O
arterial	O
hypertension	O
,	O
dyslipidaemia	O
,	O
ischaemic	O
stroke	O
,	O
chronic	O
ischaemic	O
heart	O
disease	O
and	O
aortic	O
biological	O
prosthesis	O
due	O
to	O
severe	O
aortic	O
stenosis	O
2	O
years	O
ago	O
,	O
requiring	O
DDD	O
pacemaker	O
implantation	O
due	O
to	O
advanced	O
post	O
surgical	O
atrioventricular	O
block	O
.	O
She	O
was	O
admitted	O
with	O
fever	O
and	O
a	O
slight	O
increase	O
in	O
her	O
usual	O
dyspnoea	O
in	O
the	O
last	O
2	O
weeks	O
,	O
with	O
orthopnoea	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
On	O
medical	O
history	O
,	O
he	O
denied	O
any	O
associated	O
respiratory	O
infectious	O
symptoms	O
.	O
Physical	O
examination	O
BP	O
145	O
62	O
mmHg	O
,	O
HR	O
92	O
bpm	O
,	O
SatO2	O
98	O
on	O
room	O
air	O
,	O
Ta	O
38	O
.	O
2	O
C	O
.	O
Conscious	O
and	O
oriented	O
.	O
Jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
bibasal	O
crackles	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
without	O
visceromegaly	O
.	O
Lower	O
limbs	O
oedema	O
with	O
pretibial	O
fovea	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
cultures	O
4	O
positive	O
samples	O
for	O
Streptococcus	O
anginosus	O
.	O
Transthoracic	O
and	O
transesophageal	O
echocardiogram	O
multiple	O
vegetations	O
at	O
aortic	O
level	O
the	O
largest	O
measuring	O
10	O
x	O
8	O
mm	O
and	O
an	O
inhomogeneous	O
thickening	O
,	O
perivalvular	O
and	O
with	O
an	O
echodense	O
appearance	O
corresponding	O
to	O
an	O
abscess	O
of	O
the	O
aortic	O
annulus	O
measuring	O
3	O
.	O
6	O
x	O
2	O
.	O
3	O
cm	O
.	O
Cardiac	O
CT	O
in	O
addition	O
to	O
the	O
above	O
,	O
two	O
small	O
pseudoaneurysms	O
were	O
observed	O
at	O
subvalvular	O
level	O
.	O
18F	O
FDG	O
PET	O
CT	O
pathological	O
deposit	O
of	O
activity	O
around	O
the	O
aortic	O
prosthesis	O
with	O
greater	O
intensity	O
in	O
the	O
posterior	O
region	O
and	O
absence	O
of	O
uptake	O
in	O
the	O
cardiac	O
pacing	O
system	O
.	O
EVOLUTION	O
Given	O
the	O
presence	O
of	O
an	O
uncontrolled	O
infection	O
aortic	O
abscess	O
the	O
patient	O
underwent	O
valve	O
replacement	O
surgery	O
.	O
Prior	O
to	O
the	O
procedure	O
,	O
a	O
PET	O
CT	O
scan	O
was	O
performed	O
to	O
assess	O
the	O
involvement	O
of	O
the	O
pacemaker	O
generator	O
and	O
leads	O
and	O
to	O
decide	O
whether	O
or	O
not	O
to	O
replace	O
the	O
pacing	O
system	O
.	O
Given	O
the	O
results	O
of	O
the	O
test	O
,	O
it	O
was	O
finally	O
decided	O
not	O
to	O
remove	O
the	O
pacemaker	O
.	O
Postoperative	O
evolution	O
was	O
satisfactory	O
,	O
antibiotic	O
treatment	O
with	O
ceftriaxone	B-FARMACO
was	O
continued	O
for	O
a	O
further	O
20	O
days	O
and	O
follow	O
up	O
echocardiograms	O
showed	O
no	O
complications	O
.	O
During	O
subsequent	O
clinical	O
visits	O
,	O
the	O
patient	O
did	O
not	O
report	O
fever	O
or	O
dyspnoea	O
.	O
DIAGNOSIS	O
Late	O
infective	O
endocarditis	O
on	O
biological	O
aortic	O
prosthesis	O
,	O
due	O
to	O
Streptococcus	O
anginosus	O
,	O
complicated	O
with	O
aortic	O
perivalvular	O
abscess	O
.	O
Valve	O
replacement	O
surgery	O
.	O
Carrier	O
of	O
bicameral	O
pacemaker	O
due	O
to	O
advanced	O
atrioventricular	O
block	O
,	O
with	O
no	O
evidence	O
of	O
infection	O
of	O
the	O
device	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
58	O
year	O
old	O
woman	O
consulted	O
in	O
the	O
emergency	O
department	O
for	O
dyspnoea	O
.	O
BACKGROUND	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
no	O
hypertension	O
HT	O
,	O
no	O
diabetes	O
mellitus	O
DM	O
,	O
no	O
dyslipidaemia	O
DLP	O
.	O
Ex	O
smoker	O
of	O
10	O
cig	O
day	O
for	O
10	O
years	O
.	O
Occasional	O
alcohol	O
1	O
beer	O
on	O
weekends	O
.	O
No	O
relevant	O
medical	O
history	O
.	O
Intervened	O
for	O
hallux	O
valgus	O
in	O
October	O
2017	O
.	O
She	O
does	O
not	O
follow	O
usual	O
treatment	O
.	O
CURRENT	O
ILLNESS	O
58	O
year	O
old	O
woman	O
consulted	O
for	O
dyspnoea	O
for	O
2	O
3	O
days	O
with	O
accompanying	O
palpitations	O
.	O
She	O
reported	O
worsening	O
of	O
functional	O
class	O
with	O
dyspnoea	O
on	O
moderate	O
exertion	O
not	O
previously	O
present	O
,	O
no	O
orthopnoea	O
or	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
She	O
reported	O
feeling	O
more	O
swollen	O
,	O
with	O
increased	O
oedema	O
in	O
both	O
ankles	O
.	O
This	O
symptomatology	O
is	O
sometimes	O
accompanied	O
by	O
palpitations	O
.	O
She	O
denies	O
fever	O
and	O
infectious	O
symptoms	O
at	O
any	O
level	O
.	O
Until	O
now	O
she	O
had	O
been	O
asymptomatic	O
and	O
reported	O
being	O
in	O
good	O
health	O
,	O
although	O
two	O
months	O
ago	O
,	O
during	O
a	O
work	O
check	O
up	O
,	O
she	O
was	O
found	O
to	O
have	O
a	O
murmur	O
which	O
she	O
has	O
not	O
paid	O
any	O
attention	O
to	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
125	O
66	O
mmHg	O
,	O
heart	O
rate	O
HR	O
140	O
bpm	O
,	O
oxygen	O
saturation	O
94	O
at	O
baseline	O
.	O
Afebrile	O
.	O
Jugular	O
venous	O
engorgement	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
,	O
mitral	O
systolic	O
murmur	O
II	O
IV	O
.	O
Pulmonary	O
auscultation	O
minimal	O
crackles	O
in	O
right	O
base	O
,	O
rest	O
of	O
pulmonary	O
auscultation	O
normal	O
.	O
Lower	O
extremities	O
oedema	O
with	O
bimalleolar	O
fovea	O
,	O
rest	O
normal	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYTICS	O
haemoglobin	O
12	O
.	O
4	O
mg	O
dl	O
.	O
Haematocrit	O
38	O
.	O
1	O
.	O
Leukocytosis	O
9	O
,	O
760	O
x	O
1000	O
with	O
normal	O
formula	O
.	O
Platelets	O
235	O
,	O
000	O
ml	O
.	O
Coagulation	O
INR	O
1	O
.	O
08	O
;	O
PT	O
13	O
.	O
2	O
sg	O
APTT	O
23	O
.	O
2	O
sg	O
.	O
Biochemistry	O
glucose	O
125	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
92	O
mg	O
dl	O
.	O
Urea	O
53	O
mg	O
dl	O
.	O
Sodium	O
135	O
mmol	O
l	O
.	O
Potassium	O
4	O
.	O
1	O
mmol	O
l	O
.	O
Liver	O
profile	O
normal	O
.	O
CRP	O
21	O
.	O
9	O
mg	O
dl	O
.	O
ProBNP	O
2841	O
pg	O
ml	O
.	O
CARDIAC	O
MARKERS	O
troponin	O
T	O
and	O
CPK	O
normal	O
,	O
without	O
serum	O
changes	O
.	O
THORAX	O
RADIOGRAPHY	O
cardiothoracic	O
index	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
.	O
Right	O
pleural	O
effusion	O
with	O
pinching	O
of	O
the	O
sinocostophrenic	O
sinus	O
.	O
Fluid	O
in	O
the	O
cisuras	O
.	O
Electrocardiogram	O
ECG	O
atrial	O
fibrillation	O
AF	O
at	O
140	O
bpm	O
with	O
right	O
bundle	O
branch	O
block	O
RBBB	O
and	O
left	O
anterior	O
hemiblock	O
LABB	O
.	O
CLINICAL	O
COURSE	O
After	O
a	O
first	O
episode	O
of	O
HF	O
related	O
to	O
recently	O
diagnosed	O
AF	O
with	O
high	O
ventricular	O
rate	O
,	O
diuretic	O
treatment	O
,	O
anticoagulation	O
and	O
beta	O
blocker	O
treatment	O
were	O
started	O
to	O
control	O
the	O
heart	O
rate	O
,	O
and	O
the	O
patient	O
was	O
admitted	O
to	O
cardiology	O
for	O
study	O
and	O
management	O
.	O
During	O
his	O
admission	O
to	O
the	O
cardiology	O
ward	O
,	O
a	O
transthoracic	O
echocardiogram	O
was	O
performed	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
slightly	O
dilated	O
85	O
ml	O
cm2	O
with	O
normal	O
wall	O
thickness	O
.	O
Global	O
and	O
segmental	O
systolic	O
function	O
preserved	O
.	O
Severely	O
dilated	O
left	O
atrium	O
100	O
ml	O
cm2	O
.	O
Large	O
mass	O
area	O
13	O
.	O
6	O
cm2	O
hyperechogenic	O
with	O
partial	O
calcification	O
,	O
with	O
very	O
friable	O
edges	O
,	O
prolapsing	O
inside	O
the	O
LV	O
and	O
preventing	O
proper	O
closure	O
of	O
the	O
mitral	O
valve	O
.	O
Probable	O
point	O
of	O
anchorage	O
at	O
the	O
level	O
of	O
the	O
interatrial	O
septum	O
below	O
and	O
posterior	O
to	O
the	O
foramen	O
ovale	O
.	O
Normal	O
sized	O
right	O
chambers	O
with	O
preserved	O
ejection	O
fraction	O
RVEF	O
.	O
Trivial	O
tricuspid	O
insufficiency	O
allowing	O
estimation	O
of	O
pulmonary	O
arterial	O
systolic	O
pressure	O
PSAP	O
of	O
38	O
mmHg	O
.	O
Anatomically	O
and	O
functionally	O
normal	O
aortic	O
valve	O
.	O
Mitral	O
valve	O
with	O
thickening	O
of	O
both	O
leaflets	O
,	O
difficult	O
to	O
assess	O
anatomically	O
due	O
to	O
the	O
imprint	O
of	O
the	O
left	O
atrial	O
mass	O
.	O
Severe	O
mitral	O
insufficiency	O
,	O
eccentric	O
jet	O
.	O
Inferior	O
vena	O
cava	O
of	O
normal	O
size	O
with	O
physiological	O
inspiratory	O
collapse	O
.	O
Aortic	O
root	O
,	O
ascending	O
aorta	O
and	O
infrarenal	O
abdominal	O
aorta	O
of	O
normal	O
size	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
In	O
view	O
of	O
the	O
echocardiographic	O
findings	O
,	O
the	O
need	O
for	O
surgical	O
intervention	O
was	O
discussed	O
with	O
the	O
patient	O
.	O
Coronary	O
angiography	O
was	O
performed	O
,	O
showing	O
right	O
dominance	O
and	O
coronary	O
arteries	O
without	O
lesions	O
.	O
The	O
patient	O
was	O
scheduled	O
for	O
cardiac	O
surgery	O
where	O
a	O
voluminous	O
tumour	O
with	O
a	O
wide	O
implantation	O
base	O
was	O
visualised	O
.	O
The	O
anterior	O
mitral	O
leaflet	O
was	O
compromised	O
at	O
A1	O
A2	O
and	O
the	O
anterior	O
mitral	O
annulus	O
,	O
making	O
valve	O
repair	O
impossible	O
,	O
and	O
a	O
St	O
.	O
Jude	O
type	O
mechanical	O
prosthesis	O
no	O
.	O
29	O
was	O
implanted	O
.	O
The	O
anatomopathological	O
report	O
shows	O
a	O
mesenchymal	O
lesion	O
of	O
low	O
histological	O
aggressiveness	O
in	O
which	O
the	O
hyallino	O
myxoid	O
stroma	O
predominates	O
on	O
which	O
small	O
cell	O
groups	O
with	O
little	O
cytological	O
atypia	O
float	O
,	O
although	O
some	O
present	O
hyperchromatic	O
nuclei	O
,	O
with	O
abundant	O
thin	O
walled	O
vessels	O
.	O
No	O
mitotic	O
figures	O
or	O
foci	O
of	O
necrosis	O
are	O
observed	O
.	O
Areas	O
of	O
dystrophic	O
calcification	O
are	O
observed	O
.	O
Pathological	O
diagnosis	O
cardiac	O
myxoma	O
.	O
DIAGNOSIS	O
Intracardiac	O
mass	O
.	O
Cardiac	O
myxoma	O
.	O
First	O
episode	O
of	O
HF	O
.	O
Newly	O
diagnosed	O
AF	O
with	O
rapid	O
ventricular	O
response	O
.	O
CHADS	O
VASC	O
2	O
Arterial	O
hypertension	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
73	O
year	O
old	O
patient	O
.	O
Allergies	O
idiosyncrasy	O
to	O
multiple	O
non	O
steroidal	O
anti	O
inflammatory	O
drugs	O
NSAIDs	O
.	O
Only	O
cardiovascular	O
risk	O
factor	O
hypertensive	O
.	O
Arthrosis	O
.	O
Cataract	O
surgery	O
.	O
No	O
previous	O
known	O
cardiological	O
history	O
.	O
No	O
family	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
She	O
leads	O
an	O
active	O
life	O
with	O
good	O
functional	O
class	O
.	O
Of	O
interest	O
,	O
her	O
husband	O
had	O
been	O
discharged	O
from	O
our	O
service	O
15	O
days	O
ago	O
for	O
acute	O
coronary	O
syndrome	O
with	O
ST	O
segment	O
elevation	O
STEACS	O
.	O
CURRENT	O
ILLNESS	O
She	O
came	O
to	O
the	O
emergency	O
department	O
for	O
presenting	O
,	O
after	O
doing	O
household	O
chores	O
,	O
with	O
oppressive	O
central	O
thoracic	O
pain	O
radiating	O
to	O
the	O
neck	O
,	O
lasting	O
about	O
30	O
minutes	O
,	O
with	O
progressive	O
spontaneous	O
decrease	O
but	O
without	O
disappearing	O
,	O
for	O
which	O
she	O
took	O
a	O
caffeine	B-FARMACO
sl	O
from	O
her	O
husband	O
,	O
with	O
complete	O
disappearance	O
of	O
the	O
symptoms	O
.	O
No	O
accompanying	O
vegetative	O
cortex	O
.	O
No	O
previous	O
similar	O
episodes	O
.	O
No	O
episodes	O
of	O
syncope	O
or	O
presyncope	O
.	O
Usual	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
I	O
,	O
although	O
in	O
the	O
last	O
two	O
weeks	O
she	O
reported	O
dyspnoea	O
on	O
moderate	O
exertion	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
140	O
68	O
.	O
Heart	O
rate	O
HR	O
98	O
bpm	O
.	O
Oxygen	O
saturation	O
99	O
baseline	O
.	O
Afebrile	O
.	O
Eupneic	O
at	O
rest	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
systolic	O
murmur	O
in	O
lower	O
left	O
parasternal	O
border	O
that	O
increases	O
after	O
Valsalva	O
.	O
Pulmonary	O
auscultation	O
normoventilation	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
.	O
No	O
masses	O
or	O
megaliths	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
extremities	O
.	O
No	O
IY	O
.	O
No	O
carotid	O
murmurs	O
.	O
COMPLEMENTARY	O
TESTS	O
THORAX	O
RADIOGRAPHY	O
no	O
pleuroparenchymal	O
findings	O
of	O
acute	O
evolution	O
.	O
ECG	O
asymptomatic	O
sinus	O
rhythm	O
at	O
83	O
bpm	O
,	O
narrow	O
QRS	O
with	O
hypertrophy	O
criteria	O
in	O
high	O
lateral	O
face	O
with	O
growth	O
of	O
R	O
,	O
secondary	O
repolarisation	O
alterations	O
in	O
anterolateral	O
face	O
and	O
deep	O
Q	O
waves	O
in	O
V1	O
3	O
.	O
No	O
dynamic	O
changes	O
.	O
ANALYTICS	O
Tn	O
I	O
0	O
,	O
28	O
2	O
.	O
20	O
0	O
,	O
88	O
.	O
Glu	O
126	O
mg	O
dl	O
,	O
urea	O
38	O
mg	O
dl	O
,	O
creat	O
0	O
.	O
69	O
mg	O
dl	O
,	O
Na	O
142	O
mEq	O
l	O
,	O
K	O
4	O
.	O
3	O
mEq	O
l	O
.	O
Leukocytes	O
9400	O
mm3	O
81	O
N	O
,	O
Hb	O
14	O
.	O
4	O
g	O
dl	O
,	O
Hto	O
45	O
.	O
5	O
,	O
Platelets	O
155000	O
mm3	O
.	O
Coagulation	O
normal	O
.	O
Thyroid	O
function	O
normal	O
.	O
Iron	O
metabolism	O
normal	O
.	O
Hb	O
1AC	O
5	O
.	O
5	O
.	O
LDL	O
80	O
mg	O
dl	O
,	O
HDL	O
33	O
mg	O
dl	O
.	O
Echocardiogram	O
non	O
dilated	O
LV	O
,	O
ventricular	O
hypertrophy	O
LVH	O
at	O
basal	O
septal	O
level	O
sigmoid	O
septum	O
,	O
16	O
mm	O
,	O
rest	O
of	O
segments	O
mild	O
concentric	O
LVH	O
.	O
Mild	O
LV	O
dysfunction	O
estimated	O
by	O
Teicholz	O
and	O
Simpson	O
biplanar	O
49	O
50	O
,	O
mid	O
and	O
apical	O
septal	O
akinesia	O
and	O
inferoapical	O
,	O
rest	O
of	O
segments	O
preserved	O
contractility	O
.	O
Acceleration	O
of	O
flow	O
in	O
the	O
left	O
ventricular	O
outflow	O
tract	O
LVOT	O
with	O
maximum	O
baseline	O
obstructive	O
gradient	O
100	O
mmHg	O
that	O
increases	O
with	O
Valsalva	O
manoeuvres	O
up	O
to	O
120	O
mmHg	O
.	O
Mitral	O
filling	O
pattern	O
impaired	O
relaxation	O
,	O
with	O
current	O
data	O
of	O
elevated	O
left	O
ventricular	O
end	O
diastolic	O
pressure	O
LVEDP	O
.	O
Left	O
atrium	O
LA	O
slightly	O
dilated	O
.	O
Right	O
chambers	O
not	O
dilated	O
,	O
right	O
ventricle	O
RV	O
normocontractile	O
TAPSE	O
19	O
mm	O
,	O
S	O
'	O
wave	O
in	O
lateral	O
TDI	O
11	O
.	O
7	O
cm	O
sec	O
.	O
Aortic	O
root	O
and	O
visualised	O
portion	O
of	O
proximal	O
ascending	O
aorta	O
normal	O
.	O
Mitral	O
valve	O
MV	O
thin	O
leaflets	O
,	O
correct	O
opening	O
.	O
Complete	O
SAM	O
is	O
observed	O
generating	O
MI	O
with	O
eccentric	O
direction	O
directed	O
towards	O
the	O
AIS	O
,	O
reaching	O
the	O
roof	O
of	O
the	O
left	O
atrium	O
LA	O
without	O
correctly	O
visualising	O
flow	O
in	O
the	O
pulmonary	O
veins	O
,	O
which	O
appears	O
significant	O
high	O
Doppler	O
intensity	O
,	O
although	O
E	O
wave	O
1	O
.	O
2	O
cm	O
sec	O
.	O
Aortic	O
valve	O
VAo	O
trivalve	O
,	O
thin	O
leaflets	O
,	O
correct	O
opening	O
,	O
not	O
stenotic	O
Grad	O
max	O
18	O
mmHg	O
,	O
competent	O
.	O
Tricuspid	O
insufficiency	O
TI	O
.	O
Grad	O
VD	O
AD	O
27	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
with	O
preserved	O
inspiratory	O
collapse	O
.	O
Estimated	O
normal	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAPs	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
,	O
without	O
intracavitary	O
masses	O
through	O
this	O
access	O
route	O
.	O
CORONARYGRAPHY	O
coronary	O
arteries	O
without	O
significant	O
angiographic	O
lesions	O
.	O
Intramyocardial	O
segment	O
of	O
mid	O
LAD	O
causing	O
extrinsic	O
compression	O
in	O
systole	O
without	O
generating	O
severe	O
milking	O
.	O
Ventriculography	O
severe	O
hypokinesia	O
of	O
apical	O
and	O
middle	O
segments	O
of	O
diaphragmatic	O
and	O
anterolateral	O
face	O
with	O
hypercontractility	O
of	O
basal	O
segments	O
.	O
Moderate	O
LV	O
dysfunction	O
.	O
MI	O
grade	O
I	O
II	O
.	O
CARDIAC	O
MRI	O
LV	O
of	O
normal	O
size	O
,	O
with	O
normal	O
systolic	O
function	O
EF	O
52	O
.	O
Basal	O
septal	O
hypertrophy	O
of	O
16	O
mm	O
maximum	O
thickness	O
with	O
signs	O
of	O
left	O
ventricular	O
outflow	O
tract	O
obstruction	O
.	O
No	O
areas	O
of	O
late	O
enhancement	O
are	O
evident	O
in	O
the	O
myocardial	O
thickness	O
.	O
Signs	O
of	O
MI	O
with	O
mild	O
LA	O
dilatation	O
.	O
ECHOCARDIOGRAM	O
prior	O
to	O
discharge	O
the	O
echocardiogram	O
was	O
repeated	O
on	O
the	O
ward	O
after	O
starting	O
the	O
dose	O
of	O
beta	O
blocker	O
,	O
finding	O
a	O
baseline	O
gradient	O
of	O
64	O
mmHg	O
which	O
increased	O
to	O
100	O
mmHg	O
with	O
Valsava	O
,	O
with	O
other	O
findings	O
similar	O
to	O
the	O
previous	O
echo	O
,	O
with	O
no	O
clear	O
improvement	O
in	O
contractile	O
asymmetries	O
but	O
with	O
less	O
hyperdynamia	O
of	O
the	O
basal	O
segments	O
and	O
preserved	O
LV	O
systolic	O
function	O
50	O
55	O
.	O
CLINICAL	O
EVOLUTION	O
At	O
first	O
it	O
was	O
treated	O
as	O
acute	O
coronary	O
syndrome	O
.	O
However	O
,	O
the	O
patient	O
was	O
allergic	O
to	O
aspirin	B-FARMACO
and	O
trifusal	B-FARMACO
.	O
It	O
was	O
decided	O
to	O
perform	O
a	O
diagnostic	O
cardiac	O
catheterisation	O
under	O
treatment	O
with	O
clopidogrel	B-FARMACO
and	O
,	O
if	O
there	O
were	O
lesions	O
,	O
to	O
subsequently	O
perform	O
aspirin	B-FARMACO
desensitisation	O
prior	O
to	O
performing	O
coronary	O
intervention	O
.	O
Coronary	O
angiography	O
showed	O
epicardial	O
coronary	O
arteries	O
without	O
lesions	O
and	O
ventriculography	O
showed	O
severe	O
hypokinesia	O
of	O
apical	O
and	O
middle	O
segments	O
of	O
the	O
diaphragmatic	O
and	O
anterolateral	O
face	O
with	O
hypercontractility	O
of	O
basal	O
segments	O
with	O
moderate	O
LV	O
dysfunction	O
.	O
With	O
these	O
findings	O
,	O
the	O
first	O
clinical	O
suspicion	O
was	O
of	O
tako	O
tsubo	O
syndrome	O
due	O
to	O
segmental	O
asymmetries	O
,	O
history	O
of	O
stress	O
recent	O
admission	O
of	O
her	O
husband	O
,	O
elevated	O
necrosis	O
markers	O
and	O
epicardial	O
coronary	O
arteries	O
without	O
lesions	O
.	O
Treatment	O
with	O
beta	O
blocker	O
bisoprolol	B-FARMACO
was	O
started	O
progressively	O
up	O
to	O
10	O
mg	O
24	O
hours	O
with	O
good	O
clinical	O
tolerance	O
.	O
The	O
patient	O
did	O
not	O
present	O
heart	O
failure	O
during	O
admission	O
and	O
remained	O
asymptomatic	O
.	O
Platelet	O
antiplatelet	O
therapy	O
was	O
withdrawn	O
.	O
Given	O
the	O
diagnostic	O
doubt	O
with	O
hypertrophic	O
cardiomyopathy	O
,	O
cardiac	O
magnetic	O
resonance	O
imaging	O
was	O
performed	O
,	O
which	O
showed	O
no	O
areas	O
of	O
late	O
enhancement	O
in	O
the	O
myocardial	O
thickness	O
and	O
no	O
evidence	O
of	O
hypertrophic	O
cardiomyopathy	O
.	O
The	O
septum	O
was	O
16	O
mm	O
with	O
normal	O
remaining	O
segments	O
.	O
At	O
30	O
days	O
post	O
discharge	O
,	O
the	O
patient	O
presented	O
NYHA	O
functional	O
class	O
I	O
and	O
remained	O
asymptomatic	O
.	O
Physical	O
examination	O
showed	O
no	O
congestive	O
signs	O
and	O
no	O
auscultation	O
of	O
a	O
murmur	O
.	O
The	O
ECG	O
showed	O
disappearance	O
of	O
Q	O
waves	O
with	O
negative	O
T	O
waves	O
in	O
inferior	O
and	O
precordial	O
leads	O
.	O
Echocardiogram	O
in	O
consultation	O
showed	O
LVEF	O
65	O
,	O
without	O
segmental	O
asymmetries	O
.	O
The	O
LVOT	O
gradient	O
was	O
10	O
mmHg	O
and	O
24	O
mmHg	O
after	O
Valsalva	O
.	O
MR	O
was	O
mild	O
.	O
The	O
patient	O
was	O
referred	O
to	O
the	O
cardiology	O
department	O
for	O
follow	O
up	O
.	O
DIAGNOSIS	O
Tako	O
tsubo	O
syndrome	O
with	O
left	O
ventricular	O
outflow	O
tract	O
obstruction	O
and	O
significant	O
MR	O
due	O
to	O
SAM	O
in	O
a	O
patient	O
with	O
septal	O
LVH	O
.	O

Background	O
No	O
known	O
allergies	O
.	O
Glaucoma	O
.	O
Knee	O
arthritis	O
,	O
under	O
treatment	O
with	O
corticoids	O
,	O
attended	O
acupuncture	O
treatment	O
for	O
pain	O
management	O
.	O
No	O
CVRF	O
.	O
Present	O
illness	O
The	O
patient	O
attended	O
the	O
Emergency	O
Department	O
for	O
low	O
back	O
pain	O
and	O
was	O
discharged	O
the	O
same	O
day	O
with	O
a	O
diagnosis	O
of	O
low	O
back	O
pain	O
and	O
normal	O
complementary	O
tests	O
blood	O
tests	O
,	O
spinal	O
X	O
ray	O
.	O
Seven	O
days	O
later	O
,	O
she	O
returned	O
to	O
the	O
Emergency	O
Department	O
with	O
generalised	O
asthenia	O
,	O
fever	O
not	O
quantified	O
at	O
home	O
,	O
stiff	O
neck	O
and	O
back	O
,	O
papular	O
lesions	O
on	O
the	O
lower	O
limbs	O
,	O
pain	O
and	O
redness	O
in	O
the	O
left	O
knee	O
,	O
weight	O
loss	O
of	O
8	O
kg	O
in	O
3	O
4	O
months	O
,	O
associated	O
with	O
general	O
malaise	O
.	O
She	O
was	O
admitted	O
to	O
the	O
Infectious	O
Diseases	O
Department	O
,	O
with	O
initial	O
suspicion	O
of	O
meningitis	O
,	O
for	O
which	O
empirical	O
antibiotic	O
treatment	O
was	O
started	O
with	O
ceftriaxone	B-FARMACO
and	O
vancomycin	B-FARMACO
.	O
A	O
CT	O
scan	O
of	O
the	O
brain	O
,	O
lumbar	O
puncture	O
and	O
synovial	O
fluid	O
were	O
performed	O
.	O
In	O
view	O
of	O
the	O
negative	O
results	O
and	O
progressive	O
worsening	O
of	O
the	O
patient	O
,	O
an	O
assessment	O
by	O
Cardiology	O
was	O
requested	O
on	O
suspicion	O
of	O
bacterial	O
endocarditis	O
,	O
a	O
diagnosis	O
confirmed	O
by	O
echocardiogram	O
and	O
positive	O
blood	O
cultures	O
.	O
Physical	O
examination	O
On	O
arrival	O
at	O
the	O
ED	O
Ta	O
38	O
C	O
,	O
BP	O
130	O
80	O
mmHg	O
,	O
SatO2	O
95	O
on	O
room	O
air	O
,	O
HR	O
115	O
bpm	O
.	O
Good	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
.	O
Neck	O
marked	O
stiffness	O
on	O
movement	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Extremities	O
slight	O
peripheral	O
oedema	O
,	O
red	O
nodular	O
lesions	O
,	O
3	O
mm	O
in	O
diameter	O
,	O
on	O
the	O
lower	O
extremities	O
.	O
Kerning	O
and	O
Brudzinski	O
negative	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
in	O
the	O
ED	O
leukocytes	O
28	O
,	O
500	O
uL	O
,	O
neutrophils	O
97	O
,	O
Hb	O
13	O
.	O
9	O
g	O
dl	O
,	O
HtO	O
41	O
.	O
7	O
,	O
platelets	O
159	O
,	O
000	O
uL	O
,	O
glucose	O
163	O
mg	O
dl	O
,	O
urea	O
61	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
54	O
mg	O
dl	O
,	O
Na	O
130	O
mEq	O
l	O
,	O
K	O
3	O
.	O
9	O
mEq	O
l	O
,	O
CRP	O
33	O
.	O
86	O
mg	O
dl	O
.	O
CSF	O
culture	O
negative	O
.	O
Blood	O
culture	O
Staphylococcus	O
aureus	O
,	O
sensitive	O
to	O
methicillin	O
.	O
Thoracic	O
abdominal	O
CT	O
scan	O
bilateral	O
pleural	O
effusion	O
with	O
bilateral	O
basal	O
passive	O
lung	O
collapse	O
.	O
No	O
significant	O
alterations	O
were	O
identified	O
in	O
the	O
rest	O
of	O
the	O
lung	O
parenchyma	O
.	O
Mild	O
splenomegaly	O
of	O
122	O
mm	O
.	O
Small	O
peripheral	O
hypovascular	O
areas	O
of	O
triangular	O
morphology	O
suggestive	O
of	O
small	O
infarcts	O
.	O
There	O
are	O
two	O
small	O
15	O
mm	O
accessory	O
spleens	O
adjacent	O
to	O
the	O
lower	O
pole	O
.	O
Small	O
retroperitoneal	O
,	O
retrocrural	O
and	O
left	O
external	O
iliac	O
chain	O
lymphadenopathies	O
.	O
The	O
size	O
and	O
morphology	O
of	O
the	O
kidneys	O
are	O
preserved	O
.	O
Cortical	O
cyst	O
of	O
28	O
mm	O
in	O
the	O
upper	O
pole	O
of	O
the	O
left	O
kidney	O
.	O
Abdominal	O
aorta	O
of	O
normal	O
calibre	O
.	O
Diffuse	O
increase	O
of	O
intestinal	O
pneumatization	O
.	O
Redundant	O
colic	O
frame	O
,	O
with	O
abundant	O
faeces	O
inside	O
.	O
Small	O
amount	O
of	O
free	O
fluid	O
in	O
the	O
small	O
pelvis	O
.	O
In	O
view	O
of	O
progressive	O
deterioration	O
of	O
general	O
condition	O
and	O
suspicion	O
of	O
septic	O
embolism	O
both	O
in	O
the	O
spleen	O
and	O
lower	O
limbs	O
,	O
plus	O
positive	O
blood	O
culture	O
with	O
no	O
response	O
to	O
treatment	O
,	O
it	O
was	O
decided	O
to	O
transfer	O
her	O
to	O
the	O
ICU	O
and	O
she	O
was	O
assessed	O
by	O
TTE	O
and	O
TEE	O
.	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
LV	O
with	O
normal	O
wall	O
thickness	O
.	O
Preserved	O
LVEF	O
,	O
no	O
segmental	O
asymmetries	O
of	O
contractility	O
.	O
Diastolic	O
pattern	O
of	O
impaired	O
relaxation	O
.	O
RV	O
of	O
normal	O
size	O
and	O
function	O
TAPSE	O
21	O
mm	O
.	O
Aortic	O
valve	O
mobile	O
pedunculated	O
image	O
up	O
to	O
2	O
cm	O
in	O
length	O
prolapsing	O
in	O
LVOT	O
that	O
seems	O
to	O
depend	O
on	O
the	O
left	O
coronary	O
leaflet	O
mitro	O
aortic	O
junction	O
,	O
with	O
some	O
other	O
small	O
image	O
of	O
lesser	O
length	O
over	O
the	O
leaflets	O
.	O
No	O
valvular	O
restriction	O
and	O
mild	O
reflux	O
.	O
No	O
images	O
of	O
abscesses	O
over	O
the	O
aortic	O
root	O
by	O
this	O
access	O
route	O
.	O
Mitral	O
valve	O
anterior	O
leaflet	O
slightly	O
thickened	O
,	O
with	O
no	O
clear	O
images	O
of	O
vegetations	O
on	O
the	O
leaflets	O
.	O
Central	O
reflux	O
in	O
the	O
form	O
of	O
several	O
grade	O
II	O
jets	O
.	O
Tricuspid	O
valve	O
with	O
suboptimal	O
visualisation	O
,	O
no	O
apparent	O
images	O
of	O
endocarditis	O
,	O
no	O
insufficiency	O
.	O
Prominent	O
Eustachian	O
valve	O
.	O
Slight	O
pericardial	O
effusion	O
of	O
about	O
5	O
6	O
mm	O
,	O
mild	O
collapse	O
of	O
the	O
RA	O
.	O
No	O
other	O
signs	O
of	O
haemodynamic	O
compromise	O
.	O
Non	O
dilated	O
IVC	O
with	O
normal	O
collapse	O
.	O
Transesophageal	O
echocardiogram	O
LV	O
of	O
normal	O
size	O
and	O
wall	O
thickness	O
.	O
Good	O
systolic	O
function	O
and	O
no	O
contractile	O
asymmetries	O
.	O
On	O
the	O
ventricular	O
wall	O
adjacent	O
to	O
the	O
antero	O
lateral	O
mitral	O
commissure	O
and	O
in	O
relation	O
to	O
the	O
proximal	O
mitral	O
subvalvular	O
apparatus	O
,	O
a	O
thick	O
mass	O
of	O
anarchic	O
movement	O
of	O
at	O
least	O
2	O
cm	O
in	O
length	O
is	O
visualised	O
,	O
which	O
is	O
introduced	O
in	O
its	O
movement	O
towards	O
the	O
LV	O
outflow	O
tract	O
,	O
reaching	O
the	O
VAo	O
plane	O
touching	O
the	O
ventricular	O
side	O
of	O
the	O
right	O
coronary	O
leaflet	O
.	O
Mitral	O
valve	O
thin	O
leaflets	O
,	O
without	O
calcium	O
and	O
without	O
apparent	O
alterations	O
in	O
its	O
kinetics	O
.	O
On	O
the	O
atrial	O
side	O
of	O
P1	O
A1	O
there	O
are	O
several	O
images	O
of	O
anarchic	O
movement	O
,	O
the	O
largest	O
of	O
approximately	O
1	O
cm	O
.	O
Slight	O
central	O
reflux	O
and	O
another	O
that	O
seems	O
to	O
originate	O
from	O
a	O
small	O
perforation	O
of	O
the	O
posterior	O
leaflet	O
,	O
at	O
the	O
level	O
of	O
P1	O
.	O
Aortic	O
valve	O
trivalve	O
,	O
with	O
thin	O
leaflets	O
without	O
apparent	O
images	O
suggestive	O
of	O
vegetations	O
on	O
the	O
leaflets	O
.	O
In	O
the	O
right	O
coronary	O
sinus	O
there	O
is	O
a	O
hypoechoic	O
mobile	O
image	O
that	O
seems	O
to	O
be	O
a	O
false	O
image	O
reverberation	O
of	O
the	O
mass	O
coming	O
from	O
the	O
ventricular	O
wall	O
.	O
Slight	O
reflux	O
of	O
central	O
origin	O
and	O
eccentric	O
jet	O
towards	O
the	O
AIS	O
.	O
There	O
are	O
no	O
images	O
suggestive	O
of	O
abscesses	O
or	O
other	O
complications	O
on	O
the	O
root	O
or	O
mitro	O
aortic	O
junction	O
.	O
No	O
fistulae	O
to	O
the	O
right	O
chambers	O
.	O
Right	O
chambers	O
not	O
dilated	O
.	O
Good	O
RV	O
function	O
.	O
On	O
the	O
lateral	O
wall	O
of	O
the	O
RA	O
and	O
about	O
2	O
cm	O
from	O
the	O
tricuspid	O
valve	O
plane	O
,	O
there	O
was	O
a	O
thick	O
mass	O
with	O
similar	O
characteristics	O
to	O
the	O
one	O
seen	O
on	O
the	O
ventricular	O
wall	O
,	O
very	O
long	O
almost	O
3	O
cm	O
long	O
and	O
with	O
an	O
anarchic	O
movement	O
towards	O
the	O
tricuspid	O
plane	O
.	O
It	O
is	O
introduced	O
in	O
its	O
movement	O
in	O
the	O
valvular	O
plane	O
without	O
producing	O
any	O
alteration	O
in	O
valvular	O
function	O
.	O
From	O
transgastric	O
access	O
,	O
the	O
leaflets	O
of	O
the	O
TV	O
are	O
thin	O
,	O
with	O
no	O
apparent	O
images	O
suggesting	O
vegetations	O
on	O
them	O
.	O
IT	O
is	O
not	O
adequately	O
visualised	O
to	O
estimate	O
PAPs	O
.	O
Pulmonary	O
valve	O
with	O
thin	O
leaflets	O
and	O
no	O
images	O
suggestive	O
of	O
vegetations	O
.	O
Slight	O
pericardial	O
effusion	O
with	O
no	O
evidence	O
of	O
haemodynamic	O
repercussions	O
.	O
EVOLUTION	O
The	O
patient	O
presented	O
progressive	O
deterioration	O
of	O
general	O
condition	O
.	O
Blood	O
pressure	O
figures	O
were	O
adequate	O
,	O
although	O
she	O
was	O
tachycardic	O
,	O
tachypneic	O
,	O
with	O
a	O
poor	O
general	O
appearance	O
,	O
so	O
she	O
was	O
transferred	O
to	O
the	O
ICU	O
,	O
where	O
antibiotic	O
treatment	O
was	O
modified	O
,	O
replacing	O
vancomycin	B-FARMACO
with	O
daptomycin	B-FARMACO
,	O
and	O
emergency	O
surgery	O
was	O
performed	O
.	O
She	O
arrived	O
in	O
the	O
operating	O
theatre	O
hypotensive	O
,	O
tachypnoeic	O
and	O
cloudy	O
,	O
with	O
haemodynamic	O
instability	O
throughout	O
the	O
surgical	O
procedure	O
,	O
requiring	O
the	O
infusion	O
of	O
vasoactive	O
drugs	O
noradrenaline	B-FARMACO
,	O
dobutamine	B-FARMACO
,	O
vasopressin	B-FARMACO
at	O
high	O
doses	O
,	O
associated	O
with	O
significant	O
intraoperative	O
coagulopathy	O
.	O
Surgical	O
findings	O
included	O
vegetation	O
in	O
the	O
free	O
wall	O
of	O
the	O
RA	O
approximately	O
3	O
cm	O
long	O
;	O
vegetation	O
in	O
the	O
posterior	O
wall	O
of	O
the	O
LV	O
,	O
which	O
protruded	O
through	O
the	O
aortic	O
valve	O
;	O
trivalva	O
of	O
thin	O
,	O
non	O
calcified	O
leaflets	O
;	O
impacting	O
with	O
the	O
same	O
at	O
the	O
level	O
of	O
the	O
non	O
coronary	O
leaflet	O
,	O
with	O
minimal	O
changes	O
in	O
the	O
leaflet	O
.	O
It	O
was	O
decided	O
to	O
replace	O
the	O
valve	O
with	O
a	O
mechanical	O
prosthesis	O
.	O
Mitral	O
subvalvular	O
abscess	O
,	O
at	O
the	O
level	O
of	O
the	O
anterior	O
commissure	O
,	O
lateral	O
to	O
LV	O
vegetation	O
,	O
with	O
the	O
need	O
for	O
reconstruction	O
of	O
the	O
tissue	O
,	O
using	O
prolene	O
stitches	O
supported	O
by	O
a	O
Teflon	O
patch	O
.	O
Perforation	O
of	O
fine	O
mitral	O
leaflet	O
,	O
without	O
calcium	O
,	O
with	O
small	O
vegetations	O
in	O
the	O
leaflet	O
,	O
valve	O
replacement	O
by	O
mechanical	O
prosthesis	O
was	O
performed	O
.	O
In	O
the	O
immediate	O
postoperative	O
period	O
,	O
haemodynamic	O
instability	O
persisted	O
.	O
On	O
examination	O
,	O
transient	O
right	O
anisocoria	O
was	O
detected	O
,	O
so	O
a	O
window	O
of	O
sedation	O
was	O
performed	O
where	O
he	O
presented	O
tonic	O
clonic	O
crises	O
,	O
so	O
sedation	O
was	O
restarted	O
,	O
anti	O
combustion	O
treatment	O
,	O
and	O
no	O
haemorrhagic	O
or	O
ischaemic	O
signs	O
were	O
observed	O
in	O
the	O
cranial	O
CAT	O
scan	O
.	O
He	O
presented	O
progressive	O
and	O
rapid	O
multi	O
organ	O
deterioration	O
,	O
with	O
acute	O
renal	O
failure	O
requiring	O
renal	O
function	O
replacement	O
therapy	O
by	O
haemofiltration	O
and	O
haemodynamic	O
failure	O
.	O
In	O
the	O
presence	O
of	O
bilateral	O
mydriasis	O
arreactiva	O
,	O
sedation	O
was	O
withdrawn	O
and	O
the	O
clinical	O
examination	O
and	O
EEG	O
were	O
compatible	O
with	O
brain	O
death	O
.	O
Vasoactive	O
drugs	O
were	O
withdrawn	O
and	O
the	O
patient	O
died	O
.	O
DIAGNOSIS	O
Mural	O
endocarditis	O
and	O
valvular	O
endocarditis	O
on	O
native	O
mitral	O
valve	O
due	O
to	O
Staphylococcus	O
aureus	O
.	O
Septic	O
embolisms	O
.	O
Heart	O
failure	O
.	O
Emergent	O
surgery	O
.	O
Poor	O
postoperative	O
evolution	O
with	O
multiorgan	O
failure	O
and	O
exitus	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
63	O
year	O
old	O
male	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Personal	O
history	O
exobabies	O
,	O
type	O
2	O
diabetes	O
mellitus	O
,	O
dyslipidaemia	O
,	O
myelodysplastic	O
syndrome	O
subtype	O
CRDM	O
refractory	O
cytopenias	O
with	O
multilinear	O
dysplasia	O
followed	O
up	O
by	O
haematology	O
.	O
Ischaemic	O
heart	O
disease	O
of	O
debut	O
in	O
1996	O
in	O
the	O
form	O
of	O
acute	O
myocardial	O
infarction	O
with	O
ST	O
segment	O
elevation	O
STEMI	O
posteroinferior	O
.	O
Inferior	O
re	O
infarction	O
in	O
1999	O
and	O
in	O
June	O
2006	O
with	O
syncope	O
and	O
lacunar	O
cerebrovascular	O
accident	O
CVA	O
.	O
On	O
admission	O
in	O
2006	O
he	O
was	O
diagnosed	O
with	O
multivessel	O
coronary	O
artery	O
disease	O
with	O
slightly	O
depressed	O
left	O
ventricular	O
systolic	O
function	O
and	O
severe	O
aortic	O
stenosis	O
,	O
and	O
it	O
was	O
decided	O
to	O
perform	O
surgical	O
coronary	O
revascularisation	O
and	O
aortic	O
valve	O
replacement	O
.	O
In	O
December	O
2006	O
,	O
aortic	O
valve	O
replacement	O
with	O
mechanical	O
prosthesis	O
and	O
triple	O
aortocoronary	O
bypass	O
with	O
revascularisation	O
of	O
the	O
LAD	O
with	O
IMA	O
and	O
PD	O
and	O
1st	O
marginal	O
with	O
two	O
saphenous	O
vein	O
fragments	O
.	O
Follow	O
up	O
in	O
outpatient	O
cardiology	O
clinics	O
in	O
usual	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
II	O
.	O
In	O
the	O
last	O
year	O
and	O
a	O
half	O
,	O
progressive	O
deterioration	O
of	O
functional	O
class	O
with	O
progressively	O
decreasing	O
dyspnoea	O
on	O
exertion	O
and	O
oedematisation	O
of	O
the	O
lower	O
limbs	O
lower	O
extremities	O
.	O
Last	O
echocardiogram	O
in	O
November	O
2016	O
left	O
ventricle	O
LV	O
of	O
normal	O
size	O
.	O
Mild	O
septal	O
hypertrophy	O
,	O
preserved	O
systolic	O
function	O
with	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
around	O
55	O
,	O
akinesia	O
of	O
the	O
inferior	O
wall	O
,	O
the	O
rest	O
of	O
the	O
segments	O
without	O
contractility	O
alterations	O
.	O
Normofunctioning	O
mitral	O
valve	O
MV	O
.	O
Mechanical	O
prosthesis	O
in	O
aortic	O
position	O
with	O
adequate	O
opening	O
,	O
moderate	O
periprosthetic	O
insufficiency	O
.	O
Mild	O
tricuspid	O
insufficiency	O
TI	O
.	O
Estimated	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAPs	O
of	O
45	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
Under	O
home	O
treatment	O
with	O
acenocoumarol	B-FARMACO
according	O
to	O
guideline	O
,	O
atorvastatin	B-FARMACO
10	O
mg	O
every	O
24	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
every	O
24	O
hours	O
,	O
glimepiride	B-FARMACO
4	O
mg	O
every	O
24	O
hours	O
,	O
metformin	B-FARMACO
vildagliptin	I-FARMACO
850	O
50	O
mg	O
every	O
12	O
hours	O
,	O
ezetimibe	B-FARMACO
10	O
mg	O
every	O
24	O
hours	O
,	O
ferrous	B-FARMACO
sulphate	I-FARMACO
80	O
mg	O
every	O
24	O
hours	O
,	O
ivabradine	B-FARMACO
5	O
mg	O
every	O
12	O
hours	O
,	O
furosemide	B-FARMACO
40	O
mg	O
every	O
24	O
hours	O
,	O
spironolactone	B-FARMACO
50	O
mg	O
every	O
24	O
hours	O
.	O
CURRENT	O
ILLNESS	O
The	O
patient	O
comes	O
to	O
the	O
ED	O
for	O
frank	O
clinical	O
worsening	O
in	O
the	O
last	O
month	O
with	O
dyspnoea	O
on	O
minimal	O
effort	O
,	O
bendopnoea	O
,	O
increased	O
abdominal	O
perimeter	O
and	O
oedematisation	O
of	O
EEII	O
.	O
No	O
clear	O
orthopnoea	O
or	O
DPN	O
.	O
He	O
also	O
reported	O
the	O
appearance	O
of	O
oppressive	O
,	O
continuous	O
precordial	O
pain	O
,	O
of	O
about	O
three	O
days	O
'	O
evolution	O
,	O
without	O
irradiation	O
or	O
accompanying	O
vegetative	O
cortex	O
.	O
No	O
dietary	O
transgressions	O
or	O
apparent	O
intercurrent	O
infectious	O
process	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
115	O
60	O
mmHg	O
,	O
heart	O
rate	O
72	O
bpm	O
,	O
oxygen	O
saturation	O
93	O
with	O
GN	O
at	O
2	O
bpm	O
.	O
Afebrile	O
.	O
Normohydrated	O
with	O
icteric	O
staining	O
of	O
skin	O
and	O
conjunctivae	O
.	O
Conversational	O
dyspnoea	O
,	O
no	O
respiratory	O
work	O
at	O
rest	O
.	O
Jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
prosthetic	O
sounds	O
with	O
diastolic	O
murmur	O
in	O
aortic	O
and	O
left	O
parasternal	O
focus	O
.	O
Pulmonary	O
auscultation	O
discrete	O
bibasal	O
hypophonesis	O
,	O
without	O
crackles	O
or	O
other	O
added	O
pathological	O
sounds	O
.	O
Abdomen	O
was	O
globular	O
,	O
with	O
collateral	O
circulation	O
,	O
no	O
clear	O
ascitic	O
surge	O
and	O
hepatomegaly	O
of	O
3	O
traverses	O
.	O
The	O
lower	O
extremities	O
showed	O
oedema	O
with	O
fovea	O
up	O
to	O
the	O
middle	O
third	O
of	O
both	O
legs	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
83	O
bpm	O
,	O
PR	O
190	O
ms	O
,	O
known	O
LBBB	O
with	O
secondary	O
repolarisation	O
alterations	O
.	O
ANALYTICS	O
on	O
admission	O
ProBNP	O
1	O
,	O
919	O
pg	O
ml	O
,	O
glucose	O
72	O
mg	O
dl	O
,	O
urea	O
40	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
97	O
mg	O
dl	O
,	O
sodium	O
134	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
8	O
mEq	O
l	O
.	O
Leukocytes	O
3	O
,	O
400	O
ml	O
76	O
.	O
8	O
neutrophils	O
,	O
Hb	O
11	O
.	O
4	O
gr	O
dl	O
,	O
Hto	O
35	O
.	O
5	O
,	O
platelets	O
59	O
,	O
000	O
mm3	O
.	O
INR	O
3	O
.	O
96	O
.	O
THORAX	O
X	O
RAY	O
global	O
cardiomegaly	O
.	O
Aortic	O
valve	O
prosthesis	O
.	O
Mid	O
sternotomy	O
sutures	O
.	O
Increase	O
of	O
interstitial	O
tissue	O
of	O
probable	O
vascular	O
origin	O
.	O
No	O
consolidative	O
foci	O
or	O
pleural	O
effusion	O
.	O
Dorsal	O
spondylosis	O
with	O
calcification	O
of	O
the	O
anterior	O
vertebral	O
ligament	O
.	O
Transthoracic	O
echocardiogram	O
on	O
admission	O
LV	O
of	O
normal	O
size	O
and	O
moderate	O
concentric	O
hypertrophy	O
.	O
Normal	O
global	O
LV	O
systolic	O
function	O
;	O
flattened	O
septal	O
motion	O
probably	O
related	O
to	O
previous	O
surgery	O
and	O
right	O
overload	O
,	O
inferobasal	O
and	O
medial	O
inferior	O
akinetic	O
eschar	O
.	O
Restrictive	O
diastolic	O
pattern	O
,	O
with	O
data	O
suggestive	O
of	O
elevated	O
LVEDP	O
.	O
Slight	O
biauricular	O
dilatation	O
.	O
Right	O
ventricle	O
RV	O
of	O
preserved	O
size	O
and	O
contractility	O
.	O
Aortic	O
root	O
and	O
visualised	O
portion	O
of	O
proximal	O
ascending	O
aorta	O
of	O
normal	O
size	O
.	O
MV	O
thin	O
leaflets	O
,	O
not	O
limited	O
in	O
its	O
opening	O
and	O
mild	O
central	O
mitral	O
insufficiency	O
MI	O
.	O
Aortic	O
prosthesis	O
opening	O
of	O
occluders	O
,	O
gradients	O
similar	O
to	O
previous	O
studies	O
,	O
normal	O
Doppler	O
velocity	O
index	O
IVT	O
TSVI	O
Ao	O
ratio	O
0	O
.	O
47	O
and	O
wide	O
periprosthetic	O
reflux	O
,	O
eccentric	O
,	O
running	O
parallel	O
to	O
the	O
interventricular	O
septum	O
,	O
originating	O
in	O
the	O
theoretical	O
right	O
coronary	O
sinus	O
around	O
11	O
00	O
hours	O
,	O
short	O
THP	O
,	O
holodiastolic	O
inversion	O
in	O
descending	O
thoracic	O
aorta	O
with	O
end	O
diastolic	O
velocity	O
20	O
cm	O
s	O
18	O
cm	O
s	O
and	O
only	O
protodiastolic	O
inversion	O
in	O
abdominal	O
aorta	O
,	O
for	O
all	O
these	O
reasons	O
it	O
is	O
classified	O
as	O
grade	O
III	O
IV	O
IV	O
.	O
A	O
semilunar	O
image	O
is	O
observed	O
adjacent	O
to	O
the	O
theoretical	O
right	O
coronary	O
sinus	O
,	O
echodense	O
,	O
where	O
the	O
leak	O
originates	O
,	O
which	O
could	O
be	O
the	O
origin	O
of	O
the	O
leak	O
.	O
Light	O
TI	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
IVC	O
with	O
absence	O
of	O
inspiratory	O
collapse	O
.	O
Severe	O
pulmonary	O
hypertension	O
PHT	O
.	O
Mild	O
PE	O
allowing	O
estimation	O
of	O
a	O
mean	O
PAP	O
of	O
51	O
mmHg	O
31	O
mmHg	O
20	O
mmHg	O
DBP	O
.	O
Perihepatic	O
fluid	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
and	O
intracavitary	O
masses	O
via	O
this	O
access	O
route	O
.	O
Conclusions	O
moderate	O
concentric	O
left	O
ventricular	O
hypertrophy	O
LVH	O
.	O
Normal	O
LVEF	O
,	O
with	O
segmental	O
asymmetries	O
.	O
Restrictive	O
diastolic	O
pattern	O
.	O
Mild	O
MI	O
.	O
Grade	O
III	O
IV	O
IV	O
aortic	O
periprosthetic	O
leak	O
.	O
Severe	O
PHT	O
.	O
Transesophageal	O
echocardiogram	O
left	O
atrium	O
without	O
thrombus	O
inside	O
.	O
Left	O
atrial	O
appendage	O
without	O
thrombus	O
.	O
Atrial	O
septum	O
intact	O
.	O
Aortic	O
prosthesis	O
correct	O
movement	O
of	O
hemidiscs	O
,	O
gradients	O
similar	O
to	O
previous	O
studies	O
,	O
Doppler	O
velocity	O
index	O
within	O
normality	O
and	O
two	O
physiological	O
intraprosthetic	O
refluxes	O
for	O
prosthesis	O
.	O
A	O
crescentic	O
image	O
was	O
observed	O
between	O
the	O
theoretical	O
right	O
coronary	O
sinus	O
and	O
non	O
coronary	O
sinus	O
,	O
between	O
9	O
00	O
and	O
12	O
00	O
hours	O
,	O
of	O
about	O
0	O
.	O
5	O
cm2	O
area	O
,	O
suggesting	O
prosthetic	O
dehiscence	O
at	O
this	O
level	O
and	O
from	O
which	O
originates	O
aortic	O
periprosthetic	O
leak	O
with	O
wide	O
jet	O
that	O
runs	O
parallel	O
to	O
the	O
interventricular	O
septum	O
and	O
deepens	O
in	O
LV	O
reaching	O
papillary	O
muscles	O
,	O
with	O
short	O
THP	O
,	O
holodiastolic	O
inversion	O
in	O
descending	O
thoracic	O
aorta	O
with	O
end	O
diastolic	O
velocity	O
20	O
cm	O
s	O
,	O
without	O
observing	O
reverse	O
flow	O
in	O
abdominal	O
aorta	O
,	O
for	O
all	O
these	O
reasons	O
it	O
is	O
classified	O
as	O
grade	O
III	O
IV	O
IV	O
.	O
Mitro	O
aortic	O
junction	O
and	O
periaortic	O
region	O
with	O
normal	O
echoic	O
characteristics	O
,	O
without	O
images	O
suggesting	O
abscesses	O
or	O
other	O
periannular	O
complications	O
.	O
Other	O
findings	O
superimposable	O
to	O
transthoracic	O
study	O
.	O
Conclusions	O
grade	O
III	O
IV	O
IV	O
aortic	O
periprosthetic	O
leak	O
.	O
Moderate	O
LVH	O
.	O
Normal	O
LVEF	O
,	O
with	O
segmental	O
asymmetries	O
.	O
Restrictive	O
diastolic	O
pattern	O
.	O
Severe	O
PHT	O
.	O
ECHOCARDIOGRAM	O
after	O
percutaneous	O
closure	O
procedure	O
aortic	O
prosthesis	O
gradient	O
improvement	O
,	O
currently	O
maximum	O
of	O
32	O
mmHg	O
.	O
Several	O
periprosthetic	O
leaks	O
are	O
seen	O
one	O
at	O
11	O
hours	O
and	O
another	O
at	O
3	O
hours	O
overall	O
of	O
somewhat	O
lower	O
grade	O
than	O
in	O
the	O
previous	O
study	O
but	O
still	O
grade	O
III	O
IV	O
THP	O
280	O
310	O
ms	O
,	O
holodiastolic	O
reversal	O
of	O
flow	O
in	O
isthmus	O
and	O
left	O
femoral	O
artery	O
.	O
Mild	O
TR	O
allowing	O
estimation	O
of	O
PAPs	O
47	O
mmHg	O
.	O
IVC	O
currently	O
not	O
dilated	O
with	O
normal	O
collapse	O
.	O
Mild	O
PI	O
allowing	O
an	O
estimated	O
mean	O
PAP	O
of	O
25	O
mmHg	O
.	O
Current	O
absence	O
of	O
pericardial	O
effusion	O
.	O
Rest	O
of	O
study	O
unchanged	O
from	O
previous	O
.	O
Conclusions	O
Moderate	O
eccentric	O
LVH	O
.	O
Preserved	O
LVEF	O
.	O
Inferobasal	O
akinesia	O
.	O
AIo	O
III	O
IV	O
.	O
Moderate	O
PHT	O
.	O
CLINICAL	O
EVOLUTION	O
Clinical	O
improvement	O
during	O
admission	O
with	O
loss	O
of	O
13	O
kg	O
of	O
weight	O
,	O
decrease	O
in	O
abdominal	O
perimeter	O
and	O
disappearance	O
of	O
oedema	O
under	O
intravenous	O
perfusion	O
of	O
loop	O
diuretic	O
and	O
inotropes	O
.	O
Given	O
the	O
persistence	O
of	O
jaundice	O
together	O
with	O
sustained	O
high	O
bilirubin	O
levels	O
and	O
slight	O
elevation	O
of	O
GGT	O
,	O
FA	O
and	O
LDH	O
,	O
an	O
abdominal	O
ultrasound	O
was	O
performed	O
showing	O
hepatomegaly	O
suggestive	O
of	O
chronic	O
liver	O
disease	O
and	O
splenomegaly	O
.	O
The	O
echocardiogram	O
showed	O
severe	O
aortic	O
insufficiency	O
which	O
was	O
confirmed	O
by	O
TEE	O
performed	O
after	O
depletive	O
treatment	O
,	O
visualising	O
a	O
grade	O
IIIIV	O
IV	O
periprosthetic	O
aortic	O
leak	O
with	O
severe	O
pulmonary	O
hypertension	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
the	O
case	O
was	O
presented	O
at	O
a	O
medical	O
surgical	O
session	O
and	O
,	O
given	O
the	O
patient	O
's	O
comorbidity	O
,	O
percutaneous	O
closure	O
of	O
the	O
periprosthetic	O
leak	O
was	O
considered	O
the	O
best	O
option	O
.	O
During	O
admission	O
,	O
closure	O
of	O
the	O
aortic	O
paravalvular	O
leak	O
was	O
performed	O
.	O
The	O
procedure	O
was	O
very	O
difficult	O
due	O
to	O
the	O
difficulty	O
in	O
advancing	O
the	O
guidewires	O
through	O
the	O
leak	O
,	O
achieving	O
partial	O
closure	O
of	O
the	O
leak	O
by	O
means	O
of	O
a	O
ductus	O
closure	O
device	O
.	O
There	O
were	O
no	O
complications	O
in	O
the	O
vascular	O
access	O
and	O
the	O
patient	O
remained	O
haemodynamically	O
stable	O
at	O
all	O
times	O
.	O
Subsequent	O
evolution	O
was	O
good	O
,	O
and	O
a	O
transthoracic	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
an	O
improvement	O
in	O
aortic	O
regurgitation	O
,	O
although	O
a	O
grade	O
II	O
IV	O
periprosthetic	O
leak	O
persisted	O
with	O
a	O
decrease	O
in	O
pulmonary	O
pressure	O
,	O
for	O
which	O
reason	O
he	O
was	O
discharged	O
.	O
The	O
patient	O
is	O
currently	O
under	O
outpatient	O
follow	O
up	O
by	O
the	O
heart	O
failure	O
team	O
,	O
having	O
required	O
only	O
one	O
hospital	O
admission	O
since	O
then	O
for	O
decompensated	O
heart	O
failure	O
in	O
the	O
context	O
of	O
respiratory	O
infection	O
.	O
DIAGNOSIS	O
Right	O
sided	O
congestive	O
heart	O
failure	O
.	O
Periprosthetic	O
aortic	O
leak	O
with	O
grade	O
III	O
IV	O
IV	O
insufficiency	O
,	O
with	O
partial	O
closure	O
by	O
percutaneous	O
procedure	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
.	O
Myelodyspastic	O
syndrome	O
anaemia	O
thrombopenia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
High	O
blood	O
pressure	O
HBP	O
under	O
treatment	O
and	O
smoker	O
of	O
one	O
pack	O
a	O
day	O
.	O
No	O
relevant	O
medical	O
history	O
.	O
Previous	O
surgeries	O
appendectomy	O
20	O
years	O
ago	O
.	O
Current	O
treatment	O
enalapril	B-FARMACO
10	O
mg	O
every	O
12	O
hours	O
.	O
Baseline	O
life	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
.	O
Family	O
history	O
father	O
with	O
sudden	O
death	O
at	O
the	O
age	O
of	O
60	O
.	O
CURRENT	O
ILLNESS	O
44	O
year	O
old	O
male	O
patient	O
brought	O
by	O
SUMMA	O
to	O
the	O
emergency	O
department	O
for	O
sudden	O
syncope	O
recovered	O
while	O
walking	O
in	O
the	O
street	O
.	O
He	O
reported	O
atypical	O
chest	O
pain	O
in	O
the	O
previous	O
72	O
hours	O
,	O
intermittent	O
,	O
which	O
appeared	O
at	O
rest	O
and	O
was	O
not	O
accompanied	O
by	O
vegetative	O
cortex	O
.	O
There	O
were	O
no	O
symptoms	O
of	O
heart	O
failure	O
or	O
palpitations	O
.	O
No	O
other	O
clinical	O
manifestations	O
due	O
to	O
apparatus	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
an	O
electrocardiogram	O
ECG	O
was	O
performed	O
.	O
Haemodynamically	O
unstable	O
,	O
urgent	O
TTE	O
was	O
performed	O
,	O
showing	O
cardiac	O
tamponade	O
secondary	O
to	O
cardiac	O
rupture	O
.	O
Orotracheal	O
intubation	O
was	O
performed	O
,	O
a	O
central	O
line	O
was	O
placed	O
,	O
inotropic	O
support	O
was	O
started	O
and	O
pericardiocentesis	O
was	O
performed	O
but	O
failed	O
,	O
and	O
the	O
cardiac	O
surgeon	O
was	O
notified	O
for	O
urgent	O
surgery	O
to	O
evacuate	O
the	O
effusion	O
and	O
implant	O
a	O
pericardial	O
patch	O
.	O
After	O
surgery	O
,	O
he	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
ICU	O
for	O
further	O
care	O
.	O
During	O
his	O
admission	O
to	O
the	O
ICU	O
,	O
coronary	O
angiography	O
was	O
performed	O
showing	O
left	O
coronary	O
artery	O
without	O
significant	O
lesions	O
and	O
critical	O
stenosis	O
of	O
the	O
proximal	O
right	O
coronary	O
artery	O
RCA	O
,	O
with	O
image	O
of	O
partially	O
recanalised	O
thrombus	O
and	O
distal	O
TIMI	O
1	O
flow	O
,	O
to	O
IVP	O
is	O
partially	O
filled	O
by	O
collateral	O
circulation	O
from	O
IC	O
.	O
Medical	O
treatment	O
of	O
the	O
lesion	O
was	O
decided	O
for	O
the	O
time	O
being	O
.	O
After	O
a	O
month	O
of	O
hospitalisation	O
,	O
extubated	O
,	O
clinically	O
and	O
haemodynamically	O
stable	O
,	O
he	O
was	O
discharged	O
to	O
the	O
cardiology	O
ward	O
.	O
PHYSICAL	O
EXAMINATION	O
IOT	O
,	O
regularly	O
perfused	O
,	O
tachypneic	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
tachycardic	O
,	O
no	O
murmurs	O
,	O
muffled	O
tones	O
.	O
Pulmonary	O
auscultation	O
bilateral	O
crackles	O
.	O
Lower	O
limbs	O
no	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYTICS	O
Hb	O
10g	O
dl	O
.	O
Platelets	O
228	O
.	O
000	O
ml	O
,	O
leukocytes	O
26	O
.	O
000	O
ml	O
.	O
89	O
neutrophils	O
.	O
INR	O
1	O
.	O
7	O
.	O
Urea	O
32	O
mg	O
dl	O
.	O
Cr	O
0	O
.	O
76	O
mg	O
dl	O
.	O
Na	O
136	O
.	O
K	O
4	O
.	O
3	O
mEq	O
l	O
.	O
pH	O
7	O
.	O
21	O
,	O
lactic	O
1	O
.	O
2	O
mmol	O
l	O
,	O
CK	O
3	O
,	O
000	O
mmol	O
l	O
,	O
TnT	O
600	O
ng	O
dl	O
.	O
Urgent	O
TTE	O
postoperative	O
,	O
ICU	O
severe	O
biventricular	O
dysfunction	O
at	O
the	O
expense	O
of	O
inferior	O
and	O
inferolateral	O
akinesia	O
and	O
dyskinesia	O
of	O
the	O
basal	O
segments	O
.	O
Mild	O
ischaemic	O
mitral	O
insufficiency	O
MI	O
.	O
Mild	O
pericardial	O
effusion	O
.	O
CORONARYGRAPHY	O
critical	O
proximal	O
DC	O
stenosis	O
,	O
with	O
image	O
of	O
partially	O
recanalised	O
thrombus	O
,	O
and	O
distal	O
TIMI	O
1	O
flow	O
.	O
IVP	O
is	O
filled	O
by	O
collateral	O
circulation	O
from	O
the	O
left	O
coronary	O
artery	O
.	O
Left	O
coronary	O
tree	O
without	O
significant	O
lesions	O
.	O
TTE	O
ruled	O
cardiology	O
floor	O
severely	O
dilated	O
left	O
ventricle	O
LV	O
.	O
Severe	O
LV	O
dysfunction	O
with	O
hypokinesia	O
of	O
all	O
segments	O
and	O
akinesia	O
of	O
the	O
inferior	O
face	O
,	O
large	O
posterobasal	O
aneurysm	O
with	O
partial	O
thrombosis	O
of	O
the	O
cavity	O
.	O
Right	O
ventricular	O
RV	O
systolic	O
function	O
at	O
the	O
lower	O
limit	O
of	O
normality	O
.	O
MRI	O
cardiology	O
floor	O
dilated	O
LV	O
with	O
large	O
lateral	O
wall	O
pseudoaneurysm	O
,	O
at	O
the	O
level	O
of	O
surgical	O
repair	O
of	O
LV	O
free	O
wall	O
rupture	O
.	O
The	O
pseudoaneurysm	O
measures	O
66	O
x	O
41	O
mm	O
lateral	O
and	O
inferolateral	O
extension	O
.	O
There	O
are	O
no	O
images	O
suggestive	O
of	O
thrombus	O
inside	O
the	O
pseudoaneurysm	O
.	O
Lateral	O
wall	O
thinned	O
,	O
with	O
lateral	O
and	O
inferior	O
akinesia	O
.	O
The	O
rest	O
of	O
the	O
walls	O
with	O
septal	O
thickness	O
within	O
the	O
normal	O
range	O
.	O
Contractility	O
preserved	O
at	O
the	O
level	O
of	O
the	O
anterior	O
wall	O
,	O
septum	O
and	O
mid	O
apical	O
and	O
basal	O
lateral	O
wall	O
.	O
Global	O
systolic	O
function	O
severely	O
depressed	O
19	O
.	O
Late	O
gadolinium	O
enhancement	O
study	O
with	O
transmural	O
enhancement	O
area	O
in	O
inferior	O
and	O
lateral	O
face	O
respecting	O
apical	O
segments	O
of	O
both	O
faces	O
.	O
RV	O
with	O
size	O
,	O
thickness	O
and	O
global	O
and	O
segmental	O
contractility	O
within	O
normal	O
limits	O
.	O
Global	O
systolic	O
function	O
lower	O
limit	O
of	O
normality	O
51	O
.	O
Left	O
pleural	O
effusion	O
.	O
Conclusions	O
LV	O
with	O
large	O
lateral	O
and	O
inferolateral	O
pseudoaneurysm	O
with	O
lateral	O
and	O
inferior	O
akinesia	O
.	O
Global	O
systolic	O
function	O
severely	O
depressed	O
.	O
Transmural	O
enhancement	O
in	O
inferior	O
and	O
lateral	O
face	O
respecting	O
apical	O
segments	O
of	O
both	O
faces	O
.	O
Left	O
pleural	O
effusion	O
.	O
Lateral	O
and	O
inferolateral	O
pseudoaneurysm	O
66	O
x	O
41mm	O
.	O
Transmural	O
enhancement	O
in	O
inferior	O
and	O
lateral	O
face	O
,	O
respecting	O
apical	O
segment	O
of	O
both	O
faces	O
.	O
LVEF	O
20	O
.	O
Intracavitary	O
thrombus	O
.	O
CT	O
scan	O
cardiology	O
ward	O
ascending	O
thoracic	O
aorta	O
30	O
x	O
32	O
mm	O
.	O
Descending	O
thoracic	O
aorta	O
20	O
x	O
20	O
mm	O
.	O
Findings	O
on	O
the	O
inferolateral	O
side	O
,	O
a	O
ventricular	O
pseudoaneurysm	O
is	O
identified	O
,	O
consisting	O
of	O
a	O
rupture	O
contained	O
by	O
a	O
surgical	O
patch	O
of	O
pericardium	O
,	O
measuring	O
64	O
x	O
41	O
x	O
73	O
mm	O
with	O
a	O
neck	O
of	O
54	O
x	O
59	O
mm	O
measured	O
from	O
the	O
basal	O
and	O
papillary	O
segment	O
.	O
The	O
pericardial	O
patch	O
cannot	O
be	O
properly	O
individualised	O
and	O
the	O
most	O
apical	O
portion	O
of	O
the	O
structure	O
could	O
be	O
constituted	O
by	O
myocardial	O
wall	O
.	O
The	O
papillary	O
muscle	O
has	O
its	O
base	O
just	O
distal	O
to	O
the	O
pseudoaneurysm	O
.	O
A	O
4	O
mm	O
filling	O
defect	O
is	O
identified	O
inside	O
the	O
pseudoaneurysm	O
,	O
which	O
could	O
correspond	O
to	O
a	O
small	O
thrombus	O
.	O
No	O
pericardial	O
effusion	O
was	O
detected	O
.	O
No	O
other	O
extracardiac	O
findings	O
.	O
Summary	O
Inferolateral	O
ventricular	O
pseudoaneurysm	O
measuring	O
64	O
x	O
41	O
x	O
73	O
mm	O
with	O
a	O
neck	O
of	O
54	O
x	O
59	O
mm	O
see	O
description	O
.	O
Small	O
intracavitary	O
thrombus	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
the	O
cardiology	O
ward	O
,	O
complementary	O
tests	O
were	O
carried	O
out	O
and	O
showed	O
,	O
in	O
summary	O
,	O
severe	O
ventricular	O
dysfunction	O
with	O
pseudoaneurysm	O
in	O
the	O
LV	O
measuring	O
66	O
x	O
41	O
mm	O
.	O
Treatment	O
was	O
optimised	O
and	O
enalapril	B-FARMACO
10	O
mg	O
c	O
12	O
hours	O
,	O
metoprolol	B-FARMACO
50	O
mg	O
c	O
12	O
hours	O
,	O
aldactone	B-FARMACO
25	O
mg	O
c	O
24	O
hours	O
and	O
ivabradine	B-FARMACO
7	O
.	O
5	O
mg	O
c	O
12	O
hours	O
were	O
prescribed	O
with	O
good	O
tolerance	O
.	O
The	O
case	O
was	O
presented	O
at	O
a	O
medical	O
surgical	O
session	O
where	O
the	O
following	O
options	O
were	O
proposed	O
medical	O
treatment	O
and	O
follow	O
up	O
,	O
implantation	O
of	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
,	O
surgical	O
resection	O
of	O
the	O
pseudoaneurysm	O
and	O
cardiac	O
transplant	O
.	O
Finally	O
,	O
it	O
was	O
decided	O
to	O
resect	O
the	O
pseudoaneurysm	O
with	O
very	O
good	O
clinical	O
evolution	O
and	O
follow	O
up	O
in	O
consultations	O
.	O
Currently	O
,	O
the	O
patient	O
has	O
recovered	O
LVEF	O
to	O
42	O
in	O
the	O
last	O
TTE	O
with	O
New	O
York	O
Heart	O
Association	O
NHYA	O
functional	O
class	O
I	O
and	O
free	O
of	O
admissions	O
since	O
discharge	O
.	O
DIAGNOSIS	O
Inferolateral	O
acute	O
myocardial	O
infarction	O
AMI	O
complicated	O
by	O
cardiac	O
rupture	O
.	O
Pericardial	O
patch	O
repair	O
.	O
Large	O
lateral	O
wall	O
pseudoaneurysm	O
,	O
at	O
the	O
level	O
of	O
surgical	O
repair	O
of	O
LV	O
free	O
wall	O
rupture	O
.	O
Surgical	O
resection	O
of	O
pseudoaneurysm	O
.	O
Severe	O
ventricular	O
dysfunction	O
,	O
currently	O
moderate	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
53	O
year	O
old	O
male	O
,	O
dyslipidaemic	O
and	O
ex	O
smoker	O
,	O
asymptomatic	O
from	O
a	O
cardiovascular	O
point	O
of	O
view	O
,	O
who	O
was	O
referred	O
to	O
the	O
cardiology	O
department	O
for	O
a	O
chance	O
finding	O
on	O
electrocardiogram	O
.	O
As	O
for	O
his	O
family	O
history	O
,	O
his	O
paternal	O
family	O
has	O
a	O
multiple	O
history	O
of	O
heart	O
disease	O
at	O
an	O
early	O
age	O
the	O
patient	O
's	O
father	O
received	O
a	O
heart	O
transplant	O
in	O
1995	O
for	O
non	O
ischaemic	O
dilated	O
cardiomyopathy	O
,	O
his	O
paternal	O
grandfather	O
died	O
at	O
the	O
age	O
of	O
60	O
due	O
to	O
an	O
unspecified	O
heart	O
problem	O
,	O
and	O
two	O
of	O
his	O
father	O
's	O
siblings	O
one	O
male	O
and	O
one	O
female	O
suffer	O
from	O
dilated	O
cardiomyopathy	O
and	O
are	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
CRT	O
cardiac	O
resynchronisation	O
therapy	O
patients	O
.	O
Among	O
the	O
patient	O
's	O
siblings	O
,	O
the	O
case	O
of	O
a	O
woman	O
with	O
dilated	O
cardiomyopathy	O
associated	O
with	O
an	O
atrial	O
septal	O
defect	O
is	O
documented	O
.	O
The	O
rest	O
of	O
her	O
siblings	O
,	O
as	O
well	O
as	O
her	O
daughters	O
,	O
are	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
.	O
Physical	O
examination	O
reveals	O
no	O
pathological	O
findings	O
.	O
COMPLEMENTARY	O
TESTS	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
at	O
72	O
bpm	O
.	O
Intraventricular	O
conduction	O
disorder	O
,	O
with	O
QRS	O
116	O
msec	O
.	O
Repolarisation	O
alterations	O
consisting	O
of	O
negative	O
T	O
from	O
V3	O
to	O
V6	O
.	O
ANALYTICS	O
LDL	O
Friedewald	O
estimation	O
138	O
mg	O
dl	O
,	O
without	O
other	O
notable	O
alterations	O
.	O
Transthoracic	O
echocardiogram	O
December	O
2014	O
left	O
ventricle	O
not	O
dilated	O
or	O
hypertrophied	O
.	O
Moderately	O
to	O
severely	O
depressed	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
36	O
by	O
Simpson	O
biplane	O
overall	O
.	O
There	O
was	O
a	O
slight	O
increase	O
in	O
trabeculation	O
at	O
the	O
level	O
of	O
the	O
apex	O
,	O
without	O
criteria	O
of	O
non	O
compaction	O
cardiomyopathy	O
ecopotentiator	O
administered	O
.	O
Non	O
dilated	O
right	O
ventricle	O
,	O
increased	O
trabeculation	O
with	O
slight	O
hypokinesia	O
in	O
apical	O
and	O
basal	O
segments	O
with	O
preserved	O
contractility	O
.	O
Mild	O
biauricular	O
dilatation	O
left	O
atrium	O
22	O
cm2	O
,	O
right	O
atrium	O
17	O
cm2	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
.	O
No	O
pericardial	O
effusion	O
.	O
Slightly	O
thickened	O
aortic	O
valve	O
with	O
preserved	O
mobility	O
,	O
minimal	O
insufficiency	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
No	O
tricuspid	O
insufficiency	O
allowing	O
estimation	O
of	O
systolic	O
pulmonary	O
pressure	O
SPP	O
.	O
No	O
pericardial	O
effusion	O
.	O
Cardiac	O
MRI	O
2018	O
LV	O
not	O
dilated	O
or	O
hypertrophic	O
.	O
Normal	O
global	O
and	O
segmental	O
contractility	O
.	O
Apical	O
hypertrabeculation	O
without	O
criteria	O
of	O
noncompaction	O
cardiomyopathy	O
.	O
No	O
areas	O
of	O
uptake	O
on	O
late	O
enhancement	O
sequences	O
suggestive	O
of	O
fibrosis	O
.	O
HOLTER	O
stable	O
sinus	O
rhythm	O
with	O
good	O
heart	O
rate	O
range	O
.	O
Low	O
medium	O
intensity	O
ventricular	O
extrasystoles	O
with	O
right	O
ventricular	O
outflow	O
tract	O
morphology	O
.	O
No	O
pathological	O
pauses	O
or	O
blockages	O
.	O
CORONARYGRAPHY	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O
Right	O
dominance	O
.	O
GENETIC	O
STUDY	O
the	O
sample	O
was	O
sent	O
for	O
NGS	O
study	O
panel	O
of	O
81	O
genes	O
.	O
The	O
study	O
found	O
a	O
probably	O
pathogenic	O
variant	O
p	O
.	O
Arg5902	O
mutation	O
in	O
heterozygosis	O
in	O
the	O
TTN	O
gene	O
NP_003310	O
.	O
4	O
p	O
.	O
Arg5902	O
,	O
M_003319	O
.	O
4	O
c	O
.	O
17704C	O
T	O
,	O
NC_000002	O
.	O
11g	O
.	O
179487411G	O
A	O
.	O
The	O
G	O
A	O
nucleotide	O
substitution	O
at	O
chromosomal	O
position	O
g	O
.	O
179487411	O
results	O
in	O
the	O
substitution	O
of	O
an	O
arginine	O
for	O
a	O
premature	O
stop	O
codon	O
affecting	O
most	O
TTN	O
isoforms	O
.	O
CLINICAL	O
COURSE	O
Following	O
echocardiographic	O
findings	O
of	O
moderate	O
to	O
severely	O
depressed	O
systolic	O
function	O
,	O
treatment	O
with	O
low	O
dose	O
bisoprolol	B-FARMACO
and	O
ramipril	B-FARMACO
was	O
initiated	O
and	O
well	O
tolerated	O
.	O
Since	O
his	O
diagnosis	O
,	O
the	O
patient	O
has	O
remained	O
asymptomatic	O
,	O
with	O
no	O
episodes	O
of	O
heart	O
failure	O
decompensation	O
and	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
I	O
.	O
He	O
is	O
being	O
followed	O
up	O
in	O
cardiology	O
consultations	O
.	O
He	O
was	O
followed	O
up	O
in	O
cardiology	O
consultations	O
with	O
annual	O
control	O
echocardiograms	O
,	O
having	O
recovered	O
in	O
the	O
last	O
one	O
up	O
to	O
a	O
LVEF	O
of	O
53	O
.	O
A	O
genetic	O
study	O
was	O
performed	O
on	O
relatives	O
,	O
finding	O
mutations	O
in	O
the	O
TTN	O
gene	O
in	O
one	O
of	O
her	O
paternal	O
aunts	O
and	O
in	O
one	O
of	O
her	O
sisters	O
,	O
both	O
affected	O
by	O
dilated	O
cardiomyopathy	O
,	O
which	O
demonstrates	O
cosegregation	O
and	O
confirms	O
the	O
pathogenicity	O
of	O
the	O
mutation	O
found	O
.	O
DIAGNOSIS	O
Non	O
ischemic	O
familial	O
dilated	O
cardiomyopathy	O
.	O
Carrier	O
of	O
p	O
.	O
Arg5902	O
mutation	O
in	O
heterozygosis	O
in	O
the	O
TTN	O
gene	O
,	O
probably	O
associated	O
with	O
the	O
disease	O
.	O
Current	O
LVEF	O
53	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
56	O
year	O
old	O
woman	O
with	O
a	O
resynchronisation	O
pacemaker	O
who	O
was	O
admitted	O
for	O
device	O
removal	O
due	O
to	O
local	O
infection	O
.	O
HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
known	O
cardiovascular	O
risk	O
factors	O
.	O
Cardiological	O
history	O
rheumatic	O
valve	O
disease	O
with	O
open	O
mitral	O
commissurotomy	O
in	O
1988	O
.	O
Permanent	O
atrial	O
fibrillation	O
AF	O
.	O
VVI	O
pacemaker	O
holder	O
since	O
1998	O
due	O
to	O
AF	O
that	O
was	O
difficult	O
to	O
control	O
,	O
with	O
generator	O
replacement	O
in	O
2008	O
due	O
to	O
battery	O
depletion	O
.	O
Echocardiogram	O
in	O
2013	O
showed	O
a	O
moderate	O
severe	O
double	O
rheumatic	O
mitral	O
lesion	O
with	O
predominant	O
stenosis	O
,	O
with	O
preserved	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
and	O
moderate	O
pulmonary	O
hypertension	O
,	O
severe	O
tricuspid	O
insufficiency	O
TI	O
and	O
dilatation	O
of	O
the	O
right	O
ventricle	O
RV	O
with	O
mild	O
moderate	O
dysfunction	O
.	O
Surgical	O
intervention	O
was	O
indicated	O
,	O
with	O
mechanical	O
mitral	O
valve	O
replacement	O
and	O
tricuspid	O
annuloplasty	O
,	O
with	O
good	O
results	O
.	O
In	O
the	O
control	O
echocardiogram	O
one	O
year	O
later	O
,	O
the	O
mitral	O
prosthesis	O
is	O
normofunctioning	O
,	O
but	O
a	O
slightly	O
dilated	O
and	O
dysfunctioning	O
LV	O
with	O
LVEF	O
35	O
due	O
to	O
diffuse	O
hypokinesia	O
and	O
anomalous	O
septal	O
movement	O
in	O
the	O
context	O
of	O
stimulation	O
is	O
visualised	O
.	O
The	O
patient	O
's	O
functional	O
class	O
worsened	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
III	O
,	O
so	O
an	O
upgrade	O
to	O
cardiac	O
resynchronisation	O
therapy	O
was	O
indicated	O
in	O
March	O
2015	O
.	O
Possible	O
vertebrobasilar	O
transient	O
ischaemic	O
attack	O
TIA	O
in	O
2012	O
.	O
Normal	O
TSA	O
Doppler	O
.	O
Myomatous	O
uterus	O
.	O
Total	O
hysterectomy	O
double	O
adnexectomy	O
in	O
2011	O
.	O
Usual	O
treatment	O
synthroid	B-FARMACO
,	O
furosemide	B-FARMACO
40	O
mg	O
c	O
24	O
hours	O
,	O
carvedilol	B-FARMACO
6	O
.	O
25	O
mg	O
c	O
12	O
hours	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
c	O
24	O
hours	O
,	O
omeprazole	B-FARMACO
,	O
zolpidem	B-FARMACO
.	O
BFS	O
higher	O
functions	O
preserved	O
.	O
NYHA	O
II	O
.	O
CURRENT	O
DISEASE	O
After	O
the	O
upgrade	O
to	O
cardiac	O
resynchronisation	O
therapy	O
CRT	O
,	O
the	O
patient	O
presented	O
a	O
torpid	O
evolution	O
of	O
the	O
surgical	O
wound	O
,	O
with	O
tension	O
haematoma	O
one	O
month	O
after	O
implantation	O
that	O
required	O
drainage	O
,	O
and	O
subsequent	O
dehiscence	O
that	O
required	O
debridement	O
and	O
approximation	O
of	O
the	O
edges	O
.	O
However	O
,	O
the	O
patient	O
did	O
not	O
evolve	O
satisfactorily	O
and	O
,	O
5	O
months	O
later	O
,	O
a	O
subpectoral	O
implant	O
of	O
the	O
generator	O
was	O
indicated	O
for	O
decubitus	O
,	O
also	O
requiring	O
surgical	O
debridement	O
.	O
He	O
continued	O
to	O
be	O
monitored	O
in	O
cardiac	O
surgery	O
consultations	O
,	O
with	O
good	O
evolution	O
of	O
the	O
surgical	O
wound	O
until	O
,	O
in	O
December	O
2017	O
,	O
he	O
consulted	O
the	O
emergency	O
department	O
for	O
pain	O
in	O
the	O
area	O
of	O
the	O
generator	O
and	O
increasing	O
local	O
oedema	O
.	O
She	O
did	O
not	O
present	O
fever	O
or	O
elevated	O
infectious	O
markers	O
.	O
She	O
was	O
subsequently	O
assessed	O
by	O
cardiac	O
surgery	O
,	O
which	O
observed	O
signs	O
of	O
incipient	O
decubitus	O
in	O
the	O
pectoral	O
area	O
,	O
with	O
significant	O
skin	O
retraction	O
,	O
without	O
suppuration	O
.	O
Imaging	O
tests	O
were	O
requested	O
to	O
complete	O
the	O
study	O
and	O
admission	O
was	O
indicated	O
for	O
the	O
start	O
of	O
antibiotic	O
treatment	O
and	O
removal	O
of	O
the	O
resynchronisation	O
device	O
due	O
to	O
infection	O
of	O
the	O
generator	O
area	O
.	O
PHYSICAL	O
EXAMINATION	O
Haemodynamically	O
stable	O
,	O
well	O
perfused	O
.	O
Eupneic	O
.	O
Afebrile	O
.	O
Good	O
general	O
condition	O
.	O
Head	O
and	O
neck	O
no	O
IY	O
.	O
Chest	O
induration	O
and	O
pain	O
on	O
palpation	O
in	O
the	O
left	O
infraaxillary	O
area	O
,	O
with	O
skin	O
retraction	O
and	O
trophic	O
changes	O
.	O
No	O
suppuration	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
,	O
valvular	O
click	O
.	O
Pulmonary	O
auscultation	O
preserved	O
ventricular	O
murmur	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
without	O
pain	O
or	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
AF	O
with	O
ventricular	O
rhythm	O
stimulated	O
at	O
75	O
bpm	O
.	O
ANALYTICS	O
normal	O
renal	O
function	O
with	O
GFR	O
90	O
ml	O
min	O
and	O
normal	O
ions	O
.	O
CRP	O
11	O
.	O
8	O
.	O
Normal	O
leukocytes	O
with	O
normal	O
leukocyte	O
formula	O
.	O
Hb	O
11	O
.	O
8	O
g	O
dl	O
.	O
Coagulation	O
without	O
findings	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
left	O
ventricle	O
V	O
severely	O
dilated	O
by	O
volumes	O
.	O
No	O
visu	O
asynchrony	O
evident	O
.	O
LVEF	O
43	O
.	O
Right	O
ventricle	O
RV	O
normal	O
with	O
respect	O
to	O
size	O
and	O
function	O
.	O
Severely	O
dilated	O
left	O
atrium	O
40	O
cm2	O
.	O
Moderately	O
dilated	O
right	O
atrium	O
.	O
Mitral	O
prosthesis	O
with	O
good	O
opening	O
and	O
mitral	O
insufficiency	O
MI	O
that	O
appears	O
to	O
be	O
intraprosthetic	O
.	O
Normofunctioning	O
tricuspid	O
annulus	O
,	O
with	O
no	O
residual	O
TR	O
so	O
that	O
pulmonary	O
artery	O
pressure	O
PAP	O
cannot	O
be	O
estimated	O
.	O
The	O
aortic	O
valve	O
is	O
trivalve	O
,	O
with	O
rheumatic	O
involvement	O
.	O
Mild	O
moderate	O
valvular	O
aortic	O
stenosis	O
.	O
Mild	O
moderate	O
aortic	O
insufficiency	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
.	O
No	O
pericardial	O
effusion	O
.	O
Transesophageal	O
echocardiography	O
TEE	O
pacemaker	O
lead	O
in	O
LV	O
.	O
Two	O
leads	O
are	O
seen	O
in	O
the	O
RA	O
,	O
following	O
their	O
course	O
to	O
the	O
tricuspid	O
valve	O
without	O
thickening	O
suggestive	O
of	O
endocarditis	O
.	O
The	O
intraventricular	O
section	O
cannot	O
be	O
assessed	O
due	O
to	O
mitral	O
acoustic	O
shadowing	O
.	O
Bivalve	O
mechanical	O
prosthesis	O
with	O
good	O
opening	O
and	O
intraprosthetic	O
washout	O
jets	O
.	O
No	O
stigmata	O
of	O
endocarditis	O
.	O
Trivalve	O
aortic	O
valve	O
.	O
POSITRON	O
EMISSION	O
TOMOGRAPHY	O
PET	O
CT	O
Heterogeneous	O
increase	O
in	O
activity	O
early	O
maximum	O
SUV	O
around	O
4	O
.	O
3	O
and	O
late	O
around	O
5	O
.	O
7	O
around	O
the	O
pacemaker	O
generator	O
located	O
in	O
the	O
left	O
pectoral	O
region	O
and	O
slight	O
activity	O
early	O
and	O
late	O
SUV	O
around	O
2	O
.	O
5	O
in	O
the	O
proximal	O
section	O
of	O
the	O
exit	O
of	O
the	O
pacemaker	O
lead	O
from	O
the	O
generator	O
,	O
in	O
the	O
subcutaneous	O
trajectory	O
reaching	O
the	O
clavicle	O
.	O
Findings	O
that	O
,	O
considering	O
the	O
time	O
that	O
has	O
elapsed	O
since	O
its	O
placement	O
and	O
which	O
are	O
visualised	O
in	O
both	O
the	O
corrected	O
and	O
uncorrected	O
images	O
,	O
suggest	O
active	O
infectious	O
pathology	O
.	O
In	O
the	O
superior	O
mediastinum	O
,	O
a	O
small	O
focal	O
uptake	O
deposit	O
is	O
identified	O
,	O
which	O
shows	O
greater	O
activity	O
in	O
the	O
late	O
images	O
early	O
SUV	O
2	O
.	O
8	O
and	O
late	O
SUV	O
3	O
.	O
8	O
at	O
the	O
level	O
of	O
the	O
entrance	O
of	O
the	O
pacemaker	O
lead	O
into	O
the	O
superior	O
vena	O
cava	O
.	O
In	O
the	O
clinical	O
context	O
,	O
this	O
finding	O
suggests	O
an	O
active	O
focus	O
of	O
infection	O
.	O
No	O
other	O
abnormal	O
increases	O
in	O
activity	O
were	O
seen	O
in	O
the	O
rest	O
of	O
the	O
pacemaker	O
lead	O
or	O
in	O
the	O
electrodes	O
.	O
There	O
were	O
no	O
abnormal	O
increases	O
in	O
activity	O
at	O
or	O
around	O
the	O
mitral	O
valve	O
suggesting	O
infection	O
endocarditis	O
.	O
In	O
the	O
left	O
axilla	O
there	O
are	O
several	O
subcentimetre	O
sized	O
lymphadenopathies	O
with	O
mild	O
activity	O
maximum	O
early	O
and	O
late	O
SUV	O
around	O
1	O
.	O
2	O
that	O
may	O
correspond	O
to	O
residual	O
or	O
reactive	O
lymphadenopathies	O
that	O
are	O
not	O
very	O
active	O
.	O
One	O
lymph	O
node	O
stands	O
out	O
for	O
its	O
size	O
maximum	O
diameter	O
around	O
13mm	O
which	O
shows	O
greater	O
activity	O
early	O
SUV	O
1	O
.	O
7	O
and	O
late	O
SUV	O
2	O
.	O
6	O
which	O
may	O
be	O
due	O
to	O
active	O
inflammatory	O
lymphadenopathy	O
.	O
No	O
other	O
abnormal	O
increases	O
in	O
uptake	O
were	O
identified	O
in	O
the	O
rest	O
of	O
the	O
lymph	O
node	O
territories	O
included	O
in	O
the	O
study	O
,	O
both	O
supra	O
and	O
infradiaphragmatic	O
.	O
Radiotracer	O
uptake	O
in	O
both	O
lungs	O
is	O
within	O
normal	O
limits	O
.	O
The	O
distribution	O
of	O
activity	O
in	O
the	O
liver	O
and	O
spleen	O
is	O
homogeneous	O
,	O
with	O
no	O
abnormal	O
increases	O
in	O
activity	O
.	O
No	O
pathological	O
findings	O
in	O
the	O
adrenal	O
glands	O
or	O
pancreas	O
.	O
Slight	O
increase	O
in	O
activity	O
along	O
the	O
sternum	O
translating	O
residual	O
reactive	O
changes	O
due	O
to	O
a	O
history	O
of	O
median	O
sternotomy	O
.	O
In	O
the	O
rest	O
of	O
the	O
bone	O
structures	O
included	O
in	O
the	O
study	O
,	O
no	O
abnormal	O
increases	O
in	O
activity	O
are	O
visualised	O
.	O
Reinforcement	O
of	O
uptake	O
adjacent	O
to	O
the	O
right	O
humeral	O
head	O
due	O
to	O
insertional	O
pathology	O
.	O
No	O
significant	O
alterations	O
in	O
the	O
uptake	O
and	O
distribution	O
of	O
the	O
tracer	O
were	O
observed	O
in	O
the	O
rest	O
of	O
the	O
body	O
regions	O
studied	O
.	O
Conclusion	O
findings	O
compatible	O
with	O
infectious	O
pathology	O
around	O
the	O
pacemaker	O
generator	O
,	O
as	O
well	O
as	O
in	O
the	O
proximal	O
subcutaneous	O
trajectory	O
of	O
the	O
pacemaker	O
lead	O
and	O
in	O
its	O
entry	O
at	O
the	O
level	O
of	O
the	O
superior	O
vena	O
cava	O
in	O
a	O
more	O
focal	O
manner	O
.	O
Lymph	O
node	O
uptake	O
in	O
the	O
left	O
axilla	O
suggestive	O
of	O
reactive	O
inflammatory	O
ethology	O
.	O
ANGIO	O
CT	O
coronary	O
arteries	O
bicameral	O
pacemaker	O
with	O
the	O
end	O
of	O
the	O
electrodes	O
located	O
in	O
the	O
RV	O
and	O
posterolateral	O
vein	O
.	O
Patent	O
coronary	O
sinus	O
of	O
normal	O
calibre	O
.	O
The	O
posterolateral	O
vein	O
in	O
which	O
the	O
electrode	O
is	O
lodged	O
is	O
of	O
small	O
calibre	O
,	O
and	O
its	O
patency	O
cannot	O
be	O
assessed	O
due	O
to	O
the	O
artefact	O
caused	O
by	O
the	O
electrode	O
.	O
Inferolateral	O
vein	O
of	O
good	O
calibre	O
,	O
5	O
mm	O
in	O
diameter	O
,	O
originating	O
12	O
mm	O
from	O
the	O
valve	O
of	O
Tebesio	O
and	O
presenting	O
a	O
lateral	O
direction	O
towards	O
the	O
inferolateral	O
segments	O
of	O
the	O
LV	O
,	O
can	O
be	O
seen	O
on	O
the	O
inferior	O
face	O
.	O
Median	O
sternotomy	O
and	O
triple	O
valve	O
replacement	O
.	O
Cardiomegaly	O
.	O
Pulmonary	O
parenchyma	O
without	O
findings	O
.	O
Conclusions	O
posterolateral	O
vein	O
in	O
which	O
the	O
electrode	O
is	O
lodged	O
is	O
of	O
small	O
calibre	O
and	O
cannot	O
be	O
assessed	O
due	O
to	O
artefacts	O
caused	O
by	O
the	O
electrode	O
,	O
and	O
its	O
patency	O
cannot	O
be	O
assessed	O
.	O
Inferolateral	O
vein	O
of	O
good	O
calibre	O
.	O
MICROBIOLOGICAL	O
STUDY	O
Blood	O
cultures	O
on	O
admission	O
negative	O
.	O
Pan	O
bacterial	O
PCR	O
16S	O
rRNA	O
31	O
1	O
18	O
not	O
detected	O
.	O
Blood	O
cultures	O
after	O
episode	O
of	O
phlebitis	O
positive	O
for	O
Staphylococcus	O
aureus	O
without	O
resistance	O
,	O
with	O
negative	O
results	O
in	O
control	O
cultures	O
after	O
targeted	O
antibiotherapy	O
.	O
Cultures	O
of	O
vascular	O
material	O
extracted	O
system	O
positive	O
for	O
Staphylococcus	O
hominis	O
DV	O
electrode	O
and	O
subcutaneous	O
swab	O
and	O
Staphylococcus	O
epidermidis	O
LV	O
lead	O
,	O
DV	O
lead	O
,	O
subcutaneous	O
swab	O
and	O
generator	O
capsule	O
.	O
Negative	O
control	O
blood	O
cultures	O
.	O
CLINICAL	O
COURSE	O
After	O
removal	O
of	O
a	O
cardiac	O
pacing	O
device	O
,	O
it	O
is	O
recommended	O
to	O
re	O
evaluate	O
the	O
need	O
for	O
reimplantation	O
of	O
the	O
same	O
device	O
or	O
another	O
device	O
with	O
greater	O
or	O
lesser	O
functionalities	O
.	O
The	O
challenge	O
in	O
this	O
patient	O
was	O
to	O
define	O
whether	O
she	O
had	O
responded	O
to	O
resynchronisation	O
therapy	O
,	O
to	O
indicate	O
a	O
resynchronising	O
pacemaker	O
again	O
or	O
,	O
if	O
not	O
,	O
a	O
single	O
chamber	O
pacing	O
pacemaker	O
.	O
The	O
patient	O
was	O
finally	O
considered	O
a	O
clinical	O
responder	O
due	O
to	O
a	O
slight	O
improvement	O
in	O
functional	O
class	O
NYHA	O
III	O
to	O
II	O
,	O
but	O
not	O
a	O
responder	O
echocardiographically	O
.	O
Given	O
the	O
positive	O
clinical	O
response	O
,	O
reimplantation	O
of	O
a	O
new	O
cardiac	O
resynchronisation	O
device	O
was	O
indicated	O
.	O
During	O
admission	O
,	O
the	O
cardiac	O
resynchronisation	O
device	O
was	O
initially	O
scheduled	O
to	O
be	O
explanted	O
and	O
removed	O
at	O
the	O
same	O
time	O
,	O
with	O
periprocedural	O
antibiotic	O
treatment	O
,	O
given	O
that	O
the	O
patient	O
remained	O
afebrile	O
,	O
clinically	O
and	O
haemodynamically	O
stable	O
and	O
without	O
elevation	O
of	O
acute	O
phase	O
reactants	O
.	O
However	O
,	O
while	O
awaiting	O
surgery	O
,	O
she	O
developed	O
bacteraemia	O
due	O
to	O
methicillin	O
sensitive	O
S	O
.	O
aureus	O
,	O
secondary	O
to	O
phlebitis	O
due	O
to	O
infection	O
of	O
a	O
peripheral	O
vein	O
,	O
so	O
antibiotic	O
therapy	O
with	O
vancomycin	B-FARMACO
was	O
started	O
after	O
drawing	O
blood	O
cultures	O
,	O
and	O
withdrawal	O
and	O
reimplantation	O
was	O
indicated	O
in	O
two	O
stages	O
,	O
after	O
antibiotic	O
therapy	O
.	O
During	O
admission	O
,	O
the	O
patient	O
remained	O
afebrile	O
and	O
haemodynamically	O
stable	O
at	O
all	O
times	O
.	O
Since	O
the	O
patient	O
had	O
a	O
high	O
percentage	O
of	O
pacing	O
with	O
a	O
narrow	O
QRS	O
escape	O
ventricular	O
rhythm	O
at	O
35	O
bpm	O
,	O
after	O
removal	O
of	O
the	O
resynchronisation	O
system	O
,	O
a	O
transient	O
right	O
jugular	O
pacemaker	O
was	O
implanted	O
while	O
awaiting	O
reimplantation	O
of	O
the	O
permanent	O
pacemaker	O
.	O
While	O
admitted	O
to	O
the	O
hospital	O
ward	O
,	O
she	O
lost	O
capture	O
due	O
to	O
dislocation	O
of	O
the	O
electrode	O
,	O
which	O
caused	O
decompensation	O
of	O
heart	O
failure	O
requiring	O
continuous	O
isoproterenol	B-FARMACO
perfusion	O
and	O
subsequent	O
replacement	O
of	O
the	O
transient	O
pacing	O
lead	O
,	O
with	O
placement	O
of	O
a	O
temporary	O
active	O
fixation	O
electrode	O
.	O
After	O
the	O
repositioning	O
procedure	O
,	O
she	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
,	O
presenting	O
acute	O
pulmonary	O
oedema	O
that	O
responded	O
favourably	O
to	O
diuretic	O
treatment	O
,	O
and	O
she	O
was	O
discharged	O
to	O
the	O
hospital	O
ward	O
in	O
48	O
72	O
hours	O
,	O
where	O
she	O
remained	O
to	O
complete	O
the	O
antibiotic	O
regimen	O
until	O
the	O
reimplantation	O
of	O
the	O
definitive	O
pacemaker	O
.	O
Finally	O
,	O
in	O
a	O
situation	O
of	O
clinical	O
stability	O
and	O
after	O
approximately	O
2	O
weeks	O
of	O
antibiotic	O
treatment	O
,	O
with	O
negative	O
blood	O
cultures	O
,	O
she	O
was	O
scheduled	O
for	O
resynchronisation	O
pacemaker	O
implantation	O
.	O
Unfortunately	O
,	O
the	O
coronary	O
sinus	O
could	O
not	O
be	O
cannulated	O
after	O
multiple	O
attempts	O
,	O
so	O
only	O
one	O
RV	O
electrode	O
connected	O
to	O
a	O
resynchronisation	O
generator	O
was	O
placed	O
on	O
the	O
contralateral	O
side	O
.	O
The	O
patient	O
was	O
discharged	O
home	O
pending	O
completion	O
of	O
intravenous	O
antibiotic	O
therapy	O
.	O
She	O
is	O
currently	O
clinically	O
stable	O
,	O
has	O
not	O
presented	O
decompensation	O
of	O
heart	O
failure	O
and	O
the	O
control	O
echocardiogram	O
shows	O
no	O
worsening	O
of	O
LVEF	O
.	O
The	O
patient	O
's	O
clinical	O
evolution	O
in	O
the	O
short	O
medium	O
term	O
is	O
pending	O
re	O
evaluation	O
,	O
with	O
the	O
aim	O
of	O
considering	O
other	O
therapeutic	O
alternatives	O
should	O
she	O
present	O
poor	O
clinical	O
evolution	O
,	O
such	O
as	O
endocardial	O
left	O
ventricular	O
stimulation	O
,	O
given	O
that	O
she	O
is	O
a	O
patient	O
with	O
an	O
indication	O
for	O
permanent	O
anticoagulation	O
.	O
DIAGNOSIS	O
Local	O
infection	O
of	O
the	O
cardiac	O
resynchronisation	O
device	O
.	O
Removal	O
of	O
the	O
complete	O
system	O
generator	O
and	O
RV	O
and	O
LV	O
leads	O
.	O
Implantation	O
of	O
transient	O
right	O
jugular	O
pacemaker	O
.	O
Implantation	O
of	O
resynchronisation	O
generator	O
and	O
right	O
sided	O
RV	O
electrode	O
in	O
a	O
second	O
stage	O
.	O
Right	O
upper	O
extremity	O
phlebitis	O
with	O
methicillin	O
sensitive	O
S	O
.	O
aureus	O
bacteraemia	O
.	O
Dilated	O
cardiomyopathy	O
with	O
moderate	O
LV	O
systolic	O
dysfunction	O
.	O
Rheumatic	O
valve	O
disease	O
with	O
mitral	O
prosthesis	O
and	O
tricuspid	O
annulus	O
without	O
functional	O
alterations	O
.	O
Double	O
mild	O
moderate	O
aortic	O
lesion	O
.	O
Permanent	O
AF	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
No	O
known	O
drug	O
allergies	O
.	O
Smoker	O
of	O
6	O
cigarettes	O
a	O
day	O
since	O
the	O
age	O
of	O
17	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
hypertension	O
HT	O
,	O
dyslipidaemia	O
on	O
dietary	O
treatment	O
,	O
no	O
diabetes	O
mellitus	O
DM	O
.	O
Recurrent	O
bladder	O
tumour	O
in	O
follow	O
up	O
by	O
urology	O
with	O
annual	O
cystoscopy	O
.	O
Prostatic	O
neoplasia	O
with	O
metastatic	O
involvement	O
in	O
hormonal	O
treatment	O
.	O
Surgical	O
history	O
bladder	O
TUR	O
in	O
2013	O
and	O
2014	O
.	O
Usual	O
treatment	O
amlodipine	B-FARMACO
5	O
mg	O
day	O
,	O
enalapril	B-FARMACO
hydrochlorothiazide	I-FARMACO
20	O
12	O
.	O
5	O
mg	O
day	O
,	O
iron	B-FARMACO
ferrous	I-FARMACO
sulphate	I-FARMACO
105	O
mg	O
day	O
,	O
bicalutamide	B-FARMACO
50	O
mg	O
day	O
.	O
CURRENT	O
ILLNESS	O
72	O
year	O
old	O
male	O
patient	O
brought	O
to	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
for	O
progressive	O
dyspnoea	O
over	O
the	O
previous	O
3	O
4	O
days	O
until	O
becoming	O
minimal	O
effort	O
,	O
together	O
with	O
accompanying	O
asthenia	O
.	O
He	O
denied	O
chest	O
pain	O
.	O
No	O
cough	O
or	O
expectoration	O
,	O
no	O
fever	O
or	O
dysthermic	O
sensation	O
.	O
PHYSICAL	O
EXAMINATION	O
Regular	O
general	O
condition	O
,	O
mucocutaneous	O
pallor	O
,	O
normohydrated	O
.	O
Eupneic	O
at	O
rest	O
without	O
use	O
of	O
accessory	O
muscles	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
without	O
apparent	O
neurological	O
focality	O
.	O
Blood	O
pressure	O
BP	O
81	O
56	O
103	O
66	O
mmHg	O
,	O
heart	O
rate	O
HR	O
100	O
bpm	O
,	O
oxygen	O
saturation	O
SatO2	O
94	O
ambient	O
air	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
without	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
sounds	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
ELECTROCARDIOGRAM	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
,	O
60o	O
axis	O
,	O
PR	O
160	O
msec	O
,	O
narrow	O
QRS	O
,	O
ST	O
segment	O
depression	O
of	O
1	O
.	O
5	O
mm	O
in	O
II	O
,	O
III	O
and	O
aVF	O
with	O
minimal	O
Q	O
wave	O
,	O
ST	O
segment	O
depression	O
with	O
a	O
maximum	O
of	O
2	O
mm	O
in	O
V2	O
V4	O
.	O
ANALYSIS	O
creatinine	O
1	O
.	O
49	O
mg	O
dl	O
baseline	O
around	O
1	O
mg	O
dl	O
,	O
CRP	O
130	O
.	O
6	O
mg	O
l	O
,	O
haemoglobin	O
8	O
.	O
0	O
g	O
dl	O
and	O
ultrasensitive	O
troponin	O
T	O
4	O
,	O
669	O
pg	O
ml	O
.	O
THORAX	O
RADIOGRAPHY	O
severe	O
changes	O
due	O
to	O
chronic	O
obstructive	O
pulmonary	O
disease	O
COPD	O
.	O
No	O
pneumothorax	O
was	O
identified	O
.	O
Cardiomegaly	O
.	O
Calcified	O
aortic	O
atheromatosis	O
.	O
No	O
consolidation	O
or	O
pleural	O
effusion	O
.	O
CORONARYGRAPHY	O
left	O
coronary	O
trunk	O
LMCA	O
of	O
good	O
calibre	O
,	O
without	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
ADA	O
good	O
calibre	O
and	O
development	O
,	O
irregularities	O
without	O
significant	O
angiographic	O
lesions	O
.	O
Circumflex	O
artery	O
ACX	O
good	O
calibre	O
and	O
scarce	O
development	O
,	O
without	O
significant	O
angiographic	O
lesions	O
.	O
Right	O
coronary	O
artery	O
RCA	O
dominant	O
,	O
tortuous	O
,	O
with	O
diffuse	O
disease	O
in	O
the	O
proximal	O
and	O
middle	O
segment	O
and	O
thrombotic	O
occlusion	O
in	O
the	O
middle	O
segment	O
.	O
No	O
clear	O
collateral	O
flow	O
slight	O
homocoronary	O
.	O
Transthoracic	O
echocardiography	O
ventricular	O
septal	O
defect	O
due	O
to	O
rupture	O
of	O
the	O
interventricular	O
septum	O
in	O
the	O
lower	O
medial	O
area	O
where	O
there	O
is	O
a	O
solution	O
of	O
continuity	O
and	O
an	O
anfractuous	O
trajectory	O
.	O
A	O
maximum	O
gradient	O
between	O
LV	O
and	O
RV	O
of	O
51	O
mmHg	O
is	O
determined	O
and	O
the	O
width	O
of	O
the	O
jet	O
between	O
both	O
ventricles	O
is	O
16	O
mm	O
.	O
A	O
Qp	O
Qs	O
of	O
2	O
.	O
2	O
is	O
calculated	O
.	O
Dilatation	O
of	O
the	O
right	O
chambers	O
and	O
the	O
left	O
ventricle	O
was	O
observed	O
and	O
a	O
left	O
ventricular	O
ejection	O
fraction	O
of	O
38	O
was	O
estimated	O
using	O
Simpson	O
's	O
method	O
.	O
There	O
is	O
akinesia	O
of	O
the	O
posterior	O
wall	O
and	O
the	O
basal	O
and	O
medial	O
inferior	O
septum	O
.	O
The	O
aortic	O
valve	O
is	O
slightly	O
sclerosed	O
,	O
with	O
a	O
normal	O
gradient	O
.	O
The	O
mitral	O
valve	O
shows	O
signs	O
of	O
annular	O
fibrosis	O
,	O
preserved	O
opening	O
and	O
grade	O
II	O
IV	O
,	O
central	O
insufficiency	O
,	O
probably	O
related	O
to	O
the	O
altered	O
mobility	O
of	O
the	O
ventricular	O
wall	O
.	O
Mild	O
tricuspid	O
insufficiency	O
TI	O
is	O
observed	O
,	O
which	O
allows	O
estimating	O
a	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAP	O
of	O
49	O
mmHg	O
.	O
No	O
significant	O
pericardial	O
effusion	O
was	O
observed	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
initially	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
with	O
a	O
diagnosis	O
of	O
acute	O
myocardial	O
infarction	O
of	O
probably	O
inferior	O
location	O
.	O
Coronary	O
angiography	O
showed	O
thrombotic	O
occlusion	O
in	O
the	O
middle	O
segment	O
of	O
the	O
RCA	O
,	O
but	O
given	O
the	O
chronology	O
of	O
the	O
condition	O
,	O
the	O
infarction	O
was	O
considered	O
to	O
be	O
subacute	O
,	O
and	O
therefore	O
intervention	O
was	O
ruled	O
out	O
.	O
Subsequently	O
,	O
the	O
patient	O
presented	O
symptoms	O
and	O
signs	O
of	O
heart	O
failure	O
,	O
and	O
transthoracic	O
echocardiography	O
showed	O
ventricular	O
septal	O
rupture	O
with	O
a	O
maximum	O
size	O
of	O
16	O
mm	O
,	O
left	O
right	O
shunt	O
with	O
a	O
maximum	O
gradient	O
of	O
58	O
mmHg	O
,	O
overload	O
of	O
the	O
right	O
cavities	O
,	O
Qp	O
Qs	O
of	O
2	O
.	O
2	O
and	O
LVEF	O
by	O
Simpson	O
of	O
38	O
with	O
alterations	O
in	O
contractility	O
in	O
the	O
RCA	O
territory	O
.	O
The	O
case	O
was	O
discussed	O
with	O
cardiac	O
surgery	O
and	O
conservative	O
management	O
was	O
decided	O
jointly	O
given	O
the	O
poor	O
prognosis	O
and	O
comorbidity	O
of	O
the	O
patient	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
hospital	O
ward	O
on	O
the	O
third	O
day	O
and	O
required	O
occasional	O
morphine	B-FARMACO
rescue	O
due	O
to	O
dyspnoea	O
.	O
Finally	O
,	O
given	O
the	O
situation	O
of	O
refractory	O
heart	O
failure	O
,	O
exclusively	O
symptomatic	O
treatment	O
was	O
established	O
and	O
the	O
patient	O
died	O
on	O
the	O
eighth	O
day	O
of	O
admission	O
.	O
DIAGNOSIS	O
Advanced	O
acute	O
inferior	O
myocardial	O
infarction	O
.	O
Thrombotic	O
occlusion	O
of	O
non	O
revascularised	O
middle	O
right	O
coronary	O
artery	O
.	O
Ventricular	O
septal	O
rupture	O
.	O
Refractory	O
heart	O
failure	O
.	O
Death	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
78	O
year	O
old	O
woman	O
,	O
a	O
25	O
pack	O
year	O
ex	O
smoker	O
with	O
no	O
other	O
known	O
cardiovascular	O
risk	O
factors	O
or	O
previous	O
personal	O
or	O
family	O
cardiological	O
history	O
,	O
who	O
presented	O
with	O
a	O
history	O
of	O
polyarthralgia	O
and	O
Raynaud	O
's	O
phenomenon	O
that	O
had	O
not	O
been	O
studied	O
,	O
on	O
chronic	O
treatment	O
with	O
non	O
steroidal	O
anti	O
inflammatory	O
drugs	O
.	O
He	O
presented	O
with	O
symptoms	O
of	O
acute	O
heart	O
failure	O
of	O
three	O
days	O
'	O
duration	O
,	O
with	O
orthopnoea	O
and	O
oliguria	O
,	O
associated	O
with	O
oedematisation	O
of	O
the	O
lower	O
limbs	O
.	O
She	O
denied	O
chest	O
pain	O
or	O
fever	O
,	O
but	O
did	O
recognise	O
asthenia	O
and	O
loss	O
of	O
appetite	O
in	O
the	O
last	O
two	O
months	O
.	O
The	O
blood	O
pressure	O
BP	O
on	O
arrival	O
at	O
the	O
ED	O
was	O
158	O
97	O
mmHg	O
and	O
heart	O
rate	O
HR	O
97	O
bpm	O
,	O
saturating	O
at	O
92	O
with	O
Ventimask	O
at	O
50	O
FiO2	O
.	O
Afebrile	O
.	O
Physical	O
examination	O
revealed	O
poor	O
general	O
condition	O
with	O
respiratory	O
distress	O
and	O
jugular	O
ingurgitation	O
,	O
and	O
cardiopulmonary	O
auscultation	O
revealed	O
no	O
murmurs	O
,	O
with	O
crackles	O
up	O
to	O
mid	O
pulmonary	O
fields	O
.	O
There	O
was	O
also	O
oedema	O
in	O
the	O
lower	O
limbs	O
up	O
to	O
the	O
middle	O
third	O
of	O
the	O
pretibial	O
region	O
.	O
The	O
presence	O
of	O
sclerodermic	O
lesions	O
on	O
both	O
hands	O
and	O
on	O
the	O
trunk	O
is	O
noteworthy	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYTICS	O
glucose	O
136	O
mg	O
dl	O
;	O
urea	O
130	O
mg	O
dl	O
;	O
creatinine	O
3	O
.	O
76	O
mg	O
dl	O
;	O
glomerular	O
filtration	O
rate	O
10	O
ml	O
min	O
previously	O
normal	O
;	O
uric	O
acid	O
6	O
.	O
2	O
mg	O
dl	O
;	O
alkaline	O
phosphatase	O
86	O
U	O
l	O
;	O
GPT	O
32	O
U	O
l	O
;	O
NT	O
proBNP	O
2745	O
pg	O
ml	O
;	O
C	O
reactive	O
protein	O
28	O
.	O
3	O
mg	O
dl	O
;	O
haemoglobin	O
10	O
.	O
5	O
g	O
dl	O
;	O
leucocytes	O
7	O
.	O
8	O
x	O
10000	O
mm3	O
;	O
platelets	O
117	O
x	O
10000	O
mm3	O
;	O
ESR	O
125	O
mm	O
h	O
;	O
prothrombin	O
rate	O
86	O
;	O
urine	O
sediment	O
with	O
proteinuria	O
;	O
basal	O
blood	O
gas	O
with	O
pH	O
7	O
.	O
34	O
,	O
pO2	O
55	O
mmHg	O
,	O
pCO2	O
34	O
mmHg	O
.	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
at	O
85	O
bpm	O
with	O
left	O
bundle	O
branch	O
block	O
.	O
THORAX	O
RADIOGRAPHY	O
anteroposterior	O
study	O
with	O
cardiomegaly	O
and	O
acute	O
pulmonary	O
oedema	O
.	O
Transthoracic	O
echocardiography	O
non	O
dilated	O
left	O
ventricle	O
LV	O
with	O
mild	O
concentric	O
hypertrophy	O
and	O
prolonged	O
diastolic	O
relaxation	O
pattern	O
.	O
LVEF	O
40	O
.	O
Right	O
ventricle	O
RV	O
slightly	O
dilated	O
with	O
normal	O
systolic	O
function	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Mild	O
tricuspid	O
insufficiency	O
that	O
allows	O
estimating	O
a	O
RV	O
AD	O
gradient	O
of	O
42	O
mmHg	O
.	O
Moderate	O
pericardial	O
effusion	O
without	O
involvement	O
of	O
the	O
right	O
chambers	O
or	O
transmitral	O
flow	O
variation	O
.	O
HIGH	O
RESOLUTION	O
COMPUTATIONAL	O
TOMOGRAPHY	O
HRCT	O
ground	O
glass	O
images	O
in	O
both	O
lower	O
lobes	O
in	O
particular	O
,	O
suggesting	O
pulmonary	O
fibrosis	O
.	O
Increased	O
pulmonary	O
artery	O
calibre	O
35	O
mm	O
suggesting	O
pulmonary	O
hypertension	O
.	O
CORONARYGRAPHY	O
epicardial	O
arteries	O
without	O
significant	O
angiographic	O
lesions	O
.	O
CLINICAL	O
EVOLUTION	O
Diagnosed	O
with	O
acute	O
pulmonary	O
oedema	O
and	O
acute	O
renal	O
failure	O
,	O
he	O
was	O
initially	O
admitted	O
to	O
the	O
acute	O
cardiac	O
care	O
unit	O
,	O
where	O
respiratory	O
support	O
measures	O
were	O
established	O
with	O
non	O
invasive	O
mechanical	O
ventilation	O
,	O
with	O
good	O
adaptation	O
and	O
achieving	O
clinical	O
and	O
gasometric	O
improvement	O
two	O
hours	O
after	O
starting	O
treatment	O
.	O
However	O
,	O
oligoanuria	O
persisted	O
despite	O
the	O
initiation	O
of	O
intravenous	O
diuretic	O
treatment	O
,	O
so	O
renal	O
replacement	O
therapy	O
with	O
haemofiltration	O
was	O
finally	O
chosen	O
,	O
which	O
facilitated	O
water	O
discharge	O
and	O
contributed	O
to	O
the	O
patient	O
's	O
clinical	O
improvement	O
.	O
Once	O
the	O
patient	O
was	O
initially	O
stabilised	O
,	O
transthoracic	O
echocardiography	O
was	O
performed	O
,	O
showing	O
moderate	O
left	O
ventricular	O
systolic	O
dysfunction	O
without	O
frank	O
asynergies	O
.	O
With	O
the	O
presence	O
of	O
an	O
unknown	O
left	O
bundle	O
branch	O
block	O
previous	O
studies	O
without	O
intraventricular	O
conduction	O
disorders	O
,	O
a	O
coronary	O
angiographic	O
study	O
was	O
performed	O
,	O
which	O
showed	O
no	O
lesions	O
in	O
the	O
epicardial	O
bed	O
.	O
The	O
patient	O
subsequently	O
evolved	O
favourably	O
,	O
being	O
able	O
to	O
dispense	O
with	O
ventilatory	O
support	O
and	O
starting	O
haemodialysis	O
sessions	O
due	O
to	O
persistent	O
oligoanuria	O
.	O
The	O
presence	O
of	O
sclerodermic	O
skin	O
lesions	O
,	O
pericardial	O
effusion	O
,	O
pulmonary	O
hypertension	O
on	O
echocardiography	O
and	O
acute	O
renal	O
failure	O
led	O
to	O
the	O
suspicion	O
of	O
an	O
autoimmune	O
disease	O
,	O
so	O
an	O
immunological	O
study	O
was	O
requested	O
which	O
showed	O
positivity	O
for	O
antitopoisomerase	O
I	O
antibodies	O
AntiScl	O
70	O
,	O
and	O
a	O
pulmonary	O
imaging	O
study	O
with	O
CAT	O
scan	O
showed	O
bibasal	O
pulmonary	O
infiltrates	O
suggestive	O
of	O
pulmonary	O
fibrosis	O
with	O
signs	O
of	O
pulmonary	O
hypertension	O
.	O
Treatment	O
was	O
started	O
with	O
glucocorticoids	O
and	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
ACE	O
inhibitors	O
and	O
continued	O
with	O
haemodialysis	O
sessions	O
,	O
with	O
echocardiographic	O
monitoring	O
showing	O
only	O
partial	O
resolution	O
of	O
the	O
pericardial	O
effusion	O
,	O
with	O
no	O
other	O
changes	O
.	O
Finally	O
,	O
in	O
view	O
of	O
the	O
favourable	O
evolution	O
,	O
discharge	O
home	O
was	O
decided	O
.	O
DIAGNOSIS	O
Acute	O
pulmonary	O
oedema	O
.	O
Moderate	O
pericardial	O
effusion	O
.	O
Moderate	O
left	O
ventricular	O
dysfunction	O
.	O
Diffuse	O
systemic	O
sclerosis	O
with	O
scleroderma	O
renal	O
crisis	O
.	O
Interstitial	O
lung	O
disease	O
with	O
fibrosis	O
and	O
pulmonary	O
hypertension	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
61	O
year	O
old	O
woman	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
or	O
toxic	O
habits	O
.	O
No	O
family	O
history	O
of	O
early	O
ischaemic	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
Vitiligo	O
.	O
No	O
other	O
diseases	O
of	O
interest	O
.	O
No	O
hospital	O
admissions	O
or	O
surgical	O
interventions	O
No	O
usual	O
treatment	O
.	O
CURRENT	O
ILLNESS	O
Previously	O
asymptomatic	O
cardiovascular	O
until	O
the	O
week	O
prior	O
to	O
admission	O
,	O
which	O
begins	O
with	O
pseudo	O
flu	O
like	O
symptoms	O
of	O
myalgia	O
,	O
asthenia	O
and	O
dysthermic	O
sensation	O
with	O
febrile	O
fever	O
.	O
On	O
the	O
day	O
of	O
admission	O
,	O
she	O
had	O
two	O
episodes	O
of	O
dizziness	O
with	O
associated	O
vegetative	O
cortex	O
and	O
subsequent	O
syncope	O
,	O
with	O
complete	O
recovery	O
within	O
seconds	O
.	O
There	O
was	O
no	O
associated	O
chest	O
pain	O
or	O
palpitations	O
.	O
She	O
had	O
not	O
had	O
previous	O
syncopal	O
episodes	O
,	O
nor	O
did	O
she	O
present	O
dyspnoea	O
,	O
orthopnoea	O
,	O
oliguria	O
or	O
oedema	O
.	O
PHYSICAL	O
EXAMINATION	O
Arterial	O
hypotension	O
of	O
50	O
70	O
mmHg	O
and	O
tachycardia	O
at	O
110	O
bpm	O
were	O
observed	O
,	O
together	O
with	O
signs	O
of	O
poor	O
peripheral	O
perfusion	O
,	O
with	O
coldness	O
and	O
sweating	O
.	O
Afebrile	O
.	O
Cardiopulmonary	O
auscultation	O
with	O
rhythmic	O
heart	O
sounds	O
,	O
without	O
murmurs	O
and	O
preserved	O
vesicular	O
murmur	O
without	O
pathological	O
sounds	O
.	O
Pulses	O
present	O
and	O
symmetrical	O
in	O
all	O
four	O
extremities	O
.	O
No	O
oedema	O
or	O
evidence	O
of	O
venous	O
thrombosis	O
in	O
the	O
lower	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
,	O
PR	O
140	O
ms	O
,	O
narrow	O
QRS	O
,	O
with	O
discrete	O
J	O
point	O
elevation	O
especially	O
in	O
inferior	O
face	O
and	O
V5	O
V6	O
,	O
with	O
slow	O
progression	O
of	O
R	O
in	O
precordials	O
and	O
generalised	O
decreased	O
voltages	O
.	O
THORAX	O
RADIOGRAPHY	O
admission	O
normal	O
cardiothoracic	O
index	O
.	O
No	O
evidence	O
of	O
heart	O
failure	O
or	O
visible	O
condensation	O
.	O
THORAX	O
RADIOGRAPHY	O
evolution	O
acute	O
pulmonary	O
oedema	O
.	O
ANALYSIS	O
CBC	O
leukocytes	O
6600	O
μl	O
70	O
neutrophils	O
,	O
Hb	O
13	O
.	O
6	O
g	O
dl	O
,	O
platelets	O
140	O
,	O
000	O
μl	O
.	O
Coagulation	O
INR	O
1	O
,	O
PT	O
96	O
.	O
Biochemistry	O
at	O
baseline	O
glucose	O
145	O
mg	O
dl	O
,	O
urea	O
52	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
03	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
52	O
ml	O
min	O
CKD	O
EPI	O
60	O
,	O
K	O
4	O
.	O
5	O
mmol	O
l	O
,	O
Na	O
140	O
mmol	O
l	O
,	O
CK	O
151	O
U	O
l	O
,	O
ultrasensitive	O
Troponin	O
24	O
.	O
4	O
ng	O
l	O
.	O
ProBNP	O
414	O
pg	O
ml	O
.	O
In	O
the	O
evolution	O
GOT	O
1	O
.	O
322	O
U	O
l	O
,	O
GPT	O
1	O
.	O
050	O
U	O
l	O
,	O
CK	O
3578	O
U	O
l	O
,	O
ultrasensitive	O
troponin	O
5	O
.	O
001	O
ng	O
l	O
,	O
ProBNP	O
3	O
.	O
229	O
pg	O
ml	O
,	O
CRP	O
8	O
,	O
7	O
mg	O
dl	O
.	O
Transthoracic	O
echocardiogram	O
hypertrophic	O
left	O
ventricle	O
interventricular	O
septum	O
15	O
mm	O
with	O
echodensity	O
suggestive	O
of	O
infiltrative	O
disease	O
or	O
inflammation	O
,	O
not	O
dilated	O
end	O
systolic	O
diameter	O
40	O
mm	O
,	O
with	O
very	O
severe	O
depression	O
of	O
ejection	O
fraction	O
LVEF	O
10	O
15	O
at	O
the	O
expense	O
of	O
global	O
hypokinesia	O
.	O
Normal	O
sized	O
right	O
ventricle	O
with	O
severe	O
ventricular	O
dysfunction	O
TAPSE	O
7	O
.	O
Normal	O
sized	O
left	O
atrium	O
.	O
No	O
significant	O
valvular	O
heart	O
disease	O
.	O
Mild	O
pericardial	O
effusion	O
.	O
Ascending	O
aorta	O
of	O
normal	O
size	O
.	O
CARDIAC	O
NUCLEAR	O
MAGNETIC	O
RESONANCE	O
MRI	O
very	O
artifactual	O
study	O
due	O
to	O
inadequate	O
cooperation	O
of	O
the	O
patient	O
.	O
Both	O
ventricles	O
are	O
normal	O
size	O
with	O
severe	O
global	O
hypokinesia	O
and	O
significant	O
oedema	O
and	O
diffuse	O
hyperemia	O
,	O
compatible	O
with	O
acute	O
inflammatory	O
pathology	O
.	O
There	O
are	O
no	O
areas	O
of	O
late	O
gadolinium	O
uptake	O
.	O
No	O
pericardial	O
effusion	O
.	O
Minimal	O
bilateral	O
pleural	O
effusions	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
a	O
situation	O
of	O
arterial	O
hypotension	O
and	O
poor	O
peripheral	O
perfusion	O
with	O
initial	O
suspicion	O
of	O
acute	O
myocarditis	O
in	O
cardiogenic	O
shock	O
,	O
he	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
and	O
haemodynamic	O
support	O
was	O
started	O
with	O
dobutamine	B-FARMACO
and	O
noradrenaline	B-FARMACO
.	O
The	O
day	O
after	O
admission	O
,	O
cardiac	O
MRI	O
was	O
performed	O
,	O
confirming	O
the	O
suspected	O
diagnosis	O
.	O
Progressive	O
worsening	O
in	O
the	O
following	O
hours	O
despite	O
treatment	O
with	O
vasoactive	O
amines	O
at	O
maximum	O
tolerated	O
doses	O
,	O
with	O
clinical	O
deterioration	O
and	O
onset	O
of	O
multi	O
organ	O
failure	O
,	O
with	O
oligoanuria	O
,	O
lactidemia	O
greater	O
than	O
6	O
nmol	O
l	O
and	O
increased	O
liver	O
damage	O
enzymes	O
.	O
It	O
was	O
decided	O
to	O
place	O
an	O
aortic	O
balloon	O
pump	O
and	O
ECMO	O
type	O
veno	O
arterial	O
circulatory	O
support	O
.	O
In	O
the	O
following	O
hours	O
,	O
there	O
were	O
persistent	O
signs	O
of	O
poor	O
distal	O
perfusion	O
and	O
poor	O
ventilation	O
with	O
pinkish	O
expectoration	O
through	O
an	O
orotracheal	O
tube	O
compatible	O
with	O
acute	O
pulmonary	O
oedema	O
.	O
He	O
presented	O
an	O
episode	O
of	O
severe	O
bradycardia	O
and	O
asystole	O
,	O
advanced	O
cardiopulmonary	O
resuscitation	O
manoeuvres	O
were	O
performed	O
,	O
and	O
he	O
died	O
on	O
the	O
third	O
day	O
of	O
admission	O
.	O
DIAGNOSIS	O
Fulminant	O
myocarditis	O
.	O
Very	O
severe	O
biventricular	O
dysfunction	O
LVEF	O
10	O
15	O
.	O
Cardiogenic	O
shock	O
with	O
circulatory	O
support	O
with	O
veno	O
arterial	O
ECMO	O
.	O
Death	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
a	O
67	O
year	O
old	O
male	O
,	O
ex	O
smoker	O
with	O
an	O
accumulated	O
rate	O
of	O
50	O
packs	O
year	O
,	O
hypertension	O
,	O
dyslipidaemic	O
and	O
diabetic	O
on	O
insulin	B-FARMACO
treatment	O
,	O
with	O
a	O
history	O
of	O
high	O
risk	O
STEMI	O
in	O
February	O
2015	O
and	O
implantation	O
of	O
three	O
paclitaxel	B-FARMACO
eluting	O
stents	O
in	O
the	O
middle	O
and	O
distal	O
right	O
coronary	O
artery	O
RCA	O
Luc	O
Chopin	O
3x12	O
and	O
2	O
.	O
5x12	O
mm	O
respectively	O
,	O
and	O
in	O
second	O
time	O
two	O
other	O
stents	O
Luc	O
Chopin	O
3x12	O
mm	O
and	O
2	O
.	O
5x12	O
mm	O
to	O
proximal	O
anterior	O
descending	O
AD	O
and	O
middle	O
.	O
In	O
October	O
2015	O
,	O
due	O
to	O
anginal	O
symptoms	O
,	O
angiographic	O
re	O
evaluation	O
documented	O
severe	O
restenosis	O
of	O
previous	O
stents	O
,	O
so	O
new	O
percutaneous	O
resvascularisation	O
was	O
performed	O
with	O
implantation	O
of	O
three	O
everolimus	B-FARMACO
eluting	O
stents	O
XIENCE	O
PRIME	O
,	O
one	O
in	O
the	O
proximal	O
LAD	O
3x18	O
mm	O
and	O
two	O
overlapping	O
stents	O
in	O
the	O
middle	O
and	O
distal	O
DC	O
3x28	O
mm	O
,	O
2x25	O
mm	O
.	O
Having	O
been	O
asymptomatic	O
for	O
the	O
last	O
two	O
years	O
and	O
taking	O
double	O
antiplatelet	O
therapy	O
with	O
aspirin	B-FARMACO
and	O
prasugrel	B-FARMACO
,	O
on	O
the	O
day	O
of	O
admission	O
he	O
consulted	O
for	O
typical	O
chest	O
pain	O
of	O
1	O
.	O
5	O
hours	O
'	O
duration	O
.	O
Physical	O
examination	O
revealed	O
ERW	O
.	O
Mucocutaneous	O
pallor	O
.	O
Normoperfused	O
and	O
normohydrated	O
.	O
Vitals	O
BP	O
170	O
80	O
mmHg	O
,	O
O2	O
Sat	O
96	O
GFN	O
at	O
2	O
bpm	O
.	O
Afebrile	O
.	O
Jugular	O
ingurgitation	O
at	O
45o	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
or	O
friction	O
sounds	O
.	O
Pulmonary	O
auscultation	O
diminished	O
vesicular	O
murmur	O
,	O
with	O
crackles	O
up	O
to	O
midfields	O
,	O
expiratory	O
wheezing	O
and	O
rhonchi	O
.	O
Abdomen	O
nondescript	O
.	O
Lower	O
extremities	O
no	O
oedema	O
.	O
Positive	O
and	O
symmetrical	O
pulses	O
at	O
all	O
levels	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
.	O
Normal	O
PR	O
.	O
rS	O
from	O
V1	O
to	O
V3	O
.	O
ST	O
ascended	O
4	O
mm	O
V3	O
V4	O
,	O
1	O
2	O
mm	O
inferior	O
and	O
1	O
mm	O
in	O
V5	O
.	O
ST	O
underleveled	O
in	O
V6	O
,	O
I	O
,	O
aAVL	O
.	O
T	O
sharp	O
V3	O
V4	O
.	O
T	O
inferior	O
.	O
CBC	O
biochemistry	O
170	O
,	O
urea	O
106	O
,	O
creatinine	O
1	O
.	O
50	O
,	O
sodium	O
132	O
,	O
potassium	O
4	O
.	O
5	O
.	O
Chlorine	O
95	O
,	O
GOT	O
27	O
,	O
LDH	O
1022	O
,	O
CK	O
156	O
Coagulation	O
normal	O
.	O
CBC	O
erythrocytes	O
3	O
.	O
64	O
,	O
haemoglobin	O
12	O
,	O
Ht	O
34	O
.	O
8	O
,	O
haemoglobin	O
C	O
.	O
M	O
31	O
.	O
2	O
.	O
Platelets	O
363	O
,	O
000	O
,	O
MCV	O
10	O
.	O
3	O
,	O
lymphocytes	O
19	O
.	O
6	O
.	O
E	O
3	O
,	O
8	O
.	O
Maximal	O
serial	O
myocardial	O
necrosis	O
enzymes	O
TTUS	O
10	O
,	O
000	O
,	O
CK	O
MB	O
5600	O
566	O
.	O
Chest	O
X	O
ray	O
increased	O
CTI	O
.	O
Signs	O
of	O
COPD	O
.	O
Prominent	O
hilarity	O
with	O
redistribution	O
.	O
Urgent	O
echocardiogram	O
Non	O
dilated	O
LV	O
.	O
Mild	O
LVH	O
.	O
Severely	O
depressed	O
LVEF	O
25	O
30	O
.	O
Akinesia	O
of	O
inferior	O
,	O
apical	O
and	O
septal	O
segments	O
.	O
Hypokinesia	O
of	O
basal	O
and	O
anterior	O
middle	O
segments	O
.	O
Normal	O
CCDD	O
,	O
with	O
good	O
function	O
.	O
Normal	O
LA	O
.	O
Normal	O
Ao	O
root	O
.	O
No	O
DP	O
.	O
Mild	O
MI	O
Urgent	O
catheterisation	O
right	O
radial	O
left	O
coronary	O
thrombotic	O
occlusion	O
of	O
the	O
stent	O
in	O
the	O
proximal	O
LAD	O
.	O
Severe	O
stenosis	O
in	O
distal	O
edge	O
of	O
stent	O
is	O
observed	O
after	O
opening	O
.	O
Severe	O
disease	O
of	O
bisector	O
branch	O
of	O
borderline	O
calibre	O
.	O
Severe	O
stenosis	O
of	O
distal	O
Cx	O
in	O
small	O
calibre	O
vessel	O
.	O
Right	O
coronary	O
dominant	O
.	O
Thrombotic	O
occlusion	O
of	O
the	O
middle	O
and	O
distal	O
DC	O
stent	O
.	O
PCI	O
with	O
thrombectomy	O
and	O
balloon	O
PTCA	O
on	O
mid	O
and	O
distal	O
DC	O
stent	O
thrombosis	O
,	O
and	O
on	O
proximal	O
and	O
mid	O
LAD	O
stent	O
thrombosis	O
.	O
PCI	O
with	O
direct	O
stent	O
implantation	O
of	O
a	O
2	O
.	O
75	O
mm	O
diameter	O
,	O
12	O
mm	O
long	O
XIENCE	O
PRIME	O
direct	O
coated	O
stent	O
at	O
13	O
atmospheres	O
in	O
the	O
middle	O
LAD	O
distal	O
edge	O
of	O
previous	O
stent	O
.	O
EVOLUTION	O
The	O
ECG	O
showed	O
anterior	O
and	O
inferior	O
ST	O
elevation	O
,	O
the	O
echocardiogram	O
showed	O
akinesia	O
of	O
inferior	O
,	O
apical	O
and	O
septal	O
segments	O
with	O
severely	O
depressed	O
systolic	O
function	O
LVEF	O
30	O
.	O
Urgent	O
coronary	O
angiography	O
documented	O
thrombotic	O
occlusion	O
of	O
stents	O
in	O
the	O
proximal	O
LAD	O
and	O
also	O
of	O
stents	O
in	O
the	O
mid	O
and	O
distal	O
DC	O
,	O
thrombectomy	O
and	O
balloon	O
angioplasty	O
were	O
performed	O
on	O
the	O
proximal	O
LAD	O
and	O
mid	O
and	O
distal	O
DC	O
,	O
intracoronary	O
abciximab	B-FARMACO
was	O
administered	O
,	O
achieving	O
a	O
good	O
final	O
angiographic	O
result	O
with	O
TIMI	O
III	O
flow	O
Video	O
4	O
.	O
When	O
restenosis	O
of	O
the	O
distal	O
edge	O
of	O
the	O
middle	O
LAD	O
stent	O
was	O
found	O
,	O
it	O
was	O
decided	O
to	O
implant	O
a	O
DES	O
XIENCE	O
PRIME	O
2	O
.	O
75x12	O
mm	O
.	O
The	O
patient	O
evolved	O
favourably	O
,	O
a	O
hypercoagulability	O
study	O
was	O
performed	O
,	O
which	O
was	O
negative	O
,	O
and	O
he	O
was	O
discharged	O
in	O
NYHA	O
CF	O
II	O
,	O
with	O
treatment	O
with	O
aspirin	B-FARMACO
100	O
mg	O
per	O
day	O
and	O
prasugrel	B-FARMACO
10	O
mg	O
per	O
day	O
.	O
After	O
4	O
months	O
,	O
he	O
was	O
readmitted	O
for	O
unstable	O
angina	O
,	O
and	O
a	O
new	O
coronary	O
angiography	O
was	O
performed	O
which	O
showed	O
severe	O
restenosis	O
of	O
the	O
proximal	O
edge	O
of	O
the	O
DES	O
Luc	O
Chopin	O
from	O
the	O
first	O
procedure	O
in	O
the	O
proximal	O
LAD	O
Video	O
5	O
.	O
After	O
discussing	O
the	O
case	O
in	O
a	O
medical	O
surgical	O
session	O
,	O
surgical	O
revascularisation	O
was	O
decided	O
and	O
a	O
single	O
coronary	O
bypass	O
of	O
the	O
internal	O
mammary	O
artery	O
IMA	O
to	O
the	O
LAD	O
was	O
performed	O
,	O
but	O
the	O
patient	O
had	O
a	O
torpid	O
postoperative	O
period	O
complicated	O
by	O
respiratory	O
infection	O
and	O
finally	O
died	O
of	O
refractory	O
septic	O
shock	O
DIAGNOSIS	O
Extensive	O
anterior	O
inferior	O
STEMI	O
,	O
k	O
II	O
.	O
Urgent	O
catheterisation	O
with	O
late	O
double	O
thrombosis	O
of	O
stents	O
at	O
the	O
level	O
of	O
the	O
middle	O
DC	O
and	O
proximal	O
LAD	O
.	O
Thrombectomy	O
,	O
PTCA	O
at	O
mid	O
and	O
distal	O
DC	O
and	O
proximal	O
LAD	O
.	O
Implantation	O
of	O
everolimus	B-FARMACO
coated	O
stent	O
at	O
the	O
level	O
of	O
distal	O
edge	O
restenosis	O
of	O
mid	O
LAD	O
stent	O
.	O
Severe	O
disease	O
of	O
distal	O
CX	O
and	O
small	O
bore	O
bisetrix	O
.	O
Severe	O
restenosis	O
of	O
DES	O
implanted	O
in	O
proximal	O
LAD	O
.	O
Surgical	O
revascularisation	O
with	O
IMA	O
to	O
LAD	O
.	O
Torpid	O
postoperative	O
course	O
.	O
Exitus	O
.	O
LVEF	O
of	O
45	O
.	O
HYPERTENSION	O
.	O
Diabetes	O
mellitus	O
DM	O
type	O
2	O
.	O
DLP	O
.	O
Ex	O
smoker	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
An	O
86	O
year	O
old	O
man	O
came	O
to	O
the	O
emergency	O
department	O
for	O
dyspnoea	O
.	O
History	O
No	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
controlled	O
arterial	O
hypertension	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
of	O
five	O
years	O
of	O
evolution	O
in	O
treatment	O
with	O
oral	O
antidiabetics	O
.	O
Dyslipidaemia	O
.	O
Previous	O
cardiological	O
history	O
chronic	O
ischaemic	O
heart	O
disease	O
which	O
debuted	O
in	O
2000	O
in	O
the	O
form	O
of	O
stable	O
angina	O
.	O
Coronary	O
angiography	O
in	O
2005	O
for	O
angina	O
Class	O
III	O
IV	O
CCS	O
and	O
positive	O
stress	O
echocardiography	O
for	O
induction	O
of	O
ischaemia	O
in	O
the	O
LAD	O
territory	O
.	O
Three	O
vessel	O
disease	O
partially	O
revascularised	O
by	O
drug	O
eluting	O
stents	O
to	O
proximal	O
LAD	O
,	O
middle	O
DC	O
and	O
OM1	O
.	O
In	O
2008	O
,	O
again	O
clinical	O
angina	O
II	O
IV	O
CCS	O
,	O
with	O
positive	O
stress	O
echocardiography	O
for	O
ischaemia	O
in	O
CX	O
territory	O
,	O
opting	O
for	O
conservative	O
management	O
.	O
Permanent	O
non	O
valvular	O
atrial	O
fibrillation	O
diagnosed	O
in	O
2010	O
,	O
anticoagulated	O
with	O
acenocoumarol	B-FARMACO
;	O
echocardiography	O
in	O
that	O
consultation	O
ruled	O
out	O
significant	O
valvulopathies	O
and	O
reported	O
preserved	O
LVEF	O
.	O
No	O
studies	O
or	O
follow	O
up	O
by	O
Cardiology	O
since	O
then	O
.	O
Functional	O
class	O
II	O
NYHA	O
.	O
Other	O
pathologies	O
intermittent	O
gait	O
claudication	O
in	O
Fontaine	O
stage	O
IIa	O
.	O
Bilateral	O
carpal	O
tunnel	O
syndrome	O
.	O
Previous	O
treatment	O
acenocoumarol	B-FARMACO
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
24h	O
,	O
ranolazine	B-FARMACO
750	O
mg	O
12h	O
,	O
isosorbide	B-FARMACO
mononitrate	I-FARMACO
50	O
mg	O
24h	O
,	O
rosuvastatin	B-FARMACO
10	O
mg	O
24h	O
,	O
metformin	B-FARMACO
1000	O
mg	O
12h	O
,	O
sitagliptin	B-FARMACO
50	O
mg	O
12h	O
.	O
Baseline	O
partially	O
dependent	O
for	O
ABVD	O
Katz	O
B	O
.	O
Walks	O
with	O
a	O
walker	O
.	O
Cognitive	O
preserved	O
.	O
Current	O
illness	O
She	O
attended	O
the	O
emergency	O
department	O
with	O
progressive	O
dyspnoea	O
of	O
one	O
week	O
's	O
evolution	O
accompanied	O
by	O
palpitations	O
,	O
unquantified	O
weight	O
gain	O
,	O
orthopnoea	O
and	O
episodes	O
of	O
DPN	O
in	O
the	O
last	O
few	O
nights	O
.	O
The	O
patient	O
claimed	O
adequate	O
compliance	O
with	O
treatment	O
and	O
denied	O
any	O
dietary	O
transgressions	O
.	O
The	O
previous	O
week	O
he	O
had	O
felt	O
a	O
little	O
more	O
"	O
cold	O
"	O
,	O
with	O
cough	O
,	O
mucous	O
expectoration	O
and	O
a	O
feeling	O
of	O
dystrophy	O
at	O
home	O
without	O
thermometry	O
.	O
He	O
consulted	O
his	O
health	O
centre	O
for	O
this	O
reason	O
and	O
was	O
prescribed	O
treatment	O
with	O
apyretics	O
and	O
mucolytics	O
,	O
with	O
a	O
partial	O
response	O
.	O
Physical	O
examination	O
BP	O
105	O
45	O
mmHg	O
,	O
HR	O
110	O
bpm	O
,	O
Ta	O
36	O
.	O
7	O
C	O
,	O
Sat	O
O2	O
96	O
.	O
Weight	O
70	O
kg	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
,	O
with	O
systolic	O
ejection	O
murmur	O
predominantly	O
in	O
aortic	O
focus	O
,	O
II	O
VI	O
,	O
with	O
abolished	O
R2	O
.	O
Pulmonary	O
auscultation	O
crackles	O
in	O
both	O
lung	O
bases	O
with	O
scattered	O
scattered	O
rhonchi	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
no	O
masses	O
or	O
visceromegaly	O
,	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Extremities	O
pretibial	O
oedema	O
with	O
fovea	O
;	O
paedial	O
pulses	O
present	O
but	O
asymmetrical	O
,	O
no	O
phlebitis	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
glucose	O
130	O
mg	O
dl	O
,	O
urea	O
58	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
38	O
mg	O
dl	O
,	O
CrCl	O
Cockcroft	O
Gault	O
38	O
ml	O
min	O
,	O
sodium	O
138	O
mEq	O
l	O
,	O
potassium	O
5	O
.	O
2	O
mEq	O
l	O
,	O
NT	O
proBNP	O
10	O
.	O
055pg	O
ml	O
;	O
TnT	O
US	O
89	O
ng	O
l	O
normal	O
value	O
15	O
ng	O
l	O
;	O
haemoglobin	O
10	O
g	O
dl	O
,	O
haematocrit	O
30	O
.	O
8	O
;	O
MCV	O
87	O
.	O
5	O
fl	O
,	O
platelets	O
277	O
,	O
000	O
uL	O
;	O
INR	O
1	O
.	O
5	O
.	O
Emergency	O
electrocardiogram	O
atrial	O
fibrillation	O
at	O
120	O
bpm	O
;	O
narrow	O
QRS	O
with	O
normal	O
axis	O
;	O
early	O
transition	O
in	O
V2	O
and	O
LV	O
overload	O
pattern	O
by	O
ST	O
segment	O
depression	O
in	O
V2	O
V5	O
and	O
inferior	O
leads	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
,	O
hilar	O
congestion	O
with	O
vascular	O
redistribution	O
towards	O
apexes	O
,	O
fluid	O
in	O
fissures	O
and	O
discrete	O
pinching	O
of	O
the	O
right	O
costophrenic	O
sinus	O
.	O
Transthoracic	O
echocardiogram	O
marked	O
biauricular	O
dilatation	O
.	O
Severe	O
concentric	O
left	O
ventricular	O
hypertrophy	O
with	O
ejection	O
fraction	O
at	O
the	O
lower	O
limit	O
of	O
normal	O
global	O
LVEF	O
by	O
Simpson	O
52	O
.	O
Thickened	O
aortic	O
valve	O
with	O
significant	O
restriction	O
to	O
its	O
opening	O
and	O
severe	O
valvular	O
stenosis	O
by	O
estimated	O
area	O
area	O
0	O
.	O
65	O
cm2	O
although	O
with	O
low	O
gradients	O
peak	O
aortic	O
transvalvular	O
gradient	O
25	O
mmHg	O
.	O
Mitral	O
filling	O
pattern	O
with	O
single	O
E	O
wave	O
by	O
AF	O
and	O
increased	O
filling	O
pressures	O
data	O
E	O
e	O
"	O
ratio	O
17	O
and	O
shortened	O
deceleration	O
time	O
TD	O
115	O
ms	O
.	O
Mild	O
mitral	O
valve	O
insufficiency	O
.	O
Myocardial	O
deformation	O
study	O
with	O
the	O
following	O
findings	O
Decreased	O
GLS	O
11	O
with	O
preserved	O
deformation	O
parameters	O
in	O
apical	O
segments	O
and	O
pathological	O
in	O
basal	O
and	O
middle	O
segments	O
apical	O
sparing	O
.	O
Bone	O
scan	O
with	O
99mTc	O
DPD	O
study	O
with	O
cardiac	O
uptake	O
of	O
notable	O
intensity	O
,	O
much	O
higher	O
than	O
bone	O
uptake	O
,	O
which	O
in	O
SPECT	O
CT	O
is	O
diffusely	O
distributed	O
and	O
coincides	O
with	O
LV	O
,	O
these	O
findings	O
being	O
suggestive	O
of	O
amyloidosis	O
due	O
to	O
transthyretin	O
deposition	O
.	O
In	O
the	O
rest	O
of	O
the	O
study	O
,	O
discrete	O
hyperuptake	O
in	O
the	O
sternoclavicular	O
joints	O
and	O
large	O
bilateral	O
joints	O
shoulders	O
,	O
elbows	O
,	O
wrists	O
,	O
hips	O
and	O
knees	O
suggesting	O
inflammatory	O
degenerative	O
pathology	O
.	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
cardiology	O
ward	O
with	O
a	O
diagnosis	O
of	O
heart	O
failure	O
in	O
the	O
context	O
of	O
lower	O
respiratory	O
tract	O
infection	O
.	O
He	O
progressed	O
well	O
during	O
the	O
72	O
hours	O
following	O
admission	O
,	O
achieving	O
copious	O
diuresis	O
with	O
treatment	O
with	O
intravenous	O
furosemide	B-FARMACO
and	O
heart	O
rate	O
control	O
with	O
digoxin	B-FARMACO
.	O
After	O
improvement	O
of	O
the	O
congestive	O
symptoms	O
,	O
a	O
certain	O
tendency	O
to	O
hypotension	O
persisted	O
,	O
as	O
well	O
as	O
bradycardia	O
,	O
despite	O
a	O
minimum	O
dose	O
of	O
beta	O
blocker	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
h	O
,	O
but	O
without	O
significant	O
clinical	O
repercussions	O
except	O
for	O
slight	O
dizziness	O
with	O
an	O
orthostatic	O
profile	O
coinciding	O
with	O
sudden	O
postural	O
changes	O
.	O
Given	O
the	O
nature	O
of	O
the	O
symptoms	O
and	O
the	O
semiology	O
,	O
it	O
was	O
decided	O
to	O
update	O
the	O
echocardiographic	O
study	O
,	O
with	O
findings	O
suggestive	O
of	O
infiltrative	O
cardiomyopathy	O
and	O
severe	O
aortic	O
valve	O
disease	O
due	O
to	O
paradoxical	O
low	O
flow	O
stenosis	O
previously	O
unknown	O
.	O
In	O
view	O
of	O
these	O
results	O
,	O
it	O
was	O
decided	O
to	O
complete	O
the	O
study	O
with	O
immunofixation	O
techniques	O
aimed	O
at	O
ruling	O
out	O
the	O
presence	O
of	O
a	O
monoclonal	O
component	O
in	O
blood	O
and	O
urine	O
,	O
a	O
characteristic	O
finding	O
of	O
the	O
most	O
frequent	O
subtype	O
of	O
cardiac	O
amyloidosis	O
,	O
secondary	O
to	O
light	O
chain	O
deposition	O
AL	O
amyloidosis	O
.	O
After	O
ruling	O
out	O
the	O
presence	O
of	O
Bence	O
Jones	O
proteinuria	O
or	O
elevated	O
plasma	O
light	O
chains	O
,	O
a	O
bone	O
scintigraphy	O
study	O
with	O
99mTc	O
DPD	O
was	O
requested	O
,	O
which	O
showed	O
intense	O
left	O
ventricular	O
uptake	O
,	O
significantly	O
higher	O
than	O
bone	O
uptake	O
,	O
a	O
finding	O
highly	O
suggestive	O
of	O
cardiac	O
amyloidosis	O
due	O
to	O
transthyretin	O
deposition	O
.	O
Finally	O
,	O
the	O
study	O
was	O
completed	O
with	O
a	O
biopsy	O
of	O
abdominal	O
fat	O
in	O
which	O
the	O
diagnosis	O
of	O
senile	O
amyloidosis	O
due	O
to	O
free	O
transthyretin	O
deposition	O
was	O
confirmed	O
.	O
After	O
reaching	O
a	O
consensus	O
with	O
the	O
patient	O
on	O
a	O
conservative	O
approach	O
to	O
the	O
management	O
of	O
his	O
aortic	O
valve	O
disease	O
and	O
given	O
the	O
clinical	O
stability	O
achieved	O
,	O
he	O
was	O
discharged	O
home	O
after	O
pharmacological	O
adjustment	O
for	O
outpatient	O
clinical	O
follow	O
up	O
in	O
cardiology	O
consultations	O
.	O
DIAGNOSIS	O
Decompensated	O
heart	O
failure	O
in	O
the	O
context	O
of	O
lower	O
respiratory	O
tract	O
infection	O
.	O
Preserved	O
LVEF	O
.	O
Senile	O
cardiac	O
amyloidosis	O
due	O
to	O
abnormal	O
transthyretin	O
deposition	O
.	O
Paradoxical	O
"	O
severe	O
low	O
flow	O
aortic	O
valve	O
stenosis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
45	O
year	O
old	O
woman	O
with	O
type	O
2	O
diabetes	O
.	O
In	O
2007	O
she	O
was	O
diagnosed	O
with	O
non	O
obstructive	O
hypertrophic	O
cardiomyopathy	O
,	O
initially	O
with	O
normal	O
ventricular	O
function	O
,	O
although	O
since	O
2012	O
she	O
had	O
severe	O
left	O
ventricular	O
dysfunction	O
and	O
moderate	O
right	O
ventricular	O
dysfunction	O
.	O
He	O
had	O
also	O
undergone	O
ablation	O
of	O
three	O
accessory	O
pathways	O
due	O
to	O
Wolff	O
Parkinson	O
White	O
syndrome	O
and	O
in	O
2012	O
required	O
pacemaker	O
implantation	O
due	O
to	O
high	O
grade	O
AV	O
block	O
.	O
Other	O
antecedents	O
include	O
cochlear	O
implantation	O
in	O
the	O
right	O
ear	O
in	O
2004	O
for	O
sensorineural	O
deafness	O
.	O
Baseline	O
independent	O
for	O
activities	O
of	O
daily	O
living	O
,	O
in	O
NYHA	O
functional	O
class	O
III	O
,	O
without	O
angina	O
.	O
Usual	O
treatment	O
bisoprolol	B-FARMACO
1	O
.	O
25	O
mg	O
,	O
eplerenone	B-FARMACO
25	O
mg	O
,	O
sitagliptin	B-FARMACO
25	O
mg	O
,	O
paracetamol	B-FARMACO
on	O
demand	O
.	O
Admitted	O
to	O
our	O
hospital	O
in	O
January	O
2016	O
due	O
to	O
worsening	O
functional	O
class	O
,	O
presenting	O
dyspnoea	O
at	O
rest	O
and	O
bendopnoea	O
,	O
without	O
orthopnoea	O
or	O
DPN	O
.	O
Examination	O
revealed	O
BP	O
80	O
50	O
mmHg	O
,	O
HR	O
77	O
bpm	O
,	O
O2	O
saturation	O
96	O
on	O
room	O
air	O
,	O
with	O
no	O
evidence	O
of	O
congestion	O
on	O
pulmonary	O
auscultation	O
,	O
and	O
no	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
Hb	O
13	O
.	O
9	O
g	O
dl	O
;	O
leukocytes	O
8	O
,	O
240	O
ul	O
;	O
platelets	O
147	O
,	O
000	O
ul	O
;	O
urea	O
89	O
mg	O
dl	O
;	O
creatinine	O
0	O
.	O
96	O
mg	O
dl	O
;	O
Na	O
143	O
mEq	O
l	O
;	O
K	O
4	O
.	O
0	O
mEq	O
l	O
;	O
glucose	O
76	O
mg	O
dl	O
,	O
HbA1c	O
7	O
.	O
1	O
.	O
Total	O
cholesterol	O
138	O
mg	O
dl	O
;	O
HDL	O
30	O
mg	O
dl	O
;	O
LDL	O
93	O
mg	O
dl	O
;	O
TG	O
75	O
mg	O
dl	O
.	O
INR	O
1	O
.	O
3	O
.	O
NT	O
proBNP	O
6	O
,	O
903	O
ng	O
dl	O
.	O
Normal	O
liver	O
and	O
iron	O
profile	O
.	O
Chest	O
X	O
ray	O
bicameral	O
pacemaker	O
.	O
Cardiomegaly	O
.	O
Free	O
costophrenic	O
sinuses	O
,	O
with	O
no	O
signs	O
of	O
pulmonary	O
congestion	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
with	O
pacemaker	O
mediated	O
ventricular	O
pacing	O
.	O
Echocardiogram	O
non	O
dilated	O
LV	O
,	O
with	O
severe	O
asymmetric	O
hypertrophy	O
,	O
with	O
no	O
evidence	O
of	O
dynamic	O
obstruction	O
at	O
the	O
outflow	O
tract	O
level	O
.	O
Severely	O
depressed	O
global	O
systolic	O
function	O
LVEF	O
by	O
Simpson	O
biplane	O
21	O
.	O
Pseudonormal	O
filling	O
pattern	O
.	O
Hypertrophic	O
RV	O
with	O
moderate	O
systolic	O
dysfunction	O
shortening	O
fraction	O
29	O
.	O
Mild	O
MI	O
.	O
Mild	O
AoI	O
.	O
Mild	O
TR	O
,	O
allowing	O
estimation	O
of	O
a	O
PSAP	O
of	O
32	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
EVOLUTION	O
During	O
admission	O
,	O
diuretic	O
treatment	O
was	O
adjusted	O
and	O
the	O
patient	O
was	O
discharged	O
from	O
hospital	O
after	O
7	O
days	O
.	O
The	O
patient	O
was	O
asked	O
about	O
her	O
family	O
history	O
and	O
it	O
was	O
noted	O
that	O
three	O
of	O
her	O
seven	O
sisters	O
were	O
diabetic	O
and	O
had	O
a	O
cochlear	O
implant	O
.	O
Therefore	O
,	O
this	O
is	O
a	O
patient	O
with	O
hearing	O
loss	O
and	O
diabetes	O
both	O
at	O
an	O
early	O
age	O
and	O
with	O
a	O
family	O
history	O
and	O
hypertrophic	O
cardiomyopathy	O
.	O
A	O
genetic	O
study	O
was	O
requested	O
,	O
which	O
subsequently	O
confirmed	O
the	O
existence	O
of	O
the	O
3243A	O
G	O
mutation	O
,	O
establishing	O
the	O
diagnosis	O
of	O
MELAS	O
syndrome	O
Mitochondrial	O
Encephalomyopathy	O
with	O
Mitochondrial	O
Encephalomyopathy	O
with	O
Mitochondrial	O
Syndrome	O
Encephalomyopathy	O
with	O
Lactic	O
Acidosis	O
and	O
Stroke	O
like	O
episodes	O
.	O
Two	O
months	O
later	O
,	O
the	O
patient	O
showed	O
subjective	O
clinical	O
improvement	O
,	O
started	O
a	O
cardiac	O
rehabilitation	O
programme	O
and	O
continued	O
with	O
a	O
tendency	O
to	O
arterial	O
hypotension	O
.	O
Four	O
months	O
after	O
hospital	O
discharge	O
,	O
the	O
patient	O
was	O
upgraded	O
to	O
a	O
three	O
chamber	O
ICD	O
CRT	O
without	O
complications	O
.	O
Better	O
tolerance	O
to	O
physical	O
activity	O
since	O
starting	O
cardiac	O
rehabilitation	O
,	O
but	O
is	O
in	O
NYHA	O
functional	O
class	O
II	O
III	O
.	O
She	O
was	O
assessed	O
by	O
Neurology	O
,	O
who	O
considered	O
that	O
the	O
neurological	O
involvement	O
did	O
not	O
seem	O
to	O
be	O
significant	O
,	O
and	O
that	O
cases	O
of	O
stroke	O
were	O
more	O
frequent	O
at	O
younger	O
ages	O
and	O
in	O
males	O
affected	O
by	O
the	O
disease	O
,	O
so	O
the	O
neurological	O
prognosis	O
did	O
not	O
seem	O
to	O
be	O
limiting	O
in	O
this	O
patient	O
.	O
In	O
accordance	O
with	O
the	O
poor	O
functional	O
class	O
and	O
the	O
progressive	O
nature	O
of	O
the	O
cardiac	O
involvement	O
,	O
as	O
well	O
as	O
the	O
scarce	O
significant	O
associated	O
comorbidity	O
,	O
referral	O
was	O
made	O
to	O
another	O
hospital	O
for	O
evaluation	O
of	O
cardiac	O
transplantation	O
.	O
Virus	O
serology	O
,	O
respiratory	O
function	O
tests	O
and	O
abdominal	O
ultrasound	O
were	O
performed	O
,	O
with	O
normal	O
results	O
.	O
However	O
,	O
the	O
patient	O
was	O
not	O
placed	O
on	O
the	O
transplant	O
waiting	O
list	O
due	O
to	O
severe	O
depressive	O
disorder	O
.	O
DIAGNOSIS	O
MELAS	O
syndrome	O
Non	O
obstructive	O
hypertrophic	O
cardiomyopathy	O
in	O
dilated	O
phase	O
.	O
Biventricular	O
involvement	O
with	O
severe	O
LV	O
systolic	O
dysfunction	O
and	O
moderate	O
RV	O
systolic	O
dysfunction	O
.	O
Heart	O
failure	O
in	O
NYHA	O
functional	O
class	O
II	O
III	O
.	O
Wolff	O
Parkinson	O
White	O
syndrome	O
with	O
ablation	O
of	O
3	O
accessory	O
pathways	O
.	O
High	O
degree	O
AV	O
block	O
,	O
carrier	O
of	O
a	O
bicameral	O
pacemaker	O
with	O
upgrade	O
to	O
ICD	O
CRT	O
.	O
Sensorineural	O
deafness	O
,	O
cochlear	O
implant	O
carrier	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
53	O
year	O
old	O
woman	O
,	O
diagnosed	O
with	O
mild	O
dyslipidaemia	O
for	O
the	O
last	O
5	O
years	O
on	O
dietary	O
treatment	O
.	O
No	O
other	O
known	O
risk	O
factors	O
or	O
toxic	O
habits	O
.	O
No	O
medication	O
at	O
home	O
.	O
In	O
the	O
previous	O
48	O
hours	O
she	O
presented	O
with	O
episodes	O
of	O
self	O
limiting	O
central	O
thoracic	O
pain	O
,	O
without	O
seeking	O
medical	O
assistance	O
.	O
At	O
around	O
10	O
am	O
,	O
while	O
having	O
breakfast	O
,	O
she	O
suffered	O
a	O
new	O
episode	O
of	O
typical	O
central	O
thoracic	O
pain	O
accompanied	O
by	O
vegetative	O
cortex	O
,	O
for	O
which	O
she	O
went	O
to	O
the	O
emergency	O
department	O
accompanied	O
by	O
her	O
family	O
11	O
20	O
am	O
.	O
After	O
syncopal	O
symptoms	O
in	O
the	O
triage	O
area	O
,	O
she	O
was	O
transferred	O
to	O
observation	O
,	O
and	O
VT	O
was	O
observed	O
at	O
220	O
bpm	O
.	O
Basic	O
CPR	O
manoeuvres	O
were	O
started	O
5	O
min	O
duration	O
,	O
followed	O
by	O
CVE	O
at	O
200	O
J	O
,	O
with	O
an	O
asystole	O
rhythm	O
.	O
2	O
mg	O
of	O
atropine	B-FARMACO
is	O
administered	O
.	O
Advanced	O
CPR	O
for	O
5	O
min	O
,	O
achieving	O
pulse	O
total	O
CPR	O
10	O
min	O
and	O
sinus	O
rhythm	O
at	O
85	O
bpm	O
with	O
significant	O
ST	O
elevation	O
in	O
anterior	O
leads	O
.	O
Amiodarone	B-FARMACO
infusion	O
1	O
,	O
200	O
mg	O
was	O
started	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
haemodynamics	O
ward	O
for	O
urgent	O
catheterisation	O
.	O
During	O
the	O
transfer	O
,	O
an	O
episode	O
of	O
NSVT	O
at	O
200	O
bpm	O
was	O
recorded	O
,	O
followed	O
by	O
sinus	O
rhythm	O
and	O
complete	O
AVB	O
after	O
10	O
15	O
min	O
.	O
Advanced	O
CPR	O
was	O
performed	O
again	O
for	O
30	O
minutes	O
with	O
orotracheal	O
intubation	O
and	O
adrenaline	B-FARMACO
perfusion	O
was	O
started	O
.	O
In	O
the	O
haemodynamics	O
room	O
,	O
a	O
transient	O
pacemaker	O
was	O
implanted	O
via	O
the	O
right	O
femoral	O
artery	O
and	O
cardiac	O
catheterisation	O
was	O
performed	O
via	O
femoral	O
access	O
,	O
which	O
revealed	O
3	O
vessel	O
coronary	O
artery	O
disease	O
and	O
complete	O
revascularisation	O
was	O
performed	O
.	O
In	O
addition	O
,	O
an	O
intra	O
aortic	O
balloon	O
pump	O
was	O
placed	O
with	O
1	O
1	O
assistance	O
.	O
During	O
catheterisation	O
,	O
a	O
nasogastric	O
tube	O
is	O
inserted	O
and	O
300	O
mg	O
of	O
ASA	B-FARMACO
and	O
180	O
mg	O
of	O
ticagrelor	B-FARMACO
are	O
administered	O
.	O
A	O
bolus	O
of	O
abciximab	B-FARMACO
is	O
administered	O
and	O
the	O
intravenous	O
infusion	O
is	O
continued	O
.	O
A	O
few	O
minutes	O
later	O
,	O
she	O
started	O
bleeding	O
in	O
the	O
oral	O
cavity	O
and	O
through	O
the	O
endotracheal	O
tube	O
,	O
and	O
abciximab	B-FARMACO
was	O
discontinued	O
.	O
At	O
the	O
end	O
of	O
the	O
catheterisation	O
,	O
the	O
adrenaline	B-FARMACO
infusion	O
was	O
withdrawn	O
.	O
She	O
arrived	O
at	O
the	O
ICU	O
without	O
vasoactive	O
drugs	O
,	O
connected	O
to	O
mechanical	O
ventilation	O
.	O
She	O
suffered	O
another	O
cardiorespiratory	O
arrest	O
,	O
her	O
third	O
,	O
this	O
time	O
in	O
asystole	O
.	O
She	O
was	O
resuscitated	O
for	O
15	O
minutes	O
2	O
mg	O
of	O
adrenaline	B-FARMACO
,	O
leaving	O
in	O
sinus	O
rhythm	O
.	O
Examination	O
on	O
admission	O
to	O
the	O
ICU	O
revealed	O
BP	O
100	O
80	O
mmHg	O
,	O
HR	O
100	O
bpm	O
,	O
RR	O
18	O
rpm	O
.	O
Neurological	O
examination	O
bilateral	O
mydriasis	O
,	O
Glasgow	O
Coma	O
Scale	O
score	O
of	O
3	O
.	O
Pulmonary	O
auscultation	O
with	O
bibasal	O
crackles	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
,	O
counterpulsation	O
noises	O
.	O
Extremities	O
with	O
peripheral	O
coldness	O
,	O
weak	O
distal	O
pulses	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
after	O
1st	O
CRP	O
RS	O
at	O
85	O
bpm	O
,	O
PR	O
200	O
ms	O
,	O
QRS	O
120	O
ms	O
,	O
significant	O
ST	O
segment	O
elevation	O
in	O
anterior	O
leads	O
V1	O
to	O
V4	O
.	O
Urgent	O
cardiac	O
catheterisation	O
3	O
vessel	O
coronary	O
artery	O
disease	O
.	O
Lesions	O
in	O
DA	O
proximal	O
occlusion	O
,	O
CX	O
OM	O
with	O
90	O
stenosis	O
and	O
CD	O
mid	O
level	O
occlusion	O
.	O
Complete	O
revascularisation	O
with	O
2	O
stents	O
in	O
LAD	O
,	O
1	O
in	O
OM	O
and	O
1	O
in	O
DC	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
non	O
selective	O
orotracheal	O
intubation	O
.	O
Bilateral	O
alveolointerstitial	O
pattern	O
.	O
Echocardiogram	O
in	O
ICU	O
left	O
ventricle	O
not	O
dilated	O
,	O
not	O
hypertrophic	O
,	O
with	O
moderately	O
depressed	O
systolic	O
function	O
EF	O
35	O
40	O
,	O
with	O
septal	O
akinesia	O
,	O
anterior	O
and	O
apical	O
segments	O
.	O
Better	O
contractility	O
in	O
basal	O
and	O
medial	O
lateral	O
and	O
basal	O
and	O
medial	O
anterior	O
.	O
Right	O
ventricle	O
not	O
dilated	O
,	O
with	O
normal	O
systolic	O
function	O
by	O
TAPSE	O
.	O
Left	O
atrium	O
not	O
dilated	O
.	O
Normal	O
aortic	O
root	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
,	O
collapsing	O
on	O
inspiration	O
.	O
Laboratory	O
tests	O
on	O
admission	O
haemoglobin	O
14	O
.	O
8	O
mg	O
dl	O
,	O
leucocytes	O
11	O
,	O
250	O
ul	O
,	O
platelets	O
376	O
,	O
000	O
ul	O
.	O
Glucose	O
130	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
7	O
mg	O
dl	O
,	O
Na	O
139	O
mEq	O
l	O
,	O
K	O
4	O
.	O
6	O
mEq	O
l	O
,	O
GOT	O
571	O
IU	O
l	O
,	O
LDH	O
1	O
,	O
854	O
IU	O
l	O
,	O
peak	O
CK	O
3	O
,	O
254	O
IU	O
l	O
,	O
troponinT	O
US	O
20	O
,	O
641	O
ng	O
ml	O
,	O
CRP	O
73	O
.	O
3	O
mg	O
l	O
.	O
Cardiology	O
laboratory	O
tests	O
haemoglobin	O
12	O
.	O
5	O
mg	O
dl	O
,	O
leucocytes	O
14	O
.	O
460	O
ul	O
,	O
platelets	O
631	O
,	O
000	O
ul	O
,	O
glycaemia	O
118	O
mg	O
dl	O
,	O
urea	O
58	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
8	O
mg	O
dl	O
,	O
triglycerides	O
385	O
mg	O
dl	O
,	O
total	O
cholesterol	O
199	O
mg	O
dl	O
LDL	O
145	O
mg	O
dl	O
,	O
HDL	O
30	O
mg	O
dl	O
,	O
GOT	O
74	O
IU	O
l	O
,	O
GPT	O
172	O
IU	O
l	O
,	O
GGT	O
501	O
IU	O
l	O
,	O
alkaline	O
phosphatase	O
243	O
IU	O
l	O
,	O
LDH	O
502	O
IU	O
l	O
.	O
Thyroid	O
function	O
free	O
T4	O
1	O
.	O
73	O
mg	O
dl	O
,	O
TSH	O
14	O
.	O
43	O
IUI	O
ml	O
.	O
ProBNP	O
2	O
,	O
663	O
pg	O
ml	O
.	O
EVOLUTION	O
During	O
the	O
first	O
8	O
hours	O
in	O
the	O
ICU	O
,	O
he	O
remained	O
in	O
cardiogenic	O
shock	O
and	O
low	O
cardiac	O
output	O
,	O
with	O
cardiac	O
index	O
of	O
1	O
.	O
5	O
L	O
min	O
m2	O
,	O
need	O
for	O
vasoactive	O
drugs	O
at	O
very	O
high	O
doses	O
dobutamine	B-FARMACO
and	O
noradrenaline	B-FARMACO
and	O
signs	O
of	O
peripheral	O
hypoperfusion	O
,	O
with	O
lactate	O
up	O
to	O
16	O
mmol	O
l	O
,	O
oliguric	O
renal	O
dysfunction	O
and	O
pulmonary	O
oedema	O
with	O
severe	O
respiratory	O
failure	O
requiring	O
mechanical	O
ventilation	O
and	O
FiO2	O
of	O
100	O
.	O
It	O
was	O
decided	O
to	O
place	O
cardiorespiratory	O
support	O
in	O
the	O
form	O
of	O
venoarterial	O
ECMO	O
,	O
which	O
was	O
performed	O
in	O
the	O
operating	O
theatre	O
by	O
Cardiac	O
Surgery	O
after	O
8	O
hours	O
of	O
stay	O
in	O
the	O
ICU	O
.	O
After	O
ECMO	O
placement	O
,	O
haemodynamic	O
improvement	O
was	O
observed	O
with	O
withdrawal	O
of	O
vasoactive	O
agents	O
after	O
24	O
hours	O
.	O
Assistance	O
was	O
started	O
with	O
4	O
l	O
min	O
,	O
which	O
was	O
progressively	O
reduced	O
until	O
weaning	O
was	O
achieved	O
on	O
the	O
fourth	O
day	O
after	O
placement	O
.	O
In	O
the	O
following	O
days	O
haemodynamic	O
stability	O
was	O
maintained	O
with	O
a	O
cardiac	O
index	O
of	O
3	O
l	O
min	O
m2	O
under	O
treatment	O
with	O
levosimendan	B-FARMACO
and	O
dobutamine	B-FARMACO
.	O
Echocardiography	O
showed	O
moderate	O
ventricular	O
dysfunction	O
with	O
an	O
estimated	O
LVEF	O
of	O
35	O
40	O
.	O
Initially	O
,	O
the	O
patient	O
presented	O
mild	O
delirium	O
and	O
tetraparesis	O
,	O
which	O
recovered	O
quickly	O
,	O
waking	O
up	O
clearly	O
,	O
without	O
neurological	O
focality	O
.	O
Given	O
his	O
stability	O
and	O
improvement	O
,	O
it	O
was	O
decided	O
to	O
transfer	O
him	O
to	O
the	O
Cardiology	O
ward	O
for	O
further	O
care	O
and	O
treatment	O
.	O
Favourable	O
evolution	O
on	O
the	O
cardiology	O
ward	O
,	O
tolerating	O
treatment	O
with	O
beta	O
blockers	O
,	O
ACE	O
inhibitors	O
and	O
amiodarone	B-FARMACO
until	O
she	O
became	O
asymptomatic	O
from	O
the	O
cardiological	O
point	O
of	O
view	O
.	O
She	O
presented	O
significant	O
elevation	O
of	O
transaminases	O
,	O
myalgias	O
and	O
general	O
malaise	O
that	O
resolved	O
after	O
discontinuation	O
of	O
statin	O
treatment	O
.	O
Atorvastatin	B-FARMACO
80	O
40	O
mg	O
,	O
simvastatin	B-FARMACO
40	O
mg	O
,	O
rosuvastatin	B-FARMACO
20	O
mg	O
were	O
tried	O
.	O
Hypercholesterolaemia	O
persists	O
with	O
total	O
cholesterol	O
257	O
mg	O
dl	O
,	O
LDL	O
151	O
mg	O
dl	O
,	O
HDL	O
34	O
mg	O
dl	O
and	O
triglycerides	O
580	O
mg	O
dl	O
despite	O
treatment	O
with	O
ezetimibe	B-FARMACO
10	O
mg	O
and	O
fibrates	O
.	O
It	O
was	O
decided	O
to	O
start	O
treatment	O
with	O
PCSK9	O
inhibitors	O
evolocumab	B-FARMACO
140	O
mg	O
every	O
15	O
days	O
and	O
she	O
was	O
included	O
in	O
a	O
cardiac	O
rehabilitation	O
programme	O
.	O
She	O
started	O
with	O
very	O
low	O
capacity	O
,	O
which	O
gradually	O
increased	O
,	O
with	O
very	O
good	O
progress	O
.	O
She	O
completed	O
a	O
total	O
of	O
60	O
treadmill	O
sessions	O
and	O
completed	O
the	O
cardiac	O
rehabilitation	O
programme	O
without	O
complications	O
.	O
Improvement	O
in	O
functional	O
class	O
for	O
dyspnoea	O
,	O
Borg	O
scale	O
3	O
4	O
.	O
Training	O
HR	O
85	O
100	O
bpm	O
.	O
No	O
clinical	O
signs	O
of	O
angina	O
with	O
the	O
effort	O
achieved	O
.	O
Adequate	O
LDL	O
control	O
is	O
achieved	O
with	O
figures	O
of	O
31	O
mg	O
dl	O
.	O
DIAGNOSIS	O
Resuscitated	O
cardiorespiratory	O
arrest	O
.	O
Acute	O
anterior	O
myocardial	O
infarction	O
,	O
Killip	O
IV	O
.	O
3	O
vessel	O
coronary	O
artery	O
disease	O
,	O
urgent	O
complete	O
revascularisation	O
.	O
Moderate	O
severe	O
LV	O
systolic	O
dysfunction	O
.	O
Transient	O
ECMO	O
support	O
.	O
Hypercholesterolemia	O
with	O
intolerance	O
to	O
statins	B-FARMACO
.	O
Good	O
LDL	O
control	O
with	O
anti	O
PCSK9	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
are	O
dealing	O
with	O
a	O
70	O
year	O
old	O
patient	O
with	O
no	O
known	O
drug	O
allergies	O
or	O
toxic	O
habits	O
;	O
no	O
known	O
diabetes	O
mellitus	O
but	O
hypertensive	O
and	O
dyslipidaemic	O
.	O
He	O
has	O
a	O
family	O
history	O
of	O
ischaemic	O
heart	O
disease	O
.	O
The	O
patient	O
's	O
cardiological	O
history	O
began	O
in	O
July	O
2012	O
,	O
when	O
Holter	O
monitoring	O
was	O
requested	O
after	O
presenting	O
symptomatic	O
bradycardia	O
that	O
required	O
chronotropic	O
drugs	O
during	O
arthroscopy	O
.	O
The	O
24	O
hour	O
recording	O
showed	O
spells	O
of	O
atrial	O
fibrillation	O
with	O
MVF	O
100	O
bpm	O
max	O
150	O
alternating	O
with	O
the	O
patient	O
's	O
baseline	O
rhythm	O
which	O
was	O
sinus	O
bradycardia	O
45	O
bpm	O
.	O
An	O
echocardiographic	O
study	O
was	O
completed	O
,	O
with	O
no	O
abnormalities	O
.	O
In	O
November	O
2012	O
,	O
a	O
bicameral	O
pacemaker	O
was	O
implanted	O
via	O
the	O
subclavian	O
artery	O
and	O
anticoagulation	O
with	O
acenocoumarol	B-FARMACO
was	O
started	O
.	O
Due	O
to	O
persistent	O
atrial	O
fibrillation	O
with	O
poor	O
clinical	O
control	O
,	O
electrical	O
cardioversion	O
was	O
performed	O
and	O
she	O
was	O
discharged	O
with	O
amiodarone	B-FARMACO
200	O
mg	O
24	O
h	O
and	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
h	O
,	O
in	O
addition	O
to	O
anticoagulation	O
.	O
In	O
January	O
2014	O
,	O
he	O
was	O
referred	O
to	O
the	O
outpatient	O
cardiology	O
department	O
for	O
dyspnoea	O
and	O
chest	O
tightness	O
related	O
to	O
exertion	O
of	O
2	O
months	O
'	O
duration	O
.	O
An	O
echocardiogram	O
was	O
performed	O
showing	O
LV	O
with	O
moderately	O
depressed	O
EF	O
.	O
Depletive	O
treatment	O
was	O
started	O
furosemide	B-FARMACO
and	O
eplerenone	B-FARMACO
and	O
an	O
analytical	O
study	O
and	O
coronary	O
angiography	O
were	O
requested	O
.	O
Coronary	O
angiography	O
showed	O
stenosis	O
of	O
the	O
proximal	O
anterior	O
descending	O
artery	O
DAp	O
80	O
,	O
circumflex	O
at	O
the	O
level	O
of	O
the	O
exit	O
of	O
the	O
first	O
obtuse	O
marginal	O
Cx	O
OM1	O
100	O
and	O
proximal	O
right	O
coronary	O
CDp	O
90	O
,	O
and	O
middle	O
CDm	O
60	O
,	O
opting	O
for	O
surgical	O
revascularisation	O
.	O
The	O
intervention	O
was	O
performed	O
in	O
September	O
2014	O
,	O
with	O
triple	O
coronary	O
puncture	O
to	O
the	O
middle	O
LAD	O
with	O
internal	O
mammary	O
artery	O
IMA	O
and	O
sequence	O
with	O
saphenous	O
vein	O
SVF	O
to	O
1st	O
OM	O
and	O
posterolateral	O
branches	O
.	O
Postoperative	O
evolution	O
was	O
torpid	O
with	O
multiple	O
admissions	O
for	O
dyspnoea	O
and	O
cardiac	O
decompensation	O
.	O
SPECT	O
was	O
performed	O
and	O
showed	O
mild	O
lateral	O
ischaemia	O
,	O
so	O
a	O
new	O
coronary	O
angiography	O
was	O
requested	O
,	O
showing	O
patency	O
of	O
all	O
bypasses	O
performed	O
.	O
The	O
MCP	O
was	O
reviewed	O
,	O
revealing	O
MCP	O
dysfunction	O
,	O
which	O
was	O
corrected	O
by	O
modifying	O
the	O
programming	O
.	O
Since	O
then	O
,	O
asymptomatic	O
in	O
functional	O
class	O
II	O
.	O
Treatment	O
with	O
amiodarone	B-FARMACO
was	O
withdrawn	O
and	O
replaced	O
with	O
dronedarone	B-FARMACO
due	O
to	O
hypothyroidism	O
.	O
He	O
repeatedly	O
consulted	O
for	O
muscle	O
pain	O
related	O
to	O
statins	B-FARMACO
simvastatin	I-FARMACO
10	O
mg	O
and	O
atorvastatin	B-FARMACO
10	O
mg	O
,	O
for	O
which	O
he	O
was	O
referred	O
to	O
the	O
Lipidology	O
unit	O
of	O
reference	O
,	O
despite	O
which	O
the	O
myalgias	O
always	O
recurred	O
with	O
the	O
reintroduction	O
of	O
statins	B-FARMACO
.	O
Finally	O
,	O
given	O
the	O
high	O
cardiovascular	O
risk	O
,	O
intolerance	O
to	O
lipid	O
lowering	O
drugs	O
and	O
severe	O
dyslipidaemia	O
,	O
treatment	O
with	O
IPCSK9	O
was	O
started	O
with	O
good	O
tolerance	O
and	O
LDL	O
levels	O
were	O
reduced	O
to	O
88	O
mg	O
dl	O
from	O
an	O
initial	O
level	O
of	O
218	O
mg	O
dl	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
12	O
07	O
16	O
patient	O
's	O
baseline	O
creatinine	O
0	O
.	O
98	O
mg	O
dl	O
,	O
urea	O
38	O
.	O
8	O
mg	O
dl	O
,	O
total	O
cholesterol	O
289	O
mg	O
dl	O
,	O
HDL	O
44	O
mg	O
dl	O
,	O
LDL	O
218	O
mg	O
dl	O
,	O
TG	O
240	O
mg	O
dl	O
,	O
AST	O
22U	O
l	O
,	O
ALT	O
23	O
U	O
l	O
,	O
GGT	O
52	O
U	O
l	O
,	O
FA	O
72	O
U	O
l	O
,	O
sodium	O
143	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
3	O
mEq	O
l	O
,	O
TSH	O
2	O
.	O
27	O
IUI	O
ml	O
,	O
T4L	O
1	O
.	O
14	O
ng	O
dl	O
.	O
Hb	O
16	O
.	O
4	O
g	O
dl	O
,	O
Ht	O
50	O
.	O
5	O
,	O
leukocytes	O
7	O
.	O
11	O
x	O
10	O
9	O
L	O
,	O
platelets	O
164x10	O
9	O
L	O
.	O
Blood	O
tests	O
15	O
11	O
16	O
after	O
3	O
months	O
with	O
IPCSK9	O
creatinine	O
0	O
.	O
93mg	O
dl	O
,	O
urea	O
49	O
.	O
6	O
mg	O
dl	O
,	O
total	O
cholesterol	O
201	O
.	O
6	O
mg	O
dl	O
,	O
HDL	O
44	O
mg	O
dl	O
,	O
LDL	O
109	O
.	O
6mg	O
dl	O
,	O
AST	O
26U	O
l	O
,	O
ALT	O
24	O
U	O
l	O
,	O
GGT	O
56	O
U	O
l	O
,	O
FA	O
77	O
U	O
l	O
,	O
sodium	O
143	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
5	O
mEq	O
l	O
,	O
TSH	O
2	O
.	O
47	O
IUI	O
ml	O
,	O
T4L	O
1	O
.	O
3	O
ng	O
dl	O
.	O
Hb	O
17	O
g	O
dl	O
,	O
Hto	O
52	O
.	O
6	O
,	O
leukocytes	O
6	O
.	O
24	O
x	O
10	O
9	O
l	O
,	O
platelets	O
172x10	O
9	O
l	O
.	O
After	O
this	O
analytical	O
result	O
,	O
he	O
decided	O
to	O
increase	O
the	O
dose	O
of	O
IPCSK9	O
from	O
75	O
mg	O
to	O
150	O
mg	O
fortnightly	O
.	O
Blood	O
tests	O
06	O
04	O
17	O
control	O
6	O
months	O
after	O
starting	O
treatment	O
creatinine	O
0	O
.	O
76	O
mg	O
dl	O
,	O
urea	O
53	O
.	O
6	O
mg	O
dl	O
,	O
total	O
cholesterol	O
162	O
mg	O
dl	O
,	O
HDL	O
45	O
mg	O
dl	O
,	O
LDL	O
88	O
.	O
40	O
mg	O
dl	O
,	O
TG	O
143	O
mg	O
dl	O
,	O
AST	O
24U	O
l	O
,	O
ALT	O
25	O
U	O
l	O
,	O
GGT	O
44	O
U	O
l	O
,	O
FA	O
77	O
U	O
l	O
,	O
sodium	O
143	O
mEq	O
l	O
,	O
potassium	O
5	O
.	O
1	O
mEq	O
l	O
,	O
TSH	O
2	O
.	O
59	O
IUI	O
ml	O
,	O
T4L	O
1	O
.	O
28	O
ng	O
dl	O
.	O
Hb	O
17	O
.	O
3	O
g	O
dl	O
,	O
Ht	O
53	O
.	O
5	O
,	O
leukocytes	O
6	O
.	O
11x	O
10	O
9	O
L	O
,	O
platelets	O
142x10	O
9	O
L	O
.	O
EVOLUTION	O
The	O
patient	O
is	O
currently	O
in	O
stable	O
class	O
of	O
his	O
cardiopathy	O
.	O
With	O
functional	O
class	O
II	O
,	O
asymptomatic	O
for	O
chest	O
pain	O
and	O
tolerating	O
medication	O
without	O
incident	O
.	O
The	O
last	O
echocardiogram	O
showed	O
recovery	O
of	O
the	O
ejection	O
fraction	O
,	O
which	O
was	O
classified	O
as	O
preserved	O
in	O
the	O
last	O
echocardiogram	O
.	O
Due	O
to	O
back	O
pain	O
that	O
had	O
been	O
present	O
for	O
months	O
,	O
an	O
abdominal	O
CT	O
scan	O
was	O
performed	O
,	O
which	O
revealed	O
an	O
abdominal	O
aortic	O
aneurysm	O
,	O
pending	O
surgery	O
for	O
the	O
placement	O
of	O
an	O
endoprosthesis	O
.	O
This	O
is	O
therefore	O
a	O
patient	O
at	O
very	O
high	O
cardiovascular	O
risk	O
due	O
to	O
ischaemic	O
heart	O
disease	O
,	O
aortic	O
vascular	O
disease	O
and	O
dyslipidaemia	O
in	O
whom	O
treatment	O
with	O
statins	B-FARMACO
was	O
not	O
possible	O
due	O
to	O
intolerance	O
,	O
in	O
whom	O
the	O
introduction	O
of	O
IPCSK9	O
has	O
managed	O
to	O
reduce	O
his	O
LDL	O
c	O
levels	O
by	O
more	O
than	O
50	O
,	O
and	O
he	O
is	O
increasingly	O
close	O
to	O
reaching	O
the	O
desired	O
level	O
for	O
his	O
high	O
cardiovascular	O
risk	O
,	O
which	O
is	O
less	O
than	O
70	O
mg	O
dL	O
.	O
DIAGNOSIS	O
Chronic	O
ischaemic	O
heart	O
disease	O
with	O
3	O
vessel	O
disease	O
.	O
History	O
of	O
triple	O
aorto	O
coronary	O
bypass	O
with	O
IMA	O
to	O
LAD	O
and	O
SFN	O
sequence	O
to	O
MO1	O
and	O
PD	O
.	O
Transient	O
left	O
ventricular	O
dysfunction	O
currently	O
normal	O
LVEF	O
.	O
Abdominal	O
aortic	O
aneurysm	O
pending	O
endovascular	O
repair	O
.	O
Stable	O
heart	O
failure	O
in	O
functional	O
class	O
II	O
.	O
Sinus	O
dysfunction	O
with	O
paroxysmal	O
AF	O
.	O
Carrier	O
of	O
normofunctioning	O
DDD	O
MCP	O
at	O
the	O
present	O
time	O
.	O
Severe	O
dyslipidaemia	O
.	O
Intolerance	O
to	O
statins	B-FARMACO
.	O
Treatment	O
with	O
IPCSK9	O
with	O
good	O
evolution	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
50	O
year	O
old	O
man	O
came	O
to	O
the	O
emergency	O
department	O
for	O
chest	O
pain	O
.	O
No	O
known	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
No	O
habitual	O
treatment	O
.	O
No	O
CVRF	O
.	O
Only	O
previous	O
history	O
of	O
tonsillectomy	O
in	O
childhood	O
and	O
left	O
meniscectomy	O
.	O
Asymptomatic	O
from	O
the	O
cardiological	O
point	O
of	O
view	O
,	O
until	O
the	O
early	O
morning	O
of	O
admission	O
4	O
00	O
a	O
.	O
m	O
.	O
.	O
He	O
started	O
with	O
shooting	O
pains	O
in	O
the	O
jaw	O
.	O
Subsequently	O
,	O
they	O
radiate	O
to	O
the	O
anterior	O
region	O
of	O
the	O
thorax	O
,	O
become	O
oppressive	O
,	O
of	O
moderate	O
intensity	O
,	O
without	O
vegetative	O
cortex	O
.	O
They	O
subside	O
spontaneously	O
one	O
hour	O
later	O
.	O
She	O
had	O
several	O
recurrences	O
,	O
of	O
greater	O
intensity	O
,	O
and	O
so	O
she	O
went	O
to	O
the	O
emergency	O
department	O
.	O
Arrives	O
more	O
than	O
6	O
hours	O
after	O
the	O
onset	O
of	O
the	O
symptoms	O
,	O
with	O
slight	O
residual	O
discomfort	O
.	O
She	O
improved	O
after	O
conventional	O
analgesia	O
.	O
On	O
arrival	O
she	O
was	O
haemodynamically	O
stable	O
.	O
BP	O
119	O
83	O
mmHg	O
;	O
HR	O
68	O
bpm	O
;	O
SatO2	O
98	O
on	O
room	O
air	O
;	O
Ta	O
36	O
.	O
1	O
C	O
.	O
Glasgow	O
Scale	O
15	O
15	O
.	O
Conscious	O
,	O
oriented	O
in	O
all	O
3	O
spheres	O
.	O
Eupneic	O
at	O
rest	O
,	O
well	O
hydrated	O
,	O
nourished	O
and	O
perfused	O
.	O
AC	O
rhythmic	O
without	O
murmurs	O
or	O
extratonos	O
.	O
PA	O
vesicular	O
murmur	O
preserved	O
in	O
both	O
lung	O
fields	O
with	O
no	O
extra	O
sounds	O
.	O
Abdomen	O
hydro	O
aerial	O
sounds	O
present	O
,	O
soft	O
,	O
not	O
painful	O
on	O
deep	O
or	O
superficial	O
palpation	O
.	O
Renal	O
fist	O
percussion	O
.	O
Extremities	O
no	O
oedema	O
,	O
no	O
signs	O
of	O
DVT	O
.	O
Basic	O
neurological	O
examination	O
was	O
normal	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
68	O
bpm	O
.	O
Poor	O
R	O
wave	O
growth	O
in	O
precordial	O
leads	O
,	O
isolated	O
Q	O
wave	O
in	O
lead	O
III	O
,	O
with	O
no	O
other	O
alterations	O
.	O
No	O
evolutionary	O
changes	O
in	O
subsequent	O
electrocardiograms	O
.	O
Portable	O
echocardiogram	O
Vscan	O
in	O
the	O
ER	O
LV	O
not	O
dilated	O
or	O
hypertrophic	O
,	O
with	O
normal	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O
Normal	O
aortic	O
root	O
.	O
RV	O
not	O
dilated	O
.	O
No	O
significant	O
valvulopathies	O
.	O
No	O
pleural	O
effusion	O
.	O
Haemogram	O
leucocytes	O
5	O
,	O
200	O
uL	O
;	O
neutrophils	O
61	O
.	O
3	O
;	O
lymphocytes	O
27	O
.	O
2	O
;	O
Hb	O
15	O
.	O
5	O
gr	O
dl	O
;	O
Htc	O
43	O
.	O
4	O
;	O
MCV	O
87	O
.	O
1	O
fl	O
;	O
platelets	O
180	O
,	O
000	O
uL	O
.	O
Haemostasis	O
APTT	O
29	O
.	O
3	O
sec	O
;	O
INR	O
1	O
.	O
Biochemistry	O
glucose	O
112	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
07	O
mg	O
dl	O
,	O
sodium	O
141	O
mmol	O
l	O
,	O
potassium	O
4	O
mmol	O
l	O
,	O
total	O
protein	O
6	O
.	O
3g	O
dl	O
,	O
albumin	O
3	O
.	O
7g	O
dl	O
,	O
calcium	O
8	O
.	O
6mg	O
dl	O
,	O
phosphorus	O
3	O
.	O
4	O
mg	O
dl	O
,	O
uric	O
acid	O
7	O
.	O
6	O
mg	O
dl	O
,	O
triglycerides	O
141	O
mg	O
dl	O
,	O
cholesterol	O
163	O
mg	O
dl	O
,	O
GOT	O
114	O
U	O
l	O
,	O
GPT	O
119	O
U	O
l	O
,	O
GGT	O
95	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
63	O
U	O
l	O
,	O
LDH	O
496	O
U	O
l	O
,	O
total	O
bilirubin	O
1	O
.	O
91	O
mg	O
dl	O
,	O
direct	O
bilirubin	O
0	O
.	O
52	O
mg	O
dl	O
.	O
Enzyme	O
serology	O
1a	O
CK	O
766	O
U	O
l	O
,	O
troponin	O
I	O
25	O
.	O
89	O
ng	O
ml	O
normal	O
0	O
.	O
06	O
.	O
2a	O
CK	O
727	O
U	O
I	O
troponin	O
I	O
36	O
.	O
13	O
ng	O
ml	O
.	O
3a	O
CK	O
696	O
U	O
I	O
,	O
troponin	O
I	O
27	O
.	O
52	O
ng	O
ml	O
.	O
Chest	O
X	O
ray	O
no	O
signs	O
of	O
CHF	O
or	O
parenchymal	O
infiltrates	O
.	O
Serology	O
IgM	O
HAV	O
negative	O
;	O
IgG	O
anti	O
HBc	O
negative	O
;	O
Anti	O
HCV	O
negative	O
;	O
IgM	O
anti	O
CMV	O
negative	O
;	O
IgM	O
against	O
VCA	O
negative	O
;	O
Anti	O
HIV	O
negative	O
;	O
Toxoplasmosis	O
IgG	O
IgM	O
negative	O
.	O
MRSA	O
culture	O
negative	O
.	O
Magnetic	O
resonance	O
imaging	O
MRI	O
Image	O
2	O
LV	O
with	O
preserved	O
systolic	O
function	O
.	O
Late	O
gadolinium	O
enhancement	O
in	O
basal	O
and	O
medial	O
,	O
anterior	O
,	O
lateral	O
and	O
inferior	O
segments	O
of	O
the	O
left	O
ventricle	O
,	O
respecting	O
only	O
the	O
interventricular	O
septum	O
and	O
apex	O
.	O
The	O
enhancement	O
shows	O
subepicardial	O
distribution	O
without	O
transmural	O
involvement	O
,	O
being	O
compatible	O
with	O
myocarditis	O
.	O
Coronary	O
angiography	O
LCT	O
,	O
LAD	O
and	O
DC	O
within	O
normality	O
.	O
Mild	O
stenosis	O
of	O
20	O
30	O
in	O
the	O
middle	O
CX	O
.	O
LVEF	O
preserved	O
in	O
ventriculography	O
.	O
No	O
images	O
suggestive	O
of	O
coronary	O
anomalies	O
,	O
dissection	O
or	O
thrombosis	O
.	O
EVOLUTION	O
Given	O
the	O
clinical	O
manifestations	O
of	O
chest	O
pain	O
and	O
enzyme	O
elevation	O
,	O
the	O
initial	O
diagnosis	O
of	O
NSTEACS	O
was	O
established	O
.	O
He	O
was	O
admitted	O
to	O
the	O
ICU	O
and	O
treatment	O
was	O
started	O
with	O
double	O
antiplatelet	O
therapy	O
and	O
anticoagulation	O
,	O
statins	O
and	O
beta	O
blockers	O
.	O
He	O
remained	O
haemodynamically	O
stable	O
,	O
asymptomatic	O
,	O
with	O
no	O
heart	O
rhythm	O
disturbances	O
or	O
evidence	O
of	O
CHF	O
.	O
Serialisation	O
of	O
markers	O
of	O
myocardial	O
damage	O
showed	O
a	O
clear	O
increase	O
,	O
in	O
addition	O
to	O
continuing	O
with	O
mild	O
chest	O
pain	O
.	O
Coronary	O
angiography	O
was	O
performed	O
and	O
no	O
coronary	O
pathology	O
was	O
found	O
to	O
justify	O
the	O
clinical	O
picture	O
.	O
Laboratory	O
tests	O
showed	O
an	O
increase	O
in	O
transaminases	O
and	O
bilirubin	O
with	O
no	O
clinical	O
alterations	O
on	O
examination	O
at	O
the	O
digestive	O
level	O
,	O
so	O
a	O
viral	O
serology	O
study	O
was	O
requested	O
.	O
In	O
view	O
of	O
the	O
coronary	O
angiography	O
findings	O
,	O
the	O
patient	O
was	O
questioned	O
again	O
and	O
reported	O
that	O
in	O
the	O
last	O
2	O
months	O
he	O
had	O
presented	O
catarrhal	O
symptoms	O
and	O
pharyngitis	O
with	O
clinical	O
symptoms	O
the	O
week	O
prior	O
to	O
admission	O
of	O
general	O
malaise	O
,	O
myalgia	O
and	O
dysthermic	O
sensation	O
with	O
fever	O
of	O
up	O
to	O
37	O
.	O
4	O
C	O
,	O
with	O
good	O
response	O
to	O
paracetamol	B-FARMACO
.	O
In	O
the	O
presence	O
of	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
,	O
chest	O
pain	O
after	O
respiratory	O
infection	O
and	O
elevated	O
markers	O
of	O
myocardial	O
damage	O
,	O
myocarditis	O
was	O
suspected	O
.	O
Treatment	O
for	O
NSTEACS	O
was	O
suspended	O
.	O
The	O
patient	O
remained	O
stable	O
on	O
the	O
ward	O
,	O
with	O
no	O
recurrence	O
of	O
chest	O
pain	O
,	O
heart	O
failure	O
or	O
arrhythmias	O
.	O
An	O
echocardiographic	O
study	O
prior	O
to	O
discharge	O
showed	O
preserved	O
LVEF	O
with	O
no	O
alterations	O
in	O
global	O
or	O
segmental	O
contractility	O
.	O
No	O
evolutionary	O
ECG	O
changes	O
during	O
admission	O
.	O
Clinical	O
evolution	O
was	O
favourable	O
,	O
with	O
treatment	O
with	O
ACE	O
inhibitors	O
.	O
MRI	O
was	O
requested	O
48	O
hours	O
later	O
,	O
which	O
confirmed	O
the	O
diagnosis	O
of	O
myocarditis	O
.	O
DIAGNOSIS	O
Acute	O
myocarditis	O
of	O
probable	O
viral	O
aetiology	O
.	O
Preserved	O
LVEF	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
65	O
year	O
old	O
male	O
type	O
2	O
diabetic	O
of	O
8	O
years	O
of	O
evolution	O
on	O
metformin	O
treatment	O
who	O
was	O
admitted	O
to	O
our	O
centre	O
on	O
treatment	O
with	O
metformin	B-FARMACO
who	O
was	O
admitted	O
to	O
our	O
centre	O
for	O
congestive	O
heart	O
failure	O
CHF	O
.	O
The	O
patient	O
had	O
been	O
a	O
smoker	O
until	O
March	O
2014	O
,	O
with	O
a	O
pack	O
year	O
index	O
of	O
30	O
.	O
In	O
addition	O
,	O
he	O
was	O
overweight	O
fulfilling	O
metabolic	O
syndrome	O
criteria	O
,	O
hypertensive	O
and	O
hypercholesterolaemic	O
both	O
under	O
medical	O
treatment	O
with	O
enalapril	B-FARMACO
5	O
mg	O
12	O
h	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
24	O
h	O
and	O
atorvastatin	B-FARMACO
40	O
mg	O
24	O
h	O
.	O
His	O
past	O
history	O
of	O
interest	O
included	O
an	O
inferior	O
myocardial	O
infarction	O
in	O
1997	O
,	O
with	O
no	O
information	O
on	O
interventionism	O
and	O
no	O
subsequent	O
follow	O
up	O
,	O
as	O
well	O
as	O
permanent	O
atrial	O
fibrillation	O
anticoagulated	O
with	O
acenocoumarol	B-FARMACO
.	O
In	O
2014	O
he	O
developed	O
ischaemic	O
colitis	O
and	O
a	O
Forrest	O
III	O
gastric	O
ulcer	O
requiring	O
hospital	O
admission	O
.	O
This	O
was	O
complicated	O
by	O
a	O
new	O
non	O
ST	O
elevation	O
type	O
II	O
infarction	O
in	O
the	O
context	O
of	O
rectal	O
bleeding	O
.	O
Once	O
the	O
patient	O
was	O
stabilised	O
,	O
coronary	O
angiography	O
revealed	O
severe	O
3	O
vessel	O
coronary	O
artery	O
disease	O
proximal	O
anterior	O
descending	O
LAD	O
occlusion	O
,	O
severe	O
proximal	O
circumflex	O
and	O
first	O
obtuse	O
marginal	O
OM1	O
lesion	O
,	O
severe	O
proximal	O
bisector	O
lesion	O
and	O
right	O
coronary	O
artery	O
RCA	O
occlusion	O
.	O
The	O
transthoracic	O
echocardiogram	O
showed	O
a	O
severely	O
depressed	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
LVEF	O
25	O
.	O
For	O
all	O
these	O
reasons	O
,	O
it	O
was	O
decided	O
in	O
a	O
medical	O
surgical	O
session	O
to	O
perform	O
coronary	O
revascularisation	O
surgery	O
,	O
which	O
was	O
finally	O
carried	O
out	O
with	O
the	O
implantation	O
of	O
four	O
vascular	O
grafts	O
mammary	O
artery	O
to	O
distal	O
LAD	O
,	O
saphenous	O
vein	O
in	O
"	O
Y	O
"	O
to	O
bisector	O
and	O
OM1	O
and	O
saphenous	O
vein	O
to	O
mid	O
distal	O
DC	O
.	O
Subsequent	O
evolution	O
was	O
satisfactory	O
,	O
but	O
in	O
2015	O
the	O
patient	O
began	O
to	O
present	O
symptoms	O
of	O
CHF	O
,	O
requiring	O
a	O
first	O
hospital	O
admission	O
in	O
relation	O
to	O
dietary	O
transgression	O
.	O
Since	O
then	O
,	O
he	O
had	O
been	O
on	O
treatment	O
with	O
60	O
mg	O
of	O
furosemide	B-FARMACO
daily	O
and	O
25	O
mg	O
of	O
spironolactone	B-FARMACO
,	O
in	O
functional	O
class	O
FC	O
II	O
IV	O
ambulatory	O
.	O
She	O
was	O
admitted	O
to	O
our	O
centre	O
in	O
October	O
2016	O
due	O
to	O
decompensation	O
of	O
severe	O
CHF	O
with	O
acute	O
hypertensive	O
pulmonary	O
oedema	O
,	O
requiring	O
management	O
in	O
the	O
acute	O
unit	O
with	O
non	O
invasive	O
mechanical	O
ventilation	O
NIMV	O
and	O
intravenous	O
medication	O
.	O
He	O
also	O
initially	O
required	O
inotropic	O
support	O
with	O
dobutamine	B-FARMACO
,	O
which	O
was	O
successfully	O
withdrawn	O
via	O
a	O
course	O
of	O
levosimendan	B-FARMACO
.	O
The	O
electrocardiogram	O
on	O
admission	O
showed	O
atrial	O
fibrillation	O
with	O
ventricular	O
response	O
at	O
90	O
bpm	O
,	O
with	O
QRS	O
of	O
100ms	O
,	O
QS	O
in	O
V1	O
V3	O
and	O
flattened	O
T	O
in	O
V5	O
6	O
,	O
similar	O
to	O
previous	O
records	O
.	O
As	O
part	O
of	O
the	O
diagnostic	O
study	O
,	O
a	O
new	O
coronary	O
angiography	O
was	O
performed	O
,	O
which	O
showed	O
patency	O
of	O
the	O
previous	O
grafts	O
,	O
as	O
well	O
as	O
a	O
cardiac	O
magnetic	O
resonance	O
imaging	O
,	O
which	O
showed	O
an	O
LVEF	O
of	O
24	O
,	O
together	O
with	O
a	O
transmural	O
late	O
enhancement	O
pattern	O
in	O
the	O
LAD	O
territory	O
.	O
In	O
addition	O
,	O
the	O
patient	O
had	O
moderate	O
right	O
ventricular	O
systolic	O
dysfunction	O
.	O
The	O
hospital	O
evolution	O
was	O
again	O
favourable	O
,	O
and	O
after	O
discussion	O
with	O
the	O
Heart	O
Team	O
,	O
it	O
was	O
decided	O
to	O
implant	O
a	O
subcutaneous	O
single	O
chamber	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
.	O
After	O
optimisation	O
of	O
pharmacological	O
treatment	O
enalapril	B-FARMACO
10	O
mg	O
12	O
h	O
;	O
bisoprolol	B-FARMACO
5	O
mg	O
24	O
h	O
;	O
furosemide	B-FARMACO
80	O
mg	O
24	O
h	O
;	O
spironolactone	B-FARMACO
25	O
mg	O
24	O
h	O
,	O
a	O
lipid	O
profile	O
control	O
was	O
performed	O
,	O
showing	O
LDL	O
cholesterol	O
levels	O
of	O
65	O
mg	O
dl	O
and	O
total	O
cholesterol	O
of	O
160mg	O
dl	O
.	O
Likewise	O
,	O
the	O
glycosylated	O
haemoglobin	O
value	O
was	O
7	O
.	O
9	O
,	O
outside	O
the	O
therapeutic	O
target	O
,	O
so	O
it	O
was	O
decided	O
,	O
together	O
with	O
the	O
Endocrinology	O
Department	O
,	O
to	O
optimise	O
treatment	O
with	O
oral	O
antidiabetic	O
drugs	O
.	O
As	O
the	O
patient	O
was	O
at	O
high	O
cardiovascular	O
risk	O
,	O
with	O
several	O
decompensations	O
due	O
to	O
CHF	O
,	O
regular	O
blood	O
pressure	O
control	O
and	O
metabolic	O
syndrome	O
,	O
it	O
was	O
decided	O
to	O
add	O
empaglifozin	B-FARMACO
10	O
mg	O
daily	O
to	O
the	O
previous	O
treatment	O
with	O
metformin	B-FARMACO
.	O
The	O
patient	O
was	O
discharged	O
from	O
hospital	O
and	O
continued	O
to	O
be	O
closely	O
monitored	O
in	O
the	O
Cardiology	O
day	O
hospital	O
.	O
COMPLEMENTARY	O
TESTS	O
Posteroanterior	O
and	O
lateral	O
chest	O
X	O
ray	O
global	O
cardiomegaly	O
,	O
increased	O
bronchovascular	O
tract	O
compatible	O
with	O
interstitial	O
and	O
alveolar	O
oedema	O
,	O
cisural	O
effusion	O
,	O
sternotomy	O
suture	O
.	O
Electrocardiogram	O
atrial	O
fibrillation	O
with	O
ventricular	O
response	O
at	O
90	O
bpm	O
,	O
with	O
QRS	O
of	O
100	O
ms	O
,	O
QS	O
in	O
V1	O
V3	O
and	O
flattened	O
T	O
in	O
V5	O
6	O
.	O
Transthoracic	O
echocardiogram	O
moderately	O
dilated	O
left	O
ventricle	O
,	O
with	O
normal	O
wall	O
thickness	O
.	O
Severely	O
depressed	O
global	O
systolic	O
function	O
LVEF	O
20	O
by	O
visual	O
estimation	O
.	O
Akinesia	O
and	O
thinning	O
of	O
the	O
septum	O
,	O
apical	O
segment	O
17	O
aneurysm	O
and	O
inferior	O
face	O
and	O
mid	O
and	O
distal	O
segments	O
of	O
the	O
lateral	O
inferior	O
.	O
Single	O
wave	O
mitral	O
filling	O
.	O
Left	O
atrium	O
slightly	O
dilated	O
.	O
Mildly	O
dilated	O
right	O
atrium	O
.	O
Right	O
ventricle	O
severely	O
dilated	O
,	O
with	O
global	O
systolic	O
function	O
at	O
the	O
lower	O
limit	O
of	O
normal	O
.	O
TAPSE	O
of	O
14	O
mm	O
.	O
Mitral	O
valve	O
with	O
calcium	O
ring	O
,	O
thickening	O
of	O
the	O
leaflets	O
and	O
restriction	O
of	O
the	O
posterior	O
leaflet	O
opening	O
.	O
Mild	O
insufficiency	O
.	O
Sclerosed	O
aortic	O
valve	O
,	O
without	O
pathological	O
transaortic	O
gradients	O
.	O
Mild	O
insufficiency	O
.	O
Morphologically	O
normal	O
tricuspid	O
valve	O
.	O
Moderate	O
insufficiency	O
.	O
Pulmonary	O
artery	O
systolic	O
pressure	O
estimated	O
at	O
65	O
mmHg	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
24	O
.	O
54	O
mm	O
,	O
without	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Epicardial	O
fat	O
.	O
Aortic	O
root	O
30	O
mm	O
.	O
Ascending	O
aorta	O
37	O
mm	O
.	O
Pre	O
surgical	O
coronary	O
angiography	O
right	O
dominance	O
.	O
Truncus	O
no	O
lesions	O
.	O
Anterior	O
descending	O
chronic	O
occlusion	O
at	O
proximal	O
level	O
,	O
observed	O
by	O
heterocoronary	O
circulation	O
,	O
being	O
a	O
vessel	O
of	O
good	O
calibre	O
and	O
development	O
.	O
Circumflex	O
artery	O
of	O
good	O
development	O
and	O
calibre	O
.	O
It	O
presents	O
a	O
severe	O
lesion	O
at	O
the	O
proximal	O
level	O
85	O
90	O
,	O
just	O
after	O
the	O
exit	O
of	O
OM1	O
,	O
the	O
rest	O
of	O
the	O
vessel	O
is	O
of	O
good	O
calibre	O
and	O
development	O
.	O
OM1	O
is	O
a	O
vessel	O
of	O
good	O
development	O
and	O
calibre	O
,	O
with	O
a	O
significant	O
calcified	O
lesion	O
at	O
the	O
proximal	O
level	O
,	O
the	O
rest	O
of	O
the	O
vessel	O
is	O
of	O
good	O
calibre	O
and	O
development	O
.	O
Bisector	O
branch	O
vessel	O
of	O
good	O
calibre	O
and	O
development	O
,	O
with	O
severe	O
calcified	O
disease	O
at	O
the	O
proximal	O
level	O
,	O
the	O
rest	O
of	O
the	O
vessel	O
with	O
diffuse	O
mild	O
atheromatosis	O
.	O
Right	O
coronary	O
description	O
right	O
dominant	O
.	O
Chronic	O
occlusion	O
at	O
the	O
middle	O
level	O
,	O
distal	O
vessel	O
is	O
observed	O
by	O
heterocoronary	O
circulation	O
being	O
a	O
vessel	O
of	O
good	O
development	O
.	O
Diagnostic	O
findings	O
severe	O
3	O
vessel	O
coronary	O
artery	O
disease	O
chronic	O
occlusion	O
of	O
DA	O
and	O
CD	O
,	O
severe	O
Cx	O
lesion	O
proximal	O
Cx	O
,	O
OM1	O
and	O
bisector	O
branch	O
.	O
Cardiac	O
MRI	O
severely	O
dilated	O
left	O
ventricle	O
VTD	O
295	O
ml	O
,	O
VTS	O
225	O
ml	O
,	O
with	O
normal	O
wall	O
thickness	O
.	O
Severely	O
depressed	O
global	O
systolic	O
function	O
LVEF	O
24	O
.	O
Akinesia	O
and	O
thinning	O
of	O
the	O
septum	O
and	O
anterior	O
face	O
and	O
distal	O
third	O
of	O
all	O
faces	O
.	O
Inferior	O
face	O
akinesia	O
.	O
Late	O
enhancement	O
is	O
observed	O
transmurally	O
affecting	O
the	O
apex	O
and	O
distal	O
third	O
of	O
inferior	O
,	O
lateral	O
,	O
anterior	O
and	O
septum	O
,	O
75	O
subendocardial	O
in	O
mid	O
and	O
distal	O
segment	O
of	O
anterior	O
face	O
and	O
septum	O
,	O
and	O
50	O
in	O
the	O
basal	O
segment	O
of	O
anterior	O
face	O
and	O
septum	O
.	O
75	O
enhancement	O
in	O
lower	O
basal	O
segment	O
.	O
Moderately	O
dilated	O
left	O
atrium	O
apical	O
plane	O
area	O
43	O
cm2	O
.	O
Right	O
atrium	O
slightly	O
dilated	O
32	O
cm2	O
.	O
Right	O
ventricle	O
not	O
dilated	O
VTD	O
111	O
ml	O
,	O
VTS	O
77	O
ml	O
,	O
with	O
moderately	O
depressed	O
global	O
systolic	O
function	O
with	O
global	O
hypokinesia	O
.	O
RVEF	O
31	O
.	O
Conclusion	O
dilated	O
cardiomyopathy	O
of	O
ischaemic	O
aetiology	O
with	O
severely	O
depressed	O
global	O
systolic	O
function	O
and	O
late	O
enhancement	O
pattern	O
of	O
ischaemic	O
aetiology	O
with	O
multivessel	O
involvement	O
.	O
Absence	O
of	O
viability	O
in	O
the	O
territory	O
of	O
the	O
anterior	O
descending	O
artery	O
.	O
Moderate	O
right	O
ventricular	O
systolic	O
dysfunction	O
.	O
EVOLUTION	O
Three	O
months	O
after	O
hospital	O
discharge	O
,	O
the	O
patient	O
has	O
a	O
glycosylated	O
haemoglobin	O
of	O
7	O
.	O
3	O
,	O
has	O
lost	O
3	O
kg	O
in	O
weight	O
,	O
maintains	O
good	O
blood	O
pressure	O
control	O
with	O
current	O
figures	O
around	O
120	O
70	O
mmHg	O
and	O
has	O
not	O
been	O
admitted	O
again	O
for	O
CHF	O
,	O
remaining	O
in	O
ambulatory	O
functional	O
class	O
II	O
and	O
having	O
allowed	O
a	O
decrease	O
in	O
diuretic	O
treatment	O
to	O
60	O
mg	O
of	O
furosemide	B-FARMACO
.	O
He	O
has	O
not	O
been	O
discharged	O
from	O
the	O
ICD	O
either	O
.	O
As	O
this	O
is	O
a	O
young	O
patient	O
at	O
high	O
cardiovascular	O
risk	O
,	O
it	O
was	O
decided	O
to	O
titrate	O
empaglifozin	B-FARMACO
to	O
25	O
mg	O
to	O
improve	O
glycaemic	O
control	O
.	O
At	O
the	O
next	O
outpatient	O
review	O
,	O
four	O
months	O
after	O
the	O
previous	O
one	O
,	O
the	O
glycosylated	O
haemoglobin	O
value	O
was	O
6	O
.	O
8	O
,	O
the	O
patient	O
had	O
continued	O
to	O
lose	O
weight	O
,	O
with	O
good	O
control	O
of	O
the	O
rest	O
of	O
the	O
CVRF	O
,	O
no	O
hospital	O
admissions	O
,	O
no	O
ICD	O
discharges	O
and	O
in	O
functional	O
class	O
II	O
.	O
DIAGNOSIS	O
Chronic	O
heart	O
failure	O
with	O
LVEF	O
24	O
and	O
RVEF	O
31	O
by	O
cardiac	O
magnetic	O
resonance	O
imaging	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
with	O
3	O
vessel	O
coronary	O
artery	O
disease	O
revascularised	O
by	O
quadruple	O
bypass	O
.	O
Chronic	O
inferior	O
and	O
anterior	O
infarction	O
.	O
Absence	O
of	O
viability	O
in	O
the	O
territory	O
of	O
the	O
anterior	O
descending	O
artery	O
.	O
Carrier	O
of	O
Biotronik	O
single	O
chamber	O
ICD	O
in	O
primary	O
prevention	O
.	O
Permanent	O
atrial	O
fibrillation	O
anticoagulated	O
with	O
sintrom	B-FARMACO
.	O
Diabetes	O
mellitus	O
in	O
treatment	O
with	O
metformin	B-FARMACO
and	O
empaglifozin	B-FARMACO
.	O
Arterial	O
hypertension	O
.	O
Dyslipidaemia	O
.	O
Exobtachism	O
.	O
Metabolic	O
syndrome	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
36	O
year	O
old	O
male	O
,	O
hypertensive	O
,	O
with	O
abnormally	O
high	O
plasma	O
levels	O
of	O
LDL	O
cholesterol	O
,	O
triglycerides	O
and	O
glycated	O
haemoglobin	O
,	O
who	O
presents	O
with	O
ischaemic	O
heart	O
disease	O
.	O
HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
Hypertensive	O
for	O
more	O
than	O
5	O
years	O
on	O
treatment	O
with	O
enalapril	B-FARMACO
he	O
had	O
stopped	O
treatment	O
.	O
Ex	O
smoker	O
.	O
Hypertriglyceridaemia	O
.	O
Undiagnosed	O
type	O
2	O
diabetes	O
mellitus	O
.	O
No	O
known	O
previous	O
heart	O
disease	O
or	O
other	O
medical	O
illnesses	O
of	O
interest	O
.	O
Family	O
history	O
father	O
with	O
AMI	O
at	O
the	O
age	O
of	O
50	O
.	O
Young	O
hypertensive	O
mother	O
.	O
Grandmother	O
and	O
maternal	O
aunt	O
with	O
type	O
2	O
diabetes	O
mellitus	O
DM	O
and	O
hypertension	O
.	O
Previous	O
treatment	O
omeprazole	B-FARMACO
20	O
mg	O
,	O
1	O
day	O
,	O
enalapril	B-FARMACO
20	O
mg	O
,	O
1	O
day	O
.	O
Present	O
illness	O
A	O
36	O
year	O
old	O
male	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
for	O
a	O
week	O
with	O
a	O
clinical	O
presentation	O
of	O
central	O
thoracic	O
pain	O
that	O
he	O
described	O
as	O
oppressive	O
,	O
non	O
radiating	O
and	O
without	O
vegetative	O
cortex	O
,	O
which	O
did	O
not	O
increase	O
with	O
pressure	O
.	O
He	O
reports	O
that	O
it	O
starts	O
in	O
the	O
morning	O
and	O
that	O
after	O
an	O
hour	O
of	O
pain	O
it	O
usually	O
subsides	O
,	O
without	O
palpitations	O
.	O
In	O
the	O
last	O
two	O
days	O
she	O
noticed	O
that	O
the	O
pain	O
appeared	O
with	O
exertion	O
and	O
decreased	O
with	O
rest	O
.	O
She	O
went	O
to	O
her	O
health	O
centre	O
for	O
the	O
same	O
reason	O
,	O
where	O
they	O
observed	O
supraventricular	O
tachycardia	O
and	O
a	O
tendency	O
to	O
hypertension	O
she	O
has	O
stopped	O
taking	O
the	O
treatment	O
,	O
which	O
was	O
treated	O
with	O
antihypertensives	O
and	O
benzodiazepines	O
without	O
improvement	O
.	O
Physical	O
examination	O
Killip	O
class	O
I	O
no	O
heart	O
failure	O
Weight	O
102	O
.	O
0	O
kg	O
.	O
Height	O
1	O
.	O
74	O
m	O
.	O
BMI	O
33	O
.	O
69	O
.	O
BP	O
135	O
95	O
.	O
HR	O
166	O
bpm	O
.	O
Ta	O
37	O
,	O
7	O
C	O
.	O
Sat	O
O2	O
97	O
;	O
no	O
tendinous	O
xanthomas	O
or	O
xanthelasmas	O
.	O
Normal	O
ocular	O
examination	O
,	O
no	O
corneal	O
arcus	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
without	O
murmurs	O
and	O
without	O
pericardial	O
friction	O
.	O
Pulmonary	O
auscultation	O
VCM	O
without	O
added	O
pathological	O
sounds	O
.	O
MMII	O
without	O
oedema	O
with	O
symmetrical	O
peripheral	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
Emergency	O
ECG	O
first	O
sinus	O
tachycardia	O
146	O
bpm	O
.	O
Normal	O
PR	O
.	O
Normal	O
electrical	O
axis	O
.	O
Narrow	O
QRS	O
with	O
R	O
wave	O
S	O
in	O
V2	O
V3	O
and	O
ST	O
depression	O
of	O
1	O
.	O
5	O
mm	O
from	O
V2	O
V5	O
that	O
normalises	O
in	O
subsequent	O
ECGs	O
after	O
controlling	O
HR	O
.	O
Meets	O
Sokolow	O
Lyon	O
criteria	O
for	O
LVH	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
not	O
increased	O
,	O
sinus	O
costo	O
and	O
cardiophrenic	O
sinuses	O
free	O
,	O
without	O
congestive	O
hilarity	O
or	O
vascular	O
redistribution	O
.	O
No	O
parenchymal	O
masses	O
or	O
nodules	O
were	O
observed	O
.	O
Urgent	O
laboratory	O
tests	O
icteric	O
and	O
lipemic	O
serum	O
glucose	O
309	O
mg	O
dl	O
;	O
urea	O
31	O
mg	O
dl	O
;	O
creatinine	O
0	O
.	O
9	O
mg	O
dl	O
,	O
sodium	O
134	O
mEq	O
l	O
;	O
K	O
4	O
.	O
5	O
mEq	O
l	O
;	O
haemoglobin	O
16	O
.	O
4	O
g	O
dl	O
;	O
haematocrit	O
45	O
.	O
7	O
;	O
MCV	O
80	O
.	O
7	O
fl	O
;	O
platelets	O
308	O
.	O
0	O
10e3	O
ul	O
;	O
leukocytes	O
14	O
.	O
81	O
10	O
e3	O
uL	O
;	O
CrCl	O
Cockcroft	O
Gault	O
163	O
.	O
7	O
ml	O
min	O
;	O
TUS	O
420	O
440	O
610	O
ng	O
l	O
.	O
D	O
dimer	O
354	O
.	O
Laboratory	O
tests	O
glucose	O
213	O
mg	O
dl	O
;	O
urea	O
48	O
mg	O
dl	O
;	O
creatinine	O
0	O
.	O
85	O
mg	O
dl	O
;	O
total	O
cholesterol	O
274	O
mg	O
dl	O
;	O
triglycerides	O
893	O
mg	O
dl	O
;	O
HDL	O
cholesterol	O
34	O
mg	O
dl	O
,	O
with	O
non	O
HDL	O
210	O
;	O
sodium	O
140	O
mEq	O
l	O
;	O
potassium	O
4	O
.	O
1	O
mEq	O
l	O
;	O
haemoglobin	O
16	O
.	O
0	O
g	O
dl	O
;	O
haematocrit	O
47	O
.	O
7	O
;	O
MCV	O
85	O
.	O
5	O
fl	O
;	O
platelets	O
274	O
.	O
0	O
10e3	O
ul	O
;	O
leukocytes	O
9	O
.	O
08	O
10e3	O
ul	O
;	O
HbA1c	O
10	O
.	O
6	O
;	O
CRP	O
8	O
.	O
6	O
mg	O
dl	O
;	O
T4L	O
1	O
.	O
08	O
ng	O
dl	O
;	O
TSH	O
0	O
.	O
76	O
IUI	O
ml	O
;	O
CrCl	O
Cockcroft	O
Gault	O
173	O
.	O
33	O
units	O
ml	O
min	O
.	O
Echocardiography	O
non	O
dilated	O
left	O
ventricle	O
,	O
normal	O
thickness	O
.	O
Hypokinesia	O
no	O
thinned	O
wall	O
of	O
basal	O
medial	O
segments	O
of	O
lateral	O
and	O
posterior	O
face	O
,	O
with	O
normocontractility	O
of	O
the	O
remaining	O
segments	O
and	O
slightly	O
depressed	O
residual	O
LVEF	O
biplane	O
EF	O
44	O
.	O
Slight	O
left	O
atrial	O
dilatation	O
,	O
normal	O
sized	O
RA	O
.	O
Tricommissural	O
aortic	O
valve	O
,	O
normal	O
.	O
Mitral	O
,	O
tricuspid	O
and	O
pulmonary	O
valves	O
of	O
normal	O
morphology	O
and	O
mobility	O
.	O
Right	O
ventricle	O
not	O
dilated	O
,	O
of	O
normal	O
thickness	O
,	O
without	O
alterations	O
of	O
regional	O
contractility	O
and	O
with	O
preserved	O
global	O
systolic	O
function	O
.	O
No	O
significant	O
pericardial	O
effusion	O
.	O
Inferior	O
vena	O
cava	O
and	O
suprahepatic	O
vein	O
not	O
dilated	O
,	O
with	O
adequate	O
inspiratory	O
collapse	O
,	O
which	O
excludes	O
the	O
presence	O
of	O
significant	O
systemic	O
venous	O
hypertension	O
.	O
Doppler	O
findings	O
mitral	O
Doppler	O
compatible	O
with	O
impaired	O
left	O
ventricular	O
relaxation	O
.	O
Absence	O
of	O
tricuspid	O
insufficiency	O
allowing	O
quantification	O
of	O
pulmonary	O
artery	O
systolic	O
pressure	O
.	O
Conclusions	O
Alterations	O
of	O
segmental	O
contractility	O
in	O
Cx	O
territory	O
.	O
Residual	O
LVEF	O
44	O
.	O
Coronary	O
angiography	O
left	O
common	O
trunk	O
without	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
with	O
some	O
irregularities	O
along	O
its	O
course	O
and	O
moderate	O
lesion	O
in	O
the	O
proximal	O
third	O
of	O
the	O
1st	O
diagonal	O
of	O
good	O
development	O
.	O
Circumflex	O
occluded	O
in	O
the	O
proximal	O
third	O
,	O
visible	O
from	O
heterocoronary	O
circulation	O
;	O
obtuse	O
system	O
of	O
good	O
calibre	O
.	O
Right	O
coronary	O
artery	O
with	O
irregularities	O
along	O
its	O
entire	O
length	O
,	O
moderate	O
plaque	O
in	O
the	O
middle	O
third	O
and	O
severe	O
focal	O
lesion	O
on	O
the	O
posterolateral	O
side	O
,	O
this	O
being	O
an	O
artery	O
of	O
good	O
calibre	O
.	O
Intervention	O
the	O
occlusion	O
was	O
successfully	O
passed	O
with	O
microcatheter	O
support	O
and	O
the	O
artery	O
was	O
opened	O
with	O
balloon	O
crescents	O
.	O
A	O
long	O
lesion	O
is	O
observed	O
from	O
the	O
distal	O
third	O
to	O
the	O
proximal	O
third	O
,	O
which	O
is	O
covered	O
with	O
two	O
overlapping	O
drug	O
eluting	O
stents	O
.	O
They	O
are	O
post	O
dilated	O
for	O
correct	O
apposition	O
with	O
a	O
good	O
final	O
result	O
and	O
without	O
complications	O
.	O
EVOLUTION	O
The	O
patient	O
evolves	O
favourably	O
without	O
recurrences	O
of	O
chest	O
pain	O
or	O
clinical	O
signs	O
of	O
heart	O
failure	O
or	O
significant	O
arrhythmic	O
events	O
.	O
During	O
his	O
admission	O
,	O
he	O
was	O
assessed	O
by	O
endocrinology	O
,	O
who	O
started	O
hypoglycaemic	O
drugs	O
with	O
metformin	B-FARMACO
and	O
empagliflozin	B-FARMACO
with	O
good	O
tolerance	O
.	O
On	O
discharge	O
,	O
it	O
was	O
decided	O
to	O
refer	O
the	O
patient	O
to	O
the	O
cardiac	O
rehabilitation	O
programme	O
at	O
our	O
hospital	O
and	O
to	O
closely	O
monitor	O
him	O
in	O
the	O
cardiology	O
consultations	O
to	O
control	O
cardiovascular	O
risk	O
factors	O
,	O
advise	O
on	O
lifestyle	O
changes	O
and	O
achieve	O
therapeutic	O
compliance	O
.	O
DIAGNOSIS	O
Acute	O
non	O
ST	O
segment	O
elevation	O
myocardial	O
infarction	O
NSTEMI	O
Killip	O
I	O
.	O
Proximal	O
circumflex	O
occlusion	O
,	O
treated	O
by	O
PTCA	O
and	O
coated	O
stent	O
implantation	O
.	O
Severe	O
focal	O
lesion	O
in	O
posterolateral	O
right	O
coronary	O
artery	O
and	O
moderate	O
lesion	O
in	O
1st	O
diagonal	O
untreated	O
.	O
Basal	O
and	O
medial	O
posterior	O
and	O
lateral	O
hypokinesia	O
with	O
mild	O
systolic	O
dysfunction	O
LVEF	O
44	O
.	O
Recently	O
diagnosed	O
type	O
2	O
diabetes	O
mellitus	O
and	O
hypercholesterolemia	O
under	O
study	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
56	O
year	O
old	O
male	O
,	O
with	O
no	O
known	O
drug	O
allergies	O
,	O
with	O
a	O
history	O
of	O
arterial	O
hypertension	O
being	O
treated	O
with	O
two	O
drugs	O
and	O
dyslipidaemia	O
;	O
with	O
no	O
personal	O
or	O
family	O
history	O
of	O
heart	O
disease	O
,	O
heart	O
failure	O
or	O
sudden	O
death	O
.	O
Three	O
days	O
ago	O
she	O
reported	O
an	O
episode	O
of	O
oppressive	O
chest	O
pain	O
radiating	O
to	O
the	O
jaw	O
,	O
left	O
upper	O
limb	O
and	O
back	O
,	O
after	O
intense	O
exertion	O
carrying	O
a	O
weight	O
,	O
of	O
several	O
hours	O
'	O
duration	O
,	O
accompanied	O
by	O
vegetatism	O
.	O
She	O
did	O
not	O
consult	O
for	O
this	O
episode	O
.	O
On	O
the	O
day	O
she	O
sought	O
medical	O
attention	O
,	O
she	O
presented	O
a	O
new	O
episode	O
of	O
chest	O
pain	O
similar	O
to	O
the	O
previous	O
one	O
,	O
while	O
making	O
intense	O
effort	O
,	O
and	O
so	O
she	O
called	O
the	O
Emergency	O
Medical	O
Service	O
.	O
On	O
initial	O
assessment	O
BP	O
123	O
99	O
mmHg	O
,	O
HR	O
105	O
bpm	O
and	O
SatO2	O
100	O
with	O
nasal	O
goggles	O
at	O
2	O
L	O
min	O
.	O
Initial	O
physical	O
examination	O
revealed	O
a	O
pansystolic	O
murmur	O
in	O
the	O
mesocardium	O
.	O
An	O
electrocardiogram	O
was	O
performed	O
with	O
pain	O
,	O
showing	O
sinus	O
rhythm	O
,	O
AV	O
block	O
Mobitz	O
I	O
.	O
Narrow	O
QRS	O
.	O
Pathological	O
Q	O
waves	O
in	O
inferior	O
face	O
and	O
inferior	O
ST	O
elevation	O
with	O
DIII	O
DII	O
maximum	O
of	O
4	O
mm	O
in	O
DII	O
and	O
specular	O
decrease	O
in	O
DI	O
and	O
aVL	O
of	O
up	O
to	O
5	O
mm	O
.	O
ST	O
elevation	O
V3	O
V6	O
with	O
negative	O
anterior	O
T	O
waves	O
.	O
The	O
AMI	O
code	O
was	O
activated	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
our	O
centre	O
.	O
Acetylsalicylic	B-FARMACO
acid	I-FARMACO
250	O
mg	O
,	O
clopidogrel	B-FARMACO
600	O
mg	O
,	O
enoxaparin	B-FARMACO
30	O
mg	O
and	O
fentanyl	B-FARMACO
50	O
mcg	O
were	O
administered	O
.	O
During	O
the	O
transfer	O
,	O
hypotension	O
with	O
BP	O
73	O
42	O
mmHg	O
.	O
He	O
was	O
transferred	O
to	O
the	O
haemodynamics	O
ward	O
for	O
urgent	O
coronary	O
angiography	O
.	O
During	O
the	O
procedure	O
,	O
dobutamine	B-FARMACO
and	O
noradrenaline	B-FARMACO
were	O
started	O
,	O
requiring	O
dose	O
increases	O
up	O
to	O
20	O
mcg	O
kg	O
min	O
and	O
20	O
ml	O
h	O
respectively	O
.	O
Coronary	O
angiography	O
revealed	O
3	O
vessel	O
coronary	O
artery	O
disease	O
Two	O
severe	O
lesions	O
90	O
in	O
tandem	O
in	O
the	O
anterior	O
descending	O
AD	O
at	O
the	O
level	O
of	O
the	O
middle	O
third	O
pre	O
and	O
post	O
exit	O
of	O
the	O
second	O
diagonal	O
with	O
involvement	O
of	O
the	O
ostial	O
proximal	O
segment	O
of	O
the	O
second	O
diagonal	O
80	O
;	O
first	O
marginal	O
occlusion	O
at	O
the	O
middle	O
level	O
100	O
with	O
no	O
distal	O
bed	O
visualisation	O
and	O
proximal	O
occlusion	O
of	O
the	O
right	O
coronary	O
artery	O
RCA	O
100	O
.	O
PCI	O
was	O
performed	O
to	O
the	O
proximal	O
medial	O
DC	O
with	O
implantation	O
of	O
a	O
3	O
x	O
36	O
mm	O
non	O
drug	O
eluting	O
stent	O
at	O
20	O
atm	O
,	O
with	O
good	O
results	O
.	O
Urgent	O
transthoracic	O
cardiac	O
ultrasound	O
was	O
performed	O
during	O
the	O
procedure	O
,	O
which	O
showed	O
an	O
anfractuous	O
ventricular	O
septal	O
defect	O
VSD	O
located	O
in	O
the	O
basal	O
septum	O
,	O
about	O
30	O
mm	O
in	O
diameter	O
,	O
with	O
a	O
hypocontractile	O
RV	O
;	O
therefore	O
,	O
intra	O
aortic	O
balloon	O
counterpulsation	O
IABP	O
was	O
implanted	O
.	O
After	O
the	O
procedure	O
,	O
he	O
was	O
admitted	O
to	O
the	O
Coronary	O
Unit	O
for	O
stabilisation	O
.	O
The	O
case	O
was	O
discussed	O
with	O
the	O
Coronary	O
Unit	O
of	O
our	O
reference	O
centre	O
and	O
he	O
was	O
transferred	O
for	O
surgery	O
.	O
Physical	O
examination	O
conscious	O
and	O
oriented	O
in	O
all	O
three	O
spheres	O
.	O
Signs	O
of	O
poor	O
distal	O
perfusion	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
tones	O
,	O
pansystolic	O
murmur	O
in	O
mesocardium	O
III	O
VI	O
not	O
radiated	O
.	O
Jugular	O
ingurgitation	O
.	O
Respiratory	O
auscultation	O
physiological	O
vesicular	O
murmur	O
without	O
added	O
pathological	O
sounds	O
.	O
No	O
declining	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
RS	O
,	O
BAV	O
Mobitz	O
I	O
,	O
narrow	O
QRS	O
,	O
inferior	O
Q	O
waves	O
and	O
inferior	O
ST	O
elevation	O
with	O
III	O
II	O
of	O
maximum	O
4	O
mm	O
in	O
III	O
and	O
specular	O
decrease	O
in	O
I	O
and	O
aVL	O
of	O
up	O
to	O
5	O
mm	O
;	O
also	O
ST	O
elevation	O
in	O
V3	O
V6	O
with	O
negative	O
anterior	O
T	O
wave	O
.	O
CBC	O
glucose	O
290	O
mg	O
dl	O
,	O
urea	O
65	O
mg	O
dl	O
,	O
creatinine	O
2	O
.	O
05	O
mg	O
dl	O
,	O
CK	O
1199	O
U	O
L	O
,	O
troponin	O
I	O
37	O
.	O
73	O
ng	O
ml	O
,	O
sodium	O
136	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
62	O
mmol	O
l	O
.	O
Leukocytes	O
13430	O
,	O
haemoglobin	O
14	O
.	O
2	O
g	O
dl	O
,	O
haematocrit	O
41	O
.	O
5	O
,	O
platelets	O
95	O
,	O
000	O
.	O
Emergent	O
coronary	O
angiography	O
right	O
dominant	O
coronary	O
arteries	O
significant	O
stenosis	O
.	O
Truncus	O
description	O
good	O
calibre	O
,	O
no	O
significant	O
lesions	O
.	O
Description	O
of	O
the	O
anterior	O
descending	O
artery	O
vessel	O
of	O
good	O
calibre	O
and	O
extension	O
.	O
Two	O
severe	O
tandem	O
lesions	O
at	O
the	O
level	O
of	O
the	O
middle	O
third	O
pre	O
and	O
post	O
exit	O
of	O
the	O
second	O
diagonal	O
with	O
involvement	O
of	O
the	O
ostial	O
proximal	O
segment	O
of	O
the	O
second	O
diagonal	O
.	O
Rest	O
of	O
the	O
vessel	O
with	O
non	O
significant	O
diffuse	O
irregularities	O
.	O
Good	O
distal	O
bed	O
,	O
TIMI	O
3	O
flow	O
.	O
Circumflex	O
description	O
occluded	O
at	O
the	O
level	O
of	O
the	O
first	O
middle	O
marginal	O
with	O
no	O
distal	O
bed	O
visible	O
.	O
Intermediate	O
branch	O
developed	O
,	O
no	O
lesions	O
.	O
Right	O
coronary	O
description	O
occluded	O
proximally	O
.	O
Procedure	O
cannulation	O
of	O
the	O
DC	O
ostium	O
with	O
AR2	O
catheter	O
,	O
passing	O
a	O
guide	O
wire	O
distally	O
from	O
the	O
posterior	O
descending	O
artery	O
.	O
Thrombus	O
extract	O
is	O
passed	O
,	O
which	O
is	O
productive	O
and	O
TIMI	O
2	O
flow	O
appears	O
,	O
and	O
a	O
3	O
x	O
36	O
mm	O
non	O
drug	O
eluting	O
stent	O
is	O
implanted	O
at	O
20	O
atm	O
,	O
with	O
good	O
results	O
.	O
Conclusions	O
right	O
dominance	O
.	O
Three	O
vessel	O
disease	O
.	O
PCI	O
to	O
proximal	O
medial	O
DC	O
.	O
Wide	O
VSD	O
Transthoracic	O
cardiac	O
ultrasound	O
ventricular	O
septal	O
defect	O
with	O
an	O
anfractuous	O
course	O
located	O
in	O
the	O
basal	O
septum	O
,	O
about	O
30	O
mm	O
in	O
diameter	O
,	O
RV	O
hypocontractile	O
.	O
Transthoracic	O
cardiac	O
echocardiography	O
prior	O
to	O
hospital	O
discharge	O
non	O
hypertrophic	O
left	O
ventricle	O
,	O
slightly	O
dilated	O
,	O
with	O
severely	O
depressed	O
systolic	O
function	O
EF	O
27	O
due	O
to	O
extensive	O
septal	O
and	O
inferoposterior	O
akinesia	O
,	O
patch	O
at	O
the	O
level	O
of	O
the	O
interventricular	O
septum	O
,	O
with	O
no	O
flow	O
between	O
the	O
two	O
ventricles	O
;	O
mild	O
aortic	O
insufficiency	O
and	O
moderate	O
severe	O
functional	O
mitral	O
insufficiency	O
.	O
Right	O
ventricle	O
slightly	O
dilated	O
.	O
Depressed	O
right	O
ventricular	O
dynamics	O
TAPSE	O
11	O
.	O
Mild	O
tricuspid	O
insufficiency	O
that	O
allows	O
estimating	O
normal	O
PAPs	O
.	O
EVOLUTION	O
On	O
arrival	O
at	O
the	O
reference	O
centre	O
,	O
in	O
a	O
situation	O
of	O
cardiogenic	O
shock	O
refractory	O
to	O
pharmacological	O
treatment	O
and	O
IABP	O
due	O
to	O
large	O
post	O
infarction	O
VSD	O
;	O
urgent	O
transthoracic	O
cardiac	O
ultrasound	O
was	O
performed	O
which	O
showed	O
a	O
globally	O
normal	O
contractile	O
left	O
ventricle	O
,	O
midbasal	O
inferoposterior	O
akinesia	O
,	O
dilated	O
right	O
ventricle	O
,	O
slightly	O
hypocontractile	O
;	O
and	O
a	O
wide	O
ventricular	O
septal	O
defect	O
of	O
up	O
to	O
4	O
cm	O
in	O
anteroposterior	O
diameter	O
and	O
3	O
cm	O
in	O
apicobasal	O
diameter	O
.	O
An	O
ECMO	O
extracorporeal	O
membrane	O
oxygenation	O
peripheral	O
venous	O
arterial	O
system	O
was	O
implanted	O
as	O
a	O
bridge	O
to	O
corrective	O
surgery	O
for	O
VSD	O
.	O
Subsequently	O
,	O
there	O
was	O
a	O
tendency	O
towards	O
stability	O
,	O
allowing	O
a	O
progressive	O
decrease	O
in	O
vasoactive	O
amine	O
support	O
with	O
adequate	O
ECMO	O
functioning	O
.	O
On	O
the	O
fourth	O
day	O
of	O
admission	O
,	O
VSD	O
closure	O
of	O
the	O
basal	O
and	O
middle	O
posterior	O
septum	O
was	O
performed	O
with	O
a	O
bovine	O
pericardial	O
patch	O
and	O
bypass	O
of	O
the	O
internal	O
mammary	O
artery	O
to	O
the	O
anterior	O
descending	O
artery	O
.	O
Echocardiogram	O
was	O
performed	O
after	O
surgery	O
,	O
decreasing	O
support	O
with	O
ECMO	O
,	O
in	O
which	O
stable	O
left	O
ventricular	O
function	O
,	O
hyperdynamic	O
segments	O
with	O
preserved	O
mobility	O
.	O
Non	O
dilated	O
right	O
ventricle	O
,	O
with	O
severe	O
dysfunction	O
.	O
Eccentric	O
tricuspid	O
insufficiency	O
directed	O
to	O
the	O
low	O
interatrial	O
septum	O
.	O
No	O
ventricular	O
septal	O
defect	O
.	O
It	O
was	O
decided	O
to	O
continue	O
ECMO	O
support	O
and	O
treatment	O
was	O
associated	O
with	O
levosimendan	B-FARMACO
.	O
The	O
patient	O
continued	O
to	O
evolve	O
well	O
,	O
decreasing	O
ECMO	O
litres	O
and	O
tolerating	O
IABP	O
1	O
4	O
.	O
In	O
view	O
of	O
the	O
favourable	O
evolution	O
,	O
it	O
was	O
decided	O
to	O
withdraw	O
ECMO	O
with	O
1	O
1	O
IABP	O
support	O
and	O
dobutamine	B-FARMACO
at	O
8	O
mcg	O
kg	O
min	O
.	O
Subsequent	O
good	O
evolution	O
,	O
allowing	O
withdrawal	O
of	O
IABC	O
and	O
inotropes	O
,	O
and	O
introduction	O
of	O
oral	O
treatment	O
with	O
beta	O
blockers	O
,	O
ACE	O
inhibitors	O
and	O
aldosterone	O
receptor	O
antagonists	O
.	O
Complications	O
during	O
admission	O
included	O
paroxysmal	O
atrial	O
fibrillation	O
,	O
prolonged	O
respiratory	O
weaning	O
,	O
requiring	O
percutaneous	O
tracheostomy	O
for	O
prolonged	O
orotracheal	O
intubation	O
;	O
due	O
to	O
respiratory	O
failure	O
secondary	O
to	O
alveolar	O
haemorrhage	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
nosocomial	O
pneumonia	O
in	O
the	O
right	O
lower	O
lobe	O
Enterobacter	O
cloacae	O
and	O
Citrobacter	O
koseri	O
and	O
urinary	O
tract	O
infection	O
by	O
multidrug	O
resistant	O
Serratia	O
marcescens	O
.	O
The	O
patient	O
progressed	O
favourably	O
,	O
tolerating	O
neurohormonal	O
treatment	O
,	O
with	O
negative	O
water	O
balance	O
and	O
low	O
dose	O
diuretics	O
.	O
A	O
control	O
ultrasound	O
was	O
performed	O
prior	O
to	O
hospital	O
discharge	O
,	O
showing	O
a	O
slightly	O
dilated	O
left	O
ventricle	O
,	O
with	O
severely	O
depressed	O
systolic	O
function	O
EF	O
27	O
due	O
to	O
extensive	O
septal	O
and	O
inferoposterior	O
akinesia	O
;	O
patch	O
at	O
the	O
level	O
of	O
the	O
interventricular	O
septum	O
,	O
with	O
no	O
flow	O
between	O
the	O
two	O
ventricles	O
;	O
mild	O
aortic	O
insufficiency	O
and	O
moderate	O
severe	O
functional	O
mitral	O
insufficiency	O
.	O
Slightly	O
dilated	O
right	O
ventricle	O
.	O
Right	O
ventricular	O
dysfunction	O
.	O
DIAGNOSIS	O
Acute	O
myocardial	O
infarction	O
with	O
inferior	O
ST	O
elevation	O
Killip	O
Kimball	O
IV	O
.	O
Proximal	O
DC	O
thrombotic	O
occlusion	O
.	O
PPCI	O
to	O
proximal	O
medial	O
DC	O
.	O
3	O
vessel	O
coronary	O
artery	O
disease	O
middle	O
DA	O
,	O
1st	O
OM	O
and	O
CD	O
wide	O
septal	O
septal	O
septal	O
defect	O
.	O
Closure	O
with	O
bovine	O
pericardial	O
patch	O
.	O
Internal	O
mammary	O
artery	O
bypass	O
to	O
LAD	O
.	O
Ischaemic	O
cardiomyopathy	O
with	O
severe	O
LV	O
systolic	O
dysfunction	O
.	O
Moderate	O
severe	O
functional	O
mitral	O
insufficiency	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
He	O
has	O
a	O
history	O
of	O
arterial	O
hypertension	O
,	O
type	O
II	O
diabetes	O
without	O
target	O
organ	O
involvement	O
and	O
dyslipidaemia	O
.	O
Cardiologically	O
,	O
he	O
had	O
ischaemic	O
dilated	O
cardiomyopathy	O
with	O
very	O
severe	O
ventricular	O
dysfunction	O
LVEF	O
8	O
,	O
secondary	O
to	O
coronary	O
artery	O
disease	O
of	O
the	O
trunk	O
and	O
3	O
vessels	O
revascularised	O
percutaneously	O
on	O
several	O
occasions	O
with	O
severe	O
diffuse	O
distal	O
disease	O
.	O
A	O
cavo	O
tricuspid	O
isthmus	O
ablation	O
was	O
performed	O
for	O
common	O
flutter	O
in	O
2008	O
,	O
presenting	O
permanent	O
atrial	O
fibrillation	O
since	O
February	O
2014	O
.	O
Valvularly	O
,	O
he	O
had	O
moderate	O
aortic	O
stenosis	O
with	O
a	O
maximum	O
gradient	O
of	O
36	O
mmHg	O
and	O
an	O
average	O
gradient	O
of	O
18	O
mmHg	O
,	O
and	O
an	O
area	O
per	O
continuity	O
equation	O
of	O
1	O
.	O
2	O
cm2	O
.	O
He	O
has	O
an	O
ICD	O
in	O
primary	O
prevention	O
.	O
He	O
presented	O
hyperthyroidism	O
due	O
to	O
type	O
2	O
thyroiditis	O
induced	O
by	O
amiodarone	B-FARMACO
.	O
Since	O
device	O
implantation	O
,	O
he	O
has	O
had	O
no	O
thrombotic	O
or	O
embolic	O
complications	O
,	O
with	O
stable	O
flow	O
parameters	O
and	O
pulsatility	O
indices	O
.	O
Subsequent	O
reviews	O
showed	O
a	O
tendency	O
to	O
hypertension	O
,	O
with	O
deterioration	O
of	O
renal	O
function	O
up	O
to	O
2	O
mg	O
dl	O
after	O
increasing	O
hypotensive	O
drugs	O
,	O
in	O
relation	O
to	O
previous	O
renal	O
disease	O
.	O
During	O
a	O
routine	O
check	O
up	O
at	O
the	O
Cardiology	O
day	O
hospital	O
,	O
the	O
patient	O
reported	O
worsening	O
dyspnoea	O
until	O
it	O
became	O
moderate	O
exertion	O
over	O
15	O
days	O
of	O
evolution	O
,	O
accompanied	O
by	O
chest	O
pain	O
related	O
to	O
inspiratory	O
movements	O
in	O
the	O
left	O
hemithorax	O
.	O
Physical	O
examination	O
showed	O
a	O
mean	O
blood	O
pressure	O
of	O
100	O
mmHg	O
measured	O
with	O
the	O
aid	O
of	O
a	O
portable	O
vascular	O
Doppler	O
.	O
Weight	O
was	O
stable	O
with	O
respect	O
to	O
previous	O
examinations	O
,	O
with	O
normal	O
O2	O
saturation	O
95	O
.	O
Of	O
note	O
was	O
the	O
presence	O
of	O
jugular	O
venous	O
ingurgitation	O
of	O
7cm	O
with	O
positive	O
hepatojugular	O
reflux	O
.	O
Cardiac	O
auscultation	O
showed	O
continuous	O
flow	O
noise	O
of	O
ventricular	O
assistance	O
and	O
minimal	O
systolic	O
murmur	O
,	O
barely	O
audible	O
,	O
with	O
pulmonary	O
auscultation	O
with	O
hypoventilation	O
in	O
the	O
left	O
hemithorax	O
.	O
There	O
was	O
no	O
hepatomegaly	O
,	O
but	O
there	O
was	O
bimalleolar	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
The	O
driveline	O
outlet	O
was	O
explored	O
and	O
found	O
to	O
be	O
in	O
perfect	O
condition	O
,	O
without	O
suppuration	O
or	O
erythema	O
.	O
The	O
Heart	O
Mate	O
II	O
daily	O
chart	O
shows	O
speeds	O
of	O
9	O
,	O
200	O
rpm	O
,	O
flow	O
rate	O
4	O
.	O
7	O
5	O
.	O
2	O
litres	O
,	O
pulsatility	O
index	O
6	O
.	O
9	O
7	O
.	O
3	O
and	O
power	O
5	O
5	O
.	O
6W	O
.	O
Multiple	O
PI	O
events	O
in	O
relation	O
to	O
suction	O
episodes	O
detected	O
by	O
the	O
machine	O
previously	O
only	O
occasional	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
atrial	O
fibrillation	O
with	O
controlled	O
ventricular	O
response	O
,	O
with	O
controlled	O
RV	O
.	O
Lower	O
QS	O
.	O
Wide	O
QRS	O
140	O
ms	O
with	O
BRD	O
and	O
negative	O
T	O
wave	O
in	O
V1	O
V5	O
unchanged	O
.	O
Chest	O
X	O
ray	O
pleural	O
effusion	O
predominantly	O
left	O
.	O
No	O
increase	O
in	O
interstitial	O
pattern	O
.	O
Cardiac	O
silhouette	O
unchanged	O
with	O
respect	O
to	O
previous	O
studies	O
.	O
Left	O
ventricular	O
assistance	O
and	O
ICD	O
normoimplanted	O
.	O
Analysis	O
on	O
admission	O
Hb	O
12	O
.	O
5	O
mg	O
dl	O
,	O
leukocytes	O
9	O
,	O
450	O
without	O
alteration	O
of	O
the	O
formula	O
.	O
Glucose	O
97	O
,	O
ALT	O
15	O
;	O
GGT	O
98	O
;	O
FA	O
112	O
;	O
Cr	O
1	O
.	O
92	O
;	O
Na	O
135	O
;	O
K	O
4	O
.	O
0	O
;	O
NTproBNP	O
4714	O
;	O
TSH	O
2	O
.	O
31	O
;	O
T4	O
1	O
.	O
6	O
.	O
CBC	O
at	O
discharge	O
Hb	O
12	O
.	O
2	O
,	O
creatinine	O
2	O
.	O
1	O
;	O
Na	O
137	O
,	O
K	O
3	O
.	O
9	O
,	O
NTProBNP	O
1643	O
.	O
Transthoracic	O
echocardiogram	O
on	O
admission	O
very	O
limited	O
study	O
due	O
to	O
the	O
poor	O
window	O
.	O
Left	O
ventricle	O
with	O
dyskinetic	O
movement	O
of	O
the	O
septum	O
.	O
Global	O
function	O
appears	O
severely	O
depressed	O
.	O
Segmental	O
contraction	O
cannot	O
be	O
assessed	O
.	O
Right	O
ventricle	O
not	O
dilated	O
,	O
with	O
apparently	O
normal	O
systolic	O
function	O
.	O
Transesophageal	O
echocardiogram	O
on	O
admission	O
outflow	O
tract	O
at	O
the	O
level	O
of	O
the	O
LV	O
apex	O
positioned	O
close	O
to	O
the	O
anterior	O
interventricular	O
septum	O
,	O
without	O
clear	O
obstruction	O
.	O
Predominantly	O
systolic	O
flow	O
with	O
a	O
high	O
peak	O
end	O
systolic	O
flow	O
of	O
54	O
mHg	O
3	O
.	O
6	O
m	O
s	O
.	O
No	O
evidence	O
of	O
intraventricular	O
thrombus	O
.	O
Entrance	O
cannula	O
in	O
ascending	O
aorta	O
with	O
laminar	O
flow	O
,	O
systolic	O
peak	O
1	O
.	O
1	O
m	O
s	O
,	O
diastolic	O
peak	O
0	O
.	O
24	O
m	O
s	O
.	O
No	O
thrombus	O
in	O
LVOT	O
or	O
aortic	O
root	O
.	O
Left	O
aortic	O
valve	O
free	O
of	O
thrombus	O
with	O
a	O
velocity	O
of	O
around	O
20	O
cm	O
s	O
.	O
Sclerocalcified	O
aortic	O
valve	O
,	O
opening	O
is	O
observed	O
in	O
all	O
beats	O
.	O
Mild	O
I	O
commissural	O
insufficiency	O
.	O
Left	O
ventricle	O
not	O
dilated	O
,	O
moderately	O
depressed	O
global	O
systolic	O
function	O
.	O
Long	O
axis	O
DTD	O
of	O
48	O
.	O
5	O
mm	O
.	O
Short	O
axis	O
fractional	O
area	O
change	O
transgastric	O
of	O
48	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
slightly	O
reduced	O
global	O
function	O
although	O
larger	O
compared	O
to	O
the	O
left	O
,	O
acceptable	O
global	O
function	O
.	O
Interventricular	O
septum	O
with	O
slight	O
bulging	O
towards	O
the	O
LV	O
.	O
Atrial	O
septum	O
intact	O
,	O
slightly	O
bulging	O
to	O
the	O
left	O
.	O
No	O
pericardial	O
effusion	O
.	O
Transesophageal	O
echocardiogram	O
after	O
reduction	O
of	O
the	O
assist	O
revolutions	O
inflow	O
cannula	O
at	O
the	O
level	O
of	O
the	O
LV	O
apex	O
positioned	O
close	O
to	O
the	O
anterior	O
interventricular	O
septum	O
,	O
without	O
obstruction	O
.	O
Continuous	O
flow	O
with	O
a	O
maximum	O
end	O
systolic	O
peak	O
of	O
18	O
mHg	O
and	O
peak	O
velocity	O
of	O
2	O
.	O
1	O
m	O
s	O
decrease	O
from	O
previous	O
TEE	O
.	O
Adequate	O
centration	O
of	O
the	O
IVS	O
,	O
without	O
ballooning	O
to	O
the	O
right	O
or	O
left	O
cavities	O
.	O
The	O
rest	O
was	O
unchanged	O
with	O
respect	O
to	O
the	O
previous	O
study	O
.	O
Haemodynamic	O
study	O
on	O
admission	O
AD	O
16	O
.	O
VD	O
41	O
22	O
.	O
PCP	O
17	O
.	O
AP	O
32	O
16	O
mean	O
24	O
.	O
GTP	O
7	O
.	O
Cardiac	O
output	O
Fick	O
7	O
.	O
7	O
;	O
thermodilution	O
6	O
.	O
9	O
.	O
Haemodynamic	O
study	O
at	O
discharge	O
CVP	O
8	O
mmHg	O
;	O
BP	O
32	O
11	O
18	O
mmHg	O
;	O
PCP	O
14	O
mmHg	O
;	O
thermodilution	O
CO	O
4	O
.	O
9	O
CI	O
2	O
.	O
5	O
l	O
min	O
;	O
Fick	O
CO	O
5	O
.	O
3	O
l	O
min	O
CI	O
2	O
.	O
8	O
.	O
SVR	O
947	O
dynes	O
.	O
EVOLUTION	O
After	O
admission	O
to	O
Cardiology	O
,	O
a	O
haemodynamic	O
study	O
was	O
initially	O
performed	O
,	O
which	O
showed	O
increased	O
right	O
and	O
left	O
pressures	O
with	O
high	O
cardiac	O
output	O
CO	O
7	O
l	O
min	O
,	O
PCP	O
18	O
,	O
DBP	O
16	O
mmHg	O
.	O
In	O
view	O
of	O
this	O
result	O
,	O
treatment	O
was	O
adjusted	O
with	O
an	O
increase	O
in	O
diuretics	O
,	O
which	O
was	O
not	O
tolerated	O
due	O
to	O
worsening	O
renal	O
function	O
.	O
A	O
transesophageal	O
echocardiogram	O
was	O
performed	O
with	O
recovery	O
of	O
partial	O
LVEF	O
shortening	O
faction	O
48	O
with	O
interventricular	O
septum	O
slightly	O
deviated	O
to	O
the	O
left	O
and	O
suction	O
events	O
in	O
the	O
systoles	O
due	O
to	O
increased	O
contractility	O
.	O
The	O
right	O
ventricle	O
persists	O
with	O
good	O
radial	O
function	O
and	O
no	O
cavity	O
dilatation	O
.	O
Aortic	O
valve	O
opening	O
was	O
observed	O
in	O
all	O
beats	O
previously	O
closed	O
,	O
with	O
no	O
intracavitary	O
thrombi	O
.	O
To	O
rule	O
out	O
extracardiac	O
causes	O
,	O
a	O
study	O
of	O
pleural	O
fluid	O
compatible	O
with	O
transudate	O
and	O
a	O
chest	O
CT	O
scan	O
was	O
performed	O
,	O
showing	O
no	O
tumour	O
lesion	O
or	O
infectious	O
consolidation	O
,	O
with	O
passive	O
atelectasis	O
of	O
the	O
left	O
lung	O
due	O
to	O
the	O
effusion	O
.	O
Given	O
the	O
absence	O
of	O
thrombosis	O
data	O
and	O
the	O
recovery	O
of	O
contractility	O
and	O
myocardial	O
function	O
,	O
a	O
diagnosis	O
of	O
high	O
output	O
heart	O
failure	O
with	O
high	O
right	O
and	O
left	O
filling	O
pressures	O
was	O
made	O
,	O
so	O
the	O
assist	O
speed	O
was	O
reduced	O
to	O
8	O
,	O
800	O
rpm	O
parameters	O
after	O
lowering	O
speed	O
8	O
,	O
800	O
rpm	O
,	O
output	O
4	O
.	O
2	O
4	O
.	O
5	O
l	O
min	O
,	O
pulsatility	O
index	O
6	O
.	O
5	O
7	O
,	O
power	O
4	O
.	O
8	O
W	O
.	O
After	O
this	O
,	O
the	O
clinical	O
symptoms	O
of	O
dyspnoea	O
and	O
chest	O
pain	O
resolved	O
and	O
the	O
eventual	O
disappearance	O
of	O
the	O
PI	O
on	O
the	O
alarms	O
.	O
Right	O
catheterisation	O
and	O
TEE	O
showed	O
a	O
normal	O
haemodynamic	O
situation	O
and	O
disappearance	O
of	O
suction	O
events	O
,	O
with	O
pulsatile	O
flow	O
through	O
the	O
assistance	O
but	O
with	O
peak	O
velocities	O
of	O
around	O
2	O
2	O
.	O
4	O
m	O
s	O
.	O
In	O
a	O
stable	O
situation	O
,	O
with	O
vasodilators	O
and	O
low	O
doses	O
of	O
diuretic	O
,	O
the	O
patient	O
was	O
discharged	O
.	O
DIAGNOSIS	O
Heart	O
failure	O
due	O
to	O
high	O
cardiac	O
output	O
.	O
Secondary	O
pleural	O
effusion	O
.	O
HeartMate	O
II	O
type	O
circulatory	O
assist	O
device	O
,	O
normofunctioning	O
.	O
Severe	O
ventricular	O
dysfunction	O
partially	O
recovered	O
after	O
a	O
long	O
period	O
of	O
assistance	O
.	O
Ischaemic	O
dilated	O
cardiomyopathy	O
.	O
3	O
vessel	O
coronary	O
artery	O
disease	O
revascularised	O
with	O
stents	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
53	O
year	O
old	O
male	O
with	O
no	O
known	O
drug	O
allergies	O
or	O
previous	O
cardiological	O
history	O
.	O
As	O
cardiovascular	O
risk	O
factors	O
,	O
the	O
patient	O
had	O
hypertension	O
and	O
type	O
2	O
DM	O
for	O
years	O
and	O
was	O
treated	O
with	O
metformin	B-FARMACO
850	O
1	O
12h	O
and	O
irbersartan	B-FARMACO
hydrochlorothiazide	I-FARMACO
300	O
12	O
.	O
5	O
1	O
24h	O
.	O
The	O
patient	O
has	O
a	O
history	O
of	O
nephritic	O
colic	O
the	O
last	O
one	O
a	O
year	O
ago	O
and	O
underwent	O
otorhinolaryngological	O
examination	O
for	O
progressive	O
bilateral	O
hypoacusis	O
with	O
a	O
diagnosis	O
of	O
chronic	O
sound	O
trauma	O
.	O
The	O
patient	O
consulted	O
for	O
progressive	O
dyspnoea	O
in	O
the	O
last	O
few	O
months	O
until	O
he	O
became	O
moderately	O
laboured	O
.	O
He	O
presented	O
with	O
orthopnoea	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
in	O
the	O
last	O
15	O
days	O
,	O
accompanied	O
by	O
a	O
progressive	O
decrease	O
in	O
diuresis	O
and	O
increased	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
She	O
denies	O
chest	O
pain	O
.	O
She	O
does	O
not	O
report	O
febrile	O
syndrome	O
.	O
A	O
week	O
ago	O
he	O
was	O
diagnosed	O
with	O
possible	O
parotitis	O
,	O
due	O
to	O
bilateral	O
parotid	O
swelling	O
,	O
more	O
marked	O
on	O
the	O
right	O
side	O
.	O
On	O
physical	O
examination	O
the	O
patient	O
is	O
conscious	O
,	O
oriented	O
and	O
cooperative	O
,	O
in	O
good	O
general	O
condition	O
,	O
with	O
good	O
peripheral	O
perfusion	O
.	O
There	O
was	O
swelling	O
of	O
both	O
parotid	O
glands	O
,	O
the	O
right	O
one	O
with	O
a	O
stony	O
consistency	O
.	O
BP	O
126	O
55	O
,	O
HR	O
91	O
bpm	O
.	O
CBC	O
PVY	O
normal	O
.	O
AC	O
rhythmic	O
heart	O
sounds	O
,	O
holodiastolic	O
murmur	O
in	O
aortic	O
focus	O
.	O
AP	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
nondescript	O
.	O
IIJS	O
oedema	O
with	O
fovea	O
up	O
to	O
the	O
knees	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
on	O
admission	O
biochemistry	O
glucose	O
107	O
.	O
0	O
mg	O
dl	O
74	O
.	O
0	O
100	O
.	O
0	O
,	O
lipase	O
29	O
.	O
0	O
IU	O
L	O
3	O
.	O
0	O
60	O
.	O
0	O
,	O
creatinine	O
1	O
.	O
19	O
mg	O
dl	O
0	O
.	O
7	O
1	O
.	O
2	O
,	O
urea	O
44	O
.	O
0	O
mg	O
dl	O
13	O
.	O
0	O
50	O
.	O
0	O
,	O
bilirubin	O
1	O
,	O
28	O
mg	O
dl	O
0	O
.	O
15	O
1	O
.	O
1	O
,	O
sodium	O
ion	O
138	O
.	O
0	O
mmol	O
L	O
135	O
.	O
0	O
145	O
.	O
0	O
,	O
potassium	O
ion	O
4	O
.	O
56	O
mmol	O
l	O
3	O
.	O
3	O
5	O
.	O
1	O
,	O
alanine	O
aminotransferase	O
ALT	O
28	O
.	O
0	O
IU	O
l	O
5	O
,	O
0	O
41	O
.	O
0	O
,	O
aspartate	O
aminotransferase	O
38	O
.	O
0	O
IU	O
l	O
5	O
.	O
0	O
38	O
.	O
0	O
,	O
total	O
protein	O
7	O
.	O
15	O
g	O
dl	O
6	O
.	O
4	O
8	O
.	O
3	O
,	O
C	O
reactive	O
protein	O
1	O
.	O
71	O
mg	O
dl	O
0	O
.	O
1	O
0	O
,	O
5	O
,	O
alpha	O
amylase	O
191	O
.	O
0	O
IU	O
l	O
28	O
.	O
0	O
100	O
.	O
0	O
,	O
renal	O
glomerular	O
filtration	O
rate	O
69	O
.	O
0	O
ml	O
min	O
1	O
.	O
73	O
m2	O
89	O
.	O
0	O
140	O
.	O
0	O
,	O
troponin	O
T	O
us	O
27	O
.	O
0	O
ng	O
l	O
0	O
.	O
0	O
14	O
.	O
0	O
.	O
Haemogram	O
leucocytes	O
4	O
.	O
0	O
10E9	O
L	O
3	O
.	O
6	O
11	O
.	O
0	O
,	O
neutrophils	O
62	O
.	O
4	O
40	O
.	O
0	O
80	O
.	O
0	O
,	O
red	O
cells	O
5	O
.	O
1	O
10E12	O
L	O
4	O
.	O
2	O
6	O
.	O
2	O
,	O
haemoglobin	O
13	O
.	O
9	O
g	O
dl	O
13	O
.	O
0	O
18	O
.	O
0	O
,	O
haematocrit	O
42	O
.	O
3	O
40	O
.	O
0	O
54	O
.	O
0	O
,	O
mean	O
corpuscular	O
volume	O
MCV	O
83	O
.	O
3	O
83	O
.	O
0	O
,	O
haemoglobin	O
13	O
.	O
9	O
g	O
dl	O
13	O
.	O
0	O
18	O
.	O
0	O
,	O
haematocrit	O
42	O
.	O
3	O
40	O
.	O
0	O
54	O
.	O
0	O
.	O
Mean	O
Corpuscular	O
Volume	O
MCV	O
83	O
.	O
3	O
fl	O
80	O
.	O
0	O
100	O
.	O
0	O
,	O
HDI	O
13	O
.	O
1	O
10	O
.	O
5	O
16	O
.	O
0	O
,	O
platelets	O
144	O
.	O
0	O
10E9	O
L	O
130	O
.	O
0	O
450	O
.	O
0	O
.	O
Coagulation	O
prothrombin	O
time	O
12	O
.	O
9	O
sec	O
8	O
.	O
0	O
13	O
.	O
0	O
,	O
prothrombin	O
activity	O
rate	O
70	O
.	O
9	O
70	O
.	O
0	O
140	O
.	O
0	O
,	O
partial	O
thromboplastin	O
To	O
25	O
.	O
3	O
sec	O
22	O
.	O
0	O
37	O
.	O
0	O
,	O
fibrinogen	O
442	O
.	O
0	O
mg	O
dl	O
145	O
.	O
0	O
450	O
.	O
0	O
.	O
EKG	O
sinus	O
rhythm	O
at	O
87	O
bpm	O
,	O
PR	O
174	O
msec	O
,	O
signs	O
of	O
LV	O
enlargement	O
.	O
No	O
significant	O
repolarisation	O
abnormalities	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
within	O
normality	O
.	O
Prominence	O
of	O
both	O
pulmonary	O
hilar	O
lobulated	O
contours	O
,	O
which	O
in	O
the	O
context	O
of	O
the	O
patient	O
could	O
correspond	O
to	O
adenopathies	O
.	O
Free	O
cardiophrenic	O
and	O
costophrenic	O
sinuses	O
.	O
Probable	O
bilateral	O
and	O
diffuse	O
reticulonodular	O
interstitial	O
involvement	O
.	O
I	O
recommend	O
completing	O
the	O
study	O
with	O
chest	O
CT	O
.	O
Echocardiogram	O
LA	O
slightly	O
increased	O
in	O
size	O
43	O
mm	O
,	O
23	O
cm2	O
.	O
LV	O
not	O
dilated	O
in	O
high	O
limits	O
of	O
normality	O
for	O
the	O
patient	O
's	O
CS	O
DD	O
54	O
mm	O
,	O
VTD	O
165	O
ml	O
would	O
correspond	O
to	O
a	O
mild	O
dilatation	O
but	O
indexed	O
to	O
its	O
body	O
surface	O
is	O
72	O
ml	O
m2	O
,	O
in	O
the	O
high	O
limit	O
of	O
normality	O
.	O
Global	O
EF	O
preserved	O
62	O
Simpson	O
biplane	O
.	O
Diastole	O
not	O
assessable	O
due	O
to	O
flow	O
fusion	O
with	O
aortic	O
insufficiency	O
.	O
Normal	O
AD	O
.	O
Normal	O
RV	O
.	O
TAPSE	O
25	O
mm	O
.	O
Mitral	O
leaflets	O
with	O
slight	O
excess	O
tissue	O
and	O
minimal	O
billowing	O
of	O
posterior	O
leaflet	O
without	O
insufficiency	O
.	O
Mild	O
restriction	O
to	O
anterior	O
leaflet	O
opening	O
due	O
to	O
aortic	O
insufficiency	O
.	O
Aortic	O
trivalve	O
,	O
leaflets	O
with	O
minimal	O
sclerosis	O
,	O
although	O
poorly	O
visualised	O
,	O
it	O
appears	O
to	O
be	O
right	O
coronary	O
leaflet	O
prolapse	O
leading	O
to	O
severe	O
eccentric	O
insufficiency	O
towards	O
the	O
anterior	O
mitral	O
leaflet	O
diastolic	O
reverse	O
flow	O
in	O
descending	O
thoracic	O
aorta	O
with	O
end	O
diastolic	O
velocity	O
20	O
cm	O
sec	O
and	O
in	O
abdominal	O
aorta	O
.	O
Aorta	O
normal	O
calibre	O
root	O
sinus	O
33	O
mm	O
.	O
Normal	O
descending	O
and	O
descending	O
aorta	O
.	O
Normal	O
tricuspid	O
.	O
No	O
IT	O
to	O
estimate	O
PAPs	O
.	O
Normal	O
pulmonary	O
.	O
Normal	O
IVC	O
.	O
Normal	O
pericardium	O
.	O
Cardiac	O
catheterisation	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O
Complete	O
laboratory	O
tests	O
biochemistry	O
TSH	O
Tyrotropin	O
2	O
.	O
71	O
μIU	O
ml	O
0	O
.	O
25	O
4	O
.	O
22	O
,	O
alkaline	O
phosphatase	O
85	O
.	O
0	O
IU	O
L	O
40	O
.	O
0	O
129	O
.	O
0	O
,	O
gamma	O
glutamyltransferase	O
GGT	O
141	O
.	O
0	O
IU	O
l	O
3	O
.	O
0	O
71	O
.	O
0	O
,	O
albumin	O
3	O
.	O
78	O
g	O
dl	O
3	O
.	O
5	O
5	O
.	O
2	O
,	O
globulins	O
2	O
,	O
85	O
g	O
dl	O
1	O
.	O
0	O
4	O
.	O
5	O
,	O
albumin	O
globulins	O
1	O
.	O
3	O
1	O
.	O
0	O
2	O
.	O
1	O
,	O
4116	O
albumin	O
corrected	O
calcium	O
2	O
.	O
90	O
mmol	O
l	O
2	O
.	O
15	O
2	O
.	O
5	O
,	O
116	O
albumin	O
corrected	O
calcium	O
11	O
.	O
61	O
mg	O
dl	O
8	O
.	O
62	O
10	O
.	O
02	O
glucose	O
106	O
,	O
0	O
mg	O
dl	O
74	O
.	O
0	O
100	O
.	O
0	O
,	O
creatinine	O
1	O
.	O
87	O
mg	O
dl	O
0	O
.	O
7	O
1	O
.	O
2	O
,	O
urea	O
69	O
.	O
0	O
mg	O
dl	O
13	O
.	O
0	O
50	O
.	O
0	O
,	O
bilirubin	O
0	O
.	O
84	O
mg	O
dl	O
0	O
.	O
15	O
1	O
.	O
1	O
,	O
urate	O
8	O
.	O
09	O
mg	O
dl	O
3	O
.	O
4	O
7	O
.	O
0	O
,	O
sodium	O
ion	O
137	O
.	O
0	O
mmol	O
l	O
135	O
,	O
0	O
145	O
.	O
0	O
,	O
potassium	O
ion	O
4	O
.	O
29	O
mmol	O
l	O
3	O
.	O
3	O
5	O
.	O
1	O
,	O
creatine	O
kinase	O
48	O
.	O
0	O
IU	O
l	O
24	O
.	O
0	O
195	O
.	O
0	O
,	O
alanine	O
aminotransferase	O
ALT	O
30	O
.	O
0	O
IU	O
l	O
5	O
.	O
0	O
41	O
.	O
0	O
,	O
aspartate	O
aminotransferase	O
33	O
.	O
0	O
IU	O
l	O
5	O
.	O
0	O
38	O
,	O
0	O
,	O
total	O
protein	O
6	O
.	O
63	O
g	O
dl	O
6	O
.	O
4	O
8	O
.	O
3	O
,	O
L	O
lactate	O
dehydrogenase	O
159	O
.	O
0	O
IU	O
l	O
135	O
.	O
0	O
225	O
.	O
0	O
,	O
C	O
reactive	O
protein	O
0	O
.	O
74	O
mg	O
dl	O
0	O
.	O
1	O
0	O
.	O
5	O
,	O
alpha	O
amylase	O
223	O
.	O
0	O
IU	O
l	O
28	O
.	O
0	O
100	O
.	O
0	O
,	O
renal	O
glomerular	O
filtration	O
rate	O
40	O
.	O
0	O
ml	O
min	O
1	O
.	O
73	O
m2	O
89	O
.	O
0	O
140	O
.	O
0	O
,	O
total	O
calcium	O
2	O
.	O
86	O
mmol	O
l	O
2	O
.	O
15	O
2	O
.	O
5	O
,	O
total	O
calcium	O
11	O
.	O
44	O
mg	O
dl	O
8	O
.	O
62	O
10	O
.	O
02	O
,	O
phosphate	O
1	O
.	O
02	O
mmol	O
l	O
0	O
.	O
81	O
1	O
.	O
45	O
,	O
phosphate	O
3	O
.	O
16	O
mg	O
dl	O
2	O
,	O
5	O
4	O
.	O
5	O
intact	O
parathormone	O
9	O
.	O
0	O
pg	O
ml	O
15	O
.	O
0	O
65	O
.	O
0	O
,	O
ACE	O
angiotensin	O
converting	O
enzyme	O
175	O
.	O
0	O
U	O
l	O
20	O
.	O
0	O
70	O
.	O
0	O
,	O
vitamin	O
D	O
25hydroxychalciferol	O
9	O
.	O
0	O
ng	O
ml	O
,	O
albumin	O
4	O
.	O
06	O
g	O
dl	O
3	O
.	O
5	O
5	O
,	O
2	O
,	O
globulins	O
2	O
.	O
73	O
g	O
dl	O
1	O
.	O
0	O
4	O
.	O
5	O
,	O
albumin	O
globulins	O
1	O
.	O
5	O
1	O
.	O
0	O
2	O
.	O
1	O
,	O
albumin	O
corrected	O
calcium	O
2	O
.	O
89	O
mmol	O
l	O
2	O
.	O
15	O
2	O
.	O
5	O
,	O
albumin	O
corrected	O
calcium	O
11	O
.	O
58	O
mg	O
dl	O
8	O
.	O
62	O
10	O
.	O
02	O
.	O
CBC	O
leucocytes	O
3	O
.	O
5	O
10E9	O
L	O
3	O
.	O
6	O
11	O
.	O
0	O
,	O
sedimentation	O
rate	O
23	O
.	O
0	O
mm	O
0	O
.	O
0	O
20	O
.	O
0	O
,	O
neutrophils	O
55	O
.	O
2	O
40	O
.	O
0	O
80	O
.	O
0	O
,	O
red	O
cells	O
4	O
.	O
9	O
10E12	O
L	O
4	O
.	O
2	O
6	O
.	O
2	O
,	O
haemoglobin	O
13	O
.	O
8	O
g	O
dl	O
13	O
.	O
0	O
18	O
.	O
0	O
,	O
haematocrit	O
41	O
.	O
2	O
40	O
.	O
0	O
54	O
.	O
0	O
,	O
mean	O
corpuscular	O
volume	O
MCV	O
83	O
.	O
7	O
mm	O
0	O
.	O
0	O
7	O
.	O
0	O
.	O
mean	O
corpuscular	O
volume	O
MCV	O
83	O
.	O
7	O
fl	O
80	O
.	O
0	O
100	O
.	O
0	O
,	O
platelets	O
125	O
.	O
0	O
10E9	O
L	O
130	O
.	O
0	O
450	O
.	O
0	O
.	O
Coagulation	O
prothrombin	O
time	O
12	O
.	O
4	O
sec	O
8	O
.	O
0	O
13	O
.	O
0	O
,	O
prothrombin	O
activity	O
rate	O
76	O
.	O
5	O
70	O
.	O
0	O
140	O
.	O
0	O
,	O
partial	O
thromboplastin	O
To	O
26	O
.	O
2	O
sec	O
22	O
.	O
0	O
37	O
.	O
0	O
,	O
fibrinogen	O
297	O
.	O
0	O
mg	O
dl	O
145	O
.	O
0	O
450	O
.	O
0	O
.	O
Neck	O
ultrasound	O
bilateral	O
and	O
symmetrical	O
enlargement	O
of	O
both	O
parotid	O
glands	O
,	O
with	O
smooth	O
,	O
well	O
defined	O
borders	O
and	O
an	O
inhomogeneous	O
and	O
reduced	O
echostructure	O
,	O
with	O
diffuse	O
hypoechoic	O
pseudonodular	O
punctate	O
images	O
.	O
The	O
glandular	O
vascularisation	O
is	O
normal	O
and	O
symmetrical	O
.	O
There	O
are	O
no	O
distinct	O
intraparotid	O
focal	O
lesions	O
.	O
The	O
described	O
findings	O
suggest	O
inflammatory	O
infectious	O
pathology	O
as	O
a	O
first	O
possibility	O
.	O
Bilateral	O
submaxillary	O
and	O
laterocervical	O
adenopathies	O
,	O
all	O
of	O
them	O
subcentimetric	O
and	O
non	O
specific	O
.	O
Normal	O
sized	O
submaxillary	O
glands	O
,	O
without	O
focal	O
lesions	O
.	O
Normal	O
size	O
thyroid	O
,	O
with	O
the	O
right	O
lobe	O
measuring	O
20	O
x	O
19	O
x	O
46	O
mm	O
AP	O
x	O
T	O
x	O
CC	O
and	O
the	O
left	O
lobe	O
measuring	O
13	O
x	O
15	O
x	O
46	O
mm	O
.	O
In	O
the	O
right	O
lobe	O
there	O
is	O
a	O
heterogeneous	O
,	O
predominantly	O
cystic	O
lesion	O
with	O
a	O
thick	O
wall	O
and	O
multiple	O
thick	O
septa	O
inside	O
,	O
measuring	O
15	O
x	O
15	O
x	O
15	O
x	O
20	O
mm	O
.	O
In	O
the	O
left	O
lobe	O
there	O
is	O
a	O
mixed	O
,	O
predominantly	O
solid	O
,	O
isoechogenic	O
nodule	O
with	O
some	O
peripheral	O
gross	O
calcifications	O
and	O
small	O
cystic	O
areas	O
,	O
measuring	O
7	O
x	O
8	O
x	O
9	O
mm	O
;	O
a	O
mixed	O
nodule	O
in	O
the	O
inferior	O
pole	O
,	O
heterogeneous	O
,	O
predominantly	O
solid	O
,	O
measuring	O
9	O
x	O
13	O
x	O
14	O
mm	O
;	O
and	O
a	O
gross	O
calcification	O
of	O
3	O
mm	O
.	O
A	O
directed	O
study	O
and	O
FNA	O
are	O
recommended	O
.	O
Abdominal	O
ultrasound	O
liver	O
with	O
increased	O
echogenicity	O
,	O
homogeneous	O
,	O
with	O
no	O
evidence	O
of	O
space	O
occupying	O
lesions	O
.	O
Normal	O
gallbladder	O
and	O
bile	O
duct	O
.	O
Portal	O
vein	O
permeable	O
.	O
Homogeneous	O
splenomegaly	O
of	O
16	O
cm	O
.	O
Retroperitoneum	O
visualised	O
without	O
pathological	O
findings	O
.	O
Kidneys	O
without	O
dilatation	O
of	O
the	O
excretory	O
tract	O
or	O
other	O
alterations	O
.	O
Aorta	O
of	O
normal	O
calibre	O
.	O
CT	O
scan	O
performed	O
without	O
VSD	O
due	O
to	O
the	O
patient	O
's	O
poor	O
renal	O
function	O
.	O
However	O
,	O
abundant	O
mediastinal	O
adenopathies	O
of	O
pathological	O
size	O
in	O
the	O
different	O
mediastinal	O
compartments	O
,	O
bilateral	O
hilar	O
,	O
subcarinal	O
,	O
aortopulmonary	O
window	O
,	O
prevascular	O
,	O
etc	O
.	O
,	O
are	O
identified	O
.	O
Widespread	O
peribronchial	O
thickening	O
.	O
Interstitial	O
pattern	O
predominantly	O
in	O
apexes	O
and	O
bases	O
with	O
thickening	O
of	O
the	O
interlobular	O
septa	O
.	O
No	O
pleural	O
effusion	O
is	O
identified	O
.	O
Hepatosplenomegaly	O
.	O
Spleen	O
17	O
x	O
7	O
cm	O
in	O
hepatopathy	O
,	O
sarcoidosis	O
,	O
etc	O
.	O
.	O
Normal	O
gall	O
bladder	O
.	O
FNA	O
Benign	O
type	O
2	O
.	O
Cystic	O
colloid	O
nodules	O
Parotid	O
FNA	O
samples	O
consisting	O
of	O
haematic	O
material	O
and	O
very	O
occasional	O
epithelial	O
cells	O
without	O
atypia	O
or	O
evidence	O
of	O
malignancy	O
.	O
Thyroid	O
FNA	O
cytological	O
smears	O
showing	O
foamy	O
histiocytes	O
and	O
follicular	O
cells	O
without	O
atypia	O
arranged	O
in	O
a	O
dissociated	O
manner	O
on	O
a	O
colloid	O
background	O
.	O
Diagnosis	O
Colloid	O
nodule	O
with	O
cystic	O
like	O
changes	O
.	O
FNA	O
of	O
mediastinal	O
adenopathies	O
by	O
bronchoscopy	O
with	O
confirmation	O
of	O
material	O
compatible	O
with	O
sarcoidosis	O
.	O
Cardiac	O
MRI	O
LV	O
and	O
RV	O
images	O
were	O
obtained	O
in	O
cine	O
sequences	O
,	O
late	O
enhancement	O
after	O
gadolinium	O
administration	O
and	O
flow	O
quantification	O
in	O
pulmonary	O
and	O
aortic	O
valves	O
.	O
LV	O
mildly	O
dilated	O
,	O
with	O
TVV	O
of	O
96	O
ml	O
m2	O
range	O
47	O
92	O
ml	O
m2	O
and	O
STV	O
of	O
39	O
ml	O
m2	O
range	O
13	O
30	O
ml	O
m2	O
.	O
EF	O
59	O
,	O
cardiac	O
output	O
8	O
.	O
3	O
l	O
min	O
and	O
stroke	O
volume	O
128	O
ml	O
.	O
Normal	O
segmental	O
contractility	O
.	O
Normal	O
myocardial	O
mass	O
of	O
88	O
g	O
m2	O
range	O
70	O
113	O
g	O
m2	O
.	O
Maximum	O
septal	O
thickness	O
of	O
13	O
mm	O
.	O
Mild	O
concentric	O
hypertrophy	O
.	O
No	O
areas	O
of	O
non	O
compaction	O
.	O
Subepicardial	O
hyperenhancement	O
of	O
contrast	O
in	O
basal	O
posterior	O
segment	O
compatible	O
with	O
myocardial	O
fibrosis	O
in	O
the	O
clinical	O
context	O
of	O
sarcoidosis	O
.	O
Mechanical	O
aortic	O
valve	O
prosthesis	O
.	O
RV	O
normal	O
size	O
,	O
without	O
morphological	O
alterations	O
,	O
with	O
TVD	O
of	O
74	O
ml	O
m2	O
range	O
55	O
105	O
ml	O
m2	O
and	O
STV	O
of	O
18	O
ml	O
m2	O
range	O
15	O
43	O
ml	O
m2	O
.	O
EF	O
of	O
75	O
,	O
cardiac	O
output	O
8	O
.	O
3	O
l	O
min	O
and	O
stroke	O
volume	O
127	O
ml	O
.	O
Normal	O
contractility	O
.	O
Jet	O
of	O
tricuspid	O
regurgitation	O
.	O
LA	O
Area	O
20	O
cm2	O
,	O
normal	O
size	O
.	O
RA	O
area	O
of	O
24	O
cm2	O
,	O
slightly	O
dilated	O
.	O
Ascending	O
aorta	O
of	O
normal	O
calibre	O
2	O
.	O
9	O
x	O
2	O
.	O
9	O
cm	O
.	O
Pulmonary	O
artery	O
of	O
normal	O
calibre	O
2	O
.	O
9	O
x	O
2	O
.	O
3	O
cm	O
.	O
Pericardium	O
No	O
pericardial	O
thickening	O
is	O
observed	O
.	O
Mild	O
moderate	O
pericardial	O
effusion	O
with	O
a	O
maximum	O
thickness	O
of	O
1	O
.	O
2	O
cm	O
in	O
the	O
lateral	O
aspect	O
of	O
the	O
LV	O
.	O
Paratracheal	O
mediastinal	O
adenopathies	O
2	O
cm	O
short	O
axis	O
,	O
prevascular	O
1	O
.	O
5	O
cm	O
,	O
aortopulmonary	O
window	O
1	O
.	O
2	O
cm	O
,	O
subcarinal	O
1	O
.	O
9	O
cm	O
,	O
in	O
left	O
hilum	O
1	O
.	O
8	O
and	O
2	O
.	O
1	O
cm	O
,	O
in	O
right	O
hilum	O
2	O
.	O
2	O
and	O
1	O
.	O
8	O
cm	O
compatible	O
with	O
sarcoidosis	O
.	O
Middle	O
sternotomy	O
wires	O
.	O
EVOLUTION	O
The	O
transthoracic	O
echocardiogram	O
showed	O
a	O
slightly	O
dilated	O
and	O
hypertrophic	O
LV	O
with	O
preserved	O
systolic	O
function	O
and	O
the	O
existence	O
of	O
a	O
trivalve	O
aortic	O
valve	O
with	O
severe	O
insufficiency	O
at	O
the	O
expense	O
of	O
the	O
right	O
coronary	O
leaflet	O
that	O
appears	O
to	O
present	O
a	O
flail	O
.	O
On	O
the	O
other	O
hand	O
,	O
given	O
the	O
findings	O
of	O
the	O
examination	O
,	O
serological	O
studies	O
were	O
requested	O
,	O
which	O
ruled	O
out	O
an	O
infectious	O
origin	O
.	O
Laboratory	O
data	O
showed	O
hypercalcaemia	O
and	O
elevated	O
ACE	O
angiotensin	O
converting	O
enzyme	O
levels	O
as	O
the	O
most	O
relevant	O
findings	O
and	O
,	O
together	O
with	O
the	O
chest	O
X	O
ray	O
showing	O
a	O
prominence	O
of	O
both	O
pulmonary	O
hilums	O
compatible	O
with	O
lymphadenopathy	O
,	O
a	O
diagnosis	O
of	O
sarcoidosis	O
with	O
parotid	O
and	O
cardiac	O
involvement	O
was	O
established	O
.	O
Chest	O
CT	O
showed	O
multiple	O
mediastinal	O
,	O
hilar	O
and	O
subcarinal	O
adenopathies	O
,	O
as	O
well	O
as	O
a	O
predominant	O
interstitial	O
pattern	O
in	O
the	O
vertex	O
and	O
bases	O
.	O
To	O
confirm	O
the	O
diagnosis	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
parotid	O
FNA	O
and	O
finally	O
fibrobronchoscopy	O
with	O
biopsy	O
of	O
one	O
of	O
the	O
lymph	O
nodes	O
with	O
the	O
presence	O
of	O
non	O
caseating	O
granulomas	O
,	O
confirming	O
the	O
diagnosis	O
of	O
sarcoidosis	O
.	O
The	O
patient	O
underwent	O
aortic	O
valve	O
replacement	O
.	O
The	O
valve	O
was	O
described	O
as	O
a	O
very	O
thin	O
,	O
sagging	O
right	O
coronary	O
leaflet	O
,	O
with	O
no	O
aortic	O
annulus	O
in	O
that	O
area	O
,	O
with	O
prolapse	O
of	O
the	O
left	O
leaflet	O
and	O
retraction	O
of	O
the	O
non	O
coronary	O
leaflet	O
,	O
for	O
which	O
reason	O
it	O
was	O
decided	O
to	O
implant	O
a	O
mechanical	O
prosthesis	O
.	O
The	O
surgical	O
specimen	O
was	O
sent	O
for	O
anatomopathological	O
examination	O
,	O
which	O
confirmed	O
the	O
existence	O
of	O
non	O
caseating	O
granulomas	O
compatible	O
with	O
sarcoidosis	O
.	O
Two	O
months	O
after	O
surgery	O
,	O
cardiac	O
MRI	O
showed	O
a	O
slightly	O
dilated	O
and	O
hypertrophic	O
LV	O
with	O
pathological	O
Gadolinium	O
uptake	O
in	O
the	O
subepicardial	O
region	O
,	O
predominantly	O
in	O
the	O
posterobasal	O
segment	O
,	O
compatible	O
with	O
cardiac	O
involvement	O
in	O
the	O
context	O
of	O
systemic	O
sarcoidosis	O
.	O
At	O
present	O
,	O
the	O
patient	O
is	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
with	O
functional	O
grade	O
I	O
IV	O
in	O
outpatient	O
follow	O
up	O
by	O
internal	O
medicine	O
and	O
cardiology	O
and	O
with	O
treatment	O
with	O
corticoids	O
without	O
having	O
presented	O
new	O
episodes	O
of	O
decompensation	O
since	O
hospital	O
discharge	O
.	O
DIAGNOSIS	O
Systemic	O
sarcoidosis	O
with	O
cardiac	O
involvement	O
.	O
Severe	O
aortic	O
insufficiency	O
due	O
to	O
sarcoid	O
valve	O
involvement	O
.	O
Aortic	O
valve	O
replacement	O
by	O
mechanical	O
prosthesis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
53	O
year	O
old	O
male	O
admitted	O
to	O
the	O
Cardiac	O
Intensive	O
Care	O
Unit	O
CICU	O
after	O
recovering	O
from	O
cardiorespiratory	O
arrest	O
in	O
the	O
street	O
.	O
Personal	O
history	O
Arterial	O
hypertension	O
under	O
treatment	O
with	O
enalapril	B-FARMACO
20	O
mg	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
being	O
treated	O
with	O
metformin	B-FARMACO
.	O
Hyperuricaemia	O
with	O
several	O
episodes	O
of	O
gouty	O
arthritis	O
.	O
On	O
treatment	O
with	O
allopurinol	B-FARMACO
.	O
Present	O
illness	O
Witnesses	O
report	O
that	O
,	O
while	O
working	O
cook	O
and	O
without	O
reporting	O
any	O
previous	O
symptoms	O
,	O
he	O
fainted	O
with	O
loss	O
of	O
consciousness	O
.	O
After	O
the	O
initial	O
approach	O
by	O
the	O
witnesses	O
,	O
112	O
was	O
contacted	O
,	O
the	O
absence	O
of	O
breathing	O
or	O
signs	O
of	O
life	O
was	O
detected	O
and	O
basic	O
cardiopulmonary	O
resuscitation	O
manoeuvres	O
were	O
started	O
.	O
After	O
7	O
minutes	O
,	O
following	O
the	O
arrival	O
of	O
Basic	O
Life	O
Support	O
112	O
,	O
a	O
defibrillable	O
rhythm	O
is	O
detected	O
by	O
AED	O
.	O
Up	O
to	O
4	O
shocks	O
with	O
the	O
corresponding	O
30	O
2	O
cycles	O
were	O
applied	O
together	O
with	O
2	O
boluses	O
of	O
adrenaline	B-FARMACO
and	O
300	O
mg	O
of	O
amiodarone	B-FARMACO
.	O
After	O
the	O
fourth	O
shock	O
,	O
the	O
patient	O
recovered	O
sinus	O
rhythm	O
at	O
92	O
bpm	O
and	O
was	O
transferred	O
to	O
the	O
CICU	O
sedated	O
,	O
intubated	O
and	O
connected	O
to	O
mechanical	O
ventilation	O
.	O
Physical	O
examination	O
Sedoanalgesia	O
.	O
RASS	O
4	O
.	O
Pupils	O
isochoric	O
,	O
miotic	O
and	O
reactive	O
.	O
BP	O
95	O
45	O
;	O
HR	O
125	O
bpm	O
;	O
peripheral	O
O2	O
saturation	O
100	O
with	O
FiO2	O
of	O
100	O
.	O
Rhythmic	O
,	O
tachycardic	O
heart	O
sounds	O
without	O
murmurs	O
.	O
Bladder	O
murmur	O
preserved	O
bilaterally	O
.	O
Abdomen	O
slightly	O
distended	O
and	O
tympanic	O
.	O
Bowel	O
sounds	O
present	O
.	O
Lower	O
limbs	O
without	O
oedema	O
and	O
bilateral	O
pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
haemoglobin	O
14	O
.	O
5	O
g	O
dl	O
;	O
leucocytes	O
12	O
,	O
900	O
36	O
N	O
;	O
platelets	O
191	O
.	O
000	O
;	O
prothrombin	O
activity	O
100	O
;	O
creatinine	O
1	O
.	O
2	O
mg	O
dl	O
;	O
GFR	O
MDRD	O
4	O
67	O
ml	O
min	O
;	O
glucose	O
293	O
mg	O
dl	O
;	O
BUN	O
17	O
U	O
L	O
;	O
sodium	O
142	O
mee	O
l	O
;	O
potassium	O
3	O
.	O
9	O
meq	O
l	O
;	O
GOT	O
197	O
U	O
l	O
;	O
GPT	O
159	O
U	O
L	O
;	O
troponin	O
I	O
0	O
.	O
045	O
ng	O
ml	O
;	O
NT	O
proBNP	O
636	O
pg	O
ml	O
;	O
CRP	O
5	O
mg	O
l	O
.	O
Peak	O
troponin	O
I	O
3	O
ng	O
ml	O
.	O
Urine	O
toxicity	O
cocaine	O
,	O
amphetamines	O
,	O
cannabis	O
negative	O
.	O
Chest	O
X	O
ray	O
slight	O
increase	O
in	O
cardiothoracic	O
index	O
.	O
No	O
evidence	O
of	O
infiltrates	O
.	O
Endotracheal	O
tube	O
is	O
centred	O
and	O
normally	O
positioned	O
.	O
A	O
B	O
balance	O
on	O
arrival	O
pH	O
7	O
.	O
34	O
;	O
pO2	O
427	O
;	O
pCO2	O
48	O
;	O
HCO3	O
25	O
.	O
9	O
;	O
lactic	O
7	O
.	O
6	O
mmol	O
l	O
.	O
Transthoracic	O
echocardiography	O
slightly	O
hypertrophic	O
left	O
ventricle	O
with	O
segmental	O
alterations	O
of	O
contractility	O
.	O
Moderately	O
reduced	O
left	O
ventricular	O
systolic	O
function	O
.	O
Prolonged	O
left	O
ventricular	O
relaxation	O
E	O
é	O
9	O
.	O
Absence	O
of	O
valvular	O
heart	O
disease	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
with	O
normal	O
systolic	O
function	O
.	O
Cranial	O
CT	O
no	O
significant	O
alterations	O
in	O
the	O
density	O
of	O
the	O
brain	O
parenchyma	O
.	O
Ventricular	O
system	O
of	O
normal	O
size	O
and	O
morphology	O
,	O
without	O
displacements	O
with	O
respect	O
to	O
the	O
midline	O
.	O
No	O
signs	O
of	O
intracranial	O
bleeding	O
were	O
observed	O
.	O
Cardiac	O
magnetic	O
resonance	O
non	O
dilated	O
left	O
ventricle	O
with	O
moderate	O
left	O
ventricular	O
dysfunction	O
.	O
Intramyocardial	O
patchy	O
intramyocardial	O
enhancement	O
in	O
anterior	O
and	O
posterior	O
mid	O
apical	O
face	O
.	O
Findings	O
compatible	O
with	O
acute	O
myocarditis	O
.	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
CICU	O
and	O
femoral	O
venous	O
access	O
was	O
channelled	O
for	O
induced	O
hypothermia	O
for	O
the	O
first	O
24	O
hours	O
at	O
33	O
C	O
.	O
He	O
was	O
kept	O
sedated	O
and	O
anaesthetised	O
.	O
He	O
remained	O
sedated	O
and	O
relaxed	O
,	O
with	O
a	O
tendency	O
to	O
bradycardia	O
and	O
arterial	O
hypotension	O
.	O
The	O
internal	O
environment	O
was	O
corrected	O
and	O
lactacidemia	O
and	O
pH	O
were	O
normalised	O
.	O
After	O
24	O
hours	O
of	O
hypothermia	O
,	O
progressive	O
rewarming	O
began	O
,	O
relaxation	O
was	O
withdrawn	O
and	O
sedation	O
was	O
gradually	O
discontinued	O
.	O
Seventy	O
two	O
hours	O
after	O
admission	O
,	O
the	O
patient	O
presented	O
with	O
abnormal	O
movements	O
,	O
such	O
as	O
shivering	O
,	O
coinciding	O
with	O
an	O
increase	O
in	O
temperature	O
38	O
C	O
,	O
for	O
which	O
reason	O
an	O
EEG	O
was	O
requested	O
,	O
which	O
ruled	O
out	O
the	O
presence	O
of	O
status	O
convulsus	O
.	O
Antibiotic	O
therapy	O
was	O
intensified	O
ceftriaxone	B-FARMACO
clindamycin	I-FARMACO
after	O
finding	O
a	O
right	O
basal	O
infiltrate	O
on	O
X	O
ray	O
,	O
probably	O
related	O
to	O
aspiration	O
during	O
intubation	O
.	O
Weaning	O
progressed	O
to	O
extubation	O
on	O
the	O
5th	O
day	O
.	O
The	O
cranial	O
CT	O
scan	O
after	O
extubation	O
showed	O
no	O
alterations	O
of	O
interest	O
.	O
Monitoring	O
in	O
the	O
CICU	O
detected	O
the	O
presence	O
of	O
ventricular	O
extrasystoles	O
without	O
sustained	O
arrhythmias	O
.	O
Coronary	O
angiography	O
showed	O
coronary	O
arteries	O
free	O
of	O
significant	O
obstructive	O
lesions	O
.	O
Once	O
on	O
the	O
hospital	O
ward	O
,	O
he	O
remained	O
in	O
asymptomatic	O
rehabilitation	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
showed	O
patchy	O
intramyocardial	O
uptake	O
compatible	O
with	O
myocarditis	O
and	O
left	O
ventricular	O
function	O
was	O
moderately	O
depressed	O
38	O
.	O
Two	O
weeks	O
after	O
admission	O
,	O
a	O
single	O
chamber	O
ICD	O
was	O
implanted	O
,	O
without	O
incident	O
,	O
for	O
secondary	O
prevention	O
of	O
sudden	O
death	O
secondary	O
to	O
cardiomyopathy	O
due	O
to	O
myocarditis	O
.	O
DIAGNOSIS	O
Cardiorespiratory	O
arrest	O
recovered	O
.	O
Aspirative	O
pneumonia	O
.	O
Cardiomyopathy	O
secondary	O
to	O
myocarditis	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
33	O
year	O
old	O
man	O
who	O
presented	O
with	O
ventricular	O
fibrillation	O
and	O
cardiorespiratory	O
arrest	O
after	O
taking	O
ibuprofen	B-FARMACO
.	O
HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
No	O
known	O
hypertension	O
,	O
diabetes	O
mellitus	O
or	O
dyslipidaemia	O
.	O
Mental	O
and	O
behavioural	O
disorder	O
due	O
to	O
alcohol	O
consumption	O
,	O
in	O
remission	O
.	O
Mixed	O
adaptive	O
distress	O
.	O
Intrinsic	O
rhinitis	O
and	O
bronchial	O
asthma	O
and	O
history	O
of	O
atopy	O
since	O
childhood	O
.	O
Very	O
doubtful	O
drug	O
allergy	O
years	O
ago	O
,	O
she	O
does	O
not	O
remember	O
to	O
which	O
drug	O
,	O
which	O
has	O
not	O
been	O
studied	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
No	O
chronic	O
treatment	O
.	O
Current	O
illness	O
She	O
came	O
to	O
the	O
emergency	O
department	O
with	O
an	O
incised	O
contuse	O
wound	O
on	O
the	O
right	O
forearm	O
following	O
an	O
accident	O
at	O
work	O
with	O
an	O
iron	O
.	O
The	O
wound	O
was	O
treated	O
locally	O
,	O
requiring	O
suturing	O
and	O
bandaging	O
.	O
Gamma	O
globulin	O
and	O
a	O
first	O
dose	O
of	O
tetanus	O
vaccine	O
were	O
administered	O
.	O
On	O
discharge	O
a	O
series	O
of	O
recommendations	O
were	O
given	O
treatment	O
with	O
ibuprofen	B-FARMACO
600	O
mg	O
every	O
8	O
hours	O
for	O
5	O
7	O
days	O
in	O
the	O
presence	O
of	O
pain	O
and	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
500	O
125	O
mg	O
every	O
8	O
hours	O
for	O
8	O
days	O
.	O
In	O
the	O
evening	O
,	O
the	O
patient	O
,	O
because	O
of	O
severe	O
pain	O
in	O
the	O
forearm	O
,	O
decided	O
to	O
take	O
1	O
tablet	O
of	O
ibuprofen	B-FARMACO
.	O
Thirty	O
minutes	O
after	O
taking	O
it	O
,	O
he	O
began	O
to	O
feel	O
nausea	O
,	O
vomiting	O
,	O
sweating	O
and	O
sudden	O
dyspnoea	O
,	O
so	O
his	O
wife	O
called	O
061	O
.	O
On	O
arrival	O
of	O
the	O
ambulance	O
,	O
the	O
patient	O
was	O
pale	O
and	O
sweaty	O
,	O
suffering	O
cardiorespiratory	O
arrest	O
in	O
their	O
presence	O
,	O
so	O
they	O
started	O
CPR	O
manoeuvres	O
and	O
performed	O
an	O
ECG	O
which	O
showed	O
ventricular	O
fibrillation	O
.	O
The	O
patient	O
was	O
resuscitated	O
for	O
75	O
minutes	O
and	O
required	O
5	O
defibrillations	O
at	O
200	O
J	O
,	O
450	O
mg	O
intravenous	O
amiodarone	B-FARMACO
,	O
12	O
mg	O
adrenaline	B-FARMACO
,	O
1	O
M	O
intravenous	O
bicabonate	B-FARMACO
and	O
orotracheal	O
intubation	O
for	O
mechanical	O
ventilation	O
.	O
Referred	O
to	O
ICU	O
for	O
further	O
care	O
after	O
recovery	O
of	O
pulse	O
.	O
COMPLEMENTARY	O
TESTS	O
061	O
electrocardiogram	O
ventricular	O
fibrillation	O
.	O
ICU	O
blood	O
tests	O
troponin	O
T	O
21	O
ng	O
ml	O
normal	O
up	O
to	O
0	O
.	O
05	O
ng	O
ml	O
,	O
creatinine	O
1	O
.	O
47mg	O
dl	O
,	O
urea	O
42	O
mg	O
dl	O
,	O
sodium	O
140	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
1	O
mEq	O
l	O
,	O
glycaemia	O
159	O
mg	O
dl	O
.	O
Haemoglobin	O
17	O
g	O
dl	O
,	O
haematocrit	O
51	O
,	O
leucocytes	O
16	O
,	O
000	O
10e3	O
ul	O
,	O
platelets	O
359	O
,	O
000	O
10e3	O
ul	O
.	O
PT	O
ratio	O
1	O
.	O
1	O
0	O
.	O
8	O
1	O
.	O
3	O
,	O
aPTT	O
ratio	O
2	O
0	O
.	O
8	O
1	O
.	O
3	O
.	O
Arterial	O
blood	O
gases	O
FiO2	O
50	O
pH	O
7	O
.	O
30	O
,	O
PCO2	O
41	O
,	O
PO2	O
201	O
,	O
bicarbonate	O
19	O
,	O
lactate	O
4	O
.	O
2	O
.	O
Electrocardiogram	O
on	O
admission	O
to	O
ICU	O
sinus	O
rhythm	O
at	O
78	O
bpm	O
,	O
PR	O
200	O
ms	O
,	O
electrical	O
axis	O
deviated	O
to	O
the	O
right	O
.	O
Wide	O
QRS	O
with	O
image	O
of	O
complete	O
right	O
bundle	O
branch	O
block	O
with	O
secondary	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
in	O
AP	O
cardiothoracic	O
index	O
not	O
assessable	O
.	O
Free	O
costophrenic	O
and	O
cardiophrenic	O
sinuses	O
.	O
Right	O
hilar	O
slightly	O
congestive	O
.	O
No	O
parenchymal	O
nodules	O
or	O
masses	O
or	O
pleural	O
pathology	O
.	O
Simple	O
skull	O
CT	O
scan	O
findings	O
compatible	O
with	O
significant	O
diffuse	O
cerebral	O
oedema	O
.	O
Echocardiogram	O
LV	O
neither	O
dilated	O
nor	O
hypertrophic	O
,	O
severe	O
systolic	O
dysfunction	O
,	O
global	O
hypokinesia	O
probably	O
secondary	O
to	O
stunning	O
and	O
akinesia	O
in	O
the	O
LAD	O
territory	O
.	O
Normal	O
valves	O
.	O
No	O
tricuspid	O
insufficiency	O
or	O
indirect	O
data	O
of	O
pulmonary	O
hypertension	O
.	O
Normal	O
atria	O
.	O
Normal	O
RV	O
.	O
Severe	O
systolic	O
dysfunction	O
of	O
probable	O
ischaemic	O
origin	O
in	O
the	O
LAD	O
territory	O
and	O
stunning	O
component	O
.	O
Cardiac	O
catheterisation	O
epicardial	O
arteries	O
without	O
angiographically	O
visible	O
lesions	O
.	O
EVOLUTION	O
On	O
arrival	O
at	O
the	O
ICU	O
the	O
patient	O
was	O
intubated	O
,	O
comatose	O
with	O
3	O
points	O
on	O
the	O
Glasgow	O
scale	O
.	O
Pupils	O
are	O
mydriatic	O
,	O
reactive	O
and	O
symmetrical	O
.	O
The	O
patient	O
remains	O
under	O
hypothermia	O
protocol	O
at	O
34	O
C	O
under	O
sedation	O
and	O
connected	O
to	O
invasive	O
mechanical	O
ventilation	O
.	O
Anticoagulated	O
at	O
that	O
time	O
with	O
enoxaparin	B-FARMACO
and	O
double	O
anti	O
aggregation	O
with	O
ASA	B-FARMACO
and	O
clopidogrel	B-FARMACO
in	O
the	O
presence	O
of	O
clinical	O
suspicion	O
of	O
AMI	O
.	O
The	O
electrocardiogram	O
showed	O
the	O
patient	O
in	O
sinus	O
rhythm	O
with	O
a	O
right	O
bundle	O
branch	O
block	O
which	O
was	O
not	O
known	O
to	O
be	O
present	O
previously	O
.	O
An	O
urgent	O
CT	O
scan	O
of	O
the	O
brain	O
showed	O
significant	O
cerebral	O
oedema	O
and	O
an	O
echocardiogram	O
showed	O
severe	O
systolic	O
dysfunction	O
,	O
alterations	O
in	O
contractility	O
in	O
the	O
LAD	O
territory	O
and	O
a	O
stunning	O
component	O
.	O
Given	O
the	O
results	O
of	O
the	O
echocardiogram	O
,	O
cardiac	O
catheterisation	O
was	O
performed	O
,	O
showing	O
epicardial	O
coronary	O
arteries	O
without	O
lesions	O
,	O
and	O
intensive	O
care	O
continued	O
in	O
the	O
ICU	O
.	O
The	O
patient	O
died	O
two	O
days	O
later	O
.	O
Given	O
the	O
relationship	O
with	O
the	O
intake	O
of	O
NSAIDs	O
and	O
the	O
symptoms	O
suggesting	O
a	O
high	O
probability	O
of	O
anaphylactic	O
shock	O
,	O
the	O
patient	O
was	O
finally	O
classified	O
as	O
probable	O
Kounis	O
syndrome	O
with	O
a	O
fatal	O
outcome	O
.	O
DIAGNOSIS	O
Out	O
of	O
hospital	O
cardiorespiratory	O
arrest	O
in	O
ventricular	O
fibrillation	O
,	O
resuscitated	O
.	O
Related	O
to	O
taking	O
ibuprofen	O
in	O
a	O
patient	O
with	O
a	O
previous	O
history	O
of	O
drug	O
allergy	O
and	O
bronchial	O
asthma	O
.	O
Severe	O
LV	O
systolic	O
dysfunction	O
with	O
segmental	O
alteration	O
in	O
the	O
LAD	O
territory	O
.	O
Coronary	O
arteries	O
without	O
angiographic	O
lesions	O
.	O
Presumptive	O
diagnosis	O
of	O
Kounis	O
syndrome	O
type	O
I	O
.	O

A	O
44	O
year	O
old	O
man	O
was	O
referred	O
to	O
the	O
emergency	O
department	O
after	O
attending	O
a	O
private	O
clinic	O
for	O
his	O
annual	O
company	O
medical	O
check	O
up	O
,	O
because	O
an	O
alteration	O
was	O
detected	O
in	O
the	O
ECG	O
reported	O
as	O
"	O
arrhythmic	O
conduction	O
of	O
the	O
P	O
waves	O
,	O
with	O
suspected	O
atrioventricular	O
block	O
of	O
2nd	O
degree	O
"	O
.	O
HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
and	O
family	O
history	O
No	O
known	O
cardiovascular	O
risk	O
factors	O
.	O
Never	O
smoked	O
,	O
occasionally	O
drinks	O
some	O
wine	O
or	O
beer	O
with	O
meals	O
.	O
He	O
is	O
a	O
recreational	O
sportsman	O
he	O
cycles	O
to	O
work	O
and	O
goes	O
on	O
longer	O
outings	O
at	O
weekends	O
,	O
also	O
goes	O
hiking	O
and	O
occasionally	O
plays	O
football	O
or	O
paddle	O
tennis	O
.	O
No	O
known	O
heart	O
disease	O
or	O
other	O
medical	O
or	O
surgical	O
history	O
of	O
interest	O
.	O
Mother	O
with	O
non	O
ischemic	O
dilated	O
cardiomyopathy	O
,	O
currently	O
with	O
moderate	O
systolic	O
dysfunction	O
,	O
pacemaker	O
wearer	O
since	O
the	O
age	O
of	O
55	O
and	O
with	O
radiofrequency	O
ablation	O
of	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
SMVT	O
at	O
the	O
age	O
of	O
61	O
.	O
Present	O
illness	O
The	O
patient	O
went	O
to	O
a	O
private	O
clinic	O
for	O
an	O
annual	O
company	O
check	O
up	O
and	O
the	O
ECG	O
showed	O
what	O
was	O
described	O
as	O
"	O
arrhythmic	O
conduction	O
of	O
the	O
P	O
waves	O
,	O
suspected	O
2nd	O
degree	O
AVB	O
"	O
and	O
he	O
was	O
referred	O
to	O
his	O
health	O
centre	O
.	O
His	O
family	O
doctor	O
performed	O
a	O
new	O
ECG	O
and	O
referred	O
him	O
to	O
the	O
emergency	O
department	O
.	O
The	O
patient	O
denies	O
any	O
related	O
symptoms	O
no	O
dizziness	O
,	O
no	O
asthenia	O
,	O
no	O
syncope	O
.	O
He	O
does	O
not	O
understand	O
why	O
he	O
is	O
here	O
.	O
Physical	O
examination	O
BP	O
119	O
73	O
mmHg	O
.	O
HR	O
57	O
bpm	O
.	O
Ta	O
36	O
C	O
.	O
Good	O
general	O
condition	O
.	O
Arrhythmic	O
cardiac	O
auscultation	O
by	O
extratonos	O
,	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
with	O
preservation	O
of	O
vesicular	O
murmur	O
.	O
Abdomen	O
and	O
extremities	O
normal	O
,	O
without	O
oedema	O
and	O
with	O
normal	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
with	O
complete	O
atrioventricular	O
block	O
and	O
escape	O
rhythm	O
at	O
45	O
50	O
bpm	O
.	O
EV	O
monomorphic	O
,	O
with	O
BCRDHH	O
morphology	O
and	O
inferior	O
axis	O
isolated	O
,	O
with	O
some	O
duplet	O
.	O
CBC	O
glucose	O
89	O
mg	O
dl	O
,	O
urea	O
34	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
87	O
mg	O
dl	O
,	O
total	O
cholesterol	O
167	O
mg	O
dl	O
,	O
triglycerides	O
88	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
32	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
117	O
mg	O
dl	O
,	O
sodium	O
144	O
mEq	O
l	O
,	O
potassium	O
5	O
.	O
4	O
mEq	O
l	O
,	O
troponin	O
I	O
0	O
.	O
044	O
normal	O
,	O
0	O
.	O
01μg	O
l	O
,	O
CK	O
7	O
.	O
3	O
,	O
CK	O
MB	O
4	O
.	O
40	O
.	O
Haemogram	O
haemoglobin	O
14	O
.	O
8	O
g	O
dl	O
,	O
haematocrit	O
43	O
.	O
9	O
,	O
MCV	O
83	O
.	O
9	O
fl	O
,	O
platelets	O
239	O
,	O
000	O
,	O
leucocytes	O
7	O
,	O
520	O
.	O
Echocardiogram	O
LV	O
slightly	O
dilated	O
LVEDD	O
59	O
mm	O
,	O
LVEDV	O
183	O
cc	O
with	O
normal	O
wall	O
thickness	O
.	O
Mild	O
LA	O
dilatation	O
.	O
Marked	O
asynchrony	O
of	O
contraction	O
at	O
the	O
level	O
of	O
the	O
interventricular	O
septum	O
,	O
with	O
mild	O
global	O
hypokinesia	O
and	O
LVEF	O
by	O
volumetry	O
of	O
43	O
mild	O
systolic	O
dysfunction	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
normal	O
.	O
Mitral	O
,	O
tricuspid	O
and	O
pulmonary	O
valves	O
of	O
normal	O
morphology	O
and	O
mobility	O
.	O
Mitral	O
filling	O
pattern	O
with	O
E	O
A	O
wave	O
with	O
no	O
data	O
suggesting	O
increased	O
LV	O
filling	O
pressures	O
.	O
Right	O
ventricle	O
not	O
dilated	O
,	O
of	O
normal	O
thickness	O
,	O
without	O
alterations	O
of	O
regional	O
contractility	O
and	O
with	O
preserved	O
global	O
systolic	O
function	O
.	O
Mild	O
TR	O
with	O
PSAP	O
estimated	O
at	O
26	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
and	O
suprahepatic	O
veins	O
were	O
not	O
dilated	O
,	O
with	O
adequate	O
inspiratory	O
collapse	O
,	O
which	O
excludes	O
the	O
presence	O
of	O
significant	O
systemic	O
venous	O
hypertension	O
.	O
Cardio	O
MRI	O
LV	O
of	O
normal	O
thickness	O
,	O
slightly	O
dilated	O
248	O
mL	O
TVD	O
;	O
115	O
mL	O
m2	O
of	O
CS	O
with	O
slightly	O
reduced	O
ejection	O
fraction	O
EF	O
48	O
,	O
normal	O
segmental	O
contractility	O
.	O
RV	O
of	O
normal	O
global	O
and	O
segmental	O
dimensions	O
and	O
contractility	O
.	O
Linear	O
mesocardial	O
enhancement	O
is	O
identified	O
in	O
the	O
basal	O
septum	O
,	O
with	O
extension	O
to	O
the	O
mid	O
segment	O
.	O
Conclusions	O
mild	O
LV	O
dilatation	O
and	O
systolic	O
dysfunction	O
,	O
with	O
basal	O
mesoseptal	O
linear	O
fibrosis	O
extending	O
to	O
the	O
mid	O
segment	O
His	O
bundle	O
area	O
.	O
Chest	O
X	O
ray	O
post	O
implantation	O
normal	O
cardiothoracic	O
index	O
,	O
no	O
images	O
of	O
pneumothorax	O
or	O
other	O
complications	O
.	O
Atrial	O
and	O
ventricular	O
electrode	O
well	O
positioned	O
and	O
generator	O
at	O
left	O
subclavicular	O
level	O
.	O
Exercise	O
echocardiogram	O
9	O
.	O
30	O
min	O
of	O
Bruce	O
protocol	O
exercise	O
.	O
The	O
test	O
is	O
stopped	O
due	O
to	O
fatigue	O
at	O
93	O
of	O
maximum	O
theoretical	O
heart	O
rate	O
.	O
Basically	O
and	O
up	O
to	O
minute	O
7	O
,	O
sinus	O
rhythm	O
conducted	O
by	O
ventricular	O
stimulation	O
by	O
the	O
pacemaker	O
;	O
in	O
minute	O
7	O
there	O
is	O
alternation	O
of	O
pacemaker	O
rhythm	O
with	O
own	O
rhythm	O
and	O
ventricular	O
extrasystoles	O
,	O
causing	O
a	O
marked	O
irregularity	O
in	O
the	O
heart	O
rate	O
;	O
from	O
130	O
bpm	O
it	O
remains	O
in	O
own	O
rhythm	O
with	O
subsequent	O
reappearance	O
of	O
the	O
pacemaker	O
rhythm	O
in	O
the	O
immediate	O
post	O
exercise	O
.	O
Normal	O
tension	O
response	O
.	O
Contractility	O
slightly	O
depressed	O
at	O
baseline	O
with	O
global	O
hypokinesia	O
and	O
estimated	O
LVEF	O
of	O
40	O
45	O
,	O
with	O
improvement	O
of	O
around	O
10	O
points	O
with	O
exercise	O
.	O
The	O
test	O
was	O
clinically	O
and	O
echocardiographically	O
negative	O
for	O
ischaemia	O
,	O
with	O
a	O
pattern	O
of	O
improvement	O
in	O
contractility	O
with	O
exercise	O
contractile	O
reserve	O
suggesting	O
cardiomyopathy	O
.	O
ECG	O
not	O
assessable	O
due	O
to	O
baseline	O
pacemaker	O
rhythm	O
.	O
EVOLUTION	O
Although	O
the	O
patient	O
was	O
completely	O
asymptomatic	O
and	O
the	O
block	O
was	O
detected	O
by	O
chance	O
,	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
hospital	O
with	O
continuous	O
ECG	O
monitoring	O
,	O
and	O
he	O
remained	O
in	O
complete	O
AVB	O
at	O
all	O
times	O
,	O
although	O
with	O
adequate	O
escape	O
rhythm	O
and	O
totally	O
asymptomatic	O
.	O
It	O
was	O
decided	O
to	O
implant	O
a	O
definitive	O
bicameral	O
pacemaker	O
,	O
with	O
prior	O
cardiac	O
MRI	O
.	O
Twenty	O
four	O
hours	O
after	O
the	O
procedure	O
,	O
once	O
complications	O
related	O
to	O
the	O
procedure	O
had	O
been	O
ruled	O
out	O
,	O
the	O
patient	O
was	O
discharged	O
from	O
hospital	O
.	O
If	O
familial	O
dilated	O
cardiomyopathy	O
associated	O
with	O
atrioventricular	O
conduction	O
disorders	O
is	O
suspected	O
,	O
the	O
patient	O
is	O
referred	O
to	O
the	O
Family	O
Cardiopathies	O
Unit	O
UCF	O
of	O
reference	O
for	O
genetic	O
study	O
.	O
Likewise	O
,	O
a	O
schedule	O
of	O
visits	O
is	O
programmed	O
for	O
review	O
of	O
the	O
device	O
and	O
follow	O
up	O
in	O
Cardiology	O
consultations	O
.	O
At	O
subsequent	O
check	O
ups	O
,	O
the	O
patient	O
reported	O
feeling	O
well	O
.	O
Following	O
pacemaker	O
implantation	O
,	O
he	O
has	O
moderated	O
his	O
sporting	O
activities	O
considerably	O
,	O
following	O
medical	O
recommendations	O
.	O
A	O
stress	O
echocardiogram	O
was	O
performed	O
with	O
the	O
results	O
described	O
,	O
so	O
moderate	O
physical	O
exercise	O
was	O
not	O
contraindicated	O
.	O
In	O
the	O
periodic	O
reviews	O
of	O
the	O
device	O
,	O
several	O
episodes	O
of	O
NSVT	O
were	O
detected	O
about	O
10	O
in	O
a	O
year	O
,	O
of	O
short	O
duration	O
.	O
We	O
insisted	O
on	O
the	O
family	O
history	O
and	O
the	O
patient	O
commented	O
that	O
his	O
maternal	O
grandmother	O
,	O
who	O
died	O
suddenly	O
at	O
the	O
age	O
of	O
69	O
,	O
had	O
been	O
considered	O
for	O
a	O
pacemaker	O
implant	O
during	O
her	O
lifetime	O
,	O
which	O
was	O
never	O
carried	O
out	O
.	O
She	O
has	O
3	O
brothers	O
,	O
one	O
of	O
whom	O
a	O
47	O
year	O
old	O
male	O
has	O
just	O
been	O
diagnosed	O
with	O
a	O
2nd	O
degree	O
atrioventricular	O
block	O
he	O
lives	O
in	O
another	O
Community	O
;	O
during	O
follow	O
up	O
,	O
a	O
permanent	O
pacemaker	O
was	O
implanted	O
.	O
She	O
has	O
two	O
other	O
sisters	O
and	O
two	O
children	O
aged	O
12	O
and	O
8	O
,	O
with	O
no	O
evidence	O
of	O
heart	O
disease	O
after	O
screening	O
of	O
family	O
members	O
.	O
Finally	O
,	O
more	O
than	O
a	O
year	O
after	O
the	O
pacemaker	O
implantation	O
,	O
the	O
results	O
of	O
the	O
genetic	O
analysis	O
were	O
received	O
,	O
in	O
which	O
34	O
genes	O
involved	O
in	O
conduction	O
system	O
diseases	O
were	O
evaluated	O
,	O
reporting	O
that	O
the	O
patient	O
is	O
a	O
heterozygous	O
carrier	O
of	O
the	O
Glu444	O
truncation	O
,	O
considered	O
to	O
be	O
pathogenic	O
or	O
associated	O
with	O
disease	O
.	O
A	O
defibrillator	O
implantation	O
is	O
proposed	O
,	O
which	O
the	O
patient	O
accepts	O
.	O
DIAGNOSIS	O
Asymptomatic	O
complete	O
atrioventricular	O
block	O
.	O
Carrier	O
of	O
a	O
definitive	O
bicameral	O
pacemaker	O
.	O
Familial	O
dilated	O
cardiomyopathy	O
with	O
associated	O
AV	O
conduction	O
disorder	O
due	O
to	O
laminopathy	O
A	O
C	O
.	O
Mild	O
LV	O
systolic	O
dysfunction	O
LVEF	O
45	O
50	O
.	O
Repeat	O
NSVT	O
,	O
asymptomatic	O
detected	O
by	O
pacemaker	O
.	O
Defibrillator	O
implantation	O
in	O
primary	O
prevention	O
.	O

A	O
57	O
year	O
old	O
woman	O
presented	O
with	O
dyspnoea	O
and	O
fever	O
,	O
diagnosed	O
with	O
infective	O
endocarditis	O
on	O
native	O
valve	O
due	O
to	O
Lactobacillus	O
rhamnosus	O
a	O
rare	O
bacterium	O
,	O
widely	O
used	O
as	O
a	O
probiotic	O
.	O
HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
No	O
known	O
drug	O
allergies	O
.	O
Toxic	O
habits	O
smoker	O
of	O
1	O
pack	O
day	O
.	O
Intervened	O
for	O
pneumothorax	O
more	O
than	O
15	O
years	O
ago	O
.	O
Admitted	O
11	O
days	O
earlier	O
to	O
the	O
Respiratory	O
Department	O
with	O
the	O
diagnosis	O
of	O
probable	O
moderate	O
COPD	O
and	O
respiratory	O
infection	O
treated	O
with	O
levofloxacin	B-FARMACO
for	O
7	O
days	O
with	O
good	O
evolution	O
.	O
Blood	O
cultures	O
during	O
this	O
admission	O
,	O
positive	O
for	O
Lactobacillus	O
rhamnosus	O
,	O
interpreted	O
by	O
the	O
laboratory	O
as	O
possible	O
contamination	O
.	O
Current	O
treatment	O
citalopram	B-FARMACO
20	O
mg	O
,	O
inhaled	O
glycopyrronium	B-FARMACO
and	O
paracetamol	B-FARMACO
.	O
Baseline	O
functional	O
status	O
higher	O
functions	O
preserved	O
,	O
works	O
as	O
a	O
shop	O
assistant	O
in	O
a	O
clothing	O
shop	O
.	O
Lives	O
with	O
her	O
husband	O
and	O
children	O
.	O
Present	O
illness	O
Progressive	O
dyspnoea	O
of	O
3	O
days	O
evolution	O
.	O
Today	O
dyspnoea	O
at	O
rest	O
.	O
4	O
days	O
ago	O
,	O
fever	O
peak	O
of	O
up	O
to	O
37	O
.	O
8	O
C	O
and	O
pain	O
in	O
right	O
hip	O
which	O
subsided	O
on	O
its	O
own	O
,	O
for	O
which	O
she	O
did	O
not	O
consult	O
.	O
Physical	O
examination	O
BP	O
110	O
62	O
,	O
HR	O
115	O
bpm	O
,	O
Ta	O
37	O
.	O
7	O
C	O
,	O
O2	O
Sat	O
Ventimask	O
40	O
95	O
.	O
Tachypnoea	O
of	O
18	O
rpm	O
.	O
On	O
inspection	O
,	O
the	O
patient	O
was	O
normal	O
colour	O
,	O
with	O
good	O
hydration	O
of	O
skin	O
and	O
mucous	O
membranes	O
.	O
On	O
cardiac	O
auscultation	O
,	O
the	O
heart	O
is	O
rhythmic	O
,	O
with	O
systolic	O
murmur	O
mitral	O
focus	O
.	O
Pulmonary	O
auscultation	O
shows	O
crackles	O
in	O
the	O
middle	O
and	O
lower	O
fields	O
and	O
scattered	O
wheezing	O
.	O
The	O
abdomen	O
is	O
soft	O
and	O
depressible	O
,	O
painless	O
on	O
palpation	O
with	O
sounds	O
present	O
.	O
The	O
lower	O
extremities	O
are	O
free	O
of	O
oedema	O
and	O
the	O
paedial	O
pulses	O
are	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
tachycardia	O
at	O
115	O
bpm	O
.	O
Chest	O
X	O
ray	O
cardiac	O
silhouette	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
.	O
Laboratory	O
tests	O
PO2	O
80	O
mmHg	O
;	O
PCO2	O
34	O
mmHg	O
;	O
pH	O
7	O
.	O
49	O
;	O
HCO3	O
25	O
.	O
9	O
mmol	O
l	O
;	O
lactate	O
10	O
mg	O
dl	O
.	O
Glucose	O
112	O
mg	O
dl	O
;	O
creatinine	O
0	O
.	O
63	O
mg	O
dl	O
;	O
GPT	O
15	O
U	O
l	O
;	O
Na	O
137	O
mmol	O
l	O
;	O
K	O
3	O
.	O
99	O
mmol	O
l	O
;	O
CK	O
16	O
U	O
l	O
;	O
LDH	O
194	O
U	O
l	O
;	O
CRP	O
11	O
.	O
29	O
mg	O
dl	O
;	O
PCT	O
0	O
.	O
18	O
ng	O
ml	O
.	O
Hb	O
10	O
.	O
3	O
g	O
dl	O
;	O
platelets	O
207	O
,	O
000	O
μL	O
;	O
leukocytes	O
9	O
,	O
200	O
μL	O
N	O
78	O
.	O
5	O
.	O
IP	O
100	O
;	O
INR	O
1	O
.	O
Transthoracic	O
and	O
transesophageal	O
echocardiogram	O
the	O
left	O
ventricle	O
is	O
not	O
dilated	O
or	O
hypertrophic	O
,	O
with	O
good	O
global	O
systolic	O
function	O
and	O
hyperdynamic	O
.	O
The	O
mitral	O
valve	O
shows	O
several	O
images	O
,	O
the	O
largest	O
measuring	O
19	O
x	O
6	O
mm	O
,	O
compatible	O
with	O
endocardial	O
vegetations	O
.	O
The	O
posterior	O
leaflet	O
shows	O
a	O
large	O
perforation	O
leading	O
to	O
massive	O
regurgitation	O
.	O
The	O
aortic	O
valve	O
shows	O
an	O
image	O
in	O
the	O
LVOT	O
dependent	O
on	O
the	O
non	O
coronary	O
leaflet	O
13	O
x	O
6	O
mm	O
,	O
which	O
appears	O
perforated	O
and	O
there	O
is	O
a	O
significant	O
coaptation	O
defect	O
leading	O
to	O
severe	O
regurgitation	O
in	O
relation	O
to	O
the	O
involvement	O
of	O
the	O
right	O
coronary	O
artery	O
.	O
The	O
right	O
ventricle	O
is	O
not	O
dilated	O
,	O
with	O
good	O
systolic	O
function	O
.	O
No	O
pericardial	O
effusion	O
was	O
observed	O
Coronary	O
angiography	O
coronary	O
network	O
without	O
lesions	O
.	O
EVOLUTION	O
In	O
view	O
of	O
the	O
findings	O
described	O
above	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
Coronary	O
Unit	O
,	O
where	O
the	O
TEE	O
was	O
performed	O
.	O
Treatment	O
was	O
started	O
with	O
intravenous	O
ampicillin	B-FARMACO
and	O
gentamicin	B-FARMACO
.	O
Given	O
that	O
she	O
was	O
admitted	O
with	O
heart	O
failure	O
,	O
she	O
underwent	O
double	O
valve	O
replacement	O
within	O
24	O
hours	O
,	O
aortic	O
Carbomedics	O
Top	O
Hat	O
no	O
.	O
21	O
and	O
mitral	O
Bicarbon	O
Fitline	O
no	O
.	O
27	O
.	O
The	O
cardiac	O
surgery	O
was	O
uneventful	O
,	O
with	O
an	O
ischaemia	O
time	O
of	O
102	O
min	O
and	O
CPB	O
time	O
of	O
123	O
min	O
.	O
The	O
surgeon	O
described	O
the	O
following	O
intraoperative	O
findings	O
warts	O
on	O
the	O
posterior	O
leaflet	O
of	O
the	O
mitral	O
valve	O
,	O
warts	O
on	O
the	O
non	O
coronary	O
leaflet	O
of	O
the	O
aortic	O
valve	O
with	O
the	O
rings	O
of	O
both	O
valves	O
well	O
preserved	O
.	O
The	O
specimen	O
was	O
sent	O
to	O
anatomical	O
pathology	O
and	O
microbiology	O
for	O
culture	O
,	O
subsequently	O
confirming	O
infection	O
by	O
Lactobacillus	O
rhamnosus	O
.	O
He	O
arrived	O
at	O
the	O
Coronary	O
Unit	O
,	O
from	O
the	O
operating	O
theatre	O
,	O
haemodynamically	O
unstable	O
with	O
noradrenaline	B-FARMACO
at	O
0	O
.	O
2	O
μg	O
kg	O
min	O
,	O
in	O
sinus	O
tachycardia	O
135	O
bpm	O
with	O
BP	O
80	O
50	O
mmHg	O
.	O
Echocardioscopy	O
V	O
Scan	O
was	O
performed	O
,	O
showing	O
severe	O
biventricular	O
dysfunction	O
estimated	O
LVEF	O
10	O
,	O
without	O
pericardial	O
effusion	O
.	O
The	O
findings	O
were	O
confirmed	O
,	O
as	O
well	O
as	O
the	O
normofunction	O
of	O
both	O
prostheses	O
by	O
TEE	O
.	O
Therefore	O
,	O
intensive	O
serum	O
therapy	O
was	O
started	O
and	O
noradrenaline	B-FARMACO
up	O
to	O
2	O
μg	O
kg	O
min	O
,	O
dopamine	B-FARMACO
up	O
to	O
20	O
μg	O
kg	O
min	O
and	O
adrenaline	B-FARMACO
up	O
to	O
0	O
.	O
4	O
μg	O
kg	O
min	O
were	O
progressively	O
administered	O
in	O
increasing	O
doses	O
.	O
With	O
this	O
,	O
we	O
achieved	O
a	O
MAP	O
65	O
70	O
mmHg	O
,	O
CVP	O
18	O
mmHg	O
,	O
HR	O
110	O
bpm	O
,	O
CO	O
3	O
.	O
2	O
L	O
min	O
and	O
IC	O
2	O
.	O
3	O
L	O
min	O
m2	O
.	O
However	O
,	O
he	O
persisted	O
with	O
oliguria	O
and	O
increasing	O
lividity	O
in	O
the	O
atria	O
and	O
lower	O
extremities	O
in	O
an	O
ascending	O
manner	O
.	O
Intra	O
aortic	O
balloon	O
counterpulsation	O
implantation	O
was	O
chosen	O
.	O
Despite	O
counterpulsation	O
1	O
1	O
and	O
the	O
"	O
stability	O
"	O
of	O
haemodynamic	O
parameters	O
,	O
the	O
data	O
of	O
cardiogenic	O
shock	O
with	O
peripheral	O
hypoperfusion	O
were	O
increasing	O
lactate	O
10	O
145	O
mg	O
dl	O
;	O
creatinine	O
0	O
.	O
63	O
2	O
.	O
19	O
mg	O
dl	O
;	O
GPT	O
15	O
3	O
,	O
068	O
U	O
l	O
.	O
Therefore	O
,	O
veno	O
arterial	O
ECMO	O
implantation	O
with	O
peripheral	O
access	O
is	O
indicated	O
,	O
guided	O
by	O
TEE	O
,	O
which	O
is	O
carried	O
out	O
successfully	O
.	O
Subsequently	O
,	O
the	O
patient	O
evolved	O
favourably	O
,	O
with	O
a	O
progressive	O
decrease	O
in	O
the	O
analytical	O
parameters	O
of	O
peripheral	O
hypoperfusion	O
,	O
and	O
the	O
doses	O
of	O
inovasoactive	O
drugs	O
were	O
gradually	O
reduced	O
.	O
Finally	O
,	O
after	O
14	O
days	O
,	O
IABP	O
was	O
withdrawn	O
and	O
24	O
hours	O
later	O
,	O
ECMO	O
was	O
withdrawn	O
,	O
with	O
good	O
haemodynamic	O
tolerance	O
.	O
After	O
30	O
days	O
in	O
the	O
Intensive	O
Care	O
Unit	O
,	O
she	O
was	O
discharged	O
to	O
the	O
hospital	O
ward	O
.	O
DIAGNOSIS	O
Infective	O
endocarditis	O
on	O
native	O
mitral	O
and	O
aortic	O
valves	O
due	O
to	O
Lactobacillus	O
rhamnosus	O
,	O
complicated	O
by	O
heart	O
failure	O
.	O
Mitral	O
and	O
aortic	O
valve	O
replacement	O
surgery	O
.	O
Cardiogenic	O
shock	O
after	O
cardiac	O
surgery	O
requiring	O
assistance	O
with	O
intra	O
aortic	O
balloon	O
counterpulsation	O
and	O
ECMO	O
,	O
with	O
good	O
evolution	O
.	O

We	O
present	O
the	O
case	O
of	O
an	O
81	O
year	O
old	O
man	O
with	O
no	O
known	O
previous	O
heart	O
disease	O
who	O
was	O
admitted	O
to	O
our	O
department	O
for	O
dyspnoea	O
and	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
HYPERTENSION	O
.	O
Dyslipidaemia	O
.	O
Diabetes	O
Mellitus	O
type	O
II	O
.	O
Morbid	O
obesity	O
.	O
COPD	O
.	O
SAHS	O
in	O
treatment	O
with	O
CPAP	O
.	O
Benign	O
prostatic	O
hyperplasia	O
.	O
Episode	O
of	O
deep	O
vein	O
thrombosis	O
in	O
the	O
right	O
lower	O
extremity	O
.	O
Usual	O
treatment	O
torsemide	B-FARMACO
10	O
mg	O
1	O
0	O
0	O
,	O
valsartan	B-FARMACO
hydrochlorothiazide	I-FARMACO
160	O
12	O
.	O
5	O
mg	O
1	O
0	O
0	O
,	O
simvastatin	B-FARMACO
10	O
mg	O
0	O
0	O
1	O
,	O
metformin	B-FARMACO
850	O
mg	O
0	O
1	O
0	O
,	O
doxium	B-FARMACO
500	O
mg	O
1	O
0	O
1	O
.	O
Present	O
illness	O
The	O
patient	O
was	O
admitted	O
from	O
the	O
Emergency	O
Department	O
with	O
slowly	O
progressive	O
dyspnoea	O
for	O
approximately	O
two	O
months	O
,	O
until	O
minimal	O
effort	O
,	O
together	O
with	O
oliguria	O
and	O
oedema	O
in	O
the	O
lower	O
extremities	O
.	O
A	O
week	O
ago	O
he	O
presented	O
a	O
catarrhal	O
condition	O
consisting	O
of	O
nasal	O
congestion	O
,	O
cough	O
and	O
whitish	O
expectoration	O
,	O
for	O
which	O
reason	O
he	O
attended	O
his	O
health	O
centre	O
,	O
increasing	O
diuretic	O
treatment	O
and	O
starting	O
empirical	O
antibiotic	O
treatment	O
with	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
875	O
125	O
mg	O
for	O
a	O
week	O
.	O
With	O
little	O
improvement	O
of	O
the	O
symptoms	O
after	O
5	O
days	O
of	O
treatment	O
,	O
she	O
went	O
to	O
the	O
emergency	O
department	O
.	O
Physical	O
examination	O
BP	O
160	O
80	O
mmHg	O
,	O
HR	O
71	O
bpm	O
,	O
SatO2	O
92	O
on	O
room	O
air	O
,	O
Ta	O
36	O
.	O
7	O
C	O
.	O
Conscious	O
and	O
oriented	O
in	O
time	O
and	O
place	O
.	O
Obese	O
.	O
Well	O
hydrated	O
,	O
good	O
peripheral	O
perfusion	O
.	O
Slight	O
tachypnoea	O
at	O
rest	O
,	O
no	O
signs	O
of	O
work	O
of	O
breathing	O
.	O
Jugular	O
venous	O
pressure	O
not	O
measurable	O
.	O
AC	O
muffled	O
cardiac	O
tones	O
with	O
no	O
clear	O
murmurs	O
.	O
PA	O
crackles	O
in	O
both	O
bases	O
.	O
Abdomen	O
globular	O
,	O
depressible	O
,	O
without	O
pain	O
on	O
palpation	O
.	O
Extremities	O
with	O
oedema	O
with	O
fovea	O
up	O
to	O
the	O
root	O
of	O
the	O
thighs	O
,	O
signs	O
of	O
chronic	O
venous	O
insufficiency	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
atypical	O
atrial	O
flutter	O
with	O
controlled	O
ventricular	O
response	O
at	O
75	O
bpm	O
.	O
HRBBB	O
with	O
secondary	O
repolarisation	O
alterations	O
.	O
Laboratory	O
tests	O
on	O
admission	O
glucose	O
92	O
mg	O
dl	O
,	O
urea	O
60	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
6	O
mg	O
dl	O
,	O
albumin	O
3	O
.	O
76	O
g	O
dl	O
,	O
liver	O
function	O
normal	O
,	O
sodium	O
145	O
mmol	O
l	O
,	O
potassium	O
3	O
.	O
81	O
mmol	O
l	O
,	O
CRP	O
0	O
.	O
6	O
mg	O
ml	O
,	O
haemoglobin	O
12	O
.	O
9	O
g	O
dl	O
,	O
leucocytes	O
5	O
,	O
200	O
10	O
3	O
μL	O
N	O
52	O
.	O
8	O
,	O
platelets	O
128	O
,	O
000	O
10	O
3	O
μl	O
.	O
Chest	O
X	O
ray	O
no	O
cardiomegaly	O
.	O
Bilateral	O
pleural	O
effusion	O
.	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
LV	O
,	O
hypertrophic	O
,	O
with	O
good	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O
Mitral	O
valve	O
with	O
slight	O
ring	O
calcification	O
and	O
mild	O
moderate	O
regurgitation	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Thickened	O
aortic	O
valve	O
,	O
with	O
an	O
image	O
of	O
intermediate	O
echogenicity	O
,	O
without	O
being	O
able	O
to	O
rule	O
out	O
endocardial	O
involvement	O
,	O
with	O
maximum	O
and	O
mean	O
gradient	O
of	O
50	O
and	O
26	O
mmHg	O
respectively	O
.	O
Moderate	O
severe	O
AoI	O
.	O
TEE	O
is	O
recommended	O
for	O
better	O
assessment	O
of	O
these	O
findings	O
.	O
Moderately	O
dilated	O
LA	O
.	O
Right	O
chambers	O
not	O
dilated	O
,	O
RV	O
with	O
good	O
function	O
.	O
Mild	O
tricuspid	O
regurgitation	O
with	O
Vd	O
Ad	O
gradient	O
of	O
34	O
mmHg	O
.	O
Estimated	O
PsAP	O
of	O
40	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
Transesophageal	O
echocardiogram	O
thickened	O
aortic	O
valve	O
with	O
points	O
of	O
calcification	O
,	O
with	O
severe	O
regurgitation	O
IV	O
IV	O
with	O
an	O
image	O
compatible	O
with	O
perforation	O
at	O
the	O
level	O
of	O
the	O
non	O
coronary	O
leaflet	O
.	O
Small	O
mobile	O
image	O
in	O
the	O
LVOT	O
,	O
somewhat	O
hyperechogenic	O
,	O
measuring	O
0	O
.	O
7	O
x	O
0	O
.	O
3	O
cm	O
,	O
dependent	O
on	O
the	O
leaflet	O
.	O
Mitral	O
valve	O
with	O
mild	O
moderate	O
regurgitation	O
without	O
pathological	O
images	O
.	O
EVOLUTION	O
During	O
his	O
stay	O
on	O
the	O
hospital	O
ward	O
,	O
intravenous	O
depletive	O
treatment	O
was	O
started	O
with	O
slowly	O
progressive	O
improvement	O
of	O
the	O
congestive	O
signs	O
.	O
After	O
a	O
first	O
episode	O
of	O
heart	O
failure	O
,	O
a	O
transthoracic	O
echocardiogram	O
was	O
performed	O
followed	O
by	O
a	O
transesophageal	O
echocardiogram	O
with	O
the	O
findings	O
described	O
,	O
compatible	O
with	O
endocarditis	O
.	O
The	O
Infectious	O
Diseases	O
Department	O
was	O
contacted	O
for	O
an	O
interdisciplinary	O
assessment	O
of	O
the	O
condition	O
.	O
Despite	O
the	O
atypical	O
nature	O
of	O
the	O
symptoms	O
,	O
panbacterial	O
PCR	O
was	O
requested	O
,	O
as	O
well	O
as	O
blood	O
and	O
urine	O
cultures	O
,	O
empirical	O
treatment	O
was	O
adjusted	O
for	O
possible	O
endocarditis	O
ampicillin	B-FARMACO
cloxacillin	I-FARMACO
gentamicin	I-FARMACO
adjusted	O
to	O
renal	O
function	O
and	O
a	O
new	O
transesophageal	O
echocardiogram	O
was	O
scheduled	O
for	O
follow	O
up	O
,	O
in	O
which	O
no	O
significant	O
differences	O
were	O
observed	O
with	O
respect	O
to	O
the	O
previous	O
study	O
.	O
During	O
the	O
following	O
days	O
,	O
the	O
cultures	O
collected	O
blood	O
and	O
urine	O
cultures	O
were	O
negative	O
and	O
,	O
despite	O
increased	O
intravenous	O
diuretic	O
treatment	O
,	O
the	O
patient	O
recorded	O
a	O
significant	O
weight	O
gain	O
and	O
worsening	O
of	O
oedema	O
in	O
the	O
lower	O
limbs	O
with	O
the	O
appearance	O
of	O
phlyctenas	O
,	O
so	O
given	O
the	O
unfavourable	O
evolution	O
of	O
the	O
condition	O
,	O
the	O
case	O
was	O
discussed	O
with	O
Cardiac	O
Surgery	O
,	O
who	O
decided	O
to	O
perform	O
aortic	O
valve	O
replacement	O
with	O
a	O
biological	O
prosthesis	O
,	O
maintaining	O
antibiotic	O
treatment	O
while	O
awaiting	O
the	O
microbiological	O
results	O
of	O
the	O
extracted	O
heart	O
valve	O
.	O
Among	O
the	O
analyses	O
requested	O
,	O
the	O
serology	O
for	O
Coxiella	O
burnetti	O
was	O
positive	O
,	O
with	O
high	O
titres	O
,	O
allowing	O
a	O
diagnosis	O
of	O
endocarditis	O
due	O
to	O
Q	O
fever	O
,	O
so	O
the	O
antibiotic	O
treatment	O
regimen	O
was	O
modified	O
and	O
the	O
patient	O
was	O
started	O
on	O
doxycycline	B-FARMACO
hydroxychloroquine	I-FARMACO
,	O
and	O
he	O
was	O
discharged	O
from	O
hospital	O
.	O
During	O
the	O
months	O
following	O
discharge	O
,	O
the	O
patient	O
presented	O
several	O
episodes	O
of	O
decompensation	O
of	O
heart	O
failure	O
with	O
bilateral	O
pleural	O
effusion	O
,	O
which	O
required	O
hygiene	O
and	O
dietary	O
educational	O
measures	O
,	O
intravenous	O
depletive	O
treatment	O
,	O
thoracentesis	O
and	O
inclusion	O
of	O
the	O
patient	O
in	O
the	O
heart	O
failure	O
telemonitoring	O
programme	O
,	O
and	O
he	O
is	O
currently	O
in	O
a	O
situation	O
of	O
clinical	O
stability	O
with	O
regular	O
controls	O
by	O
the	O
Cardiology	O
and	O
Infectious	O
Diseases	O
outpatient	O
clinics	O
.	O
DIAGNOSIS	O
Endocarditis	O
due	O
to	O
Q	O
fever	O
on	O
native	O
aortic	O
valve	O
.	O
Aortic	O
insufficiency	O
due	O
to	O
perforation	O
of	O
the	O
non	O
coronary	O
aortic	O
leaflet	O
.	O
Secondary	O
congestive	O
heart	O
failure	O
.	O
Aortic	O
valve	O
replacement	O
surgery	O
for	O
biological	O
prosthesis	O
.	O

The	O
patient	O
was	O
an	O
85	O
year	O
old	O
woman	O
with	O
a	O
biological	O
aortic	O
valve	O
prosthesis	O
and	O
double	O
coronary	O
artery	O
bypass	O
graft	O
who	O
was	O
admitted	O
to	O
the	O
Cardiology	O
hospital	O
ward	O
for	O
acute	O
heart	O
failure	O
.	O
The	O
echocardiogram	O
showed	O
a	O
rupture	O
of	O
one	O
of	O
the	O
prosthesis	O
leaflets	O
with	O
severe	O
aortic	O
insufficiency	O
.	O
HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
Intolerance	O
to	O
calcium	O
antagonists	O
due	O
to	O
oedema	O
.	O
No	O
toxic	O
habits	O
.	O
Hypertension	O
,	O
dyslipidaemia	O
and	O
type	O
2	O
diabetes	O
under	O
treatment	O
.	O
Sclerodegenerative	O
aortic	O
valve	O
disease	O
and	O
common	O
trunk	O
disease	O
,	O
undergoing	O
aortic	O
valve	O
replacement	O
surgery	O
for	O
biological	O
aortic	O
prosthesis	O
Perimount	O
21	O
and	O
double	O
aortocoronary	O
bypass	O
AMI	O
DA	O
,	O
SF	O
Cx	O
at	O
a	O
private	O
centre	O
in	O
2001	O
.	O
Subsequent	O
check	O
ups	O
by	O
cardiologist	O
,	O
asymptomatic	O
.	O
Last	O
echocardiogram	O
June	O
2015	O
non	O
dilated	O
LV	O
with	O
severe	O
concentric	O
hypertrophy	O
and	O
preserved	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O
Severe	O
calcification	O
of	O
the	O
mitral	O
valve	O
,	O
without	O
significant	O
stenosis	O
.	O
Mild	O
moderate	O
mitral	O
regurgitation	O
.	O
Carpentier	O
Perimount	O
21	O
biological	O
prosthesis	O
with	O
calcified	O
,	O
degenerated	O
leaflets	O
.	O
Slightly	O
elevated	O
gradients	O
.	O
Normal	O
RV	O
.	O
Normal	O
pulmonary	O
pressure	O
.	O
Usual	O
treatment	O
gliclazide	B-FARMACO
30	O
mg	O
0	O
1	O
0	O
,	O
sitagliptin	B-FARMACO
100	O
mg	O
1	O
0	O
0	O
0	O
,	O
ASA	O
100	O
mg	O
0	O
1	O
0	O
,	O
doxazosin	B-FARMACO
8	O
mg	O
0	O
0	O
1	O
,	O
carvedilol	B-FARMACO
25	O
mg	O
1	O
0	O
1	O
,	O
candesartan	B-FARMACO
HCTZ	I-FARMACO
32	O
12	O
.	O
5	O
mg	O
1	O
0	O
0	O
,	O
pravastatin	B-FARMACO
40	O
mg	O
0	O
0	O
1	O
.	O
Present	O
illness	O
An	O
85	O
year	O
old	O
woman	O
was	O
admitted	O
to	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
for	O
progressive	O
dyspnoea	O
over	O
the	O
last	O
month	O
,	O
which	O
had	O
been	O
increasing	O
until	O
it	O
became	O
minimal	O
effort	O
.	O
She	O
reported	O
orthopnoea	O
and	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
He	O
also	O
has	O
increased	O
oedema	O
in	O
the	O
lower	O
extremities	O
up	O
to	O
the	O
knees	O
and	O
decreased	O
diuresis	O
.	O
She	O
has	O
increased	O
the	O
dose	O
of	O
diuretic	O
with	O
little	O
improvement	O
.	O
Afebrile	O
and	O
with	O
no	O
other	O
associated	O
symptoms	O
.	O
Physical	O
examination	O
BP	O
150	O
50	O
mmHg	O
,	O
HR	O
110	O
bpm	O
,	O
Ta	O
36	O
.	O
5	O
C	O
,	O
baseline	O
SO2	O
85	O
.	O
Conscious	O
and	O
oriented	O
.	O
Tachypnoea	O
and	O
respiratory	O
work	O
.	O
Afebrile	O
.	O
Good	O
hydration	O
and	O
perfusion	O
status	O
.	O
Chest	O
mid	O
sternotomy	O
scar	O
.	O
AC	O
rhythmic	O
,	O
fast	O
,	O
systolic	O
diastolic	O
murmur	O
V	O
VI	O
in	O
aortic	O
focus	O
.	O
PA	O
crackles	O
in	O
the	O
lower	O
half	O
of	O
both	O
hemithoraxes	O
.	O
Abdomen	O
globular	O
,	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
with	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Lower	O
extremities	O
oedema	O
with	O
bilateral	O
fovea	O
up	O
to	O
the	O
knees	O
.	O
No	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Pedial	O
pulses	O
present	O
.	O
Saphenectomy	O
scar	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
,	O
known	O
LBBB	O
with	O
secondary	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
cardiomegaly	O
,	O
bilateral	O
perihilar	O
alveolar	O
infiltrates	O
,	O
compatible	O
with	O
pulmonary	O
oedema	O
.	O
Laboratory	O
tests	O
on	O
admission	O
arterial	O
pH	O
7	O
.	O
41	O
,	O
PaCO2	O
56	O
and	O
PaO2	O
59	O
mmHg	O
,	O
bicarbonate	O
35	O
.	O
5	O
mEq	O
L	O
,	O
SatO2	O
88	O
,	O
glucose	O
167	O
,	O
urea	O
79	O
and	O
Cr	O
1	O
.	O
35	O
mg	O
dl	O
.	O
Na	O
137	O
and	O
K	O
5	O
.	O
07	O
mEq	O
l	O
.	O
CRP	O
10	O
.	O
8	O
mg	O
l	O
.	O
NT	O
proBNP	O
10195	O
pg	O
ml	O
.	O
Troponin	O
T	O
62	O
ng	O
L	O
.	O
Leukocytes	O
9200	O
mm3	O
,	O
Hb	O
11	O
.	O
3	O
g	O
dl	O
,	O
Hto	O
39	O
,	O
MCH	O
26	O
pg	O
,	O
MCHC	O
29	O
.	O
2	O
g	O
dl	O
,	O
platelets	O
94000	O
mm3	O
.	O
T	O
.	O
Prothrombin	O
76	O
,	O
INR	O
1	O
.	O
19	O
,	O
APTT	O
30	O
sg	O
.	O
Transthoracic	O
echocardiogram	O
on	O
admission	O
non	O
dilated	O
LV	O
with	O
severe	O
concentric	O
hypertrophy	O
and	O
preserved	O
global	O
systolic	O
function	O
.	O
Severe	O
annular	O
calcification	O
of	O
mitral	O
valve	O
without	O
significant	O
stenosis	O
.	O
Moderate	O
central	O
MI	O
.	O
Dysfunctioning	O
,	O
degenerated	O
Perimount	O
21	O
biological	O
aortic	O
prosthesis	O
,	O
with	O
moderate	O
transprosthetic	O
gradient	O
and	O
severe	O
new	O
onset	O
aortic	O
insufficiency	O
possibly	O
related	O
to	O
rupture	O
of	O
one	O
of	O
the	O
leaflets	O
.	O
Moderately	O
dilated	O
RV	O
with	O
mild	O
systolic	O
dysfunction	O
.	O
Moderate	O
TR	O
.	O
Severe	O
PH	O
.	O
Transesophageal	O
echocardiogram	O
dysfunctional	O
Perimount	O
21	O
biological	O
aortic	O
prosthesis	O
,	O
with	O
degenerated	O
leaflets	O
,	O
calcified	O
and	O
with	O
one	O
of	O
the	O
leaflets	O
broken	O
,	O
which	O
protrudes	O
into	O
the	O
left	O
ventricular	O
outflow	O
tract	O
in	O
diastole	O
,	O
leading	O
to	O
very	O
severe	O
aortic	O
insufficiency	O
.	O
Severe	O
mitral	O
annular	O
calcification	O
,	O
with	O
moderate	O
central	O
mitral	O
insufficiency	O
.	O
Moderate	O
tricuspid	O
insufficiency	O
due	O
to	O
annular	O
dilatation	O
39	O
mm	O
.	O
Severe	O
pulmonary	O
hypertension	O
.	O
Mildly	O
dilated	O
right	O
ventricle	O
,	O
with	O
moderate	O
global	O
systolic	O
dysfunction	O
.	O
Coronary	O
angiography	O
common	O
trunk	O
severe	O
ostial	O
lesion	O
.	O
Anterior	O
descending	O
irregular	O
borders	O
,	O
without	O
significant	O
stenosis	O
.	O
Circumflex	O
irregular	O
borders	O
,	O
without	O
significant	O
stenosis	O
.	O
Right	O
coronary	O
dominant	O
.	O
Minimal	O
irregularities	O
,	O
without	O
significant	O
lesions	O
.	O
Grafts	O
IMA	O
to	O
LAD	O
patent	O
.	O
Saphenous	O
to	O
OM	O
patent	O
.	O
Angio	O
CT	O
aorta	O
thoracic	O
aorta	O
of	O
normal	O
calibre	O
and	O
morphology	O
with	O
slight	O
atheromatous	O
changes	O
.	O
Abdominal	O
and	O
iliac	O
aorta	O
of	O
normal	O
calibre	O
and	O
morphology	O
with	O
mild	O
moderate	O
atheromatous	O
changes	O
,	O
predominantly	O
in	O
infrarenal	O
abdominal	O
aorta	O
and	O
proximal	O
common	O
iliac	O
aorta	O
,	O
at	O
postbifurcation	O
level	O
.	O
Discrete	O
focal	O
eccentric	O
calcification	O
in	O
the	O
right	O
common	O
femoral	O
artery	O
prior	O
to	O
bifurcation	O
.	O
EVOLUTION	O
The	O
patient	O
is	O
an	O
85	O
year	O
old	O
woman	O
,	O
with	O
a	O
biological	O
aortic	O
valve	O
prosthesis	O
and	O
double	O
coronary	O
artery	O
bypass	O
grafting	O
who	O
was	O
admitted	O
with	O
acute	O
pulmonary	O
oedema	O
and	O
severe	O
aortic	O
insufficiency	O
was	O
detected	O
on	O
echocardiography	O
due	O
to	O
rupture	O
of	O
one	O
of	O
the	O
leaflets	O
of	O
the	O
biological	O
aortic	O
prosthesis	O
.	O
The	O
patient	O
was	O
admitted	O
in	O
severe	O
heart	O
failure	O
,	O
requiring	O
high	O
doses	O
of	O
intravenous	O
diuretics	O
.	O
After	O
clinical	O
stabilisation	O
,	O
a	O
transesophageal	O
echocardiogram	O
was	O
performed	O
which	O
confirmed	O
the	O
rupture	O
of	O
one	O
of	O
the	O
aortic	O
prosthesis	O
leaflets	O
,	O
resulting	O
in	O
very	O
severe	O
aortic	O
insufficiency	O
.	O
Given	O
the	O
severity	O
of	O
the	O
valve	O
disease	O
,	O
the	O
case	O
was	O
presented	O
at	O
a	O
medical	O
surgical	O
session	O
.	O
Given	O
the	O
patient	O
's	O
advanced	O
age	O
and	O
previous	O
cardiac	O
surgery	O
in	O
2001	O
,	O
it	O
was	O
decided	O
to	O
implant	O
an	O
aortic	O
valve	O
prosthesis	O
inside	O
the	O
previously	O
implanted	O
prosthesis	O
,	O
percutaneously	O
from	O
femoral	O
access	O
TAVI	O
valve	O
in	O
valve	O
.	O
Coronary	O
angiography	O
showed	O
no	O
new	O
lesions	O
and	O
aortic	O
CT	O
angiography	O
showed	O
favourable	O
femoral	O
accesses	O
for	O
the	O
procedure	O
.	O
By	O
means	O
of	O
a	O
catheter	O
introduced	O
through	O
the	O
left	O
femoral	O
arterial	O
access	O
,	O
the	O
correct	O
right	O
femoral	O
arterial	O
access	O
is	O
checked	O
,	O
through	O
which	O
it	O
is	O
passed	O
by	O
means	O
of	O
an	O
Extra	O
Stiff	O
guide	O
.	O
The	O
Ewards	O
Sapien	O
3	O
No	O
23	O
expandable	O
prosthesis	O
is	O
advanced	O
over	O
this	O
guide	O
.	O
It	O
is	O
expanded	O
in	O
the	O
aortic	O
position	O
,	O
remaining	O
slightly	O
under	O
expanded	O
at	O
the	O
level	O
of	O
the	O
ring	O
of	O
the	O
previous	O
Perimount	O
prosthesis	O
Video	O
3	O
and	O
4	O
.	O
Transesophageal	O
echocardiography	O
is	O
used	O
to	O
verify	O
the	O
normal	O
position	O
of	O
the	O
valve	O
,	O
the	O
absence	O
of	O
regurgitation	O
and	O
the	O
transvalvular	O
gradients	O
max	O
37	O
mmHg	O
.	O
The	O
absence	O
of	O
aortic	O
regurgitation	O
and	O
absence	O
of	O
leakage	O
after	O
Prostar	O
closure	O
of	O
the	O
right	O
femoral	O
access	O
is	O
verified	O
by	O
angiography	O
.	O
The	O
left	O
femoral	O
access	O
is	O
closed	O
with	O
Angio	O
Seal	O
.	O
After	O
the	O
procedure	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
Coronary	O
Unit	O
extubated	O
,	O
haemodynamically	O
stable	O
,	O
with	O
initially	O
fair	O
O2	O
saturations	O
in	O
the	O
context	O
of	O
sedation	O
after	O
the	O
procedure	O
and	O
signs	O
of	O
mild	O
pulmonary	O
congestion	O
,	O
which	O
evolved	O
well	O
with	O
diuretic	O
treatment	O
.	O
He	O
also	O
presented	O
with	O
acute	O
renal	O
failure	O
prior	O
to	O
the	O
procedure	O
,	O
with	O
a	O
creatinine	O
peak	O
of	O
2	O
.	O
2	O
which	O
resolved	O
during	O
admission	O
urea	O
122	O
at	O
discharge	O
,	O
creatinine	O
1	O
.	O
06	O
.	O
He	O
remained	O
in	O
his	O
own	O
rhythm	O
during	O
admission	O
sinus	O
with	O
LBBB	O
and	O
long	O
PR	O
,	O
already	O
present	O
before	O
the	O
procedure	O
,	O
with	O
no	O
other	O
arrhythmic	O
events	O
in	O
telemetry	O
,	O
so	O
the	O
transient	O
jugular	O
PM	O
was	O
removed	O
.	O
On	O
the	O
hospital	O
ward	O
,	O
he	O
had	O
a	O
very	O
good	O
clinical	O
evolution	O
.	O
Congestion	O
data	O
disappeared	O
,	O
remaining	O
stable	O
at	O
all	O
times	O
.	O
A	O
control	O
echocardiogram	O
showed	O
residual	O
moderate	O
aortic	O
stenosis	O
after	O
the	O
procedure	O
,	O
without	O
aortic	O
insufficiency	O
.	O
Good	O
appearance	O
of	O
the	O
femoral	O
arterial	O
accesses	O
,	O
with	O
slight	O
haematomas	O
,	O
without	O
major	O
complications	O
.	O
In	O
good	O
clinical	O
condition	O
,	O
she	O
was	O
discharged	O
home	O
.	O
DIAGNOSIS	O
Acute	O
heart	O
failure	O
due	O
to	O
severe	O
aortic	O
insufficiency	O
.	O
Biological	O
aortic	O
prosthesis	O
with	O
severe	O
insufficiency	O
due	O
to	O
leaflet	O
rupture	O
.	O
Implantation	O
of	O
Edwards	O
Sapien	O
3	O
valve	O
in	O
valve	O
percutaneous	O
valvular	O
aortic	O
prosthesis	O
.	O
LV	O
function	O
borderline	O
slightly	O
depressed	O
.	O
Acute	O
renal	O
failure	O
,	O
resolved	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
67	O
year	O
old	O
man	O
attended	O
a	O
Cardiology	O
consultation	O
due	O
to	O
worsening	O
dyspnoea	O
.	O
Cardiovascular	O
risk	O
factors	O
Ex	O
smoker	O
20	O
packs	O
year	O
and	O
hypertensive	O
under	O
treatment	O
.	O
Cardiological	O
history	O
left	O
bundle	O
branch	O
block	O
as	O
an	O
incidental	O
finding	O
in	O
a	O
routine	O
electrocardiogram	O
;	O
diagnosis	O
of	O
hypertensive	O
heart	O
disease	O
with	O
moderate	O
LV	O
hypertrophy	O
and	O
mild	O
systolic	O
dysfunction	O
in	O
the	O
echocardiogram	O
.	O
The	O
Holter	O
study	O
was	O
completed	O
and	O
showed	O
frequent	O
ventricular	O
extrasystoles	O
asymptomatic	O
.	O
Medical	O
treatment	O
nevibolol	B-FARMACO
5	O
mg	O
,	O
torasemide	B-FARMACO
5	O
mg	O
and	O
amlodipine	B-FARMACO
valsartan	I-FARMACO
5	O
160	O
mg	O
once	O
daily	O
.	O
Current	O
history	O
previously	O
in	O
NYHA	O
functional	O
class	O
I	O
,	O
he	O
consulted	O
Cardiology	O
for	O
worsening	O
of	O
his	O
dyspnoea	O
of	O
one	O
year	O
's	O
evolution	O
,	O
to	O
the	O
point	O
of	O
moderate	O
exertion	O
.	O
He	O
denied	O
syncope	O
,	O
palpitations	O
or	O
other	O
symptoms	O
.	O
Physical	O
examination	O
showed	O
no	O
relevant	O
findings	O
.	O
Head	O
and	O
neck	O
with	O
no	O
increase	O
in	O
jugular	O
venous	O
pressure	O
or	O
carotid	O
murmurs	O
.	O
Rhythmic	O
cardiac	O
auscultation	O
with	O
abundant	O
extrasystoles	O
,	O
but	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
showed	O
decreased	O
generalised	O
vesicular	O
murmur	O
,	O
with	O
no	O
other	O
superimposed	O
sounds	O
.	O
The	O
abdomen	O
was	O
globular	O
with	O
no	O
masses	O
or	O
megaliths	O
and	O
the	O
lower	O
limbs	O
were	O
free	O
of	O
oedema	O
and	O
there	O
was	O
no	O
evidence	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
,	O
normal	O
PR	O
,	O
left	O
bundle	O
branch	O
block	O
QRS	O
of	O
150	O
ms	O
.	O
Holter	O
sinus	O
rhythm	O
throughout	O
the	O
recording	O
.	O
Monomorphic	O
ventricular	O
extrasystoles	O
of	O
slight	O
moderate	O
density	O
,	O
with	O
some	O
triplets	O
.	O
Occasional	O
supraventricular	O
extrasystoles	O
with	O
isolated	O
episodes	O
of	O
supraventricular	O
tachycardia	O
.	O
No	O
pauses	O
.	O
Echocardiogram	O
,	O
new	O
study	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
moderate	O
septal	O
hypertrophy	O
1	O
.	O
5	O
cm	O
and	O
alterations	O
in	O
segmental	O
contractility	O
basal	O
hypokinesia	O
of	O
the	O
inferior	O
,	O
anterior	O
,	O
anteroseptal	O
and	O
anterolateral	O
faces	O
,	O
with	O
anomalous	O
septal	O
movement	O
.	O
Mild	O
systolic	O
dysfunction	O
LVEF	O
45	O
.	O
Grade	O
II	O
diastolic	O
dysfunction	O
,	O
with	O
pseudonormal	O
pattern	O
.	O
Normal	O
right	O
ventricle	O
.	O
Slightly	O
dilated	O
atria	O
LA	O
25	O
and	O
RA	O
21	O
cm2	O
.	O
Minimal	O
aortic	O
insufficiency	O
,	O
without	O
other	O
valvulopathies	O
.	O
Cardiac	O
MRI	O
left	O
ventricle	O
slightly	O
dilated	O
,	O
with	O
moderate	O
to	O
severe	O
concentric	O
increase	O
in	O
wall	O
thickness	O
,	O
maximum	O
thickness	O
measured	O
in	O
the	O
inferior	O
septum	O
of	O
the	O
middle	O
segment	O
of	O
22	O
mm	O
.	O
Significant	O
increase	O
in	O
myocardial	O
mass	O
116	O
gr	O
m2	O
,	O
global	O
hypokinesia	O
and	O
moderate	O
systolic	O
dysfunction	O
LVEF	O
37	O
.	O
Right	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophied	O
with	O
normal	O
function	O
RVEF	O
59	O
.	O
Moderately	O
dilated	O
left	O
atrium	O
with	O
thickening	O
of	O
the	O
interatrial	O
septum	O
in	O
its	O
most	O
caudal	O
area	O
.	O
Absence	O
of	O
pericardial	O
and	O
pleural	O
effusion	O
.	O
Late	O
enhancement	O
sequences	O
show	O
a	O
diffuse	O
uptake	O
pattern	O
,	O
with	O
greater	O
intensity	O
in	O
the	O
subendocardium	O
in	O
the	O
middle	O
segments	O
of	O
the	O
lateral	O
and	O
inferolateral	O
face	O
,	O
diffuse	O
intramyocardial	O
uptake	O
of	O
the	O
basal	O
and	O
middle	O
septum	O
and	O
at	O
the	O
level	O
of	O
the	O
posterior	O
septum	O
at	O
the	O
insertion	O
of	O
the	O
free	O
wall	O
.	O
There	O
is	O
also	O
subepicardial	O
enhancement	O
in	O
the	O
free	O
wall	O
of	O
the	O
right	O
ventricular	O
outflow	O
tract	O
.	O
The	O
wall	O
of	O
both	O
atria	O
shows	O
diffuse	O
uptake	O
,	O
as	O
well	O
as	O
the	O
interatrial	O
septum	O
,	O
mitral	O
valve	O
and	O
aortic	O
wall	O
.	O
On	O
the	O
STIR	O
sequence	O
,	O
no	O
oedema	O
is	O
seen	O
.	O
The	O
T2	O
sequence	O
shows	O
no	O
evidence	O
of	O
iron	O
overload	O
.	O
Salivary	O
gland	O
biopsy	O
no	O
amyloid	O
deposition	O
.	O
99mTc	O
DDP	O
scan	O
myocardial	O
deposition	O
of	O
the	O
radiotracer	O
,	O
indicative	O
of	O
cardiac	O
amyloidosis	O
.	O
Endomyocardial	O
biopsy	O
sampling	O
from	O
2	O
different	O
sites	O
in	O
the	O
right	O
ventricle	O
positive	O
deposit	O
of	O
amyloid	O
substance	O
transthyretin	O
TTR	O
.	O
Genetic	O
study	O
NGS	O
sequencing	O
17	O
genes	O
panel	O
,	O
including	O
TTR	O
negative	O
.	O
EVOLUTION	O
Patient	O
known	O
to	O
Cardiology	O
with	O
a	O
previous	O
diagnosis	O
of	O
hypertensive	O
heart	O
disease	O
.	O
After	O
worsening	O
of	O
his	O
CF	O
,	O
the	O
echocardiogram	O
was	O
repeated	O
,	O
revealing	O
significant	O
LV	O
hypertrophy	O
,	O
diastolic	O
dysfunction	O
with	O
pseudonormal	O
pattern	O
and	O
data	O
of	O
increased	O
end	O
diastolic	O
pressures	O
.	O
With	O
the	O
suspicion	O
of	O
infiltrative	O
cardiomyopathy	O
,	O
cardiac	O
magnetic	O
resonance	O
imaging	O
was	O
requested	O
,	O
which	O
showed	O
findings	O
highly	O
suggestive	O
of	O
cardiac	O
amyloidosis	O
.	O
The	O
patient	O
was	O
studied	O
by	O
quantification	O
of	O
immunoglobulins	O
,	O
electrophoresis	O
and	O
immunofixation	O
of	O
proteins	O
and	O
24	O
hour	O
urine	O
study	O
,	O
ruling	O
out	O
multiple	O
myeloma	O
.	O
Bone	O
scintigraphy	O
99	O
mTc	O
DDP	O
was	O
also	O
requested	O
,	O
with	O
cardiac	O
uptake	O
of	O
the	O
radiotracer	O
,	O
compatible	O
with	O
senile	O
and	O
or	O
hereditary	O
amyloidosis	O
due	O
to	O
TTR	O
deposition	O
.	O
The	O
precise	O
diagnosis	O
was	O
made	O
by	O
endomyocardial	O
biopsy	O
,	O
which	O
showed	O
TTR	O
deposition	O
.	O
Finally	O
,	O
genetic	O
testing	O
was	O
performed	O
to	O
discern	O
between	O
hereditary	O
and	O
senile	O
amyloidosis	O
.	O
Once	O
the	O
latter	O
was	O
diagnosed	O
,	O
it	O
was	O
not	O
necessary	O
to	O
study	O
the	O
patient	O
's	O
relatives	O
.	O
The	O
patient	O
was	O
managed	O
conservatively	O
,	O
with	O
treatment	O
aimed	O
at	O
systolic	O
dysfunction	O
,	O
diuretics	O
and	O
antihypertensive	O
drugs	O
,	O
with	O
a	O
good	O
clinical	O
response	O
after	O
2	O
years	O
of	O
follow	O
up	O
.	O
DIAGNOSIS	O
Cardiac	O
amyloidosis	O
due	O
to	O
transthyretin	O
deposition	O
.	O
Senile	O
type	O
.	O
Moderate	O
systolic	O
and	O
diastolic	O
dysfunction	O
of	O
vi	O
.	O
Compensated	O
heart	O
failure	O
in	O
NYHA	O
functional	O
class	O
I	O
after	O
medication	O
.	O
Asymptomatic	O
ventricular	O
arrhythmias	O
,	O
ventricular	O
extrasystoles	O
of	O
mild	O
to	O
moderate	O
intensity	O
.	O

54	O
year	O
old	O
woman	O
.	O
She	O
consulted	O
the	O
Hereditary	O
Cardiomyopathies	O
department	O
for	O
a	O
genetic	O
study	O
due	O
to	O
family	O
history	O
.	O
HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
CVRF	O
family	O
history	O
of	O
early	O
sudden	O
death	O
,	O
early	O
complete	O
atrioventricular	O
block	O
,	O
early	O
complete	O
AVB	O
and	O
dilated	O
cardiomyopathy	O
.	O
No	O
known	O
hypertension	O
,	O
diabetes	O
mellitus	O
or	O
dyslipidaemia	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
No	O
other	O
history	O
of	O
interest	O
.	O
No	O
home	O
medication	O
.	O
Family	O
history	O
63	O
year	O
old	O
brother	O
index	O
case	O
atrial	O
fibrillation	O
AF	O
and	O
complete	O
AVB	O
with	O
pacemaker	O
implantation	O
at	O
age	O
50	O
.	O
DCM	O
LVEF	O
34	O
with	O
normal	O
coronary	O
angiography	O
.	O
Monomorphic	O
SVT	O
and	O
syncope	O
with	O
ICD	O
implantation	O
at	O
57	O
years	O
of	O
age	O
.	O
59	O
year	O
old	O
brother	O
with	O
complete	O
AVB	O
and	O
pacemaker	O
implantation	O
at	O
age	O
49	O
.	O
Normal	O
TTE	O
.	O
55	O
year	O
old	O
brother	O
with	O
complete	O
AVB	O
and	O
pacemaker	O
implantation	O
at	O
age	O
50	O
.	O
TTE	O
this	O
year	O
with	O
LVEF	O
30	O
35	O
.	O
Mild	O
moderate	O
dilatation	O
of	O
the	O
left	O
ventricle	O
LV	O
.	O
All	O
of	O
them	O
have	O
LMNA	O
p332fs	O
mutation	O
.	O
Two	O
maternal	O
uncles	O
,	O
mother	O
and	O
brother	O
died	O
of	O
sudden	O
death	O
before	O
the	O
age	O
of	O
55	O
.	O
Current	O
disease	O
Consultation	O
for	O
screening	O
for	O
LMNA	O
p332fs	O
mutation	O
.	O
Asymptomatic	O
.	O
Asthenia	O
in	O
the	O
last	O
year	O
which	O
has	O
not	O
prevented	O
her	O
from	O
leading	O
a	O
normal	O
life	O
.	O
After	O
finding	O
a	O
complete	O
AVB	O
in	O
the	O
ECG	O
,	O
she	O
was	O
admitted	O
.	O
Physical	O
examination	O
Afebrile	O
.	O
HR	O
50	O
bpm	O
.	O
BP	O
143	O
83	O
mmHg	O
.	O
SatO2	O
99	O
.	O
AC	O
RsCsRs	O
with	O
mitral	O
systolic	O
murmur	O
II	O
VI	O
.	O
AP	O
VCM	O
.	O
Abdomen	O
nondescript	O
.	O
EEII	O
without	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
AF	O
at	O
37	O
bpm	O
with	O
complete	O
paroxysmal	O
AVB	O
.	O
Transthoracic	O
echocardiography	O
mild	O
LV	O
dilatation	O
.	O
Slightly	O
depressed	O
systolic	O
function	O
LVEF	O
45	O
.	O
Mild	O
moderate	O
functional	O
MR	O
.	O
Telemetry	O
asymptomatic	O
slow	O
AF	O
with	O
self	O
limited	O
bouts	O
of	O
full	O
BAV	O
with	O
narrow	O
QRS	O
nodal	O
escape	O
and	O
no	O
pauses	O
or	O
VT	O
.	O
Blood	O
count	O
and	O
coagulation	O
normal	O
.	O
Biochemistry	O
normal	O
CK	O
and	O
NT	O
proBNP	O
1238	O
pg	O
ml	O
.	O
Genetic	O
study	O
carrier	O
of	O
LMNA	O
p332fs	O
mutation	O
.	O
EVOLUTION	O
During	O
hospitalisation	O
,	O
telemetry	O
showed	O
asymptomatic	O
slow	O
AF	O
with	O
self	O
limited	O
bouts	O
of	O
complete	O
AVB	O
with	O
narrow	O
QRS	O
nodal	O
escape	O
and	O
no	O
pauses	O
,	O
remaining	O
asymptomatic	O
.	O
The	O
problem	O
we	O
faced	O
was	O
to	O
decide	O
which	O
device	O
to	O
implant	O
in	O
this	O
patient	O
conventional	O
pacemaker	O
,	O
ICD	O
,	O
ICD	O
CRT	O
and	O
also	O
to	O
continue	O
the	O
family	O
screening	O
study	O
for	O
the	O
mutation	O
.	O
Finally	O
,	O
the	O
decision	O
was	O
made	O
to	O
implant	O
an	O
ICD	O
CRT	O
,	O
in	O
accordance	O
with	O
the	O
available	O
scientific	O
evidence	O
see	O
discussion	O
.	O
DIAGNOSIS	O
Slow	O
atrial	O
fibrillation	O
with	O
spells	O
of	O
complete	O
atrioventricular	O
block	O
.	O
Familial	O
dilated	O
cardiomyopathy	O
DCM	O
with	O
dilated	O
left	O
ventricle	O
with	O
mild	O
moderate	O
systolic	O
dysfunction	O
LVEF	O
45	O
.	O
Carrier	O
of	O
LMNA	O
p	O
332fs	O
mutation	O
.	O
Extensive	O
family	O
history	O
of	O
sudden	O
death	O
,	O
complete	O
AVB	O
and	O
dilated	O
cardiomyopathy	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
47	O
year	O
old	O
male	O
diagnosed	O
with	O
HCM	O
at	O
the	O
age	O
of	O
44	O
years	O
,	O
following	O
a	O
family	O
screening	O
after	O
his	O
7	O
year	O
old	O
daughter	O
presented	O
with	O
a	O
recovered	O
sudden	O
death	O
.	O
Genetic	O
testing	O
showed	O
a	O
troponin	O
I	O
mutation	O
TNNI3	O
in	O
the	O
index	O
case	O
,	O
our	O
patient	O
being	O
a	O
carrier	O
.	O
At	O
the	O
time	O
of	O
diagnosis	O
,	O
he	O
was	O
oligosymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
he	O
reported	O
NYHA	O
functional	O
class	O
I	O
II	O
and	O
denied	O
symptoms	O
of	O
palpitations	O
,	O
chest	O
pain	O
,	O
dizziness	O
or	O
syncope	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
.	O
Narrow	O
QRS	O
with	O
30o	O
axis	O
.	O
Left	O
ventricular	O
overload	O
voltage	O
criteria	O
.	O
CBC	O
Hb	O
13	O
g	O
dl	O
,	O
Cr	O
1	O
mg	O
dl	O
,	O
normal	O
ions	O
,	O
NT	O
proBNP	O
1	O
,	O
000	O
pg	O
ml	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
.	O
Mild	O
vascular	O
redistribution	O
to	O
upper	O
fields	O
.	O
Echocardiogram	O
LV	O
of	O
normal	O
diameter	O
with	O
moderate	O
asymmetric	O
septal	O
hypertrophy	O
15	O
mm	O
with	O
no	O
obstruction	O
across	O
the	O
left	O
ventricular	O
outflow	O
tract	O
,	O
no	O
systolic	O
anterior	O
motion	O
of	O
the	O
mitral	O
valve	O
.	O
Mild	O
left	O
ventricular	O
systolic	O
dysfunction	O
EF	O
48	O
50	O
and	O
grade	O
1	O
diastolic	O
dysfunction	O
.	O
Dilated	O
left	O
atrium	O
67	O
mm	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
late	O
gadolinium	O
enhancement	O
irregularly	O
distributed	O
in	O
the	O
medial	O
wall	O
of	O
the	O
entire	O
septum	O
,	O
anterior	O
wall	O
and	O
free	O
wall	O
of	O
the	O
right	O
ventricle	O
.	O
IVS	O
15	O
mm	O
.	O
Severe	O
left	O
atrial	O
dilatation	O
.	O
Ergometry	O
sinus	O
rhythm	O
during	O
recording	O
.	O
Supraventricular	O
extrasystoles	O
and	O
ventricular	O
extrasystoles	O
with	O
BRDHH	O
morphology	O
isolated	O
.	O
EVOLUTION	O
After	O
the	O
studies	O
performed	O
,	O
an	O
intermediate	O
risk	O
of	O
sudden	O
death	O
was	O
estimated	O
HCM	O
5	O
year	O
SCD	O
rate	O
4	O
.	O
7	O
,	O
and	O
ICD	O
implantation	O
was	O
decided	O
for	O
primary	O
prevention	O
of	O
sudden	O
death	O
.	O
After	O
a	O
stable	O
period	O
of	O
3	O
years	O
,	O
he	O
reported	O
progressive	O
clinical	O
worsening	O
in	O
the	O
last	O
6	O
months	O
,	O
presenting	O
deterioration	O
of	O
functional	O
class	O
CF	O
NYHA	O
III	O
IV	O
.	O
Physical	O
examination	O
revealed	O
elevated	O
jugular	O
venous	O
pressure	O
and	O
crackles	O
on	O
pulmonary	O
auscultation	O
.	O
Laboratory	O
tests	O
showed	O
elevated	O
NT	O
proBNP	O
up	O
to	O
5	O
,	O
000	O
pg	O
ml	O
,	O
with	O
the	O
rest	O
of	O
the	O
parameters	O
in	O
the	O
normal	O
range	O
.	O
The	O
electrocardiogram	O
was	O
in	O
sinus	O
rhythm	O
.	O
A	O
control	O
echocardiogram	O
was	O
performed	O
,	O
which	O
showed	O
LV	O
with	O
moderate	O
asymmetric	O
septal	O
hypertrophy	O
,	O
which	O
had	O
not	O
progressed	O
,	O
with	O
deterioration	O
of	O
LV	O
systolic	O
function	O
EF	O
40	O
45	O
.	O
No	O
dynamic	O
gradient	O
was	O
observed	O
in	O
the	O
LV	O
outflow	O
tract	O
.	O
He	O
also	O
had	O
grade	O
3	O
diastolic	O
dysfunction	O
,	O
with	O
evidence	O
of	O
elevated	O
filling	O
pressures	O
.	O
Ergospirometry	O
was	O
performed	O
,	O
showing	O
peak	O
oxygen	O
consumption	O
of	O
16	O
ml	O
min	O
kg	O
57	O
of	O
predicted	O
and	O
right	O
heart	O
catheterisation	O
,	O
with	O
evidence	O
of	O
postcapillary	O
pulmonary	O
hypertension	O
pulmonary	O
capillary	O
pressure	O
24	O
mmHg	O
,	O
systolic	O
pulmonary	O
pressure	O
of	O
55	O
mmHg	O
,	O
mean	O
pulmonary	O
artery	O
pressure	O
32	O
mmHg	O
.	O
RV	O
end	O
diastolic	O
pressure	O
was	O
16	O
mmHg	O
.	O
Neurohormonal	O
treatment	O
was	O
started	O
and	O
,	O
due	O
to	O
severe	O
dilatation	O
of	O
the	O
left	O
atrium	O
and	O
thrombotic	O
risk	O
in	O
case	O
of	O
falling	O
into	O
atrial	O
fibrillation	O
,	O
oral	O
anticoagulation	O
was	O
also	O
started	O
.	O
The	O
evolution	O
in	O
the	O
following	O
year	O
was	O
unfavourable	O
despite	O
optimal	O
medical	O
treatment	O
,	O
presenting	O
dyspnoea	O
on	O
minimal	O
exertion	O
,	O
with	O
two	O
admissions	O
for	O
decompensation	O
of	O
heart	O
failure	O
.	O
A	O
new	O
determination	O
of	O
oxygen	B-FARMACO
consumption	O
was	O
performed	O
,	O
estimating	O
VO2	O
max	O
of	O
12	O
ml	O
kg	O
min	O
.	O
Given	O
the	O
significant	O
and	O
progressive	O
limitation	O
of	O
his	O
functional	O
capacity	O
,	O
he	O
was	O
referred	O
to	O
a	O
reference	O
centre	O
as	O
a	O
candidate	O
for	O
heart	O
transplant	O
,	O
undergoing	O
a	O
pre	O
transplant	O
study	O
and	O
is	O
currently	O
on	O
the	O
waiting	O
list	O
for	O
elective	O
transplant	O
.	O
DIAGNOSIS	O
Non	O
obstructive	O
hypertrophic	O
cardiomyopathy	O
.	O
Mutation	O
in	O
the	O
troponin	O
I	O
3	O
gene	O
TNNI3	O
.	O
Recovered	O
sudden	O
death	O
in	O
first	O
degree	O
relative	O
.	O
ICD	O
carrier	O
.	O
Mild	O
left	O
ventricular	O
dysfunction	O
.	O
Stage	O
D	O
heart	O
failure	O
.	O
NYHA	O
functional	O
class	O
III	O
IV	O
.	O
Candidate	O
for	O
elective	O
heart	O
transplant	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
a	O
48	O
year	O
old	O
male	O
,	O
dyslipidaemic	O
,	O
with	O
non	O
ischaemic	O
dilated	O
cardiomyopathy	O
with	O
severe	O
ventricular	O
dysfunction	O
known	O
since	O
2010	O
.	O
Years	O
earlier	O
,	O
a	O
genetic	O
study	O
had	O
been	O
performed	O
,	O
with	O
the	O
finding	O
of	O
an	O
LMNA	O
variant	O
of	O
uncertain	O
significance	O
in	O
a	O
gene	O
related	O
to	O
laminopathy	O
,	O
consistent	O
with	O
the	O
patient	O
's	O
phenotype	O
non	O
ischaemic	O
dilated	O
cardiomyopathy	O
associated	O
with	O
conduction	O
disorder	O
and	O
ventricular	O
arrhythmias	O
,	O
which	O
had	O
required	O
multiple	O
ablation	O
procedures	O
in	O
the	O
course	O
of	O
his	O
disease	O
.	O
In	O
addition	O
,	O
the	O
patient	O
had	O
had	O
a	O
mechanical	O
prosthesis	O
ATS	O
no	O
.	O
25	O
since	O
2012	O
for	O
a	O
bicuspid	O
aortic	O
valve	O
with	O
severe	O
insufficiency	O
.	O
During	O
2016	O
,	O
the	O
patient	O
was	O
in	O
advanced	O
heart	O
failure	O
,	O
in	O
NYHA	O
functional	O
class	O
IV	O
,	O
with	O
severe	O
LV	O
systolic	O
dysfunction	O
on	O
echocardiography	O
requiring	O
repeated	O
admissions	O
for	O
severe	O
decompensation	O
.	O
He	O
was	O
therefore	O
included	O
on	O
the	O
elective	O
list	O
for	O
heart	O
transplantation	O
INTERMACS	O
4	O
.	O
In	O
the	O
following	O
weeks	O
he	O
presented	O
progressive	O
worsening	O
despite	O
periodic	O
cycles	O
of	O
levosimendan	B-FARMACO
,	O
with	O
increasingly	O
frequent	O
decompensations	O
due	O
to	O
low	O
output	O
and	O
congestion	O
,	O
the	O
last	O
of	O
which	O
did	O
not	O
improve	O
despite	O
inotropic	O
support	O
INTERMACS	O
2	O
.	O
It	O
was	O
decided	O
to	O
implant	O
a	O
balloon	O
counterpulsation	O
device	O
and	O
to	O
place	O
him	O
on	O
urgent	O
cardiac	O
transplant	O
list	O
1	O
.	O
Three	O
weeks	O
later	O
,	O
heart	O
transplantation	O
was	O
performed	O
by	O
bicave	O
technique	O
,	O
with	O
good	O
biventricular	O
function	O
at	O
pump	O
output	O
.	O
Immediate	O
postoperative	O
period	O
without	O
complications	O
little	O
need	O
for	O
haemodynamic	O
support	O
,	O
no	O
rhythm	O
disorders	O
,	O
extubation	O
in	O
the	O
first	O
twelve	O
hours	O
,	O
no	O
neurological	O
deficit	O
.	O
No	O
complications	O
from	O
the	O
infectious	O
point	O
of	O
view	O
,	O
she	O
received	O
prophylaxis	O
according	O
to	O
the	O
centre	O
's	O
protocol	O
with	O
norfloxacin	B-FARMACO
,	O
nystatin	B-FARMACO
,	O
cotrimoxazole	B-FARMACO
recipient	O
with	O
negative	O
toxoplasma	O
and	O
unknown	O
donor	O
and	O
valganciclovir	B-FARMACO
for	O
15	O
days	O
due	O
to	O
intermediate	O
risk	O
positive	O
cytomegalovirus	O
in	O
donor	O
and	O
recipient	O
.	O
Immunosuppression	O
also	O
according	O
to	O
protocol	O
,	O
consisting	O
of	O
Two	O
doses	O
of	O
basiliximab	B-FARMACO
20	O
mg	O
on	O
the	O
first	O
and	O
fourth	O
day	O
.	O
Intensive	O
corticotherapy	O
with	O
methylprednisolone	B-FARMACO
125	O
mg	O
every	O
8	O
h	O
on	O
the	O
first	O
day	O
,	O
followed	O
by	O
prednisone	B-FARMACO
1	O
mg	O
kg	O
day	O
,	O
in	O
a	O
descending	O
pattern	O
.	O
Tacrolimus	B-FARMACO
,	O
starting	O
at	O
0	O
.	O
03	O
mg	O
kg	O
12	O
h	O
and	O
adjusting	O
according	O
to	O
levels	O
to	O
target	O
between	O
10	O
and	O
15	O
ng	O
ml	O
at	O
baseline	O
.	O
Mycophenolate	B-FARMACO
mofetil	I-FARMACO
sodium	I-FARMACO
,	O
1	O
,	O
000	O
mg	O
12	O
h	O
.	O
Without	O
evidence	O
of	O
rejection	O
in	O
successive	O
biopsies	O
and	O
with	O
serial	O
echocardiograms	O
with	O
normofunctioning	O
graft	O
,	O
preserved	O
left	O
and	O
right	O
ventricular	O
ejection	O
fraction	O
,	O
without	O
valvular	O
heart	O
disease	O
or	O
pericardial	O
effusion	O
.	O
In	O
this	O
context	O
,	O
while	O
stable	O
on	O
the	O
cardiology	O
ward	O
after	O
an	O
uncomplicated	O
endomyocardial	O
biopsy	O
three	O
hours	O
earlier	O
,	O
he	O
presented	O
with	O
an	O
episode	O
of	O
eye	O
twitching	O
with	O
sustained	O
blinking	O
,	O
during	O
which	O
he	O
was	O
able	O
to	O
respond	O
to	O
commands	O
,	O
lasting	O
one	O
minute	O
.	O
This	O
was	O
followed	O
by	O
tonic	O
clonic	O
movements	O
of	O
all	O
four	O
limbs	O
lasting	O
one	O
minute	O
.	O
A	O
few	O
minutes	O
after	O
cessation	O
,	O
during	O
which	O
time	O
he	O
remained	O
with	O
visual	O
disturbances	O
and	O
nystagmus	O
to	O
the	O
left	O
,	O
he	O
presented	O
a	O
new	O
episode	O
of	O
generalised	O
seizure	O
,	O
more	O
prolonged	O
,	O
which	O
ceased	O
with	O
benzodiazepines	O
10	O
mg	O
diazepam	B-FARMACO
,	O
as	O
well	O
as	O
levetiracetam	B-FARMACO
1	O
,	O
000	O
mg	O
in	O
perfusion	O
,	O
both	O
intravenous	O
.	O
After	O
resolution	O
,	O
the	O
patient	O
remained	O
conscious	O
,	O
oriented	O
and	O
speech	O
preserved	O
.	O
The	O
threat	O
reflex	O
was	O
bilaterally	O
absent	O
and	O
at	O
the	O
time	O
the	O
patient	O
reported	O
exclusively	O
shadow	O
vision	O
.	O
Pupils	O
were	O
isochoric	O
,	O
normoreactive	O
;	O
leftward	O
nystagmus	O
maintained	O
in	O
primary	O
gaze	O
position	O
.	O
He	O
was	O
able	O
to	O
move	O
all	O
four	O
limbs	O
symmetrically	O
,	O
with	O
the	O
rest	O
of	O
the	O
examination	O
being	O
unremarkable	O
.	O
Blood	O
pressure	O
was	O
160	O
90	O
mmHg	O
.	O
Once	O
he	O
improved	O
,	O
the	O
patient	O
admitted	O
having	O
had	O
a	O
mild	O
holocranial	O
headache	O
in	O
the	O
previous	O
days	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
haemoglobin	O
12	O
.	O
1	O
g	O
dL	O
,	O
Ht	O
37	O
,	O
RDW	O
24	O
,	O
platelets	O
107	O
,	O
000	O
μL	O
,	O
the	O
rest	O
without	O
alterations	O
.	O
Coagulation	O
APTT	O
24	O
.	O
7	O
s	O
,	O
the	O
rest	O
without	O
alterations	O
.	O
Biochemistry	O
glycaemia	O
106	O
mg	O
dl	O
,	O
GGT	O
285	O
IU	O
l	O
,	O
protein	O
5	O
.	O
8	O
g	O
dl	O
.	O
Renal	O
function	O
preserved	O
creatinine	O
0	O
.	O
88	O
mg	O
dl	O
,	O
GFR	O
MDRD	O
4	O
60	O
ml	O
min	O
.	O
Ions	O
in	O
normal	O
range	O
Na	O
138	O
mmol	O
l	O
,	O
K	O
4	O
.	O
4	O
mmol	O
l	O
.	O
CRP	O
0	O
.	O
1	O
mg	O
L	O
.	O
Venous	O
blood	O
gases	O
pH	O
7	O
.	O
21	O
,	O
bicarbonate	O
18	O
mg	O
dl	O
,	O
lactate	O
13	O
.	O
1	O
mg	O
dl	O
,	O
the	O
rest	O
without	O
alterations	O
Cranial	O
CT	O
scan	O
multiple	O
posterior	O
temporal	O
and	O
parieto	O
occipital	O
hypodense	O
lesions	O
,	O
as	O
well	O
as	O
right	O
frontal	O
and	O
in	O
both	O
cerebellar	O
hemispheres	O
,	O
although	O
also	O
predominantly	O
on	O
the	O
right	O
.	O
Brain	O
MRI	O
vasogenic	O
oedema	O
symmetrically	O
affecting	O
the	O
subcortical	O
white	O
matter	O
of	O
almost	O
all	O
of	O
both	O
occipital	O
lobes	O
and	O
occipito	O
parieto	O
temporal	O
regions	O
.	O
In	O
these	O
areas	O
,	O
multiple	O
millimetric	O
foci	O
of	O
hypointensity	O
and	O
cortico	O
subcortical	O
distribution	O
can	O
be	O
seen	O
,	O
which	O
are	O
compatible	O
with	O
microbleeds	O
.	O
EVOLUTION	O
The	O
patient	O
was	O
immediately	O
evaluated	O
by	O
Neurology	O
,	O
who	O
,	O
given	O
the	O
finding	O
of	O
seizures	O
together	O
with	O
previous	O
headache	O
and	O
visual	O
disturbances	O
in	O
a	O
patient	O
being	O
treated	O
with	O
tacrolimus	B-FARMACO
,	O
suspected	O
the	O
most	O
likely	O
diagnosis	O
to	O
be	O
posterior	O
reversible	O
encephalopathy	O
syndrome	O
PRES	O
.	O
Both	O
CT	O
and	O
MRI	O
,	O
the	O
latter	O
being	O
the	O
technique	O
of	O
choice	O
,	O
showed	O
images	O
highly	O
suggestive	O
of	O
this	O
condition	O
.	O
He	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
for	O
strict	O
control	O
of	O
blood	O
pressure	O
and	O
monitoring	O
of	O
new	O
critical	O
episodes	O
.	O
From	O
the	O
point	O
of	O
view	O
of	O
management	O
,	O
tacrolimus	B-FARMACO
was	O
withdrawn	O
and	O
cyclosporine	B-FARMACO
was	O
started	O
slowly	O
,	O
as	O
this	O
was	O
the	O
most	O
commonly	O
used	O
regimen	O
in	O
the	O
literature	O
in	O
these	O
cases	O
.	O
Mycophenolate	B-FARMACO
was	O
increased	O
and	O
high	O
doses	O
of	O
corticotherapy	O
were	O
maintained	O
until	O
adequate	O
therapeutic	O
levels	O
of	O
calcineurin	O
inhibitors	O
were	O
reached	O
.	O
Despite	O
these	O
changes	O
,	O
no	O
rejection	O
data	O
were	O
documented	O
,	O
either	O
by	O
ultrasound	O
or	O
endomyocardial	O
biopsy	O
.	O
No	O
new	O
episodes	O
of	O
seizures	O
.	O
Progressive	O
overall	O
recovery	O
,	O
with	O
somewhat	O
slower	O
recovery	O
of	O
visual	O
disturbances	O
.	O
He	O
was	O
discharged	O
12	O
days	O
after	O
the	O
event	O
,	O
neurologically	O
asymptomatic	O
and	O
with	O
control	O
MRI	O
,	O
with	O
significant	O
improvement	O
with	O
respect	O
to	O
the	O
previous	O
study	O
.	O
DIAGNOSIS	O
Reversible	O
posterior	O
encephalopathy	O
syndrome	O
PRES	O
probably	O
secondary	O
to	O
treatment	O
with	O
tacrolimus	B-FARMACO
.	O
Generalised	O
tonic	O
clonic	O
seizures	O
secondary	O
to	O
the	O
above	O
.	O
Normofunctioning	O
orthotopic	O
heart	O
transplant	O
in	O
a	O
patient	O
with	O
non	O
ischaemic	O
dilated	O
cardiomyopathy	O
with	O
severe	O
left	O
ventricular	O
dysfunction	O
,	O
possible	O
laminopathy	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
45	O
year	O
old	O
male	O
.	O
Native	O
of	O
Conakri	O
,	O
capital	O
of	O
Guinea	O
,	O
resident	O
in	O
Spain	O
since	O
May	O
2016	O
.	O
Diagnosed	O
with	O
untreated	O
diabetes	O
mellitus	O
on	O
admission	O
;	O
no	O
personal	O
or	O
family	O
history	O
of	O
heart	O
disease	O
,	O
history	O
of	O
heart	O
failure	O
or	O
sudden	O
death	O
.	O
He	O
consulted	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
due	O
to	O
progressive	O
dyspnoea	O
on	O
exertion	O
,	O
until	O
becoming	O
minimal	O
effort	O
walking	O
less	O
than	O
5	O
metres	O
in	O
the	O
last	O
year	O
.	O
He	O
reported	O
stopping	O
at	O
least	O
three	O
times	O
to	O
climb	O
a	O
flight	O
of	O
stairs	O
.	O
He	O
also	O
presents	O
palpitations	O
,	O
oedematisation	O
of	O
the	O
lower	O
limbs	O
and	O
increased	O
abdominal	O
perimeter	O
.	O
He	O
reports	O
orthopnoea	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
He	O
denies	O
angina	O
on	O
exertion	O
.	O
On	O
physical	O
examination	O
,	O
eupneic	O
at	O
rest	O
,	O
tolerating	O
decubitus	O
at	O
20o	O
,	O
well	O
perfused	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
tones	O
,	O
tachycardic	O
,	O
with	O
S3	O
and	O
systolic	O
murmur	O
II	O
VI	O
in	O
tricuspid	O
focus	O
that	O
increases	O
with	O
inspiration	O
.	O
Jugular	O
ingurgitation	O
.	O
Pulmonary	O
auscultation	O
light	O
bibasal	O
crackles	O
.	O
Distended	O
abdomen	O
with	O
hepatomegaly	O
of	O
3	O
tracts	O
.	O
Oedema	O
in	O
the	O
lower	O
limbs	O
up	O
to	O
the	O
thighs	O
and	O
in	O
the	O
abdominal	O
wall	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
tachycardia	O
at	O
102	O
bpm	O
.	O
QRS	O
with	O
axis	O
at	O
60o	O
.	O
BRDHH	O
and	O
HBAIHH	O
.	O
QR	O
pattern	O
in	O
right	O
precordial	O
leads	O
suggestive	O
of	O
right	O
ventricular	O
growth	O
and	O
overload	O
,	O
with	O
ST	O
underleveling	O
and	O
negative	O
T	O
waves	O
in	O
the	O
same	O
.	O
Poor	O
R	O
wave	O
progression	O
in	O
precordial	O
leads	O
.	O
V5	O
V6	O
notching	O
with	O
rsr	O
s	O
complexes	O
.	O
Electrocardiogram	O
during	O
admission	O
sinus	O
rhythm	O
at	O
78	O
bpm	O
.	O
Axis	O
at	O
60o	O
.	O
BRDHH	O
and	O
HBAIHH	O
.	O
qR	O
in	O
right	O
precordials	O
with	O
ST	O
underleveling	O
and	O
negative	O
T	O
waves	O
in	O
the	O
same	O
.	O
Notching	O
in	O
V5	O
V6	O
.	O
CBC	O
Glucose	O
124	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
34	O
mg	O
dl	O
.	O
GOT	O
41	O
U	O
l	O
.	O
GPT	O
16	O
U	O
l	O
.	O
Sodium	O
138	O
mmol	O
l	O
.	O
Potassium	O
4	O
.	O
55	O
mmol	O
l	O
.	O
Haemoglobin	O
13	O
.	O
7	O
g	O
dl	O
,	O
platelets	O
205	O
,	O
000	O
μL	O
.	O
Leukocytes	O
5	O
,	O
670	O
μL	O
.	O
Slight	O
iron	O
deficiency	O
iron	O
34	O
μg	O
dl	O
with	O
normal	O
transferrin	O
and	O
ferritin	O
.	O
TSH	O
1	O
.	O
95	O
U	O
l	O
.	O
HbA1c	O
7	O
.	O
1	O
.	O
Total	O
cholesterol	O
167	O
mg	O
dl	O
,	O
LDLc	O
114	O
mg	O
dl	O
,	O
HDLc	O
34	O
mg	O
dl	O
,	O
triglycerides	O
95	O
mg	O
dl	O
.	O
Coagulation	O
INR	O
1	O
.	O
43	O
,	O
PTTA	O
29	O
.	O
5	O
.	O
Factor	O
II	O
57	O
.	O
Factor	O
V	O
66	O
.	O
Factor	O
VII	O
40	O
.	O
Factor	O
X	O
57	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
at	O
the	O
expense	O
of	O
right	O
cavities	O
.	O
Signs	O
of	O
vascular	O
redistribution	O
and	O
fluid	O
in	O
minor	O
fissure	O
.	O
Serology	O
Toxoplasma	O
,	O
Echinococcus	O
,	O
Trypanosoma	O
,	O
Treponema	O
pallidum	O
,	O
Strongyloides	O
stercoralis	O
,	O
Schistosoma	O
negative	O
.	O
Peripheral	O
blood	O
parasitaemia	O
negative	O
.	O
Plasmodium	O
IgM	O
negative	O
and	O
IgG	O
1	O
80	O
recent	O
infection	O
.	O
Trichinella	O
,	O
Fasciola	O
,	O
Taenia	O
negative	O
.	O
HIV	O
negative	O
.	O
HAV	O
IgM	O
negative	O
with	O
positive	O
total	O
Ac	O
.	O
HBV	O
HBcAc	O
positive	O
,	O
antiHBe	O
undetermined	O
and	O
AntiHBs	O
positive	O
.	O
Transthoracic	O
echocardiogram	O
LV	O
endomyocardial	O
fibrosis	O
.	O
Severe	O
LV	O
systolic	O
dysfunction	O
with	O
LVEF	O
20	O
and	O
restrictive	O
diastolic	O
pattern	O
.	O
Low	O
cardiac	O
output	O
.	O
Dilated	O
RV	O
,	O
hypocontractile	O
with	O
TAPSE	O
of	O
11	O
mm	O
,	O
without	O
clear	O
image	O
of	O
apical	O
occupation	O
.	O
Slight	O
left	O
atrial	O
dilatation	O
and	O
moderate	O
dilatation	O
of	O
the	O
RA	O
.	O
Mild	O
functional	O
MR	O
.	O
Severe	O
functional	O
TR	O
.	O
Severe	O
pulmonary	O
hypertension	O
.	O
Slight	O
right	O
retroauricular	O
pericardial	O
effusion	O
.	O
Angio	O
CT	O
pulmonary	O
arteries	O
and	O
cardiac	O
CT	O
minimal	O
focal	O
repletion	O
defect	O
in	O
the	O
periphery	O
of	O
the	O
posterior	O
basal	O
segmental	O
branch	O
and	O
lateral	O
subsegmental	O
branch	O
of	O
the	O
LID	O
,	O
compatible	O
with	O
chronic	O
PTE	O
.	O
Cardiomegaly	O
with	O
signs	O
of	O
right	O
HF	O
.	O
Atheromatosis	O
in	O
aortic	O
arch	O
and	O
coronary	O
arteries	O
.	O
Increased	O
fat	O
density	O
in	O
the	O
middle	O
mediastinum	O
not	O
individualising	O
the	O
oesophageal	O
wall	O
,	O
non	O
specific	O
.	O
Coronary	O
angiography	O
coronary	O
artery	O
disease	O
of	O
1	O
vessel	O
.	O
Anterior	O
descending	O
with	O
critical	O
ostial	O
lesion	O
,	O
diffusely	O
diseased	O
vessel	O
with	O
borderline	O
calibre	O
and	O
TIMI	O
2	O
distal	O
flow	O
.	O
The	O
apical	O
portion	O
is	O
filled	O
by	O
homocoronary	O
circulation	O
from	O
epicardial	O
vessel	O
coming	O
from	O
circumflex	O
.	O
EVOLUTION	O
Admitted	O
to	O
the	O
cardiology	O
ward	O
for	O
heart	O
failure	O
on	O
debut	O
,	O
predominantly	O
right	O
heart	O
failure	O
,	O
CF	O
III	O
IV	O
NYHA	O
;	O
restrictive	O
cardiomyopathy	O
compatible	O
with	O
LV	O
endomyocardial	O
fibrosis	O
,	O
with	O
severe	O
LV	O
systolic	O
dysfunction	O
and	O
restrictive	O
LV	O
filling	O
pattern	O
associated	O
with	O
dilated	O
and	O
dysfunctional	O
RV	O
with	O
severe	O
TR	O
and	O
data	O
of	O
pulmonary	O
hypertension	O
was	O
observed	O
on	O
echocardiography	O
.	O
Depletive	O
treatment	O
was	O
started	O
with	O
good	O
response	O
and	O
progressive	O
titration	O
of	O
neurohormonal	O
treatment	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
hours	O
,	O
ramipril	B-FARMACO
5	O
mg	O
24	O
hours	O
,	O
eplerenone	B-FARMACO
25	O
mg	O
24	O
hours	O
.	O
Angio	O
CT	O
of	O
the	O
pulmonary	O
arteries	O
was	O
requested	O
with	O
a	O
diagnosis	O
of	O
chronic	O
PTE	O
and	O
thoracic	O
CT	O
to	O
assess	O
the	O
extent	O
of	O
endomyocardial	O
fibrosis	O
,	O
with	O
absence	O
of	O
endomyocardial	O
calcification	O
,	O
showing	O
coronary	O
atheromatosis	O
.	O
Coronary	O
angiography	O
showed	O
coronary	O
artery	O
disease	O
of	O
the	O
anterior	O
descending	O
artery	O
with	O
critical	O
ostial	O
lesion	O
,	O
visualising	O
a	O
diffusely	O
diseased	O
vessel	O
of	O
borderline	O
calibre	O
.	O
The	O
patient	O
was	O
screened	O
for	O
infections	O
as	O
an	O
aetiopathogenic	O
factor	O
of	O
the	O
endomyocardial	O
fibrosis	O
.	O
Given	O
the	O
patient	O
's	O
characteristics	O
,	O
absence	O
of	O
angina	O
,	O
LV	O
dysfunction	O
secondary	O
to	O
endomyocardial	O
fibrosis	O
,	O
ASA	B-FARMACO
and	O
statins	B-FARMACO
were	O
associated	O
with	O
the	O
medical	O
treatment	O
already	O
prescribed	O
and	O
the	O
case	O
was	O
presented	O
in	O
a	O
medical	O
surgical	O
session	O
endomyocardial	O
resection	O
CABG	O
.	O
The	O
patient	O
was	O
rejected	O
for	O
surgery	O
to	O
resect	O
masses	O
and	O
revascularise	O
the	O
LAD	O
due	O
to	O
high	O
surgical	O
risk	O
.	O
Oral	O
anticoagulation	O
was	O
not	O
started	O
due	O
to	O
a	O
significant	O
language	O
barrier	O
and	O
high	O
risk	O
of	O
non	O
compliance	O
with	O
treatment	O
.	O
During	O
follow	O
up	O
,	O
the	O
patient	O
did	O
not	O
attend	O
outpatient	O
check	O
ups	O
.	O
DIAGNOSIS	O
Debut	O
heart	O
failure	O
related	O
to	O
restrictive	O
cardiomyopathy	O
due	O
to	O
LV	O
endomyocardial	O
fibrosis	O
.	O
Severe	O
pulmonary	O
hypertension	O
.	O
Chronic	O
pulmonary	O
thromboembolism	O
.	O
Severe	O
functional	O
tricuspid	O
insufficiency	O
.	O
Ischaemic	O
heart	O
disease	O
.	O
1	O
vessel	O
coronary	O
artery	O
disease	O
,	O
without	O
clinical	O
signs	O
of	O
angina	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
60	O
year	O
old	O
patient	O
with	O
a	O
history	O
of	O
hypertension	O
,	O
dyslipidaemia	O
,	O
COPD	O
,	O
left	O
temporoparietal	O
ischaemic	O
stroke	O
with	O
no	O
subsequent	O
sequelae	O
,	O
dilated	O
heart	O
disease	O
of	O
ischaemic	O
origin	O
,	O
which	O
debuted	O
in	O
the	O
form	O
of	O
inferolateral	O
AMI	O
20	O
years	O
earlier	O
,	O
with	O
subsequent	O
echocardiogram	O
showing	O
severely	O
dilated	O
left	O
ventricle	O
with	O
severe	O
ventricular	O
dysfunction	O
LVEF	O
20	O
secondary	O
to	O
inferoposterior	O
akinesia	O
and	O
hypokinesia	O
of	O
the	O
remaining	O
segments	O
,	O
with	O
mild	O
mitral	O
insufficiency	O
,	O
without	O
other	O
significant	O
valvulopathies	O
.	O
It	O
was	O
decided	O
to	O
implant	O
an	O
ICD	O
as	O
primary	O
prevention	O
and	O
CRT	O
,	O
with	O
improvement	O
in	O
systolic	O
function	O
LVEF	O
35	O
.	O
The	O
patient	O
consulted	O
the	O
emergency	O
department	O
for	O
dyspnoea	O
of	O
4	O
days	O
'	O
duration	O
,	O
accompanied	O
by	O
cough	O
and	O
fever	O
.	O
Haemodynamically	O
,	O
BP	O
96	O
65	O
mmHg	O
,	O
febrile	O
at	O
38	O
C	O
,	O
02	O
saturation	O
92	O
with	O
KVM	O
24	O
.	O
Physical	O
examination	O
revealed	O
abundant	O
rhonchi	O
and	O
wheezing	O
predominantly	O
in	O
right	O
fields	O
,	O
with	O
bibasal	O
crackles	O
,	O
systolic	O
murmur	O
predominantly	O
in	O
mitral	O
focus	O
,	O
bimalleolar	O
oedema	O
and	O
jugular	O
ingurgitation	O
.	O
Arterial	O
blood	O
gas	O
with	O
Fi02	O
of	O
24	O
showed	O
pH	O
7	O
.	O
476	O
,	O
pC02	O
34	O
mmHg	O
,	O
p02	O
59	O
mmHg	O
,	O
HCO3	O
24	O
.	O
5	O
mmol	O
L	O
.	O
CBC	O
with	O
minimal	O
elevation	O
of	O
acute	O
phase	O
reactants	O
CRP	O
1	O
.	O
74	O
mg	O
dl	O
and	O
leukocytosis	O
11910	O
L	O
with	O
neutrophilia	O
81	O
,	O
slightly	O
altered	O
renal	O
function	O
creatinine	O
1	O
.	O
32	O
mg	O
dl	O
and	O
GFR	O
54	O
ml	O
min	O
,	O
correct	O
ionogram	O
.	O
Chest	O
X	O
ray	O
with	O
signs	O
of	O
vascular	O
redistribution	O
as	O
well	O
as	O
a	O
consolidating	O
image	O
in	O
the	O
right	O
middle	O
lobe	O
,	O
suggestive	O
of	O
pneumonic	O
process	O
.	O
ECG	O
in	O
sinus	O
rhythm	O
95	O
bpm	O
,	O
with	O
ventricular	O
rhythm	O
stimulated	O
by	O
CRT	O
.	O
The	O
patient	O
was	O
diagnosed	O
with	O
respiratory	O
infection	O
and	O
decompensation	O
of	O
heart	O
failure	O
in	O
a	O
patient	O
with	O
chronic	O
ischaemic	O
heart	O
disease	O
in	O
the	O
dilated	O
phase	O
.	O
Diuretic	O
treatment	O
and	O
antibiotic	O
therapy	O
were	O
started	O
.	O
COMPLEMENTARY	O
TESTS	O
Chest	O
X	O
ray	O
signs	O
of	O
vascular	O
redistribution	O
as	O
well	O
as	O
a	O
consolidating	O
image	O
in	O
the	O
right	O
middle	O
lobe	O
,	O
suggestive	O
of	O
a	O
pneumonic	O
process	O
.	O
ECG	O
sinus	O
rhythm	O
95lpm	O
,	O
with	O
ventricular	O
rhythm	O
stimulated	O
by	O
CRT	O
.	O
Echocardiogram	O
on	O
admission	O
LVEF	O
35	O
40	O
.	O
Severe	O
mitral	O
insufficiency	O
with	O
restriction	O
of	O
the	O
posterior	O
leaflet	O
and	O
probable	O
prolapse	O
of	O
the	O
anterior	O
leaflet	O
.	O
Severe	O
dilatation	O
of	O
left	O
ventricle	O
slightly	O
moderately	O
hypertrophic	O
,	O
with	O
moderate	O
reduction	O
of	O
motility	O
due	O
to	O
inferolateral	O
and	O
inferior	O
akinesia	O
.	O
LVEF	O
35	O
40	O
.	O
Moderate	O
left	O
atrial	O
dilatation	O
.	O
Right	O
ventricle	O
with	O
preserved	O
motility	O
.	O
Device	O
lead	O
in	O
right	O
cavities	O
.	O
Mild	O
tricuspid	O
insufficiency	O
that	O
allows	O
estimating	O
PAPs	O
46	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
Transesophageal	O
echocardiogram	O
severe	O
mitral	O
insufficiency	O
secondary	O
to	O
restrictive	O
movement	O
of	O
the	O
posterior	O
leaflet	O
and	O
prolapse	O
of	O
the	O
anterior	O
leaflet	O
at	O
the	O
level	O
of	O
A2	O
with	O
an	O
image	O
of	O
chordal	O
rupture	O
.	O
Coronary	O
angiography	O
right	O
dominance	O
.	O
Truncus	O
description	O
lesion	O
20	O
distal	O
.	O
Description	O
of	O
the	O
anterior	O
descending	O
artery	O
long	O
development	O
,	O
very	O
calcified	O
.	O
Lesion	O
50	O
to	O
the	O
middle	O
tract	O
.	O
Circumflex	O
description	O
very	O
calcified	O
.	O
Lesion	O
30	O
proximal	O
.	O
Right	O
coronary	O
description	O
occluded	O
proximally	O
since	O
2002	O
.	O
Bad	O
distal	O
vessel	O
.	O
Echocardiogram	O
during	O
implantation	O
implantation	O
of	O
two	O
MitraClip	O
x2	O
at	O
level	O
A2	O
P2	O
segments	O
of	O
the	O
mitral	O
valve	O
.	O
Well	O
positioned	O
devices	O
with	O
slight	O
residual	O
leak	O
grade	O
I	O
IV	O
.	O
Fluoroscopy	O
implantation	O
of	O
2	O
MitraClip	O
.	O
EVOLUTION	O
During	O
hospitalisation	O
the	O
patient	O
shows	O
improvement	O
from	O
the	O
infectious	O
point	O
of	O
view	O
.	O
However	O
,	O
his	O
heart	O
failure	O
worsened	O
and	O
he	O
went	O
into	O
cardiogenic	O
shock	O
,	O
requiring	O
non	O
invasive	O
mechanical	O
ventilation	O
and	O
inotropic	O
support	O
.	O
A	O
transthoracic	O
echocardiogram	O
showed	O
severe	O
mitral	O
insufficiency	O
,	O
with	O
restriction	O
of	O
the	O
posterior	O
leaflet	O
and	O
possible	O
prolapse	O
of	O
the	O
anterior	O
leaflet	O
.	O
To	O
better	O
visualise	O
the	O
mechanism	O
of	O
mitral	O
insufficiency	O
,	O
a	O
transesophageal	O
echocardiogram	O
was	O
performed	O
which	O
confirmed	O
severe	O
mitral	O
insufficiency	O
secondary	O
to	O
restrictive	O
movement	O
of	O
the	O
posterior	O
leaflet	O
and	O
prolapse	O
of	O
the	O
anterior	O
leaflet	O
at	O
the	O
level	O
of	O
A2	O
with	O
an	O
image	O
of	O
chordal	O
rupture	O
.	O
Coronary	O
angiography	O
showed	O
moderate	O
lesions	O
of	O
the	O
left	O
coronary	O
artery	O
with	O
chronic	O
occlusion	O
of	O
the	O
right	O
coronary	O
artery	O
,	O
already	O
present	O
in	O
previous	O
studies	O
.	O
The	O
patient	O
had	O
a	O
torpid	O
clinical	O
evolution	O
,	O
with	O
cardiogenic	O
shock	O
refractory	O
to	O
medical	O
treatment	O
,	O
requiring	O
orotracheal	O
intubation	O
,	O
invasive	O
mechanical	O
ventilation	O
and	O
implantation	O
of	O
aortic	O
balloon	O
counterpulsation	O
.	O
The	O
case	O
was	O
assessed	O
jointly	O
with	O
the	O
Cardiac	O
Surgery	O
and	O
Haemodynamics	O
team	O
and	O
,	O
given	O
the	O
high	O
surgical	O
risk	O
,	O
MitraClip	O
implantation	O
was	O
decided	O
.	O
The	O
patient	O
arrived	O
in	O
the	O
haemodynamics	O
room	O
with	O
inotropic	O
support	O
with	O
dobutamine	B-FARMACO
,	O
aortic	O
balloon	O
counterpulsation	O
,	O
orotracheal	O
intubation	O
and	O
mechanical	O
ventilation	O
.	O
The	O
procedure	O
was	O
guided	O
by	O
transesophageal	O
echocardiography	O
and	O
scopy	O
.	O
Given	O
the	O
difficulty	O
of	O
the	O
case	O
,	O
a	O
strategy	O
with	O
at	O
least	O
2	O
clips	O
was	O
considered	O
from	O
the	O
beginning	O
.	O
The	O
first	O
clip	O
was	O
successfully	O
implanted	O
after	O
multiple	O
attempts	O
,	O
and	O
a	O
second	O
,	O
more	O
lateral	O
clip	O
was	O
subsequently	O
implanted	O
,	O
thereby	O
reducing	O
the	O
MR	O
from	O
grade	O
4	O
to	O
1	O
.	O
Subsequently	O
,	O
the	O
patient	O
had	O
a	O
good	O
clinical	O
evolution	O
,	O
being	O
able	O
to	O
remove	O
the	O
counterpulsation	O
balloon	O
,	O
ionotropic	O
and	O
ventilatory	O
support	O
,	O
and	O
was	O
discharged	O
haemodynamically	O
stable	O
with	O
no	O
signs	O
of	O
heart	O
failure	O
.	O
Echocardiogram	O
at	O
discharge	O
showed	O
an	O
estimated	O
EF	O
of	O
25	O
30	O
,	O
MitraClip	O
implantation	O
x2	O
at	O
segment	O
A2	O
P2	O
level	O
of	O
the	O
mitral	O
valve	O
with	O
well	O
positioned	O
devices	O
with	O
mild	O
residual	O
leak	O
grade	O
I	O
IV	O
.	O
Six	O
months	O
after	O
discharge	O
,	O
the	O
patient	O
persists	O
in	O
NYHA	O
functional	O
class	O
I	O
II	O
,	O
with	O
no	O
cardiac	O
decompensation	O
.	O
DIAGNOSIS	O
Community	O
acquired	O
right	O
middle	O
lobe	O
pneumonia	O
.	O
Heart	O
failure	O
with	O
biventricular	O
dysfunction	O
.	O
Cardiogenic	O
shock	O
.	O
Severe	O
mitral	O
insufficiency	O
secondary	O
to	O
restrictive	O
movement	O
of	O
the	O
posterior	O
leaflet	O
and	O
prolapse	O
of	O
the	O
anterior	O
leaflet	O
at	O
A2	O
level	O
with	O
chordal	O
rupture	O
image	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
in	O
dilated	O
phase	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
middle	O
aged	O
patient	O
with	O
hypertrophic	O
sarcomeric	O
cardiomyopathy	O
,	O
with	O
symptomatic	O
left	O
ventricular	O
outflow	O
tract	O
obstruction	O
,	O
in	O
whom	O
alcohol	O
septal	O
ablation	O
is	O
proposed	O
as	O
a	O
therapeutic	O
option	O
.	O
HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
No	O
known	O
adverse	O
drug	O
reactions	O
.	O
No	O
family	O
history	O
of	O
interest	O
in	O
relation	O
to	O
his	O
heart	O
disease	O
.	O
Maternal	O
aunt	O
with	O
a	O
history	O
of	O
arterial	O
hypertension	O
and	O
moderate	O
parietal	O
thickening	O
of	O
the	O
left	O
ventricle	O
,	O
deceased	O
at	O
92	O
years	O
of	O
age	O
.	O
No	O
history	O
of	O
sudden	O
death	O
in	O
the	O
family	O
.	O
Healthy	O
parents	O
,	O
siblings	O
and	O
children	O
.	O
Smoker	O
of	O
5	O
cigarettes	O
day	O
.	O
Consumption	O
of	O
1	O
litre	O
day	O
of	O
beer	O
.	O
Arterial	O
hypertension	O
,	O
altered	O
basal	O
glycaemia	O
and	O
recently	O
diagnosed	O
hypercholesterolemia	O
.	O
Antral	O
ulcus	O
in	O
2005	O
.	O
Tension	O
headaches	O
studied	O
in	O
Neurology	O
.	O
Treatment	O
enalapril	B-FARMACO
hydrochlorothiazide	I-FARMACO
20	O
12	O
.	O
5	O
mg	O
at	O
breakfast	O
.	O
Present	O
illness	O
A	O
48	O
year	O
old	O
female	O
patient	O
,	O
who	O
began	O
with	O
sudden	O
onset	O
symptoms	O
of	O
palpitations	O
,	O
associated	O
with	O
a	O
sensation	O
of	O
dyspnoea	O
and	O
chest	O
tightness	O
radiating	O
to	O
the	O
throat	O
,	O
as	O
well	O
as	O
cold	O
sweat	O
and	O
blurred	O
vision	O
,	O
attended	O
the	O
emergency	O
department	O
of	O
her	O
medical	O
centre	O
where	O
she	O
was	O
documented	O
,	O
without	O
any	O
electrocardiographic	O
record	O
provided	O
,	O
a	O
regular	O
QRS	O
tachycardia	O
at	O
200	O
bpm	O
,	O
with	O
a	O
retrograde	O
P	O
wave	O
inscribed	O
in	O
the	O
terminal	O
portion	O
of	O
the	O
QRS	O
,	O
and	O
she	O
was	O
referred	O
to	O
the	O
Emergency	O
Department	O
of	O
our	O
hospital	O
where	O
she	O
arrived	O
in	O
sinus	O
rhythm	O
at	O
100	O
bpm	O
,	O
and	O
was	O
discharged	O
.	O
From	O
that	O
day	O
on	O
,	O
high	O
blood	O
pressure	O
levels	O
were	O
detected	O
,	O
and	O
she	O
was	O
started	O
on	O
the	O
antihypertensive	O
treatment	O
indicated	O
above	O
.	O
Apart	O
from	O
this	O
episode	O
,	O
the	O
patient	O
reported	O
worsening	O
functional	O
class	O
with	O
dyspnoea	O
until	O
minimal	O
effort	O
NYHA	O
functional	O
class	O
II	O
III	O
and	O
chest	O
pain	O
that	O
she	O
defined	O
as	O
different	O
from	O
the	O
previous	O
episode	O
,	O
denying	O
palpitations	O
,	O
presyncope	O
or	O
syncope	O
.	O
A	O
clinical	O
and	O
genetic	O
study	O
was	O
performed	O
,	O
with	O
the	O
results	O
shown	O
below	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
at	O
rest	O
.	O
No	O
baseline	O
dyspnoea	O
.	O
Preserved	O
higher	O
functions	O
.	O
Good	O
distal	O
perfusion	O
.	O
Haemodynamically	O
stable	O
.	O
Blood	O
pressure	O
140	O
70	O
mmHg	O
.	O
On	O
auscultation	O
,	O
non	O
tachycardic	O
rhythmic	O
tones	O
.	O
Variable	O
systolic	O
murmur	O
in	O
foci	O
of	O
the	O
base	O
,	O
not	O
radiated	O
.	O
No	O
semiology	O
of	O
pulmonary	O
or	O
systemic	O
congestion	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
100	O
bpm	O
,	O
P	O
for	O
biauricular	O
growth	O
,	O
voltage	O
criteria	O
for	O
LV	O
hypertrophy	O
.	O
ST	O
underleveled	O
with	O
inferolateral	O
flat	O
T	O
.	O
24	O
hour	O
Holter	O
with	O
average	O
HR	O
of	O
95	O
bpm	O
,	O
minimum	O
of	O
52	O
and	O
maximum	O
of	O
152	O
diurnal	O
.	O
No	O
ventricular	O
tachycardia	O
spells	O
or	O
atrial	O
fibrillation	O
were	O
detected	O
.	O
Isolated	O
atrial	O
complexes	O
.	O
No	O
significant	O
pauses	O
.	O
Transthoracic	O
echocardiography	O
left	O
atrium	O
of	O
normal	O
dimensions	O
anteroposterior	O
dimension	O
37	O
mm	O
;	O
volume	O
30	O
ml	O
m2	O
.	O
Mitral	O
valve	O
with	O
slightly	O
thickened	O
leaflets	O
;	O
the	O
posterior	O
leaflet	O
shows	O
a	O
complete	O
restriction	O
in	O
its	O
closure	O
;	O
the	O
anterior	O
leaflet	O
shows	O
an	O
evident	O
anterior	O
systolic	O
movement	O
,	O
which	O
at	O
rest	O
does	O
not	O
contact	O
the	O
interventricular	O
septum	O
;	O
however	O
,	O
with	O
Valsalva	O
manoeuvre	O
there	O
is	O
an	O
evident	O
contact	O
with	O
the	O
septum	O
in	O
addition	O
to	O
the	O
free	O
edge	O
of	O
the	O
anterior	O
leaflet	O
,	O
there	O
seems	O
to	O
be	O
an	O
anterior	O
systolic	O
movement	O
of	O
the	O
subvalvular	O
apparatus	O
,	O
mainly	O
secondary	O
chordae	O
tendineae	O
dependent	O
on	O
it	O
.	O
Left	O
ventricle	O
of	O
normal	O
dimensions	O
end	O
diastolic	O
and	O
end	O
systolic	O
diameters	O
41	O
mm	O
and	O
27	O
mm	O
,	O
respectively	O
;	O
end	O
diastolic	O
and	O
end	O
systolic	O
volumes	O
76	O
ml	O
and	O
24	O
ml	O
,	O
respectively	O
,	O
with	O
severely	O
increased	O
myocardial	O
thickness	O
at	O
the	O
basal	O
septal	O
and	O
midventricular	O
levels	O
septal	O
wall	O
17	O
mm	O
;	O
inferolateral	O
wall	O
10	O
mm	O
.	O
No	O
segmental	O
contractility	O
abnormalities	O
were	O
observed	O
,	O
with	O
ejection	O
fraction	O
by	O
biplane	O
disc	O
method	O
of	O
68	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
with	O
slight	O
fibrosclerosis	O
,	O
and	O
good	O
opening	O
.	O
Left	O
ventricular	O
outflow	O
tract	O
LVOT	O
19	O
mm	O
.	O
Aortic	O
root	O
at	O
the	O
level	O
of	O
the	O
sinuses	O
of	O
Valsalva	O
31	O
mm	O
,	O
sinotubular	O
junction	O
29	O
mm	O
.	O
Right	O
ventricle	O
of	O
normal	O
dimensions	O
,	O
with	O
normal	O
systolic	O
function	O
TAPSE	O
24	O
mm	O
;	O
S	O
Tissue	O
Doppler	O
of	O
the	O
lateral	O
tricuspid	O
annulus	O
12	O
.	O
9	O
cm	O
s	O
.	O
Inferior	O
vena	O
cava	O
of	O
normal	O
dimensions	O
15	O
mm	O
,	O
with	O
inspiratory	O
collapse	O
greater	O
than	O
50	O
.	O
No	O
pericardial	O
effusion	O
.	O
Transmitral	O
flow	O
with	O
E	O
wave	O
pattern	O
less	O
than	O
A	O
.	O
Pulmonary	O
vein	O
flow	O
with	O
S	O
wave	O
pattern	O
greater	O
than	O
D	O
.	O
There	O
is	O
an	O
insufficiency	O
with	O
two	O
jets	O
one	O
caused	O
by	O
the	O
anterior	O
systolic	O
movement	O
of	O
the	O
anterior	O
leaflet	O
,	O
which	O
increases	O
when	O
forced	O
inspiration	O
or	O
the	O
Valsalva	O
manoeuvre	O
occurs	O
,	O
which	O
suggests	O
that	O
the	O
same	O
occurs	O
when	O
the	O
patient	O
makes	O
efforts	O
;	O
and	O
another	O
dependent	O
on	O
the	O
restriction	O
of	O
the	O
posterior	O
leaflet	O
fixed	O
and	O
which	O
runs	O
with	O
a	O
Coanda	O
effect	O
on	O
the	O
posterior	O
wall	O
of	O
the	O
atrium	O
,	O
reaching	O
its	O
ceiling	O
;	O
from	O
a	O
global	O
point	O
of	O
view	O
,	O
mitral	O
insufficiency	O
of	O
moderate	O
degree	O
2	O
3	O
is	O
quantified	O
.	O
As	O
a	O
consequence	O
of	O
the	O
contact	O
of	O
the	O
anterior	O
mitral	O
leaflet	O
and	O
probably	O
chordae	O
with	O
the	O
interventricular	O
septum	O
with	O
inspiration	O
and	O
Valsalva	O
manoeuvre	O
,	O
a	O
systolic	O
ejection	O
gradient	O
is	O
generated	O
at	O
the	O
level	O
of	O
the	O
outflow	O
tract	O
basal	O
zone	O
that	O
reaches	O
90	O
mmHg	O
this	O
gradient	O
is	O
not	O
recorded	O
at	O
rest	O
.	O
Transaortic	O
flow	O
with	O
peak	O
velocity	O
not	O
measurable	O
.	O
Jet	O
of	O
mild	O
tricuspid	O
insufficiency	O
1	O
,	O
with	O
suboptimal	O
Doppler	O
recording	O
for	O
estimation	O
of	O
pulmonary	O
artery	O
systolic	O
pressure	O
.	O
Conclusions	O
asymmetric	O
septal	O
hypertrophic	O
cardiomyopathy	O
maximum	O
thickness	O
17	O
mm	O
.	O
Systolic	O
ejection	O
gradient	O
at	O
the	O
level	O
of	O
the	O
left	O
ventricular	O
outflow	O
tract	O
basal	O
zone	O
reaches	O
90	O
mmHg	O
with	O
forced	O
inspiration	O
no	O
gradient	O
at	O
rest	O
with	O
gentle	O
breathing	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
there	O
is	O
evidence	O
of	O
myocardial	O
thickening	O
mainly	O
in	O
the	O
basal	O
region	O
of	O
the	O
myocardium	O
,	O
affecting	O
the	O
anterior	O
septal	O
and	O
pure	O
anterior	O
segment	O
to	O
a	O
greater	O
extent	O
.	O
With	O
thicknesses	O
that	O
in	O
telediastolic	O
sequences	O
reach	O
up	O
to	O
22	O
mm	O
in	O
size	O
.	O
Measurements	O
range	O
between	O
22	O
,	O
19	O
and	O
18	O
.	O
5	O
mm	O
.	O
The	O
LV	O
outflow	O
tract	O
sequences	O
show	O
an	O
elongated	O
anterior	O
valve	O
with	O
partial	O
anterior	O
systolic	O
motion	O
and	O
an	O
obstruction	O
to	O
the	O
LV	O
outflow	O
tract	O
manifested	O
by	O
an	O
obstructive	O
jet	O
,	O
all	O
these	O
data	O
support	O
the	O
diagnosis	O
of	O
obstructive	O
hypertrophic	O
cardiomyopathy	O
.	O
The	O
functional	O
analysis	O
of	O
the	O
LV	O
shows	O
the	O
following	O
values	O
EF	O
84	O
,	O
systolic	O
volume	O
86	O
ml	O
,	O
cardiac	O
output	O
7	O
.	O
3	O
litres	O
minute	O
,	O
end	O
diastolic	O
volume	O
102	O
ml	O
and	O
end	O
systolic	O
volume	O
16	O
ml	O
.	O
No	O
aortic	O
valve	O
and	O
pulmonary	O
valve	O
regurgitation	O
was	O
observed	O
.	O
Mild	O
to	O
moderate	O
mitral	O
regurgitation	O
was	O
observed	O
.	O
Minimal	O
pericardial	O
effusion	O
.	O
Late	O
enhancement	O
sequences	O
revealed	O
no	O
clear	O
uptake	O
by	O
the	O
LV	O
myocardium	O
and	O
a	O
clear	O
enhancement	O
pattern	O
typical	O
of	O
hypertrophic	O
heart	O
disease	O
.	O
Genetic	O
study	O
positive	O
for	O
a	O
mutation	O
with	O
clear	O
pathogenic	O
significance	O
,	O
MYBPC3	O
gene	O
,	O
encoding	O
protein	O
myosin	O
binding	O
protein	O
C	O
,	O
cardiac	O
type	O
,	O
NP_000247	O
.	O
2	O
p	O
.	O
Glu542Gln	O
NC_000011	O
.	O
9	O
g	O
.	O
47364129C	O
G	O
Haemodynamic	O
report	O
coronary	O
arteries	O
without	O
angiographically	O
significant	O
lesions	O
.	O
In	O
the	O
middle	O
segment	O
of	O
the	O
anterior	O
descending	O
artery	O
there	O
is	O
an	O
intramyocardial	O
trajectory	O
with	O
systolic	O
compression	O
phenomenon	O
.	O
There	O
is	O
a	O
septal	O
branch	O
of	O
intermediate	O
calibre	O
and	O
development	O
which	O
is	O
verified	O
by	O
injection	O
of	O
iodinated	O
contrast	O
and	O
Sonovue	O
ecopotentiator	O
through	O
OTW	O
balloon	O
that	O
irrigates	O
an	O
area	O
of	O
the	O
interventricular	O
septum	O
suitable	O
for	O
ablation	O
.	O
In	O
the	O
distal	O
segment	O
of	O
the	O
septum	O
there	O
is	O
a	O
systolic	O
compression	O
phenomenon	O
.	O
A	O
total	O
of	O
1	O
.	O
7	O
ml	O
was	O
injected	O
through	O
an	O
inflated	O
OTW	O
balloon	O
with	O
a	O
diameter	O
of	O
2	O
mm	O
and	O
a	O
length	O
of	O
8	O
mm	O
.	O
Pre	O
ablation	O
gradient	O
recording	O
baseline	O
40	O
mmHg	O
.	O
Postextrasystolic	O
90	O
mmHg	O
.	O
Post	O
ablation	O
gradient	O
recording	O
Baseline	O
15	O
mmHg	O
.	O
Postextrasystolic	O
25	O
mmHg	O
Transthoracic	O
echocardiogram	O
guided	O
procedure	O
with	O
good	O
outcome	O
and	O
no	O
complications	O
.	O
Right	O
femoral	O
closure	O
with	O
angioseal	O
.	O
EVOLUTION	O
The	O
patient	O
,	O
despite	O
receiving	O
beta	O
blocker	O
and	O
ACE	B-FARMACO
inhibitor	I-FARMACO
medical	O
treatment	O
,	O
reported	O
worsening	O
of	O
her	O
functional	O
class	O
,	O
progressive	O
dyspnoea	O
in	O
recent	O
months	O
with	O
episodes	O
of	O
orthopnoea	O
,	O
non	O
specific	O
chest	O
discomfort	O
and	O
palpitations	O
,	O
especially	O
on	O
exertion	O
.	O
No	O
presyncope	O
or	O
syncope	O
.	O
With	O
the	O
titration	O
of	O
beta	O
blockers	O
,	O
good	O
heart	O
rate	O
control	O
was	O
achieved	O
both	O
at	O
rest	O
and	O
during	O
the	O
exercise	O
test	O
,	O
despite	O
which	O
,	O
she	O
remained	O
very	O
symptomatic	O
,	O
especially	O
during	O
exercise	O
,	O
with	O
no	O
obstructive	O
gradient	O
at	O
rest	O
,	O
with	O
Valsalva	O
reaching	O
80	O
mmHg	O
.	O
Admission	O
was	O
decided	O
to	O
start	O
treatment	O
with	O
disopyramide	B-FARMACO
with	O
a	O
very	O
partial	O
clinical	O
response	O
,	O
with	O
a	O
relative	O
reduction	O
of	O
the	O
dynamic	O
gradient	O
to	O
65	O
mmHg	O
.	O
Given	O
the	O
persistent	O
clinical	O
refractory	O
to	O
medical	O
treatment	O
,	O
more	O
invasive	O
management	O
was	O
decided	O
,	O
indicating	O
alcohol	O
septal	O
ablation	O
,	O
which	O
was	O
performed	O
by	O
haemodynamics	O
without	O
complications	O
associated	O
with	O
the	O
procedure	O
.	O
Significant	O
reduction	O
in	O
LVOT	O
obstructive	O
gradient	O
and	O
symptomatic	O
improvement	O
of	O
the	O
patient	O
was	O
documented	O
,	O
which	O
has	O
been	O
maintained	O
during	O
subsequent	O
follow	O
up	O
.	O
DIAGNOSIS	O
Hypertrophic	O
obstructive	O
cardiomyopathy	O
,	O
with	O
subaortic	O
gradient	O
in	O
LV	O
outflow	O
tract	O
,	O
symptomatically	O
refractory	O
to	O
medical	O
treatment	O
.	O
Successful	O
septal	O
ablation	O
with	O
alcohol	O
.	O
Hypertrophic	O
sarcomeric	O
cardiomyopathy	O
,	O
with	O
positive	O
genetic	O
study	O
for	O
the	O
gene	O
encoding	O
a	O
myosin	O
binding	O
protein	O
type	O
C	O
MYBPC3	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
60	O
year	O
old	O
woman	O
,	O
whose	O
personal	O
history	O
included	O
smoker	O
,	O
no	O
other	O
cardiovascular	O
risk	O
factors	O
,	O
severe	O
hypoacusis	O
,	O
paroxysmal	O
atrial	O
fibrillation	O
without	O
anticoagulation	O
by	O
CHA2DS2	O
VASC	O
1	O
and	O
obstructive	O
sleep	O
apnoea	O
syndrome	O
.	O
She	O
was	O
being	O
treated	O
with	O
bisoprolol	B-FARMACO
and	O
had	O
no	O
family	O
history	O
of	O
interest	O
.	O
The	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
for	O
progressive	O
dyspnoea	O
on	O
minimal	O
effort	O
for	O
a	O
week	O
with	O
orthopnoea	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
She	O
also	O
had	O
palpitations	O
without	O
chest	O
pain	O
.	O
She	O
had	O
no	O
other	O
symptoms	O
.	O
Physical	O
examination	O
showed	O
BP	O
110	O
65	O
mmHg	O
,	O
150	O
beats	O
per	O
minute	O
,	O
oxygen	O
saturation	O
of	O
90	O
at	O
baseline	O
,	O
slight	O
tachypnoea	O
at	O
rest	O
without	O
jugular	O
ingurgitation	O
,	O
arrhythmic	O
without	O
audible	O
murmurs	O
on	O
cardiac	O
auscultation	O
,	O
crackles	O
in	O
both	O
lung	O
bases	O
,	O
with	O
a	O
normal	O
abdomen	O
on	O
examination	O
and	O
malleolar	O
oedema	O
with	O
fovea	O
in	O
the	O
distal	O
third	O
of	O
the	O
lower	O
limbs	O
,	O
with	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
An	O
electrocardiogram	O
showed	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
AF	O
RVR	O
and	O
a	O
chest	O
X	O
ray	O
showed	O
signs	O
of	O
heart	O
failure	O
,	O
and	O
blood	O
tests	O
showed	O
mild	O
renal	O
failure	O
and	O
mild	O
anaemia	O
.	O
Beta	O
blocker	O
treatment	O
was	O
started	O
to	O
control	O
the	O
heart	O
rate	O
and	O
intravenous	O
perfused	O
furosemide	B-FARMACO
was	O
administered	O
to	O
achieve	O
negative	O
balance	O
.	O
An	O
echocardiogram	O
showed	O
left	O
ventricular	O
dimensions	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
with	O
a	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
of	O
50	O
55	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
on	O
admission	O
leukocytes	O
10	O
.	O
8	O
mil	O
mcL	O
,	O
haemoglobin	O
11	O
.	O
4	O
g	O
dl	O
,	O
platelets	O
265	O
mil	O
mc	O
,	O
glycaemia	O
105	O
mg	O
dl	O
,	O
urea	O
69	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
28	O
mg	O
dl	O
,	O
CPK	O
21	O
IU	O
L	O
,	O
sodium	O
133	O
mmol	O
L	O
,	O
potassium	O
4	O
.	O
6	O
mmol	O
L	O
.	O
Electrocardiogram	O
on	O
admission	O
AF	O
at	O
149	O
beats	O
per	O
minute	O
,	O
QRS	O
axis	O
at	O
9o	O
,	O
with	O
narrow	O
QRS	O
,	O
no	O
other	O
electrocardiographic	O
abnormalities	O
of	O
note	O
.	O
Chest	O
X	O
ray	O
signs	O
of	O
pulmonary	O
congestion	O
,	O
no	O
pleural	O
effusion	O
with	O
increased	O
cardiothoracic	O
index	O
.	O
Echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
with	O
mild	O
hypertrophy	O
and	O
preserved	O
LVEF	O
without	O
segmental	O
alterations	O
of	O
contractility	O
.	O
Diastolic	O
pattern	O
with	O
single	O
E	O
wave	O
and	O
lateral	O
E	O
E	O
"	O
of	O
12	O
.	O
Mitral	O
insufficiency	O
grade	O
II	O
and	O
slight	O
atrial	O
dilatation	O
.	O
Normofunctioning	O
trivalve	O
aortic	O
valve	O
.	O
Non	O
dilated	O
right	O
chambers	O
with	O
mild	O
tricuspid	O
insufficiency	O
with	O
estimated	O
PSAP	O
of	O
55	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
22	O
mm	O
with	O
reduced	O
collapse	O
and	O
absence	O
of	O
pericardial	O
effusion	O
.	O
Echocardiogram	O
in	O
coronary	O
unit	O
severely	O
depressed	O
LVEF	O
with	O
moderate	O
dilatation	O
of	O
the	O
left	O
ventricle	O
82	O
ml	O
m2	O
,	O
mitral	O
insufficiency	O
grade	O
III	O
IV	O
,	O
mild	O
dilatation	O
of	O
the	O
left	O
atrium	O
.	O
Estimated	O
PSAP	O
of	O
65	O
mmHg	O
.	O
Echocardiogram	O
after	O
coronary	O
unit	O
output	O
non	O
dilated	O
left	O
ventricle	O
with	O
normal	O
LVEF	O
without	O
segmental	O
alterations	O
of	O
contractility	O
.	O
Mild	O
mitral	O
insufficiency	O
without	O
other	O
notable	O
alterations	O
.	O
EVOLUTION	O
On	O
the	O
hospital	O
ward	O
,	O
heart	O
rate	O
control	O
was	O
achieved	O
with	O
bisoprolol	B-FARMACO
and	O
a	O
transthoracic	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
normal	O
left	O
ventricular	O
volumes	O
with	O
preserved	O
LVEF	O
and	O
mild	O
moderate	O
mitral	O
insufficiency	O
.	O
Three	O
days	O
after	O
admission	O
,	O
the	O
patient	O
presented	O
AF	O
RVR	O
again	O
with	O
haemodynamic	O
instability	O
and	O
respiratory	O
failure	O
secondary	O
to	O
pulmonary	O
oedema	O
,	O
so	O
she	O
was	O
transferred	O
to	O
the	O
Coronary	O
Unit	O
and	O
electrical	O
cardioversion	O
was	O
performed	O
,	O
which	O
was	O
ineffective	O
after	O
several	O
attempts	O
at	O
maximum	O
energy	O
.	O
Digoxin	B-FARMACO
was	O
administered	O
and	O
haemodynamic	O
support	O
was	O
instituted	O
with	O
noradrenaline	B-FARMACO
,	O
orotracheal	O
intubation	O
and	O
invasive	O
ventilation	O
.	O
A	O
repeat	O
echocardiogram	O
showed	O
dilatation	O
and	O
severe	O
dysfunction	O
of	O
the	O
left	O
ventricle	O
with	O
moderate	O
severe	O
functional	O
mitral	O
regurgitation	O
.	O
Progressively	O
,	O
after	O
haemodynamic	O
improvement	O
,	O
beta	O
blockers	O
were	O
introduced	O
,	O
achieving	O
rate	O
control	O
and	O
withdrawing	O
haemodynamic	O
and	O
ventilatory	O
support	O
.	O
Coronary	O
angiography	O
showed	O
angiographically	O
normal	O
coronary	O
arteries	O
and	O
she	O
was	O
transferred	O
to	O
the	O
ward	O
where	O
the	O
echocardiogram	O
was	O
repeated	O
and	O
showed	O
recovery	O
of	O
LVEF	O
and	O
left	O
ventricular	O
dimensions	O
.	O
The	O
patient	O
was	O
discharged	O
with	O
atrial	O
fibrillation	O
and	O
controlled	O
ventricular	O
response	O
and	O
a	O
diagnosis	O
of	O
tachycardiomyopathy	O
under	O
treatment	O
with	O
bisoprolol	B-FARMACO
5	O
mg	O
every	O
12	O
hours	O
and	O
sintrom	B-FARMACO
.	O
DIAGNOSIS	O
Tachycardiomyopathy	O
secondary	O
to	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
53	O
year	O
old	O
woman	O
with	O
no	O
remarkable	O
pathological	O
history	O
except	O
for	O
smoking	O
20	O
cigarettes	O
day	O
.	O
She	O
attended	O
the	O
Emergency	O
Department	O
for	O
aphasia	O
and	O
hypoaesthesia	O
in	O
the	O
left	O
arm	O
that	O
had	O
appeared	O
12	O
hours	O
earlier	O
.	O
On	O
arrival	O
she	O
was	O
haemodynamically	O
stable	O
.	O
On	O
physical	O
examination	O
she	O
was	O
in	O
good	O
general	O
condition	O
,	O
conscious	O
,	O
cooperative	O
and	O
oriented	O
,	O
afebrile	O
and	O
eupneic	O
.	O
Hypoaesthesia	O
in	O
the	O
right	O
arm	O
and	O
aphasia	O
.	O
PCA	O
arrhythmic	O
heart	O
sounds	O
,	O
with	O
holosystolic	O
and	O
panfocal	O
diastolic	O
murmur	O
.	O
Minimal	O
crackles	O
in	O
both	O
lung	O
bases	O
.	O
COMPLEMENTARY	O
TESTS	O
The	O
electrocardiogram	O
showed	O
a	O
previously	O
unknown	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
,	O
although	O
he	O
recognised	O
that	O
he	O
had	O
felt	O
palpitations	O
for	O
months	O
.	O
Laboratory	O
tests	O
showed	O
no	O
significant	O
alterations	O
.	O
A	O
CT	O
scan	O
of	O
the	O
brain	O
showed	O
no	O
ischaemic	O
lesions	O
at	O
that	O
time	O
and	O
she	O
was	O
finally	O
admitted	O
to	O
the	O
Neurology	O
Department	O
with	O
a	O
diagnosis	O
of	O
transient	O
ischaemic	O
attack	O
dependent	O
on	O
the	O
middle	O
cerebral	O
artery	O
.	O
She	O
had	O
a	O
very	O
satisfactory	O
evolution	O
with	O
a	O
control	O
CT	O
scan	O
showing	O
a	O
small	O
ischaemic	O
spot	O
in	O
the	O
right	O
parietal	O
area	O
,	O
suggesting	O
a	O
cardioembolic	O
cause	O
.	O
Since	O
the	O
risk	O
of	O
haemorrhagic	O
transformation	O
was	O
low	O
,	O
it	O
was	O
decided	O
to	O
start	O
anticoagulant	O
treatment	O
with	O
acenocoumarol	B-FARMACO
.	O
As	O
part	O
of	O
the	O
cardioembolic	O
source	O
study	O
,	O
echocardiography	O
was	O
performed	O
.	O
The	O
study	O
was	O
performed	O
in	O
AF	O
with	O
very	O
rapid	O
ventricular	O
response	O
,	O
showing	O
the	O
difficulty	O
to	O
control	O
the	O
rate	O
with	O
beta	O
blocker	O
therapy	O
.	O
A	O
large	O
mass	O
99	O
mm	O
x	O
71	O
mm	O
dilating	O
the	O
left	O
atrium	O
was	O
observed	O
.	O
The	O
mass	O
had	O
heterogeneous	O
echogenicity	O
,	O
multiple	O
lobes	O
and	O
a	O
36	O
mm	O
wide	O
implantation	O
pedicle	O
.	O
One	O
of	O
its	O
lobes	O
was	O
interposed	O
between	O
the	O
leaflets	O
of	O
the	O
mitral	O
valve	O
,	O
generating	O
severe	O
insufficiency	O
and	O
obstruction	O
with	O
a	O
high	O
mean	O
gradient	O
12	O
mmHg	O
and	O
a	O
concomitant	O
severe	O
insufficiency	O
justifying	O
the	O
difference	O
between	O
mean	O
and	O
peak	O
gradient	O
20	O
mmHg	O
.	O
In	O
addition	O
,	O
he	O
had	O
moderate	O
tricuspid	O
regurgitation	O
and	O
severely	O
depressed	O
left	O
ventricular	O
ejection	O
fraction	O
EF	O
30	O
by	O
Simpson	O
.	O
EVOLUTION	O
With	O
this	O
information	O
the	O
patient	O
was	O
presented	O
for	O
cardiac	O
surgery	O
,	O
the	O
most	O
likely	O
diagnosis	O
being	O
myxoma	O
.	O
No	O
previous	O
clinical	O
manifestations	O
classically	O
associated	O
with	O
myxomas	O
,	O
such	O
as	O
weight	O
loss	O
or	O
fever	O
,	O
were	O
found	O
.	O
She	O
only	O
presented	O
progressive	O
dyspnoea	O
,	O
which	O
we	O
attributed	O
mainly	O
to	O
the	O
double	O
mitral	O
lesion	O
caused	O
by	O
the	O
myxoma	O
.	O
The	O
myxoma	O
was	O
removed	O
from	O
the	O
left	O
atrium	O
without	O
complications	O
.	O
The	O
mitral	O
and	O
tricuspid	O
valves	O
were	O
not	O
damaged	O
,	O
so	O
mitral	O
and	O
tricuspid	O
anuplasty	O
was	O
performed	O
to	O
solve	O
the	O
severe	O
insufficiencies	O
described	O
.	O
Pathological	O
analysis	O
of	O
the	O
atrial	O
mass	O
revealed	O
a	O
myxoma	O
measuring	O
9	O
7	O
4	O
cm	O
with	O
patches	O
of	O
calcification	O
and	O
thrombi	O
on	O
its	O
surface	O
.	O
DIAGNOSIS	O
Giant	O
atrial	O
myxoma	O
with	O
embolic	O
phenomenon	O
.	O
Severe	O
mitral	O
stenosis	O
and	O
mitral	O
insufficiency	O
secondary	O
to	O
myxoma	O
.	O
Ischaemic	O
stroke	O
with	O
involvement	O
of	O
the	O
right	O
MCA	O
territory	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
84	O
year	O
old	O
patient	O
,	O
with	O
no	O
known	O
pharmacological	O
allergies	O
and	O
a	O
personal	O
history	O
of	O
arterial	O
hypertension	O
AHT	O
of	O
long	O
evolution	O
;	O
diabetes	O
mellitus	O
DM	O
type	O
2	O
of	O
8	O
years	O
of	O
evolution	O
,	O
with	O
diabetic	O
retinopathy	O
,	O
in	O
treatment	O
with	O
oral	O
antidiabetics	O
;	O
chronic	O
renal	O
disease	O
stage	O
4	O
of	O
arteriosclerotic	O
origin	O
due	O
to	O
AHT	O
and	O
DM	O
of	O
long	O
evolution	O
usual	O
creatinine	O
2	O
mg	O
dl	O
;	O
estimated	O
GFR	O
CKD	O
EPI	O
29	O
mL	O
min	O
1	O
.	O
73	O
m2	O
;	O
benign	O
prostatic	O
hyperplasia	O
and	O
operated	O
on	O
for	O
left	O
inguinal	O
herniorrhaphy	O
.	O
Present	O
illness	O
The	O
patient	O
presented	O
two	O
episodes	O
of	O
syncope	O
in	O
the	O
last	O
12	O
hours	O
,	O
with	O
prodrome	O
general	O
malaise	O
and	O
nausea	O
without	O
vomiting	O
and	O
subsequent	O
loss	O
of	O
consciousness	O
lasting	O
about	O
10	O
seconds	O
with	O
subsequent	O
recovery	O
without	O
post	O
critical	O
state	O
.	O
Associated	O
sphincter	O
relaxation	O
.	O
No	O
tonic	O
clonic	O
convulsions	O
or	O
tongue	O
biting	O
.	O
The	O
patient	O
relates	O
the	O
symptoms	O
to	O
possible	O
hypoglycaemia	O
,	O
so	O
he	O
has	O
taken	O
glucose	O
orally	O
without	O
going	O
to	O
a	O
medical	O
centre	O
.	O
In	O
the	O
first	O
episode	O
he	O
suffered	O
cranioencephalic	O
trauma	O
with	O
an	O
incised	O
contuse	O
wound	O
to	O
the	O
scalp	O
.	O
After	O
the	O
second	O
episode	O
witnessed	O
by	O
his	O
relatives	O
he	O
was	O
brought	O
to	O
the	O
emergency	O
department	O
for	O
assessment	O
.	O
The	O
patient	O
reported	O
epigastric	O
pain	O
of	O
approximately	O
one	O
week	O
's	O
duration	O
,	O
episodic	O
,	O
unrelated	O
to	O
ingestion	O
or	O
movement	O
,	O
and	O
associated	O
with	O
nausea	O
.	O
During	O
the	O
anamnesis	O
,	O
the	O
patient	O
presented	O
a	O
new	O
episode	O
of	O
syncope	O
,	O
preceded	O
by	O
nausea	O
and	O
vegetative	O
cortex	O
,	O
lasting	O
a	O
few	O
seconds	O
,	O
with	O
complete	O
recovery	O
of	O
the	O
level	O
of	O
consciousness	O
afterwards	O
,	O
without	O
subsequent	O
confusional	O
state	O
.	O
Physical	O
examination	O
Vital	O
signs	O
BP	O
120	O
57	O
mmHg	O
.	O
HR	O
80	O
bpm	O
.	O
Ta	O
36	O
.	O
5	O
C	O
.	O
SatO2	O
97	O
.	O
Capillary	O
blood	O
glucose	O
320	O
.	O
Conscious	O
.	O
Orientation	O
.	O
Normal	O
colour	O
.	O
Normohydrated	O
.	O
Eupneic	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
normal	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
normal	O
peristalsis	O
.	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
1	O
performed	O
in	O
the	O
emergency	O
department	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
.	O
Second	O
degree	O
atrioventricular	O
block	O
,	O
Mobitz	O
1	O
.	O
ST	O
suprasystolic	O
level	O
in	O
II	O
,	O
III	O
,	O
aVF	O
with	O
a	O
decrease	O
in	O
I	O
and	O
aVL	O
.	O
ECG	O
2	O
performed	O
in	O
the	O
ED	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
.	O
Second	O
degree	O
atrioventricular	O
block	O
,	O
Mobitz	O
1	O
.	O
ST	O
elevation	O
in	O
II	O
,	O
III	O
,	O
aVF	O
with	O
a	O
decrease	O
in	O
I	O
and	O
aV	O
;	O
somewhat	O
less	O
marked	O
than	O
in	O
previous	O
ECG	O
.	O
Emergency	O
laboratory	O
tests	O
troponin	O
I	O
10	O
.	O
46	O
ng	O
ml	O
.	O
Myoglobin	O
400	O
ng	O
ml	O
.	O
ProBNP	O
10400	O
pg	O
ml	O
.	O
Glucose	O
315	O
mg	O
dl	O
.	O
Urea	O
90	O
mg	O
dl	O
.	O
Creatinine	O
2	O
.	O
21	O
mg	O
dl	O
.	O
Chlorine	O
102	O
mEq	O
l	O
.	O
Sodium	O
135	O
mEq	O
l	O
.	O
Potassium	O
4	O
.	O
8	O
mEq	O
l	O
.	O
Leukocytes	O
17	O
,	O
500	O
15	O
,	O
400	O
neutrophils	O
.	O
Hb	O
11	O
.	O
9	O
g	O
dl	O
.	O
VCM	O
98	O
.	O
Prothrombin	O
activity	O
85	O
.	O
Cranial	O
CT	O
scan	O
centred	O
midline	O
.	O
Corticosubcortical	O
atrophy	O
according	O
to	O
age	O
.	O
Calcification	O
of	O
epiphysis	O
and	O
choroid	O
plexus	O
.	O
No	O
signs	O
suggestive	O
of	O
bleeding	O
or	O
other	O
significant	O
radiological	O
alterations	O
.	O
Urgent	O
coronary	O
angiography	O
left	O
main	O
coronary	O
artery	O
LMCA	O
no	O
angiographic	O
disease	O
.	O
Anterior	O
descending	O
AD	O
very	O
severe	O
lesion	O
90	O
95	O
in	O
the	O
proximal	O
segment	O
encompassing	O
the	O
origin	O
of	O
the	O
first	O
diagonal	O
,	O
with	O
significant	O
disease	O
in	O
the	O
middle	O
segment	O
.	O
Distal	O
bed	O
with	O
significant	O
localised	O
patchy	O
involvement	O
.	O
Circumflex	O
CX	O
severe	O
proximal	O
disease	O
85	O
90	O
.	O
Distal	O
bed	O
formed	O
by	O
three	O
left	O
marginal	O
branches	O
,	O
two	O
of	O
them	O
with	O
significant	O
proximal	O
ostial	O
disease	O
.	O
Right	O
coronary	O
RC	O
dominant	O
.	O
Moderate	O
proximal	O
and	O
medial	O
diffuse	O
disease	O
.	O
Acute	O
thrombotic	O
occlusive	O
lesion	O
involving	O
middle	O
segment	O
and	O
first	O
elbow	O
,	O
both	O
calcified	O
.	O
Distal	O
TIMI	O
1	O
2	O
flow	O
.	O
After	O
opening	O
it	O
,	O
a	O
diffusely	O
diseased	O
distal	O
segment	O
with	O
limited	O
calibre	O
was	O
observed	O
.	O
Percutaneous	O
coronary	O
intervention	O
predilatation	O
with	O
low	O
pressure	O
balloon	O
with	O
good	O
results	O
,	O
implantation	O
of	O
two	O
drug	O
eluting	O
stents	O
in	O
tandem	O
.	O
Embolisation	O
to	O
the	O
distal	O
segment	O
,	O
treated	O
with	O
repeated	O
intracoronary	O
nitroprusside	O
boluses	O
and	O
multi	O
segment	O
low	O
pressure	O
balloon	O
dilatation	O
.	O
Contained	O
dissection	O
in	O
proximal	O
segment	O
of	O
most	O
proximal	O
stent	O
treated	O
with	O
another	O
drug	O
eluting	O
stent	O
in	O
tandem	O
.	O
Good	O
final	O
result	O
with	O
TIMI	O
3	O
in	O
the	O
entire	O
vessel	O
with	O
recovery	O
of	O
sinus	O
rhythm	O
with	O
first	O
degree	O
atrioventricular	O
block	O
.	O
Transthoracic	O
echocardiogram	O
normal	O
sized	O
left	O
ventricle	O
with	O
preserved	O
global	O
LVEF	O
.	O
Akinesia	O
of	O
the	O
basal	O
and	O
middle	O
segments	O
of	O
the	O
inferior	O
wall	O
and	O
hypokinesia	O
of	O
the	O
apical	O
inferior	O
segment	O
.	O
Mild	O
diastolic	O
dysfunction	O
,	O
with	O
increased	O
LVEDP	O
.	O
Mild	O
MI	O
.	O
Normal	O
aortic	O
valve	O
.	O
Minimal	O
TR	O
with	O
mild	O
moderate	O
pulmonary	O
hypertension	O
.	O
No	O
pericardial	O
effusion	O
.	O
ECG	O
at	O
discharge	O
sinus	O
rhythm	O
at	O
67	O
bpm	O
.	O
First	O
degree	O
AV	O
block	O
.	O
Q	O
waves	O
in	O
inferior	O
face	O
.	O
EVOLUTION	O
After	O
the	O
syncope	O
presented	O
in	O
the	O
anamnesis	O
,	O
once	O
the	O
patient	O
had	O
recovered	O
,	O
an	O
ECG	O
was	O
performed	O
which	O
showed	O
Mobitz	O
I	O
grade	O
2	O
AV	O
block	O
AVB	O
with	O
ST	O
supralow	O
leveling	O
in	O
the	O
inferior	O
face	O
,	O
so	O
the	O
patient	O
was	O
monitored	O
with	O
a	O
defibrillator	O
monitor	O
and	O
an	O
infarction	O
code	O
was	O
activated	O
with	O
a	O
diagnosis	O
of	O
STEACS	O
in	O
the	O
inferior	O
face	O
.	O
An	O
urgent	O
cranial	O
CT	O
scan	O
was	O
performed	O
to	O
rule	O
out	O
post	O
traumatic	O
cranioencephalic	O
haemorrhage	O
and	O
therapy	O
was	O
started	O
with	O
loading	O
doses	O
of	O
double	O
platelet	O
antiplatelet	O
therapy	O
with	O
aspirin	B-FARMACO
and	O
clopidogrel	B-FARMACO
.	O
Urgent	O
coronary	O
angiography	O
was	O
requested	O
.	O
While	O
the	O
patient	O
was	O
being	O
monitored	O
,	O
he	O
suffered	O
a	O
new	O
syncope	O
lasting	O
seconds	O
and	O
the	O
monitor	O
showed	O
transient	O
evidence	O
of	O
high	O
grade	O
atrioventricular	O
block	O
phases	O
of	O
second	O
degree	O
AVB	O
type	O
Mobitz	O
II	O
,	O
which	O
subsequently	O
reverted	O
to	O
grade	O
2	O
AVB	O
Mobitz	O
I	O
.	O
Urgent	O
coronary	O
angiography	O
was	O
performed	O
,	O
which	O
revealed	O
an	O
acute	O
thrombotic	O
occlusive	O
lesion	O
in	O
the	O
right	O
coronary	O
artery	O
,	O
responsible	O
for	O
the	O
symptoms	O
,	O
and	O
percutaneous	O
coronary	O
intervention	O
was	O
performed	O
with	O
the	O
implantation	O
of	O
3	O
drug	O
eluting	O
stents	O
after	O
balloon	O
dilatation	O
.	O
The	O
transthoracic	O
echocardiogram	O
after	O
the	O
episode	O
showed	O
a	O
left	O
ventricle	O
of	O
normal	O
size	O
,	O
with	O
preserved	O
ejection	O
fraction	O
and	O
the	O
ECG	O
at	O
discharge	O
showed	O
sinus	O
rhythm	O
at	O
67	O
beats	O
per	O
minute	O
,	O
first	O
degree	O
atrioventricular	O
block	O
and	O
Q	O
waves	O
in	O
the	O
inferior	O
face	O
.	O
Given	O
the	O
recovery	O
of	O
the	O
atrioventricular	O
block	O
after	O
coronary	O
reperfusion	O
,	O
pacemaker	O
implantation	O
was	O
not	O
necessary	O
.	O
Subsequently	O
,	O
the	O
case	O
was	O
discussed	O
with	O
haemodynamics	O
to	O
consider	O
revascularisation	O
of	O
the	O
severe	O
lesions	O
of	O
the	O
anterior	O
descending	O
and	O
circumflex	O
arteries	O
,	O
and	O
conservative	O
treatment	O
was	O
decided	O
given	O
the	O
absence	O
of	O
angina	O
,	O
anaemia	O
,	O
chronic	O
renal	O
disease	O
and	O
diffuse	O
distal	O
involvement	O
of	O
the	O
LAD	O
.	O
The	O
patient	O
is	O
currently	O
being	O
followed	O
up	O
in	O
cardiology	O
consultations	O
,	O
with	O
good	O
quality	O
of	O
life	O
and	O
absence	O
of	O
angina	O
with	O
medical	O
treatment	O
.	O
DIAGNOSIS	O
Acute	O
coronary	O
syndrome	O
with	O
ST	O
segment	O
elevation	O
STEACS	O
inferoposterior	O
Killip	O
I	O
.	O
Right	O
coronary	O
artery	O
with	O
acute	O
thrombotic	O
occlusive	O
lesion	O
in	O
mid	O
distal	O
segment	O
.	O
Percutaneous	O
coronary	O
intervention	O
with	O
implantation	O
of	O
3	O
drug	O
eluting	O
stents	O
in	O
tandem	O
.	O
Grade	O
2	O
Mobitz	O
i	O
atrioventricular	O
block	O
with	O
phases	O
of	O
high	O
grade	O
atrioventricular	O
block	O
of	O
ischaemic	O
origin	O
due	O
to	O
involvement	O
of	O
the	O
right	O
coronary	O
artery	O
.	O
After	O
revascularisation	O
first	O
degree	O
atrioventricular	O
block	O
.	O
Syncope	O
of	O
cardiogenic	O
origin	O
with	O
cranioencephalic	O
trauma	O
,	O
without	O
acute	O
cerebral	O
haemorrhagic	O
lesions	O
.	O
Incised	O
contuse	O
scalp	O
injury	O
.	O
Severe	O
ischaemic	O
multivessel	O
multi	O
segment	O
ischaemic	O
heart	O
disease	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Female	O
patient	O
aged	O
43	O
years	O
,	O
without	O
CVRF	O
or	O
toxic	O
habits	O
.	O
No	O
medical	O
or	O
cardiological	O
history	O
,	O
without	O
taking	O
regular	O
medication	O
.	O
Present	O
illness	O
She	O
presented	O
with	O
syncope	O
during	O
her	O
work	O
activity	O
,	O
preceded	O
by	O
a	O
feeling	O
of	O
dizziness	O
and	O
instability	O
with	O
rapid	O
recovery	O
afterwards	O
.	O
He	O
began	O
with	O
central	O
thoracic	O
oppression	O
and	O
interscapular	O
irradiation	O
,	O
haemodynamic	O
instability	O
,	O
with	O
an	O
electrocardiogram	O
suggestive	O
of	O
LMCA	O
involvement	O
.	O
A	O
chest	O
CT	O
scan	O
was	O
requested	O
which	O
ruled	O
out	O
acute	O
aortic	O
syndrome	O
,	O
the	O
Infarction	O
Code	O
was	O
activated	O
,	O
a	O
loading	O
dose	O
was	O
administered	O
ASA	B-FARMACO
300	O
mg	O
and	O
ticagrelor	O
180	O
mg	O
and	O
the	O
patient	O
was	O
referred	O
to	O
the	O
reference	O
hospital	O
for	O
urgent	O
coronary	O
angiography	O
.	O
Physical	O
examination	O
on	O
arrival	O
at	O
the	O
haemodynamics	O
ward	O
Poor	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
,	O
generalised	O
pallor	O
.	O
Tachypnoea	O
,	O
sweating	O
,	O
hypoperfused	O
BP	O
60	O
40	O
mmHg	O
,	O
HR	O
120	O
bpm	O
.	O
SatO2	O
with	O
Oxiplus	O
at	O
8	O
litres	O
92	O
.	O
Afebrile	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
without	O
audible	O
murmurs	O
,	O
tachycardic	O
.	O
Pulmonary	O
auscultation	O
bilateral	O
crackles	O
up	O
to	O
midfields	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
,	O
no	O
masses	O
or	O
megaliths	O
,	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
,	O
no	O
oedema	O
or	O
indirect	O
signs	O
of	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
initial	O
sinus	O
rhythm	O
,	O
PR	O
0	O
,	O
18	O
.	O
Axis	O
60	O
o	O
.	O
ST	O
elevation	O
suggestive	O
of	O
subepicardial	O
lesion	O
up	O
to	O
3	O
mm	O
in	O
I	O
,	O
avL	O
,	O
V5	O
V6	O
without	O
elevation	O
due	O
to	O
probable	O
artefact	O
,	O
V6	O
poorly	O
positioned	O
.	O
Concomitant	O
ST	O
segment	O
elevation	O
in	O
inferior	O
face	O
up	O
to	O
4	O
mm	O
.	O
Blood	O
tests	O
cardiac	O
markers	O
peak	O
numbers	O
Trop	O
I	O
56	O
.	O
39	O
,	O
myoglobin	O
300	O
,	O
proBNP	O
9500	O
.	O
Biochemistry	O
glucose	O
140	O
mg	O
dl	O
,	O
urea	O
24	O
,	O
creatinine	O
0	O
.	O
62	O
mg	O
dl	O
,	O
Chlorine	O
99	O
mEq	O
l	O
,	O
Na	O
134	O
mEq	O
l	O
,	O
K	O
4	O
.	O
6	O
mEq	O
l	O
.	O
Thyroid	O
function	O
TSH	O
6	O
,	O
30	O
.	O
T4L	O
0	O
.	O
89	O
.	O
Iron	O
metabolism	O
ferritin	O
265	O
.	O
9	O
,	O
transferrin	O
250	O
,	O
SatTf	O
15	O
.	O
4	O
.	O
Vitamin	O
B12	O
and	O
folic	O
acid	O
normal	O
.	O
Autoimmunity	O
and	O
coagulation	O
studies	O
negative	O
.	O
Haemogram	O
25	O
,	O
500	O
leucocytes	O
,	O
Hb	O
12	O
.	O
2	O
g	O
dl	O
,	O
Hto	O
37	O
.	O
8	O
,	O
197	O
,	O
000	O
platelets	O
.	O
Coronary	O
angiography	O
aortography	O
no	O
images	O
suggestive	O
of	O
acute	O
aortic	O
syndrome	O
.	O
Coronary	O
angiography	O
right	O
dominance	O
.	O
Left	O
main	O
coronary	O
artery	O
LMCA	O
subocclusion	O
compatible	O
with	O
spontaneous	O
mid	O
distal	O
dissection	O
involving	O
the	O
ostium	O
of	O
the	O
anterior	O
descending	O
LAD	O
and	O
proximal	O
segment	O
of	O
the	O
CX	O
.	O
Anterior	O
descending	O
except	O
ostial	O
dissection	O
,	O
vessel	O
of	O
good	O
calibre	O
and	O
development	O
without	O
lesions	O
,	O
initial	O
flow	O
TIMI	O
1	O
2	O
.	O
Cx	O
ostial	O
and	O
proximal	O
dissection	O
involving	O
first	O
marginal	O
Mo	O
of	O
small	O
entity	O
.	O
Second	O
Mo	O
of	O
good	O
development	O
without	O
lesions	O
.	O
Right	O
coronary	O
no	O
significant	O
angiographic	O
lesions	O
.	O
Percutaneous	O
coronary	O
interventionism	O
PCI	O
on	O
LMCA	O
during	O
the	O
procedure	O
he	O
presented	O
sustained	O
ventricular	O
tachycardia	O
at	O
160	O
bpm	O
,	O
with	O
haemodynamic	O
instability	O
,	O
which	O
required	O
synchronised	O
CVE	O
at	O
100	O
J	O
with	O
success	O
.	O
Synergy	O
4	O
x	O
24	O
mm	O
direct	O
drug	O
eluting	O
stent	O
was	O
implanted	O
in	O
the	O
LMCA	O
with	O
good	O
results	O
,	O
TIMI	O
3	O
flow	O
in	O
the	O
LAD	O
,	O
with	O
angiographic	O
improvement	O
of	O
the	O
ostial	O
proximal	O
CX	O
.	O
It	O
was	O
decided	O
to	O
finalise	O
the	O
procedure	O
by	O
implanting	O
an	O
intra	O
aortic	O
balloon	O
counterpulsation	O
device	O
IABP	O
and	O
noradrenaline	B-FARMACO
perfusion	O
.	O
Transthoracic	O
echocardiogram	O
at	O
discharge	O
LV	O
slightly	O
dilated	O
LVEDD	O
54	O
mm	O
.	O
Severe	O
systolic	O
dysfunction	O
LVEF	O
estimated	O
by	O
Simpson	O
"	O
s	O
30	O
.	O
Medial	O
and	O
apical	O
septal	O
akinesia	O
and	O
all	O
apical	O
segments	O
,	O
medial	O
lateral	O
these	O
segments	O
being	O
thinned	O
.	O
Inferoapical	O
dyskinetic	O
aneurysm	O
.	O
Medial	O
lateral	O
and	O
anterior	O
medial	O
hypokinesia	O
.	O
Rest	O
of	O
segments	O
contractility	O
preserved	O
.	O
Pseudonormal	O
diastolic	O
pattern	O
,	O
without	O
current	O
data	O
of	O
elevated	O
preload	O
.	O
Left	O
atrium	O
of	O
normal	O
dimensions	O
.	O
Normal	O
right	O
chambers	O
,	O
RV	O
normocontractile	O
.	O
Normal	O
aortic	O
root	O
and	O
visualised	O
portion	O
of	O
proximal	O
ascending	O
aorta	O
.	O
MV	O
thin	O
leaflets	O
,	O
mild	O
central	O
reflux	O
.	O
VAo	O
trivalva	O
,	O
thin	O
leaflets	O
,	O
competent	O
.	O
Minimal	O
TR	O
.	O
IVC	O
not	O
dilated	O
with	O
inspiratory	O
collapse	O
.	O
Estimated	O
normal	O
PAPs	O
.	O
Slight	O
pericardial	O
effusion	O
adjacent	O
to	O
the	O
right	O
cavities	O
,	O
with	O
no	O
current	O
signs	O
of	O
haemodynamic	O
echocardiographic	O
compromise	O
.	O
Intravenous	O
contrast	O
was	O
administered	O
which	O
ruled	O
out	O
the	O
presence	O
of	O
apical	O
thrombus	O
,	O
but	O
slow	O
flow	O
in	O
the	O
area	O
of	O
inferoapical	O
aneurysm	O
.	O
EVOLUTION	O
Admitted	O
to	O
the	O
coronary	O
ICU	O
in	O
cardiogenic	O
shock	O
and	O
acute	O
pulmonary	O
oedema	O
requiring	O
high	O
dose	O
inotropic	O
support	O
,	O
non	O
invasive	O
mechanical	O
ventilation	O
NIV	O
and	O
IABP	O
,	O
presenting	O
at	O
the	O
acute	O
moment	O
with	O
SVT	O
and	O
haemodynamic	O
instability	O
requiring	O
effective	O
ECV	O
.	O
Slow	O
and	O
progressive	O
clinical	O
improvement	O
allowed	O
withdrawal	O
of	O
IABP	O
and	O
lowering	O
of	O
inotrope	O
,	O
with	O
a	O
control	O
echocardiogram	O
in	O
ICU	O
showing	O
moderate	O
LV	O
dysfunction	O
low	O
intravenous	O
inotrope	O
,	O
with	O
no	O
secondary	O
mechanical	O
complications	O
.	O
During	O
his	O
stay	O
on	O
the	O
ward	O
,	O
he	O
was	O
clinically	O
stable	O
,	O
with	O
no	O
arrhythmic	O
events	O
.	O
A	O
repeat	O
echocardiogram	O
at	O
discharge	O
showed	O
severe	O
LV	O
dysfunction	O
,	O
with	O
akinesia	O
of	O
apical	O
segments	O
,	O
inferoapical	O
dyskinetic	O
aneurysm	O
,	O
with	O
no	O
evidence	O
of	O
systemic	O
congestion	O
or	O
significant	O
valvular	O
heart	O
disease	O
.	O
She	O
presented	O
fair	O
blood	O
pressure	O
figures	O
that	O
prevented	O
treatment	O
with	O
ACE	O
inhibitors	O
and	O
beta	O
blockers	O
,	O
so	O
ivabradine	B-FARMACO
was	O
started	O
for	O
optimal	O
heart	O
rate	O
control	O
;	O
double	O
antiplatelet	O
therapy	O
was	O
maintained	O
for	O
at	O
least	O
one	O
year	O
,	O
eplerenone	B-FARMACO
and	O
diuretics	O
at	O
low	O
doses	O
,	O
and	O
she	O
was	O
discharged	O
.	O
A	O
new	O
control	O
echocardiogram	O
was	O
performed	O
in	O
40	O
days	O
with	O
no	O
improvement	O
in	O
echocardiographic	O
data	O
,	O
so	O
it	O
was	O
decided	O
to	O
implant	O
a	O
subcutaneous	O
ICD	O
for	O
primary	O
prevention	O
.	O
She	O
continued	O
to	O
be	O
reviewed	O
by	O
the	O
Heart	O
Failure	O
and	O
Cardiac	O
Rehabilitation	O
Unit	O
,	O
with	O
current	O
functional	O
class	O
II	O
IV	O
NYHA	O
.	O
DIAGNOSIS	O
Acute	O
coronary	O
syndrome	O
with	O
ST	O
segment	O
elevation	O
STEACS	O
anterolateral	O
Killip	O
IV	O
.	O
Spontaneous	O
coronary	O
artery	O
dissection	O
of	O
LMCA	O
to	O
LAD	O
and	O
CX	O
.	O
Percutaneous	O
coronary	O
intervention	O
on	O
LMCA	O
AD	O
1	O
drug	O
eluting	O
stent	O
.	O
Severe	O
LV	O
dysfunction	O
with	O
contractile	O
segmental	O
asymmetries	O
.	O
Subcutaneous	O
ICD	O
implantation	O
for	O
primary	O
prevention	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
a	O
47	O
year	O
old	O
woman	O
from	O
Romania	O
,	O
resident	O
in	O
Spain	O
for	O
10	O
years	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Ex	O
smoker	O
and	O
former	O
injecting	O
drug	O
user	O
,	O
which	O
she	O
gave	O
up	O
completely	O
in	O
2000	O
.	O
Currently	O
married	O
,	O
runs	O
her	O
own	O
handicraft	O
workshop	O
.	O
In	O
2000	O
,	O
the	O
patient	O
had	O
suffered	O
an	O
episode	O
of	O
infective	O
endocarditis	O
on	O
the	O
tricuspid	O
valve	O
,	O
which	O
was	O
operated	O
on	O
in	O
her	O
native	O
country	O
by	O
total	O
valve	O
explant	O
.	O
There	O
was	O
no	O
subsequent	O
follow	O
up	O
for	O
years	O
.	O
In	O
2014	O
the	O
first	O
contact	O
with	O
cardiology	O
in	O
our	O
country	O
took	O
place	O
she	O
consulted	O
for	O
progressive	O
deterioration	O
of	O
functional	O
class	O
and	O
was	O
diagnosed	O
with	O
chronic	O
heart	O
failure	O
.	O
Control	O
echocardiograms	O
showed	O
progressive	O
dilatation	O
and	O
severe	O
dysfunction	O
of	O
the	O
right	O
ventricle	O
as	O
well	O
as	O
severe	O
displacement	O
of	O
the	O
interventricular	O
septum	O
towards	O
the	O
left	O
chambers	O
,	O
which	O
limited	O
left	O
ventricular	O
filling	O
.	O
Despite	O
the	O
optimisation	O
of	O
hygienic	O
and	O
pharmacological	O
measures	O
,	O
over	O
the	O
years	O
the	O
clinical	O
symptoms	O
of	O
heart	O
failure	O
progressed	O
to	O
a	O
situation	O
of	O
severe	O
functional	O
limitation	O
NYHA	O
III	O
IV	O
IV	O
with	O
dyspnoea	O
on	O
slight	O
exertion	O
,	O
as	O
well	O
as	O
the	O
need	O
for	O
admission	O
for	O
intravenous	O
diuretic	O
treatment	O
.	O
Along	O
the	O
way	O
,	O
she	O
also	O
developed	O
atrial	O
fibrillation	O
,	O
with	O
difficulty	O
in	O
frequency	O
control	O
.	O
For	O
all	O
these	O
reasons	O
,	O
she	O
was	O
referred	O
from	O
her	O
centre	O
to	O
our	O
hospital	O
for	O
evaluation	O
of	O
advanced	O
therapies	O
for	O
heart	O
failure	O
.	O
She	O
was	O
treated	O
with	O
furosemide	B-FARMACO
between	O
40	O
and	O
80	O
mg	O
per	O
day	O
according	O
to	O
self	O
adjustment	O
,	O
aldactone	B-FARMACO
100	O
mg	O
per	O
day	O
,	O
acenocoumarol	B-FARMACO
23	O
mg	O
per	O
week	O
and	O
digoxin	B-FARMACO
1	O
tablet	O
per	O
day	O
.	O
On	O
admission	O
,	O
the	O
patient	O
was	O
haemodynamically	O
stable	O
,	O
with	O
a	O
tendency	O
to	O
well	O
tolerated	O
arterial	O
hypotension	O
.	O
She	O
presented	O
with	O
frank	O
right	O
congestion	O
and	O
signs	O
of	O
low	O
cardiac	O
output	O
,	O
including	O
postprandial	O
abdominal	O
pain	O
and	O
marked	O
asthenia	O
.	O
In	O
addition	O
,	O
although	O
the	O
patient	O
had	O
not	O
presented	O
syncope	O
,	O
she	O
reported	O
occasional	O
episodes	O
of	O
dizziness	O
with	O
sweating	O
,	O
related	O
to	O
exertion	O
,	O
especially	O
at	O
times	O
of	O
increased	O
decompensation	O
of	O
heart	O
failure	O
.	O
Vitals	O
BP	O
100	O
50	O
mmHg	O
,	O
HR	O
60	O
bpm	O
,	O
SatO2	O
97	O
without	O
supplementary	O
O2	O
.	O
On	O
physical	O
examination	O
,	O
central	O
cyanosis	O
.	O
Jugular	O
ingurgitation	O
visible	O
up	O
to	O
the	O
earlobe	O
with	O
marked	O
v	O
wave	O
.	O
Cardiac	O
auscultation	O
was	O
arrhythmic	O
,	O
with	O
a	O
gallop	O
in	O
the	O
right	O
third	O
tone	O
,	O
as	O
well	O
as	O
a	O
pansystolic	O
murmur	O
III	O
VI	O
also	O
audible	O
from	O
the	O
back	O
.	O
Pulmonary	O
auscultation	O
with	O
no	O
significant	O
findings	O
.	O
Abdomen	O
with	O
pulsatile	O
hepatomegaly	O
visible	O
without	O
palpation	O
,	O
painful	O
5	O
finger	O
traverses	O
.	O
There	O
was	O
no	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
atrial	O
fibrillation	O
with	O
ventricular	O
response	O
at	O
100	O
bpm	O
,	O
right	O
inferior	O
axis	O
with	O
BRD	O
and	O
negative	O
T	O
wave	O
from	O
V1	O
to	O
V6	O
and	O
in	O
inferior	O
leads	O
.	O
Chest	O
X	O
ray	O
sternotomy	O
suture	O
.	O
Voluminous	O
global	O
cardiomegaly	O
with	O
very	O
significant	O
enlargement	O
of	O
the	O
right	O
ventricle	O
and	O
left	O
chambers	O
.	O
Accessory	O
lobe	O
and	O
fissure	O
of	O
the	O
azygos	O
.	O
No	O
significant	O
pleuropulmonary	O
alterations	O
.	O
Echocardiogram	O
left	O
ventricle	O
not	O
dilated	O
,	O
with	O
normal	O
wall	O
thickness	O
.	O
Very	O
marked	O
systolic	O
and	O
diastolic	O
bulging	O
of	O
the	O
interventricular	O
septum	O
towards	O
the	O
left	O
ventricle	O
,	O
predominantly	O
diastolic	O
.	O
Global	O
systolic	O
function	O
slightly	O
depressed	O
.	O
Normal	O
transmitral	O
filling	O
pattern	O
.	O
Interatrial	O
septum	O
displaced	O
towards	O
the	O
left	O
atrium	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
.	O
Severely	O
dilated	O
right	O
atrium	O
and	O
right	O
ventricle	O
.	O
Dysfunctional	O
RV	O
,	O
with	O
absence	O
of	O
tricuspid	O
valve	O
,	O
functionally	O
acting	O
together	O
with	O
the	O
RA	O
as	O
a	O
single	O
cavity	O
.	O
Pulmonary	O
valve	O
with	O
dilatation	O
of	O
the	O
annulus	O
with	O
insufficiency	O
that	O
is	O
difficult	O
to	O
assess	O
in	O
terms	O
of	O
severity	O
.	O
Morphologically	O
normal	O
mitral	O
valve	O
.	O
Mild	O
insufficiency	O
.	O
Sclerosed	O
aortic	O
valve	O
,	O
good	O
opening	O
and	O
functionally	O
normal	O
.	O
Pulmonary	O
artery	O
systolic	O
pressure	O
not	O
estimable	O
.	O
Inferior	O
vena	O
cava	O
severely	O
dilated	O
,	O
plethoric	O
,	O
without	O
collapse	O
.	O
Severely	O
dilated	O
suprahepatic	O
veins	O
.	O
No	O
pericardial	O
effusion	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
EVOLUTION	O
Given	O
the	O
semiology	O
of	O
right	O
congestion	O
,	O
treatment	O
was	O
started	O
with	O
intravenous	O
diuretic	O
.	O
The	O
patient	O
showed	O
signs	O
of	O
low	O
anterograde	O
output	O
,	O
so	O
he	O
received	O
inotropic	O
support	O
with	O
dobutamine	B-FARMACO
and	O
subsequent	O
weaning	O
with	O
levosimendan	B-FARMACO
.	O
Significant	O
symptomatic	O
improvement	O
,	O
although	O
with	O
significant	O
difficulty	O
in	O
switching	O
from	O
depletive	O
to	O
oral	O
treatment	O
,	O
requiring	O
frequent	O
appointments	O
at	O
the	O
Cardiology	O
day	O
hospital	O
,	O
some	O
of	O
which	O
required	O
admission	O
for	O
treatment	O
intensification	O
.	O
Given	O
the	O
evolution	O
of	O
the	O
patient	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
pre	O
transplant	O
study	O
,	O
for	O
which	O
there	O
were	O
no	O
contraindications	O
.	O
The	O
only	O
incident	O
was	O
a	O
personal	O
history	O
of	O
hepatitis	O
C	O
virus	O
genotype	O
1a	O
and	O
high	O
viral	O
face	O
which	O
had	O
been	O
treated	O
with	O
simeprevir	B-FARMACO
and	I-FARMACO
sofosbuvir	I-FARMACO
,	O
and	O
was	O
considered	O
cured	O
prolonged	O
sustained	O
viral	O
response	O
for	O
years	O
and	O
secondary	O
complications	O
were	O
ruled	O
out	O
by	O
means	O
of	O
a	O
complete	O
digestive	O
study	O
.	O
As	O
a	O
result	O
,	O
the	O
patient	O
is	O
currently	O
on	O
the	O
waiting	O
list	O
for	O
elective	O
heart	O
transplantation	O
.	O
DIAGNOSIS	O
Right	O
heart	O
failure	O
in	O
advanced	O
functional	O
class	O
IV	O
IV	O
NYHA	O
secondary	O
to	O
tricuspid	O
valvectomy	O
as	O
treatment	O
for	O
infective	O
endocarditis	O
.	O
Severe	O
dilatation	O
and	O
right	O
ventricular	O
dysfunction	O
.	O
Secondary	O
mild	O
left	O
ventricular	O
dysfunction	O
.	O
Permanent	O
atrial	O
fibrillation	O
.	O
Cured	O
HCV	O
infection	O
.	O
Inclusion	O
on	O
the	O
elective	O
list	O
for	O
heart	O
transplantation	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
a	O
79	O
year	O
old	O
male	O
diabetic	O
with	O
chronic	O
kidney	O
disease	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
as	O
medical	O
history	O
of	O
interest	O
.	O
In	O
2009	O
,	O
he	O
underwent	O
surgery	O
for	O
severe	O
degenerative	O
aortic	O
stenosis	O
and	O
underwent	O
aortic	O
valve	O
replacement	O
with	O
a	O
Mitroflow	O
No23	O
biological	O
prosthesis	O
.	O
Postoperative	O
transthoracic	O
echocardiography	O
TTE	O
showed	O
a	O
normofunctioning	O
valve	O
with	O
a	O
maximum	O
gradient	O
of	O
25	O
mmHg	O
.	O
During	O
follow	O
up	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
until	O
June	O
2016	O
,	O
when	O
he	O
presented	O
with	O
congestive	O
heart	O
failure	O
in	O
NYHA	O
functional	O
class	O
III	O
.	O
The	O
physical	O
examination	O
at	O
that	O
time	O
highlighted	O
RsCsRs	O
with	O
systolic	O
murmur	O
III	O
VI	O
aortic	O
with	O
diastolic	O
murmur	O
II	O
IV	O
.	O
Normal	O
abdomen	O
.	O
Lower	O
limbs	O
without	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
was	O
in	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
with	O
left	O
ventricular	O
hypertrophy	O
and	O
normal	O
QRS	O
width	O
.	O
TTE	O
severe	O
aortic	O
insufficiency	O
of	O
intraprosthetic	O
origin	O
with	O
a	O
maximum	O
aortic	O
gradient	O
of	O
32	O
mmHg	O
.	O
Left	O
ventricular	O
function	O
was	O
normal	O
and	O
other	O
findings	O
included	O
mild	O
mitral	O
regurgitation	O
.	O
Coronary	O
angiography	O
coronary	O
arteries	O
were	O
normal	O
.	O
Angio	O
CT	O
to	O
evaluate	O
the	O
valve	O
complex	O
and	O
vascular	O
accesses	O
,	O
this	O
test	O
was	O
performed	O
with	O
the	O
following	O
measurements	O
annulus	O
diameter	O
17	O
x	O
17	O
.	O
6	O
mm	O
mean	O
17	O
.	O
3	O
mm	O
,	O
circumference	O
63	O
.	O
9	O
mm	O
,	O
circumference	O
derived	O
from	O
the	O
diameter	O
20	O
.	O
3	O
mm	O
;	O
area	O
320	O
.	O
9	O
mm2	O
;	O
area	O
derived	O
from	O
diameter	O
20	O
.	O
2	O
mm	O
;	O
sinuses	O
of	O
Valsalva	O
left	O
diameter	O
28	O
and	O
height	O
10	O
.	O
7	O
mm	O
,	O
right	O
diameter	O
28	O
.	O
8	O
and	O
height	O
16	O
.	O
5	O
mm	O
,	O
non	O
coronary	O
27	O
.	O
2	O
and	O
height	O
16	O
.	O
5	O
mm	O
;	O
height	O
to	O
coronary	O
ostiums	O
left	O
4	O
.	O
3	O
mm	O
,	O
right	O
9	O
.	O
5	O
mm	O
;	O
LV	O
outflow	O
tract	O
diameter	O
18	O
.	O
7	O
x	O
23	O
.	O
2	O
mm	O
.	O
Distance	O
from	O
ring	O
projection	O
to	O
coronary	O
trunk	O
exit	O
4	O
.	O
4	O
mm	O
.	O
Vascular	O
accesses	O
minimum	O
diameters	O
common	O
iliac	O
artery	O
diameter	O
8	O
x	O
9	O
.	O
8	O
mm	O
,	O
right	O
femoral	O
artery	O
diameter	O
7	O
.	O
1	O
x	O
7	O
.	O
2	O
mm	O
,	O
left	O
common	O
iliac	O
artery	O
diameter	O
7	O
.	O
6	O
x	O
7	O
.	O
7	O
mm	O
,	O
left	O
femoral	O
artery	O
diameter	O
6	O
.	O
4	O
x	O
7	O
.	O
3	O
mm	O
.	O
Estimated	O
risk	O
scores	O
STS	O
8	O
,	O
Euroscore	O
2	O
14	O
.	O
98	O
,	O
Log	O
Euroscore	O
48	O
.	O
25	O
.	O
EVOLUTION	O
With	O
the	O
diagnosis	O
of	O
late	O
prosthetic	O
dysfunction	O
Mitroflow	O
N23	O
with	O
severe	O
intraprosthetic	O
insufficiency	O
,	O
the	O
case	O
was	O
discussed	O
in	O
a	O
medical	O
surgical	O
session	O
and	O
taking	O
into	O
account	O
the	O
high	O
surgical	O
risk	O
,	O
the	O
fact	O
that	O
it	O
would	O
be	O
a	O
reintervention	O
and	O
the	O
patient	O
's	O
preference	O
,	O
it	O
was	O
decided	O
to	O
implant	O
the	O
Evolut	O
N23	O
TAVI	O
through	O
right	O
femoral	O
access	O
by	O
means	O
of	O
a	O
valve	O
in	O
valve	O
procedure	O
.	O
The	O
procedure	O
is	O
performed	O
by	O
placing	O
a	O
guidewire	O
in	O
the	O
left	O
coronary	O
trunk	O
during	O
valve	O
implantation	O
and	O
coronary	O
angiography	O
is	O
performed	O
to	O
verify	O
complete	O
patency	O
of	O
the	O
LMCA	O
prior	O
to	O
prosthesis	O
release	O
.	O
Both	O
the	O
placement	O
and	O
release	O
of	O
the	O
prosthesis	O
were	O
carried	O
out	O
without	O
incident	O
,	O
with	O
angiography	O
verifying	O
correct	O
positioning	O
and	O
the	O
absence	O
of	O
significant	O
regurgitation	O
.	O
After	O
the	O
procedure	O
,	O
the	O
patient	O
remained	O
in	O
the	O
Intensive	O
Care	O
Unit	O
for	O
24	O
hours	O
with	O
good	O
evolution	O
and	O
early	O
extubation	O
.	O
He	O
was	O
transferred	O
to	O
the	O
cardiology	O
ward	O
where	O
a	O
control	O
TTE	O
was	O
performed	O
,	O
which	O
showed	O
a	O
normofunctioning	O
prosthesis	O
with	O
a	O
maximum	O
gradient	O
of	O
33	O
mmHg	O
,	O
without	O
insufficiency	O
.	O
As	O
the	O
patient	O
was	O
asymptomatic	O
,	O
discharge	O
was	O
decided	O
on	O
the	O
7th	O
day	O
.	O
DIAGNOSIS	O
Implantation	O
of	O
an	O
Evolut	O
type	O
transcatheter	O
aortic	O
prosthesis	O
by	O
means	O
of	O
a	O
valve	O
in	O
valve	O
procedure	O
for	O
treatment	O
of	O
late	O
prosthetic	O
degeneration	O
Mitroflow	O
N23	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
60	O
year	O
old	O
woman	O
allergic	O
to	O
ASA	B-FARMACO
.	O
Ex	O
smoker	O
.	O
The	O
only	O
history	O
is	O
that	O
she	O
underwent	O
hysterectomy	O
and	O
double	O
adnexectomy	O
in	O
2008	O
.	O
No	O
cardiological	O
history	O
.	O
She	O
presented	O
with	O
progressive	O
dyspnoea	O
of	O
one	O
month	O
's	O
duration	O
,	O
associated	O
with	O
presyncopal	O
symptoms	O
.	O
On	O
the	O
day	O
of	O
admission	O
the	O
patient	O
suffered	O
a	O
syncopal	O
episode	O
.	O
She	O
was	O
attended	O
at	O
home	O
and	O
was	O
found	O
to	O
have	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
and	O
acute	O
pulmonary	O
oedema	O
.	O
She	O
was	O
admitted	O
to	O
the	O
ICU	O
.	O
On	O
arrival	O
at	O
the	O
ICU	O
physical	O
examination	O
was	O
performed	O
BP	O
105	O
57	O
mmHg	O
,	O
HR	O
160	O
bpm	O
,	O
T	O
36	O
.	O
4	O
oC	O
,	O
SatO2	O
89	O
with	O
Ventimask	O
at	O
10	O
litres	O
.	O
Patient	O
conscious	O
and	O
oriented	O
.	O
Tachypnoea	O
.	O
No	O
jugular	O
ingurgitation	O
or	O
hepatojugular	O
reflux	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
heart	O
sounds	O
at	O
high	O
frequency	O
,	O
interrupted	O
by	O
breath	O
sounds	O
.	O
Pulmonary	O
auscultation	O
bilateral	O
crackles	O
up	O
to	O
upper	O
fields	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
no	O
masses	O
or	O
megaliths	O
palpable	O
.	O
Peristalsis	O
preserved	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
extremities	O
or	O
signs	O
of	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
arrival	O
at	O
ICU	O
atrial	O
fibrillation	O
160	O
bpm	O
.	O
Chest	O
X	O
ray	O
bilateral	O
interstitial	O
infiltrate	O
and	O
bilateral	O
pleural	O
effusion	O
,	O
compatible	O
with	O
acute	O
pulmonary	O
oedema	O
.	O
Blood	O
tests	O
on	O
arrival	O
in	O
the	O
ICU	O
arterial	O
blood	O
gases	O
pH	O
7	O
.	O
48	O
,	O
pCO2	O
39	O
.	O
4	O
,	O
HCO3	O
28	O
.	O
8	O
,	O
Sat	O
O2	O
90	O
.	O
5	O
,	O
pO2	O
62	O
mmHg	O
.	O
Biochemistry	O
creatinine	O
0	O
.	O
75	O
mg	O
dl	O
.	O
Urea	O
112	O
mg	O
dl	O
.	O
Calcium	O
7	O
.	O
7	O
mg	O
dl	O
.	O
Mg	O
2	O
.	O
3	O
mg	O
dl	O
.	O
Total	O
protein	O
5	O
.	O
1	O
g	O
dl	O
.	O
Cl	O
112	O
mEq	O
l	O
.	O
Na	O
148	O
mEq	O
L	O
.	O
K	O
4	O
.	O
6	O
mEq	O
L	O
.	O
Haemogram	O
15	O
,	O
000	O
leucocytes	O
uL	O
with	O
88	O
.	O
3	O
neutrophils	O
and	O
6	O
.	O
1	O
lymphocytes	O
.	O
Haemoglobin	O
9	O
.	O
6	O
g	O
dl	O
.	O
Hto	O
31	O
.	O
2	O
.	O
Platelets	O
211	O
,	O
000	O
uL	O
.	O
Coagulation	O
INR	O
1	O
,	O
36	O
.	O
Prothrombin	O
activity	O
68	O
,	O
TTP	O
60	O
s	O
,	O
PT	O
15	O
.	O
20	O
s	O
.	O
Transthoracic	O
and	O
transesophageal	O
echocardiogram	O
LV	O
neither	O
dilated	O
nor	O
hypertrophic	O
.	O
Preserved	O
LVEF	O
estimated	O
by	O
Simspon	O
60	O
.	O
Left	O
atrium	O
slightly	O
dilated	O
area	O
22	O
cm2	O
.	O
Left	O
atrial	O
appendage	O
free	O
of	O
thrombus	O
.	O
RV	O
of	O
normal	O
size	O
and	O
systolic	O
function	O
TAPSE	O
23	O
mm	O
,	O
S	O
wave	O
by	O
lateral	O
TDI	O
10	O
.	O
5	O
cm	O
s	O
.	O
A	O
large	O
mass	O
7	O
x	O
3	O
cm	O
with	O
slightly	O
irregular	O
borders	O
and	O
homogeneous	O
density	O
was	O
observed	O
in	O
the	O
left	O
atrium	O
.	O
It	O
is	O
attached	O
to	O
the	O
interatrial	O
septum	O
,	O
prolapsing	O
in	O
diastole	O
through	O
the	O
mitral	O
valve	O
and	O
generating	O
moderate	O
restriction	O
to	O
its	O
opening	O
mean	O
transmitral	O
gradient	O
7	O
.	O
5	O
mmHg	O
.	O
Mild	O
MI	O
.	O
Given	O
the	O
echocardiographic	O
characteristics	O
,	O
it	O
appears	O
to	O
be	O
a	O
cardiac	O
myxoma	O
,	O
without	O
being	O
able	O
to	O
rule	O
out	O
malignancy	O
.	O
Atrial	O
septum	O
of	O
normal	O
echocardiographic	O
characteristics	O
without	O
flow	O
through	O
it	O
.	O
Aortic	O
valve	O
trivalve	O
with	O
normal	O
kinetics	O
,	O
no	O
restriction	O
to	O
its	O
opening	O
,	O
no	O
reflux	O
.	O
Tricuspid	O
valve	O
Mild	O
TR	O
.	O
RV	O
AD	O
gradient	O
of	O
29	O
mmHg	O
.	O
IVC	O
and	O
suprahepatic	O
valves	O
not	O
dilated	O
,	O
no	O
flow	O
reversal	O
and	O
inspiratory	O
non	O
collapse	O
.	O
Estimated	O
PAPs	O
of	O
33	O
mmHg	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Aortic	O
root	O
,	O
ascending	O
and	O
descending	O
thoracic	O
aorta	O
of	O
normal	O
size	O
and	O
echoic	O
characteristics	O
.	O
Cardio	O
MRI	O
study	O
by	O
means	O
of	O
TI	O
,	O
T2	O
,	O
STIR	O
sequences	O
in	O
axial	O
,	O
2C	O
,	O
3C	O
,	O
4C	O
and	O
by	O
means	O
of	O
iv	O
contrast	O
angio	O
MRI	O
and	O
late	O
enhancement	O
sequence	O
in	O
2C	O
and	O
4C	O
.	O
Voluminous	O
mobile	O
tumour	O
in	O
the	O
left	O
atrial	O
cavity	O
measuring	O
7	O
x	O
4	O
.	O
5	O
cm	O
extending	O
to	O
the	O
posteroinferior	O
region	O
of	O
the	O
left	O
atrium	O
.	O
It	O
presents	O
a	O
pedicle	O
with	O
a	O
base	O
of	O
implantation	O
in	O
the	O
interatrial	O
septum	O
of	O
approximately	O
2	O
cm	O
,	O
in	O
the	O
middle	O
third	O
of	O
the	O
septum	O
proximity	O
of	O
the	O
fossa	O
ovalis	O
with	O
slightly	O
mameloned	O
contours	O
,	O
with	O
part	O
of	O
the	O
mass	O
prolapsing	O
through	O
the	O
mitral	O
valve	O
in	O
early	O
diastole	O
.	O
It	O
presents	O
intermediate	O
intensity	O
in	O
T1	O
that	O
increases	O
in	O
T2	O
.	O
After	O
contrast	O
administration	O
,	O
it	O
appears	O
irregularly	O
perfused	O
,	O
as	O
well	O
as	O
with	O
heterogeneous	O
uptake	O
in	O
late	O
gadolinium	O
enhancement	O
sequence	O
.	O
Given	O
the	O
presentation	O
and	O
behaviour	O
in	O
the	O
different	O
sequences	O
,	O
the	O
mass	O
is	O
compatible	O
with	O
a	O
sarcomatous	O
strain	O
.	O
Cardiac	O
catheterisation	O
coronary	O
arteries	O
without	O
angiographic	O
lesions	O
.	O
EVOLUTION	O
After	O
performing	O
complementary	O
tests	O
and	O
given	O
the	O
clinical	O
situation	O
of	O
the	O
patient	O
,	O
urgent	O
surgery	O
was	O
decided	O
.	O
Under	O
extracorporeal	O
circulation	O
ECC	O
,	O
a	O
voluminous	O
tumour	O
infiltrating	O
the	O
atrioventricular	O
groove	O
and	O
the	O
interatrial	O
septum	O
was	O
resected	O
,	O
with	O
the	O
appearance	O
of	O
malignancy	O
.	O
Mitral	O
valve	O
replacement	O
with	O
a	O
metallic	O
prosthesis	O
and	O
closure	O
of	O
the	O
septal	O
defect	O
with	O
pericardium	O
were	O
performed	O
.	O
During	O
the	O
first	O
72	O
96	O
postoperative	O
hours	O
,	O
the	O
patient	O
remained	O
under	O
deep	O
sedoanalgesia	O
due	O
to	O
severe	O
refractory	O
hypotension	O
,	O
in	O
the	O
context	O
of	O
post	O
ACS	O
inflammatory	O
response	O
syndrome	O
SIRS	O
;	O
requiring	O
vigorous	O
volume	O
expansion	O
,	O
as	O
well	O
as	O
high	O
doses	O
of	O
noradrenaline	B-FARMACO
NA	O
and	O
vasopressin	B-FARMACO
in	O
continuous	O
perfusion	O
,	O
associating	O
continuous	O
renal	O
replacement	O
therapy	O
CRRT	O
at	O
maximum	O
doses	O
of	O
ultrafiltration	O
due	O
to	O
incipient	O
acute	O
renal	O
failure	O
ARF	O
.	O
Once	O
the	O
vasoplegia	O
had	O
resolved	O
,	O
sedation	O
could	O
be	O
withdrawn	O
and	O
weaning	O
from	O
mechanical	O
ventilation	O
could	O
be	O
initiated	O
.	O
The	O
patient	O
could	O
be	O
extubated	O
with	O
normal	O
level	O
of	O
consciousness	O
,	O
initially	O
maintaining	O
good	O
respiratory	O
mechanics	O
with	O
O2	O
Sat	O
95	O
with	O
oxygen	O
therapy	O
at	O
medium	O
flows	O
.	O
However	O
,	O
respiratory	O
mechanics	O
progressively	O
worsened	O
.	O
A	O
TTE	O
was	O
performed	O
which	O
ruled	O
out	O
cardiological	O
complications	O
with	O
a	O
normally	O
functioning	O
prosthesis	O
;	O
and	O
a	O
chest	O
X	O
ray	O
showed	O
bilateral	O
interstitial	O
infiltrate	O
compatible	O
with	O
ARDS	O
,	O
requiring	O
reintubation	O
.	O
The	O
evolution	O
was	O
torpid	O
,	O
with	O
exitus	O
7	O
days	O
after	O
the	O
cardiac	O
postoperative	O
period	O
.	O
Finally	O
,	O
the	O
anatomopathological	O
diagnosis	O
was	O
high	O
grade	O
pleomorphic	O
sarcoma	O
.	O
DIAGNOSIS	O
High	O
grade	O
cardiac	O
pleomorphic	O
sarcoma	O
in	O
the	O
left	O
atrium	O
.	O
Acute	O
heart	O
failure	O
due	O
to	O
obstruction	O
to	O
left	O
ventricular	O
filling	O
.	O
Urgent	O
surgery	O
for	O
tumour	O
resection	O
and	O
mechanical	O
mitral	O
prosthesis	O
.	O
Poor	O
postoperative	O
evolution	O
with	O
systemic	O
inflammatory	O
response	O
syndrome	O
and	O
exitus	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
a	O
27	O
year	O
old	O
male	O
from	O
Ukraine	O
.	O
He	O
was	O
evaluated	O
in	O
his	O
country	O
for	O
long	O
PR	O
in	O
2012	O
,	O
with	O
PR	O
260	O
ms	O
,	O
with	O
sinus	O
bradycardia	O
at	O
52	O
bpm	O
at	O
rest	O
.	O
He	O
had	O
a	O
normal	O
echocardiogram	O
,	O
with	O
no	O
structural	O
abnormalities	O
.	O
He	O
does	O
not	O
take	O
regular	O
medication	O
.	O
There	O
is	O
no	O
family	O
history	O
of	O
cardiological	O
disease	O
or	O
sudden	O
death	O
.	O
He	O
frequently	O
practises	O
sport	O
.	O
For	O
more	O
than	O
a	O
year	O
she	O
has	O
reported	O
occasional	O
dizziness	O
and	O
unsteadiness	O
,	O
mainly	O
after	O
exercise	O
,	O
without	O
loss	O
of	O
consciousness	O
.	O
Approximately	O
5	O
years	O
ago	O
,	O
a	O
syncopal	O
episode	O
in	O
Ukraine	O
,	O
in	O
the	O
context	O
of	O
a	O
fever	O
of	O
more	O
than	O
40	O
C	O
,	O
she	O
reports	O
being	O
aware	O
of	O
losing	O
consciousness	O
,	O
without	O
trauma	O
,	O
she	O
reports	O
that	O
she	O
may	O
have	O
noticed	O
palpitations	O
,	O
without	O
confirming	O
this	O
.	O
In	O
subsequent	O
years	O
she	O
has	O
not	O
had	O
any	O
syncopal	O
or	O
pre	O
syncopal	O
episodes	O
,	O
even	O
though	O
she	O
has	O
had	O
other	O
febrile	O
processes	O
.	O
A	O
few	O
months	O
ago	O
she	O
consulted	O
MAP	O
and	O
was	O
referred	O
to	O
the	O
cardiologist	O
for	O
bradycardia	O
.	O
An	O
ECG	O
was	O
performed	O
in	O
the	O
consultation	O
room	O
showing	O
complete	O
AV	O
block	O
with	O
escape	O
rhythm	O
at	O
40	O
bpm	O
,	O
narrow	O
QRS	O
,	O
QTc	O
490	O
ms	O
,	O
and	O
he	O
was	O
referred	O
to	O
the	O
emergency	O
department	O
for	O
admission	O
and	O
examination	O
.	O
Physical	O
examination	O
BP	O
139	O
60	O
mmHg	O
;	O
HR	O
45	O
bpm	O
;	O
SatO2	O
100	O
baseline	O
.	O
Eupneic	O
.	O
No	O
IY	O
.	O
AC	O
rhythmic	O
heart	O
tones	O
,	O
no	O
audible	O
pathological	O
murmurs	O
.	O
AP	O
bilateral	O
normoventilation	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
,	O
no	O
megaliths	O
.	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
no	O
alterations	O
of	O
interest	O
.	O
Chest	O
X	O
ray	O
compatible	O
with	O
normality	O
.	O
Autoimmunity	O
negative	O
.	O
Borrelia	O
burgdorferi	O
serology	O
negative	O
.	O
Echocardiogram	O
compatible	O
with	O
normality	O
,	O
non	O
dilated	O
left	O
ventricle	O
and	O
normal	O
LVEF	O
.	O
Stress	O
echocardiogram	O
to	O
assess	O
tachycardia	O
ergometry	O
BRUCE	O
protocol	O
.	O
Test	O
suspended	O
due	O
to	O
physical	O
fatigue	O
.	O
No	O
dyspnoea	O
or	O
angina	O
.	O
Functional	O
capacity	O
preserved	O
22	O
.	O
2	O
METS	O
.	O
Basal	O
ECG	O
sinus	O
rhythm	O
at	O
48	O
bpm	O
,	O
without	O
repolarisation	O
alterations	O
;	O
no	O
changes	O
on	O
exertion	O
.	O
No	O
arrhythmias	O
from	O
the	O
first	O
stage	O
BAVc	O
disappears	O
,	O
long	O
PR	O
with	O
excellent	O
tachycardia	O
reaching	O
a	O
maximum	O
HR	O
of	O
181	O
bpm	O
93	O
of	O
the	O
FCMT	O
.	O
Adequate	O
behaviour	O
in	O
the	O
post	O
exercise	O
phase	O
.	O
BAVc	O
reappears	O
at	O
rest	O
,	O
when	O
HR	O
decreases	O
to	O
less	O
than	O
80x	O
"	O
.	O
Basal	O
BP	O
130	O
80	O
mmHg	O
.	O
Correct	O
behaviour	O
with	O
effort	O
.	O
Post	O
effort	O
echocardiogram	O
no	O
alterations	O
in	O
segmental	O
contractility	O
.	O
No	O
changes	O
in	O
valvular	O
flows	O
,	O
diastolic	O
pattern	O
or	O
PAP	O
.	O
ID	O
No	O
induction	O
of	O
myocardial	O
ischaemia	O
.	O
Good	O
functional	O
capacity	O
.	O
Excellent	O
tachycardialisation	O
from	O
the	O
first	O
Bruce	O
stage	O
.	O
Electrophysiological	O
study	O
baseline	O
ECG	O
shows	O
sinus	O
rhythm	O
with	O
2nd	O
degree	O
BAV	O
Mobitz	O
I	O
type	O
.	O
Double	O
puncture	O
of	O
the	O
right	O
femoral	O
vein	O
5F	O
introducer	O
.	O
Conduction	O
intervals	O
HV	O
40	O
ms	O
.	O
Basally	O
and	O
under	O
atrial	O
stimulation	O
,	O
the	O
suprahisian	O
origin	O
of	O
the	O
AV	O
block	O
was	O
confirmed	O
.	O
The	O
procedure	O
was	O
terminated	O
without	O
complications	O
.	O
Interpretation	O
and	O
conclusions	O
electrophysiological	O
study	O
compatible	O
with	O
supra	O
Hisian	O
AVB	O
.	O
EVOLUTION	O
Asymptomatic	O
during	O
admission	O
,	O
denies	O
dizziness	O
.	O
No	O
syncopal	O
or	O
presyncopal	O
episodes	O
.	O
He	O
was	O
monitored	O
throughout	O
admission	O
,	O
maintaining	O
grade	O
2	O
AVB	O
,	O
with	O
HR	O
between	O
30	O
and	O
50	O
bpm	O
,	O
asymptomatic	O
.	O
A	O
transthoracic	O
echocardiogram	O
ruled	O
out	O
structural	O
heart	O
disease	O
.	O
The	O
case	O
was	O
discussed	O
with	O
the	O
Arrhythmia	O
Unit	O
and	O
ergometry	O
was	O
performed	O
,	O
which	O
was	O
normal	O
,	O
with	O
excellent	O
tachycardia	O
on	O
exertion	O
.	O
An	O
electrophysiological	O
study	O
was	O
performed	O
,	O
compatible	O
with	O
supra	O
Hisian	O
AVB	O
,	O
and	O
given	O
the	O
chronotropic	O
competence	O
,	O
it	O
was	O
decided	O
to	O
recommend	O
a	O
reduction	O
in	O
physical	O
activity	O
and	O
a	O
review	O
in	O
3	O
months	O
.	O
DIAGNOSIS	O
Suprahisian	O
atrioventricular	O
supra	O
Hisian	O
block	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
70	O
year	O
old	O
woman	O
.	O
No	O
drug	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
High	O
blood	O
pressure	O
.	O
No	O
history	O
of	O
diabetes	O
mellitus	O
or	O
dyslipidaemia	O
.	O
Neoplasia	O
of	O
the	O
left	O
kidney	O
with	O
nephrectomy	O
in	O
2010	O
.	O
Secondary	O
chronic	O
renal	O
failure	O
with	O
usual	O
creatinine	O
1	O
.	O
4	O
mg	O
dL	O
GFR	O
37	O
ml	O
min	O
.	O
Iron	O
deficiency	O
anaemia	O
.	O
History	O
of	O
trigeminal	O
neuralgia	O
.	O
Osteoporosis	O
.	O
Diagnosed	O
with	O
irritable	O
colon	O
.	O
In	O
2013	O
,	O
tubular	O
adenoma	O
with	O
low	O
grade	O
dysplasia	O
in	O
colon	O
.	O
Anxiety	O
syndrome	O
under	O
treatment	O
.	O
IQ	O
left	O
total	O
hip	O
prosthesis	O
in	O
March	O
2014	O
.	O
Left	O
nephrectomy	O
hypernephroma	O
in	O
2010	O
.	O
Cardiological	O
first	O
episode	O
of	O
paroxysmal	O
atrial	O
fibrillation	O
in	O
2013	O
,	O
prescribed	O
pill	O
in	O
the	O
pocket	O
.	O
New	O
episode	O
in	O
March	O
2014	O
in	O
postoperative	O
femur	O
fracture	O
,	O
which	O
reversed	O
spontaneously	O
.	O
Echocardiogram	O
with	O
no	O
alterations	O
.	O
He	O
started	O
treatment	O
with	O
acenocoumarol	B-FARMACO
and	O
flecainide	B-FARMACO
.	O
Usual	O
treatment	O
amlodipine	B-FARMACO
5	O
mg	O
d	O
,	O
flecainide	B-FARMACO
50	O
mg	O
d	O
,	O
acenocoumarol	B-FARMACO
as	O
prescribed	O
,	O
valsartan	B-FARMACO
160	O
mg	O
d	O
,	O
ferrous	B-FARMACO
sulphate	I-FARMACO
80	O
mg	O
d	O
,	O
lorazepam	B-FARMACO
1	O
.	O
5	O
mg	O
d	O
,	O
calcium	B-FARMACO
VitD	I-FARMACO
1000	O
880	O
IUI	O
,	O
tramadol	B-FARMACO
paracetamol	I-FARMACO
37	O
.	O
5	O
325	O
mg	O
.	O
Present	O
illness	O
At	O
rest	O
,	O
the	O
patient	O
began	O
to	O
experience	O
central	O
thoracic	O
pressure	O
radiating	O
to	O
both	O
arms	O
and	O
interscapular	O
region	O
,	O
intensity	O
10	O
10	O
and	O
accompanied	O
by	O
profuse	O
sweating	O
,	O
nausea	O
and	O
pallor	O
.	O
On	O
arrival	O
of	O
the	O
ambulance	O
,	O
an	O
ECG	O
was	O
performed	O
showing	O
RS	O
at	O
60	O
bpm	O
,	O
axis	O
60	O
,	O
PR	O
0	O
.	O
16s	O
,	O
narrow	O
QRS	O
with	O
slight	O
ST	O
rectification	O
in	O
V3	O
V4	O
.	O
Nitrates	B-FARMACO
and	O
up	O
to	O
6	O
mg	O
of	O
morphine	B-FARMACO
chloride	I-FARMACO
were	O
administered	O
,	O
with	O
improvement	O
in	O
pain	O
.	O
He	O
was	O
transferred	O
to	O
the	O
emergency	O
room	O
where	O
he	O
arrived	O
without	O
pain	O
with	O
BP	O
120	O
70	O
mmHg	O
and	O
HR	O
55	O
bpm	O
.	O
ECG	O
showed	O
persistent	O
ST	O
rectification	O
in	O
V3	O
V4	O
.	O
Analyses	O
showed	O
positive	O
troponin	O
.	O
Double	O
antiplatelet	O
therapy	O
was	O
started	O
and	O
the	O
patient	O
was	O
admitted	O
for	O
study	O
.	O
Physical	O
examination	O
Patient	O
in	O
good	O
general	O
condition	O
,	O
conscious	O
and	O
oriented	O
,	O
eupneic	O
at	O
rest	O
,	O
afebrile	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
with	O
aortic	O
systolic	O
murmur	O
I	O
VI	O
.	O
Pulmonary	O
auscultation	O
VCM	O
,	O
without	O
added	O
sounds	O
.	O
IIUS	O
no	O
oedema	O
or	O
signs	O
of	O
DVT	O
.	O
Pedial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Emergency	O
laboratory	O
tests	O
creatinine	O
1	O
.	O
53	O
mg	O
dl	O
,	O
urea	O
80	O
mg	O
dl	O
,	O
Na	O
140	O
meq	O
l	O
K	O
4	O
.	O
8	O
meq	O
l	O
Hb	O
;	O
11	O
.	O
2	O
g	O
dl	O
,	O
Ht	O
35	O
.	O
5	O
,	O
leukocytosis	O
12	O
,	O
500	O
76	O
neutrophils	O
,	O
platelets	O
228000	O
.	O
INR	O
1	O
.	O
44	O
.	O
Serial	O
troponin	O
I	O
1	O
.	O
478	O
7	O
.	O
55	O
5	O
.	O
13	O
ng	O
ml	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
,	O
no	O
signs	O
of	O
vascular	O
redistribution	O
.	O
Control	O
ECG	O
RS	O
57	O
bpm	O
,	O
QR	O
wave	O
in	O
I	O
and	O
aVL	O
,	O
narrow	O
QRS	O
,	O
symmetrical	O
negative	O
T	O
wave	O
from	O
V2	O
to	O
V6	O
,	O
DI	O
,	O
DII	O
and	O
aVL	O
.	O
Coronary	O
angiography	O
coronary	O
arteries	O
without	O
significant	O
angiographic	O
lesions	O
.	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
,	O
hypertrophic	O
left	O
ventricle	O
,	O
moderately	O
depressed	O
systolic	O
function	O
EF	O
4C	O
40	O
,	O
with	O
anterolateral	O
mid	O
apical	O
akinesia	O
and	O
mid	O
lower	O
akinesia	O
and	O
hyperrefringence	O
with	O
hypertrabeculation	O
in	O
these	O
territories	O
.	O
Diastolic	O
pattern	O
of	O
impaired	O
relaxation	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
,	O
preserved	O
function	O
.	O
Dilated	O
left	O
atrium	O
.	O
Tricuspid	O
valve	O
with	O
mild	O
insufficiency	O
that	O
allows	O
estimating	O
PSAP	O
of	O
at	O
least	O
44	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
.	O
No	O
pericardial	O
effusion	O
.	O
No	O
evidence	O
of	O
intracardiac	O
masses	O
.	O
Admission	O
blood	O
tests	O
14	O
03	O
glucose	O
78	O
mg	O
dl	O
,	O
urate	O
4	O
.	O
93	O
mg	O
dl	O
,	O
urea	O
59	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
29	O
mg	O
dl	O
,	O
cholesterol	O
176	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
69	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
86	O
.	O
42	O
mg	O
dl	O
,	O
triglycerides	O
102	O
mg	O
dl	O
,	O
AST	O
30	O
U	O
L	O
,	O
ALT	O
14	O
U	O
L	O
,	O
GGT	O
30	O
U	O
L	O
,	O
sodium	O
144	O
.	O
0	O
mEq	O
L	O
,	O
potassium	O
4	O
.	O
9	O
mEq	O
L	O
.	O
CBC	O
haemoglobin	O
12	O
.	O
5	O
g	O
dl	O
,	O
haematocrit	O
40	O
.	O
0	O
,	O
leucocytes	O
8730	O
L	O
,	O
N	O
63	O
.	O
3	O
,	O
platelets	O
222000	O
L	O
.	O
Cardiac	O
MRI	O
dilated	O
LV	O
,	O
dyskinesia	O
of	O
anterior	O
,	O
anterior	O
lateral	O
,	O
infero	O
lateral	O
and	O
inferior	O
and	O
lateral	O
apical	O
midwall	O
segments	O
.	O
Hyperdynamia	O
of	O
the	O
rest	O
of	O
the	O
apical	O
cap	O
and	O
basal	O
segments	O
.	O
EF	O
40	O
.	O
Dilated	O
LA	O
.	O
Edema	O
in	O
the	O
middle	O
segments	O
of	O
the	O
anterior	O
wall	O
,	O
anterior	O
lateral	O
,	O
infero	O
lateral	O
and	O
inferior	O
and	O
lateral	O
apical	O
.	O
No	O
abnormalities	O
in	O
gadolinium	O
uptake	O
.	O
ID	O
study	O
compatible	O
with	O
tako	O
tsubo	O
syndrome	O
with	O
midventricular	O
involvement	O
.	O
EVOLUTION	O
On	O
admission	O
,	O
an	O
echocardiogram	O
was	O
performed	O
showing	O
hypertrophic	O
LV	O
with	O
moderately	O
depressed	O
systolic	O
function	O
with	O
mid	O
apical	O
anterolateral	O
akinesia	O
and	O
mid	O
lower	O
akinesia	O
and	O
hyperrefringence	O
.	O
Coronary	O
angiography	O
ruled	O
out	O
angiographically	O
visible	O
coronary	O
lesions	O
.	O
With	O
the	O
diagnosis	O
of	O
stress	O
cardiomyopathy	O
,	O
cardiac	O
MRI	O
was	O
requested	O
and	O
a	O
diagnosis	O
of	O
midventricular	O
tako	O
tsubo	O
syndrome	O
was	O
confirmed	O
.	O
She	O
was	O
discharged	O
home	O
and	O
a	O
month	O
later	O
,	O
after	O
a	O
repeat	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
an	O
improvement	O
in	O
the	O
segmental	O
alterations	O
.	O
DIAGNOSIS	O
Tako	O
tsubo	O
syndrome	O
with	O
midventricular	O
involvement	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
allergies	O
.	O
Several	O
episodes	O
of	O
rheumatic	O
fever	O
.	O
Present	O
illness	O
A	O
15	O
year	O
old	O
male	O
patient	O
from	O
Malawi	O
presented	O
with	O
moderate	O
exertional	O
dyspnoea	O
for	O
years	O
,	O
associated	O
with	O
asthenia	O
,	O
orthopnoea	O
and	O
some	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
,	O
with	O
progressive	O
worsening	O
of	O
his	O
functional	O
class	O
,	O
up	O
to	O
dyspnoea	O
on	O
slight	O
exertion	O
.	O
He	O
was	O
assessed	O
by	O
doctors	O
in	O
his	O
home	O
country	O
,	O
where	O
he	O
was	O
diagnosed	O
with	O
severe	O
mitral	O
stenosis	O
,	O
mild	O
mitral	O
insufficiency	O
,	O
severe	O
tricuspid	O
insufficiency	O
and	O
severe	O
pulmonary	O
hypertension	O
.	O
Due	O
to	O
clinical	O
worsening	O
and	O
the	O
impossibility	O
of	O
adequate	O
treatment	O
in	O
his	O
place	O
of	O
origin	O
,	O
he	O
was	O
transferred	O
to	O
Spain	O
by	O
an	O
NGO	O
for	O
the	O
corresponding	O
surgical	O
treatment	O
.	O
After	O
the	O
transfer	O
,	O
the	O
patient	O
presented	O
deterioration	O
of	O
his	O
usual	O
dyspnoea	O
with	O
dyspnoea	O
at	O
rest	O
,	O
concomitant	O
abdominal	O
pain	O
in	O
both	O
hypochondria	O
,	O
dyspepsia	O
and	O
several	O
episodes	O
of	O
emesis	O
after	O
food	O
intake	O
,	O
so	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
the	O
Paediatrics	O
Department	O
to	O
optimise	O
depletive	O
treatment	O
prior	O
to	O
surgical	O
treatment	O
.	O
Physical	O
examination	O
Weight	O
27	O
kg	O
BP	O
90	O
60	O
mmHg	O
,	O
HR	O
90	O
bpm	O
,	O
SO2	O
100	O
with	O
O2	B-FARMACO
.	O
Neck	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
R1	O
and	O
R2	O
rhythmic	O
and	O
regular	O
.	O
Intense	O
systolic	O
diastolic	O
murmur	O
in	O
mitral	O
focus	O
radiating	O
towards	O
the	O
axillary	O
region	O
.	O
Pulmonary	O
auscultation	O
bibasal	O
hypoventilation	O
,	O
more	O
marked	O
in	O
the	O
right	O
base	O
.	O
Abdomen	O
hepatomegaly	O
4	O
traveses	O
,	O
slightly	O
painful	O
on	O
palpation	O
in	O
the	O
right	O
and	O
left	O
hypochondrium	O
.	O
Splenomegaly	O
.	O
Extremities	O
symmetrical	O
,	O
without	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
haemogram	O
leucocytes	O
11	O
,	O
600	O
ul	O
.	O
Neutrophils	O
82	O
.	O
4	O
.	O
Monocytes	O
9	O
.	O
8	O
.	O
Lymphocytes	O
7	O
.	O
2	O
.	O
Hb	O
11	O
g	O
dl	O
.	O
Ht	O
33	O
.	O
5	O
.	O
Platelets	O
106	O
.	O
000	O
ul	O
.	O
Biochemistry	O
glucose	O
120	O
mg	O
dl	O
,	O
urea	O
34	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
5	O
mg	O
dl	O
,	O
Na	O
135	O
mEq	O
L	O
,	O
K	O
3	O
.	O
9	O
mEq	O
L	O
.	O
ECG	O
RS	O
at	O
92	O
bpm	O
,	O
p	O
wave	O
of	O
biatrial	O
growth	O
,	O
incomplete	O
BRD	O
HBPII	O
,	O
signs	O
of	O
hypertrophy	O
and	O
growth	O
of	O
right	O
cavities	O
,	O
Axis	O
deviated	O
to	O
the	O
right	O
,	O
ST	O
descent	O
of	O
1	O
mm	O
in	O
V3	O
V5	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
at	O
the	O
expense	O
of	O
the	O
right	O
chambers	O
,	O
fluid	O
in	O
cystole	O
.	O
Transthoracic	O
echocardiogram	O
situs	O
solidus	O
,	O
levocardia	O
with	O
levoápex	O
.	O
LVEF	O
65	O
.	O
Right	O
chambers	O
severely	O
dilated	O
.	O
RV	O
with	O
preserved	O
contractility	O
.	O
Severe	O
TR	O
due	O
to	O
lack	O
of	O
coaptation	O
of	O
the	O
leaflets	O
by	O
annular	O
dilatation	O
,	O
AD	O
VD	O
gradient	O
of	O
60	O
mmHg	O
.	O
PAPs	O
70	O
75mmHg	O
.	O
Mitral	O
valve	O
thickened	O
anterior	O
leaflet	O
,	O
domed	O
opening	O
and	O
anterior	O
displacement	O
of	O
the	O
posterior	O
leaflet	O
,	O
fused	O
commissures	O
,	O
mean	O
transmitral	O
gradient	O
of	O
16	O
mmHg	O
,	O
area	O
by	O
planimetry	O
of	O
4	O
mm	O
and	O
by	O
THP	O
of	O
0	O
.	O
75	O
cm2	O
.	O
Mild	O
MI	O
.	O
Dilated	O
IVC	O
.	O
Slight	O
pericardial	O
effusion	O
.	O
EVOLUTION	O
After	O
stabilisation	O
of	O
congestive	O
heart	O
failure	O
,	O
with	O
adequate	O
response	O
to	O
depletive	O
treatment	O
,	O
given	O
contraindication	O
to	O
treatment	O
with	O
balloon	O
valvuloplasty	O
due	O
to	O
great	O
valve	O
deconstruction	O
,	O
surgical	O
treatment	O
was	O
performed	O
with	O
replacement	O
of	O
the	O
mitral	O
valve	O
with	O
a	O
biological	O
prosthesis	O
,	O
plus	O
tricuspid	O
annuloplasty	O
.	O
In	O
the	O
initial	O
postoperative	O
phase	O
,	O
he	O
required	O
vasoactive	O
drugs	O
and	O
pulmonary	O
vasodilators	O
due	O
to	O
a	O
drop	O
in	O
BP	O
and	O
oliguria	O
,	O
with	O
haemodynamic	O
stabilisation	O
after	O
24	O
hours	O
.	O
He	O
was	O
transferred	O
to	O
the	O
paediatric	O
ward	O
from	O
where	O
he	O
was	O
discharged	O
on	O
the	O
eighth	O
day	O
.	O
Postoperative	O
echocardiographic	O
control	O
showed	O
a	O
normofunctioning	O
bioprosthesis	O
,	O
with	O
mean	O
gradient	O
of	O
3	O
mmHg	O
,	O
maximum	O
E	O
wave	O
of	O
15	O
mmHg	O
,	O
normofunctioning	O
LV	O
,	O
no	O
pericardial	O
effusion	O
,	O
mild	O
TR	O
.	O
DIAGNOSIS	O
Rheumatic	O
severe	O
mitral	O
stenosis	O
,	O
mild	O
mitral	O
regurgitation	O
.	O
Severe	O
tricuspid	O
regurgitation	O
.	O
Severe	O
pulmonary	O
hypertension	O
.	O
Congestive	O
heart	O
failure	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
15	O
year	O
old	O
male	O
patient	O
with	O
no	O
known	O
pathological	O
history	O
came	O
to	O
the	O
emergency	O
department	O
with	O
epigastralgia	O
,	O
anorexia	O
,	O
weight	O
loss	O
and	O
asthenia	O
of	O
one	O
month	O
's	O
duration	O
,	O
with	O
slight	O
swelling	O
of	O
the	O
lower	O
limbs	O
.	O
No	O
fever	O
or	O
other	O
associated	O
symptoms	O
,	O
no	O
chest	O
pain	O
.	O
The	O
anamnesis	O
revealed	O
that	O
he	O
had	O
been	O
practising	O
sport	O
regularly	O
until	O
2	O
months	O
ago	O
,	O
when	O
he	O
began	O
to	O
experience	O
fatigue	O
that	O
forced	O
him	O
to	O
reduce	O
his	O
exercise	O
load	O
,	O
nausea	O
with	O
abdominal	O
pain	O
,	O
and	O
loss	O
of	O
up	O
to	O
6	O
kg	O
in	O
the	O
last	O
two	O
months	O
.	O
Physical	O
examination	O
BP	O
96	O
61	O
mmHg	O
,	O
HR	O
120	O
bpm	O
,	O
RR	O
24	O
rmp	O
,	O
Sat	O
95	O
.	O
Regular	O
general	O
condition	O
,	O
tachypneic	O
,	O
afebrile	O
,	O
hydrated	O
.	O
Neurological	O
no	O
pathological	O
findings	O
.	O
Cardiorespiratory	O
rhythmic	O
heart	O
tones	O
,	O
systolic	O
murmur	O
II	O
VI	O
in	O
mitral	O
focus	O
.	O
Bibasal	O
crackles	O
.	O
Positive	O
hepatojugular	O
reflux	O
.	O
Abdomen	O
hepatomegaly	O
of	O
2	O
fingers	O
under	O
the	O
costal	O
ridge	O
.	O
Pain	O
on	O
palpation	O
in	O
the	O
epigastrium	O
.	O
Extremities	O
peripheral	O
pulses	O
present	O
and	O
symmetrical	O
.	O
Minimal	O
bimalleolar	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Emergency	O
analytical	O
tests	O
Hb	O
12	O
.	O
6	O
g	O
d	O
.	O
Leukocytes	O
14	O
,	O
000	O
u	O
L	O
.	O
Cr	O
1	O
.	O
37	O
mg	O
d	O
.	O
Urea	O
69	O
mg	O
dl	O
.	O
GOT	O
1145	O
U	O
L	O
.	O
GTP	O
1590	O
U	O
L	O
.	O
TnTUs	O
1	O
,	O
722	O
pg	O
ml	O
.	O
Venous	O
blood	O
gas	O
Ph	O
7	O
.	O
44	O
,	O
PCO2	O
35	O
mmHg	O
.	O
HCO3	O
26	O
mmol	O
L	O
.	O
Lactate	O
2	O
,	O
4	O
mmol	O
L	O
.	O
ECG	O
on	O
arrival	O
sinus	O
tachycardia	O
at	O
115	O
bpm	O
,	O
normal	O
PR	O
narrow	O
QRS	O
with	O
inverted	O
T	O
wave	O
on	O
lateral	O
side	O
.	O
Echocardiogram	O
dilated	O
left	O
ventricle	O
DTD	O
59	O
mm	O
with	O
thinned	O
walls	O
.	O
Severely	O
depressed	O
systolic	O
function	O
at	O
the	O
expense	O
of	O
global	O
hypokinesia	O
,	O
LVEF	O
19	O
.	O
Moderate	O
MI	O
of	O
functional	O
profile	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
normal	O
transvalvular	O
gradients	O
.	O
RV	O
slightly	O
dilated	O
,	O
with	O
TAPSE	O
of	O
9	O
mm	O
.	O
Trivial	O
TR	O
allowing	O
estimation	O
of	O
PAPs	O
of	O
45	O
mmHg	O
.	O
Slight	O
pericardial	O
effusion	O
.	O
IVC	O
of	O
19	O
mm	O
with	O
little	O
inspiratory	O
collapse	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
dilated	O
left	O
ventricle	O
LVEDV	O
139	O
ml	O
m2	O
with	O
decreased	O
wall	O
thickness	O
,	O
and	O
very	O
severe	O
depression	O
of	O
ventricular	O
function	O
,	O
LVEF	O
14	O
.	O
Right	O
ventricle	O
with	O
slightly	O
increased	O
volumes	O
RVOTV115	O
ml	O
m2	O
and	O
severely	O
decreased	O
systolic	O
function	O
,	O
RVEF	O
22	O
.	O
Absence	O
of	O
oedema	O
in	O
STIR	O
sequences	O
.	O
First	O
pass	O
perfusion	O
dimeglumine	O
gadobenate	O
at	O
rest	O
normal	O
.	O
Late	O
multifocal	O
contrast	O
uptake	O
,	O
intramyocardial	O
and	O
epicardial	O
,	O
circumferential	O
throughout	O
the	O
LV	O
.	O
In	O
conclusion	O
DCM	O
with	O
very	O
severe	O
depression	O
of	O
biventricular	O
function	O
secondary	O
to	O
extensive	O
myocardial	O
fibrosis	O
.	O
EVOLUTION	O
After	O
initial	O
examinations	O
in	O
the	O
emergency	O
department	O
and	O
bedside	O
echocardiography	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
for	O
further	O
study	O
and	O
treatment	O
,	O
where	O
CMR	O
was	O
requested	O
,	O
confirming	O
the	O
echocardiographic	O
findings	O
,	O
showing	O
no	O
myocardial	O
oedema	O
and	O
extensive	O
fibrosis	O
with	O
absence	O
of	O
viability	O
.	O
In	O
view	O
of	O
these	O
results	O
,	O
and	O
with	O
the	O
suspicion	O
of	O
possible	O
evolved	O
myocarditis	O
,	O
under	O
optimal	O
medical	O
treatment	O
,	O
which	O
included	O
ACE	O
inhibitors	O
,	O
beta	O
blockers	O
,	O
loop	B-FARMACO
diuretics	I-FARMACO
and	O
antialdosterone	B-FARMACO
drugs	I-FARMACO
,	O
the	O
referral	O
hospital	O
was	O
contacted	O
to	O
assess	O
cardiac	O
transplantation	O
.	O
Simultaneously	O
,	O
the	O
patient	O
presented	O
progressive	O
haemodynamic	O
deterioration	O
,	O
with	O
symptoms	O
of	O
persistent	O
heart	O
failure	O
,	O
increased	O
lactate	O
and	O
other	O
signs	O
of	O
peripheral	O
hypoperfusion	O
,	O
so	O
vasoactive	O
drugs	O
were	O
started	O
,	O
which	O
were	O
regularly	O
tolerated	O
,	O
with	O
episodes	O
of	O
SMVT	O
from	O
the	O
start	O
of	O
treatment	O
,	O
as	O
well	O
as	O
levosimendan	B-FARMACO
perfusion	O
,	O
without	O
satisfactory	O
response	O
,	O
so	O
a	O
Levitronix	O
Centrimag	O
type	O
ventricular	O
assist	O
device	O
was	O
implanted	O
via	O
the	O
left	O
subclavian	O
artery	O
,	O
pending	O
cardiac	O
transplantation	O
.	O
Finally	O
,	O
orthotopic	O
transplantation	O
was	O
performed	O
using	O
the	O
bicava	O
technique	O
,	O
with	O
adequate	O
graft	O
functioning	O
during	O
the	O
postoperative	O
period	O
.	O
Extubated	O
during	O
the	O
first	O
24	O
hours	O
after	O
surgery	O
.	O
Post	O
transplant	O
echocardiogram	O
showed	O
good	O
LV	O
function	O
LVEF	O
66	O
,	O
slightly	O
decreased	O
TAPSE	O
15	O
mm	O
,	O
absence	O
of	O
valve	O
disease	O
and	O
minimal	O
pericardial	O
effusion	O
.	O
Currently	O
,	O
6	O
months	O
post	O
transplant	O
,	O
the	O
patient	O
has	O
remained	O
asymptomatic	O
,	O
since	O
discharge	O
with	O
immunosuppressive	O
treatment	O
with	O
corticosteroids	O
,	O
mycophenolate	B-FARMACO
mofetil	I-FARMACO
,	O
tacrolimus	B-FARMACO
,	O
atorvastatin	B-FARMACO
and	O
valganciclovir	B-FARMACO
after	O
detection	O
of	O
CMV	O
in	O
controls	O
.	O
Coronary	O
angiography	O
with	O
OCT	O
showed	O
no	O
intimal	O
proliferation	O
,	O
and	O
endomyocardial	O
biopsies	O
showed	O
no	O
rejection	O
.	O
DIAGNOSIS	O
Non	O
ischemic	O
DCM	O
,	O
with	O
very	O
severe	O
depression	O
of	O
biventricular	O
function	O
.	O
Cardiogenic	O
shock	O
.	O
Cardiac	O
transplantation	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
42	O
year	O
old	O
female	O
patient	O
,	O
active	O
smoker	O
as	O
the	O
only	O
cardiovascular	O
risk	O
factor	O
15	O
cigarettes	O
day	O
since	O
adolescence	O
,	O
with	O
no	O
personal	O
or	O
family	O
cardiological	O
history	O
prior	O
to	O
this	O
event	O
.	O
On	O
the	O
night	O
of	O
admission	O
,	O
at	O
around	O
21	O
00	O
hours	O
and	O
at	O
rest	O
at	O
home	O
,	O
she	O
began	O
with	O
oppressive	O
central	O
thoracic	O
pain	O
,	O
discomfort	O
in	O
the	O
left	O
upper	O
limb	O
and	O
marked	O
vegetative	O
cortex	O
emesis	O
,	O
diaphoresis	O
and	O
persistent	O
nausea	O
.	O
Half	O
an	O
hour	O
after	O
the	O
onset	O
of	O
the	O
symptoms	O
,	O
she	O
decided	O
to	O
call	O
061	O
who	O
,	O
on	O
arrival	O
at	O
her	O
home	O
,	O
performed	O
an	O
electrocardiogram	O
showing	O
ST	O
elevation	O
in	O
the	O
anterior	O
face	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
the	O
haemodynamics	O
department	O
was	O
contacted	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
our	O
hospital	O
for	O
emergency	O
coronary	O
angiography	O
.	O
Coronary	O
angiography	O
was	O
performed	O
,	O
showing	O
dissection	O
of	O
the	O
LAD	O
from	O
its	O
proximal	O
segment	O
along	O
its	O
entire	O
length	O
with	O
initial	O
TIMI	O
2	O
flow	O
dominant	O
RCA	O
and	O
RCA	O
without	O
lesions	O
.	O
After	O
successive	O
contrast	O
injections	O
,	O
the	O
flow	O
in	O
the	O
LAD	O
and	O
diagonal	O
improved	O
,	O
and	O
conservative	O
management	O
was	O
chosen	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
a	O
monitored	O
unit	O
in	O
Cardiology	O
to	O
continue	O
her	O
evolution	O
.	O
On	O
arrival	O
the	O
patient	O
was	O
haemodynamically	O
stable	O
BP	O
110	O
60	O
,	O
HR	O
80	O
bpm	O
,	O
SatO2	O
98	O
with	O
nasal	O
goggles	O
at	O
2	O
l	O
min	O
.	O
Afebrile	O
.	O
Physical	O
examination	O
was	O
unremarkable	O
with	O
no	O
systemic	O
pulmonary	O
congestive	O
semiology	O
or	O
low	O
output	O
.	O
Clinically	O
,	O
she	O
persisted	O
with	O
slight	O
retrosternal	O
discomfort	O
that	O
gradually	O
disappeared	O
in	O
the	O
hours	O
following	O
catheterisation	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
glucose	O
106	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
51	O
mg	O
dl	O
.	O
Urea	O
24	O
mg	O
dl	O
.	O
Sodium	O
142	O
mEq	O
l	O
.	O
Potassium	O
4	O
.	O
4	O
mEq	O
litre	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
146	O
mg	O
dl	O
.	O
LDL	O
Col	O
37	O
mg	O
dl	O
.	O
LDL	O
Col	O
88	O
mg	O
dl	O
.	O
Triglycerides	O
106	O
mg	O
dl	O
.	O
Normal	O
liver	O
and	O
thyroid	O
profile	O
.	O
Glycated	O
Hb	O
5	O
.	O
2	O
.	O
Peak	O
TNTUs	O
9613	O
ng	O
dl	O
.	O
Peak	O
CPK	O
3219	O
mg	O
dl	O
.	O
Rheumatoid	O
factor	O
,	O
CRP	O
,	O
ESR	O
,	O
ESR	O
,	O
proteinogram	O
,	O
complement	O
,	O
ACE	O
,	O
microalbumimuria	O
and	O
normal	O
hormonal	O
study	O
.	O
Initial	O
leukocytosis	O
predominance	O
of	O
polymorphonuclear	O
cells	O
which	O
subsequently	O
normalised	O
.	O
Hb	O
14	O
g	O
dl	O
.	O
Platelets	O
349	O
,	O
000	O
.	O
ANA	O
and	O
ANCA	O
negative	O
.	O
Electrocardiograms	O
061	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
.	O
Normal	O
axis	O
normal	O
PR	O
normal	O
.	O
Narrow	O
QRS	O
with	O
minimal	O
R	O
to	O
V4	O
with	O
ST	O
elevation	O
from	O
V2	O
V6	O
up	O
to	O
4	O
mm	O
in	O
V4	O
.	O
Minimal	O
lateral	O
upstroke	O
and	O
ST	O
rectified	O
in	O
AvR	O
.	O
At	O
discharge	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
.	O
Normal	O
axis	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QSR	O
with	O
QS	O
from	O
V1	O
V4	O
.	O
Flattened	O
T	O
waves	O
in	O
frontal	O
plane	O
leads	O
.	O
Catheterisation	O
left	O
coronary	O
trunk	O
without	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
with	O
dissection	O
from	O
the	O
proximal	O
segment	O
affecting	O
its	O
entire	O
course	O
.	O
Double	O
descending	O
diagonal	O
system	O
.	O
Initial	O
TIMI	O
2	O
flow	O
.	O
Circumflex	O
artery	O
without	O
lesions	O
.	O
Dominant	O
right	O
coronary	O
artery	O
without	O
lesions	O
.	O
Successive	O
injections	O
of	O
contrast	O
were	O
repeated	O
with	O
improved	O
flow	O
in	O
the	O
LAD	O
and	O
diagonal	O
,	O
so	O
conservative	O
management	O
was	O
adopted	O
.	O
Echocardiography	O
at	O
discharge	O
LA	O
of	O
normal	O
size	O
27	O
mm	O
,	O
29	O
ml	O
m2	O
.	O
Normal	O
mitral	O
valve	O
.	O
LV	O
DTD	O
48	O
mm	O
,	O
VTD	O
107	O
ml	O
,	O
VTDi	O
71	O
ml	O
m2	O
.	O
EF	O
by	O
Simpson	O
biplane	O
36	O
.	O
Akinesia	O
of	O
the	O
apical	O
half	O
of	O
all	O
walls	O
.	O
No	O
mural	O
thrombus	O
seen	O
.	O
Septum	O
9	O
mm	O
and	O
inferolateral	O
wall	O
7	O
mm	O
.	O
Mitral	O
E	O
46	O
cm	O
sec	O
and	O
A	O
56	O
cm	O
sec	O
.	O
Normal	O
aortic	O
valve	O
.	O
Sinuses	O
of	O
Valsalva	O
32	O
mm	O
.	O
Non	O
dilated	O
right	O
chambers	O
with	O
good	O
RV	O
systolic	O
function	O
.	O
Mild	O
TR	O
with	O
normal	O
estimated	O
PAPS	O
.	O
Non	O
dilated	O
IVC	O
with	O
inspiratory	O
collapse	O
50	O
.	O
No	O
pericardial	O
effusion	O
Video	O
3	O
6	O
.	O
Angio	O
CT	O
of	O
renal	O
arteries	O
conclusions	O
kidneys	O
without	O
abnormalities	O
.	O
No	O
evidence	O
of	O
renal	O
stenosis	O
or	O
fibromuscular	O
dysplasia	O
.	O
Double	O
left	O
renal	O
artery	O
and	O
fine	O
calibre	O
supernumerary	O
artery	O
in	O
the	O
right	O
kidney	O
.	O
Ergometry	O
at	O
the	O
beginning	O
and	O
end	O
of	O
CRP	O
clinical	O
and	O
electrical	O
negatives	O
for	O
the	O
level	O
of	O
effort	O
reached	O
.	O
Adequate	O
blood	O
pressure	O
response	O
in	O
both	O
.	O
No	O
arrhythmic	O
events	O
.	O
Start	O
final	O
functional	O
capacity	O
10	O
13	O
METS	O
,	O
start	O
final	O
exercise	O
time	O
9	O
min	O
12	O
min	O
and	O
start	O
final	O
heart	O
rate	O
recovery	O
rate	O
17	O
bpm	O
30	O
bpm	O
.	O
EVOLUTION	O
Once	O
the	O
diagnosis	O
was	O
known	O
,	O
the	O
patient	O
was	O
re	O
historised	O
,	O
orienting	O
the	O
anamnesis	O
towards	O
the	O
search	O
for	O
risk	O
factors	O
related	O
to	O
this	O
entity	O
.	O
The	O
patient	O
was	O
an	O
active	O
smoker	O
,	O
smoking	O
having	O
been	O
related	O
to	O
this	O
pathology	O
by	O
facilitating	O
endothelial	O
damage	O
.	O
She	O
had	O
previously	O
taken	O
oral	O
contraceptives	O
and	O
had	O
been	O
using	O
an	O
intrauterine	O
device	O
IUD	O
as	O
a	O
contraceptive	O
measure	O
for	O
two	O
years	O
.	O
The	O
pregnancy	O
test	O
performed	O
during	O
admission	O
was	O
negative	O
.	O
She	O
did	O
not	O
remember	O
having	O
exercised	O
more	O
than	O
usual	O
during	O
the	O
previous	O
days	O
.	O
She	O
did	O
report	O
emotional	O
stress	O
the	O
previous	O
week	O
in	O
relation	O
to	O
her	O
daughters	O
'	O
school	O
problems	O
.	O
She	O
had	O
no	O
symptoms	O
compatible	O
with	O
connective	O
,	O
autoimmune	O
,	O
rheumatological	O
or	O
systemic	O
inflammatory	O
diseases	O
.	O
A	O
blood	O
test	O
was	O
performed	O
with	O
a	O
lipid	O
,	O
thyroid	O
and	O
liver	O
profile	O
with	O
no	O
notable	O
alterations	O
.	O
An	O
autoimmunity	O
study	O
was	O
requested	O
rheumatoid	O
factor	O
,	O
CRP	O
,	O
ESR	O
,	O
immunogluilins	O
,	O
complement	O
,	O
ACE	O
,	O
hormonal	O
study	O
and	O
antiphospholipid	O
antibodies	O
,	O
which	O
were	O
normal	O
.	O
Angio	O
CT	O
of	O
the	O
renal	O
arteries	O
was	O
negative	O
for	O
renal	O
stenosis	O
and	O
showed	O
no	O
data	O
suggesting	O
fibromuscular	O
dysplasia	O
.	O
The	O
patient	O
presented	O
a	O
favourable	O
clinical	O
evolution	O
during	O
her	O
admission	O
.	O
Echocardiography	O
showed	O
akinesia	O
of	O
the	O
entire	O
apical	O
territory	O
without	O
mural	O
thrombus	O
and	O
the	O
ejection	O
fraction	O
EF	O
was	O
moderately	O
depressed	O
Simpson	O
biplane	O
36	O
.	O
After	O
clinical	O
improvement	O
and	O
optimisation	O
of	O
medical	O
treatment	O
she	O
was	O
discharged	O
home	O
with	O
double	O
antiplatelet	O
therapy	O
.	O
The	O
patient	O
was	O
referred	O
to	O
the	O
cardiac	O
rehabilitation	O
programme	O
CRP	O
of	O
our	O
hospital	O
,	O
and	O
was	O
included	O
in	O
the	O
high	O
risk	O
group	O
20	O
sessions	O
.	O
She	O
completed	O
the	O
programme	O
without	O
incident	O
and	O
with	O
good	O
adherence	O
.	O
Prognostic	O
ergometry	O
showed	O
improvement	O
in	O
functional	O
capacity	O
10	O
13	O
METS	O
,	O
exercise	O
time	O
9	O
min	O
12	O
min	O
and	O
heart	O
rate	O
recovery	O
rate	O
17	O
bpm	O
30	O
bpm	O
.	O
Echocardiography	O
at	O
the	O
end	O
of	O
the	O
programme	O
showed	O
improvement	O
in	O
EF	O
,	O
with	O
mild	O
dysfunction	O
LVEF	O
49	O
.	O
Finally	O
,	O
he	O
has	O
been	O
periodically	O
reviewed	O
by	O
Internal	O
Medicine	O
,	O
which	O
establishes	O
that	O
at	O
the	O
present	O
time	O
there	O
are	O
no	O
clinical	O
biological	O
data	O
of	O
autoimmune	O
disease	O
or	O
phenotype	O
data	O
of	O
collagenopathy	O
.	O
DIAGNOSIS	O
Anterior	O
STEACS	O
secondary	O
to	O
spontaneous	O
coronary	O
artery	O
dissection	O
of	O
LAD	O
.	O
Akinesia	O
of	O
apical	O
segments	O
with	O
moderate	O
LV	O
dysfunction	O
at	O
discharge	O
LVEF	O
36	O
.	O
Negative	O
autoimmunity	O
collagenopathy	O
study	O
.	O
Completion	O
of	O
cardiac	O
rehabilitation	O
programme	O
with	O
improvement	O
in	O
functional	O
capacity	O
and	O
partial	O
recovery	O
of	O
LVEF	O
after	O
CRP	O
49	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
32	O
year	O
old	O
woman	O
.	O
AF	O
deceased	O
sister	O
with	O
tetralogy	O
of	O
Fallot	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
CVRF	O
smoker	O
.	O
Cardiological	O
history	O
acute	O
myopericarditis	O
in	O
1999	O
after	O
respiratory	O
infection	O
.	O
In	O
2003	O
,	O
residual	O
pericardial	O
effusion	O
persisted	O
in	O
the	O
diaphragmatic	O
and	O
apical	O
face	O
of	O
both	O
ventricles	O
.	O
Echocardiogram	O
showed	O
data	O
compatible	O
with	O
restrictive	O
cardiomyopathy	O
,	O
confirmed	O
by	O
haemodynamic	O
study	O
in	O
2004	O
.	O
Coronary	O
arteries	O
without	O
lesions	O
.	O
Admission	O
in	O
2012	O
for	O
decompensated	O
heart	O
failure	O
in	O
the	O
context	O
of	O
a	O
postoperative	O
period	O
,	O
with	O
good	O
evolution	O
with	O
diuretics	O
.	O
New	O
episode	O
in	O
2016	O
that	O
was	O
managed	O
on	O
an	O
outpatient	O
basis	O
with	O
diuretics	O
.	O
No	O
other	O
personal	O
medical	O
history	O
of	O
interest	O
.	O
Pilonidal	O
sinus	O
operation	O
in	O
2012	O
.	O
Baseline	O
situation	O
CF	O
II	O
.	O
Usual	O
treatment	O
seguril	B-FARMACO
40	O
mg	O
3	O
1	O
0	O
,	O
aldactone	B-FARMACO
100	O
mg	O
1	O
0	O
0	O
0	O
,	O
hygrotona	B-FARMACO
25	O
mg	O
1	O
0	O
0	O
0	O
,	O
Boi	B-FARMACO
K	I-FARMACO
1	O
1	O
1	O
.	O
Present	O
illness	O
32	O
year	O
old	O
woman	O
presenting	O
with	O
progressive	O
worsening	O
over	O
the	O
last	O
8	O
months	O
with	O
moderate	O
to	O
mild	O
exertional	O
dyspnoea	O
.	O
She	O
has	O
had	O
to	O
progressively	O
increase	O
the	O
dose	O
of	O
diuretics	O
to	O
control	O
dyspnoea	O
and	O
abdominal	O
distension	O
.	O
Occasionally	O
DPN	O
.	O
Orthopnoea	O
on	O
2	O
pillows	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
Feeling	O
of	O
tiredness	O
and	O
fatigue	O
.	O
Normal	O
or	O
low	O
blood	O
pressure	O
.	O
And	O
on	O
some	O
occasions	O
dizziness	O
due	O
to	O
hypotension	O
.	O
No	O
syncope	O
.	O
Occasionally	O
palpitations	O
of	O
short	O
duration	O
,	O
generally	O
nocturnal	O
.	O
No	O
chest	O
or	O
abdominal	O
pain	O
.	O
Physical	O
examination	O
BP	O
105	O
78	O
.	O
HR	O
75	O
bpm	O
.	O
Jugular	O
ingurgitation	O
.	O
AP	O
normal	O
.	O
AC	O
rhythmic	O
.	O
No	O
extrasystoles	O
.	O
No	O
murmurs	O
or	O
pericardial	O
knock	O
.	O
Abdomen	O
hepatomegaly	O
three	O
traves	O
.	O
Extremities	O
no	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
on	O
admission	O
haemogram	O
normal	O
.	O
Biochemistry	O
glucose	O
97	O
mg	O
dl	O
.	O
Cholesterol	O
138	O
mg	O
dl	O
.	O
HDL	O
46	O
mg	O
dl	O
.	O
LDL	O
80	O
mg	O
dl	O
.	O
Triglycerides	O
63	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
65	O
mg	O
dl	O
.	O
Urea	O
52	O
mg	O
dl	O
.	O
Uric	O
acid	O
7	O
.	O
1	O
mg	O
dl	O
.	O
Na	O
135	O
mEq	O
L	O
.	O
K	O
3	O
.	O
5	O
mEq	O
L	O
.	O
Cl	O
96	O
mEq	O
L	O
.	O
GOT	O
29	O
IU	O
L	O
.	O
GPT	O
16	O
IU	O
L	O
.	O
LDH	O
198	O
mg	O
dL	O
.	O
GGT	O
236	O
IU	O
L	O
.	O
Bilirubin	O
0	O
,	O
97	O
mg	O
dL	O
.	O
Amylase	O
113	O
IU	O
L	O
.	O
CPK	O
53	O
.	O
Protein	O
7	O
.	O
5	O
g	O
dl	O
.	O
NT	O
proBNP	O
1077	O
ng	O
dl	O
.	O
Chest	O
X	O
ray	O
mild	O
cardiomegaly	O
at	O
the	O
expense	O
of	O
left	O
atrial	O
and	O
right	O
ventricular	O
enlargement	O
.	O
Dilatation	O
of	O
the	O
inferior	O
vena	O
cava	O
.	O
Normal	O
lung	O
parenchyma	O
.	O
Pericardial	O
calcification	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
91	O
bpm	O
.	O
PR	O
0	O
.	O
14	O
.	O
Biauricular	O
growth	O
.	O
Negative	O
T	O
in	O
V3	O
V6	O
,	O
II	O
,	O
III	O
and	O
aVF	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
42	O
24	O
mm	O
.	O
Septum	O
7	O
mm	O
.	O
Posterior	O
wall	O
8	O
mm	O
.	O
Aortic	O
root	O
25	O
mm	O
.	O
Left	O
atrium	O
45	O
mm	O
.	O
Shortening	O
fraction	O
42	O
.	O
Left	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Ejection	O
fraction	O
70	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Severe	O
dilatation	O
of	O
the	O
left	O
atrium	O
and	O
moderate	O
dilatation	O
of	O
the	O
right	O
atrium	O
.	O
Coronary	O
sinus	O
dilatation	O
.	O
Aneurysm	O
of	O
the	O
interatrial	O
septum	O
.	O
Thickened	O
myxoid	O
mitral	O
valve	O
with	O
mild	O
insufficiency	O
.	O
Tricuspid	O
valve	O
with	O
mild	O
insufficiency	O
and	O
pulmonary	O
pressure	O
of	O
40	O
mmHg	O
.	O
Normal	O
aortic	O
valve	O
.	O
Inferior	O
cava	O
34	O
mm	O
without	O
respiratory	O
changes	O
.	O
Slight	O
pericardial	O
effusion	O
in	O
the	O
acute	O
angle	O
of	O
the	O
heart	O
.	O
Posterior	O
and	O
inferior	O
pericardial	O
calcification	O
.	O
No	O
respiratory	O
changes	O
in	O
ventricular	O
filling	O
or	O
hepatic	O
vein	O
flow	O
.	O
Only	O
the	O
interventricular	O
septum	O
shows	O
small	O
respiratory	O
changes	O
in	O
the	O
diameter	O
of	O
the	O
right	O
ventricle	O
with	O
inspiration	O
suggesting	O
constrictive	O
pathology	O
.	O
Tissue	O
Doppler	O
shows	O
diastolic	O
velocities	O
with	O
a	O
restrictive	O
filling	O
pattern	O
in	O
both	O
ventricles	O
and	O
an	O
E	O
E	O
ratio	O
3	O
Haemodynamic	O
study	O
PVI	O
120	O
0	O
20	O
mmHg	O
.	O
PAo	O
120	O
80	O
mmHg	O
.	O
PVD	O
40	O
10	O
20	O
mmHg	O
.	O
Mean	O
DBP	O
20	O
mmHg	O
.	O
BP	O
40	O
18	O
25	O
mmHg	O
.	O
Mean	O
PCP	O
20	O
mmHg	O
.	O
Equal	O
right	O
and	O
left	O
end	O
diastolic	O
pressures	O
.	O
LV	O
and	O
RV	O
diastolic	O
pressure	O
with	O
dip	O
plateau	O
morphology	O
and	O
without	O
reciprocal	O
respiratory	O
changes	O
,	O
only	O
with	O
inspiration	O
a	O
decrease	O
in	O
LV	O
pressure	O
10	O
is	O
observed	O
.	O
Oximetry	O
SVC	O
63	O
,	O
RV	O
65	O
,	O
PA	O
63	O
,	O
LV	O
96	O
,	O
Ao	O
96	O
.	O
CO	O
Fick	O
2	O
.	O
5	O
l	O
min	O
.	O
IC	O
Fick	O
1	O
.	O
8	O
l	O
min	O
.	O
PVR	O
2	O
UW	O
.	O
Indexed	O
PVR	O
2	O
.	O
7	O
UW	O
.	O
m2	O
SVR	O
29	O
UW	O
.	O
Coronary	O
angiography	O
normal	O
coronary	O
arteries	O
.	O
Pericardial	O
calcification	O
predominantly	O
at	O
the	O
apico	O
inferior	O
level	O
.	O
Conclusion	O
high	O
and	O
equal	O
right	O
and	O
left	O
end	O
diastolic	O
pressures	O
.	O
Dip	O
plateau	O
pressure	O
in	O
both	O
ventricles	O
.	O
No	O
reciprocal	O
respiratory	O
changes	O
,	O
which	O
is	O
suggestive	O
of	O
predominant	O
myocardial	O
restriction	O
.	O
Ergospirometry	O
performed	O
on	O
a	O
cycle	O
ergometer	O
with	O
a	O
power	O
increase	O
of	O
15	O
W	O
min	O
.	O
Duration	O
of	O
effort	O
5	O
10	O
"	O
.	O
Peak	O
O2	O
consumption	O
14	O
.	O
7	O
ml	O
kg	O
min	O
predicted	O
36	O
.	O
2	O
ml	O
kg	O
min	O
.	O
Ventilatory	O
CO2	O
equivalent	O
25	O
.	O
0	O
.	O
Anaerobic	O
threshold	O
7	O
.	O
9	O
ml	O
kg	O
min	O
.	O
Functional	O
grade	O
III	O
.	O
O2	O
consumption	O
is	O
41	O
of	O
its	O
theoretical	O
value	O
.	O
Cardiac	O
CT	O
Agatston	O
score	O
0	O
.	O
Epicardial	O
coronary	O
arteries	O
without	O
lesions	O
.	O
Intense	O
concentric	O
calcification	O
of	O
the	O
pericardium	O
with	O
severe	O
involvement	O
of	O
the	O
free	O
wall	O
of	O
the	O
right	O
ventricle	O
,	O
diaphragmatic	O
face	O
of	O
both	O
ventricles	O
and	O
isolated	O
foci	O
and	O
lateral	O
face	O
of	O
the	O
left	O
ventricle	O
.	O
There	O
are	O
also	O
areas	O
of	O
calcification	O
in	O
front	O
of	O
the	O
root	O
of	O
the	O
great	O
vessels	O
.	O
The	O
greatest	O
calcification	O
is	O
at	O
the	O
level	O
of	O
the	O
free	O
wall	O
of	O
the	O
right	O
ventricle	O
with	O
thicknesses	O
between	O
5	O
and	O
10	O
mm	O
.	O
Aneurysmal	O
inferior	O
vena	O
cava	O
with	O
a	O
diameter	O
of	O
60	O
x	O
57	O
mm	O
.	O
Dilatation	O
of	O
suprahepatic	O
veins	O
.	O
Ventricular	O
cavities	O
apparently	O
of	O
normal	O
size	O
.	O
At	O
the	O
level	O
of	O
the	O
apex	O
of	O
the	O
right	O
ventricle	O
within	O
the	O
thickness	O
of	O
the	O
pericardial	O
fat	O
there	O
is	O
an	O
area	O
of	O
contrast	O
extravasation	O
of	O
10	O
x	O
9	O
mm	O
which	O
could	O
be	O
a	O
pseudoaneurysm	O
of	O
the	O
right	O
ventricular	O
apex	O
.	O
Aneurysm	O
of	O
the	O
interatrial	O
septum	O
.	O
Severe	O
dilatation	O
of	O
the	O
left	O
atrium	O
and	O
moderate	O
dilatation	O
of	O
the	O
right	O
atrium	O
.	O
Pulmonary	O
parenchyma	O
without	O
significant	O
alterations	O
.	O
Cardiac	O
MRI	O
left	O
ventricular	O
ejection	O
fraction	O
66	O
.	O
Concentric	O
calcified	O
thickening	O
of	O
the	O
pericardium	O
being	O
more	O
important	O
at	O
the	O
level	O
of	O
the	O
free	O
wall	O
of	O
the	O
right	O
ventricle	O
.	O
Dilatation	O
of	O
both	O
atria	O
.	O
Aneurysm	O
of	O
the	O
interatrial	O
septum	O
.	O
Normal	O
global	O
and	O
segmental	O
contractility	O
of	O
the	O
left	O
ventricle	O
.	O
Dyskinetic	O
movement	O
of	O
the	O
interventricular	O
septum	O
.	O
Good	O
right	O
ventricular	O
function	O
.	O
Small	O
pericardial	O
effusion	O
in	O
inferior	O
aspect	O
.	O
In	O
the	O
late	O
enhancement	O
sequences	O
no	O
pathological	O
uptakes	O
were	O
observed	O
.	O
EVOLUTION	O
A	O
32	O
year	O
old	O
woman	O
with	O
a	O
diagnosis	O
of	O
restrictive	O
cardiomyopathy	O
was	O
admitted	O
due	O
to	O
worsening	O
heart	O
failure	O
despite	O
outpatient	O
intensification	O
of	O
diuretics	O
.	O
During	O
admission	O
,	O
a	O
new	O
echocardiogram	O
was	O
performed	O
,	O
which	O
showed	O
data	O
compatible	O
with	O
myocardial	O
restriction	O
,	O
although	O
with	O
signs	O
suggestive	O
of	O
a	O
constrictive	O
component	O
.	O
To	O
better	O
characterise	O
the	O
restrictive	O
and	O
constrictive	O
components	O
,	O
a	O
CT	O
scan	O
and	O
cardiac	O
MRI	O
were	O
performed	O
,	O
which	O
showed	O
intense	O
calcification	O
of	O
the	O
pericardium	O
,	O
especially	O
at	O
the	O
RV	O
level	O
with	O
myocardial	O
infiltration	O
at	O
that	O
level	O
,	O
and	O
preserved	O
biventricular	O
function	O
without	O
pathological	O
enhancements	O
.	O
The	O
diagnosis	O
of	O
constrictive	O
pericarditis	O
was	O
therefore	O
confirmed	O
,	O
probably	O
in	O
relation	O
to	O
the	O
history	O
of	O
acute	O
myopericarditis	O
in	O
adolescence	O
.	O
She	O
improved	O
clinically	O
and	O
was	O
discharged	O
with	O
the	O
following	O
treatment	O
seguril	B-FARMACO
2	O
1	O
0	O
,	O
aldactone	B-FARMACO
25	O
mg	O
1	O
2	O
0	O
;	O
boi	O
k	O
1	O
1	O
1	O
.	O
Subsequently	O
,	O
an	O
outpatient	O
haemodynamic	O
study	O
was	O
also	O
performed	O
,	O
with	O
epicardial	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
,	O
and	O
right	O
catheterisation	O
showing	O
increased	O
and	O
equalised	O
right	O
and	O
left	O
end	O
diastolic	O
pressures	O
,	O
with	O
no	O
reciprocal	O
respiratory	O
changes	O
.	O
The	O
catheterisation	O
data	O
suggested	O
a	O
predominance	O
of	O
myocardial	O
restriction	O
,	O
but	O
given	O
the	O
findings	O
in	O
the	O
imaging	O
tests	O
,	O
it	O
was	O
decided	O
to	O
present	O
the	O
patient	O
for	O
a	O
medical	O
surgical	O
session	O
to	O
consider	O
pericardiectomy	O
,	O
which	O
was	O
finally	O
rejected	O
due	O
to	O
intense	O
intramyocardial	O
calcification	O
,	O
anatomically	O
limiting	O
the	O
possibilities	O
of	O
a	O
complete	O
pericardial	O
resection	O
surgery	O
.	O
Given	O
the	O
poor	O
clinical	O
evolution	O
with	O
the	O
need	O
for	O
increased	O
diuretics	O
and	O
the	O
impossibility	O
of	O
pericardiectomy	O
,	O
it	O
was	O
decided	O
to	O
refer	O
the	O
patient	O
to	O
a	O
heart	O
transplant	O
centre	O
.	O
She	O
had	O
given	O
up	O
smoking	O
and	O
was	O
being	O
treated	O
with	O
furosemide	B-FARMACO
40	O
mg	O
4	O
tablets	O
a	O
day	O
,	O
aldactone	B-FARMACO
100	O
mg	O
a	O
day	O
,	O
hygrotona	B-FARMACO
25	O
mg	O
a	O
day	O
and	O
potassium	B-FARMACO
2	O
tablets	O
every	O
8	O
hours	O
.	O
She	O
had	O
an	O
episode	O
of	O
atrial	O
fibrillation	O
,	O
and	O
was	O
started	O
on	O
anticoagulation	O
with	O
acenocoumarol	B-FARMACO
and	O
frequency	O
control	O
with	O
bisoprolol	B-FARMACO
5	O
mg	O
per	O
day	O
.	O
After	O
completing	O
the	O
pre	O
transplant	O
study	O
,	O
she	O
has	O
no	O
contraindications	O
and	O
is	O
currently	O
on	O
the	O
waiting	O
list	O
.	O
DIAGNOSIS	O
Constrictive	O
pericarditis	O
with	O
myocardial	O
restriction	O
component	O
due	O
to	O
myocardial	O
infiltration	O
.	O
Heart	O
failure	O
in	O
functional	O
class	O
iii	O
,	O
on	O
the	O
heart	O
transplant	O
list	O
.	O
Persistent	O
atrial	O
fibrillation	O
,	O
with	O
heart	O
rate	O
control	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
19	O
year	O
old	O
patient	O
with	O
a	O
history	O
of	O
Friedreich	O
's	O
ataxia	O
under	O
follow	O
up	O
by	O
Neurology	O
.	O
The	O
patient	O
is	O
wheelchair	O
bound	O
and	O
partially	O
dependent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
.	O
Non	O
obstructive	O
hypertrophic	O
cardiomyopathy	O
.	O
Patient	O
with	O
usual	O
NYHA	O
functional	O
class	O
I	O
.	O
On	O
medical	O
treatment	O
with	O
enalapril	B-FARMACO
5	O
mg	O
every	O
24	O
hours	O
.	O
The	O
last	O
echocardiogram	O
performed	O
in	O
November	O
2016	O
showed	O
left	O
ventricle	O
LV	O
of	O
normal	O
dimensions	O
with	O
LVEF	O
72	O
.	O
Severe	O
LVH	O
with	O
no	O
obstruction	O
.	O
Normal	O
right	O
chambers	O
.	O
Normal	O
aortic	O
and	O
mitral	O
valve	O
.	O
Restrictive	O
diastolic	O
pattern	O
.	O
Current	O
illness	O
The	O
patient	O
was	O
admitted	O
to	O
a	O
regional	O
hospital	O
for	O
presenting	O
in	O
the	O
last	O
5	O
days	O
with	O
a	O
general	O
malaise	O
associated	O
with	O
repeated	O
nausea	O
and	O
vomiting	O
.	O
No	O
fever	O
was	O
reported	O
.	O
Oral	O
rehydration	O
and	O
antiemetic	O
treatment	O
was	O
started	O
without	O
improvement	O
.	O
Subsequently	O
,	O
she	O
developed	O
hyporexia	O
with	O
minimal	O
food	O
intake	O
,	O
generalised	O
weakness	O
and	O
a	O
severe	O
dry	O
cough	O
.	O
On	O
arrival	O
at	O
the	O
regional	O
hospital	O
,	O
the	O
patient	O
reported	O
abdominal	O
pain	O
that	O
was	O
difficult	O
to	O
locate	O
and	O
an	O
electrocardiogram	O
was	O
performed	O
showing	O
signs	O
of	O
left	O
ventricular	O
hypertrophy	O
with	O
secondary	O
repolarisation	O
alterations	O
and	O
blood	O
tests	O
showed	O
elevated	O
markers	O
of	O
cardiac	O
necrosis	O
.	O
With	O
this	O
finding	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
our	O
hospital	O
for	O
urgent	O
assessment	O
by	O
Cardiology	O
.	O
In	O
our	O
first	O
assessment	O
,	O
the	O
patient	O
was	O
in	O
poor	O
general	O
condition	O
,	O
with	O
a	O
difficult	O
anamnesis	O
due	O
to	O
lack	O
of	O
cooperation	O
.	O
He	O
reported	O
no	O
chest	O
pain	O
,	O
only	O
cough	O
and	O
abdominal	O
discomfort	O
.	O
At	O
rest	O
the	O
patient	O
had	O
slight	O
dyspnoea	O
,	O
with	O
no	O
increase	O
in	O
the	O
work	O
of	O
breathing	O
.	O
Physical	O
examination	O
Vital	O
signs	O
BP	O
93	O
56	O
,	O
HR	O
125	O
bpm	O
,	O
O2	O
saturation	O
97	O
with	O
FIO2	O
of	O
24	O
,	O
Temperature	O
36	O
.	O
5	O
C	O
.	O
Patient	O
conscious	O
and	O
oriented	O
.	O
Neurological	O
examination	O
limited	O
by	O
underlying	O
disease	O
and	O
by	O
the	O
patient	O
being	O
in	O
dorsal	O
decubitus	O
,	O
however	O
,	O
no	O
changes	O
with	O
respect	O
to	O
previous	O
state	O
,	O
no	O
focality	O
.	O
Neck	O
without	O
jugular	O
ingurgitation	O
.	O
Pulmonary	O
auscultation	O
with	O
hypoventilation	O
and	O
crackles	O
at	O
the	O
base	O
of	O
the	O
lung	O
fields	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
sounds	O
,	O
third	O
heart	O
tone	O
,	O
no	O
pericardial	O
friction	O
.	O
Abdomen	O
soft	O
,	O
slightly	O
painful	O
on	O
palpation	O
.	O
Hepatomegaly	O
of	O
2	O
cm	O
below	O
the	O
right	O
costal	O
margin	O
is	O
palpated	O
.	O
Lower	O
extremities	O
without	O
oedema	O
or	O
signs	O
of	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
biochemistry	O
glucose	O
75	O
mg	O
dl	O
.	O
Urea	O
29	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
73	O
mg	O
dl	O
.	O
Sodium	O
136	O
mEq	O
l	O
.	O
Potassium	O
4	O
,	O
4	O
mEq	O
l	O
.	O
Total	O
bilirubin	O
4	O
,	O
86	O
.	O
Direct	O
bilirubin	O
0	O
,	O
82	O
.	O
Normal	O
liver	O
profile	O
.	O
CRP	O
6	O
.	O
24	O
.	O
Procalcitonin	O
0	O
.	O
10	O
.	O
Troponin	O
I	O
0	O
.	O
4	O
ng	O
ml	O
0	O
.	O
02	O
0	O
.	O
04	O
.	O
Myoglobin	O
31	O
,	O
8	O
.	O
ProBNP	O
2523	O
pg	O
dl	O
.	O
LDH	O
470	O
.	O
Normal	O
reticulocytes	O
.	O
Haptoglobin	O
normal	O
.	O
EAB	O
pH	O
7	O
.	O
44	O
,	O
PCO2	O
36	O
mmHg	O
.	O
HCO3	O
24	O
.	O
4	O
.	O
Haemogram	O
leucocytes	O
10	O
,	O
500	O
with	O
71	O
neutrophils	O
,	O
haemoglobin	O
16	O
.	O
3	O
g	O
dl	O
,	O
haematocrit	O
48	O
.	O
Haemostasis	O
INR	O
1	O
.	O
46	O
,	O
prothrombin	O
activity	O
63	O
.	O
Electrocardiogram	O
ECG	O
in	O
the	O
ED	O
sinus	O
rhythm	O
at	O
100	O
bpm	O
.	O
Signs	O
of	O
LVH	O
with	O
secondary	O
alterations	O
of	O
reporalisation	O
.	O
No	O
changes	O
with	O
respect	O
to	O
previous	O
ones	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
,	O
signs	O
of	O
pulmonary	O
vascular	O
congestion	O
.	O
No	O
consolidative	O
foci	O
.	O
Abdominal	O
ultrasound	O
enlarged	O
liver	O
with	O
increased	O
hyperrenfraction	O
.	O
Dilatation	O
of	O
suprahepatic	O
veins	O
and	O
inferior	O
vena	O
cava	O
system	O
.	O
No	O
focal	O
lesions	O
were	O
identified	O
.	O
Gallbladder	O
without	O
lithiasis	O
.	O
No	O
dilatation	O
of	O
the	O
bile	O
duct	O
.	O
Portion	O
of	O
the	O
pancreas	O
visualised	O
without	O
alterations	O
.	O
Spleen	O
of	O
normal	O
size	O
.	O
Abdominal	O
aorta	O
of	O
normal	O
calibre	O
.	O
Kidneys	O
with	O
good	O
corticomedullary	O
differentiation	O
.	O
No	O
excretory	O
tract	O
ectasia	O
.	O
No	O
intraperitoneal	O
free	O
fluid	O
is	O
observed	O
.	O
Emergency	O
transthoracic	O
echocardiogram	O
LV	O
of	O
normal	O
size	O
.	O
Severe	O
LVH	O
,	O
with	O
maximum	O
IVS	O
thickness	O
of	O
29	O
mm	O
at	O
mid	O
level	O
,	O
with	O
hyper	O
refringent	O
appearance	O
.	O
No	O
obstructive	O
gradient	O
.	O
Global	O
LV	O
systolic	O
function	O
severely	O
depressed	O
,	O
global	O
hypocontractility	O
with	O
LVEF	O
around	O
29	O
by	O
Teihzold	O
method	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
,	O
severely	O
hypocontractile	O
TAPSE	O
8	O
mm	O
.	O
Mitral	O
valve	O
with	O
normal	O
opening	O
,	O
mild	O
reflux	O
.	O
Aortic	O
valve	O
with	O
normal	O
structure	O
,	O
mild	O
insufficiency	O
.	O
Moderate	O
tricuspid	O
insufficiency	O
with	O
RV	O
AD	O
gradient	O
of	O
20	O
mmHg	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
IVC	O
,	O
diameter	O
24	O
mm	O
,	O
without	O
inspiratory	O
collapse	O
,	O
dilated	O
suprahepatic	O
veins	O
,	O
signs	O
of	O
hepatic	O
congestion	O
.	O
PAPS	O
40	O
mmHg	O
.	O
Conclusions	O
Severe	O
HCM	O
.	O
Severe	O
biventricular	O
systolic	O
dysfunction	O
.	O
Mild	O
PHT	O
.	O
Footnotes	O
to	O
image	O
video	O
.	O
EVOLUTION	O
The	O
patient	O
presented	O
in	O
the	O
ED	O
in	O
poor	O
general	O
condition	O
with	O
clinical	O
symptoms	O
of	O
congestive	O
heart	O
failure	O
predominantly	O
on	O
the	O
right	O
with	O
evidence	O
of	O
hepatic	O
congestion	O
on	O
abdominal	O
ultrasound	O
findings	O
and	O
alteration	O
of	O
liver	O
markers	O
in	O
AS	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
in	O
the	O
emergency	O
department	O
showing	O
severe	O
biventricular	O
systolic	O
dysfunction	O
not	O
present	O
in	O
previous	O
studies	O
.	O
There	O
was	O
also	O
evidence	O
of	O
hyperreflective	O
myocardial	O
thickening	O
.	O
On	O
suspicion	O
of	O
acute	O
myocarditis	O
with	O
severe	O
biventricular	O
systolic	O
dysfunction	O
,	O
treatment	O
was	O
started	O
with	O
intravenous	O
diuretics	O
associated	O
with	O
dobutamine	B-FARMACO
and	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
.	O
The	O
patient	O
presented	O
progressive	O
deterioration	O
with	O
signs	O
of	O
cardiogenic	O
shock	O
despite	O
the	O
prescribed	O
treatment	O
.	O
Continuous	O
diuretic	O
and	O
inotropic	O
perfusion	O
was	O
maintained	O
and	O
intravenous	O
corticosteroids	O
were	O
started	O
.	O
No	O
endomyocardial	O
biopsy	O
or	O
cardiac	O
MRI	O
was	O
performed	O
at	O
this	O
time	O
as	O
they	O
were	O
not	O
available	O
urgently	O
in	O
our	O
centre	O
.	O
Control	O
echocardiography	O
was	O
performed	O
at	O
the	O
bedside	O
,	O
showing	O
severe	O
biventricular	O
failure	O
with	O
LVEF	O
estimated	O
at	O
15	O
and	O
severe	O
PHT	O
.	O
Given	O
that	O
the	O
patient	O
persisted	O
with	O
cardiogenic	O
shock	O
,	O
aortic	O
balloon	O
counterpulsation	O
CABG	O
was	O
implanted	O
without	O
improvement	O
.	O
The	O
case	O
was	O
discussed	O
with	O
the	O
Heart	O
Failure	O
Unit	O
and	O
was	O
rejected	O
for	O
cardiac	O
transplantation	O
due	O
to	O
severe	O
neurological	O
disease	O
,	O
and	O
ECMO	O
implantation	O
was	O
decided	O
as	O
a	O
bridge	O
to	O
possible	O
recovery	O
.	O
The	O
patient	O
presented	O
with	O
ischaemia	O
in	O
the	O
left	O
lower	O
limb	O
and	O
hypoperfusion	O
of	O
the	O
right	O
limb	O
secondary	O
to	O
BACP	O
implantation	O
.	O
While	O
waiting	O
for	O
ECMO	O
implantation	O
,	O
the	O
patient	O
had	O
a	O
torpid	O
evolution	O
with	O
cardiogenic	O
shock	O
and	O
multiorgan	O
failure	O
with	O
anuria	O
and	O
severe	O
lactic	O
acidosis	O
that	O
prevented	O
intervention	O
,	O
presenting	O
cardiac	O
arrest	O
due	O
to	O
asystole	O
without	O
recovery	O
of	O
spontaneous	O
circulation	O
despite	O
advanced	O
CPR	O
.	O
Exit	O
due	O
to	O
fulminant	O
myocarditis	O
with	O
refractory	O
cardiogenic	O
shock	O
was	O
certified	O
.	O
DIAGNOSIS	O
Fulminant	O
myocarditis	O
.	O
Cardiogenic	O
shock	O
.	O
Non	O
obstructive	O
hypertrophic	O
cardiomyopathy	O
.	O
Friedreich	O
's	O
ataxia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
76	O
year	O
old	O
man	O
,	O
retired	O
miner	O
and	O
ex	O
smoker	O
of	O
half	O
a	O
packet	O
a	O
day	O
,	O
with	O
added	O
CVRFs	O
such	O
as	O
hypertension	O
,	O
dyslipidaemia	O
and	O
hyperuricaemia	O
.	O
Stroke	O
of	O
ischaemic	O
origin	O
6	O
years	O
ago	O
without	O
sequelae	O
,	O
of	O
probable	O
atherothrombotic	O
as	O
well	O
as	O
cardioembolic	O
aetiology	O
due	O
to	O
critical	O
stenosis	O
of	O
the	O
right	O
carotid	O
artery	O
which	O
required	O
bypass	O
and	O
now	O
permanent	O
AF	O
not	O
previously	O
diagnosed	O
and	O
for	O
which	O
he	O
had	O
to	O
start	O
oral	O
anticoagulation	O
therapy	O
.	O
Since	O
then	O
,	O
he	O
has	O
been	O
admitted	O
several	O
times	O
for	O
episodes	O
of	O
upper	O
and	O
lower	O
gastrointestinal	O
bleeding	O
of	O
very	O
poor	O
control	O
.	O
On	O
regular	O
treatment	O
with	O
furosemide	B-FARMACO
,	O
bisoprolol	B-FARMACO
,	O
ramipril	B-FARMACO
,	O
tamsulosin	B-FARMACO
,	O
allopurinol	B-FARMACO
and	O
sintrom	B-FARMACO
.	O
Admitted	O
to	O
a	O
regional	O
hospital	O
for	O
cough	O
,	O
whitish	O
expectoration	O
and	O
progressive	O
dyspnoea	O
of	O
a	O
week	O
's	O
evolution	O
until	O
becoming	O
minimal	O
effort	O
associated	O
with	O
the	O
appearance	O
of	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
On	O
arrival	O
at	O
the	O
Emergency	O
Department	O
,	O
he	O
presented	O
with	O
a	O
BP	O
of	O
126	O
70	O
and	O
a	O
temperature	O
of	O
36	O
.	O
9	O
C	O
.	O
Eupneic	O
at	O
45o	O
with	O
O2	B-FARMACO
at	O
2	O
bpm	O
.	O
Cardiopulmonary	O
auscultation	O
revealed	O
arrhythmic	O
heart	O
sounds	O
without	O
murmurs	O
at	O
76	O
bpm	O
and	O
hypoventilation	O
in	O
the	O
left	O
lung	O
base	O
.	O
He	O
also	O
had	O
oedema	O
with	O
fovea	O
in	O
the	O
lower	O
limbs	O
,	O
up	O
to	O
the	O
middle	O
third	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
Hb	O
11	O
.	O
5	O
,	O
Ht	O
36	O
,	O
leukocytes	O
4	O
,	O
000	O
normal	O
formula	O
,	O
platelets	O
103	O
,	O
000	O
,	O
PT	O
12	O
.	O
9	O
,	O
INR	O
5	O
.	O
5	O
,	O
renal	O
,	O
hepatic	O
and	O
ion	O
profile	O
normal	O
.	O
ABG	O
pH	O
7	O
.	O
47	O
,	O
pO2	O
56	O
,	O
pCO2	O
34	O
,	O
HCO3	O
25	O
,	O
SatO2	O
91	O
.	O
Chest	O
X	O
ray	O
global	O
cardiomegaly	O
,	O
signs	O
of	O
vascular	O
redistribution	O
,	O
fluid	O
in	O
cystole	O
,	O
left	O
pleural	O
effusion	O
.	O
ECG	O
AF	O
at	O
75	O
bpm	O
,	O
narrow	O
QRS	O
at	O
0o	O
,	O
meets	O
Cornell	O
and	O
Sokolov	O
criteria	O
for	O
LVH	O
and	O
signs	O
of	O
LV	O
overload	O
.	O
TTE	O
dilated	O
LV	O
Dtd	O
58	O
mm	O
with	O
mild	O
concentric	O
hypertrophy	O
and	O
moderate	O
left	O
ventricular	O
dysfunction	O
at	O
the	O
expense	O
of	O
generalised	O
hypokinesia	O
.	O
Elevation	O
of	O
filling	O
pressures	O
.	O
Mildly	O
dilated	O
RV	O
with	O
mild	O
ventricular	O
dysfunction	O
.	O
Dilated	O
LA	O
31	O
cm2	O
.	O
Significant	O
moderate	O
bicommissural	O
MR	O
III	O
IV	O
at	O
the	O
expense	O
of	O
at	O
least	O
two	O
jets	O
;	O
dilatation	O
of	O
Carpentier	O
's	O
type	O
I	O
annulus	O
.	O
Moderate	O
TR	O
III	O
IV	O
.	O
Severe	O
PHT	O
at	O
rest	O
.	O
Pericardial	O
effusion	O
without	O
signs	O
of	O
haemodynamic	O
compromise	O
.	O
Haemodynamic	O
study	O
severely	O
dilated	O
LV	O
indexed	O
VTD	O
116	O
ml	O
m2	O
,	O
with	O
severe	O
systolic	O
dysfunction	O
LVEF	O
30	O
at	O
the	O
expense	O
of	O
diffuse	O
hypokinesia	O
.	O
Severe	O
MI	O
.	O
Mild	O
PHT	O
PAPs	O
42	O
mmHg	O
,	O
PAPm	O
25	O
mmHg	O
,	O
PCPm	O
16	O
mmHg	O
.	O
Coronary	O
arteries	O
with	O
calcifications	O
without	O
angiographically	O
significant	O
stenosis	O
.	O
EVOLUTION	O
The	O
patient	O
was	O
treated	O
with	O
diuretics	O
,	O
resolving	O
the	O
episode	O
of	O
decompensated	O
heart	O
failure	O
and	O
in	O
view	O
of	O
the	O
findings	O
,	O
now	O
haemodynamically	O
stable	O
,	O
he	O
was	O
transferred	O
to	O
our	O
centre	O
for	O
left	O
and	O
right	O
heart	O
catheterisation	O
with	O
the	O
results	O
described	O
above	O
.	O
The	O
patient	O
was	O
referred	O
to	O
the	O
monographic	O
consultation	O
for	O
structural	O
heart	O
disease	O
at	O
our	O
centre	O
where	O
he	O
was	O
profiled	O
as	O
a	O
candidate	O
for	O
MitraClip	O
device	O
implantation	O
and	O
concomitant	O
closure	O
of	O
the	O
left	O
atrial	O
appendage	O
given	O
his	O
high	O
haemorrhagic	O
HAS	O
BLED	O
5	O
and	O
thromboembolic	O
CHADS	O
VASc	O
7	O
risk	O
,	O
and	O
the	O
intervention	O
was	O
scheduled	O
for	O
one	O
month	O
later	O
,	O
following	O
a	O
favourable	O
preoperative	O
assessment	O
ASA	O
III	O
.	O
Throughout	O
this	O
period	O
the	O
patient	O
persisted	O
in	O
functional	O
class	O
II	O
,	O
and	O
continued	O
with	O
two	O
pillow	O
orthopnoea	O
and	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
The	O
MitraClip	O
device	O
was	O
implanted	O
in	O
A3P3	O
position	O
,	O
achieving	O
an	O
improvement	O
in	O
cardiac	O
output	O
and	O
a	O
reduction	O
in	O
mitral	O
insufficiency	O
from	O
4	O
to	O
0	O
.	O
5	O
.	O
Subsequently	O
,	O
in	O
the	O
same	O
procedure	O
,	O
a	O
Watchman	O
device	O
was	O
implanted	O
to	O
close	O
the	O
27	O
mm	O
left	O
atrial	O
appendage	O
with	O
adequate	O
sealing	O
.	O
During	O
the	O
intervention	O
,	O
the	O
patient	O
presented	O
a	O
fall	O
in	O
AF	O
with	O
low	O
TAS	O
figures	O
and	O
required	O
electrical	O
cardioversion	O
,	O
leaving	O
in	O
sinus	O
rhythm	O
.	O
He	O
was	O
admitted	O
to	O
the	O
Coronary	O
Care	O
Unit	O
and	O
a	O
control	O
TEE	O
was	O
performed	O
which	O
showed	O
correct	O
placement	O
of	O
the	O
device	O
with	O
a	O
slight	O
residual	O
MR	O
due	O
to	O
two	O
lateral	O
jets	O
to	O
the	O
clip	O
and	O
with	O
an	O
average	O
gradient	O
of	O
2	O
mmHg	O
,	O
slight	O
TR	O
,	O
PAPs	O
of	O
35	O
mmHg	O
and	O
LVEF	O
in	O
the	O
lower	O
limits	O
of	O
normality	O
.	O
During	O
his	O
stay	O
in	O
the	O
unit	O
there	O
were	O
no	O
incidents	O
,	O
so	O
he	O
was	O
transferred	O
to	O
the	O
ward	O
and	O
three	O
days	O
after	O
the	O
operation	O
he	O
was	O
discharged	O
,	O
and	O
it	O
was	O
decided	O
to	O
suspend	O
oral	O
anticoagulation	O
with	O
sintrom	B-FARMACO
and	O
to	O
start	O
treatment	O
with	O
apixaban	B-FARMACO
2	O
.	O
5	O
mg	O
12	O
hours	O
.	O
Currently	O
,	O
the	O
patient	O
continues	O
to	O
attend	O
the	O
structural	O
heart	O
disease	O
consultation	O
for	O
device	O
control	O
,	O
presenting	O
a	O
clear	O
improvement	O
in	O
his	O
symptoms	O
and	O
his	O
functional	O
class	O
NYHA	O
I	O
and	O
not	O
having	O
presented	O
any	O
more	O
episodes	O
of	O
upper	O
or	O
lower	O
gastrointestinal	O
haemorrhage	O
.	O
DIAGNOSIS	O
Dilated	O
cardiomyopathy	O
with	O
biventricular	O
dysfunction	O
of	O
non	O
ischaemic	O
aetiology	O
.	O
ACC	O
AHA	O
stage	O
C	O
decompensated	O
heart	O
failure	O
in	O
NYHA	O
functional	O
class	O
II	O
.	O
Functional	O
Mitral	O
Insufficiency	O
III	O
IV	O
Severe	O
PHT	O
.	O
MitraClip	O
device	O
implantation	O
.	O
Percutaneous	O
closure	O
of	O
the	O
left	O
atrial	O
appendage	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
In	O
May	O
2017	O
,	O
an	O
84	O
year	O
old	O
man	O
was	O
admitted	O
to	O
the	O
Cardiology	O
Department	O
of	O
the	O
CAULE	O
due	O
to	O
syncope	O
.	O
His	O
personal	O
history	O
included	O
long	O
standing	O
hypertension	O
under	O
treatment	O
,	O
dyslipidaemia	O
,	O
and	O
chronic	O
kidney	O
disease	O
being	O
monitored	O
by	O
Nephrology	O
.	O
He	O
denies	O
drug	O
allergies	O
and	O
previous	O
cardiological	O
history	O
.	O
On	O
regular	O
antihypertensive	O
treatment	O
with	O
torasemide	B-FARMACO
10	O
1	O
0	O
0	O
.	O
He	O
came	O
to	O
the	O
Emergency	O
Department	O
of	O
our	O
hospital	O
due	O
to	O
a	O
syncopal	O
episode	O
on	O
the	O
night	O
of	O
admission	O
,	O
while	O
sitting	O
,	O
with	O
a	O
slight	O
sensation	O
of	O
blurred	O
vision	O
beforehand	O
,	O
and	O
fell	O
to	O
the	O
floor	O
.	O
Complete	O
recovery	O
within	O
seconds	O
.	O
Subsequently	O
presented	O
with	O
dizziness	O
lasting	O
20	O
minutes	O
.	O
He	O
denied	O
chest	O
pain	O
or	O
other	O
accompanying	O
symptoms	O
.	O
He	O
reported	O
increased	O
dyspnoea	O
with	O
moderate	O
exertion	O
in	O
the	O
previous	O
days	O
.	O
Physical	O
examination	O
showed	O
BP	O
130	O
89	O
,	O
baseline	O
SATO2	O
94	O
,	O
HR	O
103	O
bpm	O
,	O
AC	O
arrhythmic	O
at	O
110	O
bpm	O
,	O
systolic	O
murmur	O
in	O
aortic	O
focus	O
II	O
VI	O
with	O
2nd	O
noise	O
preserved	O
.	O
AP	O
bibasal	O
crackles	O
.	O
Lower	O
extremities	O
without	O
oedema	O
,	O
positive	O
and	O
symmetrical	O
peripheral	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
AF	O
at	O
115	O
bpm	O
,	O
narrow	O
QRS	O
with	O
negative	O
T	O
wave	O
from	O
V4	O
to	O
V6	O
,	O
II	O
,	O
III	O
and	O
aVF	O
.	O
CBC	O
leukocytes	O
4	O
,	O
700	O
87	O
neutrophils	O
,	O
haemoglobin	O
1	O
.	O
3	O
,	O
haematocrit	O
34	O
.	O
4	O
,	O
platelets	O
383	O
,	O
000	O
,	O
prothrombin	O
rate	O
83	O
,	O
INR	O
1	O
.	O
1	O
,	O
glucose	O
163	O
,	O
urea	O
74	O
,	O
creatinine	O
1	O
.	O
38	O
,	O
glomerular	O
filtration	O
rate	O
49	O
,	O
Na	O
141	O
,	O
K	O
4	O
.	O
4	O
,	O
Cl	O
104	O
,	O
Nt	O
proBNP	O
9233	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
,	O
bilateral	O
interstitial	O
pattern	O
,	O
free	O
costophrenic	O
sinuses	O
.	O
Transthoracic	O
echocardiogram	O
LV	O
with	O
severe	O
hypertrophy	O
,	O
non	O
dilated	O
with	O
apical	O
akinesia	O
with	O
preserved	O
global	O
systolic	O
function	O
.	O
Elevated	O
filling	O
pressures	O
.	O
Moderate	O
LA	O
and	O
mild	O
RA	O
dilatation	O
suggesting	O
cardiac	O
amyloidosis	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Aortic	O
sclerosis	O
without	O
significant	O
gradient	O
and	O
mild	O
insufficiency	O
.	O
Mild	O
tricuspid	O
insufficiency	O
with	O
moderate	O
severe	O
pulmonary	O
hypertension	O
.	O
Mild	O
moderate	O
pericardial	O
effusion	O
with	O
no	O
evidence	O
of	O
haemodynamic	O
compromise	O
.	O
Haemodynamic	O
study	O
coronary	O
arteries	O
with	O
tortuosity	O
and	O
irregularities	O
,	O
without	O
angiographically	O
significant	O
stenosis	O
.	O
Right	O
dominance	O
.	O
Normal	O
sized	O
LV	O
,	O
slightly	O
hypertrophic	O
,	O
with	O
preserved	O
LVEF	O
58	O
,	O
with	O
very	O
localised	O
apical	O
akinesia	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
LVEDP	O
13	O
mmHg	O
.	O
Slight	O
calcification	O
of	O
aortic	O
valve	O
leaflets	O
,	O
especially	O
the	O
left	O
coronary	O
,	O
without	O
significant	O
transvalvular	O
gradient	O
.	O
Magnetic	O
resonance	O
imaging	O
MRI	O
LV	O
of	O
normal	O
size	O
38	O
mm	O
with	O
asymmetric	O
thickening	O
of	O
septal	O
predominance	O
in	O
the	O
middle	O
and	O
apical	O
segments	O
.	O
Signal	O
hyperintensity	O
on	O
T2	O
weighted	O
sequences	O
in	O
the	O
apical	O
wall	O
suggesting	O
oedema	O
.	O
Heterogeneous	O
late	O
enhancement	O
,	O
transmural	O
in	O
the	O
inferior	O
wall	O
and	O
in	O
subendocardial	O
location	O
in	O
the	O
anterior	O
wall	O
.	O
There	O
is	O
also	O
enhancement	O
in	O
both	O
atria	O
and	O
the	O
interatrial	O
septum	O
.	O
Severe	O
pericardial	O
effusion	O
.	O
Slight	O
bilateral	O
pleural	O
effusions	O
.	O
The	O
findings	O
described	O
suggest	O
amyloidosis	O
.	O
Myocardial	O
scintigraphy	O
with	O
99mTc	O
HDMP	O
chest	O
study	O
late	O
phase	O
,	O
planar	O
and	O
tomographic	O
.	O
Diffuse	O
and	O
homogeneous	O
activity	O
deposit	O
of	O
remarkable	O
intensity	O
is	O
observed	O
in	O
the	O
wall	O
of	O
both	O
cardiac	O
ventricles	O
.	O
Intense	O
foci	O
of	O
uptake	O
at	O
the	O
anterior	O
ends	O
of	O
several	O
ribs	O
on	O
both	O
sides	O
.	O
Conclusion	O
findings	O
consistent	O
with	O
the	O
diagnosis	O
of	O
ATTR	O
type	O
cardiac	O
amyloidosis	O
.	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
Cardiology	O
hospital	O
ward	O
with	O
telemetry	O
monitoring	O
on	O
suspicion	O
of	O
syncope	O
with	O
a	O
cardiogenic	O
profile	O
and	O
clinical	O
signs	O
of	O
heart	O
failure	O
,	O
for	O
the	O
study	O
of	O
structural	O
heart	O
disease	O
.	O
Telemetry	O
monitoring	O
showed	O
AF	O
with	O
MVR	O
around	O
140	O
bpm	O
,	O
without	O
significant	O
pauses	O
or	O
arrhythmic	O
events	O
.	O
A	O
transthoracic	O
echocardiographic	O
study	O
was	O
started	O
and	O
completed	O
with	O
a	O
haemodynamic	O
study	O
due	O
to	O
suspicion	O
of	O
a	O
possible	O
ischaemic	O
aetiology	O
.	O
The	O
echocardiographic	O
study	O
describes	O
concentric	O
hypertrophy	O
with	O
normal	O
LV	O
size	O
,	O
without	O
segmental	O
alterations	O
of	O
contractility	O
,	O
with	O
severe	O
LA	O
dilatation	O
and	O
mild	O
mitral	O
and	O
aortic	O
insufficiency	O
.	O
Catheterisation	O
showed	O
coronary	O
arteries	O
without	O
angiographically	O
significant	O
stenosis	O
and	O
localised	O
apical	O
akinesia	O
.	O
At	O
this	O
point	O
,	O
the	O
clinical	O
evolution	O
during	O
admission	O
and	O
test	O
findings	O
suggest	O
CHF	O
with	O
preserved	O
ejection	O
fraction	O
,	O
with	O
AF	O
with	O
rapid	O
MVR	O
and	O
diastolic	O
dysfunction	O
.	O
Diuretic	O
treatment	O
was	O
intensified	O
and	O
MRI	O
with	O
gadolinium	O
was	O
requested	O
to	O
continue	O
the	O
study	O
,	O
given	O
the	O
suspicion	O
of	O
cardiomyopathy	O
,	O
in	O
which	O
normal	O
sized	O
left	O
ventricle	O
with	O
asymmetric	O
thickening	O
of	O
predominantly	O
septal	O
in	O
the	O
middle	O
and	O
apical	O
segments	O
,	O
with	O
heterogeneous	O
late	O
enhancement	O
,	O
transmural	O
in	O
the	O
inferior	O
wall	O
and	O
in	O
the	O
subendocardial	O
location	O
in	O
the	O
anterior	O
wall	O
,	O
suggestive	O
of	O
amyloidosis	O
,	O
was	O
reported	O
.	O
In	O
view	O
of	O
these	O
results	O
,	O
myocardial	O
scintigraphy	O
with	O
99mTc	O
HDMP	O
was	O
requested	O
,	O
and	O
the	O
findings	O
were	O
consistent	O
with	O
the	O
diagnosis	O
of	O
ATTR	O
type	O
cardiac	O
amyloidosis	O
.	O
In	O
the	O
following	O
days	O
,	O
the	O
patient	O
progressively	O
improved	O
his	O
clinical	O
symptoms	O
of	O
heart	O
failure	O
,	O
so	O
he	O
was	O
discharged	O
home	O
after	O
pharmacological	O
adjustment	O
for	O
outpatient	O
clinical	O
follow	O
up	O
in	O
cardiology	O
consultations	O
.	O
DIAGNOSIS	O
Syncope	O
in	O
the	O
probable	O
context	O
of	O
arterial	O
hypotension	O
.	O
Heart	O
failure	O
with	O
preserved	O
EF	O
.	O
ATTR	O
cardiac	O
amyloidosis	O
.	O
Coronary	O
arteries	O
without	O
angiographically	O
significant	O
stenosis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
adverse	O
drug	O
reactions	O
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
,	O
type	O
2	O
diabetes	O
mellitus	O
.	O
Dyslipidaemia	O
.	O
Smoker	O
of	O
1	O
pack	O
a	O
day	O
.	O
Alcoholic	O
habit	O
of	O
1	O
2	O
standard	O
drink	O
units	O
per	O
day	O
.	O
Obesity	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
.	O
2	O
vessel	O
disease	O
.	O
In	O
2015	O
,	O
due	O
to	O
stable	O
angina	O
,	O
proximal	O
anterior	O
descending	O
artery	O
was	O
revascularised	O
with	O
a	O
drug	O
eluting	O
stent	O
.	O
Subsequently	O
in	O
2019	O
,	O
as	O
a	O
result	O
of	O
acute	O
hypertensive	O
pulmonary	O
oedema	O
,	O
a	O
new	O
lesion	O
was	O
found	O
in	O
the	O
circumflex	O
ostium	O
treated	O
with	O
a	O
drug	O
eluting	O
stent	O
and	O
a	O
moderate	O
lesion	O
in	O
the	O
dominant	O
right	O
coronary	O
artery	O
that	O
was	O
not	O
treated	O
.	O
Follow	O
up	O
by	O
the	O
heart	O
failure	O
unit	O
with	O
severely	O
depressed	O
LVEF	O
recovered	O
of	O
mixed	O
aetiology	O
tachycardiomyopathy	O
and	O
ischaemic	O
in	O
baseline	O
functional	O
class	O
NYHA	O
II	O
.	O
Paroxysmal	O
atypical	O
atrial	O
flutter	O
.	O
Last	O
electrical	O
cardioversion	O
ECV	O
in	O
October	O
2020	O
,	O
effective	O
.	O
Last	O
echocardiography	O
2019	O
left	O
ventricle	O
,	O
with	O
preserved	O
diameters	O
,	O
volumes	O
and	O
global	O
systolic	O
function	O
EF	O
63	O
with	O
anterolateral	O
medial	O
and	O
apical	O
hypokinesia	O
with	O
preserved	O
contractility	O
of	O
the	O
remaining	O
segments	O
.	O
Aortic	O
sclerosis	O
without	O
significant	O
functional	O
repercussions	O
.	O
Diastolic	O
pattern	O
with	O
single	O
E	O
wave	O
with	O
indirect	O
data	O
of	O
slightly	O
increased	O
filling	O
pressures	O
.	O
Dilated	O
left	O
atrium	O
.	O
Right	O
ventricle	O
with	O
normal	O
diameters	O
and	O
global	O
systolic	O
function	O
.	O
Mild	O
tricuspid	O
regurgitation	O
,	O
systolic	O
pulmonary	O
artery	O
pressure	O
approximately	O
65	O
70	O
mmHg	O
severe	O
pulmonary	O
hypertension	O
PHT	O
.	O
Normal	O
inferior	O
vena	O
cava	O
.	O
Other	O
history	O
Chronic	O
obstructive	O
pulmonary	O
disease	O
moderate	O
emphysema	O
phenotype	O
.	O
Obstructive	O
sleep	O
apnoea	O
hypopnoea	O
syndrome	O
with	O
use	O
of	O
nocturnal	O
CPAP	O
.	O
Bladder	O
tumour	O
pT1G3	O
CIS	O
in	O
follow	O
up	O
by	O
urology	O
.	O
Stage	O
IIIA	O
chronic	O
kidney	O
disease	O
CKD	O
baseline	O
creatinine	O
around	O
1	O
.	O
2	O
with	O
exacerbation	O
in	O
the	O
context	O
of	O
excessive	O
blood	O
pressure	O
control	O
.	O
Chronic	O
constipation	O
with	O
haemorrhoids	O
and	O
anal	O
fissure	O
.	O
Normocytic	O
normochromic	O
anaemia	O
with	O
gastrocolonoscopy	O
with	O
colon	O
polyps	O
,	O
chronic	O
gastritis	O
and	O
hyperemic	O
erythematous	O
duodenitis	O
last	O
colonoscopy	O
in	O
2017	O
.	O
Peripheral	O
arterial	O
disease	O
chronic	O
ischaemia	O
of	O
lower	O
limbs	O
.	O
Aortobifemoral	O
thrombosis	O
in	O
February	O
2015	O
.	O
Benign	O
prostatic	O
hyperplasia	O
.	O
Chronic	O
glaucoma	O
.	O
Depressive	O
disorder	O
Usual	O
treatment	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
97	O
103	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
,	O
amlodipine	B-FARMACO
10	O
mg	O
1	O
tablet	O
per	O
day	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
2	O
tablets	O
daily	O
,	O
edoxaban	B-FARMACO
60	O
mg	O
1	O
tablet	O
daily	O
,	O
pantoprazole	B-FARMACO
40	O
mg	O
1	O
capsule	O
daily	O
,	O
amiodarone	B-FARMACO
200	O
mg	O
1	O
tablet	O
daily	O
,	O
insulin	B-FARMACO
glargine	I-FARMACO
36	O
IU	O
daily	O
,	O
atorvastatin	B-FARMACO
ezetimibe	I-FARMACO
40	O
10	O
mg	O
1	O
tablet	O
daily	O
,	O
indacaterol	B-FARMACO
glycopyrronium	I-FARMACO
bromide	I-FARMACO
85	O
43	O
micrograms	O
1	O
capsule	O
daily	O
,	O
silodosin	B-FARMACO
4	O
mg	O
1	O
tablet	O
daily	O
,	O
allopurinol	B-FARMACO
300	O
mg	O
half	O
a	O
tablet	O
daily	O
,	O
brinzolamide	B-FARMACO
1	O
drop	O
every	O
12	O
hours	O
,	O
saflutan	B-FARMACO
taptiqom	I-FARMACO
1	O
drop	O
daily	O
,	O
venlafaxine	B-FARMACO
75	O
mg	O
1	O
tablet	O
daily	O
,	O
cholecalciferol	B-FARMACO
25000	O
IU	O
1	O
ampoule	O
every	O
30	O
days	O
,	O
lipase	O
amylase	O
protease	O
25000	O
2	O
capsules	O
after	O
each	O
meal	O
.	O
Present	O
illness	O
65	O
year	O
old	O
male	O
admitted	O
to	O
the	O
coronary	O
unit	O
for	O
acute	O
hypertensive	O
pulmonary	O
oedema	O
.	O
The	O
patient	O
reported	O
deterioration	O
of	O
functional	O
class	O
over	O
2	O
weeks	O
of	O
evolution	O
to	O
dyspnoea	O
on	O
light	O
exertion	O
,	O
with	O
orthopnoea	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
attenuated	O
by	O
nocturnal	O
CPAP	O
,	O
with	O
increased	O
peripheral	O
oedema	O
without	O
subjective	O
decrease	O
in	O
diuresis	O
in	O
the	O
context	O
of	O
decompensated	O
CHF	O
with	O
no	O
clear	O
apparent	O
trigger	O
,	O
although	O
it	O
could	O
be	O
related	O
to	O
uncontrolled	O
arterial	O
hypertension	O
AHT	O
at	O
home	O
.	O
On	O
arrival	O
at	O
the	O
ED	O
he	O
presented	O
with	O
dyspnoea	O
at	O
rest	O
in	O
a	O
situation	O
of	O
global	O
respiratory	O
failure	O
in	O
the	O
context	O
of	O
acute	O
hypertensive	O
pulmonary	O
oedema	O
165	O
95	O
mmHg	O
.	O
Depletive	O
treatment	O
was	O
intensified	O
with	O
perfused	O
furosemide	B-FARMACO
together	O
with	O
non	O
invasive	O
mechanical	O
ventilation	O
in	O
BiPAP	O
mode	O
,	O
achieving	O
progressive	O
negative	O
balances	O
and	O
clinical	O
improvement	O
.	O
During	O
his	O
stay	O
,	O
a	O
right	O
thoracentesis	O
was	O
also	O
performed	O
with	O
an	O
output	O
of	O
1	O
,	O
000	O
ml	O
of	O
serous	O
fluid	O
with	O
clinical	O
improvement	O
without	O
complications	O
.	O
After	O
clinical	O
improvement	O
and	O
haemodynamic	O
and	O
respiratory	O
stability	O
,	O
the	O
patient	O
was	O
discharged	O
to	O
the	O
cardiology	O
ward	O
.	O
Four	O
days	O
later	O
,	O
the	O
patient	O
's	O
dyspnoea	O
worsened	O
again	O
with	O
the	O
need	O
for	O
NIMV	O
,	O
and	O
bedside	O
echocardiography	O
was	O
performed	O
in	O
the	O
acute	O
phase	O
,	O
describing	O
significant	O
acute	O
mitral	O
insufficiency	O
due	O
to	O
asymmetrical	O
posterior	O
tethering	O
.	O
Physical	O
examination	O
Conscious	O
and	O
oriented	O
,	O
eupneic	O
at	O
rest	O
with	O
NIMV	O
in	O
BiPAP	O
mode	O
.	O
Adequate	O
diuresis	O
with	O
furosemide	B-FARMACO
perfusion	O
.	O
Blood	O
pressure	O
160	O
95	O
mmHg	O
,	O
heart	O
rate	O
65	O
bpm	O
,	O
peripheral	O
oxygen	O
saturation	O
93	O
FiO2	O
35	O
.	O
Cardiac	O
auscultation	O
regular	O
sounds	O
,	O
systolic	O
murmur	O
II	O
VI	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
bilateral	O
midbasal	O
crackles	O
,	O
scattered	O
rhonchi	O
,	O
right	O
basal	O
hypophonasis	O
.	O
Extremities	O
tibiomalleolar	O
oedema	O
with	O
fovea	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
AP	O
chest	O
X	O
ray	O
signs	O
of	O
venous	O
congestion	O
,	O
bilateral	O
intersticioalveolar	O
infiltrate	O
predominantly	O
basal	O
,	O
bilateral	O
pleural	O
effusion	O
predominantly	O
right	O
.	O
12	O
lead	O
electrocardiogram	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
,	O
PR	O
200	O
ms	O
,	O
QRS	O
100	O
ms	O
,	O
poor	O
septal	O
vector	O
progression	O
,	O
QS	O
in	O
V1	O
V2	O
,	O
ST	O
segment	O
depression	O
with	O
asymmetric	O
negative	O
T	O
in	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
V6	O
,	O
ST	O
segment	O
elevation	O
in	O
aVR	O
.	O
Transthoracic	O
echocardiogram	O
at	O
bedside	O
suboptimal	O
examination	O
due	O
to	O
sitting	O
position	O
.	O
Left	O
ventricle	O
of	O
normal	O
diameters	O
and	O
volumes	O
with	O
slightly	O
depressed	O
global	O
function	O
secondary	O
to	O
anterolateral	O
and	O
lower	O
middle	O
basal	O
hypokinesia	O
with	O
preserved	O
contractility	O
of	O
the	O
rest	O
of	O
the	O
segments	O
.	O
Moderate	O
severe	O
mitral	O
insufficiency	O
due	O
to	O
asymmetric	O
posterior	O
tethering	O
.	O
Aortic	O
sclerosis	O
without	O
significant	O
functional	O
repercussions	O
.	O
Diastolic	O
pattern	O
with	O
indirect	O
data	O
of	O
increased	O
filling	O
pressures	O
.	O
Dilated	O
left	O
atrium	O
.	O
Right	O
ventricle	O
with	O
normal	O
diameters	O
and	O
global	O
systolic	O
function	O
.	O
Mild	O
tricuspid	O
regurgitation	O
,	O
systolic	O
pulmonary	O
artery	O
pressure	O
approximately	O
65	O
70	O
mmHg	O
severe	O
PHT	O
.	O
Plethoric	O
inferior	O
vena	O
cava	O
.	O
Diffuse	O
bilateral	O
B	O
lines	O
.	O
Blood	O
tests	O
ED	O
CBC	O
haemoglobin	O
11	O
.	O
4	O
g	O
dl	O
,	O
haematocrit	O
34	O
.	O
2	O
,	O
MCV	O
90fl	O
,	O
leucocytes	O
10	O
.	O
9	O
10	O
9	O
l	O
,	O
neutrophils	O
10	O
10	O
9	O
l	O
,	O
lymphocytes	O
0	O
.	O
3	O
10	O
9	O
l	O
,	O
platelets	O
250	O
10	O
9	O
l	O
.	O
Haemostasis	O
INR	O
2	O
.	O
15	O
,	O
Quick	O
index	O
33	O
.	O
Biochemistry	O
glucose	O
90	O
mg	O
dl	O
,	O
sodium	O
132	O
mEq	O
l	O
,	O
potassium	O
5	O
.	O
1	O
mEq	O
l	O
,	O
chlorine	O
96	O
mEq	O
l	O
,	O
total	O
bilirubin	O
1	O
.	O
46	O
mg	O
dl	O
,	O
GPT	O
8	O
U	O
l	O
,	O
urea	O
107	O
mg	O
dl	O
,	O
creatinine	O
2	O
.	O
23	O
mg	O
dl	O
,	O
C	O
reactive	O
protein	O
1	O
.	O
2	O
mg	O
dl	O
.	O
Arterial	O
blood	O
gases	O
FiO2	O
50	O
in	O
Ventimask	O
pH	O
7	O
.	O
42	O
,	O
pCO2	O
35	O
,	O
pO2	O
48	O
mmHg	O
,	O
HCO3a	O
22	O
.	O
7	O
mmol	O
l	O
,	O
lactate	O
1	O
.	O
8	O
mmol	O
l	O
.	O
Arterial	O
blood	O
gas	O
1	O
hour	O
BiPAP	O
control	O
pH	O
7	O
.	O
37	O
,	O
pCO2	O
39	O
mmHg	O
,	O
pO2	O
74	O
mmHg	O
,	O
HCO3a	O
22	O
.	O
5	O
mmol	O
l	O
,	O
lactate	O
0	O
.	O
8	O
mmol	O
l	O
.	O
NT	O
proBNP	O
11955	O
pg	O
ml	O
.	O
Troponin	O
I	O
hsTnI	O
43	O
mg	O
dl	O
0	O
21	O
mg	O
dl	O
.	O
Blood	O
analysis	O
admitted	O
CBC	O
red	O
cells	O
3	O
.	O
55	O
10	O
12	O
l	O
,	O
haemoglobin	O
12	O
.	O
2	O
g	O
dl	O
,	O
haematocrit	O
37	O
.	O
1	O
,	O
MCV	O
91	O
fl	O
,	O
leukocytes	O
8	O
.	O
5	O
10	O
9	O
l	O
,	O
neutrophils	O
7	O
.	O
1	O
10	O
9	O
l	O
,	O
lymphocytes	O
0	O
.	O
6	O
10	O
9	O
l	O
,	O
monocytes	O
0	O
.	O
7	O
10	O
9	O
l	O
,	O
eosinophils	O
0	O
.	O
1	O
10	O
9	O
l	O
,	O
basophils	O
0	O
.	O
1	O
10	O
9	O
l	O
,	O
platelets	O
211	O
10	O
9	O
l	O
.	O
Haemostasis	O
prothrombin	O
time	O
PT	O
26	O
.	O
6	O
sec	O
,	O
Quick	O
's	O
index	O
31	O
,	O
INR	O
2	O
.	O
24	O
,	O
aPTT	O
36	O
.	O
5	O
sec	O
,	O
ratio	O
aPTT	O
1	O
.	O
22	O
.	O
Derived	O
fibrinogen	O
433	O
mg	O
dl	O
.	O
Glycosylated	O
haemoglobin	O
HbA1c	O
7	O
.	O
4	O
.	O
Biochemistry	O
glucose	O
146	O
mg	O
dl	O
,	O
sodium	O
140	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
2	O
mEq	O
l	O
,	O
chlorine	O
96	O
mEq	O
l	O
,	O
magnesium	O
1	O
.	O
5	O
mg	O
dl	O
,	O
total	O
bilirubin	O
1	O
.	O
5	O
mg	O
dl	O
,	O
aspartate	O
aminotransferase	O
GOT	O
19	O
U	O
l	O
,	O
alanine	O
aminotransferase	O
GPT	O
10	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
167	O
U	O
l	O
,	O
gamma	O
glutamyl	O
transferase	O
203	O
U	O
l	O
,	O
urea	O
70	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
11	O
mg	O
dl	O
,	O
alkaline	O
reserve	O
26	O
mmol	O
l	O
,	O
estimated	O
GFR	O
CKD	O
EPI	O
69	O
.	O
8	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
calcium	O
10	O
.	O
2	O
mg	O
dl	O
,	O
phosphorus	O
3	O
.	O
7	O
mg	O
dl	O
,	O
uric	O
acid	O
6	O
.	O
8	O
mg	O
dl	O
,	O
protein	O
6	O
.	O
8	O
g	O
dl	O
,	O
albumin	O
4	O
.	O
2	O
g	O
dl	O
,	O
prealbumin	O
20	O
.	O
1	O
mg	O
dl	O
,	O
C	O
reactive	O
protein	O
0	O
.	O
7	O
mg	O
dl	O
.	O
Iron	O
profile	O
ferritin	O
304	O
μg	O
l	O
,	O
iron	O
60	O
μg	O
dl	O
,	O
total	O
Fe	O
binding	O
capacity	O
338	O
ug	O
dl	O
,	O
transferrin	O
saturation	O
index	O
17	O
.	O
8	O
,	O
latent	O
Fe	O
binding	O
capacity	O
278	O
ug	O
dl	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
107	O
mg	O
dl	O
,	O
triglycerides	O
83	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
47	O
mg	O
dl	O
,	O
non	O
HDL	O
cholesterol	O
55	O
mg	O
dl	O
.	O
Urine	O
spot	O
creatinuria	O
63	O
.	O
0	O
mg	O
dl	O
,	O
spot	O
albuminuria	O
1	O
.	O
07	O
mg	O
dl	O
,	O
albuminuria	O
creatinuria	O
index	O
17	O
mg	O
g	O
creatinine	O
.	O
Vitamins	O
vitamin	O
B12	O
465	O
pg	O
ml	O
,	O
folic	O
acid	O
4	O
.	O
3	O
ng	O
ml	O
.	O
Nasopharyngeal	O
exudate	O
RT	O
PCR	O
SARS	O
CoV	O
2	O
negative	O
.	O
Catheterisation	O
videos	O
2	O
4	O
dominance	O
right	O
dominant	O
.	O
Coronary	O
arteries	O
significant	O
stenosis	O
.	O
Truncus	O
description	O
with	O
atheromatosis	O
without	O
stenosis	O
.	O
Anterior	O
descending	O
description	O
good	O
late	O
result	O
of	O
the	O
stent	O
implanted	O
on	O
LD	O
CT	O
.	O
Circumflex	O
description	O
CX	O
new	O
ostial	O
restenosis	O
90	O
,	O
so	O
new	O
angioplasty	O
is	O
performed	O
with	O
implantation	O
of	O
ULTIMASTER	O
TANSEI	O
sirolimus	O
3	O
.	O
0	O
12	O
mm	O
drug	O
eluting	O
stent	O
,	O
with	O
minimal	O
protrusion	O
in	O
LMCA	O
and	O
ending	O
with	O
post	O
dilatation	O
in	O
kissing	O
balloon	O
to	O
avoid	O
displacement	O
of	O
struts	O
of	O
the	O
LMCA	O
AD	O
stent	O
.	O
Right	O
coronary	O
description	O
dominant	O
vessel	O
unchanged	O
with	O
respect	O
to	O
previous	O
exploration	O
,	O
with	O
50	O
lesion	O
in	O
proximal	O
segment	O
.	O
Left	O
radial	O
with	O
EBU	O
3	O
.	O
5	O
6F	O
,	O
BMW	O
guides	O
to	O
DA	O
and	O
CX	O
,	O
predilatation	O
with	O
3	O
balloons	O
in	O
kissing	O
and	O
implantation	O
of	O
ULTIMASTER	O
TANSEI	O
stent	O
3x12	O
with	O
stopper	O
balloon	O
in	O
TCI	O
DA	O
and	O
final	O
postdilatation	O
in	O
kissing	O
.	O
Conclusions	O
recurrent	O
in	O
stent	O
restenosis	O
in	O
CX	O
ostium	O
.	O
PTCA	O
on	O
the	O
SIRS	O
with	O
sirolimus	B-FARMACO
DES	O
implantation	O
and	O
final	O
post	O
dilatation	O
in	O
kissing	O
.	O
Moderate	O
lesion	O
persists	O
in	O
proximal	O
DC	O
with	O
no	O
changes	O
with	O
respect	O
to	O
the	O
previous	O
exploration	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
re	O
admission	O
he	O
was	O
desaturated	O
,	O
with	O
intense	O
respiratory	O
work	O
and	O
mildly	O
obnubilised	O
,	O
so	O
non	O
invasive	O
mechanical	O
ventilation	O
NIV	O
was	O
started	O
with	O
a	O
very	O
good	O
initial	O
response	O
and	O
perfusion	O
of	O
furosemide	B-FARMACO
.	O
After	O
clinical	O
and	O
blood	O
pressure	O
stabilisation	O
,	O
a	O
new	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
normalisation	O
of	O
the	O
previously	O
described	O
alterations	O
in	O
segmental	O
contractility	O
and	O
a	O
decrease	O
in	O
the	O
degree	O
of	O
mitral	O
regurgitation	O
to	O
mild	O
.	O
Due	O
to	O
suspicion	O
of	O
acute	O
mitral	O
insufficiency	O
echocardiography	O
in	O
2019	O
did	O
not	O
reveal	O
mitral	O
insufficiency	O
in	O
the	O
context	O
of	O
ischaemia	O
due	O
to	O
high	O
blood	O
pressure	O
,	O
coronary	O
angiography	O
was	O
performed	O
,	O
revealing	O
in	O
stent	O
restenosis	O
in	O
the	O
circumflex	O
ostium	O
,	O
which	O
was	O
treated	O
with	O
a	O
new	O
drug	O
eluting	O
stent	O
.	O
Control	O
tests	O
showed	O
recovery	O
of	O
renal	O
function	O
to	O
baseline	O
and	O
correction	O
of	O
initial	O
mild	O
hyperkalaemia	O
to	O
mild	O
hypokalaemia	O
,	O
requiring	O
supplementary	O
potassium	B-FARMACO
,	O
and	O
a	O
red	O
blood	O
cell	O
concentrate	O
due	O
to	O
anaemia	O
without	O
active	O
bleeding	O
.	O
The	O
patient	O
continued	O
to	O
progress	O
favourably	O
until	O
transferred	O
to	O
a	O
conventional	O
hospital	O
ward	O
and	O
was	O
subsequently	O
discharged	O
home	O
.	O
In	O
a	O
patient	O
with	O
high	O
ischaemic	O
risk	O
cardiovascular	O
risk	O
factors	O
,	O
chronic	O
ischaemic	O
heart	O
disease	O
and	O
previous	O
peripheral	O
artery	O
disease	O
and	O
in	O
stent	O
restenosis	O
and	O
high	O
haemorrhagic	O
risk	O
normocytic	O
normochromic	O
anaemia	O
due	O
to	O
digestive	O
losses	O
,	O
bladder	O
tumour	O
under	O
follow	O
up	O
,	O
poorly	O
controlled	O
hypertension	O
at	O
home	O
and	O
chronic	O
kidney	O
disease	O
,	O
double	O
therapy	O
was	O
prescribed	O
with	O
apixaban	B-FARMACO
5	O
mg	O
every	O
12	O
hours	O
and	O
clopidogrel	B-FARMACO
75	O
mg	O
daily	O
;	O
triple	O
therapy	O
was	O
used	O
during	O
hospitalisation	O
.	O
The	O
change	O
from	O
edoxaban	B-FARMACO
to	O
apixaban	B-FARMACO
is	O
due	O
to	O
the	O
consideration	O
of	O
the	O
European	O
guidelines	O
for	O
atrial	O
fibrillation	O
of	O
the	O
use	O
of	O
apixaban	B-FARMACO
or	O
dabigatran	B-FARMACO
110	O
mg	O
due	O
to	O
the	O
lower	O
rate	O
of	O
gastrointestinal	O
bleeding	O
compared	O
to	O
warfarin	B-FARMACO
.	O
As	O
an	O
obese	O
patient	O
with	O
type	O
2	O
diabetes	O
mellitus	O
under	O
suboptimal	O
treatment	O
with	O
HbA1c	O
of	O
7	O
.	O
4	O
,	O
semaglutide	B-FARMACO
0	O
.	O
25	O
mg	O
weekly	O
subcutaneously	O
is	O
started	O
for	O
4	O
weeks	O
with	O
a	O
view	O
to	O
increasing	O
to	O
0	O
.	O
5	O
and	O
1	O
mg	O
thereafter	O
.	O
In	O
addition	O
,	O
metformin	B-FARMACO
empagliflozin	I-FARMACO
1	O
,	O
000	O
mg	O
5	O
mg	O
every	O
12	O
h	O
is	O
added	O
and	O
if	O
tolerated	O
will	O
be	O
increased	O
to	O
1	O
,	O
000	O
mg	O
12	O
.	O
5	O
mg	O
every	O
12	O
h	O
.	O
Subsequently	O
,	O
insulin	O
therapy	O
is	O
reduced	O
according	O
to	O
requirements	O
.	O
The	O
patient	O
continues	O
with	O
controls	O
in	O
the	O
heart	O
failure	O
unit	O
without	O
incident	O
.	O
DIAGNOSIS	O
Acute	O
pulmonary	O
oedema	O
in	O
the	O
context	O
of	O
acute	O
ischaemic	O
mitral	O
insufficiency	O
.	O
In	O
stent	O
restenosis	O
of	O
the	O
circumflex	O
artery	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
with	O
suboptimal	O
treatment	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Cardiovascular	O
risk	O
factors	O
ex	O
smoker	O
for	O
11	O
years	O
,	O
hypertension	O
and	O
dyslipidaemia	O
.	O
No	O
other	O
known	O
cardiovascular	O
risk	O
factors	O
.	O
Benign	O
prostatic	O
hyperplasia	O
.	O
Cardiological	O
history	O
Lateral	O
ischaemic	O
heart	O
disease	O
type	O
STEMI	O
in	O
April	O
2016	O
,	O
2	O
vessel	O
coronary	O
artery	O
disease	O
with	O
primary	O
percutaneous	O
coronary	O
intervention	O
on	O
diagonal	O
branch	O
.	O
Second	O
time	O
on	O
right	O
coronary	O
artery	O
.	O
Complete	O
revascularisation	O
.	O
In	O
2020	O
,	O
repeat	O
cardiac	O
catheterisation	O
during	O
admission	O
for	O
chest	O
pain	O
,	O
with	O
epicardial	O
coronary	O
arteries	O
without	O
angiographic	O
lesions	O
.	O
Congenital	O
valvular	O
heart	O
disease	O
bicuspid	O
aortic	O
valve	O
.	O
Transthoracic	O
echocardiogram	O
in	O
2020	O
left	O
ventricle	O
LV	O
slightly	O
dilated	O
.	O
Mild	O
left	O
ventricular	O
dysfunction	O
EF	O
45	O
with	O
altered	O
contractility	O
in	O
the	O
inferior	O
and	O
apical	O
territory	O
.	O
Moderate	O
aortic	O
stenosis	O
and	O
mild	O
aortic	O
insufficiency	O
.	O
Usual	O
NYHA	O
functional	O
class	O
II	O
IV	O
.	O
Ascending	O
aortic	O
aneurysm	O
with	O
a	O
maximum	O
diameter	O
of	O
46	O
mm	O
.	O
Baseline	O
electrocardiogram	O
ECG	O
in	O
sinus	O
with	O
LBBB	O
.	O
On	O
regular	O
treatment	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
,	O
atorvastatin	B-FARMACO
,	O
ramipril	B-FARMACO
,	O
bisoprolol	B-FARMACO
,	O
spironolactone	B-FARMACO
,	O
tamsulosin	B-FARMACO
and	O
dutasteride	B-FARMACO
.	O
Present	O
illness	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
hospital	O
emergency	O
room	O
by	O
the	O
emergency	O
service	O
for	O
an	O
episode	O
of	O
chest	O
pain	O
lasting	O
more	O
than	O
one	O
hour	O
,	O
which	O
began	O
with	O
minimal	O
exertion	O
at	O
home	O
.	O
It	O
was	O
oppressive	O
central	O
chest	O
pain	O
,	O
with	O
concomitant	O
vegetative	O
cortex	O
,	O
which	O
in	O
the	O
initial	O
assessment	O
presented	O
arterial	O
hypotension	O
and	O
rhythm	O
disturbances	O
with	O
second	O
degree	O
atrioventricular	O
block	O
AVB	O
Mobitz	O
I	O
.	O
During	O
the	O
transfer	O
,	O
powerful	O
analgesic	O
treatment	O
was	O
started	O
,	O
with	O
no	O
symptomatic	O
improvement	O
.	O
He	O
arrived	O
at	O
the	O
emergency	O
department	O
with	O
pain	O
.	O
Given	O
the	O
high	O
suspicion	O
of	O
acute	O
aortic	O
syndrome	O
,	O
angio	O
CT	O
was	O
requested	O
and	O
ruled	O
it	O
out	O
.	O
At	O
that	O
time	O
,	O
cardiology	O
was	O
requested	O
to	O
collaborate	O
.	O
Physical	O
examination	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
still	O
with	O
central	O
thoracic	O
pain	O
,	O
blood	O
pressure	O
persisted	O
at	O
87	O
50	O
mmHg	O
and	O
heart	O
rate	O
of	O
55	O
bpm	O
.	O
On	O
evaluation	O
by	O
cardiology	O
after	O
angio	O
CT	O
which	O
ruled	O
out	O
acute	O
aortic	O
syndrome	O
,	O
he	O
showed	O
signs	O
of	O
distal	O
hypoperfusion	O
and	O
marked	O
tendency	O
to	O
arterial	O
hypotension	O
with	O
80	O
40	O
mmHg	O
,	O
heart	O
rate	O
of	O
40	O
bpm	O
,	O
baseline	O
oxygen	O
saturation	O
of	O
97	O
.	O
Elevation	O
of	O
central	O
venous	O
pressure	O
,	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
pan	O
focal	O
systolic	O
murmur	O
with	O
associated	O
Gallavardin	O
phenomenon	O
.	O
Pulmonary	O
auscultation	O
normonophonesis	O
in	O
all	O
fields	O
.	O
Abdomen	O
without	O
semiology	O
of	O
ascites	O
,	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
masses	O
or	O
visceromegaly	O
palpable	O
.	O
Lower	O
limbs	O
without	O
oedema	O
,	O
with	O
signs	O
of	O
poor	O
distal	O
perfusion	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
his	O
previous	O
baseline	O
ECG	O
with	O
LBBB	O
showed	O
repolarisation	O
alterations	O
compatible	O
with	O
acute	O
myocardial	O
ischaemia	O
and	O
advanced	O
AV	O
conduction	O
disorder	O
.	O
Thoracic	O
CT	O
angiography	O
bicuspid	O
aorta	O
,	O
calcified	O
.	O
Fusiform	O
dilatation	O
of	O
the	O
ascending	O
aorta	O
,	O
with	O
a	O
maximum	O
diameter	O
of	O
52	O
mm	O
.	O
No	O
aortic	O
flap	O
,	O
intramural	O
haematoma	O
or	O
other	O
acute	O
aortic	O
parietal	O
lesions	O
are	O
identified	O
.	O
Absence	O
of	O
coronary	O
calcium	O
.	O
There	O
was	O
no	O
opacification	O
of	O
the	O
anterior	O
descending	O
artery	O
from	O
D1	O
,	O
with	O
progressive	O
narrowing	O
of	O
its	O
calibre	O
,	O
suggestive	O
of	O
non	O
atherogenic	O
occlusion	O
of	O
the	O
anterior	O
descending	O
artery	O
.	O
Left	O
ventricular	O
dilatation	O
with	O
diffuse	O
myocardial	O
thinning	O
,	O
more	O
accentuated	O
in	O
the	O
anterior	O
wall	O
.	O
Signs	O
of	O
cardiogenic	O
interstitial	O
pulmonary	O
oedema	O
and	O
mild	O
bilateral	O
pleural	O
effusion	O
.	O
No	O
pericardial	O
effusion	O
.	O
Emergency	O
transthoracic	O
echocardiogram	O
dilated	O
left	O
ventricle	O
LV	O
.	O
Severely	O
depressed	O
left	O
ventricular	O
function	O
LVEF	O
10	O
by	O
Simpson	O
with	O
anteroseptal	O
,	O
anterior	O
and	O
apical	O
segment	O
akinesia	O
.	O
CBC	O
troponin	O
I	O
US	O
101	O
.	O
2	O
ng	O
l	O
306	O
,	O
540	O
.	O
8	O
ng	O
l	O
normal	O
18	O
ng	O
l	O
,	O
creatinine	O
0	O
.	O
94	O
mg	O
dl	O
,	O
sodium	O
136	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
8	O
mEq	O
l	O
.	O
Haemogram	O
leucocytes	O
30	O
,	O
400	O
mm3	O
N	O
28	O
,	O
600	O
mm3	O
;	O
L	O
700	O
mm3	O
,	O
haemoglobin	O
13	O
.	O
4	O
g	O
dl	O
.	O
Urgent	O
cardiac	O
catheterisation	O
transient	O
pacemaker	O
via	O
the	O
right	O
femoral	O
vein	O
,	O
positioned	O
in	O
the	O
apex	O
of	O
the	O
left	O
ventricle	O
LV	O
.	O
Acute	O
thrombotic	O
occlusion	O
in	O
proximal	O
anterior	O
descending	O
LAD	O
with	O
TIMI	O
0	O
flow	O
.	O
Thromboaspiration	O
and	O
angioplasty	O
with	O
conventional	O
2	O
.	O
5	O
mm	O
balloon	O
achieved	O
flow	O
in	O
the	O
anterior	O
descending	O
and	O
,	O
subsequently	O
,	O
in	O
the	O
diagonal	O
branch	O
,	O
leaving	O
TIMI	O
3	O
flow	O
in	O
both	O
arteries	O
.	O
CLINICAL	O
EVOLUTION	O
Given	O
the	O
high	O
suspicion	O
of	O
acute	O
coronary	O
syndrome	O
with	O
ST	O
segment	O
elevation	O
Killip	O
Kimball	O
IV	O
,	O
the	O
infarction	O
code	O
was	O
activated	O
and	O
a	O
central	O
venous	O
line	O
was	O
channelled	O
for	O
the	O
infusion	O
of	O
vasoactive	O
drugs	O
prior	O
to	O
transfer	O
to	O
the	O
haemodynamics	O
room	O
dobutamine	B-FARMACO
and	O
noradrenaline	B-FARMACO
.	O
During	O
the	O
transfer	O
he	O
presented	O
cardiorespiratory	O
arrest	O
in	O
ventricular	O
fibrillation	O
,	O
so	O
advanced	O
cardiopulmonary	O
resuscitation	O
manoeuvres	O
were	O
started	O
,	O
and	O
he	O
recovered	O
a	O
pulse	O
after	O
defibrillation	O
at	O
200J	O
.	O
Orotracheal	O
intubation	O
was	O
performed	O
and	O
the	O
patient	O
was	O
transferred	O
with	O
a	O
transcutaneous	O
pacemaker	O
and	O
sedorelaxed	O
,	O
finally	O
arriving	O
at	O
the	O
haemodynamics	O
room	O
.	O
There	O
,	O
a	O
transient	O
pacemaker	O
was	O
implanted	O
via	O
the	O
right	O
femoral	O
vein	O
and	O
continuous	O
perfusion	O
of	O
noradrenaline	B-FARMACO
and	O
dobutamine	B-FARMACO
was	O
maintained	O
at	O
0	O
.	O
9	O
and	O
8	O
μgr	O
kg	O
min	O
,	O
respectively	O
.	O
Embolic	O
occlusion	O
of	O
the	O
proximal	O
LAD	O
and	O
diagonal	O
branch	O
was	O
revascularised	O
.	O
Admitted	O
to	O
the	O
intensive	O
care	O
unit	O
.	O
Initially	O
,	O
favourable	O
evolution	O
.	O
Recovery	O
of	O
atrioventricular	O
conduction	O
after	O
revascularisation	O
,	O
but	O
temporary	O
safety	O
pacemaker	O
is	O
maintained	O
at	O
50	O
bpm	O
.	O
Echocardiogram	O
showed	O
severely	O
depressed	O
ventricular	O
function	O
,	O
LVEF	O
by	O
Simpson	O
around	O
15	O
,	O
with	O
anteroseptal	O
akinesia	O
,	O
anterior	O
mid	O
apical	O
and	O
all	O
apical	O
segments	O
,	O
asynchronous	O
septal	O
movement	O
,	O
as	O
well	O
as	O
a	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
Given	O
the	O
haemodynamic	O
improvement	O
,	O
noradrenaline	O
was	O
started	O
and	O
the	O
patient	O
was	O
extubated	O
without	O
incident	O
,	O
maintaining	O
oxygen	O
saturation	O
with	O
low	O
flow	O
nasal	O
cannulae	O
and	O
negative	O
water	O
balance	O
.	O
However	O
,	O
24	O
hours	O
after	O
admission	O
,	O
he	O
began	O
to	O
experience	O
unstable	O
angina	O
that	O
became	O
refractory	O
,	O
together	O
with	O
haemodynamic	O
deterioration	O
.	O
Given	O
the	O
severity	O
of	O
the	O
condition	O
and	O
the	O
lack	O
of	O
response	O
,	O
it	O
was	O
decided	O
,	O
together	O
with	O
the	O
family	O
,	O
to	O
limit	O
the	O
therapeutic	O
effort	O
and	O
,	O
finally	O
,	O
he	O
died	O
.	O
DIAGNOSIS	O
Ischaemic	O
heart	O
disease	O
.	O
Acute	O
anterior	O
myocardial	O
infarction	O
,	O
Killip	O
IV	O
.	O
Acute	O
embolic	O
occlusion	O
of	O
the	O
anterior	O
descending	O
artery	O
.	O
Severely	O
depressed	O
left	O
ventricular	O
function	O
.	O
Primary	O
ventricular	O
fibrillation	O
.	O
Complete	O
ischaemic	O
atrioventricular	O
block	O
.	O
Cardiogenic	O
shock	O
.	O
Exitus	O
.	O
Valvular	O
heart	O
disease	O
bicuspid	O
aortic	O
valve	O
disease	O
with	O
moderate	O
stenosis	O
and	O
dilatation	O
of	O
the	O
ascending	O
aorta	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
type	O
2	O
diabetes	O
mellitus	O
,	O
hypertension	O
,	O
dyslipidaemia	O
.	O
No	O
toxic	O
habits	O
.	O
Cardiological	O
history	O
ischaemic	O
heart	O
disease	O
triple	O
bypass	O
in	O
September	O
2015	O
due	O
to	O
severe	O
disease	O
of	O
the	O
trunk	O
and	O
three	O
vessels	O
,	O
proximal	O
anterior	O
descending	O
,	O
proximal	O
medial	O
circumflex	O
and	O
posterior	O
interventricular	O
.	O
He	O
had	O
lost	O
clinical	O
follow	O
up	O
,	O
with	O
last	O
transthoracic	O
echocardiography	O
TTE	O
in	O
2018	O
left	O
ventricle	O
with	O
moderate	O
concentric	O
hypertrophy	O
,	O
LVEF	O
50	O
with	O
hypokinesia	O
of	O
lower	O
middle	O
and	O
basal	O
segments	O
,	O
no	O
valvulopathies	O
and	O
normal	O
right	O
ventricular	O
function	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
diagnosed	O
in	O
2012	O
.	O
He	O
had	O
recently	O
undergone	O
electrical	O
cardioversion	O
ECV	O
.	O
Other	O
medical	O
and	O
surgical	O
history	O
vertebrobasilar	O
ischaemic	O
stroke	O
in	O
2017	O
,	O
with	O
no	O
sequelae	O
.	O
Chronic	O
kidney	O
disease	O
CKD	O
3bA1	O
probably	O
secondary	O
to	O
nephroangiosclerosis	O
.	O
Polyposis	O
of	O
the	O
colon	O
with	O
multiple	O
endoscopic	O
exeresis	O
.	O
Hyperuricaemia	O
with	O
gout	O
crisis	O
.	O
Surgical	O
interventions	O
coronary	O
bypass	O
,	O
right	O
inguinal	O
herniorrhaphy	O
,	O
cataracts	O
.	O
Current	O
treatment	O
insulin	B-FARMACO
glargine	I-FARMACO
22	O
IU	O
24	O
h	O
,	O
linagliptin	B-FARMACO
5	O
mg	O
24	O
h	O
,	O
pitavastatin	B-FARMACO
2	O
mg	O
24	O
h	O
,	O
enalapril	B-FARMACO
5	O
mg	O
24	O
h	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
24	O
h	O
,	O
acenocoumarol	B-FARMACO
2	O
mg	O
24	O
h	O
,	O
amiodarone	B-FARMACO
200	O
mg	O
24	O
h	O
,	O
pantoprazole	B-FARMACO
20	O
mg	O
24	O
h	O
,	O
febuxostat	B-FARMACO
80	O
mg	O
24	O
h	O
.	O
Present	O
illness	O
A	O
78	O
year	O
old	O
man	O
came	O
to	O
the	O
emergency	O
department	O
for	O
progressive	O
dyspnoea	O
of	O
months	O
of	O
evolution	O
,	O
more	O
marked	O
in	O
the	O
last	O
20	O
days	O
until	O
minimal	O
effort	O
baseline	O
NYHA	O
I	O
II	O
IV	O
,	O
consultation	O
in	O
functional	O
class	O
III	O
IV	O
,	O
despite	O
a	O
course	O
of	O
furosemide	B-FARMACO
2	O
tablets	O
a	O
day	O
for	O
the	O
last	O
week	O
by	O
his	O
primary	O
care	O
physician	O
.	O
He	O
had	O
an	O
increase	O
in	O
his	O
baseline	O
orthopnoea	O
and	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
PND	O
,	O
as	O
well	O
as	O
progressive	O
oedematisation	O
of	O
the	O
lower	O
limbs	O
since	O
the	O
previous	O
month	O
.	O
He	O
reported	O
clinical	O
symptoms	O
compatible	O
with	O
exertional	O
angina	O
,	O
consisting	O
of	O
oppressive	O
central	O
thoracic	O
and	O
epigastric	O
pain	O
,	O
non	O
radiating	O
,	O
without	O
vegetative	O
cortex	O
,	O
which	O
had	O
subsided	O
after	O
15	O
minutes	O
with	O
rest	O
since	O
approximately	O
4	O
months	O
previously	O
,	O
stable	O
with	O
no	O
recent	O
progression	O
.	O
He	O
denied	O
palpitations	O
.	O
No	O
fever	O
or	O
other	O
infectious	O
symptoms	O
on	O
physical	O
examination	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
115	O
69	O
mmHg	O
,	O
heart	O
rate	O
60	O
bpm	O
,	O
oxygen	O
saturation	O
94	O
with	O
O2	O
through	O
nasal	O
goggles	O
at	O
2	O
l	O
min	O
.	O
Afebrile	O
.	O
Good	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
.	O
Skin	O
pallor	O
.	O
Eupneic	O
at	O
rest	O
.	O
No	O
jugular	O
engorgement	O
.	O
Cardiac	O
auscultation	O
regular	O
heart	O
sounds	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
generalised	O
hypophonesis	O
,	O
bibasal	O
crackles	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
,	O
no	O
masses	O
or	O
megaliths	O
.	O
Lower	O
limbs	O
with	O
oedema	O
up	O
to	O
the	O
root	O
of	O
the	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
,	O
signs	O
of	O
left	O
atrial	O
enlargement	O
,	O
PR	O
240	O
ms	O
,	O
QRS	O
100	O
ms	O
,	O
precordial	O
R	O
progression	O
defect	O
,	O
QS	O
in	O
inferior	O
face	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
no	O
infiltrates	O
or	O
masses	O
,	O
increased	O
cardiothoracic	O
index	O
CTI	O
,	O
slight	O
right	O
costophrenic	O
sinus	O
impingement	O
,	O
median	O
sternotomy	O
sutures	O
.	O
Laboratory	O
tests	O
haemogram	O
red	O
cells	O
4	O
.	O
13	O
10	O
12	O
l	O
,	O
haemoglobin	O
12	O
.	O
8	O
g	O
dl	O
,	O
haematocrit	O
39	O
.	O
1	O
,	O
MCV	O
94	O
.	O
8	O
fl	O
,	O
MCH	O
30	O
.	O
9	O
pg	O
,	O
ADE	O
15	O
,	O
leukocytes	O
5	O
.	O
8	O
10	O
9	O
l	O
,	O
neutrophils	O
4	O
.	O
1	O
10	O
9	O
l	O
,	O
lymphocytes	O
1	O
.	O
1	O
10	O
9	O
l	O
,	O
monocytes	O
0	O
.	O
4	O
10	O
9	O
l	O
,	O
eosinophils	O
0	O
.	O
1	O
10	O
9	O
l	O
,	O
basophils	O
0	O
10	O
9	O
l	O
,	O
platelets	O
150	O
10	O
9	O
l	O
.	O
Biochemistry	O
glucose	O
88	O
mg	O
dl	O
,	O
sodium	O
140	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
5	O
mEq	O
l	O
,	O
chlorine	O
106	O
mEq	O
l	O
,	O
GPT	O
40	O
U	O
l	O
,	O
urea	O
83	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
67	O
mg	O
dl	O
,	O
transferrin	O
saturation	O
index	O
17	O
,	O
ferritin	O
47	O
mcg	O
l	O
,	O
C	O
reactive	O
protein	O
0	O
.	O
8	O
mg	O
dl	O
.	O
Haemostasis	O
Quick	O
's	O
index	O
32	O
,	O
INR	O
2	O
.	O
22	O
,	O
aPTT	O
35	O
.	O
7	O
s	O
,	O
derived	O
fibrinogen	O
464	O
mg	O
dl	O
.	O
Serum	O
proteinogram	O
albumin	O
53	O
.	O
5	O
,	O
alpha	O
1	O
globulin	O
4	O
.	O
5	O
,	O
alpha	O
2	O
globulin	O
13	O
.	O
6	O
,	O
beta	O
globulin	O
12	O
,	O
gamma	O
globulin	O
16	O
.	O
4	O
,	O
albumin	O
globulin	O
ratio	O
1	O
.	O
1	O
.	O
No	O
monoclonal	O
peak	O
is	O
observed	O
.	O
Free	O
light	O
chains	O
in	O
serum	O
and	O
urine	O
negative	O
.	O
TTE	O
severe	O
concentric	O
left	O
ventricular	O
hypertrophy	O
with	O
preserved	O
global	O
systolic	O
function	O
.	O
Hypokinesia	O
in	O
lower	O
mid	O
basal	O
segments	O
.	O
Diastolic	O
pattern	O
with	O
single	O
E	O
wave	O
with	O
data	O
suggestive	O
of	O
increased	O
filling	O
pressures	O
.	O
Trivial	O
mitral	O
regurgitation	O
.	O
Mild	O
aortic	O
insufficiency	O
.	O
Mild	O
left	O
atrial	O
dilatation	O
.	O
Right	O
ventricle	O
with	O
preserved	O
systolic	O
function	O
.	O
Mild	O
tricuspid	O
insufficiency	O
TI	O
allowing	O
estimation	O
of	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAPS	O
of	O
approximately	O
35	O
40	O
mmHg	O
.	O
Plethoric	O
inferior	O
vena	O
cava	O
IVC	O
.	O
Exploration	O
in	O
atrial	O
fibrillation	O
AF	O
with	O
RV	O
as	O
80	O
bpm	O
.	O
Cardiac	O
MRI	O
video	O
3	O
,	O
images	O
3	O
and	O
4	O
left	O
ventricle	O
LV	O
of	O
normal	O
volumes	O
LVOT	O
85	O
ml	O
m2	O
,	O
STV	O
32	O
ml	O
m2	O
with	O
increased	O
myocardial	O
mass	O
LVMI	O
114	O
g	O
m2	O
and	O
concentric	O
hypertrophy	O
septum	O
21	O
mm	O
and	O
posterior	O
wall	O
17	O
mm	O
with	O
basal	O
and	O
mid	O
inferior	O
hypokinesia	O
with	O
preserved	O
global	O
systolic	O
function	O
LVEF	O
62	O
.	O
STIR	O
sequences	O
show	O
mild	O
myocardial	O
oedema	O
at	O
anterior	O
,	O
anteroseptal	O
,	O
mid	O
inferoseptal	O
,	O
anterior	O
and	O
apical	O
septal	O
levels	O
.	O
Right	O
ventricle	O
RV	O
not	O
dilated	O
RVOT	O
94	O
ml	O
m2	O
,	O
STV	O
41	O
ml	O
m2	O
with	O
preserved	O
global	O
systolic	O
function	O
RVEF	O
56	O
.	O
Aorta	O
and	O
great	O
vessels	O
of	O
normal	O
diameter	O
and	O
morphology	O
.	O
Left	O
atrium	O
slightly	O
dilated	O
.	O
Estimated	O
normal	O
pulmonary	O
vascular	O
resistance	O
mean	O
pulmonary	O
velocity	O
11	O
cm	O
s	O
.	O
Gadoteric	B-FARMACO
acid	I-FARMACO
0	O
.	O
15	O
mM	O
kg	O
is	O
administered	O
well	O
tolerated	O
by	O
the	O
patient	O
.	O
Necrosis	O
and	O
viability	O
detection	O
study	O
presence	O
of	O
myocardial	O
late	O
gadolinium	O
enhancement	O
LGE	O
suggestive	O
of	O
subendocardial	O
necrosis	O
at	O
anterior	O
segment	O
level	O
with	O
diffuse	O
epicardial	O
fibrosis	O
at	O
septal	O
and	O
inferior	O
basal	O
,	O
middle	O
and	O
apical	O
segments	O
;	O
as	O
well	O
as	O
difficulty	O
in	O
myocardial	O
nulling	O
on	O
viability	O
sequences	O
suggesting	O
diffuse	O
intramyocardial	O
fibrosis	O
with	O
subendocardial	O
RV	O
LGE	O
.	O
Whole	O
body	O
bone	O
scan	O
after	O
3	O
hours	O
of	O
tracer	O
infusion	O
99mTc	O
HDP	O
increased	O
uptake	O
is	O
observed	O
at	O
the	O
level	O
of	O
the	O
cardiac	O
silhouette	O
of	O
greater	O
intensity	O
than	O
the	O
surrounding	O
bone	O
structures	O
score	O
3	O
.	O
Genetic	O
study	O
study	O
of	O
the	O
TTR	O
gene	O
,	O
ruling	O
out	O
the	O
presence	O
of	O
a	O
mutation	O
.	O
CLINICAL	O
EVOLUTION	O
A	O
diagnosis	O
of	O
decompensated	O
heart	O
failure	O
was	O
made	O
in	O
the	O
emergency	O
department	O
and	O
treatment	O
with	O
intravenous	O
diuretics	O
was	O
started	O
.	O
Diuretic	O
response	O
was	O
poor	O
,	O
requiring	O
oxygen	B-FARMACO
therapy	O
to	O
maintain	O
oxygen	O
saturation	O
,	O
and	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
cardiology	O
ward	O
to	O
complete	O
the	O
study	O
and	O
treatment	O
.	O
The	O
patient	O
's	O
evolution	O
was	O
slowly	O
favourable	O
with	O
depletive	O
treatment	O
.	O
Renal	O
function	O
deteriorated	O
secondary	O
to	O
heart	O
failure	O
and	O
intensive	O
use	O
of	O
diuretics	O
.	O
In	O
addition	O
,	O
iron	O
deficiency	O
anaemia	O
was	O
detected	O
,	O
so	O
a	O
single	O
dose	O
of	O
1	O
,	O
000	O
mg	O
of	O
iron	B-FARMACO
carboxymaltose	I-FARMACO
was	O
administered	O
.	O
Echocardiography	O
showed	O
severe	O
left	O
ventricular	O
hypertrophy	O
with	O
a	O
granular	O
pattern	O
,	O
compatible	O
with	O
infiltrative	O
cardiomyopathy	O
,	O
and	O
cardiac	O
MRI	O
was	O
performed	O
,	O
identifying	O
a	O
pattern	O
suggestive	O
of	O
amyloidosis	O
.	O
Therefore	O
,	O
a	O
serum	O
proteinogram	O
and	O
detection	O
of	O
free	O
light	O
chains	O
in	O
serum	O
and	O
urine	O
were	O
performed	O
,	O
which	O
,	O
being	O
negative	O
,	O
ruled	O
out	O
the	O
diagnosis	O
of	O
AL	O
amyloidosis	O
.	O
With	O
the	O
suspicion	O
of	O
amyloidosis	O
due	O
to	O
TTR	O
,	O
a	O
bone	O
scan	O
with	O
bisphosphonates	O
was	O
requested	O
.	O
After	O
recovery	O
of	O
renal	O
function	O
to	O
baseline	O
levels	O
,	O
the	O
patient	O
was	O
discharged	O
from	O
hospital	O
with	O
follow	O
up	O
by	O
the	O
heart	O
failure	O
unit	O
.	O
The	O
patient	O
underwent	O
outpatient	O
scintigraphy	O
,	O
showing	O
increased	O
uptake	O
in	O
the	O
cardiac	O
silhouette	O
of	O
greater	O
intensity	O
than	O
in	O
the	O
bone	O
structures	O
,	O
establishing	O
the	O
diagnosis	O
of	O
amyloidosis	O
due	O
to	O
TTR	O
.	O
A	O
genetic	O
study	O
was	O
performed	O
,	O
which	O
was	O
negative	O
.	O
At	O
subsequent	O
visits	O
,	O
the	O
patient	O
has	O
remained	O
stable	O
in	O
NYHA	O
functional	O
class	O
II	O
IV	O
.	O
DIAGNOSIS	O
Decompensated	O
heart	O
failure	O
.	O
Cardiac	O
amyloidosis	O
due	O
to	O
wtTTR	O
.	O
Other	O
diagnoses	O
Exacerbated	O
chronic	O
kidney	O
disease	O
.	O
Normocytic	O
anaemia	O
with	O
iron	O
deficiency	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Social	O
background	O
self	O
employed	O
.	O
Lives	O
with	O
his	O
family	O
.	O
Family	O
history	O
father	O
diagnosed	O
with	O
sarcoidosis	O
and	O
"	O
large	O
heart	O
"	O
.	O
Paternal	O
grandfather	O
died	O
of	O
sudden	O
cardiac	O
death	O
at	O
the	O
age	O
of	O
74	O
.	O
Personal	O
history	O
no	O
cardiovascular	O
risk	O
factors	O
.	O
No	O
previous	O
cardiovascular	O
history	O
.	O
Other	O
history	O
keratoconus	O
.	O
Asthma	O
.	O
No	O
surgical	O
history	O
.	O
No	O
home	O
medication	O
.	O
Current	O
illness	O
39	O
year	O
old	O
patient	O
who	O
,	O
after	O
aerobic	O
physical	O
exercise	O
bicycle	O
route	O
,	O
began	O
to	O
feel	O
dizzy	O
and	O
sweaty	O
.	O
She	O
initially	O
improved	O
after	O
eating	O
an	O
apple	O
,	O
but	O
later	O
started	O
sweating	O
again	O
,	O
with	O
general	O
malaise	O
and	O
nausea	O
.	O
He	O
reported	O
associated	O
palpitations	O
.	O
No	O
anginal	O
or	O
pleuritic	O
chest	O
pain	O
.	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
was	O
recorded	O
and	O
electrical	O
cardioversion	O
at	O
200	O
J	O
was	O
performed	O
,	O
which	O
was	O
effective	O
.	O
No	O
previous	O
similar	O
symptoms	O
.	O
Physical	O
examination	O
Temperature	O
36oC	O
,	O
heart	O
rate	O
67	O
bpm	O
,	O
blood	O
pressure	O
106	O
59	O
mmHg	O
,	O
basal	O
oxygen	O
saturation	O
97	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
,	O
eupneic	O
at	O
rest	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
added	O
noise	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
without	O
audible	O
murmurs	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
Lower	O
extremities	O
without	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
haemoglobin	O
13	O
.	O
5	O
g	O
dl	O
,	O
MCV	O
93	O
fl	O
,	O
MCH	O
30	O
pg	O
,	O
leukocytes	O
10	O
,	O
987	O
μl	O
,	O
platelets	O
186	O
,	O
000	O
μl	O
.	O
Biochemistry	O
glucose	O
101	O
mg	O
dl	O
,	O
urea	O
24	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
84	O
mg	O
dl	O
,	O
sodium	O
140	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
2	O
mmol	O
l	O
,	O
lactate	O
dehydrogenase	O
153	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
41	O
U	O
l	O
,	O
aspartate	O
aminotransferase	O
28	O
U	O
l	O
,	O
alanine	O
aminotransferase	O
28	O
U	O
l	O
,	O
gamma	O
glutamyltransferase	O
22	O
U	O
l	O
,	O
total	O
bilirubin	O
1	O
.	O
3	O
mg	O
dl	O
,	O
direct	O
bilirubin	O
0	O
.	O
5	O
mg	O
dl	O
,	O
total	O
protein	O
69	O
g	O
l	O
,	O
albumin	O
44	O
g	O
l	O
,	O
total	O
cholesterol	O
138	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
54	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
70	O
mg	O
dl	O
,	O
triglycerides	O
69	O
mg	O
dl	O
,	O
HbA1C	O
5	O
.	O
5	O
,	O
thyrotropin	O
TSH	O
1	O
.	O
27	O
mU	O
l	O
,	O
serum	O
IgG	O
11	O
.	O
11	O
g	O
l	O
,	O
serum	O
IgA	O
1	O
.	O
64	O
g	O
l	O
,	O
serum	O
IgM	O
0	O
.	O
79	O
g	O
l	O
.	O
Ultrasensitive	O
troponin	O
T	O
normal	O
14	O
on	O
arrival	O
and	O
at	O
3	O
hours	O
187	O
66	O
ng	O
l	O
.	O
Coagulation	O
INR	O
1	O
.	O
1	O
,	O
prothrombin	O
rate	O
81	O
,	O
partial	O
thromboplastin	O
time	O
28	O
.	O
80	O
s	O
,	O
D	O
dimer	O
555	O
ng	O
ml	O
.	O
Electrocardiogram	O
ECG	O
on	O
arrival	O
at	O
the	O
ED	O
monomorphic	O
ventricular	O
tachycardia	O
with	O
BRD	O
morphology	O
and	O
superior	O
axis	O
.	O
Baseline	O
ECG	O
sinus	O
rhythm	O
.	O
QRS	O
with	O
low	O
voltages	O
in	O
limb	O
leads	O
,	O
negative	O
T	O
wave	O
V3	O
V6	O
,	O
I	O
,	O
aVL	O
,	O
II	O
,	O
III	O
and	O
aVF	O
.	O
Chest	O
X	O
ray	O
slightly	O
increased	O
cardiothoracic	O
index	O
,	O
no	O
signs	O
of	O
heart	O
failure	O
.	O
Transthoracic	O
echocardiogram	O
at	O
discharge	O
severely	O
dilated	O
right	O
ventricle	O
RV	O
with	O
depressed	O
systolic	O
function	O
.	O
Left	O
ventricle	O
LV	O
slightly	O
dilated	O
without	O
hypertrophy	O
,	O
mild	O
LV	O
systolic	O
dysfunction	O
due	O
to	O
global	O
hypokinesia	O
,	O
without	O
segmental	O
contractility	O
abnormalities	O
.	O
No	O
valvular	O
heart	O
disease	O
,	O
no	O
pericardial	O
effusion	O
.	O
3D	O
angio	O
CT	O
reconstruction	O
of	O
coronary	O
arteries	O
coronary	O
arteries	O
without	O
lesions	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
4	O
chamber	O
cine	O
gradient	O
echo	O
sequence	O
SSFP	O
video	O
2	O
Dilated	O
and	O
hypocontractile	O
LV	O
with	O
moderate	O
systolic	O
dysfunction	O
.	O
RV	O
dilatation	O
with	O
global	O
hypocontractility	O
,	O
ejection	O
fraction	O
36	O
.	O
Gradient	O
echo	O
sequence	O
SSFP	O
cine	O
,	O
centred	O
in	O
the	O
RV	O
outflow	O
tract	O
video	O
3	O
Areas	O
of	O
dyskinesia	O
and	O
hypocontractility	O
are	O
seen	O
in	O
the	O
RV	O
outflow	O
tract	O
.	O
Late	O
gadolinium	O
enhancement	O
sequence	O
,	O
4	O
chamber	O
A	O
and	O
short	O
axis	O
B	O
uptake	O
at	O
the	O
level	O
of	O
the	O
LV	O
lateral	O
wall	O
in	O
mid	O
and	O
apical	O
segments	O
and	O
in	O
the	O
RV	O
inferior	O
wall	O
at	O
mid	O
level	O
,	O
compatible	O
with	O
fibrosis	O
.	O
Immunology	O
antinuclear	O
antibodies	O
negative	O
.	O
Neutrophil	O
anti	O
cytoplasmic	O
antibodies	O
in	O
vasculitis	O
negative	O
.	O
Genetics	O
homozygous	O
carrier	O
of	O
the	O
pathogenic	O
variant	O
p	O
.	O
T335A	O
in	O
the	O
DSG2	O
gene	O
.	O
CLINICAL	O
COURSE	O
Non	O
syncopal	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
,	O
with	O
clinical	O
involvement	O
and	O
acceptable	O
haemodynamic	O
tolerance	O
.	O
Electrical	O
cardioversion	O
to	O
sinus	O
rhythm	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
in	O
the	O
emergency	O
department	O
prior	O
to	O
admission	O
to	O
cardiology	O
,	O
showing	O
mild	O
LV	O
dysfunction	O
and	O
significant	O
dilatation	O
of	O
the	O
RV	O
.	O
As	O
part	O
of	O
the	O
study	O
and	O
in	O
order	O
to	O
rule	O
out	O
underlying	O
coronary	O
artery	O
disease	O
that	O
could	O
justify	O
the	O
arrhythmia	O
,	O
a	O
CT	O
scan	O
of	O
the	O
coronary	O
arteries	O
was	O
performed	O
without	O
lesions	O
,	O
showing	O
RV	O
dilatation	O
with	O
irregular	O
contour	O
.	O
Studies	O
were	O
completed	O
with	O
a	O
CMR	O
compatible	O
with	O
arrhythmogenic	O
cardiomyopathy	O
,	O
predominantly	O
of	O
the	O
RV	O
,	O
although	O
the	O
LV	O
was	O
also	O
affected	O
.	O
Finally	O
,	O
an	O
implantable	O
cardioverter	O
defibrillator	O
was	O
implanted	O
for	O
secondary	O
prevention	O
.	O
Stable	O
throughout	O
admission	O
,	O
he	O
was	O
discharged	O
without	O
incident	O
with	O
neurohormonal	O
treatment	O
with	O
bisoprolol	O
and	O
ramipril	O
.	O
During	O
follow	O
up	O
,	O
the	O
patient	O
remained	O
without	O
clinical	O
incidents	O
or	O
device	O
therapies	O
.	O
A	O
genetic	O
test	O
was	O
requested	O
,	O
which	O
was	O
positive	O
in	O
homozygosis	O
for	O
the	O
pathogenic	O
variant	O
p	O
.	O
T335A	O
in	O
the	O
desmoglein	O
2	O
gene	O
DSG2	O
.	O
DIAGNOSIS	O
Arrhythmogenic	O
cardiomyopathy	O
with	O
biventricular	O
involvement	O
moderate	O
LV	O
and	O
RV	O
systolic	O
dysfunction	O
.	O
Episode	O
of	O
non	O
syncopal	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
.	O
ICD	O
implantation	O
for	O
secondary	O
prevention	O
.	O
Homozygous	O
carrier	O
of	O
pathogenic	O
variant	O
in	O
desmoglein	O
2	O
gene	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Cardiovascular	O
risk	O
factors	O
Smoker	O
since	O
youth	O
.	O
Currently	O
about	O
6	O
cigarettes	O
day	O
cumulative	O
consumption	O
20	O
packs	O
year	O
Heavy	O
drinker	O
until	O
about	O
3	O
years	O
ago	O
.	O
Currently	O
occasional	O
drinker	O
.	O
Former	O
cocaine	O
user	O
last	O
use	O
9	O
years	O
ago	O
.	O
Arterial	O
hypertension	O
for	O
5	O
years	O
and	O
without	O
treatment	O
,	O
with	O
good	O
control	O
.	O
Obesity	O
grade	O
II	O
III	O
in	O
the	O
past	O
,	O
currently	O
overweight	O
.	O
Cardiological	O
history	O
no	O
personal	O
or	O
family	O
history	O
of	O
early	O
ischaemic	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
Other	O
history	O
cutaneous	O
psoriasis	O
since	O
childhood	O
,	O
without	O
arthropathy	O
.	O
One	O
episode	O
of	O
erythroderma	O
15	O
years	O
ago	O
.	O
Chronic	O
treatment	O
occasional	O
treatment	O
for	O
psoriasis	O
clobetasol	B-FARMACO
propionate	I-FARMACO
ointment	O
and	O
calcipotriol	B-FARMACO
cream	O
.	O
Present	O
illness	O
The	O
patient	O
comes	O
to	O
the	O
emergency	O
department	O
for	O
progressive	O
dyspnoea	O
until	O
minimal	O
effort	O
of	O
seven	O
days	O
of	O
evolution	O
.	O
Orthopnoea	O
and	O
paroxysmal	O
dyspnoea	O
the	O
previous	O
night	O
.	O
He	O
also	O
reported	O
rapid	O
palpitations	O
with	O
a	O
frequency	O
measured	O
at	O
home	O
of	O
around	O
130	O
beats	O
per	O
minute	O
.	O
No	O
angina	O
pectoris	O
,	O
no	O
episodes	O
of	O
dizziness	O
or	O
syncope	O
.	O
No	O
other	O
relevant	O
symptoms	O
in	O
the	O
anamnesis	O
by	O
apparatus	O
,	O
except	O
for	O
the	O
presence	O
of	O
skin	O
lesions	O
related	O
to	O
psoriasis	O
and	O
skin	O
striae	O
as	O
the	O
only	O
relevant	O
complaint	O
.	O
During	O
his	O
stay	O
in	O
the	O
emergency	O
department	O
and	O
despite	O
initial	O
treatment	O
with	O
intravenous	O
furosemide	B-FARMACO
and	O
beta	O
blockers	O
,	O
the	O
clinical	O
situation	O
worsened	O
and	O
he	O
was	O
transferred	O
to	O
the	O
coronary	O
unit	O
.	O
Physical	O
examination	O
Afebrile	O
,	O
heart	O
rate	O
135	O
bpm	O
,	O
blood	O
pressure	O
141	O
99	O
mmHg	O
.	O
RR	O
22	O
rpm	O
and	O
basal	O
oxygen	O
saturation	O
94	O
without	O
supplementary	O
O2	O
on	O
arrival	O
evolution	O
in	O
the	O
first	O
hours	O
RR	O
32	O
min	O
.	O
SpO2	O
with	O
O2	O
at	O
4	O
l	O
min	O
92	O
94	O
.	O
General	O
appearance	O
erythroderma	O
with	O
multiple	O
reddish	O
plaques	O
with	O
scaling	O
suggestive	O
of	O
psoriasis	O
on	O
the	O
trunk	O
and	O
upper	O
extremities	O
.	O
Stretch	O
marks	O
on	O
abdomen	O
,	O
arms	O
and	O
legs	O
.	O
Cold	O
hands	O
and	O
feet	O
,	O
with	O
thinned	O
fingers	O
and	O
toes	O
and	O
signs	O
of	O
chronic	O
malperfusion	O
.	O
Rhythmic	O
carotid	O
arteries	O
,	O
no	O
murmurs	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
tachycardic	O
,	O
systolic	O
murmur	O
in	O
mitral	O
focus	O
II	O
VI	O
with	O
preserved	O
second	O
sound	O
.	O
Pulmonary	O
auscultation	O
bibasal	O
crackles	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
,	O
no	O
palpable	O
masses	O
or	O
megaliths	O
.	O
Lower	O
limbs	O
symmetrical	O
pedal	O
pulses	O
,	O
pretibial	O
oedema	O
,	O
signs	O
of	O
chronic	O
venous	O
insufficiency	O
with	O
varicose	O
veins	O
.	O
Diffuse	O
psoriasis	O
lesions	O
,	O
with	O
reddish	O
plaques	O
with	O
scaling	O
and	O
inflammatory	O
signs	O
on	O
the	O
trunk	O
and	O
extremities	O
.	O
COMPLEMENTARY	O
TESTS	O
Chest	O
X	O
ray	O
cardiomegaly	O
with	O
vascular	O
redistribution	O
,	O
Kerley	O
's	O
B	O
lines	O
and	O
bilateral	O
alveolar	O
infiltrate	O
.	O
Electrocardiogram	O
on	O
admission	O
uncommon	O
atrial	O
flutter	O
with	O
3	O
1	O
conduction	O
.	O
Narrow	O
QRS	O
with	O
normal	O
axis	O
,	O
QS	O
in	O
V1	O
V3	O
,	O
QR	O
in	O
V4	O
,	O
ST	O
elevation	O
of	O
2	O
mm	O
in	O
V4	O
V5	O
,	O
qR	O
in	O
inferior	O
leads	O
,	O
compatible	O
with	O
old	O
anterior	O
and	O
inferior	O
infarction	O
.	O
Normal	O
QTc	O
interval	O
.	O
Complete	O
blood	O
test	O
Glucose	O
123	O
mg	O
dl	O
,	O
sodium	O
137	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
1	O
mmol	O
l	O
.	O
Creatinine	O
0	O
.	O
66	O
FGE	O
120	O
ml	O
min	O
.	O
US	O
Troponin	O
T	O
780	O
ng	O
l	O
738	O
ng	O
l	O
686	O
ng	O
l	O
normal	O
14	O
ng	O
l	O
.	O
Liver	O
function	O
tests	O
GGT	O
144	O
U	O
l	O
LSN	O
30	O
U	O
l	O
,	O
FA	O
139	O
U	O
l	O
LSN	O
117	O
U	O
l	O
,	O
LDH	O
634	O
LSN	O
480	O
U	O
l	O
.	O
Transaminases	O
normal	O
.	O
TSH	O
0	O
.	O
86	O
mIU	O
l	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
194	O
mg	O
dl	O
,	O
LDL	O
133	O
mg	O
dl	O
,	O
HDL	O
36	O
mg	O
dl	O
,	O
triglycerides	O
127	O
mg	O
dl	O
.	O
Anaemia	O
profile	O
iron	O
35	O
ug	O
dl	O
,	O
ferritin	O
434	O
ng	O
ml	O
,	O
IST	O
13	O
.	O
2	O
.	O
Rheumatoid	O
factor	O
10	O
.	O
8	O
kU	O
l	O
LSN	O
15	O
kU	O
l	O
.	O
Interleukin	O
6	O
19	O
pg	O
ml	O
35	O
pg	O
ml	O
16	O
pg	O
ml	O
normal	O
6	O
.	O
Proteinogram	O
acute	O
inflammatory	O
pattern	O
.	O
Immunoglobulins	O
IgA	O
5	O
.	O
19	O
g	O
l	O
0	O
.	O
7	O
4	O
,	O
C4	O
0	O
.	O
45	O
g	O
l	O
0	O
.	O
1	O
0	O
.	O
4	O
.	O
Rest	O
normal	O
.	O
Autoimmunity	O
ANA	O
positive	O
titre	O
1	O
80	O
,	O
homogeneous	O
pattern	O
.	O
ANA	O
negative	O
.	O
ANCA	O
negative	O
.	O
Negative	O
antiphospholipid	O
antibodies	O
.	O
Cryoglobulins	O
negative	O
.	O
Kappa	O
and	O
Lambda	O
free	O
light	O
chains	O
normal	O
levels	O
.	O
HIV	O
,	O
HBV	O
and	O
HCV	O
serology	O
negative	O
.	O
Quantiferon	O
TB	O
positive	O
1	O
.	O
26	O
UI	O
ml	O
.	O
Transthoracic	O
echocardiography	O
left	O
ventricle	O
of	O
normal	O
thickness	O
,	O
slightly	O
dilated	O
.	O
LVEF	O
severely	O
affected	O
28	O
at	O
the	O
expense	O
of	O
severe	O
hypokinesia	O
of	O
the	O
mid	O
anterior	O
and	O
lateral	O
wall	O
segments	O
and	O
all	O
apical	O
segments	O
.	O
Relaxation	O
pattern	O
not	O
assessable	O
by	O
wave	O
fusion	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Moderately	O
dilated	O
left	O
atrium	O
area	O
33	O
cm2	O
.	O
Aortic	O
valve	O
trivalve	O
,	O
normofunctioning	O
.	O
Mitral	O
valve	O
with	O
slightly	O
thickened	O
leaflets	O
,	O
with	O
central	O
regurgitation	O
jet	O
of	O
moderate	O
insufficiency	O
ERO	O
0	O
.	O
36	O
cm2	O
,	O
MR	O
volume	O
35	O
ml	O
,	O
intermediate	O
density	O
Doppler	O
.	O
Mild	O
tricuspid	O
insufficiency	O
.	O
PSAP	O
of	O
48	O
mmHg	O
PVC	O
normal	O
.	O
The	O
presence	O
of	O
intraventricular	O
thrombus	O
is	O
ruled	O
out	O
with	O
contrast	O
.	O
Diagnostic	O
coronary	O
angiography	O
Severe	O
coronary	O
artery	O
disease	O
of	O
three	O
vessels	O
middle	O
and	O
distal	O
anterior	O
descending	O
artery	O
,	O
first	O
diagonal	O
branch	O
,	O
distal	O
circumflex	O
artery	O
,	O
distal	O
right	O
coronary	O
artery	O
and	O
posterolatereal	O
branch	O
.	O
Very	O
bad	O
distal	O
beds	O
,	O
diffusely	O
diseased	O
.	O
No	O
response	O
to	O
intracoronary	O
nitroglycerin	B-FARMACO
.	O
Beds	O
not	O
revascularisable	O
.	O
Computed	O
tomography	O
angiography	O
thoracic	O
aorta	O
of	O
normal	O
dimensions	O
.	O
Supra	O
aortic	O
trunks	O
without	O
alterations	O
.	O
Patent	O
abdominal	O
aorta	O
.	O
Celiac	O
trunk	O
,	O
common	O
hepatic	O
artery	O
and	O
splenic	O
artery	O
of	O
fine	O
calibre	O
with	O
a	O
perivascular	O
cuff	O
.	O
The	O
splenic	O
artery	O
is	O
very	O
thin	O
distally	O
,	O
showing	O
hypoperfusion	O
in	O
the	O
spleen	O
at	O
this	O
stage	O
.	O
Superior	O
and	O
inferior	O
mesenteric	O
arteries	O
of	O
fine	O
calibre	O
with	O
perivascular	O
cuff	O
.	O
Common	O
iliac	O
arteries	O
,	O
external	O
iliac	O
arteries	O
,	O
common	O
femoral	O
and	O
superficial	O
femoral	O
arteries	O
with	O
decreased	O
calibre	O
and	O
perivascular	O
cuffing	O
.	O
Conclusion	O
findings	O
suggestive	O
of	O
medium	O
vessel	O
vasculitis	O
.	O
Positron	O
emission	O
tomography	O
No	O
increase	O
in	O
glucose	O
metabolism	O
in	O
the	O
wall	O
of	O
the	O
large	O
arterial	O
vessels	O
suggestive	O
of	O
vasculitis	O
is	O
visualised	O
.	O
It	O
should	O
be	O
remembered	O
that	O
corticosteroid	O
treatment	O
causes	O
false	O
negatives	O
and	O
that	O
the	O
sensitivity	O
of	O
PET	O
is	O
lower	O
in	O
medium	O
and	O
small	O
vessel	O
vasculitis	O
.	O
Two	O
hypermetabolic	O
foci	O
were	O
identified	O
in	O
the	O
colon	O
,	O
one	O
in	O
the	O
descending	O
colon	O
SUVmax	O
8	O
.	O
09	O
and	O
the	O
other	O
in	O
the	O
sigma	O
SUVmax	O
9	O
.	O
13	O
,	O
which	O
we	O
recommend	O
evaluating	O
by	O
colonoscopy	O
to	O
rule	O
out	O
malignant	O
tumour	O
pathology	O
.	O
Doppler	O
ultrasound	O
of	O
supra	O
aortic	O
trunks	O
Left	O
carotid	O
axis	O
with	O
a	O
small	O
plaque	O
at	O
the	O
level	O
of	O
the	O
bulb	O
,	O
predominantly	O
fibrolipid	O
,	O
with	O
a	O
smooth	O
and	O
regular	O
surface	O
,	O
which	O
does	O
not	O
cause	O
haemodynamic	O
alterations	O
.	O
Normal	O
flows	O
in	O
left	O
CCA	O
,	O
ICA	O
and	O
CEA	O
.	O
Right	O
carotid	O
axis	O
with	O
normal	O
echostructure	O
.	O
Vertebral	O
arteries	O
permeable	O
and	O
orthodromic	O
.	O
Abdominal	O
X	O
ray	O
dilated	O
large	O
bowel	O
loops	O
with	O
an	O
image	O
suggestive	O
of	O
cecal	O
volvulus	O
in	O
the	O
right	O
hypochondrium	O
.	O
Computed	O
tomography	O
of	O
the	O
abdomen	O
cecal	O
volvulus	O
,	O
probably	O
partial	O
,	O
of	O
the	O
cecal	O
scale	O
type	O
.	O
Mural	O
endoluminal	O
polyps	O
in	O
the	O
splenic	O
angle	O
of	O
the	O
colon	O
,	O
measuring	O
15	O
mm	O
,	O
and	O
in	O
the	O
rectosigmoid	O
junction	O
,	O
measuring	O
11	O
mm	O
,	O
both	O
with	O
uptake	O
in	O
the	O
previous	O
PET	O
CT	O
study	O
.	O
Radiological	O
improvement	O
of	O
the	O
signs	O
of	O
vasculitis	O
of	O
the	O
celiac	O
trunk	O
and	O
superior	O
and	O
inferior	O
mesenteric	O
arteries	O
.	O
A	O
more	O
prominent	O
perivascular	O
cuff	O
persists	O
in	O
the	O
primitive	O
and	O
external	O
iliac	O
vessels	O
with	O
probably	O
significant	O
stenosis	O
of	O
femoral	O
arteries	O
.	O
Colonoscopy	O
the	O
ileum	O
is	O
reached	O
.	O
In	O
the	O
cecum	O
there	O
are	O
aphthae	O
arranged	O
in	O
a	O
linear	O
fashion	O
,	O
covered	O
with	O
fibrin	O
compatible	O
with	O
ischaemic	O
colitis	O
.	O
Two	O
polyps	O
were	O
observed	O
one	O
of	O
them	O
measuring	O
about	O
15	O
mm	O
in	O
the	O
descending	O
colon	O
.	O
No	O
other	O
lesions	O
were	O
observed	O
.	O
Biopsy	O
of	O
skin	O
,	O
subcutaneous	O
cellular	O
tissue	O
,	O
muscle	O
and	O
sural	O
nerve	O
non	O
specific	O
inflammatory	O
findings	O
with	O
no	O
evidence	O
of	O
vasculitis	O
.	O
Electroneurography	O
electromyography	O
patchy	O
involvement	O
of	O
motor	O
and	O
sensory	O
fibres	O
of	O
the	O
right	O
ulnar	O
,	O
peroneal	O
and	O
tibial	O
nerves	O
suggesting	O
mononeuritis	O
multiplex	O
.	O
Echocardiography	O
at	O
discharge	O
severely	O
dilated	O
left	O
ventricle	O
indexed	O
VTD	O
158	O
ml	O
m2	O
.	O
Akinesia	O
with	O
thinning	O
of	O
all	O
apical	O
segments	O
.	O
Medial	O
anterior	O
akinesia	O
and	O
medial	O
anterior	O
,	O
medial	O
anterolateral	O
and	O
medial	O
inferolateral	O
septum	O
.	O
Medial	O
inferior	O
hypokinesia	O
and	O
basal	O
inferior	O
septum	O
.	O
Severe	O
systolic	O
dysfunction	O
biplane	O
Simpson	O
calculation	O
with	O
Sonovue	O
LVEF	O
25	O
.	O
No	O
apical	O
thrombus	O
after	O
echocontrast	O
injection	O
.	O
Restrictive	O
pattern	O
diastolic	O
dysfunction	O
with	O
elevated	O
filling	O
pressures	O
.	O
Severe	O
left	O
atrial	O
dilatation	O
.	O
Mild	O
right	O
atrial	O
dilatation	O
.	O
Normal	O
sized	O
right	O
ventricle	O
with	O
preserved	O
function	O
.	O
Severe	O
functional	O
mitral	O
regurgitation	O
.	O
Thin	O
leaflets	O
with	O
symmetrical	O
tenting	O
of	O
the	O
leaflets	O
.	O
Central	O
regurgitant	O
jet	O
with	O
dense	O
,	O
wide	O
,	O
holosystolic	O
flow	O
with	O
severe	O
regurgitation	O
.	O
ERO	O
0	O
.	O
6	O
cm2	O
.	O
Mild	O
aortic	O
insufficiency	O
.	O
Mild	O
tricuspid	O
insufficiency	O
.	O
Pulmonary	O
hypertension	O
at	O
rest	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
the	O
coronary	O
unit	O
,	O
amiodarone	B-FARMACO
perfusion	O
and	O
oxygen	O
therapy	O
with	O
high	O
flow	O
glasses	O
was	O
started	O
,	O
achieving	O
clinical	O
stabilisation	O
in	O
the	O
first	O
24	O
hours	O
,	O
with	O
reversion	O
of	O
flutter	O
to	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
,	O
negative	O
balances	O
of	O
almost	O
3	O
litres	O
and	O
marked	O
clinical	O
improvement	O
.	O
The	O
first	O
echocardiography	O
and	O
coronary	O
angiography	O
were	O
performed	O
.	O
In	O
view	O
of	O
the	O
catheterisation	O
findings	O
,	O
an	O
assessment	O
was	O
requested	O
from	O
the	O
internal	O
medicine	O
department	O
with	O
the	O
suspicion	O
of	O
a	O
vasculitic	O
condition	O
as	O
the	O
cause	O
of	O
the	O
coronary	O
lesions	O
.	O
That	O
same	O
day	O
,	O
treatment	O
was	O
started	O
with	O
corticosteroid	O
boluses	O
,	O
oral	O
prednisone	B-FARMACO
and	O
later	O
methotrexate	B-FARMACO
as	O
an	O
immunosuppressant	O
.	O
From	O
the	O
clinical	O
point	O
of	O
view	O
,	O
the	O
patient	O
was	O
admitted	O
for	O
a	O
very	O
long	O
time	O
,	O
with	O
a	O
hospital	O
stay	O
of	O
almost	O
40	O
days	O
.	O
Cardiologically	O
,	O
the	O
patient	O
showed	O
a	O
rapid	O
and	O
favourable	O
evolution	O
during	O
the	O
first	O
week	O
and	O
was	O
discharged	O
to	O
the	O
conventional	O
hospital	O
ward	O
.	O
However	O
,	O
on	O
the	O
seventh	O
day	O
of	O
admission	O
after	O
the	O
PET	O
scan	O
,	O
he	O
presented	O
an	O
arrhythmic	O
storm	O
with	O
three	O
episodes	O
of	O
sustained	O
ventricular	O
tachycardia	O
that	O
required	O
electrical	O
cardioversion	O
and	O
multiple	O
non	O
sustained	O
episodes	O
.	O
For	O
this	O
reason	O
,	O
he	O
had	O
to	O
be	O
transferred	O
again	O
to	O
the	O
coronary	O
unit	O
and	O
was	O
started	O
on	O
lidocaine	B-FARMACO
perfusion	O
,	O
midazolam	B-FARMACO
and	O
beta	O
blocker	O
with	O
a	O
good	O
response	O
.	O
He	O
did	O
not	O
suffer	O
any	O
more	O
arrhythmic	O
events	O
and	O
presented	O
a	O
slow	O
but	O
adequate	O
evolution	O
of	O
his	O
heart	O
failure	O
.	O
During	O
the	O
second	O
week	O
,	O
the	O
patient	O
suffered	O
a	O
paralytic	O
ileus	O
,	O
with	O
suspicion	O
of	O
associated	O
cecal	O
volvulus	O
which	O
was	O
the	O
reason	O
for	O
requesting	O
an	O
abdominal	O
CT	O
scan	O
and	O
colonoscopy	O
which	O
improved	O
with	O
digestive	O
rest	O
,	O
nasogastric	O
tube	O
and	O
antibiotic	O
treatment	O
without	O
the	O
need	O
for	O
surgery	O
.	O
Lastly	O
,	O
it	O
should	O
be	O
mentioned	O
that	O
on	O
admission	O
the	O
patient	O
had	O
very	O
severe	O
skin	O
involvement	O
,	O
with	O
erythroderma	O
secondary	O
to	O
his	O
psoriasis	O
,	O
as	O
well	O
as	O
involvement	O
of	O
the	O
hands	O
and	O
feet	O
with	O
signs	O
of	O
poor	O
perfusion	O
that	O
slowly	O
improved	O
with	O
medical	O
treatment	O
.	O
As	O
for	O
the	O
aetiological	O
diagnosis	O
,	O
computed	O
tomography	O
angiography	O
showed	O
lesions	O
suspicious	O
of	O
vasculitis	O
in	O
the	O
visceral	O
arteries	O
and	O
in	O
both	O
iliac	O
arteries	O
without	O
involvement	O
of	O
the	O
supra	O
aortic	O
trunks	O
.	O
The	O
complete	O
blood	O
test	O
showed	O
a	O
rather	O
anodyne	O
result	O
with	O
elevation	O
of	O
several	O
non	O
specific	O
inflammatory	O
markers	O
CRP	O
,	O
ferritin	O
,	O
complement	O
,	O
IL	O
6	O
.	O
.	O
.	O
but	O
with	O
negative	O
results	O
in	O
the	O
key	O
tests	O
ENA	O
,	O
ANCA	O
,	O
cryoglobulins	O
,	O
antiphospholipid	O
antibodies	O
,	O
HBV	O
,	O
HCV	O
and	O
HIV	O
serology	O
.	O
.	O
.	O
.	O
In	O
view	O
of	O
the	O
results	O
,	O
PET	O
CT	O
was	O
ordered	O
in	O
the	O
hope	O
of	O
confirming	O
inflammation	O
data	O
at	O
the	O
vascular	O
level	O
to	O
support	O
the	O
presumptive	O
diagnosis	O
at	O
that	O
time	O
Takayasu	O
type	O
large	O
vessel	O
vasculitis	O
was	O
the	O
main	O
candidate	O
.	O
However	O
,	O
the	O
absence	O
of	O
uptake	O
in	O
the	O
supra	O
aortic	O
trunks	O
ruled	O
out	O
this	O
pathology	O
.	O
Following	O
this	O
setback	O
,	O
multiple	O
diagnostic	O
studies	O
were	O
requested	O
with	O
the	O
intention	O
of	O
confirming	O
medium	O
vessel	O
vasculitis	O
mainly	O
polyarteritis	O
nodosa	O
,	O
PAN	O
.	O
A	O
skin	O
,	O
subcutaneous	O
tissue	O
and	O
nerve	O
biopsy	O
was	O
performed	O
,	O
as	O
well	O
as	O
an	O
electromyogram	O
electroneurogram	O
.	O
It	O
is	O
worth	O
mentioning	O
that	O
the	O
initial	O
intention	O
was	O
to	O
perform	O
a	O
direct	O
arterial	O
biopsy	O
of	O
the	O
iliac	O
femoral	O
territory	O
a	O
territory	O
known	O
to	O
be	O
affected	O
by	O
the	O
scan	O
data	O
.	O
However	O
,	O
this	O
option	O
was	O
discarded	O
following	O
vascular	O
surgery	O
assessment	O
which	O
considered	O
,	O
given	O
the	O
calibre	O
of	O
the	O
vessels	O
involved	O
,	O
that	O
the	O
risk	O
of	O
complications	O
ischaemia	O
and	O
or	O
haemorrhage	O
was	O
too	O
high	O
.	O
The	O
biopsy	O
found	O
no	O
data	O
suggestive	O
of	O
vasculitis	O
,	O
but	O
the	O
electromyogram	O
showed	O
a	O
pattern	O
of	O
mononeuritis	O
multiplex	O
,	O
very	O
typical	O
of	O
PAN	O
.	O
The	O
clinical	O
course	O
was	O
favourable	O
and	O
he	O
was	O
discharged	O
after	O
implantation	O
of	O
an	O
automatic	O
defibrillator	O
ICD	O
for	O
secondary	O
prevention	O
.	O
As	O
for	O
the	O
diagnosis	O
,	O
it	O
was	O
concluded	O
given	O
the	O
vascular	O
involvement	O
,	O
the	O
multiple	O
mononeuritis	O
and	O
the	O
improvement	O
with	O
anti	O
inflammatory	O
drugs	O
that	O
the	O
most	O
likely	O
cause	O
of	O
the	O
patient	O
's	O
clinical	O
picture	O
was	O
polyarteritis	O
nodosa	O
.	O
However	O
,	O
given	O
the	O
multiple	O
cardiovascular	O
risk	O
factors	O
including	O
cocaine	O
use	O
,	O
early	O
atherosclerosis	O
was	O
always	O
considered	O
as	O
a	O
possible	O
alternative	O
.	O
She	O
was	O
discharged	O
with	O
immunosuppressive	O
and	O
steroid	O
treatment	O
,	O
oral	O
anticoagulation	B-FARMACO
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
,	O
statins	O
and	O
full	O
medical	O
treatment	O
of	O
heart	O
failure	O
,	O
to	O
continue	O
outpatient	O
follow	O
up	O
in	O
the	O
advanced	O
heart	O
failure	O
unit	O
.	O
DIAGNOSIS	O
PAN	O
type	O
vasculitis	O
with	O
coronary	O
,	O
celiac	O
,	O
mesenteric	O
and	O
femoral	O
involvement	O
.	O
Ischaemic	O
dilated	O
cardiomyopathy	O
with	O
severe	O
left	O
ventricular	O
dysfunction	O
.	O
Heart	O
failure	O
in	O
acute	O
pulmonary	O
oedema	O
on	O
admission	O
,	O
euvolemic	O
on	O
discharge	O
.	O
Non	O
revascularisable	O
three	O
vessel	O
coronary	O
artery	O
disease	O
diffuse	O
arterial	O
disease	O
compatible	O
with	O
vasculitis	O
.	O
Arrhythmic	O
storm	O
.	O
ICD	O
implantation	O
in	O
secondary	O
prevention	O
.	O
Uncommon	O
atrial	O
flutter	O
with	O
rapid	O
ventricular	O
response	O
,	O
pharmacological	O
cardioversion	O
to	O
sinus	O
rhythm	O
.	O
Ischaemic	O
colitis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Cardiovascular	O
risk	O
factors	O
arterial	O
hypertension	O
AHT	O
.	O
Dyslipidaemia	O
.	O
Obesity	O
.	O
Diabetes	O
mellitus	O
type	O
2	O
.	O
Smoker	O
of	O
20	O
cigarettes	O
day	O
.	O
Chronic	O
alcoholism	O
8	O
UBEs	O
day	O
.	O
Persistent	O
atrial	O
fibrillation	O
anticoagulated	O
with	O
acenocoumarol	B-FARMACO
.	O
Other	O
history	O
chronic	O
bronchitis	O
without	O
obstructive	O
pattern	O
,	O
sleep	O
apnoea	O
hypopnoea	O
syndrome	O
SAHS	O
in	O
treatment	O
with	O
nocturnal	O
continuous	O
positive	O
airway	O
pressure	O
CPAP	O
.	O
Usual	O
treatment	O
glimepiride	B-FARMACO
2	O
mg	O
day	O
,	O
metformin	B-FARMACO
dapagliflozin	I-FARMACO
850	O
5	O
mg	O
every	O
12	O
hours	O
,	O
atorvastatin	B-FARMACO
30	O
mg	O
every	O
24	O
hours	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
per	O
day	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
per	O
day	O
,	O
amlodipine	B-FARMACO
5	O
mg	O
per	O
day	O
,	O
acenocoumarol	B-FARMACO
as	O
prescribed	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
24	O
hours	O
,	O
furosemide	B-FARMACO
40	O
mg	O
every	O
24	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
daily	O
,	O
indacaterol	B-FARMACO
glycopyrronium	I-FARMACO
bromide	I-FARMACO
85	O
43	O
mcg	O
1	O
capsule	O
inhaled	O
every	O
24	O
hours	O
.	O
Present	O
illness	O
A	O
57	O
year	O
old	O
patient	O
attended	O
the	O
emergency	O
department	O
with	O
worsening	O
functional	O
class	O
to	O
the	O
point	O
of	O
presenting	O
dyspnoea	O
on	O
minimal	O
effort	O
,	O
orthopnoea	O
,	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
,	O
subjective	O
decrease	O
in	O
diuresis	O
and	O
oedema	O
associated	O
with	O
weight	O
gain	O
.	O
Physical	O
examination	O
Weight	O
108	O
kg	O
,	O
height	O
1	O
.	O
71	O
m	O
.	O
Body	O
mass	O
index	O
BMI	O
36	O
.	O
9	O
kg	O
m2	O
.	O
Blood	O
pressure	O
BP	O
178	O
92	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
138	O
bpm	O
.	O
Oxygen	O
saturation	O
SatO2	O
90	O
with	O
nasal	O
goggles	O
at	O
2	O
l	O
min	O
FiO2	O
28	O
.	O
Tachypneic	O
at	O
rest	O
.	O
Jugular	O
venous	O
pressure	O
increased	O
.	O
Positive	O
hepatojugular	O
reflex	O
.	O
Cardiac	O
auscultation	O
irregular	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
bibasal	O
hypophonesis	O
of	O
right	O
predominance	O
with	O
scattered	O
rhonchi	O
.	O
Extremities	O
tibiomalleolar	O
oedema	O
up	O
to	O
the	O
root	O
of	O
the	O
thighs	O
and	O
in	O
the	O
upper	O
limbs	O
.	O
Peripheral	O
pulses	O
were	O
preserved	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
arrival	O
at	O
the	O
ED	O
atrial	O
fibrillation	O
at	O
130	O
bpm	O
.	O
Narrow	O
QRS	O
.	O
AXIS	O
0o	O
.	O
Poor	O
progression	O
of	O
the	O
septal	O
vector	O
in	O
precordial	O
leads	O
.	O
No	O
repolarisation	O
alterations	O
.	O
CBC	O
haemoglobin	O
10	O
.	O
4	O
g	O
dl	O
,	O
haematocrit	O
30	O
,	O
platelets	O
344	O
,	O
000	O
μl	O
,	O
leukocytes	O
7400	O
μl	O
.	O
International	O
normalised	O
ratio	O
INR	O
1	O
.	O
8	O
.	O
Basal	O
blood	O
glucose	O
260	O
mg	O
dl	O
.	O
Urea	O
27	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
81	O
mg	O
dl	O
,	O
sodium	O
134	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
7	O
mEq	O
l	O
.	O
HbA1C	O
8	O
.	O
6	O
.	O
Biomarkers	O
of	O
myocardial	O
damage	O
normal	O
value	O
range	O
0	O
.	O
0	O
11	O
.	O
6	O
ng	O
l	O
troponin	O
I	O
hsTnI	O
28	O
ng	O
l	O
33	O
ng	O
l	O
.	O
proBNP	O
2680	O
pg	O
ml	O
.	O
CA125	O
474	O
IU	O
ml	O
.	O
RT	O
PCR	O
for	O
SARS	O
CoV2	O
negative	O
.	O
Iron	O
metabolism	O
ferritin	O
78	O
mcg	O
l	O
,	O
IST	O
4	O
.	O
5	O
.	O
Chest	O
X	O
ray	O
centred	O
cardiomediastinal	O
silhouette	O
.	O
Cardiothoracic	O
index	O
greater	O
than	O
0	O
.	O
5	O
.	O
Bilateral	O
interstitial	O
infiltrate	O
with	O
apical	O
vascular	O
redistribution	O
.	O
Bilateral	O
pleural	O
effusion	O
,	O
predominantly	O
on	O
the	O
right	O
.	O
Echocardiograms	O
Echocardiogram	O
on	O
admission	O
left	O
ventricle	O
of	O
increased	O
diameters	O
and	O
volumes	O
with	O
moderate	O
ventricular	O
dysfunction	O
secondary	O
to	O
generalised	O
hypokinesia	O
LVEF	O
37	O
.	O
Aortic	O
root	O
normal	O
diameters	O
.	O
Dilated	O
left	O
atrium	O
.	O
Mild	O
mitral	O
insufficiency	O
MI	O
.	O
Normal	O
filling	O
pressures	O
.	O
Dilated	O
right	O
ventricle	O
with	O
depressed	O
systolic	O
function	O
.	O
Mild	O
moderate	O
tricuspid	O
insufficiency	O
TI	O
allowing	O
estimation	O
of	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAPS	O
at	O
45	O
mmHg	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
IVC	O
without	O
inspiratory	O
collapse	O
greater	O
than	O
50	O
.	O
No	O
images	O
compatible	O
with	O
thrombus	O
in	O
the	O
left	O
atrial	O
appendage	O
.	O
Study	O
performed	O
in	O
atrial	O
fibrillation	O
.	O
Control	O
echocardiography	O
3	O
months	O
after	O
discharge	O
left	O
ventricle	O
with	O
increased	O
diameters	O
and	O
volumes	O
with	O
preserved	O
global	O
systolic	O
function	O
LVEF	O
55	O
.	O
Aortic	O
root	O
normal	O
diameters	O
.	O
Dilated	O
left	O
atrium	O
.	O
Mild	O
MI	O
.	O
Normal	O
filling	O
pressures	O
.	O
Right	O
ventricle	O
of	O
normal	O
diameters	O
with	O
normal	O
systolic	O
function	O
.	O
Mildly	O
moderate	O
TR	O
allowing	O
estimation	O
of	O
PAPS	O
at	O
40	O
mmHg	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
IVC	O
of	O
normal	O
diameters	O
with	O
inspiratory	O
collapse	O
greater	O
than	O
50	O
.	O
Study	O
performed	O
in	O
sinus	O
rhythm	O
.	O
Haemodynamics	O
coronary	O
angiography	O
during	O
admission	O
.	O
Epicardial	O
coronary	O
arteries	O
with	O
diffuse	O
atheromatosis	O
without	O
significant	O
stenosis	O
.	O
CLINICAL	O
EVOLUTION	O
A	O
patient	O
with	O
decompensated	O
heart	O
failure	O
with	O
ventricular	O
dysfunction	O
of	O
probable	O
multifactorial	O
aetiology	O
,	O
who	O
presented	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
,	O
left	O
atrial	O
appendage	O
thrombus	O
was	O
ruled	O
out	O
by	O
transesophageal	O
echocardiography	O
and	O
two	O
ineffective	O
electrical	O
cardioversions	O
were	O
performed	O
.	O
Coronary	O
angiography	O
was	O
performed	O
and	O
no	O
significant	O
stenosis	O
was	O
observed	O
.	O
Treatment	O
was	O
administered	O
with	O
high	O
dose	O
bolus	O
intravenous	O
diuretics	O
,	O
ferrotherapy	O
with	O
iron	B-FARMACO
carboxymaltose	I-FARMACO
,	O
braking	O
treatment	O
with	O
beta	O
blockers	O
and	O
oral	O
treatment	O
to	O
prevent	O
alcohol	O
deprivation	O
syndrome	O
.	O
Good	O
clinical	O
and	O
diuretic	O
response	O
during	O
admission	O
.	O
Difficult	O
to	O
control	O
blood	O
glucose	O
and	O
blood	O
pressure	O
.	O
Discharged	O
9	O
days	O
after	O
admission	O
paucisymptomatic	O
and	O
in	O
atrial	O
fibrillation	O
with	O
controlled	O
ventricular	O
response	O
.	O
Treatment	O
at	O
discharge	O
metformin	B-FARMACO
dapagliflozin	I-FARMACO
850	O
5	O
mg	O
every	O
12	O
hours	O
,	O
atorvastatin	B-FARMACO
30	O
mg	O
every	O
24	O
hours	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
daily	O
,	O
amlodipine	B-FARMACO
5	O
mg	O
daily	O
,	O
rivaroxaban	B-FARMACO
20	O
mg	O
daily	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
24	O
hours	O
,	O
furosemide	B-FARMACO
80	O
mg	O
every	O
24	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
daily	O
,	O
indacaterol	B-FARMACO
glycopyrronium	I-FARMACO
bromide	I-FARMACO
85	O
43	O
mcg	O
1capsule	O
inhaled	O
every	O
24	O
hours	O
,	O
amiodarone	B-FARMACO
200	O
mg	O
daily	O
,	O
eplerenone	B-FARMACO
50	O
mg	O
daily	O
,	O
sacubitrile	B-FARMACO
valsartan	I-FARMACO
24	O
26	O
mg	O
every	O
12	O
hours	O
,	O
clomethiazole	B-FARMACO
192	O
mg	O
every	O
12	O
hours	O
,	O
semaglutide	B-FARMACO
0	O
.	O
25	O
mg	O
once	O
a	O
week	O
for	O
four	O
weeks	O
,	O
then	O
0	O
.	O
5	O
mg	O
once	O
a	O
week	O
for	O
four	O
weeks	O
and	O
then	O
1	O
mg	O
once	O
a	O
week	O
.	O
He	O
attended	O
a	O
follow	O
up	O
appointment	O
with	O
the	O
local	O
cardiology	O
department	O
3	O
months	O
later	O
,	O
with	O
improvement	O
in	O
functional	O
class	O
NYHA	O
I	O
,	O
smoking	O
cessation	O
and	O
alcohol	O
abstinence	O
.	O
Physical	O
examination	O
revealed	O
significant	O
weight	O
loss	O
12	O
kg	O
and	O
no	O
signs	O
of	O
congestion	O
.	O
Complementary	O
tests	O
showed	O
sinus	O
rhythm	O
,	O
HbA1C	O
decreased	O
to	O
7	O
.	O
2	O
and	O
proBNP	O
86	O
.	O
8	O
pg	O
ml	O
.	O
Echocardiography	O
showed	O
increased	O
diameters	O
and	O
preserved	O
global	O
systolic	O
function	O
.	O
Subsequent	O
follow	O
up	O
was	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
with	O
good	O
glycaemic	O
control	O
HbA1C	O
6	O
.	O
2	O
and	O
no	O
recurrence	O
of	O
atrial	O
fibrillation	O
.	O
DIAGNOSIS	O
Decompensated	O
heart	O
failure	O
with	O
depressed	O
LVEF	O
.	O
Dilated	O
cardiomyopathy	O
tachycardiomyopathy	O
versus	O
enolic	O
.	O
Persistent	O
atrial	O
fibrillation	O
.	O
Obesity	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
.	O
HYPERTENSION	O
.	O
Dyslipidaemia	O
.	O
Iron	O
deficiency	O
.	O
Chronic	O
macrocytic	O
anaemia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
diabetes	O
mellitus	O
,	O
ex	O
smoker	O
,	O
dyslipidaemia	O
.	O
Diffuse	O
large	O
B	O
cell	O
lymphoma	O
,	O
treated	O
with	O
chemotherapy	O
10	O
years	O
ago	O
,	O
in	O
complete	O
remission	O
.	O
Chronic	O
heart	O
failure	O
non	O
ischemic	O
dilated	O
cardiomyopathy	O
DCM	O
,	O
LVEF	O
33	O
,	O
generalised	O
hypokinesia	O
.	O
Current	O
disease	O
A	O
63	O
year	O
old	O
male	O
under	O
follow	O
up	O
by	O
the	O
heart	O
failure	O
unit	O
of	O
our	O
hospital	O
for	O
dilated	O
cardiomyopathy	O
of	O
non	O
ischaemic	O
aetiology	O
.	O
The	O
patient	O
is	O
in	O
NYHA	O
II	O
,	O
with	O
no	O
signs	O
of	O
peripheral	O
congestion	O
.	O
In	O
the	O
successive	O
analytical	O
controls	O
since	O
the	O
consultation	O
,	O
absolute	O
iron	O
deficiency	O
ferritin	O
84	O
ng	O
ml	O
and	O
STAT	O
13	O
and	O
Hb	O
of	O
13	O
g	O
dl	O
were	O
observed	O
.	O
Normal	O
renal	O
function	O
creatinine	O
0	O
.	O
84	O
mg	O
dl	O
,	O
GFR	O
85	O
.	O
94	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
and	O
Nt	O
proBNP	O
3	O
,	O
657	O
pg	O
ml	O
.	O
The	O
patient	O
was	O
included	O
in	O
the	O
protocol	O
for	O
the	O
study	O
of	O
iron	O
deficiency	O
in	O
patients	O
with	O
HF	O
and	O
reduced	O
LVEF	O
.	O
Chronic	O
treatment	O
insulin	B-FARMACO
Toujeo	I-FARMACO
50	O
IU	O
day	O
,	O
metformin	B-FARMACO
empagliflozin	I-FARMACO
1000	O
12	O
.	O
5	O
mg	O
12	O
h	O
,	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
49	O
51	O
mg	O
12	O
h	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
day	O
,	O
furosemide	B-FARMACO
40	O
mg	O
day	O
and	O
eplerenone	B-FARMACO
12	O
.	O
5	O
mg	O
day	O
.	O
COMPLEMENTARY	O
TESTS	O
As	O
part	O
of	O
the	O
study	O
protocol	O
,	O
the	O
following	O
tests	O
were	O
performed	O
Baseline	O
echocardiogram	O
left	O
ventricle	O
of	O
normal	O
diameters	O
LVEDD	O
48	O
mm	O
,	O
without	O
hypertrophy	O
of	O
its	O
walls	O
and	O
with	O
severe	O
depression	O
of	O
global	O
systolic	O
function	O
EF	O
35	O
secondary	O
to	O
generalised	O
hypokinesia	O
.	O
Aortic	O
root	O
of	O
normal	O
diameter	O
with	O
sigmoids	O
of	O
normal	O
thickness	O
and	O
opening	O
.	O
There	O
is	O
no	O
evidence	O
of	O
valve	O
dysfunction	O
.	O
Mitral	O
valve	O
with	O
leaflets	O
of	O
normal	O
thickness	O
and	O
mobility	O
.	O
Trivial	O
mitral	O
insufficiency	O
.	O
LV	O
diastolic	O
pattern	O
suggestive	O
of	O
impaired	O
relaxation	O
E	O
A	O
0	O
.	O
7	O
with	O
normal	O
estimated	O
filling	O
pressures	O
E	O
e	O
'	O
9	O
.	O
Normal	O
sized	O
atria	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
slightly	O
depressed	O
systolic	O
function	O
.	O
No	O
tricuspid	O
insufficiency	O
TI	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Global	O
longitudinal	O
strain	O
GLS	O
of	O
12	O
.	O
2	O
.	O
Baseline	O
cardiac	O
magnetic	O
resonance	O
CMR	O
left	O
ventricle	O
with	O
preserved	O
wall	O
thickness	O
,	O
slightly	O
increased	O
diastolic	O
volume	O
IVTDVI	O
97	O
ml	O
m2	O
;	O
IVTSVI	O
64	O
ml	O
m2	O
and	O
severely	O
depressed	O
global	O
systolic	O
function	O
LVEF	O
34	O
,	O
secondary	O
to	O
generalised	O
hypokinesia	O
.	O
Right	O
ventricle	O
with	O
preserved	O
morphology	O
and	O
volumes	O
IVTDVD	O
75	O
ml	O
m2	O
;	O
IVTSVD	O
38	O
ml	O
m2	O
and	O
slightly	O
depressed	O
systolic	O
function	O
LVEF	O
49	O
.	O
Left	O
atrium	O
of	O
size	O
at	O
the	O
upper	O
limit	O
39	O
mm	O
,	O
26	O
cm2	O
,	O
15	O
cm2	O
m2	O
.	O
Aorta	O
and	O
great	O
vessels	O
of	O
normal	O
diameter	O
and	O
morphology	O
.	O
Bilateral	O
pleural	O
effusion	O
.	O
T1	O
myocardium	O
1082	O
ms	O
.	O
T2	O
myocardium	O
35	O
ms	O
.	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
95	O
bpm	O
,	O
PR	O
160	O
ms	O
,	O
narrow	O
QRS	O
,	O
normal	O
axis	O
.	O
Atrial	O
extrasystoles	O
.	O
CLINICAL	O
EVOLUTION	O
According	O
to	O
protocol	O
,	O
1	O
,	O
000	O
mg	O
of	O
intravenous	O
iron	B-FARMACO
carboxymaltose	I-FARMACO
Ferinject	I-FARMACO
was	O
administered	O
weekly	O
for	O
2	O
weeks	O
,	O
and	O
after	O
confirming	O
normalisation	O
of	O
the	O
iron	B-FARMACO
profile	O
with	O
analytical	O
tests	O
,	O
a	O
new	O
structural	O
assessment	O
was	O
performed	O
.	O
CMR	O
after	O
4	O
weeks	O
of	O
iron	B-FARMACO
treatment	O
left	O
ventricle	O
with	O
preserved	O
wall	O
thickness	O
and	O
diastolic	O
volume	O
IVTDVI	O
84	O
ml	O
m2	O
;	O
IVTSVI	O
48	O
ml	O
m2	O
.	O
Moderately	O
depressed	O
global	O
systolic	O
function	O
LVEF	O
43	O
,	O
secondary	O
to	O
generalised	O
hypokinesia	O
.	O
Right	O
ventricle	O
of	O
preserved	O
morphology	O
and	O
volumes	O
IVTDVD	O
65	O
ml	O
m2	O
;	O
IVTSVD	O
30	O
ml	O
m2	O
and	O
borderline	O
systolic	O
function	O
LVEF	O
54	O
.	O
Left	O
atrium	O
of	O
normal	O
size	O
34	O
mm	O
,	O
23	O
cm2	O
,	O
13	O
cm2	O
m2	O
.	O
Aorta	O
and	O
great	O
vessels	O
of	O
normal	O
diameter	O
and	O
morphology	O
.	O
T1	O
myocardium	O
1037	O
ms	O
T2	O
myocardium	O
38	O
ms	O
.	O
There	O
was	O
significant	O
improvement	O
in	O
LV	O
ejection	O
fraction	O
estimated	O
by	O
CMR	O
LVEF	O
43	O
at	O
30	O
days	O
,	O
with	O
a	O
decrease	O
in	O
T1	O
mapping	O
to	O
1037	O
ms	O
,	O
indicating	O
myocardial	O
iron	O
repletion	O
.	O
In	O
addition	O
,	O
there	O
was	O
evidence	O
of	O
an	O
increase	O
in	O
GLS	O
to	O
19	O
.	O
1	O
.	O
These	O
changes	O
were	O
accompanied	O
by	O
improvement	O
in	O
quality	O
of	O
life	O
,	O
6	O
minute	O
test	O
and	O
other	O
surrogates	O
of	O
heart	O
failure	O
.	O
DIAGNOSIS	O
Dilated	O
cardiomyopathy	O
with	O
severely	O
depressed	O
LVEF	O
.	O
Absolute	O
iron	O
deficiency	O
.	O
Myocardial	O
iron	O
repletion	O
after	O
treatment	O
with	O
iron	B-FARMACO
carboxymaltose	I-FARMACO
Ferinject	I-FARMACO
.	O

We	O
present	O
the	O
case	O
of	O
a	O
71	O
year	O
old	O
patient	O
diagnosed	O
with	O
heart	O
failure	O
with	O
reduced	O
ejection	O
fraction	O
of	O
ischaemic	O
aetiology	O
,	O
who	O
was	O
admitted	O
for	O
an	O
episode	O
of	O
decompensation	O
.	O
During	O
his	O
stay	O
,	O
he	O
underwent	O
global	O
management	O
beyond	O
diuretic	O
therapy	O
,	O
which	O
led	O
to	O
an	O
improvement	O
in	O
his	O
functional	O
class	O
.	O
HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
hypertension	O
and	O
dyslipidaemia	O
.	O
No	O
toxic	O
habits	O
.	O
Permanent	O
atrial	O
fibrillation	O
AF	O
anticoagulated	O
with	O
acenocoumarol	B-FARMACO
.	O
Heart	O
failure	O
with	O
reduced	O
ejection	O
fraction	O
of	O
ischaemic	O
aetiology	O
.	O
Acute	O
non	O
ST	O
segment	O
elevation	O
myocardial	O
infarction	O
NSTEMI	O
in	O
2002	O
with	O
three	O
vessel	O
disease	O
and	O
severe	O
ventricular	O
dysfunction	O
without	O
improvement	O
after	O
complete	O
surgical	O
revascularisation	O
in	O
June	O
2002	O
.	O
Implantable	O
defibrillator	O
with	O
cardiac	O
resynchronisation	O
therapy	O
ICD	O
CRT	O
in	O
primary	O
prevention	O
since	O
2016	O
.	O
Last	O
TTE	O
performed	O
in	O
consultation	O
01	O
2021	O
severely	O
dilated	O
left	O
ventricle	O
with	O
severe	O
systolic	O
dysfunction	O
LVEF	O
by	O
Simpson	O
biplane	O
24	O
.	O
5	O
.	O
Septal	O
,	O
apical	O
,	O
inferior	O
and	O
inferolateral	O
akinesia	O
.	O
Anterior	O
and	O
lateral	O
hypokinesia	O
.	O
Severe	O
mitral	O
insufficiency	O
MI	O
of	O
probable	O
mixed	O
mechanism	O
.	O
Severe	O
dilatation	O
of	O
the	O
right	O
ventricle	O
RV	O
with	O
preserved	O
function	O
.	O
Severe	O
dilatation	O
of	O
both	O
atria	O
.	O
Moderate	O
aortic	O
stenosis	O
.	O
Moderate	O
tricuspid	O
insufficiency	O
TI	O
grade	O
III	O
.	O
Estimated	O
systolic	O
pulmonary	O
artery	O
pressure	O
SPAP	O
of	O
50	O
mmHg	O
.	O
Peripheral	O
arterial	O
disease	O
assessed	O
by	O
vascular	O
surgery	O
with	O
no	O
need	O
for	O
follow	O
up	O
.	O
Hyperuricaemia	O
.	O
Usual	O
treatment	O
furosemide	B-FARMACO
40	O
mg	O
2	O
tablets	O
daily	O
,	O
eplerenone	B-FARMACO
25	O
mg	O
1	O
tablet	O
at	O
lunch	O
,	O
valsartan	B-FARMACO
80	O
mg	O
half	O
a	O
day	O
,	O
carvedilol	B-FARMACO
3	O
.	O
25	O
mg	O
at	O
breakfast	O
and	O
dinner	O
,	O
acenocoumarol	B-FARMACO
as	O
prescribed	O
,	O
atorvastatin	B-FARMACO
20	O
mg	O
at	O
dinner	O
,	O
nitrate	B-FARMACO
patch	O
5	O
mg	O
,	O
allopurinol	B-FARMACO
300	O
mg	O
at	O
dinner	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
at	O
breakfast	O
.	O
Current	O
disease	O
Previously	O
in	O
functional	O
class	O
FC	O
I	O
II	O
,	O
he	O
reported	O
increasing	O
dyspnoea	O
until	O
minimal	O
effort	O
,	O
associated	O
with	O
orthopnoea	O
and	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
PND	O
.	O
In	O
addition	O
,	O
oliguria	O
,	O
oedematisation	O
of	O
the	O
lower	O
extremities	O
LES	O
and	O
weight	O
gain	O
.	O
He	O
relates	O
the	O
worsening	O
to	O
the	O
reduction	O
of	O
valsartan	B-FARMACO
doses	O
a	O
few	O
weeks	O
ago	O
due	O
to	O
recurrent	O
episodes	O
of	O
hypotension	O
.	O
Physical	O
examination	O
Weight	O
88	O
.	O
5	O
kg	O
dry	O
weight	O
not	O
recorded	O
,	O
height	O
1	O
.	O
65m	O
.	O
Body	O
mass	O
index	O
BMI	O
32	O
kg	O
m2	O
.	O
Blood	O
pressure	O
BP	O
109	O
84	O
mmHg	O
,	O
heart	O
rate	O
HR	O
108	O
bpm	O
,	O
oxygen	O
saturation	O
breathing	O
room	O
air	O
96	O
,	O
afebrile	O
.	O
Eupneic	O
at	O
rest	O
,	O
slight	O
increase	O
in	O
jugular	O
pressure	O
,	O
absent	O
hepatojugular	O
reflux	O
.	O
Cardiac	O
auscultation	O
irregular	O
and	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
bibasal	O
crackles	O
.	O
Extremities	O
with	O
bimalleolar	O
oedema	O
.	O
Peripheral	O
pulses	O
weak	O
but	O
preserved	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
on	O
arrival	O
at	O
the	O
emergency	O
department	O
atrial	O
fibrillation	O
at	O
80	O
bpm	O
,	O
ventricular	O
pacing	O
mediated	O
by	O
ICD	O
CRT	O
.	O
Chest	O
X	O
ray	O
mild	O
cardiomegaly	O
cardiothoracic	O
index	O
CTI	O
0	O
.	O
52	O
,	O
mild	O
vascular	O
redistribution	O
,	O
ICD	O
CRT	O
generator	O
and	O
electrodes	O
normally	O
positioned	O
,	O
without	O
costophrenic	O
sinus	O
impingement	O
.	O
Blood	O
tests	O
on	O
admission	O
haemoglobin	O
13	O
.	O
3	O
g	O
dl	O
,	O
leucocytes	O
4930	O
103	O
ul	O
,	O
platelets	O
103000	O
Ul	O
.	O
Biochemistry	O
glucose	O
86	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
26	O
mg	O
dl	O
,	O
urea	O
48	O
mg	O
dl	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
57	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
sodium	O
137	O
mg	O
dl	O
,	O
potassium	O
3	O
.	O
6	O
mg	O
dl	O
,	O
total	O
bilirubin	O
4	O
.	O
2	O
mg	O
dl	O
,	O
direct	O
bilirubin	O
3	O
.	O
2	O
,	O
lactate	O
dehydrogenase	O
241	O
U	O
l	O
,	O
alanine	O
aminotransferase	O
ALT	O
20	O
,	O
total	O
protein	O
44	O
g	O
l	O
,	O
albumin	O
36	O
g	O
l	O
.	O
TSH	O
2	O
.	O
16	O
mU	O
l	O
.	O
Troponin	O
T	O
46	O
ng	O
l	O
50	O
ng	O
l	O
14	O
ng	O
l	O
.	O
NT	O
proBNP	O
2154	O
pg	O
l	O
300	O
pg	O
l	O
.	O
Ferrokinetic	O
profile	O
iron	O
87	O
uG	O
dl	O
59	O
156	O
,	O
transferrin	O
saturation	O
index	O
23	O
16	O
45	O
,	O
ferritin	O
90	O
ng	O
ml	O
30	O
400	O
.	O
Transesophageal	O
echocardiography	O
performed	O
during	O
admission	O
severe	O
ischaemic	O
mitral	O
insufficiency	O
.	O
Posterior	O
leaflet	O
of	O
7	O
mm	O
.	O
Thrombus	O
in	O
left	O
atrial	O
appendage	O
.	O
Moderate	O
IT	O
grade	O
III	O
.	O
Moderate	O
aortic	O
stenosis	O
with	O
AVA	O
of	O
1	O
.	O
3	O
.	O
IT	O
signal	O
allows	O
estimating	O
PAPS	O
of	O
54	O
mmHg	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
admission	O
,	O
intravenous	O
furosemide	B-FARMACO
was	O
started	O
with	O
a	O
good	O
diuretic	O
response	O
.	O
In	O
addition	O
,	O
given	O
the	O
elevation	O
of	O
direct	O
bilirubin	O
,	O
abdominal	O
ultrasound	O
was	O
requested	O
,	O
which	O
revealed	O
liver	O
stasis	O
in	O
the	O
context	O
of	O
heart	O
failure	O
.	O
The	O
CRT	O
device	O
was	O
checked	O
and	O
the	O
pacing	O
was	O
found	O
to	O
be	O
in	O
an	O
adequate	O
range	O
.	O
Transesophageal	O
echocardiography	O
was	O
requested	O
to	O
expand	O
studies	O
on	O
the	O
severe	O
MI	O
described	O
in	O
the	O
last	O
transthoracic	O
echocardiography	O
performed	O
in	O
consultations	O
,	O
which	O
confirmed	O
the	O
severity	O
of	O
the	O
Ml	O
of	O
ischaemic	O
origin	O
and	O
visualised	O
an	O
image	O
compatible	O
with	O
thrombus	O
in	O
the	O
left	O
atrial	O
appendage	O
.	O
The	O
patient	O
had	O
normal	O
haemoglobin	O
levels	O
,	O
with	O
normal	O
iron	O
and	O
transferrin	O
saturation	O
index	O
,	O
but	O
ferritin	O
less	O
than	O
100	O
ng	O
l	O
.	O
In	O
this	O
context	O
,	O
in	O
view	O
of	O
the	O
iron	O
deficiency	O
situation	O
,	O
it	O
was	O
decided	O
to	O
start	O
iron	O
therapy	O
with	O
an	O
infusion	O
of	O
1	O
,	O
000	O
mg	O
of	O
iron	B-FARMACO
carboxymaltose	O
.	O
During	O
admission	O
,	O
she	O
showed	O
clinical	O
improvement	O
with	O
a	O
loss	O
of	O
up	O
to	O
5	O
kg	O
compared	O
to	O
her	O
admission	O
weight	O
after	O
diuretic	O
therapy	O
and	O
great	O
symptomatic	O
improvement	O
.	O
Throughout	O
his	O
hospital	O
stay	O
,	O
his	O
blood	O
pressure	O
was	O
around	O
100	O
70	O
mmHg	O
,	O
with	O
symptoms	O
of	O
orthostasis	O
when	O
attempting	O
to	O
increase	O
anti	O
humoral	O
therapy	O
,	O
so	O
it	O
was	O
decided	O
not	O
to	O
start	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
.	O
Finally	O
,	O
he	O
was	O
discharged	O
with	O
a	O
change	O
of	O
valsartan	B-FARMACO
to	O
losartan	B-FARMACO
25	O
mg	O
,	O
bisoprolol	B-FARMACO
1	O
.	O
25	O
mg	O
at	O
breakfast	O
and	O
dinner	O
instead	O
of	O
carvedilol	B-FARMACO
,	O
and	O
discontinuation	O
of	O
acenocoumarol	B-FARMACO
and	O
start	O
of	O
edoxaban	B-FARMACO
60	O
mg	O
daily	O
together	O
with	O
furosemide	B-FARMACO
40	O
mg	O
2	O
tablets	O
daily	O
,	O
eplerenone	B-FARMACO
25	O
mg	O
1	O
tablet	O
at	O
lunch	O
,	O
atorvastatin	B-FARMACO
20	O
mg	O
at	O
dinner	O
,	O
allopurinol	B-FARMACO
300	O
mg	O
at	O
dinner	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
at	O
breakfast	O
.	O
In	O
addition	O
,	O
an	O
outpatient	O
cardiac	O
CT	O
scan	O
was	O
requested	O
to	O
assess	O
the	O
viability	O
of	O
implanting	O
a	O
Tendyne	O
prosthesis	O
as	O
a	O
treatment	O
for	O
mitral	O
insufficiency	O
and	O
to	O
evaluate	O
the	O
persistence	O
of	O
thrombus	O
in	O
the	O
left	O
atrial	O
appendage	O
after	O
correct	O
oral	O
anticoagulation	O
.	O
One	O
month	O
after	O
discharge	O
and	O
after	O
3	O
weeks	O
in	O
NYHA	O
functional	O
class	O
I	O
,	O
the	O
patient	O
came	O
for	O
a	O
check	O
up	O
.	O
He	O
presented	O
blood	O
tests	O
showing	O
sudden	O
anaemisation	O
with	O
haemoglobin	O
levels	O
of	O
10	O
.	O
5	O
;	O
in	O
addition	O
,	O
the	O
patient	O
reported	O
clinical	O
manifestations	O
of	O
melena	O
since	O
discharge	O
.	O
It	O
was	O
decided	O
to	O
request	O
invasive	O
studies	O
to	O
investigate	O
the	O
aetiology	O
of	O
the	O
anaemia	O
,	O
with	O
gastroscopy	O
and	O
colonoscopy	O
,	O
which	O
were	O
normal	O
.	O
The	O
patient	O
is	O
currently	O
awaiting	O
capsule	O
endoscopy	O
.	O
DIAGNOSIS	O
Heart	O
failure	O
with	O
reduced	O
EF	O
of	O
ischaemic	O
aetiology	O
with	O
episode	O
of	O
decompensation	O
due	O
to	O
systemic	O
congestion	O
.	O
Severe	O
ischaemic	O
mitral	O
regurgitation	O
.	O
Moderate	O
grade	O
III	O
tricuspid	O
regurgitation	O
.	O
Ferropenia	O
with	O
normal	O
haemoglobin	O
levels	O
.	O
Permanent	O
atrial	O
fibrillation	O
.	O
Thrombus	O
in	O
left	O
atrial	O
appendage	O
.	O
Carrier	O
of	O
ICD	O
CRT	O
in	O
prevention	O
1a	O
with	O
adequate	O
pacing	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
This	O
is	O
a	O
72	O
year	O
old	O
man	O
with	O
multiple	O
cardiovascular	O
risk	O
factors	O
CVRF	O
hypertension	O
,	O
type	O
2	O
diabetes	O
mellitus	O
,	O
hypercholesterolemia	O
,	O
ex	O
smoker	O
,	O
permanent	O
atrial	O
fibrillation	O
anticoagulated	O
with	O
warfarin	B-FARMACO
previously	O
with	O
acenocoumarol	B-FARMACO
;	O
the	O
anticoagulant	O
was	O
changed	O
in	O
2017	O
after	O
finding	O
a	O
thrombus	O
in	O
the	O
left	O
atrial	O
appendage	O
despite	O
correct	O
INR	O
levels	O
and	O
rheumatic	O
valve	O
disease	O
with	O
valve	O
replacement	O
in	O
2004	O
with	O
mechanical	O
prostheses	O
in	O
mitral	O
and	O
aortic	O
position	O
,	O
without	O
significant	O
lesions	O
in	O
pre	O
surgical	O
coronary	O
angiography	O
and	O
with	O
a	O
subsequent	O
LVEF	O
of	O
30	O
.	O
During	O
follow	O
up	O
,	O
he	O
presented	O
a	O
tendency	O
towards	O
asymptomatic	O
moderate	O
hyperkalaemia	O
maximum	O
figure	O
of	O
6	O
.	O
3	O
mEq	O
l	O
that	O
prevented	O
correct	O
titration	O
of	O
neurohormonal	O
medication	O
,	O
remaining	O
in	O
NYHA	O
functional	O
class	O
III	O
IV	O
.	O
In	O
September	O
2019	O
,	O
he	O
attended	O
the	O
emergency	O
department	O
due	O
to	O
worsening	O
of	O
his	O
usual	O
dyspnoea	O
to	O
minimal	O
effort	O
,	O
orthopnoea	O
,	O
bendopnoea	O
,	O
decreased	O
diuresis	O
rate	O
and	O
the	O
appearance	O
of	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
110	O
55	O
mmHg	O
,	O
heart	O
rate	O
HR	O
90	O
bpm	O
.	O
Temperature	O
36	O
.	O
2	O
oC	O
.	O
Oxygen	O
saturation	O
95	O
basal	O
.	O
Acceptable	O
general	O
condition	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Normal	O
colour	O
,	O
normohydrated	O
and	O
normoperfused	O
.	O
Discreetly	O
tachypnoeic	O
at	O
rest	O
,	O
with	O
intolerance	O
to	O
decubitus	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
heart	O
sounds	O
.	O
Prosthetic	O
metallic	O
clicks	O
.	O
No	O
murmurs	O
were	O
heard	O
.	O
Pulmonary	O
auscultation	O
bilateral	O
crackles	O
up	O
to	O
midfields	O
,	O
no	O
other	O
superimposed	O
sounds	O
.	O
Lower	O
extremities	O
symmetrical	O
pulses	O
present	O
and	O
symmetrical	O
.	O
Bilateral	O
pitting	O
oedema	O
up	O
to	O
the	O
knees	O
.	O
No	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Current	O
treatment	O
candesartan	B-FARMACO
4	O
mg	O
0	O
0	O
1	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
0	O
1	O
,	O
simvastatin	B-FARMACO
20	O
mg	O
0	O
0	O
1	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
1	O
0	O
1	O
,	O
warfarin	B-FARMACO
5	O
mg	O
as	O
prescribed	O
,	O
metformin	B-FARMACO
850	O
mg	O
0	O
.	O
5	O
0	O
0	O
.	O
5	O
,	O
pantoprazole	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
Given	O
that	O
this	O
was	O
his	O
first	O
episode	O
of	O
decompensation	O
of	O
heart	O
failure	O
,	O
admission	O
to	O
the	O
conventional	O
cardiology	O
ward	O
for	O
depletive	O
treatment	O
and	O
study	O
was	O
decided	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
on	O
admission	O
haemoglobin	O
15	O
.	O
1	O
g	O
dl	O
11	O
.	O
4	O
15	O
.	O
1	O
g	O
dl	O
,	O
creatinine	O
1	O
.	O
78	O
mg	O
dl	O
0	O
.	O
50	O
0	O
.	O
90	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
GFR	O
41	O
ml	O
min	O
1	O
.	O
73	O
m2	O
90	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
sodium	O
139	O
mEq	O
l	O
135	O
145	O
mEq	O
l	O
,	O
potassium	O
5	O
.	O
6	O
mEq	O
l	O
135	O
145	O
mEq	O
l	O
,	O
sodium	O
5	O
.	O
6	O
mEq	O
l	O
0	O
.	O
50	O
0	O
.	O
90	O
mg	O
dl	O
,	O
potassium	O
5	O
.	O
6	O
mEq	O
l	O
3	O
.	O
50	O
5	O
.	O
00	O
mEq	O
l	O
,	O
GPT	O
21	O
U	O
l	O
5	O
35	O
U	O
l	O
,	O
GOT	O
22	O
U	O
l	O
5	O
27	O
U	O
l	O
,	O
NT	O
proBNP	O
2651	O
pg	O
ml	O
125	O
pg	O
ml	O
,	O
glycosylated	O
haemoglobin	O
6	O
.	O
9	O
4	O
.	O
0	O
6	O
.	O
0	O
.	O
Electrocardiogram	O
ECG	O
on	O
admission	O
atrial	O
fibrillation	O
with	O
ventricular	O
response	O
at	O
85	O
bpm	O
.	O
Wide	O
QRS	O
with	O
right	O
bundle	O
branch	O
block	O
RBBB	O
morphology	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
mid	O
sternotomy	O
cerclages	O
.	O
Mechanical	O
prosthesis	O
in	O
mitral	O
position	O
.	O
Signs	O
of	O
pulmonary	O
congestion	O
vascular	O
redistribution	O
,	O
bilateral	O
pleural	O
effusion	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
LV	O
severely	O
dilated	O
Dd	O
63	O
mm	O
,	O
VTD	O
201	O
ml	O
,	O
VTDi	O
118	O
ml	O
m2	O
,	O
with	O
slight	O
concentric	O
hypertrophy	O
.	O
Global	O
hypokinesia	O
.	O
Biplane	O
Simpson	O
LVEF	O
20	O
.	O
Right	O
ventricle	O
of	O
borderline	O
size	O
Dd	O
40	O
mm	O
,	O
with	O
severely	O
depressed	O
global	O
systolic	O
function	O
.	O
Mechanical	O
prosthesis	O
in	O
mitral	O
and	O
aortic	O
position	O
well	O
seated	O
,	O
with	O
normal	O
disc	O
motion	O
,	O
no	O
gradient	O
elevation	O
or	O
periprosthetic	O
insufficiency	O
.	O
CLINICAL	O
EVOLUTION	O
Intravenous	O
diuretic	O
treatment	O
was	O
started	O
with	O
an	O
excellent	O
response	O
and	O
clear	O
improvement	O
in	O
the	O
congestive	O
signs	O
and	O
symptoms	O
,	O
which	O
led	O
to	O
discharge	O
home	O
after	O
8	O
days	O
of	O
hospitalisation	O
.	O
Serial	O
analyses	O
showed	O
normalisation	O
of	O
renal	O
function	O
.	O
In	O
this	O
context	O
,	O
it	O
was	O
decided	O
to	O
start	O
a	O
potassium	B-FARMACO
chelator	I-FARMACO
patiromer	I-FARMACO
at	O
a	O
minimum	O
dose	O
,	O
i	O
.	O
e	O
.	O
one	O
8	O
.	O
4	O
g	O
sachet	O
per	O
day	O
with	O
the	O
aim	O
of	O
normalising	O
serum	O
potassaemia	O
figures	O
in	O
order	O
to	O
be	O
able	O
to	O
start	O
neurohormonal	O
treatment	O
.	O
Follow	O
up	O
was	O
initiated	O
in	O
the	O
Transversal	O
Heart	O
Failure	O
Programme	O
of	O
our	O
centre	O
.	O
A	O
blood	O
test	O
was	O
performed	O
one	O
month	O
later	O
,	O
which	O
showed	O
serum	O
potassaemia	O
of	O
4	O
.	O
1	O
mEq	O
l	O
,	O
so	O
it	O
was	O
decided	O
to	O
increase	O
the	O
dose	O
of	O
ARA	O
II	O
candesartan	B-FARMACO
8	O
mg	O
every	O
24	O
hours	O
.	O
On	O
review	O
in	O
consultation	O
November	O
2019	O
,	O
the	O
patient	O
reported	O
improvement	O
in	O
his	O
functional	O
class	O
to	O
NYHA	O
II	O
IV	O
,	O
with	O
potassium	O
levels	O
remaining	O
in	O
the	O
normal	O
range	O
.	O
Given	O
the	O
good	O
tolerance	O
,	O
it	O
was	O
decided	O
to	O
change	O
to	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
at	O
low	O
doses	O
24	O
26	O
mg	O
every	O
12	O
hours	O
,	O
with	O
which	O
the	O
improvement	O
in	O
functional	O
class	O
progressed	O
to	O
NYHA	O
I	O
IV	O
December	O
2019	O
the	O
patient	O
reported	O
that	O
he	O
could	O
walk	O
2	O
4	O
km	O
on	O
level	O
ground	O
,	O
as	O
well	O
as	O
climb	O
slopes	O
and	O
several	O
flights	O
of	O
stairs	O
without	O
having	O
to	O
stop	O
.	O
As	O
serum	O
potassaemia	O
remains	O
in	O
range	O
,	O
a	O
mineralcorticoid	O
receptor	O
antagonist	O
low	O
dose	O
spironolactone	B-FARMACO
is	O
started	O
.	O
At	O
the	O
next	O
check	O
up	O
,	O
a	O
new	O
blood	O
test	O
showed	O
slight	O
hyperkalaemia	O
5	O
.	O
58	O
mEq	O
l	O
,	O
so	O
it	O
was	O
decided	O
to	O
increase	O
the	O
dose	O
of	O
patiromer	B-FARMACO
to	O
two	O
sachets	O
16	O
.	O
8	O
g	O
per	O
day	O
.	O
With	O
this	O
,	O
serum	O
portasium	O
levels	O
were	O
again	O
normalised	O
;	O
at	O
this	O
time	O
February	O
2020	O
the	O
patient	O
was	O
taking	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
24	O
26	O
mg	O
every	O
12	O
hours	O
and	O
spironolactone	B-FARMACO
25	O
mg	O
every	O
24	O
hours	O
,	O
and	O
it	O
was	O
decided	O
to	O
maintain	O
this	O
treatment	O
unchanged	O
.	O
Due	O
to	O
the	O
SARS	O
CoV	O
2	O
pandemic	O
,	O
he	O
was	O
seen	O
again	O
in	O
September	O
2020	O
,	O
when	O
he	O
presented	O
serum	O
potassaemia	O
of	O
6	O
.	O
30	O
mEq	O
l	O
,	O
so	O
the	O
patiromer	B-FARMACO
was	O
titrated	O
up	O
to	O
the	O
maximum	O
dose	O
25	O
.	O
2	O
g	O
every	O
24	O
hours	O
and	O
the	O
dose	O
of	O
spironolactone	B-FARMACO
was	O
reduced	O
to	O
12	O
.	O
5	O
mg	O
every	O
24	O
hours	O
.	O
Three	O
months	O
later	O
,	O
potassium	O
levels	O
were	O
at	O
the	O
upper	O
limit	O
of	O
normal	O
5	O
.	O
19	O
mEq	O
l	O
,	O
so	O
the	O
same	O
treatment	O
was	O
maintained	O
.	O
In	O
January	O
2021	O
,	O
a	O
control	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
an	O
increase	O
in	O
LVEF	O
to	O
35	O
and	O
a	O
clear	O
improvement	O
in	O
adverse	O
remodelling	O
with	O
a	O
decrease	O
in	O
ventricular	O
volumes	O
,	O
as	O
well	O
as	O
normalisation	O
of	O
right	O
ventricular	O
function	O
,	O
with	O
the	O
prostheses	O
remaining	O
normal	O
.	O
The	O
patient	O
remains	O
in	O
good	O
functional	O
class	O
NYHA	O
I	O
II	O
IV	O
,	O
and	O
analytically	O
there	O
was	O
a	O
clear	O
decrease	O
in	O
NT	O
proBNP	O
during	O
follow	O
up	O
,	O
with	O
no	O
notable	O
adverse	O
effects	O
.	O
DIAGNOSIS	O
Chronic	O
heart	O
failure	O
with	O
severely	O
depressed	O
LVEF	O
of	O
valvular	O
origin	O
.	O
Carrier	O
of	O
mechanical	O
prosthetic	O
aortic	O
and	O
mitral	O
valves	O
.	O
Asymptomatic	O
moderate	O
hyperkalaemia	O
in	O
the	O
context	O
of	O
neurohormonal	O
treatment	O
for	O
heart	O
failure	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
This	O
is	O
a	O
66	O
year	O
old	O
female	O
patient	O
with	O
no	O
family	O
history	O
of	O
early	O
ischaemic	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
Mother	O
died	O
of	O
stroke	O
at	O
73	O
years	O
of	O
age	O
.	O
Personal	O
history	O
No	O
documented	O
drug	O
allergies	O
.	O
Lifestyle	O
active	O
life	O
,	O
walks	O
45	O
60	O
minutes	O
daily	O
with	O
her	O
group	O
of	O
friends	O
.	O
Currently	O
retired	B-FARMACO
.	O
Previously	O
employed	O
in	O
perfumery	O
.	O
Cardiovascular	O
risk	O
factors	O
ex	O
smoker	O
for	O
25	O
years	O
IPA	O
10	O
packs	O
year	O
,	O
slightly	O
overweight	O
body	O
mass	O
index	O
27	O
kg	O
m2	O
.	O
No	O
other	O
risk	O
factors	O
.	O
Cardiovascular	O
history	O
symptomatic	O
non	O
valvular	O
paroxysmal	O
paroxysmal	O
atrial	O
fibrillation	O
since	O
2017	O
EHRA	O
3	O
could	O
not	O
keep	O
up	O
with	O
her	O
companions	O
while	O
walking	O
.	O
No	O
structural	O
heart	O
disease	O
on	O
echocardiogram	O
left	O
atrium	O
of	O
borderline	O
size	O
and	O
preserved	O
LVEF	O
.	O
Radiofrequency	O
ablation	O
of	O
pulmonary	O
veins	O
was	O
performed	O
in	O
January	O
2018	O
,	O
still	O
paroxysmal	O
achieving	O
bidirectional	O
isolation	O
.	O
He	O
presented	O
acute	O
reconnection	O
during	O
the	O
procedure	O
through	O
the	O
ligament	O
of	O
Marshall	O
,	O
successfully	O
ablated	O
in	O
the	O
anterior	O
carina	O
region	O
.	O
During	O
the	O
blanking	O
period	O
she	O
was	O
treated	O
with	O
flecainide	B-FARMACO
100	O
mg	O
12h	O
and	O
dabigatran	B-FARMACO
150	O
mg	O
12h	O
.	O
The	O
patient	O
underwent	O
cardiac	O
rhythm	O
self	O
measurements	O
every	O
48	O
h	O
with	O
a	O
Kardia	O
device	O
and	O
a	O
24	O
h	O
Holter	O
at	O
3	O
months	O
without	O
evidence	O
of	O
arrhythmic	O
recurrence	O
being	O
documented	O
in	O
any	O
of	O
these	O
controls	O
.	O
Anticoagulation	O
was	O
discontinued	O
due	O
to	O
CHA2DS2VASc	O
1	O
point	O
female	O
and	O
the	O
antiarrhythmic	O
was	O
progressively	O
reduced	O
until	O
discontinuation	O
.	O
Other	O
history	O
untreated	O
mild	O
psoriasis	O
.	O
No	O
history	O
of	O
asthma	O
,	O
nor	O
previous	O
need	O
for	O
bronchodilators	O
.	O
Current	O
illness	O
Since	O
the	O
summer	O
of	O
2020	O
,	O
she	O
presents	O
clinical	O
deterioration	O
,	O
which	O
she	O
refers	O
to	O
as	O
recurrence	O
of	O
palpitations	O
,	O
mainly	O
with	O
exertion	O
,	O
but	O
also	O
during	O
periods	O
of	O
rest	O
,	O
which	O
she	O
describes	O
as	O
similar	O
to	O
those	O
prior	O
to	O
the	O
diagnosis	O
of	O
atrial	O
fibrillation	O
AF	O
and	O
limitation	O
of	O
physical	O
activity	O
with	O
a	O
marked	O
feeling	O
of	O
"	O
tiredness	O
"	O
.	O
These	O
episodes	O
have	O
increased	O
in	O
frequency	O
and	O
duration	O
,	O
persisting	O
for	O
several	O
hours	O
.	O
No	O
orthopnoea	O
,	O
paroxysmal	O
nocturnal	O
dyspnoea	O
PND	O
or	O
oedema	O
of	O
the	O
lower	O
extremities	O
.	O
No	O
associated	O
chest	O
pain	O
at	O
rest	O
or	O
on	O
exertion	O
.	O
She	O
has	O
never	O
presented	O
syncopal	O
or	O
presyncopal	O
symptoms	O
.	O
With	O
the	O
suspicion	O
of	O
recurrence	O
of	O
atrial	O
fibrillation	O
,	O
in	O
a	O
first	O
consultation	O
,	O
an	O
electrocardiogram	O
ECG	O
in	O
sinus	O
rhythm	O
was	O
performed	O
and	O
the	O
patient	O
was	O
again	O
urged	O
to	O
use	O
her	O
ECG	O
monitoring	O
device	O
when	O
symptoms	O
recurred	O
.	O
Similarly	O
,	O
a	O
new	O
,	O
regular	O
echocardiogram	O
was	O
requested	O
.	O
Physical	O
examination	O
in	O
consultation	O
Good	O
general	O
condition	O
,	O
blood	O
pressure	O
BP	O
125	O
60	O
mmHg	O
,	O
heart	O
rate	O
HR	O
80	O
bpm	O
.	O
Basal	O
oxygen	O
saturation	O
99	O
.	O
Afebrile	O
.	O
Head	O
and	O
neck	O
no	O
jugular	O
venous	O
engorgement	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
sounds	O
at	O
75	O
bpm	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
normoventilation	O
in	O
all	O
fields	O
.	O
Abdomen	O
nondescript	O
.	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Initial	O
ECG	O
consultation	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
,	O
PR	O
170ms	O
,	O
narrow	O
QRS	O
with	O
normal	O
axis	O
,	O
without	O
repolarisation	O
alterations	O
.	O
Normal	O
QTc	O
.	O
ECG	O
tracings	O
obtained	O
with	O
a	O
closed	O
loop	O
recorder	O
Kardia	O
,	O
symptomatic	O
and	O
non	O
symptomatic	O
there	O
were	O
several	O
recordings	O
in	O
sinus	O
rhythm	O
and	O
increasingly	O
frequent	O
events	O
labelled	O
as	O
possible	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
.	O
When	O
analysing	O
these	O
recordings	O
in	O
detail	O
,	O
there	O
is	O
a	O
clear	O
RR	O
irregularity	O
and	O
absence	O
of	O
P	O
waves	O
,	O
highly	O
suggestive	O
of	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
rate	O
.	O
Echocardiogram	O
performed	O
in	O
sinus	O
rhythm	O
video	O
1	O
left	O
atrium	O
LA	O
slightly	O
dilated	O
AP	O
diameter	O
at	O
PEL	O
41	O
mm	O
,	O
Vol	O
index	O
40	O
ml	O
m2	O
.	O
Thin	O
leaflet	O
mitral	O
valve	O
with	O
preserved	O
mobility	O
and	O
opening	O
;	O
mild	O
insufficiency	O
.	O
Diastolic	O
pattern	O
of	O
impaired	O
relaxation	O
,	O
with	O
no	O
increase	O
in	O
filling	O
pressures	O
E	O
e	O
septal	O
12	O
.	O
Left	O
ventricle	O
slightly	O
dilated	O
,	O
not	O
hypertrophied	O
IVS	O
11	O
mm	O
;	O
LVED	O
59	O
mm	O
;	O
PP	O
10	O
mm	O
with	O
moderately	O
depressed	O
systolic	O
function	O
biplane	O
LVEF	O
34	O
,	O
due	O
to	O
diffuse	O
involvement	O
,	O
without	O
clear	O
segmental	O
alterations	O
.	O
Thin	O
,	O
trivalve	O
aortic	O
valve	O
with	O
good	O
opening	O
and	O
mobility	O
;	O
normal	O
flow	O
max	O
.	O
v	O
.	O
1	O
.	O
2	O
m	O
s	O
.	O
Valvular	O
annulus	O
and	O
aortic	O
root	O
of	O
normal	O
dimensions	O
.	O
Right	O
ventricle	O
not	O
dilated	O
;	O
preserved	O
contractility	O
TAPSE	O
21	O
mm	O
.	O
Tricuspid	O
valve	O
with	O
good	O
opening	O
and	O
mobility	O
;	O
minimal	O
regurgitation	O
that	O
does	O
not	O
allow	O
estimation	O
of	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAPS	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
.	O
No	O
evidence	O
of	O
pulmonary	O
hypertension	O
.	O
No	O
pericardial	O
effusion	O
.	O
Coronary	O
and	O
LA	O
CT	O
scan	O
prior	O
to	O
AF	O
ablation	O
procedure	O
coronary	O
calcium	O
score	O
26	O
.	O
Non	O
invasive	O
coronary	O
angiography	O
epicardial	O
coronary	O
arteries	O
without	O
angiographically	O
significant	O
lesions	O
.	O
Left	O
atrial	O
study	O
slight	O
left	O
atrial	O
dilatation	O
25	O
cm2	O
.	O
Four	O
pulmonary	O
veins	O
are	O
identified	O
two	O
left	O
pulmonary	O
veins	O
and	O
two	O
right	O
pulmonary	O
veins	O
.	O
The	O
dimensions	O
of	O
the	O
ostia	O
are	O
IPSV	O
19x15	O
mm	O
;	O
IIPV	O
18	O
.	O
5x12	O
.	O
2	O
mm	O
;	O
DPSV	O
20x15	O
.	O
8	O
mm	O
and	O
IDPV	O
17	O
.	O
8x11	O
.	O
6	O
mm	O
.	O
The	O
oesophagus	O
is	O
3	O
mm	O
from	O
the	O
posterior	O
wall	O
of	O
the	O
left	O
venous	O
trunk	O
.	O
There	O
is	O
no	O
persistence	O
of	O
right	O
superior	O
vena	O
cava	O
.	O
Transesophageal	O
echocardiogram	O
during	O
ablation	O
absence	O
of	O
intracavitary	O
thrombi	O
and	O
left	O
atrial	O
appendage	O
with	O
good	O
flow	O
measured	O
by	O
pulsed	O
Doppler	O
v	O
0	O
.	O
6	O
m	O
s	O
.	O
Atrial	O
septum	O
intact	O
with	O
no	O
patent	O
foramen	O
ovale	O
.	O
Left	O
ventricle	O
with	O
mildly	O
moderate	O
depression	O
of	O
contractile	O
function	O
.	O
No	O
pericardial	O
effusion	O
.	O
A	O
first	O
manoeuvre	O
was	O
performed	O
to	O
approach	O
the	O
fossa	O
ovalis	O
with	O
a	O
puncture	O
needle	O
,	O
locating	O
a	O
puncture	O
site	O
somewhat	O
close	O
to	O
the	O
aortic	O
root	O
.	O
Due	O
to	O
this	O
proximity	O
,	O
another	O
approach	O
manoeuvre	O
is	O
performed	O
,	O
placing	O
the	O
needle	O
in	O
a	O
more	O
posterior	O
location	O
video	O
3	O
.	O
Finally	O
,	O
transseptal	O
puncture	O
was	O
monitored	O
and	O
passed	O
without	O
complications	O
.	O
Electrophysiological	O
study	O
and	O
ablation	O
Diagnostic	O
mapping	O
assessment	O
of	O
the	O
LA	O
after	O
effective	O
electrical	O
cardioversion	O
,	O
a	O
detailed	O
mapping	O
of	O
the	O
left	O
atrium	O
is	O
performed	O
.	O
This	O
chamber	O
is	O
accessed	O
via	O
transseptal	O
puncture	O
.	O
Using	O
the	O
navigation	O
system	O
and	O
traversing	O
a	O
large	O
number	O
of	O
points	O
of	O
the	O
atrial	O
wall	O
with	O
the	O
catheter	O
,	O
a	O
reproduction	O
of	O
the	O
volume	O
and	O
geometry	O
of	O
the	O
left	O
atrium	O
is	O
obtained	O
,	O
representing	O
it	O
in	O
three	O
dimensional	O
form	O
on	O
a	O
computer	O
application	O
that	O
allows	O
virtual	O
mobility	O
of	O
the	O
established	O
geometry	O
in	O
all	O
directions	O
of	O
space	O
.	O
A	O
cartography	O
map	O
of	O
the	O
pulmonary	O
veins	O
is	O
also	O
drawn	O
up	O
using	O
the	O
same	O
technique	O
described	O
above	O
and	O
labelled	O
,	O
establishing	O
the	O
existence	O
of	O
4	O
pulmonary	O
veins	O
2	O
left	O
and	O
2	O
right	O
.	O
In	O
the	O
same	O
way	O
,	O
the	O
mitral	O
valve	O
annulus	O
is	O
conformed	O
and	O
labelled	O
.	O
Reconnection	O
of	O
the	O
left	O
superior	O
pulmonary	O
vein	O
LSPV	O
was	O
confirmed	O
,	O
and	O
a	O
pace	O
and	O
map	O
manoeuvre	O
was	O
performed	O
to	O
locate	O
the	O
gap	O
,	O
which	O
was	O
finally	O
located	O
in	O
the	O
posterosuperior	O
region	O
of	O
the	O
LSPV	O
.	O
Voltage	O
mapping	O
of	O
both	O
atria	O
was	O
performed	O
,	O
with	O
no	O
areas	O
of	O
low	O
voltage	O
.	O
A	O
protocol	O
was	O
initiated	O
to	O
assess	O
atrial	O
fibrillation	O
triggers	O
not	O
originating	O
from	O
pulmonary	O
veins	O
by	O
infusion	O
of	O
isoproterenol	O
at	O
increasing	O
doses	O
until	O
reaching	O
20	O
mcg	O
kg	O
.	O
Under	O
this	O
perfusion	O
,	O
frequent	O
extrasystolic	O
activity	O
and	O
small	O
spurts	O
of	O
AT	O
began	O
,	O
mapping	O
early	O
extrasystolic	O
activity	O
as	O
a	O
possible	O
trigger	O
of	O
atrial	O
fibrillation	O
from	O
the	O
posterior	O
roof	O
of	O
the	O
left	O
atrium	O
and	O
superior	O
vena	O
cava	O
,	O
where	O
even	O
an	O
initiation	O
of	O
AF	O
was	O
recorded	O
without	O
catheter	O
contact	O
with	O
the	O
venous	O
wall	O
.	O
Ablation	O
procedure	O
temperature	O
controlled	O
up	O
to	O
43	O
oC	O
and	O
30W	O
power	O
.	O
An	O
LSI	O
of	O
5	O
in	O
posterior	O
zones	O
and	O
5	O
.	O
5	O
in	O
anterior	O
zones	O
is	O
limited	O
.	O
Two	O
radiofrequency	O
applications	O
are	O
performed	O
in	O
the	O
posterosuperior	O
region	O
better	O
pace	O
and	O
map	O
with	O
a	O
venous	O
atrial	O
conduction	O
time	O
of	O
50	O
ms	O
achieving	O
bidirectional	O
isolation	O
in	O
VPSI	O
.	O
Two	O
lines	O
of	O
applications	O
are	O
performed	O
,	O
delimiting	O
a	O
box	O
in	O
the	O
posterior	O
roof	O
,	O
encompassing	O
the	O
focus	O
of	O
the	O
left	O
atrial	O
roof	O
that	O
could	O
not	O
be	O
delimited	O
in	O
its	O
exact	O
location	O
,	O
joining	O
antral	O
ablation	O
lines	O
of	O
previous	O
pulmonary	O
veins	O
that	O
presented	O
conduction	O
block	O
.	O
A	O
total	O
of	O
21	O
applications	O
were	O
made	O
between	O
the	O
two	O
lines	O
.	O
Subsequently	O
,	O
electrical	O
isolation	O
was	O
checked	O
by	O
blocking	O
the	O
outflow	O
of	O
this	O
region	O
.	O
Next	O
,	O
in	O
AD	O
,	O
a	O
crown	O
of	O
applications	O
is	O
formed	O
encompassing	O
the	O
superior	O
vena	O
cava	O
,	O
with	O
a	O
total	O
of	O
27	O
applications	O
714	O
seconds	O
.	O
In	O
applications	O
of	O
the	O
external	O
face	O
of	O
this	O
venous	O
antrum	O
,	O
stimulation	O
is	O
performed	O
at	O
maximum	O
output	O
prior	O
to	O
applications	O
to	O
ensure	O
the	O
absence	O
of	O
phrenic	O
capture	O
and	O
minimise	O
the	O
risk	O
of	O
phrenic	O
paralysis	O
.	O
Effective	O
isolation	O
of	O
the	O
vein	O
is	O
achieved	O
after	O
the	O
last	O
few	O
applications	O
inside	O
the	O
ablation	O
line	O
,	O
in	O
the	O
area	O
of	O
greatest	O
premature	O
extrasystoles	O
.	O
Verification	O
after	O
30	O
minutes	O
of	O
waiting	O
,	O
isolation	O
and	O
blockage	O
verification	O
manoeuvres	O
carried	O
out	O
previously	O
are	O
repeated	O
,	O
verifying	O
the	O
absence	O
of	O
acute	O
reconnection	O
and	O
persistence	O
of	O
conduction	O
blockage	O
of	O
previous	O
isolation	O
lines	O
.	O
By	O
administering	O
i	O
.	O
v	O
.	O
adenosine	B-FARMACO
12	O
mg	O
,	O
the	O
absence	O
of	O
dormant	O
conduction	O
in	O
the	O
pulmonary	O
veins	O
and	O
superior	O
vena	O
cava	O
is	O
verified	O
.	O
The	O
catheters	O
are	O
removed	O
,	O
normal	O
contractility	O
of	O
the	O
cardiac	O
silhouette	O
is	O
checked	O
and	O
the	O
procedure	O
is	O
concluded	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
the	O
consultation	O
for	O
review	O
of	O
the	O
results	O
,	O
the	O
patient	O
showed	O
increasingly	O
frequent	O
and	O
long	O
lasting	O
ECG	O
recordings	O
in	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
.	O
The	O
echocardiogram	O
showed	O
moderate	O
systolic	O
dysfunction	O
due	O
to	O
diffuse	O
involvement	O
,	O
but	O
no	O
segmental	O
alterations	O
in	O
contractility	O
.	O
At	O
the	O
time	O
of	O
consultation	O
,	O
he	O
was	O
again	O
in	O
sinus	O
rhythm	O
,	O
but	O
with	O
abundant	O
supraventricular	O
extrasystolic	O
activity	O
.	O
Anticoagulant	O
treatment	O
was	O
started	O
with	O
dabigatran	B-FARMACO
150	O
mg	O
12	O
h	O
CHA2DS2VASc	O
score	O
of	O
3	O
points	O
age	O
1	O
,	O
female	O
1	O
and	O
heart	O
failure	O
or	O
reduced	O
LVEF	O
1	O
point	O
and	O
antiarrhythmic	O
treatment	O
with	O
amiodarone	B-FARMACO
200	O
mg	O
24	O
h	O
,	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
h	O
and	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
h	O
.	O
It	O
was	O
first	O
suspected	O
that	O
the	O
left	O
ventricular	O
dysfunction	O
could	O
be	O
caused	O
by	O
tachycardiomyopathy	O
,	O
and	O
for	O
this	O
reason	O
,	O
together	O
with	O
the	O
presence	O
of	O
symptomatic	O
paroxysms	O
of	O
atrial	O
fibrillation	O
,	O
a	O
new	O
ablation	O
procedure	O
was	O
indicated	O
.	O
However	O
,	O
given	O
the	O
patient	O
's	O
age	O
and	O
history	O
of	O
ex	O
smoking	O
and	O
slight	O
overweight	O
,	O
assessment	O
of	O
the	O
coronary	O
tree	O
was	O
considered	O
.	O
As	O
the	O
patient	O
required	O
a	O
CT	O
scan	O
of	O
the	O
left	O
atrium	O
and	O
pulmonary	O
veins	O
prior	O
to	O
ablation	O
,	O
this	O
test	O
was	O
used	O
for	O
non	O
invasive	O
coronary	O
angiography	O
,	O
which	O
showed	O
no	O
significant	O
lesions	O
in	O
the	O
coronary	O
arteries	O
.	O
One	O
month	O
after	O
starting	O
anticoagulation	O
and	O
after	O
discontinuation	O
of	O
antiarrhythmic	O
medication	O
,	O
a	O
second	O
atrial	O
fibrillation	O
ablation	O
procedure	O
was	O
performed	O
.	O
During	O
the	O
procedure	O
,	O
VPSI	O
reconnection	O
was	O
verified	O
,	O
and	O
the	O
VPSI	O
was	O
isolated	O
and	O
checked	O
again	O
.	O
Subsequently	O
,	O
triggers	O
not	O
originating	O
from	O
the	O
pulmonary	O
veins	O
were	O
sought	O
by	O
infusion	O
of	O
isoproterenol	O
,	O
locating	O
a	O
focus	O
in	O
the	O
posterior	O
roof	O
of	O
the	O
left	O
atrium	O
,	O
which	O
was	O
treated	O
by	O
performing	O
a	O
posterior	O
roof	O
box	O
up	O
to	O
the	O
venous	O
antrum	O
and	O
another	O
focus	O
in	O
the	O
superior	O
vena	O
cava	O
,	O
which	O
required	O
circumferential	O
isolation	O
of	O
the	O
same	O
.	O
After	O
the	O
procedure	O
,	O
the	O
patient	O
presented	O
no	O
complications	O
and	O
,	O
given	O
her	O
good	O
evolution	O
,	O
she	O
was	O
discharged	O
from	O
hospital	O
after	O
24	O
hours	O
,	O
previously	O
restarting	O
anticoagulant	O
medication	O
and	O
her	O
antiarrhythmic	O
treatment	O
.	O
One	O
month	O
after	O
ablation	O
still	O
in	O
the	O
blanking	O
period	O
,	O
the	O
patient	O
came	O
for	O
a	O
check	O
up	O
with	O
evident	O
clinical	O
improvement	O
,	O
being	O
in	O
NYHA	O
functional	O
class	O
I	O
,	O
and	O
with	O
no	O
sensation	O
of	O
tachycardia	O
.	O
She	O
provided	O
ECG	O
recordings	O
which	O
were	O
all	O
in	O
sinus	O
rhythm	O
and	O
in	O
the	O
echocardioscopy	O
performed	O
during	O
the	O
consultation	O
,	O
the	O
LVEF	O
had	O
improved	O
significantly	O
and	O
appeared	O
to	O
be	O
preserved	O
borderline	O
.	O
A	O
further	O
consultation	O
was	O
scheduled	O
3	O
months	O
after	O
the	O
ablation	O
procedure	O
.	O
DIAGNOSIS	O
Paroxysmal	O
AF	O
in	O
a	O
patient	O
with	O
probable	O
tachycardiomyopathy	O
absence	O
of	O
coronary	O
artery	O
disease	O
on	O
CT	O
scan	O
prior	O
to	O
ablation	O
.	O
Left	O
superior	O
pulmonary	O
vein	O
reconnection	O
.	O
Presence	O
of	O
extrapulmonary	O
foci	O
manifested	O
by	O
isoproterenol	O
infusion	O
in	O
the	O
posterior	O
roof	O
of	O
the	O
left	O
atrium	O
and	O
superior	O
vena	O
cava	O
.	O
Radiofrequency	O
ablation	O
of	O
reconnection	O
and	O
extrapulmonary	O
foci	O
with	O
acute	O
success	O
electrical	O
isolation	O
and	O
electrogram	O
ablation	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
43	O
year	O
old	O
woman	O
,	O
with	O
the	O
following	O
history	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
known	O
toxic	O
habits	O
or	O
cardiovascular	O
risk	O
factors	O
.	O
Iron	B-FARMACO
deficiency	O
anaemia	O
on	O
intermittent	O
treatment	O
with	O
oral	O
iron	B-FARMACO
.	O
Anxiety	O
depressive	O
syndrome	O
,	O
on	O
anxiolytic	O
treatment	O
on	O
demand	O
.	O
No	O
family	O
history	O
of	O
heart	O
disease	O
or	O
early	O
cardiovascular	O
disease	O
.	O
Usual	O
medication	O
folic	B-FARMACO
acid	I-FARMACO
5	O
mg	O
24	O
h	O
,	O
lorazepam	B-FARMACO
1	O
mg	O
on	O
demand	O
.	O
Current	O
illness	O
Consultation	O
due	O
to	O
an	O
episode	O
of	O
oppressive	O
central	O
thoracic	O
pain	O
,	O
with	O
accompanying	O
vegetative	O
symptoms	O
,	O
which	O
started	O
abruptly	O
while	O
standing	O
up	O
while	O
working	O
in	O
a	O
kitchen	O
at	O
high	O
temperature	O
and	O
associated	O
with	O
a	O
great	O
feeling	O
of	O
stress	O
.	O
On	O
arrival	O
at	O
the	O
hospital	O
,	O
with	O
progressive	O
clinical	O
improvement	O
,	O
no	O
electrocardiographic	O
alterations	O
suggestive	O
of	O
ischaemia	O
or	O
mobilisation	O
of	O
myocardial	O
damage	O
enzymes	O
were	O
recorded	O
.	O
He	O
denied	O
previous	O
history	O
of	O
angina	O
,	O
palpitations	O
,	O
syncope	O
or	O
presyncope	O
.	O
He	O
reported	O
progressive	O
dyspnoea	O
on	O
moderate	O
exertion	O
of	O
about	O
6	O
months	O
'	O
duration	O
,	O
without	O
orthopnoea	O
,	O
oedema	O
or	O
reduced	O
diuresis	O
.	O
Finally	O
,	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
the	O
cardiology	O
department	O
for	O
further	O
tests	O
.	O
Physical	O
examination	O
Asymptomatic	O
,	O
normal	O
colour	O
,	O
well	O
perfused	O
,	O
without	O
jugular	O
ingurgitation	O
or	O
hepatojugular	O
reflux	O
.	O
Blood	O
pressure	O
BP	O
110	O
60	O
mmHg	O
,	O
heart	O
rate	O
HR	O
80	O
bpm	O
.	O
Eupneic	O
at	O
basal	O
saturation	O
99	O
.	O
On	O
auscultation	O
,	O
rhythmic	O
heart	O
tones	O
,	O
with	O
systolic	O
murmur	O
II	O
VI	O
panfocal	O
but	O
predominantly	O
pulmonary	O
,	O
radiating	O
to	O
the	O
carotids	O
and	O
more	O
noticeably	O
to	O
the	O
interscapular	O
region	O
.	O
Abdomen	O
normal	O
examination	O
,	O
with	O
no	O
pathological	O
findings	O
.	O
Radial	O
and	O
pedial	O
pulses	O
symmetrically	O
preserved	O
.	O
Absence	O
of	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
RS	O
at	O
57	O
bpm	O
,	O
normal	O
axis	O
,	O
without	O
atrioventricular	O
AV	O
or	O
intraventricular	O
conduction	O
disorders	O
,	O
without	O
repolarisation	O
disorders	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
CTI	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
,	O
with	O
an	O
increase	O
in	O
the	O
pulmonary	O
vascular	O
pattern	O
.	O
Laboratory	O
tests	O
Initial	O
blood	O
tests	O
ED	O
hypochromic	O
microcytic	O
anaemia	O
with	O
haemoglobin	O
9	O
.	O
3	O
g	O
dl	O
similar	O
to	O
previous	O
ones	O
,	O
MCV	O
84	O
fl	O
,	O
MCH	O
25	O
.	O
9	O
pg	O
,	O
rest	O
of	O
haemogram	O
normal	O
.	O
Renal	O
function	O
,	O
hepatobiliary	O
profile	O
and	O
ions	O
normal	O
.	O
Creatine	O
phosphokinase	O
normal	O
.	O
TnT	O
9	O
16	O
ng	O
l	O
.	O
Analytical	O
studies	O
during	O
admission	O
summary	O
Blood	O
count	O
haemoglobin	O
stable	O
at	O
around	O
10	O
g	O
dl	O
,	O
the	O
rest	O
without	O
alterations	O
.	O
Deficiency	O
profile	O
serum	O
iron	O
67	O
.	O
20	O
g	O
dl	O
,	O
IST	O
19	O
,	O
ferritin	O
13	O
.	O
70	O
g	O
l	O
,	O
transferrin	O
282	O
.	O
40	O
mg	O
dl	O
,	O
vitB12	O
normal	O
,	O
folic	O
acid	O
2	O
.	O
4	O
g	O
l	O
.	O
Biochemistry	O
renal	O
function	O
ions	O
and	O
liver	O
function	O
markers	O
normal	O
.	O
Metabolic	O
and	O
other	O
profile	O
TSH	O
normal	O
.	O
HbA1C	O
5	O
.	O
8	O
.	O
Lipid	O
profile	O
normal	O
.	O
Normal	O
acute	O
phase	O
reactants	O
.	O
Negative	O
autoimmunity	O
markers	O
RF	O
,	O
ANA	O
,	O
ANCA	O
,	O
C3	O
,	O
C4	O
.	O
ProBNP	O
167	O
pg	O
ml	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
LV	O
slightly	O
dilated	O
by	O
volumes	O
DTDVI	O
52	O
mm	O
,	O
BP	O
vol	O
165	O
ml	O
,	O
not	O
hypertrophied	O
.	O
Dilated	O
left	O
atrium	O
indexed	O
to	O
body	O
surface	O
area	O
44	O
ml	O
m2	O
.	O
Normal	O
right	O
chambers	O
.	O
Aorta	O
of	O
normal	O
calibre	O
and	O
flow	O
in	O
its	O
accessible	O
sections	O
.	O
Absence	O
of	O
significant	O
valvulopathies	O
.	O
No	O
evidence	O
of	O
pulmonary	O
hypertension	O
.	O
An	O
anomalous	O
filling	O
jet	O
is	O
visualised	O
in	O
the	O
left	O
atrium	O
,	O
eccentric	O
,	O
which	O
crosses	O
the	O
interatrial	O
septum	O
and	O
reaches	O
the	O
mitral	O
valve	O
,	O
continuous	O
,	O
with	O
a	O
Vmax	O
of	O
3	O
.	O
4	O
m	O
s	O
.	O
Normal	O
LV	O
systolic	O
and	O
diastolic	O
function	O
,	O
without	O
contractility	O
alterations	O
.	O
Normofunctioning	O
right	O
ventricle	O
.	O
No	O
pericardial	O
effusion	O
or	O
other	O
findings	O
.	O
Contrast	O
enhanced	O
CT	O
angiography	O
of	O
coronary	O
arteries	O
and	O
aorta	O
coronary	O
arteries	O
normal	O
,	O
without	O
lesions	O
.	O
Fistula	O
from	O
the	O
descending	O
thoracic	O
aorta	O
to	O
the	O
left	O
atrium	O
,	O
with	O
saccular	O
dilatation	O
of	O
the	O
right	O
posterior	O
wall	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
LV	O
of	O
normal	O
diameter	O
and	O
morphology	O
,	O
with	O
indexed	O
end	O
diastolic	O
volume	O
of	O
78	O
ml	O
m2	O
slightly	O
dilated	O
.	O
Preserved	O
LVEF	O
,	O
without	O
segmental	O
alterations	O
of	O
contractility	O
.	O
In	O
cine	O
sequences	O
there	O
was	O
an	O
evident	O
aorto	O
atrial	O
fistula	O
very	O
fine	O
jet	O
at	O
the	O
level	O
of	O
the	O
roof	O
of	O
the	O
left	O
atrium	O
,	O
the	O
rest	O
of	O
the	O
study	O
with	O
no	O
significant	O
findings	O
.	O
CLINICAL	O
EVOLUTION	O
Given	O
the	O
clinical	O
data	O
and	O
initial	O
complementary	O
tests	O
,	O
the	O
probability	O
of	O
ischaemic	O
heart	O
disease	O
was	O
considered	O
low	O
.	O
However	O
,	O
given	O
the	O
exploratory	O
findings	O
,	O
congenital	O
heart	O
disease	O
was	O
suspected	O
,	O
and	O
the	O
echocardiographic	O
study	O
showed	O
an	O
anomalous	O
filling	O
jet	O
in	O
the	O
left	O
atrium	O
.	O
Angio	O
CT	O
of	O
the	O
coronary	O
arteries	O
was	O
requested	O
,	O
ruling	O
out	O
arteriosclerotic	O
disease	O
,	O
but	O
a	O
fistulous	O
tract	O
of	O
saccular	O
morphology	O
was	O
found	O
between	O
the	O
descending	O
thoracic	O
aorta	O
and	O
the	O
left	O
atrium	O
,	O
with	O
a	O
suspected	O
genetic	O
origin	O
in	O
the	O
absence	O
of	O
surgical	O
history	O
,	O
trauma	O
,	O
or	O
semiology	O
compatible	O
with	O
current	O
or	O
previous	O
endocarditis	O
.	O
During	O
her	O
admission	O
she	O
remained	O
asymptomatic	O
and	O
the	O
single	O
episode	O
of	O
chest	O
pain	O
was	O
attributed	O
to	O
an	O
anxiety	O
crisis	O
,	O
as	O
the	O
location	O
of	O
the	O
fistulous	O
tract	O
did	O
not	O
justify	O
in	O
this	O
case	O
a	O
possible	O
coronary	O
steal	O
phenomenon	O
.	O
The	O
study	O
was	O
completed	O
on	O
an	O
outpatient	O
basis	O
with	O
CMR	O
,	O
confirming	O
the	O
findings	O
already	O
described	O
by	O
echocardiogram	O
and	O
coronary	O
CT	O
,	O
with	O
data	O
of	O
incipient	O
remodelling	O
of	O
the	O
left	O
chambers	O
dilatation	O
and	O
hyperflow	O
.	O
For	O
this	O
reason	O
,	O
a	O
consensus	O
was	O
reached	O
at	O
a	O
medical	O
surgical	O
meeting	O
on	O
endovascular	O
repair	O
by	O
means	O
of	O
percutaneous	O
implantation	O
of	O
a	O
thoracic	O
aortic	O
stent	O
,	O
which	O
was	O
carried	O
out	O
without	O
complications	O
,	O
with	O
good	O
sealing	O
of	O
the	O
leak	O
in	O
the	O
control	O
angiography	O
.	O
DIAGNOSIS	O
Chest	O
pain	O
of	O
multifactorial	O
cause	O
anxiety	O
crisis	O
,	O
hyperdynamic	O
state	O
.	O
Angiographically	O
normal	O
coronary	O
arteries	O
by	O
CT	O
angiography	O
.	O
Left	O
aorto	O
atrial	O
fistula	O
with	O
evidence	O
of	O
incipient	O
remodelling	O
of	O
the	O
left	O
cavities	O
dilatation	O
and	O
hyperflow	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
79	O
year	O
old	O
woman	O
attended	O
the	O
emergency	O
department	O
due	O
to	O
gait	O
instability	O
.	O
History	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
hypertension	O
.	O
Dyslipidaemia	O
treated	O
with	O
diet	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
Cardiology	O
assessment	O
in	O
another	O
centre	O
in	O
2017	O
,	O
at	O
that	O
time	O
normal	O
electrocardiogram	O
ECG	O
.	O
Other	O
history	O
depression	O
recent	O
start	O
of	O
sertraline	B-FARMACO
.	O
Phakectomy	O
.	O
Traumatic	O
brain	O
injury	O
TBI	O
secondary	O
to	O
a	O
fall	O
at	O
home	O
no	O
syncope	O
.	O
Previous	O
medication	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
0	O
1	O
0	O
,	O
hydroferol	B-FARMACO
1	O
ampoule	O
every	O
15	O
days	O
,	O
hydrochlorothiazide	B-FARMACO
amiloride	I-FARMACO
5	O
50	O
mg	O
1	O
0	O
0	O
,	O
sertraline	B-FARMACO
50	O
mg	O
1	O
0	O
0	O
.	O
Present	O
illness	O
He	O
reports	O
gait	O
instability	O
of	O
a	O
week	O
's	O
duration	O
prior	O
to	O
admission	O
,	O
which	O
he	O
relates	O
to	O
the	O
initiation	O
of	O
sertraline	B-FARMACO
due	O
to	O
depressive	O
mood	O
.	O
Denies	O
presyncope	O
syncope	O
.	O
He	O
has	O
a	O
history	O
of	O
a	O
fall	O
with	O
secondary	O
cranioencephalic	O
trauma	O
,	O
assessed	O
in	O
a	O
private	O
centre	O
by	O
means	O
of	O
a	O
CAT	O
scan	O
and	O
laboratory	O
tests	O
,	O
which	O
were	O
normal	O
.	O
He	O
denies	O
chest	O
pain	O
at	O
all	O
times	O
.	O
No	O
dyspnoea	O
,	O
orthopnoea	O
or	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
No	O
other	O
cardiovascular	O
symptoms	O
.	O
No	O
fever	O
or	O
infectious	O
,	O
respiratory	O
or	O
gastrointestinal	O
symptoms	O
.	O
We	O
were	O
alerted	O
by	O
elevated	O
markers	O
of	O
myocardial	O
damage	O
and	O
electrocardiogram	O
alterations	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
117	O
70	O
mmHg	O
,	O
heart	O
rate	O
HR	O
85	O
bpm	O
,	O
temperature	O
36	O
oC	O
.	O
Conscious	O
and	O
oriented	O
,	O
good	O
general	O
condition	O
.	O
Eupneic	O
in	O
decubitus	O
,	O
no	O
respiratory	O
work	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
systolic	O
murmur	O
in	O
low	O
left	O
sternal	O
border	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
noises	O
.	O
Lower	O
limbs	O
no	O
oedema	O
.	O
Normal	O
neurological	O
examination	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
with	O
normal	O
axis	O
,	O
anterior	O
QS	O
,	O
ST	O
elevation	O
of	O
1	O
2	O
mm	O
in	O
precordial	O
and	O
submillimetric	O
in	O
inferior	O
face	O
,	O
negative	O
T	O
in	O
I	O
aVL	O
.	O
ECG	O
at	O
48	O
hours	O
ST	O
elevation	O
in	O
V2	O
V6	O
up	O
to	O
3	O
mm	O
in	O
V3	O
with	O
negative	O
T	O
wave	O
in	O
all	O
precordial	O
leads	O
.	O
Rest	O
unchanged	O
.	O
ECG	O
at	O
discharge	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
deep	O
and	O
symmetrical	O
negative	O
T	O
wave	O
in	O
inferior	O
face	O
,	O
I	O
and	O
aVL	O
and	O
V2	O
V6	O
.	O
Ambulatory	O
blood	O
test	O
day	O
of	O
TBI	O
sodium	O
142	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
0	O
mmol	O
l	O
,	O
troponin	O
1	O
.	O
4	O
ng	O
l	O
.	O
Blood	O
tests	O
haemoglobin	O
10	O
.	O
8	O
g	O
dl	O
,	O
MCV	O
81	O
,	O
platelets	O
310000	O
,	O
leucocytes	O
21700	O
neu19800	O
,	O
lin	O
500	O
.	O
INR	O
1	O
.	O
02	O
,	O
dim	O
ero	O
D	O
223	O
,	O
pH	O
7	O
.	O
49	O
,	O
pCO2	O
32	O
,	O
bicarbonate	O
24	O
,	O
lactate	O
2	O
.	O
8	O
,	O
sodium	O
104	O
mmol	O
l	O
,	O
potassium	O
3	O
mmol	O
l	O
,	O
glucose	O
109	O
mg	O
dl	O
,	O
ALT	O
23	O
IU	O
l	O
,	O
bilirubin	O
1	O
mg	O
dl	O
,	O
GGT	O
13	O
IU	O
l	O
,	O
FA	O
72	O
IU	O
l	O
,	O
LDH	O
330	O
IU	O
l	O
,	O
creatinine	O
0	O
.	O
78	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
60	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
magnesium	O
1	O
.	O
2	O
mmol	O
l	O
,	O
CRP	O
1	O
.	O
4	O
,	O
procalcitonin	O
0	O
.	O
07	O
.	O
Cardiac	O
markers	O
ultrasensitive	O
troponin	O
I	O
8517	O
8410	O
319	O
ng	O
l	O
,	O
NT	O
proBNP	O
2981	O
25000	O
11500	O
ng	O
l	O
.	O
Urinalysis	O
Sediment	O
erythrocytes	O
5	O
10	O
field	O
,	O
leukocytes	O
40	O
60	O
field	O
,	O
esterase	O
,	O
Hb	O
,	O
protein	O
.	O
Biochemistry	O
single	O
micturition	O
osmolality	O
492	O
mOsm	O
kg	O
,	O
single	O
micturition	O
sodium	O
28	O
mmol	O
l	O
,	O
single	O
micturition	O
potassium	O
51	O
.	O
2	O
mmol	O
l	O
.	O
PCR	O
SARS	O
CoV	O
2	O
negative	O
.	O
Chest	O
X	O
ray	O
favourable	O
radiological	O
evolution	O
of	O
heart	O
failure	O
data	O
.	O
Cranial	O
CT	O
scan	O
no	O
evidence	O
of	O
acute	O
intracranial	O
pathology	O
in	O
the	O
post	O
traumatic	O
context	O
of	O
the	O
patient	O
.	O
Right	O
frontal	O
epicranial	O
contusion	O
hematoma	O
without	O
bone	O
fractures	O
.	O
Echocardiogram	O
left	O
ventricle	O
not	O
dilated	O
,	O
with	O
normal	O
wall	O
thickness	O
.	O
Akinesia	O
of	O
middle	O
and	O
distal	O
segments	O
of	O
all	O
faces	O
and	O
apex	O
.	O
Hyperkinesia	O
of	O
the	O
basal	O
segments	O
.	O
Moderately	O
depressed	O
global	O
systolic	O
function	O
.	O
LVEF	O
30	O
35	O
.	O
Pseudonormalised	O
transmitral	O
filling	O
pattern	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
.	O
Right	O
atrium	O
not	O
dilated	O
.	O
Aneurysm	O
of	O
the	O
interatrial	O
septum	O
displaced	O
towards	O
the	O
right	O
atrium	O
as	O
an	O
indirect	O
sign	O
of	O
increased	O
left	O
atrial	O
pressure	O
.	O
Right	O
ventricle	O
not	O
dilated	O
,	O
with	O
normal	O
global	O
systolic	O
function	O
.	O
Rest	O
normal	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
left	O
ventricle	O
a	O
size	O
and	O
function	O
normal	O
size	O
,	O
with	O
normal	O
thickness	O
.	O
Hypokinesia	O
of	O
the	O
distal	O
segments	O
of	O
all	O
faces	O
and	O
apex	O
.	O
Basal	O
segments	O
are	O
hypercontractile	O
.	O
Global	O
left	O
ventricular	O
function	O
at	O
the	O
lower	O
limit	O
of	O
normality	O
LVEF	O
52	O
.	O
b	O
T2	O
STIR	O
a	O
hyperintense	O
transmural	O
zone	O
affecting	O
the	O
middle	O
and	O
distal	O
segments	O
of	O
all	O
the	O
faces	O
is	O
observed	O
.	O
c	O
First	O
pass	O
perfusion	O
no	O
alterations	O
.	O
d	O
Late	O
enhancement	O
no	O
alterations	O
.	O
Right	O
ventricle	O
a	O
Size	O
and	O
function	O
normal	O
size	O
,	O
not	O
hypertrophic	O
,	O
normocontractile	O
.	O
b	O
T2	O
STIR	O
hyperintensity	O
is	O
observed	O
at	O
the	O
level	O
of	O
the	O
apical	O
segment	O
.	O
c	O
Late	O
enhancement	O
no	O
alterations	O
.	O
Left	O
atrium	O
not	O
dilated	O
.	O
Right	O
atrium	O
of	O
normal	O
size	O
.	O
Mitral	O
valve	O
with	O
thin	O
leaflets	O
,	O
normal	O
opening	O
.	O
Aortic	O
valve	O
trivalve	O
,	O
functionally	O
normal	O
.	O
Bilateral	O
pleural	O
effusion	O
.	O
Perihilar	O
opacities	O
more	O
suggestive	O
of	O
heart	O
failure	O
.	O
Conclusions	O
study	O
compatible	O
with	O
stress	O
cardiomyopathy	O
tako	O
tsubo	O
syndrome	O
.	O
Data	O
compatible	O
with	O
myocardial	O
oedema	O
affecting	O
the	O
middle	O
and	O
distal	O
segments	O
of	O
the	O
left	O
ventricle	O
,	O
without	O
evidence	O
of	O
late	O
enhancement	O
or	O
segmental	O
perfusion	O
alterations	O
.	O
Global	O
systolic	O
function	O
at	O
the	O
lower	O
limit	O
of	O
normal	O
LVEF	O
52	O
.	O
Coronary	O
angiography	O
smooth	O
coronary	O
arteries	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
presented	O
with	O
instability	O
in	O
the	O
context	O
of	O
severe	O
hypoosmolar	O
hyponatraemia	O
sodium	O
104	O
mml	O
l	O
on	O
admission	O
euvolaemic	O
with	O
normal	O
urine	O
osmolarity	O
in	O
the	O
probable	O
context	O
of	O
recent	O
initiation	O
of	O
sertraline	B-FARMACO
and	O
potentiated	O
by	O
the	O
concomitant	O
use	O
of	O
hydrochlorothiazide	B-FARMACO
amiloride	I-FARMACO
.	O
Cranial	O
CT	O
scan	O
with	O
no	O
acute	O
findings	O
.	O
There	O
was	O
also	O
associated	O
hypomagnesaemia	O
and	O
hypokalaemia	O
.	O
In	O
this	O
context	O
,	O
he	O
had	O
an	O
elevated	O
troponin	O
plateau	O
8500	O
8400	O
ng	O
l	O
,	O
ECG	O
with	O
anterior	O
QS	O
and	O
residual	O
ST	O
elevation	O
and	O
echocardiogram	O
with	O
previously	O
unknown	O
LVEF	O
35	O
and	O
alterations	O
in	O
segmental	O
contraction	O
compatible	O
with	O
takotsubo	O
syndrome	O
stress	O
cardiomyopathy	O
.	O
Admission	O
to	O
cardiology	O
for	O
monitoring	O
was	O
decided	O
.	O
Sertraline	B-FARMACO
was	O
discontinued	O
and	O
intravenous	O
sodium	B-FARMACO
replacement	O
with	O
serotherapy	O
was	O
started	O
,	O
as	O
well	O
as	O
oral	O
potassium	B-FARMACO
and	O
magnesium	B-FARMACO
replacement	O
,	O
with	O
progressive	O
improvement	O
in	O
natraemia	O
without	O
residual	O
neurological	O
focality	O
.	O
Coronary	O
angiography	O
ruled	O
out	O
obstructive	O
coronary	O
disease	O
.	O
Cardiopathy	O
study	O
was	O
completed	O
with	O
findings	O
compatible	O
with	O
stress	O
cardiomyopathy	O
with	O
LVEF	O
30	O
35	O
on	O
admission	O
,	O
which	O
recovered	O
to	O
near	O
normal	O
50	O
55	O
on	O
discharge	O
.	O
As	O
the	O
probable	O
origin	O
of	O
the	O
hydroelectrolytic	O
disorder	O
,	O
the	O
use	O
of	O
drugs	O
thiazides	O
SSRIs	O
SIADH	O
secondary	O
to	O
TCE	O
Na	O
levels	O
tested	O
in	O
September	O
2020	O
,	O
normal	O
is	O
proposed	O
.	O
As	O
a	O
cause	O
of	O
the	O
tako	O
tsubo	O
syndrome	O
,	O
the	O
main	O
option	O
is	O
severe	O
hyponatraemia	O
present	O
on	O
admission	O
associated	O
with	O
creaneoencephalic	O
trauma	O
.	O
At	O
discharge	O
asymptomatic	O
,	O
afebrile	O
,	O
haemodynamically	O
stable	O
,	O
with	O
sodium	O
of	O
139	O
mmol	O
l	O
.	O
Follow	O
up	O
in	O
the	O
cardiology	O
day	O
hospital	O
,	O
with	O
normalisation	O
of	O
ventricular	O
function	O
and	O
asymptomatic	O
.	O
DIAGNOSIS	O
Stress	O
cardiomyopathy	O
secondary	O
to	O
severe	O
hyponatremia	O
.	O
Coronary	O
arteries	O
without	O
lesions	O
.	O
Ventricular	O
function	O
severely	O
depressed	O
,	O
recovered	O
.	O
Severe	O
hypoosmolar	O
euvolaemic	O
hyponatraemia	O
of	O
probable	O
pharmacological	O
cause	O
SIADH	O
to	O
TBI	O
.	O
Cranioencephalic	O
trauma	O
.	O
Arterial	O
hypertension	O
.	O
Dyslipidaemia	O
.	O
Depressive	O
syndrome	O
in	O
treatment	O
with	O
sertraline	B-FARMACO
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
50	O
year	O
old	O
male	O
patient	O
,	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
and	O
without	O
cognitive	O
impairment	O
.	O
Single	O
,	O
lives	O
alone	O
in	O
a	O
small	O
town	O
in	O
our	O
autonomous	O
community	O
.	O
Cardiovascular	O
risk	O
factors	O
ex	O
smoker	O
for	O
2	O
years	O
,	O
with	O
an	O
accumulated	O
consumption	O
of	O
30	O
packets	O
year	O
,	O
ex	O
drinker	O
for	O
6	O
months	O
with	O
a	O
previous	O
daily	O
consumption	O
of	O
5	O
6	O
UBE	O
d	O
.	O
No	O
known	O
metabolic	O
disorders	O
.	O
Cardiological	O
history	O
no	O
cardiological	O
history	O
of	O
interest	O
.	O
No	O
family	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
Other	O
history	O
no	O
personal	O
history	O
of	O
note	O
.	O
Treatment	O
no	O
chronic	O
home	O
treatment	O
.	O
Occasional	O
use	O
of	O
NSAIDs	O
.	O
Current	O
illness	O
The	O
patient	O
consulted	O
his	O
regional	O
referral	O
hospital	O
due	O
to	O
a	O
fever	O
and	O
general	O
malaise	O
of	O
15	O
days	O
'	O
duration	O
accompanied	O
by	O
inflammatory	O
pain	O
in	O
the	O
lumbar	O
region	O
.	O
He	O
also	O
presented	O
with	O
slightly	O
localised	O
abdominal	O
discomfort	O
,	O
with	O
an	O
accompanying	O
feeling	O
of	O
nausea	O
.	O
No	O
other	O
infectious	O
symptoms	O
at	O
any	O
other	O
level	O
.	O
No	O
chest	O
pain	O
,	O
dyspnoea	O
,	O
palpitations	O
or	O
other	O
cardiological	O
symptoms	O
.	O
During	O
her	O
stay	O
in	O
the	O
emergency	O
department	O
,	O
tests	O
were	O
started	O
with	O
laboratory	O
tests	O
and	O
abdominal	O
ultrasound	O
.	O
The	O
biochemistry	O
showed	O
elevated	O
inflammatory	O
markers	O
,	O
the	O
haemogram	O
showed	O
leukocytosis	O
with	O
left	O
shift	O
and	O
the	O
abdominal	O
ultrasound	O
showed	O
splenomegaly	O
measuring	O
18	O
cm	O
with	O
multiple	O
cystic	O
formations	O
inside	O
.	O
For	O
this	O
reason	O
,	O
a	O
thoracoabdominal	O
CT	O
scan	O
was	O
requested	O
which	O
confirmed	O
the	O
presence	O
of	O
multiple	O
splenic	O
and	O
renal	O
infarctions	O
.	O
Finally	O
,	O
following	O
these	O
findings	O
,	O
a	O
transthoracic	O
echocardiogram	O
was	O
performed	O
which	O
revealed	O
the	O
presence	O
of	O
severe	O
aortic	O
insufficiency	O
of	O
uncertain	O
origin	O
,	O
without	O
being	O
able	O
to	O
confirm	O
the	O
presence	O
of	O
warts	O
.	O
On	O
the	O
basis	O
of	O
these	O
studies	O
,	O
and	O
given	O
the	O
suspicion	O
of	O
infective	O
endocarditis	O
,	O
empirical	O
antibiotic	O
treatment	O
was	O
started	O
with	O
ceftriaxone	B-FARMACO
and	O
ampicillin	B-FARMACO
.	O
After	O
24	O
h	O
of	O
admission	O
,	O
and	O
following	O
the	O
growth	O
of	O
Enterococcus	O
faecalis	O
in	O
the	O
blood	O
cultures	O
,	O
it	O
was	O
decided	O
to	O
discuss	O
the	O
case	O
with	O
the	O
cardiology	O
department	O
of	O
our	O
hospital	O
in	O
order	O
to	O
perform	O
a	O
transesophageal	O
echocardiogram	O
,	O
as	O
well	O
as	O
to	O
complete	O
the	O
studies	O
and	O
assess	O
definitive	O
treatment	O
.	O
The	O
patient	O
arrived	O
at	O
our	O
hospital	O
haemodynamically	O
stable	O
,	O
with	O
very	O
mild	O
respiratory	O
work	O
,	O
and	O
with	O
basal	O
crackles	O
,	O
as	O
well	O
as	O
petechiae	O
in	O
the	O
lower	O
limbs	O
as	O
the	O
most	O
relevant	O
findings	O
of	O
the	O
examination	O
.	O
A	O
repeat	O
transthoracic	O
echocardiogram	O
was	O
performed	O
with	O
a	O
result	O
similar	O
to	O
that	O
obtained	O
at	O
his	O
regional	O
hospital	O
,	O
and	O
it	O
was	O
decided	O
to	O
complete	O
the	O
cardiological	O
studies	O
.	O
Physical	O
examination	O
Vitals	O
heart	O
rate	O
HR	O
92	O
bpm	O
;	O
respiratory	O
rate	O
RR	O
29	O
rpm	O
;	O
blood	O
pressure	O
BP	O
95	O
48	O
;	O
oxygen	O
saturation	O
97	O
.	O
Patient	O
conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Good	O
hydration	O
status	O
.	O
Slight	O
skin	O
pallor	O
.	O
No	O
pain	O
gesture	O
.	O
Mild	O
tachypnoea	O
at	O
rest	O
,	O
no	O
intercostal	O
tugging	O
.	O
Head	O
and	O
neck	O
no	O
jugular	O
ingurgitation	O
and	O
negative	O
hepatojugular	O
reflux	O
.	O
Carotid	O
pulse	O
symmetrical	O
and	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
with	O
crepitant	O
rales	O
in	O
the	O
right	O
base	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
.	O
Aortic	O
systolic	O
murmur	O
II	O
VI	O
with	O
preserved	O
2nd	O
sound	O
followed	O
by	O
a	O
protodiastolic	O
murmur	O
II	O
IV	O
.	O
Abdomen	O
no	O
skin	O
lesions	O
or	O
scars	O
.	O
Preserved	O
hydro	O
aerial	O
sounds	O
.	O
Soft	O
and	O
depressible	O
,	O
without	O
discomfort	O
on	O
palpation	O
or	O
rebound	O
.	O
Palpable	O
splenomegaly	O
.	O
Lower	O
extremities	O
extremities	O
warm	O
and	O
with	O
good	O
capillary	O
filling	O
.	O
Petechial	O
lesions	O
on	O
both	O
legs	O
.	O
Radial	O
and	O
pedial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
No	O
signs	O
of	O
chronic	O
venous	O
insufficiency	O
,	O
no	O
oedema	O
and	O
no	O
signs	O
suggestive	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Biochemistry	O
glucose	O
113	O
mg	O
dl	O
,	O
urea	O
59	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
45	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
53	O
ml	O
min	O
1	O
.	O
78	O
m2	O
,	O
sodium	O
ion	O
137	O
mmol	O
l	O
,	O
potassium	O
ion	O
4	O
.	O
1	O
mmol	O
l	O
,	O
C	O
reactive	O
protein	O
17	O
.	O
2	O
mg	O
dl	O
;	O
procalcitonin	O
1	O
.	O
56	O
ng	O
ml	O
;	O
NT	O
proBNP	O
3	O
.	O
280pg	O
ml	O
,	O
alkaline	O
phosphatase	O
107	O
U	O
l	O
,	O
AST	O
21	O
U	O
l	O
,	O
ALT	O
24	O
U	O
l	O
,	O
GGT	O
59	O
U	O
l	O
,	O
total	O
bilirubin	O
1	O
.	O
0	O
mg	O
dl	O
,	O
total	O
cholesterol	O
126	O
mg	O
dl	O
,	O
HDL	O
10	O
mg	O
dl	O
,	O
triglycerides	O
281	O
mg	O
dl	O
,	O
calculated	O
LDL	O
cholesterol	O
47	O
mg	O
dl	O
,	O
HbA1C	O
4	O
.	O
6	O
,	O
TSH	O
2	O
.	O
03	O
mU	O
l	O
.	O
CBC	O
haemoglobin	O
8	O
.	O
1	O
g	O
dl	O
,	O
haematocrit	O
,	O
red	O
blood	O
cells	O
2	O
.	O
86x106	O
μl	O
,	O
leukocytes	O
10	O
,	O
520	O
μl	O
,	O
neutrophils	O
8	O
,	O
760	O
μl	O
,	O
lymphocytes	O
1	O
,	O
150	O
μl	O
,	O
monocytes	O
530	O
μl	O
,	O
eosinophils	O
70	O
μL	O
,	O
basophils	O
10	O
μl	O
,	O
platelets	O
235	O
,	O
000	O
μl	O
.	O
Coagulation	O
prothrombin	O
time	O
PT	O
15	O
.	O
10	O
sec	O
;	O
partial	O
thromboplastin	O
time	O
PTAT	O
33	O
.	O
70	O
sec	O
;	O
INR	O
1	O
.	O
33	O
;	O
derived	O
fibrinogen	O
491	O
mg	O
l	O
.	O
Blood	O
cultures	O
growth	O
of	O
Gram	O
cocci	O
in	O
the	O
first	O
24	O
hours	O
.	O
At	O
72	O
h	O
the	O
presence	O
of	O
Enterococcus	O
faecalis	O
sensitive	O
to	O
ampicillin	B-FARMACO
,	O
vancomycin	B-FARMACO
and	O
ciprofloxacin	B-FARMACO
was	O
confirmed	O
.	O
12	O
lead	O
ECG	O
performed	O
on	O
arrival	O
at	O
our	O
hospital	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
.	O
P	O
wave	O
of	O
normal	O
size	O
and	O
morphology	O
.	O
PR	O
interval	O
in	O
range	O
without	O
prolongation	O
.	O
Narrow	O
QRS	O
with	O
axis	O
between	O
0	O
90o	O
and	O
transition	O
between	O
V3	O
V4	O
.	O
ST	O
segment	O
without	O
suprathresholds	O
.	O
Normal	O
T	O
wave	O
.	O
QTc	O
interval	O
in	O
normal	O
range	O
.	O
Chest	O
X	O
ray	O
performed	O
on	O
arrival	O
at	O
our	O
hospital	O
cardiac	O
silhouette	O
of	O
normal	O
size	O
.	O
Slight	O
vascular	O
redistribution	O
towards	O
apical	O
lung	O
fields	O
suggestive	O
of	O
incipient	O
pulmonary	O
congestion	O
.	O
No	O
pinching	O
of	O
the	O
costophrenic	O
sinuses	O
suggestive	O
of	O
pleural	O
effusion	O
.	O
No	O
parenchymal	O
condensation	O
or	O
pneumothorax	O
.	O
Abdominal	O
ultrasound	O
performed	O
in	O
a	O
regional	O
hospital	O
prior	O
to	O
transfer	O
to	O
our	O
centre	O
hepatic	O
steatosis	O
without	O
focal	O
lesions	O
.	O
Biliary	O
tract	O
without	O
lesions	O
.	O
Kidneys	O
normal	O
.	O
Pancreas	O
not	O
assessable	O
.	O
Spleen	O
18cm	O
with	O
cystic	O
formations	O
inside	O
.	O
Empty	O
bladder	O
not	O
assessable	O
.	O
Thoracoabdominal	O
CT	O
scan	O
performed	O
in	O
a	O
regional	O
hospital	O
prior	O
to	O
transfer	O
to	O
our	O
centre	O
no	O
pulmonary	O
nodules	O
or	O
thoracic	O
adenopathies	O
in	O
pathological	O
range	O
or	O
appearance	O
were	O
observed	O
.	O
Small	O
tongue	O
of	O
bilateral	O
pleural	O
effusions	O
.	O
Hypodense	O
lesions	O
of	O
triangular	O
splenic	O
morphology	O
suggestive	O
of	O
infarction	O
,	O
as	O
well	O
as	O
right	O
renal	O
lesions	O
also	O
probably	O
related	O
to	O
infarction	O
.	O
Diffuse	O
hepatic	O
steatosis	O
with	O
cystic	O
lesion	O
in	O
the	O
LHI	O
.	O
Pancreas	O
,	O
adrenal	O
glands	O
are	O
normal	O
.	O
Transthoracic	O
echocardiogram	O
performed	O
in	O
a	O
regional	O
hospital	O
prior	O
to	O
transfer	O
to	O
our	O
centre	O
left	O
ventricle	O
neither	O
dilated	O
VTD	O
128	O
ml	O
,	O
VTS	O
39	O
ml	O
nor	O
hypertrophic	O
,	O
without	O
segmental	O
alterations	O
and	O
with	O
preserved	O
LVEF	O
LVEF	O
69	O
by	O
Simpson	O
biplane	O
.	O
Left	O
atrium	O
slightly	O
dilated	O
AP	O
diameter	O
43	O
mm	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
TAPSE	O
26	O
mm	O
.	O
Mild	O
tricuspid	O
insufficiency	O
with	O
a	O
velocity	O
of	O
3	O
.	O
22	O
m	O
s	O
PSAP	O
44	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
.	O
High	O
probability	O
of	O
pulmonary	O
hypertension	O
.	O
Mitral	O
valve	O
with	O
thin	O
leaflets	O
without	O
prolapse	O
,	O
mild	O
mitral	O
regurgitation	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
leaflets	O
appear	O
thin	O
and	O
there	O
are	O
no	O
images	O
suggestive	O
of	O
endocarditis	O
.	O
Central	O
aortic	O
insufficiency	O
which	O
appears	O
severe	O
THP	O
112	O
m	O
s	O
,	O
VC	O
7	O
8	O
mm	O
,	O
without	O
being	O
able	O
to	O
determine	O
the	O
mechanism	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
No	O
suprasternal	O
or	O
good	O
visualisation	O
of	O
the	O
abdominal	O
aorta	O
to	O
assess	O
the	O
presence	O
of	O
diastolic	O
reverse	O
flow	O
.	O
No	O
pericardial	O
effusion	O
.	O
Transesophageal	O
echocardiogram	O
TEE	O
the	O
atrial	O
septum	O
is	O
intact	O
,	O
with	O
no	O
evidence	O
of	O
atrial	O
septal	O
defect	O
.	O
Mitral	O
valve	O
vegetation	O
in	O
the	O
anterior	O
mitral	O
leaflet	O
,	O
about	O
6mm	O
long	O
axis	O
;	O
moderate	O
mitral	O
insufficiency	O
is	O
detected	O
.	O
Tricuspid	O
valve	O
normal	O
in	O
structure	O
and	O
function	O
.	O
Trivalve	O
aortic	O
valve	O
;	O
endocarditis	O
on	O
the	O
aortic	O
valve	O
,	O
with	O
a	O
wart	O
of	O
about	O
11	O
mm	O
of	O
major	O
axis	O
,	O
with	O
destruction	O
of	O
the	O
non	O
coronary	O
leaflet	O
,	O
leading	O
to	O
severe	O
aortic	O
insufficiency	O
.	O
No	O
evidence	O
of	O
perivalvular	O
involvement	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
Cardiac	O
CT	O
scan	O
trivalve	O
aortic	O
valve	O
with	O
focal	O
thickening	O
of	O
the	O
non	O
coronary	O
leaflet	O
and	O
a	O
10	O
mm	O
polypoid	O
image	O
,	O
mobile	O
,	O
close	O
to	O
the	O
implantation	O
point	O
in	O
relation	O
to	O
the	O
clinical	O
suspicion	O
of	O
endocarditis	O
.	O
Rupture	O
of	O
the	O
non	O
coronary	O
leaflet	O
.	O
No	O
perivalvular	O
complications	O
were	O
identified	O
.	O
Coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O
CT	O
scan	O
of	O
the	O
brain	O
hyperdense	O
image	O
in	O
the	O
left	O
subcortical	O
sylvian	O
region	O
with	O
discrete	O
surrounding	O
oedema	O
,	O
without	O
significant	O
mass	O
effect	O
,	O
which	O
in	O
the	O
clinical	O
context	O
of	O
the	O
patient	O
suggests	O
a	O
small	O
haemorrhagic	O
embolus	O
,	O
without	O
being	O
able	O
to	O
rule	O
out	O
underlying	O
abscess	O
due	O
to	O
the	O
fact	O
that	O
the	O
study	O
was	O
performed	O
without	O
VSD	O
.	O
No	O
alterations	O
in	O
the	O
density	O
of	O
the	O
brain	O
parenchyma	O
suggestive	O
of	O
subacute	O
ischaemic	O
pathology	O
were	O
observed	O
.	O
Area	O
of	O
encephalomalacia	O
in	O
the	O
right	O
temporal	O
pole	O
with	O
discrete	O
exvacuo	O
dilatation	O
of	O
the	O
homolateral	O
horn	O
,	O
of	O
residual	O
appearance	O
;	O
we	O
do	O
not	O
know	O
the	O
patient	O
's	O
clinical	O
and	O
traumatic	O
history	O
.	O
Discrete	O
signs	O
of	O
chronic	O
small	O
vessel	O
pathology	O
in	O
the	O
base	O
ganglia	O
,	O
no	O
bone	O
lesions	O
of	O
interest	O
are	O
observed	O
.	O
Positron	O
emission	O
tomography	O
with	O
18F	O
deoxyglucose	O
PETTC	O
head	O
and	O
neck	O
without	O
pathological	O
alterations	O
of	O
the	O
glycemic	O
metabolism	O
.	O
A	O
focus	O
of	O
mild	O
glycemic	O
hypermetabolism	O
is	O
observed	O
adjacent	O
to	O
the	O
aortic	O
valve	O
area	O
SUVmax	O
2	O
.	O
83	O
,	O
which	O
could	O
be	O
related	O
to	O
known	O
endocarditis	O
the	O
low	O
degree	O
of	O
uptake	O
could	O
be	O
explained	O
by	O
response	O
to	O
antibiotic	O
treatment	O
.	O
No	O
other	O
hypermetabolic	O
foci	O
were	O
detected	O
in	O
the	O
valvular	O
heart	O
area	O
suggestive	O
of	O
endocarditis	O
.	O
Splenomegaly	O
with	O
the	O
presence	O
of	O
several	O
extensive	O
ametabolic	O
lesions	O
,	O
which	O
show	O
increased	O
glycemic	O
metabolism	O
in	O
their	O
periphery	O
SUVmax	O
8	O
.	O
27	O
,	O
with	O
fairly	O
homogeneous	O
characteristics	O
,	O
related	O
to	O
known	O
splenic	O
infarcts	O
,	O
without	O
clear	O
signs	O
suggestive	O
of	O
their	O
superinfection	O
.	O
The	O
hypermetabolism	O
could	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
extramedullary	O
haematopoiesis	O
secondary	O
to	O
known	O
anaemia	O
.	O
Liver	O
,	O
pancreas	O
,	O
adrenal	O
glands	O
and	O
mesentery	O
without	O
pathological	O
alterations	O
of	O
glycemic	O
metabolism	O
.	O
Kidneys	O
not	O
assessable	O
due	O
to	O
physiological	O
excretion	O
of	O
radiotracer	O
.	O
Diffuse	O
and	O
homogeneous	O
increase	O
in	O
metabolism	O
in	O
the	O
bone	O
marrow	O
,	O
probably	O
related	O
to	O
anaemia	O
.	O
Rest	O
of	O
the	O
study	O
with	O
no	O
findings	O
of	O
interest	O
.	O
Cerebral	O
angio	O
MRI	O
in	O
the	O
FLAIR	O
sequence	O
,	O
multiple	O
patchy	O
hyperintensities	O
of	O
bilateral	O
subcortical	O
cortical	O
location	O
and	O
in	O
the	O
right	O
cerebellar	O
hemisphere	O
are	O
observed	O
,	O
with	O
a	O
more	O
extensive	O
area	O
in	O
the	O
right	O
temporal	O
pole	O
,	O
which	O
show	O
late	O
enhancement	O
after	O
contrast	O
.	O
They	O
are	O
compatible	O
with	O
infarcts	O
of	O
cardioembolic	O
origin	O
,	O
several	O
of	O
them	O
with	O
signs	O
of	O
petechial	O
microbleeding	O
,	O
in	O
a	O
subacute	O
late	O
phase	O
evolving	O
to	O
chronicity	O
.	O
A	O
10	O
mm	O
haematoma	O
in	O
the	O
left	O
sylvian	O
region	O
with	O
discrete	O
perilesional	O
oedema	O
,	O
which	O
has	O
not	O
increased	O
with	O
respect	O
to	O
previous	O
CT	O
studies	O
.	O
In	O
the	O
magnetic	O
susceptibility	O
sequence	O
at	O
least	O
3	O
millimetric	O
formations	O
are	O
identified	O
in	O
convexity	O
grooves	O
bilateral	O
frontal	O
and	O
right	O
occipital	O
,	O
not	O
assessable	O
in	O
the	O
angio	O
MRI	O
,	O
not	O
being	O
able	O
to	O
rule	O
out	O
distal	O
mycotic	O
aneurysms	O
.	O
No	O
significant	O
alterations	O
were	O
seen	O
at	O
the	O
level	O
of	O
the	O
polygon	O
of	O
Willis	O
.	O
No	O
lesions	O
suggestive	O
of	O
abscesses	O
are	O
identified	O
.	O
Cerebral	O
arteriography	O
identified	O
by	O
arteriography	O
from	O
the	O
left	O
ICA	O
as	O
a	O
pseudoaneurysm	O
in	O
M2	O
branch	O
,	O
embolised	O
using	O
a	O
sandwich	O
technique	O
with	O
coils	O
distal	O
and	O
proximal	O
to	O
the	O
neck	O
of	O
the	O
pseudoaneurysm	O
.	O
Good	O
final	O
angiographic	O
result	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
the	O
first	O
days	O
of	O
admission	O
,	O
a	O
transesophageal	O
echocardiography	O
was	O
performed	O
,	O
as	O
well	O
as	O
a	O
cardiac	O
CT	O
scan	O
,	O
which	O
confirmed	O
the	O
presence	O
of	O
aortic	O
vegetation	O
with	O
involvement	O
of	O
the	O
non	O
coronary	O
leaflet	O
,	O
with	O
rupture	O
of	O
the	O
same	O
,	O
leading	O
to	O
severe	O
aortic	O
insufficiency	O
.	O
In	O
addition	O
,	O
data	O
suggestive	O
of	O
a	O
previously	O
undescribed	O
vegetation	O
at	O
the	O
mitral	O
level	O
and	O
coronary	O
arteries	O
without	O
lesions	O
were	O
also	O
observed	O
.	O
With	O
these	O
findings	O
,	O
it	O
was	O
decided	O
to	O
discuss	O
the	O
case	O
in	O
a	O
multidisciplinary	O
endocarditis	O
session	O
,	O
with	O
the	O
participation	O
of	O
the	O
radiology	O
,	O
infectious	O
diseases	O
and	O
cardiac	O
surgery	O
departments	O
,	O
with	O
a	O
view	O
to	O
assessing	O
valve	O
replacement	O
.	O
Given	O
the	O
history	O
of	O
splenic	O
infarction	O
,	O
it	O
was	O
decided	O
to	O
request	O
extension	O
studies	O
prior	O
to	O
surgery	O
to	O
rule	O
out	O
embolisms	O
at	O
other	O
levels	O
and	O
to	O
re	O
evaluate	O
the	O
state	O
of	O
spleen	O
involvement	O
.	O
On	O
the	O
same	O
day	O
,	O
a	O
cranial	O
CT	O
scan	O
was	O
performed	O
which	O
showed	O
the	O
presence	O
of	O
a	O
haemorrhagic	O
lesion	O
in	O
the	O
region	O
of	O
Sylvius	O
compatible	O
with	O
the	O
rupture	O
of	O
a	O
mycotic	O
aneurysm	O
and	O
a	O
PET	O
CT	O
scan	O
showed	O
marked	O
splenic	O
involvement	O
,	O
with	O
large	O
necrotic	O
areas	O
.	O
At	O
this	O
point	O
,	O
with	O
the	O
presence	O
of	O
valvular	O
involvement	O
,	O
splenomegaly	O
with	O
multiple	O
areas	O
of	O
large	O
infarction	O
,	O
and	O
intracranial	O
bleeding	O
,	O
it	O
was	O
decided	O
jointly	O
with	O
the	O
neurology	O
,	O
cardiac	O
surgery	O
and	O
general	O
surgery	O
services	O
to	O
establish	O
an	O
order	O
of	O
action	O
to	O
treat	O
the	O
set	O
of	O
complications	O
developed	O
by	O
the	O
patient	O
.	O
Initially	O
,	O
an	O
arteriography	O
with	O
embolisation	O
of	O
the	O
mycotic	O
aneurysm	O
affecting	O
the	O
M2	O
branch	O
of	O
the	O
left	O
middle	O
cerebral	O
artery	O
was	O
performed	O
after	O
study	O
with	O
cerebral	O
angio	O
MRI	O
.	O
The	O
procedure	O
was	O
performed	O
without	O
incident	O
and	O
without	O
secondary	O
neurological	O
sequelae	O
.	O
Subsequently	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
splenectomy	O
.	O
The	O
reason	O
for	O
initially	O
resecting	O
the	O
spleen	O
rather	O
than	O
the	O
heart	O
was	O
to	O
avoid	O
the	O
risk	O
of	O
bleeding	O
that	O
could	O
have	O
been	O
caused	O
by	O
the	O
extracorporeal	O
circulation	O
ECC	O
and	O
subsequent	O
heparinisation	O
.	O
One	O
week	O
after	O
embolisation	O
,	O
splenectomy	O
by	O
laparotomy	O
was	O
performed	O
without	O
complications	O
.	O
Finally	O
,	O
three	O
days	O
after	O
the	O
splenectomy	O
,	O
the	O
patient	O
underwent	O
surgery	O
for	O
his	O
valve	O
disease	O
.	O
The	O
aortic	O
valve	O
was	O
resected	O
and	O
a	O
St	O
.	O
Jude	O
No	O
.	O
23	O
biological	O
prosthesis	O
was	O
implanted	O
.	O
It	O
is	O
noteworthy	O
that	O
during	O
the	O
operation	O
both	O
the	O
intraoperative	O
TEE	O
and	O
the	O
visual	O
inspection	O
did	O
not	O
reveal	O
the	O
mitral	O
involvement	O
described	O
in	O
the	O
previous	O
report	O
;	O
only	O
a	O
grade	O
II	O
IV	O
mitral	O
insufficiency	O
,	O
so	O
it	O
was	O
decided	O
not	O
to	O
operate	O
on	O
it	O
the	O
same	O
grade	O
was	O
maintained	O
at	O
the	O
discharge	O
control	O
.	O
During	O
admission	O
,	O
the	O
patient	O
was	O
treated	O
with	O
intravenous	O
antibiotics	O
according	O
to	O
the	O
recommendations	O
of	O
the	O
infectious	O
diseases	O
department	O
ceftriaxone	B-FARMACO
,	O
gentamicin	B-FARMACO
and	O
ampicillin	B-FARMACO
.	O
The	O
patient	O
's	O
evolution	O
during	O
the	O
first	O
weeks	O
of	O
admission	O
was	O
acceptably	O
good	O
.	O
The	O
patient	O
remained	O
practically	O
asymptomatic	O
from	O
the	O
cardiological	O
point	O
of	O
view	O
,	O
with	O
development	O
of	O
mild	O
heart	O
failure	O
but	O
good	O
clinical	O
tolerance	O
and	O
improvement	O
in	O
both	O
fever	O
and	O
digestive	O
symptoms	O
.	O
The	O
main	O
complications	O
were	O
marked	O
anaemia	O
,	O
which	O
required	O
repeated	O
transfusions	O
of	O
several	O
red	O
blood	O
cell	O
concentrates	O
.	O
On	O
the	O
other	O
hand	O
,	O
he	O
also	O
had	O
a	O
deterioration	O
of	O
renal	O
function	O
that	O
made	O
it	O
necessary	O
to	O
space	O
contrast	O
studies	O
and	O
maintain	O
adequate	O
hydration	O
.	O
After	O
the	O
two	O
surgeries	O
,	O
the	O
patient	O
remained	O
in	O
hospital	O
for	O
a	O
little	O
over	O
a	O
month	O
,	O
with	O
a	O
very	O
poor	O
evolution	O
due	O
to	O
complications	O
derived	O
from	O
his	O
abdominal	O
surgery	O
.	O
This	O
even	O
necessitated	O
reoperation	O
for	O
drainage	O
of	O
the	O
abdominal	O
abscess	O
and	O
the	O
patient	O
's	O
admission	O
to	O
the	O
chronic	O
wound	O
unit	O
for	O
management	O
of	O
the	O
laparotomy	O
incision	O
.	O
In	O
the	O
end	O
,	O
however	O
,	O
the	O
patient	O
can	O
be	O
discharged	O
home	O
to	O
continue	O
his	O
recovery	O
there	O
.	O
DIAGNOSIS	O
Acute	O
E	O
.	O
faecalis	O
endocarditis	O
on	O
native	O
aortic	O
valve	O
.	O
Non	O
coronary	O
aortic	O
valve	O
leaflet	O
rupture	O
with	O
secondary	O
severe	O
aortic	O
insufficiency	O
.	O
Aortic	O
valve	O
replacement	O
with	O
St	O
.	O
Jude	O
biological	O
prosthesis	O
no	O
23	O
.	O
Acute	O
heart	O
failure	O
with	O
preserved	O
LVEF	O
in	O
the	O
setting	O
of	O
infective	O
endocarditis	O
.	O
Epicardial	O
arteries	O
without	O
lesions	O
.	O
Splenic	O
and	O
renal	O
infarcts	O
of	O
embolic	O
mechanism	O
secondary	O
to	O
infective	O
endocarditis	O
.	O
Splenectomy	O
by	O
laparotomy	O
with	O
subsequent	O
drainage	O
of	O
purulent	O
collection	O
.	O
Mycotic	O
cerebral	O
aneurysm	O
in	O
M2	O
branch	O
of	O
left	O
middle	O
cerebral	O
artery	O
secondary	O
to	O
infective	O
endocarditis	O
.	O
Embolisation	O
of	O
cerebral	O
mycotic	O
aneurysm	O
by	O
arteriography	O
.	O
Multifactorial	O
normocytic	O
anaemia	O
bleeding	O
,	O
hypersplenism	O
,	O
deterioration	O
of	O
renal	O
function	O
.	O
.	O
.	O
.	O
Multifactorial	O
acute	O
renal	O
failure	O
hypotension	O
,	O
iodinated	O
contrast	O
,	O
diuretics	O
.	O
.	O
.	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
71	O
year	O
old	O
patient	O
,	O
no	O
known	O
allergies	O
.	O
Ex	O
smoker	O
for	O
2	O
years	O
EA	O
40	O
packs	O
year	O
.	O
Cardiovascular	O
risk	O
factors	O
include	O
high	O
blood	O
pressure	O
,	O
insulin	O
dependent	O
type	O
2	O
diabetes	O
mellitus	O
with	O
good	O
control	O
and	O
dyslipidaemia	O
.	O
Cardiological	O
history	O
includes	O
permanent	O
atrial	O
fibrillation	O
.	O
The	O
last	O
echocardiography	O
in	O
2016	O
showed	O
LVEF	O
52	O
,	O
mild	O
mitral	O
regurgitation	O
and	O
estimated	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAPS	O
of	O
35	O
mmHg	O
.	O
Patient	O
in	O
NYHA	O
functional	O
class	O
II	O
,	O
with	O
no	O
previous	O
admissions	O
for	O
heart	O
failure	O
.	O
The	O
main	O
comorbidity	O
was	O
chronic	O
renal	O
failure	O
being	O
monitored	O
by	O
nephrology	O
and	O
with	O
baseline	O
creatinine	O
levels	O
around	O
1	O
.	O
5	O
2	O
mg	O
dl	O
estimated	O
glomerular	O
filtration	O
rate	O
eGFR	O
of	O
40	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
peripheral	O
vascular	O
disease	O
with	O
intermittent	O
claudication	O
and	O
multifactorial	O
anaemia	O
with	O
endoscopic	O
study	O
within	O
normal	O
limits	O
.	O
Usual	O
medication	O
acenocoumarol	B-FARMACO
,	O
manidipine	B-FARMACO
10	O
mg	O
day	O
,	O
doxazosin	B-FARMACO
8	O
mg	O
day	O
,	O
furosemide	B-FARMACO
40	O
mg	O
day	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
day	O
,	O
insulin	B-FARMACO
glargine	I-FARMACO
18U	I-FARMACO
,	O
ferroglycine	B-FARMACO
sulphate	I-FARMACO
100	O
mg	O
d	O
;	O
darbepoetin	B-FARMACO
alfa	I-FARMACO
1	O
injection	O
week	O
.	O
Present	O
illness	O
The	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
in	O
February	O
2020	O
due	O
to	O
an	O
increase	O
in	O
his	O
baseline	O
dyspnoea	O
of	O
1	O
week	O
's	O
evolution	O
to	O
minimal	O
effort	O
accompanied	O
by	O
orthopnoea	O
and	O
oedematisation	O
of	O
the	O
lower	O
limbs	O
together	O
with	O
a	O
subjective	O
decrease	O
in	O
diuresis	O
.	O
Since	O
then	O
,	O
he	O
has	O
had	O
rapid	O
palpitations	O
.	O
As	O
a	O
triggering	O
factor	O
,	O
he	O
presented	O
with	O
a	O
cough	O
with	O
scanty	O
whitish	O
expectoration	O
without	O
fever	O
,	O
of	O
10	O
days	O
'	O
evolution	O
,	O
for	O
which	O
his	O
primary	O
care	O
physician	O
had	O
prescribed	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
875	O
125	O
mg	O
8	O
h	O
for	O
7	O
days	O
.	O
Physical	O
examination	O
Vital	O
signs	O
blood	O
pressure	O
BP	O
175	O
83	O
mmHg	O
,	O
heart	O
rate	O
HR	O
120	O
bpm	O
,	O
baseline	O
oxygen	O
saturation	O
88	O
.	O
Cardiac	O
auscultation	O
with	O
irregular	O
,	O
tachycardic	O
sounds	O
.	O
Pulmonary	O
auscultation	O
with	O
hypoventilation	O
at	O
the	O
bases	O
and	O
crackles	O
up	O
to	O
midfields	O
,	O
together	O
with	O
isolated	O
rhonchi	O
.	O
Tibiomalleolar	O
oedema	O
with	O
grade	O
2	O
fovea	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
atrial	O
fibrillation	O
with	O
mean	O
ventricular	O
response	O
at	O
120	O
bpm	O
,	O
QRS	O
100	O
ms	O
.	O
ST	O
segment	O
depression	O
of	O
1	O
mm	O
V4	O
V6	O
,	O
I	O
and	O
aVL	O
.	O
CBC	O
glucose	O
138	O
mg	O
dl	O
,	O
urea	O
140	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
75	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
eGFR	O
38	O
.	O
5	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
sodium	O
Na	O
147	O
mmol	O
l	O
,	O
potassium	O
K	O
5	O
.	O
2	O
mmol	O
l	O
,	O
NT	O
proBNP	O
35	O
,	O
000	O
pg	O
ml	O
,	O
CA125	O
415	O
U	O
ml	O
.	O
AP	O
chest	O
X	O
ray	O
cardiomegaly	O
.	O
Aortic	O
elongation	O
.	O
Bilateral	O
pleural	O
effusion	O
predominantly	O
on	O
the	O
right	O
.	O
Signs	O
of	O
vascular	O
redistribution	O
and	O
interstitial	O
oedema	O
.	O
Transthoracic	O
echocardiography	O
.	O
Parasternal	O
long	O
axis	O
plane	O
and	O
apical	O
4	O
chamber	O
plane	O
dilated	O
left	O
ventricle	O
LVED	O
60	O
mm	O
,	O
with	O
moderate	O
hypertrophy	O
and	O
moderate	O
depression	O
of	O
global	O
systolic	O
function	O
LVEF	O
37	O
secondary	O
to	O
generalised	O
hypokinesia	O
.	O
High	O
filling	O
pressures	O
E	O
e	O
'	O
19	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
borderline	O
systolic	O
function	O
by	O
longitudinal	O
parameters	O
TAPSE	O
18	O
mm	O
.	O
Severe	O
left	O
atrial	O
dilatation	O
volume	O
126	O
ml	O
.	O
Aortic	O
valve	O
sclerosis	O
.	O
Mitral	O
valve	O
with	O
normal	O
opening	O
sclerosed	O
leaflets	O
and	O
mild	O
central	O
regurgitation	O
.	O
Mild	O
tricuspid	O
insufficiency	O
TI	O
with	O
estimated	O
PAPS	O
45	O
mmHg	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Dilated	O
vena	O
cava	O
24	O
mm	O
with	O
plethora	O
.	O
B	O
lines	O
in	O
both	O
lung	O
fields	O
suggestive	O
of	O
significant	O
pulmonary	O
congestion	O
.	O
Pulsatile	O
renal	O
venous	O
flow	O
moderate	O
renal	O
congestion	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
.	O
Cine	O
sequences	O
dilated	O
left	O
ventricle	O
with	O
eccentric	O
hypertrophy	O
pattern	O
and	O
moderately	O
depressed	O
systolic	O
function	O
LVEF	O
38	O
.	O
Right	O
ventricle	O
with	O
normal	O
volume	O
and	O
systolic	O
function	O
.	O
Dilated	O
left	O
atrium	O
.	O
Provocation	O
of	O
ischaemia	O
with	O
negative	O
regadenoson	O
.	O
Absence	O
of	O
myocardial	O
necrosis	O
.	O
Intramyocardial	O
fibrosis	O
in	O
the	O
entire	O
basal	O
septum	O
and	O
in	O
the	O
area	O
of	O
intersection	O
of	O
the	O
right	O
ventricle	O
in	O
the	O
medial	O
septum	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
for	O
decompensated	O
heart	O
failure	O
in	O
the	O
context	O
of	O
respiratory	O
infection	O
and	O
rapid	O
atrial	O
fibrillation	O
.	O
On	O
admission	O
,	O
impaired	O
renal	O
function	O
and	O
mild	O
hyperkalaemia	O
were	O
observed	O
.	O
Imaging	O
tests	O
showed	O
dilated	O
cardiomyopathy	O
of	O
non	O
ischaemic	O
origin	O
with	O
moderately	O
depressed	O
LVEF	O
and	O
borderline	O
right	O
function	O
,	O
without	O
significant	O
valvular	O
heart	O
disease	O
.	O
Intravenous	O
diuretic	O
treatment	O
was	O
administered	O
,	O
with	O
clinical	O
improvement	O
,	O
and	O
the	O
patient	O
was	O
discharged	O
from	O
hospital	O
.	O
Bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
day	O
,	O
valsartan	B-FARMACO
40	O
mg	O
day	O
and	O
furosemide	B-FARMACO
was	O
increased	O
to	O
80	O
mg	O
day	O
.	O
Subsequently	O
,	O
the	O
patient	O
made	O
two	O
visits	O
to	O
the	O
emergency	O
department	O
for	O
heart	O
failure	O
,	O
and	O
intravenous	O
diuretics	O
were	O
administered	O
without	O
requiring	O
admission	O
,	O
and	O
the	O
oral	O
diuretic	O
regimen	O
was	O
adjusted	O
.	O
In	O
August	O
the	O
patient	O
was	O
admitted	O
again	O
for	O
decompensation	O
of	O
heart	O
failure	O
and	O
severe	O
hyperkalaemia	O
.	O
Blood	O
tests	O
showed	O
creatinine	O
2	O
.	O
24	O
mg	O
dl	O
,	O
GFR	O
28	O
.	O
4	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
Na	O
141	O
mmol	O
l	O
,	O
K	O
6	O
.	O
7	O
mmol	O
l	O
,	O
NT	O
proBNP	O
24	O
.	O
5011	O
pg	O
ml	O
,	O
CA125	O
240	O
U	O
ml	O
.	O
After	O
depletive	O
treatment	O
and	O
correction	O
of	O
hyperkalaemia	O
on	O
discharge	O
,	O
chlorthalidone	B-FARMACO
25	O
mg	O
every	O
other	O
day	O
and	O
resincalcium	B-FARMACO
were	O
added	O
to	O
his	O
treatment	O
and	O
he	O
was	O
referred	O
to	O
the	O
heart	O
failure	O
unit	O
of	O
our	O
centre	O
.	O
On	O
the	O
first	O
visit	O
,	O
the	O
patient	O
was	O
in	O
NYHA	O
functional	O
class	O
III	O
with	O
significant	O
orthopnoea	O
.	O
Laboratory	O
tests	O
showed	O
creatinine	O
2	O
.	O
97	O
eGFR	O
20	O
ml	O
min	O
1	O
.	O
73	O
m2	O
and	O
K	O
5	O
.	O
7	O
mmol	O
l	O
.	O
Treatment	O
was	O
started	O
with	O
patiromer	B-FARMACO
16	O
.	O
8	O
g	O
day	O
and	O
a	O
subcutaneous	O
furosemide	B-FARMACO
pump	O
was	O
prescribed	O
.	O
At	O
the	O
next	O
visit	O
the	O
patient	O
had	O
a	O
creatinine	O
of	O
2	O
.	O
74	O
mg	O
dl	O
eGFR	O
23	O
ml	O
min	O
1	O
.	O
73	O
m2	O
and	O
K	O
of	O
4	O
.	O
2	O
mmol	O
l	O
.	O
It	O
was	O
then	O
decided	O
to	O
add	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
24	O
26	O
mg	O
12h	O
.	O
In	O
November	O
,	O
he	O
was	O
admitted	O
twice	O
more	O
for	O
heart	O
failure	O
due	O
to	O
recurrent	O
bilateral	O
pleural	O
effusion	O
,	O
predominantly	O
on	O
the	O
right	O
,	O
which	O
required	O
several	O
thoracentesis	O
and	O
finally	O
the	O
placement	O
of	O
a	O
permanent	O
pleural	O
drainage	O
.	O
At	O
the	O
follow	O
up	O
visit	O
in	O
December	O
,	O
the	O
patient	O
reported	O
improvement	O
in	O
functional	O
class	O
NYHA	O
II	O
and	O
orthopnoea	O
,	O
with	O
no	O
signs	O
of	O
congestion	O
.	O
Laboratory	O
tests	O
showed	O
an	O
improvement	O
in	O
renal	O
function	O
creatinine	O
2	O
.	O
5	O
mg	O
dl	O
,	O
eGFR	O
25	O
ml	O
min	O
1	O
.	O
73	O
m2	O
and	O
K	O
3	O
.	O
6	O
mmol	O
l	O
.	O
To	O
date	O
,	O
the	O
patient	O
remains	O
in	O
good	O
functional	O
class	O
,	O
with	O
no	O
new	O
episodes	O
of	O
heart	O
failure	O
decompensation	O
,	O
and	O
pleural	O
drainage	O
has	O
been	O
removed	O
due	O
to	O
the	O
absence	O
of	O
debit	O
.	O
Images	O
4	O
,	O
5	O
,	O
6	O
and	O
7	O
show	O
the	O
evolution	O
of	O
creatinine	O
,	O
potassium	O
and	O
prognostic	O
and	O
congestion	O
biomarkers	O
NT	O
proBNP	O
and	O
CA125	O
during	O
the	O
patient	O
's	O
evolution	O
.	O
DIAGNOSIS	O
Heart	O
failure	O
with	O
reduced	O
LVEF	O
.	O
Non	O
ischaemic	O
dilated	O
cardiomyopathy	O
.	O
Chronic	O
renal	O
disease	O
.	O
Cardiorenal	O
syndrome	O
.	O
Hyperkalaemia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Male	O
,	O
73	O
years	O
of	O
age	O
,	O
his	O
medical	O
history	O
includes	O
No	O
known	O
ADRs	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
hypertension	O
with	O
poor	O
control	O
and	O
dyslipidaemia	O
.	O
Severe	O
aortic	O
stenosis	O
with	O
valve	O
replacement	O
with	O
a	O
biological	O
prosthesis	O
in	O
2016	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
moderate	O
lesion	O
of	O
40	O
50	O
in	O
non	O
revascularised	O
anterior	O
descending	O
artery	O
.	O
Surgical	O
interventions	O
aortic	O
valve	O
replacement	O
,	O
shoulder	O
arthroplasty	O
,	O
tonsillectomy	O
,	O
inguinal	O
herniorrhaphy	O
.	O
Usual	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
,	O
amlodipine	B-FARMACO
5	O
mg	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
,	O
imidapril	B-FARMACO
10	O
mg	O
.	O
Present	O
illness	O
The	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
7	O
10	O
days	O
ago	O
,	O
complaining	O
of	O
fatigue	O
,	O
dyspnoea	O
and	O
a	O
feeling	O
of	O
dizziness	O
with	O
light	O
to	O
moderate	O
exertion	O
,	O
which	O
had	O
been	O
triggered	O
by	O
a	O
previous	O
episode	O
of	O
severe	O
stabbing	O
chest	O
pain	O
.	O
For	O
the	O
last	O
3	O
months	O
he	O
has	O
been	O
experiencing	O
intermittent	O
chest	O
pain	O
,	O
for	O
which	O
reason	O
he	O
has	O
been	O
seen	O
at	O
the	O
cardiology	O
outpatient	O
clinic	O
.	O
A	O
stress	O
test	O
was	O
requested	O
,	O
with	O
negative	O
results	O
for	O
ischaemia	O
,	O
and	O
a	O
stress	O
cardiac	O
magnetic	O
resonance	O
imaging	O
CMR	O
is	O
pending	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
170	O
90	O
mmHg	O
,	O
heart	O
rate	O
HR	O
60	O
bpm	O
.	O
Oxygen	O
saturation	O
95	O
FiO2	O
0	O
.	O
21	O
.	O
Cardiac	O
auscultation	O
regular	O
heart	O
sounds	O
,	O
aortic	O
systolic	O
murmur	O
II	O
VI	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
pathological	O
sounds	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
without	O
signs	O
of	O
defence	O
,	O
masses	O
or	O
visceromegaly	O
.	O
No	O
peripheral	O
oedema	O
.	O
Pulses	O
symmetrical	O
and	O
normal	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
.	O
First	O
degree	O
atrioventricular	O
block	O
AVB	O
PR	O
480	O
ms	O
.	O
Narrow	O
QRS	O
with	O
axis	O
at	O
0o	O
in	O
frontal	O
plane	O
.	O
No	O
pathological	O
alterations	O
in	O
repolarisation	O
.	O
Laboratory	O
tests	O
during	O
admission	O
glucose	O
111	O
mg	O
dl	O
,	O
urea	O
35	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
87	O
mg	O
dl	O
,	O
sodium	O
144	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
5	O
mmol	O
l	O
,	O
uric	O
acid	O
4	O
.	O
4	O
mg	O
dl	O
,	O
cholesterol	O
151	O
mg	O
dl	O
,	O
calculated	O
LDL	O
102	O
mg	O
dl	O
,	O
HDL	O
38	O
mg	O
dl	O
,	O
triglycerides	O
104	O
mg	O
dl	O
,	O
total	O
bilirubin	O
0	O
,	O
76	O
mg	O
dl	O
,	O
GPT	O
27	O
U	O
l	O
,	O
GOT	O
32	O
U	O
l	O
,	O
GGT	O
19	O
U	O
l	O
,	O
alkaline	O
phosphatases	O
74	O
mU	O
ml	O
,	O
haemoglobin	O
14	O
.	O
4	O
g	O
dl	O
,	O
haematocrit	O
44	O
,	O
MCV	O
93	O
fl	O
,	O
leucocytes	O
7900	O
,	O
platelets	O
201000	O
,	O
NT	O
proBNP	O
296	O
pg	O
ml	O
,	O
CRP	O
14	O
.	O
1	O
mg	O
l	O
,	O
procalcitonin	O
0	O
.	O
05	O
ng	O
ml	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiac	O
silhouette	O
,	O
no	O
signs	O
of	O
heart	O
failure	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
of	O
normal	O
dimensions	O
with	O
moderate	O
hypertrophy	O
of	O
its	O
walls	O
IVT	O
15	O
mm	O
.	O
Preserved	O
global	O
systolic	O
function	O
LVEF	O
65	O
without	O
segmental	O
alterations	O
of	O
contractility	O
at	O
rest	O
.	O
Ventricular	O
filling	O
wave	O
fusion	O
with	O
normal	O
E	O
e	O
"	O
ratio	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
.	O
Biological	O
prosthesis	O
in	O
normofunctioning	O
aortic	O
position	O
maximum	O
gradient	O
35	O
mmHg	O
,	O
mean	O
gradient	O
18	O
mmHg	O
,	O
without	O
regurgitation	O
.	O
Mitral	O
valve	O
with	O
normal	O
opening	O
and	O
minimal	O
valvular	O
insufficiency	O
.	O
Right	O
ventricle	O
of	O
normal	O
dimensions	O
with	O
borderline	O
function	O
by	O
longitudinal	O
parameters	O
TAPSE	O
16	O
mm	O
,	O
tricuspid	O
s	O
"	O
9	O
.	O
5	O
cm	O
s	O
after	O
cardiac	O
surgery	O
.	O
Absence	O
of	O
tricuspid	O
insufficiency	O
.	O
Normal	O
inferior	O
vena	O
cava	O
16	O
mm	O
with	O
inspiratory	O
collapse	O
50	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Continuous	O
renal	O
venous	O
flow	O
.	O
Exercise	O
test	O
maximal	O
exercise	O
test	O
,	O
negative	O
for	O
ischaemia	O
,	O
stopped	O
in	O
stage	O
3	O
of	O
Bruce	O
protocol	O
due	O
to	O
muscle	O
exhaustion	O
.	O
Work	O
achieved	O
11	O
METs	O
.	O
AV	O
conduction	O
1	O
1	O
throughout	O
the	O
test	O
.	O
Good	O
chronotropic	O
and	O
tension	O
response	O
.	O
Functional	O
capacity	O
adequate	O
for	O
his	O
age	O
.	O
Stress	O
CMR	O
left	O
ventricle	O
with	O
increased	O
septal	O
thickness	O
predominantly	O
17	O
mm	O
and	O
preserved	O
mass	O
71	O
g	O
m2	O
,	O
normal	O
MPR	O
1	O
.	O
18	O
.	O
Volumes	O
IVTDVI	O
60	O
ml	O
m2	O
;	O
IVTSVI	O
17	O
ml	O
m2	O
and	O
segmental	O
and	O
global	O
systolic	O
function	O
within	O
normal	O
LVEF	O
72	O
.	O
Right	O
ventricular	O
volumes	O
IVTDDI	O
56	O
ml	O
m2	O
;	O
IVTSVD	O
19	O
ml	O
m2	O
and	O
systolic	O
function	O
within	O
normal	O
RVEF	O
66	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
Biological	O
valve	O
prosthesis	O
in	O
aortic	O
position	O
.	O
Peak	O
systolic	O
velocity	O
of	O
3	O
.	O
5	O
m	O
s	O
.	O
Periprosthetic	O
collection	O
surrounding	O
the	O
valve	O
annulus	O
and	O
contrast	O
uptake	O
in	O
relation	O
to	O
surgery	O
.	O
Slight	O
dilatation	O
of	O
root	O
37	O
mm	O
,	O
20	O
mm	O
m2	O
and	O
tubular	O
portion	O
38	O
mm	O
,	O
20	O
mm	O
m2	O
.	O
Rest	O
of	O
thoracic	O
aorta	O
of	O
preserved	O
calibre	O
.	O
Provocation	O
of	O
ischaemia	O
with	O
i	O
.	O
v	O
.	O
Regadenoson	O
400	O
mcg	O
i	O
.	O
v	O
.	O
,	O
well	O
tolerated	O
negative	O
.	O
Baseline	O
58	O
bpm	O
and	O
135	O
85	O
mmHg	O
.	O
Stress	O
82	O
bpm	O
and	O
122	O
77	O
mmHg	O
.	O
Baseline	O
ECG	O
PR	O
of	O
0	O
.	O
480	O
s	O
,	O
without	O
complications	O
during	O
regadenoson	O
stress	O
.	O
Gadoteric	O
acid	O
is	O
administered	O
i	O
.	O
v	O
.	O
at	O
0	O
.	O
15	O
mmol	O
kg	O
without	O
complications	O
.	O
Absence	O
of	O
myocardial	O
fibrosis	O
or	O
necrosis	O
.	O
Only	O
contrast	O
uptake	O
in	O
periprosthetic	O
collection	O
.	O
In	O
summary	O
,	O
absence	O
of	O
inducible	O
ischaemia	O
.	O
Biological	O
aortic	O
valve	O
prosthesis	O
with	O
contrast	O
enhancing	O
periprosthetic	O
collection	O
of	O
uncertain	O
significance	O
.	O
PET	O
CT	O
biological	O
aortic	O
prosthesis	O
with	O
intense	O
hypermetabolism	O
SULmax	O
6	O
.	O
6	O
g	O
ml	O
,	O
late	O
9	O
.	O
07	O
g	O
ml	O
accompanied	O
by	O
mural	O
thickening	O
of	O
the	O
ascending	O
aorta	O
,	O
suggestive	O
of	O
endocarditis	O
due	O
to	O
prosthetic	O
infection	O
.	O
Hypermetabolic	O
right	O
upper	O
and	O
lower	O
right	O
paratracheal	O
SULmax	O
2	O
.	O
8	O
g	O
ml	O
,	O
subcarinal	O
and	O
bilateral	O
hilar	O
SULmax	O
3	O
.	O
7	O
g	O
ml	O
contrast	O
enhancing	O
hypermetabolic	O
adenopathies	O
suggestive	O
of	O
an	O
infectious	O
process	O
secondary	O
to	O
endocarditis	O
.	O
Absence	O
of	O
metabolic	O
activity	O
in	O
cephalic	O
lymph	O
node	O
stations	O
or	O
bone	O
marrow	O
.	O
Physiological	O
glandular	O
and	O
encephalic	O
uptake	O
.	O
Absence	O
of	O
pathological	O
metabolic	O
activity	O
in	O
cervical	O
or	O
axillary	O
ganglion	O
stations	O
.	O
Subsegmental	O
hypermetabolic	O
atelectasis	O
of	O
the	O
upper	O
segment	O
of	O
the	O
lower	O
lobe	O
of	O
the	O
right	O
lung	O
.	O
No	O
pleural	O
or	O
pericardial	O
or	O
pleural	O
effusion	O
.	O
Sternal	O
sternotomy	O
band	O
with	O
physiological	O
hypermetabolism	O
.	O
Hepatic	O
,	O
splenic	O
,	O
pancreatic	O
,	O
renal	O
and	O
adrenal	O
parenchyma	O
without	O
significant	O
metabolic	O
alterations	O
.	O
Small	O
bowel	O
loops	O
with	O
diffuse	O
metabolic	O
activity	O
,	O
with	O
no	O
significant	O
pathological	O
accumulations	O
of	O
activity	O
.	O
Absence	O
of	O
metabolic	O
activity	O
in	O
abdominal	O
,	O
retroperitoneal	O
,	O
pelvic	O
and	O
inguinal	O
lymph	O
node	O
stations	O
.	O
No	O
free	O
abdominal	O
fluid	O
.	O
Circumferential	O
mural	O
thrombosis	O
in	O
the	O
abdominal	O
aorta	O
with	O
partial	O
obstruction	O
of	O
the	O
right	O
common	O
iliac	O
artery	O
with	O
diffuse	O
atheromatosis	O
.	O
No	O
evidence	O
of	O
significant	O
morphological	O
or	O
metabolic	O
alteration	O
in	O
the	O
bone	O
framework	O
.	O
Conclusions	O
focus	O
of	O
hypermetabolism	O
in	O
aortic	O
valve	O
prosthesis	O
suggestive	O
of	O
endocarditis	O
,	O
with	O
reactive	O
mediastinal	O
and	O
pulmonary	O
adenopathies	O
.	O
Circumferential	O
mural	O
thrombosis	O
of	O
the	O
abdominal	O
aorta	O
and	O
partial	O
obstruction	O
of	O
the	O
right	O
common	O
iliac	O
artery	O
.	O
CLINICAL	O
COURSE	O
In	O
the	O
case	O
of	O
a	O
patient	O
with	O
a	O
conduction	O
disorder	O
presenting	O
with	O
exertional	O
dyspnoea	O
and	O
dizziness	O
,	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
cardiology	O
to	O
complete	O
the	O
study	O
.	O
A	O
new	O
exercise	O
stress	O
test	O
was	O
requested	O
to	O
assess	O
the	O
reaction	O
to	O
exercise	O
,	O
and	O
an	O
adequate	O
chronotropic	O
response	O
and	O
1	O
1	O
conduction	O
was	O
observed	O
throughout	O
the	O
test	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
which	O
ruled	O
out	O
prosthetic	O
dysfunction	O
,	O
without	O
observing	O
segmental	O
contractility	O
alterations	O
suggestive	O
of	O
ischaemia	O
.	O
After	O
the	O
absence	O
of	O
relevant	O
findings	O
in	O
the	O
examinations	O
performed	O
,	O
it	O
was	O
decided	O
to	O
discharge	O
the	O
patient	O
from	O
hospital	O
with	O
withdrawal	O
of	O
beta	O
blockers	O
.	O
Given	O
the	O
persistence	O
of	O
atypical	O
chest	O
pain	O
with	O
a	O
history	O
of	O
previous	O
coronary	O
artery	O
disease	O
,	O
stress	O
CMR	O
was	O
brought	O
forward	O
with	O
outpatient	O
monitoring	O
in	O
cardiology	O
outpatient	O
clinics	O
.	O
The	O
following	O
week	O
a	O
stress	O
CMR	O
was	O
performed	O
,	O
with	O
negative	O
results	O
for	O
ischaemia	O
,	O
but	O
a	O
periprosthetic	O
collection	O
with	O
contrast	O
uptake	O
was	O
found	O
,	O
of	O
uncertain	O
significance	O
,	O
which	O
could	O
correspond	O
to	O
postoperative	O
inflammatory	O
activity	O
or	O
an	O
infectious	O
process	O
.	O
On	O
assessing	O
the	O
results	O
,	O
taking	O
into	O
account	O
the	O
remoteness	O
of	O
the	O
intervention	O
3	O
years	O
and	O
given	O
the	O
possibility	O
of	O
infective	O
prosthetic	O
endocarditis	O
,	O
it	O
was	O
decided	O
to	O
readmit	O
the	O
patient	O
to	O
cardiology	O
to	O
complete	O
the	O
study	O
and	O
start	O
antibiotic	O
treatment	O
.	O
Empirical	O
treatment	O
with	O
ampicillin	B-FARMACO
,	O
cloxacillin	B-FARMACO
and	O
gentamicin	B-FARMACO
was	O
started	O
in	O
agreement	O
with	O
the	O
infectious	O
diseases	O
unit	O
.	O
Blood	O
cultures	O
and	O
serology	O
for	O
endocarditis	O
were	O
requested	O
,	O
with	O
negative	O
results	O
.	O
It	O
was	O
decided	O
to	O
complete	O
the	O
imaging	O
study	O
with	O
PET	O
CT	O
,	O
which	O
showed	O
the	O
presence	O
of	O
hypermetabolism	O
in	O
the	O
aortic	O
valve	O
prosthesis	O
suggestive	O
of	O
endocarditis	O
,	O
with	O
reactive	O
mediastinal	O
and	O
pulmonary	O
adenopathies	O
;	O
as	O
an	O
incidental	O
finding	O
,	O
a	O
circumferential	O
mural	O
thrombosis	O
of	O
the	O
abdominal	O
aorta	O
and	O
partial	O
obstruction	O
of	O
the	O
right	O
common	O
iliac	O
artery	O
were	O
found	O
.	O
With	O
the	O
above	O
findings	O
,	O
the	O
case	O
was	O
discussed	O
in	O
a	O
joint	O
medical	O
surgical	O
session	O
between	O
cardiology	O
,	O
cardiac	O
surgery	O
and	O
the	O
infectious	O
diseases	O
unit	O
.	O
Since	O
the	O
patient	O
was	O
stable	O
,	O
with	O
no	O
evidence	O
of	O
prosthetic	O
dysfunction	O
or	O
acute	O
complications	O
,	O
initial	O
antibiotic	O
treatment	O
was	O
chosen	O
for	O
6	O
weeks	O
,	O
changing	O
the	O
previous	O
regimen	O
to	O
daptomycin	B-FARMACO
,	O
ceftriaxone	B-FARMACO
and	O
doxycycline	B-FARMACO
,	O
with	O
subsequent	O
re	O
evaluation	O
.	O
After	O
the	O
first	O
10	O
days	O
of	O
treatment	O
,	O
the	O
patient	O
remained	O
clinically	O
stable	O
,	O
and	O
it	O
was	O
decided	O
to	O
discharge	O
him	O
to	O
the	O
home	O
hospitalisation	O
unit	O
HHU	O
to	O
complete	O
the	O
antibiotic	O
regimen	O
.	O
Also	O
,	O
with	O
a	O
history	O
of	O
coronary	O
heart	O
disease	O
and	O
the	O
finding	O
of	O
peripheral	O
arterial	O
disease	O
with	O
mural	O
thrombosis	O
of	O
the	O
abdominal	O
aorta	O
,	O
lipid	O
lowering	O
treatment	O
was	O
intensified	O
with	O
the	O
addition	O
of	O
a	O
combination	O
of	O
atorvastatin	B-FARMACO
ezetimibe	I-FARMACO
.	O
After	O
6	O
weeks	O
of	O
antibiotic	O
therapy	O
,	O
a	O
new	O
control	O
PET	O
CT	O
scan	O
was	O
performed	O
,	O
in	O
which	O
periprosthetic	O
hypermetabolism	O
persisted	O
but	O
of	O
less	O
intensity	O
than	O
previously	O
,	O
with	O
disappearance	O
of	O
the	O
reactive	O
adenopathies	O
.	O
With	O
the	O
good	O
response	O
to	O
treatment	O
,	O
it	O
was	O
decided	O
to	O
complete	O
4	O
more	O
weeks	O
of	O
antibiotic	O
treatment	O
,	O
replacing	O
doxycycline	B-FARMACO
with	O
rifampicin	B-FARMACO
,	O
which	O
would	O
subsequently	O
be	O
maintained	O
in	O
monotherapy	O
until	O
completing	O
6	O
months	O
of	O
treatment	O
.	O
DIAGNOSIS	O
Late	O
infective	O
endocarditis	O
on	O
biological	O
aortic	O
prosthesis	O
.	O
First	O
degree	O
atrioventricular	O
block	O
AVB	O
secondary	O
to	O
aortic	O
endocarditis	O
.	O
Circumferential	O
mural	O
thrombosis	O
of	O
the	O
abdominal	O
aorta	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
61	O
year	O
old	O
woman	O
.	O
Personal	O
history	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
.	O
Recent	O
admission	O
to	O
internal	O
medicine	O
for	O
community	O
acquired	O
pneumonia	O
and	O
debut	O
of	O
heart	O
failure	O
.	O
No	O
surgical	O
interventions	O
.	O
Other	O
history	O
depressive	O
syndrome	O
,	O
vertiginous	O
syndrome	O
since	O
2017	O
,	O
dorsalgia	O
followed	O
up	O
by	O
rehabilitation	O
.	O
Usual	O
treatment	O
betahistine	B-FARMACO
8	O
mg	O
1	O
0	O
1	O
,	O
bromazepam	B-FARMACO
and	O
paracetamol	B-FARMACO
codeine	I-FARMACO
on	O
demand	O
.	O
Family	O
history	O
diabetic	O
father	O
,	O
with	O
CKD	O
requiring	O
haemodialysis	O
and	O
unspecified	O
heart	O
disease	O
.	O
Mother	O
with	O
atrial	O
fibrillation	O
and	O
brother	O
with	O
acute	O
non	O
ST	O
segment	O
elevation	O
myocardial	O
infarction	O
NSTEMI	O
at	O
54	O
years	O
of	O
age	O
.	O
Current	O
illness	O
Consultation	O
for	O
several	O
months	O
of	O
dyspnoea	O
progressing	O
to	O
minimal	O
effort	O
with	O
orthopnoea	O
,	O
paroxysmal	O
nocturnal	O
dyspnoea	O
PND	O
,	O
cough	O
with	O
purulent	O
expectoration	O
,	O
decreased	O
diuresis	O
and	O
dysthermic	O
sensation	O
.	O
Physical	O
examination	O
Vital	O
signs	O
blood	O
pressure	O
124	O
72	O
mmhg	O
,	O
heart	O
rate	O
98	O
bpm	O
,	O
respiratory	O
rate	O
24	O
rpm	O
,	O
temperature	O
36	O
C	O
.	O
Good	O
general	O
condition	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
sounds	O
with	O
systolic	O
murmur	O
intensity	O
II	O
VI	O
in	O
aortic	O
focus	O
.	O
Pulmonary	O
auscultation	O
diminished	O
sounds	O
in	O
the	O
right	O
base	O
and	O
scarce	O
bilateral	O
crackles	O
.	O
Extremities	O
without	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Urgent	O
laboratory	O
tests	O
haemogram	O
leucocytes	O
9	O
,	O
800	O
μl	O
79	O
.	O
8	O
neutrophils	O
,	O
haemoglobin	O
12	O
.	O
4	O
g	O
dl	O
,	O
haematocrit	O
37	O
.	O
3	O
,	O
platelets	O
160	O
,	O
000	O
.	O
Biochemistry	O
glucose	O
90	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
5	O
mg	O
dl	O
,	O
urea	O
33	O
mg	O
dl	O
,	O
bilirubin	O
1	O
.	O
26	O
mg	O
dl	O
,	O
GOT	O
21	O
U	O
l	O
,	O
GPT	O
33	O
U	O
l	O
,	O
Na	O
144	O
mEq	O
l	O
,	O
K	O
1	O
.	O
5	O
mEq	O
l	O
,	O
Cl	O
104	O
mEq	O
l	O
,	O
CRP	O
0	O
.	O
47	O
,	O
TSH	O
1	O
.	O
04	O
.	O
Cardiac	O
markers	O
ultrasensitive	O
troponin	O
I	O
10	O
.	O
2	O
,	O
NT	O
proBNP	O
8026	O
pg	O
ml	O
.	O
Antigenuria	O
pneumococcal	O
antigen	O
positive	O
,	O
Legionella	O
pneumophila	O
serogroup	O
1	O
antigen	O
negative	O
.	O
SARS	O
CoV	O
2	O
PCR	O
negative	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
normal	O
cardiac	O
silhouette	O
,	O
small	O
interstitial	O
infiltrate	O
in	O
the	O
right	O
base	O
and	O
small	O
pleural	O
effusion	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
,	O
normal	O
PR	O
,	O
right	O
axis	O
,	O
incomplete	O
right	O
bundle	O
branch	O
block	O
of	O
the	O
HH	O
,	O
Rs	O
in	O
V2	O
V4	O
,	O
without	O
repolarisation	O
disorders	O
.	O
Laboratory	O
tests	O
on	O
the	O
hospital	O
ward	O
serum	O
proteinogram	O
total	O
proteins	O
6	O
.	O
4	O
,	O
albumin	O
3	O
.	O
37	O
g	O
dl	O
52	O
.	O
6	O
,	O
alpha	O
1	O
globulins	O
0	O
.	O
35	O
g	O
dl	O
5	O
.	O
5	O
,	O
alpha	O
2	O
globulins	O
0	O
.	O
79	O
g	O
dl	O
12	O
.	O
5	O
,	O
B	O
globulins	O
1	O
.	O
14	O
g	O
dl	O
17	O
.	O
8	O
,	O
gamma	O
globulins	O
0	O
.	O
75	O
g	O
dl	O
11	O
.	O
7	O
,	O
monoclonal	O
band	O
in	O
the	O
beta	O
region	O
of	O
7	O
.	O
1	O
0	O
.	O
45	O
g	O
dl	O
,	O
corresponds	O
to	O
an	O
IgA	O
kappa	O
band	O
.	O
Serum	O
free	O
kappa	O
light	O
chains	O
4040	O
mg	O
l	O
,	O
serum	O
free	O
lambda	O
light	O
chains	O
5	O
mg	O
l	O
.	O
Immunoglobulins	O
IgG	O
413	O
mg	O
dl	O
,	O
IgA	O
952	O
mg	O
dl	O
,	O
IgM	O
20	O
mg	O
dl	O
.	O
Autoimmunity	O
profile	O
negative	O
.	O
Urine	O
study	O
protein	O
creatinine	O
ratio	O
0	O
.	O
61	O
,	O
proteinuria	O
in	O
24	O
hours	O
480	O
mg	O
,	O
kappa	O
light	O
chains	O
in	O
urine	O
17	O
.	O
7	O
mg	O
dl	O
,	O
lambda	O
light	O
chains	O
1	O
.	O
5	O
mg	O
dl	O
.	O
Transthoracic	O
echocardiogram	O
videos	O
1	O
and	O
2	O
left	O
ventricle	O
of	O
preserved	O
dimensions	O
,	O
with	O
severely	O
increased	O
concentric	O
wall	O
thickness	O
16	O
mm	O
,	O
LVEF	O
68	O
,	O
no	O
segmental	O
contractility	O
defects	O
.	O
Diastolic	O
dysfunction	O
grade	O
II	O
,	O
psudonormalised	O
pattern	O
E	O
A	O
1	O
.	O
8	O
E	O
e	O
"	O
17	O
.	O
Severe	O
mitral	O
insufficiency	O
,	O
dilated	O
left	O
atrium	O
50	O
mm	O
.	O
Right	O
ventricle	O
of	O
preserved	O
dimensions	O
and	O
systolic	O
function	O
,	O
estimated	O
PAPS	O
52	O
mmHg	O
.	O
Reduced	O
global	O
longitudinal	O
Strain	O
,	O
preserved	O
in	O
apical	O
segments	O
,	O
with	O
deterioration	O
in	O
the	O
basal	O
region	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
anterior	O
ascending	O
AD	O
area	O
in	O
4C	O
25	O
cm2	O
,	O
right	O
ventricle	O
RV	O
76X46X52	O
mm	O
.	O
Left	O
atrium	O
LA	O
area	O
28	O
cm2	O
,	O
left	O
ventricle	O
LV	O
50X40X69	O
mm	O
.	O
T1	O
non	O
enhanced	O
.	O
Interventricular	O
septum	O
19	O
.	O
5	O
mm	O
,	O
slight	O
circumferential	O
pericardial	O
effusion	O
of	O
subcentimetric	O
thickness	O
.	O
Non	O
dilated	O
left	O
ventricle	O
,	O
with	O
severe	O
septal	O
hypertrophy	O
and	O
moderate	O
circumferential	O
hypertrophy	O
at	O
baso	O
medial	O
level	O
,	O
contractility	O
without	O
segmental	O
deficits	O
.	O
After	O
i	O
.	O
v	O
.	O
contrast	O
,	O
difficulty	O
in	O
myocardial	O
signal	O
cancellation	O
in	O
LL	O
sequence	O
,	O
showing	O
diffuse	O
endocardial	O
enhancement	O
of	O
basal	O
predominance	O
,	O
almost	O
transmural	O
in	O
basal	O
lateral	O
face	O
and	O
mid	O
apical	O
transmural	O
mottling	O
,	O
with	O
some	O
respect	O
for	O
the	O
basal	O
septum	O
.	O
Probable	O
endocardial	O
enhancement	O
in	O
left	O
atrium	O
.	O
Slightly	O
hypertrophic	O
right	O
ventricle	O
with	O
tricuspid	O
insufficiency	O
TI	O
,	O
mitral	O
insufficiency	O
MI	O
and	O
LVOT	O
acceleration	O
jet	O
,	O
without	O
clear	O
SAM	O
.	O
Brain	O
magnetic	O
resonance	O
imaging	O
MRI	O
broad	O
based	O
bony	O
overgrowth	O
affecting	O
the	O
posterior	O
wall	O
of	O
the	O
left	O
internal	O
auditory	O
canal	O
,	O
compatible	O
with	O
exostosis	O
.	O
Pyrophosphate	O
cardiac	O
scan	O
Perugini	O
grade	O
1	O
uptake	O
.	O
Abdominal	O
subcutaneous	O
cellular	O
tissue	O
biopsy	O
no	O
relevant	O
lesions	O
,	O
Congo	O
red	O
negative	O
.	O
Bone	O
marrow	O
biopsy	O
Congo	O
red	O
negative	O
,	O
slightly	O
hypercellular	O
with	O
mature	O
forms	O
of	O
the	O
three	O
series	O
and	O
mild	O
moderate	O
interstitial	O
plasmacytosis	O
21	O
24	O
and	O
restriction	O
of	O
kappa	O
light	O
chains	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
internal	O
medicine	O
department	O
for	O
symptoms	O
compatible	O
with	O
community	O
acquired	O
pneumonia	O
with	O
associated	O
small	O
pleural	O
effusion	O
.	O
Antibiotics	O
were	O
administered	O
with	O
ceftriaxone	B-FARMACO
plus	O
clarithromycin	B-FARMACO
for	O
7	O
days	O
,	O
with	O
partial	O
improvement	O
of	O
cough	O
,	O
but	O
still	O
with	O
persistent	O
dyspnoea	O
,	O
orthopnoea	O
and	O
development	O
of	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
A	O
control	O
chest	O
X	O
ray	O
showed	O
a	O
slight	O
increase	O
in	O
pleural	O
effusion	O
.	O
In	O
addition	O
,	O
blood	O
tests	O
showed	O
an	O
elevation	O
of	O
NT	O
proBNP	O
disproportionate	O
to	O
the	O
clinical	O
picture	O
.	O
Following	O
the	O
findings	O
observed	O
in	O
the	O
echocardiogram	O
,	O
cardiology	O
assessment	O
was	O
requested	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
cardiology	O
department	O
.	O
During	O
admission	O
to	O
the	O
cardiology	O
ward	O
,	O
the	O
patient	O
remained	O
stable	O
,	O
but	O
persisted	O
with	O
occasional	O
dizziness	O
and	O
oedema	O
in	O
the	O
lower	O
limbs	O
despite	O
diuretic	O
treatment	O
.	O
The	O
echocardiogram	O
showed	O
symmetric	O
concentric	O
hypertrophy	O
of	O
the	O
left	O
ventricle	O
associated	O
with	O
diastolic	O
dysfunction	O
,	O
high	O
filling	O
pressures	O
and	O
altered	O
strain	O
.	O
In	O
the	O
aetiological	O
study	O
of	O
the	O
condition	O
,	O
CMR	O
was	O
performed	O
with	O
findings	O
highly	O
suggestive	O
of	O
cardiac	O
amyloidosis	O
.	O
To	O
establish	O
a	O
differential	O
diagnosis	O
between	O
AL	O
cardiac	O
amyloidosis	O
and	O
ATTR	O
,	O
pyrophosphate	O
scintigraphy	O
was	O
performed	O
,	O
which	O
showed	O
mild	O
myocardial	O
uptake	O
,	O
as	O
well	O
as	O
a	O
proteinogram	O
and	O
immunofixation	O
in	O
blood	O
and	O
urine	O
,	O
which	O
detected	O
a	O
monoclonal	O
IgA	O
kappa	O
type	O
component	O
.	O
Abdominal	O
fat	O
biopsy	O
with	O
Congo	O
red	O
stain	O
was	O
negative	O
for	O
amyloidosis	O
.	O
Bone	O
marrow	O
biopsy	O
was	O
then	O
performed	O
with	O
plasmacytosis	O
greater	O
than	O
20	O
.	O
These	O
findings	O
were	O
compatible	O
with	O
multiple	O
myeloma	O
.	O
Finally	O
,	O
a	O
salivary	O
gland	O
biopsy	O
was	O
performed	O
and	O
was	O
positive	O
for	O
amyloidosis	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
haematology	O
and	O
started	O
treatment	O
with	O
bortezomib	B-FARMACO
cyclophosphamide	I-FARMACO
dexamethasone	I-FARMACO
protocol	O
.	O
DIAGNOSIS	O
Acute	O
heart	O
failure	O
with	O
preserved	O
LVEF	O
.	O
AL	O
cardiac	O
amyloidosis	O
.	O
Multiple	O
myeloma	O
IgA	O
kappa	O
.	O
Community	O
acquired	O
pneumonia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
The	O
case	O
is	O
a	O
37	O
year	O
old	O
woman	O
,	O
with	O
no	O
known	O
drug	O
allergies	O
,	O
a	O
former	O
smoker	O
for	O
20	O
years	O
,	O
who	O
in	O
2016	O
presented	O
with	O
central	O
retinal	O
vein	O
obstruction	O
,	O
complicated	O
by	O
vitreous	O
haemorrhage	O
that	O
eventually	O
required	O
vitrectomy	O
.	O
In	O
addition	O
,	O
she	O
has	O
a	O
probable	O
antiphospholipid	O
syndrome	O
,	O
for	O
which	O
she	O
is	O
being	O
treated	O
with	O
hydroxychloroquine	B-FARMACO
200	O
mg	O
24	O
h	O
and	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
24	O
h	O
.	O
The	O
patient	O
was	O
being	O
followed	O
up	O
by	O
a	O
private	O
cardiologist	O
due	O
to	O
the	O
accidental	O
finding	O
of	O
a	O
murmur	O
during	O
an	O
examination	O
at	O
work	O
.	O
The	O
echocardiogram	O
TTE	O
showed	O
moderate	O
aortic	O
insufficiency	O
AIo	O
with	O
mild	O
stenosis	O
,	O
normal	O
mitral	O
valve	O
,	O
non	O
dilated	O
left	O
ventricle	O
LV	O
with	O
preserved	O
LV	O
ejection	O
fraction	O
LVEF	O
,	O
and	O
no	O
evidence	O
of	O
pulmonary	O
hypertension	O
PH	O
.	O
Pregnant	O
at	O
20	O
weeks	O
,	O
she	O
was	O
referred	O
from	O
obstetrics	O
for	O
cardiology	O
follow	O
up	O
during	O
pregnancy	O
.	O
Monthly	O
follow	O
ups	O
were	O
started	O
to	O
rule	O
out	O
the	O
appearance	O
of	O
cardiac	O
decompensation	O
.	O
Special	O
attention	O
was	O
paid	O
to	O
the	O
appearance	O
of	O
congestive	O
symptoms	O
or	O
signs	O
the	O
patient	O
only	O
reported	O
dyspnoea	O
on	O
moderate	O
exertion	O
.	O
Serial	O
analyses	O
were	O
performed	O
,	O
including	O
NT	O
proBNP	O
,	O
which	O
was	O
normal	O
,	O
and	O
TTE	O
,	O
which	O
showed	O
a	O
non	O
dilated	O
LV	O
with	O
normal	O
LVEF	O
,	O
severe	O
mitral	O
MR	O
and	O
aortic	O
insufficiency	O
,	O
with	O
no	O
evidence	O
of	O
pulmonary	O
hypertension	O
.	O
The	O
patient	O
had	O
presented	O
proteinuria	O
since	O
early	O
gestation	O
.	O
At	O
around	O
week	O
30	O
,	O
she	O
started	O
with	O
arterial	O
hypertension	O
AHT	O
,	O
with	O
blood	O
pressure	O
around	O
140	O
72	O
mmHg	O
,	O
plateletopenia	O
and	O
incipient	O
oedema	O
.	O
Present	O
illness	O
In	O
week	O
34	O
she	O
was	O
referred	O
to	O
the	O
obstetrics	O
emergency	O
department	O
for	O
high	O
blood	O
pressure	O
of	O
168	O
84	O
mmHg	O
complementary	O
tests	O
showed	O
proteinuria	O
and	O
plateletopenia	O
,	O
so	O
it	O
was	O
decided	O
to	O
admit	O
her	O
for	O
pulmonary	O
maturation	O
and	O
observation	O
on	O
suspicion	O
of	O
possible	O
pre	O
eclampsia	O
versus	O
alterations	O
secondary	O
to	O
antiphospholipid	O
syndrome	O
.	O
Initially	O
,	O
vaginal	O
delivery	O
was	O
attempted	O
because	O
it	O
was	O
associated	O
with	O
less	O
blood	O
loss	O
and	O
less	O
risk	O
of	O
infection	O
and	O
venous	O
thromboembolism	O
,	O
but	O
due	O
to	O
the	O
risk	O
of	O
loss	O
of	O
foetal	O
well	O
being	O
,	O
caesarean	O
section	O
was	O
finally	O
indicated	O
.	O
The	O
patient	O
had	O
remained	O
stable	O
from	O
a	O
cardiological	O
point	O
of	O
view	O
during	O
admission	O
,	O
but	O
12	O
hours	O
after	O
the	O
caesarean	O
section	O
,	O
cardiology	O
was	O
notified	O
due	O
to	O
desaturation	O
up	O
to	O
77	O
.	O
The	O
patient	O
only	O
reported	O
having	O
started	O
,	O
while	O
at	O
rest	O
,	O
with	O
a	O
feeling	O
of	O
warmth	O
and	O
dizziness	O
,	O
without	O
loss	O
of	O
consciousness	O
,	O
clear	O
dyspnoea	O
,	O
orthopnoea	O
or	O
chest	O
pain	O
.	O
Physical	O
examination	O
She	O
was	O
conscious	O
and	O
oriented	O
,	O
well	O
perfused	O
,	O
blood	O
pressure	O
BP	O
160	O
90	O
mmHg	O
,	O
heart	O
rate	O
HR	O
75	O
bpm	O
and	O
oxygen	O
saturation	O
SO2	O
91	O
92	O
with	O
oxygen	O
therapy	O
with	O
nasal	O
goggles	O
NG	O
at	O
2	O
l	O
min	O
,	O
eupneic	O
at	O
rest	O
and	O
tolerating	O
decubitus	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
with	O
diastolic	O
and	O
systolic	O
murmur	O
.	O
Pulmonary	O
auscultation	O
in	O
the	O
anterior	O
plane	O
preserved	O
vesicular	O
murmur	O
.	O
Slight	O
oedema	O
with	O
pretibial	O
fovea	O
similar	O
to	O
that	O
of	O
that	O
morning	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
hypoxaemia	O
with	O
hypocapnia	O
,	O
with	O
normal	O
pH	O
and	O
lactic	O
acid	O
,	O
mild	O
renal	O
failure	O
with	O
ions	O
in	O
range	O
,	O
NT	O
proBNP	O
of	O
1466	O
ng	O
dl	O
,	O
and	O
leukocytes	O
with	O
left	O
deviation	O
and	O
CRP	O
of	O
75	O
mg	O
l	O
.	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
,	O
with	O
a	O
normal	O
PR	O
and	O
a	O
narrow	O
QRS	O
without	O
repolarisation	O
alterations	O
.	O
Echocardioscopy	O
non	O
dilated	O
and	O
non	O
hypertrophic	O
LV	O
with	O
preserved	O
LVEF	O
,	O
without	O
alterations	O
in	O
segmental	O
contractility	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
with	O
thickened	O
leaflets	O
,	O
especially	O
at	O
the	O
level	O
of	O
the	O
free	O
edge	O
,	O
which	O
generates	O
a	O
central	O
coaptation	O
deficit	O
,	O
resulting	O
in	O
severe	O
AoI	O
and	O
mild	O
stenosis	O
.	O
Mitral	O
valve	O
with	O
diffusely	O
thickened	O
leaflets	O
,	O
with	O
involvement	O
of	O
the	O
subvalvular	O
apparatus	O
that	O
restricts	O
the	O
movement	O
of	O
the	O
posterior	O
leaflet	O
generating	O
moderate	O
severe	O
MR	O
,	O
directed	O
towards	O
the	O
lateral	O
wall	O
of	O
the	O
left	O
atrium	O
and	O
with	O
a	O
Coanda	O
effect	O
.	O
Right	O
ventricle	O
normal	O
in	O
size	O
and	O
function	O
.	O
Tricuspid	O
valve	O
of	O
normal	O
appearance	O
,	O
without	O
tricuspid	O
insufficiency	O
.	O
No	O
evidence	O
of	O
pulmonary	O
hypertension	O
.	O
No	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
a	O
joint	O
assessment	O
with	O
gynaecology	O
and	O
resuscitation	O
,	O
it	O
was	O
decided	O
to	O
transfer	O
the	O
patient	O
for	O
a	O
computed	O
tomography	O
CT	O
scan	O
,	O
which	O
showed	O
extensive	O
bilateral	O
alveolar	O
consolidations	O
and	O
septal	O
thickening	O
affecting	O
both	O
lungs	O
,	O
suggestive	O
of	O
bilateral	O
pneumonia	O
.	O
Mild	O
bilateral	O
pleural	O
effusion	O
.	O
In	O
addition	O
,	O
a	O
small	O
repletion	O
defect	O
was	O
identified	O
in	O
a	O
segmental	O
branch	O
of	O
the	O
left	O
lower	O
lobe	O
,	O
compatible	O
with	O
pulmonary	O
thromboembolism	O
,	O
without	O
overload	O
of	O
the	O
right	O
heart	O
chambers	O
.	O
During	O
the	O
CT	O
scan	O
,	O
the	O
patient	O
presented	O
intense	O
dyspnoea	O
without	O
desaturation	O
,	O
which	O
improved	O
with	O
sitting	O
and	O
increased	O
oxygen	O
therapy	O
.	O
In	O
view	O
of	O
the	O
findings	O
of	O
the	O
complementary	O
tests	O
,	O
it	O
was	O
decided	O
to	O
admit	O
her	O
to	O
resuscitation	O
for	O
treatment	O
of	O
the	O
suspected	O
bilateral	O
pneumonia	O
,	O
in	O
addition	O
to	O
diuretic	O
treatment	O
to	O
force	O
a	O
negative	O
water	O
balance	O
.	O
During	O
her	O
stay	O
,	O
she	O
had	O
a	O
very	O
good	O
clinical	O
evolution	O
,	O
with	O
very	O
abundant	O
diuresis	O
,	O
resolution	O
of	O
dyspnoea	O
,	O
and	O
improvement	O
in	O
SO2	O
that	O
allowed	O
her	O
to	O
de	O
escalate	O
from	O
oxygen	O
therapy	O
with	O
high	O
flow	O
glasses	O
HFG	O
to	O
NG	O
,	O
and	O
later	O
withdrawal	O
of	O
the	O
same	O
,	O
so	O
that	O
the	O
picture	O
was	O
more	O
likely	O
to	O
be	O
one	O
of	O
acute	O
heart	O
failure	O
HF	O
.	O
The	O
patient	O
was	O
discharged	O
to	O
the	O
obstetrics	O
ward	O
after	O
48	O
hours	O
in	O
resuscitation	O
,	O
where	O
she	O
presented	O
a	O
good	O
clinical	O
evolution	O
with	O
resolution	O
of	O
the	O
congestive	O
semiology	O
,	O
and	O
was	O
finally	O
discharged	O
.	O
Since	O
her	O
discharge	O
,	O
the	O
patient	O
has	O
continued	O
to	O
undergo	O
cardiological	O
check	O
ups	O
,	O
initially	O
more	O
closely	O
,	O
which	O
have	O
been	O
spaced	O
out	O
to	O
be	O
performed	O
every	O
three	O
months	O
.	O
Her	O
blood	O
pressure	O
remains	O
practically	O
normal	O
,	O
and	O
the	O
clinical	O
signs	O
of	O
heart	O
failure	O
have	O
completely	O
resolved	O
she	O
has	O
no	O
dyspnoea	O
,	O
orthopnoea	O
or	O
oedema	O
,	O
which	O
has	O
allowed	O
complete	O
suspension	O
of	O
the	O
diuretic	O
without	O
the	O
need	O
to	O
reintroduce	O
it	O
.	O
The	O
last	O
echocardiogram	O
showed	O
severe	O
aortic	O
insufficiency	O
with	O
moderate	O
severe	O
mitral	O
insufficiency	O
and	O
preserved	O
biventricular	O
function	O
.	O
The	O
decompensation	O
that	O
occurred	O
during	O
the	O
puerperium	O
was	O
interpreted	O
in	O
the	O
context	O
of	O
the	O
haemodynamic	O
changes	O
that	O
occur	O
during	O
pregnancy	O
,	O
so	O
for	O
the	O
time	O
being	O
a	O
wait	O
and	O
see	O
attitude	O
is	O
maintained	O
with	O
close	O
clinical	O
and	O
echocardiographic	O
monitoring	O
.	O
DIAGNOSIS	O
Preeclampsia	O
gestational	O
hypertension	O
severity	O
criteria	O
thrombopenia	O
.	O
Acute	O
pulmonary	O
oedema	O
,	O
favoured	O
by	O
severe	O
mitral	O
and	O
aortic	O
insufficiency	O
,	O
with	O
preserved	O
LVEF	O
.	O
Antiphospholipid	O
syndrome	O
carrier	O
of	O
lupus	O
anticoagulant	O
and	O
B2	O
glycoprotein	O
,	O
with	O
thrombotic	O
episodes	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
59	O
year	O
old	O
woman	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
or	O
previous	O
pathological	O
history	O
.	O
No	O
chronic	O
treatment	O
.	O
Present	O
illness	O
On	O
8	O
March	O
the	O
patient	O
was	O
giving	O
a	O
speech	O
at	O
a	O
rally	O
for	O
Women	O
's	O
Day	O
.	O
Suddenly	O
and	O
before	O
she	O
could	O
finish	O
reading	O
her	O
manifesto	O
,	O
she	O
suffered	O
a	O
sudden	O
syncopal	O
episode	O
,	O
without	O
prodromes	O
and	O
with	O
spontaneous	O
recovery	O
after	O
a	O
few	O
seconds	O
.	O
On	O
regaining	O
consciousness	O
she	O
presented	O
with	O
epigastric	O
pain	O
radiating	O
to	O
the	O
left	O
hemithorax	O
with	O
associated	O
vegetative	O
cortex	O
.	O
The	O
patient	O
had	O
no	O
palpitations	O
or	O
dyspnoea	O
prior	O
to	O
syncope	O
.	O
Unable	O
to	O
finish	O
her	O
speech	O
,	O
she	O
was	O
referred	O
to	O
the	O
emergency	O
department	O
for	O
assessment	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
104	O
60	O
mmHg	O
,	O
heart	O
rate	O
75	O
bpm	O
,	O
oxygen	O
saturation	O
by	O
pulse	O
oximetry	O
97	O
on	O
room	O
air	O
.	O
Afebrile	O
.	O
Good	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
.	O
Eupneic	O
at	O
rest	O
,	O
tolerates	O
decubitus	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
regular	O
,	O
rhythmic	O
heart	O
sounds	O
,	O
no	O
murmurs	O
or	O
pathological	O
sounds	O
.	O
Pulmonary	O
auscultation	O
normal	O
ventilation	O
in	O
all	O
lung	O
fields	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
,	O
without	O
megaliths	O
.	O
Lower	O
extremities	O
no	O
oedema	O
,	O
distal	O
pulses	O
present	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
on	O
admission	O
sinus	O
bradycardia	O
at	O
58	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
,	O
normal	O
axis	O
at	O
10o	O
.	O
ST	O
segment	O
elevation	O
of	O
1mm	O
in	O
V5	O
V6	O
.	O
QTc	O
388	O
ms	O
.	O
Electrocardiogram	O
at	O
discharge	O
sinus	O
bradycardia	O
at	O
44	O
bpm	O
.	O
Normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
axis	O
at	O
0o	O
.	O
Negative	O
T	O
wave	O
in	O
V4	O
V6	O
,	O
I	O
and	O
aVL	O
,	O
II	O
;	O
flat	O
T	O
wave	O
in	O
III	O
and	O
aVF	O
.	O
QTc	O
391	O
ms	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
No	O
alveolar	O
consolidation	O
or	O
pleural	O
effusion	O
.	O
Laboratory	O
tests	O
biochemistry	O
normal	O
thyroid	O
function	O
.	O
Creatinine	O
0	O
.	O
57	O
mg	O
dl	O
.	O
Total	O
cholesterol	O
225	O
mg	O
dl	O
HDL	O
31	O
mg	O
dl	O
;	O
LDL	O
176	O
mg	O
dl	O
.	O
Serum	O
total	O
bilirubin	O
0	O
,	O
59	O
mg	O
dl	O
.	O
Total	O
proteins	O
6	O
.	O
1	O
g	O
dl	O
,	O
albumin	O
3	O
g	O
dl	O
.	O
Chlorine	O
108	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
7	O
mEq	O
l	O
,	O
sodium	O
141	O
mEq	O
l	O
.	O
CK	O
138	O
U	O
l	O
,	O
FA	O
87	O
U	O
l	O
,	O
GGT	O
19	O
U	O
l	O
,	O
GOT	O
32	O
U	O
l	O
,	O
GPT	O
13	O
U	O
l	O
,	O
LDH	O
158	O
U	O
l	O
.	O
Glycosylated	O
haemoglobin	O
5	O
.	O
5	O
.	O
Troponin	O
I	O
4	O
,	O
468	O
ng	O
l	O
normal	O
11	O
.	O
6	O
ng	O
l	O
,	O
proBNP	O
1	O
,	O
909	O
pg	O
ml	O
.	O
Haemogram	O
leucocytes	O
5000	O
mm3	O
N	O
2	O
,	O
600	O
mm3	O
;	O
L	O
1	O
,	O
900	O
mm3	O
,	O
haemoglobin	O
14	O
.	O
2	O
g	O
dl	O
,	O
platelets	O
171	O
,	O
000	O
mm3	O
.	O
Cardiac	O
catheterisation	O
Coronary	O
angiography	O
right	O
dominance	O
.	O
Left	O
common	O
trunk	O
without	O
angiographic	O
stenosis	O
.	O
Anterior	O
descending	O
AD	O
with	O
angiographically	O
mildly	O
moderate	O
stenosis	O
in	O
the	O
proximal	O
third	O
,	O
the	O
rest	O
of	O
the	O
main	O
vessel	O
has	O
no	O
angiographic	O
stenosis	O
.	O
Rest	O
of	O
vessels	O
without	O
angiographic	O
stenosis	O
.	O
Optical	O
coherence	O
tomography	O
OCT	O
was	O
performed	O
on	O
the	O
LAD	O
,	O
which	O
in	O
the	O
proximal	O
segment	O
showed	O
a	O
minimal	O
luminal	O
area	O
of	O
4	O
.	O
22	O
mm2	O
with	O
integrity	O
of	O
the	O
endothelium	O
despite	O
plaque	O
burden	O
.	O
Functional	O
assessment	O
shows	O
RFR	O
0	O
.	O
93	O
,	O
after	O
hyperemia	O
with	O
i	O
.	O
v	O
.	O
adenosine	O
FFR	O
0	O
.	O
90	O
and	O
microcirculation	O
study	O
shows	O
CFR	O
2	O
and	O
IMR	O
44	O
evidence	O
of	O
microvascular	O
dysfunction	O
.	O
Ventriculography	O
shows	O
a	O
left	O
ventricle	O
LV	O
of	O
normal	O
size	O
with	O
akinesia	O
of	O
all	O
apical	O
segments	O
and	O
hypercontractility	O
of	O
the	O
basal	O
segments	O
.	O
No	O
intraventricular	O
or	O
aortic	O
transvalvular	O
gradient	O
was	O
detected	O
.	O
Cardiac	O
magnetic	O
resonance	O
findings	O
compatible	O
with	O
takotsubo	O
syndrome	O
.	O
Diffuse	O
hypersignal	O
indicating	O
the	O
presence	O
of	O
oedema	O
in	O
the	O
middle	O
segments	O
,	O
apical	O
segments	O
and	O
apex	O
segment	O
in	O
T2	O
weighted	O
T2	O
weighted	O
TSE	O
FAT	O
SAT	O
sequences	O
in	O
short	O
axis	O
and	O
two	O
chambers	O
.	O
Absence	O
of	O
late	O
gadolinium	O
enhancement	O
.	O
Currently	O
no	O
apical	O
dyskinesia	O
is	O
identified	O
with	O
synchronous	O
and	O
homogeneous	O
contractility	O
,	O
left	O
ventricular	O
ejection	O
fraction	O
71	O
.	O
No	O
associated	O
apical	O
thrombus	O
is	O
observed	O
.	O
Right	O
ventricle	O
RV	O
with	O
normal	O
function	O
.	O
Echocardiogram	O
at	O
discharge	O
left	O
ventricle	O
of	O
normal	O
size	O
and	O
thickness	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
normal	O
,	O
without	O
contractile	O
asymmetries	O
.	O
Left	O
ventricular	O
end	O
diastolic	O
pressure	O
data	O
not	O
elevated	O
.	O
Right	O
ventricle	O
normal	O
in	O
structure	O
and	O
function	O
.	O
Mitral	O
valve	O
normal	O
in	O
structure	O
and	O
function	O
with	O
minimal	O
insufficiency	O
.	O
Normal	O
tricuspid	O
valve	O
,	O
with	O
minimal	O
tricuspid	O
insufficiency	O
allowing	O
estimation	O
of	O
a	O
pulmonary	O
artery	O
systolic	O
pressure	O
PSAP	O
of	O
25	O
mmHg	O
.	O
Trivalve	O
aortic	O
valve	O
.	O
The	O
aortic	O
root	O
is	O
of	O
normal	O
size	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
referred	O
to	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
,	O
where	O
an	O
electrocardiogram	O
was	O
performed	O
,	O
showing	O
ST	O
segment	O
elevation	O
of	O
1	O
mm	O
in	O
the	O
lower	O
lateral	O
face	O
.	O
It	O
was	O
decided	O
to	O
perform	O
emergent	O
coronary	O
angiography	O
.	O
Cardiac	O
catheterisation	O
revealed	O
a	O
coronary	O
tree	O
with	O
no	O
lesions	O
,	O
except	O
for	O
angiographically	O
mild	O
moderate	O
stenosis	O
in	O
the	O
proximal	O
LAD	O
.	O
To	O
assess	O
the	O
stenosis	O
of	O
the	O
LAD	O
,	O
it	O
was	O
decided	O
to	O
perform	O
an	O
optical	O
coherence	O
tomography	O
OCT	O
study	O
.	O
The	O
OCT	O
showed	O
a	O
luminal	O
area	O
greater	O
than	O
4	O
mm2	O
with	O
integrity	O
of	O
the	O
endothelium	O
.	O
The	O
haemodynamic	O
study	O
was	O
completed	O
with	O
an	O
assessment	O
of	O
the	O
microcirculation	O
showing	O
microvascular	O
dysfunction	O
with	O
a	O
low	O
coronary	O
flow	O
reserve	O
CFR	O
and	O
a	O
high	O
microvascular	O
resistance	O
index	O
MRI	O
.	O
Ventriculography	O
was	O
performed	O
,	O
showing	O
akinesia	O
of	O
the	O
apical	O
segments	O
with	O
hypercontractility	O
of	O
the	O
basal	O
segments	O
;	O
all	O
highly	O
suggestive	O
of	O
tako	O
tsubo	O
syndrome	O
.	O
The	O
patient	O
was	O
admitted	O
haemodynamically	O
stable	O
and	O
pain	O
free	O
to	O
the	O
cardiac	O
intermediate	O
care	O
unit	O
.	O
She	O
progressed	O
favourably	O
,	O
with	O
no	O
new	O
chest	O
pain	O
,	O
no	O
signs	O
of	O
heart	O
failure	O
and	O
no	O
arrhythmic	O
events	O
.	O
Electrocardiographically	O
,	O
there	O
was	O
a	O
progressive	O
negativisation	O
of	O
the	O
T	O
wave	O
in	O
the	O
anterolateral	O
and	O
inferior	O
face	O
.	O
The	O
study	O
was	O
completed	O
with	O
a	O
cardiac	O
MRI	O
scan	O
showing	O
oedema	O
in	O
the	O
middle	O
and	O
apical	O
segments	O
with	O
absence	O
of	O
late	O
gadolinium	O
enhancement	O
,	O
findings	O
compatible	O
with	O
tako	O
tsubo	O
syndrome	O
.	O
Prior	O
to	O
discharge	O
,	O
an	O
echocardiogram	O
was	O
performed	O
showing	O
recovery	O
of	O
myocardial	O
contractility	O
.	O
In	O
view	O
of	O
the	O
good	O
evolution	O
,	O
hospital	O
discharge	O
was	O
decided	O
with	O
treatment	O
with	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
24	O
hours	O
,	O
enalapril	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
24	O
hours	O
and	O
atorvastatin	B-FARMACO
40	O
mg	O
every	O
24	O
hours	O
.	O
DIAGNOSIS	O
Tako	O
tsubo	O
syndrome	O
.	O
Microvascular	O
dysfunction	O
.	O
Global	O
and	O
segmental	O
left	O
ventricular	O
systolic	O
function	O
recovered	O
at	O
discharge	O
.	O
Mild	O
moderate	O
atherosclerotic	O
lesion	O
in	O
the	O
anterior	O
descending	O
artery	O
without	O
functional	O
repercussions	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
54	O
year	O
old	O
woman	O
.	O
No	O
known	O
allergies	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
or	O
toxic	O
habits	O
.	O
Bilateral	O
pneumonia	O
due	O
to	O
COVID	O
19	O
,	O
requiring	O
hospital	O
admission	O
and	O
treatment	O
with	O
high	O
dose	O
corticoid	O
.	O
During	O
admission	O
she	O
reported	O
lumbar	O
pain	O
and	O
was	O
diagnosed	O
by	O
CT	O
scan	O
with	O
a	O
fracture	O
of	O
L2	O
,	O
being	O
treated	O
conservatively	O
.	O
She	O
was	O
discharged	O
4	O
days	O
before	O
the	O
current	O
episode	O
.	O
On	O
treatment	O
with	O
omeprazole	B-FARMACO
20	O
mg	O
every	O
24	O
hours	O
,	O
dexamethasone	B-FARMACO
2	O
mg	O
every	O
24	O
hours	O
,	O
metamizole	B-FARMACO
575	O
mg	O
every	O
8	O
hours	O
if	O
required	O
due	O
to	O
pain	O
and	O
enoxaparin	B-FARMACO
40	O
mg	O
every	O
24	O
hours	O
.	O
Current	O
illness	O
Patient	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
progressive	O
dyspnoea	O
for	O
48	O
hours	O
with	O
central	O
thoracic	O
pressure	O
that	O
improved	O
with	O
sitting	O
.	O
The	O
pain	O
does	O
not	O
change	O
with	O
inspiration	O
.	O
The	O
patient	O
reports	O
progressive	O
swelling	O
of	O
the	O
lower	O
limbs	O
and	O
increased	O
abdominal	O
perimeter	O
since	O
discharge	O
from	O
hospital	O
for	O
COVID	O
19	O
pneumonia	O
4	O
days	O
ago	O
.	O
She	O
denies	O
fever	O
or	O
dysthermic	O
sensation	O
.	O
Pain	O
with	O
mechanical	O
characteristics	O
persists	O
in	O
the	O
upper	O
lumbar	O
region	O
,	O
secondary	O
to	O
L2	O
fracture	O
during	O
the	O
previous	O
admission	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
100	O
50	O
mmHg	O
,	O
heart	O
rate	O
104	O
bpm	O
,	O
temperature	O
36	O
.	O
2	O
oC	O
,	O
oxygen	O
saturation	O
96	O
basal	O
.	O
General	O
condition	O
fair	O
,	O
tachypneic	O
at	O
rest	O
.	O
Mucocutaneous	O
pallor	O
.	O
Jugular	O
ingurgitation	O
and	O
positive	O
hepatojugular	O
reflux	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
no	O
murmurs	O
or	O
pericardial	O
friction	O
rub	O
.	O
Pulmonary	O
auscultation	O
hypoventilation	O
in	O
the	O
left	O
base	O
,	O
without	O
other	O
superimposed	O
sounds	O
.	O
Abdomen	O
soft	O
,	O
slightly	O
painful	O
in	O
the	O
mesogastrium	O
and	O
right	O
hypochondrium	O
,	O
without	O
abdominal	O
defence	O
and	O
with	O
preserved	O
peristalsis	O
;	O
doubtful	O
signs	O
of	O
ascites	O
.	O
No	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Extremities	O
bilateral	O
tibial	O
and	O
malleolar	O
oedema	O
with	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Pain	O
on	O
mobilisation	O
of	O
the	O
lower	O
limbs	O
with	O
positive	O
Lasegue	O
's	O
sign	O
.	O
Pain	O
on	O
palpation	O
in	O
the	O
spinous	O
processes	O
of	O
L2	O
L4	O
.	O
Venoclysis	O
scar	O
on	O
the	O
left	O
wrist	O
.	O
COMPLEMENTARY	O
TESTS	O
Admission	O
CBC	O
CRP	O
21	O
.	O
45	O
mg	O
dl	O
,	O
glucose	O
157	O
mg	O
dl	O
,	O
urea	O
42	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
72	O
mg	O
dl	O
,	O
triglycerides	O
126	O
mg	O
dl	O
,	O
serum	O
total	O
cholesterol	O
187	O
md	O
dl	O
,	O
troponin	O
6	O
.	O
7	O
ng	O
ml	O
normal	O
values	O
12	O
.	O
3	O
ng	O
ml	O
,	O
NT	O
proBNP	O
1	O
.	O
057	O
,	O
chlorine	O
104	O
mEq	O
l	O
,	O
sodium	O
139	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
7	O
mEq	O
l	O
,	O
amylase	O
110	O
U	O
l	O
,	O
lipase	O
97	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
153	O
U	O
l	O
,	O
GGT	O
304	O
U	O
l	O
,	O
LDH	O
322	O
U	O
l	O
,	O
GOT	O
150	O
U	O
l	O
,	O
GPT	O
244	O
U	O
l	O
,	O
ESR	O
97	O
mm	O
.	O
Leukocytes	O
15	O
,	O
700	O
μl	O
with	O
left	O
shift	O
,	O
haemoglobin	O
11	O
.	O
8	O
g	O
dl	O
,	O
haematocrit	O
28	O
.	O
7	O
,	O
platelets	O
178	O
,	O
000	O
μl	O
.	O
INR	O
1	O
.	O
04	O
.	O
D	O
dimer	O
5	O
,	O
600	O
.	O
Emergency	O
electrocardiogram	O
ECG	O
sinus	O
tachycardia	O
at	O
109	O
bpm	O
.	O
Slightly	O
lowered	O
PR	O
in	O
inferior	O
and	O
lateral	O
face	O
.	O
Narrow	O
QRS	O
.	O
Concave	O
inframilimetric	O
ST	O
elevation	O
in	O
V3	O
V6	O
,	O
DI	O
,	O
DII	O
and	O
aVF	O
.	O
No	O
other	O
acute	O
repolarisation	O
abnormalities	O
.	O
Chest	O
X	O
ray	O
,	O
portable	O
AP	O
cardiothoracic	O
index	O
0	O
.	O
5	O
0	O
.	O
6	O
,	O
slightly	O
increased	O
.	O
Normal	O
pulmonary	O
vascularisation	O
.	O
Bronchiectasis	O
in	O
LII	O
.	O
No	O
signs	O
of	O
cardiac	O
decompensation	O
or	O
pneumonic	O
consolidation	O
.	O
SARS	O
CoV	O
2	O
serology	O
on	O
admission	O
Ig	O
G	O
and	O
Ig	O
M	O
positive	O
.	O
Blood	O
cultures	O
on	O
admission	O
positive	O
for	O
methicillin	O
sensitive	O
Staphylococcus	O
aureus	O
SAMS	O
.	O
Pericardial	O
fluid	O
analysis	O
red	O
blood	O
cells	O
572	O
,	O
800	O
mm3	O
,	O
leukocytes	O
16	O
,	O
992	O
mm3	O
86	O
.	O
9	O
segmented	O
,	O
ADA	O
63	O
.	O
6	O
IU	O
l	O
,	O
glucose	O
0	O
.	O
10	O
g	O
l	O
,	O
LDH	O
5	O
,	O
432	O
IU	O
l	O
,	O
protein	O
52	O
.	O
9	O
g	O
l	O
.	O
Initial	O
echocardiogram	O
severe	O
pericardial	O
effusion	O
predominantly	O
posterior	O
and	O
lateral	O
to	O
the	O
LV	O
with	O
maximum	O
separation	O
of	O
pericardial	O
sheets	O
.	O
There	O
is	O
some	O
evidence	O
of	O
haemodynamic	O
repercussions	O
such	O
as	O
collapse	O
of	O
the	O
right	O
atrium	O
RA	O
and	O
dilated	O
inferior	O
vena	O
cava	O
IVC	O
21	O
mm	O
and	O
with	O
practically	O
abolished	O
inspirophasic	O
variations	O
,	O
but	O
there	O
are	O
no	O
significant	O
variations	O
in	O
valvular	O
flows	O
.	O
Fibrin	O
mantle	O
over	O
right	O
chambers	O
and	O
thin	O
fibrin	O
tracts	O
lateral	O
to	O
LV	O
.	O
No	O
significant	O
pleural	O
effusion	O
visualised	O
.	O
Normal	O
biventricular	O
function	O
.	O
No	O
valvular	O
alterations	O
of	O
interest	O
.	O
Pulmonary	O
artery	O
systolic	O
pressure	O
PSAP	O
45	O
mmHg	O
.	O
Echocardiogram	O
in	O
the	O
evolution	O
sinus	O
tachycardia	O
.	O
Hyperdynamic	O
LVEF	O
.	O
Paradoxical	O
septal	O
motion	O
with	O
diastolic	O
notch	O
,	O
without	O
contractile	O
asymmetries	O
.	O
Right	O
ventricle	O
RV	O
not	O
dilated	O
.	O
Slightly	O
depressed	O
RVEF	O
.	O
No	O
valvulopathies	O
of	O
interest	O
.	O
No	O
images	O
of	O
endocarditis	O
.	O
Moderate	O
pericardial	O
effusion	O
,	O
circumferential	O
,	O
predominantly	O
posterolateral	O
,	O
with	O
maximum	O
separation	O
of	O
pericardial	O
sheets	O
of	O
11	O
mm	O
in	O
the	O
posterior	O
sac	O
,	O
13	O
mm	O
in	O
the	O
lateral	O
sac	O
at	O
the	O
level	O
of	O
the	O
atrioventricular	O
AV	O
groove	O
,	O
7	O
mm	O
in	O
the	O
apex	O
,	O
7	O
mm	O
adjacent	O
to	O
the	O
RA	O
and	O
in	O
the	O
anterior	O
sac	O
to	O
the	O
RV	O
,	O
with	O
a	O
fibrin	O
mantle	O
in	O
the	O
anterior	O
sac	O
.	O
Echocardiographic	O
signs	O
of	O
haemodynamic	O
repercussions	O
significant	O
respirophasic	O
variations	O
in	O
transmitral	O
flow	O
50	O
and	O
transtricuspid	O
flow	O
55	O
and	O
dilatation	O
of	O
the	O
IVC	O
,	O
without	O
cavity	O
collapse	O
.	O
Echocardiographic	O
data	O
suggestive	O
of	O
constrictive	O
physiology	O
protodiastolic	O
notch	O
of	O
the	O
interventricular	O
septum	O
,	O
"	O
reverse	O
ring	O
"	O
lateral	O
E	O
wave	O
septal	O
E	O
wave	O
and	O
respirophasic	O
variations	O
in	O
suprahepatic	O
vein	O
flow	O
,	O
with	O
reverse	O
diastolic	O
flow	O
in	O
expiration	O
.	O
Bilateral	O
pleural	O
effusion	O
.	O
Control	O
echocardiogram	O
biventricular	O
systolic	O
function	O
preserved	O
.	O
No	O
notable	O
valvulopathies	O
.	O
Estimated	O
normal	O
PSAP	O
.	O
No	O
images	O
suggestive	O
of	O
endocarditis	O
.	O
Slight	O
pericardial	O
effusion	O
,	O
predominantly	O
posterolateral	O
,	O
with	O
no	O
haemodynamic	O
repercussions	O
or	O
evidence	O
of	O
constrictive	O
physiology	O
at	O
present	O
.	O
Thoracoabdominal	O
CT	O
scan	O
pericardial	O
effusion	O
with	O
enhancement	O
of	O
the	O
visceral	O
and	O
parietal	O
pericardium	O
in	O
the	O
venous	O
phase	O
suggestive	O
of	O
associated	O
pericarditis	O
and	O
right	O
heart	O
failure	O
with	O
congestive	O
liver	O
and	O
vesicular	O
oedema	O
.	O
Bilateral	O
pleural	O
effusion	O
with	O
passive	O
lower	O
lobe	O
atelectasis	O
.	O
Multiple	O
abscesses	O
in	O
both	O
psoas	O
muscles	O
.	O
Erosion	O
of	O
the	O
upper	O
plateau	O
of	O
the	O
vertebral	O
body	O
of	O
L3	O
,	O
to	O
assess	O
L2	O
L3	O
spondylodiscitis	O
or	O
compression	O
fracture	O
.	O
Magnetic	O
resonance	O
imaging	O
MRI	O
of	O
the	O
shoulder	O
septic	O
arthritis	O
of	O
both	O
shoulders	O
.	O
Lumbar	O
MRI	O
study	O
compatible	O
with	O
L2	O
L3	O
infectious	O
spondylodiscitis	O
with	O
involvement	O
of	O
L3	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
L2	O
,	O
and	O
right	O
anterior	O
peridural	O
extension	O
and	O
L3	O
,	O
right	O
L2	O
L3	O
and	O
L3	O
L4	O
foraminal	O
extension	O
with	O
potential	O
effect	O
on	O
the	O
emerging	O
roots	O
.	O
Abscesses	O
in	O
both	O
psoas	O
,	O
multiple	O
on	O
each	O
side	O
,	O
with	O
the	O
largest	O
one	O
on	O
the	O
right	O
side	O
reaching	O
7	O
.	O
5	O
cms	O
.	O
Laboratory	O
tests	O
at	O
discharge	O
CRP	O
1	O
.	O
43	O
,	O
creatinine	O
0	O
.	O
66	O
mg	O
dl	O
,	O
urea	O
42	O
mg	O
dl	O
,	O
cholesterol	O
175	O
mg	O
dl	O
,	O
chlorine	O
102	O
mEq	O
l	O
,	O
sodium	O
137	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
5	O
mEq	O
l	O
,	O
albumin	O
3	O
.	O
2	O
g	O
dl	O
,	O
alkaline	O
phosphatase	O
75	O
U	O
l	O
,	O
GGT	O
59	O
U	O
l	O
,	O
GOT	O
14	O
U	O
l	O
,	O
GPT	O
12	O
U	O
l	O
,	O
LDH	O
156	O
.	O
Leukocytes	O
6	O
,	O
500	O
μl	O
,	O
haemoglobin	O
10	O
.	O
3	O
g	O
dl	O
,	O
platelets	O
265	O
,	O
000	O
μl	O
,	O
ESR	O
76	O
.	O
CLINICAL	O
COURSE	O
The	O
patient	O
was	O
initially	O
seen	O
in	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
.	O
Given	O
the	O
signs	O
of	O
heart	O
failure	O
predominantly	O
on	O
the	O
right	O
and	O
the	O
central	O
thoracic	O
pain	O
,	O
together	O
with	O
the	O
elevation	O
of	O
acute	O
phase	O
reactants	O
in	O
the	O
laboratory	O
tests	O
,	O
it	O
was	O
decided	O
to	O
admit	O
the	O
patient	O
for	O
further	O
investigation	O
.	O
During	O
her	O
stay	O
in	O
the	O
ED	O
,	O
the	O
patient	O
presented	O
a	O
peak	O
fever	O
of	O
38	O
.	O
2oC	O
and	O
blood	O
cultures	O
were	O
taken	O
.	O
The	O
echocardiogram	O
on	O
admission	O
showed	O
severe	O
pericardial	O
effusion	O
with	O
signs	O
of	O
echocardiographic	O
repercussions	O
,	O
but	O
no	O
clinical	O
signs	O
at	O
that	O
time	O
.	O
Blood	O
cultures	O
showed	O
growth	O
of	O
SAMS	O
.	O
Suspicion	O
of	O
purulent	O
pericarditis	O
led	O
to	O
subxiphoid	O
pericardial	O
drainage	O
and	O
antibiotic	O
therapy	O
was	O
started	O
with	O
cefazolin	B-FARMACO
and	O
daptomycin	B-FARMACO
.	O
Pericardial	O
fluid	O
cultures	O
were	O
sterile	O
but	O
the	O
biochemical	O
characteristics	O
of	O
the	O
fluid	O
were	O
infectious	O
.	O
The	O
patient	O
's	O
symptoms	O
did	O
not	O
clearly	O
improve	O
despite	O
drainage	O
of	O
the	O
pericardial	O
fluid	O
,	O
so	O
a	O
transesophageal	O
echocardiogram	O
TEE	O
was	O
requested	O
to	O
rule	O
out	O
the	O
presence	O
of	O
endocarditis	O
and	O
to	O
evaluate	O
the	O
progression	O
of	O
the	O
effusion	O
.	O
This	O
TEE	O
showed	O
constrictive	O
physiology	O
data	O
suggestive	O
of	O
effusive	O
constrictive	O
pericarditis	O
.	O
In	O
addition	O
to	O
the	O
cardiorespiratory	O
symptoms	O
,	O
the	O
patient	O
presented	O
pain	O
in	O
the	O
upper	O
lumbar	O
region	O
,	O
both	O
shoulders	O
and	O
left	O
lower	O
extremity	O
.	O
In	O
view	O
of	O
the	O
suspicion	O
of	O
septic	O
foci	O
,	O
the	O
study	O
was	O
completed	O
with	O
thoracoabdominal	O
CT	O
and	O
magnetic	O
resonance	O
imaging	O
of	O
both	O
shoulders	O
and	O
lumbar	O
region	O
.	O
Imaging	O
studies	O
confirmed	O
the	O
presence	O
of	O
septic	O
arthritis	O
in	O
both	O
shoulders	O
,	O
spondylodiscitis	O
at	O
L2	O
L3	O
and	O
multiple	O
abscesses	O
in	O
bilateral	O
psoas	O
.	O
The	O
patient	O
also	O
presented	O
a	O
lesion	O
on	O
the	O
left	O
lower	O
extremity	O
compatible	O
with	O
cellulitis	O
.	O
Due	O
to	O
the	O
persistence	O
of	O
fever	O
,	O
despite	O
targeted	O
antibiotherapy	O
,	O
the	O
abscesses	O
in	O
the	O
psoas	O
muscle	O
were	O
drained	O
and	O
SAMS	O
was	O
again	O
isolated	O
in	O
the	O
fluid	O
culture	O
.	O
The	O
control	O
echocardiogram	O
showed	O
slight	O
pericardial	O
effusion	O
with	O
no	O
signs	O
of	O
haemodynamic	O
compromise	O
or	O
constrictive	O
physiology	O
.	O
Slow	O
evolution	O
of	O
the	O
patient	O
,	O
with	O
progressive	O
disappearance	O
of	O
the	O
different	O
infectious	O
foci	O
and	O
clinical	O
improvement	O
without	O
new	O
episodes	O
of	O
fever	O
.	O
Periodic	O
blood	O
cultures	O
were	O
negative	O
.	O
Finally	O
,	O
after	O
8	O
weeks	O
of	O
intravenous	O
antibiotics	O
,	O
she	O
was	O
discharged	O
for	O
outpatient	O
follow	O
up	O
.	O
Treatment	O
at	O
discharge	O
was	O
omeprazole	B-FARMACO
20	O
mg	O
every	O
24	O
hours	O
,	O
dexketoprofen	B-FARMACO
25	O
mg	O
every	O
12	O
hours	O
,	O
colchicine	B-FARMACO
0	O
.	O
5	O
mg	O
every	O
24	O
hours	O
,	O
paracetamol	B-FARMACO
1	O
g	O
every	O
8	O
hours	O
and	O
bemiparin	B-FARMACO
7	O
,	O
500	O
IU	O
every	O
24	O
hours	O
.	O
DIAGNOSIS	O
Persistent	O
SAMS	O
bacteraemia	O
with	O
multiple	O
foci	O
purulent	O
pericarditis	O
,	O
multiple	O
psoas	O
abscesses	O
,	O
spondylodiscitis	O
,	O
cellulitis	O
,	O
bilateral	O
septic	O
shoulder	O
arthritis	O
.	O
Effusive	O
constrictive	O
pericarditis	O
resolved	O
with	O
medical	O
treatment	O
.	O

Personal	O
history	O
We	O
present	O
the	O
case	O
of	O
a	O
56	O
year	O
old	O
Caucasian	O
woman	O
,	O
administrative	O
profession	O
.	O
She	O
had	O
no	O
known	O
cardiovascular	O
risk	O
factors	O
,	O
except	O
obesity	O
.	O
Her	O
cardiological	O
history	O
included	O
an	O
admission	O
one	O
year	O
earlier	O
for	O
an	O
episode	O
of	O
unstable	O
angina	O
with	O
cardiac	O
catheterisation	O
that	O
revealed	O
a	O
critical	O
lesion	O
of	O
the	O
ostial	O
left	O
main	O
coronary	O
artery	O
LMCA	O
,	O
on	O
which	O
a	O
drug	O
eluting	O
stent	O
was	O
implanted	O
,	O
with	O
no	O
significant	O
lesions	O
in	O
the	O
rest	O
of	O
the	O
coronary	O
arteries	O
.	O
The	O
transthoracic	O
echocardiogram	O
TTE	O
performed	O
during	O
this	O
admission	O
showed	O
a	O
left	O
ventricle	O
of	O
normal	O
size	O
and	O
thickness	O
,	O
with	O
normal	O
global	O
systolic	O
function	O
and	O
segmental	O
contractility	O
and	O
no	O
significant	O
valvulopathies	O
.	O
His	O
medical	O
history	O
included	O
a	O
diagnosis	O
of	O
autoimmune	O
hepatitis	O
since	O
1998	O
,	O
for	O
which	O
he	O
was	O
receiving	O
chronic	O
treatment	O
with	O
immunosuppressants	O
azathioprine	B-FARMACO
in	O
addition	O
to	O
bisoprolol	B-FARMACO
2	O
.	O
5mg	O
24	O
hours	O
,	O
lansoprazole	B-FARMACO
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
,	O
clopidogrel	B-FARMACO
and	O
atorvastatin	B-FARMACO
20	O
mg	O
.	O
Current	O
illness	O
and	O
physical	O
examination	O
In	O
the	O
last	O
few	O
months	O
,	O
the	O
patient	O
reported	O
symptoms	O
of	O
asthenia	O
and	O
dyspnoea	O
,	O
without	O
chest	O
pain	O
,	O
with	O
progressive	O
worsening	O
of	O
the	O
functional	O
grade	O
up	O
to	O
NYHA	O
functional	O
grade	O
III	O
IV	O
,	O
for	O
which	O
reason	O
a	O
stress	O
test	O
had	O
been	O
requested	O
.	O
The	O
exercise	O
test	O
was	O
stopped	O
early	O
due	O
to	O
hypertensive	O
crisis	O
with	O
dyspnoea	O
and	O
electrical	O
positivity	O
.	O
That	O
same	O
day	O
,	O
hours	O
after	O
the	O
exercise	O
stress	O
test	O
,	O
he	O
attended	O
the	O
Emergency	O
Department	O
of	O
our	O
hospital	O
due	O
to	O
a	O
sudden	O
episode	O
of	O
dyspnoea	O
and	O
acute	O
pulmonary	O
oedema	O
.	O
On	O
arrival	O
at	O
the	O
ED	O
he	O
had	O
a	O
BP	O
in	O
MSI	O
of	O
95	O
60	O
and	O
in	O
MSD	O
of	O
146	O
70	O
mmHg	O
,	O
a	O
heart	O
rate	O
of	O
85	O
bpm	O
,	O
a	O
baseline	O
saturation	O
of	O
92	O
and	O
was	O
afebrile	O
.	O
On	O
cardiac	O
auscultation	O
he	O
had	O
rhythmic	O
heart	O
sounds	O
,	O
with	O
aortic	O
diastolic	O
murmur	O
III	O
IV	O
and	O
mitral	O
systolic	O
murmur	O
III	O
VI	O
.	O
He	O
had	O
bilateral	O
crackles	O
up	O
to	O
the	O
upper	O
fields	O
with	O
no	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
In	O
the	O
upper	O
limbs	O
,	O
there	O
was	O
a	O
decrease	O
in	O
radial	O
and	O
brachial	O
pulses	O
in	O
the	O
left	O
upper	O
limb	O
MSI	O
compared	O
to	O
the	O
right	O
upper	O
limb	O
MSD	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
count	O
Hb	O
12	O
.	O
9g	O
dl	O
,	O
leukocytes	O
10	O
,	O
5000	O
57	O
N	O
,	O
platelets	O
480	O
,	O
000	O
.	O
Coagulation	O
PT	O
98	O
,	O
FD	O
700	O
.	O
Urgent	O
blood	O
biochemistry	O
Glc	O
158	O
mg	O
dl	O
,	O
U	O
39	O
mg	O
dl	O
,	O
Cr	O
0	O
.	O
98	O
mg	O
dl	O
,	O
Na	O
139	O
mmol	O
l	O
,	O
K	O
4	O
mmol	O
l	O
,	O
CK	O
172	O
U	O
l	O
,	O
TnT	O
ultrasensitive	O
,	O
upper	O
limit	O
35	O
ng	O
l	O
27	O
ng	O
l	O
.	O
Complete	O
biochemistry	O
Glc	O
89	O
mg	O
dl	O
,	O
U	O
46	O
mg	O
dl	O
,	O
Cr	O
0	O
.	O
83	O
mg	O
dl	O
,	O
eGFR	O
60ml	O
min	O
1	O
.	O
7	O
,	O
urate	O
7	O
mg	O
dl	O
,	O
Na	O
141	O
mmol	O
l	O
,	O
K	O
4	O
mmol	O
l	O
,	O
Ca	O
2	O
.	O
36	O
mmol	O
l	O
,	O
phosphate	O
1	O
.	O
51	O
mmol	O
l	O
,	O
CK	O
65	O
U	O
l	O
,	O
LDH	O
178	O
U	O
l	O
,	O
FA	O
57	O
U	O
l	O
,	O
ALT	O
11U	O
L	O
,	O
BrT	O
1	O
mg	O
dl	O
,	O
total	O
protein	O
66	O
g	O
l	O
,	O
creatinine	O
133	O
mg	O
dl	O
,	O
CRP	O
2	O
.	O
2	O
mg	O
dl	O
.	O
Immunological	O
study	O
positive	O
ANAs	O
autoantibodies	O
at	O
1	O
320	O
titre	O
,	O
with	O
nucleolar	O
pattern	O
.	O
The	O
rest	O
was	O
normal	O
.	O
Electrocardiogram	O
sinus	O
rhythm	O
,	O
left	O
anterior	O
hemiblock	O
and	O
subepicardial	O
ischaemia	O
in	O
the	O
anterolateral	O
region	O
.	O
Chest	O
X	O
ray	O
compatible	O
with	O
acute	O
pulmonary	O
oedema	O
.	O
Transthoracic	O
and	O
transesophageal	O
echocardiogram	O
left	O
ventricle	O
slightly	O
dilated	O
and	O
hypertrophic	O
,	O
with	O
moderately	O
depressed	O
systolic	O
function	O
LVEF	O
estimated	O
by	O
Simpson	O
at	O
42	O
at	O
the	O
expense	O
of	O
a	O
global	O
hypokinesia	O
,	O
more	O
marked	O
in	O
anterior	O
and	O
lateral	O
regions	O
.	O
The	O
aortic	O
valve	O
was	O
trivalve	O
,	O
with	O
no	O
evidence	O
of	O
vegetation	O
or	O
prolapse	O
and	O
presented	O
severe	O
aortic	O
insufficiency	O
with	O
a	O
central	O
regurgitant	O
jet	O
originating	O
at	O
the	O
level	O
of	O
the	O
entire	O
commissure	O
between	O
the	O
non	O
coronary	O
and	O
left	O
coronary	O
leaflets	O
with	O
coaptation	O
defect	O
of	O
the	O
leaflets	O
,	O
suggesting	O
leaflet	O
retraction	O
at	O
this	O
level	O
as	O
the	O
underlying	O
mechanism	O
.	O
The	O
aortic	O
root	O
was	O
of	O
normal	O
size	O
.	O
At	O
mitral	O
valve	O
level	O
a	O
mitral	O
insufficiency	O
MI	O
grade	O
2	O
was	O
detected	O
and	O
at	O
tricuspid	O
level	O
a	O
severe	O
tricuspid	O
insufficiency	O
TI	O
which	O
estimated	O
a	O
pulmonary	O
artery	O
systolic	O
pressure	O
of	O
approximately	O
80	O
mmHg	O
.	O
Cardiac	O
catheterisation	O
occlusion	O
of	O
the	O
right	O
coronary	O
artery	O
at	O
the	O
ostial	O
level	O
which	O
was	O
filled	O
by	O
collateral	O
circulation	O
.	O
The	O
patency	O
of	O
the	O
stent	O
previously	O
implanted	O
at	O
the	O
level	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
persisted	O
.	O
Angio	O
CT	O
of	O
the	O
thoracic	O
aorta	O
thickening	O
of	O
the	O
arterial	O
wall	O
of	O
the	O
common	O
carotid	O
arteries	O
and	O
of	O
the	O
left	O
subclavian	O
artery	O
,	O
which	O
is	O
occluded	O
with	O
filiform	O
tracts	O
affecting	O
the	O
occlusion	O
at	O
the	O
origin	O
of	O
the	O
left	O
vertebral	O
artery	O
,	O
and	O
of	O
the	O
superior	O
mesenteric	O
artery	O
,	O
which	O
is	O
also	O
occluded	O
with	O
hypertrophy	O
of	O
the	O
pancreaticoduodenal	O
arcade	O
.	O
There	O
is	O
no	O
calcium	O
deposit	O
in	O
any	O
of	O
the	O
lesions	O
,	O
ulcerations	O
,	O
dissection	O
or	O
aneurysm	O
.	O
Infectious	O
serology	O
HBsAg	O
,	O
anti	O
HCV	O
,	O
HIV	O
Ag	O
Ac	O
and	O
Syphilis	O
G	O
M	O
negative	O
.	O
Biopsy	O
aortic	O
valve	O
the	O
sample	O
submitted	O
as	O
aortic	O
valve	O
with	O
presence	O
of	O
myxoid	O
degenerative	O
changes	O
and	O
chronic	O
lymphocytic	O
inflammatory	O
infiltrate	O
.	O
EVOLUTION	O
We	O
present	O
the	O
case	O
of	O
a	O
56	O
year	O
old	O
woman	O
with	O
a	O
cardiac	O
history	O
of	O
ostial	O
LMCA	O
disease	O
revascularised	O
percutaneously	O
with	O
a	O
drug	O
eluting	O
stent	O
one	O
year	O
earlier	O
,	O
who	O
was	O
admitted	O
with	O
acute	O
pulmonary	O
oedema	O
.	O
Physical	O
examination	O
of	O
the	O
patient	O
revealed	O
the	O
presence	O
of	O
murmurs	O
in	O
aortic	O
and	O
mitral	O
foci	O
,	O
suggestive	O
of	O
valve	O
disease	O
at	O
these	O
levels	O
,	O
which	O
were	O
not	O
present	O
in	O
the	O
echocardiogram	O
of	O
a	O
year	O
earlier	O
,	O
as	O
well	O
as	O
a	O
clear	O
decrease	O
in	O
pulses	O
in	O
MSI	O
together	O
with	O
a	O
significant	O
discordance	O
between	O
systolic	O
blood	O
pressure	O
between	O
both	O
upper	O
limbs	O
BP	O
in	O
MSI	O
of	O
95	O
60	O
and	O
in	O
MSD	O
of	O
146	O
70	O
mmHg	O
.	O
In	O
addition	O
to	O
a	O
more	O
marked	O
global	O
hypokinesia	O
in	O
the	O
anterior	O
and	O
lateral	O
regions	O
,	O
the	O
presence	O
of	O
severe	O
aortic	O
insufficiency	O
AIo	O
,	O
the	O
mechanism	O
of	O
which	O
appeared	O
to	O
be	O
a	O
coaptation	O
defect	O
of	O
the	O
non	O
coronary	O
and	O
left	O
coronary	O
leaflets	O
due	O
to	O
their	O
retraction	O
,	O
with	O
a	O
normal	O
sized	O
aortic	O
root	O
.	O
Given	O
the	O
ischaemic	O
alterations	O
in	O
the	O
ECG	O
on	O
admission	O
and	O
the	O
segmental	O
alterations	O
in	O
contractility	O
in	O
the	O
echocardiogram	O
,	O
coronary	O
angiography	O
was	O
performed	O
in	O
the	O
following	O
24	O
hours	O
,	O
which	O
showed	O
the	O
previous	O
stent	O
in	O
the	O
IVC	O
to	O
be	O
permeable	O
and	O
without	O
restenosis	O
,	O
and	O
occlusion	O
of	O
the	O
ostial	O
right	O
coronary	O
artery	O
,	O
which	O
at	O
that	O
time	O
was	O
pending	O
a	O
decision	O
on	O
revascularisation	O
strategy	O
.	O
Given	O
the	O
findings	O
consisting	O
of	O
asymmetry	O
in	O
pulses	O
and	O
blood	O
pressure	O
in	O
both	O
upper	O
limbs	O
,	O
ostial	O
coronary	O
lesions	O
and	O
severe	O
aortic	O
insufficiency	O
of	O
subacute	O
onset	O
,	O
together	O
with	O
a	O
history	O
of	O
autoimmune	O
involvement	O
and	O
in	O
a	O
patient	O
without	O
CVRF	O
,	O
an	O
aortic	O
CT	O
angiography	O
was	O
requested	O
with	O
suspicion	O
of	O
aortitis	O
,	O
in	O
addition	O
to	O
complete	O
immunological	O
studies	O
,	O
acute	O
phase	O
reactants	O
APR	O
and	O
serology	O
.	O
Angio	O
CT	O
showed	O
thickening	O
of	O
the	O
arterial	O
wall	O
of	O
both	O
common	O
carotid	O
arteries	O
and	O
left	O
subclavian	O
,	O
left	O
vertebral	O
and	O
superior	O
mesenteric	O
arteries	O
.	O
A	O
diagnosis	O
of	O
aortitis	O
in	O
the	O
context	O
of	O
large	O
vessel	O
vasculitis	O
was	O
established	O
.	O
Treatment	O
was	O
started	O
with	O
glucocorticoids	O
at	O
a	O
dose	O
of	O
1	O
.	O
5	O
mg	O
kg	O
with	O
a	O
subsequent	O
tapering	O
regimen	O
,	O
and	O
the	O
dose	O
of	O
azathioprine	B-FARMACO
that	O
the	O
patient	O
was	O
taking	O
was	O
doubled	O
.	O
After	O
presenting	O
her	O
case	O
at	O
a	O
medical	O
surgical	O
session	O
Heart	O
Team	O
,	O
surgical	O
treatment	O
was	O
decided	O
once	O
the	O
patient	O
was	O
stabilised	O
,	O
with	O
resolution	O
of	O
the	O
acute	O
pulmonary	O
oedema	O
.	O
After	O
10	O
days	O
of	O
treatment	O
with	O
oral	O
glucocorticoids	O
,	O
the	O
aortic	O
valve	O
was	O
replaced	O
with	O
a	O
metallic	O
prosthesis	O
no	O
.	O
21	O
and	O
coronary	O
revascularisation	O
by	O
means	O
of	O
aorto	O
coronary	O
bypass	O
from	O
the	O
saphenous	O
vein	O
to	O
the	O
middle	O
anterior	O
descending	O
artery	O
and	O
proximal	O
right	O
coronary	O
artery	O
.	O
During	O
surgery	O
,	O
the	O
aorta	O
was	O
also	O
affected	O
,	O
with	O
marked	O
thickening	O
of	O
both	O
the	O
aortic	O
wall	O
and	O
the	O
wall	O
of	O
the	O
coronary	O
arteries	O
,	O
as	O
well	O
as	O
friability	O
of	O
these	O
tissues	O
and	O
the	O
aortic	O
annulus	O
.	O
After	O
the	O
procedure	O
,	O
she	O
presented	O
haemodynamic	O
instability	O
,	O
requiring	O
high	O
dose	O
amines	O
and	O
intra	O
aortic	O
balloon	O
counterpulsation	O
.	O
24	O
hours	O
later	O
the	O
patient	O
was	O
in	O
cardiogenic	O
shock	O
related	O
to	O
perioperative	O
infarction	O
.	O
She	O
presented	O
a	O
slow	O
evolution	O
in	O
the	O
following	O
days	O
with	O
poor	O
tolerance	O
to	O
amine	O
weaning	O
and	O
removal	O
of	O
the	O
balloon	O
with	O
severe	O
haemodynamic	O
instability	O
and	O
progression	O
to	O
multi	O
organ	O
failure	O
,	O
and	O
finally	O
exitus	O
.	O
DIAGNOSIS	O
Vasculitis	O
of	O
large	O
vessels	O
of	O
the	O
Takayasu	O
arteritis	O
type	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
44	O
year	O
old	O
woman	O
,	O
who	O
years	O
ago	O
suffered	O
a	O
skin	O
reaction	O
compatible	O
with	O
allergy	O
to	O
ibuprofen	B-FARMACO
and	O
metamizole	B-FARMACO
,	O
without	O
subsequent	O
confirmation	O
by	O
allergology	O
.	O
Active	O
smoker	O
of	O
10	O
cigarettes	O
a	O
day	O
for	O
about	O
20	O
years	O
IPA	O
approximately	O
10	O
,	O
denies	O
alcohol	O
habit	O
.	O
History	O
hypercholesterolemia	O
,	O
on	O
treatment	O
with	O
atorvastatin	B-FARMACO
80	O
mg	O
for	O
5	O
years	O
,	O
Graves	O
'	O
disease	O
with	O
mild	O
orbitopathy	O
at	O
last	O
check	O
up	O
she	O
was	O
euthyroid	O
and	O
bronchial	O
asthma	O
being	O
monitored	O
by	O
pulmonology	O
and	O
treated	O
with	O
salmeterol	O
fluticasone	O
propionate	O
every	O
12	O
hours	O
and	O
salbutamol	O
on	O
demand	O
.	O
Family	O
history	O
father	O
with	O
hypercholesterolemia	O
and	O
type	O
2	O
diabetes	O
mellitus	O
.	O
Mother	O
with	O
hypercholesterolemia	O
.	O
Three	O
siblings	O
,	O
no	O
data	O
known	O
.	O
Two	O
children	O
,	O
one	O
15	O
years	O
old	O
pending	O
analysis	O
and	O
one	O
13	O
years	O
old	O
with	O
LDL	O
215	O
mg	O
dl	O
on	O
treatment	O
by	O
her	O
paediatrician	O
with	O
rosuvastatin	B-FARMACO
20	O
mg	O
ezetimibe	B-FARMACO
10	O
mg	O
and	O
pending	O
genetic	O
study	O
of	O
HFHe	O
.	O
Current	O
illness	O
She	O
came	O
to	O
the	O
emergency	O
department	O
for	O
clinical	O
symptoms	O
that	O
began	O
3	O
weeks	O
earlier	O
,	O
consisting	O
of	O
progressive	O
dyspnoea	O
until	O
minimal	O
effort	O
,	O
increased	O
oedema	O
in	O
the	O
lower	O
limbs	O
,	O
paroxysmal	O
nocturnal	O
dyspnoea	O
crisis	O
,	O
palpitations	O
with	O
a	O
sensation	O
of	O
irradiation	O
to	O
the	O
neck	O
,	O
multiple	O
ecchymosis	O
in	O
the	O
upper	O
and	O
lower	O
limbs	O
and	O
hypoaesthesia	O
in	O
the	O
left	O
lower	O
limb	O
.	O
He	O
denies	O
orthopnoea	O
or	O
diuresis	O
curtailment	O
.	O
She	O
has	O
not	O
presented	O
chest	O
pain	O
.	O
No	O
arthralgias	O
or	O
arthritis	O
,	O
nor	O
oral	O
aphthous	O
ulcers	O
.	O
No	O
fever	O
at	O
home	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
129	O
84	O
mmHg	O
,	O
heart	O
rate	O
85	O
bpm	O
,	O
respiratory	O
rate	O
18	O
rpm	O
,	O
temperature	O
37	O
.	O
6	O
oC	O
.	O
Acceptable	O
general	O
condition	O
,	O
conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Well	O
hydrated	O
and	O
perfused	O
,	O
normal	O
colour	O
.	O
Slight	O
tachypnoea	O
at	O
rest	O
,	O
with	O
slurred	O
speech	O
although	O
maintaining	O
baseline	O
oxygen	O
saturation	O
97	O
,	O
mild	O
dysphonia	O
.	O
Glasgow	O
15	O
15	O
.	O
Cardiac	O
auscultation	O
showed	O
rhythmic	O
tones	O
at	O
a	O
good	O
frequency	O
without	O
murmurs	O
,	O
without	O
pericardial	O
friction	O
.	O
Respiratory	O
auscultation	O
showed	O
minimal	O
bibasal	O
crackles	O
and	O
some	O
isolated	O
wheezing	O
.	O
The	O
abdomen	O
is	O
unremarkable	O
.	O
The	O
neurological	O
examination	O
showed	O
isochoric	O
pupils	O
that	O
were	O
normoreactive	O
to	O
light	O
,	O
preserved	O
cranial	O
nerves	O
,	O
diminished	O
gross	O
tactile	O
sensitivity	O
in	O
the	O
left	O
lower	O
limb	O
,	O
more	O
marked	O
in	O
the	O
anterior	O
thigh	O
region	O
.	O
Gait	O
was	O
not	O
examined	O
.	O
The	O
lower	O
limbs	O
showed	O
oedema	O
with	O
fovea	O
up	O
to	O
mid	O
leg	O
,	O
with	O
signs	O
of	O
chronic	O
venous	O
insufficiency	O
,	O
without	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
,	O
with	O
peripheral	O
pulses	O
present	O
and	O
symmetrical	O
.	O
There	O
were	O
multiple	O
small	O
ecchymoses	O
on	O
the	O
upper	O
and	O
lower	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
On	O
arrival	O
at	O
the	O
ED	O
Analysis	O
high	O
sensitivity	O
troponin	O
I	O
855	O
.	O
40	O
ng	O
l	O
normal	O
2	O
15	O
.	O
6	O
and	O
C	O
reactive	O
protein	O
32	O
.	O
7	O
mg	O
l	O
normal	O
5	O
.	O
Haemoglobin	O
14	O
.	O
2	O
g	O
dl	O
,	O
leucocytes	O
10	O
.	O
08	O
x10	O
3	O
μl	O
,	O
with	O
eosinophils	O
1	O
.	O
68	O
x10	O
3	O
μl	O
normal	O
0	O
.	O
02	O
0	O
.	O
55	O
and	O
platelets	O
79	O
x10	O
3	O
μl	O
.	O
Coagulation	O
was	O
normal	O
except	O
for	O
D	O
dimer	O
1	O
,	O
785	O
ng	O
ml	O
normal	O
500	O
.	O
Electrocardiogram	O
on	O
arrival	O
sinus	O
rhythm	O
at	O
93	O
bpm	O
,	O
PR	O
0	O
.	O
14	O
s	O
constant	O
,	O
QRS	O
0	O
.	O
10	O
s	O
,	O
electrical	O
axis	O
over	O
90o	O
,	O
ST	O
depression	O
of	O
1	O
mm	O
in	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V3	O
V6	O
,	O
flattened	O
T	O
waves	O
in	O
inferior	O
leads	O
and	O
negative	O
in	O
V3	O
V6	O
.	O
Chest	O
X	O
ray	O
showed	O
no	O
cardiomegaly	O
or	O
parenchymal	O
condensation	O
.	O
Prominent	O
hilarity	O
was	O
present	O
.	O
No	O
pleural	O
effusion	O
or	O
costophrenic	O
sinus	O
impingement	O
was	O
observed	O
.	O
Given	O
the	O
findings	O
,	O
myocardial	O
damage	O
marker	O
serology	O
was	O
requested	O
,	O
as	O
well	O
as	O
a	O
chest	O
CT	O
angiography	O
for	O
suspected	O
pulmonary	O
thromboembolism	O
.	O
Chest	O
CT	O
angiography	O
no	O
signs	O
of	O
pulmonary	O
thromboembolism	O
were	O
observed	O
,	O
the	O
pulmonary	O
parenchyma	O
showed	O
no	O
alterations	O
,	O
subcentimetric	O
adenopathies	O
of	O
probably	O
reactive	O
appearance	O
were	O
observed	O
at	O
the	O
para	O
aortic	O
,	O
right	O
paratracheal	O
,	O
hilar	O
and	O
subcarinal	O
levels	O
of	O
1	O
.	O
5	O
cm	O
.	O
Control	O
laboratory	O
tests	O
at	O
4	O
hours	O
troponin	O
I	O
increased	O
to	O
1	O
,	O
770	O
.	O
3	O
ng	O
l	O
,	O
with	O
normal	O
CK	O
.	O
During	O
his	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
and	O
on	O
the	O
internal	O
medicine	O
hospital	O
ward	O
given	O
the	O
clinical	O
suspicion	O
,	O
an	O
autoimmune	O
panel	O
was	O
urgently	O
requested	O
,	O
in	O
which	O
positive	O
anti	O
neutrophil	O
cytoplasmic	O
antibodies	O
were	O
found	O
with	O
positive	O
anti	O
myeloperoxidase	O
antibodies	O
IgG	O
19	O
.	O
1	O
IU	O
ml	O
0	O
6	O
,	O
the	O
rest	O
negative	O
.	O
Serialisation	O
of	O
myocardial	O
damage	O
markers	O
was	O
continued	O
,	O
with	O
a	O
peak	O
value	O
of	O
troponin	O
I	O
of	O
5	O
,	O
065	O
ng	O
l	O
.	O
The	O
peak	O
value	O
of	O
brain	O
pro	O
brain	O
natriuretic	O
peptide	O
was	O
6	O
,	O
819	O
.	O
8	O
pg	O
ml	O
high	O
probability	O
of	O
heart	O
failure	O
in	O
patients	O
under	O
55	O
years	O
of	O
age	O
if	O
450	O
pg	O
ml	O
.	O
In	O
the	O
routine	O
analysis	O
,	O
extracted	O
72	O
hours	O
after	O
admission	O
,	O
glucose	O
157	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
261	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
59	O
mg	O
dl	O
,	O
triglycerides	O
155	O
mg	O
dl	O
,	O
lactate	O
dehydrogenase	O
449	O
U	O
l	O
125	O
220	O
,	O
complement	O
C3	O
61	O
mg	O
dl	O
90	O
180	O
with	O
normal	O
C4	O
,	O
thyrotropin	O
0	O
.	O
34	O
μUI	O
ml	O
0	O
.	O
35	O
4	O
.	O
94	O
,	O
free	O
thyroxine	O
0	O
.	O
85	O
ng	O
dl	O
0	O
.	O
7	O
1	O
.	O
48	O
,	O
free	O
triiodothyronine	O
1	O
.	O
62	O
pg	O
ml	O
1	O
.	O
71	O
3	O
.	O
71	O
.	O
HIV	O
screening	O
and	O
other	O
infectious	O
immunodiagnostic	O
tests	O
were	O
negative	O
.	O
The	O
bedside	O
echocardiogram	O
performed	O
in	O
intensive	O
care	O
on	O
admission	O
showed	O
a	O
non	O
dilated	O
left	O
ventricle	O
LV	O
with	O
preserved	O
systolic	O
function	O
,	O
even	O
hypercontractile	O
with	O
concentric	O
hypertrophy	O
with	O
an	O
interventricular	O
septum	O
of	O
14	O
mm	O
and	O
a	O
posterior	O
wall	O
of	O
13	O
mm	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Dilated	O
right	O
ventricle	O
RV	O
with	O
a	O
basal	O
diameter	O
of	O
39	O
mm	O
,	O
10	O
mm	O
lateral	O
wall	O
with	O
hyperechoic	O
image	O
adjacent	O
to	O
the	O
lateral	O
wall	O
.	O
Triscuspid	O
insufficiency	O
with	O
estimated	O
pulmonary	O
arterial	O
systolic	O
pressure	O
PSAP	O
of	O
100	O
mmHg	O
.	O
Dilated	O
right	O
atrium	O
RA	O
with	O
an	O
area	O
of	O
22	O
cm2	O
.	O
Normal	O
mitral	O
flow	O
pattern	O
.	O
Mild	O
pericardial	O
effusion	O
adjacent	O
to	O
LV	O
.	O
Echocardiogram	O
performed	O
by	O
cardiology	O
72	O
hours	O
after	O
admission	O
showed	O
body	O
surface	O
area	O
1	O
.	O
9	O
m2	O
.	O
Non	O
dilated	O
LV	O
DTD	O
47	O
mm	O
,	O
51	O
ml	O
m2	O
,	O
without	O
hypertrophy	O
at	O
baseline	O
IVS	O
9	O
,	O
PP	O
9	O
mm	O
,	O
although	O
progressive	O
thickening	O
from	O
mid	O
segments	O
and	O
especially	O
apex	O
15	O
mm	O
,	O
with	O
preserved	O
global	O
systolic	O
function	O
EF	O
71	O
4C	O
,	O
without	O
evident	O
alterations	O
of	O
segmental	O
contractility	O
.	O
Restrictive	O
mitral	O
filling	O
pattern	O
,	O
with	O
E	O
A	O
2	O
.	O
2	O
,	O
e	O
'	O
6	O
cm	O
s	O
,	O
E	O
e	O
'	O
14	O
.	O
Dilated	O
right	O
chambers	O
RV	O
42	O
mm	O
basal	O
,	O
RA	O
18	O
cm2	O
.	O
RV	O
normocontractile	O
TAPSE	O
19	O
mm	O
,	O
s	O
wave	O
12	O
cm	O
s	O
.	O
Dilated	O
left	O
atrium	O
LA	O
38	O
ml	O
m2	O
.	O
Without	O
good	O
visualisation	O
of	O
the	O
aortic	O
root	O
,	O
apparently	O
not	O
dilated	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
IVC	O
27	O
mm	O
,	O
with	O
little	O
inspiratory	O
collapse	O
.	O
Dilatation	O
of	O
suprahepatic	O
veins	O
.	O
Slight	O
inferior	O
pericardial	O
effusion	O
2	O
mm	O
,	O
with	O
no	O
signs	O
of	O
haemodynamic	O
compromise	O
.	O
No	O
apparent	O
intracavitary	O
thrombus	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
preserved	O
mobility	O
.	O
Normal	O
aortic	O
flow	O
.	O
Normal	O
mitral	O
valve	O
morphology	O
.	O
Mild	O
central	O
mitral	O
insufficiency	O
.	O
Mild	O
tricuspid	O
and	O
pulmonary	O
insufficiency	O
,	O
estimating	O
PSAP	O
of	O
49	O
mmHg	O
V	O
max	O
2	O
.	O
9	O
m	O
s	O
and	O
PMAP	O
of	O
30	O
mmHg	O
V	O
max	O
1	O
.	O
9	O
m	O
s	O
.	O
Pulmonary	O
TA	O
105	O
ms	O
.	O
In	O
short	O
,	O
he	O
presented	O
a	O
pattern	O
of	O
myocardial	O
restriction	O
,	O
non	O
dilated	O
LV	O
with	O
preserved	O
EF	O
,	O
apical	O
hypertrophy	O
,	O
severe	O
diastolic	O
dysfunction	O
,	O
slightly	O
dilated	O
RV	O
with	O
preserved	O
EF	O
,	O
high	O
probability	O
of	O
pulmonary	O
hypertension	O
,	O
biauricular	O
dilatation	O
,	O
mild	O
mitral	O
and	O
tricuspid	O
insufficiency	O
,	O
mild	O
pericardial	O
effusion	O
.	O
Given	O
the	O
clinical	O
history	O
,	O
compatible	O
with	O
Löffler	O
's	O
endocarditis	O
.	O
After	O
a	O
week	O
of	O
admission	O
,	O
left	O
and	O
right	O
cardiac	O
catheterisation	O
was	O
performed	O
.	O
After	O
obtaining	O
6F	O
radial	O
access	O
,	O
a	O
good	O
calibre	O
LMCA	O
with	O
no	O
angiographic	O
lesions	O
,	O
a	O
good	O
calibre	O
anterior	O
descending	O
artery	O
ADA	O
with	O
no	O
angiographic	O
lesions	O
and	O
good	O
distal	O
flow	O
,	O
a	O
good	O
calibre	O
circumflex	O
artery	O
Cx	O
with	O
no	O
angiographic	O
lesions	O
and	O
good	O
distal	O
flow	O
,	O
and	O
a	O
dominant	O
right	O
coronary	O
artery	O
RCA	O
with	O
good	O
calibre	O
,	O
no	O
angiographic	O
lesions	O
and	O
good	O
distal	O
flow	O
were	O
visualised	O
.	O
The	O
left	O
ventriculography	O
showed	O
a	O
non	O
dilated	O
left	O
ventricle	O
with	O
severe	O
apical	O
hypertrophy	O
,	O
preserved	O
systolic	O
function	O
with	O
LVEF	O
64	O
.	O
5	O
,	O
mild	O
mitral	O
insufficiency	O
,	O
LV	O
end	O
diastolic	O
pressure	O
of	O
29	O
mmHg	O
.	O
Regarding	O
right	O
catheterisation	O
,	O
AD	O
pressure	O
25	O
mmHg	O
,	O
RV	O
systolic	O
pressure	O
43	O
mmHg	O
,	O
RV	O
diastolic	O
pressure	O
11	O
mmHg	O
,	O
mean	O
RV	O
pressure	O
15	O
mmHg	O
,	O
pulmonary	O
systolic	O
pressure	O
45	O
mmHg	O
,	O
pulmonary	O
diastolic	O
pressure	O
28	O
mmHg	O
,	O
mean	O
pulmonary	O
pressure	O
33	O
mmHg	O
,	O
diastolic	O
transpulmonary	O
gradient	O
PAMP	O
PCP	O
4	O
mmHg	O
,	O
concluding	O
in	O
isolated	O
postcapillary	O
pulmonary	O
hypertension	O
.	O
Right	O
ventriculography	O
showed	O
significant	O
apical	O
hypertrophy	O
with	O
preserved	O
ejection	O
fraction	O
RVEF	O
52	O
,	O
mild	O
tricuspid	O
insufficiency	O
and	O
mild	O
pulmonary	O
insufficiency	O
.	O
An	O
endomyocardial	O
biopsy	O
was	O
performed	O
with	O
3	O
samples	O
taken	O
right	O
ventricle	O
.	O
The	O
septal	O
biopsy	O
showed	O
a	O
fibrous	O
cap	O
of	O
normal	O
thickness	O
overlying	O
myocardium	O
,	O
free	O
of	O
inflammatory	O
infiltration	O
,	O
with	O
no	O
histological	O
criteria	O
for	O
endocarditis	O
.	O
The	O
apex	O
biopsy	O
is	O
a	O
minimal	O
fragment	O
of	O
lax	O
fibrous	O
tissue	O
without	O
inflammatory	O
changes	O
and	O
haematic	O
material	O
,	O
unsatisfactory	O
for	O
diagnosis	O
.	O
The	O
basal	O
biopsy	O
is	O
a	O
small	O
fragment	O
of	O
endocardium	O
,	O
without	O
myocardium	O
,	O
with	O
discrete	O
endothelial	O
hyperplasia	O
,	O
suggestive	O
of	O
reactive	O
and	O
slight	O
haematic	O
infiltrate	O
secondary	O
to	O
biopsy	O
,	O
without	O
inflammatory	O
infiltration	O
.	O
Cardiac	O
MRI	O
performed	O
prior	O
to	O
the	O
start	O
of	O
cyclophosphamide	B-FARMACO
showed	O
non	O
dilated	O
ventricles	O
with	O
preserved	O
systolic	O
function	O
,	O
findings	O
compatible	O
with	O
biventricular	O
endomyocardial	O
fibrosis	O
,	O
with	O
organised	O
left	O
ventricular	O
apical	O
thrombus	O
,	O
secondary	O
to	O
granulomatosis	O
with	O
polyangiitis	O
late	O
stage	O
endomyocardial	O
fibrosis	O
,	O
tethering	O
of	O
the	O
inferior	O
papillary	O
muscle	O
and	O
slight	O
hypokinesis	O
of	O
apical	O
segments	O
and	O
apex	O
of	O
the	O
left	O
ventricle	O
,	O
as	O
well	O
as	O
of	O
the	O
apical	O
segment	O
of	O
the	O
right	O
ventricular	O
free	O
wall	O
,	O
biauricular	O
enlargement	O
,	O
tricuspid	O
insufficiency	O
of	O
doubtful	O
significance	O
,	O
pericarditis	O
with	O
signs	O
of	O
active	O
inflammation	O
and	O
slight	O
pericardial	O
effusion	O
.	O
Myocardial	O
septal	O
thickness	O
10	O
mm	O
;	O
anterior	O
11	O
mm	O
;	O
lateral	O
10	O
mm	O
;	O
inferior	O
11	O
mm	O
.	O
End	O
diastolic	O
diameter	O
49	O
mm	O
;	O
end	O
systolic	O
diameter	O
35	O
mm	O
.	O
Relative	O
wall	O
thickness	O
0	O
.	O
24	O
.	O
Indexed	O
mass	O
39	O
g	O
m2	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
at	O
4	O
months	O
video	O
2	O
showed	O
a	O
significant	O
decrease	O
in	O
the	O
thickness	O
of	O
the	O
distal	O
segments	O
with	O
respect	O
to	O
the	O
previous	O
study	O
,	O
no	O
tethering	O
of	O
the	O
inferior	O
papillary	O
muscle	O
,	O
ventricles	O
with	O
slightly	O
reduced	O
volumes	O
and	O
normal	O
systolic	O
function	O
and	O
slight	O
pericardial	O
effusion	O
.	O
In	O
short	O
,	O
compared	O
to	O
the	O
previous	O
study	O
,	O
there	O
was	O
a	O
great	O
improvement	O
in	O
ventricular	O
thicknesses	O
and	O
apical	O
thrombus	O
,	O
which	O
has	O
disappeared	O
.	O
Measurements	O
left	O
ventricle	O
septum	O
5	O
mm	O
,	O
posterior	O
wall	O
5	O
mm	O
,	O
DTD	O
48	O
mm	O
,	O
VTD	O
119	O
cc	O
,	O
VTS	O
53	O
cc	O
,	O
Systolic	O
volume	O
67	O
cc	O
,	O
iVTD	O
66	O
cc	O
m2	O
,	O
iVTS	O
29	O
cc	O
m2	O
,	O
LVEF	O
56	O
.	O
Left	O
ventricle	O
septum	O
5	O
mm	O
,	O
posterior	O
wall	O
5	O
mm	O
,	O
DTD	O
48	O
mm	O
,	O
VTD	O
119	O
cc	O
,	O
VTS	O
53	O
cc	O
,	O
Systolic	O
volume	O
67	O
cc	O
,	O
iVTD	O
66	O
cc	O
m2	O
,	O
iVTS	O
29	O
cc	O
m2	O
,	O
LVEF	O
56	O
.	O
Right	O
ventricle	O
RVT	O
143	O
cc	O
,	O
STV	O
60	O
cc	O
,	O
Systolic	O
volume	O
83	O
cc	O
,	O
iVTD	O
79	O
cc	O
m2	O
,	O
iVTS	O
33	O
cc	O
m2	O
,	O
LVEF	O
58	O
.	O
Left	O
atrium	O
area	O
in	O
4	O
chambers	O
16	O
cm2	O
.	O
Right	O
atrium	O
area	O
in	O
4	O
chambers	O
19	O
cm2	O
.	O
Sinus	O
aorta	O
diameter	O
in	O
sinuses	O
of	O
Valsalva	O
28	O
mm	O
.	O
Ascending	O
aorta	O
25	O
mm	O
.	O
Descending	O
aorta	O
19	O
mm	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
first	O
level	O
complementary	O
tests	O
were	O
performed	O
in	O
the	O
emergency	O
department	O
with	O
the	O
findings	O
described	O
,	O
pulmonary	O
thromboembolism	O
was	O
suspected	O
,	O
which	O
was	O
ruled	O
out	O
by	O
angio	O
CT	O
.	O
Given	O
the	O
clinical	O
picture	O
and	O
the	O
analytical	O
data	O
,	O
it	O
was	O
decided	O
to	O
admit	O
the	O
patient	O
to	O
intensive	O
care	O
.	O
This	O
unit	O
consulted	O
with	O
internal	O
medicine	O
for	O
assessment	O
.	O
Due	O
to	O
his	O
history	O
sinusitis	O
,	O
hypereosinophilia	O
,	O
clinical	O
manifestations	O
dyspnoea	O
,	O
oedema	O
in	O
the	O
lower	O
limbs	O
,	O
etc	O
.	O
,	O
analyses	O
elevated	O
cardiac	O
enzymes	O
,	O
thrombopenia	O
,	O
eosinophilia	O
,	O
etc	O
.	O
and	O
echocardiographic	O
data	O
of	O
myocardial	O
infiltration	O
compatible	O
with	O
Löffler	O
's	O
endocarditis	O
,	O
it	O
was	O
suspected	O
that	O
it	O
could	O
be	O
APEEG	O
,	O
and	O
an	O
urgent	O
ANCA	O
ELISA	O
study	O
was	O
requested	O
,	O
which	O
was	O
positive	O
myeloperoxidase	O
.	O
Steroid	O
treatment	O
was	O
started	O
immediately	O
with	O
boluses	O
of	O
1	O
g	O
of	O
6	B-FARMACO
methylprednisolone	B-FARMACO
for	O
3	O
consecutive	O
days	O
,	O
with	O
significant	O
clinical	O
improvement	O
reflected	O
in	O
the	O
analytical	O
parameters	O
thrombopenia	O
,	O
eosinophilia	O
and	O
troponin	O
,	O
to	O
be	O
continued	O
with	O
60	O
mg	O
of	O
prednisone	O
daily	O
.	O
After	O
7	O
days	O
of	O
hospitalisation	O
,	O
cyclophosphamide	O
was	O
administered	O
in	O
boluses	O
of	O
500	O
mg	O
fixed	O
dose	O
every	O
15	O
days	O
,	O
which	O
were	O
programmed	O
to	O
complete	O
6	O
boluses	O
.	O
Right	O
and	O
left	O
cardiac	O
catheterisation	O
was	O
performed	O
with	O
biopsy	O
,	O
which	O
did	O
not	O
clarify	O
the	O
diagnosis	O
.	O
Clinically	O
and	O
haemodynamically	O
stable	O
,	O
she	O
was	O
discharged	O
from	O
hospital	O
after	O
2	O
weeks	O
of	O
admission	O
,	O
under	O
treatment	O
with	O
prednisone	B-FARMACO
60	O
mg	O
at	O
breakfast	O
which	O
was	O
progressively	O
reduced	O
to	O
15	O
mg	O
,	O
calcium	B-FARMACO
600	O
mg	O
cholecalciferol	B-FARMACO
1	O
.	O
000	O
IU	O
1	O
tablet	O
daily	O
,	O
ibandronic	B-FARMACO
acid	I-FARMACO
1	O
tablet	O
monthly	O
at	O
fasting	O
,	O
torasemide	B-FARMACO
5	O
mg	O
1	O
tablet	O
at	O
breakfast	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
1	O
tablet	O
at	O
lunch	O
,	O
omeprazole	B-FARMACO
1	O
capsule	O
at	O
breakfast	O
and	O
atorvastatin	B-FARMACO
80	O
mg	O
1	O
tablet	O
at	O
dinner	O
.	O
Outpatient	O
follow	O
up	O
showed	O
total	O
cholesterol	O
413	O
mg	O
dl	O
,	O
non	O
HDL	O
cholesterol	O
326	O
mg	O
dl	O
and	O
triglycerides	O
308	O
mg	O
dl	O
,	O
and	O
treatment	O
was	O
started	O
with	O
anti	B-FARMACO
PCSK9	I-FARMACO
evolocumab	I-FARMACO
140	O
mg	O
subcutaneous	O
every	O
2	O
weeks	O
and	O
omega	B-FARMACO
3	I-FARMACO
acid	I-FARMACO
ethyl	I-FARMACO
esters	I-FARMACO
two	O
capsules	O
every	O
12	O
hours	O
.	O
The	O
response	O
was	O
spectacular	O
,	O
with	O
LDL	O
cholesterol	O
reduced	O
to	O
62	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
66	O
mg	O
dl	O
and	O
triglycerides	O
125	O
mg	O
dl	O
.	O
Dyspnoea	O
did	O
not	O
return	O
and	O
acute	O
phase	O
reactants	O
remained	O
normal	O
,	O
with	O
no	O
eosinophilia	O
.	O
DIAGNOSIS	O
Congestive	O
heart	O
failure	O
and	O
isolated	O
postcapillary	O
pulmonary	O
hypertension	O
related	O
to	O
acute	O
myocarditis	O
Loeffler	O
's	O
endocarditis	O
with	O
myocardial	O
restriction	O
pattern	O
and	O
severe	O
diastolic	O
dysfunction	O
in	O
the	O
context	O
of	O
eosinophilic	O
granulomatosis	O
with	O
polyangiitis	O
.	O
Apical	O
thrombus	O
in	O
the	O
left	O
ventricle	O
resolved	O
.	O
Moderate	O
thrombopenia	O
of	O
autoimmune	O
origin	O
resolved	O
.	O
Euthyroid	O
patient	O
syndrome	O
.	O
Primary	O
familial	O
hypercholesterolemia	O
very	O
probable	O
HFHe	O
.	O
Secondary	O
hypertriglyceridaemia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Male	O
,	O
72	O
years	O
old	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
Arterial	O
hypertension	O
of	O
10	O
years	O
of	O
evolution	O
,	O
in	O
treatment	O
with	O
bisoprolol	B-FARMACO
and	O
enalapril	B-FARMACO
.	O
Altered	O
basal	O
glycaemia	O
of	O
2	O
years	O
of	O
evolution	O
,	O
on	O
dietary	O
treatment	O
.	O
No	O
known	O
cardiological	O
history	O
.	O
No	O
other	O
medical	O
or	O
surgical	O
history	O
of	O
interest	O
.	O
Home	O
treatment	O
bisoprolol	B-FARMACO
5	O
mg	O
two	O
tablets	O
every	O
24	O
h	O
;	O
ramipril	B-FARMACO
5	O
mg	O
1	O
0	O
0	O
.	O
Present	O
illness	O
He	O
presented	O
to	O
his	O
health	O
centre	O
with	O
nausea	O
and	O
general	O
malaise	O
of	O
two	O
hours	O
'	O
duration	O
.	O
No	O
palpitations	O
or	O
chest	O
pain	O
.	O
No	O
syncope	O
.	O
No	O
evidence	O
of	O
heart	O
failure	O
.	O
During	O
his	O
stay	O
at	O
the	O
health	O
centre	O
,	O
frequent	O
episodes	O
of	O
incessant	O
wide	O
QRS	O
tachycardia	O
with	O
rapid	O
rates	O
200	O
bpm	O
were	O
recorded	O
on	O
the	O
monitor	O
and	O
he	O
was	O
transferred	O
to	O
hospital	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
120	O
70	O
mmHG	O
,	O
heart	O
rate	O
HR	O
80	O
bpm	O
,	O
oxygen	O
saturation	O
100	O
.	O
Good	O
general	O
condition	O
.	O
Normal	O
skin	O
and	O
mucous	O
membrane	O
colouring	O
.	O
No	O
jugular	O
plethora	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
tones	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdominal	O
examination	O
soft	O
,	O
depressible	O
,	O
no	O
megaliths	O
,	O
no	O
pain	O
,	O
preserved	O
peristaltic	O
sounds	O
.	O
Extremities	O
no	O
oedema	O
,	O
with	O
preserved	O
peripheral	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
Baseline	O
electrocardiogram	O
ECG	O
atrial	O
fibrillation	O
with	O
controlled	O
ventricular	O
response	O
.	O
QRS	O
of	O
120	O
ms	O
,	O
intraventricular	O
conduction	O
disorders	O
.	O
No	O
signs	O
of	O
acute	O
ischaemia	O
.	O
Presence	O
of	O
frequent	O
ventricular	O
extrasystoles	O
VE	O
with	O
right	O
ventricular	O
outflow	O
tract	O
RVOT	O
morphology	O
.	O
Electrocardiogram	O
during	O
tachycardia	O
wide	O
QRS	O
tachycardia	O
,	O
with	O
morphology	O
of	O
complete	O
left	O
bundle	O
branch	O
block	O
,	O
left	O
inferior	O
axis	O
,	O
cycle	O
260	O
ms	O
.	O
Regular	O
R	O
R	O
.	O
Prior	O
to	O
the	O
onset	O
of	O
tachycardia	O
we	O
observed	O
frequent	O
right	O
ventricular	O
outflow	O
tract	O
extrasystoles	O
with	O
a	O
different	O
morphology	O
to	O
that	O
of	O
the	O
tachycardia	O
R	O
more	O
prominent	O
and	O
positive	O
in	O
III	O
.	O
Laboratory	O
tests	O
on	O
admission	O
haemoglobin	O
15	O
.	O
9	O
g	O
dl	O
,	O
leucocytes	O
5	O
.	O
20	O
10	O
3	O
μl	O
,	O
platelets	O
113	O
.	O
0	O
10	O
3	O
μl	O
.	O
Prothrombin	O
time	O
PT	O
s	O
14	O
.	O
4	O
.	O
Quick	O
's	O
index	O
65	O
.	O
INR	O
1	O
.	O
33	O
.	O
APTT	O
T	O
.	O
cephalin	O
s	O
47	O
.	O
1	O
.	O
Glucose	O
93	O
mg	O
dl	O
,	O
urea	O
22	O
.	O
0	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
95	O
mg	O
dl	O
,	O
uric	O
acid	O
5	O
.	O
1	O
mg	O
dl	O
,	O
albumin	O
4	O
.	O
3	O
g	O
dl	O
,	O
total	O
protein	O
7	O
.	O
0	O
g	O
dl	O
.	O
Total	O
cholesterol	O
148	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
34	O
.	O
5	O
mg	O
dl	O
,	O
non	O
HDL	O
cholesterol	O
113	O
.	O
5	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
102	O
.	O
9	O
mg	O
dl	O
,	O
VLDL	O
cholesterol	O
10	O
.	O
6	O
mg	O
dl	O
,	O
triglycerides	O
53	O
.	O
0	O
mg	O
dl	O
,	O
sodium	O
136	O
mm	O
l	O
,	O
potassium	O
4	O
.	O
0	O
mm	O
l	O
,	O
phosphorus	O
2	O
.	O
7	O
mg	O
dl	O
,	O
total	O
bilirubin	O
0	O
.	O
98	O
mg	O
dl	O
.	O
GPT	O
ALT	O
28	O
.	O
4	O
U	O
l	O
,	O
GOT	O
AST	O
35	O
.	O
7	O
U	O
l	O
,	O
gamma	O
GT	O
34	O
.	O
5	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
53	O
.	O
0	O
U	O
l	O
,	O
LDH	O
221	O
.	O
5	O
U	O
l	O
,	O
creatine	O
kinase	O
288	O
U	O
l	O
,	O
glycosylated	O
haemoglobin	O
A1c	O
DCCT	O
6	O
.	O
0	O
.	O
Thyroid	O
stimulating	O
hormone	O
0	O
.	O
310	O
mIU	O
l	O
,	O
free	O
T3	O
free	O
triiodothyronine	O
2	O
.	O
54	O
pg	O
ml	O
,	O
free	O
T4	O
free	O
thyroxine	O
0	O
.	O
84	O
ng	O
dl	O
.	O
Myocardial	O
damage	O
markers	O
troponin	O
I	O
and	O
CK	O
MB	O
were	O
normal	O
serially	O
x	O
3	O
.	O
Chest	O
X	O
ray	O
normal	O
.	O
Cardiothoracic	O
index	O
CTI	O
within	O
normal	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
on	O
admission	O
non	O
dilated	O
left	O
ventricle	O
LV	O
with	O
moderate	O
concentric	O
hypertrophy	O
.	O
Moderate	O
severe	O
ventricular	O
dysfunction	O
LVEF	O
35	O
by	O
Simpson	O
biplane	O
,	O
global	O
hypokinesia	O
with	O
worse	O
anterior	O
contractility	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
.	O
Structurally	O
normal	O
mitral	O
valve	O
with	O
mild	O
insufficiency	O
.	O
Aortic	O
valve	O
trivalve	O
,	O
sclerotic	O
,	O
normofunctioning	O
.	O
Normal	O
tricuspid	O
valve	O
.	O
Non	O
dilated	O
right	O
ventricle	O
RV	O
with	O
good	O
systolic	O
function	O
.	O
No	O
pericardial	O
effusion	O
.	O
Transthoracic	O
echocardiogram	O
at	O
one	O
week	O
non	O
dilated	O
LV	O
with	O
moderate	O
concentric	O
hypertrophy	O
.	O
Global	O
systolic	O
function	O
preserved	O
without	O
contractility	O
alterations	O
.	O
LVEF	O
by	O
Simpson	O
BP	O
55	O
.	O
Rest	O
unchanged	O
with	O
respect	O
to	O
previous	O
study	O
.	O
Coronary	O
angiography	O
left	O
vascular	O
tree	O
without	O
lesions	O
.	O
Dominant	O
right	O
coronary	O
artery	O
RCA	O
,	O
with	O
lesion	O
of	O
doubtful	O
significance	O
in	O
the	O
middle	O
third	O
.	O
After	O
intravascular	O
ultrasound	O
IVUS	O
,	O
70	O
stenosis	O
was	O
found	O
.	O
Revascularisation	O
right	O
coronary	O
direct	O
drug	O
eluting	O
stent	O
implantation	O
Resolute	O
Onix	O
4	O
x	O
12	O
mm	O
in	O
the	O
middle	O
third	O
.	O
Good	O
final	O
angiographic	O
result	O
.	O
Electrophysiological	O
study	O
EEF	O
with	O
right	O
femoral	O
venous	O
access	O
.	O
There	O
is	O
evidence	O
of	O
atrial	O
fibrillation	O
AF	O
with	O
EV	O
with	O
left	O
bundle	O
branch	O
block	O
morphology	O
LBBB	O
ID	O
axis	O
with	O
other	O
advanced	O
complexes	O
and	O
wide	O
QRS	O
presenting	O
LBBB	O
with	O
axis	O
II	O
.	O
A	O
pathological	O
HV	O
of	O
80	O
msg	O
is	O
evident	O
,	O
which	O
is	O
difficult	O
to	O
maintain	O
stable	O
.	O
High	O
dose	O
aleudrine	B-FARMACO
increased	O
atrioventricular	O
AV	O
conduction	O
to	O
a	O
HR	O
of	O
120	O
130	O
without	O
aberrant	O
conduction	O
.	O
After	O
TEE	O
ruled	O
out	O
thrombi	O
in	O
the	O
left	O
atrium	O
LA	O
,	O
electrical	O
cardioversion	O
ECV	O
was	O
performed	O
with	O
a	O
switch	O
to	O
SR	O
with	O
200	O
J	O
in	O
biphasic	O
mode	O
.	O
Aleudrine	O
induced	O
ventricular	O
tachycardia	O
in	O
a	O
fairly	O
reproducible	O
manner	O
periods	O
without	O
AV	O
ratio	O
1x1	O
,	O
with	O
AV	O
dissociation	O
with	O
morphology	O
equal	O
to	O
the	O
clinical	O
one	O
LBBB	O
and	O
with	O
transition	O
in	O
V4	O
V5	O
,	O
well	O
tolerated	O
and	O
with	O
a	O
cycle	O
of	O
260	O
msg	O
.	O
In	O
the	O
case	O
of	O
suspected	O
branch	O
branch	O
ventricular	O
tachycardia	O
BRVT	O
,	O
attempts	O
are	O
made	O
to	O
obtain	O
stable	O
His	O
,	O
which	O
is	O
impossible	O
using	O
Josephson	O
tetra	O
,	O
His	O
tetra	O
and	O
deflectable	O
decapolar	O
.	O
Neither	O
is	O
it	O
possible	O
to	O
analyse	O
pacing	O
from	O
the	O
RA	O
because	O
of	O
the	O
large	O
pacing	O
artefact	O
that	O
prevents	O
verification	O
of	O
the	O
QRS	O
morphology	O
.	O
However	O
,	O
we	O
concluded	O
that	O
it	O
was	O
RRVT	O
with	O
other	O
criteria	O
return	O
cycle	O
from	O
RV	O
apex	O
of	O
0	O
and	O
electrogram	O
of	O
right	O
ventricular	O
apex	O
early	O
on	O
the	O
onset	O
of	O
the	O
QRS	O
.	O
Right	O
bundle	O
branch	O
ablation	O
was	O
performed	O
using	O
a	O
conventional	O
4	O
mm	O
FJ	O
catheter	O
,	O
which	O
was	O
achieved	O
after	O
three	O
applications	O
.	O
The	O
right	O
bundle	O
branch	O
was	O
found	O
not	O
to	O
lead	O
for	O
30	O
minutes	O
.	O
Subsequently	O
,	O
a	O
DDDR	O
Boston	O
bicameral	O
pacemaker	O
was	O
implanted	O
.	O
CLINICAL	O
EVOLUTION	O
With	O
the	O
diagnosis	O
of	O
probable	O
ventricular	O
tachycardia	O
,	O
treatment	O
was	O
started	O
with	O
beta	O
blockers	O
and	O
amiodarone	B-FARMACO
,	O
and	O
he	O
was	O
admitted	O
to	O
the	O
cardiology	O
ward	O
with	O
telemetry	O
.	O
Forty	O
eight	O
hours	O
after	O
admission	O
,	O
during	O
his	O
stay	O
on	O
the	O
ward	O
,	O
a	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
the	O
presence	O
of	O
severe	O
global	O
LV	O
dysfunction	O
,	O
with	O
worse	O
contractility	O
in	O
the	O
anterior	O
territory	O
,	O
which	O
recovered	O
completely	O
one	O
week	O
after	O
admission	O
.	O
Coronary	O
angiography	O
was	O
performed	O
,	O
which	O
revealed	O
an	O
intermediate	O
lesion	O
in	O
the	O
mid	O
right	O
coronary	O
artery	O
.	O
Revascularisation	O
with	O
a	O
drug	O
eluting	O
stent	O
was	O
considered	O
.	O
Given	O
the	O
clinical	O
presentation	O
no	O
chest	O
pain	O
,	O
no	O
signs	O
of	O
acute	O
ischaemia	O
in	O
the	O
electrocardiogram	O
and	O
no	O
elevation	O
of	O
myocardial	O
damage	O
markers	O
,	O
the	O
presence	O
of	O
severe	O
global	O
ventricular	O
dysfunction	O
that	O
recovered	O
early	O
after	O
control	O
of	O
the	O
arrhythmia	O
was	O
considered	O
as	O
dysfunction	O
secondary	O
to	O
tachycardiomyopathy	O
.	O
Finally	O
,	O
an	O
electrophysiological	O
study	O
was	O
performed	O
which	O
documented	O
,	O
firstly	O
,	O
that	O
it	O
was	O
a	O
ventricular	O
tachycardia	O
existence	O
of	O
VA	O
dissociation	O
and	O
subsequently	O
,	O
by	O
means	O
of	O
manoeuvres	O
,	O
that	O
it	O
was	O
a	O
branch	O
branch	O
ventricular	O
tachycardia	O
electrogram	O
of	O
the	O
right	O
ventricular	O
apex	O
early	O
on	O
the	O
start	O
of	O
the	O
QRS	O
and	O
,	O
another	O
fundamental	O
fact	O
,	O
the	O
return	O
cycle	O
was	O
very	O
short	O
10	O
ms	O
after	O
the	O
tachycardia	O
was	O
triggered	O
from	O
the	O
RV	O
apex	O
.	O
Right	O
bundle	O
branch	O
ablation	O
and	O
DDD	O
pacemaker	O
implantation	O
was	O
performed	O
due	O
to	O
HV	O
lengthening	O
up	O
to	O
100	O
ms	O
.	O
Once	O
discharged	O
,	O
the	O
patient	O
's	O
evolution	O
has	O
been	O
excellent	O
.	O
No	O
arrhythmic	O
recurrences	O
.	O
Ejection	O
fraction	O
remained	O
preserved	O
.	O
In	O
addition	O
,	O
he	O
was	O
referred	O
to	O
neurology	O
consultations	O
to	O
rule	O
out	O
the	O
possibility	O
of	O
neuromuscular	O
disease	O
due	O
to	O
its	O
association	O
with	O
this	O
type	O
of	O
tachycardia	O
in	O
patients	O
without	O
heart	O
disease	O
,	O
and	O
an	O
electromyogram	O
and	O
genetic	O
study	O
were	O
performed	O
,	O
which	O
ruled	O
out	O
this	O
possibility	O
.	O
DIAGNOSIS	O
Branch	O
branch	O
ventricular	O
tachycardia	O
BRVT	O
.	O
Tachycardiomyopathy	O
.	O
Preserved	O
left	O
ventricular	O
function	O
at	O
discharge	O
.	O
Intermediate	O
lesion	O
in	O
the	O
middle	O
DC	O
.	O
Revascularisation	O
by	O
drug	O
eluting	O
stent	O
implantation	O
.	O
Right	O
bundle	O
branch	O
ablation	O
.	O
Implantation	O
of	O
DDDR	O
Boston	O
pacemaker	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
a	O
65	O
year	O
old	O
man	O
with	O
no	O
known	O
drug	O
allergies	O
.	O
Background	O
As	O
personal	O
history	O
,	O
he	O
is	O
being	O
treated	O
with	O
ezetimibe	B-FARMACO
atorvastatin	I-FARMACO
10	O
80	O
mg	O
for	O
familial	O
hypercholesterolaemia	O
last	O
available	O
LDL	O
50	O
mg	O
dl	O
.	O
No	O
other	O
known	O
cardiovascular	O
risk	O
factors	O
,	O
no	O
toxic	O
habits	O
.	O
Body	O
mass	O
index	O
BMI	O
26	O
.	O
7	O
overweight	O
.	O
With	O
regard	O
to	O
family	O
history	O
,	O
history	O
of	O
early	O
ischaemic	O
heart	O
disease	O
in	O
a	O
brother	O
at	O
50	O
years	O
of	O
age	O
he	O
died	O
for	O
this	O
reason	O
.	O
Current	O
disease	O
A	O
65	O
year	O
old	O
patient	O
with	O
the	O
aforementioned	O
history	O
came	O
to	O
the	O
emergency	O
department	O
referred	O
by	O
061	O
after	O
presenting	O
at	O
home	O
with	O
oppressive	O
central	O
thoracic	O
pain	O
with	O
associated	O
vegetative	O
crusade	O
lasting	O
15	O
minutes	O
.	O
He	O
had	O
not	O
presented	O
with	O
previous	O
episodes	O
of	O
chest	O
pain	O
.	O
The	O
electrocardiogram	O
performed	O
by	O
the	O
emergency	O
department	O
showed	O
anterolateral	O
ST	O
elevation	O
,	O
so	O
ticagrelor	B-FARMACO
180	O
mg	O
and	O
aspirin	B-FARMACO
300	O
mg	O
were	O
administered	O
and	O
the	O
infarction	O
code	O
was	O
activated	O
.	O
Physical	O
examination	O
During	O
transfer	O
by	O
061	O
and	O
on	O
arrival	O
at	O
the	O
haemodynamics	O
room	O
,	O
the	O
patient	O
was	O
haemodynamically	O
stable	O
,	O
well	O
perfused	O
,	O
with	O
the	O
need	O
for	O
low	O
flow	O
oxygen	B-FARMACO
.	O
Vital	O
signs	O
blood	O
pressure	O
121	O
85	O
mmHg	O
,	O
heart	O
rate	O
75	O
bpm	O
.	O
Oxygen	O
saturation	O
93	O
with	O
nasal	O
goggles	O
at	O
2	O
bpm	O
.	O
Eupneic	O
at	O
rest	O
.	O
On	O
cardiac	O
auscultation	O
rhythmic	O
tones	O
without	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
with	O
bibasal	O
crackles	O
.	O
No	O
megaliths	O
,	O
mild	O
jugular	O
ingurgitation	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
extremities	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
,	O
q	O
v1	O
v2	O
,	O
ST	O
V1	O
V4	O
,	O
I	O
and	O
AVL	O
with	O
specular	O
decrease	O
in	O
inferior	O
face	O
.	O
Blood	O
tests	O
on	O
admission	O
acid	O
base	O
balance	O
PH	O
7	O
.	O
44	O
,	O
PCO2	O
34	O
mmHg	O
,	O
bicarbonate	O
23	O
.	O
1	O
mmol	O
l	O
,	O
lactate	O
3	O
.	O
8	O
mmol	O
l	O
,	O
sodium	O
142	O
mmol	O
l	O
and	O
potassium	O
3	O
.	O
6	O
mmol	O
l	O
.	O
Biochemistry	O
urea	O
37mg	O
dl	O
,	O
creatinine	O
1	O
.	O
24	O
mg	O
dl	O
.	O
Troponin	O
I	O
ultrasensitive	O
peak	O
196000	O
μg	O
l	O
.	O
NT	O
proBNP	O
8682	O
pg	O
ml	O
.	O
Coronary	O
angiography	O
Acute	O
complete	O
occlusion	O
of	O
distal	O
common	O
trunk	O
CT	O
.	O
Left	O
anterior	O
descending	O
artery	O
LAD	O
occluded	O
vessel	O
with	O
homolateral	O
perfusion	O
TIMI	O
0	O
.	O
After	O
opening	O
,	O
ectasia	O
is	O
seen	O
in	O
its	O
proximal	O
portion	O
,	O
with	O
diffuse	O
mild	O
to	O
moderate	O
involvement	O
of	O
the	O
entire	O
vessel	O
and	O
thin	O
distal	O
bed	O
.	O
Second	O
septal	O
branch	O
ectatic	O
,	O
with	O
a	O
long	O
course	O
and	O
severe	O
ostial	O
lesion	O
.	O
Left	O
circumflex	O
artery	O
CX	O
proximal	O
occluded	O
vessel	O
with	O
homolateral	O
perfusion	O
TIMI	O
0	O
.	O
Right	O
coronary	O
artery	O
CD	O
dominant	O
vessel	O
,	O
large	O
calibre	O
,	O
ectatic	O
and	O
with	O
moderate	O
diffuse	O
disease	O
.	O
Percutaneous	O
coronary	O
intervention	O
was	O
performed	O
by	O
implanting	O
drug	O
eluting	O
stents	O
at	O
distal	O
CT	O
level	O
directed	O
towards	O
the	O
LAD	O
and	O
subsequently	O
at	O
distal	O
CT	O
level	O
towards	O
Cx	O
first	O
obtuse	O
marginal	O
.	O
Echocardiogram	O
prior	O
to	O
discharge	O
dilated	O
left	O
ventricle	O
LV	O
LVED	O
61	O
mm	O
with	O
severe	O
systolic	O
dysfunction	O
.	O
Estimated	O
LVEF	O
34	O
with	O
contractile	O
asymmetries	O
.	O
Right	O
chambers	O
of	O
normal	O
size	O
and	O
contractility	O
.	O
Mild	O
aortic	O
insufficiency	O
AIo	O
.	O
Moderate	O
mitral	O
insufficiency	O
MI	O
II	O
IV	O
.	O
Estimated	O
pulmonary	O
pressure	O
normal	O
.	O
Blood	O
tests	O
prior	O
to	O
discharge	O
NT	O
proBNP	O
6009	O
pg	O
ml	O
previous	O
8682	O
,	O
urea	O
36	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
89	O
mg	O
dl	O
,	O
LDL	O
51	O
mg	O
dl	O
,	O
chlorine	O
105	O
mEq	O
l	O
,	O
sodium	O
139	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
4	O
mEq	O
l	O
,	O
haemoglobin	O
10	O
.	O
7	O
g	O
dl	O
,	O
haematocrit	O
31	O
.	O
5	O
,	O
HbA1c	O
6	O
.	O
6	O
.	O
Echocardiogram	O
after	O
completion	O
of	O
phase	O
II	O
of	O
cardiac	O
rehabilitation	O
;	O
videos	O
5	O
and	O
6	O
Dilated	O
LV	O
LVED	O
61	O
mm	O
with	O
slightly	O
depressed	O
function	O
.	O
Estimated	O
LVEF	O
46	O
with	O
contractile	O
asymmetries	O
.	O
Right	O
chambers	O
of	O
normal	O
size	O
and	O
contractility	O
.	O
Mild	O
AoI	O
.	O
Moderate	O
MI	O
II	O
IV	O
.	O
Blood	O
tests	O
after	O
end	O
of	O
phase	O
II	O
NT	O
proBNP	O
2178	O
pg	O
ml	O
,	O
creatinine	O
1	O
.	O
25	O
md	O
dl	O
,	O
LDL	O
50	O
mg	O
dl	O
,	O
HbA1c	O
6	O
.	O
3	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
the	O
percutaneous	O
intervention	O
in	O
the	O
haemodynamics	O
room	O
,	O
our	O
patient	O
presented	O
a	O
progressive	O
clinical	O
worsening	O
.	O
Tendency	O
to	O
arterial	O
hypotension	O
with	O
poor	O
peripheral	O
perfusion	O
,	O
requiring	O
the	O
initiation	O
of	O
vasoactive	O
drugs	O
dobutamine	B-FARMACO
and	O
noradrenaline	B-FARMACO
at	O
medium	O
doses	O
,	O
as	O
well	O
as	O
respiratory	O
failure	O
requiring	O
non	O
invasive	O
mechanical	O
ventilation	O
.	O
Prior	O
to	O
leaving	O
the	O
haemodynamic	O
ward	O
,	O
a	O
balloon	O
counterpulsation	O
device	O
IABP	O
was	O
implanted	O
.	O
During	O
his	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
he	O
evolved	O
favourably	O
,	O
allowing	O
the	O
weaning	O
of	O
vasoactive	O
drugs	O
and	O
the	O
removal	O
of	O
the	O
IABP	O
on	O
the	O
fourth	O
day	O
.	O
During	O
admission	O
to	O
the	O
hospital	O
ward	O
18	O
days	O
of	O
hospitalisation	O
,	O
congestive	O
data	O
persisted	O
with	O
very	O
slow	O
resolution	O
despite	O
forcing	O
a	O
negative	O
water	O
balance	O
with	O
intravenous	O
diuretic	O
,	O
as	O
well	O
as	O
borderline	O
blood	O
pressure	O
and	O
transient	O
worsening	O
of	O
renal	O
function	O
that	O
made	O
it	O
difficult	O
to	O
initiate	O
neurohormonal	O
treatment	O
,	O
and	O
he	O
was	O
discharged	O
in	O
NYHA	O
functional	O
class	O
FC	O
II	O
.	O
The	O
echocardiogram	O
performed	O
showed	O
severely	O
depressed	O
ventricular	O
function	O
.	O
Regarding	O
treatment	O
at	O
discharge	O
,	O
priority	O
was	O
given	O
to	O
oral	O
diuretic	O
treatment	O
with	O
furosemide	B-FARMACO
and	O
eplerenone	B-FARMACO
,	O
together	O
with	O
low	O
doses	O
of	O
beta	O
blockers	O
,	O
given	O
the	O
circumstances	O
described	O
above	O
.	O
After	O
hospital	O
discharge	O
,	O
our	O
patient	O
was	O
referred	O
to	O
the	O
cardiac	O
rehabilitation	O
unit	O
CRP	O
and	O
,	O
in	O
parallel	O
,	O
began	O
follow	O
up	O
in	O
the	O
advanced	O
heart	O
failure	O
unit	O
.	O
During	O
phase	O
II	O
of	O
the	O
CRP	O
,	O
our	O
patient	O
underwent	O
the	O
educational	O
programme	O
,	O
dietary	O
recommendations	O
,	O
review	O
of	O
cardiovascular	O
risk	O
factors	O
CVRF	O
and	O
home	O
medical	O
treatment	O
.	O
Subsequently	O
,	O
he	O
successfully	O
completed	O
8	O
weeks	O
of	O
face	O
to	O
face	O
training	O
guided	O
by	O
ergospirometry	O
,	O
supervised	O
by	O
the	O
cardiologist	O
and	O
rehabilitation	O
physician	O
.	O
Regarding	O
treatment	O
,	O
drugs	O
with	O
prognostic	O
benefit	O
were	O
prioritised	O
quadruple	O
therapy	O
,	O
suspending	O
furosemide	B-FARMACO
treatment	O
and	O
reducing	O
the	O
dose	O
of	O
eplerenone	B-FARMACO
,	O
which	O
allowed	O
the	O
progressive	O
initiation	O
,	O
with	O
close	O
monitoring	O
of	O
renal	O
function	O
,	O
of	O
sodium	B-FARMACO
glucose	I-FARMACO
cotransporter	I-FARMACO
type	I-FARMACO
2	I-FARMACO
inhibitor	I-FARMACO
iSGLT2	I-FARMACO
and	O
angiotensin	O
receptor	O
neprilysin	O
inhibitor	O
ARNI	O
at	O
low	O
doses	O
.	O
Finally	O
,	O
intravenous	O
ferric	O
carboxymaltose	O
was	O
administered	O
on	O
an	O
outpatient	O
basis	O
in	O
day	O
hospital	O
iron	O
profile	O
iron	O
50	O
μg	O
dl	O
,	O
ferritin	O
150	O
ng	O
dl	O
,	O
haemoglobin	O
13	O
.	O
3	O
g	O
dl	O
,	O
haematocrit	O
44	O
.	O
After	O
close	O
comprehensive	O
management	O
,	O
our	O
patient	O
showed	O
a	O
clear	O
improvement	O
4	O
months	O
after	O
the	O
event	O
,	O
improving	O
both	O
in	O
functional	O
class	O
stable	O
CF	O
I	O
and	O
in	O
analytical	O
data	O
final	O
NTproBNP	O
2178	O
pg	O
ml	O
;	O
initial	O
8682	O
pg	O
ml	O
and	O
echocardiographic	O
data	O
,	O
with	O
an	O
estimated	O
ventricular	O
function	O
of	O
46	O
.	O
DIAGNOSIS	O
Acute	O
ST	O
segment	O
elevation	O
myocardial	O
infarction	O
STEMI	O
anterior	O
Killip	O
Kimball	O
IV	O
Coronary	O
artery	O
disease	O
of	O
the	O
common	O
coronary	O
trunk	O
distal	O
CT	O
occlusion	O
Ischaemic	O
dilated	O
cardiomyopathy	O
DCM	O
with	O
severely	O
depressed	O
ventricular	O
function	O
Impaired	O
basal	O
glycaemia	O
Iron	O
deficiency	O
anaemia	O
.	O
Familial	O
hypercholesterolaemia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Male	O
,	O
61	O
years	O
old	O
.	O
No	O
known	O
allergic	O
reactions	O
to	O
medication	O
.	O
Cardiovascular	O
risk	O
factors	O
arterial	O
hypertension	O
.	O
Obesity	O
grade	O
2	O
body	O
mass	O
index	O
37	O
.	O
86	O
kg	O
m2	O
.	O
No	O
diabetes	O
mellitus	O
or	O
dyslipidaemia	O
.	O
No	O
toxic	O
habits	O
.	O
Surgical	O
history	O
operated	O
for	O
left	O
trimalleolar	O
fracture	O
with	O
osteosynthesis	O
of	O
peroneal	O
malleolus	O
with	O
6	O
hole	O
tube	O
third	O
plate	O
and	O
osteosynthesis	O
of	O
tibial	O
malleolus	O
with	O
a	O
screw	O
in	O
2009	O
.	O
Non	O
cardiological	O
medical	O
history	O
Moderate	O
chronic	O
obstructive	O
pulmonary	O
disease	O
COPD	O
,	O
under	O
follow	O
up	O
by	O
the	O
outpatient	O
pulmonology	O
department	O
of	O
his	O
referral	O
hospital	O
.	O
Sleep	O
apnoea	O
hypopnoea	O
syndrome	O
SAHS	O
being	O
treated	O
with	O
continuous	O
positive	O
airway	O
pressure	O
CPAP	O
and	O
home	O
oxygen	O
.	O
Prostate	O
adenocarcinoma	O
diagnosed	O
in	O
2016	O
,	O
treated	O
with	O
radiotherapy	O
and	O
hormone	O
blockade	O
.	O
Unfiliated	O
renal	O
tumour	O
,	O
first	O
detected	O
in	O
2017	O
.	O
Not	O
operated	O
on	O
at	O
his	O
referral	O
hospital	O
due	O
to	O
high	O
surgical	O
risk	O
.	O
Abdomino	O
pelvic	O
CT	O
scan	O
performed	O
at	O
his	O
reference	O
hospital	O
in	O
2020	O
mixed	O
nodule	O
measuring	O
20	O
x	O
18	O
mm	O
in	O
the	O
right	O
kidney	O
,	O
close	O
to	O
the	O
lower	O
pole	O
,	O
eccentric	O
,	O
without	O
clear	O
perirenal	O
fatty	O
infiltration	O
.	O
Stability	O
in	O
radiological	O
follow	O
up	O
,	O
so	O
it	O
has	O
been	O
considered	O
non	O
malignant	O
.	O
Cardiological	O
history	O
non	O
ischaemic	O
dilated	O
cardiomyopathy	O
diagnosed	O
in	O
2003	O
,	O
with	O
severe	O
left	O
ventricular	O
dysfunction	O
.	O
Loss	O
of	O
follow	O
up	O
until	O
2012	O
.	O
In	O
2012	O
the	O
patient	O
returned	O
to	O
the	O
cardiology	O
outpatient	O
clinic	O
at	O
his	O
referral	O
hospital	O
.	O
Echocardiogram	O
at	O
that	O
time	O
showed	O
a	O
severely	O
dilated	O
left	O
ventricle	O
LV	O
,	O
with	O
biplane	O
EF	O
29	O
,	O
with	O
diffuse	O
global	O
hypokinesia	O
.	O
Coronary	O
angiography	O
showed	O
irregularities	O
in	O
the	O
right	O
coronary	O
artery	O
,	O
the	O
rest	O
of	O
the	O
coronary	O
tree	O
showed	O
no	O
alterations	O
.	O
Implantable	O
cardioverter	O
defibrillator	O
implantation	O
with	O
cardiac	O
resynchronisation	O
therapy	O
ICD	O
CRT	O
was	O
decided	O
in	O
March	O
2012	O
for	O
primary	O
prevention	O
of	O
sudden	O
death	O
.	O
An	O
appropriate	O
shock	O
due	O
to	O
non	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
NSMVT	O
occurred	O
in	O
December	O
2012	O
.	O
In	O
reviews	O
of	O
the	O
ICD	O
,	O
multiple	O
episodes	O
of	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
SMVT	O
treated	O
with	O
overstimulation	O
were	O
detected	O
,	O
so	O
amiodarone	B-FARMACO
was	O
started	O
.	O
In	O
February	O
2020	O
,	O
a	O
new	O
ventricular	O
tachycardia	O
VT	O
occurred	O
with	O
appropriate	O
ICD	O
discharge	O
,	O
and	O
the	O
patient	O
was	O
admitted	O
to	O
his	O
referral	O
hospital	O
.	O
The	O
last	O
transthoracic	O
echocardiogram	O
,	O
performed	O
during	O
this	O
admission	O
,	O
showed	O
a	O
severely	O
dilated	O
left	O
ventricle	O
DTD	O
104	O
mm	O
,	O
VTDi	O
207	O
ml	O
m2	O
,	O
VTSi	O
157	O
ml	O
m2	O
,	O
with	O
severe	O
depression	O
of	O
function	O
LVEF	O
23	O
biplane	O
,	O
with	O
severe	O
global	O
hypokinesia	O
.	O
Dilated	O
left	O
atrium	O
34	O
cm2	O
.	O
Diastolic	O
dysfunction	O
grade	O
I	O
with	O
signs	O
of	O
increased	O
filling	O
pressures	O
E	O
e	O
"	O
20	O
.	O
Mitral	O
valve	O
with	O
mild	O
regurgitation	O
due	O
to	O
dilatation	O
of	O
the	O
annulus	O
.	O
Aortic	O
flow	O
with	O
slightly	O
increased	O
gradients	O
11	O
5	O
mmHg	O
,	O
without	O
aortic	O
insufficiency	O
.	O
Mild	O
tricuspid	O
insufficiency	O
LAD	O
electrode	O
that	O
does	O
not	O
allow	O
adequate	O
estimation	O
of	O
systolic	O
pressure	O
in	O
the	O
pulmonary	O
artery	O
.	O
Dilated	O
right	O
ventricle	O
44	O
mm	O
baseline	O
,	O
with	O
RVEF	O
at	O
the	O
lower	O
limit	O
TAPSE	O
18	O
mm	O
.	O
No	O
pericardial	O
effusion	O
.	O
Usual	O
treatment	O
atorvastatin	B-FARMACO
80	O
mg	O
1	O
tablet	O
daily	O
,	O
amiodarone	B-FARMACO
200	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
,	O
furosemide	B-FARMACO
40	O
mg	O
2	O
tablets	O
daily	O
,	O
carvedilol	B-FARMACO
12	O
.	O
5	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
,	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
24	O
26	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
,	O
esomeprazole	B-FARMACO
20	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
,	O
indacaterol	B-FARMACO
glycopyrronium	I-FARMACO
bromide	I-FARMACO
85	O
43	O
mcg	O
1	O
inhalation	O
every	O
24	O
hours	O
,	O
tamsulosin	B-FARMACO
0	O
.	O
4	O
mg	O
1	O
tablet	O
per	O
day	O
.	O
Present	O
illness	O
A	O
61	O
year	O
old	O
male	O
who	O
,	O
referred	O
from	O
his	O
referral	O
centre	O
,	O
was	O
admitted	O
in	O
May	O
2020	O
to	O
the	O
cardiology	O
inpatient	O
ward	O
of	O
the	O
advanced	O
heart	O
failure	O
and	O
heart	O
transplant	O
unit	O
to	O
assess	O
treatment	O
options	O
.	O
The	O
patient	O
was	O
diagnosed	O
with	O
dilated	O
cardiomyopathy	O
with	O
severe	O
left	O
ventricular	O
dysfunction	O
in	O
2003	O
and	O
had	O
stopped	O
attending	O
check	O
ups	O
until	O
2012	O
.	O
At	O
present	O
,	O
the	O
patient	O
reports	O
NYHA	O
functional	O
class	O
III	O
IV	O
,	O
with	O
sustained	O
symptoms	O
for	O
the	O
last	O
few	O
months	O
.	O
He	O
has	O
orthopnoea	O
.	O
He	O
can	O
walk	O
only	O
50	O
metres	O
without	O
having	O
to	O
stop	O
,	O
with	O
difficulty	O
climbing	O
a	O
floor	O
.	O
No	O
episodes	O
of	O
palpitations	O
,	O
syncope	O
or	O
presyncope	O
,	O
nor	O
new	O
ICD	O
discharges	O
.	O
No	O
other	O
associated	O
symptoms	O
.	O
Physical	O
examination	O
Conscious	O
and	O
oriented	O
,	O
eupneic	O
at	O
rest	O
.	O
Blood	O
pressure	O
118	O
71	O
mmHg	O
,	O
heart	O
rate	O
53	O
bpm	O
,	O
peripheral	O
oxygen	O
saturation	O
98	O
FiO2	O
21	O
.	O
Weight	O
112	O
kg	O
,	O
height	O
172	O
cm	O
,	O
body	O
mass	O
index	O
BMI	O
37	O
.	O
86	O
kg	O
m2	O
obesity	O
grade	O
2	O
Cardiac	O
auscultation	O
regular	O
heart	O
tones	O
,	O
no	O
murmurs	O
or	O
audible	O
friction	O
rubs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
added	O
sounds	O
,	O
although	O
some	O
generalised	O
hypoventilation	O
was	O
observed	O
.	O
Extremities	O
slight	O
tibiomalleolar	O
oedema	O
with	O
fovea	O
,	O
with	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
12	O
lead	O
electrocardiogram	O
on	O
admission	O
sinus	O
bradycardia	O
at	O
50	O
beats	O
per	O
minute	O
,	O
with	O
ventricular	O
rhythm	O
due	O
to	O
pacemaker	O
in	O
VAT	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
PA	O
no	O
infiltrates	O
or	O
masses	O
were	O
identified	O
.	O
No	O
costophrenic	O
sinus	O
impingement	O
.	O
ICD	O
CRT	O
correctly	O
positioned	O
.	O
SARS	O
CoV2	O
CRP	O
not	O
detected	O
.	O
Transthoracic	O
echocardiogram	O
at	O
bedside	O
poor	O
acoustic	O
access	O
due	O
to	O
obesity	O
.	O
The	O
left	O
ventricle	O
is	O
severely	O
dilated	O
DVItd	O
9	O
.	O
7	O
cm	O
,	O
DVIts	O
9	O
.	O
1	O
cm	O
,	O
indexed	O
DVItd	O
cm	O
m2	O
4	O
.	O
4	O
cm	O
m2	O
,	O
indexed	O
DVIts	O
cm	O
m2	O
4	O
.	O
1	O
cm	O
m2	O
.	O
Left	O
ventricular	O
systolic	O
function	O
is	O
severely	O
reduced	O
EF	O
Teich	O
13	O
.	O
8	O
.	O
Estimation	O
of	O
EF	O
by	O
Simpson	O
's	O
method	O
is	O
poorly	O
assessable	O
due	O
to	O
poor	O
acoustic	O
access	O
.	O
Right	O
ventricle	O
of	O
normal	O
dimensions	O
baseline	O
RV	O
dimensions	O
3	O
.	O
8	O
cm	O
,	O
indexed	O
baseline	O
RV	O
dimensions	O
cm	O
m2	O
1	O
.	O
72	O
cm	O
m2	O
,	O
RV	O
diastolic	O
area	O
19	O
.	O
6	O
cm2	O
,	O
RV	O
end	O
systolic	O
area	O
15	O
.	O
4	O
cm2	O
.	O
Right	O
ventricular	O
systolic	O
function	O
is	O
mildly	O
to	O
moderately	O
reduced	O
TAPSE	O
3	O
.	O
6	O
cm	O
,	O
RV	O
FAC	O
21	O
.	O
7	O
.	O
Difficult	O
to	O
assess	O
correctly	O
due	O
to	O
poor	O
acoustic	O
access	O
.	O
Mild	O
left	O
atrial	O
dilatation	O
LA	O
diameter	O
4	O
.	O
3	O
cm	O
.	O
Right	O
atrial	O
size	O
is	O
normal	O
.	O
Mitral	O
valve	O
with	O
degenerative	O
changes	O
.	O
Mild	O
to	O
moderate	O
mitral	O
regurgitation	O
detected	O
.	O
Difficult	O
to	O
quantify	O
.	O
Holosystolic	O
flow	O
but	O
low	O
density	O
Vmax	O
E	O
MV	O
75	O
.	O
0	O
cm	O
s	O
,	O
Vmax	O
A	O
V	O
88	O
.	O
4	O
cm	O
s	O
,	O
E	O
A	O
MV	O
0	O
.	O
85	O
,	O
mitral	O
E	O
e	O
'	O
medial	O
15	O
.	O
7	O
ratio	O
,	O
E	O
'	O
peak	O
velocity	O
lat	O
.	O
3	O
.	O
5	O
cm	O
s	O
,	O
E	O
'	O
peak	O
velocity	O
med	O
.	O
4	O
.	O
8	O
cm	O
s	O
,	O
mitral	O
E	O
e	O
'	O
lateral	O
21	O
.	O
4	O
ratio	O
.	O
Tricuspid	O
valve	O
normal	O
in	O
structure	O
and	O
function	O
.	O
No	O
tricuspid	O
insufficiency	O
.	O
No	O
indirect	O
signs	O
of	O
significant	O
pulmonary	O
hypertension	O
PHT	O
.	O
Trivalve	O
aortic	O
valve	O
normal	O
in	O
appearance	O
.	O
The	O
pulmonary	O
valve	O
is	O
not	O
well	O
visualised	O
.	O
The	O
aortic	O
root	O
is	O
of	O
normal	O
size	O
.	O
No	O
signs	O
of	O
increased	O
central	O
venous	O
pressure	O
CVID	O
1	O
.	O
84	O
cm	O
,	O
CVID	O
inspiration	O
0	O
.	O
58	O
cm	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
Blood	O
tests	O
Biochemistry	O
glucose	O
108	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
05	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
CKD	O
EPI	O
76	O
ml	O
min	O
,	O
sodium	O
142	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
1	O
mEq	O
l	O
,	O
chlorine	O
103	O
mEq	O
l	O
,	O
uric	O
acid	O
5	O
,	O
9	O
mg	O
dl	O
,	O
total	O
bilirubin	O
0	O
.	O
86	O
mg	O
dl	O
,	O
AST	O
GOT	O
19	O
U	O
l	O
,	O
ALT	O
GPT	O
13	O
U	O
l	O
,	O
GGT	O
37	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
69	O
U	O
l	O
,	O
NT	O
proBNP	O
497	O
pg	O
ml	O
,	O
total	O
protein	O
6	O
.	O
0	O
g	O
dl	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
162	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
direct	O
51	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
calculated	O
91	O
mg	O
dl	O
,	O
triglycerides	O
99	O
mg	O
dl	O
.	O
Iron	O
profile	O
iron	O
89	O
μg	O
dl	O
,	O
total	O
Fe	O
binding	O
capacity	O
291	O
μg	O
dl	O
,	O
transferrin	O
desaturation	O
index	O
31	O
,	O
ferritin	O
186	O
ng	O
ml	O
,	O
transferrin	O
225	O
mg	O
dl	O
.	O
Haemogram	O
red	O
cells	O
4	O
.	O
07	O
x	O
10	O
6	O
μl	O
,	O
haemoglobin	O
12	O
.	O
2	O
g	O
dl	O
,	O
haematocrit	O
38	O
.	O
0	O
,	O
MCV	O
93	O
fl	O
,	O
MCH	O
30	O
.	O
0	O
pg	O
,	O
leucocytes	O
6	O
.	O
66	O
x	O
10	O
3	O
μl	O
,	O
neutrophils	O
3	O
.	O
53	O
x	O
10	O
3	O
μl	O
,	O
lymphocytes	O
2	O
.	O
00	O
x	O
10	O
3	O
μl	O
,	O
monocytes	O
0	O
.	O
84	O
x	O
10	O
3	O
μl	O
,	O
eosinophils	O
0	O
.	O
25	O
x	O
10	O
3	O
μL	O
,	O
basophils	O
0	O
.	O
04	O
x	O
10	O
3	O
μl	O
,	O
platelets	O
228	O
x	O
10	O
3	O
μl	O
.	O
Thyroid	O
hormones	O
TSH	O
0	O
.	O
53	O
mU	O
l	O
,	O
free	O
T4	O
1	O
.	O
70	O
ng	O
dl	O
.	O
Glycosylated	O
haemoglobin	O
A1c	O
6	O
.	O
4	O
,	O
mean	O
estimated	O
glucose	O
137	O
mg	O
dl	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
remained	O
stable	O
throughout	O
admission	O
.	O
The	O
case	O
was	O
referred	O
to	O
the	O
endocrinometabolic	O
surgery	O
unit	O
,	O
which	O
decided	O
that	O
the	O
patient	O
was	O
not	O
a	O
candidate	O
for	O
bariatric	O
surgery	O
due	O
to	O
a	O
history	O
of	O
prostatic	O
neoplasia	O
under	O
active	O
treatment	O
less	O
than	O
5	O
years	O
.	O
On	O
discharge	O
,	O
his	O
usual	O
treatment	O
was	O
maintained	O
.	O
However	O
,	O
given	O
that	O
during	O
admission	O
he	O
was	O
diagnosed	O
with	O
diabetes	O
mellitus	O
HbA1c	O
6	O
.	O
4	O
,	O
it	O
was	O
decided	O
to	O
start	O
treatment	O
with	O
semaglutide	B-FARMACO
0	O
.	O
5	O
mg	O
,	O
one	O
injection	O
per	O
week	O
for	O
4	O
weeks	O
,	O
subsequently	O
increasing	O
to	O
1	O
mg	O
per	O
week	O
indefinitely	O
,	O
with	O
good	O
tolerance	O
.	O
Treatment	O
was	O
also	O
started	O
with	O
dapagliflozin	B-FARMACO
10	O
mg	O
1	O
tablet	O
per	O
day	O
and	O
eplerenone	B-FARMACO
25	O
mg	O
1	O
tablet	O
per	O
day	O
.	O
Education	O
in	O
heart	O
failure	O
is	O
started	O
.	O
Periodic	O
scheduled	O
admissions	O
were	O
decided	O
the	O
patient	O
lives	O
far	O
from	O
our	O
hospital	O
for	O
treatment	O
with	O
levosimendan	B-FARMACO
under	O
monitoring	O
.	O
During	O
successive	O
admissions	O
,	O
all	O
of	O
which	O
were	O
uneventful	O
,	O
a	O
gradual	O
weight	O
loss	O
was	O
observed	O
as	O
follows	O
in	O
June	O
2020	O
,	O
the	O
patient	O
weighed	O
107	O
kg	O
,	O
in	O
July	O
2020	O
he	O
weighed	O
100	O
kg	O
,	O
and	O
in	O
August	O
2020	O
he	O
weighed	O
94	O
kg	O
.	O
The	O
patient	O
reports	O
a	O
marked	O
improvement	O
of	O
his	O
functional	O
class	O
,	O
almost	O
NYHA	O
class	O
I	O
.	O
Laboratory	O
tests	O
show	O
a	O
reduction	O
in	O
glycosylated	O
haemoglobin	O
HbA1c	O
from	O
6	O
.	O
4	O
in	O
May	O
to	O
5	O
.	O
7	O
at	O
3	O
months	O
.	O
On	O
admission	O
in	O
September	O
2020	O
,	O
the	O
patient	O
weighs	O
89	O
kg	O
and	O
in	O
October	O
2020	O
,	O
the	O
weight	O
is	O
maintained	O
at	O
89	O
kg	O
.	O
Subsequent	O
outpatient	O
follow	O
up	O
is	O
carried	O
out	O
at	O
our	O
hospital	O
.	O
The	O
patient	O
indicates	O
that	O
he	O
has	O
reduced	O
his	O
weight	O
to	O
84	O
kg	O
BMI	O
28	O
.	O
39	O
kg	O
m2	O
,	O
overweight	O
grade	O
2	O
.	O
He	O
reports	O
some	O
fatigue	O
on	O
exertion	O
,	O
but	O
denies	O
dyspnoea	O
.	O
He	O
is	O
able	O
to	O
climb	O
several	O
floors	O
without	O
stopping	O
.	O
He	O
has	O
stopped	O
taking	O
furosemide	O
tablets	O
.	O
Therefore	O
,	O
and	O
as	O
a	O
summary	O
,	O
since	O
the	O
introduction	O
of	O
antidiabetic	O
treatment	O
semaglutide	B-FARMACO
1	O
mg	O
weekly	O
and	O
dapagliflozin	B-FARMACO
10	O
mg	O
daily	O
,	O
the	O
patient	O
has	O
started	O
a	O
progressive	O
and	O
constant	O
weight	O
reduction	O
until	O
reaching	O
a	O
weight	O
of	O
84	O
kg	O
,	O
managing	O
to	O
maintain	O
the	O
loss	O
over	O
time	O
.	O
From	O
an	O
initial	O
weight	O
of	O
112	O
kg	O
and	O
a	O
BMI	O
of	O
37	O
.	O
86	O
kg	O
m2	O
grade	O
2	O
obesity	O
,	O
the	O
patient	O
reduced	O
his	O
weight	O
by	O
a	O
total	O
of	O
28	O
kg	O
in	O
approximately	O
6	O
months	O
,	O
reaching	O
a	O
BMI	O
of	O
28	O
.	O
39	O
kg	O
m2	O
grade	O
2	O
overweight	O
.	O
At	O
the	O
same	O
time	O
,	O
the	O
patient	O
reports	O
progressive	O
improvement	O
in	O
symptoms	O
and	O
functional	O
class	O
.	O
Initially	O
,	O
in	O
our	O
first	O
assessment	O
,	O
he	O
was	O
considerably	O
limited	O
by	O
his	O
heart	O
disease	O
,	O
with	O
NYHA	O
functional	O
class	O
III	O
,	O
and	O
was	O
practically	O
asymptomatic	O
on	O
discharge	O
from	O
our	O
centre	O
NYHA	O
class	O
I	O
.	O
As	O
a	O
result	O
,	O
the	O
patient	O
was	O
no	O
longer	O
indicated	O
for	O
intervention	O
by	O
the	O
advanced	O
heart	O
failure	O
and	O
heart	O
transplant	O
unit	O
,	O
and	O
was	O
therefore	O
followed	O
up	O
by	O
the	O
cardiology	O
department	O
of	O
his	O
referral	O
hospital	O
.	O
DIAGNOSIS	O
Heart	O
failure	O
with	O
severely	O
reduced	O
left	O
ventricular	O
ejection	O
fraction	O
.	O
Non	O
ischaemic	O
dilated	O
cardiomyopathy	O
.	O
Other	O
diagnoses	O
Obesity	O
grade	O
2	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
.	O

BACKGROUND	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXPLORATION	O
60	O
year	O
old	O
male	O
.	O
Personal	O
history	O
No	O
known	O
adverse	O
drug	O
reactions	O
.	O
Cardiovascular	O
risk	O
factors	O
ex	O
smoker	O
pack	O
year	O
index	O
60	O
,	O
risky	O
alcoholism	O
,	O
obesity	O
.	O
No	O
previous	O
cardiological	O
history	O
or	O
family	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
Usual	O
treatment	O
none	O
.	O
Current	O
illness	O
She	O
attended	O
the	O
emergency	O
department	O
due	O
to	O
deterioration	O
of	O
functional	O
class	O
of	O
about	O
2	O
weeks	O
of	O
evolution	O
,	O
presenting	O
progressive	O
dyspnoea	O
until	O
minimal	O
effort	O
.	O
Accompanied	O
by	O
orthopnoea	O
and	O
dry	O
cough	O
.	O
No	O
peripheral	O
oedema	O
.	O
No	O
syncope	O
,	O
chest	O
pain	O
or	O
palpitations	O
.	O
No	O
other	O
symptoms	O
of	O
cardiovascular	O
relevance	O
.	O
Denies	O
consumption	O
of	O
toxic	O
substances	O
apart	O
from	O
alcohol	O
2	O
3	O
beers	O
a	O
day	O
.	O
Afebrile	O
and	O
without	O
infectious	O
semiology	O
.	O
Physical	O
examination	O
Vital	O
signs	O
blood	O
pressure	O
BP	O
140	O
98	O
mmHg	O
,	O
heart	O
rate	O
HR	O
90	O
bpm	O
,	O
peripheral	O
oxygen	O
saturation	O
91	O
breathing	O
ambient	O
air	O
.	O
Weight	O
103	O
97	O
kg	O
.	O
Body	O
mass	O
index	O
BMI	O
at	O
discharge	O
31	O
.	O
7	O
kg	O
m2	O
.	O
Mild	O
tachypnoea	O
with	O
decubitus	O
intolerance	O
.	O
Jugular	O
venous	O
pressure	O
elevated	O
up	O
to	O
the	O
middle	O
third	O
of	O
the	O
neck	O
.	O
Rhythmic	O
cardiac	O
auscultation	O
without	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
with	O
hypophonesis	O
in	O
both	O
lung	O
bases	O
with	O
crackles	O
up	O
to	O
the	O
middle	O
third	O
bilaterally	O
.	O
Lower	O
limbs	O
with	O
pretibial	O
oedema	O
.	O
Peripheral	O
pulses	O
present	O
and	O
symmetrical	O
.	O
Well	O
perfused	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
90	O
beats	O
per	O
minute	O
,	O
PR	O
interval	O
160	O
ms	O
,	O
narrow	O
QRS	O
with	O
normal	O
positioned	O
axis	O
,	O
adequate	O
R	O
wave	O
transition	O
in	O
precordial	O
leads	O
,	O
negative	O
T	O
waves	O
in	O
I	O
,	O
aVL	O
,	O
V5	O
,	O
V6	O
.	O
Blood	O
tests	O
haemoglobin	O
15	O
.	O
9	O
g	O
dl	O
with	O
normal	O
corpuscular	O
indices	O
,	O
leucocytes	O
9	O
,	O
900	O
cells	O
microL	O
with	O
normal	O
formula	O
,	O
platelets	O
197	O
.	O
000	O
cells	O
microL	O
;	O
haemostasis	O
INR	O
1	O
.	O
26	O
,	O
rAPTT	O
1	O
.	O
02	O
;	O
venous	O
blood	O
gases	O
pH	O
7	O
.	O
34	O
,	O
bicarbonate	O
31	O
mmol	O
l	O
,	O
pCO2	O
45	O
mmHg	O
,	O
lactate	O
2	O
.	O
5	O
mmol	O
l	O
;	O
biochemistry	O
glycaemia	O
277	O
mg	O
dl	O
,	O
ALT	O
48	O
U	O
l	O
,	O
GGT	O
201	O
U	O
l	O
,	O
CL	O
79	O
U	O
l	O
,	O
creatinine	O
0	O
.	O
94	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
estimated	O
by	O
MDRD	O
4	O
60	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
sodium	O
138	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
2	O
mEq	O
l	O
,	O
CRP	O
0	O
.	O
4	O
g	O
dl	O
.	O
Cardiac	O
markers	O
NT	O
proBNP	O
3015	O
400	O
ng	O
l	O
,	O
ultrasensitive	O
troponin	O
I	O
18	O
ng	O
l	O
.	O
Regular	O
blood	O
tests	O
glomerular	O
filtration	O
rate	O
estimated	O
by	O
cystatin	O
CKD	O
EPI	O
78	O
ml	O
min	O
1	O
.	O
73	O
m2	O
;	O
lipid	O
profile	O
triglycerides	O
147	O
mg	O
dl	O
,	O
total	O
cholesterol	O
220	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
35	O
mg	O
dl	O
,	O
LDL	O
156	O
mg	O
dl	O
;	O
iron	O
profile	O
ferritin	O
490	O
ng	O
ml	O
,	O
TSI	O
21	O
;	O
thyroid	O
profile	O
TSH	O
3	O
.	O
2	O
U	O
l	O
;	O
HbA1c	O
11	O
.	O
1	O
.	O
Microbiology	O
SARS	O
CoV	O
2	O
PCR	O
negative	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
poorly	O
inspired	O
study	O
.	O
Increased	O
cardiothoracic	O
index	O
.	O
Increase	O
of	O
the	O
bilateral	O
perihilar	O
vascular	O
network	O
,	O
pinching	O
of	O
both	O
lateral	O
costophrenic	O
sinuses	O
,	O
compatible	O
with	O
heart	O
failure	O
component	O
.	O
Increased	O
density	O
in	O
both	O
lung	O
bases	O
,	O
which	O
seems	O
to	O
be	O
due	O
to	O
hypoventilation	O
changes	O
.	O
Transthoracic	O
echocardiogram	O
videos	O
1	O
4	O
moderately	O
dilated	O
left	O
ventricle	O
,	O
with	O
normal	O
wall	O
thickness	O
.	O
Akinesia	O
of	O
inferior	O
face	O
,	O
inferior	O
septum	O
and	O
inferior	O
lateral	O
face	O
.	O
Severe	O
hypokinesia	O
of	O
the	O
rest	O
.	O
Severely	O
depressed	O
global	O
systolic	O
function	O
LVEF	O
25	O
by	O
visual	O
estimation	O
.	O
Pseudonormalised	O
filling	O
pattern	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
.	O
Non	O
dilated	O
right	O
atrium	O
.	O
Non	O
dilated	O
right	O
ventricle	O
,	O
with	O
normal	O
global	O
systolic	O
function	O
.	O
Mitral	O
valve	O
with	O
apicalisation	O
of	O
the	O
coaptation	O
point	O
of	O
both	O
leaflets	O
,	O
mild	O
moderate	O
insufficiency	O
II	O
IV	O
.	O
Aortic	O
valve	O
morphologically	O
and	O
functionally	O
normal	O
.	O
Tricuspid	O
valve	O
morphologically	O
normal	O
.	O
Mild	O
insufficiency	O
.	O
RV	O
AD	O
gradient	O
26	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
poorly	O
visualised	O
.	O
No	O
pericardial	O
effusion	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
No	O
evidence	O
of	O
coarctation	O
.	O
Coronary	O
angiography	O
videos	O
5	O
6	O
access	O
via	O
right	O
radial	O
artery	O
,	O
contrast	O
70	O
cc	O
.	O
Left	O
coronary	O
trunk	O
without	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
of	O
good	O
development	O
and	O
calibre	O
with	O
diffuse	O
mild	O
atheromatosis	O
mild	O
plaque	O
in	O
the	O
middle	O
segment	O
of	O
30	O
.	O
Early	O
diagonal	O
branch	O
of	O
moderate	O
calibre	O
but	O
without	O
significant	O
lesions	O
.	O
Circumflex	O
of	O
good	O
development	O
and	O
calibre	O
with	O
diffuse	O
mild	O
atheromatosis	O
.	O
There	O
are	O
two	O
marginal	O
branches	O
first	O
obtuse	O
marginal	O
branch	O
with	O
moderate	O
plaque	O
at	O
the	O
origin	O
of	O
a	O
subbranch	O
,	O
the	O
obtuse	O
marginal	O
branch	O
being	O
of	O
borderline	O
calibre	O
at	O
this	O
level	O
.	O
Dominant	O
right	O
coronary	O
artery	O
,	O
of	O
good	O
development	O
and	O
calibre	O
with	O
diffuse	O
mild	O
atheromatosis	O
without	O
significant	O
lesions	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
for	O
a	O
first	O
episode	O
of	O
decompensation	O
of	O
heart	O
failure	O
,	O
with	O
predominantly	O
pulmonary	O
congestion	O
.	O
He	O
remained	O
haemodynamically	O
stable	O
at	O
all	O
times	O
,	O
with	O
no	O
evidence	O
of	O
anterograde	O
heart	O
failure	O
.	O
Admitted	O
to	O
the	O
conventional	O
hospital	O
ward	O
in	O
respiratory	O
failure	O
requiring	O
support	O
with	O
oxygen	O
therapy	O
using	O
low	O
flow	O
nasal	O
cannulas	O
and	O
diuretic	O
treatment	O
with	O
intravenous	O
furosemide	B-FARMACO
.	O
Good	O
evolution	O
with	O
adequate	O
diuretic	O
response	O
and	O
progressive	O
decongestion	O
,	O
with	O
weight	O
loss	O
of	O
up	O
to	O
6	O
kg	O
.	O
Once	O
close	O
to	O
euvolemia	O
,	O
prognostically	O
beneficial	O
treatment	O
was	O
started	O
with	O
beta	O
blockers	O
,	O
ARNI	O
and	O
antialdosteronics	O
with	O
adequate	O
tolerance	O
.	O
The	O
discharge	O
medication	O
included	O
bisoprolol	B-FARMACO
5	O
mg	O
24h	O
,	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
24	O
26	O
mg	O
12h	O
,	O
eplerenone	B-FARMACO
50	O
mg	O
24h	O
.	O
In	O
addition	O
,	O
due	O
to	O
the	O
presence	O
of	O
coronary	O
atheromatosis	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
24	O
h	O
and	O
atorvastatin	B-FARMACO
40	O
mg	O
24	O
h	O
were	O
also	O
started	O
.	O
During	O
the	O
analytical	O
studies	O
on	O
admission	O
,	O
diagnostic	O
criteria	O
for	O
type	O
2	O
diabetes	O
mellitus	O
were	O
met	O
due	O
to	O
altered	O
baseline	O
glycaemia	O
and	O
elevated	O
HbA1c	O
levels	O
,	O
and	O
so	O
,	O
upon	O
debut	O
with	O
HbA1c	O
10	O
,	O
insulinisation	O
was	O
started	O
together	O
with	O
oral	O
antidiabetic	O
drugs	O
appropriate	O
to	O
the	O
patient	O
's	O
clinical	O
profile	O
established	O
cardiovascular	O
disease	O
,	O
obesity	O
with	O
BMI	O
30	O
kg	O
m2	O
.	O
Thus	O
,	O
diabetes	O
treatment	O
at	O
discharge	O
consisted	O
of	O
insulin	B-FARMACO
toujeo	I-FARMACO
24	O
IU	O
24	O
h	O
,	O
metformin	B-FARMACO
dapagliflozin	I-FARMACO
1000	O
5	O
mg	O
0	O
.	O
5	O
comp	O
12	O
h	O
the	O
first	O
week	O
and	O
then	O
1	O
comp	O
24	O
h	O
and	O
subcutaneous	O
semaglutide	B-FARMACO
0	O
.	O
25	O
mg	O
weekly	O
for	O
the	O
first	O
4	O
weeks	O
and	O
then	O
0	O
.	O
5	O
mg	O
weekly	O
.	O
The	O
patient	O
is	O
being	O
followed	O
up	O
in	O
heart	O
failure	O
and	O
endocrinology	O
consultations	O
,	O
with	O
no	O
new	O
admissions	O
for	O
heart	O
failure	O
.	O
Significant	O
improvement	O
in	O
LVEF	O
up	O
to	O
35	O
and	O
NT	O
proBNP	O
levels	O
400	O
150	O
ng	O
l	O
was	O
observed	O
after	O
6	O
months	O
of	O
treatment	O
,	O
as	O
well	O
as	O
a	O
decrease	O
in	O
HbA1c	O
levels	O
11	O
.	O
1	O
8	O
.	O
5	O
and	O
weight	O
during	O
follow	O
up	O
currently	O
91	O
kg	O
and	O
BMI	O
29	O
.	O
7	O
kg	O
m2	O
.	O
DIAGNOSIS	O
First	O
episode	O
of	O
decompensation	O
of	O
congestive	O
heart	O
failure	O
.	O
Dilated	O
cardiomyopathy	O
of	O
non	O
ischaemic	O
aetiology	O
with	O
severely	O
depressed	O
left	O
ventricular	O
systolic	O
function	O
.	O
Newly	O
diagnosed	O
type	O
2	O
diabetes	O
mellitus	O
.	O
Obesity	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
37	O
year	O
old	O
woman	O
with	O
the	O
following	O
personal	O
history	O
No	O
adverse	O
drug	O
reactions	O
.	O
She	O
denies	O
drug	O
use	O
.	O
No	O
known	O
cardiovascular	O
risk	O
factors	O
.	O
Bronchial	O
asthma	O
without	O
chronic	O
treatment	O
.	O
Gynaecological	O
history	O
two	O
full	O
term	O
pregnancies	O
,	O
vaginal	O
delivery	O
.	O
No	O
usual	O
treatment	O
.	O
Current	O
history	O
A	O
37	O
year	O
old	O
woman	O
with	O
the	O
aforementioned	O
history	O
presented	O
at	O
rest	O
with	O
oppressive	O
non	O
radiating	O
central	O
thoracic	O
pain	O
with	O
vegetative	O
crust	O
.	O
She	O
attended	O
her	O
health	O
centre	O
for	O
this	O
reason	O
,	O
where	O
an	O
electrocardiogram	O
ECG	O
was	O
performed	O
with	O
pathological	O
alterations	O
,	O
so	O
it	O
was	O
decided	O
to	O
administer	O
a	O
loading	O
dose	O
of	O
250	O
mg	O
of	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
and	O
300	O
mg	O
of	O
clopidogrel	B-FARMACO
,	O
sublingual	O
nitroglycerine	B-FARMACO
and	O
contact	O
was	O
made	O
with	O
the	O
critical	O
care	O
and	O
emergency	O
department	O
DCCU	O
for	O
transfer	O
to	O
her	O
reference	O
hospital	O
.	O
Physical	O
examination	O
Acceptable	O
general	O
condition	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Eupneic	O
at	O
rest	O
.	O
Normal	O
weight	O
.	O
Blood	O
pressure	O
BP	O
95	O
50	O
mmHg	O
,	O
heart	O
rate	O
HR	O
80	O
bpm	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
at	O
a	O
good	O
frequency	O
,	O
no	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
pathological	O
sounds	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
masses	O
or	O
megaliths	O
are	O
palpable	O
.	O
Hydro	O
aerial	O
sounds	O
present	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
limbs	O
or	O
sloping	O
areas	O
.	O
Radial	O
,	O
femoral	O
and	O
pedal	O
pulses	O
were	O
preserved	O
bilaterally	O
.	O
COMPLEMENTARY	O
TESTS	O
Initial	O
ECG	O
sinus	O
tachycardia	O
at	O
115	O
bpm	O
competing	O
with	O
accelerated	O
idioventricular	O
rhythm	O
RIVA	O
.	O
In	O
the	O
sinus	O
beats	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
ST	O
segment	O
elevation	O
of	O
2	O
mm	O
in	O
V1	O
and	O
aVR	O
,	O
and	O
1	O
mm	O
in	O
V2	O
3	O
,	O
with	O
ST	O
descent	O
of	O
1	O
2	O
mm	O
in	O
inferior	O
face	O
and	O
from	O
V4	O
to	O
V6	O
.	O
Blood	O
tests	O
on	O
admission	O
haemoglobin	O
13	O
.	O
5	O
g	O
dl	O
,	O
haematocrit	O
40	O
,	O
leukocytes	O
14	O
,	O
000	O
μl	O
with	O
neutrophilia	O
12	O
,	O
000	O
μl	O
,	O
platelets	O
222	O
,	O
000	O
μl	O
.	O
Coagulation	O
INR	O
1	O
.	O
1	O
,	O
TTPa	O
28	O
sec	O
.	O
Biochemistry	O
urea	O
22	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
66	O
mg	O
dl	O
,	O
sodium	O
135	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
87	O
mEq	O
l	O
.	O
CPK	O
total	O
MB	O
252	O
43	O
2	O
.	O
256	O
264	O
U	O
l	O
.	O
Initial	O
high	O
sensitivity	O
Troponin	O
T	O
176	O
peak	O
2	O
,	O
910	O
ng	O
l	O
normal	O
13	O
.	O
9	O
ng	O
l	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
113	O
mg	O
dl	O
,	O
triglycerides	O
81	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
54	O
mg	O
dl	O
,	O
LDL	O
calculated	O
43	O
mg	O
dl	O
,	O
VLDL	O
cholesterol	O
16	O
mg	O
dl	O
.	O
Echocardioscopy	O
on	O
arrival	O
at	O
the	O
emergency	O
department	O
non	O
dilated	O
left	O
ventricle	O
with	O
normal	O
wall	O
thickness	O
,	O
severe	O
hypokinesia	O
of	O
the	O
apical	O
cap	O
and	O
hypokinesia	O
of	O
apical	O
segments	O
and	O
middle	O
segment	O
of	O
inferolateral	O
,	O
lateral	O
and	O
anterior	O
faces	O
,	O
with	O
hypercontractility	O
of	O
the	O
remaining	O
segments	O
.	O
Moderate	O
severe	O
left	O
ventricular	O
dysfunction	O
,	O
estimated	O
LVEF	O
30	O
35	O
.	O
Right	O
chambers	O
of	O
preserved	O
size	O
with	O
preserved	O
function	O
.	O
Non	O
dilated	O
atria	O
.	O
Mild	O
moderate	O
mitral	O
insufficiency	O
by	O
colour	O
Doppler	O
.	O
No	O
pericardial	O
effusion	O
.	O
Inferior	O
vena	O
cava	O
16	O
mm	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
Urgent	O
diagnostic	O
coronary	O
angiography	O
video	O
1	O
significant	O
stenosis	O
of	O
the	O
left	O
coronary	O
trunk	O
due	O
to	O
probable	O
intramural	O
haematoma	O
causing	O
extrinsic	O
compression	O
of	O
the	O
lumen	O
,	O
without	O
significant	O
angiographic	O
lesions	O
in	O
the	O
rest	O
of	O
the	O
coronary	O
tree	O
.	O
Urgent	O
CT	O
angiography	O
thoracoabdominal	O
aorta	O
of	O
normal	O
calibre	O
,	O
with	O
no	O
signs	O
of	O
acute	O
pathology	O
.	O
No	O
images	O
compatible	O
with	O
acute	O
aortic	O
syndrome	O
.	O
Bilateral	O
pulmonary	O
alveolar	O
lesions	O
distributed	O
throughout	O
the	O
upper	O
lobes	O
and	O
apical	O
segment	O
of	O
the	O
lower	O
lobes	O
,	O
suggesting	O
an	O
aspiration	O
aetiology	O
.	O
Nutcracker	O
's	O
phenomenon	O
with	O
varicose	O
dilatation	O
of	O
the	O
left	O
gonadal	O
vein	O
due	O
to	O
stenosis	O
of	O
the	O
left	O
renal	O
vein	O
in	O
the	O
aortomesenteric	O
clamp	O
.	O
Bilateral	O
adnexal	O
cysts	O
,	O
functional	O
type	O
and	O
free	O
fluid	O
in	O
Douglas	O
recess	O
.	O
No	O
other	O
findings	O
of	O
interest	O
.	O
Coronary	O
revascularisation	O
coronary	O
angiography	O
the	O
left	O
coronary	O
trunk	O
was	O
probed	O
with	O
an	O
EBU	O
3	O
.	O
5	O
guide	O
catheter	O
,	O
a	O
guide	O
was	O
passed	O
to	O
the	O
distal	O
vessel	O
of	O
the	O
anterior	O
descending	O
artery	O
and	O
contrast	O
injection	O
was	O
performed	O
,	O
proving	O
spiroid	O
dissection	O
of	O
the	O
left	O
coronary	O
trunk	O
with	O
preserved	O
distal	O
flow	O
,	O
Onyx	O
Resolute	O
4	O
x	O
26	O
mm	O
drug	O
eluting	O
stent	O
was	O
implanted	O
at	O
16	O
atm	O
in	O
the	O
trunk	O
towards	O
the	O
anterior	O
descending	O
artery	O
with	O
a	O
good	O
final	O
angiographic	O
result	O
,	O
without	O
residual	O
dissection	O
.	O
Post	O
catheterisation	O
ECG	O
sinus	O
tachycardia	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
,	O
axis	O
at	O
30o	O
with	O
QS	O
of	O
V1	O
V3	O
,	O
QR	O
in	O
aVL	O
.	O
Persistent	O
ST	O
segment	O
elevation	O
in	O
aVL	O
,	O
V1	O
3	O
,	O
ST	O
segment	O
depression	O
of	O
1	O
mm	O
in	O
inferior	O
leads	O
and	O
negative	O
T	O
in	O
aVL	O
.	O
Regulated	O
transthoracic	O
echocardiography	O
prior	O
to	O
discharge	O
left	O
ventricle	O
of	O
normal	O
dimensions	O
with	O
normal	O
wall	O
thickness	O
.	O
Mild	O
global	O
hypokinesia	O
more	O
accentuated	O
in	O
mid	O
apical	O
segments	O
of	O
inferolateral	O
and	O
lateral	O
region	O
.	O
Mild	O
systolic	O
dysfunction	O
estimated	O
LVEF	O
48	O
.	O
Left	O
atrium	O
of	O
normal	O
dimensions	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Right	O
chambers	O
not	O
dilated	O
.	O
Right	O
ventricle	O
with	O
normal	O
contractility	O
.	O
No	O
organic	O
valvular	O
pathology	O
.	O
No	O
pericardial	O
effusion	O
.	O
Inferior	O
vena	O
cava	O
of	O
normal	O
calibre	O
.	O
Left	O
ventricular	O
filling	O
with	O
restrictive	O
transmitral	O
flow	O
pattern	O
.	O
Flow	O
at	O
the	O
level	O
of	O
the	O
pulmonary	O
veins	O
,	O
with	O
diastolic	O
predominance	O
.	O
No	O
indirect	O
signs	O
of	O
significant	O
pulmonary	O
hypertension	O
.	O
Normal	O
antegrade	O
flow	O
.	O
Mild	O
degenerative	O
mitral	O
regurgitation	O
.	O
ECG	O
at	O
discharge	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
with	O
QS	O
in	O
V1	O
V3	O
.	O
Millimetre	O
ST	O
subleveling	O
in	O
V3	O
.	O
Negative	O
T	O
in	O
DI	O
,	O
aVL	O
and	O
V1	O
V5	O
.	O
Blood	O
tests	O
at	O
discharge	O
Haemogram	O
haemoglobin	O
12	O
.	O
8	O
g	O
dl	O
,	O
leucocytes	O
8	O
,	O
940	O
μl	O
with	O
neutrophils	O
6	O
,	O
610	O
μl	O
,	O
platelets	O
158	O
,	O
000	O
μl	O
.	O
Coagulation	O
normal	O
.	O
INR	O
1	O
.	O
Biochemistry	O
glucose	O
82	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
60	O
mg	O
dl	O
,	O
potassium	O
3	O
.	O
28	O
mEq	O
l	O
,	O
CRP	O
47	O
.	O
62	O
mg	O
l	O
,	O
total	O
CPK	O
188	O
U	O
l	O
,	O
troponin	O
T	O
at	O
discharge	O
658	O
ng	O
l	O
,	O
ProBNP	O
5	O
,	O
147	O
pg	O
ml	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
the	O
patient	O
was	O
hypotensive	O
blood	O
pressure	O
95	O
50	O
mmHg	O
,	O
heart	O
rate	O
80	O
bpm	O
,	O
saturating	O
at	O
97	O
with	O
nasal	O
spectacles	O
at	O
2	O
litres	O
minute	O
and	O
with	O
persistent	O
chest	O
pain	O
.	O
Urgent	O
echocardiography	O
showed	O
moderate	O
to	O
severe	O
left	O
ventricular	O
systolic	O
dysfunction	O
and	O
segmental	O
alterations	O
,	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
haemodynamics	O
department	O
for	O
urgent	O
coronary	O
angiography	O
.	O
The	O
coronary	O
angiography	O
showed	O
significant	O
stenosis	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
due	O
to	O
a	O
probable	O
haematoma	O
causing	O
extrinsic	O
compression	O
,	O
with	O
no	O
significant	O
angiographic	O
lesions	O
in	O
the	O
rest	O
of	O
the	O
coronary	O
tree	O
.	O
Before	O
proceeding	O
to	O
revascularisation	O
,	O
acute	O
aortic	O
syndrome	O
was	O
ruled	O
out	O
by	O
urgent	O
aortic	O
CT	O
angiography	O
.	O
After	O
this	O
,	O
percutaneous	O
revascularisation	O
was	O
chosen	O
,	O
so	O
coronary	O
angiography	O
was	O
repeated	O
in	O
the	O
following	O
hours	O
and	O
a	O
stent	O
was	O
implanted	O
in	O
the	O
left	O
coronary	O
artery	O
towards	O
the	O
anterior	O
descending	O
coronary	O
artery	O
with	O
good	O
angiographic	O
results	O
.	O
During	O
the	O
procedure	O
,	O
he	O
presented	O
hypotension	O
and	O
sinus	O
tachycardia	O
requiring	O
continuous	O
perfusion	O
of	O
noradrenaline	B-FARMACO
0	O
.	O
31	O
microg	O
kg	O
minute	O
.	O
She	O
returned	O
to	O
the	O
coronary	O
unit	O
asymptomatic	O
,	O
maintaining	O
the	O
noradrenaline	B-FARMACO
perfusion	O
which	O
could	O
be	O
progressively	O
withdrawn	O
in	O
the	O
first	O
48	O
hours	O
after	O
revascularisation	O
.	O
After	O
a	O
favourable	O
evolution	O
,	O
he	O
was	O
transferred	O
to	O
the	O
hospital	O
ward	O
.	O
Initially	O
,	O
double	O
antiplatelet	O
therapy	O
was	O
maintained	O
with	O
ASA	B-FARMACO
100	O
mg	O
and	O
clopidogrel	B-FARMACO
75	O
mg	O
;	O
however	O
,	O
given	O
the	O
high	O
thrombotic	O
risk	O
due	O
to	O
stenting	O
in	O
the	O
left	O
coronary	O
trunk	O
,	O
it	O
was	O
decided	O
to	O
switch	O
to	O
ticagrelor	O
48	O
hours	O
after	O
catheterisation	O
.	O
In	O
the	O
post	O
revascularisation	O
echocardiographic	O
control	O
,	O
severe	O
left	O
ventricular	O
systolic	O
dysfunction	O
persisted	O
,	O
so	O
treatment	O
for	O
heart	O
failure	O
was	O
started	O
with	O
good	O
tolerance	O
,	O
presenting	O
mild	O
ventricular	O
dysfunction	O
at	O
hospital	O
discharge	O
.	O
After	O
hospital	O
discharge	O
,	O
she	O
was	O
included	O
in	O
the	O
cardiac	O
rehabilitation	O
programme	O
,	O
which	O
she	O
completed	O
without	O
incident	O
.	O
She	O
is	O
currently	O
being	O
monitored	O
in	O
cardiology	O
consultations	O
and	O
has	O
remained	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
.	O
Follow	O
up	O
echocardiography	O
showed	O
that	O
left	O
ventricular	O
systolic	O
function	O
had	O
recovered	O
and	O
was	O
preserved	O
one	O
year	O
after	O
the	O
event	O
.	O
Treatment	O
at	O
discharge	O
ASA	B-FARMACO
100	O
mg	O
every	O
24	O
hours	O
,	O
ticagrelor	O
90	O
mg	O
every	O
12	O
hours	O
for	O
one	O
year	O
,	O
bisoprolol	B-FARMACO
1	O
.	O
25	O
mg	O
every	O
24	O
hours	O
,	O
ivabradine	B-FARMACO
5	O
mg	O
every	O
12	O
hours	O
,	O
ramipril	B-FARMACO
1	O
.	O
25	O
mg	O
every	O
24	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
every	O
24	O
hours	O
.	O
DIAGNOSIS	O
Anteroseptal	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
STEMI	O
.	O
Spontaneous	O
coronary	O
artery	O
dissection	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
treated	O
with	O
drug	O
eluting	O
stent	O
in	O
the	O
left	O
anterior	O
descending	O
coronary	O
artery	O
.	O
Acute	O
septo	O
apical	O
myocardial	O
infarction	O
.	O
Severe	O
left	O
ventricular	O
systolic	O
dysfunction	O
in	O
acute	O
phase	O
with	O
subsequent	O
recovery	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
dyslipidaemia	O
,	O
type	O
2	O
diabetes	O
mellitus	O
,	O
arterial	O
hypertension	O
.	O
Non	O
ischemic	O
dilated	O
cardiomyopathy	O
,	O
with	O
coronary	O
angiography	O
in	O
2019	O
without	O
significant	O
lesions	O
.	O
At	O
last	O
check	O
up	O
,	O
patient	O
stable	O
in	O
NYHA	O
II	O
.	O
In	O
last	O
echocardiographic	O
control	O
left	O
ventricle	O
LV	O
with	O
slightly	O
increased	O
volumes	O
and	O
moderate	O
depression	O
of	O
global	O
systolic	O
function	O
LVEF	O
37	O
with	O
abnormal	O
septoapical	O
movement	O
and	O
akinesia	O
of	O
all	O
mid	O
apical	O
segments	O
.	O
Moderate	O
mitral	O
regurgitation	O
.	O
Mild	O
aortic	O
insufficiency	O
.	O
Right	O
ventricle	O
RV	O
with	O
increased	O
diameters	O
and	O
preserved	O
global	O
systolic	O
function	O
.	O
Moderate	O
tricuspid	O
insufficiency	O
allowing	O
an	O
estimated	O
PAPS	O
of	O
approximately	O
45	O
mmHg	O
mild	O
PH	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
AF	O
.	O
Other	O
antecedents	O
mild	O
chronic	O
obstructive	O
pulmonary	O
disease	O
COPD	O
.	O
Subclinical	O
hypothyroidism	O
.	O
Surgical	O
interventions	O
appendectomy	O
and	O
tonsillectomy	O
.	O
Treatment	O
eutirox	B-FARMACO
50	O
mcg	O
24	O
hours	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
24	O
hours	O
,	O
pantoprazole	B-FARMACO
40	O
mg	O
24	O
hours	O
,	O
salbutamol	B-FARMACO
on	O
demand	O
,	O
zolpidem	B-FARMACO
10	O
mg	O
24	O
hours	O
,	O
nebivolol	B-FARMACO
2	O
.	O
5	O
mg	O
12	O
hours	O
,	O
apixaban	B-FARMACO
5	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
,	O
eplerenone	B-FARMACO
50	O
mg	O
24	O
hours	O
,	O
seguril	B-FARMACO
40	O
mg	O
24	O
hours	O
,	O
dapagliflozin	B-FARMACO
10	O
mg	O
24	O
hours	O
,	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
49	O
51	O
mg	O
12	O
hours	O
.	O
Present	O
illness	O
A	O
76	O
year	O
old	O
man	O
with	O
the	O
above	O
described	O
history	O
presented	O
to	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
with	O
decompensated	O
heart	O
failure	O
.	O
He	O
presented	O
with	O
a	O
picture	O
of	O
approximately	O
one	O
month	O
's	O
evolution	O
consisting	O
of	O
worsening	O
functional	O
class	O
with	O
progressive	O
dyspnoea	O
until	O
he	O
became	O
resting	O
,	O
accompanied	O
by	O
orthopnoea	O
on	O
3	O
pillows	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
No	O
decrease	O
in	O
the	O
diuresis	O
rhythm	O
.	O
He	O
reported	O
swelling	O
of	O
the	O
lower	O
limbs	O
and	O
increased	O
abdominal	O
perimeter	O
.	O
No	O
chest	O
pain	O
or	O
palpitations	O
.	O
No	O
fever	O
or	O
infectious	O
semiology	O
by	O
apparatus	O
.	O
He	O
attended	O
the	O
hospital	O
out	O
of	O
appointment	O
for	O
outpatient	O
cardiology	O
consultations	O
,	O
from	O
where	O
he	O
was	O
referred	O
for	O
admission	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
145	O
76	O
,	O
heart	O
rate	O
HR	O
77	O
bpm	O
,	O
oxygen	O
saturation	O
97	O
room	O
air	O
,	O
temperature	O
36	O
.	O
3	O
oC	O
.	O
Good	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
.	O
Normohydrated	O
and	O
normal	O
colour	O
.	O
Eupneic	O
at	O
rest	O
.	O
Abdomen	O
distended	O
,	O
matt	O
on	O
percussion	O
with	O
moderate	O
ascites	O
,	O
pain	O
on	O
palpation	O
in	O
the	O
left	O
hypochondrium	O
,	O
no	O
masses	O
or	O
megaliths	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
heart	O
sounds	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
with	O
bibasal	O
crackles	O
.	O
Lower	O
limbs	O
tibiomalleolar	O
oedema	O
,	O
increased	O
jugular	O
venous	O
pressure	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
On	O
admission	O
sinus	O
bradycardia	O
at	O
50	O
bpm	O
.	O
Elongated	O
PR	O
360	O
ms	O
.	O
Wide	O
QRS	O
160	O
ms	O
,	O
with	O
morphology	O
of	O
non	O
specific	O
intraventricular	O
conduction	O
disorder	O
.	O
On	O
discharge	O
paced	O
rhythm	O
with	O
CRT	O
at	O
60	O
bpm	O
.	O
PR	O
160ms	O
.	O
Wide	O
QRS	O
130	O
ms	O
with	O
morphology	O
of	O
complete	O
right	O
bundle	O
branch	O
block	O
.	O
Chest	O
X	O
ray	O
admission	O
centred	O
cardiomediastinal	O
silhouette	O
,	O
cardiomegaly	O
,	O
vascular	O
redistribution	O
,	O
bilateral	O
pleural	O
effusion	O
.	O
Laboratory	O
tests	O
admission	O
CBC	O
red	O
cells	O
4	O
.	O
4	O
10	O
12	O
l	O
,	O
haemoglobin	O
12	O
.	O
3	O
g	O
dl	O
,	O
haematocrit	O
37	O
.	O
6	O
,	O
MCV	O
85	O
.	O
5	O
fl	O
,	O
MCH	O
28	O
pg	O
,	O
MCHC	O
32	O
.	O
8	O
g	O
dl	O
,	O
RDW	O
15	O
.	O
5	O
.	O
Leukocytes	O
6	O
.	O
8	O
10	O
9	O
l	O
,	O
neutrophils	O
62	O
.	O
8	O
,	O
lymphocytes	O
23	O
,	O
monocytes	O
11	O
.	O
1	O
,	O
eosinophils	O
2	O
.	O
1	O
,	O
basophils	O
1	O
,	O
neutrophils	O
4	O
,	O
310	O
9	O
l	O
.	O
Lymphocytes	O
1	O
.	O
6	O
10	O
9	O
l	O
,	O
monocytes	O
0	O
.	O
8	O
10	O
9	O
l	O
,	O
eosinophils	O
0	O
.	O
1	O
10	O
9	O
l	O
,	O
basophils	O
0	O
.	O
1	O
10	O
9	O
l	O
,	O
platelets	O
90	O
10	O
9	O
l	O
,	O
PWV	O
10	O
.	O
9	O
fl	O
.	O
Coagulation	O
prothrombin	O
time	O
PT	O
21	O
.	O
7	O
s	O
,	O
Quick	O
's	O
index	O
40	O
,	O
INR	O
1	O
.	O
86	O
,	O
aPTT	O
34	O
.	O
2	O
s	O
,	O
ratio	O
aPTT	O
1	O
.	O
15	O
,	O
derived	O
fibrinogen	O
386	O
mg	O
dl	O
.	O
Biochemistry	O
glucose	O
91	O
mg	O
dl	O
,	O
sodium	O
141	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
9	O
mEq	O
l	O
,	O
chlorine	O
104	O
mEq	O
l	O
,	O
total	O
bilirubin	O
2	O
.	O
2	O
mg	O
dl	O
,	O
alanine	O
aminotransferase	O
GPT	O
63	O
U	O
l	O
,	O
creatinine	O
1	O
.	O
06	O
mg	O
dl	O
,	O
estimated	O
GFR	O
CKD	O
EPI	O
67	O
.	O
83	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
uric	O
acid	O
9	O
.	O
3	O
mg	O
dl	O
,	O
protein	O
5	O
.	O
8	O
g	O
dl	O
,	O
C	O
reactive	O
protein	O
1	O
.	O
1	O
mg	O
dl	O
,	O
thyrotropin	O
TSH	O
4	O
.	O
00	O
uIU	O
ml	O
.	O
Ferric	O
Met	O
ferritin	O
25	O
μg	O
l	O
,	O
iron	O
48	O
μg	O
dl	O
,	O
total	O
Fe	O
fixation	O
capacity	O
428	O
ug	O
dl	O
,	O
transferrin	O
saturation	O
index	O
11	O
.	O
2	O
.	O
Carbohydrate	O
125	O
CA125	O
262	O
IU	O
ml	O
,	O
NT	O
proBNP	O
17963	O
.	O
0	O
pg	O
ml	O
.	O
PCR	O
SARS	O
CoV2	O
negative	O
.	O
Echocardiogram	O
Admission	O
LV	O
with	O
increased	O
diameters	O
with	O
anomalous	O
septo	O
apical	O
movement	O
and	O
global	O
hypokinesia	O
,	O
leading	O
to	O
severe	O
ventricular	O
dysfunction	O
LVEF	O
33	O
.	O
Aortic	O
root	O
of	O
normal	O
diameter	O
,	O
with	O
preserved	O
opening	O
sigmoids	O
.	O
Moderate	O
mitral	O
insufficiency	O
with	O
ORE	O
by	O
PISA	O
of	O
0	O
.	O
25	O
cm2	O
,	O
sclerosed	O
valve	O
,	O
dilatation	O
of	O
the	O
annulus	O
46	O
x	O
36	O
mm	O
.	O
Mild	O
aortic	O
insufficiency	O
.	O
RV	O
with	O
increased	O
diameters	O
and	O
moderately	O
depressed	O
global	O
systolic	O
function	O
.	O
Moderate	O
tricuspid	O
regurgitation	O
,	O
dilatation	O
of	O
the	O
annulus	O
,	O
systolic	O
pulmonary	O
artery	O
pressure	O
approximately	O
45	O
50	O
mm	O
Hg	O
.	O
IVC	O
of	O
24	O
mm	O
,	O
without	O
inspiratory	O
collapse	O
.	O
Follow	O
up	O
at	O
4	O
months	O
LV	O
of	O
slightly	O
increased	O
diameters	O
and	O
volumes	O
with	O
mild	O
depression	O
of	O
LVEF	O
50	O
.	O
Mild	O
mitral	O
and	O
aortic	O
insufficiency	O
.	O
Mitral	O
filling	O
pattern	O
with	O
single	O
E	O
wave	O
.	O
No	O
signs	O
of	O
increased	O
LV	O
end	O
diastolic	O
pressures	O
.	O
Moderately	O
dilated	O
left	O
atrium	O
.	O
RV	O
with	O
increased	O
diameters	O
and	O
slightly	O
depressed	O
systolic	O
function	O
.	O
Tricuspid	O
insufficiency	O
allowing	O
an	O
estimated	O
PAPS	O
of	O
25	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
,	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
cardiology	O
for	O
decompensated	O
heart	O
failure	O
.	O
Intensive	O
diuretic	O
treatment	O
was	O
started	O
with	O
adequate	O
depletion	O
and	O
the	O
patient	O
tolerated	O
oral	O
furosemide	B-FARMACO
on	O
discharge	O
.	O
An	O
echocardiogram	O
was	O
performed	O
on	O
admission	O
showing	O
severe	O
ventricular	O
dysfunction	O
25	O
,	O
with	O
interventricular	O
asynchrony	O
and	O
moderate	O
mitral	O
and	O
tricuspid	O
regurgitation	O
.	O
Given	O
the	O
indication	O
for	O
ICD	O
CRT	O
,	O
the	O
case	O
was	O
discussed	O
with	O
the	O
arrhythmia	O
unit	O
,	O
and	O
the	O
device	O
was	O
implanted	O
prior	O
to	O
discharge	O
.	O
In	O
successive	O
check	O
ups	O
,	O
the	O
patient	O
reported	O
a	O
marked	O
improvement	O
in	O
functional	O
class	O
currently	O
in	O
NYHA	O
I	O
,	O
which	O
remained	O
stable	O
.	O
A	O
control	O
echocardiogram	O
showed	O
a	O
marked	O
improvement	O
in	O
function	O
,	O
with	O
correction	O
of	O
asynchrony	O
and	O
a	O
reduction	O
in	O
the	O
degree	O
of	O
regurgitations	O
.	O
DIAGNOSIS	O
Non	O
ischaemic	O
dilated	O
cardiomyopathy	O
,	O
with	O
severe	O
LV	O
dysfunction	O
.	O
Interventricular	O
asynchrony	O
due	O
to	O
non	O
LBBB	O
conduction	O
disorder	O
.	O
Implantation	O
of	O
ICD	O
CRT	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
was	O
a	O
21	O
year	O
old	O
male	O
,	O
with	O
no	O
known	O
drug	O
allergies	O
.	O
With	O
regard	O
to	O
his	O
toxic	O
habits	O
,	O
he	O
was	O
a	O
social	O
drinker	O
,	O
non	O
smoker	O
,	O
denying	O
the	O
consumption	O
of	O
other	O
toxic	O
substances	O
.	O
He	O
denied	O
cardiovascular	O
risk	O
factors	O
,	O
cardiological	O
history	O
of	O
interest	O
and	O
did	O
not	O
follow	O
any	O
outpatient	O
treatment	O
.	O
He	O
came	O
to	O
our	O
emergency	O
department	O
with	O
a	O
fever	O
of	O
up	O
to	O
39oC	O
of	O
three	O
days	O
'	O
evolution	O
.	O
In	O
the	O
last	O
24	O
hours	O
he	O
began	O
to	O
experience	O
abdominal	O
pain	O
in	O
the	O
mesogastrium	O
,	O
more	O
accentuated	O
in	O
the	O
right	O
iliac	O
fossa	O
,	O
which	O
did	O
not	O
change	O
with	O
ingestion	O
and	O
was	O
more	O
accentuated	O
when	O
standing	O
upright	O
.	O
There	O
was	O
no	O
loss	O
of	O
appetite	O
.	O
He	O
denied	O
nausea	O
or	O
vomiting	O
,	O
alteration	O
of	O
transit	O
,	O
externalisation	O
of	O
bleeding	O
or	O
urinary	O
symptoms	O
.	O
Blood	O
pressure	O
was	O
132	O
89	O
mmHg	O
,	O
oxygen	O
saturation	O
100	O
baseline	O
,	O
temperature	O
36	O
.	O
4oC	O
,	O
acceptable	O
general	O
condition	O
,	O
conscious	O
,	O
oriented	O
and	O
cooperative	O
,	O
good	O
hydration	O
and	O
perfusion	O
,	O
eupneic	O
at	O
rest	O
and	O
without	O
neurological	O
focality	O
.	O
Cardiac	O
and	O
pulmonary	O
auscultation	O
showed	O
no	O
relevant	O
findings	O
.	O
The	O
abdomen	O
was	O
soft	O
,	O
depressible	O
,	O
with	O
hydro	O
aerial	O
sounds	O
present	O
,	O
without	O
palpable	O
masses	O
or	O
megaliths	O
,	O
with	O
intense	O
pain	O
on	O
palpation	O
of	O
the	O
right	O
iliac	O
fossa	O
but	O
without	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Given	O
the	O
suspicion	O
of	O
appendicitis	O
,	O
urgent	O
analysis	O
,	O
abdominal	O
CT	O
scan	O
and	O
PCR	O
for	O
SARSCoV	O
2	O
of	O
the	O
protocol	O
prior	O
to	O
admission	O
,	O
initially	O
in	O
charge	O
of	O
the	O
digestive	O
system	O
,	O
were	O
requested	O
.	O
COMPLEMENTARY	O
TESTS	O
With	O
regard	O
to	O
the	O
tests	O
performed	O
in	O
the	O
emergency	O
department	O
In	O
the	O
urgent	O
analysis	O
,	O
the	O
biochemical	O
analysis	O
showed	O
total	O
bilirubin	O
of	O
2	O
.	O
58	O
mg	O
dl	O
0	O
.	O
3	O
1	O
.	O
2	O
with	O
direct	O
bilirubin	O
of	O
0	O
.	O
5	O
mg	O
dl	O
0	O
0	O
.	O
5	O
and	O
C	O
reactive	O
protein	O
of	O
180	O
mg	O
l	O
0	O
5	O
.	O
The	O
haemogram	O
showed	O
discrete	O
leukocytosis	O
of	O
11	O
.	O
69	O
x10	O
3	O
μl	O
4	O
11	O
with	O
neutrophilia	O
of	O
9	O
.	O
68	O
x10	O
3	O
μl	O
.	O
Coagulopathy	O
was	O
present	O
,	O
with	O
prothrombin	O
time	O
of	O
51	O
75	O
140	O
and	O
calculated	O
fibrinogen	O
of	O
841	O
mg	O
dl	O
,	O
with	O
normal	O
activated	O
partial	O
thromboplastin	O
time	O
.	O
Urinalysis	O
showed	O
urobilinogen	O
8	O
mg	O
dl	O
and	O
ketone	O
bodies	O
60	O
mg	O
dl	O
.	O
PCR	O
for	O
SARS	O
CoV	O
2	O
was	O
performed	O
and	O
was	O
positive	O
,	O
with	O
gene	O
amplification	O
in	O
late	O
cycles	O
,	O
probably	O
compatible	O
with	O
residual	O
RNA	O
.	O
Abdominal	O
CT	O
scan	O
without	O
contrast	O
showed	O
normal	O
liver	O
and	O
spleen	O
,	O
with	O
no	O
obvious	O
focal	O
lesions	O
,	O
normal	O
sized	O
gallbladder	O
,	O
alliasic	O
,	O
with	O
no	O
signs	O
of	O
acute	O
cholecystitis	O
or	O
bile	O
duct	O
dilatation	O
.	O
Pancreas	O
without	O
significant	O
alterations	O
.	O
Normal	O
sized	O
kidneys	O
with	O
no	O
evidence	O
of	O
lithiasis	O
or	O
hydronephrosis	O
.	O
Inflammatory	O
changes	O
were	O
identified	O
in	O
the	O
cecum	O
,	O
ileocecal	O
valve	O
and	O
terminal	O
ileum	O
.	O
The	O
terminal	O
ileum	O
had	O
a	O
thickened	O
wall	O
with	O
marked	O
inflammatory	O
changes	O
in	O
the	O
vicinity	O
.	O
There	O
were	O
also	O
multiple	O
reactive	O
lymphadenopathies	O
in	O
the	O
right	O
iliac	O
fossa	O
.	O
There	O
was	O
an	O
amina	O
of	O
free	O
fluid	O
in	O
the	O
right	O
paracolic	O
gutter	O
.	O
The	O
cecal	O
appendix	O
showed	O
minimal	O
enlargement	O
of	O
its	O
base	O
,	O
probably	O
secondary	O
to	O
the	O
described	O
inflammatory	O
changes	O
and	O
the	O
proximity	O
to	O
the	O
ileum	O
.	O
Distally	O
the	O
appendix	O
was	O
of	O
normal	O
calibre	O
.	O
Therefore	O
,	O
these	O
findings	O
were	O
more	O
suggestive	O
of	O
ileitis	O
with	O
associated	O
inflammatory	O
changes	O
slightly	O
affecting	O
the	O
base	O
of	O
the	O
appendix	O
than	O
appendicitis	O
.	O
During	O
admission	O
to	O
the	O
gastrointestinal	O
department	O
and	O
later	O
cardiology	O
a	O
study	O
of	O
hepatotropic	O
viruses	O
and	O
HIV	O
,	O
anti	O
transglutaminase	O
and	O
thiopurine	O
methyltransferase	O
antibodies	O
was	O
carried	O
out	O
,	O
which	O
were	O
negative	O
.	O
A	O
determination	O
of	O
orosomucoid	O
acid	O
alpha	O
1	O
glycoprotein	O
was	O
requested	O
,	O
which	O
was	O
198	O
mg	O
dl	O
50	O
120	O
and	O
ferritin	O
940	O
ng	O
ml	O
21	O
274	O
.	O
A	O
stool	O
culture	O
showed	O
dysbacteriosis	O
due	O
to	O
gram	O
positive	O
microorganisms	O
.	O
Seventy	O
two	O
hours	O
after	O
admission	O
,	O
chest	O
pain	O
analysis	O
was	O
requested	O
,	O
with	O
elevated	O
troponin	O
I	O
high	O
sensitivity	O
of	O
522	O
.	O
8	O
ng	O
l	O
5	O
34	O
and	O
C	O
reactive	O
protein	O
352	O
mg	O
l	O
.	O
Subsequent	O
enzyme	O
serum	O
serology	O
showed	O
a	O
troponin	O
I	O
peak	O
of	O
13	O
,	O
418	O
ng	O
l	O
,	O
which	O
subsequently	O
decreased	O
progressively	O
,	O
as	O
well	O
as	O
CK	O
671	O
U	O
l	O
30	O
200	O
and	O
NTproBNP	O
3405	O
pg	O
ml	O
.	O
An	O
electrocardiogram	O
was	O
performed	O
with	O
chest	O
pain	O
,	O
showing	O
sinus	O
tachycardia	O
at	O
103	O
bpm	O
.	O
PR	O
120	O
ms	O
constant	O
.	O
QRS	O
90ms	O
,	O
normal	O
electrical	O
axis	O
.	O
No	O
repolarisation	O
alterations	O
.	O
The	O
electrocardiogram	O
on	O
the	O
ninth	O
day	O
of	O
admission	O
showed	O
sinus	O
rhythm	O
at	O
64	O
bpm	O
.	O
PR	O
160	O
ms	O
constant	O
.	O
QRS	O
88	O
ms	O
,	O
normal	O
electrical	O
axis	O
.	O
QTc	O
429	O
ms	O
.	O
Negative	O
T	O
wave	O
in	O
III	O
and	O
flattened	O
in	O
aVF	O
.	O
Electrocardiogram	O
prior	O
to	O
discharge	O
showed	O
sinus	O
rhythm	O
at	O
85	O
bpm	O
.	O
PR	O
140	O
ms	O
constant	O
.	O
QRS	O
84	O
ms	O
,	O
normal	O
electrical	O
axis	O
.	O
Biphasic	O
T	O
waves	O
on	O
the	O
inferolateral	O
side	O
.	O
An	O
urgent	O
echocardiogram	O
was	O
performed	O
on	O
suspicion	O
of	O
myocarditis	O
,	O
showing	O
left	O
atrium	O
LA	O
not	O
dilated	O
21	O
ml	O
m2	O
.	O
Left	O
ventricle	O
LV	O
not	O
dilated	O
DTD	O
49	O
mm	O
62	O
ml	O
m2	O
not	O
hypertrophic	O
septum	O
7	O
mm	O
pp	O
7	O
mm	O
mass	O
55	O
g	O
m2	O
RWT	O
0	O
.	O
29	O
.	O
Global	O
hypokinesia	O
with	O
moderate	O
LV	O
systolic	O
dysfunction	O
biplane	O
Simpson	O
EF	O
42	O
.	O
Normofunctioning	O
mitral	O
valve	O
.	O
Filling	O
pattern	O
with	O
fusion	O
of	O
E	O
and	O
A	O
.	O
Normofunctioning	O
trivalve	O
aortic	O
valve	O
.	O
Aortic	O
root	O
and	O
ascending	O
aorta	O
not	O
dilated	O
.	O
Right	O
chambers	O
of	O
normal	O
size	O
,	O
right	O
ventricular	O
RV	O
systolic	O
function	O
at	O
low	O
limit	O
of	O
normality	O
TAPSE	O
16	O
mm	O
S	O
wave	O
DTI	O
10	O
cm	O
s	O
.	O
Mild	O
tricuspid	O
insufficiency	O
TI	O
with	O
V	O
max	O
2	O
m	O
s	O
,	O
estimated	O
normal	O
PAPS	O
.	O
Normal	O
pulmonary	O
acceleration	O
time	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
IVC	O
without	O
adequate	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
The	O
control	O
echocardiogram	O
performed	O
5	O
days	O
later	O
showed	O
improvement	O
of	O
the	O
previously	O
described	O
global	O
hypokinesia	O
.	O
CLINICAL	O
EVOLUTION	O
A	O
new	O
PCR	O
was	O
performed	O
48	O
hours	O
after	O
admission	O
,	O
which	O
was	O
negative	O
,	O
and	O
COVID	O
isolation	O
was	O
lifted	O
.	O
Subsequently	O
,	O
serology	O
was	O
performed	O
with	O
positive	O
IgG	O
for	O
SARS	O
CoV	O
2	O
.	O
Seventy	O
two	O
hours	O
after	O
admission	O
,	O
she	O
began	O
to	O
experience	O
repeated	O
episodes	O
of	O
central	O
thoracic	O
pain	O
described	O
as	O
stabbing	O
,	O
radiating	O
to	O
the	O
neck	O
,	O
which	O
increased	O
with	O
deep	O
inspiration	O
.	O
They	O
were	O
accompanied	O
by	O
sweating	O
and	O
,	O
on	O
occasion	O
,	O
vomiting	O
.	O
Following	O
the	O
findings	O
described	O
in	O
the	O
complementary	O
tests	O
analysis	O
with	O
elevated	O
acute	O
phase	O
reactants	O
and	O
markers	O
of	O
myocardial	O
damage	O
,	O
electrocardiogram	O
with	O
sinus	O
tachycardia	O
and	O
echocardiogram	O
with	O
global	O
hypokinesia	O
,	O
treatment	O
was	O
started	O
with	O
beta	O
blockers	O
and	O
he	O
was	O
transferred	O
to	O
the	O
coronary	O
unit	O
where	O
he	O
was	O
monitored	O
without	O
arrhythmic	O
events	O
of	O
interest	O
.	O
After	O
48	O
hours	O
he	O
was	O
transferred	O
to	O
the	O
cardiology	O
hospital	O
ward	O
to	O
complete	O
the	O
study	O
and	O
treatment	O
.	O
During	O
his	O
stay	O
on	O
the	O
ward	O
he	O
remained	O
asymptomatic	O
,	O
with	O
no	O
evidence	O
of	O
heart	O
failure	O
.	O
Treatment	O
was	O
started	O
with	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
ACE	O
inhibitors	O
and	O
beta	O
blockers	O
.	O
A	O
repeat	O
echocardiogram	O
showed	O
normalisation	O
of	O
systolic	O
function	O
,	O
although	O
slight	O
hypokinesia	O
persisted	O
in	O
the	O
basal	O
segments	O
of	O
the	O
septum	O
and	O
anterolateral	O
face	O
.	O
The	O
control	O
electrocardiogram	O
showed	O
sinus	O
rhythm	O
alternating	O
with	O
bouts	O
of	O
nodal	O
rhythm	O
without	O
relevant	O
clinical	O
translation	O
he	O
did	O
not	O
present	O
syncope	O
or	O
other	O
alarm	O
symptoms	O
,	O
so	O
the	O
beta	O
blockers	O
were	O
discontinued	O
and	O
he	O
was	O
monitored	O
with	O
telemetry	O
and	O
these	O
episodes	O
were	O
observed	O
during	O
sleep	O
,	O
which	O
could	O
be	O
secondary	O
to	O
vagal	O
hypotonia	O
or	O
be	O
in	O
the	O
context	O
of	O
the	O
evolution	O
of	O
myocarditis	O
.	O
From	O
the	O
digestive	O
point	O
of	O
view	O
,	O
he	O
presented	O
significant	O
clinical	O
improvement	O
,	O
without	O
pain	O
and	O
with	O
normalisation	O
of	O
intestinal	O
transit	O
.	O
He	O
completed	O
empirical	O
antibiotic	O
therapy	O
with	O
ceftriaxone	B-FARMACO
and	O
metronidazole	B-FARMACO
,	O
started	O
on	O
admission	O
.	O
At	O
discharge	O
he	O
had	O
good	O
oral	O
tolerance	O
.	O
After	O
progressive	O
tests	O
showed	O
a	O
clear	O
decrease	O
in	O
myocardial	O
enzymes	O
,	O
practically	O
normalised	O
,	O
and	O
in	O
acute	O
phase	O
reactants	O
,	O
in	O
a	O
stable	O
clinical	O
and	O
haemodynamic	O
situation	O
,	O
he	O
was	O
discharged	O
from	O
hospital	O
after	O
10	O
days	O
of	O
hospitalisation	O
.	O
DIAGNOSIS	O
Myocarditis	O
and	O
acute	O
ileocolitis	O
in	O
the	O
context	O
of	O
late	O
stage	O
SARS	O
CoV	O
2	O
infection	O
.	O
Mild	O
hypokinesia	O
in	O
the	O
basal	O
septum	O
and	O
basal	O
anterolateral	O
septum	O
of	O
the	O
LV	O
.	O

Personal	O
history	O
Allergic	O
to	O
penicillin	B-FARMACO
.	O
No	O
known	O
hypertension	O
or	O
diabetes	O
mellitus	O
.	O
Dyslipidaemia	O
under	O
dietary	O
treatment	O
.	O
Denies	O
toxic	O
habits	O
.	O
Primary	O
autoimmune	O
hypothyroidism	O
in	O
substitutive	O
treatment	O
since	O
2011	O
.	O
Euthycocic	O
delivery	O
of	O
singleton	O
gestation	O
40	O
1	O
weeks	O
on	O
15	O
06	O
2014	O
without	O
immediate	O
complications	O
.	O
Hyperemesis	O
gravidarum	O
.	O
Baseline	O
situation	O
active	O
and	O
independent	O
.	O
Adequate	O
for	O
her	O
age	O
.	O
Surgical	O
interventions	O
removal	O
of	O
cutaneous	O
nevus	O
on	O
4	O
occasions	O
,	O
one	O
of	O
which	O
was	O
dysplastic	O
.	O
Chronic	O
treatment	O
levothyroxine	B-FARMACO
150	O
mcg	O
75	O
mcg	O
after	O
delivery	O
1	O
tablet	O
day	O
.	O
Iron	B-FARMACO
proteinsuccinylate	I-FARMACO
40	O
mg	O
1	O
vial	O
per	O
day	O
.	O
Present	O
illness	O
A	O
30	O
year	O
old	O
woman	O
attended	O
the	O
emergency	O
department	O
on	O
21	O
06	O
2014	O
due	O
to	O
poor	O
general	O
condition	O
with	O
thermometric	O
fever	O
of	O
38	O
.	O
5	O
C	O
accompanied	O
by	O
urinary	O
discomfort	O
with	O
dysuria	O
,	O
pollakiuria	O
and	O
pain	O
in	O
the	O
right	O
lumbar	O
region	O
for	O
24	O
hours	O
.	O
He	O
presented	O
with	O
nausea	O
but	O
no	O
vomiting	O
.	O
No	O
cough	O
or	O
expectoration	O
or	O
other	O
accompanying	O
symptoms	O
.	O
The	O
patient	O
was	O
discharged	O
on	O
17	O
06	O
after	O
euthecological	O
delivery	O
without	O
immediate	O
complications	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
110	O
90	O
mmHg	O
.	O
Heart	O
rate	O
90	O
beats	O
minute	O
.	O
Temperature	O
38	O
.	O
8	O
C	O
.	O
Oxygen	O
saturation	O
100	O
.	O
Weight	O
63	O
.	O
5	O
kg	O
,	O
height	O
1	O
.	O
72m	O
.	O
BMI	O
21	O
.	O
46	O
kg	O
m2	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
sounds	O
at	O
90	O
bpm	O
and	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
painful	O
on	O
palpation	O
in	O
the	O
hypogastrium	O
and	O
fist	O
,	O
positive	O
right	O
renal	O
percussion	O
.	O
Lower	O
extremities	O
oedema	O
with	O
fovea	O
up	O
to	O
the	O
knee	O
with	O
no	O
signs	O
of	O
thrombosis	O
.	O
Gynaecological	O
examination	O
engorged	O
breasts	O
with	O
no	O
signs	O
of	O
infection	O
.	O
Vagina	O
ample	O
and	O
elastic	O
.	O
Non	O
malodorous	O
discharge	O
.	O
COMPLEMENTARY	O
TESTS	O
Admission	O
blood	O
tests	O
glucose	O
81	O
,	O
creatinine	O
0	O
.	O
99	O
,	O
sodium	O
Na	O
139	O
,	O
potassium	O
K	O
4	O
.	O
2	O
,	O
CRP	O
11	O
.	O
39	O
,	O
haemoglobin	O
10	O
.	O
6	O
,	O
haematocrit	O
32	O
.	O
4	O
,	O
leucocytes	O
13380	O
neutrophils	O
77	O
,	O
platelets	O
275	O
,	O
000	O
.	O
INR	O
0	O
.	O
93	O
.	O
Abnormal	O
and	O
sediment	O
pH	O
7	O
,	O
haemoglobin	O
593	O
red	O
cells	O
field	O
.	O
Leukocytes	O
1912	O
leukocytes	O
field	O
.	O
Bacteria	O
2019	O
uL	O
.	O
Pyuria	O
.	O
Other	O
analytical	O
findings	O
on	O
admission	O
basal	O
ACTH	O
1180	O
,	O
basal	O
cortisol	O
3	O
.	O
3	O
.	O
TSH	O
8	O
.	O
08	O
,	O
T4	O
1	O
.	O
16	O
,	O
T3	O
1	O
.	O
8	O
.	O
Plasma	O
Na	O
124	O
,	O
urine	O
Na	O
15	O
,	O
plasma	O
chlorine	O
89	O
,	O
urine	O
chlorine	O
10	O
,	O
urine	O
osmolarity	O
294	O
,	O
blood	O
osmolarity	O
288	O
.	O
Anti	O
striated	O
muscle	O
myocardial	O
antibodies	O
negative	O
.	O
Anti	O
adrenal	O
antibodies	O
high	O
positive	O
.	O
Chest	O
X	O
ray	O
congestive	O
hilarity	O
.	O
Enlargement	O
of	O
the	O
broconvascular	O
tract	O
.	O
Bilateral	O
costophrenic	O
sinus	O
impingement	O
with	O
volume	O
decrease	O
in	O
right	O
hemithorax	O
.	O
ECG	O
sinus	O
tachycardia	O
at	O
100	O
bpm	O
.	O
PR	O
0	O
.	O
12sec	O
.	O
Narrow	O
QRS	O
with	O
indeterminate	O
axis	O
and	O
BIRDHH	O
morphology	O
.	O
Negative	O
T	O
waves	O
in	O
II	O
,	O
III	O
and	O
aVF	O
.	O
Deep	O
T	O
waves	O
in	O
precordial	O
leads	O
.	O
Transvaginal	O
ultrasound	O
involuted	O
uterus	O
with	O
collapsed	O
cavity	O
.	O
No	O
impression	O
of	O
debris	O
.	O
Abdominal	O
ultrasound	O
moderate	O
amount	O
of	O
free	O
intraperitoneal	O
fluid	O
,	O
predominantly	O
in	O
the	O
flanks	O
and	O
right	O
iliac	O
fossa	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
in	O
the	O
lower	O
pelvis	O
.	O
Kidneys	O
of	O
normal	O
size	O
and	O
echostructure	O
,	O
without	O
dilatation	O
of	O
the	O
excretory	O
system	O
.	O
Severe	O
right	O
pleural	O
effusion	O
with	O
almost	O
total	O
pulmonary	O
atelectasis	O
and	O
moderate	O
left	O
pleural	O
effusion	O
.	O
Transthoracic	O
echocardiography	O
on	O
the	O
Cardiology	O
ward	O
biventricular	O
dysfunction	O
without	O
dilatation	O
of	O
cavities	O
LVEF	O
35	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Signs	O
of	O
low	O
cardiac	O
output	O
.	O
Absence	O
of	O
indirect	O
signs	O
of	O
severe	O
pulmonary	O
hypertension	O
.	O
Coronary	O
angiography	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O
Ventriculography	O
dilated	O
left	O
ventricle	O
with	O
irregular	O
contour	O
on	O
the	O
underside	O
small	O
aneurysms	O
.	O
LVEF	O
25	O
.	O
Moderate	O
MI	O
.	O
TDVI	O
24	O
mmHg	O
.	O
Severe	O
ventricular	O
dysfunction	O
.	O
Endomyocardial	O
biopsy	O
fragment	O
of	O
myocardium	O
with	O
mild	O
hypertrophic	O
features	O
without	O
inflammation	O
or	O
granulomas	O
.	O
No	O
interstitial	O
fibrosis	O
is	O
seen	O
.	O
No	O
iron	O
or	O
glycogen	O
deposition	O
.	O
No	O
inflammation	O
suggestive	O
of	O
myocarditis	O
.	O
Cardiac	O
MRI	O
no	O
dilatation	O
of	O
cavities	O
.	O
Myocardial	O
thickness	O
normal	O
Severe	O
left	O
ventricular	O
dysfunction	O
LVEF	O
35	O
.	O
No	O
intramyocardial	O
oedema	O
.	O
Negative	O
late	O
enhancement	O
,	O
making	O
the	O
diagnosis	O
of	O
myocarditis	O
and	O
ischaemic	O
heart	O
disease	O
highly	O
unlikely	O
.	O
Microbiology	O
blood	O
culture	O
negative	O
after	O
6	O
days	O
of	O
incubation	O
.	O
Urine	O
culture	O
Escherichia	O
coli	O
100	O
,	O
000	O
CFU	O
ml	O
sensitive	O
to	O
gentamicin	B-FARMACO
,	O
fosfomycin	B-FARMACO
,	O
cotrimoxazole	B-FARMACO
and	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
.	O
Parvovirus	O
B19	O
serology	O
Ac	O
IgG	O
and	O
Ac	O
IgM	O
parvovirus	O
B19	O
negative	O
.	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
gynaecology	O
with	O
a	O
diagnosis	O
of	O
acute	O
pyelonephritis	O
in	O
a	O
pregnant	O
woman	O
.	O
Urine	O
and	O
blood	O
cultures	O
were	O
requested	O
and	O
intravenous	O
treatment	O
was	O
started	O
with	O
gentamicin	B-FARMACO
80	O
mg	O
every	O
8	O
hours	O
,	O
clindamycin	B-FARMACO
900	O
mg	O
every	O
8	O
hours	O
,	O
serotherapy	O
1500	O
cc	O
per	O
day	O
and	O
analgesia	O
.	O
On	O
23	O
06	O
the	O
patient	O
presented	O
nausea	O
,	O
vomiting	O
with	O
dizziness	O
and	O
hypotension	O
BP	O
97	O
73	O
mmHg	O
and	O
500	O
cc	O
of	O
extra	O
serum	O
therapy	O
and	O
metoclopramide	B-FARMACO
were	O
administered	O
.	O
The	O
following	O
morning	O
the	O
patient	O
persisted	O
with	O
general	O
malaise	O
and	O
dyspnoea	O
despite	O
100	O
saturation	O
,	O
which	O
was	O
attributed	O
to	O
an	O
anxiety	O
crisis	O
.	O
However	O
,	O
in	O
the	O
following	O
hours	O
the	O
patient	O
presented	O
poor	O
general	O
condition	O
with	O
mucocutaneous	O
pallor	O
,	O
sweating	O
and	O
peripheral	O
coldness	O
as	O
well	O
as	O
tachycardia	O
and	O
tachypnoea	O
.	O
Examination	O
revealed	O
HR	O
120	O
bpm	O
,	O
RR	O
40	O
rpm	O
,	O
BP	O
80	O
30mmg	O
,	O
O2	O
Sat	O
88	O
Pulmonary	O
auscultation	O
marked	O
bibasal	O
hypoventilation	O
in	O
the	O
right	O
lung	O
base	O
.	O
Urgent	O
chest	O
X	O
ray	O
was	O
performed	O
,	O
showing	O
bilateral	O
pleural	O
effusion	O
;	O
urgent	O
abdominal	O
ultrasound	O
,	O
showing	O
free	O
intra	O
abdominal	O
fluid	O
and	O
bilateral	O
pleural	O
effusion	O
.	O
Laboratory	O
tests	O
showed	O
Na	O
128	O
,	O
K	O
6	O
.	O
3	O
,	O
NT	O
proBNP	O
9162	O
,	O
Hb	O
9	O
.	O
2	O
,	O
D	O
dimer	O
8421	O
,	O
CRP	O
37	O
.	O
42	O
,	O
procalcitonin	O
4	O
.	O
50	O
,	O
GOT	O
1190	O
,	O
GPT	O
377	O
,	O
TSH	O
7	O
,	O
690	O
,	O
T4	O
0	O
.	O
96	O
,	O
pH	O
7	O
.	O
20	O
,	O
pCO2	O
19	O
,	O
HCO3	O
12	O
,	O
lactate	O
4	O
and	O
glucose	O
40	O
.	O
Given	O
the	O
haemodynamic	O
deterioration	O
of	O
the	O
patient	O
with	O
respiratory	O
claudication	O
,	O
she	O
was	O
admitted	O
to	O
the	O
ICU	O
with	O
a	O
diagnosis	O
of	O
metabolic	O
acidosis	O
secondary	O
to	O
sepsis	O
of	O
urinary	O
origin	O
due	O
to	O
E	O
.	O
coli	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
ICU	O
on	O
the	O
afternoon	O
of	O
24	O
06	O
,	O
very	O
unstable	O
with	O
sustained	O
hypotension	O
and	O
signs	O
of	O
tissue	O
hypoperfusion	O
requiring	O
initial	O
respiratory	O
support	O
with	O
non	O
invasive	O
mechanical	O
ventilation	O
and	O
administration	O
of	O
3	O
doses	O
of	O
hydrocortisone	B-FARMACO
due	O
to	O
acute	O
pulmonary	O
oedema	O
.	O
An	O
ECG	O
was	O
performed	O
showing	O
negative	O
T	O
waves	O
on	O
the	O
inferior	O
and	O
precordial	O
sides	O
,	O
as	O
well	O
as	O
elevated	O
markers	O
of	O
cardiac	O
damage	O
with	O
peak	O
CKMB	O
21	O
.	O
6	O
and	O
troponin	O
T	O
279	O
and	O
NT	O
proBNP	O
12626	O
.	O
An	O
urgent	O
echocardiogram	O
was	O
performed	O
showing	O
severe	O
systolic	O
dysfunction	O
with	O
global	O
hypokinesia	O
,	O
dilatation	O
of	O
the	O
chambers	O
with	O
LVEF	O
10	O
and	O
a	O
cardiac	O
output	O
of	O
2	O
litres	O
minute	O
was	O
calculated	O
.	O
Given	O
that	O
the	O
patient	O
was	O
in	O
cardiogenic	O
shock	O
,	O
treatment	O
with	O
vasoactive	O
drugs	O
with	O
dobutamine	B-FARMACO
and	O
noradrenaline	B-FARMACO
was	O
started	O
,	O
which	O
allowed	O
systolic	O
blood	O
pressure	O
to	O
be	O
maintained	O
at	O
80	O
mmHg	O
and	O
cardiac	O
output	O
to	O
improve	O
to	O
5	O
litres	O
minute	O
and	O
LVEF	O
35	O
.	O
With	O
suspicion	O
of	O
myocarditis	O
ischemic	O
cardiomyopathy	O
,	O
cardiac	O
catheterisation	O
with	O
ventriculography	O
and	O
endomyocardial	O
biopsy	O
,	O
cardiac	O
MRI	O
,	O
parvovirus	O
B19	O
serology	O
and	O
cardiac	O
immunology	O
were	O
all	O
negative	O
,	O
so	O
the	O
patient	O
was	O
attributed	O
to	O
possible	O
peripartum	O
cardiomyopathy	O
complicated	O
by	O
sepsis	O
of	O
urinary	O
origin	O
.	O
Treatment	O
was	O
started	O
with	O
bromocriptine	B-FARMACO
,	O
continued	O
with	O
gentamicin	B-FARMACO
and	O
associated	O
trimethoprim	B-FARMACO
sulfamethoxazole	I-FARMACO
.	O
The	O
patient	O
improved	O
clinically	O
,	O
with	O
resolution	O
of	O
the	O
bilateral	O
pleural	O
effusion	O
,	O
improvement	O
in	O
the	O
infectious	O
parameters	O
and	O
cardiac	O
output	O
,	O
allowing	O
the	O
progressive	O
withdrawal	O
of	O
vasoactive	O
drugs	O
and	O
on	O
01	O
07	O
she	O
was	O
transferred	O
to	O
the	O
Cardiology	O
ward	O
.	O
Initially	O
on	O
the	O
ward	O
the	O
evolution	O
was	O
favourable	O
,	O
allowing	O
beta	O
blockers	O
and	O
ACE	B-FARMACO
inhibitors	I-FARMACO
to	O
be	O
started	O
at	O
low	O
doses	O
.	O
The	O
control	O
echocardiography	O
showed	O
improvement	O
in	O
systolic	O
dysfunction	O
with	O
LVEF	O
35	O
.	O
However	O
,	O
on	O
the	O
night	O
of	O
03	O
07	O
the	O
patient	O
presented	O
nausea	O
and	O
dizziness	O
with	O
hypotension	O
of	O
70	O
40mmHg	O
.	O
A	O
blood	O
test	O
was	O
performed	O
with	O
the	O
following	O
alterations	O
creatinine	O
1	O
.	O
65	O
,	O
urea	O
58	O
,	O
Na	O
117	O
,	O
K	O
6	O
.	O
4	O
,	O
which	O
were	O
confirmed	O
.	O
Bromocriptine	B-FARMACO
and	O
trimethoprim	B-FARMACO
sulfamethoxazole	I-FARMACO
were	O
suspended	O
antibiotic	O
cycle	O
had	O
been	O
completed	O
in	O
case	O
the	O
alterations	O
were	O
secondary	O
to	O
drugs	O
,	O
and	O
corrective	O
measures	O
for	O
hyperkalaemia	O
and	O
serum	O
therapy	O
were	O
administered	O
.	O
Given	O
that	O
the	O
patient	O
at	O
24	O
48	O
hours	O
persisted	O
with	O
symptoms	O
of	O
dizziness	O
,	O
nausea	O
and	O
hypotension	O
and	O
with	O
peak	O
analytical	O
alterations	O
on	O
06	O
07	O
with	O
creatinine	O
1	O
.	O
99	O
,	O
urea	O
90	O
,	O
Na	O
115	O
,	O
K	O
7	O
.	O
4	O
,	O
ACTH	O
and	O
basal	O
cortisol	O
were	O
requested	O
and	O
IV	O
hydrocortisone	B-FARMACO
was	O
administered	O
on	O
suspicion	O
of	O
acute	O
adrenal	O
insufficiency	O
.	O
The	O
patient	O
progressively	O
improved	O
with	O
treatment	O
.	O
Endocrinology	O
was	O
consulted	O
and	O
the	O
patient	O
was	O
classified	O
as	O
having	O
acute	O
adrenal	O
insufficiency	O
in	O
a	O
patient	O
with	O
intense	O
stress	O
due	O
to	O
urinary	O
sepsis	O
and	O
cardiogenic	O
shock	O
due	O
to	O
peripartum	O
cardiomyopathy	O
.	O
The	O
patient	O
received	O
steroid	O
treatment	O
in	O
the	O
ICU	O
,	O
so	O
the	O
condition	O
had	O
remained	O
masked	O
.	O
Given	O
the	O
haemodynamic	O
stability	O
of	O
the	O
patient	O
and	O
the	O
resolution	O
of	O
the	O
ionic	O
alterations	O
,	O
she	O
was	O
discharged	O
from	O
hospital	O
on	O
08	O
07	O
2014	O
.	O
Treatment	O
at	O
discharge	O
omeprazole	B-FARMACO
20	O
mg	O
1c	O
24h	O
,	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
1c	O
24h	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
1c	O
24h	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
2	O
c	O
24h	O
,	O
levothyroxine	B-FARMACO
75	O
mcg	O
1c	O
24h	O
,	O
hydrocortisone	B-FARMACO
20	O
mg	O
1c	O
8h	O
.	O
Evolution	O
at	O
discharge	O
at	O
4	O
months	O
follow	O
up	O
echocardiography	O
was	O
performed	O
,	O
showing	O
improvement	O
with	O
LVEF	O
52	O
.	O
At	O
the	O
endocrinological	O
level	O
,	O
the	O
analytical	O
results	O
confirmed	O
the	O
condition	O
as	O
acute	O
adrenal	O
insufficiency	O
of	O
autoimmune	O
origin	O
.	O
After	O
9	O
months	O
,	O
the	O
patient	O
was	O
asymptomatic	O
and	O
was	O
living	O
an	O
active	O
and	O
independent	O
life	O
.	O
DIAGNOSIS	O
Urinary	O
sepsis	O
due	O
to	O
Escherichia	O
coli	O
Cardiogenic	O
shock	O
due	O
to	O
peripartum	O
cardiomyopathy	O
with	O
severe	O
systolic	O
dysfunction	O
Acute	O
adrenal	O
insufficiency	O
addisonian	O
crisis	O

History	O
69	O
year	O
old	O
woman	O
No	O
known	O
drug	O
allergies	O
High	O
blood	O
pressure	O
HBP	O
Hypercholesterolemia	O
Bronchial	O
asthma	O
and	O
pneumonia	O
in	O
2009	O
Chronic	O
atrophic	O
gastritis	O
and	O
chronic	O
hepatitis	O
C	O
virus	O
HCV	O
liver	O
disease	O
Chondrocalcinosis	O
Calcifying	O
tendinitis	O
of	O
the	O
right	O
shoulder	O
Osteoporosis	O
Hyperparathyroidism	O
with	O
parathyroidectomy	O
in	O
2001	O
Bilateral	O
sensorineural	O
hearing	O
loss	O
Dry	O
eye	O
syndrome	O
Cardiological	O
history	O
In	O
1978	O
he	O
underwent	O
mitral	O
and	O
aortic	O
valve	O
replacement	O
with	O
biological	O
prostheses	O
.	O
In	O
1990	O
,	O
both	O
prostheses	O
malfunctioned	O
,	O
so	O
a	O
new	O
replacement	O
with	O
two	O
mechanical	O
prostheses	O
was	O
performed	O
.	O
The	O
aortic	O
prosthesis	O
was	O
implanted	O
at	O
the	O
level	O
of	O
the	O
coronary	O
ostium	O
,	O
so	O
it	O
was	O
necessary	O
to	O
perform	O
two	O
aortocoronary	O
grafts	O
saphenous	O
vein	O
to	O
the	O
anterior	O
interventricular	O
and	O
right	O
coronary	O
artery	O
.	O
In	O
2002	O
he	O
was	O
admitted	O
for	O
heart	O
failure	O
and	O
haemolytic	O
anaemia	O
related	O
to	O
late	O
periprosthetic	O
dehiscence	O
,	O
so	O
a	O
new	O
mitral	O
valve	O
replacement	O
was	O
performed	O
with	O
another	O
mechanical	O
prosthesis	O
and	O
new	O
aortocoronary	O
grafts	O
saphenous	O
vein	O
to	O
the	O
middle	O
anterior	O
descending	O
artery	O
and	O
to	O
the	O
right	O
coronary	O
artery	O
.	O
In	O
2003	O
,	O
DDD	O
pacemaker	O
implantation	O
was	O
performed	O
due	O
to	O
symptomatic	O
sinus	O
node	O
disease	O
with	O
paroxysmal	O
atrial	O
fibrillation	O
.	O
Cardiologically	O
asymptomatic	O
until	O
2014	O
,	O
when	O
she	O
was	O
admitted	O
several	O
times	O
for	O
heart	O
failure	O
,	O
the	O
last	O
one	O
in	O
August	O
2014	O
.	O
Current	O
illness	O
Patient	O
admitted	O
for	O
a	O
new	O
episode	O
of	O
heart	O
failure	O
in	O
December	O
2014	O
.	O
A	O
control	O
transthoracic	O
echocardiogram	O
TTE	O
was	O
performed	O
,	O
followed	O
by	O
a	O
transesophageal	O
echocardiogram	O
TEE	O
which	O
confirmed	O
the	O
presence	O
of	O
two	O
mitral	O
periprosthetic	O
leaks	O
one	O
septal	O
and	O
one	O
posterior	O
.	O
Taking	O
into	O
account	O
the	O
patient	O
's	O
morbidity	O
and	O
the	O
high	O
surgical	O
risk	O
,	O
the	O
patient	O
was	O
scheduled	O
for	O
percutaneous	O
leak	O
closure	O
.	O
This	O
procedure	O
was	O
performed	O
on	O
08	O
01	O
2015	O
under	O
general	O
anaesthesia	O
and	O
with	O
transesophageal	O
echocardiography	O
control	O
in	O
the	O
haemodynamics	O
room	O
.	O
Initial	O
access	O
was	O
via	O
the	O
right	O
femoral	O
vein	O
and	O
,	O
after	O
transseptal	O
puncture	O
,	O
an	O
attempt	O
was	O
made	O
to	O
cross	O
the	O
posterior	O
mitral	O
leak	O
as	O
it	O
was	O
the	O
largest	O
in	O
an	O
antegrade	O
manner	O
,	O
without	O
success	O
.	O
Therefore	O
,	O
it	O
was	O
decided	O
to	O
puncture	O
the	O
left	O
femoral	O
artery	O
and	O
cross	O
the	O
mechanical	O
aortic	O
prosthesis	O
with	O
a	O
guide	O
and	O
a	O
catheter	O
with	O
good	O
haemodynamic	O
tolerance	O
.	O
The	O
posterior	O
leak	O
is	O
crossed	O
and	O
the	O
guidewire	O
is	O
captured	O
in	O
the	O
left	O
atrium	O
LA	O
with	O
a	O
loop	O
,	O
externalising	O
via	O
the	O
right	O
femoral	O
vein	O
,	O
thus	O
creating	O
an	O
arteriovenous	O
AV	O
shunt	O
.	O
The	O
size	O
of	O
the	O
defect	O
by	O
3D	O
TEE	O
is	O
10x4	O
mm	O
,	O
so	O
a	O
10x5mm	O
Vascular	O
Plug	O
device	O
is	O
chosen	O
for	O
closure	O
.	O
A	O
release	O
sheath	O
is	O
advanced	O
from	O
the	O
right	O
femoral	O
vein	O
through	O
the	O
defect	O
into	O
the	O
left	O
ventricle	O
LV	O
and	O
the	O
device	O
is	O
released	O
from	O
the	O
LV	O
to	O
the	O
LA	O
with	O
good	O
placement	O
and	O
effective	O
closure	O
of	O
the	O
defect	O
video	O
3	O
and	O
figure	O
1	O
.	O
The	O
procedure	O
is	O
completed	O
and	O
the	O
left	O
femoral	O
artery	O
puncture	O
is	O
closed	O
with	O
good	O
results	O
.	O
The	O
patient	O
was	O
extubated	O
in	O
the	O
ward	O
and	O
transferred	O
to	O
the	O
coronary	O
unit	O
for	O
evolutionary	O
control	O
in	O
good	O
clinical	O
condition	O
.	O
Physical	O
examination	O
BP	O
110	O
48	O
mmHg	O
.	O
HR	O
107	O
bpm	O
.	O
Sat	O
.	O
02	O
100	O
Reservoir	O
at	O
100	O
.	O
Afebrile	O
.	O
Conscious	O
and	O
oriented	O
,	O
good	O
skin	O
and	O
mucous	O
membrane	O
colouring	O
,	O
good	O
peripheral	O
perfusion	O
,	O
eupneic	O
at	O
rest	O
.	O
Head	O
and	O
neck	O
no	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
,	O
no	O
masses	O
or	O
megaliths	O
.	O
Sounds	O
present	O
.	O
Lower	O
extremities	O
no	O
oedema	O
.	O
Pedial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
No	O
haematoma	O
in	O
puncture	O
sites	O
.	O
Sensibility	O
and	O
mobility	O
preserved	O
.	O
COMPLEMENTARY	O
TESTS	O
Preoperative	O
TTE	O
LV	O
neither	O
dilated	O
nor	O
hypertrophic	O
,	O
with	O
good	O
global	O
systolic	O
function	O
,	O
apical	O
aneurysm	O
.	O
The	O
mechanical	O
mitral	O
prosthesis	O
has	O
a	O
slight	O
systolic	O
Doppler	O
signal	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Mechanical	O
aortic	O
prosthesis	O
with	O
mild	O
regurgitation	O
and	O
maximum	O
gradient	O
of	O
40	O
mmHg	O
.	O
Moderately	O
dilated	O
LA	O
.	O
Dilated	O
right	O
chambers	O
.	O
Right	O
ventricle	O
RV	O
with	O
moderate	O
dysfunction	O
.	O
Moderate	O
tricuspid	O
regurgitation	O
with	O
RV	O
RA	O
gradient	O
of	O
65	O
mmHg	O
.	O
Estimated	O
PsAP	O
of	O
80	O
mmHg	O
.	O
RV	O
pacing	O
lead	O
.	O
No	O
pericardial	O
effusion	O
.	O
Preoperative	O
TEE	O
mitral	O
prosthesis	O
with	O
two	O
periprosthetic	O
leaks	O
,	O
one	O
septal	O
and	O
one	O
posterior	O
,	O
both	O
moderate	O
.	O
EVOLUTION	O
In	O
subsequent	O
outpatient	O
controls	O
,	O
the	O
patient	O
reported	O
feeling	O
better	O
,	O
with	O
improvement	O
in	O
her	O
functional	O
capacity	O
.	O
She	O
has	O
lost	O
weight	O
.	O
In	O
the	O
subsequent	O
control	O
TTE	O
she	O
presented	O
mild	O
periprosthetic	O
mitral	O
insufficiency	O
.	O
DIAGNOSIS	O
Leaks	O
or	O
periprosthetic	O
mitral	O
dehiscence	O
.	O

A	O
48	O
year	O
old	O
man	O
came	O
to	O
the	O
emergency	O
department	O
of	O
a	O
regional	O
hospital	O
referred	O
from	O
his	O
local	O
health	O
centre	O
due	O
to	O
progressive	O
dyspnoea	O
,	O
asthenia	O
,	O
orthopnoea	O
and	O
cough	O
in	O
the	O
last	O
24	O
hours	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
DM	O
,	O
no	O
hypertension	O
,	O
no	O
dyslipidaemia	O
.	O
Sporadic	O
smoker	O
1	O
pack	O
day	O
at	O
weekends	O
and	O
regular	O
drinker	O
3	O
4	O
beers	O
daily	O
,	O
with	O
other	O
drinks	O
at	O
weekends	O
.	O
Severe	O
mitral	O
stenosis	O
of	O
probable	O
rheumatic	O
origin	O
no	O
reports	O
,	O
mitral	O
valve	O
replacement	O
in	O
April	O
2011	O
with	O
Carbomedics	O
No	O
27	O
metal	O
prosthesis	O
using	O
a	O
minimally	O
invasive	O
technique	O
Heart	O
Port	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
at	O
discharge	O
Normally	O
functioning	O
mitral	O
prosthesis	O
.	O
Mild	O
aortic	O
regurgitation	O
.	O
Mild	O
atrial	O
dilatation	O
.	O
Normal	O
ejection	O
fraction	O
EF	O
.	O
Permanent	O
atrial	O
fibrillation	O
secondary	O
to	O
his	O
valvular	O
pathology	O
.	O
Previous	O
surgical	O
interventions	O
'	O
Cervical	O
'	O
no	O
reports	O
.	O
Usual	O
treatment	O
Sintrom	B-FARMACO
4	O
mg	O
,	O
pitavastatin	B-FARMACO
2	O
mg	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
12	O
hours	O
,	O
digoxin	B-FARMACO
0	O
.	O
25	O
mg	O
every	O
24	O
hours	O
without	O
rest	O
,	O
lansoprazole	B-FARMACO
15	O
mg	O
,	O
lorazepam	B-FARMACO
1	O
mg	O
occasionally	O
.	O
The	O
patient	O
had	O
no	O
chest	O
pain	O
or	O
other	O
symptoms	O
apart	O
from	O
those	O
mentioned	O
above	O
.	O
In	O
the	O
following	O
hours	O
,	O
during	O
his	O
stay	O
in	O
the	O
Emergency	O
Department	O
of	O
the	O
regional	O
hospital	O
,	O
the	O
patient	O
suffered	O
a	O
progressive	O
deterioration	O
of	O
his	O
general	O
condition	O
,	O
with	O
increasing	O
dyspnoea	O
until	O
he	O
became	O
resting	O
,	O
pink	O
expectoration	O
,	O
pallor	O
and	O
diaphoresis	O
.	O
He	O
was	O
transferred	O
to	O
the	O
observation	O
ward	O
with	O
acute	O
pulmonary	O
oedema	O
APE	O
requiring	O
non	O
invasive	O
mechanical	O
ventilation	O
NIV	O
,	O
presenting	O
haemodynamic	O
instability	O
,	O
and	O
entering	O
AF	O
with	O
RVR	O
around	O
140	O
150	O
bpm	O
.	O
The	O
patient	O
continued	O
with	O
poor	O
respiratory	O
mechanics	O
despite	O
NIMV	O
,	O
with	O
refractory	O
hypotension	O
and	O
oligoanuria	O
,	O
so	O
orotracheal	O
intubation	O
OTI	O
was	O
performed	O
,	O
connection	O
to	O
mechanical	O
ventilation	O
MV	O
and	O
noradrenaline	B-FARMACO
and	O
furosemide	B-FARMACO
were	O
started	O
in	O
p	O
.	O
c	O
.	O
Given	O
the	O
rapidly	O
unfavourable	O
evolution	O
of	O
the	O
patient	O
,	O
an	O
urgent	O
TTE	O
was	O
carried	O
out	O
at	O
the	O
regional	O
hospital	O
,	O
and	O
the	O
report	O
from	O
the	O
aforementioned	O
centre	O
showed	O
that	O
the	O
mitral	O
prosthesis	O
had	O
not	O
opened	O
.	O
The	O
suspicion	O
of	O
prosthetic	O
thrombosis	O
was	O
reinforced	O
by	O
the	O
finding	O
of	O
an	O
INR	O
of	O
1	O
.	O
12	O
in	O
the	O
ED	O
analysis	O
.	O
It	O
was	O
decided	O
to	O
perform	O
fibrinolysis	O
with	O
10	O
mg	O
of	O
rTPA	B-FARMACO
as	O
a	O
bolus	O
and	O
then	O
90	O
mg	O
of	O
rTPA	B-FARMACO
in	O
pc	O
for	O
90	O
min	O
,	O
simultaneously	O
initiating	O
anticoagulation	O
with	O
a	O
bolus	O
of	O
4	O
,	O
000	O
IU	O
of	O
sodium	B-FARMACO
heparin	I-FARMACO
and	O
p	O
.	O
c	O
.	O
of	O
the	O
same	O
at	O
800	O
IU	O
h	O
.	O
The	O
patient	O
was	O
transferred	O
by	O
ambulance	O
to	O
the	O
ICU	O
of	O
our	O
centre	O
for	O
urgent	O
assessment	O
.	O
On	O
admission	O
to	O
the	O
ICU	O
of	O
our	O
centre	O
,	O
the	O
patient	O
was	O
sedoanalgesiated	O
midazolam	B-FARMACO
at	O
0	O
.	O
2	O
mg	O
kg	O
h	O
,	O
morphine	B-FARMACO
chloride	I-FARMACO
at	O
1	O
mg	O
h	O
,	O
under	O
OTI	O
and	O
connected	O
to	O
MV	O
with	O
100	O
FiO2	O
according	O
to	O
standard	O
parameters	O
,	O
maintaining	O
100	O
SatO2	O
.	O
Haemodynamically	O
he	O
maintained	O
BP	O
around	O
130	O
60	O
mmHg	O
with	O
amine	O
support	O
noradrenaline	B-FARMACO
at	O
0	O
.	O
3	O
μg	O
Kg	O
min	O
,	O
in	O
AF	O
rhythm	O
with	O
RV	O
around	O
90	O
100	O
bpm	O
.	O
Preserved	O
diuresis	O
with	O
support	O
of	O
furosemide	B-FARMACO
in	O
p	O
.	O
c	O
.	O
at	O
40	O
mg	O
h	O
,	O
which	O
was	O
subsequently	O
lowered	O
to	O
20	O
mg	O
h	O
.	O
Diuresis	O
on	O
admission	O
300	O
cc	O
.	O
Anticoagulated	O
with	O
sodium	B-FARMACO
heparin	I-FARMACO
at	O
10	O
mg	O
h	O
10	O
,	O
000	O
IU	O
h	O
.	O
Physical	O
examination	O
on	O
admission	O
BP	O
110	O
60	O
mmHg	O
,	O
HR	O
90	O
bpm	O
,	O
O2	O
sat	O
98	O
baseline	O
.	O
Conscious	O
,	O
oriented	O
,	O
reactive	O
,	O
perceptive	O
.	O
No	O
palpable	O
lymphadenopathies	O
.	O
Cardiac	O
auscultation	O
Rhythmic	O
heart	O
tones	O
at	O
85	O
bpm	O
,	O
pansystolic	O
murmur	O
of	O
intensity	O
III	O
VI	O
at	O
mitral	O
focus	O
level	O
,	O
radiating	O
to	O
the	O
axilla	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
no	O
masses	O
or	O
megaliths	O
palpable	O
.	O
Lower	O
extremities	O
No	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Auscultation	O
showed	O
arrhythmic	O
tones	O
at	O
about	O
100	O
bpm	O
,	O
no	O
murmurs	O
or	O
extratonos	O
,	O
with	O
audible	O
prosthetic	O
click	O
in	O
the	O
mitral	O
focus	O
.	O
Vesicular	O
murmur	O
was	O
preserved	O
bilaterally	O
,	O
with	O
crackles	O
in	O
both	O
lung	O
bases	O
.	O
Abdomen	O
without	O
findings	O
.	O
Lower	O
limbs	O
without	O
oedema	O
or	O
signs	O
of	O
DVT	O
.	O
The	O
patient	O
was	O
assessed	O
by	O
on	O
call	O
Cardiology	O
,	O
and	O
a	O
new	O
TTE	O
was	O
performed	O
followed	O
by	O
transesophageal	O
echocardiography	O
TEE	O
which	O
confirmed	O
the	O
diagnostic	O
suspicion	O
,	O
showing	O
thrombotic	O
release	O
to	O
the	O
left	O
chambers	O
and	O
the	O
existence	O
of	O
a	O
severely	O
depressed	O
LVEF	O
see	O
images	O
and	O
description	O
in	O
the	O
complementary	O
tests	O
.	O
Urgent	O
catheterisation	O
was	O
subsequently	O
performed	O
,	O
as	O
described	O
in	O
the	O
evolution	O
.	O
Additional	O
tests	O
ECG	O
AF	O
with	O
RV	O
at	O
about	O
120	O
bpm	O
.	O
Normal	O
electrical	O
axis	O
.	O
BIRDHH	O
.	O
ST	O
depression	O
of	O
1	O
.	O
5	O
mm	O
in	O
inferolateral	O
face	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V4	O
V6	O
.	O
Blood	O
gases	O
pH	O
7	O
.	O
25	O
,	O
pCO2	O
56	O
,	O
HCO3	O
24	O
,	O
EB	O
2	O
.	O
1	O
,	O
Hb	O
18	O
.	O
4	O
,	O
SvO2	O
70	O
,	O
ions	O
normal	O
,	O
lactic	O
2	O
.	O
1	O
.	O
CBC	O
on	O
admission	O
to	O
ICU	O
Creatinine	O
1	O
.	O
50	O
previous	O
normal	O
,	O
urea	O
37	O
,	O
ions	O
normal	O
,	O
glucose	O
135	O
,	O
total	O
bilirubin	O
1	O
.	O
49	O
,	O
direct	O
bilirubin	O
0	O
.	O
83	O
,	O
CRP	O
39	O
,	O
19	O
,	O
060	O
leukocytes	O
,	O
85	O
.	O
9	O
PMN	O
,	O
Hb	O
16	O
.	O
9	O
,	O
platelets	O
192	O
,	O
000	O
,	O
INR	O
2	O
.	O
08	O
,	O
TPTA	O
No	O
clotting	O
.	O
Urgent	O
TEE	O
Non	O
dilated	O
LV	O
with	O
severely	O
depressed	O
EF	O
with	O
global	O
hypokinesia	O
.	O
Normofunctioning	O
trivalve	O
aortic	O
valve	O
.	O
Autocontrast	O
in	O
LA	O
with	O
images	O
of	O
scattered	O
thrombi	O
,	O
in	O
atrial	O
appendage	O
,	O
interatrial	O
septum	O
and	O
anterior	O
portion	O
of	O
the	O
mitral	O
annulus	O
.	O
Mitral	O
prosthesis	O
with	O
fixed	O
anterior	O
disc	O
and	O
posterior	O
disc	O
with	O
preserved	O
mobility	O
.	O
Peak	O
transprosthetic	O
gradient	O
of	O
7	O
mmHg	O
AF	O
at	O
100	O
bpm	O
.	O
Mild	O
regurgitation	O
.	O
The	O
ventricular	O
side	O
of	O
the	O
anterior	O
disc	O
shows	O
images	O
compatible	O
with	O
the	O
presence	O
of	O
thrombus	O
adhered	O
to	O
it	O
.	O
From	O
the	O
bicave	O
plane	O
,	O
autocontrast	O
and	O
mobile	O
thrombus	O
can	O
be	O
seen	O
at	O
the	O
mouth	O
of	O
the	O
inferior	O
cava	O
which	O
is	O
not	O
seen	O
again	O
later	O
in	O
the	O
study	O
.	O
RV	O
not	O
dilated	O
with	O
systolic	O
function	O
at	O
the	O
lower	O
limit	O
of	O
normality	O
.	O
Conclusions	O
Mitral	O
prosthetic	O
thrombosis	O
that	O
does	O
not	O
cause	O
significant	O
stenosis	O
.	O
Multiple	O
thrombi	O
in	O
LA	O
.	O
Severe	O
LV	O
dysfunction	O
coronary	O
embolism	O
?	O
.	O
Clinical	O
course	O
In	O
view	O
of	O
the	O
TEE	O
findings	O
,	O
on	O
call	O
Cardiac	O
Surgery	O
was	O
notified	O
and	O
it	O
was	O
decided	O
to	O
perform	O
coronary	O
angiography	O
due	O
to	O
the	O
contractility	O
alterations	O
and	O
ECG	O
changes	O
and	O
then	O
urgent	O
surgery	O
,	O
both	O
procedures	O
being	O
carried	O
out	O
in	O
the	O
following	O
hours	O
.	O
Catheterisation	O
showed	O
no	O
angiographically	O
significant	O
coronary	O
lesions	O
,	O
and	O
once	O
again	O
the	O
non	O
mobility	O
of	O
one	O
of	O
the	O
prosthetic	O
discs	O
was	O
confirmed	O
.	O
During	O
the	O
surgical	O
procedure	O
,	O
a	O
large	O
amount	O
of	O
LA	O
thrombus	O
and	O
thrombus	O
causing	O
occlusion	O
of	O
the	O
aforementioned	O
disc	O
was	O
observed	O
.	O
Remnants	O
of	O
the	O
posterior	O
mitral	O
leaflet	O
that	O
may	O
have	O
contributed	O
to	O
the	O
occlusion	O
were	O
observed	O
.	O
It	O
was	O
decided	O
to	O
remove	O
the	O
prosthesis	O
and	O
implant	O
a	O
new	O
one	O
.	O
During	O
CPB	O
,	O
with	O
the	O
heart	O
at	O
low	O
preload	O
,	O
marked	O
LV	O
hypocontractility	O
was	O
observed	O
,	O
mainly	O
at	O
the	O
expense	O
of	O
the	O
middle	O
and	O
apical	O
regions	O
septum	O
and	O
basal	O
region	O
with	O
good	O
mobility	O
.	O
He	O
was	O
connected	O
to	O
an	O
epicardial	O
pacemaker	O
for	O
sinus	O
bradycardia	O
.	O
Times	O
ECC	O
138	O
min	O
.	O
Anoxia	O
78	O
min	O
.	O
Temperature	O
32	O
oC	O
.	O
He	O
left	O
the	O
operating	O
theatre	O
with	O
significant	O
inotropic	O
support	O
dobutamine	B-FARMACO
at	O
10	O
μg	O
kg	O
min	O
noradrenaline	B-FARMACO
at	O
0	O
.	O
3	O
μg	O
kg	O
min	O
adrenaline	B-FARMACO
at	O
0	O
.	O
3	O
μg	O
kg	O
min	O
levosimendan	B-FARMACO
at	O
0	O
.	O
05	O
μg	O
kg	O
min	O
,	O
maintaining	O
AMT	O
around	O
80	O
85	O
mmHg	O
.	O
He	O
also	O
presented	O
a	O
significant	O
coagulation	O
alteration	O
,	O
which	O
was	O
controlled	O
with	O
transfusion	O
of	O
blood	O
products	O
800	O
cc	O
plasma	O
1	O
pool	O
of	O
platelets	O
4	O
g	O
of	O
fibrinogen	O
2	O
red	O
blood	O
cell	O
concentrates	O
.	O
In	O
the	O
immediate	O
postoperative	O
period	O
he	O
presented	O
abundant	O
bleeding	O
through	O
the	O
drains	O
and	O
anaemisation	O
,	O
which	O
again	O
required	O
transfusion	O
of	O
blood	O
products	O
.	O
The	O
patient	O
is	O
currently	O
still	O
in	O
the	O
ICU	O
,	O
under	O
sodium	B-FARMACO
heparin	I-FARMACO
p	O
.	O
c	O
.	O
and	O
with	O
good	O
prosthetic	O
function	O
.	O
In	O
the	O
last	O
few	O
hours	O
he	O
has	O
been	O
extubated	O
and	O
has	O
no	O
neurological	B-FARMACO
deficits	I-FARMACO
on	O
examination	O
,	O
and	O
is	O
progressing	O
favourably	O
.	O
Diagnosis	O
Mitral	O
prosthetic	O
thrombosis	O
in	O
a	O
poorly	O
anticoagulated	O
patient	O
.	O
Urgent	O
fibrinolysis	O
partially	O
effective	O
with	O
thrombotic	O
release	O
to	O
the	O
left	O
chambers	O
.	O
Severe	O
LV	O
dysfunction	O
with	O
alterations	O
in	O
contractility	O
and	O
ECG	O
changes	O
in	O
this	O
context	O
,	O
with	O
no	O
evidence	O
of	O
coronary	O
embolism	O
.	O
Impaired	O
renal	O
function	O
secondary	O
to	O
low	O
output	O
,	O
now	O
resolved	O
.	O

